<SEC-DOCUMENT>0001213900-24-053881.txt : 20240618
<SEC-HEADER>0001213900-24-053881.hdr.sgml : 20240618
<ACCEPTANCE-DATETIME>20240618171729
ACCESSION NUMBER:		0001213900-24-053881
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		79
FILED AS OF DATE:		20240618
DATE AS OF CHANGE:		20240618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279387
		FILM NUMBER:		241053031

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>ea0205122-02.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:59 UTC 2024 -->
<html xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head><title> </title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><div style="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">As filed with the Securities and Exchange Commission on June 18, 2024</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:right;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">No. 333-279387</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"> UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington, D.C. 20549</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">AMENDMENT NO. 1<br/>to<br/>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-4</span><br/>REGISTRATION STATEMENT<br/></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-size:9pt;">UNDER<br/>THE SECURITIES ACT OF 1933</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-32"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:16pt;">ARCA BIOPHARMA, INC.</span></ix:nonNumeric><span class="Bold" style="font-style:normal;font-weight:bold;"><br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(Exact name of registrant as specified in its charter)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-43"><span class="Bold" style="font-style:normal;font-weight:bold;">Delaware</span></ix:nonNumeric></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2835</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">36-3855489</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(State or other jurisdiction of <br/>incorporation or organization)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(Primary Standard Industrial <br/>Classification Code Number)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(I.R.S.&#160;Employer <br/>Identification No.)</span></p>	</td>	</tr>	</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:4pt;text-align:center;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940-2100<br/>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Thomas A.&#160;Keuer<br/>President and Chief Operating Officer<br/>ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-2100</span></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"><br/>(Name, address, including zip code, and telephone number, including area code, of agent for service)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:1pt;text-align:center;margin-top:1pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-size:9pt;">Copies of all communications, including communications sent to agent for service, should be sent to:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Brent Fassett <br/>Ethan Lutske <br/>Ross Tanaka <br/>Savir S.&#160;Punia <br/>Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. <br/>1881 9</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;vertical-align:super;">th</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;"> Street, Suite 110 <br/>Boulder, CO&#160;80302 <br/>(303)&#160;256</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-5900</span></span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Ryan A.&#160;Murr, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Branden C.&#160;Berns, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Chris W.&#160;Trester, Esq.</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Gibson, Dunn&#160;&amp; Crutcher LLP</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">One Embarcadero Center, Suite 2600</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">San Francisco, CA&#160;94111</span><span class="CharOverride-1" style="font-size:9pt;"> <br/></span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">(415)&#160;393</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">-8373</span></span></p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Approximate date of commencement of proposed sale of the securities to the public: </span>As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">If this Form is a post<span class="nobreak">-effective</span> amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non<span class="nobreak">-accelerated</span> filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b<span class="nobreak">-2</span> of the Exchange&#160;Act.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:2pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#160;biopharma,&#160;Inc. <br/></span>Large&#160;accelerated&#160;filer</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 2', sans-serif;"><br/>&#163;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accelerated filer</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-169">Non<span class="nobreak">-accelerated</span>&#160;filer</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9746;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Smaller&#160;reporting&#160;company</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-181"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Emerging&#160;growth&#160;company</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-195"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></ix:nonNumeric></p>	</td>	</tr>	</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">If applicable, place an&#160;X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">Exchange&#160;Act Rule&#160;13e<span class="nobreak">-4</span>(i)&#160;(Cross<span class="nobreak">-Border</span> Issuer Tender Offer) <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;">Exchange&#160;Act Rule&#160;14d<span class="nobreak">-1</span>(d)&#160;(Cross<span class="nobreak">-Border</span> Third<span class="nobreak">-Party</span> Tender Offer) <span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><span class="CharOverride-6" style="color:#d2232a;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. ARCA biopharma, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>
		</div>
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">PRELIMINARY PROXY STATEMENT/PROSPECTUS <br/>SUBJECT TO COMPLETION, DATED JUNE</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">18, 2024</span></p>
		<table class="Basic-Table _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="Basic-Table _idGenTableRowColumn-19" style="height:12pt;">
					<td class="Basic-Table CellOverride-13" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;vertical-align:bottom;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="tarca_001.jpg" style="width:206.08px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="toruka_logo.jpg" style="width:107.52px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-14" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSED MERGER<br/>YOUR VOTE IS VERY IMPORTANT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_______________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">To the Stockholders of ARCA biopharma, Inc. and Oruka Therapeutics, Inc.,</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; The term &#8220;combined company&#8221; when used in the following proxy statement/prospectus refers to the post<span class="nobreak">-Merger</span> corporate structure including Oruka Therapeutics, Inc. (f/k/a ARCA biopharma, Inc.) as the parent entity and Oruka Therapeutics Operating Company, LLC as its wholly<span class="nobreak">-owned</span> subsidiary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (as defined below) and excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B non<span class="nobreak">-voting</span> convertible preferred stock, par value $0.001 per share (&#8220;ARCA Series&#160;B Preferred Stock&#8221;), which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Options</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Warrants</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (v)&#160;each in<span class="nobreak">-the-money</span> option to acquire shares of ARCA&#8217;s common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive an amount in cash equal to the excess (if any) of the volume weighted average closing price of ARCA&#8217;s common stock for the five consecutive&#160;trading days ending three (3)&#160;trading days prior to the closing of the First Merger (the &#8220;Parent Closing Price&#8221;) over the option&#8217;s exercise price and (vi)&#160;each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, and will be unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024 (the date the Merger Agreement was executed) and taking into account ARCA&#8217;s current cash position, each share of Oruka capital stock is currently estimated to be entitled to receive approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimated exchange ratio does not give effect to the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">proposed ARCA reverse stock split and is subject to adjustment based on ARCA&#8217;s estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare a special cash dividend (the &#8220;special cash dividend&#8221;) to stockholders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend will be determined by The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date of the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors to purchase shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), referred to herein as the &#8220;Oruka pre<span class="nobreak">-closing</span>&#160;financing,&#8221; immediately prior to the closing of the Merger. The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be converted into the right to receive a number of shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, equal to the exchange ratio described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement (the &#8220;registration rights agreement&#8221;) at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415 under the Securities Act (&#8220;Rule&#160;415&#8221;). The Oruka pre<span class="nobreak">-closing</span> financing is more fully described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on page 153 and 155, respectively, of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, based solely on the estimated exchange ratio as described in the accompanying proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. On &#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the last&#160;trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of ARCA common stock was $<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders are cordially invited to attend the special meeting in lieu of the annual meeting of ARCA stockholders. ARCA is holding its special meeting in lieu of the annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. At the ARCA special meeting, ARCA will ask its stockholders to:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the accompanying proxy statement/prospectus, certain ARCA stockholders who in the aggregate owned approximately 28.5% of the outstanding shares of ARCA capital stock as of May<span class="nobreak"> </span>3, 2024, and certain Oruka stockholders who in the aggregate owned approximately 90% of the outstanding shares of Oruka capital stock as of May&#160;3, 2024, are parties to stockholder support agreements with ARCA and Oruka, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Oruka stockholders holding a sufficient number of shares of Oruka capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the combined company will not be considered a &#8220;controlled company&#8221; under the relevant listing rules of Nasdaq, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis). As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs, though they have no agreement to do so or any expectation of entering into such an agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After careful consideration, each of ARCA&#8217;s and Oruka&#8217;s boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. ARCA&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the proposals described in the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">More information about ARCA, Oruka, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. ARCA urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 15 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are excited about the opportunities the Merger brings to ARCA&#8217;s and Oruka&#8217;s stockholders and thank you for your consideration and continued support.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">President and Chief Operating Officer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Chief Executive Officer</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA biopharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc.</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy&#160;statement/prospectus. Any representation to the contrary is a criminal offense.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The accompanying proxy statement/prospectus is dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, and is first being mailed to ARCA&#8217;s stockholders on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the stockholders of ARCA biopharma, Inc.:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE IS HEREBY GIVEN</span> that a special meeting in lieu of annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) will be held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m. Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held in person at the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The ARCA special meeting will be held for the following purposes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I </span>to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These proposals are collectively referred to as the &#8220;Proposals.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has fixed<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 as the record date (the &#8220;Record Date&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the ARCA special meeting and any adjournment or postponement thereof. Only holders of record of shares of ARCA common stock at the close of business on the Record Date are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, ARCA had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock outstanding and entitled to vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Your vote is important. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">6, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">7, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">8, Proposal&#160;No. 9 and Proposal&#160;No. 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No. 2 and Proposal&#160;No. 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">5, the director is elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">All stockholders are cordially invited to attend the special meeting in person. Even if you plan to attend the ARCA special meeting, ARCA requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the ARCA special meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO ARCA AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL.&#160;ARCA&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT ARCA STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy statement/prospectus and annual report to stockholders are available at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">By Order of ARCA&#8217;s Board of Directors,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Thomas A.&#160;Keuer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President and Chief Operating Officer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPLANATORY NOTE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-466">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre<span class="nobreak">-closing</span> financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre<span class="nobreak">-funded</span> warrants that will be issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the pre<span class="nobreak">-closing</span> financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</ix:nonNumeric></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying proxy statement/prospectus incorporates important business and financial information about ARCA biopharma, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>) or upon your written or oral request by contacting 10170 Church Ranch Way, Suite 100, Westminster, Colorado, Attention: Corporate Secretary, or by calling (720)&#160;940<span class="nobreak">-2100</span>. ARCA also maintains a website at <span class="Italic" style="font-style:italic;font-weight:normal;">https://arcabio.com/</span>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.&#160;However, the information contained in or accessible through ARCA&#8217;s website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 to receive them before the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional details about where you can find information about ARCA, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of the accompanying proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="TOC001"></a><p class="H1_TOC" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T27"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">iii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T26"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROSPECTUS SUMMARY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T25"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">14</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T24"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">RISK FACTORS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T23"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">88</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T22"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">91</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T991188"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">96</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T21"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">135</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T20"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">153</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T19"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">156</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T18"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">159</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T17"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">166</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T16"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">172</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T15"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">173</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T14"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">175</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9980"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9981"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 1 &#8212; THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9982"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 2 &#8212; THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">178</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9983"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 3 &#8212; THE REVERSE STOCK SPLIT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">180</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9984"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 4 &#8212; THE OFFICER EXCULPATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">187</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9985"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 5 &#8212; THE DIRECTOR ELECTION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">189</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9986"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 6 &#8212; THE AUDITOR RATIFICATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">190</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9992"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 7 &#8212; THE STOCK PLAN PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">191</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9993"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 8 &#8212; THE ESPP PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">194</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9994"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 9 &#8212; THE MERGER COMPENSATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">196</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9987"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 10 &#8212; THE ADJOURNMENT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">197</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T13"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">198</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T12"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">214</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9988"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">250</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T11"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">261</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T10"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">273</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9989"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">280</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">284</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9990"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">289</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T8"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">296</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T7"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND ORUKA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">301</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T6"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">312</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T5"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">315</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T4"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">317</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T3"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">LEGAL MATTERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">319</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">EXPERTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">319</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T1"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">320</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9991"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">321</span></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T111">INDEX TO FINANCIAL STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T100"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">A-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T101"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;B OPINION OF LUCID CAPITAL MARKETS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">B-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T102"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;C FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">C-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T103"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;D FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">D-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T104"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;E FORM OF LOCK-UP AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">E-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T105"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;F CERTIFICATE OF DESIGNATION OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T106"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;G CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT INCREASE&#160;IN AUTHORIZED SHARES</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">G-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T107"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;H CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT REVERSE&#160;STOCK SPLIT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">H-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T108"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;I CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT DELAWARE&#160;LAW PROVISIONS REGARDING OFFICER EXCULPATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">I-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T109"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;J Appraisal Rights (Section&#160;262 of the Delaware General Corporation&#160;Law)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">J-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T110"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;K 2024 Oruka Therapeutics, Inc. Stock Incentive Plan*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">K-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T112"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;L 2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan*</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">L-1</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To be filed by amendment.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T27"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements, each dated March&#160;6, 2024 and subsequently amended and restated on March&#160;28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross<span class="nobreak">-referenced</span> sections.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, ARCA, Oruka, First Merger Sub and Second Merger Sub entered into the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span>.&#160;The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger. Oruka will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, ARCA will change its corporate name to &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Immediately after the Merger, based solely on the estimated exchange ratio as described in this proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0<span class="nobreak"> </span>million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare the special cash dividend to stockholders of record of outstanding shares of ARCA common stock as of the record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">will be determined by Nasdaq. ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date for the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why are the two companies proposing to merge?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA and Oruka believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Oruka&#8217;s Reasons for the Merger</span>&#8221; beginning on pages 104 and 110, respectively, of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will happen to ARCA if, for any reason, the merger with Oruka does not close?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed merger with Oruka. In the event the Merger does not close, ARCA will have a limited ability to continue its current operations without obtaining additional financing. Although ARCA&#8217;s board of directors may elect, among other things, to attempt to complete another strategic transaction if the merger with Oruka does not close, ARCA&#8217;s board of directors may instead divest all or a portion of ARCA&#8217;s business or take steps necessary to liquidate or dissolve ARCA&#8217;s business and assets if a viable alternative strategic transaction is not available. If ARCA decides to dissolve and liquidate its assets, ARCA would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of ARCA and setting aside funds for reserves.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why am&#160;I receiving this proxy statement/prospectus?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You are receiving this proxy statement/prospectus because you have been identified as a stockholder of ARCA as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a proxy statement of ARCA used to solicit proxies for the ARCA special meeting to vote on the matters set forth herein; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a prospectus of ARCA used to offer (i)&#160;shares of ARCA common stock issued in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Oruka pre</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-closing</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> financing?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, pursuant to which such investors agreed to purchase shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). Shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued pursuant to this financing transaction will be converted into shares of ARCA common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iv</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Immediately after the First Merger, the shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing are expected to represent approximately 58.2% of the outstanding shares of common stock of the combined company, on a fully<span class="nobreak">-diluted</span> basis. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">For a more complete description of the Oruka pre<span class="nobreak">-closing</span> financing, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on pages&#160;153 and 155 of this proxy statement/prospectus, respectively.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals will be voted on at the ARCA special meeting in connection with the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the ARCA special meeting in order for the Merger to close:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 1 &#8212;&#160;The Nasdaq Stock Issuance Proposal</span> to approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 2 &#8212;&#160;Authorized Share Increase Proposal</span> to approve an amendment to the ARCA Charter to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Additionally, Proposal&#160;No. 2 must be approved to have an adequate number of authorized but unissued shares of ARCA common stock to complete the Merger; and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 3 &#8212;&#160;Reverse Stock Split Proposal</span> to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors, the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">In addition to the requirement of obtaining ARCA stockholder approval of Proposal&#160;No. 1 and Proposal&#160;No.<span class="nobreak"> </span>2, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the Proposals.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">v</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals are to be voted on at the ARCA special meeting, other than the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Authorized Share Increase Proposal?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the ARCA special meeting, the holders of ARCA common stock will also be asked to consider the following proposal:</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;4 &#8212;&#160;The Officer Exculpation Proposal</span> to approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;5 &#8212;&#160;The Director Election Proposal</span> to elect one (1)&#160;Class&#160;III director nominee named in the accompany proxy statement/prospectus to ARCA&#8217;s board of directors, to serve until ARCA&#8217;s 2027 annual meeting of stockholders or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;6 &#8212;&#160;The Auditor Ratification Proposal</span> to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;7 &#8212;&#160;The Stock Plan Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;8 &#8212;&#160;The ESPP Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;9 &#8212;&#160;The Merger Compensation Proposal</span> to approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger; and</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;10 &#8212;&#160;The Adjournment Proposal</span> to approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The approval of Proposal&#160;Nos.<span class="nobreak"> </span>3,<span class="nobreak"> </span>4,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10 are not a condition to the Merger. ARCA does not expect that any matter other than the Proposals will be brought before the ARCA special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What stockholder votes are required to approve the Proposals at the ARCA special meeting?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will Oruka stockholders, participants in Oruka&#8217;s 2024 Equity Incentive Plan, option holders and warrant holders receive in the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Oruka stockholders will receive shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan, as amended, along with issued and outstanding awards under such plan. Outstanding and unexercised options to purchase shares of Oruka common stock immediately prior to the First Effective Time will be converted into options to purchase shares of ARCA&#8217;s common stock, with necessary adjustments being made to the number of shares and exercise price underlying such options in order to reflect the economic equivalent of the prior equity award in light of the exchange ratio. Oruka warrant holders&#8217; outstanding and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vi</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">unexercised warrants to purchase shares of Oruka common stock immediately prior to the First Effective Time will be assumed by ARCA and each outstanding and unexercised warrant will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio. Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash less than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">For a more complete description of the treatment of Oruka common stock, Oruka&#8217;s 2024 Equity Incentive Plan, Oruka options and Oruka warrants in the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Merger Consideration</span>&#8221;<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>and<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on pages 135 and 136, respectively, of this proxy statement/prospectus. For a description of the effect of the Oruka pre<span class="nobreak">-closing</span> financing on ARCA&#8217;s and Oruka&#8217;s current securityholders, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Will the common stock of the combined company trade on an exchange?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the common stock of the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. </p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">On<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the last&#160;trading day before the date of this proxy statement/prospectus, the closing sale price of ARCA common stock was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the directors of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the combined company&#8217;s board of directors will be composed of six members, all of whom will have been designated by Oruka.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Effective as of the First Effective Time, ARCA&#8217;s board of directors will appoint the following Oruka designees: Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, to the board of directors of the combined company and concurrently therewith all of ARCA&#8217;s current directors will resign from their positions as directors of ARCA&#8217;s board of directors effective as of the First Effective Time. Dr.&#160;Kulkarni is expected to be appointed as Chair of the board of directors of the combined company.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The staggered structure of three classes of directors of ARCA&#8217;s board of directors will remain in place for the combined company following the completion of the Merger. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; for additional information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the executive officers of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the executive management team of the combined company is expected to consist of the following members of the Oruka executive management team:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>

		</table>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>As an ARCA stockholder, how does ARCA&#8217;s board of directors recommend that&#160;I vote?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of ARCA and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in connection with the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, respectively; and (iii)&#160;recommends that ARCA&#8217;s stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; each of the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What risks should&#160;I consider in deciding whether to vote in favor of the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You should carefully review the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of ARCA and Oruka, as independent companies, are subject.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>When do you expect the Merger to be consummated?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is anticipated to close in the third quarter of 2024, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What do&#160;I need to do now?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder of Record: Shares Registered in Your Name</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a stockholder of record, you may vote in person at the ARCA special meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the special meeting and we will give you a ballot when you arrive.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote over the telephone, dial toll<span class="nobreak">-free</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;using a touch<span class="nobreak">-tone</span> phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote through the Internet, go to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">viii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from ARCA.&#160;Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote in person at the ARCA special meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What if&#160;I return a proxy card or otherwise vote but do not make specific choices?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Officer Exculpation<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What happens if&#160;I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8,<span class="nobreak"> </span>9, and 10.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If my ARCA shares are held in &#8220;street name&#8221; by my broker and&#160;I do not provide my broker or bank with voting instructions, what happens?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion or your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are broker non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-votes</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> and do they count for determining a quorum?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Generally, a &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect as votes &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>May&#160;I revoke and/or change my vote after&#160;I have submitted a proxy or provided proxy instructions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the ARCA special meeting in one of four ways:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may submit another properly completed proxy with a later date by mail or via the internet.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can provide your proxy instructions via telephone at a later date.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ix</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may send a notice that you are revoking your proxy over the internet, following the instructions provided on your proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may attend the ARCA special meeting in person and vote during the meeting. Simply attending the ARCA special meeting will not, by itself, revoke your proxy and/or change your vote.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the Merger to U.S.&#160;holders of Oruka common stock and Oruka preferred stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S.&#160;federal income tax purposes. It is not a condition to Oruka&#8217;s obligation or ARCA&#8217;s obligation to complete the Merger that the Merger so qualifies, however. Assuming that the Merger so qualifies, a U.S.&#160;holder of Oruka stock (as defined in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128) will generally not recognize any gain or loss for U.S.&#160;federal income tax purposes on the receipt of ARCA stock (as defined in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128) in the Merger. For a more complete discussion of the material U.S.&#160;federal income tax consequences of the Merger, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the reverse stock split to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The reverse stock split is intended to be treated as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code for U.S.&#160;federal income tax purposes. Assuming it so qualifies, a U.S.&#160;holder of ARCA common stock should not recognize gain or loss for U.S.&#160;federal income tax purposes upon the reverse stock split, except with respect to cash received in lieu of a fractional share of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Proposal&#160;No. 3 &#8212;&#160;The Reverse Stock Split Proposal&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span>&#8221; beginning on page&#160;184 of this proxy statement/prospectus for a more complete description of the material U.S.&#160;federal income tax consequences of the reverse stock split to a U.S.&#160;holder of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the special cash dividend that ARCA will declare and pay to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The U.S.&#160;federal income tax consequences of a holder&#8217;s receipt of the special cash dividend generally should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the holder&#8217;s basis in ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining amount. ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated. Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Considerations &#8212; Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span>&#8221; beginning on page 130 of this proxy statement/prospectus for a discussion of the material U.S.&#160;federal income tax consequences of the special cash dividend to holders of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who can help answer my questions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">x</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<a id="T26"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the ARCA special meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>3 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Companies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a biotechnology company dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka&#8217;s mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic and inflammatory diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and its telephone number is (650)&#160;606<span class="nobreak">-7910</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">First Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">First Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Second Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Second Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 96)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the satisfaction or waiver of the conditions to closing set forth in the Merger Agreement, at the closing of the Merger, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (see page 104)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis as well as the risks of accomplishing those objectives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 110)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s board of directors considered included the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an initial public offering (&#8220;IPO&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected financial position, operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger, the Oruka pre<span class="nobreak">-closing</span> financing, and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger or Oruka pre<span class="nobreak">-closing</span> financing might not be completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there is no adjustment to the exchange ratio if ARCA&#8217;s net cash as of closing is above $5.0&#160;million, and thus Oruka stockholders are expected to own at least approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis) following the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash to an amount below $5.0&#160;million prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could consider certain unsolicited acquisition proposals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs, time and effort involved in connection with completing the Merger, related disruptions or potential disruptions to Oruka&#8217;s business and related administrative challenges associated with combining the companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject following the Merger as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 92)</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement, and the change of control of ARCA resulting from the Merger, is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on the ARCAs board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes it that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 121)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of ARCA common stock held by ARCA&#8217;s executive officers and directors will accelerate and fully vest, and (i)&#160;each such option with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s executive officers will be eligible to receive retention bonuses and severance payments in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s directors will be eligible to receive special committee fees in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus. As of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 121)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>as of May<span class="nobreak">&#160;</span>13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Fairmount Healthcare Fund&#160;II L.P. (&#8220;Fairmount Fund&#160;II&#8221;), an affiliate of Peter Harwin, an Oruka director, currently holds shares of Oruka capital stock and an unsecured convertible promissory note with an initial principal amount of $25.0&#160;million at an interest rate of 12% per annum (the &#8220;Convertible Note&#8221;) of Oruka and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of Oruka common stock held by Oruka&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the combined company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are expected to become directors and executive officers of the combined company upon completion of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus. As of May&#160;13, 2024, the directors and executive officers of Oruka owned or controlled 73.5% of the outstanding shares of Oruka capital stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid Capital Markets to the ARCA Board</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 112)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) orally rendered its opinion to ARCA&#8217;s board of directors (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion addressed to ARCA&#8217;s board of directors dated April&#160;2, 2024), that, as of such date and based upon and subject to the various assumptions and limitations made, and such other factors Lucid deemed relevant upon the review undertaken by Lucid in preparing its opinion, the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The full text of the written opinion of Lucid, dated April&#160;2, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span class="Bold" style="font-style:normal;font-weight:bold;">Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of ARCA&#8217;s board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of ARCA&#8217;s board of directors&#8217; consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of ARCA common stock of the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of ARCA or Oruka as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and qualifications and limitations upon the review undertaken by Lucid in preparing its opinion.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Consideration </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis). Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options and Oruka&#8217;s 2024 Equity Incentive Plan</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 174)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, the combined company&#8217;s compensation committee will succeed to the authority and responsibility of Oruka&#8217;s board of directors as administrator of the Oruka 2024 Equity Incentive Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Warrants</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 139)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock that is outstanding and unexercised immediately prior to the First Effective Time (including any pre<span class="nobreak">-funded</span> warrant issued pursuant to the Oruka pre<span class="nobreak">-closing</span>&#160;financing), whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka warrant will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Common Stock and ARCA Options</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 140)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA common stock will be cancelled for no consideration.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger</span> (see page 148)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To complete the Merger, ARCA stockholders must approve Proposal&#160;No. 1 and Proposal&#160;No. 2 and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-Solicitation</span></span> (see page 145)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains&#160;non<span class="nobreak">-solicitation</span>&#160;provisions prohibiting ARCA and Oruka from soliciting a competing transaction. Each of ARCA and Oruka have agreed that, subject to certain exceptions, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Board Recommendation Change</span> (see page 146)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Neither Oruka&#8217;s board of directors nor ARCA&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;) or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party has provided at least four&#160;business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four<span class="nobreak">-business</span>&#160;day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three<span class="nobreak">-business</span>&#160;day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 150)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Either ARCA or Oruka may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fee </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 151)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $440,000 or Oruka could be required to pay ARCA a termination fee of $440,000.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Support Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into support agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the &#8220;Oruka Support Agreements&#8221;). Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into support agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals (the &#8220;ARCA Support Agreements,&#8221; and, together with the Oruka Support Agreements, the &#8220;Support Agreements&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days following the closing of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see pages 153 and 155)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span> warrants, representing an aggregate commitment of $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants that are issued in the Oruka pre<span class="nobreak">-closing</span> financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement also contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Management Following the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 273)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code for U.S.&#160;federal income tax purposes. It is not a condition to Oruka&#8217;s obligation or ARCA&#8217;s obligation to complete the Merger that the Merger so qualifies, however. Assuming that the Merger so qualifies, a U.S.&#160;holder of Oruka stock (as defined in the section entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128) will generally not recognize any gain or loss for U.S.&#160;federal income tax purposes on the receipt of ARCA stock in the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risk Factors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 15)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the potential merger with Oruka could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Some of ARCA and Oruka directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the proposed merger with Oruka could expose ARCA to other operational and financial risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA has a limited operating history, no history of commercializing products, has not generated any product revenue, has incurred significant operating losses since inception and anticipates continuing to incur net losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If the Merger is not consummated and should ARCA pursue additional clinical trials for its product candidates, it may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of its common stock, which could have a material adverse effect on its ability to consummate the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Even if the Merger and Oruka pre<span class="nobreak">-closing</span> financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. If Oruka is unable to raise such capital when needed, or on acceptable terms, Oruka may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts and/or file for bankruptcy or cease operations altogether;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka has never generated any revenue from product sales and may never be profitable;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is substantially dependent on the success of its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, and its anticipated clinical trials of such programs may not be successful;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The regulatory approval processes of the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) and other comparable foreign regulatory authorities are lengthy, time<span class="nobreak">-consuming</span> and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company may incur losses for the foreseeable future and might never achieve profitability;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka pre<span class="nobreak">-closing</span> financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. ARCA and Oruka both encourage you to read and consider all of these risks carefully.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 131)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to file an initial listing application for the combined company common stock with Nasdaq. If such application is accepted, it is anticipated that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of ARCA common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of Oruka capital stock are entitled to appraisal rights in connection with the Merger under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Comparison of Stockholder Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 301)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law (&#8220;DGCL&#8221;). If the Merger is completed, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of ARCA (the &#8220;ARCA Bylaws&#8221;) and the ARCA Charter, as may be further amended by Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 if approved by the ARCA stockholders at the ARCA special meeting. The rights of ARCA stockholders contained in the ARCA Charter and ARCA Bylaws differ from the rights of Oruka stockholders under the amended and restated certificate of incorporation of Oruka (the &#8220;Oruka Charter&#8221;) and bylaws of Oruka (the &#8220;Oruka Bylaws&#8221;), as more fully described under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of Rights of Holders of ARCA Capital Stock and Oruka Capital Stock</span>&#8221; beginning on page 301 of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T25"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The closing price of the ARCA common stock on April&#160;2, 2024, the last&#160;day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $1.71 per share. The closing price of the ARCA common stock on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, as reported on The Nasdaq Capital Market, was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the market price of the ARCA common stock is subject to fluctuation, the market value of the shares of the ARCA common stock that the Oruka stockholders will be entitled to receive in the Merger may increase or decrease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a private company, and its shares of common stock and preferred stock are not publicly traded.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming approval of Proposal&#160;Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of ARCA common stock will trade on Nasdaq under ARCA&#8217;s new name, &#8220;Oruka Therapeutics, Inc.,&#8221; and new trading symbol &#8220;ORKA.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the Record Date for the ARCA special meeting, there were approximately&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of the ARCA common stock. As of&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, Oruka had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>holders of record of Oruka common stock and one holder of record of Oruka preferred stock. For detailed information regarding the beneficial ownership of certain ARCA and Oruka stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of the Combined Company</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never declared or paid any cash dividends on the ARCA common stock and does not anticipate paying cash dividends on the ARCA common stock for the foreseeable future, except the&#160;special&#160;cash&#160;dividend&#160;that ARCA will declare and pay to the holders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the anticipated closing date of the First Merger. The aggregate amount of the special cash dividend shall be up to an amount equal to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as calculated pursuant to the terms and conditions of the Merger Agreement) will exceed $5,000,000. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization&#8217;s then<span class="nobreak">-current</span> board of directors and will depend upon a number of factors, including the combined organization&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then<span class="nobreak">-current</span> board of directors deems relevant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has never paid or declared any cash dividends on Oruka capital stock. If the Merger does not occur, Oruka does not anticipate paying any cash dividends on the Oruka capital stock in the foreseeable future, and Oruka intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Oruka board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Oruka board of directors deems relevant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T24"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">RISK FACTORS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of ARCA common stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 320 of this proxy statement/prospectus for further information.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential merger with Oruka, announced on April&#160;3, 2024, could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA entered into the Merger Agreement with Oruka, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub, with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.&#160;Consummation of the Merger is subject to certain closing conditions, a number of which are not within ARCA&#8217;s control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. ARCA cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect ARCA&#8217;s ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect ARCA&#8217;s business and its relationship with collaborators, suppliers, vendors, regulators and other business partners. For example, vendors, collaborators and other counterparties may defer their decisions to work with ARCA or seek to change their existing business relationships with ARCA.&#160;Changes to, or termination of, existing business relationships could adversely affect ARCA&#8217;s results of operations and financial condition, as well as the market price of ARCA common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if the Merger is approved by the stockholders of Oruka and ARCA, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; of this proxy statement/prospectus. ARCA cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">closing being equal to $5.0&#160;million. In the event ARCA&#8217;s net cash is below $5.0&#160;million, the exchange ratio will be adjusted such that the number of shares issued to Oruka&#8217;s pre<span class="nobreak">-closing</span> securityholders will be increased, and ARCA stockholders will own a smaller percentage of the combined company following the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the market price of ARCA&#8217;s stock before the completion of the First Merger will not affect the number of shares Oruka stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of ARCA common stock increases from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially more value for their shares of Oruka capital stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the First Merger, the market price of ARCA common stock declines from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price<span class="nobreak">-based</span> termination right.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The issuance of ARCA common stock, including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before the Merger can be completed, ARCA stockholders must approve, among other things, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, neither ARCA nor Oruka is obligated to complete the Merger if there is a material adverse effect affecting the other party between April&#160;3, 2024, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry<span class="nobreak">-wide</span> changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S.&#160;generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect ARCA or Oruka, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and ARCA consummates the closing of the Merger, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of ARCA, Oruka or both.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger is not completed, ARCA&#8217;s stock price may decline significantly.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of ARCA common stock will likely be volatile based on whether stockholders and other investors believe that ARCA can complete the Merger or otherwise raise additional capital to support ARCA&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of ARCA common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including commercial partner agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into the Subscription Agreement with certain investors, including existing investors of Oruka, pursuant to which the investors agreed to purchase, in the aggregate, $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in shares of common stock and pre<span class="nobreak">-funded</span> warrants of Oruka immediately prior to the closing of the Merger, referred to as the Oruka pre<span class="nobreak">-closing</span> financing. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing will result in dilution to all securityholders of the combined company (i.e., both ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and former Oruka securityholders). Furthermore, pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at approximately 5.0% on a fully<span class="nobreak">-diluted</span> basis (the &#8220;Target Ownership Percentage&#8221;) until Oruka has raised an aggregate of $200.0&#160;million (the &#8220;Covered Limit&#8221;). As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit. Such additional options granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and Oruka&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, as a result of ARCA&#8217;s assumption of the Paragon Option Agreements in connection with the Merger, the combined company will be subject to the obligation to grant to Paruka, on each of December&#160;31, 2024 and December&#160;31, 2025, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of ARCA common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transfers of the combined company&#8217;s securities utilizing Rule&#160;144 of the Securities Act may be limited.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A significant portion of the combined company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the combined company&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. ARCA&#8217;s expected disposal of its historical assets and operations in connection with the Merger with Oruka will make it a shell company. ARCA anticipates that following the consummation of the Merger, the combined </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company will no longer be a shell company. As a result, ARCA anticipates that holders will not be able to sell their restricted combined company securities pursuant to Rule&#160;144 without registration until one year after ARCA files the Current Report on Form&#160;8<span class="nobreak">-K</span> following the closing that includes the required Form&#160;10 information that reflects that the combined company is no longer a shell company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has two remaining ongoing development programs, Gencaro and rNAPc2, and it will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger. As such, ARCA expects to become a shell company upon consummation of the Merger, and its Merger with Oruka would be subject to the requirements applicable to shell company business combinations; provided, however, that if the Merger is not consummated, the disposal of ARCA&#8217;s legacy technology and intellectual property is not expected to occur and ARCA would therefore not expect to become a shell company. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements applicable to shell company business combinations are as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to file a Form&#160;8<span class="nobreak">-K</span> to report the Form&#160;10 type information after closing with the SEC reflecting its status as an entity that is not a shell company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA is not, and the combined company will not be, eligible to use a Form&#160;S<span class="nobreak">-3</span> until 12 full calendar&#160;months after closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to wait at least 60 calendar&#160;days after closing to file a Form&#160;S<span class="nobreak">-8</span> for any equity plans or awards;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will be an &#8220;ineligible issuer&#8221; for three&#160;years following the closing, which will prevent the combined company from (i)&#160;incorporating by reference in its Form&#160;S<span class="nobreak">-1</span> filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well<span class="nobreak">-known</span> seasoned issuer status despite its public float;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investors who (i)&#160;are affiliates of Oruka at the time the Merger is submitted for the vote or consent of Oruka stockholders, (ii)&#160;receive securities of the combined company in the Merger (i.e., Rule&#160;145(c)&#160;securities) and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form&#160;S<span class="nobreak">-1</span> resale registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rule&#160;144(i)(2)&#160;will limit the ability to publicly resell Rule&#160;145(c)&#160;securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one year after the Form&#160;10 information is filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing SEC requirements would increase the combined company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of combined company shares by affiliates of Oruka and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Some of ARCA&#8217;s and Oruka&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors and executive officers of ARCA and Oruka may have interests in the Merger that are different from, or in addition to, the interests of other ARCA stockholders generally. These interests with respect to ARCA&#8217;s directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, certain current members of Oruka&#8217;s board of directors will continue as directors of the combined company after the effective time, and, following the closing of the Merger, will be eligible to be compensated as non<span class="nobreak">-employee</span> directors of the combined company pursuant to ARCA&#8217;s non<span class="nobreak">-employee</span> director compensation policy that is expected to remain in place following the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to ARCA and Oruka stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre-closing financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, ARCA stockholders and Oruka stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the completion of the Merger, ARCA&#8217;s current stockholders will generally own a smaller percentage of the combined company than their ownership of ARCA prior to the Merger. Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. The Chief Executive Officer of Oruka will serve as the Chief Executive Officer of the combined company following the completion of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, ARCA&#8217;s current directors and executive officers and certain significant stockholders have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Oruka&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of ARCA capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Because the lack of a public market for Oruka common stock makes it difficult to evaluate the fair market value of its capital stock, the value of ARCA common stock to be issued to Oruka stockholders may be more or less than the fair market value of Oruka common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The outstanding capital stock of Oruka is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Oruka capital stock. Because the percentage of ARCA&#8217;s equity to be issued to Oruka stockholders was determined based on negotiations between the parties, it is possible that the value of ARCA common stock and ARCA Series&#160;B Preferred Stock to be issued to Oruka stockholders will be more or less than the fair market value of Oruka capital stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger does not qualify as a reorganization under the Code, U.S.&#160;holders of Oruka capital stock may be taxed on the full amount of the consideration received in the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is intended to qualify for U.S.&#160;federal income tax purposes as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code such that no gain will be recognized by U.S.&#160;holders of Oruka capital stock who receive only ARCA common stock in the Merger. None of the parties to the Merger Agreement have sought or intend to seek any ruling from the IRS regarding the qualification of the Merger as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code. If the Merger does not qualify for the U.S.&#160;federal income tax treatment described herein, U.S.&#160;holders of Oruka capital stock may be taxed on any gain realized up to the full fair market value of any of ARCA common stock they receive in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawsuits may be filed against ARCA, Oruka, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, Oruka&#8217;s board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and ARCA or Oruka may not be successful in defending against any such future claims. Lawsuits that may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, or Oruka&#8217;s board of directors could delay or prevent the Merger, divert the attention of ARCA&#8217;s and Oruka&#8217;s management and employees from their&#160;day<span class="nobreak">-to-day</span> business and otherwise adversely affect ARCA and Oruka financially.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has never paid and, other than in connection with the Merger with Oruka, does not intend to pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. The amount of such special cash dividend is currently uncertain, pending the determination of ARCA&#8217;s outstanding obligations and net cash position as of the closing of the Merger. Other than such potential special cash dividend in connection with the closing of the Merger, ARCA does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which ARCA can give you no assurance.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that the Merger will be completed. If the Merger is not completed, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as ARCA funds its operations while pursuing the Merger. In addition, if ARCA&#8217;s board of directors were to approve and recommend, and ARCA stockholders were to approve, a dissolution and liquidation of ARCA, ARCA would be required under Delaware law to pay ARCA&#8217;s outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to stockholders. ARCA&#8217;s commitments and contingent liabilities may include obligations under ARCA&#8217;s employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of ARCA, litigation against ARCA, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of ARCA&#8217;s assets would need to be reserved pending the resolution of such obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, ARCA may be subject to litigation or other claims related to a dissolution and liquidation of ARCA.&#160;If a dissolution and liquidation were to be pursued, ARCA&#8217;s board of directors, in consultation with ARCA&#8217;s advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Accordingly, holders of ARCA common stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of ARCA.&#160;A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to ARCA stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is substantially dependent on its remaining employees to facilitate the consummation of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of April&#160;4, 2024, ARCA had only three full<span class="nobreak">-time</span> employees and one part<span class="nobreak">-time</span> employee. ARCA&#8217;s ability to successfully complete the Merger depends in large part on its ability to retain certain remaining personnel. Despite ARCA&#8217;s efforts to retain these employees, one or more employees may terminate their employment with ARCA on short notice. The loss of the services of certain employees could potentially harm ARCA&#8217;s ability to consummate the Merger and run its&#160;day<span class="nobreak">-to-day</span> business operations, as well as fulfill its reporting obligations as a public company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal purposes of the reverse stock split are to (i)&#160;increase the&#160;per<span class="nobreak">-share</span>&#160;market price of ARCA common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of ARCA and the shares of ARCA common stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per<span class="nobreak">-share</span> market price of ARCA common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of ARCA common stock will proportionally increase the market price of ARCA common stock, it cannot be assured that the reverse stock split will increase the market price of ARCA common stock by a multiple of the reverse stock split ratio mutually agreed by ARCA and Oruka, or result in any permanent or sustained increase in the market price of ARCA common stock, which is dependent upon many factors, including ARCA&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of ARCA common stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although ARCA&#8217;s board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the&#160;per<span class="nobreak">-share</span>&#160;stock price of companies that have effected reverse stock splits subsequently declined back to&#160;pre<span class="nobreak">-reverse</span>&#160;split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA&#8217;s Business and Financial Condition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro or rNAPc2 in a timely manner, it may not be able to continue its business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA currently has no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to demonstrate that a product candidate, including Gencaro or rNAPc2, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect ARCA&#8217;s business. Failure to obtain marketing approval of Gencaro or rNAPc2 from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect ARCA&#8217;s business and could, among other things, preclude ARCA from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. ARCA does not currently have the capital resources or management expertise to commercialize Gencaro, rNAPc2 or any of its other product candidates and, as a result, will need to complete a strategic transaction or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, rNAPc2 or any of its other product candidates, if approved. Failure to successfully provide for the commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, would damage ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in its future clinical trial of Gencaro, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may encounter difficulty enrolling a sufficient number of patients in its clinical trials, due to circumstances which are outside its control, including other clinical trials that may limit the availability of study participants. As a result, ARCA may need to delay or terminate its trials, which would have a negative impact on its business. Delays in enrolling patients in the clinical trial would also adversely affect ARCA&#8217;s ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s clinical trials from its product candidates may not yield results that will enable ARCA to further develop its products as a therapy and obtain regulatory approvals necessary to be used as a drug.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will receive regulatory approval for its product candidates only if it can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. ARCA does not know whether any future clinical trials for Gencaro, rNAPc2 or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results from preclinical testing and early clinical trials may not be predictive of results from later studies. ARCA may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, ARCA may decide to repeat or redesign a trial or discontinue development of one or more of ARCA&#8217;s product candidates. If ARCA fails to adequately demonstrate the safety and efficacy of its product candidates, ARCA will not be able to obtain the required regulatory approvals to commercialize those product candidates and ARCA&#8217;s business, results of operations and financial condition would be materially adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, administering ARCA&#8217;s product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of ARCA&#8217;s product candidates, and could result in the FDA or other regulatory authorities denying approval of ARCA&#8217;s product candidates, for any or all targeted indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA may not achieve its projected development goals in the time frames it announces and expects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA sets goals for, and makes public statements regarding, the timing of certain accomplishments, such as the initiation of its clinical trials, the steps for commencing and continuing its clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which ARCA sometimes refers to as milestones. These milestones may not be achieved, and the actual timing of these events can vary </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">dramatically due to a number of factors such as delays or failures in ARCA&#8217;s clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale<span class="nobreak">-up</span>, delays in achieving manufacturing or marketing arrangements sufficient to commercialize ARCA&#8217;s products or ARCA&#8217;s inability to obtain sufficient financing in a timely manner. There can be no assurance that ARCA will make regulatory submissions or receive regulatory approvals as planned. If ARCA fails to achieve one or more of these milestones as planned, its business will be materially adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects a Phase&#160;3 PRECISION-AF clinical trial will require substantially more capital, and ARCA cannot guarantee when or if it will be able to secure such additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will need to secure additional financing in order to initiate enrollment of its Phase&#160;3 PRECISION<span class="nobreak">-AF</span> clinical trial. Even if ARCA can<span class="BoldItalic" style="font-style:italic;font-weight:bold;"> </span>begin enrolling patients, it expects to have to raise significant additional capital to continue enrollment. If ARCA is not able to obtain financing in the future or on acceptable terms, it may have to terminate the clinical trial early, which could adversely affect its business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions or partnerships, to continue development of Gencaro, rNAPc2 or any of its other product candidates. If ARCA is unable to raise such financing or complete such a transaction, it may not be able to continue operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the expected development timeline to potentially obtain FDA approval for Gencaro or rNAPc2, if at all, the substantial additional costs associated with the development of ARCA&#8217;s product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing Gencaro or rNAPc2, if approved, ARCA will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If ARCA is delayed in obtaining funding or are unable to complete a strategic transaction, it may discontinue its development activities on Gencaro, rNAPc2 and its other product candidates or discontinue its operations. Even if ARCA is able to fund continued development of Gencaro, rNAPc2 or any of ARCA&#8217;s other product candidates, ARCA expects that it will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities or partnership to successfully commercialize Gencaro, rNAPc2 or any other product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial clinical trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, ARCA common stock in an &#8220;at the market offering.&#8221; As of December&#160;31, 2022, ARCA sold an aggregate of 9,928,272<span class="nobreak"> </span>shares of ARCA common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. Sales of ARCA common stock dilute the ownership interest of ARCA stockholders and may cause the price per share of ARCA common stock to decrease. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 and ARCA&#8217;s other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to ARCA stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of its capital stock and could contain covenants that would restrict its operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has received a Special Protocol Assessment agreement from the FDA relating to its planned Phase&#160;3 program for Gencaro. This Special Protocol Assessment agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2019, ARCA received a Special Protocol Assessment (&#8220;SPA&#8221;) agreement from the FDA for its planned Phase&#160;3 clinical trial of Gencaro. The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45&#160;days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter ARCA&#8217;s SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, ARCA fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by ARCA in its request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA obtained an agreement on its SPA, ARCA cannot assure you that its planned Phase&#160;3 clinical trial will succeed, will be deemed binding by the FDA under its SPA agreement or will result in any FDA approval for Gencaro. ARCA may also alter the design of the trial to focus on endpoints that are not covered by the SPA.&#160;Moreover, if the FDA revokes or alters its agreement under ARCA&#8217;s SPA, or interprets the data collected from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the clinical trial differently than ARCA does, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to maintain the requirements for listing on the Nasdaq Capital Market, it could be delisted, which could have a material adverse effect on its ability to consummate the Merger, raise additional funds as well as the price and liquidity of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of ARCA common stock on the Nasdaq Capital Market, ARCA is required to meet certain listing requirements, including, among others, (i)&#160;a minimum closing bid price of $1.00 per share, (ii)&#160;a market value of publicly held shares (excluding shares held by ARCA&#8217;s executive officers, directors and 10% or more stockholders) of at least $1&#160;million and (iii)&#160;either: (x)&#160;stockholders&#8217; equity of at least $2.5&#160;million; or (y)&#160;a total market value of listed securities of at least $35&#160;million. In addition, pursuant to the terms of the Merger Agreement ARCA is required to use commercially reasonable efforts to maintain its listing on Nasdaq until the First Merger Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, ARCA received notification from Nasdaq of potential delisting of its shares from the Nasdaq Capital Market because the closing bid price of ARCA common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30&#160;business days. ARCA subsequently regained compliance with Nasdaq&#8217;s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1<span class="nobreak">-for-6</span> reverse split of ARCA common stock in March&#160;2013, a 1<span class="nobreak">-for-7</span> reverse split of ARCA common stock in September&#160;2015 and a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019. Despite effecting a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019, there can be no assurance that the market price per share of ARCA common stock will remain in excess of the $1.00 minimum bid price for a sustained period of time. The continuing effect of ARCA&#8217;s reverse stock split on the market price of ARCA common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of ARCA common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing ARCA&#8217;s market capitalization, and there can be no assurance that the market price per post<span class="nobreak">-reverse</span> split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of ARCA common stock may vary based on other factors that are unrelated to the number of shares outstanding, including ARCA&#8217;s future performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The delisting of ARCA common stock from a national exchange may impair ARCA&#8217;s ability to consummate the Merger and could impair the liquidity and market price of the common stock. It could also materially adversely affect ARCA&#8217;s access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect ARCA&#8217;s ability to consummate the Merger or raise capital on terms acceptable to ARCA, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In future periods, if ARCA does not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, it would be subject to delisting from the Nasdaq Capital Market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;9, 2024, the closing price of ARCA common stock was $3.37 per share, and the total market value of ARCA&#8217;s listed securities was approximately $48.9&#160;million. As of March&#160;31, 2024, ARCA had stockholders&#8217; equity of $35.1&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. ARCA&#8217;s management has concluded that due to ARCA&#8217;s need for additional capital, and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, there may be uncertainty about ARCA&#8217;s ability to continue as a going concern in future&#160;years.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. The going concern basis of presentation assumes that ARCA will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from ARCA&#8217;s inability to continue as a going concern. As of December&#160;31, 2019, ARCA&#8217;s management and independent </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">registered public accounting firm concluded that, due to ARCA&#8217;s need for additional capital and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, substantial doubt existed as to ARCA&#8217;s ability to continue as a going concern for a period from one year after ARCA&#8217;s annual financial statements had been issued. ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see discussion above regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. ARCA&#8217;s Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuits of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. ARCA cannot be certain that it will be able to make any other sale of ARCA common stock in any future offering to cover its future capital needs, or at all. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. If ARCA is delayed in completing or is unable to complete additional funding and/or a strategic transaction, it may discontinue its development activities or operations, but there are no assurances that these reductions would be sufficient to allow ARCA to continue to operate as a going concern. Therefore, even if ARCA resolves this uncertainty, its independent registered public accountants and/or management could conclude that uncertainty as to its ability to continue as a going concern could exist at a future date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. ARCA may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings. However, ARCA cannot guarantee that it will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on satisfactory terms. If ARCA is unable to raise sufficient additional capital or complete a strategic transaction, it may be unable to continue to fund its operations, develop Gencaro, rNAPc2 or its other product candidates, or realize value from its assets and discharge its liabilities in the normal course of business. If ARCA cannot raise sufficient funds, it may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its financial statements, and stockholders may lose all or part of their investment in ARCA&#8217;s securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March&#160;10, 2023, Silicon Valley Bank (SVB), where ARCA maintains certain accounts, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. If other banks and financial institutions with whom ARCA has banking relationships enter receivership or become insolvent in the future, ARCA may be unable to access, and may lose, some or all of its existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC.&#160;In addition, in such circumstances, ARCA might not be able to timely pay key vendors and others. ARCA regularly maintains cash balances that are not insured or are in excess of the FDIC&#8217;s insurance limit. Any delay in ARCA&#8217;s ability to access its cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on ARCA&#8217;s operations and cause it to need to seek additional capital sooner than planned.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be adversely affected by the effects of health epidemics in regions where ARCA or third parties on which ARCA relies may have clinical trial sites or other business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s business could be adversely affected by health epidemics in regions where ARCA may have concentrations of future clinical trial sites or other business operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, third<span class="nobreak">-party</span> manufacturing of ARCA&#8217;s drug product candidates and suppliers of the materials used in the production of ARCA&#8217;s drug product candidates may be impacted by significant delays or restrictions resulting from any future health epidemic which may disrupt ARCA&#8217;s supply chain or limit ARCA&#8217;s ability to manufacture drug product candidates for its clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ultimate impact of any future health epidemic is highly uncertain and subject to change. These effects could have a material impact on ARCA&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in any future clinical trials, its future trials could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA has difficulty enrolling a sufficient number of patients in any future clinical trial, ARCA may need to delay or terminate its trial, which would have a negative impact on its business. Delays in enrolling patients in any future clinical trials would also adversely affect ARCA&#8217;s ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on ARCA or on any future collaborators.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the development of vaccines for the SARS<span class="nobreak">-CoV-2</span> virus and the development of other therapies for COVID<span class="nobreak">-19</span> disease impacted ARCA&#8217;s ability to enroll patients in its rNAPc2 (AB201) Phase&#160;2b clinical trial and such enrollment was slower than expected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The GENETIC<span class="nobreak">-AF</span> clinical trial required that ARCA identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC<span class="nobreak">-AF</span> was slower than expected, with ARCA&#8217;s first patient enrolled in June&#160;2014 and enrollment completed in August&#160;2017. Because of the rigorous enrollment criteria, ARCA&#8217;s clinical trial timelines were delayed from ARCA&#8217;s original projections. ARCA anticipates that any future Phase&#160;3 clinical trial of Gencaro, including PRECISION<span class="nobreak">-AF</span>, may have similar enrollment criteria, and ARCA cannot guarantee that it will not have similar enrollment issues in any future clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside ARCA&#8217;s control, including as a result of continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will rely on contract research organizations to conduct substantial portions of its clinical trials, including any future clinical trial of Gencaro, rNAPc2, and as a result, ARCA will be unable to directly control the timing, conduct and expense of all aspects of its clinical trials.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently have sufficient staff with the requisite experience to conduct its clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. ARCA previously contracted with a CRO to conduct components of its GENETIC<span class="nobreak">-AF</span> clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for ARCA&#8217;s other product candidates. As a result, ARCA will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if ARCA were relying entirely upon its own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct ARCA&#8217;s clinical trial. ARCA may experience unexpected cost increases that are beyond its control. Problems with the timeliness or quality of the work of a CRO may lead ARCA to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA anticipates relying on CROs in the future, it will likely have to devote substantial resources and rely on the expertise of ARCA&#8217;s employees to manage the work being done by the CROs. Due to ARCA&#8217;s limited experience in managing clinical trials, ARCA cannot guarantee its employees will do so effectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects to depend on existing and future collaborations with third parties for the development of some of ARCA&#8217;s product candidates. If those collaborations are not successful, ARCA may not be able to complete the development of these product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA collaborated with one or more clinical trial networks in its development program for rNAPc2. As a result, ARCA lacked direct control over certain aspects of the development program and the amount and timing of resources that these collaborators devote to the project.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA had a collaboration agreement with Medtronic that supported ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. If ARCA&#8217;s arrangement with Medtronic, as amended, is continued as part of ARCA&#8217;s future development of Gencaro, ARCA will have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties and ARCA may seek additional third<span class="nobreak">-party</span> collaborators for the development of Gencaro, rNAPc2 or any other product candidates. ARCA&#8217;s ability to benefit from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations involving ARCA&#8217;s product candidates pose the following risks to us:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not pursue development and commercialization of ARCA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ARCA&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ARCA&#8217;s;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not properly maintain or defend ARCA&#8217;s intellectual property rights or may use ARCA&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate its proprietary information or expose it to potential litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes may arise between the collaborators and ARCA that result in the delay or termination of the research, development or commercialization of ARCA&#8217;s product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may elect to take over manufacturing rather than retain ARCA as manufacturer and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to issue equity securities to collaborators that would dilute ARCA&#8217;s existing stockholders&#8217; percentage ownership;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to assume substantial actual or contingent liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not commit adequate resources to the marketing and distribution of ARCA&#8217;s product candidates, limiting ARCA&#8217;s potential revenues from these products; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may experience financial difficulties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether ARCA reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of ARCA&#8217;s clinical trials, the potential market for ARCA&#8217;s product candidates, the costs and complexities of manufacturing and delivering ARCA&#8217;s product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of ARCA&#8217;s intellectual property, and industry and market conditions generally. If ARCA were to determine that additional collaborations for its Gencaro development are necessary and were unable to enter into such collaborations on acceptable terms, ARCA might elect to delay or scale back the development or commercialization of Gencaro in order to preserve its financial resources or to allow it adequate time to develop the required physical resources and systems and expertise itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaboration agreements may not lead to development or commercialization of ARCA&#8217;s product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ARCA were to be involved in a business combination, the continued pursuit and emphasis on ARCA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, ARCA will be unable to directly control the timing, conduct and expense of the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA anticipates that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient&#8217;s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta<span class="nobreak">-1</span> 389 Arg receptor as detected by a beta<span class="nobreak">-1</span> 389 Arg/Arg genotype. Accordingly, ARCA anticipates that any future clinical trial for Gencaro will require the use of a third<span class="nobreak">-party</span> diagnostic service to perform the genetic testing. There has been limited experience in ARCA&#8217;s industry in prospective development of companion diagnostics required to perform the required molecular profiling. ARCA entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption (&#8220;IDE&#8221;) for the companion diagnostic test being used in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and similar regulatory authorities outside the United&#160;States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization. Changes to regulatory advice could delay ARCA&#8217;s development programs or delay or prevent eventual marketing approval for ARCA&#8217;s product candidates that may otherwise be approvable. In July&#160;2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA&#8217;s evolving position on the topic of companion </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">diagnostics could affect ARCA&#8217;s clinical development programs that utilize companion diagnostics. In particular, the FDA may limit ARCA&#8217;s ability to use retrospective data, otherwise disagree with ARCA&#8217;s approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make ARCA repeat aspects of a trial or initiate new trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Given ARCA&#8217;s limited experience in developing diagnostics, ARCA expects to rely primarily on third parties for the design and manufacture of the companion diagnostics for its product candidates. If ARCA, or any third parties that ARCA engages to assist it, are unable to successfully develop companion diagnostics for its product candidates that require such diagnostics, or experiences delays in doing so, the development of its product candidates may be adversely affected, its product candidates may not receive marketing approval and it may not realize the full commercial potential of any products that receive marketing approval. As a result, ARCA&#8217;s business could be materially harmed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test for Gencaro. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect ARCA&#8217;s ability to market Gencaro.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The drug label ARCA intends to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, ARCA believes developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third<span class="nobreak">-party</span> diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulatory approval is required for the genetic test to be used in ARCA&#8217;s Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect ARCA&#8217;s business, operating results and prospects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third<span class="nobreak">-party</span> diagnostics provider must obtain FDA Premarket Approval (&#8220;PMA&#8221;), for such test. The FDA may require additional validation of the genetic test ARCA used in GENETIC<span class="nobreak">-AF</span> prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. ARCA anticipates the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect ARCA&#8217;s business, operating results and prospects for commercializing the genetic test.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If a third-party diagnostics provider responsible for the genetic test associated with Gencaro or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any diagnostic for which a third<span class="nobreak">-party</span> diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post<span class="nobreak">-approval</span> clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third<span class="nobreak">-party</span> diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Regulation (&#8220;QSR&#8221;) and International Standards Organization (&#8220;ISO&#8221;) requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third<span class="nobreak">-party</span> diagnostics provider, or certain of its third<span class="nobreak">-party</span> manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm ARCA&#8217;s reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent ARCA from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce ARCA&#8217;s potential to successfully commercialize the product and generate revenue from the product.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for ARCA&#8217;s clinical trials. ARCA believes that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although ARCA anticipates that Gencaro, if approved in a timely manner, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta<span class="nobreak">-blocker</span> class currently on the market. Prescribers may be more familiar with these other beta<span class="nobreak">-blockers</span>, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF.&#160;For instance, the top<span class="nobreak">-line</span> results of ARCA&#8217;s Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL<span class="nobreak">-XL</span>). If ARCA&#8217;s future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta<span class="nobreak">-blocker</span> class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unless ARCA is able to generate sufficient product revenue, it will continue to incur losses from operations and will not achieve or maintain profitability. ARCA is&#160;years away from commercializing a product and generating product revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s historical losses have had, and will continue to have, an adverse effect on ARCA stockholders&#8217; equity and working capital, among other things. ARCA is&#160;years away from commercializing a product and generating any product revenue. As a result, ARCA expects to continue to incur significant operating losses for the foreseeable future. Even if ARCA ultimately receives regulatory approval for Gencaro, rNAPc2 or ARCA&#8217;s other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, ARCA may experience larger than expected future losses and may never reach profitability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase ARCA&#8217;s future development costs or impair ARCA&#8217;s future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of ARCA&#8217;s product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United&#160;States and elsewhere. These regulations also vary in important, meaningful ways from country to country. ARCA is not permitted to market a potential drug in the United&#160;States until it receives approval of a New Drug Application (&#8220;NDA&#8221;) from the FDA for such drug. ARCA has not received an NDA approval from the FDA for Gencaro, rNAPc2 or any of its other product candidates. There can be no guarantees with respect to ARCA&#8217;s product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To receive regulatory approval for the commercial sale of any product candidates, ARCA must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well<span class="nobreak">-controlled</span> clinical trials of the product candidates. This process is expensive and can take many&#160;years, and failure can occur at any stage of the testing. ARCA&#8217;s failure to adequately demonstrate the safety and efficacy of ARCA&#8217;s product candidates will prevent regulatory approval and commercialization of such products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2008, ARCA submitted and the FDA accepted ARCA&#8217;s NDA filing for Gencaro for the treatment of chronic HF.&#160;In 2009, the FDA issued a Complete Response Letter in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase&#160;3 clinical trial of Gencaro in patients with HF.&#160;ARCA completed a Phase&#160;2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF.&#160;ARCA enrolled 267 HF patients with AF in the Phase&#160;2B clinical trial. ARCA reported top<span class="nobreak">-line</span> Phase&#160;2B data in February&#160;2018. In the third quarter of 2018, ARCA submitted a SPA to the FDA for a Phase&#160;3 clinical trial. In 2019, the FDA approved ARCA&#8217;s SPA request for a Phase&#160;3 clinical trial of Gencaro. Even though the FDA approved ARCA&#8217;s SPA, this product candidate will require&#160;years of additional clinical development. Even if ARCA conducts additional studies in accordance with ARCA&#8217;s SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA or its collaborators conduct preclinical studies that do not comply with Good Laboratory Practices (&#8220;GLP&#8221;) or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices (&#8220;GCP&#8221;) or those clinical trials fail to demonstrate clinical significance, it is unlikely that ARCA will be able to obtain FDA approval for product development candidates. ARCA&#8217;s inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm ARCA&#8217;s business. Significant delays in clinical development could materially increase product development costs or allow ARCA&#8217;s competitors to bring products to market before ARCA does, impairing ARCA&#8217;s ability to effectively commercialize any future product candidate. ARCA does not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to ARCA&#8217;s product candidates or similar product candidates of ARCA&#8217;s competitors or failure to follow regulatory guidelines;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of clinical materials to meet pre<span class="nobreak">-established</span> specifications at product release or during ongoing stability studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in reaching agreement on acceptable terms with prospective study sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining approval of ARCA&#8217;s clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other clinical trials seeking to enroll subjects with similar profile;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s clinical trials and clinical investigators to be in compliance with GCP;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unforeseen safety issues, including negative results from ongoing preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>inability to monitor patients adequately during or after treatment;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulty recruiting and monitoring multiple study sites;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s third<span class="nobreak">-party</span> contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, any approvals ARCA may obtain may not cover all of the clinical indications for which it seeks approval or permit it to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, ARCA may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on ARCA&#8217;s commitment to conduct further clinical trials, which ARCA may not have the resources to conduct or which may negatively impact ARCA&#8217;s financial situation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacture and analytical testing of Gencaro and rNAPc2 is performed by third<span class="nobreak">-party</span> suppliers, who must also meet cGMP requirements and pass a pre<span class="nobreak">-approval</span> inspection of their facilities before ARCA can obtain marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United&#160;States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>side effects;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>safety and efficacy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>defects in the design of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the FDA or other regulatory officials may not approve ARCA&#8217;s or ARCA&#8217;s third<span class="nobreak">-party</span> manufacturer&#8217;s processes or facilities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In pursuing clinical development of Gencaro for an AF indication, ARCA will be required to amend the Gencaro HF NDA or prepare a new NDA.&#160;The FDA could approve Gencaro, but without including some or all of the prescribing information that ARCA has requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact ARCA&#8217;s ability to successfully commercialize Gencaro and effectively protect ARCA&#8217;s intellectual property rights in Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s product candidates receive regulatory approval, ARCA would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit its ability to develop and commercialize other potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a product candidate of ARCA&#8217;s is approved by the FDA or by another regulatory authority, ARCA would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow<span class="nobreak">-up</span> or post<span class="nobreak">-marketing</span> clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, ARCA&#8217;s third<span class="nobreak">-party</span> manufacturers and the manufacturing facilities that they use to make ARCA&#8217;s product candidates are regulated by the FDA.&#160;Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by ARCA or its collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. ARCA and its third<span class="nobreak">-party</span> manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post<span class="nobreak">-market</span> information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The marketing and advertising of ARCA&#8217;s drug products by its collaborators or itself will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of ARCA&#8217;s products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S.&#160;Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize ARCA&#8217;s ability to market the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the FDA, state or foreign regulations, the marketing of ARCA&#8217;s drug products by itself or its collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti<span class="nobreak">-kickback</span> law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far<span class="nobreak">-reaching</span> nature of these laws, ARCA may be required to discontinue one or more of its practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against ARCA for violations of these laws, even if ARCA successfully defends against it, could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent&#160;years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. ARCA may become subject to such litigation and, if ARCA is not successful in defending against such actions, those actions may have a material adverse effect on its business, financial condition and results of operations. ARCA could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few&#160;years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of ARCA&#8217;s product candidates or limit ARCA&#8217;s ability to commercialize its products. ARCA cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United&#160;States or elsewhere.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA, its collaborators or its third<span class="nobreak">-party</span> manufacturers fail to comply with applicable continuing regulatory requirements, ARCA&#8217;s business could be seriously harmed because a regulatory agency may:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issue untitled or warning letters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend or withdraw ARCA&#8217;s regulatory approval for approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refuse to approve pending applications or supplements to approved applications filed by ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend ARCA&#8217;s ongoing clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrict ARCA&#8217;s operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek an injunction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue criminal prosecutions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>close the facilities of ARCA&#8217;s contract manufacturers; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>impose civil or criminal penalties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reliance on third parties to commercialize Gencaro, rNAPc2 or ARCA&#8217;s other product candidates could negatively impact ARCA&#8217;s business. If ARCA is required to establish a direct sales force in the United&#160;States and are unable to do so, its business may be harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. ARCA currently intends to pursue a strategic partnership alternative for the commercialization of Gencaro or rNAPc2, if it is approved, and ARCA has suspended its efforts to build internal sales, marketing and distribution capabilities. If ARCA elects to rely on third parties to sell Gencaro, rNAPc2 and any other products, then it may receive less revenue than if it sold such products directly. In addition, ARCA may have little or no control over the sales efforts of those third parties. If ARCA is unable to complete a strategic transaction, ARCA would be unable to commercialize Gencaro, rNAPc2 </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">or any other product candidate without substantial additional capital. Even if such capital were secured, ARCA would be required to build internal sales, marketing and distribution capabilities to market Gencaro or rNAPc2 in the United&#160;States. None of ARCA&#8217;s current employees have experience in establishing and managing a sales force.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event ARCA is unable to sell Gencaro, rNAPc2 and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro or rNAPc2, if approved, may be delayed indefinitely.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is dependent on ARCA&#8217;s key personnel.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of ARCA&#8217;s business is highly dependent on the principal members of ARCA&#8217;s board of directors and executive management. The loss of the services of any such individual might seriously harm ARCA&#8217;s product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and ARCA competes for talent with companies that are larger and have more financial resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has no manufacturing capacity which puts it at risk of lengthy and costly delays of bringing its products to market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently operate manufacturing facilities for clinical or commercial production of its product candidates, including their drug substance or active pharmaceutical ingredients, or API.&#160;ARCA has no experience in drug formulation or manufacturing, and it lacks the resources and the capabilities to manufacture any of its product candidates on a clinical or commercial scale. ARCA does not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. ARCA has contracted with several third<span class="nobreak">-party</span> manufacturing organizations for production and analytical testing of its product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute ARCA&#8217;s products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability, may not be able to manufacture ARCA&#8217;s products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock<span class="nobreak">-outs</span> or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, ARCA may be unable to find an alternative third<span class="nobreak">-party</span> manufacturer in a timely manner and the production of its product candidates would be interrupted, resulting in delays and additional costs, which could impact ARCA&#8217;s ability to commercialize and sell its product candidates. ARCA or its contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt ARCA&#8217;s business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, ARCA&#8217;s contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S.&#160;Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If ARCA&#8217;s contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, ARCA may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize ARCA&#8217;s regulatory approval for Gencaro, rNAPc2 and other product candidates, and ARCA may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of potential manufacturers is limited and ARCA may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>long lead times are often needed to manufacture drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the manufacturing process is complex and may require a significant learning curve; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of ARCA&#8217;s control and, consequently, ARCA can provide no assurance of its successful and timely transition from a clinical development stage company.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a clinical development stage biopharmaceutical company with a limited operating history. To date ARCA has not generated any product revenue and has historically funded ARCA&#8217;s operations through investment capital. ARCA&#8217;s future growth depends on its ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of Gencaro, rNAPc2 and ARCA&#8217;s other product candidates, which in turn will depend, among other things, on ARCA&#8217;s ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct additional clinical trials and develop and obtain regulatory approval for Gencaro, rNAPc2 or other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully partner a companion genetic test with the commercial launch of Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into a strategic transaction enabling the continued development and commercialization of Gencaro or rNAPc2, or alternatively, raise significant additional capital to enable these activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue additional indications for Gencaro or rNAPc2 and develop other product candidates, including other cardiovascular therapies; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain commercial quantities of Gencaro, rNAPc2 or other product candidates at acceptable cost levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any one of these factors or other factors discussed in this report could affect ARCA&#8217;s ability to successfully commercialize Gencaro and other product candidates, which could impact ARCA&#8217;s ability to earn sufficient revenues to transition from a clinical development stage company and continue ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If approved by the FDA, Gencaro or rNAPc2 will be entering a competitive marketplace and may not succeed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a new type of beta<span class="nobreak">-blocker</span> and vasodilator being developed for AF.&#160;While ARCA anticipates that this drug, if approved, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, and potentially the only beta<span class="nobreak">-blocker</span> approved for AF, Gencaro will be one of a number of accepted treatments for AF.&#160;In addition, ARCA&#8217;s proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that ARCA believes responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID<span class="nobreak">-19</span> disease. ARCA does not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While ARCA anticipates that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other vaccines and therapies under development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of ARCA common stock and the value of ARCA&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of ARCA&#8217;s products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, rNAPc2 or ARCA&#8217;s other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro, rNAPc2 or ARCA&#8217;s other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and/or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side<span class="nobreak">-effects</span> could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of Gencaro or rNAPc2 would significantly harm ARCA&#8217;s business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is unable to obtain acceptable prices or adequate reimbursement from third<span class="nobreak">-party</span> payors for Gencaro, rNAPc2, or any other product candidates that it may seek to commercialize, then ARCA&#8217;s revenues and prospects for profitability will suffer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>governmental payors, such as Medicare and Medicaid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>private health insurers, including managed<span class="nobreak">-care</span> organizations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other third<span class="nobreak">-party</span> payors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many patients will not be capable of paying for ARCA&#8217;s potential products themselves and will rely on third<span class="nobreak">-party</span> payors to pay for their medical needs. A primary current trend in the U.S.&#160;health care industry is toward cost containment. Large private payors, managed<span class="nobreak">-care</span> organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third<span class="nobreak">-party</span> payors, including Medicare, are challenging the prices charged for medical products and services, and many third<span class="nobreak">-party</span> payors limit reimbursement for newly approved health care products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cost<span class="nobreak">-control</span> initiatives could decrease the price ARCA might establish for products, which could result in product revenues lower than anticipated. If the prices for ARCA&#8217;s product candidates decrease, or if governmental and other third<span class="nobreak">-party</span> payors do not provide adequate coverage and reimbursement levels, then ARCA&#8217;s revenue and prospects for profitability will suffer.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Health care reform measures could materially and adversely affect ARCA&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third<span class="nobreak">-party</span> payors to contain or reduce the costs of health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While ARCA anticipates that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health<span class="nobreak">-related</span> industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test (as defined elsewhere in this proxy statement/prospectus) is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and ARCA expects that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs is subject to government control and ARCA expects to see continued efforts to reduce healthcare costs in international markets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although ARCA is unable to predict what additional legislation or regulation, if any, relating to the health care industry or third<span class="nobreak">-party</span> coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on ARCA&#8217;s business. ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third<span class="nobreak">-party</span> payors, and any change in reimbursement levels could materially and adversely affect ARCA&#8217;s business. Further, the pendency or approval of future proposals or reforms could result in a decrease in ARCA&#8217;s stock price or limit ARCA&#8217;s ability to raise capital or to obtain strategic partnerships or licenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s competitors may be better positioned in the marketplace and thereby may be more successful than ARCA at developing, manufacturing and marketing approved products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many of ARCA&#8217;s competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than ARCA.&#160;Other early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with ARCA in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to ARCA&#8217;s programs or advantageous to ARCA&#8217;s business. ARCA expects that its ability to compete effectively will depend upon its ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost<span class="nobreak">-effective</span> manner;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develop competitive formulations of ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attract and retain key personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identify and obtain other product candidates on commercially reasonable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA fails to identify and license or acquire other products or product candidates, then it may be unable to expand its business, and the acquisition or licensing of other products or product candidates may put a strain on its operations and will likely require it to seek additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of ARCA&#8217;s strategies is to license or acquire clinical<span class="nobreak">-stage</span> products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of ARCA&#8217;s competitors may have greater resources than ARCA does. If ARCA undertakes any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into ARCA&#8217;s business may put a strain on ARCA&#8217;s operations, divert personnel, financial resources and management&#8217;s attention. In 2020, ARCA&#8217;s research and development activities were dedicated to initiating the clinical trial of rNAPc2. If ARCA is not able to substantially expand ARCA&#8217;s research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then it will likely be unable expand its pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require ARCA to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect ARCA&#8217;s operating results.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA would be subject to applicable regulatory approval requirements of the foreign countries in which it markets its products, which are costly and may prevent or delay ARCA from marketing its products in those countries.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulatory requirements in the United&#160;States, ARCA would be subject to the regulatory approval requirements in each foreign country where it markets its products. In addition, ARCA might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture ARCA&#8217;s products and any companion genetic test for Gencaro. If ARCA decides to pursue regulatory approvals and commercialization of its product candidates internationally, it may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause ARCA to incur additional costs or prevent it from marketing it products in foreign countries, which may have a material adverse effect on its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA&#8217;s business and stock price could be adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002 requires ARCA to evaluate the effectiveness of its internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of its internal control over financial reporting in its annual report on Form&#160;10<span class="nobreak">-K</span> for that fiscal year. ARCA&#8217;s management, including ARCA&#8217;s principal executive officer and principal financial officer, does not expect that ARCA&#8217;s internal control over financial reporting will prevent all error and all fraud. ARCA continues to operate with a small staff for financial reporting. Though the process and design of ARCA&#8217;s internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit ARCA&#8217;s ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in ARCA&#8217;s internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and ARCA cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost<span class="nobreak">-effective</span> control system, misstatements due to error or fraud may occur and not be detected. ARCA cannot assure you that it or its independent registered public accounting firm will not identify a material weakness in ARCA&#8217;s internal control over financial reporting in the future. A material weakness in ARCA&#8217;s internal control over financial reporting would require management to consider ARCA&#8217;s internal control over financial reporting as ineffective. If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA may experience a loss of public confidence, which could have an adverse effect on its business and on the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations that are applied adversely to ARCA or its customers may have a material adverse effect on ARCA&#8217;s business, cash flow, financial condition or results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of ARCA&#8217;s domestic and foreign earnings. Any new taxes could adversely affect ARCA&#8217;s domestic and international business operations, and ARCA&#8217;s business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to ARCA.&#160;For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect ARCA, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to ARCA&#8217;s operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of ARCA&#8217;s deferred tax assets, could result in significant one<span class="nobreak">-time</span> charges, and could increase ARCA&#8217;s future U.S.&#160;tax expense.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s ability to use ARCA&#8217;s net operating losses to offset future taxable income may be subject to certain limitations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had net operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax&#160;years beginning after December&#160;31, 2017, is limited to 80% of taxable income. In addition, under Section&#160;382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre<span class="nobreak">-change</span> NOLs to offset future taxable income. ARCA has not determined whether it has experienced an ownership change in the past, and ARCA may experience ownership changes in the future as a result of subsequent shifts in ARCA&#8217;s stock ownership, some of which may be outside of ARCA&#8217;s control. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, ARCA&#8217;s existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, ARCA may not be able to utilize a material portion of the NOLs reflected on its balance sheet, offset by a full valuation, even if it attains profitability, which could potentially result in increased future tax liability to ARCA and could adversely affect its operating results and financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Security breaches, cyber-attacks, or other disruptions or incidents could expose ARCA to liability and affect its business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is increasingly dependent on its information technology systems and infrastructure for its business. ARCA, its collaborators and its service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with ARCA&#8217;s business operations. The secure maintenance of this information is critical to ARCA&#8217;s operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees, nation<span class="nobreak">-state</span> and nation<span class="nobreak">-state</span> supported actors, and others. Cyber<span class="nobreak">-attacks</span> are of ever<span class="nobreak">-increasing</span> levels of sophistication, and despite ARCA&#8217;s security measures, ARCA&#8217;s information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has implemented information security measures to protect ARCA&#8217;s systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever<span class="nobreak">-changing</span> information cyber<span class="nobreak">-threat</span> landscape, ARCA cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and ARCA may be subject to data breaches through cyber<span class="nobreak">-attacks</span>, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise ARCA&#8217;s networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If ARCA&#8217;s systems become compromised, ARCA may not promptly discover the intrusion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any security breach of other incident, whether real or perceived, could cause ARCA to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under ARCA&#8217;s contracts with other parties and federal and state laws that protect the privacy and security of personal information. Any one of these events could cause ARCA&#8217;s business to be materially harmed and its results of operations would be adversely impacted.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and its partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to ARCA&#8217;s operations or the operations of ARCA&#8217;s partners. In addition, ARCA may obtain health information from third parties (including research institutions from which ARCA obtains clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended, or HIPAA.&#160;Depending on the facts and circumstances, ARCA could be subject to criminal penalties if it knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA<span class="nobreak">-covered</span> entity in a manner that is not authorized or permitted by HIPAA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the California Consumer Privacy Act, or the CCPA, became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt<span class="nobreak">-out</span> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase ARCA&#8217;s compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Foreign data protection laws, including, without limitation, the European Union Directive 95/46/EC (the &#8220;Directive&#8221;) and the European Union&#8217;s General Data Protection Regulation (the &#8220;GDPR&#8221;) that became effective in May&#160;2018, and member state data protection legislation, may also apply to health<span class="nobreak">-related</span> and other personal information obtained outside of the United&#160;States. These laws impose strict obligations on the ability to process health<span class="nobreak">-related</span> and other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross<span class="nobreak">-border</span> transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United&#160;States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United&#160;States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United&#160;States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross<span class="nobreak">-border</span> data transfers, such as the European Union<span class="nobreak">-U</span>.S.&#160;and Swiss<span class="nobreak">-U</span>.S.&#160;Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the GDPR, regulators may impose substantial fines and penalties for non<span class="nobreak">-compliance</span>. Companies that violate the GDPR can face fines of up to the greater of 20&#160;million Euros or 4% of their worldwide annual turnover (revenue). The GDPR increases ARCA&#8217;s responsibility and potential liability in relation to personal data that ARCA processes, and ARCA may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compliance with U.S.&#160;and foreign privacy and security laws, rules and regulations could require ARCA to take on more onerous obligations in its contracts, require it to engage in costly compliance exercises, restrict its ability to collect, use and disclose data, or in some cases, impact its or its partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U.S.&#160;and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business. Moreover, patients about whom ARCA or its partners obtain information, as well as the providers who share this information with ARCA, may contractually limit ARCA&#8217;s </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ability to use and disclose the information. Claims that ARCA has violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached its contractual obligations, even if ARCA is not found liable, could be expensive and time<span class="nobreak">-consuming</span> to defend and could result in adverse publicity that could harm ARCA&#8217;s business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Intellectual Property and Other Legal Matters</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against ARCA, then ARCA will incur substantial liabilities and may be required to limit commercialization of Gencaro, rNAPc2 or other product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces product liability exposure related to the testing of its product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once it begins marketing and distributing ARCA&#8217;s products commercially. If ARCA cannot successfully defend against product liability claims, then it will incur substantial liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or eventual outcome, liability claims may result in:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>decreased demand for ARCA&#8217;s products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injury to ARCA&#8217;s reputation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>withdrawal of clinical trial participants;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>costs of related litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantial monetary awards to patients and others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>loss of revenues; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the inability to commercialize ARCA&#8217;s products and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to ARCA in sufficient amounts or at an acceptable cost, or at all. ARCA may not be able to obtain commercially reasonable product liability insurance for any product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. ARCA cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. ARCA may be sued or be required to pay fines for any injury or contamination that results from its use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair ARCA&#8217;s research, development and production efforts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The loss of any rights to market key products would significantly impair ARCA&#8217;s operating results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Termination of ARCA&#8217;s license agreements could result in the loss of its further rights to develop and commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables ARCA to market a key product or product candidate, could significantly and adversely affect its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain intellectual property licensed by ARCA is the subject of additional licensing arrangements to which the party that has licensed rights to ARCA is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, ARCA&#8217;s and ARCA&#8217;s partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and ARCA&#8217;s business would be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Third parties may own or control patents or patent applications that ARCA may be required to license to commercialize ARCA&#8217;s product candidates or that could result in litigation that would be costly and time consuming.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2 and other product candidates depends upon ARCA&#8217;s ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to ARCA.&#160;ARCA may choose to seek, or be required to seek, licenses under third<span class="nobreak">-party</span> patents, which would likely require the payment of license fees or royalties or both. ARCA may also be unaware of existing patents that may be infringed by Gencaro or rNAPc2, the genetic testing ARCA intends to use in connection with Gencaro or its other product candidates. Because patent applications can take many&#160;years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro, rNAPc2 or ARCA&#8217;s other product candidates. Moreover, a license may not be available to ARCA on commercially reasonable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that ARCA is infringing on its technology, then ARCA&#8217;s business and results of operations could be harmed by a number of factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>infringement and other intellectual property claims, even if without merit, are expensive and time<span class="nobreak">-consuming</span> to litigate and can divert management&#8217;s attention from ARCA&#8217;s core business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>monetary damage awards for past infringement can be substantial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a court may prohibit ARCA from selling or licensing product candidates unless the patent holder chooses to license the patent to ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if a license is available from a patent holder, ARCA may have to pay substantial royalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also be forced to bring an infringement action if its believes that a competitor is infringing ARCA&#8217;s protected intellectual property. Any such litigation will be costly, time<span class="nobreak">-consuming</span> and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to ARCA.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s intellectual property rights may not preclude competitors from developing competing products and ARCA&#8217;s business may suffer.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s competitive success will depend, in part, on ARCA&#8217;s ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that ARCA licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and ARCA cannot be certain that its patents and licenses will successfully preclude others from using its technology. Consequently, ARCA cannot be certain that any of its patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United&#160;States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, ARCA cannot be certain of the priority of inventions covered by pending patent applications. Moreover, ARCA may have to participate in interference proceedings declared by the U.S.&#160;Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post<span class="nobreak">-grant</span> challenge proceeding such as an <span class="Italic" style="font-style:italic;font-weight:normal;">ex parte</span> reexamination or <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review at the U.S.&#160;Patent and Trademark Office, any of which could result in substantial cost to ARCA, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid and enforceable. An adverse outcome could subject ARCA to significant liabilities to third parties, require disputed rights to be licensed from third parties or require ARCA to cease using such technology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA owns the clinical development program of rNAPc2, including Phase&#160;2b clinical trials. If rNAPc2 is successfully developed, ARCA believes it will have intellectual property protection for a specific use, including 12&#160;years of market exclusivity as an innovative biologic product under FDA law in the United&#160;States, 10&#160;years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by ARCA&#8217;s exclusivity. ARCA has also filed a patent application for rNAPc2 and its use for COVID<span class="nobreak">-19</span> disease, but there is no assurance that this application will ultimately result in an issued patent.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. ARCA may have to defend against such claims and possible associated antitrust issues. ARCA could also incur substantial costs in seeking to enforce its proprietary rights against infringement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the composition of matter patents on the compound that comprises Gencaro have expired, ARCA holds intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta<span class="nobreak">-1</span> and alpha<span class="nobreak">-2C</span> receptors. ARCA has obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. ARCA anticipates that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. ARCA believes that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved or it is approved after the relevant patents expire, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and ARCA&#8217;s business may suffer. The approved label may not contain language covered by the patents, or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has obtained intellectual property related to the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3. The approved label may not contain language covered by ARCA&#8217;s patents and it is possible the intellectual property may not preclude others from commercializing a generic version of Gencaro, which could cause ARCA&#8217;s business to suffer. Additionally, the patents may be invalidated and/or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may not be able to effectively protect its intellectual property rights in some foreign countries, as its patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA requires its employees, consultants, business partners and members of its scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with ARCA.&#160;These agreements provide that all confidential information developed or made known during the course of the relationship with ARCA be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for ARCA, utilizing the property or relating to ARCA&#8217;s business and conceived or completed by the individual during employment shall be ARCA&#8217;s exclusive property to the extent permitted by applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third parties may breach these and other agreements with ARCA regarding its intellectual property and ARCA may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect ARCA&#8217;s licensed intellectual property, which could seriously harm ARCA&#8217;s intellectual property position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is not able to protect its proprietary technology, trade secrets and know<span class="nobreak">-how</span>, then its competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with ARCA.&#160;Further, ARCA has trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. ARCA&#8217;s issued patents and those that may issue in the future, or those licensed to ARCA, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of ARCA&#8217;s product candidates. All of these factors may affect ARCA&#8217;s competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the manufacture, use or sale of ARCA&#8217;s products infringe on the intellectual property rights of others, ARCA could face costly litigation, which could cause it to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know<span class="nobreak">-how</span> and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S.&#160;Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination, <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review, or post<span class="nobreak">-grant</span> review) in the United&#160;States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time<span class="nobreak">-consuming</span> to pursue, and their outcome is uncertain.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or outcome, ARCA&#8217;s involvement in any litigation, interference or other administrative proceedings could cause it to incur substantial expense and could significantly divert the efforts of its technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against ARCA could cause ARCA&#8217;s stock price to decline. Adverse outcomes in patent litigation may potentially subject ARCA to antitrust litigation which, regardless of the outcome, would adversely affect ARCA&#8217;s business. An adverse determination may subject ARCA to the loss of its proprietary position or to significant liabilities, or require it to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent ARCA from manufacturing and selling its products, if any. These outcomes could materially harm ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Ownership of ARCA Common Stock and Stock Price Volatility</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s stock price has been and is expected to be volatile.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock has in the past been, and in the future could be, subject to significant fluctuations. Market prices for securities of early<span class="nobreak">-stage</span> pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to complete, or delays in completing, the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory status of Gencaro, rNAPc2 and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>progress of any future clinical trials for Gencaro, rNAPc2 or ARCA&#8217;s other product candidate, including enrollment and any data that may become available;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of ARCA&#8217;s future clinical trials and any future NDAs of ARCA&#8217;s current and future product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including key strategic alliance agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results and timing of regulatory reviews relating to ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of any of ARCA&#8217;s product candidates, if approved, to achieve commercial success;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of clinical trials conducted by others on drugs that would compete with ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issues in manufacturing or testing ARCA&#8217;s product candidates or any approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation of or material developments in or the conclusion of litigation to enforce or defend any of ARCA&#8217;s intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new commercial products by ARCA&#8217;s competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in estimates or recommendations by securities analysts, if any, who cover ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the structure of health care payment systems;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in ARCA&#8217;s financial results; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm ARCA&#8217;s profitability and reputation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales or the possibility of future sales of ARCA common stock may depress the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales in the public market of substantial amounts of ARCA common stock could depress prevailing market prices of ARCA common stock. As of March&#160;31, 2024, approximately 14.5<span class="nobreak"> </span>million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act&#160;of&#160;1933, as amended, or the Securities Act, except for shares held by ARCA&#8217;s directors, officers and other affiliates and unregistered shares held by non<span class="nobreak">-affiliates</span>. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there were approximately 646,000<span class="nobreak"> </span>shares of ARCA common stock which may be issued upon the exercise of outstanding stock options, and ARCA anticipates that it will continue to issue stock option and restricted stock unit awards to its employees and consultants in the fiscal year ended December&#160;31, 2024 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect ARCA&#8217;s ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of ARCA common stock received, may also result in downward pressure on the price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the absence of a significant strategic transaction, ARCA will need to raise significant additional capital to finance the research, development and commercialization of Gencaro, rNAPc2 and its other product candidate. If future securities offerings occur, they would dilute ARCA&#8217;s current stockholders&#8217; equity interests and could reduce the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA does not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. As a result, other than the potential special cash dividend described below, only appreciation of the price of ARCA common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in ARCA common stock. In addition, pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the closing of the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. See, &#8220;ARCA has never paid and, other than in connection with the Merger with Oruka, do not intend to pay any cash dividends in the foreseeable future&#8221; for further discussion on the special cash dividend.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be negatively affected as a result of actions of activist shareholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Responding to actions by activist shareholders could be costly and time<span class="nobreak">-consuming</span>, disrupt ARCA&#8217;s operations and divert the attention of management and ARCA&#8217;s employees. For example, in connection with the negotiation and entry into a cooperation agreement in June&#160;2022 with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>, collectively, Cable Car, one of ARCA&#8217;s stockholders, ARCA appointed two new directors in 2022. Activist shareholders may advocate for certain governance and strategic changes at ARCA.&#160;In the event of stockholder activism, particularly with respect to matters which ARCA&#8217;s board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, ARCA&#8217;s business could be adversely affected because responding to actions by activist stockholders can be costly and time<span class="nobreak">-consuming</span>, disrupting ARCA&#8217;s </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and diverting the attention of management, and perceived uncertainties as to ARCA&#8217;s future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, if faced with a consent solicitation or proxy contest, ARCA may not be able to respond successfully to the contest or dispute, which would be disruptive to its business. If individuals are elected to ARCA&#8217;s board of directors with a differing agenda, ARCA&#8217;s ability to effectively and timely implement its strategic plan and create additional value for ARCA stockholders may be adversely affected. In addition, ARCA&#8217;s share price could experience periods of increased volatility as a result of shareholder activism.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to ARCA stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions of the ARCA Charter and ARCA Bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire ARCA, even if doing so would benefit ARCA stockholders. These provisions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish a classified board of directors so that not all members of ARCA&#8217;s board may be elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by ARCA&#8217;s board of directors to increase the number of outstanding shares and hinder a takeover attempt;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of ARCA stockholders; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish advance notice requirements for nominations for election to ARCA&#8217;s board of directors or for proposing matters that can be acted upon at a stockholder meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, the ARCA Charter provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The ARCA Bylaws provide, however, that ARCA stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of ARCA&#8217;s outstanding common stock. These provisions of the ARCA Charter and ARCA Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. ARCA designed these provisions to reduce its vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for ARCA&#8217;s shares. As a consequence, they also may inhibit fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in ARCA&#8217;s management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is permitted to issue shares of ARCA preferred stock without stockholder approval upon such terms as ARCA&#8217;s board of directors determines. Therefore, the rights of the holders of ARCA common stock are subject to, and may be adversely affected by, the rights of the holders of ARCA preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of ARCA&#8217;s current stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the Delaware anti<span class="nobreak">-takeover</span> laws regulating corporate takeovers. These anti<span class="nobreak">-takeover</span> laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three&#160;years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on or after this date, the merger or sale is approved by the board of directors and the holders of at least two<span class="nobreak">-thirds</span> of the outstanding voting stock that is not owned by the stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The provisions of ARCA&#8217;s governing documents and current Delaware law may, collectively:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lengthen the time required for a person or entity to acquire control of ARCA through a proxy contest for the election of a majority of ARCA&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>discourage bids for ARCA common stock at a premium over market price; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>generally deter efforts to obtain control of ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if the Merger and Oruka pre-closing financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka had $27.7&#160;million of cash. Should this financing be successful, Oruka will need to raise additional capital to continue to fund its operations and service its debt obligations in the future. If Oruka is unable to raise additional capital when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. As a result, Oruka has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statement as of February<span class="nobreak"> </span>6, 2024 is available to be issued. In light of these concerns, Oruka&#8217;s independent registered public accounting firm included in its opinion on the financial statement an explanatory paragraph expressing substantial doubt about Oruka&#8217;s ability to continue as a going concern beyond twelve months from the date Oruka&#8217;s financial statement is available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Developing Oruka&#8217;s product candidates requires a substantial amount of capital. Following the Merger and Oruka pre<span class="nobreak">-closing</span> financing, the combined company will also incur additional costs associated with operating as a public company. Oruka expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its product candidates through clinical trials. Oruka will need to raise additional capital to fund its operations and such funding may not be available to Oruka on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S.&#160;capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. Oruka may be unable to raise capital through public offerings of its common stock and may need to turn to alternative financing arrangements. Such arrangements, if Oruka pursues them, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for Oruka common stock. In addition, if Oruka issues debt securities, the holders of the debt would have a claim to Oruka&#8217;s assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make<span class="nobreak">-whole</span> has been paid. Interest on any newly<span class="nobreak">-issued</span> debt securities and/or newly<span class="nobreak">-incurred</span> borrowings would increase Oruka&#8217;s operating costs and reduce its net income (or increase its net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of Oruka common stock, the market price of Oruka common stock could be materially and adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently have any products approved for sale and does not generate any revenue from product sales. Accordingly, Oruka expects to rely primarily on equity and/or debt financings to fund its continued operations. Oruka&#8217;s ability to raise additional funds will depend, in part, on the success of its preclinical studies and clinical trials and other product development activities, regulatory events, its ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect its value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond Oruka&#8217;s control. There can be no assurances that sufficient funds will be available to Oruka when required or on acceptable terms, if at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka is unable to raise additional capital when required or on acceptable terms, it may be required to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significantly delay, scale back, or discontinue the development or commercialization of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that Oruka otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>dispose of technology assets, or relinquish or license on unfavorable terms, Oruka&#8217;s rights to technologies or any of its product candidates that it otherwise would seek to develop or commercialize itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue the sale of the company to a third party at a price that may result in a loss on investment for Oruka&#8217;s stockholders; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>file for bankruptcy or cease operations altogether (and face any related legal proceedings).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could have a material adverse effect on Oruka&#8217;s business, operating results, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if successful in raising new capital, Oruka could be limited in the amount of capital it raises due to investor demand restrictions placed on the amount of capital it raises or other reasons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span>&#8221;</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka has never generated any revenue from product sales and may never be profitable.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products approved for commercialization and has never generated any revenue from product sales. Oruka&#8217;s ability to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of its product candidates. Oruka does not anticipate generating revenue from product sales for the foreseeable future. Oruka&#8217;s ability to generate future revenue from product sales depends heavily on its success in many areas, including but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completing research and development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining regulatory and marketing approvals for its product candidates for which it completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and Oruka&#8217;s supply needs in sufficient quantities to meet market demand for its product candidates, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>qualifying for adequate coverage and reimbursement by government and third<span class="nobreak">-party</span> payors for any product candidates for which Oruka obtains regulatory and marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>marketing, launching, and commercializing product candidates for which Oruka obtains regulatory and marketing approval, either directly or with a collaborator or distributor;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>gaining market acceptance of Oruka&#8217;s product candidates as treatment options;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>addressing any competing products and technological and market developments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>implementing internal systems and infrastructure, as needed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>protecting and enforcing Oruka&#8217;s intellectual property rights, including patents, trade secrets, and&#160;know<span class="nobreak">-how</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiating favorable terms in any collaboration, licensing, or other arrangements into which Oruka may enter;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors and maintaining pricing for Oruka&#8217;s product candidates that supports profitability; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attracting, hiring, and retaining qualified personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if one or more of the product candidates that Oruka develops is approved for commercial sale, Oruka anticipates incurring significant costs associated with commercializing any approved product candidate. Oruka&#8217;s expenses could increase beyond expectations if it is required by regulatory authorities to perform clinical and other studies in addition to those that Oruka anticipates. Even if Oruka is able to generate revenues from the sale of any approved products, it may not become profitable and may need to obtain additional funding to continue operations. Oruka will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of its product candidates. For instance, if the costs of manufacturing Oruka&#8217;s drug product are not commercially feasible, Oruka will need to develop or procure its drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if Oruka is not able to generate revenue from the sale of any approved products, it may never become profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history. Since February&#160;6, 2024 (inception), Oruka has incurred significant operating losses. For the period between February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka reported a net loss of $7.1&#160;million and had an accumulated deficit of $7.1&#160;million. Oruka will need to raise substantial additional capital to continue to fund its operations in the future. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on Oruka&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause Oruka to consume capital significantly faster or slower than it currently anticipates. If Oruka is unable to acquire additional capital or resources, it will be required to modify its operational plans to complete future milestones and it may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. Oruka has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Oruka may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings or entering into strategic collaborations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has devoted substantially all of its financial resources to identify, acquire, and develop its product candidates, organizing and staffing its company, and providing general and administrative support for its operations. To date, Oruka has funded its operations primarily from the sale and issuance of convertible preferred and common equity securities and unsecured convertible notes. The amount of Oruka&#8217;s future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations, or grants.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Oruka expects its losses to increase as its product candidates enter more advanced clinical trials. It may be several&#160;years, if ever, before Oruka completes pivotal clinical trials or has a product candidate approved for commercialization. Oruka expects to invest significant funds into the research and development of its current programs to determine the potential to advance product candidates to regulatory approval. If Oruka obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive approval, and its ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors, and adequate market share for its product candidates in those markets. Even if Oruka obtains adequate market share for its product candidates, because the potential markets in which its product candidates may ultimately receive regulatory approval could be very small, Oruka may never become profitable despite obtaining such market share and acceptance of its products.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to continue to incur significant expenses and increasing operating losses for the foreseeable future and its expenses will increase substantially if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the preclinical development and initiates the clinical development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues efforts to discover and develop new product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the manufacturing of its product candidates or increases volumes manufactured by third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>advances its product candidates into larger, more expensive clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates additional preclinical studies or clinical trials for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks regulatory and marketing approvals and reimbursement for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market for itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to identify, assess, acquire, and/or develop other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>makes milestone, royalty, or other payments under third<span class="nobreak">-party</span> license agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to maintain, protect, and expand its intellectual property portfolio;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>is required to pay penalties under its registration rights agreement for failing to timely register the applicable securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to attract and retain skilled personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays or encounters issues with the development and potential regulatory approval of its clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow<span class="nobreak">-up</span>&#160;for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, Oruka cannot be certain that its planned clinical trials will begin or be completed on time, if at all. In addition, Oruka has not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial<span class="nobreak">-scale</span> product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Oruka&#8217;s future success or viability may not be as accurate as they could be if Oruka had a longer operating history. Further, the net losses Oruka incurs may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period<span class="nobreak">-to-period</span>&#160;comparison of its results of operations may not be a good indication of its future performance.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial revenue from the sale of its product candidates, Oruka expects to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that Oruka raises additional capital through the sale of equity securities or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of Oruka common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its research programs or product candidates or grant licenses on terms that may not be favorable to it. If Oruka is unable to raise additional </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">funds through equity or debt financings or other arrangements with third parties when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that Oruka would otherwise prefer to develop and market itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that Oruka raises additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of its stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of its stockholders. For instance, in March&#160;2024, Oruka sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock and the Convertible Note to Fairmount Fund&#160;II for gross proceeds of $28.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If Oruka raises additional funds through strategic collaborations or licensing arrangements with third parties, Oruka may have to relinquish valuable rights to its product candidates or future revenue streams or grant licenses on terms that are not favorable to Oruka. Oruka cannot assure that it will be able to obtain additional funding if and when necessary to fund its entire portfolio of product candidates to meet its projected plans. If Oruka is unable to obtain funding on a timely basis, it may be required to delay or discontinue one or more of its development programs or the commercialization of any product candidates or be unable to expand its operations or otherwise capitalize on potential business opportunities, which could materially harm Oruka&#8217;s business, financial condition, and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Discovery, Development and Commercialization</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka faces competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by Oruka.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and commercialization of drugs is highly competitive. Product candidates developed by Oruka, if approved, will face significant competition and Oruka&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Oruka competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trial conduct, regulatory approvals, and marketing than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s competitors have developed, are developing or will develop programs and processes competitive with its programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Oruka&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Oruka&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Oruka develops, or if Oruka&#8217;s competitors develop competing products or if biosimilars enter the market more quickly than Oruka does and are able to gain market acceptance. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Competition</span>&#8221; for more discussion about Oruka&#8217;s competitors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because of the competitive landscape for&#160;I&amp;I indications, Oruka may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as Oruka&#8217;s programs. An increase in the number of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approved products for the indications Oruka is targeting with its programs may further exacerbate this competition. Oruka&#8217;s inability to enroll a sufficient number of participants could, among other things, delay its development timeline, which may further harm its competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products on the market, and all of its programs are in preclinical stages of development and have not been tested in humans. As a result, Oruka expects it will be many&#160;years before it commercializes any product candidate, if ever. Oruka&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, its product candidates, either alone or with third parties, and Oruka cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Oruka has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of Oruka&#8217;s product candidates, Oruka or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of Oruka&#8217;s programs and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka or its collaborators may experience delays in initiating or completing clinical trials. Oruka or its collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that they could conduct that could delay or prevent Oruka&#8217;s ability to receive marketing approval or commercialize its product candidates, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize Oruka or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trial sites deviating from trial protocol or dropping out of a trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and Oruka may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Oruka may decide to abandon product development programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of subjects required for clinical trials of any product candidates may be larger than Oruka anticipates, especially if regulatory bodies require completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials, enrollment in these clinical trials may be slower than Oruka anticipates or subjects may drop out of these clinical trials or fail to return for post<span class="nobreak">-treatment</span>&#160;follow<span class="nobreak">-up</span>&#160;at a higher rate than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s third<span class="nobreak">-party</span> contractors may fail to comply with regulatory requirements or meet their contractual obligations to Oruka in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Oruka add new clinical trial sites or investigators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may elect to, or regulators, IRBs or ethics committees may require that Oruka or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Oruka&#8217;s trials are being exposed to unacceptable health risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of clinical trials of any of Oruka&#8217;s programs may be greater than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality of Oruka&#8217;s product candidates or other materials necessary to conduct clinical trials of Oruka&#8217;s product candidates may be inadequate to initiate or complete a given clinical trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s inability to manufacture sufficient quantities of its product candidates for use in clinical trials;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reports from clinical testing of other therapies may raise safety or efficacy concerns about Oruka&#8217;s programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as Oruka&#8217;s product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA or other regulatory authorities may require Oruka to submit additional data such as long<span class="nobreak">-term</span> toxicology studies, or impose other requirements before permitting Oruka to initiate a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commencing clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Oruka to complete additional preclinical studies or it is required to satisfy other FDA requests prior to commencing clinical trials, the start of Oruka&#8217;s first clinical trials may be delayed. Even after Oruka receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Oruka has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Oruka&#8217;s trial design or the clinical endpoints selected, which may require Oruka to complete additional preclinical studies or clinical trials, delay the enrollment of Oruka&#8217;s clinical trials or impose stricter approval conditions than Oruka currently expects. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if it experiences any issues that delay or prevent regulatory approval of, or its ability to commercialize, its product candidates. Oruka or its current or future collaborators&#8217; inability to complete development of, or commercialize Oruka&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is substantially dependent on the success of its two most advanced programs, ORKA-001 and ORKA-002, and its anticipated clinical trials of such programs may not be successful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future success is substantially dependent on its ability to timely obtain marketing approval for, and then successfully commercialize, its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. Oruka is investing a majority of its efforts and financial resources into the research and development of these programs. Oruka anticipates initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA<span class="nobreak">-001</span> in the first half of 2025 and of ORKA<span class="nobreak">-002</span> in the second half of 2025, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of Oruka&#8217;s programs is dependent on observing a longer half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans than other extended half<span class="nobreak">-life</span> monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as Oruka believes this longer half<span class="nobreak">-life</span> has the potential to result in a more favorable dosing schedule for Oruka&#8217;s product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half<span class="nobreak">-life</span> Oruka has observed in&#160;non<span class="nobreak">-human</span>&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans. To the extent Oruka does not observe this extended half<span class="nobreak">-life</span> when it doses humans with its product candidates, it would significantly and adversely affect the clinical and commercial potential of its product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Oruka generates any revenues from product sales. Oruka is not permitted to market or promote these programs, or any other programs, before it receives marketing approval from the FDA and comparable foreign regulatory authorities, and Oruka may never receive such marketing approvals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of Oruka&#8217;s product candidates will depend on a variety of factors. Oruka does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Oruka&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Oruka cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Oruka is not successful in commercializing its ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span> programs, or is significantly delayed in doing so, Oruka&#8217;s business will be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Oruka&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of Oruka&#8217;s Phase&#160;1 studies, clinical trials in PsO and other target indications, as well as the submission of regulatory filings. From time to time, Oruka may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Oruka&#8217;s estimates, in some cases for reasons beyond Oruka&#8217;s control. If Oruka does not meet these milestones as publicly announced, or at all, the commercialization of its product candidates may be delayed or never achieved and, as a result, its stock price may decline. Additionally, delays relative to Oruka&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Oruka to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any drug delivery device that Oruka potentially uses to deliver its product candidates may have its own regulatory, development, supply and other risks.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to deliver its product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Oruka&#8217;s product candidates may not be approved or may be substantially delayed in receiving approval if the devices that Oruka chooses to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single<span class="nobreak">-source</span> unaffiliated third<span class="nobreak">-party</span> companies. Oruka may be dependent on the sustained cooperation and effort of those third<span class="nobreak">-party</span> companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, Oruka may also be dependent on those third<span class="nobreak">-party</span> companies continuing to maintain such approvals or clearances once they have been received. Failure of third<span class="nobreak">-party</span> companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s approach to the discovery and development of its programs is unproven, and Oruka may not be successful in its efforts to build a pipeline of programs with commercial value.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s approach to the discovery and development of the research programs with respect to which it has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half<span class="nobreak">-life</span> and other properties designed to overcome limitations of existing therapies. Oruka&#8217;s programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well<span class="nobreak">-established</span> mechanisms of action. However, the scientific research that forms the basis of Oruka&#8217;s efforts to develop programs using half<span class="nobreak">-life</span> extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half<span class="nobreak">-life</span> extension technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long<span class="nobreak">-term</span> treatment in humans. The long<span class="nobreak">-term</span> safety and efficacy of these technologies and the extended half<span class="nobreak">-life</span> and exposure profile of Oruka&#8217;s programs compared to currently approved products is unknown.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may ultimately discover that utilizing half<span class="nobreak">-life</span> extension technologies for its specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. Oruka currently has only preclinical data regarding the increased half<span class="nobreak">-life</span> properties of its programs and the same results may not be seen in humans. In addition, programs using half<span class="nobreak">-life</span> extension technologies may </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If Oruka&#8217;s discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, Oruka may not be able to develop viable additional programs. Oruka and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Oruka or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Oruka intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Oruka&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Oruka may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, Oruka must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Oruka&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Oruka depends on the availability of NHPs to conduct certain preclinical studies that it is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for Oruka&#8217;s future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to Oruka&#8217;s development timelines.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early<span class="nobreak">-stage</span> clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, Oruka expects to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Oruka&#8217;s control, and can vary widely from&#160;day<span class="nobreak">-to-day</span> for a particular participant, and from participant to participant and from site to site within a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot be sure that the FDA will agree with its clinical development plan. Oruka plans to use the data from its planned Phase&#160;1 trials of its ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> programs in healthy volunteers to support Phase&#160;2 trials in PsO and other&#160;I&amp;I indications. If the FDA requires Oruka to conduct additional trials or enroll additional participants, Oruka&#8217;s development timelines may be delayed. Oruka cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo&#160;</span>or&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro&#160;</span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">testing, releasing, validating or importing/exporting sufficient stable quantities of Oruka&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Oruka&#8217;s CROs, other third parties or Oruka to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by Oruka&#8217;s CMOs or Oruka to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Oruka&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Oruka is required to conduct additional clinical trials or other testing of its product candidates beyond those that Oruka currently contemplates, if Oruka is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Oruka&#8217;s business and results of operations may be adversely affected and it may incur significant additional costs.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka encounters difficulties enrolling participants in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may experience difficulties in patient participant enrollment in its future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Oruka&#8217;s ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants in future trials for any of Oruka&#8217;s programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if Oruka&#8217;s competitors have ongoing clinical trials for programs that are under development for the same indications as its programs, and participants instead enroll in such clinical trials. Additionally, the number of participants required for clinical trials of Oruka&#8217;s programs may be larger than Oruka anticipates, especially if regulatory bodies require the completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials. Even if Oruka is able to enroll a sufficient number of participants for its future clinical trials, it may have difficulty maintaining participants in its clinical trials. Oruka&#8217;s inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require Oruka to abandon one or more clinical trials altogether.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Oruka&#8217;s clinical trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit and verification procedures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then<span class="nobreak">-available</span> data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Oruka also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Oruka reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Oruka may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from Oruka&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Oruka&#8217;s assumptions, estimates, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and Oruka&#8217;s company in general. In addition, the information Oruka chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Oruka determines is material or otherwise appropriate information to include in its disclosure. If the preliminary, topline or interim data that Oruka reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Oruka&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Oruka&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Oruka&#8217;s product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Results of Oruka&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies in NHPs conducted with respect to Oruka&#8217;s programs have not shown any such characteristics to date, Oruka has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of Oruka&#8217;s future clinical trials, Oruka may have difficulty recruiting participants to such trials, participants may drop out of the trials, or Oruka may be required to abandon the trials or its development efforts of one or more programs altogether. Oruka, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early<span class="nobreak">-stage</span> studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half<span class="nobreak">-life</span> could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment<span class="nobreak">-emergent</span> adverse events could also affect participant recruitment or the ability of enrolled subjects to complete Oruka&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Oruka&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Oruka&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Oruka&#8217;s business, financial condition, results of operations and prospects significantly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, even if Oruka successfully advances its product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to Oruka&#8217;s product candidates. As a result, Oruka cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Oruka&#8217;s product candidates over a multi<span class="nobreak">-year</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of the foregoing events occur or if one or more of the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be unsafe, Oruka&#8217;s entire pipeline could be affected, which would have a material adverse effect on its business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Oruka is initially focused on its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. As a result, Oruka may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Oruka&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Oruka&#8217;s spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If Oruka </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any approved products resulting from Oruka&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Oruka may not generate any future revenue from the sale or licensing of such products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Oruka&#8217;s current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. Oruka may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However, Oruka&#8217;s programs incorporate advanced antibody engineering to optimize the half<span class="nobreak">-life</span> and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of new treatments, such as clinicians and third<span class="nobreak">-party</span> payors, may not adopt a biologic that incorporates half<span class="nobreak">-life</span> extension for Oruka&#8217;s targeted indications, and Oruka may not be able to convince the medical community and third<span class="nobreak">-party</span> payors to accept and use, or to provide favorable reimbursement for, any programs developed by it or its existing or future collaborators. An extended half<span class="nobreak">-life</span> may make it more difficult for patients to change treatments and there is a perception that half<span class="nobreak">-life</span> extension could exacerbate side effects, each of which may adversely affect Oruka&#8217;s ability to gain market acceptance. Market acceptance of Oruka&#8217;s product candidates will depend on many factors, including factors that are not within Oruka&#8217;s control.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Oruka cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that its product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of Oruka&#8217;s product candidates is approved but does not achieve an adequate level of acceptance by such parties, Oruka may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain of Oruka&#8217;s programs may compete with its other programs, which could negatively impact Oruka&#8217;s business and reduce its future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is developing product candidates for the same indication, PsO, and may in the future develop its programs for other&#160;I&amp;I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact Oruka&#8217;s business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Oruka&#8217;s future revenue.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted in such locations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may choose to conduct one or more of its future clinical trials outside the United&#160;States. Although the FDA may accept data from clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that Oruka conducts outside the United&#160;States, it would likely result in the need for additional trials, which would be costly and time<span class="nobreak">-consuming</span> and would delay or permanently halt Oruka&#8217;s development of the applicable product candidates. Even if the FDA accepted such data, it could require Oruka to modify its planned clinical trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Oruka&#8217;s clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Oruka&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Oruka cannot commercialize product candidates in the United&#160;States without first obtaining regulatory approval from the FDA.&#160;Similarly, Oruka cannot commercialize product candidates outside of the United&#160;States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Oruka&#8217;s product candidates, including its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, Oruka must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Oruka&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Oruka&#8217;s obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Oruka&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Oruka&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Oruka&#8217;s clinical trials; Oruka may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug<span class="nobreak">-related</span> side effects may be experienced by participants in Oruka&#8217;s clinical trials or by individuals using drugs similar to Oruka&#8217;s product candidates; Oruka may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Oruka&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Oruka&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United&#160;States or elsewhere, and Oruka may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Oruka&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third<span class="nobreak">-party</span> manufacturers with which Oruka contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Oruka&#8217;s clinical data insufficient for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Oruka&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm Oruka&#8217;s business, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka were to obtain approval, regulatory authorities may approve any of Oruka&#8217;s product candidates for fewer or more limited indications than Oruka requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post<span class="nobreak">-marketing</span> clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the successful commercialization of that product candidate. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be able to meet requirements for the chemistry, manufacturing and control of its programs.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to receive approval of its products by the FDA and comparable foreign regulatory authorities, Oruka must show that it and its contract manufacturing partners are able to characterize, control and manufacture its drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Oruka&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Oruka is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting its products approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA<span class="nobreak">-licensed</span>&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of their product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that any of its product candidates approved as biologics under a BLA should qualify for the&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Oruka&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for&#160;non<span class="nobreak">-biological</span>&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka receives regulatory approval of its product candidates, Oruka will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Oruka may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any regulatory approvals that Oruka may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post<span class="nobreak">-approval</span> study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Oruka&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Oruka&#8217;s product candidates, its product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post<span class="nobreak">-marketing</span> information and reports, registration, as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">well as&#160;on<span class="nobreak">-going</span>&#160;compliance with current cGMPs and GCPs for any clinical trials that Oruka conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Oruka, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on Oruka&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit Oruka&#8217;s ability to commercialize its product candidates and generate revenue and could require Oruka to expend significant time and resources in response and could generate negative publicity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may face difficulties from healthcare legislative reform measures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Oruka&#8217;s product candidates. Oruka cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United&#160;States or abroad. If Oruka is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Oruka may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Healthcare Reform</span>&#8221; for a more detailed description of healthcare reform measures that may prevent or limit Oruka&#8217;s ability to generate revenue, attain profitability, or commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Oruka to penalties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third<span class="nobreak">-party</span> payors, patient organizations and customers may expose Oruka to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Oruka conducts its operations, including how Oruka researches, markets, sells and distributes its product candidates, if approved. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Other Healthcare Laws and Compliance Requirements</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Ensuring that Oruka&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Oruka&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, Oruka may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, integrity oversight and reporting obligations to resolve allegations of&#160;non<span class="nobreak">-compliance</span>,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations. Further, defending against any such actions can be costly and time<span class="nobreak">-consuming</span> and may require significant personnel resources. Therefore, even if Oruka is successful in defending against any such actions that may be brought against it, its business may be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, it may not be able to offer such product candidates at competitive prices which would seriously harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to seek approval to market its product candidates in both the United&#160;States and in selected foreign jurisdictions. If Oruka obtains approval in one or more foreign jurisdictions for its product candidates, Oruka will be subject to rules and regulations in those jurisdictions. Oruka&#8217;s ability to successfully commercialize any product candidates that it may develop will depend in part on the extent to which reimbursement for these product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third<span class="nobreak">-party</span> payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third<span class="nobreak">-party</span> payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Oruka&#8217;s products in an attempt to reduce their costs, which may reduce Oruka&#8217;s commercial opportunity. Additionally, if any of Oruka&#8217;s product candidates are approved and Oruka is found to have improperly promoted off<span class="nobreak">-label</span> uses of those product candidates, Oruka may become subject to significant liability, which would materially adversely affect its business and financial condition. See the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Coverage and Reimbursement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Other Government Regulation&#160;Outside of the United&#160;States&#160;&#8212;&#160;Regulation in the European Union</span>&#8221; for a more detailed description of the government regulations and third<span class="nobreak">-party</span> payor practices that may affect Oruka&#8217;s ability to commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Oruka can face criminal liability and other serious consequences for violations, which can harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti<span class="nobreak">-bribery</span> and anti<span class="nobreak">-money</span> laundering laws in the countries in which Oruka conducts activities. Anti<span class="nobreak">-corruption</span> laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Oruka may engage third parties to sell its products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Oruka has direct or indirect interactions with officials and employees of government agencies or government<span class="nobreak">-affiliated</span> hospitals, universities, and other organizations. Oruka can be held liable for the corrupt or other illegal activities of its employees, agents, contractors, and other collaborators, even if Oruka does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Governments outside the United&#160;States tend to impose strict price controls, which may adversely affect Oruka&#8217;s revenue, if any.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between&#160;low<span class="nobreak">-priced</span>&#160;and high<span class="nobreak">-priced</span> EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Oruka or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost<span class="nobreak">-effectiveness</span> of Oruka&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third<span class="nobreak">-party</span> payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Oruka&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, Oruka could face significant new costs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">A breakthrough therapy, fast track, or other expedited designation for Oruka&#8217;s product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of Oruka&#8217;s product candidates qualifies under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Expedited Development and Review Programs</span>&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Intellectual Property</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Option Agreements to protect the intellectual property related to its programs and technologies and to prevent third parties from competing unfairly with it. Oruka&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its platform technologies, programs and their uses, as well as its ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. However, Oruka may not be able to protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and Oruka&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, Oruka may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if it applies for them. Oruka&#8217;s competitors may operate in countries where Oruka does not have patent protection and can freely use Oruka&#8217;s technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Oruka does have patent protection or pending patent applications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Oruka&#8217;s programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Oruka may license or own covering Oruka&#8217;s programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if Oruka encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Oruka could market its product candidates under patent protection would be reduced. Thus, the patents that Oruka may own and license may not afford Oruka any meaningful competitive advantage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to seeking patents for some of its technology and programs, Oruka may also rely on trade secrets, including unpatented&#160;know<span class="nobreak">-how</span>,&#160;technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Oruka&#8217;s employees, the employees of third parties with whom Oruka shares its facilities or third<span class="nobreak">-party</span> consultants and vendors that Oruka engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Oruka&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Oruka&#8217;s technological achievements, thus eroding Oruka&#8217;s competitive position in its market. In order to protect </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka&#8217;s proprietary technology and processes, it relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Oruka may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Oruka undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Oruka may not be able to assert any trade secret rights against such party. Costly and time<span class="nobreak">-consuming</span> litigation could be necessary to enforce and determine the scope of Oruka&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Oruka&#8217;s competitive business position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lastly, if Oruka&#8217;s trademarks and trade names are not registered or adequately protected, then Oruka may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be successful in obtaining or maintaining necessary rights to its programs through acquisitions and&#160;in-licenses.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Oruka&#8217;s business may depend in part on its ability to acquire,&#160;in<span class="nobreak">-license</span>,&#160;or use these third<span class="nobreak">-party</span> proprietary rights. Oruka may be unable to acquire or&#160;in<span class="nobreak">-license</span>&#160;any compositions, methods of use, processes or other third<span class="nobreak">-party</span> intellectual property rights from third parties that it identifies as necessary for its programs. The licensing and acquisition of third<span class="nobreak">-party</span> intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka may consider attractive or necessary. These established companies may have a competitive advantage over Oruka due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Oruka also may be unable to license or acquire third<span class="nobreak">-party</span> intellectual property rights on terms that would allow it to make an appropriate return on Oruka&#8217;s investment or at all. If Oruka is unable to successfully obtain rights to required third<span class="nobreak">-party</span> intellectual property rights or maintain the existing intellectual property rights it does obtain, Oruka may have to abandon development of the relevant program, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka plans to obtain the right to control prosecution, maintenance and enforcement of the patents relating to its programs, there may be times when the filing and prosecution activities for patents and patent applications relating to Oruka&#8217;s programs are controlled by its current and future licensors or collaboration partners. If any of Oruka&#8217;s current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Oruka&#8217;s business, including by payment of all applicable fees for patents covering its product candidates, Oruka could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and it may not be able to prevent competitors from making, using and selling competing products. In addition, even where Oruka has the right to control patent prosecution of patents and patent applications it has licensed to and from third parties, Oruka may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Oruka assumed control over patent prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties such that Oruka&#8217;s future licensors are not the sole and exclusive owners of the patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights to Oruka&#8217;s future&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is possible that Oruka may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Oruka is able to obtain a license, it may be&#160;non<span class="nobreak">-exclusive</span>,&#160;thereby giving Oruka&#8217;s competitors access to the same technologies licensed to Oruka. In that event, Oruka may be required to expend significant time and resources </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to redesign its technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Oruka is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Oruka cannot provide any assurances that third<span class="nobreak">-party</span> patents do not exist which might be enforced against Oruka&#8217;s current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting Oruka&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Oruka&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Disputes may arise between Oruka and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation<span class="nobreak">-related</span> issues; whether and the extent to which Oruka&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Oruka&#8217;s right to sublicense patents and other rights to third parties; Oruka&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know<span class="nobreak">-how</span>&#160;resulting from the joint creation or use of intellectual property by Oruka&#8217;s future licensors and it and its partners; and the priority of invention of patented technology.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to patent infringement claims or may need to file claims to protect its intellectual property, which could result in substantial costs and liability and prevent Oruka from commercializing its potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Oruka&#8217;s freedom to operate and guarantee that Oruka can operate without infringing on or violating third<span class="nobreak">-party</span> rights. If certain of Oruka&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of Oruka&#8217;s product candidates infringing. If a third party successfully brings a claim against Oruka, Oruka may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against Oruka, whether or not successful, may cause Oruka to incur significant legal expenses and divert the attention of its management and key personnel from other business concerns. Oruka cannot be certain that patents owned or licensed by it will not be challenged by others in the course of litigation. Some of Oruka&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Oruka can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Oruka&#8217;s ability to raise funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate Oruka&#8217;s patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Oruka may be required to file claims, which can be expensive and time<span class="nobreak">-consuming</span>. Any such claims could provoke these parties to assert counterclaims against Oruka, including claims alleging that Oruka infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Oruka asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Oruka&#8217;s patents do not cover the technology. Similarly, if Oruka asserts trademark infringement claims, a court or administrative body may determine that the marks Oruka has asserted are invalid or unenforceable or that the party against whom Oruka has asserted trademark infringement has superior rights to the marks in question. In such a case, Oruka could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Oruka is successful, any award of monetary damages or other remedy Oruka receives may not be commercially valuable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Oruka may be required to protect its patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Oruka&#8217;s patent rights, which could adversely affect Oruka&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if Oruka&#8217;s programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Oruka&#8217;s future licensees and other parties with whom Oruka has business relationships and Oruka may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Oruka to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, Oruka may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Oruka&#8217;s intellectual property rights, there is a risk that some of Oruka&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is common in the biotechnology industry, in addition to Oruka&#8217;s employees, Oruka engages the services of consultants to assist it in the development of its programs. Many of these consultants, and many of Oruka&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Oruka&#8217;s competitors or potential competitors. Oruka could in the future be subject to claims that it or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Oruka tries to ensure that its employees and consultants do not use the intellectual property, proprietary information,&#160;know<span class="nobreak">-how</span>&#160;or trade secrets of others in their work for Oruka, Oruka may become subject to claims that it caused an employee to breach the terms of his or her&#160;non<span class="nobreak">-competition</span>&#160;or&#160;non<span class="nobreak">-solicitation</span>&#160;agreement, or that Oruka or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka may litigate to defend itself against these claims, even if it is successful, litigation could result in substantial costs and could be a distraction to management. If Oruka&#8217;s defenses to these claims fail, in addition to requiring it to pay monetary damages, a court could prohibit Oruka from using technologies or features that are essential to its programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Oruka&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Oruka&#8217;s business, results of operations and financial condition. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing Oruka&#8217;s ability to protect its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Changes in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the Leahy<span class="nobreak">-Smith</span> America Invents Act (the &#8220;Leahy<span class="nobreak">-Smith</span> Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s owned and&#160;in<span class="nobreak">-licensed</span>&#160;patent applications and the maintenance, enforcement or defense of its owned and&#160;in<span class="nobreak">-licensed</span>&#160;issued patents. The Leahy<span class="nobreak">-Smith</span> Act includes a number of significant changes to United&#160;States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost<span class="nobreak">-effective</span> avenues for competitors to challenge the validity of patents, and enable third<span class="nobreak">-party</span> submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO<span class="nobreak">-administered</span> post<span class="nobreak">-grant</span> proceedings, including post<span class="nobreak">-grant</span> review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy<span class="nobreak">-Smith</span> Act, the United&#160;States transitioned to a&#160;first<span class="nobreak">-to-file</span>&#160;system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">claimed invention. As such, the Leahy<span class="nobreak">-Smith</span> Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s patent applications and the enforcement or defense of its issued patents, all of which could have a material adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States Supreme Court in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen, Inc. v. Sanofi</span>&#160;(<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty<span class="nobreak">-six</span> exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Oruka will be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Oruka is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Oruka&#8217;s patents, when issued, relying on the reasoning in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>&#160;or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States and other countries that, if adopted, could impact Oruka&#8217;s ability to enforce its proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Oruka&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Geopolitical instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Oruka&#8217;s business. In addition, a decree was adopted by the Russian government in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit<span class="nobreak">-making</span> activities in the United&#160;States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Oruka would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Oruka&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although Oruka does not currently own any European patents or applications, if it obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Oruka&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Oruka&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Oruka may decide to opt out from the UPC any future European patent applications that it may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for&#160;non<span class="nobreak">-compliance</span>&#160;and brought under the jurisdiction of the UPC.&#160;Oruka cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Oruka decides to opt out of the UPC.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Oruka&#8217;s patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non<span class="nobreak">-compliance</span>&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non<span class="nobreak">-payment</span>&#160;of fees and failure to properly legalize and submit formal documents. If Oruka fails to maintain the patents and patent applications covering its programs, Oruka&#8217;s competitive position would be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Oruka&#8217;s ability to develop and market its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Oruka be certain that it has identified each and every third<span class="nobreak">-party</span> patent and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Oruka&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Oruka may incorrectly determine that its products are not covered by a third<span class="nobreak">-party</span> patent or may incorrectly predict whether a third<span class="nobreak">-party</span>&#8217;s pending application will issue with claims of relevant scope. Oruka&#8217;s determination of the expiration date of any patent in the United&#160;States or abroad that it considers relevant may be incorrect. Oruka&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Oruka cannot be certain that others have not filed patent applications for technology covered by its issued patents or its pending applications, or that Oruka was the first to invent the technology. Oruka&#8217;s competitors may have filed, and may in the future file, patent applications covering products or technology similar to Oruka&#8217;s. Any such patent application may have priority over Oruka&#8217;s patent applications or patents, which could require Oruka to obtain rights to issued patents covering such technologies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may be subject to claims that former employees, collaborators or other third parties have an interest in Oruka&#8217;s patents or other intellectual property as an inventor or&#160;co<span class="nobreak">-inventor</span>.&#160;The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Oruka&#8217;s programs or as a result of questions regarding&#160;co<span class="nobreak">-ownership</span>&#160;of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Oruka may enter into agreements to clarify the scope of its rights in such intellectual property. If Oruka fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Oruka&#8217;s business. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties, such as the U.S.&#160;government, such that Oruka&#8217;s licensors would not be the sole and exclusive owners of any patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights or other rights to Oruka&#8217;s&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect the competitive position of Oruka&#8217;s product candidates for an adequate amount of time.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Patents have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United&#160;States&#160;non<span class="nobreak">-provisional</span>&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Oruka&#8217;s product candidates are obtained, once the patent life has expired, Oruka may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Oruka&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Oruka&#8217;s.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s technology licensed from various third parties may be subject to retained rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may retain certain rights under the relevant agreements with Oruka, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Oruka&#8217;s licensors limit their use of the technology to these uses, and Oruka could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Reliance on Third Parties</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently relies on its licensing arrangements with Paragon through the Paragon Option Agreements for a substantial portion of its discovery capabilities and&#160;in<span class="nobreak">-licenses</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations or licensing arrangements that Oruka enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Oruka&#8217;s current or future collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with Oruka, disagrees with Oruka&#8217;s interpretation of the terms of such agreement or terminates their agreement with Oruka, the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements and development timeline could be adversely affected. If Oruka fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Oruka&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Oruka may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Oruka&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Oruka has licensed from them, if required by Oruka&#8217;s agreement with them, or even infringe upon, Oruka&#8217;s intellectual property rights, leading to the potential invalidation of Oruka&#8217;s intellectual property or subjecting it to litigation or arbitration, any of which would be time<span class="nobreak">-consuming</span> and expensive and could harm Oruka&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Oruka&#8217;s programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Oruka&#8217;s.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of Oruka&#8217;s strategy, Oruka plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or provide development or commercialization capabilities that complement Oruka&#8217;s. Oruka may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Oruka to incur&#160;non<span class="nobreak">-recurring</span>&#160;and other charges, increase its near and long<span class="nobreak">-term</span> expenditures, issue securities that dilute its existing stockholders or disrupt its management and business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka considers attractive. These companies may have a competitive advantage over Oruka due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Whether Oruka reaches a definitive agreement for a collaboration will depend upon, among other things, its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time<span class="nobreak">-consuming</span> to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Oruka may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Oruka fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Oruka may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Oruka. Oruka will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Oruka controls only certain aspects of their activities. As a result, Oruka will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if it were relying entirely upon its own staff. Nevertheless, Oruka is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Oruka of its regulatory responsibilities. Oruka and its third<span class="nobreak">-party</span> contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Oruka&#8217;s programs in clinical development. If Oruka or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Oruka&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Oruka to perform additional clinical trials before approving Oruka&#8217;s marketing applications. Oruka cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Oruka&#8217;s clinical trials comply with GCP regulations. In addition, Oruka&#8217;s clinical trials must be conducted with products produced under cGMP regulations. Oruka&#8217;s failure to comply with these regulations may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Oruka&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any third parties conducting Oruka&#8217;s clinical trials will not be Oruka&#8217;s employees and, except for remedies available to Oruka under its agreements with such third parties, Oruka cannot control whether they devote sufficient time and resources to Oruka&#8217;s programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Oruka&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Oruka&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Oruka&#8217;s product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Oruka&#8217;s clinical protocols or regulatory requirements or for other reasons, Oruka&#8217;s clinical trials may be extended, delayed or terminated and Oruka may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka currently relies on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited (&#8220;WuXi&#8221;) for formulation and manufacturing of Oruka&#8217;s stage 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The BIOSECURE Act, if passed, would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed BIOSECURE Act, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Oruka, delay the procurement or supply of such material or have an adverse effect on Oruka&#8217;s ability to secure significant commitments from governments to purchase its potential therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Oruka&#8217;s collaborators in China which could have an adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United&#160;States and the UK, could also negatively impact Oruka&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Oruka&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE Act is passed and one or more of Oruka&#8217;s collaborators or vendors in China, including WuXi, is deemed to be a biotechnology company of concern, Oruka&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Oruka has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Oruka&#8217;s collaborators in China could introduce delays into the development program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies and expects to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture its product candidates, and Oruka may rely on third parties to produce and process its products, if approved. Oruka&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own any facility that may be used as its clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture its product candidates. Oruka has not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Oruka currently has a sole source relationship for its supply of the ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> program. If there should be any disruption in such supply arrangement, including any adverse events affecting Oruka&#8217;s sole supplier, it could have a negative effect on the clinical development of Oruka&#8217;s programs and other operations while Oruka works to identify and qualify an alternate supply source. Oruka may not control the manufacturing process of, and may be completely dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of its product candidates. Beyond periodic audits, Oruka has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Oruka&#8217;s product candidates or if it withdraws any approval in the future, Oruka may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect Oruka&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Similarly, Oruka&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Oruka, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Oruka&#8217;s product candidates or drugs and harm Oruka&#8217;s business and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, Oruka&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which Oruka will rely fail to manufacture quantities of Oruka&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows Oruka to achieve profitability, Oruka&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Oruka&#8217;s CMOs </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">are responsible for transporting temperature<span class="nobreak">-controlled</span> materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Oruka&#8217;s integrity and purity specifications. Oruka and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Oruka&#8217;s business could be materially adversely affected by business disruptions to its third<span class="nobreak">-party</span> providers that could materially adversely affect its anticipated timelines, potential future revenue and financial condition and increase its costs and expenses. Each of these risks could delay or prevent the completion of Oruka&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of its product candidates. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Manufacturing</span>&#8221; for a more detailed description of Oruka&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Oruka&#8217;s programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Oruka&#8217;s Business</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage Oruka&#8217;s anticipated future growth, Oruka must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Oruka&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Oruka may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is highly dependent on its key personnel and anticipates hiring new key personnel. If Oruka is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biotechnology company with a limited operating history, and, as of May&#160;3, 2024, it had ten full<span class="nobreak">-time</span> employees. Oruka has been and will continue to be highly dependent on the research and development, clinical and business development expertise of its executive officers, as well as the other principal members of its management, scientific and clinical team. Any of Oruka&#8217;s management team members may terminate their employment with Oruka at any time. Oruka does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Attracting and retaining qualified personnel will also be critical to Oruka&#8217;s success, including with respect to any strategic transaction that it may pursue. The loss of the services of Oruka&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Oruka&#8217;s industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and Oruka may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Oruka also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery and nonclinical and clinical development and commercialization strategy. Oruka&#8217;s consultants and advisors may be employed by employers other than Oruka and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Oruka. If Oruka is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates in foreign markets for which it may rely on collaboration with third parties. Oruka is not permitted to market or promote any of its product candidates before it receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Oruka must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of its product candidates, and Oruka cannot predict success in these jurisdictions. If Oruka fails to comply with the regulatory requirements in international markets and receive applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Oruka obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Oruka would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Oruka competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet Oruka&#8217;s size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of Oruka&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Oruka has adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions Oruka takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Oruka from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Oruka&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Oruka&#8217;s brand and material disruption of its operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of its business, Oruka and the third parties upon which it relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the implementation of security measures in an effort to protect systems that store Oruka&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Oruka&#8217;s internal information technology systems and those of its third<span class="nobreak">-party</span> CROs, other contractors (including sites performing Oruka&#8217;s clinical trials), third<span class="nobreak">-party</span> service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Oruka&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber<span class="nobreak">-attacks</span> by malicious third parties, which may compromise Oruka&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Oruka&#8217;s data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some actors now engage and are expected to continue to engage in cyber<span class="nobreak">-attacks</span>, including without limitation nation<span class="nobreak">-state</span> actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Oruka, and the third parties upon which it relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber<span class="nobreak">-attacks</span>, that could materially disrupt Oruka&#8217;s systems and operations, supply chain, and ability to produce, sell and distribute its goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Oruka&#8217;s operations, ability to provide its products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Oruka may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Oruka&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Oruka could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Oruka&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from any such disruption in, or failure or security breach of, its systems or third<span class="nobreak">-party</span> systems where information important to Oruka&#8217;s business operations or commercial development is stored.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s fully<span class="nobreak">-remote</span> workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Oruka to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Oruka may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Oruka may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Oruka to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies on third<span class="nobreak">-party</span> service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Oruka&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Oruka&#8217;s third<span class="nobreak">-party</span> service providers experience a security incident or other interruption, Oruka could experience adverse </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">consequences. While Oruka may be entitled to damages if its third<span class="nobreak">-party</span> service providers fail to satisfy their privacy or security<span class="nobreak">-related</span> obligations to it, any award may be insufficient to cover Oruka&#8217;s damages, or Oruka may be unable to recover such award. In addition, supply<span class="nobreak">-chain</span> attacks have increased in frequency and severity, and Oruka cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third<span class="nobreak">-party</span> partners&#8217; supply chains have not been compromised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka (or a third party upon whom it relies) experiences a security incident or are perceived to have experienced a security incident, Oruka may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Oruka&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Oruka&#8217;s platform, deter new customers from products, and negatively impact Oruka&#8217;s ability to grow and operate its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Oruka&#8217;s contracts are sufficient to protect Oruka from liabilities, damages, or claims related to its data privacy and security obligations. Oruka cannot be sure that its insurance coverage will be adequate or sufficient to protect it from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Oruka&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and third parties who it works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. Oruka is or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Oruka&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Oruka or third parties related to Oruka to comply with such laws, regulations and obligations could increase Oruka&#8217;s compliance and operational costs, expose it to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on its business, financial condition, and results of operations. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Data Privacy and Security</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Oruka&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Oruka may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Oruka&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect Oruka&#8217;s stockholders or Oruka. Oruka assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. Oruka cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;), which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, Oruka has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Oruka&#8217;s effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. If Oruka acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Oruka may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing Oruka&#8217;s business. There is no assurance that, following any such acquisition, Oruka will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Oruka&#8217;s business and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Oruka&#8217;s ability to pay its operational expenses or make other payments.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s cash held in&#160;non<span class="nobreak">-interest-bearing</span>&#160;and interest<span class="nobreak">-bearing</span> accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, Oruka could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Oruka may experience in the future or inability for a material time period to access its cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect its business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General Risk Factors</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which Oruka competes&#160;achieve&#160;the forecasted&#160;growth, its business&#160;may&#160;not grow at similar&#160;rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet its size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Oruka gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of its addressable patients is not as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">significant as Oruka estimates, the indication approved by regulatory authorities is narrower than Oruka expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and its product liability insurance may not cover all damages from such claims.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Oruka currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Oruka to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Oruka, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Oruka&#8217;s products or any prospects for commercialization of its products. Although Oruka intends to obtain product liability insurance for its future clinical trials, it is possible that any liabilities could exceed Oruka&#8217;s insurance coverage or that in the future Oruka may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Oruka for uninsured liabilities or in excess of insured liabilities, Oruka&#8217;s assets may not be sufficient to cover such claims and its business operations could be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Oruka&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time&#160;Oruka&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Oruka may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on its results of operations and financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the&#160;COVID<span class="nobreak">-19</span>&#160;pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Oruka&#8217;s business or the third parties on whom Oruka relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Oruka by increasing its costs, including labor and employee benefit costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Oruka&#8217;s results of operations and financial condition.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to ARCA&#8221; or &#8220;Risks Related to Oruka&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to ARCA</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to Oruka</span>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed financial and development projections the combined company may provide to the public;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed the financial and development projections of the investment community;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additions or departures of key personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significant lawsuits, including patent or stockholder litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the market valuations of similar companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sales of securities by the combined company or its securityholders in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>trading volume of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span>&#160;fluctuations in the combined company&#8217;s financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may incur losses for the foreseeable future and may never achieve profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The combined company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the combined company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or&#160;in<span class="nobreak">-licensing</span>&#160;or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will require substantial additional funds to conduct the costly and time<span class="nobreak">-consuming</span> clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span> and Oruka&#8217;s other programs and future product candidates. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the combined company&#8217;s stockholders&#8217; ownership interests or inhibit the combined company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will incur significant legal, accounting and other expenses as a public company that Oruka did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the &#8220;Exchange&#160;Act&#8221;). The combined company&#8217;s management team will consist of the executive officers of Oruka prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of the Merger, ARCA, under the new name &#8220;Oruka Therapeutics, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, ARCA agreed to use its commercially reasonable efforts to cause the shares of ARCA common stock being issued in the Merger (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to ARCA, ARCA anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. ARCA&#8217;s board of directors intends to effect a reverse stock split of the shares of ARCA common stock at a ratio of between 1:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the&#160;over<span class="nobreak">-the-counter</span>&#160;market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results and cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will be subject to the reporting requirements of the Exchange&#160;Act, which requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b<span class="nobreak">-2</span> under the Exchange&#160;Act, in at least the near term, the combined company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the combined company&#8217;s periodic reports and proxy statements. Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provided the combined company continues to be listed on Nasdaq, the combined company will be subject to the reporting requirements of the Exchange&#160;Act, the Sarbanes<span class="nobreak">-Oxley</span> Act and the rules and regulations of Nasdaq. The Sarbanes<span class="nobreak">-Oxley</span> Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10<span class="nobreak">-K</span>&#160;filing for that year, as required by Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act. As a private company, Oruka has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the combined company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is not able to comply with the requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for ARCA and Oruka included in this proxy statement/prospectus are preliminary, and the combined company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma financial information for ARCA and Oruka included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The combined company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The exchange ratio reflected in this proxy statement/prospectus is preliminary. The final exchange ratio could differ materially from the preliminary exchange ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;284.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions will:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continue the use of a classified board of directors such that not all members of the combined company board of directors are elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require the approval of the holders of at least 66 2/3% of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Moreover, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although ARCA and Oruka believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the combined company&#8217;s board of directors, they would apply even if the offer may be considered </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers, employees or stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings (i)&#160;any derivative action or proceeding brought on the combined company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of the combined company&#8217;s current or former directors, officers, employees or stockholders to the combined company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&#160;any action asserting a claim arising pursuant to any provision of the combined company&#8217;s certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange&#160;Act. ARCA and Oruka expect the combined company to also amend its bylaws to provide that, unless it consents in writing to an alternative forum, federal district courts of the United&#160;States will be the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor is referred to herein as the &#8220;Federal Forum Provision.&#8221; There is uncertainty as to whether a court would enforce such a provision. In addition, the bylaws of the combined company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived the combined company&#8217;s compliance with the U.S.&#160;federal securities laws and the rules and regulations thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Delaware Forum Provision and the Federal Forum Provision may impose additional costs on stockholders of the combined company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the bylaws of the combined company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the combined company or its directors, officers, employees or stockholders, which may discourage such lawsuits against the combined company and its directors, officers, employees and stockholders even though an action, if successful, might benefit its stockholders. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision contained in the combined company&#8217;s bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, there had been no public market for shares of Oruka capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for the combined company&#8217;s stockholders to sell their shares at an attractive price or at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If existing securityholders of ARCA and Oruka sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of March&#160;31, 2024, after giving effect to the estimated exchange ratio and the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants to be issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated ARCA reverse stock split, the combined company is expected to have outstanding a total of approximately 357.5<span class="nobreak"> </span>million shares of common stock immediately following the completion of the Merger. Of the shares of common stock, approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are freely tradeable upon completion of the Merger and approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares will be available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of&#160;lock<span class="nobreak">-up</span>&#160;agreements between ARCA on the one hand and certain securityholders of Oruka on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options or warrants of Oruka (excluding the&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing) will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants prior to the closing of the Merger pursuant to the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre-closing&#160;financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the combined company or its stockholders. The combined company will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where the combined company has operations to determine the potential effect on its business and any assumptions the combined company will make about its future taxable income. It cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect its effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed above, ARCA has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2023, ARCA had NOL carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under current law, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections&#160;382 and 383 of the Code, U.S.&#160;federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three<span class="nobreak">-year</span> period. The combined company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including, weakened demand for the combined company&#8217;s product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply disruption, or cause the combined company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the combined company&#8217;s business and the combined company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T23"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This proxy statement/prospectus contains or incorporates statements that constitute forward<span class="nobreak">-looking</span> statements within the meaning of the federal securities laws in relation to ARCA, Oruka, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward<span class="nobreak">-looking</span> statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward<span class="nobreak">-looking</span> statements. These forward<span class="nobreak">-looking</span> statements include, but are not limited to, express or implied statements regarding ARCA&#8217;s or Oruka&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward<span class="nobreak">-looking</span> statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward<span class="nobreak">-looking</span>. These forward<span class="nobreak">-looking</span> statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka or the proposed transaction will be those that have been anticipated. These forward<span class="nobreak">-looking</span> statements involve a number of risks, uncertainties (some of which are beyond ARCA&#8217;s or Oruka&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward<span class="nobreak">-looking</span> statements. In addition to other factors and matters contained in or incorporated by reference in this document, ARCA and Oruka believe the following factors could cause actual results to differ materially from those discussed in the forward<span class="nobreak">-looking</span> statements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to meet expectations regarding the timing and completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Oruka pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the Merger and the transactions contemplated thereby, including the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>statements regarding the special cash dividend that ARCA may pay to ARCA stockholders in connection with the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s continued listing on the Nasdaq until closing of the proposed Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expectations regarding the strategies, prospects, plans expectations and objectives of management of ARCA or Oruka for future operations of the combined company following the closing of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of the combined company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of ARCA, Oruka and the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s and Oruka&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the closing of the Merger would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that under the terms of the Merger Agreement, ARCA and Oruka are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effect of the announcement or pendency of the Merger on ARCA&#8217;s or Oruka&#8217;s business relationships, operating results and business generally, including disruption of ARCA&#8217;s and Oruka&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger Agreement may be terminated in circumstances that require ARCA or Oruka to pay a termination fee;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome of any legal proceedings that may be instituted against ARCA, Oruka or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of ARCA and Oruka to protect their respective intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>competitive responses to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legislative, regulatory, political and economic developments beyond the parties&#8217; control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation, timing and success of clinical trials for ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>success in retaining, or changes required in, ARCA&#8217;s and Oruka&#8217;s officers, key employees or directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s public securities&#8217; potential liquidity and trading;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory actions with respect to ARCA&#8217;s and Oruka&#8217;s product candidates or their respective competitors&#8217; products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s reliance on third<span class="nobreak">-party</span> contract development and manufacturer organizations to manufacture and supply product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected potential benefits of strategic collaboration with third parties and ARCA&#8217;s and Oruka&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>developments and projections relating to ARCA&#8217;s and Oruka&#8217;s competitors or industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should one or more of these risks or uncertainties materialize, or should any of ARCA&#8217;s or Oruka&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward<span class="nobreak">-looking</span> statements. There may be additional risks that ARCA or Oruka considers immaterial or which are unknown. You are urged to carefully review the disclosures ARCA and Oruka make concerning these risks and other factors that may affect ARCA&#8217;s and Oruka&#8217;s business and operating results under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward<span class="nobreak">-looking</span> statements are discussed in reports filed with the SEC by ARCA and incorporated by reference herein. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of ARCA, Oruka or the combined company could differ materially from the forward<span class="nobreak">-looking</span> statements. Any public statements or disclosures by ARCA and Oruka following this proxy statement/prospectus that modify or impact any of the forward<span class="nobreak">-looking</span> statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward<span class="nobreak">-looking</span> statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. ARCA and Oruka do not intend, and undertake no obligation, to update any forward<span class="nobreak">-looking</span> information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T22"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date, Time and Place</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA special meeting will be held on&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, commencing at&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held at&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. ARCA is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by ARCA&#8217;s board of directors for use at the ARCA special meeting and any adjournments or postponements of the ARCA special meeting. This proxy statement/prospectus is first being furnished to ARCA stockholders on or about&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Purpose of the ARCA Special Meeting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purposes of the ARCA special meeting are:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to this proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s board of directors recommends that you vote:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on ARCA&#8217;s board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. ARCA&#8217;s board of directors that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Record Date and Voting Power</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only holders of record of ARCA common stock at the close of business on the Record Date of<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, there were&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of ARCA common stock and there were&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding. Each share of ARCA common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Voting and Revocation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of ARCA&#8217;s board of directors for use at the ARCA special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for ARCA common stock, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the ARCA special meeting or vote by proxy. Whether or not you plan to attend the ARCA special meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The procedures for voting are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a stockholder of record, you may vote at the ARCA special meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the ARCA special meeting, ARCA encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the ARCA special meeting, you may still attend the ARCA special meeting and vote. In such case, your previously submitted proxy will be disregarded.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the ARCA special meeting and we will give you a ballot when you arrive. If you attend the ARCA special meeting and vote in person, your vote will revoke any proxy that you have previously submitted. Simply attending the ARCA special meeting will not, by itself, revoke your proxy.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the telephone by calling the toll<span class="nobreak">-free</span> number found on the proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the internet by following the instructions provided on the proxy card.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from ARCA.&#160;Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote at the ARCA special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221; A &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter. Abstentions will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4. If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All properly executed proxies that are not revoked will be voted at the ARCA special meeting and at any adjournments or postponements of the ARCA special meeting in accordance with the instructions contained in the proxy. <span class="Bold" style="font-style:normal;font-weight:bold;">If a holder of ARCA common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of ARCA&#8217;s board of directors.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The presence at the ARCA special meeting of the holders of a majority of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be counted towards the presence of a quorum. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock, if deemed necessary, will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR,&#8221; &#8220;AGAINST&#8221; and &#8220;WITHHOLD&#8221; votes, abstentions and broker non<span class="nobreak">-votes</span>, if any, as applicable to each proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;">As of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting. As of&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the ARCA stockholders that are party to a support agreement, including the directors, executive officers and certain stockholders of ARCA, owned an aggregate number of shares of ARCA common stock representing approximately&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock. Each stockholder that entered into a support agreement, including the directors and executive officers of ARCA, has agreed to vote all shares of ARCA common stock owned by him or her as of the Record Date in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement and the change of control resulting from the First Merger, and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Solicitation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to solicitation by mail, the directors, officers, employees and agent of ARCA may solicit proxies from ARCA stockholders by personal interview, telephone, email, fax or otherwise. ARCA and Oruka will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of ARCA common stock for the forwarding of solicitation materials to the beneficial owners of ARCA common stock. ARCA will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. ARCA has retained<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Matters</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this proxy statement/prospectus, ARCA&#8217;s board of directors does not know of any business to be presented at the ARCA special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the ARCA special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T991188"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page 135 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While ARCA and Oruka believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 320 of this proxy statement/prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA&#8217;s board of directors and management regularly review ARCA&#8217;s operating and strategic plans in an effort to enhance stockholder value. This review involves, among other things, discussions of opportunities and risks associated with ARCA&#8217;s product candidates, development programs, financial condition and market, as well as a consideration of strategic alternatives available to ARCA.&#160;On March&#160;28, 2022, members of ARCA&#8217;s board of directors and management reviewed the results of ARCA&#8217;s Phase&#160;2 clinical trial of Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) (the &#8220;Clinical Trial&#8221;). The results of the Clinical Trial indicated that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In light of these results, ARCA&#8217;s board of directors initiated a process to identify and evaluate strategic alternatives available to ARCA that ultimately resulted in the execution of the Merger Agreement. The following is a summary of the background of the process undertaken by ARCA, the identification and evaluation of strategic alternatives and the negotiation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;28, 2022, ARCA&#8217;s board of directors held video conference meetings with members of ARCA&#8217;s management and a representative of its legal advisor, Cooley LLP (&#8220;Cooley&#8221;) in attendance, to review the Clinical Trial results. ARCA&#8217;s board of directors discussed strategic alternatives available to ARCA in light of the negative Clinical Trial results, including continuation of the development of ARCA&#8217;s current products, possible licensing opportunities or a sale of ARCA.&#160;Following this meeting, Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, instructed management to provide ARCA&#8217;s board of directors with management&#8217;s assessment of the viability of continuing to develop ARCA&#8217;s current products in light of the negative Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;29, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a proposed product development plan prepared by ARCA&#8217;s management which included a plan to conduct a Phase&#160;3 trial for ARCA&#8217;s Gencaro product in patients with higher ejection fraction heart failure. ARCA&#8217;s board of directors instructed management to further refine ARCA&#8217;s product development plan and to explore other potential strategic alternatives to the product development plan available to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Following the close of markets on March&#160;31, 2022, ARCA publicly announced the Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;10, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a refined product development plan prepared by ARCA&#8217;s management and the strategic alternatives to that development plan including a sale of ARCA or other strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Later that same&#160;day, ARCA&#8217;s board of directors held a video conference meeting without members of ARCA&#8217;s management or representatives of Cooley in attendance. ARCA&#8217;s board of directors discussed ARCA&#8217;s prospects as a stand<span class="nobreak">-alone</span> company pursuant to the refined product development plan presented by ARCA&#8217;s management earlier that same&#160;day, and the potential strategic alternatives thereto that were available to ARCA including a broad outreach to potential reverse merger counterparties or a liquidation of ARCA.&#160;It was the consensus of ARCA&#8217;s board of directors that in light of the negative Clinical Trial results, ARCA should explore and evaluate its strategic alternatives while continuing to evaluate its ability to continue on as a stand<span class="nobreak">-alone</span> enterprise. ARCA&#8217;s board of directors discussed the evaluation and retention of a financial advisor to assist ARCA&#8217;s board of directors in its exploration and evaluation of strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;17, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors discussed the formation of a special committee of ARCA&#8217;s  board of directors (the &#8220;Special Committee&#8221;) for the purpose of identifying, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">considering, evaluating and making recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives. ARCA&#8217;s board of directors approved the formation the Special Committee and appointed Mr.&#160;Conway, Dr.&#160;Hove and Dr.&#160;Grais to serve on the Special Committee, with Mr.&#160;Conway serving as chair. The Special Committee was not formed for the purposes of addressing potential or actual conflicts of interest of any director or officer of ARCA.&#160;ARCA&#8217;s board of directors delegated to the Special Committee the full power and authority of ARCA&#8217;s board of directors to, among other things, identify, consider, evaluate and make recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives and proposals which may be available to ARCA and further resolved to not approve any transaction unless the Special Committee had recommended that ARCA&#8217;s board of directors approve such a transaction. It was also discussed and concluded that: (1)&#160;ARCA&#8217;s board of directors would continue to have an active role in (i)&#160;the evaluation of any acquisition proposal, (ii)&#160;any discussions with potential acquirers with respect to a potential strategic transaction and (iii)&#160;any broader review of strategic alternatives; (2)&#160;the Special Committee would update and seek input from ARCA&#8217;s board of directors as appropriate; and (3)&#160;members of ARCA&#8217;s board of directors who were not also members of the Special Committee would be invited to attend the meetings of the Special Committee. ARCA&#8217;s board of directors also discussed potential candidates to act as financial advisor to ARCA in connection with a potential strategic transaction and directed the Special Committee to interview potential candidates and engage a financial advisor in connection with a strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;18, 2022, ARCA publicly announced its initiation of a process to evaluate strategic options for maximizing stockholder value and the establishment of the Special Committee to assist in the pursuit of such a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Between April&#160;25, 2022, and April&#160;29, 2022, the Special Committee, and members of ARCA&#8217;s management team met with representatives from five investment banking firms telephonically to assess their ability to act as ARCA&#8217;s financial advisor in connection with a review of potential strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;2, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team in attendance. The Special Committee discussed the qualifications of the financial advisors it had interviewed. After consideration of the relative qualifications and expertise of the candidates, including industry expertise, knowledge, access to potential transaction candidates, and recent transaction experience, the Special Committee approved the selection of Ladenburg Thalmann&#160;&amp; Co., Inc. (&#8220;Ladenburg&#8221;) as ARCA&#8217;s financial advisor to assist ARCA in its review of potential strategic alternatives and authorized and directed ARCA&#8217;s management to negotiate an engagement letter with Ladenburg. The Special Committee also determined that Ladenburg&#8217;s outreach should be focused on identifying potential reverse merger transaction candidates because the Special Committee believed such a transaction had the highest likelihood of presenting the highest value for stockholders in light of (i)&#160;the value that would be ascribed to ARCA&#8217;s public listing in such a transaction which would not be taken into account in a traditional merger or other similar strategic transaction and (ii)&#160;ARCA&#8217;s limited non<span class="nobreak">-cash</span> assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;4, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors reviewed the qualifications of the potential candidates to serve as ARCA&#8217;s financial advisor, the terms of the proposed engagement letter with Ladenburg and the Special Committee&#8217;s recommendation to appoint Ladenburg as ARCA&#8217;s financial advisor. ARCA&#8217;s board of directors approved the engagement of Ladenburg and authorized ARCA&#8217;s management to enter into an engagement letter in substantially the form presented to ARCA&#8217;s board of directors, which ARCA&#8217;s management executed later that same day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;5, 2022, ARCA publicly announced it had retained Ladenburg to act as its financial advisor to explore and review a range of strategic alternatives focused on maximizing stockholder value including an acquisition, merger, business combination or other strategic transaction involving ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;6, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Cooley and Ladenburg in attendance. At this meeting, Ladenburg reviewed the process it proposed to undertake in order to identify and evaluate potential strategic alternatives and over 250 potential counterparties that it believed may be interested in pursuing a reverse merger transaction with ARCA.&#160;The Special Committee discussed the anticipated timeline for contacting and receiving and evaluating proposals from interested parties in connection with a strategic transaction. Ladenburg also reviewed its proposed selection criteria to be used by the Special Committee in identifying and evaluating potential counterparties. This criteria included an evaluation of (i)&#160;the quality of the assets owned by the potential counterparty, (ii)&#160;whether the potential counterparty had clear, proof of concept clinic data, (iii)&#160;the development stage of the potential counterparty, (iv)&#160;the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">counterparty&#8217;s product pipeline, (v)&#160;whether the counterparty was pursuing a concurrent private placement financing in order to ensure the counterparty had sufficient cash resources to reach the upcoming milestones with respect to the counterparty&#8217;s product candidates, (vi)&#160;the quality of the potential investors that would participate in such a concurrent financing, (vii)&#160;the amount of cash from ARCA required by the potential counterparty and the amount of cash ARCA would be able to distribute to its stockholders in a special dividend immediately prior to the closing of a transaction, (viii)&#160;the industry within which the counterparty was engaged, (ix)&#160;whether the counterparty was willing to ascribe any value to ARCA&#8217;s products in the proposed transaction, (x)&#160;whether the counterparty was expected to have value inflection points within 18&#160;months, (xi)&#160;the capital structure of the counterparty, (xii)&#160;whether the counterparty had sufficient infrastructure to maintain ARCA&#8217;s public listing or the ability to maintain such infrastructure, including whether the counterparty had financial statements sufficient to satisfy public company reporting standards, and (xiii)&#160;whether the relative valuations ascribed to ARCA and the potential counterparty in light of the foregoing factors was fair. Ladenburg also proposed limiting outreach efforts to companies in the pharmaceutical and biotechnology industry in light of ARCA&#8217;s enhanced ability to evaluate and assess the products, and related operational, industry, regulatory, financial, market and other risks and opportunities, of companies within those particular industries. Following a discussion, the Special Committee authorized Ladenburg to begin outreach to all of the potential counterparties presented by Ladenburg and adopted the proposed criteria for purposes of evaluating potential offers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beginning on May&#160;6, 2022, Ladenburg conducted a process of identifying and evaluating potential counterparties for a strategic transaction with assistance from the Special Committee and members of ARCA&#8217;s management. In its outreach efforts, members of ARCA&#8217;s board of directors, ARCA&#8217;s management, and representatives of Ladenburg, contacted over 250 companies that met the criteria adopted by the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From May&#160;6, 2022 until June&#160;15, 2022, ARCA delivered bid process letters to 74 companies, received a total of 50 formal non<span class="nobreak">-binding</span> proposals (all of which were for reverse merger styled transactions) and entered into 37&#160;non<span class="nobreak">-disclosure</span> agreements to facilitate further diligence with potential counterparties which also contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA. During that same period, the Special Committee, members of ARCA&#8217;s management and outside advisors met numerous times to consider the various non<span class="nobreak">-binding</span> proposals, and to receive updates regarding the solicitation and evaluation of the proposals. The Special Committee determined not to pursue 48 of the 50 non<span class="nobreak">-binding</span> proposals that were submitted due to, among other reasons, the failure of those potential counterparties to adequately satisfy many of the criteria adopted by the Special Committee. Of the two non<span class="nobreak">-binding</span> proposals that the Special Committee determined to pursue, the Special Committee determined to abandon one in June&#160;2022 in light of that counterparty&#8217;s early stage of development (Phase 1/Phase 2 clinical trial for its lead product candidate) and its need for all of ARCA&#8217;s cash to fund its operations. The other counterparty informed the Special Committee in December&#160;2022 that it was no longer interested in pursuing a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;15, 2022, ARCA entered into a Cooperation Agreement with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>. Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Jacob Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022, and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From June&#160;15, 2022 until December&#160;15, 2022, at the direction of the Special Committee, ARCA&#8217;s management engaged third<span class="nobreak">-party</span> experts to examine and evaluate its ability to further develop Gencaro as a stand<span class="nobreak">-alone</span> enterprise and prepared an analysis of the potential value of ARCA&#8217;s assets in a liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini Goodrich &amp; Rosati, P.C. (&#8220;Wilson Sonsini&#8221;) (who at such point had been engaged as ARCA&#8217;s counsel) and Ladenburg in attendance to discuss the strategic alternatives available to ARCA including having Ladenburg undertake a renewed search for new strategic transaction counterparties, pursuing a liquidation or continuing to pursue ARCA&#8217;s development plans as a stand<span class="nobreak">-alone</span> enterprise. The Special Committee determined that continuing to pursue potential strategic transactions was reasonably likely to result in a superior alternative to a liquidation and ARCA&#8217;s development plan as a stand<span class="nobreak">-alone</span> enterprise and as a result authorized and directed Ladenburg to re<span class="nobreak">-engage</span> with potential counterparties. As part of that authorization, it directed Ladenburg to broaden the scope of potential counterparties to include companies outside the pharmaceutical and biotechnology industry in order to evaluate all possible alternatives available to ARCA and determined to further refine its selection criteria to favor companies with later stage assets and/or near<span class="nobreak">-term</span> revenue as well as companies that did not require all of ARCA&#8217;s cash in order to achieve its key milestones to ensure a significant dividend of its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">cash assets could be made as part of any such transaction. In addition, the Special Committee also determined that ARCA&#8217;s management should continue to further refine and pursue its development plan as a potential alternative if a compelling counterparty for a strategic transaction was not able to be found.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From December&#160;15, 2022, until January&#160;5, 2023, the Special Committee and representatives of Ladenburg met on multiple occasions to review eleven potential counterparties for a strategic transaction in light of ARCA&#8217;s board of directors&#8217; revised selection criteria and ultimately refined the number of potential counterparties down to three potential counterparties that presented a reasonable likelihood of resulting in a superior alternative to the strategic alternatives the Special Committee was considering including a liquidation of ARCA or the continuation of its business as a standalone enterprise. ARCA and these three potential counterparties entered into non<span class="nobreak">-disclosure</span> agreements to facilitate their discussions which contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;5, 2023, until January&#160;20, 2023, the Special Committee, members of ARCA&#8217;s management and representatives of Ladenburg met with and reviewed presentations prepared by the three potential counterparties selected by the Special Committee. Following the presentations, the Special Committee determined that a potential transaction with Party A was the most attractive because (i)&#160;it had a promising late stage asset that was expected to reach near term value inflection points along with a promising early stage product candidate and (ii)&#160;it did not require all of ARCA&#8217;s cash to fund its operations. While it did not abandon the other two potential counterparties, the Special Committee focused its efforts on engaging with Party A in light of the attractiveness of that counterparty when compared to the other two potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On January&#160;26, 2023, members of ARCA&#8217;s management and representatives of Ladenburg were given access to a virtual data room hosted by Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;26, 2023, until March&#160;10, 2023, ARCA&#8217;s management and representatives of Ladenburg undertook an extensive preliminary due diligence review of Party A and engaged numerous advisors to assist ARCA in its due diligence review.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;10, 2023, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to Party A providing for a reverse merger transaction and which ascribed an enterprise value to ARCA in the merger of $10,000,000 and an enterprise value to Party A of $75,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From March&#160;10, 2023, until May&#160;30, 2023, the Special Committee and representatives of Party A met multiple times to negotiate the substantive economic terms of a potential reverse merger transaction including the size and type of investor for a private placement transaction contemplated to close substantially concurrently with the closing of a reverse merger transaction and the relative valuations to be ascribed to each party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On May&#160;30, 2023, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the final terms of the term sheet negotiated with Party A, which provided for a reverse merger transaction ascribing a $11,000,000 enterprise valuation to ARCA and a $60,000,000 enterprise valuation to Party A.&#160;The term sheet also, among other things, allowed ARCA to distribute to its pre<span class="nobreak">-closing</span> stockholders all of ARCA&#8217;s net cash in excess of $21,000,000 and gave ARCA&#8217;s stockholders a contingent value right representing the right to receive net proceeds of any sale of ARCA&#8217;s legacy product candidates. The term sheet also obligated each party to exclusively negotiate a transaction with one another. The Special Committee determined that it should continue to pursue a transaction with Party A on an exclusive basis in light of (i)&#160;the Special Committee&#8217;s view that each of (A)&#160;pursuing ARCA&#8217;s corporate objectives on a stand<span class="nobreak">-alone</span> basis, including the proposed development plan and (B)&#160;the liquidation of ARCA, was not reasonably likely to result in superior value to ARCA&#8217;s stockholders when compared to the proposed transaction; (ii)&#160;the Special Committee&#8217;s view that the $11&#160;million enterprise value ascribed to ARCA would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; (iii)&#160;the Special Committee&#8217;s view that the combined company was likely to possess sufficient cash resources at the closing of the Merger to fund development of Party A&#8217;s product candidates through upcoming value inflection points; (iv)&#160;ARCA&#8217;s positive preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Party A&#8217;s assets and (v)&#160;the Special Committee&#8217;s view that the proposal from Party A was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic transactions available to ARCA in light of the extensive outreach process undertaken to date. As a result of that determination, the Special Committee authorized and directed ARCA&#8217;s management to execute and deliver the term sheet to Party A and began exclusively negotiating a potential reverse merger transaction with Party A.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, ARCA and Party A executed the non<span class="nobreak">-binding</span> term sheet and representatives of ARCA, Party A, and each of their respective legal and financial advisors participated in a video conference meeting during which the timeline and process for the signing of definitive agreements providing for a potential business combination were discussed, including the signing of definitive agreements for a private placement in ARCA that was contemplated to close concurrently with the business combination. The participants tentatively agreed on a work plan that contemplated the execution of definitive agreements in late June or early July&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between May&#160;30, 2023, and July&#160;20, 2023, representatives of ARCA and Party A engaged in exclusive negotiations regarding a potential reverse merger and conducted detailed due diligence reviews of one another.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;20, 2023, Party A informed ARCA that its product approval had been delayed due to a request for additional information by the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between July&#160;20, 2023, and August&#160;25, 2023, the Special Committee, Party A, and each of their respective legal and financial advisors participated in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, the Special Committee met with members of ARCA&#8217;s management, and representatives of Wilson Sonsini and Ladenburg to review the status of Party A&#8217;s application with the Office of New Drugs at the FDA and discussed the other strategic alternatives available to ARCA if Party A&#8217;s approval continued to be delayed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;25, 2023, the Special Committee determined that it was no longer viable to continue to exclusively pursue a transaction with Party A in light of Party A&#8217;s ongoing financing challenges, regulatory difficulties, increased expenditures and the Special Committees determination that Party A would not be able to successfully market or obtain commitments for the private placement investment contemplated by the term sheet in light of the foregoing. On that same&#160;day, ARCA allowed its obligation to exclusively negotiate with Party A lapse without extension.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From August&#160;25, 2023, until December&#160;7, 2023, the Special Committee continued to participate in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.&#160;At each of these meetings, Party A stated that regulatory approval was imminent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During this same period, the Special Committee conducted video conference meetings with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives available to ARCA if Party A&#8217;s regulatory approval continued to be delayed including a renewed search by Ladenburg for potential reverse merger partners or a liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December<span class="nobreak"> </span>7, 2023, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> called Mr.<span class="nobreak"> </span>Conway and verbally proposed a potential partial tender offer for 50.1% of the shares of ARCA&#8217;s capital stock at a price per share range of $1.95 to $2.05 to be led by a stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, the Special Committee conducted a video conference meeting (without Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> attending) with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance. The Special Committee further discussed the strategic alternatives available to ARCA including the proposal made by Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> earlier that day. The Special Committee discussed the proposal and noted that the proposal was unlikely to be attractive in light of (i)&#160;the fact that ARCA stockholders were expected to receive approximately $2.25 per share in cash if ARCA liquidated at that time based on the previous liquidation analysis prepared by ARCA&#8217;s management in June&#160;2022 and (ii)&#160;the outcomes that the Special Committee expected it could achieve in a potential strategic transaction. The Special Committee authorized Mr.&#160;Conway to continue conversations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer in order to see if negotiations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> could eventually result in a price per share that presented a superior alternative to the various strategic alternatives the Special Committee was considering and instructed ARCA&#8217;s management to prepare an updated liquidation analysis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From December&#160;7, 2023, until January&#160;12, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending), conducted numerous video conference meetings to discuss the strategic alternatives available to ARCA which included, a liquidation of ARCA, a renewed search by Ladenburg for potential reverse merger partners, and a tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to discuss and negotiate a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, on December&#160;12, 2023, the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors met to discuss, among other matters, the compensation that should be paid to each of the directors serving as members of the Special Committee in light of the prolonged strategic process that the committee had undertaken and the extensive work that the Committee had performed and was expected to continue to perform. The Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors determined that each member of the Special Committee would be entitled to $7,500 for each month of substantive service on the Special Committee that each such member had previously performed and would perform going forward.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;12, 2024, the Special Committee conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives ARCA had been considering. At this meeting representatives of Ladenburg delivered a presentation comparing the potential value to ARCA&#8217;s stockholders that would result from a traditional merger, a reverse merger, a partial tender offer, or a liquidation. The Special Committee also reviewed a presentation prepared by ARCA&#8217;s management comparing the tender offer proposal made by Mr.&#160;Ma<span class="nobreak">-Weaver</span> on December<span class="nobreak"> </span>7, 2023 to the liquidation analysis that it had prepared which showed a potential value of $2.04 per share to stockholders in a liquidation. For more information regarding the liquidation analysis including the key assumptions therein, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; ARCA Liquidation Analysis</span>,&#8221; beginning on page 108 of this proxy statement/prospectus. Following those presentations, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> left the meeting. The Special Committee then discussed the presentations and determined that pursuing a tender offer at the price per share offered by Mr.&#160;Ma<span class="nobreak">-Weaver</span> did not have a reasonable likelihood of resulting in a superior alternative when compared to the other strategic alternatives available to ARCA.&#160;In light of that determination, and the continuing delay of regulatory approvals for Party A, the Special Committee directed Ladenburg to renew its search for potential reverse merger partners and to focus its outreach on companies that did not require a material amount of cash to remain on ARCA&#8217;s balance sheet after the closing of a transaction. The Special Committee further instructed Mr.&#160;Conway to continue negotiating the terms and conditions of a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> in parallel with Ladenburg&#8217;s renewed search and ARCA&#8217;s continued discussions with Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#160;12, 2024, until February&#160;26, 2024, Ladenburg renewed its search for a potential counterparty in line with the Special Committee&#8217;s revised criteria and received non<span class="nobreak">-binding</span> proposals from eight potential counterparties interested in a reverse merger transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway continued his discussions with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer and the Special Committee met multiple times to discuss the status of those discussions, and the other strategic alternatives the Special Committee was considering.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February<span class="nobreak"> </span>15, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending) conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini attending. As a result of the negotiations that Mr.<span class="nobreak"> </span>Conway and Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> had been engaging in, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> increased his verbal offer to a price per share of $2.25 for 50.1% of the shares of ARCA&#8217;s capital stock. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then left the meeting. The Special Committee discussed Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s offer of $2.25 per share and determined that while the price per share was higher than the most recent liquidation analysis presented at the January&#160;12, 2024, meeting, the offer was still not reasonably likely to result in a superior alternative when compared to the other strategic alternatives available to ARCA, including a reverse merger transaction which was expected to provide ARCA&#8217;s stockholders additional value for ARCA&#8217;s public listing. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then rejoined the meeting and the Special Committee informed him that his offer was not compelling in light of the other strategic alternatives available to ARCA, and that the stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> needed to increase its proposal to a price of at least $2.50 per share for 100% of the shares of ARCA&#8217;s capital stock. The Special Committee directed Mr.&#160;Conway to continue negotiations with the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February<span class="nobreak"> </span>15, 2024, until February&#160;23, 2024, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to continue to discuss the potential tender offer. On February&#160;23, 2024, Mr.&#160;Ma<span class="nobreak">-Weaver</span> informed the Special Committee that the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> was no longer interested in pursuing a tender offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;26, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg to review, discuss and evaluate the eight non<span class="nobreak">-binding</span> proposals it had received to date as a result of Ladenburg&#8217;s renewed outreach. The Special Committee determined that Oruka was a counterparty that merited serious consideration because (i)&#160;it required the least amount of ARCA&#8217;s cash and would therefore permit ARCA to distribute the largest amount of cash to its stockholders, (ii)&#160;the company was backed by a reputable investor </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with a history of successful reverse merger transactions and (iii)&#160;the company already had informal commitments for a substantial private placement investment that was contemplated to close concurrently with the closing of the Merger. As a result, the Special Committee focused its efforts on pursing a transaction with Oruka while continuing to discuss a potential transaction with two of the other potential counterparties that had submitted non<span class="nobreak">-binding</span> proposals in case a transaction with Oruka did not come to fruition. The Special Committee determined that the remaining five non<span class="nobreak">-binding</span> proposals that had been submitted were not compelling in light of the quality of the counterparties&#8217; assets, the substantial cash needs of the potential counterparties, and the valuations sought by the potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg and Oruka in attendance to discuss Oruka&#8217;s fitness as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to representatives of Wedbush Securities Inc. (&#8220;Wedbush&#8221;), Oruka&#8217;s financial advisor, which proposed a reverse merger transaction ascribing a $10,000,000 enterprise valuation to ARCA and a $175,000,000 enterprise valuation of Oruka (which would be reduced to the extent the price per share in the proposed private placement financing ascribed a value to Oruka of less than $175,000,000) and setting forth certain other material terms including (1)&#160;the minimum investment amount to be received by Oruka as a result of a private placement transaction investment to close substantially concurrent with the business combination; (2)&#160;conditions to execution of any definitive agreement, (3)&#160;conditions to the closing of the business combination transaction; (4)&#160;the ability of ARCA to distribute any net cash in excess of $5,000,000 to the pre<span class="nobreak">-Merger</span> stockholders of ARCA; and (5)&#160;the exclusivity period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024 and February&#160;29, 2024, the Special Committee conducted video conference meetings with representatives of Ladenburg and the other two counterparties that it was considering in attendance to discuss each counterparty&#8217;s value as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;29, 2024, representatives of Wedbush delivered a revised term sheet to Ladenburg which ascribed a $6,000,000 enterprise valuation to ARCA and included proposed changes to a number of the other legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, Mr.&#160;Conway spoke with representatives of Oruka and proposed an ascribed enterprise value of $7,500,000. Representatives of Oruka informed Mr.&#160;Conway that it was not willing to pursue a transaction at an ascribed enterprise value over $6,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, the Special Committee held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the revised proposal received by Oruka. The Special Committee determined that the revised proposal represented a promising strategic alternative that was worth pursuing on an exclusive basis in light of: (i)&#160;the Special Committee&#8217;s view that ARCA was not likely to accomplish its corporate objectives on a stand<span class="nobreak">-alone</span> basis in light of its financial condition and product candidates; (ii)&#160;the Special Committee&#8217;s view that the $6,000,000 enterprise value ascribed to ARCA was within the range of values ascribed in other recent reverse merger transactions (for more information regarding the range of values ascribed to recent reverse merger transactions, please see the section titled &#8220;The Merger &#8212; Opinion of Lucid &#8212; Analysis of precedent Reverse Merger Transactions,&#8221; beginning on page 118 of this proxy statement/prospectus) and would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving an immediate cash payment on account of the special cash dividend ARCA would be permitted to make; (iii)&#160;the fact that the $175,000,000 enterprise value ascribed to Oruka would be validated by independent third parties in the private placement investment and that any reduction in the valuation ascribed to Oruka by such investors would also reduce Oruka&#8217;s valuation for purposes of calculating the exchange ratio; (iv)&#160;the Special Committee&#8217;s view that as a result of the substantial private placement financing that Oruka was committing to obtain at the closing of the Merger the combined company was likely to possess sufficient cash resources to fund development of Oruka&#8217;s product candidates through upcoming value inflection points; (vi)&#160;the increased likelihood that the transaction could be consummated in a timely manner in light of the informal private placement commitments that Oruka had already obtained, and (vii)&#160;the Special Committee&#8217;s view that the proposal from Oruka was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic alternatives available to ARCA in light of the extensive outreach process undertaken to date. The Special Committee concluded the meeting by directing Ladenburg to continue negotiating the final legal terms of the term sheet and authorized ARCA&#8217;s management to execute and deliver the term sheet once the remaining legal terms had been finalized.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the morning of March&#160;1, 2024, representatives of Ladenburg delivered an updated draft term sheet to representatives of Wedbush finalizing the remaining legal terms in the term sheet and finalizing the $6,000,000 enterprise value that Mr.&#160;Conway and representatives of Oruka had agreed to. Later that afternoon, representatives of Wedbush returned a proposed final draft term sheet which finalized the remaining legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, ARCA&#8217;s management executed and delivered the term sheet to Oruka and began exclusively negotiating a transaction with Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;4, 2024, the Special Committee met with representatives of ARCA&#8217;s management team, representatives of Wilson Sonsini and Ladenburg, Oruka&#8217;s management team, and representatives of Wedbush and Gibson, Dunn&#160;&amp; Crutcher LLP (&#8220;Gibson&#8221;), Oruka&#8217;s legal advisor, via video conference to discuss the timeline and process for signing definitive agreements providing for a potential business combination and a concurrent private placement financing and discussed and tentatively agreed on a work plan for such definitive agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, ARCA provided Oruka and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to ARCA and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;7, 2024, Oruka provided ARCA and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to Oruka and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;7, 2024, Oruka met with representatives of Jefferies LLC and Cowen and Company, LLC (together, the &#8220;Placement Agents&#8221;), representatives of Cooley, counsel to the Placement Agents, and Gibson, via video conference, to discuss the timeline and process for completing the concurrent private placement financing. Later that&#160;day, representatives of Gibson and Cooley met, via video conference, and tentatively agreed on a work plan for the definitive agreements related to such concurrent private placement financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;11, 2024, Mr.&#160;Conway met with ARCA&#8217;s management team and representatives of Wilson Sonsini to discuss the proposed terms of a draft of the Merger Agreement prepared by representatives of Wilson Sonsini. Mr.&#160;Conway then authorized Wilson Sonsini to distribute the draft Merger Agreement to Gibson which was sent out later that same&#160;day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;11, 2024, Oruka authorized representatives of Gibson to distribute the draft form of subscription agreement for the concurrent financing and other related documents to Cooley and Wilson Sonsini, on behalf of the Placement Agents and ARCA, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;15, 2024, the Special Committee met with representatives of Oruka and ARCA&#8217;s management team in attendance to discuss Oruka&#8217;s business and answer the Special Committee&#8217;s questions regarding the materials provided in the virtual data room.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between March&#160;15, 2024 and April&#160;2, 2024, representatives of ARCA&#8217;s management team conducted further business and financial due diligence with respect to Oruka, its business and the market for treatment of chronic skin diseases and, over the same period of time, ARCA&#8217;s legal and financial advisors conducted due diligence with respect to Oruka and its business based on information available in the data room and written responses from Oruka&#8217;s management team, and such advisors negotiated the terms and conditions of the Merger Agreement at the direction of and in coordination with the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Wilson Sonsini and Gibson met on numerous occasions to discuss and negotiate the legal terms of the Merger Agreement, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing attached as an exhibit thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Oruka and its financial advisors held conversations with the representatives of the Placement Agents and prospective investors to discuss the contemplated private placement financing, addressed questions from potential investors and negotiated the terms and conditions of the definitive agreements for such a transaction, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;19, 2024, at the direction of the Special Committee, ARCA entered into a new engagement letter with Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) engaging Lucid as ARCA&#8217;s financial advisor in light of restructuring events that had occurred at Ladenburg which resulted in the financial advisors primarily responsible for this transaction moving from Ladenburg to Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;20, 2024, at the direction of the Special Committee, ARCA terminated its engagement letter with Ladenburg.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Lucid in attendance. At the meeting, ARCA&#8217;s board of directors was provided with an overview of the proposed Merger (including the potential benefits and the risks related thereto), the key terms of the related ancillary documents, and its fiduciary duties. ARCA&#8217;s board of directors also reviewed the proposed resolutions which would be adopted by ARCA&#8217;s board of directors in order to approve the entry into the proposed Merger and related transactions, including among other things, the form of Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock. Lucid then presented its oral opinion that, as of the date thereof, and subject to the assumptions more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s board of directors,&#8221; beginning on page 112 in this proxy statement/prospectus, the Exchange Ratio is fair, from a financial point of view to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors&#8217; meeting was then adjourned and a meeting of the Special Committee was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. The Special Committee then unanimously (i)&#160;determined that the transactions contemplated by the Merger Agreement including the Merger Agreement and related ancillary agreements contemplated thereunder, are fair to, advisable and in the best interests of ARCA and its stockholders and (ii)&#160;recommended that ARCA&#8217;s board of directors approve and adopt the Merger Agreement, the related ancillary agreements and the transactions contemplated by the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Special Committee meeting was then adjourned and a meeting of ARCA&#8217;s board of directors was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. Based on the factors described below under the caption &#8220;The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger,&#8221; ARCA&#8217;s board of directors then adopted and approved, among other resolutions, resolutions (a)&#160;determining that it is in the best interests of ARCA and its stockholders to adopt and approve the execution and delivery of the Merger Agreement and the ancillary documents thereto, (b)&#160;adopting and approving the Merger Agreement and ancillary documents thereto and approving ARCA&#8217;s execution, delivery and performance of the same and the consummation of the transactions contemplated by the Merger Agreement and the ancillary documents thereto, (c)&#160;recommending that the ARCA stockholders vote in favor of the Proposals with Dr.&#160;Bristow abstaining from voting on the passage of such resolutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, the parties entered into the Merger Agreement and the related ancillary documents and the private placement investors executed and delivered the Subscription Agreement for the $275.0<span class="nobreak"> </span>million Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, ARCA and Oruka issued a joint press release announcing the execution and delivery of the Merger Agreement, and ARCA filed a Current Report on Form&#160;8<span class="nobreak">-K</span>, which filed as an exhibit (a)&#160;the Merger Agreement, (b)&#160;the form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, (c)&#160;the form of Oruka Support Agreement, (d)&#160;the form of Oruka Subscription Agreement, (e)&#160;form of ARCA Support Agreement, (f)&#160;the form of Lock<span class="nobreak">-up</span> Agreement, (g)&#160;a joint press release, dated April&#160;3, 2024 (h)&#160;an investor presentation providing information on Oruka, and (i)&#160;a transcript of a conference call held to announce the proposed transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors and the members of its Special Committee held numerous meetings, consulted with ARCA&#8217;s senior management, ARCA&#8217;s legal counsel and financial advisors, and reviewed and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors took into account the input and recommendations of the Special Committee, as well as other information presented to it during the process, and considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis in light of:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s decision, announced on May<span class="nobreak">&#160;</span>5, 2022, to initiate a process to explore strategic alternatives in light of and its subsequent decision announced in July of 2022 to reduce its workforce by 67%, which were each driven in large part by the results of ARCA&#8217;s Phase&#160;2 clinical trial of its primary product candidate Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), which found that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investor interest and value perception for possible further development of its programs, the product candidates&#8217; efficacy and safety profiles, stage of development, regulatory agencies&#8217; feedback regarding development pathways, and probability of success in relation to the requisite time and costs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulties encountered in ARCA&#8217;s related business development efforts to license, sell or otherwise partner its assets that could result in meaningful new capital or shared future development costs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s product pipeline and development candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the recommendation of the Special Committee that ARCA&#8217;s board of directors approve the contemplated transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief, after thorough discussions with ARCA&#8217;s management, financial advisors and legal counsel, that a potential liquidation and dissolution was not reasonably likely to create greater value for ARCA stockholders than the Merger based on, among other things, the need to hold back a potential meaningful amount of ARCA&#8217;s current cash balance to cover current and potential unknown future liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Oruka, terms of the Merger Agreement include the most favorable terms to ARCA in the aggregate that were achievable and consistent with other similar transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that Oruka&#8217;s product candidates have the potential to create meaningful value for the stockholders of the combined company and an opportunity for ARCA&#8217;s stockholders to participate in the growth of the combined company, based on the business, scientific, regulatory, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">intellectual property, financial, accounting and legal due diligence conducted by ARCA management and advisors (which included diligence calls and a comprehensive review of Oruka&#8217;s due diligence materials) regarding:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory pathway for, and market opportunity of, Oruka&#8217;s product candidates, including in light of the stage of development of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality and scope of the preclinical and clinical results available for Oruka as opposed to other parties with which ARCA engaged in discussions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s plans to explore the potential of its product candidates to treat other diseases, including through collaborations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of value inflection milestones prior to the time in which the combined company would need to raise additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; consideration of the expected cash balances of the combined company as of the closing of the Merger resulting from the approximately $5.0&#160;million of net cash, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, expected to be held by ARCA upon completion of the Merger, together with the cash Oruka currently holds and the $275&#160;million of expected gross proceeds from the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure, operating plans and cash burn rate of the combined company and the expected cash resources of the combined company (including the ability to support the combined company&#8217;s current and planned clinical trials and operations);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of Oruka to take advantage of the potential benefits resulting from becoming a public reporting company listed on Nasdaq, should it be required to raise additional capital in the future through the sale of equity or debt securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with ARCA based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by the Special Committee, ARCA&#8217;s management and its advisors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the combined company will be led by an experienced senior management team from Oruka, many members of which have extensive experience in drug development, research and development, business and regulatory expertise; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the financial analysis reviewed by Lucid with ARCA&#8217;s board of directors as well as the oral opinion of Lucid rendered to ARCA&#8217;s board of directors on April<span class="nobreak">&#160;</span>2, 2024 (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion dated April<span class="nobreak">&#160;</span>2, 2024 addressed to ARCA&#8217;s board of directors), as to, as of April<span class="nobreak">&#160;</span>2, 2024, the fairness, of the exchange ratio from a financial point of view, to ARCA&#8217;s stockholders, as more fully described below under the caption &#8220;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors,&#8221; beginning on page 112 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the calculation of the exchange ratio, closing net cash and the estimated number of shares of ARCA common stock to be issued in the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to dividend all of its net cash (as determined in accordance with the terms of the Merger Agreement) in excess of $5.0&#160;million to the current ARCA stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number and nature of the conditions to Oruka&#8217;s and ARCA&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, including the fact that Oruka&#8217;s obligation to complete the Merger would not be conditioned on ARCA having a specified level of closing net cash, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger,&#8221; beginning on page 148 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the respective rights of, and limitations on, ARCA and Oruka under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Non<span class="nobreak">-Solicitation</span>,&#8221; beginning on page 145 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential termination fee of $440,000, in the case of the fee payable by ARCA, or $440,000, in the case of the fee payable by Oruka, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Termination and Termination Fees,&#8221; beginning on page 150 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements, pursuant to which certain stockholders of Oruka and ARCA, respectively, have, subject to certain exceptions, agreed not to transfer their shares of ARCA common stock during the period of 180&#160;days following the completion of the Merger, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Lock<span class="nobreak">-Up</span> Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain stockholders of ARCA and Oruka, respectively, have agreed, solely in their capacities as stockholders, to vote all of their shares of ARCA common stock or Oruka common stock in favor of the proposals submitted to them in connection with the Merger and against any alternative acquisition proposals, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, and will constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Section&#160;1.368<span class="nobreak">-2</span>(g)&#160;and 1.368<span class="nobreak">-3</span>(a), with the result that Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes upon the exchange of Oruka common stock for ARCA common stock pursuant to the Merger Agreement, as more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger,&#8221; beginning on page 128 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of its deliberations, and in addition to the consideration, input and recommendations of the Special Committee, ARCA&#8217;s board of directors also considered a variety of risks, uncertainties and other countervailing factors related to entering into the Merger, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the future financial performance of Oruka may not meet ARCA&#8217;s board of directors&#8217; expectations due to factors both in and outside of Oruka&#8217;s control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that, while ARCA&#8217;s management team performed an extensive due diligence review of Oruka, there may have been relevant Oruka information not considered by ARCA&#8217;s management team and accordingly, ARCA may not have properly valued Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by ARCA upon the occurrence of certain events in deterring other potential companies from proposing an alternative acquisition proposal that may be more advantageous to ARCA&#8217;s stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s obligation to not solicit alternative acquisition proposals during the pendency of the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the substantial expenses to be incurred by ARCA in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible volatility of the trading price of the ARCA common stock resulting from the announcement, pendency or completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various risks impacting the financial condition, results of operations and prospects for ARCA, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges associated with pursuing any strategic alternative to the Merger available to ARCA, including the discussions that ARCA&#8217;s management and ARCA&#8217;s board of directors of directors previously conducted with other potential transaction partners, and the time to negotiate and complete an alternative strategic transaction and anticipated cash burn;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and delays associated with, and uncertain value and costs to ARCA stockholders of, liquidating ARCA, including the uncertainties of continuing cash burn while contingent liabilities are resolved, uncertainty of timing of release of cash until contingent liabilities are resolved, and the risks and costs associated with being a shell company prior to cash distribution;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges of attempting to continue to operate ARCA on a stand<span class="nobreak">-alone</span> basis, including, without limitation, (i)&#160;the considerable time and resources that would have been required to successfully address the uncertainties associated with its Gencaro product, (ii)&#160;the inability to finance ARCA&#8217;s continuing operations through the sale of securities in the capital markets due to, among other things, the lack of near term data catalysts and the general downturn in the U.S.&#160;capital markets for biotechnology companies and (iii)&#160;ARCA&#8217;s other product candidate profiles, stage of development, feedback from regulatory agencies regarding development pathway, and probability of success in relation to the requisite time and costs required as well as management&#8217;s related business development efforts to license, sell or otherwise partner the assets;.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of retaining or rebuilding staff with limited cash runway in light of the reductions in force that ARCA previously undertook; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of maintaining ARCA&#8217;s Nasdaq listing without completing the merger and the transactions contemplated in the Merger Agreement, including the reverse stock split; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the various other risks associated with the combined company and the Merger, including those described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Cautionary Note Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information and factors considered by the Special Committee and ARCA&#8217;s board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Special Committee and ARCA&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Special Committee and ARCA&#8217;s board of directors did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Special Committee and ARCA&#8217;s board of directors may have given different weight to different factors. The Special Committee and ARCA&#8217;s board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, ARCA&#8217;s management team and the legal and financial advisors of ARCA, and considered the factors overall to be favorable to, and to support, its determination.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Liquidation Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the evaluation of the Merger by ARCA&#8217;s board of directors and the Special Committee, ARCA&#8217;s management prepared an analysis with respect to the estimated value of the liquidation or dissolution of ARCA as a potential alternative to the Merger, including for such purposes ARCA&#8217;s estimated cash position at the time of the potential dissolution or liquidation, ARCA&#8217;s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to ARCA&#8217;s stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assumes that the entirety of ARCA&#8217;s cash balance at the time of the dissolution or liquidation would be available for distribution to ARCA&#8217;s stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by ARCA or any of its officers, directors, affiliates, advisors, or other representatives with respect to the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by ARCA&#8217;s board of directors and the Special Committee in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of ARCA do not purport to be appraisals or reflect the prices at which shares of ARCA common stock may actually be valued or trade, either before or after the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP.&#160;Neither the independent registered public accounting firm of ARCA nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of ARCA nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, ARCA management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed<span class="nobreak">-upon</span> procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Oruka&#8217;s financial statement. It does not extend to the prospective financial information and should not be read to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP.&#160;Non<span class="nobreak">-GAAP</span>&#160;financial measures should not be viewed as a substitute for GAAP financial measures and may be different from&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures used by other companies. Furthermore, there are limitations inherent in&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly,&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP.&#160;The SEC rules, which otherwise would require a reconciliation of a&#160;non<span class="nobreak">-GAAP</span>&#160;financial measure to a GAAP financial measure, do not apply to&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus to comply with requirements under state laws, including case law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents estimates prepared by ARCA&#8217;s management of the cash which could be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key assumptions underlying the Liquidation Analysis included: (i)&#160;that the entire distribution of ARCA&#8217;s net cash would be made in June&#160;2024; (ii)&#160;that ARCA would have approximately $29.65&#160;million of net cash as June&#160;2024, after deducting costs and expenses, including legal fees, the fees payable to ARCA&#8217;s strategic financial advisor, accounting fees, employee retention bonuses, severance and benefits, insurance expenses, other transaction<span class="nobreak">-related</span> costs and other liabilities; (iii)&#160;that these costs and expenses were forecasted to total approximately $7.28&#160;million assuming the closing of a liquidation in June&#160;2024; and (iv)&#160;approximately 14.5&#160;million total shares of ARCA common stock outstanding as of December&#160;31, 2023. The analysis resulted in an estimated cash distribution per share in June&#160;2024 of $2.04 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s&#160;board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Oruka pre<span class="nobreak">-closing</span> financing will generate capital resources to fund the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the competitive nature of the industry in which Oruka operates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; fiduciary duties to Oruka stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an IPO;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of appraisal rights under the DGCL to holders of Oruka capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Oruka capital stock as determined by the Delaware Court of Chancery;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the determination that the expected relative percentage ownership of ARCA stockholders and Oruka stockholders in the combined organization was appropriate, based on Oruka&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of ARCA (including the value of the net cash ARCA is expected to provide to the combined organization) and Oruka (including the value of the amount of proceeds from the Oruka pre<span class="nobreak">-closing</span> financing);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will be treated as a reorganization for U.S.&#160;federal income tax purposes, with the result that the Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes with respect to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the limited number and nature of the conditions of the obligation of ARCA to consummate the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Oruka receive a superior offer;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the conclusion of Oruka&#8217;s board of directors that the potential termination fees payable by ARCA or Oruka to the other party, and the circumstances when such fee may be payable, were reasonable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the shares of ARCA&#8217;s common stock issued to Oruka stockholders, including shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, will be registered on a Form&#160;S<span class="nobreak">-4</span> registration statement and will become freely tradable for Oruka stockholders who are not affiliates of Oruka and who are not parties to lock<span class="nobreak">-up</span> agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain directors, officers and stockholders of Oruka and ARCA, respectively, have agreed, solely in their capacity as stockholders of Oruka and ARCA, respectively, to vote all of their shares of Oruka capital stock or ARCA common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Oruka Therapeutics, Inc. prior to or upon the closing of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood that the Merger will be consummated on a timely basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed; the possibility that the Oruka&#160;pre<span class="nobreak">-closing</span> financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Oruka&#160;pre<span class="nobreak">-closing</span> financing on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Oruka&#160;pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the exchange ratio used to establish the number of shares of ARCA&#8217;s common stock to be issued to Oruka&#160;stockholders in the Merger is fixed, except for adjustments due to ARCA&#8217;s net cash balances, the amount of proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span> financing and outstanding capital stock at closing, and thus the relative percentage ownership of ARCA stockholders and Oruka&#160;stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of ARCA to obtain the required stockholder vote or the failure of Oruka&#160;to close the Oruka&#160;pre<span class="nobreak">-closing</span> financing, and the potential adverse effect on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs involved in connection with completing the Merger, the time and effort of Oruka&#160;senior management required to complete the Merger, the related disruptions or potential disruptions to Oruka&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Oruka, and related administrative challenges associated with combining the companies;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject to following the Merger that Oruka&#160;has not previously been subject to, and the operational changes to Oruka&#8217;s business, in each case that may result from being a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post<span class="nobreak">-closing</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that future sales of common stock by existing ARCA stockholders may cause the price of ARCA common stock to fall, thus reducing the potential value of ARCA common stock received by Oruka stockholders following the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by Oruka&#8217;s&#160;board of directors in its consideration of the Merger Agreement, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Oruka&#8217;s senior management and legal counsel, Oruka&#8217;s&#160;board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, Oruka&#8217;s&#160;board of directors unanimously approved the Merger Agreement, the Merger, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and the other transactions contemplated by the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As stated above, pursuant to an engagement letter dated March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), ARCA retained Lucid to act as a financial advisor in connection with the Merger and to render Lucid&#8217;s opinion (the &#8220;Lucid Opinion&#8221;) to ARCA&#8217;s board of directors as to the fairness of the exchange ratio, from a financial point of view, to the stockholders of ARCA.&#160;On April&#160;2, 2024, at the request of ARCA&#8217;s board of directors, Lucid rendered the oral opinion, subsequently confirmed by delivery of the written opinion dated April&#160;2, 2024, to ARCA&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the stockholders of ARCA as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the Lucid Opinion is attached as Annex&#160;B to this proxy statement and is incorporated by reference. ARCA encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the sole benefit and use by ARCA&#8217;s board of directors in its consideration of the Merger. The Lucid Opinion is not a recommendation to ARCA&#8217;s board of directors or to any stockholder as to how to vote with respect to the proposed Merger or to take any other action in connection with the Merger or otherwise.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to Lucid by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to Lucid by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed IPOs for certain companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information  concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with ARCA&#8217;s consent, assumed and relied, without independent verification or investigation, upon the accuracy and completeness of all financial and other information provided to or discussed with Lucid by ARCA and Oruka, respectively (for their respective employees, representatives or affiliates), or which is publicly available or was otherwise reviewed by Lucid. Lucid has not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Lucid has relied upon, without independent verifications, the assessment of ARCA management and Oruka management as to the viability of, and risks associated with, the current and future products and services of Oruka (including without limitation, the development, testing and marketing of such products and services, the receipt of all necessary governmental and other regulatory approvals for the development, testing and marketing thereof, and the life and enforceability of all relevant patents and other intellectual and other property rights associated with such products and services). In addition, Lucid has not conducted, nor has it assumed any obligation to conduct any physical inspection of the properties or facilities of ARCA or Oruka. Furthermore, Lucid has assumed, with ARCA&#8217;s consent, that there will be no further adjustments to the exchange ratio between the date hereof and the date the final exchange ratio is determined. Lucid has, with ARCA&#8217;s consent, relied upon the assumption that all information provided to Lucid by ARCA and Oruka is accurate and complete in all material respects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to Lucid. Lucid has not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor has Lucid been furnished with such materials. Further, as ARCA&#8217;s board of directors was aware, Oruka&#8217;s management did not provide Lucid with, and Lucid did not otherwise have access to, financial forecasts regarding Oruka&#8217;s businesses, other than certain cash burn projections, and, accordingly, Lucid did not perform either a discounted cash flow analysis or any multiples<span class="nobreak">-based</span> analyses with respect to Oruka. In addition, Lucid has not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the merger, as to which Lucid has assumed that ARCA and ARCA&#8217;s board of directors have received such advice from legal, regulatory, tax and accounting advisors as each has determined appropriate. The Lucid Opinion addresses only the fairness of the exchange ratio, from a financial point of view, to the ARCA stockholders. Lucid expresses no view as to any other aspect or implication of the merger or any other agreement or arrangement entered into in connection with the merger. The Lucid Opinion is necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaims any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering the Lucid Opinion, Lucid assumed in all respects material to Lucid&#8217;s analysis, that the representations and warranties of each party contained in the merger agreement were true and correct, that each party will perform all of the standards of the covenants and agreements required to be performed by it under the merger agreement and that all conditions to the consummation of the merger will be satisfied without waiver or amendment of any term or condition thereof. Lucid has assumed that the final form of the merger agreement will be substantially similar to the last draft reviewed by Lucid. Lucid has also assumed that all governmental, regulatory and other consents and approvals contemplated by the merger agreement or otherwise required for the transactions contemplated thereby will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on ARCA, Oruka or the contemplated benefits of the Merger. Lucid has assumed that the merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes, rules and regulations. ARCA has informed Lucid, and Lucid has assumed, that the merger is intended to constitute a reorganization within the meaning of Section&#160;368(a)&#160;of the Code and the Treasury Regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that the Lucid Opinion is intended for the benefit and use of ARCA&#8217;s board of directors in its consideration of the financial terms of the Merger and, except as set forth in Lucid&#8217;s Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, unless pursuant to applicable law or regulations or required by other regulatory authority by the order or ruling of a court or administrative body, except that the Lucid Opinion may be included in its entirety in any filing related to the merger to be filed with the Securities and Exchange Commission and the proxy statement to be mailed to the ARCA stockholders. The Lucid Opinion does not constitute a recommendation to ARCA&#8217;s board of directors of whether or not to approve the merger or to any ARCA stockholder or any other person as to how to vote with respect to the merger or to take any other action in connection with the merger or otherwise. The Lucid Opinion does not address ARCA&#8217;s underlying business decision to proceed with the merger or the relative merits of the merger compared to other alternatives available to ARCA.&#160;Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the merger. Lucid has not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the merger, or any class of such persons, relative to the compensation to be paid to the ARCA stockholders in connection with the merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Analyses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with ARCA&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of ARCA and Oruka.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon the exchange ratio of 7.4631 at the time of the signing of the merger agreement, it was estimated that at the closing: (a)&#160;Oruka equity holders as of immediately prior to the merger (including the shares issued in the approximately $275&#160;million Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, and (b)&#160;the ARCA equity holders as of immediately prior to the merger (excluding for this purpose the ARCA Out of the Money Options) will own approximately 2.39% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, in each case, subject to adjustment of the exchange ratio as set forth in the merger agreement and described herein.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pre-Financing Oruka Equity Value</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the purpose of the Lucid Opinion, Lucid utilized a Oruka equity value of $175.0&#160;million, which was the pre<span class="nobreak">-money</span> valuation utilized in the Oruka pre<span class="nobreak">-closing</span> financing. The post<span class="nobreak">-money</span> Oruka valuation is calculated by adding the negotiated value of $175.0&#160;million plus $275.0&#160;million raised in the pre<span class="nobreak">-closing</span> financing totaling $450.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed certain publicly available information for the IPOs of 19 dermatology/inflammation/autoimmune<span class="nobreak">-focused</span> biopharmaceutical companies that have completed an IPO since September&#160;2017 and whose lead product at the time of IPO was in a preclinical or Phase&#160;1 stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Applied Molecular Transport</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Avidity Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Biora Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>DICE Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Dyne Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Evelo Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Hoth Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kezar Life Sciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Krystal Biotech</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kymera Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Morphic Holding</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Prometheus Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Ventyx Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Virpax Pharmaceuticals</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The total enterprise value at IPO is defined as the&#160;pre<span class="nobreak">-money</span>&#160;equity value plus indebtedness, liquidation value of preferred stock and&#160;non<span class="nobreak">-controlling</span>&#160;interest, minus cash and cash equivalents at the time of its IPO.&#160;The Selected Precedent IPO Companies had total enterprise values between $33.0&#160;million and $638.5&#160;million. Lucid derived a median total enterprise value of $315.2&#160;million for the Selected Precedent IPO Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $177.4&#160;million to $504.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent IPO Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Filing Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Issuer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise<br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/7/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">511.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/13/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">384.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">359.8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ventyx Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/11/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prometheus Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">442.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/16/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Virpax Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/17/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dyne Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/20/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kymera Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/19/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biora Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">638.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/12/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Avidity Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">292.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/4/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applied Molecular Transport</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/26/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Morphic Holding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">154.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hoth Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/20/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kezar Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/8/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Evelo Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/19/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Krystal Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.3</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Publicly Traded Companies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Oruka within the biopharmaceutical industry, Lucid selected financial data of 13 publicly traded companies (referred to as the &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Traded</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Companies</span>&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in preclinical or Phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on April&#160;1, 2024. The Selected Publicly Traded Companies were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Aditxt</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Astria Therapeutics, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Forte Biosciences, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rani Therapeutics</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Spyre Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Surrozen, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Tharimmune</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ZyVersa Therapeutics</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $18.8&#160;million and $2.9&#160;billion. Lucid derived a median implied total enterprise value of $63.1&#160;million for the Selected Publicly Traded Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $5.3&#160;million to $539.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly Traded Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Company Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise <br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,863.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">818.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">575.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">536.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Astria Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rani Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aditxt</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ZyVersa Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tharimmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrozen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Analysis of Selected Precedent M&amp;A Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 9 most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in the preclinical or phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space (referred to as the &#8220;Selected Precedent&#160;M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Oruka to which they are being compared. Lucid reviewed the total enterprise values of the target companies (including future milestone payments). These transactions, including the date each was closed, were as follows below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $20.0&#160;million and $2.0&#160;billion. Lucid derived a median total enterprise value of $250.0&#160;million for the Selected Precedent M&amp;A Transactions. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $65.0&#160;million to $1.0&#160;billion. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent M&amp;A Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Announced Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Target</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Acquirer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Implied&#160;Enterprise</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value ($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">IMF Tre</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aiolos Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">GSK</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/18/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calypso Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/9/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Eli Lilly</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,028.7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ORIGIMM Biotechnology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Sanofi</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pandion Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Merck</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,850.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rodeo Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amgen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/8/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Confluence Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aclaris Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/26/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Delinia, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Celegene Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300.0</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions dating back to January&#160;2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target, along with other quantitative metrics. These transactions, including the date each was closed, are as follows:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent Reverse Merger Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/21/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">LENZ Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graphite Bio (Nasdaq: GRPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">$12</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/14/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunogenx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Wave BioPharma (FWBI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/6/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adaptive Phage Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Biomx (NYSEAM:&#160;PHGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cyclo Therapeutics (Nasdaq: CYTH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Applied Molecular Transport (Nasdaq: AMTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/18/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurogene</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neoleukin Therapeutics (Nasdaq: NLTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/13/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cartesian Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Selecta Biosciences (Nasdaq: RNAC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/3/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Korro Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Frequency Therapeutics (Nasdaq: FREQ)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/31/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lung Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aileron Therapeutics (Nasdaq: ALRN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notable Labs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/11/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dianthus Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Magenta Therapeutics (Nasdaq: MGTA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">EIP Pharma (CervoMed)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/29/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">TeraImmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Baudax Bio (Nasdaq: BXRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aeglea BioTherapeutics (Nasdaq: AGLE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/1/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Elicio Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Angion Biomedica (Nasdaq: ANGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GRI Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vallon Pharmaceuticals (Nasdaq: VLON)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">CalciMedica</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graybug Vision (Nasdaq: GRAY)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/7/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carisma Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sesen Bio (Nasdaq: SESN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/23/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enliven Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Imara (Nasdaq: IMRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catheter Precision, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ra Medical Systems (NYSE: RMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/29/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Disc Medicine</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemini Therapeutics (Nasdaq: GMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GNI Group (Gyre Therapeutics)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catalyst Biosciences (Nasdaq: CBIO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/19/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kineta, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics (Nasdaq: YMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">26</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/8/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARS Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Silverback Therapeutics (Nasdaq: SBTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/28/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aceragen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Idera Pharmaceuticals (Nasdaq: IDRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lisata Therapeutics (Cend)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Caladrius Biosciences (Nasdaq: CLBS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/30/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vivani Medical (Nano Precision)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Sight Medical (Nasdaq: EYES)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>

		</table>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/5/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Syros Pharmaceuticals (Nasdaq: SYRS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tyme Technologies (Nasdaq: TYME)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/16/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aprea Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Atrin Pharmaceuticals (NasdaqGS: APRE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quoin Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cellect Biotechnology Ltd. (Nasdaq: APOP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/26/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aadi Bioscience, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/3/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Decoy Biosystems, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cytocom, Inc. (Statera)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cleveland BioLabs, Inc. (Nasdaq: CBLI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tempest Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc. (Nasdaq: MLND)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ReShape Lifesciences Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Obalon Therapeutics, Inc. (Nasdaq: OBLN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Leading BioSciences, Inc. (Palisade)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seneca Biopharma, Inc. (Nasdaq: SNCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">MyMD Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Akers Biosciences, Inc. (Nasdaq: AKER)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/31/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">StemoniX Inc. (Vyant Bio)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cancer Genetics, Inc. (Nasdaq: CGIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ChemomAb Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anchiano Therapeutics Ltd. (Nasdaq: ANCN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viracta Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quellis Biosciences, Inc. (Astria)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catabasis Pharmaceuticals (Nasdaq: CATB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteostasis Therapeutics (Nasdaq: PTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Petros Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurotrope, Inc. (NasdaqCM: NTRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/23/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">F<span class="nobreak">-star</span> Therapeutics, Limited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spring Bank Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/5/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocuphire Pharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rexahn Pharmaceuticals (Nasdaq: REXN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/27/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viridian Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Miragen Therapeutics, Inc. (NasdaqCM: MGEN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adicet Bio, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">resTORbio, Inc. (NasdaqGS: TORC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anelixis Therapeutics (Eledon)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Novus Therapeutics, Inc. (NasdaqCM: NVUS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/6/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kiq Bio (Cogent)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Unum Therapeutics, Inc. (NASDAQ:&#160;UMRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tocagen Inc. (NasdaqGS: TOCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/28/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Larimar Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Zafgen, Inc. (NasdaqGS: ZFGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/26/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Conatus Pharmaceuticals (Nasdaq: CNAT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Qualigen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ritter Pharmaceuticals (Nasdaq: RTTR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/18/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Timber Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">BioPharmX Corporation (AMEX: BPMX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Curetis NV (Euronext: CURE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OpGen, Inc. (NasdaqCM: OPGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Protara Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteon Therapeutics, Inc. (NASDAQ:&#160;PRTO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/30/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuroBo Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemphire Therapeutics Inc. (NASDAQ:&#160;GEMP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/7/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Venus Concept Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Restoration Robotics, Inc. (NASDAQ:&#160;HAIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/27/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocugen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogenics Corporation (NASDAQ:&#160;HSGX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Brickell Biotech, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vical Incorporated (NASDAQ:&#160;VICL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ESSA Pharma (NASDAQ: EPIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Realm Therapeutics plc (NASDAQ:&#160;RLM)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/22/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Salarius Pharmaceuticals, LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Flex Pharma, Inc. (NASDAQ:&#160;FLKS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/15/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuBase Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ohr Pharmaceutical (NASDAQ:&#160;OHRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/10/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncternal Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GTx, Inc. (NASDAQ:&#160;GTXI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edesa Biotech Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stellar Biotechnologies, Inc. (NASDAQ:&#160;SBOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Armata Pharmaceuticals (f.k.a C3J)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ampliphi Biosciences (NYSE:&#160;APHB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/6/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adynxx, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Alliqua BioMedical, Inc. (NASDAQ:&#160;ALQA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/23/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mereo BioPharma (AIM: MPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncomed Pharmaceuticals (NASDAQ:&#160;OMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/12/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunic AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vital Therapies, Inc. (NASDAQ: VTL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>

		</table>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/26/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enlivex Therapeutics Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Bioblast Pharma Ltd. (NASDAQ:&#160;ORPN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/18/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PDS Biotechnology Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edge Therapeutics, Inc. (NASDAQ:&#160;EDGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">X4 Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arsanis, Inc. (NASDAQ:&#160;ASNS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/24/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seelos Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Apricus Biosciences, Inc. (NASDAQ: APRI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/7/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OvaScience, Inc. (NASDAQ:&#160;OVAS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/12/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aravive Biologics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Versartis, Inc. (NASDAQ:&#160;VSAR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/13/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vaxart, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aviragen Therapeutics, Inc. (NASDAQ:&#160;AVIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/30/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Innovate Biopharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Monster Digital, Inc. (NASDAQ:&#160;MSDI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/17/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Evofem Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neothetics, Inc. (NASDAQ:&#160;NEOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/4/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rocket Pharmaceuticals, Ltd</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Inotek Pharmaceuticals Corp (NASDAQ:&#160;ITEK)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0.0&#160;million to $44.0&#160;million. The 25<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile and the 75<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile for the value delivered for the public vehicle (net of cash), was $5.0&#160;million and $17.0&#160;million respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised ARCA&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of ARCA and Oruka. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of ARCA, Oruka, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by ARCA&#8217;s board of directors in making its decision to enter into the merger agreement and should not be considered as determinative of such a decision.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid was selected by ARCA&#8217;s board of directors to render an opinion to ARCA&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and because, as part of its investment banking business, Lucid is continually engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid and its affiliates may trade the equity securities of ARCA for its own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. In the two&#160;years preceding the date hereof, Lucid has not received any fees from ARCA.&#160;In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka and has not received any fees from Oruka. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or certain of their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Engagement Letter between Lucid and ARCA as of the time the merger agreement was approved, if the merger is consummated, Lucid will be entitled to receive a transaction fee of $800,000 payable in cash at the closing of the transaction. ARCA has also paid Lucid a fee for the Lucid Opinion of $250,000 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(in addition to the $800,000 transaction fee payable upon closing of the transaction) upon delivery of the Lucid Opinion. Additionally, ARCA has agreed to reimburse Lucid for its&#160;out<span class="nobreak">-of-pocket</span>&#160;expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between ARCA and Lucid, and ARCA&#8217;s board of directors was aware of the arrangement, including the fact that a portion of the fee payable to Lucid is contingent upon the completion of the merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration. The following table sets forth, for each ARCA executive officer and each member of ARCA&#8217;s board of directors the aggregate number of ARCA stock options that were unvested and vested as of May&#160;3, 2024 and the weighted<span class="nobreak">-average</span> exercise price.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Unvested<br/>ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Unvested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Vested&#160;ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Vested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,443</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.95</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,828</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,872</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.82</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.96</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.05</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.17</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Retention Bonus Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to a retention bonus letter, as amended from time to time, pursuant to which the ARCA executive officer will receive a retention bonus of $165,000, subject to his continued employment with ARCA in good standing through the earlier of a corporate transaction of ARCA or certain clinical development decisions. The Merger will constitute a corporate transaction of ARCA for purposes of the retention bonus letters.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to an employment agreement that provides certain payments and benefits upon a termination of employment without cause by ARCA or a resignation by the officer for good reason (each as defined below) on the same&#160;day as a corporation transaction of ARCA or within 13&#160;months after a corporation transaction of ARCA.&#160;The Merger will constitute a corporate transaction of ARCA for purposes of the employment agreements. These payments and benefits include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Severance pay equal to (i)&#160;12&#160;months of the ARCA executive officer&#8217;s base salary, payable in installments over 12&#160;months, plus (ii)&#160;a pro rata portion of any bonus compensation approved for the fiscal year in which the termination occurs, payable when bonuses for such year are otherwise paid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reimbursement of out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for up to 12&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the employment agreements provides that ARCA may, in its sole discretion, pay additional severance pay of up to 12&#160;months of base salary to extend the term of the restrictive covenants applicable to the ARCA executive officer. The severance payments and benefits are subject to the ARCA executive officer&#8217;s release of claims in a form acceptable to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The employment agreements do not contain tax gross<span class="nobreak">-up</span> provisions with respect to excise taxes under Section&#160;4999 of the Code. Instead, the severance payments and benefits are subject to a &#8220;best<span class="nobreak">-of-net</span>&#8221; provision in the event of excess parachute payments under Section&#160;280G of the Code. In the event excise taxes under Section&#160;4999 of the Code would be imposed on payments made under the employment agreements, the ARCA executive officer will either pay the excise tax or have his payments and benefits reduced to an amount at which an excise tax no longer applies, based on which result is more favorable to the ARCA executive officer on an after<span class="nobreak">-tax</span> basis</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For purposes of the employment agreements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Cause&#8221; generally means that the ARCA executive officer has committed or engaged in: (i)&#160;willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; (ii)&#160;refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or (iii)&#160;violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement, intellectual property agreement or any other contract with ARCA</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Good Reason&#8221; generally means, with the ARCA executive officer&#8217;s consent: (i)&#160;geographic relocation by more than 30 miles; (ii)&#160;a decrease in base salary by more than 15%, other than a decrease resulting from a general reduction in the base salary of all ARCA executive officers; or (iii)&#160;significant detrimental reductions in the ARCA executive officer&#8217;s job responsibilities, in each case, subject to standard notice and cure provisions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As discussed under &#8220;ARCA Director Compensation&#8221; below, Chairman of ARCA&#8217;s board of directors, Robert&#160;E. Conway, and other members of ARCA&#8217;s board of directors, including Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span> (served from June 2022 to April 2024), served on the Special Committee beginning in 2022, pursuant to which they each received enhanced retainers totaling: $105,000 for each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $90,000 for Jacob Ma<span class="nobreak">-Weaver</span>. In April 2024, James Flynn replaced Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> on the Special Committee. Each member of the Special Committee will continue to be paid $7,500 per month for each month of substantive service on the Special Committee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Dividend</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0<span class="nobreak"> </span>million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage. For a discussion of the indemnification and insurance provisions related to the ARCA directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In accordance with Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span>, the table below sets forth the compensation that is based on or otherwise relates to the Offer and the Merger that may be paid or become payable to each of ARCA named executive officer in connection with the Merger. Please see the previous portions of this section for further information regarding this compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The amounts indicated in the table below are estimates of the amounts that would be payable assuming, solely for purposes of this table, that (i)&#160;the Merger was consummated on May&#160;1, 2024, (ii)&#160;each ARCA named executive officer&#8217;s employment was terminated by ARCA without cause immediately following consummation of the Merger, (ii)&#160;the value per share of ARCA common stock on consummation of the Merger is $3.09 (which, in accordance with SEC requirements, is equal to the average closing price of a share of ARCA common stock over the first five&#160;business days following the first public announcement of the Merger on April&#160;3, 2024), and (iii)&#160;the Parent Closing Price is $3.09. The ARCA named executive officer will not receive pension, tax reimbursement or other benefits in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some of the amounts set forth in the table would be payable solely by virtue of the consummation of the Merger. In addition to the assumptions regarding the consummation date of the Merger and the termination of employment, these estimates are based on certain other assumptions that are described in the footnotes accompanying the table below. Accordingly, the ultimate values to be received by an ARCA named executive officer in connection with the Merger may differ from the amounts set forth below.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Equity&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Perquisites/<br/>Benefits&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total&#160;($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">380,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">505,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,746</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549,635</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">435,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,310</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,579</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473,889</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The cash amounts represent: (i)&#160;with respect to Mr.&#160;Bristow, the cash severance payments that are payable to him in connection with his prior termination of employment pursuant to his Separation Agreement and Release with ARCA dated April&#160;3, 2024, as described under &#8220;ARCA Executive Compensation&#160;&#8212;&#160;Narrative Disclosure to Summary Compensation Table&#160;&#8212;&#160;Employment Agreements or Arrangements&#8221; below, which are being included herein out of an abundance of caution but which will be payable notwithstanding the consummation of the Merger, and (ii)&#160;with respect to Mr.&#160;Keuer and Mr.&#160;Dekker, (A)&#160;a $165,000 retention bonus payable in connection with the closing of the Merger, which constitutes a single<span class="nobreak">-trigger</span> benefit, and (B)&#160;aggregate cash severance payments of $340,000 with respect to Mr.&#160;Keuer and $270,000 with respect to Mr.&#160;Dekker that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Employment Agreements</span>.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents ARCA stock options (which ARCA refers to as the &#8220;Executive Equity Awards&#8221;) that will accelerate and vest in the Merger, assuming, solely for purposes of this table, continued employment or service of each ARCA named executive officer through the Closing Date. Pursuant to the Merger Agreement, each Executive Equity Award will fully accelerate on the Closing Date and thus constitute a single<span class="nobreak">-trigger</span> benefit. No value is reflected herein for any Executive Equity Award with an exercise price in excess of $3.09, as Executive Equity Awards with values in excess of the Parent Closing Price will </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">be cancelled for no consideration. The values for each Executive Equity Award with an exercise price in excess of $3.09 in the table below represent the product of (i)&#160;the difference between $3.09 and the applicable exercise price of the Executive Equity Award, multiplied by (ii)&#160;the number of shares of ARCA common stock subject to the Executive Equity Award, as applicable, that accelerate and vest in connection with the Merger:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of<br/>ARCA<br/>Shares&#160;Subject&#160;to<br/>Executive&#160;Equity<br/>Award (#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Per&#160;Share&#160;Value<br/>of&#160;Executive<br/>Equity&#160;Award<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total ($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,194</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,861</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,966</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:8pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated value of the premiums ARCA would be required to reimburse to Messrs. Keuer and Dekker for continued health coverage under COBRA for a period of 12&#160;months that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;&#8212;&#160;Employment Agreements.&#8221;</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, terminated employment with ARCA on April&#160;3, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Ownership Interests</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual. Each of Oruka&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, Fairmount Fund&#160;II, an affiliate of Peter Harwin, an Oruka director, Lawrence Klein, Oruka&#8217;s President and Chief Executive Officer, and Turtle Family Trust, of which Cameron Turtle, an Oruka director, is a trustee, also currently hold shares of Oruka capital stock. The table below sets forth the ownership of Oruka capital stock by Fairmount Fund&#160;II, Lawrence Klein and Turtle Family Trust as of May&#160;13, 2024. Fairmount Fund II also holds the Convertible Note and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Private Placement of Securities</span>&#8221; beginning on page 281 of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stockholder</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares of <br/>Capital Stock <br/>hel</span>d</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II L.P.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Turtle Family Trust</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount Healthcare Fund&#160;II GP LLC (&#8220;Fairmount GP&#160;II&#8221;) is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;), as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200&#160;Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein. Such shares were purchased by Mr.<span class="nobreak"> </span>Klein, in anticipation of his service as Oruka&#8217;s Chief Executive Officer, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on February 26, 2025 and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee. Such shares were purchased by Dr. Turtle, in anticipation of his service on the Oruka board of directors, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on March 1, 2025 and in equal monthly installments for the 36 months thereafter.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Klein Anti-Dilution Provision</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at the Target Ownership Percentage until Oruka has raised an aggregate of the Covered Limit. As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger under Oruka&#8217;s 2024 Equity Incentive Plan and that, following assumption by ARCA at the effective time of the First Merger, will be eligible to be registered on Form&#160;S<span class="nobreak">-8</span>, whether or not vested, will be converted into an option to purchase shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Oruka common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Oruka&#8217;s 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Oruka common stock is evidenced. The table below sets forth information regarding the Oruka stock options held as of May&#160;13, 2024 by each of Oruka&#8217;s current executive officers and non<span class="nobreak">-employee</span> directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the exchange ratio.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">225,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Employee Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">350,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Management Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the section captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; beginning on page 273 of this proxy statement/prospectus certain of Oruka&#8217;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For a discussion of the indemnification and insurance provisions related to the Oruka directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i)&#160;at the First Effective Time, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and (ii)&#160;as part of the same overall transaction at the completion of the Second Merger (the &#8220;Second Effective Time&#8221;), Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration and Adjustment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka pre<span class="nobreak">-closing</span> financing) shall be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock that a holder of Oruka preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On or prior to the closing date, ARCA and Oruka will select an exchange agent and, at the First Effective Time (as defined herein), ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka preferred stock calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Oruka preferred stock who will receive ARCA Series&#160;B Preferred Stock issuable in exchange for such Oruka preferred stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock or ARCA Series&#160;B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or ARCA Series&#160;B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">First Effective Time and Second Effective Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the Second Certificate of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, ARCA must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC.&#160;ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of U.S.&#160;federal income tax consequences of the Merger generally applicable to a U.S.&#160;holder (as defined below) of Oruka common stock or Oruka preferred stock (&#8220;Oruka stock&#8221;). This discussion applies only to a U.S.&#160;holder that holds its Oruka stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their Oruka stock that constitutes &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their Oruka stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who exercise dissenters&#8217; rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of Oruka stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their Oruka stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the Merger under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the Merger under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, (iv)&#160;the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including any transaction in which shares of Oruka stock are acquired, or (v)&#160;the tax consequences to holders of Oruka stock options, Oruka warrants or similar rights to acquire Oruka stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has not and does not intend to seek any rulings from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the Merger. There can be no assurance that the IRS will not take positions inconsistent with the consequences discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds Oruka stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any Oruka stock and each person that is treated as a partner of such partnership should consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of Oruka stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka intend that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the Merger so qualifies, a U.S.&#160;holder of Oruka stock generally will not recognize any gain or loss for U.S.&#160;federal income tax purposes upon receipt of ARCA common stock or ARCA Series&#160;B Preferred Stock (&#8220;ARCA stock&#8221;) in the Merger, as applicable. Each U.S.&#160;holder&#8217;s aggregate tax basis in the ARCA stock received in the Merger will equal such U.S.&#160;holder&#8217;s aggregate adjusted tax basis in the Oruka stock surrendered in the Merger. The holding period of the ARCA stock received by a U.S.&#160;holder in the Merger will include such U.S.&#160;holder&#8217;s holding period for the Oruka stock surrendered in the Merger. If a U.S.&#160;holder holds different blocks of Oruka stock (generally, Oruka stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult his, her or its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA stock received in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each U.S.&#160;holder who receives ARCA stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S.&#160;holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Oruka is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such U.S.&#160;holder&#8217;s Oruka stock surrendered in the Merger, the fair market value of such Oruka stock, the date of the Merger and the name and employer identification number of each of Oruka and ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the Merger is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the Merger to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of the material U.S.&#160;federal income tax considerations generally applicable to U.S.&#160;holder (as defined below) of ARCA common stock who receive the special cash dividend. This section applies only to U.S.&#160;holders that hold their ARCA common stock as capital assets for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations; qualified foreign pension funds (or entities wholly owned by one or more qualified foreign pension funds);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock in a transaction subject to the gain rollover provisions under Section&#160;1045 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion right under convertible instruments; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S.&#160;federal taxes other than those pertaining to U.S.&#160;federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S.&#160;state or local or non<span class="nobreak">-U</span>.S.&#160;taxation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has not and does not intend to seek any rulings from the IRS regarding the special cash dividend. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Partnerships holding any ARCA common stock and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S.&#160;federal income tax consequences of the special cash dividend to them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual who is a citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is treated as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons (within the meaning of Section&#160;7701(a)(30)&#160;of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person (within the meaning of Section&#160;7701(a)(30)&#160;of the Code).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion assumes that the distribution of the special cash dividend to holders of ARCA common stock will be treated for U.S.&#160;federal income tax purposes as a transaction that is separate and distinct from the Merger and the proposed reverse stock split. If, contrary to that assumption, the distribution of the special cash dividend to a holder of ARCA common stock were integrated for tax purposes with the proposed reverse stock split, this could affect the calculation of the extent to which the distribution constitutes a taxable dividend or capital gain.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Receipt of the Special Cash Dividend by U.S.&#160;Holders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of the special cash dividend should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the U.S.&#160;holder&#8217;s basis in its ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining value. Such capital gain will be long<span class="nobreak">-term</span> capital gain if the U.S.&#160;holder&#8217;s holding period in the ARCA common stock exceeds one year at the time of the special cash dividend. Preferential tax rates may apply to long<span class="nobreak">-term</span> capital gains of non<span class="nobreak">-corporate</span> U.S.&#160;holders (including individuals). ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder of ARCA common stock may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes with respect to the special cash dividends. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of ARCA common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the ARCA Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing date of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Oruka in preparing and filing an initial listing application for the ARCA common stock issued to Oruka stockholders (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Merger Agreement, each of ARCA&#8217;s and Oruka&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Nasdaq Listing Application is approved, ARCA anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the combined company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;GAAP as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the DGCL, ARCA stockholders are not entitled to appraisal rights in connection with the Merger. Oruka stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The discussion below is not a complete summary regarding Oruka&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span>.&#160;Failure to follow precisely any of the statutory procedures set forth in <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Oruka stockholders exercise their appraisal rights under Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten&#160;days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, within ten&#160;days after the effective date of the Merger, Oruka will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Oruka capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Oruka within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Oruka of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Oruka capital stock held by such stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025 and should be executed by, or on behalf of, the record holder of shares of Oruka capital stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ALL DEMANDS MUST BE RECEIVED BY ORUKA WITHIN&#160;20 DAYS AFTER THE DATE ORUKA MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Oruka capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be effective, a demand for appraisal by a holder of shares of Oruka capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Oruka. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold your shares of Oruka capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Oruka. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and ARCA, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP, Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In Cede&#160;&amp; Co. v. Technicolor, Inc., the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Oruka capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T21"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE MERGER AGREEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about ARCA, Oruka, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement contains representations and warranties that ARCA, First Merger Sub and Second Merger Sub, on the one hand, and Oruka, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure letters exchanged by the parties in connection with signing the Merger Agreement. While ARCA and Oruka do not believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure letters do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about ARCA or Oruka, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between ARCA, First Merger Sub, Second Merger Sub and Oruka and are modified by the disclosure letters.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the closing of the Merger, First Merger Sub, a wholly owned subsidiary of ARCA formed by ARCA in connection with the Merger, will merge with and into Oruka, with Oruka surviving as a wholly owned subsidiary of ARCA, and immediately following such Merger, and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub and with Second Merger Sub being the surviving entity of such Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Completion and Effectiveness of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the certificates of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Oruka common stock (including any shares of Oruka common stock issued pursuant to Oruka&#8217;s pre<span class="nobreak">-closing</span> financing) outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio described in more detail below, and each share of Oruka&#8217;s preferred stock outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA&#8217;s convertible preferred stock equal to (x)&#160;the exchange ratio described in more details below <span class="Italic" style="font-style:italic;font-weight:normal;">divided by</span> (y)&#160;1,000. No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) shall </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exchange Ratio</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio is calculated using a formula intended to allocate existing ARCA and Oruka securityholders a percentage of the combined company. Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio was estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimate is subject to adjustment prior to closing of the First Merger for net cash as of 11:59&#160;p.m. Eastern Time on the business&#160;day prior to the anticipated closing date (and as a result, ARCA securityholders could own less, and Oruka securityholders (including, for this purpose, investors in the Oruka pre<span class="nobreak">-closing</span> financing) could own more, or vice versa, of the combined company). ARCA management currently anticipates that ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the estimates set forth above, after giving effect to the Oruka pre<span class="nobreak">-closing</span> financing, and certain other assumptions, immediately following the completion of the Merger, ARCA securityholders would own approximately 2.39% of the capital stock of the combined company post<span class="nobreak">-Merger</span>, and Oruka securityholders, including shares of Oruka common stock and Oruka warrants purchased in the Oruka pre<span class="nobreak">-closing</span> financing, would own approximately 97.61% of the capital stock of the combined company post<span class="nobreak">-Merger</span>. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. For more information on the Oruka pre<span class="nobreak">-closing</span> financing, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Subscription Agreement</span>&#8221; beginning on page 153 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Oruka merger shares (defined below) by the Oruka outstanding shares (defined below), in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Aggregate valuation&#8221; means the sum of (i)&#160;the Oruka valuation plus (ii)&#160;the ARCA valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka allocation percentage&#8221; means the percentage (rounded to four decimal places) determined by subtracting the ARCA allocation percentage from 100%.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka merger shares&#8221; means the product determined by multiplying (i)&#160;the post<span class="nobreak">-closing</span> ARCA shares by (ii)&#160;the Oruka allocation percentage.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka outstanding shares&#8221; means, without duplication, the total number of shares of Oruka capital stock outstanding immediately prior to the First Effective Time, (including any shares of Oruka common stock or Oruka preferred stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Oruka pre<span class="nobreak">-closing</span> financing), expressed on a fully diluted and as<span class="nobreak">-converted-to-Oruka</span> common stock basis, assuming, without limitation or duplication, the exercise of all options and warrants to acquire Oruka&#8217;s capital stock and other rights or commitments to receive shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including the convertible promissory note convertible into Oruka common stock), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. The calculation of Oruka outstanding shares:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>excludes, to avoid the double<span class="nobreak">-counting</span> of, any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including any convertible promissory note convertible into Oruka common stock) to the extent such shares or securities are contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>includes to the extent not already issued prior to the First Effective Time, (i)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable to the &#8220;Paragon Entities&#8221; (as such term is defined in Oruka&#8217;s organizational documents) as a result of the contemplated transactions pursuant to Oruka&#8217;s organizational documents and (ii)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable pursuant to an offer letter set forth in the Oruka disclosure letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka valuation&#8221; means (i)&#160;$175&#160;million <span class="Italic" style="font-style:italic;font-weight:normal;">plus</span> (ii)&#160;the amount of proceeds actually received by Oruka from the Oruka pre<span class="nobreak">-closing</span> financing (including in the proceeds actually received from any convertible promissory notes convertible into Oruka common stock, and any interest thereon, contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA allocation percentage&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by dividing (i)&#160;the ARCA valuation by (ii)&#160;the aggregate valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA outstanding shares&#8221; means, without duplication, (including, without limitation, the effects of any reverse split, if completed) the total number of shares of ARCA common stock outstanding immediately prior to the First Effective Time expressed on a fully<span class="nobreak">-diluted</span> basis, and assuming, without limitation or duplication, the issuance of shares of ARCA common stock in respect of all options, warrants or other rights or commitments to receive shares of ARCA common stock or ARCA preferred stock (or securities convertible or exercisable into shares of ARCA common stock or ARCA preferred stock, but excluding any ARCA convertible preferred stock issuable as a result of the Merger), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time other than options to acquire shares of ARCA common stock to the extent cancelled at or prior to closing under Section&#160;6.6(c)&#160;of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA valuation&#8221; means (i)&#160;$11,000,000, minus (ii)&#160;the amount by which ARCA net cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Post<span class="nobreak">-closing</span> ARCA shares&#8221; means the quotient determined by dividing (i)&#160;the ARCA outstanding shares by (ii)&#160;the ARCA allocation percentage. The estimated exchange ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully<span class="nobreak">-diluted</span> basis as of March<span class="nobreak">&#160;</span>31, 2024 using a stipulated value of Oruka of approximately $450&#160;million (including the Oruka pre<span class="nobreak">-closing</span> financing) and of ARCA of approximately $11&#160;million. For more information, see &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information.</span>&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Calculation of ARCA&#8217;s Net Cash</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Merger Agreement, ARCA&#8217;s &#8220;net cash&#8221; means, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in ARCA&#8217;s SEC filings or ARCA&#8217;s balance sheet;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Certain ARCA prepaid expenses set forth in ARCA&#8217;s disclosure letter; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All receivables which ARCA and Oruka may mutually agree are recoverable by or provide benefit to ARCA after the First Effective Time (if any).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s consolidated short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> contractual obligations and liabilities accrued at the closing date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the ARCA&#8217;s SEC reports and its balance sheet;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The aggregate amount (without duplication) of all fees and expenses incurred by ARCA prior to the First Effective Time in connection with the contemplated transactions or the sale of ARCA&#8217;s legacy business, in each case, to the extent unpaid as of the First Effective Time, including;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of ARCA in connection with the transactions contemplated by the Merger Agreement or the sale of ARCA&#8217;s legacy business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees and expenses in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees associated with the filing of Oruka&#8217;s initial listing application with Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any bonus, retention payments, severance, change<span class="nobreak">-in-control</span> payments or similar payment obligations (including payments with &#8220;single<span class="nobreak">-trigger</span>&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the contemplated transactions or the sale of ARCA&#8217;s legacy business, together with any payroll taxes associated therewith;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the dividend by ARCA of any excess net cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All remaining rent payments and any other liabilities under ARCA&#8217;s lease obligations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Any unpaid taxes of ARCA and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All costs and expenses to be mutually agreed by ARCA and Oruka relating to the winding down of ARCA&#8217;s legacy business, including the sale, license or other disposition of any or all of ARCA&#8217;s legacy business to the extent unpaid as of the closing; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The amounts due and payable to holders of options to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price that are cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such options, in accordance with the Merger Agreement, to the extent unpaid as of the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No later than five&#160;business days prior to the anticipated closing date, (i)&#160;ARCA will deliver to Oruka a net cash schedule setting forth, in reasonable detail, ARCA&#8217;s good faith estimated calculation of its net cash and (ii)&#160;Oruka will deliver to ARCA a Oruka valuation schedule setting forth, in reasonable detail, Oruka&#8217;s good faith estimated calculations of the components of Oruka&#8217;s valuation, in each case, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, prepared and certified by ARCA&#8217;s and Oruka&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back<span class="nobreak">-up</span> materials used or useful in preparing the net cash schedule and Oruka valuation schedule, respectively. No later than three&#160;business days after delivery of such net cash schedule (the last&#160;day of such period referred to as the response date), Oruka will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to ARCA (referred to herein as a dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to ARCA&#8217;s net cash calculation. No later than three&#160;business days after delivery of such Oruka valuation schedule (the last&#160;day of such period referred to as the response date), ARCA will have the right to dispute any part of such schedule by delivering a written notice to that effect to Oruka (referred to herein as an Oruka valuation dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Oruka&#8217;s valuation calculation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka disputes the net cash schedule or ARCA disputes the Oruka valuation schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed<span class="nobreak">-upon</span> determination of net cash and/or Oruka&#8217;s valuation, as the case may be. If the parties are unable to negotiate an agreed<span class="nobreak">-upon</span> determination of the disputed items or component thereof within three&#160;days after the delivery of the relevant dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by ARCA and Oruka. The determination of the amount of net cash or Oruka valuation made by such auditor shall be final and binding on ARCA and Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s net cash balance is subject to numerous factors, some of which are outside of ARCA&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if ARCA and Oruka are not able to agree upon the amount of ARCA&#8217;s net cash as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka stock option assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka option assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Warrants</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock (including any pre<span class="nobreak">-funded</span> Oruka warrants issued pursuant to the Oruka pre<span class="nobreak">-closing</span> financing) that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock issuable upon exercise of the Oruka warrant that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price for the ARCA common stock issuable upon exercise of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of ARCA common stock subject to such Oruka warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Oruka warrant will otherwise remain unchanged.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock and ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and<span class="Superscript" style="vertical-align:super;"> </span>the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the volume weighted average closing trading price of a share of ARCA common stock on Nasdaq for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;) will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Oruka Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing date of the First Merger, ARCA will select an exchange agent and, at the First Effective Time, ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock and ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock and Oruka preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock or Oruka preferred stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or preferred stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Officers of ARCA Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, each of the directors and officers of ARCA will resign effective as of the First Effective Time and ARCA&#8217;s board of directors will thereafter consist of a total of six new directors designated by Oruka. Oruka has designated Lawrence Klein, Kristine Ball, Carl Dambkowski, Cameron Turtle, Peter Harwin, and Samarth Kulkarni to serve as members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, upon the closing of the Merger, Lawrence Klein will serve as Chief Executive Officer and President, Arjun Agarwal will serve as Senior Vice President, Finance and Treasurer, Joana Goncalves will serve as Chief Medical Officer, and Paul Quinlan will serve as General Counsel and Secretary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA agreed to amend its amended and restated certificate of incorporation to (i)&#160;change ARCA&#8217;s name to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the Merger consideration and (iv)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to the amount proposed in this Proxy Statement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Representations and Warranties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains customary representations and warranties of ARCA, First Merger Sub and Second Merger Sub, on one hand, and Oruka, on the other hand, for a transaction of this type relating to, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>corporate organization and power, and similar corporate matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>due organization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>organizational documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authority to enter into the Merger Agreement and the related agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>votes required for completion of the Merger and approval of the proposals that will come before the ARCA special meeting of stockholders and that will be the subject of the Oruka stockholder approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>capitalization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial statements and, with respect to ARCA, documents filed with the SEC and the accuracy of information contained in those documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material changes or events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>title to assets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real property and leaseholds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>intellectual property;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material contracts;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach of such contracts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory compliance, permits and restrictions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legal proceedings and orders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>tax matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>employee and labor matters and benefit plans;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>environmental matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>insurance;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial advisors fees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain transactions or relationships with affiliates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>privacy and data security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to ARCA, the valid issuance in the Merger of ARCA common stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to Oruka, the lack of ownership of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of the Company form the basis of certain of the conditions to the obligations of ARCA and Oruka to complete the Merger, subject to materiality thresholds.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Covenants; Conduct of Business Pending the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has agreed that, except as permitted by the Merger Agreement, as required by law, or unless Oruka has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, ARCA and its subsidiaries will use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain material contracts. ARCA has also agreed that, subject to certain limited exceptions, without the consent of Oruka, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of ARCA common stock from terminated employees, directors or consultants of ARCA);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for ARCA common stock issued upon the valid exercise of outstanding ARCA options or ARCA RSUs), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other similar organizational documents of ARCA or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment in excess of $25,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit<span class="nobreak">-sharing</span> or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire any officer, employee or consultant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights of ARCA (other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of business: make, change or revoke any material tax election; file any amended income or other material tax return; adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against ARCA or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the operations or businesses of ARCA or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by ARCA or any of its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>forgive any loans to any person, including its employees, officers, directors or affiliate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>materially change pricing or royalties or other payments set or charged by ARCA or any of subsidiaries to its customers or licensees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to ARCA or any of subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to ARCA or terminate any of ARCA&#8217;s material contracts outside the ordinary course of business; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing restrictions, ARCA is expressly permitted to engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of its legacy business (including terminating its real estate leases and other contracts) and is expressly permitted to declare and pay a dividend on the shares of ARCA common stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of ARCA&#8217;s common stock issuable pursuant to the Merger), up to an amount equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash at the First Effective Time will exceed $5.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has agreed that, except as permitted by the Merger Agreement, as required by law, or unless ARCA shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Oruka will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain contracts. Oruka has also agreed that, subject to certain limited exceptions, without the consent of ARCA, it will not, and will not cause or permit its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Oruka);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other organizational documents of Oruka or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing actions with respect to more than 25% of the shares of Oruka capital stock outstanding as of the date the Merger Agreement was signed: any capital stock or other security of Oruka or its subsidiaries (except for shares of outstanding Oruka common stock issued upon the valid exercise or settlement of Oruka options or warrants in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Oruka or its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights owned by Oruka, other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against Oruka, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Oruka or any equitable relief on, or the admission of wrongdoing by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to Oruka or terminate any material contract outside of the ordinary course of its business; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Solicitation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka have agreed that, except as described below, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for non<span class="nobreak">-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by Oruka, on the one hand, or ARCA on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Oruka or any of its affiliates, on the one hand, or by or on behalf of ARCA or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than a sale by ARCA of its legacy assets, the issuance of convertible notes by Oruka or the Oruka pre<span class="nobreak">-closing</span> financing) involving:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger, consolidation, amalgamation, share exchange, business combination, issuance or acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction: (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of ARCA or Oruka or any of their respective subsidiaries or (ii)&#160;in which ARCA, Oruka or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of ARCA or Oruka and their respective subsidiaries, as applicable, taken as a whole.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the ARCA stockholders or Oruka stockholders required to consummate the Merger, each party may furnish non<span class="nobreak">-public</span> information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non<span class="nobreak">-public</span> information to, or enter into discussions with, such third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between ARCA and Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information to a third party, such party furnishes the same non<span class="nobreak">-public</span> information to the other party to the extent not previously furnished.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A &#8220;Superior Offer&#8221; means an unsolicited <span class="Italic" style="font-style:italic;font-weight:normal;">bona fide</span> written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a)&#160;was not obtained or made as a direct or indirect result of a breach of the Merger Agreement, (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business&#160;day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Recommendation Change</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, subject to certain exceptions described below, both Oruka and ARCA agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, the fact, in and of itself, that ARCA meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or, in the case of ARCA, any sale of ARCA&#8217;s legacy business) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four&#160;business days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business&#160;day notice period and provide the other party with certain information regarding such Superior Offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business&#160;day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel and financial advisors, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Stockholder Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of ARCA common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and an amendment to the ARCA Charter as further described herein (collectively, the &#8220;Merger proposals&#8221;). The ARCA special meeting will be held as promptly as practicable after this registration statement on Form&#160;S<span class="nobreak">-4</span> is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S<span class="nobreak">-4</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after this registration statement on Form&#160;S<span class="nobreak">-4</span> has been declared effective, and no later than two business days thereafter, Oruka is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Oruka&#8217;s capital stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, in each case, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL.&#160;Reasonably promptly following receipt of such consents, Oruka will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. ARCA and Oruka do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Indemnification and Insurance for Directors and Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, from the First Merger Effective Time through the sixth anniversary of the date on which the First Merger Effective Time occurs, ARCA and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of ARCA or of Oruka, whether asserted or claimed prior to, at or after the First Merger Effective Time. From and after the First Merger Effective Time, ARCA and the surviving corporation in the Merger will also fulfill ARCA&#8217;s and Oruka&#8217; indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the ARCA Charter and ARCA Bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From and after the First Merger Effective Time, ARCA will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date of the First Merger, on commercially available terms and conditions and with coverage limits customary for U.S.&#160;public companies similarly situated to ARCA.&#160;In addition, ARCA will secure and purchase a six year &#8220;tail policy&#8221; on ARCA&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, ARCA and Oruka have further agreed that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of ARCA common stock (including any shares of ARCA&#8217;s common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Merger Effective Time.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will keep Oruka reasonably informed regarding any stockholder litigation against ARCA or any of its directors relating to the Merger Agreement or the transactions contemplated thereby.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">ARCA will (i)&#160;give Oruka the opportunity to participate in, but not control, the defense, settlement or prosecution of any such litigation (to the extent that the attorney<span class="nobreak">-client</span> privilege is not undermined or otherwise adversely affected), (ii)&#160;consult with Oruka with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Oruka&#8217;s advice with respect to such litigation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Conditions to the Completion of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following contains a description of all material conditions to the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, which include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn; and any material state securities laws applicable to the issuance of the shares of ARCA&#8217;s capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of ARCA&#8217;s capital stock by any applicable state securities commissioner or court of competent jurisdiction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of a majority of the outstanding shares of Oruka common stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent (the &#8220;Oruka stockholder approval&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of the shares of ARCA common stock constituting a majority of the votes properly cast at the ARCA special meeting must have approved the Merger Agreement and the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initial listing application for ARCA&#8217;s common stock on Nasdaq (including any shares of ARCA&#8217;s common stock issuable upon conversion of the shares of ARCA Series&#160;B Preferred Stock) shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements executed by certain stockholders of Oruka will continue to be in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ARCA Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the ARCA Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party&#8217;s representations and warranties being true and correct as of the closing date, subject to applicable materiality qualifiers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Merger Effective Time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of a material adverse effect that is continuing with respect to the other party; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party having delivered certain certificates and other documents required under the Merger Agreement for the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the obligation of ARCA and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $175&#160;million having been received by Oruka, substantially simultaneously with the closing of the First Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Termination and Termination Fees</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may be terminated at any time before the First Merger Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of ARCA and Oruka;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the Merger has not been consummated by October&#160;3, 2024 (subject to possible extension as provided in the Merger Agreement); <span class="Italic" style="font-style:italic;font-weight:normal;">provided, however</span>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before October&#160;3, 2024 and such action or failure to act constitutes a breach of the Merger Agreement; and <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, that such date will be extended by 60&#160;days by either party in the event that the SEC has not declared effective the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, by the date which is 60&#160;days following October&#160;3, 2024;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if a court of competent jurisdiction or governmental entity has issued a final and non<span class="nobreak">-appealable</span> order, decree or ruling or having the effect of permanently restrains, enjoins or otherwise prohibits the Merger or any of the transactions contemplated by the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, if the Oruka stockholder approval has not been obtained within two&#160;business days of the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, becoming effective; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that this right to terminate the Merger Agreement will not be available to ARCA once Oruka obtains such stockholder approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the ARCA special meeting has been held and completed and ARCA stockholders have taken a final vote on the Merger proposals set forth herein to be considered at the ARCA special meeting, and such proposals have not been approved by the ARCA stockholders; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that ARCA may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of ARCA stockholders was caused by the action or failure to act of ARCA and such action or failure to act constitutes a material breach by ARCA of the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by Oruka, at any time prior to obtaining the approval by ARCA stockholders of the Merger proposals set forth herein to be considered at the ARCA special meeting, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA fails to include in this proxy statement/prospectus ARCA&#8217;s board of directors&#8217; recommendation that ARCA stockholders vote to approve the Merger proposals set forth herein to be considered at the ARCA special meeting;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors, or any committee thereof, makes an ARCA board recommendation change or publicly approves, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, at any time prior to obtaining the Oruka stockholder approval, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors makes a Oruka board recommendation change or publicly proposes, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by Oruka, if ARCA or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of ARCA has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that Oruka is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from Oruka to ARCA or Merger Subs and Oruka&#8217;s intention to terminate pursuant to this paragraph (it being understood that ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by ARCA or Merger Subs is cured prior to such termination becoming effective);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA, if Oruka has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Oruka has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided </span>that ARCA is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from ARCA to Oruka and ARCA&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Oruka is cured prior to such termination becoming effective); or</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA (at any time prior to obtaining the ARCA stockholder approval), upon ARCA&#8217;s board of directors authorizing ARCA to enter into a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a superior offer, subject to certain conditions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA must pay Oruka a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA or Oruka pursuant to clause (e)&#160;above or by Oruka pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the ARCA special meeting, an Acquisition Proposal with respect to ARCA will have been publicly announced, disclosed or otherwise communicated to ARCA&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (e)&#160;above, within 12&#160;months after the date of such termination, ARCA enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka must pay ARCA a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA pursuant to clause (d)&#160;or (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Oruka stockholder approval, an Acquisition Proposal with respect to Oruka will have been publicly announced, disclosed or otherwise communicated to Oruka&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (d)&#160;above, within 12&#160;months after the date of such termination, Oruka enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment and Waiver</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the Merger Agreement and authorized by such party&#8217;s boards of directors at any time, unless the Merger Agreement has been adopted and approved by any party&#8217;s stockholders, in which case no amendment which by law requires further approval by the such party&#8217;s stockholders, may be made without such further approval.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T20"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Support Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into Oruka Support Agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals. Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into ARCA Support Agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Lock-Up Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Oruka stockholders in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days after the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka stockholders who have executed&#160;lock<span class="nobreak">-up</span>&#160;agreements as of March&#160;31, 2024 owned, in the aggregate, approximately 90% of the shares of Oruka&#8217;s outstanding capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing description of the&#160;lock<span class="nobreak">-up</span>&#160;agreements does not purport to be complete and is qualified in its entirety by the full text of the form of&#160;lock<span class="nobreak">-up</span>&#160;agreement, which is attached hereto as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;E</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase immediately prior to the First Merger, shares of Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span>&#160;warrants, representing an aggregate commitment of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span>&#160;financing. Under the Subscription Agreement, the number of shares of Oruka common stock or pre<span class="nobreak">-funded</span> warrants, as applicable, shall be determined at a purchase price per share or warrant equal to (i)&#160;a valuation for Oruka equal to approximately $175.0&#160;million, (ii)&#160;divided by the number of shares of Oruka common stock outstanding immediately prior to the First Effective Time of the Merger (but excluding the securities being issued under the Subscription Agreement). Each share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger. Accordingly, by approving Proposal&#160;No.&#160;1 relating to the Merger, ARCA stockholders will also be approving the issuance of shares of ARCA common stock to be issued in exchange for all shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants that are sold in the Oruka pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each purchaser&#8217;s obligation to purchase shares of Oruka common stock and/or Oruka pre<span class="nobreak">-funded</span> warrants from Oruka pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a compliance certificate by the chief executive officer of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a secretary&#8217;s certificate by the secretary of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than the condition regarding the Oruka pre<span class="nobreak">-closing</span> financing) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no injunction having been issued prohibiting the consummation of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having delivered the registration rights agreement required by the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>this registration statement on Form&#160;S<span class="nobreak">-4</span> shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Nasdaq Listing Application shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka shall receive at closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $175,000,000 (including in the proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an opinion from Company counsel, dated as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s obligation to sell shares of Oruka common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the representations and warranties made by the purchasers being true and correct as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date of the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by each purchaser;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than those conditions which are to be satisfied at the closing of the transactions contemplated by the Merger Agreement)) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Registration Rights Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of Oruka common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time, including the shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing and ARCA pre<span class="nobreak">-funded</span> warrants assumed upon conversion of the Oruka pre<span class="nobreak">-funded</span> warrants sold in the Oruka pre<span class="nobreak">-closing</span> financing (including shares issuable upon exercise of such warrants).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree to prepare and file a resale registration statement covering the resale of the ARCA common stock within 45&#160;days of the closing of the merger pursuant to&#160;Rule&#160;415&#160;and to use its reasonable best efforts to keep such registration statement continuously effective under the&#160;Securities Act&#160;until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold, thereunder or pursuant to&#160;Rule&#160;144&#160;of the&#160;Securities Act&#160;(&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner<span class="nobreak">-of-sale</span> restrictions pursuant to&#160;Rule&#160;144&#160;and without the requirement for the combined company to be in compliance with the current public information requirement under&#160;Rule&#160;144, and (b)&#160;five&#160;years after the date of the registration rights agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree that neither the combined company nor securityholders of the combined company (other than the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing and party to the registration rights agreement) may have &#8220;piggyback&#8221; registration rights and that the combined company will be prohibited from filing any other registration statements until all of the registerable securities subject to the registration rights agreement are registered pursuant to an effective registration statement, subject to certain exceptions. The registration rights agreement also provides that the combined company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of registration rights agreement is attached as Exhibit A to the Subscription Agreement filed as Exhibit 10.2 to this registration statement on Form&#160;S<span class="nobreak">-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the registration rights agreement is qualified in its entirety by reference thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T19"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following sets forth certain information, as of May&#160;3, 2024, concerning ARCA&#8217;s directors and executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s directors, executive officers and key employees as of May&#160;3, 2024 are as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">Name</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Age</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Position</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">65</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">59</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Linda Grais<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)*(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">67</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)*(2)(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;II Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(3)*(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">58</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">36</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;III Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">43</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Audit Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Compensation Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Special Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See &#8220;Election of Board of Directors&#8221; below for discussion of Class&#160;I&#160;&#8212;&#160;III Director service terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer</span>. Mr.&#160;Keuer has served as ARCA&#8217;s Chief Operating Officer since December&#160;2014, and ARCA&#8217;s President since April&#160;2024. Mr.&#160;Keuer served as ARCA&#8217;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining ARCA, Mr.&#160;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&#160;Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&#160;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&#160;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C. Jeffrey Dekker</span>. Mr.&#160;Dekker has served as ARCA&#8217;s Chief Financial Officer and Treasurer since May&#160;2021 and ARCA&#8217;s Secretary since April&#160;2023. Prior to joining ARCA, Mr.&#160;Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr.&#160;Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr.&#160;Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Linda Grais, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Grais has served as a member of ARCA&#8217;s board of directors since May&#160;2007. Dr.&#160;Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January&#160;2008 and became President and Chief Executive Officer of Ocera in June&#160;2012, and served in that role until Ocera&#8217;s acquisition by Mallinckrodt Pharmaceuticals in December&#160;2017. Dr.&#160;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May&#160;2005 until February&#160;2011. From July&#160;1998 to July&#160;2003, Dr.&#160;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&#160;&amp; Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&#160;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr.&#160;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September&#160;2015, Dr.&#160;Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr.&#160;Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January&#160;2019, and joined the board of Collective Health, a private healthcare services company, in March&#160;2023. ARCA believes Dr.&#160;Grais is an appropriate member of the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of ARCA&#8217;s business from her service on ARCA&#8217;s board of directors since 2007.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Robert E.&#160;Conway</span><span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Mr.&#160;Conway was appointed to ARCA&#8217;s board of directors in September&#160;2013, and has served as the Chairman of ARCA&#8217;s board of directors since 2014. Mr.&#160;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&#160;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&#160;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July&#160;2017, Advarra, Inc. from 2019 to August&#160;2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July&#160;2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr.&#160;Conway continues to serve on the board of directors following such combination. In addition, Mr.&#160;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April&#160;2023, Mr.&#160;Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr.&#160;Conway received a B.S. in accounting from Marquette University in 1976. ARCA believes Mr.&#160;Conway is an appropriate member of ARCA&#8217;s board of directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anders Hove, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Hove has served as a member of ARCA&#8217;s board of directors since February&#160;2017. Dr.&#160;Hove is the manager of Acorn Bioventures, a partnership focusing on long<span class="nobreak">-term</span> investments in biotech, specialty pharma and medical device companies. Before Dr.&#160;Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr.&#160;Hove was a founder of Venrock Healthcare Capital Partners, Venrock&#8217;s public funds focused on small capitalization biotech companies and late<span class="nobreak">-stage</span> private companies. From 1996 to 2004, Dr.&#160;Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr.&#160;Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba<span class="nobreak">-Geigy</span> and Novartis. Mr.&#160;Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June&#160;2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr.&#160;Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Europ&#233;en d&#8217;Administration des Affaires). ARCA believes Dr.&#160;Hove is an appropriate member of ARCA&#8217;s board of directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Jacob Ma</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Weaver</span></span> Mr.&#160;Ma<span class="nobreak">-Weaver</span> was appointed to ARCA&#8217;s board of directors in June&#160;2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr.&#160;Ma<span class="nobreak">-Weaver</span> was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge&#160;&amp; Cox and a corporate finance business analyst at McKinsey&#160;&amp; Company. Mr.&#160;Ma<span class="nobreak">-Weaver</span> received a Bachelor of Arts in Comparative Literature&#160;&amp; Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Ma<span class="nobreak">-Weaver</span> is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">James Flynn</span> Mr.&#160;Flynn has served as a member of ARCA&#8217;s board of directors since December&#160;2022. Mr.&#160;Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr.&#160;Flynn has served as a board member for Axiom Health (a provider of software and big<span class="nobreak">-data</span> solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, and joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January&#160;2024. From 2017 to 2018, Mr.&#160;Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr.&#160;Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr.&#160;Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr.&#160;Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr.&#160;Flynn is a </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Flynn is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix (as of May&#160;3, 2024)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table below provides certain highlights of the composition of ARCA&#8217;s board members as of May&#160;3, 2024. Each of the categories listed in the table below has the meaning as it is used in Nasdaq Rule&#160;5605(f).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12">
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix as of May&#160;3, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;Number&#160;of&#160;Directors&#160;and&#160;nominees:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="7" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">5</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;I:&#160;Gender Identity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Male</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Female</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Non-Binary</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Did Not <br/>Disclose&#160;Gender</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;II:&#160;Demographic Background</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">African American or Black</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alaskan Native or American Indian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Asian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hispanic or Latinx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Native Hawaiian or Pacific Islander</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">White</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Two or More Races or Ethnicities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">LGBTQ+</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Did Not Disclose Demographic Background</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T18"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Independence of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. ARCA&#8217;s board of directors consults with ARCA&#8217;s counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and ARCA, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq&#160;listing standards: Mr.&#160;Conway, Dr.&#160;Grais, Dr.&#160;Hove and Mr.&#160;Flynn. In making this determination, the Board of Directors found that none of the directors had a material or other disqualifying relationship with ARCA.&#160;Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer was not an&#160;independent director in 2023 by virtue of his employment relationship with ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has structured its board of directors in a way that ARCA believes effectively serves its objectives of corporate governance and management oversight. ARCA separates the roles of President and Chairman of the board of directors in recognition of the differences between the two roles. ARCA believes that the President should be responsible for the&#160;day<span class="nobreak">-to-day</span> leadership and performance of ARCA, while the Chairman of the board of directors should work with the President and the rest of the board of directors to set the strategic direction for ARCA and provide guidance to, and oversight of the President. The Chairman also sets the agenda for meetings of the board of directors and presides over them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Conway, who is an independent director, was elected Chairman of the board of directors in 2014. In this capacity, Mr.&#160;Conway, among other things, calls and presides over board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&#160;Conway can effectively coordinate between the board of directors and management regarding risk management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the board of directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the work of the board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Role of the Board of Directors in Risk Oversight and Risk Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the board of directors&#8217; key functions is informed oversight of ARCA&#8217;s risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, while the board of directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#8217;s accounting and financial reporting processes. The Nominating and Corporate Governance Committee monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing illegal or improper liability<span class="nobreak">-creating</span> conduct. The Compensation Committee of the board of directors of ARCA (the &#8220;Compensation Committee&#8221;) assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk<span class="nobreak">-taking</span>. The entire board of directors and its committees address risk management issues from time<span class="nobreak">-to-time</span> and at least annually meet with the employees responsible for risk management in the committees&#8217; respective areas of oversight. Both the board of directors as a whole and the various standing committees receive periodic reports </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">from the employees responsible for risk management, as well as&#160;incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the board of directors as quickly as possible.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Meetings of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors met three times during the 2023 fiscal year. The independent members of the board of directors met separately as a group at each of the board meetings in 2023. All members of the board of directors attended at least 75% of the aggregate of (i)&#160;the total number of meetings of the board of directors held during the period for which each director served and (ii)&#160;the total number of meetings held by all committees of the board of directors of which each director was a member during the periods that they served. All of ARCA&#8217;s directors then on the board of directors attended ARCA&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;) whether in person or via telephone.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Election of Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at ARCA&#8217;s annual stockholders&#8217; meetings. The ARCA Charter, as amended, provides that the board of directors is divided into three classes to provide for staggered terms and that each director will serve for a term of three&#160;years or less, depending on the class to which the board of directors has assigned a director not previously elected by the stockholders. There is currently one Class&#160;III director whose term expires at the annual stockholders&#8217; meeting in 2024, three Class&#160;I directors whose terms expire at the annual stockholders&#8217; meeting in 2025 and one Class&#160;II directors whose term expires at the annual meeting in 2026. The one Class&#160;III director, Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span>, is currently scheduled for re<span class="nobreak">-election</span> to the board of directors at this 2024 special meeting in lieu of an annual stockholders&#8217; meeting, for a three<span class="nobreak">-year</span> term ending on the date of the annual meeting in 2027 or until his successor is duly elected and qualified or appointed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s executive officers are appointed by and serve at the discretion of ARCA&#8217;s board of directors. There are no family relationships between ARCA&#8217;s directors and executive officers.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabiopharma.com</span>. If ARCA makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, ARCA will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form&#160;8<span class="nobreak">-K</span> required by applicable law or Nasdaq listing standards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of its securities by its directors, officers and employees, as well as their immediate family members and entities owned or controlled by them, and that is designed to promote compliance with insider trading laws, rules and regulations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information Regarding Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors has three standing committees: The Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended December&#160;31, 2023, for each of the committees of the board of directors:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Audit</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Compensation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nominating <br/>and <br/>Corporate <br/>Governance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Raymond L.&#160;Woosley</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Dan J.&#160;Mitchell</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total meetings in fiscal 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, the board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D and James Flynn (joined the Special Committee in April&#160;2024). Jacob Ma<span class="nobreak">-Weaver</span> served as a member of the Special Committee from June&#160;2022 to April&#160;2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Below is a description of each committee of the board of directors. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.<span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">&#160;</span>The board of directors has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Audit Committee of ARCA&#8217;s board of directors of ARCA (the &#8220;Audit Committee&#8221;) was established by the board of directors in accordance with Section&#160;3(a)(58)(A)&#160;of the Exchange&#160;Act, to oversee ARCA&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non<span class="nobreak">-audit</span> services; monitors the rotation of partners of the independent registered public accounting firm on ARCA&#8217;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by ARCA regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review ARCA&#8217;s annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of ARCA&#8217;s disclosures under the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; discussion in its Annual Reports on Form&#160;10<span class="nobreak">-K</span> and Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>.&#160;The Audit Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Mr.&#160;Conway (chair), Mr.&#160;Flynn and Dr.&#160;Grais. The Audit Committee met six times during the 2023 fiscal year. The board of directors has adopted a written charter of the Audit Committee that is available to stockholders<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>on ARCA&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors reviews the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule&#160;5605(c)(2)(A)(i)&#160;and (ii)&#160;of the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards). The board of directors has also determined that Mr.&#160;Conway qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The board of directors made a qualitative assessment of Mr.&#160;Conway&#8217;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee is currently composed of three directors: Mr.&#160;Conway, Dr.&#160;Grais (chair) and Dr.&#160;Hove. All members of the Compensation Committee are independent, as independence is currently defined in Rule&#160;5605(a)(2)&#160;of the Nasdaq listing standards. The Compensation Committee met two times during the 2023 fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee of ARCA&#8217;s board of directors acts on behalf of the board of directors to review, adopt and oversee ARCA&#8217;s compensation strategy, policies, plans and programs, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>overseeing succession planning for senior management of ARCA, including a review of the performance and advancement potential of current and future senior management and succession plans for each and recommending, as appropriate, the retention of potential succession candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>assessing the overall compensation structure of ARCA and evaluating and recommending changes to ARCA&#8217;s compensation philosophies and strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving performance<span class="nobreak">-based</span> compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>administering, reviewing, and approving all executive compensation programs or plans, and all of ARCA&#8217;s incentive compensation and stock plans and awards thereunder of ARCA, including amendments to the programs, plans or awards made thereunder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparing and approving the report of the Compensation Committee to be included as part of ARCA&#8217;s annual meeting proxy statement, to the extent required.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Committee Processes and Procedures</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Typically, the Compensation Committee meets, as it deems appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee. However, from time to time, various members of management and other employees as well as outside advisors or consultants<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>may be invited by the Compensation Committee to make<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>presentations, to provide financial or other<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>executive<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. In general, the Compensation Committee has set executive compensation to be in line with peer companies identified by the Compensation Committee and to incentivize ARCA&#8217;s executive officers in achieving ARCA&#8217;s short- and long<span class="nobreak">-term</span> corporate goals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Compensation and Nominating and Corporate Governance Committees of ARCA reviewed ARCA&#8217;s current employee and director compensation, including ARCA&#8217;s 2013 Equity Incentive Plan. As part of this review, the Committees considered certain changes to the ARCA&#160;2013 Equity Incentive Plan that were included in the 2020 ARCA Equity Incentive Plan. Both Committees recommended approval of the 2020 ARCA Equity Incentive Plan, and the Plan was subsequently approved by the board of directors and ARCA&#8217;s stockholders on December&#160;10, 2020.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current compensation for the ARCA named executive officers was set by the Compensation Committee and the board of directors in 2020. On December&#160;21, 2020, the Compensation Committee approved the following base salary compensation and target bonus percentages for the ARCA named executive officers and principal financial officer for the 2021 fiscal year:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Michael R.&#160;Bristow, former President and Chief Executive Officer, $345,000 base salary and target bonus of 50% of base salary; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Thomas A.&#160;Keuer, Chief Operating Officer, $340,000 base salary and target bonus of 40% of base salary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;3, 2021, the Compensation Committee approved a $270,000 base salary and target bonus of 35% of base salary for C.&#160;Jeffrey Dekker, Chief Financial Officer, ARCA&#8217;s principal financial officer hired in May&#160;2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high<span class="nobreak">-level</span> strategic issues, such as the efficacy of ARCA&#8217;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee reviews and approves the compensation of the President and the other executive officers of ARCA, including annual base salaries, annual and long<span class="nobreak">-term</span> incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the President, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>by the President. The Compensation Committee evaluates the performance of the President in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other non<span class="nobreak">-employee</span> members of the board of directors and lead the board of directors in an overall review of the President&#8217;s performance in an executive session of non<span class="nobreak">-employee</span> members of the board of directors. If the compensation for the President or any other executive officer is governed by an employment agreement, the Compensation Committee approves such employment agreement and any amendments thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company<span class="nobreak">-wide</span> compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee also considers the results of any &#8220;say<span class="nobreak">-on-pay</span>&#8221; vote of ARCA&#8217;s stockholders with regard to the compensation of ARCA&#8217;s executive officers when making compensation decisions. At the 2023 Annual Meeting, ARCA&#8217;s stockholders approved, on an advisory basis, the compensation of ARCA named executive officers as described in the proxy statement for such annual meeting, with over 81% of stockholder votes cast in favor of ARCA&#8217;s &#8220;say<span class="nobreak">-on-pay</span>&#8221; resolution. The Compensation Committee believes that this advisory vote supports that ARCA&#8217;s current compensation practices are aligned with the best interests of stockholders and anticipates taking into account the results of the advisory vote, and any future advisory votes, when making compensation decisions in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee of the board of directors of ARCA (the &#8220;Nominating and Corporate Governance Committee&#8221;) is responsible for identifying, reviewing and evaluating candidates to serve as directors of ARCA (consistent with criteria approved by the board of directors), reviewing and evaluating incumbent directors, recommending to the board of directors candidates for election to the board of directors , making recommendations to the board of directors regarding compensation for service on the board of directors and the committees thereof, making recommendations to the board of directors regarding the membership of the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">committees of the board of directors, assessing the performance of the board of directors and developing a set of corporate governance principles for ARCA.&#160;The Nominating and Corporate Governance Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Dr.&#160;Hove (chair), Mr.&#160;Conway and Dr.&#160;Grais. All members of the Nominating and Corporate Governance Committee in 2023 were independent (as independence is currently defined in Rule&#160;5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met once during the 2023 fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee periodically reviews the compensation of non<span class="nobreak">-employee</span> Directors for service on the board of directors and committees thereof. In 2015, the Nominating and Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies, and in early 2016, the Committee recommended, and the board of directors approved, revised compensation for non<span class="nobreak">-employee</span> Directors, discussed in &#8220;ARCA Director Compensation&#8221; below. Since adoption of this policy, the Nominating and Corporate Governance Committee has reviewed Director compensation on an annual basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Nominating and Corporate Governance Committee (together with the Compensation Committee) engaged a consultant to evaluate the current compensation of ARCA&#8217;s non<span class="nobreak">-employee</span> directors and make recommendations to the Nominating and Corporate Governance Committee. The changes made as a result of this evaluation are discussed in &#8220;ARCA Director Compensation&#8221; below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The board of directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an individual to the board of directors for membership on the board of directors, the Nominating and Corporate Governance Committee canvasses its members and ARCA&#8217;s management team for potential candidates for the board of directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance Committee will consider stockholders&#8217; recommendations for nominees to serve as director if notice is timely received by the Secretary of ARCA.&#160;Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the board of directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the stockholder notice of nomination is timely made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the board of directors has not adopted a fixed set of minimum qualifications for candidates for membership on the board of directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#8217;s education, professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, the reasonable availability of the potential member to devote time to the affairs of ARCA, as well as any other criteria deemed relevant by the board of directors or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the board of directors, the operating requirements of ARCA and the long<span class="nobreak">-term</span> interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given the current needs of the board of directors and ARCA, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that board of directors members come from a variety of backgrounds and experiences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall contributions to ARCA and the board of directors during their terms, including level of attendance, level of participation, quality of performance and contribution to the board of directors&#8217; responsibilities and actions, and any relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">164</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">backgrounds and qualifications of possible candidates after considering the function and needs of the board of directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then determines whether to recommend a nominee to the board of directors by majority vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the board of directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90&#160;days before the one<span class="nobreak">-year</span> anniversary date of ARCA&#8217;s last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#8217;s business experience for at least the previous five&#160;years, complete biographical information, a description of the proposed nominee&#8217;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#8217;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2023, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Hedging Prohibition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s employees, directors and consultants are prohibited from engaging in any hedging transactions of ARCA&#8217;s securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, as required by ARCA&#8217;s insider trading policy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholder Communications with the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to communicate with ARCA&#8217;s board of directors may do so by e<span class="nobreak">-mail</span> by using the following email address: <span class="Italic" style="font-style:italic;font-weight:normal;">directors@arcabio.com</span>; or by mail by following the directions as set forth on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, under the section titled &#8220;Corporate Governance&#8221; and the subsection titled &#8220;Governance Documents&#8221;. Communications sent in accordance with this process will be transmitted by ARCA to the appropriate board members.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">165</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T17"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31, 2023, collectively, the ARCA named executive officers:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Summary Compensation Table</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name and Principal Position</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Year</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Salary <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Bonus <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Stock <br/>Awards <br/>($)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">All&#160;Other <br/>Compensation <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Total <br/>($)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Former President and Chief Executive Officer<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,802</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,802</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,400</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">448,993</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">270,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,072</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,072</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide with the first and last&#160;days of the year, these amounts may differ from the base salary amounts authorized by ARCA&#8217;s board of directors.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s Annual Report on Form&#160;10<span class="nobreak">-K</span> for the fiscal year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents 401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of 2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579 for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023, group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023 and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Narrative Disclosure to Summary Compensation Table</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Employment Agreements or Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Michael R.&#160;Bristow, M.D., Ph.D.</span>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow provides certain consulting services to ARCA through the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term, Dr.&#160;Bristow will continue to vest in his outstanding equity awards.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">166</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer.</span>&#160;&#160;&#160;&#160;Mr.&#160;Keuer serves as ARCA&#8217;s President and Chief Operating Officer under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Keuer, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Keuer&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Keuer terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Keuer a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Keuer&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Keuer of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Keuer&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Keuer&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Keuer&#8217;s job responsibilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, ARCA&#8217;s board of directors appointed Mr.&#160;Keuer to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s employment is expected to conclude upon closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C.&#160;Jeffrey Dekker.</span>&#160;&#160;&#160;&#160;Mr.&#160;Dekker serves as ARCA&#8217;s Chief Financial Officer under an Employment Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker has served as ARCA&#8217;s Secretary since April&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under his employment agreement, Mr.&#160;Dekker is entitled to receive an annual base salary of $270,000, subject to annual increases if approved by ARCA&#8217;s board of directors or Compensation Committee and is eligible to receive an annual target bonus of 35% of his base salary as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">167</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Dekker, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Dekker&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Dekker terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Dekker a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Dekker&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Dekker of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Dekker&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Dekker&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Dekker&#8217;s job responsibilities.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">168</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Outstanding Equity Awards at Fiscal Year End</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal year<span class="nobreak">-end</span> for ARCA named executive officers.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="8" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option Awards</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Exercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Unexercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Exercise<br/>Price<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option<br/>Expiration<br/>Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, Former President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,511</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,333</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">142,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer, President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker, Secretary, Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,479</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.06</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5/10/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,800</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,900</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 48<span class="nobreak"> </span>monthly installments measured from December&#160;21, 2020.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 36<span class="nobreak"> </span>monthly installments measured from December&#160;14, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vested 25% after one year, then in 36<span class="nobreak"> </span>monthly installments measured from May&#160;10, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a change in control of ARCA, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i)&#160;the one<span class="nobreak">-year</span> anniversary of the closing date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">169</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non<span class="nobreak">-employee</span> directors of ARCA:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Director Compensation</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Fees&#160;Earned <br/>or&#160;Paid&#160;in <br/>Cash&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Awards <br/>($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nonqualified <br/>Deferred <br/>Compensation <br/>Earnings&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">All&#160;Other <br/>Compensation <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raymond L.&#160;Woosley, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dan J.&#160;Mitchell<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, was also a director during the year ended December&#160;31, 2023, but did not receive any additional compensation for his service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The valuation assumptions used in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements included in this annual report on Form&#160;10<span class="nobreak">-K</span> for the year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Ma<span class="nobreak">-Weaver</span> was 18,000, of which 12,000 shares were fully vested. Includes $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>These directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA revised its compensation plan for non<span class="nobreak">-employee</span> directors to provide that non<span class="nobreak">-employee</span> directors will be compensated for their service on ARCA&#8217;s board of directors, as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-employee</span> director will receive an annual retainer fee of $40,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>As additional compensation for their services, each non<span class="nobreak">-employee</span> director will receive (i), upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the board of directors received a one<span class="nobreak">-time</span> retention option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan and (iii), on an annual basis as of the date of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non<span class="nobreak">-employee</span> director </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">170</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date of grant (unless such six<span class="nobreak">-month</span> period is modified by recommendation of the Nominating and Corporate Governance Committee and approved by the Compensation Committee);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee of $30,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s Audit Committee chair will receive an additional annual retainer fee of $15,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Audit Committee will receive an additional annual retainer fee of $7,500; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;30, 2024, ARCA approved paying compensation to its existing non<span class="nobreak">-employee</span> directors, pursuant to ARCA&#8217;s Director Compensation Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span> options to purchase 6,000<span class="nobreak"> </span>shares of common stock at an exercise price of $1.64 per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions of the Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The options vest in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s, Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s continued service on the Board for such periods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma<span class="nobreak">-Weaver</span> (joined the Committee in June&#160;2022). Payments for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">171</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T16"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-34" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Plan Category</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>to&#160;be&#160;Issued&#160;Upon <br/>Exercise&#160;of <br/>Outstanding <br/>Options&#160;or&#160;Upon<br/>Vesting&#160;of <br/>Restricted&#160;Stock <br/>Unit</span>s<br/><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Weighted <br/>Average <br/>Exercise <br/>Price&#160;of <br/>Outstanding <br/>Options<br/>($)<br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of&#160;Securities <br/>Remaining <br/>Available&#160;for <br/>Future&#160;Issuance <br/>Under&#160;Equity <br/>Compensation <br/>Plans&#160;(Excluding <br/>Securities <br/>Reflected&#160;in<br/>Column(a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans not approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;10, 2020, ARCA stockholders approved the ARCA biopharma, Inc. 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The 2020 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9, 2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the 2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Risks</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk<span class="nobreak">-taking</span> that could harm the value or reward poor judgment by its executives. ARCA believes several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long<span class="nobreak">-term</span> compensation target opportunities in such a way as to not encourage excessive risk<span class="nobreak">-taking</span>. The multi<span class="nobreak">-year</span> vesting of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk<span class="nobreak">-taking</span> on an annual basis.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">172</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T15"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, certain executive officers of Oruka will become executive officers of the combined company. Because Oruka was not formed until 2024, there were no executive officers during 2023. This section sets forth the current compensatory arrangements for the following executive officers of Oruka as of March&#160;31, 2024, each of whom is expected to become an executive officer of the combined company.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">February&#160;26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;30, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">March&#160;22, 2024</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employment Agreements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreement with Mr.&#160;Klein</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Klein are party to an employment letter agreement, pursuant to which Mr.&#160;Klein receives an annual base salary of $600,000 and a target annual bonus of 50% of his base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with his entry into his employment agreement, Mr.&#160;Klein purchased 1,491,646<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date, which will vest as to 25% on February&#160;26, 2025 and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provides that Mr.&#160;Klein will receive periodic grants of stock options, subject to approval by Oruka&#8217;s board of directors, sufficient to maintain Mr.&#160;Klein&#8217;s ownership at approximately 5% on a fully<span class="nobreak">-diluted</span> basis until Oruka has raised an aggregate of $200&#160;million in financing. Any such stock options will vest in equal monthly installments over 48&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of Mr.&#160;Klein&#8217;s termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, Mr.&#160;Klein is eligible for the following severance benefits, subject to his execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination, (iii)&#160;accelerated vesting of 30% of the unvested portion of any outstanding time<span class="nobreak">-based</span> equity awards, and (iv)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to 12&#160;months. If Mr.&#160;Klein is terminated by Oruka without cause or by Mr.&#160;Klein for good reason on or within 12&#160;months following a change in control of Oruka, Mr.&#160;Klein will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements with Other Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Quinlan are party to an employment letter agreement, pursuant to which Mr.&#160;Quinlan receives an annual base salary of $460,000 and a target annual bonus of 40% of his base salary, pro<span class="nobreak">-rated</span> for 2024. Mr.&#160;Quinlan&#8217;s employment agreement also provided for an initial grant of stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Dr. Goncalves are party to an employment letter agreement, pursuant to which Dr. Goncalves receives an annual base salary of $460,000 and a target annual bonus of 40% of her base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with her appointment, Dr. Goncalves was granted stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of her start date and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provided for a $100,000 signing bonus, which is subject to pro<span class="nobreak">-rata</span> repayment if Dr. Goncalves is terminated for cause or resigns within one year following her start date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Agarwal are party to an employment letter agreement, pursuant to which Mr.&#160;Agarwal receives an annual base salary of $360,000 and a target annual bonus of 35% of his base salary. Mr.&#160;Agarwal&#8217;s employment agreement also provided for an initial grant of stock options to purchase 225,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">173</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements with Messrs. Quinlan and Agarwal and Dr. Goncalves provide for the following severance benefits upon their termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, subject to the executive&#8217;s execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to six&#160;months of the executive&#8217;s base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination and (iii)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to six&#160;months. If the executive is terminated by Oruka without cause or by the executive for good reason on or within 12&#160;months following a change in control of Oruka, the executive will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary Description of Oruka&#8217;s 2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka maintains the 2024 Equity Incentive Plan, the purpose of which is to advance the interests of Oruka&#8217;s stockholders by enhancing Oruka&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Oruka and by providing such persons with equity ownership opportunities and performance<span class="nobreak">-based</span> incentives that are intended to better align the interests of such persons with those of Oruka&#8217;s stockholders. The 2024 Equity Incentive Plan provides for the issuance of up to 872,912<span class="nobreak"> </span>shares of Oruka common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock<span class="nobreak">-based</span> awards to eligible employees, officers, directors, consultants and advisors of Oruka on such terms and conditions as approved by Oruka&#8217;s board of directors or any committee appointed by Oruka&#8217;s board of directors to administer the 2024 Equity Incentive Plan. No grants will be made under the 2024 Equity Incentive Plan following consummation of the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">174</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T14"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka was not formed until 2024, there were no directors during 2023. In connection with his appointment as a member of Oruka&#8217;s board of directors, Dr.&#160;Kulkarni entered into a letter agreement, pursuant to which he received: (i)&#160;stock options to purchase 250,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter; and (ii)&#160;stock options to purchase 100,000<span class="nobreak"> </span>shares of Oruka common stock, which vest upon the first anniversary of the date Dr.&#160;Kulkarni is appointed Chairman of Oruka&#8217;s board of directors and will be forfeited if Dr.&#160;Kulkarni is not appointed Chairman of Oruka&#8217;s board of directors prior to March&#160;22, 2025. In connection with her appointment as a member of Oruka&#8217;s board of directors, Ms. Ball entered into a letter agreement, pursuant to which she received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of her appointment date and in equal monthly installments for the 36&#160;months thereafter. In connection with his appointment as a member of Oruka&#8217;s board of directors, Mr.&#160;Dambkowski received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In anticipation of his service on the Oruka board of directors, Dr.&#160;Turtle purchased 149,164<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is expected that Oruka will implement cash retainers for all non<span class="nobreak">-employee</span> directors, including an annual cash retainer.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">175</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9980"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS </span></p>
		<a id="T9981"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 1&#160;&#8212;&#160;THE NASDAQ STOCK ISSUANCE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement, which shares of ARCA common stock will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of ARCA resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the First Merger, ARCA securityholders as of immediately prior to the First Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down, including if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will assume outstanding and unexercised options and warrants to purchase shares of Oruka common stock, and such securities will be converted into options and warrants, as applicable, to purchase shares of ARCA common stock, subject to certain adjustments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>.&#8221; A copy of the Merger Agreement is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reason for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of ARCA common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 97.61% of ARCA common stock on a fully<span class="nobreak">-diluted</span> basis immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), ARCA must obtain the approval of ARCA stockholders for the issuance of these shares of common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), ARCA must obtain the approval of ARCA stockholders of the change of control resulting from the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">176</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Nasdaq Stock Issuance Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal is not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">177</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9982"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 2&#160;&#8212;&#160;THE AUTHORIZED SHARE INCREASE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock (the &#8220;ARCA Share Increase Amendment&#8221;). On<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA&#8217;s board of directors approved a proposal to amend the ARCA Charter to increase the number of authorized shares of ARCA common stock from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which would also have the effect of increasing the total number of authorized shares from 105,000,000, including ARCA preferred stock, to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;ARCA Share Increase&#8221;), in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus. On the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the ARCA Charter in its entirety as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, consisting of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of Common Stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background and Reasons for the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter currently authorizes the issuance of up to 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock. As of the close of business on the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>,&#8221; pursuant to the Merger Agreement, ARCA will be required to issue shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders and to assume Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares of ARCA common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock. In addition, there will not be sufficient shares of ARCA common stock available for issuance in connection with possible future acquisitions, equity and equity<span class="nobreak">-based</span> financings, possible future awards under employee benefit plans and other corporate purposes that ARCA&#8217;s board of directors may determine to be desirable. Therefore, ARCA&#8217;s board of directors has determined that the ARCA Share Increase Amendment is in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA will have a total of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>authorized shares of ARCA common stock, with&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding (as of the Record Date), and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares reserved for issuance (as of the Record Date), leaving a balance of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock authorized and unissued and not reserved for any specific purpose. The ARCA Share Increase Amendment will have no effect on the authorized shares of ARCA Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">178</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and (ii)&#160;the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, each pursuant to the terms of the Merger Agreement, ARCA does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Possible Effects of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of ARCA&#8217;s board of directors and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized ARCA common stock would have the same rights and privileges as the shares of ARCA common stock currently issued and outstanding. Holders of ARCA common stock have no preemptive rights. The ARCA Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of ARCA common stock authorized by the ARCA Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of ARCA common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of ARCA common stock or limit ARCA&#8217;s ability to raise additional capital. ARCA stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the ARCA Share Increase Amendment or the ARCA Share Increase.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Effectiveness of Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by the stockholders at the ARCA special meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G&#160;</span>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Copies of the ARCA Charter and the certificates of amendment to the ARCA Charter are available as exhibits to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Authorized Share Increase Proposal by the holders of ARCA common stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal and the Merger are conditioned upon the approval of the Authorized Share Increase Proposal. In order to have an adequate number of available shares to effect the Merger, the stockholders of ARCA will need to approve the Authorized Share Increase Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Authorized Share Increase Proposal, if approved, even if the Nasdaq Stock Issuance Proposal is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">179</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9983"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 3&#160;&#8212;&#160;THE REVERSE STOCK SPLIT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range of<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to be determined mutually by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time, assuming this proposal is approved by ARCA&#8217;s stockholders. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, ARCA&#8217;s board of directors adopted resolutions approving the proposed certificate of amendment to the ARCA Charter in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus. If this certificate of amendment is filed with the Secretary of State of the State of Delaware, upon its effectiveness (the &#8220;reverse stock split effective time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of ARCA common stock. At the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically without further action on the part of ARCA be combined into a smaller number of shares in accordance with the final Split Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">By approving the Reverse Stock Split Proposal, ARCA stockholders will approve the amendment to the ARCA Charter pursuant to which any whole number of issued and outstanding shares of ARCA common stock, between and including<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, would be combined into one share of ARCA common stock, and will authorize ARCA&#8217;s board of directors to file the certificate of amendment. As of the Record Date, 100,000,000<span class="nobreak"> </span>shares of ARCA common stock were authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock were outstanding and no shares of ARCA common stock were held in treasury.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock or preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All holders of ARCA common stock will be affected proportionately by the reverse stock split. No fractional shares of ARCA common stock will be issued as a result of the reverse stock split. Instead, ARCA stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each ARCA stockholder will hold the same percentage of the outstanding ARCA common stock immediately following the reverse stock split as that ARCA stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in ARCA stockholders receiving cash in lieu of fractional shares.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors approved the proposal approving the amendment to the ARCA Charter effecting the reverse stock split for the following reasons:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes effecting the reverse stock split will result in an increase in the minimum bid price of ARCA common stock and reduce the risk of a delisting of ARCA common stock from Nasdaq in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may help generate investor interest in ARCA, and ultimately the combined company, and help ARCA attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may increase trading volume in ARCA common stock and facilitate future financings by the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the stockholders of Oruka pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">180</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Requirements for Listing on Nasdaq</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application pursuant to the terms of the Merger Agreement for the combined company to list the securities of the combined company on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non<span class="nobreak">-Nasdaq</span> entity, resulting in a change of control of the issuer and potentially allowing the non<span class="nobreak">-Nasdaq</span> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require ARCA to have, among other things, a $4.00 per share minimum bid price for a certain number of&#160;trading days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, it is a condition to the closing of the Merger that the shares of ARCA common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in ARCA&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of ARCA capital stock, which will continue to be authorized pursuant to the ARCA Charter.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Increased Investor Interest</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:0pt;text-indent:24pt;margin-top:8pt;">On<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA common stock closed at $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share. An investment in ARCA common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, ARCA&#8217;s board of directors believes that most investment funds are reluctant to invest in lower priced stocks.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot predict whether the reverse stock split will increase the market price for ARCA common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share of ARCA common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of ARCA common stock outstanding before the reverse stock split;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will increase the ability of ARCA to attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the combined company&#8217;s common stock to be approved for listing by Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock will also be based on the performance of ARCA, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of ARCA common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of ARCA may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of ARCA common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">181</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Reverse Stock Split</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the reverse stock split is implemented, after the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically, without further action on the part of ARCA, be combined into a smaller number of shares proportionately based on the Split Ratio and each ARCA stockholder will own a reduced number of shares of ARCA common stock. The reverse stock split will affect all ARCA stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in ARCA, except that ARCA stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of ARCA common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the ARCA common stock now authorized, and ARCA common stock issued pursuant to the reverse stock split will remain fully paid and non<span class="nobreak">-assessable</span>. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by&#160;Rule&#160;13e<span class="nobreak">-3</span>&#160;under the&#160;Exchange&#160;Act. ARCA will continue to be subject to the periodic reporting requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Shares of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the reverse stock split effective time, ARCA common stock would have a new committee on uniform securities identification procedures number, which is used to identify ARCA common stock. ARCA common stock is currently registered under Section&#160;12(b)&#160;of the&#160;Exchange&#160;Act&#160;and ARCA is subject to the periodic reporting and other requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA preferred stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reduction in Stated Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not affect the par value of ARCA common stock. As a result, after the reverse stock split effective time, the stated capital on ARCA&#8217;s balance sheet attributable to ARCA common stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid<span class="nobreak">-in</span> capital account will be credited with the amount by which the stated capital is reduced. ARCA stockholders&#8217; equity, in the aggregate, will remain unchanged.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Equity Plans and Outstanding Derivative and Convertible Securities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of ARCA common stock, and the number of shares reserved for issuance pursuant to ARCA&#8217;s existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If (i)&#160;the ARCA stockholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;ARCA&#8217;s board of directors and Oruka&#8217;s board of directors mutually agree that a reverse stock split is necessary, and (iii)&#160;ARCA&#8217;s board of directors still believes that a reverse stock split is in the best interests of ARCA and its stockholders, ARCA will file the certificate of amendment to the ARCA Charter with the Secretary of State of the State of Delaware at such time as ARCA&#8217;s board of directors has determined to be the appropriate reverse stock split effective time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, ARCA&#8217;s board of directors and Oruka&#8217;s board of directors may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval or abandon effecting the reverse stock split; otherwise, ARCA&#8217;s board of directors may, in its sole discretion, delay without </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">182</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">resolicitation of stockholder approval or abandon effecting the reverse stock split. Beginning at the reverse stock split effective time, each stock certificate representing pre<span class="nobreak">-split</span> shares will be deemed for all corporate purposes to evidence ownership of post<span class="nobreak">-split</span> shares.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Beneficial Owners of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the implementation of the reverse stock split, ARCA intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding ARCA common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of ARCA common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Book-Entry Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of ARCA&#8217;s registered holders of common stock hold some or all of their shares electronically in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>Computershare Trust Company, N.A.&#160;These stockholders do not hold physical stock certificates evidencing their ownership of ARCA common stock. However, they are provided with a statement reflecting the number of<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>shares of ARCA common stock registered in their accounts. If a stockholder holds registered shares in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent, no action needs to be taken to receive post<span class="nobreak">-reverse</span> stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post<span class="nobreak">-reverse</span> stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of ARCA common stock held following the reverse stock split.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Certificate Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As soon as practicable after the reverse stock split effective time, the ARCA stockholders will be notified that the reverse stock split has been effected. ARCA expects that the ARCA transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre<span class="nobreak">-split</span> shares will be asked to surrender to the exchange agent certificates representing pre<span class="nobreak">-split</span> shares held in certificated form in exchange for certificates representing post<span class="nobreak">-split</span> shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by ARCA.&#160;No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the exchange agent. Any pre<span class="nobreak">-split</span> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post<span class="nobreak">-split</span> shares.&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so</span><span class="Italic" style="font-style:italic;font-weight:normal;">.</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">No Fractional Shares</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre<span class="nobreak">-split</span> shares not evenly divisible by the number of pre<span class="nobreak">-split</span> shares for which each post<span class="nobreak">-split</span> share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment to the ARCA Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where ARCA is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by ARCA or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">183</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Anti-Takeover Effect</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti<span class="nobreak">-takeover</span> effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of ARCA&#8217;s board of directors or contemplating a tender offer or other transaction for the combination of ARCA with another company, the reverse stock split is not being proposed in response to any effort of which ARCA is aware to accumulate shares of ARCA common stock or obtain control of ARCA, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to ARCA&#8217;s board of directors and stockholders. Other than the proposals being submitted to the ARCA stockholders for their consideration at the ARCA special meeting, ARCA&#8217;s board of directors does not currently contemplate recommending the<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>adoption of any other actions that could be construed to affect the ability of third parties to take over or change<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>control of ARCA.&#160;For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to the Combined Company</span>&#8221; beginning on page 80 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a discussion of material U.S.&#160;federal income tax consequences of the reverse stock split that are applicable to a U.S.&#160;holder (as defined below) of ARCA common stock. This discussion applies only to a U.S.&#160;holder that holds its ARCA common stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their ARCA common stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the reverse stock split under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the reverse stock split under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, or (iv)&#160;the tax consequences of transactions effectuated before, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">184</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">subsequent to or concurrently with the reverse stock split (whether or not any such transactions are consummated in connection with the reverse stock split), including, any transaction in which shares of ARCA common stock are acquired.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not and do not intend to seek any rulings from the IRS regarding the reverse stock split. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any ARCA common stock and each person that is treated as a partner of such partnerships is urged to consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of U.S.&#160;Holders in the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to treat the reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the reverse stock split so qualifies, a U.S.&#160;holder generally will not recognize gain or loss upon the reverse stock split. A U.S.&#160;holder&#8217;s aggregate tax basis in the shares of ARCA common stock received pursuant to the reverse stock split will equal the aggregate tax basis of the shares of the ARCA common stock surrendered, and such U.S.&#160;holder&#8217;s holding period in the shares of ARCA common stock received will include the holding period in the shares of ARCA common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of ARCA common stock surrendered for the shares of ARCA common stock received in a recapitalization pursuant to the reverse stock split. If a U.S.&#160;holder holds different blocks of ARCA common stock (generally, ARCA common stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA common stock received in the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder that receives cash in lieu of a fractional share of ARCA common stock pursuant to the reverse stock split will generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S.&#160;holder&#8217;s tax basis in the shares of ARCA common stock surrendered that is allocated to such fractional share of ARCA common stock. Any such gain or loss will be long<span class="nobreak">-term</span> capital gain or loss if, as of the effective time of the reverse stock split, the U.S.&#160;holder&#8217;s holding period for such fractional share exceeds one year. Long<span class="nobreak">-term</span> capital gains of certain non<span class="nobreak">-corporate</span> taxpayers, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S.&#160;holder who receives shares of ARCA common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">185</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as part of such reorganization. Each U.S.&#160;holder who owned immediately before the reverse stock split at least five percent (by vote or value) of the total outstanding stock of ARCA is required to attach a statement to its tax return for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such holder&#8217;s ARCA common stock surrendered in the reverse stock split, the fair market value of such stock, the date of the reverse stock split and the name and employer identification number of ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes on cash paid in lieu of fractional shares in connection with the reverse stock split. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the ARCA Charter to effect the reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Reverse Stock Split Proposal by the holders of ARCA common stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Reverse Stock Split Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Reverse Stock Split Proposal, if approved, even if Proposal&#160;No. 1 is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on&#160;page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK&#160;SPLIT&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">186</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9984"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 4&#160;&#8212;&#160;THE OFFICER EXCULPATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL was amended effective August&#160;1, 2022 to authorize exculpation of certain officers of Delaware corporations (the &#8220;Section&#160;102(b)(7)&#160;Amendment&#8221;). Specifically, the amendments extend the opportunity for Delaware corporations to exculpate their officers, in addition to their directors, for personal liability for breach of the duty of care in certain actions (the &#8220;officer exculpation&#8221;). This provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors. Accordingly, ARCA&#8217;s board of directors believes that the proposal to extend exculpation to officers is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the proposed form of certificate of amendment to the ARCA Charter to effect the officer exculpation is attached as<span class="Italic" style="font-style:italic;font-weight:normal;"> Annex&#160;I</span> to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors may determine to effect the officer exculpation, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal. In addition, notwithstanding approval of this proposal by ARCA stockholders, ARCA&#8217;s board of directors may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the officer exculpation, as permitted under Section&#160;242(c)&#160;of the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors desires to amend the ARCA Charter to maintain provisions consistent with the governing statutes contained in the DGCL, as it may be amended from time to time. Prior to the Section&#160;102(b)(7) Amendment, Delaware law has permitted Delaware corporations to exculpate directors from personal liability for monetary damages associated with breaches of the duty of care, but that protection did not extend to a Delaware corporation&#8217;s officers. Consequently, stockholder plaintiffs have employed a tactic of bringing certain claims that would otherwise be exculpated if brought against directors, against individual officers to avoid dismissal of such claims. The Section&#160;102(b)(7)&#160;Amendment was adopted to address inconsistent treatment between officers and directors and address rising litigation and insurance costs for stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is currently the case with directors under the ARCA Charter, this provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims. ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors, and accordingly, ARCA&#8217;s board of directors believes that this proposal which would extend exculpation to officers, as specifically permitted by the Section&#160;102(b)(7)&#160;Amendment, is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the outstanding shares of ARCA common stock is required to approve the Officer Exculpation Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Officer Exculpation Proposal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">187</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Officer Exculpation Proposal. If the Merger is not consummated for any reason, the actions contemplated by the Officer Exculpation Proposal may still be effected if the Officer Exculpation Proposal is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Officer Exculpation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE OFFICER EXCULPATION&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">188</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9985"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 5&#160;&#8212;&#160;THE DIRECTOR ELECTION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members. In accordance with the terms of the ARCA Charter and ARCA Bylaws, ARCA&#8217;s board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three<span class="nobreak">-year</span> terms. The members of the classes are divided as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;I directors are James Flynn, Linda Grais, M.D. and Anders Hove, M.D., whose terms will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;II director is Robert E.&#160;Conway, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2026; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;III director is Jacob Ma<span class="nobreak">-Weaver</span>, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the expiration of the term of a class of ARCA&#8217;s board of directors, any director in that class will be eligible to be elected for a new three<span class="nobreak">-year</span> term at the annual meeting of stockholders in the year in which their term expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws provide that the authorized number of directors shall not be less than two nor more than ten and may be changed only by resolution of ARCA&#8217;s board of directors. ARCA Bylaws also provide that ARCA&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least two<span class="nobreak">-thirds</span> of the voting rights of the shares of capital stock then entitled to vote in an annual election of directors, and that any vacancy on ARCA&#8217;s board of directors, including a vacancy resulting from an increase in the size of ARCA&#8217;s board of directors, may be filled only by vote of a majority of its directors then in office.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has nominated Jacob Ma<span class="nobreak">-Waver</span> for election as a Class&#160;III director at the ARCA special meeting. Mr.&#160;Ma<span class="nobreak">-Weaver</span> is currently a director and has consented to continue to serve as a director if elected. If Mr.&#160;Ma<span class="nobreak">-Weaver</span> becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders should understand, however, that if the Merger is consummated, the approval of the director nominee named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the combined company&#8217;s board of directors will consist of six members designated by Oruka, including Carl Dambkowski, Peter Harwin, Lawrence Klein, Samarth&#160;Kulkarni, Cameron Turtle and Kristine Ball. All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The nominee for Class&#160;III director who receives the most votes properly cast (also known as a plurality) will be elected. You may either vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the nominee or &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">WITHHOLD</span>&#8221; your vote from the nominee. Withheld votes and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the election of the director nominee named in the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the election of the director nominee named in the Director Election Proposal. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as ARCA&#8217;s board of directors may designate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEE NAMED IN THE DIRECTOR ELECTION PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">189</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9986"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 6&#160;&#8212;&#160;THE AUDITOR RATIFICATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to ratify the appointment by the audit committee of ARCA&#8217;s board of directors (the &#8220;ARCA audit committee&#8221;) of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for the fiscal year ending December&#160;31, 2024 if the Merger is completed. KPMG LLP has served as ARCA&#8217;s independent registered public accounting firm since 2006.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA audit committee is solely responsible for selecting ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Stockholder approval is not required to appoint KPMG LLP as ARCA&#8217;s independent registered public accounting firm. However, ARCA&#8217;s board of directors believes that submitting the selection of KPMG LLP to ARCA stockholders for ratification is good corporate governance. If ARCA stockholders do not ratify this appointment, the ARCA audit committee will reconsider whether to retain KPMG LLP.&#160;If the selection of KPMG LLP is ratified, the ARCA audit committee, at its discretion, may direct the selection of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A representative of KPMG LLP is expected to be present at the ARCA special meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from ARCA stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Auditor Ratification Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Auditor Ratification Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL, PROVIDED THAT PRICEWATERHOUSECOOPERS LLP IS EXPECTED TO BE APPOINTED FOR THE FISCAL YEAR ENDING DECEMBER</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 IF THE MERGER IS COMPLETED.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">190</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9992"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 7</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE STOCK PLAN PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;2024 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2024 Stock Plan was approved by ARCA&#8217;s board of directors on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval. If the 2024 Stock Plan is approved by stockholders, no further awards will be granted under the 2020 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the 2024 Stock Plan is to promote and closely align the interests of employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants of the combined company and its stockholders by providing stock<span class="nobreak">-based</span> compensation and other performance<span class="nobreak">-based</span> compensation. The objectives of the 2024 Stock Plan are to attract and retain the best available employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the combined company through incentives that are consistent with the combined company&#8217;s goals and that link the personal interests of participants to those of the combined company&#8217;s stockholders. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock<span class="nobreak">-based</span> awards and incentive bonuses (collectively, &#8220;Awards&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the 2024 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2024 Stock Plan, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the U.S.&#160;federal income tax treatment applicable to the combined company and the participants who receive Awards under the 2024 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non<span class="nobreak">-U</span>.S.&#160;taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S.&#160;federal income tax law. Because individual circumstances may vary, all participants should consult their own tax advisor concerning the tax implications of Awards granted under the 2024 Stock Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Options granted under the 2024 Stock Plan may be either incentive stock options, which satisfy the requirements of Section&#160;422 of the Code, or non<span class="nobreak">-qualified</span> stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long<span class="nobreak">-term</span> capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The combined company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">191</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized by an optionee upon the grant of a non<span class="nobreak">-qualified</span> stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non<span class="nobreak">-qualified</span> stock option.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized upon receipt of a SAR.&#160;The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the cash consideration (if any) paid for such shares. If the Section&#160;83(b)&#160;election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock<span class="nobreak">-based</span> awards or incentive bonuses. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2024 Stock Plan will be subject to the $1&#160;million annual deduction limitation. The Administrator may grant Awards under the 2024 Stock Plan or otherwise that are or may become non<span class="nobreak">-deductible</span> when it believes doing so is in the best interests of the combined company and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2024 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">192</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Stock Plan Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Stock Plan Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">193</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9993"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 8</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE ESPP PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) to be effective on the closing date of the Merger. The ESPP was approved by ARCA&#8217;s board of directors on <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the ESPP is to provide employees of the combined company and its designated subsidiaries with an opportunity to purchase Common Stock through accumulated contributions. The ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub<span class="nobreak">-plans</span> that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the ESPP</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the ESPP is not intended to be complete and is qualified in its entirety by the complete text of the ESPP, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub<span class="nobreak">-plans</span> are established for employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries, the tax rules may be different than discussed below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the employee holds shares acquired under the ESPP for at least two&#160;years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first&#160;day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long<span class="nobreak">-term</span> capital gain or loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short<span class="nobreak">-term</span> or long<span class="nobreak">-term</span> capital gain or loss depending on the length of time the employee has held the shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the combined company receives a tax deduction for any ordinary income recognized by the participant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">194</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The benefits that will be received by or allocated to eligible employees under the ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of combined company common stock under the ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the ESPP Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the ESPP Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">195</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9994"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 9</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER COMPENSATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to Section&#160;14A of the Exchange&#160;Act and Rule&#160;14a<span class="nobreak">-21</span>(c)&#160;thereunder, ARCA is seeking non<span class="nobreak">-binding</span>, advisory stockholder approval of certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span> in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span>&#8221; beginning on page 123 of this proxy statement/prospectus. At the ARCA special meeting, ARCA will therefore ask its stockholders to adopt the following resolution:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8220;RESOLVED:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That certain compensation arrangements for ARCA named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-K</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> in the section titled &#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-binding</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">, advisory basis.&#8221;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the vote is advisory in nature only, it will not be binding on ARCA.&#160;Accordingly, to the extent ARCA is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA common stock is required to approve the Merger Compensation Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Merger Compensation Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">196</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9987"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 10&#160;&#8212;&#160;THE ADJOURNMENT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal, ARCA may propose to adjourn the ARCA special meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal. ARCA currently does not intend to propose adjournment at the ARCA special meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is not present at the ARCA special meeting, under ARCA Bylaws, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, or if no stockholders are present any officer entitled to preside at or act as secretary of the special meeting, will have the power to adjourn the special meeting until a quorum is present or represented.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is present, the affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Adjournment Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Adjournment Proposal.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL, IF NECESSARY.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">197</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T13"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is a biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In April&#160;2022, ARCA&#8217;s board of directors established a Special Committee and subsequently retained Lucid to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value (the &#8220;Strategic Review&#8221;). ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, First Merger Sub, Second&#160;Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In connection with the Merger, ARCA will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger and is expected to occur immediately prior to or concurrently with the closing of the Merger. In the event that ARCA shall enter into an agreement for any such sale or other disposition of its legacy assets at or prior to the closing of the Merger, the net proceeds received at or prior to the closing of the Merger will be included in the calculation of the net cash of ARCA as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, ARCA may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is developing Gencaro to treat AF in patients with HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction (&#8220;EF&#8221;) of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">198</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;) for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under an SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for ARCA&#8217;s planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">199</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or are unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s mission is to become a leading biopharmaceutical company developing precision targeted cardiovascular therapies to enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. To achieve this goal, ARCA is pursuing the following strategies:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Evaluate strategic options.&#160;&#160;&#160;&#160;</span>In April&#160;2022, ARCA&#8217;s board of directors established the Special Committee and, subsequently retained Ladenburg Thalmann to evaluate the Strategic Review. In March&#160;2024, ARCA terminated its engagement with Ladenburg Thalmann and retained Lucid Capital Markets to evaluate the Strategic Review. ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction. Following a comprehensive review, on April<span class="nobreak">&#160;</span>3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka, entered into Merger Agreement pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Advance the development of Gencaro for the treatment of AF in HF patients.&#160;&#160;&#160;&#160;</span>ARCA is planning a Phase&#160;3 clinical trial for Gencaro as a therapy for AF in HF patients, focusing on patients with EF &#8805; 40%, a patient population for whom few approved or effective drug therapies currently exist.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Partner the development of rNAPc2.&#160;&#160;&#160;&#160;</span>ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">200</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Build a cardiovascular pipeline.&#160;&#160;&#160;&#160;</span>ARCA&#8217;s management, employees and consultants are experienced in cardiovascular research, molecular genetics and clinical development of cardiovascular therapies. ARCA is seeking to leverage this expertise to identify, acquire and develop other cardiovascular products or candidates, particularly those with potential for targeted development based on genetic or other biomarkers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The above strategies are dependent upon ARCA&#8217;s ability to obtain additional funding through the sale of public or private equity or debt securities, the completion of a strategic transaction, or a combination thereof. If ARCA is unable to secure additional funding or complete a strategic transaction, ARCA may not be able to continue development of Gencaro or rNAPc2, or to continue operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Atrial Fibrillation in Heart Failure</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Market Background and Opportunity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Heart failure is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. HF has numerous serious consequences, including severe impacts on quality of life, increased hospitalizations, loss of economic productivity, and premature death. HF is a leading cause of death in the developed world, and despite the availability of multiple effective drug classes, mortality due to HF is increasing. According to the 2020 American Heart Association (&#8220;AHA&#8221;) Heart Disease and Stroke Statistics, there were an estimated 6.2&#160;million Americans aged 20&#160;years or more with HF in 2016, projected to increase to between 8.3&#160;million and 10.7&#160;million by 2030. One of the fundamental classifications of heart failure is based on the percentage of blood in the left ventricle of the heart that is ejected with each heartbeat, known as EF.&#160;The spectrum of HF includes HF in which EF is 50% or more and is considered preserved ejection fraction, known as HFpEF; HF in which the EF is less than 40%, considered reduced ejection fraction (&#8220;HFrEF&#8221;); and HF in which the EF is at least 40%, but less than 50%, sometimes referred to as mid<span class="nobreak">-range</span> ejection fraction, known as HFmrEF.&#160;Together, HFmrEF and HFpEF, that is HF with EF &#8805; 40%, comprise more than half of all chronic HF in the United&#160;States and Europe. In 2012, the economic cost of HF in the United&#160;States was estimated to be nearly $31&#160;billion, of which two<span class="nobreak">-thirds</span>, or over $20&#160;billion, was attributable to direct medical costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Atrial fibrillation, the most common sustained cardiac arrhythmia, is a serious disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular, rapid and uncoordinated. AF can have significant quality of life impacts and potentially serious medical consequences, including increasing the risk of stroke and other cardiovascular problems. In individuals with HF, AF contributes to the disease processes that lead to the progression of HF and worsening of clinical outcomes. AF is considered an epidemic cardiovascular disease and a major public health burden, similar to HF.&#160;The estimated number of individuals with AF globally in 2015 was 33.3&#160;million. According to AHA Heart Disease and Stroke Statistics Reports from&#160;2017<span class="nobreak">-2020</span>, the prevalence of AF in the United&#160;States was estimated to be 5.2&#160;million people in 2015. In the European Union, the prevalence of AF was estimated to be 8.8&#160;million (age 55 and over) in 2010. It is estimated that AF costs the U.S.&#160;economy about $6.0&#160;billion annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">AF and HF share many of the same risk factors and commonly occur together. It has been estimated that&#160;30<span class="nobreak">-60</span>% of HF patients will also develop AF, with this incidence increasing in HF patients with higher EF; ARCA estimates that&#160;40<span class="nobreak">-60</span>% of HF patients with EF &#8805; 40% will also be diagnosed with AF.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Need and Current Therapy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The goals of current medical therapy for AF are to provide anticoagulation to reduce the risk of stroke, and also either maintain sinus rhythm (known as rhythm control), or reduce the high heart rate caused by AF (known as rate control), in both cases to minimize patient symptoms and reduce the risk of further complications and disease progression. Unfortunately, the current treatment options for treating AF in patients with HF have significant limitations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beta<span class="nobreak">-blockers</span> are considered standard of care for the treatment of HF patients, including in patients with co<span class="nobreak">-morbid</span> AF.&#160;They are also viewed as foundational therapy to treat AF in HF patients for their ability to provide rate control. Their safety in this patient population is well established.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">201</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, current beta blockers approved for HF patients are only modestly effective at providing rhythm control, and none are FDA approved for this indication. Importantly, none of these drugs have been shown to be effective for treating HF in patients with EF &#8805; 40%, so they are currently used off<span class="nobreak">-label</span> in this setting. When used for rate control, these drugs can cause bradycardia, a condition in which the heart rate drops below a safe threshold, which often leads to dose reductions and potential loss of the drug&#8217;s treatment effect. Furthermore, recent evidence indicates that the mortality and other clinical benefits of these beta blockers in heart failure patients are uncertain when sustained or permanent AF is present.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Anti<span class="nobreak">-arrhythmic</span> drugs are a drug class that is often prescribed to provide rhythm control. These drugs are frequently used in patients with both HF and AF when a rate control strategy using a beta blocker fails to control the patient&#8217;s symptoms. However, these agents have significant safety issues. For example, in the United&#160;States, anti<span class="nobreak">-arrhythmic</span> drug therapy for AF used in addition to beta<span class="nobreak">-blockers</span> is generally confined to the drugs amiodarone and dofetilide, which have multiple safety and toxicity concerns. Because of these concerns, physicians treating HF patients seek to limit the use of these anti<span class="nobreak">-arrhythmic</span> drugs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Non<span class="nobreak">-pharmacologic</span> interventions such as catheter ablation and electrical cardioversion (ECV), are also used to treat AF in patients with HF.&#160;Catheter ablation is now guideline<span class="nobreak">-recommended</span> in this patient population and its use is increasing. However, it is not a replacement for drug therapy; it is invasive, expensive and generally impermanent. Drug therapy, including beta blockers, is generally continued in patients post<span class="nobreak">-ablation</span>, both for rhythm control and for HF benefit. ECV is expensive and less permanent than ablation, but like ablation, post<span class="nobreak">-ECV</span> patients will generally remain on drug therapy to treat their AF and HF, including beta<span class="nobreak">-blockers</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of the serious medical consequences presented by AF in the presence of HF as well as, the limitations of current therapies, ARCA believes there is an unmet need for a drug therapy that can provide greater rhythm control compared to the current standard of care; can reduce the need for toxic anti<span class="nobreak">-arrhythmic</span> drugs, catheter ablation, and electrical cardioversion; can provide effective rate control with a lower risk of treatment<span class="nobreak">-limiting</span> bradycardia; and can provide foundational beta<span class="nobreak">-blocker</span> benefits for HF.&#160;This need is particularly significant for HF patients with EF &#8805; 40%, for whom there are few approved or Class&#160;I guideline<span class="nobreak">-recommended</span> drug therapies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical Development</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The GENETIC-AF Phase&#160;2B Clinical Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">GENETIC<span class="nobreak">-AF</span> enrolled 267 patients from the United&#160;States, Canada and Europe. The primary analysis compared the evidence of safety and efficacy of Gencaro versus an active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;The primary endpoint of the trial was time to first event of AF/atrial flutter (AFL) or All Cause Mortality (ACM) during a 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period after the establishment of sinus rhythm. Randomized patients had an EF &#8804; 55%, a history of AF in the past 6&#160;months, and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype that ARCA believes responds best to Gencaro. Laboratory Corporation of America (&#8220;LabCorp&#8221;) developed the genetic test, obtained an IDE from the FDA and provided the companion diagnostic test and services to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the primary endpoint of time to AF recurrence, Gencaro demonstrated a similar treatment benefit in the overall population (p = 0.961) compared to the active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;However, based on further analysis of the trial, ARCA believes it has identified a population that shows greater response to Gencaro compared to TOPROL<span class="nobreak">-XL</span> across multiple important clinical assessments, including the primary endpoint of time to AF recurrence, maintenance of normal sinus rhythm, cumulative AF burden, and AF<span class="nobreak">-related</span> clinical interventions and complications. ARCA plans to study this population in ARCA&#8217;s Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These further analyses of the GENETIC<span class="nobreak">-AF</span> population (shown in the table below) demonstrated that Gencaro, as compared to metoprolol, reduced AF burden, improved maintenance of sinus rhythm and lowered the need for additional rhythm control interventions.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">202</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Endpoint</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Entire GENETIC-AF Cohort</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Time to 1</span><span class="CharOverride-3" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">st</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;"> AF/AFL/ACM <br/>(Primary Endpoint)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.01<br/>(neutral)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.71, 1.42)<br/>p = 0.961<br/>N = 267</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Cumulative 24-week AF Burden <br/>(substudy</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.64<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">36%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.46, 0.86)<br/>p = 0.002<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Burden at Week 24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.45<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">55%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.39, 0.50)<br/>p &lt; 0.001<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ECGs in Normal Sinus Rhythm</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.39<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">39%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(1.22, 1.58)<br/>p &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Interventions <br/>(ECVs, Ablations,&#160;&amp; Class&#160;3 AA Drugs)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.68<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">32%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.50, 0.91)<br/>p = 0.011<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Bradycardia prevalence <br/></span>(Buc. vs. met., VR &lt; 60 bpm) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 12.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">0.39<br/>(</span><span class="CharOverride-4" style="font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">61%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:6pt;text-indent:0pt;">(0.31, 0.49)<br/>P &lt; 0.001<br/>N = 256</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dose reductions</span> <br/>(pts. w/bradycardia vs. non-b.)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 10.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.25<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8593;</span><span class="Bold" style="font-style:normal;font-weight:bold;">4X)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;">(2.06, 9.60)<br/>P &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Time to first AF/AFL/ACM treatment effect = hazard ratio (95% CI). AF burden = % time in AF per&#160;day. Cumulative AF burden treatment effect = AUC ratio (i.e., AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) over 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period with significance assessed via null permutation. AFB at Week 24 = Instantaneous estimates of average daily AF burden at week 24 with comparison between groups expressed as the ratio of the estimates and tested for significance using a Wald test. Normal Sinus Rhythm = total number ECGs in sinus rhythm with ventricular rate&#160;&#8805;&#160;60&#160;and&#160;&#8804;&#160;100 bpm during efficacy follow<span class="nobreak">-up</span> period. AF Interventions = ECV, ablation, or guideline<span class="nobreak">-recommended</span> antiarrhythmic use during efficacy follow<span class="nobreak">-up</span> period. Treatment effect for normal sinus rhythm, AF interventions and bradycardia&#160;=&#160;prevalence rate ratio (i.e., PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) modeled to test significance using Poisson regression.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment with Gencaro was associated with a 36% reduction in cumulative AF burden over 24&#160;weeks of follow<span class="nobreak">-up</span> compared to metoprolol, leading to a 55% reduction in AF burden at the end of 24&#160;weeks. Consistent with the results in the device substudy, there was a 39% increase in the prevalence of ECGs demonstrating normal sinus rhythm in the overall study population. Treatment with Gencaro also led to a 32% lower utilization of adjunctive rhythm control therapies, including electrical cardioversion, catheter ablation and antiarrhythmic drug therapy. There was also a 61% reduction in bradycardia with Gencaro versus metoprolol. The consequence of bradycardia is a reduction in beta<span class="nobreak">-blocker</span> dose, which 4.2<span class="nobreak">-fold</span> higher in patients exhibiting bradycardia than without bradycardia.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The BEST Phase&#160;3 Heart Failure Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The effect of Gencaro on heart failure endpoints in an advanced HFrEF population was evaluated in the 2,708&#160;patient, placebo<span class="nobreak">-controlled</span> Phase&#160;3 BEST clinical trial co<span class="nobreak">-sponsored</span> by the NHLBI and Department of Veterans Affairs. In addition to the parent population, BEST included a 1,040 patient DNA substudy that evaluated the effects of adrenergic receptor (&#8220;AR&#8221;) polymorphisms on Gencaro effectiveness. The BEST trial was terminated early because, after positive mortality results from two HF trials involving other beta<span class="nobreak">-blockers</span> had been reported, a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. ARCA&#8217;s reanalysis of the BEST results in accordance with the FDA approved, pre<span class="nobreak">-specified</span> statistical analysis plans (which had not been performed by the sponsors of BEST) demonstrated a 13% risk reduction on the primary endpoint of ACM in the BEST trial with a p<span class="nobreak">-value</span> of 0.053. The risk reduction on HF clinical efficacy endpoints such as mortality and hospitalization ranged from 34% to 48% in this beta<span class="nobreak">-1</span> 389 arginine homozygous genotype. The DNA substudy revealed that Gencaro exhibited greater efficacy in patients homozygous for the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), encoding for receptors that exhibit higher function and greater affinity for norepinephrine compared to the patients who did not have the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (i.e., beta<span class="nobreak">-1</span> 389 Gly carriers). In the 47% of BEST trial patients with a <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype Gencaro reduced (p &lt;0.05) the primary endpoint of mortality or heart transplantation by 43%, all<span class="nobreak">-cause</span> mortality, cardiovascular mortality, heart failure hospitalizations, heart failure progression, development of atrial </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">203</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">fibrillation, and incidence of ventricular tachycardia or ventricular fibrillation with degrees of reduction (effect sizes) ranging from 34% (heart failure progression) to 74% (atrial fibrillation). Beta<span class="nobreak">-1</span> 389 Gly carriers had no statistically significant reduction in any endpoint.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pharmacology and Pharmacogenetics of Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro (bucindolol hydrochloride) is a nonselective (blocks both beta<span class="nobreak">-1</span> and beta<span class="nobreak">-2</span> adrenergic receptors) beta- receptor blocking agent with mild vasodilator properties. This combination of properties initially placed Gencaro in the &#8220;3<span class="CharOverride-6" style="font-size:58%;vertical-align:super;">rd</span> Generation&#8221; category of beta<span class="nobreak">-blockers</span> that is based on the strategy of their development. When its pharmacogenetic properties were elucidated and its development became pharmacogenetically based, ARCA subsequently considered Gencaro a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span>. The dominant beta<span class="nobreak">-receptor</span> on human heart cells is the beta<span class="nobreak">-1</span>, with smaller number of beta<span class="nobreak">-2</span> receptors present. Importantly, beta<span class="nobreak">-2</span> receptors are also present on adrenergic nerve terminals in the heart, where they regulate the release of the neurotransmitter norepinephrine (&#8220;NE&#8221;). The blocking of these receptors prevents them from binding with other molecules, primarily NE, which activates these receptors to release more NE.&#160;ARCA believes Gencaro has two unique anti<span class="nobreak">-adrenergic</span> properties not possessed by other beta<span class="nobreak">-blockers</span> currently approved for the treatment of HF: (1)&#160;it is moderately sympatholytic, i.e., by blocking beta<span class="nobreak">-2</span> receptors on adrenergic nerves it lowers adrenergic drive to a level that can be detected on measurements of central or systemic venous NE levels, and, (2)&#160;through &#8220;inverse agonism,&#8221; as it binds to a polymorphic &#8220;389 arginine&#8221; form of heart cell beta<span class="nobreak">-1</span> receptor in isolated human heart preparations it promotes the inactivation of the active<span class="nobreak">-state</span> of this receptor. These properties, as described below, were observed to interact with receptor polymorphisms in such a way that ARCA believes targeting a specific genotype of the beta<span class="nobreak">-1</span> receptor gene (known as ADRB1) could improve the therapeutic response of patients. ARCA believes Gencaro&#8217;s efficacy is enhanced in patients with the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), which has been shown to be present in approximately 50% of the North American and European general populations. To date no other beta<span class="nobreak">-blocker</span> has been shown to possess pharmacological sympatholysis, or beta<span class="nobreak">-1</span> AR inverse agonism in human heart preparations. ARCA believes that Gencaro&#8217;s sympatholytic and beta<span class="nobreak">-1</span> AR inverse agonist properties contribute to its enhanced lowering of HF and arrhythmia event rates in patients who have an <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical and Regulatory Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to advance Phase&#160;3 clinical development of Gencaro as a therapy for HF patients with AF, focusing on HF with EF &#8805; 40%. The regulatory strategy for Gencaro is to obtain an initial approval to treat AF in a HF population with EF &#8805; 40% and &#8804; 55% and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype; the population demonstrating the greatest efficacy in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. Indication expansion for Gencaro will focus on genotype<span class="nobreak">-positive</span> HF patients with EF &gt;55%, which ARCA believes would substantially expand the addressable patient population, if successful. ARCA has obtained an SPA agreement with the FDA to conduct a single, 400<span class="nobreak">-patient</span> Phase&#160;3 clinical trial that, if successful at a statistical threshold of p &#8804; 0.01, may be sufficient to support an NDA for the marketing approval of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The clinical trial design is similar to GENETIC<span class="nobreak">-AF</span>, including the active comparator, TOPROL<span class="nobreak">-XL</span>, and the primary endpoint of time to AF or atrial flutter (&#8220;AF/AFL&#8221;) recurrence or mortality during a 6<span class="nobreak">-month</span> follow<span class="nobreak">-up</span> period. The planned clinical trial will use a standard significance criterion of p &#8804; 0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement. The NDA submission for Gencaro is eligible for expedited review in the United&#160;States under the Fast Track development program designation that was granted to Gencaro in 2015. Based on the use of this same endpoint in GENETIC<span class="nobreak">-AF</span> it is anticipated that &#8805;90% of the primary events will be due to recurrent AF/AFL.&#160;Secondary objectives will examine other important endpoints, such as AF burden and AF treatment<span class="nobreak">-related</span> interventions. The planned clinical trial will use a standard significance criterion of p&#160;&#8804;&#160;0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single&#160;Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Gencaro Test</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, ARCA believes that Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic. This would be a test for the patient genotype approved for the drug, and could be performed by a variety of laboratory processes or platforms.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">204</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In collaboration with LabCorp, ARCA developed one such genetic test, obtained an IDE from the FDA and used this test in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA retains all rights to this particular test platform, and ARCA believes it could be used for commercialization. Future clinical trials of Gencaro, including PRECISION<span class="nobreak">-AF</span>, are expected to use a similar diagnostic test to identify the patient&#8217;s receptor genotype (the &#8220;Gencaro Test&#8221;). ARCA believes the Gencaro Test could be developed and commercialized through one or more diagnostic providers, by the company potentially marketing Gencaro, or a combination of approaches. ARCA also believes that point of care genetic tests, which could be performed during the patient&#8217;s visit to the physician, will be part of the commercialization strategy for Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Development Pipeline</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, is a potential treatment for HF patients with AF.&#160;Gencaro (bucindolol hydrochloride) is a pharmacogenetic<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that is considered a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span> based on its novel pharmacogenetic profile. ARCA believes the treatment of AF in HF patients with EF &#8805; 40% is an unmet medical need with a near term and straightforward regulatory pathway.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s plan is to obtain an initial approval for Gencaro to treat AF in a genotype specific HF population; HF patients with EF between 40% and 55% in patients with the genotype ARCA studied in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA believes that, if approved, there are additional indication expansion opportunities for Gencaro in other AF populations, including expanding the patient population to selected HF patients with EF &gt;55%. ARCA continues to evaluate the feasibility and potential timing for initiating PRECISION<span class="nobreak">-AF</span> relative to the COVID<span class="nobreak">-19</span> pandemic. ARCA may seek additional capital or a strategic partnership for the Phase&#160;3 clinical trial and potential commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has exclusive pharmacogenetic and other patent rights to drug targets and candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. ARCA may seek partners to assist it in the development of these candidates or who may license them. ARCA may also seek funds to advance the development of the compounds on ARCA&#8217;s own.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and its general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes ARCA&#8217;s cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">205</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Licensing and Royalty Obligations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is also a party to licenses for patents relating to Gencaro that are now expired. ARCA believes that there are no future milestone or royalty obligations that will be payable under these licenses.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Current HF treatments include three beta<span class="nobreak">-blockers</span> approved for HF in the United&#160;States. However, their efficacy in providing control of the arrhythmia caused by AF, or rhythm control, is only mild. It is also now acknowledged that evidence is lacking that the approved beta<span class="nobreak">-blockers</span> provide outcome benefits for patients who develop permanent AF.&#160;Furthermore, these drugs have not demonstrated efficacy for HF patients with EF &#8805; 40%, which is the focus of the Gencaro development program. Current AF treatments include pharmaceutical, procedural or device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF.&#160;However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with HF.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Drugs that are currently approved or used for the treatment or prevention of AF in HF either have not demonstrated efficacy in these patients, or have notable risks due to adverse side effects or lack sufficient efficacy. Therefore, in HF, and specifically in HF patients with EF &#8805; 40%, ARCA believes there is a substantial unmet medical need for AF therapies that are more effective and have fewer side effects than those currently available. ARCA believes that Gencaro&#8217;s treatment of AF in HF patients could provide a more effective and safer pharmacotherapy than treatments currently used in these patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pharmaceutical industry is highly competitive. ARCA faces significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Most of these companies have significantly greater financial, product development, manufacturing, and commercial resources than ARCA has.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, some of the drugs which Gencaro would potentially compete with are generic in the United&#160;States and are used, though not approved or shown to be effective, for the treatment of AF or in HF patients with EF &#8805; 40%. Gencaro could be priced at a premium compared to some of these therapies. In addition, Gencaro, if approved, would be prescribed in conjunction with a diagnostic test, adding additional procedures to the process of prescribing Gencaro, which could make it more difficult for ARCA to compete against existing or future therapies.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing and Product Supply</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the active pharmaceutical ingredients (&#8220;API&#8221;) and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. ARCA outsources all manufacturing and analytical testing of the Gencaro API and drug product. ARCA has selected third<span class="nobreak">-party</span> contract manufacturing organizations on the basis of their technical and regulatory expertise. ARCA&#8217;s approach with its contract manufacturing partners has been to replicate the manufacturing processes that were used to support the prior pivotal clinical trial with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk. For API production, ARCA contracted with Groupe Novasep which completed the drug substance registration batches successfully. The resulting drug substance was used to manufacture the drug product used in the clinical trial material for the Phase&#160;2B clinical trial and is expected to be used in the proposed Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For drug product production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths have been manufactured, with the maximum recommended dose of 100mg twice daily. Registration </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">206</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">batches were successfully completed by Patheon, Inc. and tablets from these runs were placed in cGMP storage to supply clinical trials. In addition, ARCA contracted with a separate service provider for packaging and distribution of its clinical trial materials.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Governmental authorities in the United&#160;States at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products. In the United&#160;States, the FDA regulates these activities at the federal level pursuant to the Federal Food Drug and Cosmetic Act (&#8220;FDCA&#8221;) and the regulations promulgated thereunder. In Canada, Health Canada regulates these activities. In Europe, the Competent Authorities and Ethics Committees of the respective countries regulate these activities. In South America, the Health Authorities and Ethics Committees of their respective countries regulate these activities. ARCA anticipates that all of its product candidates will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and ARCA&#8217;s products may be subject to new legislation or regulations. Both before and after approval or clearance, failure to comply with the requirements of the FDA and other state and federal statutes can lead to significant penalties or could disrupt ARCA&#8217;s ability to manufacture and sell these products. In addition, the FDA could refuse to provide certificates needed to export ARCA&#8217;s products if the agency determines that ARCA is not in compliance.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Premarket Approval of Drugs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">FDA approval is required for marketing of any new drug, dosage form, indication, or strength. The steps required before new human therapeutic drug products are marketed in the United&#160;States and foreign countries include rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries. There is no guarantee that products will be approved in a specific timeframe or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Preclinical studies are generally conducted in the laboratory to identify potential drug candidates and to evaluate their potential efficacy and safety. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate short and long<span class="nobreak">-term</span> toxicity in animals. Preclinical studies are governed by numerous regulations, including but not limited to FDA&#8217;s Good Laboratory Practices.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Before human clinical trials can commence, an Investigational New Drug (&#8220;IND&#8221;) application, submitted to FDA must become effective. For an IND to become effective, the applicant must submit, among other things, information on design of the proposed investigation, reports necessary to assess the safety of the drug for use in clinical investigation, and information on the chemistry and manufacturing of the drug, controls available for the drug, and primary data tabulations from animal or human studies. The clinical phase of development involves the performance of human studies, including adequate and well<span class="nobreak">-controlled</span> human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase&#160;1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. Phase&#160;2 trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase&#160;3, larger<span class="nobreak">-scale</span>, multi- center trials are conducted with patients afflicted with a specific target disease over a longer term to confirm Phase&#160;2 results and provide reliable and conclusive data supporting efficacy and safety of a drug as required by regulatory agencies for drug approval. The conduct of clinical trials is subject to extensive regulation. FDA may delay or suspend clinical trials through clinical holds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">NDA Submission.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the United&#160;States, the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of a NDA.&#160;Under the current Prescription Drug User Fee Act after submission of an NDA and payment, or waiver, of the required fee, the FDA&#8217;s goal is to review most standard NDAs within 10&#160;months from the time that a sponsor&#8217;s application is accepted as </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">207</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">filed by the FDA, which can occur within a 60<span class="nobreak">-day</span> window following the initial submission of the application. At the end of the 10&#160;months, the FDA&#8217;s goal is to issue a &#8220;complete response,&#8221; or approve the NDA.&#160;While FDA&#8217;s goal is to issue a complete response within 10&#160;months, the process may take longer than 10&#160;months, particularly if multiple review cycles are required. Gencaro has been granted Fast Track Designation which allows for a rolling review of a marketing application. A rolling review allows FDA to consider reviewing portions of an NDA before the sponsor submits the complete application.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy the statutory and regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase&#160;3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than ARCA interprets data. Under the Food and Drug Modernization Act&#160;of&#160;1997, the FDA is authorized to approve a drug based on a single adequate and well<span class="nobreak">-controlled</span> study if such study and other confirmatory data are sufficient to establish the drug&#8217;s effectiveness. However, it has long been the FDA&#8217;s general position that the standard of proof of a drug&#8217;s effectiveness generally requires at least two well<span class="nobreak">-controlled</span> and adequate Phase&#160;3 clinical studies demonstrating statistically significant results as compared to a placebo or active control (with p<span class="nobreak">-values</span> of less than 0.05) with respect to the primary endpoint or endpoints of the trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, in accordance with current FDA law and regulations, the FDA may refer a drug to an advisory committee for review prior to approval. Most new compounds are referred to an FDA advisory committee, which could add additional time to the review process. There is no guarantee that the advisory committee will recommend approval of a drug candidate. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase&#160;4 clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post<span class="nobreak">-marketing</span> programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the FDA approves the NDA, the sponsor is authorized to begin commercialization of the drug in accordance with the approval. Even if the FDA approves the NDA, the FDA may decide later to suspend or withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require additional clinical studies, to require changes in labeling or to prevent further marketing of a product based on the results of these post<span class="nobreak">-marketing</span> programs. The FDA also has authority to request implementation of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) that could restrict distribution of Gencaro or require ARCA to provide additional risk information to prescribers. Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-approval</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Compliance.&#160;&#160;&#160;&#160;</span>If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including compliance with cGMP, as well as labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse events. In addition, the FDA closely regulates the post<span class="nobreak">-approval</span> marketing and promotion of drugs, including standards and regulations for labeling, promotion to health care professionals, direct<span class="nobreak">-to-consumer</span> advertising, off<span class="nobreak">-label</span> promotion, industry<span class="nobreak">-sponsored</span> scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Companies are responsible for compliance with such requirements and would be responsible to ensure that all contract manufacturing organizations who perform work for them also comply with such requirements. Similarly, if a drug manufacturer hires contract sales representatives or consultants to promote its products, such organizations or individuals must comply with all of the same requirements applicable to the drug manufacturer. The FDA regularly inspects companies to determine compliance with cGMPs and other post<span class="nobreak">-market</span> requirements. Failure to comply with statutory requirements and the FDA&#8217;s regulations can result in a variety of administrative or enforcement actions, including but not limited to an FDA Form&#160;483 (which is issued by the FDA at the conclusions of an inspection when an investigator has observed </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">208</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any conditions that may constitute violations), a public warning letter, suspension or withdrawal of regulatory approvals, product recalls, product detentions, refusal to provide export certificates, seizure of products and criminal prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, also known as the Hatch<span class="nobreak">-Waxman</span> Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch<span class="nobreak">-Waxman</span> Act also provides for patent term restoration and the award, in certain circumstances, of non<span class="nobreak">-patent</span> marketing exclusivities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Generic Drug Approval.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The Hatch<span class="nobreak">-Waxman</span> Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA.&#160;Generic drug applications are &#8220;abbreviated&#8221; because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;) must certify to the FDA that (i)&#160;no patent information on the drug has been listed in the Orange Book; (ii)&#160;that each patent listed in the Orange Book for that approved drug has expired; (iii)&#160;FDA should approve the product on the date on which a listed patent expires; or (iv)&#160;that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a certification pursuant to (iv)&#160;above, or a Paragraph&#160;IV certification, and the NDA holder files an infringement suit against the ANDA applicant within 45&#160;days of receiving the Paragraph&#160;IV notification, the NDA owner is entitled to an automatic 30<span class="nobreak">-month</span> stay of FDA&#8217;s ability to approve the ANDA.&#160;This 30<span class="nobreak">-month</span> stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Patent Term Extension.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>While the term of a U.S.&#160;patent is generally 20&#160;years from the earliest priority date of a patent application (excluding a provisional patent application), a U.S.&#160;patent that covers subject matter requiring regulatory approval to market is eligible for an extension of that patent term. The Hatch<span class="nobreak">-Waxman</span> Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. Patent Term Extension (&#8220;PTE&#8221;), extends the term of an issued patent for generally (i)&#160;the length of the FDA approval process, i.e., the complete period of NDA review, and (ii)&#160;half of the time spent in clinical trials, i.e., the IND period. However, the maximum period of restoration cannot exceed five&#160;years, or restore the total remaining term of the patent to greater than 14&#160;years from the date of FDA approval of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under 35 U.S.C. &#167; 156(a), a patent covering a method of using a product is eligible for PTE if the following conditions are met:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent has not yet expired;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent was not previously extended;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent owner submits an application for PTE that includes all necessary supporting information within 60&#160;days of FDA approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the product was subject to regulatory review before its commercial marketing or use; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the drug application is for the first permitted commercial marketing of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that, if Gencaro is approved by the FDA, one of its U.S.&#160;patents may be eligible for PTE, which could provide up to 5&#160;years of additional patent life for that patent based on ARCA&#8217;s current clinical trial plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Supplementary Protection Certificate (&#8220;SPC&#8221;) is a form of patent term extension that is available for pharmaceutical products approved for marketing in the European Union (&#8220;EU&#8221;). ARCA obtained a patent in Europe on methods for using Gencaro that is similar to one of its U.S.&#160;patents and this EU patent is in force in certain countries in Europe, including the United Kingdom, France, Germany, Italy and Spain. ARCA believes that this </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">209</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patent may be eligible for an SPC, if Gencaro is approved for marketing in any European country in which the patent is in force, which could provide up to five&#160;years of additional patent life. ARCA believes that its patents in other jurisdictions may also be eligible for similar term extensions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Patent</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Marketing Exclusivities.&#160;&#160;&#160;&#160;</span>Separate and apart from patent protection, the Hatch<span class="nobreak">-Waxman</span> Act entitles approved drugs to various periods of non<span class="nobreak">-patent</span> statutory protection, known as marketing exclusivity. The Hatch<span class="nobreak">-Waxman</span> Act provides five&#160;years of &#8220;new chemical entity&#8221; marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2)&#160;NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand<span class="nobreak">-alone</span> NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph&#160;IV certification. Four&#160;years into the five<span class="nobreak">-year</span> exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Hatch<span class="nobreak">-Waxman</span> Act also provides three&#160;years of &#8220;new use&#8221; marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA&#8217;s approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA&#8217;s approval or were conducted by or for the applicant, this three<span class="nobreak">-year</span> exclusivity prohibits the final approval of ANDAs or 505(b)(2)&#160;NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for other products containing the same active ingredient, without those changes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar non<span class="nobreak">-patent</span> market exclusivity is provided for in the EU and other international jurisdictions. ARCA believes that, if approved in the EU, Gencaro may be eligible for ten&#160;years of market exclusivity in the EU, measured from the date of approval there.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">FDA Premarket Review of Medical Devices</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless an exemption applies, each medical device that a company wishes to market in the United&#160;States requires either approval of a premarket approval application (&#8220;PMA&#8221;), or clearance of a premarket notification, commonly known as a &#8220;510(k)&#8221; from the FDA.&#160;The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class&#160;I or&#160;II, which may require the manufacturer to submit to the FDA a 510(k)&#160;requesting permission to commercially distribute the device. Clearance of a 510(k)&#160;usually requires between three&#160;months and one year from the time of submission of the 510(k), although the process may take longer. The FDA&#8217;s 510(k)&#160;clearance procedure is less rigorous than the PMA approval procedure, but is available only to companies who can establish that their device is substantially equivalent to a legally<span class="nobreak">-marketed</span> &#8220;predicate&#8221; device that was (i)&#160;on the market prior to the enactment of the Medical Device Amendments of 1976, (ii)&#160;reclassified from Class&#160;III to Class&#160;II, or (iii)&#160;has been cleared through the 510(k)&#160;procedure. 510(k)s must typically be supported by performance data, including preclinical data, bench testing, and in some cases, clinical data. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class&#160;III, and require a PMA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PMA Pathway.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Generally, a PMA must be supported by extensive data and valid scientific evidence, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in<span class="nobreak">-depth</span> review of the submitted information and will generally conduct a pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities to ensure compliance with FDA&#8217;s QSR. By statute, the FDA has 180&#160;days to review the &#8220;accepted application&#8221;, although, generally, review of the application can take between one and three&#160;years, and it may take significantly longer. The PMA application process can be expensive, and there is a substantial &#8220;user fee&#8221; that must be paid to FDA in connection with the submission of a PMA application. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several&#160;years. In addition, if FDA discovers that an applicant has </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">210</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">submitted false or misleading information, FDA may refuse to review submissions until certain requirements are met pursuant to its Application Integrity Policy. If the FDA approves the PMA, it may place restrictions on the device. After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval. PMA supplements often must be approved by the FDA before the modification to the device, the labeling, or the manufacturing process may be implemented. Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Trials.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Clinical trials are generally required to support a PMA application and are sometimes required for 510(k)&#160;clearance. These trials generally require an IDE application approved in advance by the FDA for a specified number of patients, unless the proposed study is deemed a non<span class="nobreak">-significant</span> risk study, which is eligible for an exemption from the IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin if the IDE application is approved by the FDA and the appropriate IRBs at the clinical trial sites. Submission of an IDE application does not give assurance that the FDA will issue the IDE.&#160;If the IDE application is approved, there can be no assurance the FDA will determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that may affect its scientific soundness, study indication or the rights, safety or welfare of human subjects. The trial must also comply with the FDA&#8217;s regulations, including the requirement that informed consent be obtained from each subject. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance to market the product in the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">In Vitro Diagnostic Companion Diagnostic Devices.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The FDA has described <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostics (&#8220;IVD&#8221;) companion diagnostic devices as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic product. An IVD companion diagnostic device could be used to (i)&#160;identify patients who are most likely to benefit from a particular therapeutic product; (ii)&#160;identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product; or (iii)&#160;monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, dose, discontinuation) to achieve improved safety or effectiveness. Although FDA&#8217;s regulation of IVD companion diagnostic devices is evolving and implemented on a case<span class="nobreak">-by-case</span> basis, FDA&#8217;s stated policy for a novel therapeutic product is that an IVD companion diagnostic device should be developed and approved or cleared contemporaneously to support the therapeutic product&#8217;s safe and effective use. The clinical performance and clinical significance of the IVD companion diagnostic device is to be established using data from the clinical development program of the corresponding therapeutic product. FDA recognizes, however, that there may be cases where contemporaneous development may not be possible. With respect to the Gencaro Test, there is no assurance that ARCA will be able to develop and obtain approval or clearance contemporaneously with Gencaro. Failure to develop the Gencaro Test or obtain clearance or approval could delay approval of Gencaro, if FDA regards the Gencaro Test as an IVD companion diagnostic test that is essential to the safe and effective use of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Continuing Regulation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a PMA approval. Unless subject to an exemption, medical devices distributed in the United&#160;States must be manufactured in compliance with the FDA&#8217;s QSRs and current good manufacturing practices. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing, as well as complaint handling, corrective and preventative actions and internal auditing. In complying with the QSRs, manufacturers must expend significant time, money and effort. Companies are also subject to other post<span class="nobreak">-market</span> and general requirements, including but not limited to product listing and establishment registration, post<span class="nobreak">-market</span> surveillance requirements, limitations on promotion, and requirements for recordkeeping and reporting of certain adverse events, malfunctions, corrections and removals. As discussed above, FDA regularly inspects companies to assess compliance with the QSRs and other post<span class="nobreak">-market</span> requirements. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, and potential civil and criminal penalties. As part of such arrangement, ARCA will seek to have the diagnostic company take responsibility for compliance with the FDA&#8217;s device approval and on<span class="nobreak">-going</span> regulatory requirements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">211</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">International Marketing Approvals.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Regulatory Requirements.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>ARCA is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Device Tax</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2010, the U.S.&#160;Congress adopted and President Obama signed into law comprehensive health care reform legislation. Among other initiatives, these laws impose significant new taxes on medical device makers in the form of a 2.3% excise tax on U.S.&#160;medical device sales, with certain exemptions, beginning on January&#160;1, 2013. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The future success of ARCA&#8217;s business will partly depend on its ability to maintain market exclusivity for its product candidates, if approved, in the United&#160;States and important international markets, and for other products or product candidates that ARCA may acquire or develop. ARCA will rely on statutory protection, patent protection, trade secrets, know<span class="nobreak">-how</span>, and in<span class="nobreak">-licensing</span> of technology rights to maintain protection for ARCA&#8217;s products.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, will have market exclusivity in the United&#160;States and in major international markets. ARCA recently obtained a patent in the United&#160;States for the use of Gencaro for the patient population ARCA plans to study in the Phase&#160;3 pivotal trial. ARCA has filed similar patent applications in international jurisdictions. If Gencaro is approved by the FDA or international regulatory agencies based on this planned clinical development, ARCA believes that the commercialization of Gencaro will have patent protection extending into 2039.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an existing patent portfolio of United&#160;States and international patents covering the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3, that ARCA believes will provide additional patent protection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patent protection, Gencaro will qualify as a new chemical entity and if approved will have data protection in the United&#160;States and other jurisdictions in which it is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has other patent rights in additional drug candidates having possible indications in cardiovascular disease, oncology, and other therapeutic areas; these are in both early and later stages of development. ARCA may seek collaborators to assist it in the development of these candidates or it may seek to raise funds to advance the development of the compounds on its own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information about ARCA&#8217;s Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to ARCA&#8217;s executive officers is included under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Directors, Executive Officers and Corporate Governance</span>&#8221; in the proxy statement/prospectus and such information is incorporated herein by reference.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Human Capital Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had 5 employees, 4 of which are full<span class="nobreak">-time</span>. None of ARCA&#8217;s employees are represented by any collective bargaining unit. ARCA believes that it maintains good relations with its employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">212</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to compensation of ARCA executive officers is included in &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Executive Compensation</span>&#8221; of this proxy statement/prospectus and such information is incorporated herein by reference. The structure of ARCA&#8217;s compensation programs balances incentive earnings for both short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> performance. ARCA is committed to providing comprehensive benefit options and offering benefits that will allow ARCA&#8217;s employees and their families to live healthier and more secure lives. Some examples are employees are eligible for health insurance, prescription drug benefits, dental insurance, vision insurance, life insurance, disability insurance, health savings accounts, flexible spending accounts, paid and unpaid leaves, a retirement plan and life and disability/accident coverage. ARCA also offers a variety of voluntary benefits that allow employees to select the options that meet their needs, including hospital indemnity insurance, accident insurance and critical illness insurance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA continually monitors employee turnover rates as its success depends upon retaining its highly trained personnel. ARCA believes the combination of competitive compensation and career growth and development opportunities have helped increase employee tenure and reduce voluntary turnover. The average tenure of ARCA&#8217;s employees, as of March&#160;31, 2024, was approximately eleven&#160;years and approximately 40% of ARCA&#8217;s employees, as of March&#160;31, 2024, have been employed by ARCA for more than ten&#160;years.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Corporate Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;27, 2009, ARCA completed a business combination between Nuvelo, Inc., a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the business combinations, ARCA changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. ARCA&#8217;s principal offices are located in Westminster, Colorado.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA files its annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span> and current reports on Form&#160;8<span class="nobreak">-K</span> pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act electronically with the SEC.&#160;The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.&#160;The address of that site is <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may obtain a free copy of ARCA&#8217;s annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span>, current reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.arcabiopharma.com</span> on the earliest practicable date following the filing with the SEC or by contacting the Investor Relations Department at ARCA&#8217;s corporate office by calling (720)&#160;940<span class="nobreak">-2100</span>. Information found on ARCA&#8217;s website is not incorporated by reference into this report.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s headquarters facility consists of approximately 5,200 square feet of office space in Westminster, Colorado, of which approximately 5,200 square feet is leased until September&#160;2024, after which ARCA can continue to lease on a month<span class="nobreak">-to-month</span> basis. ARCA believes that this facility is adequate to meet its current needs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, ARCA may become involved in legal proceedings. ARCA is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on ARCA because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">213</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T12"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221; and reflects the company&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells (&#8220;TRMs&#8221;). Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Pipeline</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_001.jpg" style="width:601.6px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ORKA-001</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> monoclonal antibody (&#8220;mAb&#8221;) designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">214</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential not only to generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence. It is the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated to grow to $32&#160;billion by 2028. Around half of PsO patients have moderate or severe disease that cannot be adequately addressed by topical corticosteroids or oral therapies. The American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Several classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured via the psoriasis area and severity index (&#8220;PASI&#8221;) scoring system. The first biologics approved for PsO were tumor necrosis alpha (&#8220;TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a 90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a 100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL<span class="nobreak">-23</span> that is shared with IL<span class="nobreak">-12</span>, was approved next and achieved efficacy on par with Humira. IL<span class="nobreak">-17A</span> inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL<span class="nobreak">-23p19</span> inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally, IL<span class="nobreak">-17A</span>/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL<span class="nobreak">-23</span> inhibitors, but with slightly less tolerable profiles.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today, Skyrizi, is widely viewed as the leader in PsO biologic therapy and achieves PASI 100 in&#160;40&#160;&#8211;&#160;50% of patients at the 16<span class="nobreak">-week</span> primary endpoint with maintenance dosing every three&#160;months. While this is a remarkable advancement, there is still significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and a continued desire for more convenient dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety profile of biologics. Oruka believes that a long<span class="nobreak">-acting</span> biologic with higher efficacy and potential for disease modification represents the next step in advancing the standard of care in PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is expected to enter Phase&#160;1 clinical trials in the first half of 2025. Oruka plans to carry out a Phase&#160;1 program that could provide validation of half<span class="nobreak">-life</span> extension in 2025. In addition, Oruka plans to include PsO patients in its Phase&#160;1 program, which would give Oruka the opportunity to demonstrate 16<span class="nobreak">-week</span> PASI response rates by the end of 2026. Oruka then plans to proceed into Phase&#160;2/3 development. Based on recent precedent for PsO, Oruka anticipates that the entire development program from first<span class="nobreak">-in-human</span> to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved medicines. However, Oruka has no control over the length of time needed for FDA review, and this timeline could vary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> (IL<span class="nobreak">-17A</span>/F). IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">215</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Team, Investors, and Paragon Collaboration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management and hold options to acquire intellectual property rights with respect to certain research programs, including ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, from Paragon. Fairmount Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including Apogee Therapeutics and Spyre Therapeutics. Oruka is led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, and Protagonist Therapeutics. Together, Oruka&#8217;s team has a proven track record of building successful biotech organizations in high<span class="nobreak">-growth</span> environments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since its inception, Oruka has raised $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note. On April&#160;3, 2024, Oruka entered into a definitive merger agreement with ARCA to create a new public company focused on advancing Oruka&#8217;s pipeline of antibody therapies. In support of the Merger, Oruka has secured commitments for a $275.0&#160;million private investment (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase Oruka common stock from a syndicate of premier healthcare investors led by Fairmount Funds Management and Venrock Healthcare Capital Partners, with participation from RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP, and Redmile Group, as well as other investors, including multiple large investment management firms, that is expected to close immediately prior to completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the exercise of its Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, Oruka will have exclusive worldwide development and commercialization rights to Oruka&#8217;s programs, with IL<span class="nobreak">-23</span> rights for all indications outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon leverages a dedicated in<span class="nobreak">-house</span> team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics, to generate unique therapeutic concepts and enable its rapid proof<span class="nobreak">-of-concept</span> validation. Oruka considers Paragon to be a related party. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Oruka&#8217;s Relationship with Paragon and Paruka</span>&#8221; for additional information.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">216</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To achieve its goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, Oruka is applying antibody engineering to validated modes of action. Oruka believes this approach will enable it to improve meaningfully upon the efficacy and convenience of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. The key elements of Oruka&#8217;s strategy include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:&#160;&#160;&#160;&#160;</span>Oruka and its collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with the potential to improve upon existing therapies. These parameters include extending half<span class="nobreak">-life</span> to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and enable convenient, high<span class="nobreak">-dose</span> formulations. Together, Oruka believes these features have the potential to translate into more efficacious and convenient medicines for patients.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Target validated mechanisms of action:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s initial targets, IL<span class="nobreak">-23p19</span> and IL<span class="nobreak">-17A</span>/F, have established efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL<span class="nobreak">-23</span> class, including three targeting IL<span class="nobreak">-23p19</span>, and four biologics in the IL<span class="nobreak">-17</span> class, including one targeting IL<span class="nobreak">-17A</span>/F.&#160;While these therapies have advanced the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not achieve complete skin clearance. By applying Oruka&#8217;s advanced antibody engineering to these validated targets, Oruka believes it can maximize its chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms may allow Oruka to progress its programs more efficiently and rapidly.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leverage insights from earlier entrants to optimize Oruka&#8217;s approach:&#160;&#160;&#160;&#160;</span>Oruka benefits from a large body of clinical evidence generated by prior therapies targeting IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. Oruka continues to extract and apply learnings from this precedent to its programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations, regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, Oruka has designed ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure<span class="nobreak">-response</span> relationships for efficacy and safety for other therapies, Oruka plans to select dose levels and regimens that could maximize efficacy and maintenance of response while maintaining safety.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pursue opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside case&#8221;:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s strategy seeks to maximize the potential for Oruka&#8217;s programs to reach a base case product profile that could meaningfully advance the standard of care&#160;&#8212;&#160;for instance, for ORKA<span class="nobreak">-001</span>, SQ dosing one or twice a year with equal or greater efficacy compared to today&#8217;s standard of care. At the same time, Oruka aims to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for instance, significantly increasing rates of complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient<span class="nobreak">-specific</span> dosing intervals.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Build a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I indications:&#160;&#160;&#160;&#160;</span>Oruka is assembling a team of exceptional people and helping them reach their full potential and flourish so that together it can bring forward meaningful new medicines for patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that pursuing the focused strategy outlined above will help it to succeed in its mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Targeting IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> are designed to target two key cytokines that play a related role in multiple indications. IL<span class="nobreak">-23</span> is an upstream regulator of Th17 cells, a pro<span class="nobreak">-inflammatory</span> subset of T helper cells </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">217</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">characterized by their production of IL<span class="nobreak">-17</span>. IL<span class="nobreak">-23</span> has a critical role in maintaining Th17 cells in the tissue as well as activating these cells to secrete IL<span class="nobreak">-17</span>, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA.&#160;The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> can break the inflammatory cycle that drives disease.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Immunopathogenesis of PsO and the role of IL-23 and IL-17</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><img alt="" src="timage_002.jpg" style="width:599.04px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic cells (&#8220;DCs&#8221;), specifically those producing IL<span class="nobreak">-23</span> and other cytokines like IL<span class="nobreak">-1</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#946;</span>, IL<span class="nobreak">-21</span>, TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, and IL<span class="nobreak">-12</span>. These cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that produce IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-23</span> plays a key role in the differentiation and activation of Th17 cells to secrete IL<span class="nobreak">-17</span>, as well as Th22 cells to produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-17</span> and these other cytokines induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis plays an important role, as supported by the success of therapies targeting this axis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> &#8212;&#160;can result in lesional skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL<span class="nobreak">-23</span> appears to play an important role in maintaining and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">218</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL<span class="nobreak">-23</span> inhibitor but not an IL<span class="nobreak">-17</span> inhibitor, which may explain the longer remissions observed with IL<span class="nobreak">-23</span> inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL<span class="nobreak">-23</span> blockade could modify the disease biology of PsO, possibly leading to durable remissions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells, a subpopulation of T helper cells that produce pro<span class="nobreak">-inflammatory</span> cytokines such as IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, were the predominant mediators of the disease, which led to the use of biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors) to precise biologic therapies targeting the key cytokines involved in disease pathology (IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span> inhibitors), with each new therapeutic class raising the bar on both safety and efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biologic therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Each biologic approved in PsO has raised the bar on standard of care, with therapies that have improved upon efficacy and/or reduced dosing frequency achieving the most commercial success, even when launching many&#160;years after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira was approved for PsO with an every<span class="nobreak">-other-week</span> (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3 data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule with improvements in efficacy, as evidenced by higher PASI 90 and PASI 100 rates in clinical trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Biologics have raised the bar on the standard of care in PsO, but leave room for improvement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_003.jpg" style="width:500.48px;max-width:100%;"/></span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">219</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. Oruka believes that it is unlikely that a novel mechanism will emerge that is as safe and efficacious as targeting the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis. Therefore, Oruka believes that innovation now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. Oruka believes that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriasis (PsO)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence, estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well<span class="nobreak">-demarcated</span>, erythematous plaques with overlying, coarse, silvery<span class="nobreak">-scaled</span> patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur and can be particularly difficult to treat. Around half of PsO patients have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed earlier, PsO is a complex immune<span class="nobreak">-mediated</span> disease driven primarily by Th17 cells and the cytokines IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. The interplay of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system, in genome<span class="nobreak">-wide</span> association studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsO Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;As a result, the American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.&#160;Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3 clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months. Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and while early signs are present, the promise of disease modifying therapy remains unrealized. Oruka believes that ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriatic Arthritis (PsA)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsA is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third of patients with moderate<span class="nobreak">-to-severe</span> PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Entheses, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">220</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsA Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti<span class="nobreak">-inflammatory</span> drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span>, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL<span class="nobreak">-17</span> inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span> inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;30&#160;&#8211;&#160;35% at 24&#160;weeks with Q2W dosing. Approved IL<span class="nobreak">-17</span> inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab) has not yet received approval in the United&#160;States for PsA; however, in two Phase&#160;3 clinical trials, bimekizumab achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of 34% and 37% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly SQ dosing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of additional opportunities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to PsO and PsA, inhibition of IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including HS and axSpA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HS is a chronic inflammatory skin disease characterized by lesions that include deep<span class="nobreak">-seated</span> nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA<span class="nobreak">-approved</span> medication for the treatment of moderate<span class="nobreak">-to-severe</span> HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023. However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">axSpA is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor is typically used, followed by an IL<span class="nobreak">-17</span> inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Solution: Half-Life Extension and Antibody Engineering Technologies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended serum half<span class="nobreak">-life</span> in non<span class="nobreak">-human</span> primates (&#8220;NHPs&#8221;). Half<span class="nobreak">-life</span> extension is possible by modifying the pH<span class="nobreak">-dependent</span> binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half<span class="nobreak">-life</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">221</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Antibody engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past two decades, with the so<span class="nobreak">-called</span> &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221; mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half<span class="nobreak">-life</span> that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate half<span class="nobreak">-life</span> in humans, with the human half<span class="nobreak">-life</span> equaling around 3.1&#160;times the NHP half<span class="nobreak">-life</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Clinical experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_004.jpg" style="width:380.16px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While this increasing body of clinical precedent serves to validate half<span class="nobreak">-life</span> extension, Oruka does not yet have clinical data showing that the introduction of these amino acid substitutions in its programs leads to a longer serum half<span class="nobreak">-life</span>. However, Oruka aims to establish this favorable pharmacokinetic profile early in the clinical development of its product candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target the p19 subunit of IL<span class="nobreak">-23</span>. Based on preclinical data generated to date, Oruka believes ORKA<span class="nobreak">-001</span> has the potential to become the leading IL<span class="nobreak">-23</span> inhibitor and achieve an optimal product profile in PsO consisting of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:bold;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">One to two maintenance doses per year.&#160;&#160;&#160;&#160;</span>Standard<span class="nobreak">-of-care</span> therapies targeting IL<span class="nobreak">-23</span> require maintenance dosing every eight to twelve&#160;weeks. Oruka engineered the Fc portion of ORKA<span class="nobreak">-001</span> to include YTE mutations to increase the half<span class="nobreak">-life</span> of ORKA<span class="nobreak">-001</span> in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half<span class="nobreak">-life</span> extension technology. In </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">222</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">preclinical studies, serum levels from&#160;NHPs indicated an elimination half<span class="nobreak">-life</span> of 24&#160;days following SQ administration of a precursor antibody to ORKA<span class="nobreak">-001</span>. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, Oruka anticipates this half<span class="nobreak">-life</span> in NHPs to translate to a half<span class="nobreak">-life</span> in humans that could allow subcutaneous dosing every six to twelve&#160;months while maintaining high antibody exposures.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Higher PASI 100.&#160;&#160;&#160;&#160;</span>ORKA<span class="nobreak">-001</span> benefits from the robust validation of IL<span class="nobreak">-23</span> inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA<span class="nobreak">-001</span> is designed to bind a similar epitope to the market<span class="nobreak">-leading</span> anti<span class="nobreak">-IL-23</span> antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures in patients due to half<span class="nobreak">-life</span> extension. Skyrizi and Tremfya both have a robust exposure<span class="nobreak">-response</span> relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated this exposure<span class="nobreak">-response</span> relationship, and ORKA<span class="nobreak">-001</span> could lead to higher response rates, including higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few as one or two maintenance doses per year.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Validated IL</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-23p19</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;"> safety profile.&#160;&#160;&#160;&#160;</span>Existing commercially approved antibodies targeting IL<span class="nobreak">-23</span> provide a robust precedent for the safety of IL<span class="nobreak">-23</span> inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the patient level between exposure and safety. While Oruka is not pursuing IBD, the approved Skyrizi regimen for Crohn&#8217;s disease supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase in Crohn&#8217;s disease are over 2.5 times higher than the peak ORKA<span class="nobreak">-001</span> exposures at dose levels Oruka currently plans to evaluate in PsO.&#160;In addition, an exposure<span class="nobreak">-response</span> analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated safety endpoints in the 12<span class="nobreak">-week</span> induction or 52<span class="nobreak">-week</span> maintenance periods. In this assessment, the top quartile of average exposures spanned 176 to 342 &#181;g/mL in the induction period and 25 to 62 &#181;g/mL in the maintenance period, which are approximately 7 and 5 times higher, respectively, than the highest anticipated exposures with ORKA<span class="nobreak">-001</span> in the same periods.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Potential to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</span>Emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt, chair of Oruka&#8217;s Scientific Advisory Board, pioneered some of this work by using two- and four<span class="nobreak">-times</span> the approved dose levels of risankizumab to achieve best<span class="nobreak">-in-indication</span> response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL<span class="nobreak">-23</span> inhibition, which could lead to longer<span class="nobreak">-lasting</span> remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention early in the disease course can lead to longer treatment<span class="nobreak">-free</span> remissions. In addition, retrospective claims data suggests that treatment with an IL<span class="nobreak">-23</span> inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial. Given the high antibody exposures expected with ORKA<span class="nobreak">-001</span>, Oruka believes that ORKA<span class="nobreak">-001</span> could lead to durable remissions for some patients, especially those with short disease duration. Oruka plans to pursue patient<span class="nobreak">-specific</span> dosing intervals to provide each patient the greatest possible freedom from their disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that this target profile for ORKA<span class="nobreak">-001</span> could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka evaluated ORKA<span class="nobreak">-001</span> in numerous preclinical studies for several key features:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Potency that matches or exceeds Skyrizi (risankizumab) in vitro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has tested the potency of ORKA<span class="nobreak">-001</span> <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;in multiple assays, including assays evaluating the inhibition of IL<span class="nobreak">-17</span> release from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">223</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">experiments, Oruka believes ORKA<span class="nobreak">-001</span> has the potential for greater potency than risankizumab. Data from the existing commercially approved therapies targeting IL<span class="nobreak">-23</span> indicate that the potency of IL<span class="nobreak">-23</span> inhibition, in this case, measured by affinity, correlates tightly with efficacy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The affinity of approved mAbs targeting IL-23 correlates tightly with efficacy</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_005.jpg" style="width:272.64px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Significant half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka assessed the impact of incorporating YTE modifications into a precursor antibody to ORKA<span class="nobreak">-001</span> in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. The mAb with YTE modifications had a significantly longer half<span class="nobreak">-life</span>, reaching approximately 24&#160;days with SQ administration. Based on clinical experience with YTE<span class="nobreak">-modified</span> mAbs and pharmacokinetic modeling, Oruka believes that this half<span class="nobreak">-life</span> extension could enable dosing once or twice per year, as shown in the figure below.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_006.jpg" style="width:590.08px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to enabling less frequent dosing, an extended half<span class="nobreak">-life</span> would increase the exposure of ORKA<span class="nobreak">-001</span>, which has the potential to increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short<span class="nobreak">-term</span> (at 16&#160;weeks) and long<span class="nobreak">-term</span> (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four<span class="nobreak">-times</span> higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16&#160;weeks. Based on Oruka&#8217;s pharmacokinetic modeling, ORKA<span class="nobreak">-001</span> could achieve four<span class="nobreak">-fold</span> higher average exposures than the approved Skyrizi regimen over the first 16&#160;weeks and over two<span class="nobreak">-fold</span> higher average exposures at steady<span class="nobreak">-state</span>, exceeding even the exposures in KNOCKOUT.&#160;Based on the exposure<span class="nobreak">-response</span> relationship observed with other IL<span class="nobreak">-23</span> inhibiting antibodies, Oruka believes that these increased exposures could result in higher efficacy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">224</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001 is projected to extend the exposure-response relationship established by studies of Skyrizi</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_007.jpg" style="width:536.32px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Safety in vitro and in vivo</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has evaluated ORKA<span class="nobreak">-001</span> in several&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;and&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo</span>&#160;preclinical studies to assess safety. In addition, Oruka has initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti<span class="nobreak">-drug</span> antibody profile of ORKA<span class="nobreak">-001</span> in NHPs, including a single<span class="nobreak">-dose</span> non<span class="nobreak">-GLP</span> dose<span class="nobreak">-range</span> finding study and one<span class="nobreak">-month</span> and six<span class="nobreak">-month</span> GLP toxicology studies. Collectively, this nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA<span class="nobreak">-001</span> benefits from the favorable safety precedent for IL<span class="nobreak">-23</span> inhibition provided by the existing commercially approved IL<span class="nobreak">-23-targeted</span> antibodies across several indications.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Characteristics that support ease of manufacturing and potentially enable high-concentration formulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Finally, Oruka has assessed a variety of attributes essential for manufacturability and high<span class="nobreak">-concentration</span> formulation, including viscosity, solubility, and stability, among others. ORKA<span class="nobreak">-001</span> shows evidence of desirable properties across these characteristics, which Oruka believes will enhance its ability to manufacture ORKA<span class="nobreak">-001</span> successfully and consistently and to deliver high doses of ORKA<span class="nobreak">-001</span> subcutaneously using convenient, low<span class="nobreak">-volume</span> presentations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on these potential advantages and preclinical data, Oruka is advancing ORKA<span class="nobreak">-001</span> towards a Phase&#160;1 clinical trial in the first half of 2025. This trial will encompass a Phase&#160;1a single<span class="nobreak">-ascending</span> dose portion in healthy volunteers, followed by a Phase&#160;1b, multiple<span class="nobreak">-dose</span> portion in patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible for an open<span class="nobreak">-label</span> extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early safety and pharmacokinetics, including half<span class="nobreak">-life</span>, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial, Oruka plans to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well<span class="nobreak">-established</span>, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks, and potentially rapid enrollment due to the large patient population. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-001</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;Dual inhibition of both IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> has shown superior efficacy compared to IL<span class="nobreak">-17A</span> inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q8W dosing in PsO and Q4W dosing in PsA.&#160;By binding </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">225</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">IL<span class="nobreak">-17A</span>/F at similar epitopes and affinity ranges as Bimzelx while incorporating half<span class="nobreak">-life</span> extension technology to potentially enable dosing two to three times a year in PsO and PsA, Oruka believes that ORKA<span class="nobreak">-002</span> could become the leading therapy in the IL<span class="nobreak">-17</span> class.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical program Oruka is conducting to inform development candidate selection and support clinical trial initiation for ORKA<span class="nobreak">-002</span> mirrors that for ORKA<span class="nobreak">-001</span> and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these experiments, Oruka believes ORKA<span class="nobreak">-002</span> has the potential for comparable potency to bimekizumab, but with a significantly longer half<span class="nobreak">-life</span>, which Oruka believes could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025 following ORKA<span class="nobreak">-001</span>. As with ORKA<span class="nobreak">-001</span>, initial data on ORKA<span class="nobreak">-002</span> in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical development of ORKA<span class="nobreak">-002</span> will initially focus on one lead indication, Oruka plans to evaluate ORKA<span class="nobreak">-002</span> in a range of indications over time. Oruka sees ORKA<span class="nobreak">-002</span> as highly complementary to ORKA<span class="nobreak">-001</span>, with the potential to provide an optimal therapy for the approximately one<span class="nobreak">-quarter</span> to one<span class="nobreak">-third</span> of moderate<span class="nobreak">-to-severe</span> PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL<span class="nobreak">-23</span> inhibitor. Furthermore, ORKA<span class="nobreak">-002</span> could address indications beyond PsO, including PsA with limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-002</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, that targets an undisclosed pathway. A core tenet of Oruka&#8217;s strategy is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. ORKA<span class="nobreak">-003</span> provides the potential for indication expansion beyond PsO as well as combination opportunities with Oruka&#8217;s more advanced programs. In the future, Oruka may add additional programs to its portfolio beyond ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span> that fit its strategic focus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. Oruka has not yet exercised its option to acquire exclusive rights to any IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> patent applications, but retains the right to do so. If the provisional patent applications are pursued non<span class="nobreak">-provisionally</span> and mature into one or more issued patents covering ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>, Oruka would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Commercial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should any of its product candidates be approved for commercialization, Oruka intends to develop a plan to commercialize them in the United&#160;States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Oruka to realize the full commercial value of its programs. Given its stage of development, Oruka has not yet established a commercial organization or distribution capabilities. Oruka currently holds exclusive Options (as defined below) to acquire worldwide development and commercialization rights to all of its programs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">226</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own or operate facilities for product manufacturing, testing, storage, and distribution. Oruka has contracted and expect to continue to contract with third parties for the manufacture and distribution of its product candidates. Because Oruka relies on contract manufacturers, it employs personnel with extensive technical, manufacturing, analytical and quality experience. Oruka&#8217;s team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support Oruka&#8217;s regulatory filings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Oruka believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Oruka faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that Oruka successfully develops and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key competitive factors affecting the success of all of Oruka&#8217;s product candidates that it develops, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third<span class="nobreak">-party</span> payors. Oruka&#8217;s competitors may also obtain FDA or other regulatory approval for their products more rapidly than Oruka may obtain approval for its products, which could result in Oruka&#8217;s competitors establishing a strong market position before Oruka is able to enter the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as Oruka&#8217;s two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, including major pharmaceutical companies. Oruka does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or comparable results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are several approved biologic therapies for the treatment of moderate<span class="nobreak">-to-severe</span> PsO.&#160;These include mAbs targeting IL<span class="nobreak">-23</span>, such as Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL<span class="nobreak">-17</span>, such as Bimzelx (bimekizumab) from UCB, which targets IL<span class="nobreak">-17A</span>/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL<span class="nobreak">-17A</span>, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL<span class="nobreak">-17</span> receptor A; and biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including the phosphodiesterase<span class="nobreak">-4</span> (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol<span class="nobreak">-Myers</span> Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and other&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka is aware of several product candidates in clinical development for moderate<span class="nobreak">-to-severe</span> PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart from Innovent Biologics targeting IL<span class="nobreak">-23p19</span>, sonelokimab from MoonLake Immunotherapeutics targeting IL<span class="nobreak">-17A</span>/F, and izokibep from ACELYRIN targeting IL<span class="nobreak">-17A</span>.&#160;Also, there are several oral agents in development, including JNJ<span class="nobreak">-2113</span> from Janssen targeting the IL<span class="nobreak">-23</span> receptor, DC<span class="nobreak">-806</span> and DC<span class="nobreak">-853</span> from Eli Lilly targeting IL<span class="nobreak">-17A</span>, and TAK<span class="nobreak">-279</span> from Takeda and ESK<span class="nobreak">-001</span> from Alumis, both targeting TYK2.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">227</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">License Agreements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Therapeutics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement initially included one of two selected targets: IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17A</span>/F.&#160;Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL<span class="nobreak">-23</span>, Oruka&#8217;s Option excludes the therapeutic area of IBD.&#160;From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. As of the date hereof, Oruka has not exercised any Options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, Oruka initiated certain research programs with Paragon that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing antibodies directed to the respective target. For each Research Program, Oruka established or may establish in the future a research plan with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities or (ii)&#160;with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to a Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). Oruka may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that Oruka must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or a Research Program immediately upon written notice to Oruka if, as a result of any action or failure to act by Oruka or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million became payable by Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred by Paragon prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred by Paragon prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred by Paragon prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred by Paragon from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 (the &#8220;pre<span class="nobreak">-effective</span> date development costs&#8221;). This amount was recognized as a research and development expense during the period from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">228</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the filing date of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post<span class="nobreak">-approval</span> monitoring and post<span class="nobreak">-approval</span> reporting of biologics such as those Oruka is developing. Oruka, along with its third<span class="nobreak">-party</span> contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Oruka wishes to conduct studies or seek approval or licensure of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">United&#160;States Biologics Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.&#160;requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United&#160;States generally involves the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of adequate and well<span class="nobreak">-controlled</span> human clinical trials in accordance with GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA Advisory Committee review, if applicable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">229</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United&#160;States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical and Clinical Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to beginning any clinical trial with a product candidate, in the United&#160;States, Oruka must submit an IND to the FDA.&#160;An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30<span class="nobreak">-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;1.&#160;&#160;&#160;&#160;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">230</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;2.&#160;&#160;&#160;&#160;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;3.&#160;&#160;&#160;&#160;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so<span class="nobreak">-called</span> Phase&#160;4 studies may be made a condition to approval of the BLA.&#160;Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND.&#160;When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">BLA Submission and Review</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company<span class="nobreak">-sponsored</span> clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty&#160;days after an end<span class="nobreak">-of-Phase</span>&#160;2 meeting or as may be agreed between the sponsor and FDA.&#160;Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten&#160;months after the filing date, or, if the application qualifies </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">231</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post<span class="nobreak">-marketing</span> testing and surveillance to monitor safety or efficacy of a product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post<span class="nobreak">-marketing</span> requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&#160;4 post<span class="nobreak">-market</span> studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post<span class="nobreak">-marketing</span> studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expedited Development and Review Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">232</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A product intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase&#160;1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six&#160;months of the 60<span class="nobreak">-day</span> filing date (as compared to ten&#160;months under standard review).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, products studied for their safety and effectiveness in treating serious or life<span class="nobreak">-threatening</span> diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well<span class="nobreak">-controlled</span> post<span class="nobreak">-marketing</span> clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act&#160;of&#160;2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post<span class="nobreak">-marketing</span> studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre<span class="nobreak">-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed by Oruka pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record<span class="nobreak">-keeping</span>, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA.&#160;Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Oruka and its third<span class="nobreak">-party</span> manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Oruka and any third<span class="nobreak">-party</span> manufacturers that Oruka may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">233</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<span class="nobreak">-market</span> studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, warning letters or holds on post<span class="nobreak">-approval</span> clinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure or detention, or refusal of the FDA to permit the import or export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>mandated modification of promotional materials and labeling and the issuance of corrective information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off<span class="nobreak">-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Oruka and approved by the FDA.&#160;Such off<span class="nobreak">-label</span> uses are common across medical specialties. Physicians may believe that such off<span class="nobreak">-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off<span class="nobreak">-label</span> use of their products.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Biosimilars and Reference Product Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.&#160;In September&#160;2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">234</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12<span class="nobreak">-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A reference biologic is granted twelve&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42<span class="nobreak">-month</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A biological product can also obtain pediatric market exclusivity in the United&#160;States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six<span class="nobreak">-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA<span class="nobreak">-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA.&#160;In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID<span class="nobreak">-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12<span class="nobreak">-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed below, the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Healthcare Laws and Compliance Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti<span class="nobreak">-Kickback</span> Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act&#160;of&#160;1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Oruka&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">235</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">se illegal under the AKS.&#160;Instead, the legality of the arrangement will be evaluated on a case<span class="nobreak">-by-case</span> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third<span class="nobreak">-party</span> payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#160;federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse<span class="nobreak">-midwives</span>, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are also subject to additional similar U.S.&#160;state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Oruka&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Oruka may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non<span class="nobreak">-compliance</span>, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data Privacy and Security</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health<span class="nobreak">-related</span> information. In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to Oruka&#8217;s operations or the operations of Oruka&#8217;s partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">236</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non<span class="nobreak">-compliance</span>. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Oruka submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Oruka may be delayed or denied.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, certain state laws, such as the California Consumer Privacy Act&#160;of&#160;2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act&#160;of&#160;2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health<span class="nobreak">-related</span> information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#160;&#8212;&#160;unless it is subject to HIPAA&#160;&#8212;&#160;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, Oruka&#8217;s use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for Oruka and the third parties upon whom Oruka relies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Coverage and Reimbursement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Oruka obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third<span class="nobreak">-party</span> payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third<span class="nobreak">-party</span> payors. Decisions regarding whether to cover any of Oruka&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan<span class="nobreak">-by-plan</span> basis. Further, no uniform policy for coverage and reimbursement exists in the United&#160;States, and coverage and reimbursement can differ significantly from payor to payor. Third<span class="nobreak">-party</span> payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">237</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time<span class="nobreak">-consuming</span> and costly process that will require Oruka to provide scientific and clinical support for the use of Oruka&#8217;s product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost<span class="nobreak">-containment</span> measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third<span class="nobreak">-party</span> reimbursement for any product or a decision by a third<span class="nobreak">-party</span> not to cover a product could reduce physician usage and patient demand for the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the U.S.&#160;government, state legislatures and foreign governments have continued implementing cost<span class="nobreak">-containment</span> programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out<span class="nobreak">-of-pocket</span> costs. Each year, CMS will select and negotiate a preset number of high<span class="nobreak">-spend</span> drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Healthcare Reform</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The United&#160;States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United&#160;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government<span class="nobreak">-funded</span> health care programs, and increased governmental control of drug pricing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United&#160;States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Oruka expects there will be additional challenges and amendments to the ACA in </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">238</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out<span class="nobreak">-of-pocket</span> cost and creating a new manufacturer discount program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act&#160;of&#160;2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Bipartisan Budget Act&#160;of&#160;2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point<span class="nobreak">-of-sale</span> discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march<span class="nobreak">-in</span> rights under the Bayh<span class="nobreak">-Dole</span> Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March<span class="nobreak">-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march<span class="nobreak">-in</span> rights. While march<span class="nobreak">-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United&#160;States with respect to specialty drug pricing practices. Specifically, Oruka expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Government Regulation&#160;Outside of the United&#160;States</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulations in the United&#160;States, Oruka is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post<span class="nobreak">-approval</span> monitoring and reporting of Oruka&#8217;s products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Whether or not Oruka obtains FDA approval for a product, Oruka must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post<span class="nobreak">-authorization</span> requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">239</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">European Data Laws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May&#160;2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United&#160;States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU<span class="nobreak">-US</span> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S.&#160;companies participating in the framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.&#160;Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation&#160;No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Oruka, harm to Oruka&#8217;s reputation, and adversely impact Oruka&#8217;s business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that Oruka faces with regard to data protection regulation. With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four&#160;years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">240</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in section&#160;3(10)&#160;(as supplemented by section 205(4)) of the Data Protection Act&#160;2018 (the &#8220;DPA&#160;2018&#8221;)), the DPA&#160;2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5&#160;million or 4% of global turnover.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September&#160;21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March&#160;21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">With regard to the transfer of personal data from the UK to the United&#160;States, the UK government has adopted an adequacy decision for the United&#160;States, the UK<span class="nobreak">-US</span> Data Bridge, which came into force on October&#160;12, 2023. The UK<span class="nobreak">-US</span> Data Bridge recognizes the United&#160;States as offering an adequate level of data protection where the transfer is to a U.S.&#160;company participating in the EU<span class="nobreak">-US</span> Data Privacy Framework and the UK Extension.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug and Biologic Development Process</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the former regime, which will expire after a transition period of three&#160;years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A more unified procedure will apply under the new CTR.&#160;A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt<span class="nobreak">-out</span>&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three<span class="nobreak">-year</span> transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.&#160;On July&#160;19, 2023, the EC </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">241</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&#160;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk<span class="nobreak">-management</span> programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Marketing Authorization</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA.&#160;To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast<span class="nobreak">-tracked</span> MHRA review to obtain and/or update a MA in the UK or Great Britain.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post<span class="nobreak">-authorization</span> procedures including line extensions, variations and renewals.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Centralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA.&#160;The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto<span class="nobreak">-immune</span> and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post<span class="nobreak">-authorization</span> and maintenance activities, such as the assessment of modifications or extensions to an existing MA.&#160;Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA.&#160;However, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">242</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Decentralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk Management Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk<span class="nobreak">-management</span> system is modified, especially as the result of new information being received that may lead to a significant change to the benefit<span class="nobreak">-risk</span> profile or as a result of an important pharmacovigilance or risk<span class="nobreak">-minimization</span> milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA.&#160;Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">MA Validity Period</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk<span class="nobreak">-benefit</span> balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five<span class="nobreak">-year</span> renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five<span class="nobreak">-year</span> period expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">243</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA.&#160;Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three<span class="nobreak">-year</span> period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advanced Therapy Medicinal Products</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, medicinal products, including ATMPs are subject to extensive pre- and post<span class="nobreak">-market</span> regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exceptional Circumstances/Conditional Approval</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to accelerated approval regulations in the United&#160;States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data and Market Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As in the United&#160;States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An additional non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10<span class="nobreak">-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">244</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU.&#160;After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight<span class="nobreak">-year</span> data exclusivity period. Additionally, another non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well<span class="nobreak">-established</span> substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Another year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre<span class="nobreak">-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE.&#160;Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Orphan Designation and Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S.&#160;The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life<span class="nobreak">-threatening</span> or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan<span class="nobreak">-designated</span> medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC.&#160;Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s)&#160;that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten&#160;years of market exclusivity in the orphan indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the 10<span class="nobreak">-year</span> period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two&#160;years of market exclusivity for an orphan<span class="nobreak">-designated</span> condition when the results of specific studies are reflected in the Summary of Product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">245</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 10<span class="nobreak">-year</span> market exclusivity may be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e., the condition prevalence or financial returns criteria under Article&#160;3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, following the post<span class="nobreak">-Brexit</span> transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK<span class="nobreak">-wide</span> orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Pediatric Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA.&#160;The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA.&#160;The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six<span class="nobreak">-month</span> extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PRIME Designation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small<span class="nobreak">-and</span> medium<span class="nobreak">-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non<span class="nobreak">-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick<span class="nobreak">-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">246</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to the United&#160;States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure by Oruka or by any of its third<span class="nobreak">-party</span> partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti<span class="nobreak">-corruption</span> or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post<span class="nobreak">-authorization</span> safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk<span class="nobreak">-management</span> measures, which may be time consuming and expensive and could impact Oruka&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post<span class="nobreak">-authorization</span> Phase&#160;4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA.&#160;Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">More generally, non<span class="nobreak">-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.&#160;Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">247</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Sales and Marketing Regulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The advertising and promotion of Oruka&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off<span class="nobreak">-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off<span class="nobreak">-label</span> promotion is prohibited. Direct<span class="nobreak">-to-consumer</span> advertising of prescription<span class="nobreak">-only</span> medicines is also prohibited in the EU.&#160;Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Oruka&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA.&#160;Following Brexit, the requirements to display the common logo no longer apply to UK<span class="nobreak">-based</span> online sellers, except for those established in Northern Ireland.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anti-Corruption Legislation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self<span class="nobreak">-regulation</span> codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU.&#160;The provision of benefits or advantages to physicians is also governed by the national anti<span class="nobreak">-bribery</span> laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act&#160;2010. Due to the Bribery Act&#160;2010&#8217;s far<span class="nobreak">-reaching</span> territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Bribery Act&#160;2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act&#160;2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten&#160;years and in some cases both.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Regulations in the UK and Other Markets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long<span class="nobreak">-term</span> set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">248</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK government has adopted the Medicines and Medical Devices Act&#160;2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU.&#160;The MMDA introduces regulation<span class="nobreak">-making</span>, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employees and Human Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;3, 2024, Oruka had ten full<span class="nobreak">-time</span> employees. Oruka also engages temporary employees and consultants to augment its existing workforce. None of Oruka&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Oruka considers its relationship with its employees to be good.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka recognizes that attracting, motivating, and retaining talent at all levels is vital to continuing its success. Oruka invests in its employees through high<span class="nobreak">-quality</span> benefits, professional development opportunities, and various health and wellness initiatives and offers competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of Oruka&#8217;s incentive plans (bonus and equity) are to align with the long<span class="nobreak">-term</span> interests of its stakeholders and stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently operates as a virtual company and does not maintain physical corporate offices. Oruka&#8217;s employees currently work remotely. Oruka believe these arrangements support its current needs. Oruka maintains a mailing address at 221 Crescent St., Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA.&#160;In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP for office space located in Menlo Park, California. The lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may become involved in legal proceedings. Oruka is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Oruka because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">249</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9988"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following discussion and analysis of ARCA&#8217;s financial condition and results of operations should be read in conjunction with ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to ARCA&#8217;s plans and strategy for ARCA&#8217;s business, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks and uncertainties. As a result of many factors, ARCA&#8217;s actual results could differ materially from the results described in or implied by the forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements contained in the following discussion and analysis</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA&#8217;s common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock calculated in accordance with the Merger Agreement, (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA&#8217;s then outstanding but not then vested or exercisable, and cancel each Out of the Money Options to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA&#8217;s common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the combined </p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">250</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.39% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA&#8217;s common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA&#8217;s common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA&#8217;s common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the ARCA Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA&#8217;s common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA&#8217;s common stock that it is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of ARCA&#8217;s common stock on Nasdaq and cause the shares of ARCA&#8217;s common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the SEC and causing to become effective a registration statement to register shares of ARCA&#8217;s common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA&#8217;s stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the Subscription Agreement (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to its&#8217; transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">251</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Preferred Stock, par value $0.001 per share (the &#8220;ARCA Series&#160;B Preferred Stock&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends actually paid on shares of ARCA&#8217;s common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which ARCA&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA&#8217;s common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA&#8217;s common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Merger Effective Time (the &#8220;Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of six (6)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Subscription Agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. There can be no assurance that the strategic review process or any transaction relating to a specific asset, including the Merger or any asset sale, will result in ARCA pursuing such a transaction(s), or that any transaction(s), if pursued, will be completed on terms favorable to ARCA and its stockholders in the existing entity or any possible entity that results from a combination of entities. If the strategic review process is unsuccessful, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">252</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is developing Gencaro to treat AF in patients with chronic HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;), for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under a SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for its planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">253</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201) is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">254</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under ARCA&#8217;s prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $2.3&#160;million for the three&#160;months ended March&#160;31, 2024 compared to $1.4&#160;million for the corresponding period of 2023, an increase of $0.9&#160;million. During the three&#160;months ended March&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually agreed to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. The increase for the three<span class="nobreak">-month</span> period was primarily a result of a $1.1&#160;million increase in professional fees primarily related to the Merger Agreement discussed above, offset by $0.2&#160;million lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reduction discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $6.3&#160;million for the year ended December&#160;31, 2023, compared to $5.8&#160;million for 2022, an increase of approximately $0.4&#160;million. During the year ended December&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually<span class="nobreak">-agreed</span> to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits. The increase in expenses during 2023 was primarily a result of increases in professional fees and fees to the Special Committee in connection with the Strategic Review, offset by lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reductions discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses in 2024 are expected to be higher than those in 2023 as ARCA incurs professional fees related to the Merger Agreement discussed above and maintains administrative activities to support its ongoing operations. ARCA does expect to incur significant costs related to ARCA&#8217;s exploration of strategic alternatives and the Merger, including legal, accounting and advisory expenses and other related charges.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While ARCA does not believe that inflation had a material effect on its financial condition and results of operations during the periods presented, it may result in increased costs in the foreseeable future.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development (&#8220;R&amp;D&#8221;) expense is comprised primarily of personnel costs, clinical development, manufacturing process development, and regulatory activities and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense for the three&#160;months ended March&#160;31, 2024 was $0.2&#160;million compared to $0.4&#160;million for the corresponding period of 2023, a decrease of $0.2&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $0.2&#160;million for the three&#160;months ended March&#160;31, 2024, as compared to the corresponding period of 2023, due to decreased headcount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Manufacturing process development costs for the three&#160;months ended March&#160;31, 2024 and 2023 were consistent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense decreased $0.1&#160;million related to the unrestricted research grants with ARCA&#8217;s former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">255</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, the Company made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the former President and Chief Executive Officer resigned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development expenses were $1.0&#160;million for the year ended December&#160;31, 2023 as compared to $4.7&#160;million for 2022, a decrease of $3.7&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $1.2&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding periods of 2022, due to one<span class="nobreak">-time</span> termination benefits incurred in 2022 and decreased headcount from the July&#160;2022 personnel reduction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical expense decreased approximately $1.0&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022. Manufacturing process development costs decreased approximately $1.1&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022.&#160;The majority of clinical and manufacturing close out costs related to ARCA&#8217;s rNAPc2 (AB201) international Phase&#160;2b clinical trial were incurred in the first half of 2022, with no comparable costs for the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense in 2024 is expected to be lower than 2023, as ARCA completed its rNAPc2 (AB201) international Phase&#160;2b clinical trial. Should ARCA resume clinical trials of product candidates, it expects research and development costs to increase significantly for the foreseeable future as ARCA&#8217;s product candidate development programs progress.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest and Other Income</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $473,000 and $450,000 in the three&#160;months ended March&#160;31, 2024 and 2023, respectively. Interest income was higher due to higher interest rates in 2024 compared to the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $2.0&#160;million of interest income for the year ended December&#160;31, 2023 as compared to $0.7&#160;million for 2022, resulting in an increase of $1.3&#160;million. Interest income was higher due to higher interest rates in 2023 compared to the corresponding periods of 2022. ARCA expects interest income in 2024 to be lower than 2023, as ARCA continues to use its cash and cash equivalents to fund operations, assuming interest rates remain consistent with 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There was no other expense for the year ended December&#160;31, 2023. Other expense was $5,000 for the year ended December&#160;31, 2022. The amounts were nominal to ARCA&#8217;s overall operations. Based on ARCA&#8217;s current capital structure, other expense is expected to be negligible in 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of March&#160;31, 2024 and 2023</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,903</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had total cash and cash equivalents of $35.9&#160;million, as compared to $37.4&#160;million as of December&#160;31, 2023. The net decrease of $1.5&#160;million primarily reflects the cash used in operating activities during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of December&#160;31, 2023 and 2022</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,445</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">256</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had total cash and cash equivalents of approximately $37.4&#160;million, as compared to $42.4&#160;million as of December&#160;31, 2022. The net decrease of $5.0&#160;million during the year primarily reflects cash used in operating activities during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Operating, Investing and Financing Activities</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net decrease in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the three&#160;months ended March&#160;31, 2024 was consistent with the same period in 2023. This was primarily due to lower outflows related to changes in operating assets and liabilities and a higher net loss in 2024, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">There were no financing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by (used in):</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,912</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,914</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2023 decreased approximately $5.9&#160;million compared with 2022. This was primarily due to lower outflows related to changes in operating assets and liabilities and a lower net loss in 2022, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the year ended December&#160;31, 2023. Net cash used in investing activities for the year ended December&#160;31, 2022 was $2,000 for the purchase of property and equipment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no financing activities in the&#160;years ended December&#160;31, 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Sources and Uses of Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s primary sources of liquidity to date have been capital raised from issuances of shares of its preferred and common stock. The primary uses of ARCA&#8217;s capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">257</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s ability to execute its development programs in accordance with ARCA&#8217;s projected timeline depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than ARCA currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. If ARCA resumes the development of product candidates, ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development and potential commercialization Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of ARCA&#8217;s board of directors to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s board of directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">258</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. On April&#160;20, 2024, ARCA&#8217;s board of directors approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker will be paid by ARCA via payroll within 30&#160;business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&#160;As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020, ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (the &#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in ARCA&#8217;s primary business office. The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation. Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively. As of March&#160;31, 2024, the lease liability was $48,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A critical accounting policy is one that is both important to the portrayal of ARCA&#8217;s financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While ARCA&#8217;s significant accounting policies are described in Note&#160;1 of ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus, ARCA believes the following critical accounting policy affected its most significant judgments, assumptions, and estimates used in the preparation of ARCA&#8217;s financial statements and, therefore, is important in understanding ARCA&#8217;s financial condition and results of operations. ARCA had no significant outsourcing expense activity in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing ARCA&#8217;s financial statements, ARCA may be required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">259</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnifications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, ARCA enters into contractual arrangements under which it may agree to indemnify certain parties from any losses incurred relating to the services they perform on ARCA&#8217;s behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. ARCA has entered into indemnity agreements with each of ARCA&#8217;s directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. ARCA also maintains an insurance policy for its directors and executive officers insuring against certain liabilities arising in their capacities as such.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">260</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T11"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of Oruka&#8217;s financial condition and results of operations together with the sectioned titled &#8220;Oruka&#8217;s Business&#8221; and Oruka&#8217;s financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Oruka&#8217;s plans and strategy for its business and related financing, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those factors set forth in the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka,&#8221; Oruka&#8217;s actual results could differ materially from the results described in or implied by these forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. You should carefully read the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8221; to gain an understanding of the factors that could cause actual results to differ materially from Oruka&#8217;s forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements.&#8221;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221;&#8212;&#160;reflects Oruka&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly intending to reduce technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells. Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (&#8220;IL<span class="nobreak">-23p19</span>&#8221;) for the treatment of psoriasis. Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka Therapeutics, Inc. was founded by Paragon and has since assembled a management team with significant experience in clinical development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of Th17 cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety when applied by other companies. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the Fc domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal FcRn. As a result, it has a pharmacokinetic profile designed to support an SQ injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential to not only generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as HS and axSpA.&#160;More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">261</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception in February&#160;2024, it has devoted substantially all of its resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of Oruka&#8217;s programs and component materials, and providing general and administrative support for these operations. Oruka does not have any programs approved for sale and have not generated any revenue from product sales. To date, Oruka has funded its operations primarily with proceeds from the issuance of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note, both of which were related party transactions. Through March&#160;31, 2024, Oruka received gross proceeds of $3.0&#160;million from the issuance of its Series&#160;A convertible preferred stock and gross proceeds of $25.0&#160;million from the issuance of the Convertible Note. Under the Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Convertible Note was sold, Oruka can sell up to an additional $30.0&#160;million in convertible notes. Oruka intends to sell an additional $30.0&#160;million in convertible notes but there is currently no expectation as to when that will occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has incurred operating losses since inception. Oruka&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Oruka may develop. Oruka generated net losses of $7.1&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, Oruka had an accumulated deficit of $7.1&#160;million. Oruka expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues its research and development and discovery<span class="nobreak">-related</span> development of its programs, ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submits for and receives allowance to proceed with its investigational new drug applications, or INDs, for certain of its programs in order to commence future clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully completes future preclinical studies for its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks and identifies additional research programs and product candidates and initiates discovery<span class="nobreak">-related</span> activities and preclinical studies for those programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hires additional research and development and clinical personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays, challenges, or other issues associated with the pre<span class="nobreak">-clinical</span> and clinical development of its programs, including with respect to its regulatory strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals for any programs for which it successfully completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develops, maintains and enhances a sustainable, scalable, reproducible and transferable manufacturing process for the programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which it may obtain marketing approval;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">262</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adds operational, financial and management information systems and personnel, including personnel to support its product development;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks timely and successful completion of preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues effective investigational new drug applications or comparable foreign applications that allow commencement of its planned clinical trials or future clinical trials for any programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates enrollment and successful completion of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues positive results from its future clinical trials that support a finding of safety and effectiveness, and an acceptable risk<span class="nobreak">-benefit</span> profile in the intended populations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals from applicable regulatory authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains, expands, enforces, defends and protects its intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks maintenance of a continued acceptable safety, tolerability and efficacy profile of any programs it may develop following approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>further acquires or in<span class="nobreak">-licenses</span> product candidates or programs, intellectual property and technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes and maintains any future collaborations, including making royalty, milestone or other payments thereunder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains a continued acceptable safety profile of its products following approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>incurs additional costs of operating as a public company, including audit, legal, regulatory and tax related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premium and investor relation cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Oruka may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the FDA or another regulatory authority were to require Oruka to conduct clinical trials beyond those that Oruka currently anticipates will be required for the completion of clinical development of a program, or if Oruka&#8217;s experiences significant delays in its clinical trials due to patient enrollment or other reasons, Oruka would be required to expend significant additional financial resources and time on the completion of clinical development. Oruka may never obtain regulatory approval for any of its programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka will not generate revenue from product sales unless and until it successfully initiate and complete clinical development and obtain regulatory approval for any product candidates. If Oruka obtains regulatory approval for any of its programs and do not enter into a commercialization partnership, Oruka expects to incur significant expenses related to developing Oruka&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, Oruka will need substantial additional funding to support its continued operations and growth strategy. Until such a time as Oruka can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Oruka may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If Oruka fails to raise capital or enter into such agreements as, and when, needed, Oruka may have to significantly delay, scale back or discontinue the development and commercialization of one or more of Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks associated with product development, Oruka is unable to accurately predict the timing or amount of increased expenses or when or if Oruka will be able to achieve or maintain profitability. Even if Oruka is able to generate product sales, it may not become profitable. If Oruka fails to become profitable or are unable to sustain profitability on a continuing basis, then Oruka may be unable to continue Oruka&#8217;s operations at planned levels and be forced to reduce or terminate its operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">263</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that the expected net proceeds from the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, together with Oruka&#8217;s existing cash and sales of additional convertible notes under the Purchase Agreement, will enable Oruka to fund its operating expenses through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Liquidity and Capital Resources</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Without giving effect to any proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as any proceeds from additional borrowings under the Convertible Note, as of March&#160;31, 2024, Oruka expects that its existing cash will be sufficient to fund its operating expenses through the end of second quarter of 2024. Beyond that point, Oruka will need to raise additional capital to finance its operations, which cannot be assured. As disclosed in Oruka&#8217;s financial statements for the period February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka concluded that there is substantial doubt about its ability to continue as a going concern within one year of the date those financial statements are available to be issued. See Note&#160;1 to Oruka&#8217;s financial statements appearing at the end of this proxy statement/prospectus for additional information on its assessment.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Impact of Risk Factors on Oruka&#8217;s Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Uncertainty in the global economy presents significant risks to Oruka&#8217;s business. Oruka is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and Israel and Gaza and the responses thereto, and supply chain disruptions. While Oruka is closely monitoring the impact of the current macroeconomic conditions on all aspects of Oruka&#8217;s business, including the impacts on its participants in future clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the impact on its business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Oruka&#8217;s control and could exist for an extended period of time. Oruka will continue to evaluate the nature and extent of the potential impacts to Oruka&#8217;s business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If Oruka&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Oruka may generate revenue in the future from product sales or payments from future collaboration or license agreements that Oruka may enter into with third parties, or any combination thereof. Oruka cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product candidates. Oruka may never succeed in obtaining regulatory approval for any of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Expenses</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of Oruka&#8217;s programs. These expenses include costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Oruka&#8217;s behalf, expenses incurred in connection with continuing Oruka&#8217;s current research programs and discovery<span class="nobreak">-phase</span> development of any programs Oruka may identify, including under future agreements with third parties, such as consultants and contractors, and personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation expense.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses research and development costs as incurred. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 Oruka recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees associated with each Research Plan on its condensed statement of operations and comprehensive loss. See &#8220;&#8212;<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;Contractual Obligations and Commitments</span>&#8221; below for further details on Oruka&#8217;s research plans.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">264</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s primary focus since inception has been the identification and development of its pipeline programs. Oruka&#8217;s research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Paragon Option Agreements. Oruka separately tracks the amount of costs incurred under the Paragon Option Agreements with Paragon between ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. See &#8220;&#8212;&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span>&#8221; below for further details on the Paragon Option Agreements.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation, for individuals in Oruka&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters, professional fees for accounting, auditing, tax, information technology, insurance, and recruiting costs. Oruka currently operates as a virtual company. Therefore, Oruka does not incur material operating expenses for the rent, maintenance and insurance of facilities or for depreciation of fixed assets. In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The Oak Grove Lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months. Oruka&#8217;s lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects that its general and administrative expenses will increase substantially for the foreseeable future as Oruka increases its headcount to support the expected growth. Oruka also expects to incur increased expenses associated with a reverse merger public transaction and becoming a public company, including increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Oruka also expects to incur additional intellectual property<span class="nobreak">-related</span> expenses as Oruka files patent applications to protect innovations arising from its research and development activities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense of $0.2&#160;million incurred for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 relates to the Convertible Note issued to Fairmount Fund&#160;II in March&#160;2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from Oruka&#8217;s net operating losses have been fully reserved as Oruka believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $5,051 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">265</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $848 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $214 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s research and development expenses incurred for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">External research and development costs by selected target:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-002<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,155</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-001<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">750</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other research and development costs:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">264</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:30pt;">Total research and development expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $4,155 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $750 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $146 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses were $5.2&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$4.2&#160;million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of research initiation fee expense due to Paragon related to the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.2&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.1&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s research and development team.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s total general and administrative expenses for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">781</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">444</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Legal fees related to patent<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">189</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Total general and administrative expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $505 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $256 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $87 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">266</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses were $1.7&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.5&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s executive team, legal, and finance and accounting functions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.4&#160;million of professional and consulting fees associated with increases in accounting, audit, and legal fees due to an increase in Oruka&#8217;s business activity and as Oruka began preparation to become a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.3&#160;million of legal fees due to Paragon associated with patent related activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of investor and public relations costs and fees associated with company formation; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of costs due to Paragon related to company formation fees.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception, Oruka has incurred significant operating losses. Oruka expects to incur significant expenses and operating losses for the foreseeable future as Oruka commences the pre<span class="nobreak">-clinical</span> and clinical development of its programs and continue its early<span class="nobreak">-stage</span> research activities. Oruka has not yet commercialized any products and Oruka does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Oruka has funded its operations primarily with proceeds from the sale of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note. In March&#160;2024, Oruka received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. As of March&#160;31, 2024, Oruka had cash of $27.7&#160;million.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s cash flows for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash used in operating activities was $0.2&#160;million and was primarily attributable to a net loss of $7.1&#160;million, offset by a $6.1&#160;million increase in related parties accounts payable and other current liabilities and a $0.8&#160;million increase in accrued expenses and other current liabilities. The increase in amounts due to related parties and accrued expenses and other current liabilities was primarily due to an increase in Oruka&#8217;s business activity, as well as vendor invoicing and payments.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash provided by financing activities was $27.9&#160;million, consisting of $2.9&#160;million of net proceeds from the issuance of Oruka&#8217;s Series&#160;A convertible preferred&#160;stock and $25.0&#160;million of net proceeds from the issuance of the Convertible Note.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">267</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Funding Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated any revenue from product sales. Oruka has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if Oruka&#8217;s development efforts are successful, it is uncertain when, if ever, Oruka will realize significant revenue from product sales. If Oruka obtains regulatory approval for any of its product candidates and start to generate revenue, Oruka expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes its existing cash, together with the anticipated net proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as issuances of additional convertible notes under the Purchase Agreement, will be sufficient to fund its operating expenses requirements through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. Oruka expects that it will require additional funding to advance its potential product candidates through development, regulatory approval and commercialization if any of its product candidates are approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial product revenue, Oruka expects to finance its cash needs through a combination of equity offerings and debt financings. To the extent that Oruka raises additional capital through the sale of equity or convertible debt securities, ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit Oruka&#8217;s ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Oruka is unable to raise additional funds, it may be required to delay, reduce or eliminate some or all of its planned operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Contractual Obligations and Commitments</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the terms of the Paragon Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17A</span>/F (ORKA<span class="nobreak">-002</span>). Under each of the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and potential products directed to the selected targets. If Oruka exercises its options, Oruka will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties established a Research Plan that sets forth the activities that will be conducted, and the associated research budget. Oruka and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at inception of the arrangement related to IL<span class="nobreak">-17</span> and IL<span class="nobreak">-23</span>. Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">268</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Paragon Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the Research Plan for each respective research program, Oruka was required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million related to the research initiation fee for ORKA<span class="nobreak">-001</span>. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of issuance of Oruka&#8217;s condensed financial statements, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> Research Plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Option Agreements provide for an annual equity grant of warrants to purchase 1.00% of the then outstanding shares of Oruka common stock, on a fully diluted basis, on each of December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Option Agreements, at the fair market value determined by Oruka&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Purchase Agreement with Fairmount Fund&#160;II, whereby Oruka issued a convertible note, with an initial principal amount of $25.0<span class="nobreak"> </span>million that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount Fund II. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon Oruka&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to Oruka&#8217;s next equity financing, the Convertible Note will convert into the series of issued convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the aggregate principal amount of outstanding borrowings under the Convertible Note was $25.0&#160;million and Oruka has the right to issue and sell up to an additional $30.0&#160;million in convertible notes under the Purchase Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">269</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed financial statements requires Oruka to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Oruka&#8217;s estimates are based on its historical experience and on various other factors that Oruka believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statement and condensed financial statements included elsewhere in this proxy statement/prospectus, Oruka believes the following accounting policies used in the preparation of its financial statements require the most significant judgments and estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing Oruka&#8217;s financial statements, Oruka is required to estimate its accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when Oruka has not yet been invoiced or otherwise notified of actual costs. The majority of Oruka&#8217;s service providers invoice the company in arrears for services performed, on a pre<span class="nobreak">-determined</span> schedule or when contractual milestones are met; however, some require advance payments. Oruka makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to Oruka at that time. At each period end, Oruka corroborates the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities and any research organizations in connection with studies and testing. Although Oruka does not expect its estimates to be materially different from amounts actually incurred, Oruka&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka measures stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of Oruka common stock, based on their fair value on the date of the grant using the Black<span class="nobreak">-Scholes</span> model. Oruka measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Oruka common stock at the date of grant. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non<span class="nobreak">-employee</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if Oruka had paid cash in exchange for the goods or services, which is generally the over the vesting period of the award. Oruka uses the straight<span class="nobreak">-line</span> method to recognize the expense of awards with service<span class="nobreak">-based</span> vesting conditions. Oruka accounts for forfeitures as they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Black<span class="nobreak">-Scholes</span> model uses inputs that are determined by the Board on the date of grant and assumptions Oruka makes for the volatility of stock<span class="nobreak">-based</span> awards, the expected term of stock<span class="nobreak">-based</span> awards, the risk<span class="nobreak">-free</span> interest rate for a period that approximates the expected term of Oruka&#8217;s stock<span class="nobreak">-based</span> awards and its expected dividend yield. Oruka has historically been a private company and lack company<span class="nobreak">-specific</span> historical and implied volatility information of Oruka&#8217;s stock. Therefore, Oruka estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Oruka&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Oruka has estimated a 0% dividend yield based on the expected dividend yield and the fact that Oruka has never paid, and do not expect to pay, any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">270</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Determination of Fair Value of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As there has been no public market for Oruka&#8217;s stock<span class="nobreak">-based</span> awards to date, the estimated fair value of stock<span class="nobreak">-based</span> awards has been determined by Oruka&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that it believed were relevant. In addition, Oruka&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its share<span class="nobreak">-based</span> awards as of each grant date, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prices at which Oruka sold shares of Series&#160;A convertible preferred stock and preferences of the Series&#160;A convertible preferred stock relative to Oruka&#8217;s stock<span class="nobreak">-based</span> awards at the time of each grant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the progress of Oruka&#8217;s research and development programs, including the status of discovery<span class="nobreak">-phase</span> studies for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s stage of development and business strategy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s financial position, including cash on hand, and Oruka&#8217;s historical and forecasted performance and operating results;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of an active public market for Oruka common stock and its Series&#160;A convertible preferred stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of achieving a liquidity event, such as the proposed reverse recapitalization transaction, or sale of Oruka in light of prevailing market conditions; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the analysis of reverse recapitalization transactions and market performance of similar companies in the biotechnology industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value&#160;of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability<span class="nobreak">-weighted</span> expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM.&#160;The PWERM is a scenario<span class="nobreak">-based</span> methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability<span class="nobreak">-weighted</span> present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk<span class="nobreak">-adjusted</span> discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Oruka had used significantly different assumptions or estimates, the fair value of Oruka&#8217;s incentive shares and its stock<span class="nobreak">-based</span> compensation expense could have been materially different.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Once a public trading market for Oruka common stock has been established in connection with the completion of this Merger, it will no longer be necessary for Oruka&#8217;s board of directors to estimate the fair value of its stock<span class="nobreak">-based</span> awards in connection with its accounting for granted stock<span class="nobreak">-based</span> awards or other such awards Oruka may grant, as the fair value of Oruka&#8217;s common stock and share<span class="nobreak">-based</span> awards will be determined based on the quoted market price of Oruka&#8217;s common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A description of recently issued accounting pronouncements that may potentially impact Oruka&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Oruka&#8217;s condensed financial statements as of March&#160;31, 2024 appearing at the end of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">271</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka did not have any off<span class="nobreak">-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Convertible Note bears interest until December&#160;2025 at a fixed rate per annum equal 12%. An immediate 10% change in the prime rate would not have a material impact on Oruka&#8217;s debt<span class="nobreak">-related</span> obligations, financial position or results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inflation Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Oruka believes the effects of inflation, if any, on Oruka&#8217;s results of operations and financial condition have been immaterial. Oruka cannot assure you its business will not be affected in the future by inflation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">272</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T10"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s board of directors will initially be fixed at six members, consisting of six current Oruka board members, namely Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle. The staggered structure of the current ARCA board of directors will remain in place for the combined company following the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each executive officer of the combined company will serve at the discretion of the combined company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed combined company&#8217;s directors or executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawrence Klein, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Klein has served as Chief Executive Officer of Oruka and as a member of its board of directors since February&#160;2024. Prior to joining Oruka, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested in and helped to grow early<span class="nobreak">-stage</span> biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of Wisconsin<span class="nobreak">-Madison</span> and his Ph.D. in biophysics from Stanford University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Klein is qualified to serve as a member of the board of directors of the combined company because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">273</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Arjun Agarwal.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of Oruka since March&#160;2024, where he is responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Joana Goncalves, MBChB.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Goncalves has served as the Chief Medical Officer of Oruka since April&#160;2024. Prior to joining Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol<span class="nobreak">-Myers</span> Squibb Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paul Quinlan.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Quinlan has served as General Counsel of Oruka since April&#160;2024. Prior to joining Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Kristine Ball.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Ms. Ball has served as a member of the board of directors of Oruka since May&#160;2024. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq<span class="nobreak">-listed</span> biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non<span class="nobreak">-R</span>&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq<span class="nobreak">-listed</span> pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">274</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has served as a member of the board of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, since May&#160;2020. She previously served on the board of directors of Soteria from September&#160;2020 to August&#160;2022 and Forty Seven, Inc., a Nasdaq<span class="nobreak">-listed</span> biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Ms. Ball is qualified to serve as a member of the board of directors of the combined company because of her experience as an executive officer and director of life sciences companies and her background in finance, corporate development and strategic planning. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Carl Dambkowski, M.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Dambkowski has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP<span class="nobreak">-398</span> through the out licensing of the compound to Bristol<span class="nobreak">-Myers</span> Squibb based on initial clinical data and for low<span class="nobreak">-dose</span> infigratinib in achondroplasia through initial proof<span class="nobreak">-of-concept</span> data. He was part of the core team that brought TRUSELTIQ<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (infigratinib) and NULIBRY<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski co<span class="nobreak">-founded</span> Novonate, Inc., a private medical device company focused on building life<span class="nobreak">-saving</span> devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski has coauthored numerous peer<span class="nobreak">-reviewed</span> publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Dambkowski is qualified to serve as a member of the board of directors of the combined company because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Peter Harwin.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Harwin has served as a member of the board of directors of Oruka since February&#160;2024. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co<span class="nobreak">-founded</span> in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Mr.&#160;Harwin is qualified to serve as a member of the board of directors of the combined company because his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Samarth Kulkarni, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Kulkarni has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">275</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading scientific and business journals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that Dr.&#160;Kulkarni is qualified to serve as a member of the board of directors of the combined company because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cameron Turtle, D.Phil.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Turtle has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under<span class="nobreak"> </span>30, San Francisco Business Times 40 Under<span class="nobreak"> </span>40, and the Biocom Life Sciences Catalyst Award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Turtle is qualified to serve as a member of the board of directors of the combined company because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late<span class="nobreak">-stage</span> clinical trials and commercialization.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Composition of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three<span class="nobreak">-year</span> term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2025 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the combined company board of directors following the completion of the Merger as follows: &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;I directors;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;II directors; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are expected to be Class&#160;III directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Independence</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nasdaq listing rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors who, in the opinion of the board of directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria under the Exchange&#160;Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, ARCA and Oruka expect that the combined company&#8217;s board of directors will determine that each of the directors other than Lawrence Klein, Oruka&#8217;s current President and Chief Executive Officer, who is expected to serve as President and Chief Executive Officer of the combined company, and<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, will qualify as an &#8220;independent director&#8221; as defined under applicable Nasdaq listing rules. In making these determinations, the combined company&#8217;s board of directors will consider the current and prior relationships that each director has with ARCA and Oruka and all other facts and circumstances that the company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each combined company director in the Merger, any relevant related party transactions and the beneficial ownership of securities of ARCA, Oruka or </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">276</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the combined company by each combined company director. See also the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; beginning on pages 124, 280 and 315, respectively, of this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, Dr.&#160;Kulkarni is expected to serve as Chair of the board of directors of the combined company. The combined company&#8217;s Principles of Corporate Governance will provide its board of directors with the flexibility to combine or separate the positions of Chair of the board of directors and Chief Executive Officer. Oruka believes that having these positions be separate is the appropriate leadership structure for the combined company at this time as it will help facilitate independent oversight of management by the board of directors of the combined company and allow the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the combined company&#8217;s board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, ARCA and Oruka anticipate that the board of directors of the combined company will establish an audit committee, a compensation committee, a nominating and corporate governance committee and science and technology committee, each of which will operate pursuant to a charter adopted by the board of directors of the combined company. ARCA and Oruka believe that following the completion of the Merger the functioning and composition of these committees of the combined company will comply with the requirements of Nasdaq listing rules and SEC rules and regulations. The board of directors of the combined company may also establish other committees from time to time to assist the combined company and its board of directors. Each of the audit committee, compensation committee, nominating and corporate governance committee and science and technology committee is expected to have the responsibilities described below.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s audit committee are expected to be&#160;&#160;&#160;&#160;&#160;<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>,&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director for audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the combined company&#8217;s audit committee.&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the audit committee.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)&#160;of Regulation&#160;S<span class="nobreak">-K</span> promulgated under the Securities Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s audit committee will be to oversee the combined company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will also oversee the system of internal controls established by management and the combined company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s compensation committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules and also meets the additional, heightened independence criteria applicable to members of the compensation committee.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the compensation committee.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">277</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the combined company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the combined company&#8217;s Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the combined company&#8217;s board of directors the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the combined company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s nominating and corporate governance committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to be chair the nominating and corporate governance committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s nominating and corporate governance committee will be responsible for engaging in succession planning for the combined company&#8217;s board of directors, developing and recommending to the combined company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the combined company&#8217;s board of directors regarding candidates for election or reelection to the board of directors at each annual stockholders&#8217; meeting. In addition, the nominating and corporate governance committee will be responsible for overseeing the combined company&#8217;s corporate governance matters. The nominating and corporate governance committee will also be responsible for overseeing the structure, composition and functioning of the combined company&#8217;s board of directors and its committees.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Science and Technology Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s science and technology committee are expected to be&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>,&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>is expected to chair the science and technology committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s science and technology committee will be to assist the combined company&#8217;s board of directors in overseeing the combined company&#8217;s innovation, new product development and research and development activities.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">None of the expected members of the combined company&#8217;s compensation committee has at any time been one of the officers or employees of the combined company. None of the combined company&#8217;s expected executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Conduct and Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the combined company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the combined company&#8217;s directors, officers and employees. The full text of the combined company&#8217;s Code of Conduct and Ethics will be posted on the combined company&#8217;s website at<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. The Code of Conduct and Ethics is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The combined company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The combined company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the combined company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the combined company&#8217;s website to be part of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">278</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, Oruka did not have a formal policy to provide any cash or equity compensation to its non<span class="nobreak">-employee</span> directors for their service on its board of directors or committees of its board of directors. Oruka&#8217;s non<span class="nobreak">-employee</span> director compensation is described under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>&#8221; in this proxy statement/prospectus. Except as described below, determinations with respect to director compensation after the closing of the Merger have not yet been made. In connection with closing of the Merger, it is expected that the board of directors of the combined company will adopt a non<span class="nobreak">-employee</span> director compensation policy designed to enable the combined company to attract and retain, on a long<span class="nobreak">-term</span> basis, highly qualified non<span class="nobreak">-employee</span> directors and align its directors&#8217; interests with those of its stockholders. Employee directors will not receive additional compensation for their services as directors. It is expected that each director who is not an employee will be paid cash and equity compensation for serving on the board of directors of the combined company, the amount and terms of which have not yet been determined. The combined company will also reimburse its non<span class="nobreak">-employee</span> directors for reasonable travel and out<span class="nobreak">-of-pocket</span> expenses incurred in connection with attending the board of director and committee meetings.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">279</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9989"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS<br/>OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Oruka&#8217;s and ARCA&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>,&#8221; the following is a description of each transaction involving ARCA since January&#160;1, 2022, each transaction involving Oruka since February&#160;6, 2024 (inception) and each currently proposed transaction in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>either Oruka or ARCA has been or is to be a participant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Oruka&#8217;s or ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two completed fiscal&#160;years, as applicable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s or ARCA&#8217;s directors, executive officers or holders of more than 5% of Oruka&#8217;s or ARCA&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a smaller reporting company, SEC rules require ARCA to disclose any transaction for the last two completed fiscal&#160;years or any currently proposed transaction in which ARCA is a participant and in which any related person has or will have a direct or indirect material interest involving an amount in excess of $120,000 or 1% of the average of ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two fiscal&#160;years. A related person is any executive officer, director, nominee for director or holder of 5% or more of ARCA&#8217;s common stock or an affiliate or immediate family member of any of those persons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other than the compensation arrangements and other arrangements disclosed above under the headings &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Director Compensation</span>&#8221; and the transactions described below, since January&#160;1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which ARCA was, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of ARCA&#8217;s total assets amounts at December&#160;31, 2022 and 2023) and in which any director, executive officer, holder of 5% or more of any class of ARCA&#8217;s capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transactions With ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cooperation Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span> (collectively, &#8220;Cable Car&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at the 2022 annual meeting of stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">280</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation Agreement until the earlier to occur of (i)&#160;the 180<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day after the First Director Appointment is no longer serving as a director of ARCA and (ii)&#160;the 90<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation Period&#8221;), including that Cable Car will not, among other things, (i)&#160;seek additional representation, or the removal of an existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a<span class="nobreak">-2</span>(b)&#160;promulgated under the Securities Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period expired on November&#160;1, 2023, the 90<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span><span class="Superscript" style="vertical-align:super;">&#160;</span>day prior to the 2023 Annual Meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Cable Car also agreed to customary mutual non<span class="nobreak">-disparagement</span> obligations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Policies and Procedures for Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s Audit Committee reviews and approves all related party transactions. This review covers any material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which ARCA was or will be a participant, and a related party had or will have a direct or indirect material interest, including, purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by ARCA of a related party. In evaluating any related party transaction, ARCA&#8217;s Audit Committee considers, among&#160;other things, the relative benefits of the transaction to ARCA, what, if any, alternatives may be available from persons not affiliated to ARCA, if the terms of the transaction have been negotiated on an arm&#8217;s length basis and any other matters that ARCA&#8217;s Audit Committee may deem relevant in determining whether such related party transaction is in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of each transaction or series of similar transactions since February&#160;6, 2024 (inception) or any currently proposed transaction, to which Oruka was or is a party in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of Oruka&#8217;s total assets; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s directors or executive officers, any holder of 5% of any class of Oruka capital stock or an affiliate or immediate family member of the foregoing persons had or will have a direct or indirect material interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compensation arrangements for Oruka named executive officers and directors are described elsewhere in this proxy statement/prospectus under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Private Placements of Securities</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Series&#160;A Preferred Stock and Convertible Note&#160;Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka completed a preferred stock and convertible note financing (the &#8220;Oruka Series&#160;A Financing&#8221;) and issued and sold to Fairmount Fund&#160;II (i)&#160;an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock at a purchase price of $0.15 per share and (ii)&#160;the Convertible Note with an initial principal amount of $25,000,000 at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund&#160;II is expected to contribute the aggregate principal amount and all accrued interest under the Convertible Note in exchange for Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in connection with Oruka&#8217;s pre<span class="nobreak">-closing</span> financing. Fairmount Funds Management is the investment manager of Fairmount. Peter Harwin, a director of Oruka, is a managing member of Fairmount Funds Management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Pre-Closing Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, in connection with the execution of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors to consummate the Oruka pre<span class="nobreak">-closing</span> financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 Oruka pre<span class="nobreak">-funded</span> warrants, at an estimated price of $5.80 per share of common stock </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">281</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and $5.79 per warrant, respectively, for aggregate gross proceeds of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The aggregate purchase price of $275.0&#160;million is fixed, while the purchase price per share or warrant and the aggregate number of shares and warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>.&#8221; The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Three of the investors or their affiliates are, or are expected to be as of immediately following the Oruka pre<span class="nobreak">-closing</span> financing, beneficial holders of more than 5% of Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants expected to be purchased by such holders at the closing of the Oruka pre<span class="nobreak">-closing</span> financing (based on the currently estimated purchase price per share or warrant, as applicable).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Participant</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Shares of <br/>Oruka <br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Pre-funded <br/>Warrants of<br/>Oruka</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Total <br/>Purchase <br/>Price</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Fairmount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,597</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,813,325</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with FMR LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,308,409</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes $25.0<span class="nobreak"> </span>million of proceeds previously received by Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Relationship with Paragon and Paruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is party to a number of agreements with Paragon and Paruka. Paragon and Paruka each beneficially own more than 5% of Oruka&#8217;s capital stock through their respective holdings of Oruka common stock. Fairmount beneficially owns more than 5% of Oruka&#8217;s capital stock, has one seat on Oruka&#8217;s board of directors and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in Oruka in order to share profits with certain employees of Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due from Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received such rights and has not paid such development costs. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon for the pre<span class="nobreak">-effective</span> date development costs. During the period ended March&#160;31, 2024, this was recognized as a research and development expense, and Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">282</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of filing of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of the Paragon Option Agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of Oruka&#8217;s outstanding shares on a fully<span class="nobreak">-diluted</span> basis as of the date of the grant, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional detail regarding Oruka&#8217;s arrangements with Paragon, including the Paragon Option Agreements, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;License Agreements</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Agreements with Oruka Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Oruka Series&#160;A Financing, Oruka entered into investors&#8217; rights, voting and right of first refusal and co<span class="nobreak">-sale</span> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Oruka preferred stock and certain holders of Oruka common stock. These stockholder agreements will terminate upon the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Indemnification Agreements and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Oruka to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Policies for Approval of Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">283</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into a Merger Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the Merger. Immediately following the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. The transaction is expected to be completed in the third quarter of 2024 (the &#8220;Closing Date&#8221; or the &#8220;Effective Time&#8221;) following the filed Form&#160;S<span class="nobreak">-4</span> being deemed effective by the SEC and receipt of approval by the stockholders of each of Oruka and ARCA, in the latter case pursuant to a special meeting. In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &#8220;Exchange Ratio&#8221;) (together with the Oruka pre<span class="nobreak">-closing</span> financing, the &#8220;Transactions&#8221;), immediately prior to the Effective Time, (i) each share of Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued in connection with the Subscription Agreement (both defined in Note&#160;1 of the accompanying notes), will be converted into the right to receive shares of ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Oruka Series A convertible preferred stock will be converted into the right to receive ARCA Series B convertible preferred stock, (iii) each option to purchase Oruka common stock will be converted into the right to receive an option to purchase ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre<span class="nobreak">-funded</span> warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement will be converted into the right to receive a pre<span class="nobreak">-funded</span> warrant to purchase shares of ARCA common stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Exchange Ratio is currently estimated to be approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock for each fully<span class="nobreak">-diluted</span> share of Oruka common stock. Under the Exchange Ratio formula, the former Oruka stockholders immediately before the effective time, including those purchasing shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing, are currently estimated to own approximately 97.6% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis, and the stockholders of ARCA immediately before the effective time are currently estimated to own approximately 2.4% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis and are subject to certain assumptions, including, but not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka closing on approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior to the closing date of the Merger, plus $6.0&#160;million, and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under United&#160;States Generally Accepted Accounting Principles, or U.S.&#160;GAAP.&#160;For further detail related to the accounting for the Merger, please see Notes 1 and&#160;3 below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of ARCA and Oruka as of March&#160;31, 2024 and depicts the accounting of the transactions prepared pursuant to the rules and regulations of Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended (&#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the three&#160;months ended March&#160;31, 2024 for ARCA, the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 for Oruka, and the year ended December&#160;31, 2023 for ARCA combine the historical results of ARCA and Oruka for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2023 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">284</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(&#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, pro forma balance sheet transaction accounting adjustments and pro forma statements of operations transaction accounting adjustments are referred to as &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed financial statements of Oruka as of March<span class="nobreak">&#160;</span>31, 2024 and for the period from February<span class="nobreak">&#160;</span>6, 2024 (inception) to March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed consolidated financial statements of ARCA as of and for the three&#160;months ended March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical audited consolidated financial statements of ARCA for the year ended December<span class="nobreak">&#160;</span>31, 2023, and the related notes included elsewhere in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span>,&#8221; and other financial information relating to ARCA and Oruka included elsewhere in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had ARCA and Oruka been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">285</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET<br/>AS OF MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Historical</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(A)<br/>ARCA<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">biopharma, <br/>Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(B)<br/>Oruka<br/>Therapeutics,<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Transaction<br/>Accounting<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Adjustments</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Notes</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Pro&#160;Forma<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Combined</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,903</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,004</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,786</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(19,512</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,973</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(256</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">767</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">51</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,670</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,642</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,055</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Operating lease right-of-use assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Property and equipment, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Other assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="text-decoration:underline;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accounts payable</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">529</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">533</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued expenses and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,052</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,262</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(21</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,326</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(919</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(48</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Related party accounts payable and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,165</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(988</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Long term liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued interest payable, related party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Notes payable to related parties, noncurrent</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">32,359</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(26,182</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Stockholders&#8217; equity (deficit) </span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA common stock, $0.001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka common stock, $0.0001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">0</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">6</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Additional paid-in capital</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">225,861</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">25,214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">263,449</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,782</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">22</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(197,446</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accumulated deficit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(190,750</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,053</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(278</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">197,460</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,125</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,059</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">228,312</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">256,378</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-5" style="text-decoration:underline;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">286</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE THREE MONTHS ENDED MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 23.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,358</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,317</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,250</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(49</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">287</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,283</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,990</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(d)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,050</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(h)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">288</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9990"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1. Description of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Oruka, First Merger Sub, and Second Merger Sub entered into the Merger Agreement to which the First Merger Sub merges with and into Oruka, with Oruka becoming a wholly owned subsidiary of ARCA.&#160;Oruka will merge with and into the Second Merger Sub, with the Second Merger Sub being the surviving entity. Subsequent to the Second Merger, Second Merger Sub would remain a wholly owned subsidiary of ARCA and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;):</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">a)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of, and pre<span class="nobreak">-funded</span> warrant related to, Oruka common stock, including (i)&#160;outstanding and unvested Oruka Restricted Stock (defined below) will be converted into the right to receive a number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, ARCA common stock, based on the Exchange Ratio;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of Oruka Series A convertible preferred stock at closing will be exchanged into ARCA Series B convertible preferred stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the Exchange Ratio divided by 1,000; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">c)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding and unexercised option to purchase shares of Oruka common stock (&#8220;Oruka options&#8221;) immediately prior to Closing will be assumed by ARCA and will be converted into an option to purchase shares of ARCA common stock which continues to vest pursuant to the original terms, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All Oruka restricted stock outstanding and unvested immediately prior to Closing (&#8220;Oruka Restricted Stock&#8221;) that is assumed by ARCA in the Merger will remain unvested to the same extent and will be subject to the same repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, the board of directors of ARCA will take actions to accelerate the vesting of certain outstanding options to purchase ARCA common stock held by a current employee, director or consultant of ARCA as of the closing of the Merger. The acceleration of vesting of ARCA&#8217;s options occurs either upon a change of control as defined, pursuant to the terms of the original awards, or a modification of the awards as a result of the Merger. The incremental fair value of ARCA&#8217;s options associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately following the Merger, ARCA stockholders are expected to own approximately 2.4% of the outstanding capital stock of the combined company on a fully diluted basis, former Oruka stockholders are expected to own approximately 39.3% of the outstanding capital stock of the combined company on a fully diluted basis, and investors participating in the Subscription Agreement (defined below) are expected to own approximately 58.3% of the outstanding capital stock of the combined company on a fully diluted basis. Oruka stockholders are expected to receive approximately 238,540,759<span class="nobreak"> </span>shares on a fully diluted basis in connection with the Merger, including (i) 47,510,340<span class="nobreak"> </span>shares of ARCA common stock and stock options subject to vesting terms, based on the number of shares of Oruka common stock outstanding immediately prior to the Merger, including Oruka Restricted Stock, (ii) the number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, Oruka common stock issued to investors participating in the Subscription Agreement (defined below), and (iii) Oruka convertible preferred stock outstanding as of March&#160;31, 2024, which will be exchanged into shares of ARCA Series B convertible preferred stock. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka raising approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">289</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to the closing date of the Merger, plus $6.0&#160;million and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the combined company outstanding following the consummation of the Transactions:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Equity Capitalization Summary (fully diluted basis) <br/>Upon Consummation of the Merger</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Pro&#160;Forma <br/>(Assuming&#160;ARCA&#160;Net&#160;Cash <br/>at&#160;Closing&#160;of&#160;$5.0&#160;Million)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares&#160;Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">% <br/>Ownership</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Oruka stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238,540,759</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investors participating in the Subscription Agreement<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">353,695,101</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total common stock of the combined company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,737,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 67,241,225 pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement after reflecting the estimated Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of ARCA common stock to be issued in connection with the Merger and (4)&#160;the effectiveness of a registration statement filed with the SEC in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements for ARCA employees include entitlement to change in control payments for certain executives, and severance and retention bonus payments for certain non<span class="nobreak">-executives</span>, the aggregate of which will be treated as pre<span class="nobreak">-Merger</span> compensation expense of ARCA and will be reflected as an increase to accrued expenses of ARCA, which will be assumed by the combined company at Closing. Prior to the Closing, ARCA also (i)&#160;discontinued its research and development activities, (ii)&#160;sold its assets held for sale, and (iii)&#160;terminated and/or expired its operating leases. Additionally, ARCA&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at Closing.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Private Financing Transaction&#160;&#8212;&#160;Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka to purchase, prior to the consummation of the Merger, approximately 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, at an estimated purchase price of $5.80 and $5.79 per share, respectively, for an aggregate purchase price of approximately $275.0&#160;million, which includes $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of a convertible note and accrued interest. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to the Subscription Agreement will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of ARCA common ctock at Closing per the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2. Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the combined company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the three&#160;months ended March&#160;31, 2024 and the unaudited pro forma condensed combined statement of operations data for the year ended December&#160;31, 2023, give effect to the Merger as if it had been consummated on January&#160;1, 2023. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2024 gives effect to the Merger and combines the historical balance sheets of ARCA and Oruka as of such date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of ARCA&#8217;s net cash to be assumed at the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">290</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">Closing Date, and (iii)&#160;other changes in ARCA&#8217;s assets and liabilities, which are expected to be completed after the Closing, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3. Accounting for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under U.S.&#160;GAAP as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka, as the transaction is, in essence, the issuance of equity for ARCA&#8217;s net assets, which will primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. Under this method of accounting, Oruka will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka stockholders will own a substantial majority of the voting rights in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s largest stockholder will retain the largest interest in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will designate the initial members of the board of directors of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s executive management team will become the management of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will be renamed &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a result of Oruka being the accounting acquirer, Oruka&#8217;s assets and liabilities will be recorded at their pre<span class="nobreak">-combination</span> carrying amounts. ARCA&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time, which are expected to approximate the carrying value of the acquired cash and other non<span class="nobreak">-operating</span> assets, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of ARCA following the determination of the actual consideration transferred for ARCA will be reflected as an adjustment to additional paid<span class="nobreak">-in</span> capital. For periods prior to Closing, the historical financial statements of Oruka shall become the historical financial statements of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4. Shares of ARCA Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Oruka Stockholders upon Closing of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">At Closing, all outstanding shares of Oruka common stock, on a fully<span class="nobreak">-diluted</span> basis, will be exchanged for shares of ARCA common stock based on the preliminary estimated Exchange Ratio of 7.4631, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of ARCA common stock that ARCA expects to issue to Oruka&#8217;s stockholders assumes ARCA&#8217;s net cash at Closing is $5.0&#160;million and is determined as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock outstanding as of March&#160;31, 2024<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,460,019</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock to be issued upon conversion of Oruka convertible preferred&#160;stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock issued upon exercise of Oruka stock options<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares to purchase Oruka common stock upon exercise of Oruka&#8217;s CEO&#8217;s stock options&#160;granted immediately prior to the closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,804,003</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued in connection with the Subscription Agreement, see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,382,693</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued upon exercise of Oruka pre-funded warrants to be issued in connection with the Subscription Agreement,&#160;see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,009,825</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Oruka fully diluted shares prior to the closing of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,355,209</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated Exchange&#160;Ratio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.4631</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated fully diluted shares to be issued to Oruka stockholders and Investors participating in Subscription Agreement upon closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">592,235,860</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents shares of Oruka common stock outstanding as of March&#160;31, 2024, including 3,863,361 shares of unvested Oruka Restricted Stock.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the outstanding options to acquire Oruka common stock as of March&#160;31, 2024. Such stock options will become exercisable for shares of ARCA common stock following the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">291</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company pursuant to his employment agreement immediately prior to the Merger.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the total estimated fully diluted shares to be issued to Oruka stockholders at Closing based on the preliminary estimated Exchange Ratio of 7.4631.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2024</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(A)&#160;&#160;Derived from the unaudited condensed consolidated balance sheet of ARCA as of March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(B)&#160;&#160;Derived from the unaudited condensed balance sheet of Oruka as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense of $1.7&#160;million related to severance, retention bonuses and change in control payments resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that is expected to be incurred upon closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $1.7&#160;million for the severance and retention bonuses payments made subsequent to March&#160;31, 2024 and an increase to accumulated deficit of $1.7&#160;million.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(b)&#160;&#160;To reflect the exchange of all outstanding shares of Oruka Series&#160;A convertible preferred stock, with a carrying amount of $2.9&#160;million, into ARCA Series&#160;B convertible preferred stock at closing of the Merger, with the terms of ARCA Series B convertible preferred stock resulting in classification within stockholders&#8217; equity.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the issuance of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, pursuant to the Subscription Agreement entered into concurrently with the execution of the Merger Agreement, for an aggregate purchase price of $275.0<span class="nobreak"> </span>million, which includes $25.0<span class="nobreak"> </span>million proceeds received as of March<span class="nobreak"> </span>31, 2024 from the issuance of the convertible note. The aggregate proceeds are net less than $0.1<span class="nobreak"> </span>million of debt issuance costs and include accrued interest of $0.2<span class="nobreak"> </span>million as of March<span class="nobreak"> </span>31, 2024 adjusted through accumulated deficit (see Note 6(e)), for net proceeds prior to transaction costs of $249.8<span class="nobreak"> </span>million. The proceeds received in connection with the Subscription Agreement are recorded net of transaction costs deemed to be direct and incremental costs of the equity financing in the amount of approximately $20.0<span class="nobreak"> </span>million (see Note 5(d)) for net proceeds from the Subscription Agreement post<span class="nobreak">-transaction</span> costs of $229.8<span class="nobreak"> </span>million. The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Oruka common stock at par value, with the remaining amount recorded to additional paid<span class="nobreak">-in-capital</span>. Additionally, 1,804,003 options to purchase shares of Oruka common stock will be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company, pursuant to his employment agreement, subject to vesting conditions (see Note 6(f)).</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment to additional paid<span class="nobreak">-in-capital</span> upon close of the Merger is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aggregate purchase price of the Subscription Agreement</p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">275,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds previously received from issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Debt issuance costs recorded as part of issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable as part of issuance of convertible note as of March&#160;31, 2024, see <br/>Note&#160;6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds received prior to direct and incremental transaction costs from the Subscription Agreement upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,786</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of Oruka common stock and pre-funded warrants at par value upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital related to the issuance of Oruka common stock and pre-funded <br/>warrants upon close of the Merger (excluding Oruka common stock to be issued in connection with conversion of convertible note)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">292</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(d)&#160;&#160;To reflect preliminary estimated transaction costs of $19.5&#160;million, not yet reflected in the historical financial statements, that are expected to be incurred by Oruka in connection with the Merger, and $0.5&#160;million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of ARCA, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated transaction costs of $4.1&#160;million, not yet reflected in the historical financial statements and $0.9&#160;million reflected in the historical financial statements, which are expected to be incurred by ARCA in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.7<span class="nobreak"> </span>million cost of a D&amp;O tail policy, as a reduction in cash of $5.0<span class="nobreak"> </span>million, a reduction in accrued expenses of $0.9<span class="nobreak"> </span>million, and a reduction in accumulated deficit of $4.1<span class="nobreak"> </span>million in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To derecognize $0.7&#160;million of ARCA&#8217;s prepaid expenses consisting of $0.1&#160;million of prepaid expenses related to software that will not be utilized and $0.6&#160;million of prepaid insurance primarily related to the current ARCA&#8217;s D&amp;O policy that will be fully utilized at Closing.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(g)&#160;&#160;To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(h)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements, which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, and to reflect the one<span class="nobreak">-time</span> cash payment of $0.3&#160;million to settle in<span class="nobreak">-the-money</span> stock options per terms of the Merger Agreement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(i)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect an estimate of the one<span class="nobreak">-time</span> dividend of $20.0&#160;million declared and paid on the shares of ARCA common stock outstanding prior to the Merger. The dividend will be treated as a decrease in additional paid<span class="nobreak">-in</span> capital in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(j)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the recapitalization of Oruka, pursuant to the Merger Agreement, through the contribution of 238,540,759<span class="nobreak"> </span>shares of Oruka common stock, including 47,510,340<span class="nobreak"> </span>shares of Oruka Restricted Stock and Oruka stock options (see Note&#160;4), and the issuance of 286,453,876<span class="nobreak"> </span>shares of Oruka common stock and 67,241,224 pre<span class="nobreak">-funded</span> warrants and 149,262,000 preferred stock, reflecting the estimated Exchange Ratio of 7.4631 and to reflect the derecognition of the accumulated deficit of ARCA which is reversed to additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;margin-top:8pt;">The derecognition of accumulated deficit of ARCA of $197.5&#160;million is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit of ARCA as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">190,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compensation expense related to ARCA severance, retention bonuses and change in control payments, see Note&#160;5(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preliminary estimated transaction costs of ARCA, see Note&#160;5(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,053</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA prepaid software expenses and prepaid insurance, see Note&#160;5(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA operating leases, see Note&#160;5(g)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Merger stock-based compensation expense for ARCA&#8217;s accelerated awards, see Note&#160;5(h)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total adjustment to derecognize the accumulated deficit of ARCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">197,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">293</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6. Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(A)&#160;&#160;Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of ARCA for the three&#160;months ended March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(B)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the period February&#160;6, 2024 (inception) to March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(C)&#160;&#160;Derived from the audited consolidated statement of operations and comprehensive loss of ARCA for the year ended December&#160;31, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(D)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and ARCA did not record any provision or benefit for income taxes during the three&#160;months ended March&#160;31, 2024 because each company expects to incur a pre<span class="nobreak">-tax</span> loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense related to severance, retention bonuses and change in control payments recorded in general and administrative expenses of $1.7&#160;million, resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that will be incurred upon Closing assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(b)&#160;&#160;To reflect the derecognition of ARCA&#8217;s prepaid expenses of $0.1&#160;million related to software that will not be utilized, and prepaid insurance of $0.6&#160;million primarily related to the current ARCA D&amp;O policy that will be fully utilized at Closing, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized, assuming the adjustment made in Note&#160;5(g)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(d)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect Oruka&#8217;s interest expense related to its convertible note that is recorded in its historical financial statements, to be derecognized in the unaudited pro forma condensed combined statement of operations for the three&#160;months ended March&#160;31, 2024 assuming that the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect stock compensation expenses of $1.1&#160;million and $0.3<span class="nobreak"> </span>million for the year ended December<span class="nobreak"> </span>31, 2023 and the three months ended March<span class="nobreak"> </span>31, 2024, respectively, in general and administrative expense related to stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership pursuant to his employment agreement, assuming the adjustment was made on January&#160;1, 2023. These options vest over 4 years from the date of issuance.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">294</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(g)&#160;&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the three&#160;months ended March&#160;31, 2024. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods. Pro forma weighted average shares outstanding includes the pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. For the three&#160;months ended March&#160;31, 2024, the pro forma weighted average shares have been calculated as follows:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December 31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and<br/>Diluted</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and<br/>Diluted</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Historical weighted average number of ARCA common shares outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of ARCA common stock expected to be issued to Oruka stockholders upon Closing, assuming consummation of the Merger as of January&#160;1, 2023, see Note&#160;4<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma combined weighted average number of common shares <br/>outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated shares of ARCA common stock expected to be issued to Oruka stockholders at Closing, excluding (i)&#160;the outstanding and unvested Oruka Restricted Stock and Oruka stock options at Closing that will be converted to the right to receive 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options, respectively, after reflecting the estimated Exchange Ratio and (ii)&#160;the outstanding Oruka convertible preferred stock that will be exchanged for 149,262,000<span class="nobreak"> </span>shares of ARCA convertible preferred stock. The 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options are subject to the same vesting conditions (see Note&#160;4).</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">295</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T8"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following description of ARCA capital stock and provisions of the ARCA Charter and ARCA Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms part.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Authorized Capital Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter authorizes ARCA to issue 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock, $0.001 par value per share (&#8220;ARCA preferred stock&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting Rights.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Each holder of ARCA common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors; provided, however, holders of ARCA common stock may not, unless otherwise required by law, vote on any amendment to the ARCA Charter that relates solely to the terms of one or more series of ARCA preferred stock that ARCA may issue if the holders of such ARCA preferred stock are entitled to vote on such amendment. In all such matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the election of directors. ARCA&#8217;s stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors to be elected at any particular time. See the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Description of ARCA Capital Stock &#8212; Anti</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Takeover</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span>&#8221; for a description of elections of members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Subject to preferences that may be applicable to any then outstanding ARCA preferred stock, holders of ARCA common stock are entitled to receive dividends, if any, as may be declared from time to time by ARCA&#8217;s board of directors out of legally available funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the event of ARCA&#8217;s liquidation, dissolution or winding up, holders of ARCA common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of ARCA&#8217;s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of ARCA preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Rights and Preferences.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Holders of ARCA common stock have no preemptive, conversion, subscription or other rights, and there are no redemption provisions applicable to ARCA common stock. The rights, preferences and privileges of the holders of ARCA common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of ARCA preferred stock that ARCA may designate in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Fully Paid and Nonassessable.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>All outstanding shares of ARCA common stock are fully paid and nonassessable.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by ARCA&#8217;s stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of ARCA preferred stock, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, voting rights, terms of redemption and repurchase, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of ARCA common stock. ARCA preferred stock may be convertible into ARCA common stock or other securities of ARCA, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. Because ARCA&#8217;s board of directors, without stockholder approval, can issue ARCA preferred stock with voting, conversion or other rights, ARCA preferred stock could be issued quickly </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">296</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with terms calculated to delay or prevent a change in control of ARCA or make removal of management more difficult. Additionally, the issuance of ARCA preferred stock may have the effect of decreasing the market price of ARCA common stock and may adversely affect the voting power of holders of ARCA common stock and reduce the likelihood that ARCA&#8217;s common stockholders will receive dividend payments and payments upon liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Delaware General Corporation Law provides that the holders of any class or series of ARCA preferred stock will have the right to vote separately as a class on any proposed amendment to the ARCA Charter that would alter or change the powers, preferences or special rights of the holders of such class or series of ARCA preferred stock so as to affect them adversely. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has designated 135,000 of the 5,000,000 authorized shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Convertible Preferred Stock ranks:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>senior to all of ARCA&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on parity with any class or series of ARCA capital stock specifically ranking by its terms on parity with the Preferred Stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>junior to any class or series of ARCA capital stock specifically ranking by its terms senior to the Preferred Stock;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">in each case, as to distributions of assets upon ARCA&#8217;s liquidation, dissolution or winding up whether voluntarily or involuntarily.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Convertible Preferred Stock is convertible into 100<span class="nobreak"> </span>shares of ARCA&#8217;s common stock (subject to adjustment as provided in the related certificate of designation of preferences) at any time at the option of the holder, provided that the holder is prohibited from converting Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of ARCA&#8217;s common stock then issued and outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of ARCA&#8217;s liquidation, dissolution, or winding up, holders of Series&#160;A Convertible Preferred Stock will receive a payment equal to $0.001 per share of Series&#160;A Convertible Preferred Stock before any proceeds are distributed to the holders of ARCA&#8217;s common stock. In addition, each share of Series&#160;A Convertible Preferred Stock will be entitled to receive, on an as<span class="nobreak">-if-converted</span> basis, <span class="Italic" style="font-style:italic;font-weight:normal;">pari passu</span> with each share of ARCA&#8217;s common stock, any distributions of ARCA&#8217;s assets or surplus funds which ARCA makes upon shares of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of Series&#160;A Convertible Preferred Stock have no voting rights, except as required by law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for stock dividends or certain other distributions set forth in the certificate of designation, shares of Series&#160;A Convertible Preferred Stock will be entitled to receive dividends (on an as<span class="nobreak">-converted</span> basis) in the same form as dividends actually paid on shares of ARCA&#8217;s common stock when and if declared by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to redeem or repurchase any shares of Series&#160;A Convertible Preferred Stock. Shares of Series&#160;A Convertible Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No shares of Series&#160;A Convertible Preferred Stock are currently issued and outstanding.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;B Non-Voting Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors will designate<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA preferred stock as ARCA Series&#160;B Preferred Stock through its certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex</span>&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">F </span>(the &#8220;Certificate of Designation&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">297</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">actually paid on shares of ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s charter, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger (as defined elsewhere in this proxy statement/prospectus), each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws include a number of provisions that may deter or impede hostile takeovers or changes of control. These provisions include:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Issuance of Undesignated ARCA preferred stock.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of undesignated ARCA preferred stock with rights and preferences, including voting rights, designated from time to time by ARCA&#8217;s board of directors. The existence of authorized but unissued shares of ARCA preferred stock enables ARCA&#8217;s board of directors to make it more difficult or to discourage an attempt to obtain control of ARCA by means of a merger, tender offer, proxy contest or otherwise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Classified Board.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides for a classified board of directors consisting of three classes of directors, with staggered three<span class="nobreak">-year</span> terms. Only one class of directors will be elected at each annual meeting of ARCA&#8217;s stockholders, with the other classes continuing for the remainder of their respective three<span class="nobreak">-year</span> terms. This provision may have the effect of delaying a change in control of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Board of Directors Vacancies.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter and ARCA Bylaws authorize only ARCA&#8217;s board of directors to fill vacant directorships, unless ARCA&#8217;s board of directors determines by resolution that the stockholders shall fill such vacant directorships. In addition, the number of directors constituting ARCA&#8217;s board of directors may be set only by resolution adopted by a majority vote of ARCA&#8217;s entire board of directors. These provisions prevent a stockholder from increasing the size of ARCA&#8217;s board of directors and gaining control of ARCA&#8217;s board of directors by filling the resulting vacancies with its own nominees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action; Special Meetings of Stockholders.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides that ARCA&#8217;s stockholders may not take action by written consent, but may only take action at annual or special meetings of ARCA&#8217;s stockholders. Under the ARCA Bylaws, stockholders are not permitted to cumulate their votes for the election of directors. The ARCA Bylaws further provide that special meetings of the stockholders may be called by the chief executive officer, president, ARCA&#8217;s board of directors, or by holders of ARCA common stock who hold, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">298</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting. These provisions may prevent stockholders from corporate actions as stockholders at times when they otherwise would like to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Bylaws provide advance notice procedures for stockholders seeking to bring business before ARCA&#8217;s annual meeting of stockholders, or to nominate candidates for election as directors at ARCA&#8217;s annual meeting of stockholders. The ARCA Bylaws also specify certain requirements as to the form and content of a stockholder&#8217;s notice. These provisions may make it more difficult for ARCA&#8217;s stockholders to bring matters before ARCA&#8217;s annual meeting of stockholders or to nominate directors at ARCA&#8217;s annual meeting of stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of ARCA&#8217;s board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of ARCA.&#160;These provisions are designed to reduce ARCA&#8217;s vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for ARCA&#8217;s shares and, as a consequence, they may also reduce fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits certain Delaware corporations from engaging, under certain circumstances, in a &#8220;business combination&#8221; with any &#8220;interested stockholder for a period of three&#160;years following the time that such stockholder became an interested stockholder, unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to such time the board of directors approved either the business combination or transaction which resulted in the stockholder becoming an interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&#160;shares owned by persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66<span class="nobreak">-2</span>/3% of the outstanding voting stock which is not owned by the interested stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;203 defines a business combination to include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger or consolidation involving the corporation and the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority<span class="nobreak">-owned</span> subsidiary);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section&#160;203, provided by or through the corporation.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">299</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. ARCA has not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Effects of Authorized but Unissued Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock and ARCA preferred stock are available for future issuance without stockholder approval. ARCA may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital stock or as equity compensation to ARCA&#8217;s service providers under ARCA&#8217;s equity compensation plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The existence of unissued and unreserved ARCA common stock and ARCA preferred stock may enable ARCA&#8217;s board of directors to issue shares to persons friendly to current management or to issue ARCA preferred stock with terms that could render more difficult or discourage a third<span class="nobreak">-party</span> attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of ARCA&#8217;s management. In addition, ARCA&#8217;s board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of ARCA preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in the ARCA Charter. The purpose of authorizing the board of directors to issue ARCA preferred stock and to determine the rights and preferences applicable to such ARCA preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of ARCA preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of ARCA&#8217;s outstanding voting stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also, if ARCA issues additional shares of authorized, but unissued, ARCA common stock, these issuances will dilute the voting power and distribution rights of ARCA&#8217;s existing common stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendments to Governing Documents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the amendment of the ARCA Charter requires approval by ARCA&#8217;s board of directors and a majority vote of stockholders, provided that the provisions of the ARCA Charter relating to (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of directors, officers and other persons requires approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote. Any amendment to ARCA Bylaws requires the approval of either a majority of ARCA&#8217;s board of directors or approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for ARCA common stock is Computershare Trust Company N.A.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">300</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T7"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND <br/>ORUKA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, Oruka stockholders will receive shares of ARCA common stock and ARCA Series&#160;B Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, the ARCA Charter will be amended to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to effect the proposed reverse stock split and to reflect Delaware law provisions regarding officer exculpation, respectively, as set forth in the forms of certificates of amendment attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G, Annex&#160;H </span>and <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are both incorporated under the laws of the State of Delaware. The rights of ARCA stockholders and Oruka stockholders are generally governed by the DGCL.&#160;Upon completion of the Merger, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the ARCA Bylaws and the ARCA Charter, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The material differences between the current rights of Oruka stockholders under the Oruka Charter and Oruka Bylaws and their rights as ARCA stockholders, after the Merger, under the ARCA Charter and ARCA Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of ARCA or Oruka before the Merger and being a stockholder of the combined company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Organizational Documents</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">The rights of ARCA stockholders are governed by the ARCA Charter, ARCA Bylaws and the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The rights of Oruka stockholders are governed by the Oruka Charter, Oruka Bylaws and the DGCL.&#160;Rights of certain holders of Oruka preferred stock are governed by the Investors&#8217; Rights Agreement (the &#8220;Oruka IRA&#8221;), the Right of First Refusal and Co<span class="nobreak">-Sale</span> Agreement (the &#8220;Oruka ROFR Agreement&#8221;), and the Voting Agreement, each dated as of March&#160;6, 2024.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Capital Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that ARCA is authorized to issue is 105,000,000, of which 100,000,000<span class="nobreak"> </span>shares are common stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.001 per share.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Oruka is authorized to issue is 85,000,000, of which 65,000,000<span class="nobreak"> </span>shares are common stock, par value $0.0001 per share, and 20,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Oruka common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Oruka preferred stock that may be required under the Oruka Charter) the affirmative vote of the holders of shares of Oruka capital stock representing a majority of the votes represented by all outstanding shares of Oruka capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">301</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized common stock consists of 100,000,000<span class="nobreak"> </span>shares of common stock, par value $0.001 per share. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Each holder of a share of ARCA common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka&#8217;s authorized common stock consists of 65,000,000<span class="nobreak"> </span>shares of common stock, par value $0.0001 per share. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Each holder of a share of Oruka common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preferred Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized preferred stock consists of 5,000,000<span class="nobreak"> </span>shares of preferred stock of which ARCA&#8217;s board of directors has designated 135,000<span class="nobreak"> </span>shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221; </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">No shares of ARCA Series&#160;A Convertible Preferred Stock or undesignated preferred stock are currently outstanding. ARCA&#8217;s board of directors is authorized to issue shares of undesignated preferred stock in one or more series and to fix the designations, powers, preferences and relative, participating, optional and other rights, and any qualifications, limitations and restrictions, on such shares. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">In connection with the Merger, ARCA&#8217;s board of directors intends to designate shares of undesignated preferred stock as Series&#160;B Non-Voting Convertible Preferred Stock through a certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;F </span>(the &#8220;Certificate of Designation&#8221;). No shares of Series&#160;B Non-Voting Convertible Preferred Stock are currently authorized or outstanding. As long as any shares of Series&#160;B Non-Voting Preferred Stock are outstanding, ARCA will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series&#160;B Non-Voting Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Non-Voting Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the ARCA Charter or ARCA Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of ARCA preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the ARCA Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series&#160;B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Non-Voting Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">All of Oruka&#8217;s 20,000,000<span class="nobreak"> </span>shares of preferred stock are designated as shares of &#8220;Series&#160;A Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. Each holder of a share of Oruka preferred stock is entitled to cast the number of votes equal to the number of whole shares of Oruka common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">302</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA with or into another entity or any stock sale to, or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority on an as<span class="nobreak">-converted-to-ARCA</span> common stock basis of the capital stock of ARCA, immediately after such transaction or (iv)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Number and Qualification of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of ARCA directors is not less than two (2)&#160;nor more than ten (10), the exact number determined from time to time by resolution of ARCA&#8217;s board of directors, acting by the affirmative vote of a majority of the directors. The ARCA&#8217;s board of directors currently consists of five (5)&#160;members. No decrease in the authorized number of directors constituting ARCA&#8217;s board of directors will shorten the term of any incumbent director. Directors of ARCA need not be stockholders of ARCA.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of directors of Oruka is established from time to time by the board of directors. Oruka&#8217;s board of directors currently consists of six members.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Structure of Board of Directors; Term of Directors; Election of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Election of directors need not be by written ballot. The term of office of the first class expired at the first annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004, the term of office of the second class expired at the second annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004 and the term of office of the third class expired at the third annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004.&#160;At each succeeding annual meeting of stockholders, or special meeting in lieu thereof, directors are elected for a full term of three&#160;years to succeed the directors of the class whose terms expire at such annual meeting or special meeting lieu of thereof. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The holders of record of the shares of Oruka&#8217;s Series&#160;A Preferred Stock, voting together exclusively and as a separate class, are entitled to elect one director of Oruka. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as<span class="nobreak">-converted</span> to Common Stock basis, shall be entitled to elect the balance of the total number of directors.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Removal of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of sixty<span class="nobreak">-six</span> and two<span class="nobreak">-third</span> percent or more of the voting power of the outstanding shares of capital stock of ARCA entitled to vote at an election of directors, unless otherwise provided under the DGCL or the ARCA Charter.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any one or more or all of the Oruka directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors, except that any director elected by the holders of Series&#160;A Preferred Stock may be removed without cause only by the affirmative vote of the holders of a majority of the outstanding shares of Series&#160;A Preferred Stock, together as a single class on an as<span class="nobreak">-converted</span> to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">303</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Vacancies on the Board of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time by giving notice in writing to ARCA Chairperson of the board of directors, if one is elected, the ARCA Vice Chairperson of the board of directors, if one is elected, the Chief Executive Officer or the President. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Any vacancies and any newly created directorships resulting from any increase in the number of directors, will be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, or by a sole remaining director, and not by the ARCA stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to Oruka. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Series&#160;A Preferred Stock can be filled by either (A)&#160;the vote or written consent in lieu of a meeting of the stockholders entitled elect those directors, or (B)&#160;the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">If the holders of shares of Series&#160;A Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;A Preferred Stock elect a person to fill such directorship.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action by Written Consent</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">No action may be taken by the ARCA stockholders except at an annual or special meeting of the ARCA stockholders called in accordance with the ARCA Bylaws, and no action may be taken by the ARCA stockholders by written consent in lieu of a meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Oruka, a written consent signed by a sufficient number of stockholders to take action are delivered to Oruka.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">304</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Quorum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Subject to the provisions of the ARCA Bylaws, ARCA Charter and the DGCL as to the vote that is required for a specified action, the presence in person or by proxy of the holders of at least one<span class="nobreak">-third</span> of the outstanding shares of ARCA entitled to vote at any meeting of stockholders shall constitute a quorum for the transaction of business.&#160;In the absence of a quorum, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, regardless of whether or not they constitute a quorum, or if no stockholders are present, any officer entitled to preside at or act as secretary of the meeting, may adjourn the meeting to another time and place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Special Meetings of Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders may be called by ARCA&#8217;s board of directors, Chief Executive Officer, President, or by holders of ARCA common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by Oruka&#8217;s board of directors or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Notice of Stockholder Meetings</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Notice of all meetings of ARCA stockholders shall state the place, if any, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote at the meeting, and unless otherwise provided in the DGCL, the ARCA Charter or the ARCA Bylaws, the notice shall be given not less than ten nor more than sixty&#160;days before the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting, and, if mailed, shall be deposited in the United&#160;States mail, postage prepaid, directed to the stockholder at the stockholder&#8217;s address as it appears on the records of ARCA.&#160;The notice to stockholders for any meeting will be given in accordance with Section&#160;232 of the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, notice of the place, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">305</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Nominations of persons for election to ARCA&#8217;s board of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i)&#160;pursuant to the corporation&#8217;s notice of meeting, (ii)&#160;by or at the direction of ARCA&#8217;s board of directors, or (iii)&#160;by any stockholder of ARCA who is a stockholder of record at the time of giving notice provided for in the ARCA Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the ARCA Bylaws as to such nomination or business. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">For the avoidance of doubt, the foregoing clause (ii)&#160;shall be the exclusive means for a stockholder to bring nominations or business properly before an annual meeting of stockholders (other than matters properly brought under Rule&#160;14a<span class="nobreak">-8</span> (or any successor rule) under the Exchange&#160;Act).</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Neither the Oruka Charter nor the Oruka Bylaws contain advance notice requirements for stockholder proposals.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Certificate of Incorporation</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The ARCA Charter provides that it may be amended by the affirmative vote of the majority of the voting rights of all classes of capital stock entitled to vote, provided, however, that no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the holders of 66 2/3% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the ARCA Charter relating to: (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend the ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of ARCA&#8217;s directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of ARCA&#8217;s directors, officers and other persons.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as<span class="nobreak">-converted</span> to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Oruka Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Oruka unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Bylaws</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by law, the ARCA Bylaws may be amended or repealed by ARCA&#8217;s board of directors. The ARCA Bylaws may also be amended or repealed by the stockholders by the affirmative vote of not less than&#160;66<span class="nobreak">-2</span>/3% of the outstanding shares of capital stock entitled to vote, voting together as a single class.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Bylaws may be amended or repealed by Oruka&#8217;s board of directors or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Oruka Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">306</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Limitation on Director and Officer Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of Article&#160;IX of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a director at the time of such amendment, repeal or modification.</p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended, an officer of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as an officer. Any amendment, repeal or modification of Article XIII of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as an officer at the time of such amendment, repeal or modification.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by law, a director or officer of Oruka shall not be personally liable to Oruka or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Oruka shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. Any amendment, repeal or elimination of the foregoing provisions by the Oruka stockholders shall not adversely affect any right or protection of a director of Oruka existing at the time of, or increase the liability of any Oruka director with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA will indemnify any person who was or is a party or is threatened to be made a party to, or otherwise becomes involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and whether internal or external to ARCA (a &#8220;Proceeding&#8221;), by reason of the fact that the person is or was a director, officer, employee, or other agent of ARCA, or is or was serving at the request of ARCA as a director, officer, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise (any such person, an &#8220;Agent of ARCA&#8221;). Expenses incurred by an Agent in connection with a Proceeding shall be paid by ARCA as they are incurred and in advance of the final disposition of such Proceeding, subject to certain conditions. These rights to indemnification and advancement of expenses shall not be deemed exclusive of any other rights to which a person seeking indemnification or advancement of expenses may be entitled. ARCA has the power to purchase and maintain insurance on behalf of any person who is or was an Agent of ARCA against any liability asserted against the person and incurred by the person in any such capacity, or arising out of the person&#8217;s status as such, whether or not ARCA would have the power to indemnify the person against such liability.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by applicable law, Oruka is authorized to provide indemnification of (and advancement of expenses to) its directors, officers and agents (and any other persons to which the DGCL permits Oruka to provide indemnification) through Oruka Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL.&#160;Any amendment, repeal, modification or elimination of the foregoing provisions shall not (a)&#160;adversely affect any right or protection of any director, officer or other agent of Oruka existing at the time of such amendment, repeal, modification or elimination; or (b)&#160;increase the liability of any Oruka director, officer or agent with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal, modification or elimination. The Oruka Bylaws require Oruka to indemnify, to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended, and except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Oruka or is or was serving at the request of Oruka as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">307</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee (an &#8220;indemnitee&#8221;). The Oruka Bylaws also provide that an indemnitee will have the right to be paid by Oruka expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Oruka of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Oruka Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Oruka Charter, the Oruka Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any outstanding shares of Series&#160;A Convertible Preferred Stock or undesignated preferred stock. When the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock is issued in connection with the Merger, the holders of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock will have the right to convert such shares into ARCA common stock at any time a ratio of 1<span class="nobreak"> </span>share of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to 1000<span class="nobreak"> </span>shares of ARCA common stock.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Oruka Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm<span class="nobreak">-commitment</span> underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds to Oruka and in connection with such offering the shares of Oruka common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New&#160;York Stock Exchange or another exchange or marketplace approved by Oruka&#8217;s board of directors; and (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, all outstanding shares of preferred stock will automatically be converted into shares of common stock, at the then effective conversion rate as calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">308</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of First Refusal</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of first refusal in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement wishing to transfer any shares of Oruka capital stock (other than any shares of preferred stock or common stock that are issued or issuable upon conversion of preferred stock) must first provide Oruka with the right to purchase such shares. In such an event, if Oruka does not elect to exercise its right of first refusal in full, certain stockholders party to the Oruka ROFR Agreement have a secondary refusal right to purchase all or any portion of such shares of Oruka capital stock which are proposed for sale or transfer and not purchased by Oruka pursuant to its right of first refusal.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of Co</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Sale</span></span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of co<span class="nobreak">-sale</span> in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement have a right of co<span class="nobreak">-sale</span> with respect to any Oruka capital stock proposed to be transferred or sold that is not either purchased by Oruka by exercise of its right of first refusal (as further described above) or by any Oruka stockholder by exercise of their secondary refusal right (as further described above), each pursuant to the Oruka ROFR Agreement.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preemptive Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA stockholders do not have preemptive rights. Thus, if additional shares of ARCA common stock are issued, the current holders of ARCA common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Pursuant to the Oruka IRA, if Oruka proposes to offer or sell certain new equity securities, Oruka must first offer such securities to each Major Investor (as defined in the Oruka IRA, who will then have a right to purchase securities in such new offering equal to the proportion of the ownership interest of such Major Investor prior to such offering.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Distributions to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Dividends upon ARCA capital stock, subject to the provisions of the ARCA Charter and applicable law, if any, may be declared by ARCA&#8217;s board of directors. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the ARCA Charter and applicable law. ARCA&#8217;s board of directors may fix a record date for the determination of holders of ARCA capital stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60&#160;days prior to the date fixed for the payment thereof.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">309</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exclusive Forum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have an exclusive forum in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that, unless Oruka consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Oruka, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Oruka to Oruka or Oruka&#8217;s stockholders, (iii)&#160;any action asserting a claim against Oruka, its directors, officers or employees arising pursuant to any provision of the DGCL, the Oruka Charter or the Oruka Bylaws or (iv)&#160;any action asserting a claim against Oruka, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Oruka, except for, as to each of (i)&#160;through (iv)&#160;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Oruka&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Oruka&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Oruka or its directors, officers or other employees, which may discourage such lawsuits against Oruka and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Registration Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any registration rights in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Under the Oruka IRA, certain holders of Oruka capital stock that are party to the Oruka IRA, have certain registration rights, including the right to demand that Oruka file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Oruka is otherwise filing, so<span class="nobreak">-called</span> &#8220;piggyback&#8221; registration rights. The registration rights granted under the Oruka IRA will terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation Event (as such term is defined in the Oruka Charter), (ii)&#160;such time after Oruka&#8217;s initial public offering when all registrable securities could be sold under Rule&#160;144 of the Securities Act or a similar exemption without limitation during a three<span class="nobreak">-month</span> period without registration or (iii)&#160;the third anniversary of Oruka&#8217;s initial public offering.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">310</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Transfer Restrictions Applicable to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of ARCA are transferable in the manner prescribed by the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of Oruka are transferable in the manner prescribed by the DGCL, subject to additional limits on certain holders of Oruka capital stock party to the Oruka ROFR Agreement and Oruka IRA.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Rights Plan</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a stockholder rights plan in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka does not have a stockholder rights plan in place.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">311</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T6"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Security Ownership of Certain Beneficial Owners</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding the ownership of ARCA common stock as of May&#160;3, 2024, by: (i)&#160;each director of ARCA, (ii)&#160;each ARCA named executive officer, (iii)&#160;all executive officers and directors of ARCA as a group and (iv)&#160;all those known by ARCA to be beneficial owners of more than five percent of its common stock. Unless otherwise noted below, the address of each beneficial owner listed on the table is c/o ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has determined beneficial ownership in accordance with the rules of the SEC and includes voting or investment power with respect to ARCA common stock. Except as indicated by the footnotes below, ARCA believes, based on the information furnished to it, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of ARCA common stock that they beneficially own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders of ARCA and Schedules 13G or 13D, Form&#160;4s or other ownership reports filed with the SEC.&#160;Except as contemplated by the Merger and the Merger Agreement, ARCA does not know of any arrangements, including any pledge by any person of its securities, the operation of which may at a subsequent date result in a change of control of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In computing the number of shares of ARCA common stock beneficially owned by a person and the percentage ownership of that person, ARCA deemed outstanding shares of ARCA common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60&#160;days of May&#160;3, 2024. ARCA did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The percentages below are based on 14,507,143<span class="nobreak"> </span>shares of ARCA common stock outstanding as of May&#160;3, 2024.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares<br/>Beneficially<br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage<br/>Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Named Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, M.D., Ph.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">254,274</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">97,146</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">All current directors and executive officers as a group (7 persons)</span><span class="Superscript" style="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,371,408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">5% Stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Funicular Funds, LP<span class="Superscript" style="vertical-align:super;font-size:58%;">(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Adage Capital<span class="Superscript" style="vertical-align:super;font-size:58%;">(11)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,200,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Janus Henderson<span class="Superscript" style="vertical-align:super;font-size:58%;">(12)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,080,107</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Allostery Investments<span class="Superscript" style="vertical-align:super;font-size:58%;">(13)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,065,016</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Avidity Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(14)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock<span class="Superscript" style="vertical-align:super;font-size:58%;">(15)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">754,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes the following: (i)&#160;1,109<span class="nobreak"> </span>shares owned by Investocor Trust, of which Dr.&#160;Bristow is the sole trustee; (ii)&#160;1,414<span class="nobreak"> </span>shares owned by NFS as Custodian for Michael Bristow&#8217;s IRA; and (iii)&#160;options to purchase 249,466<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 92,791<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 57,146<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">312</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,499<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024. Also see Footnote (10)&#160;below.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 8,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See Notes (2)&#160;through (8)&#160;above.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024 by Jacob Ma<span class="nobreak">-Weaver</span> and shares reported on the Form&#160;4 filed on December&#160;19, 2022 by The Funicular Funds, LP (the &#8220;Fund&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span>, reporting stock ownership as of December&#160;16, 2022. The Fund, the Funicular Fund (&#8220;Funicular&#8221;), Cable Car Capital LLC (&#8220;Cable Car&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span> may be deemed to be a member of a Section&#160;13(d)&#160;group that may be deemed to collectively beneficially own more than 10% of ARCA&#8217;s outstanding shares of common stock. Despite such shared beneficial ownership, the reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Funicular, as a feeder fund to the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Cable Car, as the general partner of the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Mr.&#160;Ma<span class="nobreak">-Weaver</span>, as the Managing Member of Cable Car, may be deemed to beneficially own the securities directly owned by the Fund.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(11)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13D filed on April&#160;5, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Adage Capital Management, L.P. (&#8220;ACM&#8221;), Robert Atchinson, and Phillip Gross. ACM and Messrs. Consists of 1,200,000 shares of ARCA common stock held directly by Adage Capital Partners, L.P. (&#8220;ACP&#8221;). Adage Capital Partners GP, L.L.C. (&#8220;ACPGP&#8221;) is the general partner of ACP. ACM is the investment manager of ACP. Adage Capital Advisors, L.L.C. (&#8220;ACA&#8221;) is managing member of ACPGP. Adage Capital Partners LLC (&#8220;ACPLLC&#8221;) is general partner of ACM. Messrs. Atchinson and Gross are managing members of ACA and ACPLLC. Messrs. Atchinson and Gross may be deemed to have shared voting power and dispositive power over the shares held directly by ACP. The address of each of the entities and persons listed above is 200&#160;Clarendon Street, 52<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, Boston, Massachusetts 02116.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(12)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;11, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Janus Henderson Group plc (&#8220;JHG&#8221;) and Janus Henderson Biotech Innovation Master Fund Ltd (&#8220;JHB&#8221;). JHG and JHB each reported that they hold shared voting power and shared dispositive power with respect to 1,080,107 shares of ARCA common stock. JHG has a 100% ownership stake in Janus Henderson Investors U.S.&#160;LLC (&#8220;JHIUS&#8221;), Janus Henderson Investors UK Limited and Janus Henderson Investors Australia Institutional Funds Management Limited, (each an &#8220;Asset Manager&#8221; and collectively as the &#8220;Asset Managers&#8221;). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as &#8220;Managed Portfolios&#8221;). As a result of its role as investment adviser or sub<span class="nobreak">-adviser</span> to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 1,080,107 shares of ARCA common stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of JHG is 201 Bishopsgate, EC2M 3AE, United Kingdom, and the address of JHB is C/O Janus Henderson Investors US LLC, 151 Detroit Street, Denver, Colorado 80206.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(13)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;15, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Allostery Master Fund LP (&#8220;Allostery Master Fund&#8221;), Allostery Investments LP (&#8220;Allostery Investments&#8221;), Allostery Investments GP LLC (&#8220;Allostery Investments GP&#8221;), Christopher Staral, and David Modest. Allostery Master Fund, Allostery Investments LP, Allostery Investments GP, and Messrs. Staral and Modest each reported that they hold shared voting power and shared dispositive power with respect to 1,065,016 shares of ARCA common stock. Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Master Fund. Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investments. Messrs. Modest and Staral, as the managing members of Allostery Investments GP, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investment GP.&#160;The address of each of the entities and persons listed above is One Stamford Plaza, 9<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Floor, 263 Tresser Boulevard, Stamford, Connecticut 06901.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(14)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;9, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund&#160;I LP, David Witzke, and Michael Gregory, which each reported that they hold shared voting power and shared dispositive power with respect to 1,000,000 shares of ARCA common stock. Avidity Partners Management (GP) LLC serves as the general partner of Avidity Partners Management LP. Avidity Capital Partners Fund (GP) LP serves as the general partner of Avidity Private Master Fund I LP. Avidity Capital Partners (GP) LLC serves as the general partner of Avidity Capital Partners Fund (GP) LP. Messrs. Witzke and Gregory serve as the managing members of Avidity Partners Management (GP) LLC and Avidity Capital Partners (GP) LLC. The address of each of the entities and persons listed above is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">313</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(15)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;29, 2024 reporting stock ownership as of April&#160;17, 2024 with respect to the following reporting persons: Venrock Healthcare Capital Partners&#160;III, L.P., VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management&#160;III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, which each reported that they hold shared voting power and shared dispositive power with respect to 754,669 shares of ARCA common stock, consisting of (i)&#160;164,442 shares held by Venrock Healthcare Capital Partners&#160;III, L.P., (ii)&#160;16,450 shares held by VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, and (iii)&#160;573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.&#160;VHCP Management&#160;III, LLC is the general partner of Venrock Healthcare Capital Partners&#160;III, L.P. and the manager of VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC.&#160;VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P.&#160;Messrs. Shah and Koh are the voting members of VHCP Management&#160;III, LLC and VHCP Management EG, LLC.&#160;The address of each of the entities and persons listed above is 7&#160;Bryant Park, 23<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New&#160;York, New&#160;York 10018.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">314</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T5"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information known to Oruka regarding beneficial ownership of Oruka capital stock on an as<span class="nobreak">-converted</span> to Oruka common stock basis as of May&#160;3, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is known by Oruka to be the beneficial owner of more than 5% of Oruka capital stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each of Oruka&#8217;s directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each Oruka named executive officer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of Oruka&#8217;s directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to Oruka&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of May&#160;3, 2024. Shares of Oruka&#160;common stock that an individual has the right to acquire within 60&#160;days of May&#160;3, 2024 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The percentage of beneficial ownership shown prior to the Merger and Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing in the table below is based on 29,460,019<span class="nobreak"> </span>shares of Oruka&#160;common stock deemed to be outstanding as of May&#160;3, 2024, assuming the conversion of all outstanding shares of Oruka&#160;preferred stock into shares of Oruka&#160;common stock. The following table does not reflect any shares of Oruka&#160;common stock or Oruka&#160;pre<span class="nobreak">-funded</span> warrants that such holders have agreed to purchase in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II, L.P.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon Therapeutics, Inc.<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Holding LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">McKenna Capital Partners LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (9 persons)<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,640,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">73.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000 Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount GP&#160;II is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management, as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">315</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paragon. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak, and Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paruka. Paruka is managed by its sole manager, Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by McKenna Capital Partners LLC (&#8220;McKenna Capital Partners&#8221;). Mark McKenna is the Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office. Mr.&#160;McKenna disclaims beneficial ownership of such shares of Oruka common stock except to the extent of his pecuniary interest therein. The principal business address for these persons and entities is PO Box 9542, Rancho, Santa Fe, CA 92067.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i)&#160;20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock and (ii)&#160;1,640,810<span class="nobreak"> </span>shares of Oruka common stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">316</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T4"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;&#160;&#160;&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is expected by ARCA and Oruka to be the beneficial owner of more than 5% of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a director of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a named executive officer of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of the combined company&#8217;s excepted directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to the combined company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024. Shares of the combined company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To ARCA&#8217;s and Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table lists applicable percentage ownership based on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock expected to be outstanding upon consummation of the merger, after giving effect to the anticipated ARCA reverse stock split and the Oruka pre<span class="nobreak">-closing</span> financing. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. The table below assumes that, based on ARCA&#8217;s and Oruka&#8217;s capitalization as of May&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio is estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock, prior to giving effect to the anticipated ARCA reverse stock split. The estimated exchange ratio was derived on a fully<span class="nobreak">-diluted</span> basis as of May&#160;3, 2024, using a stipulated value of Oruka of approximately $175.0&#160;million and of ARCA of approximately $11.0<span class="nobreak"> </span>million, assuming net cash of $5.0&#160;million as of closing. The final exchange ratio is subject to adjustment prior to closing of the Merger based upon ARCA&#8217;s net cash at closing and the aggregate proceeds from the sale of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">317</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> persons)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">318</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T3"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. will pass upon the validity of ARCA&#8217;s common stock offered by this proxy statement/prospectus.</p>
		<a id="T2"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXPERTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of ARCA biopharma, Inc. as of December&#160;31, 2023 and 2022 and for each of the&#160;years in the two<span class="nobreak">-year</span> period ended December&#160;31, 2023, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statement of Oruka Therapeutics, Inc. as of February&#160;6, 2024 included in this proxy statement/prospectus has been so included in reliance on the report (which contains an explanatory paragraph relating to Oruka&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">319</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T1"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the informational requirements of the Exchange&#160;Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains ARCA&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also makes available free of charge on or through its website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, its Annual Reports on Form&#160;10<span class="nobreak">-K</span>, Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>, Current Reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act as soon as reasonably practicable after ARCA electronically files such material with or otherwise furnishes it to the SEC.&#160;The website addresses for the SEC and ARCA are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has filed with the SEC a registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock) to be issued to Oruka stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about ARCA and ARCA common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has supplied all information contained in this proxy statement/prospectus relating to ARCA and Oruka has supplied all information contained in this proxy statement/prospectus relating to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you would like to request documents from ARCA or Oruka, please send a request in writing or by telephone to either ARCA or Oruka at the following addresses:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>Attn: Corporate Secretary<br/>Tel: (720)&#160;940-2100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Oruka Therapeutics, Inc.<br/>855 Oak Grove Ave., Suite 100 <br/>Menlo Park, CA 94025 <br/>Attn: Secretary<br/>Tel: (650)&#160;606<span class="nobreak">-7910</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a ARCA stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact ARCA&#8217;s proxy solicitor, <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at the following address and telephone number:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">Banks and Brokers Call:<br/>Stockholders Call Toll Free: </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">320</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9991"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR&#160;2025 ANNUAL MEETING</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an ARCA stockholder would like ARCA to consider including a proposal in ARCA&#8217;s proxy statement for its 2025 annual meeting pursuant to Rule&#160;14a<span class="nobreak">-8</span> of the Exchange&#160;Act, then the proposal must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices on or before&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. In addition, stockholder proposals must comply with the requirements of Rule&#160;14a<span class="nobreak">-8</span> regarding the inclusion of stockholder proposals in company<span class="nobreak">-sponsored</span> proxy materials. Proposals should be addressed to:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.<br/>Attention: Corporate Secretary<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, Colorado, 80021</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in ARCA&#8217;s proxy statement. In order to be properly brought before ARCA&#8217;s 2025 annual meeting, the stockholder must provide timely written notice to ARCA&#8217;s corporate secretary, at ARCA&#8217;s principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the ARCA Bylaws. To be timely, a stockholder&#8217;s written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA holds its 2025 annual meeting more than 30&#160;days before, or more than 60&#160;days after, the one<span class="nobreak">-year</span> anniversary of this year&#8217;s annual meeting, then such written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than the 90<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than close of business on the later of: (i)&#160;the 60<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting or (ii)&#160;the 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day following the earlier of the&#160;day on which public announcement of the date of ARCA&#8217;s 2025 annual meeting is first made or notice is first given.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Availability of Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the ARCA Bylaws may be obtained by accessing ARCA&#8217;s filings on the SEC&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>. You may also contact ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Householding of Proxy Materials</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the ARCA special meeting, a number of brokers with account holders who are ARCA stockholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or ARCA.&#160;Direct your written request to Secretary, ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021 or contact Investor Relations at (720)&#160;940<span class="nobreak">-2100</span>. ARCA undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">321</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T111"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS </span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended December</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T201">Report of Independent Registered Public Accounting Firm, KPMG LLP</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T202">Balance Sheets as of December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T203">Statements of Operations for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T204">Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T205">Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T206">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-7</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three months ended March</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 and 2023 Interim Financial Statements (Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T207">Balance Sheets as of March 31, 2024 and December 31, 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T208">Statements of Operations for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T209">Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 and interim&#160;periods </a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T210">Statements of Cash Flows for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T211">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-23</p>
					</td>
				</tr>

		</table>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of February 6, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T212">Report of Independent Registered Public Accounting Firm</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T213">Balance Sheet as of February&#160;6, 2024</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T214">Notes to Financial Statement</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-36</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from February&#160;6, 2024 (Inception) to March&#160;31, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T215">Unaudited Condensed Balance Sheets</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-41</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T216">Unaudited Condensed Statement of Operations and Comprehensive Loss</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T217">Unaudited Condensed Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-43</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T218">Unaudited Condensed Statement of Cash Flows</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T219">Notes to Unaudited Condensed Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-45</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T201"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Stockholders and Board of Directors <br/>ARCA biopharma, Inc.:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Opinion on the Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of ARCA biopharma, Inc. (the Company) as of December&#160;31, 2023 and December&#160;31, 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the&#160;years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and December&#160;31, 2022, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S.&#160;generally accepted accounting principles.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">/s/ KPMG LLP </p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2006.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boulder, Colorado <br/>February&#160;1, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T202"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-36462">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-36463">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-36464">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-36465">254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-36466">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-36467">42,699</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36468">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36469">343</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36470">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36471">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-36472">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-36473">18</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-36474">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-36475">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-36476">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-36477">334</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36478">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36479">173</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36480">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36481">216</ix:nonFraction>&#160;at December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36482">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36483">625</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36484">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36485">1,132</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-36486">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-36487">280</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-36488">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-36489">1,412</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36490"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36491">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36492"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36493">5</ix:nonFraction></ix:nonFraction>&#160;million shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-36494"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-36495"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36496"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36497">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares&#160;issued or outstanding at December&#160;31, 2023 and 2022</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-3">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-4">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36498"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36499">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36500"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36501">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-36502"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36503">14,501,143</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-36504"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36505">14,410,143</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-36506">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-36507">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-36508">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-36509">225,061</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-36510">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-36511">183,402</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36512">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36513">41,673</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-36514">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-36515">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T203"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-36516">6,283</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-36517">5,847</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" sign="-" unitRef="usd" id="ixv-36518">91</ix:nonFraction>)&#160;and $<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-36519">432</ix:nonFraction> as of the&#160;years&#160;ended December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-36520">1,013</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-36521">4,749</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-36522">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-36523">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36524">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36525">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-36526">1,957</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-36527">675</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-6">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-36528">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36529">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36530">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7">	<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-36531">0.37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-36532">0.69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9">	<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-36533">14,415,877</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-36534">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T204"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional<br/>Paid-In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2021</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36535">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36536">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36537">224,505</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36538">173,476</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36539">51,043</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-15">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36540">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-16">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36541">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-17">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-18">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36542">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36543">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36544">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36545">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36546">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36547">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36548">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-36549">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-19">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-20">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-21">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-22">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-23">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36550">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-24">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36551">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-25">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-26">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36552">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36553">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36554">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36555">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36556">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36557">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36558">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T205"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36559">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36560">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36561">15</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36562">20</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-36563">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-36564">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-36565">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-36566">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from disposal of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-51; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" sign="-" unitRef="usd" id="ixv-36567">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-36568">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-36569">808</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-36570">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-52; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-36571">28</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-36572">783</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-36573">73</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-36574">752</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-36575">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-36576">934</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-36577">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-36578">10,912</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-53; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36579">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-54; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-36580">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-55; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-56; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-36581">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-36582">10,914</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36583">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36584">53,359</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36585">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36586">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-57; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-58; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-59; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-60; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T206"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-21079"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-21082"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-21090"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-36587">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1"><ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-21140"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-21146"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_UseOfEstimates-c6_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-21151"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p></ix:nonNumeric>
		<ix:continuation id="_UseOfEstimates-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-21156"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p></ix:nonNumeric>
		<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ConcentrationRiskCreditRisk-c6_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-21161"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-36588">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-21167"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-21186"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-21192"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_2" id="_LesseeLeasesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-21201"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-21206"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p></ix:nonNumeric>
		<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in <ix:nonFraction contextRef="c6" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-36589">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-21211"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p></ix:continuation>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p></ix:continuation>
		<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c6_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-21234"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></ix:nonNumeric>
		<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-21242"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></ix:nonNumeric>
		<ix:continuation id="_IncomeTaxPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-21247"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-36590">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36591">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36592">704,960</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-70">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36593">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36594">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36595">795,960</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-21313"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-36596">37.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-36597">42.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-21334"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-36598">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36599">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36600">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36601">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36602">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36603">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36604">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36605">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36606">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36607">44</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36608">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36609">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36610">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36611">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36612">229</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36613">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36614">204</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36615">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36616">25</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36617">15</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36618">20</ix:nonFraction>,000, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21494"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" sign="-" unitRef="usd" id="ixv-36619">91,000</ix:nonFraction>) and $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-36620">432,000</ix:nonFraction>, respectively. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-36621">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-21507"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-36622">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-36623">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-36624">86,000</ix:nonFraction> was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-36625">311,000</ix:nonFraction>, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-36626">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" unitRef="pure" id="ixv-36627">67</ix:nonFraction>%, or <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" unitRef="pure" id="ixv-36628">12</ix:nonFraction> employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-36629">755,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-36630">470,000</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-36631">285,000</ix:nonFraction> were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-36632">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is <ix:nonNumeric contextRef="c85" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-36633">42&#160;months</ix:nonNumeric> beginning October&#160;1, 2020 and includes an <ix:nonNumeric contextRef="c86" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-21524">option to renew for an additional <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-36634">36</ix:nonNumeric><span class="nobreak"> </span>month term at the then prevailing rental rate.</ix:nonNumeric> The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-36635">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c88" format="ixt-sec:durwordsen" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-36636">29&#160;months</ix:nonNumeric> and terminated in October&#160;2023. <ix:nonNumeric contextRef="c6" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-21526">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-36637">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-36638">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-36639">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-36640">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-36641">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-36642">314</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-36643">34</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-36644">76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-36645">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-36646">119,000</ix:nonFraction> and $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-36647">125,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-36648">280,000</ix:nonFraction> and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-36649">127,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-36650">131,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is <ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-36651">3.2</ix:nonNumeric>&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-36652">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-36653">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-21637"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36654">0.001</ix:nonFraction> per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell" scale="6" unitRef="usd" id="ixv-36655">54.0</ix:nonFraction>&#160;million (the &#8220;Shares&#8221;).</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to <ix:nonFraction contextRef="c93" decimals="3" format="ixt:num-dot-decimal" name="abio:SellingCommissionPerAdditionalSharesSoldPercentage" scale="-2" unitRef="pure" id="ixv-36656">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-36657"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-36658">No</ix:nonFraction></ix:nonFraction> sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-21664"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is <ix:nonFraction contextRef="c96" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-36659">1,167,425</ix:nonFraction><span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36660">601,900</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36661">3.45</ix:nonFraction> per share were outstanding under the Equity Plan, and <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-36662">459,718</ix:nonFraction><span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least <ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-36663">100</ix:nonFraction>% of the fair market value on the grant date and exercise price of options granted to <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="abio:PercentageHoldingForStockOptionsExercisePrice" scale="-2" unitRef="pure" id="ixv-36664">10</ix:nonFraction>% (or greater) stockholders must be at least <ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-36665">110</ix:nonFraction>% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36666">14,807</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36667">57.73</ix:nonFraction> per share were outstanding under the 2013 plan.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did <ix:nonFraction contextRef="c103" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-36668">no</ix:nonFraction>t grant options in 2023. ARCA granted options to purchase an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="abio:PurchaseAggregateShares" scale="0" unitRef="shares" id="ixv-36669">60,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-21695">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-36670">5.5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-36671">107</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-36672">3.56</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-36673">0</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-36674">1.87</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-36675">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36676">904,123</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36677">5.59</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-36678">60,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36679">2.31</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-76">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-77">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-36680">259,163</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36681">4.74</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36682">704,960</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36683">5.62</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-21887"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p></ix:nonNumeric>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-36684">18</ix:nonFraction></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-78">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-79">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-80">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-81">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-36685">88,253</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36686">11.68</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36687">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36688">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-21970"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p></ix:nonNumeric>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-82">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-36689">463,068</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36690">5.28</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-21993"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p></ix:nonNumeric>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-83">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-36691">616,661</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36692">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-22016"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p></ix:nonNumeric>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-84">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-36693">367,000</ix:nonFraction> which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c108" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-36694">1.1</ix:nonNumeric>&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-36695">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-85">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-86">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-36696">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-36697">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-87">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-88">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-89">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-90">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-36698">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-36699">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-91">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-92">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-36700">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-36701">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-93">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-94">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-95">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-96">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was <ix:nonFraction contextRef="c107" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" unitRef="usd" id="ixv-36702">no</ix:nonFraction> unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-22201">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36703">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36704">423</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36705">160</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36706">133</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36707">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36708">556</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-22264"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a <ix:nonNumeric contextRef="c6" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" id="ixv-36709">matching contribution equal to <ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-36710">100</ix:nonFraction>% of the employee&#8217;s first <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-36711">3</ix:nonFraction>% of the employee&#8217;s contributions and <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-36712">50</ix:nonFraction>% of the employee&#8217;s next <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-36713">2</ix:nonFraction>% of contributions.</ix:nonNumeric> ARCA adopted the plan in 2006 and contributed $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-36714">56,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-36715">96,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22268"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-36716">208.1</ix:nonFraction>&#160;million, and approximately $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" unitRef="usd" id="ixv-36717">2.4</ix:nonFraction>&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. <ix:nonNumeric contextRef="c6" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-36718">The net operating loss carryforwards beginning in 2018, have no expiration.</ix:nonNumeric> <ix:nonNumeric contextRef="c116" continuedAt="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="ixv-36719">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_2" id="_IncomeTaxDisclosureTextBlock-c6_cont_1"><ix:continuation id="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance" scale="6" unitRef="usd" id="ixv-36720">55.5</ix:nonFraction>&#160;million at December&#160;31, 2023, reflecting an increase of approximately $<ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" scale="6" unitRef="usd" id="ixv-36721">1.2</ix:nonFraction>&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-36722">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-36723"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-36724">21</ix:nonFraction></ix:nonFraction>% for 2023 and 2022, as a result of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-36725">1,121</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-36726">2,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-36727">192</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-36728">357</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-101">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-102">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-36729">47</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-36730">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-36731">107</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-36732">186</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-36733">1,159</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-36734">2,254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-103">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-104">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_IncomeTaxDisclosureTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-36735">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-36736">51,190</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-36737">50,008</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-36738">371</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-36739">393</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-36740">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-36741">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-36742">951</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-36743">979</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-36744">354</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-36745">356</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-36746">232</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-36747">205</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-36748">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-36749">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-36750">69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-36751">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-36752">55,594</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-36753">54,461</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-36754">55,531</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-36755">54,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-36756">63</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-36757">89</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36758">61</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36759">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36760">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36761">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-36762"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-36763">no</ix:nonFraction></ix:nonFraction> reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. <ix:nonFraction contextRef="c6" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-36764"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-36765">No</ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T207"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31, <br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-36766">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-36767">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-36768">767</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-36769">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-36770">36,670</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-36771">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36772">17</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-36773">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36774">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36775">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-36776">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-36777">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-36778">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-36779">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-36780">529</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-36781">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36782">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36783">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36784">968</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36785">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36786">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-36787">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-5">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-36788">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-36789">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-36790">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36791"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36792">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36793"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-36794">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at March&#160;31,&#160;2024 and December&#160;31, 2023; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-36795"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-36796"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36797"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36798">14,501,143</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-36799">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-36800">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-36801">225,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-36802">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-36803">190,750</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-36804">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36805">35,125</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36806">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-36807">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-36808">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T208"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-36809">2,317</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-36810">1,406</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-36811">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-36812">108</ix:nonFraction> as of March&#160;31,&#160;2024&#160;and 2023, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-36813">165</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-36814">390</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-36815">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-36816">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36817">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36818">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-36819">473</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-36820">450</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36821">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36822">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">	<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-36823">0.14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-36824">0.09</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13">	<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-36825">14,501,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-36826">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T209"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional <br/>Paid-In <br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36827">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36828">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36829">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36830">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36831">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-27">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36832">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-28">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36833">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-29">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-30">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36834">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36835">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36836">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36837">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36838">225,265</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36839">184,748</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36840">40,531</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-31">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36841">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-32">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36842">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-33">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-34">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36843">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36844">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, June&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36845">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36846">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36847">225,452</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36848">186,228</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36849">39,238</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-35">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36850">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-36">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36851">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-37">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-38">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36852">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36853">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, September&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36854">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36855">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36856">225,606</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36857">187,652</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36858">37,968</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-36859">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-39">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-40">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-41">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-42">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-43">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36860">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-44">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36861">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-45">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-46">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36862">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36863">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36864">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36865">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36866">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36867">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36868">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-47">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36869">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-48">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-36870">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-49">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-50">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36871">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36872">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-36873">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36874">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36875">225,861</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-36876">190,750</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-36877">35,125</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T210"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Quarter Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36878">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-36879">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36880">3</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36881">4</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-36882">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-36883">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-36884">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-36885">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-36886">606</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-36887">598</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-36888">167</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-36889">32</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-36890">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" unitRef="usd" id="ixv-36891">62</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-36892">803</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-36893">22</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-36894">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-36895">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-61; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-62; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-63; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-64; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-36896">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-36897">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36898">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36899">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36900">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-36901">40,850</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-65; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-66; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-67; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-68; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental disclosure of noncash investing and financing transactions:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leased assets and operating lease liabilities&#160;&#8211;&#160;amended lease term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-36902">214</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T211"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-24530"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-24533"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-24548"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c0" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-36903">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation>
		<ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-24610"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-24630"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-36904">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-24636"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-24642"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-24651"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-24656"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-24669"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-36905">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36906">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36907">664,857</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36908">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36909">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-36910">755,857</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-24726"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-36911">35.9</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-36912">37.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-24755"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-36913">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36914">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36915">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36916">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36917">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36918">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36919">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36920">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36921">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36922">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-36923">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36924">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36925">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36926">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-36927">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36928">215</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-36929">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36930">7</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-36931">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36932">3</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-36933">4</ix:nonFraction>,000 respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-24915"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was <ix:nonFraction contextRef="c127" decimals="0" format="ixt:fixed-zero" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-36934">no</ix:nonFraction> expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-36935">108,000</ix:nonFraction>. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-36936">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-24921"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-36937">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-36938">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-36939">86,000</ix:nonFraction> was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-36940">311,000</ix:nonFraction>, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-36941">444,000</ix:nonFraction>. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-36942">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-36943">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-36944">42</ix:nonNumeric>&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-36945">to extend the <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="ixv-36946">lease</ix:nonNumeric> term six (<ix:nonNumeric contextRef="c5" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-36947">6</ix:nonNumeric>)&#160;months through <ix:nonNumeric contextRef="c0" name="abio:OperatingLeasesExtendedExpiryYearsAndMonth" id="ixv-36948">September&#160;2024</ix:nonNumeric></ix:nonNumeric>. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfBaseRentToBePaidMonthly" scale="-2" unitRef="pure" id="ixv-36949">125</ix:nonFraction>% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-36950">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c131" format="ixt-sec:durmonth" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-36951">29</ix:nonNumeric>&#160;months and terminated in October&#160;2023. <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-24949">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-36952">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-36953">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-36954">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-36955">1</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-36956">48</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-36957">22,000</ix:nonFraction> and $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-36958">31,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-36959">48,000</ix:nonFraction>, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-36960">23,000</ix:nonFraction> and $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-36961">33,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-36962">0.5</ix:nonNumeric>&#160;years. The discount rate for the operating lease is <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-36963">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-36964">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-25022"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36965">0.001</ix:nonFraction> per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-36966"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-36967">No</ix:nonFraction></ix:nonFraction> sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-25036"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-25040">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36968">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36969">163</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-116">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36970">41</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36971">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-36972">204</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-36973">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36974">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36975">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-25149"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p></ix:nonNumeric>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-36976">42,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36977">1.64</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-117">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-118">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-36978">12,862</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36979">17.45</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-36980">645,845</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36981">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-25213"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p></ix:nonNumeric>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-36982">502,517</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36983">4.71</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-25230"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p></ix:nonNumeric>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-36984">645,816</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-36985">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-25247"><p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p></ix:nonNumeric>	</td>	</tr>	</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-25257"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-25262"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (<ix:nonNumeric contextRef="c138" format="ixt-sec:durday" name="abio:NumberOfConsecutiveTradingDays" id="ixv-36986">5</ix:nonNumeric>)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately <ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-36987">97.62</ix:nonFraction>% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately <ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-36988">2.38</ix:nonFraction>% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfAdjustedExchangeRatio" scale="6" unitRef="usd" id="ixv-36989">5.0</ix:nonFraction>&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfDeclaredCashDividend" scale="0" unitRef="usd" id="ixv-36990">5,000,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $<ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="abio:SubscriptionAgreementReceiptAmount" scale="0" unitRef="usd" id="ixv-36991">175,000,000</ix:nonFraction> (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfOtherPartyTerminationFee" scale="0" unitRef="usd" id="ixv-36992">440,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-36993">0.001</ix:nonFraction> per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedShares" scale="-2" unitRef="pure" id="ixv-36994"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedOutstanding" scale="-2" unitRef="pure" id="ixv-36995">30</ix:nonFraction></ix:nonFraction>% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-36996">1,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at <ix:nonFraction contextRef="c147" decimals="4" format="ixt:num-dot-decimal" name="abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares" scale="-2" unitRef="pure" id="ixv-36997">9.99</ix:nonFraction>%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of <ix:nonFraction contextRef="c148" decimals="0" format="ixt-sec:numwordsen" name="abio:ExceptedNumberOfBoardMembers" scale="0" unitRef="pure" id="ixv-36998">five</ix:nonFraction> (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="abio:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-36999">275.0</ix:nonFraction>&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (<ix:nonNumeric contextRef="c150" format="ixt-sec:durmonth" name="abio:NumberOfMonthsBaseSalary" id="ixv-37000">12</ix:nonNumeric>)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="abio:CashPayment" scale="0" unitRef="usd" id="ixv-37001">25,000</ix:nonFraction>, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-37002"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-37003">200,000</ix:nonFraction></ix:nonFraction>. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-37004">165,000</ix:nonFraction>, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T212"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Opinion on the Financial Statement&#160;&#8212;&#160;Balance Sheet</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>balance sheet of Oruka Therapeutics, Inc. (the &#8220;Company&#8221;) as of February&#160;6, 2024, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). In our opinion, the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement presents fairly, in all material respects, the financial position of the Company as of February&#160;6, 2024<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statement has been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the financial statement, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audit of this financial statement in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&#160;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is free of material misstatement, whether due to error or fraud.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i)&#160;relate to accounts or disclosures that are material to the financial statement and (ii)&#160;involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">/s/ PricewaterhouseCoopers LLP</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boston, Massachusetts<br/><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">May&#160;13, 2024</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T213"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>BALANCE SHEET<br/>(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value, 65,000,000 shares authorized, 5,596,658 issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of this financial statement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T214"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company is subject to risks and uncertainties common to early<span class="nobreak">-stage</span> companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company&#8217;s potential products will require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompanying financial statement has been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of February&#160;6, 2024, the Company had no cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company will devote substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In March&#160;2024, the Company received $3.0&#160;million in proceeds from the sale of Series&#160;A convertible preferred stock and $25.0&#160;million in proceeds from the sale of an unsecured convertible promissory note, both of which were related party transactions (see Note&#160;7<span class="Italic" style="font-style:italic;font-weight:normal;"> Subsequent Events</span>).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares and pre<span class="nobreak">-funded</span> warrants of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, which will precede the closing of the Merger Agreement transaction. Shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate purposes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s financial statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve&#160;months from the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of February&#160;6, 2024, the Company has the authority to issue a total of 65,000,000<span class="nobreak"> </span>shares of common stock at a par value of $0.0001. As of February&#160;6, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding for a nominal consideration, which was received in March&#160;2024, prior to the date the financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued 5,596,658<span class="nobreak"> </span>shares of common stock, through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February&#160;6, 2024, Paragon, Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common stock holdings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may be subject to legal proceedings that arise in the ordinary course of business. As of February&#160;6, 2024, there were no material proceedings to which the Company was a party, nor did the Company have knowledge of any proceedings threatened against it.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company&#8217;s Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock<span class="nobreak">-based</span> awards to its employees, officers, directors, consultants, and advisors. The Company reserved 372,912<span class="nobreak"> </span>shares of its common stock for issuance under the 2024 Plan. As of February&#160;6, 2024, no awards had been issued under the plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated all events subsequent to February&#160;6, 2024, through May<span class="nobreak"> </span>13, 2024, the date on which the financial statement was available to be issued.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February&#160;2024, the Company&#8217;s Board of Directors authorized and granted 2,073,387 restricted stock awards at a price of $0.0001 per share to employees of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March 2024, the Company&#8217;s Board of Directors authorized and granted 1,789,974 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;5, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 372,912 to 872,912.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;22, 2024, the Company granted options for the purchase of an aggregate 698,669<span class="nobreak"> </span>shares of common stock, at an exercise price of $2.90 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company granted options for the purchase of an aggregate 1,365,000<span class="nobreak"> </span>shares of common stock, at an exercise price of $3.89 per share.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Antibody Discovery and Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-001</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-23</span>&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due to Paragon. This amount was recognized as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company also entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-002</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-17</span>&#8221;). The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expenses during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of issuance of the Company&#8217;s financial statement, the Company has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Antibody Discovery and Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, the Company will grant Paruka warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company issued 20,000,000<span class="nobreak"> </span>shares of Series&#160;A convertible preferred stock to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a related party of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A convertible preferred stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, or (ii)&#160;the vote or written consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The conversion ratio of Series&#160;A convertible preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue Price is $0.15 per share for Series&#160;A convertible preferred stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A convertible preferred stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A convertible preferred stock calculated based on the respective Original Issue Price of Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A convertible preferred stock are entitled to an amount equal to the greater of (i)&#160;the applicable Original Issue Price per share of Series&#160;A convertible preferred stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A convertible preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Series&#160;A convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Convertible Notes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;6, 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A preferred stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025. Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T215"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED BALANCE SHEETS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long term liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable to related party, noncurrent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;10)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of March&#160;31, 2024 and February&#160;6, 2024; 20,000,000 and no&#160;shares issued and outstanding as of March&#160;31, 2024 and February&#160;6, 2024, respectively; liquidation preference of $3,000 and $0 as of March&#160;31, 2024 and February&#160;6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value; 65,000,000 shares authorized, 9,460,019 and 5,596,658 shares issued and outstanding as of March&#160;31, 2024 and February 6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T216"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Period&#160;from<br/>February&#160;6,<br/>2024 <br/>(Inception)&#160;to<br/>March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $5,051 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $848 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $214 (see Note&#160;12)</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T217"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED&#160;STATEMENT&#160;OF&#160;CONVERTIBLE&#160;PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;DEFICIT<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Convertible<br/>Preferred Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Common Stock</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Additional<br/>Paid-in<br/>Capital</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.58%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" colspan="4" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Total<br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of February&#160;6, 2024 (inception)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;border-top-color:#000000;border-top-width:0pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">5,596,658</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of common stock</span><span class="Superscript" style="vertical-align:super;font-size:6pt;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">3,863,361</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-25" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $69</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">20,000,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Stock-based compensation expense</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">9,460,019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes issuance of 3,863,361 restricted stock awards (see Note 7)</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T218"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC. <br/>CONDENSED STATEMENT OF CASH FLOWS<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Period&#160;from<br/>February&#160;6,<br/>2024<br/>(Inception) to<br/>March&#160;31, <br/>2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,831</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of Series&#160;A convertible preferred stock, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net increase in cash</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at beginning of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at end of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Supplemental disclosure of non-cash financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs in accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T219"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to risks and uncertainties common to early stage companies in biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential products require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial information. Accordingly, they do not include all of the information and notes required by U.S.&#160;GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows. The results for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 are not necessarily indicative of results expected for the full fiscal year or any subsequent interim period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of March&#160;31, 2024, the Company had $27.7&#160;million in cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $7.1&#160;million during the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, the Company had an accumulated deficit of $7.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) and $25.0&#160;million in gross proceeds from the issuance of a convertible note, both of which were related party transactions (see Note&#160;12).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors pursuant to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, inclusive of $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of the Company&#8217;s convertible note, which will precede the closing of the Merger. Shares of the Company&#8217;s common stock and warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, as well as for general corporate purposes, which may include capital expenditure, working capital and general and administrative expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, and the need to raise future capital, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s condensed financial statements are available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for one year from the date that these condensed financial statements are available to be issued.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the Company&#8217;s condensed financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock<span class="nobreak">-based</span> compensation awards and related expenses. The Company bases its estimates on known trends and other market<span class="nobreak">-specific</span> or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is dependent on third<span class="nobreak">-party</span> organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note&#160;9).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional, accounting, and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financings as deferred offering costs until such financings are consummated. After the consummation of equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid<span class="nobreak">-in</span> capital generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing (see Note&#160;1) be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of March&#160;31, 2024, deferred offering costs of $0.5&#160;million were recorded as Other assets in the condensed balance sheet.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Debt Issuance Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt issuance costs incurred in connection with the Company&#8217;s convertible note (see Note&#160;4) are recorded as a reduction of the carrying value of the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;1 &#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;2&#160;&#8212;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. The Company accounts for its convertible note at amortized cost.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has classified the convertible preferred stock outside of stockholders&#8217; deficit on the Company&#8217;s condensed balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then<span class="nobreak">-outstanding</span> convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s Series&#160;A Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note&#160;5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Note&#160;Payable to Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for its convertible note at amortized cost. The Company considers if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible note (see&#160;Note&#160;4) and are accounted as interest expense in other expenses within the condensed statements of operations and comprehensive loss using the effective interest method.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third<span class="nobreak">-party</span> service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related<span class="nobreak">-party</span> Paragon (see Note&#160;9).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) between Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of March&#160;31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one<span class="nobreak">-time</span> cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, finance and administration costs, human resources costs, information technology costs, professional service fees, and other general overhead costs to support the Company&#8217;s operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of March&#160;31, 2024, no liabilities were recorded for loss contingencies (see Note&#160;10).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company measures all stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company grants stock options and restricted stock awards that are subject to either service or performance<span class="nobreak">-based</span> vesting conditions. Compensation expense for awards to employees and directors with service<span class="nobreak">-based</span> vesting conditions is recognized using the straight<span class="nobreak">-line</span> method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non<span class="nobreak">-employees</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance<span class="nobreak">-based</span> vesting condition will be achieved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has issued stock options and RSAs with service<span class="nobreak">-based</span> vesting conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company classifies stock<span class="nobreak">-based</span> compensation expense in its condensed statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the two<span class="nobreak">-class</span> method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The&#160;two<span class="nobreak">-class</span>&#160;method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The&#160;two<span class="nobreak">-class</span>&#160;method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two<span class="nobreak">-class</span> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company&#8217;s outstanding convertible preferred stock, stock options to purchase common stock and unvested RSAs are considered potential dilutive common shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company generated a net loss for the period presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti<span class="nobreak">-dilutive</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for uncertainty in income taxes recognized in the condensed financial statements by applying a two<span class="nobreak">-step</span> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Segment Reporting</span> (<span class="Italic" style="font-style:italic;font-weight:normal;">Topic&#160;280</span>) (&#8220;ASU&#160;2023<span class="nobreak">-07</span>&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU&#160;2023<span class="nobreak">-07</span> requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU&#160;2023<span class="nobreak">-07</span> are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU&#160;2023<span class="nobreak">-09</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</span>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Accrued Expenses and Other Current Liabilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,</span><span class="CharOverride-2" style="text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,040</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued recruiting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued employee compensation and benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the Private Placement, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note. The principal payment along with the accrued interest on the Convertible Note is due in full on the Maturity Date. As of March&#160;31, 2024, the Company had outstanding borrowings of $25.0&#160;million from Fairmount under its Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon the Company&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to the Company&#8217;s next equity financing, the Convertible Note will convert into the next series of issued convertible preferred stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC&#160;815, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging</span>, and as a result did not require separate accounting as a derivative liability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of Convertible Note on the condensed balance sheet and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company recognized interest expense related to the Convertible Note of $0.2&#160;million, which includes non<span class="nobreak">-cash</span> interest expense related to the amortization of debt issuance costs of less than $0.1&#160;million. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the weighted average effective interest rate of the Convertible Note was approximately 12.0%.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the issuance of the Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 73.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred&#160;Stock<br/>Authorized</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred Stock<br/>Issued and<br/>Outstanding</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Carrying<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidation<br/>Preference</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Common Stock<br/>Issuable Upon<br/>Conversion</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A Preferred Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of the Series A Preferred Stock have the following rights and preferences:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Voting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A Preferred Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Series&#160;A Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the holders of shares of Series&#160;A Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Series&#160;A convertible preferred stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company. The Company controls the Board of Directors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conversion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, net of the underwriting discount and commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The conversion ratio of Series&#160;A Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.15 per share for Series&#160;A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock. As of March&#160;31, 2024, each outstanding share of Series&#160;A Preferred Stock was convertible into common stock on a one<span class="nobreak">-for-one</span> basis.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A Preferred Stock calculated based on the respective original issue price of Series&#160;A Preferred Stock. For the period from February&#160;6, 2024 (inception) through March&#160;31, 2024, no cash dividends had been declared or paid by the Company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of Series&#160;A Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A Preferred Stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Redemption</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Series&#160;A Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the Board of Directors authorized up to 65,000,000<span class="nobreak"> </span>shares of common stock at a $0.0001 par value. As of March&#160;31, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding and 3,863,361<span class="nobreak"> </span>shares of RSAs were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock and RSAs are subject to and qualified by the rights, powers and preferences of the holders of Series&#160;A Preferred Stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of Series&#160;A Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the preferential dividend rights of Series&#160;A Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there are 20,698,669<span class="nobreak"> </span>shares of common stock reserved for issuance for the potential conversion of shares of Series&#160;A preferred stock into common stock, the exercise of outstanding stock options for common stock under the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;).</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 2024 Plan was adopted by the Company&#8217;s Board of Directors on February&#160;6, 2024. The 2024 Plan provides for the Company to grant stock options, restricted stock awards, restricted stock units, and other stock<span class="nobreak">-based</span> awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options have been granted with vesting terms less than four&#160;years. Upon adoption, the 2024 Plan authorized 372,912<span class="nobreak"> </span>shares of common stock reserved for issuance under the plan. On March&#160;5, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 500,000<span class="nobreak"> </span>shares. As of March&#160;31, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 872,912, with 174,243<span class="nobreak"> </span>shares available for future grants.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of each stock option grant is estimated on the grant date using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company is a private company and lacks company<span class="nobreak">-specific</span> historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service<span class="nobreak">-based</span> vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the weighted<span class="nobreak">-average</span> assumptions used in calculating the fair value of the awards from February&#160;6, 2024 (inception) to March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">103.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term (in&#160;years) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the stock option activity for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and expected to vest, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercisable, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant<span class="nobreak">-date</span> fair value of stock options granted from February&#160;6, 2024 (inception) to March&#160;31, 2024 was $2.37. As of March&#160;31, 2024, there was no aggregate intrinsic value for the outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February 2024 and March&#160;2024, the Company issued 3,863,361<span class="nobreak"> </span>shares of RSAs to certain employees, directors, and consultants at a price of $0.0001 per share, the par value of the common stock. Such RSAs have service<span class="nobreak">-based</span> vesting conditions only and vest over a four<span class="nobreak">-year</span> period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>RSAs</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paruka Warrant Obligation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board of Directors of the Company (the &#8220;Paruka Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post<span class="nobreak">-grant</span> date service requirement. As of March&#160;31, 2024, the pro<span class="nobreak">-rated</span> estimated fair value </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of warrants to be granted on December&#160;31, 2024 was $0.7&#160;million. For the period February&#160;6, 2024 (inception) to March&#160;31, 2024, $0.1&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense related to the Paruka Warrant Obligation. The warrants expected to be granted to Paruka are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the classification of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6,&#160;2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested stock options was $1.6&#160;million, which is expected to be recognized over a weighted average period of approximately 3.40&#160;years. As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1&#160;million, which is expected to be recognized over a weighted average period of 3.92&#160;years. As of March&#160;31, 2024, the unrecognized compensation cost related to the Paruka Warrant Obligation was $0.6&#160;million, which is expected to be recognized over a weighted average period of 0.8&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the award types of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka warrant obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17</span> A/F (ORKA<span class="nobreak">-002</span>). Under the Option Agreements, the Company has the exclusive options to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;), with </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Option Agreements, the parties initiated certain research programs that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties will establish a research plan that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). The Company and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at the inception of the arrangement related to ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company&#8217;s exclusive Option with respect to each Research Program is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, the Option Agreements shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then<span class="nobreak">-existing</span> Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Each party has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one<span class="nobreak">-time</span>, nonrefundable research initiation fee of $0.8&#160;million. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date these condensed financial statements are available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. The Company will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Agreement provides for an annual equity grant of warrants to Paruka to purchase 1.00% of the then outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Agreement, at the fair market value determined by the Board of Directors of the Company. The warrants are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note&#160;7).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in<span class="nobreak">-process</span> research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one<span class="nobreak">-time</span> cost on a research program<span class="nobreak">-by</span> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on<span class="nobreak">-going</span> development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses in connection with services provided by Paragon under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains a defined<span class="nobreak">-contribution</span> plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986 (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre<span class="nobreak">-tax</span> basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of management. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company has not recorded any expense related to 401(k)&#160;match contributions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed financial statements as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of March&#160;31, 2024, the Company was not a party to any material legal proceedings or claims.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Net Loss per Share</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted<span class="nobreak">-average</span> common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted<span class="nobreak">-average</span> number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti<span class="nobreak">-dilutive</span> effect:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible preferred stock (as converted to common stock)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock awards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options to purchase common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,562,030</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon and Paruka each currently beneficially own more than 5% of the Company&#8217;s capital stock through its common stock holdings. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Plan on its condensed statement of operations and comprehensive loss. As of March&#160;31, 2024, the Company had $5.8&#160;million in amounts due to related parties pertaining to services provided by Paragon and Paruka under the Option Agreements and reimbursements of recruiting and start<span class="nobreak">-up</span> fees on its condensed balance sheet. In addition, under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note&#160;7). If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;) beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Company&#8217;s Board of Directors, and beneficially owns more than 5% of Paragon. In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, an affiliated fund of Fairmount Funds Management, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million (see Note&#160;4). In March&#160;2024, Fairmount entered into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $25.0&#160;million (see Note&#160;4). As of March&#160;31, 2024, the Company had $0.2&#160;million in amounts due to related parties pertaining to accrued interest related to the Company&#8217;s outstanding borrowings of $25.0&#160;million under the Purchase Agreement with Fairmount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of related party accounts payable and other current liabilities (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable Option Agreement fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,983</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable recruiting and start-up fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">848</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Warrant Obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The following is a summary of noncurrent liability, related party (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,194</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated events and transactions occurring subsequent to March<span class="nobreak"> </span>31, 2024 through May<span class="nobreak"> </span>13, 2024, the date at which the condensed financial statements were available to be issued. In connection with the reissuance of the condensed financial statements, the Company has evaluated subsequent events through June<span class="nobreak"> </span>18, 2024, the date these condensed financial statements were available to be reissued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Amended 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669. On May&#160;7, 2024, the Company granted options for the purchase of an aggregate 1,365,000 stock options, at an exercise price of $3.89 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T100"></a><p class="ParaOverride-1" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:right;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Annex A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:210pt;orphans:3;text-align:center;widows:3;margin-top:210pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">among:</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA THERAPEUTICS, Inc.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Dated as of April 3, 2024</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;">Table of Contents</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;1. Definitions and Interpretative Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-2</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Definitional and Interpretative Provisions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;2. Description of Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effects of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing; First Effective Time; Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents; Directors and Officers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing of the Company&#8217;s Transfer Books</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrender of Company Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-18</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calculation of Net Cash and Company Valuation.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Further Action</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Withholding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Appraisal Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;3. Representations and Warranties of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-21</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-27</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-31</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-32</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ownership of Parent Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;4. Representations and Warranties of Parent, First Merger and Second Merger Sub</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-35</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC Filings; Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-38</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-47</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valid Issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;5. Certain Covenants of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-50</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of Parent&#8217;s Business</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of the Company&#8217;s Business.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-52</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Access and Investigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-53</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Solicitation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-54</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notification of Certain Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;6. Additional Agreements of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-55</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Registration Statement, Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-57</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-58</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Efforts; Regulatory Approvals.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Options; Company Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee Benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-61</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Indemnification of Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-62</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disclosure</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legends</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination of Certain Agreements and Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Section&#160;16 Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Allocation Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wind-Down Activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Obligations of Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Closing Financing Restructuring</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Re-Domestication</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;7. Conditions Precedent to Obligations of Each Party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effectiveness of Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Regulatory Approvals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Restraints</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholder Approval</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Certificate of Designation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Company Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Pre-Closing Financing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;9. Additional Conditions Precedent to Obligation of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-67</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Parent Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;10. Termination</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-68</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expenses; Termination Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;11. Miscellaneous Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-71</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Survival of Representations and Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Waiver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applicable Law; Jurisdiction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assignability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notices</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cooperation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Severability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Remedies; Specific Performance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Third-Party Beneficiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exhibits:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Parent Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Company Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Lock-Up Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;C</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Subscription Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Second Certificate of Merger, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;E</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Certificate of Designation</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">This Agreement and Plan of Merger and Reorganization </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(this &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub Corp.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with First Merger Sub, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Certain capitalized terms used in this Agreement are defined </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Recitals</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with this Agreement and the DGCL.  Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">B.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the First Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), with Second Merger Sub being the surviving entity of the Second Merger.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">C.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties intend that, (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3(a).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">D.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Transaction Committee of the Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders and (ii) recommended that the Parent Board approve and adopt this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">E.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and the constructive issuance by the Company of shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a) of the Securities Act) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Constructive Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve this Agreement and thereby approve the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement, the Constructive Issuance, and, if deemed necessary by the Parties, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">F.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The First Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">G.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">H.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split, and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">J.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">K.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, all of the stockholders of the Company or Parent listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter are executing lock-up agreements in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">L.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>It is expected that within two (2) Business Days after the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;C</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> among the Company and the Persons named therein (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subscription Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein (including by contribution of Company Notes) (i) shares of Company Common Stock and (ii) pre-funded Company Warrants, in each case, immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Agreement</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Parties, intending to be legally bound, agree as follows:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>For purposes of this Agreement (including this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">):</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acceptable Confidentiality Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition Inquiry</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proposal</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any transaction or series of related transactions (other than any Parent Legacy Transaction, the issuance of Company Notes, or the Company Pre-Closing Financing) involving:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affordable Care Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Patient Protection and Affordable Care Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Anticipated Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Day</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;E</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">COBRA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Code</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company Common Stock and the Company Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.0001 par value per share, of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that the Company or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v) utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any executive officer of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d) any change in GAAP or applicable Law or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (f) any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business; except in each case with respect to clauses&#160;(c), (d) and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Merger Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the product determined by </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">multiplying</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (i) the Post-Closing Parent Shares </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) the Company Allocation Percentage, in which:</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Aggregate Valuation</span>&#8221; means the sum of (i) the Company Valuation, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">plus</span> (ii) the Parent Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Allocation Percentage</span>&#8221; means the percentage (rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">subtracting</span> (i)&#160;the Parent Allocation Percentage <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">from</span> (ii)&#160;100 percent.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Equity Value</span>&#8221; means $175,000,000.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Outstanding Shares</span>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. For the avoidance of doubt, Company Outstanding Shares shall (a) exclude, to avoid the double-counting of, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including any Company Notes) to the extent such shares or securities are contributed as consideration in the Company Pre-Closing Financing and (b) include (i) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable to the Paragon Entities (as such term is defined in the Company&#8217;s Organizational Documents) as a result of the Contemplated Transactions pursuant to the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;margin-left:72pt;text-indent:0pt;margin-top:8pt;">Company&#8217;s Organizational Documents and (ii) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable pursuant to the offer letter set forth in Section&#160;3.6(d) of the Company Disclosure Letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Valuation</span>&#8221; means the (i) Company Equity Value plus (ii) the amount of proceeds actually received by the Company from the Company Pre-Closing Financing (including in the proceeds actually received from any Company Notes, and any interest thereon, contributed as consideration in the Company Pre-Closing Financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Exchange Ratio</span>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Allocation Percentage</span>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Valuation <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii)&#160;the Aggregate Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Outstanding Shares</span>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Convertible Preferred Stock issuable in accordance herewith), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. Notwithstanding any of the foregoing, no Parent Options, if any, shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares to the extent cancelled at or prior to Closing under <span class="CharOverride-9" style="text-decoration:underline;">Section&#160;6.6(c)</span>.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Valuation</span>&#8221; means (i) $11,000,000, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> (ii) the amount by which Parent Net Cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Post-Closing Parent Shares</span>&#8221; mean the quotient determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Outstanding Shares <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii) the Parent Allocation Percentage.</p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Notes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the convertible notes issued pursuant to that certain Series A Preferred Stock and Convertible Note Purchase Agreement among the Company and the purchasers party thereto, dated as of March 6, 2024, or any additional convertible promissory notes that may be issued from time to time prior to the Closing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series A Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Series A Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a series of the Company&#8217;s preferred stock designated as Series A Preferred Stock, $0.0001 par value per share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company&#8217;s Amended and Restated 2024 Equity Incentive Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a) the Company Board shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">any committee thereof shall have publicly proposed, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Confidentiality</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the letter agreement dated as of February 9, 2024, between the Company and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contemplated</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transactions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment), the Company Pre-Closing Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DGCL</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DLLCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Delaware Limited Liability Company Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any effect, change, event, circumstance, or development.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (A) an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (B) other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A) above; and (C) all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Enforceability Exceptions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Environmental</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections&#160;414(b),(c),(m) or (o) of the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Sub Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of First Merger Sub.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authority</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d) self-regulatory organization (including Nasdaq).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authorization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Hazardous Materials</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">HSR Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">In the Money Parent Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Patents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (b) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software, including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign rights arising under or associated with any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IRS</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Internal Revenue Service.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Knowledge</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, (i) with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities, (ii) with respect Parent, the Knowledge of the individuals listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Schedule&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter as of the date of such knowledge is imputed and (iii) with respect to any Person that is an Entity (other than Parent) the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Legal Proceeding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiemployer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c) of the Code or Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Welfare Arrangement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Reverse Split</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means The Nasdaq Stock Market.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Order</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Course of Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development; provided, however, that during the Pre-Closing Period, the Ordinary Course of Business of Parent shall also include actions required to effect and effecting any Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Out of the Money Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Balance Sheet</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the audited balance sheet of Parent as of December 31, 2023, included in Parent&#8217;s Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Parent Common Stock and the Parent Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Closing Price</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5) consecutive trading days ending three (3) trading days immediately prior to the Closing Date as reported by Bloomberg L.P.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.001 par value per share, of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which Parent is a party, (b) by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c) under which Parent has or may acquire any right or interest.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Convertible Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that Parent or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related or pertaining to any Parent IP Rights.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) an executive officer of Parent; and (ii) any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the business of Parent as conducted at any time prior to the date of this Agreement, including but not limited to business related to the assets listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation thereof or (f) general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates; except, in each case with respect to clauses&#160;(d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Net Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means without duplication, (i) Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) all prepaid expenses set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iii) all receivables which the parties may mutually agree (each in their sole discretion) are recoverable by or provide benefit to Parent after the First Effective Time (if any), </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iv) the sum of Parent&#8217;s consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (v) the aggregate amount (without duplication) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions or the Parent Legacy Transaction, including: (a) any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions or the Parent Legacy Transaction; (b) 50% of the fees paid to the SEC in connection with filing the Registration Statement and any amendments and supplements thereto, with the SEC; (c)&#160;50% of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto; (d) 50% of the Nasdaq Fees; (e)&#160;any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions or any Parent Legacy Transaction, together with any payroll Taxes associated therewith; (f) the dividend of any excess Parent Net Cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and (g)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in each case, to the extent unpaid as of the First Effective Time, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi) all remaining rent payments and any other Liabilities under Parent&#8217;s lease obligations, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (vii) any unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (viii) all costs and expenses to be mutually agreed by Parent and the Company relating to the winding down of Parent Legacy Business, including the sale, license or other disposition of any or all of the Parent Legacy Business to the extent unpaid as of the Closing, including any costs incurred costs incurred by Parent following the Closing pursuant to Section&#160;6.17 and </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ix) the amounts due and payable to holders of Parent Options pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the extent unpaid as of the First Effective Time; </span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">that if any portion of the fees and expenses described in subclauses&#160;(b), (c), and (d) of clause&#160;(v) have been paid by Parent prior to the First Effective Time in an amount greater than Parent&#8217;s share of such fee and expense described in subclauses&#160;(b), (c), and (d), then (x) such portion in excess of Parent&#8217;s shares of such fee and expense described in subclauses&#160;(b), (c), and (d) shall not be deducted by reason of subclauses&#160;(b), (c), and (d) of clause&#160;(v) and (y) such portion shall be added to the calculation of Parent Net Cash.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent, including the Parent Convertible Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Restricted Stock Units</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any equity award with respect to Parent Common Stock that represents the right to receive in the future shares of Parent Common Stock pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s stockholders and subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b) the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, publicly proposed, endorsed or recommended any Acquisition Proposal or (c) Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Alternative Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves have been made on the Company Budget or the Parent Balance Sheet, as applicable, in accordance with GAAP, (b)&#160;minor non-monetary liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">leases or rental agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f) liens arising under applicable securities Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Person</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any individual, Entity or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Personal Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; mean, collectively, (i) all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, and state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (ii) any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Representatives</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Sarbanes-Oxley Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Sarbanes-Oxley Act of 2002.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Securities Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsequent Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsidiary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Superior</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Offer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of this Agreement, (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions, (c) is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d) is reasonably capable of being completed on the terms proposed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Return</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Treasury regulations promulgated under the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b) Each of the following terms is defined in the Section&#160;set forth opposite such term:</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">AAA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accounting Firm</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Allocation Certificate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Option</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Warrant</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Capitalization Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cash Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Audited Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Budget</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Interim Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Required S-4 Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Written Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Termination Fee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Delivery Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Concurrent Investment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">D&amp;O Indemnified Parties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dissenting Shares</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.12(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Drug/Device Regulatory Agency</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Employment-Related Laws</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">End Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Exchange Agent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Step Surviving Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form S-4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GAAP</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Consideration</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.5(a)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Listing Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ordinary Course Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.16(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.4(b)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Legacy Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend Amount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stock Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PHSA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Post-Closing Welfare Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.6(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Pre-Closing Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Privacy Policies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Company Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Parent Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stockholder Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Surviving Entity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tax Certificates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.10(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Transaction Litigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.4(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">WARN Act</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Definitional and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules&#160;are to Sections, Exhibits and Schedules&#160;of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule&#160;but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit&#160;D-1 (including Exhibit&#160;A to such Exhibit) and Exhibit&#160;D-2 is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United&#160;States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">&#160;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Description of Transaction</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">The Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Step Surviving Corporation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).  Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease.  As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Surviving Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effects of the Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing; First Effective Time; Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Unless this Agreement is earlier terminated pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to the satisfaction or waiver of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the consummation of the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.&#8221; Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. At the Closing, (i) the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and together with the First Certificate of Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents; Directors and Officers</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A) change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC,&#8221; and (B) make such other changes as are mutually agreed to by Parent and the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split (to the extent applicable and necessary), (iii) increase the number of shares of Parent Common Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, and (iv) make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;after giving effect to the provisions of&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, or such other persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or Parent:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (A) each share of Company Common Stock (including any shares of Company Common Stock issued pursuant to the Company Pre-Closing Financing) outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (B) each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x) the Exchange Ratio </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">divided by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (y) 1,000 (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein: (i) one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All Company Options outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing of the Company&#8217;s Transfer Books</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b) the stock </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Surrender of Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange Agent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in exchange for Company Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii) instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (B) the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculation of Net Cash and Company Valuation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, Parent will deliver to the Company a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Parent Net Cash (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule&#160;and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> necessary to calculate the Exchange Ratio.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, the Company will deliver to Parent a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the date of delivery of such schedule being (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Delivery Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the last Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule&#160;and, if reasonably requested by Parent, the Company&#8217;s accountants and counsel at reasonable times and upon reasonable notice.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Cash Determination Time (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Company Valuation Calculation as set forth in the Company Valuation Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or the components of Company Valuation as of the Company Valuation Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5) days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AAA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Accounting Firm</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Net Cash Schedule&#160;and the Dispute Notice and the Company Valuation Schedule&#160;and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five&#160;(5) Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Further Action</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a) of the Code (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Withholding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appraisal Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dissenting Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on an as-converted&#160;basis, and (ii) the holders of a majority of the shares of Company Series A Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Company Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity or performance of any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) the Required Company Stockholder Vote, (ii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii) compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of the Company consists of (i) 65,000,000 shares of Company Common Stock of which 9,460,019 shares have been issued and are outstanding as of the date hereof and (ii) 20,000,000 shares of Company Preferred Stock, of which 20,000,000 shares have been designated Series A Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company&#8217;s capital stock is held by the Persons and in the amounts set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, which further sets forth for each such Person (i) the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, (iv)&#160;whether such Person is or has ever been an employee, and (v) the state of residence of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company&#8217;s capital stock and the Company has never declared or paid any dividend or other distribution.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding Company Capital Stock as set out in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Company Stock Plans and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding as of the date hereof: (i) the name of the holder, (ii) the number of shares of Company Common Stock subject to such Company Option as of the date hereof, (iii) the exercise price of such Company Option, (iv) the date on which such Company Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii) whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Company Option, the plan pursuant to which such Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Company Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Company Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Capital Stock are uncertificated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter includes true and complete copies of the Company&#8217;s budget overview for March 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Budget</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii) access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c) of Regulation S-K under the Exchange Act) effected by the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii) any claim or allegation regarding any of the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, between the date of its incorporation and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required consent of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Liability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), except for: (a) Liabilities disclosed, reflected or reserved against in the Company Budget, (b) normal and recurring current Liabilities that have been incurred by the Company since the date of the Company Budget in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts, (d) Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement, (e)&#160;Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter and (f) those Liabilities that are not material to the Company.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Company Budget and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a) an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies (i) all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i) Company IP Rights licensed to the Company, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (ii) any non-customized software that (A) is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b) in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i) each such agreement is valid and binding on the Company and in full force and effect, (ii) the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii) the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.12(b),</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by the Company, (i) the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole and (ii) the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.13(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract (A) pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B) pursuant to which the Company granted any Person an exclusive license under any Company IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of the Company taken as a whole; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Company Real Estate Leases.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Drug/Device Regulatory Agency</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Public Health Service Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">PHSA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Company Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner, other than immaterial adverse modifications. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610 and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code in the last five (5) years.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary Course Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company or any of its Subsidiaries, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of the Company&#8217;s and each of its Subsidiaries&#8217; employees is terminable by the Company and/or its applicable Subsidiary at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Company Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WARN Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employment-Related Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and in each case, with respect to employees of the Company and any of its Subsidiaries: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification within the last four (4) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.22<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (i) has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Policies</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Ownership of Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. None of the Company or any of their directors, officers, or Affiliates or, to the knowledge of the Company or any of its controlled Affiliates, any employees of the Company or any of its controlled Affiliates (a) has owned any shares of Parent&#8217;s capital stock; or (b) has been an &#8220;interested stockholder&#8221; (as defined in Section&#160;203 of the DGCL) of Parent, in each case during the three years prior to the date hereof.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of Parent, First Merger and Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except (i) as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no Subsidiaries other than Merger Subs and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Subs. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and (iii) make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.  The sole member of Second Merger Sub (by unanimous written consent) has:  (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions.  This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the affirmative vote of a majority of the shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses&#160;(i), (ii) and (iii) of the definition of &#8220;Parent Charter Amendment&#8221; (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Parent Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) any Consent set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter under any Parent Contract, (ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv) compliance with any applicable requirements of the HSR Act (if applicable) and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of Parent consists of (i)&#160;100,000,000 shares of Parent Common Stock of which 14,501,143 shares have been issued and are outstanding as of March 28, 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Capitalization Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) 5,000,000 shares of Parent Preferred Stock, par value $0.001 per share, of which 135,000 have been designated Series A Convertible Preferred Stock. No shares of Parent Preferred Stock have been issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Parent 2004 Equity Incentive Plan, Parent 2013 Equity Incentive Plan and Parent 2020 Equity Incentive Plan, (each as may be amended from time to time, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. Parent does not have any employee stock purchase plan or similar program. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i) the name of the holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option as of the Capitalization Date, (iii) the exercise price of such Parent Option, (iv) the date on which such Parent Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the date on which such Parent Option expires, (vii) whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Parent Option, the plan pursuant to which such Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Parent Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent, (iii) stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding shares of Parent Common Stock and Parent Options, and other securities of Parent have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">SEC Filings; Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule&#160;13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Documents (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certifications</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule&#160;13a-15 of the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, between December 31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Parent Legacy Business or the Contemplated Transactions, (e) Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter and (f) those Liabilities that are not material to Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Parent Balance Sheet and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent IP Rights licensed to Parent, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as may be set forth in the Contracts listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.13</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days&#8217; or less notice without liability;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any Parent Real Estate Lease;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>a Contract disclosed in or required to be disclosed in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter; or</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvii)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken as a whole.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner other than immaterial adverse modifications. Section&#160;4.14(d) of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg.&#160;46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Parent Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent 409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i) result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.22<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Valid Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Covenants of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of Parent&#8217;s Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Pre-Closing Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others or (D) make any capital expenditure or commitment in excess of $25,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>forgive any loans to any Person, including its employees, officers, directors or Affiliate;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), Parent may:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of the Parent Legacy Business (including terminating its Parent Real Estate Leases and other Parent Contracts) or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Business (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that to the extent any Parent Legacy Transaction results in material obligations of Parent that will extend beyond Closing, such terms shall be reasonably acceptable to the Company and any such post-Closing obligations shall be a reduction to Parent Net Cash; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions), up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (such dividend, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend Amount</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of the Company&#8217;s Business.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, including the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Access and Investigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c) permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything herein to the contrary in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no access or examination contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v) publicly propose to do any of the foregoing; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, notwithstanding anything contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, (C) at least two&#160;(2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E) at least two&#160;(2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one&#160;(1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notification of Certain Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y) determining whether any condition set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> has been satisfied. Any failure by either Party to provide notice pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be deemed to be a breach for purposes of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, unless such failure to provide such notice was knowing and intentional.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Agreements of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Registration Statement, Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form S-4 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Form S-4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in which a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be included as a part (the Proxy Statement and the Form S-4, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form S-4 pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i) cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii) cause the Registration Statement to become effective as promptly as practicable, and (iii) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL and DLLCA, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement (including the Company Budget) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i)&#160;Parent, Merger Subs or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) for offering or sale in any jurisdiction, or (3) any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Required S-4 Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two (2) Business Days before the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent has included the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as reasonably practicable following the date of this Agreement, the Company will use commercially reasonable efforts to furnish to Parent (i) audited financial statements for each of its fiscal years required to be included in the Registration Statement, or an audited period balance sheet, as applicable (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Audited Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Interim Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Written Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Reasonably promptly following receipt of the Required Company Stockholder Vote, and in any event no later than ten (10) days thereafter, the Company shall prepare and mail a notice (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the certificate of incorporation and bylaws of the Company and (iii) include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to Parent&#8217;s advance review and reasonable approval.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company agrees that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (i) the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if, Parent has delivered </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four&#160;(4) Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve this Agreement and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such meeting, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than 45 days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> above and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or (C) any Parent Legacy Transaction) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules&#160;14d-9 and 14e-2(a) promulgated under the Exchange Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of Regulation </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; or (iv) making any disclosure to the stockholders of Parent that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Efforts; Regulatory Approvals.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart&#8211;Scott&#8211;Rodino Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction Litigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely effect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Options; Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B) the Exchange Ratio; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Company Option </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a) of the Code; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, each Company Warrant (including any pre-funded Company Warrant issued pursuant to the Company Pre-Closing Financing), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Warrant</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee Benefits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or contemplated by </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, subject to the provisions of such agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1) of ERISA (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Post-Closing Welfare Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A) the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B) the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Option Cash Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">within ten (10) business days after the First Effective Time. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Indemnification of Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">D&amp;O Indemnified Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Costs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Wilson Sonsini Goodrich &amp; Rosati or such other counsel selected by the D&amp;O Indemnified Parties.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6) year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancelable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in connection with their enforcement of the rights provided to such persons in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Unless directed otherwise by the Company in writing no less than three&#160;(3)&#160;Business Days before the Closing Date, Parent shall use reasonable best efforts to take all actions as are necessary to terminate any 401(k) or other plan(s) with a cash or deferred arrangement (as defined in Section&#160;401(k) of the Code), effective as of no later than the day immediately preceding the Closing Date.  Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3) Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Disclosure</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form 8-K announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist the Company in preparing and filing an initial listing application for the Parent Common Stock on Nasdaq (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Listing Application</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Nasdaq fees associated with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, including any fees related to the engagement of a consultant (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall be shared equally by the Company and Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement and Proxy Statement, (i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Registration Statement and Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legends</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules&#160;144 and 145 under the Securities Act reflecting the restrictions set forth in Rules&#160;144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter are elected or appointed, as applicable, to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination of Certain Agreements and Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;16 Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Allocation Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a) each holder of Company Capital Stock, (b)&#160;such holder&#8217;s name and address, (c) the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Allocation Certificate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Wind-Down Activities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Following the Closing, Parent shall use its commercially reasonable efforts to continue the wind-down activities of Parent associated with the Parent Legacy Business, including termination of its research and development activities set forth on Section&#160;6.17 of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligations of Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pre-Closing Financing Restructuring</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event the structure of the Company Pre-Closing Financing either violates applicable Law or materially and adversely effects Parent&#8217;s ability to cause the Registration Statement to become effective in a timely manner, and in any event 60 days prior to the End Date, then Parent and the Company shall, and shall use their reasonable best efforts to cause the investors in the Company Pre-Closing Financing, to cause the Company Pre-Closing Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its Subsidiaries, and the number of Parent shares ultimately held by the investor in respect of such amounts as though the Company Pre-Closing Financing has been consummated by its terms.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then, prior to the First Effective Time, Parent shall deposit the Parent Pre-Closing Dividend Amount with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Re-Domestication</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The parties shall discuss in good faith whether to change the domicile of Parent prior to the First Effective Time.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conditions Precedent to Obligations of Each Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effectiveness of Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) shall have been complied with and no stop order (or similar order) shall have been issued in respect of such shares of Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) by any applicable state securities commissioner or court of competent jurisdiction.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Regulatory Approvals</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Restraints</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder Approval</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Nasdaq Listing Application shall have been approved by Nasdaq.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Lock-Up Agreements shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.15</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is true and accurate in all respects as of the Closing Date;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate pursuant to Treasury Regulations Sections&#160;1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Company Valuation Schedule; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Allocation Certificate.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Subscription Agreement (as may be amended, restated or supplemented pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall be in full force and effect and proceeds of not less than $175,000,000 (including in the proceeds any Company Notes contributed as consideration in the Company Pre-Closing Financing) shall have been received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) or will be received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) substantially simultaneously with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then the Parent Pre-Closing Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligation of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by an executive officer of Parent certifying that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Parent Net Cash Schedule.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below):</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of Parent and the Company;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if the Merger shall not have been consummated by October 3, 2024 (subject to possible extension as provided in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">End Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is sixty (60) days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional sixty (60)&#160;days;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that once the Required Company Stockholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty&#160;(30)&#160;day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Parent shall not enter into any Permitted Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Party desiring to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effect of Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the termination of this Agreement as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Agreement shall be of no further force or effect; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that (a)&#160;this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.8)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Expenses; Termination Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent or the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Termination Fee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If this Agreement is terminated (i) by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (when at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) then Parent shall pay to the Company within five (5) Business Days of such termination, the Company Termination Fee or (ii) by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then Parent shall pay to the Company, concurrent with such termination, the Company Termination Fee.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii) in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve&#160;(12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If either Party fails to pay when due any amount payable by it under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties agree that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the payment of the fees and expenses set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> on more than one occasion. Subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, following the payment of the fees and expenses set forth in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall limit the rights of the Parties under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;11. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Survival of Representations and Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.4<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that only Exhibit&#160;D (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.5<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause&#160;(a) of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.6<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.7<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to Parent or Merger Subs:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO 80021 <br/>Attention: C. Jeffrey Dekker<br/>Email: ***</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>1881 9</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> Street, Suite 110<br/>Boulder, CO 80302<br/>Attn: Brent Fassett<br/>Email: bfassett@wsgr.com</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>One Market Plaza, Spear Tower, Suite 3300<br/>San Francisco, CA 94105<br/>Attn: Ethan Lutske, Ross Tanaka<br/>Email: elutske@wsgr.com, rtanaka@wsgr.com</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to the Company:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics, Inc.<br/>221 Crescent Street, Building 23, Suite 105<br/>Waltham, Massachusetts 02453<br/>Attention: Lawrence Klein<br/>Email: ***</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Gibson, Dunn &amp; Crutcher LLP<br/>One Embarcadero Center, Suite 2600<br/>San Francisco, CA 94111<br/>Attention: Ryan Murr, Branden Berns, Chris Trester<br/>Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.8<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Cooperation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.9<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.10<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Remedies; Specific Performance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.11<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third-Party Beneficiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of page intentionally left blank</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ARCA </span><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">biopharma, Inc</span><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB II, LLC</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T101"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;B</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">OPINION OF LUCID CAPITAL MARKETS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:14pt;">LUCID CAPITAL MARKETS, LLC</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">April&#160;2, 2024</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">10170 Church Ranch Way, Suite 100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Westminster, CO&#160;80021</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Attention: Robert E.&#160;Conway</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Chairman of the Board of Directors</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Members of the Board of Directors:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have been advised that ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;), by and among ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of ARCA (&#8220;Merger Sub&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221; or the &#8220;Company&#8221;). At the Effective Time, Merger Sub will be merged with and into the Company (the &#8220;Merger&#8221;), and the separate existence of the Merger Sub will cease. The Company will continue as the surviving corporation in the Merger (the &#8220;Surviving Corporation&#8221;). Pursuant to the terms of the Agreement, upon consummation of the Merger, each share of Company Capital Stock (other than shares of Company Capital Stock held as treasury stock immediately prior to the Effective Time which shall be canceled and retired and shall cease to exist and excluding Dissenting Shares) will be converted into and become exchangeable for a number of shares of Parent Common Stock equal to the Exchange Ratio. The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Agreement contemplates that Parent may declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions) up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (the &#8220;Parent Pre<span class="nobreak">-Closing</span> Dividend&#8221;). The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement pursuant to which such Persons will have agreed to purchase (including by contribution of Company Notes) (i)&#160;shares of Company Common Stock and (ii)&#160;pre<span class="nobreak">-funded</span> Company Warrants, in each case immediately prior to the Effective Time (the &#8220;Company Pre<span class="nobreak">-Closing</span> Financing&#8221;). It is a condition precedent to the obligations of Parent and Merger Sub to effect the Merger that proceeds of not less than $175&#160;million be received from the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have assumed, with your consent, that the Parent Net Cash amount is expected to be, and we have assumed, with your consent, that it will be approximately $5.0&#160;million at Closing after taking effecting the Parent Pre<span class="nobreak">-Closing</span> Dividend.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming that the Parent Pre<span class="nobreak">-Closing</span> Dividend has occurred, the holders of Company Common Stock, Company Options and Company Warrants will in the aggregate hold approximately 97.6% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger and the holders of Parent Common Stock will in the aggregate hold approximately 2.4% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger, in each case, after accounting for the Parent Pre<span class="nobreak">-Closing</span> Dividend and the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have, with your consent, relied upon the assumption that all information provided to us by ARCA and Oruka is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that ARCA and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Merger Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In your capacity as members of the Board of Directors of ARCA (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to us by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to us by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as we deemed relevant for the purposes of our Opinion.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the Draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on ARCA, Oruka, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with ARCA, dated as of March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of ARCA or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address ARCA&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to ARCA.&#160;We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on ARCA, Oruka or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. We have acted as ARCA&#8217;s financial advisor in connection with the Merger and will receive a fee for our services pursuant to the terms of our Engagement Letter, a significant portion of which is contingent upon consummation of the Merger. In addition, ARCA has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We will also receive an additional fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with ARCA or its affiliates and has not received any fees from ARCA or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka or any of its affiliates and has not received any fees from Oruka or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, ARCA, Oruka or any other party that may be involved in the Merger and/or their respective affiliates.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to ARCA and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Very truly yours,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;"><img alt="" src="tlucid_sig.jpg" style="width:179.20000000000002px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T102"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;C</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Company Capital Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, and (ii) all additional shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, the Voting Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consent.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in&#160;each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company pursuant to the Company Pre-Closing Financing on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), and (vii) to the extent required by applicable Law; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as the beneficial owner of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement; provided, that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Exercise of Appraisal Rights; Waivers</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders; provided, that (x) the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, the Voting Agreement, the Investors&#8217; </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Rights Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Investors&#8217; Rights Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Right of First Refusal and Co-Sale Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">ROFR</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, except for the Voting Agreement, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Agreements</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the Effective Time each of (a) the Voting Agreement, the Investors&#8217; Rights Agreement and the ROFR and (b)&#160;any rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein).  Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature:&#160;_______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T103"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;D</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II, LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Parent Common Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Matters</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the approval of the Merger Agreement and the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii) all additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case, which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Matters and against any competing proposals.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement), and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent Common Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by the Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">herein).  Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">arca biopharma, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature: _______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T104"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;E</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF LOCK-UP AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:right;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">April 3, 2024</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10170 Church Ranch Way, Suite 100</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Westminster, CO</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Ladies and Gentlemen:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned signatory of this lock-up agreement (this &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) understands that ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (as the same may be amended from time to time, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) with Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent, Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Restricted Period</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that if a registration statement covering the shares of Company Common Stock and pre-funded Company Warrants issued and sold in connection with the Company Pre-Closing Financing (other than any shares or pre-funded Company Warrants held by affiliates of the Company) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Undersigned&#8217;s Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>publicly disclose the intention to do any of the foregoing.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The restrictions and obligations contemplated by this Lock<span class="nobreak">-Up</span> Agreement shall not apply to:</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers of the Undersigned&#8217;s Shares:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Family Member</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by or under common control with  the undersigned and/or by any such Family Member(s);</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a corporation, partnership, limited liability company or other entity, (A)&#160;to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares or (D) transfers or dispositions not involving a change in beneficial ownership; or</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a trust, to any grantors or beneficiaries of the trust;</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="text-decoration:underline;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock<span class="nobreak">-up</span> agreement in the form of this Lock<span class="nobreak">-Up</span> Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed;</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common Stock; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the Effective Time;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to an order of a court or regulatory agency; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company (including any shares of the Company issued upon exercise of any pre-funded Company Warrants), if any, purchased from the Company on or about the Closing Date but prior to the Closing.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, further, that, with respect to each of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of the Company&#8217;s voting securities if, after such transfer, the Company&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE <br/>SUBJECT TO AND MAY ONLY BE TRANSFERRED IN <br/>COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY <br/>OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF <br/>THE COMPANY.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy.  The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached.  It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto.  Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pro-Rata Release</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Pro-Rata Release shall not be applied unless </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement.  In the event of any Pro-Rata Release, the Company shall promptly (and in any event within two (2) business days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.  In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.  The exchange of a fully executed Lock-Up Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:1pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[SIGNATURE PAGE FOLLOWS]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Very truly yours,</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:right;">Print Name of Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for individuals):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for entities):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accepted and Agreed<br/>by ARCA biopharma, Inc.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 2.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 34.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T105"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;F</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Arca biopharma, Inc.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RIGHTS AND LIMITATIONS</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">OF</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to Section 151 of the</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">General Corporation Law of the State of Delaware</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board of Directors</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DGCL</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), at a meeting duly called and held on [&#8226;], 2024, which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series B Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WHEREAS</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issuable from time to time in one or more series.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RESOLVED</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of [&#8226;] shares of &#8220;Series B Non-Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 3, 2024, by and among the Corporation, Atlas Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc. (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and (iii) the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of such series of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:20pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TERMS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For the purposes hereof, the following terms shall have the following meanings:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Business Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&#160;close.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Closing Sale Price</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Non-Voting Preferred Stock in accordance with the terms hereof.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a holder of shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the principal Trading Market is open for business.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Market</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Designation, Amount and Par Value</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the number of shares so designated shall be [&#8226;]. Each share of Series B Non-Voting Preferred Stock shall have a par value of $0.001 per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Dividends</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B Non-Voting Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Rights</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided herein or as otherwise required by the DGCL, the Series B Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series B Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series B Non-Voting Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series B Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of Series B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Non-Voting Preferred Stock, (iii) at any time while at least [&#8226;] shares of Series B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Common Stock basis of the capital stock of the Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series B Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any vote required or permitted under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed by Holders representing a majority of the outstanding shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Rank; Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Series B Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Upon any Liquidation,  each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">pari passu</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion at Option of Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each share of Series B Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Optional Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">Annex A</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Notice of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DTC</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DWAC Delivery</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for each share of Series B Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of each share of Series B Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series B Non-Voting Preferred Stock with respect to a Holder, and a Holder shall not have the right to convert any portion of the Series B Non-Voting Preferred Stock pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion with respect to the Series B Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the United States Securities and Exchange Commission (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Attribution Parties</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)) would beneficially own a number of shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall initially be [19.99]% of the number of shares of Common Stock outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i) each Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage applicable to such Holder, not to exceed 19.99%, which increase will not be effective until the sixty-first (61</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) day after such written notice is delivered to the Corporation, and (ii) each Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i) applicable to such Holder, not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, each Holder may waive and/or change the Beneficial Ownership Limitation applicable to such Holder effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series B Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Mechanics of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.1<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Delivery of Certificate or Electronic Issuance</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Delivery Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.2<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligation Absolute</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series B Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the event a Holder shall elect to convert any or all of its Series B Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series B Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, issue Conversion Shares upon a properly noticed conversion.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.3<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Buy-In on Failure to Timely Deliver Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series B Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B Non-Voting Preferred Stock as required pursuant to the terms hereof.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.4<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reservation of Shares Issuable Upon Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) upon the conversion of all outstanding shares of Series B Non-Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.5<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fractional Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued upon conversion of the Series B Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series B Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.6<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer Taxes</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series B Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series B Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status as Stockholder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon each Conversion Date, (i) the shares of Series&#160;B Non-Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series B Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Adjustments</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stock Dividends and Stock Splits</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation, at any time while this Series B Non-Voting Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time while this Series B Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then, upon any subsequent conversion of this Series B Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental Transaction, converted the Series B Non-Voting Preferred Stock immediately prior to such Fundamental Transaction (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Alternate Consideration</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.2</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and insuring that this Series B Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in the Merger Agreement) shall not constitute a Fundamental Transaction.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculations</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All calculations under this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made to the nearest cent or the nearest 1/100</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of a share, as the case may be. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Redemption</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Series B Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Holder may transfer any shares of Series B Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The transferee of any shares of Series B Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Series B Non-Voting Preferred Stock Register</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), a register for the Series B Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder in whose name the shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Series B Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address of each transferee of any shares of Series B Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B Non-Voting Preferred Stock or his, her or its legal representatives.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series B Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Book-Entry; Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Series B Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series B Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series B Non-Voting Preferred Stock. To the extent that any shares of Series B Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">13.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lost or Mutilated Series B Non-Voting Preferred Stock Certificate</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If a Holder&#8217;s Series B Non-Voting Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">14.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series B Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series B Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">15.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">16.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status of Converted Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If any shares of Series B Non-Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series B Non-Voting Preferred Stock. Any share of Series B Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Intentionally Left Blank</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;"><span class="CharOverride-11" style="font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span>, ARCA biopharma, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be duly executed by its [&#8226;] on [&#8226;], 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 45.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA biopharma, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ANNEX A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOTICE OF CONVERSION</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK)</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B Non-Voting Convertible Preferred Stock (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on [&#8226;], 2024.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series&#160;B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">CONVERSION CALCULATIONS:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Date to Effect Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number&#160;of&#160;shares&#160;of&#160;Series&#160;B&#160;Non-Voting&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to&#160;Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Series B Non-Voting Preferred Stock to be Converted:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Common Stock to be Issued:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Address for delivery of physical certificates:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 43.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:justify;text-indent:0pt;">For DWAC Delivery, please provide the following:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Broker No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Account No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-13" style="font-variant:normal;text-transform:uppercase;">[HOLDER]</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T106"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;G</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The first paragraph of Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is [&#8226;], consisting of [&#8226;] shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on [&#8226;], 2024 at [&#8226;] [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T107"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;H</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended to add the following paragraph at the end of Article IV:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Upon the effectiveness of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation adding this paragraph (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effective Time</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each [&#8226;] to [&#8226;] shares of  Common Stock issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock, without any further action by the Corporation or any holder thereof, the exact ratio within the [&#8226;] to [&#8226;] range to be determined by the Board of Directors of the Corporation prior to the Effective Time and publicly announced by the Corporation, subject to the treatment of fractional share interests as described below (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reverse Stock Split</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. Each certificate that immediately prior to the Effective Time represented shares Common Stock, as applicable (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Old Certificates</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall, until surrendered to the Corporation in exchange for a certificate representing such new number of shares of Common Stock, automatically represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On [&#8226;], 2024, the Board of Directors of the Corporation determined that each [&#8226;] shares of the Corporation&#8217;s Common Stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock. The Corporation publicly announced this ratio on [&#8226;], 2024.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on [&#8226;], 2024 at [&#8226;] [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-bottom:8pt;text-align:center;text-indent:36pt;margin-top:0pt;"></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T108"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;I</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc. (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">General Corporation Law</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), does hereby certify:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The current name of the Corporation is ARCA biopharma, Inc. The date of filing of the original Certificate of Incorporation of ARCA biopharma, Inc. with the Secretary of State of the State of Delaware was March 16, 2004 under the name Nuvelo Merger Sub, Inc.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on March 18, 2004 (as amended, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The existing Certificate of Incorporation is hereby amended to add Article XIII to the Certificate of Incorporation to read as follows:</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">XIII.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, an officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as an officer.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither any amendment nor repeal of this Article XIII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article XIII, shall eliminate or reduce the effect of this Article XIII in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article XIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of 242 of the General Corporation Law.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective as of _____, 2024 at _____ Eastern Time.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation has caused this Certificate of Amendment to be executed by the undersigned authorized officer of the Corporation as of this _____ day of _____, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T109"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;J</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights (Section&#160;262 of the Delaware General Corporation Law)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#167; 262. Appraisal rights</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(a)&#160;Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection&#160;(d)&#160;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(b)&#160;Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger, consolidation or conversion to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167; 388 of this title):</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title to accept for such stock anything except:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a corporation as a result of the conversion, or depository receipts in respect thereof;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(4)&#160;[Repealed.]</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(c)&#160;Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(d)&#160;Appraisal rights shall be perfected as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;If the merger, consolidation or conversion was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or conversion. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&#160;each such constituent corporation or the converting corporation shall send a second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective date of the merger, consolidation or conversion or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days following the sending of the first notice, such second notice need </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the&#160;day next preceding the&#160;day on which the notice is given.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(e)&#160;Within 120&#160;days after the effective date of the merger, consolidation or conversion, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation or conversion, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion. Within 120&#160;days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(f)&#160;Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(g)&#160;At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(h)&#160;After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(i)&#160;The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(j)&#160;The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(k)&#160;From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection (e)&#160;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60&#160;days after the effective date of the merger, consolidation or conversion, as set forth in subsection (e)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(l)&#160;The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T110"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;K</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 Oruka Therapeutics, Inc. Stock Incentive Plan</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T112"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;L </span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PART&#160;II <br/>INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;20.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Indemnification of Directors and Officers</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Delaware</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are corporations under the DGCL.&#160;Section&#160;145(a)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145(b)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors for monetary damages for breach of fiduciary duty as a director. Please see Proposal&#160;No. 4 for details regarding the proposed amendment to the ARCA Charter to eliminate, to the maximum extent permitted by the DGCL, the personal liability of officers for monetary damages for breach of fiduciary duty as an officer. The ARCA Charter and ARCA Bylaws provide that ARCA shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the ARCA Charter and ARCA Bylaws, and it intends to enter into indemnification agreements with any new directors and executive officers in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her incurred by him or her in any such capacity, subject to certain exclusions.</p>
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka Charter contains provisions that limit or eliminate the personal liability of Oruka&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Oruka Bylaws provide that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Oruka, subject to limited exceptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into indemnification agreements with its directors and executive officers. These agreements provide that Oruka will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Oruka will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Oruka will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Oruka or in furtherance of Oruka&#8217;s rights. Additionally, certain of Oruka&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Oruka has agreed in the indemnification agreements that Oruka&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the&#160;Securities Act.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;21.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibits and Financial Statement Schedules</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibit Index</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A list of exhibits filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> is set forth on the Exhibit Index and is incorporated herein by reference.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Financial Statements</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> are set forth on the Financial Statement Index and are incorporated herein by reference.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;22.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Undertakings</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(1)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To file, during any period in which offers or sales are being made, a post<span class="nobreak">-effective</span> amendment to this registration statement:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post<span class="nobreak">-effective</span> amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:72pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Provided, however</span>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post<span class="nobreak">-effective</span> amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange&#160;Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining any liability under the Securities Act, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(3)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To remove from registration by means of a post<span class="nobreak">-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(4)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange&#160;Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d)&#160;of the Exchange&#160;Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(5)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(6)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to paragraph (a)(5)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act&#160;of&#160;1933, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(7)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b),<span class="nobreak"> </span>11, or 13 of this form, within one business&#160;day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(8)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to supply by means of a post<span class="nobreak">-effective</span> amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="https://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of April&#160;3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub&#160;II, LLC, and Oruka Therapeutics, Inc. (included as Annex&#160;A to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm">Amended and Restated Certificate of Incorporation of ARCA biopharma, Inc., as amended (incorporated by reference to Exhibit 3.1 to ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513090814/d498361dex51.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 5.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;5, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459015007723/abio-ex31_74.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;3, 2015).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019010715/abio-ex31_7.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/0000907654/000156459021034792/abio-ex31_47.htm">Bylaws of ARCA biopharma, Inc., as currently in effect (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on June&#160;28, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock of the Registrant (previously filed with the SEC as an Exhibit and incorporated herein by reference from ARCA biopharma, Inc.&#8217;s Form&#160;S-1, filed on March&#160;25, 2013, File No.&#160;333-187508).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex31.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-5_arcabio.htm">Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-6_arcabio.htm">Bylaws of Oruka Therapeutics, Inc, as currently in effect.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509013220/dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on January&#160;29, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019017210/abio-ex42_106.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;8, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.3***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Investor Rights Agreement, dated March&#160;6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.6&#8224;&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.7#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_1.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and Thomas A, Keuer dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.8#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_1.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.9#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.10#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_2.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.11#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_2.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.12#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020042033/abio-ex101_7.htm">Office Lease Agreement, effective August&#160;7, 2020, between ARCA biopharma, Inc. and Potens Partners&#160;LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on August&#160;31, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024035373/abio-ex10_1.htm">First Amendment to Office Lease Agreement, dated March&#160;19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;22, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.15#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex101.htm">ARCA biopharma, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.16#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex102.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.17#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex103.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.18#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex104.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.19#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex105.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.20#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex106.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.21#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020056751/abio-ex101_7.htm">ARCA biopharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;10, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.22#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex101_6.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.23#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex102_11.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.24#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex103_7.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.25#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex104_8.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.26#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex105_9.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.27&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex101.htm">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.28&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex102.htm">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.29</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1046.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.46 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1048.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.48 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.31</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1052.htm">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers (incorporated by reference to Exhibit 10.52 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.32&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312511223373/dex105.htm">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;15, 2011).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.33#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1043.htm">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow (incorporated by reference to Exhibit 10.43 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.34#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459013000333/abio-ex10_20130629569.htm">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow, effective as of June&#160;13, 2013 (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed August&#160;13, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.35#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312514457143/d842508dex102.htm">Amended and Restated Employment Agreement, dated December&#160;29, 2014, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K/A filed on December&#160;30, 2014).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.36#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021026534/abio-ex102_75.htm">Employment Agreement, dated April&#160;21, 2021, by and between ARCA biopharma, Inc. and C.&#160;Jeff Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;11, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.37&#167;&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021040795/abio-ex103_140.htm">Assignment Agreement for Patent Rights, dated July&#160;1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;4, 2021).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.38**#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K </span>to the proxy statement/prospectus and incorporated herein by reference)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.39**#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L </span>to the proxy statement/prospectus and incorporated herein by reference)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.40***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.41***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.42***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.43***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.44***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.45***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-45_arcabio.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.46***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-46_arcabio.htm">Amended and Restated Employment Offer Letter, dated February&#160;14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.47***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-47_arcabio.htm">Employment Offer Letter, dated March&#160;11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.48***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment Offer Letter, dated March&#160;15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.49***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.50*&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512202ex10-50_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.51*&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512202ex10-51_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex21-1_arcabio.htm">List of Subsidiaries of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512202ex23-1_arcabio.htm">Consent of KPMG LLP, independent registered public accounting firm of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512202ex23-2_arcabio.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.3**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit 5.1).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#T555">Power of Attorney (included in the signature page hereto).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form of ARCA biopharma, Inc. proxy card.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T106">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Increase in Authorized Shares (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.3*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T107">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Reverse Stock Split (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.4*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T108">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Officer Exculpation (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-5_arcabio.htm">Consent of Lucid Capital Markets, LLC.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-6_arcabio.htm">Consent of Lawrence Klein to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.7***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-7_arcabio.htm">Consent of Kristine Ball to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.8***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-8_arcabio.htm">Consent of Carl Dambkowski to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.9***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-9_arcabio.htm">Consent of Peter Harwin to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.10***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-10_arcabio.htm">Consent of Samarth Kulkarni to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.11***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-11_arcabio.htm">Consent of Cameron Turtle to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.INS*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Instance Document.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.SCH*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Schema.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.CAL*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Calculation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.DEF*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Definition Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.LAB*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Label Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.PRE*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Presentation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Filing Fee Table.</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed herewith.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To be filed by amendment.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">***<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Previously filed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Indicates management contract or compensatory plan or arrangement.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> under the Exchange&#160;Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;&#8224;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Confidential treatment has been granted as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;&#167;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Schedules have been omitted from this filing pursuant to Item&#160;601(b)(2)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> of the Exchange&#160;Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, &#8220;*,&#8221; have been omitted because such portions contained information that is both (i)&#160;not material and (ii)&#160;would likely cause competitive harm if publicly disclosed.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SIGNATURES</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on June<span class="nobreak"> </span>18, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARCA BIOPHARMA, INC.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Signature</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">President and Chief Operating Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A. Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">(Principal Executive Officer)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Financial Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Officer and <br/>Principal Accounting Officer</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Robert Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jacob Ma<span class="nobreak">-Weaver</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">June<span class="nobreak"> </span>18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">*&#160;By:</p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Attorney<span class="nobreak">-in-Fact</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-9</p>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:OtherNonoperatingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-7" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.37</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-8" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.69</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="0" id="hidden-fact-9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-10" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14415877</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.09</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="0" id="hidden-fact-13" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14501143</ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-48" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-49" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-50" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-52" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-55" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-56" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-58" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-62" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-64" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-66" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-68" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-69" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-70" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-71" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-72" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-73" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-74" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-75" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-77" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-79" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c98" id="hidden-fact-97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c99" id="hidden-fact-98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-99" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P10Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c106" id="hidden-fact-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">P1Y</ix:nonNumeric>
<ix:nonFraction contextRef="c6" id="hidden-fact-101" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-102" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-103" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-104" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-105" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-106" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c114" id="hidden-fact-107" name="abio:OperatingLossCarryforwardsExpirationYear">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="c115" id="hidden-fact-108" name="abio:OperatingLossCarryforwardsExpirationYear">2037</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-109" name="us-gaap:OpenTaxYear">2009</ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-110" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-112" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-114" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-115" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-116" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-37127">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-37128">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMzXSpgRNKF6i837wJX54UslA==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-28</xbrli:startDate>
    <xbrli:endDate>2020-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>2
<FILENAME>ea020512202ex10-50_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED ANTIBODY DISCOVERY AND OPTION AGREEMENT (IL-17), DATED MARCH 28, 2024, BY AND AMONG PARAGON THERAPEUTICS, INC., PARUKA HOLDING LLC AND ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.50</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL
IF PUBLICLY DISCLOSED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANTIBODY DISCOVERY AND OPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>This
Amended and Restated Antibody Discovery and Option Agreement</B></FONT> (&ldquo;<B>Agreement</B>&rdquo;) is entered into and effective
as of March 28, 2024 (the &ldquo;<B>New Effective Date</B>&rdquo;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Paragon</B>&rdquo;),
Paruka Holding, LLC, a Delaware limited liability company (&ldquo;<B>Paruka</B>&rdquo;) and Oruka Therapeutics, Inc., a Delaware corporation
(&ldquo;<B>Oruka</B>&rdquo;). Paragon, Paruka and Oruka are also referred to herein individually as a &ldquo;<B>Party</B>&rdquo;, or collectively
as the &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Recitals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B>,</FONT>
Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant
targets<FONT STYLE="background-color: white">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,
</FONT>Oruka Operating Company A LLC, a Delaware limited liability company and, as of the Effective Date, a subsidiary of Oruka (&ldquo;<B>OpCo</B>&rdquo;)
engaged each of Paragon and Paruka to identify, evaluate and develop one or more antibody candidates directed to certain mutually agreed
therapeutic targets of interest to OpCo, pursuant to an Antibody Discovery and Option Agreement (the &ldquo;<B>Original Agreement</B>&rdquo;)
dated March 6, 2024 (the &ldquo;<B>Effective Date</B>&rdquo;), by and among Paragon, Paruka, OpCo, and, <I>solely</I> for purposes of
certain sections of the Original Agreement, Oruka;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT>,
Paragon and Paruka have been performing certain antibody discovery and development activities pursuant to the Original Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT><FONT STYLE="font-variant: small-caps; background-color: white">,</FONT>
pursuant to the Original Agreement, OpCo received an exclusive option to enter into separate license agreements with Paragon and Paruka,
as applicable, to develop, manufacture and commercialize the resulting antibodies with respect to a given target, all on the terms and
subject to the conditions set forth in the Original Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,
</FONT>in connection with an internal reorganization of Oruka and pursuant to a Merger Agreement, dated March 22, 2024, by and among Oruka,
OpCo and Oruka Operating Company B LLC and Oruka Operating Company C LLC, OpCo was merged with and into Oruka, with Oruka being the surviving
entity (the &ldquo;<B>Merger</B>&rdquo;), and Oruka assumed all properties, rights, privileges, immunities, powers, franchises, debts,
liabilities, obligations and duties of OpCo pursuant to the Merger; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT><FONT STYLE="font-variant: small-caps; background-color: white">,
</FONT>the parties desire to amend and restate the Original Agreement to, among other matters, update certain terms of the original arrangement
and to amend the parties to the Original Agreement following the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now
Therefore, </B></FONT>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
1</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
DEFINED TERMS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.1   </B></FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Active
Research Program</B></FONT>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>5.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2   </B></FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Actual
Annual Costs</B></FONT>&rdquo; shall have the meaning set forth in Section&nbsp;<FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>5.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>1.3   </B></FONT>&ldquo;<B>Affiliate</B>&rdquo;
shall mean any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &ldquo;control&rdquo;
(including, with correlative meaning, the terms &ldquo;controlled by&rdquo; or &ldquo;under common control&rdquo;) means the direct or
indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the
right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding
the foregoing, (a)&nbsp;with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such
Party and its subsidiaries, (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.4   </B>&ldquo;<B>Agreement</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.5   </B>&ldquo;<B>Antibody</B>&rdquo;
shall mean any molecule, including [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.6   </B>&ldquo;<B>Antibody
Production Activities</B>&rdquo; shall have the meaning provided in Section&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.7   </B>&ldquo;<B>Applicable
Law</B>&rdquo; shall mean any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case,
as applicable to the subject matter and the party at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.8   </B>&ldquo;<B>Bankruptcy
Code</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>9.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.9   </B>&ldquo;<B>Bankruptcy
Event</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>9.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.10   </B>&ldquo;<B>Background
IP</B>&rdquo; shall mean all Patents and Know-How Controlled by a Party (a) as of the Effective Date, or (b) that otherwise arise outside
of and independently of this Agreement. Paragon&rsquo;s Background IP includes the Paragon Platform Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.11   </B>&ldquo;<B>Budget</B>&rdquo;
shall mean the agreed budget for the activities set forth in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.12   </B>&ldquo;<B>Business
Day</B>&rdquo; shall mean any day other than Saturday, Sunday or other national holidays in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.13   </B>&ldquo;<B>Calendar
Quarter</B>&rdquo; shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30
and December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.14   </B>&ldquo;<B>Calendar
Year</B>&rdquo; shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.15   </B>&ldquo;<B>Commercialize</B>&rdquo;
or &ldquo;<B>Commercializing</B>&rdquo; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported,
export, have exported or otherwise commercialize an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific
Antibody or Multispecific Product, as applicable. When used as a noun, &ldquo;Commercialization&rdquo; means any and all activities involved
in Commercializing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.16   </B>
&ldquo;<B>Confidential Information</B>&rdquo; of a Party shall mean any and all non-public scientific, business, regulatory or technical
information that is disclosed or made available by or on behalf of one Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) to any other
Party (a &ldquo;<B>Receiving Party</B>&rdquo;) in connection with this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding
any provision of this Agreement to the contrary, all Project Antibody Inventions and Project Antibody Technology shall be the Confidential
Information of all Parties, and each Party shall be deemed as both the &ldquo;Disclosing Party&rdquo; and the &ldquo;Receiving Party&rdquo;
with respect thereto; <I>provided, that</I> if Oruka does not exercise its Option or the Parties do not enter into a License Agreement
in accordance with this Agreement, then the Project Antibody Inventions and Project Antibody Technology shall thereafter be the Confidential
Information of Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.17   </B>&ldquo;<B>Control</B>&rdquo;
(including any variations such as &ldquo;<B>Controlled</B>&rdquo; and &ldquo;<B>Controlling</B>&rdquo;) shall mean, with respect to any
Technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant
a license or a sublicense of or under such Technology or Intellectual Property Rights without violating the terms of any agreement or
other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its Affiliates shall not be
deemed to &ldquo;Control&rdquo; any technology or Intellectual Property Rights that (a) prior to the consummation of a Change of Control
of such Party, is owned or in-licensed, or (b)&nbsp;after the consummation of a Change of Control of such Party, becomes owned or in-licensed
(to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder
and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party
immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a) or (b)), by a Third
Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party
after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation
of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.18   </B>&ldquo;<B>Cost
Advance</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.19   </B>&ldquo;<B>Cover</B>&rdquo;
or &ldquo;<B>Covering</B>&rdquo; shall mean, with respect to a Patent, that, in the absence of a license granted under, or ownership of,
such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such
Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.20   </B>&ldquo;<B>Deliverables</B>&rdquo;
shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.1(c)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.21   </B>&ldquo;<B>Derived
Antibody</B>&rdquo; shall mean any Antibody that (a)&nbsp;is derived from or constitutes a modification of a Project Antibody, including
[***], and (b)&nbsp;[***]. For avoidance of doubt, any Antibody that [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.22   </B>&ldquo;<B>Derived
Antibody Patent</B>&rdquo; shall mean any Patent that Covers the composition of matter of, or any method of specifically making or using,
any Derived Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.23   </B>&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Developing</B>&rdquo; shall mean to discover, evaluate, test, research or otherwise develop an Antibody or product, including
a Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable. When used as a noun, &ldquo;<B>Development</B>&rdquo;
means any and all activities involved in Developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.24   </B>&ldquo;<B>Development
Costs</B>&rdquo; shall mean (a) [***] (such amounts, the &ldquo;<B>Third Party Costs</B>&rdquo;), and (b) [***] (such development fees,
the &ldquo;<B>Development Fees</B>&rdquo;, and the development fees to be paid in any given Calendar Year during the Research Program,
the &ldquo;<B>Annual Development Fees</B>&rdquo;); in each case ((a) and (b)) to the extent consistent with the applicable Research Plan
(including [***]).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.25   </B>&ldquo;<B>Directed
To</B>&rdquo; shall mean, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [***],
and (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.26   </B>&ldquo;<B>Dispute</B>&rdquo;
shall have the meaning provided in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>11.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.27   </B>&ldquo;<B>Effective
Date</B>&rdquo; shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.28   </B>&ldquo;<B>Election
Notice</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.29   </B>&ldquo;<B>Equity
Grant</B>&rdquo; shall have the meaning provided in Section&nbsp;<FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>5.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.30   </B>&ldquo;<B>Field</B>&rdquo;
shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.31   </B>&ldquo;<B>Final
Deliverable</B>&rdquo; shall, on a Research Program-by-Research Program basis, have the meaning provided in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.32   </B>&ldquo;<B>IL-17A/F
Pre-Effective Date Development Costs</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>5.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.33   </B>&ldquo;<B>Indemnified
Party</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.34   </B>&ldquo;<B>Indemnifying
Party</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.35   </B>&ldquo;<B>Intellectual
Property Rights</B>&rdquo; shall mean any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright
law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in
Know-How, or the expression or use thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.36   </B>&ldquo;<B>JDC</B>&rdquo;
shall have the meaning provided in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.37   </B>&ldquo;<B>Know-How</B>&rdquo;
shall mean all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets,
data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like),
methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions
or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes
for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions,
processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding
the foregoing, Know-How excludes Patent claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.38   </B>&ldquo;<B>License
Agreement</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>4.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.39   </B>&ldquo;<B>License
Template</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>4.4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.40   </B>&ldquo;<B>Losses</B>&rdquo;
shall have the meaning provided in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.41   </B>&ldquo;<B>Manufacture</B>&rdquo;
or &ldquo;<B>Manufacturing</B>&rdquo; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality
assurance testing, release, ship or store an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific
Antibody or Multispecific Product or any component thereof, as applicable. When used as a noun, &ldquo;Manufacture&rdquo; or &ldquo;Manufacturing&rdquo;
means any and all activities involved in Manufacturing an Antibody or product, including a Project Antibody, Derived Antibody, Product,
Multispecific Antibody or Multispecific Product or any component thereof, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.42   </B>&ldquo;<B>Multispecific
Antibody</B>&rdquo; means any Antibody that is comprised of (a) [***], and (b) one (1) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.43   </B>&ldquo;<B>Multispecific
Product</B>&rdquo; means any product that comprises or contains any Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.44   </B>&ldquo;<B>Notice
of Dispute</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>11.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.45   </B>&ldquo;<B>Option</B>&rdquo;
shall have the meaning provided in Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.46   </B>&ldquo;<B>Option
Period</B>&rdquo; shall have the meaning provided in Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.47   </B>&ldquo;<B>Oruka</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.48   </B>&ldquo;<B>Oruka
Indemnitee</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.49   </B>&ldquo;<B>Paragon</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.50   </B>&ldquo;<B>Paragon
Indemnitee</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.51   </B>&ldquo;<B>Paragon
Platform Know-How</B>&rdquo; shall mean (a) Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating to antibody
discovery and development, (b) all methods, materials and other Know-How used in the foregoing Controlled by Paragon or its Affiliates,
and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b) Controlled by Paragon
or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.52   </B>&ldquo;<B>Paragon
Platform Know-How Improvement</B>&rdquo; shall mean all Know-How developed or discovered through or as a result of the activities performed
by or on behalf of Paragon under a Research Program that constitutes an improvement, enhancement, modification, substitution, or alteration
to the Paragon Platform Technology; <I>provided, however</I>, to the extent any of the Know-How developed or discovered under a Research
Program specifically and solely relates to a Project Antibody, such Know-How will be considered Project Antibody Technology and not Paragon
Platform Know-How Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.53   </B>&ldquo;<B>Paragon
Platform Patents</B>&rdquo; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon
Platform Know-How or Paragon Platform Know-How Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.54   </B>&ldquo;<B>Paragon
Platform Technology</B>&rdquo; shall mean Paragon Platform Know-How, Paragon Platform Know-How Improvements and Paragon Platform Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.55   </B>&ldquo;<B>Party</B>&rdquo;
or &ldquo;<B>Parties</B>&rdquo; shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.56   </B>&ldquo;<B>Paruka</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.57   </B>&ldquo;<B>Patents</B>&rdquo;
shall mean (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues,
renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like
of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.58   </B>&ldquo;<B>Predecessor</B>&rdquo;
shall have the meaning provided in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.59   </B>&ldquo;<B>Product</B>&rdquo;
shall mean any product that comprises or contains any Project Antibody or any Derived Antibody thereof, other than as part of a Multispecific
Antibody or a Multispecific Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.60   </B>&ldquo;<B>Project
Antibody</B>&rdquo; shall mean any and all Antibodies that are Directed To a particular Selected Target and that are discovered, generated,
identified or characterized by Paragon in the course of performing the applicable Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.61   </B>&ldquo;<B>Project
Antibody Invention</B>&rdquo; shall mean (a) any invention or discovery, whether or not patentable, that was discovered or reduced to
practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically
making or using, any Project Antibody, and (b) all Intellectual Property Rights therein that are Controlled by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.62   </B>&ldquo;<B>Project
Antibody Patents</B>&rdquo; shall mean all Patents that Cover the composition of matter of, or any method of specifically making or using,
any Project Antibody, that are in each case Controlled by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.63   </B>&ldquo;<B>Project
Antibody Samples</B>&rdquo; shall have the meaning provided in Section&nbsp;<FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>2.1(c)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.64   </B>&ldquo;<B>Project
Antibody Selection Criteria</B>&rdquo; shall mean those criteria agreed to by the Parties in the applicable Research Plan that establish
that a Project Antibody is suitable for clinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.65   </B>&ldquo;<B>Project
Antibody Technology</B>&rdquo; shall mean (a) the Project Antibody Inventions, (b) the Project Antibody Patents, (c) the Sequence Information
and Results, and (d) all Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates. For clarity, if the Parties
execute a License Agreement with respect to a particular Research Program and the Research Term for such Research Program continues following
execution of such License Agreement, any Project Antibody Technology first conceived, reduced to practice or otherwise generated following
the execution of the License Agreement shall be licensed to Oruka under such License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.66   </B>&ldquo;<B>Representatives</B>&rdquo;
of a Party shall mean such Party&rsquo;s and its Affiliates&rsquo; officers, directors, employees, contractors, subcontractors, agents
and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.67   </B>&ldquo;<B>Research
Plan</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.68   </B>&ldquo;<B>Research
Program</B>&rdquo; shall mean a research program agreed to by the Parties to identify Project Antibodies with activity against one Selected
Target and to perform such additional activities with respect to such Selected Target as set forth in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.69   </B>&ldquo;<B>Research
Term</B>&rdquo; shall mean, on a Research Program-by-Research Program basis, the period of time beginning on the agreement by the Parties
on the Research Plan and continuing until completion of the activities under the Research Plan for such Research Program or such other
date mutually agreed upon by the Parties; <I>provided, that</I> (a) if Oruka does not exercise its Option in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3
prior to expiration of the applicable Option Period, then upon such expiration the Research Term shall automatically terminate and Paragon
shall have no obligation to perform any activities under the applicable Research Plan thereafter, or (b) if Oruka exercises its Option
during the Option Period in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3 but the Parties are unable to finalize
and execute a License Agreement during the [***] day period referenced in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4(b), then
upon the expiration of such period the Research Term shall automatically terminate and Paragon shall have no obligation to perform any
activities under the applicable Research Plan thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.70   </B>&ldquo;<B>Results</B>&rdquo;
shall mean the data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf
of Paragon in performance of a Research Program, excluding Project Antibodies, Project Antibody Inventions, Project Antibody Patents and
the Sequence Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.71   </B>&ldquo;<B>Selected
Target</B>&rdquo; shall have the meaning set forth in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.72   </B>&ldquo;<B>Sequence
Information</B>&rdquo; shall mean electronic files containing all Project Antibody sequences generated under a given Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.73   </B>&ldquo;<B>Shares</B>&rdquo;
shall mean shares of common stock, par value $0.0001, of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.74   </B>&ldquo;<B>Target</B>&rdquo;
shall mean a protein molecule that (a) [***], and (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.75   </B>&ldquo;<B>Term</B>&rdquo;
shall have the meaning provided in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.76   </B>&ldquo;<B>Territory</B>&rdquo;
shall mean worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.77   </B>&ldquo;<B>Third
Party</B>&rdquo; shall mean any person or entity other than Paragon, Paruka or Oruka or an Affiliate of any of Paragon, Paruka or Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.78   </B>&ldquo;<B>Third
Party Claim</B>&rdquo; shall have the meaning provided in Section <FONT STYLE="font-size: 10pt"><B>&lrm;</B></FONT>10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.79   </B>&ldquo;<B>Valid
Claim</B>&rdquo; shall mean, with respect to a particular country, a claim (including a process, use, or composition of matter claim)
of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned,
permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental
agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision
is final and un-appealable or un-appealed within the time allowed for appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
2</B></FONT><BR>
<B>CONDUCT OF RESEARCH PROGRAM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.1   Research
Program.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   Target
Selection</B>. The Parties intend to initiate one or more Research Programs, each focused on a particular Target (each, a &ldquo;<B>Selected
Target</B>&rdquo;). No more than one (1) Selected Target will be included in any Research Program, unless the Parties otherwise agree
in writing (e.g., in the case of a Research Program seeking to develop a [***]). As of the Effective Date, the Parties have agreed to
the Selected Targets listed on <U>Exhibit A</U>. Additional Targets may be added to the Selected Targets by mutual written agreement of
the Parties, it being understood that each Party may accept or reject a new Selected Target in its sole discretion and no Party shall
be obligated under this Agreement to agree to any further Selected Targets. The Parties acknowledge that, prior to any agreement with
respect to a Selected Target and a Research Plan, it is intended that the Parties may initiate, from time-to-time, &ldquo;proof-of-concept&rdquo;
studies [***] at no up-front Research Initiation Fee to Oruka; <I>provided, that</I> the costs of any such &ldquo;proof-of-concept&rdquo;
studies may be recaptured by Paragon within the specified Research Plan and associated fees, in each case, as agreed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   Research
Plan. </B>No later than [***] after the Effective Date (or in the case of any Selected Target added after the Effective Date, no later
than [***] days after the Parties&rsquo; written agreement on such additional Selected Target), the Parties will agree on a research plan,
to the extent a research plan has not been previously agreed upon, for the applicable Selected Target that will include design, modeling,
synthesis, evaluation, and other mutually agreed activities (&ldquo;<B>Research Plan</B>&rdquo;). For clarity, if at the end of such [***]
period (or any extension thereof mutually agreed in writing) (i) the Parties have not agreed on a Research Plan, or (ii) Oruka has not
paid Paragon the Research Initiation Fee, the applicable Target shall cease to be a Selected Target and Paragon shall have no obligations
with respect thereto. Once the Parties agree on a Research Plan and Oruka pays the Research Initiation Fee for a Research Program, Paragon
and Paruka shall conduct research under such Research Program during the applicable Research Term in an effort to (1)&nbsp;produce Project
Antibodies against the applicable Selected Target for further Development, Manufacture and Commercialization (&ldquo;<B>Antibody Production
Activities</B>&rdquo;), and (2) perform such other Development and Manufacturing activities with respect to the Project Antibodies as
set forth in the Research Plan (which other activities, for clarity, may be performed following Oruka&rsquo;s exercise of the Option or
execution of a License Agreement). The Parties may amend the Research Plan upon mutual written agreement. Paragon and Paruka will use
[***] to conduct and complete the activities set forth in such Research Plan on the timelines set forth in such Research Plan and in compliance
with the Budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   Deliverables;
Project Antibody Samples. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i)   Following
completion of the Antibody Production Activities set forth in the Research Plan for a Research Program, Paragon and Paruka will deliver
to Oruka a data package that includes Sequence Information for all then-existing Project Antibodies and Results (the &ldquo;<B>Deliverables</B>&rdquo;).
Additionally, upon request by Oruka, and at [***] cost and expense, Paragon and Paruka shall provide to Oruka samples of proteins corresponding
to such Project Antibodies that have been expressed in accordance with the Research Plan (&ldquo;<B>Project Antibody Samples</B>&rdquo;)
to enable Oruka to evaluate the Option. Following completion of a Research Program, Paragon shall deliver to Oruka the Final Deliverable
for such Research Program, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii)   During
the Option Period with respect to each Research Program, Oruka will review the Deliverables and Project Antibody Samples for such Research
Program to determine whether [***] Project Antibody meets the Project Antibody Selection Criteria. If Oruka determines that [***] Project
Antibody meets the Project Antibody Selection Criteria, then Oruka shall so notify Paragon in writing prior to the end of the Option Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   Conduct
of Research Program. </B>During the Research Term, Paragon and Paruka shall (i) perform the activities assigned to it under the applicable
Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with the
applicable Research Plans; (ii) ensure that its Representatives and subcontractors diligently perform the applicable Research Program
in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant
fields and in compliance with Applicable Law; (iii) keep Oruka fully informed regarding the progress and results of the Research Program;
(iv) promptly provide Oruka with any additional information regarding the Research Program that Oruka reasonably requests; (v)&nbsp;participate
in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Oruka on the performance of the Research Program;
and (vi) give Oruka prompt written notice with respect to information known or believed by Paragon and Paruka to be likely to materially
impede or otherwise adversely affect the performance of the Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.2   Subcontractors.
</B>Paragon and Paruka may perform some of the activities under a Research Program through one or more subcontractors; <I>provided, that</I>
Paragon and Paruka shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance
of their obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.3   Research
Books and Records; Audit</B>. Paragon shall maintain complete and accurate records related to the activities performed by Paragon under
a Research Program. All such books and records shall be retained by Paragon and Paruka until the later of: (a) [***] after the end of
the applicable stage of research; and (b) such longer period as may be required by Applicable Law. Upon Oruka&rsquo;s request and at [***]
expense, Paragon shall provide copies of such records or such records shall be made available for Oruka&rsquo;s reasonable review, audit
and inspection upon reasonable notice and with reasonable frequency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
3</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
GOVERNANCE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.1   </B></FONT><B>Joint
Development Committee</B>. The Parties will establish a single Joint Development Committee (the &ldquo;<B>JDC</B>&rdquo;) to oversee and
coordinate the activities under all Research Programs in accordance with the remainder of this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article
3. The JDC shall be comprised of two (2) employees from Oruka and two (2) employees from Paragon, with each Party designating one (1)
such employee as its JDC co-chairperson. Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC
from time to time, and may change its Representatives, in its sole discretion, effective upon notice to the other Parties designating
such change. Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and
ongoing familiarity with the activities to be performed under the Research Programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.2   </B></FONT><B>JDC
Meetings</B>. The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently
than once every three (3) months until, on a Research Program-by-Research Program basis, the end of the period specified in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>3.5.
The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. As appropriate,
additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers; <I>provided, that</I> any such
consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <I>provided, further that</I>
no Third Party personnel may attend unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance
of the JDC meetings by its representatives. Each Party may also call for special meetings to resolve particular matters requested by such
Party. Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned
or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within [***] Business Days after
a meeting for review. Each member shall have [***] Business Days from receipt in which to comment on and to approve/provide comments to
the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify
the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.3   </B></FONT><B>JDC
Functions</B>. The JDC&rsquo;s responsibilities are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Developing,
reviewing, overseeing and coordinating the activities under each Research Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Periodically
reviewing the progress of activities under each Research Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>Updating
or modifying each Research Plan; <I>provided, that</I> such update or modification does not obligate any Party to perform any task or
expend any resources outside of or beyond its obligations under the applicable Budget;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Reviewing
performance against the Budget and timeline for each Research Program periodically (at least [***]), and periodically meeting to review
and (subject to mutual approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than
[***] percent ([***]%);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>Reviewing
the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year for each Research Program; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(f)   </B>Determining
whether the Project Antibody Selection Criteria for a Research Program are not achievable for any reason and therefore such Research Program
no longer warrants further research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>3.4   JDC
Decision Making and Disputes</B>. The JDC will endeavor to make decisions by consensus, with each of Oruka and Paragon having one vote.
If consensus is not reached by the Parties&rsquo; Representatives pursuant to such vote, then disputes relating to: (a) the reconciliation
of Actual Annual Costs against the Cost Advance, as set forth in Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.2(c),
will be resolved in accordance with Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>11.7; (b) technical or
scientific decisions in the course of operationalizing each Research Program, including the nature of activities to be performed by Paragon
and Paruka thereunder, shall be finally decided by [***]; and (c) the Budget for any Research Program, and all other matters not covered
by clauses (a) or (b), shall be finally decided by [***]. For clarity, and notwithstanding the creation of the JDC, each Party shall retain
the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion
unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The JDC shall not have the
power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions
of this Agreement. It is understood and agreed that issues to be formally decided by the JDC are limited to those specific issues that
are expressly provided in this Agreement to be decided by the JDC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>3.5   Disbandment</B>.
The JDC shall remain in effect from the date on which it is established in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3.1
until, on a Research Program-by-Research Program basis, the expiration of the applicable Research Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
4</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
OPTION; LICENSE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.1   Grant
of Option.</B> Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, Paragon hereby
grants to Oruka, during the Term and subject to delivery of the Election Notice in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3,
an exclusive option (&ldquo;<B>Option</B>&rdquo;) to be granted an exclusive license under the Project Antibody Technology for the applicable
Research Program to Develop, Manufacture and Commercialize Project Antibodies, Derived Antibodies and Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.2   Limited
License Grant During Option Period.</B> Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program
basis, and effective only during the Term, Paragon hereby grants to Oruka a limited, exclusive, royalty-free license, without the right
to sublicense, under the Project Antibody Technology arising from such Research Program solely to evaluate the Option and for the purpose
of allowing Oruka to determine whether to exercise the Option with respect to such Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.3   Option
Exercise.</B> On a Research Program-by-Research Program basis, Oruka may, in its sole discretion, exercise the Option by delivering written
notice of such exercise to Paragon (&ldquo;<B>Election Notice</B>&rdquo;) at any time during the period beginning on the initiation of
activities under such Research Program and ending [***] days following Oruka&rsquo;s receipt of the Deliverables for such Research Program,
or such longer period as agreed upon by the Parties (&ldquo;<B>Option Period</B>&rdquo;). If Oruka fails to exercise an Option in accordance
with this Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3 prior to expiration of the applicable Option Period, then, upon such expiration,
such Option shall terminate and be of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.4   License
Template; Execution After Option Exercise. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Within
[***] days of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form of agreement template (&ldquo;<B>License
Template</B>&rdquo;) to be used in connection with Oruka&rsquo;s exercise of its Option, which will be consistent with the economic and
other terms set forth in <U>Exhibit B</U>, and upon mutual agreement by the Parties on the form of such License Template, will be attached
to this Agreement and replace the terms on the existing <U>Exhibit B</U>. If the Parties are unable to reach agreement on the definitive
terms of either License Template within such [***] period, the matter will be resolved in accordance with Section <FONT STYLE="font-size: 12pt">&lrm;</FONT>11.7
unless the Parties mutually agree to resolve the matter otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Within
[***] days of Oruka&rsquo;s exercise of its Option with respect to a Research Program as set forth in Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3,
subject to any extension as mutually agreed by the Parties, the Parties shall use [***] to finalize and execute a definitive written agreement
consistent with the License Template (the &ldquo;<B>License Agreement</B>&rdquo;) with respect to such Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
5</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
PAYMENTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.1   Research
Initiation Fee</B>. Oruka shall pay to Paragon, on a Research Program-by-Research Program basis, a one-time nonrefundable, non-creditable
fee of Seven Hundred Fifty Thousand Dollars ($750,000) (the &ldquo;<B>Research Initiation Fee</B>&rdquo;) no later than [***] days following
finalization of the Research Plan for such Research Program. For clarity, the Research Initiation Fee is nonrefundable, non-creditable,
and separate from any Development Costs (including the IL-17A/F Pre-Effective Date Development Costs) or Cost Advance paid or owing with
respect to a particular Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.2   Development
Costs</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>The
monthly rate for the Development Fees (the &ldquo;<B>Monthly Rate</B>&rdquo;) shall be determined and charged on a Research Program-by-Research
Program and calendar month-by-calendar month basis based on, with respect to any particular calendar month, the total number of Research
Programs being conducted under this Agreement and each other similar Antibody Discovery and Option Agreement between Paragon and Paruka,
on the one hand, and Oruka or any Affiliate of Oruka, on the other hand (each such Research Program, an &ldquo;<B>Active Research Program</B>&rdquo;).
For the period beginning on the Effective Date and continuing through December 31, 2024, the Monthly Rate for each Active Research Program
in a particular calendar month shall be [***]. Paragon shall have the right to adjust the Monthly Rate on an annual basis to account for
inflation and other increases in costs by providing written notice thereof to Oruka at least [***] days prior to the commencement of each
[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>On
a quarterly basis, Oruka will advance to Paragon any Development Costs contemplated in the Research Budget, including [***], and any [***]
reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] in accordance with
the Research Plan and Research Budget (less any pre-payments for Third Party Costs from earlier [***] that Paragon reasonably anticipates
will be carried over to such upcoming [***]) (the &ldquo;<B>Cost Advance</B>&rdquo;). On a quarterly basis, Paragon will deliver an invoice
to Oruka for the Cost Advance, and Oruka will pay the Cost Advance within [***] after receipt of Paragon&rsquo;s invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>Within
[***] after the end of each Calendar Year, Paragon will calculate and provide to Oruka a written reconciliation of its actually-incurred
Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&ldquo;<B>Actual Annual Costs</B>&rdquo;)
against that portion of the Cost Advance for such Third Party Costs for that Calendar Year, including reasonable documentation of such
Actual Annual Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for anticipated
Third Party Costs in the Cost Advance exceeds the Actual Annual Costs, then Paragon will credit such excess payment against Development
Costs contemplated in the Budget and reasonably expected to be incurred by Paragon in the performance of the Research Program during any
upcoming Calendar Year and Oruka will deduct such amount from its next quarterly Cost Advance. If the Cost Advance is less than the Actual
Annual Costs, then Paragon will invoice Oruka for the difference and Oruka will pay such amount together with its next quarterly Cost
Advance. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation
will not apply to Annual Development Fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Notwithstanding
Sections <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.2(a), <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.2(b)
and <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.2(c) to the contrary, the Parties acknowledge that Paragon
has incurred (i)&nbsp;[***] in Development Costs through December 31, 2023, and (ii) certain additional Development Costs between January
1, 2024 and the Effective Date, as a result of work performed by Paragon at risk on the Research Program for IL-17A/F (the costs described
in (i) and (ii), the &ldquo;<B>IL-17A/F Pre-Effective Date Development Costs</B>&rdquo;). Oruka shall reimburse Paragon for the IL-17A/F
Pre-Effective Date Development Costs within [***] after Oruka&rsquo;s receipt of a written invoice that details the IL-17A/F Pre-Effective
Date Development Costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.3   Financial
Records.</B> Paragon shall keep complete and accurate books of account and records in sufficient detail to enable the Development Costs
payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for
at least [***] following the end of the [***] to which such books and records pertain and Oruka shall be entitled to inspect such books
and records at Paragon&rsquo;s offices upon Oruka&rsquo;s reasonable request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.4   Manner
and Method of Payment</B>. All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise specified. Each payment
shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless
otherwise specified in writing by Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.5   Tax</B>.
Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs and any payments
that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary
in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced rate under an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.6   Late
Payments</B>. In the event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash
payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported
by the <I>Wall Street Journal</I> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.7   Equity
Grants</B>. Except as expressly agreed otherwise by the Parties in writing, upon completion of each of the Calendar Years ending December
31, 2024 and December 31, 2025, Oruka will grant to Paruka a warrant to purchase a number of Shares equal to 1.00% of the outstanding
Shares as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred
stock, stock options, pre-funded warrants or similar instruments), with an exercise price equal to the fair market value of the underlying
Shares on the date of the grant as determined by the board of directors of Oruka (each grant, an &ldquo;<B>Equity Grant</B>&rdquo;); <I>provided,
that</I> if Oruka undergoes a reverse merger transaction the rights and obligations of this Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>5.7
shall continue and Paruka shall be entitled to warrants from the ultimate public company parent to purchase a number of shares of such
parent equal to 1.00% of the outstanding shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise
or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), as applicable.
Such warrants will be exercisable for a period of ten (10) years following the date of the grant. Each Equity Grant shall be effected
on the last Business Day of each applicable Calendar Year and the corresponding grant date shall be such date. If the Term ends prior
to the end of a Calendar Year, the Equity Grant for such Calendar Year shall be pro-rated for such Calendar Year and such Equity Grant
shall be effected within five (5) Business Days of the end of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
6</B></FONT><B><BR>
INTELLECTUAL <FONT STYLE="font-variant: small-caps">PROPERTY RIGHTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.1   Ownership.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   Background
IP</B>. As between the Parties, each Party will retain all right, title and interest in and to all of its Background IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   Project
Antibody Technology.</B> Subject to the rights and licenses granted to Oruka in this Agreement, as between the Parties, Paragon or its
Affiliates shall own all right, title and interest in and to all Project Antibody Technology, irrespective of inventorship. Oruka agrees
to assign and hereby assigns to Paragon all of Oruka&rsquo;s right, title and interest in and to the Project Antibody Technology, including
any and all Intellectual Property Rights therein. Oruka shall execute and deliver, and shall cause its Affiliates to execute and deliver,
such additional documents, instruments, conveyances and assurances and take any such further actions as may be reasonably required to
ensure that all right, title and interest in the Project Antibody Technology is effectively assigned to and held by Paragon. Oruka and
its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project Antibody Technology
to assign without additional consideration all ownership rights in such Project Antibody Technology to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.2   Patent
Prosecution, Maintenance and Enforcement &ndash; Project Antibody Patents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Prior
to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain
or enforce any Project Antibody Patents at Paragon&rsquo;s sole expense, and Oruka shall reasonably cooperate and assist Paragon in such
preparation, filing, prosecution, maintenance and enforcement, at Paragon&rsquo;s request. Following execution of the License Agreement,
(i) with respect to Project Antibody Patents that have been filed prior to the execution of the License Agreement, the Parties&rsquo;
respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project Antibody Patents shall
be as set forth therein and Oruka shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and
maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement, and (ii) with respect to Project
Antibody Patents that have not been filed prior to the execution of the License Agreement, (1) Paragon, at its sole expense, shall have
the sole right, but not the obligation, to prepare, file, prosecute, maintain and enforce such Product Antibody Patents until the date
on which the Final Deliverable for such Research Program is delivered to Oruka, and during such period Paragon shall provide Oruka with
drafts of all proposed filings to any patent office with respect to such Project Antibody Patents in reasonably adequate time before submission
of such filings for Oruka&rsquo;s review and comment, and (2) following the date on which the Final Deliverable for such Research Program
is delivered to Oruka, the Parties&rsquo; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement
of such Project Antibody Patents shall be as set forth therein and Oruka shall reimburse Paragon for any costs and expenses actually incurred
by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Oruka
covenants and agrees that it will not file or prosecute any Patents Covering any Project Antibody or Derived Antibody (including without
limitation any Project Antibody Inventions) during the Term of this Agreement except as permitted under a License Agreement executed by
all Parties with respect to a given Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.3   Defense
of Claims Brought by Third Parties.</B> If a Party becomes aware of any actual or potential claim that the Development, Manufacture or
Commercialization of any Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product infringes or in
the future will infringe the Intellectual Property Rights of any Third Party, such Party will [***] notify the other Parties. In any such
instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding the best response to such notice.
Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the applicable License Agreement
(to the extent applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.4   No
Implied Licenses.</B> Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right
of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly
provided in this Agreement or the applicable License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
7</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
PROTECTION OF CONFIDENTIAL INFORMATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.1   Confidentiality.</B>
Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] years thereafter,
it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than
as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential
Information of the Disclosing Party to those of the Receiving Party&rsquo;s Representatives who have a need for such information; <I>provided,
that</I> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative
is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall
be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the
same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care)
to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party.
The Receiving Party shall [***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information
of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.2   Exceptions.</B>
The Receiving Party&rsquo;s obligations under Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>7.1 shall not
apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or
hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or
available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished
to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered
or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.3   Authorized
Disclosure.</B> Notwithstanding the provisions of this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article 7,
the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure
is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>required
by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation
(including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or
by the disclosure policies of, a stock exchange; <I>provided, that</I> the Receiving Party shall give reasonable prior written notice
to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&rsquo;s
efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only
for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of
such Confidential Information; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>reasonably
necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations
under this Agreement, in each case, in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.4   No
Requirement to Disclose Paragon Platform Technology.</B> Notwithstanding anything to the contrary in this Agreement, Paragon will not
be required to disclose any of the Paragon Platform Technology to Oruka other than as required to be included in the Deliverables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.5   Use
of Names.</B> No Party shall use any other Party&rsquo;s name or trademarks in any advertising, sales, or promotional material or in any
publication without the prior written consent of such other Party or Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.6   Confidentiality
of this Agreement.</B> This Agreement and its terms are considered Confidential Information of all Parties, and each Party shall keep
confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable
other Party, except as expressly permitted by Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>7.3 or Section
<FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>7.7, and except that any Parties may disclose this Agreement and
its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations
by such Third Parties or in confidential financing documents; <I>provided</I>, in each case, that any such Third Party agrees to be bound
by obligations of confidentiality and non-use at least as restrictive as those set forth in this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article
7 (<I>provided, that</I> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.7   Publicity.</B>
Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release
announcing that they have entered into an Antibody discovery partnership, without the other Parties&rsquo; prior written consent, which
shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
8</B></FONT><B><BR>
REPRESENTATIONS<FONT STYLE="font-variant: small-caps">, WARRANTIES AND COVENANTS; DISCLAIMER</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.1   Mutual
Representations and Warranties.</B> Each Party represents and warrants to each other that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>it
is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>this
Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement,
instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.2   Paragon
Representations, Warrants and Covenants</B>. Paragon hereby represents, warrants and covenants to Oruka that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>it
will perform its activities under a Research Program with due care and in accordance with (i) Applicable Law, (ii) the terms and conditions
contained herein and the applicable Research Plan, and (iii) generally prevailing industry standards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>neither
it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction with any Third
Party or Affiliate that conflicts or derogates from its undertakings under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>it
has the unencumbered right to the Paragon Platform Technology and the right, power and authority to use the Paragon Platform Technology
in performance of the Research Plans and the performance of its obligations under this Agreement, in each case in accordance with the
terms hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>each
Representative employed or engaged by Paragon or its Affiliate to conduct the activities under a Research Program has assigned and has
executed an agreement assigning its entire right, title and interest in and to Project Antibody Technology to Paragon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>there
are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices received
that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets
or business, which would, individually or in the aggregate, have a material adverse effect on, or materially prevent, Paragon&rsquo;s
ability to perform under this Agreement or to grant the Option or other rights granted to Oruka under this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(f)   </B>none
of Paragon, its Representatives, or any other person used by Paragon in the performance of the Agreement has been or is (i) debarred,
convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act,
21 U.S.C. &sect; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any Federal healthcare programs
(as that term is defined in 42 U.S.C. 1320a-7b(f)) or government procurement or non-procurement programs, or excluded, debarred, suspended
or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of
healthcare items or services, or is subject to any such pending action. Paragon agrees to inform Oruka in writing promptly if Paragon
or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim,
investigation, or proceeding relating to the foregoing is pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.3   Disclaimer.</B>
EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
9</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
TERM AND TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.1   </B></FONT><B>Term.</B>
The term of this Agreement (&ldquo;<B>Term</B>&rdquo;) shall commence on the Effective Date and, subject to earlier termination in accordance
with this Article 9, shall continue on a Research Program-by-Research Program basis until the later of: (a)&nbsp;the expiration of the
Option Period if Oruka does not exercise the Option in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3; (b) if Oruka
exercises its Option during the Option Period in accordance with Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3 but the Parties
are unable to finalize and execute a License Agreement during the [***] day period referenced in Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4(b),
the expiration of such [***] day period; or (c) the expiration of the applicable Research Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.2   </B></FONT><B>Termination
of Agreement for Material Breach.</B> Each Party shall have the right to terminate this Agreement or a Research Program upon [***] days&rsquo;
prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the
breaching Party has not cured such breach by the end of such [***] day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.3   Termination
for Convenience.</B> Oruka shall have the right to terminate this Agreement or any Research Program for any reason or no reason upon [***]
days&rsquo; prior written notice to Paragon; <I>provided, that</I> Oruka will pay Paragon any unpaid fees due for Development Costs accrued
prior to such effective termination date, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with
its activities under any terminated Research Program, as evidenced by Paragon&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.4   Termination
for Delay</B>. Paragon shall have the right to terminate this Agreement or a Research Program immediately upon written notice to Oruka
if, as a result any action or failure to act by Oruka or its Affiliates, such Research Program or all material activities under the applicable
Research Plan are suspended, discontinued or otherwise delayed for a period of four (4) consecutive months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.5   </B></FONT><B>Termination
for a Bankruptcy Event. </B> Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect
to any other Party. &ldquo;<B>Bankruptcy Event&rdquo; </B>means the occurrence of any of the following: (a) the institution of any bankruptcy,
receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other
similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under
any similar laws or statutes of the United States or any state thereof (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), where in the case of
involuntary proceedings, such proceedings have not been dismissed or discharged within [***] days after they are instituted, (b) the insolvency
or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the
institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) the
appointment of a receiver for all or substantially all of a Party&rsquo;s assets, or (e) any corporate action taken by the board of directors
of a Party in furtherance of any of the foregoing actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.6   </B></FONT><B>Disposal
of Confidential Information.</B> In the event this Agreement expires or this Agreement or any Research Program is terminated and the Parties
have not entered into a License Agreement with respect to an expired or terminated Research Program, each Party shall return to the applicable
other Party all Confidential Information of such other Party (including all copies thereof) in such Party&rsquo;s possession related to
any expired or terminated Research Program; <I>provided, however</I>, that each Party may retain one copy of such other Party&rsquo;s
Confidential Information in such Party&rsquo;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder
or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.7   Accrued
Rights; Survival.</B> The expiration or termination of this Agreement for any reason shall not release any Party from any liability or
obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period
prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all
rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of
expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination
in accordance with their respective terms and conditions: <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article
5, <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article 7, <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article
10 and <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article 11, as well as Sections <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>2.3,
<FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>6.1(a), <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>6.2(a),
<FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>6.4, <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>9.3,
<FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>9.6 and <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>9.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
10</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
INDEMNIFICATION; LIMITATION OF LIABILITY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>10.1   </B></FONT><B>By
Oruka.</B> Oruka hereby agrees to defend, indemnify, and hold harmless Paragon, its Affiliates, including Paruka, and its or their Representatives
(each, a &ldquo;<B>Paragon Indemnitee</B>&rdquo;) from and against any and all losses, damages, liabilities, expenses, and costs, including
reasonable legal expense and attorneys&rsquo; fees (collectively, &ldquo;<B>Losses</B>&rdquo;), to which any Paragon Indemnitee may become
subject as a result of any claim, demand, action, or other proceeding by any Third Party (&ldquo;<B>Third Party Claim</B>&rdquo;) to the
extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any Oruka Indemnitee in the performance of this Agreement;
or (b) the material breach by any Oruka Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the
negligence or willful misconduct of any Paragon Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are
subject to indemnification pursuant to Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>10.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>10.2   </B></FONT><B>By
Paragon.</B> Paragon hereby agrees to defend, indemnify, and hold harmless Oruka, its Affiliates and their Representatives (each, an &ldquo;<B>Oruka
Indemnitee</B>&rdquo;) from and against any and all Losses to which any Oruka Indemnitee may become subject as a result of any Third Party
Claim to the extent such Losses result from: (a) the negligence or willful misconduct of any Paragon Indemnitee in the performance of
this Agreement; or (b) the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses
result from the negligence or willful misconduct of any Oruka Indemnitee, the material breach by Oruka of this Agreement, or where such
Losses are subject to indemnification pursuant to Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>10.1 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>10.3   Indemnification
Procedure. </B> In connection with any Third Party Claim for which a Party (the &ldquo;<B>Indemnified Party</B>&rdquo;) seeks indemnification
from another Party (the &ldquo;<B>Indemnifying Party</B>&rdquo;) pursuant to this Agreement, the Indemnified Party will: (a) give the
Indemnifying Party [***] notice of the Third Party Claim; <I>provided, however, </I>that failure to provide such notice will not relieve
the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of
such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party&rsquo;s expense, in connection with the defense and
settlement of the Third Party Claim; and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim;
<I>provided, however, </I>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&rsquo;s prior
written consent, which will not be unreasonably withheld or delayed, in the event that such settlement materially adversely impacts the
Indemnified Party&rsquo;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and
be represented in any suit or action by advisory counsel of its selection and at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>10.4   Limitation
of Liability.</B> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>7 OR
FOR INDEMNIFICATION CLAIMS UNDER ARTICLE <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>10, IN NO EVENT SHALL ANY
PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT,
EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
11</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
MISCELLANEOUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.1   Independent
Contractor Relationship.</B> Each of Paragon&rsquo;s and Paruka&rsquo;s relationship with Oruka is that of an independent contractor,
and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. No Party is
an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.2   Force
Majeure. </B>No Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other
than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the
affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable
Law. The Party affected will give prompt written notice to the other Parties of the nature of the cause of any material delay or failure
to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent
efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue
performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written
notice to the other Parties of such resumed performance. If any such failure or delay in a Party&rsquo;s performance hereunder continues
for more than [***] days, any of the other Parties may terminate this Agreement upon written notice to the affected Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.3   Entire
Agreement; Amendment.</B> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement
of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating
to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written
instrument signed by all Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.4   Non-Waiver.</B>
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.5   Severability.</B>
Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement
shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect,
and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision
which conforms as nearly as possible with the original intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.6   Assignment.</B>
Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other
Parties (which consent shall not be unreasonably withheld); <I>provided, however</I>, that any Party may assign this Agreement and its
rights and obligations hereunder without the other Parties&rsquo; consent to its successor to all or substantially all of the business
of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations
of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties,
and the name of a Party appearing herein will be deemed to include the name of such Party&rsquo;s successors and permitted assigns to
the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.7   Dispute
Resolution.</B> The Parties recognize that a <I>bona fide </I>dispute as to certain matters may arise from time to time during the Term
relating to any Party&rsquo;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of
this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to
&lrm;Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability,
inventorship or ownership of the Parties&rsquo; respective Intellectual Property Rights (hereinafter, a &ldquo;<B>Dispute</B>&rdquo;).
In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or
disagreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>The
Party claiming that such a Dispute exists will give notice in writing (a &ldquo;<B>Notice of Dispute</B>&rdquo;) to the other Parties
of the nature of the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>The
Dispute will be referred to the then Chief Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer
or President of Oruka who will meet no later than [***] days following the initial receipt of the Notice of Dispute and use reasonable
endeavors to resolve the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>If,
within [***] days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described
in Section &lrm;11.7&lrm;(b) hereof has not been held within [***] days of initial receipt of the Notice of Dispute, then the Parties
agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive
Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions
of this Section&nbsp;&lrm;11.7&lrm;(c). The arbitration will be conducted by a panel of three arbitrators. Within [***] days after the
initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly
appoint the third arbitrator within [***] days of their appointment, who will serve as chairman of the panel. All three arbitrators must
be independent Third Parties having at least [***] years of dispute resolution experience (which may include judicial experience) or legal
or business experience in the biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators
selected by the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments
for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed
arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration
proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be
submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters
in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed
by the Federal Arbitration Act, 9 U.S.C. &sect;&sect;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be
entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant
to this Section &lrm;11.7 will be deemed the Confidential Information of all Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Notwithstanding
any provision of this Agreement to the contrary, any Party may immediately initiate litigation in any court of competent jurisdiction
seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce
its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>The
Parties agree that any disputes relating to &lrm;Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity,
scope, infringement, enforceability, inventorship or ownership of the Parties&rsquo; respective Intellectual Property Rights shall be
subject to the exclusive jurisdiction of the state and federal courts in New York, New York and each Party hereby submits to such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.8   Governing
Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference
to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.9   Notices.</B>
Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier,
by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated
by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of
actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered
by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party
to any other Party in accordance with this Section <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>11.9, the Party
shall send a copy of such notice by email to such other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Paragon or Paruka:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paragon Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building 23, Suite 105</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waltham, MA 02453</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Oruka:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oruka Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building 23, Suite 105</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waltham MA 02453</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.10   Interpretation.</B>
Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be deemed to encompass references to
either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &ldquo;include&rdquo;,
&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;, (c)&nbsp;the
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall&rdquo;, (d)&nbsp;any definition
of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&rsquo;s
or entity&rsquo;s successors and assigns, (f) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words
of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references
herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement
include all Exhibits hereto, (h) the word &ldquo;notice&rdquo; means notice in writing (whether or not specifically stated) and shall
include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that
a Party, the Parties or any committee hereunder &ldquo;agree,&rdquo; &ldquo;consent&rdquo; or &ldquo;approve&rdquo; or the like shall
require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or
otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or
other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation
thereof, and (k) the term &ldquo;or&rdquo; shall be interpreted in the inclusive sense commonly associated with the term &ldquo;or&rdquo;.
The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted
solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation
or construction. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of
which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language,
and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all
written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the
extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and
conditions of this Agreement will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.11   No
Third-Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted
assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any
of these provisions against any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.12   Counterparts.</B>
This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this
writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the
same force and effect as original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.13   Expenses</B>.
Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.14   Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.15   Construction</B>.
The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall
be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible
for the preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.16   Cumulative
Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Remainder of page left intentionally blank;
signature page follows.]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof,</B></FONT> the Parties hereto have executed this Amended and Restated Antibody Discovery and Option Agreement on the
New Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Paragon Therapeutics, Inc.</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Oruka Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ K. Evan Thompson </FONT></TD>
    <TD STYLE="text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lawrence Klein </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Paruka Holding, LLC</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ K. Evan Thompson </FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page to Amended and Restated Antibody
Discovery and Option Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="background-color: white"><B>[***]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">[***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; width: 15%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; width: 65%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; width: 20%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>3
<FILENAME>ea020512202ex10-51_arcabio.htm
<DESCRIPTION>AMENDED AND RESTATED ANTIBODY DISCOVERY AND OPTION AGREEMENT (IL-23), DATED MARCH 28, 2024, BY AND AMONG PARAGON THERAPEUTICS, INC., PARUKA HOLDING LLC AND ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.51</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL
IF PUBLICLY DISCLOSED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANTIBODY DISCOVERY AND OPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>This
Amended and Restated Antibody Discovery and Option Agreement</B></FONT> (&ldquo;<B>Agreement</B>&rdquo;) is entered into and effective
as of March 28, 2024 (the &ldquo;<B>New Effective Date</B>&rdquo;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Paragon</B>&rdquo;),
Paruka Holding, LLC, a Delaware limited liability company (&ldquo;<B>Paruka</B>&rdquo;) and Oruka Therapeutics, Inc., a Delaware corporation
(&ldquo;<B>Oruka</B>&rdquo;). Paragon, Paruka and Oruka are also referred to herein individually as a &ldquo;<B>Party</B>&rdquo;, or collectively
as the &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Recitals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B>,</FONT>
Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant
targets<FONT STYLE="background-color: white">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,
</FONT>Oruka Operating Company B LLC, a Delaware limited liability company and, as of the Effective Date, a subsidiary of Oruka (&ldquo;<B>OpCo</B>&rdquo;)
engaged each of Paragon and Paruka to identify, evaluate and develop one or more antibody candidates directed to certain mutually agreed
therapeutic targets of interest to OpCo, including IL-23, pursuant to an Antibody Discovery and Option Agreement (the &ldquo;<B>Original
Agreement</B>&rdquo;) dated March 6, 2024 (the &ldquo;<B>Effective Date</B>&rdquo;), by and among Paragon, Paruka, OpCo, and, <I>solely</I>
for purposes of certain sections of the Original Agreement, Oruka;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT>,
Paragon and Paruka have been performing certain antibody discovery and development activities pursuant to the Original Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT><FONT STYLE="font-variant: small-caps; background-color: white">,</FONT>
pursuant to the Original Agreement, OpCo received an exclusive option to enter into separate license agreements with Paragon and Paruka,
as applicable, to develop, manufacture and commercialize the resulting antibodies with respect to a given target, all on the terms and
subject to the conditions set forth in the Original Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps; background-color: white"><B>Whereas</B>,
</FONT>in connection with an internal reorganization of Oruka and pursuant to a Merger Agreement, dated March 22, 2024, by and among Oruka,
OpCo, Oruka Operating Company A LLC and Oruka Operating Company C LLC, OpCo was merged with and into Oruka, with Oruka being the surviving
entity (the &ldquo;<B>Merger</B>&rdquo;), and Oruka assumed all properties, rights, privileges, immunities, powers, franchises, debts,
liabilities, obligations and duties of OpCo pursuant to the Merger; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Whereas</B></FONT><FONT STYLE="font-variant: small-caps; background-color: white">,
</FONT>the parties desire to amend and restate the Original Agreement to, among other matters, update certain terms of the original arrangement
and to amend the parties to the Original Agreement following the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now
Therefore, </B></FONT>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
1</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
DEFINED TERMS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.1   </B></FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Active
Research Program</B></FONT>&rdquo; shall have the meaning set forth in Section 5.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2   </B></FONT>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Actual
Annual Costs</B></FONT>&rdquo; shall have the meaning set forth in Section&nbsp;5.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>1.3   </B></FONT>&ldquo;<B>Affiliate</B>&rdquo;
shall mean any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &ldquo;control&rdquo;
(including, with correlative meaning, the terms &ldquo;controlled by&rdquo; or &ldquo;under common control&rdquo;) means the direct or
indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the
right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding
the foregoing, (a)&nbsp;with respect to either Party, Affiliates of such Party do not include [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.4   </B>&ldquo;<B>Agreement</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.5   </B>&ldquo;<B>Antibody</B>&rdquo;
shall mean any molecule, including [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.6   </B>&ldquo;<B>Antibody
Production Activities</B>&rdquo; shall have the meaning provided in Section&nbsp;2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.7   </B>&ldquo;<B>Applicable
Law</B>&rdquo; shall mean any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case,
as applicable to the subject matter and the party at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.8   </B>&ldquo;<B>Bankruptcy
Code</B>&rdquo; shall have the meaning set forth in Section 9.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.9   </B>&ldquo;<B>Bankruptcy
Event</B>&rdquo; shall have the meaning set forth in Section 9.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.10   </B>&ldquo;<B>Background
IP</B>&rdquo; shall mean all Patents and Know-How Controlled by a Party (a) as of the Effective Date, or (b) that otherwise arise outside
of and independently of this Agreement. Paragon&rsquo;s Background IP includes the Paragon Platform Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.11   </B>&ldquo;<B>Budget</B>&rdquo;
shall mean the agreed budget for the activities set forth in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.12   </B>&ldquo;<B>Business
Day</B>&rdquo; shall mean any day other than Saturday, Sunday or other national holidays in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.13   </B>&ldquo;<B>Calendar
Quarter</B>&rdquo; shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30
and December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.14   </B>&ldquo;<B>Calendar
Year</B>&rdquo; shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.15   </B>&ldquo;<B>Commercialize</B>&rdquo;
or &ldquo;<B>Commercializing</B>&rdquo; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported,
export, have exported or otherwise commercialize an Antibody or product, including a Project Antibody, Selected IL-23 Project Antibody,
Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable. When used as a noun, &ldquo;Commercialization&rdquo;
means any and all activities involved in Commercializing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.16   </B>
&ldquo;<B>Confidential Information</B>&rdquo; of a Party shall mean any and all non-public scientific, business, regulatory or technical
information that is disclosed or made available by or on behalf of one Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) to any other
Party (a &ldquo;<B>Receiving Party</B>&rdquo;) in connection with this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding
any provision of this Agreement to the contrary, (a) with respect to any Research Program other than the IL-23 Research Program, all Project
Antibody Inventions and Project Antibody Technology shall be the Confidential Information of all Parties, and each Party shall be deemed
as both the &ldquo;Disclosing Party&rdquo; and the &ldquo;Receiving Party&rdquo; with respect thereto; <I>provided, that</I> if Oruka
does not exercise its Option or the Parties do not enter into a License Agreement in accordance with this Agreement, then the Project
Antibody Inventions and Project Antibody Technology shall thereafter be the Confidential Information of Paragon, and (b) with respect
to the IL-23 Research Program, (i)&nbsp;prior to completion of the IL-23 Selection Process, all Project Antibody Inventions and Project
Antibody Technology shall be the Confidential Information of all Parties, and each Party shall be deemed as both the &ldquo;Disclosing
Party&rdquo; and the &ldquo;Receiving Party&rdquo; with respect thereto, and (ii) following completion of the IL-23 Selection Process,
(x) the Selected IL-23 Project Antibody Inventions and the Selected IL-23 Project Antibody Technology shall be the Confidential Information
of all Parties, and each Party shall be deemed as both the &ldquo;Disclosing Party&rdquo; and the &ldquo;Receiving Party&rdquo; with respect
thereto, and (y) the Excluded IL-23 Project Antibody Technology shall be the Confidential Information of Paragon; <I>provided, that</I>
if Oruka does not exercise its Option or the Parties do not enter into a License Agreement in accordance with this Agreement, then the
Selected IL-23 Project Antibody Inventions and the Selected IL-23 Project Antibody Technology shall thereafter be the Confidential Information
of Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.17   </B>&ldquo;<B>Control</B>&rdquo;
(including any variations such as &ldquo;<B>Controlled</B>&rdquo; and &ldquo;<B>Controlling</B>&rdquo;) shall mean, with respect to any
Technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant
a license or a sublicense of or under such Technology or Intellectual Property Rights without violating the terms of any agreement or
other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its Affiliates shall not be
deemed to &ldquo;Control&rdquo; any technology or Intellectual Property Rights that (a) prior to the consummation of a Change of Control
of such Party, is owned or in-licensed, or (b)&nbsp;after the consummation of a Change of Control of such Party, becomes owned or in-licensed
(to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder
and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party
immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a) or (b)), by a Third
Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party
after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation
of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.18   </B>&ldquo;<B>Cost
Advance</B>&rdquo; shall have the meaning set forth in Section 5.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.19   </B>&ldquo;<B>Cover</B>&rdquo;
or &ldquo;<B>Covering</B>&rdquo; shall mean, with respect to a Patent, that, in the absence of a license granted under, or ownership of,
such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such
Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.20   </B>&ldquo;<B>Deliverables</B>&rdquo;
shall have the meaning set forth in Section 2.1(d)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.21   </B>&ldquo;<B>Derived
Antibody</B>&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>With
respect to any Research Program other than the IL-23 Research Program, any Antibody that (i)&nbsp;is [***], and (ii)&nbsp;[***]. For avoidance
of doubt, any Antibody [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>With
respect to the IL-23 Research Program, any Antibody that (i)&nbsp;is [***], (ii) [***], and (iii)&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.22   </B>&ldquo;<B>Derived
Antibody Patent</B>&rdquo; shall mean any Patent that Covers the composition of matter of, or any method of specifically making or using,
any Derived Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.23   </B>&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Developing</B>&rdquo; shall mean to discover, evaluate, test, research or otherwise develop an Antibody or product, including
a Project Antibody, Selected IL-23 Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product, as applicable.
When used as a noun, &ldquo;<B>Development</B>&rdquo; means any and all activities involved in Developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.24   </B>&ldquo;<B>Development
Costs</B>&rdquo; shall mean (a) [***] (such amounts, the &ldquo;<B>Third Party Costs</B>&rdquo;), and (b) [***] (such development fees,
the &ldquo;<B>Development Fees</B>&rdquo;, and the development fees to be paid in any given Calendar Year during the Research Program,
the &ldquo;<B>Annual Development Fees</B>&rdquo;); in each case ((a) and (b)) to the extent consistent with the applicable Research Plan
(including [***]).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.25   </B>&ldquo;<B>Directed
To</B>&rdquo; shall mean, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [***],
and (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.26   </B>&ldquo;<B>Dispute</B>&rdquo;
shall have the meaning provided in Section 11.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.27   </B>&ldquo;<B>Effective
Date</B>&rdquo; shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.28   </B>&ldquo;<B>Election
Notice</B>&rdquo; shall have the meaning provided in Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.29   </B>&ldquo;<B>Equity
Grant</B>&rdquo; shall have the meaning provided in Section&nbsp;5.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.30   </B>&ldquo;<B>Excluded
IL-23 Project Antibodies</B>&rdquo; shall have the meaning provided in Section&nbsp;2.1(d)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.31   </B>&ldquo;<B>Excluded
IL-23 Project Antibody Technology</B>&rdquo; shall mean all Project Antibody Technology for the IL-23 Research Program other than the
Selected IL-23 Project Antibody Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.32   </B>&ldquo;<B>Field</B>&rdquo;
shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas, except with respect
to IL-23, where &ldquo;<B>Field</B>&rdquo; shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders
except the therapeutic area of inflammatory bowel disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.33   </B>&ldquo;<B>Final
Deliverable</B>&rdquo; shall, on a Research Program-by-Research Program basis, have the meaning provided in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.34   </B>&ldquo;<B>IL-23
Prior Development Costs</B>&rdquo; shall have the meaning set forth in Section&nbsp;5.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.35   </B>&ldquo;<B>IL-23
Research Program</B>&rdquo; shall have the meaning set forth in Section 2.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.36   </B>&ldquo;<B>IL-23
Selection Process</B>&rdquo; shall have the meaning provided in Section 2.1(d)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.37   </B>&ldquo;<B>Indemnified
Party</B>&rdquo; shall have the meaning provided in Section 10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.38   </B>&ldquo;<B>Indemnifying
Party</B>&rdquo; shall have the meaning provided in Section 10.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.39   </B>&ldquo;<B>Intellectual
Property Rights</B>&rdquo; shall mean any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright
law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in
Know-How, or the expression or use thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.40   </B>&ldquo;<B>JDC</B>&rdquo;
shall have the meaning provided in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.41   </B>&ldquo;<B>Know-How</B>&rdquo;
shall mean all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets,
data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like),
methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions
or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes
for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions,
processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding
the foregoing, Know-How excludes Patent claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.42   </B>&ldquo;<B>License
Agreement</B>&rdquo; shall have the meaning set forth in Section 4.4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.43   </B>&ldquo;<B>License
Template</B>&rdquo; shall have the meaning set forth in Section 4.4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.44   </B>&ldquo;<B>Losses</B>&rdquo;
shall have the meaning provided in Section 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.45   </B>&ldquo;<B>Manufacture</B>&rdquo;
or &ldquo;<B>Manufacturing</B>&rdquo; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality
assurance testing, release, ship or store an Antibody or product, including a Project Antibody, Selected IL-23 Project Antibody, Derived
Antibody, Product, Multispecific Antibody or Multispecific Product or any component thereof, as applicable. When used as a noun, &ldquo;Manufacture&rdquo;
or &ldquo;Manufacturing&rdquo; means any and all activities involved in Manufacturing an Antibody or product, including a Project Antibody,
Selected IL-23 Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product or any component thereof,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.46   </B>&ldquo;<B>Multispecific
Antibody</B>&rdquo; means (a) [***], and (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.47   </B>&ldquo;<B>Multispecific
Product</B>&rdquo; means any product that comprises or contains any Multispecific Antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.48   </B>&ldquo;<B>Notice
of Dispute</B>&rdquo; shall have the meaning provided in Section 11.7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.49   </B>&ldquo;<B>Option</B>&rdquo;
shall have the meaning provided in Section&nbsp;4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.50   </B>&ldquo;<B>Option
Period</B>&rdquo; shall have the meaning provided in Section&nbsp;4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.51   </B>&ldquo;<B>Oruka</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.52   </B>&ldquo;<B>Oruka
Indemnitee</B>&rdquo; shall have the meaning provided in Section 10.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.53   </B>&ldquo;<B>Paragon</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.54   </B>&ldquo;<B>Paragon
Indemnitee</B>&rdquo; shall have the meaning provided in Section 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.55   </B>&ldquo;<B>Paragon
Platform Know-How</B>&rdquo; shall mean (a) Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating to antibody
discovery and development, (b) all methods, materials and other Know-How used in the foregoing Controlled by Paragon or its Affiliates,
and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b) Controlled by Paragon
or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.56   </B>&ldquo;<B>Paragon
Platform Know-How Improvement</B>&rdquo; shall mean all Know-How developed or discovered through or as a result of the activities performed
by or on behalf of Paragon under a Research Program that constitutes an improvement, enhancement, modification, substitution, or alteration
to the Paragon Platform Technology; <I>provided, however</I>, to the extent any of the Know-How developed or discovered under a Research
Program specifically and solely relates to a Project Antibody, such Know-How will be considered Project Antibody Technology and not Paragon
Platform Know-How Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.57   </B>&ldquo;<B>Paragon
Platform Patents</B>&rdquo; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon
Platform Know-How or Paragon Platform Know-How Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.58   </B>&ldquo;<B>Paragon
Platform Technology</B>&rdquo; shall mean Paragon Platform Know-How, Paragon Platform Know-How Improvements and Paragon Platform Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.59   </B>&ldquo;<B>Party</B>&rdquo;
or &ldquo;<B>Parties</B>&rdquo; shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.60   </B>&ldquo;<B>Paruka</B>&rdquo;
shall have the meaning provided in the first paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.61   </B>&ldquo;<B>Patents</B>&rdquo;
shall mean (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues,
renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like
of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.62   </B>&ldquo;<B>Predecessor</B>&rdquo;
shall have the meaning provided in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.63   </B>&ldquo;<B>Product</B>&rdquo;
shall mean any product that comprises or contains (a) with respect to any Research Program other than the IL-23 Research Program, any
Project Antibody or any Derived Antibody thereof, or (b) with respect to the IL-23 Research Program, any Selected IL-23 Project Antibody
or any Derived Antibody thereof, in each case ((a) and (b)) other than as part of a Multispecific Antibody or a Multispecific Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.64   </B>&ldquo;<B>Project
Antibody</B>&rdquo; shall mean any and all Antibodies that are Directed To a particular Selected Target and that are discovered, generated,
identified or characterized by Paragon in the course of performing the applicable Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.65   </B>&ldquo;<B>Project
Antibody Invention</B>&rdquo; shall mean (a) any invention or discovery, whether or not patentable, that was discovered or reduced to
practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically
making or using, any Project Antibody, and (b) all Intellectual Property Rights therein that are Controlled by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.66   </B>&ldquo;<B>Project
Antibody Patents</B>&rdquo; shall mean all Patents that Cover the composition of matter of, or any method of specifically making or using,
any Project Antibody, that are in each case Controlled by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.67   </B>&ldquo;<B>Project
Antibody Samples</B>&rdquo; shall have the meaning provided in Section&nbsp;2.1(d)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.68   </B>&ldquo;<B>Project
Antibody Selection Criteria</B>&rdquo; shall mean those criteria agreed to by the Parties in the applicable Research Plan that establish
that a Project Antibody is suitable for clinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.69   </B>&ldquo;<B>Project
Antibody Technology</B>&rdquo; shall mean (a) the Project Antibody Inventions, (b) the Project Antibody Patents, (c) the Sequence Information
and Results, and (d) all Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates. For clarity, if the Parties
execute a License Agreement with respect to a particular Research Program and the Research Term for such Research Program continues following
execution of such License Agreement, any Project Antibody Technology first conceived, reduced to practice or otherwise generated following
the execution of the License Agreement shall be licensed to Oruka under such License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.70   </B>&ldquo;<B>Representatives</B>&rdquo;
of a Party shall mean such Party&rsquo;s and its Affiliates&rsquo; officers, directors, employees, contractors, subcontractors, agents
and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.71   </B>&ldquo;<B>Research
Plan</B>&rdquo; shall have the meaning set forth in Section 2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.72   </B>&ldquo;<B>Research
Program</B>&rdquo; shall mean a research program agreed to by the Parties to identify Project Antibodies with activity against one Selected
Target and to perform such additional activities with respect to such Selected Target as set forth in the applicable Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.73   </B>&ldquo;<B>Research
Term</B>&rdquo; shall mean, on a Research Program-by-Research Program basis, the period of time beginning on the agreement by the Parties
on the Research Plan and continuing until completion of the activities under the Research Plan for such Research Program or such other
date mutually agreed upon by the Parties; <I>provided, that</I> (a) if Oruka does not exercise its Option in accordance with Section 4.3
prior to expiration of the applicable Option Period, then upon such expiration the Research Term shall automatically terminate and Paragon
shall have no obligation to perform any activities under the applicable Research Plan thereafter, or (b) if Oruka exercises its Option
during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute a License Agreement during
the [***] period referenced in Section 4.4(b), then upon the expiration of such period the Research Term shall automatically terminate
and Paragon shall have no obligation to perform any activities under the applicable Research Plan thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.74   </B>&ldquo;<B>Results</B>&rdquo;
shall mean the data, results, analysis, conclusions, outcomes, information, documentation and reports that are generated by or on behalf
of Paragon in performance of a Research Program, excluding Project Antibodies, Project Antibody Inventions, Project Antibody Patents and
the Sequence Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.75   </B>&ldquo;<B>Selected
IL-23 Project Antibody Invention</B>&rdquo; shall mean (a) any invention or discovery, whether or not patentable, that was discovered
or reduced to practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method
of specifically making or using, any Selected IL-23 Project Antibody, and (b) all Intellectual Property Rights therein that are Controlled
by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.76   </B>&ldquo;<B>Selected
IL-23 Project Antibodies</B>&rdquo; shall have the meaning provided in Section&nbsp;2.1(d)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.77   </B>&ldquo;<B>Selected
IL-23 Project Antibody Patents</B>&rdquo; shall mean all Patents that Cover the composition of matter of, or any method of specifically
making or using, any Selected IL-23 Project Antibody, that are in each case Controlled by Paragon or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.78   </B>&ldquo;<B>Selected
IL-23 Project Antibody Technology</B>&rdquo; shall mean (a) the Selected IL-23 Project Antibody Inventions, (b) the Selected IL-23 Project
Antibody Patents, (c)&nbsp;the Selected IL-23 Sequence Information and the Selected IL-23 Results, and (d) all Intellectual Property Rights
therein that are Controlled by Paragon and its Affiliates. For clarity, if the Parties execute a License Agreement with respect to the
IL-23 Research Program and the Research Term for the IL-23 Research Program continues following execution of such License Agreement, any
Selected IL-23 Project Antibody Technology first conceived, reduced to practice or otherwise generated following the execution of the
License Agreement shall be licensed to Oruka under such License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.79   </B>&ldquo;<B>Selected
IL-23 Results</B>&rdquo; shall mean the data, results, analysis, conclusions, outcomes, information, documentation and reports that (a)
are generated by or on behalf of Paragon in performance of the IL-23 Research Program, and (b) are related solely and specifically to
the Selected IL-23 Project Antibodies, in each case excluding Selected IL-23 Antibodies, Selected IL-23 Project Antibody Inventions, Selected
IL-23 Project Antibody Patents and Selected IL-23 Sequence Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.80   </B>&ldquo;<B>Selected
IL-23 Sequence Information</B>&rdquo; shall mean electronic files containing all Selected IL-23 Project Antibody sequences generated under
the IL-23 Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.81   </B>&ldquo;<B>Selected
Target</B>&rdquo; shall have the meaning set forth in Section 2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.82   </B>&ldquo;<B>Sequence
Information</B>&rdquo; shall mean electronic files containing all Project Antibody sequences generated under a given Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.83   </B>&ldquo;<B>Shares</B>&rdquo;
shall mean shares of common stock, par value $0.0001, of Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.84   </B>&ldquo;<B>Target</B>&rdquo;
shall mean a protein molecule that (a) [***], and (b) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.85   </B>&ldquo;<B>Term</B>&rdquo;
shall have the meaning provided in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.86   </B>&ldquo;<B>Territory</B>&rdquo;
shall mean worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.87   </B>&ldquo;<B>Third
Party</B>&rdquo; shall mean any person or entity other than Paragon, Paruka or Oruka or an Affiliate of any of Paragon, Paruka, or Oruka.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.88   </B>&ldquo;<B>Third
Party Claim</B>&rdquo; shall have the meaning provided in Section 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.89   </B>&ldquo;<B>Third
Party Collaborator</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>1.90   </B>&ldquo;<B>Valid
Claim</B>&rdquo; shall mean, with respect to a particular country, a claim (including a process, use, or composition of matter claim)
of an issued and unexpired patent (or a supplementary protection certificate thereof) that has not (a) irretrievably lapsed or been abandoned,
permanently revoked, dedicated to the public or disclaimed, or (b) been held invalid, unenforceable or not patentable by a court, governmental
agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision
is final and un-appealable or un-appealed within the time allowed for appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
2</B></FONT><BR>
<B>CONDUCT OF RESEARCH PROGRAM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.1   Research
Program.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   Target
Selection</B>. The Parties intend to initiate one or more Research Programs, each focused on a particular Target (each, a &ldquo;<B>Selected
Target</B>&rdquo;). No more than one (1) Selected Target will be included in any Research Program, unless the Parties otherwise agree
in writing (e.g., in the case of a Research Program seeking to develop a [***]). As of the Effective Date, the Parties have agreed to
the Selected Targets listed on <U>Exhibit A</U>. Additional Targets may be added to the Selected Targets by mutual written agreement of
the Parties, it being understood that each Party may accept or reject a new Selected Target in its sole discretion and no Party shall
be obligated under this Agreement to agree to any further Selected Targets. The Parties acknowledge that, prior to any agreement with
respect to a Selected Target and a Research Plan, it is intended that the Parties may initiate, from time-to-time, &ldquo;proof-of-concept&rdquo;
studies [***] at no up-front Research Initiation Fee to Oruka; <I>provided, that</I> the costs of any such &ldquo;proof-of-concept&rdquo;
studies may be recaptured by Paragon within the specified Research Plan and associated fees, in each case, as agreed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   Research
Plan. </B>No later than [***] days after the Effective Date (or in the case of any Selected Target added after the Effective Date, no
later than [***] days after the Parties&rsquo; written agreement on such additional Selected Target), the Parties will agree on a research
plan, to the extent a research plan has not been previously agreed upon, for the applicable Selected Target that will include design,
modeling, synthesis, evaluation, and other mutually agreed activities (&ldquo;<B>Research Plan</B>&rdquo;). For clarity, if at the end
of such [***] day period (or any extension thereof mutually agreed in writing) (i) the Parties have not agreed on a Research Plan, or
(ii) Oruka has not paid Paragon the Research Initiation Fee, the applicable Target shall cease to be a Selected Target and Paragon shall
have no obligations with respect thereto. Once the Parties agree on a Research Plan and Oruka pays the Research Initiation Fee for a Research
Program, Paragon and Paruka shall conduct research under such Research Program during the applicable Research Term in an effort to (1)&nbsp;produce
Project Antibodies against the applicable Selected Target for further Development, Manufacture and Commercialization (&ldquo;<B>Antibody
Production Activities</B>&rdquo;), and (2) perform such other Development and Manufacturing activities with respect to the Project Antibodies
as set forth in the Research Plan (which other activities, for clarity, may be performed following Oruka&rsquo;s exercise of the Option
or execution of a License Agreement). The Parties may amend the Research Plan upon mutual written agreement. Paragon and Paruka will use
[***] to conduct and complete the activities set forth in such Research Plan on the timelines set forth in such Research Plan and in compliance
with the Budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   IL-23
Research Program.</B> Notwithstanding anything in Section 2.1(a) and Section&nbsp;2.1(b) to the contrary, the Parties acknowledge and
agree that (i) prior to the Effective Date, Paragon initiated a research program in collaboration with a Third Party (the &ldquo;<B>Third
Party Collaborator</B>&rdquo;) to identify, evaluate and develop one or more Antibody candidates Directed To IL-23, (ii) Paragon has the
right to select certain Antibody candidates generated under such research program for further Development, Manufacture and Commercialization,
and Paragon and Oruka desire for Oruka to have an exclusive option to enter into a license agreement with Paragon to Develop, Manufacture
and Commercialize such Antibody candidates, and (iii) in furtherance of the foregoing, such research program initiated by Paragon prior
to the Effective Date shall be deemed to be a Research Program under the terms of this Agreement and referred to herein as the &ldquo;<B>IL-23
Research Program</B>&rdquo;, and the research plan for such research program as provided by Paragon to Oruka shall be deemed to be the
Research Plan for the IL-23 Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   Deliverables;
Project Antibody Samples; IL-23 Selection Process. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(i)   Following
completion of the Antibody Production Activities set forth in the Research Plan for a Research Program, Paragon and Paruka will deliver
to Oruka a data package that includes Sequence Information for all then-existing Project Antibodies and Results (the &ldquo;<B>Deliverables</B>&rdquo;).
Additionally, upon request by Oruka, and at [***] cost and expense, Paragon and Paruka shall provide to Oruka samples of proteins corresponding
to such Project Antibodies that have been expressed in accordance with the Research Plan (&ldquo;<B>Project Antibody Samples</B>&rdquo;)
to enable Oruka to evaluate the Option and, with respect to the IL-23 Research Program, to enable Oruka to prepare for the IL-23 Selection
Process. Following completion of a Research Program, Paragon shall deliver to Oruka the Final Deliverable for such Research Program, if
any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(ii)   This
subsection (ii) shall apply with respect to any Research Program other than the IL-23 Research Program. During the Option Period with
respect to each such Research Program, Oruka will review the Deliverables and Project Antibody Samples for such Research Program to determine
whether [***] Project Antibody meets the Project Antibody Selection Criteria. If Oruka determines that [***] Project Antibody meets the
Project Antibody Selection Criteria, then Oruka shall so notify Paragon in writing prior to the end of the Option Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">(iii)   This
subsection (iii) shall only apply with respect to the IL-23 Research Program. During the [***] period following receipt of the Deliverables
and the Project Antibody Samples for the IL-23 Research Program, Oruka will review such Deliverables and Project Antibody Samples. Oruka
acknowledges and agrees that the Third Party Collaborator has the sole right to determine whether [***] Project Antibody meets the Project
Antibody Selection Criteria, and the right to select certain Project Antibodies based on the selection process set forth in Paragon&rsquo;s
agreement with the Third Party Collaborator (the &ldquo;<B>IL-23 Selection Process</B>&rdquo;), which Project Antibodies selected by the
Third Party Collaborator shall be excluded from Oruka&rsquo;s Option for the IL-23 Research Program and shall be referred to herein as
the &ldquo;<B>Excluded IL-23 Project Antibodies</B>&rdquo;. Paragon shall collaborate with Oruka to enable Oruka to select as part of
the IL-23 Selection Process the available Project Antibodies that will be subject to Oruka&rsquo;s Option for the IL-23 Research Program.
In furtherance of the foregoing, Paragon shall as promptly as possible notify Oruka of any Excluded IL-23 Project Antibodies, and, <I>provided
that</I> Oruka has provided timely direction to Paragon, select as part of the IL-23 Selection Process any available Project Antibodies
based on Oruka&rsquo;s direction. The Project Antibodies that, following the completion of the IL-23 Selection Process, are selected for
purposes of Oruka&rsquo;s rights under the Option for the IL-23 Research Program shall be referred to herein as the &ldquo;<B>Selected
IL-23 Project Antibodies</B>&rdquo;. Following completion of the IL-23 Selection Process, Paragon shall provide to Oruka a list of the
Selected IL-23 Project Antibodies. For clarity, Oruka&rsquo;s Option with respect to the IL-23 Research Program shall be limited to the
Selected IL-23 Project Antibodies and the Selected IL-23 Project Antibody Technology, and Oruka shall have no Option or similar rights
with respect to the Excluded IL-23 Project Antibodies or the Excluded IL-23 Project Antibody Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   Conduct
of Research Program. </B>During the Research Term, Paragon and Paruka shall (i) perform the activities assigned to it under the applicable
Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with the
applicable Research Plans; (ii) ensure that its Representatives and subcontractors diligently perform the applicable Research Program
in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant
fields and in compliance with Applicable Law; (iii) keep Oruka fully informed regarding the progress and results of the Research Program;
(iv) promptly provide Oruka with any additional information regarding the Research Program that Oruka reasonably requests; (v)&nbsp;participate
in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Oruka on the performance of the Research Program;
and (vi) give Oruka prompt written notice with respect to information known or believed by Paragon and Paruka to be likely to materially
impede or otherwise adversely affect the performance of the Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.2   Subcontractors.
</B>Paragon and Paruka may perform some of the activities under a Research Program through one or more subcontractors; <I>provided, that</I>
Paragon and Paruka shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance
of their obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.3   Research
Books and Records; Audit</B>. Paragon shall maintain complete and accurate records related to the activities performed by Paragon under
a Research Program. All such books and records shall be retained by Paragon and Paruka until the later of: (a) [***] after the end of
the applicable stage of research; and (b) such longer period as may be required by Applicable Law. Upon Oruka&rsquo;s request and at [***]
expense, Paragon shall provide copies of such records or such records shall be made available for Oruka&rsquo;s reasonable review, audit
and inspection upon reasonable notice and with reasonable frequency; <I>provided, that</I> with respect to the IL-23 Research Program
following completion of the IL-23 Selection Process, such rights shall be limited to the portion of such records that relate solely and
specifically to the Selected IL-23 Project Antibodies and the Selected IL-23 Project Antibody Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
3</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
GOVERNANCE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.1   </B></FONT><B>Joint
Development Committee</B>. The Parties will establish a single Joint Development Committee (the &ldquo;<B>JDC</B>&rdquo;) to oversee and
coordinate the activities under all Research Programs in accordance with the remainder of this Article 3. The JDC shall be comprised of
two (2) employees from Oruka and two (2) employees from Paragon, with each Party designating one (1) such employee as its JDC co-chairperson.
Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC from time to time, and may change its Representatives,
in its sole discretion, effective upon notice to the other Parties designating such change. Representatives from each Party shall have
appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the activities to be performed
under the Research Programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.2   </B></FONT><B>JDC
Meetings</B>. The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently
than once every three (3) months until, on a Research Program-by-Research Program basis, the end of the period specified in Section 3.5.
The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. As appropriate,
additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers; <I>provided, that</I> any such
consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <I>provided, further that</I>
no Third Party personnel may attend unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance
of the JDC meetings by its representatives. Each Party may also call for special meetings to resolve particular matters requested by such
Party. Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned
or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within [***] Business Days after
a meeting for review. Each member shall have [***] Business Days from receipt in which to comment on and to approve/provide comments to
the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify
the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>3.3   </B></FONT><B>JDC
Functions</B>. The JDC&rsquo;s responsibilities are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Developing,
reviewing, overseeing and coordinating the activities under each Research Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Periodically
reviewing the progress of activities under each Research Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>Updating
or modifying each Research Plan; <I>provided, that</I> such update or modification does not obligate any Party to perform any task or
expend any resources outside of or beyond its obligations under the applicable Budget;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Reviewing
performance against the Budget and timeline for each Research Program periodically (at least [***]), and periodically meeting to review
and (subject to mutual approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than
[***] percent ([***]%);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>Reviewing
the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year for each Research Program; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(f)   </B>Determining
whether the Project Antibody Selection Criteria for a Research Program are not achievable for any reason and therefore such Research Program
no longer warrants further research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>3.4   JDC
Decision Making and Disputes</B>. The JDC will endeavor to make decisions by consensus, with each of Oruka and Paragon having one vote.
If consensus is not reached by the Parties&rsquo; Representatives pursuant to such vote, then disputes relating to: (a) the reconciliation
of Actual Annual Costs against the Cost Advance, as set forth in Section 5.2(c), will be resolved in accordance with Section 11.7; (b)
technical or scientific decisions in the course of operationalizing each Research Program, including the nature of activities to be performed
by Paragon and Paruka thereunder, shall be finally decided by [***]; and (c) the Budget for any Research Program, and all other matters
not covered by clauses (a) or (b), shall be finally decided by [***]; <I>provided, that</I> [***] shall have no decision-making authority
with respect to the Research Plan or the related Budget for the IL-23 Research Program to the extent relating to Antibody Production Activities,
and [***] shall have final decision-making authority with respect thereto. For clarity, and notwithstanding the creation of the JDC, each
Party shall retain the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights,
powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The
JDC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention
of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JDC are limited to
those specific issues that are expressly provided in this Agreement to be decided by the JDC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>3.5   Disbandment</B>.
The JDC shall remain in effect from the date on which it is established in accordance with Section 3.1 until, on a Research Program-by-Research
Program basis, the expiration of the applicable Research Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
4</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
OPTION; LICENSE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.1   Grant
of Option.</B> Subject to the terms and conditions of this Agreement, on a Research Program-by-Research Program basis, Paragon hereby
grants to Oruka, during the Term and subject to delivery of the Election Notice in accordance with Section 4.3, an exclusive option (&ldquo;<B>Option</B>&rdquo;)
(a) with respect to any Research Program other than the IL-23 Research Program, to be granted an exclusive license under the Project Antibody
Technology for the applicable Research Program to Develop, Manufacture and Commercialize Project Antibodies, Derived Antibodies and Products
in the Field in the Territory, and (b) with respect to the IL-23 Research Program, to be granted an exclusive license under the Selected
IL-23 Project Antibody Technology for the IL-23 Research Program to Develop, Manufacture and Commercialize Selected IL-23 Project Antibodies,
Derived Antibodies and Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.2   Limited
License Grant During Option Period.</B> Subject to the terms and conditions of this Agreement, (a) on a Research Program-by-Research Program
basis for each Research Program other than the IL-23 Research Program, and effective only during the Term, Paragon hereby grants to Oruka
a limited, exclusive, royalty-free license, without the right to sublicense, under the Project Antibody Technology arising from such Research
Program solely to evaluate the Option and for the purpose of allowing Oruka to determine whether to exercise the Option with respect to
such Research Program, and (b) with respect to the IL-23 Research Program, (i) effectively only during the Term until the completion of
the IL-23 Selection Process, Paragon hereby grants to Oruka a limited, co-exclusive (with Paragon and the Third Party Collaborator), royalty-free
license, without the right to sublicense, under the Project Antibody Technology arising from the IL-23 Research Program solely for the
purpose of allowing Oruka to prepare for the IL-23 Selection Process, and (ii)&nbsp;effective only from and after the completion of the
IL-23 Selection Process and during the remainder of the Term, Paragon hereby grants to Oruka a limited, exclusive, royalty-free license,
without the right to sublicense, under the Selected IL-23 Project Antibody Technology solely to evaluate the Option for the purpose of
allowing Oruka to determine whether to exercise the Option with respect to the IL-23 Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.3   Option
Exercise.</B> On a Research Program-by-Research Program basis, Oruka may, in its sole discretion, exercise the Option by delivering written
notice of such exercise to Paragon (&ldquo;<B>Election Notice</B>&rdquo;) at any time during the period beginning on the initiation of
activities under such Research Program and ending (a) with respect to any Research Program other than the IL-23 Research Program, [***]
days following Oruka&rsquo;s receipt of the Deliverables for such Research Program, or (b) with respect to the IL-23 Research Program,
[***] following completion of the IL-23 Selection Process, or in each case of (a) or (b) such longer period as agreed upon by the Parties
(&ldquo;<B>Option Period</B>&rdquo;). If Oruka fails to exercise an Option in accordance with this Section 4.3 prior to expiration of
the applicable Option Period, then, upon such expiration, such Option shall terminate and be of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.4   License
Template; Execution After Option Exercise. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Within
[***] days of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form of agreement template (&ldquo;<B>License
Template</B>&rdquo;) to be used in connection with Oruka&rsquo;s exercise of its Option with respect to the IL-23 Research Program, which
will be consistent with the economic and other terms set forth in <U>Exhibit&nbsp;C</U>, and upon mutual agreement by the Parties on the
form of such License Template, will be attached to this Agreement and replace the terms on the existing <U>Exhibit C</U>. Within [***]
days of agreement by the Parties on a Research Plan for any Research Program other than the IL-23 Research Program, the Parties shall
negotiate in good faith and use reasonable efforts to agree upon a License Template to be used in connection with Oruka&rsquo;s exercise
of its Option with respect to any such other Research Program, which will be consistent with the economic and other terms set forth in
<U>Exhibit B</U>, and upon mutual agreement by the Parties on the form of such License Template, will be attached to this Agreement and
replace the terms on the existing <U>Exhibit B</U>. If the Parties are unable to reach agreement on the definitive terms of either License
Template within such [***] period, the matter will be resolved in accordance with Section 11.7 unless the Parties mutually agree to resolve
the matter otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Within
[***] days of Oruka&rsquo;s exercise of its Option with respect to a Research Program as set forth in Section 4.3, subject to any extension
as mutually agreed by the Parties, the Parties shall use [***] to finalize and execute a definitive written agreement consistent with
the License Template (the &ldquo;<B>License Agreement</B>&rdquo;) with respect to such Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
5</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
PAYMENTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.1   Research
Initiation Fee</B>. Oruka shall pay to Paragon, on a Research Program-by-Research Program basis, a one-time nonrefundable, non-creditable
fee of Seven Hundred Fifty Thousand Dollars ($750,000) (the &ldquo;<B>Research Initiation Fee</B>&rdquo;) no later than [***] days following
finalization of the Research Plan for such Research Program; <I>provided</I>, <I>that</I> Oruka shall pay to Paragon the Research Initiation
Fee for the IL-23 Research Program within five (5) Business Days of the Effective Date. For clarity, the Research Initiation Fee is nonrefundable,
non-creditable, and separate from any Development Costs (including the IL-23 Prior Development Costs) or Cost Advance paid or owing with
respect to a particular Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.2   Development
Costs</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>The
monthly rate for the Development Fees (the &ldquo;<B>Monthly Rate</B>&rdquo;) shall be determined and charged on a Research Program-by-Research
Program and calendar month-by-calendar month basis based on, with respect to any particular calendar month, the total number of Research
Programs being conducted under this Agreement and each other similar Antibody Discovery and Option Agreement between Paragon and Paruka,
on the one hand, and Oruka or any Affiliate of Oruka, on the other hand (each such Research Program, an &ldquo;<B>Active Research Program</B>&rdquo;).
For the period beginning on March 31, 2024 and continuing through December 31, 2024, the Monthly Rate for each Active Research Program
in a particular calendar month shall be [***]. Paragon shall have the right to adjust the Monthly Rate on an annual basis to account for
inflation and other increases in costs by providing written notice thereof to Oruka at least [***] days prior to the commencement of each
[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>On
a quarterly basis, Oruka will advance to Paragon any Development Costs contemplated in the Research Budget, including [***], and any [***]
reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] in accordance with
the Research Plan and Research Budget (less any pre-payments for Third Party Costs from earlier [***] that Paragon reasonably anticipates
will be carried over to such upcoming [***]) (the &ldquo;<B>Cost Advance</B>&rdquo;). On a quarterly basis, Paragon will deliver an invoice
to Oruka for the Cost Advance, and Oruka will pay the Cost Advance within [***] days after receipt of Paragon&rsquo;s invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>Within
[***] days after the end of each Calendar Year, Paragon will calculate and provide to Oruka a written reconciliation of its actually-incurred
Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&ldquo;<B>Actual Annual Costs</B>&rdquo;)
against that portion of the Cost Advance for such Third Party Costs for that Calendar Year, including reasonable documentation of such
Actual Annual Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for anticipated
Third Party Costs in the Cost Advance exceeds the Actual Annual Costs, then Paragon will credit such excess payment against Development
Costs contemplated in the Budget and reasonably expected to be incurred by Paragon in the performance of the Research Program during any
upcoming Calendar Year and Oruka will deduct such amount from its next quarterly Cost Advance. If the Cost Advance is less than the Actual
Annual Costs, then Paragon will invoice Oruka for the difference and Oruka will pay such amount together with its next quarterly Cost
Advance. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation
will not apply to Annual Development Fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Notwithstanding
Sections 5.2(a), 5.2(b) and 5.2(c) to the contrary, the Parties have agreed that (i) [***] invoice [***] of the Development Costs for
the IL-23 Research Program incurred from and after the March 31, 2024 through completion of the IL-23 Selection Process, and (ii) [***]
of the Development Costs for the IL-23 Research Program incurred prior to March 31, 2024 (the &ldquo;<B>IL-23 Prior Development Costs</B>&rdquo;),
provided that Oruka receives rights to at least one (1) Selected IL-23 Project Antibody following completion of the IL-23 Selection Process.
Within [***] following completion of the IL-23 Selection Process, Paragon shall deliver to Oruka an invoice setting forth the IL-23 Prior
Development Costs, and Oruka shall pay such invoice within [***] following receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.3   Financial
Records.</B> Paragon shall keep complete and accurate books of account and records in sufficient detail to enable the Development Costs
payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for
at least [***] following the end of the [***] to which such books and records pertain and Oruka shall be entitled to inspect such books
and records at Paragon&rsquo;s offices upon Oruka&rsquo;s reasonable request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.4   Manner
and Method of Payment</B>. All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise specified. Each payment
shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless
otherwise specified in writing by Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.5   Tax</B>.
Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs and any payments
that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary
in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced rate under an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.6   Late
Payments</B>. In the event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash
payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported
by the <I>Wall Street Journal</I> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>5.7   Equity
Grants</B>. Except as expressly agreed otherwise by the Parties in writing, upon completion of each of the Calendar Years ending December
31, 2024 and December 31, 2025, Oruka will grant to Paruka a warrant to purchase a number of Shares equal to 1.00% of the outstanding
Shares as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred
stock, stock options, pre-funded warrants or similar instruments), with an exercise price equal to the fair market value of the underlying
Shares on the date of the grant as determined by the board of directors of Oruka (each grant, an &ldquo;<B>Equity Grant</B>&rdquo;); <I>provided,
that</I> if Oruka undergoes a reverse merger transaction, the rights and obligations of this Section 5.7 shall continue and Paruka shall
be entitled to warrants from the ultimate public company parent to purchase a number of shares of such parent equal to 1.00% of the outstanding
shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting
preferred stock, stock options, pre-funded warrants or similar instruments), as applicable. Such warrants will be exercisable for a period
of ten (10) years following the date of the grant. Each Equity Grant shall be effected on the last Business Day of each applicable Calendar
Year and the corresponding grant date shall be such date. If the Term ends prior to the end of a Calendar Year, the Equity Grant for such
Calendar Year shall be pro-rated for such Calendar Year and such Equity Grant shall be effected within five (5) Business Days of the end
of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
6</B></FONT><B><BR>
INTELLECTUAL <FONT STYLE="font-variant: small-caps">PROPERTY RIGHTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.1   Ownership.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   Background
IP</B>. As between the Parties, each Party will retain all right, title and interest in and to all of its Background IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   Project
Antibody Technology and Selected IL-23 Project Antibody Technology</B>. Subject to the rights and licenses granted to Oruka in this Agreement,
as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project Antibody Technology, irrespective
of inventorship. Oruka agrees to assign and hereby assigns to Paragon all of Oruka&rsquo;s right, title and interest in and to the Project
Antibody Technology and the Selected IL-23 Project Antibody Technology, including any and all Intellectual Property Rights therein. Oruka
shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances
and assurances and take any such further actions as may be reasonably required to ensure that all right, title and interest in the Project
Antibody Technology and the Selected IL-23 Project Antibody Technology is effectively assigned to and held by Paragon. Oruka and its Affiliates
shall cause all of its and their employees who, in each case, generated, conceived of or created any Project Antibody Technology or Selected
IL-23 Project Antibody Technology to assign without additional consideration all ownership rights in such Project Antibody Technology
and Selected IL-23 Project Antibody Technology to Paragon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.2   Patent
Prosecution, Maintenance and Enforcement &ndash; Project Antibody Patents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>Prior
to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain
or enforce any Project Antibody Patents at Paragon&rsquo;s sole expense, and Oruka shall reasonably cooperate and assist Paragon in such
preparation, filing, prosecution, maintenance and enforcement, at Paragon&rsquo;s request. Following execution of the License Agreement,
(i) with respect to Project Antibody Patents (or Selected IL-23 Project Antibody Patents, as applicable) that have been filed prior to
the execution of the License Agreement, the Parties&rsquo; respective rights relating to the preparation, filing, prosecution, maintenance
and enforcement of such Project Antibody Patents shall be as set forth therein and Oruka shall reimburse Paragon for any costs and expenses
actually incurred by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the
License Agreement, and (ii) with respect to Project Antibody Patents (or Selected IL-23 Project Antibody Patents, as applicable) that
have not been filed prior to the execution of the License Agreement, (1) Paragon, at its sole expense, shall have the sole right, but
not the obligation, to prepare, file, prosecute, maintain and enforce such Product Antibody Patents until the date on which the Final
Deliverable for such Research Program is delivered to Oruka, and during such period Paragon shall provide Oruka with drafts of all proposed
filings to any patent office with respect to such Project Antibody Patents in reasonably adequate time before submission of such filings
for Oruka&rsquo;s review and comment, and (2) following the date on which the Final Deliverable for such Research Program is delivered
to Oruka, the Parties&rsquo; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project
Antibody Patents shall be as set forth therein and Oruka shall reimburse Paragon for any costs and expenses actually incurred by Paragon
in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>Oruka
covenants and agrees that it will not file or prosecute any Patents Covering any Project Antibody or Derived Antibody (including without
limitation any Project Antibody Inventions) during the Term of this Agreement except as permitted under a License Agreement executed by
all Parties with respect to a given Research Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.3   Defense
of Claims Brought by Third Parties.</B> If a Party becomes aware of any actual or potential claim that the Development, Manufacture or
Commercialization of any Project Antibody, Selected IL-23 Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific
Product infringes or in the future will infringe the Intellectual Property Rights of any Third Party, such Party will [***] notify the
other Parties. In any such instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding
the best response to such notice. Certain additional rights and obligations of the Parties with respect to any such claim will be set
forth in the applicable License Agreement (to the extent applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>6.4   No
Implied Licenses.</B> Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right
of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly
provided in this Agreement or the applicable License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
7</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
PROTECTION OF CONFIDENTIAL INFORMATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.1   Confidentiality.</B>
Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] years thereafter,
it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than
as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential
Information of the Disclosing Party to those of the Receiving Party&rsquo;s Representatives who have a need for such information; <I>provided,
that</I> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative
is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall
be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the
same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care)
to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party.
The Receiving Party shall [***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information
of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.2   Exceptions.</B>
The Receiving Party&rsquo;s obligations under Section 7.1 shall not apply to any Confidential Information of the Disclosing Party that
the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of
the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving
such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and
without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application
of any Confidential Information of the Disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.3   Authorized
Disclosure.</B> Notwithstanding the provisions of this Article 7, the Receiving Party may disclose Confidential Information, without violating
its obligations under this Agreement, to the extent the disclosure is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>required
by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation
(including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or
by the disclosure policies of, a stock exchange; <I>provided, that</I> the Receiving Party shall give reasonable prior written notice
to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&rsquo;s
efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only
for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of
such Confidential Information; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>reasonably
necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations
under this Agreement, in each case, in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.4   No
Requirement to Disclose Paragon Platform Technology.</B> Notwithstanding anything to the contrary in this Agreement, Paragon will not
be required to disclose any of the Paragon Platform Technology to Oruka other than as required to be included in the Deliverables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.5   Use
of Names.</B> No Party shall use any other Party&rsquo;s name or trademarks in any advertising, sales, or promotional material or in any
publication without the prior written consent of such other Party or Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.6   Confidentiality
of this Agreement.</B> This Agreement and its terms are considered Confidential Information of all Parties, and each Party shall keep
confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable
other Party, except as expressly permitted by Section 7.3 or Section 7.7, and except that any Parties may disclose this Agreement and
its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations
by such Third Parties or in confidential financing documents; <I>provided</I>, in each case, that any such Third Party agrees to be bound
by obligations of confidentiality and non-use at least as restrictive as those set forth in this Article 7 (<I>provided, that</I> the
confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>7.7   Publicity.</B>
Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release
announcing that they have entered into an Antibody discovery partnership, without the other Parties&rsquo; prior written consent, which
shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
8</B></FONT><B><BR>
REPRESENTATIONS<FONT STYLE="font-variant: small-caps">, WARRANTIES AND COVENANTS; DISCLAIMER</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.1   Mutual
Representations and Warranties.</B> Each Party represents and warrants to each other such Person that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>it
is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>it
is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>this
Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement,
instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.2   Paragon
Representations, Warrants and Covenants</B>. Paragon hereby represents, warrants and covenants to Oruka that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>it
will perform its activities under a Research Program with due care and in accordance with (i) Applicable Law, (ii) the terms and conditions
contained herein and the applicable Research Plan, and (iii) generally prevailing industry standards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>neither
it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction with any Third
Party or Affiliate that conflicts or derogates from its undertakings under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>it
has the unencumbered right to the Paragon Platform Technology and the right, power and authority to use the Paragon Platform Technology
in performance of the Research Plans and the performance of its obligations under this Agreement, in each case in accordance with the
terms hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>each
Representative employed or engaged by Paragon or its Affiliate to conduct the activities under a Research Program has assigned and has
executed an agreement assigning its entire right, title and interest in and to Project Antibody Technology or the Selected IL-23 Project
Antibody Technology, as applicable, to Paragon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>there
are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices received
that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets
or business, which would, individually or in the aggregate, have a material adverse effect on, or materially prevent, Paragon&rsquo;s
ability to perform under this Agreement or to grant the Option or other rights granted to Oruka under this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B></B></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(f)   </B>none
of Paragon, its Representatives, or any other person used by Paragon in the performance of the Agreement has been or is (i) debarred,
convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Food Drug and Cosmetic Act,
21 U.S.C. &sect; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any Federal healthcare programs
(as that term is defined in 42 U.S.C. 1320a-7b(f)) or government procurement or non-procurement programs, or excluded, debarred, suspended
or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of
healthcare items or services, or is subject to any such pending action. Paragon agrees to inform Oruka in writing promptly if Paragon
or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim,
investigation, or proceeding relating to the foregoing is pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>8.3   Disclaimer.</B>
EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
9</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
TERM AND TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.1   </B></FONT><B>Term.</B>
The term of this Agreement (&ldquo;<B>Term</B>&rdquo;) shall commence on the Effective Date and, subject to earlier termination in accordance
with this Article 9, shall continue on a Research Program-by-Research Program basis until the later of: (a)&nbsp;the expiration of the
Option Period if Oruka does not exercise the Option in accordance with Section 4.3; (b) if Oruka exercises its Option during the Option
Period in accordance with Section 4.3 but the Parties are unable to finalize and execute a License Agreement during the [***] period referenced
in Section&nbsp;4.4(b), the expiration of such [***] period; or (c) the expiration of the applicable Research Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.2   </B></FONT><B>Termination
of Agreement for Material Breach.</B> Each Party shall have the right to terminate this Agreement or a Research Program upon [***] days&rsquo;
prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the
breaching Party has not cured such breach by the end of such [***] day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.3   Termination
for Convenience.</B> Oruka shall have the right to terminate this Agreement or any Research Program for any reason or no reason upon [***]
days&rsquo; prior written notice to Paragon; <I>provided, that</I> Oruka will pay Paragon any unpaid fees due for Development Costs accrued
prior to such effective termination date, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with
its activities under any terminated Research Program, as evidenced by Paragon&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.4   Termination
for Delay</B>. Paragon shall have the right to terminate this Agreement or a Research Program immediately upon written notice to Oruka
if, as a result any action or failure to act by Oruka or its Affiliates, such Research Program or all material activities under the applicable
Research Plan are suspended, discontinued or otherwise delayed for a period of four (4) consecutive months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.5   </B></FONT><B>Termination
for a Bankruptcy Event. </B> Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect
to any other Party. &ldquo;<B>Bankruptcy Event&rdquo; </B>means the occurrence of any of the following: (a) the institution of any bankruptcy,
receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other
similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under
any similar laws or statutes of the United States or any state thereof (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), where in the case of
involuntary proceedings, such proceedings have not been dismissed or discharged within [***] days after they are instituted, (b) the insolvency
or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the
institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) the
appointment of a receiver for all or substantially all of a Party&rsquo;s assets, or (e) any corporate action taken by the board of directors
of a Party in furtherance of any of the foregoing actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>9.6   </B></FONT><B>Disposal
of Confidential Information.</B> In the event this Agreement expires or this Agreement or any Research Program is terminated and the Parties
have not entered into a License Agreement with respect to an expired or terminated Research Program, each Party shall return to the applicable
other Party all Confidential Information of such other Party (including all copies thereof) in such Party&rsquo;s possession related to
any expired or terminated Research Program; <I>provided, however</I>, that each Party may retain one copy of such other Party&rsquo;s
Confidential Information in such Party&rsquo;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder
or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>9.7   Accrued
Rights; Survival.</B> The expiration or termination of this Agreement for any reason shall not release any Party from any liability or
obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period
prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all
rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of
expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination
in accordance with their respective terms and conditions: Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1(a),
6.2(a), 6.4, 9.3, 9.6 and 9.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
10</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
INDEMNIFICATION; LIMITATION OF LIABILITY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>10.1   </B></FONT><B>By
Oruka.</B> Oruka hereby agrees to defend, indemnify, and hold harmless Paragon, its Affiliates, including Paruka, and its or their Representatives
(each, a &ldquo;<B>Paragon Indemnitee</B>&rdquo;) from and against any and all losses, damages, liabilities, expenses, and costs, including
reasonable legal expense and attorneys&rsquo; fees (collectively, &ldquo;<B>Losses</B>&rdquo;), to which any Paragon Indemnitee may become
subject as a result of any claim, demand, action, or other proceeding by any Third Party (&ldquo;<B>Third Party Claim</B>&rdquo;) to the
extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any Oruka Indemnitee in the performance of this Agreement;
or (b) the material breach by any Oruka Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the
negligence or willful misconduct of any Paragon Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are
subject to indemnification pursuant to Section 10.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>10.2   </B></FONT><B>By
Paragon.</B> Paragon hereby agrees to defend, indemnify, and hold harmless Oruka, its Affiliates and their Representatives (each, an &ldquo;<B>Oruka
Indemnitee</B>&rdquo;) from and against any and all Losses to which any Oruka Indemnitee may become subject as a result of any Third Party
Claim to the extent such Losses result from: (a) the negligence or willful misconduct of any Paragon Indemnitee in the performance of
this Agreement; or (b) the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses
result from the negligence or willful misconduct of any Oruka Indemnitee, the material breach by Oruka of this Agreement, or where such
Losses are subject to indemnification pursuant to Section 10.1 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>10.3   Indemnification
Procedure. </B> In connection with any Third Party Claim for which a Party (the &ldquo;<B>Indemnified Party</B>&rdquo;) seeks indemnification
from another Party (the &ldquo;<B>Indemnifying Party</B>&rdquo;) pursuant to this Agreement, the Indemnified Party will: (a) give the
Indemnifying Party [***] notice of the Third Party Claim; <I>provided, however, </I>that failure to provide such notice will not relieve
the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of
such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party&rsquo;s expense, in connection with the defense and
settlement of the Third Party Claim; and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim;
<I>provided, however, </I>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&rsquo;s prior
written consent, which will not be unreasonably withheld or delayed, in the event that such settlement materially adversely impacts the
Indemnified Party&rsquo;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and
be represented in any suit or action by advisory counsel of its selection and at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>10.4   Limitation
of Liability.</B> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 7 OR FOR INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY
BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT,
EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
11</B></FONT><B><FONT STYLE="font-variant: small-caps"><BR>
MISCELLANEOUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.1   Independent
Contractor Relationship.</B> Each of Paragon&rsquo;s and Paruka&rsquo;s relationship with Oruka is that of an independent contractor,
and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. No Party is
an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.2   Force
Majeure. </B>No Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other
than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the
affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable
Law. The Party affected will give prompt written notice to the other Parties of the nature of the cause of any material delay or failure
to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent
efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue
performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written
notice to the other Parties of such resumed performance. If any such failure or delay in a Party&rsquo;s performance hereunder continues
for more than [***] days, any of the other Parties may terminate this Agreement upon written notice to the affected Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.3   Entire
Agreement; Amendment.</B> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement
of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating
to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written
instrument signed by all Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.4   Non-Waiver.</B>
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.5   Severability.</B>
Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement
shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect,
and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision
which conforms as nearly as possible with the original intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.6   Assignment.</B>
Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other
Parties (which consent shall not be unreasonably withheld); <I>provided, however</I>, that any Party may assign this Agreement and its
rights and obligations hereunder without the other Parties&rsquo; consent to its successor to all or substantially all of the business
of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations
of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties,
and the name of a Party appearing herein will be deemed to include the name of such Party&rsquo;s successors and permitted assigns to
the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.7   Dispute
Resolution.</B> The Parties recognize that a <I>bona fide </I>dispute as to certain matters may arise from time to time during the Term
relating to any Party&rsquo;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of
this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to
Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship
or ownership of the Parties&rsquo; respective Intellectual Property Rights (hereinafter, a &ldquo;<B>Dispute</B>&rdquo;). In the event
of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(a)   </B>The
Party claiming that such a Dispute exists will give notice in writing (a &ldquo;<B>Notice of Dispute</B>&rdquo;) to the other Parties
of the nature of the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(b)   </B>The
Dispute will be referred to the then Chief Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer
or President of Oruka who will meet no later than [***] days following the initial receipt of the Notice of Dispute and use reasonable
endeavors to resolve the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(c)   </B>If,
within [***] days of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described
in Section 11.7(b) hereof has not been held within [***] days of initial receipt of the Notice of Dispute, then the Parties agree that
such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration
Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this
Section&nbsp;11.7(c). The arbitration will be conducted by a panel of three arbitrators. Within [***] days after the initiation of the
arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the
third arbitrator within [***] days of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent
Third Parties having at least [***] years of dispute resolution experience (which may include judicial experience) or legal or business
experience in the biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by
the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments for
such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed
arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration
proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be
submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters
in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed
by the Federal Arbitration Act, 9 U.S.C. &sect;&sect;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be
entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant
to this Section 11.7 will be deemed the Confidential Information of all Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(d)   </B>Notwithstanding
any provision of this Agreement to the contrary, any Party may immediately initiate litigation in any court of competent jurisdiction
seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce
its rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><B>(e)   </B>The
Parties agree that any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity,
scope, infringement, enforceability, inventorship or ownership of the Parties&rsquo; respective Intellectual Property Rights shall be
subject to the exclusive jurisdiction of the state and federal courts in New York, New York and each Party hereby submits to such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.8   Governing
Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference
to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.9   Notices.</B>
Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier,
by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated
by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of
actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered
by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party
to any other Party in accordance with this Section 11.9, the Party shall send a copy of such notice by email to such other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Paragon or Paruka:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paragon Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building 23, Suite 105</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waltham, MA 02453</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Oruka: </FONT></TD>
    <TD>Oruka <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221 Crescent Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building 23, Suite 105</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waltham MA 02453</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.10   Interpretation.</B>
Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be deemed to encompass references to
either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &ldquo;include&rdquo;,
&ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;, (c)&nbsp;the
word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the word &ldquo;shall&rdquo;, (d)&nbsp;any definition
of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or
other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&rsquo;s
or entity&rsquo;s successors and assigns, (f) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words
of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references
herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement
include all Exhibits hereto, (h) the word &ldquo;notice&rdquo; means notice in writing (whether or not specifically stated) and shall
include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that
a Party, the Parties or any committee hereunder &ldquo;agree,&rdquo; &ldquo;consent&rdquo; or &ldquo;approve&rdquo; or the like shall
require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or
otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or
other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation
thereof, and (k) the term &ldquo;or&rdquo; shall be interpreted in the inclusive sense commonly associated with the term &ldquo;or&rdquo;.
The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted
solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation
or construction. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of
which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language,
and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all
written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the
extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and
conditions of this Agreement will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.11   No
Third-Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted
assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any
of these provisions against any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.12   Counterparts.</B>
This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this
writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the
same force and effect as original signatures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.13   Expenses</B>.
Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.14   Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors
and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.15   Construction</B>.
The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall
be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible
for the preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>11.16   Cumulative
Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be
cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof,</B></FONT> the Parties hereto have executed this Amended and Restated Antibody Discovery and Option Agreement on the
New Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Paragon
    Therapeutics, Inc.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Oruka
    Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    K. Evan Thompson</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence Klein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Paruka
    Holding, LLC</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    K. Evan Thompson</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. Evan Thompson</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page to Amended and Restated Antibody Discovery and Option Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="background-color: white">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>[***]</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">[***]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; width: 15%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; width: 65%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; width: 20%; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>[***]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-top: gray 1pt solid; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; text-align: left; width: 10%"><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="border-left: Black 1pt solid; padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; text-align: left"><B>&nbsp;</B></TD>
    <TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD>
    <TD STYLE="padding: 3pt; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 3pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 3pt; border-bottom: gray 1pt solid; text-align: left"><B>&nbsp;</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020512202ex23-1_arcabio.htm
<DESCRIPTION>CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCA BIOPHARMA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 20%">&nbsp;<IMG SRC="ex23-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 25%">&nbsp;</TD>
  <TD STYLE="width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">KPMG LLP</FONT></P>
</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>1023 Walnut Street</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Boulder, Colorado, CO 80302</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">We consent to the use of our report
dated February&nbsp;1,&nbsp;2024, with respect to the financial statements of ARCA biopharma Inc., included herein, and to the reference
to our firm under the heading &quot;Experts&quot; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex23-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boulder, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June&nbsp;18,&nbsp;2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated
with KPMG International Limited, a private English company limited by guarantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ea020512202ex23-2_arcabio.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We hereby consent to the use in this Registration Statement on Form
S-4 of ARCA biopharma, Inc. of our report dated May 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears
in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts <B><BR>
</B>June 18, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tarca_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tarca_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M3FSU5-C-S_,#M6HQLLGBJ9NJNGY*.6I@ DCF2DW!V/F*.LHRSHIBJJ;&XUP
M28,A>S>_=>ZNLZR_E5?R^>J:"&BP?Q;ZRW')&O[V0[-Q4O:U?5RE0'FF?L2H
MW)31,Y%]$$4,*']"+[]U[HRJ_&'XUHJHGQYZ-1$4*JKU-L%555%E55&  55
ML /I[]U[H'.QOY<?P3[5IJZGWA\5.EO+DDD2LRNUMF8W8&X)FD1XS.=R;"3;
M6>6J"OQ**@2*0MCZ5M[KW5,_RC_X3H; S%%D]Q_$CL_,;.SJ)4U4'6W:D_\
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M9))U&'$T,"$\ E;@ <#Y[/?+FB?G+W?YBYAG(/BWT\<9%:>#;M]/;\2<B*)
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MR'R594A(E9D! 9XQKL'M?:ILK<^\_%K79H:&.,=MQ?R'X(( <A6IW2TPH)7
M9T)[[F.1KP;)LE);QOB8YC@7\3R>I'DOK2OD"".]<Q5;FR;5TU/34-)3PK0X
MC$4,8BQV%Q4+R/2XVAB %HHO*S.[7EGE=Y9"TCLQA+GC=;KF?<FO)XT@AC7P
M[>",!8K:!22D,:@# J26/<[%G8EF)Z%FTVL>W0"%&+LQU.[&K.YI5F/SI@<
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M2P ]XA<[K/S'SC?75NAD>:=DC"@DLJ'PXP !4DJHZEC92FW;1#'(=(1 6)P
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M?NO=>]^Z]U[W[KW6LGCTN;_U:W^M]/?S4;>FJ3K/J8T7I=XR/D$_X $?F_\
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M%CS!O5I&+$/H,54^$%L&E"37APZ8=T;WZYZHBEIL3A\7)G0C 8O"4U)!4AB
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MHWMVSU;%_+V&GIG=(_IVEF__ 'E-E>^J']W_ (]G-S_Z75Q_V@[=UCE[U_\
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M98)71@58@^Z]U]-3K/L#;W;'76Q.S]I5(J]L=A[/VYO7 5 96:3$;FQ%)F*
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:17\_KY._Z8?EMCND\%6K4;.^-V!?
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MM9D<ID:D*\=!CQD,C+55<[#13P*\C>E3[]U[JU7_ *!_/Y@?_*ETU_Z,IO\
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M:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\
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MJ%)9UYM 7-'MQ=M%)?\ )%[#O]HHU'Z8TNXT\C/8M29?.I574 $DCH<;=O\
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MQ??NO=6*?RJ/D6?C/\Y.EMXUU8:/:>[\S_HHWVS&T!VOV'+3X9*NK;R1Z:3
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MF[S0/-_BQ;305U4J&ID @Y%>!QCR'0CMD95[Z5^7^S_J^?5NO\O/_F2VY_\
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M)(TBWC!&A1#6^I6_O<E@HD (R:^EK52@U2S?^8X_<"-6NQ3?E"H'4 +N*J*
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M[!5'VDTZLY^//P=./J*+>'=4%//402156-V%%-%5TL<L;:XIMSU5.\E-6:7
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MY7+&HIZ6F"%654J-1$;,P]U[HZ/QLS_<79%=NGMS?M5+@=C[LBIJ;KKKQJ9
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M&&2E#65D@IF )6=A[]U[H\'<79%!U+UMNK?E<J2MA<<W\-I') R&:K'6CPU
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*OW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>toruka_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 toruka_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MLOE\[73. LN2KJO)5+R.=*JC5$LTA)+6 '^L/<C06MI91Z+:WCBB X(H4?R
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M[-]JV+=-ZD*;?;%E'Q.<(OVL<5^0J?ET%^9><N7.4H%FWS<5C=A6.):M(_\
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M!J&A$:@:I"#CR6N"P..C%S?"%/M!X.QG->!=C-M<"DD-F] 5,ZTT(N1ZKO\
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MN]P;KW1D@ J*#+4U4Y"I'&HTPTU)31* !Z(:>!/[*+P+%6PV3;M(TPV$"?D
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MQ]WD\6VV6%R(M(EFIYDDZ%/V4K3Y@^74]^P/*MO]+?\ -MU"#<F0VUJ6_"H
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M6B=HJ6B6P8TP9I);Z9?& R/&_,W/L*Q26.Q.6E/:UQP"CST5R3_2X#B*X(R
M]O?9*Z>XM]XYSA"6R'7'8$@LY\C,02%3ST9+<&T@%2O/EOMWK4;;HLOE:N/#
M[WIX12[:BQM-%-5YFC@95;'5U(LE.JXFD\EQ4LP-,39!(6\+E7M]>;U];);V
M\9DVPG5.7) 0G\2G/>:</Q>=*:@)O?/:N4?W/;W]].(.8D719B)06E4',;K5
M?TEK763V?AU5T-6[[F?K$?I4T>^=[8Y43'[PW30I&RM&E'N#+4JHR6T,BP5:
M!632+$?2WM!)M>V3$F7;H&)XEHT/^$='<',O,=JJK;<P7T:@U CGE4"G"E&%
M.AOV)\J>S-J5$4><K%WIA[J)J/,E4R2(/U-29J&+[H3, /\ @0*E/Z*"2?88
MW7D/9+]&:UC^FN/)H_A_-":4^RG4C<M>]?-^RRHFYSC<+# 9)Z"0#U651JK_
M *?6/D./5B6R-][-[?VK-78EH<ACZN%\?G,'DH8FJ:)JF$K/CLK1,9(WCFB9
M@&!>&9;Z6-C:'MTVK<N7K]8K@%)E.N*5":-0X96P<'\QY]96<N\R;!SWLKW-
MB5EM)%,5Q;R@:D+#NCE3(R#\U8<">B/=O?%'<&"JZS.=;T\N?V_*\E0V 1]>
M<Q"F[F"D21M>:I$^D>@M56(4I(09#)_+O/UI=1QVN].(KL8\8_ _S-/@/K7M
M\ZCAUCESW[([IMT\^X\HQFYVPDL;6M9HO.B5_M5'E0Z^ HV6Z*>)=P;8KI85
MDS.WLG$0D\0>MQ-=$1R%E0&GJ$()X! ]C\K9WT2L1%- >![74_9Q'4(!]VV6
MYDC#W%I>##*"\3C[1VMU$K\GDLK*)\GD*[(SBX$U?5U%9* 3<@25$DCBY'//
MMR*""W71!"B+Z( !_+IBZO;V^<27MW+-(.#2NSG]K$GI?]18G8F;WSB*#L/+
M3XK RS1D%$"TE=6"6/P8[)9#RH^*H*LDK).JFPXU17\JE',5QNMMM=Q+L\ D
MNP/S44RRK3N8>0_D>!%'(=CRUN/,EC:\U7K0[:6%*#M=ZBD<CU!C1N!:GRJO
MQ ^/R@VMU>-A4=9GIX-OYO#TAH-D-BZ:*2MK%IHTTX&/'K) M1AT#J68LBT9
M8.K#44EBKD:^WS][21VB&:VD;5=:R=(K_HA;-'_X]P\JC)CWDV;DW^K$,^Z2
MK:[A GA[<85!=M(%(0E1JBX5R E:@YHU8/N<>L->GU=T[F2B.-7<6=7',JJU
M N7R HF5195-**@0%5'T&GCVD-A8F7QC9Q>-_'H75^VE>C0;YO2VYM%WBZ%J
M10QB6313_2ZJ?RZ5&R>J-_=@U$,6VMN5]12RL ^8J87H\)3KJLSRY2H5:9B@
MN2D9>5@#I0GCVBW/?]IVA&:]O$$@_P!#4U<_8HS^9H/4]''+O(_-'-,L:;1M
M,K0,<W#@I"!ZF1AI-/05;T!ZLSZ4Z*PG4E!)523)F-W9&G6'*9GQE(((=0E.
M-Q$3_N042N%UNUI*AD#,% 6-(1YFYINN8)@@4Q[>C5CB\R>&ISYMZ#@. KDG
M,'V\]MMNY&M7F:03[Y,H6:XI0 <?#B!RJ5XGBY )H** K[B^5U!M>KJMM]>P
M4>=S%.7@KL_4LTV$QU0K%'@H8861LM51$'5)K6GC8"WE]2J?<N<@S7T<=[N[
M-%;'*1+AV'JQ/P ^E*GY8J"^?O>VUV6>?:.5HH[G<$JLER^88VX%5 IXK#S-
M0H-/BR 2?-]R]J;@J&J<EO[<^ICJ\&/RE1AZ(&Y(*4&(:AHE*ZB 1'<#CW)M
MKRWL-F@2':8/M=0[?[T^IOY]8[[C[@\[;K*9;OF>\K_#%(8D_P!XBT)_+I!Y
M#+97+R+-E<GD,G,@8)+D*RIK9%#MK<*]3)(RAVY-CR?9K#;V]NI6W@1%/DBA
M1_(#H,W=_?7[B2^O99I!6C3.SD5R<L2<GI3]=8[9V5WAAZ'?F7J\+MJ>H5*V
MMI(4<ZR0(8*FH9Q_#J.=S:2I"2^)>2H!,B(=YFW*WVZYEVJW66] [58_M('X
MB/):BO\ (G/*5IR_>[_86W,]\]OL[-221!Y^2LU?TT8\7H=(\@*LMIW8/2&R
M>PMF8W;=/34V%_@E&D>TLMC(HW.)B,::(E <??8VK55,T;/>0^L,) ']P1M'
M,^Y[1N4UZSM+XK5N(W/QGU_HL/(TQPI3'6:7-/MWR[S5R_:;1'"EN+>.EC/"
M!^D*"@'\<;4&H5SQJ&H>JTM_]*=A]<U$PS6"J:K%QL_AW!B8Y<AAIHD/$LE1
M%'KH"PYT5*0OP; CGW->T\S[/O*+]-=*LYXPR45P?0 _%]JU'6(/-'MWS5RG
M+)^\-M>2R!.FZ@!>(@>9(%4^QPI^WCT@H-S;DI:44--N#-T]"$$8HX,M7Q4H
M1=0""GCJ%A" .;"UN3_7V;/8V3R>*]G$9>.HHI/[:5Z#,6];Q# +6'=KE+:E
M/#65PM/32&I3/3*2222223<D\DD_4D_U]JNBTFN3QZG8S*Y3"UD61P^2K\3D
M(-7AKL965%!60ZU*OXJFEDBFCU*2#9A<>VIX(+F-H;F%)(3Q5P&!^T&HZ56=
M]>[=.EUM]W+!=+\,D+LC"O&C*017[>C"[%^4W9VTZB"/,UXWGAE(6:AS97^(
M>/C4U-G(XFKEG-A8U'W* 7]%S?V#]UY$V2_1VMHOIKGR:+X?S2NFGV:3\^I4
MY;]ZN<=DEC3<;D;A8##1W%!)3^C,!KU?Z?6/EY]6/===D;9[/P$>>VW4L0C+
M#D<;4Z$R.)JRNHTU;"CN!J )CD4M'*O*G@@0UO&RWVQW9M+U,\4=?A<>JG_"
M.(\^LM.5.;-GYQVM-SVB8E:Z98GH)(F_A< FGR(J".!Z7WLIZ$W7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5GY5=G
M56R-F4VW<+4O2YW>355)]S"Q2>AP=(L7\4GAD4WAJ*MJB.G0\'0\K*0R @=\
MA[''NFY/>7*!K6VHVD\&<UT@CS H2?F #@]0Q[U<XS<N<OQ;7M\Q3<]P+1ZU
MP4A4#Q&!\F;4%'G0L0:KT0GJ/JG,]L[F&$Q\OV&.HXEJ\YF9(6FAQM&SZ$"1
MAHQ/75;@K#%J7659B0J,1*_,._6W+]C]3,NN9CIBC!H6/^11YG[/,CK&3D3D
MF_YXWC]WVS^%9Q@/<W!%1&O 4&*NQPHJ*Y/ 'JT#:'1?5VS*.&FQ^T\7D:J-
M5$N7S])39K*U$@ #3-45L+QTK/:Y2G2&*_T4>X.W'FG?=RD9YMPD1#PCB)10
M/2BG/YDGY]9D[#[<<F\O6\<5ILD,LP&9[E5EE8^NIP0M?10J^@ZG[GZ;ZRW=
M2RTV7V9@Q)*&MD,;0P8G*1.;D21Y'')351*N=6EV:,G]2D7'MFQYCWO;Y%>W
MW*6@_ [%E/VJU1_EZ5;SR#R?OL+Q7^P6VIO]%B01R#YB1 K<?(DCU!ZK<[JZ
M#S_5==)7T2U>;V5.Z_9YP1*\U TC!10YQ8%5*:H#D!)M*PSW&G2^J-9GY9YL
MM-^B$4I6+<Q\45<-_22O$>HXCSQDXD>X?MAN?)5P]U;+)<\NL1HN:5*$XT3:
M1137 :@5L4H>T-/7'?G8/6-)_#,)58_(84.TB8?-49JJ6%GD:60TT]/-1U].
M'>1FT+-XM3%M-R25&\\I[1O<GCW,;I<\#)$:$^E005/[*_/I!RE[G\T\G0"R
MV^:*7;@:B"X74HJ23I92KK4DXU4J:TK7H5,G\S>QJJF,.-P6U,5,R:6J_MLC
M73(WY>GCJ,@M,A_PD24>R*#VVV:-]4UU<2+7X:JH_.BU_81T-KS[P/-4T7AV
M>UV4$A&7(D<_:H+A1^8;HME;7[P[(W,LU9-E=U;HS,Z01#2]55U#DGQT]-!$
MHCIZ:$$Z8XU2*) ;!5'L9Q1;=LMB5C6."QC%3Y >I).23ZFI/417%SO_ #?O
M*O/)/>[S<,%4?$Q]%4#"J/0 *H]!U8)U'\4]LX#'T>8[$HXMP[DF1)WPTTOE
MP6'8G6M.\,15,O5HIM*TI>FU75$8 2-$?,//M]=S26^SR&&R!H)!B1_G4_ /
M2E&]3Y#*3D7V3V;:[6"_YJ@6[W=@&,#&L,7]'2,2L/Q%JK7@,:B9*3K[84M)
M]A)LG:3T0! I&VYAS3*"H4Z8?L_&ATJ!< '@>P8-WW59/%7<[@2_Q>(]?VUZ
MEQN6.6G@^E?EZQ-MP\/P(M/IPTTX=%*[M^*^'DQ==NCK*DDQ^2HHI:NNVK')
M)-19&GC5Y9WPRRF2>ER"BY6G#&&4#3&J-8/('+//ERL\5COD@>%B%6<@!E/
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MW[KW7O?NO=>]^Z]U[W[KW56WR_R4M9VRM$TC-#B-LXBDBBNVB-JF2LR,K!2
MODD^\%V%R0J@GT@"=?;N%8]@,H7NDG=B?L 4?X.L,??F[>XYW2W+DQP6<2*O
MD"Q=R:>IU"I^0].C1?$+ TF-ZI&8B1/O-QYS)U55/I_=,6.E_A=)3,U@3%":
M61U'(#3,?S[ ON'=23;]].Q/APQ*JCRJPU$_::@?D.IF]B=M@M.2%OD4?47=
MQ(\C>=$;PU7[!I)'S8^O1I_8$ZFCKWOW7NL4\$%5#+35,,513SQO#/!/&DL,
MT,BE)(I8I R21R(2&4@@@V/NRLR,KHQ#@U!&""/,'UZI)''+&\4J!HF!5E8
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MDLI-69_<>:J8*2F@IX2[NS,(J/'8ZB@73%"A;3'&B_4DF[%B94M+3;]DL!#
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M_=.4+=-JW"W-YLJGL7522('B$8U!3ST&F>#*.C5I\Q.IS1_<M2[N2?\ ./\
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M'@SCU8\54_M/R%*X_>XWO/%LLDVR\J-'-N2U6:Z/='$>!5!P>0>9-54XHQJ
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M_LY0"S+3^,^:?TCD'C4<(M]W_;'9;/;[CFO97ALW0CQ[8E4CDKYPC 64_P
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M,AHL+!+$VJ\$QQ%+135,!#6*RLX8?6]O;5CRIR_M[K+;;:GBC(9RSD'U&LD
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MSD;X_+8]X:V@KZ*:4054 E8T>6Q-8%AE:%I824<!)(Y$*L%=642[MFYV&^V
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ME*B1FD>;%O78)GD8$&21<)5X^.5R6N=8:YY-S[/[3FSF*R4)!NDF@8 DTO\
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MD*,D T!ITJ^G^V,QU-N9<M1*U;B*X14VX,,9"D>0HD<LLL)OHBR-'K9H)""
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MRDTLF1Q]?BI3)$;^2DFGB@,FGZAXR1;D&WLWM[S;]QC;Z6ZAGCIW!&5Q0^1
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M%MNVWQ!+'<%=V1115F0CQ*4P X96IZZJ8X#U\,MUSY/9^X]IU,QD.V,I3UE
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M?#"DT\F*GRR?KM'K[%]F;-RFVLC%']Q)$]3A:UE!DQF:ABD%#6QM^I4#N4E
M(\D+NMQ>_N)]CW>?9-Q@O86.@'3(O\2$]RG_  CT(!ZR<YRY6LN;]@O=GNT7
MQ2I>WD/&.4 Z''GQ-&]5)'GU3[M3/Y'8F\<-GX%EAR&V\S#434]PDCBEG\5?
M02$W 6JI_)"_^TN?>1-_:0[KMMS:,089HB WVBJM^1H1U@;LFYW?+',&W[FB
MLMU9W 9TX$Z6I(A_TRU4_;U=_3SQ55/!54[K+!4PQ3PR*;K)%,BR1NI_*NC
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M%F]%%3_+K1( J30?/H)?]FT^*O\ WDS\??\ T<W7/_V2>WOH[S_E$E_WEO\
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MM' BO0FM[B*YC$D1QYCS!]#T=3V5]/\ 5 ?_  ID_P"W3G:O_B3ND_\ WO\
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M>.-W2G@;L7#TRS3LH*PQ-4U$<89K O(J_5@",^0#_P BBQ_TLG_5MNB[=?\
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M8RR)3-#()>5=_?E_<UN&!:S<:)T'$KY,/FIR/7(J*UZ17UH+N H,2#*D^O\
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M-3U%%#V7N6JEKXT7R0U>*Q^,JT=EF4+!?N+O*7VYQ;=;O6"U!#^GB'XA\](
M'R.H="G9[8Q0&9QW/D?Z7R_;_@IUM.^X[Z-^B^_+3_LE7Y,_^*^]S?\ ON=R
M>U-G_N9:?\U5_P"/#JDG]G)_I3_@Z^.3[ROZ 76_+_PD:_[),^4W_BQ.)_\
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MOK8-&OPXPR]Z+(*$N*]KBN./25_V<+J7_CANW_SS4G_UU]K_ /6ZY@_BM_\
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MW91S[,=KVB_WFX^FL("\@%6/!5'JQ.!_A/D#T0\Q\T;)RG8?O'?+P10$Z44
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M:[_W6GV8>V?_ "4-S_YHK_Q[HB^\/_R0N7_^>MO^K9Z.3C/^+;C_ /J!I/\
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MJQJ104()/1FMU]/];[TAIHLYM3%,U)44\\-504T6,K0D$RS/2/5T*P3R454
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MB>A&I'4,IHP#"JD&A (\Q7HLOS"_YE+!_P"';AO_ '$ROL;>W7_*P-_SSO\
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MSVEU(%8NN@&XL;_T]RI[:AFBYA5/C*Q ?;2:G6-?W@FC2ZY$>:G@B2Y+5%<
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M_P!Y#;_O(3D?_E5MK_YN?]7I.L%?>3_IY',?_4/_ -HL'0!^Q9U&/5V75/\
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M']RQUC'U:/\ #W_F4L__ (=N9_\ <3%>X+]Q?^5@7_GG3_"_69_L-_RHS?\
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0O]*/\'6?W7ISKWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>timage_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZOSZWK7^'^77M$7X27_8NI_Z*][_ &_ZOSZUJ'I_+_9Z\5C_ -1)_MU_Z/\
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MO7/]3_M_?NO5/7KG^I_V_OW7JGKUS_4_[?W[KU3UZY_J?]O[]UZIZ]<_U/\
MM_?NO5/7KG^I_P!O[]UZIZ]<_P!3_M_?NO5/7KG^I_V_OW7JGKUS_4_[?WZE
M>O5KUZY_J?\ ;^]4'6NNKW^OO=*=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN<
M?ZU_U_>CPZ=@^,?:.OK7?%K_ +)D^.?_ (@CJ+_WG\?[QGNO[5_],W^$]3_#
M\"_8/\'0[^V.G.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[JL7Y=?]O!?Y2?_B3/F%_[Z#<'LZV[_<6[_P":<?\
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M-3Y.HHY(?)'X%D"@,^D^0J40%T<)I8GTA]5S]/;L-CI'^QT4S;H(23J^=/\
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MGRZ[J=V;;DG04NWE,9U2>B!($UDQGA7,EE4:E^O(YL+^[5TXSGSZ9E 4UP*
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7./\
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M-_\ 6]O'9!&*U/[!]O263GRXG^&)/7XF..&3_L_;U":@Q2!!_$GG+79C! P
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M+3MXIHW$D;1\%2OTTV^A]I7N-1[0!_J_+H06NS! 0Y8^1)()I7S-2:5 .*9
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M.AJD ?(T)_('HO7P1_EB_+#^8Y_I4_V6#;FT<_\ Z&_[C_WX_O3O6CV?XO\
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MK[,+_G&SVX1F37^K&LJ46O:W"N<'Y=([3EBYO=831^G(T;58CN7C3'#HSO\
MT#%_S8/^?==2?^CIP_\ T=[+_P#7#V[_ (;_ +Q_T-TL_J5>?\+_ -Z/_0/5
M=OSK_EI_*C^7/7]:XWY.[>VG@*KMFCW57;-7:V\J3=XECV:^/CKC,U(2("C9
M.ETAOUW:WZ3[/MEYAM]^U^!J[-.K4M/BK2F3_">BC==EFV?3XVGOU4TFOPTK
MY#UZ()[/.BCKWOW7NO>_=>ZYQ_K7_7]Z/#IV#XQ]HZ^M=\6O^R9/CG_X@CJ+
M_P!Y_'^\9[K^U?\ TS?X3U/\/P+]@_P=#O[8Z<Z][]U[KWOW7NJE.R/YV_\
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK%^77_;P7^4G_P"),^87_OH-P>SK;O\
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MC]O26:_>6FD$CU"FG\A3'V?[*;JZ*.@JM,L6*IJ>(L3%)$:YN25!+B%4=K<
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M:@:4S4CB/F#]DYAN8KE0[LZNZJP=B0-1I45K2E:XH#P]*7A_SJ/Y;_5_;_\
M.4_ENU$>*I\)A?FSGZ[ =XT6.I/MDRR_'RIQE?F:LM3HLJY/*[7R--CWG+D)
M]O3S,MUE9PARMOLMIM5V*U\$*8S7*F:JCUP&&JGJ3Z]"3?MICN=PMC@>*6UB
MF&$5&SPR0=-?0#TZ37_"D7^9G\@_BOV=U%\%_B)OO+?'G9N#Z;V]OK>>?ZCK
M_P"YF6*YBJR.*P^WZ"OQ[15>$QV+Q^*6?11R4\DIJH06\4"!G>0^7H-R1[NY
M42'7I56RM0 Q8@\:ZJ9J...F^;MZEL66W@)2JZF9<&A)  /EP)Q0\*'HN_\
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MGF,Q4X[*P-F,I4U*RF6MJ&EGF)+M(VJ_L>#;K._1':&)ET+HU1H=*4J *@T
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M+24ZY'&Y?%T"P34\ G_REWD++&&C+/;K?I]RN9+.\D>5)(FH)69R2" 15JD
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M#210U6/GEFI9J-:RGK*BJ68!R(DC[F2[N=WO_P#&HEAF.B-E4,M?($ZV;)!
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MK'TF\-_?%'!T.V7RSF*FDK<7G>R,A3TTTBW,*5<E(L'ELPB\GD*L%*DT]O\
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M_P#.7Z.V)_+T^1WPY^8GQ2V#@^J*N3=.XI-S[;V%%!L[$25^PIL75TT46/I
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M]Z4JW'I/*YH6@'#@#4#]M#UPGCC',;%K@FQ]/U_I_7W25%'PD]*K*^F=?UU
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MM32G&G\J]8_N.27DU$-_4^V_%-<]*OI"HHB*!3KF)%<@<W^EE-N#[L&#>OV
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M)<_LKQZ/?W[K=?#AC6AJ0&TX7.,T!-/G4TITGYH)$:T;,]@2-"D7L2+V^HN
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M5+L6"D>@P/V@_+H"WG-5Y>+H+!000="T)!^9J?V$=7O_ /".S_NHI_Y:-_\
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M?N=+);6189/$=T9%"AA34"-1) H!6M.)./4@*[/RO=_4(TJZ%1@Q)*FND@T
M!/']@&?D;0_YW/\ ,OZXZG_G$?R^6Q-71[JP7P.S\^XNZ9\9,V5%)-W568V#
M<6+BBIW).6Q6V,925(47(J:B*"52T+Q@.\J;!)>;7=>1G $=<5,56!SBA8TK
M\CT=<P;Q':W]OY^%J+^=!)13PJ:A16GS'2U_X4-_RNN\OG9NWHGYU?"';Z_(
M7$9CJ##[&WAM[9&?H*F>;$TE36YK;NY<)%-+",M2UL.8JZ>I2GJ9)T\=#)#2
MO&]7-"WR1S'#LZ26MV?#[]:L5;XJ!64TK3X13'K4\!U;FO8Y=S9+BW&OMTL
M0,5+ BM*\37/I0<>K%OY/O8_\Z;?V\JF@^?'2^Q>FOC7LCJU=L[,I:G;5+M3
M<M?F\;+0TN.$=)'E<C6_8TN.IJTU,M53TRRR2TQIVG'E\9#S';[5 @^BD>20
MM5JY0+0UXHN22*4KP-:8Z.=FGW"9C]7&B(%Q3XBU1_2;%*UK3B*>?5??\K:K
MI:[_ (4P_P TVJHJFGK*:3J7O81U%+,M0C&+?G62, Z$J=+*P-CP00>1[/-[
M%.7[3_FJO_'9NBG:S7>;C_FF?\,70';N_GN?(SX:_P YSY"=2]X=AY'?WPKH
M>^<WUUF-D9+"T-1/M3%U,D*4^9PE7#3PY"^(DD\DU++4S15%)YXUB%3]O+$H
M@Y/AW3:8YH5TSZ"U:FDA!/:1D5(&* 9I7'3,W,LEAN+Q2FL.H+2@[*@9KC%3
MFM<<.D%_PID_EOU]-D=F_P R+H[.;H[(ZM[$I]O[9[3BR&^,CV&F)J-SS"7;
M.7P4M?4UTD6V\Y)7/ *:FG2CI:R2E-+#IR#"-3[?[\JAK&4!2*LATA:T!U!B
M*9 %:G- :G '3'..SL]+N.K#"N*DTJ>TJ#7!)H0/,@@9)ZN6Q$/PA_E%?RB.
M@?BW\^7S>.VCWOLO*[)[BVOM.GSU77YG<'9V/GS6\*-YL%/0YB"AI!4/CFJ(
MIZ<B!*:$Z?+I]A4F[YEW*2XLQ5D;6A.@:50A4/=VUX&F<U.>A !;;'8I#<FB
MLNAJ:C5F!+?"*TXYQ^77'^4Q\O\ ^25_>[</PT_EVX_=>RJ_N-=P;[S'7^^(
M-[9.@S,^W\:D%?X)MYY7+HM4^(A)DIX'C$]/3LSH_A%K<R;;NU!=7X!TT0,/
M#J 22,1@>=<GUZUL=[MP)M[,TK5RI\3. #E_E3 /5 ?P%^(M;\'/^%.77OQT
M^PK*/:FU=Z_(W,]85%4E0ZU.T]X=5;VRFWI(JBI:1ZPT^.JH:2HF$TG^64U3
M&SF6.0 ;;ONG[XY?:<D%BL8?A\:S1@\.%:5IZ$=!3;K#]V[RL0!TU<IQ^%HG
M(X\:<*^H/5]_Q3[!VUV1_-P_G@_ [L5Z3*;,[IV=U/O>+;%7#'**BAJ-@8':
M.[D"2I)#,M70YS!(\<BL-,5]#(9+ C<;=H-ML+R.H93(NH>1$KNGV&H8]"NR
MF$M[=VST(/AMI/F#$JM]H^'H0>R^WL9)_/G^"/Q1VOYZ7;'Q^^%_>.YY,?#/
M:FBJ>RJ-:"EIC$#ZIJ/$[8H65V'$=59+:I+IH;0C:9KEJ5>XC0'S[0S'\B7_
M )=*);FNXQPBO;"['T[F4#\QI/[?MZTC/YY/_;V/YM?^)4H?_='B?<O\F?\
M),@_TK?\?;J->:?]SY?M7_CB]50^Q/T'^O>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZWF/\ A1G_ -N<
MOY<?_AZ=!_\ OK<Y[AOD#_DI3_\ -.3_ *NIU)_.7^X,7_-1/^K;]/\ _P )
MO^K^O/A!_+Q^27\R[Y 2/MC;^_Y\G44F>^RGKZB+9'3<DU*STE,J*\M1E]S2
MY.%(8@YJ&I*,*^IM*ZY[NGW:_CL8>XI1:8 ,DE#Q^0T\>!KUOE*W7;K1[J7&
MJK5S_9IPQ3UU'%:BG2L^-?\ ,0_X3A].?*JN^0O1U%VAL+Y%=P;BW#B=S]G9
MX=GY"EJY^WLI'4Y:;*09O/5V#AI:K(NE3-(] $IR@EC\?C4AG<-EWVXMA#,%
M:*( A08:@1J0*:0&-!CCGIVSW+:8;@RQ$B20D$TEH2[ GXNT5/[.JLO^%4?P
MY'4'S!V1\K]J8=X-D_*?::4V[:ZCIYI*>/>/64%+05+2R7>FIFRN!;#2PQCQ
MFIEI<A4!9'6>3V)?;G=/J;9K5CF(U7A70Y)X<31JU.?B ].B'G;;_!F6X48D
M%&XTU+0<>&5I0?T2?7J]7_A25\W?E'\'^M?B7O;XO=LY;JS/;E[2WS0;F>@Q
M>.S=/DJ;#8VAJ8*:MI,G1UM-- LK.=)C!(9A?GV#>1MHM]XFECN%U 1U&2"#
MJ J*$="?FO<IMLBC>%M)+T. :BA-,@^GEGI/UN0VA_PH^_E+Y>HVSN/(]>_*
MCKZB>ASNQ<-OK)[>V_#OO;4<5=2TV8Q"5LM#7;8W.:>&6AJ:VDJIL=Y&>"1J
MF@F#V57Y&W,:@&C)PQ4%C$V"5) HP%0:$5(H<'K1*\UV!TDJ],C40!(N:&E:
MJ30Y!QGB,5Z_\)9^_MO]7=B_+K^7;W730;)['W=GGW-MO;N=8XVLJLML6*LP
M&\=NR%GT'(T4$5'-% G[I2#(R>M8?0>>XEF;E8+^+N32%)' !N]#ZT-3_+UZ
M*>2[GP#+9R=KABP'G4=K#TQ0?;GTZ)SL'^6K_.-_E._.'>F^?AM\=*_NFCIU
MWAL3JSM08J@W[B,IMC=E53M2U.0@CR&-;$Y44\--'5I61T\<%0E0T/EI?%4N
M9W._[7S)9HEW*8SVLZ@,"' (-.UP1DD4J:4K0U'2&WV?<-BN6>VC#@U56)!!
M4D$5[D(.!7@*UIC/6QO\X\U\L:K^0%\C\M\\Z+8.UODSG.ILC-O? ;'GIHL=
M1MD]STKXC'*:>IJZ1\C#C#21U*T]941-5++X9I4TL0+MB6Z[Q$+0LT0E326^
M(T J> Q6M, TI4 ]"V_:9MMD-R%$AC;4%X"M:#B<TI7)%:TQT7OX!X+OW<__
M  F VA@/BW/OVF^0.4V'W]2]73]7[CGVEGUR+=R;J-\9DJ:JHIZ.?[<3WD6J
MBLFL%K$^S'?GACW\M<:?##PE]0U+I\*.M10U^RG2'9DDDV<+#764E"T-#J\1
MZ4-13[:]4$?[+'_PI_\ ^>E_F6_^E<9__P"S3V,_WIR]_#;?]DX_ZU]!C]V[
MUZS?\Y_^NG5#?=O6/:_3?:^^>M>\\#F]L=N[8S<D6_L)N6M3)9"'(9)$K9#6
M5$<]2LU1,M2DKOYW9F<ECJO[&=C<Q7<2R0$&,CM(%!08P"!2E*<.@O>02VTK
M),"'![JFIJ<\036M:\>MT7Y%?]PD?6'_ (9?1G_OT:+W$NV_\K(W_-2;_JV_
M4C7_ /R0U_YIQ?\ 'TZT9_<R=1AU[W[KW7O?NO=>]^Z]USC_ %K_ *_O1X=.
MP?&/M'7UKOBU_P!DR?'/_P 01U%_[S^/]XSW7]J_^F;_  GJ?X?@7[!_@Z'?
MVQTYU[W[KW7O?NO=:57Q&^6G1?PV_G'_ ,P_L[Y [KK-G[-SN\/EKL/&9.AV
MWD=TN^3RG:>-R$,!I\92U=0BM2XNM?R-&(P4"E@SH#/N^;+<[[L5E#:KK<+;
M.1J5>T6[+6K$#BPZP[Y2YHL>4N;]UN=PD\*-I+Z-6T.]7-ZC 4C5CP1C6E,<
M>'0O_P T7YW[*_FD4W1WPJ^#6&WOV?F<WVQBM[9[<<VVJ_:])KQ]%78ND@>&
MJACJUQU-_%ZBKKZJHIHJ>F6GAD!D]31EG*/+TG)S2[AN6B-5C**NI68DD-BA
M(J0M  :FI\NA%[C\X0>YR6^R[$9)W>=9)'T21QJBJR]^I0=(+AB=-!I'%J#H
M</Y]/6&.Z3_EM_#7IS$3?=8WJKL?K7KNCK"H1ITV;L;-X\5#V509*C[?R.=(
M+.Q8\D^T/MM=M?[M<SMQDCD<_:TT;?Y>C7WUV]-IY=LK6/X(;B")?,Z8[:9!
M_(=&Z^<?R5^7GQ*^ GQ7[L^+N%VGG<)@^O>N<9W(FXMGS[M>AQ^3VWCCCLHH
M@K*7[6AIJJ&:&JD9)!KJ:8DQHKE@]RWM-EO6X36]XS*69S$58+J8.:KE6R0:
MCAPIDD=#GG[F'=.5MHAO=LCCDT!/'#HSZ(C'\=%=#12 &XT!J: $]%Y[Y_F=
M_P F'Y/] Y?.]V[/Q>[>T\OL*ME'7U;TAE&W=0Y:KHBGV>.W;%C(<?25$=1I
M1*J+<L4954=F &@&^W<G;]M%R!;DHH<#Q!,OAE0>)3421YT*$_+H+;U[G\G\
MQV1^M E8QD^"UM(9E<H>U9- 57S0.LH .=0&>GG_ (3X=.;^D^#W>%/V-09C
M%]:=V;ZS5/L.AR=.8Q4X^JPD6*RV4HXYM2M25DI$",8M$DE)(?6O/MOW.O8G
MW&/PB"\<:AR/)@[$ T\P/V5IY=*/87;;F#8Y/J594FF=H0WG$T:*6 /!68-3
M KEA4$$DV_ES?*#%_P G?N?Y%?#GYN8_<>QMHYS>5'NO9':%%LZNS-'4-CXY
M*'^*B''_ 'U75X?.8V/&S4[4E-424LT4U/5 3:T@/N:-I;GJ&"_V_2[A-$D6
MM05SJIW:0"I+ U(U"A7&2#N0>84]H[F[V?>@\41E,L%QX3LLN A;L,A*LH0J
M%!T'4KD-@&N[0_G ]M_)SY@="_'[^5W+1;QV_755:G:&\]^]7UE5B:FFR-12
M)+DY:.M?$9FAP^VJ&.HJ)I3-0S54LZTT89_"LI+;<CQ;19376\50BGA(DBZB
MP!.FH$BDN: <: $G&>A3?>Z\_,>ZVNW\M:9E:IN)98)"B(64:J,\# 1BI:I7
M42JJ2QH3,?SW_B-O[Y._$G"[EZNPN1W5OSH7=TN_&VIAJ9JNKR.%R-')29F.
MBIA(&GJZ4"DJUB199I(J>:&!'FD16*_;O>XMGOB)B%25/#U$T"M4%233@:4K
M@"M2:#H_]ZN5KCF;9_\ %5+RV\@F$:BK2*%9&"BHR VH 5)TZ5!+#H-OBC_/
ML^&]=T/LRA^2&\-Q]4]S[.VKBMN;SP,W7>>W+3Y3(8"F2GFK<548BCRB1PUK
MQZ_%734TD,C/$Y=$$\BK=O;B_2X;Z1!+$S%D821@A2:@'45R!Y@$'RZ+^7_?
M#9Y+2,;C*UO<JH6:,P3$>(HHQ70LE 2#0,=0X'/1(OCW7[M_FW_S=-M_,';_
M %_EMO\ QC^,3[=CQ&X-ST%S(>NS5Y';]&SJ6IFSM=N#(_Q-J>.5OL:,!I'>
M1(6J#[<U7DO9&L'<&XN"254_"'TJW^UTIIK^(DTJ :!'87;W2YK7>(HB+*Q4
M(LDBXD>/6R4KP?7+X@ J455+49EZ/[_PH-^.$W;'PXQG=.WZ/R;Q^-.\:3=C
M5=-2^6J_N_NYH<;F8H9%99(EAJ_X/72,-06*BD8J/\X@=]M=U%C?^ _P7"E"
M"<:QE:BAKYJ/]-T-??+EYMVV?ZN$?JV4@F# =_AGM<!J@J!VR$BO]F,5H00G
M^3$.P_G;\^>V/GGW13C(5G4?5VRME8>HF2>JI4W%FL+3X!)L<]072(+B,9FZ
MFHA1F>*;*)([LTIDE$7/:Q<M[;%MEN?[21Y&R Q0,6 8#CEE )XZ.&* %>TD
ML_/6]W&_W:_V,$4$8HS(LK1JC&,M\- CL5%2/&R36K'(_P"%*/\ V0QU3_XM
MCL7_ -X_??LG]J/^2C)_SS/_ -78>A#]XG_DB0?\]T?_ %8N>DS\5_YK7\JO
MKOXP_''K[L/<N&@[ V+T-U!L[?,$O0&:S+)F-L;>QU%DT:LBP,T56RUL$X,R
M3.LI]:NP8,=[UR3N]W>3RQ1DH\TKH?%C%59V(P7!&#PZMRM[K\M[=MEG;SS@
M216MO'(/IYVHZ1(K"HA(-"#D$@^1ZMW^'WR]^+?RSVUNVO\ BUFX\OMO8F7H
M,;N.*GV)7["B@J\Y%)/$$IZZAH?*TD<+%GCC8"P#&_'L$[ULEWLCJEVNEF%5
M[U>H!IQ5FZE3ECFK;^:XGEVZ3Q$1]#'PWCHU U*2(AX$9 IUK,_\)W?COT+\
M@:'YHX_O'IKK+MJGPU-T%28&3L'9..W5/C4W$N^5KCBZJLIY:G&2U0I:7R24
MLL,C&&%M6J*,K+ONCN=SMIM3;RR1U\;5H=EU:?!I6A%:5-*UXGUZQJ^[_L-C
MO@W 7MO#/H^ET>-$DA35]3JTEU)6ND5I2M!Z#I6;6W-OC^1/_,%/5^?RN9R?
MP,^1>4ES6':K'\26AI*^2"E&4$CHL@S.TIS!3Y$12L:W%-#/)%)4/1I CFB3
MW$VSQE ^MMP U!36!J-*#%'R5QAP0*+4DYMKB7V6WT6CD_NJ]8M'4@^$QT*6
M)8!JQ&BMW$&(ACJ<4&WI25=+7TM-74-33UE%64\-71UE),M1%+%4*'CDCD0E
M)(Y$(964D,"""0?<+$4P>LH :Y'6IY_*CI:8?SS?YCJBG@"T1^8;4:B%0(BO
M;FWX@8A;]LB)W3TV]+%?H2/<T<YG_D.V/_4+_P!HS]8M^UX_Y&V[?]1__:?%
MUME^X6ZREZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[K5B^=O_<0/\&O_  V.E?\ W=[K]RYL'_*L7G_-1_\ CL/6.O-G_*_;
M9_SS+_AO.A-^:?\ W$&_R^?_ !!>V_\ W:=H>TVR_P#*KWG_ #7_ .V;I3S/
M_P K_M?_ #QG_M>Z+;_/4^)V\OCQV)E_G/T#Y\'M7O;:VY>F/DGC\:'DA%3O
M['28MJZH@]40H\]1Z8Y39$BRE-35-FJJK7[,_;S>(]TC7;;K+1.LUN?/]-M9
M%?49(]5+"M .B3WHY;GV"63?=OPMQ"]I?+D@K,@B#4\@10&A%'5&H26/5H?\
M@G_MVSUI_P"'[VU_[O*GV$O<?_DKR_Z6+_JVO4B>R/\ RK=K_IKC_M(EZH8_
MD6_/#XR?";_9I/\ 9C-\Y'9G^DS_ $)?W.^PV=E]V?<_W,_O=_$-?\*HJS[?
MP_Q:AMY=&O6=&K0^F2_<7EV\W_Z?Z1-?A^+J[D6FKPJ?$PK72>'4$>R/.VV<
MG?6_O&4Q>-]-X?Z<LFKP_'U?V:/2FM>-*UQP/0Y_-/NK"?SM?F%\6_CU\6\'
MO?,=/]75^=R'8_8^1P]3MZGCHMYU.+;,Y*2&6-FHX,?B\-XZ%ZN.*6IK*AZ>
M.)=:F0HV*Q?V_L;BZO"BS2 +$@*LU5#4&#FK,"U#0 5/0IYMW.+WDW6QL-L$
MDEK;LTEU*5>./2Y2O$ A@L;*A(!+.0*#4>KM/YB7\J?9/\PK</5F<W'VQN'J
MZ+JO;V>V]B\;MG:U)F(YX\]/33,SF>H@$0A%+&J(B6L3<_0  \L<X2\L"01Q
MJ_B%2=1(IIU>G^FZE_GSVUM>?F@-Q++%X D"B+1GQ-%:ZE;AH%*4\^B6_-3X
M:X+X)_R/_DWT3MW?&6[!QD.\.M]W)N#-8B'"SZ]Q=A[*#P&&"6:,K&8.&U G
M58CBY$'+N]OS#S#!<NH0E76BDD=L$@\^@;SURO%R=R7=6$+O(B-$P9Z:N^\A
M8UT@#B<8Z+]_+)_F4?RV^@/@_P!)=2=^Y_%47;6T_P#23_>REJ>DLMN]U_CV
M[L_DZ#5D:;"U<%1JQE;1D::A_&"(CI9"H,N;^4-TW3<9I[="8V\/2?%1:Z8D
M4X+@C(/ET1>V?N5L'+^R6UI>S!)H_&UKX$STU7$KKW)$P/:P.":<./5W'P]^
M=WPK^56XMW;*^*VX:?)9C;.%IMT[HH*+K+)[ C6FEG6DBF9ZW&T$50_ED"@*
M7<"YL![C_>N7+[9%5[Q-(8D*=:O4C)^%FIU,W*_.VT\V-(FVR^(8PK2#PI(Z
M!B0/[1$K6AX5ZJ9_E-8G&9[^9%_.4P>:H*7*8;-=R=DXG+8RNA6I@J:;([\W
MA#/!-&P*R131.Z.I%F4D'@^QISNQ3;-J(-"(5((\B(H>HL]IU#[]S"I%0;M@
M0>!!N+OJBO\ F>_&3L7X'=J;S^,V,KLE)\8NR-\T'?O3E-52RUT-\?2Y#%+!
MYYBSC(XB')3T-6?(TE3#'05,Q.N("0^3MVBYDC6\;_<F.,P2D4%06#@T'D=-
M1PH=0 IU"WNAR]<<CROMD?\ N!/,+NW!)8JZHT;+4YJHDTFNHE1&2U:]7Z_S
MOOD?6]??!#H;XV;.FKY]_P#R?H]CXJ;%X=:B2KDV_LJEQE56PQ+3*6:3(Y6?
M"TBPEKU4,E5$J2 2!8T]N]J%UN$EW)01VP9B6I0.VH"M3B@#-7R('#'4[^]O
M,#;?L\6W0:C/?,D:JFK68TT%P-(-=1*1Z:]P<@ @$=(7KO\ DQ_S ]J=&4G2
M.'_F'1[)ZMS6U\QBMP=/4.RZROQ,<6^EGES>-F3[\15D-1-6U:3,4TS!F-@I
M"A1=<];=<7/U+6.J0,I$GC$-5*!3A<$4%.DNW>U&][?8BPCW<);E'4P_1HZ4
ME+%U.J0D@EVK7C7TQTF/Y'6\MT?$WY9?*_\ EI]JUT?\4H=Q9;>FQIT5(*:L
MR>S4AI,C/3+YGDON#;AQ&1@C*LR4U#)Y620:&4^X,2;U9VV[P\&41N,D@&I
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MNHN]F[ZZW'FBXDOJ^.+1XI:BAU0-;0Y_I?I]WJ:GHY74'_<2KW;_ .&QFO\
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MDOP4O<Z6O93ZOZ^\I/8V 2;*U16DIXBOF.L)/?Z_>RWT%25K$*D&G 5S\O\
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MBSLX[")88AI11114F@K7B23Y^9Z8N;E[R0RR&K-DF@%<4X  >71\NKOYS/\
M,FZ<Z/VS\;MB_(Y(ND]GXB/ ;=V)NOIS8/8\-/0P5!JH:0U>X]JY;(3T]+,0
M:>.6KD6G1(XH!'%%&BDUQRGM]U*TSQ5=B26#R+4GB:*X&?LZ-8.8[VW01I)1
M5  !1#0#RJ5)Z [Y@_S"/F!\^*_8>2^6?<,_;%5UC2;AH=BZMD;;V/'01[K>
MCDR.B#;>'P\$SU34%%KDFCD>T**K!1;VMVO9+79M7TR:-=-7<[5TUI\3-PJ>
M'22_W6XW33X[ZM-=/:JTK2OP@>@Z ;H_N[M+XW]L;([QZ4W94;&[3ZXR_P#'
M=F[KI<=1Y=J.I:&6G9C29&FK*"JCD@FFCDBJ*66&2-V1T921[5WEG%N$30S+
MJ1L,*D5H0>((/$>1Z36MU)92"6(Z67@: TJ*>8(X'HWFZ?YKOSXWI\I>M?FI
MN/O*CKOD[U#M7+;(Z_[3AZ@V+C)J/%YNDS%#44LV-I=LP87) TF?R\:/6XVH
MEA%03"\;)$4+(N6K*&W>U6,B*0AF37(02""#4O4?".!%:9Z72;[=2S+<,_ZB
M A6T(" 013"T/$\0:5QTG=M_S,OF]M#Y9;N^<FW.[Y<9\I-^8F7![M[.CZ]V
MI.*VDFH*#&M ^#EP4FW$4T>,H$_;Q"$-"LH(F+2&\G+UG+;+:-'6)#J5-3X-
M2>.K5Q8^?GU5-ZN8YVN0])&%&;2F10#AII^$>766@_F=?.7&?+?+?.JD[UJ1
M\J,YA!MO(]HU&P-JUP-",53X44L6"GP4FVZ:(8VEABM#AXSJ#37\\DDKZ;EV
MR:V%H8_T@VH+J<=U2:Z@VH\?,_+@!UL;W=+.;G7^H1I+:5X8Q330</(?/S/1
M8N\N\.T?DGVSO?O+NK<_]\^TNQLJF;WENC^"X[;OWE5'!#3++]EB:2@QU/:&
M")=,%)$GIOIU$DF-E9Q;?$L,(THM0HJ32I)XL2>)\STBNKJ2]D,LIU,U*F@%
M: #@ !P'04>U72?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NCS?(W^9/\U/EITYUQT!\@NZ/[_]1]25
MN R/7NTO]'6T]J_P^;:^*GPM"_W^$P6-R=7X,94S0VJ:V97U>20/*%D!-M_+
M]GM<K301Z78$,=;M4$ACAF(X@<!T:7N\W.X((YGU*I! TH*$ CBJ@\#U.WM_
M,Y^</8GQ2POP@W9W8M;\7-O839NW,7U70=9[/V]&M'U_4T]9BHILMCMOTF=J
MC3UE)3SN\^4DDJ9T\M4\TA9CJ'EZS@N3=I'24EF+ZW.7!!P6*YJ?+'EUZ7>K
MF:#Z9GK& HTZ4&%H1D+7%!Y_;T0OV==%?1^ODC_- ^<WR\Z<V?T'\C>[H^S^
MK-@Y/;^:VC@LEUALW#U5'5[7H)\91U"YK&;>H<Y+*M#53Q2M+DG-0'+5'E>S
M DL.7+/:Y3-;QZ'(()#R$$$U(H6(XCTQY=&MYO=UN$?A3/J4$$#2@H1BM0H/
M\^HOR^_F9_-WYZ8'9FV?EAW9_I6PG7N7R>=VA1?Z-]H[&^SJ\S#'3U,ODVW@
M,/-4>2&*-=,\DB+:ZJK$DVVSEZSV=B]M'H+"A.MVJ*U_$S=:O]ZN=S4).^H
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M&,112:56M!H0TJ23DJ3Q)\^AM_Z"+/YR/_>8?_LOO5G_ -A'M)_4?:_]\?\
M52;_ *V=*?ZV;A_OW_C$?_0'54G>7>':/R3[9WOWEW5N?^^?:78V53-[RW1_
M!<=MW[RJC@AIEE^RQ-)08ZGM#!$NF"DB3TWTZB21%96<6WQ+#"-*+4**DTJ2
M>+$GB?,]$MU=27LAEE.IFI4T K0 <  . Z,?N+^9/\U-V?$C%_!7<'='W_Q6
MPU%@L=C>K?\ 1UM.E\<.VLHF:HD_C<&"CW&_AR<:37?+LSV\<A:(E"@BY?LX
M;DWBQTF)8E];\6!!P6TY!].EDF\W,L'TS/6, #3I3@I!&=->(]>B,^SGHKZ]
M[]U[KWOW7NO>_=>ZYQ_K7_7]Z/#IV#XQ]HZ^M=\6O^R9/CG_ .((ZB_]Y_'^
M\9[K^U?_ $S?X3U/\/P+]@_P=#O[8Z<Z][]U[KWOW7NBR9_X4?#7=>=S6Z-T
M?$GXR;DW-N3+9'/[BW%G^A=JYBNKZ[,3/45=;6U=1BI*BJJZJHDDEFFED:26
M1F=V9F))O%S!?PJ$2YN%50%55FD   H  &H !@ <.@W/R;M%T[2RV-F[NQ9W
M:VA9F9C4LQ*$DDFI)R3D]";UOTGTSTY2U%#U%U)UCU715=_NZ/K?86*V/%+J
M;6?)'C*2E1[OZN0>>?K[175]-?'5-(\A]7=G/[6)Z-K#:[;:D\.UABA3/;%&
MD:Y-3A !QSU([+Z=ZC[HP]#M[N+JSKCMC 8S)+F<;@^R]D8S?='3UB120+5P
M4V4I:J&&I$,TT8E1 X21TU:68'UI?3V#%X)'C8BA,;LA(J#2JD&E0,=5W':;
M7>$$=W#%.@;4%FC250P!%0'# &A(KQH2//I8T^"PE)A(=LTN'Q5-MRFQ4>"I
M]OT^/AAH8Z&&$4Z4:4BH($I4@ C$0C$8C 0+IX]IRY)U$FM:UKFO&M?7I<$
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M0!54  >V)96G8NY+,Q)9F))).223DD^9/2N"".U18HE5$10J(H"JJJ*  "@
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M;CL-CJ##X>@HL5B<514N-Q>+QM+'0TU-34,:Q04]/!$J10P0Q(J(B*%10%4
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MQQAJF5(I&\<,4_ $AN6)YY/TL /ZW]K9=[6):BISY'H(2<@R7DQ0LJD"M2&
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MG\NG?"IB-  /4C_9ZX:GED55C6&,G]3#G^O^//O6HL0*4'5]:0*2W<1Q&/\
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MFM:U_P W0QAV<)(J@410>S34-4$$U-<Y]#_EZ8TK*:%KO+4U#E;-'$= N/\
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M_G5D_7^4O_)./^O\#K__ "U>PO\ U4_Y?+__ +*/^A.C_P#K#3_B+:?\X?\
MH;KK_AZK_P %+?R3?_2#O_SJ]^_JI_R^7_\ V4?]"=>_K#_R[6G_ #A_Z&Z]
M_P /5?\ @I;^2;_Z0=_^=7OW]5/^7R__ .RC_H3KW]8?^7:T_P"</_0W7O\
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M_P!"=;_K#_RZVG_.'_H;KW_#U7_@I;^2;_Z0=_\ G5[]_53_ )?+_P#[*/\
MH3KW]8?^7:T_YP_]#=>_X>J_\%+?R3?_ $@[_P#.KW[^JG_+Y?\ _91_T)U[
M^L/_ "[6G_.'_H;KW_#U7_@I;^2;_P"D'?\ YU>_?U4_Y?+_ /[*/^A.O?UA
M_P"7:T_YP_\ 0W7O^'JO_!2W\DW_ -(._P#SJ]^_JI_R^7__ &4?]"=>_K#_
M ,NUI_SA_P"ANO?\/5?^"EOY)O\ Z0=_^=7OW]5/^7R__P"RC_H3KW]8?^7:
MT_YP_P#0W7O^'JO_  4O_)-_](.__.KW[^JG_+Y?_P#91_T)U[^L/_+K:?\
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M5_X*6_DF_P#I!W_YU>_?U4_Y?+__ +*/^A.O?UA_Y=K3_G#_ -#=>_X>J_\
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M .=7OW]5/^7R_P#^RC_H3KW]8?\ EVM/^</_ $-U[_AZK_P4M_)-_P#2#O\
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M/[>O=>_X8R_\'#_SUO\ TX+_ /FC[]X?S/[>O=>_X8R_\'#_ ,];_P!."_\
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MUO\ TX+_ /FC[]X?S/[>O=>_X8R_\'#_ ,];_P!."_\ YH^_>'\S^WKW7O\
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MX+_^:/OWA_,_MZ]U[_AC+_P</_/6_P#3@O\ ^:/OWA_,_MZ]U[_AC+_P</\
MSUO_ $X+_P#FC[]X?S/[>O=>_P"&,O\ P</_ #UO_3@O_P":/OWA_,_MZ]U[
M_AC+_P '#_SUO_3@O_YH^_>'\S^WKW7O^&,O_!P_\];_ -."_P#YH^_>'\S^
MWKW7O^&,O_!P_P#/6_\ 3@O_ .:/OWA_,_MZ]U[_ (8R_P#!P_\ /6_]."__
M )H^_>'\S^WKW7O^&,O_  </_/6_]."__FC[]X?S/[>O=>_X8R_\'#_SUO\
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MO=>_X8R_\'#_ ,];_P!."_\ YH^_>'\S^WKW7O\ AC+_ ,'#_P ];_TX+_\
MFC[]X?S/[>O=>_X8R_\ !P_\];_TX+_^:/OWA_,_MZ]U[_AC+_P</_/6_P#3
M@O\ ^:/OWA_,_MZ]U[_AC+_P</\ SUO_ $X+_P#FC[]X?S/[>O=>_P"&,O\
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M!_P=>DWR&(TD !^>/YGJ$M 0W_ QT%_2&96'^V/(_P!A;_6]MB$#SI^8Z?\
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M[>JDAII:9\IB\\T$IJ8T?QFKHL14T:O&K@R:*N1%L0':U_=;WE9K88);\O\
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MZEZX^W/^K[.A!:SR78406IBC!"]X"$CB3QX<!YUIQ\N@[:2CJ'FDD,A93=+
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M&4ROV,FDM223Q)'P/J49BE_^0?:B.Q5A\34^U1_A/19+NKAP#'&'!P0LI/\
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M;9_^4:\_WF'_ *W=>_X'[=/^4BU_;+_UJZ]_L]'77_/);U_ZET/_ -6>_?\
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M_E(M?VR_]:NO?[/1UU_SR6]?^I=#_P#5GOW_  2VS_\ *->?[S#_ -;NO?\
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M/_U9[]_P2VS_ /*->?[S#_UNZ]_P/VZ?\I%K^V7_ *U=>_V>CKK_ )Y+>O\
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M]_L]'77_ #R6]?\ J70__5GOW_!+;/\ \HUY_O,/_6[KW_ _;I_RD6O[9?\
MK5U[_9Z.NO\ GDMZ_P#4NA_^K/?O^"6V?_E&O/\ >8?^MW7O^!^W3_E(M?VR
M_P#6KKW^ST==?\\EO7_J70__ %9[]_P2VS_\HUY_O,/_ %NZ]_P/VZ?\I%K^
MV7_K5U[_ &>CKK_GDMZ_]2Z'_P"K/?O^"6V?_E&O/]YA_P"MW7O^!^W3_E(M
M?VR_]:NO?[/1UU_SR6]?^I=#_P#5GOW_  2VS_\ *->?[S#_ -;NO?\  _;I
M_P I%K^V7_K5U[_9Z.NO^>2WK_U+H?\ ZL]^_P""6V?_ )1KS_>8?^MW7O\
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MKDU-4""J @$!$!U7!]/T ^E_:6>(@TCUD?,^0^S/1M':[A=)JE^EA6N2@U,
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MALPE-;Z6:8X!"!HT_8A4'I(RULQ8M)DT9V.LE'<&_P"!Z4"CC^GM"\I;-?\
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MUC;_ (GV[]6!P'1<]KX)I^0 I3/69MST;J8S3(P5B[D1",7;ZVOSR>3[<;<
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MVT'^G?\ ZM/UI]_SYIL73?S>OFE-6Y%(*DY?HA?M322R'0O5>QBKF1+@!RS
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M0D @^H()J:!CF'ET[,0Z$M&QH"::E:E:&E*U )!'S!'"MU^U_P"3K_);Z?\
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MT"U-?55E<*>):?&48$E143R1B*EIHY)9'"(2&.7N8S-MS7EZP[68$@ 5 I0
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MWH\.G8/C'VCK?FVA_P >/U]_XCCKO_W24'OB'[M?\K-N?_/9-_Q[KK][<?\
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MDN6H(K?51FR*LU*E4 KDC)H!\I Y"Y N>=KC2 T=NM?%GTU P:*M:!F)I@'
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MJW<QFOU:-C0+$;U26^)>#*HX_BX=9"[UMFV[KROMD>Z7!MHA%9,L@ ),@M&
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M]Y]Z,U>K+$B^8_;U@%9)(?01;Z%K:O=-1/3RHOEUD621R-1<C\E5TCW85ZN
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MFW))\*YU#Y"6-,#\XR?M)ZQ,^\#9"+<;:X _M+<H?F8Y&-?V2 ?ET=_WD=U
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M=Q%1B'D1:9%+HE1'&SH&!%P"+\>X+^[ULMYLNWW27D$T#-<!E6:)XF9?#45
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ME;-*T@-%4&BJ,#)XDDR/SEL>T<ZW/CW&^6ZHHI%"LUMHC&*TK-DFE2QR<#@
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MIV3;PW#A]I_S]8&W)6'Z*NG\*2?S[:^L/H?]7Y]+A'3\(_U?F.L)S=3(>5A
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M?]O!?Y2?_B3/F%_[Z#<'LZV[_<6[_P":<?\ U?CZ+KO^V@_T[_\ 5I^M(_\
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M]Z\9O]5.O!:X'^$]=^>7GUL!]38_X?[R/="S1')_9U4Q*AH*?EUX5$Q'^=D
MO8#7;_8>_-<4(7.?/K;1:3Z_9T9SXP_$/Y#?,+>4VS>B=AUVY9L8E/-N3<M;
M4IB,/B(:EPB293(SD0P-(-;10H)*F=8Y33P2^-[.JKN>VI/V]%6[;K:;$GB7
M3A"?A%"78_T0*UIY\ *BIZNJP/\ PG%[SJ,/23[C^2G6.'SDL"/78O#[4RNX
M*6*0J"4CK9I,=),H:XU&ACO]=/X]J1;2^H_:?\W0!E]S[0-V02D>I*J?V M_
MAZKI^77\J;Y:?#K%56\MZX3#;ZZRIYRE3V3UG63YRBHUD:T;92FJ*>DR&-U
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MB [^Z\WOU9N.LVAV3LK=>P=U4 1JS;.\<!5;:K8D<LJL]-6102Z7*-I<1Z6
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M[T>'3L'QC[1UOS;0_P"/'Z^_\1QUW_[I*#WQ#]VO^5FW/_GLF_X]UU^]N/\
MD@V'_/+#_P <'3_[CSH:]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=6V?#';K
M8?IY<K*A$FZ=QY?*QLW!\-'XZ%!;^FNEE8?UU?6UK9V_=[VD[?R^)CQN9Y9<
M_P *Z81^58B?SZPS]\]S^MWOP1PMX8XS_IFK*?Y2 ?ET;3W.?4-]>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0=]O?\RF[0_\1WO7_P!UM3["?/O_ "0M
MQ_YX+S_M'DZ$W)7_ "6;#_GMM?\ J^G5>?QT[TR'6.R<I@:7K;<V\8ZO=5=E
MVR>%+B*-JBDH83 VFEF'D44X<^L<.O'Y.*GM'[DR\G;;);)M]S=AKEY?$A!T
MJ6BA32:1MD:*\>##'62ON?[?Q\UW\=P]];VQ6W2/PY::B!)*VH5=<'73AQ!Z
MSX_?E1V-\KNOMQU.V<GM.4R8^A.(RY8S 4M/56D.J*$Z7U<>C\?4^W[7F=^;
M>>;&[>WEM3V)X4U=?;'+G*K@UQCRZ:N>7EY8Y.O+59X[@=[^)'33W/'C#-D4
MSGH;/FQL^6KVGMOL+'!XLAL_+)1U=3"2CK39=D\4FH<WAK(X0G(L9F/N0_O%
M[ T]A;[K#426DH5F!H1'*10_:LBK3TU'H">P^]B&\GVV7*7,995.07C!J/\
M;(6K_I1UC[X[ACRGQGV[EJ*8)DNSZ;%XN=8M)T?;#R951;TZ%EIWIVL+_N?1
M3^G7N=S\+SDZ"XB-)-Q6*(TH=-!JG'V HT9\^[@/*WMYR2;3FJ:&052P:205
MKFO;"?M(<./]+Q/F8/HC9'^C_JK:6 EB\61?'KE\R"/5]WF/\HE1OZF'6L(_
MVF,?Z_N4_;3ES^JNR6MHPI)X?B2^OBR][ _Z75I^Q1U&WN%O_P#63=[BY!JF
MOPXO3PX^Q2/]-0M]K'IZ[>_YE-VA_P"([WK_ .ZVI]K^??\ DA;C_P \%Y_V
MCR=(>2O^2S8?\]MK_P!7TZ(9\9>_NO.J>O<S@MUU&67*56[Z_,T]-CL6U9J@
MJ*/'P*=>I(PVNGEN"XX /Y'O&/V:]T-IY(VF:VOFD$C73RJJ1L]4:*!!G K5
M&P3UD/[K>W.Y\X;E%<6:QF-;9(BSR!:.LLSG%":4<9 Z=?CU'/O_ .1>Z>S]
ML;?JMO[(CBR[LK0+31ZLA"D$4#>(F'[B9]52\:,ZH0>3Z&)A[4JW-/-MUO5G
M T%GIEXJ%6KJJ!3I.G6Q!D8 D*>)X$H_<IEY<Y8M]INYEFNJQ^99J(S,6[N[
M2HH@)H3C'$!']K;[3K/Y=[DWNU V3;"4U*8*%9!$))LCM.&D@#M_9B$TZ%R+
MMH#:06L"'>=^9AR=S[<;D4,G@JM$!IJ>3;$B6I\AJ<%CQTUH"<='G)_+QYJY
M+@L _A^*S5>E:*FX-(U!YG2A \JTKCIP^/;8OLKO#+YCN.6MK=^)3PY;:^&S
M--]M3-) #*0()+$&DIS%)2PZ-&C7-ZF13[7>U30\X<R2W',!=KX*LMM#*NF.
MH[L(WG&I5HDI33J?) /27W*$O*NP1P;&$6T+&.>6)M3T/;\2_P ; K(]:UHN
M 2.K0O>9G6)G2+W[L#;G9. ;;.ZH*JHQ+U=/7-%25LE"QDI=6@EXR"5!8G2;
MB]C:X'L/<S<L6G-UJ;.]5FB+*Y"NR$E:TRI!\ZTX5IT>\N\QW7*UR+NS*K(%
M9064.*-2N&^SCT4SY/[@VCMGK7"]#;6HQE-PUPVWCL/A:)#75%)!BIHC#*^@
M%C5U;1")1;R2^21R.;M!WO/NECL^SQ<L62>)/)]/'#"E7>)(G0JQI4ZWTZ1^
M)M3-]LQ^TVW7NZ[K+S%=MX<*>.\LK=B2/(K!@*XT)JU$_"NE1]CWVIM>OV7\
M-ZG;&58MD\1@MEP9!?+YPDTN:Q\DD2N"0RPNYC4@VTJ+<6]K^>-FEY>]OVLI
MS^I%!9J^:T?ZJ LH/F%)TCRH,8Z0\H;M'OO/"W</]G)-=%,4JHMI@"1Y%@*G
MYGH)>E/D7D]B=9;:VI3]3[NW-#BOXSHS>+,@@G^^R%74G1IHY1^V9C&W[A]2
MGZ?0 ?VY]UYN6MFM[)-LN[@1^-2:(-H?7/+)BD;<-6DYX@]#'GSVRBYAW:>\
M;<+: R>%^E)36NB&-,UD7CIU#' CJ/T/N67>/RKW+N:;$5F!ER^)SM2^'KR3
M- 1'2IHDND9U>F_Z!]?;?MGO#;_SQ<WC1/ 989F,4GQI18EH:A<XKP''IWW"
MVH;)R?!:K(LPCEB42)\+]TAJ,GU]>CNY+JK8<F_J?MO)T\J[EP],=%?5Y)EI
M8HX*:2 .T,C>!!%$[L&XTO\ N7U"_O(V[Y)VR3=%WR93]1$N)&D;PU41LE2I
M.D4#$U\CW<>H$M>;]Q3;FV:)AX$K914'B,2ZO0,!J-2 *>8[>'10L?71=X?*
M[$[KV532-M38%)1IE=R0HT$=1_"ONF20L0-1JYYE@C4^IX(R]M"M:!K6Y7W'
MYYBOMN4FVL442W J%D\/Q2#7SUL^A1Q9%+4T@]33<VYY!Y.DL[]A]1>,QC@)
M!9/$\,$4\M"IK8\ [!>)'3S\G,9OW/=P]6)M78^9W53;9IZ;,TH%!,E!-5O6
M^:2FGK&"TT:".BIC+>5+(_++<$+_ 'DL]SW/?]L%E9S7*VP$RT1A"\IEUE&D
M(" 4A355A0-Q%1TA]J+K;MOV3<#>7<5NTY,3=ZF98Q%I#*@JQ-96TT!J1P-#
MTJ=C=Z[IQG9&+ZV[HZ\P.R\_GFIQ@,G@PGA\E:S1TT;_ .45B2+42*T2RQ51
MM+9&C%V9#OEOW+O;/=X]GYBL8;2>>G@20Z=!+DJ@/?*#J(*AE<]]%*YJ"C?_
M &^M+O:Y-TV*]ENH8:^,DM=5% +D=D9&D$,59/AJ0V "<SWD#U!W7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW58ORZ_[>"_RD_\ Q)GS"_\ ?0;@
M]G6W?[BW?_-./_J_'T77?]M!_IW_ .K3]:0'_"D1A_P\Q\Q.?[/Q^_WCK+9G
MN0^4S_NNC^T_\?ZC+F/_ '.<_P"KX1U1MK7^O^\>Q'T2]>UK_7_>/?NO=<;_
M .T?[Q_QKW[KW7AI;\6]^Z]US-_Q]?\ 'W[IS7UB86L?Z_7W[IQ)*==@%3?Z
M7^I O]/Z^]=:>0$'_8ZXD<F_%^1Q];^]]-HU.NO?NG>O>_=>Z][]U[K$GU_V
M'OW7NLP4GZ#W1I O'KW7/Q/8&WU_H?>O$'7NNM#C@@C\V]Z,H'7NO L1I ''
M!]Z\8=>(Z\_ 4?X>[JX?AU[KA[OU[KD$8WLI-OKQ[KJ!\QU[KC[L#7KW3IA,
M7D,YEL?AL12U%=ELK64V-Q=!21F>6>HKG6*&&*,>J21Y'4*JD$FWXN#X L0!
MYD=,75VMC$\KBJ*I+^@4#)/'_ >MY?X2_!#X[?RQ.B,AWQW=5;:/;F-VFNXN
MV>W]P4RU*8&.HB3RX/ (GG,4,4TAIS)3(:S*U,A',<E+1P&<,"6JZC]M?3RQ
M_JJ:]8]<P\Q77-MU]+;!A$6TQ0J31@#AFP/(5S0*!\J]%OK_ /A1C\:J7?38
MBEZ2[BR/7T<[0MO6*HQ4&095.D2Q8-ZCQM&S<KY,Q$V@@NJ-J1:2;BBF@J?V
M?Y^C&'VNO983*'CJ!72#_EI_DZN9^/'R"Z2^7G6FV^ZNH<E!NO;*97(TU'-F
M,+]AD<1E*&)H*NEJ*>=6>BKXZ:J*LT4C))!/>*62*6Y513+-D?ZO+_B^@+N6
MVS;/(89:@T%?0CB/M&*@\,8X=47?\*1-I;QR'5GQCWMC7JCL7;&^.Q-O[KAB
M5VB&1W?18J;#33:0471#B,Q&K-;F72OZC[0[B2I0^56!/IBO\Z=23[43Q+)<
MQ,!K98F7Y*A<-_-E_P!5.M274X-PYO\ 3C^G^Q_K[1^/HX9ZFK!QU?W_ ,)V
M1NMOF#V?)BYJO^ZAZ!S@W8BEA3M+'G,&,:)+#1]RDAJ3&#ZM!G*C3<^W]O=I
M&)\JG_5GJ+_=&:)+2*,CN,C%37Y#57RS5?V#Y]&/_P"%)FU=U-7_ !5WQ'35
M<NS*6C[0VK+6H'>"FR=:V)K4BD-M$<M;1TLK1W(,BTDMK^/V]?88>E/\''I%
M[3SQZ+F,D!ZQMFE2O</Y'CZ5'KUJ[!I#_4E;?0\?[Q[0#..I;HJX]>MFG_A-
ME+O-M\_*A86K1U^NT>N?XRD@9(CFGK:\XTZ3QY5HUS0/Y -C]?:^P!4LOD"*
M?L/^QU$GNTB#Z>C"JJZ!0?P@H%-*^@-/M-.MA;Y-=]?&_P"&>U\_\D^XHL7@
M<IEJ3#[$3,87 09#<F?.-^]K<;M^A;]J:J$329">*&6JBI*?7/42R0J9)/:Y
MV6+N/GBO48;3MMYO["TM@STU/IK1%X MZ"N!7B<#JI39W_"BSXVYC>4N'W?T
MKVWM#9\E1414.[:&MQ>Z*D(K$135N*6:C^VCT --X:^K:(:M"S:1J2G<HAY_
M\7^WH8S>V5VB:D=6(I44(&H^0)^>!PKY#JS+O_X[_&C^9;\;L-5538;=>W-Y
M[8?<_3/<&'HV2NQ4^1C84]?12.*>K2-)U"5M!-XQ(8W@J(XYHU:)^:%;A?*M
M.T\:5'^#_5QZ#.S[O=\I7(8!ER!)$X(#K7(((P?0TJ/L.= CN'J/=?1?:._>
MH]]TJT.[NO=TYC:V8B$;*KR8F70M3!J52]+5Q-%/!)I DAD1UX8>RM8A^*E?
M/Y$<>LC;._3<8UFCRKJ&'V,*@'C0^H\B".@O-KWO<GZFUOI[J13I:#UX7)%O
MK^/=>O$@"IX=90)C?\"_T][TGIGZB,>7^'K$\?\ JB/K]0;^]Z!U=9M65!IU
MTD2DW+6M_C_QKWHQ@\.O/,P\NLQ2/_5?\G?\:]Z*?/\ P]-B9_3_  _YNN)B
M46NZ<_DCW>I'2A;ICY=<UIU*%OVS_KFQ_P!L#[NJAOB/_%=4-T3\ORZZ-.H"
MV=-7)-K^]-&I&#UHW'^K/7-5(-^2/Z(+>ZB@.>J>(3Y?ZOV==VC-_2P.KDM[
MM5>M%VZD**=1^\S@?C0 WU_UQ[=5@//JH5Y>'E]O6+RPG4([E;7!=1?_ 'CC
MWYFP<^OGUOP)/]5>NVD4VL3P .+>TYEKUKP3\_V==>0C@7_V]O>_' ]/Y=5,
M1'7O*W%F*DFU]7OPFU<*?RZ]X1Z]KD/UD'_)7OVIO]0ZUH/7(-<VUM^?K_R+
MW8/_ *J#JG65&%N3>X+?[ >[ZJ]:)IUFB<:@P%[%N/\ 8>[JU.MKVFO4L3-_
M90"_]>?^)]N"0^5/Y]/>.?EUF260'] /];'_ )'[N')_U'JR3MZ=2U8L"#;B
MWT'MWI<KEA3K*.+&XX1A]?\ 'W0\?]7RZV>'7<)O9KV%_P#B#[VG26,:A3J>
ML@](-^; ?[Q[OUZE*_9UG3]0_P!C[]TUUD7D7_U_>^/52M>I"D$?ZUA[>'#I
MHBG7!P!:WY][ZUUP]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0A]58GLW*;^VW/T]MS=&Z.P]O9
M2BW9MO'[/VO-O&MCJ-LRQUD=4F/AIJLSQTTD22.'IWBL+2*5)!37CQ+&1.RJ
MC J2S!00P(I4D<1\Z]*+5)6D!A#,ZD,-*ZB*&M:4/#K9$WKNO^5Y_/#WOCM[
M]A=F[J_EY?S(.QJ/:FV=Q9+=,']^>K=ZYK#TV.Q%#(E1)-#-B9ZJ@H8*6!9:
MW%B%WC1DS$R"2H $2;ER<I14%S:K4BG;(@-2?7S-3AA\UJ>AE(UCS.P8L8+@
MT!KE'. .-*XP,J?D:=$HR?QR^6.2_F+]"? #YV;([O\ D[3_ !E@V_USA^F^
MA:^BK*NJV+AL9#D,93;6RM6,-2TNVJ^DCQ[5-?55-%/2TC5)GEH\C$XC-1?V
ML=A+?631PF8DEY=6)"QKJ4:^X5)  (.#0KT7FSN)+N.TNU>18A0+'0532*4)
MT=IH 22#Q%0W6P[\?_BYV#W?W_OKI3Y:?RN/Y9?QZ^![X'N"?$8;:TG7,7;F
M#QBXBK^QR^/R>SMU;ASG]YXACL+%FJI_L=!*SQ37HTB(&O=RCLX5EMKRZEN>
MS43XG@D@UH1(J]N3I'=7((%>A9;6+W4K1SVMO'!W:11/%%12HT%LX&KX2,4)
MIU2E_+WP7Q;^.'\IGYB_.7Y(?''K/Y&[QWA\B^JOCM\=MG]O;<I*RD&8V=1I
MN.I?&U\E*<I24=53Y&KDS*4%;$^0H\2,?Y:?5),!?OSW.X[E#96\KQ*(VDD:
M,M4!B1W &GX1IKP+5\^@ULR065C+=3QK(2X1%<"A( /;45\SJIY+\NC.]_\
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M"5/%216AX9'#J,9HQ$[*"& 8@,.! -*CCQZWM?Y?F/V]U[\"_P"7Y_+QW/\
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MX_7W_B..N_\ W24'OB'[M?\ *S;G_P ]DW_'NNOWMQ_R0;#_ )Y8?^.#I_\
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M_P 1WO7_ -UM3["?/O\ R0MQ_P">"\_[1Y.A-R5_R6;#_GMM?^KZ=%W^#?\
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M>%58,*T\CIH3FE:T/#HNV>_&V7*3L"P4FH'&C*5-*^8K7Y\*CCU<Q\6_F_\
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MA>16?YDV<[W:-"M ]5:-F) 5E/' /D2.!X]-;%N8VJX$K5*T*N  25(^=/,
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MWH\.G8/C'VCK?FVA_P >/U]_XCCKO_W24'OB'[M?\K-N?_/9-_Q[KK][<?\
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M"/>F4.*$5!X@\.MJQ4U&"/,=<(H8:=/'!%%#&"2(XHQ&+GZFP '/NJ1K$**
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MGXWR$\^4>.%*K+54<2P,:>%*>G@-0J35"U1$!S;0F,5;C^6.'^;J(.=N<AS
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M3J1$KW!(]-C;Z>_=5?AUF7D7_P!?W[IATZD+>W/^P][->M,"13K*OT/^NO\
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M?\_7OX'FO^=/E/\ SWR_]&>_?NFZ_P!\R_\ .-_\W7OKX/\ ?D?^]K_GZ]_
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MF7_G&_\ FZ]]?!_OR/\ WM?\_7OX'FO^=/E/_/?+_P!&>_?NFZ_WS+_SC?\
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M \U_SI\I_P">^7_HSW[]TW7^^9?^<;_YNO?7P?[\C_WM?\_7OX'FO^=/E/\
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M?]O!?Y2?_B3/F%_[Z#<'LZV[_<6[_P":<?\ U?CZ+KO^V@_T[_\ 5I^M'?\
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MCCG@3,;<S-$D<_AF"F9:'/8*K9-2L&BE6S 5%#4J9CYE6[CXU!X$"F1YBO\
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M=>ZK%^77_;P7^4G_ .),^87_ +Z#<'LZV[_<6[_YIQ_]7X^BZ[_MH/\ 3O\
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M0A%\4+B,F'9XO\PRQ_U?ZJ]0;$FY>Y%^06U-DY)$<*>0 %?L %6)R2<GJK+
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M9@B(SMSL&BEVRN,-03=8,$M/04.+><!=20X^$R74NK$)[)+FYDN&I*3JX4/
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MZT_R_P#%]%7LL[F&Y3\'B1G\]+ _R ZUCV'J)-OK8'_6 ]AF22E%^W_#U-:
M+@?/_#UQ]TUCJ_7/0?\  _[?W[6.KZ#UQ86/X_V'NC&O5U%.NS^D?[#_ (GW
MY./7C_F_P]=#ZC_7'MT\.FI//K/[<A^'I-UVOZ#_ *R^U,G5%XGK,OZS_KK[
M>3CTGD^$]2?;W2+KG^%_UG]V3CU=./7'\#_7/_$>WNK/PZS^U'2+J1[4=>Z]
M[]TEGX_EUEB_4G^NW^]>[)QZ9ZSR?C_8^U4?7NO1_G_8>W.FY.L\/ZY/^">[
M+Y_9TF7XS^74P?0?ZP]O=.]3Z5 NG^I ^O\ 3CW91GI3&:$=37^O^P]O=/\
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M>N.U,7 ODE.&SE13S?>TP_-5BJNFIJM%',JQ20"QFU!;M\P@D#4)-#2G[?\
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M<@,C C[:J?EK5C_A/K\\CN]=OF3I@8 UW@._?](,OV(A^OW!I1C?XL>!PO\
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M>'_H/KW^S==$_P#/45__ *#60_\ J;W[_7WY9_Y2G_[)[C_K7U[_ %E^8?\
ME'3_ )SP_P#0?7O]FZZ)_P">HK__ $&LA_\ 4WOW^OORS_RE/_V3W'_6OKW^
MLOS#_P HZ?\ .>'_ *#Z]_LW71/_ #U%?_Z#60_^IO?O]??EG_E*?_LGN/\
MK7U[_67YA_Y1T_YSP_\ 0?7O]FZZ)_YZBO\ _0:R'_U-[]_K[\L_\I3_ /9/
M<?\ 6OKW^LOS#_RCI_SGA_Z#Z]_LW71/_/45_P#Z#60_^IO?O]??EG_E*?\
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MB<#^MO\ >+>ZD\>G8_[1?MZWXMH?\>/U]_XCCKO_ -TE![XB>[7_ "LVY_\
M/9-_Q[KK_P"W'_)!L/\ GEA_XX.G_P!QYT->O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NA'ZG[#R'5^^\)NVA:
M5H*6<4N9HXS;[FAJF45,!%P"2@#QWX65(W_L^Q?R+S9+R7N<-]'72ITS(/\
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MY-[FWNDRU%.MAPO7,@G\_G\M?V7^%0].*=?#KC]/=&&*=:X'KWMK0>G=8Z[
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MS$?C=WC\?.[^Z-@]:TW5?7WR-^/.4WQ-B>UL;F:@4-9O7!4<@BI8'$TQ9JE
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M$\HB%6:JFN6K84"CGGEF29Q>VBL7J!(J EB?)P!7/D:?(^IZ9Y3WY(U-K<,
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MB?$WI_N;9.*^.?5>YX=J;U^0U?N^AV_M*&O[:R6)I\_F4KJ^:DQ4^(VG@\7
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MV/J/]<>_=;''J0W%2!^+-_O ]T<4/[?\'3T8I(/M'6_!M#_CQ^OO_$<==_\
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MIH-/7KA[OUOKWOW7NN)8&R@B[$?4:OI_R/W9(]1KZ?S_ -5.M:]&1Z'JSO\
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M0.6%C]/S:]O8>EW#QSIT,,<?RZGRWM1&P""C%:D4S4@G[>MG'_A-74[Q7?\
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M501Y9/%:&Y50#_7\_CV964PA^W/2:>+QZ#]OV?LZ@U5=/7U4M15'6SK;GU
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MUL/%F(*FCGIU=U81SH) CZA[!)MI%F,1K6OY=93V^]VUUMXO58"+PC,6;%*
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M />EK?99[K?\KSL__4O_ .[A-TN]M/\ E3=U_P"H[_M!BZ-AW_\ \R7[(_\
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M#H]-A8+ 2[ES.[XL1VCT7+6UE&DV4W%DZ^O,.0H\B8::-J^JEDK,TT44,,$
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M(3_9&D?ZFP/'^M;WZO6Z$=1_&78B-387']>1[NKGKU:=9)X#$H8\$GD7U?\
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MS86/-74451M_IWI79[PX(UIPD40J:^NJBDKP44#2TYK:^2*HJ9YYU)6>>5V
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MYT0P135,L,,A?NFYQ;1"T\Q(5:8&6))H  2*G_)4G Z6[?82;G*(8N)KDUH
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MX7"Q-597.9+P+=*6AI8VT!Y(EGJ7IZ02I)41GV9[QNL>RV[7$F0N M0"S'
MK_/C0 FF.D&U[<^Z3+"F*Y+4)"J.)-/Y<*D@5%>N?SG^+%1\)OE;V_\ %NLW
M[C.S:[J+*;?PU?O;#X>3 4U949C#8[*SI'22U%5)#]G+7O2MJG8L\+/9=6A?
M;+N7[XMDN=.C7J[2:THS+QH.-*\.O;K8?NR=X-6K33NI2M5#<*GUIQZ*9[-.
MB_HZ?P#^$?8/\P#Y&83H'86<P^S*;^[FYM^=A=D[DB:?%[8VYL^ 2U^:R"))
M$[P+/+1TL:B10U350*[Q1EY4)]\WA-CMS.X+&H54!H69O*M#3 )^P>O1GM&V
M-NTPB4TP69J5TJ/.E17) _/IC^=GQ+S_ ,%_E?V]\5-S[IH=[9KJ;(;9HZC=
M>,Q;X6"NCW5@\9G::>*EDGJ7A4TN4A&EIV:X).DG2'-EW,;Q;)<A=.O5VUK3
M2S+QH/3TZINEA^[)W@+:M-,TI6JAN%3Z^O12/9IT7]>]^Z]U[W[KW7O?NO='
M-_E_?#+=GS_^5_6GQ8V?N2#961[!AWC6UF]Z_ S[BH\32[.PF1S,M564]/+
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MIPD[CT\<$9X@C_$&WLL_K9>_]&Z?]K?]:^C'^KEK_P IL/\ QG_K9T _6?\
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M0_X\?K[_ ,1QUW_[I*#WQ#]VO^5FW/\ Y[)O^/==>_;C_D@V'_/+#_QP=/\
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M1FZ=P9; [#[$2BP/9--A:>GEGR^W)YD.9V^9:B.44M-G:(2T53/&GGCIYI?
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M-/Q%S&$W%N+$81\W6X^?M_(1F#)T<43&>6JI*+;F32*".!FF>=1Y(]&B5SW
M9YX[>TC6KRS57- = I3.,F09KBG[-<F*L+37#FBQQ4.*X8ZJX]-'"F:]!/\
M[+U_PG8_[V!?-G_T02?_ &.>W_K]_P#^4:#_ 'L?];>FOHMF_P!_S?[R?^M7
M0D?"F+:GQZ_E&_SK/DIU_D,MF=I=O[QV#\+.FCN:%,5DY<1FZ^1,C4UTU,KH
M:VHVSN^DJ)Z=:>&'R4;QB1A,HA8W8O?[GM]O( K(IG>F1J K0?+5$0#4\?EE
M[;@MG87DT9+*S>"E<'3PJ?G22M*#A\\:WGN0>@5UN-?\)_N@<W\I/A3WC\?/
MFGL"/+_R^]X]T=:[FZ&S6[=SR[1JJ[LG$92%:_![1D,D=148_*Q4B4U=)32P
MQ)4-64M.TE159)J6)^=[Q=OO(Y[5Z7 C82!0#1"M 6Q\5&-*U- IP M9%Y4M
MFO;5XKA:PEU*5)%6!J0,_#4#Y5)&<THL_FS?,/N_Y._)S<&QNR]AQ=#;"^,]
M?F>D.HOC#@U6BQ.R<;LVI>A:E2G@6.CFR=1]O']S610JDR1T\5/IHX*9$&/*
MNTP[?;"2-O$>4!WE/%B<T]:#T.:UKG'09YBW*6]G,;C0L9*K'Y"AI7[2/RI2
MGJ:N/8GZ(.O>_=>Z]>US_@?]Z]Z;AU[J2_\ P*'^LWOTO']O^#I]#^HOVCK?
M@VA_QX_7W_B..N__ '24'OB'[M?\K-N?_/9-_P >ZZ^>W'_)!L/^>6'_ (X.
MG_W'G0UZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[JY?XM['DV1U!@EJX#!E-SR3;KR*,NEE_BBH*56OZ
M@5HXZ<E2!I<N+7N3T)]EN6CRWL$ D73)<$W,@\QXH&@&N01&J5'D:]8-^[F_
MC?\ >YBAK' !;H?+],G6?^<C-0^8IT8GW*_49]>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW58ORZ_P"W@O\ *3_\29\PO_?0;@]G6W?[BW?_ #3C
M_P"K\?1==_VT'^G?_JT_6CS_ ,*1?^WS?S$_P7X^?[QUELT>Y#Y06FW)^?\
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M$+1^RN/9%C\P?Y?\5^WJ3U]W+9X0K6\HE(RRNI4'\Z'^7^?J_C^7M_+TZU^
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M=)D5ED*@2@A=)(&""#4GRR,@#A3JJ_V)>B+KWOW7NNC]#_K'W5^'7NI3_P#
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MOP6Z]JK_ *AUY@]@"I_X-[:Z\*#KB!?D<_@V]V60H>K=2C4U"PO"CLD3G4R
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M->K3,'_/D_F [:Q4&#J]U]:[SJJ<.K;EW/UM2I62 W(##%MBZ-M(LJM]F&(
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M5QU%_P *2^JC@C497XP=@4VY0B*,;CM_X^OQ[2<AA_$9:"FJ FH$*?X86/\
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MEM_S@B_Z Z4?UEW+_E+N?^<\O_077O\ 1YL#_GA]G_\ H,T7_7CW[^K&V_\
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M/XT;4JMP8FGW+7]!]03T6"FK42JE1MO43!XX2=;+:*0W _LM_0^\:+K^U?\
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M>O5Y?+Z--KZN/K[]UJO2EW!N7;^U* 93<N9QV"QS3QTHK<I5I1Q>24,536Y
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M33AB@<QDZ2P5K7^MC[]UZM>F3*=L=9X3(56)S&^]K8W)T,IAK*"MS,%/+$X
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M)$JS2EC8_7C_  ^OX^EOS_OC[3LWAX.?//1B7TFO7$)JLA UWX4CU?6U^>;
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MQ13HT4T<<T36U1RH)%.DW%P00;$ ^_=>ZQP4=)3%FIJ6GIRP 8P0+$2!^#I
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MY3T=)4E6J:6GJ"H(4SP+*0#^!J!M[]U[K)%%% BQ0QQPQ+?3'$@C4:C<V
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MZYSTE+4E34TU/4%+A#/"LMK_ %MJ!M?W[KW62*&&!!'!%'#&"2(XD$:B_)X
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M.G[FFIZC1JT>>%9;:K7MJ!M>PO\ ZWOW7NN44,-.GC@BBAC!)$<48C%S]38
M#GW[KW6 8['K()5H:,2AQ()!2H&# WU Z;WOS>][^_=>ZS34\%2H2H@AG0,'
M"31K* 0"+V8$7L3[]U[KT%-3TP9::G@IU8W98(EB!(_)"@7/OW7NL,F.Q\KM
M)+0T<DCF[R24J.2?ZDE23[]U[J1+%%.C131QS1-;5'*@D4Z3<7!!!L0#[]U[
MK'!1TE,6:FI:>G+ !C! L1('X.D"_OW7NN$M!0SN9)Z*DFD-@9):=)&-N!R0
M3P/?NO=9S%$T7A:.-H2GC,10%=-K:=-K6M^+>_=>ZPPT-%3OY*>CI8)+%=<-
M.D1L?Q=0#;W[KW7<U'1U+!JBEIJAE&E6F@64@?6P+ V'OW7NLL<4448BBCCC
MB4$+%&@10#]0% M_O'OW7NH\>/H(762&AHXI$-UDCID1A?C@A01Q[]U[K+/2
MTU2%%33P5 0DH)XEEM?ZVU VO[]U[KE#!!3IXZ>&*".Y;1#&(A<_FR@"_OW7
MNL'\.Q_D\OV-'Y=?D\GVJ:M5[ZKZ;WOS?W[KW6>:""H3QU$,4\=PVB:,2BX_
M-F!%_?NO=<8*6FI@PIJ>"G#D%Q!$L5[?2^D"]O?NO=8I,?03.TDU#1RR.;M)
M)3([&W')*DGCW[KW4B2**6,Q2QQR1, &BD0.I ^@*D6_WCW[KW6*&CHZ9BU/
M2TU.S#2S0P+$2/K8E0+CW[KW74U#15#^2>CI9Y+ :YJ=)#8?078$\>_=>ZS>
M*+Q>#QQ^'Q^+PZ!ITVMITVMIMQ:UK<>_=>ZPPT-%3OY(*.E@DL1KAITC-C]1
M=0#S[]U[KE/1TE25:II:>H*@A3/ LI /X&H&WOW7NLD444"+%#''#$M],<2"
M-1J-S8  "Y)/OW7NH\>.Q\3K)%0T<<B&Z21TJ(0?Z@A01[]U[K-/34]2%6II
MX*A5-U6>)90"?R P-C[]U[KT-/!3*4IX(8$+%RD,:Q D@"]E %[ >_=>ZPG'
M8]I#*U#1F4N9#(:5"Q8F^HG3>]^;WO?W[KW6>6&&H3QSQ131D@F.6,2"X^AL
M01Q[]U[K(JJBJJJ%50%55%@ .  !] /?NO==^_=>Z][]U[KWOW7NO>_=>ZK%
M^77_ &\%_E)_^),^87_OH-P>SK;O]Q;O_FG'_P!7X^BZ[_MH/].__5I^M)G_
M (45)?\ G*_,V_J4#X_@BU^/]&&S+\>Y0Y)S8*?FW_'CU&F[XO9OL3_ >JAL
M7E\?C<++XJ:H?/O6A!.Q0P)3(L=U'K#F5V\H>ZV "V+"X]CF&<0J:#N\CY =
M!V\MGNY I8"(#N7S+>1X<!@_ETE:RKFKY'FFEY<65=.D+;C@<6'''^^/M*S%
MLGHP@A6W72OEY^O[>FY8 YL7 X_#@_\ &_=-->G"M37KST2FUG<?\&%_K[KX
M?3,D&OS_ )=2H))*820HQM*4#7']/Q_K>[UTBG5FC7%?+I34%0])BJR-$.NJ
MEN[R,C!%'T"!@"?]O[5*^E"/7[,=);J+QI%-:!:X%<GYT-.DQ4EG<NVI@7Y8
MV'XMS;VC8]*?[,4 _P!BO4*6&,/Z+#_&U_>M5.K:J<.HWB ))#-<_P"M_P 1
M[T'ITUXQ7%"?]7V=9D6X(T6"B_(_XU[\S:NMB4R<13_5]G7-4#&U@/\ 8>Z=
M;ZS4U*\KZ$#DGT@ :KW/T'_(_=U35ULT45)IU-J\;)0NJU)".8]9"GU+?Z!Q
M^"00?K^?;QB\/C]O58)%G!9<@>?ECJ[7^4]_(K^1G\S'(P]@YF?(]$_%2BJ*
MJGK^ZLUAGJZO-S49,;T6T,;.:?\ BCQSJR35\DB4-*RNNNHJHGHP!]_YP39R
M8XU5W\CJX?: *\/F/SZ$NS[(VX=Y)5?L.:_LZWI/C3_(0_E7_&C;V+QE%\5=
M@=T[CHZ&*ERF_/D=B:?NJOKY4.HU4E%F(9L!13LWT^PPU(H4!0O%S%&X;_<[
MBY9V(^2U '\R?Y]#BUV>WM5TA ?FP!_R=66P]3]!XE*?;T'6G4&,CC18Z3!P
M[-PM&%68DA8Z9:90 S$D )R?9278^9_:>C'2H\A_+HE?R/\ Y./\M#Y38S+T
MO9WQ!Z?QN<S'V\D^_.L-L0=1[A$]$@CIZELOMQ<;55<M/&J(BU;5$1C41/$\
M0T>S"QWJ[VZG@RNH'X:U7_>34>?ITFGV^"YJ7123YTHW[10_SZT<?YN__"=S
MMW^7UALWWQT3N#.]^?%+'!)<[ELE0P)NO9T3LD2-N*GHH8*+(XQY'0#*4-+!
M'&69:NBHXTCGGE;ESG./=V$%P DOX2*Z'/H*U(/H"37R-:#H";YRX;53*E74
M9(/Q+P],$5K4T%,8I4]:X:T\2!CIT\7 /-[?[U_O/L=@"F?V=!A8TI4@?9QZ
MWF_^$K7PX^)G?_Q"^1F_^^?C+T#W;O#'_)K(;-Q6>[=ZDP/9E51XJFVEM6K6
MAII,U05II:=JJKJ966(*'9[OJLH6'N>+Z>"Y 1V04K16(I@#B"*UX_GT..5K
M6&Z@.N-30_B4-ZGS'6ST?Y7W\M!F+'^7?\%RQ^K'XD[ )/\ L?[O^P0VY7#\
M99#]KM_GZ%@L8%X1H/\ :+_FZD0_RR?Y;=,Q:G_E\?!^!F4HS0_$_841(/!!
M*X 7!'X]^7<KA.$L@^QV'^7JC;;;O\449^U%/^3HK??G\A/^5#\@L!/A\Q\0
M^O.L<B8YACMU]#4[=-9"CEEB,0F2/"FGQ=6R ZECKL;5P:P&:%C[70<QWUN:
MB9S\G.L?L:O2>;9+69=)B0#^B-)_:M.M('^;U_(>[6_EG5,?:6S-UU';WQ/W
M!EEQ>,["K<::;,[?KZV_VN(W-244#4^JLMHH\C J4U5*K0RQT52]+!52URGS
M-'O]89-,<P%0,Z9 /X?.H\UR:9!(K0";MRZ=JHT>IHR0*T!*M_2RHIZ$>>"!
MBM2'Q%VGM_>/RX^+FR=WXC';@VMNKY*]#[7W/@,G$M=25^.S^Z\32UM'41L-
M,D%332R1R+<ZE8B_Y]G6]EH;68J:%5J/R(Z*;% TX5A@,HIZU_S5Z^L-%_*Z
M_EG0JBI_+N^# \:(BL?B7L%VL@L+L< 6)_Q))/Y/O'T;E< ZA+(#ZAV'^7J6
MS80,-)C0CT*+3_!U\GSY9X+#;6^4'R0VWMO&8_"83"]]=Q8G#83"8^+%4=#1
MT&XLE%345)30*D-/3T\*I''%'&J1Q*JHJJ !D7M.HVL+,2S&*,DGB24!-?4G
MJ(I[;P;B:A%/%>@ H -;4 SP P/LZ+GX_*P5[!'-BXM<!2+_ *BJ_0GZD?XD
M"Y"TBIITGGH:+_%7/I3/6V+_ ,)G?AC\;^U?DEV;1_(CJSJCOJLG^.<F]\?U
M[VQUMBNPJ#!15N<Q5'05[4V7IZRE-?E:6HK2H-,&AI5B<-JJ&2,$^Y*-86T1
M1R"S9 -#2E?(UST<\F7,=_=30F,%8J#6<JS"M<%:8]:G_!U=-_PH.^"OPCZ3
M_E2_(/L3ICX<_%?J/L'"[CZ.BPV^NL/CWM'8.9HURV^-OTE4M+D\5B*2MIUJ
M:6>>&4),HDBD>-PR.RD <H7<TM_$AD<J==068@T1CPK3RQ\^A;S79QFQDTJJ
MFJ48**BLB#&/3!]1CKYYO4.%H<]W#U1@LQ04E?A\MVCUWB,O05L(J(:BER.7
MI(9H948%7CDB9T96!!5V_KQ,.\@BVD8&A45X<>@1M\8:0!OPZ1]M01^5/SZ^
MNCCOY6_\L_'4U#!3?R\_A!_D-/2PT\\_Q4V+5S?Y*JA'>HEP3SRR^D$R/(SL
MWJ9BQ)]X]G<)PQ82.#4\'8?Y>I7%E"5H40XS50:_RZ^4Q\\<+AMK_-#Y>[0V
MO@\3MS:NV/E)\A-O[<VY@,?%AZ#'T.)W=EX*2CHJ.G1*>EI:6"-(H88HTBBC
M541  />0&VNSV,-:DM#&2Q)K4J#4\:G/4-[I&EE)*J)@R2<,!:.:"@'"@H.B
M[=?];;X[9W[M/K'K7:F=WKV!OC/8O;>TMJ[=QLF3K:ZLRTJPQT\,,2N26=AZ
MB- 35)(\<:,ZZO+E+&(M*:4'R'^K_4<=-V5B]XX4 U-#3TQ_J_P<>/TEOY37
M_">/XP_$SHJGR'S(Z;Z7^3_R1[!I:#*[WA[2V'A^V-O;55HETX#;U-F:&JI)
M&IR3]WDOMQ-5376)DI4C5H7W?F&:^8JC%4!/ G/$?+R/Y^?H)7VO9TLEJP!8
M^H&/\/5'_P#PH1^5?\N#IM=T_!OX,?#KX3X?N-)ZG!_(7O'8OQ9V)2U.UEIG
M19MK[=RM+ADDI-S-(@7(5L-WQ2J:6FDCRI>3'"?D[:;B\87,\D@0912S?J'U
M.?A'\SCAQ#O--]! I@B2/Q#\1T*= IY&F&/KY#T-"-/)X-(O8CZ_F_\ Q'N3
M/ /KU'VDTKU<)_(S^!*_/[^8)U7L#=&WL?N+I+JU9.YN^J/, 2TM1@=HS1I3
MXEXBR>?^.YBIQ]!)$&#&CGK);%86#!#F[<7V^ *,$\/M/R_U>?0FY7LOKI>\
M&B_\7U]*E?Y77\LY5"C^7;\%["UK_$G8+'@6N2=ODD_XDW]Q&-PN%R))/][;
M_/U*'TD7\"?[R/\ -U\V+^>Y\":?X$?S"NTME;-VY!MSI#MF.'NSHZCQ=-]I
M04F(WC-**_"4R1T\-+31X'.0Y*D@I8B_@QRT#N1YE7W,'*6Z-N-H-35>,Z6K
MQ/H?,Y'F>)!ZBWF6Q&W7-56B/5EIP^8]*@^0\B.J:B@!YN!_4&X_WKV)0*]!
M\,#UQ8*/ZD?UO_QKWO3Z9ZW7KDL>LA0""03S_A[V$KTV[4'68*193_B!_L/=
MM Z9)!ZZ4L;V'TXO]?>PE.MD#SZY"X^H8?ZRCW[33AU32/\ 4>N>HCG^G-BI
M_'O8!ZJ1UR$I:_Z!P?JUOK[<I3_BNM=28TN@-Q^?IS[WHKU<)7K(JZ3>]_\
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M2RROP2[R,Q/U/L>BS@T>$% 08 &!0?9T%#=F1RS%JU.34D_MKU?[_*G_ .%
M'RB^!NYMK]==P;FW3\B/B9-7I0YO9&],N^5SFV:>O:*,U^ULU5Q35J14"1ZU
MPT\TF/D19(J?[&:;[H S?^38+J/7:J0ZU)I7/"G'[#_GZ$6U\PO"P5BS*2 2
MP- /Y?F>OI5[=W!UEW]U3A]S8"LVUV=U!W#L6CRV*K5BCS>)SN WQ0K)&QCE
M5HJFBR%#4C4DD=FC<JZ\D>X?DC>U<JP*LISY$$=2+'(LZAEH01^1!Z^5#_.<
M^!U+_+O^>':/2^U8IH^J=QTV)[;Z5-7+]U*FV-]2U(BHY7(#-_!\I1Y7&([
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M=>ZK%^77_;P7^4G_ .),^87_ +Z#<'LZV[_<6[_YIQ_]7X^BZ[_MH/\ 3O\
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M6KZVNRLSSU596U=2SU-565,TCR3S3.TLDK.TCLUS[R.AB6(!$ " 4 &  !0
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MVWU%N_:NV*ZK)6&#,2TS3X::>S(?!%E8:-I/4/0&]PWMEY^[[B.>E=#JQ'J
M02/S'4HWMO\ 5PO%6FI66O&A(I7RZ^0'O3:6Z>N]W;@V;O+"U^W]S;-W%FMJ
M;PVSE8A3U5!DMOU4U)7T-2GUBGI:F&6*1-5U="I-P?>3"2K,J2H=2, P(\P1
M4?MZ@.]$L,P%* '2ZXP5J#_JKQ'2>=XRQ*1G2[WC53>P;D#Z\\>U!<>GV=+#
M*L= ?/\ R]98:6H>>%(89)9:B1(H8((VF=FD("HB*&9W)/I4"Y/ !)M[TQ\
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M)+)22-[QRW_9)-CG\-\@BJD5I3TR!GJ:]DW-=SBK^)>UACB//K5O_P"%)O\
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MRPH&8WL/I86O_O?NR])T!5B?4U_U?MZD:8Q^H:@+?7T_[:U_;A Z5,Q8"G7
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MRL1\T;$G,T>E@$89#**TI]IZ6[#<3[%<^*I9P10JWF"< :0*#\B!UL:=N?\
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MPY7'X/!X?'0-55%76965(*:F@B0%I)IYI$1% )9F ')]G,DBPJ78T"@DD\
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M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW62*62"6*>%VBFAD26*5#I96C(*L#^""
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M"/;8S108Q0G!DDH=1I_"&'V9/GU('(UO'9V#[BXJ[B1J@9"1DC2*GS*D^5<
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M^Z__ !+?8_\ [N:WW)6V?[C1?\TH_P#C@Z ^X_[D2_\ -1_^/'K=G_X5<?\
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M !_VY]W4],R1BE ?Y5_RTZDF8LA1$1P01:8%[7^MN?K_ +&WOPD)%*?MZ+E
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M8OO+=50:SP+-/+64F)SE+3T<#+*J1::=4.C3^H$LEFF;51?+[/0<=749?O\
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M4 BG&M1PI4^5:CH,[AM%RUTZB)R6D;20IH0S$@UX4SQKCSI0];2?_"M/.X[
M?&+X.]8UU91_WIJ>Q=VYV.BBJ@SM3;*V]28^LF2,@.T(J,M2KK( N0+7/$?>
MVL9:ZF< T$8%?*K."/\ CIZ&7/,@%O&GF9*T\Z!2#_QX=)+^<OG\UAO^$W?\
MK?'8O)55#0[KP_P'P&XZ6G?0E914W3.<RD=-./[42Y'&T%0!_P =((S^/:GE
M>)9-^NR14J;AE^1\8+7]C$?GTGW^1DVBW .&$ /S'A%O\*@_ET_?RW7;,?\
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M[$ 066,!J<15V(!],&M/0U\^O<D(RVCD@@&0E:^?:H)'YBGV@] 3_P ([/\
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MZ](7_A.1LK(;)^&_\T+H79&;QU7\@=@][]H[*@R&&J#1SM446UCAMN5T0?\
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M )C[83-X]MPSTU)G?X)]PHJ_L8<)DJ=JM8"0YITFD2,N!I#E5)N1[17T:A5
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M&)\_X:X^5*5\^(,-_+?P&"^3OPF^6GP3IMYX+9O:&\]V8'LW:'\><E*F.A?
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M/+!4Q0S1C.^V:WW"W%K(OZ8 "@$@II%%(/J!PK7Y@CH,6FZSV<YN$;O))8D
MAM1J01Z$^E/E3J\3M+_A53\[-YT>U/[A]2_'3JC-XO<>T-P;PW!A\%F\[/G(
M=H9&AR/\$D:IS2246!RII:BER$,<SUDE%4O#2UU)*#.X/M?;BTB+>))(X((4
M8734$5X&I%01P%1D$8Z$MQSQ<2 >&B)D$DU:M"#3RH#0@\30X(.>J;_Y@O\
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MTJHX&E<GRZ1M9VANULD^1H,SD\36-3_:BHQE?+2.(@!= Z/Y &*H2-5CI'Y
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M,CLIKJ-@WJL@<LO]-19 !^/S;_'VW*(!C4H_F?Y=.;-<;@:RF&4D8 ^%:<<
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M?004!D*_0M)#"KN!;@,]A^/J?;CW[G -!Z ?['58N7;*)M<@UFH(9R2<>M"
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M ^U\%H'&HT_RGHCW*[5>U%JV,D8'YBH^>>O34S:%CBII/(;AG#ZP1^/2 /\
M>^?>I(#P537[>BZVO9+>KRZ3&"*54_X144!J.F6IHLA$"L],T:*VH&2+3]!]
M#^!]?:"6VDC'<I'VBG0GL+NTO^^"4%N!57!(!^1SY=-4SS+IUQA3:X.C3_MO
M^*^TDC,OET=1-HJ Q.>%?^+ZAEGU?J87_5[9)/5C$R$9QUE 9UL 3_B0%]W\
MJ=/T"T8^G^?K@8W866X(8C4I_P!;\^]:2>'3J2+723Q' C[3Y]89*6I7CU*2
MH)Y]U\)AT^NAL@CCU&(F0V]3 '@^VZ%>O&)0:T_/KM4J)BJJC$MI!^OXO?\
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MFM%'KP\N./V5Z8<K69R-HF&#DQ^.IB(:2CJ,6DB*+'F0U,9%1*5MJ9E)^A
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M/K,4%<E&8\W <6]D<]I0X_R]#G]ZZ@-5!PJ1D<?*G3,]HR NM;CD-P/K[1L
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M#0GSP2<$^1'627=61G(-8D-0ZNP#-$8R"/\ :%L%_P +*!_4>WOW@5/"N?\
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M]'>R[_6NY>_Z-]M_SC'2W_7)WW_E-G_WH?YNO?[+[TM_S[?;/_G&?^CO?O\
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M$GA6N?.O3&L>YA%]O3".AH@TBZPP#JT9T,"2SSD7/^J4?T ]IRA!ZWXT2+J
MJ01C )/#S(]>DGG:<TT(AILE425;,=7VTGVX)XNK!G+-S]>.>/J+@II5/1WM
M<HE(/A >60/+YTZ#VGBSU15I04\#U3-*(%BGB\US. 1<16E!8FRD$&_TM[0P
MAI&*_P"H="DR6UL-;46N:8\\8K3[?V=&1RV%7K/ 8&IKGVWN3<F9QZSUM!3X
MFH,6':=&,4350DA\U<$_SJ+'+'"3I\CD^UU#"/\ 5G'0/>\&Z7%(I"H&<5_B
MI2JD_;PZ V7=E O^09? 4U;#3NNE9(A4JQ07M=I 4"E%7AVN"3?\'50_'_5_
MAZ$*[3+"H,5P:X/XO\A'^ #T^?%]E]1[FI_/1UN<VO7O&S2*DD6;A\CC5H6G
MM13Q!#P1=[G]+'V4W&U0R>=/V_Y.CY>;+_9)1&@+H>)HN,@9U @_+_9Z25)T
MT@KZACNF@J<+1H)I:VAHY_(>7]+05"1>-D55+DEP/)'IU FR%=E*M56Q_E_U
M>M>CNYYS5(@%CUNPKHQY^>#CC^$ 8%:]8-RR[.VPLE)M_;%9F<@MHQF<_#+-
M3VD0$O31 0HXU GU4RW4<BWMJZ$<(HH)?R/YY_XH=+]F>XOJ2S.L4?'PJ_%7
M !..%2U2"1P].@K9,GD7^X-%*Y9?2U/0>% OU  C0*% ^G'T]EI5Y/7UX?YN
MAWM]S!;URI%=)%>VG&N3DUK_ )!UA7%UTK,@IRA#(&6:9:>QDY7];+]0;^Z"
MV8\:]4GWB-9"4TG- :"E/(\/\Q^73C38G'1F-\IF8($<G5!06KY;"_%]2QH3
M8B^IO]8_EY+9:Y/V?ZJ]([C?)]/Z2TK\1^+(_P!J:<?(^8^73LN2VY02ZL7C
ME'CTZ*O(!LK.++8E4+4](I)%P?MV9#R') ]J J19KPZ*(X[K<CI\R>TUSZ<3
M0G\Z_P AU+B[".*:.3'XTSUD<:H*O,51KPUM9)>"):>*H74W"5*SJ  INH'N
MDNZZ,#I;#RLTF9R*''K]G&GF?G]F3TR9;?N\<Y.M17YROD1$EBIX*:7^&P1I
M-JU+%3PA:>)26(LL(XX%AQ[0&[EE:M?\G^?_  =&J['9VH!5/3MJ":C!X!,&
MG\6 :4/2.J)JF3F1B6=M3/(Y8DV/U/YO[32L_P"+/SKY]+9K\)$HC!4!N'I@
MXH<C]IX==PJLGZAP;<7_ *?G_8^]+"#Z=&-GNNL"HH/.N33U^SJ=C,SD</-Y
M*.4!6/[U//$M3"X_VN)U:,FWT;3J'U!!Y][A9H34>N?]7Y\>BK='CNU H&-,
M&IXX\S4D?T2:>A''H:<%V'MZ6F@CRVTL":U-,<LRX>*J5EBC505 DC>,FPU7
M$ES>Y]BNQOPX D&?EZ4ZBK?M@9I"T,DJ*!0*'95)J34Z645X9IGH2Y=_[:I,
M4B'&::/((?-1XK:5!AXG0$G2TPB$T]F%F+2Z21R"03[-&GC1>'YXZ#(V:\N.
MU)Z&N-3N3_AIZCC^WS:J+(8;-VIH>J<O6R5"JE.F+QB4Q)?@ZDAIF:8#TV7R
M)R" >?:=IH9!D4_9TIBVV]V^H>YUT)R/$(.33B01\L5IQ ZQ9C:.%?*4^/H=
MF8S&R2?:T]11;BR2T=5YYFL]Z.GR4-1 J\V_:;^MB;#VS/%"P&E17CP'1E;[
MO=VJDM.^D _C84H/FQQ3R],4\^E9B=J;#QM2B9S!;/T1L3-'35BNS?V2H^ZK
M;@W!-S:W%[7'M3;6]LH!<"OG@?Y?MZ"M_O>Y7"'Z>9@!6E&8_9E2,X_+A]HC
MY#!;0RN*APFU-EX*2&FD:OGR./Q5,U1,8I$^WI6J)&,JQH7=Y#]Q&LMD128P
MQ>]U'!(10#@/(?ZO^+Z+MCW2Z[UN9&)\@68CB0:@M7/#\J9X=*#"@TF)8UG5
MV8W#N"HJJF22OR&>#01HJJ$6&BHZ)[R7\C&4S-^H*D:6+,86VK30FO\ @Z+-
MU$==1?P,UK%@^7H4_/\ 9PZRY"K["W#CX\-%@Z#;V(H4?^'X[;^$>=(7TDM(
M\<[!7)CUZC]HH)T@_P";!:WT?B?%2M>-,](X-WM; BKR3$<&D./L%6? \N.:
MTZ#_ /T3YG*5*#<6:W%51^-FIJ3-/)40#2XN$B6:EDCCY'I07/XM[:?:%/I]
MO2UN?U1:0QQ885T$:R*TX:/Y]%PW5U?FZW=61I-KXN')4T-0B)58Q&@IS=8Q
MP\\K@:7D"F]0XOZ@[+R Q=;:5:BC^7'J6]EYLMUA5V)5BH-":T/Y5]>N&-^/
MW9-?4*8\'5@&[JT,R/<1J7:S1M(5LE^2H L23:Y]M1;(TIJ>'V?[/6[[W&LH
M5 $AKG!(KDGY+CCZ]*[=_3&6V@E-=\E#25%'%-?*[>CKHPY7](J9"@_4?JB7
MMR"Q'M3<;28% K]O2';N>;?<6.BK5- :_">/J?('_(.@8S&#J::HEI4AHJJ[
M2-]Q30R1$%B; ^M QM_M)'^O[*S8$\ /G4<>A9:;[#'5JD,/A((QFA_U#J9@
M-A97(582JQ\HIC$Y#B9(;D*&!0,X,G!-PO\ MP.?;L&V%CP_9UO=N:-,55D)
M;%>%:U)X@="?B=JY_"21-C<;3U*K_FY9:F5-#,+A1KE" WY(L0U^#87]GUK9
M/$M!CJ/;GF>WN!^LYU>?R/Y<10<:="%C-HYZEJ!NC<&T:VOI\C6M.:NJR(:.
M0(R>A#)1UE/HB)!6\5VYXY ]O-:NO<3Y_P"KSZ);[F&UG3PTE9#7RQ4>AR/4
M<:^G#H=99]U9&@IJ# [$QF.TTSAZF:ER-4ZJ5X!6FH<9 @"WL3!*O-K!KW61
MJ7%/3UZ"SSVS.69S(2:9H:_;5F-./2#I>J]^AVJ\CF8\*9HXYXXMM'1JU.4*
MR.GV@C(8.2LDK$&X)'%]1[2S8KTLO>=[*UC7P$-.'%:"OEBH\_4]*:HZ-W;6
M423X3:DV0RB4]I,C6T--DI';4K>9%C4L&"F]Y)'<W%F-K>_3;.8\L?Y5Z26?
M/:"0*!6J@\:<<8XC^?GFGF7C>W6^4I)98]W5QQ,_G8,T^-HJ60&G !66=9P[
M&P/#NND<_BWLBN+-02/\GY]2EMO,<DH!C6IX@5J#BGH?+R/0+[@P&V<'")(\
M]1[@EEIY5IJ''E)F620>EYI8I61!&2&L&D+$ 6 N?9)>1(!BA_P]2)L$]XTH
M:2)AD'SH <9!6@!KC@/+AT#TXGNVHV1"^D%]7]/I;\B_L*RHYX\.I'-]&9"M
M,ZB#0<#4^OV==,FM>?Q8?7W1E+#H1Q72, ,UKC[#3J'(C7)#*+"]P^FUN;^T
M[ ^O[#TH"PT."?/*UKY^?4!R5]8D0F]F"GG_ 'JW^\^V":>?2RS%1ITD"F*@
M4ZC^:6,FU['Z#GVV7*]+BBOQ'7'[EC_GHPP'T/OQD)XYZI+;5%$)'6:.6G4$
ME9 P(L!(+?[8@C_>?>U91ZUZ+Y()6."M*>8/^$$?X.GR%HFII'@KU66%;BF=
M6%Q_KV(_WGV8HPTG0]"/(XZ*)8VBDK+!4,?C!#9_R=-<E1,YU.MR#:ZFPX^G
MT]HGE9LGHXBL8I!7CY#54FE:^?S/6%7)_58\?1DN/]A_C[J#7_9'2SP5A';7
M\C3KGI;1=%XYX50?]X-O][]^TD^73?U(!HW\R?\ (.N+)*;6;5_KJ!_R/WK2
M3U9;D+Y4'V]<"!&MY5U,00#'Z;?[ 'Z^]?",_P NE"R&:@4XKYYK^WIJEG;0
M5]6G^GU^I_/UN?\ 8^TSN:4Z,TMQ2N*_ZOLZ@^1[6 _J3I-B?];@^TX?I\PB
MM>L$DLZD#E02;Z5'^P_K[UK(ZNL:,:\>FZ4,PN222?R;^Z<>E9HO43^G^/NC
M '/6^L!^I_US[:Z?'#K%+_FV_P!A_O8]^ZI/Q7[.H?OW3?7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]Z/#KW4I?^!+?\L3[UY_D>E$/]H/M_S]?6G^+7_9,GQS_P#$$=1?
M^\_C_>-%U_:O_IF_PGJ?(?@7[!_@Z'?VQTYU[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5B_+K_MX+_*3_\ $F?,
M+_WT&X/9UMW^XMW_ ,TX_P#J_'T77?\ ;0?Z=_\ JT_6IM_/(AA_X=Q^:+_>
M04\HW+T6MJC4%L>I^OR.44VNUQ?WDS[+*/W/3_AIX_Z;K"SWZ6F]UH3^D.'E
MBGH?^+ZJUIZ::9)F"-/'"!Y)H=4R*#]+G@*3_B>?Q[FZ*$#_ %?\5UCQ.Y!K
MG_!T\T%(!) 5DC221E),\AHUL/JH9AHMS;]7^V]K =/2*60,M*#A^?2SH:FH
MH3:Z.%D&EED2=@ 238AFXXX-_;RRZ<FGY]!Z:%7 K_*G^;_5Y\>E/2;EW D0
M2"LJ(7;A&CG="!<6 (^GT^GUY/X][^H;\/\ J_GT7/8HZZ<T]#Q\OETK\-F,
M_4U CGJ*DEROJDF=?4X87#-=CJ'!YYN?9A;,9./0=N88[8$+7SIGSJ:8Z&/;
M"U3MXZZHADA91&U.+Z[O_1B-1']>?^*>S6!0:CY^O^QT#-XOS9*7 %13B*\3
M4^8]?/\ V.EC!M>A?R^"JCID9)04CC,\A\G)!9M)OQ876_M0;?5P_G_Q?07/
M,C+W-2HX::@D4KYCB/SZ<L5T5'N.2EGIZ^E0/,\*K55T5,5-M6J:.075;7]1
M:WU%OZL-8KY]4_KU,AH@:A/$ZA0')(R/7! IZGU&K9/3^%V%!E,PVXL7D:C%
MT-34O/21I7*DM4"/%3OKT>5%'#(EU+@D_3W>&S2'-#^=!_DZ(-_YFNMT*^&1
M0 Y&LDU^>H9(XD4QQ\NBV=H4.V*RMIEQD&X31PF-Y<AE\A%4S3R%@96(2-(U
MC8@:=+MQRQO]"^Y@S_JIT.>6)IO#J IK2M0Q(!/ 9'KYBOS]"O;AH2U0U-BZ
M2EEBB\D,*39 %B%XYD"K&;+]"#Q_C^2:>-1Z_P"K\NIEV9U _4H36AKYD^?^
MJE/V=!;EMMYB(3RP)(D-W4)"ZRJNEA<W1FOI(L.>!S^?9')&X'GT+['<X8^U
MPI.<FE<X]#_A^WI*PR9JC(D6LJFDB=@B-43 E0H4^I74E?2./H"/:0RR0FAU
M?SZ.?J(IP!X8SG6H (QPJ!Y4Q]O7:YVNNL+TJNQLD0\\B !V!X"L0/H/][/J
ML0X9P#6@K\_GU9;-"*B0\*4/']IIQ^S[!U+>+=.0E2."CKH(0PBLH=% 4V]3
MR'Z6^EVYXX]^U-+P ZVQCMQW/\N-/EZ_ZO7J')M;)2-JGC1"SGDU )L/ZJO(
M'^O;CZ>]"Q=SG[>DQW6&$]IQ7%:'_.>HW]TI@&9JA0%#$B-6D/!_J!R/]B#_
M (>]&P9:<?\ BOL^WI8-_66H[ .!IZ>?'[/YXZGT6PZC(&1*;)P7("K',CP,
MQ9;@"ZZ5%^+DV'U/O<NUGAG/3L?,XA'Q*  >!S2GR\_G_+IIK=C[GQT_CDPN
M1E4 .7AIWK%T_P!=<*NEO^0N?Z>RU[(HU*8Z.-OYBCD *MDYHQ!7Y>8].H,F
MW=P:R8\)ER@MQ_#IAR!SP(_];WN2V8'M!\O7Y?+I4V\IXA+E"#Z4Q7/DQH?7
M)\^N<>UMP59\:X;*)>S)Y*&9+\?U\9%^1[TUL].!I^?^;IJ7>(G\XU(IW=O=
M04XZA7.?V=*"AZPW94W08#.F;R)&(8L;.]]1 N"L1X /UM[?BVYI!Q'#S'_%
M=$<W-,-LQK*!G.E@.'E\1'\^A9VO\8>T=QB:6@V/NC(04S)#455#AIVBB9@-
M)GFDA1*8%E<:I"J^D\CZ^UOTJH:G_-_A'0?N>:80/TS7&:FH!-<=OR'RS7[>
MEQFNEZ#J&2#(]@15U&QEEC@IZ/&/N"!WC74H6M5H<+(Y(8L(LG4&, ^@L+>[
MB2-'SQ X?GT7QWLV\BBT"&G=G\Z'[/\ +DXZ"[,]QPL\L6)VQC)8V33!+G)7
MK])!X*10&GA0I]%!,BW"FQ-R:W&XTX!:#Y?[/1I8<N11U:E&)^( !OR)%?MK
MT&F6[&WCEE*3YW(0TSJP%)13?PZ"_P!#:"G$4(-R?]U_XCDDDN>[,V0!^S_5
M_JX="*';TB _RU_XJ@.?SS44 G=?Y):?-)5U53XUI4GJWDJ2\@U"X'"ABQ!/
M/I) NP(^GM?M=W]/6M"<\?*O^;I#S!9+<JJ!5 TJ#10/A KY$9P?\@ZG;OWI
MEMS9):RI2CI8XH(X*:AQM*M!"D<(X%E'D9C]2S-J)O\ 3VS=2&1M2_['23;=
MMAMTTE?Y#_)QZ2G\5RC-I6>HBU*&40RL!Z2 #QR#Z5Y!!/Y/MM)9.&/\/1K]
M/;L,HF*YTT\C_P 7FO0I8&IR-%A9LU-6Y"(K4+3T4@J2I8H S:?*LHO9EOQ>
MU^?9@K&/)/\ /H)7OAL^A8TH:?A%?Y"G^K/67']O[LQM5'+3U5:(@'B<G(3,
MI U:B44H""I(L ![?@W)E\@>.<_Y^JW?+%O?BC5\L40C^:TZ%##]U[MW/54V
M+R>;FPU'XIZ>""*9FI29@+"9'9BVHJ!ZU;_  \^S6/<6E[#3\J_Y^@CN'*5G
MMJ^-#$I85X(@:AXY5.'RIT*M#N3=T="=O25<E523SPS-2XNBAI)9) AOKFAA
M2<H S>EI- !L%''M='\Z5Z TQ2?5I8I_IC4&M?73P_R?GTO<!2[2CR<+=@;P
MKL=1!I9*NCQ= -RY-BZJR*D$D])!&Q( O)6H5N?VV].JWBD#M ^72.-:L Z*
M<Y.BM17RKY_ZOF4)V!!M#,Y:KDVAG,]C,3'&(L=!F8F@J="G0'D,%1)!#,S(
M2Z)=1_JF^OMG29#W<?EY]&]E?-;5I&HR#@$4.?RX?9FO0<XO:^?FR:BFRL^0
MHDEB$Y&5>']=R;K+/8_0_3Z_T_'M/%9 2#[?.G1[<[\LL9C HQ% 0>%?^*.>
MA?IL[V1B*2?$8/(Y_%T8&AJK'F3'HDL;"[1O3JH 8+9O]6.#>_M=);!3_L?[
M'SZ"[WHMV&IW;@=(?_B\4'[*]!#N# [SGJS4YC=6XJN=R\H&/HY)C^YR=0UQ
M@<#DL#:Q'/Y0RPL:4KT+-LWJSE4U1 0,U()IGS(_V/7I]Q57N?KAJ?/KN/?>
M/F#4];C::&!ZUV)-P\OFC>F1  =2L7N&'H(O[I(SVZU;-32G[?MZ\IMMW.F.
M.$T(R0O ^AT_/RK\^HNY_DKO++Y*?+9/ 0Y')S./-69M8J?67.JX@HZ2@IP3
MQ^B'GZFY)+,Q[DT7!1^PGS]:CI;_ % M;YJ--(E37]/1Z>8T]3*GYP]V1U$P
MQ$N#VE13,A;';&P-/M*-$IQ8*&ID:9O[1(<OJ8EK$@>RV#<L\!]IJ3T=MR7;
M&/PA*XSY%!FE/(#/^'I^QO;FZ^RZ:HD.=J*O+UT$\=1#61RS3+H8,+U9H;1Z
M022$E4-?];"Q]B2*^\5:&@_+Y= 2ZY,&S3U%7U*#JK4UJ1P\ABOY^1Z"7<6Q
M\16U&G<N[=NT,GE>-J5LXGW2V(THT#:VELIORP-[>I>?9#?A"QJ<8X$#H<[;
M=W%O%JBB-0 !16K0X\A\^@RR6'ZBPT\2R9/+9-OWO((J2T:LO"LHAJ)"5!'T
MD"D7YC<>R>1(1YGC49_V.A?MUUO%P#X:-P*GXA2N/D?]0KT%6]FV[5S";!%8
MQ(J*4-*M"%T@#],<:(7)7FQM];?@^R7<41EHGKC[/R^SH7;!>W=M(?J!4_C#
M DAL@UU$T.?MKQZ#Z2G90+$F]S<'5R/];V3/;M3J1(=RCB 915CA@?*GICYG
MJ(\#6YU<CD'ZV^O]/:9H2./^K^71M;S)+0G4*$9_/Y]1C!8?7DW%P?R?]?VG
M\/'1Y%<*.%33[*?RZX"E+>DN 0!>XO\ 3WOPJXKT^;]5H=).?E_E/7"2D72!
MKO<CE$_XGW5H1_Q0ZI+N@7)6F:98#_(>L+4:?JUN.0#^U;_>S[H8:>O[.FOW
MPIP "?36/\@/4JGHHRX3R.%7U%M%R+?DV()]NQ0!C2O^K]HZ+MQYE>U4,(U-
M:U-3_FZ>)L',M(E9#/%41,2KJ$D5T))MJU(J\C^CG_BJQ]O;3J7(_GT00\R)
M?248>&W#U4T^>*$^E#\^/4"3&U:TS5(1GB32K,J< N; 7O\ D ^V'LW5=0R/
ML_V>A%;;S;CM=@&P*$UJ?G@?D.FU3+'RHU( =2N2/]8@CVD!*]' TSBHI4\*
M4ZQR2RVL^I3RP-_Q_2_NC.W ]*8+9%^&F>.//J(?(>0K$#FR G_;V]T.KHS*
MI'Q-,^=*=09"S <M_B+?2W^L/:=L\>E2LH! I^W_ &>HX13;ZBXYOS8_[;VR
M%!Z8-PPK@?S_ ,_7!D73:U[FW/'OQ  Z41.7R>L)IHC;4SZ?R5(_V'X/OU /
M/J[2LPP!^?\ Q?4>2A06T,Q%B.2#_P 0/=63'RZ<BEUC/'IODIBO-[_UY'MG
M1TZMQFGIU!F%E<?X#W3J\K5TG[>H/OW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][T>'7
MNI:"]2WU_P PQL.?>CQ/V=/Q']1?M_RGKZTWQ:_[)D^.?_B".HO_ 'G\?[QH
MNO[5_P#3-_A/4^P_ OV#_!T._MCISKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK%^77_;P7^4G_ .),^87_ +Z#
M<'LZV[_<6[_YIQ_]7X^BZ[_MH/\ 3O\ ]6GZU(_YZP8_S<?FO:QTYSH4?CZC
MJG8/')'O)?V:J=E-/*0_X>L+/?<TWNG_  E?\#=5A8^I--&W^4NOE= \#221
MH O(:Z@DD?0&UP3Q[F>*Z*KGC_@Z@">/Q3FG'Y9_F?7K/1Y[)XYYC2UL\"2C
M0R4Y"1D?DF-U\3AA<6:,_P!;>VDNF)/\NJBV&#0FGV_Y.A/V[N[;\HAI]P8&
MGJ7("R5U \>+J!?@:$A6*$B_^K#<>S..0/AJ@=$5W9N!51\P10<?2HZ6V)V[
M09^KIZ?;N11JFJE:&GI,E-3T+ZV8E1Y9I*>%K:1_NS^E_J+F"Q!L)T&;EI(1
M4J?3 /\ J/0]U_3?8_6Z)4;VVQ48F.2!*FGJ\C02202B34VN.H@6>FD_UQ/8
M@6Y-A[66A Z!NY7*1N5)%6'#XB:D^E?V?RZRTV=HZ 135V0I:)'N8IZ9&<,(
MP >8XV:SV^EKD&]K<^S%7$>2:?ZOE7H/7VWM>:ETEM1% *9%!_%09]/RZ=:/
M>6(R-;!2T.1@=YC82:Y$">JQ)\D:O92/PAM[<2_%:5Q^?^7HCFY3D722A-,Y
M*BGGBA_9Q].A'P\^<H)Y*W'YZDD9TE6I%"@J9(D!TG6[TW@ (<W&LL/Z#VH6
MXUUS^SRZ*K^PB@HI4UKD$$ZA7 Q4>?E_L]);,[ZJX7F2HJJR>6,!G>0>98UD
M^I:]@;GZ@*?\#[\;L+45]1^?3FU<M^*0[@J*@T)\N'F"?M'G3H(-P9JEKZQ9
M9)5?2$=)9DUDL"=3%N1S^ /P+>RR645_XOJ0H+4VYH@J*?*F/]5.FDXS;V4A
M4_?T=!5DZFE+LH)TBR\V",Q']+<\GVSX:/Y\?]7F.GTN9 , @UK3]O\ J_E]
MDB3K[(1PM6 --")C"LD!%23HL+\?I8W%K_ZW%_>S:>=/YC_/U1>8$#>'*=,E
M?A%36GE501_/I*U^TMJ9.62++3U=#.(_$*RDI!)8AD:\B"RRV*GTA;_G42 /
M:*YLD?CQ\OY]'EIS->VP&D+I\U-!48_I<#_J].D[5])T=9&TN'WA@ZX$ Q15
M,51BI0 =/*- VIC_ ,'X^OT]D[6!/P@GT\O\-.C^#GU$&F5*&@J:5S6G$$^G
M4?#=:=ETD,KX:JA-%#%.T^J9#"JAK'6U3#X%!%C?6/K8D&X]O"R=!\/\QTJ?
MFRQNEK6M>':33'R ^S[?GU$R.'[&5*AWH\34"AC:1O%3XJK8)IO<)&SS$ #E
MA%<_VC87]L,DZ?A\_4?Y_GT_:W5I=4TL<@4PP\J^:_Y>DBFX:Y ROB,'42&2
M.=C)CS$%X]7$4T:L#_4@6M=?5[3+)(&HX_R_X">C/Z>*08(%?2G_ $"0*5\_
M\O4E-T2JT@_@6$@!#/&M,T\2CT_4&2:0^K\_G_7^GM5+.RX_S_X3U4[3&Y!+
M8 ^5#^P'^9_EU)@W=12?MUF%1)'8/YZ6KD+>@&UQ(75B/]>UO:8RA\GIBXVV
MHI$<_P!&A_P=.[[JV\8V"TF6+ZXPTBUD4YO8&P TZC:P-SZ?Q<W'MU;\0TQ4
M>M#T@_<CJ*EB/+- /(^8Z7NR=U[=J\M0TF4CW/)22R:GCQB)+([>L,(XQ.?5
M+>_!N%)/J!T,NM[\MD**<,FG^$]$FY[,8QJ+%L@Z05)X'RK7&>CPXOLGIK9$
M=!*_2RP0*:>:KRW96[ZC=]?.D>GS2TN*IZO&4I9E33&D]$\:DZF%N#1XOJLE
M@OJ 0./[3^>.@Z$61BL,1D/]):Y!'"M%/"E#J'Y])GLWYAU&X$@H^O=MOA*/
M#UIDV_E\]'!G*BDAC9Q&E'CA",+1L0[,[1TIE)Y:5B /;0*DU/Y\3T9OL[@
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M9;GF_-O?C]G7D@*U_P!CK&'0D:@>.;_7GW4,#QZ4")U&*=87>.UU)!M]"O\
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M\.+VL;@D'W6R*],.U>NMF[)J*NJVQA_X9/70I!5/_$*JMU)&VI1:HGE"V/Y
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M^&T,]9)7RP?=SUEYI4CC9]51+*XND48L&T\7M<DGW7@*=);_ $.=;_QC^/\
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MDA3T0U,<:Z8XT'""]KFY))]UHJ#TL:_ XG*86;;M=2>?#ST:4$M'YY(KPQ@
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M32K)))3XNKJD\:@#TL7588WE06N39S8V X]UETNN.K[5#=6<I+@::U^=./\
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MTM51U=%5P8RAH,W'42$4P;3_ )-C:*CAIX2"1XKF"(A2[_461?O6&$E>%?0
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MM;@_4&WX/Y'T]T\4CX:]+I;$2$%J'\O]CC\^/SZXZU(_SR@@6L4/^'T(!/\
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MDU&<'(ZF$WE0*'_4./\ J_XKK'#M2:LD+4]($IX4"S5<\BT\"Z>;23. @/\
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MD^R.]A8-J!/1G8R&E./RJ?.N>)Z*QW%T%N?K'*/3U]J_'2>JDS='3OX)-=R
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MTXH_47_35_U?LZ^BCUE\DNZ=L]7=5[?PF\_LL1A^K.M:#'4G]W<34^.&GP=
MJ)Y)J"25[#\L[,?R3[Y&^XWN]S%LN^W]I;7>B**YE2-? MFTJ&-!5X68_:23
MUT]Y(]K=BW7:+.YN+75));Q.[>-<+J9E!)HLH ^P #I:_P"S7=_?\][_ .NM
MA?\ ZW>P7_KX\T_\IO\ V;6G_6CH4_ZSW+G_ "B?]G%U_P!;NO?[-=W]_P ]
M[_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)_P!G%U_UNZ]_LUW?W_/>
M_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_ "B?]G%U_P!;NO?[-=W]
M_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)_P!G%U_UNZ]_LUW?
MW_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_ "B?]G%U_P!;NO?[
M-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)_P!G%U_UNZ]_
MLUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_ "B?]G%U_P!;
MNO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)_P!G%U_U
MNZ]_LUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_ "B?]G%U
M_P!;NO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)_P!G
M%U_UNZ]_LUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_ "B?
M]G%U_P!;NO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+G_*)
M_P!G%U_UNZ]_LUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZSW+G_
M "B?]G%U_P!;NO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?ZSW+
MG_*)_P!G%U_UNZ]_LUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.O?ZS
MW+G_ "B?]G%U_P!;NO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]:.O?
MZSW+G_*)_P!G%U_UNZ]_LUW?W_/>_P#KK87_ .MWOW^OCS3_ ,IO_9M:?]:.
MO?ZSW+G_ "B?]G%U_P!;NO?[-=W]_P ][_ZZV%_^MWOW^OCS3_RF_P#9M:?]
M:.O?ZSW+G_*)_P!G%U_UNZ7FT/FIVAAJB%=U4N&WCC]0^YUT:8.K(_YMS4B+
M3J?^#4;W_P /K[%.P?>*WG;W ODBNH_Q=HAE_)HP$'YQG\N@[O7L1M-\I-FT
MML_X:,98_P UD)8_DX_/JP[J_MS9O;6';*;7KF%33:%RN$K@(*RD=QP)8PS!
MHV_LRHS1MR VM65<K>3.>]OYZM_'LG.I:"2%Z++$3_$*FH/DRDJ<BM00,:>;
M.3+[DV?P;M.UO[.5*F.0?(T%"/-2 PXTH02)WL9=!/KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JL7Y=?
M]O!?Y2?_ (DSYA?^^@W![.MN_P!Q;O\ YIQ_]7X^BZ[_ +:#_3O_ -6GZUH/
MYP]-YOYIGS:"@%CO7IG\7!/^B/KFP/T%^?\ 7]Y4>PXILK_\U/+_ $W7.O[U
M5P(=^3(J8L5X5TCJM*II9X@_[DHD.IBHO8%>?R+_ .P^GN9P[>?\^L:H;D2&
M@*_D?//^7_+TR!ZNY1_UH%8:A9EXMP;7Y]U:+6:UZ,/$&G2!_JSTZ4<\<'C(
M8O,+%0%+#@@W!'U(^HY^O^W]U5"#_L?[/225(R*,,$$<?7\OV=&6V?G<YD]N
MR5LL<KT5%(E"M151&>,N4C-@&8C7XPM^?9Y!/],O::_F*8ZC+?=HC@D,K+ZD
M44DYIQS0_P"?K!75674^-Z(10$%DE96A5?(#ITW*@C\BW^N/H26WD^H.0<>0
M_P"*_P"+Z+[.T@/><:OQ&E2?]M_Q8Z>L+O/*XDTPE?&L GB$B8J').2"GT,I
M$)-N&):]B%/IUV:>W$BDY'VX_P /1JC0Q'M%2, G-,>5/+.?M^WKK(TN W92
M_85^R,!-E98I8:'*X:E_@,\IC6W,5&6B8H6#,P4WL1^/98Z+&I)('VFG1W#N
M%VO]F&8>BJ6KZY%>@F["Z=W!UU6XV#-T%51KF,;'F*"&JIC!,(JAIE"NCZ2-
M'B>WY:W-B#9I$\7(S]F?3TZ$D&[MX=)%*G@:X.?DP^?2(I]N.PC80F1FMK@#
M<V(  (4,X8@WL 3_ $N>/:D2^$*'%.DIO6DH$5F\CI!Q]N/\W0U[<Z)S&7P\
MFX,M+BMN[8I:J"F?*YVN7%0--;7)30&0225U8([M]K2TTTPM9FCYNENK_P -
M,#4?0>73L%O+.1IJ@;B37_5_L_9T=FEWA\8OC)MVGQ"X3,=@]C97'P355=G,
M='A3CHZBS^+^'7JY,:[ATD6"L$M;(H!F2"-XBX;7ZN\<Z20/LX?S'0T@2QVF
M,&0+(V :&IJ?L#4_,CH)]X_(+I[?T:4]1U3D,'&[/'!68C<XJ-!1Y"Y$#TL$
M" N]PKJCV4%FY )I:V\T9JQ/V$$?ZN/04WUK>^;LC*<,$"GGZ@>G0.9S =#9
MNE4XC.;NPF2E(=H-PX5(("9&4VDJ:-\H_IT?5::$$R:G 52Q,W=U/K3TSY\,
M=$L+I$M0:9./3UXBF/\ 8Z0^6Z2SN/ISD::.3)8Y6#1Y7'RQ;DI=+\J1/1J0
M ;D'7I(/I=0QTF\=R7[:?ZO]0Z4?O+0*4QG"ZLX_TI]?R].I6*Z\W%&]/^[7
MTZ3,QCFCQ\]I-1!-K@ A@J@L7L-(]J4D /#HF,YF<@(PXFM"?RH%Q^WH8L1O
M3=?5N/K<_6;DJ(<-M:G,V222OH7E6.JT0BG2E2=:PRSMICCI_/&A?2',2@.J
M#<Y4E72:#R_D.CW8-INKF?6J#2#74U0//CCT]<DX Z1V#W-O?Y,;PIMZ[SI]
MN8[:&VQ24N(V_)4P82)YI6C2IGDD:-15Y6N0.9ZN8ZE5VCCCCA,$<9##LX)+
MU-?+Y\>'4A[ON9M(@BF-:>2M5F-*FOK3/V5IY]6.;<CZLSVV/X)V7FJ79U!C
MZZGB;&8>D@SE/5U,$4,$;O#BJ6IHBD**+**A0OJ",%&H)YS<VYH(W(']%J?R
M'19':[?NL*M,Z(_F ZAOYYZQ1=';=W K4FT^Q9MQ8ZMKD6CP>'VQ3[-ADA^H
M8U,@J8I6&FXBU \$M>UPP=[>V^.-A3U##_#TE'(T5[407(*'BHT%O\_4??/Q
MPW!2%)J/8V]:_'KCQ3K/5;\I,Q^[ $,FA$A,C*018+,0/3XT)-@JM.8EE;.D
M?(G_ #]%6^<B&T33"DC4\\5K]@C/KQ_/HO6'VGMALDN/K=E4,K25-+30KE*
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ME9A@LBLD4BF0I422)$VH?10C+*%NBG\$$VQ-!72#_P 7T,-LYS^IHL@3C3-
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M>CBWW$N<*V/Z)'^&G^#J$\*D"[@C\<^V"O1M'>/3@1]HZA21(+!F-KW^MO\
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MW7O?NO=>]^Z]U[W[KW58ORZ_[>"_RD__ !)GS"_]]!N#V=;=_N+=_P#-./\
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M%0)\<]QT4(GJV:HCBID$S/!]M(9&*VM&9V<(_P!"5C8J!<!0;AF;F:$CM/\
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M<Z[JXD9A$NH@<"(D8* !4@$U%:>9)ZER64<J[>NA5UG2/4&1A4DF@) H:<,
M#'51W\O7_A3O\F^NNU,O1_S#-UY+Y!]%YS;6Y)6JMH=6[7P.Y\5E:2F>?'QX
MZ+$0[8Q=;19&>,TDT-;_ )HSQ3I4P102Q2BG?/;Z":,&Q'AN" 0SL4*DT).K
M4:BM<'@"*$TZ(-IYREB<B[.M:$@A5#!@,#MTBAI3AQ(R!7JF+NW [4_F$?S$
M-T8CX"],[GVIB/DOV72U/6'3V>3'XZ?'5V;I(JC-F1J&HJ,=18F*NBRN1)64
M0T% 2A_;IB["BR=M@L ;UP3"M&=2345HH%0#7(7[?/H@NU7>KT_2J1XC5"L
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M=6D83_A*+4T-#M7;/;'\Q_I?KSO7=>*IZK&]28[K$;D6HJI(_P!R#'5U?O#
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M96HXUQY$O\<\M1)5>*&D/A9V"T?N+]0OZ5J[N-195<D*@ .HD1GYUQ0 5KG
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M\M(& 81^JR@VN/IP'Y]YBD6M!7[1U6+E5[.4?I$?[4@?X.C3]>]=KE,HM;!
M**BIZ6-)JJ!BB$2)H(C;4+.P#*2?P; ZK^PAN6ZDL0H\_P"74E;?L'B*&-1C
M(],="?G?[M[1RK5FS=I1O)%IJ)I\W$:A&-&=<LH-1(L:IK-S9;V'IY)ND61K
MH4/^JO2J54VKSX_.G#\^D/N#OFCGRS5V[]QS[@KZHIJI*+%4=51*%0*D$:22
MQLT8\<H)"<7YU'CV_'LQ8&G'[.B_^ML,)J:5'J>E7COE_M"CVZ<)7]5;,AAK
MJ=L1+587%5V&JGAB"DZQ0Y*&%)%^WD.MJ=D) L&%_;5YRW* &!/[.EDG.-M=
M(58*?M(Z1^>Z]ZW[NQ$F5PBRTT>/J3"^1S!",BRL9'@66%(6ET+Q8EBA-F)]
MJHKB3:SH8G%/E\^B:;EFVYMB+(ZJ<]H -*8\F7CT7'(?$%XY)H/[VXN+_*:I
MVJZ:*:L\:*B:8WCU! %<OJ/E5B +#^AZ.:"%&DFN//\ /H(M[7(:ZI@ #7A7
MU]7X= ]F^N>O.O,Y+09_L"FW/4TL$THI<=M6N%/%/XY/&E5--,BSJ'"%5I_*
MK-8-8W]F-M>3W_PU_:3_ *N/1#=\M6NT'OF6OVT!'^]GR'0!U%-'#//2Q21U
M,4#M'#4QHT0DT,?4%9=2@W^AY_Q/L5QBIZ ]^8U;M/[*CY9]. _;U':/TE H
M)7AP!<@^K_&_X_IQ[?Z*W70:KP S3/K_ )NN#TE2MVA5E55(8B0J>+#B^DV/
M]+'_ (GWHD+GI6D^I=/GCTKY>O\ @ZB&.52K'D,Q!N2XN1_M7(N3[99RYQTX
MI0BIX_EY?ZO+J1$0&6(K9VNBD_XC@WY^O^^X]^\,C_+UY@)!BGRI3B?\'^KR
MKTHL3C:FIF6FIPX\C1J#IU@,7C ]+ @7!8#@WXL/;;2"$%F. /7\CU>WVUKI
ME*C@P).>'^K_ %>ES/Q6V92]9]5[Y[&WEBZ?$;AEPM70;8Q=?#(DD$#1NC5%
M0)I J&::1'1A(K*HL(V4$+%?,5Y^])1H;@1YUP.LDM@VA=JM!*5%67TIY?9U
M6/V7MC/UN3FSSTL5505-2$J:RFJXZH+-INZ2K"KD-J!(8  W]1)(]C?:KP00
M #J%N9-H^LF+YKBAH?LXU'0+U6(KXRD4U.\+N 5$B:>'%[BQ8'_;_P"N/8CB
MF$X!]>@));-:U^7'B?\ #3T_V>LPP3:D))$LFD:06<7! )].HV'U/Y!X_K[;
MDC/$>M?Y]+XI68$(,D4_(C/J?/\ V>C&=(];/F<]2U&;KX,7M['_ .Y7,9&2
ML^UBCC0^-%D+M&P,NJ1>"6M8A>-0"6_;BKN%7B.)%,]#KD?8W)+S$@-Y'RX^
MM.E9V5VW7RU&1BHZ#&1QTE7/#CILE0PN)8"QAAD-/,\CO-H1&8ZG1666RA61
MO;>W6)!!)XY_R^O1AS;O,2R:5 [<5&.&/3Y?Y>BZU'9.X91^_5FIJ H5998A
M4!-)("1JP<6LH]=M1%E8L +'WTX44KQ_/_+T!$W=XV;2/.N:C[,TZ0F1K:[*
MU4U=7U$M15S/)-+/4N3(23IU7X-R%'T_XK[<MW2V.0#Y]-SWIN""S, ":@D@
M8_/_ %<.LM"Z12LKR*"Q1F9U)&HVY<F[Z+?[5;^OM;<AKA*Q^AST6N4,RF1J
M@TQGUKZ_/Y?X>CS4O=W4VU>H]E[8V!UQ4+VA04F:J]V[[SL-/,M1DLI(H1XJ
MJCUUDV/H*&")(:;7 (YI)GD>Q*N!YMHNFG:1BVDTH*&@  '[20?]529EVSFF
MTVFT46B*9=)UD&I9BQ(K@T %/YDG( 2.T^P,SN+>6'S&6JJBN9LQA:5X?MXZ
M>GA7S)&T,<*1A(8K.=0C;4Y(,FM['VY=6U(F]:?+JFS[_-?7"F8$!C2E32I-
M?3JR/-;AS=?+48Q8II2\CP0T]+2_<,6:S754MZB.%*\^DB_N/U*YK_DZF6/O
M<1C_ %?Y^F&79_9=(%FIMC;UDAF,2K+)M2O"6D5=3AG@75H.H%A*% #$BW/M
MV6_1H@1_Q6.F$6:&0HP-/*M>F'>7Q]I^P<1C,Q78:KQVZ\;!41++-1R4D=4M
M$S(ADAF4Z@-3H7L?45 8@#V_8[VZT5:T^WHAWKEA+RLA !^P?['1)Y\'@L(U
M5JI5>IIZF>&K17: _LLZZ05&H:&!') Y7^@]B+ZMYUHPP?\ -T%[:QCLSI)H
M/V="EU;VUN;8N9H*K9&WZVHFJ&JOXH*A:NII76&./E@"8%(=D++;R'BVDW))
M+A5U'H<[7N'A+2//Y^G2VW[4]B_)[/8C ;VS,6SNM:&0RU=)00+C$DDE?34K
M*Z/KJW">$11R3NJG4TD*NQ=DWU MN'2Z:PGWB1:B@X^?^QT,E-\;<>F-QN)V
M9M"48:D5H\56X"KFGY&K6:EG6*$U#J%$EUB]5E4H@7472;IK-/RX]'$.R):Z
M@GQ'CBE/3UZ0F2^.W95)42P4V/J90KA&,FJDN#Q(?3JC#7N00Y7\$D^V5O@@
M(X5ZL+4VY_4R*\#T4WY*=!56.I,,J8I1O5IF.5AQE M7&L,>EE-3)$W+F_I]
M!/UN;>SK:=T6,T8^GG]G0;WW;/JLQJ/R'^;H@VXNN<M1>F:AEI?&NLK4T[4I
ML%=BH#J03:*3Z?[Q[%O[SB8T!]//H!-LEPIX''R/0197;-73'2T8<MS&(Y/(
M?SR1;@?6_P#L/:V._C\LGY=,&PEM\M4#\_\ +TBZNDD3R!D;R(2I ']#S]1[
M<,XFX=*(EI4U_P G2;J(K:C8<D#WKI>CUZ:)48'Z'BP]M/QZ6Q$D9ZPDD6X_
MWGVD:O0BA"D#CU$E)\G!/Z?];VED/1C"HZX'_7N?S[:/2R(58>7IUC?Z#_7]
MZZ53!J=86(/]""?SQ[8.>C)!09].H;BQL4%O];^OME^C>)%(%/3T^?31.0O*
MZXVU<:1<<WO>W//Y]I7-.'1O%QH:''Y_ETP5EG(8%"Q()T^C\_TX]HWST:)@
M4SQ\\^?3++Z7'!])Y%OZ_3_8_7VR1TKXU^SKZ ?\V;K_ 'E_-1_D@_&'O/XK
MXNO[/R^R*KJ_NS/[%VM%'N'+3187;F6VWNK%TU-0ZC49G;N5KI?N:6!&D(HZ
MI(HFD$:&$>69UY:W:2&Y(0$/%J-0HJRLK9'PL%%":8()QU+6^QG?MN26"K?#
M)I%"3VE6&#\0J:@5R"!GK6#_ )7/\G+OC^8)WW6;#WMMGM'HOIK:VW-Q93?_
M '!F.NZJGCH:Q:25,-C:.+)K0T]?D*O)O3-+3+4*ZT4=5+JC98R9!YBYLAV>
M$-$T<LC$!4# XKDG2304P/F?.AZ!VR\N2[E*5E5XT )+%2#7R U#\S\AY5'5
ML/\ )3^.'7_PA_GX=L?%O(=P;1[FR_772'9VR]L[\QV!;;,=5N0Q[=R>1Q])
M1SU5:\.3QF+7-TU6B5<NAJ>LC#LJL2&^:]Q?>=FCN?#,8:925U:NT!UK6@P3
M2F/3H\Y>L5VO<W@UARL1S33W$H:4J<@?/JN3^=)U7\K\C_.9[EQ5+MCM+*=F
M]A]H;4R/QK?;\.0GKJ_&QTM -N/M>HAL]L>T2IJI9%%'50SEVCDCD8'G*5U:
MIM*EB@55;QJTH"2:ZAYU% *\10#TZ*N8[>X;<3I#:F*^$17R ^$^5#4GA0U)
M]>M@C_A2;D-LTU+_ "H=M;SJL!7_ " I^_,5D*B:F6.6L7&1+M^GW!*C+^Y#
MCZS-C%E0P"S/!=+F!]('Y(#D7A6OA_3M7TU9T_G35_/H6\TE:VH--?CK3UTX
MU?E737\NBW_\+!\SEUS7P-V\N2KEP,N+^0V9FPZU+K3/5P2[.@CJ9(01&\\4
M,DJ1NRED6214($CZC;VP0'ZAJ"H\(5\Z'Q"1^=!^P=%?/K']!:FGZAIY5&BG
M^$_M/0O?\*+<_FZ?^3/_ "_*"#+Y&&CW'O3X]#<%/%62(M<*/K/-U,2U8#?Y
M0B5*I,%?4OE1)+:T1@AY!16W.8D#$<A&.!\1!CTP2/LZ6<XN18Q@$Y=*_/L8
MY_,5^WIM^2,TM5_PDGZMEJ99*B6/8_0L,<D[F9E2E[-H88E4L20L<*JB@<*@
M"BRBWNVVBG,C?\U)O^K;]5OS78U_YIP_\?3KW\W/9G;F[/\ A.!_+?KNN*/<
MF3VGLWJWX.[J[GH=NM(5CV]3]5R4T-=DXXB&GQ5%G*G$F16#QQU#TU4Z 4PF
MA<Y;FBBWZY\0@%GN%C)_C,W >A*U'SR/.A;WN.23:(/#J0$A+T_@$?GZ@&A^
M7'RJ%'_(6Q^3V3_(O^<^Y._J&NI.C,[5?)G/;?IMX0M]C6[:78&/H<V]#'4E
MHY<96Y"GR--HCB\<U6E4H$DCN/:?G1Q-NT(MS^H!$IT\1)XA(R/Q %?LQZ=/
M\K(8MND,X["9"-7#P] KQ\B:_P SY]!)_)5_[AR/YM/_ )?C_P"^*VK[,.:_
M^2[9_P#4/_VD/TAY>_Y)-S_S>_ZLKT\?R-<_FMJ?\)Y_YINZ=N9*JP^X=M9C
MYOY_ Y>B?Q34M;AND-HU%+4PMSIE@GCC=#;AE!]TYPB6;>K1&%580*1Z@SN"
M.K\LR-#M=PZFA4RD'T(A4CHN?_"0RNJX_DO\N<:D[K0U?1>SJZHIA;2\N/SZ
MQPN?SJC2IG Y^CG_  ]JO<X?I0'^D_\ @7ICD,]\P^2?X6Z7/P9_EL[1[Q[-
M_FS_ "W[F[Y^1?6OQEZ.^7'R_P!H9_ISXU;LR6UJW<L.P'R&;S\.13'>:JR%
M'_ <K2TL-!2TWW5:TDD G5;1RI=YWIK6*SMHHH6D>W@(DE56TZJ**:L#*DDG
M K7''I3M>V">2ZG>2546>8%(V9=5*DUTY."* 9QYUIU:Q_PG[[1_E\]CM\G*
M?^7O\->U?COL7;3];4^]>U.VMU5>ZLANNOKSF#28XO-E\_34CX>DA^XDI:;*
M^.(Y /\ ;J9O-,0\YV]];F+ZZ=)6(;2J  (,9H%3XCBM,Z>..C;EB:TF63Z2
M)XU!74S9U'.*ZFX#RKBO#/5??_"5#+19_P"0_P#-!SL&,R>%@S69ZGRT.&S5
M$,;64B9+.;\F6FJZ=6<05, <)+&'8(ZLH)M?V<^X*>%;V2U!HCBJFH-%B%0?
M,'RZ+.3G\2>Z:A%74T(H15I#0CU]>JF/Y+-'64G_  H&Z?:KI:FE6J[6^9L]
M*U1 T(D2+979$#/&6 UHL\,T9(N Z.A]2L )>9&#;$U#PCMP?D=4)_P$'HBV
M52N[BHXR3D?/MD'^$=7K]*9+:=!_PK7^7]/N.?&0Y;+_ !VVOC=B+7Z1))EE
MZTZMJI4H]7/W/\$ILPQT^KP+./TZO81O58\MV]*T$S%OL\2<9_,CH1VA WR>
MO^^A3[=,/^2O6O5_.DZK^5^1_G,]RXJEVQVEE.S>P^T-J9'XUOM^'(3UU?C8
MZ6@&W'VO40V>V/:)4U4LBBCJH9R[1R1R,!GRE=6J;2I8H%56\:M* DFNH>=1
M0"O$4 ].@SS';W#;B=(;4Q7PB*^0'PGRH:D\*&I/KUM#?SG\AMFF^37\@W;6
M\ZK 5_R I_GUT/D*B:F6.6L7&1;@V=3[@E1E_<AQ]9FQBRH8!9G@NES ^F/^
M4PY@W K7P_I9:^FK2VG\Z:OY]#+F(KXEF#37]3'3UTU&K\JZ:_EU2)_PK=S^
M:J?G[T'M:?)54NWL-\/MJ9_%XAWO#!6[EWIOBGKZF-?Q+508G&I(;\K3QC^S
M[&/MI$HLY'IW&8J3ZA40@?EJ/[>@OSU(QN8TK@1 @?-G8']ND?LZL"_X4:4=
M;NK^4S_+;K3"^5W1F>P>C*.GJ#;S33[CZURSRH#Z5O4U$<)/T&H#Z#V'>0G$
M.X7!.%$4A/R D3H\YP4RV<(&294 ^9*/T+V\_P"8GT_1]"_'GK'^?Q_+4W?U
MYD*K#Y#![+[5W1UQB.U=O5V1VO18V+)U]%3TM6^Z-H9&NI9Z%YZ:GIY2[!U2
M4I 4A2P[)*TTC[-<AZ<55VCD"DFE=056 (I6OH:"O2B;=$6)%W. I7\159(]
M0'EI+%20>!'KDTZKU_G7_P LWX>8WX%=4?S%?A)V%V;%U*/]'6+VGUQO3=^Y
M=WX%MK]B'[;'S;<IMW/-G]N24LXHE-#),M+]LNE(*=X4$I[RCOUR+Y[&Z5-9
M+ZF"HKZTJ3J* !O/.34UKQZ*>9-H@:T6Z@9M*A2JEF*Z'( TAS5>(P*"@I3K
M6*P7RI[ZVU\;-[?$/";[^R^._8O86*[4WEU[_=?#5/WF>PL5%#2U_P#%IL=)
MG*?Q18^C7P09.*G;QW>%B[EI%?;()+A;IEK*BE%:K84UQ2NG\1XBO0'2_FCA
M:W#?ILVIEHN2*9K2OX1P/1>_:_I'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]Z/#JR<>IDW_  -/_(7N
MTWQ'\^G_ /11_IO\_6^[M#_CQ^OO_$<==_\ NDH/?$'W:_Y6;<_^>R;_ (]U
MUZ]N/^2#8?\ /+#_ ,<'3_[CSH:]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW5WWQ]_YDMUO_P"&S1_[VWOI'[7?\J]M_P#SS1_X
M.L!O<G_DNWO_ #7;_ .AB]CWH$=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6+\NO^W@O\I/_P 29\PO_?0;@]G6W?[B
MW?\ S3C_ .K\?1==_P!M!_IW_P"K3]5>_+!6J?YB?SUI9(2U%%WCU3//,TRF
M,,_2?4^E6B(!;4$/.HV_I[D_D>33MJ'YG_CW6.?N+%KW20?)?^.GH,EBS]34
MQMAZ1J>D4Q".J@@<%2EP0)+ DDL-37'KOR%)]C 3^)QZ /TGV]*"+K3=-4::
MMK88X)*K_*(7K:^)96^Y'I9*=#+-(7&DG1&UKW]M&18B37]O3?TK:\@TZ'#!
M[5R77F,?+Y_:45?!5*\-+'N+&S NTR@\0L].PB9M)_<D5B/I<^TKSAS52*_:
M.C V?;T%V\=F]=[PHY15;2I=M_?N:GR8_(G;M)&ZDM:BHHZF* :'TO8H^I@C
M/<JWNUO>.A-.B#<MG2[XD_R^?5;_ &-U=@GKLKBMOU_W,$4OW,%3,:>I,<ID
M+E>%8%F)!(9K$7'L=[=N<L8J/0?X.HKY@Y<BG:AKC'EY8\^@<J^OL/CVE)FE
MDKHW\CM),D2N6Y5FC5+#^@'T7CV=KO$CX>E?MZ"<W*]O$N*U]*#I-G9!KZYI
M(S7ACIEU\3B-I";L&X#+&.'N1R+*?Q[5)N*KW5&/MZ+X^69I&!4,5KG X?MZ
M.G\6=E;KI=Y1T6V,QC(Z>H59LQ/GZZ# T!2*-[+**J=$!C'C36K%@#K4V!20
M+[[=?4(0!_J_9U*_M_L,E@6U5&KUIG^?5K'8GPXPG]V<CO/8,,N^LFT,55D,
M5MO+PLB/(%:22BGNZS>AI6L2"54_K)YCF3<GVYL#CZUS^SH=S;40PH"='Q4\
MAQ_S_LZ*WL/;:392*@Q> K_XI)(3#"<H))(V#7T"26.$$V!)NRV-P''LW,HN
MHQ(:5/1LMFJ&J^?0L;^ZHVUAXL=E<S2I)DI:99\A154C<3+;@*K1:B5\6H@(
M;)8,5'*%+QH2:#IN6R5LGH.JRCIE@6+"4$%+1J5AI:)%$&O4Q:Z*Q=BS%1=O
MU#ZCZ>WOJO\ 5GIM($K4?MZ%'K_<NYL7",))@X)!+4!@];=%(T,K1%PP4R$%
M-+'U$+=2'X9B6?5^SHTC((H.'#HPG6.^ZZ)\CCJV7[S!31I2?=4,S3@QL'5U
M64@$WE+:6!L2J*+Z2/:"60GKSV2N#7_)TG,_MJEQV12:@EG-%E?&DM1]^BRM
M+4L=,08*64*>  QC%N!^3H7)4<.M&RB4= _\H:7<>W-G[3Q>P,CD:*JS=)X5
MJZ2L@AED>CC9O*.1*2JJ]I8H!9Y!(Q!(]J[.1I7&OA7'V=!K=E+(5BXBHI_+
MJH+L,]QU-2W][,[O.7(NE1%][F*H9?1&UY'75/$%6)/* RKJ*@%.- 'N2+*6
MW50%8?//^QU#NZ;=?2$ED:F0.T?YS_DZ+WDZK*15%109%X:BII]5.M33TH0#
M5Z&*JJH0/&2;%>".>/8IM9HM/$=1_-#/'5&4U(('VD4_U?X>FAYLW*LBQQU-
M8(@HC$W^46*$K&5"D :6'/)XN2I%_:G5$HJ"/V](HX;H'2%8_E7_  4ST:'J
M/I7N/L*@DW S5NT=B4&(GK?[UU-;44=.U0',5+3T=/%4QO4U4DL,DK,@M#'9
MY %8>PYN.[PQ2!0034?ZL#J3N6>7KV6%G=6 \J@?Y2.@:P>]^X'JY*?%5&Z*
MBIE5)Y<9/6-G0ZQJIE!299_#%&C 6D9D!9?43:RR1;&9 \K >F?]CHAA_>J3
MM#%&2@;XM.*#'DWSZ.#B=F;@W-M^C_T@8_ UV0UQ-!C<AC*6I10"6U#2)Q%J
M95N5 (Y91>WL'W=^ENQ$!!'^K[.I.L^6GW*.MP&%1D4'^4]+FA^*'4M300Y?
M+[8K!)7IYHI*#-5-#3@N3+#HIU9R#= 2#($&@:0S:V]IAS5-Z#]IZ6+[<V7J
MW[%^STZ76 ^$G1678TV:GW+M[(5$,2T5;1[EIX6C:!5:*+P38JI4:DT(&:9B
MO);0+,=?ULF4T '\^KR>VMDRY9OV+_FZ36:_EV;.DR4^*Q>X=ZO-'15#0/7'
M':*O[5W\82;^'01^=M+E=3,74C]3%;J5YTGC' ?\:Z)9O:FSE-5+5QFB>7_%
M=!-N3^7[)MW%9O-QG?2-B:M/N*>?%4,,#4QT(SB6/S'2FN0OZKV%U-[ +;;G
MZ=3^'[.[HFN?::"WSW^>:)_DZ .K^-FTZ"36F[:RG\K.DIJ\7%6QQ!T#1%D!
M1QY)) B"X(*AB0.?9Q#SE+-DZ<YXGSZ*9.08X?XJ#Y+]G2^ZVZGVKM+=&.W3
M4UM)OF+!STT\&!JY'P$4E082JM4324M8_P"W)8IIE9KDZO&#;V6[CO9G6C$>
M?KT?;%R>EA.)$KCU _R$=#OV'E=]=LI!0%J3:^!IX_3MW&9(5H=YXO&LD\S?
M933*0J!8M)6$GTA@2P#UC,D3$L1GH6[];3;P0@4X'$"OE\^D7M#XC=G[QKM&
MU<5DLM*Y9RL96@T03F,-9GC\<BH3>RO)J$?Y:WLP;F*. 4#+^T_YNB&UY*GI
M0JW[!_T%T.V5_EB=UYV5OXFJ12S1ZDJ)*'+Y Q:4"QHTU-BY(7,<;: $#A;!
MAS:[<7.C6V %_:?\W5KGVP>\R=9'#@A'_'NB]=H_%ZB^/F0HJ/>^U-\[CS,D
MQJJ9LX*7:6#J$IRBB1/55UM?Y+O^FGH;,K%Y$:1#[4+S2;]M)I0^>?MZ0R\@
MP;6*E&9AD+0?MI0]%XW=O#>N7AQ]#B9<7M_!P235>)Q&UEIV2F+*26@UJ\BN
M1<&1'# !B2JBP/[&>-LDC]OSZ#>ZB_<>#""BCY9'^]%>B\56/GJ:BHJ9Y3/5
M33322U*3?>2%]0-W;FY-[,2[6^G#6]B>*Y7^(?MZC&>PG9B&1C0G\-<_E7_#
MTU28J8,B)$TDT@E/BA'EU-=%!1HRP9&++?GD>W6GB_&X_:.D4NUS(<(_[/Y?
MZORX]<QA,G)*B0T,S"9P$UND9)0,1I%P2-')%N!:X]LF_ACX,,?/IQ>7YCE8
MS7RQ]O\ J].GW&;0R-75"D>EJ/)"[M)'XB%]/T5"+$LUPUQP-//M(^]1$UU+
M^T]&%CRU=,XU1N"/Z(^6/+H7-C]=5^6J(\/C8ZG,5T[1I1T-&IK96:<'Z(K!
MWT&,)Z2#];$6)!)N.^I&"P(X>O\ L=2)M7*<H(JK\ /A%/+Y]6.];_!+L[;\
M.!WAV!MZ'"87^(T%=BJ!\W3I7U4B U").RS1+0NTB,0#Y95T$>$$\A2]YG:5
M-"TX_P!+T/4B[3RI]/)K:O @?#C(^9].K",!4KAOXGD-D]0;NPU%D*2*FR&:
M-5%EXRL(4^1JH4TX:X"\23Z7:-2#'<>PM/KN34CY_MZDR&"*):5_F.F+.]\4
M.'AR39KL'/5D[Z_!@\=V!CB'5D\3&4TA_P EC34X#3PEM3:0#IX<^F;T_ETW
M)<1KP(_;T!.;^0.)W"9(JC?=/M[;]?'-!4QTD[5K,K*S/%4U$,9EJ+LKZ@DD
M:D\F+U L[%:&E<^G#HLN+N*0=Y'#U\N@7RNV/CO+1PU>5J,-D8*])1255/4U
M>'$K+=M'C>2!4Y:1K.J'DD:K $P6X:):<?V]%[[=;3 NC=PX</L]/MZ;:#!]
M1TS+2TNP(:FB>*ZID^P:S0RRN7(TTS03R1M=CI6JTZ JWXY32S._ETJM+)(<
MU_P=++&;IVOC3'2G:>W:&DIHI*7$"CIFSJTLO+,3)5RR/)9@+D,K_D6/M-H8
M^71Q;NB$Y'Y]#_LS>&0B,.8GEEGPR>2"#'4#K)31^M75TB15"*9%:/U &Y/U
ML6;QBJ,CHY@B2:I)X4]//I4[@WA2H)65L/)"YJ--+5534U0 ITK((B5X/%P5
M-OH1^/:=H*D5KTQ+$!PZ+GN:L@W)7RU&<IM/D\$=/2TE,*O2#=5TEHY+2$FY
M+,%_P'M]80G24P5\^D?2[&Q&^*&HQ.8\ST]$_P"WN*#;]! ^@*6\+ P@EM)=
M?J38_P!>/;379B?2/+_*.D=WMYE6HKT N_\ I_;&U :BHS%)D*>>1F.W9-HT
M<C2I$#P\CDE48\,3H']D?7V8Q7SCX?3Y])[?;U8:7J/\_1*-^]+=3[E6:/%8
M/);+R&F62.IP>1@>)I+LQ67'S).D<3"ZL894**1I1R/9I!NDJ>0_U?GT7W?+
M4$_KY\*=5Z[UZ_S6S\K4X_)4$JPK/(E'7B$B*H U,ICL OT(]/ZA^0+'V*]O
MW!910D=1_N6UR6#4121Y&G']G06U-+)J)>-EMJ (L>$//T_I_OOI[6LH4X\\
M])XV9/(C_53_ "=-3"S"WT!_WQ]L.*='5O*9,GJ+4'2!Q_7_  ^MO:1U!Z.X
MI"I^T?X.L/M@BG1K"=9'7"3Z?['W1N'2QZ$BM/SZBM<V/]1]?;)Z,X"!CJ&[
MDJ0"?\/]X]L$UZ-8U H:=-4SO?\ !%K?2_M*Y/2Z.-0V/2O^#IEJO5P54G_B
MGM*^>C6$4&/7IFE')'(M>]N?]X/MKI2.K/?Y>_\ .!^9?\MJ:OPG2NZ<)NOJ
MC-9#^*9SI7L_'S[@V^]5*8A+7T(IZFBR&(R$L491Y*.NBBFNK5<%28H= :WS
ME6UW[ND!60"@D3#>= :U!'VBOD"!T(MIY@N-H[4(9*Y1LC)J:$4(/\LU()ZL
MJ[Z_X55_/CM+9.2V;UAU_P!)= U6:Q^0Q^0WWM;'97=6>IQ6)XUDQ,^4R#XZ
M@F16D/E?%U,JOXWA>%D)<@LO;BT@;5*[R4((7"J:>1I4FOR(Z.[KGBXE6D:(
ME0:G+'\N %/F#UKI[%[C[4ZT[5P/>.QM_P"Z=N]O;:W8N^</V)29:67*IEO,
MU1)72U4QD>JEJ)7D^X$_D6I621*A9$DD5AW-9Q7$1@=5,9724IVZ?04X4\J<
M/+H(174D$@F5B'!U:JU-?G7C7SKQ\^ME3:W_  K*^<6)V538K='1/QGWOV#C
MJ&MI,?V)78;.X8-).@5*BKQ5%F8X7D+ &9:6IHXY0 JI#:Y $GMK;,]5ED"5
M%5HI-/.C4'Y5!I\^ADG/4X2C1H6H>ZI ^6,_GD5^75$/R+^=/R-^5WR2H?E/
MWMN^+>_9.'S6W,IM_'U%*]'A,93;4JDJZ'$8W&P3(M%BHY4):**59)7DEGEF
M>IEDF886.QV^W6S6T((5@P8XUMJ%"2:<:'&*#TZ#5WN\U[.)Y""RD%1G2*&M
M *\,9S7Y]#O_ #(_YK?R'_FBY/J/*]_[-Z7VA4=,4&],?M=.GMNYS;Z3IOJ3
M&259KQFMQ;@:5HVQ5/X3"T 4-)K$EU*)]AY;@Y>UB%I&\33765--.JE-*K_$
M:\>G=WWR7>M'BA!HU4T!A\5*UJS?P]*+YI_S@?DM\[/C5TI\6>W-C]&;=Z^Z
M(RFT<MM',=<[:S^(S-3)LO 56W:5<E49/<V7HIDDHJR5Y1#CJ<M.%9"D8,3-
M;/RK;[+.]Q$TA9U*D.5*T9@V*(IXCUZ=W/F&;=8EAD5 %(8%0P-0"OFQ]?3K
MV]/YP/R6WU_+MP/\LW+;'Z,I^B-O8O:F)HMVX[;6?AW<T>S\]%N*F:6OEW--
MAF>2MB5)2N!4- 2J!)+2#T'*MO;WQOPTGB%F:A*Z*NI4XT5X''=UZ;F&::U%
MF530 JU ;512",ZJ>6<=&LZP_P"%)/S]ZDZY^-'4NS]K_'>AZ_\ C3U[M+JJ
MBPC;*S]5_>O [/P5'@*:EW4:G=-1!-.:>A@J/N,=38V5*K68RE+++2R%MUR#
M9W<DLK-+JE9GKJ6BLS%L#0,9I0DX^>>EMMSA<VR1QA8]**J\&JRJ-.>[CCB!
MQ^6.D=_,$_G_ 'S ^>_4,GQ]JMM=;]"]+94XUMX;5ZII\@*O.+BY?-#19'(U
MU9,1B$E2GD%'34T >2(>>2>.T2N;)R1;;/+XY9I7'PE@ J_, 5SQR3]@!%>J
M[KS7/N4?A!1&A^(*22WRKC'R ^TT-.BX?%_^;7\COB;\*OD/\$NN=E=)9KJ+
MY+_Z6O[][CWKMS.Y'<=)_IEVGC]G93^$5E#N3&XR#P8S&P2TOW&'JM%4TCR^
M>(K IEN'+4&Y7<5Y(T@>+1I"E0IT.7%05)XG-",>G1?9;Y-8V\EL@0K)JU$A
MM0UJ$-*,!P&,'/7OB_\ S:_D=\3?A5\A_@EUSLKI+-=1?)?_ $M?W[W'O7;F
M=R.XZ3_3+M/'[.RG\(K*'<F-QD'@QF-@EI?N,/5:*II'E\\16!?;ARU!N5W%
M>2-('BT:0I4*=#EQ4%2>)S0C'IUZRWR:QMY+9 A635J)#:AK4(:48#@,8.>D
MA_+E_F;]\_RQ-_=A=B]";2ZBW=F^RMH4.RL[2]O8',Y^EBI:"M2N22D3#9_
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MNR?Q/)U>5HTQ4BU\F7QW\%J*ZJCHF?(U)%/*\=4*IB)%.]XY6@WBWC@=F!B
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MQ9_KRSM<'VY^FO'IMY9":"M/Y],JUE5#1HU"U53/)42E@%:(6(:-@NDA0R@
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M=>]^Z]U[W[KW7O?NO=>]^Z]U6+\NO^W@O\I/_P 29\PO_?0;@]G6W?[BW?\
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MY=[]70328WJ'9\$&T*B&E;(8:OHJG8"ZYM2L)XL9E7%<!'XO75 3>-W0J=*
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M.'#H+=QT5=M>2J^YHC#/)62M$K%S))H8,)"MP%4Z4(Y!TL+VO;VK24,*],3
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M[/MN2?PAQZNEN^K2%QT(V(Z7R>9T2YM8Y*>.LAAK<-ML#+52*2I\=0X/AIY
M66P G/Y>,"RLDDW31PKQIT:Q;4L@[@/]G'0JX7I/"8"L:MV[MN+"RUM+CH))
M\VTM16R&G!D#S>9S%%4L)%)$5'&#I"B(*HLD.Y%_^+Z,(MIB7T_9T+:8'.ST
M<%/49Y*6CB:22NA%'/6P!/+I0M)(D=,-.LL?4 I(#,MK^VV?6/GT8P0+!]GE
M\NAEV9OK:6R,2,5F]PUFX8D,03'4%!2?:#6LB&GDFJ9KZFD6,Z8Z>0#7Z7L
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MA:4CU+?TDK=R;<$@"X_'^\CWKP^ED=S7_-TB\I7B=2LIECD:]PH"VU:#;]3
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MDW_ T_\ (7NTWQ'\^G_]%'^F_P _6^[M#_CQ^OO_ !''7?\ [I*#WQ!]VO\
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M'; Q^/U05N<DJV2;3'+%3^;5H!D]+"GC,?IU@#QV/H&KWHWI.*_SZVJ4X_\
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M]M'7O]D;[9_YZ'KO_P ^V2_^M'OW_ V;[_O^P_YRW'_;+U[_ %_]F_WS>_\
M..#_ +:.O?[(WVS_ ,]#UW_Y]LE_]:/?O^!LWW_?]A_SEN/^V7KW^O\ [-_O
MF]_YQP?]M'7O]D;[9_YZ'KO_ ,^V2_\ K1[]_P #9OO^_P"P_P"<MQ_VR]>_
MU_\ 9O\ ?-[_ ,XX/^VCKW^R-]L_\]#UW_Y]LE_]:/?O^!LWW_?]A_SEN/\
MMEZ]_K_[-_OF]_YQP?\ ;1U[_9&^V?\ GH>N_P#S[9+_ .M'OW_ V;[_ +_L
M/^<MQ_VR]>_U_P#9O]\WO_..#_MHZ]_LC?;/_/0]=_\ GVR7_P!:/?O^!LWW
M_?\ 8?\ .6X_[9>O?Z_^S?[YO?\ G'!_VT=>_P!D;[9_YZ'KO_S[9+_ZT>_?
M\#9OO^_[#_G+<?\ ;+U[_7_V;_?-[_SC@_[:.O?[(WVS_P ]#UW_ .?;)?\
MUH]^_P"!LWW_ '_8?\Y;C_MEZ]_K_P"S?[YO?^<<'_;1U[_9&^V?^>AZ[_\
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MTD6Y/T"Q;J(<#T7_ +N9?PG^70=3XN91JC$$DQ+AM"K&65Y"219B040W/IY
M_P ?:VWDC;_BQT5RVL@_U'IA>DD\3CP.)"5D=5%[A%:]A] !J^OLP:14IIS]
ME.D?A.IZYN:FKEU!D5V1A'ZF(]2J ;D$74K>WNGCZL =;TM45/375GQ*> JP
M%F5G4,Q"D7T_6XT_X"]K_0^[1@])KC4G$]-,DVI%\BNP-R&C!_M_H)0?U!_I
M];>[FE>%>D<<32=V37SZR&,K&K)(R@.")&CN0H*W 3]14L;?0\@'W7 \NE3Q
MN. -:].JUU=24D30AED9U!DD74+J;%K,0NDFX-OH?Q[]J'IT_'X@Q0]/,<M;
M4E9Y9YG>G^CAI(VTH$"1J4%Q;2QT_DV_%_>IF\3@.K!V!!-:>G2II\O49&G%
M-XX!5-&?)//2B61V!,A8IJ-KGC2(R!=2;^FQ;+%Y'H^M[^H%/(CCT*NU>X.Q
M=G4].FW-Y[LPR!/VZ;'YB6DBE(1(I-:"19-#>-+KZ+ 1V $84ELUCKSCHY@O
M@:>O1]>BOF*K8VEVGV ]&TDOCDI<G,T2_OZG\OE= I74AX>2.9B=6J]_:&XM
M213H^BN$G6G2H[@V)0]BG^\&R9H<=N"BQJ?>8N5HVAKXP%*STN0I8E1'UC2$
M9$"VOP6M[* &B:A&*]-:# 2:5K7AU73N&:NQ5=/0[HPM7!-2NE/5X^LI!))>
MY;67TW=>03R00;FQ/LWCD XGK94R\1]G0<Y)-DS-//+1S4T!IY4A2BD=-/E!
MULMW#B]SP&5/S;VO28D8Z3_3*OF.H0_T;,!+-3YZ:UKZ7@0%@!;2SLS$BQ_/
MOWB-Z?RZVL('F.LS;NV'BX)OX3LB2LR&DZ*W-9:293H L7@IV2.2[7X+$$6!
M^GO88MQZOX2D\?\ 4.@XW%V9NC)4?B%=3X7&4A=XL7AZ<4$%M"HRLHU,S,%N
MQ9V^EP/;JQZND\KJG:,YZ!2KW5D)DJ'JJF>2+6 B15#<:KCF[,MR+<Z1Q;@>
MWUAIQZ9U@^O25?>.?CE9Z'*UT#*/0:*M: KK4\C18EB+BY_K^>07A"!UM"%'
M"O49=\T&:ADQ^_L%_$:F60^3<U D6/R%U9?&:A88XHJK0H(U.I8\<BUQ?0>(
MZ<\17&<?+H/\OL^>I@-7@ZV#=$ 8%Y<?3_;UB-(  D]&K.T;EA]5=U&H7-N?
M=XY2IR/MZ8>#7@$5\N@NK($5AK9H_JNHG58_X\W!M]1^#P?I[5K*&Z22PF/C
MTWQ?Q&@J5JZ&29:A6U0STT@5E\8NP!L1IM]1:]O="23PZW$*'CUQJ]R[@F\P
MJLE62EM;@^<AAKYL=1(M?Z<#W1UU4Z-%>J\?\/3;-FZV>!4GJJB6R'3*S+:X
MX' 6QTCCW8+IZJ<^8_GTF:E\D/5!5U+HX=R8ZDH!;_:0R_[W[L>FR#Y=-9_C
M\RAHGK6);ZEC,+'Z$ZBUA_K^_=6!'G7_ %?EUQKG?1$E=71Q-%&JO&/W#<B]
M[ 6_WD^[H<];TAL#^>>@NR<4&MG#-/=GNYNO];7%OP/;QSU=(R.!H>F"8*$^
MB_H( ^O^^X]LN.C" FM#7CTG:E1;4+#G\?GVF<=&9.1TR,+$@_4$CW3I0.NO
M?NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=<E.E@?Z'WXXZLITFO6=%_R@)?_-4\ES;ZZB/^*>]4
MICY'IR,'Q5/^K/\ Q77UJ/BU_P!DR?'/_P 01U%_[S^/]XSW7]J_^F;_  GJ
M?H?@7[!_@Z'?VQTYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5B_+K_ +>"_P I/_Q)GS"_]]!N#V=;=_N+=_\
M-./_ *OQ]%UW_;0?Z=_^K3]5._-6A>;^8/\ /F8QSO G=74Z 1L%];=*=3V"
MV]6KG_6Y'!X]C_E68)8+4^;?GW&O4&\ZP%]Q:@\E_P".]!#M_9V[-PUR4F(P
M%9D*@TCR/(B.D2!"/\Y4,GCC-OJ>;"_^/LSENHP,?X.B".RDK_J_S="[#U?@
M]LHM5OC=.(2:$S(^"VZRUU0SNJ2*C2*$6)G2(Q@-=@VDH%)8E,9?$R*T^?2Z
M.W"#/'TZ6VVNW*';M7#A^M-J8#;CU(J&?<6Y*<9JMET.2GDG:1TIPL>HJBH/
M42(R3$S%MXRPQT^NDX''I?57;M?%4JV<S-7F,HD \\L]8\R!2 -*K(9&T79S
M8,+V%QQ<HHXFKQ^SI]943_BND]E.\]SXJ"LAVIF<EBH):>U6<95R44KA%8 E
MZ0K*N@&X4N+M9FY]J(XB>/5Y9E=<?X.@J?N'=HR%16OFZMYD:E DJ4-2U0WJ
M9I-4B2-'I5402 EB#9RUA928Q3I 6"GSSUSK^V,QF8:DU='BZFLDIHQ%7"@_
M0I4$J$B\975(3I8L)!?FUA;T,8&>JF44J>D1#OV&N66&;!X^GKQ*(VE3%+$J
MIJ$=E760 [>IKKJ:P!86'M4#_JKU=)UK_L=+W [QKC :04C28]8*=17TT_CB
M#0>3SR2IJ(1G=X='B;Z>2Y)'M'+Q/3H-3CH9]K[ZHZ:N_ATRR21R(:=:F%G1
MV%3)ID7R%@ZH8RS(UO2%*N%#6*0Y'1G&0!G_ #]'2PO=F*Q>,9(L=_EE2T)A
MK(:&.KC@C.A6"K4L4N2SFY:_.JY/)22#'6]&H] WN#MG-Y+(39">>LJ?-4F&
MAC9T9$2,ED"TZ,(H]"/I+V)=?26(X-ZCUZ:X=0J??.4?S&98W:P"_>&2<>OU
M$+:500QU?ZI@Q)(*DD;I7KQZ4E10T&ZJ3#',4*318ZHCKTBHJF6CC+^%X1YH
MXI%6:-?/K6.7]O7I?3J1"*,=(KUIA4=.K46(F8BED^W5H=>FIC,:6*@J%;5X
MT73:P!+$W_K[:$M.J:!UUC\?AFE+-',CKZWGI@ MY.-.D@E06-[#C_"WOU:]
M.Q1@]"#M[/2K'4XN:>NR&)E2.G3&5#O5!0'.LLVDOH8$@ -8?3@6]^UZ.FY;
M77P\OGTI*3JNMKZ@5V-AR='CR@DD,\#)Z9. B.T81B0;69KC_ >_>+TR$TFE
M.A&VUUCX'4R34.-I:=I'DR.1(DD8*RC2!JT^3QE@69RO^' ]V#$]6:,@]#5M
MNAH,54RTT<E,*5%AB0P57E+\#E@/2Q)()/\ C_K>VIF)'3\5MXB@_P"7T-.E
M>V.QT<Z5</G+:F=T,FH$6X)!/T!)X^G/^V1NY _/_/T\VWA14>OKU):"\@=5
M,<S1@^-I#HT_072]OK;G3[:\0]-^ %/02;[[/3:U3'C\6F/GJ&C::9JN=X@J
MPL@<@+8KI0L0&MJM;DGV_'$7X])Y'\E_/HFFXOD]BZMHZ7)Y?5(AA22JQFU)
MJQ/($)D\8J=>G2[, 2"B@<FUO9A''H'3) 'S_GT#>YOD*CN?X7F<UD+ RJ\K
M0;>0D  Z11M$&! L'!!_H+>_-5NMAPN>@ERWR0[+6DKL9AZ^GH8I0X\[YJLR
MDRB8>H&26KC(8\6-K\GZ_A1%;%^/2:XF\AT5+/9S<=14U-1+4UT\M1++7U-2
M:B:1S(['UJ 7LQN3JU7!L+_U,HXPM/L'1>7;CTA9-Z;KIY%%+N7.02HS*GVV
M1J*(@.""6T2(2Y%[?DV^HL+*%CU<.DKW!A'V_GUPB[E[-HI(9?[UU]4T,@91
MDF3,*H4DVTUWF4:QIU #BUA:[7N(=6.F4OSFO2TQWR4W^*5Z;,0[,W32()I(
MJ7<.U8/&V@Z3J2(PQJ"+L/"J,"UTM[4M9TS7^?3BW@;_ %?[/2MV9OCXT;LR
M/V?9'6.[]K53H\IR?4NYV$"O(A]:X[-RU4?*J^E8IV%["VH^V'MRH_U<.O-,
M)&S_ ,5TY9;K+H'<%3)'U?W;1T&48R?:XSM7#G:[7(_9@.1@DDH/)J,BE@ "
M+DJ.#[0^&5-6K3S_ -5.MA:_"?V](:JZ-[QVR),KB:>3-4T,:^*MVANBFR](
MZ*SJH%/(\#S@JS65(&U"YX]JH[F./C7]AZ:>-C@4Z#_-U]89I%W]U_CH_$DE
M-55$FV3LZLM,RQW$T4=$64HI*AO)JU*WJY/M5'<4S4?MZ2R6E>(/2?K-H==9
M>EF.W\AN3!9&ELLE#G,7%G:>=:D>I(Y(5IJF%ED)"D1SZA<\6%U1W#PZ>?\
MJ^WI.;%7XT_;TFATSF,TE15;>RFVLS!!3BH,&.RZT<XCL2+T612@JP[1W-A
MQN!P?SM=SJ?]C_9Z3'8PV1^RO^QT&^YNO,_MZ&*+-87+X>H)],.7II(XR$?2
M-$SK%=7U?J5BEQ8_2P-K:_!\QT7W6R&G _M_V.D>VW&B265+Q^-QY27:IN+
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MH'TAB^D6"V^B?D@V*GZ&XVRCJRU'#IZR]=+,KF6;]R>58X2KL"HC  ^A)O\
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M(B3$BEIHT8E=!)-P;<\'_;?XBZM&5Q4]52)@<=<5EJHI%BBII'#B1Y(W$O\
M:]5E4@?60RV-_P K8BY LZ(PITX[,AZ5VW-W;YV=6M6[7SV;V]6R!D:6GKV5
M6"W#"2(K)3SH;_IE@<6MZ;\^TYM(VZHL[0YZ,9M/Y3[NH\;2X?<>WL+N:'_*
MDJ#!*-OFH$KW824L<%1C6#0R."5H4U/<N+!F=%-8A.%.CNUNA<CNX?/H0/[X
M?&#=T;_WCV+_ '%RLJ2K++B\954FAF4699<-,89K'A7-$JK<GQ6]/M$RO$<=
M/-9PMF@Z2C];?'.MO#2]]-B()2[10[@PLV2,1DY*KHHJ._V_T)N[VO< \>]
MN<=-F!5^']O2:?;F8P;52;.[KZYW%ALD]141QT78D.W7F*SI(C)1ULM-#Y9"
M#J#SF1-132U[!T:UZTMH9/B/^K]G4:3:U#/7(-S'9D4TD:R":?<V&E,HC#.2
MLE'6#F5G#,I4DZ48D<CVTT\@/3GT,9XTKTK\KM#IK;% QQ]?L7>U4U/+DEQF
M.[)@VG&SM&GGA(R$^/<.A\@8F)@7/J\B^I=K</YUZLEC&N,?ZJ=!9+M?#[DG
MK8*#;@QFFJD6BQB]K8#*R!*OEXQ LYGB;4X)O+*KR:V! LK7$C(:](+FS4G
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MO4/3I\GY]+_#=L;N2'[:BW169>AAB6 T>Z()<W'%)2O8,TM3*DRB-9 & D
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M%/\ .?!S\W+V!.U./6%_V_NG[WL/XV_WCJW]7K[TB_WI_P#H#K'5],_S=ZI
MK_R_^M_2JJ-7SJP<E@ 1IL=J$!1P>/S[L-ZL?XW_ -X_V>M?U=OO2+_>W_ZU
M]-Z=#?S:4T-_PWUUPTHOK8_.;! 6/^I']TS9O\?Z>[?ONP_C?_>.JMRS>OQ$
M8_VS_P#0'6;_ $$?S8Y(S#-_+WV'&I1D\M!\\L!2NNKBZ$[.:QM^>#[]^^[
M_C?_ 'GK7]5KS_A?[6_Z Z<8.F_YM5,@6+^7OL9) C0FI7Y^X9I71@JGR/\
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M"'\V6&2!_P#9'^JZIX69P9/F5@XV),10:77;UU9&.I#I-OR.?='YDL:?$_\
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M^<F J%!;^JG:2ZO\>1?^H]M-O.WOQ9^'\/3R<JW0X^'_ +TW_0'1<]\_"_\
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M_P"%?[VW_6OKW_0,Y_-P_P"?5]6_^COP'_7_ -^_UP-O_B?_ '@]>_J5>_\
M"O\ >V_ZU]>_Z!G/YN'_ #ZOJW_T=^ _Z_\ OW^N!M_\3_[P>O?U*O?^%?[V
MW_6OKW_0,Y_-P_Y]7U;_ .COP'_7_P!^_P!<#;_XG_W@]>_J5>_\*_WMO^M?
M7O\ H&<_FX?\^KZM_P#1WX#_ *_^_?ZX&W_Q/_O!Z]_4J]_X5_O;?]:^O?\
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M?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IMW^_9_P#G"G_6[KWBW7^^X_\
MG(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_4V[_ '[/_P X4_ZW=>\6Z_WW
M'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZFW?[]G_YPI_UNZ]XMU_ON/\
MYR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4_P"MW7O%NO\ ?<?_
M #D;_K7U[^._SH/^\._A?_Z5=FO_ +$/?J;=_OV?_G"G_6[KWBW7^^X_^<C?
M]:^O?QW^=!_WAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\
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M_P#]*NS7_P!B'OU-N_W[/_SA3_K=U[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\
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M]^IMW^_9_P#G"G_6[KWBW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\
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M/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L0]^IMW^_9_\
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MN/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4_P"MW7O%NO\
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MAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\
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MJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\
MI5V:_P#L0]^IMW^_9_\ G"G_ %NZ]XMU_ON/_G(W_6OKW\=_G0?]X=_"_P#]
M*NS7_P!B'OU-N_W[/_SA3_K=U[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\ Z5=F
MO_L0]^IMW^_9_P#G"G_6[KWBW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[
M-?\ V(>_4V[_ '[/_P X4_ZW=>\6Z_WW'_SD;_K7U[^._P Z#_O#OX7_ /I5
MV:_^Q#WZFW?[]G_YPI_UNZ]XMU_ON/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_
M]B'OU-N_W[/_ ,X4_P"MW7O%NO\ ?<?_ #D;_K7U[^._SH/^\._A?_Z5=FO_
M +$/?J;=_OV?_G"G_6[KWBW7^^X_^<C?]:^O?QW^=!_WAW\+_P#TJ[-?_8A[
M]3;O]^S_ /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L
M0]^IMW^_9_\ G"G_ %NZ]XMU_ON/_G(W_6OKW\=_G0?]X=_"_P#]*NS7_P!B
M'OU-N_W[/_SA3_K=U[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IM
MW^_9_P#G"G_6[KWBW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_
M4V[_ '[/_P X4_ZW=>\6Z_WW'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZ
MFW?[]G_YPI_UNZ]XMU_ON/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_
MW[/_ ,X4_P"MW7O%NO\ ?<?_ #D;_K7U[^._SH/^\._A?_Z5=FO_ +$/?J;=
M_OV?_G"G_6[KWBW7^^X_^<C?]:^O?QW^=!_WAW\+_P#TJ[-?_8A[]3;O]^S_
M /.%/^MW7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L0]^IMW^_
M9_\ G"G_ %NZ]XMU_ON/_G(W_6OKW\=_G0?]X=_"_P#]*NS7_P!B'OU-N_W[
M/_SA3_K=U[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IMW^_9_P#G
M"G_6[KWBW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_4V[_ '[/
M_P X4_ZW=>\6Z_WW'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZFW?[]G_Y
MPI_UNZ]XMU_ON/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4
M_P"MW7O%NO\ ?<?_ #D;_K7U[^._SH/^\._A?_Z5=FO_ +$/?J;=_OV?_G"G
M_6[KWBW7^^X_^<C?]:^O?QW^=!_WAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW
M7O%NO]]Q_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L0]^IMW^_9_\ G"G_
M %NZ]XMU_ON/_G(W_6OKW\=_G0?]X=_"_P#]*NS7_P!B'OU-N_W[/_SA3_K=
MU[Q;K_?<?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IMW^_9_P#G"G_6[KWB
MW7^^X_\ G(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_4V[_ '[/_P X4_ZW
M=>\6Z_WW'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZFW?[]G_YPI_UNZ]X
MMU_ON/\ YR-_UKZ]_'?YT'_>'?PO_P#2KLU_]B'OU-N_W[/_ ,X4_P"MW7O%
MNO\ ?<?_ #D;_K7U[^._SH/^\._A?_Z5=FO_ +$/?J;=_OV?_G"G_6[KWBW7
M^^X_^<C?]:^O?QW^=!_WAW\+_P#TJ[-?_8A[]3;O]^S_ /.%/^MW7O%NO]]Q
M_P#.1O\ K7U[^._SH/\ O#OX7_\ I5V:_P#L0]^IMW^_9_\ G"G_ %NZ]XMU
M_ON/_G(W_6OKW\=_G0?]X=_"_P#]*NS7_P!B'OU-N_W[/_SA3_K=U[Q;K_?<
M?_.1O^M?7OX[_.@_[P[^%_\ Z5=FO_L0]^IMW^_9_P#G"G_6[KWBW7^^X_\
MG(W_ %KZ]_'?YT'_ 'AW\+__ $J[-?\ V(>_4V[_ '[/_P X4_ZW=>\6Z_WW
M'_SD;_K7U[^._P Z#_O#OX7_ /I5V:_^Q#WZFW?[]G_YPI_UNZ]XMU_ON/\
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M_P"3?\K3-?'SY34F/VE_,!^$?S_^ O1WRZV1#4JWW]91=H[8."WYBT\5.TV
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MVSVWJNJBH<ENZ#)YV*;+9G]NOR5#"U'-)(HA5/=>Z=^POE?L7I+X_P!!W_\
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M.K<1F,5D:=:NGJJ7)1-#44\\3@I+#-$[HZ,"K*Q!!!]^Z]UH]=1=H=_]-_\
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MRLGMWY=?*';W=76M'M?)5U=64>*Q6R=N;<D@S<=5CJ*"FKS78FI=8Z:HK(C
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M]\_OA-\BOE'V1_+DQOQ+[3Z-^:':&5^1'9/2WR6WAN/I^LVCV7N2BH:#-Y[
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M&4QE5MQ:;KRFJLAC,?E,K)2ON*5IZ?\ A]$D=/.]7'[KW1R/YU7\N+OKY_\
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MFV:?#8N:AR4[X7;7W-%+)D*R/$5>:&5GIE5I<5BWJDD]U[K8EZ+^&_9O6?\
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M<C1Y%VI[X^&>05$(]U[JOGM7!?/K?W\\?^2W!\O.R_C'D-X;-'S<[(R7QO\
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MRLGMWY=?*';W=76M'M?)5U=64>*Q6R=N;<D@S<=5CJ*"FKS78FI=8Z:HK(C
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MO;L#=?\ !<AN+^'XS#)Y*FI^QQ-)7Y*J\:<^.FHYI6^BQL??NO=$>Q/\X_\
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MT5!45$LDBA(R+D>Z]T-R.)$210P5U5U#HT3687%U8!E/]00"/H1?W[KW0?\
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MP]>8WLC'=CT^?I9<,V$JJ%:W^(G(B3[44D=-=WD,H5 K:B-)M[KW6HSTJO\
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M5"(!4G:F+ZMR7V<64M.M3XCEJFL.-+4SQDIE LL;*R2>Z]TD\U4=I]W=6?\
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MW[KW56&^H\=!\<?^%>D'3S;0/Q13>D;]?ILEHVH5['FZ]@/< 04W^2"5<S_
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MK9M^?SK4[2B<]_R_SC?D^N]8=R"9\R=GOC-M#8BL*W55':WV!R(P/)I#0_\
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MY.]90XV*18JP4^T<0DS5-/JJ5"+2UGNO=6R]&?\ ;_#Y^_\ B@'PB_\ >C[
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MLRJ^%P_X3(;?_C,^U$^+R_RN*"EW ,@]%'*,T^QE^]2<45HO[Z/O%I"PIO\
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MMUP?'3+[SI>N\E'ENM^ONV>[M^=P[/V]44]O"^(VAN?<N5V[3BF4!(%;'2)
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M['==;'Q2;4QM/CLG%)#4T\$5!X#"TZ2RF25'$S.[2F0R$O[]U[KGT;T=U?\
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MJ5]'VB0".,+[KW1>?CY_)]^ /QG[*V=V]UYU#N7/]@]8T55B^H,]W/W5O?Y
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M=Q>1I9:&6GV;-N/=>1GV9,]!/)2M5X26AKFI3]N]2T5T/NO=&'^2?\M;X?\
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MQ/5Y*DD@R61J:J2IR%755&F0>Z]T<'?W0W3W:?2^9^._9/7^W]\]*;BV=3;
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M[I+=9]F=?]R[ VGVIU5N[!;^ZYWWAJ7<6S=Z;9KER>/R=!7 F"LHZA/1/3S
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M"_:W;6P]Z=D]:;*^/7S*JMW[4V!U+DN\<G-%G=@KB**2+;.)H<C75\<&5R-
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M).T8TBT94<_7W[KW1P/?NO=:P\/\T/L[X[_RL=]?+CJ7XS_'3$[KP?\ ,W[
M^/4W3'477%1L7$9S'9#NNJVADLA3T-/G:4?W[W#1F6IER4]?]K/F9S5U-(T+
M/ ?=>Z&[M/YW_P SWX2]Q_##-?-[K?X8;B^./S:^5'5OQ#CVK\;Z_=PWGUSN
MSNZ"M;;@K,SN"J_@N]<5!)057\3JZ?#XAU\+M24[B2%#[KW1.]][>^:>Y_\
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MZV9:R&*:C\BQ>Z]U?;T=W5_'/YK?RHZ%_P!$O2>'_N#\+?B7O_\ TSX+8?\
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M4O[KW5V<V9^9,_S$V]1XG;_0<WP$K?C]_$LSN:JGS,?9D?9,N7JO'2P1"L&
M.T3@!1,;T!K16O)^_P"(!![KW0^]C_\ ,O-^?^&9NC_W!G]^Z]UIG?R OYB?
M\GWHC^4E\8.J_E3WM\5]F=X[7F[W._=K]DX*DK<U"N;[$W;D<;]V9<942S"?
M#5>/DA'D?]EXT%K:1[KW1L/Y0%)@=]=E?SPOE%\6=E97KG^6A\A\GL'*?$S"
MS]>9'J7$YS.[8Z_JJ;?^[=M;=R./QTE+A\UEI*=A4+2PI.P6 Q12T<L,/NO=
M4T?RZ_YIV:V;_*E_EL?RT.A]\;CZ$S7:_9?8W37RF^?;;.K<WM?I].].Q]^9
M[ [=H<S#$V'B['W7@ZFF>A%361IB(ZI*JH"RQ3-0^Z]UO6_$#X?]%?!OHW;'
M0'Q]VL=O;-V^:C(93*9&I_BN9SV7RA#Y+<&X<FZK/E<YE)[RU-3+R3:.-8X8
MXHD]U[HSWOW7NJ:?G%\X_F1U/\]_B9\(/B;U+TOV#D?E%TGW9O:LW=VU4YC%
M4NTJOK#)[?5MP9.IQE<&JL!18BLR@?&0XTUN2R<F,IHLACX7GF'NO=.GQR^9
MORYV3\Y(_P"7M\_-H='5V^^QNDMP]_\ QJ^1OQJH\SM7;&Z\?L7(4M!N?;>6
MVON/*YK+X#<V#-?1U*-%F*^BK:$F;RTT]J<^Z]U4U_*PW?\ S5MP_''Y*X;X
M.;)^'>U-C=4?/'YU>'<7RNGW7N.L[!S60["S^5J,1A*3:U7BXMJX>CCJZ2D;
M+UU37RS5YG1,=%34AFJ?=>ZM&Z _FC=O?++^4YTW\_/C5\2\_P!G]Z]U6V;M
M_P"/%'N(4V/HMQXK==?L[,Y'*9P12/2;.QE7BJ_)/5_;-4_P\0Q-$M7(53W7
MN@6[?^</\S'X&]U_#VF^9_\ LAO=/1_R]^475OQ,GQ?QJQ>[NJ]Y;/W#W/-4
M0X/)4\&[-R9REW=@J>6*5:^1*?'521Q)-'3@2NL7NO=0<1\Z_P":_P#)#YK_
M # ^,GQ$ZC^%^(ZV^%GREZ^V9V1W'\@YMYT7\3V7O;;N#RHPF Q^"KJK^)[Z
M@EDS]345<\V-Q<%(V(I_MGGJ)J@>Z]T[X'YL?S2_E%\K/YA7Q<^)NQ/AMU[@
M_AIW/MS9>(^0'?\ B]X9ZCKZ7=FV,+F,=M_^[N!S4-3D<Z:N7,2Y#+"OQ]%0
MT+XV*'%UU5--+%[KW02=$_S$_P"<'\VOB[O[OKX_= _"SH+._&G<G;76W<.W
M>^\YNWL2'?>\NAZ[(P;BQNR#@JO#';6W#!34<4.1RT];4MDY:NC^V2DQZY/(
M>Z]T=C!?S ?E!\BO@Y\&OD'\-_BWBMW]N_-?&;'K,C3;_P!PUK[%ZPILMCY:
MK/9[=N4QU-!E<EB<55P/345/24M/591WCTFE]>GW7N@GV9\XOGI\=?YA?Q2^
M#OSE3X=]OX'YMX7NU^HNT?BGC]Q=99;;F9Z(V_\ WCR=#NC:>Z=Q;EFJ,36X
M]%%)7T>2#"IE,4T"*B&3W7NG27YJ?/SYE_)'Y1=3?RW<7\0]B=+_  O[)RO0
M':W?GRLQFZ>S)=R]E;?H::LR^V-M[<V?FMOG'8S;CUD-+D\E79>2?[JZ4U!(
MJN1[KW67?W\U;OCX_?!C;_;7R3^'N2V-\WM[?*2A^#75'QEH]T346!WSV-NO
M-U&)VSD]L[ER%%%.VQL]10295*Z6A:2."*>E0U$BQ5$WNO=(+??S6_FE?R_C
MT3VM_,?VE\)NU?C1VQV;UETOW!NSX=X[>/7V6ZIS7:]6,;B\U5P[US68I=X;
M/3,5%)1UD\3XJOIE=:F.EJBW@/NO=!/VI\R>CO@Q_.$_F,]X=Z9^HH</2? C
MX,8+:&S\!2'-[BW7G\SN7L"+%;9VOB(C]SE\[E:EDB@IXE-KF69HH(Y)4]U[
MH7OE'\E?E]L?X%=>=Z_,KXU?$&7?G9_S8^(V$VA\8][;!K^VJ/8FW>SM_8'%
MXW^\>1JL^:'-]F8&.I.0BR>,H\?C\7DUBC@IJX4AJJCW7NEAW1\W_P"8+N;^
M97W+_+M^(?6OQI^WV?\ &CIGOJE[Z[TAW'+C]KQ[RK]P8[+C+X["Y:*IW16U
MU338:/"XZD3$I$JY2JR&3D2&"FD]U[IZ^%W\S+M7)[M_F5="_P P?;?3_77;
M_P#*VQW7N_.[.V.BJS)_W$SFR^T=H5^],5GL?1YZHJ,SB:VFPF,J9<A1U%5/
M'"TD20U$A64)[KW1>]H?.S^<!W/\9*K^8ET_U#\%:'X\9?:%=W9U'\-M]YW=
M0[2W1U_34<F0HZFNW]294;1VYN[-8T?=TF.&T\C117@IZBO$DLCP^Z]T3S^<
MU\@.R_E_U#_(+^37Q5S?3^/ZK[S_ )G?P*WST^>U]JYO+Y7'[_W.<_+@EW##
MB\M003[5Q3">GS-#2S09&:IA*TF0A0:O?NO=7(?'?NC=^:_FB_)3H/L'JOXW
MX_?O7_P<^'N_=[]W=8==U6$W-GLQO7([KILEAZK.UU?55M;LW%5N/FFP=!40
M^:C%3.TL\TDK$>Z]T5WJ;YQ_S1/Y@.V^SODW_+RV?\']L?$+:V].P=D]!0_)
M!=X;RW7VZ_4^5JL1ELM39#;&8Q6$V-@LK7X^KIL1/-39N<L/N*NG2(!6]U[J
M%O?^:G\LM]=E_"OXN=?=5=+?!OY)_)KXM;A^2O9-5\^TS>1QFUZW:&?H]MU>
MPL%A<77[3K-T[BK*YJVJIY'S&/MB4AK6HR\Q@B]U[JQWX0]I_.K=E?W?UG\Z
M^B.N]C;MZBW5M_']>]_]%YJ6;879^%W-1O5IE,%ALKD:_<^W,CB"L=/E*+(2
M2P+4RJ,?6UD:3-'[KW1^??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\.Z8]Y?RP_YJGS1^8>Z
M^A_D/W;\7/YDFP/C(<KV!\<NJLIWWD=A[U^,&#R>W?X;N#;&W*.IS]-@<[B*
MF&IILG'1U4"UNNEE>(O&H]U[H/OE?U5\W/YU_P#+W_F1]:9KI7)_&?K#?]?U
M5-_+MV#W7M27K??^<DZ;J<9N3)YS>U+4Y.I&"QN\<U0+08BBK,705V/IC+55
MZ2"2G9/=>ZQ?,/YX]\_//X2]K_![I#^7?\UML_,WY-=<Y;X]=A;8[LZ*S/4^
MP>OAOR(X3=.YLOV1D(&VQE=NXFFFKIL9+B*S(U66_P E:GI?')(T?NO=&#VK
M\4=V]#_S+?Y4^S]E[(WQF^D?B]_*X[R^.%9VA3;:R.1P=#4;4?KC$X2AR6:\
M+T=+D<E1X>:6G@J*E9ZA8I717T.1[KW3A6]3]IO_ ,*4\1WBO6G8#=*Q?R3Y
M>K9.X%V;D3M9=S'N^JRO]W&W *;^$C._PMEK/L#5_=_:D5'B\1#^_=>ZK\ZJ
M^#7R8QO\T_&?"'-=5[PB_EF?'[YC=F_S<>N^R\I@ZRHVO7Y+L#"4*;8ZUQ]<
MU/#B_O-J=J9O=.X?L7FJYXX((9Q'$I@F3W7NA7_FU? C8.9_F1=#?S"^_P#X
M8;J^?/Q-_P!E7W#\5^\^JMA[.D[0S^R,A@]PU6Z=K[]QNTJ%X<MN&FD_B.7Q
ME:E&9YJ2*7SB!RR*_NO=*[^6IT-\<,G\X\CV]\-/Y1V+^'GQDZPZJRN)I/E=
MW;U;N#H+?VZ-V;M>2EJ</L_9V6FBR*[4IL4Q^]R65Q].TU2&AI:<HL53)[KW
M1U?Y*'6W8O5GQ+[.VYV=L'>O7.X:_P"<'SEW50X+?FUJ[:%9-B]U]E[@KL7D
MHJ7(04\\E!DJ*:*HI:A4,-1 Z2PN\;!C[KW5%OQB^+WR8P?_  FU_E_=(9OX
M[=Z8?NG9WSQZ<W=N[J'*=29_'[HQ6)QOR6K\Y4Y/);?FQZ9:AQU/A73(25,U
M(D*43+5,X@(D]^Z]T./S*^ /Q[ZE_FK_ "B^8?S<^ ._/G7\4?F9UST36[9[
M#ZTZDR7R RG5V].F<3'M;)XG([2VZK;@&%W1BH,56+DH**K1)Z<4[A0'9/=>
MZ,[_ "ZOC_L2"G^=_;GQV_E8X3X"=#;JZBRO57QZRVY=G978?;'9$1Q<]3E,
MAFMF35-2V P+95($PU/4PKE*I6$LT-,QDIQ[KW2PZDZ;[>QO_"8O*]$9'JKL
MB@[PD_E%]U]<Q]-5NQLI2[K;<.5ZXSU%2X%=NR4JY<YFIK)H8(J(4?W,DSI$
MD1=E4^Z]T2WHCICO+X#[F_E+_P R;/?&_P"0O9^RL5_)CZ+_ )='RTZFZOZU
MR&[M_P#7U9BVVYNK%9^;84=+'N2NIZ;+15V-S<$$,M7C1&DTM(JK*3[KW5B:
M]B?)7^;%0?-OI+%]+=B_&?\ E\=D_#'?_P ?-B]E?(KJ')]4;]W;V'V]2Y/%
MUN=PN"R]5#E<7LG;>'G2)_XGMF.?)5TJ2T4P@AFC;W7NJ)>I?BW\)>@?B?M3
MX^=Z?\)]^X>XOYFG6/75%U=_ L#\<LUO79?8FZ]NP/BZ+>#=KT=0-GT>VL[/
M3PY/*5=3D(*FABFJ$AHZB6.*.7W7NMF;:O8.?_EZ_#?X6[&J?A9O/,[AW7OC
MJKHC<G1?P1V;7]I[?ZXK.S8\GDLEF*J2LJ?NZ78&VJR&:&NRKLZI+/3E(Q',
M@3W7NC1?-7N'?O0'Q+^0W<?5/6N].XNT]A=4;NS'6/5_7NU\AO/+YS<;TKP8
M*@I<=BZ/(5\Z392:D\[144QAIQ+.R%(V]^Z]U2E\'_\ A/!\-\1\4NDJOY:;
M![BW7\J=W;+H>Q/DCN3&_+7MK8"U>]NQ"V:W 'QFVMZ8/#12TE?6R4K/!C(3
M-X!--Y)GDD?W7NFWX%?'7M+X ][?S5?Y<6TNG^ZJOX<[UV5EOEQ\(>Q:G#;L
M["P=,_9^ 3#[PZ_.Z\A#7TSYRDST5-+0XZ;,39.KA%5D9A4354LOOW7N@;^$
M?SH^3?QN_E2]$?#;<W\L_P"<\_SCV[\9</UATUUK0]%96/:FX?XIBY*?;V9R
M^^:R*#;^S(*&FF@;<=#GZC'Y/%5-/5PK15$;T4U5[KW4_N7XG_)[X%_&?^0#
MU[U)T%V#\NM\_![N^;.]V;9ZAQCUO^2S]=[N_O5-39"<0XRB82Y3(P80Y*MH
MJ:OR H*!ZF%ZH,/=>Z,GO7?N_P#^:S\T_@(_57QJ^3/4/QB^$/=66^5W='=_
MR;Z:R_QXDK=U8# 9'![:V)MK ;FIZ+/9:L\^;J:K*UJ4(QU+!"L*5,T\@5?=
M>Z,__+IZN["VG\J_YR.8WSL+>^SMM=J?-G:^X^O,_N7:U=MZDS^)7K+:&/ER
M>#JJRGCI\K0QUD%13FHIFFA6>*2(MK1E'NO=:[WQK_E__!+^7WUCO'XL_P P
M+^3CWG\J>^.L>PNUH^F_D'TQ\8<W\BZ+N#;&;S-5DMI3IG<%*F)VYGHL?7TV
M-J*+-28R&D%*DDE0%,A3W7NK^_BC\#Z+LG^4OOOXE]V?$CI[X0K\G]D]K+NW
MXW=)YNKW#CMI-V5"T&+FJ:ZIDF$FYJ.&'&5=:U,!3Q5T>B)28V9O=>Z*M_(X
MZB^9'8O:7;'S!_F#=7;QZW[IZ5Z*Z3_EJ=08[L/!5>*K\AB^@Z9<CV!OVA>M
M@I158SL7=U315%/64E)'3U46,4K+4QB,Q>Z]T&O:G4G\PS;_ $U_PHMK_AOL
M7L?9GR+[9^5/7^X_CAGZC!5NSZK<.#AV7U[0[ER&Q\C614T&0K_X/39^EH*J
MDG=4R4:Q1RI4H-/NO=59_/#XB?%#Y#?R[>[-L?R^OY2'SH[ ^7]?M+96;WMW
MW\M^BNR?[[[9BVCD:+-Y=*//]AUDV>W-NG)#&5.(BQ.T(\A%KK7-1!#BC)K]
MU[JYW^9]5=H]<?/W^1Q\^L3\:ODQW9T=\=,3\V,5W3COCWTSE^V]TX&H^1'6
M>-PVVUK-K4$*YJ&*6M6J6>66DCBI6IWAJ&BJ9::"?W7N@$[]_EO]Y?-GH;_A
M1!\?L9LS=>P]T_('Y?=4]I_&[.[]V]7;,Q>Z)^K=G]>9:D..KLA3P4U;B\ED
M,'4XF2LB:2"FGDD+L)(&5?=>Z&#YA_/'OGYY_"7M?X/=(?R[_FMMGYF_)KKG
M+?'KL+;'=G169ZGV#U\-^1'";IW-E^R,A VV,KMW$TTU=-C)<169&JRW^2M3
MTOCDD:/W7NC![5^*.[>A_P"9;_*GV?LO9&^,WTC\7OY7'>7QPK.T*;;61R.#
MH:C:C]<8G"4.2S7A>CI<CDJ/#S2T\%14K/4+%*Z*^AR/=>ZEY3J;MJ3_ (4F
MX[O"DZVWV.G8_P"254]6IW%+LK)S;33=1[MJLJFW9<\L"XO^-_PUDK#C_O5K
M#2'SB,1$/[]U[JH#Y*]2?%_OA>ULS\L?Y0'S0Z"_FXX#,=MXOKGM_P#ER].[
M]QF.W/FLU45-+M;?.W>Q-HU*[*KH\A3#'25U;N^038Z49$5*) S^;W7NM@3X
M\]Y?)CXY=7?RQOC/\K.H/D#W[\C^]^KZ[;/?7?\ UCLW^_6T]DY[K'!XNLK:
MOLC<<$J0XV3,RUWVM'5B*1,E74M:Z%0 6]U[JU'W[KW5$O\ (MZE[5ZGI?YM
M"]I]9]@]:-V)_.G^<7:'7Z]@;,R6S3G=L[K7:_\ "]Q889&FIOXG@LE]O/\
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MNZ?YL73]7_*)[3EQ=5402X[+[WS-)D=H[Y\%,HF>;;FUZKL&.:JCJ:=J:G2
MRRK"IEI_=>ZV=>DNHME] =.=5]&=<XV+$;"Z>Z\V=UGL['11B,18[9./I\=2
M!M/!D,-.A=N2[EF8EB2?=>ZI,_F [J[WZ(_FT_!SY3;&^*7?/R,Z1Z]^(GRI
MV5WUF>D=AUN\J[;^-WGGMF/#5X^FBC6'-9F"II*>H_@D%3_%:W&19&?&4M;4
MTJ4TONO=9.IZ;L+^9!_,WZX^8Z=!=W]&_#_XD_&;NOISKC=?R"V'6],[A[#W
M7\DYL=2Y^7%;4R\=/N+';;V[B,.D0K<A14K5==,?M(WAB:5O=>Z+E_+L[VW]
M_)O^*U/_ "U^^OAI\W>U=]_'+>/=$/Q\W_\ '#XXYKNS;/:NW^S-X[AW3M^H
MH-R8>.3";<SCR9J2DR%%FZO')CO''43S>"3R#W7N@3E_EX_*GHC^574_)V?I
M#+3_ ,P;:W\T&K_G/U'QVZPR=5V/DJ?+;VW/2TN>V!0-C:6H;+UDG6,M10U-
M)34TL$U>C",R.B3GW7N@D[X^+'SQ^/O\K7^6Y\Q/CCT=V9V/_,1VONCY*=C=
MR];8;9F:@W)!5?S7L%NNMW7'E,!24LE>L.RMWY[:4\^/R$*?9MAXWKJBGFI9
M:@>Z]T?[^8M_**R^Y/Y1_P (?BST[UQ3]_Y3^79V-\6^YZKH3*92DP:]I4/2
MU!5XK>NVY:J18J:*MW3CLSG*A LD*RU)$"$&55]^Z]T3_#_';^7]W!VMT#UY
M\$OY!6X,/V55=I[9R/>W9WR^^,^[/C1M/J_;FWY7GRM><Q7U%.VY-W)/%"N(
MH<(];33N'FEK(D6)9O=>ZN:Z:ZV[%QG\[/YO]J9+8.]<=UANOX/_  \VKM?L
M>NVM74F!R64VWG]\S9'&T&8D@7'UE?0155,]33PU#S0)-$TJ*)$)]U[I6?SJ
M?A#OC^8C_+2^2WQ6ZORF,Q/:&\<-M#=/7+YIO%1U67ZOS^+W)38JHD+QK3KF
MUQ<F/6H=O'2R5254BR1PM&WNO=4X?S;_ )M?(GYZ_P K/Y#?%WX^?R[/GWA_
MDQO/:&SJ7N[:V\_C%E\-C-ITVT-PXG(;AI,5E:REGH]^U>6DQLN-Q";83*5$
M\-6,L&I*>F:H3W7NK3>BNLNSL1_.7^:/9U=L#>6(Z]W/\"?AGM':?8V8VCD*
M7;]?F=LYG>\N0QM)E7ABH:VNQR55*]72PU1G@26,R*@D0GW7NJ.ODKU)\7^^
M%[6S/RQ_E ?-#H+^;C@,QVWB^N>W_P"7+T[OW&8[<^:S514TNUM\[=[$VC4K
MLJNCR%,,=)75N[Y!-CI1D14HD#/YO=>Z57R _ER=EX?MK^7;\XOYFWQ3W3_,
MEPF!_EXX7XB?-_9>Q-MGN3<>T=X[:R<NZ,-O^EV]C7@R.[F\F1R^)RLU :B1
M&>2MCA?S1J_NO='8_EM]#?';)_-S+]O?"S^4=AOAY\;.L.I<SB<9\KN].K=P
M]!;[W1N_=K2TL^'VCL[*S19-=HTV,;_+LEE,?3O-4AH:6G*K%4R>Z]U79\:.
MH>O]S;=W=0?S4OY:?SE^>'\VJ+L/N&HR^$['ZNWOV=U)EJBHRV3J=J'9&=S.
M1AZ1VQLUL ^+IOO*BHHC"\51%(780P-[KW1EO@GUK\H?C%_()Z=Z,WE_+M'R
M:RG57R&[EV+\KOAGV'UY639;+]?Y/M/=&3R^4V'A-TBBAW/D*?&5]!78)9WE
MAR4866"H:=5]^Z]TD/B/\8>G<9_,)^-&^?Y0'QL^>WPUZ.ESG:NX_P"85BNZ
M]C=B=(]4YG [HP\\5!AZ+;79+M_$-YIG$H_LH]OTRX_%4J%I=$2TR+[KW17/
MC7_+_P#@E_+[ZQWC\6?Y@7\G'O/Y4]\=8]A=K1]-_(/ICXPYOY%T7<&V,WF:
MK);2G3.X*5,3MS/18^OIL;446:DQD-(*5))*@*9"GNO=7G]!]E5'\JO^4+N;
MY+=K?R_:/H [$7*=V=A?"_X6Q2]CUFWL9NW,4%'/5U,F2K8:22NPF!:++;EJ
M5JH:&@IJ2NF)"4TCM[KW5W&V<Y%N?;>W]R04M50P;AP>)SD-%7((YX4RT$=0
ML4RJ2%EC$@5P"0&!L3[]U[JF[#]);NW%_/*^4F\=W=7[OK.A^POY5G3G4DN^
MLGM*O3;.4KWW[NA\KM^+,/ ,;4Y&/&UB25%&E2T\<$R2/&J.K'W7NB'_ ,E[
MXP?,G;GRDRVQOEKUGO\ V?TQ_*,ZK[+^%/PFWQO7'2TM-V31]M;QKZX=@8^9
MJ>GI*@8OK;;^RL)&U&KPQK65:R3+4RSX_'>Z]T63J_X _*C=7\I?XM[LVST7
MOY/DC\#?YON\_P"8#M7X\;\PU3UAF-Y8;K?M/<V1EPU%%G(J'PS9W"Y!:S&3
MR!(JKQ1)#*4J0Q]U[HVOSY[@WE_.KZ5Z^_E_=!?#+YD[*VEW'W%TIN'Y==J_
M*?H7</Q;PW7FRNM-P8_<N8HQ5[@IJ>;<&[\F^+CH:*APRUD2EY9IZRGC$3O[
MKW2SS'P#Q_\ -*_FG_,#N/YM=-]UX?XP?$?9/7GQ3^'-!5;VW[\>CN/*Y$/N
M'L'>V)J]O5FULCD<4U=/28JGJ8<G5XVOAA$@UR4Z"#W7N@E^:W\K[9/\M'M+
MX5?S&OY;O17R&WIO;X_?(K#[.^2O5>UNS.T_E#FMR=3=U4M1@-S''8+,9C>&
M2J:G R3TU9#!14T<>MVKJI930P&+W7NKVNJOFCMWM/YE?)KX81=2]Q;,W9\:
M=B=*=D578F^=L1X';FZ\/WC254V/KMJ3O4&MR%+15V.R^-JYI*.&),ECJ^D1
MGEI)UC]U[H(?YR6Q=[=F_P K#YY]?];[.W5V#OS=WQL[%PFU-D[(V]5[LR^3
MK:RE*PT>/QM!#45E;52GA(H87D8\*I]^Z]T5C^:[U)VMV'_+ Z#V#L#K+L+?
M.^\/WA_+MRF7V5L_9F2W-EJ6FV7O?:-5F*FIQM%33UD$&)IJ>HEK)'A5*6**
M22<HB,1[KW0F_P SKK/L??OR8_D\9W8W7^]]YX3K3^8(N\NQLSM/:E?N*EV_
MB!L#=U)_%<W44=/-#BL;]U44\/W-4\4/EECCUZW4'W7NJJ_F5\ ?CWU+_-7^
M47S#^;GP!WY\Z_BC\S.N>B:W;/8?6G4F2^0&4ZNWITSB8]K9/$Y':6W5;< P
MNZ,5!BJQ<E!15:)/3BG<* [)[KW0<57\KS ?.SX;?S.>O?B9_+-V?_+BZU[?
MV!UQM#XD[J[$PU?U%V1V/D>J,]AM[O/NO;5=-6P[3VCD,_@*2CQPK8$R,E/.
M:J=*(B2*/W7NK(MP_P U7Y9=O]9['Z3^*/P ^6.Q?GMNK<.Q=F;VI?DY\:,]
MM;K#KA*3)4<&[MT9_>$]9A\!N?;]#01Y%\7'@]PRU>7+TSTJ>K2?=>Z,%TKU
MIV3B?YU_S:[2S&Q=Z4?6NZ?@W\.MI[;[,K-IUU!@,IEMLY[?$N3Q^/RTD(QU
M57T,=5325%-#522TZ31-*JJZ$^Z]T3?K;J+Y?;:_F0?\*7.S.E>N=U[3WUW!
MT)\'J?X:]F;\VA78+:NX]X[)Z3S6.ISA\S6TT>*S$>%W,]#3Y#[>HF2CG(BJ
MQ&25]^Z]U4IAOC#T)W7\$=Z=<[B_E9_/#Y-?S@=U?&K=6Q>T^Q_F;U7V%G<=
M@.P\]AY,9N'=N-WSO?)KLR@P^,S$\V6PU/M2J.3K8(Z08NCFK#J7W7NK,NO>
MG.[<A\>O^$O%')TCW%CLI\?=R]7X[O;#Y3K#.XVKV9_<_H_<&VZN;==+48^&
M?;L"Y>-*82U\<$;32Q1H[&2/7[KW1KOY@74_:>\?YRW\A/LW:/6G8&ZNM^HL
MC_,O?MCL';FS<CG,'M==\]:8&APAW%EJ6FEH,*,Q6PRT]":RHA^[G1XH/)(K
M*/=>Z"OX7;'^6G2O\I[Y=X[8?Q7H>R>^I/E;\\MW;2^,WR.VU6;*H=[8/=O9
MV=J_LI*?*QT:S4FXMO5$\F.DF5J&N\D +-3S%Q[KW58U'\;>@-U?(/XW]D?R
M>O@A_,,_EZ_,[)?(?J#<GR3DS74>_?CEU5A=D[<G2/>V"WY1[@G/7.4IOX9)
M5P4..VO'))7UQ-1"7B>>63W7NKY/Y;_6W8NQ_EI_.)W'O38.]=H;>[+^<&T=
MU=<9W=&UJ[ 4>X,73]:;/H9,EA*JK@A@RM!'6T]13M44KRPK/%)$7$B,H]U[
MH,/Y4_4W:?7OP1^9>T=_=:=@;'W7NCYA_P QO<NVML;OV;D=M9'(X[>N[<[4
M8;(4-%6TT%35T67@EBDHIXHGBJHW5X&D5@3[KW1@_P"2AL#??5G\J/X)]>]G
M;*W;USO_ &GT)MO$[JV/OS;E9M#,8RKBFJ6>FR&,R$-/6T50JLI,<T". 02.
M1[]U[HI/S$V%V1\./YLW6O\ ->P/1_<?R%Z)WM\*,Y\&/D-MWH#9E3VENW:$
M@WI0;OP&\:;:M!JR^<P\\U.*#(K00SRT$2&L:%T+6]U[IFZWQO8W\R/^;'\9
M/G%2_''NOH[XE_R_ND^_,%U-V%\BMFY'I3<6_-^?):BIMOY,XC966A@SL&U\
M#MV"K0UV3I:,U%=./M:>6)$J/?NO="'_ "..I^T^J?\ AW+_ $H]:=@=;?Z1
MOYU_SH[1Z]_O]LW([._CVV=V?W8_A6X\-_$::F_BF"R?@G^TKZ;RTE1XY/#*
M^AK>Z]TN?YY>*^5^8^(VP*?XQXCN?<6TH/D[TK7_ #'VU\:JNMH^R<ETK0SU
MDF^*#8QQLL&4DSE2JX]!'0S+624YG2&X+J?=>ZH&^1?Q7^-.[L]\!^S_ .6I
M_*>^46W:'H_^8_\ $+NSY&_*?MSX^]@X/>SX/9^Y:*&KQ5,=[R5G9F[(9ER2
MY/*UXQU7@Z*FQ3/4UBUB4J)[KW5H'Q]WIN7^3=\A_P"83UMW'\;/EIVQT=\P
M?F1VK\\N@>\OC3T-G?DE1SU7>%%ADW!LG/TNU:&IKMN9O%9;':,>*ZD2GKJ2
M02K5L8I6]^Z]T''\S#:G\QSY^?R$?G*.Q_C%F=M=W]I=H[>W]\?/BAM/;OWF
M^L7UCU_V-M/,8FBW-24N6RT>6WY)@<1E,G54>/$<VB2GQL- V2C>*7W7NC7;
M5W7O+Y4?S3?Y=_R\VM\>_DSUMU%-\'?F_M3<DW>716>ZKK]N9:7>.TJ*BQ>Y
M*?(4HCPU?EQB:RJQL-14+)7T(6KIU>(DK[KW0&?&+=^YOY,O>/S_ .G.Z/C3
M\L.S^C/E;\U>WOG/\=N^?C1T%N#Y(X^H'>%#@HLMLG<%+M6ER&2V]G,)78J*
M*B:MI$@R4#O.E0/$X'NO=%\W)\2/E!V+\#?^% WS(WS\9^Q^M.^?YGFVD/4?
MQ9AII=][YI]F]"[4DVSLBGS&#PJURTV[LT*O*5E3C*-ZN6#S10O*[IHC]U[H
MZ?\ /4Z;[>[8_P"$_G=_3O5G579'97;N4ZR^'E!C.K-@;&RF\MQU,^V>P>NZ
MS)0P8/'4M3DYIL?2459/4HE*6@A@FEE"I$[+[KW5F4OS*P6V_F[UC\!LGU'W
M#3[J[!^+^>^1NW.Z)MMPT^R)Z;8>7IL'F=NQ9.2I6IJ-R8J6NP]164T5&Z4M
M-D\<\\D9JX%?W7NC7[^IJBLV+O2CHX)JJKJMI;CIJ6EIHFGDDDGHYE2.-%!9
MW=B J@$DD "_OW7NJ/O^$Y7QUW#U3_)P^(NP>_NBLUUMVQ@:CY _WGV5W#UC
M/L[<5$N4[.WG6T/W^-S5#39*F%3CZFEG@\L*^2GEBECO$Z,?=>ZNJ[8Q]36]
M3=E8K%4,]765?7>\L?C<;CZ9JB666HQM3'#!!#&I9Y'8JJ(JDDD*H)('OW7N
MM?'^37_+XVUV[_PGGZ<^$WS5^/6=Z]J.T,)\@,=V]UOO[K:?JK<M)7R=D[J?
M;V?J\?64./R-+N"BQ]'MVNQU?44_W#I3T-1KEBT%O=>Z%/\ EP?(/YK_ !7Z
M*^4/Q%^</1'R/[R[0_ES]>[@S?3/R"Z[ZGS>Y:/O_8.U,94UFW*?:V3F22CR
M79*TM-2XRIQ$N5DK9ZB:EU3U=4F2FC]U[JW[XH_(C;'RW^-?1_R=V7@=R;7V
MCWQUIM7M';.W]WQ4\&3I*'=]*E7315R4D]52BH$,B%O%4RQ\W1V6Q/NO=4=?
MS'.^]]?&[^=;_+I[.VCT1V9\@MO47PV^8N-[;VITUB(]U;IQFU:W-;-:LW#A
ML#YHJS<4V)R,6+:?&T"S9&>D>H:BIJF>-(7]U[H4>EY>Q/YAG\U#I[YOT/07
M>?1OQ1^%7QU[AZYZGWC\ANO:SIO.[_WK\AZG'TN:EQ>T\P*;<%%MK;V%Q C^
M\R-!3&KKIR*:%H8Q._NO=#W_ "4.MNQ>K/B7V=MSL[8.]>N=PU_S@^<NZJ'!
M;\VM7;0K)L7NOLO<%=B\E%2Y""GGDH,E1315%+4*AAJ('26%WC8,?=>ZH/\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IAW3B\GG-L;CPN$S]7M/,YC
MY?%XC=-!2PUT^-JLA3R14^0A@J%:GFFHY729$E4QNR!7!4D>_=>ZKA^!GQ8Z
MX^,_;/R<J-W?+W(?,GYU=J2=7;J^2N_^P*_:N&W5C=O8F@J<?L;$KL[;,5)!
MM':J0PY>>@C%"D==639"I664^B'W7NK//?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= 5TOM/H;:&;[VI>
MFJW:]=NO-=UYG=GR(DQ&\3O3+)O;<^(PM88-R2S5M;74%?!M>7;*4&/J&A6A
MP(Q%/0T\&,2B0>Z]T.OOW7NO>_=>Z][]U[KWOW7NO>_=>Z KLO:?0V3[6^/.
M[^U*W:\79VU=U;ZQOQNH-U;Q.*:;<>Z-MY#^+R8#"S5L-)F-RP[0H=PB.9**
MHR%!AWS9IG@HZK)&3W7NAU]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5+E?B)LO
M%_S!^KOD_P#*;YNYOLO<,&:[6Q/P%^*'8LNS^NL)MG+[VQ"G<<VV*.E@I<[O
MK<M#MREKTAJ*F>JJ,;C:FO81A"LL/NO=6M>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z _Y)[3Z-WMT3V=MWY,UNV\?\?9]LSY+N*IWKO%M
MA8'^[^WI(\CDH]PY/[W'P1[<FIZ5H\M#552T%9CFJ:/()+0SU$,GNO=#7!X?
M##]MXOM_%'X/!;1HL-.C3Z=.FUK<6^GOW7NLOOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[H"MG[3Z&P??G=6XMJ5NUZGY%;UVKU%DNY*;^^)S^X:?;F'3-X[9
M<<^,GK:BHP6VGJ:;=<F.AAI:7'U.2?.UD22UTV1F?W7NAU]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO= 57;3Z&B^2NV]\Y>MVNWR9KNE-W;3V)CLOO$RYE-DX
MK-XBLW//@-OSUI6"@DS=;M9<YD*+'*T\B8&FR-0ZTV,BC]U[H=??NO=>]^Z]
MU[W[KW7O?NO=)K>> PVZ]G;LVON.JR-#M[<FVL[@,]6X?<59M"KAHLQ2RT]5
M+2Y;'5%'D,74QP2.T=735<%13.%FAFCD177W7NDKTE1=08WIOJC'?'Q]BR=#
MT'7.RZ+IB3K"OI,KMMMJTN.IX\ V!JJ"2:AJ<.<6M*:.6GF>&2#QO&[(0Q]U
M[HK_ &!T?TCGOYB7QT^0.=[LP^"^0'7OQT[VZ]Z]Z#FW!B*:MS^W=\9+;]3G
M\_#C)IES55#A:O'XF)IZ:%J6#[G14G7-"4]U[H]_OW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
F[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>timage_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M5R/QW[<GZ=S^W_DS1[_R\=?/LW?LL>/KLW2X@XIH)*G$USY)E@^]$:R"-0Q
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M5V!'EVI&ERRU=/7"@3!MC&)"9QLTPQYIC(+5)%Y/&!)[H8E_*E?*M?\ B_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K0?\ YH_\@O\
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M<?)_^5GT3\@^MOE!)L!-R=E=J8K?NU4Z^W/6[HA2'&8*EH)'J :*CB=?N-(
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M_P F_P#&_;GA]>ZD>W.O=1_!_M?_ ";_ ,;]M^'U[J1[<Z]U'\'^U_\ )O\
MQOVWX?7NO>#_ &O_ )-_XW[]X?7NH_MOKW4CP?[7_P F_P#&_;GA]>ZC^V^O
M=>]^Z]U(\'^U_P#)O_&_;GA]>ZX^"E_HO_4P_P#%?>Z+U[KEX/\ :_\ DW_C
M?O7A]>ZD>W.O=1?!2_T7_J8?^*^Z47KW7+P?[7_R;_QOWKP^O=2/;G7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZK^^?WSSZ5_ES_'W+?)CO^#><O6^&W'M+9TJ==8"'<F0%;O.:.."
M04=3+%%%I9Y&]<HN !_:O[K%$(Q4U-<=7)8&@H*9-?D:>7V]4A_]!AW\H_\
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M//\ [1_R=_QKVYXG7NO>?_:/^3O^->_>)U[J/[;Z]U[W[KW6?[@_Z@?\E_\
M&O;?U7^JG^SUO'7#SP?UC_ZEM_Q3WKQ(/4?SZ]3K)Y_]H_Y._P"->U/B=:ZD
M>W.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M)?-9(T%,+6NU_>F>@Z;C34>BR[N[ABQ#5MN+_CW;7IZNXU4Z,QMVK6NV]@<O
M?TU=!09$_P#(="%/^\@^VE; /^KATZXHQ'Y?SZ57MSIOKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][+^O=<-8_Q]W^J/\ J_XOKW4;R?X?[S[2
M=>Z]Y/\ #_>??NO=8_N8_P"O^]_\4]^Z<\/K#]Y_M*_\E>_:_G_/I_Z4_P"K
M_BNO>=/Z-_MA_P 5]^ZIU[[S_:5_Y*]^U_/^?5_I3_J_XKKWWG^TK_R5[]K^
M?\^O?2G_ %?\5U[[S_:5_P"2O?M?S_GU[Z4_ZO\ BNO?>?[2O_)7OVOY_P ^
MO?2G_5_Q77O.G]&_VP_XK[]U3KWWG^TK_P E>_:_G_/J_P!*?]7_ !777WH_
MHG_)?OW37A?;UW]Y_M*_\E>_:_G_ #Z=^E/^K_BNO>=/Z-_MA_Q7W[JG7O.G
M]&_VP_XK[]U[KJ>8V_ L#JOR!_QO_C7MX3_2GJ@&>N1F4?AO]M_QOVQ!_C/3
MA6G7-/TC_8^VH>'34G3+H_RKZ+IT?ZC_ 'W^]^W=,/\ J/\ L]6^F-*T_P!7
M[.G;SI_1O]L/^*^]]6Z]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA
M_P 5]^Z]U[SI_1O]L/\ BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_P!L/^*^_=>Z
M]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_VP_XK
M[]U[KWG3^C?[8?\ %??NO=>\Z?T;_;#_ (K[]U[KOR?Y7ILFG3_O'^M]?]]]
M/>OT./5J'3UBED70"2OZN>?]?_'VH,4U/T>'S_V>FA. <_ZOY])C*9G#82 U
MF2S-!B:0B^FORO\ ";6/Y%C[)-PW6#:E_P <N/I_YUZ5I:,QHJU/0</W1B*^
M4T^S=L[HWE,+)]]08_\ AE(0?^FV<*1^?Q_O'L+2>Z%G=?HV=;H_ZOMZ-8>7
M7CRY"#YY_P W3?\ ?]MYL!Y?[I;*I@ .!_>BK(Y-^2;_ )]H9MQWS<CV?HP]
M."RLK/,P+']G^&G3-F-O0TE/][OSM/<%- WT R-'M>DYM_QQ8V'^P]D5[<PP
M8O\ <O\ FST8VTY_XB68^VG^?H/FV]B]U0>#K_;FZ\M?Z;LSVXJO%4E*1<^;
MGB?BY]DWT#;K_P DRW_U?RZ]]5$W]JP^P"I_P_Y.C;[6QV2P6W\/B<KFER^0
MIJ$+75U<034ZK\W/T !_VWXL3[G3E^RFMX?UN@E.ZR,2 ?R\NEGY_P#:/^3O
M^->S7ZEO]5/\W2+K']W_ ,V_^3_^->W/#Z<\/J9[;Z;Z][,.O=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO= GV74^&DKQS];W_VP]W)H*=:(X'JGGOC
M>E?1O5B*J_-?<V_K^/\ >O=&ZN'ZN9Z:E2KZBZPK)N?-UWLRO((O^O$TE_\
MH;WLY1:^@/\ +JIJ)7 _B;_#T+/O77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NF_P!I^O=>]^Z]TX>U'7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU1]4_P!9_P#B
M/:.Z_P W^7K?EU%-62+!(S_B2#[H;LVX_6/2GZ4?ZO\ BNI7W!_U _Y+_P"-
M>[_5?ZJ?[/2;'7#[O_FW_P G_P#&O?O#ZOX?63S_ .T?\G?\:]J/$Z;ZQ^3_
M  _WGV5]>ZCRO_0*/\2/I_QOW4OIZ4"+7U&GG3@?7ZV'/^W/MO\ QCY]7"G_
M %5Z[\LG^J_W@?\ %/;>L=*] ZQB83\#_#Z^VB9SUH+HZ:?,O^^_Y%[=UCKW
MU77.[_Z@?\E_\:]T^HA_U#KWU74MI2/JEA;GU?T_V'ND-Y!<?V/3E*=</*?\
M?^2O;OU!_P"&?ZOSZ<T#KEY7_P!2?]M_QKVD_>4'3=#UWY_]H_Y._P"->W?'
M/IUN@]>N'W%-_A_U+_XU[OXPZKUQ$M%4@^#2#R?S?_8^[F05Z\%(&>LW']#_
M +?_ (U[WK'3/C#J-[9\?Y?SZ44'KUGGJ#!]5LW^O?\ WKWOQNM  ]=05OW
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M/^J6WM!/[A[?!Q\7K0Y=NSY ?G_L]>_TZ]>_\[NO_P#07JO_ *C]V_UQK/\
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M>E)C?_5>"W^]>R"7W&K_ &'3B\LA?B)/^E4_YCTEZCMG-5Y;[WM_8VWPP_X
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MRM/V<.FBMH-^RF^:Z=V'GQ?G[#<5&GT']:VG]E\^T;A;?VUIT^M]:'X;MO\
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M44]3*#;CE3<'^@_VW'L[V#F.+>\>?^4=%=W8FRXY!R"#@CH2?N_^;?\ R?\
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MM>$/]0Z]YO\ :%]^\4_ZCU[PA_J'7'[A?]2O^V]^\4_ZCU;Z?K#]VW_'./\
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M/Y?[/4:7=6!B6U3G\#2F_P!5RR$_[RZ^_#?XE_XO_8ZK]&?X3^SI/UW9FQZ
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M/4W;%5S]#C+?3_8^U'T&Q0?Z!+^WJK;ING\<8^T?[(Z4$9ZRHOU=+;[-P?\
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MYRFXJS)_]:_^*>WV&[W']M;_ .K]O556Q7\;'\A_T#TW5^V>TLW3Z,FG4;P
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M[,XY.?[.2#_[TWMK]Y0>G7OIW]/Y=8O[T;;_ .=OM[_S[4O_ !7W[]YP?/\
M;U?Z-OG^P]28\[@IB+97''Z_IS-OI_AK'O?[V@].M&U<>1_9TX1UU).EJ<_>
M$6))LW^]@#\_T]NPWL SP_GTP4;K-Z_]I_WGVI^H'S_U?GU7'SZ]Z_\ :?\
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M/7OIQZ?S_P!GKWW2?T/OVL]>^G'I_/\ V>NONE_U/^\_\:]OTZU]+U[[I?\
M4_[S_P :]^IU[Z7KWW2_ZG_>?^->_4Z]]+U[[I?]3_O/_&O?J=>^EZS>3_#_
M 'GVFZOUUYJ;_5'_ )(_XU[MCY]5S\NN'FI-5KL?^G?_ !KVBS:&O6LGTZXF
M0,H\5C]+'Z>Z&]^GQT^5KQZZ\JVM45@-B+VLO]?K[40'ZKB>JD!. ZY>985-
MQ?\ '^O?_??U]^M[@W!IUYEQ7K+Y/\/]Y]O=5Z]Y/\/]Y]^Z]UCB9#:S?[<_
M[P?>OJ!_J_XOJS1XZD>?_#_>/^-^VOJ_L_U?GTUH'43SO3F^H7/XM?VK,WKT
MQ]*/7_5^WKA]P/\ CHO^\^T_A?+_ %?LZO\ 3KUSU4G^I/\ O/NGBCU/2GZ8
M_+_5^?6?R?X?[S[KU;P^O>3_  _WGVHZ;Z]Y/\/]Y]^Z]U[R?X?[S[]U[K%]
MTG]#[MX/S'^K\NO> /0=>^Y']!_R5_QKVE^I_P!7^H]:H.HGFJIQJ8?9_P!2
M0#_ON/:6>^@_U8_P=.*M/G_/K%(8Z=09Z[\GA44?\4_WKVI6X>XQTFI/QI_@
MZ1.=[1V'AU%#/EFK,C:WV.!7^+50X'YAL+^R#=.:;;;_ (<?9QZ7VNW74AJ1
M4?/ATD/](>]<J##M?8C45(05;(;\R?\ #KW-[_96X_V'L/MSC>W&+6 =&,>T
M(N;EC_M17K$V'[-R?[V=[!.WZ9>30;7VR,6/]A-6\_[Q[*Y4W"7-S<&#[/\
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MJ#_RHT%7M@?^J52!_O'M%#R:\'!+?I8=WD(_W(NQ^S_*.H?^C[/XTFVPZ_\
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MB%%%UMNBJIE +UN2%)M>EYO]/O*L"W^N/97_ *X<'_*/)T__ %?;^-1_,_R
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M[_8>ZTZWX!^?\NB^]CXK=D.6HLS1UV[*K:1H0N0Q^TLG_#*JEL/^!A_Y7?\
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M@O\ Q#>TG]:[ ?\ $G_CW^;IX;+=^2-^Q?\ /TWR=P]=D '>V#Y_Y48ZH?\
M11O[3R\X[?;<"/RU?YNO#8[IOPG\PO\ D)ZC?Z:.O#<Q[B%3_A08VM'^VY-O
M;(YZVY?+_5^WIT<M7;<?YD?[/7+_ $V;#_YW59_YP5WO?]<;;Y]._P!5+GY?
MMZS0]P]<#G^]5'2$?3_<34WX_P 0H]V_KK8MQN_\/_075/ZM70_XC$_FO_0/
M3A%V5LF8_P"0[SP=5S^,B%(O_7TD?[S[-[?F;;[O_B7_ "_V.F+C9+JU_P"(
MQ_8/\W3LN[-NR\P[FPG^/^7TC?[U[T-\MSPN /V=,-M]P/(_L/4O^]6!'TS6
MW]7_ &M%]ZFWF#RN!^0/^;KWTK'R;_C/3?4[[V92@>7>6!I1?BV4H_\ >N?;
M0YGLQ_Q(C_WD'K7T,A_"?SKTQ3]P[ I*7P0;KH*BL('-$E7E?I_3U$?[Q[03
M<[;>N!/^S_BNMIL%TW%:?;I_R=-/^EHU8M@=H[LSX^A'\..+I3;G_E,^AY]H
MI>>)^$$'^K\NEO[A ^)@/\/\NHTV<[1R!&C$[?VG3 6&0SF1_B]5S^+\CV63
M\T7MQ_9"WAZVFW1+BI/V<.D?E:+!7\W8':+9>UO\@&1&+I>/P**C/]/8>GEM
MKG_DH3^-_J^SHRM[2X7_ '%0CY_\6>G##[RV7B8/L]B;2K<^5'+;5VUJ'/\
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M/_/U:3F!#_Q#@_U?LZQMT+AY5O6;R[(R9 MZ]PJ?]MS[5?ZV<)_MKNX/\O\
M(?\ !UIN9BO"U0?E_P 5U/A^.?6# ,U-F\F;_3);AK#_ -"V_P!Z]ZA]J]L/
M^_>D9Y@F_H_L_P!GITH^C.JL:"L.T<'657T!R$A_%_I8&_\ MO9O#R!M-O\
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M@'1A;[;=77PH?V'_ "]%:W#EMH[?SE5NCJK?NU,3D<L@.X-I5N2_R6J/%R"
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M;_8R*/L'4\8/.[?I_-#L_I;9GU_R[/;D_B=[_P!+DB_^P]L&T_=W%$L_\/\
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M'LS_ '/?#_EH2?MCZ2"^M1CZ2GY=>'4O;,\_^1]S+5'ZF\E6/^*^UIY:O_\
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M_!_L]*#=6Y_XA#_JK_FZQ?P#?\7_  '[DR-_Z9';=.H_WF_NWU-U;_\ $O\
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M _[/7?\ ??:W_/2[:_\ /_3>[_UCVW_E,7^73G[JW#_E%E_8?\_7#^^NV/\
MGH\/_P"A!2^[?UDVS_E,_P"-#_-U7]T[A_RB2_[R?\_77]\MG_\ /5[4_P#/
M[2_]&>_?UEL/^4O_  =5_<EU_P HQ_WEO\W7FWWLB(?O;PPG-O\ EY4:_P#$
M>V6YKL?^4BV/_-SJR[5<G\+=,E3VQUQ&.=PTM4W],>+?\3;_ 'GVU_7.P'_$
M@G]G5AL=R?PTZA'MW9=P(5SM;S],?MVL'(_V/LLO/<-+?^Q[_P NE*[#<GB!
M^WI-Y+OB&C!IZ#8^^:FG:W.1QG\,)M_4"P_K^?91/[F01GLM^_IZ+E=KK^W8
M#^?31'WQDL@3X-OX3% 6O_'MR5>,_P#C4<>R^+GS<=P_L0/]7Y]+?ZJ!>+-_
M+_-TJ!V#O<6^WQ'7P/U!_OG?_>W_ -?V9Q\ZW-QY67_.;IL\NVP\[O\ YQ?[
M/71[%WB$M5;3VQDJ<7YPF\J0#_;<$_C\^V/ZXW*G.D_8W_%],_N2V<=IE!^:
MG_+3J;'V54Q#_<GL'=M*?K:AQHR/^\P*3[-++GGZ;^VC_P!7[1TT^PZN%S7^
M74R+M39 4_?97(8NIO8KG<?68S_>+@?['V:0\[VQZ3G8;D>7["/]CI20=@;&
MJQ>'<&&8?]K0#_B?:H\V6%U_Q(B'Y'K1V:Y3\+?R_P _6=]\;<3F7<F%/X-\
MA1K_ ,1[T>;-J'&X_D/\_28;-<^2G]C=,-?VSM"E'@_O'0U+<_\   ?Q7Z_U
MY]H[GG3:K?A<'I1;\MW1_#0_L_P=,=7V\IN<9MW/U.H6/WWVF*I?]?56 GG_
M %[^R.ZY]M_]!_ZK9Z,!RK.>)_,5K_+I)U7;&Z*N]LMUOM;\C[[<0R=4/]C$
M;>R(<W?4?Z/;?\Y/\U3TJ_JP!^%S^6/YT'3#/NVHJTM4]I9JL:]A0;(VZRC_
M 'BEY^OM,]T+P_J7=S3_ (1_Q=.O-:6=J/U+1*_TS_Q?6/\ A_\ &"#2;:[+
MW#4$?\#<]DJS:]+_ *X(_P!;VQX/[RA\&""3IPW_ -(:EE^P"IZ6VW^K</)B
M"=W$U.9!R(%=09*K^YI:8?6C^]_K$;?GV*N7^0G2'P9O\ORQT77>^S7![?\
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M<'2>Z/QS1Q4F5/\ M[#V4R[X_P#Q-L)?\'^3JWT]M^"11]M?\XZ;Y>S]J_\
M*1U-N87^A79(7_>B/=!NEG_OBX_[)NGA8N/QC_>A_FZX1]E;88_Y!T]OF_\
MTP;) ^O^(N/]X][_ 'U9VW_$>X_YQ]>^A?S=?S/4_P#TFRG_ #'3W8XM_P!F
M_2'_ *)O[>_K-#YV+?LZ;.WU_P!$A_WH_P"?K/\ Z7*^Q!ZB[&_Y"VX/^*#_
M 'OV_%S##_T;STY^[%_WZG[1U[_2V3=JCJGLK\@C^[?^]<>_3<SPC'T'3?[I
MKP=>N7^FG&?\\#OW_P!!$>[?UGA_Y19/]Y'2C]U'_E*M?^<QZQ2]U[4_Y2-E
M[O'_ )* _'^N?;7]:(3_ ,17_P!X'^;KR[0__*5:_P#.8_Y^FJ7M/K&J_P"+
MGLW/7YXKNO%_XK;VT-VLKC^VM)/]YZ<_=LB_#=6O_.8]).LRGQ[K/WJ[KC/T
M=3;G_?F5>*O?_#4;#V6S7&U2=.+;WUK^(?MK_FZ8=71 (^Q_TDXN_P!?L1E1
M[*9K#;#_ ,2+D?L/^;IT1W XZ#_+_/U[[_JS_E'W?W31CZ?6J/U_VWMO5;?\
MI%S^P=/^)=C\,?[3_FZQ+E.OW%O[]][U(^FD"J_XK[T;FU7_ (D7/^K\NF==
MU/P6,?G_ +'7$_Z*Y;&8][97Z6YJOQ_MO>_I()_^4F;]G^SU0F4</#7^?^;K
M-34?5<JDTG5?9.X*D<G[VAJ[#_7_ 'Q^?;L>RVUO\5K<_P"K]O2N*ZNJ?HW2
M#U\_\W2UH:L8X#^[WQOKVJK'U5^-I<=_Q%O9C%'/9_#MO31B%R*W%[^P]+&#
M.=WU=.*?%]68+$TI/ R&X0#S_C"5_/L3)^^[^&D-A;0_\Y.B"<649[I&/Y#I
M34<7;_\ =W,_?T/7O][/'C_X#04_WGV.D _<?<<WU:+Z/QJM^+ B6WV_?!MD
ML'^+>,67_CR_E_J/GT7,UC]2#5Z9KPKT.'N1>B/H!>VLEMRHI$VQDX]V4U4&
MQN>H<YA<#6;D2EJ<>;Q-PK\V/'TO<EC<GW'7.U]MDB?2WOB_L^WY]'FS6\D\
M^A-/F*$T_P AZ"^+LW<%)^S_ 'QQ-7_09'8F6Q?^]#W&O]9/I_T8=7_./H6?
MN16R1'_V5=<(^Q<]46#;PQ],/P:/K/+Y?Z?ZX_XCVB&\7C_VO\K<=6;:TM_P
MU^V['7*3<62JN/[^;\J_S_N!Z>&-_P"MQ'M5KA_T;Q/^R/\ V>M-: _A3\[S
M_8Z\M##D!^[MOOO<)%KG)5YVP/\ ;?<P_P"WO[W (+[^V^IF_P"J72$W##@8
MU_+5_FZ<(=I4@'FAZ$R-6UO^7[OBW'^M:;V:_NJ'_HV?]5.M_5/_ ,I@_P!Y
MZR#:-3"+Q=([$;\#[_<U*W^]4_M]K=X_[&TZ8AFMX.-XW[.NUV%EYX!;JKJ;
M^H_W(L./_.>WM]+2]N/[&TLOVQ]7GO4'&[D_8>HTO7M8@M4])[3)/_.BWP<8
M?Z_U_P"(]H9]JOY/] _[/>F%^GN.$C'[4_S =07P^ H69<]UUVOM^F47:MP&
MXZO+TO/]31U/ Y_I[8FVVSVK_<VWN8/G]3)/_DZ6>,R&B21M\BH!_P!7Y=2L
MA!U?0X[$UV.W+VQGI\FK-A<+@]QY;(5%4!^>?H!;FYX_Q_&[Y=C3$'UQ_P"<
MXZM;[E>7%:B-?4D#'\_Y]8O[N-77-)U;V55C\G/[V_AO/^O]RH_V_M"=HLYO
M]QK>Y_XW_FZL-S;_ $>2/\EK_@/7([$R,H$Z]4X%5L+'.[[K<M^?\"/Z>_)L
M?@8^D_[/>K3;H/\ E*_[-*=3XMHY[%J;[:Z6V\.3_$'QAR)_VS7/M5##],?^
M(W_93&>DYD$GG(?E0C_-U*%=D\3:"?N+86)I3S;';<I6^O\ A]P/][]J)C]/
M_;7=M_U3ZN%#&HM'_-C_ )^FZ3<^)-_XI\A<@1^!CA2XKZ_]4P'M-_6.S_L1
MN7_5,].>"W'Z+^?^SU!.9ZBD!&2[KWAE_P# ;@K%_P"M5_:)]TVFZXW%S_U4
MZU!;7B?#&@^R@ZFT_P#LN4I!FW%25?\ 4Y[<E8!_UE'_ !3V<0S[5^.?_LX_
MV.F;V&^_T5?V ?Y^E'CL!\?*KTTB[%JV_#'*E?K_ ,A6^GM19G8#-XU>_P#Y
MJG_-TB9;BE*-^P?Y^E#2=<]45E_#MK:%:3^,=*P^O^%_8D\/;[__ (D1#IDW
M5VG\74ANH>M66YVY0TH!Y./RU:Q_VVCW0\L;?=G'_5SKPW*\M\U_XR/\_4?_
M $0[3I[>$[II/\<=O3+L?Z?0U/MF;DF&?/3R\SL?3_>1_GZR?Z)L:PO%N'?E
M)R+E][5)_P"B?:3^H>WK_P!?.M?OVY/%5/Y#J!6==[5H01F=R[LG/!TUV^*O
M_>@OLON-AV2PS/<=*;?>+MO@51_M1_D/3"F;Z1V$*J>C_A];D:3C(+0K6;HJ
MN3_RNFUK?GVT^Y;'M?ZT/ZW594OK[!Q^P#]F>IU+EM\;]IOXKA:O'[!VK5<4
M.07&?Q+*55,+_P"O%"+_ .)L?=K7>;G?/[$_2_X:=62*VV_B/$.,5HH/Y_[/
M4*OZIV7+.M9NO<N;SV1I>#6Y[>G\-MS_ *_''O4O+MA>3>-N%Q'^?3Z[M<V@
M MEH/0 GKBV)Z%P4_FGKMI-5 ZOOJ[)G+6_VU@?I[4I-L%H?[?\ [.?]CI#.
M;B\' _D /\O3HO=74>%/V5%N*A"#C[' 8NW]/^.)O_MC_L?;HYTL-L_L:_\
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M^/75E-/Y:.DS#5'_ (<0_/\ AI'^^Y]V7VWV\XG+?L'3,W->X'_?7[#TH?\
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M:/8V3M]3C]G50^O^/'/MY>=/^4?ZG_G&/]GI//L94=Y0?G_Q73G3=F[ID_X
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M?HMM86M!0VU<U].I-'O7/T0$4>5V/NFG87M0;B_AI_V/E)^O^Q]HI;_P_/\
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MF_N\6X6P_L(/^J/3_P!#<CB__5;_ &.H\1VK+S2]6YVI ^I&S+_7_7M[O]5
M/^(DG^K\STF <<;H?[U_Q74ZEAGEO_"^GP0./]R I,9_MK 7Y]OZIO\ 0;4]
M6\8>=W_AZ=4'8%)3\T>T]ET_U!-LB3_A_J?]]_C[UX5Q'_OO_G+_ ,6>D_\
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M!4'[5ITH8MY;^JM@?Q<49RV97('[$#'?PS[FE_YV?@_XGV)3N4ES8?I?ZO\
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M?]<>U@]NX_\ 1]S'\^DYY@@_#9_M/_%]9TZ(VA(OFSVY]]Y[_4_?[NK" /\
M6@O_ +W[-(>0-J_T:X'_ &5CI/\ UHNAA5 ^R'J73=;=$8(>:KQ6T;D'_@;E
MCE!_K?NW]FEML'+NV?[[_P"<G_%=)Y]ZO[WS/Y"G6:??O2& A\:Y+8=.OZ?L
M:*C@D-_^"PC3Q_P;VIN-_P"6;;RC_8!_@ZHEINMU_%]I8_Y3U"3Y ;"<^/$8
M?=N?J +Z<#M*J'X_H-)_WOVC7G?:8O[&W_XSTK?EV[N1E@!\Y1U@3N?<#J4P
MO4&^*O\ J:X4F*/^]$GVC_UP)I/[&P'6OZNBW^.0?S_S]>;?O<U4+T?5-!2#
MZ?Y=N*D!_P"(]M#FC?+G$&V_R_V>MG:[)>-X?R_XKKJ7<W?7'^_*V& #_P I
M>X+'_>/^1^Z3;UNQ_M[2/\_]D]:6UL%X73?L/^;I(YK<?95+3U=9F-B=3+3T
M_-<]9GP_U'Y)U*+^PQNF\36GZSVEM_SDC_P5Z-;:V2X(6"Z>O^E;^>.F?;FX
MNI=VX'<>?WKUUA,#C\ O^69R@QUJ2J(X HP #^?Z_P"V]F?+^Z[?O%GXVYV$
M5M]G5;NTO-H8+'(6^1\NF&2/IEU^[BZA[4Q>/ N<ACZ#(<V^E[U)_P![/LD-
MQL]S^M#;W7_&^EHEW.^P7@)_ZA_\@ZZCD^/4@M/E^P,4WT!KLAD+<_X<^T+[
M+RW<?VWUG[)CT8PINJ\!:?\ 9OU)3"?&2=?.F^\G_337[@J[_P"/]D#W>/E#
ME63_ )2?^J_1/-NV[VW\/\NGBGVA\9(_\UN\_P"QW)_V#]F\/)/)MQ_Q(/\
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M!]4*%M-#4^?^K\NAN]R)T5= #V%VK0;&SHP57AS6J,>M<6H\E_"R=7//^O\
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M_P!OP/8>N+'F:W^ -^W_ #]+H+GE]Q^N*?;U ,??%/\ \76IWP0> ,+D-O\
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M*Y^?;F#^VM;C_LI/2A-MMFP+H5^0ITQTW<68SD_@PO7%=E;?3[#(4G^2D?\
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MK4Y^IKMQ!?I_7[(K]/9S!8WE?T;#P?\ FXG^7HMFFB_%*6_('_)TYC%?(;(
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MP7^Z-L4(^G+8ZB//^W]F Y?L+C_BNF_JK@<2?]Z/^?J?%$8.:;'_ &'^-_\
MB/\ ??GVL-G]-UK46'KU-LO^KO\ ZX]U@EG/_$?K>.->L9E-S<"W(Y;\_P"%
M_=Q<0G^WZ;-Q\NL']+LH'Y%C_P ;]WA$'_*1_+IXV_R_GUAEL3?@7_H+_2_^
M]W]J)YIIO[']:G3(_P 3X]-V9RV(P6/^]S57C\5CJ0^BOR UDVYL./\ B/\
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M/^\@C_>?8GM+ZPM^%OT5M979XN#_ +8C_!T_#MS9L%A)A-U8CB_^Y#956/\
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MBVX@/KS^&'LJFY _WS?];7F?^)5)^P_Y^F>HZF[5Q(/\ [;K:NUO^![?6_\
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MT_PU>_#DS:I_^(O^'_-UL[M=CA=?X/\ /TP5?2?4]6 :?:5'3'^M _\ "O\
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M>BD[N'_/KJ$C^@JN;_ZU_;PGWW_5C_)U6E@/XCUP:'NACQN/K&F/ ]./J?\
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MF*VSMK"_M8[;U!B[V]5#C=7U_P!C[.[2WMK'I$;JX;S_ &]*.)JF 6)'^O\
M[X>UO@?+_!TE$/V_RZSPO4"WJ M^?K]?]A[]6O6OH1_JIUSM5_X_\DC_ (I[
M<T_,=-_3_/\ P=3(I7^G']/]]?VY],.F1'7U_E_GZETGW(^OT%_J2/Z_B_\
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M_5^SK<^YP7.0I_E_EZ4=-A]XTE/XH-P4=)3GZ?8;;'^Q_/L\M-IN+'_1Y/\
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MG_BNEAWF8<?\(ZZ@Z]VL!R:ZZ\$C)?\ &_Q[;/)=N_5?W_<7'IU)_N7MFW_
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M/A[AZRN+[OHOS<Z3_O'!]N0^X^U7&(9H^FVV"\]#_/J%D^[NL<+BLMF<CNO
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M\Q7EL?C-/2B_] ] %O'K4;,S6(H8,MC\BFX*UJ.AJ:Z*3;J4@Q=O\[6$SR$
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MM0I][&Q[C_RD_P#&.M?O+;_*T'YW1_S]=#:V\1_G^R\C_KG;*#_XX'^'M_\
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MXKM6IQ]*<>:P9VJR$V,I>?\ E%M%*_/^'T_P]A_==XO3=?2PWY^E_C\,:?\
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M[N.7D_W\?VR?]!=)?WL3_P 1S_QG_-U!R&$WFM.)J'>QB!%M55ZA_P!9&?\
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M\<,E,!_O%/[V$WK^)O\ C/\ T#TS6U R/\/^?K,E!ON"<0S[QQE-^=)Q5/\
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M&8G_ 'D'V_\ U,VC^!/VR?\ 0?3'[VNA^)OV#_-UG;IOJZ8<;$Q=P;\S3?\
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M_9ZM]6_I+^UO^@NN_P"$8S_G48;_ ,]U#[;_ '-MG]'_ +)NO?4MZ2_[T_\
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MLA^#^8U'IYQ.V-T[>'WN-ZJVJ]1;_@>=QZJK_P!Q_K_L/9S!LLVW_P!C:?\
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M''=^5@/W6Z]EXRG_ .F#;]7?_>;6_P!O[.+.TWBY_P"4=/\ FV/\@Z3$VD?
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MO@_ZORZHVY.WXC^T]=_W=VQ_SS. _P#/=0_\5][_ '%9_P"H?[/5/KV_B/\
MO1Z]_=W;'_/,X#_SW4/_ !7W[]Q6?^H?[/7OKV_B/^]'KC)M7;TA_?VUM\'Z
M?\ *,_3_ )#]^_J[8>HZT-QNE]?SU=-\VP=C55_OMM;1JA^!_#Z,'_8DM[O%
MR_8?[[_GT^-[N1@7)_83TG9NFMA'_@#A\CBK_P#.BR-;BS_O(_XCVEN^5K.X
M_P!CIT;O(!Q_:*_X*=8FV#NO& ';'96?I  ;X_.VW2!_K@'_ !_I[*)N4MP@
M_P!PI[G_ )R'I.-PM&^-5_(4ZZGRW;.*-\ML_ ;K@M_Q<,'7C%57_4FMYN/Z
M>]0;]NVS?VW?\^EGA6<I[33Y$5'\O\_4%^XL7134M%F=M[MQ.2K+?8T QJY4
M?]8 I^MO9>?=*W\;P9_+^71@-EN"*J5(/$CIPD[+J*DAL!UQOO+3$%5&1QK8
MJE!'Y_>)_K]+#_7]FR<XP7']AW_ZOET5S[>5^-E'^'_5^76)\=VSNA--;FL'
ML[&@6:BPC#<]6;?DSR@ W_P^G]/;/@[ANY_6G\#^>/Y].JUI%P4N?GCKA'T_
MB)U!SVYM]9Z<<?Y?N2L/^Q$,*\#_ &'M,W*,,>&GD_YR=/Q[PUO_ & 4>N/\
MII_@ZG1].=>1+_QZ%!4G^M9E*S*_G_:0;>S&'E3:1\_]7RITG??KP^=/R _P
MUZ45-U[LB 6AV5M._P#48VD'^]$>UD/+]@/P5_,'K9WNY/&Z;\@?]CJ>-J;<
M@ \6VL"#SR:&D'^\%OZ^U*;-8#_0_P#!TGEW>X/_ !);_C0ZD?W8VW_SS&#_
M //=1_\ 1_MO]W;?_1Z9_>%UZO\ M;_/U!DVEM0\U.V\!_0*<?1H?]AZA_O7
MN_[JL)/]#Z<_>]S;X%T?Y_Y>F*HZVV%5 &;9FU"WY_W'7_WJWMT<O6W\'5OW
M[<>5S3_5]O4&;IS8,P'VV&R%(>?^ .2K,6!_R4/9>.4]O/\ 9?YNG_W_ '?R
M_D>HR]48>,:<;N/?6,'UMCM\+_O5S_C[33\GP+PGE_U?LZV-\8CN"'[5/^4G
MKH]=9V#_ #7:F_*(?@9!:/*_7_$4_ML<NSP8AN.O'<T_@4_RZ[.UNS($_P F
M[2H:^F//^7;*HD_WDG_B?;IVG<X_@N/^J7^QUJ&^VZY_MT/^]8_GUV<7V_%<
M'=^Q:OD<#;M3_MN*GW9;+F*W_P")%M^W_8Z>@DLG_ X_-?\ /TF]P]<[[W9/
M2U^6W/MS$5%'?[&OP.VZP57^V%0+>PYN/+.[;Y_;74?_ #BZ5;=N-G85I;'Y
M]PZ>Z;K//TE+]O/V]O@ "Q4M2*/ZVY_Q%_9O8<J3;>NGZBY_YR?[/2*YOPTW
MC>&G\Z?X.IDO6<\H K>R^Q:P#_4Y&XY_P]JOZK?4?VUW-T[^]:<+2']@ZQQ=
M/;/FM_$J_.[A/Y_O!N:LC^G^)7_6_/O8Y/AM^/B?\Y.DAWIO*@/R%?\ *.G#
M_0YUR5)79U"/^UH]O]M]/][]J9N3MO'^@=5&_79\Q^0Z<8.K]AQ']G8>$'TN
M6QQ/T^G]??H>6K.#_B/;'_FW_L]:-\[?C;]H_P W3G_<G:L0_8V7@OK_ ,ZZ
MB;_B?=_ZL6'^^(^DQW"Y_B/\QU&J>O-CU?\ GMFX/_SW4)_Z*'N@Y6VX?Z!T
M^-WNAYG^?2:DZFV!P(=LG$_DM19.MQ7^]K[;FY4V\]77?KOUK]H'^3J%/UBM
M)_Q8=][[P%K\G<8RM'S_ $-;I]I/ZJ%?["XZ=_?>O^T16_*A'^'K'_#NW,.0
MT&Y=H;JIK"W\>H1BZK_82T7 ^GNEY!NUIQG\?Y_[/2@365WY%?L./V''28K>
MZ/[OM]EO3;2TM0 >,%7T>Z?]C<_OC_;G_8>R9O<:*S;Z::W_ %NC6#EGZV'Z
ME3C\Q_J_9T]MVE1U%/\ Y+M+?=3<WL^W%'L\AYIDN?["W_U?SZVVS2Q_$P'V
MGJ,,_OW,W;";0Q^WZ;Z-7[MR0MQ<_P"9AMS[9_>E_=_!!X/3?TUK:9G;5]G6
M$[:[!JE$V1[(%*/^5#!T5&/]ZN?\/I_L?;_[MW*XSX_\NG#N6WK@+^T_[!ZC
M?W K^1/OC?57_0?Q'^%?4_X^_+LA_P"4CI5!N(/X%_9U'EV#4 7_ +\[X^MQ
M;)W_ .-^Z_N#_1O'EZ5?O #&A>HTFR,Q!Q%OO.*?^FXTA_XD>]_NZ8\)QTZ-
MR _#^SJ(^U=VQ7\79%;]/^5"D/\ O5_=QM]\.$_^K]O3HO[8\0/VUZ[;![]3
MF+>]&?QSMM?^-^V?W3?#A3IX[A:M^$_MZ@R4._(ASN':M2/Z';P/U_UK^[_2
M[H/]]?S_ ,HZN#:'R8?[;_,>L<DF_HK\[3FM].:O%G_>;^VO"W0=+ ;5O4?L
M/^?K!]WV!S#_ '=P9_-OXB/Q_A[>\:XN.G--N,U_ETG,M@-W9"HI*S*5>#J3
M2@C^"$U0I2?\?S>_]1;V77>S7T'ZT.>EJW5MD9'SQTYR[GRM+<9G;E?3'2#]
M_0'^*VM_M_9NFZ7D/]M!TQ#8+^%J_P"K\^H\F]MM>#S'+T1!6WV?^//%K>V/
MWC%!_;=+Q;'A3\_]0Z;ZC>ODF%'B,1792<7+$,,6/]OQ_7V@_K#%<?V/3_[I
MTBK4Z;IY>R*P?L4F/Q2@_7C\_C^GM),-PN^E2_06O4!]L[TF_P"!.[13_3^C
MGW8;!?3_ !8_ETI.X6PQ"*_SZZCV9FS]=[UY_I;U?3_D+WO]Q;C_ *C_ +'3
M7UZ>G^#J4FV-R1\1;WKC]/J ?I_L?^(]J8-FW0<#U7ZZV?B/Y ]9TQF]J?AM
MQX2J _%=CPG_ !/M:(+VWS_J_GTVUQ;MY']O^;H&_D9NWL+8O1/9>YMOU6$Q
MN8VSLC*Y?'5V-]5IZ!P" 9K6LH'N\LVY0Q$C ) /[>C'D_:[;=]UMX)LUK2N
M1PK_ ).B>?R]^\>\.^-H=KR[XW7C]SU&"S&-IZ.MR]'34 I8,E3,#ZHH/H0@
ML#Q_Q*!KB_W>/]0U%!6N>A][D<I[5R9.((QFIIIJ :?93H /DC\Y.RZ;L7'=
M)_&+*/)7TN<_@-5F,%1_QZIR648V-#C#+J8@FPE _4?ZWY0;)->[8Q2W) \J
M?X>'[.A)M?MK9G;/WIN8%?GY?Y.K->@=C?(7%['@'<_:YW9OC(N*S.1R8:FJ
MH,:%'%+2F(VE+#_=P.GV(;BWW CQI[FF.!R>H7W>^VKQZ6=MV#TQ7'0\2;;R
MU93?>9#=N<_-@1_"QQ_K_0?["WMJ':)I_BGZ*C<J,0J/\/62'9&WS3^;)??5
M=2!_RG9,G\\<C@>_1; @_MI_]7Y]/G<9SP_P=.%+M3!1&D^RQ- =;<?FW]/S
MS[,%Y?B@_P! CZ1S;@3YGIXBI:>'[W_(A2&CL3^?Q[=-EX'3(N-74L57C^R^
MM+!5@FYXO;\>UT5IXORZJ3XWS/4>6H6!O +WM:W^N+^[0^-K_/IK'@?ZO3JN
M;<?S:R+?,7!_&3:FS_\ )J+<G\,WKNS.5_DU*F*%>8</2DV2P!(GL2?ZV]EM
MQ>Q)-]+IP#0'SXT)ZDVV]NOJ>7CO9N!7_?/#RK_@Z6/S3J?E3%M[8=5\9!4?
MQRJRN0&[QC1C&/A^U7[,'[[U:=%_K^?K^/>Y9)+<(4)I\O7HLY%LMKFFN!N=
M/+!K^?\ D_/HT_5\N]_]&.P5['(&_#M+:_\ ?@)_G/XF:7_*=?B_/WEKW_J?
M:I83H[J_G]IZ"%X8?J#X-*?+[!_+H2_N1%3@U%J,V N?Q_QOVZ?UYNF<4ZX>
M5KBHU6Y^GU_WW^^_'NGBPV_Z/5/GUXU&1$Y\!^\6W]+#_;<>]BTKU74/0=1Z
MC^'U $$WV%5]T?\  7_WD_[W[33;5]7_ &T'5M?TO G^729K=B8+(6M1_:_X
MT/JO?_6]D5WRK#/TN7<V'2<DVG48V>V.RWW5B1_#VR55B^?]@?K_ +'V7_U5
MFVF'Q8?\O2X;D),''[/\AZPT>+R^<@'\.;-8RA//\0KMQ?Q/C^MN3_7W402[
MEPZ=EG%I\1%?D*=.O^CDS?\  S+U]63<V _XU_Q'MF;E^&W_ +6;IH;K7RZY
M#K_;45.)JW^(?UXR5_9H_*5H>D4UZW^H?\5U71WM\J\9UO\ )#97QQV?L45N
M7S^X.OHMU;XS]>)8(,7O72S18ZEA"JE1ZA8B_P"?9;/M]E9,%"X'\S0'_+GJ
M4N7>3;G>]LN-T-Q3144_,BM?RQPZL&D_N%BIQ1"C85-OZU@^O^'NTMI8V/4>
M?XR_4EZO9]-]G"-MU]P/JV-O_4<_['W6-MLO/[:'_JGUZ&"YFR#_ #Z<(<SA
MJ07I-NUR4YX_R+&\\^U:-8_Z#!TS%!..)ZF1;KQR+Y/M:VF_\ENK_/U^A]F'
M[Z2V_2\#_JGU4V$[>=?SZS1;XQ,MO]R]#]>+#_BOMV'?K/IH[>P_V.GRBS&/
MJO\ ,U5!5C\<<_[V>/9I'NT5]_H_2)MOT^7\O]GIR\]7_JE]N5AZMX7V=8?,
MO^^_Y%[>T?\ "?Y=7\+Y_P"#K!Y#_J1_R5_QKVYX/377*HR$&/O-6U5!1C\$
M ?G^OT/]?93--]/_ &O6Q#J&!_+IO?>^W5MIJ_NS_2BQU7D_^B3[*;CF"SM<
MGQ!]G_%]>AVU[G _F0/\ ZY)OG' 66DSEK_\\Y5FW^\^]+S/9#_KWU:;:9_E
M^T?Y^N?]]\;_ ,<<Y_Z#U9_T=[]_6>R]/^J<G2?]R7'K_,?Y^IR=@X?_ )4\
MV+GZ_P!WJLGWJ7F.QN/]^?\ 53KW[CN/E^T=2AV#MSZ25.:Y_/\ =^MO_P!"
M^Z_UAVJ'^R,O[!_GZI_5V[/DO^]?['4R/?FU?Q5U[#Z7.*K/Q[=_K7:?/_G'
MTC_J[??ZJ==-V/LJ+B;+&EYY_P!QU8/K;_'WI.9K?_5'TFGV"YX?Y1TXMV'L
M.7]W^\6$Y']I=7^%O;J[WM5QF>G26;;;I< '_#TVUF^NOZN"JAHJ*@W54Z;_
M &&"VT<E:W];_7V2;C=;5_PSIA+"Y&:T^T](79^[,CM05U'DMC[J&/JZ_P"_
MH*&AQA/VI/'V?U%_8?Y?YK;:_P"V@D_;3I9>V4%[\+#[>/4?L'M#$M0?N[;W
MU15-KF^W;>Q8.<X3_8]%R;2?E^WJH;OGL.F,U3]CM7=E6#]#44/\,M;^EK_C
MV:MS8J1?JP@=)X]IG7@>K7^I\!N;*]6=8Y./L[=&)%?UIL^L_A[+J^T"XJF'
MB%S:PY/T]@-K'<KB?QA<?X>C*L<-0R Y/$<<]"HN'[%IC^QVED19N/OL>1[6
MMMFZI_Q+Z3S7%I<\;4=34F[FC&F'LG"5/_4?MZW_ !!]I!<;]_O^/_G%_L=,
M^#MO\)_:/\_4B*M[KDY_OCL3_P X?^D?=_J=[]/Y#_-TQ]/9#^+]O7"6@[5R
M'%=VG18NQ'_%AVZ3_P 4]LB+>[C_ $?_ %?ETU6T7@E?M-?\/0-=Y;(RD?3G
M;]?D.P-[9@T>P<[I+5W\.I3:F'UN/Z?C^GL >ZFSWIV&XGN)Y'H1CRXCY]"O
ME&_2"[MA BBI_/S^7'H3/C7&C?'WI>Y'JZVP8/XN33D#\>S[VDA5=EMO](>B
M/F1IYMQNO2H_;UF[^[7EZDVE1Y+$XN@SF[]S9K'[6V7B/J:C)5XY:_U,,/\
MO?NON'S1-MEC^C]OY=:V+;!NUQ1B0 *D_+/^H]!3%T+W#EJ#^.[C^2N],7O.
MKH#7U_\ !J&FQV#IJC_C@:4']Z'^ME_XK["-IR5N>YP^,-PN$E]#QZ5'=[:T
M.D6BE0<9J:?LZ7'4/9.\Z/96ZZGO+$T&TLMUWFTP]7NFNQHQN.R5.WTRU'P
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MI$5'<>U2O@PQW!NBH -SM+&+D?\ K.3X?]X]DLW/ULO]C6Y_GT8#E^XGRU%
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MH,S;A<W7$G[,?YNE[%^_2W_QXL/Z?\C]J8HK(?Z!W]4J3Y]< 8_R"/\ 8>S
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M!_M]!_WKV6R\X[5Y7:?L/5EV.[_Y1?Y]0#V]AJM?]PVV=^;@_/\ D6WZQO\
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M?K_K$^VY.=;8_P"C]++?9+@>0_;U@D[+VB>31;N'XXV_6?\ %/:;^MMM_O\
M_P '2K]S7/D!_O1ZQR=D[.4VE6MHS^?O\96?\5O[:_K;:'_1S_+I1^Y+\< /
MY=>;L'94MB-QFE/]/H?]ZM[40<QVT_\ H_6SL]P,Z:]<CO':,UQ!N3' _C_<
ME;_B?^)]K(=UL?GUL[?<^G\NLD68Q,@_9S..JP. #D_Z_P#%/:V*Y2X_T?\
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M;YR^1VQBQO!VHJG.5-:,=7[%K"LK4@D-@DFEOI];^TVW12&Z6+5IJ:'TR/\
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MJZJQ(O3<_P!?K:G[LOMQ@,GBCY5RQ^?0NW3GG9MHOA8PP'P?]$H!0>G^H?\
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M/\/0CWJ.SY6Y1@\:"EU-_J^5>BN]R]&[OV7\NL9TM7;\J\QNG.9[9JTN^_\
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MSD_;TQHKZ?RZGQ_?RCFL'U_LK;_??[?VSXT7EXG3.G3Z=9]<O_*SC_\ >?\
MBOO7C0_T^M=9H9JGCA1;_:?^-7]N:_\ FITT8:>G4CR^;_E")M^" /I_L?\
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MG/YC_..IT?868I!_N:Z\W]2<CU4.-.4_WF(>[0\XS6_^YEI)TG;:5;X;M?\
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MJ%;UFZ_V>0/];VR)Q_RC]*@/GUR_UR.?]A[<N)I[G_B/^P=.@ >?7O\ */\
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M7)^/1_+IL2VB?\1R?F3UX;(WE-8U?;F^"!?BAH,3B_\ HOV]_5:6?];]X/\
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M/^E/0T?S0=U8O>O5716Z=M[QHM[;5SVYLG6XG-X[&_PLSDXI 9&4_FZG\7L
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M-W4N+WSUSL7&;<K>OV2\U14;>IS2PFF8#3(:KQB]_H +7]KHMZ@LH*'5J4T
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M>'^A !_/M9O4=G&(&B%!0<1YU_S5Z"WLGNDVVWL]C??VTW#[/VGAT'^+ZO\
MY;AZ,Q?:.:WYV#_?.GQ%"F=ZPHNQXQECF? ?N:(4!C_S=K<ZR?K^>/=H;;;C
M I+'5^5*>OP\/0]5N[CFZWWRX@AMQX>37Z<\/+'1\?Y=VV^@!L_>^[>DMK]J
M8'"[ASN-QF7':E;'D5GGVP2Z_8>-4]47DO\ U\]@.+^S""TL9(J*N3]A_P
M^?49>X=[NGC?[L[@/HX8(/YU)].K)Y,'A#?_ ""XX^F*][_=]OT"_K;CK%+M
MC 2?\NC'_P"Q(_X@#W3Z%3_H'^K]O3WUUQZ_X/\ -UW_ '0V_P#\Z:A_VW_2
M/NG[CMO]\=>_>L_K_@Z:I]IK0S-5X&L_@500 P;FE-_Z@\7]^DVR:OZ/A];-
MZ&%&S\NNT_OO".!@\L?H /\ <:?Q_KCWH17Q_P"4;^0_S=6_Q8?Q?S)_R]<_
MN]Y_\Z'"?^?"H_XI[:T7WI;_ ,_\_5? @_C;^7^;J;&-[2_\HN"I[?2_W?\
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M%8;"X3#X7;NUL6F$VOMZCBPN%PU)$8EIJ?'FP -N23_M_P#8^\WK6%;50JX
MQ2E!U'MQ<&N>G#]KR^/_ #\W^/LP!!/2+KWPLZ'R'S^_F>=+=:XV&LROQ[^!
MFYL;\CODANJG!^SFW71F0[5VAY#Z9Y144RR31?J,/WC+]0?>-_O'SDMM#]%
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M!_3QF_\ L%O_ +W[(MPAT_ZOMZ769J.H?D_P_P!Y]EWU)Z4^.?3J+J_VE?\
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M_P" ?8-=4TY_.;H*3)?\2?8NL_<+<X.,VO\ U?/HE;8+4^5/VCI5Q=L=G8X
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M#IWBV=OK<W^4;YW;_"L/47MM78P&,O<?2;)?YT?B_P#Q7VHBV&\W?%_/X/\
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M$_\ &Q[M^Y;8]._7W/\ J/39)U[MD_\  -:^C_Z@,E5D?\3[T=BA'3AO"?\
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M-@XZLV_M2AK*RMIZ;-K4UA^XW#4B2J'ER!%@  !_KW^M_:FVW2,KX<E?\/\
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MS9]4NG:0]^2/6E<_ET[SBH%_!I-R3_K?[S[6PVUG<3?K5Z>:7&*==1\CD <
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MB^]]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>]P]>ZK_W1C,KDOG"(,-E_P"
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M:?\ 'U_G_EZ+9+-_WJG"M#CRX'_5]G1K_<X] ;H%=U]C;1VUE#C<MF5QM2:
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M.AIM_+-Q=?'3_#T&.7['[1RES"VU=K0$@7H6_B=5_P 3].?Q[C;=O<>]O_\
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M[13>[L-Q_8VS_E7_ &.E(Y)QFY_ETP2]V=FU-1>BV508"$@_Y=I_B=5S]?\
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M'^W^OLENO=R[N/[&T_ETO@Y*4<;H^O4.JW#V=E0!DMWT.)I--OX=M+'7^O\
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M7]]/-Q_ETR-KM@./6/[;>A'-7@Z07_-!6>W=%R?]0Z1^#;'U_;URG7?<(O\
M[]2K_P!8?PSZ_P! /ZW]HYX;B"3S'2B&TMO&_P!1ZC1[DSE ;9_:%=]O^:_
MC^*'_;\CVKAWN6#^UZ<.W*<#INR-!B=UU/\ $\-F*$9 _2AKN/\ 'Z^RS<4?
M<9O&,_2A8H;,4ITSR;:W7%Q]KB:OZ?\  #) \>TT"[B?[&G[.GS<)_PW_5^?
M66/;FYIC?[3!4G^OD@/][/N\$%]/QKU4W%MU+CV/E)1>MR^/I*<6'^18[_??
M[Z_MZ7;)O]&GZ9^J!X#IPH9Z>+_</LVD^Z^U_P"+A75_-+]/]M6^[6%S]/\
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M?[&WTY]HV&CS'2V&W^HZSG*[DJO^ >U*X7'UKLB?][M_Q/NTLPG\_P!G3AA
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MU83+9!Q1-:UM0/\ O'T_U_K[;%O%'_Q703^H^F_XOK)&:?S^ "QM>U_]3?\
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MR)_P$=/D796WI91#5_?8NHMR:W&\?Z_U!^GLVCYSL6Q-T73[-<6XQTN,9N7
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M^GK>5K?_ %5Z;OX1N.@XQF8_BOU_W'YVP^G/^>^GM)]/-;_V/2CQU;B/V?\
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MD4=FBCJ:]GJ&^RH:(BU^$8-;/[3VH;Q[K]G1_><^W#KX4&!]M/MX?/TS7^9
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MGZ6#;3Z=1_[\X_\ YU6<_P#/</>X>883_8GIH[:?,_SZ[_OS@A;S"OI3^/\
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M3UB_W^DW_.BI;G_IKRG_ !7Z^]UW*?\ XC]>&CU/7A0;LDL!N.@N+G_(,?\
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M[U/D.E518Z@QW[.,HS2 V^OL]MMMALX?!ZU<,;HU/4O0?\/:GZ:7I-X9]?\
M5^SK+[9Z>ZP6']1_O/\ Q3VKUP_ZO^*Z3]9?7_M/^\^V?J8?]\=;U-Z_X?\
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M /\ AZ$O;%'"_P#*P:>*0$CKS<0$%OJ!F)?5_L#?VTT/97^D.B22<GFNE/\
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M_%^8)_MDZ&;X*]C;(R/QKVCUW3;HP-3O3&;=W<U1M=JVT\'V53PLD?YU&6_
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M)_Q;_BGM)+-:0?VT_285/ ?ZORZ>H<_@H3ZJJ@/^&F__ !/NW[WLQU7Z=O\
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M\W63%9W%Y.;_ "2LM/P31UYM4\#_ 'CV7-54STJ$/Z^>G&26",_O_P"24W'
MY^GO6L_;UKZ8?ZJ])V3=N)DG$&'HZ[/U'Y^QN/\ K-_QKVWXK>>.K?34/'_#
MUE_W^-2?^7%@H/\ SY57/^W:_M_M^9_D.J]<HL'E:HWK-V9K_&YI,;]?]C[>
M,2CR'^K\NDYG'^K_ (OJ93;8)M_N?W7R?J,A?_B?;QB^2_SZ8^HI_J_V>G%=
MK?G^\&ZCR!?^(6]K+>"OD.D4]]T]4NT<3*?\MJLY5< 6KMQ@>S6"W/R_9T73
MWWETJ*+;VW*#Z8JAI?S_ )?_ -AK>S:"TB@_MC_J_+HJGN2W3Q4#9TMX*L;4
M'U TBD'^]?Z_LSCM[2X]?Y]%<T[#KG!CMB_YZCRW\+'_ $Q;C]F,%I:>?^#H
MJN&;I1TN+KI;3X7?0JZ<?4UQI,F>/\+_ /$>UUO80C^RGITS<)ZK_AZ<Q_?.
MD(_XL65X)Y^\Q?\ Q3V<)%N3<.BR9D^?^'KE'G,Y#<3;;_I?[#)#*>Z_O2:V
M_MH.J?3J>!ZS_P![*>'_ (&X?.4MOR,<!]?]<>]#F*&;^V@ZU^[3/P/62/=F
MV9?IF&I?P37_ .XO_8>S!-\L^F)]N8>73K%E<35<PY?'C_7R1_XI[=_>4,_^
MC]>\,KY'IQB(E/[%P>;$>[^)#YW'5?ISZ?ZOV=>DL?R3<_ZH>]B<]>\ ?ZA_
ML=-U3FL32_\  W+T%+_Y$;^VI]R,'5O#U>O3/_>W&U?[.,HJ[*U X_R'&C\_
MZP]I?W^?]1Z>^DIU[[G=F0'[%)08 D_2O'\4JOS_ +'VU^M/U;M7K&-NSU=S
MF]Q9RK%^/L/]QGT_U_I[T=EFG_MNK?5@<!_EZGQ;/VU$/^+/0U=AR*\_Q3_>
MO^*>UD.VV=OTF-V3Y]3J;#X^(_L4M >;_P#%M]O^!9M_8]6,Q/'K(];!C_\
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M?CG^=/+/08]0_%'I?IW?V:W7LM]U4&>SU%7T=5'N#><U;3?;UR_=5=S&H+6
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M4_R])*H_E_?&,;)I]EC9^XJ&G&3_ (ZN7QVXYCG:B>_AO-6E= AL1^QQ]/\
M'E3'%%\5:GA_L4I3^5>GXO<C>A*:&@I7Y#SKQKP^=/ET-U9T!UK7]/T/1N=Q
MU9N#KVAP5%A*.'.UJUM28J(WI2M>/W!+2F]IKVT\<_FKQH10U!K7^?V=$-EO
MM[;7GUD-#BGI4T]*_P"7\^@MZ;^%'1_2.Z)]X;/@WNV9KL?7X%$W!N&:NIOM
M\B+7/C6XX_QX_'/MJ211B(U'E04_P4Z$&^\[[CS ?UZ8I7/F/MKT]],?&#I7
MXY;DW1O#KB7/0YK=F+;&Y-,_O.?/?Y,U2M5>(Q*"6\JC_6_ O[96Y5PT2G!X
M8_S =%&[\PWO,_T\-[_H'#]GS)Z<.Y_CGT1W[#2U'96!DK,])0BCI-R84B@K
MX"O^KJ8[J?Q^.!_3VR;^-C5FI_@/2W9^8-SY?_W"S\C7H+NN?A+\7>KLY!N?
M';9W/N?.8I/O,.-\5-1FZ6GJ1R-5*H'^\@BWMI+V-&[C7Y"G^09Z.=ZYYWK?
MX#$2!Y>A_:3_ ).AS[IZEV9W_LZAV7O3%[FEV\:ILPM+@*Q<#4?<8^]P9'!!
M%B?]C_C[U]<-5#Y?ZO\ 5CH+;?NLNU S04J12M"<5_+IPZHZXINF]D8GK[8N
M,K8=M[9-?)!3;CKA75+??U2U7$B\+_L/]YY/M1/=F!B!Q/\ J_P=-[K<B_\
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ME_L]$7^;_P R=A93XI?+[:^%PV:R-'F/C?\ ('%8[.$4N/IE:KVKE:*]@-3
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MN3HZ#-?9[9-(M)2TU>+T@EK)ENWW8L3_ *_L2<Q^_6Q["G@P?K#(K3T%3]I
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M9C4ZC2@\OF?D//\ S]%AS,N1QJ5+UE,?]QE8:.LMS!3SG_=7E^E[?X^P.=K
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M>;/?[9^CT)[#?K6^X'\C@](Z/*8K*7FQM90U7^\>PW]7,//H2:!U#J8K\?\
M(N?9 ]Y]?-X)Z7PC2*_ZO/I/RQ_[ '^OLBG+T_S='</@=,E3%:P_/]#_ +[_
M %_91)-3/1P!3I*Y/)8N@@_W(U=%2<_\ /K]?:!5BN>'2P ])QJ:@S,Y.)V9
MFLZ!]31;?T_U^O/'M7;\MWMUCP?YU_R=.MNHM,EA^>/\O3Y%L;>4G_%OZ?K$
M_J7-*/Q].?9A![?;K=?Z#^P'I&_-UK'Q8#[3U-.U]^TG^?ZPSM+^0:!:5?=I
M.0=UC_XCR_SZ<AYCL+G/U(Z3M7EFQTP&<Q&Y\#/P!_&]O50'^PM[03\NW]K_
M &UK(?SZ6+>V]T.VX'Y4ZDTF7HJX^;&U=#50'C_7_P!?V3%?I^..E/3A(X!_
M5:W^!_WU_;&N+IOP#_JKUR^A_>^G)_K^?>_%_P"4;JWG_C'77JD_U5[_ .M[
M>[DZ]^A<]-U91T5=#X<E2D4Y''WWMEC3AT[;\/\ 5Z])S$39E\D<3M.FS.^,
M?3 BNHJ,?Q$4Q_ZB_9_9\MW6XYBP?LK7JES?V,8JQ ^9P*]*&JS%7BOV<[AM
MT8*XY^_V_;C\'S6]WCY:GLIO'EMATFAOH7%%N0?SZYID*&IOXJK^GUY]GDL!
M3I7_ &_#J94HDW[,Y^[_ *?3_>_=QI'27]8^O3'4[8Q5?!X3_$*7G@4//^^_
MV_LJW. CTZ6P7G35_</%$_OY;-6_ZC[^PA,)_P#0 .EHW/K/%LK C_/&NJK\
M7_B/]/Z^TEO$+C_BNMSSSCI]HL7BZ'_@%34-+S_7_C7M3]03\/1?-G^WZF@_
M4Z?K]1[5O<?3_H].305Z:ZS/8RBG-']W]U7U0/\ D5#;)5/^'X'MP0O)-X/\
M^ Z3T@MQ7I1XG;'8>=!.(VF<93#G[_>]?_#>#_2'\^QA8^W^X7?G^0Z(;GFJ
MPM,G^0Z7U'T=O*N8+GMZT5*; _98/':AS_268CV-;7V9$?\ :S?M/0:O.<!<
M' /2@I?CYM^H!_B^X][Y1R18C< QX_QXO_Q/L1Q^S6TD_P!M<?X/\/1?'SG?
MVXP%'[3_ (.FRK^,6REF\])N#>U+4TMOLRV0&2^O^L#>_M//[16'^@T_9TO@
M]P[\<0/G7'^?IFR'4/8V#].*RF$WA0?44-</X94G_C?U_/L/;O[:7=MFW[OL
M\NE,?.B76)P1^6.D755]1A)Q%N+;V<P%1?\ Y3L=_%*4_P#3Z_L#W&Q7.V_V
ML(/\CT=P7T%UD$'I[Q>3Q>3L*/*T-58W_P AR '_ !KWJ/PA_HW\NFLCRZ5S
MXVGKX!]Y1T-53?2]?Q_MO]]^?:RQTSS_ *'ZO15/-.!G'7HMF[:E-_X50?UL
M#_R+CV<V^WC_ $: ]%\US/Y'KDN.ZXH"3+2T8J1P*"A/\4'/^)]KI+.UM_\
M53I#-<,>E+CO W_%@V+?\_?UY_AG^^_V_M1$81Q/1<01Q/\ EZ?8J7==7S+5
MT&WQ?_E QO\ %/\ 8_X^Q%#)>7_^^^BQIE'SZE1;5@FO_%*RNRM_S79+3[M^
MXQ/_ &W28S4X=.]/@<12\T>)H:4\?2Y]K8=KAM^F&NF/3M&((OKS_K#_ (W[
M-OIX>D_C-TQ97<^)PMX9:L&?\X^A_P!RHX]E$W,"V/2I;2=ND[_?H?2DV[75
M7^ _W%_[U;\^R9^8I+G_ $#I9#MDP\^H_P#?7+_C%4!X_P"4[(^]3[Y>>72D
M;:O66/?>6'^>Q%!^>/XG_P 4]I1N]R?[:#^737[HM_(GKA'N/$Y:?PY_;GVG
MW0^P_B'_ !=/]N/>X;Z%_P!&6#JAMC;94]/LFT,#](J.OQ53<_\  ')?PO\
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M #14Z%[O&L?'_ SX]83G[_<N=@KR;WXQO\1%O^LP]R3S;=3#EG98/^(]'/\
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MW)LVBVGG_A/U_B6'W\.!V]G*VMA'_*3N?*T,TTI^O((]C'F7EVWV?]S-"?\
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M*.+J_P"(E/CB?XMG=^;RKJ\6^E1_'<?1K_A](![A2PBCBO+&4_Q#_>?&-/Y
M="K^W_>$/V?X#7HZW>DB;L_F'=)8*/\ R@[0Q.VLI6G_ ((<AD[_ %M]"/<R
M<XV45]S7#;S_ -BZH/RH2?YTZ ^P>%#R]<3C!.O_  T'5?V^:>6K[6[!V'M<
MBDVKNGNV2AAHJ(DT]CE&6C_U_"*LV]P5?[:%WA[%#I(<JM3FG<G[!FG4L[7<
M6?[JL;W^V=,G]@/1X<]MV@P'\PKIK9^U[4]%L_8VV\>E-?\ Y1\9BJ\_[[_'
MW,MGR];;=SE!:V8K&9%S\_#J>H[M)YWY-N';CW?\>Z ?LRLHLWWE\S-T51%3
M!MW96X</$5_)2LQ&(A/ ^NF/W%'.<+7&Y31KYRAO]Y/_ $-T)-L86MAM\OJ!
M_,$_Y.A$^*T34/874_EM_E/QBRM8/]?([@JA_P B]B[VLMF@WZ"0?[\(_8.D
M_-$T.X;?<3?\,'5DMOS]Y_A?Z_\ $^\N_!^G_L>HCX\>NB;<_9?>?X?CV@FF
MZ4 >70$56?RN9GJQ/EJ[%T]*.*"AX'/N/[B]^O\ ]'Z$T%L$'#J%_#: &U_N
MS_OO]?V[#8Q6_"?7TN*$^77*/'4'_*I1?T'/_&_;W[O'^K_BNJ:CUFDQ]#^:
M2@_Q Y]I_I+/_1NF=3>73560XRF'^1?\7>Y^Q^RXJ>?:25'M_P"QZT(X3QX=
M&#PR5\.(PW\2%LA]B?O[?ZY'L?[2DTEL89N@_)$+:XQT)&(C<[$W==!897!Z
M3?\ K7@<?X6O^?<C65O)_52YA\_TO^K@Z"4LTG[[3_;?\=Z-3[R5ZBKHJ7>>
M#I]Q9JEHP?M:FDH*"M/']#:W^PM;_8>\<?>NTAEG@\;J3N1F(0T]3T %1M;=
ME+/>&DH,K_2O_B/]?]Z]P>-J$']CU(?[P#=0(L%N27G^$G_SY'V\6W(=>^M7
MU_P=3HMG[NGY_P AI/Z6R7]?]Y]Z_==Y/UXW2KTZTVPN3-F:P57-S04'^XS_
M  _UOQ[6V_+W22XW+I?114X/@I_K>W M^/\ 8^Q5$_TGZ/13XWU.>L/NW7NO
M>U'2?J!E<-B<M>>MI+57YK_I]?9+^XO'Z,%E(Z2M;LHFH,]#6_Q6F_Y4,[DB
M/]]]?9)=\OWEN.ER[B#TY8G*8FBGH\9/B#@,CQ>A_P"1\^W[&:&T_1_'TQ<W
M9NN[B.E1_7V)X9H>D!ZZ]ZZ]TR;MP4VX,?1Q4]9>II:XU_\ #_\ 8#_??3V1
M;Q:37!Z76KA?V=!X<7GJ7]F?;C!OZ4 ]AF..\@_T#HZAO5;@>L/CRO\ SI\]
M_P">QO?O!G_WQU[ZT?Q#J1#AMS2\0[;R'/\ RNCVXMG,?/K4\X]>GJEV575=
M1_N9J_M*<"QH:'Z_[;V8VVV?4<.D=Q= </\ !T(,<1I*?P0?\!A] ?8CA3P.
MB9I:\>I'CD_H/^2C_P 5]O\ U/\ J_U#IGZ0?ZO^*Z@UF4H* G[RKQ].I_YV
M N3_ +Q[8\77T\%^GX=1*;+_ ,0'BPVW-VY6F')^QVZ/^NU_>OI4W'_0.MM/
M!&*E@/S_ -CK#7[*W'D#Y8>K3]R%_LY&DQ=5;_6AOQQ[HW)MY/\ V/3<N]V
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M_D=#_$!D_P!5O\/Z'^O^'L \S<@)8V_C6_Z.>C?;.;IWN MQ0@^?#^70?87
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MZ_\ :?\ >?8DT'HI\4]8?;O3?7?]3?VV(?'Z]U)/FOQ]/S]/=Q$]OTV#,?\
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MTZQ?Q"NE'[.&K?K?_+^/][/M&6/^JO5P/+K/]G7S#_*:M:3Z6%"+_P"]^V?
M Z\9J_ZCU(CQ%##;S &H_K[<BABZUXW3GQ&OYTC_ &/U_P!Y]K?TO]5>M<>H
M\T5!6668+4V_I<_[U[;DQQZ;%3PZ:9,/3D>:A^_I2;7./!_WW^\^ZBW(_P!7
M^QUKQ^N:TV5IC>&K^[I[6 8<\?X^V?#(Z>U5/^?K/'FX!>&M_P E(^E_\?\
M6]N13]:,%.'4K_)9?\;?T)'U_P!C[5_7Q>O3?T_IU%J<ECX/\_66)_*GGVGE
MNJ]/ T%.H_W.0J_^ E)]H0?KD%/^]#VW]7X_#KW#K+]OEC;SY;[>WT%!CM7^
M\\GVF_=XFZ;)QC/4@8NI/$F9R#?ZW'_%?=?H*?ZCTU6G6)<0/QF:^_\ MO\
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M!]Y/54([6VGC1^:ELI1I60@?U(8?[R?<S>V>R3\R\HSV$WZ>G4WV&@)_90]
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M+"?*YW)82AN +8K;;" 6_!)(-_\ 6_Q]A+EC_')O'G_U8STNW _2@(,T /\
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M.,746Z)03/OFAI#_ -6_;GM;#[=W)_T?_LV_V.DIYNMAP0_[T/\ /UVG3F>
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M5X K_P!Z_)_$-A:_/]?K[+(X:_VO&GGT1;3R[+NLW@P_9^?0$;N_F$=#;57
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M]G>>1RKM>\2,/\:D5#XH!^*NDT^TC\^@#SELO[WW#;93\+$U&*'S_P '0?\
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M#1M_<6'W1B:/-8RL:KQE7<,A/Y'^V]R!L]_#?P_K]!N2R,;%?.F.E!/^@?\
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M^+ZSPYO:<7TJK_3@<CC_ 'W^W]ETF]=)YV)ZD4FY(<W44>,VSAZ[<&2JR>*
M_P *I?\ J:/\/^(]TMKZYOYO!MN_I#</ @K<&G0G8;J;=V<(FW=EVV]3'C^
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M\<>G^'J0FWL?8B5<C5V/X5B.?Q_OC[6_N^;K7C#IW@I::E!AIZ3[4$#Z ?\
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M%#+L$T+S>3 @>G^H=+)YQO,%_3_1I/ /VZP.C=_RQJ=(.M>\.Q:L?<U]?N=
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M:*K;-MYX^7^U&>@BDIYMS=3_ !-Z?HW^ZRVZ>Q]P[CJUI!?[:#<F4&-I ?\
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M).#]>"+?X?[[GV=P24Z%, IURCE$.X=NU"\355?D:$_[#C_>C[>VO,IZU>T
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M</;W5.H!!'U_V_MFL-S_ &/5OMZ:J_,8;$TWDRE504E-]?\ +\HQ_P!L#?\
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M^.>TMH]/;WGWMMZKVC'NG9V-V^SY"$X##BE<RPA2UBH!''YY^GL\W':Y+E%
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MR2\'AQKY4X$Y.JG^$=/^U7-^U\O;7<P7\X!8G2*@$@ ?Y03T;/Y^=2[DW?\
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MZFN+C5J8G/H12A]?GY=,O67;N+VGU1WQU9F]OTV;QO9F$2KP];1BU2N:B8&
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M^\/8.R<!%Q/@:T;VSE_I2TN-/[/^PM;_ &/^/LXV6P_>-] 8?P8_9T0;K/\
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M^K\^I:;FS]6;T6TLZ;@\5WJ^GNDMU,/[&#I@(OF>NOMM\URDS5F"P$%Q_P
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MP@NR)J=+;;FVZF/J_L;&R[EK:BEGR>V7I:WG[J!(ZF)G3_IXMU^GY]R)M6V
M<O7T/]*W_P"TM>@Q/=5WN(_Z:H\O@/1Y?>4?41=,E;/:P!YT_7_6M^/8<W"'
MZG/SZ6V@Z"[>NRZ7=V-I1%5G%YK%5YR&"SIM_DM4WU7_ 'P]@[?^7OZWV?C
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MW7O?NO= [W+GIJ#8]3AJ"XSN\;;7PM #_P I.2_'^\_[S[).:+W]+]'X_/\
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M /%/8H_T;HB_#_J]>G^DAO<_U-@W^M]>/:U3P'15,M"?]7IUBSW_ ![>Y_\
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MT[UM0((:4:@3]$'];?[W_A[>5'3_ (OI---!;=1L'M6HG[/W#3U%J9AM7;C
MGZ#75V^G^LWL,V;_ %%^=?\ JR.BS<>8 EJ##GN-/V'HPE'@<=1?YF@)(MRZ
MV'^\<_[Z_L9P0Q1_['0$O]XN+G_5GJ3EIFH\)6S0V^ZI,?EAP/\ >?\ B?;.
MZS?3V<_@=([1=; 'U'^K^71;^MJ<Q[<Q%8+&IW ?X[7UWU^ZJ\L3Q_KGCW$F
MTPPR6WC?ZL=2%,WT\9'IC[.EHRWY'!'LT@GZ0$>1Z2>_J2GJMMY>:X^XQ?\
ME^/K;_\  6JQ?!_Q^G^^^GLDWQ/#A_1Z-8H_J6'1@\#45&2V[B:N:QJJFBQ=
M>U_\;'Z_X@_[S[EO9)OWQ#_J^8ZCZ['AL:>1(_P'I16']!_MO:OZ@_ZO^+Z;
MZ[]O]>ZYI]?]A[]U1^'0+[A<'N+8<?XI=K[SKO\ J9]NO^M[ UQG=?\ 5\ST
M9VII9M_IEZ%H_I'^M_Q!]CF#^QZ3]2_?ND_4&;ZC_EFW^]^V)//K=KP'^KSZ
M+#D=R[CW[7Y:'"91-O[.HJ\T*U]#_P "LG_#A:<WL#R/K8?3\?CW%V\;S-S?
MFV.CH:[=MJVU/J!4\<^5?\'3-)L/%JX$U9NSS_\ *[_>*K^O^N>/]X]I+78W
M0:YI^C@S0W!\  ?90?Y^LR97<VP=63DRU;NG:S$_QVASXO4TU,>+T<UP;_3_
M 'W/MP;A>;+_ &/]CTQ>[0M^",!O(CS/S]>A[AEIZVGI*RG'W5-5?Y<IO]./
M][]RA%-#/#^CT&Z'(.*8Z]_8/_(/^]#V\?B_U>O3T/ ?9U#][Z?Z;ZK_ (#R
M_P#!?^)]I^E'08;=M4[SWQ6\@??XNA_\]E'<_P"]>PGLQ^IO/&Z7W(TH!_JS
MTOY/HX']03_O'_%/8J?_ !>;[>F[?(_/I#[MW"-OT]*M/2&LR&4(Q^/H/J./
MJ+?X?[[_ !*>9+WZ?HRL[?7^1X]!L]/NJO'W%?N.MI#?BAP0 _XU[!C233XS
MT)([=%S0?:>N+4NZ<?S1;DKZK_#.WROU_P!?_BGO?C7%OQZ>-E >E9MK.#,T
M]69Z,TM?1_Y#7T(_WO\ Q_/L8[/N?U7]KT4W-J+:E/V]*&K_ .B?^*^S(<>M
MP</SZ;?;_3W74?Z*O_@A]IY/[>#[>JS^?^KRZ0,D=MX?C_)L"/\ >*S_ (H/
M9)_N3>]&WPV_Y_X.E/[.^F^O>_=>ZQ26A/GO8"P;\_4>VYIO Z]TCGW/7UEO
MX-1CP6_XN%?_ (?X'V&KO=9O]!Z7K8>O'J)_%MV 6(P-1^><=6$_[S?VU#ND
MO^B]/-8KY8_/I\Q>X173_P -K*48O($ BQ!'^P_Y'[,+/=]7^HUZ1SVWT^?^
M*Z4OL^\7QL])NO>_=>Z[/U/^N?::3C!^?5AP/23SAMG-J?G_ '(94_[8^T.Y
M?KW?[.MP'M/Y]*OV;]4Z][]U[KE(@N 1];$>Z18'6@:]!J0*_+9:LK"3_"J[
M[''D&WVUOR!_MO8,DC^NF\;HV@C"@"O$?MZ>(HO];Z<#Z_7_ &W/!_/M1--X
M/3JK7K#545/54XH);_;5?*V_Q_'MR6+]+QNJ]2=J5TU3B*6"<7GIAD:*XX_X
MM?\ OA[7;/+X_P#J^1Z*[OM_U>M.E;[/.F^O>_=>Z][]U[H#HNT>L\WVSB]C
MXO?VU*G=U+_'L?7;=H<W2FO>JH!^[ M->Q-P?R#_ $]D5^%ADU?ZATO&UW$-
MB;PC&,TP0?YX\^ANEN*C3<'_ (*/]?V()6Z*1-Y?ZO\ #US]MU'3_28RNY*?
M'S?94='_ !/(?\J% ;?C_;?[[\>R?<MS\'I1!;U'I]N.F89;=A'F^UV_2_D_
M\"[_ .V ]DL6ZRCU'^KY]+A8K]O[.I$.ZIZ6;P9ZD6EIJCZ5]$?\FY_!_/LP
MLMY\#^VZ3S[?7A_/CTN?]C?V=B[\?I$13KKVHZUU[W[KW7/0?\/;?BCKW2-W
M-_Q<-H_]KW_XU/L@W+^V_;TIM^!_U>9Z5_L1])NO>_=>ZZ1  %4>_=:)IU$K
MJV@I*<3SUGVE/] 1Q]/]N?\ >/:"6[\'K:J3TR_WQP,?^:3[G_@N._XJ![3?
MOJT'#/\ J^WI_P#=SM\OL_V1U,QFYL5E)S#1UG^4V/%N>/\ 8?ZWOT&Z6G5)
M[!AGI9>S#I'UF_M_\@_\3[46W^K^728\.O4_Z4_Y"_XGV\_#I,G#IU3Z_P"P
M]T3CUI^'2.7_ )F&?_#1?_W+/L.M_P E$_\ -#IN7^S'^FZR[@W144%<</AZ
M-LGF30?>'^S2TPO_ +NMS]?;5]OO[H_1_P!0Z<MK7Q!4X'#TKTQD;OJ@9I]W
M&FXX_A^/M2C_ &-P/K_C[*89[[^VAZ7&RMEQ2OY_[/6<;@WKMZ\U6:'=.-I5
MO7$?[C*H7_XK[K;;CN-O_;=(KC;T([:C_!T,F*R-/E*&FR5!4_=4^4H?O,?<
M?X?\5]CS9IO'_6/0<N1I[:<#3ITA^A_Y!_WKV^?[?_5Z=,IPZG>]]-=!-V)^
MBL/^U_[V/=3/\NFD&>J5]_/Y*[?56?\ E)W1D?\ UG'V7;,?'>?I_<<3+]G5
MA/7^S<%+LG9=96C.U535;+P%?QD+?\HI_P!M[@+>=A,]_P"-T.=MNR(2/G_E
MZ7%7LG'R07HZO.4>1I;5_JR-7D^3_K#Z_P"Q]E5[R\MQ_8_]5:=+()IP<T].
MNTRF[,3<9/$_Q2G'_*=@AQ_U)]ZFCW':_P"U_GUOQ4O.&.I=)O? N;5Q.*J;
M?\I^,O?_ &UO;*<PF3I!/L)GZ5-/D*"KO]E68^J_J/:Z&[B?_1^DYL?IO+H,
M^ZO^91=H_P#B/,[P/^H1?81]R8?]U5S^O^+_ "]&?+_^Y]MCHVOQ7L/C;TH1
M_P ^SVO_ +Q2G_BGO*WV//T_*^W#^BW^'J&.=L[I=_:/\'1FO<O]!+KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[JK'^9M_,0ZG_EM?'FK[?WU3UN[MZ[HS$&Q>DNI=L2K%E=V;JR"+)0XNAD(
M8BB\3)]]4JEZ6E9B@,DB*5FW;=/N]P4A!-*!57+,QI0#\^)P!U4N8(Z?M)\A
MG_#Y?MZTO^YY_F/\^)Z_>?\ ,&^1W9"8S<YR%;BOBETANJKZ\V;MNFDU@4-1
M#1LYS5<@DT5$\CSM)]9"S 'WDORK[6V]A%JN0?$(4Z8R BT)\Z5:M0#7!H,#
M(Z#E_NLGX /2IXG_ %?LZ/#_ "+._MS? CYBX7^7/F,W)NCXH_+*@WSV'T3D
M\U3Q466V_OO;]*:C,8FHKJ>[UD.8H:;]M)'+:A'(NA1,KQ][I<FKM0\=,J02
MOJ& R*^>*>7\R>ENU7HE717*T_,?ZL_Y^MZWW#O1QUK'_P#"A?YG;_ZHZPZC
M^#WQ\R&-PW=7SGJ]Y;*W'N[)XXULNW>O<33>#=N4$3J1+5UT%:M%"UC9GJ +
M3N& MY!Y<??+U8?PABP)SI2G<>(X@TQYGI!N<XAB,C?A'#U:O^3'Y=:PG4'Q
M1W'\5DH<Y\-/E5\A/C[V;AXX9$W+BMT/78/+5$2IZ,[MMF&/J()2@CE5XP&A
MOJ)!8')6^]MK.[@\,:E-!FM0:'S4C(/ D\/G@]$2;FL>& .3@_/K:P_D^?S>
M,]\O\IN/XB_+O$8+K'YV]48&+,U>/PD0QF%[%PAD$8W=M=$16BDC51]_14Y)
MC8_=4PLC+28R<V<G7/+<IC8:4X >3#.13^8QGRIT)+.]^K&M:E3_ "_;Y?\
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M?[V/;,T/U'6U:O07;OZXH-RSC.0U==B]Q4Z_Y%G, -0-_P"MK\_UYM[#V_\
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M04V0W/G,ANG-T/T^V_O-:T-OK^/:78]MT</Q]*+VX%RWV8_9T+(FI9N(>?\
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M .3W6/R4IMVY+K:/<]3B-H3XZERU9FL&E 6FR),G&@D#D?3^GM;9S+<'4@(
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MVN@%I0\:^0^VA/1YO/MONO+X\>:A3T!J3]@('1KL-^Y]W63<5%57Y-:^Q^@
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M=XT.!%4+$9!<[4"<'_:@I7_6O_0#W.?LDH%S+6E0&I_SD8GHEWH4B/\ IO\
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M\*X\QY_MZ#4=%["/$)SU)3'ZT-!N2K:D'Y^MO8:FY!LKCA_J_ETL7=9?E^8
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MGLDGCXZ<MS3J/[OT]UF_'_(7_$^T_P#HW7N@PA_X_#)?]J3&_P#N8?9+9?\
M)4N/L'1D_P#N.OVG_ >EC[.NJ]>]^Z]U KZ"#(05E',3]M5T/V(%K_UO_MO:
M5X/K8?\ 5\NJPS4./6O^'I TU3_"9SALR136(%#77'^54O\ 0_T/^Q^GL(^)
M])T>U^KR/V?/IWDK((:<RBIHA=KZS;_B/]C[4^-X^?Y=.B'/ ]-&._W\65I)
MHN,-BB<A]Z/^4JI^GUX^G^^_'MNU_P :EZ9O?\5'S]!Y#H3?8KZ)>O>U'7NL
MT7Y_X,G_ !/M'<<(/]7F.FI.'^KY](C*'Q;DV[4R#AADJ+C_ !'_ !OV5[W^
MA=P _P"K/1C'0J:?;TL?8@Z1]>]^Z]UW&-,];/R?^->Z?Z#_ *O3I$XH>M<+
M!X7%_)?^8[N;$=IQ-F<!C]W[TPC;=R1T0STW7.LT&//^IIK*%_P'/L*QZ]PN
MQK/Q$</G44!^P?LZRM2^O>3>4?\ $10?[^IFIR3]M34]68]U_P N3H+MG.;:
MJL7+4]:+0T@HJU=@8ZFQ8J:>_P!7'@!#4M^1S]1Q[7MRV]XQD4Z1QH<TIY]0
M[LGN_N6WV^?ULXS3/14_YF_QTCQG5777:6%J\OG<AUPN/V+G<[6C[ZH-#7*6
MI)IC>_[=?K%^?\\HO[27^T&W"B3A3H;^SG-2[G?7&V3T'C&N,9\^DI\E_E.F
M]?Y?G4D$&8>'>/9IH=E;KHZ:Q_X\$6S;$_AI_#%_L+B]O:C<;SQ-O13QJ2?L
M\J_G3J_)/*@V[F>X/^@P^OKFM/RQT+%!MW,?&+^6#FJS$"IP>]=[8P9C<593
M$-403=CU,%* .+@4V.4WYN"?P?:RX@^BM01\3-G_ $OI^8'\^BJXOASESA^O
M3P!PKZC-?VG]HZ8/Y9?Q_P"I]S]+9_L/=VQ=N[WW-FMV5>VE7=%%]\*:@QU+
M QIP)&%VEU?[Q_K^TVRVBWBEBNH@X'EZUZ,/>'F"]VW<A907!A@\.N./$C_9
M/1L^E_@CUST3W+E>XMI9K>^/;*)GFH=EJE+_  RAIL^"/M7;Q_<M%1W_ &/\
MK!-@;^SF/;Q X\'R./7_ %9ZCK>/<>]YAL/W7/D>9KBH\_3B/RZK=Z7"G^;+
MO1?HH[5[H%Q_RRE]DKO7> /Z9_PMU+E^-/(?C>BQ?X!T%_R5WYB-T?/K>&4[
M2V]N+?FQ]B[PFP%%LC;M(*RHGQ^W*0JM)%3G@7J%\TYM^2?K[1[A<QM=DR $
M5RI-, TXYICH2<C;6+;E>D4XM9YABY\JD?+Y]8OEUV!U)W1CMI5O1_QJ['ZG
MW;@:HTN9RG^CM\%3U% :8>*.V/8C_@5JN_\ K?CVYN>CM9$TXR-2D5_8,])N
M0=KFY;EN+?<]PMKJ%^']K_G^?5U/0NY=PYWIKJW>6YJ7+0Y#=^RMMU.Z'S%$
M:&HI\AC":.2>4D?\IO\ M_S[27$/T489LBI_D3U!._*(KZ>"&E5P,\00#PZ,
MC'()%$T/^5#Z?@?[WQ[M%=>O2$@4Z:<KD;7QN,_RG+U7UL?^ W^/^^_U_:&Z
M'CS=5'KY#^?2WQ='!0XRBH:<6IZ96(Y_K_QKV-H(O!7/1%.=4W3E[4=5Z][]
MU[KWOW7NDIN/_BX;2_[7H_\ <4^P]N7]O_J]!TH@X'[/\IZ5/_*/_P @_P#1
M/L0])?/\NN7OW5NN,0M2 ?[6W_$^VIC]0>F!T&RVH,U5T<IO3Y3_ "_'_3\_
M7_>O84O8?H;CH104>"OSIT]^U'2WJ/45T%'#6UU0+T](01;^O'_&_;$H_1Z0
M#CTH]E4<U!A**&72:CBN-_P<E_R/V?;8#X/Y_P"3HDOR"_\ +]G2R?Z?['VJ
MM^/^KY=(>O0?2/\ UV_XGVMGX?M_R])U_P _^7IX7ZGBWX//^I]Z']C/+TQQ
M(Z1>TW\N7WA4?4-GACR?^U72#V%MH43TE^7^?IZ[-*?9_E'7'<^#KX*_^\&W
M_P#*\E1J*&OQ_P"K[JE_Q_YO#_?6]L[_ +9X'ZW5+.ZJ*'_4>FFFW;@I[P?=
MBDJ2#]_19 G&57'^M:Y]E9WV&#^VZ.C:,>'Y'CU%GSQR0&)VFHRN:-Q]]0\T
MM-?_ ([37(]MM+]7-X4/269?I15A3Y>?0R[6P=/@L#B,?%]*,*03_KGV/]MV
MS]V0^#-T$[FX-VQ8<.E=3Q:K?BY!O]?;]OB;I%<<.LWMSJG05[__ ,U6?[#_
M 'I?;;</SZ3R>7Y=4F[V_P" VZ?_  YMW_\ N4/9+L_^XH_YJ=.;QQ'V#H].
MPB(]E;5_PVQ@ /\ 7-)3>X YB;5NL_4I[=#^A^9Z5FJ8GZ 'V%82@F_L.E_A
M3>O7'R2_CZ_B][>ZSZ:=57QO^*KTVU=5!)/]I#_N4GJCQ0_3_??[[_'V47$7
MUX\'JTL.G/0T[7H)\5@Z7&UH/W-*2;\_\B]R'L5O]/#T$]RCU'I!=V_\R@[4
M_P#$?9W_ -QE]A7W-_Y(EQ_IA_A/1ERS_N?;?ZO3HVWQ7_[)PZ5_\1EMC_W&
M/O*SV7_Y5W;O]*W^'J&.=_\ DJ7?Y?X.M>W^:K_V_O\ Y!O_ %$_(O\ ]TTW
MN6A\'053@G^K^'I4?&K_ +BH/Y@__B@G1O\ UMVG[NW!O]*/^?>F!\*_:?\
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MZ/&PX+)?&CKG>F1J*0F1ZC*[QH(\UEZMK?VYLA5R2,+<.X7Z6/MMA2E/2O\
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M@<'_ +>7;(_WB.'V&_&#4IY5_P *]/Z<-^7^!NI?>O\ W%/_  <_\9U]S_\
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MK"I]OE=QX^FJ@O\ P"L<M5<_C]@\?[[GV2[CS#9;?_;7!Z?3;Y'^%:_/@/\
M*>DU_I)W#DD-/M#8>?R@8 '(YT_W7I>.?]W$S?[S_M_9&.;IY_\ DFP=/_NU
M5_M& ^RI/7&+!]K[C);/[DH=J0<'^'[3QW^5<?TK:SZ?[ _[?VHBAW+</[?]
M'K1>*(54%OF3C]@Z?<)U=L_&9#[VHHQE\C8VK<]E/XK5_2_Z91_K^U<7(YL_
MUI^FFWEKL4!_8#3_ "]"2_T!)-F)]B&*\^G_ $>FDZC^U'3?3A[]U[KWM/U[
MKWM1U[KH?0?ZP]L7''_5\^O= V\<-'W>/$!_N7V &-OZXNL^GU_JO_$>P:1X
M&\P4_P!]XZ7K4P5/\6?S_P"+Z%V#^W_R#_Q/L8](.I'OW7NH %^![M--]/U;
MAT'V[>R,#M:7^%_[D,KN.J_X!X' DY*I%A_C]/IS_O7L,[US'#LG]C^72RTV
MMKW)H .)..D5_I#[%F;53[$P%*2+#[_<>JJ_U[_;<_['V&_ZX;P/UOI^CO\
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M3U<GD@J8?ZX_)@_\A&W_ !7V6RYAZ71G21]O^;H'^CI;=98V#B^*S.=PI/\
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MX.K?%UW[KTHZQD6-K_[Q_K?[;VX(9C_8]>K3I%[BW?MO:$ EW!EL=2W'JH%
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MC[IU[K!4?3_D/_BOO9X]+(^FL14\7_ ?_6)!O[UT]PZD^_=/=,M1^E_^0?\
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M.TF%Q]'FLR,>,>*BI(;RRBD^EI01]/Z<<6]G4L<UTJ>-GJ!);Q;B:<K^F*U
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MQ]__ +EN/]?CVDGVZ&?KRN5^&OV 4_P] ;V7L?8^)VO53X_:6"ILS65^,PE
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M"]O\>/\ ??[W[176YPPS=4%J3P'2/V-GL%%BC][EZ 9"KKLC7?8?Q'Z_Q/\
M']?9/M-W#!#U;<48GAB@_ET+%/)3S#STY-5].;WM_M[>SZ'<(9_['HM(/G_J
M_P '4R-N% %OK^?:HR5Z:ZDPQ*+<&WX'_$GVT;OIG3Y]3H/T'_@Q_P!Z'LQZ
M+>ID'ZS_ ,%/^]CW1^'7NI\D>CD$GFU_=/&'2?H%NS<MC\=BJJMR%908RFIK
M6^^-_P#6^G^^O[;>X2W_ %>GVMYY"/.OIU1WWM5YK.9VKWAMK&-2X[$T8H:&
M"M_W'5&6I_ZV_/U]A+3/<2^+'Y_RZ6F6%!0_LZLQZ]W1#1]?=<R9_%9W;8J=
ME[/%!75N-!I2%Q5.!]; WM];_G_;P[N6YOM]Z?%@N#_S;DZ$EH\+ T(XGS'K
MT*<&9P60/^19:@JN+VTE?^)]M0[I#/Y?ZOV=&1MBO3K"U/S_ )7CQ].1DM7N
MZW\,D'C=(IY#;GKEY*>$G_+: 6_ZN7]/]O[:FEAZ3BIZ9:O>.TZ"WFRU"?Z_
M8?[E?;,VXP^75!&QZ"OM[/5V6ZB[1.'VGNNHQO\ HUW *_)5V._AM*/\E-[?
M@_3W'WN'<37>UW'A&G</GYCHXV%Q:W]M4BOD*Y/1U_BMIC^-O2OUXZRVNIX_
MU=,?>8'LA+]1ROMWS4_R/4,\[K7=+O[:_P A_FZ,Y[E_H)]>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'G_L?\A?\1[;DZ]T
M4WY"?+/XS_%K 4V>^0?=O673&*JXZNOQD^_M\46W*BJ7#D6DQ\%4'DKE=E N
M ;7N ;W]UMH9I,I$!]I _P!GJ[^''D5-,?\ %FO7SW?B]T;)_/F_G>_+3M#9
MF;WET5\8%K,]O+=^\.C:D]?U^4P^!88+;,KS#R(<QN^>.3(5)DB,A262J*,
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M )K'^9Z&/_='F_W1_7_??[Z_L3=,=)S([LVW05!@K,M0_<$_\ *$_P 4^GM
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M_'V+"]G;>1_XS_GZ0AB_37)B</-_P(V_1U5C:PQ:_P#1Q]HA96=S_P 18/\
MLF7_ *#ZN7<<'(_VW^QU"FVALN0 S[?V[.?IZ\32@_X<!/;K\MV;?VT%L?LC
M'^<=46YDMN!8'[3_ )>L/]RME1W$.V]L @\?[BJ<?[R$]M?N#:_]\0?[P/\
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M0PZ-;F[C"!I8QJ;.,&G[:\.A)\/;^.B6.LAV)F(#8_=TU=E,:W/_ "R@=?\
M>?8D>7=[#\:R_P"]_P"1>D?CPS9[A\J*?\/3U+7[SOSMS;K6%O\ B]U)^O\
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MZ8_09A9,=5<'\^%)1_C]?:>:VNJ5U#3Z9K_@Z\&7T/Y<.L\^X,C2$BKVY/5
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M[?NJ_P"QE=5DX_X)[93:KK<\7; _9J_R@=;^H51513YGKC+LI:5EEVQ6_P
MJ#:YM>EJ-5N&^I_K]+^]IL4VUTFM)Z?;_L5ZTUX'PPK_ (>I-1G,SA%)S>&F
MK#IN:K;2RY"G'^!\R0@?\E>VY-RT?[E0ZOF*T_F!UI0'PII]N#_AZ[HM\8C)
M2?;0U,4<QY--D&AT\?X"4M_O'M^'=K6?\)_XS_T%U9K,CSZ6$4 G'^3G0#QS
MZO\ >O\ 'V90-$/[($?L_P A/2-O\5QQZZ^U/^J7_;'_ (K[>\?K?C'KWC'^
MT_\ ) ]M>%+ZK_J_+K7U0^?\ND[ELWBL->:I>EC)Y_:,?Y_X.Z?T]I9[Z,?V
MLK'_ 'G_ "MTX!Z#IM@W>,F0V+Q.=E%@!]U?'4W/^,'F_P!Z]HANE<0X^W_8
MKT_]'IXD?ED_M/6=J;=]<!XZG;F)I^;BG62O/_62.(>WO]VMW_8NJ?;K_P"@
M>M52VP:G^77HMJUU1?\ B>X\[+_U"$8L<_\ !"WT]IVVV:;^VF)_U?.G5_J@
MOP@=.%-LK XVH,HI&KY[7O6#^)6OQ>S:?:V'8K2O#_!_GZ0_6,1Y_P NGPX?
M%5,)AK<)2U?UY&-4_P#$W_WGWM=IM/3_  ?Y^F9KAJX)Z:6Z[P#?O4E.N'J/
MRV$R#XX'_DE&_P!Z]IOZM"W_ +$B']O^4=4^M/GGKC!'O#:JRU+9*'=F 1+I
M#*LARL5_J$*(\<Q%_P"TR_3VBD3<=G'QK<?;JQ^Q3U53'>&E"I_D?]GKR=L[
M3FY#5US^3)3?_5!]J&Y[BMO[92?LT_Y6'37[G8\"/Y].F)[%3*TH^SVQN]@!
MZOOL<M!]?^"-4>V+?FBSN?[)&'VE?\C'I*]BRC+#_#_FZ=ZNMWU4CPXK%[.I
MP.+9:NK,C_3GBDB]JH[S<;LTA('VAO\ (IZJUJD>6)/V=87VIOZM).2WP8*<
M#_@'M[&@'G^I;0?I[;GVK<;\?K7%?EW?YNDHN8TR%SZGH/-Y]<;;H(#DZJ*L
MW'DJ;D5^;R+9.]_]= +^WH^2XE'CS35^RG^4CJR[@QP!2ORZK![T?UY2_P#4
M>QAM7A7,/^*BFCUI_D)Z)9YCY]7(]24E/)U!UI#6A:RF/76S;K7 ?\ZBF(_W
MU_:+ZE]X@'V>?^QTF629';A\1_P_9U.J>KNOL].)J_9V&AJ/J#+0#%?X<Z"W
M^]>P==<J[;-_:P?ZOSZ6/N$D8H"3_/H*.T>K^N=K[,W!F,7B:C&Y&FH0*$C*
M3<:OR=4H/TO] ?8*YSY-L+7:? AKK]32G^?^71[L_,%U>2#413SQ3IUZTZ)V
MO_!Z7(;J@7(9;) 9'[:KNJT]*/K!9PCZO]=0/\?=.4_:^V6#QKLUKY"H_P (
M'3.]<T7%:)2@Q7S)Z'C%;)VO@*:V*VW@*5@+W&/_ -?_ !O[D_;.6+;;LPP1
M?F#_ )N@K)=W$QRQ_(_['0:_)>HA;XZ]S74W'5&[QS].*5+?G^O_ !/L)^[\
M(M^7=Q_1'P+Z_P 7V=&'*<!&YVAKY_Y.G?XM@?[+=TP">?\ 1AM4'G^M/S_O
M%O8I]GC%<\K[=4&FD^G&OV]$W.%5W2ZZ,_[EOH-=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3Q_-N_F58#^6]T%M[<.-V=6
M]C=U]V[KGZGZ%V/1UE/#CZG<U>B/]UFE^Y7)M@L:SI/7M04%94BPA:%(ZAI$
M6[9M3;S<43)9@B+G+'%< X'$T!Q7IN6X\"*AX#+'SIG^9X=:94'0N>[9["W5
MW_\ -G<\?RI^46ZZJ?*9S=N]8'RFW<!#"?\ )L+M;#3JL%#24R!5B!@B<JJE
M1'J-LN>5N1;+8XXWD&MZ"KTHBGY FBC/S].@GN>XRR82@'IG_57SZ5'6V]$_
MEV?,SXP_+KI"G_N)MG=G;FSOC[\F.O=GJN,QFZ-L]J5\=#'.V++QXYLEC:PQ
M5$4DLL:I+&9%.M0 &O='EB*>U,Z454(210.(; (H: @D5/H.%>E6V77U,A4\
M:"E?(@FG^KY]?2(I/]V?\@?\3[Q2DZ%4G4SVLZ;Z][]U[KWOW7NO>_=>ZT@/
MY[_:&1^5W\Q78/P3S>1S\7QT^*746![[[2Z_^^%-1;OW1OJ2V%%?%"95FH<1
M2>$B.98R)IJDQI949Y@]G]B2_D:XDII [AD:BY%*TI@:N'17NMSH0Q^;5'EP
MX4S\Q7]G59W8GQ#Z$["Q-'44&R<7U9NS$&&?9W9?4D2;'W%A:C'\T551U5&L
M;-'$;?MF1>?I+[R)W'EBVO8Q"RK4<&  (/D<#Y_ZCT$[;=",>7H>MAG^2E_-
M+[?[([%/\MKYJ95M[_*#86P:[?O6GR!H&@Q^.["VC1,AUYE*]Z:O?>.+1I15
MM04-93U(CDDJ:J.6*9ZC$7G'DJ7EB8ZF4HP)% PU)PKE0-0X-3!^7#H;6-]]
M6-+C& 13@<4I\C_+-*];2_L(=*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ?LG%[@S/SZ;';8_A?\1F^.T2K-FED
M>E@MD.3^S'*W^W4<GW@=[F;++NON#2-J?XN.-?X37@#U._+>Y"RY;U&I'C'A
M2O''GT8+&=$'(S_[_K=U;G)N?]Q-&?X91@_TL+O_ -8Q[DK:_:>$_K74]7^7
M^S3H,[AS@9L(N/7!_P O^7H9=O[%V?M> _P?;%'2M8M^YC ?I:W]L>Y+MN6;
M'8\Q _R_S]!RZW.YO\%@!]N?\'2T\%+_ *@?[Q[$GZW^H'_-TAZY?=?\&L?]
MI'O=PLP/ZQK^W_*!UX4\NN?M)JA]#_+_ #]>ZB2&FG/VU2K5U^ QL?Q_@3]?
M;LW^^>O 4X=!)N3H[9N=J/O,72U^T,R!<U^&!QJ_["Q8W]Q_N7MO8[E_8_XM
M_J^?1YM_,5Q:#)#@?SZ#2;J_LO#1>2DSN%W%CK6T5<=3CZNP_P"H>"=;<?ZK
MV!MQ]O=UVY_\4D0?:)#_ ((ST)K;G*.[F[@1_O./^-=/6WI<O+U_V#"=NU\.
M6ILIMW'C&RI/XIF>HA3R1*8O+H0,S-:/](/XO[$FU6NX?N*^BUK]3KMZ-1J?
MVR_T:_RZ+[B^3]Z17'EW'RK\)^=.CG^\DNHMZ;JKZC_@G_$>P[N7]O\ L_P=
M*K;@/RZ@>RGI=U'\'^U_\F_\;]^Z]T$6 93W#OJ+FU9M/;==8G_5"H'^\$^P
MG9"FZS]&$Q_Q)/M(ZS]F;HR^W=K^;&$_QG+U^,P5"00+5>4 )(_WW_%?:CFR
M^^CA\;KVQVPNVH?+/[.D!A]GXC#7G<C+9JL_X'Y[(?[E:JJJS^+7_P!]_K^P
M/8[29/UINA5')]-C@/3A0=/=10X_(0^&LI*"LIK\_P 1QA'^]$^U?[KADZM]
M29\YZ:]@O_=/>QV92<[4W#CVR&"H3S]K58DG[R$W_K;_ )'[MRA<?0WGT715
MNT =/$/$>?J.C#?3D^Y5A_QCH-'.>G#VSU7KWOW7N@B[AIHZOKC<0@)^[HJ(
M5Y!'_.IX_P!]_P 1[#'.D!_=/C=&&RMINP/7_+T(F(J?XECZ.LY'W>/Q.0_V
MQU'V)K85@_9_E'2"Y&DD?,C_ "]//M3UKJ/Y_P#:/^3O^->_=>Z!S>/8];39
M1=L;2Q-!E\^5#9!JXWI<7^/\L*_7_ @_ZWL&<Q<P36?Z-E37T;[;8"Z&IR0/
MEQ;_ "](Z2;L^93--OS'TH N*"AVW1G_ 'B?\^P6;S=;D^-X_0A&WVJXH?S)
M/4VD[ WKLV]1NRCQ^XMN,=60S^"QQQ=72W_Y7:/@?GV9+S?-M/\ N9B'HHFV
MA)?@J#Y DD'H?8*REDIJ"IIQ_P #V4#C_;_U_/N4/%^H_L.@]FI!\NG+V[U[
MKWOW7NH\W]A1_4_\1[23?[_ZV.@CZG.FGW_ UP:'?>Y;D<_0$?\ $^PMRE^A
MX\/2S=#\)]5'^'H5/8LZ1=>'/T]VO/\ %\]6'05=M9W+XW 45%A:X4E?NW/8
M[!4-;8'[092QG!/!^OL(<]W\VUP_H_CZ,-FMENFJW!14_.G#I.X;;F)VW3?:
M8RC'VS ?Y?8-551-B9YY^!;V$K';O#BZ%<;F+B<_M ^73C+%][3B"<#[;^MO
M]M[,WL+/</\ <R#IB"X(X'I.;$4;5WM6;8I!;;NX,"V=H*$\_:5.,YF_K^1_
MO7M)RR\UI>?1?\X>B[>X!&FOS!H?LZ,S[EKH-=>]I^O=>]^Z]U[W[KW7O?NO
M= IV5$D>X>L,HG-/!OD?7_J[T=Q_T5["7,_;>6_VU_P=&FU]Z.OJE/V:AT*/
M]O\ Y!_XGV/?]!Z(^GKV7]*.N@;_ .!'U'O<\%.O=,F0QF.S%+64>2HONZ2K
ML:_'UQL+6X((_P!;\'VW>0P;A#X,W3L;%*%3]A&>@L?H_9B3_P"XIL_MV"US
M0X7<59C:7C_&W^^_'L+OR/92'A_J_GT90<P26ZU)%?4KG_#TL-L]?;6VA8X>
MC6GJ*T_Y=7UJC)554"/^.Y8_7\V']./9EM?+-EMG]A ?S_V.D=W?R7WQ$'[,
M ?MZ6QBL I?\@VT^S^#^V\<=):XIU@]L]:Z</?NO=-E8/MO\J%_J+FW]/^*^
MV;N:N.K#NQT%O3<7^_"IOQ]Y6[DR/_)%:/\ BGL/<G?[A7'2W?&I(?L'^7H9
M?8GZ0=-D_P#F5_X/_P 5]OP<3THZBDZKG^BK_O9]H%A^F\?_ (=_L=.P'_5^
MWHL6[=I9O9V=RV?V=2C<&W<^179W:N/(-535)X^[I/\  _[[\'W$6];#^X)O
MT.AIL^[B90KFA& Q_%\OS\QT'E7V+MR$CS4F;IJC_E0.VZH57^P/'Y/LCO-S
M2Y_MO\/0Q4Q#T_E_DZ;Z#;^Y-]9S$YC,XFOV_M# UW\0H*&OXJLG4\>$S0V_
MR.'_ &%O>MGV.;<A_C']CU:3<5LP1;GN/\NAXF/(_P""-^/\?<EM+#!#X/13
M "<],[_7_8>TW1G!P/3+,3!35D]A]U;ZC_&W_%?:(1#QL_\ #.E'V<.@2Z5M
M+M[=F1AO?-]A;PKQS_6J^G^\>PGRA^O9S5_Y2!_@!Z/-X%' ]%'\^AA3Z?['
MV(>D73/GL7!N#"93!5__  &SE%DJ2LO_ -7.W^/]+^VMRL#N,'@^?^H]:MG%
MI,". R.BO[0RU1CP=B[C_P EW-MC_(A]X/\ @53#_@)5P_C_ (U]/<+WO^ZZ
M;PY?\U.I$M)OJA4<#_AZ7@:G/[\_/] &_ _V_M#-<K;XZ=$$QZ056QWMOK:F
MU<,J5/\ #LYCMT;HK*'_ ("TM-C/\U%_3_*_9AL=M-N4]3]@]>FKZ;]UVY/J
M,?;T;T_4_P"N?<T0\!U'G77MV7_)U[H).\:/[SJ;=\'!JJ/"K6DW_P"=7;_8
M?D^R_F:+ZFV8_,=&W*9^FO[?[:?ZOV]$6@F\L'F7@7L1_B.?<9K+3K):48ZG
MH^GZ_P"\>[&;I-5>AAZ4D^XW_A83:WV61_Q^ES_Q'L2<N]\DYZ W/W^+6(Z>
M]II!%F.SJ7)DG+TW8>1:K/T_XN)_R3_K%[ NXJ?KC3TZ#D3?H6Y'H.E]XF_U
M!_Y*'M'K'3?TO6.6*F^VO./K>W^Q_'MJ4_40]7J.G;H/[C_1QM__ (XZLE]E
M;_E6^[J/#?\ QO\ \1[F+E44VTRS= GF'_<FG^KRZ&TN?R/Z@^Q#6'_0>BXK
M7K'[;ZWT#FYU$?<W6,P/%5@]XT /_!;G_>_8>NYM-_;0_9_EZ,K;NV^Z^1'^
M?H;-8_VCV,JGHD^G'^K_ (KJ72BQ;ZW*J3S_ %]^$U.J29-?]7GT\1CRJ8/R
M/S^/Z^U$<U.BR< UZ+9UY*=>[)IP/XS4;WW!_&S_ (XRK_:XXX^S_P /<-PM
MXE^-70ON8/IX/T/04Z&"EEJ .3S=>+_ZD?[[\>SVVFZ(;@UZ<Y(X<C05E%/8
M4U5CQ06'U_VW^\^W;E?&_MND%O!G'0H])U=17]9;2EK!P,$Z@GG\CG_;>Y5Y
M&O/J+ S=1CO"Z+HT\Z="U3,/3]>-5_\ 8W]B\P_3]%7'J7YT_HW^V'_%?=.O
M=!)OJU5V-U33CZ"LW+D 0;<?:7_XCV$=T'U.\V/V]*[+LB>GH!_AZ&*+Z#_7
M_P"*^Q?%_N1<?ZO+HN/^K]@ZS^]=5ZB^,_<:["UKVO\ ["]O]]_K>W?%/@_3
M]7\J_ET"7<\512T6W-W _P"3[3SYK,@/^F7)VHYA_O/^\^XYY[L_J? O/^4;
M_+T;[,PJ4_B '[!7_+UZ*7SW\(N;\G_6'^P'LM9[,?K?]6>CZ:!C_L]<KTW
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M13!A)Z=5M/\ :O:]_I_KCWA*W=PZ&C=W#J=[6=-]>]^Z]U[W[KW4>?\ L?\
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MU[VUX'7NO>U'7NO>_=>ZZL0..#>_U_XGWH_XR:S]_6^'#K@L8--8?J^IL/\
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M_P#T=[3[E_N+^8_P]4M_]R>@SZ4/_&/,,W_*H<IC_P#DNM'L@Y27_$+G[/\
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M_BK_ .KY]+MC.F^MOM'^&G5:>(K#+14I_I0XXV_UO<6,O;^9ZRJ_T;IW$O\
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M3&$45_\ 8>S+V]M_'$\W\?\ L_Y^B'?9PI5?1:?F:'_)T,_L?>+]G150^O\
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M7FV4G]&#HREVR@JQ'\SU(I-_T,=0(<UB:_ 7/%?7#_)?^I__ !KVJ7F[Q/\
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MZ^XW]T_^2)N'_- ?X1T>\I?\E*T_U>1Z<OBG_P!DZ]-?^(QVG_[BGV(?8_\
MY5?;_P#3'_#T4\Y_\E2Z_P!7GT:+W+_08Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z2N3R"XW'Y?)#_*6IL;E*\+8 ?[B0?3_ $X(
M_P!X]TC(,IKZ?YNJ@5H/F.OFF_">5\KTWO+?55)*^7["^1_R"W?N"68W=I*W
M<50Q+_FY55!_Q]YJ>W\/TUC E:E@S$GYGA^5 .@=O,VG]@_G_P 7T<+4+^*_
M[W]/]]_C['_15TL_Y;'1T_S-_F\;!J5I7K^F/Y<>#RO:&_LUS]K5=B;WC:EV
M[B@0K1&?%IYJD(>&6GE+C\C'#WBYC$:1VD=* FII_HC"@_D/3\?'U%>SVVHG
MU84'V>>/]6>M]UI]1TZ;?F^K_C7O'&YSG\O\/1]3%>I7M;UKKWOW7NO>_=>Z
M][+^O=:C/_"E?I#(]=YCXC?S+=IT<N1Q_P ?MPUG2G?]-BP9?#L;MZH44V3;
M2A"IBLNR$FX!2J/]E>9-]NN8SLU[&)!EV,;BO%&XTJ0,<?/Y<>D.ZV^K4<YR
M*^; 4/"O^KCU6!#64M9%0UV-GIJW%5M-25&-J:?CSPUG^;D]YGH0PJ.'0&(I
MTF.Q\)#N'8G8&$KQKH-P]?;TQ=8?K9:K'2H?]YO[:O(M4;CR*D'\\=,6UQUM
M$_\ ">S=65W?_)X^#6;S]0)<C3=:[BP;51-O\EV-NC<.(I5)_P *2A=1_A;W
M@5S'%X5_/&/,_P @2.I+M^W57Y#\](ZO#]EO5^O>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKCJ_^WATG_BLX_P#=X?>(?,/_
M $\1O^:7_6'J7+7_ )5H?;_EZ/)[R$Z ?7O?NO=-_OW7NO>_=>Z</?NO=>]^
MZ]TW^_=>ZG4_Z4_Y"_XGW[KW6:+_ #-5_P!1$?\ T.OLQ_T#JC<1^?\ @Z6G
ML3]$73=5?4?\$_XCV'=R_M_V?X.E5MP'Y=0/93TNZP3#5HM^=7_$>VYI?I^M
MCH$^L7.6RN_-Z@6IL_GOLJ!1S_DFV/\ (OI_2Q/L)<LI]3<SS=&.XS!+=4]!
MG[3G_/T,'FU$V N%(/L:S14_;T5_4]!%G^JE.7JLSM+,5VU<CE"&K,?1C_):
MHC\S0V%C_O5_8#O>2)W_ %K+X_ET=6N^K;@+)W <">(/^KSZ8DZV[%JOV<KO
MS&XFFL;UV"Q_^5?GC]ZQ^H]HH.4KRX_W,_;TM;?D [5)^1/^7H5=H[2Q&T*
MX_%4P:,A?XCD3;[FJJAS^]^;6/\ 6W^PO<9;=R_#L>(>B"6^:]-6_('@!_GZ
M5(%^![-9IOI^F^'4_P!UZKU&F^D?^L?^(]WFXGJR^?V=1*V,/2_;V'%S^?\
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MZ][]U[KWLPZ]T!_:EJ;-=.9D7'\+[#QU /ZVR5)/%?\ Y-]@[F(_K6UQ\O\
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MV-OY$AMLB_;_ %?GU>3W5YK;'[F'Y2(/^?>E<OS4_F$?G^55VT.?I_?9Q_\
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MD?\ *SC1P/\ 7TD_['W%=ON7T^YF'Y="&6(M OR8G\C_ +'1@=:\?6QOS?\
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MI*_<N6S78.7I[_Y=N?(?Q&EI?I_RABU+?Z\7_P ?:?\ JTO^C_J=/-O,Q%(
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M]]S[>B'U'2+K-3SV ^H^A!^MK_\ $>WHA7I <=)7<V^MK8&!AF]P4%-56O\
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MMC<=C\73M0TM&U)2&X(TZ1_K<\^WE3Q.'4?3S&ZR3T\(?J1^/Q_C_MO=I?\
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M!_M?_)O_ !OW[P^O=2/;G7NO>_=>ZC^#_:_^3?\ C?MOP^O=>\'^U_\ )O\
MQOW[P^O=1_;?7NH_OW2CKWOW7NGCVHZ3]>]^Z]U[W[KW3/[3]*.IGVG_ #<_
MY,_XW[;\3IOQ.J0?YZBRI\3.M%&D1M\GNGW  _Z::O5_O%O8\Y#>."ZD$O\
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M,/V$?MZPKN_?&UE(WKMG^+8TW S^U/\ <ER0;7H[>:Q_UO\ >O:&3?;W8?\
MDIP>-U:6))O[,T^1QZ=+[;>]-L;L@$^&S%!5-SZ6%O\ B@_WGV?6>]V6\0_H
M](YH7AX@_ETJA>Y (_)/'L]CBQTB%U\NI7^)^ONL\_5^N_;/7NHF@?X^U/C=
M.>)UBE(IP+:>;_X_[[GVFFW+T_1_EU=>X=(#-=E[1P>J&MS&/J\BP+' X]1E
MJFK_   88;"]S?D$?7_6)1+S;^[_ /1_&ZH-N:0\*?/H%:K:79N\MT-OFC%!
MM6H/\._@?\0R0^YI:4W \\,-[_>F_P#K\^XON>7MVWJ\^M_L>A%!>V=BGA'N
MXUQ@]"-#OS/;3O#V7MF]/>PWA@2<K2C^GFA_SU&/]M^/]?V/)N8I[?\ Y*<'
M1/\ 0+)_9-^1J.A)Q&=P^;IS78.JQ^4IJSAJ_&Y0I]/\+7X_U_9WMU_9W_\
MN'TFDM&4]U1\B"?\'3V;?V;V_H?9D1-;XGZJ,9'4_P!UZIU[W[KW7O?NO=>]
M^Z]U[VHZ]TE\I7XW%TU=5Y*K^TQE&-&0KJ\?6UK6''U/^^X]H+N]_<Y\2?\
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M^MTL79W;N;M'SQ_D_P O3)-MWL?>EJC=&779.$%].#P63'W0O_RO9,_6]O\
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M- ;U7_4[_'VG3;Y9_P!7K<S!109ZE3;1H!#2X['4GVJZ?OZ"OH2!4BI'Y/\
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MCKWAC_J/^2Q[]XA_U?\ %=>\8>HZ]X8_ZC_DL>_>(?\ 5_Q77O&'J.O>&/\
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M^']/]]_OOZ^SBY!N./7K>WITU2RK)ITAM0/%Q_QL_P"'NL<=?T>EW2-W!NG
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M^QO^.GJL?!?M'^$=::O8HU?\(O-C$_5=L[4(_P!AV+4>VZ_X3_EZN14'\O\
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MQT%.'3A[KUKIKD^B_P#!O^(/NEY_8'\_\G3P_P!7[3T%W2__ #+'$?Z^4_\
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MR#:3S_M[^Z;EM4-X?\<ZJEV;+*](H]:Y?"6_N3O#/XJ J?\ (*T?WHI/]?\
M=%K_ $_'L(WG(_\ HT,_@]*QN*L.]03Z_"?]CKA%6=P8M2:O;6T=U4IY+8'(
MC%_[?SC_ (CW:&]WO;_T3X;].:+.3()4_,5_PUZR_P"DJHIR1G^N-]XI?Z)C
M?XM2_P#JF1^??FYJAMA_CEO<_P#-KQ*?RI_AZ\ECK^!U/[-7\R>I$7;.P6O]
M[F?X14VL?OL968K_ 'HF_P#M_:F'FFR']CXG^W\3IDVD@^?V$'_#TZ1]D[!J
M[_[^_ +S]1D"/^*>S+^MMM_RD?SZ;^@ND_#_ "_XKKE_?;9'_/98#_SO_P"D
M?:;^MMKU;P;O^'^0_P _394=G]=4=B=VX*HU7XH,C_%?I_C]/]Y]L3<W;3_H
MWB_\V?\ KEU86MYY"GVXZB3=F3Y&_P#='9^[]Q?4-_N-_A=+_A>>L!_Q]I?Z
MQS3_ /),@_YS9ZW].$_M& _P_P J=8),)V1N,DYK+T&TL:1S0;2.BJX_Z;!_
MQ7Z_CW4[=NVZ?K7G_.&$=/AK2R^$$_-NE;MK8NVML0 XVBO/67-?7Y%1EJJK
M'^$]SSS^/9]M>RP6?2.ZNVO#G\O(#^?2M^SI_P"A^G^]?X^S2 _3_P!CU5L\
M>DGN/8^W]SWGR=*?XE2&]%GJ$?PJJI?]>8D?X?C_ (V3;ERI9[C_ *?J\=ZT
M5*5IZ'(/0/;IPO96UZ"K_AN9H-_XWZ?P_.G^%Y4#\_Y6>;7]DJ6&Y;#B+];H
MRM;F*7B-/V</V?['53GR W_B7K:O$9^AKMF9:Y)Q^9QP_P"L-7_M_9]:\PF9
M/\;'A3=,S6?C35!J/6O1;OY=KI-_-3PTL!$\(^->]#>DY^OVWTL1ZOP/\?S[
MF.UECGV=/M'^3K%JR!_KQ<_\T)/^/=;8OLIZFWKWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H#.Z.ML7VKU9V-
MU;ELKD<?B>S-B[JZ\K\MC;&MHJ/?6/\ X:S4P ]2-]2#;4?J?J195U CUJ/L
MK3JKN58-Z$'[:5ZJWSG\FCIG.?RL,'_*?D[;[.7IW%T.,Q"=A)-A3N-H\?E?
M[Q%R!BOX8+SAP/V6M;]97@4U+C./7_8KU>K $4SZ?ZOG\N@#QW\B?MO$4--A
M\5_.M_FSXW%8ZDIJ:CHZ#O?"0TU-34?^9B"IA(U55_L@( .>+>[B73@.?VG_
M *"Z::+5QC!KZTJ?^,]72_'[K#*].]+]=]29?LK??;V5V#M3$;4S7:G:&2BR
MNZ-PFBHO&,GG*A(XUDR56S*H5E5@HY<M:^G&D4/^K_5Y=71M;5&/EY#]G\^'
M58'\PK^39LG^81\CND/DCF?E?\E^A][_ !YV_54'5K]'9O"82DQ%35UCUTN9
MI)\AALA+'F)UF9/N4;5HIU:ZZ$MI)/$-:D4^7Y_+KV@Z:4K6O$\:X/E_JKTF
M^JOY._;_ %GV9L7L/)_S?/YG_96,V1O+;.Z,EUUO_M[&Y?"9DX>I6L&,R\*8
M)!)BZK1IF+62Q_2Q9?>Q)3.L_9G_ #GK6@'\"^8\OL_A!Z$?Y=_R:^E/E!WO
M%\K.N^Z?D;\._E%5[?IML;D[V^*'8K]<5^?QBIXXZ7,P5-%68_(MXPJ+(JQR
MV4&5G90PWXB@U!H?EUHJT@TD!AZ'C]GV?:.AC^!7\L#X\? &+L+=O7E;V1V1
MW?W'7XW,=V_(OO+=#;_WEN2?&QZ(H<AE62*+^'Q3('%%2&*(26(4%584EF6,
M8J2?,]6T," : #R'[.K2_>^M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>?\ L?\ (7_$>VY.O=4D?SU_^R5.M?\
MQ97I3_W)K/8@V/\ W(?_ $C_ .!NH<]ZO^25;_\ /;:_]7X>K=X*7]BQ+<L1
M^G_6]QS>P4NNIYVY_P!#^?0<YSK6@JJ^KS>WZZOVIN*JN:^OP7/W(_Z;(/K-
MS["%WRU#<?K6?Z,W0@6^*@!J%?*OE]G32<OV=MD'^.;:Q^]:8$WR&U.*H7^G
M^1RC\?ZW^Q]E_P"\=SV__<SK1$<G E?MP/V_[/05]B=L;'FHO]R.7R.!J?\
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MVEL_,SA1497"8ZNR%_S:D(_/^(]R+LES^]]N@F_U8Z"<ML(G(Q2O^$]/-9*
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M@E^G_M^C)=+;$\>[=A9?=^/-3B-RUWV=%AZT7O48^F^[I*F7Z?FW^\>S?EY
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MD?MKT,O4&],EN/99&;_X^C!5N0VMF#P?\IQXXF_I^]Q[GGEB_P#J;?J->8+
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MV'LTGE\^A_M^U#;13IN\=JAF_'/Y_P!]^/?H^CNN*]>AD_RDP?4E.?\ 8_\
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M_.+HZMMUM-L6N@!O09)_S?MZ&O9_3&Q]HJ9X<2V6K_K]_G ,K5<?[2I/Y/\
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M2_:48Y_Q_P ?^)]G&P1&?<89_7J*=V(2V-?/ ^?1LP\S4UQR?Z7_ -M_OO\
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MEA\NDA&,\.H%=%B\'B#GMSY#$[>P=*M)BH]R;CR%)C:8U.<.B*'SSF]VO?\
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M+CH/7+4ZX& P<DWT\V_K?B][GWJ'_$.FNBX;FI?[G=AM65P^TPO8 QI^]O\
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M[KW7O?NO=>]^Z]U&J/JG^L__ !'M'=?YO\O6_+JDG^>?_P!DG]:_^+.]*_\
MN17^Q9R]QD_TA_XZW40^\?\ R3K?_GKMO^K\71Z.ON7WP9;&O_OUD#6D7^A'
M['^\V_XGWB(N;R2;\?B_+K*:Q'^(VH_H_P#%]"']*C_7;G_8?3_>_9Y%_C Z
M?..L%734TU/6P_3[MCC_ .G]?K_C[0[E#]?#X,W3EB0IK\^@CQ%1/-T]A_/Q
M]J<KCP/^U75@G_>_]X]BGD"::>SZ#',0 D/52WR"_1E;<\?6W^)]CF&YBL\2
M]%4PKU<SU1OG:&$Z<ZGI,SNW 8NK'6O7H^SKLAJX_A-/Q_47M_L/I[#5YSC8
MVY ^S&?(=&ZV-RZ$A?-L@#U^VO0S8K=FU\X"</N# 95OP*'),#_ME/T]ZM-_
M2_\ ^)'^K\P.FWM+E.*D?:*_X#T_B191PHM;@ZB/H?\ 6]F;)]/TP)Z?ZO\
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M4G_*PZ_[*KNO,50?(+M/:M!E,IM^K[CV)LZC&&K4Q)94J\935U5#D,G1,6U
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MW2O:R/$ ]0P_9T*%))YK5)&D5JA0%Y^@]B#;9OT>DS"A^SIT]O=5Z;_=IO\
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MW::WO:?H_P#5[_5_+I#=7:PJR @M0Y\E'^K]O1D!#<*H^ER1^>3^3_A_OO\
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MMM?':@M-:_'\P2" -.=- ?3(QU>UB<'08;'4F,QU'08O&TE"U%0T-!8TM-3
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MZ0P-C[BCFW>3N$Q0"FF@'^ESZ^M>NA/W?.0_ZG[=]5/4M<L9'KPU,H%!3T4
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M9 LH"4RQQMJ+)[TS:S4>O^'_ (OIZ.$DD'.,FE. K7CZCK/_ #R^K.LMF?\
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M?NO=>]^Z]U[W[KW7O?NO=5Q5//\ ,5JQ_7XT*/K_ $R8]X@;Y+]-[B_\V?\
MK >I8ML\L?[?_G\=#'G%7=7>F(Q,Q^XPG7^".<K?S_E61Y@X_P!M_MO8UW(_
MOG=?IN/1(GZ-D;@8+&@_U?8.AY! '%@H_/+7U'_8?T]RI-#$_1+_ +E_ZO\
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M]Y]O>,>GL_+KE[9ZMU[W[KW63R?X?[S[KH'2?H*MIK]KO#?6&'(%?C\[C_\
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M/;1_QC^QZ9Z ;MB:NRV?V%M_;0QYS-)6Y+=H%< *0TV.;@S6_P"*>X[YL?\
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MZ!JT''KUG_J/]]_L/;?B=>JO0,?)C_LGCN7_ ,1/N[_W&3W'WN;_ ,D7<?\
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M;NN67(=@=OY[GC-T6#'^MBJ2W_$CV/N4_P#&-UG/^K_5CHDW#LM57Y$_X/\
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M_D-3T-1C$ZF"8#\'B_\ OA[$<LI_T;I'0=(;/]=;%W +YK9]#DZCZ^F@$?\
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M5%GIAL=9/)X*?_+:SGZ$CCZ_[S[]X,USTT.WH.=UO3[IIZO$UI'\/J@#]?\
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MT)LQC(IH/2ATJ-+7-I"=#C_5QZ;'%/M'V\">MGKVFZMU[W[KW6D]_.C^=?\
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MBAH:8SCY^728V)\A?C;W#G\]M/IOY$=(]J[SV]1Y"NW+LSK/L*@WQ7T=-C9
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MC_7O[I+S%#;YO>K_ $9D/;7\O^+Z#BN[8@R=2:#8V'R&]\BU@!0@XJDI+_\
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MB:E5"OJ753@&U$5/ ]9S_<\Y^VW:Q?\ +MY.+8[B8O!F8T \(9/V*14T!-.
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M[I_\1'N__P!Q8_8!]T/^5>W'_F@/^/='?*O_ "4K3_3'_CO3O\5?^R;^EO\
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M^KS^71Q?<TP6T-%R?3Y?,^0^9ZI2V_\ \*8?Y/F;WG%LF7M_MO!8ZHD_AO\
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M]'UQ;FV)#?9^1ZC9[*@@4,%EO;\?T_XT/:Z&*G2JRLJYZ2L$>HVO]/\ B?\
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH[_GM?\
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M_P":"_\ 'AT=\J_\E.U_TP_P'IZ^*G_9.73'_B,]D_\ N(?9[['_ /*K;?\
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MPKL[<U'*?^/KH<;GJ"XO_P 6P_9S<?[S]/\ >_<4[A =OWR>:;\?0KVDZ[,
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MJ#Y5]A=K?)CNN@_TA[GW7V7NW$[.Q&YKY&AP^&VI7/24V,IZ67]D%00  -(
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5'?\
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M7Y#_ &.L]/F<SAAXZ3+5D$ -EN0I%O\ &W(_WKVFLK^YC/82/7JTFU6]R*S
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MKJFGIZL7@K2P_-C[=^M@N.FWMRO3)N/;./W-0_95I'^2C^(4%?0?\"J6J/\
MNZ"WU%A[07FS?O>'_5PZJ@\(U'V9X'I,8#<673+#:6[23FK:<?D/^47*4H_W
MGS_\B/M+MVY?1?XG-T^\0@&M>'\U/2:K<?D-B5%7%]I]UM6JYH*^@Y&,O^/Z
M_9CCV$=QL)H.CFQN1+0\#Z'S^WY].=%D\=D(#-1U>/JJ<<_[C_\ #\^R2&<S
M^O1F8:_+]G3C+*(:<^?_ (I?V[X-3CIWCTC*FHJ-V?=X#:G^4P5=OX[G/^46
MDI?S_KUG^M_L?\%UG9:ICXW2*]<6@!;CY#SKTL-^18W%8':%% #24"[MVW0?
MTN,9>_\ O7L2\Q0FPLH#_P ,_P!7^'HAVW]1V)X@'^9_V.N^PP,?-L_/W_R?
M%UIH:\#G_BZ6OQ_M_;/.&:_;_E/3NRY++ZBH_8!U)]A'POLZ$5#Z_P ^O>Z]
M.]>]UE_R]-KQ/22W+]=N6^G]_-M?P^_^P_WW^V]NVO\ ;_ETCF_R9Z'WW+O0
M7Z][]U[I#[XS,^$P-9/0@#)5A%!@2!<_<Y/ZGGVAW&\K#_J^73L4>HT_;^5>
MG7;F'I]O8>BPL7/\,H?H/\?^1?[;W?;8/!A\;KSOK-?4_P"?I0J +VO_ (W]
MJ1-]1TUPZ\&N+V_-K>_3'Z?KW'KNX_J/]O[:^H/^K_B^O==>D+_A[<_W)Z]U
MR]WZ]U[W[KW7O:CKW2&WCGI\)BK45ZO,Y6O%!@:&U_\ *?9+N-WT\B!C\@,G
MU&?\W4W;. I]O8JDQEC5&EM]]76XJJK)_P">F_UK?[Q[4[=:?00]4D<R$G\P
M/0#I6>U%OP_U?+JG7O>^O=>]J.O=8_1_3_DX?\5][^KAZW0]([/;4QV>EHZP
MFOQ69I!_D&=H?^!-+;G\^T[6VC^QZ](GBCR/RX ]9,)V#D,+4TN&[#/VGW8(
MH-V8X?[BZH<VX 'V5=_C_M_8VY=YO^GI#>]!^\VK7F/]GF/Y\.AQ659@18DD
M_@V^G_$^Y%B)N>BT+3KCY5/'J%O\!^?Z?3WJ:'Z?K?1=:^'^+=G;FER8%34X
M"AQV/P5 MA]M397_ '?_ $_I_P :]Q5O)KN<\,W0EVQ=,0IY\3ZGSZ4?E\XO
M];_G_7]J88;RW_WWT8$JWKUA\5.:7[>=ONZ6W'\1-N3^!?VS?P7DT/ZWA?ET
MY;P <*]3NH):B+$;FPT"BMH,!NO(T&!!Y_R7^GXX%S_M_8@Y%FF\'];UZ"N\
M#N!X$KG[?+_">AE_38D?ZP]C*&'5T@ZR>W>O=>]^Z]TGLO6T^&P]7EY?^ ^)
MQ^5R"VY^OT_V]_9?N\_T]E<?ZOEUJ-=3@>I _P O2-ZOI_X?U[B()OX;]S64
M1K\B&.DVRO[W%O\ 6_K_ +#V2\H30V]ATNWCNN_/_57H2(IH)A_DU:OU']&_
MW@_\4]G\-W!QZ0$$<1US]J^K=8/(?ZG_ ))_XU[7:)>D?U-M\NNO-Q:J7BUQ
M8\_2Q_'T^OM'X7^C?4=;-QY4ZE\?ZH?\D>[_ %AZ5]9?;77NO>_=>ZC16"6L
M38G_ (CWX0FYZ]T"V8J:?<':FVZ"C(JJ;9'\2SN<-_\ E+REJ*CAYL 00/\
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MMWBM34$@4ST*X[;R@^G56^OZ?\6]O^*>]'G.:W_T"7JG[J!_&O45NP]Z5/\
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M8EMQRTT8_1<R1_\ &2?MTBG^#H5[+[J07DHAW.W^ANS6B,5U&F32CL#C-.(
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MO=2/?NC#J*#^#]?=X9J=(2/,=93%;_6'XM_Q4^[RB'JX@(_U?[/77B;ZK?\
MUN/Q_@#[0S64-QU;P3UQ]F'3'3E3_P#%MR'_ "TI_P#H9?;R_P"XA^S_ "CK
MS_[E+]A_P'I?>QET'^@^S^)Q^?Q]7ALQ2"KQ=7CQ0UU#6G_6.H$7O>XY_/\
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MN#]UD,?15X_/VV3JS;_;W_XCV&N;)OT<=*]L'?\ M(^VE.N$9 )AA-P 3?\
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M/_O+2\?B&LM]U8?ZWLM_<D^V?[BW/^]8Z./W[;[GF_M?S@X_X.NAFN^J)?\
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M+/X8?\RFSG_B3NRO_=U4^\9=H_W'_P";B_\ 5I>NXW-7Q6__ #S#_CW1PO\
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M'_F@/^/=.<J_\E*T_P!,?^.]//Q3_P"R<>F/_$:;6_\ <0>SSV+_ .56V_\
MTQ_P]$W.?_)5N_L_R]&?]S'T&>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z;_ &GZ]U73_,9^1F?^,WQJW#N?KRF%7VWO;*;9Z@ZC@B34\VXM[U#4
MN/?GU*],B-.I'%R./K[/>7[-;^;0WPU#-]O^P.@![E<RS\J;6;F#,[?HP#U)
M- #\BS $XQ7HO_Q4^,6V/C5U]38IJ^/='9V\4.=[K[/S@_B62W#FZ_\ X$35
M%3;_ (!BX\+$^H\_6X(HO;YD:G%1D$YJ2?MX?[/4:;#L%OL\% /UWIXYP"Q
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M\Q7@PW;>9HIP+;LP.-SU#>W_  *QO_(C_O7N2++QMNW_ ,'_ $'Z;_9'0<D
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M4E+"RTF$[ _B.JA;TC^)XOG_ !%JS_?<>SWD2XAV>]I_O[I'ND7C1UXE*9]
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M\$ ?[ #V&/ZY[G<04_33_5\^C<;%$AXD_.@I_@ZS4O;=?A)[;YVV<53'ZYW
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M/=G77:&W/[R;7R,G^XNML&>*6FFB+E164<ZM1U,8.E)+&[(1=O2* CY_ZO\
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M?G_BO_%?:6ZLS?P>#U4/X9!\SY>N.D]L_/U\HK-O[@_X^#;_ /P/!Y^ZI?\
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M8X6U#=)..JA_U60 &W^/_(O8EN?;J\M_['HIMN8(FXBGV9'[.HL-'VC";?W
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M85/AY_XQL"IJ]CYVF%Z+^#DM35/Y\-72&_\ Q3VQ!N-YL$WAPU_R]-&\%Z/
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MDL\_KTI:2@+?4?T-O;X73T47%S7IZAAT_P!;W-A?_D?]?]]^%BKT43STZF^
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M?7\,=(X'^ ]A=_:[Z?\ W%N!T9P\PKPN%_WG'6/^Y?9!/[V[]IGZ<C;E4?\
MXX]L#VMW$_Z/_AZ4'FFT'X3^T?Y^FC-].;GRE%HK.QZRLR6F[8_^'_PO&5/]
M(9O +$$#_7OQ;Z^Z[C[1SW$/Z$_?TS'S6J'X,>I-2.N.*W3CMD8\;7WOLP[
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MZ]U#G_W;_P @?\1[W#T\G#H-=T9G%8O=/7,V3K:+$4])75^<KC7<VIL727_
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M_)$W'_F@/^/=&?*?_)2M/M_Y]/3S\5/^R<NF/_$9[)_]Q#[/_8G_ )57;_\
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MR=._.7P@="&9\F&#?4@R77B]O8DY-WW]RW'B-E&RPX54\1_+Y9ZAGWP]M?\
M7"V8FW8+>0$- Y)[)5K0FA!H02I&<'@>'6MAMC>&(W=15-.9:O'Y;&ID*3.;
M7RQ^QR6,G/\ RBU,?Y'^P^GN7_%^LF\6+_9ZYP7T%S:V-+S'D5- 03Y&A_U<
M>FR&*G_T3? +_#9_R1M^/^8HK1_O7MNRK]1<?9_UEZ%O.*K^Y=@^7BT_[)3_
M ).G.LDWCO;=&#ZBZBH$W/VWNVJ%)M?;>*(_R,G_ #N0R=[BCI*8"_G-A8$F
MP!/NJ;DFVP2LX))/ #HDVKE;=><+@VMFZ*5&,\*XJ10^>!0&IQ3K;^^%7QQP
MOQ,^.77O1^'T555@J=,AF\LI!^_R&1"5-94C^UI>95 N!P ;>X0WF^_>\\D@
MSYD^I-2>NHW(_+J<H;7:[>F%10BC%0JB@K\_7\^CA^RGH6].'M1U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJT,QC<=EOYB87(TB5<5-\;4.FKL
M!_Q<?KQQ^3_L;^\/>9-NAWCW#(]8#_U9ZE_;&:/ED4P?''Y=PZ.]_4_[[CW/
M$,/@?XG\'_#N@&<YZ2>X>OL%NJ7[FN,=#DZ10:#.X\C%51/UL1P#8_GC_#V7
M[ORS%N?]A_V4]*XK\V0^W\/'I+1T_:NV;^&LH-[XVF%[5_\ N*JO]\/]?V0>
M#N>W_P!O/XW2VL4OD5)_,=91V;4T0MN+:&[L59;WH,:,I_C_ $L+_P"M[O\
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M2HOJ::I'T!/U(/\ C[CAX_H^A:DWC_S_ #'2ELW%M M>WU/U]I(DZT8@>L(
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M,;FFWB,[J/%Z;<]^?]< 7_WKV#.39/H[V<]*+^7ZI$8>:T_,?\5T,W@_VO\
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MF'$C'F_!]E=SS)MVWR&"Y<JS<5(-,XRPX?X?/J4N3/9SFOGZW\;9]MG:%?\
M1M):IXX!&?\ !UJQ_!GY=]"]0?S%^Y?D!V-OEL#U/O>H[YIMK[N?;F2KWD_O
M7FZ:JQ9DI8:1)T'VOJ:]/_P8?2\$\J7MGMN\2SW!;PU)90--:,6%<$GKJ_\
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MHH],HC<JMQ'R;^[DJ02!P%1U41LA",<$CR_XKAUIT?"CM?YM]/?+#N#^8O\
M+W^3Q\^>[OFQW%49?#Q9WKRAPVP=C[5VHB*F,P>&QJR1S9&J2BB1:FNRE1-,
M%$;JFH/+/X(]31&K]C8K^77C*@ 9G4*!3BN<_P"F'5UOR?Q7S _F_?RS.TL)
MLGHOLKX(?)#;W9F-R_5_7GR7BPYGW!/UJM+D8FF>.DJ*6##YA:JHI(JE(%\=
M1$',K1%BJ<Z8Q2A6AP#Y_M Z4#7$M:@@C)%,9^1/13>^OEC_ #??GA\<=R?
M[&?RI.T>A.[^W=F3=2]L?(GM;?&#CZVP-)E8C0Y_<.*E@1JG,*814BC@A,I5
MGB+1SGCV_4E/A.>)S3IEA5M.H$#@HI7(/H2?]6>E;W#_ "^NV.E_F_\ \)X]
MC]3[(WKV;TU\']I;SV!V'VW0X])*2@I<1M9<?25N597?[1*ZJ)T^B]C9;VU%
MLX_+B:8ZOK5BN::JT%<^5/MX=6M?S8?Y?6V?YEGPF[3^+V4R<&W,_5O)N[JK
M<XK*K[?'[DVX_DP]16QP.6J:*6:>2"I1D=44R,%UQ@KJ)Q*E/,9'7GKJ!\B
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M;3>3V<O\NA_#.)55QPI0_*GETLZN(3P5E%"0&J: @&]_Z@?[W[+9;2D/[/\
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MZO\ >/S_ ,B_I_OOSIET].P3UZ::BDU_ZQM_C[;(KTOM[GIDJ*$#Z _UM?\
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MLK*NU'CJ46R '^'NDUP3U1;>OIU%V-M>?<61_OYNBB%(  =IX'($DTE*2/\
M+> ;5D]_\!^?8_Y*Y5_6^MO/G3H.;MNN@>&I_P!,1Y_+HPU-3  ,P]/U53^?
M\3_OO]X]R\S4P.@TS4P.I_M9TUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,_M/THZG3D>AA]#>_\ O'MN: 'ATRO0
M5[@ZOV?G)FK9L4,-EX^*'/8!OX=5 @?\V23Q^2;W_P #Q[#VY\H66^\./^K[
M.C"UW%[+SQ\^'2,J-E=CX: 383,T&]\<P#+09PC%U1N.;5L)MP1[C>^]NYMM
M_L>CZWWZ.3C53PQG^1Q_+I.Q[YI:*I%%N>@KMJU*D$C/8P"F_P#.PCP>P9,+
ME!^L>CTK!=?#0_8:'I=K(9K2PV-.1>Q_XCW>.[].G0M,'CT'>\=\P;?@_AM#
M_N4W35C[&@PE#S_E+#_=W/\ CQ[#NY;M^[\?[^_1Z4PQ:SJ\N-3YCY>@Z?=I
M8&#;V(\!_P KR-6!7YZN/_*5597_ )'[,;2S_=$/]/I#))XK?+R'R'2>WIN.
MO@GH]L;>J_M,U54(K:^O-O\ ):7Z?]3OI[(N8]W^C'@P_P NC/;-O^JJ6&*T
M%1Q->DUBL%C\9:6BI--35?6OKO\ <I5<?ZP_'^O[ /B?6=" Q>!_JH.G@3*>
M &_VP_XK[O##T8$TZZ,1O?7_ ,F_\;]TKX_2?IOVK6#:>>I,!$/]^YG^,)1'
M_E%J1?\ 9_/%83_ON?8CY6WO7-X'1)NEM5=9XCB?4#_-T,B2^8:N./Z>Y*DZ
M((S_ "ZY>V^K=>]^Z]T'VX]R5,,YV]M^D&4W#5\"@ _R6EI3;_+:P?35[(KN
MXFN?T8>G4M@.YJ ?SJ?+_5QZ=ML;8I]N4]5-)6?Q3,Y2U;G,[6CBIO?_ 'BW
M_&_9KMUI"?\ #]O5';5\@, #R_V.E7[4=;T'KFMQ?Z?XW][\'Q\=4ZXJBW_V
M%[@^Z2P^#U?6>N;_ *)?^0?]Z/M2O]A_J^72>3A_J^?23W%MR@W#3_L 8O(4
MH^_P6=H.*JFJOJ01]?\ >?:26*:W_P!]];4G[1P8'@1TM>N]S5NY-O\ EREJ
M3-8JO_@.>)%[U.+YO^1S?G_7]RMRWNDV]P]!C=;1;)L<"*C[#Q_P]"'YKD>C
MG\>JW_$>Q!--]/TC(IU[S_[1_P G?\:]UZUUU^/\LM_A_OO]M]?:CK7V=%ES
M6+R/6^8RT]'AZ[+;$RE<,@3CQ_$ZG%U:V\_!O:CO^#_2Q_-X:W[9)N6+SZS_
M $'H5;;>"X4 GN_97_9ZX)O39LL'F@W=@Q3?6W\1/_%?=OW_  W'^.4_U?LZ
M.OI&7MH?]7Y]-\4%3VC74>,QE'7_ -S:2O\ XAG\]78W^&_<_P +X^RHC:YX
M_P"-\<^V[:TFYGG_ $?['HLW.X%J,TU>E:TKY^71I(8P :<_3^OZOKS_ (?3
MW+T-EX,/069JYZS?]>_>O]!_/_)UOH&*ESMSM^DJ+$TN]L#_  \@<6JMK6G/
M^O:AM_M_8/W$_N^]M^E2CQ(SZ@_X?]GH:X/[?_(/_$^Q]<_Y/\O1=Y=1_;?6
MNN,T0F!IB6!O<-;CVU>6D]SG\'5@P'099'I_KK(3?>+MO[2IXO\ 99&NQG_6
MA3[#=]R;MESF'I0NYRI@FOVC_BNE%MO8NT=KB^%Q&/@321]^QU57J'U\UCQ]
M?H?:FTY:LK/]#JCWTE[DD_9Y?Y^D7N'?^0ER%;MC9-(:K(TEAGLYD/5BL5;Z
MV!_STPY_;_P^OUL&][YO^G_Q*SZ,+/:?QO@'@!\1Z3-/LF@J9_XKN#^(;LS5
MA_E^=-__ %3_ .4,6]@!+::ZF\:\Z.H1],*)@?+_ #\#TJ?X!@?M_P!W"X\_
MUU8VC'T_WCV]>6=D/['I2':O^RW26K=B;8-2*W%T=?M_(@ FOP'^XRQ_J?\
MD?M+#8>O6PIX$@_SZ1^:FW1MO=6W<]N4C/X>CH<C@J[.T7-524V2^G\4_I8G
M_;^R_<[VYM[VW\?_ %#JUM';2(RH*&H-#P)%#CY?9T-T=33S*# 0;7'^M?V?
M1M0=4*D<>@_WM_P!K?\ 6?W>/A^?^7JC_P"K]G52WR&_55_['_B?9[8_%TD_
MT7]O^ ]%;_EO_P#;TS&_^*Z[U_ZW4WO)':O^20GVC_!UBQ9_\KM<_P#-%_\
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MH:^9'4'_ 'K]M@YGY,&Z7H)OK2Y_M_6*J"IQ6IU&N> '6UY%IFC-[VUG^G/
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M?/[>Q2\?_3=9B\OC_$;<?\*_;7IXEN/2?4>2?Q];GV5!?$Z-O'^G'6,?5_\
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MC[$UVQ@'2#CUS]UZ]UQ#7%[?FUO=9C]/U[CTR9_<&*VU1')96K^UIAQ_K_\
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MT'_#VW4=+M8ZR^V]!Z:Z][IU[J//_8_Y"_XCVY'U[J/[<Z]U(\'^U_\ )O\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25S?_%GR_\
MVK\E_P!#-[I/_9'_ &W2BP_W)7[5ZTL_A=_S*G/_ /B3.S?_ ':U/O&3:?\
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MGV])!TEGG].E*D(_H"1^2/\ D?O>CHH\;H"M]]>[AQ>9;LSJVU-O"FM_&=M
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M6^O]OV_ZO\'4<^XN^?1VO@>;$ ?Z4"I_U?/JR^66_)N;G_??[#V=-,3PZQ_
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M#_ RW\']3;_'VBNKG0O^K/1SRY8"ZG+'-*$5I\72(IZ>AH**EQV.I#3T-/\
MY'1T=);_ &Y_WW'LC9-?4F0Q?3_X<]3D'C%CQ?Z?GVWT^17J%/!#4PU<-93?
M<PU0_P LHJW_ ')4W'/M43TF'^KUZD=5Y:NVANVEZ]FJJRIVGN>DK:O9HK+Y
M#^'56/\ \[BQS?[7PG]CGV8V<NOM_P!GH%\Q6/@CQ_.HU4Q4>OY?['1HO9KT
M#>D!V-NZ;9VWA-C:3^([GSM;_!MEX8 $U&1R1_H+&\/_  (G_P ?]O[:?_5]
MO5HE!/I05)Q@#_5CK+L+:4.RMO4V(8_<UP_B&:W-F[_\",EDA_E=7S^1]/\
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M7]W]U-U+O "A46I:D&F^L/UN>!_O/)''L)^YG,?T&P7*3<? 'YY'1IROM?\
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MDM3J5[;\/ICK-1P^2>P^@ _Q_P!;_??[X.(E3TGFGH/LZ?XHH(8!P--N3_Q
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MLM.U%]U_"LA?_BWYT_PGGVML.9X9.DESMKV=32OV9/\ /I<^);7O_P 3]?\
M"WU]G,WZ_P#8],:SUS9K^E?:F**F!U3I"[_S,^#VQ534?&2JS]A1?G_*<G_R
M/CV0;S>>!%TJM$U-G_4!T\[4P$.V\!B,+" W\+H>?S_E)^O^]GVLVV+P(?\
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M)<= Y_+CD"?S6L=)^%^..Z+\?X4QX_Q'^O[S#Y?D_P!TD?\ IA_DZPQM;?\
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M)"UQ>5($HJ*\0,FF0,>GG6^7.8BFRV.J\1D-%5CLA0Y"AKZ*]BU/DQX!8&W
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M)'(UM!0[H!-9E\LB2 :G@9U%,=#MJO\ V1[DCD3E>>SGFO9ZAUJ@C(H== H
M'$*H8\<DD\*=8$?>8]\=FWW8[?E?8*30"8S7ER#75GC6F*TX5(%/7K8>AF#5
MK @WY''^/N55.>L$Z8KT[>WNM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U'G_L?\A?\1[;DZ]U23_/9_P"R3>L__%ENDO\
MW(J_8JY8_M7_ .:;_P#'6ZA;WP_Y)=O_ ,]UG_VD0]75T'_ 8_ZTGL/3?#_J
M^?4Q6_'_ %?+IS]M=/\ 0(]IX')9G!IEL3Z=P[6J_P"/X&,@$U7\+)_R,FX_
MX&VXX-^/Q[C[GK9!N]AXM<PU_9T:;9*(KFA&&P?E7_-T7'>>7@S>VQD\8/\
M)JK'A2+G\>X0VJ;ZC];H?RKI-.J8_D"^@YKR_P!?^*<^QG8=$S\#_J]>K[?C
M_,N3Z$Z1JSZ36=2=8R?TYCQ.,Y/^V]C:RQ#^W_#T7'XV_P!,3_,]#'[?Z?Z]
M[K_HWY_Y>F_P_P"KUZ"_?1&2S&S]KCZ5N>_B%?\ C_BV<?[U["?--9YH(.E4
M!HK/\NA0]BL^-!-XWX.D%Q0BGG_Q703]S;#/8O6>]]F4)H1F-R;8S^&P*9I@
M*;[K(THBA YX)M]?Z_[P"?<GE9^<=EFL;*XT:R#TLVB]EVVZ%R1@<:>7Y=%$
MV1MSY[]=[2P?7^"_V7&?$[/P]%AZ+[Z?)FI^VH?VCJ-P"1^;CCZ"WN+>7K?G
M?E2 [= ]D(XC@>$I(S_S6'^ ?9T+;N\Y<W>?Q&@NZGTE(Z7$V4_F01C]IOC+
M5@_6_P#$A_O<H]KKCF'W"MO^4+\HU_[:>FX;'EH_\I?[3_UKZ99-R_S'(P <
M7\>S_C?)'_KK[*9N=_<,\?H_^R9?^VKI>NT<M'@9OVG_ +9^L?\ >G^9!_SJ
M^@O]MD?^O_M/_7?W"_@M?^R8?]M/6OW+RW_RD']O_7/J9#G?YD,BL5QGQPI4
M(Y%4^3B^O^M+S[6Q<Y>Y!X_2?]DR?Y;GIH[5RQ%P,WY$_P"2#J;!E?YC\O\
MGF^,U)]/U#)_[S]?9S!S![AW'#Z'_LF3_K?TA,'+(_Y2_P R>N?W?\QO_CK\
M:/\ DC*_]'^U7[\]Q_XMM_YP)_UNZ2:>7_\ ?%Y_SE/4C^)?S'/^.GQH_P"I
M&?\ ^*^W/WU[D?Q[;_S@3_K?TWX?+W^^+O\ YR'KW\2_F.?\=/C1_P!2,_\
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MD/\ UKZE?Q+^8Y_QT^-'_4C/_P#%?:K]]>Y'\>V_\X$_ZW](?#Y>_P!\7?\
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M,UC_ /SY7_WCV9_OX_/IO]VD\>F!4GW]4BAHJ2NI-J4G-?77_P"!5C_NB_\
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M4_G_ *A^/]C?V72RFN,?ZOGT.K'E>W7R+?,C_(!_DZ:X:+=5/^[CNTNP:6O
M)'WN2I\G_P!8C![TD[#/^QTLGV&W;!44_P!7V=*/"]O;FV9/30=BBESNVZK_
M ",;^P]!_#S37X_W*X_Z'_EO_O?M7'>>3=!^\Y6!!^GJ#DT/^0Y]. ]>C54\
MM/54_P!Y"/NZ:K"VL?QS[4-^AT"YL?LZ!GLGK.?<5;2[NV;E/[N=DX1;X?,D
M%::IIQ:V/K^/\KIK?G_;^U3'TZ46K:11LKY^M?4=)W9_=U3D,+5U6\NNMSX7
M^!YFOVWE\UA]O5.\L=39''<UE_MO\KI/J/\ /?[?Z^ZQ3LF:8X$YZ3WYAM31
M6!)%0*@$C^=1]@'3])W[U*:?Q?WL=OK>A_AF5%3<\?7[>_\ O/O79!U3QD_U
M4ZD8[?VY=VR_8]1=2]F[YF^G\9J]O_W.QG(L/]R&6!M_L;>TZZY_B0_ZOS/2
M*;=;?;!_C5PH'I6O\@!T)VW_ (J]J=BS+5=Z;TQVU\%4('JNL>M:T7J*7Z>+
M(YJ_E7Z?2DO<<CVV]MH[YOSH?]0_P] ;=?<U/[';Q4C@S#A7T'^>G1W-D[,V
MWUY@:7:^S\#2[:P..;50X3!8\XUB3^2Q^H_QXO\ GZ>S.)4MT[/\'447VZ3[
MK<5G-?G6H_9_Q72@U^8$,/\ ;'_?<^]>,>M=8O:'K77O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=9:2>I )@XL;?TM_P 4]JH;GZ+AU4VWU?'I6T.Z
M2H*UXL""5T+]+>SVUW<CHNN+$>72QIZVFJ+B WMR0%M[//JCZ?ZOV]%9%.IO
MM;UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC5'U3_6?_B/:.Z_S?Y>
MM^715Z>D_N;N[+[7R!%+CLKD,CGMID?2J_BEOO*,<_YZ#C_BOO''?K#^KUY_
MCG^XS]#^PNO'4,N2*!CZ4R#]G2V1A*/K_@+#3_K\7M[1>'#;^71@T5,]2-8_
MQ]L>".O= SOZ09S.X?::V_AHH/X]GC]/\E!_R*#Z?CV!N<=R\?\ U?ZO+HWV
M1=()_(?;7)_;U-%C_DY_U-R/]B+?C_6]A9/+H_@Q7K)[]TJZ@9#'X_+T_P!I
MD:,U=/\ 3@<\_P"^_I[JZF>''3,D=#4'J3L3*UT-;5;2RE9]R*0C(8*NO_P*
MI?H.>?\ ,?X'_#V,N7-V,$/@CH+[I8  /^WY="LZ@3><7N+"Q'Y]C:.+Z?\
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M?SZ4_NJ-NN<6X.P\429UP>ZJ?Z'[+_<75?T^OT_WOVML^8)CTP=H1O4?X/\
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MA8'(=?\ 9%&V@[8SF0XJ3R/-BJN_BRM+?Z<V/XO[1>(]NVEQ3_)U-UI<P[G
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MX_XI[..FM9ZYZQ_C[MX(ZIUS]UZ]TW??4W^8^]H=7TMQ_O6KZ>V/JX?]5?\
M-U?0>.?]7Y]./M[Z@?ZO^+ZIU[WOKW7O?NO=<-8_Q]V\$=>Z"K<=L?V7L3)?
M[HRE#N' G\\@>8?X?4^PGN'^+RP?ZO7I;&-:,/,:3^=!_FZ%:QL;GF]_^(]B
M>\'C](NN7M7U[KAK'^/MGP1U[HO.-2;:M=_=+*#\Y)L%7?3[JF'/'^V]Q3N=
MH=OS-T++*]$V1\C3T/']O2L_;O;4;_7_ 'W'M'K^HZ,_$'#_ #](C==S0+S]
M H]K+6"O2>?B.JE/DM6MC8\A4-^Y5U1OC,:/^4CD<^QCLT-:?S/1'<G\^BB?
M"C?V Z%^=F:W[NH$TVU?BWNJJR0HN#435.1IT$7^P,G_ !7WFK[?;>U]LL.C
M@'8T^?;U@US5S);\O<Y[C>SX)LHZG^BK.?Y5_GU8[1?S?M\#<D-1F>FMLKL6
MJ4C[6DSM5]_]L?\ 'P_;>4&UN/8]?D@%1H9O%3RJ:_YNHOA^]05F_P 8MXQ9
M$5\2O^'Y?F>A7^0'\T[&[-K:3$=*[#I>P*E,+09BMRF7K$H((3DK'[6T942R
M_7[B[\WYO8$-[1R6US&':01U%2S$T'[.A-[@?>1@V%&;:K1[QAPCBTU/YNRC
M'V].W7O\U/:&0Z\WON'?FS9</OC:1I/L]K86O%:N;&1YB6GED&JR?[OY)-_K
M?VPO)\TX1@_::4H>/V>GSZ-MH^\7MILKFXE@(EAKJ!&1CY<?E\^@<V1_-SW2
M^Z<>.P>J\/%L-ZI5J*O;>:J<E7TU-D+VF!DYJCS_ (?CZ6]OS\ER:J1.-2X(
M>N!_E_V.@3LGWJ2\H^NMB()<A[?N!/EP_P!GCTN.]OYJ%1M+?-3M3I;KO#[R
MQ6(K/LZS<6Y:^J%/4U'-S0"E-E!!/[QU7_/MJWY, @-PSB,#!9,U^S_/T=\]
M?>/'+TXM=KMC=.?PRG2/S-#^RG2@H_YL.T).GANX;!D':AJ?X*>OQ7)I]?\
MR\#5:=7V'-M-_P#D+W5^2?I[CP]0T5X9_;7TZ76WWE=NEVCZT0M]32NF@U?9
M3U^=:=)7I3^:[5;@WQ0;8[IZXPNV=OY2K>EI-Z;:K3*,?4/<$5\-0[ @<_NV
M5>3_ %-UU]R,;6 2+(#G"/Y'YU_P\>BSEC[RRWFY&RW.U>*@_P!R(:,AXXJ,
M@_:*?/H,M\_S:NUY]W5$/776FT*;8T%3:C@W+7U#9*OM].8Q:F/T/T'].1[9
MBY*\& RER&K@$$D_YN@[S)]Z&\CW,6=C:QO!3+A@N?2@4U^VHZ.=7_S%>O\
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M+KLRD[7:/<$9"1T\OFQ _G^SIUVS_-?V_6=/;DW!N7KIJ+MC#U=#3T77M+D
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MMV?=?WIT2;E:_0\?/^?^#I0^S;J_7O?NO=>]^Z]TEL_5> B>W^27 )/'Z?\
MD7_&O:2]NH8D_6ZMMUN;BXZ+QU52C<V>W=V7.3_N3KLC@\"#]338T7_'] /\
M/>//+:?O::?<IO31T,KZ?PU6,>5#T8#V,>B/K@+C5>UK\GVI\;Z;'3I X==W
M_%Q_M[^TW@_4?T.MUIUW^?H??A"+C_1^JUH.'2=RFU=LY>W\3Q6"J.0#]YC
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M37A]3/>^G.O>_=*.O>_=>Z][]U[J)8?X_P#)/_&O>_&FZ0_L_;_L]25_M?\
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M8_[E=R?\6>QO_#L-_P HE+%;Z>0#SSV_WCV4SRM(W4K[=8PVD&GR'\SQJ?\
M5Y]*CVFZ/NO>_=>ZX>3Q_NQ<@_BWOW6B*]/G2N2_@6[MT=?M_P 6G*4/]_\
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M;]DNP;ZALYA-V:<MU(/N1[57&U[H+7;AX_U%? U<%('R_P GGT#6&ZYV3/\
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ML/;XN:.BS]80.;XP$?[SS[8GWV$?[/32;6PXT'Y]<4WWD)!_N+V=GZN_'^Y
MG$?[U[3_ +\A].G_ -U^K4_9_FZ9LG_??.4]=%E1@=IXZ_\ EXKS_%:O[0?2
M]_\ B?;&X7FYW$/Z_6[+PX_AJWI3 K3]G[>HFU-VP8+_ "')UE=5;=:U!@L]
MIO\ 2_\ QK_BGNNU7EY_H]='3UY%J^&E<$CU_P!7KT,,<M-4'[BFO]>1^/\
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M'2:6+QS@?EZ]#OTWO:LW7@*RCW!JI=U[1K?X-N47TT]3.1^U5Q \>+(1?O\
MLYBD^J7/^H]1)NMA]%/C@>%.('^QP'0M^[],:!U%JI?%3B9A8$76Q]IC*1UZ
M #ATG'^O^P][Z,^D93R-0[QRT)T_[E<)CZ[D?\I.-_9_WKVW7'^KCTIH2/+B
M?V'I94D'DJ-,P  N #[4*E>D,TW2N]M]%G3554=#D*>JH\C2_<T%50_8UYM^
M<G^?]]]/:N7IG-<'/^'HEDD$_6M;3;-W;4_;8FGO2[-WE5@FFR-,>8HI9?\
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MTRCYN:M3\@#^SIYZ)QV-QOP<^:&^ZD_=9G=.:QNU35D7L4DIR2/KQY:E@?\
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MU_Q_UO:JW0W'^,]-SQ4/C>?4KR_[5_O'_&O=NGM ZZY_J/\ ;?\ &_:G0?\
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M?^O^\V]J(=X^G_1O.O-9ZA5,_93I>Q3">T]VN>?Q^/8FA?Z_$/2,V]./6/\
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M\<U+_$+20_UJ_34>W*5;_5_J\NM2$1P*M?(D_/-/\)'0S[[QT^9VKNG"4?\
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MS_ET$'.IR?(U'YANG[VNZITF=ST0R.!S%'+]:K!Y*B_VXX_VY]I;R(B&>O\
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M%$.S=H;Q^^ZVVU29^ER.0S.'QP!U4@B-\A5Q0,/H/T@W/(]I(Y5BO&8?V;C
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MG\NBH="8'LC8/R6Z-[,[$VC5[;PV*Z)HJ3>.9S!IL93XXX^D-)IR!8C[2_\
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MIWG_ ,6RK_Z=?]"^S!N!_P!7ITG'Q#JGCY)_YRJ_UZ__ 'L^W$^.?\^KR?V
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M(XMO6WFN9')Q7S_BQ_AZD/>^;Y]SY?V6TMO]&TD5\A$NL_X*?GT(>Z\+/O\
M_F&X+K_+5=9DX-F=%C;-<Q'_  ("8&H^[/\ U5?<GF_^/MJSD^EMQI.&EH?R
M;/\ AZ-]SMAO/-/T4W^@;?J _P!-%3T^70<_&3:,O:'PY^6G04]7]I/L;-+N
MK"#ZWJ<<K%A>U_%-44!_V/MR^D-O>;?<>;=O[*?Y1T5\@6*[QR[O.S^4)9S]
MC"O^7I$;PW9+V_\ RT\+7973_%ND^UJ#;7WVGG[95:.EN;\V-1;_   ]N_1&
M"_%>+)3\B,?X>B+>-X7FCD5V'"RN"W^VC?\ V.A;^1V\JGL;?'\O6%*H!GV=
MLC<;D#G[K(>!3-Q^?]QP]L[?:)'/+7^.0_S_ -CHZYYWNXOEY?IP,%L?RT$]
M 'U-VW5=/_&[Y@[PQE0E-D^SNUL7M#$UM(MZD&NI9Y*J87Y'^2HHN/:G<-O-
MQ=1L#F.($?826/\ AZ!O*G,$?(^Q[]>/PN[]T/VZ8XA_QT#[.A1[TZK'2'\N
M'K/:M40<KV+V5A.RZRBJSJ_RC(P_="(V^AY!(_Q]H[.?Q+QG/&.,1_SZ&'.'
M+2[!RA#;*,7-S]5]K$:R?S/3WO[ P]8_+_XHYZFTF;?W2>S]NUG'/VS8I,$3
M^.1]R?:JRF\>WE3TF(_:NKI_F"Q_<W,]A<CB^W ?D'6+_G[HAU-0S8KI:IW1
M0'_*-A_(W_([?TR>-M:__45CO9W)#&)(5'E#_DK_ ).H8M8+KZ!KC_I*$_EJ
M(_R]6D]\=C[M[O\ F5\7NL]GYW+T&+H-M;3W=F6Q%=_#/N/XD/XL3,1QQCZ7
M\^PG!9K8PRAB:!B<?/M_P=9'\Q<PS\P\P[?8P#_0D)\R.$HI]IZ+K1[;E[UW
M]_,FS\E4*BF3!Y!J32+TUMOY431?ZW%!;V8DFQ^C7[3^Q*_Y.@%';CGF^YBD
M\CIC^7]LU?\ #TN*_%5O;'\M[K/?:557!D^@=QL**KHQS]K057VI-[W_ ,D)
M7^EA_K^T]ROT^ZN!@D4_G3HT,J[QR/;7YX;>P;\U&>E[W9OFLW?C_@UW]*5.
M6J:O'G+D#ZU&)JL=Y2?\2;_[Q[1;;$8+FXB/&M#]H(Z/>8]Y7=+;:-[' Y'V
M.I_R$=4R=#2*/YH'S2RP%H,?@_FO6CG^K)%S_C^\/>,WMB0.;3_IIC_*?_-U
MWJ^^F:_=\M!_R[6?_5B/JS[);ISN.^'O2_1NT"*>N[EWCGI*P4?^X\FGQV2^
MS6$_U%55@D?T_P!;WE6L*)>>.W^A!J_96G7SX#>IK;E[;ML@_P")TBJ/0574
M3^SH:OECL.'8.X_@CT_0_P"4Q[<0T7WM:#R7KZ%N?Q]3_CQ_L?97M,^A)V]/
M\P'1][BV_P"Y[GE_;/XFX?Z5CTE][XF#:'R7^8>T8K"BWSL+>.<L#JY?[?,
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M'NS9M&_U>?0MC_@4G^P_WOV)[7^P_9TQUR]EW7NN(_X!'_77_B/Z^U<']O\
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MO&4)L+X3'$?3_"*F_P!;\>WZQ+CHN\=[DU-?V]/#=X]6Q']G==%]/[.-JO\
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M ):]1KS%;W-CRR=W\[S<5:GH&D5?Y*.CW_$:"FW1_,+WMF(2:BAV%UO18>B
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M;8BN0S4X'\O\'3QTIWOV7U9M#LG96T?\IP>\=GG[NCK*$FGQ]1(/#_%/\/\
MCA_MOZ#W;?MOAAO4+<5:AQ6G#/1OR'SS?[3;7%A .R:$,IZ"K$557BY::JIJ
MDXZMPW^5T57^*?\ XG_>?:J>QCE-?3H([(UU9W-#T:?N7N3?'=&\\=G-^Z::
M?#X:@I*3# !13_Q"E\DO%K7K_P#/GV&+.Q"021\*@  =2QOW-E[SCN%I/>B@
MCR>-:]5!?$_=.2V_\M^YZ#$24E.N[,!W7M++5592%E7'97,XN1@%_LD^$7X_
MI[Q,Y"18^;95<]NJ0?R<'KZ(?ON[I,?NX;--!Q5K,C'$B1?\YZLSVQOS<_7V
M[=L;TVKE/M=RX2M%=1Z3_$+:?^47^GVDOO-"_B@DAD5CV"#'^;KYN>6N9-PL
MK^UFA%;AJAAT.OS)[(W;V#WKGOXS;'4^U:.@PN(HR/X?44PKJ450E_ZJO^-?
M3V2;!M\*J2V:4 ' \/\ +T-/=_FC<=TW-43]/U/26ZR[AWOL?8W9&Q-O_9#;
M^\Z##??DT%_X?_$!]I/+_A]V/\G_ *V]L;W9QM"U>"ZJXX?ZN'7O:?FW=MHN
MA8QC,PA(_P!7VCJFSX.;CS.S/E9OS<N!K31YK 56^ZS$U;"_@ON*#FUK'CWB
MY[60K+S!= X_2E-?F%Z^@[^\'W2?EOV;Y>6'-9+$_M,8ZM;[MWWE]_\ 96^=
MY9;&?P6OW#5_9UE'1DX\WH/]U7)N3-_C<G^OO,#:+%$B0'NT'APX=?-SSWS'
M<;O>W,J_IBX6@/[>L9[U[+@^.N2Z$M]SUT-QT-7]X?\ E'IC_E7\*BEM_P I
M56./]C_4^VX-HCFNS-^*M?\ +3]O2R#GS=;+8/W'I'A!=-?E2G^ TZ"CJSL#
M.=:]D;1[ V?5&HW#MO,4'VE'_P 7#SFO_;^U_P!X\$''M6VG<(9+-O[,G'S\
MN@/R1S)-LVXMN$.;FW&EA\CG_)C\^H7:?8N[^VNQM^]A[PG^XW-EZL!5_P"+
M<*>"@J?V<?\ X"DL!8?0>U&TV\$<4<0-4!D)ZWS)S7N/-M_>7\BTN$4*HX<*
MG)_P_;CI6YOO#?.=^.W772U936Z^V7NVJJ,/E?X?;[@8NF(AH!_U >7_ &Q_
MP'M&FWP_O*Z=OCD!-?4_[%>C1>;;V^Y1LMIB%+>VD2,XH-*8P/+X1TH_B1VG
MOOK3OKKZLVE5V_OEFL?M#<>'!_B J*?)\$'_ *AO\_\ Z_O7,>WP^ I/X.TC
MU!_S='?LGS7N&U[LZH,7(U#U! KT@^]=][K[$[?[$W?O#C)U.7K\16\_P_[>
M"@J?M?M.>1^!_L/Z^U'+UA!)&BCB6-?\'0>]P-UW/=]XNI90- 0 9_U<:]/N
M0[JW_4_&^F^/TN%I#UUCM],**H- -.G'4AJ(L1;D:;$U5K>T9L(H;S5XW>&K
M7-:\?\.>ENZ<YWJ\N'EX;>/IC'X6CMT: *4IZ4%*<*8Z@]"]O;TZ=[*PF^MG
M'^)90#^$UV( %?\ Q"FR/UQYOQ;_ (X<>U.[VL%U$ >U>%.-:^723V^YQW+E
M64WT0\>1O3C7RIP^SH+\QDY\SDLYD:XT5--N/,5]75_9_P"XZGOD*G_CD/Z>
MU<%E$\\)/^AFOIQ/0=WR[NX[@W"_\2\9_+^?0U=J_('M'LWJ+JKK?>:KD<#U
MY_'S2YBLH#]QD!CS]M';^II3^Q?^@M[+MGVRU$C2KEY*T^?I^SH8<[<[[US)
MLUO93*/I[2AD^>D>0^9ZX?'KNS??1N^:C=?7T#9'*9K;6<I*JF0_?_<4YION
MONK_ .=_R:4>?_>_>[_;HI[,O-V$L01_J].J^W?/E]RQ/XMA^NA@# @_ZJ\>
M@.RN2R6Y,ED\KN8?QBMS%;7UE7E_^5BHR/\ RE?CV:0+'+'"R9(XG[>@Q<3W
M>[7)N+L "3 IT-7<W>V_^XL=U#2]BZO#L39^.HJ*KI*(T'GT5)_RX7O82_:_
M3V6;-M?A2/)_OU: \*C_ %#H6<W\\7W-]K:VVX"AM&5VI@:A_J^WUZ*?VIO#
M=%)UC2[#I\JC[1R7<G4^XDPR@HPK\=5F$R$WY_SY_P!A<'VKDLD5YF!/B>%,
M3Z5R/3TZ#'+>];J"(#=AK7]Y;8JT!#:2T9()KG(!X<*CK>RH/^ Q_P!:3W!,
MWP_ZOGUU?M^/^KY=.?MKI_KWOW7N@#[7_P" E=_P8>ZP</V?Y.M^GV]4??(C
M_@3F/]?_ (K[2S?Y^G4X=6X=0X7<V1ZFZT:MW']GCSUQLT4%%0?6W\(IK D<
M_3\?[Q[CZYM[VX(\&X_1].A5;W"+&QT]U2"?SZ%&EV+@8/WYJ/\ B]1^:^O/
M^/M&=ELKC^VZ>^L;R_9T^TV+Q])?PT..H>2><4W_ !2_M;9VT/2!KDGI@W!B
MJ^.NI-Q;=!_B-*H'\/O_ ,"Z0_VK?[;_ )'[*MS7Z7]>'\NEEK.'&EN' _;T
MYX?<5!G=/BTTE32?\7"@KQ_E?^PY_P!?V:6-_P"/#7I/=6A7!S]G#IZ _)M>
MUN/9C##X'28FO4GVWTNZC^)/Z2?[Q[OX)].FM9Z]XD_I)_O'OW@GTZ]K/7O$
MG])/]X]^\$^G7M9Z]XD_I)_O'OW@GTZ]K/7+P)_5O]N/^*>_:SU3KCXD_I)_
MO'OW@GTZOK/6;]7_  7_ 'OVY##UIFU=8?;LO#I+T5[Y >?(8046'U561Q.K
M.Y!2?^ G\+X_WOW"/NC;?71>##T,>7IZ'4>A*VMFH,U@,1F8AZLGC\97_P#)
M!]UVR[^NM()OGT[=KH)'^KCTHD^O^P]K.K=</;5UU1^'2:W9MRGW+MG+X"7_
M #&4H-0XM:QY^O\ A;VQ?6O[VBG\;JUJ_AD$>717_C9496H[K[SHLQ1_:Y?&
M[7Z@PU>+?3^%4E<3_O(]Q3[(2S'<[B&;@=5/Y='_ #0 +2V*^I/[37HZ=;6T
M^*@K<AD*W'4V(I<;]]75U=S34M+B1Z9I1QJ) X]Y67</UH\&'J-?]QN/GC''
M/5;OQ]_FZ?R[?D_VA5]-='_)?9N].R:6IK:3![5K*:OVS_>%\.0*MMI9#,TE
M!C]S^KBV-C$DG.E2 ![$^X\LW>QJ;THK,*]OG2OS&>DL.Y),.X4J.(^0^7^S
MU8YM*GJ*+&UT]82*C+Y 5^0_/'/X_P ?<?[1%-O!GFZ7;E1:?(4Z]G]T;<VG
M@Z[=6Z,UMW;^V,3BOXIG]P;BKJ3'45'0-^E:NLE *LU@  /4>!S8>SF&TANO
MT33QOR_U#I'F#A7Y<>/R'G_@ZU"?Y]_S)^.W;'<'P5ZLI/D+U#N_XVT![1[L
M[!;:&_<=O;!5.Y=CB"AVM!N?^'!A'2T-5/620?=CUU#7_423D-[.[;%9W:&\
M(*4U1CB-8X5_VM/+U'01W8F>IA!!.!44^?[*UZ*#\<_C5V/_ #9-[T_6_6F*
MW3B?A=B,SA\K\F?DUF\'7XB@S^/PCBHGV-L/[SQ/FZC,2*8ZROC8PT](2X:2
M5XU]R-[J>Z%K:V,MI;$A@0C,?PTH:"O%C09XTK\CT3['LDOC9R3P'\JFGEZ^
M76XW7TV)I/D1\;*?$4@P6*H^G.UL5BZ"BLQI8,6,6OB)XNUE!']>!_B>;^[7
MWUN_[=_M?\#=31# ;:RN_/N''YD='1]S5_HW1'Y?GU']^ZKU(]I^O=<>2?Z$
M?['Z^U?^Y'6^'2'S.'K_ +@9S!']^W^Y#'V_X%?CCV&MTM_ Q#T86UR *'\N
MD\<]3PW%9_$L14\W_B!O_MA_K^RF#>OI_P"V@Z4EJX!KUG_C_F)APE%D,O4Z
MKVT_Y)^?Q<_[U[;N-PFW#^QZW,H7CTI-O8C^&BMKZX"LR=7P 3_7_C?L]VC;
MOI_UNBJ5BV!TL/9OTSU[W[KW4.OC\U-60GZ6RA_VU_;EW_9?ZOE_FZ]'Y'[.
MF/9\OEV_B!;A<;*/]N3[+=E_LNG910]*#V;=(NO>_=*.LW]O_D'_ (GWZ?K8
MX],^<K:C'8?-5L%Q5TE HX^G]/9;N$WT\/5D&HC[>D=B*(XZ@HX8.#SD<@;C
MZ#\?7\^R"TA_V.CQF\^INMOZ_P"\>S+P>D'7OIP?I^1[U+%U[J/MY#1[@K*&
MGYIZS'_Q"Q^GW8_XU?VALY? STW)PZ$3^W_R#_Q/L70=)#QZP^U'2;J9!_P%
MKO\ @M/_ -#CVH_XB?GUL_[E?ZO3H1/8HZ#W7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)C(Y_&T);A&J])4>C^G
M]2/9=<;CX/2I+0MQITE*W/5>1_R=B*$6^@_P_'L+76Z_4<.C.VLPG3-^C_$'
MV4S0UZ6JVGK%[]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH\LE7">5_WF_NW
MB5Z5_2]1_O/\/]]_MO;GC'IWJ/\ <K_J%_Y+]^\8]>Z<*6;3?G_>/^1_U]^U
M#JAMR>FC=^4GQN%K# #]S5G^&W/^ _'^P_P_I[J9_#3HQV2P^JGKT!!B(#BW
MY7Z?['D>R^3J7(#3J+[<ZKT(>P<9YLC]].%^UH^>?K_O'^P]JE%/U.@AS3??
M\1^A=]UZC;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZY0R^"][FY^@_P]
MWB'T_6R:]*/&[CJ:<B&H -, 5!L+@?Z_LXL]XITC?;*^O2UH,G2UP;[?Z@#@
MC_D?L1P3?58/11)&4X].WLRZ9Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z;_:?KW3A[4=>ZC^#_:_^3?^-^V_#Z]U[P?[
M7_R;_P ;]^\/KW4CVYU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[I"[X_XMB?['_H4^ZOPZ\O']G5//R7D/W=;_75S^/?E_3CZ<C_
M ,:GZK#^+/66P^W/YEE?L+?N,.0PF8^+6YXJVE5O[)GI")H1>Q;4HM_KV_/N
M0[6\GV_:4,0P7'[>L66Y=V[FKFZY2]^-;>0 'AH9Q7' \/R^5>KR>K_Y>OQS
MZHW52[RPN,S>X<ICJHUV(&]*\5]/3U-_\[%:W[E_Z_[;V53[Y=3*%DK4<-)%
M.AERY[.[%RQ,9[502?.:I/\ .O4?L/\ EV?&_L?=-7N^MH,[M[*9&K%7EQLG
M.+0T]15$?B-C<W-S^D>[6N_75LFFA)/'612O5M[]G]CWR<3D!2.!@P:9]*="
M'F?AST!N+J_&=*U?7])3[.P]4*O!R41&/J:>H]7FJXZDK]S]U,MON/QP!;T@
M^TXW:9) Q?O&00>!XU!]?7H]GY$VNZL3M1M@;<C25([2,8IZ#RZ3O3GP:Z+Z
M1W%_>S:U!79C-BC6DH*W>E>,@*?^(CZTG ^G]?Z<@C\>N=RGN5TO@\.SU^71
M;RS[:;7RI+XMN-=>/C<?YU/2)W#_ "V/C'N+=M3N\X/=&%&0JS5U>VML[@J*
M'$6^MS&0!$3R/\G6_P#2P]KH^8[FWA\"BC-=8/=_J^S'19?>SFR;EN'[Q/BE
MJ4$))\#_ 'GA7Y\>A7[-^&'07:FQ]M;&W#UU1X^@VO$]%MZIVT_\.J*"G(Y@
MCT7!#'^O^O\ 4FY;8[E<;>5,<E"O#7@CSXCH1<S^W>T\VV#[==VP='PRQ"H8
M?ZCY=1>G?A5T1TI%D%VYA&W'E<SC_P""YG+[VR9W#4+37'^2?O7)CG'Y^O//
MMZYW:XNI#+(-!/$IZ'R\N/3'*WMQM?*%J+2UK,JX'CDL<>9+$DD>I/Y]!9_P
MV)\7O[Q_QK^"[G^RO?\ N7_'JC^':?IXM%O^ WX\/^\6]N_UDN].C%/XZFG^
M#^71#_K);%X_U&E_3P/+]G#HP7;/Q:Z6[NVKC=J[PVB%@VZ2=N5N$']W:C'J
M0!:D6/TF 6'_ !OZ@OL[VXV]]2/PX$=I'0WYBY,VOFVW^GN;8,#Q#=P/$](G
MI;X3=$='5E3E=L8.OSF2R% :*NR^]:[^/U(I\CP:2P/-_P"MB/\ $@^U5YO,
M]T:O@GCHSCTX=$O*/MCM?**A+8:@.'CFM?M)S^T]!K6?RROBU5;AJ,Y#A=S4
M^,GJQ55FVJ7/U&-H./K^W:_V8_J+FW^Q]JTYENHUT]M/2N*_YNBB?V8V2ZW#
M]XE7U\-7G_AIT*O<'PXZ'[@Q&SL?G]GKC:[9=*,-B<SMV+^[E134ZW_R4!@1
M]L+GG_$_B]T%KNMQ:.ZQR4UB@*FF./EQ'1MSA[8[/SC#;P7MJKBW.I0P#4:E
M*BHP>I'57PO^/74FW]X;9VQL=<E3[SH/M,Q6[FK?[P5-33,5_P F&L!?M;CZ
MVY_(^A#]]O=UN+HSR5T>;&IIZ=.;'[:['R]!<06MJJ"<U(4  GU^WH-<'_+E
M^.&,W%_&/X=N3)PBK^\.V,QG:JNICQ_4 \_ZY_V_MH[W=QMJ.FG'634=%%C[
M.;);3^.!(#P\'_8Z$?L_XM="=U;J_B&=CQ]+N2AI%I*I-D91<?4?;4)"@U</
M-A2$J!]?\+BUD\&Z3VZZ$H"W\6#T(]^]OMMYGE\:<?V9XQ>O^SUK5_RX>J]D
MUO\ -A^1W5.4Q2Y39+8'Y/[9^SS7^7-]OB]Q8<@FUOW1H'T^A-_>.?)=Z1S-
M,PI_:/7[*RC_ "==J/O36$&[>Q.R12G)-K6G#^Q3_/\ RZV+MD? WHK:>[:7
M=T>.RV=FPU>M51T&;SU3D*>GJ1R)1$!^]8_\K'!'O)F3?9YH1":FAX$XKUQ"
MV?VIVO;K[Z\"A(R:#H1^Z/B;TWWY6TNXMVXVNI\Y3T7V39C:V0%!4_;#@&8W
MM(/]@?K]?H/:6TW.XLB%3CZOT;\U>W^V<X#Q;@5'&D-<'J3L'XG]&;"VOG]E
M879-)4X?<F/ON=]T$Y&JJ.+CR!>./KQ_QOVQ>;O/*"TC\>.C)Z7\L<C[9RZ1
M#;6X%/A\7 '6KW_)ZZ>V%O?Y\_(;%;@VX<SAMF1=BUF QM97?Y.*FEW,*>#S
MBQ%2H5N>+?VB&'!QW]MI6;=KHAA70S?]54I_AZ['??DV^"[]N>7HY+>F(!7Y
M&$$_S_V.ME/MKX6]!=R9R3=&9P]9C=UQWHZJMV/GUH146_Y6_2;?3Z 7/^/O
M)*SWF6S30DI">>IJ?MZXH\P>U&R<R7 N+BU!G%:&(=WK@UKT[TOQ%Z(QO5F1
MZ<&QJ2JV7DU^\JS6'34U%2 ;5?W9'D^Z ^GIX^E@";^3<YXY3<&3OXYXD^M?
M7I5#[>[7!8_N@6P%N!ITT&G3Z4].@YZR_E_="]6[GI=]8O&YG,Y+'5@K<,-S
MYU:ZGIZA.1-%"IOP;'E3_K>UEQOL\RB*2I(X:C@=$?+OM)M/+4YOK50I."1Y
M_P NHW9G\N[XY]G[HJ-]9C&9K"Y2OK/OLM_=G-I0T\]3R3,(GY\OY_2/^)][
ML>8+NP7P8ZBO&AH#U3F7V:V'FJX6_NT5RI[2PJ1T(N7^'/06=ZNQO4-7UY2_
MW.PU8:O#M0R:ZFFJ/^5HU)_RG[H@F_'/']!9-!N\]I*)"_>#@CC7UKQZ/[CV
M^VR[L?H3; V]*%2,$>E.&/+I/=(?!;H?H[=)WIMK'5N2W#2$4>/S&]JX5_V[
M#\TH_P!U6_Q'']?;VX;W/?+IDR?+2<#[.BGDGVHVGD>7Q;5=->/C5S3[?\_4
M#M?X _'WM[=U7V!F,?F-O9W(ZFS57LJO&/%15<$RR\FTQ)O8?[;W2VW>>T7P
M4TOZZJ<?7JG-'M'M?-LXOK@2PD<#"2#3[13'2PJ?AMT!-TV>D3UW2G8E+5FK
M)UWK_N"+??\ W5M?W5OJ/I_A:WMM-QG^I^H#T>M:_A^VOKT93^W>U-M/[H-L
MIMM.G33]33Z4X4Z2?4'P-Z#Z9W52[VP&,SFY,SC.<-5[UKQD!3G\&+2>?]C?
M_6]JK[?Y]R6C@@^6CI%RM[5[5RE*9;8!J\3-6O[34])G>?\ +>^,V]]Y3[VE
MPVYMNS9"H^\JZ39>?J:*A^Y8?0PZ0L-SS].+\"UA[;BWZ[LQIHI!R0_Q_P"#
M'Y=%^^>RFQ;YN W!A*K+P,)(A_, @'\P>A0WK\+^@]_=;83JW,]?T5!@MIAU
MV_\ P@"AJ* 26N$D;4"LPOY_^.][V-N:6^\SV<HFC>FGX2N"OY]"+>?;S:N8
M[!MON[8.K@JZ. RL,BA!&>/#TQTT]*_"3H/HG(5.:VWBJ[(Y:7'BE.:WM7_W
MBG%/D!S2PK<7_P!<WX_P/MNYWF;<(RBY/JN?\%*=(>3O:38^1%$=H-*CRF))
M^52U2?V]!SD_Y97QAR>YI]PC#;GI:2HK5J_[F4FX*J@Q&DVO%J*@?;?\V=-_
MZ>U"<RW2#31:<==:-_@_ET37'L?L5W?_ +P(E)I3P:GP/MTUH?V="QVQ\-NB
M.X]O[/Q&?V.<8=J40HL35[*!V]44U,+G[4AAQ%]3<C_6_-VH=WGLW>2-Z5P"
MV*#H_P"8O;7:N9X8+:YMM03-(J<>'EU49_,_^+747QM^)6VAUKC:YJ[+_)OI
M.AK,QEZU:^HGIEJZMA%Y5-OJ%/T'^Q]F^R[E<WDU9N)27)-<:6ZBSW)Y VGD
M[: M@H %[MQHN!BXA'^JO6RU0?\  8_ZTGL"S?#_ *OGUE1;\?\ 5\NG/VUT
M_P!>]^Z]T ?:_P#P$KO^##W6#A^S_)UOT^WJC[Y$/>KRO^L1_MQ[K'U<"H'Y
M]71=+_\ ,F>I_P#Q'6T/_=-3^P;+\0_+H_M_@;[3_AZ$OW7IWKE<3 D&_P"/
MK_ON?=I/EU:W\^N/NO5>D_F-N8_,7GN*3)49M]_C^?\ ;?U^GLMO]E\<>-TI
MM;HC'EZ=,46<W!MP"'<5'_%J6W_%_H/\?^*?[#V6Q7<VWS>#-U<HL@JN/E]O
M2RH<GC<E3F>AK364US<$7]FT-W#?_P!CTP5*'NZR_P"5?[5_O'LQ\9>D74NU
M5_S=_P!Y_P"CO:;ZJ'Y?M_V.E-.N/F3_ !_VWM[]'_41_GZWGY]<_P#8-_R5
M_P ;]Z\:'K=&ZP^U/23K+YA3BP%^/S_O?^O[332P]*:'I-UV\L#26@%6:NHM
MQ]C_ +E+'_8_U]EDV\P6_2E;1CY?Y.FF7)[HS!\&*PQQ%,;?[D*X_@?[Q[*O
M&FW#,/5@%3B:_+K&VT\?C\/6T?\ P+%389#(5XL!_3_'V\^RPQ_HS<9NG8;L
MVYKZ<.@$ZKK)MOY?<76V47G UYK\$?\ IFR(/_$&_N#>6X?W3+/MMY_S6Z%C
M4D D7[#_ #Z'7Z?[;_>_8ZF_W]TB'H?RI_Q74I_K_L/;77NN'O=QQ_U?/KW1
M8-@X4Y'Y(]\"&KKJ2HI=L]0M]\/]JIJX\_XF_N-^2[3ZCF7<)O\ A9_R=&&\
MWVFRM13BS?X3TJ?D7U1V)W!\=N_NF,;D<4F<[=Z/[-V)BLS2)_#ZFGKMSX*I
MHH82+7T2!-+?ZYOQ[R+V*6:&]AD'F"/VBG4>WJ)-#4UP0?V$=:#.P-BX#N[X
MW;&ZLW'AH>ONT.C0>LZJ3"T/\&W)UUV'U'+]M_$,<T;4]92U-%4P?<1->]1
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MB! >DK)^/]C[0="Z/KWD_P /]Y]^Z]X?0T[5QW\-PU#!;_*JV_-O\?\ D?\
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MT8O_ ))GLF;G_6X]EFV8@ITLN#4@_P"KATHD^G^Q]FD7'HN?CU+]M].]<?\
M@3_JKZO\!]!_MOI[M\'7NN7NO7NDWE\#39&I\US29.C&HY+'>K_C?'M%>;5]
M1_8TZ<CNM(S7\^FG^$;JBM3PU^WJS_6>WY_Q_P"*>RG]V7=OTM&YHV<]>.!S
M59<Y:LM2W%\?C_K[U#M<T_\ ;=6-Q3ATIJ:G^SIFH*>A^RI:,WO?_7O[$=I-
M#;]%I-<].?\ 6W]?]Z]WFF_6ZL!CK![7=).G&G_XM]?_ *]/_P!#CVH'^XI^
MW_+UYO\ <H?ZO(]+_P!BCH/](_+;@^QJ%IQ0AP5#:V%[W_I;_BA]DE_NYLCC
M_)TLM;+ZSJ!_?.3_ )4C_MS_ ,4]EG[^^9_U?GTN_=?V]>_OG)_RI'_;G_BG
MOW[^^9_U?GU[]U_;U[^^<G_*D?\ ;G_BGOW[^^9_U?GU[]U_;U[^^<G_ "I'
M_;G_ (I[]^_OF?\ 5^?7OW7]O7O[YR?\J1_VY_XI[]^_OF?]7Y]>_=?V]=?W
MRJ/^5'_H;_BGNO[^/K_J_;UO]UCY_M_V.N_[YR?\J1_VY_XI[M^_OF?]7Y]:
M_=?V]>_OG)_RI'_;G_BGOW[^^9_U?GU[]U_;U[^^<G_*D?\ ;G_BGOW[^^9_
MU?GU[]U_;U[^^<G_ "I'_;G_ (I[]^_OF?\ 5^?7OW7]O7O[YR?\J1_VY_XI
M[]^_OF?]7Y]>_=?V]>_OG)_RI'_;G_BGOW[^^9_U?GU[]U_;UU_?*H_Y4?\
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M^?3O[K^WKK^^51_RH_\ 0W_%/=?W\?7_ %?MZW^ZQ\_V_P"QU[^^51_RH_\
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M_/KW[K^WKK^^51_RH_\ 0W_%/=?W\?7_ %?MZW^ZQ\_V_P"QUW_?.3_E2/\
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M]WJG7N Z^CV+VC@J9%JQD1C:2)EQVXJQIM JZF4)#4M8&.@8%]C6@)JI %:
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M>EQVT*!*^LD0_P!J1@X46_/]2;>[O,""?0?YNJI:F,A1YG_8ZI3_ )/_ /.
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MW8]HY?=T^BA&[,9#"4AIYV24%XD0J\;W+2+I9E:J14T%?(UI_,]7E7!'ADD
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M?Z?0_P"P]OF7KR<:]5,_(\_O50E^OT_W@^UB3=G3<J_J]%#_ )>,9_X=.L+
MK\=M[-SQ^D4Q_P"(]S#935V-#\QUC%9?XSSS<C_A#_\ '^MI+VCZE'KWOW7N
MO>_=>ZX8_P#XN'^P7_>O;;?!^WI1%_;?ZO7K63_X3%>KXT_.P?\ @R_Y& _\
MAC'?\4]LJWA5/](_RZ57<6I!]@_D.KB?GG\2.KOGC\5>T_C-W%0P?W:WCA,A
MD<3N/'HTM5@,QA4>IQ6<HAZ0M?CZQQ)H)L^EU(LVH7D41I5OF?\ 5^?5;:8L
M_AK]E/4&G5$G_"<'I'+=M]?]A_S*_D7V#D.\OE'D\Y/\*]I[MW'BFT[>V/\
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MK]J>D'4:*(2 DEKZC^?;2KJZ>S7K6@_X5/1R-_+MZ/ OI/\ ,!^-P//Y,.X
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M'_C_ +Q[]X?7NO>/_'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_ !_WCW[P^O=>\?\
MC_O'OWA]>Z]X_P#'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_'_ 'CW[P^O=>\?^/\
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M_P#%E>D?_<RM]GO+GXO^:<G_ !QNH>]Z_P#DEV__ #W6?_:3!U;:G_ 7'?\
M!A_O9]PO>_[DR=90[?\ V%M_J\^IWLNZ5=<'^G^Q]^Z]T _:G_%IJO\ 6_XG
MVW'U9O+[.J4._C^YDO\ !K"W^M[-)(OTNDO5X'2-1!-U'T]X:PW/7W70(_\
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M(OUC\@J?J#XE]%TE%2UN^^T]Z[3J,+L+KEEU3Y"9W9;FWJ_AP%A8CGZ#\Z8
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M?Y+4UE(XXO\ YJ16_P!@+^UHM?\ $STE-R?J1_J'0M>QMT'>@OW7_P 79_\
MJ!/^]^PCNW#_ %?/HSL^'^KUZ3_@_P!K_P"3?^-^R7HQ\3KW@_VO_DW_ (W[
M]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q
M.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#
M_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^
M3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\
MC?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW
M7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z
M]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]
MK_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-
M_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-
M^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>
M\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW
M@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO
M_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_
M (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[
M]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q
M.O>#_:_^3?\ C?OW7O$ZC^_=.=2/!_M?_)O_ !OW[IOQ.O>#_:_^3?\ C?OW
M7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z
M]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]
MK_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.FS<_P#Q;LA_K_\ 1OM/+_9_G_GZ
M/]C_ +?H.>++IN03:Y/-_P"A]^CDZ&DT-.FG,U7V6.KJBWU ^O\ K^]Z.RG2
MJQAI/GH+<6-=<@/XN;C_ %O;8.K_ %?/H=7_ &_LZ5>DQ,1_K7MS?_;^](:?
MZOLZ)X!4=+OK>@^XJ:RN'_*)CC:_/Z0?]MR/;M-#] WG"_%O;C]G0M^#_:_^
M3?\ C?M_J,O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?O
MW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/
M]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW
M[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>
M#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^
M-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3K
MW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW
M_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$
MZ]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y
M-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[
MQ.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_
M^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=
M>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_V
MO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?O
MW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/
M]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW
M[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>
M#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^
M-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3K
MW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW
M_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$
MZ]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y
M-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$ZF>/_'_>/;?B=.=!
MQOC_ ( UG^NWM7#TX.(^SJI+Y&?\":K_ 'W^I]N0?&>J6W]L.BA_R]/^WHS?
M^*Y]A_[U![EJP_Y):?\ -O\ PCK%S;?^5ON?^:-S_P ?'6TI[:ZE+KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IO]^Z]TX>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZP1_\
M"G_X)'_O?N@^+IU> _U>O5,O\\C_ +)1ZV_\65Z2_P#<NM]G>P?C_P":;_\
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MG/M_X?,NT>#_ ,HZ?]6#T&]I@^IVR\K_ !?SQTV_%&$1=J_,>L2DO4U/=?\
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M''_5\^JG@.J3_D+_ )ZI_P"#-_O7LP_U?SZ;7_5^SJ^OI3_F275'_B).N_\
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M2(%O25HL?3-"O^Q+J+?ZWLWT?XK7IHS_ .,4Z$;V*>@]T'>X_P#BZ?\ 4O\
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MJWBR>HZBU?\ ,EZAG"&GZ_[/%72?1FI,0?\ X\]H!82?/]G5_%?U7]IZD_\
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M6G^U:W^M?V[$W5- '^H=0_\ 9<S_ ,JI_P"2?^D?;E>MZ!_JI_GZY?[+B_\
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MW_*L_P#R;_T;[W4_ZJ]>\,>O^#KW^RWM_P JS_\ )O\ T;[]4_ZJ]>\,>O\
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MHZ][]U[J/[]TGZ2&_P"3_?O9#CZC$CZ_T"^ZS?#^WH3\K8GZ+?EY_%0U8%@
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MY41_MA[]I'^H'KWB-Z]>_NE1?\J(_P!L/?M(_P!0/7O$;UZR?W,H_P#E1/\
MR3_QOW75\AT_X1]?Y=8_[K4/_*D/]M_QOW:@^7^K\^D^L]>_NE1?\J(_VP]^
MTC_4#UOQ&]>LG]S*/_E1/_)/_&_==7R'3_A'U_EUC_NE1?\ *B/]L/=M(_U
M],>(WKU[^Z5%_P J(_VP]^TC_4#U[Q&]>O?W2HO^5$?[8>_:1_J!Z]XC>O63
M^YE'_P J)_Y)_P"-^ZZOD.G_  CZ_P NO?W,H_\ E1/_ "3_ ,;]^U?(=>\(
M^O\ +K'_ '2HO^5$?[8>[:1_J!Z8\1O7K)_<RC_Y43_R3_QOW75\AT_X1]?Y
M=>_N91_\J)_Y)_XW[]J^0Z]X1]?Y=8_[I47_ "HC_;#W;2/]0/3'B-Z]9/[F
M4?\ RHG_ ))_XW[KJ^0Z?\(^O\NO?W,H_P#E1/\ R3_QOW[5\AU[PCZ_RZY_
MW0HS_P H8XX_4?\ BGNTS@=,K$?7_#T6'Y/8B#$8K:/@/_ RNW&?]M2_X^UM
MG<5 _/K3P$U_+_-T8S$[/@EQ&'F!6W\ QA)^MP:*_P#C^/:*:YZV8J$_;_EZ
ME?W5H?\ E2_WO_BOMZ@]>JZSUE_N91_\J)_Y)_XW[3ZOD.E'A'U_EUC_ +I4
M7_*B/]L/=M(_U ],>(WKUD_N91_\J)_Y)_XW[KJ^0Z?\(^O\NL?]TJ+_ )41
M_MA[MI'^H'ICQ&]>O?W2HO\ E1'^V'OVD?Z@>O>(WKUD_N91_P#*B?\ DG_C
M?NNKY#I_PCZ_RZQ_W2HO^5$?[8>[:1_J!Z8\1O7KW]UJ'_E2'^V_XW[]0?+_
M %?GUK6>O?W2HO\ E1'^V'OVD?Z@>M^(WKUD_N91_P#*B?\ DG_C?NNKY#I_
MPCZ_RZQ_W2HO^5$?[8>[:1_J!Z8\1O7KW]TJ+_E1'^V'OVD?Z@>O>(WKU[^Z
M5%_RHC_;#W[2/]0/7O$;UZR?W,H_^5$_\D_\;]UU?(=/^$?7^77O[F4?_*B?
M^2?^-^_:OD.O>$?7^77O[F4?_*B?^2?^-^_:OD.O>$?7^77O[F4?_*B?^2?^
M-^_:OD.O>$?7^76/^Z5%_P J(_VP]VTC_4#TQXC>O63^YE'_ ,J)_P"2?^-^
MZZOD.G_"/K_+KG3;1H?N*$&B))M;_'_;7]K+<?ZOV=)KES_J^WH5CL_&%25H
MR>?J&]B^T('$=!VY!/GU._N9B_\ 5-_MQ_Q3W>@^?^K\^M9^777]UL/_ ,J+
M_P#)0]ZU_+_5^WK5&Z?J/$4M(+A=3<_7_'W4)Z].EB>G7W?JO7O?NO=(?</_
M  +/_(/_ $*OL,[WQ/V?Y!T=[9Y=)?V2]+>I'OW2CJ/[]TGZD>_=*.H_OW2?
MJ1[]THZ][]U[J/[]TGZD>_=*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZC^_=)^O>_=>ZD>_=*.H_OW2?J1[]THZ][]U[J/[]TGZD>_=*.H_OW2?
MKWOW7NI'OW2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW2?J1
M[]THZ][]U[J/[]TGZ][]U[KWOW7NI'OW2CKWOW7NO>_=>Z][]U[J/[]TGZ][
M]U[KWOW7NI'OW2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW2
M?J1[]THZ][]U[KWOW7NO>_=>ZC^_=)^H_OW2?I)=A_\ 'J57_:QQ_P#Q'NK_
M -G^8_P'H5\J_P"Y'Y?YNBIYN;_)J6'F^D$?CZ#_ (W[0/)U/6U6]*])O6?\
M/:#H[Z4.VOW<F#_A_K?0V]K;?XO]7GT4[K_85]>C@;(B^RV]0W_Y3+Y$GZ?4
M#C_>O9LB42O^KCUCKOEP/J,]*SW3HOZ][]U[KWOW7NH_M1T7]2/:?HPZA:#_
M (>[Z#T7]9?;O2CJ3<_U/^W]M^*.KZ#U@I_U)_R%_P 3[]^'_5Z]).LWMOHP
MZC^U'1?U[W[KW7/0?\/:?I7H/6?[=O\ 4?\ )W_&_?NKZ!TV^_=(>I'M1THZ
MYF(PG^GT]I^KD:<]=<U!_P!\+6]N8ITDZX^W.O=2J?\ 4G_(7_$^T_2Y.'4?
MG_@1_C_OO^*?7_#VYC^7^K\^D/6;VWT8=1_:CHOZD>_=*.L6@_X>T_5]!ZSW
M\!'VQ(M:U^/I[> KQZIU@T'_  ]L]7T'KA[4=).I'OW2CKWM/THZ][]U[J/[
M]TGZD>_=*.O>_=>ZC^_=)^I'OW2CJ/[]TGZD>_=*.O>_=>Z][]U[KWOW7NO>
M_=>ZC^_=)^O>_=>Z][]U[KWOW7NI'OW2CJ/[]TGZD>_=*.O>_=>Z][]U[J/[
M]TGZD>_=*.O>_=>Z][]U[KWOW7NO>_=>ZC^_=)^O>_=>ZD>_=*.H_OW2?KWO
MW7NO>_=>ZD>_=*.O>_=>ZC^_=)^O>_=>ZD>_=*.O>_=>Z][]U[KWOW7NH_OW
M2?J1[]THZ][]U[KWOW7NH_OW2?J1[]THZ][]U[J/[]TGZ][]U[J1[]THZ0&^
MO^ 8_P!;V^G#_5Z])Y./^KY=5&?)+_/UG^P_WL^UEK\?31_M>B@?R^O^WJ5-
M_P"*\;U_ZW4WN4K'_DD1]8PQ?\KO=?\ //)_Q\=;/\OW/W"Z?\W8:K_3_??7
M_>/9>:UZEG[>/1)>XOG9\:NE=U5FQ=T;UK:S=5*ZU=?M?K_;E9O?)TYM8K40
MXZ*1*4C^CG_8^Z1L=&I#G^EGH.;KSCM^U3>%. /^:./\/0D=(_)WIGY%X"?.
M=0;RHMQG;U4*?<%%)&,;D:">Q&JJIY1Y(QQ]1Q^+G\;9 C://]A'[>C#:^9+
M3?8/J+/@?.M0?]7_ !?1E/1_P'_VG_#_ %_I_3W;^CT99X_/_8Z2N8S>(VI@
M<GN'=&5IJ#'XZC6JKJJKR'\-IZ6F(-OI8#A?Z?D &]@7% 9RJG^= !TW(YBA
M\67SK3SKU/I\A!D,-@ZR'05J@U?15]@1R/\ 'D6_WH^Z!0CR'UR#TX9_'AMQ
M\^GO^Q_E&G_?#GZ?CWK_ $W7O/%?]7V]1K_[C?XC". UVXO[O3OT#IHC]'QO
MRZD_O_[[3[;[O]5.GL?/^?0/=4=M]?=RXJJW-UMN"FW/A,=E\SM2MJJ<52'^
M);5J+5--^]8^E3>]S>X/%K"H9I!H;AD>?$'IFSO(KK]:+CQ'V="\LY-2:"_&
MD#_;K_3VX%SKZ=%QCP>N%-^FN_B'ZN?Z?6W/^\>_-YZ.MP_\.ZAQ2AJ<&"L!
MO]#]?=@<8/37#IRU1_ZO_DT^V_#Z>\<^G63TPK_:(+?Z_P!?]M_3W;X.F\D]
M<)7$"<"W)_%_]\?I[T3IX=;TU.>L_N_3?6'SI_1O]L/^*^Z:QU?0>O>=/Z-_
MMA_Q7W[6.O:#UF]WZIUA\Z?T;_;#_BONFL=7T'K-[OU3KWOW7NO>_=>Z][]U
M[IO]^Z]TX>_=>Z][]U[KWOW7NO>_=>Z;_?NO=.'OW7NO>_=>ZC_[O_WW^I]M
M_B_U>G3WE^?^7JEG^>#_ -DH]:_^++=.?^YV3]B#8N#_ .D?_CC=0][W?\DJ
MV_Y[K/\ [28>KD:?_@,?]=O<-7G]IUE'M_\ N-^767VQTHZ][3]*.O>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[J/[]TGZD>_=*.H_OW2?KWOW7NI'OW2CKWOW7NL6@_P"'OW36
M@]9??NG>O>_=>Z][]U[J/[4=%_13OEU_Q8MA?]1NXO\ W%]O0_#^W_ .MGXC
M]@_P]&DPG_%DVW_X;V*_]PO;%U\/3T'$_G_AZF^]],=2/:?HPZ][]U[J/[]T
MGZD>_=*.H_OW2?J1[]THZC^_=)^I'OW2CKWOW7NH_OW2?J1[]THZ][]U[KWO
MW7NH_OW2?J1[]THZC^_=)^I'OW2CKWOW7NH_OW2?J2O_  *;_7_XGVIM>'[.
MDUYQZ%?V-^B#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0&X?^!9_P"")_O0]A[?
M.)_U>0Z--JX'[>F;V4=&G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[VGZ4=>]J.
MD_7O:?I1U[VHZ3]>]^Z]U[W[KW7O:?I1U[VHZ3]>]^Z]U[W[KW7O?NO=>]^Z
M]U[VGZ4=>]J.D_7O:?I1U[VHZ3]>]^Z]U[VGZ4=>]^Z]U[VHZ3]>]^Z]U[VG
MZ4=>]^Z]U[W[KW7O:CI/U[W[KW7O:?I1U[VHZ3]>]^Z]U']J.D_4CVGZ4=>]
M^Z]U[W[KW7O:?I1U[VHZ3]>]^Z]U[VGZ4=>]J.D_7O?NO=>]I^E'7O:CI/U[
MVGZ4=>]J.D_7O?NO=>]^Z]U[W[KW7O?NO=<OMV_U'_)W_&_==8Z]UQ]VZ]U[
MW[KW7O?NO=>]^Z]U[VGZ4=>]J.D_7O?NO=1_?ND_2,[*_P"/4JO^H_&_]$^T
MK_V?YC_ >A7RK_N1^W_)T4+.R@3TL(X)N;?[>WM <]9"6!I^W^73/[8Z.>GS
M:\7FR+"US_#@?:R$TDZ#F_?[C_ZOGT>+$PBEQU%3_BDQV,)_V]O:X)^G7K&B
M]N/\8Z<O;W3/7O?NO=>]^Z]T@]^]A;-ZLV1N/L/?^7QVR]A=?;?R.]=[Y_).
MV&IJ'"X"@6JKZZHT7:5D9U4( 26X_J?=K>W^KX],RS?3&@SG[<U_R=$XZ^_F
M8?!SL;XP;G^:NW.^=MP_%W9>Y:':^Y^X]RXC)[0QE'68^LI<=$(HZVBGEFD.
M0R=%'I0:B]V(M<>U!L+DBOS_ )^G3$=S"IH:5(.../Y>A'0()_/4_D_S31T,
M'\P#X^-)--3I!.<ADT425).MRS4@  XY)'/!/Y]NQ[--+\34_;U[ZV,?A_F/
M\_1R.@OF5\3?E+]Q'\=?D+TWW=64%)]Y68KK_?E%EZND@X0LE&!%6*+FQTZA
M?\\K>D]E/;Y4CCUN.YBF'<*#]O\ ,&G1HO:/I9T4'Y/_ #U^&OPO@H*CY2_)
M+J_I.IRT9?;N)W;N227-SJ!?5!AX(VR2HR@\NRC@W^GM3#93W'Q&G3$EU%%\
M*U_D/V_['05?'G^;#_+=^5>]GZ\^/_RZZ;W_ +[JB5HMI2[FDVME*YU'"XZB
MRL<$.2D<V 2.0,38!?I[]+M<T/PFO^KY]42^27XA]O _MIT8SY-_*/I7X<].
MYWO?O[>C;&ZPVGD<7BL[NB7;\^X8Z!\M7+C<8C1T;+(%6J9R?J?J ";78MT^
MJ^WY=6D<Q<*4(KGTZ6_4';'7G>_5VSNW.I-SX[?_ %IV/MG';PV7N_;+,*&L
MH\R"MB& :*TD;KI(NI%C[]<6_P!'G_)UZ&4W)H<?9_J/0LV/]#_MO;/A#I7K
M/4;VYTDZY?;M_J/^3O\ C?N_@KU[K-[ITHZC^U'2?J38_P!#_MO:/PATKUGI
M*Q;CV^^?JMKTV<Q-9NO"XC'Y.MVV,@6KZ6@KK"CEFH_RU8U@1_B/Z^W?INDX
MN#QICUIQ_P"*Z)_N/^8[\']G?).E^'FX_DSU9A/DS)E]N;4I.GI\A65&;CR.
MY\;%EL?12JM.U$K5%#5PLX,UU9P& :WM6=JE'<3G\Z_ZL]-_5%OT0,?EFAX_
M\9Z/']NW^H_Y._XW[+^W_57K?6>Q_H?]M[]X0Z5ZSU@YIS_OC>_M1BG23KC[
M<Z]U[W[KW2=.Z, N?K-I'/XH;NI<3_>&NVU_'J/[_P"P(O\ Q#[#Q^4TOYMJ
MU?[?VCT=7\<_EPKG_#Z]$][ _F.?!7JWO["?%7L?Y(]9;.^1V7S6W,12=/9:
MHKJ;,5&0[#@CEQ 98H&I$->L\)C#2^CRH6TZO:U=O<?K<.D\MS$W 5_93_/T
M>V7]CFH!_'U-K_[W[1>#_JIT8:SU@^W;_4?\G?\ &_;_ (*]).O?;M_J/^3O
M^-^V.W_57KW6>Q_H?]M[]X0Z5ZSU&]N=).I'OW2CKWOW7NO>_=>Z][]U[KWO
MW7NO>T_2CKWM1TGZ][]U[KWM/THZ][4=)^O>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][3]*.O>U'2?
MKWOW7NN7V[?ZC_D[_C?M/T]H'7'W[JW7O:CI/U[W[KW7O?NO=>]^Z]U[VGZ4
M=>]^Z]U[VHZ3]>]I^E'7O?NO=>]^Z]U[VHZ3]>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'^\X2*%> /Z_\ %/\ 7Y]^!Z])
MQ_U?+JI#Y&?\"*O_ ()_Q7VIB^/]G33_ -I_J].B:_R_/^WI-/\ ^*T;V_ZW
M4GN4['_DD)^76,,?_*[W/_-"3_CPZV!/D;V+ENGOC9W+V!BBHR6P=@YO*XJ3
MZ:)Z"CT0D'_7_P")]E\I3Q49>,C8_P  Z'O-&]2\N;-<W+?#;PEC]@JQ_D.B
MV?RV^H,#UQ\9.OM^5=&,IV?W5A9NS^P]]UTG^45^1SA-2J2U9O\ JOZ@18?4
MFY][.J5Y/X8QI(\^/1%[;64-GM5M>"GBW0$^OR)(J>A+?XD[-3Y-8OY3;4RN
M1VOO:CVS6;<W5M? +2T&/W+!7@"+^*$:@!0DCQW') (-Q?WJ36!1C5/-QP->
MCJ#E>#]XG<81HG(IX6:C-?\ BOS]>H?Q(^1.\>WH>\=N=G[?P6V>TNE>ULSL
MW=N'PD50E-]C=JC$UT7W1/[-="&'UY]/-B![TJ>)I4@:&%"/Z?$'/5]EW>[O
M1,UW_:Q28\_T?\^1U6?\L?D#W#\C?A1\C]Y8+:>R*3H6@[2S^R8\Q4K4ID:C
M;>R:E8(\K2@MX34C.%4)"^$1L1;ZGVI)*^(J@:QBOG2H_P M.HUYQWJYWO9+
MB6 GZ>IJ?('-?+T_U4Z-5G_D_P!^=+]$=';?W=L+K+<WR,[AW;0[%Z2V7LS<
MM9]A44RT:::FOJ:I]$9I:9K5/K^A!) #'VF1 3K82'3\8'F,"I_;3H3_ -8K
M_:MNL()VMA=38MOF]"Q Q4X4G X GY=-^[/D/\T?B_D-K;O^5&/Z2W[T=NO<
M]-M+=.Y^I&R&/J=H5&Y:@102R1SKJKJ!7L1Z&5@ +_INV55B$[T>M26\ZG_!
MT_<[_NNR5FW VTUL!H'@C^R_GQ^>/\-'WLOY0_)/-_*#?'Q9^/77O7=94XG9
M^S]XT':&Z:NI,-!39Q9&JZS*)&VFJYDO30PI91S8@ !]]2Y5QY$*?+S)Z]<<
MQ74VY#;;:W:E*F?%/D*<:_\ %5Z5/0'R/[LQO=^2^*GR<P&TL;V4=J_WTZSW
MWL'[I<'N&@-1HJ6%-46D@JJ<!O5I_L_BW.@K2-4 4I60#@HX];V??[J*Z_=^
MX?'7_%G.?&X>7E2O^#\B]?#OM;<72_PM[S[&VKUAENV]P8OY+]M1X?9NV+^>
MOGR.;B2YT@L56RF:P/UL;7N/&-%C50Y0Z:?Y.BKE:^GV+:IY3;^-_C!-,9R?
M6F3\R.E+VKW3_,;^//7=5\A>SZ'XY9G9F'QF.SFZNHMKC(X[*4]/EC^_]MDJ
MA0U15TQ^I60D'FW'%$#2II[:?Q9_+_57_+U7=][YBV*#]YWOT6JE3 ":?/)&
M?E517Y="W\F?E]O7:6Y/CGU;U##UIB-\?)/;U3N:CW?W'75-!A\=CH*4:;6'
M^55SV)B@*$#@V-[^]:U*%(O$T+FL?  ]&G,_-LFVW%A;H;3ZC<&("W3:2=()
M-!YD#RJ,5].ECT3OWYJT?;LW67R"ZYV'G-E#:[[BP_R"ZCAJ<=CO/]UQB:JG
MJ55/N=0L$TJ?S;F_O3!%-7=B]/@;A]G1KM=_NWUABNK>(08I<PFI^>#_ (:F
MO^$MFP_DK\X?DZ>TX_C]L7I+9U/U3V1N_9E9N/>+9&MIZ_\ @E2324=#2.S*
MT_VO_ JI"7;CPV^GMR-@-&J1QJ6E3T&=NYDW7F07'[MM[<F&6@^9QZ#\O0?/
MJ!U5\I?GC\H>NZK='2NT.F^O<CUYDLS@^P).Q*^:O@R&<VVI>IH,(L'$-$1?
M_*:I0+_1A8^[:NXH !KPM?/[.-/]6>F]IYCWOF2 7%J;:L(_7 JPKPH" *T^
MRN*T%>CN_"WOBN^3G1&V>T<I@HMK9N<YO$;LPBBU-!6[7JA3SM".2+JQ_/\
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MU'2?J/[]TGZ*=\NO^+#L3_J+W'_[C#VZO ?:?\'6S\1^P?X>C283_BR;;_\
M#>Q7_N%[JW =.P\3]I_R]3?;O3/4CVGZ4=>]^Z]U[VGZ4=>]J.D_7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]I^E'7O:CI/U[W[KW7O:?I1U[VH
MZ3]>]^Z]U[W[KW7O?NO=<X/^!=#_ *Z_]#'W:VX?G_FZ3W? ?8.A5]C;H/\
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M+HSH##Y^O1/"*K,UN]]I5N<R-CZF>NS]772*>+&-0?Q[>BFUS4Z:>/PUKZU
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M^UGKW6;W3KW6'P)_5O\ ;C_BGN^L]>Z]X$_JW^W'_%/?M9Z]U[P)_5O]N/\
MBGOVL]>ZS>Z=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZP^!/ZM_MQ_Q3
MW?6>O=9O=.O=>]^Z]U[W[KW6'P)_5O\ ;C_BGN^L]>Z]X$_JW^W'_%/?M9Z]
MU[P)_5O]N/\ BGOVL]>Z]X$_JW^W'_%/?M9Z]U[P)_5O]N/^*>_:SU[KW@3^
MK?[<?\4]^UGKW7O G]6_VX_XI[=Z]UF]I^O=>]^Z]UA\"?U;_;C_ (I[OK/7
MNO>!/ZM_MQ_Q3W[6>O=9O=.O=>]^Z]U[W[KW6'P)_5O]N/\ BGN^L]>ZS>Z=
M>ZP^!/ZM_MQ_Q3W?6>O=9O=.O=>]^Z]UA\"?U;_;C_BGN^L]>ZS>Z=>Z][]U
M[H->U>-G5T]^1D,41_YW$>TUT:C]O0JY.Q??GT26IDUU%6!QI"CV523ZL]9-
MVX H.HVL_P"'NWB=7Z$/J1!4;YP\%K@-8<?T'M3;/K/0.Y]/TU@>CP+_ ,!_
M]M_O8]F\?6-ES_J_EUD\"?U;_;C_ (I[UK/3?6;W3KW7O?NO=?/1_GTU'^E/
M_A2/\%.N=P">#;.V7^(N"HJJM8?:R4M=N:3.2^$K?]K75%&_PM?DGV*+/^P
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MNFO_ $/<?_T?[W]"_P#J(_S];_K!8_[]3]A_Z"ZR?[.E\1?^\F.FO_0_Q_\
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M_P!!=>_V=;XD?]Y-=-?^A[C_ /H_W[Z%_P#41_GZ]_6"Q_WZG[#_ -!=9O\
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MEM_C]?K_ +#W;Q>J@L/7J'_H&QO_ "JC_;?\;]L:/D?Y?YNG*'UZ]_H&QO\
MRJC_ &W_ !OW[1\C_+_-UZA]>O?Z!L;_ ,JH_P!M_P ;]^T?(_R_S=>H?7KW
M^@;&_P#*J/\ ;?\ &_?M'R/\O\W7J'UZ]_H&QO\ RJC_ &W_ !OW[1\C_+_-
MUZA]>O?Z!L;_ ,JH_P!M_P ;]^T?(_R_S=>H?7KW^@;&_P#*J/\ ;?\ &_?M
M'R/\O\W7J'UZ]_H&QO\ RJC_ &W_ !OW[1\C_+_-UZA]>O?Z!L;_ ,JH_P!M
M_P ;]^T?(_R_S=>H?7KW^@;&_P#*J/\ ;?\ &_?M'R/\O\W7J'UZ]_H&QO\
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M>ZB_8'_#_DKW['SZ]U[[ _X?\E>_8^?7NI7\-?\ P_WW^Q]^J/3KW7OX:_\
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M>ZZ^\_VE?^2O=M(]>O=>^\_VE?\ DKW[2/7KW7OO/]I7_DKW[2/7KW7OO/\
M:5_Y*]^TCUZ]U[[S_:5_Y*]^TCUZ]U[[S_:5_P"2O?M(]>O=>^\_VE?^2O?M
M(]>O=>^\_P!I7_DKW[2/7KW7OO/]I7_DKW[2/7KW7OO/]I7_ )*]^TCUZ]U[
M[S_:5_Y*]^TCUZ]U[[S_ &E?^2O?M(]>O=>^\_VE?^2O?M(]>O=>^\_VE?\
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M_.!_^VKK*O2?\Z3@M\P?BL1_XB^L;Z?X\^Z2'8?]]-^W_H3JL.T<\^>XV?\
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M_JW^W'_%/=]9Z]U[P)_5O]N/^*>_:SU[KW@3^K?[<?\ %/?M9Z]U[P)_5O\
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MOYGOPRW;"5F[(K]@S5/UHMZ;=J=L_P"VFA,E%^/]2/94^R2IYT^WIY]X6/\
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M?CAE>R8]P[AW+OW877F!ZUZNV%ATS6X<Q64&,H/W*6D8A8U!8![J=6H!=1#
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MB:3;]Q;_ &%Q[..8FIMNVM_2 _;< =0Q[(U_KCSP/52?Y(>@A^<G_,K=K?\
MB8MB?^Y;^RS<?AB_YJ_]8VZEWE+^SNO^>*3K<SVS_P >[AO^U5M__P!Q/<_K
M_;1?Z1?\'7$C</\ <ZY_YK-_AZ=_;?23HIWSE_[(R^57_B M_?\ NG7V(N5_
M]SD^T_X!T"/<+_DBWW_- _Y>@Q_ET_\ 9#OQC_\ $';/_P"M4WLIYL_W//\
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M4YI:Y:*K^UJ#Z<?D2QM1AK7! _K?VICEK-TDN!PK^SUZ)#\&_AAB_AML/>6
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M-VYOCML9>NP%-MT4Z;K946A>)'<B2F"*[*6])N+"_.^:^;Y=_G)$1CJJQU(
M/<>&.G=NVGZ<@\,4I6OJ?EZ]-/Q6^("?&7?'RUWU3[_R.^9ODCVU5]L56-R6
MVZ#;7\%2N$BG&G7(RU3/J=?,ME]-P/4/=.8>8!N<$,*FNA]9\J>73%EMGTD\
MLQ%*BGF:X \J>GGU-Z0^)"]/?*GY3?)JFWO69V?Y0-MR279F6V\<7%@QM>D%
M,]ZHEA5$MZ!90"IOR+>U=_S5)=6D-K)DP%213 *XZ;M>7%ANYKK@9?.N3CT\
MOGT4*J_E,5^TM\;[S_QL^:7?_P 9.O>T-Q93<V]^HMDXS'5-&TV2U&K7%5=7
M/!/A%0$J#)&6"FUV^A/5]Q#>0M;WMI'*6-8Y%!+,?E4=O^KTZ0GED6]#%,%(
M]2/YU#5_+SZ'_P"(OP(V+\/]Y?([-]>[OS==MKO.':=%0;=W BY"KQD^V**H
MIZFIFS$9U9>IRU56"MF540!?U V ]E^]\]W>\+ 36D14D<:4%./S)KUO:^5[
M>SFG)4 S$L2, DT\O(T%,]+_ .#?Q-B^&?2E/T]1;TR/8HBWYO+??]YJ[;\>
MW2J[YJ8:A:81>1[FC6$2'GDL!_9 !)OV]P;G*)0:T)-:4X]&.S[+^[XO"H!@
M"E17%?3^74?X<_$6#XDQ=_Q4._LAO]NY.[<UVVS9#;T6.7'2YO4?X80LC&8G
M6 UPMK<#FQ<WSF:3F&:#ZJOZ4;*U1P9O^*Z?V7;!M@GH*8]:U^>*=,'3WP@V
M]UWVO\U^P]P;DEWYMWYE9>CR^Z^O\A@HL8N-I:['S4<N+6L#M]R628*EM%](
MX)]J+WFZXO?"AX_3&J _81_@/1?MW+HMI)9EP9<UKQ("BO\ QD=%-VM_*-[#
MZ\P_^C'JG^87\GNN/CI+6UR473&%AH8I:>ER'%114&=.F:"!A]6\(##ZJ3Q[
M$D_N-#N,GU-U81+..$_ZGB"OHVD*/V](%Y6D2W^B@E!B I7!%/3S/\Z^AZ%'
MI'^5]LOX\[2^7&PNMNWL]3=>?*':D&U<3A\]BX,W4;?K)\37X^>O;(M5JF;$
M_P!X90)U3CZV*BZ&]]P+C<9[.\F0RO;<0,E33C7S]?GUO;.3K?93.;>6AF;6
M349)IY&I!Q3[>@=VG_)ZW#U;L/"=;='_ #U[^Z>VQ4[;QF,[5Q&V\;0UV-W#
MD):5DJ<OCXIYK[<JZ\ )*(-;6!NUO3[.IO=7]YRR75S:Q,X%$D!4Z3YG([2?
M.G27^I(,'@&:7C@5S3YU!K_+]O5F/QE^,'5?Q*ZEV_TWU'CJN@VMA<EDJ_*5
MVX:]<QD\GD*Y0M3E<K5)H2IR%0H"QHJV M_C:.=^WN7F:[$ET**/VD^9K3H4
M;%M$/+\/@P4^7H!7AG/'))_S]&-\"?U;_;C_ (I[(]9Z.NLWNG7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZI^^-*7_ )QGSX_(/1?10'_)8'^^_P!C[E:]3_=)%%_3_P"?4ZQVY5_Y
M7+<3_P N,/\ U<NNKH?/_M'_ "=_QKV >IYZ[_V"?[=O^*>W<_ZJ=._2]4I_
MSU<5E<G\!=V5..HJBNAV[V!UQF<RU+2"K$./H,K,KU<Y_P".+.5'X'T'-_8)
MYZC,FW-C"R<?0L'49^TXZRL^YENUOM/.T!N+CP!-#+$3Y@U& /7JC/OGN_I_
M*?&W=./Q?8>VZ_*[@Z[BQ5#AZ1Q]V:BJ\(L8?U#^I_H!S;W$=WNUO>@PQ,Y*
ME*@J0!I-3FE/+KIWL?)NZ[9O/U-Q;M%;++,3<D5AH=0X\//&>C(_-C$Y78?Q
MR_DTYO>V,KMMXK8VW$P.]*NKHR1CZK,XG;E7%25/] 84D-S_ +5^5X%?,T#6
MMGMHDR55&;R++XP;'Y9IUC#]WW<H=[YRYOAL:S^."D(!XDT7]II_D\NBQ?+#
ML#9/8.SMA[4V1N;#;RW3D>W]C'%8#;5?_%9YQ]T?KIN>;\&U@2+GV%[J_AO_
M *5(Y&8*\E25(H"ND<1ZD#K(W:>7=PY;@W":_MF@0V,M3/V_B'KQ_+RZW8L%
M'-2[=P]+/2WJ:?!8ZDKDO]+T9+ ?UY/O(^!_$>*3TH#^RG\Z=<*[Z43SW,U?
M,D?MKT]<TI_Q_P"2;:?]O>]_=^D_'HHGSG/E^&'ROAO<_P"@3L#C_@N(B_X@
M^SWEC]"XB_TQ_P  Z /N8/\ =+N _P"78_X&Z07\ND7^"?Q>AM<?Z$-G_P"\
MTLG^/^'LIYM'^.-*?X?\IZ5>U7_*O6X_TO\ @'1V8/T'_@Q_WH>PV_'J1>LW
MNG7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#KM7?<'7'778W8#XH
M9"38&RLYN-,(,B<:*@[=I5K/$9AR0-1_WW'LQVC:AN,[0'R!/[.DNY7GT,2R
MUXD"M*\>JBNN?YJ/R=[CV/A>QNJ/Y77>6\MC;@H9:G;NY]M]S8F2GGIXR5(O
M'B=)((()T_46MQ[DBY]M[+;'$4U[$9#D=R GH(1<Q2[A6>**0<.*C[?XNC2?
M$_Y^[3^2&^MV=+;KZOWU\<OD+L+'TV<W)T[V+,YDJL;5("]=CYPL=/64UB"4
M:)3I92FI=3*2;MR8NPP1R>*TT;\7\_M%.(Z666_&^F\('2OJ ,?X?\/[.'1@
M]C]I]G;G[I[7ZQW'T=N;8^PMA-@&V)V]F\I29#'[O7)L!5M04;HLE#_#%+.H
MBD) %FYL/9%?6L"6Y8RH,"A)%#7H\C>5)1'6IS4#%//_ ">?1C1,O LWX'T_
MXW[#\*TST9'/7O.G]&_VP_XK[MH/6NNS4_;@@KP?Q_O5Q_QOWJ1H1D3]:M[@
MGRZR4_\ 7GD&X(_Q]ZF\#_E(BZ]:U'E_J_;TS[BRAP&$W)N'[(59V]@,CGQC
MC_9_AE$)A?Z7Y;VKVR#Q93$>FII]9 ]33^?15?A5\HJ3Y@_';:?R"BV/7=<P
M[DR6Y\:^TZRN;<D=,-I5<T",*J(4S*9_,!^ 2IL./9QS/L<FPW$MO<@A7\CQ
MP:<<=%VV7_[TB\4'50 UX<?V]"/\@>R=^]5]6;DW_P!8].9SO;>."FQRX7K'
M:V1H\;-DDRE3K\B5M;%*[BB*^?T1EKG\"Y!=MNWQ7+:&&?0?ZCTY?W8BB\6)
MM5>)/^H#/0PX&HJZW X?(5E(N*RE704.3R.WZ]=(I0:/_@%Q:WV9)/\ B3[3
M7$UL6^F/R_U?ETJB\=8C,/GD?;Q_/IW-S5?;<6_K_P 3?VFQ..E0-.NH9R?K
MR;<6_/\ QOWZ(?4=:Z]YE_"M>]K?3V[#^OU[KKS+QP>?I;VEAE^HZV13KEY:
M4?A?]>WO<TW@=> KU%\Y_P!7S^3;_C7M5+ +?]$]:!KGK."A_K_KC_D7MJ:/
MP.M&ZKUCBEI9[ @?2X_WW^^O[=M88+B?/2>Y)4=$I^,_RVQ7R1[4^5W5U+UY
M5;.D^,7;#=;2[@GW8:YLS,#(/NT@TI]HS."WZFMJ U?7V)-]Y?.T00SS_P"B
M,%/G4GHFVK=8-UFFA@-?#%>%*=NKU^?1V/ND_H?8;\'H0^.?3J3[8ZWU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UG@_X%XW_73_H;
MV[:\/]7RZU=>?^KSZ$9/I_L?8FM>/^KY=$'7/VMZ]U[W[KW7O?NO=>]^Z]U[
MW[KW2/S7_ I?^6:_[T/9!N']O^SI;:?#TS^R;HSZ][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NH_OW7NI'OW7NO>_=>Z][]U[KWOW7NH_OW7N
MI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>ZC^_=>ZD>_=>Z][]U[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ@/Y@7\QJBZ0CK>F>
ME9J'(]S?:&'=N[&9<K3[:-@I1#8K69TV(+&XHQPOJ)TBC;]O$@H?B\SZ?[/^
M#HHN[HIWQ_#Y#U_S#_#T0CH7^7COKMJH_P!+7RDW%NK%0[I\F<&UZNM.1W3D
MPQYK,M4SW_AZDW)9[SGZZ?S[$T=G!#W,>.:5R?M].B O*_8P&,5_"/L]?\'5
MM_6/275'2U :7K#K[:6VIZ8ZCGI* Y7)@_[3D:P?=*/I] /;@=)A10!\^)ZT
M-:Y9B?EP'[!T+LDGF_SW^Q]I>M=8??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4CW[KW59
MWS7^#-+W7!D^TNJ*6CQ?;34VK.8(#["#<Y/U>-2;TN7-R3*>*GZBQ^J^1(I>
MYL-YCR/^S_AZ>AF\'L;X?(^G^Q_@Z"OXE?S.MW]-SCI+Y;8[=M=A\!5R84;S
MJ*+_ '\&%^O^1YNE>W\2HH6O^XW^4+<F\_"@-[EMAG&F/R\Z9'V]&UK<A.]J
M9S3R/V>G^#J_;9>\MJ=E;:Q6\M@;DPV]=K5SF.'+[9KCD(*AORKJVEE( )Y'
M_%/8/-C+:BLIKZ4Z-TG\8D-@\<XQTM_=.G>O>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZX/]/]C[;EX]73CU[P@_Z_\ 721?V]+9W?GU35;'U_GUR!'/UO?F_NOB
M_4=;(IUW[]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NN$_Z1_P0?[V/;8X_G_GZU/Q'50GQRGI/^'@OGU+<",=,
M])L;\FQ*6_%_PWN5;Z.3]U1^E1_@3J .5KBW;FV_"\? 0G["TX'\P>K3=T=Q
M=3;)4#<N^,%BS1J=./7*>6I!_H81:X/U^G^Q]AI+"67B@'4I77,-K8C$Y^>,
M?SZ C.?.3H3&@#&YC.Y^XY.%V_4Q_P#6\G_>O9O%RM)=_P"AD_8.@9>^Y^SV
M_&Y ^T@] 5NCY[[0S-!E<9+U-4YW$9.AKJ&LPVZ,G3-35%.#^[%+#*+?[Q;G
MZ>S&+D<7K>"[KX/I6G^'I'_KPE9P8(9:C((!K7AY=47]'9OI+;_\R7Y*YF@^
M,_755MC;>SNO<WUUL&J-/]CA<CE10^:NHF\'B+RL7-K 7:X-P#[A?ESDVSNN
M8KJTC(TJL@C# Z:C13!)X9H#7B1UTJ]U?=_?7]G]KOX;FZF"W*-@4-2N>&?L
M(R.K9.R?E1A.Z]JU?77:/Q^Z^WOL?-TQASFU\_D7K(4(O9E?[<E&%S8CG@7N
M/<RW')5K?+&;A%<*:@JP!4_(CKFWRU[][U8[G!)90SVLQ%,A^'YXZJ+_ )76
M>Z5ZWWO\C>PZGH':>Y]U;$^1NYMK]5[IDR;"?;F,IPVG'XX51TDQK8B=@;<$
M6O?W#?MIRG9[NT\YUZDD@H"V!4R58@<> X^G72;[]'O9OFP6>PV7U-+6ZLVC
ME\_&D'A?Y2?/K8+PW\PCKJII_MLML?=N)-K%J+)4N5)_V&E+>YBGY.:'M0 #
MY$?ZOY=<U(O=S;!^A,SD_81_EZ&3!?,WXZYA# ^ZZ_!WY*YS;U5BQQ_0HS?[
MU[+9>5I+7&BGV@]'5G[B;1<_\2 WV,/\W2&^8N]=I[N^%ORLJ-L;NPF4@_T#
M[_"_89*ER.DOAE]1N.2-)!L/J;_D#V]L%H\5Q%$Z T8G[>'2;GF^BW?9;_P;
M@K6W.?3#9SZ=,W\O%U_V1OXR5%7^D='[17C_  AE-N/]I]D7,JS17!B_HC_C
MO1G[:3@[/ ?6G_5SH[D4/%J8V^EB;+[#7C-<<?\ +U)'^,+_ ,6.LGO77NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>T_7N@&^3/\ V39\C_\ Q"'9O^\8
MR;V+>67\&^@^UOY GHJWS_<27_FHO5!_\N+Y^;IZ8^%_2_66(^"GRJ[9H-LX
M#)TI[(ZWV;#F\/7'+9:HJ-%%4B=P"M[<-?4#Q[F+G+E0[CN#,+FV%%I5W0OD
M^6>@#R]NX2SU&$+@=I(' 4]?S_9T)GQ#[/\ ]G&_FA;J^0G8F.'QXWEU/T?)
MU;L#XV[U>IQ^\*^DJ97FGSF42H2G@-!&)'=?%9B- "MZG*'?+']P;.UO$/'5
MDU2%L @FI)_;Y=7L[G]Z7XEE_2J:U%*#/E2OH*?ZJ'$^/_>7;.]?Y@?\P?J#
M<&\),UUGU!MW8>0ZVVQ)BZ%EQ,V<Q:M+X25^X6X<@J#I:Y)YM</W/+FWVMA;
M7,?QR@Z_+++4_/HR@WJ8W\L-*>"<YXU_U?ZAT0[X8XW^8)_,0Z,??.Z/G!O7
MH7;.U-[;VV?MBOZZV_04N?W+F*>I:5J_+5$<M.$HZ-9!1TL$;V_9\@ "EO8D
MWYMKY2G%JUI]2)(HQ557]*A.6^0]/M/VEVV?O#F.+QUE$)XD8..&-0/I7_*>
MG#XF[A^?OSKV9OCJ[>?RSRW1.%^-N_L[UENOMSJK!P4^[=YY^&L/B^XJ99H#
M14./IBWJB<?=W4%78ZE:YD.S\DI'=F#ZH/$6**.Z.GV@T _GTSM-SN/,9,,L
MO@&(UI@"@'H01G_BB!T9?^7Q\G^VMOXWYQ]6?*+L2H[1K/A%NZ2FI>V/M*6G
MR61Q$&.JJZ6*KDD#.TSI "-3$\E=1](]EW,_+45^UJT$>A;MLFE"5I7/S_U5
MZ-=BW>4Q2F3'@=M/*M >'Y_[ Z+ETYFODS\[=K-\D][?S&#\+]L[LKZVIZ4Z
M&ZUS.!I4QN&C8KC9]S&LR%+/D992-(IV21V'JL 0/9E?V-ERVPL(['QP:F24
M5-!0_$?,GS^W[>B.TGFWTB]6]:W&G,%%S6A\U8U\\$ <,FAZ--\-ODQV9V1L
MSYA_&;OG<FUM\=S_ !JV_D8I.WMF24J8S=FV]WXVHEQ>5(I+4D-8C>-JMPNI
ME>T@U*Q]D6[;%!M][#>0Q"-GXTP&![@3\^'0CV[=)K^*6T4&BD8/%2/]1Q_L
M=5W?"CYI[@ZI^!?0?Q7^,F%H.R?FCW#N'LR+8NU:NK#4>VL9)FJDU&ZMR:QH
M6DI*9'FIX2=##5-(;*%84<P<IW.[WLU]NU%@0$*I/Q5)JR^G^7RZ(]EW);>U
M-G":2*!7U-/Y^?\ DZL,^7>X/E#\/OY:O8>]*OY'9KL#Y![:J=E9&M[A;;.,
MP^BIW)F*"FJ:#'8MZ'[,T$)4F%P/.QN;(M@P(V&SM.:=Q2UMHP60 ZOM('H/
M4="#=;Z3:;;QRM%H>W.: FO'C_JST.';'3'S*[HQW4>[^COF2/CMBZKJK!2;
MJV[_ *)L9O[^*9BO\-4V6:IJ0?MC-J%VY(TD_1S[3VF\;?MEQ+92VGBS 9':
M^H_[;J\VWW5["9S*8AJ-#6E!Z<?\G57VR-X_S#MX_-"A^-?5/SVRG>VW>KJV
MDS7RIW['U)@]MX'!1QU>F7 15)$PR^7R-.HIUA( B<Z!=59@-+NVL(=D\>ZB
M$3<?@7NKP%0,L3CH-V"W\MX4AE$H([022?6OE0?X!GS%;$.K>]NVMP_S5OE?
MT-F=Y9"MZ<V!T=UOO/9FT&Q]"B4.0W!'B?)5K4E36 J9W/#DG5]3]"$=PV"Q
MBVF&[;X:JP'S-,U^?1YM^Y7D^Z36=!6HSY&OB C\J8ZB_(_O/N#8G\QKX$=+
M[8WKDL-UGV_BNQZOL/:JXV@B3*KA*>5*0RNOK;3'&H&D\6XYX";E[8+.;:;J
MYE^%@Y8?Z5<=*=TW*:"_BBH*MP->'"OG\^BW]B]E_-7NC^8[\B/AYU!WI4=4
M=58+KGK3>.5W7286BW+E=NX^EHX#5C;[W1QE\WD*\LTU5(KP7^OI ]B>TL]L
MVK9TNI8P6&DUID5\A\R?/\QZ=%<EY=7U^+:-:\>)H#4MQKY +_JKT%V#RW\P
MGJ7YC9/^7EA/EI7]AX[LKKS']G[<^1':>"CW7N79N#QFI\X]-3/)-%6U]4J/
M3TB32&%B5G4Q%M2F,D6UR;=^]_!J(U\01D!F4 D>E"3_ *O/I"O[PBW'Z4S4
M%::105-0/(#[> IFM:=#!U5F/E'\/OYB'1'QB[,^3F^OE+T_\F-@;UW)CJGL
MZ!)LQAJ_:JO8PRI+.T<4;H+E7L5)L P!!7<V>W\U[4=RMH3 L3.02.Y2HKQ_
M,=/I/=[1N$,,TXE,H\J#S'H%]?2H]<]+CL3K_P#F ?(KO'MJ+>GR$W7\#?C-
ML.OQ> ZBCV')@Y,MNVSE8\S/DYJB!D1D42/"TQ"DA NJY]E]BVV6$22V\'U4
MHP^D LWS)/2[<8[F64":<01'C_1X8R",<*?F3TD?A!W1W+LGYV;Q^%F_?D_B
M_F3UU#U7#VAL[LJ04-7E\+5T-6E.]!DJJD=WED%K,OF:W[!!4:A[.N:]E@N-
MNCO4M!;&0@ T 9<TH:?Y^BW9=X6&Y-FMP;AQQ4TK0U\A0>6,#SX]%+^.'57R
M<[K^87\Q[8O2?=V6^.G6"?)C,;@[-[,V1BH:K<^2R*0RP8W"83SR1QTD#1^6
M6HE$BJ."[?0$VW;>=OV_;;>65/J&\*I8#N-0,#R^=:?*H!/2#:K.22[F,2^"
M=8H"<?"M2:@^@^W\NCM_&;M+Y'_'+YIXWX,?);LZL[ZVSVGUYE^S.@.ZLQCS
MB,Y$FWU=LAB\VZEI521:>1'C>1M)"V(!-@?NNUVO,NUR[O9-I$9+&+AD&A4]
M"6SNY;*[^DE%-6"!P\N&*>8]//TZN=A_Y6"J_4FP!'^^_'N*_"F']MT.3<@<
M.IONO6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K/!_P+QO
M^NG_ $-[=M>'^KY=:NO/_5Y]",GT_P!C[$UKQ_U?+H@ZY^UO7NO>_=>Z][]U
M[KWOW7NO>_=>Z1^:_P"!2_\ +-?]Z'L-;K_;_L_P=+[+X?R/3/[+.C'KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC^T_2CJKK^8G\ZH
M?CIMRMZWZ[RM+6=W[GHQKE0V.U\=DAJ_B%3P-.4Y7[2$'T_\">&*DB/;;3Q!
M0<?\ Z);RXH=3?".'S/^;U_9T1?X'_#Q9UI?DEWE35F1SV4KDSFP-LYU?OPP
MR!-]R95I#=:P&QI+_4_Y0?2.1O;QQVL8./D/\O1!/=?4=[_F?\@ZN(:UE\GT
MY_WW^]_3VS)UOKA[;Z3]>]^Z]U[W[KW7O?NO=2/?NO=1_?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=2/?
MNO=%D[_^+'4/R0IG;?6'&)WE1X]/X%V/ME?X?7P#_IH0_P#%RB'T\,]F'X;\
M>UD+H@[AGR(X_P"SUXL_X>'\)X?EZ=5&YG8_RX_ER;I_OYU]N(YOKJLJVBR.
M<QU&<EMG)7%C3[CQ)_X 58#<2&S*3=)[B_M#>6<=]_:9'KY'[?3I4MRR"AP1
MY'B/L_U?:.KR/AS\X>OOEUAUQU%3ILOM#;E(:_<_759D&R"24O :OQ,C$G(4
M2FQ:,F_-@+"Y UYMLEL,8/G_ +'0CM[@S_,'@>&> !]/MZ/;[1=*^O>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NIM)%_E8)8WL#]+_ )'_ !7V]9_XQU2[%!^76LY_+Q^5
MGR6[1_F/=H=7=A]P;QW;UYBJGOHX_9V7GBJ**+^[F7DBH[QM$47[1!=2!Z3]
M ?H<C^<^4=OVS88+V*.LDNKQ!0>34ZAOE_F"^W#>3;S*!& E&%:YX];*WO&K
MJ9^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ\Y_U(_P!O
M[WX ]>J?5=1C<?Y.2!I_'U^O^/X]^\00]/\ @?5]9 #4$>#_ & O;_6]O1VW
MCCIJXN:=$D^1'\P7XI_&(5=!V-VK2UV\:73&^SMMLNX,V";_ .ZJ8I'1GZ<5
M#,;<B_L3[/RE>[[_ +CKGT%2?Y<.HUYK]U-HY*37>W2QIZN=(_GQ_(=4F]R_
MSW.VMRY.JVG\7^D*/!5U0--/G]XPKV+G"PL=9PN'_1SQ;0?]<_7W(NV^V444
ME+UPP/"M4/\ D'^'K%WF?[T]UN!-ILEFZ.!D@"X1<#BL;,]/M"_LZ#KX+X?Y
M5=_?(SY-9#L^IRF*[<W!MSKNJ[$7<LAV*M[LU 10TMB;QNOT'/T _'L2[S86
MEA L0FHM*J3@YH #@>F!3_#T$?;MN8^;-VN[NY31<#0DZ*0R"@9NWN;^/)J:
MG'EU<GMSX.1R_:S;L[$ N?\ @'M7'%[_ /3Z:P _U_80EW:&/X5_(#K(*UY&
M^I_MIZ_:>AXP?Q'Z#Q5A5[>KL]4<W&<W%51 FW^ _'^O[23;L7_T2OVGH06?
M)&WVW_$< ?(5Z$FAZ>ZJQ?[-'USM2G8'Z/CS?_H8'VFCO)'_ !CHUAVRT@_T
M$]!'M;XE]';*[M[5^2&!Q>2INQN[MI;6VKO7'G*/_"EAVGH\;8G'Z?)2B]*N
ML,[6%P.#;V&[+8X+&YGOH&)8EC6@ !>FKAZT^74M[Q[EWN\;!!L$X_Q2*@BB
MSG3@5_;T95,/B//YZ?;6/'_D+_K^/][]GSRMH\/6/]7Y]1S"T/C^/].?V]%>
MZ,^'O07QSH.SJ/8FWJJM@[6[:S?;FY5WC3C=@7([K%G%%I(\6,'-V)NPM=C^
M"/:=LAV"-H[-G%8PV6&$7@, </\ 57J1O<GW%O?=$P?OGPI?IV+140_$>/'H
M4<GT7TGFO^+GUW@_TV(H,<<3_P!:;CV?)>SI\#C_  =0W-R_MT_]O ?SH>@M
MS_PQZ?R@OB%W7M@\!A0UO\2%A_U&'@?[$^U\6]SIPJ/Y]%5[[?;9<\=)_P /
M\NB0?+'X>;@V)\?>]-R8#>E#D*3"=8[TK9Z2LQYQM6*<4_I;3&"..#];<?[#
MV?;#>H]S; 1U#J212AIQZC/W$]NKFWVV\DM;DH\*L$89"MI-#^1ZIPZ9^57\
MR7X>]8[&SVU\-GMP_'O(;8P==MBEW1M$[VV]]A]EII0:G'AJC'7L2=)4V'JX
M'L0;ARO8[W,&>=A*<BHJF<X]/V]0?L'N%SA[6VRK%;QS;<B*JLK$2J  HKQK
M\R%( XG'5K?Q\_GN]6;J2GPO?W7%=U)DIP%K-T[5#;RPAN2"3$7-;3<'_55!
M'^IYM[CS=/;@VLNN-]8/FO</\_\ AZR0Y.^]#9[K_B]];/:.*G1+VU_,'2?S
MH?EU==UCVYU=W/M6#=_4O8>V^Q-K5@77E]I5%'5R+<?4B105/^]_C_"/=PV2
M7;WTE OE\^LB]DYGL=ZMQ<07'C@@%2""K ^8(K4?9^70D^2L)_R<<\AA_K6]
ME$S?3]'GCCSZR?I_K>_^ ^@_V/\ 7WO^VZ=_W$^WK+[IU;KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7N@%^3\T$'QG^1E3,+FFZ2[,3ZW/KQL]K_ .Q8>S[E>3PMRM_M;^0Z
M+-U-;:6GFZ]4H?RP_P"9)\(>C_@C\>^K.U?D[L?9&^MH;9W51YS;^0EK*BKI
M9LOEJ^L0HT<31D,KWL'^IY_-Y+Y\Y6NM_P!QFG@B4 +P-:UK\OE3J-N5>88K
M*PMFN+@-J5!JJH#445^(_;QZAY3M_9/S]_FB_$W?GQ-:IWIM'XQXS<&:[@[]
MH]MU.%P\]#E/(T&'@KYPC5$?C!C0OI9FJ#]!:QC;VK;#RZT-T 7N';0M,=W!
M:X/^KCQZ5+=0;YN[2VI_L12G') ],'R)IPH*^71@_BO+1O\ S0_YLD.M+P;0
MZQ-3!#5Z9/WZ%5Y)(TV)^OXX'LKW*;38[;%^GV@#]B'I59PUGO3G)Z4O\B2:
MGJ?@UCYJ.6%XG[O[A!^W0Y%@?OA]0.1<$6X_%_S[*^>KB2ZO%EDX:E_P]+^4
M:"U/^E_Y^;I+?R9Y::?&?/V6&>.H6F^<>]!DUQ?U+4S*01Q^G4#;WOW!N?%B
MM?"\U?\ P+UODT4,O^FQ]M>@S^)FQ(.U_D;_ #RNK4R-#35^]-WMLL5+R66D
M.Y-OUU-_2\(# C@?3CV>;W>1PP6,S'M( _WK'1/M,<\DMW%/P!!_(*G1!/BW
M@?Y2?7O6QZD_F-=%[<ZE^5O5<V2VQOJIW]#NW&?Q]<<Y^SR>+..JOMJIZN@<
M+^VBJP574G5R<;Y>[K>$3;=.JV_ Z@*K\Q3!_P _Y=%NUVMA!$#=6ZF5 . 3
MTH<L*_X?0]6,_P NO']#[BV7\Q>V/CA\.*7XX=22;5SNRNM^TZ[,9NLR.]\7
MCJ:IEK)CC,O-+%24\$\(+E/TLP0DV) ?YBCDL+BR#W7U+9$B<, '-.(ST>[8
M8KF&:2.#P3J!II  X>E.-2!7[?/)&OAW\':#L[^67U]\H/CC%3[<^:.QNR=W
M=H;)W]0UQC.9K]BY*:D_NP\NK2<9DJ-DA2&P9JD%3=6]BGF'F^%MR>&X$HMB
MIB$6OB<X^8(Q3''Y9#NS<NF';OJH=/C*HJ:>9'$T^?\ +HU'S.^7NR?F'_)M
M[?[?P-11XC.1UO7VU>S]G5,Y@JMN;BV]GJ,UN+R"DZO$R>NF)! NPU%PRJ&M
M@VI=AWQ=6(BH$8\U8,*C7T>;KNIW3:/%'HQK3B-)\O4'J=_,%_F&T?2?7W1_
MQ/ZPWQM_K#MWM?K'K:IWOW1N>H2&CV/MW(T(C;(($4NV3J%8M3,-3(O*CR$%
M7^4>6CN>ZWMW.@D2(4#%\,I&3GSSUKF'?EMK*"U;S9J#U(-!6OE3 'F?SZ7_
M ,2_F-_*-^)75.V.E^I_EAUQ-%)6T-?NG=E;]_5YG<.XLXIU9+(K]E^TSSZ;
M*KD!1X"UR68MW_E[>N8&>26"/!K%65"2WJ<?MKTMV3<]OVOZ>&#[  PX'T.K
M)^?&N:=(KL7N_9'PA_F]]K=G_(NHJMB]2?(GXZ;%P>U.S\GCJN+$?=;7@QXG
MAEJ*?6\"K)1NK*H;2; BWLRLMLDY@Y=-K;G3+ X 8N::D\B1T6W4HV+=5O93
MF8TICR+GSQ7NQ7C3SX=(7=/REV!\J?YJ_P  =[]5C-9KJ#:U'W'L[;?:%?C:
MG;U!N/-1XZLGRLF$%6/+/0X\2T7[S#4O (_3<PVG8FV78KF*45E DHGD25.!
M7C]O^;IO=-UAW/=H1$14T)%1@54#AZTKC'IT9KH"KHIOYUOSPIX:V(31?%WJ
M49!6R.J2(JF##%G'!()L?Z ^P]S'_P J];#]/^U'\NCK:8?]VDO^D'E\Y*?9
MUAS55"W\^78E/>G^YF^#^XR:;ZSW^Z8Z?QZB/:=9Z[)*O]!OMX])Q;TWGQ\?
M'_*HQUU\KJRD3^<;_+"@>375OU7W9-1TWW%[,T-1I&@?I) '^O\ 7VHY*B\?
MERZ']!Z?[STUS(P&[V7S/^ )U6CB]P_$;?'RB^4[?S?>Q=^;>[/VEVGFL3UG
MU]O'<&=Q.UJ7; 9FQ";?@Q,<L=4TJ%= &B/00P+7]C;<K%_W;81;*EN(S&1(
MI,/BAJ=NEEH%]3Z]%MN8[W<[CZT2\!DFD)]3W&A^9R1P].A,^ >Y_C7DOYL^
MWX/C/U/5]+])9OXS[VV_U?3Y7$5>W#N=MO5GEK]PTD>189+U&.2+S @@4_(#
M:@$G,ZS3;%JN)];1RG2:4"T:I(KGY5.>F]@DLX[\V\5N$;!-  /2E!]H_;Z=
M++XE_-KJ#XK_ #%_F0X_O*OJ]D]8[_\ E+EY<?VQ/BZO*XC%9W$Q2LV%S#T5
MWHZBLHW>2F*W*LM_T@L$W.FQ+N]A916^'T\?+5I I7'Y</Y=/\N\P1VUU,93
ME5&*@&A5?6H'Y^O0X]*;]QOS^_F?[(^2/3=-EJKXS_$#J;<^RJ3LZNH*C&TV
MZL[O-)0L6%2JLTL5.E0-+$A@BW;3J%B:]A_JIL<EA/,3/<JRZ2?B=Z\/L'\_
MEGI?&1S#NWUE #"<4P .T^6/P^6,X\^KY5O9!_4M[A2.SG_MINI,N2. _P!7
M#J5[WTWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9X/^!>-
M_P!=/^AO;MKP_P!7RZU=>?\ J\^A&3Z?['V)K7C_ *OET0=<_:WKW7O?NO=>
M]^Z]U[W[KW7O?NO=(_-?\"E_Y9K_ +T/8>W3^V_9_EZ76GP_E_E'3/[*.C+K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NH_OW7NI'OW7NO>_=>Z][]U[KWOW7NO>_=>ZC^_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ&$5 !!/X'(_WW/N
MU=.#U[JH3YE_S0MI]-PY/KOX_P!;2;\[/NF.K]UA5R.!VU41BQ6)64_Q&ON3
M>,BQL/.6Y7V(MOL!*,Y/KY#HIN;@IE,+Z>9Z))\0/ACNWM/=3?)#Y/+G,KC\
MO5ONS#XG=1+9'=&0D.J+)Y8M=OX<6-XHCS4_0?L$M[%"V:V>3^0\S]O[?SZ(
MI5EE&IJ5X$C@!PQ\_P#!U=6Y\X\QXMQQS;VV[]7G@T]>]^Z3]>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4:>"BKX*O&Y*DH<I09
M2@%#6T-<VFEJJ4?0S0_BWO?5ZTR/7\P>J&/EO\?=Q?#WL_:7R&^/59D=O;0.
M=+8.4'G YZ$W./#'_@9@\A#8J;687I6^G-Y5\<"05 K^P].I.&D,:4K3/S'^
M0];$/QG[\V_\E>DMK=MX,+1R9RD.*S^#3].-R6)]61IU'UTO'8C_ (K](_O(
MA!<!O]5>A1#4Q%/3/VCR_9T/_M'THZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NI=+_ ,"\;_KC
M_H8>WMO_ +<=4N_AZU)OY5__ &]?[D_X+\G?_=VWO+;W!_Y52T^Q_P#CW4"\
MJ_\ )?;_ )M];9WO$/J?>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZP*"W^3'\D<C_ 'KWZ/\ 6Z8N?\3ZK5^5?\T?XU_%8UF J\DO9/:9
M BCZVV@ZUM53% H/\7K0#38@J2P*JFH$"_!O['NQ\H7NY5\+^S^7^7T^SJ(N
M=_>C9N52IE<?4M0 'B?L %:?,X'KU0OOWYH?S$_YAV7GV/TQA<MM+9565HJO
M$]4'^ 4L%.E[C+;EE5KD^J\%.2/J? I]RS8<N[3L*:[ZH_HL*?M-1_D'H.L0
M=^]U>;?<VX^EVE4"U[IH9 >!R*E&%:BE KD>=#T87HC^2QA\2BY;Y$]E'.9"
ML'W=7LKKQEQL''%ZO*7^_K1;ZCU?BQ]L[CS;*,VL8'R7_/\ YAT;[!["QQ"F
MZWCSD\6:B T%,Z>XXQWLPQPZM]ZO^/G272&.I*+JSK3:>T(2"/OX*-I*FJ_%
MEJB?NQ_C8?[Q[#$VYK./U' F_F?\/4[;7RW9[(-(MZ*. 4  ?LH.JW8^Q.\/
MBW\YOEGV[M_XP]U=V[9[@PW75'AL[MK[*@I5&UZ92I29E9;$*"0#;B_]/9K=
M[='>6L =HU"<" 17@>(!^SJ+=JW*^Y'W_=-PM[:]N?JA&:!HM*E 4HJNZ$5K
MJ/&I)\\$>E_F1]^*/ G\M+Y(U%OZ5V+4DC^ME/LNBY8M5X7:1?F?^@>AE#[L
M;@<_NJ__ &V__;3UG'\S#OR,$?\ #:7R3M^;Y#%CZ?\ ('M3#RY:+_RT4_WJ
M3_H'IP^ZUT?^63?_ /9M_P!M/7/_ (<T^17_ 'K;^1/_ )V8W_BGOW]6(/\
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MENS4>"H:/%TQU'Z^*(EKV_Q_Q]E,MS<[OBXG 'H!0?L'2BSA@V[,-37U)/\
M,]-E!L[:6*R^=W1CML;;I<QN953/[DHL;1"HRX8>L5<AXJPW&KBU_P $>[?7
M"9/!Q7S^?3/[L)F&309 -<?Y1UGVSMG:6U<<<-L[;&V=H8W3]^,5MVBI,;2F
MJ7CDQ6)/^%N/Z^_7<URTU!CY #I5])##\1K]I-:?GUUM[9^RMLKF:7:6U]M[
M=_BV57*;G_NY14F/^ZKT*VEKA%S*M_P0 "3Z;D^WWW9IJS3#_ /\_345G#8
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MY\*)FB^T X_/JMWMUG-PA;_>B,_Y^H*=%]$F3R1=(]2"H@%RW^C+%+_3D P
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M)%U4VY-[C_:=NCM?U9>%>)X?:>@[=W =O#CXTS_D ZMNZ$Z"V!\=MF/M'8L
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M_ ,#5P/$/K"!MMG,9NH3;S\/-OQ#->WA7/EQ]/08S<Y^R<=KN WO8Z+,H/\
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M_P!7_%=>Z][]].?]7_%=>ZR>)_Z?[W[UX'7NL?O?TY_U?\5U[KWOWTY_U?\
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M3?V==9JL;\&JTD_T]Q1S9RQ-L$WU"9C:A^T>1_R?;UE-[(^Z:>Y&W>',--]
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M[7J?]%;_ 'I?^@>N_P#H'JV__P!Y8S?^B<7_ .N/N_\ KY_\+7]H_P _5/\
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ML3I)]7]./P+$\][/N6)+H >@%,_ZO+HXMK6*RR;>I]2:U'2]]I^E_7O;,O\
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MW[KW7O?NO=-<OZS_ +[\^_3])^LGM/THZ][]U[KWOW7NO>_=>Z][]U[JA/\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_4CW[I1U[W[KW7K?N\?T_/\
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M8K8W_NMR?O(/V!_Y*?\ M/\ /U$?NK_N"_\ S3/_ !Y>C0_RG_\ MW)\7/\
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M #_[>_\ MV_XI[9_KHG^^$_EU7_6TF_Y3KC_ %?EUD'1N[1].^>S_P#DAO\
MBOMZ'G>(X\%/V]:;VXO3_P 3;C_5^76'_0%NW_G_ )OG_DE_^*^V_P"N\/\
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M/_%?;G]3S_OY?V]6_P!<6\_Y0I.L8[MWR?\ F@^]^?Z91S_Q'M+_ %*BN/\
M1HNM_P"N->#_ (@R?ZOSZR_Z;][?CI7? _U\HW_$>VYN3Z_Z,O6A[BWG_*#)
M^S_9ZX1]Z;VE'_,E=[$'_JY-_P 5/M._)1C_ -''34/N5=W/_$&3K'_IOWK
M/^9)[UM_4Y%Q:W^/M;#R<?\ ?PZ9/N)=G_B"_4AN[-YS#_F0>]5O^!E1^/\
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MP!5L\"/G2G1F?V?\S_O'^'_%/:;O^/H1_P"+_P"X_P#GX]2/N--AKM_3T_\
M&O;4UQY]- 5Z /Y$_(CK3XS=49_MKM'(:-OX2D\5)1-I$M?/I)I*'%QD_N5U
M4 =368_X6N0_8VTUY-IR?0>9/RZ*^:>9[#EBP:ZOV"JHJS&N /L_D/,T R:%
M3]?=F8GL?I[;W=6-Q67Q]%N;8M+V-0X:/U9#764QJ32J3]:OF][?3_'W6>!U
ME"@8(TT''A6G\NE.W;A!NUI^\@?/QJ^5/LIU7*W\T/<55%22-_+K^=U7IU E
MMDT(!O\ TO6CV>1;#'<?VUS'%]@;_-U'?^NM=[U\.Q;E^?@C_#.#T+GQ4^?F
MV/EEV!V3UQB>F.Y>M,]U=B<35[JE[ IZ>C\%1*RJ<;**:6I85WJ-D^M@6TVM
M<KWC8X]LDC;7&=8KGY8_U?GZ86\B^XL'/4]W +:\B-JP4AE !)75@@L#CCFN
M5/!@2+_RR^4NQ?B/U;0=K[XQ6:S<&0RU#L_ ;6VW]I!DLIE:T>N2C>2Y"_T.
MDFY^G(O;;;.;<"D25)7@!DDT/^;H3\U\P;?R7!!?W3!0]*L> J=('GQ) QQ/
M0C= =X;4^0G4FU.XMH+6+M_>6WI<C2/4D-4TS*1>EJS_ &I*3DJQY/UM[8N(
MWM9JN*<1]A]/RZ4<M[S;\UV(OK4AE8!@16C*<@YIQ%.DCNC'T_3F_P#;?8NW
M U-M/>E8^#W1A@+4PN+&5;WY-S^/^-WO;>#<8W=LNG%S]O\ L=$,\+<DWD&X
M0FD,_"'_ %>G'HVT4HF#"W]/3_K7]Q)-'X761?C_ %767VWU3KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[K)%_P)7_8_P#$^U-KP_9TFN^A<]C?H@Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7N@^W+_ ,"V_P!9?]Z'L-7W1I9_#_J]3TPV/]#_
M +;V@\(=+.O6/]#_ +;W[PAU[J-[I].?]7_%=>ZDV/\ 0_[;W?PAU[J-[I].
M?]7_ !77NI-C_0_[;W?PAU[KUC_0_P"V]^\(=>Z]8_T/^V]^\(=>Z]8_T/\
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MOI5].O>)+Z_S'7?^S!]S?\\_CO\ T'*KWOZ9?3K6N3U_F.O?Z<^]/^>?H/\
MT"ZKW7Z5?3^77O%?U_XT.O?Z<^]/^>?H/_0+JO?OI5]/Y=>\5_7_ (T.NO\
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M_-U[0?7^;=<_XS\J_P#E5WE_YZX/>O#'^H#_ #=;TGU'\^NOXQ\JO^53>/\
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M ,5]UK >O5?T_D?\W7?^ACOO_G?_ /KZU7_%?=?&@]>M4?T_EU[_ $(]^?\
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MOV7IX45/LT+3JRMZPTW[]2!24IXY ]DJ*'ZE6>V^GP.N-+D:&:HM3UN-K/\
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M)_(;L/,"MZQZOJM[T_V^1J_M2#4AD.LB_P#@2;7_ *B?>]I:1$10@(C![F'
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MS_GAL'_R6WOWCR^G^K]O7M#_ ,7\^O?Z'>K/^>&P?_);>_>/+Z?ZOV]>T/\
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MJ#GB#7[.DGT3\!]G?'7L4=D;>[J^2^^\Q%@*["IANQ.S:K<>))R/]EJ=1<I
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MJ8C_ (BQ_']/86V^V>"XD1S\*M3Y]33SE/!?PV\T/^CRQC[#T:U(?MZ=@?\
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M!UMM2A3T_FMRLW^]ZA[./=:2EI;1_+_#_P 5U"7W1K<OO.^7?DSJ!]J*Y/\
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M[;PW*W[_ /AO6*1V:ZN<&U/^\G_)U@_TA;"_YZS:G_G_ */_ (I[:_KU8?\
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ;_ *);_B/:>?\
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M1W3W;V[U/M?O;,U66S=08TBQNZ<WMZNRM13*I#H];422B6[<@V!T;X#ABO\
MJ\NBXVVK(S0#Y5]:UZ(M_(^VSOC*8C^<_P#%+X_=T[OK/C_LOY%;KZL^'/;M
M=F<GDL1M2MST.4AE&UJ?&2T5'BZ+%59HIE_@Z46ADBJ  0@&[T:1XX\AQ^TF
MGYTZ8B856-N))J/L J,^AX=&(Z9_EA?RQO@!\)#@?YGD_P ,>U^W\M!V;NSN
M;Y7?('8.U,[NS(Y#<M4DDM7M[+;MV_7;LR_V,:GPJ\555?=226_45%[+<%N@
M0OG4_,"OE_Q77IK9X7U.#B@SP)I7.:?SX=*S_A,['W(G\M&E':TW957LVK[Y
M[.E^.&5[7J,A/E*SKJM2F7#F&*OD<4F%9H:LT,$"14:2&I9$"R!F+M\3Q%'^
MK]G2S;I!))@^1K^W'\OY4ZO]W+E(-OX'+YJJL8-OX3(YNO\ Z_[BZ,\_Z_J!
MO]1;CV"M_O?W-8/<?P#[/\'0FM;?ZNYMX!YR@?ZOV]4]=$B2JVWNCL#-59^_
MW=FZ_+U5?D'-1)]LGU#2L6E<7/T9R/\ #WQMN=R_>=Q=7$_"YDTBN:Y)S6M<
MD\>LWN:+<6@M[)<>'Z8'I@#'2ZRW9G6FW?L8<_V-LO&#.O\ ?[?-?NF BKIB
M/^4;BRB_^P_P]^AV2Z:I16.D=U >W/G3H*S+)-2M>/F?\_0@4]1#50&>D8FG
MJE^[HOLC8?Z_' Y'XY]H+FRN#Q<_M/V^O3HEH*> ,?(5_P '1'?F?WSDMA[3
MR6S.NY*ENQ,K@H=RY'(X#(3P38/!X1M2YAZFD:"6-JRX@B*R#T>EN" 9#Y,V
M$7;K)-_9AM(J!WN:=HJ",5J:\!TKM[3ZH$+2O'[.->A^P&\Z?;70VW^RMTU\
MN4IL'U'B]X[GFJ)VJ9*NI^Q\C^1Y2[2R5A;EW+,U@6)]A>*V\6\:U49:32@I
MP[Z#Y>G3#VVJY\*/'S&/PU/#\^B4[:ZX^6'<VUJ;N7$]RY+KZ3=M%+G-J=8T
M.X<W#1_;_P#*)]_)#E(Z>%;?I CX'TTCZ2%)=;=L3&WT!M+:7D[ QH:'1V$@
M?;7HPM98;,>'+ LOI(45O*N217H8<#O@]\_&R;<^0Q5'CMY;,R4VWMSX68>=
MJ3);5J=-4VN0O+KK*4C4U]36TL2![COG3:/HF9$;4K+]0KC&M)!4&E/*O[1T
M=\LR?NW<H*U'R]",4Q]G\^G_ &!\,.W>P-IX+>6W)>OZK";FI?OL-_$L_P#8
MU!@4"]E> @#_  ''N1^6/N]<V\Y6D%_9.V:C_<L>OGFO\^CCFGW]Y6Y:OC92
M0*#&16ENOH/0=*?_ (;Y[T_Y6.L__0A/_7CV?_\  P\V_P#*2W_99_L]$W_!
M)\J_[X_[-#_FZ[_X;Y[S_P".?7W_ *$"_P#7CVS_ ,"]SG_RDM_V6G_H+KW_
M  2?*?\ OC_LT_V.LP_E[]\G][Q=>""_U.ZHS_UPM[I-]V/G"W'C:SHK_P I
M@K_AZO\ \$3RS6G@-_V2-_FZ+?#U)EY]\5&Q<?783-Y7'L*3+9?;=8M;CJ>W
M^=O5  6%N?\ >?>/.\VFX;->_0&Z8Y.D&:0U_($"@ZE$<U;9/M0OA;@5'!H5
MC/\ QH$UZ/+MK;.V.M\!0XN2KQ^+$M10XNKRF3JZ/!FIF '+D@%W_P";3$O_
M +5[716?BC3!]NH#(K]E,=0EO>[3<R3_ %&3_P )JQ%/L)(_EGKA+V/UXNX?
M[F0]B[5_O1S'_=8;IIUJM7]/%<#5_A_R+V93[1=,/%T/IK\5#IKQX]$?T\D$
M=/\ +T\;GW#A-I8/+;DW%F*; [>P%+'D\]GZ_4T$%/(;*H*V9KFPL+_TM[];
MVC;C=BU4:F8T"@5)/6[1M K7]O1$=H?(O<7;'RDZJQVVZ/>&V.IZC;.X:C$T
MV::JQHW2N/I9+Y*II4F%)40$C]3Q.PL1JOP!Q<\O)MUC(\FEIA(@;30B+B"I
M-/BQY&G'I<NW&2U^J%=)!()''[/LZ&+Y,]I;LVK3;#ZOZUQE-4=I=O9I<+MV
MOKZJ;&IBX VFJKFDIWCJ86<MSHE!(N6O]/:#E3:X+R%WNL1QC4V%);( 4:@1
MD^O >76["*-HQ*]"<C(J*XR?R_.O0)Y3"?(?XN45-W#N?MFI[TVC@JNA7?\
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4B+_@10_\ !?\
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MX8OX6 :XU98A0@&HGT^W[F..\X$_L _P$]5CGDM14?+^+_**?Y>B"_(KYO\
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M&F%136^OUJR?]A[$?*5_^[-P0^9!(^WB/\'01]R-B7F?8[BW?X356^Q@5/\
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M+BWL\A*]C[6IX .?]P=:?Z?@+_O?OW_ 4S.U%O#^9_V.K?\ !=1V\-9MO/\
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MY[WQ_7<?6W4_R8QL'W4W6>1?8&\:^@!_XLF<JWDHI#Q8+25VH&QN3,M_<O\
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MC/FND^K,A4?]-.R8(?\ W'8'VX6+<57K:A%X,W[?\_2=3XI_%J+Z] ]9G_R
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M;*<.KS=</=^M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4].2W]0#J_WW^P]O(/
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MNXY&W#ZB#X?,>M1_+JLBDR.[.D]W4O4/;8!I@;;1WS^JFJ*5O\R1_@>+&_\
MD_\ L/?*OG/DRZ]OKDV&X\.(.<?ZJ]9FV=Y8\_6(W#:O^;UMT+&X]S8K:>*J
M<QGJHXR@>ALM8OJ-[_2"W]3[!UW;"RH;@:B3@#CT1;;:S;S-X,'\^DQTQTWG
M?DON.EW[V1BZ[!]48VMT[9VFJ@??D?[ME_Z8_P"I_P!<#WDI[!^PT_.]Q^\=
MQ-;<\1_D'^4]%GN+S]!R-;_0V.;[_?W^^NK5::A@HJ>CHZ.DQ])1TF/_ (?0
M8_'D?D_\;]](=IVC]UPZ(?AAZP_9_JB;@DF0FIKUD_Q]F /T\WC0])N(H>I$
M0^GI/^M?Z^V73/C=.005Z[]VZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_4CW[I1U[
MW[KW7O?NO=1_?ND_4CW[I1U[W[KW7O?NO=>]^Z]U']^Z3]9Y#I%@/4%'^]_[
M;\^WX?TET=/4^J@\#_5_JSUKC_SN_B=50Q8CYI=<PU,-=C),'M?MO(X8DBBA
MH*D?P3=!Y/\ P!G!HYP=(U#3:[CW,_MMS!0BPO!\E'\@O^ ?LZPN^\K[?O+$
M=^VPTD329VX=BL&,N1W%,L!BJEQY]'*^"7RFC^3/1&-W!DJNB_TH[&7'[6[,
MPSZ;')RGTU]P #'E#:8D@7(O]/9CN^U_N63QS^LIP?\ (?S_ ,/1E[?\Z+S?
MMZN*+.OQ &NEJ"H]<5QZ@@^?1U"@_''^\^PY"O4@F'TZQ>]MQ'2<\#_J]>O>
M[]>ZD0?V_P#D'_B??NFY.J6OYL'5]1M_,=+_ "ZV[3(8MFUXV#VG'0M8+A-R
M5-J6:UCJ\4S$<G\#F]O8ZY/O ^M).!&EL?.H_P O6/7W@>47<66Y6@JT4@)R
M1^FXTOZ@D88 ^0)XXZ*HCPU,/EB_S%2/NZ,_],X_XGV<_P!A+UC\.\=<O&_]
M5_VQ]J?$Z8\-?7J+[<ZWU(]I^E'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=1_:CI/U(COY_]B>?;?A?45Z\:+T//\LGKF3MSN/?GRMR5,5V]L& =
M6]0BN)%SRN7JC;_4JKL1SP1_B/8?YFO-,ACCX-2GVD#_   _M/4W^PFQ?O"+
M]YW0S"71/7PT:A/R+.OSP%X5(ZO85M98$$@V^GL I^GUE%<?XT>HWNW6NO>_
M=>Z][]U[KWOW7NO>_=>Z][3]*.N:?7_8>W7X=,0]27^I_P""C_>_>G_R_P"3
MJS\>M>W^;9\E*C?6Z:#X<]4-6YNJ?+TM9V!0X@#(U%7F\@UL)MJX'.@#RS6)
M!.HVU >Y'Y6V_P"A7ZB[R%(J.-6\@/L_P]8U>^?,3<QN>7ML)\65.(_"GSKP
MU4.?)03Z=7?? #XHXCX@?'C:O6J_:5&^-P1)N;MS*TQN9,YF"5A3C@0TA_8?
MFVIOZ6]P=S+OS[U?2--Q)JO^;\NLP?:?D6VY!V:ULX_AC4++Y5QEC\V-2>CR
M7_\ .C^G^^_WW^Q]A(_XO/X/4I<17K)[:Z?Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NH_OW2?J1[]THZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[J/[]TGZD>_=*.O>_=>Z][]U[KWOW7NLGD_P_P!Y
M][(^IZ]U2O\ SX2/]DNVG(/HGR2V5);_  .-R-O<X^PI_P!W7_-BO^'J)O=?
M_<)_]/\ \_)T9#^5-+X/Y<GQ:_\ #;WI_O&XLS[#?NO;?6\Q7?\ S3_Y^;H2
M^W9T[9;_ &)_U;7JQ3W&2<?]7IT,H>/7O>NK=1_?ND_4CW[I1U[W[KW7O?NO
M=>]^Z]U']^Z3]2/?NE'7O?NO=>]^Z]U[W[KW4?W[I/U)C_X$4'_!/^*>U5I_
MJ_9UZ[_R'_">AG]C;H/]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0=;B_P"+G_L4
M_P!Z7V%]P_U?SZ.MMX?MZ3GLOZ7=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U']I^D_4CW[I1U[W[KW7O?NO=>]^Z]U[W[KW4?W[I/U(]^
MZ4=>]^Z]U[W[KW6.+]FW@XM_O'O=>D_56'S#_EG]?=_5N3WYU75T76O:V0!K
MLQCLA1:,#GJES>V0IA<XO)$7O4PWC8\\$D^Q%MVYB+A@_P NB^ZVYFP^5\CY
M@?Y1_/JK_;/?OR_^".?INN.YMIYG-[6H_)1X[:>_JMJ^F%,39CM?<0)T G^U
M&Q7\_7V*+._CNL,*CT/^0]!Q[%HAJ0T/J.-?F.K<.A/E%U-\C\>)=BY@TFY:
M=2<OUOF#_#LK!I_U+ G[RD_K/  P_('LR,*-\/'^'S_V>F=+6_Q</)AP_P!7
MV]&+]HNM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)7=>Y]M[)
MVKN/>V[\A)@-L;6@KMP9>JJQ=H(*$V50!^6:P_V/O;$**GJZH9"%'$]44;8V
M[V-_,\^4ZK4U55M?K+;E-JKI"=:[;VPM5S%%]0V;S1:P']N0_P!(>$M]N!LX
MO#X #]@_V>EMI"MRWJQ_:QZV:]B[#VKU?M7;6P=CXVCVKLS:E*]/B,-2G6\M
M-(>2Q/Y:X^Z_PM[ ,]U^\A0="B*T,+:FR?/Y'_5PZ5WM-THZ][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL_\ P(L + ?4_P"]\_T]J(X^FKBX
MZR_8U/\ SK\A_P D_P#&O:K]VWGH>F?K+;KO^&U7_.OR/^\^TU9O^4@]6U)\
MOV]<?L*CD&@R)(_H/Z_['W243]>U+ZCK#,DU.?//1Y!;?0,PN/\ >O;[P)%_
M;5_GTY;R3W7 CKC$0/K>_P#7Z?[WS]?:'7XO]CTI-O\ 2\>N'O?3?7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UT:*H),H:O\! *C'D_3^OM]98;>Z_Q6 S#K4!)M
MZ7! /H3T'7:G3.V.X<$,%O+ G)0B]=25X Q=3351',E'-?D<C\C_ !'L$<_>
MU>U\_KX%[ :^H_U?MZ/N5.=KGD>?Q[=OM'$$?/\ U?;T6C;_ /+[ZPQ.6IZ_
M+93?N\J/&U8K:/;.3J@M/8<BY%B1<_U'N >7?ND[;:7_ -33Q\4)G4*2/M_(
M<:]2UN?WBMUN;?P%\& ^L))]?+\_7H\%-B#18^CI*7$_:4U+0-08^@H& _XM
M)_/^Q_V)_P ?>6-OMTFQP_HBG6/\[V]X3J-:FO[>N_%_E7^4%KW/X(_5[I](
MEO\ VW^3JP,!X5ZA^_=:ZD>_=*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNH_OW2?J1[]THZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZC^_=)^I'OW2CKWOW7NO>_=>Z][]U[KWOW7NH_OW2?J1[]THZ][N_P#C
M'59\GI-;PVEMC?NVL]L_>.-I=P[7W;B*W$Y?$5+Z::>GR!$<L2L!Z=-OK]>>
M"#8AW;KY[&X+**@ BGRZ+-XVV&_@$4N"Y'6G]GL9V7_*)^;IBF-;NCI?,1JM
M&%C:(;DV95*2K"W(S.W=7]"5;@ ^7G)_;MT7F&Q\')>OKARQ_P /^ CC3KFU
MOVRW'L9S9]0NE;!TTNH4UB@B4D4R2=)/H:HU "PKULR;!WIM3L+9N#WKLO(T
MF>VON>G;*XK+T@YJ*?(<,I!M:Q_XCW'MU8-$VEN!SUE1L][!N$'CP?ZO3ATL
M;ZYC_K?XCA?^1^TD(\./IYO\6N/RZ@>WNG.IT'ZS_P %/^]CW[KW2$['Z\VG
MVWLG?/6^]:=LOMG>&(K\'G:-;*4@KR&5N/Z$@'C_ &_T]J+.=]O9"OGT5[IM
MMOOD%S!<4(H00<A@10@_;_EZUD-N8'=W2N]NP?C-V>VO=O6S.VU<W6"W\;PA
MO]A44O\ 6WX-A<$&WU]RE%<1[@L4R  CRS_E\CQ'6!V[[%=\GSWMC=L6% T<
MC 59#P!H<LA!5L"N#3/0IA1)<PCZ\7-_]Y_-_P#6]WX])?IOK>'7?MKI_KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_M1TGZD>T_2CH,-TX_>/;V
M]L!\:>I+#?W9S(F;JZ-2T&%PK_\  K)56FQY4&_/ N?J/>RS;>!,XJ3Y?ZJ_
M:?\ 9Z?L-BN>=)FL+1M':"[<=*'CYJ:M\*Y'F:XZV5.E.IMH=&]4]=]7;+IV
MH]L[0P[XJ N>:HM_GZN8\_N5GT^I^GN-=VNVOI7+<!_A-<]9W<N[7;['8VUM
M;<!15^0 H.)/"GY^?0A^T'1GU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<]!_P /
M=-8ZWX/7#W?K71'?GC\O=O\ Q*ZA;+8^IHI>W]V1U^!ZGQ*C2WG8_NY6J/T^
MRH3Z4'_(1X!]G?+VTR7TP*G#8;SIZD_(>7SZCOW,Y\M.2MK>]ES,O^XX)IK?
M\*BOKYGR%3T1C^39\+L_O+=55\Z.Y159R7^+Y^NZ>ARKZI\AE*FS93<\@YXC
M)$-,;&[Z1JN"/;ONKS0DJ?2V>0"=9/%F\SGY_P S^?0:^ZU[7WF]2'F[>36:
M=0;<#A'"15<# +"GJ0H )R5&S5)>3D&W !-[W!_VU_>/D@>:3QNL\(+>#<H*
M?/KC8?<BHM^?K;WM6\?KT$P7KOW;K?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!_>WQ^Z9^2.
MS*+9'=FRX-X[,QN4H=UX_'2Y6KQ$C5]$&"55Z,$:74L.1Q_M[G6R[_=\NO\
M46JZE.:9X]%6X;?%N?\ :FAX9 (I^?2HZFZFZ^Z0ZZVIU7U;M[^[FQ-J4.1@
MPFVY,C59%XX,M5_>%F,][6)8J"W%^#R?;-YO$V_7(NY111@ ?;7I;MVW0V%8
MHR*XK@ 8%*?ZJ>G0AB/P_CZ_[#V6Z='3YA^FZR^Z];Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLL?_ @?ZR_[V/:J
MT_U?LZ37'#_5\^AC]C;H@Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@ZW%_Q<_\
M8I_O2^PON'^K^?1UMO#]O2<]E_2[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>T_7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[I';XV/LWLW;<NS-_;<P^]=JY9R]7AMPT)R-.C
MV^JLEF5O]8_\3[=2<6@H>F)(VG-5-#U07\L?Y:^Z.E9JGO/XG93=E=@]K:<Y
M7[5I\@!N?;!H&XK,'5(0V1I(C8^!?\H2XU#ZGV+MMW(R=TOE\\CH/W>W"7L6
ME3BOD?MZ'3X5_.2B[Z.,ZQ[.JZ'%=P-2E,)FW(QV/W.?PLAM^UEC]%B_/TI[
M'@B-/U<QX;R/ '_9Z(Y?\7_37X?,>:_9\NK&$_S?_(?_ !'O3\.MQ?Y>N_;7
M5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NL$\T-!0U61R-518K$8NA%;75U;D?X;34M
M+B_H)IOZGVKA_7&3@<:\.K9/#)KP\S7JAOY3?(7=OS&[+VE\<N@Z2NS>T)<V
M,?@WI%T/N7(N;?Q.K!X@P=#^ 395O4&US9)N,_TB#3\(\_7I9:VXF4H]*^?R
M'I_G_9U?)\4_C5M3XK=08_KG!:LIFZQ8LUOW=H"M'ELCD0VE5LS'[.B#?;P&
M_)OQ<GV ;Z\&XG2.A-9PFVC+'AP ]/\ 9/'HSP%O\;F_LNM/T.EASUW[UU[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/[]TGZD>_
M=*.H_OW2?J1[]THZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I!=G8W<6=ZW[!P
M&UJS[?<NX-B9_";8K/XG_"R^2R5)4M2 37 _SW'^/T^IN#OEB9;:](N.-"!\
MCY=%V]12SPJ8>%03YX!%>M6NF_EU_P XPTE M1V)NPEC^VO^S63"_'X'\0M;
MCWDM9\Y<NVL7ZEJO[2!_U=IU#!Y?W>Z/^Y8_YQ@_\^]%B^376O\ ,,^(.*VI
MG>\.Y>R,+1;RGR&/VV-N]Y9'/DS8^!9ZKR&FJWM^VP_U_P#8>QSR[N'+G. T
MVUH28SI>E3GCT%>8+3=>7 3-=*1CB@'KGA\NAOZ_^%7\UWLS96SNPMF=H;TJ
M-L;RP6$W/@J[*_(^?&3?85U/Y:7]EIU=9M-B 0#8BPY%R;=N<.4[2:2)K0J(
MP#^FA^,BH_T3CT9[;RSO=Y!XL5V-5<UC'#@>"]'%^'_PE_F9=9?)KJ+??=&[
M-PU/5F SF1K]Y453WO/NJ 4T>/J(UO0I,QJ=50" --F/'TY]Q[S?SARO<[<K
MV:.TF:@!6/#T+]"GEKE[>8I66X*U.!12/3STCK8ZO8>?ZZN/]?\ QO[QWGD\
M7J8_ ^EZ][8ZOU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=49?S)/BO\ .ONSO#9^
M[OBSN;,X;K^@ZZPFW\A18;NBIZ\IAE%FJ9748_RQLUV!(LIO:Y-_<[>U?.&R
M[9:2"^3Q0!W#45%:D]15SYL5YNT@DA-&U$@E:U&/D>J_XOY<O\X1I8V3?>YB
M\H^@^4K&_P#MJ^Y_V'N1;'GKE.4^$+3]A/\ DDZ!\/*^\VN?JQ^<?_0O1-OC
MYC/G%\F>PMT=6=1=V]E9K>&U,!79_*T.2[PR>!A^VQU2M$3'4SY-%DM4NO%_
M\?I?V-]\EY>Y9M6NKJU.EQ4U!IZ>O0;V>"^O[@P172T!I\(/&OR^1Z.5_P -
MW?SAOWO^,D[DIW%* P/RG(_V'_%P_'L"_P!>N5:^%])_,_\ 6WH4?U6Y@I_N
M6/\ G%_T+UL$_"#KWMSJCXN]:=?]^UU7F.U\'3[N;=)J]R?W[JTGR.<EEBM6
M!F#G[13P'-C]>3;WC]SC?66Z7R/;FJ"NH@U\SY]2]R_M]Y%&3)PQ3%*T \L>
M?1N_8(Z.^I'OW2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NH_OW2?J1[]THZC^_=)^I'OW2CKWOW7NO>_=>Z][]U[J/[]TG
MZD>_=*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW2?KGX_]JM_L/=PG
MU&>GQ">B6_-7XC;+^9G2N0Z[S%2<+O+"1-G^NNP=06;%Y20@LAX.FDJSZJFG
M'"0<D-;@3\I\X/MUWX#94Y5#G)_U9_;U%7N7R-;>XVW%3595&9TP5(X$>51Y
M8H>!J#0ZZ'PP^4^^_@#VSF?BO\H(:W:VS/XV^-S%%5IH_NIDJJQ7+4Y-A/M_
M+  &UPRD3CCR7R W.U&_6K7U@" #W+DER?,4\C7A_L]8*<G<VW'L_N$?+O,,
MBMJ!:*3"QVR ? Q8K6E**U :_%0'&SC1N):>CEAJS54]50G(45?0?6J_BA(_
MV-[?U_/N.&M7_P WSKUF%%<3 G[?V4_9UE,>K\_7D'WLRF/HO'^-=0M!_P /
M=-!_U4Z5Z/L_GUU:XL+\7))X^OO<I^HZ:^'CU7Y\]_B%D/D7L[';TZUDI,)W
M_P!9S5V;ZYRL:C_<A2C]>!JU_$57_9X((.FW-_9[L>[_ $CB-AA<CYCT_P W
M4:>Y'(W]:;0K;MIN.*M_"W#S!P<AOE\P.J<NO-^IO2EJL=7XY<'O3 58P>^=
MFY _PZKQ=6;V_:_XY$W_ !_Q/N1 L<\7BQC/#_5_JQUART%S+=FS:FI::U!'
M;45'#R(X'@?+H1^8O\Z!_M_^->V/#ZWK"\1U&]N=;ZD>T_2CKWOW7NO>_=>Z
M][]U[KWM1U[KWOW7NLW!/E/^4_X?\:_XW[3^+_H472JGF>@MWIO7)8?+8K86
MR,75;N[;W>BTNS=@XF_W$_\ $K6JJO2+QTQ)( 'U]N.C1L'DK4F@ Z1VNW7&
MZW1LK,KKTU"DTQ_$W&BU\Z?(5ZNJ^#7PUH_C-MC+;MWQ646Z.]>Q7-=O[=*$
M TPX)Q6-'.K&4O\ :-[#@"_!]@C?-VD=S;KP/_&1Z#_+Z]9E>W'(UMRO;>/-
MFX-"[TH7;(_(#@HK@>9-23^%&'Y4#^OU]A:&/J07N*GIM]N=:Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NLD?Y_V'MB?@.G(^@4^0W?FP/CAU;G.T.Q,CX<-0G[*
MEHV $^0R.1&JEH*9C^EW!%S_ *WLZVK;6OI2%K\@.)/H/V=!WF3?K;8=O-U=
M,J*H!+$T %=.?M)H!YG R>M?'XY=*=P_S8?E'G^U^VYZK%=2X::B??>1HE/V
M]+C;Z:38V"=M(^[JFO\ =S-SQ<@Z6N(MZW.#ENW-E#V/$>X^@_B\\TP!]IKU
MCGR#R=N/O?O2[W=$?1E*31FIS2A@X*:!NZ1F )[8P  :;?&!P6$VOB\5MC:]
M)C\1M_;%)C,-A<'1&]+3T^-(\,<37Y+6')OQ;_#WCY<;BTTNILN_ >@'71K;
M;*%OT8:I#"<GU)Z=?9;T8=>]^Z]U(]^Z4=1_?ND_4CW[I1U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_7O?NO=2/?NE'7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?
MW[I/UU8?X_[<^W?$F_WQU;1\_P#!UZX_J/\ ;^V_!FZ]^S]G^QUE\?\ C_O'
MOWU?5>LGO72CKWOW7NO>_=>Z][]U[K!YQ_J3_M_>O&Z;\/K/[>\$>G3G7?']
M#_M_^->VH5!X]6-M3KKW[I+U']^Z]U(]^Z4=>]^Z]U[W[KW7O?NO=1_?ND_4
MCW[I1UT"%'] /=YX/HNJ _5]=^ZIQ_U>G6X>/7O>NK=>]^Z]U[W[KW7O?NO=
M=Q_\"*#_ ()_Q3VJM/\ 5^SI/=_Y#_A/0S^QMT'^O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[H,]U?\7:3_M7M_T3[">\<.CO;/+IC]D?2WKWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NHB?3_8^WX>FY.I?O?3G7O?NO=>]^Z]U
M']^Z3]2/?NE'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<_+X>:<6
M_'%V]ZA/T_3''JC+Y\?RYJZLK:GOOXO8I\5N2"J&=WWUGAU-#42U#$D9W;0B
M/->Y'-$#=6YI[J0 *]HW;7@\?3HJO+(K^HO#R/R]#7I#?%7^8U@Z^@I^N_DG
M4MA=R0)_!\)VI54'FI)P?]U9N#@TM</Q5#U#\C\^Q;I\3OCP> :G^'_/T1,A
MMC5N'$K_ )O\W5L>/GARE#29''55#E,?4\4-=19(Y2EJOZWFAY]LC.>/39&D
MY_P4(ZD>]=4ZD>_=>ZC^_=>ZXZU_K_O'M[P3U[KE[9Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW4CW[KW0<=C]H]==3T"U/8V]=I;.I_KX\_6F6
MKY_Z8A_EH^OM5X(&6-/SSUYF9/A!/V</V\.J]^S_ .:/T]MX5-%U9M7<W8M:
M>#FLZ_\ </%6^MQ&A-8?^0I/?BR+\()/SP.O$NV7('R&3_FZ*2Q^=G\Q&J_A
M6)P^0H^M/O>1&G]S=H4E^?\ *ZKB?+D?BYJ'_I[07&X);?V>%_8/]GI7!9%\
MGXOVL?\ 5^75W_P^^$_7?Q-PU5/1!-\=H;AH30;J[$K,<<:D=,+EJ#&QOZL?
M0&RC65!J>0+#CV#]SW03KCCZ]">UV]H#G \A_G^?1RT^G^Q]D</2J3KG[=EX
M]:3CU(]M].]1_?ND_4CW[I1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_4CW[I1U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U']^Z3]2/?NE'4?W[I/U(]^Z4=>]^Z]U[W[KW7O?NO=>]^Z]
MU$UC_'WKQNF_#ZE^[_4GK?T_6N7_ ,*"]QX=MH_%[:!J=693.=K;N-%IMIH(
M*6*C7F_-Y87_ !^/>4/W>6N;22[=N)J?R IU!ON\@O+6'TJH^TZ6/^7JZ7XE
M8VLP_P 3OC?A<C2+393&_'OJ_&Y1B.0DV)C=1_K$<_['W!7.,Y:_O7/$,1^Q
M0.I6V2$6UM# #^%O]7^7HQI))N6 X/\ 9M_K^PS"J?1]'I@@U?ZO\_7$_OWO
M^?K^;W_VWOT_^K^?30QUD]I^G^O>_=>Z][]U[KWOW7NO>_=>ZC^_=)^IC7@-
MK'Z _2W_ !/M3%XW6KBGGUS@2YQ_TL";G_7/'O5D\UO)T[?P!K<]:FW\F&MI
M=F?S"NZ=K[JBCHMP9K8';FWL/22FP6KVSN%,C4?ZW$#_ .Q]Y>>[SR;GRW"R
MC) '[%!ZQ\Y"4G>V,Q/Q*?R[A4?[T.ML62;^A_UOQ^/S[Q(MYIK>'K(J_ ;_
M %?+K'_E(J_]M]?I?_;^V9I/T.F1;]8/;'374CW[I1U[W[KW7O?NO=>]^Z]U
M[W[KW7O;O@CTZ]U[VUU[KWOW7NO>_=>Z][]U[KWOW7NH_OW2?J1[]THZ][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO2>KZ<7YY_%N/K_QKW>-M'5)Y_I>O);^S]/SJ_P"(O[4O
M=P^#V]>F4U_0ZK(_F)?R]]H_,_:=)F\'%1[8[SV91K!L?<M2=5)EZ9;-_=_.
M>-3IHQ;BY'AO8DG38;<C\RW/+-P0V$?&>!XY/^K'V5K WO-[/V7N=:J@%;FW
M(=6'%3@F,'S5J#4//'F 12/\,/G/OCXA;QK/BE\HL;N;%[7VMEFP\-7G+UT^
MS*P,0:< @_<8"X!A\'U^HY^LS[S9+NZ?O2V!"EJ> <E#3_!UB7[?>X.X<A7B
M\L\PD&2*,,LXPLB5(S@9 H*^9P:$9V3<1FJ#.T%-DL-4T61H,C1FLHZNCR/\
M1IJFFR7U6$&UOQ_7^GN.1#]/\=/VU!'65<ET;_$/^#ATXW-OJ+ZOKS_JOZ?Z
M_NFO_0^F_I\?4=0/?NM]3_5].+?Z_P#QKW[PQ_;=>\ \.JQ_FO\ ! ]\Y?\
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M[O=W35/N>G'_ %64<)_WA_9H-WMS_9Y_+_+TE^AE3A3\FIT];0_FP[VQM?\
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MZ[_TY]#_ //^.F?_ $:V)_Z_^W/ZJ;C_ +XF_P!Y7_H+JO[VC_W\W^\'KO\
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M '@_YNLG^G/HG_G_ #TQ_P"C5Q7_ -4>]?U3W'_E'E_WE?\ /U3][1?[]?\
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M]L+!7<KQKEZD #Y?[/4^;9MD&SP""'TI0< /D/+I<Z/J(;_Z_P!/^*>T.O\
MCZ?^G_Y1^H'NW7NO>_=>Z][]U[KWOW7NO>_=>ZD>_=>ZEZ2"0#_O9_XCW75]
M1_;=/^/Z#HI_RA^6G4GQ5V:=S[_J5R>>R./KEVMU_B&T93)CZ7=K'PTE[6G^
MI(X^A]G6W;-+N%SX:9C/!AQ/^8= GF[G3;^4K1KR\.E5XQ<?R \R?3]N.J#-
MC=9_)_\ F[=XU6X-QUL>W.GMJ5(QE3FF#?P7:]/<!:#"6-\EN"4D@*&NUQY_
M[48$N[;[;\J0Z+7^WCXG\*+Z#_57S].H VCE3>/?W<2;D*-IC^%!_:22#%21
M6E#JX&E.T@G4.MK[X_\ 0?5_QLZXQ?574N&; ;7P,@E9L@B9#(Y&HCXJJVNJ
M1Z:NIJEX   _PM8+CUN?,$G,L@:3 K^9^9ZZ%\M<HV7*=B+>Q H!04P /(9J
M?]7K7H<8B'O<_7BXY^G/^'LF23Q3T*88/I>L'O?3/7O?NO=>]^Z]U[W[KW7O
M?NO=2/?NE'4?W[I/U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=2/?NE'77%KDC_7^GOTL'^_NM@TZIN_F-]=]Z[,^0'Q4^=?1O6+
M=\T_QUPV\L'OCI["QFFR,M!N=YI!FL7#'J<3&.4G6H;QLH/(5@)@Y'W.*\MI
M=OU:/%6*K^9#"E1\\=1YS:TNWR1744'C$G'#T&,D#B.%17/4'!_SC/@KWE@=
MQ],=]'?O1<^^L)DME[JV_P!S[-GQ-*HW!3"*JITKH6TH5*@^J)>1^!]%4WMI
MNVTW'U5J8I3$*%08C^5>FH>:;-X1%,0A<@@U()IG@V#^71DJK)]#_P MSX)Y
M+<?7V1S^]>F.G]CU^:V/0Y#=L6ZJ[(R;LJU&+H*;)1",3PUM75LT>A;BGNQ6
M]_84M3><];KX;:K=BWZH'82/+/SZ/)I;/8MNI$!^PX"CT-3@"F34GHLFV=F_
MSG.UMDX_O&G^1?2G6&X=P8D[IVQ\6*CJ5\YCH:.O_>IL?F,Z_DF6K<$6\DSM
MR [@AM(INALFTP_30P.LJBOC!*^)\B.-?RZ#\\5[._BPSD@8,7F#^W_!3[#T
M*FQOYEVWJ[^7_OWYC[XV3+MW?W3E=N#9O9/4V-K6B:GWCMVHCQT.)IE)UQT&
M0J',CKK8B%6'JM[++[D*2SW6.RAE*I+ID=*YU-BG[?V=&,7,--N^KGK0@D&E
M>T5KZU(I@^?1?X,=_.CW#U"/DI0=[].;:W)-M->P</\ $K%=215U*^*%.:J+
M"29EM52<F:?E8?*TA4B[ W /GN>6K?</W8\#R/34)=&,9IJXU_U5Z0-;;J8?
M%,XI6FHUX\*X-./GC[.EYW)\X_DE@MN?RW\W%UR>A]S_ ";[=Q>PN[>N]_;3
M^ZR%)1P111S4]*M0A>D1Q(SP2A5-F'/UN3[/RM;7,M^U/&C72K*>(Q7_ (KI
MZZWVZ(A%?"H"10^>3Y&ASQ\N/1J/YE_?'97Q?^('9?<?4-5B,=O[9M1L7%XF
MHW'1Q[BI0M5EXZ60I3,&57N@^H(X)%C8^PKR1M4&[W[Z>*4I7YD#HZW[=);*
MT"L!1@3C%2 3FG'HD_RXW8M5\X/Y.^^]WU5'BHWQF_=U[FK:D?PVGIRN$I:V
MMFL;+%%^1^+6]R9R_M4,%GN$%O09D)^W17Y= [=;P_56<TWKI'KY@=#)TY\I
M/D5\S_D1D-T?'J'$=?\ P0ZUR,6!W'VWN#8[5V3[(R&-XEAVL9TC>@Q@!NM8
M'4P(=<C:B$]@W<MFV_EVVTW,H%P/]#/%33\(]/G_ *@?VFZR[K)XT0K:L*BA
M- /RX_Y?YD5NG?DEVSOG^8E\M_C%N#*8-^J.E^J>O=T]?TU%A$7)15VZ_M#,
M\]6%$LY)J'#:F(N00  ?>MRY;@N=HAGAF[YW0@^?<":GC7T_/I2F[K)<S)3,
M/'C0Y8</+X1U7[\8N]_YF7SOZ]W>_7O;'5?06WNNNPM_;3S7;5-U5%N.OW#7
M4E0KP8O'XA62GHJ;&4)B^YJT1342, Q>YL+=SV/8>3Y5;<(Y;C7$RES*7*T/
M"A+T'S]?LZ(X-WW#>XKCZ<9K@&H IBM?,_M\^%>C=?R_/DUWWV3O#Y2?&CY/
MKLS-]R_%W/T6.GW]M/')C\=N#'9ZBJJ>FJ7IT1%=E]+(3$"0;$ @W#G-FRV,
M0LKRS \*Z902O!@PJ#Z5^SHPVC>I5FN+22H$/S^PXK4^="/D>E]_+#^1'9_R
MI^+LG:?<.3VMD=X4'=6_MHQG 8"/;U+_  W;%? E.&I8E76$DE(6Z\ VN3[*
M_<#8+?EK<[>. "OA.N/1X:='.Q;@N[1&5:TH.)/'4?7[.FKXJ?)GMWMOY/\
M\POJ3>M=M>JV=\:MWX>BZNCH]O)CZJEAK*6MEF^^E55:LNL8U:]5VO:U_9AN
M^PP;=':R&E)F4#UH03GHNLMSEE22):UC&<\<*?\ 53HCGQA[I_FA?S .I)]U
M[#[=Z?Z Q.T-T[HV75=B#K*/,97=.3QE6DHAEHT5Z;'8?&Q/!3^<1H)92 ?(
MQ-A)NVQ;7RO=1+,5>BF0&FFI!IPP*?ZJ=$MGN-[O,)\$$U\B30#/S!K@X]/0
M=3OC9\C?YF_SAVSN3KS:6\NI?CQN7HS=><V3W+WY-L:+>=5G]Q8^:04M+M_
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MJ_![YV?RRVE[NZ9[8J\KM#% 5.XMW=8U%30QX^ V(3<6UZD+"U"Q*W#*T9N
M3?CV)=MYPV+W(<VUY!X3\6H*?[R//HJW+8]UY/MC+;W-2. <5'Y4(_D0>KWO
MY<GSRPWS9ZLK(,[BL;MWNC8L=#2=A83 ((J22/-OII<KCUN=-'4-PX_W14$.
M.&/O'WW.Y!')U],(@%C'QJ.$GV?+J2>1^:_ZPVZLI)9OAKY&G#Y_+U'5B_N+
M>I"ZD>_=)^O>_=>Z][]U[KWOW7NO>_=>ZD>_=>ZC^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NH_OW2CK,#JOQQ[<BE\#IHBG4AEJ'0H1K5K7%[W_U_=9;CZQ_#?'IU<QB
MWG\>'SX]%T^27Q=Z>^5O70Z[[BVLU?0TL+5F)SM*@Q^4QD[V8U6.R!4+2QW!
MX)^IOZB%L(=DYEN^5W$<0X9!'$'[>@)SSR-MWN-:M:[D Z.*,C9!'Y4R/(C(
M.10]:PG<_P 0?F)_+&W_ "]M]-;@R&[.HXH]%1O?#XTQ(:=^/M-]8-M12Q^E
M>1:]K>/W/6U\PV?,*D.6::OQC_(/\^/.HZP6YE]I]Z]I+@3[)X8LPM/ .*FG
M^C-2I R0R48<"I4$]6,_$W^:KTCWK%BMG]IMCNI>T9P*&@%56%,'D;\#^&Y$
M7-/]>8:HE>.2";!+N7+4L5'([3P/X3^?E^?[>AYR%[Q[5S:3;:]-ROQ1DC6/
ML_B_+N]0.K5.9S_4G_8_7V$^/4Q\.N*?7_8>_3=63CUF_>_POQ:_^^_WOW3L
M_P!$ZM^O_P 1_P _]1Z[O,#^ZMO]C_7W[Q$_!UX6UQ_HYZS>0"T%S]M^HX[G
MVIAFFM_\W39 /V^O049CIOIW=%QG>H^O<F0!S-L6ER7T_P 4//M=)N5U+\#'
M]HZ#TO+5G-_N1!'_ ,XSTQ)\;OCW33&6'I#IK_7&QJ8_]%>_?O><?B?]@Z2#
MD[:O^4>U_;_L=")M_8VPMJ,4VQL':^W"03JPN!I<?^/ZNYO[+VFE;XG ^P="
M**QLX?[& G[?]@=+!YFG:]1^%/'U_I[K*>E2BG#J(7_H+@?4_3Z^Z1)JSTHD
MN,\.I>I/]3'_ +8>U7BOT7_3V_S_ &]1_:?I_J/[]U[KWOW7NO>T_2CIP$9L
M " >"?J?K[5QUGX=(8O\G4/1_L/]Y_XI[I,WT_2E8-7'K,9Z>FIJV:>W^1D
M@?[[_??Z_O2)]7\'58)C:D"?SZIB^7?\V+8778RNPOC948'M#>M%>AJ]ZQ);
M:N,MQ^R2&&3R YN3^R?PNDW]C+;.5)P?J+@Z/Z7XOR&*_;PZ@[G/WAM+2MKL
MJ_6/_"K4MQZAG (!_HY;U &06OXF_P LSO/YG[QD^0OR[S^?PG7.<*5\?\;J
M_#NC<-(@N4A)-MOX5!_;/I (%/"WT]TYBYVMN7X/I[,LKGB:]K_8/(?/^71=
MR-[$W_N1=-N'-:Q208\./3^NE*_$5/$&I 4\2<C(.T/L#KW9?5.R\-L'K7;M
M/M7:6#I'BQ&W<#1&BIZ>GD_4S.QU/Q_M_>/FX[FUZVJ7XA\J=9W;-L$/+T A
MLZ>#C&/+R'V="#';C@_ZW_%?9/-'7^QZ/Q<^M>F[V[TWU(]^Z3]>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=1_?NE'4CW[I/U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U']^Z4=3^&']0?;O^Y'7NJIODQ\S^Q/B9\U.D:;N#
M*X7;WP;[@V%-A?[YTVW8YOX+O.BCT3'+Y54$O@DU(S@/_FW5@#:WN4MJY1M]
M^L)Q9D"ZB4@-3(&: GT-.@+?;[+M5W!BMO,3Y_81\L@_M%//H:/E/O[^7YO_
M *@W1N?Y&[C^.F[>MFP5960;@K-P8S<N1O5TUM&$EA09/[_5I,(A4 6.JPN?
M:?EB+==GNO"M)YV;_12Q!'"F/GZ4Z<W9K"_@_55!]HH.->[RIZ]4V]9]!=Y=
MJ?R(MZ[%H<'N;*UK;FS_ &CT[L_(HSUU1M/:>9BKZ.E2+\I/3K4/3@ ZB"1^
M+R'-?VVV\QQ#\)!*@G- =0'Y@U'K7Y]!&;9Y=QVDP>JZ23ZY K_(?+SZ:^J^
MI?Y*.].B<3W'N/Y"]A;!KJ+$T==O?8^X_DOGL1F\=D:*F'GHH<%YVKJ^-ZJ_
MK@@L!8DJ05]^O+G>[*^EBMK*"04KXA#@@^A%:_ZL=.1P[4(3/]15?(YI3ADU
MH/L/2K?H;;';W\GSNVN^+G27;O7M%N/M"#NG;^R>U=SQ[RR6X:/KS(1%\K1
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4CW[I/U,\?^/\
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MKU[G^@_V_P#QKW[Q.O57KW/]!_M_^->_>)UZJ]>Y_H/]O_QKW[Q.O57KW/\
M0?[?_C7OWB=>JO7N?Z#_ &__ !KW[Q.O57KW/]!_M_\ C7OWB=>JO7N?Z#_;
M_P#&O?O$Z]5>O<_T'^W_ .->_>)UZJ]>Y_H/]O\ \:]^\3KU5Z]S_0?[?_C7
MOWB=>JO7N?Z#_;_\:]^\3KU5Z]S_ $'^W_XU[]XG7JKU[G^@_P!O_P :]^\3
MKU5Z]S_0?[?_ (U[]XG7JKU[G^@_V_\ QKW[Q.O57KW/]!_M_P#C7OWB=>JO
M7N?Z#_;_ /&O?O$Z]5>O<_T'^W_XU[]XG7JKU[G^@_V__&O?O$Z]5>O<_P!!
M_M_^->_>)UZJ]>Y_H/\ ;_\ &O?O$Z]5>O<_T'^W_P"->_>)UZJ]>Y_H/]O_
M ,:]^\3KU5Z]S_0?[?\ XU[]XG7JKU[G^@_V_P#QKW[Q.O57KW/]!_M_^->_
M>)UZJ]>Y_H/]O_QKW[Q.O57KW/\ 0?[?_C7OWB=>JO7N?Z#_ &__ !KW[Q.O
M57KW/]!_M_\ C7OWB=>JO7N?Z#_;_P#&O?O$Z]5>O<_T'^W_ .->_>)UZJ]8
M/;?3O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW4CW[I/U']^Z4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,&9WSL';.7
MVO@-P;LVAM_<>ZZT4>S\/F<_1T&3R"M95..I!Q6*Y) )L#]+_3VH6RN;O%>/
MJ>/3$TL,%2 309(&!TLM!_P]I^M=(_;F]=B;LR.Z,)M+=FV-UYS:=<M+O#"8
MC/TF0J<?46(-'7PP@+2(K74D<7'^M=3<07-K_;$?8*?SZM#+#-D@BN0:'/V=
M*7S_ .T?\G?\:]INK>'U(]^Z;ZC_ / G_"W_ "%?5_MK6M[]TY\'4?W[ISID
MW9OC9FPJ!<QOG=NS]F81Z]J(9K=^XJ7;E.:K)_6$2UESYQQ<Z>/S;Z^U-E!+
M=_V1 _9TS-(;? !/G@$X'V>72F,EO[-_]C[U9P4\?KQ-:#_5Z=5P?)OX,?$S
MY+=^=?;\[PWUNO#=QP[=I*/K_9V"['AV4^7I]DUCY(&GQ4\4CU9>5B)B)!8A
MB+6N)&Y5YZO-DL'MK4$ZO[2C4X9Z".[\O1WLWCR@4&:D,:$^M"!^WJREIC4:
MI[\#Z$W'TXO?_#CW&UQ;_42>--T+;"WTV]!U!_/^PY_XC_B?>O\ FC_J_9U?
MRSZ]=^V^F^H_OW2CJ1[]TGZD>_=>ZC^_=>ZC^_=*.O>_=>Z8=O;XV-N^MW+B
MMI[MV?NNOVM5?P#>%'BMP4M=48^=[C[7(-%88ZJ)U+]NITW!Y_JIN+.Y@KXI
MK0YITG@FA !((J,5!S]GK]O3][3=*.I'OW2?J/[]THZ][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NI'OW2?J/[]THZ][]U[J1[]TGZC^_=*.G
M#W[I/U']^Z]U*'Z*T_T4?[U[::;P'@Z6W K/T05/Y=/QXC^6/^SHM5]B'N'^
M]IW;]M_>NV#^\^U^QM_#OM/-HYU:=7TXO[DN7G^X%M]$ =/K7'"G"GIT#_ZI
M1?5?54%*::YK3]M.C]R@&WY_V/UM_P 1[CVGU$W0D\"@\NH+_3_8^[S=7CZQ
M>V.G.I$__33_ (VT?[S>_OW38^7\^H_OW3G7O?NO=>]^Z]U[W[KW4CW[I/U'
M]^Z4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3A[]TGZ;_?NE'7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UGY_H/\ ;_\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=2//_M'_)W_ !KW[IOP^O>?_:/^3O\
MC7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW
M7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z
M]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]
MH_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y.
M_P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"-
M>_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>
M\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KW
MG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC
M_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_
M (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[
M]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P
M^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?
M_:/^3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^
M3O\ C7OW7O#Z]Y_]H_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\
MC7OW7O#Z]Y_]H_Y._P"->_=>\/K"LBDL;'\>_2^?7I.J3OYC$5/+_,0_E#SS
MPT<\M)VYNT0^-K#2E7C;?U_WKW.G)F=EN?\ 3R?Y.H\YL _>-G]G\_#8?X.K
MPX9?]R:W-A_$P/Z^X8G/ZO4@>O5&_P#+0GQ>&^6G\XS-9"6CQ]-0?(ZDR-97
M93D*,9_&YI9*H<\W^H_J?<T\]6K75A8VZ#Q?T1G[&X]1CRI-#;7E[/-ZC&?]
M]Q\/SZ4K_P W*JW31Y;>O3GP9^5W=G0^&KLDU9W;@<=CL=15=/M?FIJ<;02P
MS5V0I@.7#U/ _5IY'LM?VVS"SW4-O(.,2J #3T"$$CC_ *AT:2\ZF>HCAN-)
MX<,5^U@?S R>%>N/S ^>NS]__P MO<?=_0%+VSN/%=Y[4WAU_A=Y=?8&MQLF
MS,D:;R5D^Z"/1A5HI5$#U*N1(K'2;7O7E?DM9-Y:*Y$)[4 95S(<Y;.*>?KU
M??>9/H=M^MB([:M0\"/E^SSX="%\ _EILBM^%%'NWL3:W8O46U/C7U?LK%[O
M[&[=PIP]'G:>'&2-/E,-5 ,<OCY7 &H ><,HY8W-.?.3IHMR@M[22(B50"5%
M"@T@ZAPK7_-Z]*N7]^U;:;Z;.HD@>E#YUX4]>D!_P[K5U.$':B?!#Y9U7Q?F
MIC-/WU3X2EI:<XZ^DY0[?\;5)QVK5+;[P)JXN+:36Z]M#M\<UN;I3.7K2@I]
MM*UITD7G,-"/&B7PO3S_ ,]?+A6G2,_F][^V/W1_+MZZ[*V-N##[UV-OGO#I
M'<^VLY2ZLG3RTF5K9$4.&]2.C*RD'Z6(M[5\E;8^Q7\ENQJOA8/EQ_V>DO.6
M\?7V$$\/&F?0]RYP?LZ/?\EOFYUG\;=Q=8==Y3#[T[9[?[>K,9%L3I;K2EIM
MUYB6!_U9%WEGC:BQ,ER$>52YM:PLU@LG(UQO3&\BF: 6_P *J :_M\O7_BZ"
M.7>_HH(.%)B:DDC_ "?ZO\*6[=["^/5'\T/B#LWLOI3(YGY$;QVYONLZ8['^
MTH<F=G0TM%(,CCYL@E3XV*S+,Q+(VC5P!>WM_:;&_O-NFNX1VN[%SZ <>DMU
M=PK=10RL-(\OXCC/ TKCI-]U_P R7JGI'NW>'QVFZT[>WYW#MG;6T<KM?9'7
MN#.Z:G=U5OB))1CL"H5B10QR"6OFJ4:*&$.$74 &>V[D)[NW_>"R,8M(8*!6
MM1Y?9Q->'3=_S7%'*+.&!14G)Q0!B*G-/+RIY5I7IOZ _F/8_M?O:C^-?='Q
MW[A^*W=E7AJO<&R]F]G2TM;#F:*A5FDCH\E3T]*\,SA3I;3I-F%[V!KN7*(V
MJP-W:$RIQD4C#+YT-37INTYI,\WT<L0B'J*5\O2H\^''(^WHPW4ORNV7W1WA
M\C.B-OX;>%!NKXRY7!8O=V6SN)HY<7D)\YPIQ<8 ,+%Q=?4;CD>R2_Y7FVF"
M.Z6OA3D!@>'=D4Z/[;>H+Z[$51^F#PKJP!Q_EUGR/RNV-C/F+MGX:U.'W=_?
MS>G5N1[7IL[01TJ;>^PQ5R()KC[QZWQ(RD@BS $$@@#2<L37-D+LUU%=0]*<
M.F_WI!;W9ML4!T_/B!]E.BO[]_FE]=[3[7[4^/O7W1?>W=/?W7>[SMBAZYV5
M@((YL\[TQJZ[,+,))(J+"TQ#E9*Q96 *FVF^@06OM]'<1,]Y((X1^-^)'&M3
M@#Y]%C\T,\JQPE0Q%?L!X#I!;3_F]=;YVCW+MK,_'OOS:WR<V_NV+90^(\6%
M7=>=RN3K86J2*&6332)CC*@%96S0^6FN= 8&P-&]M[FSBUQ&(;>#372K5IY9
MI3U/E_A1Q<Z0L? \(&ZI6O#%1Z?L%#3U^0T_%G^8'A_DAV;O'X^;]Z2["^-O
M?^S,-2[WKNM.T)(\@F3P]4 TDU+74<4$$LA1T90\15AS<W]DO,O(]ORS:IND
M#Q7"RBI5Z&H/ J0*'_5QZ--DYG:^F\&8Z16E1BG'CD^A\\?LZ3'<?\R7;FT>
MV]T]!_'KXZ=S?,/M7K)E3LS']3NF.PF(JJHZ9:?(Y6M^XDDKDDNI0A%N+!K\
M"^R<D:X%NKZ\C@>?XM.L 5^9/Y_[(Z+[WFL[>L\5E!XH\AVZCZ#N( K]M?\
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MQ[!5M)--T)KB#Z7KAY_]H_Y._P"->_=)_#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\ :/\ D[_C7OW7O#Z]Y_\
M:/\ D[_C7OW7O#ZR>3_#_>??NF^LAJZR#_@.H']?Q_Q/M1]5)Z'_ %?ET_\
M2VYZS?Q&M_VK_;_\:]Z^ND_U5ZU^[;;KC]_4?[3_ +Q_Q3W?]ZR>G3/[HMO4
M]9),CD^+5K6_QO[K^\_L_;T]^[!YC^7^SU@^[J?ZO_OO]C[:^JZ]X'V_MZC>
M?_:/^3O^->Z=5\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^
M->_=>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/K
MWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[
M_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#
MZ]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y
M._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[
MP^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/
M^3O^->_=>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=
M>\/KWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_V
MC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7O
MW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#Z]Y_
M]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#ZB:Q_C[]TYU3
M?T8X7^>1\UYUN?#\7>NZCGZ\)MOW-V]'P.3;7^G+%_A4]1OMHKOLWV_Y93T7
M7YL;ES'\ISOC/_+_ ./5-M9NM?EAC\]M_LWHROJ:?&4B;XQD"UF-W9C(&U!E
MCD=)*\6!1F?](D32<\D6G]>[4VMZ!2V;2Z<,#@*?X>B_F33RK=^+:"IF\_4'
M'$T]*9X@ ^1Z,CT/T_7_  3^!/R(^4%?E<)V!\H^RNKMP=\]H]LL?XH]=F,E
M315F.IJ.K8>K#8TUQDF93ZV:YU*J6(-UG3>]V%L2&@B)5X_5M)I2GD/RZ-+:
MVGVW;Y9#42@T].&/\E!Z#Y]5A_$CL?X5;5Z2H9N]_@1\GOE-W+V=3S[N[4[K
MS'Q_E[$&>R6Y6)48?(U,JNF.U<P/#ZV<FY(( 'VZ6-_.T4UO<_3P,=!@KJI4
M>I^?#_54";??VMK#2]C2YN%4 S\*T&210_LK0#HW'\OO/;EH.C?YA?4^+V+W
M-LSXZ[2VUV#OCX\XSN3:-9M^NH,/OS;^:CJ,&LF1)00TLI1R%9M3*6_M,?87
MY@MX9+FV4AA.,GM(PPX9KBIQD\>A7MUW-HNW)4Q%@#I/H5/^0_ECRZKT^.?<
M6Z._.D_A+\#-X;BW?\?/B?N3-[EV%V!VMC:*;'OV!N.&NGRJ;,QN1-H\=C E
M=#!(W*/4.)I5:RV&O,>U)M%Q=7Q)EN!&5*TIX9%3@_/U_+RZ#FUWBW]O!;(
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M:2A<C1POI\XK_6?\.;\^X2FEI=:.I"IJMO'ZH)_EV_W(W/VU_.0W?O&MQ_\
MHDW/W=G]O;@W#DLG]A2#%O29J7)?Y6+G0:5 1,!R=/\ 7F=^>IY+&/;U@S*%
M/'A0#/45<NP,LU[-/\(H0*9J%C'^&O2/Z;^/'\Q'XY]=;>R'\O;Y2=)?*WXK
M9)\G5]:]=]A8VCHM>/6JG6II:;(3JFC]S5"X7)I<DFW/M1<;[M.YN!N,20S_
M (77T->#8_GU66TW:S8_33&6*@!KY>8RM?E2H/V]*^M^2N*^2/\ *5^:E5)U
M+M[H/=W56V>R>K-[]:;*Q--28A<SCX:1IY,4D;:D=45E93JM;46)-PCCY=CV
M/>XD1=::=+#% P]*=*MVW<W>WS>.2P6I!R32A'_%=!S\Y6SH_D@_'9*5JJFQ
MPQGQ2.[JJL_X"0XKPU(7[L?4T0K!2^7\!M/-R![-.5XK:3F>>-OU#IDU'R [
M?]CHLYDB(V.(P&F8Z?[TO^2M?E7HT%!L3^<#)M##TF/[_P#Y?T_7E;M.A;%0
M4G766_AAP7VI,6F]*#_#A2W_ #_4>R/ZS9UO(D5KS7QD&F.E*?.GETNGAW3P
M3$1!X5:>=:U_T_&O5:'=76E1U!_)FVUM#$=N]5]WK'\R,'EMD;@Z@R,V3P:)
MDJF1X:#_ "R.*2)X,GJ:8% +$6)!)]B_E[<H-VW^YDBCE$0A763\1J,8_/HI
MY@M/H-JMX:4.H4!'],4X$]&B^*6,WO\ $?\ F 5F"^9LNVM]]T_,78&)R?4_
MR9K0::F&2I:>V2V%3M+9:"G?]%*5 ,Q%*%&AQ[).<K&QWK;=>WG0T,S'2,"H
MX_X<>1_P*N6Y;C:[FW.XG$N(F_+TR<<<DGCG%29GY8JP_FR?RS(JAS]S#L;N
MU7@;_:8*MO\ C7^P]E'+=W_R';P_!1Y?\'2S?U_W>V?V?] ]-'6>,H:O^>;\
MEZR1&.0PWQ"ZYJ</7 #_ "=Z]L&)&M^>'86_Q_U_>YV_=_*D*^+P914^FH?[
M'3]E)KYAFA]2"?G4R?YNH_S7@6/^:#_*WJ5T4^2K:CMVEG/^%- P%_\ 8EO]
MA[2<E7,ESR]/:_Z&#*/^,].[W*-MW:,_(=<_@PM)_P .0?S9H $^\.]>N:ZC
MI"W!%0CVM?ZGU#_>3]/;G-EQ+<;;:1)_9QJ2?R'5.79!;;M>&;@?\&@4ZP;X
MS%/6_P ]KIB.DK(9Z[&_"W<<5;CZ.P>F:LK:DLGU/(#W^O\ MO9EM,6CEN<?
M\.;'VL/\_3%P1/S%;U_WV3G[3_FZR?!+'TE3_,E_FTYF:E_W(1;OV!1BJ_AV
MJI%,_P!SYXH ?HS:%'^MQ_C[2<[7=-CV^.'P_BB'Y:3PZWRQ!IWB])\_\(44
M_P /7NGL71S?SQOE_63T]**K$?%_KN3&UA:T],];-CTG9?\ $!W'^Q]M[Y--
M#R_%&/[+2@SY"HZ4;/!!^^I3YDCAYYD_EU-W-"R?SV.H1?7)/\,-QG[LVY)K
MJ_\ <_WC^OOVW3%N6YXHI?U:D>#Z'6<?Y>F[K&\P$BH#-^?P=!;UOW?\E^[N
MUODL?Y;W0OQDZPZWC[0R&U^S.\^V6FQ];NW<V%)AEJ8\3CF L6?R>J!@I:[,
M-1]F=YL]K91V9WF2[!$95GBP& II^(?S.<\:=,6^[W=[=S_2FW*@=HFJ2OVT
MX_M'V=)'XFX[O/#_ ,YW)8SY)=E=<=J=JTWQ JESE?UKA$V[08N,5L'VM (_
M%#,*H#3?2@/J^M[^UV]V]LO+A%G&6B\85$H(<#6/]]]OS_/I#9QRG?N^H'A"
ME>)R?,D\?\G0O?RP4VS!\J?YKRP1XP[Y;Y-O35(87G@P/W,X8_0_Y&*G66'Y
ML#8@>R/W MB=FL(?[*/PJ'U ICHVY4CA.Z7IKZ5^WPU_XO\ ;T^=KLLO\\'X
MI+M2;'MNJ'XO=HMV]%3\C^'/'DAC!D=-^33$"#^GH)]I=IE8\LRQS\=3ZOL!
M-.G[R6;]Z0^#\)./S*?Y:]7)"]D L>6N3[A]H>I$F[NIOMKIOKWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NL,'Z#_P8_[T/>H>O=:M?\]^I&Y/E3\.
M.O<O)]MLJ3;>&EFJ9>(+[XW-%2Y!A_6T"J#Q_9]Y6>QB"&UW)D^,6V?S('^#
MJ&^=[;]YW=M]E?MHHQ_,];0=+C(-O4E+M_#4>/IL/@J'%T>"H<?:]-38KF&$
MWOS]/R;?X^\:[R]FNX:/P$N.I<L;(6]G6$Y-:_,^O6KC\KJ6FZL_GU_'_-[$
M6EP>9WGO7HC([NH*)OX8)GW[3_P[,*;_ *5R-/(_G_'K-_>2G+MQ)N/*=TC]
MQ2H/SK4?X.H(Y@N1!S/: G.CSXT6I'["!^P=!;\ZNRMZ=/?SI,IV7UYU_/VC
MO7:;;%KMM;'PT=3+-DIZO;;4Z1!:0%BT=,0+"]R/SS[/N5]M6?ED)*Y6(*1(
M!@FJD'I-O-]/%O*I!P*D_P#&V_+RZ?>]OYI7RH^9&"W?\)]O?%["=:]B]LU4
M>S<[09K>#_Q14JY5F:@=,ZN/IJ.JGD '^<6][1"]K(.7O;^PY>E.\P2^,D8T
MT+\ >/$ 9_XKRZ7W_.EYNK?1&V? )U472!PKVDDT_P!7GU893?%7._#G^3;\
MC.HMX9+'9#>55U_V/O;>E3B&&4HJ7)[CFI(4QT4ZDKY*>!/$TGTO< D6)C<<
MR_UCYB@N(XO!(1R3'YD@XZ%<^T"RVJ:$<. !XTR?\/#K7"VIW;\@=R_$C<'Q
M)ZMPNX#U;M'.;X[X[QK=L*U<:B@7[.*)LBPO]M@L<44^+A:JH8,UV@0KD=?\
MK;9MVXQW5Q(OC-10@_AK7]G4.0;I?O8_1VP'@ : 33%:G'[:?ECSZV@?Y+F8
M^/V3^'&)CZ,P=#A]U4.7CHN]J6OK?O:]MQ'5_E-9+<_Y)4T?D&.LHIQ'K#7(
M9CC7[NV]_!NLBW 'T[4\"G$)BI/V^7R^?4S>V\MO>62SP$?HU\7/IQ'VCS^6
M>%.D!_/9[O/6_P 2\)TWB:N:'<?R+W<]/D,7C[))_!-FLV1R@< ZM53*U#3C
MZ"T9^O-G_9?EUMUOIYKGX(&TC[!D_P"3IOW.W$&Q,(K^L*#[6'^8'JO3Y\_%
M#:75W\MSX<9C8NXMMU'9G02PTN[X<!GZ7)U0G[9)R=>'$)NIQFXO!%]/S]?I
M[D/E?<Y]YW>:"7^Q;YY[>/Y5Z"/-6WP[99Q3VXIYK4&G;@?MXGK8-^-GR@VC
MVY\/-A?*7=FXZ7!;?J.LY-P=D;BR<7F@QF4VE2K0Y]ZI1<M>IID91R26N!J)
M'N!>9N7#;[Q):6YH&8,3P IQ_9U*FQ;[#/MOU<HK_"/.AR/EYYZZZ^_F#?"'
MLW>^V-E[$^4FQ-U;KW17)0;4VYA<I5PR553-P($=H18,QL/R?H+^U"\D[MM"
M"XEB+1G@H.>JGFG;=U!\"<8XD,#0=4J_R#(_[P=Z?-[=U?.\FYY*O!+59!?5
M42?Q+=&8K)P+_75-1+?C^GN6_=BVEL]NMU\&IU+_ (6Z ?M[N*W=[< ' =@1
M]@I3^?3K\'JI]H?SM/FUM_;-.(\974'<[OC*,W \=;09!%%[7TU<DEO\0/\
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MY<.'Y_EU5U_*9WA\DOY=/\]'/_RJ=C?*/</RZ^,^2H-TT&^(URU;E:'%246
M.<_B20(^03;^<P5>O@KG@J&IR9#&78LK,9WL:Z<'S&1BO_%?Y^FK>61#4BAI
MP.2/^+X?GZ];\+_3_8^P)-T>]5A=O_S=_P"7QT'\C-W?%7NSO?%]<=T[,VQ-
MO_>F(S>S<G0XNBQRX(YTELW%&^-=VQRQQW#F[, M^ QV=G<&F?3\^D2WT; %
M0"#\\TK3TI_/HL_Q>_X40_RM?EGWMC?CYL#L;L#9V^<]D4P77U9VWU__ *.<
M3N"ID:3P)B:R.JE=35Z *;[X4;7( 1-1]VN-H,8JM?G\OY_/K?UL>:T-"?(Y
M'YCRZ.1\E/YG?PJ^'?>'5?QN^17;5/UKVSVQMV'<^Q:?+;2RLV-:CJZRLQT>
M3K<H(OM,:C+CIKWD72;@_4CW2TVX7(SP]?+JKW[197/R/'A]E/Y]!M\#/YPG
MPQ_F1;][@Z]^,&:[&R]5TA2G.;JW/O;KX[.PM52"L>DCR>+S<;R 1S)&C 5B
M4LA4@Z"K#WJ?;OI!^7RZ<CNVF].(&*\<GS^SRZ)]W'_PIO\ Y3O3/8F:ZTF[
M)[7[/JL#F),/N?>_3'6*[PVS1QK4&#_*,M)DL:U:+JR_<113$_4?CWO]RL17
M_-_J/6OW@@]/L.K_ "5 _*O5OOQ=^5WQ]^:'56#[E^,W96U^V>N,W5_8S93$
MN8JVDK^$&/RU%*34XBN9@=/W;,S7%N"+I+G;M/[>'3D=Z9/B].(_R=51=V_\
M*2OY4_1/=U7T=G.WNP-\[AVYF$P.]]Z]3]:S;YV=@:K!Y!UK9JO(&6.MJXJ5
MD;[A\?%6+):ZM8BYK!M"K_J_V>DDUZ[>@^VM>'R%/Y]44_RD>YL1W-_PJ%^8
M&\>ONS:KL#J7?VUOD3O/KW(8/=M;E<3646XWP$]%54JK.Z.I21"!]2./Q;VH
MN[75"BTX%OM&&Z8AE*-4^B^>/PU^7EUM?=/_ ,RWX=]\_*CLSX5]6=I29GY!
M]/+NIM][%K-A5^"I\>O7ICI<D!E98UIJL1EH@I1P"5!X^GLO^@_2\\_LZ,_J
MF&<8I4 Y%:?+Y]>[2_F:?#?IWY=]??!+L+M&HQ/R:[(;8,.TNNSU[5[BIZP]
MB*(L(IRJ+]B3&*=[D$@,P^MC:D6WCPM7\^F_JB1X6*9\\X)^7GTT_/+^:U\+
MOY;&$PE;\I^S:O#;GW30U%5M;KC8V/;=NY\C31'QI5QT!>(TU,[D@5-2QUV)
M#V%PGM]N^IZV]T8N%*>IKG]G^KY] O\ !?\ GA_R\_YAV_FZ<Z1[$WEM3N9:
M/(9.BZG[NV''U_D\BV/0RU1QH@FKL76NBLI2G\B53>IP]^/9E+MPMQ4?['\N
MF4OFE&:'[":TX>?\SU7EO+K'X7O_ ,*/-N=AY+YQ]G8'YAE=KRT?PSH^I,C_
M '?>5=BPQ4C+NDSG%^"MHM%>6^R*D.;G\^U<%#;Y_P '^6O261FUTXBG\7E]
ME/\ +U;)VY_-V_E[]#_(;?OQC[?[]Q6Q^X.L-HY;?&\\1G=K5V.Q]#C\3B?X
MLIBR0@:C8M3E8U@\I<LUOKI)+H[)KC)K3AT8+>)".VF?GGC\Q3HJWQ<_X40_
MRQ/EQW]B_C9U]V)VEM#L3=.0BP?7]3VYUB-E8S/UTZNT$&+J5JWDBJ:M"BTC
MY$4;,2 %0-[=?:B8J9S]E/\ 4>FH[Q$SC'H2,?F/(='8^=G\RCXE?RW=F87?
M_P K>RLEM9=Q25N/V=M# XI-Q[CS'\+6]0F(Q.J.Z4DA$9J:N2F742KN3<>T
MMEM^K'^ST]+=&,5'[> K^7'\J_;T0_8W_"E#^4-O'JVJ[-RG=^[>MTPFX\)M
MO*["[&ZSR$6Y(6S5/+54E6N.H!7PS8R1H5#5$,C#FSM:UW#LS>O^STP+]/0?
M;GU^RO#\NKP=A;TV_P!D;#VAV#M.K;,;.W[LW:^[]O5[M_"6K<5NG'FNHY7'
M(#+&K CZ?[W[++A-!Z6^-XY(/D3\^@Q^0?R'Z8^+/4^ZN\/D-V+MOJOK+9BM
M'DMR[AD8$C)*?M(*:FI09JNOKELRTE&REE&IF%FM:UMY;KINZF\$T%/G\J<?
M]7GU2GUU_P *A/Y2/8?8]%L$]B=S]>4N>RTF*V[VAV=U#+A]M51CG$%ONZ7)
M5]1%&ILIJY*"-P&_<4D $PEV5B*C_9'\^FOW@GH/Y@?EC_">KDODS\L_CW\1
M>C\GW]\ANU-L=<=18XXU*#=M7+_&4R:Y9'?'T>#6@8'.UM:HUT_VK Q)=W(
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MOUSTKUSV_P!;;_ZVVMNW+[<EPV1EW/D,GN&JK:!<7BJ^/(HB+-4I2:0:)2;
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M-46K'I*/]?U$_417-]XZ8QBG^7_)T76=KIE -<&O#RH?0GUZIZZB_P"$Q_\
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MT$U=D::#["IR6/5J=<A.*^M6*2^A@@'M>F\)-3..&37_ "#I)'MTF=*Y)KP
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MM;Y9=H;3Z&JMX9+?&WL/DNR\RNSZ9J_8F_,GD:J!J^I5%AKA"\4U*"A6H"Z
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MO^%7/_;S/^4U_P!J#&?^]U0>VK#_ $;[?\AZT/P?:W^3K>XR'_%TR?\ KO\
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MUN?9(%^MZ,##])TP9;%8/<&&RVW,W2ME,)N6BR&"SM"K!354V5HQ%+"O'!!
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M#M.++XKL:OA[1/\ ":#<E'N221\%C<AG\J$D&+C@E^RHIXQ+([)K!]%86]/
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M24+Y&(\)#MC:(H16GK_A _PG\NO?59-3@4]/,5XT\OEDXX=")A_E)_-4^/\
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M]F?&S$9O;>[^JH^PZW[&AR0R65>JH-TT&)KZF*.MD8PERHE7Q^4!:G;K=_\
M+Z_X/\I].O)=R1FBDB@P<T_P\/R'3MNGY=_S3^\/Y@7S<^%7Q!Q_Q;V;M/X\
MQ=([@P_?'>FV<SE<?MW&=B;<I<I+AFQ.,JW;<.<STKW$CLD6+QZ64:G#"OT4
M=N?]0_S].B232":UQP\SGYCA]H'V]$!_F)_-GMGY*?R=_P"8WT_\F.I=L]??
M++X5=U]&=7]X[4V'D)<IMS/"MW%B<EM[<FW_ +D25*4&Y*0SHL3782B1E$@
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M=.V2E9"TFI(2K(K*I79%!()&*_B"^=/.OI^SSZ8%[15:C&O\()I45\J?S\^
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M&8/;VV<=F\_N+<.4J334-#18.D$E?7EUN6:*(J%&FY) M?ZK+?\ 5ZI/6VH
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M6=%KF'\+$BO4:U9(T.N1B%1B203+;T@N!4 &G^KUZ2S7#PFFHY_U?PXZ/-\
MODQVG\POBMU?\C>U^A*[XTYGM*/)Y[!=;5^YH]TU:[>21!B\G+!-#3R4\>:C
M:*1:1F$NEP'578#V2;I;I;RU_P"*]>C2UDFD- 2<9KQ_ET>J*/[VK$%1;Z#Z
MBP'XX]L/'TIGN,5ZH^V9_-^R&X?Y=OSA^><70L&&G^'O=/<W4%+UK!ORJ:'<
M(ZIRN'HI:]LA]L10-7#, -K@'D900>;*>B.59@@(\CP/V?RZ+)::-&3\6<5Q
M7AC@:=6_]7[^K^R^J^O=^UV/_@)[ Z^V+V*V.%?_ !/[ [JH),F5 (!TQ^06
MO]1;D^RZZ>:<]*H;902!Y$CAZ?\ %=5Z_,'^9+0?'3NGKKXA= =#]C?,3YH=
MB[;J-XX[H7KW,X_9E%MS;TC&--R;UW)7$8_;V++6"*-(E8%;:"I+]C9_QT_U
M?97_ %>?226ZJ*PF@]>/#_5]OH.@HV#_ #/NX-C_ ""ZB^,O\Q'X99KX<[H^
M1V=R>W_C[VWMGM*B[FV+N#<"AF;;E7F*3P56WL\%$2 F%I9G<B,1A=1?N-N\
M?X?]7#_5QQTS%<C)D-0./V#]G\QGUZC]F?S-?DEG.[N_>H/@?_+]W3\M\#\5
M<Q4;6^0'9&<[7QW2U))N.&GFJJS9NRJ:NH3_ 'DS5 +:U$8I8W0H68%'D?@V
MHGXLTXC_ %?,?/UZM+?**%#2O#_)QKY4KPX\>EW!_,\PV^OY>%%_,6Z&Z;WM
MV)LS"R+F.[NF<GFAA]Y;5Q6Q<J:#L-R%\D=3N'9@^]J#0,FFOA(:ZA&0)9[*
MIS_J\^E$-SI.GAYBE/Y\?G7/E0'JSG9^]-H]A[3VQV-LO+8[<>T-_;?VQO;9
M&XJ*/S4E3A=ZT+U]!D2ALZ!X$8%38WXL#Q[+9DFM^EBSU\O7^72\]M^,>M=<
M-8_Q]L>-U[KG[?\ &/7NO>V>O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7"'_@30_P"M_P 5]JK7B?M_R=)[GX?]7J.AK]C[H/\ 7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]T%VYO^+G_P"0P?[T/84WGAT>;;_E/^'IH]D72SKW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJS_G.=#[K^1?\ *^^8
MO3VP(FK=_9/J<[MV328NF%2]74]2UE)N-\9 J^K[B6"BDCA !)(L.?JMVYP'
MJ<_RQY])9XOTP!_JJ,?X.BP?,;H7_AVS^6-\1NTOCTG7>\-][8J_CQ\NNG]A
M]NS#+;1W-DL!CS2YC8FY'C:0+35C-DL<-94)7J8[BP8&0G%L]&_E_J_XOIL1
MZXVIZ_[()I7R.3Y8].BV].?&CNGLOOKX_G!?R//AY\"]G;"WSB,]\BNZ>U:?
M:O<%=)!MQUE;&=;8_;T,4YR%17*WAR]6@^U95!,14LQA<7 T<*?MS^W_ %?,
M=(8K;3*>[57@,"G[/V^7V'JS;YI[>K_EST=\_?B%W=L*H^-_Q\K.ES3;1^:'
M9'86$I-MY*NW)3^;SSQ!HVPL6V:S6E>:VP4 @!&" E\)\(_8:^?K7I1<TEHP
M-32A 'E3/^J@ZUZOYD'R'_FCG^3/OSX^=M_#S8/7>S>ONG>J]J=U_,G"_(#"
M[OVAN39^V\MA:3"Y+K[%TOERM1E=URC%ZU>4I$J%F)57T&B0T;Y8_/\ S_ED
M_+I.KC1JKDDX\P?/YCSH#0?;UM&;([$[2VIG?BIU9C/CQO+=/7VZ^A=K5^_^
M_J;=M!A\9L7*[8PD30XC)8*20Y6OK,F%BU+'=F\HNK6< GO$K2OH/7I;%*-3
M-7\38QG/V_X!UR^-WRDJ_D'V=\O>I]Q]-;EZFS_Q8[9P774^1W#N7'[L7<-'
MNC$MEL7G*!<:Y6D^_P 6\+?:M9F5U\BDBWMJ1/!]/L].(]/EY8Z<C?Q@#6M:
M_+T/K\_//1#_ .=%TK\B>T,7\#NP_C=T5DN^]Q?%S^8#U_\ ('=G7^U<U18.
MIJ<#LW YN(+#4Y!EIA++/($*#5;_ %))%S#:WI6E3Z?,U!_R=,;G$ <D"H\\
M>O\ GZ"KY,=M_P W'YR=2;Y^,O4'\O+</PEA[PQE?L#LGY-=]_(##9FDVKMC
M=\*4.9EQ.!P(>NR^8?'I((S'(IC)U,-15E>>T@MOPT-?,_/[!^?29Y'>AU ^
M@ 'E]A/Y<!TH?DO_ "J]\[)Z9^ .[?Y=^8VU@?E%_+ Q])A>F,5V?*-O8G?>
MW-S8^.FW7MG.31")<=6[G5?NC(554\\J!@KLX8CNP'_R_/C7_8\\].2P!H3J
MX&OS\J>0_GZTZ8^WNWOYRGS"ZIROQEZZ^ +? G=?9V-.T>X?E)V9\@L+O?%;
M+Q>21:7+U>R:';\4.7S66F4,M!*%0JQ1U07#K<P0+WT_;P_R?X3U19I)*1:J
M^8 I7^1/^3H_\O<N2^)W;GP=^#U5L/L[M_!=Q;!W/UG!\E]V[UQ]?50YCHS;
MS9NJ.>I:@1Y+)Y+,8ZB:N%0(T0"1!'I(;VC?]7I5"!%5_GP_+U_(C[>A:^;N
MR]W=J?#/Y8=:;#P46Y-]=@_'ON;8NS-M8^?QOE\MF<'54]##&ZWT.CHQMSJ(
M_!]EUKFX@^P]&-V:1 G KYTP,]4Z_*GX6?)OL3^1Y\1OBSL_JO-9WO[K6M^#
MT^^.M*+*T"5%%_HRSV,K<Z78U(I3_"J90') )#ZA<*1[/_%/U>D@\"*>>:]$
MRH A:HIC/EC3_F/1P_Y@_P ?.XNZ?F5_)][/ZNV76;MV%\:N_>X=Y=T;IH\K
M0A]OT>YMH1T&/R%<D[6<+6*[!A=6*A; L"&[:ZI]N/\ "#_DZJ8*:JX^T\<,
M,?MZI,ZN^!OS(Z/Q/?77VZOY/O27R_\ F/V7VWV]N+&_S(.[.X-N;TVWE\?V
M%6Y"3$;BR]/FS69;'U.!H*I5_AL,*JRPJX,<@(*_Q<4H3]O^JGYG\^F:*Q#!
MJ#TH >./.ORH!3T/0O=4?RYOGEL+X*_RGNSMC]3;:C^</\L/L_N3/Y3XW=A;
MPI,3C-\X'LC*9J+)T6+SE.)L=CZZIQ61^XQR:_'XG<LOD$0>AO@*4/#A^VO_
M !?\NG4MA5JFNJE:' [:'U\L_P"'H[F?S/\ -E^95-\A)-U= 1_#7XRR_#KY
M"]=;?^-VZ-XX'LK>_96^=^;;RF/Q4]1D*1=.VL3C7:)D?S0M7*OCD#K,S1)@
M4'K_ *OY]/Z'%!4$U&?3(]"1C[?/I,5/\M[O7N;^1'\7OA96SX[I;Y9]$[ Z
M*WWLY=UYJ,4V+WQTO419"DH\LU"92M+D8Q]D'NP0LK*UB3[;^I!D/I4X\Z$G
M_/UK3I4D?PJ*C(P!D>M",]!]\C,#_-;_ )GO6O6WPO[>^#^V_A=UIN'?W76Y
M/F+WUF>Z,'V71Y.@ZZR4.5FQ&PL'AP:S(?Q^IQ\@1II5\*B-3*\>J7VX\R)6
MM?.F/,CC_JK7IM@['54'&!C'^K'&GV=!UM#N7Y?=)?SC/YM^?^,GQFI/EOUO
M4R_$7&=E]58#?^/ZUW30Y3^Y4'\ R>,;+I_#:S%Q1:::NTRF1U?R1Z@6?V_*
MI$)'[>O"0.ZZC0^7VT->./Y])/O/^6_\[>T_Y?W\Q_L+L'K_  5?\YOY@WR
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MFE;;^<7Q77/;\PFV>L<YN:I,F2Q>T]MUGW,'VF.K$DR6&HCH +69O+H9Q8S
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M3;1[2Q6%31A:/<V!EKY,:&_L4U="5KJ2/])(8VX _'M^TYEN>6S]5'(KBYX
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MOZMK,Q03FDFH,9W#NG&8K*D:2++-3,RL;W(+ <,?9OM,5&J?(_Y/]CIC<_@
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M<=)OW>ASIK]H7_H'HS_S#_EF=)?,"LZK[%RF^>VNI?E#T+1BFZB^472&\O\
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M@R/N_P"[MPV6.ZMK0Q2^-J 8,*'52N!Z5_V>@!MUQ-9;M])+.&K3 TU%":\
MO_%_/H0OY'*/+\3^V5@IEDJ8/ECW32UE 0#=6JX0;?GZ'Z#_ )&3^[;/;W=O
M%#_OA*_[UT?<E^/;QSZO]^$C_>FZ2/PYR>U,C_,2_F_5>:R=(NQZI]N8C<U5
M]_: 4='CY*7+,)K$7I$%7I-OKP/9KS2B_NNTK_:53_CM#^SHDV,1VVXWE*\1
M3]@(_;T%72_QK^>'0&PZ'<?\LSY:]0_(WXJ9++YK,; Z\[$H*61XJ>JJE^[Q
ME)E8TTQ@55H3HKZ8L?6%75[7W6\V.Z$'=HDAF%2K/QH<88?[&>FTV>YL8=.T
MS%HL#S(&*XIQQPJ#CH(/D-\EL]\A?Y4?RDPXZ:QW0^\ND.[-G]>=^["V31@8
M*,_QND%=7T\=.Q\-+YXU2<6(U >LZE'LPV+9;3;][CFO)/T980I44H"&%:?Z
MOSZ2S;Q]9M\Y!+>"K%2QSP_GC-?Y#HY77&QOYR-9UKLNHZ^^0?P*GZ]FV3A/
M[FT5+UIE33##BC7[<>J7_@,*2VH%R;W^IO[(+ZZV*WOI8%6;XQC2W C' GT\
MNEUO#NUQ9^/%.FK.:8K7Y/Z_GT3^3JFJZD_DK_,O R=O=,]RXS(;XW=N3&Y_
MI/)U65Q6-_O!D\"E=B79H_\ )O#.L;""PX)//%C&YNY+C>%G1ECD\-N/"A*]
MP],]-:!%9+XZL,&NH4\G/J?4C\NEY_,6AWW4]*?R=:7K"J@QG9#;FZVQO7-7
MD9%\5)EQMK$BBFJ&/"FF?2>1Q]3^?:CE>\@VBYW"ZNHA+'X9^H/EX8<D?LST
MQOTLQCM! >_6?+B*-7^70M?RXZ&H^*?RH^1_Q%^0E/0YGY,=FU![MVE\CA,:
MB;LG%UJ^6LI ]0")*C#50:5:?^W(DBOZE6Y%[B6;;IM\-_MO=;@Z9(:953@_
M85/ET9\H*-LNYHY?]R&_'Z>0.*<,#Y"GKTN=NRTP_GI[\@73Y,C\)<$M$3P-
M;E!_MPH/^Q'MLO;CEBV>'^V?33Y'5_FZM#.3S#<P'@&'^%NL'\P2LHI/YA/\
MI;"6\&1C[7[ SJXHK>>.FG-"5E(YO?01_L+>VO;ZSNIMFW*>::M7-!Z 2=*.
M8+A5W"*W XKQ'F0K?ZOSZY8"AH*S^>]V+7-3^2;#_"_!5^&)6_VPK$B('^/I
M<C^O-_Q[52W$L'*K0^7C #[-?26*$#F,0G_?=#]FINI??^/I:G^=S\(9,E3T
M55)3?%7L[)P_?&P^YQDN?M*?\0RJ1[:Y?GEBY7DCBS_C$E/VGI_>13?(O^:9
M'Y$Q?Y^N7S\8?\.'?RE)U(97["[7,QO?E:6F_P")]I/;]HQM-[-+_:ZY*_[R
M.E',>;F,#A0?X&Z3F]>^.[]^?-_O+K'^7Q\<^AAVEUKMK;.V/D3\D>V,A)C3
M4"O=:JEQ4*T/AFK$H)"$'FC=W\8)X4#VKL-L8;<E_N+JD+S2B"(XIIKJ';DX
MK]GG3HNO+ZYGN1;[>6,M 9I!P'\C]M, 5QT7#/8GY5X7^:1_+SIOEUV_U'OS
M?\D?:.1PFU.I]K3;;I-MXIL>[::E)XQ-+]^VLQ<,1]L;_BXJ)M+C9;[Z)3IH
M:!Q0 :?GG]O12NM;^']X3EILT\M35%?,]&8^"TNV1_,Q_FK5#TV.FWU_?38+
MXV)N)X\:8&-:8;BWVOWWA^X-@;6(_/L.<SQ7@V/;Q>3#P@D>KR-*^7^7H1<O
M70;=[V"6M,?932*?Y:=.'RS>"7^;;_+?;:L!A[%AVCVU-O.GI;-4IMO(TTC
M5-B>1(:@0WYL!^+>R_8I1#M%S;/-^B!XA/\ 2(_U8/3N]P5OHC",<!Z>7^QU
M<]XD/%V_WW^P]P[^C/U(-2.N_.G]&_VP_P"*^V^MZ#UF]^ZIU[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<(?^!-#_K?\5]JK7B?M_R=)[GX?]7J
M.AK]C[H/]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW09[J_XNTG_:O;_HGV$]XX='
M>V>73'[(^EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UB)\^J 7YM]1_7WKZR;;OUH>K@!L'HL'R;^
M+'37R\ZTDZJ[HP8RV#CJ),KMC,[;RRXK.X'*4/Z:_%5L@)BFE LR-P0;V+ 6
M%'+F_2<MW1GM142<+>M$!]01P/Y?ET3[]M46_P %9OSKP/[/Y$&H\CT1>G^"
M/\P#;5'3[#V+_-'W_%UY)$E-32;EZSH\SNBEHO2P6'-K5%](0#2JU"WL/2O
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MKS_\5UXW<O\ JI_EZCRQ50M4<BQX _XI[2>%'!U8&XZZEB\ ^X]-C]>1^?\
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M(F:8BA-:"H7C4?EY]-=+\Y?AE624U+1_*WHFHGF-!CJ)I.SL6EJ[(_K8DTX
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MO_F7?.S'=Y]]U>T?CYUMTWU/D-OX#=^Z)*?#X:LS5+C]#8VDN5^[J@SBR)J
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M]XTLL(J8O4W@K098V!(!//I! NJWKGN*>2UDBR+=W;\F%,]4L.7A 93)DR@
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MZ@[EVG\F#@ZC>^S.U=PU.SLMB,C24OK$.1EG3[BA636!&LS K8,+J&!U#O\
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M4XS0MQ8D<3T_MVU76ZW7U6X5SQ/R]!4#[!@ "O5P,'A'^40V#:1?Z@<?Z_\
MC[AHZ_Q]#_\ 1_T#K-[<Z;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NN,?_  +HO]C_ ,3[56O$_;_DZ3W/P_ZO4=#5['W0?Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7N@NW-_Q<_\ R&#_ 'H>PIO/#H\VW_*?\/31[(NEG7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW6#_ "DP4/W/%7J'U'^M_P :]M-^OTLGQPZ[/Z5^XO\ :7Y_
MXU^/;\WP_P"KUZ19^GZX:&%N&_V%C[?U0V_]C!TJ\<MQ/70!L1/SS_Q'^]^[
M1W&C]&'KT\OTW'KJX_V%_P!.C_??[U[;\!?B\?IKP+?^WIURN?Z'_>/^*^TG
MB=/_ %77M#_\KI]T\/Y=>^JZS<?U'_)9]J? MO3IKPX/7_#_ )NN,4-B/J;G
MZ<?7\\^ZP_XG-UJGU8ZP>+B]-8W/%OZ_Z_U]WN._^Q[.O2_XSQZY&.RCZVU<
M6'O2R?[^X],P05ZR'_IH'UM_O!]U:.&X_1'9_P .Z=GN",_RZPZ_^F+Z?X6]
MN30_[^[^M5],=<]-/_L>#<+_ ,:]TNYY9_UO'Z4+/3%/\'7.X_X#_8\?TXO_
M +;WK3-_O_I/]/UF]J/"A].GJGK!Z/\ :[?[#_7]MZ/]!Z9^H\^N<37)_P @
MYN" /\/]\?;2+#+_ &WZW6X(#:\,=>,O];CFW%OR/Z>W96F?KWC"YX]<_P#,
MG\@@_P"V]I?U5^?5\6I\^N'^9']KZ_X$_3_;?0>U_'^ATQU#LL'TKF%_Z<_7
M_6_UO:+P^G?'/I_@Z</;G377O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UPA_X$T/^M_Q7VJM>)^W_)TGN?A_U>HZ&OV/N@_U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=!=N;_BY_^0P?[T/84WGAT>;;_E/^'IH]D72SKWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MN$/_  )H?];_ (K[56O$_;_DZ3W/P_ZO4=#7['W0?Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7N@TW/#IJON.>4:P_P!;C_B/8/WG^V_U?+H]VW@.DE[)^E?3A[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][>FX]>Z]2_P#%RH?^UH_^]^_6G]OU2YX?ZOET-'N0N@UU[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=(#=\>HT-2%^E@1_C_P B/L.;Y%T9V/F.DM[#71KU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW3AAH_-DJ'Z6 +_7^GM9MT%9Z?/IN\:BG[.A8]CSH-]>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW2?S5/\ =XRKC Y,?'/X0>R>^A^J@KTJM6T-3H-O,?\
M'_;#V$M!Z$GC'KOW3IGKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZPP?H/_!C_O0]MR=/0\>ECM:A#$Y!C;EE !O[%6SQ
MY'^KR/1+?SXITO?8BZ*^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@LSM']
MCE""/\DK;7%[_BY^OU]@7=K:DV.CZRN:CIJ]H>E77O;W@GKW7O;/7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL-/1U4U0U,+'Z?X_4
M?\4M[O90_4'IV_(&>A@HZ=*>E$4!%@"%OS:YY]CNWM_I^@HS:CU.]JNJ]>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-F3QE/E*?[>HX4<\?[[Z>TMQ;^/Z<
M.KH^CH+JV"JH:HTYM>W];@_T]@62TKT*+:Y!'7I?\XW^P_WH>V^E%UUC]^Z2
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6!8O,#8_ZGZ^VD/6
MP:'H1,#BS1TOW%4+57(^O^V_V_L:;;MW@9Z)KV[U8'2K]G/1?U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,N8P]-EJ9:>H919;*QX^GLNFA
M^IZNCZ.@\J\?4T=5JG-]0U @WX_'(_V/^M["M_;>%T*+6Y^KZ;O.G]&_VP_X
MK[1=>T'KK4W^J/\ MA_Q3V[H'3WA#_5_Q?6'6?\ #WOP3TS1>IOMGJG7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UA\Z?T;_ &P_XK[>\$];IUF]L]:ZQPP^?_)Z?BUOQ?Z_D^U$,/C]6)Z$
M'%8)::]54&]5<VMS_OB?]]Q[$^W[8;?HFNKW7PSTJ_9ST7=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U#J*:EE ^X (']3_7
MVB^E/^K_ (KK8-.DO7;7IY%#T'^1'CD?3_7M<F_LMN=N-:=&-O?4X_RZ24N'
MR=%ZOL24_+ W'U^G!]DTVS3'HR_>8]>H<L57!_4_F_U]H_"F^?[>GA0\>NOQ
M_E7^P_K_ (_3\>V^K?Z7K-[]TWUA]'^U?[Q[OH/3WC'KCHC_ *-_M_?OI>J?
M5=<O1_M7^\>_:#U?QCUF]W\$],]>]^\$]>ZCZ(_Z-_M_=/I>K_5=<O1_M7^\
M>_:#U?QCUSUC_'W[Z7JGU77+S'_'_;#W[0>K^,>N.@?X^[^">F>N'H_VK_>/
M=-!Z>\8]<]8_Q]^^EZI]5UP]'^U?[Q[]H/5_&/7'1'_1O]O[]]+U3ZKK/YC_
M (_[8>_:#U?QCU@T1_T;_;^_?2]4^JZY>C_:O]X]^T'J_C'KWH_VK_>/?M!Z
M]XQZS>[^">F>H^B/^C?[?W3Z7J_U77+T?[5_O'OV@]7\8]<]8_Q]^^EZI]5U
MBT1_T;_;^_?2]>^JZRZQ_C[]]+U[ZKKAZ/\ :O\ >/?M!ZOXQZ]Z/]J_WCW[
M0>O>,>LWN_@GIGK#Z/\ :O\ >/=-!Z>\8]<]8_Q]^^EZI]5U[6/\??OI>O?5
M=<O,?\?]L/?M!ZOXQZQ>C_:O]X]^T'KWC'KGH'^/N_@GIGK%HC_HW^W]T^EZ
MO]5UR]'^U?[Q[]H/5_&/7'1'_1O]O[]]+U3ZKKEZ/]J_WCW[0>K^,>LOF/\
MC_MA[]H/7O&/6#1'_1O]O[]]+U3ZKJ1[OX)ZIUA\"?U;_;C_ (I[9ZOK/67S
M'_'_ &P]WT'J_C'KWF/^/^V'OV@]>\8]=^Z=,]8?1_M7^\>[Z#T]XQZR^8_X
M_P"V'OV@]>\8]8O1_M7^\>_:#U[QCUQT1_T;_;^_?2]4^JZ]HC_HW^W]^^EZ
M]]5UR\"?U;_;C_BGNG7M9ZR^8_X_[8>[Z#U?QCUW[ITSU'T1_P!&_P!O[O\
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MJ'3'U'V=.46/JIC_ )/0<#_"WX]M"UFN>M&Z _U?['3U2;<K#Q4:01]?5?\
MXG\^SJ#9*]%[;F!_J/2QI,=2TBD4Y 'Y]5_^*^SVVM/I\]('N3)C'3K[5],=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW3?[3]>ZR_;TW^'_4S_C?MKZ4_ZO\ BNO=8/L:/_E4
MA_WC_H[W[PX/0?SZMK/7OL:/_E4A_P!X_P"CO?O#@]!_/KVL]>^QH_\ E4A_
MWC_H[W[PX/0?SZ]K/7OL:/\ Y5(?]X_Z.]^\.#T'\^O:SU[[&C_Y5(?]X_Z.
M]^\.#T'\^O:SUR_A]'_RJ+_ME_XK[]].W^H]:J>N/V-'_P JD/\ O'_1WOWA
MP>@_GUO6>O?8T?\ RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_T=[]X<'H/Y
M]>UGKWV-'_RJ0_[Q_P!'>_>'!Z#^?7M9Z]]C1_\ *I#_ +Q_T=[]X<'H/Y]>
MUGKWV-'_ ,JD/^\?]'>_>'!Z#^?7M9Z]]C1_\JD/^\?]'>_>'!Z#^?7M9Z]]
MC1_\JD/^\?\ 1WOWAP>@_GU[6>O?8T?_ "J0_P"\?]'>_>'!Z#^?7M9Z]]C1
M_P#*I#_O'_1WOWAP>@_GU[6>O?8T?_*I#_O'_1WOWAP>@_GU[6>O?8T?_*I#
M_O'_ $=[]X<'H/Y]>UGKWV-'_P JD/\ O'_1WOWAP>@_GU[6>O?8T?\ RJ0_
M[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_P!'
M>_>'!Z#^?7M9Z]]C1_\ *I#_ +Q_T=[]X<'H/Y]>UGKE_#Z/_E47_;+_ ,5]
M^^G;_4>M5/7'[&C_ .52'_>/^CO?O#@]!_/K>L]<OX?1_P#*HO\ ME_XK[]]
M.W^H]:J>N/V-'_RJ0_[Q_P!'>_>'!Z#^?6]9Z]]C1_\ *I#_ +Q_T=[]X<'H
M/Y]>UGKWV-'_ ,JD/^\?]'>_>'!Z#^?7M9Z]]C1_\JD/^\?]'>_>'!Z#^?7M
M9Z]]C1_\JD/^\?\ 1WOWAP>@_GU[6>N7\/H_^51?]LO_ !7W[Z=O]1ZU4]<?
ML:/_ )5(?]X_Z.]^\.#T'\^MZSU[[&C_ .52'_>/^CO?O#@]!_/KVL]>^QH_
M^52'_>/^CO?O#@]!_/KVL]>^QH_^52'_ 'C_ *.]^\.#T'\^O:SUR_A]'_RJ
M+_ME_P"*^_?3M_J/6JGKW\/H_P#E47_;+_Q7W[Z=O]1Z]4]<?L:/_E4A_P!X
M_P"CO?O#@]!_/K>L]>^QH_\ E4A_WC_H[W[PX/0?SZ]K/7OL:/\ Y5(?]X_Z
M.]^\.#T'\^O:SUR_A]'_ ,JB_P"V7_BOOWT[?ZCUJIZ]_#Z/_E47_;+_ ,5]
M^^G;_4>O5/7OX?1_\JB_[9?^*^_?3M_J/7JGKW\/H_\ E47_ &R_\5]^^G;_
M %'KU3U[^'T?_*HO^V7_ (K[]].W^H]>J>N/V-'_ ,JD/^\?]'>_>'!Z#^?6
M]9Z]]C1_\JD/^\?]'>_>'!Z#^?7M9Z]]C1_\JD/^\?\ 1WOWAP>@_GU[6>O?
M8T?_ "J0_P"\?]'>_>'!Z#^?7M9Z]]C1_P#*I#_O'_1WOWAP>@_GU[6>O?8T
M?_*I#_O'_1WOWAP>@_GU[6>N7\/H_P#E47_;+_Q7W[Z=O]1ZU4]<?L:/_E4A
M_P!X_P"CO?O#@]!_/K>L]>^QH_\ E4A_WC_H[W[PX/0?SZ]K/7OL:/\ Y5(?
M]X_Z.]^\.#T'\^O:SU[[&C_Y5(?]X_Z.]^\.#T'\^O:SU[[&C_Y5(?\ >/\
MH[W[PX/0?SZ]K/7+^'T?_*HO^V7_ (K[]].W^H]:J>N/V-'_ ,JD/^\?]'>_
M>'!Z#^?6]9Z]]C1_\JD/^\?]'>_>'!Z#^?7M9Z]]C1_\JD/^\?\ 1WOWAP>@
M_GU[6>O?8T?_ "J0_P"\?]'>_>'!Z#^?7M9Z]]C1_P#*I#_O'_1WOWAP>@_G
MU[6>N7\/H_\ E47_ &R_\5]^^G;_ %'K53UQ^QH_^52'_>/^CO?O#@]!_/K>
ML]>^QH_^52'_ 'C_ *.]^\.#T'\^O:SU[[&C_P"52'_>/^CO?O#@]!_/KVL]
M>^QH_P#E4A_WC_H[W[PX/0?SZ]K/7+^'T?\ RJ+_ +9?^*^_?3M_J/6JGKW\
M/H_^51?]LO\ Q7W[Z=O]1Z]4]<?L:/\ Y5(?]X_Z.]^\.#T'\^MZSUR_A]'_
M ,JB_P"V7_BOOWT[?ZCUJIZX_8T?_*I#_O'_ $=[]X<'H/Y];UGKE_#Z/_E4
M7_;+_P 5]^^G;_4>M5/7OX?1_P#*HO\ ME_XK[]].W^H]>J>N/V-'_RJ0_[Q
M_P!'>_>'!Z#^?6]9ZY?P^C_Y5%_VR_\ %??OIV_U'K53UQ^QH_\ E4A_WC_H
M[W[PX/0?SZWK/7OL:/\ Y5(?]X_Z.]^\.#T'\^O:SUR_A]'_ ,JB_P"V7_BO
MOWT[?ZCUJIZX_8T?_*I#_O'_ $=[]X<'H/Y];UGKE_#Z/_E47_;+_P 5]^^G
M;_4>M5/7'[&C_P"52'_>/^CO?O#@]!_/K>L]<OX?1_\ *HO^V7_BOOWT[?ZC
MUJIZX_8T?_*I#_O'_1WOWAP>@_GUO6>O?8T?_*I#_O'_ $=[]X<'H/Y]>UGK
MWV-'_P JD/\ O'_1WOWAP>@_GU[6>O?8T?\ RJ0_[Q_T=[]X<'H/Y]>UGKWV
M-'_RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_P!'>_>'!Z#^?7M9ZY?P^C_Y
M5%_VR_\ %??OIV_U'K53U[^'T?\ RJ+_ +9?^*^_?3M_J/7JGKC]C1_\JD/^
M\?\ 1WOWAP>@_GUO6>O?8T?_ "J0_P"\?]'>_>'!Z#^?7M9Z]]C1_P#*I#_O
M'_1WOWAP>@_GU[6>O?8T?_*I#_O'_1WOWAP>@_GU[6>O?8T?_*I#_O'_ $=[
M]X<'H/Y]>UGKE_#Z/_E47_;+_P 5]^^G;_4>M5/7'[&C_P"52'_>/^CO?O#@
M]!_/K>L]<OX?1_\ *HO^V7_BOOWT[?ZCUJIZ]_#Z/_E47_;+_P 5]^^G;_4>
MO5/7'[&C_P"52'_>/^CO?O#@]!_/K>L]>^QH_P#E4A_WC_H[W[PX/0?SZ]K/
M7+^'T?\ RJ+_ +9?^*^_?3M_J/6JGKC]C1_\JD/^\?\ 1WOWAP>@_GUO6>O?
M8T?_ "J0_P"\?]'>_>'!Z#^?7M9Z]]C1_P#*I#_O'_1WOWAP>@_GU[6>O?8T
M?_*I#_O'_1WOWAP>@_GU[6>O?8T?_*I#_O'_ $=[]X<'H/Y]>UGKWV-'_P J
MD/\ O'_1WOWAP>@_GU[6>O?8T?\ RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[
MQ_T=[]X<'H/Y]>UGKE_#Z/\ Y5%_VR_\5]^^G;_4>M5/7'[&C_Y5(?\ >/\
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M-'_RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_P!'>_>'!Z#^?7M9Z]]C1_\
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M_P#E47_;+_Q7W[Z=O]1ZU4]<?L:/_E4A_P!X_P"CO?O#@]!_/K>L]>^QH_\
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M_*I#_O'_ $=[]X<'H/Y];UGKWV-'_P JD/\ O'_1WOWAP>@_GU[6>O?8T?\
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MNDK"$:B3BF?M]:#USCJP4UHIY!3$<BP!O<C_ (W[2AB,=+--17J=Y_\ :/\
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M2-4J)))5\ !,H(&)&*UJ0/L\ST77EX+92J$A@0"0*Y/D,4!]/6F*GH@O:?\
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M(]>M=2O.NC[G^S;1:_\ L;W]L:O/\NO=1OXC_A'_ ,E^]:SUNAZ]_$?\(_\
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MJ<C)QI*O5[K:FN #^M?R3_K5,6O)T_L'']O6IY;A:41_*M7( ^SM/^3HVO\
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M=DZ9(KI24N"H&B"4M/(KL9:NQ+?1/3,)9M(J0-)-?G0X^722.#Z*V29@M:$
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MC]44=*#^IZ;)2K%3_06-1,K)>_X]K[%ZR4KP=?SX_P#%=%&_34@:@K^D]?\
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M<R*ZE&I5#T+=P]*Y^T</R_U5565M],Q2!RIU4#9H?4$L37[/MK7RVBX/[?\
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MWH6/YV78_8>POF=_(RP.S-\[QVCAM]_/"FP&^,7M_=-?C*;.8^JK-O'[/)M
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MHVAU))W'U7783:V^]X[^"KE<ABYLC2Q8W-I1BJE5)(D,/^1PZ@$876K,(?U
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M'?RJ/YD6,^6?>_7V:ZEFVKV+\5]S["VIMNMW_1'%UN3K=_5T";=;&4$595/
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M-./R_P!7Y]))$F0+(OQEU:E">!(S^W-:4'Y @5\Q-Y?,3^83_,&_E-=O[$^
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MLKI'J3+;SWE@H>S*+#"@:KVQ3P2Y!:RF\<J3"32/)3V8C@^WX'BBH0,9]/\
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MYC?$_OCXR[N: 8/N3K#.[0BG?T24F3J0AQ.34QC6'Q>8C@JHQ<>1[CZ7]MJ
MQ8GSK^WB.C6Y&A%3T-<\*4S@_+K67_X3R;9[K^6W>V1^;/R7P<2?[)#\=-C_
M ,M7HW.5M,U?0U.2V'+4T^\<]BZQCX:F0B,T8F@UQVK9XI#<$>U5Y(B*= %0
M !@\1Q\SZ</GT3;;$YD$C-51@'4#5"*@F@ -:C(QC'$]'*_GVXX?)#LO^6-_
M+]VE1R9_>/;?S&V;W'O;"X.F:NJL+LKIA-.6W)78^$-+38:!:V>.*HD"P?<(
MR"34=/M*8ZU^9_D//\L]/[GKN@BJ:%5 \ZG5^'AQ/IZ$];.5.0==B#]/H?\
M7]I4!''HX!!X=2?=^M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TW^T_7NG#VHZ]TW^T_7NO>_=>Z][]U[J
MBG._&S 5_P#/AV1\HY/D;T50;EP_PEWGUK%\9*S=L478=>E3FX*B3<L>%,NH
M;=A!B@DJ#$.1;QD$N#(ARE<?"<9K3_-T7)X N6 \V4DXH" U/SR<?+J];V6]
M&/3A[4=>ZCS_ -C_ )"_XCVW)U[J/[;Z]U(@_M_\@_\ $^W(^O=2/;G7NO>_
M=>Z][]U[IO\ :?KW7O?NO=>]^Z]U[W[KW3A[4=>Z][]U[KWOW7NF_P!I^O=>
M]^Z]U(G_ +'_ "%_Q'MR3KW6./\ /^P]J(^D_4SVWTHZ][]U[IO]I^O=>]^Z
M]TX>U'7NF_VGZ]U[W[KW7O?NO=.'M1U[IO\ :?KW4B?^Q_R%_P 1[<DZ]UK]
M_+KXG_+JL^=L?RJ_EV_+OJ[:?>E-U?@]@]W_ !8[]RU;N[:N6Q-/.G\)S#X;
M#UHK,-F530L=6ZDSHHE24%GC*^-*I4&AI0@^G\^BF[Q<X )KVD'(/G@T_P!5
M/3(+]=_$_NG<?\P/XT?*G^;K\P?BJO<>S,;O3;WP4^(/5%=_<;&R[AS-+!_'
M,K!#N2L7,;FSM)2-3ZTHHO(@$1+B,+&:!BT):(+BH"X J>/$Y(IY?F>E1A*3
MQB5VJ0"#0DZ16@P"0IJ :XJ 0.MG3V3]+.BP_)##].;AZ/[,P'R%J\!BNF<Y
MUEO'$=HUV\,Q!A<=3;>KJ()EZBMR-8WCI(XJ4C7, 0CZ'-K:@9("S$+@9KZ4
M\^/GTU*T:Q#Q!4UJ/M_+R^71+_Y3O4_8O1/Q"VUTONGM+8?>74NP,CDJ#XJ]
MY]>Y]MQKN/JW):*O9T^2E$C47\1H<5/!1HU+)-0.*=7%PRRN_< J03FG#U*U
MQC_4.DU@$\'2GF.[A0$8XC'V_M^75MWM-TNZ][]U[KWOW7NO>_=>Z][]U[IO
M]I^O=>]^Z]U[W[KW3A[4=>Z][]U[IO\ :?KW3A[4=>Z][]U[KWOW7NF_VGZ]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3A[4=>Z][]U[IO\ :?KW
M0$]R3]I4G5.^YNEL?@,OVPNU<D>MJ3=]7)08HY;[%1B/XN\;AC0C(7-0$;DV
M!M?4%BDZ34>0I7[.F9@NH>&<5S3[?+JOS^4OT3U!\?/BQ-USU[W1L/OSLR+M
M/L;<?RI[.Z\WI1[M%9VOGZY:S>L-=)CF9J*NHJU%I6H95^[BI""%&H@J)A(I
M &34ZO/N\_\ 5]O2.Q6#16OD O\ I?+]M?RQU;S[*^C+KWOW7NO>_=>Z</:C
MKW4>?^Q_R%_Q'MN3KW4?VWU[KWOW7NO>_=>Z</:CKW7O?NO=-_M/U[IP]J.O
M=>]^Z]TW^T_7NO>_=>Z][]U[IP]J.O=>]^Z]TW^T_7NO>_=>Z][]U[KWOW7N
MO>_=>Z</:CKW7O?NO=-_M/U[JD#^75TG0]/?)GYMYCXS=L]-=L?!#NOM#,]F
M0XKK[?%!NJ78/=0K(*;?VV4AQ#K1+096U%5K!(WW>+K%\%M#1O*92K33FM37
M'DWF,?E_+HOL6H\F@=JBF:]R4P<^@^="*_/J[_V6]&'4B#^W_P @_P#$^W(^
MO=1_;?7NO>_=>Z][]U[KWOW7NL2?YO\ V'_$>UDO'KUM_J_EUE]H^O=>]^Z]
MU[W[KW3A[4=>Z][]U[IO]I^O=.'M1U[IO]I^O=1_?NE'4CW[I/U[W[KW7O?N
MO=>]^Z]U[W[KW3A[4=>Z;_:?KW4?W[I1T\>U'2?KWOW7NF__ "G_ )M^W.[_
M %4Z3]>]H^E'3A[4=>Z;_:?KW7O?NO=:]/R,^*?SBV[\]NS_ )9?RYOEMU/5
M;NW=LO ;.^1'Q'^3&:R6[]NQ5&#Q]*<)G,70XF=9MO9&MQ<>.OY*+6\3-HD:
M%VC4S0 1U)\AJ!!X^5*>?IT63R3,_P"BIK4E2M*\<U!SZ\/M/2/^,WQ.['H_
MYD>Q?E/_ #-_F#\9MX_-^?J3=>R/A_\ %?I^M795-@]NO+4MN')XC%9[('<>
MX:IQ]_'/6(LBPJ)I6ED9@J:8KHK0'T%: #\SD]6@@D) ED8,#5R14L?E08'R
MI]M13K96]I>C'J//_8_Y"_XCVW)U[J/[;Z]U(@_M_P#(/_$^W(^O=1_;?7NO
M>_=>Z][]U[IP]J.O=-_M/U[KWOW7NG#VHZ]TW^T_7NLDGX_V/M9)TGZR0?V_
M^0?^)]IX^E'56G\Q;8G\Q?L/96R\%_+N[AZ*Z;W#6Y#,8WM/-=T;8J<]+_#,
M_30T]%58*>B!^SR&,KA/,;*Q\K1F-F*Z"IM58K1RH-<UX=)+]R6)*M3R -/G
MY_L^SIH_E2]'?''XS?#':'3_ ,=.YMF_(K ;3W/N./M3N':VZ*3>E-G-^UE=
M,^[:NKJ\=5Y!4R?\6#+]N2&I[(/5JN:W8)X^7&G$G[!TWMHB@33'W @::FH"
M4&G+$XIPR<4 QT$6P.CL>O\ -J[(^2GRB[<ZB/<55U=E^K?@?\;:;L#'G<='
MUSB:G[K=6ZSB:P?Q&JR.>S;!9Y*0BEQU HIR]KJ'B#2H]"*?T?,_GU6-1XW?
MPJ"O'XL4!%?+RQ7J[>C_ $2?['_>O;3_ .;_ "]*8.G#VWTHZ][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
$>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>timage_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
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M=>]^Z]T0#^;%_P!NLOYEG_B@'S(_]]UN/W[KW5;7_"53_MQY\3O_  YOD?\
M^_)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\ "B3_ +?<?\)S_P#Q:WJ__P!^WUS[
M]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54O\ ,+^7?SC^
M&.[MC]K]-_"K)?-#XCP;7K(^_,+TYG1'VAMJNI)ZF5,S@<#*'BW-BOL?$M11
MQ(*E9560300^5_?NO=5\_+_Y/_'W^?+_ "U^\.C?Y>G;VS][?(&GRW6N\\Y\
M5.ULG)U%NBM7JK=6-S.7V?N/#5\]'6TE+E:?%U=')5Q//CO,51JO06=?=>ZJ
M'3X?_*[Y?]@]&=/;!_X3>_'[^6%EMF?(GHOLO='S4PN\=N8VIVUB^J-P46;R
M38Q\5@,36Y6?(T^/DIHXZ>IKP\DT9=5!^[A]U[K?8]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1 /YL7_ &ZR_F6?^* ?,C_WW6X_?NO=5M?\
M)5/^W'GQ._\ #F^1_P#[\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT6 ^I]["D]:+ ==:U_K_O'O>@
M]:UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]
MH/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>
M_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O
M'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_
M[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^
MO^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U
M_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKV
MM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z
M]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6
M.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>
MUCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/
M7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:
M#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'O
MV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q
M[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^
M\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K
M_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?
MZ_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K
M7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.M
M+'_A1&0?YW'_  G/M_WE;U?_ ._;ZY]Z(IUL&O6ZA[UUOKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZIE_F=_S,/D#\3^T^A_BK\*/AQEOFM\NOD!M7L+L
M;$[&;?%)UYAL!M?KIZ2EJ\WEZ^JLL@FR-?3P0PM4T<)"3:ZV.4TT-1[KW5,.
MV.L=I?S6?E[D?C/_ #1/Y;6Z?Y7_ /,FHNF\C\C?C]\N/BUVM!C<[E,7MK(1
M8:JJ8MRX'[JBK<EB:S(1L:?(5>2=(=5C0N\)E]U[H^.TMT_SQOY:&[MM;.[A
MPF%_F\_#&LW'B=OKWILJ"/K?NG9N-R53)",AN?"#[FDW918V%XGJ)Z;[JKDC
M22HJ:VG4:/?NO=;(_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(!_-B_[=9?S+/\ Q0#YD?\ ONMQ^_=>ZK:_X2J?]N//B=_X<WR/_P#?D[K]
M^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NH=3+XV4?U6_P#ON/;\2ZATGF:AZC_<_P"/^^_VWMWP^F=9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9ZTN_^%#<GD_G;_\ "=$_D?*[J[_W[?7/MF5=-.E$+5KUNL>V>GNO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JA'^;1\7/A'\LN_P#XW[+["^?.
M_OY?/SLVKM/=5?\ 'GLOJ7N,=,;DS6V]VU#09?"4DU5/0T^;A-=C(YVI:.OC
MR$!0,2*:I=9?=>Z$O^7=_)GV7\(>[=S_ "H[%^77RO\ G/\ )/<G7%1U)@^V
M?E'V94[X."VQD\A!E:S'X2GJ)ZN6-LC64M&\\T^0J;+"%I$I%J*S[KW7NKHF
M954LQ"JH+,S&P 'U)/X ]^Z]T7C87RU^,_:G<F]/C[UAWCUKV-W'UMMV#=/8
MNP]B;JI=VU> HZN>&FA_C)H))X<94SR5$9CIJB6.I="95B,8+^_=>Z,1[]U[
MH!/E7VINOHOXO?)'NW8>S:GL7?'3O0?</:FS>OJ..>6;.Y7KW;V1R^.PT2TL
M%34M)E*RCAIE$--+*6E CCD>RGW7NM8WXP?"BN^6_P#+%PW\S#M?^:/\U\?\
MM>T.I*SY-2]^;&^3^1V-LWK[*;<I#7#:E%L:CDI]G1[:P4M!)09>BK,=++4,
M^1"U$'EA\/NO=&$D_F\?)#$_\)T^J?YA^1V2B?,CN+8VV^I^O,'D\-#A(LGO
MG>>\*K86$W-'C:OPT\E%E$IUW)!3J!35%+(@C*TL@=?=>Z:/DM_*T^0WQ'^&
MN^?F-T%_,$^=N\OYA?QRV)NSY*[OW5O[NS.]J;4[(KMFT%9G-Q[+R'63U$>V
MAM_*TR5=#AZ2@Q\510M'CRDE5+"?+[KW5]?PU^1F*^7GQ/\ CG\H,-BI<#0]
M]=-=?=HG 3-Y&Q\^[L;3U=7CR]V$GV-5)-!K#$/X]0)!]^Z]T97W[KW1 /YL
M7_;K+^99_P"* ?,C_P!]UN/W[KW5;7_"53_MQY\3O_#F^1__ +\G=?OW7NMB
M3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]TT9&0)*@()O'_P 2?:B&I'2&Z?21]G3?YQ_J3_M_;U#Z])?%^?7O./\
M4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_
M &_OU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]
MO[]0^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V
M_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;
M^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_O
MU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0
M^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#
MZ]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/
MKU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]
M>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O
M%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\
M7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q
M?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y
M]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7
MO./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>
M\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[
MSC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X
M_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]
M2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U
M)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[SC_4
MG_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X_P!2
M?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?\
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M\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\
MJ1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_
M &_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^
M\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%
M\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_ &_OWA?+KWC'KWG/^I'^W]^\+Y=>
M\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KW
MG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG
M_4C_ &_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'
M^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;
M^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_ &_OWA?+KWC'KWG/^I'^W]^\
M+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KW
MC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QC
MUIY?S[WU_P [+_A.]?BWRRZHX_\ *M==^RK<ETE?S_R="/8GUJ_VC_+UO#>R
MSH_Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM,S_A5-EY^Q._?Y47PX[Q
M^06XOC/\!ODAVSO=ODKV)CA%1XUZG:=?M:+'/EZV=&I*:/%PY*H>GFKBV+Q\
MU7_&:^GJ(\8A@]U[I'_S(OC3UA\Z/YT'PK^"7S*^1&^=M_RZ=J?!F/?_ ,>8
MZ7?.+V?B.P^P-G5\F'RU%'N**"+%5VZ),0U-/6K2QK5TU%!''104,>5,T_NO
M=%1^2OQ)^)?\FS^<5_*E;^53W=NVC[*[_P"^]H=6?(KXH4/9%9VS3MLO=N9Q
M6#JLGDC#425U-2U])DLR4ILK/4QBJHH\I0)!_#)[^Z]U]!'W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?]NLOYEG_B@'S(_]]UN/W[KW
M5;7_  E4_P"W'GQ._P##F^1__OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05;]DTY&C'%OL@?I_P W
M']GVU+5#_IO\@Z"',3Z95_TO^4](7S#_  _VQ]FF@]![Q?GU[S#_  _VQ]^T
M'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>
M\P_P_P!L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_M
MC[]H/7O%^?7O,/\ #_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O
M>+\^O>8?X?[8^_:#U[Q?GU[S#_#_ &Q]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\
MP_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P /]L??M!Z]XOSZ]YA_A_MC
M[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\ ;'W[0>O>
M+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_
M  _VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV
M@]>\7Y]>\P_P_P!L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOS
MZ]YA_A_MC[]H/7O%^?7O,/\ #_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#
M_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_ &Q]^T'KWB_/KWF'^'^V/OV@
M]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P /]L??M!Z]XOSZ
M]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\
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M]H/7O&'7ON&_U?\ R;_QKW[0>O>,.O?<-_J_^3?^->_:#U[QAU[[AO\ 5_\
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M7OV@]>\8=>^X;_5_\F_\:]^T'KWC#KWW#?ZO_DW_ (U[]H/7O&'7ON&_U?\
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M1'_S3_Y^;H)=;?U_WCV(- Z!?7M;?U_WCW[0.O=>UM_7_>/?M Z]U[6W]?\
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M&U<1UUBOBGV%A>N\;)M>FRU'MRLZ\VY4U&ULI04#&&-:C;V0H:"JIO'+ ZO
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M#VY64G4ORMS&Y]^=-;PFH7IXEW9M:C%!DH8Y]&BJI<G282*ED'D+TU92TBA
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M^+_SQZ!WC@>CMIY+%[>W1VM#-GL'L^GW/2XK&9.GW7C)L8*C&Y'^#TE+5RK
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M5D&,R&.KXY8H3+X//#4/H6NCN(N80T[).N8V0!3Z')H:>>:_M'D>K,*8]/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FO\
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MU;34]91U$%725<$532U5-*L\<L<ZADDC=25='4@JP)!!!!M[#?5.JH_YG?\
M-BZP_EOX79-#)M&D[H[<WOD?+2]3T._(MDU%'A88YO-FZ^K&,S4E+ U2D4%-
M&V/O5.9C'(%II?9KM>UMN;$ Z5 RU*Y].(S^?5M.*_L^?^K_ #='T^-/<O\
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MEAAQTL;>Z]U]$WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
M_FQ?]NLOYEG_ (H!\R/_ 'W6X_?NO=5M?\)5/^W'GQ._\.;Y'_\ OR=U^_=>
MZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW1>NX/^+WC/^U4/^MTGL7\N_V3?Z;_ "#J,^=_]R(_^:?_ #\W02>Q
M#T"^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOO:5!O[8^\MB95Y(\7O7
M:FX=I9*2*^I:?<='-1S,NED;4(YF(LZF_P!"/K[V#0UZVK:2#Z&O6JE_+S_F
M"[9_E++V1_+H_F X7<W7E5U7OG<>Y>M.TMN[;JMV8K(XG=TJU:EH*%:BO>FK
MYFEK:&J@I9E*5$U)6I1U5&5E%-_8-N]+FWHVH ,M0"K 4\Z#&/\ "*@]78#_
M #?,5_/H>M^?S</DO\].U9/C9_)^V3#'4XW&+F]_?)SM[ P8^@Q-&Y2-9Z/&
MY."L@I(1/(L8>NQM75U3B5*7%%(C4E.FTQV"^)>&E3VQJ06:A\SZ?8?,9!QU
MX ?[.:</VU_U9\DINKY9_P X/^5A6[:WY\]EZZ^87Q@W#GJ/!;JWYU)2TM-D
MMNS9(CPK%4QX+:;I)*1)XER6*DHZB4+2)D*266&]UM+3="5MM4;@85_A;C7S
M8U_/AY')ZT*$9_EQ'^2G0K?)O_A0O\/Y>B-UXWXQUN_.SN^M\[>R6U=@[0J>
MN,IA(\=E-Q0-2TM5E):I:>*ICIII5<4]!/4S5$BK"IC5S,C,'+\Y<>* B#+-
MJ7X1QI0GR]13UZVH /&OI0')_ET1+^6?\V:S^3E5[U^$O\Q'8^\NK,=N^IP/
M?NP=UXW'OO>/'C?F+I*6LHZN#'R5,ST+28I8@]!%4"#*09&&9#J,R+]RL_WS
M2XM:-2J,/A-5.#FE<$<?*GV#Q&,G_**>G[:_ZN.?^9;\XJO^</)M'X/?RZ]A
M[S[5I-O5F4[UW[N[)4@V-%D(MA8ZK@IJ*DI\H]+-'1+-DT5I:X4OFR+T-/#&
M01*VMMLOW,?J+JB_@4#N-6\\5& #ZXK\J^ P:'CQ^ST_;3_56AX/BQ_PH4^)
ML/1^W,!\L)M^=0]_]>8:FV=O_;"==Y3/0Y/)[7A6EGJ\<]%#4&B-7+$3+29#
M[22DJ3+ 6EBC6ID17/+\P>L(#H<JP9>!X5J1Y>8P?Y=:8 GT^6<?X>JFL]\X
M/DCN;YHO_.ZVY\>]UM\.NM=WXGX\Q09.JH**KFVWDZ"IQ4T4EIIF^]:KR3U+
M5,(DH*?*5%-C#63!9"306,2P_0EQXK5D\RH8>7YJ//RJ:<!U8</E2GS.>/Y'
M_5QZN.[?_P"%'?P=VWU5+N+I>#L3MGMK*X\1[<ZMKME5NSA2U]7$3"N;R=4A
MHDIH9M*2_P .FR$KMZ8593Y5*8N7;AFHX"+YL6!%/L!K^VGVCJH45XU^RN?Y
M=!%C<7_PI/[*VQC?D!C^P_COUG'-C'W%C?B]6[?Q.-R-1!-JGCH9XJ[;N5^W
MGJHA&BQUF]H*B %5DDI9_,0YJVV.J4E;/]IZ?9D?S7K9 !IC^=/]7V8Z$SH#
M_A0]\:Y]MY?:GS2V[NSXW_('K[(Y/:G8&UL9L[*[SQ53E=NS24E:N.-##65V
M/E%3#*LE'7(/M7O$*RJ"F8TGY?FJ&AI(C %6J%-#G(8C^7\N'6BH'G^7_%=
MU\-]Q;@_FJ?S9*?^8IMW8>XMD?&#XH]=5_4'6F8W(T5#69W*34N;2&&HAA,Z
M&=/[VY6OGCAJ66DC7'PS3.TS([MX/W7:?2L07D8.P'!1CS]>T?S^1ZV5 %?R
M'S^?V>7^H@;0OL-]-]>]^Z]U[W[KW6IU_P *B>[=SXC9_P 8_C[BJJHH]L;U
MRN^.SMX)!520BLEV8*"@Q%/*B%4E@A?)9"9DD##RK3R*%:($BKE: .[R'BH
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M/D4:E @K<3&3+.K1E5UOK4W)=>Q+;WC"0=OB5('\!(;%*>1ZL2"?V9/K3/\
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M:@BIH9C&TL0JIEN(;,;\MV;23>-2BH#GR+$4I^PU_P"+Z\!09\^'[>/\J?\
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MJ>FECAJYH#!+HBEHZJ%]B.8;:JDJZ\5![2WS%>!I@GA\Z&KGP\.!\\X^6/\
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MD9SM^\M9*8V42(?PGR^S!P?,4_9GJZM3UKZC_5GI-?R^_P"1]M7XF]WGY/\
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MT_EQZ\S:C^0'[ !T83^9_P#R\/\ AR'IK8G4G^E__0S_ ')[-I.QO[P?Z/\
M_2)]S]KBLGC/L_M/XW@O#J_B7D\OW,EO'H\1UZU8VO</W;(9-.JJE:5IQ(/H
M?3JO09_*/!?%'X:_RT>M/CW\TJ?=G;706)VMUE\;]Q;LVAL&:2=*O$XR7^';
MDDI*>MJIL"L55B$D@G2LJ&IZV2D@5IFE ;=N9;NY,D&'+,X&H#B:TS0'!R/,
M5Q3JZY/Y>=:?R'5'GQ8_E,?RW.Z,'D^Z-L?S(=SY_P"*4.<-3N[J;=$>-Z>R
ML;;2E6=Z?=60K<I (H?$H=9AMFCD,#B>DJ(]22@ZO-XN8&"/$JRTPU-6&_AX
M_P"$BN".G #2@#$?(FA/[!_GZ9?Y">W,!FOYKGRVWIT]B81T9M_97>-+M+(X
MR!X*&EQ.ZM[8D[8I8A)^X@J,922-!&WJ\5/(3RA]N[\Q%G"KUUDH2#QJ$(:O
MYG/39'$_.F/]7RZO%_F0?R=.J_GKNO!]R[=[#SG0GR(VU1XG'T?9. Q(SU-7
M0X*99J+^)4"5>-J36T(#)25M/DH)H 4\BU"0Q1H1[=NS[>"A =&K53\Q3CG\
M\&O7@^*>G ^8Z)AUO_PGTW+O'M+:G8GSO^:W97RQP^R!3QX;8^9.7J_/%3.)
M%HJG,YW.Y>KAQ3,B>6DI::$RCCSH 0RR7?\ 2A6WB6+5Q9:5_DJY^>>MZ@/4
M^E>'[,_ZN->ME6CHZ3'4=)CZ"F@HJ&AIH*.BHZ6)8(HHJ50D<4:* J1QHJJJ
M@    <>P[TV37J3[]U[KWOW7NO>_=>Z][]U[KWOW7NM2G^>#_P!OK?\ A/9_
MXMMU%_[]GKWV%.8_B3[&_P (ZD7D;X)?],G^!NM[;V&NAWU[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5._P SW^;]\$_Y7^%VMA_F%7[SRN6[6VUNO.[&
MZQV3UG-O^JW!3[.DI(ZRG1ZEJ3;]/+YZRE1%R.6I(V9M1<(K,ONO=:,_RZ_F
M&_RL_P"8SF\KM_X9_P#"=C>W<G8-7D*G.YO?'64E?TCN&"OS+.(*JLP/3>,S
M29A\C(:QY?XAD"LDRF4+-.3+%[KW2B_DZ?R6_P">5U7\SN@>Z<1UQVO\+_C+
MM[Y+=/=H]P[2W#\A).NH\OM';^Y<?D,YMZJVWC\Q/FL\:C;]-/0O!E,4L-6C
M""JE"O)I]U[KZ;'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(
M!_-B_P"W67\RS_Q0#YD?^^ZW'[]U[JMK_A*I_P!N//B=_P"'-\C_ /WY.Z_?
MNO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZK;^=/S$K.FZ=NJNNS-!V-G<3'69+<;1%4Q%%D-:H]*6%I
M<A.%?0PND"^OF0J%Q'^\O]X!_;B/]S;54;A/$':8CMM87+*&6HHTK:3HXA*:
MFJ=(,Z^T/M@O-+?O&]H;6-RJQ5S-(M"0U.""HKYMPX5ZH9CR>2AR4>9BR%=%
MF(JY<G%EHZN1*E:E)/*M0LX82B<2@.) ^L/ZKWY]\NEOYTG%T))!,)/%$P=A
M*)0VO7KKJUZN[575JS6O68K6\;1^$54H5T%"HT%*4TZ:4I3%*4ICJ_'X1_,Y
M.Z*6EZP[%G2#M3&4,CX[*B,1Q9ZFQ\9:2:R@)%DH(E+3Q@!)5!GB  DCBZE?
M=P^\*/<F,;/NQ"[G%&2L@%$O8D&7  HLRC,B8##]2,4U)'AM[L^UAY48[A8B
MMH[#4E:FW=C0#.3&2:*>(/:WD6&/YN?)O_93?C]N3M'&[=GWEOFNR6%V)U7L
MFEII:V3+[FWA*:?%T0A@(J)T#"6>6*$^:6*&2.&\K(#F!M]G]=*$KI&2S'\*
MC)/6-'-W,/\ 5BQ>Z5#))58X8E!)DFD.E% &3DU(&: T!-!UJ_;@_E@_S7OD
MWO-_D3VK0X:F[%R]50Y^@'8_8&/IJZF6DE:IHJ6GQD KJ;%TM*UO%0R+ L&K
M0\*-Y !DF\V-FG@I4K2ATJ:&HSDT)/SZQRG]MN:>8[@;E=&-9JAE$LHU)I.I
M0%59%51Q"U\\BI/5^7REF^5_>?\ +Z[;Z]I>@<UMOY,;MVQMS8V7V11;EPF3
MQE8F9KZ*'.9'#Y>/*-0MC9\8N2:.&JJ(*V'4D<T%S&\H6L_!M[E6+UC!U!J&
MN!4 BG&M.%1\^IQYG&Y;OL4\$=N5NY(Q$8@\90ZV579'U :=.HC5I;@"H/1%
M.R/C%\F/D[@/AK\><-\,S\:]@_'W-=89+=G?&^]];6S.4^QZVQHQ[45%3X2L
MK,C/]T&EG :>0U%6*=YS3JDL_M?#=Q6AEE,OB-(& 158"K&M3J '0.W'E[<.
M85V^QCL3:0VDD#O<2RP,X6!=.A1$\C&M:U)RP!-,GK%V;\<_E3V)B/YNV^-L
M]-[MJ>Q/D9V/UCU#U#B\NM-MI\AM'KS("CK<Q2RY&HHHGH:_!4].(]4RFZI=
M7.I#:&ZAC-LK,-,89V(J:,V0, \#U3<^7]SO8]]GA@;QKR2&W@1BBZX(J1LX
M+,HHR$D5(X#'ET;[>/Q1[-K/E!_+'VYA]F/)\>_A]UEN&HW3NH9&ECIHLU38
M&#&8FF%+]R*NIJHZS"X^5913F-%GD<REF9&0QWB"&<L>^5A04\M1)S^?0JO>
M6KAMRVA8D_Q6QBEUMJ&D/X*QQ@+6I(*@@TH 3FIH0&DZR^>?5.7_ )C7R!ZA
MZ2K,EWQ\CN\]N;!Z<@R&X,%*<=LK9M/EX*;=R+-DTI&EDHVH8XJ6HEUQ50@>
M2GDACE212)K:8012/V1H6?#9=B"5P/YCR\^B,[=O6V-NU_:6];J[N$BMU+Q4
M6WB5E6;+@5(/PL:@TJI -7CI[XF=C5?P2^2OQKP_QWW_ -0=Q]C]>5&1W-W%
MVUO;;N;R'8.Z\N\M15?=5F*RN:GI::26.2$+53+'#%5EM<DTE54&DUZOU,<Q
M=656%%4, BBF "J_R].E&U<L3'9;O;DMI8)YH6USW$D+-=3R!M3,T4DQ&<'5
MP#8J:GI ?&+I:GV#L7=&XZ'^7W\A]H?)_IOXH[ZQ.V=^=H[TK=^8E]QT&*_A
ME/AMAQ569RD<+9RHJJAU-+CJ=*2C$\$4CI+HG<NY_%;29D,;R"H5=)TUK5J*
MO#YDU/2/ES:!80M*NUW27EO9.(WGF\6/Q0FD1P%II=.LDT*HH"U%:&A==I](
M?([:?\OGXV? 'KSJ?=&)WCW_ (+<"?(7M'=.V3)A]BX+?>4K\EF4KFE"PR[@
M:BJ&HZ6D1A+%X0[O#42TLK^DN8I+J2Y9A1"-"CBY4 #[!BI/6[38[^SV&TV.
M"%@]RC"ZF<#1;1RLSR5_BDHQ1%'"E21@DRG\JKIC?O1'5'>_Q7[>ZBGP^)Z_
M[@WA#MG?.4VE#2XS?NWMTO+##D7EO+%DYO'1E9%EYCH9J&F9?VF54N\7"W4B
M3(U2RK45-48>7R_SUZ/O;79Y]BM)]MN8=*Q7$HCD*KIN87)HYH34T%"#P72/
M+JU?!;?P.U\9!A=M83$;=P]-)4RTV)P6-AQ--&U;*\\S)!3I'$C2S222.0@+
M.S,UV8DE#,7-223ZG)ZDF*)85TH HSA0 ,FIP/4FO3O[KTYU[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T7KN#_B]XS_M5#_K=)[%_+O\ 9-_IO\@ZC/G?_<B/_FG_ ,_-
MT$GL0] OKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?/_ (4I4F_*
MC^7U@)]J&J_NO0_(3KZH[.6DD$?^XJ3'9V&B:I!8!Z09^7$ J S?<-3.!I1R
M#_EO3]3W<=+:?]-C_GVO5AP/^K%>KMNBJ_JC)],=65O14VW9NFI-A[7CZQ.T
M_",<F$IJ2*+'Q4JP?M1QP4Z)&8P 8V5D8!E(!)+JU'7754ZJ\:US6OG7K3"A
MSUK=5_4/2/2/_"D7%YSL# XK;&([OZQ?L_II\A2)28N;?F<Q?\+J*F$B&*F2
MNKZK&9^93*\CR9>J1T?[FHID @\9Y]MTC\$@#9SHXBM3ZD#'I\CTYY5]1_@/
M^;K9'[P[8VKT5U!V1W!O7,8[ [:Z[V=GMTY'(Y2;PQ#^%T[R11<7:26HF$<4
M4:*TDLCI'&K.RJ0]'&96"J*DD #YGJBKJ-.M>S_A,KNSKC<'QZ^1ZM6X^L^0
M>1[ZJMT=FUU?61U>9K\+F,3C3A:R9C%'.:#^*?WB"JTDVFK:JE:1?N4C40\R
MQF.5!^ ( N#04)J./'AZ8I]O6V)85^9_;UB_X4^9+J=/BYT/B<ZN.E[GJ.ZY
M*[KH1RPQY"+!TV'KTW+(0\;S-BGJ9-OI,B-'JJ_L7+E86C??*X?QV(^'1W<:
M<13\_2OE7K0X'_5G_57J]?X;Y/I_,?%3X^9'H$8A.GI^I]F+L2+"Q^**.DIZ
M..-XI%,<,BUL-0DZ5@EB2<5:S_<*)_(/9!<!UD82?%J.JOK7/7GX_P"KAY=:
MZU7\@/C]TY_PI&J)=H9W"[5P?9&P3TCW3FZ:LCI,;-OC<6,%5'!.Y5(4GJ<E
MC]LT50$9O]RVLSN)ON @@%O)-MM34Z7UJ.)T#!X>A).?*IX=7^1XZ?\ +7_!
MP_(=;./=5=UAC.H>SJ_NR7!0]0TNQ-TR]F2;FTF@_@:T<W\2%4'X:)J7R@J
M68D*H+$#V'(PS, M:U%*<:^5.J+6N.M>W_A,ATK2;9^*G;O>62VM#0[C[/[@
MK]K8/=%13C[BMV_L/'8X(M/(5U"B7.5>7C8"2SSP.&4>)&(AYGFUSA <*HJ/
M1B2?\%.O'  _/_)T(O\ PI+JNK9/@_M'!;FCH*SMG+=U;17I>@AB^YR9J$BJ
M1F7IXX[S_9-C&>*8Z3$U1)1HP,S069Y=U"YJ,*%8OY#33_/3K:@D'\A^=?\
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ME<Y-EJW$0UE89&$-358_.T]#6TMF2-7JMLU,Z*BO+)4R^H'O[ZCG6EQ"CL:
MN.UB!3T!-?L('E0#JX85'_%_L!Z"'J_!K_-<R/9_\NS^9CMN38/SK^'$;9[9
M/?'6C4F'R5=C)Y,?#5Y!8?$V.J(JPU&$J9XXJ6*DKZ2LIJNDAQ]3 )0Y(QVK
M3<VIK%*""K D Y[3GRS0UK@BI''9[?Y<#_,?Y?\ 4 7KYZ_R8OGQL[H[,[YC
M^;G9?SBV+U/JWGD>C^SLONJAD.(VW"\]3+BZ"HW5G*>KJZ6GC8-3T\U'4R0>
M3[*0U/BIY%=CO5NS@&)8B<>(NG!./-10?//S%.M UX>?EZ_LZ:/CUVKTK0_S
M!OY77R+^%>U:3I3'?+?868ZE^1'QYVE5&HQ^.DV)(V!KA)#X0\E-(:6FK8JA
MHT-2V-BR,VBJFJW9NXC<6\\4QU&)E9'/'O/V^8\O*OV=.'/'@0?Y"H\O(X_V
M.C>=0].]?_/;^=;\[)_E9BJ;L'"?&/9E%UUU#U%NL"JQB8O+1'%2UWV,BI]Q
M#&E56UJ:D=$K<O'5HXEAI'5++,UE91"+M,A9G8<:JPIGR_+T^9K4]HQY4_F*
MGH*/Y;_;O97Q?Z0_GC=,=79W*YWK_P"$F4[FW!\=LYF'?+G'5F,&^J)9;G73
MO!*NV<7D6@C6.+SBKF8$U;NJC<X5NGM7;XI0@>E!6NC/V]Q'Y >75?R\SZ_L
M_P!7KU5GCNL>L^UOAC\3?C9U#UQC.]OY@WS[[.WKW=NOM7/Y^89+;5%L;<FX
M\%%')6SF"H:&MI,1FZBO^\\U. F3K[5$C8ZHB,S*\-Q),Y*0PJ$"@8.I1@ 8
MXD'U^$&GE89%/7_BZFN<<,?.GSNSV3_(![M["Q6R]N_-+^8WWAW!UGMP8ZME
MZ2P&5SF2QD%12Z1X<?D]QYW(TU-!'&K1"2/;$4K(UT,!4!B=]^2.I@@1&\FH
M*T_)1G\R/D>J:J$\3_*OV\>D7@]^_+GYO=H[Q^$/\L+<N/\ A9\&OAW5R=6Y
MKN[!I529+)U>(^YIS'05L>FOEFJJZ&KF2.EKX)Y8B<GDL@9:JGISKPX;)%FN
M099)!J"5H ":U-/4?*G$4Q4.'''CPX5\N !QC_BNCN?%[^2/LSK?M_;GR)^6
M_P BNU/G#W5LJHQ^0V-ENU*NO3&8FJQ=1]W2U7VV0S&=R&1J**H_<I_N,G]H
MDI:8T1F$;Q);K>6E4QQ(L2-\00"I^T@#^0&,''3>N@_S_P"3TZO+]DW5.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZU*?YX/_ &^M_P"$]G_BVW47_OV>O?84YC^)/L;_  CJ1>1O@E_T
MR?X&ZWMO8:Z'?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1&.Z/Y
M8W\NSY$[HFWQW?\ "/XO]E[VJA&M;O/='2^!K,O4K%KT+59):)*VJ13(Y"RS
MN 3<"_OW7NI'2/\ +1_EZ_&W<R[VZ(^%/QBZMWM$K)3;UVETQ@<?F8$<H6CI
MLK]DV0I8G:.-FCAJ$1F5692R@CW7NCO^_=>Z][]U[JD/_A2!N;>>TOY)GSXR
MNQ*&JR&;J^O=@[9KH*2CJ:YUPV]=[;8PVXYRE*Z2K%2[>K\I-)(Q\,4<;2U"
MM3I*I]U[HM?0_P 4?YN_R)^(_5_R&H/YDF1^(7:6[NHNO=Y]!?$_K+H?:>>Z
MZVC@QAZ.IVUM?>%3G<=7[EW%E9Z+[=,UD(JVCA@GEEBH\>T--&LONO=$K^5O
MS6WE_,(_DC_%CM;Y#[.H>K^S*7^9U\7OC_\ *W9VVZF2HQ4.9ZD[/CPV?DIQ
M>I0T%;]M2UPIC+614L\@I4J*S[=*B7W7NMH[YHXW$9GX=?+'#[@H,;E<#E?C
M1WMC<WB\Q2Q5U)4TE=M;*Q5-/503JT,U--"SI*DBE'0LK J2/?NO=$E_D,SY
M:H_DZ_R\I,TM2M8OQQVG!"*JG^V;[2FEJ8Z A=*7C-"E,8WM^Y'I>[:M1]U[
MJW#W[KW6DM_-,_GP?-G(]2?S&OB'/_)"^4U#U37=<_+SXWS?+"7<F[6V]#MZ
MJQFX=L-V&T!ZA3&G#1XUCF"AW*M-]L-)R8B_RKW[KW5HO_"53_MQY\3O_#F^
M1_\ [\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA?]&77O\ ?H]F_P!SMO\ ]_S0#&_W
MM_AL?WOA"&.WFM?7XCX_)_G/%^UJ\?I]A[^J>V?O'][_ $L'UOA^%]5X:^-H
MX4UTKPQ7C3%:8Z-_W]>_2?0>/)]/JU^#J/AZJUX?;FG"N:5STNO8AZ*.O>_=
M>Z][]U[H-^U>O?\ 29M:CP$>8;;]=B][=;[[Q.82A&2\57UON#&9^!'A,L!D
M@JWQWVTX$R$P32 ,"?>QCK1ST4[#_P O'JK&PXV#(=E=X[IAV['MVAV?'N;=
M.(K%PV/V[3Y^)<9CT@P-,@I*J?<==43M.L]27CI((:B&AI8:1;:^JZ.E_FOA
M5T[N6BW#B=QS[NS>#W9+MO\ O%A*W*4B4]7!MS8U?U\*.0PT$4ZTU9@<C4M4
M:)ED-5IDBDAB!A.M1_U?MZWI'2.@^ O7LS[/K]S]K=W;XW/U[3Y^/8F\]RY;
M;<62Q$V:RFQ,M#6438S:^-I8ZK'U'7V(2%C2,M1#5Y6/))7_ '[LN]?R'^JO
M^?KVG_5_J^SIO@_EV=204.X<2O8W>383=G260^/FY,&V\,:*6JVSD:3-TS4A
M1<(K4[K+N#)5>J!XE>K:.65)!$B#WB'_ "]:T#I2[4^"W6FUZ'>]--O[N+=F
M0[#QO9-!NO<>\MTX_-Y&ID[6VIL[:&6JS4_PB(?<F@V3C)X;QF&*JFJ[1&E:
MFI:;1>OY?YR?\O6PM.D5V5_+7Z1[0[(J.S\QO3N'$9O(;LP&[,SCMO;@PU+1
M5S;8QFPL=0T4Z5& JJE*"&3KG;U:5@JH99:LU(FFDI'BI8+"0CT_U5_S]:*
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M\3FTDCR%+CL]08R@Q:5XE_>%75T^/:O<2'R(*Q4E"RJX#F^72W4_932@""G
MTKP^5304\AUY_P"?G]I_U?MZNN]D_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4I_G@_]OK?^
M$]G_ (MMU%_[]GKWV%.8_B3[&_PCJ1>1O@E_TR?X&ZWMO8:Z'?7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T1[Y\?S%/BE_+3Z83O'Y7]@2[0VUDLNNW-H
M;?PF*EW)G=P9-HVF_A^%QD%GJ9DA1I)99)(:6G0!ZBHB5E+>Z]UJ^9W_ (6Y
M?#FGRABVS\,ODQE\+?BOSNY]K;=JO\XX_P" =/6Y2+_-"-O^!WZV9/HHD?W7
MNK7?Y:'_  I)_E]_S,NU:3H+98[,Z*[US461GV9U[W?B<;C4W&,5#]S40X+*
MXK)Y.@J:Z*G663[.>2EJY(XIGIX9DB=E]U[K8']^Z]U[W[KW1>OEG\<-F_+_
M .,O>WQ>[!K<EB]G]\=7[OZRS6:PJQ-6X]=T4<E/%DJ(3I) U9CIVBJ8!+&T
M9EB02*R7!]U[JC;IKL_^>3\.?CEMSX24_P#+SVM\L.S^GMLX;I7HKYM8;Y-[
M9V=L3,X#!"+$;>W1O? YZO;>M#DL/AXX9LM1P0U4F1GIV6EG0U(D7W7NE[B?
MY(V0K/Y*&\?Y;.\^WQD/D'V%-N'O3<G?>-\V.I8^WLSN5=[PY>F6DAHZA,-2
MY^"DHR5IXYWH$>58XZAE5/=>Z"3NO=G\\GYF_%;=7\O;>O\ +[Z_^/\ V+W1
MLG-_'[Y%_.7+?(K;6\^MX]K;AB?"[GW1L_:N+KY=Z5M9N7!SU$F.Q=;%3RT,
ME44K9-5/);W7NM@+XW=$[,^+_P ?NE?CEUVE0NQ^C>K]D=6;7DK&USS4FR,=
M3X^*IJ6NVNJJA 9IFN=4KNU^??NO=#5[]U[H@'\V+_MUE_,L_P#% /F1_P"^
MZW'[]U[JMK_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+UW!_Q>\9_VJA_U
MND]B_EW^R;_3?Y!U&?._^Y$?_-/_ )^;H)/8AZ!?7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22WSL+8_9VU<QL;L?:&VM][,W#2M1
M9S:N[L)3[AQ]7$_]B>DJHY8) #8BZ$J0&%B ?=D<H05)!&01@CK8-.BA]<_R
MRO@%U/N^EW[L+XH=/8;=N/JUR&+S%3MS^/M1U",S)/0Q9&2K@HIHV8E'@BC:
M.PT%=*V4R7\\HTM(Y'H6-#]N<]6\0_+\@!_@'5)6T<)\U/Y(G<7=.!ZM^+V[
M/EO\"^YNQ*[L39M'U4E95YK:E5DH41HJF*AH,K/2O24-/3T4S5-#]G71TE%+
M#74D[34WLY=H=Y12\@CE1=)U_"X!]2>.:^N3BF>K8;]OEQ'Y8QZ>G0>?(3:_
M\Q'^>MFML=??[+MG?A%\4^LZK-[WI<_W?CZ_[O,[C@QM12XJ7P5-%B:VM$D=
M;+3Q_94+4=%#/733UM74)34C/6TEOL57UB61@!1#V@5SG(\OMX8IGK1 &/GQ
M\_V5^?KT,G5?\S+^8S\-M@8GXV?)C^6QWAW7V9UGA*39NRNS^KQDLAB]RT^%
MA>#'/4UF-P&=HJB84U/%Y:JCJI9)0&>:B@G5PZ>3;;:Z;7%,B*34JY 9>&!4
MBO'Y>E3QZL1JR:_ED'_!3_5CRZ&7X$?![OSY"?(OO'^8+_,EZRVWB<_W+L>H
MZMZZ^,^ZL73;CH\7MG))2QR?Q3&5HK%I@M%2I2Q4M0RU#O49&IK:>*6>(!F]
MO(X8UM[<DA6UF3(+/\N%*?Y!3A4Z9M/#[/6@KZ^=?V?X!91LG^6#_+[ZZWG2
M=@[/^)73>+W9CJT9'&9&;;?\7BI*A6UI/245;)44-++$]FB>*F1HB 8RI ]E
M[[A/(-+2.0>(+'/\^J^(?E^0 /\ (='P]H^J=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:E/\\'_M];_PGL_\6VZB_P#?L]>^PIS'\2?8W^$=2+R-\$O^F3_ W6]M[#70
M[Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM0'_A4!T]V/M;M[^6Y_,:JO
MCC'\N?BU\'][]@9/Y*=+3H^0ABQ^Y:K;U=!E*ZB,-7 V(9<-**JHFI9*2&:F
MHDR,<E%,^CW7N@XVW_PL6_E&4.'IJ*J^&WRWV\:2".&DQ&V^GNLJZCB54'[<
M;MO_ !VA%?4H I0-(#6!.D>Z]U7KN3Y6];_\*"?YKO\ +:W%_+S^".Z.GJGX
M?]]=>]U_([Y1[TPF-VK7Q;8VIN/%[B3'9I]K29''K'%+A,FV$^^RD]74Y*KD
MAHEH(9,C-+[KW7T3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT0#^;%_VZR_F6?\ B@'S(_\ ?=;C]^Z]U6U_PE4_[<>?$[_PYOD?_P"_)W7[
M]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%^[=C+YK&$?\ZL#_K+)[%G+[A(V_TW^0=1ISLM;B/_ )I_\_-T
M$WA;_??\C]GWC#H&:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[
M_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ
M]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^
M_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.
MO:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?
M[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]X
MPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[P
MM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?O
MWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7
MO"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1
M^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U
M[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D
M?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H
M/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO
M^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#K
MV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^
M^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,
M.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_
MOO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC
M#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"
MW^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_
M>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]:DW\\1"G\ZW_A/7?\
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MF_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\
M&_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?N
MO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U
M[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[
M7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;
M_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;
M]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]
MH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O
M!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?
M_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_
M !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW
M[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@
M=>\'^U_\F_\ &_?NO:!UJ#_SW4T?SL/^$\8O>_RTZF_%O^:L]=^R'>>*_8?\
MG0PY7%%D^U?\!ZWF/9+T*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ/
M^8Y_.9^%7\K#<?5VV/ECE.RL5D>X<)N7/;*?8NP9-Z12P;2GI*>N$[15,34\
MD<E;3:0R6</=22K >Z]U6Q_T%[?R</\ GK?D+_Z(JK_^K??NO="ATA_PJ7_E
M1?(/NGJ#H/KK<_>E1V#W?VAL#J#8D&7Z9J<72/F>RLM287%I5535;+34[5U;
M ))2I$:%G(-K>_=>ZV,_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T0#^;%_VZR_F6?^* ?,C_ -]UN/W[KW5;7_"53_MQY\3O_#F^1_\ [\G=
M?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T%^^8P^1I"?\ E2 _Y/?V=;8VE#]O^0=!+F%=4J_Z7_*>D3X5
M_P!]_P C]F7B=$'A]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^
M1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X
M?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??
M\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/K
MWA7_ 'W_ "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_
M )'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?
M7O"O^^_Y'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\
MC]^\3KWA]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P
M^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_
MY'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KW
MA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_
M "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7
MO#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y
M'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA
M]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_
MR/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_Y'[]XG7O
M#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[
M_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_ "/W[Q.O
M>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7O#Z]X5_W
MW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#
MZ]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_P"^
M_P"1^_>)U[P^O>%?]]_R/W[Q.O>'UI\_SZ4"?SL?^$\%OS\L^J/]X[:Z[]D^
MYG45^P_Y.A3RZNE7^U?\!ZWC/97T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[JO3^9/_ "U?C;_,Z^.F[>C>^-FX:HSTN&RDG5/;$&-A&?V?G'C)HLIB
M,AH-3%"M2L7WE'Y/MJ^G#05$;JP*^Z]U5Y_)_P#Y..Q^LOB%@NGOYF/\M/\
MER[C[VZIS57M/;W;N*Z%ZZ[4JMX;:BCBDQN2SF0FVV*]\_2NU12U,U4&EK(H
MJ:KEE>JFJ0ONO=6W[3_EE?RV]A;JVUOK8O\ +Y^$&R][;+W!AMV;.WCM/XH;
M#VYE<3E=N5,=9C\GC,A1X"&KH,A05<,,]/403)-!,B2Q.KJK#W7NCO\ OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_
M[[K<?OW7NJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MWP"6MIB1>U+
M;Z_[6W^/LWV\G2?M_P G0:WN,/(I_H_Y3TDOM%_I_O/_ !OVOJ?3HF\$=>^T
M7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z
M]]HO]/\ >?\ C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_WG_C?OU3Z=
M>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]HO\ 3_>?^-^_5/IU[P1U[[1?Z?[S_P ;
M]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_P!Y
M_P"-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z
M?[S_ ,;]^J?3KW@CKWVB_P!/]Y_XW[]4^G7O!'7OM%_I_O/_ !OWZI].O>".
MO?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_ 'G_ (W[]4^G
M7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\ QOWZ
MI].O>".O?:+_ $_WG_C?OU3Z=>\$=>^T7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_
MXW[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/\ >?\ C?OU3Z=>\$=>^T7^
MG^\_\;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]
MHO\ 3_>?^-^_5/IU[P1U[[1?Z?[S_P ;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\
M$=>^T7^G^\_\;]^J?3KW@CKWVB_T_P!Y_P"-^_5/IU[P1U[[1?Z?[S_QOWZI
M].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_ ,;]^J?3KW@CKWVB_P!/]Y_X
MW[]4^G7O!'7OM%_I_O/_ !OWZI].O>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[
MS_QOWZI].O>".O?:+_3_ 'G_ (W[]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]H
MO]/]Y_XW[]4^G7O!'7OM%_I_O/\ QOWZI].O>".O?:+_ $_WG_C?OU3Z=>\$
M=>^T7^G^\_\ &_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/_&_?JGTZ
M]X(Z]]HO]/\ >?\ C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T_WG_C?O
MU3Z=>\$=>^T7^G^\_P#&_?JGTZ]X(Z]]HO\ 3_>?^-^_5/IU[P1U[[1?Z?[S
M_P ;]^J?3KW@CKWVB_T_WG_C?OU3Z=>\$=>^T7^G^\_\;]^J?3KW@CKWVB_T
M_P!Y_P"-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_>?^-^_5/IU[P1U[
M[1?Z?[S_ ,;]^J?3KW@CKWVB_P!/]Y_XW[]4^G7O!'7OM%_I_O/_ !OWZI].
MO>".O?:+_3_>?^-^_5/IU[P1U[[1?Z?[S_QOWZI].O>".O?:+_3_ 'G_ (W[
M]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\
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M_C?OU#Z]>\/KWB_VG_>?^-^_4/KU[P^O>+_:?]Y_XW[]0^O7O#Z]XO\ :?\
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M[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\
M#_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7O
MMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O
M!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%
M^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M
M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /
M]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V
M_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$
M]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y
M]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]
M^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _W
MW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_
M  _WW^W]^\7Y]>\$]:6__"A^/Q_SM_\ A.@/Z_*[J\_^Q;ZY]MNVKIZ--'6Z
MI[;Z<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL4\\%+!-4U,T5/34\4D
M]143R")$2(%G=W8A515!))(  N??NO=4.?.O_A2-_*N^"XSVW<IWA%\B>W,'
M45F-FZA^,PI>S*V&MQ]2M)4TF2S:U5-M;$3T4QD^ZIZK-I6Q+#,J4DLZ+"_N
MO=4_?%/^=)_.N_FX?*GX^Y#X;_"Z/X]_R],/\BNH).^>VLGCX-SU61V;@-UQ
MR[PHQO/<R8O U3U&WJ*KII\?M["396DJ&,:UVNIIBONO=;M/OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_[[K<?OW7
MNJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!O
MN/\ A.?_ .+6]7_^_;ZY]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[I'[PW[
MM/85-1UF[,K_  FFKYWIJ23[&IKM;QKK*VIH9F6R\W8 ?XW][ KUHFG2!_V8
MWIG_ )[+_P!=[*__ %#[WH/6M8Z]_LQO3/\ SV7_ *[V5_\ J'W[0>O:QTJ=
MH]L=?[[R4^(VIG_XKD::ADR4U/\ PJMH=,,,D43/KJ::%#9YHQ8,6YN!8$C1
M4CK88'H1?>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6GW
M_P *MOA9_,\^66SNAJOX08?M[L7I#:&U^RZ#Y$=/=5]F288Y:;+S8R?%5=;M
M!<E1C=:TL%'6Q(L='6U,+3Z8H-$LK#W7NM>_X(_)G^0'\:^FNW>HOEA_+][>
MZ#^=.)Z@WAMQM_?*S 5_R3AAW4<56##3T.-.'QTFS\J]3-0UD4J=?4DE&\B
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M=J4">*S@D#230'$;V\^\A[A<\"RW)>3S^Z;ZXAB2Y2_42QQ2S+%XY1X_$>)
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MXN)=)O81&0!XGAR*Z,?,*Q 8#YL@(KYYK8OLW:U!LC:6VMG8N:LJ<?M?!8O
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M2VHA#'[W5]R]QY%V;9;7;Q"OUFSPK/*T0>5HQ!&@0,2**/$9AZ,:CSK?[O\
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MS&&E@BIXC45$E7)I@4*NN65GEE>P%W=V=C<LQ))]X;R.96+&E2230!14YP
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M6C_/GJC9O9'\O[Y@=.YR@-)LK<GQ/[OV@]+B4AIWHZ;^ZN1BII*'RQ3P0U%
MR0RTQ:"1(Y8HV,;!=)]U[HOO\D'?F?[)_E'?R^-U[GKJW)YN3XR]>8"KR.1K
M&R$\Z[+@;"P2S3. \DDE/CXF8L6:Y]3NUW;W7NK3_?NO=:K7\U/_ (4'?RI<
ME\5_YC_PQI/D/GI/D37_ !^^8'QAI=DMTCOB.)MZ56W-Q;43%'+-MX8D1G.,
M(/NS6_:!?WC/X?W/?NO=&!_X2J?]N//B=_X<WR/_ /?D[K]^Z]UL2>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[J!E<=3YC%Y+$59D%+E*"LQU286"/XZZ-HGTD@@-I8V-C8_CWX8
MZ9N(%N8VC:M'5E-.-&!!_P /57#_ ,J7K,NYC[1WTL99BBOCL?(0+\ L(U#$
M#ZG2+_T'T]K?KF]!_/K&4_=:VJN+R[_9#_T .N/_  U)UM_S]/?'_GLH/^C/
M?OKF]!_/K7_ M;7_ ,IEU^R'_H#HY7QM^-FV?C3MG/;=VYGLWN+^\6:3-5]=
MFE@B*M#"D$<<4<$:!455))+,2Q/(  ]IY9C,:GJ8/;OVZM?;BUDMK:2642R>
M*S2Z:@Z0H "*N*#SJ:]+GMO=&]-M87 Q=?T6WJS=.Z-VXO:F/;=2U+T-/_$X
M:EVJYTHWCJ)4I1!Y&C21#*JM&)(BPD1L=2 >B7;4^1W9T#;LV[@</TMLO ;9
MZUK]U;>;?V;RN"5&;(I%-N"2JJJEH<EMVCFDK8:VGIYTJZ:HAA#U")74ZI:E
M<]5K3'07;U^6?:^\.I<S69[ [$Q^R]P;;SVR<OD=L?Q;^)KG8^O,AO5JNACG
MD'CQ87#5\21O')5MYZ=3H:&1I]A?]7YTZT34?ZO3HQ9[O[$R=)B=Y[2Q'7]-
MGM^[<Z%K\-C,K29'+2UF.[:W%NF##4#-3Y6"""JQ&*C^]R$\<4JK:O98Y(H8
M NJ?Y>MUZB=@_)GM_';3V]EM@;4Z_K\QD.D=F=Q9>/<]17P4T4>4P.[LWD*:
M 4\PD=G;;E+2TVIO0U4TTS.D6@^ 'GUZIZ1>\/DAW7"L^T=UXSIW#M/F>P=A
M;OQV-RN3DRL_WF'@R&.FP,$DBND>'I\E1)DJFKI_%43NJP)2,Z1>]4''KU3P
MZ&C8GR+I]MXV3:/>.XNM]E]B2UV&QG7N$AS+X[^-1YO!X7(4E)315\WW-7D*
M2MRO\.G:(*M3)''4QQ4QJ?M8/$>G6P>DME^[/D+B\-MBNF;H:BK]P]493L_-
M+FH<OB<9MRF>IQ\%')D\L^4*5,<0RBEHTI:>2N^PKC3&%C'&FZ#Y]:J>IW27
MR+[*[![*V7M?=-%U5#@MV],4>]Y*+:&2R%9F*/)PTV$FFJ*R.H/BH\1D9\CD
M(:"FGACK2E":AI)4E*1Z( _;UL&O1WO=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:6'_"B3_M]Q_P )S_\ Q:WJ_P#]^WUS[]U[K=/]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=$)^5V_\ ^(9?'[ Q\]Z7#>/*9S0W#552G[$3
M6_XX0.6/XO*+\I[=0>?33GRZ"SH'?_\ <7?M$*R;Q8/<7CPN7U-9$\S?Y/4'
M\#P3$78_2-Y/Z^]L*CK2FAZM)]L]/=>]^Z]U[W[KW50W\WKL/%Y7KWX^_"1\
M[@\%7?/WOG;_ $[O7(;A>!*.BZSV+&=U=IUU6:BHIX5IJK:^,;!J78HU7G*.
M)A^Z"/=>Z 3X!_)2A^.'QG_F(?&#&9;;O86?_E69+MW.]14M%74T6/R_5&Z<
M)D]_]41P3T#.K46,Q?W>U99H481S8&9-;SI(J^Z]TKML?S#_ )HXS8_P.^3_
M ''T/T7M?XP_-OL'XT=6-L;;NYMRUW8NSZGY:K0T>R\YE9:F@CP,\$^:R6.@
MR>)%/%-BTJU492NFIY%D]U[H!OBOV=W]32?\* ]R_(/%]9]J;'ZO[:[=2OV+
M)NK<.:IYSMGI79>1CVK1+D80M'L^LQ4M0)DC9)4K*JI:* (YD?W7NKB/C3WC
MU!6_'+XTUDF8ZQZFDW7T#TGN+"=5Q[PHJ!</2[HV[C:FAQ5#!5SQU3TE)#-'
M3TQ:/4\:*>2??NO=:P/\P_\ [(V_X58_^+#_ !R_]][TU[]U[K<OJ:FGHZ>>
MLK)X:6DI89:FJJJF58(XXX%+/)([$*B(H)9B0  23;W[KW23VSV-U[O6HJ:/
M9N^]F[MJZ.%:FLI=L[HH<])%&[:1)(E+/*T:%B &8 7XO?W[KW6OG\>>K^]^
ML_Y_NW7^1GR*R_R&[.WO_)Z[@WAFZFAVTG7FT-O/+W%UM0MA-D;8CJJ]\5A4
M:A\SS5N3K\I6SRO+65KQI2TU+[KW0A?//X7_ ,O_ *HZY^37=7RUZ]P_RR^3
M_P J=\[LQGQUK=S[;H,YVJ<[F<=X=C]:],5QFBS&W3MQZ03T,F%K<<:0_=YK
M(SK)]Y6M[KW0GXG;G?N9?^3;\/OD#OE-T=\]?[+H/E=\PLO%3R;D3,S?%C9M
M'@4%1DQ3Q4VN?M?>FTLDE0?#/6OB)I(04^XM[KW1+?GG\#/B[T3T!2]5=6;7
MQ7='\Y+Y#;YRN\OC+\G3CZ#']W5N^9-P1Y%^P<ENVG89S#;"V'!54XRRK5#!
M4^&IXL-'CY4J*;&R^Z]T>SYL_##XWRS=I?++Y1_$C?'\SG?.6ZVVMUML?H>+
MK3!]NKM2GVOA\C594[&Q.<J*#'[;?<^3B:HR&4@=<H]4U#!%*\<-+3Q>Z]T/
M'\H_-Y#._P N+XH39KN7'=\Y[&=;_P!W,]V#C\_7[H9:S;60K:"? 5F0RU+0
MYBLR>TFI_P"!UTV0H::OFJ\?-+6P15+R(/=>ZL;]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=:9'RI_DU?SC?B/\T_DE\K_P"2!\H=G[$V1\P=X97M#N'I_?5;AGEI-QYF
MKJZ^M:&BWC@MQ;:R5'+7Y3)U%'4$TM71+424:H8(XG;W7NLGQ1_DN_S?_EE\
MT/CE\NOYX'RIVIO[:?Q'WAB>S>GNE=AY#%&6IW%@:RGR%"]32;3P>W=K8FAB
MR./QE3530BLJ\@E.M%*L<+M(ONO=;F?OW7NO>_=>Z(W_ ##O@EL;^8U\;LC\
M9.R.Q^T.L-GY;>^P]\Y#/=39#'4.2FGZZR$>5Q]+,N6QV6QU11?Q&"DJ'BGH
M)5,E/"XTNBL/=>ZU@?\ A0Q_+M[2^/G\I?Y"]E;A_F8?/KY#[>VUG.C**7IS
MO#=VS,GM:O&6WOMZAA:LIL/LS#UQ;'O.E33>*OC59X8BX>,,C>Z]U9_\_P#^
M7C\@=S_R:MW].=2]U=Q_++Y(=6;HZO\ ECT]N+OVLQ^Y,_E,KU!E<3N*/;%/
M_!J+!4CQMCZ*OI<; M*KR3S1Q/(7D,R^Z]T$7RA_GV?%OY*_!CLWIKXC3]H[
MY_F'_)+JK?'Q\V!\+\5U5E5["VGOS?M#5[:KXMUXZNHQBL+3;)R,]3/D*JLK
MC0Z*0E))TD ;W7NKO/Y>_P ;<A\/O@[\4?C#F:R@R&X>D>B>NMA;KR&*@2GI
MJC,XG'0_QB>G5.##-E&JW1B2[J0\C,[,Q]U[HXGOW7NJ'OYK7\LS^7?2? K^
M9+WQ3?"'XLP=UTWQ#^8G;E/VQ%T=MU-PINF'9FXLRFXERXH/OAF5RP%8*SS>
M<5/[VOR>KW[KW0>?\)5/^W'GQ._\.;Y'_P#OR=U^_=>ZV)/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW2<W!MR#<$^VYYJF6G.V]QTVXX%B4,)'IJ>
MJIQ&]_HA6J8W'-U'^/OW7NBG9CX8XS*R8:0=K;[ISM9LCE=G1O28W(+B,M7S
MXR;[RB-12R2I1@XFE=\<9312U+35;Q^>34M@U.JE:]=CX7;<;9Z;1J]_[IR
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MOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOG1_P!E6]P?]K7 ?^Z;'>SBU_LQ^?\
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M.PLOU^FT-J]>[<V3112Y&&DADR(J-Q5M34R.M#)62(6,9CFA'E6:-Q(XY 7
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MS9>#(04;XE(T#/5+DZ2HF#4VAHYFA3SA8$DD35EE]/DP(/V4ZW>835P*D$=
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MV+U'NC$4&;WQ/@:*BJ>R\%NC.S4\]7#A\A-)%1P[9DBC=:0&:2=2XA5"2SX
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\
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M-X(F8/+XD(9]*G2INUA[]U[KV2R>.PV/K,MF,A18K%XZFEK,ADLE5QT-/!#
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MG!JJJ62Q1'\0=858CRS%(EY;B2O:?VWO/=#>8-NMT8Q:T:[F .F"W#5=BU"
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%$G_ &^X_P"$Y_\
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MN1JVKGR>#V)E\_6[1Q<T59)-+31P8=(*-G(I(8%2)8_=>ZM_]^Z]U[W[KW1
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!ON/\
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M\@NU=W=P[Y@PM-NK>M3CJK+P;>HY:"C5L914U!'X(9IZF5 8:6,MJG:[:B+
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M4\NC)NP1&=@Q5%9B$0R&RB_"J"S'^@ )/T O[3R.(E+&M "30%C0"N H))]
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MH%E$NK4"P*I&=>.UM1"U!8$ZB>E<]ZC>&891&B@52C5K7/!:'\S3B?/J^?\
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M:2RQQHJJ&"@#@7+$M/(9#5C7J0>5.3MNY*MVMMMB\*-G,C#6[EG("U)=F/
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_P *)/\
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MGVT=LTN\QUO0[MHJG-'$UL,-1#DACDF-4:*6"H@D67QZ&21'!TL#[\'#</\
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M\DZZ_P">D?\ 5I>JN/>#W60W7O?NO=&;^&G_ &5!TU_X=?\ \:U'N;ONX?\
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M"M-G)%W-GJO<HJDRN#IL,U%D<9F*M:C'U=)!3STDM/33(YGB\K>Z]T&/5_\
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M%6%'57HR,IP11@Q[@5 ::_:/W*MN2?&M[U7,4Q5U>,!BCJ-)JI(J&%,@U!'
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M:Z(W5UATYTUGMB_?];= [KZ+WOU)MS^\^9I?X3E/C5D,;E-DU7WD.0CKZ_\
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M:+?6+IZ;"[RWO/ELOBSGMRYFNP53C,3#3XW/R8FFIZNM6AHC4_<5'NO=%1Z
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M&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\
MZ*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\
MWO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\
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M4V/_ .BA@_\ L:]^Z]U[_AK;_A2__P![U-C_ /HH8/\ [&O?NO=>_P"&MO\
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M .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\
MHH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38
M_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\
M][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4
MO_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_A
MK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=
M>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:
M]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_
M +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38_
M_HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C
M_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O
M_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2
M_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\
MAK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U
M[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QK
MW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/
M_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z
M*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-
MC_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\
M>]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A
M2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:
MV_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]
MU[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O
M?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8
M/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#H
MH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>
M]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#]
M[U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_
M (4O_P#>]38__HH8/_L:]^Z]U5]W%_+V_F*[8_G;?R/-I_S%/GKA_EGF,_W;
MOCMGJW<& V4FWVP<'Q1DPG8&0QDL8Q^-65-Q5.-H*?R6=H5#N.0%/NO=?0;]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW12_EE\,.F_F-MG"8+L^'.8W*[6JJJJVMO'
M:=;#09*A&0\7W4"M4T]7334M7X(?+'+3/RBM&T<@U^POS1RC:<V1JER&#(24
MD0@.M:5&0P(-!4$?90YZG'V/^\%O_L'>37.S&&2.Y55N;6Y1GMYM&K0Q$;Q.
MKIK;2RN/B(8,IIU7Y_PQ5\:_^?K]X_\ GPP'_P!8O8$_UEMO_P!_W'[8O^M?
M64?_ "<GYO\ ^C;L_P#SCO?^VSKW_#%7QK_Y^OWC_P"?# ?_ %B]^_UEMO\
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M;B^+WPBZDZ/RF;IZWN"'8>3W3VWOM*!*-LKV+VK+5;AWCN":-$%WKMV9;)5
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M$T./Q^%A>HJZVLJIV2&GIJ:".2221W"HBEF( ]^Z]U4!M+_A0!_*YWCNW:6
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M=7<N!_F4?S1_YH7P:[?^=E=A".I.I*'Y,;6J]@=#XO,*Q?";)QC9B:GDW)-
MT*Y7-2/-*\Z,M'+8RU57[KW1QO\ A0OTWC/GO_*/I^U/CYM'&_+7$]1]I]*_
M,/8.W.N\\V:IMVX#9LU50YY\348Z22+*4]1L_.YZ0"*.J,L =Z2">K%,I]U[
MH8?EE_-J_EF[N_E;=N]VTG?'3'9?6?<WQWWILK9?3-!N#&9;<&XLKV)@*W'T
M6Q5V?),F47,U%1*U)4T$]#$U(D<\E4(:>"61/=>Z-3_)ZZ?[)Z#_ )7OP9ZB
M[@QF0P?9.R_COL2BW7M[+2>2JQD]? :U,74^N3QSXR"IAI9(PY$30F-;! ![
MKW5DGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JG;X;?S@>
ME^\>P/E1T)\FJGK'X:_)[XM=Z;[ZXW1TOV3W#C*>HRNVL ,>^&WSB:K)QX5Z
M["YNEKZ9PR4MH-<.IWBGIIIO=>Z(S\&>R>O._/YP'\SC^:'U1N*/'?!'KGXI
M=??&[.=YP24\&T-_[HZNEAW#N3=V,R*N5RE#LC#8QL6<A&33/%.S1221E&]^
MZ]U7WMWYW_"_^=+VU-V]_,,^<OQR^.7\N;J7LNLF^/G\O/=WR$P6P\YV35;-
MJ&AI]X]ST,N3IZS^$BMITJL5@&6-&%GG\M(3)DO=>ZV[/C?\E/BY\E-G5F6^
M*'='3?<^P=BUE'LNMKND=X8K>&*Q,]'2PR08MGQ$TU+1R0T3T[)3^DI"T9"!
M"OOW7NC#^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7N@Z[6Z@ZE[WV/ENL>\.KNNNY>ML]+C9\YU[VMLG&=AX.M?#5
M,591O5XG+TU905+TM9!!/"9*=C%-&DJ:716'NO=%%_X:=_E9?]ZT_@!_Z1OU
MU_\ 8Y[]U[HVW4W373_0>R<?UIT7U3UMTMUSB:G(UN+V!U-L;%]<X2FFR\SU
M%7-3XK#TM'00RU51(\LS) &DD9G<LQ)]^Z]T)/OW7NO>_=>Z][]U[KWOW7N@
MZ[6Z@ZE[WV/ENL>\.KNNNY>ML]+C9\YU[VMLG&=AX.M?#5,591O5XG+TU905
M+TM9!!/"9*=C%-&DJ:716'NO="!!!!2P0TU-#%3TU/%'!3T\$8B1$B 5$1%
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MTDN+HMOT>WLYONEBGQ[)E0^7W-OXSU4E+#YZRGI:V#T_=&-_=>ZJ3^1W;_\
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M-.VXYZ62MI*.*AHF$./7$K65M>V1R50M-1Q^Z]TT_P T/^6?\\^K?YG75_\
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KZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>timage_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_004.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZ]U[W[KW7O?NO=>]^Z]TL=H516HJ*,GT2Q^9!^!)$0K6'^*OS_P7W[KW2_\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$N<).6KK
MDG]\CG^@50!_O'OW7NFGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@-G:W'[-2/]O3R@^_
M=>Z5F\6/GHE_ AE8?Z[.H/\ T*/?NO=(WW[KW7O?NO=>]^Z]T57Y(_-WXJ_$
M&?:U/\ENY-O=0'>\.3FVE4;IH-QB@SXPSTJ9:''9/'86OIWFIOOX&G@\HD19
MXW9 LB$NQPO-\ )^S/26ZO8;( S.J \"QH#^WHS.'R^*W#B,7G\%D:+,83.8
MZAR^'RV-J8JS'93%9*FBK<?D:"K@9TEAGAF26*1&*LK!@2#[:Z4@UZ<??NM]
M%*VI\[/B1OOOW.?%S9/>&U=W=^[9KL[CMR=:[:I\]F\QM^KVPO\ OXTS57C<
M/4T5*M"]H*N6>J1(IR('83$1ETPNJZR#0\#Y'I*E]#)(85=2XXJ#5A]H\N/1
M:_\ AZ_^5;_WFKU-_P D[L_^QKV[]%-_ W[#TC_?UE_O^+_>U_S]>_X>O_E6
M_P#>:O4W_).[/_L:]^^BF_@;]AZ]^_K+_?\ %_O:_P"?IYVY_.-_ED;OW#@=
MI[9^876&:W'N?,XO;NW\/11;KDK<MF\U708W%8VDC.W%#2SSU,<48N+LX'O1
MLY5%2C?LZLF]6DC!5FC))  #BI)P!QZ'/Y'?/CX>_$7<.WMJ?)+OG9O4>X=U
MX:;<.W<9N=,WY\MAJ>NEQL]?2OC<3D$*)/"T;!F# CZ6();C@>;X%)IQH*]*
M+K<(+*@FD5*\-1 K3TKT7/\ X>O_ )5O_>:O4W_).[/_ +&O;OT4W\#?L/27
M]_67^_XO][7_ #]>_P"'K_Y5O_>:O4W_ "3NS_[&O?OHIOX&_8>O?OZR_P!_
MQ?[VO^?JS#;FX<-NW;V"W7MROBRNWMS8;%[AP63@65(,CALU0P9+%U\*3QQ.
M$F@J4D4.JL W(!X]I3CHU!KD=//OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NBV;2^8'QIWUW[O+XM[2[<VWF_D#U[C:W+[TZMI
M8LNFX]O8S'G""KKJ[[C&PT_C3^\=#ZDG?4*J,K<'VX865=9!H>!\NDRWD3R&
M$.I=14H"-0&,D?F/V]>[P^8'QI^-NZ^L]C=X]N;;ZYW=W)DIL1U?@<W%EY:[
M>F3@R6%P\U#AEQN-KE:1:G<5##I=D]52EN#<>2%I 2H) XT\NO3WD5LRK(ZJ
M7-%!(!8X%!Z\1^WH=MS[GVYLK;F=WAO#.XG;&U=L8FOSVX]QYZOIL5A<'A<5
M325N2RN5R5;)#%!3P10M)++(RJJJ23;W0"N!TH9@HJ< <3U5;UY_/-_EC]K=
MP;=Z-Z]^0E?NG?V[=UKLS;<.,ZB[FEP>8SLDTM/"*7<)V"M)]H[Q$C(/(M*(
M_P!]YEIP90L?;YHUULM!]H_S]$D',=E<RB&.34Y)  5Z$BOGII3'&M.CR?''
MY;?''Y=;>W!NSXV]L;<[;VYM7,Q;=W!F-LQY5:+&9N:AAR4>-GDRF.QY,O@J
M(Y2$#65U)M<>TTD+0FC C[>C.VO(KU2T3JX!H2I!%>-,?;T8OVWTIZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NFC"9_!;EH3E-N9G%Y_&"NRF,_B6&KZ7)X\Y'"9
M*KPN:H5K:*6>,S4=;05%'51ABT4\$D,@62-U'J4ZT#7AT ?3GS ^-/R![ [/
MZKZ:[<VWO_L'I?)56([3VOA8LN*_9.3H\WD=N5-#F7KL;21+(M;B*JGTQR27
M:![7 )]N/"T8!8$ \"?/I/#>17+,D;JQ0T8 @E34BA].!_9T9/VWTIZ][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:,SG\%MVGI:O<&9Q>$I:[*8K!T-1EJ^
MEQ\5;F\]D*?$X+"T;U<L0EJZVKJXJ6CIH]4DTTJ11JSLJGU*]:)IQZ=_?NM]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1;,%\P/C3N;Y#;E^*&![<VWE/D3L[&R9
M?='5--%ESN/"8R+&8?,O75S/C4IEC^US]%*&%0;BI0"[&WMPPL%UD'2>!\ND
MRWD3R&$.I=14I4:@,9(_,?MZ,G[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]TCNPNP-
MF]4;%W=V9V)GZ/:NQ-A;>RN[-X;ER(G:@P.W,'1RY#+Y:M%+#42>*"&!Y)-"
M.=*FP/NRJ7-!DG@.J22+"I=B  "23P &23TENC^]NH_DEUOA>WNC=]8CLCK7
M<51EZ7";OP2UJXO)5&!RM9@\O'3_ ,0I**4F"KQ\T#DQ@:HS:XY][>-HC1@0
M?0]4@N$NE#QL&4UHP-0:&G'[1TCNFOEM\<?D)O;M7KGICMC;?8&]^C\S_=[M
MC;F%3*+7[&S?\6SF"_AN9^^QU'&)/N]M5\%HGD&JE?FP!.WA:, L" >%?/JD
M-Y%<LRQNK%#1@""5.10^G _LZ,7[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T][<8KF:/\ HQF4
M_P"(:GE_XFQ]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z"3.?\ %VK_ /EN?^A5]^Z]TU>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLT'Z
MV_Y8U'_N/+[]U[I5[Q_X$T?_ "PD_P"MGOW7ND=[]U[KWOW7NO>_=>Z(5_,E
M^"6Q/YAWQ6WST%NO['%;H>/^]'4F^:FD%3/L#M##TU2-NYQ2JM(:2<5$N.RL
M,9#2T59.B%9?&Z*+6X-JX<?F/4>G1;NVV)NT#0O3.5:E=+>1'#\_45'GU2A_
MPGM^<>^]LU^_?Y3?RPIZO:??'QJK=R4/4U+N%VCR.5V?MW(RKNKK4U,S,E3/
M@I)_O\++!)(M5AZ@FG'VV/$DB_<[<&DZ?"W'Y$_ZOV]![E7<77587&)(<+@B
MJ"@_E44X54@BN3U9!_.C_F/T'\O?XK9*?9V0IY_DEW5%E-@]";?AFIY<IC\M
M44T=-G>S7QLD-8TM+MV+(Q3QJ8)(YJ^>AI7TI.SHEL;7ZI\_",L?E_L_[/1M
MO^[C:8*KF1^V-?,L<5H*D@5K\S05%1T%'\BO^6;5_"+H2O[C[IH*ZK^7/R5@
MHMV=I5^XIYJ_/['VY5RRYC!]=3U55453_?F6NDR6XI]0EGKIQ!,TBT,#^[[A
M=_4M1::5PM/\/3/+>S?NN(O)4S2T:0DU(.33B>%34^9KFE*&2_X90_E6_P#>
M%74W_)6[/_LE]L_6S?QM^T]+?W#9?[XB_P!X7_-UK$]2_!GXEYW_ (4;=U?$
MK+]';0KOCCMS:N5KL)U+,V8&V<=5P] ["W1%/"4RB5)*Y#*U%4 U0PURGBU@
M#>6X<6BN&.HG)KGBW0-M=MMWWF:$QH4$8(32-(.F,\/S/[>MH_;G\G+^61M#
M<.!W9MGX>]887<>V,SB]Q;?S%%+NN.MQ.;PM=!DL5DJ20[C8++!/31RQFQLR
M ^R<WDK"A=OV]#1-EM(V#+#&""""$%01D'AUK_?\*%-I;<W]_-2_E8;%WCB:
M;/;1WKD^M]I;IP5;Y?L\UMS<?R,Q&'SF)J_#)$_BJ::LEADT.K:7-B#S[,]K
M)6*4CB!_D;H*\V1K+>6:L 07H0>!!>,$=7T?\,H?RK?^\*NIO^2MV?\ V2^R
MWZV;^-OVGH4?N&R_WQ%_O"_YNO?\,H?RK?\ O"KJ;_DK=G_V2^_?6S?QM^T]
M>_<-E_OB+_>%_P W5F&W-O8;:6WL%M3;E!%BMO;9PV+V]@L9 TKP8[#86A@Q
MN+H(7GDE<I#!3)&I=F8A>23S[2G/1J!3 Z>??NM]%AA^:'Q7E[=[5Z'D[RV)
M0]L=&[*K>Q^WMHY?(3867KS8F-@VS59#=FY\MEZ:AH*:A@BWEC))9VJM*I6(
MQLH8J[X+A0U#0X!I@G_4.DHO83(T6M=:C4RU%5&,D>0R/V]%'PO\[W^53N#L
M4=6XSYE]=G=+UZ8V.KK\%V)A]BSU<CP1QK3]IYC9E!M>1&:H4+-'F&C)O9O2
MUGVL)E744-/Y_LX_RZ+X^8K*63PEF0M^>DUIP:FDG/ 'HUWR:^;WQ/\ AOMK
M&;K^2W>6RNJ\7G(9JC;]-E)Z_,[DW)3TX0U%1MG9NUJ#.YC)1Q^5/(]#0U"K
MK6Y%Q=B*!YS1 2>E]Y?PV"ZYG5!\SD^>!Q)^0!/29^*W\PWX7?-DY.'XP_(#
M9_9^5PM-)6Y7;$=+N+:.]:''1U/V;Y6?8N_<)M;,BC\I5/N_L?"2Z6?UK>TU
MM);_ !J1_@_:,=-V.Z6^Y"L#JU.(%0P\L@@$</,9Z.5--#30RU%1+%!3P123
M3SS2+%###$I>6665RJJJJI+,2  +GVQTOZJJ[*_G@?RJNIMW5&Q]W_,;8DVX
M*2IEHZK^Y&V.S>T<'2U4%4U'/!4[MZPV-O#$QLDB$.&K1I U&R\^UB6$T@J%
M-/G0?X:5Z);CF*RM7T/,M:TQ5J&M,E00/SIT??I'Y!]'_)39D/8?0?:NQNV]
MF2SO2/GMC;AH,[345='?R8[*PTLK3454H%VI:N.&4 ABEB"4SQM$:,"#Z''1
MI!<1W2ZXV5E/FI!'\NEYO/>NS^N=JY_?78&ZMN['V5M7&U&9W-N[=N9QVWMM
M;?Q-(NNJR69S>6J*2FIH(Q^J6:1%']?=54L:#)/D.KNZQ*68@ "I)-  /,D\
M.JU=J_SMOY5V\^QTZJP/S)Z[;=LM?_#*>?+8/L+;6RJNM,T%/'#1=G[EV;B-
MLS^1ZA%B>'+NLG.@MI:RIK"95U%#3^?[./13'S#92R>$LR%OSTFM,!B-).>
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M8U1"K6(QXU%7#"X4-0T. :8)_P!0Z3B]A:1H@ZZU%66HJHQDCR&1^WHFL?\
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MD43K*ET)<M[,IKK;\R2/V="638;*12AAB (I4(H;\B "#\Z] 9_*(^$/S*^
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MDRTN5O(DE7@ZAA7B*BM#QR.M>C_A6-_V0[\??_%K<+_[Z'MGV:[)_:M_I?\
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M6Z G-/\ N=9?\U!_U<CZW#_9)T.^O>_=>Z][]U[KWOW7NM2/XS_]Q4OS,_\
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MHX''4,-4Z22UF2VYV9'EHHH?*JIC:M2[%%+;O?UK>-UX+@_;2G^3_!UK8?\
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M7G7,+3C(15$NJ>EG?3(H$ND:%07;1,P\$$"F:UX_F3T(MGBNXHR+QU=]6"H
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M08^?<>@QN>WQS;S''2BRH'D X/IU-0CA0^&M1Y\>.>MLKY6?%?HGLWX;=R=
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MZ#NT\N2[3*&6X=HAJ_2*FE&K3\9 (-#4**_*IZ-M\!OY6?\ LCOR>^:'R/\
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M+#N[;FP:$5F;R,U.L$24>Z>L&Q-:?+:EIZ^GKJEHX7/L\ ^JM J\4.1Y^?\
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MR_E<9;N'^:=\>/YC\'<^.P.-Z+V5A=H3]22[%J<C7;E.*'9JOD(MZ)NNCCI
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M;%I$5:&JQS>.28%RS(\:JWNVME95 [A0UK\QC(]>BK<-GBW*2*5RP,+:ETD
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M>^27\HSX_?*OXA_'_P"&7:_:/R&J>O/CC5[6JME[TQ.Z^O(.T<VNS=F9S86
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M4]2E?41R+?7WH@CCU96#<"#]G2U]ZZMU[W[KW718*+L0HNJW) %V(51S^22
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MJ*N\T_V]09(S"8Y$=SN'U":-"@5Q3R'[//'"G1UM?+?[MF\<S2.Q6CZB:.U
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M+99 TDGP+Q^9]/\ 5ZCJ_,.ZR6QCM;:GC3&@/'0M::B,GUS2E Q\J= CA_\
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M+:]#!A'87.J&0Z5[5\A\5%/'UX=1GS'M8BO+<>)*?&E-:O7PZNGP8[::L<>
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MZ1<PVKW6ZPHCM$6CHL@K4$>(<4*Y\L'SZL"_X8K_ )B/_?0!\T?_ #A[Q_\
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M,G-5U,6/R-#N6CJ8Z6>>I>FE::F,]0(1/(@OK7Z233Q'$'Y="+8-V_?-N)2
M&!*N!6@84.*^1!!\Z5I4TZM)]H^CKK4C^;/_ '% _P OS_Q"^S_^M?R5]G=O
M_N&_^F_Z!Z VX?\ )<M_^:1_P3=;2_<'_,I>T?\ Q'6]O_>:R?LF3B/M'0W?
M@?L/6M;_ ,).?^R'?D%_XM;FO_?0]3>S?>_[5?\ 2_Y3T"N0O]Q'_P":S?\
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MCJ7-97QA")LQB)L9F9#H4%ZYP+Z3[*+Z#Z>4KY<1]A_U4Z&?+^X_O.T20FK
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MRR6MVH66,!NWS7%:Y85%0:@T(.!@UV*O99T*NO>_=>Z][]U[KWOW7NGG;_\
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M_BB2YO=I&8 $F@X#R'3*6\<;,ZJH9J:F %6I@5/$T\O3K6$_D&?]O//YS_\
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MFDHZ1?"E)+F.VC,<-26^)CC%/+A_J]>G;;;+K<KE+J^"((ZF*%2&H:\6.17
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M)R&?Z[W[@L33_=Y7-;+W3B<92^6"#[G(9'!UU'14_GJ9(8TUR3*NN1T47NQ
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MGD?=S$%5)%% X.*UH0:8^7IQZIMEX\DLUM(=30E*/0+J61-0K0TU"AK0 '%
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M.#_FC'_QP='U]INC/K3P_D-_]O?_ .;O_P"'KW'_ /!/[@]G>Y_V,/\ I?\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9H/UM_RQJ/\
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MII_,9'<AE57KV%82FC@45JGB:D](=AO9KU9C-34EP\8"\%"A, T!.:Y.3\N
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW029S_B[5_P#RW/\
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MO_=5S_QM%\Z/_F7>S#</]#_YI)_EZ#?+G_$K_GLG_P"?>AI_EF/+V7A/E/\
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ME@G42Q05$<\$2"[MC:.4.?,'U'0AV?=$WB 3(*>3*34JPXC_ "@XJ"#0<.K
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M=85"I<W:J, "8  ?(!.K8OCETA_LNO4>W.I?]+W>7>O]W:G.U/\ I,^1N_\
M_2=VYG?XYG,AG/!N/>?\)PGW45'_ !#[.A7[9/%30117;1J*&63Q6U4 ^2B@
MZ/K.V^CC$>MWI7ND;4YJ2<F@K2M!\J=#C[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%!Z4^&>P?CYM/Y5
M;9ZTWGV-2U'RT[[[Q^26\MPYO(;8R67V9V5WQC<5C]P_Z/Q1;4Q$$&.QS86"
M?%4V2BR<R.&^XJ:E2 K\LYFTUIVJ%%/0=(+/;TLA($+?JR/*U:&C/2M* 8QB
MM?MZ4VV_BWLO9OQ&Q'PXV=N??>S=AX/HJGZ$Q&]=JY3$XWLS$X&'9HV8^[,3
MG*G!Y&CASK1EZT5AQTD:U3F406LONK2EGUFA-:YX<:^5.G4M5BA$"$J F@$?
M$ !I!%0<CY@YZK$V!_(AZ_ZHVEB-@=6_S(OYN/6NQ-OI51X'96P/F%A-G;2P
MD=;6U.2K8\1MO;O4&.HZ99JFLFJ)1#"@>25W:[,Q*UMR+FICB)]2E3_AZ(H^
M5UA4*ES=JHP )@ !\@$ZMB^.72'^RZ]1[<ZE_P!+W>7>O]W:G.U/^DSY&[__
M -)W;F=_CF<R&<\&X]Y_PG"?=14?\0^SH5^V3Q4T$45VT:BAED\5M5 /DHH.
MCZSMOHXQ'K=Z5[I&U.:DG)H*TK0?*G0X^V^E/7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6>G!:1@.3X*H_P"P6FF8_P"\#W[KW2JW
MC_P)H_\ EA)_UL]^Z]TCO?NO=>]^Z]U[W[KW50O\]OHD]]_RM_E#BZ181FNL
MMKT7>V&J)J8U(I1T]DJ?>.Z&C5;,CS8"AR]*LBD:#/J:Z!E*W;I/#F4^II^W
M'^7HBYFMOJK&9:THNOU^ A_Y@4Z</Y&7=*=X?RM?B=F9-2Y+86QZGI;*P,2W
M@?I[-9'86%L]S<2XK"X^H']/-I_'OVX1^',X]37]N?\ +U;ENX%S8PL/) G^
M\=G_ #[U6%\,:7$_//\ GV_S"?D#F11;EZM^*?6=1\8-H4=112M'!D<X*SJS
M)O13RK;P58VKOUVD%C*F5O&3%?VIN!]/;(OFY+G_ %?81T4[<PW'=+B6H*PH
M(0*'B2:_L*L/F#CYYO\ A.ED\Q\=^X/YC_\ +9W3)7"H^/W>M;OK9$F7F093
M,X*?(U?6N?S1I!'3H*>HI-J;6R,,U/&(Y/XL7TH&37O=*2B.4?B6AH/,?\73
M\NJ\I@V;W%F:_I256IJ2K5I\N"@X_BX#I)_SSJ2;Y=_S-OY7/\O+'SIE,)6;
MB';/:FVVUBAGVCN/=44.9K*YQ$ZO/1[9ZGW-+! &!"UAUZ5F1_>]O_1BEE^6
MD'Y_\61U3F3_ !^\M;,$$:O$=2,%1^7HKBGSSY=;9:(D:)'&BQQQJJ(B*%1$
M4!51%4   "P ]D_0VZH[_P"%&G_;I#Y%?^')T7_[_'K_ -F.U?VZ_P"V_P".
MGH-<W_\ )/E_YM_]7$Z'W^2A_P!NK?A5_P"(F;_WK-R^V+W^V?\ TQ_P]+]A
M_P!PH/\ FDG_ !T=6D^TO1MU[W[KW6O]_*C_ )@_R6^6GS>_F/\ 1W<NX-MY
M3K[XS]C9W:_5E!A=I8C U]'C*+MSL3:%-_&<I0QB6LD6BVO2IKD(NVMR"6%C
M*\M%@CC9:U85-?L!_P O0:V3=I=PN+F*332%]*T!!IJ<9R?X1Z= E_,K_G"=
M_P#P1_FB=2=%XC KV1T)N7H.EW55]1;=VMB9^P-^=M[SINYMI];;?PV[9HY*
MJD@J]RX;;<=3X8YV2 5!CAF9A"[EK8+<0EZT(-*^5!0G^5>DV[<P2;;?1P4#
M(R5H!WESK50#4#+!1GU/28WUB_\ A4AN/ U'?>W-^?%WK>DI\=#NF#XB[8PO
M7N>WA/1TSRY@[/J,GO#J_=R35\L++05"P[\I2S):GDAF.OWM#9CM(<^6O@/2
MN#^? ]-3)O<GZJM"@ KX(R3YZ22AS^$D.!Z4X]'Z_DO?S0<]_,DZ8[$':NT<
M'L+Y"=#;GQ&T^TMN[?3)4>+RE%G:"KDV[O&EP>8DJ*K&M5U6!RU%58Z2>I\,
MV.=A(%E6*--?6GTC"AJK"H/1IR_O)WB)BZZ)$;2Z^A]:'(!H<'@01FG5S?M#
MT?\ 6K1_PK&_[(=^/O\ XM;A?_?0]L^SG9/[5O\ 2_Y1T".??]Q$_P":R_\
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M"<U_F?\ #^72\;M?['*B7^B2.0T\5:#2309P@H.)JM:$D$TIUM[JP8!E(96
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M?]D._'W_ ,6MPO\ [Z'MGV<[)_:M_I?\HZ!'/O\ N(G_ #67_CDG3;UYW/\
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MFC5M:C[F4!?4P)UM@U13 _P_Y&Z W-!T7MDPP?$(J.--<>/YG]O2R_X5G_\
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MP?\ [K*7V3GCT-APZ4GO76^M13^6=_W$I?S0_P#Q$W=O_O[OC1[.KG_<./\
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ML?'2Q@K'410E;FTNU2U)%"O$-4 4XUR>JVG-UHR*KZDD^$QZ')##%!I7.>'
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M/RR_[BD_@+_XKLO_ +R'RO\ 9Q!_N$_^F_RKT";_ /Y+EO\ \TC_ ()NA_\
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M_P"*>_=>Z]_!\I_RH57_ %*;_BGOW7NO?P?*?\J%5_U*;_BGOW7NO?P?*?\
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MG_X*OHWV8;5_;K_MO^.GH-\W?\DZ7_FW_P!74Z,A_)M_[=8_ _\ \5OZ]_\
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MO=>_@>6_Y4)_]LO_ $=[]U[KW\#RW_*A/_ME_P"CO?NO=>_@>6_Y4)_]LO\
MT=[]U[KW\#RW_*A/_ME_Z.]^Z]U[^!Y;_E0G_P!LO_1WOW7NO?P/+?\ *A/_
M +9?^CO?NO=>_@>6_P"5"?\ VR_]'>_=>Z]_ \M_RH3_ .V7_H[W[KW7OX'E
MO^5"?_;+_P!'>_=>Z]_ \M_RH3_[9?\ H[W[KW7OX'EO^5"?_;+_ -'>_=>Z
M]_ \M_RH3_[9?^CO?NO=>_@>6_Y4)_\ ;+_T=[]U[H*N[>U>MOC=UCN;NGOG
M>^V^INJ-F?P;^]?8&]\I383;& _O%N#$[4P?\3R=2X2+[K)9VCHH=7ZI:F-!
MRP]^Z]T0'_AZG^4U_P![!OBW_P"C3P/_ %^]^Z]U8UUEO':W<W7^T>U>J\_B
M]^]<;]PE'N79F\]MU4>0P&YL!D4\M!F,/71G3-3S+ZHI5X92""00??NO=+G^
M!Y;_ )4)_P#;+_T=[]U[KW\#RW_*A/\ [9?^CO?NO=>_@>6_Y4)_]LO_ $=[
M]U[KW\#RW_*A/_ME_P"CO?NO=>_@>6_Y4)_]LO\ T=[]U[KW\#RW_*A/_ME_
MZ.]^Z]U[^!Y;_E0G_P!LO_1WOW7NO?P/+?\ *A/_ +9?^CO?NO=>_@>6_P"5
M"?\ VR_]'>_=>Z]_ \M_RH3_ .V7_H[W[KW7OX'EO^5"?_;+_P!'>_=>Z]_
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MR?\ RWG_ ."KZ-]F&U?VZ_[;_CIZ#?-W_).E_P";?_5U.C(?R;?^W6/P/_\
M%;^O?_=:?;%Y_:O_ *9O\/1ALG^X<'_-*/\ XZ.K+O:;HTZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH!_X5'?\ ;BCYS?\ ELW_ ,&'\???NO=?(%]^Z]U]J?\ D>_]
MNA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z36\_^//W9_X;6=_]U=5[]UH\.M>+_A*Y_P!NJL;_ .+"=Q?]
M"[6]F6[?VY^P?X!T&.3O^2?']K_\?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>)MR> .23^/?NO=)S(;FH*/4D!^\G'&F)@(5/
M^US6(_Y)#?XV]H)]P2+ [C\N'[>E\&WO+D]H^?']G2(K\UD,@2)9BD)_Y1X;
MQQ6_HPN2WT_M$_X>R>:[>?B<>@X='$-HD' 5/J>/33[3=*>O>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZET==54$@EI9FC-QJ6
M]XY /Q(AX/\ L?I^/;L4S0FJFG^#IJ6%9A1A7_#T(&*W)35VF&ITTM4;  G]
MF5CQ^V[?0G_4M_L"?9W;7ZS8;!_D>B2YL&ARN1_,=*7V8=%_7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:F?_"D[^:-\/J?XD?(C^7=M_?==OWY,;YJ>J*7)X+8V-@S6U^LZC9?<VP.
MRLM1]E;MER%%2TE8:/8]33C&4/\ $JZ&IJ*=:NFIH9&G0YVFT<R"6E%%<GSP
M1C]OV= CG'>(%MWM-59&T=HSIHP;N/ 87AQR,4->A?\ Y"7\WOX7=K_'3XQ?
M!%]X9SKKY)=8]7X/KRDVIV/B:3"87L[*;8H(ONY^L-UT&4R]%6M*LUX,;728
MW)2F&8PT4D41E+6XV4D3-(1522:CRJ?/_53Y]*N6M^M[N*.V!*R(BKI84U:5
M )4Y!^S#8)I3K9M]E?0MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_X5'?]N*/G-_Y
M;-_\&'\???NO=?(%]^Z]U]J?^1[_ -NA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_\ CS]V?^&UG?\
MW5U7OW6CPZUXO^$KG_;JK&_^+"=Q?]"[6]F6[?VY^P?X!T&.3O\ DGQ_:_\
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MJQ)^ >7<_P"I1!<D_P"M[;EE6$58TZ<BB:8T45Z0.3W/4U>J*CU4D!N"X/\
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MX'Y=1QN/),=O!))$TC."610*C37"T +$T\Z_EUL"?RZO^$[7SC^67:&U:WY
M=3[]^*WQWQ^9AJNPMT=M8"NV-V3F,)CJPC([:V!UMN2FH\O_ !&N$/@@R.2H
M:6AIXY35AZHQQTE2KN]TCA!"'4WE3('VG_-]F.B79^4;F]=6F4QQ@@MJJ'8
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M/_CS]V?^&UG?_=75>_=:/#K7B_X2N?\ ;JK&_P#BPG<7_0NUO9ENW]N?L'^
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MZ][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]^Z]U]J?^1[_VZ%_EU?\
MBJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z36\_P#CS]V?^&UG?_=75>_=:/#K7B_X2N?]NJL;_P"+"=Q?]"[6]F6[
M?VY^P?X!T&.3O^2?']K_ /'SULA>RWH4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW2*W%G='DQ]&_K.I*J9?[ /#0QG^OX8_CZ#F]BB_O:5C3\S_ ).C
M:PL]7>_Y#U^?2$]DW1UU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=8:BHBI:>>JF+B&FAEJ)3'%+/((H4:20I# DCN;*;*BLQ/ !/'NCN(U+
M'@ 2: DT&> J3]@SU9$,C!1Q) %2!DXXF@'Y]!3M;OGJ+>N;I-N;8WSBLKFZ
M\3FBQT<60IYJK[:"2JG6%JRCIU9ECA=](:]E) X/L+[9SQM.\S+;VUS')(U=
M*#4"VD%C2JC@ 3]@Z$NX\F;IM,+7%Q;ND:TU,=) J0!72Q\R!^?0N>Q7T&.@
M>K^_NG\;N&?:E5OC&C<5/DQA9<33TN5K:D98SK2_PY/LJ"H5YO*PC*(S'7Z?
MU CV$YN>MIM[@VC7,?C!_#,8#,WB5TZ>U35JXH,UQQZ%,/)6ZW$ N5MW\(IX
M@<E%&BE=7<PH*9J?+/#IOR'R3Z/Q60KL7D.PL52Y#&UE305U,]'F"]/64<ST
M]3 Y3&LI*/&RFQ(XX/M/<>XFRVDC127<:NC,C*0]0RD@CX?(BG3\'(.\7*+)
M':N5=0RD%,JPJ#\7F#U#_P!FCZ#_ .?DXC_SBS?_ -:_;/\ KF;%_P ID7['
M_P"@>G?];K>_^423]J?]!]/^U^^NHMZ9VAVSM?>^.R^=R7W/V..@ILI'+4?9
MT=1D*G0]300H-$-+(YNPX7CFP]KMLYYVG>)UMK:YCDE>NE &J=*ECQ4# 4G\
MND6X\E[IM,+7%S;ND:4U,2E!J8*.#$Y) _/KAN3O_I[:.;K]N;DWSC<5F\7)
M'%7X^>ERKRTTDL$53&KO!02H;QSHPTL>&]ZW'GO:-IF:WN;F..1*!D(:HJ P
MX*?(@];L.2=UW2%9[>W=XWJ58%*&A(\V!X@],?\ LT?0?_/R<1_YQ9O_ .M?
MM%_KF;%_RF1?L?\ Z!Z6?ZW6]_\ *))^U/\ H/I4;0[OZKW[F%V_M#>-!G,P
M]-/5K0TU-DXY#34P4SREZFA@0!=8O=OSQ[,]IYSVO?9O M+A)9*%M*AJZ1Q.
M5'KT7;IRAN6RQ>/=0-&E0NHE:5/ 88GH5?8GZ#?7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]TP[GW1M_9F$K=R;HRE-AL)CA":S(57D\,/W-1%24ZE8DD=F>2=$55
M5B2PX]H=RW*#:(6N+EUCC2FIVX"I"C]I( Z6[?MT^ZS+;VZ&21JZ57B: L>-
M. !/27V3VYUQV/55U#LG==!GZO&T\=56T]-%6PRP4TLGA28K64M-J75Z25U6
M)%[7%RW9N:MOYA9DLITE9 "P6M0": Y Z,=WY8O]A57O(6B5R0I;202!6G:3
MT(WL0=$/09;<[DZSW;N.HVCMS=E%E-QTOWWW&*AILE'/#_#9/%7:WJ**&,>-
MO2?7]?I?V'-OYMVW=;AK2WG1YEU:HP&J-!HW%0,''0@O^5=PVRW%U/"R1-IH
MY*T.L5'!B<CY=";[$?0?Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ?>Q/^RX<?\ ^):ZO_ZV
M;1]XB\Q_\KNG_/=8_P#:OUE-L'_*G-_SQ7G_ %GZN"]Y==8L]>]^Z]U[W[KW
M50/R7_[*QI/^UEUS_P!:<1[Q+]Q_^5MC_P!/9_X4ZRC]O?\ E67_ -+=?\_]
M6?=I]K=:](; W/VIV_OK:_6W7.S,9-F-T[TWCF*/!;?PF.@%WGK<A72Q("Q(
M2.,$O([*B*SL%.6RJ7- *GK%IF""IP.M?KY8_P QG<O\T/\ EU_)8?R).XLO
MV!\D.OMY=>;9WAB\)C:KJKMO$]?;GS-0N8RVR(>VZ#:;4[9*BQU4U#DHG@F\
M5'714LD>2A2(+(X/IY!XPP:_,?RZ12S_ %$9\$U./D:?GU3Q_*<_X2H[FW)G
M<=\E?YKM37O656:;=6,^+^/W0N8SFYLC43SU=1E?D)OK'SUNH5%1*:F3#8BO
MEEG)5JZO4-44+*KG<:=L?[?\W26VVXGND_9_GZWH=B[$V3UAL[;77G6^T=M;
M"V%LW#T6W]I;,V=A,=MS:^VL%CHE@H,1@L%B*>DIJ6FA10L<,,:*H^@]E#,6
M-3D]'"J%%!@=*OWKK?7O?NO==@D$$$@@W!'!!'T(/OW7B*]"YAZ[^(4$,Y(\
MH'BG _$T?#&W^U"S#_7]BBUF\= WGP/VC_57H+W4/@.5\N(^P].?M1TGZ][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH^_X
M4(?+;Y2?![^7?EODC\0\Q5X3M387<W5-3D:I-EXS?F)GZ^EK\HV]Z#=>#RV)
MRT2XB>EA\=?6**66G0^6"JIIE29/=>ZUXOA3_P +7=OUW\&VI_, ^+E9@JES
MC:&N[B^,M=_%<099ZA*6KRN9Z?WYEX:NEIX4;[FHDQVX\I*P#K!0EM$;>Z]U
MMM_#7^:A_+]^?F-I:KXK?*'K3L;/3TLE94=<U63FV9VWBX8:RHQT\F4ZIWM3
M[>S\42S4S(M2,>T$BE)(99(I8I']U[JP/W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW5 /\ PJ._[<4?.;_RV;_X,/X^^_=>Z^0+[]U[K[4_
M\CW_ +="_P NK_Q5+JC_ -T$/OW7NK4??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2:WG_P >?NS_ ,-K._\ NKJO?NM'AUKQ?\)7/^W5
M6-_\6$[B_P"A=K>S+=O[<_8/\ Z#')W_ "3X_M?_ (^>MD+V6]"CKWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NDMN+-_9(:.E;_ "N1?W''_*/&P^H/^K8'C^@Y
M_I[+KZ\\$:5^(_R'^?HQL;3QCJ;X1_,_YN@X)OR>2>23^?9!T?\ 7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5&?*?K'*=,=
MFXOM38_EQF&SN8CS%!44JA8L#O&GD:NJZ$)<CQ5'B:JB1AI8&:(+HCL<3O='
MEJ7DW<X]VL:I'+()%*\(K@58K3T>A8#@>]:4'63_ +;\PQ\V;<^V7E'>.,HP
M/&2 C2&^U:Z2>([6K4]&QW9\I<+#\>Z?LS"RT\6Z=PQ2;<QF'#K(^+WB(=.3
M\L3ZV,5"I-6A=;2(T :WF4^Y6W7W/@CY?&YPD>-*/"2/CHN*=U0?)/CS\0T_
MQ#J,]L]N)GWP[=,"88CXKOPUP5[:$>;_  XX'5_">@$^%'3M1G<Q5=U;JCFJ
MH:*KK:?:K5K/-)DLY*7CRVX99)68R>#RO#&[:M4SR-</"#[ 7LMR@U[*V]75
M6HS"#422\AJ'D->-*E036K%CQ4=#7W=YJ6SB7:+:@+!3-IP$C%"D8IPK0$CR
M4 <&Z,3FOA?TYG\SEL[7R;N^^S63K\M6>#-TT</W>1JI:RH\,9Q;Z5US'2+F
MPXN?<B7OL[L^X323R>/KD=Y&I+0:G8L:#3PJ>@):>[.[6420IX.F-%1:QDG2
M@"BO?QH.JX-A];;<W'\ADZPR+9 ;:;>.Z\$6IZI(LE]CA5S9HS]TT#KK_P!Q
M\>MO'SSP+\8Y[%RU;;CS%^ZY-?@_47$6&H^F(2Z<TX]@KCJ?-ZY@N+#8OWC'
MI\7P(9,BJZI/#KBO#N-,]6?=?_%/JWK7=V)WKMQ]S',X7[_[,9#+T]51_P"Y
M'&5N)J/- F.@+?M5[Z;.+-8\VM[R9V'VMVOER[CO;;QO$CU:=4FI>]&0U&D>
M3'\^L=M[]RMRY@M7M+CPO#DTZM*$-VNKBAU'S4?EU7;WKB:7/_+'-X*O,HH<
MUO?9F)K# XCG%+D:';E'4&&0JX5]$QTD@V/-C[Q\YYM$W#FUX)*Z9+FUC:AH
M=+I"IH?6AZG;DRZ:RY8CF2FJ.WN'6N1J1I6%?E4='@_V1GI+_CIO/_S_ %+_
M /6GW-G^LCLGI/\ \Y?^A>H>_P!>/>/^$?\ .,_]!]"!UI\8^M>J=S)NS:TF
MXSE4H:O'@9/*4]92FGK1&)@84Q].=7[8((86]G_+?MKMO*MS]5:>+KTLG>^H
M:6I7&D>G1)S![A[AS+;_ $USX6C4K=B%35:TSJ/KT8?V/^@+T@NQNR-K]6;>
M7<^[IZNFQ+9"FQGEHZ.6NE%55QSR0@P0^K213-<_CCV1\P\Q6O+%O]5=EECU
M*E54L:M6F!GRZ.MAV"YYDG^FM0I?27HS!11:5R?MZ"C+?+/I7$;;P>Y)MP5E
M1'N**LGQF(H\;--G6IJ')5F)GJJO'LT8IXS-02B-IY(_(%)358V"UU[J[+:6
MT5RTQ(F#%$5"92JNT9)7\(U(0"U*TQ7H2VWMEN]U<26ZQ*#$5#NS@1U9%< -
M^(T85T@TKFG3YL7Y*=1;_P =G,CC-R+BEVW1/D\S2[CA_A-728M'$9R*J\DL
M<L6ME0^&21@SHK*&= RW8_<7:=_CEDBF">"I>02CPV5!C5G!%<8)H2 :$BJ/
M>>0-TV22..2+7XK:(S$=89^.G%"#3.0*@$BH!HA:?YJ=%5&53&_Q7/00/4+3
MKF:C 54>*LSJ@J'];5*Q^JY+TRD $D#V1Q^\NQ22^'XL@!-/$,3!/M_B ^U1
M3SZ.7]I-Z2+Q/#C) KX8E4O]G\)/V-T:NEJ::MIJ>LHYX:JDJX(JFEJJ>1)J
M>IIIXUE@G@FC+*Z.KAE920001Q[E&.195#H058 @@U!!%001Q!\NHVDC:)BK
M A@2""*$$8((/ CJNSY\=A>"@VIUC0S$25TAW7GE22Q%)3-/082FD50;K)+]
MS,RDBQIXS8WN,>_?CF#PXH-L0Y<^/+0_A6JH#\BVH_:HX^4[>RFQ:WFW%QA1
MX,>/Q&C.?R&D?[8]%JZJJ\_\<N^]LT^[(QCTK*;$8_<*D_L#!;RQ]!5>5Y7,
M8(HIIXI)BI($E&Z\V(,<<JR3^W._PI=]H=8TE]/#N%1JU-,(Q!8^J$=2!S+'
M!S[LDK6IU%2[Q>OB0,PI3/QJ"!\G!ZNO]YG=8C=4^_'_ '+@=H?)#?6X=S96
MDPV%QL78<U9D*V31#$IS"JB*%#,\CL0L<4:L[L0JJ6('O$CD'<8-IYDN[BY=
M8XT%V6=C0#]4?M)X #). ">LIN>-OFW38+:"W1I)'-J%514G]/\ D!Q). ,D
MTZ.A0_-3HJMRD>.;+9ZAAEF$*Y:NP-3'BP68*DDC0R3SHA)_4\"@#EM(]S'!
M[R[%-*(_%D4$T#M$P3\^) ^9 IYTZB6;VDWF&,R>'&Q KH612_\ .@)^0.?*
MO1J:6MHZVCI\A1U5/54%53QU=-6T\T<U+44LT8FBJ8:B-F1HV1@RN"00;@V]
MRA'*LRAT(96 8,""""*@@C!!&:]1O)$T3%'!# E2I!!!!H00<@@^718=R_,C
MH[;F3GQ2YK*Y^6EDDAJ*K;N*:NQR2QD!DBKJF>BCF'/$D!E0VX;W&FY>[^Q[
M=*8O%>4J:$Q(72H]&)4'[5J/GU(>W^U.\W\8E\-(P14"5]+4/JH#$?8U#\NE
MKUI\BNJ^UZ]L/MC.30YT1O-'A,U1R8S(U,,:L\DE%K,D4^E4+.D,KNJ@LRA>
M?9URW[@[7S4YBM93X@%?#D4HY \UKAJ>84D@9(IT4<P\B;ERTGBW,8,=:>)&
MP=03ZTRM?(D $X!KT.7L:] _KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NJ?>Q/\ LN''_P#B6NK_ /K9M'WB+S'_ ,KNG_/=
M8_\ :OUE-L'_ "IS?\\5Y_UGZN"]Y==8L]>]^Z]U[W[KW6MI_..^:NPO@+N+
M<'R$W[A,KNM,7F>M\'M/9F%J:2@R&\=Y5F%_BV,P29.NUQTD/V^#JZJKJC'.
MT5/32O'!/($A?&_?^6)^:^=%@@*KX:6\\C-6BQQ",DXK4DD*!YL14@5(R!V/
MF2#E?E$SS MK>>&-5I5I)"]!G@  6)] : G'6HMG-S_S=/\ A4!\CJ;"XS&G
M$]$;$W.U3#C*-\GMGXO?'/'UZ/#'EL_DJAIY<[N8T-44#Z<AE:A9I/M:>DH'
MD2'+$"+;U^9_:>L729=P;Y?R'6^+_*._E ]#?RE>H-P;2ZYS>:[%[<[1AVM4
M]X=Q9^$8R3>F4VG'FOX+C]M;5AJJZ'#8:A?<E>:.B6>KG;[@M55=2X0H3W-T
MUR<X X#HXMK46PQDGB>K;_:;I3U[W[KW7O?NO=>]^Z]U[W[KW2KVI7>"L>C<
M_MU:W2_T$\8++_MUN/\ 7M[,MLFT/H/!O\(Z+-SAU*''$?X#T(OL^Z(NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN+HDJ
M/'(BR1R*R21NH='1P59'5@000;$'W[KW6OI_-3_EU?R <WMO)=E_S ]G?&?X
MW9[-U;5,7;. W?B_CUVMN7.OCJR*.2DAV/68:IW;7_;44KQTE;B\\S+2ZQ P
MA!3W7NOF6?/C97\N7J#MS$R_RQ_E%\EN\=J8RJH\FFY>W>H\=UI+M[(4-345
M-!D]J=ATN;V;F:^KCEIZ=PD^P=N" VECJYG)BB]U[JPKX8_\*+?YPGP1P?7E
M=GNQ=T_(/H#/SU\6U=N_*G";BWMB-V8G;>X?'O"CZ^[FR$E!N!Y:*2M;'LT6
M:R=-CV:&)J/1%'![]U[KZ4'\I?\ F==5_P V#XC8#Y+]=X"JV'N*@SM=U_V]
MU9DLK39K(=<=F82@QF1RF'@S%/!1??XVJILQ2U^)R+4U*T]-4J)8(*F.>"+W
M7NK-O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[<4?.;_RV;_X,
M/X^^_=>Z^0+[]U[K[4_\CW_MT+_+J_\ %4NJ/_=!#[]U[JU'W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TFMY_P#'G[L_\-K._P#NKJO?
MNM'AUKQ?\)7/^W56-_\ %A.XO^A=K>S+=O[<_8/\ Z#')W_)/C^U_P#CYZV0
MO9;T*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF7-99,73W72U5*"((S^/P97'^I7_>
M3Q_6R2[N1;K\SP'^7I7:6QN&^0XGH+))'E=Y)&9Y)&+N[&[,S&Y)/L-LQ8U/
M'H2*H44' =</>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]TA^Q]A87LS9F<V7G4/V68I=$53&JFHQU?"PFH,E2EAQ)#*BN
M!]& *-=68$EYAV*'F2SELIQVR+2HXHPRK#YJ0#\^!P3T<;#O4W+UW'=P?$AK
M0\&4X93\B,?+B,@=4>[-ZVR>ZNUL7U%4Y-*63^]F3PE;51O)-24IQKS)G*VA
MB=5#2-#ASX[JFLI&KD 7&$VS<M2[INR;.[TI/)&Q!)5?#KXC*".)6/&!6B@X
MX9A;MS!'MNV/NBI7]%)%!H&.NF@,1Y R9R:5)%?.^/;^!Q>U\)BMNX2E2BQ&
M%H*;&X^E0DB&EI8EBC#.URS$+=W8DLQ+$DD^\Z+&RBVV%+>%0L<:A$4>2J*#
M_B_/CUA?>WDFXS//,=3R,78GS+&I_P!@>0QT[^U?27JFOJ3_ ++*C_\ $E=A
M?]:]T>\/^4_^5S_ZC+S_  3]97<S_P#*I_\ 4):_X8>KE/>8'6*/5)?R'H,C
ME?E!NK%X>?[7+Y+=6UJ#%U7GDI?MLC68K 4]#/\ <PAGCT2R*WD0$K:XY'O"
M[W#MY;OFB:*$Z9'FMTC:I72[1PA349%"0:C(X]9><B3QVW+D,DHU(D,S.* U
M17E)%#@U .#QZ&K_ &63Y:?\_/\ _8E;Q_\ J'V-?];7FW_E/_[/+G_H#H(_
MZX?+'_*'_P!FD'_071D_C=U3W'UWE]SU?9^Z_P"\='DL;0T^*B_O3FMP?:U,
M%5+)42>+*P0B/4CJ-27)M8^Y']NN5MXY>EF;=+CQU=4$8\>672023B112H(X
M<>H_Y^YEVG?8H5VZ'PF1F+GP8XJ@@ 90FN?7HV_N5>HQZ)Q\YO\ F24?_AYX
M'_W%RWN(?>[_ )(A_P":\7_/W4J^SG_)8_YL2?X4Z#GX==*==[@ZRJMW[LVO
MAMT93.9K)441SE%#DH,=C<:$I(X:.GJHW2.1Y&ED>9!K(* ,- ]AWV@Y+VZ^
MVPWEU!'.\LCJ/%0.$1.T!0P(!)J21GAG'1_[J\W7]CN(M;::2%(XT8^&Q0L[
M]U25() %  <<<9Z*1MCK?;V:^3U1UC)#-'M2'LW=6%-$M3*LDF"VYD\O/'CG
MJAJD_<AQ2Q,X(;FX96LPB7:^7+>^YG;;""(!>3QZ0QS%"\C!:\<B, GC\P<]
M2?N._P ]GRZ-Q!!F-I#)JH*"25$&JG#!>M.'R(QT93YL=6; V;LS96;VEM7"
M[:K1N%\'.V%H8<>M;138NKK%^^6G"":1'H1IED#/9F&JQM[DGWIY7V_:+&WG
MM((X6\;PCX:!-2F-V[M--1!04)J>.>H_]H>9+[=;NXANII)5\+Q!XC%M+!U7
MMK6@(;@*#ACHU'Q7RC5WQ[Z[KJQUC6FQN:HWDED&B.FPVX\WC(G>1](51%0J
M>>% M?B_N4?:ZZ-SR_:.^*(Z9/E%+)&/Y)^74;>Y%L(-\ND3-71J <3)%&Y_
MFWY]5I5V]MK]H_)@;PWOF*?%[&_O6E4:FO2>:F_NSME2V'Q[T\%/4-:M7'Q1
MR*J'U5+DD<M[QOFWNUYGYG^LO9 EL)ZZFJ5\& =BT /QZ!44XL?MZR"AV>YY
M<Y=^ELT+W'@THM WBS?&U21\&HD&O!1]G0B_,G=W5?8E9M'=NP]UX[-YND@J
ML!G*6EIZZ&9\<&:OQ-66JZ2E!$4DE3&W+$^9/H!R(/>/==KY@:WN[&=))5#1
M2*H:I3XU.0,*=0\_B'"G1#[4;9N6Q+/:WL+QQL1+&S%2-?PL,$\1I(^P]'U^
M-'8@[(ZAVQE*B?SYG#0?W9SY9D:4Y/#1Q0K4S:+>JHIW@J3P.9B!]+^YV]N.
M8?ZR;1#,QK(@\&7A7Q(P!4T\V72_^VZA;W V+^K^Z31**1N?%B]-$A)H/]*V
MI?RZK.ZFZZQ'9_R3RFW-P(T^!@W)O+-9:D21H6KJ;&5];)%1&5"K!)9WB672
M0WC+A2I(88V\J\NP\S<RR6]P*Q+-<RNM::PCM1:CR+$5^51CCUD'S-OTO+O+
MZ3P&DAB@C1J5TEU6IH?, &GE6E:\.C>?+#H?KG'=297=^U-I8C;6;VC+BIXW
MV]CX,:E?CZS*4&)K8,C!2)&DNA*P3B5P7!B/JLS RS[J\B[=!M,EW:V\<,L!
M1@845-2,ZHP8* #0-JJ<BG&A-8N]L^=+^?=$M;F=Y8YPX(E8OI949P5+$D5*
MZ:#!KPP.D[\:\INK?7Q<[.V3C)YILWAX-SX';#>9DE-+F,$E;2XN.9W&EC/4
M5,<;ZE""5!P$O[0^VUU=;[RO>6<9)EC$\,!K0TDB#*M2<=S, <4!'ITN]P+:
MVV;F.TNY !'(899L8JDFDM3S[0I(\R#QKT4_IGL_:?3^1SF,["Z@Q6[ZN6M\
M,M3F:.B_O!MV6ECDI:FA@HLUCJM%#%V$J TS$FS,P 411R9S/:<G221;C8).
MVNA:15\:$@%2H61#QS454^M>'4F\V<NW/-4<<EC?/ H6H$;-X4H)!#$QNI]*
M'N'H!QZ-#U;%\2M^]GX[=>VJS<FQ-X'*8[(X39M7-2[8P292C,6F'$+C8ZB%
MC/(GJI%KE$@?0D !93*'*Z\I[]N:7=JTMM<:T>.W8B",.OD@0%3J\T#T8&@3
M)'4<<R-S/LFW/;7"Q7$&AEDG4&:30U<MK(/:/QE,4J6X'JR'WD1U G7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4^]B?]EPX
M_P#\2UU?_P!;-H^\1>8_^5W3_GNL?^U?K*;8/^5.;_GBO/\ K/U<%[RZZQ9Z
M2F^M][)ZPV=N7L/LC=VVMA;"V;AZW<&[=Y[QS>.VYM?;6"QT33U^7SN=R]12
M4U+30HI:2::1%4?4^]JI8T&3UIF"BIP.M$O^;C_PJBW5O?-9KXN?RJHLK%%D
MLBVSLM\HQAZNIW;NW(Y!EQL>)^.^TVA,]-Y)Z@04^>KH'JIWO_#Z.$>"MF.+
M;;M/=)^S_/T3W.XENV/]OG^70I?R]_B7\JMZ_'JFZB_F[XC=7;^3['[)VKNS
M#=>_(W<N4[#[*V_L"O&WJS!46^,OFJZOR=%5O4)-64V/J,@]50Q3B"5:60R4
ML6+7N=O"V'-UJ^WLT4JK!',Z=H?Q)"*<<CPV"G&?G2O62OMMM#7_ "O<1WX6
M6)FF>%'[BFA*U^1U@D9Q^=.MS;I+HGIKXV]<8'J'H/K+9?4766V5J?X)LG86
M!H-NX&CGK9WJLC7-24$47FJJJ:1IZNKG,D\\KM)-([L6.1SN9#5C4]0"B",4
M44'0K^Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLD,KP2QS1FSQ2)(A_HR,&7
M_>O=E8H01Q&>JNH<$'S%.AEIITJ:>&H3]$T22 ?D:U!TG_$7L?8KC<2*&'F*
M]!21#&Q4^1IUG]WZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=47_\ "B/=GS/VO_+AS])\"*ONVE^1.]^WNLNO\*OQXQVX*_M>
MLVWNJ;-4FZ*7;DNU*.KR5$33Q^23(T+4TU((_.E1"4\@]U[K3J^*_P#PDJ_F
M=_,3=R]P?/CMW%_':CW5/#D-V9'L3==;\@ODSN-Z.HQN.ISD<;C<]5XV,S8Z
MED$-5E-UO4TWBIXI,>REQ#[KW6W!\(?^$S7\J7X6QXC.3]*M\G>SL:U/5'L?
MY.OB^QA%D::N;(T]7A>NDQ>+VM1&"30*:5</-5(D2:ZJ5PTC^Z]U8_\ S"_B
MCUS\K/@I\C_CCN#JG&;_ *'<O278.-ZZV=B\-M(9;$=ATNSLP.MLKUR^YH%Q
MF+S=#E?M)</7S&"&FG5'D=(1(??NO=4H?\)8/Y=7S-_EV?&CY,;0^9/5U5T]
MN#LWNK;>[]C[/J=]=>[W:? X[85!B<AN)GZXWGO*EHY*B<K2O3U3TU3_ )"I
M>,Q^(^_=>ZVE??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_PJ._[<4?.
M;_RV;_X,/X^^_=>Z^0+[]U[K[4_\CW_MT+_+J_\ %4NJ/_=!#[]U[JU'W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TFMY_P#'G[L_\-K.
M_P#NKJO?NM'AUKQ?\)7/^W56-_\ %A.XO^A=K>S+=O[<_8/\ Z#')W_)/C^U
M_P#CYZV0O9;T*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J+6UD-!325,YLB#A1;4[G],:7_)
M_P"-^VY91"I8^7\^G(HC,P4>?025M9-7U,E3.UW<V51?3&@_3&@_H+_\3]3[
M#$TIF8L?/^70GAB$"A1_Q?43VUT[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U37U)_V65'_XDKL+_K7NCWA_
MRG_RN?\ U&7G^"?K*[F?_E4_^H2U_P ,/5RGO,#K%'KWOW7NJ:^I/^RRH_\
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M/<;[AM]IO>\QP<N)*J$QZ2=9TN#5I!K)8(N#5CBA/"G4@6%[=;/M+S;^\;.
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M+C<'C*2NFHZB./,)A(:W(5L:1I4YXQ@4L/NO= [_ ,(E/^R%/EO_ .+:1?\
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M3(4,<B,5='JX$=&'!5E:0$$?T/MHSHIH64?F.G1 ["H5OV'KA_%L5_SL\?\
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MZJ!^2_\ V5C2?]K+KG_K3B/>)?N/_P K;'_I[/\ PIUE'[>_\JR_^ENO^?\
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M]U[W[KW3?EO^+5D_^U?6_P#N-)[9N/[-O]*W^ ]/6_\ :+_IE_PCJIWX#_\
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M([.S$DCN9"6/$]'B((P%' ="M[KU;KWOW7NO>_=>ZI][$_[+AQ__ (EKJ_\
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MCH,?-5204<LD6E89&'NO=4:?] 5/\K+_ )_Y\_\ _P!&G\=?_N5??NO=>_Z
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MEEU14;?43XK&X[(]?;IHLKO39L,,-/33U$.,CQ-%#*X6*NJ 96?W7NFG8_\
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MO59.658(*<Y!:=*J>0VCAHZJI6&&9V/"K%(Y)( N2![#=ISQM%]*(8KN!G)
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M4QV%H*K*9:MIL=CJ*(S5595RI#3PQBPN\CD"Y) 4#DD@ $D#W>*)IF"H"2>
M&3U22585+.0 .). .B'=K_)K)YPU."Z^>HP^'N\,^X"&@S&23])- I"M21'D
MAO\ /,+&\7J4CK:N6U@H]Q1F\E_"OV^I_E]O0%W7F1IJI;U5>!;\1^ST'\_L
MZ*2[O([R2.TDDC,[N[%G=V)9G=F))))N2?8K IT%2:Y/7'W[K77O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T8SH[O&KZ]JX]O[@DGK-EUDY_#S5&WJB9[O6T2#46@8MJJ*=?\
M&2,:]2RA[>]D%^/$CQ(/V./0_/T/Y'' 0[)O9L#X<E3&3^:'U'R]1^8SQLFI
MJFGK*>"KI)X:FEJ88ZBFJ:>1)H)X)D$D4T,L9965E8%6!((-Q[CEE*$@BA&"
M#Q!ZD96#@$&H.01P(ZS>]=;ZJ>[9_G=_RT^F/E1L_P"&N[?D3CLAWGN_=NV]
MAG$[*VWN;?6VMJ;TW=G8MM8#:V]]Y[5Q>4QN,KY*V>.*IIIJ@O1"19:X4T3!
MRI6TD==0&/V=)FNXU;17/#K6B_F)?R&OYLO\S'^:UV#N+N;L7 8OX7C<N1JN
MI.Z,CO/"93;G673=1/C9J'K78?1-/O+(9Q-RK"J1Y"IFH<9CLC5TDM=+70K)
M!2JO@O(K>/ [O,>I^WI!/9R3R$GX?(^@^SK:N_EW_P KOXB_RR.L3L'XV;!B
MI]R9JBQ\/8_<>Z129CMGM"MH%O'/NK<Z4E+XZ1)&>6EP^/BH\?3-([PTRRR2
MR2%T]PUP:M^0\AT8P6ZVXHOYGS/5B'MCI_KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI][$_[+AQ__ (EKJ_\ ZV;1
M]XB\Q_\ *[I_SW6/_:OUE-L'_*G-_P \5Y_UGZN"]Y==8L]>]^Z]U[W[KW50
M/R7_ .RL:3_M9=<_]:<1[Q+]Q_\ E;8_]/9_X4ZRC]O?^59?_2W7_/\ U;][
MRTZQ<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NEGLY+SUTG
M^IBA2]O^.CNWU_Z=^S;:AEC\A_J_ET4[J<*/F?\ 5_/I>^SKHEZ][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5>_X6%=5]D]D?RBZ?/; I
M:VLPW37RCZD[4[7IZ"3(^3_1L-I=I=;-53TF/IYUG@IL]V/@:J=:DQPQ)"U2
MSAX$!]U[JIO:_P#-Q^!G;W_"7SL#X?TG;NQ.K/D_U?\ $7'='5W1&[:^';&Y
MMZ;KVIF\/3)N3KY<@*:#.C/0TAS,JX^2::*>IGBFC5XR6]U[H9.M_P"<_P#R
M^OBO_P )M^K>AMS=J];]U?(K=WPWWET33?%S;.1H-Y;E_O=V/2;UVQ]KVMB:
M(U,&$Q%#!F37Y;^+24LDE-$8*6.:JGIX9/=>Z,Q_PBWZSW?M/^6YWCV!N#$U
M6,V]VO\ *[<U?L2IJH]"[@PFS^N^OMJ9;.X]M1UTPRU)7XW58?OXZ=?[-_?N
MO=;A/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@'_A4=_P!N*/G-
M_P"6S?\ P8?Q]]^Z]U\@7W[KW7VI_P"1[_VZ%_EU?^*I=4?^Z"'W[KW5J/OW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I-;S_X\_=G_AM9
MW_W5U7OW6CPZUXO^$KG_ &ZJQO\ XL)W%_T+M;V9;M_;G[!_@'08Y._Y)\?V
MO_Q\];(7LMZ%'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF
M=U57@QOA4V>KE6/_ !\:?N2$?[$*#_K^R_<I-$=/4T_+CT8;;'KDKZ"OY\.@
MU]A_H0=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3?EO^+5D_^U?6_P#N-)[9N/[-
MO]*W^ ]/6_\ :+_IE_PCJIWX#_\ ,X=R?^(US'_O4;.]XH^PW_)8F_YXY/\
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MOKC=NWLO3;CP^0[8WQ@:^1,]7TM114Q;#8F48M'BD2>KRT$OBC:NMQU55.'
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M7XA?"S^9O\-Z_J_LWY#;)ZMZ?S_9^U]QUG>'7.[.J(_NMS[5J,G51;=@WIN
MY+%F:HFJ&:IB8RRL(V  8EE]U[I7_#3"?R_OAC\7^F?BYM;Y.?'G?FW>EMI+
ML_#;OWIV7TJ^ZL[00Y+(5\%7G7QV3IH&J *[QNT4<:MHN%6^D>Z]T9O_ &8'
MX._\_M^*7_HR>H?_ *]>_=>Z&SK?>'56]L'5Y7J#=/7V[MM4^6GQ]=DNM\WM
MS/X.#.14=#4U-#5UFV*JKIUJUIZNFDDB=A((Y8F(TLA/NO="#[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_P"%1W_;BCYS?^6S?_!A_'WW[KW7
MR!??NO=?:G_D>_\ ;H7^75_XJEU1_P"Z"'W[KW5J/OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[I-;S_X\_=G_ (;6=_\ =75>_=:/#K7B
M_P"$KG_;JK&_^+"=Q?\ 0NUO9ENW]N?L'^ =!CD[_DGQ_:__ !\];(7LMZ%'
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-^5G^VQU;->Q6GD"G^CR
M#QQG_DIQ[8N7\.-C\O\ 8Z?MD\211\_]GH'_ &%NA3U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U6W\T.^-SX/.0]5[/R55A(%Q=/7[JR=!+)39&L;)K(:;
M"PU495XH!!IEG,9!E\P0D(KB3'/WEY[NK"8;79NT0T!YW4T=M=:(",@4RU,M
M4"H (,^^TO)=M>PG<KI!(=96%& *+HI5R#@FN%K@4)XD4KYVEO'=&Q,S!N#:
M.;K\#EX%,8JZ"8Q^:G:2*62CK(3J2>!VA0O#,KHQ4$J;#WC]M&\W6PS"XM)&
MBD&-2GB*@T8<&4D"JD$&@QCJ<]TVFVWJ$P74:R(<T85H:$5!X@BIH10BO'J]
M3I+L5NU.LML;TGAAILAD*:>ES%-!J$,.7QE5-CZ\PJQ8K'*]/YXD+,5255+$
M@GWG)R7S#_6G;(+T@*SJ1(HX"1&*-3C@E:@9H",]8:<W;#_5O<)K0$E5(*$\
M2C@,M?F :$^9!Z%;V*>@UU[W[KW7O?NO=>]^Z]UXFW)X Y)/X]^Z]U6A\@^V
MFW[N X+#5);:6WYW2G:)[Q9C)IJBJ,JVFP:-03'3?J].IP?W2!)&P;5]#'K<
M=[C/]$>G^?\ 9Y=1QO\ NOUTFA#^FIQ_2;U_R#]OGT7;V(.@]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW01[@[EV-#F-Y==[0WIL#=7>6VMF93=E+TS3;WVX-
M_5"0T-1)AWR&UDR1R%-25=1&D"U<M.D8+_JX]T,@R 033A7/5Q&<$@@$TK3'
M6D&/C3_-F_G*=^3U_>N%WKUCL_:U=3Q9#(=G[2W?UCT]U1C:FKD2LQG7FP<S
M3Q3Y/+"+R:HH?NJR73"F3R$$30S*'?!GOV[J@#U! 'V#_5\^A%XT%@O;0GY$
M$G[3_J^76UM\"?Y6_P 8_@#@8:CKW!'>G;M;CY:+<_>&\J*BGWMDXJMEDKL9
MM](D>+"8QRB**"@(,B11_=SU<J>4G5M9I:C&3YD\?]CHEN;U[KC@>@X?[/5D
M7M7TDZ][]U[K'-#%4PRT\ZEH9XWAE52%9HY%*.%9E< V)L2#_K>T&Z[='O%K
M-:3"L<T4D3C^C(I0_P CTOVO<9-HN8KN'#PR)*G^FC8,.'S&>A5IO@?OW(U%
M)5XW>VRYML5Z4U729.?^.0Y=L;5Q)/#.V&CQ<\/ET2 ^,5^F_P#;]X 3^P&X
MQ7!C%S;^&&(UGQ!)0&E= 0K7Y>)^?6=D'OC82P!S;S^(5!TCPRE2*_'K!I\]
M'Y=6'=-]/[<Z8VFFV\$\E=55,PKL[G*F-8JS,Y$QK%YFB5Y!%#&JZ(*=68(M
MR6=V=WGSD_E&VY-M!;058DZI)&PTCTI6F:  451@#U)),)<U\TW'-EU]1-10
M!ICC!JL:5K2N*D\2WF?0  "S[%709Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ^N[/AWN_LKL?/;VPV],+%1YPT<H
MHL['DONL>]-104;4D$E)!5HT(^W#1G]L@-I*FVIH#YU]H+KF7<9;V*YC"R:3
MID#U32H6@*U!&*CA2M*>9F_E#W5M>7K".SEMW+1ZAJC*T:K%JG40:YH>/"OR
M 4?[(#V)_P ]KLO_ ))SG_UL]A3_ %@[_P#Y2;?]DG_0/0F_U[K'_E'G_;'_
M -!=+_JSX4;RV5V#M3=V6WQA%HMMYBDS$D6"3*'(5AHI!,N/U55+2HL-1I\-
M02Q)B=U"DGV?\K^R]WLFX07<MU'IAD$E(@^IM.=-6  5N#>JDCSZ).8_=VUW
M>QFM8[>35*A0&0II75C5@DU7BO\ 2 /5COO(CJ!>O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZDT<'W-734__ !VGBC/^"NX#
M'_8 W]N1)XC!?4@=-ROX:EO0$]#.!;@< < #\>Q9T$^O>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIM_GM?R\NZ?YGOP&SGQ8Z#W/U?M'L
M')]I];;X@S';^:W9@-FIB=G5N0J<G3S9#9FRM_UPJ)%JU$"+CF1B#KD3@GW7
MNJDLY_PG]^9.3_X3\;-_E20=E_&5/D1MWY!57:];O*;>7::]+R[=G[*W7O)*
M*EW$G3,F<:M^USL,9C?;J1>577S: KM[KW5 ?_0%3_--_P"?^? #_P!&G\BO
M_N5??NO=>_Z J?YIO_/_ #X ?^C3^17_ -RK[]U[K<=_X3T_RO\ OW^4U\+^
MSOCI\B]W]/[TWMO3Y/[T[KQ>4Z4S^]-Q[5I]J[CZIZ5V+0X_(5V^NO\ KBK3
M()5]<5TDL4=#+"(98&6=G:2.+W7NKWO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW5 /\ PJ._[<4?.;_RV;_X,/X^^_=>Z^0+[]U[K[4_\CW_ +="
M_P NK_Q5+JC_ -T$/OW7NK4??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW2:WG_P >?NS_ ,-K._\ NKJO?NM'AUKQ?\)7/^W56-_\6$[B
M_P"A=K>S+=O[<_8/\ Z#')W_ "3X_M?_ (^>MD+V6]"CKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NDSNN;QXP1@\U%1$A']50-*3_ +=%_P!O[+MS
M?3'3U(_S]&.V)JDKZ _YN@U]D'1_U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U63\U^DMS5FXE[8VW05.8Q51BZ.@W/2T,,U56XFHQD<D4.5D@C#DTCP+&D
MCJMHFB+/8.",:_>GDFYN+@;K;*TB%%295!9D*5H]!7M*T!H.TBIP<9"^T7-]
MO#!^[+AA&X=FB9B KAZ$K4_B#5(!^(&@R.B [<VSN#=^7I<#MC$5V;S%:X6G
MH,? T\S#4JM+(1Z8XUU O+(51!RS <^X!VW;+C>)E@M8VED;@J"I^T^0 KDF
M@'F1U-VX;C!M41GN76-%XLQH/L'J3Y 5)\AU>OT5US-U5U?MK9M;+#496DBJ
M:W,S4YUP-E<I5S5U5%!(4C+I#YA CE066(-87M[SFY(Y>/*VV0V;D%U!:0CA
MK=B[ 8%0*Z0?,"O6&G.6_#F7<9;M 0C$+&#QT(H45R:$TJ1Y$]"[[%G07Z][
M]U[KWOW7NO>_=>Z+%\E^S6VGMM-I8FH\>>W33RK4R1.!-CL#J,-3-;DAJHAJ
M>,_ZD2D$,JGV)>6]M^JD\5QVH<?-O+]G']G0:YDW+Z6/PD/<_'U"^?[> _/J
MN3W(?4>=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0,IE,?A,9D<UEZRGQV*Q%!5Y3)Y
M"KD$5+0X^@IY*NMK*F5N%CBCB9W8_0*3[\33K8%<=:>?\P3_ (4'[W[.R55T
M5_+PQ^X,+C\Y6X_ )WG+@ZMNR-WU^1JA2+A>J-C5N.FGQPJFDBIX*^L@?)2&
M9EIZ6AG2*=R&ZW0OVQ?M\S]@Z/;7:PG=+^SR'V_ZJ=#!_)S_ ).OR$ZW[RV9
M\[?E?N'*;+WCB)=X[BVOU9D*ELWV)N'-[[V]G]MY#=/;&=J*JK^S:6GW+5U9
MQ^NHK99IHVK9*5HYJ:9RPL'1A*^#G'GG&>F[^^5U,29&*GR%/3]G6UW[.NB7
MKWOW7NO>_=>Z][]U[KWOW7NK7NBLH<OU-LFI9BS08M\6=1!91A:VJQ$:FQ-A
MHHETC^A'N+-[B\&[D'JVK_>@&_R]2GLDOC6D9]%T_P"\DK_DZ%KV5=&O7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]TH]K4_FRBR$76FBDF_P -1 B4?]9+_P"P]K]N
M37)7T!/^3_+T@W*31'3U('^7H3?8AZ#W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4;_ /"DGLOL;I_^2U\S>Q>I
M=_[VZN[!V[_LNW]W]]==;JSNR=Y8/^+?*_HO!97^#[GVU7XRMI?NJ+)U-'4>
M"=/)!42Q/>.1E/NO=$;_ .$@?>'=/?O\M7N_>/>W;_:/=6[L;\Y.RMM8[=/;
M6_\ =G8^XZ#;E'T)\9\I2;?HLYO'+9FJBHHJK,UE3'21RK$LM7-(JAY7+>Z]
MUM6>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?^%1W_ &XH^<W_
M );-_P#!A_'WW[KW7R!??NO=?:G_ )'O_;H7^75_XJEU1_[H(??NO=6H^_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDUO/_CS]V?^&UG?
M_=75>_=:/#K7B_X2N?\ ;JK&_P#BPG<7_0NUO9ENW]N?L'^ =!CD[_DGQ_:_
M_'SULA>RWH4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA=Y2^JAA
M!^BSRL/ZZC&B&W_(+>R;=6^$?:?\'1SM2_$WV#I$^RCHWZ][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z;\M_Q:LG_P!J^M_]QI/;-Q_9M_I6_P !Z>M_[1?]
M,O\ A'53OP'_ .9P[D_\1KF/_>HV=[Q1]AO^2Q-_SQR?]7K?K)KWK_Y)47_/
M6G_5F?JW+WEIUB_U[W[KW7O?NO=>]^Z]U#R.0H\3CZ[*9"=*:@QU)45U942<
M)!2TL3SSRM_@JH3[O'&96"J*DD #YG'5))!$I9C0 $D_(=5";^WA6[[W;F=S
MUID7^(53?94SMJ^QQL/[6/HE ) \<2J'*V#.6?ZL?<M6-HMC$L2^0R?4^9_;
MU$U_=F^E:4^9P/0>0_9_/I'>U?2/KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK,^?'\UCXP?
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M=?1XZE5E1JFOJH*.G#N;(AFJ'C6Y_ OS[]U[IC_OOLO_ )Z_:_\ Y_\ $_\
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M+^<K_P \'T+_ .CXVW_]1>_=>Z]_T")?SE?^>#Z%_P#1\;;_ /J+W[KW7O\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$':-'XZ::M8>JH?QQW_XY1$ZB/\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9_P"&UG?_ '5U7OW6CPZUXO\
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M6QLAU_V5L%MT24T%-,QI:7);NQ\=7)J18HZDRO\ MH[)[KW6F_\ *7^?KO\
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M(SX6@6*-@+,WFC(!X8'GVQ'RKLLYT)*"QP LZDD_(9Z>?F;>(06>$@#))@D
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M,.[-C;8Z$QN7QV P\]?59O;E%3[&S>T:A8<@9XHFACJH(E1>58*J'W7NA?\
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MK4J\<+&G"I>,GU\^B2_R;NZ>H^G_ /9C?]*?9.R^O?[Q?Z(?X%_>_<.-P/\
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M\R_Z _\ #QWK_P"Z3"^PC[;?V\W_ #37_CW0J]P?]QXO^:G_ #Z>BL[ ^?\
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MZAS-)!45%)@/DWM:/)&*">H%'2Y7K'M6F@KZRH4.(HA/#%3^24@-+4QH#J8
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M4@5.11"&-3G>S]XK=9.=:V/_  IU_P"R.^B?_%EL9_[Z[LKW-?L9_P E.?\
MYY6_ZNQ=0Y[V?\DR'_GJ7_JU-T9S_A/G_P!NS.L?_$@=O?\ O=9/V0>[O_)=
MG_TD/_5I.CWVH_Y(<'^FF_ZO/U=E[C/J1NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NLD,4D\L<,2EI)75$4?EF-A_O?NR*7( XG'5
M78("3P'0P8^CCH*2&ECY\:^MO]7(W,CG_7)X_H./8I@B$"A1Y?X>@M/*9F+'
MS_P=3/;O377O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UJ6_\+-<)N[+?RF^OJ_;<&1EPVV?FKU!F]_R456*
M:FIMHU'5G?&VZ*?+PFHA^XISGMP82-80LMIY(9= \>M/=>Z)_O#J3XT?*C_A
M'U#@/C?5=>UVY?CW\=NN.X^PX-M4>$J-P[3[NZ;W12[[[\7>5!C_ !5=)D:^
M [L:.IJPDDE/D14J9:>3]SW7NCB?%CO;X&_S!?\ A-?A:GY;[LZTR>.ZD^)6
M8Z/[BR_8>8VKD>R>N.U.@=JU6U=G[GAK*BMJ\C!GZH87#[DV\1(*RK3*TI97
M>IDC;W7NGW_A('\J.T/D)_+&W!UQV=E&S\?Q7[LRG3'6V8G,SY"/JJ?9.S=Y
M[9VSD9YZB<RG$5&X,A143((DCH$HZ94_R<N_NO=;6/OW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]^Z]U
M]J?^1[_VZ%_EU?\ BJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z36\_P#CS]V?^&UG?_=75>_=:/#K7B_X2N?]NJL;
M_P"+"=Q?]"[6]F6[?VY^P?X!T&.3O^2?']K_ /'SULA>RWH4=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@MXQ6GHI_\ 5Q2Q'_ITZN.?^GQ]DNZK
ME6^1'[/^+Z.MJ;##Y@_M_P"*Z1GLIZ-NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/5TL%=255#51B6FK*>:EJ(C])
M(*B-H9HS_KJY'NR,4(8<001]HZJZAP5/ BA^P]4U[FP55MC<.:V]6@_<X;)U
MF/D8J5$HIIGCCJ$! ],B!9$/Y5@?<OVTXN8UD7@P!_;_ )NH@N8#;2-&W%21
M^S_/TQ^W^F.O>_=>Z][]U[JH;^;]_,KS'\NKJ#957L;8L>[^U>YJW=F#V'D<
MY'5'8^SFVK0X:?+;@W**30]7.AW%2B@Q8FION")I&E$=,Z2(;Z[^E44%2:T]
M!3I=8VGU3&IH!2OJ:]:UOP__ )97S/\ YMO9<GR>^66_-[[;ZHS[TM17=M;P
MIX5WEV'C%>::'"=,;5FHX*.EQD0E815RTE-BJ?S'[.&K=)H$*8+.2^.N0FGJ
M>)^S_53HWN+R.Q&A *^GD/M_U5ZW5OCC\;>G?B?U1@.E^C=I4VT-C8 RU*TR
M32UN2S.8JTA7);BW%E:EGFK*^J-.AGJ)3]$2- D4<<:B"*)8%TJ*#H/S3-.V
MIN/0Z^W.FNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZXLJNK(ZJZ.
MI5E8!E96%F5E-P00;$'W[KW2<I]E[.I*I*ZEVGMFFKHI#-'64^"Q<-5',;WE
M2HCI5<,=1]0-^?;AF<BA8_M/50@&:#]G2E]M]6Z][]U[KWOW7NO>_=>Z][]U
M[KP%^!R3P /S[]U[JR/X\=0G8V'_ +S9^ET;KSM,H6GF2TN$Q4A26.B*GE9Y
M=*O47L5LL=@5?5'7,&[?6OX49[%/'^)O7[!Y?MZD7E_:?H4\20=[#A_"OI]I
M\_V=&5]ASH1]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TPYS:NU]S
MK FY=MX#<*4K.U*N<P^.RRTS2 "1H%KZ>H"%@!<K:]O;B2M%\)(^PD?X.J/&
MLGQ '[0#T[TM+2T-/#245-3T=)3QK%3TM+#'3T\$2\+'##$J*JC\!0![H26R
M>K !<#K/[UUOIASFU=K[G6!-R[;P&X4I6=J5<YA\=EEIFD $C0+7T]0$+ "Y
M6U[>W$E:+X21]A(_P=4>-9/B /V@'IWI:6EH:>&DHJ:GHZ2GC6*GI:6&.GIX
M(EX6.&&)455'X"@#W0DMD]6 "X'6?WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2YVIC+:LE,O)U1TH(_'
MZ99A_P!"C_8^SC;;>GZA^P?Y_P#)T3;E<5_3'VG_ #=+?V<=%'7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW1:_E_\3^F_G#\<.U/BWWW@7SW6/;.W7PF96D:FAS6$KZ:I@R>WMV[8
MKJJEK4ILKB:^BILACJEHI52>G0NCIJ1O=>ZJF_D]?R/MG_RONC_F/\>]W[]P
M?R#V1\I-_9'SY>KVK/MC-9'I2;8U1LO&]>;]Q_\ $,E3S5$46;RYFGHY$AE_
MB,C+%%?0ONO=:D_R#_X1<?.W!]R;@QGQC[M^/&_NBJ_-54NR-T=N;NWAL7L#
M!;>J:V0T&/["P>W.LMSTL]920.B3UN&>6.J,;3)24A<4J>Z]UN^_R@?Y8FP_
MY3OPYV]\:=K[D7?^\<GN3,]B]Q=F#%'")OSL?<$-#05%;08AZJN>EH*''X>@
MQ=! \\K^*B$LA\LTGOW7NK2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW5 /_  J._P"W%'SF_P#+9O\ X,/X^^_=>Z^0+[]U[K[4_P#(]_[="_RZ
MO_%4NJ/_ '00^_=>ZM1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=)K>?_'G[L_\ #:SO_NKJO?NM'AUKQ?\ "5S_ +=58W_Q83N+_H7:
MWLRW;^W/V#_ .@QR=_R3X_M?_CYZV0O9;T*.O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z2V[8?)CHY@.8*A"3_1)%9#_R=I]ENYIJC!]#_AZ,ML>D
MA'J/\'0<>R'H^Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z('\L=CG'9_%[ZHXO\ ),_$N,RS*EECR]!"!22R
M-QS/31Z5%O\ E%8D\CV/.5;WQ(V@;BN5_P!*>/[#_AZ ?-5EX<BSC@W:W^F'
M#]H_P=%#]BSH)]%T^3OROZ%^'O6]9VEW]O[%[*V[&9Z;#T4K?=[FW?F(H&J$
MV_LW;L#&IR-:ZBYCA31$MY9WBA5Y%:FF6 :F-/\ +T[# TYTJ*_Y.M+WY7?S
M*/FO_-\[0A^+WQ:V+N[:75.X:FO@I.J-H5OFW%O; T]9'%_>GNS=E,*6GIL;
M#&T4M30>:/&4SS:)YJZ1:>?V037<E\=" @>@\_MZ$$-I'8KK<U(\S_DZVL?A
M9\'CUG\)^E_C=\OZ7K_Y+[CV!-7;BJ4W_MO']E;8VSF*[-9;,8;#[;??M!DW
ME7!P98T%%7>&G8(A6!(8=$:G5O;Z(PDE&(]<_P"'TZ)+BXUR%XZJ#Z8_P>O5
MBU-34]'3P4='!#2TE+#%34M+31)!3TU/ BQ00001*JHB*H5$4    "WM5TEZ
MS>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z.Q\=>CV9Z+L+=]&R)&4J=KXBJCTF1
MAI>#.U<;&X4?6EC9>3:7Z>,D&<P[UQMX3\G8?\='^7]GKT,^7MEX7$P^:*?^
M/'_)^WTZ/![!70UZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IQQ>/?)5D=.MPE]<[C_ '7"
MI&LWL>3>R_XGV_;0&X8*.'F?0=)[F<6ZEO/R^WH7(XTAC2*-0D<:*B*/HJJ+
M #_;>Q0JA10<!T&&8L:GB>N?O?6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JD'_A0;\ZOD#_+J_EVYSY*
M?&?+;;PW9^,[>ZOVA!5;LVS0[MPSX/==9E:7+P38C(%$+D0(T<BLK*5^I!(/
MNO=:'O\ T%V_SE?^>\Z%_P#1#[;_ /JWW[KW7O\ H+M_G*_\]YT+_P"B'VW_
M /5OOW7NO?\ 07;_ #E?^>\Z%_\ 1#[;_P#JWW[KW6[A_P )LOYC/R8_F=?!
MGM;OKY59?:.9["VC\L-\]0X:JV9M*BV;BX]F8'J#HK>>/IY\702S))4"NW]D
M6:<F[(Z):R#W[KW6PA[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH
M!_X5'?\ ;BCYS?\ ELW_ ,&'\???NO=?(%]^Z]U]J?\ D>_]NA?Y=7_BJ75'
M_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M36\_^//W9_X;6=_]U=5[]UH\.M>+_A*Y_P!NJL;_ .+"=Q?]"[6]F6[?VY^P
M?X!T&.3O^2?']K_\?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW3=EJ?[G&UL(%RT#L@'YDB_=C'_ "4@]L7*>)&P^7^#/3]L_AR*?G_(
MXZ"#V%NA3U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]TD]\;1Q^^MK9?;&2LL.2IBL%2$#R4-;$1+15T0NO,4B
M*Q (U+=";,?:JRNVL95E7R.1ZCS'YCI+>VBWT31-YCCZ'R/Y'K1__F4?SW.G
M?AKO3,=)=$XK;7R-[KVKN3(;>W_44&Y'CZKV!4X6HFI,IBZC=.&@K/XOE%GA
M^W>BQ[K'3$2BJJ8ZB$TCR/+NZ!08^ZH!SB@(KGY_+J.8MH?41)BA(QFI'^3I
M#]Y?!.?^>7T7\*_ECN7>FX?B[FFV)EGW+U]5[7CWW25^WLYN6,RY/:LTFY-O
M_:??)@S7XNMG2I\]%749GA1XBC6DMOWBJ.25QPX]4CN?W<SH!JSQX=6]_$7X
M3_'?X1=>1]>=";'I<#'5+!)NG>&1\63WWOK(0>5DR.[MS/#'-4%&GD-/3((J
M:G#LM/!$I(*^"W2W%%'Y^9Z0SW#W!JQ_S#HV/M[ICKWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NCF]#_'V2L>CWIOVAT4*^.JP>W:I/77-P\.0R\##B$<-%3L+R
M?J<".RR _?-_"5A@.>#./+Y#Y^I\O+/ 8['L!>DTXQQ5#Y_,_+T'GYXXGK M
MP. . !^/8'Z&_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==JK.RJH+,Q"JJ@DLQ-@ !^3?W
MX"O6B:9Z%7!XL8RD"N!]S-:2H;@V-O3$"/PM_P#;DGV);.W^G7/$Y/\ F_+H
M-WEQ]0WR&!T]>U?23KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#D,9C<M *7*X^AR=,)%E%/D*2"
ML@$J!@D@AJ8Y%U .0#:XN??NO=,O]R-E_P#/(;7_ //!B?\ ZD]^Z]U\QW^6
MSBL74?\ "Q7L7$U&-H)\4OSZ_FMP+C)J.GEQZP4NQ_F*U-"*-XVC"1F)"BZ;
M+I%K6'OW7NOIQ?W(V7_SR&U__/!B?_J3W[KW3SCL5B\1 U-B<;08NF>5IWI\
M=1T]% \[(D;3-%31Q*7*Q*I8B]E _ ]^Z]U/]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=4 _\*CO^W%'SF_\MF_^##^/OOW7NOD"^_=>Z^U/_(]_
M[="_RZO_ !5+JC_W00^_=>ZM1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=)K>?\ QY^[/_#:SO\ [JZKW[K1X=:\7_"5S_MU5C?_ !83
MN+_H7:WLRW;^W/V#_ .@QR=_R3X_M?\ X^>MD+V6]"CKWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!S(TWVE=54WT$4SA/\ EFQU1_\ )K#V
M%)X_"<KZ'^70J@D\5 WJ/Y]0O;73W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO= -\A?E'\=OB;LE.QODIW/U[TKLN:MCQM'G
M>P-QT&"@R>2D*!<=AZ:HD\];46D#-#213.JW=E"@D72-I#103]G5))%B%6-.
MM7S_ (4>_*;^8QOKKWXM]1_RRL-V/V'\</EULG*9G<_>'Q;VYG]_Y3?ZY2LQ
M5'MO8%)V1LB#*Q8/"9*@S<5>]1#-129*-Y(?NOLJ>N@E,+&- 29* KY'%.B^
M^D<@"/(/F.BW_P LK_A*W%U!U_@?DA\XZ;$]@?("GAI=Q[?^+L,F,W!UQL*(
MI'5"#?N2I9*JFW'N.F"@_94\T^'B<21#^)N8*F$VL=TA$X$@[.&H\ ?(D>G_
M !?15>[7,8"8SW\=(\QYBOK_ ,5U>DD"4R+31PK3QTZK D"1B)($B C6%8E"
MA0H72% %K6]C\=1^>N7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NI=!05V5K*;'8
MVDJ:^OK)5@I:.DADJ*FHF?\ 3'##$K,Q_P  /=))%B4LQ  R2< =7CC:5@J@
MDG  R3T?GIGXXTVVWI-T;[BIZ_/QE*C'X.\=1C\/(+.D]8PU)45*'](%XXR+
M@NVED N\<PFYK%!4+P+<"WV>@_F?ET.]GY>%M26>A;B%XA?M]3_(?/HVGL*=
M"KKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z![NSY!]%_&S:
MN/WS\@NW^N.E=F97<%+M/&;I[/W?@]E8"OW/78[*YBBV_297/UM##)62TN"K
M:F.G5R[1TLK@:8V(<BA>8T0%CQH 3C\NF9[F.U&J1E05I5B%%>-,T].EWLS>
M>TNQ=I;;W[L+<F$WELG>6$QNY=I[LVUDJ7,;>W)M[,4L5=B<WA,M0RS0U-+4
MPS)+!/$[(Z,&4D$'W1E*$@BA&"#Q!Z<1Q( RD$$5!&00?,=*;WKJW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW2VVOB+D9.H7@7%(C#ZL"0TY'^%K+_L3_3V;[=:U_4;
M_:_Y^BC<;K_0U_VW^;_/TNO9ST3=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5]_-[_ )D?
M_#5'PWR_RU_T,_Z>?X7V'L78?]P/](G^B[S_ -]:NMI?XK_>K^XO8FG[;[/5
MX/X:WDU6\D=KGW7NM43_ *#G/_!7?_L[/_ZH_OW7NM8'XT_S6_\ 9=_YR6X_
MYMG^@7^^']X/D!\L>]/]E_\ ]*/]W_M/]F@P7<F%_NM_I6_T=9OR?P/_ $M^
M7[[^[:?>_P /T_;TGGU0^Z]UL_?]!SG_ (*[_P#9V?\ ]4?W[KW6S]_)4_FM
M_P##P?Q8W]\E_P#0+_LN_P#<?Y ;IZ+_ +E?Z4?]+?\ %/[L]==5;_\ [T_W
MC_T==9>#S_Z3?M/L?L)M'V7E^X;S>.+W7NK?O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW5 /_"H[_MQ1\YO_ "V;_P"##^/OOW7NOD"^_=>Z^U/_
M "/?^W0O\NK_ ,52ZH_]T$/OW7NK4??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW2:WG_QY^[/_#:SO_NKJO?NM'AUKQ?\)7/^W56-_P#%
MA.XO^A=K>S+=O[<_8/\  .@QR=_R3X_M?_CYZV0O9;T*.O>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MW4I2J@JU'IGB\;D?\=83P2?\58
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MQ^18?X".L$/QYZ<@8NFS(6)4K:;,[CJ5L2#<)49B50>/J!?_ &Y]V/,%X?\
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MW]NW^D/_ !Y>@?SM_N*G_-5?^.2=7-_RH?\ MV3\ O\ Q4/H#_WVFW?99?\
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M )IQ?\>?HTWQP_YD9UC_ .&O2?\ 6R;W*7M]_P D2R_YYT_P=1QS[_R6;O\
MYK-_DZ&SV,>@CU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJQ?\ "NO_ +=N=)?^+O\
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MT=P=H[KC/^?HZG"8%6ZUV:9Y'+@C1DJ&954VO%9?0"/>V[4'^KY]:&3U9/\
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M3VMO/<--CZO<^1V=M7,[G?:>":*IW%EQB\76Y*EQ6.HM1;[BM-$8*4, 'D8
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M (<(RO\ SZW'_P#H65/_ -8/8]_X(&3_ )05_P"R@_\ 6GH$?ZQL?_*8W_.
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M;-U_Y3;O_LHF_P"@^L4_2?3D\,T#]5==(DT4D3-!LO;E/,JR(49H:B#&QNC
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MKW\8RG_*_5?]36_XK[]U[KW\8RG_ "OU7_4UO^*^_=>Z]_&,I_ROU7_4UO\
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MXJJI,@8J:D6HCHZC RAXJN1/=>ZV8?A_\$OB+\!NO*GJWXA=%;.Z3V?D*_\
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M]Q3_ -!'+K4?["99#_O/M*^VQMPJ/L/^>O2I-RD7C0_:/\U.FR79I^L%</\
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M.\U!M3:E!,ZZG;2)*NKD @I( T\[!0 U;>W:Y;2O^P!ZGIS<MRBVJ(RRF@'
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M,L*/55"4$\\LCL(Z>FIIZF4B*%S[2V]NURVE>/\ (#U/1QN.XQ;7$9I30#
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M%OS%=6T:QI83:54*,OP H/\ 0>J]?YHGR#_F$?S%LC\<][;8_DX?-;XY=O\
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MG:V*P1EYZ@_A .3C_5]G3;[_ ";A<I!84=0?UI"IT@5I@U'H:>1Q0TKT-O\
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MOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O\
MVZ%_EU?^*I=4?^Z"'W[KW1[]XY3[_)&FC:]/0:H18\/47'W#_P"P("#_ (+_
M (^_=>Z2/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HI?R"_P"/EPO_ &HQ_P"Y]7[=3ATT_'H _=^J=&U^/O\
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M^]B]?]-]3]Y;*K.M-H4&\<[GNQ\7L*EVX]-DLS%A:+$0U.V=^[DJA73O))-
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M !=*_P#ZBI?^AC[]U[IM]^Z]U[W[KW7O?NO=:;O_  J+V$>U?D5_+ ZO%?\
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M=5/Y)122!&:.WIM<$@$G1&E-%!)]!T,I[B.T77(P51Q)-!G'1,?^'K_Y5O\
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MX_%UMN>R3H<]:HGQ-_[BD_GU_P"*[-_[R'Q0]G4_^X2?Z;_*W0'L/^2Y<?\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _\
M"H[_ +<4?.;_ ,MF_P#@P_C[[]U[KY OOW7NOL7_ ,EW_MU!_+]_\5>ZN_\
M=%#[]U[JSGW[KW7O?NO=>]^Z]U[W[KW7O?NO=)#?_P#QY&ZO^U%D?_<9_=DX
M]5?AU7][>Z9ZGXNF@K,GCJ2JF^WIJJOI*:HGU(G@@GJ(XIIM<EU&E6+7;@6Y
MX]^Z]T??9FW<=MC T^,Q-;+D*$RS5<-7+)!*915,'U))3(B,O^I('^Q]LL:]
M/**=*KW7JW7O?NO=0\A7TF+H:O(U\O@HJ&"2IJIO')+XH(5+R/XX4D=K ?15
M)_H/>P*]:)IT%65[RV)CUHVI)<KG355]/23IBL<T+8ZGF)$F4K#FY<.&@AM>
M1:<SS&_[<+F]MZ#UK6.M.+^?%\/_ .;O_,L^9&#Z:^/]109SX&M1]:Q;&@G[
M-V=U]U]B=[55 J;PW7VUM3)9>DW+E*VAR4U0U/-3X7+QPT/V_P!C$:EJH-[2
M>O:AU<C_ "G/^$__ ,3_ .6?18?LC.4U#\@_EBL<554]W;QP=&*#K^NFQTM!
M7X[I+;-0M2,)"R54\4F4EDJ,G4)-(C5,--)]HE>K=7V^_=>Z][]U[KWOW7NO
M>_=>Z2^3WKM3#5DF/RN<H:&MB6-I*>=V61%E19(R0$/U5@1[L%)ZT6 Z;_\
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MVOELYM"?JV@Q)QO7N+^XP&$H]BT&6BJ?'UM0G749NJ35+.?'9HQ%M[MGB$1
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MCIH7@R=/25V;R/DE>]3'1TL-H,B]DX]5?AU;/[>Z9Z6'7_\ Q^^U?^UYC_\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *CO\
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M\(CTZIK'4N+^:S\5H,E0X_<2=J[,BKW*QY+=/7.1I*&-5=$DE=*"KR52R)Y
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M](T+6O\ EB. /\3;W[KW2YP^V%@9:G(Z))5(:.F!U1QD<AI6'#'_  ''^O\
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MBIVAB2>F,E.#.MW1I(Q0JSPPU9J'2?#%!Q\^J#NST;O^8> OPM[[50 !M7&
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M -&^_=>Z]_",7_SKZ3_J1'_T;[]U[KW\(Q?_ #KZ3_J1'_T;[]U[KW\(Q?\
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M9TF2G6:2<3.Z^[APK5'#JI4D=*_YV?%+Y"_)7:?5>P^L=\[#P.S-LP2U6_\
M;>[\WNG#X_=6;HH\/%MV4MMG:>:FJ*>F$%8?'++3!7F215,BH\>HV"\>ML">
MFO!]=_S2MM8;%[>V_O3X5X7!82@I<7B,3C<3V!24&-QU#"E/245'30[!54CC
M2,*JJ  ![]V_/^77L_+HPF'Z?[L[:^/79O4?RTW'UYD-R[\DS6'H,WU#397^
M$8G;-3B<(V"JY*?<>)PSOD*3*4U55%?&8V00KKOJ"ZJ%-1_/K=*C/14.LNA_
MYEG4VT,=TCM3MKX_MUU@X9\-MWL++XW<V3WQM[;LC.],F.Q4N)6G:6E60I2T
M]5]PD=EC\YC5"MBRG-#U4 CH6OAC\,MV_%KL_OC<65W?C=X;7[)CV?\ W=RD
M^2RM=O>NKL0<S5[CS&\H:K"4%-%-65>8DG1::KK>&(9[B[:=]8'6U6G2P^#'
MQGWW\9-H]I8#?F6VEEJS>_:V9WUBI-HU^8KZ:GQ&1QF*HH*?(/F<#@&2I#4+
MEDC25 "+2$W T[:OV=>44ZS?[+9OG_9[_P#9H/XKM/\ N#_HB_N#_"/OLQ_?
M#^,7O]S_  _^!?9?;?[7_$-?_-OW[5VT^=>MTS7K#\Y_C/OOY-[1ZMP&P\MM
M+$UFR.UL-OK*R;NK\Q04U1B,=C,K13T^/?#8'/L]26KD*I(D2$ WD!L#Y&T_
MLZTPKTT?+SXJ]A=K[YZH[ZZ+WGA-I=V]-33)A*?=T,\NTMQ8::>6JFQF0EHZ
M*OFA?_**B*XB=)8ZIT9H2%E7:/2H/ ]>9:YZ1&Y.D?G1\C]M97KKY!=B=*=4
M=:Y6G:GS]'T)C-VUV[]XTXBD=,17Y;>E770T5$\RPFH-.':9%>%X_&QU>U*N
M17\^O4)X]0-D?#3N/!?R_MZ?$W-9KK5M]927-0[=SF,S>Z*C:34&5W;C]UJ^
M8K*K9E%60RJ_W416&AJ5L(CJ]3!-EP6KUK3BG2:ZYZ"_F)_'3K_ ]6=0=D]!
M;YVG%@:#Q5'9D6\7S/7NX*R@HI=RXG:E;08^".KQ$.0>JEQ3UU-*XA?3)2Q6
M5/?BRL:FO7@".C.?$;XIR?'>AWONK>N[Y.R>[>VLT=P]F[^EADIZ>LJ%GJZF
MEQ&%I9-)CI89*^:1I"D32O)?1'%'!##5VU?8.'6P*='(]TZMU[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
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MRB[EDD,#!5U)]T]3=B3ZM2WXL/=>ZV%_?NO=?!\_V:+Y,_\ >17>O_HW-_\
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MW[KW7O\ 9HODS_WD5WK_ .C<W_\ _9![]U[KW^S1?)G_ +R*[U_]&YO_ /\
ML@]^Z]TSYKY!=];EI8Z'<7=W;N?HHJA*N*CS79.\\K2Q54<<L*5,=/79J=%D
M5)W0. " ["]B??NO=)C_ $E]C_\ /?[V_P#0JSO_ -7^_=>Z7D7R>^2D,<<,
M/R&[RAAA1(HHHNV=_1QQ1QJ$2.-$SX"JH      ]^Z]US_V:+Y,_]Y%=Z_\
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M]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\
MWD5WK_Z-S?\ _P#9![]U[KW^S1?)G_O(KO7_ -&YO_\ ^R#W[KW7O]FB^3/_
M 'D5WK_Z-S?_ /\ 9![]U[KW^S1?)G_O(KO7_P!&YO\ _P#L@]^Z]U[_ &:+
MY,_]Y%=Z_P#HW-__ /V0>_=>Z]_LT7R9_P"\BN]?_1N;_P#_ +(/?NO=>_V:
M+Y,_]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW3)F^_>
M]MS0PT^Y.ZNVMP4]-*9J>#-]C[QRL-/,RE&EABK\S4*C%38LH!MQ[]U[I-_Z
M2^Q_^>_WM_Z%6=_^K_?NO=+_ /V:+Y,_]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R
M9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\ WD5WK_Z-S?\ _P#9![]U[KW^S1?)
MG_O(KO7_ -&YO_\ ^R#W[KW7O]FB^3/_ 'D5WK_Z-S?_ /\ 9![]U[KW^S1?
M)G_O(KO7_P!&YO\ _P#L@]^Z]U[_ &:+Y,_]Y%=Z_P#HW-__ /V0>_=>Z]_L
MT7R9_P"\BN]?_1N;_P#_ +(/?NO=>_V:+Y,_]Y%=Z_\ HW-__P#V0>_=>Z]_
MLT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\ WD5WK_Z-S?\ _P#9![]U[KW^
MS1?)G_O(KO7_ -&YO_\ ^R#W[KW7O]FB^3/_ 'D5WK_Z-S?_ /\ 9![]U[KW
M^S1?)G_O(KO7_P!&YO\ _P#L@]^Z]U[_ &:+Y,_]Y%=Z_P#HW-__ /V0>_=>
MZ]_LT7R9_P"\BN]?_1N;_P#_ +(/?NO=>_V:+Y,_]Y%=Z_\ HW-__P#V0>_=
M>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\ WD5WK_Z-S?\ _P#9![]U
M[KW^S1?)G_O(KO7_ -&YO_\ ^R#W[KW7O]FB^3/_ 'D5WK_Z-S?_ /\ 9![]
MU[KW^S1?)G_O(KO7_P!&YO\ _P#L@]^Z]U[_ &:+Y,_]Y%=Z_P#HW-__ /V0
M>_=>Z]_LT7R9_P"\BN]?_1N;_P#_ +(/?NO=>_V:+Y,_]Y%=Z_\ HW-__P#V
M0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\ WD5WK_Z-S?\ _P#9
M![]U[I/9SO3N[<[4S[E[C[4W"]&LJTC9SL+=N6:E6<H9EIFK\O4% YB4L%M?
M2+_0>_=>Z9Z;M3L^CJ(*ND['WY2U=+-%4TM53;OW#!44U1 ZRPSP319%61T9
M0RLI!! (-_?NO=+G_9HODS_WD5WK_P"C<W__ /9![]U[KW^S1?)G_O(KO7_T
M;F__ /[(/?NO=>_V:+Y,_P#>17>O_HW-_P#_ -D'OW7NO?[-%\F?^\BN]?\
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M[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\Z>]?_18; _\
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M"#^,W_>=/>O_ *+#8'_UV]^Z]U[_ * @_C-_WG3WK_Z+#8'_ -=O?NO=>_Z
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M!69#!8_LOL+;VS*W,T%)4LD<LU+'FFGBCD(5F0*Q )]^Z]UO\?\ 0$'\9O\
MO.GO7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>
M]?\ T6&P/_KM[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\
MZ>]?_18; _\ KM[]U[KW_0$'\9O^\Z>]?_18; _^NWOW7NO?] 0?QF_[SI[U
M_P#18; _^NWOW7NO?] 0?QF_[SI[U_\ 18; _P#KM[]U[KW_ $!!_&;_ +SI
M[U_]%AL#_P"NWOW7NO?] 0?QF_[SI[U_]%AL#_Z[>_=>Z]_T!!_&;_O.GO7_
M -%AL#_Z[>_=>Z]_T!!_&;_O.GO7_P!%AL#_ .NWOW7NO?\ 0$'\9O\ O.GO
M7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>]?\
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MUL#:75?5>TL)L+KG86$H]M[,V9MNC3'8#;. QR>*@P^'H(O3#3PKZ8HELJJ
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M[&QU5?/'222/+4U-)24T4;U%94T].CRCW7NM>/(?\*O\MLNA/;W;7\GCY_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1W^)&%P_\
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M&DK:3S*$EIR?=>ZR_/S$8K^91_PJP^(?PH[$^RWM\?/A!U=1=B[YZTS5*T.
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M87<G^D]J*(I][48"BWGC.LTJY(XF>3[2CKI*J41LD$$TK1QO[KW5E'_":_\
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MSG_@KO\ ]G9__5']^Z]UJV_SF_YI'_#NORQV[\H?]!G^R^?P#I/:'3W]Q_\
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M/B]C[ZVKF*RA7-X:ODRK?<4E$] B)41H(YF#'0"C>Z]UIJ?'SX-=U=O_ ,V
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M\*N-J?)+X,_S+.L_D[TEW5VKL+87R8VMB.S=KXO"=A[F7;>"[OZ1KMO8+?\
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MY-CXZI7*4,0Q^:BCR+5 J:*FJ4IY14U<T/NO=7H?\)QOAC\E?@9_+4V[\?\
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M1R)55<55*I:GE@]U[JE?X4]?_P#"OKKGHO9GP"Z[ZSV=T3U=M_"5.R-H]_\
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MK:&R]F_S1>LML;3VKMS#4D5!A]O[;VYA/E]0T=#14D$"0TU)2PQ111HJ(JJ
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M_6^05ZN@ADQ5?M;:W>O<%3,TBOYR),.T12E8,XD\4<GNO=;3?\B3_A.CL/\
ME19:N^1'<N_,3W;\PMR[-?:"Y?;5-D*;JSIW"9DP5&Z\-ULN8I<?6Y.LKVIH
MJ:IW#D:2AF:EA,%-1T4=36K5>Z]UA_X4I_R4^U/YK74W3/8?QLS.#B^1/QL?
M?--AMB;LS46W]N=I[%WZFWJO-X"ES=31U$-'FZ.LVG2S8F6JFHZ.1*JKBJI5
M+4\L'NO=4K_"GK__ (5]=<]%[,^ 77?6>SNB>KMOX2IV1M'O_NNKZ:GS'2NR
MJ2GJ!18K%[RV[NC?=9/2TP44>-:EVON&MIUEC$!CAA62#W7N@B^+O_"?/^:_
M_+Z_G']"_(387357\K>@NI.\.O,_N[Y&5O</0>T,EV!MK?VT\7B^^]\Q;#WS
MW-3[F2KQLV]-PM34M92S5%3+CT*RU F2HD]U[KZ-&7Q.,S^)R>"S5#39/#YK
M'5N)RV-K(EGH\AC,C32T=?0U<+@AXI8IGCD4\%6(/OW7NOB/?*/X2UG7W\SS
MMS^7]TIG=M;YKZ;Y?9+XW=1Y#&;AES>+JZK<O9<6S-@8'/9J"CFD7)4+9BDQ
MFX(EAF>ER%-5P?NM#=O=>Z^T!\9>A-F?%KX[](_'#KV P;+Z/ZNV5UCM\O<U
M%91;/P%#A3E:Z0\R5-9)2O5U4K>J2:9W;EC[]U[K3S_GH?\ ";3Y%=V?*G(_
MS&_Y8^>PF/[MR^X<!V7OGI^?=4/7VZ).X-HM3Y''=K=.[WS%72XN#*5=5AZ.
MJJ:+(UF)1:Y7K8JHM,\2^Z]T6#LSL'_A9UW9TAEOC+G?CU-A(-V;9R'7V[>U
M-KT_QBV/V;N3"9'&G#9L5'8D7:5)B,7-5P"96RN%I,1,IG:2FJ(G\3K[KW5S
M_P#PG1_D+[A_E/;?[+[Q^16XMI;K^6?=. IMBU6/V/,V7VEU)U719JGW!-M#
M$[IK,9C*G(9#-5V,Q]=G94CCI$;%T5/3B7[>2KJ?=>ZK,_X6\]^8_'].?!_X
MNTZF?*;N[,["[\R[JR@8S']=[6AZ\VXLJ%=3??R=HY4QE39?X<^H>I??NO=;
M1O\ *!^*$_PD_EH_#KXW9/%KAMU[*Z>P^<[$QPJ*JK:D[2[*K,AV?V?3-55M
MI7$6>WCD(8P0JHD:1QJD2(B^Z]U9'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5@_X5"_RD>R_GWT%U=\C/BIL
M_*[I^7GQ>S\%+A=N;3EBHMX]B]4[JS- V7PN"KI<EBU_B&W<DL.X,;>4.L/\
M32G#5$\2-[KW5]/P/[+[N[<^'_Q\WS\E^M]Q=2?(C(]:;<H>\=A;FPE3M^NQ
M/:>#HDPF]*RBQU14U^G'Y"NH)<EC2E35#[6KB5I6D5[>Z]T;;W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]UJD_P ]ON'_ (4+]??('&;-_E5[$W9N?XX;VZ$V
M3/F]Z;%ZNZEWENS8O<$>_NR:?>>,PN5WC%D*R"2JPF.P32S5%#40Q)5@T4D%
M6'D7W7NJYO\ A.K_ ,)Y?EMTA\O$_F$?S&-K_P!QMR=?INO*]0]:[EWACM[]
ME;H[9WDF4P^9[:W_ )/;>Y,Y2P145)D:]Z2"NJ:RKK*S(I6R)3_:1/5>Z]UO
MG^_=>Z][]U[KWOW7NO>_=>ZTG]X?RU_E?_-&_P"%&%5\L/E5\=][=4?!'XBO
MMW$]0UG96'.+7N[ ]%9C(UFP<=A8*7-U32T>>WIGLCN^1*J*F!PKK1U5,M1-
M(OOW7NMV#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
4=>]^Z]U[W[KW7O?NO=>]^Z]U_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>timage_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M<_V'N_ ;?A\N*QD^>RGR!HSD9H# \P-&DB,L,2P>Z]TC_BM\O?CS_)4^:_\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\
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M .0]%MZV4RG4.;GS&YL3N?:^7W?14KT>-R&+SN(\=3*(Y98A(*NF]U[JSO\
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M0OO#?/75/L+K/?VV<IN?)S^#<L*Y(8MEW13U3253P9BJ:G]U[HR>T?Y</>&
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_P *!/\
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M_)7[IS,N V]\X]C[2R<>D@]O[.[0Z8PTL;@VDBW7V?LC:VTCZ@04->)5M<J
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M;L_^4'\]-S;2^/G1^UMR8;I*HJ\1N#;G4^P\)G,55#<^VXQ4XW+8S 4M?0U
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M)7RXJ/(4+Y2"$5,^-2K@:OAIR8P)Y:-9#41PDS)9BH7UCGD>_=>Z]D,GC<3
M*K*Y"AQE,9%B%1D*N"C@,KABD8FJ9(XS(P0D"]R ??NO=>J,GC:22CBJLA0T
MTN1D\6/BJ*N"&2OE.BT=&DDBM52?N+P@8^H?U]^Z]TF6[(Z[3=2[$??NRUWN
MRZUV:VZ<&NZF33&VM=O&N&7*Z95-_#:S#^H]^Z]UFW5O_8>Q1CVWOO;:.SER
MU2*/%'=6Y,-MX9.K9D1:7'G+UM&*RI9Y% 2/4Q+ 6Y'OW7NE135-/64\%91S
MPU5)50Q5-+54TJ3T]33SHLL$\$\3-%-#-$P9'4E64@@V]^Z]TE]W]@;"Z^H1
MD]^[WVCLC&E9'&0W?N3#;:H2D.DRL*O,UM% 5B##4=5EN+^_=>ZG[;W9M;>>
M,BS6S]R[?W7AIM/ARVV\SCL[C)=2+*OBK\74U5+)JC=6%G-U(/T/OW7NJ$/E
M]\FN_=B_\*$?Y27QEVCVKNS ]!=X=(?*S/=L]54%;&FTM]9G9'3G=V?VIDLW
M0O"[R5>$S.#HZB%XWC.NFCU:@H'OW7NKV<-V5USN+/5^U=O[_P!DYW<^+5FR
M>W,-NK!9//8Y59U9J_#T5?/D*-5:-@3)&MBI_H??NO=+7W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1*_G7_+[^+'\Q
MCI?+=)_*+K'!;UQ4E!F8]F;R..QZ=A]49W,4T$$F[.L=W34E1DMJ9Q9*.G:8
M0M]M7I3I#615$%XC[KW6F?\ R5?Y6^W/CY\Y?E+_ "T_YD'\N#:/R+V'@<OF
M=R_';YP;M^*>:K=@Y^;$4./R;[>F[<RF$J-O' ;_ -C5M-D\;039&JDPN<I*
M[&>>:6=%C]U[K:Z_X9%_E$_]ZZ/B7_Z)_:__ -2>_=>Z-+\:?A%\1/AO_?3_
M &5;XY]2] _Z1O[N?W[_ -%NS\7M/^]G]T/X]_=?^._PV&+[_P#@/]Z,C]KK
MOXOO9;?K/OW7NC2^_=>Z][]U[K2T_GO]L?\ "8S;7R!W#2_-SI[</<_S+PL.
M.G[$Q7P]AW#@.SI)\E3XS'T%-W'N_ [\ZMZKS6ZL?A<33'[;.Y2KW%C,8D82
M*..>!)_=>Z7'P;ZU_P"$V?PI_P"&]/E5B>F*OH_L/^8-B]U9KXI;G^468WCV
MA4[,R6QLEMK"U\68R>1W/OCJ[J7<U;D-YX^*CR[F*\E0T<=?&JNOOW7NMQ)6
M5E#*0RL RLI!5E(N"".""/?NO==^_=>Z][]U[KWOW7NO>_=>ZK__ )@O\N'H
M_P#F1[1Z/V9WENKM7:N+Z"[^V=\C=G3]49S:.#K\EO?9&,SV*Q.*W++N_8V^
MJ>LVK44^XIVJ(*6*CJW=4*5,8#!O=>Z/O6T5'DJ.KQV1I*:OQ]?33T5=0UL$
M551UM'51/!54E72SI)!4TU3!(R21NK(Z,000??NO=:XV[O\ A-%\;4S^_J3X
MZ?-3^8S\+^C.U,ME\UOOXO?&#Y)R;)Z(K*W<#R'-Q8;9V3VSG:;'XK(Q.(S1
M5?\ $:6&%5AA2.!4A3W7NKIOB!\//CW\$NA]I?&_XQ["I>O>K-H/75E+C5K:
M[+Y;,YS+S"JS>Y]S[@RL]5E=P;CS52 T]342,51(X8ECIXH8H_=>Z$;O38&Z
M>UNF^SNLME=D97I_='8&R=P[.Q':6!P]#GMP;!FW%CI\5+NC;V+RD\&-GW#B
M:6J>6@>H+P0U:QRO'*J&)_=>Z#3X7?$GJKX*_%WICXH=+T4M/L'IK9U%MJCR
M-9!0P9G=>:=Y<CNS?6Y?X=3TE#+NC?.Z*VLRV1>**.(U=6XC1(PB+[KW5:G;
M'\E2?(=F?)#=OQ/^=WR:^#/7WS(SV4WA\GNF^CL7UED]K;WW[NBA?$[Y[#V+
MG-Y;8RNZ>G]\[XQD\AR&1P=5'*U9HJ$"-&J>_=>ZM-^+7QCZ;^&OQ_ZP^,W0
M&UHMG]3=2;=3;VUL.KI/63>6KJLIF<]G*](8&R^Y]T9[(562RE:ZB2LR%5-,
M_J<^_=>Z'_W[KW7O?NO=4[?\*!/^W,_\P;_Q!53_ .]5MGW[KW5L>RO^/-VE
M_P"&S@?_ '54OOW7NE-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/5Q2STM3!!4/2334\T4-5&JN]-+)
M&R1U"(_H=X7(8 \$CGW[KW59VWOD7W+\9=[CKWY8K/N?9.;R%0=J=T8G':H=
M$K^0)708^EA2JHXE;5+3")<A0\Z5J8#$5>**XK'Q].FZE31NK-()X:J"&IIY
M$FIZB*.>":,AHY89D$D4B,.&1T8$'\@^V>G.LOOW7NO>_=>Z][]U[KWOW7NM
M.OXOYK)=F_\ "QSY\)V'4+5OT5\%\3A>G*'(4D$3[;QM3MGX@3O3X9GACJ2V
M4A[9W)D6F9I)'3*3A&$!1%]U[K9:^<_R]V[\%/C3OCY,;IZO[9[DPNQJ_:%!
M4]>]'[=H=U]EYM]X;NPNT:>7 8'(Y7"4E;%BI\TM76%JF,Q44$L@U%0I]U[K
M7_C_ .%6?Q'K-[]7X'>WP$_F"[!K]Z=@;>Z_V5NOM#IGK/;.&QVZ=Z5D6%IE
MI\UENT?-3/)!,[U"TBR5#4L<A$;A2/?NO=+?_A0S_P!E7?\ ">__ ,:\] ?^
M_(ZJ]^Z]U?\ ?+C_ +)1^3G_ (KUW1_[[?<OOW7NM:/^2AF.^]O_ /"5RJSG
MQ:@R51\C,3T]\ZZ_I5,+24F0ST?8U-VQW9+MBIVYCZ^*>AR.Y:/(JDV.IIHY
MHJBN2*-HY%8HWNO=5E?RK-G?\)FOE!\7]N]8_-3.;6_X< WKC8Z7Y0;N^8/9
MO;G77;F4[MSU958W+56Q^V-Y;CV]M R0YBDT4=-BZ\U\=HQDX7J)G,_NO=;
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M:SMCI7J7L^KZCW+C]Y]4U78?7&SMZU/6.\<3)22XK=G7L^Y,-DI=E[EQDM!
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MY2_RT_YD'\N#:/R+V'@<OF=R_';YP;M^*>:K=@Y^;$4./R;[>F[<RF$J-O'
M;_V-6TV3QM!-D:J3"YRDKL9YYI9T6/W7NMKK_AD7^43_ -ZZ/B7_ .B?VO\
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MW<N)CJMH4:?>U%!]M7UL%8V32IBGIP9O%22I3I-$\C*CEELJ,PJ.M%@#0]&
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M=>]^Z]U[W[KW7O?NO=>]^Z]UI)_\+7<=V+4_';X'9%J7)57QPQ7R"WX_=/\
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M<A645=(:6KIHC[KW0V]\Y?\ E =C?\)TNB?E1UW3_$CHO^9#TG@^@<;MC/\
M3^Q>J=@_(C-_*;I_>&V]O[NI-Z]?[)7;&6WC3[XV[2U^X*NLS%)68]*6KI\U
MXIF@IXF]U[K>Y_E[=[9SY/?!7X@_(?<^$H-N;F[F^.74/8>XL)B:3[##T&>W
M+LC#9',1X.B$4*TF"DR,LCT,:KI2D:,*2 "?=>Z.'[]U[KWOW7NO>_=>ZH._
MG;_S /DS\?,Q\//@W\#O[OX[YK_S">SLKU]U_P!A;JQ=%F\!TIU]MI<+%OOM
M&?$Y6EKL179;#C<L%13+5TU=3QT5#7S&EJ)8H89/=>Z+9VG_ "GOYL'2'4F]
M_D!T#_/ ^7?:?RZVYM%MZ9/8G<6*VIFOB_V=G-FX:>OGV3M#IG*#/[>ZAIMT
MBC^UBJ*9:Q7G</4@L[31>Z]T9+XK_P [;:G97\D#)_S8>X=KXS!Y_JOK;>%-
MVML?#UU/@L#N#O+8^:38>/VWLZIS&3R,F'Q7;6^J_%+AZ>JJ*JKI!FH:8M52
MQAIO=>Z)5\9O@]_-J_F-?'S9?SS[R_FU?)/XA]S]V[>KNW?CM\>_CKC*';OQ
MVZ=Z_P"P<3%DNM<)VSUS4C#S]RS2X&:DJWCR\CU=!'/9:J:J,LQ]U[H]7\D+
MY]_(SY(X3Y._#GYWQ[:A^>W\OCLZ@ZG[KS6UH#2X7MG9N<I:]^NNYZ"&FPV$
MP2S;N.!R"U"XZ&&&2&*EKFI: 9&*DC]U[HF?5VQ>XOYU7S*_F<93>_S.^8OQ
M>Z ^#OR W=\'?CAUG\2NXLUT%5TG:'7,<M#V=WSV-7[5R&1?L;-ONFAADV[#
M7,M+!CIG1Z>)VD3W[KW1\?Y%WS0[9^3_ ,/NW\7\G=]46^>Y_A5\I^^/A_VI
MW)4XW'[4H^SDZ5EPF4Q/:61H8:IJ#%OD=J;GIXJZ1O!JJ:&>9U]7D?W7NF?^
M5?O/LCYQ]_?+'^9YN+>_8:_'3?NYJ_XT_ OJF3>.ZJ3K*3H'IK.U.(W?\AY.
MNHLZVS,CO+O#LN@K)*++U./;*T.'HS303K35+J_NO=7H>_=>Z][]U[KWOW7N
MJ=O^% G_ &YG_F#?^(*J?_>JVS[]U[JV/97_ !YNTO\ PV<#_P"ZJE]^Z]TI
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]T%O972?57<%''1]C;(PNYO"NFFKIXYJ+,T::@QCHL]C)J+-4<3LH
M+)%.J/;U ^[!F7@>M$ \>A Q6*H<#B,;A,-2QTF,PV-H\5BJ)9)3%2T..I8Z
M2AI1+*9IC'#3PJFIB[6%S<^Z];^SHAV*^>^&VWNVMV7\@NK]W=)92.MJ(J#(
M52U>YL'4444K(E7+44^(QF1EIW-ECJ**EK::8>O6BFWMWPJBJ&O5->:$4Z/7
M@-P83=6&QVXMMY6ASF#RU.M7C<KC*F.KH:VG8LHEIZB)F1U#J5/Y5@0;$$>V
MR"#0]7XY'3Q[UU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[H NF_E3\;OD)E]^;=Z2[PZS[-W/U;NS<&QNRMI[3W;B,EN[
M8&[MJY:IP6?P.\MJ+4KN+;=?CLK220D5E-"KE;H64@GW7NBN_&G^53\/OB+\
MH_DU\K>A=F9#9>[?EG@,1A^U]A0U>.J>JUK:'/9O<6:W!M3:\V)^]V[7;VR.
M;+9>D2MDQ,IIHFIZ2G=IVF]U[JB3?/\ PC2_EX[N^0N0[5Q?;_?&R^HLOO"/
M==?\>-O-M&/ 4E'+D1D<GLO;N]Y<2=QX+9]8-5/#&(YJ^CI7*0U098W3W7NM
ME?L;N7XB?R_NC-K_ .E#L;J#XO\ 0_66UL!L78]%NC<.&V7MO"[:VKBZ' ;9
MV=LW$U51'5Y-L7BJ2GI:3'T$514E$54C;W[KW1H_?NO=>]^Z]U[W[KW6*6"&
M;Q^:&*7Q2I/%Y8TD\4T=]$T>L'1*ES9A8B_OW7NM>;^<_P#S3LMUC2O_ "U_
M@=CY^]/YF7RFPF2Z[VALC8E5C\BWQYV]N[$/397MGLZM?[K&[4K\1MRNDK\7
M39#QI%&HR59HH8A]Q[KW57'\USX&4O\ ++_X2LY/XCT^Y6W5N3:V]NDL]VCN
MFFO!0[F[&WU\@=N[SWA_#XDAI6?;6'S-6E!BQ,GF:@QU,\VJ?6Y]U[K<1Z+H
MZ7'=(].8^AIX:2AH>J^O:.CI*=%B@IJ6FVEB(:>G@C4!8X884"JHX"@#W[KW
M6L/\",WE<#_PJ[_G0=?87'5%7LK<WQ>Z$WWG\_"M2U!C=XX/KWXD+B<+4R4B
M#$K6Y,=D9YXUF(JB,=-HO:H/OW7NC;;I^!W\RWX<?*[YA]X_RM-R?#G<O5/S
MPSLW;?973GRQE[*V9%TM\FGQ*8W)]N[ R_4VV-PG>^"[ R%54Y3<.,R*T=1-
M6)&(IC=Y??NO=%![E^,6\/A+\*NDOY+W2O;U1V+\X_YM'?W9>X_DUWSB<'1;
M<R=)L;?=33[I^:WR/DV]B:6:+!8;&=98RGVGAEGT25'EC\3K+%XH_=>ZL8W?
M_-A_EG?RYJFH^%>W_P#2U7[>^&/7&QMN]KP]"?'WM3N/K[XN;%I<"T6V&[KW
MEU_M?*87:,KX/$O4U&IIJ@:9&F19 ZCW7NKA.M.RM@=R=?[.[6ZKW?@=_=<=
M@[=Q>[-E;SVQD(,I@-R;=S-+'68W*XRNIV:.:GJ:>0&W#HUU<*RLH]U[I<>_
M=>Z0':V9[#V[UIOW/=2;*Q/9':&'VEG<CU]L#/;JCV-A-Y[PI,=/-M_;.6WG
M+C<S'M7'9G))'!-D#1U0I(W,GBDTZ#[KW6JS_.7^1'\W'=7\KWYG;=[T_EM]
M!=2=29;J.>EWWV1MCYVXWLK/[1PIW#@7;*XO8D71^W)-S5*U21Q_;BNIB5<M
MK]-C[KW6U_LK_CS=I?\ ALX'_P!U5+[]U[I3>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2^[M
MD[0W]AYL!O7;6%W3AISJ?'YS'4V0IUD'Z9X!41NU-4QGE)8RLB'E6!][!(-1
MUH@'CUDVAL_;&P=NXW:6SL+1;?VYB$GCQV)QZ,E+3"IJ9JVI9=;22/)45=3)
M+([LSO(Y9B23[\22:GKP%,#HEO9GRV[+Z-[ SE'VGT5F).I!E'@VYV)LZJ?(
M^3%E[4M5D5J0N'_B-6C"])-58^6)@P7RJ Q<6,,.TYZJ6(.1T:WJKMS87=.U
MEWAUYFAF<.*R;&U?DI:JAK<=DZ>*">HQV0HJR*&>GJHH:F-_H4='5T9D8,:,
MI4T/5@0>'0D^Z];Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZUO^W.H?\ A4K7=K]G5O2GRG_E7X;IJL[#WI5=28C?.WNVI=ZXKK*H
MW)DI=A8W>$N.^.65Q\FZ:':KTD60:"JJ835K(4ED6SGW7NJO/A#\M?\ A3G\
M^-W?+79G3WR/_EM[;RGPU[^W)\<NSY^RNO\ ?&'H,[O?:^3SF*R&5V'+M?IO
M>-1E-JS5& F:&?(18NK9&0M3(2P7W7NK?J78/_"C_ _$;M*@S_=OP!WI\SZ_
MMCKZ?I[-;'Q.Y*7J'"]/4V,RX[(H][1;PZCVGD9=SU^3>E- ::DJPJH+O&/(
M&]U[I;_S]_G3\D?Y='\MBI^27Q^S&U\3W)B^SNHMGUE;N;;&.W9@9:3=3Y"D
MW)$</6>*F+234X:*1"A0J+>DE3[KW5YWOW7N@A^0>[\YU]T)W?OW;,\-+N39
M'4/96[]O5-13Q5D%/G-M;,S69Q,\]).KP54,-?11LT;@HZ@J18^_=>ZK]_D>
M?+ON7YX?RNOC#\K?D%7X#)]O=J?Z:O[W5VV,#3;9P<_]Q_D/VUUO@?L<'2/)
M3T7BVQL^B272Q\DRO(>7/OW7NK8/?NO=>]^Z]U[W[KW5$G\YOY\?(KX3]J_R
MLMJ=$9G;6*PWRP^<NP>@.X(=P[6Q^XYJ_K[<VX]DXW(Q8.HK;28/,+2YFH$5
M3$25+@E6*K;W7NKV_?NO=$7_ )A]#\^,C\=:BF_EMYCJ7!?)=MZ;7:BR'=D4
M,VP4V2AKSNR.N23%9F4UTL?@%-XH"_EM<A-9]^Z]T=C$C(#%8P9=HWRHQ]$,
MFT6@1-D!31BM:+QJJ>,U.HKI %OH/?NO=.'OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[JO'^;'\C>SOB-_+F^6OR4Z8K\5C.T>GNK:C=
M^RZ[.8BES^(@R]/G,-2#^(8>M_R:OI9*:KD1D8C]5P0P!'NO="]\"^WMY_(+
MX,_##OKL:HH*KL+N[XG_ !U[>WY58J@CQ6+J=Y]E=0;.WGNBHQN+A9H<;039
MO-3M# A*PQD(#8>_=>Z-A[]U[JJ[^:=_-X^-G\HK8?5/8?R1V1WAO;"]P;NS
MFS-M4O2&VMA;DRE#E,!AH<Y63YV'?G9?6M)34$E),%B:GGJI#)<,BCU>_=>Z
MI3_Z#5OY67_/@_G_ /\ HK/CK_\ =5>_=>Z]_P!!JW\K+_GP?S__ /16?'7_
M .ZJ]^Z]U;__ "I/YU?Q8_G!_P"GK_9:-@_(#8_^R[_Z+O[Z_P"G3:W76V?X
MI_I;_P!(O]W/[K?W [5[-^]^R_T95_WWW?V7C\U/XO-JD\7NO=6_>_=>ZU<?
MYCG_  F!Z"^4'<&<^6_PO[HWQ\"_E[FMQ9G>N:WCL"?.5>PMV[SSZ,N=W-+B
M<+N';>ZNN]U;B^XJ379+;^1A@J9JRHGJ,?4SS2R/[KW5/VXOBK_PM"^*F/PF
MS^K?D?7_ "0VSC*<TD.Y-K=L_'7M6JI(L?40P4297)_+O;&T^T,X]>CZTD:"
MM/B0_<M&;*?=>ZD;2^//_"U3Y(G+;?[ [^J_CUA*X203;GW;O_XI];AS7S"2
MK_A,_P 9-I[K["Q!HO$I66GI*81H^BF8_N*/=>ZLJ^%__"5'JG =AX[Y#_S2
MOD?V'_,=[TI(Z<4NW-]YG=57U#CXX#35E/1;EJ]ZYO<?8O; Q>6>M> 5];BL
M-/#6NM1AY''D]^Z]UMN^_=>Z][]U[KWOW7NM:C_A13_.(W7_ "[^O>H/C7\=
MMU[.V-\LOEWDSA-N]L[]J8(]E_&WK YO';:SO=.YH9L3GXWJ!DLBU-C6FHJF
MFIDI:^N>*H:@2CJ?=>Z+?_*Q^27_  G^_EG=?Y>OIOYD73W>ORO[76/,_)'Y
M:=D9;>&:[,[7W75,*W)T]+DLUBLOE=O[(I\F[O2X_P"[GJ)B!/7U%75$S>_=
M>ZL/_F5[;ZH_G8_R<?E7M;X2]@X3OK^\&%?+=39G8TRI2;H[=Z*W3MSLJBV#
MC*W<M-BJ2.OW15X!<&TLC0P1MD3JF0*S+[KW0?\ \NC^>Y\ MW?!3J/+_)OY
M5],?'CY"],=7[?ZW^1W3?=&\\7UEVGA.V.KL!2;6WXF"ZUWCD8-\;G@RV:P\
MU31P8Z#(U2^84TO^5Q31K[KW0$?R"<#NCY4?+/\ FD?SC,CM++;+ZG^:_:VU
MNL_BW1;AH9:'.[IZ7Z+I:G:A['J(*E(IZ:BW9!B,-"(0FB')8^OA$DR11RM[
MKW6SSGL[A]KX/,[FW%DJ/#;?V[B<CG<[F,A,M/08K#XBCFR&3R5=4.0D%'0T
M5.\LKGA40D_3W[KW5"/\H? Y#YH]_?*?^='V+AZF.D^1>1E^.7P.QN?Q;TF4
MV1\$NEMQY.AQ6Z*&GR^V<#N+!UGR)[)CR&Z:ZFG:HT1^ 12M Z^_=>Z*E_(@
MWYU3TKU-_.WP'RLW;LK9>\MF?S2?F=O_ .0E+V-D\=M7(#J?.[)V%54N[]PP
M;ER<54-D[E&,W!4455-/)35$3RND\BOY&]U[HS7_  EFVUO?:_\ ),^*E'O;
M$9O!_P 3S/>&Y=HT.=HZK'U$FR-S=V;\SF!R]#25D4,XPFX_OI<C0S:?%64M
M6E3$SPS1NWNO=;"_OW7NO>_=>ZIV_P"% G_;F?\ F#?^(*J?_>JVS[]U[JV/
M97_'F[2_\-G _P#NJI??NO=*;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UBFAA
MJ89:>HBBG@F1HIH)HTEAEC<%7CEC<,DB.IL0001[]U[I@VQLW:&RJ.HQ^SMK
M;=VI05=7)755%MO"X["4M36S6$E7/3XVFIHI:AU &M@6T@"]@![V23QZT !P
MZ*WW[OSY7=<[NI]Q]8=>;9[/ZJAQ<!R> H::N;>T%<GF-<P2GR35U4SZ%-.]
M'1U2A&*20%@)&NH0BC&AZJ=0-1PZ5GQY^46U/D$VX,11[=W'LS>>T8J63<VU
MMQ0Q:Z0U,LM.S4-;&8Y*N&GJ8C')YZ>DG1R+Q $$Z="F>/6U8-T9SW3JW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJJ?\ ":__ )GU_/A_
M\:H]P?\ O9=E>_=>Z&O_ (53]N=K](_RF]S[[Z8[.[#ZBWQ3=\=+XVGWEUAO
M3<FP=UP8[(Y+,Q9"@AW%M3)8G+Q45?$H6:)9@DJBS CW[KW0,?\ "L266?\
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M52U/24M%CJ34\T\A2-$0LQ !M[KW2DSWR7[U_G[_ "/W5\?_ (*=X[^^./\
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MM7K#:N/S%3NO<&;K=[;LW-5;.V_G\@M!CH:.DAQ\60GFDE1'%-.1[KW5I_\
MPIUZQVGWCBOY'G3.^$K:G8W<'SDZTZQW?'BJUL?D*C:?8%-UYM7<"8W)1K(U
M%6RX?+S"&=0QC<A@#;W[KW2;^4'4F-_X3<_S!^L?GQ\<-FOMG^5=\L8-A?';
MYN=1;-VYDLSC^C=S;<QT^.Z\[=P=%CYI\BL)/DR*R/'5S5-:V;HB7J\YC_'[
MKW1HO^%:^?PFZOY*62W1MK*T&=VYN3N[X\Y_ 9S%545;B\SA,Q4Y3(XK*XVM
M@9X*N@R-#41S0RH2DD;A@2#[]U[HQO\ -P_FX/\ !WJ[I/XH_&*##=D?S'_E
MAM_9FTOC_P!;3ST\F,ZXQ.Z3#MQ^\NT9I:FFHMO[1PU13U8QIK9H(*NKHYZB
M4_P_'9*6'W7NA?\ Y2WPF^./\N#I?-S;I[ZZY[B^8'?62C["^7'R4W!V!@LI
MN[M+L6ODJLC-B8,UELU4Y1=C[1K,I40XV M']Q))-6S1BHJI /=>Z)3_ ,*T
M'AWG_)5W[N3:-51;FV_B^].B\O79O!5M)E,5!C5WG5[7:L^^HYIJ:6%-PY2G
MHV*,Q6HD"FQ!M[KW5WF7^?WQ&V_\5X_F5F^]^M*/H63K:E[/BWDF[L/4TE9A
M:S#+F*3'8N)*A:S);AK"WVL&/CA-;-6$0"+R^CW[KW6O+_PCZW1E-[_#WYU;
MTSF#FVQFMW?S&NV-T9?;=0*@3[>RF?ZOZ?RN0P<PJX*6K$V)JZMZ=O+%')>,
MZE4W ]U[I;_\)1_^9"_S*_\ QJC\A/\ WC>K_?NO=.__ '=U_P#F)?\ ^:A[
M]U[IH_X5<?\ ,A?Y:G_C5'X]_P#O&]H>_=>Z#;^8SO7L/YQ_SW^H/Y3?:GRN
M[4^)GP_Q'QLI.\AMWI3L.3I_?'RD[*K)<E4'8E3O97:IS..DQ%)5K%C(XI$2
MGPF0EBC^\,513>Z]T4C^>#_+-_D@_P JS^7AW[FMF]+X!_E[W=C,9L?HVLW_
M -L;][/[7FW7E]T8RLS>]\#AM[;QS6/V_1[7V\U=65^7IL;3O,1'3/.9:B$'
MW7NC_P#=C*W_  D&PQ5@P'\J_H!;J01J39_6ZLMQ^58$$?@CW[KW5D/\D'YD
M=!_(S^5/\/\ =&R.RMCU$W2'QMZCZ7[KQT=;A=MMUGV)TSUMM79>],9N7 "'
M#4VS\?\ <XQ*^A'V]/028JMI9J8M32Q.WNO=49?#OY9=,;O_ )S/\W#^=/G-
M]T:? GIS;/QI_E^[([R,-)C^M,EGNS.R_C!U9N+=D&[Z/'TU/N#:.TMYX'^.
M5>5J9*B"EV[N*CJ6G%$*1X_=>ZB?\++^]>U).LO@I\$NMJFHH<;\M.V-VY[>
M8&4&+H-R57662ZSP'7&T,N0CBJP4^\NSAE:CRLD5/5XBBE"R,MXO=>ZZ^=7Q
MYP/_  G&_P"$\O>7Q\Z>[TWQO'MSY>=M;<V/7;XS,%/BH(^TNW^OMK;>[NDZ
MPH-J8O'Y;9NTY^F.D\O_  TY7)5U3154J%ZV69X8']U[HHW\CS_A-+\./F[_
M "N<?\COE5BNTZ3NKY'2]CS]2;GP^Z<YM'_1'M' 9W-;%V;NC#[11H<)NZ?.
M9; SYE9,S35M'6X^>F$")&WFE]U[HP'_  C([1[0VK-_,8^#V]\]#F]L=!=B
M[%W;M:GHJO)5N)PF[LSENQ^O>TOX!-DEI7CV_N"JZ_P]53QBDI&\J3S2)Y)V
M"^Z]UO.^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_P"%
M G_;F?\ F#?^(*J?_>JVS[]U[JV/97_'F[2_\-G _P#NJI??NO=*;W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%/
M<_5&/[GV'D-C9'/[AVPE7545?39K;5<U%D*2LQ\OE@\BW\-=127*RP2#2P(9
M2DBHZV5M)KUHBHIT4+9_5_S>Z8W1M_%X'LO;O=O6+Y6AILE3[XJ9J+.XS"B>
M/[V<5.2:MR]$\5 ACIEI\CD8HY"":4JMC<M&PJ10]4HXX=6#Y'(X_$4-9E,M
M74>,QF/IY:NOR.1JH**AH:2!#)/55E74O%3TU/#&I9W=E50+DV]M=.=,>U-[
M[-WUC_XKLO=6WMUXW44:MV]EZ#+T\;AF4QRR4,\PAE#(05:S CZ>]D$<>M @
M\.E1[UUOKWOW7NO>_=>Z*I\:_A)\8?B#GN^-S_';K+_1YG/DUVIF.[.[Z[^^
M?8.[?[[=G9^MR>0RVYOMM\[LW-1[;^[K,Q4O]EB(Z#'Q^2R0*JJ%]U[J5\OO
MAC\:OGGTW5_'_P"5_6_^E7J.NW#@MUU6TO[X;]V-Y<_MJ6>?"5_\>ZWW3L_<
MR?92U#GQ+6B&2]I$8 6]U[J+\L/A)\8?G#T=_LMWRBZR_P!)_2XR^VL]_<S^
M^?8.RO\ <KM#R?W=JO[Q=>;LVENO_<=Y6]'WWCFO^ZK^_=>Z&#N'IGJCY!=<
M;HZ@[OZ\VEVIUAO2A7';IV-OC"T6X-N9JECFBJH!5XZOBEB\]'5P1SP3+IFI
MYXTDC9'56'NO=5+=$_\ "=3^3M\<M\U_8O6?P^Q*[JJ]O[AVQ25F\^S^Y>QJ
M;;^+W30SXO,3;8Q^_.PMPT6!W V-J'@ILQ3HF8H49C354+/(S>Z]U8GT5\,?
MC5\:?B]C?AATGUO_ '*^-6(V]V!M3'=;?WPW[N/[? =IY_=6Y]^4']\-V[IS
MV_I?X[G-ZY.?ROE6FI?N=%.\4<<21^Z]THOBY\7.B?A=T3L;XT?&C8W^C7I+
MK7^\W]RME?WFWCO'^"_WQWCN'?\ N/\ W\>_]P[JW;D?XCNW=5?5_P"5U\_A
M\_BBT0I'&GNO=%!^<'\FS^7!_,6W;@^POEC\;<)OSL7 8^GPU)V#@-T[YZVW
MI78*D%3]E@MP;@ZXW+M:NW/B<>]6[4L61:J^T)(@,:LX;W7ND;M3^1+_ "G=
ME_&K?_Q+V_\ #C8]%TQVM/M6I[,IX]S]D0]C;ZFV1NZ+?>T_[P=VTV]*?N>>
MEP&Z(O/2TT>>BI(8G>F6(4LCPM[KW1H^YOY?7Q'^0E%\8:#N3JNLWS#\-=Z[
M/[%^.,N0[*[9HJ[8.]=AIA(]JY^LR>'WUCLEOVIQR[=HRZ;DER\-6T1:H25G
MD+^Z]T-'R"^/O3GRIZ;W]\?OD!L7&]D]/]GX1]O;WV;E*O+8V#+XUIX:N(T^
M7P&0Q&X,)DJ*MIHJBEKJ"KI:VCJ(DE@ECD16'NO=%6WE_*H^"'8?PTVA_+[W
MSTSFMV?$?8-?B,AL_JO.]W=_Y&JP3[>RF1R^WJ*D[(J.TW[7;"[?J<I+'08^
M3.O045&(Z2&%*6"&&/W7N@Y^8'\DW^6-\]NS,%W#\L?C/_I6[&VUU_@.K<)N
M+_3-\@MB_9;$VOD,YE<%@OX1UMVML[!5/V-?N2MD^ZFI9*R7S:9)75(PONO=
M%4_Z!<?Y%'_>#/\ [,S\P_\ [H+W[KW5I/4GP3^)71_Q,H_@MUYTIMR#XF46
M"WKME.E-W9#<O9VVZO ]B;KW%OC>.+R]=V=G-X;CSM+F-U;KKZNU;6U!IVF"
M0&*.*)(_=>Z('TW_ ,)U_P"3GT1W'C>]>OOAIM@;\P.=&YMM1[OWWVIV%L[;
M.>ARD&9H,IA-@;ZWQN'9E-58?(4R/0EZ&04.D> )86]U[JQ7XR_#?XW_  ZI
M.W*#XX]<_P"CJD[V[CW9W_VK%_>_?F[O[T]M[YBQ\.Z=V:]][HW/)@_XI'BH
M!]AC31XR#Q_LT\99K^Z]U ^*/PD^,/P@P/9>V/B]UE_HQP?<':FX>[.Q:'^^
M?8.]/[Q=G;JHL7C\]N;[GL/=F[*S$_?T>%ID^RH9*7'Q>*\<",SEO=>ZS?[)
M9\9_]F[_ -GO_P!&O_.5O^B7_09_I4_OEO\ _P"96?Q3^-?W6_N/_>K_ $<?
M\7/]W[[^#_Q'^S]QH]/OW7NL/RN^$GQA^;^!ZTVQ\H>LO])V#Z?[4V]W9UU0
M_P!\^P=E_P!W>SMJT64Q^!W-]SUYNS:=9EOL*/-5*?95TE5CY?+>2!V5"ONO
M=!E\Y?Y87P8_F/X7;&(^8G0>W^U:G9+U']SMU19?<^R]][8IZVHIZG(XS$[Y
MV+F]M[HBP>3EI4:HQ[U4E%*X#F+R*KCW7N@#Z(_D0_RH/C?UYVYUIU;\/]F4
M.%[UV)O'K#M#.[AW-V%O'L7.]>;^Q4&%W7L_$]H;HW=E>PMCX/*4%+%>+ 9+
M%^.HB6I0K5#S>_=>Z-E_L@_Q0/PV;^7[+UA657Q'.PAUA_HHK>Q^U:^5-AI7
MKDH-MQ=A5F^)^THJ.DJ440.N;$U/"BPQNL*J@]U[H@7;W_"<?^39W=5;#K-Z
M?#?#4U3UWU_LGJ_"U.SNSNYMBU>3V7USM?![+V71;RK]I]AXG(;XS6%VKMVD
MHOXUEI:S-U440-363/9A[KW5AD/P0^&]-\7:OX44_P ;.HX/BA7T"X^NZ'AV
MCCHNOJU4W%3;P3(5>*1%:ISZ;PHH<N,F\C9$9:)*SS_<JLH]U[K7Z_X5;?RU
MN^OF=\:>BOD?\5-M;GWGWO\ "W>.[]RMM'8M1D$W_E^L-[T.W:_<V:Z]Q^)5
MLMG]]['W3U]A*^BHJ(K7R4C5KTGEJDAIYO=>ZU8OD_\ )#^</_PI'[*^-?Q,
MKOBQ5;&I>B\\N%[%GVOL'?FU=A[?[-S-)@\?O3MONK.;YJI:797]VMGUD512
M8$SBM@IZVH6G6LFK:>)?=>ZVHOYRO\QSL?\ X3]_"_X0_%#X@='XO?M5OOJ/
M=70O6/;.Z<]FJJ'JO+=';6ZMVWA\I7;#I-M5\6_=V[U&^'R%%'/FZ)/N\;/K
MIJN-F5/=>Z8/^$G/\M;OGX<_'/OGY/?*'";KV?W!\T]P["S>*V1O:HJ_[WXG
MK#8M)NK+8#=6]<;D*:++XC>O8FX>Q\G5U5-7RSU<5#343RK3U$M5%[]U[K;2
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_PH$_[<S_S!
MO_$%5/\ [U6V??NO=6Q[*_X\W:7_ (;.!_\ =52^_=>Z4WOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND!VO
MVAL;I'K#L3N3L[/4NUNN>JMD[G[#WUN.MUFFP>TMG86LS^?R<J1J\TWV>,H)
M7$:*TDC *@+$ ^Z]U\OC^8)_/9^=_P#,6WENF3:O;'8_Q1^*-?65]'UUT9T_
MNBLV/N[<.R)&:&BRO=^_]LU<>=W1G-QT8$U5BJ:K3!TR2"%(I2KSRR?RSR&E
M[:KN&[LRJ^4C4T)4\"QH:5X@#-.)\N@%OO-[6L[6>VJ&*89VR*^84?+@2?/R
M\^B!=)_,7YJ?%O=U+V%T%\G.WJ+,XXQR/M+?6_=U;SV/G88I&FEQ]7193+'*
MXAJ]C9ZK'5=)5"PTR):_LXW7V[L7A:3:7:.0#"N=2-3RR*@GUJ1\NBS;^=+M
M)0FXJKH3EE&EQ\\8-/2@/SZ^I-_*=^=FT?YBOP6Z6^1^W9YX]SU.'78?<6W*
MZICJ\MLONG9%+1XSL';>4J(X:;[EC7O'7TE08:=JW&5U-4F&'S>-8<EC>*5H
MI!I9201Z$&A'Y=2;&ZR1K(AU*P!!]0<@]"S1_.CH,;WW%L'=&3W#U_F]NYVM
MV_-+O3 RT&-K*S'RO3U$D5=CI\K'CZ;S1-I>N%(&6Q_M >_>$]*C/7M8K3HU
MV#S^"W/BZ7-[;S.*W!AJY/)1Y;"Y"DRF-JTO8M3UU#-/33*#P=+&Q]MTI@]7
MZ=O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5)7\P;^>'_ "F/@W7_ &_?/;VQ
MNW.[-@2UU3@>GNH,+@>Y^W]N9R7&T^1-&TE-.-M]6Y?*TR4NDYS,80S+)$]V
MC&I?=>Z#K^27_/ B_G*[Y^:(VYT-)TEUI\;)>@X=A29O=Z[JWSO.#MH]U#*9
M+=\-#C,=@-O2T8ZOIC3T5%)7"+[F4/53V1A[KW5_7OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NJ=O\ A0)_VYG_ )@W_B"JG_WJML^_=>ZM
MCV5_QYNTO_#9P/\ [JJ7W[KW2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=!#\@.[]C?&GH_MOY"=G2Y2#KKI3KS=G9^^9\)CFR^8@VI
MLK"U>?SLV,Q:RP/D:V+&T,C1PJZM(P"CDCW[KW3!\6_DEUI\P/C]U;\F.G9<
MY/UAW#MM=V;+GW)B3@\Y/AGKJW'Q39'$-453T$TLM"["-G+!"+V-P/=>Z]\I
M/DEUI\/_ (_=I?)CN*7.0=8=/;;;=F])]MXDYS.089*ZBQ\LV.Q"U%*]?-%+
M7(QC5PQ0&US8'W7NG_X_]W[&^2W1_4GR$ZQERD_77=?7FT^S]C3YO'-B,Q/M
M3>N%I,_@ILGBVEG?'5LN-KHVDA9V:-B5/(/OW7NA>]^Z]UCEEB@BDGGDCAAA
MC>6::5UCBBBC4O)))(Y")&B DDD  7/OW7N@7Z(^1W1_R=VON#?'0'96V.V-
MD[;WQN+KG(;QV96_Q?:U1N[:7V2;CQ^%S\"G%[@IL545RPO5T,M11M.KHDK%
M&M[KW0V>_=>Z][]U[HDG;/\ ,!^/?2WS'^-_P5WO5;PB[Y^56 W=N/J2EQFV
M7R&U*S&[(Q>XLQN'^.[C6MC3"3TU!MBI=%>)O*2BJ26('NO=';]^Z]T23MG^
M8#\>^EOF/\;_ (*[WJMX1=\_*K ;NW'U)2XS;+Y#:E9C=D8O<68W#_'=QK6Q
MIA)Z:@VQ4NBO$WE)15)+$#W7NCM^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z +Y2?)+K3X?\ Q^[2^3'<4N<@ZPZ>VVV[-Z3[
M;Q)SF<@PR5U%CY9L=B%J*5Z^:*6N1C&KAB@-KFP/NO=*WI#M_9OR#Z6Z@[\Z
MZFR-1U]W?U?L#M_8D^7H'Q>6GV;V5M/$[SVQ-E,9(\KX[(R83-0-/ S,89"R
M$FU_?NO="A[]U[JH#^?SM_>^YOY-G\PC'=?U2T>>IN@,MN"OF:CEK@^R-IY[
M ;J[,I1!#6X]T:NZWPV6@$QD9*<R"5XYE0PR>Z]U\KC%U%+5XW'U5$T;T=11
M4LU*T15HS3R0HT.@KZ2OC(M;WE1:2136L<L!!1E4K3A0@4_EUC[<1R17#QS8
M=6(->-0<]3O:CIGK?*_X1W8+/TWPM^7>ZJB@R5)L[=GS.SB[1JZJ&JI\?FJK
M;O4G6&'W7E,*LZ)!6TBY9%I)*N#5')44KQ%B\#*N-O-$L,W,%W)!E?$(_,4#
M?S!SY\>IPV".6+9K9)OBT _D<C^1'6U/V!U#UCVI2"C["V/MW=*I&T4%5DJ"
M/^*4:/;6N/S-/X,OCM=A<P3QDV]D08KP/1N0#QZX]5]2[%Z7VP^S^O<548C!
M2Y6MS4E-4Y3)Y:1LA7K!%/**C*U=7-'&(*6*-40J@":B"[.[>9BQJ>O  <.@
M [W[<^375F\TR&R.D\;VEU*F)I9:B7!SY%]Y)E"TGW\,L5#49"JI8(%CNK)B
M*J$QN"90P9%NJHPR:'JI+ X&.E3\?_E/M#OZOW!MW'[;W9L[>&U*2GJ\_M[=
M%%!$8(YZ@TK_ &=73SN\OVU1I5UJ(:2:[@B,@,1IT*9X];5J]&?]TZMU[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M5'?\\_\ G&2?R=NBNL.QL1T<G>&\>YMY9S8VT<7D=Y-LW;6WJ_!8BDS=9E]Q
MU%-@\YE,G2&BG98Z:E6!Y)5 ::-26'NO=:@NT]P_\*9?^%%.VX=V;)W]A^B/
MB5GY\KCER>S=\M\;_C[65F%J\KMS,X;(P;4RF]_D)V51RUDE7!44]9'G\6LU
M+ZQ')'%[]U[HJNQ?Y(W7/Q*_GX_"/^6W\G-XXCY3]>=I8'"]C=CQ8S!;FZLP
M>2@RNU.V\K2[.C?$[VK=S56.H,IU]332UD=90/5I*T+0(@8R>Z]U]/GH3XT?
M'KXL[)BZX^-_2G6/1VQXG2:3;?6&S,#L['UU6@?_ '(Y9<+14DN:RLAE8R5=
M6\]3(S,6<DDGW7NAO]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U3M_PH$_[<S_S!O\ Q!53_P"]5MGW[KW5L>RO^/-VE_X;.!_]U5+[]U[I
M3>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJV/YR/_;IS
M^9#_ .*4?)'_ -]3N?W[KW01?R ?^W-7\OC_ ,0+C_\ WI-Q>_=>Z]_/^_[<
MU?S!_P#Q N0_]Z3;OOW7N@A^+OS3ZA_EZ_\ "?#X<_+CO%LS-L'JCX(_%ZHE
MPNVJ1*_<V[-Q[BV)L;:VSMH;>I)9(:<Y3<NZ,S24@FGDBI*..1ZFIDBIH99$
M]U[HOF<_FA?SSL3TI4_+&#^2KL:OZ.I]KU/8"]50?+G'5/R;DZ^%\S2;ADVC
MB=C99QDY-J()I,)38NLSJRR"U&71J?W[KW1X,9_,EW=\P_Y7%#\Y_P"7-\<,
ME\F=U]@8JHQE%\?=[]E;,Z+S^%JL?N&KV;VM09W>V[ZB?:=-7]<FDK*N,1R2
MQYF"",TK$5$9'NO=4A?\) .VOEM+\0<%T[4?$J@I?AQ3;Q[QW10?,;_3?L.?
M(9+L]LSM='ZN_P! L;#L&CBCCGF?^,N#0G[>WU=;>Z]U8AN;^='\H?DS\CNX
M/CG_ "B_@?%\NL-\=]TY'87=ORI[=[>P73?QQP.^J*D$IVWLFO6+)9;L66GK
MHYJ6H%+-3UR2QK,M&^/ECKS[KW0Z_"7^;QNWM+Y59C^7O\]_C#E/@M\X(]OU
M^].M-F5N^\1V3U/\B-DXV/(UV0S/2G9>+I:"CSN6Q>&QD]=4XO3+,M)353B0
MRT=;!2^Z]T1'^8S_ -Q-_P#(R_\ $1?)[_WW'<?OW7NK"_DG_-CSV'^:>S/Y
M>OP/Z I?FA\F:66ESOR5J6['/6_37Q,Z[JC%#%FNV^R*/:.^@F\)Y*N*9-OT
MU&]>:;TV^YFIZ>3W7NG?Y)?S":?I#^:M_+Y^!N4^/FR]ZY[Y=;![+W$_?$VX
M(Z#/=5S=<[8WUN"HQFW\#4;.RE9G,?FIMNR1*3EL<8%JW8K(;JWNO=(S^8K_
M #H-K?R[/E[T'\9=Y='[Q[2I_D#TOOW?&Q7ZQ.9W'V?NWMO"9Y-L=?=)[-Z^
MQVVJVAK\CV-FJB.(96ORF/HL:H9I=0T^_=>Z(#WK_/+_ )KWP@VSB/D3\\OY
M+$W5/Q!K,]M_%[KWEUI\K^M.U.PNLJ7<V7FPV+_O)A<#'4TDV5JJJ>C2F7(0
M[>QU155,-(];3U4WBB]U[JS?^:)_-AP7P&_EV[8_F$=5=?87Y([+WQD^FIMD
MX@;[?96(W/LONC&G,[=W;0;JH-M[S5J:3#ST]3"J4DB5$<HLZBS>_=>ZN#]^
MZ]U4W_*4_F8Y3^9OU_\ )K>V4Z>H.G)/CS\KNP_C1#CJ#>]1OA-V0;$PFULL
M-Y2U-1M;:S867*-N0H: )5"$0W^X?59?=>ZK0ZC_ .% 7R=^8>.WIUG\"/Y;
MF;^1GREZT[F[+V+V]MVN[@QW7'0O2W7FSMT5VV=G;VWCW7V%MS:.'W#O3LIL
M;-64>U<2)9Z>B@J':KDFA2GG]U[J+U1_PHR[4QN^.W/AY\KOY<_:O6_\SW9V
M;V;M[IOX==6;TPO8M/\ (RMWKMVJW/%D=N]DK31[0V/MG:>W<?49C-Y>IK<G
MAJ?")YJ>LJJK51+[KW2HPW\[OYW_ !O^4_QLZ-_FJ?RQT^(_6'RXW_CNK.I.
M\.M>^MJ=[;>P?8FXZG!8_;NU]['929G#02+E\TM/6N]?CZI85EK*2DJZ2FFE
M]^Z]U:'_ #.OYG76'\M#K3K7.;BV)O#NONCO_LC'=.?&_P"/?74E##O;MSLK
M+FG@I,?35>0+08C;]%D,E04U;7"&JEBGR-+%%3S2SQQGW7NJO.[/YI7\\[XQ
M=3Y3Y.]X_P FOJA>@]G;:K]\=J;?Z_\ F3MG=/;75&R,#22YG<VY]T18_!9#
M&Y&DPV IIJB=<70UHI%B:2I>&-7*^Z]T(_\ ,A^7W5GSU_X3A?*+Y:],MD(]
M@]R?%W(YRAQ69-#_ ![;&9QN]L9M[=FS]P+C:JNH$SNTMU8BLQU5X99(FEIB
M\;,C*3[KW1.OY=G\RO\ F7]E_P O?XG4'\NK^6+BN^^D_CG\1_CMT[F>X^\/
MD#M[I";NGM7IWJ;;&P^WMI]%[*R5 U5EL3M#>.V*S$1YVNK8L?69"GF1%O$5
M;W7NKI?Y6?\ -,ZZ_F8===A,O7NZ/C_\E/C_ +H@V!\G?C%O^<S[TZ@WI.<C
M%2D54N.PM5G-I9RJPM='05\E#0S/-0U$,U/%)$0?=>ZL_P IB\;G,9D<+F<?
M1Y;#YB@J\7E<7D::&MQ^2QN0IY*2NQ]?1U"24]71UE+,\<L3JR2(Q5@02/?N
MO=:!G\PK_A*A\DNN>Q=V]@_RRJ[8G:G2&X*G-;AQOQE[(WL-A=D]:9"=%K8M
MF]<=@;H:?96\=HU-9YXZ(YW(8:JQRO!#-+5J)JT#+8.=-PV.'Z1D$\(K122I
M6O\ "U#CY$'Y4Z#&\<K6>[2_4JQAE/%@*AOM6HS\ZCHK/QA_X2Y_S2>]]SXB
MC^2^.ZU^$G6#9#Q[QRE3V1M#N_MR7"Q2Q"HCV-@.J\KG-C+D<E SK#/D<[3"
ME_SC1NRB-S+=/<7<+VW-O90BVU8+:B[4_HG2H'VT/RZ0V')5G:S":ZD,^G(7
M3I7\Q5J_97KZ#_Q.^+'3/PI^//6'QA^/^V5VIU5U/@!@]O4#RK4Y*OJ:FKJ<
MKGMR;@R CA;*[GW5GZ^IR.1JBJF>LJ9&"JI"B.^AKT8GW[KW7O?NO=>]^Z]U
MQ"(K.ZHBO)I\CA0&?0++K8"[:1P+_3W[KW0 _(+IC<7<F"P='M7M;=O5&<VY
MDYLK0Y3;537I2UTTD"Q)%EJ/'Y;#3S_;LEX)1-J@+N0K:B/=T8*<BO52*^?0
M,]3;?^;^Q-^X+;_8.YMA]I]6S5%2F6W/+/'1;DQ6.CHY!2M"RX[%9*IR+UA1
MM$T615P'1IX@RRKMC&148/6AK!Z.%O#>&VM@[:RV\-X9:GP6V\%3K597*U2S
MR0TL,D\5-%^U313U,TLU3.D<<<:/))(X5020/= "30=6)ID])G8G<?5?9L*2
M["W_ +7W.[IY#0X[+4W\6A2P:]5A9WAR]&;'Z2P(??BI7B.O @\.A*]ZZWU[
MW[KW7O?NO=>]^Z]UI&_SN?\ A1UW/UQWGV!\*?Y<.?VGM7+=2Y2?:7?7RGK<
M/B-^9#!]A4;5%-N/JGJ?;6>H:_9PSFS:A12YO+5\5>:;("6DA@@FIFFD%'+?
M*UUS#(S*WA0H:,Y%<\=*C%33CG%1T0;YO]OLJ*I7Q)7%56M,>K'-!_AZUYMF
M_P ZS^<-U]NNCWKA/Y@?:^Z<E2Y6FRE9MCM#;W7>^.OL_'%6K5UF#R.UZK:-
M.N,PV5CUT\AQDM%54\,EZ:6%TC91U<>V=B82+2Y<2>1<*5K\P I'[33Y]!*'
MGNZ$H^H@0IYZ20W[22/Y?LZWR/Y'_P#.)P?\UKI'=5/OG:N)ZP^670\N!PW?
MO76"DJGV?E8\_#6';/:O5SY*MR&6/7^\SBZE?LJR>>NPM?!+232U$?VM;615
MN&WW6UW;V5XNET/Y$>1!\P?+_/U(5E>6^X6RW5L=2-^T'S!'J.KP_:+I5U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M5W?S'_Y77Q-_FG]2X3J3Y4[?W=5TFS<CFL]UWO#86\<GM#=_7VY\YAI,'5;B
MPA05^U\Q5QTC*R4V;Q>6QYDB4M3MR#[KW6G/W)_PEA_F7? C>.5[P_D__-W=
M.X*RCDI\I#L8[TKOCUW'DZ7 K_$L;MFNS^+S,74/;%-4Y))$:ESAP&+FCJ#%
M-3O&TI?W7NJ7=Z?.[^8S\0_YNGQ1^<?\V;H7LW,]T_';'T.RZO%;BV;B.E\K
MVGL3;^"W?@Y,MM_<.&VR_7&[\O@Z;M)JAZ[$PM0USI!#--"\K5(]U[KZ.'\J
M[^<5\3/YNNR.PMR_&R#LK;FYNGO[F)VUUUVCM2'!;AV7+V!4[WI]G2)F<)E-
MQ;,W+1;@3KS)SPOCLE43001Q_=PTLL@A'NO=6M^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\ >JVS[]U[JV/9
M7_'F[2_\-G _^ZJE]^Z]TIO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW5<_\ -^Q>1S/\JK^8WC<30U62R%3\)_DM]M0T4+U%74&'J/==
M1(E/!$&EGE$43$(H+-:P!-A[]U[HK7_"<'L#!]C_ ,E7X)97!>:-,!U]O#K_
M "E+5-2FKI<YUWVOOW9F5\T=+45*PPU]1A?O*4.RRM15,+NB,Q0>Z]UU_P *
M/^P<%UO_ "5?G9E<Z*B1-P]?[/Z^Q5+2&G^ZJ<[V)VKL/9N+,:5,].CT]!/F
M?O*K2QD6CIIF17=0C>Z]T&/7WP@ZN^:W_"=OXD?$#Y)[GJNG,#OKX/\ Q-MO
M&OJJ'"Y7KW?&V]A[#WELW,RTN<J\=1U$^/S&+A^[QM3)$U13--3L8G.M/=>Z
M(]M[9W_"I;^7!A:;;>WZGXM_S:?CUL>.CQN'PN4EINN/D$W7V,PE+CXL333U
MIZZ+Y&A^U)1:BLWWD9@Q53.&2*'W7NK;OY6G\R'J;^9I\(M\]O=<=1Y'X_;H
MZ]S&^NI.Z.C<G34\4G6_:>!VKC\QF,7CZZFPVW8\WAJJASM/)!5OCZ&HU>2&
MHIX9X9$'NO=5.?\ "8VOW%B_^$^G8>3VA]Q_>S';F^7]?M?[0N*K^\5'@?N,
M)]L8WBD%1_$HXM&EE.JUB#S[]U[JOO\ X3S[1_GE0_RT>O\ *_R]MP_RF</T
M#N'LGMK)M!\DZ+Y/?Z<9=[TN[JK!;BFWY-UAMBLVC4/X,/2KC&AGED7#+2+*
M5<,B^Z]T>WM7^7=_/-^2/S__ ):GRE^7G>'\IK9E5\-.\*?=.+QGQ[W=\DMI
M=@]C]7[DW?UW5=T;)HL9V7U+N*AW1DLEL;;%5C\;%'/CHX),O/Y9U\J2P^Z]
MT#?\_P#VI\H]]_SQ?Y1VQ_AAOC =8_)/>72??.U.O.R=RPPU&+Z]I]Q8[?V(
MWSO@4\]/5I/E=I]=5F7K\>@BED;(4\(C1G*@^Z]T-_\ PG7W=3_!KY$_-#^3
MC\G]LX3 ?-':?:&Z^_MK]\/A,O2YSYO=1;BDAR478^:WAG,GG*O=.Z<)#E!7
MP0FKU+C*Z>'Q/6XK,U+^Z]T(?\QG_N)O_D9?^(B^3W_ON.X_?NO=1OYDE'25
M_P#PIJ_D805M-#50IU7\DJQ(IXUE1:O';$[<R%!4JK@@34==2QS1M]4D16'(
M'OW7NK+O^% *))_)I_F#JZ*ZCH>M<!U# /'N?;<D;@$$:HY%#*?J" 1S[]U[
MK7;_ )LO_<(;\"__ !%O\OK_ -]_1>_=>ZWI4G@E@2IBFBDII(EGCJ$D1X'@
M=!(DR2J3&T31G4&!L1S[]U[K5%_X25YO$;E^-?\ ,3W'@,C2Y?!;@_F>]Z9O
M"9:AE6>ARF(RNPNJ:_&Y&CG2ZS4M;1SI)&XX9&!]^Z]U+_X2BT=(G2/\S+()
M30K757\TCOFCJ:M8U%1/24&TNNYZ*FEE UO#2S9&H:-2;*TSD?J/OW7NG.7&
MXZ?_ (5Y4]5-044U31_RI&R5)42TL$D]+D6W_/B&KZ>5XS)!6MB:J6E,JD.:
M>1H[Z&*GW7NHW_"K,F'H[^6;60DQ5E-_-2^/AIJJ(F.IIS_=#LN6\$ZVEB/E
M@1O21ZD4_4#W[KW1W_YO/\P?KOXA]A?$CJ78?PUV_P#.?^8%WGO/)-\0^I\G
M1[2P]1M"MP$M"F=[%;M'=6!S)Z\CQQJ1X)*-Z66<P3/+4TE-3S5,?NO=$^^0
M[?\ "D?M'H#Y(Y;M_/\ \KGX9=(TO0G;67W(-EX_MWNGN?%[:H]@9C(9K&#(
M[IRD_4SY(XI*F"7*2-#24K 2)2S*"Y]U[JN'XH?]P5';/_B+?D]_\%GO'W[K
MW6T__*1QFV,/_*S_ )<U%L[2VWS\(?B]74TPI*;'SUE9E>F-FY3,Y#(4%)D,
MM34&7R.:K*B>M@2JJ!%5R2)Y'MJ/NO=4A?"PST?_  K,_FQT'6TF7'759\,N
MGLCW53RQ8N/:Z=S+MOXGOM*3"2XR2HJ*FK.W<AEGD-7X)AD9\PKJ1' S>Z]U
MMD>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;L
MOA\3N#&5V$SN-H,SA\I32T62Q64I(*['U]).I2:FK*.I26GJ()%-BKJ0??JT
MR.O<<'HF>]/Y??QUW56IE,/B-P=>9):N"L-3L;.RT4)EAE62\./S$.:Q^.X4
M:?M(J<(P# 7OJ<$KCY]4T+T=*@I!04-%0K/552T5)34@JJV8U%;4BFA2$3U=
M00IGJI@FJ1[#4Y)_/MOJ_5>F=^9?<?5N:R\/<_QBW1B]K4E?6B#=NS:^JS.+
MAQT,TOVSM6U6+BPN1>2F4.9&K:!K DP)<JCHC5OA;IO41\0Z.5U%VSM+NS8^
M/W_LI\C_  7(5%;1^#+47V&1I*S'U#4]5354"RU%.71@&#12RQE6%FO<"C*5
M-#U<$$5'0F>Z];Z^)U'_ *1?X[V!_ID^_P#]-'^E3M'_ $R?Q;['^+_Z5/[^
M[@_OU_%_X9_N._B?\?\ -YO!^SKOX_1I]S_R'X?]68-''5)J^WQ&X_E3J'.;
MM?[^EU\*)3[-"\/SKU-]C'H-=;%7_"4W^]G_  [=O;^[?\3_ +N?[)-V5_I+
M^W^Z_@OV7^E3JC^Y?\4\7^0_Q7^.^;[/S?N^'[CQ^GR>X7]R_ _>EOH_M/#[
MOLU'37_C74H<B^+]!-J^#7V_;I&K_)U]([W&_0XZ][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ'O^%!_P#-AW=_*=^&
M.&["ZCP&%S_?G=6_H^K.IIMSTR9';&T)X\'D=Q;GW]F\,*RCGSJ;?Q./6"DI
M WA?(UU.U0&@22*3W7NM+K*?.3_A5_TATQM[^8IOS>/R)'QPR-/M;>;;HWEL
M?I'*]=Y#:.?J*&IPN3W'U#CL#'G-I[%W1#60QKDQA\3$8*N-H:J)I(I/?NO=
M;V/\MWY2=._SK/Y:_6'=G=_1_7.YJ'L2BW#LCNCI_>VU,1O78%+V+LO)U&W-
MVQXG#[J7<$4NV\Q)!'DL6*AY:NGHJV%)9#/&[>_=>Z&WX3?RN?A;_+LWK\@M
MZ?#_ *NJ>HE^2]3L&O[)VC0[JW)G=E0Y#KFL[%K<#4;.PFY<CEY-GTSR]GY)
M)*"BGCQD4*4\5-34\<6EO=>ZL(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U3M_PH$_[<S_ ,P;_P 054_^]5MGW[KW5L>RO^/-VE_X;.!_
M]U5+[]U[I3>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH
M&5Q>-SF+R6$S-#2Y3$9B@K,7E<9701U-#D<;D*>2DKJ&LII5:*HI:NEF:.1&
M!5T8@BQ]^Z]UJ:;-_DX?S;/Y7>^.Q8/Y,7S&Z+S'Q/[%W9G=WTGQ#^:6(W7D
M,1U=D\U3T=VVCO; XC=F9W#4T+X\4\-5]UMYZBD:%<E'DJF$UK^Z]UWNO^3A
M_-L_F?[ZZ[@_G1?,CHZ@^)G76\</O6I^('PQP^Y<7B.SLGB*2J"1[MWUE\%L
M_/8$U<M9]O-4M6;BFIZ,3KC!C*J<5\?NO=7J_P QG^7;U#_,6^%._/A=O:IG
MV#MG.8_;D_7VY]L8ZCEJ.L=W;$GIZO8N<Q&'E-/1U6-Q;4OV=50AX/N<5//3
MI+ TBRI[KW52VT.H_P#A4_UQL?%]!8;O/^5#OG:^VZ6EV1@?E#OK"?(F?OBI
MVA0HF*Q>]LYMBDQ,/757ONFPR)/44T^,K8)*]&1ZFJ0FID]U[JRG^5I_++VG
M_+;^*>>Z(D[!S/<79?;N^=Y]P_(SN?*4]1BJ_LWMWL2CH<=N3/4&'JLEFDP&
M+H\5BZ6DI8%E<R&!JJ8&IJ)RWNO=5R?R:/Y9G\T#^5GV#F_C#N/N7XK=N_RR
MHMU=H[ZVS514>\L=\F$S&[\3C8-OT,^,;94&T::B.7QZS9.EDRM6EY)I*>JT
MF.C'NO=)[!_RHOYE/\L[MWNO=/\ )6[C^)!^-GR%[#J.S=S_  T^96U^Q:/K
M[JC>F1HDI,EF.J=U=1RIGSBY:2AI:&&@:3&I3XZGIX&-5]K"Z^Z]T*/QE_E2
M_-'N;YS=9_S(?YO?>/2/9?;GQ\PF4Q?Q@^-OQ?PN\L=T!TUELPU1'6[XFS&_
M%HMS[CW&8I%G2&>"H*5Z03/6S+14L4?NO=&$^6'\N'O#O;^<-_+?_F"[1W5U
M5CNF?A]L7N/;'9>V=QYS=U)V=G*_L+:>_L#A9MBX;&;&R^U<G1TM9NFG:J;(
M9K&.D:2&-)&"J_NO=)C^<7_*H[0^;&>^,WRL^%F_=A]%_P POX@=C8/</4G;
M._,KN[;NSMR=?-E17;HZT[$R6P]N[KW#D-N2R-)-3TQQU7!/#59#'RB.ERM6
M_OW7NL/>7\NCY5=__P T[^5A_,.W'E?C[M+!?$7I_LC;OR)V!A=]]CY[+5'8
M'8VP=[8.JINEJRNZBPM'O'9V,W%NI!'6YR3;5;)11F0T@EM$?=>Z5ORP_EP]
MX=[?SAOY;_\ ,%VCNKJK'=,_#[8O<>V.R]L[CSF[J3L[.5_86T]_8'"S;%PV
M,V-E]JY.CI:S=-.U4V0S6,=(TD,:2,%5_=>Z-S_,_P#B[O\ ^:WP"^4GQ5ZL
MS&SL!V%W=UG5;,VIF>P,AFL5LS'Y2?+8JO2?<.0VYM_=6;I* 0T+@M38ZKDU
M$>BUR/=>Z)'VY_)\JODM_)%Z@_E8]P]AX/:?976OQ]Z#V53=J;$IZ[=>T<'W
M#T;@MO14.>Q5+N'%[5S6?V1E<KAIJ2H66FQ>0FQ59*4%//IT^Z]T5CK;XD?\
M*0]V; QGQ*[]^9'P8V%\?*;;%-UKNGY.=+[6[5W+\Q]S]=4*T^ JY]OC=6(V
MYUOM[L3<^TA(C9F2E\F-JV$Z+/*NIO=>Z-K_ "+_ .5MV'_*@Z8^472F]-Q]
M>[AVSV7\ONPNXNFEV'N3=FYZK"]-Y7:FQ]I['PF_*_=FR-D2IOZBQ^T?]R"4
M<==1:BK1U4A9@ONO=.O\DS^7#WA_+<ZS^7>S.\MU=5;JRG?OS3[2^1NSI^J,
MYN[.4&-V1O? ;-Q6)Q6Y9=W[&V+44>ZJ>HV[.U1!2Q5E(B,A2ID)8+[KW4__
M (;K[L_X?3_X<Y_O1U9_H%_V1[_9:/[I?QO=O^EW^_?]\O[Q?Q;^ _W(_N9_
M=+[+T^?^/_>>7C[73ZO?NO=0/YV?\N'O#^9'UG\1-F=&[JZJVKE.@OFGU;\C
M=XS]KYS=V#H,ELC9& WEBLMBMM2[0V-OJHK-U5%1N*!J>"JBHZ1T5R]3&0H;
MW7NDI_-J_E=_('Y5]U?$GYU?![NK9?3WS;^$V3S\G75%V]B:S+=,]E[0W.&;
M/;+WE)A<7EMPX%ZZ"6JH_NJ:"<2T.3JHK4\Q@K:;W7N@2WM\+?YX?\P[K/?'
MQR_F)_(GX0?%[XV[VQ,N$WWC/Y>FT^X\UW/V[@ZO'Y%:O9V7WQW]E\WMOKW:
M-9DOLCD&H<=D:G*T(J:-XX(I/(_NO=)_X_\ \GGY<];_ /"??MK^4QO7>7QS
ME[YW'@NV]M[%WSMC>G9>1ZADH.P^T9.S<?5;IS64Z?P>\\55453EJVFFCI<#
MD%"Q0NKMK=8_=>Z#+XZ? S_A0[_+M^.W6/Q;^(/R6_E]]\]88CK[;<8J_EI0
M=Z3[TZ WWD-L[??L/8W4>ZMDX?&TN^>E<-V$<O5[1EW!B/XA1XBHCI)J&..&
M&)?=>ZLT_E-_RM:C^7K@>\>R^Y>YLC\GOFM\MM_/V5\GOD3E,6,%!N/)4]1D
MY]N[,V;@ [C";+VM_&*IXEM&:BIJI"D-)1QT./HO=>ZM\]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW6*&&&GB2&GBB@AC!"10QI%$@)+$)&@55!8D\#Z^_=>Z)YWE\4\[V;O1^Q
M]B]X=A]6[N..H,?XL;DLI6;?,>.1DB6DH:/,X:JQ"5((,R0RM3O)JE,)DDD9
MW%>@TD ]4*U->M3G^:A_PG,^2.]TWG\B_B1L3J3L'O?='862WQVYMC$]@UO7
MV4[FCSM%D:W<&YL1@]TXC&=:8[LRLW)X:JKF:OQ8RK3U,M3)553QL!/R]S3<
M<OR$1+XD+FK1DTSPU*<T-,>A''@*$.];!!O* N=$J"BN!7'H1BH_F/+SKK\X
MO^3O_,QE3-_Z0OC+E?CK%BI:6AI=Q?(')S8'9^>RU6*QAB]N9OKW%=D',UD$
M%#),P$<,+1 %9>>!S-[DV;0GZ.V<R>CE0H_-2Q/[!]HZ"<7(UR)1]3.H3^B"
M6_80 /VGK=-_X3^_"+XN_P OCJG<N+7O+;W;GS'^0M?A\CW3NV3$Y?:6.B3;
MT&0;:?4_56+W-CL;6U&S=HT^0J934:I*S,9">:IE6&-::BHXJW&\O-QNWOKT
MZG<Y/D!Y #R &!U(5E:VUC;+:6HTHHQZ_,D^9/6R/[0=*^O>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1]_X6]_]DP?
M!K_Q/79/_OO:#W[KW5I_\P;^:%_*][$_E4_-#J/:7SJ^'^[=Z[G^!7?NS]D]
M>[?[WZTR.X<WOJ?H/=%!LS;&WMO8_<+UU;GZC=*TD%%1PQM+)5>.-$+$+[]U
M[JH3_A)5_,$^%?Q?_EO=P=<?)SY>] =&[UJ_FGV3NC;FR^X.X-F['S\VR<GT
ME\=J&CSF(PFY\U05AV[7;DQ.4C2:*/P25D%2 3(LGOW7NMQOX\_,CXG?+;^]
M_P#LKWR0Z3^0?^C_ /@']^/]#W9&U.PO[H_WK_C?]V?[Q?W8R>2_A'\?_NWD
M/M//H^X^RFT7\;V]U[HR?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH=9D<?C_M_XA7T5#]W4)2TOWE5!
M3?<U4E_'34_F=/-426]*+=C^![]U[J9[]U[J&V1QZ5R8MJ^C7)RTYJX\<U5
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M7NJ&_B?_ "$L)\X?C/UQ\Q?YD?R1^7>^OGI\@=FGNO!]F;5[MW+U^_Q/';^
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M_L?8_4&[.R]D;8[1[-QF?S'7&PMP;DQ6&W1O['[4J,/2[EFV;B,C4T]5N63
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MV^%WRW^!/R)^,_P!["@^6G>'R*^-?9]/6X?:N&W;M':O1O1<VSI:GN;O?O\
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MX6GP> KQ644<\$M-B*LZ%II\;4U7NO=6;?S(OYHM'\ OEI\/.I?DSU9LZE^
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M%+59'*_$[XH56!Q5=%.DVYMQ4_\ ?;/TE9 8Z[%QT]09'G+:O=>Z:=D_-/\
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M X=J2&?X0]E3314S8^G,$4TR_(V-998XB S!5#$7L/?NO=/W^@_^?+_WGU\
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MO9?_ -TA[]U[KW^@_P#GR_\ >?7P _\ 2'>R_P#[I#W[KW7O]!_\^7_O/KX
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MD/?NO=>_T'_SY?\ O/KX ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?7P _](=[+_\
MND/?NO=>_P!!_P#/E_[SZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_ -Y]? #_ -(=
M[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\ Y\O_ 'GU\ /_
M $AWLO\ ^Z0]^Z]U[_0?_/E_[SZ^ '_I#O9?_P!TA[]U[KW^@_\ GR_]Y]?
M#_TAWLO_ .Z0]^Z]U[_0?_/E_P"\^O@!_P"D.]E__=(>_=>Z]_H/_GR_]Y]?
M #_TAWLO_P"Z0]^Z]U[_ $'_ ,^7_O/KX ?^D.]E_P#W2'OW7NO?Z#_Y\O\
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M -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\
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MNO>_=>ZUMO\ A61_VY0[]_\ $E_'K_W\.U??NO=7_=+_ /,G>I__ !&FQ/\
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'KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>timage_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_006.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MDO6][ ]C?6EJ!X5O Z!JU,C&.74Q(P:D8(X\>! $>3VTJW5K<7!/B32JQ6E
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MZWF2.Q-T$*.-(*2!L$N%/\)(S4''^3H#?A%_,^_FQ_+[<O07?^9^*?2G4O\
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MF/R&U\SBQD6E2G>NPV8I*#)P4\[P3+%4&E-/,8W$4KZ3[;W+9[G:&"W$92O
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M0?B !"YI4XI4,[YN9LK0S1$$L%T,!J7N(SBHX$D$XK09K0G9Z^^>_P 7LO\
M$;&_+W<?<%#M7H[&8^/';A[)[*V_ENM%.0QDB4%3&N/SN/QN5FGJ<C>*ECCH
M&>L=D%(DNM+D[[5.+CZ94U2>2H1)Y5XH6&!DYQY]&"WT1B\8MI3^)P4\Z<&
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MIGCGT\Z=+K^8;\V=]_S!?^$[_=_R8WG\?:OX[T>ZNR.I,5L_;]9OAM]#,8[
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MZ"7/U5&D=)4YJ2*F5JZ6!%ADJ3*\2A"H]Q+=3&YE>0A1J9FHHHHU$FB@\!G
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MJFQT5"NY<M%3T\$=?59"HR6(FJE%'&DM14*XCCT*@&5P/\=CA9 LDFV&)$&
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M+_A3//''(Z)4_P JP05"J;!T7?"2!6_J!)&C?ZZ@^]_\L'_J-_ZP]:_Y:O\
MU"_]9>M@WV#^A%U[W[KW7O?NO=>]^Z]TR;FP=-N?;FX-M5A H]PX3*X.K+(9
M!X\M!)3R7560L-,AX#J3^&'U][4Z2#Z=:(KUKE_\):]QYJ3^7MV5U=N6F^PS
MW2'RS[7V#58_[Q:[Q+48S;V5D&N-G@].2K\E':*1XV\?D#'R7]C?G]%-\LJ&
MHEACD!I3^)1QSP4'/K3H,\I,PM3&PH8Y'0YKG#'^;$?EULG^P/T)^O>_=>ZU
ME_YS%75=7_S3OY%W=L5',V,K_D!NOIW.9.,+HIUWKE]GXR(3-)'(BAJ;/9.4
M #6R03:"CJK@<\LH+G;]PAKGPTD ]1'K8_X /S'08WIC#=VDE,:W0GT,@51_
ME/Y=;-'L#="?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NM-;_A4%LNE[(^5O\IWKRNR>6PE#OW>_8&RZS,X&H6DKJ2+=.Y.O
MZ&2JHI721(ZNG2<O"[1L%D5258"QD[D&;Z>VOI  =**U&%0:),:'Y&F>@1S9
M'XT]JE2-3L*C!%6C%1\_3K-_,$_X3U=!]%?$;N_Y!CYL_)C/;BZ%Z]W7VOL[
M$?(;=>W]^;>R&3V=135M-AGH*G%T*R5>>D@3'TX$SZYJB-&IZI28'ILO.4MS
M<QPBW@42LL;&)61PK$ D$,>''\N(X]6W/EQ(H'E,TS&-2ZB1E=:J"<@KY\.C
ML_$#^81M'M3^0ANOY.?/W8F/WAU[L#;&ZNF^Q]K[+VQ#L^EWAC\+DZ+;.#HZ
M/&X]\?CJ$YFHK\;C9UI?M<?'.)RD-+2@P1E6Z;(UOO'TMD2&+*R$L24)7637
M)[<FN33U.>C"QW,3;=X]T 0%8,   P#%0*8'=@4P*GR'5/?S@B^1&_\ ^3!7
M]D]>_!WX-_"[X#SX[K/>>Q,&=Y9#M'M?(4^\-[X@82IP>3BI(*&CJ*Z6NEJ\
MB:Z62MEQLE3'>)_)$1+LJP0;L$DGGGN 74MI"Q K&P8&I+-2E!0 5%<BG1)N
MC2R[<62***$A2!4M(09%*D4 "UK4Y8T-,&O0Y[]^)':O<?4_\D;Y$?$?Y0?&
M_;GS0ZG^%/4&UMA_%[Y";^Q$4VYL?C]OR9%ZW;>W<L*^*OK32UM=35X;'0ZJ
M-*6HCR%--CZ<^T<6Y16\FX0744K0/.Y:6)<HWB$#4PIBH!6I(K4:3J/2E[*2
M9+.6"1%E6)0J2'##0*T&<TP:#A3(H.AF^(7S#[7V%_-!Z-ZG_F@?RR^ENE?F
M3W+MZ?;75'RBZHQM)!5F"&GRE'2K*E'EMPXBJAJQ_$J&KK,=F8YHTEIHYZ1J
M7QLB7<]JA>PDEV^[>2"-@7A>HR2!7(3Y$57R-#4=*++<)1=)'>6ZI*ZD+(M#
M@5-.+?.M&],4/18/AE4?*+?O\Z'^:[O3:OQP^./R"[UVWV7O+;=-@_DUOZIZ
M\GPFU\1N.LPV-J=N1C YP5U.V$QNWZ9ZG[>,BC:C:*9HJUPZ_=UMXMJLD:65
M(RFK])1(&<A6;55TH0S-09S4>723;FF>_NF"(SA@.]BA" D"E$>M0!7AY'SZ
MM"_DT_&[NCHWYN_/K>68K_B7M/JGN>L_BV>^/GQC^0M/VQ%LC>FU,MXJC'56
M&AH*%\19<AF5D5Z>G:E=8J+P!%B$8>YDOXKNUMD7QB\8(\26,(9(SD4.IJTH
M*<?,UZ.-GM)+>>9SX85R#HC<L%88/%5XUS^SJPG^=AGM^;;_ )5?S9RO7!G7
M<G^B%\;4R4U5)1R)A\[D\=0[DE62)'<&+;M3E7M8!@NEGC4EU*N6$23<(!)P
M\1?*M2,J,D<30?Y^'2W>V9+24IQT'SI0>9^T"I'5<_\ +I^-O\M'<G\B+KC+
M=X;,ZI?I+<'6F:WQ\D^QLICH:;*1;@P^5J%S-959JCB.;ILGBZVF2CHF@F%5
M%314M/2^@Q*3C?;Z^3=W\-G\19-,2C^$_" .!!!J12AJ2:U/1=M5K:MMRA@N
M@IJD)_B_$2>-01QXB@I2@Z3GSU[S_E:]1_!OX']/]8_'/#?/GKSLWL3)[(^"
M/4]1VYFI,)/D]I9&'$Y"IJ]UYROJZI:/%Y3,T^+\%2TZ1&H..$=+0PS"!S:+
M+<+J[N)7D:V9$UW$FC2P5AJ^% ,D+JQ2M*\:5KN%S:6]O%&J+,&8+"FH,"1V
M_$Q.!737-*TX=5B?S*]O?+S$?S"/Y/NY?E-U+\->B9LU\H-KTW5W7OQ7GR&3
MS5#C\#O+KIJEMYY:IIJ.DKB:JJ48DT,$<$(6O4KY&9W$'+S6IL+X6[3/2 ZV
ME"@$E)J:5!8C'&I-<=%&\^/]7:&81K^J-(C)) U15U$A:YX4 I\^K ?Y@OQ+
M^4M/_-4SWS!_EM=__%7M?Y/U_2-)B^Q?ACW%OW;N7W/38O;-)C\5Y<1@,U4F
M.CPM>:7'RO/][A&ILBTK?=2Q9"J'LEV;<+9]N%K?QS+%XM4GC4A=1J>X@9(%
M?)R5\AI'1EN-G.MYX]H\9D\.C1.<E1Z"N 33S4:O,U/3[_*J^7]?6?S ^[?C
MI\HOY<?5/Q-_F);GZNRF]MQ=G=64 Q=-N>&CI\;624-;"];E$HZ6OIH<;5)/
M0YNLHJFI@G:58:H$NWS#M:QV<<]M=/-;!]"H]:H34_+/&M54T(I4'IS:+]I+
MEXIX%BFT!BRTHX%!QSZBF6''@1U6G_(LI/E=V-@?FWV!M#XC?$7Y+]H;^[KR
M=-\@\O\ *+L2HV)N2CGW%#45M;C9L-)M?.K'BLAD*K+/,6\#2U25$$\;BECT
MGO.(MH6MXS-,B)"OA") Z$ T!!\1,T X5Q0UST5<MF>19G$<;,TC>)K8HP-
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M)-*>0(UP&T+JM>PO;W'!Z&'6HE_+YPNU.R/^%&W\SJM^0^%VWGNUMGXG<_\
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M2I!"J*5K@#C7/3>W!Q>7'B%"VB+5H4J*]_&K,:TIDGA3HVW_  F_VY@\9_*
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MON^FYC69:FDCIY(IIZ>?!FOD:!7!EE@@ ((! BY7NEANA%+_ &<ZM!)P^&3
M-34"C4-?+HGWN!I(-:?'$1*G'BF:4!%:BHI\^BM]<=O;8_FC_P TWXX]C;"J
MUS?Q]^!WQ%VO\DC31UK2PMV5\SL3#+M['Y.E,:(*G"[5C>KB,CK/25T,T>B,
MF=2OFMFV+;Y$D%)+B8Q<!B.W/=0_-R!C!ITFCG7=+M&0U2*(2<3EYAVU%/)
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M5Q\.+IZ..."*E2G$$<*K$L810H9:5W8N6)8DL6))8L34DGC6N:].+&J*%
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MBG6&EFJ/OEJ8:QI9*P92+)VKTK'F>H^^45+.TMR0BNZ3K<"[UGQ0VK6<FO\
M@IY4X4QPZ$9LHFA\#2/#*Z=(P*?ZO/CU5+MG_A.)\0J'JO<'2>__ )!_-OM_
MJ^;&U5%UQLC?G>L,F'V54U32'^-;:P='AJ7 19Q!*ZK/58JJIP&>U("[$B&3
MG6Y:59DCMXW!JS)'1I/DS%BQ'J 17UX=$\?+4*QF)GE=2* ,]0GS4   ^E0:
M?MZ'/MG^1E\0.W>D/CCU1E]U=Z8'??Q/VCB=B]'_ "<VEO+&;7[$QV*V]5O5
MXZAJLGC\'28FMI\>S:*:^%26G77+3RQ54T]1*CMN:KFVFEE C*S,6DA92T3%
MN."Q/\_MJ,=*)MBAGC2,EP8P%212!( /F!3ACA_/I_\ B7_)A^.7Q@[VI/D_
MNGM'Y&?+'Y X+"2;<V-V9\JNR4[,J]N4<JSHRX55H:/PS%*JK199GG:%9YA3
M" S3&2NX\SS[A#].J10Q$ZF2%- 8XRV37@/E@5X#K=GLD5I)XQ:21P*!Y6UE
M1Z# IQ/SR?4]8_E__):^,WRN[V7Y187L/Y ?%SY%U=!3XK<_;7Q@[$7KO(9J
MGI*5:*,9,2T5:AJ%I(H(#/3_ &\LL,4<=0TRQQA/;;S//MT7TY6*:(&HCF36
MJFM:C(/KCADFE3UZ]V.*\D\8,\<E*%XFTLP]#@_Y\#TZ,%\!_P"6Q\:_Y=6T
M]XX3HZBW9G=W=F92CS?:7;?9F>7=6Y]Q55 )C"U?6QT]) D$,M35RI#!211^
M6HFE<22R/(4>[[W/O3*9B $%$1!I1!Z ?D!FIH *XZ4[?MD6VJ1&"2QJS,:L
MQ]2?]0R?7H\.Z-L;=WMMK<&S=WX3&;EVINS"93;>YMNYJC3(T=?C\W ]-64=
M53RAHYJ>IIY9(Y$92KHQ4@@^RI',9#*2"#4$8((Z7LH<4.0<$'K7ER__  F0
M^#E=G<W187N3Y>[-Z.W)O*CWOF_C3MCMVCAVA/4T1A*PF*JPM57O"WV\*>66
MMEKHXAH@K8F6%XAHG/EVH!*0-(JE1,T=90#7SU >?I0^8.:AIN5;<D@-*J%@
MQB#TC)QY4KY>M?0C%#^?+S^4?\0/F!\=NH/C=N';^XNJ=K?'EL?_ *!-S=/9
M2#;V8VJE!#!3O3T%174N2@FI:Z*EIA5I44TKS2115(E2KBCJ$)MLYBN=LG>=
M2',@(D$@U*]<YR#Q^?RX$CHROMHAOHEB8%0A!0H:%*>F#Y8X?S Z*S6?\)\_
MBGN"HZBW=OKY _-;L+N_IK?NWM^;:^0F^^\*3?>Z'_NE4+5XK"R?W@P.7P\&
M Q]7''-%34V)@E,@)EJ) S*R\<X7">(J1P)'(A1HDCT(-0H6&E@=5/,D_9TE
M/+T+:"SRLZ.'#L^I\&H'<"-/R '#H>_FC_)R^,OS([@P_P CUWCW=\;/DEB:
M.EQE1WE\9M]IUUG,C24E,]%'!DY)*.MCG9*)Q M1$D%7X$BIWJ'IHU@]I-KY
MEGVR,PZ8Y8CGPYEUH#6M0*BG^#SI7/3]]LT5\XDJ\;C&N-M+$>AP?\_2I^#?
M\I[XY?!G?F^NZ,!N;M_OGY#]D4$6&W7\@OD;O5.Q-T-CX1 HQ]+5I1T4=-3.
ME+2+*QBDJ95@ACDJ&ABBB1O=N89]V18F"1Q(:K%$NA 37-*G.3]E33B>K6&T
M1;>Q<%G=L&21M3D>E<8X?L%> Z+GW_\ R#OBMV_W5V)WQUGW!\H_B3O'N1LM
M+W)C_C'VE#L7%;EESTAFKYJZBJ,;7:&KIGFDJ88Y5I)I9))6IO*\CNML^;KB
MVB6&1(9U3^S\:/64 \@:C^=:  # Z37'+\4TC2(\L3-\?A/I#'YBA_U$DYZL
M4^%WPC^/?P%Z8H^B_CCM6IV]M-<O6[DSV5S.0.:R^:RN12**;)Y>N*1_<U;0
M04\*A(HH8H8HXH(8XT"^R;<]UGWB7QIVU-0 >0 'D . _P M2<]&5C81;='X
M<0H*U]22?,GS/_%<.C:^R[I9U[W[KW7O?NO=8:B)IZ>>!)YJ5YH98EJ:?3Y(
MS(I DCUJZ:T)NNI&6X%U(X]^'7NM>S8G_"=KJ?JVGS])UE_,1_FC]=4NZ]R9
M#>6Z*;8GR6QNT8\EE\NL:U>5KTQ^UJ=:S)52Q1"6IF#S2!$#N0HL-)N=9+BG
MB6MFVE0JZH2U%' "KF@'D!CH-1\LI#71/<K4EC24"K'B31,D^O5HWPN^&,/P
MSVSO;;<7R5^5'R5_OIG<=G&SGRH[5':N0QG\.IVIQ28JH%#0_:4<NHR21Z6U
M2>JX^GL/;IN7[S</X4,5!2D*:%.:U(J<_/TZ.+&R^A4KKDDJ:UD;41@"@-!C
M'2E^9_Q!Z]^</1]9T+V=N#>6V=JUN\=B;UDRNPZNAH<@*KK_ "=/E:.-9,A0
M9&F\$M13(LP-,7:,L$>-B'#6W;@^V2^*@!.EUHU:4=2IX$>1Q\^KW=JMZFAB
M0*JV*5JK!AQ!\QGIP^6/Q2V%\P>OMJ=<=B9W=^W\/L_MWK'N;'5FRZNBHZF3
M)=4Y),I04\[5U#7Q-0SSQA:A5B25H[B.:)O5[U8WS;>Y= "2CIFM*.I0\",T
M./GZ]6N;9;I0K5%&5L>J,&'KBHS\ND[\O_A9UI\T:#H3']E[BWUMV'X\_(WK
MGY-;0;8U?CZ!JO-]9I7)1462.0QV1$F+F%?+YTA6"<E4\=1'8ZG=MW23;/$\
M,*?%B>%M0)HKTJ10C.,5J/ETW>6*7VC62/#D604IEEK2M0<9SP/SZ#;Y8?RZ
M>M_D]VYUI\C<'VKW5\:_DKU3M[);*VWWE\?]QT&!RU7M_+//-+M[-4^5QF7Q
MV6PZ5-54U$4,E(K13RNZR:69&>L-Y>QB> HDL3D,8Y Q4,/Q+I92&I@D'(P>
MF[K;EN764,R.H(#I0$J?PG4&!%<Y&#PZ"3;G\H+HW$]\]&?*S<O<GR2[.^3_
M $GNVKW*>[^S.P*/=>3S]'6X^JQIVWD:.7$KA\9MJ"GKJYJ>BPN.Q9AFJ)I_
M*TLCNSS\PRF&2W58UBD 'AJI"J0P;4,U+54"K%L8X 4;&TQ^(DS%FD0UUDBI
M[2M#B@&:T4 5SYFIFNLOA'UGU7V7\SNTL#N7?5=G?G!E=MY?LZAR];CY:3&2
M;8PE3@H%P*0XZ":!'I*IWD%7-6$S ,K*ET]H9]Q>XCAC8+2$%5I6I!8OG/J?
M*F.E45HL+R.":R$%JTH**%QCT'SSTL?B7\6-B_#SXS];_%GKO.;MW#L3K#!Y
MO 8/-[TJZ.LRT\.=R%=DI6JY:&BH*-Y4FKY54QT4:Z%2ZE@2:;A?/N4[W#@!
MG;40M:5^523_ #ZW:6JV42Q+4A10$TK^= /\'19-E_RH_C3M/^737_RR,AD^
MQ]Z= 9&AW+339S<^:QXW(D^?W+-NV"NBK:#%T6/2KQ6;DAFI#_"S&/!$L\<Z
M^0.83<PW$M]]>-*RU4T4'3A0E*$DT(%#GS/2.+9X8[7Z3+)0CN(KEBWD!D$X
MQUEJ?Y6_2N\OB-A?B#WMVA\@OD7@=H[MH]\]>]R=L=C)6=@;8RN"54P]=M[<
MN/H:"7'U&%C#I2L8)+QRS15'GAE>,T&^RQ7!N85CB+ JR(OZ3*>(*L6!!\QP
M]*4'5SM:20B&0O(%((=F[P1P(9:$$>O'UKGI%;$_E)]?0=I]7=L?(_Y.?+#Y
MJY/HO-4^YNE=J?);L''9[;^ R]%?[?._PG$8;$0Y7.TQT&*LKFG9'1'":T1E
M<DW]Q&\<$<4 D&F0Q*VIE/X:N[D+ZA:5X&HZHFU*75Y7DE*&J!RNE6]:*J@G
MT)J1Y4Z-M@_B#U[@?F=O?YP4FX-Y2]G;\Z)V_P#'[*[9J*NA; Q8C;F57+P5
M=/ M N07(O4+H=WR+PF,V6!6]?LO;<'>V6UH-*R-(#G5J90I\Z4H/3\^E:VJ
MK,9ZG44"4Q2BDGTK7/KU%?X:];O\XXOGR=P[W_TL1?&H_%U=K"NH/[N_P,[B
M;<GWQI_X=_$OXM]XQCU_Q3[?P\?;Z_W/;G[SD^D^CHNCQ?&K0ZM6C13C2E/E
M6OGU7Z%/J/J:G5X?ATQITZM7I6M?G2GET5K<O\I_9=+W;V]W7\??E/\ ++XC
MS?(3<2[Q[RZ^Z WM@\;M[.YN<RFMST5'FMO9B;$9S*&:5JNKHZF-GD/E18Y+
MLRU=_9XDBFBBF\,:8WD#ZU7R6JNM0/(,#3APZ3?NI4D:2)WCUFKJFG2S>9HR
MM0GS(I7CQSTL?CA_*M^-_P 4>P>_M_\ 3.7[1Q3_ "4ZUP^P.T\'N/>"[UCK
MJS%&O>7=4N2RM+59VIW-DILID)JZHJ<K/!433M(:96M9F^WV?<8XXY=)$3,4
M(&F@;3V@"BA1I%  *<.'3EKMD5F[O'4%P V:U(U9)-26.HU))K]O1D_B7\6-
MB_#SXS];_%GKO.;MW#L3K#!YO 8/-[TJZ.LRT\.=R%=DI6JY:&BH*-Y4FKY5
M4QT4:Z%2ZE@24>X7S[E.]PX 9VU$+6E?E4D_SZ46EJME$L2U(44!-*_G0#_!
MT ?47\K[XO\ 5_P*B_ERYW';E[C^.QI=W4U?!VCD*6IRU0=V9ZKW']Q][AZ+
M#QTM9C<I5B6AJ*:GAFIGA@D5S*GD*VZW^XN;SZX$)+52"@( TJ$X,6P0,@U!
MJ1PQTE@VF&"V^E(+QY%&H2:L6X@#@3@BA&//H&-I?R>^NZ?<W6DO='RO^9?R
MDZJZ6W!C-T]5]!=_=JT&Y=K460V]('Q%7E8:'"XZOW'+A=*BA&1K9DB4:9$E
M4E?;LG,#E6$<4,3.*/)&K!R#@@58A=5<Z0/3ACJJ;4 5+R22*IJJ.P*@@U!-
M%!:GEJ)]>.>A\^5_\NOJCY1=C[([YQW8'<7QR^2_7.!JMH[6^0_QWW=%LO<3
M8.NE>>; 99:JCR&-S6%::2:1::KHG,3R2&&2,2RATUAO$EC&T)5)(F.HQ2 E
M=0%-0H596^:D5X&HZ>NMN2Y<2 LDBB@=" VFM:&H((^1!IQ%.N'Q3_ET=3_&
M'L[>_P @,IV!W%\CODSV+@:;:6Y_D)\A]VP;QS\>$I)EGCP6'CHZ+'8S"882
MI$[4])0IY&CC\CNJ(J^O]YDOHUA"I'$IU"*,$+J(IJ-2S,?FQ-. H.O6NW);
M.9"6>1A0NY!;2#6@H  /D *\3GH_T\$-3#-35,,513U$4D$\$\8E1TE!5T=&
M!5E9200000;'V4]+^J<D_DI]#XIMU["V1\@/EOUQ\3=_9[*;AWK\)MC=O1X7
MKNL.X)6FRF)IHAC7W!BMMY>1W-=BZ+.0T\ZO+#Z*>0P@1GF:9Z.Z1-,H 6=D
M)E%, _%I+#R9E+#!K4 ]$XV6-:HK.L9))B##PS7)'#4 ?-0P4\*4)'1M/B_\
M >B/B]\-,?\ !7&1[@[8Z+@Q'8N S%#V])09RJRM!VADLED\I29$X['XNCDA
M9\I411^.CC98@EV,@,A0[CO$VXW1O#1)"5(T5 4H% (J2?P@\>/2FSVZ.R@%
MN*L@##OH:AB20: #S].'1,6_DA]23[.@Z+K_ )<_.C(_#^DFBCI_B'5=WTPV
MK_#89?,FWGR4>&3=;[<BE"F.C_CX:-5"B>P]F']9Y _C"*#Q^/C:#KU?Q:=7
MAZOGH^?'/27]R)I\+Q)?"X>%J&FGI6FNGRU?+ACHX7R3_EW?';Y(]6].=8U%
M'NOI:3XW5V&R?QL[ Z SR];;@V%-@*./'TR;<JXZ>II8:+[&&""6CGHIZ65(
MH2T/E@@DC+K+>)K.1Y,/XH(E60:UD!.HZJYK7-00P/ ]*[G;X[A%3*Z*%"AT
ME*"F/*E,4((]1T&_2/\ +'V-UWWIM'Y+]T_(#Y'?,/NKK+"YK =.[E^1F\:#
M+4.SH=RP+39.HV]A,+B\/BZ;)Y.F58JJNEIYJB5%3UAHT97KG>WEA,$4<<,;
M$%UB#5<KD:B[.Q \A6@.:5Z;AVU4D$KL\CJ"%+D=H/&@55 )\S2OE6G63OW^
M6-UQVOWIEOD_U)W;\@_B!\@MVX/$[9[+["^-F\*+;T>[Z' QK%01[HP^5QF6
MQ.4J:")(XZ>J-+'4)&D<;R2)%$J>M=[>"(6\B1S1J2424$Z">.DJRL*^8K0\
M:5SUZ?;%DD,J,\;D ,R$=P'#4&#*:>1I7RK3I?\ Q<_EU_'KXN;5[AP^.CWE
MW-O'Y&O._P C.W^_MPCLC=&^!44LU$U-G:Z2"GIWQJ4M351144%)#3(DTO[;
M,[LS-_O$U^4K1%CQ&D8TI'FO:/6O$DDGS/3EIM\=H&I5F?+LYU,^*9/IZ 4
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MX(+=OW:3;?%T!3XT3Q-JJ:*_$BA&?MJ/ETLO+!+WP]1(\.19%I3BO &H./\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
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MK_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P!
MZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?
M] ZO\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_
M $#J_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#
MZ]_T#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^
MO?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3
M_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_
MZ#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\
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MKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\
M6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_
M]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#
M_P!:^O?U6L/]]?\ &Y/^@^K1/CK\=>F_B=TWL[X__'_9W]P>H]@_W@_NEM+^
M\&5W5]I_>K*UV:K_ /+\U79+)S^?)Y*MF_>K9-'D\<>B)(XU#U]?2[E*T\[:
MG:FIJ 5H HPH X >71Q:VL=E&(HAI5:T%2:5))R23Q/0V>TG2CKWOW7NM9?^
M;1D:3JG^<Q_(W[>JI/M%WEV!V3TNU4H<EFSU=@<)#$WB=V"-+O<*2840!V,D
MC1Z_$.>78S<[7N$8\EB?\E+N?Y)T%]XD$-]9L?,R+^;!5'\VZV:/8&Z%'7O?
MNO= M\DMBTO:'QU[\ZTKH(:JB[$Z5[3V+5TM0BR1R1;MP5?CY(Y%9D5D=*@A
M@6 ()!('/M1:S&WE21<%75@1Q!!!_P G34T8E1D.0RD$'@013JF[_A,WNY=R
M?RF.I,,LS2'K_LKNW:+H69O&:W<57GM #,0 1FPUE"K=B;:BS$4<^)IW.4^H
MC/\ U34?Y.B+E1JV,?R+C_C;'_+U?U[!_0BZ][]U[KWOW7NO>_=>Z][]U[JL
MS^8/_+>_V??)=69#_9J_D?\ &S_1C0[OHOMN@]V?W83,?WLDQSZ\IS^^U#_#
M[4_^H$\W^J]G>T;U^Z=?Z,,NK3_:IKTTKPR*5KG[!T6[AMO[PT_J2QZ:_P!F
MVFM:<<&M*8^T]5S?] ZW_@TG^8I_Z-?_ (W[.?ZY?\N=G_SA_P!GHM_JY_R\
MW/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE
M_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW
M_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?
M^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^
M8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C
M7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^
M_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y
M<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_
M^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU
M[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_
MR\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\
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M *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\
MXW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7
M+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7
M.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_
M[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^
MKG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<
M_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_
M &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?]
M ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X
M-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YB
MG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?
M_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]
M_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ES
ML_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_Y
MP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7O
MZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+
MS<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.
M7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O
M?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_
M (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F
M*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU
M_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?O
MW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_
M )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\
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M_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\
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M ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\
M8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z7G5G
M\@[_ $8=G=<=E?\ #DWSVWA_H\WYM#?/]TMU=F_?8O*?W3R%/7_P[)0:OWJ"
MN^W\-0G]N)W7\^V;CFSZB-H_I;1=2LNI8J,M014&N"*U!]>G(=@\%U?ZBX.D
M@T:2H-#6A%.!\^MA#V$>A!U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=:V7<W_">C.]M=O=H=ITW\S#Y<[,@[)[!WAOR+9^(K)IJ/%#=N0J*
M_P#AM$5SE.HHJ+S^&G40IHA1%MQ?V,[;F\6T:1_26S:55=13+4%*GYGB?GT'
M9^7S,[/]1.-1)H'P*FM!C@/+H-/^@:;<O_>U7YD?]3ZC_P"R+V__ %V'_*':
M_P"\=-?U:/\ RDW'_.3_ &.O?] TVY?^]JOS(_ZGU'_V1>_?UV'_ "AVO^\=
M>_JT?^4FX_YR?['7O^@:;<O_ 'M5^9'_ %/J/_LB]^_KL/\ E#M?]XZ]_5H_
M\I-Q_P Y/]CKW_0--N7_ +VJ_,C_ *GU'_V1>_?UV'_*':_[QU[^K1_Y2;C_
M )R?['7O^@:;<O\ WM5^9'_4^H_^R+W[^NP_Y0[7_>.O?U:/_*3<?\Y/]CKW
M_0--N7_O:K\R/^I]1_\ 9%[]_78?\H=K_O'7OZM'_E)N/^<G^QU[_H&FW+_W
MM5^9'_4^H_\ LB]^_KL/^4.U_P!XZ]_5H_\ *3<?\Y/]CKW_ $#3;E_[VJ_,
MC_J?4?\ V1>_?UV'_*':_P"\=>_JT?\ E)N/^<G^QU[_ *!IMR_][5?F1_U/
MJ/\ [(O?OZ[#_E#M?]XZ]_5H_P#*3<?\Y/\ 8Z]_T#3;E_[VJ_,C_J?4?_9%
M[]_78?\ *':_[QU[^K1_Y2;C_G)_L=>_Z!IMR_\ >U7YD?\ 4^H_^R+W[^NP
M_P"4.U_WCKW]6C_RDW'_ #D_V.O?] TVY?\ O:K\R/\ J?4?_9%[]_78?\H=
MK_O'7OZM'_E)N/\ G)_L=>_Z!IMR_P#>U7YD?]3ZC_[(O?OZ[#_E#M?]XZ]_
M5H_\I-Q_SD_V.O?] TVY?^]JOS(_ZGU'_P!D7OW]=A_RAVO^\=>_JT?^4FX_
MYR?['7O^@:;<O_>U7YD?]3ZC_P"R+W[^NP_Y0[7_ 'CKW]6C_P I-Q_SD_V.
MO?\ 0--N7_O:K\R/^I]1_P#9%[]_78?\H=K_ +QU[^K1_P"4FX_YR?['7O\
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M-N7_ +VJ_,C_ *GU'_V1>_?UV'_*':_[QU[^K1_Y2;C_ )R?['7O^@:;<O\
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MDW'_ #D_V.O?] TVY?\ O:K\R/\ J?4?_9%[]_78?\H=K_O'7OZM'_E)N/\
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MH_\ *3<?\Y/]CKW_ $#3;E_[VJ_,C_J?4?\ V1>_?UV'_*':_P"\=>_JT?\
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M)4ZE5KM(.>>9#<R6TS<7M8R3ZDEF/#_3=!?E>,0)/&O!;B0 ?(!0/\'6S/[
MW0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZU^_P#A37LN#=/\IWL[.34T<\G6W:G2F]*65X]9ADKLY#MTR(?&
M^AC%GY([ZH_2[+K.KQN,>0I"FYQC^)9 ?GV,W_/O0<YK758N?0H?^-J/\O5T
M/QVWS2]G_'[HOLNAJ8*RB[#Z<ZQWS1U=+,M1'+%NW"4-?')'(A9'1TJ RLK%
M2"""0?85NHC!*Z,*%692#Q!!(Z/X9!*BL,@@$$<""*]#'[8Z<Z][]U[K64_D
M[XQ>J/YMG\]#ID3SI3;@[GV-W+C,;-)&$B3=>5W9F93!$AB6.(1[KHXQHIS^
MU' LDA*(9!US+)]5MNWRD"HCDC)'F$T(/^.D_:33H+[*G@7MY&"::T>A]7#,
M?\/[ .MFOV!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*FOH*.2EBK*VDI)
M:Z84U%'4U*0--(?I'$&8&1S_ *E03_A[]U[KNMKJ+&TTM;D:REH*.'1YJNMJ
M$I8D\C!%U2.51=3,H%SR2 .3[]U[K+!/!500U---%44U1%'/3U$$@E1TE 9'
M1U)5D92"""00;CW[KW46DRN+R$]934&2H*VIQTO@R%/25D=2\#W9=$R(S-$^
MI'%F -U8?@^_=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ/YT&QJ7L/^5?\X\!64T%5%C^BMP[Y
M2*HA6=1+UA-3;E@D"N" \,^)CD1K:D=592& (/>6)3#N%N0:?JJN/1CI/[0:
M=%>]QB2SF!S^FQSZJ-0_81U/_DX[T@W]_*X^#&<IJF.JCH?CWLG9;2Q2>4"3
MK:-]NRQD^26S0RXIXV&H:64KHCMXUKS+&8MPN ?]_.?]Z8M_EZWLK:[2$_\
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M-#2ZY*>&.HCD;(30!YE]U[IWZ_\ YBW>&VN]NE.E/G#\*:_XATWRBSN<V?\
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M'\/K<XQ'^;NJI)=92I'/*P6XL=P@/$PB0?\ -O6W^'3T&-\)ANK24<!*4/\
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M #KW%_\ 7CW[P^4/XMR_ZH_] ]>U<R>EA_U6_P _7OX__P *-?\ GB/Y<_\
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M\&<]2YR/&OH,].*3Y"25"52I_G(UIH8W8.#98XWXT(1[KW4O^0,V<KOYRO\
MPI)G[!@K#ET^4U+0TQW-1?;3?P&+>_:46(55G1&.-DP4.*,#6\4U**>4%T9'
M/NO=%I_X2L_%?J3YR?R9/E)\;_DYMO*]@=#9KY]MEJ[9AS]=@:>JFV/MWK3<
M45)]U0ST]7%2G)4E#-4PP5$7E5BKG3-)K]U[HW_\ISK7K[IS_A1E_.@ZLZIV
M9MOKOKC8?0_Q4VWLW9.S\1#@<;C:'';9V:L--24E.B10QJ+DV6[,6=B69B?=
M>ZO][;^$_P#I6^:'QN^8O^S!]X[)_P!EUV[NK;_^@C9VYOX;LO=O]Z:;)TWW
M.Z\=8_Q&;'_Q+RT9NO@FAC>[?0>Z]U@_FBY/>N&_EJ_S LMURE8^^<=\+_DW
M5[7.-5Y*I*N#9F9:.:C2-7>2L@L9*=%1B\RH@4EK'W7NJ-N@NO/YC.(_E%=!
M?-?X]_.B@Z-BZB^"^P>V.E_AF>DML[WZR.S^LMI0Y'&;<W7F:VAEW[E\UE]N
MT@CK\Q3YVC>+(2K-3T<8@(E]U[I:]I_(A_EM\_O^$K/R.CV_7;9V+\@>O_GO
MW-DMNY*-)J?'YK=/16(R.&HY:H&2/[FGGJ\DE&/.&G",X1F0A/=>Z-/_ #(:
MUJ;^;7_((IL340P[FR';OSS@6.D:-,A-A(>J/-FHD(_REL6#'CY*U%/@+QTC
MS@O' 5]U[IH_X3&R5]1_)4^)M;GDE3>.0W5\JZW?:UE.*.K_ (Q+W!OT50KH
M-*-!5A5B#QM&C* HT@6]^Z]T[_\ ";BM;(?RE.E:FEJ(:G;)[=^7,&Q9,>T;
M8]<)2=K[RAH8L2(/\F3%PA'CITIP((T71$ B@#W7N@9[#^-."^;7\ZCYC="]
M[]F=\57QGVC\)/B7OC*?'KKSO'=73N!SV<W!F=ZT,&0S%1M/+X7,2145+#/>
MCAR4-)6S-2SY"*IDQM!X/=>Z+)_+D_EX=7_++-_S%OCS\C>W_EEVE\<?@]\Z
MNU_C5\0>GZSY4;VVA3[)Q%!38O</W0RNV\OA,WN>MI:C*TU/C3N+(Y>+&4M%
M%%2QJ\]9+4^Z]T&'4GRS^37:'\G;^6'\?*KN_M/$]A?,#^8-DOY=/87R<PFX
M9?[[TVP^O=Y;YIZNMI<LX:JCW+DMJ;2I,2V3%0M3")9\B)&J%"M[KW0M?S,_
MA9L?X =H?R=]V?#[L_Y!=-;+[*_G!?!'H[N7IR#Y$;QWE@=WT^8R66JX<MEJ
M?<.9RM6]?'!1Y.EKC#614V6CR1;+4];/3T4M-[KW6UQN#!8O=&!S>V<W2I6X
M7<6(R6"R]&_Z9J7+PO3U$1_PDBD=3_K^_=>ZTY>D\INC>OPB^"'\G@YBKS.\
M-B_S<.Q/ASW-(:GQ5HZN_ER;PR'9M?-DZ>E246RNU<;L6BCD:**BE7*TE2=4
M$\,51[KW0_?)[M_=/\OGLC^?WUOM:2.DR7R5^/\ U+\U/BI2&*2FDJ-\?(O'
MQ]&YJAHP9$AR&0DW[C=J5*")HY0V2IH)48>.63W7NE7_ #(_C]%\3/A/_P )
M^?BWAFFK=H=-_P V;^4YU'V+D9*96@K*/:5/F8,CD,FZ^2&EAR.>IZ>HE<2)
M$*B9(D8*ZH?=>Z-?_/JK6H>L?Y;LF/J(:;=<_P#.3_E\46R98VCCKSD:W.9.
M-X\4Q_?6MFQK9"-Q3D2O2-51M>!YE/NO=7L^_=>ZU_?^%%LF57XN_#6&J&-_
MT1U7\U#X)4_R-.;B9L>-D_Q^L>H.1<@P0T/\?3;XE>=EBT^@MK9 ?=>ZOZFJ
MZ6FDI(:BIIX)J^H:DH8IIEB::5(I9S%$K$&2000S2%5!(2-WMI5B/=>ZUSOY
M>:[I;^:7_P *,:/J[+8C#=+R]@?%9]KYZJK$IL?0=F3]7S?WWJ?)3G7$\&5-
M,^5=D+(\4&@^19@?=>Z#GK?^5Y\_?@+_ "\L#_H!_FI[QA[!^*736Z=X==]1
M8WJC9-/TOF(]J#(;@DQ63ILC@LEO">EW*)*DU^5DW6T\=56356/CH*:*CI*7
MW7NK*NL_Y@'QGD^!/0/\UGY&X'8_3.:[6^-VP*VHK8,1%N'<DDV_X(,J=@;6
MJ%IAGL^V2SL1_AN*IU+UTZPS?;B4%E]U[H$_A-\<>\/E!\D^Y_YFWS;ZOJ.F
M\MV[T)_LJGQ4^+>8S$N1RFS.H<[6IG<G6[U@#F@I.P-YY1H9,A34Z,V*HZ:#
M&M4S-Y@/=>ZJ/Z3RFZ-Z_"+X(?R>#F*O,[PV+_-P[$^'/<TAJ?%6CJ[^7)O#
M(=FU\V3IZ5)1;*[5QNQ:*.1HHJ*5<K25)U03PQ5'NO=#]\GNW]T_R^>R/Y_?
M6^UI(Z3)?)7X_P#4OS4^*E(8I*:2HWQ\B\?'T;FJ&C!D2'(9"3?N-VI4H(FC
ME#9*F@E1AXY9/=>ZV&_AA\>L7\3/B1\:OC-B)354W172'6G6$^1=55ZRKVCB
M:6DKZ^0(SQK+D*Z.HJ9 C: \K!+)I ]U[HS'OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K6,_GA]L?S<:'XW?S%=D;$^)OQ@
MSOP8?XU=K8VN[OS7=M5C-Y)MG(;-=MQY)-N*3 V0QT\N46E@O:H6&%F ,A ]
MU[JT3^3*]6_\IC^7 :V*.&8?##X\HB1-J!BCVSCU@8FY]3P"-F%^&)%A:P]U
M[JR_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(S?>RX=^X$X&HW)O/:L9K*>L_BNQ-S
M5&TJ^]-JM']W3$2>%]7K3Z-87^@]^Z]T"4WQ;Q<T,L)[P^3Z"6-XRZ=ZY<,-
M8(N+L1<7XN"/\/>J=;KUKW[9_DJ_)N@[NQ>+K\WM"DZKQ>[::L;L[&[D"538
MRAJ5E66GQH1:Z+*O3J L940QU'_*2T:B5F]!Z4&84ZV%/]E?QG_/[ODY_P"C
MUS'_ $=[<ITGKT.6RMIP[)V[1;<@SNZ]RQT4E7(,QO7<,^Z,C+]W*\I$U;4$
MRR+'KT1@\(BJHX'O?6NE5[]U[K63[1^'.V/F!_/A^6&#W-W=\JNE(MF?R]?B
M=DJ/(?%GY#9_X]UE:^8W5OB$IE:K S0RY*"G$(:"&8M'&[.^DEN/=>Z1'\O?
MI/:O\NS^;/OGXR_+[<'8_P @>]>\>M,YG?Y='S[^2/<VXNU]T;HV-A#'6;MZ
MMJ5S^2J<1AMU;8JG%5*V#H:-<QC62IG@@(2%_=>Z)-\4-A;/W3T9_+3W/LCY
M:;=^(GSBV-\I?YOY^)NY>X>I$[0Z\W/3;E[5SJ;SVQF_OJG&4-%EYZ*BQ<N/
M:ES-/E[">2C@JDBD,'NO="[O[YI[1ZV^-G\Y/9'S5^'OQ#[<['V)G_B!C?DI
MV#\2NRMP;4ZI[2S/R(KJ/;^U9-Y9:H>/+;/K=OQT^,GW) M55$44@0M.LZ+/
M[KW4KYH[J^2F,^8W\D?!?)3Y*_R^<QG:G^8EU+5=8?'[X<]6Y;;.4PNWZC"Y
M:@JZP[IS&]<K55NVHEK\;C6IX=L8ZFR,U533+XA *0^Z]T_?'CK'KJ?_ (3,
M?S(\S/L;:DV7W+MK^;MO'<&4FP--+45F5V5NWL:/$9&HF:,R2U>,3%8T4LK,
M6@^VA\970/?NO= =\NNC?F!\L^[/Y?767Q%[UHNG>ZMZ?\)]]TY7.Y[-455/
M+NG')D>O:BMV>N7HJ['Y#;4F[<DV/I*G-4M3]U14<E6T(,C@CW7NC/?);Y+?
M&_N7^4W_ "X][=-;-VS\<]@]/?S./Y>W5_9W1DZP[5CZLW!T]V)0T6Z]J9B.
M;P"A. K*>I=JFH"&II6CR+L5J-9]U[H9=D=J=,_S?ODQC.[]_P#:W2^VOY6_
MQ4[%K6^/74V;W;A\-7=V]D]>ULM+-V)N>FFKXY$Z[VA7030[;Q4],/XOD%ER
M]<GVT%% WNO=#9\:NT.M>N?YW_\ -PJ-_=@[(V91]E_&7^6[V+L#(;HW9C\'
M3Y?!;1PF^*')97'SU-1'%54-%55$*2S1LR(74LP5E)]U[JF+&9'KOO+^6%C\
MMCY<!V)U/W#_ ,*>J3(T4X$>9Q>=V[V!WRLL;V.J&JQ^3QM6I_*2PR_E6]^Z
M]U=-W3TQU'DO^%"GP:W57]9;%K-QX+^7+\ILCALU4;6HY*BEJ-J;LVKC\9/!
M(8;QRX^BW+GX*=ULT,60JTC*K,X/NO=5:=I]F]5]&]M?/?K*KZ)Z:[&S/='\
M_;XU[0Z"PO=VZ*[K7K';78>8ZDVEN6BW=N]\.4:LIX*N@JYUQWV\HRN1DA$J
M$J98_=>Z&W%[J[V;_A0/_+6VW\D/DY\/>Y^XH/C=\VH<[LWXD=59'J]=NXG(
MX/'U&-I-PU.6WON_)9I,G4XVNGQ\%0E$*,4%1,D<WW&N+W7N@H_ER;Z_E\X#
M_A._\SL1V[G.F((JK)?S"HOE1MN3)XR@SU=N#([CW;%MR.JAB>/*S;BJ-LG:
M<6%D4&K!%$*%U:*/3[KW6R'_ "S,+VWMO^7;\'=O]\KGX^Y,+\4^B<9V-#NR
MIDK<M'E*+;>.CJ(LM-,SSRY2(J$JVE=Y6J%D,CN^IC[KW1XO?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=:RW\G_&KU/_ #=?YYO2XJJA*?<G;^QNZ\=BJJH2T:[N
MR>Z,U.]/"$@T0A=W4D8*0$"):=))9"L<D@YYDD^JVW;Y2!4))&2!Y)H05X_P
MD_;6@Z"^S)X%[>1@FFI'H?5PS'_#^P#K9I]@;H4=>]^Z]UK/?\*@YLMLGXH?
M$_OK!XV;*5_1?SBZNW:\44GB"1)AMPU:-([Q5$,4<E?CJ"#6]/*%>9!H8,RL
M.>0D6>YF@8T\6VD0>>25^SRJ>(X=!?FMC##'*!7PYD<^6 &_RT'Y];+-)54]
M=2TU;22":EK*>&JIIE!4/'4*'1@" 0&4@\@'^OL#D4Z%'4CWKKW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U&K:*CR5'5X[(TE-7X^OIIZ*
MNH:V!*J&:&J0QRPS12!DDBD1F5E92K*2""#[]U[HL?2GP>^&GQMWAN7L'X^_
M%7X]])[YWBLL>YMW=6]0X+8V1K(YY'F>&6KQM#3S"!Y9'=HE=8V8W*D@6]U[
MI:]\_&;X[?*3:E-L;Y(]'=4=[;0HJY,GC]O=L;#QF^Z6FJ8RA%12QY*FJ!2S
MGQJ#)%H9E&AB5)!]U[I=]==:]==/[*V_UMU-L+9G6'7>TZ+^&[6V'U[MBBV9
MAL;3ZVD\%!C,=!345)$9'=BL4*J69F(N23[KW2U]^Z]UI8?\+;?^R'?B%_XM
M;6_^\AG/?NO=;I_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[JL?^:#_ "IOCC_-4ZGVEL3NBIW3L/L'JK<C;QZ/
M[ZZTJH<7NG:.2J'I6JSCJF:*6.7'Y,45&*VDD71*U/2U,3P5M'25,'NO=4Y9
M/_A.A\S/D-A=E=*_S!?YV/R/^5'Q(V36X.IJNDL)UJO6E=N-=KSPR4"[AW#4
M[HW!4Y)D$"N9LA!DZI)B)X:J*H1:@^Z]U;G_ # OY6G7_P R/Y:N=_EI]4[N
MQ?Q;ZUDQ73VW-C9K"[ /8=+@<9T]G</F*2BAPS9K!/5+/%B5IS(^71U,AJ',
MS@H_NO=&,[/^$O4'?/PCG^"W?&-I.R>K\KTGM;I[<%948M,?+))M''4E+09Z
M@B>2J_AN5H*^AILC0NL\CTE7#"Z2NT88^Z]U37A?Y ?;3_R=NR_Y0O87\P8]
MA;/SN]ME;AZC[DK?C++05FT,3MG<V,W34[=;#2=CU@S-!/7T$XI&&7H30+52
M*$J(HX84]U[JTVI_ET]5[T_EB[+_ )8G=.0@[1ZZV[\3.K/C!F-Z/MF'"S54
M_5&W<7AL;NRAQD]3DX\5E*3)XFDR]"GWM2:*KBATU$K1"5O=>ZI/J?\ A-IW
MONK^7GU-_+/[1_FF9_?/QTZL^26+[J@BI?B[+MG)56VZ"FG4]?"IC[.J57"Q
MY.NR.3I):F.M^SK98&CIFBH:.*+W7NMFN7I'J*;8\G6[]<;..R9=J/LA\ <#
M3O"<4]']@:,EHRYC^T/CY<L5^I)Y]^Z]U7!_)_\ Y7>=_E.=-=N?'ND^2V4[
M_P"H=V=SY[M7J' 9WKN79=5LNDW)#%!5X):M]S9^/*TTGVE'.7BI,:GWC5U6
M:8R5S^/W7NA&_FE?RS.K_P":-\?<+T]OC?&]>HM\=<=@83M_H[NSKJI,&8VK
MNG;D51!2Y"&,2P?=TS0U,JS0"H@DU>*>GJ*>JIX)X_=>Z*9_+\_DV=@_'3Y;
M[O\ G]\V?FCNWY[?,/*=<4O3>PNP,SUM1=28O;&V(D59J6CP]#D,C#-7U-I0
MU0K4Z*D]43!)45=14R>Z]T4;Y!_\)P-^;G[)^5-+\1OYCO;/Q(^*/SSWA4[U
M^7WQ?I.M:/LRBRU7G*N2JS0VWE*G+8Z;;\&8%361RHM/+^U(E).U7C8(*"+W
M7NMB;XT?'CK/XF= ]2_&SIS&5.(ZRZ8V3AMB;0HZ^J^_J6IL0EFJ*RH*K]Q6
MUDS2U%1+H7R3RR/I&JP]U[HC?QR_EE?Z /YG'SF_F-?Z;?[V_P"SH[0ZPVK_
M *'/]&W\!_NU_HWQN&Q_G_O#_'ZW^,?>_P )\FC^!T/A\NC7+X]3^Z]T*N$^
M('>&+_F.[P^:M9\T>U<MT'N3H&EZAQ7P6J8<N-H8O.05.+G;>E.[;KEPIRLD
M=!4Q$)M"*HTU<MZXC4LONO='KSN#Q.YL)F=MY^@I\K@MP8K(8/-8NK3R15-)
MEH7@J:>5;B\<T,CHPOR"??NO=41TO\HSY7;.Z;K_ (-]4?S'\[LW^77EZ3([
M.3KG)=%TVY.U<%L;-RS_ 'W7^W>SY-PQ4\.&EH)GQU/7U>TZK*4- YBAJ&EC
MCF]^Z]T:[O;^6MB\H/BAOGX<=EI\1.\?@_U_GNHOC]N.EV6G8VUYME;DQE!C
MJW9&[=K25^*.:P%1_",1/%)%E*6NHJNE6JIJ@2-(LGNO=*WX>_![>W2W;G;O
MRL^3'>E/\F/E[W=M79W6^X>Q<'UM!T]MS;^SNOZBNK<1M':>VHLEF9Z/'1U^
M1JZNLJJS,UM97U;B9WAC2.!/=>Z+1D_Y8_RFZNR/=FP_A)\]8OC;\9?DAV;V
M%VOOWK/=?Q[I.Z<_M#*]NS"KW8W5^XZK<6+IL#39VNFR%7%39/"9:GQ5;4/4
MT<3(33'W7NK/?C3\>>LOB;T%U)\;.F\548;K'I?8^$V'M"BK:LU]2U-AH]+5
M-94$*:BNK9S+45,NE1)/+(X50VD>Z]T#&Q?AY_<OY\=__.'_ $B_Q+_3G\?^
MD>B_]&']T?L_X7_H;R6X,A_%/XU_$Y?O?XE_'?']M_":?[?P:_N)_+IC]U[I
MG^%_PF_V4+?'S=WG_I,_TA?[.1\O-[?*K^&_W,_NG_=S^^.+Q&-_@/F_BV3_
M (O]M_"O)][XJ+R>71]HFC4_NO=58]R_!/XX? S^4QMKXT_*+MKM[<G7NSOE
MB.V\#\N>ENO:;9F4ZJW3V#V'E-X;8["K*6KS.:@Q6#V7E\C34F0R$DM9$:>5
MIJBDIZ::9J7W7NJY.[:&'YA?-'^4OUYA?YMNT_YJ?;?6?\P7JGY*3;;^-VUM
MD;;VKL/KGH:+,;@S>XMUTNPJK<5.V:K\C!M?&#(97,4R+K-/C<=1/DYS+[KW
M6ZQ[]U[JIOK?^51M3KO^:CW!_,RB[>SF4@[)V#EL-MWX\MM1*7&8#<^]<5LG
M!;IW?#F6R4\U55Y[#;!P%,]*N,I4BTRR-+.74)[KW4[YV?RLMF?.+Y-_"7Y'
MYOM'+;";XG;RFRN]]A4.V%SU)V'@:;<>T]YXS;N3JOXE02XJ'%[OV5@\C'-'
M%5+*!44\],ZR(\/NO=&N^:'Q)V#\W?CSO'X^=A9K=6TJ3/5VU=T[3[ V'D1B
M,[MG<O7F3I,YMO<F&J65T2OPV9H*.H19$:*94>"96BE=3[KW1,MC_P O?Y,=
M@]]=']Q_/GYC[8^3NW_BCNK(;]^.G5W6WQTIN@<<-US8ZMPU-O;>50-Q[CJ,
MYGJ'%U]6M'2T?\,QE)4S35(IYBT20^Z]T.F9Q_RJD_F?[(R6W^S-S3?#"+X4
M[QA[+ZCK.MX,=A:+L*'>5#_=G.T.[Y*>2JS&7S>"JL]3U6(AGAAQ%-A::LJ?
M-)FJ58_=>Z$/YO?#7K[YR](KU%OC.[DV3F-M;[V5W!U%VELQX%S.S][=8U?W
M^V]SXM*J.:CJ*G&5>K5!4P205$$DT$BZ9-2^Z]T2?#?RX/E1W;VGTCO+^8S\
MV=I_)_K?XU=@X/M[JOHSJ+XT4_QUP65WGLX2_P "W=O:5]T;IJ\W4X9YGGH\
M73/18R&K"U$L=2514]U[H7_DI\$^V]Q_))/FC\,_D;C?C5\D\MU)C.BNSZ;?
M_5Q[NV/O/;>W\G/E,+_&MNQYO;M92YW;M379,T&3H\M')X:F2DJ8IZ<@)[KW
M47IO^5[US@/C]\M>IODEOS-?)SL7Y^U&XLC\RNY*[!T_64VY)\]@H=M4U+@L
M3C)JB':V'V]A::GI\-315E3/1E//+65-0S2GW7NB_4W\K#Y/=CX[I_H;Y;?/
M=/D-\)^B-T=8;LP/4<'QZHMA[RWM-TO5461VI2=E;X3<&0AR]!B<CCZ.>J7&
M;=Q<V8E@AEK)H_WHYO=>ZO"]^Z]T2CXM_#S_ &6KN?YP=N_Z1?[Z?[.7\@,+
MWI_=[^Z/]W/[M_PC:F$VQ_"_N_XG7_QCR?P;[G[G[:BT^;P_;MX_*_NO= C\
M5?Y;/^RR_P N?L?X _Z9_P"^W^D#&?*K'?Z6?]'7]V_M/]F:RFX\EK_@/\=K
M_/\ P3^\'CM_&8_O/!KO2^73'[KW56W>_1'QY^"-?_+AZ<S'STS?P,^6/QL^
M%&1Z"Z@_F(=A=:;8QW4V]]N[=&,H<WL3=N+W9N/^$ODS7T>-S]%B9,]2SPJ6
MGH\G4LDZP^Z]TG/Y6>RL?VU_.R^4?RVV/\N,O\^MI["_E_;)^-O9_P M<50X
M>BV;E=_[\W\-SS[;V@FVJ;^[%+C=M;7P& 7[+&Y&M,)JC65U555F1>H?W7NM
MI+=6UMN[XVQN+9>[\-0;BVINW!Y7;6YL!E(!4TU;09R"2FK*2HC/#PU%/+)&
MZ_E6(]^Z]UKX;Y_DH_);!=,YOX;?'+Y];>HO@3F8,93;7^.WRW^,<?RFR.Q%
MP^3ARM"NT-X)N_:V9DH\-70T]1AJ;(M/+B9::$TU;9833>Z]T]?"?^4!\F?@
M/D_EIL_J/Y:;<[(Q/RXZDF&2^9G>^TLMO?O+;&_-LX*CVWMCR3KE8<5O+9&'
MIFKZ^@HZG+8JKQ50JTD<M=#4M/3^Z]T#7QM_DH_S7OB%U=CNF?CI_/EQG6O7
MF.R>7SIQ5)_*=ZLW!5UF1W!.U37Y3+9C+[FR&9S>5K9F+3UN0R%35S$*))F"
MJ![KW5I??O\ +[W9\E?CW\9]K]F_)_=T'S(^*N;V=V9UK\W=B]>XG9=>-];?
MQLF+RN=J=E4\LF ?![GI:JNAR> $XI7IIS##/$\<4R>Z]TCNDOY?_?65^377
MORX^?7RBVO\ */LWH+;6Z=L?&?9/671Z]#[-VC/O^E6AW%NI\7/N#=%?E]WY
MC'J*+[J7)QTU#1F6*CI4:>23W[KW6+NS^51M3NC^9Y\=?YCM7V]G-O4W1^U,
M11;EZ#HMJ)6X_=FX=A4>]Z#9NY*W,29)6H9]L4O8.X5CABQ,C5!>+54Q*C*_
MNO=/?\UG^6)MO^:+U!U=UAENV\YTED^M.V/[\+O/;VVANJ;(8#=&W\YM+>.T
M9H#DL4T%'NK;>X*ZEDJHJL34LBPS(DJK)!+[KW5GF-QU#A\=08C%TL-#C,71
M4N.QU%3KHCA@H8UBAB0?A(XU50/P /?NO=3??NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8Y8HIXI()XXY
MH9HWBFAE02*ZR AE92"&5@2""+$<'W[KW5+^4_DE]11X;<?3_7/RL^:72?PU
MWK79^LW;\(^J>T\3@=C20;KJ:JJRN&Q%;4;>J]Y;8VSDY*N59\1B-ST=&D3/
M#2I31-I'NO='1[]_E_\ QE^0?QZZ^^-.;V=5]=[!Z5KMA9OX^Y3IK)GK?-]=
MY3JV#[7;N6V5DJ2-CA:[$4A>FBM#)!)2R2TM3#/3S2Q/[KW0:?&_^6]M+I;N
MJ#Y,=N?(/Y#_ #+^1>%V3DNM=@=I_);/8*N.TL#G)(I,E0;4PFV<!MO XB?,
M-!#_ !'(#'RY*M1%AFK#3*(1[KW5CWOW7NBZ_+__ +)+^47_ (KKW9_[S63]
M^Z]UK&?\(J?^W67?G_B__:?_ +[KJKW[KW6W[[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB3?S _Y?\ \=/YE?QMW/\
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MT>=P&0V]456.R..J)46KIY-8FBJ(XIT]U[I#_'GX&=TTGR9P?S,^<GR2VO\
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MU[KWOW7NO>_=>Z][]U[K2P_X6V_]D._$+_Q:VM_]Y#.>_=>ZV<OYAOS4VY\
M_BUO?Y%9[;DN\Z_#UF%VSLS9D617$?Q3-;GF\-'3253)(8*:)%GJ:ATADD%/
M!+XXWDTJ1'RIRZ_--]'9HP354LY%=***DT\SY 5 J14CCT3[]O"[%:O<LI;3
M0!0::F8@ 5\AG)S05P>'1/\ ^3Y_-<I?YCNQ-[;=W_MK$[!^1/4CT=1O?;F"
M,L.-R6,S4\\5'EL5#5335<(@DB^VKH))9?!,8)!*4JXXXS_G[D9N3Y4:-C)!
M*#X;FFH%0*JU,>=01Q'V'HJY3YH',<;!ET2QD!US2AK0BOV4(X@_EU<[[CWH
M6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW4:MHJ/)4=7CLC24U?CZ^FGHJZAK8$JH9H:I#'+#-%(&22*1&965E*LI((
M(/OW7ND3L7JCJWJ^/)Q=9]:[ Z[BS==/D\S%L79V.VBM74U3M)+452X^FIQ4
M3R2,S-)(&9F)8DDD^_=>Z7_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2>]-A;&[(P-3M;L39FT
M]^[8K"QJ]N;TV[1[IH)=4;Q'R4==#/3O>*65#JC/I=E^C$'W7NG#;>V-M;-P
MM#MS:&WL'M7;V,B$&-P.V\33X.BIT']B"EI8XH(E_P %C ]^Z]T^>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NBZ_+_P#[)+^47_BNO=G_ +S63]^Z]UK&?\(J
M?^W67?G_ (O_ -I_^^ZZJ]^Z]U:U2?SU_A;5?->H^%YEWG3Y"/>Z]54O<D^.
MIXMKS;J%4M V)UM4+7QP#(EJ,5[T@I6J%+!_M"E4TA-[:;DNVC<J)IT>+X0)
M\414U:Z4IP[J5U4\JU'01'.MD;WZ&K:M6C73L\2M--:UK7%:4KBO5T?N/>A=
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=1ZNDI:^EJ:&NIJ>MHJVGFI*RCJX5J8I8JE2DD4L;ADDCD1BK*P(8$@@@^_
M=>Z1>Q^J^L.L8LC!UKUQL+KV#+UE1D,M#L?9^/VFE545<CS2SU"T%/3B>:2:
M21W=PS,[,Q)9B3[KW2\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=58?-+Y8_/
MS9_9E'T%\ _@+7=^;SGP.,SFY_D5WCV%C^H>I]MKG(Z_P4S5 JGW)NK+4\E+
M3M5T&,H8O!#54[&J+.ZQ^Z]U7U'@_P#A633P+GVWC_)7KI%EDJ3LB2E[21V&
MM@*<RIBH8]&FQ!&7#:;:I->H>_=>ZLF^&?RO^9_8._,ET7\XO@CNCXV]FXK;
M64W-B>X^L][8[N3J?<U/B)Z&"2+'9VFGCS&"S$IKA)%BLMC(YI(8*B6*HE$3
M*/=>ZLN]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:QG\\/Y^?)G:_P ;OYBO
MQBP_\L7Y/[RZ?J?C5VMLR;YBX7-8>/9L./W?LUY:[<#T\H&0./P+UM1'5*/6
MS4DWC)!4GW7NK1/Y,L\E3_*8_EP22TTE*R_##X\P"*7DE:7;./B20<#TS(BR
M+_M+#D_7W[KW5E_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM9CYBTN0ZQ_X4G_RRNSJ>L^VP?<OQO[(Z?S%)X/(*B;;
M]'OZ07<F9T!J,W@F 2*(*:<%I"DLVD<[:RW&Q7<9&8Y8Y :_QE%_P*WKQ^70
M7O5,.Z6[@XDC="*>2AF_PD?L^?6S/[ W0HZ][]U[JNO^;GM--Z?RQ/G;AY(Q
M*M'\8^UMV!2NJS;"QDV=5O\ .1_H;'!KZC:U]+_H8YY=?1?VY_X=&/VN!_EZ
M+=X&JTF_YI/_ "4GI"?R1]^TO9'\J3X1;AI*@U,6.Z>BV$\A61+2]59/([7G
MCM+'$W[,V'D2X4H=-XWDC*R,]S3 ;?<;A6Q60M^3]XX?)ATWL4HFLX2/X%7\
MU[3_ #'5I_L@Z-NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%MO_9#OQ"_\6MK?_>0SGOW7NCA?
M\*4ZVN[$J?Y>'Q1H:JJC3O/Y!YFMJHJ9PNB?&-@]MT$I&B4^6V[ZX1$0R6M)
M=3PK33[/CZ(;AN&/T+;%?.NN3Y8_1%<CRZC7W$(NOH[,U_6G&1Y :4^>?U<8
M/0;_ "=V]AOY9W\]KXI][[/Q]/LWHOY?[8QO5V]Z/'@4]&*JL^UVME5>(:1%
M2T%2VR\U.RDEY_+(59BP=5LLC<X<KW5HY+36;^-&3QT]T@SYDCQ5'RH.FMS4
M<O[]!<+01W2^$_S;"_D*^&<?/K;5]P9U)_7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW3!NG=>U]C;>R^[MZ[DP&S]J8"CDR.>W/NG,
M4^W\=14\5M<]76U<D--30K<7>255%^3[]U[HKG2G\PGX'_)'>DG7'Q^^97Q@
M[I[!CHZG)+L?K'O+;>]<M)341"SU,&.Q^1GJZFF@+)Y)8HGCCUIK9?(FKW7N
MAPW5WETGL3L+K_J/>_</5FS>UNV?XM_HKZQW5V#B=O;AW-_ (Q+7_P!W\+5U
M<.2S/V41#S_9TTWA7U2:1S[]U[H4O?NO=>]^Z]U[W[KW02]L=^=%="TVUJWO
M/NKJ7I>CWSN:DV7LJK[8['P_7468S.05G@Q.+DS%91ID,G.B.T=+ 9)W"DJA
M /OW7NA:]^Z]T&W;/<O3_0>R<AV7WIVMUMTMUSB:G'464W_VSOG%]<X2FFR\
MR4])#497,55'00RU51(D4*O.&DD940,Q ]^Z]TN,1E\3N#$XO/8'*8[-X/-X
MZBR^%S6(K8\E25=)DHUFIJJEJ86>&HIZB%TDCDC=D=&5E8J0??NO=./OW7N@
M;^07R"Z;^*W3F_?D!\@=^8KK3J'K+"3;AWIO++T]571TM-$RHHBI*&"KR%=5
M3RND4%+24D]54S.D-/#)*ZH?=>Z=.R>Z>K^G^H=V=]=E[OH-H=1;&V76=A[M
MWME*>I-/0X;'TWW<U=+#%#)5E$I_646G:7^R$+<>_=>ZKMZ>_GG?RG._>T-C
M=+]0?-/KC>_:'9>XJ#:6Q=H8_!;CI)\CD<HVBGI(9*O"T],LDS<+Y)D4FPO<
MCW[KW1JOE#\[/BG\-/[K4WR'[7AVAG]\QY*HV7L3;FSMP=K[HR\&%:%*ZKQN
MT]H8G/;EKJ"@:H@^ZJH<4]/3!U,\L8-_?NO="ET%\AND_E)UEANX_C[V3MKM
M3K7/5.4H*#=.V*EI8UJL'.]+6T55!,D-70U]%41O'44M3!#40N-,L2FWOW7N
MAF]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0$_'SY+])?*?:&X]]=$;U.^-L[0[)W]
MU!N>LDVWE]IS4.Y.KZ]\9G<544.;H,;71S4%;&R%S3>*4:98))8G1V]U[H-_
MC[\]OB-\J>X/D=T+T!W/ANR.V/B5N?'[-^0&U<;@<SC!@LEDJK*T*4T=?D,;
M1XS,F*MPN3IZA\76UL5+-"(JIX7EA63W7NA,P7R1Z7W-\@M__%G!;R;)=[=6
M]>[,[3W_ +)AVWEU3&8/L*IK*3#54V7>@7!M-7S8^LT4D>2>L6.(S/3I$5<^
MZ]T5.L_FY_RYJ#N$=&U7R@VHF]?[\)U@^93;&XY]H)N=ZW^&_P!VI.PH\,VP
M8MQ+D/\ )WQC[E6N2;]MX%;CW[KW5CWOW7NO>_=>Z+K\B/EI\=OBA3=6U7R"
M[0P_7'^FOMO9G175-)6T%?FJO.;J[ J!2XK%45%BZ2NK&,TI'FJ&@6DI(_WJ
MR>"+U^_=>Z,5[]U[KWOW7NB _+'^:%\'OA3NW;W6W?'=4%)V]NV&@JMM](];
M[-S_ '7O6II\I(\5-6-M79^+S>:HL?4RQ2QPUE71T])-,I@AF><K&WNO=+#X
ME?S!_B#\X8MT0?&WN3&;RW3L-:0]A]9Y[ Y;K?=^W36N\<7\<VEN6@Q.XL;%
M+)&ZQ3S8U:>>P:GFEC9';W7NAJ^07R"Z;^*W3F_?D!\@=^8KK3J'K+"3;AWI
MO++T]571TM-$RHHBI*&"KR%=53RND4%+24D]54S.D-/#)*ZH?=>Z$2HW7MNA
MVM/OC)9S&8C9]'M^7==?N3-5:86CI<;3TQK):ZKGJC"E)30TH:6628HL2*S2
M%0IM[KW5>O6O\X'^7#VYV%M;K/8OR;P==G]^YVFVOUUG,WL3=FS-K[GR=:C/
M#CMJ[US6 QVS=SUTP1Q'!B\]5RNZM&J&0%1[KW1M.JODOTEW9V!WOU9UGO4[
MBW_\9M[X?KON_;4VV\OM^;!Y?<&-@S%#3E\G04<&0AJ\;40SQ55#+54DBDJL
MY='5?=>Z#?;/SV^(V\OF)OSX!;9[GPV7^7/6/7T':.^^H*? YE9<=AJ@8=UF
MDS#XU-O2UGAS^(F-!%EY,@L%0*AJ401RR)[KW0F9_P"2/2^U_D#UY\6LUO)J
M;OCM78.]NT-C;#@VWE\B:K ==ST=-E\E/DJ:@FQ&-AIJG(4<2+6Y"GDJ))-%
M,DS*X7W7NAR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M%U^7_P#V27\HO_%=>[/_ 'FLG[]U[K4N_P"$EG9<?3'\C?YU=P2O#''U3\H_
MDWV0[U$;RQ@;'ZAZWR?K2..61U_R7E4B=F^BHQ(4KMLLSN-S%;KQEECC'#B[
M!?,@>?KTFO+E;.%YFP$1G)^2J2>%?3HDG4?\OJ#N?^2E\@/FDU%+7]][)^1F
M8[/Q.[Y/+49*MVAL>BQ]!N"FJ*V:$S2+]YD<SE9669@9<=$S3"0SQC*'<.;/
MW;S+!MHQ;M;K T?X!+(2R$*#3@$3(X,12E#U!MGR_P#6['+>G,PE:97_ !E$
MHK L17CK;!X@&O'K=!_EC?*$_,'X-_'_ +MR%?'7[PR6SH-J]D2*/&W]Y-BN
MV)S$LD?^ZOOJFE-9&M^(:F(@V(]X[<X[)_5[<I[4"BJY:/S_ $W[U_8" ?F#
MU,/+NY_O>RBN/-E ?R[U[6_F#3Y='U]AGHZZ][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7N@:[^^0_1_Q8ZMW#W7\B>T=G]/\ 56U?LUSF]M[Y
M9,31Q29*58*:G0F\M35U4[K'!3PQR3S.0D4;MQ[]U[JM3XR?S_\ ^4;\O>U,
M=TKTE\P=KUW8^?R,&*VE@=^[)W1U ,W4UCM'!38BJW9A,-25M;4.%6&D6<5<
MK.BI SMI]^Z]T>OM7YI_&?I/Y"?'[XK=G=E?W9[Z^4O][/\ 01L3^YNX,S_'
M?[C0"IRO^Y3'XJKPV,^U@(;_ '(9&D\GTA\C<>_=>Z-+[]U[KWOW7NO>_=>Z
M*9\L/G-\6?@[C.K<Q\H^T?\ 1AC>Z>S,1T]UI4_W)W%O7^);CSL<DM+CM&W<
M1EY*/RQQ2'[BJ6"E6UGF4D ^Z]T;/W[KW1;?EE\N_CQ\&^D\_P#(KY2]A?Z+
M^G-KY/;V'SN\/[IYS>W@J=U5D6/H(_X?MW&9?*R^>KGBCU1T+JFK5(R("P]U
M[H<=H[KP&^]J;8WQM2O_ (KM?>6WL+NO;>4^UFH?N:#<--%64<_@J8X:B'S4
M\T;Z)84D2^ET5@5'NO=*'W[KW0.?(#Y ]-_%CIW?O?\ \@-^8GK3J'K+!5&X
M]Z[RS,-361TM-3D*%BI:*"JKZ^KGD9(J>DI*6>JJIG2"FAEF=$;W7NA(;<>$
MCVXV[I*^.+;B80[CDRDR/"BT2P?=&H=642(JP>L@H& X*WX]^Z]U4%A/^%"?
M\F?<69Q.W\-\\^KJ[,9W)T&&Q-$NW=T0F:IR<J001!Y,"D:F25T6[.JB]V(%
MS[]U[HZ7RP_F ?#_ .#\>SX_DYW7ANO,WV%-5P[ V/CMO9OL?=&<_ASPI528
M?:>U<9F]RY."C:>(U,U-B98J=6US/&@+#W7NADZ(^0/2OR=ZWQ/;W0'96UNU
MNM\W59/'T.ZMI5_WL(JL).]-6T51&RI445?15$;QU%+40Q5$+C3+&IX]^Z]T
M,7OW7NO>_=>Z][]U[KWOW7NO>_=>Z 7J?Y.]&]X=A=]=4]7[YCW+V'\8MZX;
MKSO/:\FWLM@9\%EMQ8Z/+4$#MDJ"CAKX*S'RK-#54,M322 .BSF2.1%]U[I!
M[3^=OQ,WU\N^RO@=M/N7"YGY9]0;%QW9/8O4$&%R\-1C<-E$Q,L52<I+CX\%
M53"+.XB22EILI-5PQU4;S01IJ(]U[H1,[\DNE=M?(+8'Q7S.]5IN^^S^O=Y]
MK;*V!#M_*U[U.WNOZFCH\MDYLA3T,N)Q\-/55]+$BUE?3RU,CE:5)C')H]U[
MHI+_ ,X+^6JG=]=\>?\ 9M>O9.R<7O"FZZRLU/C<U4[9I-R5=;_#8]M5>^H\
M6VQJ7<C5W[(Q,NXTR&O@TUN??NO=64>_=>Z][]U[HNOR(^6GQV^*%-U;5?(+
MM##]<?Z:^V]F=%=4TE;05^:J\YNKL"H%+BL5146+I*ZL8S2D>:H:!:2DC_>K
M)X(O7[]U[HQ7OW7NO>_=>Z(+\N/YG_P9^#N>V_LOY%][XG;G9>[8#4;5ZAV?
MMK-=L;PR$874)(-K[5QN9S2P.H9EGEHXH"JNWELC$>Z]TM/B3_, ^'WSGQ6=
MR'Q?[QVMV3DMI0XR?>^QV@K-H[HP S*EJ4YW:V;I<=N'$I4%)%BDJ<;'%,T<
M@ADDT-;W7NAC^0'R!Z;^+'3N_>__ ) ;\Q/6G4/66"J-Q[UWEF8:FLCI::G(
M4+%2T4%57U]7/(R14])24L]553.D%-#+,Z(WNO="5_>+!KM[^]D^5HJ+;2X7
M^\4V;R4PQE/%0B#[EJJ>2H\0IX8Z>\CM+H$:@E]-C;W7NJY>JOYQW\M/NKLW
M"]1=<_*K:F6W?NK<M)LW9%7EMI;GV=M_<>6R$334V.VON[-8/';3W/65,:WA
MBQ6;K'F+(L89Y(U;W7NC<]3_ "=Z-[P["[ZZIZOWS'N7L/XQ;UPW7G>>UY-O
M9; SX++;BQT>6H(';)4%'#7P5F/E6:&JH9:FDD =%G,D<B+[KW2#VG\[?B9O
MKY=]E? [:?<N%S/RSZ@V+CNR>Q>H(,+EX:C&X;*)B98JDY27'QX*JF$6=Q$D
ME+392:KACJHWF@C341[KW0B9WY)=*[:^06P/BOF=ZK3=]]G]>[S[6V5L"';^
M5KWJ=O=?U-'1Y;)S9"GH9<3CX:>JKZ6)%K*^GEJ9'*TJ3&.31[KW0Y>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[I'9[L3K_ &M7#&;GWUL[;F2:".J7'Y[<]%B)S%*6"R"*HGCD
M\;%6 ;38D$ \'W[KW58/\X;OW9^"_E;?//,]=]U;:PV^\5\9.T*_:&6V7V/2
MX_+TV1I<?(]+-C9Z&L2LAK8Y@K1/"XE5P"A#6]^Z]T8?^5[G\[NO^6?_ "[M
MT[IS67W+N;<OP6^)&?W'N//Y*;,U^0K\SL#;]165M;65#R5%55U51))+--+(
MTDLC,[LS,2?=>Z/1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZHC_ )UGSY^$
M6U_@C_,:^,6Y/EK\>,#\BZGXE]X[-I^C<OVYA,?NN3+;PV?52XK&I@I:Q<DU
M;DHJZC>FA%/Y)EGB:-6$BD^Z]T;+^37/#4?RF_Y;\D$B2HOPK^.4#-&VH!Z;
M:V-CD7C^TDB,I'X((]^Z]U95[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NH$>5Q<V1J,/%DJ"7+4=/#5U>+CK(WJ8HJ@D1
MRR0!C*D;D$*S* UN"??NO=>GRN+IJ^AQ53DL?3Y3)I528W&SUD<514+1*&F:
M"%F$DPA4@N44Z 06L/?NO=>QV5Q>8@>JQ&2H,I31U$]))48ZLCKHUEI6TRQ%
MXF91)&PLRDW4\$ ^_=>Z:\YO':.V98(-R;IVYM^:JC:6FASF<I<2TBH;%HUG
MEC+J#P2 0#Q[]U[J)BM_[#SU=%C,'O;:.9R4ZR-!C\5N2CR,[B%2[E(H9GD8
M(BEC9> "3P/?NO=*[W[KW7O?NO=>]^Z]UBGG@I8)JFIFBIZ:GBDGJ*B>01(B
M1 L[N[$*J*H)))  %S[]U[K'1UM'D:2FK\?5TU?0UD$=31UM'.M5%+', R21
MR(621'4@AE8@CD'W[KW463-X:*NGQ<N7QD>3I<<<O58Z2OB2>.D#%#520EQ(
ME/K!7R%0EP1JO[]U[K/09"@RM'3Y'%UU'DL?5QB:DKJ"I2LAE0_1HY8V9'4V
M/(8CW[KW4SW[KW3)/N7;E-F*;;U3N#"4^?K(C-28.?*P15DJ+:[QTS2"=U%Q
MRJ$<^_=>ZSYC-X7;U!-E=P9?%X/%TY03Y+,5\6,IT,ALH>:=TC742 +L+G@>
M_=>ZG4U33UE/!64<\-5254,532U5-*L\<D<ZADDC=25='4@JP)!!!!M[]U[K
M-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K64_GK05_7_P Y?Y'WR&HI(Z>@VG\P
M_P#1WNB>6E\JFDWOG-D2%1(8S%&QQU)G -;ZP662)?VY"!SRF5FM+^!OQ0>(
M,^<8<_X2.@QOP,5Q:3#RFT'[)*#_   ];-?L#="?KWOW7N@N[PV='V)TKV_U
M_+"M1%OGJ[L#9TM.RE@Z[FQ-71,A CE)#"<BWB?Z_H;Z%V!_"=6]&!_8:]4D
M76I'J"/V]4>?\)A]\4V[/Y4VR,#!5PU$O6/<G<VQZV&.5)#!+7Y&/<HBD">J
M-S#N&*4*_JTR*P]#)[%W/T1CW)R1\2QL/F- 7_"I'0>Y3D#V* ?A+@_(ZBW^
M CK84]@SH2=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\+;?^R'?B%_XM;6_^\AG/?NO=&X_F?:>
MUOY[?\JGI6J#2XS8U!LON$JLJR*9X-U9K+20O&(Y&%X]DTAD#>EXI /0MW]S
M5R8#8<L;I=#C(3!^6A$_ZSFGS'4;<QE;S?+"W(/8#+^=68?SAST:/_A1K\=_
M],'\OW(=I8BEF?=_QGWYMSLO'U-'$K5!Q.;E7!YN!7-GC@C2NH\A*4-_]QR$
MW ]DOM'NW[NW986IHN4:(UX:J:U_,E=(K_$>C'W!V\WFWM(M=4++**<:#M;]
M@.K'H.K-O@'\@1\I?AA\;N]YJZGR.9WYU7MN7>%52R^5/[P8",XO<2 ZG(\6
M<H<@FEF++ITMZ@?8-YGVK]Q[A<6M"!'*P6N#H)U(?S4@]"39;\;I:17&*NBE
MJ&H#4HP_)@1^71OO9#T:=>]^Z]U[W[KW7O?NO=5E_P##OOP+_P"?KYS_ -%G
MN/\ ^MGNNL=.>$WI_@Z]_P .^_ O_GZ^<_\ 19[C_P#K9[]K'7O";T_P=>_X
M=]^!?_/U\Y_Z+/<?_P!;/?M8Z]X3>G^#H6>D_P"8?\4OD-V#C>K^J=_93/[S
MRU'E*^AQM5LG,X1&BPT#U-0QJ*VA@@71$C$ R L> "??@P/6C&5R>CM^[=4Z
MUI/^%2'QN^2OR*^"G50Z%ZNWIW[LSJ/Y*;)[<^1OQ]V#G<EB,CN[9FUJ#)_<
MT*PXE7R%=%#5R4[LE-'+4TS%*^F@DGI$*>Z]UK[8;LW_ (3G_/G?_P ==@]5
MX7MC^1I\U.F>[<7%M?>&,ZNIMMRS9?#KX1A,CF*6LK\*E1%F8*/PU^X:;'UL
M%72S4K($KIDG]U[JY/\ G(]C[&Z;_GC_ ,B3M+M?>V"V?U[UWM3YA;LWUO[<
MU9%B*"BQ^!VVD]9D*J7B**)8T9R%')(5%)*J?=>Z.G\4?YL?RQ^=O1GS)^7'
MQF^'NVA\9.F\7VDWQ"RW8N],GAMQ]U9#JZ&J\L-#CSC:6CVYCJ^KH:BDCK)J
MNJ,-:RT4U.)*>LDI_=>Z:]I_SZMA;A_D>[A_F]U_76-Q&?VWC<]MFNZ*.YY*
MR,;WI=S#:^-V_P#Q.&E>H%+D:BIQM9]P:'R0X^H^YE@3QNJ^Z]T#ORJ_GL?*
M/XN)_+ VC4? E>SN^?YCG2V?WK1]&[4[#EQ&4P.[,G2X]]K[6\]=1"FD@EK\
MYBJ?,U]2U,,9!%75OV\OA%,/=>Z!G^8]\RNVMI_$3^7WV#_-._EE=&Y7OCLO
MY[476&%Z,R7<$^=Q^QJB<5283>5%E]O5N7H<GE#2T[RK#'7,BQSJGG@E69/?
MNO=&L_F;_P TW^:3\ ,U\@.SL'_+'ZIW_P#!_I>GP&2QORDWI\UME]9/E*7*
MT.-$H&UJNN?< K_X]6S8NCH8J"6LR$Z0BC@F>IA1O=>Z(_WW_-FW/\H?Y"?:
M?SZ^;O\ +(V/DNL*SO/K/"];?''L3LG++B-[;=K<G@Z:@WB*^/&TE?!2Q9JM
MK31A\>T-3]@M1$SPS0S#W7NKTN[/D'\E^GOY?G1O;WPA^'U#\D^S\MLKHM,%
M\<,9O@;-IJ/";DP<,U1]OF*\N$@PD(@2,SEGF4!"?(X/OW7NK+<7/5U6,QU5
M7TOV5=4T%'/6T5]7AFFC5I(K_GQN67_8>_=>ZUE_^%*OPPVSV)\#/F9\K^S.
MS.T=ZGJ/I/:5-T1T7/N$X?8^ULO5[BQ-)E=UG$4@C.=W17TU6\$-7D99H\=3
M@I0P0RR33R>Z]T<G^<=UKWYW=_*0W?T;\;^MMY]K]A=QT'QUV)E-G;"FI*3)
M5&V:C<&WZ[=T<=3D*R@H*6.JVW0Y.DDEJ*V% M05$J2,CCW7ND]7_P Q+YD_
M$'LOXZ[:_F!_#;I7ICXV_(GM7:?QNZ[[;^-OR$RW>W]S]U[VO%M/$[RQ^1V9
MMAX\5E!!)1_Q6C+T]-4QH9XTAF#1^Z]TV?#G.U/:G\^;^<SD]VC^)5OQ7Z5_
MEP=$=235>BI_AF#[DVIN+?F?AH[QJ:49#-RQR3@,S2F*,NY5(XX_=>ZS? Z2
M?8?\Z#^==TYMJ8T/6F>QGP3^1HVE'!%%2T6[>R=FY'%;ER5$(HXV5L_'@<7/
M6B5I2]3#Y(VC#.C>Z]T-7\T/Y4?++X_[]^ ?5WQ$3J-]]?+?Y+;AZ'R]1W1A
MZW+X:AI)MG9W+Q9F1,;54=?+_ ZG'QU[TD-5"^2B@?'+44CU2UE/[KW1&Z[O
M'^<)UK_,!Q?\LB;Y/?&+N#._('XTR_)W:/R\W%\8:C8M1UE0;)S4N#W+01]=
MXG<LV/WH*ZK;&IB/O-VT#TK5<DU=45JT:T]9[KW0M?'G^81\@_CCOK^;%T?\
M_.P]D=_#^6QU'UU\GL%WWUIUS_HGKMQ[/[,VWN#<!PF9VU3R5F/HL]BGP2P0
M2T$L\%6E4ID\<L1$GNO=!%O/O#^<]M?^7)V%_-"F[V^,E!FE^-O8'REH/A)4
M]!?Q; [<V?5;7J=PXJG3?E-N!,[F-W;>QOV]=4S20+B<A)'/CEHX%>.O7W7N
MKK_@GW%O#Y$?"#X;_(#L+^%?W^[S^*OQY[BWQ_ J(XRA_C'9NT<1F\G]G3-)
M,U/2_>UT_BC,KF./2I=B+GW7NJ;_ (_]M[7_ );ORP_G][8WI#C=O=4;4I]F
M_P V#95-1TG@CK*3N/9=71[WE^VIY&<UDV\=CRP:(J?RU,DL<NMI)UBC]U[H
ML'P$Z4W-_+_^2'\GSMC>N+S&"W-_,L^)7=G2GRVAJZD.$[7W769'Y"X&KRE/
M*S2QUWWN9[ PRO#+(8]5-2NG@B69/=>Z&CHO?VZ<=\<?^%#W\UG;DDD&\-[;
MC^76+Z%S\LJM71;8_EU[#RVTMN/'*Z3)1TTNZ\-N.KAIT5XU\@J)5,\TL:^Z
M]T,74W0_6^XO^$QVU.LLQ@Z>IVYO_P#E$0=C[A801&=]P=@=8'=]9FQ)+'*K
MY9-Q5CUZ5$J2,:I5E<.;@^Z]U8S_ "L.R]Y=Q_RUO@9VCV'EY-P;[WS\2>@]
MP;OW!.@CER&1K-M8[[NNG"V3[BLF#33:%5#*[E$1+(ONO='0WIO/:O76T-S[
M^WUG\9M79>R\#EMT;KW+FJE:.DH,?@X'J:NKJ96X2&""-W8_T' )X]^Z]UIP
M?S$-I[W^4..^%O\ ,\[MP>8VW#OW^:1\#NJO@OU+NG#C&56T.HLOOB/(-NC(
M4=0'J:'>/:U1C,7EJT,89Z'"0X?$210SQY!9O=>ZW1??NO=>]^Z]UKN_\)Q\
M3@NY/BCVG_,5WKMU:GY0_.CY*=_;W[BWWG\:$S,5!L7=.3VWMO:D4LC2ST6$
MVWB\7%%2T"R^.!WE'J-F]^Z]TU_SH\9MWXP_+K^43_,"ZQV_2X;O_</\P;IO
MX)=C9S SRX>LW7US\D<=N&')8'-K3LL69I<54X^.KQR5<$_VE:R2TYB8W]^Z
M]T'W_"E7X8;9[$^!GS,^5_9G9G:.]3U'TGM*FZ(Z+GW"</L?:V7J]Q8FDRNZ
MSB*01G.[HKZ:K>"&KR,LT>.IP4H8(99)IY/=>ZO#[C^-G7_S"^&N<^,G:U=N
M[']<=S]1;=V;O.HV)N [6RIH*JGHY9X::N$4XB6H6+Q3*T+I+ \L,B,DC ^Z
M]U41_.KRNQN[>E]@_P E_P"+F"Q6X/E9WYE>F(MEXC;."FSE%TGLOK#-XO*R
M]F;DJJ*6*3:E/BL9B)J7!.U7!65];(D5&LZ+./?NO="/L_&T_P 4OY]';(R%
M118_8/S]_ET;([,S>ZJF.*ADR&]_@IFGP&2GR3++&KR1;*W5CYS4-"[,H>.\
M4<%Y?=>ZJGZ>IJK9O^R(?SQZC$YO#Y3Y5_S7^]J7M*IF9Z*27I?Y]5B=5=?3
MUM%6$N,;B*;:'5F4A0.D\44L\Z1/+/) ?=>ZN$^*V.?O[^<[_,<^2M7"*O;'
MQ1ZFZ _E]]85=<?.\63R-,>S-_O0QG4E)$U1GMKTTLBD2U3TY611%!"7]U[J
M[CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77Y?_ /9)
M?RB_\5U[L_\ >:R?OW7NM%7^2!OM.N?^$NG\T/<#LR#(?*[L[8@*1F0W[2VA
MTQMA18 V#-EP";>D$L2 +@9>WUH;S>K1!Y2B3\H@93_).@[S;<"VVVX9O.(I
M^<E$'\V'6U1_)>Z5P])_**^/W76\L?3Y7#]K["[/R^[<?)&HCJ\=VWG,Y.()
M +ZA)AJVGA8L238\*+(JWW%W$R[]<31DJ8Y$53YAH41:_P"]*3TFY.LQ#M4$
M;9#(S'YB5F>G[&IU7/\ \)Z=RY_X]]\?/W^6UO.O\];T[V9F.P-G+4WIY:E-
MO9!=JYVOCB;]5+6P0[3J(B@"A9B_(E! N]UXEW>VL-YC&)HA')3@K4\117U!
M,@S_  _+H/<A.=NFN]M<_P!E(72IR5)TDT]*!#C^+Y];4GN$NI,Z][]U[KWO
MW7NH]750T5+4UM0Q2GI*>:JG<*7(2G4NQ %R;*#P.??NO=5I_P##OOP+_P"?
MKYS_ -%GN/\ ^MGNNL=.>$WI_@Z]_P .^_ O_GZ^<_\ 19[C_P#K9[]K'7O"
M;T_P=>_X=]^!?_/U\Y_Z+/<?_P!;/?M8Z]X3>G^#H;.A/GQ\8?DQO>HZ\Z>W
MQDMQ[KI<!7[FGH*O9N7P""CQLM/!-)YZZCIX25DJH!H#ZCJN 0"1L,#UID*\
M>CD>]]4ZU\/^%&O\OSY'_/7XD].CXM[3V3VKV;\9OD9M/Y#1]$=AFG_A6]J/
M;>/R5%4869*VLH:"I+K6C72U%5 E92M4TJ3QRRIJ]U[K7_[X_F$_!3Y1Y[H+
MX^_SO_Y37R+_ )8.]^N.UHX.JOD=U)B:GKO%XRMQM,M-/*F;."V_FZ';)JUH
MYRF)_CL$;4N-R"U0AB\R>Z]T?[^>7\C^G/BU_.%_D<_)KN#>:XOICJG87RUW
MUN7>,2'-R3T$.WJ;[=J6.F4M75F3EEIXJ6.);U%1/$B?K'OW7NCE?R^OF_\
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MA\&\W+A<J^273&LCQ[.W=C98ZDM(_CAEC<(J*S>Z]U4WTA35FS*_X ?SOJC
M5.#S/S'_ )IO?^#[GS8IJF&H;IOYT3U'6_6+9.FK9!(F'QYV9U96TJQIYJ<U
MJU/C05&10^Z]T<3LKL#=5?\ *;_A03_,!VS"(:K^7_\ R^Y_B)\>MS--%-/!
MN'8&P<_W!O5J-G^X_AZPYK+[2B=A"?N7@!E3_)E5O=>Z&+JCH#J[=/\ PF0V
M=UCN/;M/D-K;[_E(4/9VXE2*%:E]P[XZS&\:K.)--%4)_&(]QU;U\=5+%*WW
M2I+(LG*GW7NK)_Y7_:>[>[_Y<?P6[<W]5QY#>W87Q0Z(W1NS)1HR"JR&2VWC
MVJZHAF<AZF;7*XU6U.;6%A[]U[HX^\MX[6Z\VCN??N^,[C=K[,V7M_,;JW7N
M3,5 I*2@QV IY*JMK*F5N(X*>GBDD=OPJGW[KW6G%_,2VOO;Y18OX5?S..Z\
M#E]LT^^OYI/P/ZL^"W4NZL*F-K-H=29K>\%?+NC(4LZ-5T6[^UZG%8O+5B.T
M4V/PD6(Q#Q13IDO/[KW6Z#[]U[KWOW7NM>/_ (3I8S;?=?Q;[6_F.;OVLC_)
MWYS_ "4[_P!Y=L;XW%C8CG:?%[#W3D=M;9VBM1H$M+A]N8G$4\4-&FF-)FF9
ME9B&'NO=-_\ .-H-N_%7YD_RCOG_ -8[>H\-W;O;Y[]3_ 'MG)[;ITH,AN[K
MOY.469%9BLL$4#+I@ZW$15F-2>[05;@121"4L/=>Z##_ (4M_"O;'9?P-^87
MRP[/[0[8WG_H7Z;VE_H#Z(_O5+M[8FV,U5YW'X[*;KGPN/,"[FW+74F2G@@J
M<M)50XV$+_#Z:"HU5)]U[J\/N?XT[!^8OPSS?QB[3R>\L1USW-U-MC:&\ZOK
M_/C;&6;'S0T,]13TU:T%2L4=8D!IZA6@=9::6:)A9R1[KW51'\ZVJZ^[YZ:Z
MZ_DM_&;!T.>^4_>^<Z2EV7BMHX^MKJ/I/9O4V<Q>8D[-W+5XNLHI=LTV)QN&
MFIL&DM?#/E:V1*:"*J@^YC;W7NA5VG04'Q6_GS]S2Y X_$['_F#?R^=F=I9+
M<[&GQK5N\O@OF9,'EJC+1PQ4T#SC9^[L=,M0BFR131F.*-$U>Z]U5#TA35FS
M*_X ?SOJC 5.#S/S'_FF]_X/N?-BFJ8:ANF_G1/4=;]8MDZ:MD$B8?'G9G5E
M;2K&GFIS6K4^-!49%#[KW5OOQ)H)>_?YR_\ ,P^35=00U&V?BYUG\=?Y>O4V
M9J6CK)!7"CF[*[$2E&MVH8UR&XML0R:0IJFA'D"_;*&]U[J[OW[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=44_S:/Y4?\J;Y#P]A_/\ _F$[$WWF5Z"Z%JTW5NG:?8FY,":?:W61
MRN:\,&)PE7 M75B;(5VBT1EE>1(RVE5T^Z]UJ$8;I?\ DK[KQ5!N797_  GN
M_GB;LVCG:6+*;:W/AL9O+(4N0H:P:Z:KIYZ3/U5++%/$5=6BJ98R#Z)'%F/N
MO=?0V^%N.V?A_AS\3<3UYUSOOI[8&+^-'1&.V-U'VC'/%N;:V'HMK8J+&;<W
M&E4\E2N=P=$L%%7B:1I15PRB1F>Y/NO=&7]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=41_SK/@-\(MT?!'^8U\G=R?$KX\9[Y%TWQ+[QWE3]Y9?J/"9#=<>6
MV?L^JBQ623.RT;9):W&Q4-&E-,*CR0K!$L;*(U ]U[HV7\FN"&G_ )3?\M^.
M"-(D;X5_'*=EC72"]3M;&R2-Q_:>1V8G\DD^_=>ZLJ]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW0;=K=I8/I_:4F\MP[?[)W-CH\A18TXOJGJO<7<66+UQ8*ZX;:^-R
MV4:G32?),*3Q1<>1UU"ZNRLFOY!&AC4D$UDDCB3']*5D7[!7/ETGN;E;5"[!
MR!3"(\C9_HHK,?V8Z*?F_P"8/UC38;+U%%T]\X(:R#%U\U)-4?R_.YXHTEBB
M=HVD:78XC5%8 L7(4"Y8VO[/$Y4G) ,MGQ'_ !/L_P#K?T6-OT('P7/_ &27
M/_6KK30V1_PHA_F893>FT<9FNQ-BU6'R.Z,!09:FQ72N)JZJ2FK*N*.>.FBI
MZ62>6H>)G$:1QM(SD!%+$ Y"WGM#L\4,CHLFI48KJFHM0I(J30 5XU(%.HBM
M/<;<)941_#TLZ@Z8R6H2 : $DFG#!SY=;H7_  X#U/\ \^:^<W_IOGNK_P"P
M;WCQ_56X_P!^V?\ V7V7_6_J7OW]#_!<_P#9)=?]:>C4=9=BX?M;9F+WS@<+
MO[;V,RTF0B@Q'9O6^=ZFS,1QM1+3.:K!;DQ^+R](LCQ%XFEHT6:)DFB+QNK$
MDO+1K&0Q.48BF8Y$E3(!PT;,IXYH<'!R.C.VN%ND#J& -<.CQM@TRKA6'#S&
M1D8Z7WM+T_UK/]C_ #(ZP^'?\^'Y8Y[L_:'?6[:'>O\ +Y^).(Q<?1/Q_P!V
M]^U$$N+W5OJ9VR--M/%96?'0ND@$4M0D:2L&5&+*1[]U[I(9/YJ]4_,?^>G_
M "GZWJ_9WR!VE#L#HS^892YE>^/CMO'H!YVW)MS;;P'&)NW$8ILJL8HI?N&I
M1**<M")BAFCU>Z]T=_\ D%_]D,;V_P#%Y/G[_P"_:W5[]U[HA?\ .?R'PVQG
M\UC^734_.GINJ[VZ,_V53YCQML&BZ.S7R%D?,/E=D?P^K&W<#C<K7,*914DU
M'VOC@#>MU++?W7NC*?R](_Y).[_DWMJK^%GP4J.E_D%LS;N[]T;6[(S7P/WA
M\>SCZ6>BDP^4%)N+<.V\31)4UF/RU13&G2J,\\$TX6-HUD*^Z]U;7\O^[>WN
MBNIJ3</0GQYW-\F>WMW;\V7UGL;KO"Y&3;N-IJS>]5]M_'MUYN.BR38#:.#B
M$E3DZ_["<Q1JL:)Y)D(]U[H@W27\P#Y:;9^='5'P6^</3_Q;V]NOY#=9=N]C
M].;^^)/>F?[7H(9>EQ05&6PFYL=N7:FVLCCJIJ"O6:GJD5J>=HWC1-6KQ^Z]
MT4C'_P X#^8?O+XC=G_/GKSX*?'NM^,/QTR?R)'<%)NSY.9?!;PS^,^.6Y\]
MB\YD]DXZEV;7XN*FI,1AC,XRV4AFFKHZRG@IS!#3U%7[KW09X#Y(_*/L[^91
M\[MY5&Q>G]]_$/*_RN.E^UFVAN+O'=E!60=?[]Q'8V:PU1BL+3[=:@IMT;KJ
MX4HMP00Y6DBI:."EK*?)5\\:TT7NO=7;_P MGL3K_?7\OGX4;WV3L3;726R]
MX_%_I3<^T>H<-N*;-T>VL9F\!0U%%A*2MKRM964V-IY$@CFF DD6,.P!) ]U
M[JK#M?\ [???/'_Q@M@__>^WA[]U[H]_\D7_ +=$_P NC_Q4OI__ -U</OW7
MNK.Y<E0B1J5,CCXZTGPQPRU".PD?A08@ZNQU$>D$$_0$>_=>ZU3/G1_+<^#W
MPR_EX=R[L^4%/C/EI_,L[SR?8HZ?^5E/LH[6[CWQW=V155U9L&EV U/5[BSF
MWCMNL.&AHJ:AKJFDQ6)Q9J:A&IXI5/NO='X[5^#FV^R^H?B;\E/YJ%+NSY45
M7Q2^'.UL%VA\1-O=:5?>^V<UVON6AP]'N/?=/M/'TE77[PW+&_\ $,=C8&Q<
MZP155154T44TC$>Z]TBOY &X-J9_K7YM/U%2Y;K'XY4?S8["I_C[\2]]5-3C
MMW=3X5,=C$K\'N#;-;-/6;*@S>>CRF8Q>#>3QTE!61M"L4<OAC]U[J__ -^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK3?\ "H_&9_$_!SHCNC:D5-_>#HGYD=6;
MXBJZA6_8BDQ&XX(G#1Z)K'+G$!E2>*ZW;5K1+#GD I)>20O6DL$D>/F5)_D#
MZ]!?FS4ENDJ4K'*CY^50/YD=;)&'RE)G,1B\W0,7H<QCJ'*43EE:\60B6:,W
M1G0W1UY5V7^A(Y]@<BAIT*!GIQ]ZZ]U[W[KW6LU_PFOI*3KW:O\ ,D^/-%&E
M)3=,?/OL6DIL7"-$=/#54T6#B5$262%5T[7T#03P@&MU"6''.[&=K69LE[2,
MDGB35F/_ ![H,<LJ(EN$& MQ( !P [1_DZV9?8'Z$_7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:6'_
M  MM_P"R'?B%_P"+6UO_ +R&<]^Z]T;[N:.;>_\ PJ"^,5%3J]33=<= 5LF7
M>C7QM2I#LW?F0A,YD!#AZO+T2$H/T3(HLP9A-6VL+;DJZK@R7("U\SXEO6GY
M(3^74:WR&;F:WID);DM\AIF'^%@/SZV.^]>IL!WSTMVQTGNI6.W>V.N]X=>Y
M=T8H\<.[:">B::-@"4E@,PDC8"ZNJL.1[B+;KY]LN([F/XHI$D7[48,/\'4A
M7ELM[$\+_"ZLC?8P(/\ AZU\_P#A-?VWN#&=0?);X3=BN]%V'\6.ZLQ(F"J2
M%>EH=V3U-'D:*'Z&1<?N7#Y:25M-U>NC!-F4"5?>&Q22YM]SA_L[N!3J]64
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MW?BX:2CI*FJB&>J6B\"3S2CW7NCG_P X#XR=V]_?$C;>1^).S<%NSY5?%[Y
M?'SY0_&K:N0SE!LB.KS/3FXJ*2NQ4&8KYZ2BQ(R>UZC.T>J6HBIYDE^TG9()
MW=?=>Z%#XA_"NCZG_EF]2_!KM*6HR]3)\8I>J.[JW[S[F:OS79V)J?[\5;5*
M5%09IJ_-9?,3-,*N0R/(9/*Y;6?=>ZJCP'7_ /-=V'_+_HOY0N)^(]+FMWX_
MHK)?#[;?\PFD[HVM1=:4FP#05&UL=O*JV_6Y*IW['N2@VH(%.WXMOSJ<@L9C
MKTH"98O=>ZLDJMY[J_E_;B_E1_!/IGHF/L'X]=A4&X?BQN'MQ][PX>NV8W0G
M7+YO;$[[?$-9D<Z-R4&VMPM6UOECIL?+2J:ZK-1D*..H]U[HZ/R4^.G5/RVZ
M,['^./>.$R&X^INV,)%MW?.!Q>X:[:L]71QU,%68%R&,J*6NIU>6FC#F*="Z
M:HV)1F!]U[K6M^?'_"<#X\2[-Z%G^&?3W=>[-[+\P_CAD>Y!N+YE[SF^TZXQ
M^=%5O3)TS;HWQ34XKZ2CAB:&2B9\LC$R8U/NE1T]U[JYOY&=C[C_ );?QT^(
M^S/C3T%6]S]=4?R(^*_Q#SF(SG:\U-D]K;-[6R<6T*7="U.47*YO=^0QN8J\
M!3/11^:MG2LFKZB:*DHZRIB]U[JRCW[KW6OELCI;YW_RGM_=X[;^*/QKI/F_
M\#.\^XMU=S["ZEZU[&V_U-V'T_F>RB*K<5#0P;QK:/;^[-GUN8,E51009&FJ
M\=),Z/!)3&26/W7NB ;)ZU_FZ[]^6?\ +_[:_F?=&=O[_P#AQ\<^ZLMN#I'
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M%DUI+U$?NO=63]Q;QW=_*_\ B;\&NJ?CKT>.^=B[1[?^&'P<W''7[YI]DUN
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M*56>HZ:G:L=/=>ZO*_G0_';N/Y9?RO\ Y>_';X_[/_O_ -Q=H[!P6$V+L_\
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MA*?W[KW5K_;_ &M_,OZY[4Z0^2^Q?CONSNCXY[Z^-='M_OOX";;W9UYC=_;
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MM'N*+!8C-Y^JKGEQM/\ PJGQU 5J5:MDK*JA2BC^\]U[H..O?YQN:ZW^._\
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MQ5LV.VI'DMI8FJKJ-MQ34]9CZE,.)X4^Z\-;#,8M0BD60J??NO=:2GRB[O\
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M*DI2M, HW6V-[@SJ4.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
M_FQ&ED^6O\D"GSHHQM9_YD%14SODZ@04_P#&*3K?>9V^+.HB:L:N9OM091(9
M]*1)(SG3[KW3I_-2Z5H.X?D!_+TR?4/RVZN^-_\ ,!ZDWQWYOGX7;([LP-1O
MC:^^WK]J+C]Z8W(;?@K**2IFQV&DIYH<C TM9BA)*U-$S51/OW7N@)^.7R [
MNQOSF[@^.WSW^('QQZS^=787P"S/9E)\J_B5V-D-Y;8WMLWJW-28B?$9#$Y^
MDH=R;>EQN5R\-1CUK/OA+#-/']Q"852;W7NB!?&SNCI/J;_A.K_*4V3W!T)C
M/DKO+Y#]T]-=*?&KI3=N[J_KS;^3[*W)V#GZ_:%;N;,T<<RT>W<3642U]5YZ
M6JAF6%(_MIBZE?=>Z?/YHF[?YA>!^1/\DC,?+G._!C8%;E_YP7Q:P6P^K?C#
M3;PWON04&X<GD<3G:JKWANU\)!485,#E:''UM'2[&A+5U9%5+D8D2"G;W7NK
M)_Y6NQ-F+_,#_GE]D#:^#._LA\UNNMCU>\'QT3Y!\/B>M-JUU/C/NF4RK11U
ME?63>)6"-)(6<,573[KW5'NY,GN[%?R4?^% G7?7N/EP/7'47\[KY<=1YK%[
M/I)V?&=3_P"D?K^OWE3P0(T\D5'3;>S&=2<4D"M'C_*\<?F5YC[KW5M/_"AW
M9GQTJ/Y2>V<A28;8OV^Q^[_A15?%:JH**C=*.;);\VK0$;?E*,\44^R*C.*?
MMG4R4@;66C# ^Z]TLMP]Z]A]E_S2OF%U_P#RX?C1\8LS\G?CSUE\9>OOF3\H
M_EGVOO+:U/#B^PER&X-K[4VGMS 87-39%:/&1Y:IJIHI\72/6STZU$TS1 O[
MKW1,_P"5YN/MFK^9W_"E_:/;N_>H-^[MV[0_%#+;NK^@=G5NP]G+N?-=8[UH
M-Q+A\9E,SN+*P24\N%HZ&M-5FZB2:MH9Z@I3-,]/'[KW0%;FZRQ777_"17J_
M(]1[)QNW%W+\<^ALYWGG]I;=B_BTNT.RM]8*O[1K9:B"%Z^5*W"5&5>O:/R3
M+1^4Q@>&,Q^Z]U8?_P *'=F?'2H_E)[9R%)AMB_;['[O^%%5\5JJ@HJ-THYL
MEOS:M 1M^4HSQ13[(J,XI^V=3)2!M9:,,#[KW6Q!G&RJ87,/@HXI<VN+R#8>
M*<@1M5+$YIU?4RKH,V@&[ 6^I'U]^Z]UKY?R3]I])[T_D>4>*^0&+P&83>Z?
M+AOGE!OO%T[SS[NJMW[J&_ANFGKH/"M?3:6#++!X8X4IV@!@$3'W7NJD>N8:
M;)_R(/\ A//MCL-89?C!N_Y^_'#;WREH\C'Y,95;>GWEO6;#TF=TJTBX2?=L
M&!%0?3%Y! *ET@+W]U[J['^>EC]GX3K'X%[AVW#C<1\BMM_S)?A?AOC%/M]%
MH=PFHS&ZJ.DW'B<(M,%JY<=5[2.57)4B?Y)+1I:J1D5![]U[HMNQ>G?EMUMW
M=\].T/Y3G=WP?^:_0/=7S"[=S_S,^+/R;K=P;:W)MWL.LQ>.QV[]K8G?F+_B
ML$:0""C2+&9C#K0XVDDDI(%8 ,/=>Z!?:'>_5'R+V/\ \)Q>P.ENB/\ 98MB
MXWY[=U=;Q=!09RGW12;5R756R^R]O9K%8S*TI^WRF)AR^.K3152)%YJ9HG,%
M.Q:&/W7NC^_RM=B;,7^8'_/+[(&U\&=_9#YK==;'J]X/CHGR#X?$]:;5KJ?&
M?=,IE6BCK*^LF\2L$:20LX8JNGW7NJ/]P5V[J#^2O_/^Z\Z^QSX3K7IS^=]\
MM^KL[A=J+44_V'4U)V/U_D]YT<4<4K3Q4,.W<MG8YTH4204!E$49FUR/[KW5
MB'_"GC$_&''?R%-^T^WZ3K"BPN,JOC)1_$6+"04:TZ%]U[:M#M0PJ56%MC)F
MV(IV"-0I(22H /NO=',_GY&E3XE?'JHC%&=TTG\R#^7W4[ 2:H%/4-F$[(Q
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M"39N>JXX<S#DJ%*:>&JD3$-#/5RPYI)4HX9EN]W&S;9%%#XY2VN[=I));%U
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M^3$@?\=/6S3[ W0HZ][]U[K63_GFQY+KSY\_R-_D#0?:P8S;WRXJ>M=V5M2
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M(/+&R(M84J)51M:!'1+^-2Q .>9.=I]RMWM$18XIYWNG'Q-JDDU!=5!A=(R
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M1^(DQ.6IF$U/4J(LO/JAE6ZR+X:FG>X)&F1#]&'N8_=Y3&U@C"C+:*"#@@U
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MQ4VZJVGIMW[[3$15>,V_'62TKP?[D(9$5L8/NUB]^Z]T=;YA_P O'?6U]F_
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M"/4F]>]^Z]U[W[KW7O?NO=$9_F _\RGZ:_\ %YOY?/\ [^K8WL2\J_[D2_\
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M=<[;JLIB=F;3E29:/$8[/T])7P9?(LB5<$#QBAEUM)&?=>ZK;I/E!OWX>_\
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MZ]U[W[KW7O?NO=$YZ+ ;Y1?.96 96WAT.&4BX(.PL5<$>SF__P!Q;7_2R_\
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MN+L]ML6ZR6UHFB-5C(74S4+(I.79CQ/KT/>3]QFW7;XYYVU.Q>K45:T=@,*
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M6MI>Z"3B*'.@D>:^1_$M&]0%7*G,8WZ"C]L\?;*G @C&H ^1IP\C4>53<![
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MFJ=A9?\ BU?]_1[BG:=H2ZY"-:2H:$3P&-BWMF^Y=MHHHKI&GCA>98F$Z 2
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M[J;L/JE<3V5F=\;FVE0U6%Q^T^FMW[UI9EGK4TJ<KA\'78F*4?;3%HI*Y)$
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M+"MI\;L.B^05?EZ>BI*L!%H:>6@K,$II(H0(@LE,[-$J+([D%F]U[H<>B?\
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M5!;W7NMQ3X(57=U;\)?B)5_)49$?(2I^-/2,W=AS*11US;IDVWCCG'KUI_\
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M>CZO+_E,?]NU_A;_ .(%V9_UJ;V3\\?\EB\_YZ)/^/'HTY9_Y)UM_P T(_\
MC@ZL.]A7H\Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NBL?,+X;]&?./IK+])]\;:.8P%7,F4V]G\:Z467P.4IE98,K
MAJUHY#2UD2NZ,"CPU$+R4]3%+!))&QUL',%URU<"YM6TL,$'*NIXJP\P?V@T
M(((!Z+=VVF#>H3!<+J4Y'DRL.!4^1_PBH-02.M:3XY_*'Y#?R(.\X/A?\W6W
M%V/\)=WY2IJ>A^]\/C)\C'AJ:MJ/54T<9>21:"(RZLQ@Q+)58Z8M68Y:J&=/
MXA,&[;+:>YUL=QVS3'>H/\8MR0-9 _PG\+X#<&HP-(]L-RGY(F%G>DO;,?T9
MJ5T#T/R'F.(XBJ\-N;;.YMN[TV[@]W;1SF)W-M;<V)H,[MW<6"KXLI15U%E(
MEFIJJEJ86>*>GGB='1T<JRD$$@^X)EB:!BC@JRDAE((((-""#P(\QU*2.) &
M4@@BH(R"#YCI\]M]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z#7N?\ YD]VO_XC7?7_ +JZKVIL_P"VC_TZ
M_P#'ATW-\#?8?\'6O[_PEO\ ^W?_ &__ .+B=@?^\5U][EKWO_Y*T7_/)'_U
M>GZCOVO_ .2?)_ST/_U;BZV3/<.=21U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW5%G\VO^4%@?F1C/]F%^.AI.K?FKU^U%N';N[<)5?W6&ZI-MB*2
MBH\E74[0O29ND-/#_"\MY%DIW2."HD^V$4M))7(G/S\N-]+=5ELY*J\;#5X8
M:M2H-00:G4G!A7SX@OFKE-=Z7QX/T[E*%'';J*\ 2,U%.UN*GY=!Q_*N_F_Y
M?M/=+_![YY4,G47S3Z]KAL>GR>[(8]N1;RK,=(*=::6 K%#0[K<&(F"(FFRE
M_NL?I\@I46<[\@K8(-SVL^-92#7VU8P@_P RGE4Y7X7R*E/ROS6UVYL;\>'=
M)VFM ):>GEJ\R!AAW+C V&O<4]#SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7N@>[\^0'37Q<ZEW9WM\@NPL!U7U#L;^!?WNW[N>22*AH/[S9.CP]!Y
MVACED'W63R%%3I:,_N3(#87(]U[JMS_A_P"_DU?][!^A?_/ADO\ ZW>_=>Z]
M_P /_?R:O^]@_0O_ )\,E_\ 6[W[KW5B7QU^2W1/RUZOQ?=7QP[+V_VWU5F\
MCF,3B-\;7\[4-34;?G:EK8X7J(8'<TU2CQ.0FD.K+<E3;W7NAR]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=%U^7_ /V27\HO_%=>[/\ WFLG[]U[K3V_X1^J
MR9;OQ'5D=/CYT$K*PTD%9*P$$'D$'W-ON2"NR;.#_P HZ?\ 5B#J,N2C7<MR
M(_W\?^KLW6\G[A+J3>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NJ8/YL?\I/9OSVVM3]H=7U./ZP^8'7E)%5]
M?]D4K'#QYH8DK+38?/U-,GW(6)XQ]A7KJGQTI!424[20F0N1>>Y.5G,,P,MI
M)B6(YTUP60'%:?$IPXP<T("/-/*J;\@DC/AW"9CD&*TR%8C-*\#Q4Y'F"5?^
M67_-XWC0[\D^ /\ ,R@EZ?\ EGL;,4NR-L[XWH(,-3;FE=1]I0Y:JCD.-BSE
M2K0_8UL$WV.<CEIS3.U5+&:TZYRY"C,7[UV4^-:."[*E28J<2 >[2,U!&I*'
M5@5!;RYS6^OZ#<AX5RI"@M0"2O#([=1\J&C?A].MD?W$?4@=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW19_F;\D<=\/?B?\B/E+E=L5N]*'H/J+?':,FT<?7)BY<FV
MTJ&6JBH5JI$D2E6IE1(WF,4AB1FD$4I41M[KW6J9LS=/\XS=>_-O?+K9'_"7
M[^792]I[KIL9OO;7=>0[%ZDVWO4+FZ/_ "6NFR5=N+'[CHLH^/J!#*\R4]8(
MSX)D0+XE]U[K;[Z0SO:.Z>ENH-S=X;'QW6/=.XNK]@9WM_K;$9NGW+2;>W1E
M\325&X,'2Y&DJ*NER%/B<M)5TL=3#5S13I$LL<LB,'/NO="A[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZKQ_FK[7P&:_E_?+'<64QE/6YKK_ *![;WCL[(2E
MM=!D\9@ZQH*N(!@K21D @.K*?RI]Z(KU930]2?Y>72756U_C7\>^R<!LK$XO
M?&=Z>VU/EMQ4S3":=\W3135;.IE,6J>7U.1&+M<_D^]*.MN:D_;U8+[MU3KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZU&?YA'SP[4WI\G=U[#R6V=FR=<=!]E;TVI
MMO96?VX*O[Z3#R/BZC)UE<)(LE#45+0/44<U#5T<E(K02P/]Q$*AFF:O2J.,
M4KZ]7K]6;E^1?7_5G6G9VWZ'<WR(Z;WMU[M'?$_7FY,E$_9FUX=SXVGR/VM%
MEJIJ>CWM%1^=HC#D)*3*W TUU<]HO=QTP0#CA_@Z.#U9W)USW-AJK-=>[C@R
MXQ57_#=QX6IIIL-EL/6 $M09G$UD<&1Q-<EC>&JIHG(&M0R%6.P:]5(IT)WO
M?6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z))_,KWM5==?R]/F]O+'U2T.5PWQ5[W.%K62.7PU]?MK(
MTM!+HFCEBD*5D\!"/&R.1H86)]FFR0BXO($85#31@CU!<5X?+I#N<AAMI77!
M$;D'T(4TX]%,_D!]?S==?RD/B#C:LEJW<6W=^]@5#F%H+IV!NS.Y:CLK<V7'
MU5(NJ]GTZULK  RYPN/J=RG8>3!/]X54/\UZ1\NP^!91#U75_O9+?Y>KCO89
MZ.NO>_=>ZUENAZVO[5_X5!?,K+O1.^!^._PJVEL6@R@=M(JMPT^P*X1%-,+*
M[R9W.*H83(13M(&&N((.;Q%MM@@%>Z6X9Z?)1(A_XZOIQZ"]NQGW:4TQ'"J5
M^;%7'^$^O#K9I]@;H4=>]^Z]U[W[KW5:WS=_E<?'?Y^]]?#'N[Y!4L6\<9\-
M,QW)E,-TUNK:&#WYM#=B=TT>"HZVEW3BLW05T=7!0_P"DGI%30$J/W)!)H0#
MW7NM<;Y%?S!/Y(O7/?7:70_QE_D![#^=-5TANJHV+VMV%\>_Y?/7N6V_CLSC
MI9Z>MQT%3'M6MJ:J6DJ*>:(R/2T]/,\<AIIIHU\A]U[HU'0OQH_D>?S]O@_W
MCLWXV?#_ *H^%_8&(W;M;8?;-3LOXF===/\ ;/765VSG:/,QQ4]?086KA@IM
MPT^&JZ(SP53B>BER%%4)3U4=530^Z]UM,[1V]#M+:FV-J4]1)60;8V]A=O05
M<R"-Y4PM-%3+(ZKZ59UB#$#@$V'OW7NE#[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZU+/^%:,$LW0_P5DC34E+\I]WSSG4!I1NO=T1 \D$^N1!87/-_H"1(O
MM1&S[];D<%$Q/R'@2+_A8= SG]PFU3 ^9B ^9\5#_@!ZO0_E2T-1C_Y;OPJI
MZI DLGQZZ\KE"N'_ &\G1K4PFXN+M#*A(^H)L>0?9'SNP;>+RG_*3*/V.1T;
M\M"FW6W_ #0B_P".#JP/V%NCSKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HOWR>^,/3?R_P"F]T]&]Y;6@W/L
MK<\&I'733UV,KJ=6%)EL35E7>BR=$[EHI5!!!>*5)8)98G--GWBXV&X6YMF*
M.A_(CS5AY@^8Z1;AM\.Z0M!.H96&1Z?,>A'D>M6WK3N/Y7_\)\.ZL9T+\C/[
MR=]?RX^Q<^\76G9V*Q\CMMR;*S25$\E ")A29&*,5$V1V\]1XJH*^1Q4BN:H
M5,UW>W6/NO;&ZL],&XQK66(G$H  ^51P"R?A/8^-)$9P7EUR#,(+DM+9.:1R
M4J8B:FG^&J^8[DR&4[:G5W:G7/=FPMM=H]3;RP._^O\ >&.CRFW-U;;KEKZ6
MIBDN" PLT4T3AHYH9$2:"57BFC21&003>6<NWRM#.C(Z&C*PH0?]7[>(ZE.W
MN$ND$D;!E85#*:@CI?\ M-T]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO= =\G:RJQWQK^0N0H9GIJV@Z-[9K*.HCMJ
MCEI<!D'C=;W%U=01Q^/:_:U#74(/ RQ@_P"]CIBZ-(G(_A;_  'JF3_A-#14
M=+_+<GGIJ2FIYLE\A.T:W(S00+"T\R4F#IUEF90#+**>""(,Q+"..-+Z44"1
M?>-RV],"20(8@*G@*$T'H*DG[23T#/;I NV(0 *O(30<3JI4^IH /L '6P9[
MBOH==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5-/\V#^4WM
M/Y\;3QW9'5M9ANJOE_UP:;(=?=JQ++B/XK'B09*?"9RLHK52Q1SK%)0Y 1S5
M.,F6\"F&6>)Y!Y%YZDY5D,,P,MI+B6$T-*X+*&Q6F&7 <8.0" CS3RLF_()(
MR([B/,<@J.&0K$9I7(/%3D>8)0_Y=_\ . W_ +.[./P%_FEXY^FODKM&7%[6
MVEVINP1XRAW+)*H%)3YRJC)Q]/D:V$PO1Y2*;^'Y;5;R0U;1"M/>:^08IX/W
MKLA\:V:K/&M2\/K0'N*CS4C4@R:K4@LV'FN2*7Z#=!X<XHJN?AEKPR, GR/!
MC@4..ME+W$/4@]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$M_F&_"38G\QC
MX>]O_#7LO=V[=B;)[B_N!_&MU;%%&V5I?]'NZ,)NJF^U&0IZJD_?J\'3PR^2
MG;]F233I?2P]U[J@_P#F&=F?R-_Y9>\>K/BY+_**Z"^8ORKW/L'%[DHNG>BO
M@?UWNS.?P>EBJJ2/.YNI?;[F)LA5XZ?]N&*KJB-=1)$L.AY/=>Z:?Y<WR,_D
M6_/GO_+_ !'W-_)?Z'^'GRFHMH2;[P/4'R2^!/6VV9<]C:2(SUC86=<"M3+5
M45,K5,D%5CJ-I:,-4TAJ4@K/M?=>ZOE_EL? 3K[^6;\3]G?$?J_>V\>P=F;*
MW#O;<.,W-OV.BCRDC[YR<^4J(Y_X=3TM(RPU%3(L92G0^,*&U,"S>Z]T?/W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77Y?_ /9)?RB_\5U[L_\ >:R?OW7N
MM1[_ (2'XY):_P"467,CB2AZD^.N.2$ :67*/GI68GZW0T:@?\&-_H/<Y^ZS
M4VS:AZPD_LB@_P _46>WX_QS<#_PP?\ 'YNMVOW!G4I]>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5A
M_,Z_E5],_P Q[KV)<K)2]?=][1Q\D'6G<M)CC6RP1AVE.(S%.DD)R.%J)&<Z
M2_FI)6-12L-4\-0->3.=[GD^:J=\+']2$F@;YJ:'2P]?/@:^0:YDY8@YCBTO
MVR+\$@%2OR/"JGS'[*'JJ#X4?S4N]?@;VCC/Y?/\VK'9G Y##Y"DV[U5\H<S
M5FOH)\4TGV>-GS.4ECC_ (KM^5HP(L^S^>E4F/-1QM#4STPYYBY(M>:(3NNP
M$,I!:6U HZM340J^3?\ "Q@_Z&2"!T%]GYGGV.06&[U4@TCN":JZUH-3>8_I
MG-/C ()ZVI:*MH\E1TF1QU735^/KZ:"MH:ZBG2JAFAJD#Q2Q2H622*1&5E96
M*LI!!(/N$F4J:'!&"#Y=28#7J3[UUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HO_ ,KNHMQ=_P#Q
MD^0/1FT=P[9VGN;N'IWL3K+";FWIL>@[,Q%!4;XQ55C8ZK)[=RD-1C<Y0PFI
MU3T-5 \%5&&AE4HY]^Z]UJ!=5=<_/CK?=NS_ (1]<?\ "L+XJ1]A[#@QG5FT
M^G<GU5L'>FX8I<#&E+2X(U.9R&0RV1RL"(D*TT]=/7>C05)2P]U[K<OZ3VUV
M)LOIGJ/9W;^_X^V.V=I]8["VUVAVG#@X=L)N7<6"Q5)2YO<"8VF"T^.7,Y.*
MIJQ31*(X!-XD 5![]U[H3O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6N%_-X
M^?GR9VOUI\UOC%A_Y8OR?WET_4]0;KV9-\Q<+FL/'LV''[OVW%+7;@>GE R!
MQ^!>MJ(ZI1ZV:DF\9(*D^ZV./5P/P$GDJ?A=\:))::2E9>H]J0"*7DE:6#Q)
M(.!Z9D19%_VEAR?K[T.'6WXG[3T;SWOJO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU6K\C_B-\;NPOE5\=-X[RZEVWG-P;YW!OF'>M54/5019==F;;J*S&_Q*CAJ(
MZ*N,$]- &,U.YFBC6"<R0 1^ZD#JZN0*=63Q11011PPQQPPPQI%%%$@C55C%
ME55%@JJ   !8#W;JG0"=J_'79?9F9H]\X^NSG6G<&&HVH]O=Q==U$>&S<$0Y
M6CK2\4U'G,3K +X_)4U32GDI''(1(-$5ZL&IT&47>O9'1+'%?*? 0U>SJ9XJ
M?'_)?KG"S2[?DC"*/)NS"QR5F0VC.7OKJ@:K#W)9JRC&F+WZM./6].KA^SHW
MF+RF,S>.HLQA<C09?$Y.FAK<=E,75QY"FJ(:A0T<T$\3/%+$ZD%65BK#D$CW
MOJG3;NS<M'L[;N5W-D*#<64HL/3"IJ,?M/;-?O'(R@LJ::3&8NGJJ^LDNP.B
M&G=@H+$:5)'NO<>B[;;^875^Z]SML_$;1^09SM-EL+ALO3UOQFW[CDQLVX!&
M]*V6FFV^D6+@DAE28RU+11K ?,6$0+>]5ZMI(]/VCHU7O?5>O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ7_P#A0AORIV#_ "C/EI54
M$D4>1W/C^L=ATOF_2T>\=X[?HZ];"6)RQQ;UVG3JL^DNC1AQ[%')D N-S@!X
M LWYHC,/Y@=$?,DQALI2/,!?R9@I_D>CJ?RZ-AU76'P#^%>PLA3Q4F5VS\6N
MBJ#.4\*A57(-MK&RY "R1ZO\MDG]10,WZGNQ)]E.\SBYNYY%X-+(P^PN2/Y=
M&&W1&"WB0\5C0'[0H!Z.9[+>EG7O?NO=:RO\G2N7M;^;+_/.[L2EJ!0X/NO9
M/3.)R<].J1SC:N5W9B:@4\JK(DB!-K4,I"U"L(YJ=Y8KR((QSS+']-MVWQ5%
M3')(0#P#Z&%?]Z(^T&G07V5_'O+R0 TUH@)]4#*?\ _(CK9J]@;H4=>]^Z]U
M[W[KW56O\RO^9Q_PW)_H6_YPZ^6GRS_TQ_Z1O^R7.N_[_?P#_1[_  '_ (OO
M[D?VG\5_CG^1?7R_9U?T\?OW7NM87^6[_.9WE\!-J_(+I:G_ )/'\Q[<G4N[
M/D/VMWSU+O/#]!UN,W15KW)7OE:O%[SHGH10/5X29DHJ3)TN4J35T$5,LM%2
M/3VD]U[JSK_A/COK*_(_Y,_S8_F?V3\5OD+\4NZOD=V=\?\ ,YK8_;'7%;LC
M;D.V]OXG/X?;M)MS(Y 4M7N3.(<57U^XZML/01Q5.2HXH(I$+2O[KW6T5[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4]_X5A_]D_?"W_Q9;=?_ +Q.
M=]R?[0?\EN/_ )IR_P#'#T!?<7_DF/\ Z>/_ (]U>Y_+'_[=V_"+_P 5=Z4_
M]T%#["O.7_)7O?\ GJG_ .KC="#EO_DGVW_-"+_CB]'F]AKHZZ][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[H*^ZNDNJ?D5UINCI_NK9&#["ZZWA1?99W;6>I_-&WC(>&H@D0I/25M+*J
M2TU5!+'44\RI+#(DBJP6[=N,^TS+<6SM'(AJK*:$>1^T$8(.",$4Z37=G%?Q
MM%,H=&P585!\_P!HX@\0<CK4U[ ZC^8'_">[N?)=U]!-NCY!_P N'?.9H_\
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MML;<F#WAL[=6*HLYMK=.VLI#F\?7T6102055'5T[R05$$R,&1T=E(/!]P=/
M]J[1R*R.I*LK JRL,$$&A!'F#U)T4JSJ'0AE8 JP(((.001@@]*+VUTYU[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW16OFG\G/\ 9-_C/V5\D/\ 0YVUW]_HY_N;_P 8DZ,V
M[_>S=66_O?N#%8'_ '%X_4GW'V'\4^]J?4-%)3U$G]BWOW7NM.&@_G*;JV-_
M-(W;\^]C?R>/YC^X-M=Y_'/:'0_<>&WE\?:S&;CP,_6=;4U>)R^T*JGH\C3U
ME+EH*B*ERN.J:C'+>EIJR.JE9#3GW7NC']#?-G._S1_YZ/P.[4[&_EW?-CXO
M[$^,O6GR3P_2>]^Q^FJW$P5VY.PMKUE575F_,U.E#1X/!T.)Q%;1X>CIFR<E
M5F,C&TLM/'(R'W7NMS3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1=?
ME_\ ]DE_*+_Q77NS_P!YK)^_=>ZU,O\ A(>ABC^6<9()CZX^,:$C_:!NH>YS
M]VET;?M0](6'[([?J+/;TZKN_/K(O_'YNMU?W!G4I]>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW1./FM\$_CQ\]NK)^LN^-IQU\U##D9-B]@8A(J/<&V:S(K$'K,-7O'(8O*T%
M.:BFD22DJQ%&M3!*(X] @Y=YFN^5YQ/:O3AK0U,<@%<,*BO$T."*U!!Z*=XV
M6WWR(Q7"UXZ6&'0^JGR/\CP((QUK6=7?(?YI?R ^T\5T%\ML=N+Y _R_]W9N
MIQO5/:NWUDR,V%C1G>/^"FIGT4%0M,&DKMM5<ZK='JL15&-)Y*V7[S:-N]U(
M&N]OTP7Z+JEA:@63U)H,Y.)!]D@J01'EON%YR'*MO=UEM&-(Y14LGH/R'%#Y
M90X(.V+TIW?U1\B^M=L]O]*;YP78?76[J/[O"[DP%3YHR4.F:GJ(F"3T==2R
M:HZBEGBCJ*>56BFC212H@W<=NGVF9K>Y1HY$-&5A0CT/S!&01@C(-.I0M+R*
M_C$L+!T;@RFH/^R.!'$'!Z%7VBZ4]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1%_P"9U!W-4_R[OFQ!\>!N
M1N[9/C-W O6J;.&K+MD_X+5F%,6 "[9!UUK3B,>4RE!%^Z4]^Z]UI*[XWU_P
MF.R/\E2IQO5>W>J,;\UJGXQ+2]:T%!M',Q=S0=R4F,A_AAJ\K24S9%HDWH(&
MGD%>V(J,<)DIFDI&"'W7NMZ3X(4O=U%\)?B)2?)4Y$_(2F^-/2,/=@S+Q25R
M[ICVWCAG$KVI_P#)VR"9#[A:HQ$Q&H$AB9DTL?=>Z-=[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z(%_-6W!!M/\ EI?/+=551')4VVOB=WIN"HQP<1FHCPVW
MJ^I>$,RLJ^58RMRI O<@CCWHYZV,=.?\L+=L&_\ ^75\(]]TL%52TV]?C#TU
MNVGIJYQ)-''N3!T=8D<S*65I468!R&(+ D$CWX8Z\QJ:]'J][ZUU[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=%C[<_[*"^)?\ X<G</_O(U_O1ZV.C.>]]:Z][]U[K
MA)&DJ/%*B21R(T<D<BAU97%BK W!!!L0?K[]U[HGF7^,V>ZVRF5WK\3-VT75
M68RE;-EL]U#N&DDR_7N;GJ"6F=\5"4JMM5\[$$UN'F@4L-5515@)'NM*<.KZ
MJ\?]GI8];_)+#;AW/!U9VE@)ND^\&25J?KO=.6AJZ?,I3+KDK-HYD+!2[FH5
M2[/X8HJRG /WE%3$<[KUHKY]8.H_^R@OEI_X<G3W_O(T'OPZT>C.>]]:Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUL?\ A4GN+-Q_
MR]>MNL-M4K5^<[N^6O4_7]/0BK%")1#C-Q96)3)(R4_KR./QT=I940:_*6'C
MO[''("*+YI7-!%#)(32O\*GAG@Q./2G08YM9C:B-14R2(@S3.6'\U _/K8SV
MS@Z;;&W-O[:HR#1[>PF*P=(50QCQXF".GCLK,Y4:8QP78C\L?K[!#'42?7H3
M 4Z>_>NM]<7=(T>21UCCC5G=W8*%"BY))X  ^I]^Z]UK,_\ "97(TW9'3WSZ
M^1$#--_II^?'9616LF1UEECCQ>)SD9D\KO/?_?SLUI/4"S79F+6'//49MI;:
M%N*6L8(^8+*?^.]!?E:03I/(.#7$A!^1"D?X>MFCV!NA1U[W[KW7O?NO=%7^
M67S>^)GP7V%'V5\M.^NO>CMJUD69?!'>&8MD<P^WX%J*RFP.%I4J,SGZV")X
MRU-CJ"IGO)$HC+2(&]U[K4Z^:G_"N[(1===A[O\ Y:?PF[8[FZWV!6_W=WC\
MP.\-E9G![ P-?E9*"FQ?DQV'1YY175.1@CBCRV?P-1Y7I8UI)_NE">Z]U>M_
M*)Z@_FM;3HN]^Z?YI_R1V'VYNWOD]7Y/J/IOJ^DCI,%UWC=NMN2IK:.F^UQN
M,HGGRD>;Q,4C*E74&/&0?=Y.NDLZ>Z]U<O[]U[KWOW7NB3?/WX^]Y_*/H.#H
M[HWNJ3H7^^_9W6-+W/OG$UN1PV;EZZH\K#/O/#;;R>+9*S%9[-8J-J2"J62,
M+'+-&9H/()H_=>ZI.^8OQ8^.'\N7Y/?RS8_Y9_7<_3_S![X^8G7VP-^=;]8;
MJKJR+??4,"5]3V;F^R<37Y*<Y[';=H)14QYZJ63(4.1J4>*J)EE4^Z]T.&=Z
M\ZS_ )H/\W7YQ?&WY0[=?M#XU?RXND?B?MS ]!YO.9&+:V7WI\L,?D]YU>Z,
M_AH)Z:BS==C,/BL71X\5*5$-%^[-#HJ)I-'NO="C_++W!F^C?G+_ #+?Y;5!
MN3<NYNB?C35_''N[XU4F[=PU.YZS:^!^3.$KZ_+[+AK<C)4Y*IP^&SN-GGQG
MGKI_MZ:L-(@BBIXE;W7NK2:[Y9?%C&5M9C<E\E_C_C\CCZJHH:^@KNY=N4DT
M$U(YCEAFBDR2O%+$ZLKHRAE8$$ CW[KW6KE_PJ#[KZ5[6Z*^(6-ZR[AZN[$R
MF&^0FZ,MD<9L3?V)WA40T[[0S%.)IH<?65$D,/DF1?(RA=1"WNP]RE[/)JWI
M#Z12G^0'^7H!^X[4VQOG)&/YD_Y.MCK^6]0)COY>_P ':=)&D63XE?'JO+,
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MW<NZDJ)8:C*/0P5607"X>@I*[(U_VE)-524]*U/31M43Q>_=>ZI(_EN_S/\
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MJ6C3)U&' 6JGVY45D<+5#K(LHEQDQ&2I#'*&CG@B-6X2YP]OKGEC]>,^/:L
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M&ABK^A=S['2:>>.F5I>S7@VW!"&E>-2]1-EHXD4,7=W5(U=V5&/>68C-N%N
M*_JHV,X4ZC^P"O17O<@CM)B33]-A^;#2/VDTZS_R;ME0[!_E;?!G!04XI4K_
M (_;-WJT8C6*[]DK)N*22R11 F:3*M(3I);5J9Y&)D:O,LAEW"X)_P!_./\
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M_P E:]_YZ[G_ *O/T)N7O^2?;?\ //#_ -6UZ.)[#W1QU[W[KW7O?NO=%O\
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M?\*TK_22@_ 3C8Y^&/\ ,(^+7SRV@VY.@.Q:/+9W&8^AK-X]:YQ/X'N3!/6
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4O\
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M'#JS\3]IZ-1[WU7KWOW7ND#V/U=U]V[MN;:?9&T\/NW!2R+4PTV4IM4E-41
M^*LH:E"E305T!.J&IIIHIXFLT<BL ?>B*];!IT6]<;\A_CDE\+4;D^5/3=+8
M?P#+UM,O8^"IDT7^RR50]-1;WIH4\A$-:])E[ #[W)2D(?<.K8;Y?X.DSW5W
M#UQW+U/UOG>O-S4F;BH?EA\1Z#.8J6*7%9/%U<796VA)0Y?%5:09'%5T;*0T
M%5312#]04J0QT37KP%#^1_P'H^GNW5.NB0HN2 !]23;WL"O6B:=</-%_QUC_
M .2Q_P 5][T'T/[.M:QZC]O7O-%_QUC_ .2Q_P 5]^T'T/[.O:QZC]O7)71O
MTNK6^NE@?>BI''K88'AUR]ZZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5='\W;=R;)_EA_.W,O+XA
M6_&;M+:(;2S7._\ '2X%5LJ2'UMD@M]( O=F1074ZY<37?VX_P"'1G]C _Y.
MBW>#IM)O^:3_ ,U(Z0O\D78%/UK_ "H_A%MVEB>&+(]0+O\ 9)&=B9.U\KDM
MTS/ZWD;3)-F78 ,% ("*BV17N:IS<;C<,?*0K^2=@_DO3>Q1"&SA _@#?FW<
M?YGJU'V'^C;KWOW7NM9?X>TU=V?_ ,*4OYF79LU9)/@^FOC;UOU#AZ/[?2()
ML]1; =QY0(6(%5ALX^EXI-1J#HET0QZASN3+;[%:1@9DEDD)K_ 77_ R_L^?
M07LE,VZ7#DX2-$ IY,%;_"#^WY=;-'L#="CKWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5S_A53')-\
M<OBA%$C22R]^[@CC11<LS[<K0 !_4D^Y<]EW$>[2,QH!:RDGT >+J//<M#)8
M(JBI-P@ ]24DZ-%_(VVZ^:G^5'<]7K>7=.[]M;=HG>,@JT9R65KKO<ZFD.0H
M+BPTZ+DMK&F(V?Q69O4D_M->I(D&@*OH/]C_ "='F_F3?#*'Y7]-/D-H8^,=
MX=9I49WK7(0RQT4M8MT>LPDL[E0(ZU$UTY:1!%6)"VM(WGUU85ZU&^@])G^6
M7\UT^276S]8]BU4N.^074%#383>.,S,C05N7H\9II$S?BF5)34K,O@R269H:
MK3))H6KA0>4UZ](FG[.K0?=NF^J(=[HV?_GJ=2Q1WKX-I=6UCY&.9O32C^Y^
MY)HM D(# 5&0I7 B#6>0L>5D*T/Q=/#"'[?\W5[WN_3/7O?NO=>]^Z]U6G_,
M)^!='\J,#C>Q>N:Y=F_(WK>F6IV/NFEJ&Q?\1CQLAJH,9654.F:"2&HU24%4
MKZJ2=VO^W*Y2K+7IR-].#PZ#C^7I_,&G[:9OCE\DYGV;\H-EUE5MPT^X*'^
MON+^#*ZR?M,%2'/TPAD^[IM$8F ^XIE*F:*GTK5ZW)'3(X=6Y^[]-=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0W_-C1-T?*W^73L-@TPK.S)$>F
MC158KNS<FTJ.P>0&,E_M" &!"D786;W1N(Z>BX-]G^?J^3W?IGK#4TU/64\]
M'600U5)50RTU52U,2SQR1SJ5>.1&!5T=20RD$$$@BWOW7NM</?V+WA_*%^6-
M3VCLW;^8W%\/>^*P4>;V]CF##&R*[U!QT;L1%'D<,TM1-BO.4%70//2&4R1U
M-3$W\!Z4#]44\QUL&=<=C;+[;V/MKL?KS/4>YMF[MQL65P>9HBP62-R5971P
MLD,\,JO'-%(BR0RH\4BJZLH<X],$4P>EM[]UKKWOW7NO>_=>Z][]U[KWOW7N
MBX?(GXA?&7Y9[=.V?D3TIL/M.A2DJJ*@R&X,.L65H$K%*R'%YJE-/F,5(P-]
M='70O< ZK@$&VT[]>;$_B6DSQ&H)TGM:F>Y356'R8$=(-PVNWW5-%Q&KC/Q#
M(J*8/$'Y@@]:Z'R'_P"$W^\]K2]AUO\ +W^5&Y.JMI]E;:K,!O7HSLW.Y2/%
MY2FF$P_AM3G,1Y'K\65G=8*?)82LDIY/W362.VJ*6]I]WDG\,;O:I,T3!DGC
M50Z$$'4%; :H%2K*",4]8_O_ &\:+6=NG:(.I5HF+%&!!%"0:TH3\08BM0>K
ML?Y4WQN[-^(OP&Z&^//<=-AJ/L?K[_2C_>.FV_EUSM&O][-Y[BSE'X:I%19;
MT&3I2]E&ERR?5;^XZYYWF'F#=)[RWU>')X>G4-+=D,:&HJ?-3^70OY7VR39[
M"*VFTZTUUTFH[I'84) \F'EU8;["?0@ZH@_F9(^]?GC_ "Z^M67STL&^,+G*
MNG<V7[?/;HP\=8P\C&)B:;#/Z0FIM(!U70"C<1T]'\+=7O\ N_3/03=X=+;#
M^0G6&Z>INR,6N3VQNFB\$C(1'44E1 1)2U]'+8F&KHYU22-N02"CJ\;NC:(K
MUL'2:CJCCX>]\;R_EU]W9KX0?*2KJ:?J_,YUZ[IOLNHAE7'T_P#')R(9UDD-
MH\'E7/[VG4,=D/,)[1O430T!TX/3SKX@U#\^MA\$, RD$$ @@W!!_(]N=,==
M^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ'OY@)&]_Y
MFO\ +]ZU<O-#@J[:6_)Z55-O'4;GEGEN7(C*R1[:97"G7I4_4E![HW$=/)A2
M>KX?=^F>@&^2GQXV%\H>HMR]1]@TI_AV9B6JPV;IXEDJL3DZ,,:+*41)6T],
M[$,NH+/"TM/+>*:13HBO5E;2:CJGWX#_ "+WI\0NX\__ "^?E;F4Q]-BLK'3
M=';TR3F&A(RCO)3T,59,%U8K,B19<<TAO3U1EH'(=HX8**:8/3LBZAJ'Y]7]
M^W.F.O>_=>Z][]U[KWOW7NJNOEG_ "<?@)\P?XGE]\],8[8'8>26=W[3Z9:+
MKK,M-.NDU%8E/!)B,O/PG[F1Q=6X"A595)!&FP^X&Z\NT6&8O&*?I2_J1TK6
M@J:J/](5Z#>[<IV&\U,L8#G_ $1.QZTI4D8:GEJ!'5/55_+(_F]?RWIJC<7\
MNKY6S=_]2XR5JI>@.P98J";[:-F<4M/@<W45>VYFT22":IQV4Q%;.53PP:BB
M(/ASGL'-XT[O:^!*?^)$/"IXDE0'\A0,L@%3GU"AY<W;E[NVZX\:,?Z#+Z#@
M!4Z?,U*F/RX]"MTY_P *,<9L/<J]2?S'OB[VC\7.T,?#%_$LUA-LY&MQ[@^1
M#5U&WLJE-N#&TLLL4BPFG?+K(02)0H)"*_\ :-[I/J-GN8KJ(\ 64,#QIJ!*
M$@$5KH/RZ46ON"EN_@[E#);N//264CA6E U"0:4##Y]7R?'?Y?\ QC^6.WDW
M+\=^[-A=I40I::KK<=@,PL65H5K$UQKD\)5"GS&+D9;_ +=70PO<$:;J;1CN
MVPWFQ/X=W"\1J0-0[6H:=K"JL/FI(Z'&W[I;[JFNWD5QCX3D5%<CB#\B >C(
M>RCI?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T77Y?_\ 9)?RB_\ %=>[/_>:R?OW7NM![^2?M^H[+[*^.76TT1GQ5-\A
M\%NVIA6,REX:*AP%=D48?A&H\%8G^R"S'@>Y>]Y"#<V0\_HT/Y:F_P QZ /M
MJ*6MT?6Y<?\ &5_S]?14W!@,)NK!Y?;.Y,50YS;^?QM9A\UALG3K5T]52Y&-
MHIX)HG!5XY8V96!'(/N(>A]UKG8JHWK_ ">_E<V%R4N5SWPN[[RWFI:V3RY-
ML6()"@E(%BN:P*2QK4Z$;^)8THZJ]3&D=(W\!^72C^V'S'6QKA,UB-R8;$[B
MV_DZ'-8'.XVBS&%S&+JDK::JI,E&LU/4T\T9:.6&:)T='5BK*002#[<Z3]%*
M_F$9+^%?"CY*57W(I?+U?F\;Y6L;_P 9,='X^0>9O/XQ_BW!!Y]Z;AU9.(^W
MH)/Y1]&E-\ ND9D9V;(U?:-9*&M963=V=I[+8?33 IYOR3^+>])PZM+\1_U>
M75D?NW3?7O?NO==$!@58 @@@@BX(/X/OW7NM>?Y1_'OM#^73WDWS6^)N&%;T
MWDYRG</5-'KBHJ&#)2@U<#T\"'Q8"JDT2TTR(_\ "JS39!3>*+VV1I-1TH5A
M(-)X^1ZN.^,ORCZH^5_75)V%U=F/,$\-+N;:V19(<IAJUTU-25].K-IOR8ID
M+0SJ"T3M9@MP:],LI7CT8OWOJO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=4)_)NV[?YTWQ+P1:&:+;6P=M5'@8NRI)B'W=F]17D";3XB" !98]7T
M)]T/Q=/+\!^W_-U?9[OTSU"R6-Q^9QU?B,M0TF3Q65HJK&Y/&U].E7!44]<C
M1303Q2!DEAEC9D=&4JRD@@@^_=>ZUQM_;8[+_D__ ".F[5Z[Q67WI\.NXLJ*
M7<>UH9&F;&'6TBX]YY 8X,EC?-*^*J)G K:424D\AD6:=6_@/2@'Q13SZV".
MK^SMD=R[!VQV9USG:3<>SMW8R#*8?)TK<Z919X)XSZZ>KII \4\$@62&9'BD
M574@.<>F"*8/2^]^ZUU[W[KW7O?NO=>]^Z]U[W[KW2&[$ZPZW[=VQ7[*[4V%
ML[L?:&3BDBK]L[XVW1[IH91*I0ZJ:MAFBU:6(#:=0^H(/M1:W<MBXDA=HW!J
M&1BK _:"#TU- ERI21592*%6 ((^8/5!7R0_X3F_'3=>Y9^U/AUVGV)\..V:
M6>3(8,;5R-1GMOTU1*&65J.%:JBSV(>HBDEB+4N=\$*-:.B*!HWE+9_=N\MT
M^GW"..\A.&$@ <@<*FC*U#0]R$GU\P!MQ]O[:9_&LW>VE\C&3I!/'%0145':
MP&>!Z+,>Z_\ A0+_ "UX8*/M[JW#?/\ Z'VY5L:C?>WON=]YMJ"*,KH.3Q:0
M;LI#"(UGEKLUMC(QIY'5JF10/$<?N[E3G#-O*UA.WX'HL>KB31B4-:T"K(G
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M'+)LCL?&4<<F3Q$TA#,JLVG[G'U! %12.XCE%G0Q3I%-'HBO5T<IPZJ/Z_\
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MI-1C,UCH<K3R:?IKAG22-K?BZGW9':,U4D'U!H?Y=:90PH<_;U5G\F?Y)_\
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M[TOU'M3H?J_9_4>QVRK[4V1CIL9AGS=8N0JVCGJ)JEVGF2*%'<RSR&XB4 6
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M5-73QPO#M3M;=^$ID:)/&LL5&F<:EBDTA;A(0CL-;HSO(SG-O[I;[;J%%SJ
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M]BQ[]U[KW_;6'_X)-_\ 8L>_=>Z]_P!M8?\ X)-_]BQ[]U[KW_;6'_X)-_\
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M?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z]_VUA_^"3?_8L>_=>Z]_VUA_\
M@DW_ -BQ[]U[KW_;6'_X)-_]BQ[]U[KW_;6'_P""3?\ V+'OW7NO?]M8?_@D
MW_V+'OW7NB19GYS_ /"F+#?S"=J?RZ:J#^4M_IUW9\8*GY48VII\#V*^T_[N
M4V?R6WF2?)-6#+IFOOL94$0)0&F\'C<S:V9![KW1W?\ MK#_ /!)O_L6/?NO
M=>_[:P__  2;_P"Q8]^Z]U[_ +:P_P#P2;_[%CW[KW7O^VL/_P $F_\ L6/?
MNO=>_P"VL/\ \$F_^Q8]^Z]U[_MK#_\ !)O_ +%CW[KW7O\ MK#_ /!)O_L6
M/?NO=$B^8?SG_P"%,7PRW3\2=K=K0?REI\C\O_D_UU\5^K_]'^![%S4";C[*
MJ$IL>^>?(UE))1X59&'GGI%GJ46YCA<V]^Z]T=W_ +:P_P#P2;_[%CW[KW7O
M^VL/_P $F_\ L6/?NO=>_P"VL/\ \$F_^Q8]^Z]U[_MK#_\ !)O_ +%CW[KW
M7O\ MK#_ /!)O_L6/?NO=>_[:P__  2;_P"Q8]^Z]U[_ +:P_P#P2;_[%CW[
MKW10?GG\R/\ A3?_ "__ (H=J_+GNR#^474]8]2_W&_O-#U?A>R-PYUO[^;D
MP^V:+[&CRM70T$ULAF:0S>6J313B5TU2*B-[KW1G]J;@_P"%6V[-K;:W3C?^
M&6/X=N7 8;<%!]_'VK#/X,S3QU,7F2,M&DOCD76%8J&N%)%O?NO=/_\ VUA_
M^"3?_8L>_=>Z]_VUA_\ @DW_ -BQ[]U[KW_;6'_X)-_]BQ[]U[KW_;6'_P""
M3?\ V+'OW7NO?]M8?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z1?9&]?^%5O
M6O7>_>QL^/Y+YP6P-E[IWKFAAX.TZJL^TVK0SUU3]K%.R0R5/A@?Q+(ZHSZ0
M[!23[]U[JWW^5=\G.QOF9_+T^*?RA[<I]LTG9/<_64&[MWT^S<9-AL8M6];6
M4Q%'2U%56S0Q&.G0Z6JI#JN=5B /=>ZL!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4:LK*?'T=
M77UDGAI*&FGK*J70TFF.F4N[:5#,VE5)L%)/X!/O8%>O=:U/_"7PY7>/Q+^5
M7?6;Q\V-K^]OF_VENZ*&:H%7J@_@^WJAG61%A20)D:_(PEA30EFA8Z I0 <<
M^JL%S# IKX5O&AQ3(+?Y*'B>/07Y48S0R2D4\29W'G@Z?\M1P'#K9?\ 8&Z%
M'7O?NO=:S?\ ,>J:7L?^?G_)IZ;$D=35[%V[VMW1/0*P+QQF'+9"&=E6,R!&
M?8LQ4LY0F%K!+.S#C95,6SWTGDQA0'RJ&%1^QQ^WH,;DP?<;1/,"5J>="N/^
M.G]G6S)[ _0GZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NJ%?Y&"9$;G_G52;D,?]ZF_GF?-E)!*\)J?X*F,V4=N:UB
M/%/_  UAX"PN1K#$R+);W7NIG\EN.LB[I_G;IXO%AS_-_P"]9:,('1#53[8V
M>]:0MA%K932LY4EV+ O_ &"?=>ZK4[B[[_X6$XWMSM/'=.?"7XQ9_J*@[&WO
M1=5YW+;KZSAJZW;=+DZI,'5U*5';E%4)45.,6EDD$M'!('8AX8FNB^Z]U4)_
M,M^;_P#/5Z6VOU+O?^<;\4NLNO\ I)]T[BVYU?-TWN79%56U6Z<K0I4:*K^!
M[ZW94+2Q8FBKS^Y301EV7]UG"H7$TFH8D BE0*^8/F1Z>O6PQ0U K^=/\AZL
MU_V8C_A:C_W@?\4O_0PZM_\ MS>V^M=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#M
MS>_=>Z]_LQ'_  M1_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_
M -##JW_[<WOW7NO?[,1_PM1_[P/^*7_H8=6__;F]^Z]U[_9B/^%J/_>!_P 4
MO_0PZM_^W-[]U[KW^S$?\+4?^\#_ (I?^AAU;_\ ;F]^Z]U[_9B/^%J/_>!_
MQ2_]##JW_P"W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_
M '@?\4O_ $,.K?\ [<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_
MV8C_ (6H_P#>!_Q2_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO
M=>_V8C_A:C_W@?\ %+_T,.K?_MS>_=>Z]_LQ'_"U'_O _P"*7_H8=6__ &YO
M?NO=>_V8C_A:C_W@?\4O_0PZM_\ MS>_=>Z]_LQ'_"U'_O _XI?^AAU;_P#;
MF]^Z]U[_ &8C_A:C_P!X'_%+_P!##JW_ .W-[]U[KW^S$?\ "U'_ +P/^*7_
M *&'5O\ ]N;W[KW7O]F(_P"%J/\ W@?\4O\ T,.K?_MS>_=>Z]_LQ'_"U'_O
M _XI?^AAU;_]N;W[KW7O]F(_X6H_]X'_ !2_]##JW_[<WOW7NO?[,1_PM1_[
MP/\ BE_Z&'5O_P!N;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM
M1_[P/^*7_H8=6_\ VYO?NO=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#MS>_=>Z]_
MLQ'_  M1_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_ -##JW_[
M<WOW7NO?[,1_PM1_[P/^*7_H8=6__;F]^Z]T%?>/ST_X6!_&_J'L7OGNCX:_
M%+9G5'4VU,MO?L#=7\6Z]W%_#\7@XS+557V.)[;KLE5>*,$^.FHYIF^B1L>/
M?NO=)3XN?S*_^%;?S1Z)V-\E_C1\2/BEV5TEV5_>;^Y6]?N=B[.^]_N=F,A@
M,E_N-S_:N*R]-]ME\57P?OT$7D\7EBUPO'(_NO=#_P#[,1_PM1_[P/\ BE_Z
M&'5O_P!N;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7
M_H8=6_\ VYO?NO=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#MS>_=>Z]_LQ'_  M1
M_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_ -##JW_[<WOW7NO?
M[,1_PM1_[P/^*7_H8=6__;F]^Z]U[_9B/^%J/_>!_P 4O_0PZM_^W-[]U[KW
M^S$?\+4?^\#_ (I?^AAU;_\ ;F]^Z]U[_9B/^%J/_>!_Q2_]##JW_P"W-[]U
M[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_ '@?\4O_ $,.K?\
M[<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_V8C_ (6H_P#>!_Q2
M_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO=>_V8C_A:C_W@?\
M%+_T,.K?_MS>_=>Z]_LQ'_"U'_O _P"*7_H8=6__ &YO?NO=>_V8C_A:C_W@
M?\4O_0PZM_\ MS>_=>Z]_LQ'_"U'_O _XI?^AAU;_P#;F]^Z]U[_ &8C_A:C
M_P!X'_%+_P!##JW_ .W-[]U[KW^S$?\ "U'_ +P/^*7_ *&'5O\ ]N;W[KW7
MO]F(_P"%J/\ W@?\4O\ T,.K?_MS>_=>Z]_LQ'_"U'_O _XI?^AAU;_]N;W[
MKW7O]F(_X6H_]X'_ !2_]##JW_[<WOW7NO?[,1_PM1_[P/\ BE_Z&'5O_P!N
M;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7_H8=6_\
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M^_=>Z]_LJO\ PLY_[V6_";_T ]E?_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\
M<_\ OW7NO?[*K_PLY_[V6_";_P! /97_ -S_ ._=>Z]_LJO_  LY_P"]EOPF
M_P#0#V5_]S_[]U[KW^RJ_P#"SG_O9;\)O_0#V5_]S_[]U[KW^RJ_\+.?^]EO
MPF_] /97_P!S_P"_=>Z]_LJO_"SG_O9;\)O_ $ ]E?\ W/\ []U[KW^RJ_\
M"SG_ +V6_";_ - /97_W/_OW7NO?[*K_ ,+.?^]EOPF_] /97_W/_OW7NO?[
M*K_PLY_[V6_";_T ]E?_ '/_ +]U[KW^RJ_\+.?^]EOPF_\ 0#V5_P#<_P#O
MW7NO?[*K_P +.?\ O9;\)O\ T ]E?_<_^_=>Z]_LJO\ PLY_[V6_";_T ]E?
M_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\ <_\ OW7NO?[*K_PLY_[V6_";_P!
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M*79>ZMG[IVBTAQFY=K9N!7EQF7HUFJ(P_CEAF@FGIJF&>GFEB;W7N@'^-_\
M+>VETMW5!\F.W/D'\A_F7\B\+LG)=:[ [3^2V>P5<=I8'.2129*@VIA-LX#;
M>!Q$^8:"'^(Y 8^7)5J(L,U8:91"/=>ZL>]^Z]T77Y?_ /9)?RB_\5U[L_\
M>:R?OW7NM8S_ (14_P#;K+OS_P 7_P"T_P#WW757OW7NMOWW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIV_\))?^ZN7_ (O56_\ R;]^
MZ]UN)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.W^3I
M_P!Q(/\ /D_\AW_N^H??NO=;B7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7N@1[\^2WQ\^+&R5[(^27=/671FQ),E3X:GW5VCO*
MAV91SUE4K/%1TTM=-"*FKD2.1EAB#R%59@NE21[KW2IZG[>ZJ[WV%@.T^E.Q
MMD]L=;;I@EJ=N;[Z\W-1[NQ-:D#M%(:>NH99Z>1HI4>.11)JC=61PK*0/=>Z
M$7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@,KVKUOA.R-H]/9;>VW*#M/?N
MW-U[OV=L"?)QKE<CBMC24$.7R--1W,ST6/FRF/CFFTB-9*B)-6IP/?NO=!3\
MB?F3\3_B-2;;KOE!\C>F>@J?>-5446U#VOV%C-E/DI*/1Y_LHJZHAEJ4I_)&
M9G1&2$,ID90PO[KW0[;5W7M??6VL%O/96X\%N_:&Z,519W;6Z=LY:#.X[(46
M3C66GJZ*MI9):>JIIXF5XY8Y&1U(*D@^_=>Z?_?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T2W>/\Q[X ]>=S'X[[[^:'QCV?WFF:QNVY^JMQ]U[?P^;@R69\'V>-J:
M&>O26ER-7]U3>"EE"3S>6/QQMK6_NO=#)WY\EOCY\6-DKV1\DNZ>LNC-B29*
MGPU/NKM'>5#LRCGK*I6>*CII:Z:$5-7(D<C+#$'D*JS!=*DCW7NE3U/V]U5W
MOL+ =I]*=C;)[8ZVW3!+4[<WWUYN:CW=B:U(':*0T]=0RST\C12H\<BB35&Z
MLCA64@>Z]T(OOW7NO>_=>Z][]U[KWOW7NO>_=>Z*Y\C/FY\/OB'-M:E^47R:
MZ0Z"K=[BM?9^/[6['Q>RZG)1XQHDJIZ*FK:F*>HIJ5YX5FF2,Q0M(@D=2Z@^
MZ]T,S=J=8KUN>XSV-L7_ $1KM8[X/:2[MH&V[_!1!]U_%QFA4'&G&?;?N_="
MI\'C]>O3S[]U[H)_CM\R?B?\N:3<E=\7_D;TSW[3[.JJ>BW6>J.PL9O5\;)6
M:_!][%0U$TM,E1XY#"[HJ3!6,;,%-O=>Z,K[]U[KWOW7NO>_=>Z][]U[KWOW
M7NNF954LQ"JH+,S&P 'U)/X ]^Z]T&/5W=?47=NR7[)Z@[*V3V5U]'E=RX-M
M[;+W'2[@Q7W>S:N>@RL KJ:22F9\?6TU1#/:0B.2-U8W4^_=>Z!_H[YV_"[Y
M,[VW1UM\>?E5T#W7O_9<-14[GV=UEVIAMY9&DAHY1!-4/24-7-,]+%.RQO,B
MM$DA",X8@'W7NC7^_=>Z][]U[KWOW7NO>_=>Z][]U[I#]D]F=>=-[%W-V?VS
MO?:W6_7.R\:^8W=OG>V<I]M8K&4D;*AJ:ZNJY(J:FA#NBZY)%6[ 7N1[]U[H
MM72G\Q;X$_)+?=+U?\??F/\ &SNKL>NQV2R])L;J_N+!;VRLE+AT\E54K0X^
MMGJ#!3QD-(_CTH"-1%Q[]U[IYW5\]/A/L;O/&?&3>7RP^/FU_D)F:O&X_&]-
M9WMC"XS<4E5FE5J*D_ADU8M2E96J\9IZ=T6:<,IB1PPO[KW1M/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UQ=TB1Y)'6..-6>21V"*JH+DDG@ #DD^_=>Z*)U!_,!^
M#?R![1S/2?1ORY^.O;?;F CRTV3ZZZ\[<PF[,NL> 8)7R145%6335,5$[ 5#
MPK(L)XD*^_=>ZG=X_.WX7?&;>VU^MOD-\JN@>E-_[TAIZG;&SNS>U,-LW(U<
M-9*8(:A*2NJX9DI99U:-)G58GD!17+ @>Z]T:J">"J@AJ:::*HIJB*.>GJ()
M!*CI* R.CJ2K(RD$$$@@W'OW7NLOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJG?YYO8,'6G\I[YJ9Z:4
MQ'+]8X[KZ ("S._:6<Q6VPBJLL3$6RK%O40J!W9)$5D80\J6YN=QMU'E('_)
M 7/_ !WHHWZ80V<Q/FA7\V[1_,]"W_*=V>-C?RSO@G@?MQ2O-\7NG]RST_B$
M!67>^'ILU-K0 6D,N0<O<:M9;5ZK^TW,,GBW]P1G]:3/R#D?Y.G]I71:P@X_
M23_CHZL']D_1AU[W[KW6LW_+AIJ7L?\ GY_SENY#''4U>Q=N]4]+P5[*"\<9
MAQ./F@5FD,@1GV+"&"H4)A6Y2R*PXWIC%L]C'Y,9G(\JAC0_L<_MZ#&VJ'W&
M[?S B6OG0KG_ (Z/V=;,GL#]"?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)7\V_Y>'P[_F,[
M&VAUO\RNH/\ 3'LO8>ZWWOM/#?Z0-T]>_:922CGH&JON-JYO!U<]Z2IFC\<T
M\D/JU>/6%8>Z]T=3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!
M7WCTGUC\D.H>Q>ANZ-L_WSZH[9VIEMD=@;5_C.0V[_$,7G(S%54OWV)JZ')4
MOEC)'DIJR&9?JDBGGW[KW24^+GQ<Z)^%W1.QOC1\:-C?Z->DNM?[S?W*V5_>
M;,;Q^R_OCF,AG\E_N2S^0RN7J?N<OE:^?]^OE\?E\46B%(XT]U[H?_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3OXD_ /XD_!7_2[_LJW4_\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!FQ?C'\=NL>U.Q>\>NND.K=C]R=O?\
M,U.TMK;)Q^$SVXOW5G'\:RE/!'69+3,B.//*^E@"+>_=>Z'/W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&&>P6.[Q_P"%!M%M
M[LJCPVZ]F?$C^6+BNRNG-G9_&PY>GQV[_D1V%D\)F]UTT=0DBPY5-N[;AQ<<
MR*'CIJNH0-:=A[]U[KW\OG%4_3O\V/\ G*?'38D6(PO2M0_PN^4FW=@[?I8L
M=0X+=/?6V<Y1[REIZ2FCB@II-R5NVJ/*5*A-4E3+)4LS-4-;W7NKS_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW6LKU5\/*SXR?SV?BKOCL'OKM7Y.?(/O/X&
M?,#(=R]T=G5,&*BK/[E;EZ]CQ&+VWM?'!,)M#;>*3)UPI<;0QMZYY9ZJHJZF
M62=O=>Z,E\.]JX+O3^;]_.'[4[6Q&W=\9GHG_90_BATO2;CPM-FCMK:>2V'%
MO3<-+CS4QR-3Q[IW#G?N*\)I6<T5,CAA OOW7NG/^2#3R;!P_P#,F^,^%FH5
MZE^+7\T3Y*]:=#X#%HD-'M[:FZJ/;N\*;:U#%$D<%/08'(;DR,$$$:*M/&13
M@:8E)]U[J\7W[KW7O?NO=>]^Z]U[W[KW7%U+HZJ[1,RLJR(%+*2+!AJ#+<?4
M74C^H(X]^Z]UK6?-SH?XA?!3^71NG^61U/L#)_*WY3_-G"]W;,Z0Z]["3&;Z
M[$WSO3NJIRE=E.R-Y9;'4>#-)B-J9'*-D:_/%,=#0P4=/24<T=5]LA]U[J=\
M=^E]S57\W/XU?'[Y*[IQ/>>2_EZ?R5.DY-KY'<>(CR,%7V/VEN67:6[>P:>"
MK\[096MQ.TOLHYKF:.EKJA&D9IW)]U[H>/Y?.*I^G?YL?\Y3XZ;$BQ&%Z5J'
M^%WRDV[L';]+%CJ'!;I[ZVSG*/>4M/24T<4%-)N2MVU1Y2I4)JDJ99*EF9JA
MK>Z]U>?[]U[KWOW7NO>_=>Z][]U[KWOW7NJS_D3T-M+H??W?'SLZI^'V]_FY
M\I^Y=E=:].5W6\&]-M4#0[;V!#DI(<?A:C>=718?;N$GJ*F6IRT4,LLM?5-%
M(M+4SJD1]U[K6OZFGVIV'_+9_EB_#Q=R8<;0[M_G>GJ#YH_&N3 38BDV$N"S
MN].S<[\>LAB*^.,C%8.MQ^%QDR-3)35M':2EA6CJHE'NO=71_,/:V$Z,_G#_
M ,G;L[J?$[:V1F>^J?YA?%7NC'[=Q--A)-R[3PFQ'WIM^GK5IH8WJH=K;@PI
MJ*0NQ2E-;.B*!4L1[KW5[OOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ1^>W:.\N_.
MTMJ_RQN@=W5.S=T=K[5BW]\R.Y\!G8\75]<]0U-4U%54>/GBGCJZ/?/9CQ5N
M'V_)& U!31Y7.$@T%*E1[KW5 VU))NE_^$Q_??4?26>GZ\Q><^:?;_Q2Q66Q
MV5EK*K#[4[9^3$FQJY8JF>:6H>1MLU]93K--,[L',K.[ D^Z]U:__-<Z>ZV^
M+N)_E+]N?'G9&Q.H]U_'?^8_\0N@]A#:&W:+;CG8'>LT^Q]S;)IS2TZ2G$9+
M%5%)+)2JX3R8^"H*LU.H]^Z]UL$>_=>Z][]U[KWOW7NO>_=>Z][]U[JH/^>)
MU%W]\@O@7ENBOCMTY6=[;I[2[V^->&WCUW#NJFV135FU-N;UP^X=PQ93+58D
MBH,-5T>&^SKI?MJDK354EZ6I75"_NO=%\ZD^2F\?B_\ +OJ+H+YB_P N[XE_
M&3?7R6VIW'7?%3O7XG;@C['PU;ENJ,1)FLULS<-?4;&VCE,#E9\'>:EG"FER
M0CG@B19$*^_=>Z*G\,?C/UE\@O\ A-OV;O?MC"[/W/VU\M^A/E;\M.W.XLO@
MJ'^*3]@[GKMS;AQ.Z)<C)!+-%D=HU-#@XL=4%VDHHL52+$5\*^_=>ZO/_EI=
MJ[R[R_EW_!ON/L2N;*;][-^)O0&]=Z99P0U9E-P;7QE175K W(:LJ7DF(N0"
MYL2.??NO='<]^Z]U[W[KW7O?NO=>]^Z]U2/_ ,*)^[\OT)_*-^3NZ\5G-V[7
MIMSUG3_5>[MR;"$/\;H]M=I[SP.#W6<2:B6"G3)5.VJS*TU*TDR(L\\;,R@:
MA[KW1-L]NNEZZ[1_EET7S3_E6;)^&GQTP7R+ZZV?\(>V.D?D7!F]Q];[USF+
MK\=LW:G8^!V_M[!4F/Q.Z\?]QC\G2TFX<UB%R#4U)5O7 I5)[KW0^_RI^G.M
M?E%@OYL';WR"V1LCMK=7R0_F,?,#HG?<V\-LT6X6_N!T94Q;$VOLIWJX9G?"
MXO%4E7+'3L?'YLA53: TQ]^Z]T-7_"?W>.\MV_RI_CICM\[FGWIENK<_WUT/
MC-VU-4:V3(8;HCL'=&T\!*\Q \QBPN(H(/(  XB#V!8@>Z]U<U[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[K73_X5%=@4^SOY6F8VW-4>*7MCOGJ#85+$$=_*^,?(;H9#I5@H6/;;O=RJ
MW4+JULBL-O;^ R[DK#\"2,?L(T?X7'09YNE$=DP/XF11]M=7^!3U?AU7M--A
M=8=<;&BC$,>R]A[0VG'$%T:5V[CZ>C"V\DMM(AM;RO\ \&;ZD&2OXC%O4D_M
M/0D4:0!Z#I>>Z=6Z][]U[K68_P"$\6,I=V=H_P X#Y%PJ9).Y?GSO'&&N\LD
M@EBVQD=QYV( $1Q^D[QD;4*>-FUC6+!%0<\Y2%8[*$\$M4-/FP"G_C@Z"_+D
M8+W4GFUPX)^2DD?\?/6S/[ W0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ.,%VU\R_Y@_R=
M^9.U?C!\M(_A[\>?A'W)COC1!E]M="[8[=SN]NPMLX:DS&[US,V\J;(TE#M;
M$2YG&4$=/C*2CR-2\4]0N4ACDC'OW7NC1_RQ?F#V!\L.H>V,#WEB=M83Y+?$
MOY%=H_$?Y%0;,CFIL/D-Q=3R4QBW'B()S(]+C-S8BNQN1BIA55 I7GEI//(T
M#6]U[JR3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7M\\M]_-.CKOCCTG\*=L
MTV&W1\@.T\KMKM'Y.[CV.O8V"ZKVIM+#U68K\W58=ZV@IZW,Y>6"#'8>.KG^
MS:JD<3+(YAC?W7NB8XKO#Y?_  7_ )@'PT^)/R-^5T'S@ZN^?M'W=A-B9[>'
M4FT.G=^[,W)T5MV#<-74^#8^-P>!SVR\C2!H7,F(3(8^LGC+U=53LJ)[KW7#
M+]X?+SYV?(_Y7;/^.?S!PGP(^+/PK[7;XPY?M;"=6;-[=W5OOM.FPN/RV<HG
M._*'*[<PFV-KKF\53B"GH&RN1K3./NZ.% K^Z]U8/\%,_P#-+)]1[DV]\\-H
M;.Q?=/7?:N_MAX?LSKEL;08#L7:N&J5?;6_<=A:'/9^JVV^:QTR)68NOG@J:
M>MIZATIHJ66G'OW7NCI^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"OE%W/B?CE\:?D
M'\@<[4BDP_2/2G:/;.1G\'W3"+K["5V58)#_ +OE?[72D0!,KE8U!+ 'W7NJ
M-_AOMG^;[\@^J?CGVEO?^<QT#L_?/:O5G57<^\OC=2_R_-D[ERV*IM]8NASL
MN$FR%-V%0UDCQT54(FK%Q$%KF580 ![]U[JP;Y@9[Y[]A_)#ICXN?$S(U/QS
MZIW'UEOWMGO?YOUG5N,[9.'. K:+%X;9.U<=G)6V^FZ<K-635TLV3Q]=%%0P
M"2&DFTU 7W7N@-^,/R-^372O\R3<O\L?Y.][X?Y<G<WQ2G^8G3?>YZ^P/56[
ML9B\9NI=L9+;F^,)M>EQVVZA9*JH23$93'XJA$T-/-!54SU"F=O=>ZNI]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4N?-3N/N3NO^8E\8?Y872W<
MF[N@,%N'H;L#YI?*;LWJFHI(-Y/LO9&<HMK[>VW@ZVKI*V/;L.XMSU,JUV3%
M.:@TU,]-1/%*[O[]U[IF^-^Z^\_AS_,L_P"&]NQ.]>W/DY\?._?BWF_DE\<.
MP>^<]1;UWKMC/=39RDPV]-JY3/04M!69K"5M)E\/DJ"IK8I9Z>8S42/XE+>_
M=>ZN\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T73Y<9;Y'X/XT]T9'X
MA;5VUO3Y-Q[&RE-TGM_>61IL5BGSV0T4]'4Y":LJ:2F-)CS*U7)&]2@F6 P@
MEI #[KW5$'S@Z5^4'\MWX/;G^>U#_,[^6^_/E+TCMSKS<&[MI]Z[WP^YNLM_
MY7)9A:>NV93]>4&$I,7AY-P5.<FQ^(FPYBR$$D6,$E35)3LS>Z]T87YR?,+=
MV\/D[\=?A%2_(6G^"VP<W\2MX?/CYN]Y+NK%[/W-MG8&ULKBMM8[;F)S>>B_
MANUY<WN;)5-/6YJ6G-33T]#,M"(*DF5/=>Z$'^791[XJ>\MW[M^.7\R+ ?S"
M_P"7-G>K*#&K'V+W;C.\]_;+[)P=?X9%HMQX;#>3);=SN)2:6IILQEHZBCJT
MC?'Q24LKA/=>ZND]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JRLI<?255?6S
MQTU%0TT]95U,S:4CBIE+R.Q_"HBDD_T'OW7NM'_XE=O=8_+O9VWNX?DM_P *
M*/DO\2>ZOD_VIW!O?K_XP[&^7.S-J8_ ;7W/O;/4NQ\=%19C"U-3BFK,'!CY
M(*6LEIIE2:",TL#D0CW7NMC_ .4_2OSERW5GPW^+'Q;[UW]MO:L^5VQLCY>_
M-?(9G;N4[+I=G]=;>2.3*8DY>F?'U&]-\Y:"G2JR4."J5HC+554=-&6BM[KW
M10,_'W'_ "[_ .8E\ ^D=@?+[Y%?)_J[YT;J[YVIVIT)\HM_)W5G<''L7!UV
MYXM_;4SC8Z#+8;"XFMEAQ^0H)97QO@J*&*E6F,7'NO=;!/OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JIWY>?$KY+4/S"ZK_ )B7P@_T
M.;A[WVET1NCXL=O]-=[[DS&Q<%O38F<S4.Y<6*3<6%Q^:FPF?VUN*.:III9L
M'605--5U=,YIRR2>_=>Z6W\O[XA]N]*[R^5ORE^4F:ZXS7RS^;/8>R=W=GX_
MJ%LC6[9VQM[J/!Q;=V5LO#5^7BILEE8<'C_O9JFOEHJ-:NOKJN:.C@0C5[KW
M5EGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JOWL7XL]B[L_F6?&/Y@XW);1B
MZOZ:^+OR3Z6W3BJS)5<6;FRO<&9V9D<9-0TJ4,E'+00P;=K14R29"&5'> 10
MS*TC1^Z]T6WMSXJ?-/H#YK=Z?-/X 8GXZ=FI\P-@=2;3^271_P B]][AZIAB
MW'T5256)VQO7 Y[!X3<J2?[@:O\ A^4QL^(B>H2FI)X*T/&T7OW7NC,_RY?A
MUN#X:=';NP79.\,!V)W_ -]=Y]M?*7Y+]@;3Q51A,3E-\]UY 5F3&'I:R6>M
MAPN)HX,=B\>*B9IC1T,+.(RWB3W7NC]^_=>Z][]U[KWOW7NO>_=>Z@Y1\E'C
M,B^&AHZG+I0U;XJGR$[TM/)4K&Q@2>6-))(X6ETAV6-F522%8@ ^Z]UK%?$_
MX@?SS?C;OOM_OC=?6/\ *F[[^5'?&X<CD.R?D5O_ .0/:M-E_P"#BI:3#[/P
M--%UQ-#MW:& IA#%2XVDD$<DB&KJFGJI&E]^Z]T>OO+XH_-N+O[XX?S&OC_C
M_C55_,_;/Q9E^+WRJZ%WGO?<F V'NS!;@KZ3<[4^VMW4^%K,MCZK:F\$K9L7
M55^UY?O<?55$%1%1RR!A[KW0V?R_OB'V[TKO+Y6_*7Y29KKC-?+/YL]A[)W=
MV?C^H6R-;MG;&WNH\'%MW96R\-7Y>*FR65AP>/\ O9JFOEHJ-:NOKJN:.C@0
MC5[KW5EGOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ5[?ZB_F7=,?*/N;OSX=[OZI^
M1W5'R&VSUO1Y?XS?+/NK=O7^.Z\W%UW1S8ULWL'(8W"[MIJ?";BI'@FS&%7&
M4(?(0M7PU+25$D?OW7NBHT_\F3MVN^(NZX=S=[]?5?\ ,7W1\_,/_-/@[LQF
MT<E1;"Q?;NUJBF7%8.@PHJUS1V%3;>IC@92]3_$*FFJ*FME4RR+2K[KW1B^G
MOBS\TN^_FGTI\T/Y@&%^.'6R?$?KKMG9OQLZ1^.^^<_VQ$VX^\X*'&[GWQG,
M_G<'MM8F_@%#_#<7CJ?$R201559-/7$RB'W[KW5QOOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZKI^0W\I'^6]\L>T\UW;\C?B+U9V[VMN*BPN.S.]MW05]363P;=I8
MJ*BA/BK8HDCIZ6&-%5(U'!8W9F8^Z]U6?\;/^$^/3777\M_Y=?#/=FWNN>M^
MT/E;NGLJ;,=O]/UF5W!)28W;6^\KNOIZ25LG'C)9JO8T4F'/A2.,"2&:%*N8
M-]PWNO=#M1?$O^8[\M^VOB G\PQ?B1M?I3X2]P;=^10/QZW;NC>N4[3["ZWQ
ME=C]I9JLQ^<PN'H]F8'$UM?49F3'FKS-1)7K2PQU"1T_W#^Z]U>A[]U[KWOW
M7NO>_=>Z][]U[KWOW7NB5?.SHSY%=X=4;2'Q2[[K>@N]>J.WNO.Y-GY"MK\G
M!MG=";&J6DKMD;XI<5-%55NT=S4<LM/6*B2O#((*A(I3$8W]U[HFFQ?BC\XO
MD]\ROCM\K/G[C_C?U+L7X9XSLROZ#^/GQTWSN#MV7,;T[5QK8&OWANG<^;P6
MU8XL?B\ ]13XO#TV&E8U%5-65E9^W%3'W7NBJTO\N#^9)T]\8^W/Y67QTW9\
M6*'X)]I5W<6U-@_(S=^Z-UTO8O7?77?V3R.1W#M*GV?2XN;$[BS6*AS69HL'
MDQNO'4\<,M*]32*U(8Y?=>ZV!^H^K]H=(=4]9=,=?8Y<1L+J/K_9O66RL4H4
M"FQ.Q,=38O'0>E57]JDI85X4 V^@]^Z]T(?OW7NO>_=>Z][]U[KWOW7NB<_S
M /AUM/Y]?$'NKXG[PW#EMFTG:6"Q1P&^<"\D=;@<_LS)T.?VWG*;PS4TKOBL
M_B\=4M$M1']Q'&].SJDK>_=>ZKMSOQ,_F5_,S=_Q7V+\\YOB5L;H;XK=]=;?
M(S>6X/COO+=&[<YVSN3I&.:?:R28C,X'#4NQ,"^=>GRV1I5RV8G=X$Q\,O@U
M5+^Z]URF^(O\QWXA=K_,&'^7HWQ,W;TK\V^YMU_(_7\B=X;IV;E>K.PNT*"D
MHMV9BCH,)ALU2;SV_DZVBI\O#CA5X:>*M-3 \[15 G3W7NK'O@?\2-J_!/XA
M]$_$_9^8J=RX[I[9HQ.5W;6TPHI\WFLY55.6W#G9X@\ICFS6>R&2K70S2,C3
ME6DD(+M[KW1N/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=:S7_"BJLH=Y;Q_E+?'.>3R5/<_S[V161XY4
MUO-!MZJP^"G90(V<Z&WA MA(MS(/0YL4'')B,BWLPX):2"OH6&H?\</[.@QS
M(X+6T9XM<(:?(8/_ !X=;,OL#]"?KWOW7ND;V+NJ#8O7V^][U4J0TNSMF[GW
M54S2E0J1[>HIZMV;6532JPDG4P%OJ0/=XUUL%]2!^WK3'2*]:^__  EMV!_=
M/^6)+N^62IJ*SN+Y%]M]@5535OY6;^&0X?; 57,,;F/5MZ1[&6;]V25O("QB
MC&GN!/XNX%* ".-$%/0@O_S_ /+%.@SRC%HLP]22[NQKZUT_\^_MKUL=>P1T
M)^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[JAK^2=B5ZV[;_G:=)YZLAC[ QO\Y+Y(]_9#!/+"
ME1%MWY/[?V=N+:M:T"3RS+!7T<53XI714E\+Z?6LL<7NO=.'\DS&3Y;=/\V_
MN;%SC(=<=T_S8_DGE>L=PP2!Z7+4.Q:/!;<R&1HKJ'>E&<QN3HUE)T3-1N\.
MJ$I++[KW5ZOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HG'S9^:W6OP@ZOP^]]
MXX/=O8N^^P=WXOK'HKHKK3'KF]U[ZW9N!9'H<!@:-F1"YCBEFJJJ9TI:*ECD
MJ*B1555?W7NBH_"GX2=Y57?6:_F)?S!-T8+=OS"WALF?8/5O36RYQD]C]([0
MRE0]1/MK:51-"E3D]Q99/MO[Q9^32]=-&::E6/'HB/[KW54O\LG^7Y\<?D7\
MA?YO_6/SJV5M3Y);IZ:_F:?(/+]=]3=I5/\ >#%8';'R$D7>^-W53;<9XJ:+
M-;I3<%1Y<O+2256BE2CI*P4]/I]^Z]U8-_([DRFT]H_.OX[[7WSNOM#XQ_%;
MYV]H](_$_>^\=QU6]JF+;&,Q>$R.0VO3YZKFJ)<SC=F[AR.3Q5-.:B5XU@:E
MD?53E4]U[J\GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$C_F19+XV8OX+_ "8F^8F1
MWAB?B[6=;5N#[SR&PL?D\IE(]N[DJ:;'UW@BPU+6Y,1,E4%J)*>G9X:8S3:H
MUC,B>Z]U1Q_--_EQ_P N[XE?RQ]W_*;XB]:[-^/OR/Z)PG679'Q.^4?5%.C=
M@YK>51D,9!MVGJ-PS+59;>M3OB2K%'70U[5SY)*Z>61&D)<>Z]U;C\K?GMG?
MC-LCH3J_;/6&3[V^?'R8VY%CNE_C7MV1<5]QEL9CZ:3.;@W17 R0[9V+MNKJ
M8VRN2D+%$(@I$J*@A5]U[KC\ /@?N_XZY_MKY-?)[M*+Y!_.OY._P"H[M[4I
ML8N*PF Q>!B4XWKSKZA=!48G8N F:5H$E=JK(5!-?7LU0P$?NO=6:>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ OD-6[>^-'_"@KXK?)_M7<&-V
M7U7\H?Y;G:GP7V[O3<TQQ>'@WGL/L3'=AX[#U&3F2&@H<EGL?55@H(IZPO6F
MCJ(X(=<3.?=>ZDY?+;/^4?\ PH Z*SW5%=0=B;:^!/P>[L'<N_MIYF+,8C [
MM^2.7Q6/V_M6LJJ5W@_O!48"ARV0:B+L\=&\<\BQGQZO=>ZOT]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!WR5^1O4?Q'Z([.^2'>VYUVAU/U'M>KW7
MO#."EDR$JPP,D4-/2TT(:6JKJZJE@IJ6!!JFJ)8XUL6O[]U[K7\Z;WWU-\_N
MW.O/F9_,F^6GQ2V#U1UQN:E[*^''\N%?D!M%Z?:M6B(^(WIV_4'.-%N3L2EC
MM+2XE8!C=MSO(JM65FIX/=>ZZ^:G4/16-_X4$?!?Y5_*%=H5_P ;^X?@?N_X
M^]5;HWX8ZC9K=F=<[NK=XX.CR5=4SG!R5&4P>?JJO"TU6NB>MQ_W=&LM53+)
M3^Z]T(^WL+U'1_\ "@GK.?X0T'7-!BA\(>W*C^8HW3%-%286623*XBGZP_O1
M_ U7"R;R-9#7B@^^_P!R'\(AK/'^Q%8>Z]UL7>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7N@][;KX<5U3V;E*G96=[)I\;U[O2OJ.NMKHDF3SZ4>-J9'PN.62:
MFC-=E54TT :HB4RRIJD078>Z]U1%ANV_Y*>5_DT[VWQCNOOCUT?\/:_H[L5=
MV]';HQ6W\+N#;N:R,5;3Y';&1Q4,];DX^P(=P,]+##'+-DI<F8&I&DD>!C[K
MW21Z4^=^_?Y:/\G/^7-MGY,T[;T^='='5FV^KNDNJ>SMZT^SC7Y0Q256,FWE
MN/)-#3;>V[M#:\V(DS^0JY3+311>!?N*Z6,/[KW0^_R\M@?'C =S9/Y+?([Y
MY?&/YD?S+>],#2;(K=Q[![2VZV'VI@UM5KU[U/M>+,5U;CL!#+'Y:RIL^1S5
M1&U=6>(%::'W7NKT/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UK+?S-EQ?:G\]G^2WTO5"DR4^PX^S>\I,3(8*IX30-/EZ*
ML:!UG>,+4[!9XI3 GKIF:&99(F>$<[%JM]HOY14!O"2N17NH17[),CT.>/07
MW33+N%HAH:>*U,&G;4&GVI@^HQPZV:?8&Z%'7O?NO=$*_FF;SJ-@?RW?G-N>
MBK9\;7T_Q:[JQ6-R-).]+-!5;FP-;C*::"6.2*2*>.>LC:-U<,D@5E#$!2;;
M!&)KZW4BH,T=0<@C6*U^71?NKF.UF8&A$3T(P0=)Z #^0]U\O6W\I;X982S^
M;-;#W+V#42R! [GLW<F:W!&6,?!"09*&-+^H1H@;U ^UO-MQ]3N4[>CZ/]X
M3_GWI/R_"(+*)1YIJ_WLE_\ +U;I[#G1QU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$!^3_\
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MMOX*NS&*&"R]9AL9597"+.M2*.IJ($>>E$BV604\I:/4!9M-QP??NO=:'/\
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MCN/K^#^\>W'N%=HW3.XG'LLBHS(0&"M:Q]U[K2 ZW[R@_FB?$O\ X3-_RO\
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M,K@,30XV?';4I):&2"CKLB))JV0+4B*G#5/NO=2_YBW_  G7[2^9/\Z;H/\
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MV7MFAW_E-J4_66RMNR[PH#2XW"4C8/;QS=3A<=*\TDF0K,=5Y"8RD+!'%'%
MONO=$:[%_P"$_P#W1)_+'_EW=3=#;YZ&Z8_F7_RY]TX7?W5O>6VZ[*X+:%;D
M\OG?O]UTN1RM'M8[@JJ#+1F"N,DFW#+59"D6GJ46EK*N4^Z]T:/Y.?%[^>A7
M]G83NOX^?(#X0]L;5W_U'MG;/=GP'^8>W,SO/JS;^YS04$>;RFR<]@MNX3=&
M<QTM?122TB9F.DFA6KK ZRQ2PTE+[KW3C_)?_E'=K? [L_Y;_*[Y&9GX]X7O
MOYBYC SY[H[X<[5KME]6;.QNVJBLJ*>DP-+D8*2LFJ:F6K,DI>E1*9O)'%+5
M&66JE]U[K8"]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2'[-PFR-S=;=A;;[,F
MIJ;K?<&Q]V83L&HK=P3;2ACP>5H*B#+/+E::IHJC&1)025!:KBK()*=09DFB
M9 ZN1,R.I3X@01BN0<8-:_9Y]5<!@0>!!KFF/MZUK_\ 9 ?^$JW_ #WGPG_]
M.69C_P"VK['W[ZYC_AG_ .R5?^M/01_=FS>L7_.<_P#6SKW^R _\)5O^>\^$
M_P#Z<LS'_P!M7W[]]<Q_PS_]DJ_]:>O?NS9O6+_G.?\ K9U[_9 ?^$JW_/>?
M"?\ ].69C_[:OOW[ZYC_ (9_^R5?^M/7OW9LWK%_SG/_ %LZ.G\"?BK_ ",^
MGN^XMX?R_=T?&O+_ ""_N=N/%P4G5_S)K^\\K_!JTTYR;+@ZK?.X8_ OCI_)
M4#'ZH@0!*@<ZBC>MQW>ZA"WPE$>H$:X!&-5#3(C7-*XKT8[79[?;R%K4H7TD
M'3*7.FHKC6WG3-.KM?84Z/\ KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
>=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>timage_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_007.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZFE5*EJ9Y*<RDTQ8A)&4:K!C:Y3;A9-MT[P.02C%216A(]*TZ>M+D7<2RJ"
MRA@#QH>C(>T?2CKWOW7NO>_=>ZJ7_FC?S=.H?Y5W^@S_ $J]7=D=D_Z=O])O
M\!_T?3XR#[+_ $8?W?\ NON_XE5TM_N?[Q4_B\>JWBDUZ?3<1\O\M3<Q>)X3
M(OAZ:Z]6=>JE**?X3T3;OO<6S:/$5CKU4TT_#IXU(_BZM7P^13,8G%Y:*-X8
M\ICJ+(QPN0S*M;$LH4D<$J&L;>PZ10TZ.1GIQ]ZZ]U[W[KW7O?NO=>]^Z]T4
M2H^=7QA_V:W;WPHQ'9F*W5\C\SBMRYS+[ VHRYQ\!2;7QZY*9]Q5$3_;XJ>>
MGD@\%+(YK)?+'+]N*<M,IA^ZYQ;_ %10B*H4.<!B21VUX\#4C I0FO23ZZ(R
M^ &!>A)49( IQ].(I7CT7;^9Y_--ZN_E<[0ZHWEVEUKO[L?'=L;DW'MC%TVP
M*G'034LVW:6GJF>H&1J*9&BE2>P*2%@R\J0;A=L.P2\P2-'$RJ574==:4K3R
M!Z2[KNT>T('D#$,VGMI6M"?,CTZLDVGGXMV;5VUNF"GDI(-R[?PV?AI)G$CQ
M)F::.I6-F6P9D$@!(%B1<>R-ETDCT-.C0&HKTH/=>M]>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=(GLO>U)UIUQV!V/7T51DZ'K_9.Z][5F-I)%BEJ(MJ4$
M]?)!$S^A9)4@*J6X!()X]WB3Q6"CS('[33JK-I!/H*]$'_ED_P S;K/^:!UG
MV+VAU?UUOKKG#]<[ZI]A9#'[]J,?/4U%3/CZ?(F:$8ZHJ8E@6*IC7U2!RX;T
M@ %CG?MAEY?E6*5E8LNL%*TI4CS SCHMVK=8]WC,D88 -I[J5K0'R)]>K+O9
M'T:=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0,_(GO[JWXK
M]&]I?(KNO<D&TNJ^GMFY?>^],[-$]2T=+B4N(:>"-6FJJVLF:*GI:>)&EJ*F
M6*")6DD53[KW0#[(^:&+P/P9POS@^8^U</\ #S;,G6R]M[YVCN?>[[SDVUB,
MU(9<)2Y*L.'PLDFXJW'SXP5&,@QLCP96I;%4LV0:..IJ/=>ZJ>'_  H^ZTQ?
M7VW/D=OK^7;_ #(.OOA/NG+4L6+^8.X.D*&JVU'A\M(T>-W/5T%#F:K,4^W\
MB?$T%6*5TF6:$0>:66*)_=>ZV#^ONP-D]K[$V=V=UKNC"[WZ][!VSA-Y;)WA
MMRN3)4&3Q6XZ>.KH:ZCGC)26GJ::6.1&'U5A]#Q[]U[I8>_=>Z0G9W9_7G2_
M7V[^UNV-Y;>Z]ZWV#@,ENC>6]-UY*/$8_'4&)B::HJ:F>4A51$4V NSM9$5G
M8*?=>Z*%_+@_F$=4_P S7X[5/R;Z4VUO#;774G9V_P#KG Q[X@IZ.NK5V)41
MP')FGIY9Q305PD$D44DGF1+"54>Z+[KW3O\ /7^81\=/Y<_45!VOW]E=Q5M7
MNO<%-LGJCJ?KK!_WOWAO;<60 %)@-K8598&K\A4.T:ZI)X::$O'YYXA(FKW7
MNJYL;_/WZ^V%V1TSLGYJ?!KYQ? 7:?R W%B]D]8=U?(SK?&Q;2FSV<:(46(R
MN0P^5R$V$J*E92Y-53*M/''-/5_;TT$\\7NO=7]>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[H%ODEW;@OC/\ ';OOY'[IQ&7W!MGX_=+=I=V[
MCP. ,(KZV@ZIP==GJRDHON)(:?[NIIZ"2.'RRI'Y&76ZK<CW7ND+\*?E/M;Y
MN?%?I/Y7;)VUG]G;2[QV@N\\!MG=,M/+D:2FFJ:BGCCK#2234WG/V^IA'*ZK
MJTAVM<^Z]T:/W[KW7O?NO=,NY:K/T.W,_6[4P^.W#NBCPF5JMMX#+YM]M4E=
M7T\$CT='59&.CR+X^GJ:@1QR5*X^I:!&:44\Q7QM[KW10O@'\V-G_/'X^4/;
M^%V[)USV!MC=6Y^H_D'T=DL_%N/*=?=A=<SBCW1LW*U44%)YZC%5EF@J#14W
MWM%+2UR011U*(/=>Z.O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[K%//#30S5-3-%3T]/%)////((D1(@6=W=B%554$DD@ "Y]^Z]UJW?)/\
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M=9ZJ0Q4=-Y%-141!EN86.US[EJ\%"P0%G;\*@ G)X# -!Q/D#TDN;Z*SH)&
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MN&C4Z43+N16@J0!Y5)I@5' GRZ5[OO";1$'859L*M:5-,^N!YGYCUZI/S?\
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M^(X8XPV %)."3@ 9J#/?=X?;?#CA4-)*:+J^$9 SD<:@#('F3BA)#VG\N_\
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MJ.@ZBI]O9C'_ ,/-30O5;?GP&4KL?-))>E6HR^,F"QQ2Z?-'2RD:TBD\:[D
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M5584V8F-/49Z"!O&\M#D8ZI4:&H#)[KW1#JW*9S"?'+M'_A-)MW)?8;WW?\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7+Y>]O[[^/\
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M6DB@H85C@1(!65^1FCIHZJBCM(Y'R_L=K]!)N-TK2A"0L2DJ#2@J2*'BWV
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M_+DWONA((<+W'_+E[@Z:Z\K6B\A.X>O:WL;<F1C=W58Z=3A\E"D;K(SR23>
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M 'OW7N@X[CZLVGWEU'VCTKOR@@RFR.W>O-Y]9[OQM3"*B.?&;ZQU3C*Z)D)
M8/354@M<?ZX^OOW7NM"CX>=PYSY&=6_RG_Y&F[=]5>;[D^*?\U3O#;GRHP&/
MI%FE_N%_+OKLEN[%Q9*.1/-0[?R=174>*QTLL<?EGPLL"NTU(Z/[KW2I^;7>
MV?\ Y;W8O_"@W^7QU]%CX-[?S$-U="]M_"S8E!GI*/*9S+_/"H_NIV:<=)-,
MK>:GEJJO[:GC*"G:F #"D8&#W7NK%?\ A07\2J[XZ?\ ";C;GQNZOI\SF]N?
M%FA^)VWMT5<6NLJ*C&['JZ+$U^6K12PI$XFRU3!65+>&*"-F:8+&L:J/=>Z.
M7T]_+,[D[?ZHZW[4ZI_GN?S)-R=:=A['VQO'8><PFY=@5M)4XG<%'#4T,D,L
M6TW1D-/(@L&.D@J;$$>_=>Z!G^5S\<?BQB-N?SD,O\+/FY\A/FYW+VWD-Q=4
M_(S=G;FSY]OTT'9&Q,7O*BIY<'G*7;&!Q6=K*Z?,3M5U6*J:^-XEQ]075)Z5
MY_=>ZKE_X3P?!SLGY+_RS>N,MUC_ #8/G!\;\MU[V%W)L#M#XY=.Y;:5#BMG
MYREW/E*Y:4T.5V[796CJ,IBJW'9*9:F<DU%7-H"H B^Z]U8+U%\,_C#U;_.M
M^.%+VK_-/^9GRI_F'='](;\WOLGJ;M3:-)NC&Q['W[B=Q8BNASV>V]LVGQ&(
MIU%?55D%-7YNEF^ZDQ\D<;M6TBU'NO=44]&?R<,]_-7^1?\ PH&KH?D3V-UW
ME.D_YD'RLRGQSZRVUEVPV!?M*;>&Y:S%[IW Q=EE$-!2-B(7CB2IHX<A65-/
M41L#'+[KW6V1_)*_F09CYY?&W,;'[TQ$?7OSD^)6>_T&?,#J.O:*BKZ/.[;:
M:BIMP+0JL9AQ^XTH9Y!XXS3PUT-?1P2S1TR32>Z]U5[0_P K+X5_S%>V/D-\
MZ_Y.O\Q/Y,_!KNRH[DS>SN_5Z3I\WL[;=1V!LBJ?(9";<_7V8CVCN%9ZJHR<
MIJJ>>MCQ=67GECH6>:N>J]U[H=?Y;?R]_F2=+_S0NPOY0W\POMGJCY;56)^,
M3_)KJCY.[ VQ#L?.?PV+,4N-BQVZ,714U)0)+.E3,-)IONH&@@D>LR,5>LT7
MNO=3/^%:>7Q]/_)UWYM%KU.Z.S^_?CUL/K[!TRK45F4S+YP99:#'TP/GJZR3
M'8G(R+#3QR3,D3L$T*[+[KW6R'M>AJ<9MG;N-K$$=7C\%B*&JC5Q(%DI*>.-
MP&4D, RGD&Q_'OW7NGWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2
M[YZ?!;J3^8CT'4?'3NK<78VU]DU.[]M[T?*=79?&83*BJVOY_MXQ/EL1FZ3[
M=_N'\B_8ES9=+IS<TV?=I-EG%Q$%+ $4<$KW"GD5/\^D.XV";E$89"P!(-5H
M#@U\P?\ !TD/^&XND/\ AOG_ (;:_O5VK_H-_P!'?^C/^]?\<Q'][/L/XC_$
M_-]]_ _X/]W]QZ=7\"\?CX\6KU^[_OF7ZSZZB>)XGB4H=&K[-5:?G^?6OW<G
MTWTM6T:-%:C52E/2E?RZ$/X-?"SJWX ?'C;GQHZ;S^_]R[$VOF]TYZ@RW9F4
MQV9R[S;NK9:^I6:?%8K#4;1)-*PB"T",$ #,[78M;MNDF\SM<2A0S:00H(7M
M 7S+'R]>K;?8IML0A0DJM:%J$Y)/D!Z^G1:?B9_*%^-GPW^8/>OS7ZQWOWCG
M>U/D'0=GX_>> WYN7 9/;]*G;&Z,;NW(G%TN/VSB\C"T.1Q=/'3&?*U(2F:1
M)1-*5F0PW'F:?<[6.TD6,)%HTE0P8Z$*"I+$<#F@&>DEGLD5C</<(7+2:J@D
M:1J8,:44'B,9..@D_F%?R&_A5_,.[$?NG>;[^Z@[HKZ3'T.Y^P.I,C0T)ST6
M'I_MJ,YS'9*@KZ*KJJ:G6&):N)*>K:"&&":>6&&%(W]EYOO-C3PHRKQY(1P2
M%)-30@@C[*TJ2:5->F=SY=MMT;6X*OBK(0":8S4$'[:5P!6G0"Y?_A,1_+=R
MW2.R^F8*[O;;57MG=-?O'<';6V-U[>CW7N.KKZ.*B6#,5V3VME:2/%44<;/2
M4-#0T<$,LLTS"6::61UB<^WZ3M.=#572$8-H05K@*RY^9))&/(=)WY4M&B$0
MU"C:BP(UL:4R2IQG@ !7JUGYE_ KX]?.[X]'XW]^X3+Y/:5#)C,CM/<^!R$>
M*SV!RF%II:.ES&)K7IYZ>*NCIYYXV6:CFI9HY9(YZ:2-M/L.[5N\VSSB> T;
M@0<JRG)!'F#^T<0017HYO]OBW*(Q2BH\CYJ?(@^H_P!@XZJ.Z._X2^_R].HX
M>QWW)N'NON#+;ZZ_WWUW@LMOG-8-/[L1[\QE;B9<UA*2EP,5"^Y*"FKFDHJO
M(4];3TM7'#50T231J0);SG^^NRE!&@5U<A0W>5(8!JL3IJ,@$5&">B6VY2M;
M<-\;%E*U8BJA@02**!7/$@]6F_R\/Y>'2O\ +0Z5W/T3T3N?M'=FT=V=HYKM
MK(Y'MK-8G.Y),EG<3A,/-!!-A\)@:5:%:7 T;(C4;RB5YF:9D9$C(-\WR7?Y
M1-,$#! @" @4!9OQ,V>X^?1KM>UQ[3&8XRQ!8MW$$U( \@/3HA'SA_X3L_!'
MYL=K9WO*IJ^SNB>S]WUM9EM]9#I[*8NEQ>=KZ\*9<GD<1E<7D88\C)(GDFFH
MIJ/[F22::K2>HE\RFVT<[7FT1B%=$B#X1("2H] 5933Y&M/*G2#<>6;;<7\1
MM2,>)0@:OM!!S]E/G7HQ7\NW^33\-_Y:V1SN\.FL9O'?';&X\9-@LAVYVQEZ
M3/9B#'5$B2R8W&1T%!C,;C*2:2.,RF&A%3/H19ZB5$1%1;WS/=;]19B @-0B
M"BUI2IJ22?M)IFE*]*=KV.WVFIC!+'!9C5J<:8  'V#.*UIT7/YY?\)YOAQ\
M\N_\S\D=S[W[DZG["WC#B(^P8>MLGASCLO)@Z2&A@KC2Y3$5[TF1:DIZ>.62
M*?PRB-7:G\S22R+=FYUN]EA\!!&Z@DKK#56IJ0-++BIKGI+N7+-ON<GBL75C
MQTD9IC-0<]&)^8/\G3XU?-KX^_&;XX=N=B?(/';.^*V Q&WMA[BVAO+!Q9[)
M1X?"4&!2HW#7YC;69AKZN:EQ\,LTL-)2F2H>20C2P14.U<RS[1/)<1+&6EKJ
M!4Z15M7:%9:9X?+I7?[+%N,20R,]$I0@C4:#3DL&K\_GT<?O?X>_'_Y-_'X_
M&7O?8]/V-U8,+A,33T>7J7I:ZFFVY3K3T.3HZ^C^VGH<K3*NI:BG,?+.A4PR
M/$Q79[A-83">%BK@UJ/GY4-:CY'I?<6D=W&8I &4BA!_U8/S'5">(_X2=_R^
M\=OREW%7]K_)[/[+IL@*^3KO([MV_315"+(S_93Y2CVY2Y 414I&WA>&JT Z
M:I9&#J,F]Q[]DTA8@U*:PK5^VA8K7\J?+H-+R9:!]1,A%:Z2PI]E0H-/SK\^
MM@C;'QAZ7Z_^.<_Q5ZQVC2]9=,'KO<'66/V]LP+2R4>/W-1U%'5SPSU25;3Y
M*7[F:>2JJA42SU+-/4F>1W+ J6\DGF\>0EG+:B6\R#7]GR].'0GCMTA01H-*
M@4 'D.BX_P NC^6ET3_+(ZXW[UAT-NSMK=N [$WM%OS-5?;N=P^>K(JR&@I\
M>(Z63#8' 0I3>&FC8K)3R/K+'R:2%!AOF^S;_(LLP12JZ!H# 4J3^)FSGI%M
M>U1[0ACC+$%M1U$$UH!Y >G0=8[^4+\;,9_,CD_FBP;W[Q?O^6ORF0;:$VY<
M VSM>7V7-L20#'KME<UI7$3/,H_O!<5@$A)AO3E0>9IS8?N[3'X?\5&U_P!I
MXG'53C_1X?//37[DB^K^LJ^OTJ-/P:.&FO#Y\>K4_8=Z..M/K_A7M_S(CX:?
M^);[-_\ =-0>Y*]L_P#<F;_FD/\ CXZ!?._^X\?_ #4_Y];HQ&>_X3#_ ,O3
MO6HV+V]C<_WATU3[LVELK/[KZYZNW)AX<'+4UM##/628^/+8/*5>*^\ED):.
M*J:FB_334\"V4((.?[^S4Q'1)0D!W#%P/M#"M/F"?4GI7/RE:7+"3N2M*JA
M4_D5-*_(@>G5[_6GP^Z(Z7^+\GQ"ZBVH>NNF7V#N?K\4&W9U-=X=XTM139+(
MR5M7'5-5YBK:JFGDJJE)C).VJ160!/81N=PEO)S<2MJ<L&)/RX"@I0"E !P'
M#H0P6D=M&(HQI4"@ _U<?F>)Z _^71_+2Z)_ED=<;]ZPZ&W9VUNW =B;VBWY
MFJOMW.X?/5D59#04^/$=+)AL#@(4IO#31L5DIY'UECY-)"A;OF^S;_(LLP12
MJZ!H# 4J3^)FSGI)M>U1[0ACC+$%M1U$$UH!Y >G0=8[^4+\;,9_,CD_FBP;
MW[Q?O^6ORF0;:$VY< VSM>7V7-L20#'KME<UI7$3/,H_O!<5@$A)AO3E0>9I
MS8?N[3'X?\5&U_VGB<=5./\ 1X?//37[DB^K^LJ^OTJ-/P:.&FO#Y\>@+^<G
M\@OX@?-SOK_9F:S>/<W0O<N0_AC[LW)TGN#'8B/+U&)6&"')5,&0Q=>]/EXZ
M.%(!4TL\ 8*CSQ32*693M/-]SM,)MPL<D?DLJE@M<D"C#!.:&ORIGIF_Y>@O
MY1-5T?S:,@$^6:@Y'"HI_@Z"[/?\)GOY>^5Q/4O\&W;\F-B]@=6Y_/;QR'<^
MT>Q<)-NK=6:SE3C:Q,KN:OS>U\U3S5&-JL<)*)*&CH((7J:MWBFDF+A1'SU>
MKX@81,C@+X;*P1% (TH%=: @T-:G SCIE^5K9M!!=60EM8*EV8D&K%E:IJ*C
M@,G'5C?SP_EI?%;^8UU[@=C_ "3VMELEF-G+D'V'VGM/)1;:W1A)LM"L-5)1
M5JTTM'+#4E(I)J.JQ]1CY)HH96I#)#"R$FS[[<['(7MVI6FI2*HP!K0C_*""
M 30Y/1GN.U0[H@685I72PPRDBF#_ )#4&@J,=5,;5_X2U_"2EW!M.J[0[W^6
MW=6R-D-X]O\ 6.\NQ<9CL4M,\4,<E"TN,PU)D:6DD,,99<=68^33'"ODM'ZA
M$_N!=T;PHX(V?+.B'436M>YB"<GB#Q/1.O*5N2OB/*ZK@*S]H%*4P 1Y<".
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MO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?TMO\ C?\
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M ,^W^#__ )W8S_Z_^_:.7_XKO_C'_0/7M6[^EM_QO_/U[^]/_"J7_GV_P?\
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M_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\ /M_@_P#^=V,_^O\
M[]HY?_BN_P#C'_0/7M6[^EM_QO\ S]>_O3_PJE_Y]O\ !_\ \[L9_P#7_P!^
MT<O_ ,5W_P 8_P"@>O:MW]+;_C?^?KW]Z?\ A5+_ ,^W^#__ )W8S_Z_^_:.
M7_XKO_C'_0/7M6[^EM_QO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_
M ,8_Z!Z]JW?TMO\ C?\ GZ]_>G_A5+_S[?X/_P#G=C/_ *_^_:.7_P"*[_XQ
M_P! ]>U;OZ6W_&_\_7O[T_\ "J7_ )]O\'__ #NQG_U_]^T<O_Q7?_&/^@>O
M:MW]+;_C?^?KW]Z?^%4O_/M_@_\ ^=V,_P#K_P"_:.7_ .*[_P",?] ]>U;O
MZ6W_ !O_ #]>_O3_ ,*I?^?;_!__ ,[L9_\ 7_W[1R__ !7?_&/^@>O:MW]+
M;_C?^?KW]Z?^%4O_ #[?X/\ _G=C/_K_ ._:.7_XKO\ XQ_T#U[5N_I;?\;_
M ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\ ?M'+_P#%=_\ &/\ H'KVK=_2V_XW
M_GZ]_>G_ (52_P#/M_@__P"=V,_^O_OVCE_^*[_XQ_T#U[5N_I;?\;_S]>_O
M3_PJE_Y]O\'_ /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_
MX52_\^W^#_\ YW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE
M_P"?;_!__P [L9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_
M /G=C/\ Z_\ OVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?
M_P#.[&?_ %_]^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW
M8S_Z_P#OVCE_^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_
M -?_ '[1R_\ Q7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/
M_K_[]HY?_BN_^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R
M_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_
M (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_
M\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_
MT#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\ %=_\8_Z!
MZ]JW?TMO^-_Y^O?WI_X52_\ /M_@_P#^=V,_^O\ []HY?_BN_P#C'_0/7M6[
M^EM_QO\ S]>_O3_PJE_Y]O\ !_\ \[L9_P#7_P!^T<O_ ,5W_P 8_P"@>O:M
MW]+;_C?^?KW]Z?\ A5+_ ,^W^#__ )W8S_Z_^_:.7_XKO_C'_0/7M6[^EM_Q
MO_/TL>N]S?\ "G"3L#8L?9/7GPSI^NI-X[93?T^#K<8U:F%:M@&5>C'\<>]4
MM#YS%Z&_<"^D_3VU.FQ>&WAM<Z])TZM.G53%:#A7CTY"=TUKK%OIJ-5-==-<
MTJ>-.'6R?[!G0BZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z"_N^7M6#I;MZ?HJFP=;W?#U?O^7INCW.RKC9=U1XFK.WHL
M@7DB04,F7%&LY:5%\1>[J.0_:^&94\:NC4NO3\6BHU4^=*T^?34^O0WATU:3
MIU<-5,5IY5X]:Y_]Z?\ A5+_ ,^W^#__ )W8S_Z_^QCHY?\ XKO_ (Q_T#T'
MM6[^EM_QO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?T
MMO\ C?\ GZ]_>G_A5+_S[?X/_P#G=C/_ *_^_:.7_P"*[_XQ_P! ]>U;OZ6W
M_&_\_7O[T_\ "J7_ )]O\'__ #NQG_U_]^T<O_Q7?_&/^@>O:MW]+;_C?^?K
MW]Z?^%4O_/M_@_\ ^=V,_P#K_P"_:.7_ .*[_P",?] ]>U;OZ6W_ !O_ #]>
M_O3_ ,*I?^?;_!__ ,[L9_\ 7_W[1R__ !7?_&/^@>O:MW]+;_C?^?KW]Z?^
M%4O_ #[?X/\ _G=C/_K_ ._:.7_XKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?
M^?;_  ?_ /.[&?\ U_\ ?M'+_P#%=_\ &/\ H'KVK=_2V_XW_GZ]_>G_ (52
M_P#/M_@__P"=V,_^O_OVCE_^*[_XQ_T#U[5N_I;?\;_S]>_O3_PJE_Y]O\'_
M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
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M ._:.7_XKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\
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M]?\ W[1R_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\
MK_[]HY?_ (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W
M[1R__%=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\
MXKO_ (Q_T#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
M&_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y
M^O?WI_X52_\ /M_@_P#^=V,_^O\ []HY?_BN_P#C'_0/7M6[^EM_QO\ S];0
M'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBG4?S=
M^->3^8E7\#<1V'29GY.8OJ"N[QSVP\11RY%<9@*&OHL<TF2KHE:DH:Z2?(T3
M1T<LJU+P2K.L9B.KW[KW2F^4WRR^/WPLZ@S7>GR5[&Q?6O7.&JJ+%KD:REJ<
MM5U^1RI9:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^
MW9^@>O\ ='9.R.[?[L2;TPW5O?G2.[>@,QF,33$K45^#IMV8C%?QB&D(O.*5
MY)(D(D9!&"X]U[H9OF#\[OC'\%=J[3W/\B]^U6WJGL/<D.SNM-C;4VIE>QMT
M;FRDI351;?VU@:/(9G*2P)(CSM#2-' K*9736@;W7ND;\0?YDWQ,^;^X>P-B
M]([QW71]H=61XZLW[U!VUUEN'I3=F.HLN%^TR3[?W1C<7D9L94,VA:J&&2%9
M/VY&1V56]U[H^/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[H(^^.]NJ/C-U#O[O;N_>6)V#U=UIMW(;GW=N?,SB&.&GH
M$+:(D_74550^F*G@C5I9YG2*)6=U!]U[K/T7W1L'Y&],]6=^=5Y&LR_6G<NP
MMK]E;"RN0QDV%GJ<1O*CBK\?/+25*1U%-)+33QL8I461"=+J&! ]U[JNWO;^
M=G\ /C_V?V3U'N+>_:F_]U=+>&/NJLZ+^/F]N\\1L^>59'>CW)F]KX/)8K&5
MU/%%(\]/)5>:G52)D1P4'NO=6.]0=Q]7=^]8;,[HZ:WSM_L7JSL+ TNY=F[W
MVU6"KHJZBJP2LL;D*\;(0R21R(DL,BO%*B2(RCW7NJL=V?S]/Y9VT-S[JQ%5
MVMV3G=E[%WK_ */=[=\[+^/.^MZ];8K*0S14]3#5[\Q> JMMB&AGF1*FHCKY
M*>(W)E*J6'NO=7!8#/X/=6#PVY]LY?&[@VYN+%T&;P.=P];'D:2LH\I$L]-5
M4M1$SQ3T\\+H\<B,5=6#*2#[]U[IV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%]
M^4_7'=';O0^^NM_CYWM4?&?M;=AVMC\'WC1;+H^P:K T4>:QTV=EH<5D'CHI
MLE6;?BRE'1RRMII:JHAJ[,8 I]U[K5O^#?PEZK^!'_"E9>E>KL_V-OB7,_R?
M\[V7V9VGW!O*HW]NK=^[-V]I4L>7W+N#*5&GSY&O6BI581111(D4:JEPSM[K
MW5@/S?VB._?Y\G\I?J#=\57ENL>@NB?EE\OWVG/61S8NMW)1#%[9P60R&.G7
MQ5%1@*N>"HH9E#ST\TKF+Q1/4F3W7NI7_"@S!5&RNI_@]\PMDQRXKN#XF?S$
M?B[GML[LQH@IZHX/M',':FX\!4U$B/*<-GH<I21U<* ^4QQ!U,7D!]U[J+LS
M:([N_P"%*'>N]=ZQ5>9P_P */Y<W3VU.H\1D*R.OQ^+S/R'W%D<EDL]1T<JZ
MJ/,56.HZN@>I@75)2J(ZB4JM-''[KW4K^9M@JCJ7^:Y_)*^4&PHY<+NS??=?
M='PU[6KL<(*5,_M7M?;#Y2AQN7;0T]7%A\CB:FNH4_1'.7<E9!$R^Z]UL#^_
M=>Z][]U[JN#L_P#F[_RV^F.P=W]5=H_+3KG9G8>PLY6;;W?M7+4F7^YH:['G
M3-3S>+&R1%T-N4D92+$$@W]G%OR_>W2"2.&1E85#!:@CHOEW6V@8H\J*PX@L
M 1T8OXT_,+XT?,3;VX]U_&;MW;7;VWMHYF#;VY,KMJ*KBCI*VJ@6ICIY/NZ:
MF8NT#*_I4BQ^M^/:.]V^?;F"SHR$BH#"A(X5_ETHM[N*[!:)E8 T)4U%>/\
MEZ,I[1]*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOYZ7\M[*=^]"?S
M ?EE\DODIV=V1U)T3\5^W=]_$/X>8!8]A;+VIG]M=?*LNZMRM0O][O?<:;BI
MLE78V2L>.#&0U"TR13)Y+^Z]T?/^7%O.OZX_D7_$#L/%1+-E-A_RU.L-YXV%
MG$8>HVOU]3UT*EBD@4-) HN8V ^ND_0^Z]T''_"=CIG%=8_R@_BEEJR*IR^]
M._ML[F^0W;.[=PS19?)[AS7=&7R&7DR&7K;R2Y"<XZHH:<25$DDY@AC6=C*'
M]^Z]U3[AM[;U^'7\OO\ X4_=!=;9+-;:V=\:^_>]JOX_T>,R@PLNTL5\MMOT
M>2:@P,M$BOC:+#RYB6KH%BD62.25G#15#/+[]U[K9+^#GQ0ZLZG_ )<'QP^)
ME5LO#U_7=+\7MA;#WUMC*8^DGAR\NY=OTXW'-DHZ=?M:FHS%=55TU4Z@K)+,
M[@D$'W[KW1%_^$X^7WE3_P M/$]/;TS.7W!/\6OD7\F_B]MS*Y^ICJZUL+U!
MN[(4N*IZAX56.^/I9DI(U0LB001)&1&J*ONO=7P>_=>Z+K\D_EI\<_A_M'";
M]^2W:VWNHMG[DW'%M'!Y[<D57+#49*:EJ:U*1/M*:I<2M2T=3(-2!=,;<WL"
MLLMOFW%BD",[ 5(45(%0*_S'2>XNH[0:I65030%C05XT_ET5K8?\XS^67V=O
MG9G6NPOE_P!:;FWUV'NO;NQME[;H*;+K/D,MNRLAH,=0PF7&1QB6KK*B&)-;
MJNIQJ8"Y]KI>7+Z!2[P2!5!9B5P !4D_8.DJ;Q:RL%66,DD  ,*DG '5E_LE
MZ,NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM;'_ +NQO_,*/_S5O?NO=*O^:#NVF^&O\TS^5]_,4[*J
MO[O?%>FVSWY\,?D;V?5+6G';.?N:GIJ[966S4M-!)3T.&K=R4ZTM36UDJ4E*
M DDK(0CCW7ND-_.1[WZN^;.[/@+_ "W?B]V+LGN_MSNKYF]%=Y]IT?5VZ(]\
MP;3ZLZ"R$N;W#NG.5F$:OI,7$]7%CX*%:UXUK)?*L :2)2/=>Z4_:/8^WO@5
M_/\ 3W-W]N#&=<?&S^8I\+]F=)[,[AW76SXC 4G:?0^=EJ*+:^5R<L:8;%39
M;;554S4+UE7&:BH_R>G;6[HWNO=-7RN[=V/\^/YQG\L#X\_&;=^W.W]N_!W<
MG:WS*^6N_>OLR=U87:JUNW_X-L/"U>6QHJL/_&L[D9ZQC0O4BJCI=$X58I')
M]U[K9*]^Z]U[W[KW1"^P_P"5W_+S[9WON?LKLOX?]';VW[O7+U6?W7NS<.SH
MLA6U];6F\M34S.=4DKFUR?\  #@>S6#?+RV01QSRJHP%5V  ^0!Z0R[9;3L7
M>*-F/$E%)/YD=4M_\)=MOX7 =:?S :7#8VEQM/0_,C+[?I(:5/&L=%@<>%HZ
M91^(J99I0@_ 8^Q-SW(TDEL6))-K&23YDEJG\^B7E=!&LX44 N'  \@ M.MI
MCV!.A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;'\Y'_ +=.?S(?_%*/
MDC_[RF3]^Z]T@?Y8FR(^S?Y)?PGZWFJ?LXNP?Y=73^R):NY'B7=>PZ2@:2X#
M$:!4%N%)X^A]^Z]T2'^1_P#.7H7H[^71M[XL_+;N3K'X\?)#^7<=^=#_ "4Z
MW[<WM#L&MQ$'7^5RD^%S4$6?>AJ:_!9;;'V%32UM+%)22D2PT[?M:![KW11_
MC3\;^T/Y@_\ +5_GN=\;2VSF,4O\TKN3OS?GQ!P^X*+(8"JSNTNML1!C>OLI
M+2U]*E52+NBIQEHP8V0Q,CQVA9/?NO=64?#G^<A\)*'^5_UI\B.Z>_NO.N=S
M]$=%[=V?\C>J=U;F3#;PP6^>J<32XK<6UI-L9)X=R3YF7-TTD-! :!IZ\3TT
MD(E$ZL?=>Z4G_"?;IGM7J/\ EH=;YWN[;%=L?M'Y$=D]U?*;=&R<I'505.)7
MO?<==F,;25,5;%#5PU!Q#X^:2.9/+&\K)(=8;W[KW5U_OW7N@*[]^,?Q^^4V
MV,1LOY%=1[)[CVG@,]'NC#;?WUB$S5+39&*GJ*1:R*)SI6H6FJJF,-]0DCC^
MT?:JTOIK!B\#LC$4)0E214&F/+ Z8N+:.Z&F55< UHP!%>%<_;UJ=_S5OB'\
M8_BA_-!_D:4OQNZ0Z]Z7IM\?+K951NZ'8."CPBY%]O\ 8?6JT3503_.-3+65
M0CO^D2O_ %]R/RUN-QN&W[AX\CR:8#IUL6I6.:M*^M!T#-[LXK2[L_"14K**
MZ5 K1XZ5I]O6YS[B[H==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!K_ *&>G_\ 2S_I[_T4=:_Z=/[D
M_P"C3_31_<7%_P![/[N?=_?_ -W_ .\?VO\ &/X)]]_E'V/WGVOG_>\7D]7O
MW7NE1NW:&TM_[:S>R]][7V[O79VY:";%;CVGNW"4VY,9D*6I%I*:MH*R*:EJ
MJ>0?JCEB9&_(/OW7N@/Z ^&_Q+^*0SH^,WQIZ+Z"?<YC.Y*CJ'JW"]?S5XAT
M:$K)\91TTU3'&44JDCLBL-2J&))]U[H2^V.GNIN^-CYCK+NWK/87;O76?1$S
M6QNRMI4&]L35>*^AIJ#(P5%,\D9),;F/7&WJ1E8 ^_=>Z3/17QI^/'Q?VO5;
M)^.'1O4O1&T:^N;)Y#;O4G7^+Z_I*FI<L?N*F'%TM,M3.-; 22AF53I!"@#W
M[KW0V^_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B\&[O_<&'V..=_CM?^>2/
M_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ36\MF;/[%VGN38/8.U-M;[V+O+"9+;6[]E[RP5+N?$Y7&YF)H*S'Y+'5T4]
M'7457 [QS03PO%+&S(ZLI(]^Z]U[9NS-G]=;3VWL'K[:FVMB;%V;A,;MK:&R
M]FX*EVQB<5C<-$L%'C\;CJ&*"CH:*D@1(X8((4BBC54154 >_=>Z+WW/\%_A
M;\C-ZX+LCO[XF_'/NCL';24L.#WKVATUM_?&4IXZ&1)8(5KLC05%0T$,D:M'
M&TC1H;Z5&IK^Z]T9Z@H*'%4-%B\714F-QF-I*:@QV.H*9*."G@HT6.&&&&-5
MCBABC551%4*J@*H  'OW7NBK;K^!'P?WWW#3_(/>OQ!^-&[>\J6KILA%VWN/
MI+;F9W#]S1!Q!5/E:C'25DE7"'/CG>5I4LNAQH33[KW1M/?NO=>]^Z]U[W[K
MW6JG_/9_[>D_R"O_ !;3!_\ OQ.K/<B<G?\ )/W'_FA_UCFZ!W,G^Y=E_P U
M?^?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM7__ (3&_P#,N_YAG_B\&[O_ '!A]CCG?X[7_GDC_P +=!GE
MKA<?\],G_/O6T![ _0FZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\ V])_D%?^+:8/
M_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%UM6>X[Z&/7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#_  F-
M_P"9=_S#/_%X-W?^X,/L<<[_ !VO_/)'_A;H,\M<+C_GID_Y]ZV@/8'Z$W7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\ (*_\6TP?_OQ.K/<B<G?\D_<?^:'_
M %CFZ!W,G^Y=E_S5_P"?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;VJF#,
M+_1B/I_3_8>U(A!'2)IR#2O\NN/W;?U_WC_C7O?@CK7U!]?Y?['7ONV_K_O'
M_&O?O!'7OJ#Z_P O]CKWW;?U_P!X_P"->_>".O?4'U_E_L=>^[;^O^\?\:]^
M\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^QU[[MOZ_P"\?\:]^\$=>^H/
MK_+_ &.O?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\ &O?O!'7OJ#Z_R_V.
MO?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\:]^\$=>^H/K_ "_V.O?=M_7_
M 'C_ (U[]X(Z]]0?7^7^QU[[MOZ_[Q_QKW[P1U[Z@^O\O]CKWW;?U_WC_C7O
MW@CKWU!]?Y?['7ONV_K_ +Q_QKW[P1U[Z@^O\O\ 8Z]]VW]?]X_XU[]X(Z]]
M0?7^7^QU[[MOZ_[Q_P :]^\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^Q
MU[[MOZ_[Q_QKW[P1U[Z@^O\ +_8Z]]VW]?\ >/\ C7OW@CKWU!]?Y?['7ONV
M_K_O'_&O?O!'7OJ#Z_R_V.I%/,92P)O8 _3_ (U[;D0)T]#(7KU*]L]*.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM7_P#X3&_\R[_F&?\ B\&[O_<&'V..=_CM?^>2
M/_"W09Y:X7'_ #TR?\^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K53_ )[/_;TG
M^05_XMI@_P#WXG5GN1.3O^2?N/\ S0_ZQS= [F3_ '+LO^:O_/\ %UM6>X[Z
M&/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW2'J*H+43@GD32@\?T8_X>S1$&D?8.B&26C'
M[3_AZP_=K_7_ 'C_ (U[MH'5/&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[
M]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:
M!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNGO"3"66>QOIC7\?
MU/\ K#VEN@ !TNL7UD_9TH_:/HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?_ /A,
M;_S+O^89_P"+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\ /3)_S[UM >P/T)NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM5/\ GL_]O2?Y!7_BVF#_ /?B=6>Y$Y._Y)^X_P#-
M#_K'-T#N9/\ <NR_YJ_\_P 76U9[COH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= K7U
M[K7UJ@FRU=2OU_H[?X>Q'%$2H^P>0].@/<7)61A_2;_"?EU$_B#_ -3_ +?_
M (U[<\(_Z@.F?JCZ?ZOV=>_B#_U/^W_XU[]X1_U =>^J/I_J_9U[^(/_ %/^
MW_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[]X1_U =>^J/I_J_9U[^(
M/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7OWA'_4!U[ZH^G^K]G7OX
M@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\ M_\ C7OWA'_4!U[ZH^G^
MK]G7OX@_]3_M_P#C7OWA'_4!U[ZH^G^K]G7OX@_]3_M_^->_>$?]0'7OJCZ?
MZOV=>_B#_P!3_M_^->_>$?\ 4!U[ZH^G^K]G7OX@_P#4_P"W_P"->_>$?]0'
M7OJCZ?ZOV=>_B#_U/^W_ .->_>$?]0'7OJCZ?ZOV=>_B#_U/^W_XU[]X1_U
M=>^J/I_J_9U[^(/_ %/^W_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[
M]X1_U =>^J/I_J_9U[^(/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7
MOWA'_4!U[ZH^G^K]G7OX@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3W.54JYK, '@93(
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MV=NK;>).4SW8D5,-KX>KU%4>5(VF,XC*/+X'ECCTH5+NRV8+S[T%J>MEJ#I
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-,[_Q>\S_ -K7(?\
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MI=MP3?7Z\R*#<?CZ>_?3W3?Z*!]B _X>O?6[>O"V9O\ 32L/\'7?]RMYR?\
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MZ]UJI_SV?^WI/\@K_P 6TP?_ +\3JSW(G)W_ "3]Q_YH?]8YN@=S)_N79?\
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MZ-MXC.XG+461^.^_-L]J/+5P4;['Q52N%9W=C#*4:6>(1JE@_AB9)+,ZR("
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M_P!7_%=>^_7_ 'W_ "+W[POEU[ZL?ZO^*Z]]^O\ OO\ D7OWA?+KWU8_U?\
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M"8N;9K3>&WBW&AVN9)]&JHTRNS-&305!#%2:"HS0'I+_ !KZ _V7G:>=VO\
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M1]K\2.(:K*0:4+ZOPG[1HL9)LS#?*+>=#UQ)K@7;C8ZI8I2R?JI0(\M' 8V
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
M%M,'_P"_$ZL]R)R=_P D_<?^:'_6.;H'<R?[EV7_ #5_Y_BZVK/<=]#'KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7N@[[7V-_I(Z_W'L]:B.DJ<G2PR8^JE!*)4
MT$J5$!?2"PC:2)5<@$A&8@$V'O8-#UHBHZJ-R73O:6*RLF&JM@[KDK4F\*&B
MPE1D(9.;!HJB!)(94/\ JED('-R+&SVH=,Z3U9+\9NI\MU?LVN;<:+!N'<U;
M#7UU DHF%-%2(4IX'9&:-I1KE=RI(&L)<Z;^VF->G$%.C(^Z]7Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[IKS>7H]OX;+9W(NR4&%QE=EJUU&HB+'1--(0/R="&P_)]^&>O''546[/
ME/VWN#,S5V)SQVOBUG9L?A\52P,L: G1YI98I)*B0K;66;06N5C0'3[>"#ID
ML3T9+J/Y;X2JV[70=L9%,?G<4T(I<E1XR67^(QSZO]T4L3)%41%;.0J1,&4@
M*0P]U9/3JP?UZ$K_ $];GW'Z.M>F-\[C23TP9;<*Q[1H6O\ 1DGF\D<B_0V,
MD9M]=/O6FG$];U5X#KLT?RCW*+5&6ZVZYI)+ G&4DVXJZ,-^")_/1NP^EPZ_
MX?U]^P.O9/7A\<US89^Q.T.Q-[R2+:6B_BW\"H&O];441FT"_P! LP']0>+>
MU4X=>T>IZ7F Z,ZCVTB+C-@[>DDCL5J<K1_QZ4'_ %0EK34.K?\ !2+?06''
MNNH];T@="E3TU/21)3TE/!2P1@!(:>)844#BP50 /]M[UU;K-[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H$?D#UI7=I]=U."Q$B+F\;D:7/X:&:00I
M-/11S1&!W:RIY8:B8*20HDT%B%N1930]585'56:]0=I/E!AEZ^W=_$#,(-#8
M*H6,$FVHSE!3B+F_D,OCMSJMS[=U#IK2>K5NA^MZCJWKO'[>R+POFJJKJLUG
M#3,'C6IKPB^-6 ]?A@BAC+7(9D)4Z2/;3&IZ=44'0R>Z]6Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NB\Y2CU9/(MI_5759^O]9&_P ?8O@>B+_I1_@ZC.[MZRN?
MZ;?X3\^H/V/^T_\ )W_&_;OB=)_IO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]
M>^Q_VG_D[_C?OWB=>^F_U?ZCU[['_:?^3O\ C?OWB=>^F_U?ZCU[['_:?^3O
M^-^_>)U[Z;_5_J/7OL?]I_Y._P"-^_>)U[Z;_5_J/7OL?]I_Y._XW[]XG7OI
MO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]>^Q_VG_D[_C?OWB=>^F_U?ZCU[['
M_:?^3O\ C?OWB=>^F_U?ZCU[['_:?^3O^-^_>)U[Z;_5_J/7OL?]I_Y._P"-
M^_>)U[Z;_5_J/7OL?]I_Y._XW[]XG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]
M7^H]>^Q_VG_D[_C?OWB=>^F_U?ZCU[['_:?^3O\ C?OWB=>^F_U?ZCU[['_:
M?^3O^-^_>)U[Z;_5_J/7OL?]I_Y._P"-^_>)U[Z;_5_J/7OL?]I_Y._XW[]X
MG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]"#U]3^&LR!M8&FB'UO\ VO\
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MO=>]^Z]U[W[KW7O?NO=:J?\ /9_[>D_R"O\ Q;3!_P#OQ.K/<B<G?\D_<?\
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M:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^W9^@>O\
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M+D88^1^.7'MLSH.++^T=/K9S/P1S]BL?\G4&;>&TX+^;<^WT*C44.8I]5O\
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M-A]PY/&U,&%RM132T]5%408_)/35$D;TLRR+&5:*0$H?=>ZT_MT_S]_YMO\
M*_R-1L3^;I_+,J.P]JX21,;1?+/XR5]3@=MY=$MXJQJEZ3,;8JJNM5D<T_\
M$<!407TRXR%[Q+[KW2N;_A:[_+3&#%0GQO\ G*VY?M$<XEME;!2A\YMJC_B
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M3*\24>#I:8*4M8J$B4 BPM;Z6'OU3UZ@Z?H:>"F4I3P0P(6+E(8UB!) %[*
M+V ]ZZWUF]^Z]U[W[KW0-]MT_G_N_P $Z/XK_P G?;?XC^GL1; Y7Q*?T?\
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MW,F&WA@M\]4XFEQ6XMK2;8R3P[DGS,N;II(:" T#3UXGII(1*)U8^Z]TI/\
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MOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_ -ZY_B]_U/\
M_P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'_A2K_P!ZY_B]
M_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[_9P?^%*O_>N?
MXO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U[_9P?^%*O_>N
M?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_
M -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'
M_A2K_P!ZY_B]_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[
M_9P?^%*O_>N?XO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U
M[_9P?^%*O_>N?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3
MU[_9P?\ A2K_ -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\
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M[]K/7OI^O?9C_'_;_P#&_?M9Z]]/U[[,?X_[?_C?OVL]>^GZ]]F/\?\ ;_\
M&_?M9Z]]/U[[,?X_[?\ XW[]K/7OI^O?9C_'_;_\;]^UGKWT_7OLQ_C_ +?_
M (W[]K/7OI^O?9C_ !_V_P#QOW[6>O?3]>^S'^/^W_XW[]K/7OI^O?9C_'_;
M_P#&_?M9Z]]/U[[,?X_[?_C?OVL]>^GZ]]F/\?\ ;_\ &_?M9Z]]/U[[,?X_
M[?\ XW[]K/7OI^O?9C_'_;_\;]^UGKWT_7OLQ_C_ +?_ (W[]K/7OI^O?9C_
M !_V_P#QOW[6>O?3]>^S'^/^W_XW[]K/7OI^O?9C_'_;_P#&_?M9Z]]/U[[,
M?X_[?_C?OVL]>^GZYQT@$D9YX=3]?Z'WIG-.K)!0C[>E9[+>CGKWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IDW-N3";-VW
MN#=^YLA%B=N;5P>6W)N#*3(\J4U#@X)*JKJ'6-7D988(I'(5&8@652;#W[KW
M6AIF/Y[?\_7^9AN7LG<W\G[X54VW/C'LK=%=M3 ]BY'8N-WGF:R2B:-PV0S6
M[,A1[3_B4U*]-42XJ@QD\N.CJ5CGJJL&*I;W7NF2#YQ_\+*^C*>L[*[)^)T/
M:VS]M0G*9O:V6Z,V5N5):>@5I9Q]GU[EL=N653&K:OMI=8 &FQ^ONO=;3/\
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MOOWC'KW@CKWVT?\ 3_>_^*^_>,>O>".O?;1_T_WO_BOOWC'KW@CKWVT?]/\
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MO>_=>Z][]U[KWOW7NM5/^>S_ -O2?Y!7_BVF#_\ ?B=6>Y$Y._Y)^X_\T/\
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MJ839_P#*D^+&T-A]9E)J:OFQE)C\WC!3YGL7.X'.K$<SD:R:K2&#&SS&:O\
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MYRW!;6;R%+R99QKH&:)E\4!M..W]('U(KCAT2\M33[WO<T]RJ!K:(PG14J)
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M>-I7E::94D5F2AD(#J"2"=:TK3X:4] /MEC--OMU=2*X1(TBB+(P5JA*E6(
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MF-YYA303U>1J?\HK:J=ZFMJI7G8.JH<\V\WS<V21ET2*.%-$44==""N>.*D
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
M%M,'_P"_$ZL]R)R=_P D_<?^:'_6.;H'<R?[EV7_ #5_Y_BZVK/<=]#'KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND/V#V'M
MKK3;\^X=S59A@5O!144 $E15SL"5@IXR1K=K7))"HMV=E4$^]@5ZT33H%-G]
M=[C[0S='V=W-3^.G@;[G8_6<@)IL=$Y#1SUR$+YZMP%9ED2_T\H "P0V)I@=
M5I7)Z-&    + < #CZ>Z=7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT'OF5B?CIO+Y"?,U^XOYW_P#,X^4?
MR@Q.?[ RW6G1'\K?:&YTVSU[C:*3(QXO:VY,?M[%[IVT)L'D:>6CJQ'NG%UA
MCIWER'CJIFJ&]U[HY_\ +OW!\S?YI/\ PF9WYCW^1?=*?+S:S]LX3ISO+;W9
M60VGN^NR'1N2AS&W,=D-QT)3)U1RU/&,)6U$\TM354L[R5%0]0QG'NO=%0[>
M_G2=O=\?\)X?AEM#H;LW=,/\PCY9]O\ 7W\O)]Q;7W?'0;I@W'US68V/-YML
MA3RFMH\AN3#R;6\M0@BJX7W3#4PM&WBG]^Z]T"GRX^2N:R/\Q[9G\HKY%?.G
MY]='_#KX!?&#K>A[0[/^*9W9O[LOLWL:MVUMS)U^?SV6P.$W/G/M:RLW3S)7
MXVKQ\#T;A(XJG(4TD7NO=6>?R!?E_P!P0?.'Y;? )>T/ES\HOA+MK8=%W)\.
MODO\N^O=S;?W1&E$=O0Y_:V4R>Y</ALC4F.LS\Z4D<M%#$!B*J>CBBI:J*)?
M=>ZKE_EN?&OYB_S>?D;_ #5.HNU/YCOSCZ0^._Q7^:.^*_K^#JCLC(T]979S
M?F=W9C(<7%GLC)4M%@=IX/;<0CPE-(E/3OEXJA8X3*#)[KW1R?YEV ^->X?G
M_P!F;/\ E%_.L^?4]91[9V]C>A_Y?O\ +$PFY9]W;(CQ&-QWW\>['VYBM]TV
M2K,BLU'6BHR]/C,E4-6%E=J2*-(O=>Z+/_+8_FR?)[XX?R6OYPG;>Y^S.Y>Z
MMP?!SN^+J[XP[@^2=.^<WAAT[CRV/VIM^'<\&4F^]=\!F<G35U5CZNMG-):H
MQ\"_;PPTP]U[IYV;\!_EYMS^2EO[^;/0_P V/Y\R_+[L?X8]G_(_=N!RG<AW
M#U_-M[L##5N5KL+38*:%\IC,_%MZ:U#EZ/<$#XG,)#5T5' M.D ]U[IAS'\U
M[Y4?$;_A)]\-.]]J]K;_ -S?*?Y*]N]Q]"T/?6^=RU._=P8J"3L3M2MJLN<E
MFI*ZIJ:^EP.V4Q= \LCO1B:"6 K]G&H]U[HJ^?\ DM6_R\Z[XL?)/^7U\Z/Y
MO?S?[JHNQMGX;YE?'CY1]4=F9/9VY-JY/'U-5N6MPU+N79N)H\?4Q9&F2FHA
M-E\ED('KHJF&JT4]4TWNO=?1\H:R#(T5'D*4NU-74M/64[/&8F*5*!T)5@&4
ME6%P0"/H>??NO=2O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U'K*RDQ])55]?54U#04--/65M;63K30PPTRE
MY)99'*I''&BLS,S!54$D@#WL L:#)/ =:)ID]:^3_P VSY=?+KLGL#97\JCX
MB;:[JZZZVRDNW,Y\E.[]S2;4VO49 1R.JT5"*S"33TY5(WC1,J];)%-%+-1T
M<3QR22G_ %%L=@ACEWRZ:&20:EMH4US:*@9/<%/'BM,$ D@@ 3^M5UN\KQ[5
M LJ(=)N)'TQ:Z$X H6'#@:Y%0 02._P8_FD]B=T?)+>GPC^9'QWE^+?RMVSA
M'W5M_;M)N!=R8C/4%+3I4U/V-2&EC,\5.S5,34]=74U53).Z3H],Z,6<R\E1
M;;9IN6WW NK5FT,VDH\;U- P.<\,A2#3%"#TNV3F:2]N'LKN$V\ZKK"Z@ZNG
MJ&&,?(D<<U! "'YR?S)/G%LC^8?L/X"_!3JCX_=E;MW%U!3;]SE3W%1YJ<TU
M?XLWDZF*6MQNY<'18VBBPV.HG0U,;O+4U4<:N#+"K&/+/*.V7.T2;KNDL\:K
M-X:B$Q@D=@P'1RQJQX4H%)\CTAWSF&_AW%-OL(XF9HO$8RAR!\?$JRT%%&36
MI8#'0.]E?S3_ .:%\%=R]7Y_^8U\3?CGC.A>R]\8C8[=@="[MK8*C%S5(FEK
M&FBJMR;F:IG@H8I*N.%J2ECF2"6-*KR$^)=:<E;+S0DB[/<W'CQ1M)X5PBG6
M!0"A5(P,FG$FI&*=);CF;<]A:-MSA@\*1U3Q(68:":G(9F)P*^0H#FO1R/YE
M_P#,3[F^)OR(^"?QRZ%VGUENC=7RM[+_ +J[MJNQ</E<\<9CJW-;>PM%-CZ;
M%9G#'SU$N5R#M)/-)&@I /&0[,A!R=RG;[[:7UW<O(JVL6M A5=3Z)&H2RMC
ML H!4ZN(\S?F3F";:;FTMX%1C<2:6+!CI4,BX"E<]Y-2:"G#T3_SS_FN;IZN
M[EVU\,/@3UM@OE#\UMP9:.'<&UZZ.JK]N[3I846:4YZ>BKL9JK3&ZM)%_%::
M&@AU3U]1"WAIZASECDB.]MVW+=)#;6:CM84\29N%$!#8QQTFIPH/<5IOG-#V
MTRV5@@GN6R5-=$2TK5R"/V5&,DBJAK6>F6[HQW5F J_DMFNJ*KM9,?-D=[U7
M46!R>T]M4;,#(:>D7.9C,UTT5%'=)*N:JB$Y4RBFIE/C4$;A].\S?2+((JT0
M2LKR'YDHB#/&@&.%3QZ%%H)EC'U!0O\ B,:LJ?D&9CCU)SQH.'6NQUA_/D[8
M[A_F,]<=(;/ZYZMI/A)VMWQN+HSKWMO,X'-?Q_-U.VJ*GIWJ\?E$SRX4BLS.
M0Q$L,1P;.E#7TL,I6H<RK+-[[90;?L\EU))(;V*%)I(5*Z(UD; 93'JJ%5J]
MWQ*?(9CZUYXFO-S2!$06LDCQ)*0VIVC7)4A]-"Q6G:<$>?#:$]PQU)?1:_EU
M\I^L_AA\?]_?(;MB>K_NOLB@B--A\9H:NRV1R3B#'8F@61D1JNNJG1%+,$B3
M7/*RQ1.P-]BV6;F&ZCM+<#7(:5/PJHR6-*X R?/R&>B_==SBV>W>YF^%!6@X
MD\ !7S)P.J.\1_.*^<W564^.'=7S+^'?6W3WPO\ E3O# [4V/N;;^\JBKW5M
MZ/=$35%#DLZE57M%44T]$?OEC.#QTAHX)WNLQBA>1Y.0=LOEN+?;KN2:[M49
MW5HP(I0A 8)0$@@]M=3 L13%3T#%YMOK5H)KVV2*WN'5%(>LD9:I!<&@H1FE
M 5 -<T'1\/G]_,AW7\=.U^H_B3\7>I*'Y#_,GN^)\GMK8.1S1Q&*PF*3SVRV
M>FC>*012"DK'6+[FF"T]//4S5$2+$LX9Y8Y23=H);^\E-O:0X:0+J9W-.Q!Y
MG(SFE1CT/-\Y@;;Y8[2VC\:XERJ:M*JH_$Q\A@_;0],/\OG^8MW'WG\@N]?A
M+\Q>IME=-?+CH;!8?>&4QW7&8GRN!S.'RL>-E>JH5J:K(R4SP19G#3!#E*GS
M05B.N@PS*KW-7*4&V6D&Y6$CRVD[,JF10LB.I84:E :Z&R ,J?E5K8>89;ZX
MEL;M%CN(0K,$)*.K!35:Y%-0P:\1GCT W\R;^?=\?/B1B]P=<_'7*[3^0OR0
MIY)<<M%05$F;VCMZHIIO%/\ W@R6/JJ;[VJ@*3(<=05WW"RJ4JYZ+C4:\F^U
MUYS"RS70:"V.=1&F60$5&A6!P:BCL--,C5PZ+N9N?+;95:. K+/P"C*(:D=Y
M!\J&J@ZJX.FM>KT>OZS=61V'LG(;Z@Q=+O>NVCMNLWC2X2EFH:*/*U5'"^0C
MHX:B>JGAI4JVF$225,TB1A5>61@7,97 19&$==.IM-:$Z:FE: "M..!]G0ZB
M+%1JIJH*TX5IGS/^'I7>V>K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5)W\V3^1
M=\:?YO\ NCI?=7?O:G>?759T?@-Y;?VU3]09+ 8^*JBWM44%35/7?QK YEGD
MC;'0B+Q-$ &?6')4K[KW5.F1_P"$7W\LC$86HW)EOEM\P,7MVDHADJK/9'>W
M7]%114Y4,)Y*J79*P)#I(.LR!;$&]O?NO=")\._^$J_\L'K?O?I3Y/\ 0OS*
M^0O;N=^.'=?5O<>%I,9V7U[O+#RY;J_-46?Q]#E6PVU5F6EJJC'(DR1U<$S0
ME_'(C6=?=>ZV^/?NO=>]^Z]U[W[KW7O?NO=$S[.^?OQ8ZC^7'07P7WEV1%%\
MG_DGAMS[CZSZSQ.*J<U4?P[:E)75LM?EIJ>-X,-25<.+RHHI*N2(5DE%51T^
MMX7 ]U[H0?E-\LOC]\+.H,UWI\E>QL7UKUSAJJBQ:Y&LI:G+5=?D<J66BQ.(
MQ=!#4Y++Y:N=66"DI*6:>32S!-".R^Z]T67XO_S8OAE\L^W9^@>O]T=D[([M
M_NQ)O3#=6]^=([MZ S&8Q-,2M17X.FW9B,5_&(:0B\XI7DDB0B1D$8+CW7NK
M)??NO=>]^Z]U[W[KW6K_ /\ "8W_ )EW_,,_\7@W=_[@P^QQSO\ ':_\\D?^
M%N@SRUPN/^>F3_GWK: ]@?H3=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=(3?'9FQ^N*2"KWAGZ7$_=$BCI=$E943:?J8Z>!))F138
M,^C0I(U,+CWL"O6B0.FS8O<?7/8]1/1;2W)!79&GC::7&5---C:C0IL9$BJ(
MXFE1;C4T>H+<:K$CWX@CKP8'H2)ZB"EADJ*J>&FIXEURSSR+"BC^K,Q"J/\
M7/O76^O4]13U<*5%+/#4P2#5'/3RK,C _E64E2/]8^_=>Z!3?/?.T]JUYVU@
MH:O?>^I9334FTML*:R02C^S4SHKQTX7^V+/(HY,=@2+!:]5+4Z+'W[@N^=R=
M?U6[=[S8K"X/&UV/G/7VW-=888IM2&KKZA6=99(':($"22,!FD BTD&ZD XZ
MHP/GU\^G_A1/_+O[]WEWAB/F)U!L?<O9^QLSL+;NS^QL7L[#S;@R.#KMJ230
MT];+14PEJI<76T<U.IFC@9:>:&4U!1)8F.G%>MHU.J//Y?\ _*Y^8?\ ,<[I
MVEU1T-U)O1]O93<D&)WWW)EMK5E-M7:E#35,<.3R.8RTB0T8DQT3NXH$J375
M4BBGIH7E8 -].=?:=ZCZIV=TIUULWK/8V+I<;@-E[7V[M6B:&ECIY:B+;='#
M10SU31JOFJ'B@4N[7)-^??JUZ]2G0D^_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/>W,-N
M[<?5'9VWM@91L)OO/=>[TPVR<TF0DQ+4>7RF-J8,;5"JA#2TQIZQX9!*BEX]
M.M06 ]^Z]UH:_P##1/\ PKB_[V8Y#_TM_>G_ -8O?NO=>_X:)_X5Q?\ >S'(
M?^EO[T_^L7OW7NMHC^2;\<_YBOQC^*V_]A?S->\YOD!WQE_D%NK=^TMY3]J9
M/MTTVT:_;FU**@QG\2RU)1U$ AS./S\_VRQ&-/N/*&+3.%]U[JX3W[KW7O?N
MO=>]^Z]T!/R9^2O2WP^Z+[%^1_R%WOCNO>HNK<&<[NS<N05YR!++'34E'24\
M0:>MR61K9J>EHJ2%'FJJJ:*")&>11[]U[I_Z-[IV!\BNE^KN_P#JW)5>5ZR[
MCV#MCLS8F7R6-FPDU1A]X4<5?05$U)4K'44KRTLT;M'*BR1WTNJL"![KW57V
M[/Y^G\L[:&Y]U8BJ[6[)SNR]B[U_T>[V[YV7\>=];UZVQ64AFBIZF&KWYB\!
M5;;$-#/,B5-1'7R4\1N3*54L/=>ZN"P&?P>ZL'AMS[9R^-W!MS<6+H,W@<[A
MZV/(TE91Y2)9Z:JI:B)GBGIYX71XY$8JZL&4D'W[KW3M[]U[KWOW7NM5/^>S
M_P!O2?Y!7_BVF#_]^)U9[D3D[_DG[C_S0_ZQS= [F3_<NR_YJ_\ /\76U9[C
MOH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(;L+L
M+;O6NW9]P[AG8*&^WQV.I[/45E0X/CIZ>.]V=C]3^E%NS$*/>P*]:)IT$G7O
M7NXMW[B@[=[=@49T+KV3LE[O3X.G<AD=T86;(,-+$LNI&LS 2!$@V33 ZJ!7
M)Z,I[KU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KBZ"1'C8L%=61BCM$UF%C9E(93_0@@CZ@W]^Z]UI]?"S
M^3#_ #A_Y?\ 2?)KX<_&OY-?"O%_"/Y+]D[TW9F?DGV'M'=>^>Z\-0[QPD&%
M>HQ>)IQB-JS;CBI*:G0&NKJJ@6I\N1C"&5J ^Z]U:Y_(4_E[?(K^6)\%Y/BK
M\DLWTKN?=6'[BW[O;;NXNC]V9W=6/J<5O.+'3*M:<]MK;-32Y""NBK4,<5//
M"T @D$PD:2-/=>ZK9^.?_"<3=W3'\[[=GS]R>_NN*CX5;:[-[5^1/0'1V*W=
MG<AGL?OWM[%T$-?+DL)6[>3 T.,H\I+DJFGFH=Q25;#%[?253%%+!#[KW1FO
MG/\ RH?F3B?YB=+_ #8_Y5/;G1&P?D_NKK*GZ?[]ZE^3."KZO:&\<73TU#CZ
M>M:OPM)496DK:>CQ6#\D:>%I6Q=&R5D*"II:SW7NCB_RS?C;_,VZSW'W9W/_
M #+OE[M/N7?7;61B?9?Q[Z/HZF#KK8=(DYDD&'J,KCJ',U53/%'21*DB^.E1
M9P9JZ:H>I]^Z]T&'\F[^6EWK_+SW?_,3W!W3NSJ7<]'\N/E[NOO[K>+J_.YC
M-2T6&SE5E)X:;.+EL#A$ILFJ5T0>.E>L@!#Z:A@ 6]U[HA>T?Y3_ /-H^$_\
MQWYO_)C^7EW'\(<_T]_,&[$I^P>R<S\P<3O+<VZ=G29/-9K,UM/@\?MQ**FR
M28F?/5XQR5&:6&K@2BI:Z*%J;[U_=>Z3/Q>_E%[C_E_?"?\ G5[#_F;=[]=;
MY^*7RKJM\=LYOY#]4C/YO>E'B3%G#DMT[@VJ=GBAQ^?HTEQ69BI<349R%*]:
MFG5*B"&%ZCW7NJ>)>M_E#A_Y*WR2VK0_SQ_BSVO_ "N.MNEM_KT+BNO-C#8_
M96]9<=BJL8CJ_.T^[L7C,OLS&U.[),8AQJU>9R];3R-C$GHJ2>.*/W7NK6O@
MU_*8Q'\QG_A+K\-_A[VQF9NL=Z55+OWY ].[^3%KF_X)EMS;^WUG=M9.:CD\
M+55#DMM;F>"JBCFBD:EKI/#,KA']^Z]T9CJKX>?\*.>P]_\ QXV/\I/GC\5^
MG/CKT)E,6=Z[V^(N*S7]_NRJ';ZTU(M+G8,W@*; 4;Y2CIYGFGIHZ2*DGJ&E
MCQ]0ZQ"G]U[K9P]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5G_ ,X[>&\=C?RR/F%G=BTM75YZ?K"'
M;$Z4,YIY(\7OG+8W"9VI#J"0M)@\AD9WM:Z1L+K>X&/M_;Q76\VB2D!?%#9%
M060%U'^V90OY]!SFZ:2WVRX:,$MX9&#0@-16-?Z*DM^743^31LWK_97\L[XE
M4O77\.EQ^?ZTIMY;EK<?()VGW!NNHGK,]]S+J=GJ:7*25-(P9KPI3I3J$CB2
M-=^X-S+<[S=F:M1*R+7%(T[4I\M(!^=:Y)KUKD^".#;+<1\#$K'S[G[F_P"-
M$_9PX"G57-9E\5\M_P#A25L+<?5%1_$]J?";H#+[6[5W5AX3-2/DZ*DW532T
M?W:7B,T64WO2T$@8W8T-7$@(A+@:J&V+DYXYQ1KVX#1*3G16(ZJ<:4@)_P!L
MI\^@PP&Z\RJ\1J+6 K(0#34?$&FO"OZO_&2/(T)/U5B?G+\N/YP/\Q/Y'_ 7
M?G2VR]V]1;AJ.HLAGN^A6Y"BFPU)*-L428J*CP6=02UHV3)-&98X-$#D%BSR
M "2^;;-BY>V^SW5)G68>.!;Z0P8_J=VITX"<#SR/D.B2U^NW7>;RYV]HE,=(
M3X^JFD=G;I#<3"3Y8/J3TM/BEUC\DOYLWS$W/L#^9%\E)J'-_ KLVESF6^'F
M%Z]IMK4F4_A%1%2ODX:FB6BI:G&SU\"1SU<L-?5&DJT2CFIJ7(Q.$F^WMGR-
MMZ2;/;U6_A*B\:36RUJ2E,T8 \ 5&H9#,AZ5;3;7/--ZR[E-1K.4'Z94TJ2*
M4>N*J2#QJ:'!"MTF?YEN-^2_S#_GH;=Z;^(F:.'[/^/W46S]JTN\ZJJ6DH=J
MPY6BJ,SF=R/*R2^&7'Q;QI46>GADJQ5I31TX-1%"$4<GM9;!RN]QN*ZH[B9F
M"#XI=)"JF/(F%L$@4KZY9YB%UNV_)#9-I>&( L?ABU EFH>)I*O 5K0>6!S_
M )0]-D/Y</\ ,H^2?\OKY%1[?S_8?=E)CM[]3_(>JQ?VN2W3]I'/D5IGK:F6
MIK'IL[225=48'K9!3Y;'UE.SU$\PD4LY^9>;]GMMWL]2QPDQ2VX-4AR "
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M/F9^/JI&<TIRXG[PWN^O5KH4" &F&8:%-#\O"X>C XQ4"_YCOQ(^/&QOFO\
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M ,V]'CM_8]VU'JND=#A3T]/200TM)!#34M-%'!3TU/$L,<:1 *J(B@*JJ
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M^SHRFU-H;<V1AJ; ;7Q5-B<93#B*!;M(Y #2S2->2:9K#4[L6/ O8 "I->K
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M*WHGL3O#"[@S/9&Z^N,IM&#+&MKL1@*V3$:U$SXK;N.W!.^1R-EIHY*N$1S
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\
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M3@\KD,9F*P4\,XIJ6DW-O;;R3U10+'(D:.X9% +.7-DGFY0GC@ ,UU(S1J"
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MYKC XD=,\T\U)RTB=AED<G3&&T]JBK,3I:@&/+.?('H\GQ+^0%#\JOC7TO\
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MU.W,-D\<,!1;:V>^2?!;6CR]!#XX:N65,A3T[/$M+3*?=>Z:OG;\5]@?,/\
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M38P4=-3'+22U@D;/U<8JY#*U))"D5,DN3>XVVFX_>J63?O J%):2MN&"!-8
M:I.GMII&!\5:GJ/(N2[U8?W>UT/H]1("H!,5+%M!-* 5S7-22*4QU8Q\Z_Y6
MNW/D9\?/CMUM\>MU8SX_=C_#?<&V-R?&7=;X89NAQIVQ%2Q+05T9629H*E\?
MCJEZ@1S2&KI(IIHJE6ECD"/+/.C[/=3S72&XCNU=+E-15G#DDD$>8J1]A(!&
M"!%OG+2[E;Q10,(7MV1X&"A@I3 !!\L#\P":\"%GQ>_EG_)#,?*G;'SA_F3]
M^;*[\[SZPV[)MGI7875>%EQ.T=M:ONHSDU,^.PS5U<T=5-+&K8:'PU<IG::I
M>GHFIEV]<X6<=BVV;/ \,$C!II)2&FEI0A30L%4$>3&H'E5M23;.7;F2Z6^W
M*59)44K$D8(BCK4$BM"Q(/F!0GSHM#E_S,OCEW/\M_ACVU\=>A]Q[&VGOGL\
M[2Q,V<["RM?AL='B\;F*'(9.%IL;BLS5"2LI:-J<*M$0RRN&=/K[#_)N[6VQ
M;C#=W2N\<19M,8!;5H8*:,R##$'CY>?1MS+M\^ZV4MO;LJO( M7)"Z=0+#"L
M<K4<//H:?B)T=)\:/B[T!T%55M!D\GU+U-LC9.>RN*\GVM7D\-00IE*NE\T<
M4PIJK(_=2Q"2-7$;J'&H'V7;[N7[XO9[H @2RR2 'B%9B0#3S H.EVU67[MM
MHK>M?#C1"1P)50"?S.>C%^RGI?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG]V;6P.^=J[FV3NFA
M_BFV-X;?S.UMQXS[J:B^XH-P4TE)60>:GDAJ(?-3S2)KBE21+ZD=6 (]U[JB
M'_H%Q_D4?]X,_P#LS/<7_P!L'W[KW7O^@7'^11_W@S_[,SW%_P#;!]^Z]U9_
M\*O@5\3OY=O5F?Z4^'75/^A_K+='8&5[2SNVO[\[E[ \^=S>.Q6)JJ[[W=.8
MS>0B\N/PF+B\,=6E.OAUI$LDDKR>Z]T;_P!^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\ %M,'_P"_$ZL]R)R=_P D
M_<?^:'_6.;H'<R?[EV7_ #5_Y_BZVK/<=]#'KWOW7NO>_=>Z][]U[KWOW7NB
MO=O5];V9O+$=$[>J98:!Q3;@[1R=*UC38^G:.2&B#<@351,;6_&J$D,AD NN
M,]4;..C*X^@HL504>,QU-%1X_'TL%%14D"Z$BBIE"1HH_"JH 'NG5^IGOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NM7[_A2-G<[V'+_ "_?A_LB''93>_=_R+&=PN'SC-_#7KL<:#:^%3)J
MBO(::LJ]VU*$I&Y$4=1<7*!IH]GXEM?K]PD)"06Q5BOQT:LA*^50(?,C)'49
M>X\AG^CLT +RW *AO@JM$ ;SH3+Y#A7H%/YGV(R'\ISJ2FS/67R+[>W9\S/G
MUEDV)VE\H.T]R/7UF+VYUU-_$MPS;:H\7C&.W*-Z[<6+IXH*.&>6AH0%QR+4
MQQRA=R33GNXTSV\2VEBIDCMH5H&DD 5 Y9P78B,DEF[F'<=)(Z3\TO\ U4@U
M13.;FZ8(\\K%BJ(2S%0JD*H+THJX![14#H@'<'>/P%^)6:^-/R _EE?,#OON
M3Y68/MG9F-^0F-SU!OJD_P!(&"FI*A\G4Y2#<F QM#4M45M-!0Q4$58[>/):
MDB>6F6JA%FW[/NN^)<VF]6MO#;&&0VY'@4MI*C2%,3L0 "6+$?AR:$@AV[W3
M;]K>"XVNXGEG\5!.#XQ,\="#J$B@$XHH'#5@8!%L7\]&H[TP?R-Z W=VWU_W
MYVK_ "O,#L#+MWKL+X^[DK]LM59B<9L5LFYZC'RP^.C@I_X%+"U;-#2/3Q5M
M-#4TL]1-+[ GMHMK+:3QP201;FTB_3R7"JP"@I3P]0;N)U# +5*FA Z%O.[7
M$=Q$\J2R6(1O'2$L&+4>NO25[0-)R0,,"14=&7_DS-\.4P'?':?PV^4/?.YN
MB:2FQ$><^+'=,S2Q]<24]''4P30_>?=U1,T-+DD2HH\E+0SPWII7J:G'"5"7
MW"&XJ\,.Y6T"3]Q%S" #< L1G11>-,%0PXX#=&O*#6;I))8S2M%VCP9"2(2%
M&!K!:E/1BOD.'55/\H'X*;2_F7X[YU?)#OK>_;6+ZH[G^0>YJ&JZKZ^WU4;&
MI<KG:UI=SS9+<+T9/\7?"P;JA3'4\XDI8I*JME>.4R@ =>X/,DO)S6-E;)$9
M8+=#XSH)"JC].B!A1=1BJS :C1144R$>3MFCYD%W=3-)X<T[CPE8I4GOJY4@
MM024"DZ15C0UPI/@[\V.Y?A-\$_YM.*&[-P]G;=^&'<.'ZO^,.\-Y5S[F R.
M_LUDMHPP10SS"*+%8F2BQ&8>DCE6G_RJI$4>J4K(QS'RW;<R[GM1"I$U[#XM
MRB#11402DX![F!9 2*U45/3VS;Y/LEC?ZBTBVLIC@=SJ))8Q@'(PITL<\&-!
MY=*:'^6!MS<O\KS<O\QOO?O_ +\W#\V,C\<]S?+G9_<G^E6OHWPS9##2[FP6
M!H8M9T09"C:GIZA@ZRK-6S"D:GC2&-&3SBT&]KL]M!;K9"Y2T>#PE(DI((F=
MB14D'N'E@:JFI+G]7!-M1W*>:9KKP&N$E\1@4JGB!5 - *8/VFE, "!WK\WN
MS^S?^$V=#VYVCF&K.V.XX*3H"JW16)XY,TN(WO5X>LKG "":LK]MX'(?<NMP
M]4*B6P%T";;.68+'G'Z6$?I1-XX4?@_1$JCSP'< ?*G3U]OLMWRT;B0CQ)%\
M(D_B_5,9/EDJ"<>?12OF/\#(?C/_ "<^AOD+VWW)W36_*';$?1IZEP\6]I=L
MX'9O]\I%KAMK#8+'M'1T]9C,1+D)JO)*[Y"JRD=15&I$,GA4[Y=YF&]<Q36M
MO#"+60S^*3&'>8*#WL[@M1F"T3"*I TUR2W>MD;:]ECGFEE^HC$/AT<HL52!
MI54(6JJ2"^6)J:TP+!_YKM-\\6^(?\O3(XRC[J[,ZOPFWNN\I_,"Q70>6K<!
MNO/RT^+VR:Q99\4)ZR''5Y_O-KD2.:EIZN6GGJT=8H&4)\BMM1OKX.88Y&\0
M6!N K0QU,E*ZQ0L.RE<D @9-.A#S6-P%K:E/$= 4-V(=2RN $K32:@'NK0X)
M%< GK)_)B/P#WWWEN3>_P([Z^2?5N)P_72/V!\#NTLB^5Q:K7SSPR9^*>NJ,
MQ%6105\]$T<M!E#4TLMQ5ND&2^U._<1=VM(%CW6"WD9I#HO8U <T [.P)3%<
M.N1PRM>M<FOM]Q(7VZ69%5!KM7)*K4GN[]6:^:M]O'JKZ+YJ_"G^81\F?DMO
MS^9]\J^Q=B?'+ YU=J?%/XY[&I=[2XJ7&4U34A<_D!M?;V0IVK(X*:AGUU,@
MJ:BKJYM2QT='2P$;_P!6-SY5LK:/9;5&N677=7#^!K#$#L7QI 0,D&@I0#-2
MW05._P!AOUS.VYSL( VB"!/%T%0?C;PDS6@(J2:DXH%ZMW_X3T_(3/\ 9&UO
MF3T72]E;X[IZ4^.?=M#0_'3M7?JUDE9D-H[UGST6-I_)7T])61A*7 TU<:2:
MEADH_P")>+PP)H@B 7NOLZ6,EI<F..&:X@K<0QTHLR!-1HI(H2^D$$AM!-2:
MDBSV_P!S:\CN(=<DL<,Q$,KUJT3:M(J0#4!:D$5&H# H!L9>XDZD/KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B
M\&[O_<&'V..=_CM?^>2/_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWO
MW7NO>_=>Z*7N:KF^06_/[A8B6;_11L;(156_,O QCCRE?2/>+&02*09(8V4Z
MV4@<-(#=:9GN.W[>J'N/RZ-=3T\%)3P4E+#%34M-#%3TU/!&(DCCA4*B(J@!
M550  !8 6'NG5^LWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZI%^:/\ (D^-WR]^6%-\W-M=^?+WX:_)BNVI2;(WYVG\
M,>WZ?IW*;EQV.IJ6@IAE:Q\1D:G[N#&T5+1":":)9:6"GAJHJA::G\7NO=")
M\*/Y*_Q,_E__ "I[6^67QSW=\@\;NKNOK>CZ^[*Z_P![]F4_8>W<I40U&-K:
MC<]7-E<14;LJMU9')8^:LJZR?=,L4M3D,@XIE6=$B]U[KW>?\D_X8?(7^8_T
MW_,_["7L>3OCI>BV2N)V1CLE@1LO,9'KALB^"SN>QM7MRLS-5FL4];1M3S4^
MX*6.-L7C&$-X)?/[KW1H/GM_+[^,/\R?H;(?'GY3[*GW1LZ3*TNY-M9W!U_\
M"SNWLO0))%!E\#DQ',:*M2&:>)P\,U/402205,$\+M&?=>ZKY^(W_"?_ .,'
MQE^1FS/E9V'W]\Q/FMW7U5COX=TON'YB]SKVG!L\.DZ//@Z:+&X_14%9W\9G
MEGBIV"RTT,,X\I]U[HY^1_EI=%9/^9)@?YHT^[.VD[_V[T=-T#1;0ASN'79S
M8:<UI-3+CVP+9ILG_ETUI%W L'"?Y/PVKW7N@5_F,_R9?C=_,;[/Z9[_ -S]
MD?(#XW_);H:BEP?7WR*^+>_J?K;=D.)>6LJ$Q4N1GQV1;[6EJ\A7U%*\ @J:
M:6IJA'.(JJHBE]U[H/OCQ_(7^)GQG^8/4GSJV)W'\P-P_([KK8>=V-OW>G:?
M=M/VI+V6VXZ"NQM5F.PJK.X.NRN0RQI*NF2(XO)XFD@7'8Y(:1$IRLGNO=:L
MORYD_D\X+^8W\IMW_P T3X7?./\ EL[T.]^P,;GZCH3M#-;BZX^0^.W3(AJ,
MCD$P>U*"JQJ[F@AARM5287<%/25%343OE:^HR J+>Z]U;!_PE?\ B9O/8"_S
M0/E)G.A-T_'SX^_-/Y!X%_C;TMV7L7^Y-?3;+Z_R._*RE$F(E+PQXI:/>E)C
M840-3LV/J1#)-3F-S[KW1F=[_P#"6WX,Y[<N_*+KOO[YQ_'_ ..O:N\!O;LO
MX;=)]^1[7ZRRU7/+#)5PR8.HQ%;,E%5Q4U+!XC5NU-!#'%124T<5.L'NO=;!
M'2?2_67QUZEZ^Z,Z:VGC]C=6]6[7QFSMC[4Q>MH:.@Q*:(TURL\TTKG4\LLD
MCRS2N\LKM([,?=>Z%'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_ #V?
M^WI/\@K_ ,6TP?\ [\3JSW(G)W_)/W'_ )H?]8YN@=S)_N79?\U?^?XNMJSW
M'?0QZ][]U[KWOW7NO>_=>Z0O96^L?UQLS-;LKPLAH*?1CZ,MI-15U'HIX%MS
M^Y(1J(!*H&?Z*?>P*]:)ITB^B]B9#:NV:K/[GUS;\WY6-N;=E3.+2(]7=X*,
MW_2M*CFZ?19'D4'2%MMC7K2BG0W>Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH'Y ? 3NWO3^:M\3
M_F1D-U=7Q_&_XU;"K<<FQZS(Y&3<TV?J(]R3"OIJ,81\8837U^!)>3.*R1T+
M/'")3^X/=KYGMMMV.ZV\))]1<R*=8"^&(U,>"==:X?@OXLGT"=_L4][NMO>%
MD\&!&&@UUF1@X)';2F5XM^' Z%C^95_+ZB^>?7W68VKV1-TSWKT'V%1=H](=
MJ18--P)09&E,+S4E73,\4IHZN6DH9B\4H>&II*6<QU$<3TTR'D_FK^K$LFN/
MQH9XVBFB+%=2GS!%:$5(R.!88)J%?,>P_OV- K^%+%(LL4@4-I9?4&E0?MX@
M'(%"#_2/QB_FI;I[IV%V#\R_FMUWC>N>KZBL>EZC^)V KMO4^\=8A\<F[*[)
MX['/"DCQ S4]-3SJJ:THYJ5IGE"S<]VV2&W>+;[24R2 5ENG#&'C41JAH?DS
M'[0:=)[&PW-YEDO+B,(A-(X$($E:4+E\C_2K_O76#NCX@_S(ME?)+LSY"_"K
MYC;3S.W>U<91TN4^-WS&J-R[QVCA)XW4RR[:J,:]?/B*8,9I8::FQ\"*TLD,
MS3PF+P7V[?=HN;2.TW*T<&(DBYM/#29P?)PX ?TJ36@%*&NJE[M6XPW$EQ97
M"D2 #P+C6T2D>:%35<>0%":UKC24+-?#RK_E7?R]/YGGR([ [3P^^?D;\F]H
M[LK][[QVEMT;*PF/R?8M1D,5AZ' XXLRQ+'G-WU,P?Q0JQ>"%*>..G4,?1[_
M /UXW7;;..(I;V[(J1LVMRB:6<NU!6J1"OI0FM2>BE]I_JK87MTT@,TRN[.!
MH4.VH(%4DTHTF/4FGIT6;^7%\!_YF/7/P<ZXSWPQ^5?477&T?ESM.E['[0VM
MVWL^KEKML5&YVJ*.'/[,KZ#'Y,S9&KVM%@]4-8D,?W$(DCGC_;:,ZYPYIV>_
MW25=QMI7:U8Q1-#( )0A!T2AB*+KU]RYH:4-.BOEK8=QLK",V4\:BX59)!(A
M)C+CXHR*U.G3VL*$BM16G5LG4O\ )SZ)Z\_EV=A? ;,[BS&Y1W$DNYNTNWEH
MUI,A6;M$M%5T6<I*1Y9EIZ?$5>,QOVM&U0X>" I42RRU%3-(!K_W NKO=TW5
M55#%18HJU58@""A.*Z@S:CC)-    *K3E&"WVYMO8EA)4R28#-(2#J\^! H#
M7@*DY))*G\JO^:/O[HW:WP4[A^;O2=#\)]GP[8VU_&>M=D9&'?V:VSM.2!J/
M;U?%44%)C:.CIX8DCB*Y>K-H*?[O[V,20L(SSOLMK=-NEO9S&\<N^F613;QR
MM6KK2K,234@A:5.G2:$$PY7W.>W%A-<QBV4*NJ-")GC7\!KVJ*8!!:H U5R"
M9+^8C_*DW1\D_CC\.?B!\<<AUSU_T#\?NQ-O9K>N-W[N;,4=?+A]M8]\3"N,
M>@PV5^_RTU)DLU+-+55%('J)$<RGRR-&3\I<\+LMY=[A=>(\\\3JA14*^([!
MZM5EHM57 !QY8Z,>8N5CNEM;V<&A8HI$+!F8'PT4K0$*Q+48Y)&?/H3/YK7\
MOOM3Y\;8^+/5'7^7ZPV]U%UGW;B>P^XL?O7.Y;#5E3B<+3IC8:/ PX[#96GJ
M:DXRNS2VJJBD1'-.JRE9)6C1\C\TP\K/<SR"0RR6[10E%4@.QU58LZD ,J\
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ME#M=C')':P,7!F8/+(Q+T+:11::V[02,^@'3&R<NR6=U+?W3H]Q,H4B-2L:
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M8>CB-!425$Z4UZ?(4,D:OY7$>[[DR\L[:UNTT31W9"Q>#XC$.:41@T:T<FH
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MFE@_@-=D\=2T,%=-*E=424RPX^D:.2BR,%3#YT/MKGGEVQL[*VO]O,L4=R[
M6TQ-5X]P!+4&!6K'XE()!PYRKO-W<W,]G>".22!5K/%32U:=IPN<G@H&&! H
M*E7_ )(_RNZ)ZM^/G\QOY[?('?VS-C[F[2^2^Y]X[QP59N.F?,5,='0ON*AH
ML?22O'6Y&>ORFZLM342QPEJFH215 *OI/O<K8[J[O-OVJU5Y!%:HB$*=-=1C
M9CQ"@+$I8DT XFG1/R/NL$%M>;A.RQZ[AW>I%:4#@>1.9"% %2> KT7[^7]V
MAD\)_+A_G;?S$<KX=K[U^06\]_;=Q]?/5>1:/*[NIZN:F6DJ)@B3RIF^R($C
M/@7S3Q0JRN;1J:\VV(EWC9]G'ZB01Q5 &656 :H%2.RWJ<X%3\^D'+MYX>V[
MEN?P/,\I4DX!()4"HH>^:@QDX^75GW\I?X[YWXV?R:,]V1U/M.A;Y,=V]*]R
M]W8S(4CM-59'+5^/RO\ <.C6I;3+% N.IL&5IXV2**JGJ9%!DEDED!7/V[IO
M7,/A3N?IX9HH#@=J*RB4T'$ZBYJ<D4'   3\G;<VV;.'B4&:2-YN)[F8$Q@D
M\.T*"!@&ISQ-27\IWL[Y8]-?!OLO?G2G:7\IC;75^=WIO;<O=]5\M]V=AG?0
MJH((Z)H,Y38)S3RT=100QR8VGIHY34+52,JO6U%0I'W/MIMM_NB0W4>Z-*J1
MI"+5+?P=/$:-8K@DAB>!%/A Z"/*-Q?VU@TMN]@(R[O*;AIO%U<#KTF@P 0!
MQ!!XD]7T?R(_CQN/XX?!.FV[F.WNMNZ\'OGMC>?96P-W]2U.8KL$F&S5'B*
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z)'\R?@=U)\X\G\9)^Y,YO<;;^,7R(V?\
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M[O7/5U539?>KHVN.ORI#?;XYB."D'K$BW_$ZM9A&1<=HZH>XTZ-4 % 50
M  +  ?@>Z=7Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW17ODQ\*_BQ\Q<1B\+\E.E-G]J0X..KAP.4RJ5.(RN/CR!0U$6/S6,J*',
M4,4[1QM(D%=&DC(C.I9%(.MFYBON7V+V<SQ$TU!2"K4K34K JU*FE0>)Z+-R
MV>UWA0MS$L@%0"1W+7C1A1A6@X$<!TF^O_@#\0NINE-Y_'KJWIC%];]6]BXU
M,1OR@V)N7.;2R^8ITC\/CR6Z:#*0;IJ[PEXF:3-,S1231,QCFE5W+OF>_O[E
M;N>4R2H:H9%1U4UKA&4H!7- M/EU6VV2ULH#;PQB-&%&"%E9L4RRD,33SU5^
M?47:?\O+X9['^-.[/A_MCHK;V-^.^^IJ^JWAL!\WF<@^1GR,\52U74YJJR4V
MX)*V&:GIC3U/\5\]((($I9(4@B5+W'->X75ZNX23,;A*:9*(-.D4 "A0E*<1
MIH:FH-3U2'8+.WM39)&!"U=258UU&I[B2U?0UJ,4I0=4N_S5OA3F\LW\KKX&
M_&7X_P#;&<^+N [[FSW9%?BZ'=?:F'VKAY\MBJ)%R^X<I+F'H:&*@S>YI52M
MRBI3TT2PTR+ J1I(?)',2I^\]TO)XEN6MRL8/A1/+(58U5$"5;5&E2JY)JQK
M4] [FC9B_P!!86T+M )PSGOD6-%(%&9BV*.U 3@"@QCJW&E_E7_R]:/N]OD5
M3?%3K-.V6RO\?7,-#72XU,C]R*T9*+;;UC;9BR2U:B9:M,.M0LGK64$D^P(>
M==U:U^C-S+X-*::C5IIITZZ:]-,:=6FGET+!RSMXN/JO C\3CJIBM=6K373J
MKG535\^C6=S=(=1?(?863ZO[OZ\VOV=L',2TU36[9W9C5R,'FHB6@J82;2TU
M5 23'/#)'-'<Z'%S<CL-QGVJ436TC1N*T9"0:'B,>1\QP/1I=V<5\ABF170\
M58 @TSY^GET7GXR?RX_A)\.<S5[E^.?Q\VCU]NJLI:NAEW?/D,KO;,I3Y#Q^
M>F@R^X<AELE2TLWBCUPPU4<3:1J0^S;>N;MRYB 6\G>100=':B5%:'2@5:Y.
M:5Z+MKY>LMF-;:%4.1JRST.::F+-3'"M.IOR8_EY_"[YAUT.9^1OQ\V5V)N.
MGH*/%1;P\E=M'."DQ\IF@I#G<%68S,-2PR-(4A:M,:B250NF60-79>:]QY>Q
M9SO&M2=&&CJ10G0X9:T\Z5P/0=6W/E^RWG-S"CF@&K*O0&M-2D-2OE7S/J>A
M0^/?Q:^/7Q2VK7;*^.W4FT.J-NY6MAR68I=LT++-75%-&(8YJ^MG>>NKY8HA
MI1JBID* MI(U-=#NF\W6]R"6[E>5@* N:T%:T X ?( =*[';8-L31;QK&I-2
M% %3PJ?4_,]%WPW\JG^7GM_M;/\ =F'^*_75%V3N2>OK*[-K)DI:>"IR>LS5
MF+Q,E>^'PM>6D=UJL?04M1&Y\D<J. P-9>=-UFMUM6N9#$M %J,@4H&--3+C
MX6)'RZ01\M6$4YN%@02'):GF:Y K0$U-2 "?7I04O\MKX5T/Q=R7PPH^EDI?
MC5F-Q1[LRW6]/V%NN$U.0BKX,FM3/F5SHW!*5K:6FD"ME3&!%''I\2*@H>;]
MQ:^&Y&;_ !D#2)/#BP-)2FG1H^$D?#\^.>MCERR%H;$1_H$U*:WR=6OXM6KB
M*\?EPZ-KU[L':/56PME=8[ PT.W-B]=[4V]L?9N @J)ZQ*+%[5I(J&@I5FJ9
M9JF;P4L$2>2::25[:Y)'<LQ(KJZDO97FE.IY&9W8T[F8EB<4&2?+HV@@2V18
MXQI5%"J!P"J* ?D!T1;?G\H_^6_V9V@_<6\_B5UIDM^5&4K,WD:NC?)[?QU=
M69%F>HJLG@,=D*3 92>HE=Y)7J\9,TDK-*Y:1BQ$MKSWN]E!]-%=2B.@4"H+
M*%X!68%U X45AC'#HCN.5-NNI?'DMXR]22:4#%N)900K$\:L#G/'JP?#X?$;
M=Q.,P&W\5C<'@L+04F*PV%P]#%C*2DI<?&L4%-2TT"I#3T\$2*D<:(J(H"J
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MW/[=_BF6P?\ 'L+E<+_&L#/'2UU'_%()(/NJ*6:*>*.KI_)Y(6>"1%D52R.
M5/NO=$=^+?QS^,7\H[X04'6&-WP=J=$]"83>^^]_]Q=NYNECKJM\UD*W-YG<
M&Y<HD-+#4UL]15R#4L* (L-+31)&D,*^Z]UK*=!;IWYUQ_)2_G[?.CJG:.Y.
MC.F_F7W1\K>\OB'MR*HR&U*ZGVSV71T>UDWOCUGBAK<2^=DE>MI$A$20"FA%
M"8:5:60>Z]ULW_!SXH=6=3_RX/CA\3*K9>'K^NZ7XO;"V'OK;&4Q])/#EY=R
M[?IQN.;)1TZ_:U-1F*ZJKIJIU!6269W!((/OW7NB+_\ "<?+[RI_Y:>)Z>WI
MF<ON"?XM?(OY-_%[;F5S]3'5UK87J#=V0I<53U#PJL=\?2S)21JA9$@@B2,B
M-45?=>ZO@]^Z]T!7?OR<^/WQ9VQB-Z?(KMS9/3FT\_GH]KX;<&^LNF%I:G(R
MT]15K1Q2N-+5#4U+4R!?J4C<_P!D^U5I8S7[%($9V J0@+$"H%<>61TQ<7,=
MJ-4K*@)I5B *\:9^SK4[_FK?+SXQ_*_^:#_(TJOC=W?U[W13;'^76RJ?=TVP
M<['FUQS[@[#ZU:B6J*?YMJE:.J,=_P!0B?\ I[D?EK;KC;]OW#QXWCU0'3K4
MK6D<U:5]*CH&;W>17=W9^$ZO245TL#2KQTK3[.MSGW%W0ZZ][]U[KWOW7NBM
MJK=M]]O(X\VR>D1XXA?7%4[@KK%C_1OL= _VJ.6$?V9O=_A'V]4^(_9T:3W3
MJ_39F\11;@PV6P.21I,?FL;6XJNC1M),60C:*0*;&S:'-C;@\^_#'7CGJJS=
M?Q/[:PF9GH\%AXMU8EIW&/RU#D*6CU1D^CSPU$\3PR:2-0]2 WTNP%_;VL=,
MZ#T<;XV]&5W5&/RN8W++2R;JS\5/324U))YTHZ:G)?P^46$DLLA5I"MT&A I
M:Q8T9J]75:=&@]TZOU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5$?SD?YIF
MUOY7/QUVUNNDI-I[B[\[WWG!U'\=-H;XW-3;/P;9K(+&*C/[ER=5/3PX[:FV
MTJ*>HR=2\\4:^6G@>>F6H^XB]U[JM?\ EX=I?RH/C=O;=GS$^67\VSX;?*O^
M8[W7A:>B[3[]W+\C]J28_;&.G"RML;K?&MD(X=N;0H)BZJ(H8ZBL-WF\<)CI
M8?=>Z&C^9)V1M_XM_P S'^5-_,XW3G**#X<9C8O=GQ-[Q[G@FJZS"[9IN_**
MCRNP,_DZJCAEI*7;^4ST<,,V0JIDHZ=#'-(Z?MN/=>Z37\Y'O?J[YL[L^ O\
MMWXO=B[)[O[<[J^9O17>?:='U=NB/?,&T^K.@LA+F]P[ISE9A&KZ3%Q/5Q8^
M"A6M>-:R7RK &DB4CW7NMESW[KW7O?NO=5P=G_RB/Y;?<_8.[^U>T?B7USO/
ML/?N<K-R;OW5EJO+_<UU=D#JFJ)O%DHX@[FW"1JH%@  +>SBWY@O;5!''-(J
MJ*!0U !T7R[5;3L7>)&8\25!)ZJ,_P"$NN(QNW^I/GO@<-21T&(PGS.W!B,5
M0Q%F2&FQN,IX8(E+%F*QQ(JB[$V'))]B/GMS+);,QJ3:QDGU)+$]$_*Z"-)U
M44 N) !Z !1UM)>P)T*.O>_=>Z"WN'L).M]D9'-4ZBHSU:R8;:V/">9Y\AD+
MI %C^LBQ<RNHY*H5'J8 [45ZJQH.L?3/7[==['H<97.U1N/*2R9_=E;)()GE
MR.3"M/>3^V(;+&&OZ@FOZL??F->O**#H5O>NK=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG-X[
MNVUU_M'=6_=YYFAV[L_9.W,YN[=>X,I.*:FH,;MNEEK:ZLJ)&LL<%+2PRR2,
M3944D\#W[KW6E7M[YV?#+^=-VY/W#_,+^=7QV^./\N7J?LJ>7X]_R[]V_(/
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MAQ.X:27/Y.HI&<M3P1TU;%2$K2EZVD@1GE&^YTVW>Y1>M?[C:]J>)91-)1F
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M^\=SWRRRS1P>&0.WPG8EC_I@!7.10=>V/:)C.+B:TM+95':D:1O-KJ1J\15
M44\A4^M.K[_<9=#?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\
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M*G/'K9?_ .'5OY:/_>>GQ+_]'QMS_P"N'L'?U>O_ /E'G_YQ/_FZ$7[WM/\
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M]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]7K__ )1Y_P#G$_\
MFZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_^N'OW]7K_P#Y1Y_^
M<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\ KA[]_5Z__P"4>?\
MYQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\ T?&W/_KA[]_5Z_\
M^4>?_G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_]YZ?$O_T?&W/_ *X>_?U>O_\
ME'G_ .<3_P";KW[WM/\ ?T7_ #D7_/U[_AU;^6C_ -YZ?$O_ -'QMS_ZX>_?
MU>O_ /E'G_YQ/_FZ]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]
M7K__ )1Y_P#G$_\ FZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_
M^N'OW]7K_P#Y1Y_^<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\
MKA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\
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M_1\;<_\ KA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\
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M /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J]?\
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M -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\
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M>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\
MS=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]</?OZO7_ /RCS_\
M.)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\
M\XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE_P#H^-N?_7#W[^KU_P#\
MH\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\
MRCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J
M]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^
MKU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]
M</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\
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M1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\
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MY^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\
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M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
M5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?
M_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_
M /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UX
MW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-
MT_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^
M_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_O
MW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__
M &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\
M]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?2%
M[1_X3W?R@MN=9]B[APWQ%^SS&"V)N[,XJK_T^=GU'BJ<7CZB>"3QR[U>)]$J
M*VET96M9E()'N\?.^Z,P!FXD?Z'%Z_\ -/JK<KV !_2_XW)_T'U4I_(3_E$_
MR\OFE\"*3NGY+_'S_25V9+W%V/M5]R_Z6-\;.O08%<>:2#[/ ;EQ6/'B,\OK
M^U\C:O6[6%A)S?S1?;7?-#!+I0*A T1MDK4Y9"?Y]$W+VQ6E]:K)*FIB6J=3
MC@Q' ,!U=+_T#J_R</\ O#W_ -F"[3_^S?V&/Z\;I_O_ /ZIP_\ 6OH[_JM8
M?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[
MZ_XW)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_
MOK_C<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK
M_C<G_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^
MO^-R?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^
M-R?]!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_
MXW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW
M)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C
M<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G
M_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R
M?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]
M!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_
MT'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'
MU[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0
M?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7
MO^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]
M>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]!]>_
MZ!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_T'U[
M_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'U[_H
M'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0?7O^
M@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7O^@=
M7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]$C_F
M2_R-/Y6G07P,^5W='4OQ>_NGV7UKTON[=FR=R?Z;.Q<[]ED,7"&@J/L\GNZL
MQ]3H;G1/2RQM_:0^S39><-QN[R&*2:JO*BL/#B%06 (J$!_9TAW+ERRM[>61
M(Z,L;$'7(:$*2.+$=)C^59_)$_E@?)'^7O\ %OO'NGXR?WS[1[&Z^J,YO+='
M^FCL+;OWE4F4R%.)?LL3NRAQU/:&")=,%)$GIOIU$DWW[F_<;*\FBBEHB2,%
M'AQ&@'S*$_M/6MKY<L[FVCD>.K,BDG6XJ2/DP'5@?_0.K_)P_P"\/?\ V8+M
M/_[-_91_7C=/]_\ _5.'_K7TO_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O
M^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_
M *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\
M0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T
M'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-
MR?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_X
MW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z
M_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?
M[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM
M8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_
MJM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]
M>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_Z
MU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_
M *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U
M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
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M_9O[I_7C=/\ ?_\ U3A_ZU]6_JM8?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\
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ML,T(_"1ZGK3Z_FQ?RLO@A\9OGM_*)Z5Z0Z+.R>LOE'\AL3L3O;;([/WEN/\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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M>?V=!JYV:VCW.*W"?IM&69=3Y-)#QU5_"//K8!_Z!U?Y.'_>'O\ [,%VG_\
M9O[!G]>-T_W_ /\ 5.'_ *U]"7^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I
M_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\
M[,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^
MS!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>
M'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]
MX>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y
M.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_
MDX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z
M!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\
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MU[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\
MK7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.
M'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4
MX?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__
M /5.'_K7U[^JUA_OK_C<G_0?5#^ _E1? 2M_G^;V^$U3T+Y?C'B/BO2=D8[K
M/_2EO1/'FI:'$3-6_P 97<8W ]Y*J<^%LLT'JMXK*H J;F:^&SBZ\7]4W&C5
MHC^'232FC3Y<:5^?1$-BM3N)@T=G@:].I_BU 5KJKP^=.KX/^@=7^3A_WA[_
M .S!=I__ &;^PK_7C=/]_P#_ %3A_P"M?1[_ %6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MW3@[I$CR2.L<<:L\DCL$5507))/  '))]^Z]TF?[[[+_ .>OVO\ ^?\ I/\
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MZ]U[W[KW7O?NO=5R_P PC<G\Q>IQ77'3/\NSKWJ^FWAW"F\Z3L3Y5]S;E6/
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MI0[I6CP6YL3%4U-528*NSV.D2!\;1QTD/AE^YD299:1*3W7NDU_+M^)?2/\
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HC_\RSY)[@^'WP!^7WR8V?\
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MZVFQ\6XJS"8_(8W(;<EEJRD$<F3QF1J31NT\"C(0TBRSI3M/J]U[JD#XY?\
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M7>_16Z\5F,^:M9:W#;WV=0YM:_:^3HI8*7+;=R.$DI:P179V2:54]U[HQ_\
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MXZHZ ZQW'W;VWA=_['W/U/E,3LS:?W/W^[QB-TX3#93(;7A^TG*Y6BHZF@F
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M@M[]U[JLC8'\T3+=V]%?/GNSK#M7XH;?V-\<?G'U?\;^E.W]_P",W/D=I9#
M;HH^H9Z^/<:X;)2Y:;=-9E-\Y_"T!I(:.&ERO\,AKZ!A35PG]U[H[M=_,>^$
MV,[@BZ*R/?VVJ'L*H[&I>G8/N\+F:? OO"MJ110[17=[8T;1;=4M<PI5PXSG
M\1-5_DPIO/\ M^_=>Z<.^?YA/PT^,F])>O.\.^-L;)WC0;=Q^\=R848S*[E;
M 87+23Q4V;W1-B,?D*;:F$G>FJ1'D,Q-0T;"*5A.5C<CW7ND*OSGZNZ\W+\S
MMX=[_([XQ8'X[_';<_QPQN/W-@*O+XZNVI3=[[>V[442=AY:NEGP$\N?S.?H
M:G#5.*,=*F(KJ+[ZTRR5#^Z]T'G;_P#-&Z%K?BK\YNU_BKV5L[L7N?XG?$CN
MKY(8O8.^=J[AVU'5)L?;6<RF!R\N+R4.W<IG-FY3*8@TXR>*J?LJM5EBI<BL
MMG7W7NGAOGMMGKK?6/ROR'[Q^-/6/4"?"[XX][[LV]7TVX,5NW#Y_O;>,^TZ
M3,5M;-/5;>BV'E\G/CL5C8R/XE%E(JMZF>2D9&A]U[H>_C]\[/B5\I=X[JZ]
MZ'[JV]OO?.S,#C=W9O::XW)[:KVPF:E\%'G\?39BAQ\N7V[5SVCARM M3CI9
M"$2I9B ?=>Z#O!_S1/@5N7MC;72V#^1>VLAO/>N]9>L]D9./;F?CVOG-S4]3
M6T<FV<)OE\2NR<QN2*LQU9 ^*H]PSUZ31&-J<.5#>Z]TRY#^;7_+>Q7;[]"Y
M'Y=]44O;4/:==T=5;0DJZTO3[SQV?_NS+M6KJQ1G'TFX/XSJC2@FJXZF6!):
MV*-Z&*2I3W7NCHR]L=>0]K4?1[[HH?\ 2O7[ KNTJ?94<,\M5_=_'9"'%2Y6
M1DB:"&F_B-1%3IY)E:20L(U?0Y7W7NJU/D_\D/G#/_,'ZO\ A'\1<[\4]C4>
MY?AMV9\J=U;V^1W4&[^VI3+L'>VV-HIBL?!MC?\ LE*>.=-RQSM),*@@P,HL
M)!I]U[K+\9/F1\F*#YK=N_ SYHTGQWSF^=B?&#;/RWV[WO\ &K&;@V3MD[=S
M.XZ_;=7A]TX+<V8W)5;7SE+/2Q5=*TFY:B')4/W-33J@HZI(?=>Z,MT3_,2^
M%_R8W\>LNDN^-N;UWG58O*Y_;&/.%S&VZ?<N-P2TCUV6V9DLOC:#&;XP]"M=
M2?<5^WZS)4<!E599T-P/=>Z$.+Y>_&N;HK</R83MS;0Z-VGF-R[=W-O^6.K@
M@H<EL[/3;7R>-J:5Z9<A%D:3<4$N/:E:D$YJ@(TC8NFKW7N@7Z^^:FPMN=2?
M(#N;Y'=]?'6BV#U1\J.YND:+=_74.>P5)CXMJ[D.#P>TLU39QJBMR/8]+4/#
MC<E3XJ.2GK<K>/%TPUB!?=>Z46Q?YBOPN[&VK@MX[9[VP*8O/=P]?_'],;NC
M;^;V%F<?O3M:..7;.V\_MW.XS&Y_;.4SR30?8Q9?&47W+30)$6>>)7]U[H35
M^6OQM?=OR.V&O<FRCO#XB;8V[O3Y+8 9!O/LW%;LP]5N#'5V9'CTPP5.%HZF
MK!1G*PI=PI90?=>Z%FBW_L^OV!2=IP9VECV!6[.@W_#N:MCEQL*X>IHAD5KI
MDJ8XIJ>(43"5A+$CHMPZJP('NO=41;O_ )BOSH[!V_\ RUJKXVX_XN[,RO\
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MTYG_ (]1YSK3:N^*SYJ[FKMC;'P&;Q><K]V93967@W;0E*]AELK!+B73*P>
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MMZ6EBBQ"R)7YJ16JJAH9:6F]U[K%G.QOYTG4^$P??6]NL_B%WOM"HS>R!O\
M^%OQ[VYNG$[]PF&W7D**CR=1M[L'/[E. W=FMJTU3+65-+/M'"TV4BIZB.CG
MI)/MQ)[KW22W!\H?YF'=G\P7YL_%'XD;@^#'7O7?Q#V/\2]S+E_D=TEV#V%F
M\O/\F,'G\FT9J-N=B[8HZ:+'3[>J%"G%!]$\88L\;LWNO=&]^$WRX[&[LWE\
MC/C?\CMA;0ZU^5_Q,W+LO']H8CK?.U>X]JY[;_;%#49/9V\]KU&1AI\E%B\Y
M3462@EHJR,U-!74%53R2S)XI7]U[H0.]_G[\0OC5V##U'W+W1B=M]MU>Q\5V
M7CNJ,/MS-[]W16;?S%?D<9%F*#;VW<9E<Q7X]*W$Y&.>:GHI4I1 TE488RCM
M[KW25[*_F=? 7J'KWIWM7?\ \I.L,3L+Y"[7W+O+HK/8^NJ=T?WOQ^SCC%RC
M[<I<32UU9EZBA.8QWFI::GDJE\C$PVAG\?NO=2>W?YE/P?Z)R^W,#VEW]@-N
MY7<FRL'V6:6EVYG=S_P?;6Y:>HJ:#<N[),3BJ^+96W:N&DJC'D]P/C*%FBDC
M^X\BE1[KW2B[M^?OQ"^/%?MW&=J]T8G&5^Z-FT_9&+I=K;<S?9S)MJK9TBW-
M7_W7QF9&*VU*T4P3+5II\<_CETU)\;Z?=>ZC]J?S"?AKTWMKJC=F\^]MMUN(
M[UVS1[XZ=BZYQ.6[EK]R8"M6A<;CQ&)V?C\[E:S;4,62H)*C+I1'&TL4\<M3
M511L']^Z]T_;T^<WQ Z\Z;ZP^0V\?D5U9ANC>Z,GC\-U5VL^YHJW!YVKRN)R
MN<IJ?'U]-YH)I9L7A,M,JZ@3]M+%_G@(S[KW1(/E=_.>^+W3OP=^4/RUZ*W;
M@>[]R?'04NV*[JS)T.X-@U\&Z-P0M/A\7N''UV$3.8"GR%+'/54]368N"GK(
M8K4]3^ZDGOW7NC$=G_S3O@7TZU&G8'?M)BYI=I8'?^;IL5U[NW=\VWL#NBGJ
MJO'9S>,.&P.0EV1AZRGHJIXJW<"8VF81L!+>P/NO=(?Y"_S..J.E/DU_+OZ$
MQ,^%WK@/G9E]YUU/V)AYLGFJ6AV[0[*SFX-MYC$-B\;6T69CW%FJ''489:Y5
MI:2=JV5?MV29/=>Z?^K?Y@74FV/AW\=_D-\H?D'T!D\IW;1G';>W;\=\%NK(
M;?WEEE>OE\77^VJV'+;WRJ?8T4LS4Z4M941K%-*6:!1(?=>Z$6I_F._!JBZ:
MVK\A,A\F>LL9TWO3L3*]18'?.5R<V+ISNO!4.6R5;MJL@J((ZS&9ZCH\'EGG
MH*VFIZJ)J=XY(EE*(WNO=*WI?Y;='?+S:?:@^*_<.W-R[PZ]DJMI;BILQMC*
MXFOVQG,O123XEMP[7S,&$SE/3SC14P+-!3I7TRLU+.R'R#W7N@K^+_S\ZO[C
MZPZ&J>SLUMSK+OGM;L;MGXY9?JB*LJ\HJ]H_&^?,4'8.VL55/1P-508NJV[F
M:JDGGBIVJ<9'%5:%UE%]U[HT?=_?/3WQMZ^R':?>78&!ZWV'CLAA\,^=STLA
M,]?N*H2DQV-H*6GCFK<EE,C5RQPTE%24T]54RL(X(9'-O?NO= %U[_,:^$W:
M>WN[]S['^06T\GC?C1UZW:GR%IZ_'97;>0V3@EI<I7&LW1B<ICZ/*X6046%R
M=0:6JHHJL00^4P>.2)G]U[H.Z+^;C_+HRVTLAO;;WR>VKN[ TNZ)-F8@;(VO
MN/?%=N#)PXR3,O2;.Q.(PU;EM[LN+AFJ2VWZ+)QB-'N]U('NO="YU?\ /SX>
M=S8_K')]:][[2W+3]P]F[SZ5V#$*;(8BIJ-X]=XVIS&;VI64=?14M7AMR8[%
MT=34RXW)04E9XHV986M[]U[H?L!VQUYNGL/L'JC;VZ*'+=A=4T.SLCV)MJDA
MG:7$Q=@P5-3AONI3$*99*^FI*B6.-9FD$:AW15="WNO=%4^3_P#,9^)/Q:R&
M\=B]D=Y;)VOVMMKKVIWW5[:R5'D\W38:GKJ>K.'K=W5N,I9J':F,RM52O'35
M&8K\=%5E66FF9A<>Z]TANE/YBG6,'P)^$_RS^6N]]C]6;M^5?1726^8]K[3P
MV7RAR>Y^R-J4FX\AA]H;;I#G]SY44ZR5DD=+ N0JH:2(O/(X1Y3[KW06?*'^
M<1\:^F>G/C5W1U1NO;/=&TOD)\P.H?C%)DL7_&5&%@S^ZL;A-ZU=;24N(JJ^
MFS^TJ*L>0X2M@HZZ6HTQ")FC>)O=>Z,QVW_,F^$/1.\:[8W;7?VWMEYO!T6W
M<AO&LK]OYRLQ&VH=W0PU.,?=^X*3%U& V=]_35%/-",WDJ!GBECD T.K'W7N
MC7]@=A[)ZKZ]WMVQV%N3&[5ZYZXV9N3L/?&[\E(WV>-PFSZ&;)9/)5#QJ[?;
M4=!3SS.55CH0E038>_=>Z(W2_P VO^79DM@YOLW"?)[:6Y]FX;>%'L"CK]H;
M;W#O"ISN9R&.GRT&.V?C,7AZO*;XJ)<;2U50HV]19,&*&9@?VGT^Z]T(.7_F
M-_!O =,[.^0>>^3/6.#Z=W[V55=,[8WMF,I+BX9=X4,&4J)]IU--/!'78[<L
M*87*))BZNE@KDG@-,T J'CB?W7NG[KWYW_$SM'JSN7N;9_<F'DV!\=L7G<WW
MQ6;CP68V+D=GTFW,0^?JJC<> SN.QNX,3%_!$:OA:HQ<?W-):>F\L9#'W7N@
M@I?YM?\ +LR6P<WV;A/D]M+<^S<-O"CV!1U^T-M[AWA4YW,Y#'3Y:#';/QF+
MP]7E-\5$N-I:JH4;>HLF#%#,P/[3Z?=>Z%2?Y_\ PZ@Z/Q?R,3O?:E?U)F]X
MU/6^(S6&H\CG<C4[GH):F&IVM!MRBHI]RR;II9:.K6?##$')P>";S4J")RON
MO=/_ %_\V/BCV=TUV#\@MH]Z;$DZ?ZCJ]PXWMS>>XJZ38\>TJO:5+!79.AW5
M29R+'9#;=?0T552SS4N2I*6H2&>&1HPDL9;W7ND-UQ_,>^%7:VT^W]Z;0[UP
M\>$Z$V!F^V>VX=X[7S_6F2PVT\!'D):C=<F%W)B<3F:K:[Q8K(/3Y>FH)\=6
M+"S4E3."M_=>Z;-B?S./@AV;O.LZ_P!A_([:&YMV0;+W?V%C,;08K,"/-8?K
MZ"2HSU7MBLDQJ46[3AH8I#70X6HKYZ4J5GB1O3[]U[II_EF?/' _S%/C#1_(
M/%8&FVE7R=F]W;&RNU*)\C70T</76]-P8'#2K75^/QPKI,G@L9C:^9H8=$,]
M5)3,$DA>-?=>Z7/??\POX9_&'>4_7W>/>^VME;PQNVZ#>>Y<*F*RVZ'P.%RD
MD\5-F]T2X;'Y"#:N%J'I:D1U^7EHJ-_%*5F(C8CW7NBL]G?S5>JNC_GGFOCO
MVQOK8.+Z1R7P8Z0^4?56>VEM?<'9.Z]Q93L?>F_<'DSC*+;1S4V7VW0X/;6'
MK/)1;>8TOW$M35UQII84B]U[HU.[OY@WPWV7UIU+V[D.]-NY[8??&-J\UTQD
M.N,/E^VZS<]%C8XI*RLPN'VMCLSF:^DQRS0_>S18]HZ)G1:MH68 ^Z]U@W%_
M,1^%6V>B]C_)*L^0>S,MT_V=ELKMWK+/[,@R'85?N7*X%JY,AA=O;>P-%DMR
M9S.X^3%Y-*O&46(GKZ:2DJ4GIXW@E5?=>Z?6^=WP^B^.>7^6]7\@^NL;\<=N
M9VDVONOMC+Y5L/CL+E*O.TFV3C,ZM5%#5X/)4V?KJ2AJJ6OIJ>>CGD"U<<(#
M$>Z]U@^,/SU^(/S.R.^\-\8^]=H]LYOK&+ U&_\ !8:"OQ5?B8MU2U\6,FK*
M')T=#5QP9#^&5<E-)X3'/ (JF-FIZFFEE]U[J)O'^8#\/-A]-;6[^W%W?@1U
M=O[<>X-H=<9?!83,;NR&Z,KM:;(P5V.VIM_$8ZNW%NBM@?$Y)A#BL562214\
ML\2O"OD]^Z]U,?YZ?#R/H%OE!)\@=@IT:FY6V,^]'K)U<;B6O_A1VN<08/XV
M-UC)_P"2'"?PW^+?<_L?9^7T^_=>Z+[\0?YB&V?F)\Q?ESTQU5N#8^[NE_CY
MT[\4]W83/8O YG;NY:?<G=%;V+#N+"[HHLQ+3U&-J,;3;5P<D%!/@<?6TXJI
MGJC.D]/XO=>Z"KY2?*/YZU'\R+8/P/\ AQD_B)LZ@S/PAW=\N-S[V^3'56\^
MS)FFVIOS%;-;%4";6WUM)((Y4S5+.&EAF8-#*-=G14]U[IQZ9_F"]L=<[^^;
M_2?S[H>C\3N_X0_'_KWY3;E[F^/DF6PVT\SLS?-#N.>5IL)N6OR65VYF\;5;
M6R2-229G(15,$E//%4(7,?OW7NGG^5-\Z?D#\NMG]H[1^8O56PNB?E-UC-UA
MO_+=7]?5==442["^1NWJ7=&Q,E?)U=7625T4+Y;"Y:0,E.<UA<B*>..'0@]U
M[HK?6?S:_F=?*7K'L[Y9?%2G^#>X]A]?;D[NQ>W?@=G,=N;)=I9B+IC,YG"#
M$9[>L6YJ#$[-WIN"HQ.NFH:C9-11T+5%-#4U,Z,]2/=>Z/31_,CM#(?/KXP?
M%^IZ_P 1LW8?>7P/[6^4^[L3N[&57]\,%N'96X=C8NEP4M1!D_X5%!2P;GR$
M=?$<=/*U7!&8:J.-727W7NAH^9WRBS7Q6ZGDW;LGHCMCY)]H[AGR6#ZTZBZH
MPJNU?D:*@JL@]1GL_6O38':.W**GI)9:W*Y2N@BC0+!2I69">EHJCW7NB(;5
M_F1]U[J_E[?RWNY\'LCJO*_+_P#F-GH[8NP-L5JYC ;(Q>X>Q]N5^ZMP9JNA
MBJ<EFO[O;:V]A,W7"B7)_=5KPP4"5T+U/W,?NO=*79/\PGM+H2'YX]?_ #ZQ
M_5]=V3\$?C[MSY;9'L;X[8'+;7V[O3KS>E#NF6BFH=NYS+[BS&"W)CLILW-X
MVMI),Q6T\S-0UE).$JI:6D]U[IMZM^8GSFZ^[D^'.,^:>S/C72=5?S *C*;2
MZQQ?1%+N*CS_ %GO*#9V2WWC]M;MR>=R]90;VH<G@\'F*0Y7&8;"-39:")#C
MYJ*L$U)[KW5BGR.^5?QU^(>SL#V#\E^W=H=-;,W1N^FV!MW<.\ZQZ*GK<Y78
M[)Y6FQ-,4CD:7(55#A\B]/ JF2=H?#"KS/'&_NO=%>W-_-W_ )=FTL'@]QYG
MY'4#8C,[0Q'8-9-A>M]X[GDP. SR5LE'F]XTV,V]65.Q<14KC:XQUFXH<73L
M86'DO8'W7NF:D_F<=49S^8SU5\%MISX7<^$[0^(6X?DOA^U<'-D\Q#5UE1E]
MIIMO&8]J;&R8JHQ.7VWG*_*?Q5<F]->*"EU1S/ID]U[H8-K_ ,Q_X1[T[IC^
M/^V/D'M/*]EU6[,EU_B(H\;EH,%D]R81J]:[;&&W?-CX]H9O=- V+R JL-09
MVIR=,:>03TD>GW[KW7J[^8]\)L9W!%T5D>_MM4/851V-2].P?=X7,T^!?>%;
M4BBAVBN[VQHVBVZI:YA2KAQG/XB:K_)A3>?]OW[KW1C>T.Z.KNEJ?8U7VGO+
M%[)H^R>S=E]-[)K,PLRPUVY^Q9VI<%AUECBDCAJ<K5J*>F,S1QR5#Q0!_--$
MC^Z]TA5^6OQM?=OR.V&O<FRCO#XB;8V[O3Y+8 9!O/LW%;LP]5N#'5V9'CTP
MP5.%HZFK!1G*PI=PI90?=>ZK1^6/\V>A^+'0W\P3Y'4^YNB^ZMM_'K'=$5?0
MO5VSZ#=^V=PPU7<^Q<3N>BQO9%;545=14M1E_OI,KC9**CI8X\1+2TE?X<@_
MED]U[I1;W_FY]3=6?/-^A.R]Z[*V[\?-R_ ?J;Y4]6YN#8FZLQOG.Y[?.^-[
MX#(T='@J!*S*UN(H<%MFCJW@AVF*JCD>>:LJA \44?NO=&LQ7S!V?VEVS\*V
MZ'[U^.>\>C?E'UW\@]\XV"0YK,[HW;3]94^WGHLAL2MH)%PE/0X"IR-5'N.'
M+4_W :HH8:4P5$-3%)[KW3#UY_-8_EY]L;QZTV+UW\INO=U9SN.OH,+UC54%
M/E$Q.:RF4IEK:;!T>X)L?'@6W%44CK+'B&R2Y-XR&6D(/OW7NCK]@=@[&ZHV
M1NKLOLW=^W-@=>[&P61W/O+>N[LQ!@,9C,?B(VFJ:RNK:EXX*:GAC4LSNX '
M^-O?NO=%QZ-^>WQ&^1D>^SU3W/AJ^JZRV\V\M]8?>. S/4^2QV!$M9%'N23%
M[LQN#R,FUZAZ"L^WS45*^*J5B9Z>KE2S'W7NDKTO_,L^$'R$[0P7374O?&)W
M)V%O#"Y7<O7>*K]H[BV?2;NQN"I(:^MR6R<QF\/CL-O;'4E%413S5.!R&1@C
MCU.\@$<FGW7NG#:?\QOX1[Y[@H^B-J?(?9>:['RN[]P]>8&EIZ;)1XC*;BVG
M]U_%-N8?=$E"FU\QN''_ &5:*C%T69GKXC3SAZ<&*0+[KW1(/Y:W\Z/X\?+G
MX]?$/)=T]P]1;2^4_P C<+1XG*;$V+A,]B]L+O&K:KE&TL=F<@^7Q-/N)Z.G
M61,+4;HFRS>JT!-E'NO=7;^_=>ZK(^5G7FZ]V_S#OY7^YJ'8VX=S;!V?3_.*
MD[&W!2;9J<SA\7%O'8=!0T$6;JT@DHJ&/*SB2GIUJI$%3(&BC#L"OOW7NJO>
MHOAM\D/BQ_./^&O4V"V7NG=O\O?ICJ_Y\;U^,?95)C,AFJ78='\BZ38[5W5&
M9KQ%+28['[<S6W9YML?<52--BLFF,ID*8=@ONO=(7<5#O_JKX#_S&?Y6.X/B
M?\E-]_*OY']D_/Z@Z=W)M/X_;AW?L;?*_,K<6Y<WM'?E5V528^796$@V_2;B
MQHS SN<Q^0QT^'E1::8"C>H]U[H$OF+\4?E#G.U?GOT?B>O._-V[VWW\>OY*
MG:VS]\]?];U&9Q^]8?Y?.XL[DNR<9@MT9S%9'8G]^(S/2U.(P^?E*Y*M-.LM
M)-3NY/NO='E^(>PLCW/\Y=J]\T6Z_P":5\E:/J;XM=Y]?UO9OSFZ8VS\.]MT
M4_;%9MR238$.#/2_6NZ=UY')38B&LDK87JL1AC0EFF>HK$BD]U[HN?PNH^XN
ML^Y?A#TG\;]G?.1NN=E]KC#=W_"_YY_%>IW3M;X^[7P&V]QTF0R'7'?V1V5A
M(LI/BLE_#<5@EQ^[\^F9QE<\D+_:!YO?NO=;(NU._<-N7H[>/=N-ZO[HP&+V
M9#VM-)UYNKJK)[9W77/U75Y*FJAC-N-!)D:\9B;&RR8EJ>"3^*0STU12"5*F
M(O[KW6N1L;^3O\R_DU_+W[8J^R?FWW=T)W%\Z,[NSYN=C_'%.G.N#0[;[,W_
M %]/NS:..J]R97:4O9M!5;)DQFT,;Y8-X457CQB%@Q_\,@AAI(/=>Z%WXT?(
MWM/K?OBB_F$_+KXN?*W%1_+[X#_&/I?)X?8GQ3WUVQN'9O9/QJS_ &!'OK9V
M2VM@-N5NY\/B-RY/-4^1P>1EQ:XC*Q*)5K GVSR^Z]T W6='\D.J?Y7?PKK*
M/XR]F_'Z*+^8M\PM]]HY=OA^/D=V=T/MG?\ V!W+6[>W1LGK]\3GY?XX3FL-
MBXLM1[=S5-3X;*5-5%2U=#4B8>Z]T0_Y9[1[-QW67\W7MOLG:?S8^1G579FR
M_P"20>O=_?-;I+"=19/LREV=\B8/XQ@<?A:39FQL7B:0/7Q4"XG-X&CRZ1U"
MUE;!_#:ZAE?W7NKJ>W)-Y?/SY387N/H'I#Y!;$V!\<_Y?GSXZ3W[G.Z^BMR?
M'VKW+NKY-46T8-M[%PN.W;C<179P8.HVO7UE76T<,V)AGFI8X*V9YS;W7NB$
MX'KCN6?H[^1S\E2/G]\>M@_%#X%[@^%_?V6Z%^+<FX^T=@[Q.W.N\945]3UW
MO7KG>>:K]H9"NV7E,75Y/#;0J:I2<?4QS?PF:KF'NO=+;8/QS[$V;N#8'SYH
M^N_GUW%U;U__ #.I/DYVU3?)'KK"+V+O3!'I+*=80=H[>ZAV?L+9>7Q0PV2K
M\3IQ<^W/[QUM+CZC,)1LS0I+[KW5D/\ +^WC6]V?S,?YDWR-V_\ 'WOGJ'I[
ML7HCX#[2V!V!W=T3N/HA]\UO7,W:Z9C+46-W/C,5EP: 9#'T31UM%3U@IX:.
MJ, H:V@GJ/=>Z'_<NQM[3_SG>E>RH=G[IFZYQ?\ +#^3^QLEO^+;]7)A*?-Y
MWM;J&OH<//E1":&'*UE#CLA4P4CSB>:"EJ)HXVC@E9?=>ZI_^/GQK[/Z!_EA
M?R'.RZCXU=JY7&?!OM6@[O\ DW\==L=75U5O>B'9NU-_8+([F@V2U-#F<KG-
ML;GW?3YBJH8*.3+-!]W/24U351K#)[KW0C]][7[-^79_G1?+#ICI'O?;_3_:
MO\F3=GP_ZPP&_P#I/<W56ZNRM^[5QG:V6:OPVQ\[C<?NZHBI*;=&,PM#+58.
M&:OJ7D@Q\<T2:W]U[HU%)\>\K1]^?R LI1]'Y"EPOQP^/WR!VUG,C3=:204N
MPVS73^V\/2X^KF6B$6UVJZBD-#%!(U,99(?MD5FCT#W7NAX_EA[$W]L;>G\U
M%M[;-W?L[&[S_FJ]W;[ZY.Z=O5NWH,M@,]L#J]4S.$^[AACKL/6Y:#+@5=+K
MIIJN.L D:9)K>Z]U6%VG\O:;Y6?*?=T/S0^,_P#,4P'Q"^,7=$M/T3\8-B_R
M].W]^XSLS/=8UD;T'9W86<PNUJO&YG;M-E8#5;7VS#,]#>&GS69^ZK/LJ7'^
MZ]T9-.W=P_ GY"?S&<QGOCW\JNTX/G%N?KWY-?%6?I;X\[C[83-YJIZUV[LS
M(;$R]5A*&NH-F9_'9O;-/,9=RU&)QK4.1AG^]84E=X/=>Z/5\(OC7O?XM?RN
M?C_\7]X0T^0[+ZI^(^"V#NZAV_*^8B.X(=OM_$J2AD5 ]7%'DY9X8'6,&955
ME0:@H]U[JLC;'1E90?R0?Y8VU.ZOCU\G3N?I'9/Q=SFY\UT/1Y7:7<O2^3V[
M@)Z-]_[8VVFW<WG,OF]M3U'VN0P2X2>6IQM97I44-=3QST,_NO=#1_*]Z%SU
M7\QOE?\ -&G?Y49CJS?_ $;\>?COL#M'YIXC([(["[ R?5^1W7F-R[MJ=IY/
M!;5J=K;?B_C>#Q.,IQM3"PU<F/KJVFQJ4\T=97>Z]U[Y;?RZNJOG)_-DV]5_
M)SJ#>W9'QUV[_+8W+MB..I_B^+V76[GW%OZH@CI<I44GAQ^1SN(Q57/D,92S
MU+R4%3X<Q! M91T573^Z]T1_Y+[+^7U;_+@^57\K/OGI[NSY(;M^/W;'P1I.
MA^]X^K\QVA0]Q=.Q]U]<5=/5YBMI,=64-5O3:6$H<C1;NHJAQ42T]"^=DA>@
MJ9:@>Z]T<O\ F5]<=[U?S&7L7HSXRT/R'K\9_)X_F(==8G9^]>O&W;LC/[AW
M+N'K.? ;)W-YOM\570YV*ER?CPU1D(&R-/%610V7RNGNO=$5ZXQO>';GS9_E
M(]ET>]OYDOR#V%U=WEV8_;4W>/P:H?B/UOUC4;AZAWCC<;B\3@EZPV;NGQ&K
MJDQ\61?+9G"44445)6Y)LA74+2^Z]UW\>.F=_;O^+?\ *RZ#WK\<^\*?=?Q-
M_GT]R;^[JP6^.BMQXBAQ5#/EODAO3;F[8:VNQ:8[([9C?<6T98<Y2SS8U*ZJ
MI:=:L5+1H?=>ZN+P.P=]Q?SP.U>T9=E;MBZRK_Y5'0&P:'L63;E8F"GSN([=
M[+R-7A8<N81CY,M2X^NHJJ:C6H-1'3U$$SQK'+&S>Z]TT9K!RX#^=9]]N^IK
MVVO\B_Y7]1UWUJ)6J%IH\GT+V/69+=U#3N"::.MK\5OS;M3;2LTD6/D8%TIR
M$]U[HI_PL^3&Z/Y7_P ;-L? +Y)?&'YD[\[%^,$>Z.N^D][_ !S^*>[^\]M=
MG;/H\M7/LG(XG<&VL?D,)A\]/A9J"CS%%FZ[$FDR4,]0XBH*BFD/NO="9V_B
MOF9W-L;^3EO[Y%=-4VW^Z<;_ #.]O]M]O=?]1X*NW-1;"VM6]<]V4V&CW)74
MU9FJ9*C#T.5V[CLQE%K(\7+F9RE+XHZBFC;W7NB)?RY/C9W!MRH_X365?8G0
M79.!JOCS\./YCV/[&J=Z=693%R;&SN]Z;K^BQ$&;>NH$;;.6R]&,O!1I5&FJ
M*J$5D4(D03+[]U[JW3^7AU_O/9'?_P#-GR>Y=D;GVA@NPOYA"[VV%D,YMJJP
M%)G,=4=2=744^7Q$M1#%#DZ)\I15]/)54[21-505$32&:*15]U[HCV,_ET[=
M^3G\WG^:7V+WSM[Y3;+Z^EZU_EY473F^NKNZ^R_C/AMQ34FV=YP;EB@R>SLW
MMVBW7+A9X,7'*LD]8V*>H* 4S5L@F]U[H1/E[\!.JNFL-_*DZC^+_P =:ZIZ
MTV+_ #@^G^_NTJ;$X'+=JU$4M+L3LYZW?V\\SD6S&4K*M,W)AFGSV8KY)5K6
MH==6)C3CW[KW0 _.W9?R)VM\I?YFG:O5/QGJNU\-N?H#^4U309G<?QYF[VQG
M@ZX[+W[6[OW)MS;4T24F]]Z]<8*:DS6/QM,]36T]=%BYQ2RD003>Z]T0_NSK
M7Y$=S=H?*#?NVLI_,M^7VS]Y?R*OYH_3&S>W_D]\1Z;HU*W>N[J7;;T6R]I;
M1PG677VX*.MR/VQ>G7*X1_XS.W@P,U6U%7JONO=6[_*GXZ9:JZ5_D-=;[.Z4
MS68VMT#\\OA;N+=6T</U[49>FVAANK>I.P:2#*9:CBHY(\'0X'+MB(Q5U$<$
M5'7-2+Y(ZAH0?=>Z?EZ+W)%\C_Y]V[H^G,Y&O??07QWP&T-SIU[4(-Z2[;Z@
MW!B)J+&UHHQ_>.2@J9HJ)X89:@P2NE,RJ[!#[KW5<76U;\F>LL'\"]D=C4OR
M_P#A[AG_ )2'P$V,G>'Q)^ 2_(?M;>.\]M86IBW/UKOG<V5Z^[$FV-2;1K:J
MAJ*3'9;!XH#(9')U4F255JHD]U[I(_ /KCO3X@XKX"_*OY!_'/Y5Y'8G3&X?
MYNG2W;VW*KINO[4[%V1EODSW!2;FVYO;*;6V7B)JK/8[.8K;\]%7Y;:V'JZ"
M]?2U=)#_  B9ZB#W7NC8'<^>VG\V^D_YG.1^ ';'6WQ7JD^9?5M;4=:]$YS=
M_8\V0[MCZOJ<1W=O;J_#[:BWUBYMU0[(R^WJB^+R>:I<;!A)LG'2T=28:'W7
MN@R[7Z8[R[>^./\ -'^06T.BNYMN;)^9/\QG^6-VST%TUGNLLO@-WU. Z-WG
MT1A-T[UR&S7IOXW@XLR^U\MEY4K\?35L6,HS7Y&"GCOH]U[K:I]^Z]U51_+$
MV#OO8V^OYK-7O;96[=G4N_\ ^:OW+O[8E3NG;E9M^/-X+)=<]4T5-FL0]7#"
MN2Q-168^O@CK*<R4[S4U1$LA>&15]U[JJ+IGXT=K;7_D)_RH^H:;X_\ 86W>
MTM@_*[^7WOO?'6$'5.2Q.?PLF)[SQ.<W-F<KA%H(\CC7IJ.6OR&3JZBFC,<+
MU%752!&DD/NO=%HW=\9>X=@]8?.WX6]N;F_FSY[=_?/R)^6FY-L?'#XL?'K8
MVX.LNU,!\F]T93.X[*TO;>:Z7W50;2DJL?EXH,Y4;EWY0UV%K:.>2GCCI$QS
M/[KW5XO4G0>?V[_.&SG:N<V#NRLQ.T?Y/OQ=Z*V[W%N'$39FG?)TO9_8U?N+
M!IN84--0UF9:"FV_69"&$Q2LCTE5)31Q30>_=>Z??AE15VY?YF'\WOMC$M6K
MUZN<^$WQZI'>-HZ2LW5TKL3(YS<];2GR/%,8*7?VW<7/(J1R"HQDL$BLD$+G
MW7NJY/E=E/D?E?DU_,!ZT"_,WX\U&^FQ2] [%^ OP=V]N>/O>CGZ[Q%!!F^P
M>Z=P]>[VVWC\Q#E*7(X#1E-P;:7$XBCI$E:5?!/[]U[IR^'_ $#V=2[Q_P"$
MR^6WAT?V%0?[+G_+K^6>V>R\ANSJ_*8]MB[FS.Q.H<)2T6<DKJ"-MLYJO^US
MU%3QU1IJBI2.NAA$B"=??NO=(W<O0_<VPOEAW7\KZ_HSMO=/3?QX_G<Y#Y,;
MLV7M;J_*;CR>>VEN[XQX+87]^=GX&"B>LWB=M;KRGEE_A$554DP9%J=)ZND>
M$>Z]T>G^7]O&M[L_F8_S)OD;M_X^]\]0]/=B]$? ?:6P.P.[NB=Q]$/OFMZY
MF[73,9:BQNY\9BLN#0#(8^B:.MHJ>L%/#1U1@%#6T$]1[KW4[^9%7[6KNVL/
MLKYS_P O_'?,G^7=E.M*#.[+[ ZV^.&8^3.\=C]EX^OKZ?+1YW!8C^*9JAP.
M9V_48L8S+87"+)!4Q9"FR=0L,U*1[KW5.':OQI[MWI\%/YCNR/B%UE\X=A?"
M/L/L[^6I%\/.FN\=L;OW!OK#[BV?W+M.M[)W1L3:F\HLIOC [!HL5!AJN"DS
M$(IEFQ>2R5+1T^++S5'NO=6.=<_"+>1Z2^>_\GGMC"=B[BVAO;"[P^0'Q;^;
MV1VY-63YZ?M#+S9S'UF[MUT>.AH5[:ZT[#IJ.ICGED6LKL9#ALE3#7!4+![K
MW5?4O7?>_P#,:_EH_+?YG]Y?'S<&1[B^7?=/\M7X[XWI;$8.H[!KZ;KGX==Q
M==T.]8OLZ*GJ$GQ-9OR7MW.5%1#"\,F#^UK*F04\ 2F]U[JZ_P"7^V]YXW^9
M[_+*[DP_6O8N[>N.FOCI_,^GWYF]A['K]T4^.ESF'ZKDPV,EEI(6IH,GG3BZ
M^+%4DLT<E?-3RQ4P=HWT^Z]T2#X4_+;!=Y?*2C^5WR_^,_SJVS\DM_;@EZ5^
M+O5VX_Y?'<2;9Z3V1O/(TM%]M5[KJMF1;?CW/NJ:*ER.[]R?<Q45+3)3XJ"I
M.+Q;U59[KW1_OY'FP=]]6_RF?@MU]V;LK=O76_=J])T.+W1LC?>W*S:.7QM2
MF0KW-/7XW(0T];1SA'1C'+"CV8&UB/?NO=:W/1_Q@_E_K\-).ONSOY0GS5W=
M_,2>D[K6AW[LGX,]G];YE]Y5&X-PUFU<Q0=GSX[![=Q$M(K8>>++29R*FIQ&
MLCM)H*-[KW5OO;^>^1'QQW-_(Z[D^6.PN]^]^Q>D^G^^-M?+3=_QMZ'W/\AZ
MFGW=O/K/ XB:LK:'9>&R$RID<\M4OW*T<-/-(LLL21QC0GNO=9_G-VYN;^:G
MU%U/\(_CWU9\R.G]H?)/Y#[5VQ\D^X.X/B#O+IN';'7G45,V^<_(8-^;=H<3
M7C<U7B<-M^"GKH9\?7G)5-+/39"&.JH9/=>Z[S/Q:^6/PK_F+?$7YC9'Y#?(
M3YR[2[TIJSX#_)F"KZ'VA@ZK;6W=U-4[AZ_W94T/5&SMNTLF&VUO&EJ*2NR>
M5QM0N)HLY/(*ZAHWJA+[KW1JOGO\?)_D+\R/Y?FT]Q==Y[>W2N6V+_,(Z[[K
MR<&UI\[AL?B^W>MJ;!Q4^;J13S4%$F6,T]/3+5.BU,H:*,.P*^_=>ZHYWG\>
M_FAWC\%?D%N;OOI3NC<7>_Q=S?\ +[_EQ=.T>0ZJJCF=W8CXS_(+KO<'97;&
MW:"FHI\I5;9[!CQNW:^2LBDDHWHMK_>:V@@:I/NO=61;P[)W[\4/F!_-OP>=
M^,WRA[1R7S7INF.R?BADNDNB\_V?@]T56V>EL'U_DMO5^Y,=1OM_:.5QV?VP
MSU#9_)XVC6AK:2K6J93,L/NO=5![P^)GRDS'P![6V3COCEWC/O&L_P"$Q_\
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MQN^=[;]WULZOQN"7.D8I\%/)M^*5Y:Z&:6."CCA@IQ-D9:RA]U[IKZ3^<O\
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M[?P]/692JHZK"_=335,%7%[KW1M?@Q\R/DON?Y<8?H/=F5^5?R4Z.W]U%O\
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MO.5NXZC;F:7&U,./QF.6LAG3W7N@+_F(]6[_ $^6G\V7>>X^VH=TT&W-S?R
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M4;6@V3N[&;9ZN3^"U=-19.KQKUF9J):FGIZS%RX])JOW7NB^=R_('Y(?.O\
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MSNW:.]JFCK\6?O=EX38E7B<=#2T5'/'B:S"X.$S1U-14S---.1.L92-/=>Z
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M9WG(L^XZBDR=1M:MWUM.GW54JT^8IMN[OQ4%542U-3&D%15U4LWNO=*/N_\
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%W7NO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tlucid_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlucid_sig.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&7\S'_ (4)_P O3^61E*_KO?\
MO/*]U?(&@D6"OZ#Z..$W+N_:DTD..JXQV5F*_+8W;'7328_)Q5,=)7U7\6GI
MW$D-%)&=?OW7NJ?-J_\ "D7^:OW5TUV/\N^C_P"3)24WP\ZCV_NSL+>7:_:/
M?3;1QM;UQM+%OGLED]J;GWAMWKG';ORE+AZ.4M%M['[AEGJY(Z6G@EGTQS>Z
M]UL>_P K;^8_U/\ S4/B+M/Y5]48/)[-2MW!N#8?8/7.<RN)S6<ZX[(VG]C+
MF]KY')8>0TU9!4XG+T&6QT[Q4E158C)TD\M-3O*84]U[JQ/W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4)_S;/\ A0I\
M,?Y5(J.N\L:_Y!_*2IH):G'?'WK?,8VCEVN9\9/78?)=Q[WJDKL=UMA,G,L*
M)%'2Y7//'4)418N6FU3+[KW1ZOY7/S![(^?'P=Z3^7':/2U/T#G>Z:+<VXL1
MUU3[EJ]UQP[+I-W9W"[-W*F6K\'MZJDI]X[?QD&4IPU,H>EJHI$)21??NO=6
M!>_=>Z][]U[HDGS'_F._"'X [:7<GRV^1W774,E7CZS)8+:.3RCYGLK=M/0/
M2153;.ZRVW!E]^;H2"?(4Z2R4>/E@IS.C3/&AU#W7NM6+Y/?\+8OC/LW)9'"
M?$OXE]H=Y"DR!HX=[=L;QQ'2>UZVD6GE+YC#X/%8;LO=F1IGJPB105T6%G>)
MF=_$RB-O=>Z+#L;_ (5&?SP^^,W@]W?'/^4AA>S.GZT1^2CV-T#\N^WLWFRK
MU4TYP?9NQ<[1[7I@]&T(4' 5NAHW<ZED5(O=>ZMO^#7_  IEH.R/DCL7X7?S
M(_A?W!_+D^1W9]5@L?ULW9>-W9C=E[MK]UUHQ.SZ;,X?L?9_7^_>OSO+.)-0
MXJIEI,KB:FIBTR5\#,$'NO=;4_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ1]5V'L"@W=C>OZ[?.SZ/?F9@J*K$;)JMS86GW=E::EIFK*JHQNVYJU,S704
MU&C2R/%"RI&"Q(47]^Z]TL/?NO=>]^Z]U[W[KW4>KJZ6@I:FNKJFGHJ*BIYJ
MNLK*N:.FI:2EIHVFJ*FIJ)F2&"G@A0N[N0JJ"20![]U[K3Q_F1?\*X.EOCWW
M#_LNGP%Z<A^:?9-%FQM7.;]_CV4QG5/]\:FK_A5!M'KFFVSB\ONCMW,-EV6"
M26B-!CY)&2.CJ:UG8Q>Z]UM)?%#-?(W<GQOZ:W'\N=O]>;1^2FX-BXC.=P;2
MZII<Y1["VIN[+(^0GVO@H-R;CW?E]6W:.HAHZMY,G6QRUT,SPR&%HP/=>Z&3
M=F[=K;#VUG=Z;XW)@=G;/VOBZS-[EW5NC+T&!V[M_#8^%JBNRN:S64J*7'8S
M'4<"%Y9II$C11<D#W[KW6LG\GO\ A7'_ "I>D<9V-0]1;A['^4/8>S*@XK;N
M V!LW-;5V+OC-QY"3'UJXWM'>6.H\9%MO&M"\LF5IZ*N@JH-,E M:CJ??NO=
M;$WQU[BC^0W0O3G>\&Q=[=90=P];;.[(INO^R,=3XC?FT*;>."HL[38+=>,I
M*JM@H<U0P5JK-&)"5/Z@K75?=>Z&;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:3_P#PHO\ ^%(J?&AMU_!C
MX!;VI*KY# S87O'OK;\U+D*'I!+Z*[86Q*NU115W:\RWCR-8 \6WD)B35D2Q
MH?=>Z*5_)3_X3N=<[3ZXR/\ -%_G4G$4NW7P^3[?P72'?>16FV_A-N5-MQ5?
M='ROK=U587(Y7/)-)51[6RFM(XIA+F1+63MCJ/W7NB<?S;?YMO?/\];OS9/\
ML#^6#LO<E5\6,ANS;N&QN.Q. R.V*OO3)8/,8V3&;_[ Q\^.I)^N.A^O:^&G
MR%)29&"E6D^W3(Y%(YXZ:FH_=>ZWR_Y5G\O_ &C_ "R_A!T]\3=M9.FW+F=J
M45=N/LW>U-1-0)OKM7=M1_%=Z[CBI9)9IX<:M8R4&.25WEBQ5#2QN2R$^_=>
MZL1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)RDWCM'(;DRFS:#=.W*W>&#H
M:3)YK:E)G,94[DP^-KW:.@R&4P4-4^4Q]#6NA6&66)(Y""%)M[]U[I1^_=>Z
M][]U[KWOW7NM13_A1=_PHDH/@-B\Y\,_AMN'%9KYH;BP\2[^[ IACLWAOC#@
M,U2K/2F2DG6LH,EW1F\;.E1CL=4QO#B*2:*OJXW,M)!/[KW6L%_(._D3]M?S
M8.Y?]F]^5DV[J/X<[>["K=S[VWCNJLR=9O;Y;=BTV>DRNYMF[?SF6EFRN2V[
M69[S+O+=3R22M*\U!1RODGJJG%^Z]U]57"X7$;;PV)V[M_&4.%P.!QE!A<)A
ML72PT.,Q.(Q=+%0XW&8ZBITCIZ2AH*.!(H8D54CC0*H  ]^Z]TG^Q.Q=A]1[
M%W9V=VCO#;G7_7>Q,%D-S;RWKN[+T6!VUMG;^*@:IR&6S.7R,T%'0T5+"A+.
M[@7L!<D ^Z]U\_3^;Q_PKUWMN/,;MZ$_E:TZ;0V92.^'RORZW3B1/O+<TJ?>
M4^1;IW8V:I'H-J8,GQ&FS>8BJ,E4J7,5#0E8YY/=>ZH[_EJ?R3OYA'\[7L#,
M=Y9_=NY]L]19S/U2]C?,KO\ JMT[\R&[\WCX7Q]=!LY,YEH=T=T[IQT]!'1U
M+#)4]#1-'XJFOAD186]U[KZ$_P !_P#A/9_*[_ERXC%;DQW4^$[M[=H:K&FH
M[]^3,6WM\[DI\W45U51XK^YN"R./I>O>NI369W[*D;$8VGR=2I@CJ:NLF1)/
M?NO=+_\ FW?SJOBE_*/ZGJ'WA6X[L+Y#9G R#IWXT;4R='2[CSE2:>2#$9?>
M$T"5*]>=:4<\:_<9*>!Y9(D:.AIZJ>T7OW7NOFM]+4OS7_X4)?S;-D9'>^Y\
MO6]H=F;MVWN+?>[=D5&3VWMWX[=#=>Y'%MF\EUU'5S;D.Q,%L/%S6PD1>H>J
MW)7PO/)/75\T\ONO=?9 ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG
M,'O':.YZW/8[;6Z=N;AR&U<BN(W108/.8S+5NV\L\*U"XO/4M!55$^'R+4[!
MQ!4+'*4(;3;GW[KW2C]^Z]UQ=TB1Y)'6..-6>21V"(B("S.[,0JJJBY)X ]^
MZ]UIT[L_X4D?([Y&_P VW9/\O;^5ST5TGWMU12=@3;([&[C[(I.QZQ\]C]LO
M"_:6_P#9>9V?NK X79W7.P(J.OC@R^0H,U%GI(X7I42.>F^Y]U[K<8]^Z]U[
MW[KW7O?NO=>]^Z]T7KY0_*SX]_##IO=/?GR:[1VUU-U;M&F>;(9_<-2YJ<C6
MF*22DV_M?!T4=5G=W;JRIB*4>+QM-55]6XM%$UC;W7NM'GY#_P#"@_\ F*_S
M7.P>TNA_Y1>UJ/XF_&WJ_;66W?W9\T>W<GC=M9;8?5>+H6J\GV3V1V!6T>:V
MC\=-I:,9D32P8],SNNOIZ;S4<T,T=120^Z]U1_\ R3O@K\E_Y@'\W#;G8O5?
M=O8N\>O_ (T]\XGN3M3YM9B+>E+F]R;/V!O*.?:TT=5N^NEW+%O[O/$X6*DH
ML3DZF>LHJ"JJ):R*:GHJB)_=>Z^N7[]U[KWOW7ND9V)V+L/J/8N[.SNT=X;<
MZ_Z[V)@LAN;>6]=W9>BP.VML[?Q4#5.0RV9R^1F@HZ&BI84)9W<"]@+D@'W7
MNOG._P Z_P#GC=M_S&>B>[\?\<MU[L^,W\M7;>1J.K<3OC);:K<?VW\_>WWJ
M(/+UO@,<^?PTF Z9QV#<9G.PO-'44.$,39B":MR%%M\^Z]T\?\)&/Y0,/<?8
MTG\SSOO;<-7UIT[N&NV]\7=OY2-Y(-V]Q8K53;A[3GHY$%/4X3JT3?:XEV\J
M2;CDDG7Q38E"_NO=;['S&^9WQU^!?16ZOD1\F^PL9L#KS;$$J0":2"?<>\,^
M:6IJL;LO8F :>"KW3O'-BE=:6B@-R%:21HH(Y94]U[KYTW\W+^:SWU\Q^O,'
MWU\K<7E>I/B]VA-4[C_EZ_RXZ7)3TF9[PP>W\C11XKY;_-6KH*B"JJ>F:&MU
M5&W,0IIAN_*HD.(08FBKMPU/NO=0_P#A,/\ R+U^<G9>/^<?RBVG62?$GI?=
M\9ZXVCF:6:EQWR'[:VM64]7X9X:B)?XYU)U_DXT_B^B]%F,K&<6[RQ4^5IA[
MKW7U"5554*H"JH"JJ@!54"P  X  ]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZU,OY_/_"A^F^%$^0^#OP/EA[,^?6]'QNV,IG\#BJ7>V*^/%3N=X:7
M%T$&WEI<M3[W[ZS7WD*X?;STU134#U$55D(ICX,=6^Z]T)'_  G_ /Y-/<'Q
M0J]R?S"?Y@>^=]=F?S#?D'M:JQ=?3;TWQFMVUG3/6^Y:O'9ZOVIN/(U>1JXM
MQ]E[BKZ"FERTCR5%'AHZ>.@H-!%9-5>Z]UM"^_=>Z][]U[KWOW7NO>_=>Z!/
MY'?(?J/XG='=F?(OO;=E+LKJCJ7:V0W;O#/U$<E1-'0T* 08[%8^ -5YC<&;
MKI(J/'4,"O45M;/%!$K/(H/NO=:WO\D'^>)\YOYOGRS[XIG^,/3?6OP2ZKQ<
MTU/OVFB["/:V(W#EP\>Q-G97==9NS)=?[RW1G(J2?(9"EH,/C%Q5"H#2S%H)
M*CW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:EG_  I:
M_GS'^7_U_4?#GXK;BA?YD]L[<>7=.],75TTS_&SKK+0HL><*+(\L?:N\Z2=A
M@862V.I!)DI2KB@CJ?=>ZU4?Y*_QY^(_QIH:'^;%_-$RE+F=J8G.5\OP;^*2
M4T&]^]?F!W7A<O34=5OK:75-9/%6[KVSM+=N1I*+&5]<\>(GW%,TU944\5%&
M]3[KW5PWR ^.W\]W_A2-ONAI>P>O<G_+<_ELP;E3*[0V5W#%E<)N++XO%UD\
M%!NK=O6'DPW8_;N_!)2&LH5R-)MW:L*RQ-15%P*R;W7NMJC^5[_)Z^'G\J'K
MJLVS\?MK56>[*W524T/9O?>^5H\EV?OYH!3N,<]?!!%2;7V?3U5.LM/A<:D%
M$DG[LOGJ2\[^Z]U:G[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK/_F[[H^=N
MU_@=V^?Y;VR*W>_RQW')MG9^R/X7+MM<SM'#;ESU'CMX[YP46[,KB,'+G]N[
M;DJ&H6FD=:6KDCJ3%*L#1M[KW5)7_"=/^13\C_@SV=V+\^/GCOW(Y+Y6=Q[%
MR&S*3KG^^4^^\QM/#;MS6'W/O3.=N]APYO,X_?F_L_D-OXY%@IYZRDQ_V\LK
M5=7-.GVGNO=;<OOW7NO>_=>ZUT/^%"G\[G;7\JWH1>N.J,A19KYK=YX#*P=2
MX0P09&CZMVT=>-R7=&\:>=)J(18FID,6"Q\ZO_%LHA)C>DI:LK[KW6I%_(S_
M .$\?;/\S[>Q^<'SV?=^"^*VZ-S9K>KTV9R&;PG:WROW/G*Z7,Y/-X_*HE+E
M<-UQE\O72SY#<23Q5F4D+18X^N2MI_=>Z^FYU_U_L?JC8^TNL^L]I;?V'U[L
M/;^+VILS9FU,7283;>V-MX2DBH,3A<+B:"*&DH,?04D*QQQQJ  /Z^_=>ZC=
MF]E["Z9Z\WKVQVENO"[&ZYZYVSF-X[VW?N&MBQ^%V[MK 4,V1RN5R%7,0D<%
M+2P,;"[NUE4%B ?=>Z^35_/A_GU=J?S5NS*WK#J^LW'UM\']A9J3^XO73U$V
M-RW;&2QU2#2]G=LTM--XJNLDDA6;$8>0R4V&BTN==8TDH]U[H]G_  G=_P"$
MW^1^:TFV/FM\X]NYK;?Q,HZRDS'4?5%4LN(SWR3JZ&KCF3/9SRQ"MQ/1J/"8
M]<?BJ]R$D4TD5$IGJ?=>ZW'OYLG\W_XO?R,^D>G-OU?3.?W=N;L+";NVY\<^
MB^K<=B-D;'@QW5N+V_'7#<6ZI:5L+L#96%J-T8FC(H,?ELE>M5H,?+%'/)%[
MKW6AO\A?^%2GS@^0VX=R;TSFR]A[?W'A<O3Y#XW;>QE;6Y#IOX\Y"@K:VKQ'
M:4O5&:Q];3=W_(?;K2TTF(W%O'(Y+;6#KJ..NQNV:2LM,/=>Z)A\'OY6G\R?
M^=KWGG>R,-0[TW'B-X;G&4[A^8G>M3N)]BPU3U<=!E9AO')0U%7V'NK%TE+X
MH<)AS4STZ0Q0R"CIM,B>Z]U]0?\ E0?RBOC)_*2Z/J>M.E*6JWAV3O1J#)=T
M]];KH,?#OSM#.4,<OV=(5HU:+;&P=NO4S+A<#3R20422R2S2U==/55M1[KW5
MJGOW7NO>_=>Z:L[G<)M?"9?<NY<OC-O[=V_C*[-9W.YJNIL9A\-A\932UN2R
MF4R5;+#1T&/H*.%Y9II76..-2S$ $^_=>ZTBN\O^%0GR9^1G\QOJ'XG_ ,G_
M ./N)^0W66&['I<1OS-9S;^4RF=^0>#H\O24F[\CLVLCKL30].]68+#FIFBW
M/E/*6?Q5M0M/1QM35?NO=;Q*DE02I4D E6TZE)%RITEEN/\  D>_=>Z[]^Z]
MU0M_PH8K?YGN0^%6/ZU_E>;$WKN/L/M+>-9MSN3=_6N4PN)[%V+T[2;5S62R
MJ[+R&3S^"K\/F=V96&GH6R&.,V0@IO+%3B.>HBFC]U[K0L_DY_SL-F_R5MN?
M(9I?BMV1W[\G>\]XXG$]F3;X[>/3FT-B;?ZVGSJXC!' ML+L?<NY]]/N7<>7
MERM3D(\3)3F:.G1+PS25/NO=6%]I_P#"V;YS9V-8>F_B=\6^MPTP,]3OVL[2
M[8K13""$>.C;#[MZIHH*AJM)&,DM/4)X7"",.OE;W7NB =\?\*B/YPGRVV#N
M[X^P;JZVV90=U8,]8U>/Z%ZDJ<5V!E:?==8,95X79^9K<YN_=%#G=U4E:<2#
M0,*LQ3VI3%4LLP]U[HF'PHZG_G9?#CM:K[J^%'Q3^<.Q>U*K:F;V'4[JVK\,
M-_\ 8-7_ '8S-7A<KF\2F.W7U!O'$4S5%1AZ-WFCIDJ41=(D5)'5_=>ZV-NK
M>Q/^%NE=E<7E<5MWLW+4HKZ.:IP7:6P?@-M7%9:GHL@AFQ>4&],7M+,8N@R/
MC,4TM+54%5]NY>*>/TR+[KW6WM_+(["_FW[MV=6X_P#FE?'OXY]6;D@PM-DM
MO[OZ0[1&:S.2R53+1RS;6WKUOCWWGM7$U^,I*V1),KB=UU='-443HE((WBJ)
M/=>ZM3]^Z]T0W^8O_,7^./\ +'^..XOD7\B]Q?;T5/YL1U]U]B)J5]]]N;[>
MEEJ,7L?8^+J)4^XK:C1Y*NKDTT>+HU>IJ72-.?=>Z^;GMJ@^?7_"G_YG;N[>
M[_[&7I+X9=%+7;D[%WGD<C)COCU\1>G*8U.7J<!M./+2X[![C[7S6#IG:IR5
M9:OK_%]U7RP8VEIZ>#W7NC5)@-U?S6-Z8;^37_(YZVR'07\K_J_<E%E/DW\I
MLI@LC!4=ZYC%RTM-D>ZOD%NZ"FP^3WI-7KCD79^SY9X<AG)*>"66.AQ]&HPO
MNO=;^O\ +Z_E]?''^6I\<=K?&SXV;6_A6W\5IRV\MY99:6IWWVOONII:>GS7
M8786:IZ>F_BNX,K]LB1QHD='CJ..&CHX8*2"&%/=>Z._[]U[H*^[>[^I?CAU
M=O#NKO/?^VNL.K-A8MLONS>N[,A%C<-B:,21P0J\LEY*FMKJN:."FIH5DJ*J
MHD2*)'D=5/NO=:"7=/R5^2W_  J$^1V]NM=H[GW!\2_Y)GQ+R\O87?W;&36'
M#5NX]N;3I*K-)N'>516&;&YCL/-8S$U%5@,"Z5.+VG2,<ID8JNIA@CF]U[JB
M./;&4_G:?S-^@OAG\3]L93J/XC;+K8NEOC?L9)<SEZ#I#XJ;"J*O.[[[>W2U
M7!6/4]E[]QM'6;DSM?D2]3D]QY"EQTU9*L=*X]U[KZ5ORK^97P2_D.?!WKO"
M[GF@VOL+JW8F*ZT^/?0VV<A2U_9W:$VU,?18^#%;<I,M6BMRM5Y)TK,]GZ^4
MQ12U#U-9.]1.JS>Z]UJ!?(?L7?>Z=I8S^>-_/*HES"92I8_RLOY11RLN+VEG
MY] K-J;Y[+VKEZB*OCZ]Q,E939?<%=4T<F5SL"Q/5J*63%81_=>ZK5_E@_R_
M_E)_PHP_F![\^1?RESVZ).B,#N6@W#\C>V*&)\/AUI8#2MM+XV]-)*\]/A:I
M]NHE-24M(LT&VL! *BH83S425ONO=?5AZVZWV%T]L#9O5?5NTL%L/KGKW;F)
MVCLG9NV:"'&8';6V\'1Q4&*Q&+H8 (X*6DI854?5F-V8LQ)/NO=+;W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UIO?\*)/^%%L7Q*3</P5^!FYH-P?+G.+_=_
MM'M7;GBS--\?8LD%@_NMM80I5097N_)).$"!9$V^KAG5JYHXX?=>Z=O^$ZW_
M  G[RGQ6J:#^87\]*"7=OS-[!@KMT;!V-O&1-S5W1T>[V;(Y/>N[LGE37U63
M[]W0E9(U55>5I<+%4S0^1ZN:H:/W7NMPOW[KW7O?NO=5K_S*OYCU+_+5ZE;N
M[=GQ1^3??W6&+HJFOWOOGH?&=69?;?6%-#645!3S=@P;K[0VOO7&TE?49"-E
MK:+"9#&T\*2O55-.55']U[K4Y[/_ .%Q.-ARD])TQ_+QKLCA46,TV?[/^1%/
MALI4.64RQS[1VIU/G:2C5$5@KKFYRY8$JNFS^Z]U7]V1_P +3/YE6XJ]_P#1
MMT3\0.ML)X(EC@R.T>U-^;A6ITK]Q-+FJOM? X:2!W7]J-<2C1JQ#/(;$>Z]
MU5[\QOYP7\V+^<UMG#_'+>T>3[+VGM[.UO9\W3/QHZ:RJ-F)\=X:#'9C=>*V
ME!N7=.>P&RFR92B%5,]+!45BRS^6H%-)%[KW0L_R^&_X4F?$O:^9Z?\ @7T%
M\W^J-F=B;KJ-^9ZG3X:++MK*;G&UZ*C_ (MD^P.XNFLCC,0LVW=O014T,F4I
MJ:60*L$;5$]I/=>ZNDZU^6W_  K\Z0["Z]Q7=^<Z0HJ;LC)5.WMG[0^9^[?Y
M>'4F(W%7QM39/+Y/#0X??74?<F[*G:^%I9ZJIH\+49">.@%1(M%*\:%/=>ZW
MG/B-O+Y.;\Z/VQN+Y=]7=5=2=UU-QF]N]+]FUO:W7F1Q[T=#58_<6$W!D-OX
M&JQRY(U,BOCB^32F,-TKZM'63W[KW1F/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2
M'_/-_G#]??RF/B]7Y[%UNWMQ_*OM;&YC!_''J_)EJY9\S%$E-6]E;OQ-)/3U
M8Z^V++5QS5 :6F_B=7XZ&*57D>2+W7NOG&?RH/Y>_P @/YZW\PS.UG:N\MRY
M_:2[H3N[YG=Z9MY:O,28#-9V6IJ<!CZN$TE-!OKM&MII\9A88_'!C::.HJXX
M'IL:U.WNO=?7&ZQ^./0?3&&VE@>J^F^M=BX_8NV=N;/VFVW-F8#'9##;;VEA
M8]N;<Q=/EH*!<HT.)PD0IHB\S.(B02=37]U[I<]@=@;'ZHV/NWLSLS=NW]A]
M>[#V_E-U[SWGNO*4F$VWMC;>$I):_+9K-9:OEAI*#'T%)"TDDDC  #^OOW7N
MJ/OY>O\ PH!^/G\S?YK=G?%GXN=(]V;BZOZWZ^K=ZR_*;,8@87861J:++P8N
MGH,AM.OHX-Q;/QVZ!4ZL'-E)*?)9"2GJ4?'4ZP-(?=>Z-!_-@_FS?'+^5'\?
M<UV7VIG</G^X-P;?SYZ$Z#@R\=)N_MS=V/BAIZ6(10PUM;@MB8O*Y"E_C><>
MGDAH*9R(TGJG@IIO=>Z!?^1M\Y_Y@O\ ,-^.&9^27S3^-G4GQ]V+O#(4-5\<
MJ[8$V^\/G>T-FRS9:6NWED=B;WR^ZZO$;/DIFH(L-ECE$;<#)4UD-%#0/13U
M'NO=8/YK_P#/P^%'\J.B_NAOS*UO='R3R= U9@?CEU?DL14;HQ<,M)!5X[,=
MJYRIGDQW5>V\C'60M3O61U&5KXI/+0X^KACFDB]U[J@_?ORV_P"%#7S(Z?S?
MS*[6[XZ%_D:_R^\/05>:CW%OO&4P[3W%MO)XVB&VGPF-W/MG<W:>[]T9K*A*
M?#T\$FQSF):]OLJ:L<4D9]U[HMO_  E,^;_\V/Y6?.K?6#[2^1'>'?\ \3<'
MU]OC=O>%9WAN'</9.%VSO'-QX^DZXQNP]W;HDR-;LO<M?N&$24V#H:N#%MA8
M,G(M$'5)4]U[K;[_ )K/\V7XV_RFOC_4=N=SU<V[.P-QS?P/ISHK;%;1IOOM
M#=,\=2\943F2/:^Q<+'2R5&8S]8GVM'#%X8$J\C/14%5[KW5>W\AC^;!_,4_
MFPU7;/<'=GQ4Z0Z7^'>!KLE@^LNRMJY+L2CWANS>=//CT?9V&HMS9//8OL+'
M[7I_N3F]Q01X&BAJY*>CIZ:>=*T4ONO=;*'OW7NM5G^;I_PJ9^+/P#S6;Z-^
M,>(P/R]^36'KLKA-V08G<_V72O3^9Q4K459CM\[RPT-?4;NW?C\HKP5&W\*R
M/2R4]1%75^/J(TAF]U[K6%^7GS?_ .%++]*P_/#Y.?)C<OP9ZAKMR;2SO1_5
MT6XMM?'C<?:F6;,055#M/K#HC;=%D.W]_8#$TT*Y#+)OE),35X:0M5U%53R>
M,^Z]T=_^4-_*"^0O\ZCY)9/^;Y_-P;(9[I_>.?I-S]9=59;'28"E[Z3"E(-L
MTU-MM2G]UOC%L^EI8Z:AI%_>W1XB6DEIGJ:FO]U[KZ#U;7;1Z\VI-79&LVYL
M;8VS<'KJ*RMJ,9MG:FU-MX2C"AYJB=Z+$8/!XC'TX%V,5/3PI_95>/=>Z)Y\
M-/Y@G1GSVR7=.0^-='OK>'3W3VX\1LF@^1%;MB;!]-]R[S>KW71[UQ'2.<R4
M\&5W]B>MY]O4J9+-1446&JI,K3C'U-8JS/'[KW6E'_PL4_FG97<F_MO?RM.H
MMP-3[0V/#MCL[Y53X^8@[BWMD::BW-U7U?634U;IDQ.TL-4TVX\A330LDV1K
M,8ZLDE P;W7NJL/^$V_\E _S.._*[O#O7#3-\+OCON3'IO:F,Y@_TQ]H4L>*
MW!BNFX-,,DAVY'B*R"NW/*KPS)CJFGIH6$E;YJ?W7NOJ_P"&PV)V[B,5M_ 8
MR@PF"P6-H<-A<-BJ2#'XO$8G&4L5%C<9C:"ECBI:*@H*.!(H88U6..- J@
M>_=>Z+?\M_A9\6_G9U7-TO\ +/IC:7='7K5QRV/QFXXJZDRNV\Y]E5XU=Q;-
MW7@JW%;KV9N*/'U\T"U^*K:2J\,SQERCLI]U[JK[I?\ X3/?R6^D=V0[SP_P
MXPF_LQ2-(:.D[HWYV/V]M.G21H6,<VP=\[JR^Q,LJF'TM7XVK=0S -9B/?NO
M=&Z^??\ ,L^$/\I/I#&;I[[W5A-F0?P:OI.G^@^N\?A6[&[#_@,4$1P?6G7U
M+48FDIL/CIJNG@J,A4-0X3&&HB%34PF2,/[KW6E[N/\ G7_S\?YQV[-Y4_\
M+3ZRC^*/QEZ_R50V\NT<54[-Q6)V1@*.D%3D\MW1\G>W8*':.&J,+M^O7,5>
M+VW!192"C4/'#6Z4>3W7NG;_ (3]?S:OYSG<7S3V%\%*;?NU_G)T)U[V'NRM
M[[[N[,RVY=V9O;_24.2H=NY/?> ^06;,&[-QT5'68YZ_9M'F*&JR&=J<FU'4
M-!2%)L3[KW7T(^P^Q=A=2;(W1V7VCO+;/7O7NR<+7[CW?O7>.:Q^WML;;P6+
MIWJLAE<SF<I/34%!14E/&S.\CJ !_7W[KW7SH/YLG\Y#Y$_SU_D%MC^5U_*F
MPV\:WX^;WW!1XK/[JCH,[M+-]_"E>FJ,GNC?<5904^9ZX^/&RK-63T^0ABJJ
MV.%:FOA1_!0)[KW6Q%\(_CY_*3_X32=%OC?D%\H^GL!\E.Q-NIF.W^T]YUD5
M3VQON/"T5)DJ[;/5O56VZ?<795-UEA*NH1Z+'4%!5U5=/-%+4M/4R0HGNO=7
MZ?&?Y1?'_P"8_3VU^_?C)VGMGN#J3>$<IPN[MLR5L2I54VC[[#9W"9>CQFX]
MJ;FQ;2JM9BLK1T62HG8+/!&Q ]^Z]U6+_.E_G8](_P H/J'"5^6Q%-VQ\D.S
M8JP=/=%TV:&(?(46/F@@RV^=]9:GILA4[8V+B))Q&D@@>IRE9_DU*MDJ9Z7W
M7NH/\C#YX?S _P"8O\=,U\E?F5\<NG>A.N]V9)#\>,AUY-OW%9_M#;*5F2&0
MW;7;)WKF-V38G9T,2TU+C,J<HKYV>*IJH:*"B-)+4>Z]U<)N7K+JW<K5N0WA
MU]L#/O-2319*NW+M/;N5:6AT2FHCK:G*4$YDI/'(Y<2,4TLU^"??NO=?.]_G
MG?S==E_.O>V._E,?RA^F=B=D[;WSNO']<;U[*ZKZQVK45O<VY,3FXY*/KKHR
MJ@PL%/0]8X;)8=:NNW93/#29*GIO-25289)*NM]U[K9!_D3_ /"?SIS^5QU[
MA>W.XL7MGM7YU;MQ"S;N[#:+^+;=Z<H\E##)/UQU M8@A@^R"^+);A$4>0RL
MWD6-H:(I3^_=>ZN)^:OSE^,O\OKI#/=_?*7LK#]?;*Q:55+@\=+44DV\>P]S
MPXZLR='L7K;;$M52UF[]YY6GH9&AI("%CC1YZB2"FBFGC]U[K1Y[9_X40?SA
M/YM';&Y.@_Y+7QLW3UEL[$"GJ:W>E-A-E[F[>@PTU1/)CLOV+V'ONJ;HGH['
MYU<;-%%3R3R3.\<B0968@JONO=%4_E]?S9?Y\W5_S_JOY?W7'=^Q/YB^^]R]
MYXB3>D&_]ZYCN'KK%P8J*KR';M#M'OIEH,AU[UI@(,O-!E*FAIZ[#XFNP<2X
M6EFA8T^3]U[KZ2?>7=?6WQQZ>[([W[@W+1[0ZQZGVAFM[[TW#7.BQ8_"8.D>
MJG$".\9J\C6.JT])3J?)4U4L<2 NZ@^Z]U\@GY\?S$*S^=#_ #%\+V-\GNWJ
MGXT?%JES.2VML(97&;DWUC>@>C,2*[.5M71;'VHN5FW+VQO>EQ<?WIH8A_%,
MY-24SS)14T#0>Z]UL4_'CX:_(G^=1UYUM\5_A[L#>W\L[^0CTIFX99-T9ZBD
MI^]_G%N&#Q_Q_L/. _:1=CYS<0#:*B>2IVA@ZR5I97S-=CZ?&T?NO=;H_2O1
MOPG_ )4WQ4?:77^.ZX^,OQOZFP\V?W?N[<V9H,)25%3'3P093?'9&^<]415F
MY=V9IH8TEK*V>6HF;Q4\ $:P0K[KW3W\)/F3LOYW]-U?R"ZMV#VCM#I_,;VS
MV!ZAW5VGM@;+J^[=A8:BPQI.Z=E[7JZN7<N+ZXW5F:RNI,0V9IL;DJR+&M5&
MDCIYZ=I/=>Z$GY,?)CI#X?=(;^^17R*W]A^MNI.ML.^7W+N7+N[,S,ZT^-PF
M$QM.LN1W!NC<&1ECH\9C*..:MR%;-'!!&\C@>_=>Z^=#W+\C_FM_PK*^>FVO
MC/T5C-X=$_ /J?*0;KSPRE,E9BNN=J*E; .VN[7Q&1?![D[@WA]O/CMK;>IZ
MRHAII9)$IW-/#ELH/=>Z-O\ \*2^^.COY7?P:Z,_DA?!FCQ^Q:#?F Q^_?D;
M58:I4;OR'7N-KZ=L1'OS,49AJLEN[O+>V(DR68FE8/)C,.M+XUH*R.+W[KW1
M)?Y1WR8^-'\A7X4;O^=_=F"PW:W\P/YJ;<@QOQ.^.E!E<<NYMG?&>AK:IJ'L
M[LFO^P&8ZPV1W!OO#353L#6S9S%X+$M01?N5LE/[KW5COQK^*>Z=LXO?/_"B
M;_A1KNBNR^Y,!!1;P^+?Q)WG M'0[9KZI!6]6XJFZIR,TM'@,Y4U,4*[4V48
MC/0RK)F\_P"3(">2#W7NM?;&0_.__A4/_-(1\@9<'@ZZJ2IR$<59DZ[JGXC?
M&[%Y&)9J7'2S4XBK<W+2V2(B""JW3N:H\DBTT#2-2>Z]U]#'L_Y%_P L[_A.
M;\'.MNK,YG*79.TMH[9R%/UAU'MPXK.]]?(+=U#%2ONO=-+@?N,2<YN'<>=J
MXILUG:UZ#"4$]9%'+/2Q&GA]^Z]UJC[C_G7_ ,_'^<=NS>5/_+3ZRC^*/QEZ
M_P E4-O+M'%5.S<5B=D8"CI!4Y/+=T?)WMV"AVCAJC"[?KUS%7B]MP464@HU
M#QPUNE'D]U[IV_X3]?S:OYSG<7S3V%\%*;?NU_G)T)U[V'NRM[[[N[,RVY=V
M9O;_ $E#DJ';N3WW@/D%FS!NS<=%1UF.>OV;1YBAJLAG:G)M1U#04A2;$^Z]
MUMM?SV-V?+CK_P#EC?(SL+X6=LX'I3M_8&+Q&\\GOO-;AVOM*LI.M-O9**O[
M"Q^U-T;R0[>P6[\E@HFCHI99()Y#JAIIHZJ6!A[KW6@%\"_^%8?\R?X?;4H>
MM^V9=K?-/K_&2R-C*SOC)[F'<F*II)*1SC8.Y,77SY7<%$#'4.LFX:'.UZR5
M%EJ1!%' /=>ZL:S/_"X'Y SP1+M_X$=.XRJ$VJ:;,]R[USL$D&AP8XJ:BV?M
MV2&;R%3K,KKI!&BYN/=>ZW/?Y3OS\J/YE_PBZN^5^1ZFW+TQGMV2YG!;EV;G
M<?F(<.^>VY4I2UF>Z^SF8H* [QZ]SB2QS8_)0"2/49:61S4TLZK[KW5 _P#P
MI$_X4.Q?"W&[A^#GPKW9CJ_Y8;CP[T?;G:>%JZ>OA^-N#RU.57!XIXO-3GNK
M,X^7RQJY)V_221U$B_<RTXC]U[JB;^5KTY\*OY20VK_,1_F[97(=@_,OLN#'
M;[^('P+P& J.R?DKBFW/6Y&HP7?/:&S<OE*"BVWO7?\ 7PN^VTW)-2?9*16>
M67+3)38_W7NK$OE#_P *_?F+\>N]=D;3WC_+#H^B=B9,X??N0V'WWO'>=-WW
MNOI+/RYFDV]FZ"BI\'M#%]6;IW"*!:V&/)XS.P11(T(6>.:*N]^Z]UN*=H?/
M?XU=$?#_ &_\WN_-ZOTITIN'K39_9-*.Q,7D<!O<+OG:M)NS;^Q8]B5E-%NF
MK[-JZ:K%,,!%2MDA6H\31*T;Z?=>ZTV-X_S_ #^;+_.'^0^=^+7\D_IR'H[K
MW$R+4YWOS>^(P>;WMA-HFJACBWKV/N?<F.W)UETS@,J]'41TV/IZ',YVJ%UH
MZB2H4Q1^Z]T#O\N+YW_S,.E/YX_7GP07Y_YG^:9UYO[/T>VOE++)D]Q[VZ=V
M+7/MR:L[4R'56Y]RR9%\'0=&-1*7K<0N*PF7K8YZ"2B6>8,/=>ZWI/D:_P -
M.@>I=\=\_)':O1VT.K>M**7>NZ]X[UV+M&II,;-12%Z6KIDJ<-4U>0W+6U\R
MPT$%,DM=5UDR10*\LBJ?=>Z^;U\B.Q?DK_PJ1_F$;8Z"^'?36V.E/BCTUD,E
M68;<$VQ\)B:/K78&8K*7'[@[L[OW#@**"IR&[]X4^)CCPVUZ:K9"\24E-J9:
M_(^_=>Z^A?\ RXOY9GQ;_E?]$8GI/XX;.AIZV>FH:KLKM7-P4]5V1V[NR&EB
MAK-S;QS876D,DR,:/%TQBQF,B;QT\*W=W]U[HNW\V'^<]\>?Y8&TL7M6>CJN
M]_F#V='2XSH7XF=>SMD^P=Z;@SU4</M?);II,5!D\IM+9>2SSK2P3_:SU^6J
M ]/C*6KF280^Z]U\P[^=*W\SO(_+# [X_FLT==MOO[M[JC$]M;(ZZDR^UY\/
MUKTSGM[[]VQM':.WML;.S6>Q.P\90979>15<945$N:*A:C*22U\\\K^Z]U]3
M#^1[MF;:?\H7^75BYUK4>J^*75.YE%?)').8=Z8"'>-,T;1)&HHGI\\K4RD:
MDIBBL2P)/NO='0WO\I>ANO.]>EOC-N?L7"4W?/R EW:W675U%))E=VY/#[&V
M3NC?NY]V9?%8Y*FHVSLO'X?:53 ,OD!34$V3EIZ**5ZJ>.(^Z]T8'W[KW7O?
MNO=>]^Z]T0[^8[_,-Z#_ )97Q?WI\E^^LU"M-BH9</UUL"DK:>#=O;O9-71U
M,^W.O=GTLHDDEKLE)3M+657CD@Q>-AGK9[0P/[]U[KY&?9_8GS7_ )Z7\Q-<
MNV.K^R?D-\B=VT.V-C;,H*FN&S>LMD8]I1B-MXDU!J:?9_6'7>$,U97U)54U
M?=Y"H\E74SR2^Z]U]93^5'_+4ZG_ )6'Q"V3\;>O#0Y[=KK%NONWM"+'?P_(
M=J]L9*AI(-P;EEBEDJ*NCP-$M,E#AJ%Y9/L<93Q(S/,TTLGNO=64,RJI9B%5
M069F("JH%R23P ![]U[KYR'\W[YY]]_S\_YA.Q?Y0W\OC<E>_P 9]M=@5F)W
M_O#%-7)LOM+<NR:Q:G>G<._:V@ DR/2?30QDSX&%G2CS.4"5<2U-3-A6A]U[
MH^WR1_FC?R[?^$UWQCF_E]_RY\!MGO\ ^8]+C_NNR-RUM1#E<#B>SJVA:AK>
MQ_D;O#!&E;<N\*>:"]%LK%U%.^.H%BIY),93M"T_NO=$M_E _P I;N/^:IVG
M6_SF_P"=5OFKW/T6\IWAUOLSMO)46!PG<.+VY65530;BW9CJY\=M_K_XJ[/J
M1*<;A(TI*3<CAY)$7#ESF/=>Z-]_."_X5H]4=2;<W5\;/Y5]1C.P>R4QB;;E
M^4RXG'3=/]9H%>BG'4&W,K1RTO9.X\120A*.NJ:1=L4[O'+$N4C5H??NO=!/
M_P )I?Y(W^S 5E+_ #??YB5!F.V]W=B;HRN_/CKL3M>FK<S_ 'DS$N7JI*OY
M+]ETNY8GFW77Y7+Q23;1AJ4DH?$%S2^=I,9+3>Z]ULQ_S!?Y+/Q#_F2=I;2[
M7^7_ &!\D=S;,ZWV[+28GHG$]V3;+^/>/K(G$]=OR?;.,P<&>QV[YL:DE+4Y
M"FS5*KT<C!TNJ.GNO=4A?)W^=K\3/Y?6T-T?R]?Y"_QQZV[>[4ZYVWO/=._=
MX[%HZ2C^,O1."V9MJ3*[^[6[ [%JJZDI.V,WM2AIH6R^9R.9BPE-("M?F9*F
M$T$GNO=:CW\OCXG?*K_A0'_,TBQW?'<6]>SZ=)H^P?DSWYGGR-<<#T]MS-4]
M,^"VC&]!BL7M>JW9-6C%[8Q$-+04E :EYXZ-8*2>(>Z]U]63<&\/AQ_+(^+6
MWH=U[HZQ^+OQAZ/VQB]H[;7-9&BV[M_%4%'$8\=A,/3.QR.Y=U9NIUR""FCJ
M\IE:Z6233-/([-[KW6A-_-X_X5&=Q_.>ME^%'\K?;?9G7&P^RMUXWKF7MZD6
MKPWR![VK,WF:C;.-V7UE@<+43Y/KO:6_:^LHQ"WF3<^3BE2FFCQJR55'-[KW
M6?ISXW_ K_A-3UAM_P"2GSVI]G_+;^;5O/:E%NWHKX=8K(8O(;;^. R=,Z8K
M/;PJ4?.45)EDKTE^YW764S@-32TFW:2:6FJ<E4>Z]TF?Y2_PS^57_"D#YM[B
M_F ?S*]T9??'Q3Z5W*:)-L,M5@-A[PW7%54F=PWQUZGVK2N*3;W5FV,;-#4;
MGJ8YGR-5$]+#4U%;75]570>Z]UN9?S(/YSGP#_E)[(I-N]K[QQ^7[2H]M4*=
M=?%KJ-<3D>R*K#P4=11;;:KP4$]-B>M=BD8LT\&1RKTE,4A=*..IDC,/OW7N
MJ-OC]\=_YCO_  HWRV([^_F15&Y_B#_*K;*46?ZN^"VP<EG-K[E^1$>%K)*W
M![E["W*]/M[>62V@:]H9X,U7QTT=?]E'/@\7CUE3*R>Z]UN+=;];; Z>V%M+
MJWJO9NW.O>N=AX*@VSLW9.T<31X/;>VL#C(1!0XO$8J@BAI:2E@C'T5;LQ+,
M2S$GW7NOBL[]@[7_ )LG\TG>T'7E17;K[$^:7ROW,NR:S*15!7&;>WKO6N.W
MJS)Q+2TM10[9Z_Z_2&2<>",T>+QK>A?'I'NO=?8P^$7P_P"I_@7\6NG/BETO
M0&GV3U'M.CPARU33T4&:WEN2<M7;NW[N=\?34E+4[FWKN.IJ<C6ND:1K+.4C
M5(DC1?=>Z-4[I$CR2.L<<:L\DCL$1$0%F=V8A555%R3P![]U[K6R_F:_\*=/
M@C\$Y<UU;TQE(/F=\H(*B7"TO6G3N<I,AL':VY!5Y'%'&]B]K8V/+X2@RN/S
M..:FJL+B(\MG(:ADCGIJ8.)1[KW1:^Q_YGG>'\J'X+9#YU?S.MS83?O\S3YH
MX:F_V7[X8[=K<[MSKGI78N*IJ>KV[L+%;&&1RZ;0Q6TY-P+G.Q,[/)+FLME:
MFBP<N1K#C<6T/NO=:R_PS^%&_P#^;UN_M?\ G+?SH_DM4]5_!O8&YHZ;?'86
M[:F;:-9W-_=F1J6@Z2Z'AC2"FVSU[B,Q40X75@J>KK:W)2U&+Q<<N;DJJND]
MU[I/?.O^:#W/_-H[/ZC_ )37\J;J(?'_ .$%9N3&]8=.] ;'Q='L[)]T5%'4
MQY([Z[@EQHE3![(P$6*J,R<:)&AI*6*HR67EK*M4-'[KW6UIU[V1_+"_X2E?
M"3$=0[^W[2]H_*_?F-I-X=A;;V'CL16=X=\]A&BGDIIJB@C9(NNNG=JO6S4F
M"FSU5%3TU"9&C:NR-1.*CW7NM-+^9]_,R_F'_P WGOW!?'C>N(W#M[,Y;=M/
MMG87P<ZRS533[%ZRR4TN+R]*O:-6N7QJ[Z[SQ'V\L>XI]U0T=)U]#25D,U/C
M:ULG38CW7NCP_"3MOM/XQ8R+^7'_ "'>OL3\E?GYW%18I/F3_,>PN&Q^YNN^
MOTJ<>LE=U_\ 'K=V:QU-MS;/2/7F25@^^-QA*;.Y.*62AQ\TT^->#W7NDK_,
MH_E_?!;^5C\>][1?/3O+=W\PW^<A\D]DI/A]JXWM/?46Q_CKE\[AZK&S]U;_
M -SIEJ/?^_I]IR2HV"_O3,HW578^F4X2+&#(R1>Z]U<M_P )D'RW\L#^3[\S
M/YB/RVS.;V5\?=^;CQ_:/6&R,V:7$R9S$;"P55LRAW+M&DR5%0U4VX._][YR
M@VYAUDJ)8<F^*H'ID1)_+/[KW50W\KWXH]S?\*4/YJW;?S8^9*UE3\<.M-QX
M3=/9^ $V8EVW48Q?O4Z?^+'7]<YI8*/;]#C\;Y\R\&B8T$51/,BUN62=O=>Z
M^B)\K/FE\-?Y;G2N.WQ\CNTM@]#]:8#&0;=V+M=$AAR^;AP&,2''[.ZNZZP,
M$N<W%/C<72I'%18NCDCI*= 7\42ZA[KW7SF?YN__  J#^3W\Q.GSWQE^'&W=
MZ?&SXT[UJX-L5L&,JF;Y(]XXW*^"B.T]U97:.0R5-M+;NY*N8TU3MW;]3529
M2!VI*ROK*2HFHV]U[K:M_P"$WO\ (SQ/\MSI6@^27R'VOCJCYR=U;9)S,-0Z
M9(] ]<9MZ6OH>J\/4 M2)O+)4]-3U&Z*VG'IJR<;!++2TK5%9[KW0Z?S=_\
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MXQAP'FDV_05<DC@9.:*EK8?=>ZW+D1(D2.-%CCC54CC10B(B *J(J@*JJHL
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M?RF8LGL_L3N1_EE_.?[>Q$6;[R[<GWGE=^;>^"F,W#01S0T^T]X962;/;O\
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M'6[XW[F&J=P9T4\D[FFI3+'CZ!7*4E/!&='OW7N@@[D_DN?RO_D+\G*GY?\
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MEGWQM7K'/YC)=9;1W=59N-,A)D,;B*:J_B*FK5UJ7DE?W7NK.\OB,7N#$Y3
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D[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E %X# 2(  A$! Q$!_\0
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MZ C _"NPKF]!_P"0B_\ O7G_ *5O5QG+E>HI15UH:'_"-Z%_T!=._P# 5/\
M"JVH^'-#73+MET;3@PA<@BU3(X/M6[574O\ D%7G_7!__0341G*ZU93BK;&%
MHVCZ9?"[FO-.M+B7?$N^:!7./L\7&2*T_P#A&]"_Z NG?^ J?X5#X<_U%W_U
MTB_])X:VJ<YR4GJ*,5;8YW5-$TFSCM)[73+*"9;VWVR16ZJPS*H."!3=!T#1
MI] L)9M(L))'@1F=[9"6)'))(Y-:.N_\>EM_U^VW_HU:9H$L</A?3GE=406R
M99C@#BJYI>S6O45ES;#O^$;T+_H"Z=_X"I_A4$.EZ?I_B2U:RL;6V9[2<,88
M50M\\/7 K5@O+:ZS]GN(9L=?+<-_*JLW_(Q67_7I<?\ H<-0I2U38VET.!^-
MNK_8/#%C:12-'<W%UO1D8J0J*=Q!'^\H_&N.NO&MYHO@K3?"^CSS3ZS=ION[
MA6+O&9#D1KWWX(!]/KTD^(PG\9_%:U\/6D@ A"VX8C(5B-[MCV'_ *#6-\.W
M?0/B-_9]Y!:I?%GM4DN4+"*7..,$<G&W/O[U[=&E&.'7,KM>];\CSZDVZKMH
MGI<]4^'_ (-N/#.GMJVO7LTNH-&6*23%DMDQDCK@MCJ?P'<GS'PKI]]\1/&F
MJ.-2N["W;S;DM"Q^3<_RJ!GW_0UZ7\3-8U;1?!%X9Y[+_2_]%411N&.\'."6
M_NAJX+P%\.]=U?P__:VG^(Y])CNF9-D.\>8JDC)*L,C.X8K*C)^SG6G))O1,
MNHO>C3BKVU((I-6\(?%2RT:PU^ZOT^TPQ2AF;:X<C<K+DC@'KV]JI>/]<U#6
MO'VK1V-W.MO:AXPJ2D*%B4[SQQU#?F*[BR\ -\/K>_\ %%Q?6VH7=K"\J//&
MPPV.PW?>).,GUK@/".E7=[X?\6:YF-A%9-$S2*26+_,Q7'?"_P#CU=%.=.3]
MJM;)*_=MF4HR2Y'I?7Y'I/PLUJ'2_AA?:MJ4[&*WN9&=V;).%0 #/<\ #Z5Y
M)KOB37=;O;G79;JX@@GG,<:)*RJN!G:HSV&W/U'K1I%QJ_B"PL/!M@H\J6[:
M<@9^9B ,M_LJ 3^?M6Q\0].?2;_1O"D'DR"R@&TQ*5+R2MR6R3ECM4_B!5TZ
M<:==M[RN_1$RFY4U;9?F=H-<?PG\&=)NYI3-J=U.MQ LQ+;R)-XSSG 4#\QZ
MUS7A#P/K'Q$A.HZMJD\.FPGRH2V6+$=D4\*H]?7\:9\78+[3[W0]+N'A:VM+
M ) (5( P=IZD\X5:[[PWIM_K_P *;/3=*U.SM();=8VEBC8R1L&RX.&ZDY_.
MN=R]G1]I%I.3W[(U2YY\CV2V[G%:_P#"#Q!I&LQ2>%Q/>0!0ZSF>.*2)\GC)
M8>QR/6O8-(&H"30QJHQJ TR07/(/[S,.[D<=?3BOGVXT[5H/':^&8=:NKI_M
M26YF$CJ"3C=QGMD_E7T=;6>H?VG%=7DMJ4B@>)4AC8'YBAR22?[GZUAC7+EB
MIR3T[69IATKOE5CF_#WPXBT3Q?=>(Y]3>]NI_,;:T(0*SG).<GMD?C5;Q9\*
MK3Q+XA&M0ZE+I]R57?Y<0;<R]&SD8.,#\***X5B:JESWUM;Y'3[*'+RVT+WC
M/P')XSM-.@NM8> 6@)<I ")7( +8W<=#Q[UTFB:5#H>B66EP$M':Q+&&(P6P
M.2?J<G\:**SE5G**@WHBE"*ES+<H^+O#I\5>'Y=(^VM:)*ZL[JF\D*<XQD=P
M/RK+T?X?VVC^![_PW%>L_P!M$GF7)C .6 7.W/8 =Z**:K3C'D3TO?Y@Z<6^
M9K4C\#_#BP\%SW-RERUY=S ()7C"[$[@#)ZG&3["JVH?#&'4_':>)[C5)&99
MXYA;>2-OR 87.>GRCM115?6*O,YWU>A/LH64;:(V_%_@O3/&5A'!?AXYH23#
M<18WIGJ.>H.!D>U>:CX+SV>HK:6_BF6(3+DLEJ5XYX.).>E%%71Q-6FN6+T%
M4HPD[M:G4>%/A)9>&M<@U>75)[VZAW%0T81<E2"2,D]_6O1:**QJ59U7S3=V
(7"$8*T4?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < (0# 2(  A$! Q$!_\0
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D>=HY/3%>GT4 1P00VL$<%O$D4,:A4CC4*J@=@!THJ2B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>abio-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:57 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.arcabiopharma.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" id="abio_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abio_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" id="abio_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="abio_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" id="abio_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" id="abio_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" id="abio_r_ARCAandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShare" id="abio_r_NetLossPerShare">
        <link:definition>008 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures" id="abio_r_FairValueDisclosures">
        <link:definition>009 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment" id="abio_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements" id="abio_r_RelatedPartyArrangements">
        <link:definition>011 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies" id="abio_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancings" id="abio_r_EquityFinancings">
        <link:definition>013 - Disclosure - Equity Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation" id="abio_r_SharebasedCompensation">
        <link:definition>014 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" id="abio_r_EmployeeBenefitPlans">
        <link:definition>015 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxes" id="abio_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEvents" id="abio_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" id="abio_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables" id="abio_r_NetLossPerShareTables">
        <link:definition>996001 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" id="abio_r_PropertyandEquipmentTables">
        <link:definition>996002 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" id="abio_r_CommitmentsandContingenciesTables">
        <link:definition>996003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables" id="abio_r_SharebasedCompensationTables">
        <link:definition>996004 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables" id="abio_r_IncomeTaxesTables">
        <link:definition>996005 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" id="abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
        <link:definition>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" id="abio_r_FairValueDisclosuresDetails">
        <link:definition>996008 - Disclosure - Fair Value Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" id="abio_r_PropertyandEquipmentDetails">
        <link:definition>996009 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" id="abio_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" id="abio_r_RelatedPartyArrangementsDetails">
        <link:definition>996011 - Disclosure - Related Party Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" id="abio_r_CommitmentsandContingenciesDetails">
        <link:definition>996012 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable">
        <link:definition>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMzQF1p3TpdC1+6rkD/gYWaTGlCtqbHaRP0] CSR-->
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails" id="abio_r_EquityFinancingsDetails">
        <link:definition>996014 - Disclosure - Equity Financings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" id="abio_r_SharebasedCompensationDetails">
        <link:definition>996015 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" id="abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
        <link:definition>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" id="abio_r_ScheduleofStockOptionActivitiesTable">
        <link:definition>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" id="abio_r_ScheduleofRSUActivityTable">
        <link:definition>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable">
        <link:definition>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" id="abio_r_EmployeeBenefitPlansDetails">
        <link:definition>996020 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails" id="abio_r_IncomeTaxesDetails">
        <link:definition>996021 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" id="abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
        <link:definition>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" id="abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable">
        <link:definition>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
        <link:definition>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" id="abio_r_ScheduleofPropertyandEquipmentTable0">
        <link:definition>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable0">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0">
        <link:definition>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" id="abio_r_ScheduleofStockOptionActivitiesTable0">
        <link:definition>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails" id="abio_r_SubsequentEventsDetails">
        <link:definition>996029 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCommitmentsDueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
  <xs:element name="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfRsuActivityAbstract"/>
  <xs:element name="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract2"/>
  <xs:element name="CostsAndExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CostsAndExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract4"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAbstract"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
  <xs:element name="ResearchAndDevelopmentExpenseReversed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ResearchAndDevelopmentExpenseReversed"/>
  <xs:element name="DescriptionOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DescriptionOfBusinessPolicyTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="AccruedOutsourcingExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
  <xs:element name="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
  <xs:element name="DeferredTaxAssetResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetResearchAndDevelopment"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="FairValueDisclosuresDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_FairValueDisclosuresDetailsTable"/>
  <xs:element name="FairValueDisclosuresDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueDisclosuresDetailsLineItems"/>
  <xs:element name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
  <xs:element name="RelatedPartyArrangementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_RelatedPartyArrangementsDetailsTable"/>
  <xs:element name="PaymentOfUnrestrictedResearchGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfUnrestrictedResearchGrants"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RetentionBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonuses"/>
  <xs:element name="PercentageOfRetentionBonuses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfRetentionBonuses"/>
  <xs:element name="RetentionBonusPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonusPaid"/>
  <xs:element name="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
  <xs:element name="LesseeOperatingSubleaseTermOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LesseeOperatingSubleaseTermOfContract"/>
  <xs:element name="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
  <xs:element name="OperatingLeasesExtendedExpiryYearsAndMonth" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
  <xs:element name="PercentageOfBaseRentToBePaidMonthly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfBaseRentToBePaidMonthly"/>
  <xs:element name="EquityFinancingsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EquityFinancingsDetailsTable"/>
  <xs:element name="EquityFinancingsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EquityFinancingsDetailsLineItems"/>
  <xs:element name="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
  <xs:element name="SellingCommissionPerAdditionalSharesSoldPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
  <xs:element name="SharebasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SharebasedCompensationDetailsTable"/>
  <xs:element name="SharebasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SharebasedCompensationDetailsLineItems"/>
  <xs:element name="PercentageHoldingForStockOptionsExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageHoldingForStockOptionsExercisePrice"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PurchaseAggregateShares"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EmployeeBenefitPlansDetailsLineItems"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLossCarryforwardsExpirationYear"/>
  <xs:element name="DeferredTaxAssetsAndLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfConsecutiveTradingDays"/>
  <xs:element name="ThresholdAmountOfAdjustedExchangeRatio" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfAdjustedExchangeRatio"/>
  <xs:element name="ThresholdAmountOfDeclaredCashDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfDeclaredCashDividend"/>
  <xs:element name="SubscriptionAgreementReceiptAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_SubscriptionAgreementReceiptAmount"/>
  <xs:element name="PaymentOfOtherPartyTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfOtherPartyTerminationFee"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedShares"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
  <xs:element name="InitiallySpecifiedPercentageForBeneficialNumberOfShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
  <xs:element name="ExceptedNumberOfBoardMembers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ExceptedNumberOfBoardMembers"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_AggregatePurchasePrice"/>
  <xs:element name="NumberOfMonthsBaseSalary" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfMonthsBaseSalary"/>
  <xs:element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CashPayment"/>
  <xs:element name="IncreaseOfRetentionBonusToEachExecutive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncreaseOfRetentionBonusToEachExecutive"/>
  <xs:element name="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
  <xs:element name="ArcaBiopharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncMember"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="ClinicalDevelopmentDecisionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ClinicalDevelopmentDecisionMember"/>
  <xs:element name="CommonStockAndPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAndPreFundedWarrantsMember"/>
  <xs:element name="FirstMergerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstMergerMember"/>
  <xs:element name="FirstThreePercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstThreePercentPayContributionMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncentiveStockOptionMember"/>
  <xs:element name="JonesTradingInstitutionalServicesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_JonesTradingInstitutionalServicesLLCMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_MergerAgreementMember"/>
  <xs:element name="NewCapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NewCapitalOnDemandSalesAgreementMember"/>
  <xs:element name="NextTwoPercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NextTwoPercentPayContributionMember"/>
  <xs:element name="OrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OrukaTherapeuticsIncMember"/>
  <xs:element name="PatentAssignmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PatentAssignmentAgreementMember"/>
  <xs:element name="SecondAmendmentOfCertainRetentionBonusLettersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
  <xs:element name="SeperationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SeperationAgreementMember"/>
  <xs:element name="ThomasAKeuerAndCJeffreyDekkerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
  <xs:element name="TwoThousandAndThirteenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndThirteenPlanMember"/>
  <xs:element name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
  <xs:element name="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
  <xs:element name="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_WeightedAverageSharesOutstandingAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>abio-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:57 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMzFDYrkiBlbWqcm6MrD84IWg==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>abio-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:57 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMz17QprkAhEdcRml31G4OVBAOXO4P5iMrn] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_RelatedPartyArrangementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_PaymentOfUnrestrictedResearchGrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_PatentAssignmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="abio_ClinicalDevelopmentDecisionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonuses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfRetentionBonuses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonusPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_LesseeOperatingSubleaseTermOfContract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PurchaseAggregateShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_MergerAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_FirstMergerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SeperationAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_CommonStockAndPreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_PresidentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_ArcaBiopharmaIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_OrukaTherapeuticsIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfConsecutiveTradingDays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubscriptionAgreementReceiptAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_PaymentOfOtherPartyTerminationFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ExceptedNumberOfBoardMembers" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_AggregatePurchasePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfMonthsBaseSalary" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_CashPayment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_RetentionBonuses" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>abio-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:57 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total remaining lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity Financings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Purchase options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfRsuActivityAbstract_lbl" xml:lang="en-US">Schedule of RSU Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="abio_ScheduleOfRsuActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="abio_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses and other liabilities - related party (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract0" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl" xml:lang="en-US">Related party expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract1" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract2" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CostsAndExpensesAbstract0" xlink:href="abio-20240331.xsd#abio_CostsAndExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CostsAndExpensesAbstract0_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract3" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract4" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Income tax refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash investing and financing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Leased assets and operating lease liabilities &#8211; amended lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities, excluded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Financings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Non-cash, Share-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal income tax benefit at statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Deferred tax asset adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable contribution carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Capitalized intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed lease interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Lab Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Computer Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xml:lang="en-US">Off-balance-sheet concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xml:lang="en-US">Fair value hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US">Debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl" xml:lang="en-US">Payment of unrestricted research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonuses_lbl" xml:lang="en-US">Amount of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_RetentionBonuses_lbl0" xml:lang="en-US">Retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfRetentionBonuses_lbl" xml:lang="en-US">Percentage of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonusPaid_lbl" xml:lang="en-US">Retention bonus paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US">Remains unpaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Workforce reduction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease renewal option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl" xml:lang="en-US">Square feet office facilities (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl" xml:lang="en-US">Sublease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xml:lang="en-US">Lessee operating lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl" xml:lang="en-US">Royalty obligations (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Indicates (true false) whether lessee has option to extend operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl" xml:lang="en-US">Additional operating lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xml:lang="en-US">Percentage of commission rate equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock options award, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options award, expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Stock awards granted service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Matching contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employee&#8217;s contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Equal contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Company&apos;s contribution (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl" xml:lang="en-US">Increase in net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US">Number of consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of noncontrolling ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl" xml:lang="en-US">Adjusted exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl" xml:lang="en-US">Declared cash dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock convertible shares issuable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl" xml:lang="en-US">Excepted number of board members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfMonthsBaseSalary_lbl" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl" xml:lang="en-US">Increase of retention bonus to each executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Outsourcing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMzP5a7++3CZeSGHNDB1TUup39trPsJs/QP] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl" xml:lang="en-US">Clinical Development Decision [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl0" xml:lang="en-US">Clinical development decisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xml:lang="en-US">One-time Termination Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl" xml:lang="en-US">University Medical Center of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PatentAssignmentAgreementMember_lbl" xml:lang="en-US">Patent Assignment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xml:lang="en-US">Jones Trading</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">2020 Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xml:lang="en-US">2013 Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xml:lang="en-US">First 3% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xml:lang="en-US">Next 2% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xml:lang="en-US">Earliest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US">Latest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncMember_lbl" xml:lang="en-US">ARCA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl" xml:lang="en-US">ARCA and Oruka</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstMergerMember_lbl" xml:lang="en-US">First Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OrukaTherapeuticsIncMember_lbl" xml:lang="en-US">Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Common Stock and Pre Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SeperationAgreementMember_lbl" xml:lang="en-US">Seperation Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_PresidentMember_lbl" xml:lang="en-US">Thomas A. Keuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl" xml:lang="en-US">Second Amendment of Certain Retention Bonus Letters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">C. Jeffrey Dekker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsTable_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="abio_FairValueDisclosuresDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsLineItems_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RelatedPartyArrangementsDetailsTable_lbl" xml:lang="en-US">Related Party Arrangements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="abio_RelatedPartyArrangementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="abio_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsTable_lbl" xml:lang="en-US">Equity Financings (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="abio_EquityFinancingsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsLineItems_lbl" xml:lang="en-US">Equity Financings (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="abio_SharebasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US">Retirement Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="abio_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="abio_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="abio_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Accrued outsourcing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0" xml:lang="en-US">Area of real estate property sublease additional office facilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CashPayment_lbl0" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0" xml:lang="en-US">Common stock, authorized offering amount under agreement to sell.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0" xml:lang="en-US">Deferred tax assets and liabilities valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Description of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl0" xml:lang="en-US">Excepted Number of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0" xml:lang="en-US">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0" xml:lang="en-US">Adjustment of the carrying value of deferred tax assets during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0" xml:lang="en-US">Increase of retention bonus to each executive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl0" xml:lang="en-US">Lessee operating sublease term of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0" xml:lang="en-US">Minimum percentage of originally issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfMonthsBaseSalary_lbl0" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl0" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl0" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl0" xml:lang="en-US">Payment of unrestricted research grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0" xml:lang="en-US">Minimum ownership percentage for 110% fair market value on the grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl0" xml:lang="en-US">Percentage of base rent to be paid monthly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfRetentionBonuses_lbl0" xml:lang="en-US">Percentage of retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0" xml:lang="en-US">Potential upfront and milestone obligations and royalty obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PurchaseAggregateShares_lbl0" xml:lang="en-US">Purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl0" xml:lang="en-US">Research and development expense (reversed).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonusPaid_lbl0" xml:lang="en-US">Retention bonus paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonuses_lbl1" xml:lang="en-US">Retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0" xml:lang="en-US">Selling commission per additional shares sold percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl0" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0" xml:lang="en-US">Threshold amount of adjusted exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl0" xml:lang="en-US">Threshold amount of declared cash dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0" xml:lang="en-US">Valuation allowance deferred tax assets and liabilities change in amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Arca Biopharma Inc and Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncMember_lbl0" xml:lang="en-US">ARCA biopharma inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital on demand sales agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl1" xml:lang="en-US">Clinical Development Decision Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl0" xml:lang="en-US">Common stock and pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstMergerMember_lbl0" xml:lang="en-US">First Merge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstThreePercentPayContributionMember_lbl0" xml:lang="en-US">First three percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl0" xml:lang="en-US">JonesTrading Institutional Services LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MergerAgreementMember_lbl0" xml:lang="en-US">Merger agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">New Capital on Demand Sales Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NextTwoPercentPayContributionMember_lbl0" xml:lang="en-US">Next two percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Oruka therapeutics inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PatentAssignmentAgreementMember_lbl0" xml:lang="en-US">Patent assignment agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0" xml:lang="en-US">Second amendment of certain retention bonus letters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SeperationAgreementMember_lbl0" xml:lang="en-US">Seperation agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl0" xml:lang="en-US">Two thousand and thirteen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand and twenty equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1" xml:lang="en-US">University medical center of Johannes Gutenberg university Mainz.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Accrued Outsourcing Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl0" xml:lang="en-US">Area of Real Estate Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl1" xml:lang="en-US">Excepted Number Of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl0" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl1" xml:lang="en-US">Jones Trading Institutional Services LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0" xml:lang="en-US">Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl1" xml:lang="en-US">Two Thousand And Thirteen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl1" xml:lang="en-US">Threshold Amount Of Declared Cash Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarliestTaxYearMember_lbl0" xml:lang="en-US">Earliest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">New Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PatentAssignmentAgreementMember_lbl1" xml:lang="en-US">Patent Assignment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1" xml:lang="en-US">Thomas AKeuer And CJeffrey Dekker Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0" xml:lang="en-US">Proceeds from Income Tax Refunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0" xml:lang="en-US">Operating Leases Extended Expiry Years And Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CashPayment_lbl1" xml:lang="en-US">Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl1" xml:lang="en-US">Payment Of Unrestricted Research Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstThreePercentPayContributionMember_lbl1" xml:lang="en-US">First Three Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1" xml:lang="en-US">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0" xml:lang="en-US">Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonusPaid_lbl1" xml:lang="en-US">Retention Bonus Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl1" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1" xml:lang="en-US">Selling Commission Per Additional Shares Sold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfRetentionBonuses_lbl1" xml:lang="en-US">Percentage Of Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1" xml:lang="en-US">Increase Of Retention Bonus To Each Executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl1" xml:lang="en-US">Common Stock And Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl0" xml:lang="en-US">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstMergerMember_lbl1" xml:lang="en-US">First Merger Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl1" xml:lang="en-US">Payment Of Other Party Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl2" xml:lang="en-US">Clinical Development Decision Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SeperationAgreementMember_lbl1" xml:lang="en-US">Seperation Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1" xml:lang="en-US">Threshold Amount Of Adjusted Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl1" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MergerAgreementMember_lbl1" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LatestTaxYearMember_lbl0" xml:lang="en-US">Latest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc And Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonuses_lbl2" xml:lang="en-US">Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfMonthsBaseSalary_lbl1" xml:lang="en-US">Number Of Months Base Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl0" xml:lang="en-US">Principal Owner [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CostsAndExpensesAbstract0_lbl0" xml:lang="en-US">Costs And Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1" xml:lang="en-US">Percentage Holding For Stock Options Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl1" xml:lang="en-US">Research And Development Expense Reversed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets And Liabilities Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1" xml:lang="en-US">Potential Upfront And Milestone Obligations And Royalty Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0" xml:lang="en-US">Defined Contribution Plan, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NextTwoPercentPayContributionMember_lbl1" xml:lang="en-US">Next Two Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl1" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1" xml:lang="en-US">Common Stock Authorized Offering Amount Under Agreement To Sell</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PresidentMember_lbl0" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Non Cash Share Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US">Number Of Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1" xml:lang="en-US">Area Of Real Estate Property Sublease Additional Office Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl1" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl1" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl0" xml:lang="en-US">One-time Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncentiveStockOptionMember_lbl1" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PurchaseAggregateShares_lbl1" xml:lang="en-US">Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl0" xml:lang="en-US">Restructuring Reserve, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1" xml:lang="en-US">Initially Specified Percentage For Beneficial Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1" xml:lang="en-US">Second Amendment Of Certain Retention Bonus Letters Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1" xml:lang="en-US">Income Tax Reconciliation Adjustment To Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl1" xml:lang="en-US">Lessee Operating Sublease Term Of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl1" xml:lang="en-US">Subscription Agreement Receipt Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl0" xml:lang="en-US">Interest and Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>abio-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 18 20:45:57 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="WeightedAverageSharesOutstandingAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccruedOutsourcingExpensesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4YyOJ7CXT6fXimJ/+uV7byuZGtFyIeWVZT+w6uOt1BaasyWg31kJejh7qRixMb3bJF40sjvbG6ORRaBTApHD6N8YC+3ksd5gLtFTtDI8TCMzsCyes7fJD0YyU5rc1a8ApkRxr+wfISxg] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="FairValueDisclosuresDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyArrangementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PaymentOfUnrestrictedResearchGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ClinicalDevelopmentDecisionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PatentAssignmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonuses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfRetentionBonuses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonusPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LesseeOperatingSubleaseTermOfContract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OperatingLeasesExtendedExpiryYearsAndMonth" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfBaseRentToBePaidMonthly" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityFinancingsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NewCapitalOnDemandSalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JonesTradingInstitutionalServicesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="EquityFinancingsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="SellingCommissionPerAdditionalSharesSoldPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="SharebasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrincipalOwnerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_PrincipalOwnerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndTwentyEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndThirteenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="SharebasedCompensationDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PercentageHoldingForStockOptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PurchaseAggregateShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="FirstThreePercentPayContributionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="NextTwoPercentPayContributionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="EmployeeBenefitPlansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LatestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsExpirationYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="FirstMergerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SeperationAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecondAmendmentOfCertainRetentionBonusLettersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_PresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ThomasAKeuerAndCJeffreyDekkerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ArcaBiopharmaIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="OrukaTherapeuticsIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockAndPreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfConsecutiveTradingDays" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfAdjustedExchangeRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfDeclaredCashDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SubscriptionAgreementReceiptAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PaymentOfOtherPartyTerminationFee" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExceptedNumberOfBoardMembers" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregatePurchasePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfMonthsBaseSalary" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CashPayment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IncreaseOfRetentionBonusToEachExecutive" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RetentionBonuses" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abio-20240331.xsd#abio_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5EF;9JL_HHIIB$CL)EF/AXO O05,70@9V"-)QR(Y8H\,)U;B3JJ7+XN7(2D
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M-Q.TR^,NZ'BBQ:[8%SP)C;N,XC#!G2-((\#[&R'TZXG9:E1[T>4/4$L#!!0
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M#0"#KEJ4,L/&)C!:&^\<81KCUIX[Q]Q/S-9V.\<XMM7::7KCR$F![M19SU!
MBHR7GY=ZMFXGOJA3M#6_,*=+LV/>%^U'V2W\DR][%_&%W<7BA$I@*T(9@Y%8
M*2W[@7+ 2:X.O&?"Q?&I;B/10@&5 /%\2P@_#F2 NBGS_@)02P,$%     @
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MMQBEF$H!\?N&$/YR(U_0GBU<_0]02P,$%     @ $XK26)+4"E-U%0  )4\
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M3(<("2>38)I6^O2SA>UNV=$Y4O;ECZYX337S:B\"^I!^'JY"8SU'ALB7)Z2
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MBS?>XJW&/7]V:?)<>[C%.R&+1%R:PNMBK(I8*W>RZ\&"#N[&%;F+0"YZA-Q
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M4>]Y_9P?LJK\HO_\60BLH _%*X/E,!)YF#E&:JR+@@RT1)I!+N1@ +D59JJ
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M=E06_F=!%ULT+$#G*TT[MWU@ _U5>?X74$L#!!0    ( !.*TE@ (@- ZP<
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M1++2Z'5E+'@E?&^J-JT'=5S!M(UX9RJ,\-U8N7< 9_C!H;RW>XTUE["/B !
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M W;/+IG-_\,CP73Y]I["=&L^TW8[/(:CVG3L+;.3[ U KFSTGB,MFY!9X67
M]&MZE?(RO$'8WQ[>P_P@[2TMURJUP-'9](>G!V&[V7WQIN'W">?&>[/BCTLE
MT;_I!EQ?&..[+\0@O6#ZZC]02P,$%     @ $XK26!!EGH; %@  R%D  !D
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M9I2F4\%9KLG-71NXN6MR9'B2=+8U*VQ 5Y"-1I/S(J8'[-.WB8#^L3@41U!
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M!/8ZFLVTXM",B<U<;'ORITU [M"Y?/TR].^=R)2'MBNW*EBN NX0S^V6A:L
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M='/[9DYO*]1N <T?%<6LZ3@#W6MM_0502P,$%     @ $XK26)3,2-[P @
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M;H$_$Z"L *[G4IKUP&[0_YXDOP%02P,$%     @ $XK26.8ZJ\,A P  9@@
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MR03[FFD&SN;#Z<H/>4OM<&3TRS7.Z&!( /]G6KOM!QGHIO[Y_U!+ P04
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M PVN7IO6R=;8VXT6M?/&G=#&:=VR-'<A2!M@WN="Z./&)NAOU_074$L#!!0
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M?/^58+\CV;9X;W['I&1IL;DA."9<%ZCS:\;D\XY^%5]]JUG^#U!+ P04
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M!MT1]8LJAWFY,;)P W0M#8UCM]S2^X?*&M#W5$ISVEB"^D6-?@-02P,$%
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M@!HU2L%Y0/ORL1K1HW[-NC2EMPV:=L(6.;T+T/FDWI=905]F50,&#P&#74O
M#C.Y-T7U%3';X%"^<)(--PH<5!V</:^6IV8J.7$.MVJ'R'E#O$#O<%="#ZVF
MI6V2FA>&2^FUFQSA"RG]&;X15*#WNRNOA^[0TK>'E]:*2^G66M>Z=NA];=,&
MO '5H@_HR\5J@ ^=KJ5O=1N4CDMCJ#6@32GI *0I)3V9%?1E5C6 AX;<TG>*
MBE+R.T4I5_X@>J<':[VAO-.6 9JF6<]T'2954WTZGV<>SU?E\- 16_J6^,WJ
MH6.TSZYU5J =%P5KZ#EU0OMJ;A73P:%MG>'ST.!:K3O</:-J#GOJ*0L..Z"I
MV)GW!13T %2-Q*%?MBYLF/5QZ:E1+>+2 4T=EYZ @AZ JM=$AQX<ZIM+Q0[Y
M1.@21_M*&\IR&L?JN.C!V\:E0#O.JE<6](]^*BXNGQ1RO@_=VL$V4,E!=VQY
MMCJOP$.?"_5][INKN0V'?3:FLP*MDK='PY-;#968R._UWX<48J(U<&KT&4<W
MO FFJ^QJG8&0;%.>7UF6H^7U_6UV:5T;GUO707X)?X#)_R?@"Z(K<28$,5X*
M2',X$F<=FE^SYR^<;+)[Y"?".4FRQS5&"TRE@/A^20C?O\@)RG]VF/X'4$L#
M!!0    ( !.*TEB<%,RW;@,  .L.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;+57WV_:,!#^5ZQLFC:I;7Y *>T@$J7KMH=.55';AVD/)CG :F(S
MVT#[W^_L0 I=\,AH7Q+;R7UWW^=S<M=9"/F@)@":/.895UUOHO7TS/=5,H&<
MJB,Q!8Y/1D+F5.-4CGTUE4!3:Y1G?A0$+3^GC'MQQZY=R[@C9CIC'*XE4;,\
MI_+I'#*QZ'JAMUJX8>.)-@M^W)G2,0Q WTZO)<[\$B5E.7#%!"<21EVO%Y[U
MPX8QL&_<,5BHM3$Q5(9"/)C)][3K!28BR"#1!H+B;0Y]R#*#A''\7H)ZI4]C
MN#Y>H5]:\DAF2!7T17;/4CWI>FV/I#"BLTS?B,4W6!(Z-GB)R)2]DL7RW< C
MR4QID2^-,8*<\>).'Y="K!F$K2T&T=(@>FG0W&+06!I8Y?PB,DOK@FH:=Z18
M$&G>1C0SL-I8:V3#N-G&@9;XE*&=C@<3*N'0")&2OL@Q.Q2U^GZ\ $U9ICZ1
M0S+ Y$EG&1 Q(C>#6](SVC/]A(_>$Y\H@Z$ZOL9X#*J?+'V?%[ZC+;[#B%P)
MKB>*?.$II)L /A(IV40K-N>1$_$"DB/2" ](%$2-BH#ZNYM'CG :I;@-B]?8
M)NXVW7[VADI+3.%?5:H5H,UJ4'.NS]24)M#U\. JD'/PX@_OPE;PN8KQ*X%M
M\&^6_)LN]/C'+!^"-.QMFJD#HX(B^#51FO*4\?$!&<*8<8Y#\]H4)!-IE2:%
MHY9U9#Y-\_@T#(*@X\_7R3K#J29+'#R/2Y['3I[W]F.!)Z@W!XD?/_)54JX)
M'D@H+I>427)'LQGL(4$10WM-@N@H"E\HX RTO@*M4H'6WCMM17EYS MJ3O"=
MHB[8M_Z1)1O<3DIN)V^YNP[:3K\U:)^X,V.#=;MDW=Y[1^] &5UPBG_T#,Q/
MI(IF^Z]=.:PZO,YXZJ?N:4GT]"VW=T<-3G<YO,Y ZRL0!L]%0+#W9F/5- *V
MXII0GF#M54W6[:U&8K\"T*8B:V51^)9944<L9R!UQ-H?:%.LZ%FL:._T 7O'
MDCLS8E0*X7121XBHSF\@?*[F0F>QM&].[*# ?Q1KU0HT=ODC^&MM0PYR;+LI
M11(QX[JHN<O5LF/KV3[EQ?JYZ>1L._(,4[2!5U1B;:-(!B.$#(Y.L#Z116=5
M3+28VN9D*#2V.G8XP6X4I'D!GX^$T*N)<5#VM_$?4$L#!!0    ( !.*TEC^
MV W'DP,  +H0   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;,58;6_;
M-A#^*X16#"V01*]67F8+L"UU*[ .0=QN'X9]8*2S)502-9*VT_WZD92LV#(C
MI"B!?HE)ZIZ'=_><S[I,]X1^83D 1T]56;.9E7/>W-DV2W.H,+LB#=3BR9K0
M"G.QI1N;-11PID!5:7N.$]H5+FHKFJJS>QI-R9:710WW%+%M56'Z=0$EV<\L
MUSH</!2;G,L#.YHV> ,KX)^;>RIV=L^2%174K" UHK">67/W+G$="5 6?Q:P
M9T=K)$-Y).2+W'S(9I8C/8(24BXIL/C8P1+*4C()/_[M2*W^3@D\7A_8WZO@
M13"/F,&2E'\5&<]GUHV%,ECC;<D?R/XWZ *:2+Z4E$S]1?O.UK%0NF6<5!U8
M>% 5=?N)G[I$' $$CQ[@=0!O" A> /@=P!\"PA< 00<(7GO#I .HT.TV=I6X
M&',<32G9(RJM!9M<J.PKM,A74<M"67$JGA8"QZ-5CBE<RE1G:$DJ47\,*P7?
MQL!Q4;)WZ!*M1'EFVQ(06:,_2'V98I9?H!>AR9-<@P!^7L7H[9MWZ TJ:O0I
M)UN&ZXQ-;2X\E_?;:>?EHO72>\%+'WTD-<\92NH,,@T^'L>[W@B!+5+6Y\T[
MY&WAC3)^Q/0*^>X%\APOT#BT?#W<U\4S#H\A'84GKX=[(\GP^R+R%9\_6D0+
M50GW^*OH(QS-*<7U!N3ZXE 1&1+RHR5N"H[+XC_(+M"\(EMA_??O@A)]X%"Q
M?W3ET=X?Z.^7S?2.-3B%F26Z)0.Z ROZ^2<W='[126.2+#9)EA@B.Q$QZ$4,
MQMBC3T2(@J!52OL=;?$3A9<_0+O(=47M[XYS>V[C.0.;^-PFO E/;9)SF\GD
MV>8DP$D?X&0TP%^A!BI"E#4XST0O+1BG6/Y.Z8(=Y?K6BC-)%ILD2PR1G0@2
M]H*$/[AMA"9%-$D6FR1+#)&=B'C=BWC]G6VCQ8>C;4-C$_J#MG%N,_&&;>/<
M)O!\?=NXZ0.\&0WP0:0,TS1711C#3KQ;-[(\=:&.,GUKO9DDBTV2)8;(3N2X
M[>6X_<%-X]:DB";)8I-DB2&R$Q%=YWGL<+ZS;8P3Z!U$.@DZHN-WB< =]!:-
MC0AUT%QT1OZPN]A'LU@%=*.&8(9267KM&W5_V@_:<S5>#LX7[MW2U9S'<C!7
ML]\S?3O5BZ%B4]0,E; 65SE7U\)3V@[*[8:31DV"CX2+N5(M<\ 94&D@GJ\)
MX8>-O*#_=T7T/U!+ P04    "  3BM)8'Q.K/F,#  "E#@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6RU5UUOVS@0_"N$>FU3X,ZB)'\EM074=HH6
M: Y!@]X]'.Z!D=>64(I423I._GU)2I$E52$:PWFQ18HSW!EQB=W9GHOO,@50
MZ#ZG3,Z]5*GBPO=EDD).Y( 7P/2;#1<Y47HHMKXL!)"U!>74#S$>^SG)F!?/
M[-RUB&=\IVC&X%H@N<MS(AX60/E^[@7>X\37;)LJ,^''LX)LX0;4M^):Z)%?
MLZRS')C,.$,"-G/O0W"Q#"(#L"O^R6 O&\_(2+GE_+L9?%[//6PB @J),A1$
M_]W!$B@U3#J.'Q6I5^]I@,WG1_:/5KP6<TLD+#G]-UNK=.Y-/;2&#=E1]97O
M/T$E:&3X$DZE_47[<NUP[*%D)Q7/*[".(,]8^4_N*R,:@"E^ A!6@+ #"(9/
M *(*8)WSR\BLK!51))X)OD?"K-9LYL%Z8]%:3<;,9[Q10K_--$[%EWE!^0,
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MYPFX=.4F*D DP)2N(OI,*)D#W#B30>?4.C<_4MIY+>W<+<U>5L_0<_ZK'CS
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MPQ5U+6:84F.)0AO0]X1S=9SH#=I6-?P;4$L#!!0    ( !.*TEC_5&F$!P0
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M9+<29W;-$K,4N&*"$PFSD779&81]$U\$_&"P4FMC8I1,A7@TDZ_QR'),0I!
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M1(B"H%5*^QUM\1.%ES] N\AU1>WOCG-[;N,Y YOXW":\"4]MDG.;R>39YB3
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MW7XH^H&6CFTUNI6D<@'FQR\I*Z9I,[35'@TPB66++Z4W/.1Y2%K73Q5_$&L
M29Z+O!0WH[64]?OQ6"1K*)@XJVHHU2?+BA=,JD.^&HN: TO;0D4^#B>3\W'!
MLG(TNV[?N^.SZZJ1>5;"'2>B*0K&7SY 7CW=C(+1ZQM?LM5:ZC?&L^N:K> >
MY,_U'5='XZU*FA50BJPJ"8?ES>@V>$^GH2[0GO&_#)[$SFNB;V5150_ZX%-Z
M,YKH*X(<$JDEF/KU"'/(<ZVDKN./3G2TK5,7W'W]JOZQO7EU,PLF8%[EOV2I
M7-^,+D<DA25K<OFE>OHG=#<TU7I)E8OV)WG:G'L1CDC2"%D576%U!456;GZS
MY\Z(G0)!_$:!L"L0GEH@Z@I$IQ:(NP)QZ\SF5EH?*)-L=LVK)\+UV4I-OVC-
M;$NKV\]*_7>_EUQ]FJER<G;?+ 3\T4 IR0^/ZJ<@[RA(EN7B._)WLO\I^?4S
M% O@OZG/?KZGY-W?OKL>2W496FR<=%5^V%09OE'E;<W/2#CY7OT/8T?Q^0G%
M)]&;Q>D)Q2-G[6/EW=; <&M@V.I%?\+ 7W]4)Y-/$@KQF\NGC7+L5M81_U[4
M+(&;D0II ?P11K-OOPG.)_]PN88I1I'$+$>CK:.13WU&(<D9AY0D3*Q)FCUF
M*92IRS^O3E__-F+35DSWEH^SZ:3]=SU^W+4&J5++FGAK3>RUY@M(U<1T?[FH
MRD: <+GBE>CK"J88C0\LCN-XUV'+E.G6E*G7E-LO\UO"RI3\ES</S.6(MWQ?
M1S#%*)*8Y=OYUK?SP7JN<TQ',<4HDICEZ,76T0MO2[P#GB@C5;Y$JB6IGDK@
M8IW5)"LEJ-JDRTFO8E\G-V)!N!-AD[.KB_-PKP]#JM0RZ7)KTN71<'49X2W5
MUPA,,8HD9KEUM77K:K @O<)T%%.,(HE9C@83D_).O"WP/XW.876()E4I(&DT
M>A#)69J5*Y*R%^>PZA?M:^>12YR^=1D4ZS)L[W9P(?!';_J[@A*5G,%SLF:E
MZNDX4PF)TS"O4F_#@A/S,ZQJ;8,,#@3>W'B3C7PEQY,2OTYO>U#3?RPUVT,#
M $$T6*<7H$(!JAK%4K-M-? 0^.G!3D_*JE3=G^15GNMN[[1LQ5]#;W=C5[XR
M":/+_9A&JM8VS@!&< )A?"7SJB@4>MW+*GEPFH/*&:AJ%$O-=M"@1C <:P2H
ML(&J1K'4;%L-;P1^X/A49C)C>?Y"1 U)MLS4P%R;*%]6G"R@A&66J+-(N<U[
MQ)IQ]^2!O\+>9CN!9')U=;4?X$,026"0)/ S23M(DY_6P%D-*AU,!/E4)GLA
MWP[G=QS(QZ9,E=&_,,Z9;LJODZ)./U&Q!E6-8JG9IANR"89#FP"5;5#5*)::
M/1UMZ";TH\/M:L5AQ220NN$J1Q?J!<\2<$Y HS)-I[:;HH<7[B0=JV+;(T,Q
MH9]B[H%G(,@''<Y+X'JR^<U1W2_5VR-,-8JE9MNXL_0QX-H'[N('[NK'$/@3
M&OP)_0L@G[,R*YIB=R37TXD\6V5E.]AG0C2JR5:-%%(-2BI]=SJ,2D*=FIY^
MV!G*H_VX'H)P0D,XH9]PL)Q#I9Q.[9AS0R!.:! G]"/.3^NJ8(+<GI%_0Z.2
M1)WKS,_(OV"YY/!"*#P\J'=]F8Z_@MZFH=(/EIIMKJ&?<#CZ"5'I!U6-8JG9
MMAKZ"?WT<])J:*>QFY0$Y].#C&3NKZNW,T/P3&AX)O3SS&?@*Q6NMRH3A$(W
MNU,F)/V:O5L:*JI@J=E^&E0)AT.5$!554-4HEIJ]S\.@2N1'E3OVTK9./49+
M!=^D9ER^$ F\4.-U&]E+<(*+7[CWUH]#<&GW)1QL_1B"6B)#+9&?6AQ1_9KP
M^ 9FOVIOKU !!DO-=M0 3#0<P$2H (.J1K'4;%MW-G#Y 4;;FO"LWNSLW#97
M#@FH-PDKJJ9T+B_X=7M[>KBE*WAC/@*K8MLPPRW1$6XYC.P^4Q1^]=ZVH>[Y
MPE*SG35<$TV'BW!4HD%5HUAJMJV&:")O:C\SC5+H1OF]'KG)(\L;(.^RDM J
MSQD7FL,W:PW.;<+^.GK[NU&[L)<:)L%^I _!+)%AELC/+!\S+B3IXOTK<2\\
M.,U"79A!5:-8:K:GAG:BR^%B'!5Z4-4HEIIMJX&>R)O]SWYX3J#66WW,NN&B
M8CPE19MK.FG;+]G;SHW:^>Z>G_UP'H)@8D,PL9]@]L+YK4'[E;^/[R'PU]=[
M]S:F&L52L[TV^!,'@X5YC,I J&H42\VVU3!0[-^PMC>4ZSV1C\!EMLBAVR?0
MSIHS?:S']OOV/>> [J^IM\OA0?0'AYD[5IVV>P9UXB.H RK'V4Q5;+-WIS6H
M9(.J1K'4; MWOM,2#Q?7J.2#JD:QU&Q;#?G$_A4=L\M9#3AR+=JO1Q+!5&+^
MXK02E7:.7%P0=E?E-&X(MHD-V\1^MIGKKYW5FZE)IU&HV-*I69LF#I<G*%:E
MMB<&6V(_MMR#&A92<JL\25^G;.=JE&!J0##+,!_T,@SY$:14Z:%*=O86%9UF
MHF(-JAK%4K,]-U@3#X<U,2K6H*I1+#7;5H,UL1]K%%]ST%VA:L+<7D$DLB+
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M2O%.Q%:*UQH0=]T@(H[=NXWE@0AL%[#>@?SN/-!3[I@PA%W%M&%W,([$,89
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ $XK26,*)X\%7!   S@X  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !.*TE@\34M6I 4  #(9   8
M              " @9H,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  3BM)83WGWO'8#  "7#@  &               @(%T$@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $XK26-;=!;E?!
M\A(  !@              ("!(!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( !.*TE@DG/U;[0(  * )   8              " @;4:
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  3BM)8<0,$
M ?X&  !Y,P  &               @('8'0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ $XK26!ATZGOQ!@  9R@  !@
M ("!#"4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !.*
MTEB2U I3=14  "5/   8              " @3,L  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  3BM)8IG-#B.H#  "O#0  &
M        @('>00  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ $XK26"4I #,;!   &@T  !D              ("!_D4  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  3BM)8/S6,A3(#  ":"0
M&0              @(%02@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( !.*TECV<"0RJP,  +\+   9              " @;E-  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ $XK26*G%-'.P
M"P  IR@  !D              ("!FU$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  3BM)8CB?]); %   V#P  &0
M@(&"70  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !.*
MTE@ (@- ZP<  .H6   9              " @6EC  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ $XK26"@UGHZ3 @  _@4  !D
M         ("!BVL  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  3BM)8WWJ0&*4(  ";%P  &0              @(%5;@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !.*TE@SC&G.;@X  &PJ
M   9              " @3%W  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ $XK26!!EGH; %@  R%D  !D              ("!UH4
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  3BM)8\J_[
M;&,#  "Y"0  &0              @('-G   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( !.*TEB4S$C>\ (  *H(   9
M  " @6>@  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M$XK26.8ZJ\,A P  9@@  !D              ("!CJ,  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  3BM)8QA!W9.8%  "T$@  &0
M            @('FI@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( !.*TEB^M\FG_ 0   $,   9              " @0.M  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ $XK26)3(3(*; @
M:0<  !D              ("!-K(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  3BM)8C*U*BW(#  #1$   &0              @($(
MM0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !.*TEBO
MS)[5+@,  !$-   9              " @;&X  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ $XK26&%-3>J6 @  S0<  !D
M     ("!%KP  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !.*TEA1B1;A8P0  /\>   9              "
M@377  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ $XK2
M6&0LGS1\!P  LT@  !D              ("!S]L  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  3BM)84<59#^ "  !=!P  &0
M        @(&"XP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( !.*TE@'PIOJF@4  /@@   9              " @9GF  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ $XK26)P4S+=N P  ZPX
M !D              ("!:NP  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  3BM)8_M@-QY,#  "Z$   &0              @($/\
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !.*TE@?$ZL^
M8P,  *4.   9              " @=GS  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ $XK26#@$*<9Y!@  \B0  !D
M ("!<_<  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  3
MBM)8 PQG07 #  "V"@  &0              @($C_@  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !.*TEC_5&F$!P0   T/   9
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M970T-BYX;6Q02P$"% ,4    "  3BM)8]DF+!PT%  #>&P  &0
M    @($.%0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M !.*TEBD;9Z-0P@  ,=$   9              " @5(: 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ $XK26-V#.,-1 P  2A0   T
M             ( !S"(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  3BM)8
MEXJ[',     3 @  "P              @ %()@$ 7W)E;',O+G)E;'-02P$"
M% ,4    "  3BM)8C#C9=!H$  !,(   #P              @ $Q)P$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ $XK26)(LH):X 0  YQP  !H
M         ( !>"L! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ $XK26(Q/ZH^Z 0  [AP  !,              ( !:"T! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _#P  4R\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancings</Role>
      <ShortName>Equity Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Fair Value Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosuresDetails</Role>
      <ShortName>Fair Value Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/FairValueDisclosures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Related Party Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails</Role>
      <ShortName>Related Party Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/RelatedPartyArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity Financings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancingsDetails</Role>
      <ShortName>Equity Financings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EquityFinancings</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of RSU Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0205122-02.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abio-20240331.xsd</File>
    <File>abio-20240331_cal.xml</File>
    <File>abio-20240331_def.xml</File>
    <File>abio-20240331_lab.xml</File>
    <File>abio-20240331_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="ea0205122-02.htm">ea0205122-02.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tarca_001.jpg</File>
    <File>timage_001.jpg</File>
    <File>timage_002.jpg</File>
    <File>timage_003.jpg</File>
    <File>timage_004.jpg</File>
    <File>timage_005.jpg</File>
    <File>timage_006.jpg</File>
    <File>timage_007.jpg</File>
    <File>tlucid_sig.jpg</File>
    <File>toruka_logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="650">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0205122-02.htm": {
   "nsprefix": "abio",
   "nsuri": "http://www.arcabiopharma.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "abio-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abio-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abio-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abio-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abio-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0205122-02.htm"
     ]
    }
   },
   "keyStandard": 209,
   "keyCustom": 39,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 20,
   "hidden": {
    "total": 122,
    "http://fasb.org/us-gaap/2023": 114,
    "http://www.arcabiopharma.com/20240331": 5,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 409,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 650,
    "http://xbrl.sec.gov/dei/2023": 9
   },
   "report": {
    "R1": {
     "role": "http://www.arcabiopharma.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Balance Sheets (Unaudited)",
     "shortName": "Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Statements of Operations (Unaudited)",
     "shortName": "Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Statements of Operations (Unaudited) (Parentheticals)",
     "shortName": "Statements of Operations (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Statements of Cash Flows (Unaudited)",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - ARCA and Summary of Significant Accounting Policies",
     "shortName": "ARCA and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShare",
     "longName": "008 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosures",
     "longName": "009 - Disclosure - Fair Value Disclosures",
     "shortName": "Fair Value Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipment",
     "longName": "010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangements",
     "longName": "011 - Disclosure - Related Party Arrangements",
     "shortName": "Related Party Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingencies",
     "longName": "012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancings",
     "longName": "013 - Disclosure - Equity Financings",
     "shortName": "Equity Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensation",
     "longName": "014 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlans",
     "longName": "015 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEvents",
     "longName": "017 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShareTables",
     "longName": "996001 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentTables",
     "longName": "996002 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables",
     "longName": "996003 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationTables",
     "longName": "996004 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesTables",
     "longName": "996005 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)",
     "shortName": "ARCA and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
     "longName": "996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails",
     "longName": "996008 - Disclosure - Fair Value Disclosures (Details)",
     "shortName": "Fair Value Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails",
     "longName": "996009 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
     "longName": "996011 - Disclosure - Related Party Arrangements (Details)",
     "shortName": "Related Party Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996012 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
     "longName": "996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
     "longName": "996014 - Disclosure - Equity Financings (Details)",
     "shortName": "Equity Financings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c93",
      "name": "abio:SellingCommissionPerAdditionalSharesSoldPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
     "longName": "996015 - Disclosure - Share-based Compensation (Details)",
     "shortName": "Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable",
     "longName": "996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "shortName": "Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
     "longName": "996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable",
     "longName": "996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity",
     "shortName": "Share-based Compensation (Details) - Schedule of RSU Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
     "longName": "996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails",
     "longName": "996020 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesDetails",
     "longName": "996021 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable",
     "longName": "996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable",
     "longName": "996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
     "longName": "996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0",
     "longName": "996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0",
     "longName": "996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
     "longName": "996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEventsDetails",
     "longName": "996029 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-02.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ARCA and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r524"
     ]
    },
    "abio_AccruedOutsourcingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AccruedOutsourcingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Outsourcing Expenses",
        "documentation": "Accrued outsourcing expenses.",
        "label": "Accrued Outsourcing Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r87",
      "r390"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r412",
      "r546",
      "r547",
      "r548",
      "r655",
      "r671"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r240"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r283"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncAndOrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Oruka",
        "documentation": "Arca Biopharma Inc and Oruka Therapeutics Inc",
        "label": "Arca Biopharma Inc And Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ArcaBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA",
        "documentation": "ARCA biopharma inc member.",
        "label": "Arca Biopharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet office facilities (in Square Feet)",
        "documentation": "Area of real estate property sublease additional office facilities.",
        "label": "Area Of Real Estate Property Sublease Additional Office Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r89",
      "r109",
      "r144",
      "r156",
      "r160",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r309",
      "r311",
      "r330",
      "r383",
      "r446",
      "r524",
      "r535",
      "r559",
      "r560",
      "r661"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r309",
      "r311",
      "r330",
      "r524",
      "r559",
      "r560",
      "r661"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r169",
      "r379",
      "r552"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "abio_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "documentation": "Capital on demand sales agreement.",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r85",
      "r499"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r51",
      "r107"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r51"
     ]
    },
    "abio_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "documentation": "Cash payment",
        "label": "Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "verboseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C. Jeffrey Dekker",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90",
      "r91",
      "r92",
      "r109",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r166",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r196",
      "r200",
      "r203",
      "r209",
      "r330",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r434",
      "r455",
      "r477",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r537",
      "r544",
      "r549"
     ]
    },
    "abio_ClinicalDevelopmentDecisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ClinicalDevelopmentDecisionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Decision [Member]",
        "verboseLabel": "Clinical development decisions",
        "documentation": "Clinical Development Decision Member.",
        "label": "Clinical Development Decision Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r384",
      "r433"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r177",
      "r178",
      "r496",
      "r558"
     ]
    },
    "abio_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Pre Funded Warrants [Member]",
        "documentation": "Common stock and pre funded warrants",
        "label": "Common Stock And Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAuthorizedOfferingAmountUnderAgreementToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price (in Dollars)",
        "documentation": "Common stock, authorized offering amount under agreement to sell.",
        "label": "Common Stock Authorized Offering Amount Under Agreement To Sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r546",
      "r547",
      "r655",
      "r670",
      "r671"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r434"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r40",
      "r434",
      "r452",
      "r671",
      "r672"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r386",
      "r524"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r73"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r192",
      "r198",
      "r356",
      "r500",
      "r502"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt outstanding",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.",
        "label": "Deferred Tax Asset Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAndLiabilitiesValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "documentation": "Deferred tax assets and liabilities valuation allowance.",
        "label": "Deferred Tax Assets And Liabilities Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charitable contribution carryforwards",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "abio_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r654"
     ]
    },
    "abio_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution (in Dollars)",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equal contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r22"
     ]
    },
    "abio_DescriptionOfBusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DescriptionOfBusinessPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "documentation": "Description of business.",
        "label": "Description Of Business Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contribution",
        "label": "Defined Contribution Plan, Description",
        "documentation": "Description of defined contribution pension and other postretirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r241",
      "r272",
      "r273",
      "r275",
      "r519"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r129",
      "r131",
      "r134",
      "r135",
      "r136",
      "r140",
      "r321",
      "r322",
      "r380",
      "r393",
      "r503"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r131",
      "r134",
      "r135",
      "r136",
      "r140",
      "r321",
      "r322",
      "r380",
      "r393",
      "r503"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r137",
      "r138",
      "r139"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r290",
      "r304"
     ]
    },
    "abio_EmployeeBenefitPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "verboseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r81",
      "r98",
      "r99",
      "r100",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r167",
      "r168",
      "r210",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r349",
      "r396",
      "r397",
      "r398",
      "r412",
      "r477"
     ]
    },
    "abio_EquityFinancingsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EquityFinancingsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ExceptedNumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ExceptedNumberOfBoardMembers",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excepted number of board members",
        "documentation": "Excepted Number of Board Members",
        "label": "Excepted Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueAssetsBetweenHierarchyLevelsTransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "documentation": "Fair value assets between hierarchy levels transfers amount.",
        "label": "Fair Value Assets Between Hierarchy Levels Transfers Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r325",
      "r361",
      "r362",
      "r363",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureOffbalanceSheetRisksAmountAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance-sheet concentrations of credit risk",
        "label": "Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset",
        "documentation": "The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r219",
      "r325",
      "r361",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r361",
      "r362",
      "r363",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r328"
     ]
    },
    "abio_FirstMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstMergerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Merger",
        "documentation": "First Merge",
        "label": "First Merger Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FirstThreePercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstThreePercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First 3% of pay contributed",
        "documentation": "First three percent pay contribution.",
        "label": "First Three Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r457"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "verboseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "abio_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Option",
        "documentation": "Incentive stock option.",
        "label": "Incentive Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r173",
      "r462"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r462"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r286",
      "r291",
      "r293",
      "r298",
      "r302",
      "r305",
      "r306",
      "r307",
      "r408"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalties recognized",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79",
      "r126",
      "r127",
      "r147",
      "r289",
      "r303",
      "r394"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r287",
      "r288",
      "r293",
      "r294",
      "r297",
      "r299",
      "r402"
     ]
    },
    "abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxReconciliationAdjustmentToDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "documentation": "Adjustment of the carrying value of deferred tax assets during the year.",
        "label": "Income Tax Reconciliation Adjustment To Deferred Tax Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal income tax benefit at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefit, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and experimentation credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "abio_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "abio_IncreaseOfRetentionBonusToEachExecutive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncreaseOfRetentionBonusToEachExecutive",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of retention bonus to each executive",
        "documentation": "Increase of retention bonus to each executive.",
        "label": "Increase Of Retention Bonus To Each Executive"
       }
      }
     },
     "auth_ref": []
    },
    "abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "InitiallySpecifiedPercentageForBeneficialNumberOfShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initially specified percentage for beneficial number of shares",
        "documentation": "Initially specified percentage for beneficial number of shares",
        "label": "Initially Specified Percentage For Beneficial Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r106"
     ]
    },
    "abio_JonesTradingInstitutionalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jones Trading",
        "documentation": "JonesTrading Institutional Services LLC.",
        "label": "Jones Trading Institutional Services LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Latest Tax Year",
        "label": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease description",
        "label": "Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component",
        "documentation": "Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indicates (true false) whether lessee has option to extend operating lease",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Commitments Due",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed lease interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal option",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "abio_LesseeOperatingSubleaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LesseeOperatingSubleaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease term",
        "documentation": "Lessee operating sublease term of contract.",
        "label": "Lessee Operating Sublease Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r310",
      "r311",
      "r312",
      "r330",
      "r432",
      "r504",
      "r535",
      "r559",
      "r661",
      "r662"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r388",
      "r524",
      "r545",
      "r553",
      "r656"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r109",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r310",
      "r311",
      "r312",
      "r330",
      "r524",
      "r559",
      "r661",
      "r662"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "abio_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r233",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r561",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement",
        "documentation": "Merger agreement",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r233",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r561",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_MinimumPercentageOfOriginallyIssuedOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued outstanding",
        "label": "Minimum Percentage Of Originally Issued Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abio_MinimumPercentageOfOriginallyIssuedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued shares",
        "label": "Minimum Percentage Of Originally Issued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of noncontrolling ownership interest",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "verboseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r53",
      "r69",
      "r82",
      "r95",
      "r96",
      "r100",
      "r109",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r133",
      "r144",
      "r155",
      "r159",
      "r161",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r322",
      "r330",
      "r392",
      "r454",
      "r475",
      "r476",
      "r505",
      "r534",
      "r559"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abio_NewCapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NewCapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Sales Agreement",
        "documentation": "New Capital on Demand Sales Agreement.",
        "label": "New Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NextTwoPercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NextTwoPercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next 2% of pay contributed",
        "documentation": "Next two percent pay contribution.",
        "label": "Next Two Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Number Of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfMonthsBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfMonthsBaseSalary",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of months base salary",
        "documentation": "Number of months base salary",
        "label": "Number Of Months Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time Termination Benefits",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r155",
      "r159",
      "r161",
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r523"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r344"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r523"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r523"
     ]
    },
    "abio_OperatingLeasesExtendedExpiryYearsAndMonth": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLeasesExtendedExpiryYearsAndMonth",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional operating lease term",
        "label": "Operating Leases Extended Expiry Years And Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "abio_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r54",
      "r55",
      "r66"
     ]
    },
    "abio_OrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Therapeutics Inc",
        "documentation": "Oruka therapeutics inc member.",
        "label": "Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "verboseLabel": "Accrued expenses and other liabilities - related party (in Dollars)",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r524"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other loss",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PatentAssignmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PatentAssignmentAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Assignment Agreement",
        "documentation": "Patent assignment agreement.",
        "label": "Patent Assignment Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfOtherPartyTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfOtherPartyTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of other party termination fee",
        "documentation": "Payment of other party termination fee",
        "label": "Payment Of Other Party Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfUnrestrictedResearchGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfUnrestrictedResearchGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of unrestricted research grants",
        "documentation": "Payment of unrestricted research grants.",
        "label": "Payment Of Unrestricted Research Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r517"
     ]
    },
    "abio_PercentageHoldingForStockOptionsExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageHoldingForStockOptionsExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share",
        "documentation": "Minimum ownership percentage for 110% fair market value on the grant date.",
        "label": "Percentage Holding For Stock Options Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfBaseRentToBePaidMonthly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfBaseRentToBePaidMonthly",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Base Rent To Be Paid Monthly",
        "documentation": "Percentage of base rent to be paid monthly.",
        "label": "Percentage Of Base Rent To Be Paid Monthly"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfRetentionBonuses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfRetentionBonuses",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of retention bonuses",
        "documentation": "Percentage of retention bonuses.",
        "label": "Percentage Of Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations (in Euro)",
        "documentation": "Potential upfront and milestone obligations and royalty obligations.",
        "label": "Potential Upfront And Milestone Obligations And Royalty Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract0",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock convertible shares issuable (in Shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r195"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r434"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r195"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r434",
      "r452",
      "r671",
      "r672"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r385",
      "r524"
     ]
    },
    "srt_PresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PresidentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer",
        "label": "President [Member]"
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax refund received",
        "label": "Proceeds from Income Tax Refunds",
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r52"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r74",
      "r77",
      "r78"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r86",
      "r391"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r382",
      "r391",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r74",
      "r77",
      "r389"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "abio_PurchaseAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PurchaseAggregateShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate shares",
        "documentation": "Purchase aggregate shares.",
        "label": "Purchase Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r212",
      "r233",
      "r267",
      "r268",
      "r269",
      "r364",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r528",
      "r554",
      "r561",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r212",
      "r233",
      "r267",
      "r268",
      "r269",
      "r364",
      "r365",
      "r395",
      "r424",
      "r425",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r497",
      "r498",
      "r507",
      "r514",
      "r518",
      "r525",
      "r528",
      "r554",
      "r561",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668"
     ]
    },
    "abio_RelatedPartyArrangementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RelatedPartyArrangementsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r353",
      "r354",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r353",
      "r354",
      "r355",
      "r356",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r660"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r462"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r353",
      "r354",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r451",
      "r453",
      "r484",
      "r660"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Arrangements",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r357",
      "r409",
      "r410",
      "r411",
      "r460",
      "r461",
      "r462",
      "r481",
      "r483"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r192",
      "r198",
      "r356",
      "r501",
      "r502"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r285",
      "r669"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "abio_ResearchAndDevelopmentExpenseReversed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ResearchAndDevelopmentExpenseReversed",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party expense",
        "documentation": "Research and development expense (reversed).",
        "label": "Research And Development Expense Reversed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce reduction percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r174",
      "r175",
      "r555"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains unpaid",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r556",
      "r557"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r61",
      "r387",
      "r399",
      "r400",
      "r407",
      "r435",
      "r524"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r167",
      "r168",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r315",
      "r316",
      "r318",
      "r320",
      "r396",
      "r398",
      "r412",
      "r671"
     ]
    },
    "abio_RetentionBonusPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonusPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retention bonus paid",
        "documentation": "Retention bonus paid.",
        "label": "Retention Bonus Paid"
       }
      }
     },
     "auth_ref": []
    },
    "abio_RetentionBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of retention bonuses",
        "verboseLabel": "Retention bonuses",
        "documentation": "Retention bonuses.",
        "label": "Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r518",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r518",
      "r538",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r109",
      "r145",
      "r146",
      "r154",
      "r157",
      "r158",
      "r162",
      "r163",
      "r164",
      "r166",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r330",
      "r381",
      "r559"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets and operating lease liabilities \u2013 amended lease term",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares of Common Stock",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash, Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfFutureMinimumCommitmentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfFutureMinimumCommitmentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Commitments Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNonCashShareBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Non Cash Share Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Shares of Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "abio_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "abio_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SecondAmendmentOfCertainRetentionBonusLettersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SecondAmendmentOfCertainRetentionBonusLettersMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Amendment of Certain Retention Bonus Letters",
        "documentation": "Second amendment of certain retention bonus letters.",
        "label": "Second Amendment Of Certain Retention Bonus Letters Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r163",
      "r506"
     ]
    },
    "abio_SellingCommissionPerAdditionalSharesSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SellingCommissionPerAdditionalSharesSoldPercentage",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission rate equal",
        "documentation": "Selling commission per additional shares sold percentage.",
        "label": "Selling Commission Per Additional Shares Sold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SeperationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SeperationAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seperation Agreement",
        "documentation": "Seperation agreement",
        "label": "Seperation Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r541",
      "r562"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expense",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards granted service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, RSUs outstanding, beginning of period",
        "periodEndLabel": "Number of Shares, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period",
        "periodEndLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issuable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Options outstanding, ending balance",
        "terseLabel": "Purchase options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding, ending balance",
        "terseLabel": "Weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r245",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r279",
      "r280",
      "r281",
      "r282"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, expiration",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Computer Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90",
      "r91",
      "r92",
      "r109",
      "r131",
      "r132",
      "r134",
      "r136",
      "r142",
      "r143",
      "r166",
      "r183",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r196",
      "r200",
      "r203",
      "r209",
      "r330",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r434",
      "r455",
      "r477",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r537",
      "r544",
      "r549"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14",
      "r81",
      "r98",
      "r99",
      "r100",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r141",
      "r167",
      "r168",
      "r210",
      "r276",
      "r277",
      "r278",
      "r300",
      "r301",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r349",
      "r396",
      "r397",
      "r398",
      "r412",
      "r477"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r141",
      "r366",
      "r401",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r529"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r141",
      "r366",
      "r401",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r529"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61",
      "r403",
      "r477",
      "r491"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61",
      "r251"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r39",
      "r40",
      "r61"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r56",
      "r436",
      "r452",
      "r478",
      "r479",
      "r524",
      "r535",
      "r545",
      "r553",
      "r656",
      "r671"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Financings",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r108",
      "r194",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r319",
      "r480",
      "r482",
      "r495"
     ]
    },
    "abio_SubscriptionAgreementReceiptAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubscriptionAgreementReceiptAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement receipt amount",
        "documentation": "Subscription agreement receipt amount",
        "label": "Subscription Agreement Receipt Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r359"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r360"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, limitations on use",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, limitations on use",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThomasAKeuerAndCJeffreyDekkerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThomasAKeuerAndCJeffreyDekkerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer and C. Jeffrey Dekker [Member]",
        "documentation": "Thomas A. Keuer and C. Jeffrey Dekker.",
        "label": "Thomas AKeuer And CJeffrey Dekker Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfAdjustedExchangeRatio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfAdjustedExchangeRatio",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted exchange ratio",
        "documentation": "Threshold amount of adjusted exchange ratio.",
        "label": "Threshold Amount Of Adjusted Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfDeclaredCashDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfDeclaredCashDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Declared cash dividend",
        "documentation": "Threshold amount of declared cash dividend.",
        "label": "Threshold Amount Of Declared Cash Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r551",
      "r659"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndThirteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndThirteenPlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "documentation": "Two thousand and thirteen plan.",
        "label": "Two Thousand And Thirteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "documentation": "Two thousand and twenty equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176"
     ]
    },
    "abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University Medical Center of Johannes Gutenberg University Mainz",
        "verboseLabel": "University Medical Center Of Johannes Gutenberg University Mainz",
        "documentation": "University medical center of Johannes Gutenberg university Mainz.",
        "label": "University Medical Center Of Johannes Gutenberg University Mainz Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Estimates in the Preparation of Financial Statements",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r71",
      "r72",
      "r75",
      "r76"
     ]
    },
    "abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in net deferred tax assets and liabilities",
        "documentation": "Valuation allowance deferred tax assets and liabilities change in amount.",
        "label": "Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r136"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r136"
     ]
    },
    "abio_WeightedAverageSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "WeightedAverageSharesOutstandingAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Shares Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001213900-24-053881-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-053881-xbrl.zip
M4$L#!!0    ( !"*TE@3A1M7^!$  (:Y   1    86)I;RTR,#(T,#,S,2YX
M<V3M76USVSB2_CZ_@N>MNLK6K"/)K[$WR98L68X=._))\B29K:TIB(0DQ!0I
M Z MY==? R0EBB1 2'8RG#M^LDSBY6D\C49W X+>_FL^=:U'3!GQO7<[C=?U
M'0M[MN\0;_QNYZZ_V^RW+B]W_O7>LGYY^U^[N]8%]C!%'#O6<&&U_.FL;Q-K
M0)''1CZ=6J_X]._6KC7A?'9:JST]/;VVH0RS"<7,#ZB-F7A@[>Y"@W&3+8I%
M@Z?6(,#65>!9C3?67OWTX/#T\-BZ&[3@G[V#L,HO;^?LE-D3/$46=O$4>[P#
MW;;Q" 4N?[?S$""7C AV=BR0RX.RE._RQ0RS=SL1IA%BP]<^'=>6KVK0_OZ.
MQ1$=8_X)33&;(1LO*P@A$+71D/BS":)3)"00=0[J^_N-N".7>/=K5>9#ZLI^
M]NKU_9IX/40,Q\7GF?)/^[)TX^3DI";?QD4#II(@?A,)$+7,\IH%$(W:EYOK
MOAR[95G Z/!E^23DPUKX,BXJQ-]P2!Q.\T<$7M0$<%%C;[>^O[NJ(\H0S3@2
MCW'DV7A'Z,\OEB7T 7F>SQ$'!8X>1H]G,^*-_/?1(W@H1O4T9J*'1Y8<YU,!
MY=T.(].9*_B1SR84C][M" %W8['^<-'P-:",B\  4-_%>A)K,^K/,.4$6$KH
M@&P@4WM=5/&Z!GUB]WH%>:?V_J7$F5'\T\6!/AG,64E62JH7H\G!HY\N%_1)
M/)(CU0O)9"/WI\L$?=J!FTO5FE2B\ #DL,2'N]YE@960;;=\C_DN<83=/T.N
MF-']"<9@;8@3ROX'_4-9**$L,8@5 >_!TL$*U <ED^L#?(XJ6[(VLU[=>2AP
M"+3Z][>U=.ULTP'#3M=[+S^G]3>J'Q715EU7D71%?;<I*E*58S9J:W1D9M1+
M\O3'+:(P#A/,"6!C1K2EZQ2QN&?,HO5JO>E\6BMB%<1>@K\WQ<NA5I*9+O<^
M1[@U!O=3#"X_,\L?6=V9<"2A9#4C7X8XTTE94*V0UH,M:*VFZ,9,]^%_//%=
M!X*S\X> \(5H8<^G^VO,:HIE!V6-QT,MCWWNV_=1N__]MS=[C>-_6F'[A=.U
M8C%_OK80FW1<_TDY,Y<%<N59(^](2YYHR!(M5;9U ZZ:O583>4X_F$X17?BC
M/AE[9 3VRN--V_8#CQ-O? MDV>!3KY&X6<UB=H^!T39AMNNS@&+X1W1@00]6
MU(6<H:M.K%4O5MQ--34+Z/Z$^;7/V"VFTH:N$9I^5TS9FS1ET(0EVK"@$4NV
MDL-(1<>2C@XB]#?D!G@UBNN3++= ,3$G:6)$.Y9L*/%<,5TJ@E8$W8;YA 68
M(>$(S#+!0FZ!0H(:]31!<3O2X"U;J@@J(JB'7>%%@*?-%TU*D3<./8(UDI2%
M"N+Q1B--4]22)9NRDFU52T^A5SB=$B['"G0<7$"Q<F,OXU?HRA7%:8V]-&&)
MUN346FLOC[.*L25C8>C3(1Z"T?+&ZS1E7NHCK\9^FIDHL%JU4!D[H_!8)*4=
ML0N)/28Q9$/C;)'"B7.0ID<VM"M;LI)-57-&/V>F,]=?8'R&/8#/;UWDI>9-
M7H%BA^$P,WVB=JRH(4NV5,VA(H+"3.  S5/+3O)Y@2D[2G,1UK5DY8J!0BL6
M#!E^"$#D\\>,JY9Y6<!%)FNP:L *6Z@(*<P!9=(U9POY:;&>\%$7TY)T<G)4
MKV<"GISLS3_$^9JP1>M5_# W@U>1I\KH#-#035FV_!+%E&6"GVQVQWH5ME:E
M6;?((^10I2E6S%<F]LG/*6@YJR@SB5=SF"LNG4E\IOG+1$C:V%4_]2HBBZ*F
M' ZU!0OI,XZ@*N:V\-5SZ,J^+8AR)4V90"KIO%>V\0?L&K8Q1\1]QN9AW( )
MO9G8;(M=1.M5U&.E!@66U9Y@)W"Q/[KU.0A.D.LNVL0-.'G$TOPQ?R16,=^3
M1RODY%HWN5NU4&B+,U%AGNL:DRQ,=01#*$<"B!4C":N$QPPDF/"H2*4>&^]N
MYAD#73F3.9_9AL[?[=1/ZXHX?;221YRNG EQF6UJ5<12$;>Q059%DBKSJRQ?
ME)L63)KN9ZN-;K7]_:+;WWFSM:AL889AD^WPRH=Z?IHACT2#XOI##9+(S;;)
M"^QO16>N!>X$',;V!D28!M/$^+8#K#/$A=4,%M;L9KLAORFK'&*Q(C!KC0"<
M__O*(+^J^^_/-[\=_N??7^Q9,/_J'9XXWX\?QU\7WET[>+HXIB?''_>^W0T6
MS#U^M+_7W2M>XWU\]?UX_W[>L*]Y_?=.9Z__L?8X/VM]K3\Z??KUZ>&L\WA[
M]31VV3$YJ[6.'\97+L%WGE?_U#SLMLC)P<=/_K?NI/7QFH][H^/KR9O;3U_0
ME^.'1><$'?6O'H^G'P8'Y.#KHGMUW/HR.!I](=.KVJ_!;\?#1?#[!>\L+O'G
MWWX?_/IT%'1YXPPAMO@\WF_<7^%OD^.''IG?#/>'5YV#.OOV.+PXZO9ZZ&S0
MG'UH'WUZ\[7UZ_X]<P['U[PSX.W+-X/6S??_Z31F^X.9TVK\>D3OV[7QU\]H
M<.&V^,/P ^K=UO]CM?J]^#O.SYU%Z<,E>9905:8H.,P>=<B<1*D<SN?E5O/H
MTI<T6+,RB3MU?K5:KC9?KLX9)U/AS'W&9#R!O\U'3-$87X!/Q]OP8AFEKVTD
M*E:Q;5LS"C8R.;YB34@M;$MX5HS/B@!:$J$E(";3"+KS[)5"Y2J4S)!U9P)"
MT^;DD?!X+TRA,YH*Q:%)]AS(ICHAN[?"_JT5@(IP4\)[_;MHV!8ZFC/%BLG-
M)/@V)A<ZC3E=5 &I(:&??,]&;)*_<I_/Q4?M(F!>OU@%,JG"C54 T.P*./]0
M5XTP50JR\1'77 ==4\X@B-W+Y!3SC[Q6SOH6V^EY?.6\+HJE]C(9P?7=](J9
M36WNDH1(QYN<4S(,N#"3W.\&5.QBCJ@_7=TYH#/!6S=7:)'W,CG$?.I35GA5
M:#F+DY@L[EN *MRK%;@2=RM49METW<8<),"48H>C.6(,RV2Q2Z":6^B&F]8N
M#MGW,FE((Q41>_4Q @L@6"$&F;=,H*C4X>7/9M2??SBC;J(8F11<=3ZCG+O%
M2H505RA>.3*9O&JSN&1[4RK:B^L5>HR9Y%VU-?47B?)52K%! R9AW_,S>56D
M_Q.3N2JMT-4P48/GY_RJA.Z+?#TS=S-/4:;0^F?3>.FO:U9) U.BVKX=B!6O
M"3X8+)E\<>F)^\@3=P)H2Q1,PN@KFU$+R8]-X77)YJQ$>_\/3.G;VMH5V^)A
M^&CM,F[Y&)Z2Z<RGW/)R+U=7W/!MA?>\7_NV;$Y31?RW&]?;%8]V&WN[^XW7
M<^;$]Q5OB$(('5Z8O!F*N-XV*%3WNN<A8/%U[<E*8X1FLDX-NYPMFQ'72.]O
M-Q:Y-[6K\!35E/^S)1 #[<B_D-Z0D;B"H.)PU:LQ"^G?!S"C 6HE*%BVL<Z!
MJ>@,VZ_'_F.-$=L$1+JX^+#6<=1I],L)LM=W.[&;T%T&LLU$(-L<,DZ1#<,>
MWE4N+^@_A6<0EEQR/!5&8<="4:EW.YP&XI9Q60H:([XSD/6<@$;&V".N*UR?
MN"R#50\,:"#>7E _F,6=$&@^L=(:XEP?7Y6HFN"MC!*;P*V]-Y![\[,H91R.
M9TAAIAZY#GL91T(/-&'O59+V6!"?!2BC?'GP#*2"J+<5A^%GBC"\C.)NA-M@
M''1;7H-XRZNSMN55QF%YCA@FVH)Y.]IC@3Z:<H<%UI;KU?Y*&0=E ]1)QV=]
M$.X\^0LS8$%+(V$6T@;PZR7$7]<N.IGBC1**T-A,A+T2BK"G%:'E,SE[(AO+
M2J1/:F@:CR\C_OZ?+T@.IHVTZJ"$(AQH1<C;*L9V0*5U/I_;;N"4R?)N!E>C
M?=EUJ30RJJ%IY-EH8$I@,C;$J\H,]###B-H3,#YM_(A=7T;:D1WJ8?&KD>*7
M%I/23GT/<T07>?*.D,L*! [?#<-?>H(7>$CX]L-@AE_M7;0QLRF1P55W=!8P
MXF'&PCOY!GC.SUR(O6+Q'4Y/>?QP2^FWUVD#G&HQK\E#0!PB\RD7/BAKRX?1
MIUX))36%JIG+(J*B> (J +-"W@4HZY906$.DR@"G:=O0G],-N/SI51BMV(4H
MH;#F8-6*O P3>]@&O8 H2()J.M\")O-E S]M_DMLO;:11F7)TP7S+>,+#$:X
M"\-?>BP,\6_BDEQCQ' B6/[K")^%;B9WHD9/I$V[HSN&7VH6J&2WH>\7$EZ#
M7VT3-/<I10=_?[*SYO#3"=2D=C#$E^NR%F+=2LQK< =$1^S/]TN-4*ILV+)R
M. G.,'_"V/M ,!668'$M[  +?XD<'+OF5-QD]R/-^W,U>RMY-#.]X$J;TFF[
M$5Z5,MRBA?@/3( '.@1RV-!4O"K(;:"7,.@_C'L3^/IT5='--Z6CVQ2RTITM
M;J!$EFX3L#JB>UA&\KYWYGL!^Z%>RG-U.@-5.7=!/\1QI['8WU/()T*165CN
M)P<B6G3F5-TB4N[42 :L3K8FQ4@,!W+/F?BAT?@$1C^ OL$9;3J./(2&W.YH
M1&S<07;*K1:$(FAE.U7=.JK<'K=*>Z\Q+-<XVFCTQG%+ TRGW9&8Z-D\9TSB
MSTZ6&"%5SM(XAW@W&U%?GIN\(2XL5J#&W:%+QM$^J^?T_ 5R^2+QL-1+[W/D
MTLV1Y4#+\(R=SZ$?!XMM&T(77V%E%VW>0(\3T^7I!^K&!F!U>?&$K13'%7HR
M*W&&A3V1E=U%N0RZ"J1&1L756J7SK[0X=7JKJ%@B9ZH0H3HN3GPCLQGPB4_)
M=^R K<="BC"FN@/%I\TQQ3A,JO6QZY;8S=I6(MWQ0'@O<^G@LS(&_<.46:V,
MX==)^[[KK&;2<V?ULQ?V+2"KE41['5OI)KH!6O69)UW=$LUX0YS:O?<E\Q]
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M S=8_)-:Q8G'\1C_[)A%BT]]CC?.E\0)E+6451F]; 5B#7/QB,@-&2:V:?H
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MP&E:E8^ %=/:21[\4'%!/UP#?0,W3L5_%X:0';)^D/JCN6["24..NP);_5O
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M*9J$)&8HT@.2MI5??P&0E$B)(!Y$$Z3''W:/HY'0C>Y&H[O1CW_^U],Z.'I
M./:C\.=7;[]Y\^H(A6[D^>'RYU>WL]>CV>G%Q:O_^K]'1__QS_]\_?KH(PH1
M=A+D'=UMCDZC]?W,]8_FV GC18371_\[6?^?H]='JR2Y_^GX^/'Q\1N7?"=V
M?8SB*,4NBND'1Z]?DP6+)4\QH@O^=#1/T=&G-#QZ^\/1NS<_??O=3]]].+J=
MGY+_>/=M]I/_^&?@AY_OG!@=$;S#^.=7)4A/=SCX)L++XW=OWKP_+K[X*OOF
M3T_T@\KW']^S;[_]\<<?C]F_;K\:^W5?),N^/?[]ZG+FKM#:>>V'<>*$+@40
M^S_%[,/+R'421DDA7D?<;]#_>EU\[37]Z/7;=Z_?O_WF*?:V*)+O>,D63'F!
M[XZS?WQ%Z75T]$\<!6B*%D=LBS\EFWOT\ZO87]\'%'/VV0JCQ<^OG#L_>DU)
M_>9]!NM_T4_^Q'^>1F$<!;Y'F73B!'3/LQ5"R:LCNO3M]**R6P>[]'?W*P>O
M'<KL8_JM8^XBQTP28#']\\;!*$Q6*/%=)XB-(+Z_)M0^+LAI7*-90OY>$WC:
MN.^O0_"%QM44V07+FMK)C*" 5E'@$6UX]B7UD\V<+/(NPN^5,&]8)I,1XV0_
M=>+5>1 ]:A-XN\"Q*9TQFIZ.G-";I>NU@S?18N8O0W]!^!4F(]>-TC A%\P-
M@>_Z2$TPU%8VMJ%KE%Q&<7R#,..O$LK[OS6&U+GCXU^=($5C/W:#*$ZQ(C%K
M%S"&W@V.[A%.-H1=]"#<*^NOV@6,H3=% 15^HDV2S0@3$V;)U(L:!;F+F+T/
MUFL_8>L24I"32V6<F&FJ9Z=I'5-:-%-YYWY(;DJRNAJ"!S\VJ#'9V:,FE4?-
M5A3&S%)35^V'2Q@C'?ENM$'HA-C8"S^Y(<:&(OGJ%C!V7K)K>.X\*4I=^7<F
M^9G>Q>A+2H3Y[$'YV![\V"!BA]?0R8;]M5&[Z/C+&$1V[VZ:.W>!(GOK5S"(
M8MTMH(%GPS)&[3*NBM7 6;P:0QU0/VH@W;B0.7Q+:D4#R<-?&W,CW!7RT@!%
MBYLH(9SSG2#8C/T@3?P'Q&@31PO*V"B<)9'[F8%7([ 6!(.2LH//.U.Z^^&N
M9^P6VP$[3Q-B[U[YH;].UZ63-DY1FST(ES4O:&=QXJ^I&?H;\I<K\K^C!X2=
M)?I([-%D3/YA:^=7M+3F!G6A ;"0B??DGNJ7D4NDWT\*S:BYMX8%39HN6WC3
MV6T.9],&[8-E0)"]CD+7B5?U^OWLB?[92K#DUP?9WO9*R,WG49)@_RY-*,0D
MFJ28FCD+'*TG]S0$3G!J)6K:X&!XBQ(/+1#&R$N<)R>.$3,Y I]\,VA]K&17
M-^DT:]V2;^ OXC=0N^3=G=I[XB\((H*BBU-W'^)U(4PC:66FNRT% .8M#OX]
MJ;N=IA5-X:\4.QZCQ/$57RVT )C:75TP5V<33>N8PK5.M^C@VK2.*5QY(5X=
M?$5K=1.)T,%<8CF3]]I^)%@'9=X:T#$3'5R;5S)*V9H@L19U&]8Q=?1*41H=
M%&M^;I#W>R%D+:YSUC" Y3AR4WI:1T0SDK.:;"Y"FJ&C_NC1N%#.:/)364PY
M:2]%U@K-=_F.;<#S"52:EO2:N Y.&B2OCG(P9<2W:_AA<DQ^<IQ_Y_CPY]W@
M&JT=/]1&-?OU[A: 0'9%EL!N>H=>;P&KX5NW0$E#@1"8$>;U&JWO$%:D;N6G
MVY,%@25Q_]1PHS_88D3DE/@H]%A=$M@Y!O1KK?*K*KM#3\1-]9#W*H=)H :1
M6_E*0%/8(ES\+G#N4/#SJS1^O72<^S^W23B317ZO.L%-%#.L1W=Q@ATW.21>
M7-!@X<1WC!#Y>H2,[]X?HR")BT^H$GO/B*D$,CO;RML9L4C$:8II0A$0_O4P
MM@CON#["5=0)IPM4<GE1%?;\US2(I,?")!+2*L(>PC^_(FY?=AI^HBX#\GY^
ME>"T'-!1Y@U-2B)W#OT?:L@]. &](4?)J8/QAIASS$4QS"LYF,>[T],Y]QHE
MMLPN2?()V:?#NDFR0KB"J6$^U0"H2%I_V5)'FIP';_E'J+5N@]1I0R%]/=7?
MF:5Z'JP/EY>(.'-3^D V6=S&B $W?0H:8>UV,)@K1D \\3G18ED10Z(>+/-R
MBD#2M7&.-8*R>XQT>=9,/:!#ME.B- H.?<648 S/;./0*F?,>^-F6P8*Y+X9
M(/4+:N3D_M8XN2]W3ZBP;DP#H.&QI8EJ.:N^,W\RLA>@^,;9T&<M(,NL'HA-
MET4LHI43PZ$2B*-2Q+#S9YE#3 US1PS/KA&@QBH)ZL&X-MF=YKID#7B>"8!M
M8[7]YY>(;&)CS=0=!7XW#>H<-?"BP3YK[YT6<#=P1K00WC"='@DZY@S\WBP#
M2Z("=X:&;=!M2?_!?$AZEP,Q.JC#,QN(;H!DTY;3Y4\CY7)^_6#4M&/Y9)4R
M;+#W*2Z@X9VC)JKE;/K1^+&ZP7EN,(,.\:Y3!\%J?%0DF]4(6PUY))[==#5<
MGJP,\KZVO[S-$Z+"@T.Z2 2C-<,$GL?H0 ZLXWL7X:ES[R=.4,+ =,A #' P
M9T6&>!)NC@[?IC1W*T3>F8-#FFU('*UTG3+/>$R(YOJF+QX)@!;Y)B_&9?[)
M$!$D$G0H9N!F@NUW4RT&U=$)3!66K'IB-8*S2 ANB):WF(8%^QIL"9J>=ES-
M3]OE^X'DK1WTCBJ3V%P:&\$879 _3?MO-0!:G(/M:GD-'@RJE2I=XR+.<B,;
M!?N %U6]4R7!X25 ?$HB%V<!^];/KV*TS/H-F0R_E,LW6--#<N@H?9Y\TP+4
M! E,#=5F!C?RK"*0U8N\@5)@.8,<J.,\*;L+#HUW*=P@-\5!IGD=?R3D5()9
M!=G$[#+.JS_?=,XM<'X550S0#*.T S/)RI"O*N8* *.N2CG[U@PO*9W"8TY!
M(C"-]_(4JF1&2#Z!\L]-^_@FD8L)9MAZE28IH"%/+M">O+\U,DV6?E#OUU7X
M65^'49JL(NS_C3Q0OAT &\ 9$Y%+^+1MBD<7<9QVPI\<4 ^>>Y094]!(G*!H
MBBN3-*&-TVF'^0Y84X8V1/Y4J"5.36SYYM/1W20#<0"*3HIPPCR0EBP#OHZ:
M(/4B'"K+(>X]U)0F8H0W(-<0#\H0[#DNA82)(*98 G<'-8(:)'/J;J#&')!N
M'@L.YF)P'@ATY&5O;:#$(1Z45@EJ,4NPRMM_Q4"8<\%8?&\6\*PJXCPJ@85I
MLK%) 0$Z\M:$,!0@;1*8HV"8/R)H]@QAD8"6V22D&5 .U!3%B&R)5L^/T0,*
M(E;.",.I9E@6CY,*HP0$ XFI;3.P"P1-ASH/UK=I[:IPHX8R4(&Q+:A,^=*&
MM5!L*$$8R*FH)0Y([.LB3! QU&CU-8MO9P"-6RNU0&R>"H4KGT<BH)8"#,9U
M%$9[9Q'B/:8.S##L,#Z59!26%F.N40*FJZIKV_7U%+BP1Q*9Q@!:I;9Y1F<1
M&0-R3;A@AG$D^%0"ZR"P#_+$B7T7F"L9#'MNB$@8FUB2T\>P\\&:BNX-U#B(
MO]2?&4Z'4NG%K$;:)<Z&(FDD^C?H'),]!*Y3NJ?)X@ 1B..C!ML*/[7DMWS,
M%.DK&ZGI/A(IF[G\DK?\DK=L.6\Y/ME4&M)WEL9<!WC 6<VU=.PDR1D\L[F2
M(-N_C.8&">;Q33JKV0QO0#.9NTLVUTA>UN:-; +S2_ZR:OZR^:1E91^G\;%@
M2C[!\7ZR!,?!D5NIOTDJ*N0 R^??]V[9]#+CV2H\*$-(B.!2".I5A>,)Y7"A
M$UA4H??W?&G34R($"N=9,GPJ%;IS0L)W$7[/]21;NV<OWN2+-ZG#B$P^Z<"J
M*&2MG<P[D,VPH-ADT&44$ NFMG(/%HB76 \#*J8OY21*"6;E;J^G$TROV3I8
MQKU#+E>L>HAF& /I%Y;27D'<PL/U;1I.C?J!DPTL[14:;'H%PHIF6!;?B:6Y
M(J 64%++?F\FH/!)+9!!'!8>@82.XDO#*G/>GFZ#JI>ZDA[4E1B/I3!X67G1
M.,5T^#;"?I35Z$U1G&#?3?)ZR]&C@[V/V'Q>F!X.0^"I)G6A4LPXZ&3B5H?/
M-:+=U"*\0'Y"IYQWPW@%? 90!&N Z,+4-CV+\J\TSCI.SR..P50_='N*R+41
M^PF:(?S@NRC;T!2YT3*C/T1G7'!T^U[\#L\OF.KYKR6C6(Z+]<G$#4,0NDK2
MHG-0SX/HL2F(WBH6.ED4(*"J+AM!M<N)I^O=X.C!)[0XV=S&-*EM6[\R<A/_
M(6L@"K,Q#03Z<3$V\'SO4"@3&"3*\K7H*GV)%NLRTW&OTJU'KZS0]0-4@3R/
M[)Y.$!2M-I17.[TP+ )+Z!BC>XQ<GUE&M'1Z'>'$_YO]IV'!:()D,UX'>:;*
M@M%(:=.Y4P70QA')912 *@Y5P=ON<=^-**AS!>S\%S5*51_)M"E:#^1K./4\
M^D)%,#^2C5/D)^',"=!D49FWO1VV;9B_DD"_CL,MRP&PD=ID/YCJE3'*_K>T
M@SPP M>A2!9P+]( )2TZ%7H"#0NJ08$6PQ?#0B%FJ$N!M!<E5!=R 4MKZ GB
MPG% [V:!=LG- ZAVR][-<_20K%"/NX<([(TF!^?H/CSK+26,LO. FIVI6O[<
M<G"6-H!^1B>UB<!0C[^U K;7YK_H_K-SUSIDO2(ZST@<5!DAT^H$]J'#V@.'
M[7Y:+?BN0EVPI]@Z#"["!Q3;?,AJ0N Y/&0U$AAFVH.S*3(%7.* 8U3QR6F#
M/J# B )@FR=9_R14YA$H4!FLVX'\5JP=YF? :A4J@X6N.4CDXT[MZ>\F!)Z#
M_FXD,$ARGCPBUCC<QT,M<1+TV VHORD&]/_H7?'@!/0^V66%TG\@]TCU@](W
MLU2^0[O4#5*/]0MU5TZX1%-R#,X6"V2^T7VWR ]*F73-6*'/T+ET]DG8;/;T
MMW+"C8DB7*[&++V_SPKQG: X4A?A(L)KIVYJNZFW>4FH TK!DB:D3+YQJQ;K
M-!V=7*O&@X75U>W> VI26]=E?4LEF.X&Q*!Q$?+B<X)W]M8_=YZF:)&&GFF=
MW C*<D*^/I^:"0CGWT6A2Q#=.96AM[5%644!E%LG#;<'13*RKIP\+<5S[K2J
MP:M);I.[K/;Y(BRN[/,(5]/BBAB_Z4+E-IA8O 253T.EU+P-]>5:EP,5Y8RF
MIR,G]&;I>NW@3;28^<O07_@NC2AF+\*TAC *?+?D_9NJUCF$ )4TSP>D._ (
M+YTPSR+=%39EJ<<WY-*E]P#]S\DBER(GV.J4>.S'E,<I1N3;C12?$R*?$$P^
M&R9(Y^A;S445BEDE>;ASSLKD00$=?V(6TES*_<'"I@YX?Z:,M,,;ZACRX5CU
M.=K,XU"1:T#!/G=\S J-=R?2^/55!P-(PAM!M? !ZM:%$O9F6!9-/QD^ED5>
M0#3+LS"*5V&GYMG=E.1S7YZ!Q%\,K\49X"Z^8R_4D5 ";?&$2/-[+ZRA0%?+
MIZ;2&A]CZK.MRX\*-2?'Y.0/H',C!->B^US]RO!G1@5R?UK]-S%;9J2)[IF!
M;.>Q7OM9O1>Y:HBG1+T;%#;&"72[NN5P1GMP2MX6U&1U%=CM.M<)X4 =*$7@
M%E\V=21AO^F="IDE7R*!#EC6+G$;A&QT7UJT0(;RR:N+ZS<WW^\?>1TE"/Y0
MR,.U.#:SEG_-W3>YU+-ZE]1W$C-ZC>PV/5E4VY6Q"Y>-$M^A4>3: AV.ELAH
M6VW2<$_*<*'.6%ML[%IW9@2JTL&D+7>LGN&BRNP$A629A'I]QB-N9:JP)*+$
MQZCJ4L)9@M*0V\0BLO;]14'6#6$YWH+**=N!2:B-AE7C4%4T*L$*;<+;C')O
MLT6:@]NZ%9S9VN!GJPE2FSKC_46A3DLC*.M5XB(F[A6+-A#-KHF8WL7H2TJ'
MECP( G.ZZ:%5 &#YH!PPVA[2WH)@'A$7CN7\R&:V51-7N:2RJ<4/DP-.-NRO
MC7$A'V#&#9O+.4:QB_W[+._B)(W]$,5Q1B..O'.FE$HM9,^*D4M542")V91?
M!OC2_Y+Z'HT\A-['B%:C1Z&+<*C##MFU++Y]*;!$FC)@.;W$,_3CR6(/YTTC
M:UJ?=4F@EMO3*26!R=)1W"1'KQ[SL0091R'YT\W>([O@IS+X(7%6G;;B%CDZ
M/+Z-T61Q%B?^VDF,U]7N+=Y[[<DCBD3K&=TR0_H M%?[!GJHY& .)TU6DH8P
M9:+T6@T3G$5'_?CS*4;DVJ5_&0_[\2$-B%=-]!(6Z1G-J8(]9-)@K;JL:LR3
M)Z6XLDC#VJ=Q58Q6-#SZP)KX2E@@'&-?<JDA6!-*I,GY\H,IOA2H7A*'#R%6
M3@1\>35!&HX:;*17SJ0?C:A!)AYYGSTZ6#%*L<O*YUF[>:W A?QJ@XA>*!"G
M<)8%<6?UP"E:4C4Z1?=T($ WKK(<S.$<*4D:%BQL"'CH):'&B&R-VJ%C](""
MB-V+N2!5(ZC&DD_%$ =D6T@1L&!>XRP%@\,Q)O?Y&^X%LUK)W<IR"4#XJ8-!
MW_5K*^H6S#;;('+[K@BK7;E@!A, X1.J8(RH#6\WA:)SVB,<("-UH/6B,W>%
MO)1.(QD15GM^D-*#-4-NBEE#M[,GVD )>;3#!SV,:5%"W%6A*0""-HT4E0)5
M"-[830ROJ_ #.I!?1Z%?Y^&H7MQ,9HOZ^E/*UU"8)#HE+_5)39$F3@>;*R>A
MJG3#B L;@5+#8,"52EH$MWLKU==P0)RXEU*.BEES4!(P>G2PQTI_,F<OILT*
MLL3H.$[7V6>@I]4P<L^MT,,T[^02<XV(6)D 933SYM6PEX !A.S="=V(D2I_
MA)EH[03G.F+]]%"IWR_#ZI:0OFN9T<'E>8J+%E>$J6[M)*4H'YLA_."[J%ZB
M1P%;CKGG=,3L,O3_)IMG3:L91>"ER#2>%AU 2!$SSD[)077PA58"B_8K++4J
M<9WUA/<?T*Z-,9&D8ABTO_,(.CBGZJA8?;A3K-1J1W.P\2([M,9H@3!&'L$G
M&PU+'.'26,&.I$ -BV$*@"*E96L/H,($.=[1XB9*Z .D$P2;<1&5I]=$'-';
M:)W;K_/R;%\S\8.6[P!DTXAUA#8LM<;0,J#(VSZ5  QD-HP<8$R!2#3G+=BP
MX,$\<U7&/Y>NB"A,R,D[RX8<_/PJSE)_C%\A+=$_V=0O,'KR>W9@&S$%<CQ7
MY)?83>_0:_)IUO*@7E1A5$%98$'Y#!01JP=Y[:S1F%WPG0A8"1S<&WPA':^]
MRL:,ZC.9HRJ6F#+UH49'B2#_^<8*Y\%YCQ9.&B2#8#YE@=BTU6Y!EX51KRKV
MN\E6<Y7UK>;_2JJX@S9S50K!C)JJBU=.9[<@;&F&93.C4(-# L+)^(3*]0]U
M_MV!GJB/<W%J(-16M)N'#6#JZU 51B6VW-UH35-B^V6-YSA9.-?ZA\6@.5VP
MQ'(.R2XXQ,MQ;$IQ-)H4"!7FD0#8/@V9GZ8'&ID1@(73R-R0BSQ[ZX,I(D*:
M"),8%=N3S9S\'"#:(0,1CL$:@0NY,R"5W%HF*I2/R4>7_!@DO" #$="(D@HQ
M*,BY7)IRB9@R<]<@V&@\6B#)2(O! C@VROG]^NV&TP3A+5@01Y,'Q6[6HX(Z
MVANQ4$\RD,,&RYAZA@R+'SP^-)T5'4Z<I\2?2+*YE^?^$_TK!F%* R![R7J:
MS&DBFKBSG*:/$"V21R>;3YK_62K]9EE7,%%.:;B#8Z,"226SV,Q9'1]Q%'?F
M"63 ^JDF&_T]$?E@HFA<J+<Q6J3!I;\P[:G+0'Q.["L3$J95Y\AUTW7*\F7'
MZ!XC-TNX(W\'*&^T,%K3WBC90&DNIJ:#H:;0LOD4I2<,YCC2N;*^1IW54U-0
M/74P](XZHYU$O]!NPM?G*37FKLA2ZW1=J@8=IZ@YBJW\RK:+=S7 5'IE4UL1
MJ*BXJ#8@H*X)>>:/*'A 5U&8K$Q;,]IH=&^GZC-<NK:XD>X@/KPL.G\@!\\?
M(TO<+Z#;N ^[9?N6SC!&KQ(:A,FF36!U^+:>A+OE>$9JJ*B#"BKG46HZ^* ,
MWHYIU#W;,UI+&+J03+?$;#N>;K<\EC>)S7+W-O3\F#6^0][9DTN^"I+SHX?#
MLSW<?*H+V_#KR0 'C],48_,Q#0&P 9]F$1F%+?IUSS '\'44NEVRL 1OR&=3
M@IH2+?J["$\4(U:\WY"_7)'_'3T0U)?H(W;"9$S^X=SQ,>T\@^K+>%KFWNV1
M6QT;S7A&"T!MNQP?-,8:80)TF8V7W1QT66!M@+;8E%K_T-[,-(U[CO#ZK>DG
M.CA$^Z"<VXO907=E(*Y"]7.J;\)Q@/)!/ZHFE'^- K(,U7.T[0"$1 )C;-^]
M!Q!,:"X#55J91)U.-SK'"%T0:QBC..F[>-;BVX-P8X^ELY[%,C$L^^)9G*RQ
M_^![Q([JNWC6XOLBGNHLEGE5[E8\\Q:!C&+Q19CUWQ*2LR_"JHF]]=>[G@BN
M+O-EXHI=N+*EVN.\<V'1\ZC)6VWCKM9"U/1(F]?JW([*A8%.Y4J<T//#Y74*
MD0MJ'#_KIUE**$P>V!H>P75U,X?KGF8Y>T+8]6-T@WVW;S>*+-:]"%G:E+]F
MG@*ZBCKA%R'Z4T1I3CZG;?LI]5(GH'&9=WV)MK7801_"<'J2VC6KP<HOS!T[
MXO5B/XQ]MX_F.!]/^_$VF[IRGVE J1=M,<YU.#6C>VD!'N+W]5F -3P"2_8P
MB.N +$!9K+]."U":I^+D$QL6(!]]GEG0F_?6%COX*BU +5;+)-U8EMNJ,=%C
M\=Q']&N7P@/&2>0%6;FW?V5C8FB=59&A$-&/^AX@E$;[*W1&Y%F:"^4//?--
MQ!L8D(G9<C-?G]?3EONY4/\(XR*UN!Z4-S84,]7@Q@;L:/6#@-MH?&]R"YOW
M6+*91LLE1DLG0;V.>^KOXT65*_"\$&/#<RN-)E% M-Z!P'# 2M4TKPJQ:GKV
M 1&LN$UZCE7[UB#F/<@F-"^&)CE;B&?#:Y'V@(N+.$Z1-TZ)FEUFN#"TX_(0
MX0(=S[20J2,PS B2!J$+GEMXTQ&);H'E(/62&O+#%+>.&5R(:E.5L1WOXCS"
M"\0Z;<:9N>ECML)V8STST\3X/LN[LCT7"Q%L>+7II?SU27."[N5Y*E)8]A="
MW?@ZU$FR_71VFU-L YIB/XW3 HYF8GW="IV??MJ<,-E<A 1^RN[;2;)">+YR
MPEPPKJ/P@05!^O6*IHQW'TYU@\P8.<OJS(2:%-+!%@93_65R2SVPJ?HCQ/(E
M8#V)P0JW5HVT#$: ]]"VG[%@74;W&2F1J]]G27P^NE:C!O=%F#4+;_DQX'[)
M>O;(-SBMNX?VB]8]8*1$K4&?)?'Y:%W5?;UH70U9$-8P]$O6\XC3 !7O(>8O
M\EK+3V%]0B\EDL9 GX_J5=K4BPVA* 0]:99*^[<Z\:H^BY.FKH6QN#VJWGC+
M]7T0;1":(?S@NXC#EX MXM.I[E/D1LO0_YNPA6D)-GON$FB0N6GLVD\]-X,1
M[(ATDSA:F*<.))+UP]>-\M/6I/:+D.@4-$N(;J/+7^;( DQH;X($9D1I#&8'
M.*9E^6DD.,@((PY$D*'MS;# ; RI8>T2HB[!*.GQ[.9Y97PRNYA;X/QJ&LMN
MDF&R@]BUN/81A<1,#.CL1F]-Z$2-5V+(HMS\ IE8+ ?3YH!,*;U39J D&:$>
MKJ<H1F1[*P*_-" 9DH<R$*T.O%5FH10-87JNY5<R\NIO[!P'PQR4!&IWEFD'
M5K$L\655,+C;G$GVW'DZ(4IGX2>C),'^79I0LRV))BF^C.*8DC$?FQ*%L&U;
MF_"9%_B<5_#1S#UK ZF=64-@4LD*73_(IAYO/\[E8XO1.?+H34 53TI6W>Q^
M;[X/N5G<>A .-B!*AV:5,=X!NC@'.+*+BUQ%]-X*MM]!,)ZM//2O1D;X] =)
MSN)@03XXQ<CSD[BP3KKA?PU<ZU74W?"]CN+&YUZPG7$0&'E_I3&;BC:/QFB!
M,,&&?&D4Q_LS[#G7I<ZZSX6Y^H05MPLU>*S9Z\T.GXZ4^@%4^^]FW9SI0W(#
MI=APX)^NZ/O>1;@O=3%]CMMZ,(].:+PDR0!"ST4UF.21Q-#7E@)4M4RAI&(/
M2B_Z54"Q>Y^BXBZ4G3R!H\3+)2YQGAPF<4[H!?F(4XF)*RT<=P+\0-RIR;L#
MKNFG*RRLK&L9J,/551#E_[H/Y5;J7-E:/@UD@8H\'X#<S>HEY_34P7BSB##-
M88EGZ=U?R"76UZY.T[!B:XF,->=6*,YEC=:6XC"O?P=8D0L5^TQKLUYI5(73
M:[:,'C3W95 8*,^EJ OS6'& R]9EKH '"EBH0A\H?T4T%8<D6M^I]>]A6A<L
M9RF+]J84=Y3( C9]\@#5CU'D/?H!?6R^"!/BMOBTH1_[)^C#U@3:5C2AW4%K
M)*;D*$8C*K3X+/=3*N^;H9>[+7']&R5]Y.Q S[9&<9@B8H0Y,B&#;D6I-P+3
M^WO !*TEAEZT]X(O$1&^DJ.HYPT?K-)W_L@20V86A*$K&J!#+0=(#UYD]2(6
M(N+)Y-L8819X%%XRS/[<^-@0.3?DMW!!7^^_E9KGX34:<KBPF7(PCZ$E6,(0
MLTE^<</.SX5SM;\0^RYM[(T2R"DM-YPL;F,DGZ,@MY+-#' Y8:VS/II( QY[
M+0&_P=$]PLGF)G#"A'9'_)+Z-2$<H)/&ASX,KFK3%JQ2X]# W>'3P7VW!XVF
M!?SS/U^_/OKOWZY^_>Y__OMW]SY]^B/\[D?O[P\/RS\VX>TX??SX ?_XX9=W
M?]W.-W'PX<']^TWP*3E.9NC3WQ_>?WYZZUXF;_Y]?OYN]LOQP]/)Z1]O'KP9
M_N/QR\GYP\VGQV40?_!/CD\_?%E^"GQT&X9OKD??34[]'[_]Y3KZ:[(Z_>4R
M64X7'RY7/]Q<_^[\_N'+YOQ'Y_O9IX</ZW_-O_6__6,S^?3A]/?Y]XO?_?6G
MXW^DOWZXVZ3__IB<;R[0;[_^>_Z/Q^_32?+VQ''BS6_+]V\_?T)_K3Y\F?I/
M5W?O[SZ=?_LF_NOA[N/WD^G4.9F/[O\U_O[ZAS].__'^<^Q]M[Q,SN?)^.*'
M^>G5WV\__+][_'FT.O/<Z3IX__;CMY-?3T:3WR??WGSG7^'P?XY.9]/7KY_3
MM5,OA1*!CBX>UF^BA!Q'WPF"S=@/4EJ+DW6#CQ;$1U_3!,_(_<P>U[>E:2U?
MU[<%!02N5\!$;HH9<<Z>W" ER]+4!1HE2).\8N',P72B4'R#,,/P$JBJW!A:
M^AV(MC+8$A?80G(CR '&3+@EY*8%K[YVW SO3!2-VSB=)YOZ!0"JSB$Q!<KJ
MTZA9-ZD**F5=D'R6R*8Q)YO7SAJ!5+P+P<&9ZE)5[QT<5;'$E*D/E40E@FR\
M>EZ.\U8KZ'O&?+DB?.TA45D;)Y!*[</U;7K@LBKN8+I3E4(P@90I(HZ/3P<F
M,I"W(2T#FMU"%= WP++P4MZ&0P+"F7[*81YMG8=WH"<*5W9/@7+"DHI+=E\:
M 6GI:Q%5@K,6C/31.DJ-QSG-X&0K!4;OM!@TJ N>R-A0W42(\ABN4PK?"N-!
M>N+,#1=#Q7HD +9O"L@% AN>$8"UT+I/GKWU$141(6TUV./B=;*9DY\#A#QD
M(,(Q6"-Z(7<&RFR7(BJ4H\E'E_P8),8@ [&3;FT-<08%.9?B9)F8(#U#)" ;
M#QE(,M)BQ ".C;(=^'1XF1E-"&_!@GB;/"AVNWLIJ*,RQ[@D SELL(RI9\BP
M^,'C@VFO\#PE+@7M<4Y0._>?6+=S$*8T ++G\VLRIXEH,HUMM'R$:)$\.@QD
M\6>I5HJUY(,)=4K#'1P;%4@J4XEFU.J R'87 .NGFFST]T3D@WE=X$*]C=$B
M#2[]A6E/70;B<V)?F9 PZ>TCUTW7:4![E([1/49NUK*&_!V@O-!HM(YPXO_-
M/N\J\=,86C;?H_2$P1Q'.E?6YE-%&T'UU,'0.^KE!,?&HN!. MCG*37FKLA2
MZY3&WM=^UMYLG")1'+M%TZ &J)K=@F16U#\(ERB.$=KU2"E7!6[R&4OQ%%%1
M(GPEV/BQZP1_(,>T<=H"D5XTYE)@?/DPM:$_4)J5%$ICX]/2I,%:M8[:GQ=E
M[H]3J.;*C>!O0X_@3E\E:?FV2[X*\FZLAX/=>U/UA$BSG$]S$/YSL#A-,39O
M#PN ]?]4<Q@J(B)0M(\#E@X-[))])7@#.)/2BEF"NI(O'OT9$\DW>%]F1+[,
MB'R9$?DR([*8 O4R(_)E1N3+C,B7&9$O,R)EN/8R(U*!?2\S(E]F1+[,B'R9
M$6GW;:A4,C=RB9+9C9(PXR3OO0W4@M-\#FI>2]M/K9<*C.G8ERQ)=/>5/)HR
MHDVW,TSB29K$B1-Z?KB\3B%2EXSC9WUPCY105'Q/\SR2K3:R*4^_(=HF#'FC
M!V(>+(DY0%PZ/T8WV#?>B;(KK'OQ8&E3_IIY"E1(7AL@/43_3AG]+*I,/F?#
M)@CU4B>8([Q^!R&>'>^@#YT@]22U:U:#90NW/';YX:+&32^OYD/\OKZKN89'
M8 ,S#.(ZH*M9%NNO\VJ6YJG9MKFF]#4??9Z^?MNSJUEG!U_EU:S%:JCI(FV/
MW:\HIOB';#P&;0\SC^A'?7>FI=&V/T&Y<TTJSU+#(T^ZV\" ;OV6F_GZ#-&V
MW >;(=/VWE#>V% L!X,;&[#MVP\"%N+_ X!YW.)0?R1?3.*+,'O.@2A'A<!P
MP-)HFE>Y6/W8L5C%2KCVR2PPB'D/!HB9%T*3G"VB]89SH=BF+^(X1=XXQ43;
M9KAD4PI*%"D\0N29%C)U!(;ID6L0NN"Y^62JUJ);8#E(O:2&_##%K6,&%Z+:
M^"YCQ2P[C_ "L=XS<69]^IBML-U8SXPT,;[/\JYLS\5"! T/# 3'O$^:$W0O
MSU.1PK*_$&I;C1Y&T],1<<]GZ7KMX$VTF/G+T%_X+NU)X;(26FK*1('O$CJ.
M4>+XP2YWT40!W"$4H%F=#8 T:T*FZ &%Z?X ; ,)S?FR=A->Q8RIYBP7M("I
MZ3AW?$Q'_:*Q'],%R7F;+!9W3D G_LY6""53/_Z<UWG7C AMWZU/'0&K6>=J
M[-,A+U2OTNQE9[+8%@_/LJH]T^>,#V= C&L@EF0F%=#%4B-11N\/=N\W +FL
M+XGF)(9++:1X38@6KBE"5L>N5"7<29&P,MFW0S_$E&A?OMOJ9CG9;/_\ET].
M$W97FTM:?P-0QRL)%- "$!;U*HEO[5TB("A(G>X6XA5R*+9,%QZB 5*WJP;;
M=C]Z-;FO9; <C:%*#970,%[VJ\QLBS7 ';$:;GI=:0,E1,XQ^I*BT-W *F@N
M1(LS0DPH9SXEH3JKUPC3%G)G&GD?8H_TL$BV12?S@)B=7;%[D#O1MC6,[(>.
M-<Q&R+D@):R95W\:.#'$E&D^G($KT7VJ23C=K?C$X,6YL'B3<$IGY-'GYA,G
M]N/;,+J+$7Z@B%^$]VE"B]!#UP^RSM%E=&'UK6DTNYD4+*>EZP]*K7P8YQ:X
M+6T88[B+ $+"^G%]V).O#@SXLA^QQ19FO(X,2'L36A2,8:%#=D!(*#5Q%85H
M<^7@SR@Y3T,/9KX.!XC-+DS0UV^9PSP: [4IWVZ-(1RS:,!;V -9 ZD7S%4)
M&=:>R3H2@O4&.75BVB&*_@\='?'@!!6\=^:L83;*P[54]Z/Z.J%!4+.79!7K
M3,6<H.01H; :I8OGV GC!<*U/>1%CT<J"UM+06OWM*1$.YGW4:V3.49WR644
M+A.$UW22VBK""?W[-%K?D3UX( , )(%:+ ?1/9>RY(0:<C1Z("C2*_T\PC.B
M%'9CZ2EFN_\RG:\D"]9>VITN1^4I*FR4 )? 4,QG<DJCF2 2X+ASH(#RX,3P
M6JF^W9RRO?%DQO4='U(O1[TU9?$TDDW.\ <Z!5/$YL_=.&1+Y>H"T4G0%: R
M/'9C$XIEF(,,.!""4_:KF&(44$T^\T=J(2 [FSL@0)9'6_M,CAPFNO>;E+GX
M9%-!W/RKB )@>\W]E06ZFA8L3UJXEM0[2""O'C4 K+]7J,LTCVV@;\F'@(R_
M&'"X8S'6;YHW$ _$,4[^/%WY:''V1,QQVD!^LECX+L+RH4&R1(D_Y+]VO!&M
M;J'CD5A;4"8(R6):B>7:MZ$A/*V\P =UVUQ[0F8EF_:SAG$A11S3!X3!SNO!
M)HO;D+B^"?9IXY,"H:SZ7XHM,NM8+4I0YHH49:0&F0,Y-J79LL3#ISUH?&+4
MA#)E;AJ"(H;&\7 X J.RGH9E+ E#WH^170M*\=?7,6AP92O@TM1I[=:\3"33
M=%H4!=C<@+&7"6,O$\8ZY=;+A#$9KLW)=R:+4O@"0!W6PP"*T(&K00[%A!S2
M>F8KA96(+7\=A<[ND[*;#)*<H@H=SD624I*-HEQY:E.E*E043A$1XTI4B\%6
M]2H4C^&R/&?I7<PR&).S!PJ:_ 1 Q?*@6"^6;:%HN90#JB>H@0=B:/+AV"Z[
M$LBJ@#G0^?A<D,;U8B.'+&H_$_R!TW13&M-*W81U>J23'8G>I=$M_ "A\430
MAFI>"JDH3.G2=P,JL$%T'Q^.;=TG*;V'GD MT6!<;"Y XQJPD4]6GPG-<0G$
MKV:/833W$N%[^C!P[:REM9_H<;!NV>&%$_D4DDEL5&+$%-VGV%TY,1HM,6*F
M_SYD>2TGX(X\+&MY$"+9++BC0#;3MIX2>#FM9Y1O%E2?<:Z9MP#SU\T$L3YX
M_C)DGGF!15ULBOOFV[R&O=)$S4A<Z>U70!V@4K8]/P D3E@/PQZOA(Y\@Z,$
MFK-R&_HT]<)/-E?(\UTG.$7T?$X6GZ*5$X8H_I@2*2'PEZ5O$KS_5CA";6'8
M*8;1NJVWAZLU7<$*$B<AFA/U3F?X^&%6\(I"0M0$)F(O!&<SBTGH8Y:/I9AP
MQGF6&;3D$RI!I;2I,7)]>CTK'$+Q*G;[&$N]J^_2.L0T@?%W&]/80 Z0#$2K
M26?2G%.B(4Q \",YL=@):/&.1TZQ3VM]:'HH) /E8-I4@\H<E"2CZ2'Q>2(I
M-5NI]HW"--ZOY^0FU.[]R%+1>YM4ML.-&WW@SWP"A%T"Q%FR:U&#T(T+6*QJ
M;D/X9J(8?OJK8?6-X\NFC1_\;* DKR. 1.&XECM*<\]I_WP:NXV-#SS=6]U>
M%;@F.[AD$H9&#3S9Y7'TTQ1C9+P50Q,D:XTU6G*ID7HR@^';\XP]?[ R!"HI
MQ>"#FRAF-(S/ I^Y3\C+YN[DRA62MYH8/0L9T.6&Q+SV+F6E%^)AH][-GD#(
MC#=OGY.Q<O 28#13#8C!WKSU!!,/W];,_T0.M7*=X"RF_F#1)\,PA[A@!GK$
M^&2#F69]B>(8H>TTH4ODQ"PP.5D48]H-,TP"X$!9)T-*B:G/QMB8#2R<1V>L
MDK$#-NX!?$9LW">ES"!G4VR<HA ].@&5I YX6(8VK-"6- W-CS9F:/,T]RR]
M"R@.(\]C)'2"K(7 N4,;Q1XVDN.$9%HL/]#031N"2LP.UF#QGF@5B#3=EQQN
MRJTT-,=1A4@R@W!-J=!1'*?K;'PO\5H^I5XV,G$4!/D#Q621?8\EOS!TZ7#@
M*#0?3S".WF"]$?.,*D2J,2ZEE>E009*ZNZ9S&PX!#$]I-U&K8$U#&*@]8RY]
M@CZY 4S[F#PHSX5%);H5?#(<JJG"RWO%F [6<( ,[1(5T:Q@$3]@TYY#>S/L
M:;M?FJTVI5882)A=&?QS.7LRE"XX;BCTDSU%1^Q=U EN[\G66.?:*S] <4+N
MTLE=X"^=XA:>1ALG2#:E#^7>[]L &)Q18X"FQ?._V8:+C=(V1908Y5B5Z5=K
M9?#/]%S74KK@N.'4M#K#^NS)CXEPNHA.CN\X+,B'/;ACKDGB@M%F\]>JX..S
MO&'=V=.]CS=_( =337-%MK:24M@*RPW-I%(F5\$P4RE"!]E?)UE0,IE')X@F
M)3&XP4;N9I589W G2YY"!6]LS(B@S?V3S;D?.F1#X5+<.5)92#@0#FC6*"'"
M1?0$F+.L?%?(Q@4 ;_[Z;I"RI-Z*9_/^3;2S?^ER)EV=+2.,\JW-S%='O;0W
M>VEO]M+>;)#MS3SD$PM_Z01GQ'@1#@*)D?O-,GH@!H>?,8[\L>-7W5I0B1%F
M%6<M%8SW%*%0,@#";A5B0E<6@F_F4J/0&D2GH&EUM\;OGWT0C9I'G:165(@B
M526;WZC7SSKW?N($DW",UL2WH9/L8IU.$#+K6"W$;-L00HI09LMJ&=QK]&B*
M1Y)+V2UU;LLG67H9U_H,^J<H1'1*JT=NH8LP)N<WS=)Y9@@_^"Z*+R]/%3BF
ML)R-^!7OHMLR0X4<<$.FH_4Z"F=)Y'Z^<? $LU)>C\W\O$%XMG+,CY>6@&@O
MFJ42(U"B(4"3HA+<49JL(NS_C;S)8H%8M08;FGL;$JC;XSV/9F@7&1'.\]!9
M>QB<:T<^D.)TNC1K [A>^S&UC(CH[!(>F1#%LRCP=B%3*3YJ+#L@%NH0#6J*
M-!.DBSA.D3=F!3=975R&!+EXV3\9;Y4M!]3B(ZN.0I4EI40A,>2$*8;/G1/3
M@K@U;5^1];XP/URJ$9#:2X'D4KHF7N/R\N\&$LMT.TA*C0,[_21!#BOCHT:/
M#O;V6VZ;BE16UK;>M%]>)"LQR2J!H!H:4MQ.]G$K>WDGF]UW\I1 AMH.O]"C
MD\C5VK^JW# 0*-H=0%4K_)7[!X0M Y(A\T,(H*3(Z@N'%4&2"G;JE=>_3$D'
MN4LT9J0;GV;Q,B']94+ZRX1T]?;M5%$;&GFP6\MJ'HV:#MLC@DSH2X_(QL;.
MEU>S.IW@0'8J] 1JE;ZWOIFI GL4M30W0(:>8,9188,!F#^5I0=IX%2)(PZP
MMF$ B/G2*_>T3M3JJ T[G@G8(>R;*Z=&=+!I2U=DY^MT;>PRK*YGY66'<\,7
MRGMOQQ S>*Z<)[-$K:S72Z)6=VS:,F97Q?PQFJ^BE!9]C$)O_HC"9),]]ER$
M]+'-?T#TT"@D=*BM:#5AJOXVVL;]%6D#,I]E#X>5CQ.$PG8L.5S$9O-Y-2;4
M$ #&4L1^Z/KW3C!Y#!$&2?:O!6'U// #3)5+M)8T1J,JC//;0\8>DK/B3 6A
M;_BYQ3E0@$]%VR/31#BP%+2S]7T0;9"(6:U/#1^.U:,#S5@),@..4/9=HA88
MR%M"U7@ZNX4:==, RT)CRJZY*R"V,&X'\O+(VUK1.SI+Z-DEWW7]Z*B,GZ4&
MF>K9)X L,NU,M$8UTV7Q)$WBA-AZ?KC,D.^+-''Q^WJDB<\BT[FT *CN=78Y
M>T+8]6-$C%G7=&Y\5UA;S ?MA?0ULU08P&Y9:)&7X&2J-1^UXIU'^#Q-4HQH
M<BN=EF-8M-3AVVKGK2\A&C06IQ!WJGW8__N5V'+;I&?C8Z5,HO;UW&"UC)$9
MBZ0M/@?[.\3R;A]+UMN(?3G#$4)VC. UW O(#%N$0Y(Z%9N;?%0UN_]HS^Y=
M/1M(\T] 1.T5+UF0*PF^B2<QM>EK]J\HH.84N5=+4:6XP4(6=CB367%(/-8A
MF,2 IH[-DLR,RBJR+@#O%F.X66M8:,$TJ6>.>'J4UM'/-<YHN<1HZ20H RYW
MR#F_'90MT$P%F6E/[=Y(LM8 ];)R'84/Q$)%F;$:SR/B )7_G8WMBY(_4#)%
M;K0,:3ROK(:@WEM <1Z<"](1*V4F5MEP;J?H2^K'?E+LOX]>+@_'(1D>P-R2
MFJG5+TVW72G[T219(3Q?.>'0M)]H'R\:49[E4F/#^B7'V1$D'D3^$?V>:?79
M,?)#U*M=\U=F?!ID(^Q\NR<H),LD-"%!V Q;O=\T'\@!+YK[3LLLI)-9UK"P
M0E=LT2)@WBNG+[8"V7>]L864:-\?6R_K*/$Q P!8LL,!8KEX1U8XJWE#]>0"
MR_8[! A4D,P!8[>VIUDZFQD#6^_#@P=0C-S &<M%R6V9 U(7Q,[VN8_C9$Y8
M4$P)(ZX:FZWJWZ6*Z<V22]GM="I2$]M[2)8P(-UGGY+Y8]2:(3+K6,[NEV2&
M%$6@$@C'*':QSSR[R6),:82\,OR;3 >,0H_Y@3?$]L:5C9FV$@P@9,F75[4(
M3;( )AF]#AD"+]\HOG(2=\4Z29:195(\6;!_-"X;;?&QV*936SI:\P DCUT?
MK]X(A=4.GYV+ UP35PY.-$ZSB]!TP_4]F-9>M VS=Y^4$CU<X:):%R'Y$\V=
M)R0,9FE5(>XMKA;$:OJ]7N+.X8KR02O>;SN?XB9!UG(]8_V&K<UN<YZR^"[$
MS+;*VM;[K@J$K3*JK4H5F #'%@A(O&E_]4Z"&4T#UNH$K9;F*H.)#-#=>#RI
MAO(VAYXITMW\,+,2H%.,/#\Y=3#>+"+,'O5!U X'#MP9@-! /&)!A2MJ08+%
MPT70K Q/DQ95(:O@X^,"L!!J3<0PN],=#?(,)&R^"U[&B.QM!=5WH+RXQ48#
MDNIDKV= A3) #<K/'!SX*$X(AG3J.DQOCUH8]KJU<(S-2@))/5F@S+!+)P'F
M01T$NP="Q():FL!88Q-BL#BT>/ RBN/R$35MCC4 LO28(.FPRU#*\)#/YKN,
M30#KQ%C.(%F+\"DRJ)%:(+/1^"*QJZRD1U@JD"6]F+T'%I40ESQMH&+FM?)0
M>@GLX@B5P0WZ'%7H)C/?S!C'+OVUGS!QB2?A;6RZ_X0<S$'S[I""IAL$,%3'
M:($P 4YP&,4Q8I. +WWR3P&A%HKIW-&LQB,(HL?#3B(<M:B^JJW^("K:48-6
MPM)\#98=PA$@=KJBY3D789T1PF%@6Q@67Y!5.-J:E.**>"TG=[% +NV<N=W+
ME#@7]*$S= DB&<;).2*PG8 ."$[)6IO*ETV[Q 8P&HHZ-D)]F;)[3=<OS'U,
M\[[>=N7!.'<[6DB4J&M%.O*SOSF/\"W1#YB@18'>1#$C2WR:$G5AW+63!MM[
MOT*=D#)U[SJLW")\]N2L_3!OH1,Z 57L1,U?A G"*$Z(JX-"XR:K*O2A:$ME
MJDK7DD,-6D[O8O0E):)V]D!;YIK/U>% ."!C\]1BT2)ZQB-G685IRDT+=)Z_
M(TOJW1#EQOU;R^0AWYDL2G7T$$_KM3#L3H^3$,:*HUQ/)K#RLG)G;:+*KJ/0
MV7U2GC0(\@2B"KV+1]RF=_<F&:Y,PU:E*M0KEB(BQE_EM1AL]YT>B,=PB4M[
M*H:UP#>O6WE0K.=-JFI8+KDZXP[,W'DN'-NIE0+Y%/ &.MV2"]+\3/<F#EG4
M>";X8UZ[T;%L<S\)B#*^"#W_P?=2)S T6;A^W<%HL@;2&*WWJH7SFY^LV/0J
M>K6M_/MY=!8FOLJ8=%7F""#::5 @%$\NHT0$-#K>2P,#(R.0=9AH;5 R!!\A
M!JQOM7#B),S*/ V<.)XL6"-#")./"\=VIKJRS<>G&%261QD2B,%7 Z ;[ZG)
MU!-)9F7Z1 V%H*R\0UC&S3L./VP:=NVX8=ZF\Y#_YR5:.D&F*04J*T;N-\OH
MX9C\*J,_^6-']KJUH.AM5BG54D$F=4F9UI*6F9C0^W=U]QJF070*FBJ:46T)
MVJA U$EJ15,H4E72J%$U4-E@;D.NW6ZM083]][9O.O^-,_:\+7T[#=9RG*\#
MH:F0$ZA$9V]](Z[2/D4M.4$R])0Z_ZT\FFSH.VWY&H4LL [HU=3"&H8)(4DW
MPZF9V^RQ*C 0[Z8>AM6J6RDAK639U=/):("G$99Q'X?+E7[X.:T8 Q&QH?IS
M\A@B3 -$ABR<ZGI#B<344,+PJ*T*!&/1Z/T5+64@< 7I@+9@8>0]"$9LGUKJ
M6C.!5 @,H2W8@;I">(GP:(D14VD*;5'K?VFOIELSM6B;Q\:AA&&3?M<4-X.G
MVABX\BL;&:VFR%U# Q !GZ&L I,01D/(^;^VVO&W+?$;B"*N$-9@@1N%WHA
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MJR1=H]_GZR_1(7K,\\UW;]X\/S]_Y9-O,C],<984J8\S^ 4Z/"0 *Y G*0:
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M]U[Y,90+AZ]GT:-8PBA!?V+1(@TOUU7J3-F H2V,(\M+]WQ.>N5V8267H[3
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M+F-HK@_8@R;)H!O/4YIK[&^GE4'IC,ZTF0PCB?!QGZ/Z^[E)71=?)2*G),4
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MJ4W_XW=_>O?VFS]GC=T@;,7@YMP938B:6V,,HIJ?#J:SSV9#..K!:XJN; ]
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M)Z#")#Y.XB*[2\X\__'LI0RFT+1%]6#9W=N:6'5%^Y/-GE;CR<%/ * \09B
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MSU1T&/[1PKI%><FZ;)'U0QA#X^'2IO8>B$I>IN%#&'M1M(5\NK*<N-1-4P)
M.PC@L=G!0 Q(F:GHU(>IO=86DWI2Z97$*3*4&?H6$M?*7-52'MH9:J_K=51$
MO%'?0.7<>15O]CV#%.<7X^K6UK9$]E$EUHCE%J]SK;L&6#QL<5&4/*NR[X5%
M^NKAJ![OMEEGY_)$[-:FBM5[5VV0\A7U5_=>!/C</F),^W.5EBC%6\8ZSJS?
MP3H@=_ 541<4W"&%1WN:994CYH!QV:D2Z$\#90A83TI:9;?4(]^C+)+R(4.C
M,M*<'C$T*R/U)YNM>\4-AC9N1(D<)W&104*Y[ )1?XGHIS3YW%G$5!OMUEU
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M7:_&%>'SW3..GC"UP:5JSJC<ZS)V7&;:E I#_$1BBMH,8]2(+^):\ X-Q>)
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MAI*FH"PN59Q$A!%U+0"+&N(98K<W[(9)Y?CHP2'+CP0^W5&/AF'(7Y._MMV
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M\#1GVC8'SNI M;B6%S$4$T&-!L$:T.J[])6 3<6M)!!:,1-J^E@>?FI2#IC
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M4$0375M._;VFG3H4TQL_N*6(W/.E"3^ MXWP7>S%+?VS"S)KF*')M!U\;MQ
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MOZ =P/%Q#+%?!W7#"5)@AZU)4@>2SK&'R-@)T3HXC@9IR2</SU;,5$\\1[R
MR]/0$\U\ZWC>:409T;2=YUX&;UBB.>*%G>2, SEG6T36V%]_),%#N.'E18X/
ML7O*X0[!+ZOEBXWLB@-1?* (N0OB#L<B^V/,$['(;APL(6XT]? 'X3Y(,0IV
ML%)YH.JGUYRN6X<B_F__"U!+ P04    "  0BM)82&=U6F 5#0"R7[$ $
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M1-880(7(&-JH6"><#M/.#$W"- G;)Q*VOAJD2=AS)6'M<J_<+PL\:$UGMOL
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MTN[1Z9RT*W@ HBX:IEXVK8RMO*M3SVW;U_6-K'LC1R"B5)[&SS0S>U;,K/<
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M,$$#SJ:B/9<?P^F[\G%UZ^>0,%DK9D819"*>JA0'BP-X*>N43&X(W%*!\4%
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MV:?N+ZU>I]%IMC2CUXQ>,WI-F';"Z+=BH#_62KUF_L\%Q]+,?\->]_QV5HG
M>]3OS[OP!\;@15*"E@VT;+ _QZME@WVD6]N7#4ZU$4#+ 2\&G])RP(9KTI(1
MH/5;JWDS:/_2 M9^==WJ]'6)',W2-4O7)&AG+/UXR_%X6MW7;'[/<2S-YC=<
M[U:P^?_>M >_IW@\N[YL='1=/,WT-=/7!&G73/]=3>OQFL&_&'Q*,_@-%[WM
M]FY^UHJ\YNE[<[R:I^\C#=H^3]]R@)Y6Y#6?WW,<2_/Y#1? %7Q>^>,UF]=L
M7K-Y38)VS^:WG'.G6;IFZ7N$3YDB."<;SK"[:@P&&'A_WJ(2MS?G5^V!3+-K
ML%^P(*ZN@Z?Y_5X<K^;W^TB?ML_OM7]>RP O&\>R,L"&J^A<][K7W7[CDG6Z
M959E__KAI%:MO:<P_$ZC?]'XK^#]K-WOWV# /5,O:#% BP%:#- DZGL0 S3+
MURQ_C_ IR_(W7 H_Q?)K*9;?N!E\[O;:_]NZ8/W/C5Z+M3O-7JO1UVQ?LWW-
M]C69VC';WW+_&ZW]:U%@SW$L*PILN %>2A2HIT2!7NN75@\8OU#_^]>7[8$6
M K00H(4 3:!V*@2<5+3NKQG^B\&G+,/?<!Q?BN$?IAB^K,/'6K\U;RZO99J>
M9OB:X6N&KPG4+AG^.ZWU:R'@1>-85@C8<-)>2@@X2@D!481_ZQ+^U2* %@&T
M"*#)T\Y% %UI3[/[EX-/67:_X2(\*79_G/'W7[21V_= W0?M7RO]FN-KCJ\I
MU.XY_NF6K?Q:Z==2P)[C6$8*.-UFU-^[E!0@7/Q4DD_S?LW[->_7=&FGO+^J
MM7W-YU\,/F7Y_#9#^DY2?+[5O[[6'%YS>,WA-47:+8<_U-J]YOHO&L>R7'^;
M<7VG*:Y_U>I]:O4RY?>U$*"% "T$: *U2R% )_%KAO]R\"GKU-]P [UTW9Y*
MVJM_\9_N3:]SU>KHE#W-Z36GUY1IQYQ>1_!K[O^R<2Q=C'_#)GXLR4O\_MW[
M/CN_Z;<[K;XNRZL9O&;PFOCLAL%ON3"/9N::F>\1/J69^8;C\JBSCN;FFIM_
M^^/5W'P?J<^VN7FMNA7O_+%6US6'?RXXEC76GVQ18;]J=!J?6FB<C[ZZ:/>;
M-_T^>N8;G0OX7^/R]WZ[C^UW/K8[C4ZSW;ADS6[GHCU0S_1:_9O+ 3W2O6[U
MR*VOI08M-6BI05.TG4@-1UO)V#O6-@ M(>PC/J5M !MNPI.V 6@!00L(W]/Q
M:@%A'PG:U@6$XRVG]6FS@A8:]AS'TD+#QKOW*C&!?>Q>7G9_Q2:^<<"_9O6:
MU6M6K\G0+EC]N[JV!6BV_F+P*>LM.-TL.C5;O4&CW0$-_E)H[9_;<,Q"IX=O
M6A?LNM$;_,X&O4:GWZ JO:3F(^]O=J_.VQUX!-/]&IW?M12@I0 M!6BJM0LI
M8-N=>K3"KR6#/<>QM&2P6?RZZ5"U7F3_O2ZH_+VK!IG\6YV^X/>"\<?^@':'
M'D+Y0(L!6@S08H F43L1 [8<3JA9OF;Y>X1/V<(^&[;R=[J#5I\-NJ3=:Q%
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M&T#.Q'@PI<W18IXB"2,@%7Z*+CHNG>JK#P<1G3,E%*IM^//<ZK\'#>'Z>K8
MN<1*LR68+#;2Y+ LE+272=A):1J$YK,\&T_UW:-M/!(2?IT8 ;/\!*#_3Q&E
MTI"Q'<AH;.EJN\"'9IXE9=FZXI68!U123/*CY?F!O'C6#X=$>OH<)&\S^2UI
ME20A2VHC?XOX7 GHV\B=/:"<+$0/@"DC"(#G(P_WV28DMD2O5R5LRP2FG!4I
M[4& -BQ_*N@J;LT29%9&+4?:@2+TUREI)V^S<\=V;X$X.<6_A22&,]%AR7.F
M+X4TANNRG!!9$YR+ <?EHI[DWJ.B@R*095K(06!UE+*%0^$J_-"[L^[PM5$<
M5:WVD%Q064Y$:X(?G=R%S5VR7.3\Y0\Y3II> L9S!0]J]M0[DE'B$\#OR 1@
M" YL22D6(0E6L(+0:_@I#MPFG="1#)V6&_\L(%OL>@0X##NV0'I5A\69 R(E
MSBM%MB('M938M*"V+4$M)L4I,U5,FA.D,4A =XMT>M3N\2Q++)RA,I-";D"?
M/Q-Z?P+7?1Z@2 408SD%2/W:>B/("6DJB#@%XA0(A@"M#MYY)$]-,.T!T$'A
M^!14$6EF>&TY(SLD;8(>\PN>LWP_5+8.+A^8>;Q@$2/;]1,+&%N.X8S@"]!+
M^-?,? &Y;4"%'7'TW,R6T#<ZRG@08$(^8G,TWAN!9# D @ *I<+4 \>-KG@D
M8Z[-[8>871#$X70>'W&\08,YX70(D\)1Q(="")PZ$Q#/0?B5H\"2!%X3[6.O
M4Y8;DJY-#B3?5D>H)'\@5;AMB?<;X$1Y_$8QX)-:M2;Y<$NMMX?KE3>E5/XA
M!U!W\%!1-P'48M7Z\0IFIC<(J)N#U%E$D<6!JYN-[_)1E]@'JL9]U8_U.IJ$
M8GY*4D3 A= .Y&06>AYHNFJI4JGD[XG)C2R FM)"L#$M5-?(?TG3E!!<C!'P
M"1,1)&8K@JQ(%I='+IYR#;$M9J8"H')(0H1G0!JF8LU"?$L0.L-$_[_ VY7H
M'&+W:^ON\6N_-SQ/DH]H\0LI6P%0&4M&RKG8Q^\[DJ-0CR8Q5<RM[;7[P.A;
M"(41:9KG X%44R6/)!-C#)B@:13*"0+X/#Y%:V7!ZSD$ $7'I%RAEN>7LD+&
M(N="*0+]T#%H60*)4T+M%##; D*/1BB\A)1,.S3\F)]*>0?-1%.RAV9(&^!!
MBB<N82528@8V&7H@S8,>8J)=S"#DLQ++ BW2]3+2 A'OKS.Q)?@)]!=FS' R
M6AN\52O73_^IZ&?RN&,,'QDSY+/RR.2C</%#\OJ@K<QP'MAKM"2S<0@R1@&1
M,BT[#&+K%AR:A8Q2VM% _6%J<Q&!DKL&+I44T(1Q>U.2V/(S.GU7/JY^VT-*
M@'-DU$=V0PS*1^XH#P> ,0S(Q69;4TML28!0Y#1Q.'I*_(F$(7DR4H.,F/(_
MCLH5P7R 8-ID(;T!VN!%\X\L;Q1.\2C0-?,BQ3SA,46C@.=/K!E#]SD\ 0/X
M;&H\D%! #!!V',X8H*>)T+7DLJSQ2O<%*[.YC[HW'&'.;0GZ'()$1Z9S18]\
M2::#PH$C>2:%!#C#8F%/SER2!/)6&B%23E[R.@. T;1"R'/,4FR-2B+B_!)J
ME=77( 6)^0,P"RX,Q%^;5BKO_$\!L5KTV ?1H^U$?I92FM/EFQU2"#1T#<]$
M"#<MT(H"UU-P1DJWR>%>T0A6!)[X$)'U!'N"<5PQ9CX[F!>.C$A+D>^BEW65
MK0A,0-%9*A:+]@6S(!JC,@+S&+[K&$.2#="Z-Z*H,1CO=41V#"'*&,Z;PA6@
MJ1 Y9"'#$J>D.!9M"XB^<G.CVDF"6>[1+@A)[>F05!V2^JB05!V3NG<QJ;L+
M2=5L^ANR:24Z@NP/:CFI/L"T.H9O&G])B;2 D]Y/7.5T(Q:%3R!+LCS&8:UD
M=5S$7D-XU49B\P48I3OC3J2'K\6XU ;(=68+.71F/)!M2K+O7$8FF&0^CXO&
M)-5*ZD/&+2@KMS@ES)#BZA';!MY_Z[J@'!OD$XQ$X81'T9BZL'$\8R%!Y^L-
MK\GD$-W(,L_"FZP@SK^..'Q:6\=([U.NE71E6)00:TS+#T!M#.5,!<"1+SMA
M\$VQT%:@Q:RL0NB@FQ<?=// E%X0W+O2AH.F*&%,)$N4*]SV.ASG.PG'B8(Y
MA#UQ"+R'WW%!SH0U3X59I$%"VJ_]T [(4!U9_$0\!X+,U"*045'%&(P#M ]C
M86UNF-(@$7!C&H79!ABW2X1-V!9A?#?T1FC>'KNCT!>QMB8LT'9G.+;CPD<V
MM$ @OK5&9)2#TY6D%;B! 3SAGI&ZBIJC(J !7$V@6-QH FNR1LS_ ON L\0@
M1C\_.E+8_&9)AB28EQ\-K2SD,AC2YSQI#?2W:0[,,0*FV&,O=ZD9RV B''S;
MBTM'MJ^TNCF[I0_:DPC3KE8K):6#@R9O/Y16L&=JGO?B>1[0.:)E$Y";N*.$
M4V:-2R+8&4B:P'%A^YX*V3$1.1>E^) =2C/&[XDQ8HZ*Y=QQ<F@@:Z$$,M0D
MT(<KHA9)&S!+,CPILK(F=3MZJ)0: )]T?++"VX94!E)^VSE HT!#4O#ND',E
M%)DT!"8C#B<&!<0H9XLQM&P,D$PNCZ(1A4*#:J0(X!29.YAJX [1]T7>[#CL
M/W(F@D)DXW.WDZ6&6G0/<?0WE&1"C,BL P+MW/ID]#4"H,\SX?)3'-=PQ&,@
M., I 8]/AVZ.5\+)Y=9Q7)SEP"T;)BI4<-\B^0]% ,R8D@P_/4P(X@WZHY!A
M&5_0P\YGJ(2"O.)CJ"SLP[;^"BD_BUQAEN^[-EQ(_C"4*N2#U.+CO@QV9Y%]
MR; !>QR#K-,%IR"V:MP9EHVO *!(@X$)>J(I(NVBR7&:>%EX^V)2!39N:)NH
M1F(.BN5%!@%Q'F,9O.H$:%]'[=X= MH:TBEK.+'DY</,D>L4,\,\.%8BJ3,7
MK64HYXW#($3YRC:LJ1^YL#P*"L0U."XY?3T*@#!\A2.Q8JV<7H".)!1(T[O:
MGTKDC)1N>8_140D5&FF./".IF\^IYL+#!^>@I.'$OE,QT;#W0 11X_['H6.*
M3:L3T!+'BY<X,(M0-58108L"J!9*JEJN^$[DBM_=D*PL*]\\$,*1 ;HO>X W
MB:$/.0BJ:/0+0)H0B2Q&DES%!"DR(X)P:TMW:$]8%"]@)D%R'^2*DB;@.U<0
M03(FW@D==HH,VDL&-2*MMAR96F&"ADXZM23UAG\V!ZSGEW],]QI.;6 !XL4#
MM'@A?3]#AS><=O*WX&'&SS"W>"%@'Y[L(V"GZ.(PM$'.RE#&Z!A?"<7[^'UN
M):?'HT(A<LA_C"PZ1!!--B!DSBZ LQ70<Q:/K0;"XR+MXU/. VFT)'B6#I(B
M.";CAP99#;*/!EE%L;/0ZHXQ)3K*Y%GDUHN#/*,H6H3MA8'L.T[E2:9Z+-L*
M<1Q*B>)?N3>R?'*8%T^* G,<#"J#X?VB4UE[G)5S WSTQC[QH%1.PR,.2Z0D
M^ FU<W'NRJI@D\VK264E:-7DQ:LF<=9]#/22S.7"_A,WDD&=O*G6'S1&0*TS
M?2<Z4T'- *"2<2A&E" 'C&84QJ8?;EM4_Z<P8TY ^EPM@7XXC)U]<;X63:/,
M6L(TC 9$S.*6QBO+264G)(R=?HE]-"R/K%<E]@MW/*3!G[EA!Y,1:F!-Z?>\
M-KS H>=[@U]9FV:1]8H:(S0OLG,+!-K1Q$''YT.)-9&5F&X\1(E=<#YC \^
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MM3 7-@^?YN1&+$-B2#0QL7I'D,2 !&!C.:W0D>;DA9B1R.6*27U^I*T&DN^
M2M=9Q@@CJL\*$;)/K>V>2)]E?44CMVU>-DFOH+1NVJ%"@Y$?7I)2CX27(0_N
M,=.B>K8I6HTUQ#<VF(PR\D'FH1*:)LJ)9B+_4%;/BQU&I=B0@#9$.Q%\P%4%
M/)'1*//HXKM0[A-C")]<1\7D9YX2)6ZF(68&HHM+>$)6J>*GEKCHH:6E T%M
M+:F<T,6J2Y0SF="8YXHUE9(UA&2MX^5[*>V"&7]>G1EK,^26K$2K50\'T,A3
MM:FG7PY+1ODQ=N,DV&?"71 WM$GKV+G11_.) 9O6JH7ZMTJ,^B*;9ER_=GW-
M4>CSB,^4ASVSC1&6-J=BP>L</FH1"RE"-DY+N/FHN5[ S?)*:>8134GP,J*L
ML70E*LY'>DCD>)UG=T#L,&X3G@ \F:0WD+_+ZHJD+[8S)BN.21.AIBG?BJ8D
MR@+'75<I!E&QY+A@0_96Y94;]EI$:7'4::VTP$^-C2G370F*_=]<$DL*%1'.
M;#GF.NV25B[;E#-X2,7>\TUO^7[6;U;;O3D7*- LX!++Z[X?GN@Z27N,\ .J
M"8-VZA$7'86#@$?]069 JP4FB68&D4U;T'6ZT-)"9X^$EH1Q&IY&:,=0[Z*
M!( 6+PJV6M->3MI&-M-\H3LJ4U,%.2Z\CE4Z#/97Z'KA5+VO7E&.*T7,_$5Q
MU+KLMHZC?DP<M0ZCUF'4F@^^[)@>*I?KKAK54XJB;PUG!2.5$*T765 C?72Y
M,TS'#'TG,4.-1?"5$>7F)3$1VXUAZM2_\8N0P5"DLI3V,Q]A-!_PHX%F-]+_
MIMTS,MQ]/M*G.QY;(P" UM=1:,]$S.P3_32JO=0%MXU[I$GPC\@F\$ESQ?18
MSQ0ZB)B<QY/ORJO=EIN;=UEK$'_.('XT#^(7T@S+6K8TW^0 .%4H)9OJZZJ,
M,VKBTB2TM-N1-9<Y+EIQN4S]5UTN1BJ+9D%!MVP#C%PGDBOJJ,D^'ZGG:Y7:
M.T!!)TSK\>DH,T^^.2$K'%4-@.^PH"V5CS-#6]9CE:9B[-5!Y>1*Z7>YX=D6
M%IGE1C"A0"NX=D,9\#P^18NB1I_O"WV.Y]&G$9H6@CVVD\0:QD48A#[E\8,T
MDRI, ^C\^?KJ$[O$$@]^QD4/NYMQVJ),+J-"'+-P" 2<$"H4;=['%K "9=H9
M6_X(P/\!P)-)>]@%'W&,59%50JJB3(@&S>\+--_-@Z90C:YM8Z',$F=:P3N>
M,>-A8(V TH*J5"9(47J8@\8BC"G $37X?%_@<S(//JW^]?73 *<UG=GN X\@
M455\T0#T_0'0Z3P 28\=^N"XXR]3GD0Z._IQJ0+3@\A6+\5MII/#4.;^K<R\
M1-Y'6I80.66AJSNN%"@_SJX6#=J%C$9&IWLLO2AZ#:03%/)C,36,/F<8K59R
MY#?S3S?T1.3>$LT^\:1T[N5;FZQQ[)DK):OR)EI%J *](BP/XU,\3O$G?HA
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M+5K@/%6BVBUPB,\6WKY!Y99U"-+CN%H_MBHAK^EQN'OSC,D*WCW@27Y Q;*
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M3/M3[K&\(O^$9R0HGI)@"1[-TZXQ4]#N0R.E^QRW\ =M;;3AH@UW'S9<+:W
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M;.M\UOFZ=$(6]=V"RF$H>D1Q WO^)PYGIMQG0+5.,^HR@'/O:L+!(@&8MVZ
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M=H6-Q9BJ/GO#AO^WQ\>G)RR@$*S2X6_(Y B@M$??G!Y+O]+SI\<30OP4'F'
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M5\@[7*Y=ZZ8K"*8,"^,&^^H=;Z(N55[XCXSB*(JCAQ1'@DXF/O^77Q\=\\V
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M'G:AH2 @-:_3C?G@"0#=?*X=&+#B>>)84HVR"%:,14329W\=_$<\M0S$;M[
M^[=NF#F3S+1Q&_W<3\3/_9= 6CVL[_KD>?1=#]!W)2/L6H4.03;VWOW//F+3
M#?'83%%9/RIYL^HR-N-<B=F-$:YN6N@1#9Q/UA$V)WW@/O#4,O\8]U=6\R?V
M=&]V'G=R<O>PV0_AWV[=H8-V;<W*HU?[QPO]$8**#NV>'=H(PA:KI^ZY>NJ;
M6#T5JZ?NK7HJ!J0.+"!%JN:,5<VY!9VG3Z4:8ZSI\79/NV8(ZV';+)\>QZC8
M'HW"CW.];L<1\K0#S<C+.9;/:5-EYYQ"":;_!]WZ+?91T#;P5L;U);]61\FU
MQLX:Q\4N:,02I*81CGF1C^(Y_M=<#_MTN*@GUUA4.G);\G.L=Z/(^'/;R;'&
MZ.P<4K1WV[!NOTMI^SPP+'0ROC)#3QIG&ED$BSXY'X18FYEC$6R^"PC5M+[0
M%QQ:11_%>NJ%0)QQ0V^_4$K-X2EU/[PZ.C# 3B/IQ21<( 6V2+6FDP;?Z*VB
MD4AGLD=O\7KR';F1$Z3#[?HICQ+I]=XZ*KT7?+S/=RX0KX=>$[?:[Q\=>V47
MZ:8S*,8+P,:[9DM36(SM5:I9IK0D(  +KYI>8P&RWLE8ERF$X(A<L&T<N=^Q
M>1,=G/9U%Q3Z#U&A)H1:]$)N:U!>!]/G-O;DF0O5"8V=30Q*,/DDWS;[]G%4
M7GN $JS,] H]T$-AZ\.J0T1F03P>FC$G) 2&GY^Z"NZQ^V4@(:8[J<< EL4\
MJS6;CUX4;=RP'-$!4N:!<!)F9H^TPI+0,LKA)L >_#H8LP09U2QR5J97"F3Q
M5,@Y"JQ#$UB_5N68OVD3UO?RD*_.*_A&H,7"Z1Z!_'L6Y=^>H%0'O(QB!-PJ
M01:9'LS9#$^2?^(&6Z%3M\QG#(1,0M6)0\J&RSVH\H(KR^C?GEB3_)RQF-SO
M:4BO&:Q'<,=>PL2TUFORNG$I:?_W/%)P(\(OKTT" NU'3#+D6:X08(7M,O 5
M4OA/+9UE.8G*M:JQD*TV]\%<3O!3Z[/3M%Y,KK;>,_UQ9@;0'B2RS#N%?\)Y
MEPADK8"8ZE)O&DH4HEVKZ/.\1,^%#FVFR@_T<T%0;?")M9;IP0K?"AOS<%-8
M.>3MMH4C$@"OKMCP8&/S5YP6O/[C)SIM5P"'.;Q)6#V5L9PM\<2'DD90(TQ"
M"82-TY;P@JR;T]<+-<>4N7'UT5WJ2IMD7*D/!&,!E(OS/R7-J,H2.&1NQNBF
M1./D?_'12VB+)VC[G^<E^FB;.(LO$OBM"'S1U66.O<'E9LLXZW4W SXP)H^/
M7=W/@N>MP1P&S=$0@0ZPIGGFO%16:[X^$GLD]@<G=EU>H*$.Q(=[W#5L[F&\
M2E]4*-[I;XD#6@KNDW@4S9%:]T*M-#B*3 JJ"S&]PYL$%MMR?BVG\@)C%-,4
M*41>=T$5BIC707&=?#I"R9X'\SW\*A)N)-S;$"Y;"U0N2_E8 GFI?!\2M^*B
M J*)<;9/),Y&4\F2=^%TB3.JSQV+A'T=(V%[B(3]*B&=G2V)& /:E:;&/@PI
M5<?(2F^0"!:-JTO7S&B2#ARKXCX&FRRGC.:: )(HY2@A)PG9>+-(.%F@BM2[
M;M<:3;&Z76S97RM6&4M=/278<< (4 E8:)F^U$6U-A-5W!U"-$LS?^TUJMU+
M36#,+R\)R]G.8AN:A? .8#'FM$<+3HVW=O"++$<FV]@%S6H_ES&(:N:+&+DZ
M "7\V<PBOQZ74=T_AZJ][AK@$H>+ELI(/@':Q_@MEQC0%!4^;#!3+VA.; =>
M?L'C_5C[J[SH:C(+A)EI79/\?$7S8RQ F[2+!=AB./NKQ E:-!W/M"@L\JR;
MYZK>)%E'.+LT! :E#F@Y*M$MU-7W$;,T5MW?<]7]M]&LC57W]U9U'S5^U/AW
MU_B@T!LWAQ)4<0$*%4MDNII_..N:'.<O)AD(8S/<D6UZ,]L-+%G4\U(:5GGY
M9,8WX$K%,FL\W3YMJ'.Q:M;1^#5>*-K/&:Z4O\,ESU77R+3C N?'#>9NVGKN
M@<U!&6$3V_4*3OV%!V8-+GNE/FA>C6M<M-5PHTVM3>5LF]' \!R+X^D>P:S&
MT%^@)NEH[?_QO/\ILGF^\/ 9?/(.;'D:Z,TVLR<7E!O=R'XK^+)%&];'U[TF
M[E%O53B9 WQ=/9%+-&(FJ+X!D6.8WXX$PG7,JDM]W># -=R6Y-%-W9;'6_V6
M+4&(AW5:8I?(?H#-J8[^DHLR*(!M(S<*CWHE'=W4O1Y(<\8C8P8SI?"&.7IQ
MHBLW'I7J[8D\1%$/^)G(1-2PJ>@?69.4W *QVKLKT(17\"%PZRTY<U$5!56^
M\&-Q%:9YWO ^8W^;5Z="-//\:@:'H(3ZJ8 91,\%UKM9O2P;P!K7]6"1%(@4
MOS^*QVX=)OAD$ +U";OID( M03"CL!@&^EVML0Z/J&0SH&->L,A1J:2<$*4\
M4KMG@N9-P"Z-+;>RS+!0<\$C"8.[M@I=X/Z<7!V\J["1:J^I@3SCEZS(+>\4
ML?X.O;7Z/5D08T/M]S1O^%EL==YGJS.GTJC>NI*4&N6;6J$#/4X"W?14-#,*
M@U7@NF;YZ-V%LD$S+8TK3;>BD5M1-GQ2LN$5,.S#RH&3* ?V: )-I6(;)PFR
M[5PO7;)C5CW($VGDL'=#&EIHLK>^?/KT&"?/.@$T>1?N"]EVDRA&#EZ,G'?K
M=56WCLJ:!Y8D3Z(DV9\D.1/I,-)(B_]+3D\XX_5XQX#7,6!ABG=1!M. "S1"
M5<I1%7G8O58RN/*RPC@T8B^:=K+MS^H7 5$KL $3,+4\D\:RA9><;/^EB,6,
M@=<I--!PYQF%(TOJ!QL-L#?)([RQ5.WPRH>\98IWCA)S,L..Z?&#.?WVZ-F.
MHQDB(SS4P0R?U#^67U63J=\%#^IU@_C.<]?_S0[\"P?,<TZ 'J\-AH^%WS'G
M]4[ =/A^YP2F$UQT^Z/BD?"#DTKEJ/#NL-SJ@C&E;9QHZH3YU>3>6P@@:L9#
MUXP_ ZE]]<]UU(R?M68<3-/@E@>4':ZUV!NL ;(FE-9]$<LA:\RH382XNW40
MW%:>Z/"1\-EOMT$_C&/[G=N$P539XE=X$S.,O.<)2"I@7>@,>T0;C7BZMDL#
M50)]@O_E\OBUP9WU+S+ ^*F#R)^^F.]XP8C0]JI4X(8(X&* N)^&+2*DH!<,
MXH_IRHJBP5.]U=RK>AV )>E2\>;>"RQ2CM%74I$AFA7_R3%4^GLA=<S!?5-O
M$FI5LQ'!R5"<79ZE;GC\=BV*BA(?TJUI1@RNS" .LY[2V&7.A/,#:$"3ISRW
M/^=THT7\#A'L[60%^9G5W7XY-2)\P>_-K'O&2Y;X=&IN9HXM,[^^T]"&_B")
MZ^^1!9B":V\X?J*9VJ\;W^?:$R ;$!JWV[#$'W#1E6U>)"??'MOT6.,EQB9A
MXB*V<ZPRO>\JT^>QRC16F49LY\_5!SKO9E@!P59>&$8!B<#3Y?"K=SQY8R]9
MR09=)5K"R;-GT67:8UIB:@J-N$P2A),:O\U4$"ZU.0LL!J+9+Q]SAJ)E7"8"
M83+V4Q"]PMM-D"0%9N@GDVZ4NWL @>49;R,F6U6G[%SICLUZ]$)VV6[C=F+J
M<*78T(4EP!JP($GF00KT3O+EZ3?/CL2Z W(L\%4?\9NPH0RT^>4I7#+^?,-]
MYJ=D&U<X8+*A%'!>=0V<H8"^9IP#QKW-3:!.CN[,\XU^I7@@AMKF\YK-9@:$
MQ4I&4XRE'Z=WM6]CD=6>\.NV>BHN%'QS;PB+E3"<Z]RKN]"#A?<U&'+$O %Z
M\4RG'@@=A@-Z6,<[(M<1^7SOQ#<AQ0V$8C+OX'166('L8_%AM@8I4V@M]\F7
M1%/15+>[!Q44BAJH;<"-!'Y;1:KX8ZG"'JMDZ1IBX]0[>%)>5KW3\<WSM1*C
MXF[RARP0OA&UV->^X6M&SKFUCB+%W_;A([9,B@CM>&>><+>$JYKQR=."^H]+
M\\NY%QR@#-]#YDPK=BN-@;9-;EHQO]2%14U^J#-@"P5'SJ(5B/_K[\N[KM!L
M+#T]>3:263L]3#;]++S*:[IQXD_^HDI8$#'*JR!@*4["0R;83K^)";8]RW,O
M*$T1JT9C<Q$!HM.,'H732O%L% F97]2&V?A)RC/J42J9CCX[DU5$*F9_0)YU
MF,^_6E8)CU9US4T-UM'CC6U"C_6^R^7)C09BTZUZ/C%XP"*B\&L)$?U:?46!
MN:_.\7 M*4GGW<GQ\='Q7VSH=PX/4>M&?Y>8?YFOOJ,H,@?5,/9F?R(W\@*]
M%'5NDV/Y'PRG85@?%U:/KRKY=Y[]79?TR;OJZJPJNE7YU5.[V"53G' [W0MN
MEED^.7-I@B"&+03-0>SPFW[ D C6L)'[E AW^#$0U-B]\6-WK3"I88VGWD?$
M'4^\#YA!_$^09O%]R=6=JT((GF\6WNB821Z/X<GIT?&SOWA1SF-0<OC_3S#\
MGY??#T^M%_7W(Z9KG*I3ZEYF0-Y<<@-?))>T,MQZ_)9.FX_(%V5G#YW)>;X7
M;??$M>'N)Y'3EW5W5G:_@G@+%0X>U%_;+/(5\-78RQSW'W \>(#'@2='I]_>
MC '!@&[U5W B<V"JLKJJU7J$JTQS<SRH<0$X>2!?'ST]^:,E8A2']YK7]@[Y
MSO+PQ444AU$<?NH'=?T#>?;MT?-OHCR,\G!"'KX5SW:+4(1_U7^[C4?WS+&E
MFG^XJ*NNS+Y+_NOL[.7+5Z^^W^7E_3#!U -NO#'K3O+HDYOSZ)/K\VCO,OCU
M'=PXQV5PGS$6FU79YM\L3S_+@-)],-NVL.,]%:^\M)7<;Z22^[KFQZ=._UL?
MN$5Q3;/)?1L7Q#E;+8M/_0SNM-TW]Z3^3%L;R?N//X,[;?<M+.,=>WL/AE(T
MBJ)1=-!&T<_JJM98G?>/0N?E9V_$1('^Z6SWG>V5*"_N6UX, QM?_.WI290:
M46H<S';?W0R,8N/^S8RWM4:H6&S4.%OF>I$,XBA41_.CU-'$L&6TT"/K,.N\
MJ'_KL'!9U5>JB*HVJMJ#V>YHH!^<N!@UT+^-4B-*C8/9[FB@'Y[8^.)OY[K$
MYNO_G1.BGC767U&W#/?HOD<<O:[6#V6=1TL\6N('S2/_JU*E2OY>E7!FE[J)
M6C5JU8/9[FB+'YS &+/%GQU'J1&EQL%L=[3%#T]L?/$WCI#_HC,\-!,?CR'Q
M:(A'!I%LDNJ*Y/_O\K)0L60EZM/#V>YHA1^<M!BSPK^.)2M1:AS.=D<K_/#$
MQA=_ ZM9UV!_G_' ; J!G^MYK5M5;V((/%K>?T:FN)<>NE^K\JN7JW51;;2V
M)5^FC^Z[J)JC:CZ8[8X]<Y&2/X_M/LCVN!A]C#;0)V<#G2MX7+M,_M$5'U1=
MYM%@B6+^8+8[1B /3F*,UN0^BU(C2HV#V>X8@3P\L8%U "K?2U]<-+FCR7W0
MG/"/FH9YZ>0'5<0>N*@Y#V>[H[U]<.)BM.[V-$J-*#4.9KNCO7UX8N.+OT7T
MB6AY1Y[H^:"J+I(?U6KV 3[Y$&/=48L>SG9'V_O@!,:8[?WD>90:46H<S'9'
MV_OPQ,:#V][1SHYV]D'3_UL-MTI^4O551&&.ZO* MCL:V0<G+4:-[ CR%J7&
MX6QW-+(/3VS$ '<TO"-/# /<*UU79?*^J]M"1R4:E>C!;'<TO0].7HR:WD^C
MU(A2XV"V.YK>AR<VKF-Z_[_T#[2M\5.W^3^='N:6WW2X=K#AY ^8/7_^?&33
M+ZL\N^.N]Y]WY^':ORA86JZ*Y)]'YT<L@5[IC%!"7I?S:J63]^IC<E:5C?Z]
MPZEZ35(MDG:IDU]T?:'KQ,P*]I=QME3U&V#G.L_T5R?77)!\],7?'C5:)[A-
MR<GIMX_#6<0> \,&_1LVZ# IZ8[,^ZU'2J?WQ[ZG3U$3,2T]Z3_OB[^]=Z>:
M-TD.M@#\+$O:*OF]@SLN-HEJ$I7\C__Z]O3T^/M:5_6%*O/_*!S.3A^>?)]<
MY>T2!#,2R$K#M^4%TLLY" JZ".GKR=??/E*/^=]"2V=5IA-X!X\*%T*%.5-A
M"U2X[NIUU>CF*'G=X@K+JH7ES*LRH_GPN- W=?=!X5I.OOD>*'4&^T#+2^#>
M+]Z=O1C["GX&CU@7NM4^8;=+U?I_-V8;<MVDR;*ZTD#A1\F+INE6^)K;KU?>
MJRV!]> ">'=:+A!P-?^0/(+-S?0B+V'+90<;WK8$SBX'3RXS6Q\PVXW@2BR3
MN;/F-='&G'[/?]Q5* C/&IJ8:: S)H72,3:02E$D%PQ)5&SH-$&A5!= 4HC.
MOTDN5$X'5U1-<WWJP(?@4N!>.E^WN#(\>=EEV5E>Y]% JD3-=#":Z5W>?$A>
M*0+2>5@M\RPJF?TIF1^J=LD,B5V + !5#;*NF_T&X@ZE,;YRU35)#10 "J=I
MJGD.$BDCY8+LF]?)K&M 4C;([W@?_A!6T#5MG9.**!,\(I2?J<?R*8J,HLM8
M8@,%@&S)9WF1MYN!!%\IEDHS;14$'!X+&964W6K&4IS7"0O7:KZD2U%ZX;+R
M%MY"-VN4XY<DS[L:GL0*H.FO95$5176%?]$=OQM*IR=[)D1?@WSNTNDVL%_O
MZ.3?Z8+($RA@H ,'9_C#S_]>';0X*?)&?O@5D#HQT'=5U^+X'/^[=K/6WV5Y
M,]]Z\$^1Z?<N@KX*95!_U655ZJ%@"@ABUA7 [CUBL'O[!9LV7XLA)A=)].'T
MF_7'[V%CUH7:? <<7H"<^FI6@/'QO8GQ7/^_EHKH?UZIO.A 5GH6:XH&4@8$
MN$&+W7P,I)2*>&O1> 1+:<4RC40H2]UYU149"#FV]0J66"H#C=IH_&NQ0'D<
M6,T@R[JB)6NO6H,!AL0!8LP(XS19T' E?)ZY%&[Z5U@B+&Q5E6*$K>M\KJWQ
M]=<LO^18@662G]_]=- \\D<&921(NU70?9? ^WU,\/_E'^WWR>"!B2JN@&[
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M?S%:A;<+,A;7E3ZZ.X\<H*/?T8W?VA9@[^B?!W\B:PM.Q!WBU*_"8^03P]X
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MNOU^"&?,B3Z)LQJ9,PP=PS6$Y%/5'!DP+M?X,H9O%(V$_5;Y^L[8P 6SXV/
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MDMO0R4$^A!#6H/]W: D0W5K:-A*![<&QQG@GL_O+(LMTB44"2:(.X+[NZ;E
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MIDG?19]X(XPQP@X?AR*Q%E$XZIC3([4B3!/6"P9%S]-A^^2&+?^W$YU(?H:
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M>]%S?UU+9A+K/7H*I%!Q5GL>/J<_%VU^(>_SS#B__N2DV'*&+(%\(RZ\DQM
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M5]K#5QJ;XS@W"?4-R:9P\5&AKN+3F/P)ZD:K]:W6]TO#Q7.D BF4/,K=:P7
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MCEF29(6-R$&DSBOI=FH]##QO?HEKC9@\:@X(5_M[ZNR>O/J):,S]Q%@/LZ)
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M!#OQ)F![%Q>,!U#$A/7$DO!5 ]"D0-:5G=CMB6B4$Z7R$E^I69.9'!YH3K+
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M^)/;$F@V56UAU5<DZV)Z41[A'G@_?)LAW.>J=L>6Z 7>Z<44NOXM17DH4-D
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M."J<)!KHXA\IJ=;N1$H.FIGA'X.1@!5+%5YUK9Z7.CQ7E987@_#4-Q95*#7
MQ@N5W.))ZN.1V5:LE'1)S9;%8BFN8KP@!\7BN)%,)X4H'%N,@W&8CTW)4<D&
MDF"V*G)5-B=VN^=)+"GRSCW.288M#@[VZ(9",I"=UH#GM(B^NJ7!$+>ZP?9-
MXGH3)W@7/B=T?A8)'=:$47NDE(W;QC\;W2Z-OF D@X= (B80DWIP_^C=,Q5>
M3$PU*9QAZ*\+%ARN)?FY^>>I%K4VOU;755NY(Z#F>M_,M'-"Z.FV]'?A54NZ
MFA6\]B1EW <LR!=G$FX&_NJ:!-7+P5J)^^F7S@RN:7-Q_Z.@I(5C'_4KHY#'
MTML;%NJCNP43VD)Z;^B\[9#AC F3$1QT&%.6XGD&K7/S,.;YM\4Y/\.Y)/4
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MV62[2*N(!6%AU0UN_)7'8LM6T'D*058:B 2U"?/@WE:G@E_K:E\VNT(H*H)
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M_:2^X;CPTY]X!OZI.\\&][!NTU:V<B:T@IN%AW [V^8C]O_H]&1[Z4-BZ#(
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M5=8+/O\$>PRZ& %&$(BZVV"UC9@QH,.WW)O.CD0\-><Y@Z#N<!>KK[%"2QJ
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MCTW<&;=]Y]K94Q- 5Q%V*P*LB\K4L)0G$+BA9U>;?6'<]R02.G?0K < 3"(
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M9?_,E;MU(RMP\"D"HHO8QGFCJ[JZ+LPV$/ >L<Z[7SN,WJ_F\#@S,/<-%W1
MU'X'*:RR;H)&\/G&]!50>!X&2H>+V=1H?IRCKD*%Z1G+H>G3N1!OL!$GJCN&
M8X;-BA.URT4?-G %O<\1GWUUA%(:LK[ISD;2.3WU5Y6[D#*K. >T'CTS'7"V
M L)VAKU9[GHJE+R,94/,4@#D1-95'[INJ2= 6\_QF5'L(G_IDA3,NM.1($]E
M3RXZG?<]B<P)WK"7E/*,NIMI$QF_89AE;T"3Z&NPVO5 =\!98L6Z [.YVM3G
MC)I*B;1\*P)?0/1E-+H_^+-^Q<[^Y=D'].^_^O:#QO.H#FKF7G$LMW<V67)
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M&Y7BN,T2$!GQ,Z5 =( N2<:30\T<IU;IXJTGL961C<GHH8W:.LP>&+RP'Q!
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ML=@#=.TXJ,75V<R416L.6M(#RU[G7;,9%;0CZQJBA:]_7'U; I3!!B 1 ?+
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MB:5_[ ERSR4+=C?32V\;A01R?I.O[W)!F^"YGL"'SD<;VH25BV/@B@E13)9
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M94HR8LS<FB2L#!0]_&)X0#-M8N8YLP)1%,XVLW4&$'@*&1>38-\P=(9@AIK
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MQX]+A([*CZL'L\<>79=E'1NG_$$15MW4-DFD4XI4J<2=N9XM-P&]1!9#]1=
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M$YX"N2Q]LV@YLBAVI0#L2LI,*-\O,UV X&)*H&B*OMYWAU)5DV1?JXTFM$(
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M.FA+ZDK1A4 48N$!(,H0' ."]91)*Q5*K*I/=4%L#0NA/ \IL1W=:\6W%U6
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M2MDE:)YZ!IOWZTQUZIN,3H7SW45_?_9A&O+_$=[&E)\Q]ZY_^*^_27[E-7'
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M<G N!^>OJ/YQ?II1Q6 /3PK=Y:8"_^*AW(:/ZW(2MQ%K.3D$1.0P'>6V$)^
M_V?Q 3^ I?PQKEI&'_>\K+0?U, 0&Y"KULU=#(C)_Z.E&/PR%?P6=3A>LHZH
M7:HO97M7;>8;5]"UNRS?9?F^R_)EG>(9QL&^^:-\[HD'?;N@T07.Q=D1TBR=
M6@LAV!,TD7X;+M*8'+AV^)J G]9(P)3EJ3L]];'CZ!.M#+) /6$NB;>0^.\2
M:A1)^Q&*HFQ!)UUS9R@)*=U5V\%+2JAZQ77;%(J;3/I0F0=PWS73*@^:[7E\
M^VFF94Y$:!L6+B&>T&/+_QV1=]W0$?2MC!QB\K2LF'ZY,,6#)7L#Y%%IU+C
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MV/12W=GQ_W_^GU_\:8V'.E!-;;OZA'XO>E,3OX4^U*</I*W<3NG#:<&#2^E
M NFIDM0O2+4 UA<&N^1.3!ZQ(ZD^JR46O1M!IT[\;**.F*:YM^5=TZ<93B1C
MPD<WDG<!1+&G;+B#T,X.>I*'8V?(4"Z<&*.4U0;GR:0A"!</2P>9=5HG,V)5
M!\Y[\17W^UCM\O=G+5X%)LYX#F]=^NQD1HJ(I]SR<:>S.V I#T*85CI!"6(0
MOMSMN'R7N(03>V!45%N[Y+_,Y_2@KE?MH 5C-VZ9LCS7N@1"0]D]2PL[V&N8
MV08CG6^IZQ+;.7OHM13W@'.&=#A5$U/=;X7K33G-$T7SO.R&J:!*)CL@X4(3
MH%&6#^</N$^X+]F/M!\7W<1N6,M7Q%-2[Y!:-CABJ,4M2L7BY;::0,.6DBOJ
MW]PO:6*=QT0NU.(+??"^T(_DQ*08@VA?URN5?IACO!G;#]$8I^W&J7XRK]NP
M8K'2_G?1;8N?V1(K7,(\:"X7\!:D7Q-"KY:?++[0T_E"#ZP)DJ-<.[^"$"!U
M\!340>#C^@>TS@$M$.S/JWISM58A28VYQ+AO35AD:ODDQRJJ0ER"88>Z<N6D
M1@ELM.E$<B%H2^C<4I)3YNR=PD]R"^^2_^& 5K"_WG3J*E>K[ZEN6=1]ZK>L
M7MRT9<D061K-54'_QCB0;)LF<!C+LR<GHPA'!.QJN=N!8I(VGFF\Z1ON^&I)
MY86W$Y@E3<14GN*3:.S%M_!BA1UG#@9>#%2PZ=QBP(W>4 ='QX[@EZOOD:"B
M^7Q#E_A41 ZY9$6:1LAWB)*63@:=_%SR<*(;'!'=27DL67Y7JR\9NDN=+NA>
MPA*E-%&)\E "-N"ERD-L$AZ=!O]J=G0]1ORDK<;_YT]7GWVV(K3Q80BFJ=I*
M>\Z9M;-2WVW?=+(*W9@/]9X*1L%_X+?DF)&[/_AINN#@]5<F9\RM1V-? '@>
MKL)+U\CDA0S8=F:)%/@M#21]?EWV]]0X]OE?IUH</__B'5H<U78_4<MD&)+/
M_SKQZ<3MO_CL/=X^>8@LW<K-63U.F^F)XN@$S4V*6B^R_CGU,4V?-IE&7M5(
MW\%]1@)#MI3-+M8"K[!O)C0HU[/9MJIS^T,=?MG#4[9OK1]*!%'MYEP(VXRV
M1)/7LG&Y+J>\@L4=>!)WH'"!U+;4"8?#QE/A5XZK^\^O)DBGWX9-$:YV R@
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M>_)]=TFL?]'N&SSH^>G9,[7^9"BHS2/M&>PGZ'O@VVH;V.)_H[WX!WG>:L_
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MUS0I4=M\+7AM^X^Z+G',>[JP?K@3EG;K>;ZE$EPO=:\2PEGAUL$<O,_C0#K
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MOO)$61/WFL!'?A^,9:CG^A:>^4 8% K 9 #I$FE+"5 JL>"^^]7;'XDFZY9
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M>MT0A6&A=YCI^87,F,=NVC5_JF;!$,J FUK.)1YNU2#$,"5$]XKF,YUQON;
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M90W+WXSND.582@D!.@P##%BT+7R;VC^HGZ R?9RSGI'4!R!W#\'QA>+"!7#
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MB*(I'XV[_T/*4-\T.O8F=6+0N98ZCT)$)4$"'9E"1 M>Z=QR2;D>]H@$VPP
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M L] +\CE"Z#7@_6U8N#2=A%$7BHKH1V3= 4FA/W-XR'._+>)E.++ZAJ>-7K
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M(IJV2KT5\-&(Q^+>'(MOZA2$Y]6LL[4ES_.$S<X2BQ(7)>XF$L<6WDV[#8/
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M[' K&;,#!SV;M2C]\0S',WS'=AAYKILF7:W9D2SU?)%A8I]1HGLB<<#4U&(
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MJPO8[;1[]']=@#@</[#!M8:"I<78 0H !;!!RR##/E\:;!!L<+4U>'-[&]N
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M@A2NM@;WMCO8#@0!7 ^_CQO$;[:[>P!L.'F@@&L-!0?NP U$FKJ\(P@\ !Z
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M'P!!"0@.HG 49"+TA'/LCX1S[OG\"X) @ 8$@=8;&O9)E+&?(#8,6$!,: 5
MPSY&C9@08D*KK<$]Y DA3K3&/F"WW=M&H AN'P)%ZXX$[T3@A[[;=(Y"KP4\
M !X@.K36>' @ G$I0N$<T-.BV$W]"!E#@ 5$ARP%#?NX-:)#B ZMM@9OW-Q_
M_A?Y \=_^--B1C[V[)R#010,[S,#%:]#QJS,%.SMU<S!5>0/'^)Z+,Y!_KQ&
M_PTA>F@$^Y9>(!?MDO<OOVNCOQ^ZP2SQ$R<:.:>Q\ 0_T3D3M)03X9R(^%+$
MSD5,[^1Z[.$D;]K\P+Z>]-(JHP'_3@.V<V;OO[HJ<[M;FMK>X_F4O<W"I=R8
M?UZC?YQY_M")Q94OKL702<?"&?FA&WJ^&SCTW$G2=-)(?DXWY7GC'_UPQ"_+
MD^5<NXDSS0:![P4SQ[UR_8 78Y,G.^!DAT0G._!#Y(1/U(2GI0EWAG2O\-+A
M<"T_[G_=,'/CF3)>O4YWUWD>BY&(8QYBY- 3>11__W6WU^N\/B<GV4OI+W?2
M+7E1]_6+EE/SZFE$\.U,8S'QLPD_R7.3L3,D5D[W4\\6KC=V4A*C2)N.&T0T
MZFL_'3L171\[?V:D''Y*;W/%+YK&OI>T>'.7!E-^X2:)T LRUEGY8'I_H6[-
MXO2"*!&DF&XL^%U'41#P]"VL!V#<0S&N]#6/_B3BQT>]^ZGE'.1)@[9DRT/^
M_)GN%/M#\;*;C\HX.&POR<'1T^^1\KC3A/QQ\Y/Y$SLWWYPD"F@5_-KI=/)+
M2JZ/H_7*84UP.OH?WC;YY2$;,]V].V?K'GQ<XI(JN<MAOZYS5KO?X:S6W/M&
M'W;S_CYL[][[-MU.:W/G?AYK12ZO"*!"TGO6>8>D0\0LS)6@*E6E#7=R>$OS
M\S38L_=#H.<)'%P-*+<CCP2H.9PY&+MQOK9[]T.< VDVE-%\1P:EC"EZO2[C
M?UAMED69,"$W;%_MMK8W (@_"2#64/Y'0\3S++[RK]C)/H@F=,]9U<T"'@(/
M?X()V>RTMN\9J <>KB4>GLHX#< 08/CS3LAV:_.>N0P P[4$PR]ND GG71[<
M?3.(VWT:HZ-1\HL8^UX@U.>?1,H1[0..!\L/GC]S)A,.)G=W7B<O;H!2G&R_
M_^[MW-?HZN\(AA7KD^Y3MSA)]62\]7?&8CLCZJN2L+31[G7;O4YO$QD'-VKQ
M(WL-4K'7/6MIN;@?$#"Z,VBL+%[<M ?W)&#1*0/%\>&G_\.A5P"&G>)^0$0%
M@/&T@/&!%)A5FOLK.\\_N<G0_?.5\^'L].,+0 >@PQYQWS_^ .AX2NA8C#4T
M^L^Z/5!U4/4UI^K=35!UF$^[Q VJ;IGY;/2/)I,LC"Y%^ U( :2P1MS@Z-8A
MQ7L_3E+G_[E7DJ6?CET:K_/\_?][>P2.#NBP2-S@Z'9!1QU'[VX]*D7O=<#1
MP=%7CJ-O@Z+#>MHE;E!TRZQGH[\_=*?RR#'YW)<"^^J #CO%#<YN'70049]\
M<YY_^L_YX?[)*Z6ZIQ\_'(*Q S@L$C<8NUW 4<?8/^V#L8.QKS=C[_;:O1WF
M[!NPG["?UH@;G-TR^]GH'\R\(*I0]2*M]> _%TAK!8!8)&XP=^L 9'\Z#7PQ
M=$ZB0'A9X.J"<M,H3@LDV3^YP.8[D,0F<8/*VX4DM9OO2(\'D5]W(M_=!9&'
M];1+W"#REEG/1O^3R&).CQ< "@"%->(&8;<0*(BI9U]I#NJC?I^.+_X-K@X0
ML4C<X.IV@4@M5Z]-#P99!UE?'[+>;7<W0-9A/NT2-\BZ9>:ST3]PXU0D-'PD
MR0,U[!0WF+MUJ*%ZN;E\JCUO9YC3]K-/^P>@[4 0B\0-VFX7@M32]EJN MH.
MVKY.M!VL'=;3,G&#M5MF/1O]WZ(XCMC[!E  **P1-XBZ=4#Q/A9_9L3/9TNV
MV-^?'?X37!T@8I&XP=7M I$?4(L.7!U<?>6X>J>]T059A_FT2]P@ZY:9ST;_
M. LOL;L.P+!3W"#MU@'&OA^(.%J6%;]_?/8)E!T08I&X0=GM@I!:RMX!90=E
M7W?*WMT&98?YM$O<H.R6F<]&_U,DI><<NP.P=6"%/>(&6[<.*[ZXB:HV]];G
MJA?,U8_38:L@[%_>'E^ L -%+!(W"+M=*%)'V'L@["#LZTW8]]I=;+'#>EHF
M;O!URZQGH_^.1S[.$FRS S3L%#>(NW6@<4+7AZF[9)O]Y,/%/E@[(,0B<8.U
MVP4A/X"UH^<;:/O*T?9=;+/#?%HG;M!VR\QGHW]X=,H=VFF4SO,#$5]%)V((
MGQN@88^X0=NM XUW_FB4)7X4:NCP)'-W@Q)W?_?^/5+D@2,VB1O<W2X<08H\
MJ+M=J\$*ZDZ\?0_4'=;3+G&#NEMF/1O]"Q&[1Y-)ABYO0 J+Q V^;AU2O'6S
MH?N-L^,+@O[VWV?H[ ;@L$G<(.AV 4<=04>%>/#SM>?G/?!S&$^[Q U^;IGQ
M;/3/I[-8(!T>B&&GN,'3K4.,?7$9"-G2;4G=N0_'A^#L !&+Q W.;A>(U";$
MHU0\2/NZDW:<8H?QM$S<X.R6&<]&_S#P/3\":0=DV"END';K(&,_O.1,>"+M
M$S&D62O1]4\?D ,/^+!)W*#K=L%''5W? 5L'6U]KMKZ)+7883^O$#;INF?%L
M]#^<':$%.V#"*G&#HEL'$U_<(+CIL/J7X\\@Z@ 1F\0-HFX7B-3NJ^^!J8.I
MKS53WR":#J8.ZVF7N,'4+;.>C?Z!&WC^B=P@ U0 *JP1-]BZ=5#Q(79G@^S2
M^>++$G,Y2_]PMO\?L'2 AT7B!DNW"SQJ2\HA^QTL?=U9^@Y(.HRG7>(&2;?,
M>#))C_UDXB+]'9AAI[C!UJW#C'.1B+!:6N[\\!S;Z< -F\0-HFX7;H"H@ZC;
MM1JL(.J]=F\#3!W6TRYQ@ZE;9CT;_<,P\*_([P93!V98*6XP=>LPXXB>5CJ=
M?G1RAN[JP R;Q V6;A=FH$,;6+I=J\$*EMYMHT$;C*=EX@9)M\QX\G9Z.A9T
M-^<T%IY,9FTZ1Z'7 FX -ZP1-XBZ=;AQYCKJI$S@G,^25$SXJ/I_S@]?.6<G
MA^_ V0$?%HD;G-TN^*CC[)N@[*#LZTW9>[JK>@_6$];3&G&#M%MF/1O]=W[B
M*??;1V-U@(5%X@93MPXL/HB)'_I.?;>V#R<7Z+ .!+%)W"#K=B'(#]A@[W5
MUT'75Y"N[X"NPW[:)6[0=<OL)WG@GXZ<#W&439WG'^;;K</Y!GC8(V[0=^O
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M]\#>83TM$S?8NV76L]'_[&6H- ^LL$_<X.W6887I),E;[95B=572?OX!->L
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MWP$B%HD;]-TN$,'V.^B[58O!$OK>W0)]A_&T2]R@[Y893UER_JV;5(M& S.
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MQ-TN#/D!M>9['5!W4/>5H^Z;8.ZPGG:)&\S=,NO9Z)]%WE>1+K:).TZ'@ Y
MAS7B!GFW#CJ.PB@57^>APSF@Y\[Q^*.+P]_ XP$G%HD;/-XN.+EGX;I?Y \L
M;?ZT.@F_T]U_RCG8I8>:6>@]WBST-@OJN#'_O$;_.//\H1.+*U]<BZ&3C@4O
MA$PX0Q'XM,+H,WJ._'R:#0+?<Z[$V/<"X3P/R;.,1H[G)N,7SBB.)O);YR(0
M7DJ7G<;"$SP$YTS0C1+AG(CX4L3.14ROZ'JI'X7DBA+0>6.'/KKD1_%=GG5:
M'85M-&L!?<M)(^?9YN;<IRT^XN7TMMX02(9&0\ZS*3W*B_UIFBO)'$XD_)72
M;&\1,C?ZZ?A-FV_4=^BOK*,^O:(;*HGL/.5#C'@?(G82GYLXS[;F!<8#?];=
MF?\X%LF4)H<>$,S,[AU6UQ.N+M;0))O0YS.20\ISFHX==Q!=T4Q')"YRLFB"
MXRE]SEH^()USO&@R#43*NJ"4C*>.9MP- JD0;N@&LX0N)B6B&TY(5P8S1RYD
MM2:FL9BZL9M?YXQ</PY%DCC1U _Y4S^\BH(KN@4+/,H2>A1)8>*'\J+$(:6B
MT?##)E&2.NYT&D=3FII4K8F8UO@5S9,S$>DX&B;\E!%=''J^&^CQ^4F^?.AR
MTN!\//01@8&Y5#]GR@66O"QP8\?S8R^;)*G+.\WRC6(Y&Z1*&4$%J5;^&DJ
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M-0"B3!3=\A:\HZMHY%_-VA\*ST^TGRK9C;JK-)_*Y74O8R$8[.4PD['$(M;
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M[WHT#MXRJ3A>^;M5'#!ENT/S<)U<H=(_9-('#XQ3I8ST3EWIA!SH@9W*KYM
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MKO,A=OVDZ9RTWK5 >F$A5FH&L$.V6J'KS>96!_OP0)G5F@$D^ZP6RG1;VYL
M&8#,2LT 7)G5 IE>I[E;?ZH(2@Z8L78&D.RS6C"SW>H@V0<Q2QL6AQ4QR[-H
M0'/M'.K3B@=1>.W.8(5AA5=J!N#LKY851MP2*+-Z,X"XY6JA#.*6 )F5FP&X
M,JL%,HA; F96< 80MUPMF'G*N"7R+Q'+_!EBF?OT>9PX'Z,K 7L,>[Q2,P"W
M?[7L,2*80)G5FP%$,%<+91#!!,BLW S E5DMD.EUFIM[>X 9P,Q*S0 BF*L%
M,YNMW=I:CLB\1+1R':.5_^MZT< Y<5_^/^%>H3,$[.^*S0#<_-6ROWO-[G;M
M%B)T'"AC[0P@8KE:*--M[0%D #*K-0-P958,9#:;NQO8& ',K-8,(&*Y6C#3
M:_4VD'.)**:E"\:2*":+X7TP"T/88]CCE9H!N/VK98^[780P 3,K-P,(8:X6
MS/1:'9SG!,BLU@S EUDMD-E&!!,HLW(S@ CF:J%,K]7=61[!_$7^P"%*_K28
MD(__G[TW[VTCR?)%_[[W4R1J:@820*NT>/?<!E2R7.5I;U=23;_&PT,CR Q*
M64YFLG*1S/GT[VP1&9$+1<J23-DQP'199#(REA-G/[]S<,]'X+8177($U%IT
MC0/PW&'D534G\.)%SQ%<YDE\$Y]8]PCH?;O^\>_QB=Q*<]437<&+DSR+?LVS
MNHP.SPNM9_!1J]NJ<\=@OO^"^7XO=\L[VN?.R>[?GJ]S_W'CZCQPW_?4/]FG
M=+#':G(1Y=/H\.3H\#_^[?G^WK-7932IBP*&BO07/:FKY%+#$]-D@E7J20EL
MM*@6495'*BKLB8[I1%-=P=1'D2HC!0<;ZSB:%ODLJN @\!?XWU$TKXNRACW%
M3T#6P02J"TTSZ+XQNDK2%-XST?AA]XTP]9_WGCX9[>[NPKG6XS_UA,:]@(E.
MX*R2K(9)Z-D\S1=(:C!>=<'O @%PGN<QD);*D)9@%D5>G_-LM"K2!%X/XRL8
MJ)CGA:I@#06<EIK0!&37HKR(8**52O"")!D*LRC6ESK-Y_3&6$^2$GY0[D1G
M,/)[79R;=<$,RRJIZDI?^Q8X?-RX>5YJ6C5.LG_[2]/ Z3]_B9-+YI?V1IV<
M_/Y=7J;;$%,3V$Q=+&>2H$WLHM8 _R__J%"Q:+TP4NF56I2O(D_[@M_"+\H\
M!88=.7.'D79H'&]YI)E$_GZTGZ1MX0>==42RD*@Y%/M#]T0C.E(X43K03Z=P
MG(].]'F=*OCM)$]S6,@X59//Z,3<W^OGSM.T+B^^2Y*Z(_YL26J__3(0LRJZ
M*/3T__ST;V<?CW9W]W[Z&X5B\;X?P<)85"J6D_!__^L_X8*;T^#0[4?B@!3,
M_0BJ=9'$^M'>&L?C_SF7B&Y0LAZ,DG7<B+J@7SUP_2IS%1=E3A-$OZJB>9%?
MPN4NK>XQ5_0<:%Y9'(UUIJ<)_%'/03M0(!V*69(IHU&T]*&\KJ*)JDL=C1=6
MIT%=JX0=X!_!%ZAQ&*T,M1%2GF#K2OAZ2^,Z0>V+X;69Q@FD^=5V!%_ASTK0
M!ME?$:L%:8=6V\'!![0JG!HL;.^ ?SH#TKB G^+I73^ (,/?LL;5=QZLU\'F
M]9] DDW2.M8O.Y?OUW?_FFWTQ4N34G[X"#8AP<UY":12 MFYWU6+N7X9)^5D
MZ4U]_'R^+.WCCB[KH_5NJ\>!QW4*"G6+^]I=10?<\_W]IZ_X-_*0N)#VG\V_
MO((MF:<*U*PD [, 9I[FI$HQ8:[^OY9YTW].P;( 8IT0N47ZKQJL#> 56\DV
M/[VW[]T6H=M^X\HRI+$J\9*"XK<8X;BD=,#52^"RJ#1EJL[AQ9$_/#P,ZA^\
MW+Q=(5^*X$K!/_+"7">5+<1"F>2SN8:;1M^H.3(QM!'AIN$LIT!$L)P%&%_X
M]L8V]-C7!-AGV4SSZD*+_0-7 D<J:_@5C:$*6"K\OKA*Z'J"# ^W,-S"6[B%
M)SJ9C8$,62 #B<.)>-/.<MJBG_[V*)_"N4T^ZTI^"G>@A-L$=];X)R+,J)Q'
M%UJEU07>N9HO>"/$$2$P.OKXZPE+)7@8?NY?Q9V@W-VE<L?VV5M@6K!U> ='
MP_I HYN1ID:\=Z: LR)'A:_+'-@67M5"\TC(R<VXP/]*C\4#<?6=-W[NL&U\
M -:A0?,P#+/Q$I55D4R(\4^ WV:*=)3Y'"P(XJ#HF!N4$>RT\J;4H^0@IW6\
M;RN(G$*G&J</DP1Z36:H*(%*!L<TB]1DHN>5F1MI<X&Z[]UT.1ND[SB/LKPB
M_H661Z6^( LKRP$.6,\-ZZ.+0;Y0]L,":<Z%9/27"0II&$L;AG>J22%GJG_\
MXL4+0]%'>:QWHK>@G&@5\T5<DT!51'(#2 0NQS#CSBS7IL?W7C4K0'(E#G I
M$@ 6H$NRWL 40OO"3J1G-?O/=W]KK\89;MW-B*[R.L751LD,[948#2_[_IF"
M)WB409XUNM8'KQ/4I(@ET2AVBFBJ72AX_(*,U[[=+W1<3V!6;-2J65[CRRO1
M\-#.;4;+\BC-,S38B$5IF!KR.5H2/P]44Z<5FLHS(/MHJB[!B+N6D>'O\>5X
M@P9.'%YO*!5>F92!Z=P[TWFSJM$=[.F@R=^&)B]RX C=7X;)GP/?*L#N740S
M#1O(:MP2SG*AR+*=)56%?*J(='8.>QM'&"^RECERT6F=1C,XVCP#AEB-6&Q&
MF3Z'[=8@O8@-3^&+::%J($ 8BPS8"'ZKST$WA ]@'R[R#.169(=! QLNB[#3
M0I.;"\BJ8)X+<F&FX-@36M.%*F8X#U&M7CGF>Z&G->B3(Y 6.%NX-_ >8,!3
ME:1UH6D^8(>/DS1A%^5<%Z2QF>&C/_-Q%,/NX.W%C1DG%7HHU+C$F)1.RMDK
M_ )>:=YYF>2I=4Q.$UA0@OHL# (:L_<EKA(_QG\#0P!K:4$SLB]'6F9W*SYJ
M/W:5X3Y>@HIYI6&#)S17$/&P+'A-XW%%=RAN,1T%JCT@XYU0<F!%@17='BOZ
M#?WJ)^17'V!((R:]%:PLY .X60T7.M?Y>:'FP"G0!,LGUKU/NA1PNBPZV 4>
ME>KRE>?8B_6D((L-%%_7\/1^NO?DWT=R3>AOYV>LM6&>!:6$*+,H5@XK1Z5V
M1\>[#,IG_S++-B_!>$4"7RE*NP"K%V^O^XK2O..:?4,VAL8)LE'B=J2'PF^)
MP4Q@@EZV":60J")&LPC&(>5W @S3,7BZ%FP(I6YX*/5U4L#Y H4=.5[K$$K]
M5J;!84E.L[I$8Y#-6>&8=)E[3\LP4 I'CJ*C"Y44N+WMB.PXQ]L+G\8R"MQV
M[C'-C.5X)^(>TR.ZV\SA9GHVQICM*H-Q%!"YWSM8O(I^*U0"'[_?>;TSBIP.
M,/P1O<0@+0X8JP9_D>W5+2"42Y-N]U]UIJ/]W?U]TO'F19+B7X^WB9PNV91&
M)G@ZUQ-4D(Y$=T67,^QYAM,$7H<C#&3K+9@12EY># KO!3I?,!Z,+B%<397C
MQ<)TZY_W=BE!CWS71D/K[> ]6GUW?GZQ:\=<9Z?(T]+LR2AR2L%A]B#6<1GO
MBYW^P2(99L5C&=KHG8@2 YB"C&[:/0X3LN8P 6OR&,:*?GZ&C3Q0_8[('=QL
M+?\)(X)X0K%$X@V/'>72X'2"<'IHPNE(E1? \S#.D,5!*'TKH?2I2#!XS8['
M20JV%/!.N<]OD@*,=,X^&1F-$_W=%/T#Q3A%4UVA.GD!LH*/THPU+_0 AZ%A
M#8.1W!8:O*S "KD \D!VR9D!HNVJ<S!ESRG1)?=E%>?OH/=TQ D]8.H#_Z#0
M_)=D9FUO&H7]MJ#PLQSP!LITQ0MA9_&7B08V^O.3G=WE?'2&;@:,@2%/%S>&
M-ZZ5H?1$3\84.6=H(],R[]D(FD]Y@4]@A E>00D"_J:CS<_Y"F1E\1DDQ9JG
MD%^AY+M(YC:'"+U"><830AFM)5C!]DZ55"GLDF@QWHO68@ERD8@:LTDRAX,_
M=;= 9M,*932RGH(%YSHZV-OGLT[*:$D.^;N00QYRR&^40[X?<LA##GG02FY;
M*_%(HT]+06&^0"]51?[L7^!O"KS7G#'GY)XD&?KS6>RCRE"0S=HOD>43MHA%
M')O/4/3 +\M>2?@*_61 E(O1>D8NZ0CPHC11%1F=%3GF0%R?:[+(\:W18RH&
M>_QD?[GF02I!__Q&: C"E_@"%(^8^+C_[-\ES\O6BRT983M85 _.HGH++YZQ
M^YC34X':WIIDO&!A?2L+ZP^;N&)LG29NMYZE@"8 \8R4PZ)-?6CB'_V([+2L
M!)LBOL33YWAA%CO)F9A)5\#:=Z(W5"PAKDG'7$IZZ*GYO9,*5>B4^)F;ON(O
MQBZA7K(9<TZHNW,CXZSG[33\WOZK:.DE(F'SVEO91UG9M;;)WN-GUC89%F>!
M[3XXMOM_T;G<$ R<\:><RII!&_GD9I/]:K+)Q(<1?5 S(.QC>]%;M!1X];WS
M:LR/GDQ@"^FV4Y#Z+=Q125K<W=^J)%"+ 0"R$IN<QM,!%?#O<IR<H<A9P13.
M@8VO2'^54+A76T)>H:1L4@=-)@V5@C#'+0W'!<+!=$/)G1;>1B/,U,+ZW&&$
ML8:7:%MZ@FFK3GU?E!%!=O.#$!D@SS)AR#9VSR_:B3[YC!LTS\LD!]5</%*E
MY7N&I2,;G=8%)P;U*NP5XQ\T&Q(2J.^A/.#,.DDQSR!&ED;*18=R21,I*_2O
M-FF.YI=$>#:AU] :G%D]@U,94?E NN@I3X0CK]B32T/8E ^'J*\4YX34LQG-
M#8CFO5I(Y=A((F)-U@=1]S+2MLJ76U$*[S %6U@)*B6E?J%I,H/QT(RCE:2P
M*4BV=FJ.&F7\Y\VL\--+E=::XE_LVNUUN.;9DA&1._Q\L+/[(MHB=S:E=[2Y
MU^GQ$=RJOVK0621-.BF;HCLZ-58#K>]_7E"@#6%#ELWL4IN2-XP13&%+>6WC
M&D;!//)8+4IG9YIGY_48)"EPJPS(96(+D)R%Y1+@Y!$/1B;XBPS.29;!7WQ2
M5(A\))/_1),W&\.E'TLY&SG7L1; (+0@P^'J&/4%/O2JI$PNHU,:NXPO!HYU
M]QSK%,59B_^ 6!6IZG&N#D<2/@3W^S(IJMJ.,WSE*/9NG$WV B%CFU=B"34"
MK#50C-$KG\Z54^S46]Q.*D/ILEJ\D%8E,)7S3)7N/&Q,*=;EI$C&#1>?YGD%
M](Y#35"^JFQAINLP^)WHD!@)?(5.+OP6<]]P#LRY2@GFVP0*V$4@R9MK$:2I
MQ DI,@RYU'NB/#MSLWC&_9T@Z-\][E^#J;>[NX/(G7+?)L"HU+S4+R/S+_/5
M2XIS4, B^K?=W5W[$P=M+W+B(E6T&QW@_Z+7^'_?I%W%TY7[ZQXU<2P?)I$O
M/D=9^@ 4]^8W!U#L&7LIKN+C^=JXBKC>Y;B*%D31-*IXMK.W)DIE*RP%4@J8
M#+*>"'8'9$*F6Z$K6;D$KWH0%N6X/99_]/N_<*YWS/)?W(CCKVO"WP&RXC+[
MO<<^[[/,AQ;VT]_0OO9MZ6'(UQ_O*@T!JZZ 4_HMD6%_O(-:XT#6AZ.^?2[8
MPP(#][MYLH4'+/N5#!%S[OAR;?V\;3AC>\A'IS68I:@VSML5)DN';Q%OB:,X
MA_0$6,5/?]O:VPX<.7#D!WY0@2,'CGP['/GXKSJI%M^8)^\'GAQX\D,_J,"3
M T^^'9[\21? E4NX@^4O_SDN?OF;"=Q_8S9]$-AT8-,/_:#6.) G.P??W*4;
MV/3&LNDSK,_ML.3;[!O^++0-OYU02^@)?A\]P=\GDPNET^A$2M)_+9*RRJ^\
M:]:GH*RF?3Q>6?MXZ(2_](4;JD@\]#V_4^LM-,.[34:T;C.\@V<$=!'81F ;
M@6T$MK$JV]C;'3UY\OTW! ]<XSOC&FV2#USD6W(1*>L+;"2PD6_)1M9W90:V
M\4UMEN>#VL<M>!.#YS!X#C?*<WAV :LO(]-S\.^Z1LR2[UQD!NFX*=L;3/.'
M)1V?,!QNX!"!0P0.$3A$G_X\>O[\1> /@3\$_A#X0P]_>+P[>O;X:6 0@4$$
M!UQ@$'TFQN,7HZ<'=^6 "^E\P2FW\4ZY(_'&_9>>3@N]B%[KSY^#6R[(S*!4
M;P2/V#R9^?@@N.4"AP@<(G"((0ZQ/SK8"_PA\(? 'P)_Z'7;/QT]>1;\]H%!
M!+=<8!"])L:SP<@>N^6HXQ[!LK:@C_$C@ST[;9T(-X"C#FX6=)6+M;TI]#:#
M>_1DWFX%M_^8V[RYW>#^K,LJF2[D0_GK991@R?*C)):>\O*U;$7TR(SDTJ?7
M4>[%US64^Y?S?[BG _OUK_:&;4;-^0H43.C-PXXTNCIW !K]:! UFLD84>BH
M*K:%"?Q\_N55G)3S5!%MI$D&;TYS.BMFV<O_5RID$76<VG,:_&+;C>ME VI/
M^,?P*?9]03#E]X5?MLNHRS1,J1&CG9KNF'XB%N#9:>5PD<SZ,):YX0QU>1W"
MF?9Z9./SIWJN"GZP:9&#<-4GFGL]T,C<Z(= \KMX[:-(E0[\=+??>=/WQ&]X
MSMM):?O\QP=5X%S@P==)B3#U=4'K/45L[6+A_9QAGWL&.6X6:U=4(J3[(0R>
MG?/?K6[KW"66(+=U0BW%L0<Z+.9"%QIQMVM"K@<Z4F-8'YT0_#T!^L2IC.%K
M'H)0YAWD<;C4N(&V$=MRU'$+?'\=Y5#>)CUL/V*G\2C:.I0?J^CGO:?<S;S0
MU*8&9YIGV*Y#9C> T]UJ#FSFQBO$V5=)51.P>(3/I4.-9RM@!.=-3SP!TY=%
M_FJF:1O^#MT F,;/!X^YA_H*._+S_K-KGN6M:K5-6;HC@ESN7A[NNBO#(\DZ
METPU=%?/L;64=R';;2:.J,T$]FQ9-%VUAJ#5L9?&;]C]^(3:(4N_&!P*IKYW
MP NDSNIN3P8%5Z>8YP5N\QEL;ZEX@5MP<ZG',,ZO%!SY*3!#BR*OYO,4%#_<
MF[X%;F/S]C]E@WE+*A!%Z<),71IK@9 ?())"7^;<4,EVHL>.%(6P'YC&5%WF
MA6E.T4^&<5Z/UR1#[H8VRZG9LFU,,]B;3(WS2R11@MV_U29EUS,OF?F.,*UN
MMPE/A9A]IRK$[CWH#PR1>(<*PXG1#TJG_W>42S.'K:9;.5R *?4,SU&Z(B4*
MQ37"E!$EH\,K5<1&H&U+3QX40VHR@4M$=QZOX*4N*W.KK;A9IU5/TX30X03P
M/!#(I722N;8+#PQ8Y/4Y<U73R^4U3'$G^N0SUYZV@31Z__IYQ=,:6Z([Z\ZS
MSHND%T==.BSD9H)L)_J02W>?!#6_:0J\HM$9J%UMMAB>,#:OSW"+B@EV^N)V
M/$E&'>E+$7L[NR](O1HX=1Y%^G1X/QULF4,;M:1E^DEHF1Y:IM^H9?I!:)D>
M6J8'9>36E)$EO=)YW\>HD(*IE&+77!0W&74*+N%(V:3GMF@B'O"!Y1)T18'4
MUR;0^CVD+V0>UQ,RF;W6?MSU2:-U-];5E=:9C&CZ8[G6AC\-$6G]<Q]%,VQ:
M!;_E_E1^ [ZLGHTU&1!+VJ"W[)C!%X$L;B8I[0L'%*UA0_+EIK>UXO_<N*_5
MWHO0V&KUH(F<PY/'.P??'*PZ-+8*C:T>SE4:BIIN>-CWQSNHM3))7CSYUERP
MAP4&[K<96- ?2)DSK=D)M!]U.?K'*:EWTJ.=U3G1 G/ZWNITXFLEQ8Z'( UX
MZ]\"[G[@M0_]H.XT:R_PVA^(UWXRC)88*__SO]&90#PSGPH;-5R5>:S3YHJX
M*GVZ'+;_![^P@;,^D(-:XT#V=Y[O!<X:..L 9Z6.)E%H9G*/U<\W<*^%ZN=O
MV<SD>Z]-6/K"#97Y#WW/[]0/%0H6OF7!PM[!:._%X\ U M<(=9"!:ZS*-79W
MGG__9=*!9VPTSUC?5Q!XQC?5-$+'@&">_S#F>>@8$(1C,,,WE$-LGG!\/'K^
M="_PA\ ?@L$=^,./:G ']K IVQMLZX?%'JX!'0K1\&!N?]_F=L "#Q(S&-P;
MRR,V3V+NCQX_>1[X0^ /P> ._"$8W($]!(,[L(<U@MFC%T][V_.%6'8PKK\_
MXSH*=G40C,&NWCCVL(&"<2\8UH%!!,,Z,(A!PWKW(+"'P!Z"81W80U\D^W%O
M,=HUS7-@^("=>B-;;[ 1S'.?%AA'=^O@OF#>$?53EU4RH^XI#!<N8*;PS"RI
M9P(%?Y77:8R]* K]5YT4\'"5P[^3V;@N2FJ#\EZ795'N1$VO"^ED@="N#3K[
MA59IA1T2L)/&N9:&+$<??STY9%#R: Z4D,<XC;U]KV-$:(D16F)\;4N,Z_M9
M##>R".SOKOI@/;Y3?O>ZT](*"9,HX=DK@IZ>P47]!*PAB4V#J:.+1$\=G.6/
M?)U'EC'XC2::/E38JJK3A&JG0TR_[V^F-K,NW(W?1PU]Z89^7KSH(:#+/(EO
M0D%=;<:^[ZOA;MXBN@X(08+>_EC4GY4EC=<@Z2957I1$$QUJ*/V.)3Y<3JO1
M "QD,T]\,]L,+%68\,PLEGPBC<O@I/(97,;8MB[SSW*<(XHF?!S;0VWWX +9
M6>279D#3AH80V"^ 5O# RPNC"*DKE+ZDD_@OBCVBZ6@$972A+C6W?"2J\VBH
MZ:AGX.BK:%KDLQ%J#? D$@RMK\JY,U_2H5Y_PN<@/0N5I@N"VR_='Z JY0#C
MSP1D?U+5*L77S7-JS 9_P%Y/0:O@EY@!1@88WQUT9"#JX2QQ7%0L@?32D>@J
MI@\? ?-WV6*X*K=^5:Z_!=@U@(B9-7_L:K#\Y.G@S?W31 - H JTV/,HAS\*
M/'9X%*@!2+; O@YXJ9(*.S%.DI+I5ZZ;[NVG9)LNN+T'R>206\X7!9_H(?J>
MD16U5*I09I/P)MV=6E+F7Q;P:_@0W_L+_$W\H"Y[A/;!/=.EVYGM>Q?::_6G
M$]'-1__Q"EA<>9',(RO*@RB^-_YR2*SAO1)8U3W;=]5G/).Z(&$V;%BR.JU-
M1X'KY2@;AI,$I5N4 Q'$(VL%V[Z=Q J^D(,#GGIVL//DWXV'HVFXPG0$QB*2
M&K,28[?V]IP#&]K8F?H+-6,MJ9N:L"(>-RG+FNQP<BG8CC'4DZZJ4F9S]N6F
MR]Z%3HDYD94/)Y!<)C'(XYWH&+OC=+0:LQFCUG8I^#Q-B--YG)%T#Y66>42@
MDN0W0%8,[YO/\\+Q%"QWK; UKM@>CW6E$FSS \;:I"Y+IW5L9]ART&*ODBJ]
MU=Z53H/=$\U<W^O>U].>]U2FVVEOV;3D!>K/4)K!C/$R17M/#BQ=K"-, BNZ
M"U:$SIF8G3^CZ(U*"FI]';VILYA/^.W;$75*-O<#S^Z3ADE%OZOB*LGH6[Z2
MYD:-HG?JBAM#_3W5^(A_!U?T'."79W4!1 X3PS.,SHH:U6B8 ?.:(S73!3:/
MIJ=Z9Y*@]ZS"WVE\ "^R<%88#R_Y<J[&/;?<WEC B\@%(K<[M[*T?P!D34/;
MZN_2T'I1$^L3&#NM<:.W;WE]N"KV5!_E&46J</8?<FEH=8'J*UY7NMW JB<7
MQ%UX&_ )L'$&1,X4O<^Q$3A7V. [:RPR7O[PKZ43M?GY-,E4-H$/5N2-)=JL
M*5FKN.'WR!B/8!,5+/+$?;WIJTY\\I,JJH7K>;9M.X_RV9C\S=CN'&1>#Q/E
M?7-_W//0IR*YQ.OW*543*PI/X=(48-_JZ]GN_O.]==AN3R_1=Z&7:.@E>J->
MHH]#+]$?MY?HDJZ(]]H%\>"KFB#N[Z^<"!]:*9@TE^<'.P<'W[IQ0FB">)=-
M$(] ;;3<8G^]0-)I8VB'?C+?83\9X-IXJO_GI_T?[=#6.)PG.P=KGL[ML\@>
M_AA8XUWTEOD:;NGW2HR<'HF1^?-(/ _$6/FC"YT*;XT#$,^=UPK>0.$)M8+W
M42O8N,I^IWS*"89O76]<]&[GT\YW7P"P](4;JDD\]#U?8WL/=IZNN;\WJ J
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MH5$'A"'(:0,,[;E0//KT-&&#PC: ;48**B+VF?>P8[FRB'39\B.AY;@GLF-
M^F$X6KE>;_>("LCSY1[INF2!DF8R@8NJ4$1;*< 4B.C]J'#3[@L.%GX;.Y*N
M39[;7<R_:\F@1?$\,UF)HUHLQ CB1:^[T#+2EXAZ-M'Q4E0Q!ZP?B0>,GT0
MEAW@5A_^<  A#&>L>U$0#;AD#TCD\F8&@YB3O*2,:I3))6KWPML%U]W9[&)I
MS\$ZX.'Z$STPK:L8HX"HZR Z)7S'/(+P;:<I67#T8SB'##2+ G=O&93528"R
M"E!6-X*R>A*@K *455\^+_V[YV7&Z7>7T%;\GYMC6ZU> /?CX>\,)24?/-EY
M_.Q; [<$;*M-Q;;ZH&8Z@%I]AZ!6/]9!K7$@CW=>//W6_+"'&08^N)E 5J#-
M&?XX./#!.@/32F(]R<GZRUZRJ9E@HO/?" KKVM>MN8[_)H?, U^$N%DE"4JG
M,;UEZ]^690__X#PQ"*\'<E!K":]UV[4'X?5#"J]_T%\/GNT?<C?A![Z*8_$6
MVPX)DX>^HGP:?4]J!2L3/P=E(B@3#_V@@B4<E(E@"?>OXX_L\CL26L$6#N+K
MNSNH-0XD="0(XBO8P@]M%=^E+?Q]*18K6,,!.>Y6D>-ND*01D./N SFN4RBP
M-K/SRW++557TAT[I2U^XH=KV0]_S.W7]_&![&>AWP^EWW3CH#[:7@7XWG'X#
M_PWTNV%[?J>^M^OW,O3%"?;C]V8_AKXX@4$_$ 6C#0U\ ]CE!\LK-@UM&>GX
M^?[>_JO ,0+'V%B3.G",P#$VFJ0#QP@Z1N 8@6,$CK$AV[N^VRAPC ?",4)&
M2/#H_0@>O?_*5::BW_(,CO)2ET%X!N$9U.T-9!8/2GC^J"0=.$9PZ06.$3A&
MX!@;LKVWD9<4.,3]<8C'TJ0Q<(C (3;5A1<XQ+?D$ <[SU_<D;\N^.:";VZC
M?'.'Q9]U%AV>J^)*I4$F!IFXL5ISL+,W248&.SMPC."9"QPC<(S ,39U>X-G
M[F%QB/W])\$S%SA$\,P%#C'$(79>]+*'D$D7O'4_@K?NDZK3Z/_629:J4!D;
MQ.3F*M+!]-XDL1E,[\ Q@K,N<(S ,0+'V-3M#<ZZA\4A0AI=X!#!61<X1$BC
M"XZYX)C[2M#S#WGVZ'@V3_.%UM'KI-"3*O]Q@,^#B-V4[0T8NX%4'\CV!CCS
M0*H/9'L#5PVD^D"V=T-!RD-R1K !-]X&_*1AN.AW55P%V/+ LC=8NPBAUDUR
MDX90:^ 8FVXZ!XX1.,9&DW3@&$''"!PC<(S ,39D>S?4D12<1L%IM%%.HR,U
MTT6>16=U4:4Z,.C H(-*MX&\(JAT#X"D \<(;J/ ,0+'"!QC0[8WZ!B!8WQG
M)!TXQH:YC0+'>" <(Z2!!8_>C^'1*]+HM9J-/\,GGY,@/(/P#.KV!C*+!R4\
M?U22#APCN/0"QP@<(W",#=G> -/SL#C$7L#4#AQBPUUX@4,$F)[OXU8$W]QF
M^^9.%;RRNHC^7J>?59$%YUP0BYNK. =3>Y/$9#"U \<(SKG ,0+'"!QC4[<W
M..<>%H<X>!(PM .'",ZYP"%"P[O@L-NPR[ 1#KN_%TE9)9F.?E5I&N1DD),;
MJTD'VWN3Y&:PO0/'"-ZZP#$"QP@<8U.W-WCK'A:'"*ET@4,$;UW@$#=-I?O?
M] ]TQ^&GS8'\?G#/1Y#@P4^N/0+J3;;& 7CN(7(AFA-X\:+G""[S)+Z)CZA[
M!/9]/7W8WM):^[JQN;O@=V/[6-2?5?1>93"Y&;PR>I.G:7X%YQ%5%SIZKXMS
M7?C-V9SK!5/]%TSU>[E6WJD^=PYU__;<?ON/&Z_?0?M]/_WML(QB74Z*9*SC
M"-@?'D*I)U62PU&K.?X7OD %?A^DADL!:YV^[,U/?UOMY.E]>Z^BL8;99O@(
M3 <7'^T_.XCR*?PB*:-YD7]9P/M510/^ G^7<YA[7483$ \*E@./$L61!?+L
M%2S6- ",5!9'^HN>U%5RJ>'!:0(_@H\+#1_C,+#N*H<I3/*9IBE>^UN:F([@
M!^,$MPW^ :M91/4\YYV=I'E)JYDZ:][IT'G@6AO&M=["BV99 L>LZ&;@^;_-
MRKI0V40';G5OW.I-7D0*[F$YJ<L2#T(N4M)S/HDY'^03EPD^7D:%3I5<;/P=
M2R/_7MO;7,.@A7-/H\/S0A.G&47S5*L2.:7V.&:55.FMLLNSGK>S!B\^%?YC
M*7U&L/5-XU/Z[J.L\5IVN_?XV0KLMH>#[6\FU7\7'&R]_K=P9V:^P D,Z]X8
MUFD]_A.NB.$W\*89W\!)GL5)13S).QN7R3 7B]1D IM.-_DJJ2[HX=>_';T;
M15O)-M]_5=&G;Y*BK*+CZ139$2@F>"(C^52&APG!*&D:S?!O'I#? U,D=CCB
M#YDUPC2K)*N1)2B8>'1U 4K;(LJO4+TIZW&9Q(DJ%KB&PY.C0QJ*&&)=7":7
M^#.8^SPOF"W)2KT)X2^V$KL08#.JJ,R3I0+5*P=;7\&,*^!FI6)&*PM&!2O5
M[MBG&G?6#+Z%'PDWEF_\W1'.MSV2]0YNC3\N[*)L4^=S8*)&I6TV 8XSJ1:]
M<PR\<X-YIQSK$5S3!':]$:Z'\9]U6>$U#<ST_FS595S.VE@-CRU]YNNPW%)7
MJ!7!_163M\M\+6_5:D(\-_-H*<MI:3_][5%>5Z 397BD0@M1>8%6I+$]D4O-
M8')EE4\^P[C9)*WQ:7ZL''@N*<NZ,<GY@7FA!R8AAJ69P#3)0%X0UR9+M?5&
M,FO!O >1@NKJO"[*&@C%;%1[,V@04+I+9&-VE&UFEC 0GNM,D3L69 -L,SIG
M43[DJ88/B'_BN$1(^!)0136>G(JR>C:&5\$6-)M!@L3;"_U7K5(S.U@-T!TP
M:+J.T9;GOI@!G46Q!ML_;7LSOI5N?FSF>X+SO5[C/GBZ@L:]/7*$YM=3*!#6
M5!<%GAEMN#G9YBQO=(BGP*QTR9/\-?ID7W**+P$!>I' Q,GA@BN0ER7C5//K
M]B@DU+NF2!:RA&I&2\DF!L$<PU3&"W[-:$C38G8RJ*/!*7S%,>1S)LT<[R#,
MK]1]K,#>,V ),YXSKG;D,CAE!5(TAF'B2+AA:]EJ)=['.MGES==UI8I"&(I=
MV%)N-T!PZIJ1>@[];O;$*K93L:9D7EWM+<C]6Y?['_)H6K#B#_=YF: P9-0(
M3R"H3 2 O=)\N$SF64Z^8G:=X+!%A.)D3DX3]-V6-5!_]_7^FW:B0WATQ4G"
M%W5*@G1:Y#.CF@#9&X_6TIMR,_W!D.DOP/<X6F8)]MW)[]\EK=Y&D'("U*F+
MY>;&RPC6]R7"_Y=_5*^BS@LCE5ZI10D2WPVLPV_A%Z G@>D3.7.'D79H'&]Y
M%)>._/UH/TG;P@\ZZXAD(5%S*/:'[HF2+EW"B=*!?CJ%XWQTHL_K5,%O)WF:
MPT+&J9I\II2-I_W,;YK6Y<5W25)WQ/XL2>UW>=]_JN@"]*;_\]._G7T\VMW=
M [43H]QXZ<$JK>#GY7_^HMC\A/_[7_\)%]R<!A>I?"1Y2&4K'X')%*#V/-I;
MXWC\/^=2O!($WNT)/(\6_$P+)H*;6G_;*"(\B0BZSI3"KN7+QL+-,]T8!%UY
ME;#NJ\Y!&3H'(1FI65YGY*-;4>+!ARA*88FH=:-2?I&G,9L,(KK4'$VMYHUD
MSCMB$:PAJ\Z#9 853NNXC'9WGNSBWXTQ! )]V50V93&I+L$.![JB)8@S$941
M55Z("W&NDMBJ(>W)13I-9G#.%=L#I*50P1G\\CIM9*E9AI,"=;>SJ(Z)F-<I
M:-2PF<55 DHYT!AY.5..KAGKT-HN9L-C<:S"Q\,S;+\,J9?8'HQ,2Y79H09'
MJX8GZ[DQ]3*-@U7DK&Y1MLT#<(W-UMN"1W:#/;*?BGRBXQJ)!:^&.%?PNC#U
M'CG*?'#-WIN)]C%#+CPO$OA?XVZ57)<8CF+41(><.$NI4[3480NM10X38V-[
M%"V):45;"M.6II1D PP(V.6VO((&CO4<WETU%E]K?(V^'_3R %<8Y_GG ;$*
MCQ8+SV.&"03 +8PCE-R+RX2-85MM#^M2IQ+:;';"2.1W8 _>7*/8NA5O<C-(
MCU_9!A'7$5MWM-=M2311Z:3F')(!AV'[%<%%= _\!\3";%ZEBXC>LB1,U,,-
M..:+$0.@&')V@O("V]_5ZWZ >[=L_1T5\"+GS3/*WCK7M'/Q4*WK?T_OC6;W
MW=+K..K?AR9K K3PJN(54G+!+*E0;_=3$I*LK(IZPH%#GBG,#7/#C CPMLMJ
MF,(O7.=B>\WXXQE/;^*&F'>B/]!BB$''!R5UT0EA,-VB(1+%-1 ]IZ+"'O2O
M9X!1^</9>7OK-:PXUD"J$O^FF:LO-!"NF6R5N@"1J\N127S@'3)L=]4=&J&U
MI.;S%/X$(N$SOGX;B';(%(GB?%+C*9=HZL[4 J\(W*T2K(PQ[%0!1F12L,W4
M-U8AD97.I.UK>HX5?K6>%C&B9!IGF<9*ZK.@7*+!)2+#_&JMI0G9.4;2D,%;
MK'6Q6R;:=6QI)SIS*0:SIMV]]6:^E-'"-*\)9@JG# +Y/G(UKI'#'/%M3MH_
MZ'6.E_P5%W"ALKR"8]:91TPBGV3L*,_217\8^ZMO0.=2#VJD'8D$GW,L'+]M
M^(T-/[G[A(XPX1+!47%[CHH.:=^ZY^+WC^]>'Y^<1A_?1!]/_OC[873T\?W[
MCQ^BT[./1W^'C^333R?';XY/3HY?RQ>GOW_\X]WKZ,/'L^CT^,/KZ.V'Z.SW
MX[?F<7[HZ/CD[.V;MT>'9\>GT1\?SMZ^PX?^&9T<'QV__>_CZ#!Z=WQV=GR"
M+S\[.?QP^O[MV=GAN^C-R<?W^&1T_/\<_7[XX3=X\K?C#V?1/]Z>_0YO.CT[
M^>/H[.W'#Z?1&Y@@/GCZ!\SMPVL>:F@*.T.>ET"?&^-(Z_6KH+K5FR<;7&GW
M)CG[TLJ,WEJ2A, ,Z80-0#0;ZMD,!8,C612ECHE!C/]&/SM)I6C+))6#;-&7
M;/Y6%VB=7N4LV,8U6* 8G8C5 HU"$N3HKK?5;3:-LDFLY$DX>=COK5F#=7B-
M =RU2@M,\ZZ2<II@ADX172D@NACSL8RI2@&;6'*EAAPYHM"SCD!BFP5I8\.
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M(2F9M<DZ,8Z>F<80H=W*<:X*DG)Q@I'%O/FF^S;R3B67_9OY14]J!M=1F1(
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MYT5%".-%YPT[D:-G=4]HV78TU3&H_V2QP,_H=.HK*$M/F_,"%F9D-];9P;X
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M)55B2PPNA//!?.QO/*=7;5[0N]WL!>H_"<[U:!7LK[]U'CQ>Q9EI!27O8G)
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MG4OYN>V*+$D<TW81U.,G?KV5ZP'YNJI@2N@1>=U][]Y>J[*LKS1I1#5%MU=
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MU5L37DTF8#E*\:NTFFFJQEG*B71@W;=<LO7MZ;+=B9U9: _C("+N042<>6$
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MFXE0F44&6;YH&;:LMJ@_S]&]1!R5ZS_/3$6*IV&9LZ0A_G/_V6AW=S>(CAN
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M/0JL3-B:7 8 #0"Z?C0!118A(*:YXKRHQEWB R(21<]ZU]@26W8\EQ(?0#*
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MYQ5)E.W%!(WG/C2>R=)M)3JE[EZ8--V*8D!U)[6F'_$K%M>!SG6!:N2%@Y#
MF'#TLB^ ]GL!J"?1@-8%L]^6D#P81[&9LG.T):8[MJ)P_4W)X6<RA->K6I=Y
M$S*TO1Q'';RU&^.M/;&H=]HX.Z(#FVT?'+;WY[U"%P.&R(WA=3(]UH,N7)?G
MA &$XN#(-#9/1%SO17)D\0J;I&+2AI>;@3B,MX[&7ZVY^AWCL:NK(!4WD"1A
M*!W"B8TIM!&%-D3.T6(850K;(#4A<!KP"=@@NN%X+W+3C!?= #T>:5MB2M@G
M[ ['5H@XG *?P-,H,0J7^%GCFL5Q@>)N@=*7LLLO73!WD0A26:RM:UA*#.GV
M3G3F2E  &:9 %CD\"@D"@CS5*85C.H,W_8W[DX(6XBZAP+!S(-Q,8<E(+0T2
MLN@- #)SP=.!(.6G+CX9G83P,Z*R)L<.WG,#0J=-!:*#6*($#3OG.%@IR_UX
MI:?/'/?U73O-R.3D(4BYI1T$P>X>B,Q'!XVW#'[H!1]CVL@R$#*LM<&KNLRC
MMBN'D)Q69>N(F7;Q%HY-;OOSQTU(+3EVL>J0S;/QR!?ZM7[/"R_[K%6;"TO;
M-9U:G7U>:M(QP1M9<D81T5B/$7!8:GA1$515#I5OY&)A.K%'!>*D*1W96W>9
M@-!81X:OYP"S#4 8QZ/J6ZX&:1GQE19'/C8*?(BI1!2<[=9GZ^E/\CF3Y&O1
M;/E!>,&Z%'P4;2WL_#&VG4EU<JX;:=E=-[*NS T&A]@TM>_ZV5H!QABWK"Z5
MJT&%T4K<R1OS /7,[E<9U(F%M<%#<N1^3^]3+65%<;7[/^[;FWK]Z^';T? :
M.E$B&4GSR'/C?$ZWO6I<CB3^WZ$CXG!H4PR$N1!#6] 98  696&F$EKA]BS'
MT2T0W#J&GAXG'@P(2-#-4"-H8BW-,<OF06];2/L?JPD5K3I?\+&%>!X+P[/8
MX4,X:70AQV";N!B::UZYJ 6A#:6E+!*VBU@AU"E6-<=ZC=&_:^1\J&B3#TB7
M4\P;3?@@I7%!9P9E92MDKC&6=R0OL#LNVD10B#99(4)70)6#(!W4H*_41%#"
MC"3&-(_JDCN,Z0)E[=0+3B>1-"^8QDP,-[9O:G=S 7+*PRGS/!L2PGUQMC>E
M!M4LUJ>(NXT$R:F6[9RFIY@HUB_RN&:;K6>Q\269L::54B*+%U5ENT9U5U\M
M/2E1<:TJMM+%T([3)N+K)-,00<]E#9X: Q,C;.-0,&W;;DN-"GA0%_77O\J=
M;J?')">JRN$O-+'6GYB'- CI.!QG'2$K*VKNDL!G[S\K4YG&ONW5_O,/))#C
M#2;'QS#%+&LR0!!BCN$J"V*K**N]=H9<@B;IUAE(]D:D&CAU[ V%_\D#1\Z,
M@.<)OQ=Y?<[R46D^4V.RC+P-:,ZR'5F)0MN"TU<-R>&I7C]9CK4N+CAY5&J1
MB#X)PG<.CUA)UK$=(["W:*QD( K/4E1:.7)<>J>!6$@IAY<4..UT8344D+Z:
MVV #VRFR"6!YNFR_N6+/(Y>J2WTZ;-_:I8JY(R_$'>U=ZAST:JPC 4P.D,3,
MX-C2'.O\8JE@-<8VGU1&-U$S@!WXX_<Z.9^QN#NAM%M1:"Q+GE"+W#@OA2^B
MKR*C\1K]SS7.%7V;7J*G$U..X>ZTS "OU*38]N@?4DC;S$9B!<5 .^3WP"8P
M1%MZ>7 S7K2JTB.VK4D,L("%1@LS,QD&E*L$_A!;R(7NO$F&C,*4-&9-R@7F
MJ;#_4@R=-HZ\T5TM"!GT(-D+*9I[,N0MN_3RK <OSVK^S08P5+NH.%V;CD$G
M#EHH>A:CLYV(LP)T=J(WS%"3ZST_B%>@[X XQ)1:D$L&()V+LBDG=3K!#ZT(
M=2<(6'"0@T-;"!O$6>YJ@RX<^3(>CAP"WCDJ[80BG"'D[-9#SGX*(6<AY"P(
MJG>3X8\!1ZQ-T&4WVBMR()O+:<4>*O$P)Y77V;YM,GU7EB0&)W6V_#I=Z/A
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M$-.;.P5;VCF#4AVBNY+.T,%#M\$>ND.O*PW#T"$WYUA2MX+;[EXC=UIUKU&
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M0-."1#>MZ"[H 3<U6@Y7CDT1US/T<V.S+PZD)^4ZA"QO#@33@G[:G_>4!'H
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M/CUUG0.3NWTF9^[.G^V"TAA;B'ET6)NIE@H1W3=C\Q;W+7*VR-56L+0C,+;
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MJ5<YN0+E7-WNKQI])WK#K'V68]="$"ZD57O.UX7&RNZ2KS<R+PZNE5.5&RC
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M#0Z=ISHYQT;/.DU'3=X[ADG3-_A?-EW,/3^Q>PA6%D^!8(W<7RL>YA'/,=_
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M Q0HGSQ&T+$4"$N%%D;,"M?9!CF1O/:N8N:CT[),< GTI?);YF?N-D8%MC/
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MA>$<K]1G +/H-ZW2:AIC=TN::._Y\Y]E(G]+_/2U)NKLY12 I<K/=2;;Z8P
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M&%S_BD9VM(S#K03P[&] ^)P$N\^TM*'NU11P%BE[A+B8\FON7%3,) ;Q>[R
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M4GP <5V 7%&E"UY*N;04._[2J0,^L-0)ZVB] 9+015UV<<>CF3 9K"M!WC]
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M';\_/3IX'6WA>\<@5YJJKJ*C&J2D__NG_2=/7L!;B9"+@V0&X$G.-KR7! C
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M?PSXHPGG[#5/Z-&6R,N'BJ.K&(2=&<9QN1I?@?D\%.;3U+7J<@3Z]HL5]6X
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M::0E2H@S-<(,[8,D69AD-D?9)+$%*7&F3&%HM^/D=FL1V2)HC3G'Y[GSIT
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M9%5C?R]-S19_*:O,7@H=_6TBBO42Y.($ &6B(X.'4I\R"@\*JR)N-^S$QU
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M^5T9W^<3I 4LY#BFEX%HAF^^B_+=D8$JP_&:'E7RZ)@J)_FS:66+LB0Y%9J
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M(C&E8N "CI)*JRPV(6S)A*#.CX3(IB:(0=R-(OB2RJKA)2KHCO !SU4*LYW
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M)R<U1',;^8-UJ&8V9B5_W[,W)9'A+4S@(\TU7^"&5;!G_.S-9S?&>L2P?>]
ML@BB) .I!VC@.AN/49*W!1M!_*\I:G9K#W9S:U</1VK>W+J0C/O?VY7V54_W
MV9N+@D?/D+75 0'@?P8['MZHOYLV\RL,]"\8Z-Y&V<S;TN/[L48T(OSQIK:T
M08QSQ*?6NY8COHS@A][1IO-@YB" +;E52DU)6:FK77[Q77H9884.#](:'4S+
M(C:\_BI7V7+2(VL$O0>DDG]DH53#.,"3HGWLX!?NF#2:EO@" DWFHDTD$DD&
M\JEUWKCF@<[,\23NX"$3D-?\-,U/LM0/,RE&/EI&W %(<)ZXB^)ON4+U9P@3
MBA,_G>+ SM%PYPZB7"#U?!EZ0,OGE-M,DS-WGKOQP(]NW<1#HY_X&":IGV:I
M!#*/1!"%-S@G'R8.RBI:8,@(.42MDFPO.*0!+"<\W%UVO6&$N$LUDAGSZZ;Y
M]6.(Y!.B< -T3%O6* \E<N+&ZHQ$FI\1A!PE:^'6SA M$1:0*Y!')%S[43FI
MB^=(;\:D6%R0,Y<V.;P0$XMS[D8 %^K%9#"9E0%%D(TGP&%CHS#(?Z.% N[]
MN:=R=!T1R 0(=#(!4"*[3.I^I\48@?P =.7HU\!2)?!422:]Y[Y643M=]7,,
MQ# BSF]<PI+Y,#<^HDF2D ,_0(Z19:!Y[IM7N:!$*975<Y,1VC_Q(C+JV&NJ
M/]?F'1CUP,?/<=SA[ HAV\;R-OIF++!UB\_<N 5N;.8?-P"XK3 14F,64)L-
MZ[R8IZJ46.R\N'V&Q9P:'IL9TR2.;@'-$]#4X]3U0WM >.#Z>*3 [32K=!1'
MV8TRQDLW#GP%]#D3D>4?Q/! *H 9%H]0YR\=1C5#=DKL@88,/U2T"R-R/0\H
MT(7#K7 %X"4YZ]4_43-=\5B02$"8Q)O(6!,%YI 2SX&-!W+HA[0O9?$"EKPM
M+OZ=X;'[,<3"(;@M7P*@=GLCZ#+\U*S^BY9X9_E#BB'BT.LD C\("BD 5OQ6
M)G@2$Y9$69JD,"&\7ZJQN'=PJ!>>B%\'_JUR=N:\_<?5AT?)UIN(.]<%8.9J
M.>B61O<S_%__0H[7R@NUN^I4E'ST<"_<D40!:%S"&CMZNMN6?WB.'[ERI?(D
MTX6V&UE/Q'8!FQO7]0%WCH[JSXEAD"6C1TE2]W12Y"35K5&R7#&*Y? _G_WT
M]?*\W>X\>T,V"R7:AZE2>5VE[\)__^<W8'"S&RJ'Y[+_-QP2E-5S"8I!###^
MLK/"]I3_G.A\'Y8-=ENSKC.(+U*E/\4E\SDITLE2BO1,$[!"D3Y3.K#6HN%X
M0I&ZSI0#!Z";DL9;B#5:N7;#C((.2 )'\:9SR#+J%NCPLNI6/G:TCT?)4Y8E
M%?X@*X5$U0J$1=SQJJ-;N6_:I(<I+UZ)X&"M,\(JV] QL!4DDNOFB9BY]*8D
MU)+T!N_+A=? #S$.#:2Y6QE$$V7.D9Z?H%NN)6#>GV$*ECO]Q-'>JF4FKAQ6
M0/;T7"U]5M<"A%^TO_1E>B=E6*C3%2:$I<CE9C_T8'=!JZ07W #CW* B6?C&
MZM[3GXK#]B\.Z<"=0ZT#ES5-6!'B"[P&6 D$32U!@V8<]8%R7.6NA.\BSR<&
MSB5L%#^1[U%<UJM+4P&02&/?PVM!;O6^ 2#XJ99&':-.#!3/_ZS*X\ SZG H
M!Y[JS,@XAG: J)Y,>[21EF;4;1OC!87WS,3KY*12VLE$HE*]R0U==Q][O5:O
M]POM9%=QD;(&Q'(,ZXZ[@($86J6J>P;M&NS,1#-9E?^TS4/OY\^=HT-%+J1T
M]&$=QA+M#22 &/N(84M\7P3(!1I94-:[&A8*U\8*U\J7%\;5?!?#_C8,A9H-
MC((-"]3 DA5L!OW3*+H4R.>8R"' 7G\XPPG%XRN&,"(H_:";*!H(9)<B#@GU
M<!6^I^C,C:6MEU>M:D; >*&-EB.TS.>^88PKK P,;98@*9,I09O72)V^Q6C%
MM 3)S]U&PR .P[(!.K@"9/NW[1:1YV4(/"K*(0$NR.,52?B):2U@4IU>Z?FT
M_V*.L<+!>Y_W]>@2__N"X=6.;A#!WJ#)D(9Y+Z.T#3H N@+$2->&,8P'4@#@
MV:>N$2^G>J>EU%=-T.)"IPIN<Q^1.$?SQ1&;.;K!'H_\<6V0&DQ3&<DJ=):3
M,Y%57ZJSR4WS-1.IC__@V&BE_=Q,I-$YRH(!#!L_P''3_2-WD%NRS+;D.Q++
MP8P!JQ0_HR2I6Q2.LK0A(B\:OIS  2U3$YGG14F:E)Q-*G!HI#Q(?IADBC?Z
M,@2N2XW5[OSR[=49+=GS[[5<\2 L,&U@@0>B][N1I/A*E%L#(#IZ&A(2(+6O
M*0^(42)9J 5];H0EAZ+;?+H=\ F-ET1,^#M.!QZ93X">K1^M_FYXO(.WT?EN
M/B:1ND"[2*_3"@0DOR.CFK!6X#ID)1P%1KA^]Z06K#2=C32+Y-2D^$!Y;FS*
M4E,D-P<:R/6,7K3$1^#Q@7)[:(C'<&ZU!+!D^,PD@KD/@(MCJ2[3R&_N@U<5
MF)\[C3!:+A*ST%Z"=04&UH/,D:'G\1WD&#-AV"F7PLCA$UNR5M-L.&0O#,)]
M#%,9X*QP>%_B")3N% 9P'H5#4LA]..[1Y L/_QR%#;M%RDMJ@EXL]1L9EW;:
MG@I(0=' ^)RJ9Z*?5/U-1#O*R8N"V\S)2BI: .(NDEM ,C!:[O'=8S3@RTEJ
MX)?<PNK>LQ*3XCAM(:.(3J88KT99!8E\F 5B#%0 H\Z\E"(B$V 0>0-;@6YQ
MT@R&\,4P=K,! 4A$_ ;WTJCA Z B#%1,*)A3/0;/(9B:IH18"\<#<N"HLV ,
MYP((B1B6-G+C,8Y#S_$45F*8 3$Y0 4X1A!9X>D ED/7#[)8TBA@\GV?=A<)
M5\:T8'@ F0>+OZ.^\;[#]2.X7&5>]#'.5DH_&9,8=NM'@6L.5R";#!0Z./WA
M3J"DTI<X*?P8?P?Z ^R?TE#R-R)%J5!;';2K/J;XTAKG9DYH.#Q_6V1-0Z;]
MH7VTG&>Y,:%ER.GW65$S)RHT9@21YQK"5M:,!E)34K\*R\AO@C?C$B'@A:+7
M!CH,9'(*#QY(K0ZB90(/=5@C6S*#MXVC6*H;.X>_Z*$;=1L1=4(P<IH'0>8C
M :T[P+>2K4/9-R@&!=0"?^A[ $:!6MF!!'4=%X9H% @W T9OF!Z2&FJ12.1$
ME4!TK)AM03&[J!A&F^(RYDFX( U'&+A39Y@@B^\"@R^\,O3\"1"4S*-Y(F7T
M;54?27*%"CE0L@4RHG6\E$1Z?S8\A8*<U'@5AOS 8.IT5D2H[V@,J80)9T#:
M F-'M24$C[5/,KYA^\.^N#_JDPZ6=H#H'(4&#TA#;;':X,$EW!N?7./:4/;)
MCD6Z>B"HRS;$-5[CZ9'B.9&@0EFV=]:F33'!;II@_Z2-;Q)XG)GMQ M!KDD#
MA3L%.L+_**7./O[1$MLUP6N6AT1?:HS)I-&N8NJ(XD9'!B!K@TI:#!%([D:F
MA6.G=_A+G5F)0F:4^/ZCPZI7Y9C 'Y,C4#$(>P)+CB.-&OOJ"IP3>W;%L6<<
M>[96[-DKCCWCV#,^ZG_XJ*]63IXA@HT$<J@3[-%$<A0'\NZ%<A@)BF,YGB([
MKQ3+4>'*-8,Y##/L7C2''AF'<W X!X=S<#@'AW-P.,>#A'-4SME'$<^AS];M
M!G14%I(C.CBBX]XB.BJT]NA".BKSFQO3P5G#;+G=F.7VF"VW;+E]]J&[FWN]
M^W7S9H&F.H*:2GHOKV&BP;D[2>HB:>K6)L$;7GIP1UV5O4NKTH2N>G%&)F'4
MD-\K]?I_4+V^" =<DFUKUCZ4ZX=1$$1W5$*$>!YDV[MDY7++3BZ,^"&*IDK@
M0?-V3)O>6&H$"<!Z28-P)W.RH)&1EA>"8CZ8#>0KQ! UG_I^I?1[CE0%N.2=
M(^#<^B4_1^%0"H"RX3PSOYFO7M.13&>K^*G=;N>W6#TEA'6$IZ(M>O@O MQ_
MK--4M5,,=E%7U7.0N6+835BW_WQ6W%9N^Z&H7$D'=0U!.C_0$*3FV7/[A!RL
MWB>DNWR?$+TEO5>MSHI=5RKB%' +<!3R&4A6J6[A4;>J6NBJ:>FJ][Z$;^<?
M_L*Q[F15X57/N7OH:#SOD*L<8>>@8M>((0W3KA:$'5=*O#9W?V4&V^$^1[@Y
M -=J<XYY<YHVYZC3.CQX:#RL 4/&P?7-!:76[AN#QLN)*OQ(@ML<C%R[87QW
M^8[Q%GTP1U?A]J#56;'O*7/TD^3HSUFARD5#\5L__O7--2A4,1ETU=^4K1!,
M47/3?X/.%7M^(@?TMT*%A'Y__M,+==&%NF2V7OY\8>II<713_\5]$JQ8ZF48
M9AC>51C.+V(@?J1 _+0VBL&7P?>>M%I;;)7TQY?8]]1OSW]^P>#)X+GG&[7"
MAARV>@_N(F'PW!OPU-@Y\55K&/KSG9O.DSC7MA%VB@Z*?=?[AL'IX>"U^.G\
M_.+B_?O317;#MPU</\.N*_-V(Q/W5F?BWO),O+Y7<QF>ZT>#Z=X&7'2L#,5[
MBMV;[7/:T9MB').-/>NP^[6,EVM\ME#LV'>RGOO"'94@]GW-[U696A9<_J*7
MT:5[BS/W?\#3@U<XWP_:QPP9#!D/"1G=5N]DM?6MTCM#R$-""*5Z=$\?/8RL
M@ABO.C^.&!5%>8YF3%\Q$SPL$R@P?^0\P$?I3N,.2]_[A1K=@\/6JS:C!J/&
M0Z+&ZC;\I5%#V9L?%6QL.:L70.+7[M&O6)1LH];QHQ\SCO]U)2?231\;DVS2
M1CX?7A[I NX8B#^Y568)<,\DP/;A8O'OR5$Q8P4;7AD[-F9X?7*4S?;7I\<+
MR]E?GQXK\%'*8C?#104NC@]:!UU&"T8+-KCN/%P\@,&UTT&#:ZUFS@97-KCN
MT@(REK/DMS=0O@.27\<Y['18\F.T8),KHP>;7-GDRKS )E<^2O=OE5GPWB^X
M.#QI'2P1ZOKDZ)C1@DVNNP876S>Y'OUZC!;7([:XLL5UUQ>0H9P%O[U!\AT0
M_+I.K]=CP8_1@BVNC!YL<66+*_,"6USY*-V_56;!>[_@XN"PU6:+*Z,%6UQW
M'RX>(LCU$$VNKW:JYNXCY1*VN3*8[_4JL^BW7Z)?YZ#K'++PQWBQ-U;7-? "
M6 9D#)F^9.#8G,[XBG%CGZVMS!.;YHEJ#X=*3Y3K;"+CQ(O]2<$,%6)+\!)K
M[0[A!'KVYGGGQ?.#I;M%/4&&XX.:!7O&HNKYW*JWV#QQ,F:P8)/NKJ'%UDVZ
MG>ZO72Q<T*N5W]FFRS;=G5I 1G,6_?8&S'= ]#OJ.;U>;1'P)T[(#!=LTF7<
M:,2-7L<Y.JK-K'KB%,TFW2?*$_=FTNVR29</ZH=>99;K]PF+GKWIMKHG#!8,
M%FS2W7FT> B3;N< 3;JU)0LW8=)=:+Y];+RP2;MM/>7O+;73D^^7X$G>MLG]
M94=OBB'YKR.8?2+.6@JI_RDS&3OB2RP3'V\0;C@0YR-?#L4ER.!N"NLJ+H=#
MWY/QHV^DN>O'Y]-97A:R]TO(/EZB L73H5X&AQTSE7/-B5T"BZ5K3CP=DMX3
M6SDSP=:+33PA'N!3DT5J!HC<;GUPV'JU1*K0TZ%@!@BV5>\,0CQ 18GN$5:4
MJ U1VT 17PXTYD#CQP#83VZ56;#;+\&NTS[F> 3&"C:=,G9PN5ZVH#(OW+,%
M]>FQ A^E+'8S7%1#% Y:!UU&"T8+-J[N/%P\1+E>+.W0/63C*AM7=VD!&;=9
MRML;V-X%*8]3L1DKV+C*V,'&53:N,B^P<96/TGU<91:[]PLN#D]:!US6GM&"
MC:N[#Q=;-ZX>_7J,MM5:Q9QMJVQ;W3U 8=AF(6_'4'L'A+R.<\"]BQ@MV+K*
MZ,'65;:N,B^P=96/TGU<91:\]PLN#@Y;+'@S6K!U=0_@XB%"5P_1O%K;MW K
M)6P?*4>P?96!>Z]7F<6\_1+S#KO<')[A8H\,K-QM:2=PH_.*<6.?#:O,$WO3
M@:S#'<CXH'[H56:Y?I^PZ-F;@U:]<>:)DS&#!5MO=PTM'J(#61<K#_1JY7<V
MW[+Y=@<QA9&;Q;P= ^X=$/.Z/:?7JZW._<0)F>&"S;>,&\WFVXYSQ%5+V'S+
M/''OYMLNFV_YH'[H56:Y?I^P".3Z5O>$P8+!@LVW.X\6#V&^[1R@^;9S7^;;
M/LB6-W&4A8/7XJ?S\XN+]^]/%YIT'QM_;-*66\\->\L!].3[90*2P6T6>-G1
MFV+8X+RE8/L?<CB,Y52\D]^^R=@1U]*+9>K&4T><CWPY%._]T T]WPW$Y7#H
M>S+F_I;<WY+E[AW D=V3NWN'SF&W]EQ]JA3, ,$6=$:*&@OZB7/P:@D=_>F0
M,IO.GR@SW)OIO+>2Z?P)<1J?R2RT,_KD0GNKO80K^^G0+\,#F\=W!A^V;AX_
M_+73WCWK^"-U(FW22,Y>N(='\2>WRBSK[9>LU^DXQYQWSG#!YEK&C97JW#@G
M#!MLM&66X'AG/J<?_RJS6+]/6,3QS@P6;-#=$[38R7CG_Z!?T&2+GUJ[@!\-
MHR@-HU0.*UM ,Z =%EI:-;)K:<+JBO(*B9>'L-S"7B;1/6CA'@AK:N+O+$G]
MX51_J/]Z+7R<\4M_(*,;X-"1_EI/7KPT3[(I\E04>RU.U/<VG0@B%* 3(I,O
MUT D+Z_D31:X\:GPHB""R?4#$*)A1?^R_L,U;5BOOZH+MFF:/;DODNT>3.8%
M*!.O&,+MKDVXLS'*]%Y-NKV9-U(M-R5EZV4U"'0\^7XZ\)-)X!)Q!'X(KPXB
MVBP%UO/_U>+VY23UHS 1MS))X3'BX+@DTX<13>?9&Z&O'\.JCH(I7)J 1!.,
M80Z)&$LWR6(Y$,,X&HMWTI/COHS5>[H=1W3;W79+<V(3X8P?*>&TMTLUFFBZ
M6R6:WM&&B:9S0$338:+9)M'TMD8TL.O=PU\$S4? \2FFTHT=D8YDN"%Z^N1.
M-2FUF92V3TH']TI*'T,D%2%O82PB&@I7>###&XFTX\'JQ5& 'Y]=G9\YXK#]
M"_Z!-V2A)KYDY,:P:TG6_UMZJ4@C^-I/A'OGQO1E$(B^]**Q%,,L $)SPX'P
MQV,Y\-U4PM_Z,=DD4B/Q@B@!2A$#^!I?EF3>:'9,CIC$T2V(<$ >H^@.AD\T
M[\(<](3<./"1(X;BN?]"31D_!PZI9XB7R#=Z46"0H0^/3-QX:B9<'E<,3S6/
M]</;*,A"3'H"23(>^Z&+[.G 4^!NS:HTMEB.79A#OG8P5IJ>&2P]>^DU:PG#
MA[\._%LEA><<>77U@56>M50>O5H"Y@<**/Q?_T(:0>6%P@WNW&E2,;?#O7!'
M$@7^(%=22-GIM)7FL%C!J5RI5!RZT-9O]$1LW<3<N*YRTCDZF45W>.5?PR!+
M1H^2I([O1QW)2:I;?=FS-[^Y8A3+X7\^^^GKY7F[W7GVADY0Q)ISF!@>PK_]
MZBH#OOKO__P&/&XV1,5(71+B4M34)8!5#&CXLK/"#I7_G.C0J6+;/W1W<[O[
M43!8>[,I1LSL]LE)S7;?1L"V/[+?G1JLJ8Z@XN]Y"U-Z>0T3#<[=29(O^X*U
M2?"&EQ[<,;L^S][@D2W>^3'0"!Q7Y]%X(L.$3J:R>ZC"YS";W=SVW>3R1NE-
M,?I7D!R&41!$=R@[D(D,#GBX&#Z-2:X8^HGG!B2U"PG/'%3TMYY2^GL.H'V<
MHOC@AT-<"MQ)<>>G(Q KDDDN>X&D8FTUB70@3H2PZ_5BCQQ/@F@JI1%]!IIB
M$B/VO9ZA$P:&O0:&N9@P^_(:5W3#Z^W7+-M<H8)%BD/J(X/I]_RD*VC0:$1M
M$'U^R44QD&L"6  0B<QOI[F9N6W$,_%3N]W.;[%<#,*2 E/1%CW\%P_(_U@G
M?+E7',N+0I7//S1X?M1R*Z&RSB?4^0&?4,VSY[J*#E9W%767=Q69J.;CUL&*
M7N2*% Z8"WR'/ <">3HO,$9-O<:OI/>[=$J>?_@+Q[J31HY5(? >G,_S\*^"
M;N<C-ZX179> EV=O/KMCN6R<R]-CJB:O\8Y[OY_>1JVP(9U6[^"A\; &#!D'
MU[<RE:)P-@:-[Z5,%)M=N'$(&L5O_?C7-Y%6*+ZX_L 8+M4WYVXRTFR)?S[_
M>>D PJ?'KPRL>[)1RV_(<:O38UQE7%V(J\KMJC#S#/U;B:@"YG;5YRX#-0/U
MOF_42OE?1UU&:D;JQ<:!*/QW!H,8^D;Z?2>'\"CSEVWY5)^@I P[EK <S/#Z
MJ#:*X97A==/P>A8$BLLNTY&,FR"5\9/Q<_\W:H4-:;<.5MP1QL\GB9]?H]0-
MEI8TUZZ:=<0M)3;C5^:6$MMH*?$'?.&*WV/73QSQJ?6NM;$ZMD^EB.W<%^ZH
M1+'O:WZO#EPNB_"091$Z1UWG<)FZ17M.P@P;NPP;J[LGJR3/*/*0*/+__'3<
M[71/&44811Y2^%C=N,LPPC#",,(PPC#",+)W),TPLM,PLKJKA&%C1TTA&W!/
ML"N"71$[Y8JX<J?C*!R(/W27Z_^.HB20TXVZ)0Y>/.^TGXQK@H_>75E>]D+L
MU]%[>.BTGX 3@@%B1Y:7_0W[C1=/1<-GP-B5Y66;("/&(R-I1@Q&#$8,1@Q&
MC!U97G88[!="-%LM.)V!?0A/PH<0]6$CQ85V(9Q'X9T[W9#OX)#]!GP"L]]@
MAR!G]T[@S@D[#A@AV'' @,%*/0/&3BXOFP$9,1X923-B,&(P8C!B,&+LR/*R
MXV"_$&*.V8(S#=A+\-B\!.]@ZO_0+H)/?NJ-9!!LR$EPQ D&?.*RHV#'4&?W
M3MS#IU'EB %B1Y:7_03[C1>LPS-@L-6/$8,1@Q%C5Y>7$8,1XY&1-",&^PD8
M(9:P6G"" ;L.GH+KX P^CQ/Q(;J5&_(8O&)O 9^[["W8(:#9O7.W<]CFM )&
M"'87,&"P*L^ L8O+R\8_1HQ'1M*,&(P8C!B,&(P8.[*\["[8+X288[;@M +V
M#3PVW\ _7"_JBT_NR_^6+FSIAOP#Q^P?X(.6_0,[!#8[>-#VV#_ ",'^ 08,
MUMT9,'9R>=G:QXCQR$B:$8,1@Q&#$8,18T>6E_T#^X40<\P6G$_ /H.GX3/
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ME7?JICI?7,5<86*HEI):1P=HNU$!4@X95[P@HE34_*K29I2>&S70C,HR-7.
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MZRE@L[AS8^P* Y?%@HA6]:>QGY%AP0$]*GCA*<X])NITJ$PL];U(U,BE</M
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M7F6RF7FEH_GQQK^EI1X.K2P"<[S2XT%KQBJY RLKUB;1V5=UVZT%GHYB#.%
M$6<^730'CRD$OGY;X,@,:*1H"H;7_JW<.XSFVY# +"$+^+T,/[B562B_PUY1
M'3+C!B-?K!NK2$/;)S;?W86WJ;)D!3H:TE:"56J<GW5O<G3L9>![*) Y#6^N
MD?3JT(TP@%P)3&=;<H$-5 RM4S[W#<CI,ZU&D%#01)0VD+!%<*"Z91PSSP(A
MN.'<H\>:4\^<&22EV(*Y.IWTR5*4W(.GEV!:9>4H(J0TG:&+GN@",ZW 67<<
M90#^_:F&VGJ\?PZD/9 J60A+?RW0"UXHOI'?/0E7SYX]3-';24Y4$>+1T-$D
MH1U;>1R[FRC*+0516[5LS5EI2;TE 6> #JV<(!,=]D!/4T?E]REFR*?TM%_A
M;WI?!JSBIP$\ @FMVSXM\<1*E:STSJC95H>OV:E%;^F<"H3=R;1QLNCG35/7
M&ZDL@0T,ZBR$PTD703"\31PS=W$XX6R';7!7*N'1>/>_Q-$D2M@FMT5<4UI8
MC2FF9(EYWD$-.%<\ Y\4*M@Y?:./I^2_,S_62F^?I"[KL"UJ\Y:D =MZ5Y$>
MX?<;C:N8!WM#:NE,.!B=N1Z\.?&+ZIGJ+CW8<DJ5@_H>WA1F)F3,TKIM0YE2
MC'" ",X)Q:?  9S0E9:Q;?&#1C*TY6P=51.A>Q-5-'L-%EGOREJP$@A,\M\O
M5N)/G6E-1=F45;_"D-ADHZBQ(*Y5Z]@V!!6Y1U:ND3CS/&!=^#28TE83'U.N
M5XC-7&@_ Y]6BK9^*9I56CG(_H8FB6 ,+9KYE:3"NB0Z^+ND=31O"@MC.P):
M_<TC%M90LMT-FKW=U%CET?B-Y. :46S&4FZ$)\WK>EAZE"U1%V"E!TROR)4&
M]96%!9C%!V)@AD:FM5^_61;LK\=_QMHYXV2H<2YPGB('@-U7 -@1!X ]W0 P
M5A9W45G4Y_6_0'9F%7&KIB]W.,2<*JH?<!NI"DU8?^3O**8"&XM5%]1VR$J%
M*0/T!&WFTM9Z>'BJHPV,3H+=<ZA6ABJPJC^6INK']ZE)9ZB+**E*>"9ZQ%*/
M*&9#?#0BG;$^@!S43T@[R]NHC%Q]9^*.I7&UN0E-)*FUNZU.WF>_GWW\?/U5
M$[:1U!8/5]5!B:-OL'K- ?8T4OUL4H)!X'.LR861F9;>EP5KQ(RW'<;3XCT0
M<UZ5A%S9T:PHO0QE?XY2E-R+&EXK/R.WH!0CP_B O(I(7F]VJJWDCC;2*'9"
M81Z3/4R-M"7HFX@4W]$WK"<'3'];HK\%>U.ARP:J/,O2$1P4_XMQ<GA$8#&:
MF(H2W@ME+GZ=E31,M7WNA4:K_A[[&HM=F)2W0,KG.A!@UMQ IQ\E71>B"8+7
MW"#*NS"GC#%U8P.!.5X6@Z^EW*"KSNHU<R45R9;<R#7AZ]<954&;[9%JA(Z^
MA-6C:OHP9=P,T3GL+>.(')J*J'Y(1=4XL&=K%M& 7!/H^;CS$TG9LW&&, 2P
M2%9%4XPNM.,53"VZT!T707:NIRV"2 %JMSU,4S;LH5EC5B*'IV$ &)4=Q;B&
M_-9-R<CO+Z]JY.,5A2"FQXW3XP*C(EPZ:_KY,4K %!P"YK>79U?O,&7+E!ZZ
M%O#S\M.GB\_OKDU&EZ8^(!]#-XM3>%H5$P-G%[-Q>6/&Y5=L7'ZZQN4B=[3+
MN:./.7>TVY [>O;GUP^75Q__OXMWXOK#V=6%^/CY_.KB[)KS1_?('<'YHWN:
M/XIE9$!Q'5"8JM:5Z>YST&M2%?#@&XM1.<3++2Q+\^P#S_$N+7.JK-&R&>K,
MO%Y+HR]:XE(;[C6Q*)(@J>ATX">3P 4)PP\#/X0U#2*2(@RX%/\:6JQY4F^U
M)RWS;^Y-4!4E2Z'N=27]3!UMEU1%,IOAKHRE-I-M=@\H1D3705RZ<EL:K;<4
ML_^:7*N[* L&JA];[D0RCI:AF:*Q=Z81)OW-FZJ>U:&9E9W)1FLPR3.2$Y.1
MO*DI+:!J0\N.,2/@V7B/,>"_KQ ##NQ%0[J2&. DWL$E=@G43:W0HLQR;1.V
M@D$I36H;KT=+37RKG3,FBJT2\56* =W\H.HH?':@5MYD0?VQ'%,:UZWK!R3#
MV[- [[#.]:R?)4M1NRM%O4>0,&ZB>4<ERUE;]?O-W0MSJM'1C8B&+3XH=2XO
M^SAQ8_<F=B<CXO(X]3T3&_KQ7Z7]-@<^L#<*;6B>CB6VBS*]KI+7O.?WO^?Z
M7/]:@]$%@F,-1]H"]:<)@(:S]QQ&'.E687"]B2K1$*[: =$)"/_6"KJ]-<33
M.>)N]]4&Q=U<T$6OK8YUCH8UUVU5[BZVY5R=G[H$#7">KNGZ<[O5;G?0QZ/V
M4.5D'ZXD$</C9XK<-+]!Y;94;C"'LY: 5/ VL" );O!3A9J'ZAQ'YV%"-78<
M(5W*'L<_[#H%DUCGD0RHY[;QTKN@:]#>9'Z""4.FH#;&[F/DF3.;>J3"V IG
M+TF$T="D.++<L+MRPUO7^X;]&O4!=&4EY+(HL3O'RM?J,5\CWB<SZ5:J9]FJ
MRGNM.K$6XE64:%"3BK240/=KZV>@MI//G55+5BT90^[1[)N4RR3<P,-3*@ZU
M!^42'!-PL+CX7V'!)G(K0M>5J+(;U0UUP3/;M.ZJBBRZHM"RS6*K<+6XW-!L
MD2%FORT=X77*X)+XJJI*64<41L#6@JD)RDTR;.3IHYT!OVXL]_E@;+"(E6M*
M9A;E]6:[U-PSCXA2,28MF5BAR-9RSQ6DZ@_(FIH,DRA)J#?K,$LQ:]BJSX!*
MG>X&#C-0OR[3^'7HAZK9,#Q@YO&J*:PJ?F#Z2)BVYKJ->U&CQ].&BKP=LN[C
MN\A[A5* E7U-VBCJGS$N":F],;';8C_8J%S\*4_DGF]Q4Q4H\+H^-A J=16F
M.ZFZ0\7KR?BXC5IG2QBO=2>TO(^PO4F.@B$R?I)C$+@?%0M'-T$#),W2^BJ/
MRH]*0BQ"F*X[+))) )1?DIE,\*M"I,]12RP3SVW+),J>IZ5L8_VJ->6M;WJ;
M9]#[43N:?O9RWF.'UGW! ^M&N8X9<PD+W[(Z'U66T_J0I9"^F*L+;LM^FH>-
MUYW]C0,/I$N4[XJ^&^BC?W=,KS7GY"JB#]D>,9(%3F!S("D;Z@+_2W/>9C.!
M5^08KIK!@<V;#VP^YL#FIQO8S&+F_8F9%]\].5F@$>^ B6A6]5UR@$H10C5+
MU]'*BSP]G.ZL79!5?=_4@9UGQQM$4B?&YT81)4'#B4\ZJ9-'029H9:8!Z=+Q
MN<D/+\8H01BH=:QC2?Y<K*BO2<<A3SOLNOQB#!@7)+CEE,0^R]U VI45>BK
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M@+S5R4C*E$+0T"Y@,EN;NU@88]"R)B;'E@Y<C,? F(O!WUF1]:6-#'DB%+J
M3:O"&0.*4S0UU(GH\!5:"!IT:S\T=1C,2F!_LLQJ>^AAYD(I@\4=TP7]J9:^
M:I;33\Q*M&:-27J1A:1JAT[NN[ZY 0F,VAK91HXL5. \8)3=>90M!!Y=R1+K
M5^HVF)8-^9TD Y&OXY+.H_ 6&U\A<UWGPC_#\M9@^8L-5A;Z%-UPQA@Z7N@O
MV@(KO\O84VF0OJ=Q=;;E(>:'XM92&TLR'.K;'(%1ZE1[(L:>.JER5Y#HA2;6
M54J>(FIZI#JI#%)5A@E>Z\SOG&?0<F;8F-$9FSBUO/*K;:$MG1?RNPYE4Z"&
M0<VJA*MCDDE4W5?R*.CH9?U-/H<),<NZ)PE7)=CEJ@3&<D'D=)$WG:CK.(DD
M8K1]U1X6OSLO6@,R-&[5Q?K<UV:?W,-3\HS9_3_G5Y'.P69^G]'GOGGA1MI+
ME]M6Y^5R&UP_IN"40D88RK)C ?0CW*I4Y6UP32OTZJMT=>.*- A-&4R5UO:.
MY=59V"ZSMBO1.KV7L5  .2K)10WGRJ)5&%%M\;P9NG([D7"+5 +')+Y@"6^X
MS@&WX=W$LLXCGE)'<$-M"XA2._RJC<1K5O_'2=&=SI!CA.UOX/-E&O&H: #J
M*.Y[OJX -UM!B(0!U=)]\6-/"U_VXEG"!$A=(>K$MKV8V #$1.4HU#S,*+D6
M-,>P;CR&M<LQK!S#RF+>#XMY)5JH*TJ5GS%Y%L8/'S0M\5;"2T+R]S67>*G:
M*E7 DTK%L,2=6$Y00PU3%6_3%#J36 &TU0ZW ZP+J?1;EV)E8M S\=F@D()H
MH&I 28J/\NS8,5@,^#I=_HULN-MYP]U;&4I,\OO_V?O6YK:M+-O/]U^@>B:W
MY"J$T<N.W9[I*EF68DT[DJ_DI&<^38'D(8D8!-AX2&;_^KM?YP4"%"5+M!R?
M6W<ZB4@"Y['//ONQ]MH@TQ>TT:SN DSF*[B<O^DXF0'P>OUW.F&1;7IR2A+H
M S]3&9GUGMN:FB;5%7Q9U5$.[I-&Z>VD S7 >%Y9-%,DD@8E]RD6BHDX&C7P
MJ#$LNB%# Q<"/1[US$3S"7H)6YJCOJQ<;$4;5UH9>E!F-#-?Y">E)0VM OT)
M@ZCT*"IG&-7*.*R62W.87S.2BD%E\TMK^M+"*X?V0.BAXC][&F[COYA%'$3O
MBANE2><J18NW\;BIG2(B9,8IC+6DJEL+>Z&ZO[ZUQ-'3=ZMJ;<-O*@7^1!='
MLC2%OAU8W#.L(G0O/OQ'=4LW]_HN\L*]'JEF<AG]L\%P,(9Y:><IAS0%'RQN
M!5PP\IR/B@9Y]FA7$>:9\+;BUFWX[G M/?EKZ=)*^CO;Y\V]EU!4WA3%IQ]/
M\KI<1J>P>.&JVMI5=2R4^*(*3.C$T5!.?SY/4>#?I;Z;[4^^WM)2JQ>5@:8N
MBYR+07"?A[#//5:GPMW75B>A"$D1>8,B-/H$KZ,I]KM[@(HGCY !I'+1U&@C
MHX+Z6(+>04GEVO;SP=& O_V1K@1/H0D_$ZW(8K:LJ,Y@Q>2OM"TNNAU6RK/)
M.R 2[CVTC)A[A_A*QUI/4]J>K@!P>3/'@3'YL(=>IG671]?=+W"$_MO(O0TE
MX_C0HD*\AXP>@GN#+2R,ZR:?5"YLNE3CLL8MDHO8.$;.?:Q7I#37L5,FTP'P
M2"=.>K-C69#8 'MJ9'PY?LF@XE;+$2LNJ^5:5&#A!-^[:I% SY;"G8,,Q"7N
M\YC0O6VQ6VMDD$%KVZ+<1B,0[O=O^WYW4I_A@M\RXA_S' A;P*))5 *D=.X!
MM^NH*-0=?PO<7-15ZYB/T4>@WB6:LT5P9>JS%.#I'S-KG*>_-1-2C=-0.K/.
M'Y'/I.-=('O&Y]:*13F9^-4[>>#*[?W"<$GUB15U184(TN/'>S4/U;,%OB#^
M1]H3CI7SO#%?A$QNQN\DIK+^-]XI $A%D]3#27H]2R;6=6RY0$_1CM0SY@S,
M5%WS;4 ;BJ4B0G(O5XWD*L6T.B^XJ,0=M0D#<(4EUP4[ER68%FGF<,9KTR*I
M['Z@9='Z@KG17)"2\^*=2F,&BBD3/KN37J@2[DLD/H(92J96?5:C!O^C=]*K
M(H$M I9WW/VJ&5+)#0=^]4&)#3&UBW""I4HR91UGI# 3JK?8X\&/>^P!/5Q^
MV1VCQF[WA7L#;ZY<E5/-J  )C>VQJL"Y6-JJZ<[=PXUQ?L1K1[_I^G:39VC<
M</-S%"LLYE&5A)[ RJ\*?75]N5$]Z*7%"$;.TS)R0"V=6BN>2U&#";,U$P:6
MOX>:P.ND-BKR7$ECQ36M&@:1IU&L(X,$"985P9">N9Z8=A-7A^.T15ER'"!Q
M7*&[*7A45##N'#0PLAM4!*L6IK;[/A.U-V/]*1UY)T6._BA?V3!__#I9>['9
M KU",0.$;[.",([4:Y;P-2VN*UU@1#O1]JMQFQ0"QA"BQF1_H*GM+:LWB&GT
M>!;PD5OMX#"!, N?V7IWT^?831-6Q'+EZ=Y_AF)0N! =UGG=AT]C?,<.0FV2
M9D[GP#OAWS9(4)\*GR>>.V%R$-,XIA"=]<E7W7&87Q*YY"A#IZ)C'.W4LZ;R
M^XOF!?>&HYQ&D:^>"T*:\R.?,6&%%_!*W!]H%*$M)9JF LJ409E-A]N;*4%B
M0_]A31RA!M%D*$YL1V2HEN:=$2']JE&9#C'*"7],\U"$O@5]WF71H:P17A/=
MP-CIZ P;-,-,:);<&(HQ7) "A/&/IDPK;,I"*2?JINM[J"!/(!VQ?*2KN<?%
M/!VEF9CM_!D=&FK*9,$59"FC6JL:["S5J':6S0)?38\NHNF'/4?O($M2A&=8
M5]NZU:Y&\/K%&L9I5KC$#".Z &055IO.HO5\&5R"2M-=#%Q LF3A8L/BLR)G
M"(CQP0WGC\:*BMYH.ZP%_*HDP(MW<)GZ1Y8+^_!R71OB7A>(G"7O!'.J[8%)
M)QI:DE92T.K?KAO7>Z,A" *#7*E/3N=A>,9<T)[8C1G[F9G:-N\"6$8WN.VX
MOH&L-  ]'Q[H>1" G@'H&0JXGE !EVDK>P3_^/%C\HGZ2DHI5W#GMY>1R+"^
M8LI^6&I:_/K=KTV'ZU4*#]V7VOR!",ZUS3@20(/7"B\6RB*LWJS3'L>W%HG0
MOB];:S&;69\3#/7&:"^)A4,^D-3B>$3IXY1XXXV7V?9YX/<5>EY@N9 O9S!M
MB28Q$7L*P\L2K%W!9W24MDAC$JQ-Y71L0OU5*5J F13C(;GY8+\!A,]8SPB#
MG']D2/[[\CM2A<0-Q&DS*S8"V0"MR/Y"UPUF6S#O)UMCVBP7^Q\3];!S#?8(
M6-_<K=16'TZ[+#)+)2KSG%%OS<[ D&YOD%-M< 3CUV2D"57QXD8[;=&]AKL)
M'5\>EF[4:#SW:J6PN*?6RC5^!]&%';%.,6!M5R7K:6/^;F!@!3O(@ N8+[H]
M)>^FFU5#&@K4@'.EV'V^;:#C0N)1EF/+RIBR:R)!B8>&FB1C*;H6KY_W-1&'
MC\Z<Z6Z LZY+G2*R*%&G'Q5X*C!!W&C='QF./+5OH,-#A^^AI]"23<F)8)R&
M0B=I3FTUV&D##8-5Y)42[2%"*]Z0@'T?8("7:?4I.N46';HQ#<C OO2GN:3.
MMY=^EXYC3<TKB"C#Z,EXXZ&IC$"6-Z2J?;DK2TYLO9^7%GKR$_PW$:(T784%
MP6)Z*A;3K]BH!-7%;X,K+;<*]4H6G>4C!/Y]3#ZCI5UAEHRNP;MSP <#ZU$X
MFBRV"F]6JG)MJ#\[;M%\=6,GLK$I;VP-&SOJV-BNB]_$OBRFC2/W]ND2P-VA
MB.N$U,A0P?B>]3)L8YC.CIF>C*/ G$CWLVD4C"?$VMZ._K,5)1.$(JD2H,+Z
M)3"XDITI4^,CISFG_^%&$1!;Z31V?[8Z=EK_JIG/J5X]%^YO<['*-RDZGP@7
M-2S*NF'QO<Y]Y774,%/7DO)OKXQTAP;9M !=N@)'&+EHM8SV%L3B?,!HTJ8#
M:O&FLNW.0__H1>A[=Y^^=Z:89JR23+'_0@UN66(MAVRLRV_27#<N-YW/M:D/
M.@4^2.F85& O"0$\6EG$5L"AX]!K-,CJO605YIM%BK,(5MF#N#957;U& 'O#
MQK+SH9'1UZBS^Z#LG\&5,MGVHIS"+[AO' GO%'V3G H(,__3(,I!E.\ER@L8
M6U\ C(M%3?P+TW I 0ZQ=6-%5H-$LD#Q7IEZ<Y1'S,177.P'Q\#\E!*F:^PJ
M-(6R=$[LE%FJ775S=,!B]'JAUYRE?Q:D/TC__:2?8J\2.A(:>S -=$*?HURC
MI1M 1+?'VL1C\*N2,LA?D+_[-7M./B^2I2H=Q$BKMP#,JJ_NK2Y^G%.+6:VA
MI;*.VMXTF0I&01#++U.+"($E\*I7Q]N9?9'@NWA;2D>G$83)Q4#4NRT:-A4V
M6Q8J0!TM[FS.L;NOHTS'Q9B+BBO]V-97#P_]Y[5K@%:_[CPYG))P2A[ >+#'
MI#/6:-.)%48UQI@\EA050P"Q,">.9FH\I4S<B"BT.4*K$[6(+YR6Y%@BO[*D
M&IWT;1#E(,I?K/"%=7L3I=]N;VCHP^';FN#;K2K#@X#.G *!K46T+251?UC$
MW"+:TD&&3NZIQ-EYYSGM<22:7EP $?I4"2Y<4"(.83WS"U'N/IRG<)X>^CQU
MDDVU2!E\%V"*F)82$WB(3"#"CXJ/5MNRV3U\[EDV&$\)(AQ$^#XBK, SK8G>
MFG0XPE)04<)V_$NQ6L^*?-KGFBI#ZB!%%[;[7?1;CO$]?B<1='? /@(,X!%@
M "N):*_S!&J,V"#UX@A1746)66H,NF)&+8L^(CBS@3\QT)UO>/C)O,FX*LP6
MZO#C\*=_-&/FW</_2,;S-,>NS-PMADIF%LC>KC%<5-,52_Y;BPS5QYARK[&F
MEV+ 8"MJPK@MW4A2()0,"T/< ':%K,LB(:M;LN_RJ06)K> =5@K#5O+Z)H.O
M*7&\+@-W 5#P&JYF_/N[07,H71\X?%>6W,  =%)><E5Q-$TG=>SRYFW\1%4]
M<QL9W&].,@K03TRUV__^WW1;:[T(,JDJ=EL8"*=F8GMI)1G(4\ZRA8(V;^:<
M8?!N31-4<)8(_[;W_ ?O5SZ"A9Y/K734V,DP6PHER6A(02LC46U*Y)DNJOI5
M(4-2J1BG*MW)Z7U$1U6[64-^)&W93GI]V^);&Z(2$'%#IY(U2!PH[$-ET\-7
M-AV&RJ90V10,ML>GL <;A]4]F3D<S; X_'4<%]&.)@.B2Y<);[@-CGMER)U$
MX,3Z3B0:Q!(M-VE,3W?]67@.&V/K8DF$&!57.?@#6_ '_J$XX\WR,-:DI<PY
M;FJI<2_+!CDJ*EL_?79Y)4S.:]DGJ+8[&F'UC"+&S4H#]@RY&S[)$#Q0^85V
M^0E3BI4K5<V,;R)]7C6+L< U@IAMK,21</N\&T/[A&QC8,8EC#Q&G@LDG^[@
MEPQB]QC]UZCJ"R%!2\KJ8716ZJHLG0SCLQV(T1W0V0S[[N@-J0UGK^,N2XGS
M(G(P\Z4NS*,OMP;4^3N28P,,1\(((B+)#>5 PP G<CT9#R6^B'ZJZ?3;]PU\
MSR Z25IOUD3V..H.S8ID=/03F1">#^3PV7!BV/$S:DI+S8Z4+X2J)Q]I#(X5
M)V=U.U&+)G^(@H)P*K=#"]I4)KJ!+,&2:6_#_W6*G<H8G)X*5-2Z!AJ05IL?
MX%!#$&+6]XI94WTO44 AQE]BU7C'Z!AT?P@ZI/J"S-U/YMP@7[1C8JMBX&CE
MU[9LW!]MK!B?V<?)W8VOXSH I&2CDAESJ7=]YQDZ8T7IQ.E=(JW58Q$+GVK"
M# 8<FY<XYEL,XZ<<>STNLF8^3!,_W>]9&+]YL5QS(C>>?#BAX83>]U:06AWN
M326RE59NUFBM"+*OFTFC ^X5VY0C]1K$/4AED,K[W1M4+H;-/W;V-#NU(X84
MD:#@B4$S+<ITCOG8J@%/CM-9S%;!F2F;6)4&EQS@PY<DY(@2B)9H)NQK-%*%
M"?3P.4RP4R]U'RYDJR"NT&:(9<%$F316(S^;QJ_!+-6^S$4H_I/H&O9PS,U_
M)!@(JSE2NN5*]Q7!PPH-/YX\%_9'-Y1B]^^=K34/!!!?W;GO["79ERN@DRC>
M?ZF$(4'J3+7W[[!\SE62"X.Q!T8[>/%R)Q%=X*3<!]%1537S=>T,JR+2@$_J
M5[3"[6!C;"9TC,Q#4[1P&2U'Z"2XK1O=>;,S/GVT\FC;UT@3'=/]/TRJU,CR
M^GY7PJ/:1L9VS9,&+S35,]7Y2DT):UYIJ)N\USJ-+1AR0ZJ_=W(Z7 A*-BW&
M=YH7C9E3/9:+^6[/<@8[Z 44(8LSW#)U0KR\5,VD^QH73G<INU+4=M(?R\KB
MK1V+H3[;:!T(L]D^'9OLNK3W6I%ICEG;%J%D9/2,PF4?Z0CW:KPI@I+,\\8:
MR)?47B/2=$3(GDZ!V2CN2XD9Y'1S$*NP<4B*EWMM;F6ON,KWIZ)L;5>'L*]?
M_Q N_HHW2@_ACNQ/Q2S]3M>[9)4+?J.*@EZ]:>\ J_HUFX]W!>!)A?\_Q\I(
MORF /@8CI/BO;Y 'F_0P?Q517#@)(W(Z.=.K5N]T4[B:1P=U1+GIYE'(<+W)
MHG'3(/J^-W/-7+XA3K=[]1"*:8ZFWP=L;?_JM2O54M2H>;NGBZS]V)X1?9>E
M2LI!]/[NDZE<1%X_Y%!'Y%S4(Q?G.N &)[Z,M@D,T0HBHB3'J%\7I6+]BJY2
MR5W%/I):'&.QER4@U*/$I595*R)!/ A\(P8_Z,G[06>6N!%L&6*NI83L.'J3
MC#XUB^@?<$^*W ?79XMYS5N<#>-IL-^S8M+=W].).>F^<E%B39"Y)]==$?TV
M3D2=U&UG",3/8UP%%&"2<^]?;&%4X5_P$^$5[O7XN'^\=%70OTVNP?@V['UP
MPSC4RPC;*283,!Z%O1898(NE0DUWY3Y$VGD06]S$-'YF]\'A.FVAB?@*CODV
M98]FDJ0ED2&H&B-*#=?VP06G&]Z5PAE-5'SX"T."-TF01,^^ >>BR65XXT%&
M.$\"@@7?:-)J!O\=^D $M/2#HZ6?![1T0$N'F_[QT=(.YX)<:RYAGH#H.B]G
MA#*-HW0.=P*6/U+CTTDA3:$Z[\\Z0J9NN&FHKY@J47-$.T-J2T9)%[JQGIE(
M2$'\?4ZC66&PGQCR>_=V3^H:QYHXE4;8\T#B,'#W-Z4E[D<OR0*NU]@/+M!;
MD[?4Y"UQ'P9[-V-.D$,N'=$Z 0MX9<@#L(AZG*P#L7UWAL_$4K"3FE,ZS(DM
M;N9IT^ZVOK#>W^XWK-AO[;0U;,/@V)8DKJEXT^&"/)DKUT2"W4&AY2Y_N+RV
MA:-#"-\MG5WQ.(J_M8-R]/E\X90%P.@HBAK"8U\G/";,S(Y_[YN_KL<X9(_Q
MQGJ,=P _P].D168Z=B-PJSU*[](C]<WJD$SNA:IJ8SB"-_C+N(>0&S6K*8F=
M@,I"(UN04"4MB81;>LX'U>ER>TQ5F=0#'PIIY:Q7MF/]X#GHLYS"BO,(_M&C
MH%Y9\E7BZ38Y;SA+FG$']TU*,O6$^D;F=+$C:E>NH5@=8%]:P%05ZYS(QNMU
MKQDS=(W=**<9*76CJ'4#FUZ)7BB0+G*ITCFW>Y$>J3 0F19&*MF[8QYQXDRW
M8+2.G>/<CR$V1^)F]M4P6GICX'2@UU'I4KR/<YL=A\12BA:=J]WEAL>(T*!.
M-[(%8SDE<D&[QQA!]=SL40NXZ9=AEV"54%V<9*W1F2?$4>>5[Q[#AQ*U&%G\
M(.-$YMP>I4?(> ]A&B,U;G078.Z98WKMNL]ASUMN2^Q 7'=M$ :NB8]_3$=?
MYWZ4K!M#_6E[8C%8< ^=]D-XF1.0W/#7\YA"'=A6+JLO[ K2YD&XI5E!NWYK
MC04E)0,28/<.FG/;"86#W *,<M#]4B49/G,+OVQ?H*2*S2D;J4'T5B371*%&
M1!5_I]X71;0L&BW&9(*IS]Q6%F]+6Q($WRI-5 PN%BS4I\X6_/&$F_%$7A]9
M"45Z/9H^Y<5-IL93I=M]E44VB/X'QM!2*O3"V_*VPG=0;[*/A!OF^7;/!!2\
M8A(/HP7<58131'VSK?)??9W -E$(TDG-VH.N@TX$LT$J"\-$3,D>B;5WWGU?
M*/J&I:+K)7=_G)F^JQIQB;R.N7W)@] HZ<DT2CI:+,HDK9CCY&U:511(K.30
M1I?$/!>20%N[X3ZT0 5O?SE^W^HVK76LVVLZ,=LH7(&PFV.]FT8#RV==ZM1T
M/33= +UV?<?@AE$K<-/Q<6-(2SCL3^:P7VI'X/?"0 ?"H=Y.5[-D,DG))+Q6
M$FI%MVZ>_,$ =C'4\)-*G%IL6$F16BJ*\OS%#HQR]$'Z;FI'UC2G[\S7ML*V
M"W08U:W/'D1'0^(X8 X.C/]0*Z0U4!6:D<B:]4_)Q!1*!ZU1BE[\M7U_D-;M
M2"OWF$4Q\;85KX&.)-,&RH?>/\9,.YG<?R63&$M4X(5PF1DL5)&/J<H'^?DT
M()JE,\G6M&AT)73,3["8TW5=8M']L6$ _WI;]QX693XV("\8<<"_Z(_9.#XO
M!M&>=O?TE_7Y7&F#&X1["\)]+-BZU2;$W%)E6BI6B:2CR4U;U\?Y)C<;.L?H
MTP3N_7(S.;U2Z@'[XA[AP+F)<ZO[+1]E7=SE],J]:A88R8_L3]<TQI52)^R.
MN_?\8(/VN'1MM?L$!Q'?@HC_EG/UIPGGIT+=CXJ*8U6<-I6+W/"V2'D=9@%-
M*!7[M%#39&F-_AF-DM*>$#D=I5K /]#;H.-@#!CU68V:FN%.\M.J4^KO;LR>
M7ERVY/7.=T60QL?!.O2#J[K0#U\:U'UWPIKYS<71Y=OHXC1Z>W9Y<OSQXO(J
M@G]>_/KKR?G;J^@H^OWBXXF6/1 >+37X^\N3WT\NKTZBJX\7QW\7[?CA_=E'
M_M</EQ<?+JZ.WK?C68&:-(#M'@QL]R* [;Y?L%T2I6/8\%>O7A["*'$(-GQV
ME\=_D^&S+HVR8?1L$Y6R-G[VXU&6'2>+ZK8KY[:%H!$PO!N^\5>PK%4Y2BKT
M;O7M$9U?#*+##CL<+Z"+T].SXY/+Z.2_CW][_^'HX]G%>:1_&+(H3SZP^@OG
M?4-(=6M.3JN9S/[.\-G.SWYA"Z9.HAO,Z<XYSVY+ H^::5/5\N,XVM_=WZ<P
MJ*X:P6*^)EN8[+*NR#-U)/"WM^!FWS -L27.CW;PS9V=__PQ'NDTBYBA"#%U
M"D]BJ2V1+U58[:$$I5F0V][D&#9&)[M[(!C*DDDH0>+HT<=4:"IA,@D3I*4-
MBL7<E)#<0:SX,T@D_#/NXFAFFETTNCJ0''VS4)JFV5T.>;V[MG;R'R6:(%0Q
MEO_63L(L/D&&-AE55BR3K(;%I*H:#,S,TXJY8!B $4V+@NIUZIEAXTWSZR*[
M=OQC6 +X&48FFU'-6#N$,J!#?)T6F1$2V 5"VO522M/FR2+ 69=*702@,8C-
MK+A C ;1.8(?:"EJ?WWLJA 2:MW2@ Y*YQ4&ZALXN^B=%Z6!%>-QUJOFB$]L
M&F?3.#EKP0\*3O.66%#61:V'*DL5UN1Q."=7(U552+>$R$9!7\(_:\'+(@6[
MEA")"DZ0:*JJ6:_45(Z7UA*]P88L5%<]YHQO4M<(R)5*-3K?,-2H3C+X*>@M
M@9HZ+T0V)2SEAH&J'%-?12E )S.'070TPKH[D(]-XO1FQH:.>Z'S7:3I2#NZ
M6MN=,Z*S$"?O0 2'JF($5@G_8J.[](VZ"G'Y[</01\7"I$$-&@&M:7T!,XB4
M$Z=W "ET7#N$ Z5*%8+6/4#X/3K*<_69K_8S4Y1?W!8D#Z+U!)3INA1@A_!0
MYH_U;CNEYVH-FQ.DYQBP.JJL2@CEDE&M\YRBU.9*<6F%8'QLAM'O_G2>5./D
MGQ+5/JL0,C123G*2SH2M@;XBAHJS'&E6*_L]4_BS/E-U9JU%Q"G6B!\RY6!^
MP)VEW> 05K)L&R5DR3YEYLI,$5X7>Z@2QGL(;Y6L< =BB5I#F)U<E"F7%WET
M(+DP8Z*5-DDSK@Z1<A(PV/%^*TD/7=5.U93Y#V-L4Q.(VV4EJ9R[M:-W^/[A
M_LYHU6\),*HG[.U?PB%"'T+7,>J3$MS_)Z/3QZI*,2^)UNM<.\YM(V$.EBR3
M4=B.>UUM7*9(7,IE)]@9 Q%:4H!J\Z2,TTS((A=(O0X[<"L:)"%"703_'(#$
M.*JI.TP0F0A!;)4.6N8S3Z5LX/S;5:&1]/CU\R)GU3=.YK!=1#51C%)"$M!*
ML(MM:PI<US^.ADW-IKGC!8Q3[<+K-CU)YWC-1FJ#?8#A>.D?A<Z!6\JUR'#7
MTLE$$!M2JCJFIMSPWA&.:5C";N&&F>:&[ 33"-FAMNGQH0WWX'Y.C*NL$7=.
M8$3_R:'N=STK4E=X8V&<@>]$<J3%=29FI8VB0ARW&A<+ 7+H1IU>GR';&D9S
M@GD\)W;?N9DI/T%*&9!/9&KK.&!2TNYH5* _1#17P0?:>F,3+'8W;=(H*(/V
M&IT_NYVVG,35:'$[1A1B:$\VAK9YN./;#?#$TD#J"X(\KC?!V\\;N3[<0]>P
MQ^+D3;[_RFWIX/C!XT;!AG]"-GPHA7C:I1 >Y\PZZKG^4H8+N2A.'$7QB*4,
M% )""A4)"H :XGJ.AP$\'OUR='9^];$#]+AVGH$:+J#5'ARM]G- JWV_:+5P
M/W['Q5?K[]2SB5-SHBN?7/JVB3AW)<508TU>H6-O-89S$L=27_<Z"K15M5"'
M\Z7+$9Q;?^DD;T)H(]2D;+<F92-S+4CC=UZ3T@$)#N4HP<#?DH'_,ACXWZ^!
M;\M1GH=RE#]S.<KSGG(4?5M%)^_AGZ$8Y9L*;8=BE*>&1K$I7<G>4RB;&-CG
M"AEP*P;94:Z,LO &>X)@-K^;H@:P8,B:;<PEL@K>GETC[DMFA04_"[.$I5(L
M%=B\\AC_11"L_G^=T;N\OYS%/$09/KZ(DL?T-)2%:X'+3*?2-@S>U1-61QIX
M YG%Z3).PGDT959YG(2,U--($*B U+K57T-KZ]#:^CZMK5&T7,EV43,@:?^5
MH"B<9LL\CZ/W,.TD^@6)]N+HU\'; 9_!G.ACWA77BO\:2^]V/KK<.?7S AZ+
M(%_OD"9YC@@B#?I%M)#+2,,@8:*=3G,L4GO^.HAY$/.'$',KYW@M7!:@:>OH
M1#A=P?FX012V%>,'E>(7K_'<!$D.DOP@DNR+\G\EHV(8_9KTV!K_4 GXR2:'
M_T@2?ABBN-O(*>@4%>V:W[]9<=E8(@:I $?66,<Q9:6L).6,0>.?Z^ZT"L:9
M2I=!^D]..%%.*\IA<^YBYNJ2GUN$2W(>*[V2L.T"/H5%-@!TMY6<7>>#&6BF
M*5)U^E#:WDG6Q*QFB32FP=['F"&#7\*&WQ3P1Z'/X[^H7%I?,EL__&U*;=.Q
MXQ=F4ZLB:_0)N$74!]Z0DZPJ_'%[/_?+Y*BMR9Q*WNC5A(U-&@31<[JV"]K5
M(J,U'<A@EGW=D6=I.=9(*X<:EWJL"+]UNP&[[D_,H##X+/<(LFDPTE^;#QR=
M7EFQ%FB56QF /KA.1N".+Y&:]E;]80OT$O,[&%N3T; )5(Q 95V#I_MN(]O$
M)NI)EG\"JLC9^&[X'")1[<;16ACRBJ HGD! ".'3>3%/<X(ZW&:S."8+G3@C
MN=1.J,\8$@W$)9B(AK:7S"#ZM11;?S-+R:]+2)R7P&G!R5"[C+PV[=[@+0U=
MDQ@*4CQ0>[E.]-5)@)&[CF6HL+$'ED%PM@3[:^ -+9V#Z8UNBR^N%?V<VM9,
M>&KTM4UMLU*LZN(=47 F]<4N%:SK=&DX3=LY3;Y1) UC",=$(&%OO[$ I8U#
M<C!(<2<HPTBGE@(/<O)6?WJBSYZ!$I%Q2/J8&81S#?]MX!1D4A6"S75< U4&
M!J),MZ?^DKB5&UP(QB;%[M6Y2+# MOI>Q[P_'4%F&8TA AY$IQ16U=7F^N<R
MS"$5/@H&Y]8Q2LB;#-OTLPGK8H7F--=0KXNR^92X=^AQ4F;1VV0^_ 1"\2F-
MHP]8UQV]2TH851R]3VY*[,T3_3U3^-]7"4A-/6,]\O<F^Y24.?SH&/:PA&7X
MV)1@")"V^GL)@\'R\#=@>H$IE&4KJRV:KA4*!$.;M0(U,<?!2V4GV>)ZZZ@W
MN_VA/#IVN*<2)Z1=5&+RVU4.52-/.+46JD:^GN.E]3)>VWTV#S;NA']5Z;5T
MMYP7H'FZFFKLD-^#-8AB1BVRIDRPX.^9X^Z+D?(_TB=-I43C04;W8P(&]51A
M1@_SFG^<?7SW[N+]V]:[J!\:S49K,OWJ0?0/W?&25^]Q>GWT7ZO!L/H>P>:N
M3_XE1EF0GH#I?EQ,]X-):O1..R[BL^@'I,;#-6YT47*742RX9\?!-+;N\+-]
MUU=?:M;W;4^#N\:ONL-)M6$7'3'HP^$+$':&L!L8X?G%KV?G)R?1^=&O)V^C
ML_-H/<AP V1[*%T-R/;[(=M?!61[0+:_>ODB(-O_S,CV%SW(]J/?WI[AG7-Y
M]/'L].PX=%KXQB)P =R^]>Q+?QZ1,>?L6B35IQ4&) J5)W4Z6>J42P'>(#/6
MR9^:<5H3GPOR,VV2"?=:"C#WDO\,W5, ?_7W#[_^$KU__V'%A\&I+Q3-'WS*
M*1+J85AWT0RS=$3.*&9O,&^?EG/C+4W2:@2S)RR.8F::MVI$"0W6, ?<3.(P
MUH@*P1)\*-.1N@'?J)P5X+8=%^BV5C2RM/(R"T.S3(Z7MO%[N_)>E O"**99
M#$S8DK\X_L)UJ5),P>SO[KX(/M\VX4?M4Y,R57)&@),%YMO0V"(.1W;P8<.V
M*?X#)I(6QDZ3:14ZB!9;$\KZ QU4)YAR-ZJYJAGB4NI\9^6&1<S08+BKF6A<
M&U)QR$TOU/(<GQ$F0$T?BQE7@CNL/F-<\+IH3<GD%%I5QE;]MO>=%"\G@%-<
MZ9N9H@0%92B)QD\/7A 60L_1/3\DTJ*9Z!1YUSMCQ)4POLC2<E/XAY9V]?$8
MCYI,%"54[R9V@L$BYEP8PABNGK'=,*16%!R<L (.#:C*(^D+O1V^MMXZLF%;
M1@:VI*YU_\E7UP&8:"]M7@G6V6V*1-3.GQ2">W3/!;P89Q1 K3!8:]FAX>Q5
M!8/^"M&>ED9N42+_<?3/!L2(<ON4)MN@<7=P&)Z,PQ!2]D^=Z'$=N>,*A%<2
MA7!A8WP(GE5K'+96&\CG3ADF/.VK^:+/R[6*I8]*\@BO07C@I7O7=W-)/@%"
MR+6C?:1<_OH5"D?N.TSGMS&6042^MHA\USG[('XA:[U!UGIMBB#&?_O][.W)
M6_CNT4?XK[/CDW\<?3RY?'?QVQ6\X>+#";P+/9NSJ^CDOS_ R_&[%]$;>/*'
M#Q=GY_C?\$IZU^G9U?'1^^A_3HXN(QC9V?DOT=N3XY-?WYQH >Z^GK]PF2*_
MIO8+GV:BCV>G-*E?3RY_.;G$^<."?WA_ A,.7'4AH_]8&?U7NR&C'S+ZKU[M
MAXS^-C/Z=[LCO.3\SWWWSA90 AVX@(>Y!?'FNX+#\??HP_NC@"GXAD*$ 5/P
MC6$*O!XO6#F(A'%ELE!-G8ZJ&!O=#M@BE0:Y.6H[C$)^R& '7 2!\RW\S( '
MA.'#5.U)1$.7[(V=WK!2MT>D=:W'<1L_ITOP;6E)'8[SZ730GKL#G8ZGS_PG
M'=SM27>@Y]' !QV91=!Z1Q+8M AHKU2KG;+?-#@OHDE34FX3NT>.+9Q]"DK>
MMM:5!^_2(X-'OZ68XZ(IL1.S/@\=.\M=Z^88%,+@,YXB1"O0*TW R714DY:>
M2$II>[KU1ZKUUW4HTN][Z73JI!KPK(;EMR6XK6KFSB2Q1*W@*4QJ"9_T#&4(
M-L;8AD3G"Y57MLFF- %7)1HEB >XZU-8QQ1TP*C$L6?%L5RYIZV?SHXGUTF:
MD06_C=5&E(2MD*9:DR'6[=>H^ UFA?LM2BX6A 6;)H)T)25H]71!#\(V?XLZ
MG2-KBE2W3-(Z<7XZ+8N;>M:[O_6,>CABI3E?"0(HX):TJ[U_>\O=IP7V<3=L
M,:!(/SF14D2[N"+=GD0]<PY,[SN\)'/G_9(0^ZE!Z) V-!12M%0P)VF@2_H5
M[UH22.'1V9%[\.KHLM*77XQ;4I<IY>3IIZM_B3#5;G]^>?6;\W,6](T/BJAT
MEA]]4P^+O$&^UQUP]S.6=VPAJ8%_]!/]QI" ?\+6]172;I3+'ET5C.ZM7M43
MP^LQ5M6H3!=NDJ?CXN86OS4W,F>;6"-*^;Q6T3]!V1-H#--"J!/P ,-UL]08
M7_,#'&O/NV($<Q4+DA*FN$-[L*ZQXSBA5#TA/*OAE:,N,4SIDZZ] J<CS]5G
M80@Q1'Q%I-O,?EY:N) '8&3ZCZ:<:NZ/9-R]7/[T@U)ZPDKI5(W1Y4?/L)BK
MZ&/RV;:<'QG<0]!*V]9*>.JCRK\Q?AM<"7QU(KN6\J[5L&LUC(4K"L"Z@:.O
M"Z9[C7NRT5QKS.$,B=BL\)U)[XR3W:*# 1W#(4K%-&]!8VRT8%75_ 3_C2&0
MNB$3#Z'<,OUN]:L^SY*F8B8AF,ZX4/PUD+\24_M(*,FH*,R\9^H:+4)T!F36
M#77RM@O@32DM3>/L:)26HV:.5CH<"+8^]<C49\SH5^#!F=<C'+BI-'K 7X^"
MP$,\Y3B:@^6(KT:+G7J]]_L:O\DY- ( CT0I^:,ITVJ<CAA]K&W?=%+'D9*W
MJ,\CA#?L6$8I_$[99*IJ2<I83519BI08?XU%P.L3?KC[ZDC+Y'$Q5L_XU6:6
M#+U&MLZU$@M?'D1OA/C+]9?<]29(-1QU6"'<4$]@A?Q,_"O9-N2QP:<GX^NT
M0E;. AY3YGKB^%$ZIVD;'TR$O3."X@I]QT5VL&4%Z%[K?_:+[$[&C5QG-L#)
MVW;!CE^XQK9VC<F*WWZ:- >E<$E9A[?ELK,5C-JHDO(Y@:;BI4'GUU=.^_NN
M;KI%L1J;7=O!G2]'L[=] V&4GJLOW.$,HO,"=0SI5-%UU)=]5$QS8C\67X#?
MH)3&X%)QAV[XSLX(K2#S\.:W/!3#'B"F:4[7I56Q$I"LO+<XKZ": U7B#3%&
M!5O/*";4>A=N%$AI)8/%_\'G$&UH5F-)#^W;/,W3>3/W7CR(!&B'>ZS8JI'(
M!5R4O/J$FL-0O,3%))@1$X$@.6=#7#<%EE'LKYTI^Z%EB+(BG_81*:MR;@*)
M0I \Q3B@,"'/L> F4C@@;33!Q:F8,7TG?2:W+F+]^*OPW(R6WF \JX0Y6/GZ
M<^9CH(--.9J1C:&!WM?PQ9W4?;K>#3".TA':9ZDM?N1?#:*CJ'?IHF(T:I K
M77/QV$]@Z3U>;7XGEK#!GJ!"\ PTB9^5SF]@Q;GBS7[;C!9_IA,:>IO7#-*%
MN].6YNM6?)+ M0YZYA,<N.LD:^2<8-Q0+V2^.AP<_ ZL T[@6=2[<\SU(UOG
M#?(^FV.R,?H$(<=E^UP6GA##?J)!/F;0L!9+7/FB\LZX$31WE/I]B2_5\G.3
M8S(G!LN!-MJ<MK ZV[3B31B:0*=&@1F^M1X"G=EP(9Q>+[U /IT_[4:'/'L'
M4_81!MI>VG5J%F?-+.26J<J\AZWZ[HD)*;T_N67W[-*>Y=[D( P"R4^ !#XX
M)' O0 *_7TA@\%.?JI]Z7N0V71!<U:_CJF[@JE%!M5SFQ@ SR>7DOIZEX!?T
MD\'^F3+TKNW2M"R<N+<+4K='U^/0K+&JN]R43NOZNNT#]!K%L0DW^X[;4'E%
MIJZ'CU85(@\P[^04H[+'[T<MR63DU5EGQ6UHGGZYH4F "41R"/;+7:/QO>4E
M1!Z?ND9G)7[D(DLN"5D2%/J34>BDP2G%M1#]?75T*0F*CWXZ[!9%W*^'X8DM
M);Q)B&FM1N9*8_(>G39?+CO >A6-B2U1SS8C9XB/C6ZB;8R[<H-_0GWMSB[%
M3C%Y+E0]!O%F5E.V 64EZ.&GKH<O+3Y/5#)E]X(6WB++D:<ZW$XD30[_6SNF
MY63U^'N*S43@K"8F\*JOY?WLAA,8QL2-3D0-F]IE),%1(5-21XB6,@]$K,0A
M3^>!"-<E; RV?\.YQ'=,'_0J>=_8QD?;\HK54/0HJ6:1ICMC:V.'J4F>=2<-
MVM?;'/M:FU9AQ%/6E>I_>; SE-<Z236<(^,).B/<[MW(]Y>_ZPFE"*H& 6VW
M+EYRGTP /=U=O.%=UX[S K)X$D7O6QG#\I8B7 %SCIWWYZH8.U%_+<F>X/6+
MW5.Y.MV31TNV(@M=R4_G">%&_?9NU-\0\1Y'%Y3HI#_]^(8"!GS5QDZ9V1L&
MKX?;=VNWK]1P8HG ;:B!U8 65B_<MVJA<#$<4K2P>N_<UZVBEQ"_JZI)L\&G
M6N>7I-+Y75:1<?M+?JS1BZ[.V_ JUBEQO%.H6Z3<K.Z;Y%*AVP,'1F,D,*9\
M3,-_=-_*8@Z?XOW@+*UC <AJTOK)6Q ;"BL9KH8G?S6\96F1JC.0CA.BLD(-
M<.R 2(/ZWYKZ]VS4O1?[._,.\SU+YUB@0=K-VT&T?#N0N@9&AOZ:*JF T@,)
MD^(38(3 NT9H>,/YUF62FE@*(U#&NO_W/1[<'+M68UKDK/9Y<%&'>V\R^HEK
M_=AA]-^T$H)/-L3W&O7HE&[CUUJCA)?FJ!JMJJ3U= I3C\:(A0.K*4&6-83/
M\0U[*ZI>P\>(D<Z48\HSN-WWFA2"WLO,U*22'Y'6EN1[7% 4L<!5[N*(OEL]
M<*CL><*5/;B6)%1OP"*<I"$1L>U&[2/0$^#R2Q-MK!'!SMW82E#.'6\+ 90;
M[!U ]<K&X=<:2)0&:0.!3&M-)B=XTM0-%[K#,9]2RP.O3F)-%8_3=MTX 4>V
M"AG'6YF6B/H#?M=0V0F9H6#W!8<1W_"=N@IQ'= M<-\%H-O]@&[[ >@6@&[!
M_G@Z]D?H-Q#Z#3Q OP''6GFR708ZQOA(O06Z5B,<JM!1( A&Z".P_3X"0>A"
M]X#>[@$=%,"AG7T( #Q: . @! "^WP" );\_".3WWPCY_<L_*_G]R=6'#X'V
M_MN)5 7:^S\M[?V)Q@2(JR*UC:OT]WAFOY3SGL[]W8GNHRY^^OV?'Y"?_H[,
M].$$?!6Z>!(?PQ%_#9:1I22_%9:!G9RG>4(H^V98I>,4%HP(:>I91UMH7>2+
M,"T,^O+QT)S@R6C4S,',KNE%>5VFPX:"K5;.+991^+,[N+VI][1^DU! 48PK
M9OB))=,2?I1.LL'] Y?/Z[4M6H!Y]H15X="80GI.G$MG>2+MHD&OIQ#S7FF(
MRJH:C-VTFBE;7B%)?"+KU[EW;]/NP.GH[5O/?@?$S1.V(UH$WWA,@DWQ=%B]
MM7Y]-"IOT8O;Y.]^'_B[OV^=$_B[GZ;^(0K$(5SEDRY5M):_FPP6\G^FNI:'
MZCR6&H_,2#U456Z)NMAA%NS'ZLBP6C\&23=6:F)CG;7SP:*1A9.K'ZN%R@UW
MN*'9!N,548R:(YN*"1>F91 GT0Q'-#$\UVR86FO)K2N,_/VX"Y=XC(4H\!NN
M@_(J1<&YM$S?PDW:(MRN"G)G*S5J2F+VEK^#[X;IVI*QUGDBA9\XDY%S8@=P
ME$UA*&$"D'@3(> @I)O:O*CGV^;J0YBEL:E(8@)QL8S'*0A0*;*;:PIT3=H:
M_,DM:1]MX'1Y5E18K(,=IE*"L3[&&5S8QG\;N&)R5"RQ9NS(&);]F^-8F\(^
M#I%HTM+)!#<9Q!.NUI*+V#S-X00J-$Q(EY]X#ISH$%N"AL.C@R0:-&;G4XB<
MN]25>P3=+@%<QK9:*5D;SB?/G98,O:^$->YIJ&#/B(F>E)S^_0+$MJ!".'H-
MF5Y&KW<1N\CC2(FN/F@0_=;%%&NQY6WRF&0DR"MZO7NEF$?W5+3;^ZE5-(/:
M692VJ'7\3[]BDNL:O?O@9J;JF>85TS(*ZRKUD*GB1Z)"A>,"VES71,K,@Z)Y
M?$4C7 AV>V +*E/7:43)/P!4JE5'F4JJNDT^/2F+N7.VM/6!Q@?\"L7!,0/,
M0PP;M?DY_7!&5V5%6!J-)[1(QYU2M[C $\[('%&)?3)E>[FA5<+DRB[?MX>D
M=-B?V=GKX7Z&U79J@Q% Q,4?743CH-%L%?2&)<O.2NZD S7@XSM)RZKFYX^3
M94N)\6R?46V>&LNRM;C]=-!+ZX2BS4KR!4/6VTZKRH.HNL;@C7H]=_;*;MR'
M'UXS:0?5LC75XEXSE<JRRB^+Y$O-&OTB1SP&$9E%*L0N^CL]IUM8S5W6 5WL
MU-6E0-M&SKW:<S.VZOG["0^\*GMM1X_05JAOE)# W/$(>:?&/^7Z4O[R0U7-
MBK+>X##1[^Y][,0V(),I%V693Z6KJ>84\"R%F<I<E1_.[99\CY7$E#C:;=I\
M6S3=191ZUP/@V[$>RVQ;QM,.Y2)69;561S@]2))A<<U]+AP>BPJ^[6J?WN>D
MCAT;=V?S#%%:TM$V ;]P)_:-4&@9<)8/C[,\##C+)XVS?)-4Z>A'W),?3\MD
MKNZP)Z&8\JFF>0*9P]<U;PQ9@TW.D(E/US7=O=0,#6/\-1L['7"05E!$^"%\
M'@6*[2$("*U;EY[!!L\6R;(LLLREPC$@'7YW.QQY*\UJ:V2I3OYF2S+34A-.
M='@=5#*:>>;43HLVQ[+B5$Y*@&RHT*C^*2N;4+D=*K<?H'*;8?!/M6;;&]TC
M56O[*Q".4*C3#B(1*K2W6:$=Q"W49G?49GL5:J$J.T0+'RU:^#Q$"__<T4);
M>7T8*J^_D<KK5W_6RNM?3RY_.;F,X!+\<')^=?3Q[.(\%&)_.X&G4(B];>?H
M0U-B5PN*V?K4\8='QF7]/()1315_<#3BTH/+)E/ZJTE/P&1_3[9R9V118J8&
ME(Q8ZNBA/J$[U1]X&::$ 3&AEV1\G5:88>\J7^XEJ4_*$J?!D&%,J-, V+U3
MIF]!,9FD(ZHSU_3KIH+"@R&5"NMC=:R;8PZ$AL90=U;@3Q;.XI[5:BXHZMW]
MG=J2\K/I9!?^JF<-_J[##)II67I.2;"ORXF\7W69$T(1+1V=N>SP7D'[6U/'
MCC)ANS]<Z%64T?(#.W3__\,%POH/@]?Z4) C#AOY(5E*EQ-X]AN3@2EXX\YI
MXU9?V?*"'=!U3B9WM*=A[+>4MVQ(4D B3>B/7KJ"<;'@9]EZ%%C.(J.BZK\&
M/?=8>HX&0Y\\ME,NQ^_RY.KB_>\G;__:1>FP=W /2@>1YH_4".,!M%I/K].'
MU%\=UIQ18U^XS$8+/HS)>(LN[7G'?1KE_$F4ZD.<$NX!0Q'67N4;T\6+BA49
M5#Z "0^'"A5X0E;"8TJ8;VL\S+P=BP6,B;0:R$($0W=KANX;!TI!D7HLT-6;
M O*HJT]S;)R7.AT[AV  I@:"C(=DH WA$:$QI_@+O[!#6[8$RTA H*E&JAC"
MR#4\9)%8(@&MR^.5OQBD"7S=;?+6I]XMMP].1'_;)*;\?G%XO.HBULA8FS;3
MY 8@,J6:)N4X<[J4%TU-R%/=V$ZO(2YJ0'4\8><ZH#H"JF,-JL-[&_4)[49U
MB)IPV_L]79#'NL$^$N9C[?J$\Q8@($%"OK:$?->(D""- 3!R=\#(NL3:!OB1
M4&T6\"/WPX^\"/B1[P0_\O+G@!_9)GYD"U@/#W2RM]L1J::[Z>U_7?QV>0ZW
MT,< UOAVXDD!K/$5^%'(CILD:58)K8@BSL*H:C "G&+8Q_:2YAA+*WYSGE3C
MY)]"]WI688)OI(S%SR'HHZ:>%26Q"ERA^X+LHC"12GG!DY^$#N@2Z;@K3;%_
MM<C A;+/HQ$C3^""_J0X(?Y'T93YFO0Z\1T89K0)DW<SPP((PXM=0V-4Q8:6
MR*%31VMGE%)UDD-D@BY6^K579"#A-ML57/-),FV?T+_33&2=B MO70461_"%
MW\X1A2<@ ,&%W(YB2*)_-D79S#7OB@X"KQ&;6,I^V3=<(AEL[&-7-(%);ZBZ
M,]1LP\O(4-N*6Q-K6(H'VG\5"ID9,Q*=<$;+^SU^CET18$ZH'CB07"FL279H
MUU=FZ<>A%\4-ECK[2JA]H!IX:^:MJ1Z;'TH/":\G;*"$A->3T$9R6/AB^082
M82N7:W\N[,BYGY]L#JQKD(^4^^I<CW#D0LXK2$;(=3V!7-<=I) "S/][3$&V
M(([WBD)V2.,3R&1U11OCZ.PT.C\Y/KFZ.KK\GU /'?)9CY;/^CGDLYY:/FO[
M;:KW0I/J/UNJRRG@N(K>_'9U=@Z72<AB/?D@$9[NZU3=A/C0%ER2%SZZZ05M
MH"Z62*)A6L!88$8C:N0,=KOI<HOMSS@2#:[%**W04P'')!V!.\IF/K)1:A9Q
M=:VR8L%IDYPH+^?(!0[#_9=M"P#C4#4WNBB3!>:%,)&$3DD*/D,UP@L<B^$P
M[5$-P%]8>2]U$ZGT6^LDA;M>NOO0=Y#8WW9U*\31,CW,1C#7!!RQ,JVP;353
M>]:8N*GBJ*%.TU.5%_-T%*\)TLA7M#<.:SA'HG2.@'$'LS1'=<4SIZIF*E,9
M8\^$)3CO45G <N?([YE,\P('$R&-Z10S0(FT!,!-&JHL5==*DZ!2YP2L%)FS
MJS<J2JQ;RY9=>S2"L:M\1KFFVC;K)@)X;+T4XZ,HL"9KH M-*NXT7"+9*9:$
M)5D]&V&V8 0C#?S^7^' GN71T:),,\[![N_N[\>W=CEWF]$ET96$6+'Y=%K7
MBMM#8:,Y:L&%(H0Y'>*K?=^,4B;41>9_++FOX 8&Z03AD;:",;+A9PVEJNAV
M3H06-\VOB^Q:,EA2X:K;]B09->-# MN5 DP0)(6'4!?\PY>E9=^U;JF-9WE:
M<&AAGGQ.Y^F_J,V@0TC G0K<)O-79N27"B\=W5Q(SA<N D^7PJLE?0<;>F-^
M%?/7IHC3+H$W7U9V\)6\4=Z239J2YF&?X.K(]O359]1(N&JR#M208\QI,YFL
M6IVJS,+DLVD2";QI0AN)C,88/33Y>CL)GBF&A488K#*=Q?G/"![ YW&3.1P,
M-8C4?2-Y\KA7SEH$O;!]O7#AZ86#F/H*QP[G04+W>:G@XJA2(^"$US"BX)XT
M5BMQ=(J-JW1\^ZH9QDA5 A<7O\C^G03GHFP^)1%Y#!2X] @ZHJ-IJ>B^BKWJ
M=FI7Y;?]Y#R2W#XM9FMNXV$%[R:!X9:V*8DIMX3C@^(.^L(KV7:'T9X<YU=(
M6[&FH9;4. V:6<Q_Y%G*6>>C"LM[ \<1"TUO\+R9OIU+DTC3!ZMJP.8EO0AW
M]J+P>R5Y Z*>:Y71DB:)59!&RMPC%Z]YM,S>>W3O/'ES_26!SU?__.73IV2B
M23MZ;^ &LC:ITM54$S591R]) 2)5/"KX2X_I-@$AT'9;J8IRFN3:0+6$[&@4
MD2U%!J+'T7/PXN5.8ID8\-MGW%LV(TP.W@+4J!,^W'OU\@4WZYS3-(*"_"J&
MTSKN#4LI(RW.J"5@(=*GA6$DM=C2@XS<C6=$.Y.I:3):1K4:S?(B*Z9+?:14
MEBDJ0I=4##8E=BRF66'HC$BZ?U$Y&-@%F]WG1Q]&^]P2C-JB\6O9[KG#"TTA
M.Y_9J=)-58LAVGEMT\DD;K2MX*@C;$[P&6DB>+3%:-3 $LW1TX 9D/>1%F2J
M%-2\V2+MS(HCOXDX:O;AU"^6BOBOE>["S8" &6HZNE%808%T)UJ!F\Y,M#IL
M7&JKL=5^U=DC-JP$R&3&VSLT5JVYJED L#6B:3VQZ3/,#O#.VZ0>N*DC87#1
MO\ WC9)J9C6G*?^79P?U\74")<9&GS3,5['0C<F9,06&CI!2ZII'IKT&QXQ&
M#H>#<YH8-XK>^9  ';"739EP%^29P&): B0/FS1XV6+?9&RMCF"XO@-D/ )-
M++&J]M#&AU.=48_S'F/0J"RV@8JF=EJ,H)W&IZ[3-])P53+ZR"M)*TW 1>N0
MI?]LTK$Y!<3S$63\Z\IXIA+""F";&Q31<4HM+N$"D"L*OGGX<O]UM#,$KSD?
MPQV41;/E&'3D#$-Q8_7,7" V$(>^?UVB#SQ)A^"N9"(_.^*D'YUJMYR 8Q*1
MX\MC-"N+'"1KIM @1AP^'D+]RW>GUJ'7EVB*4394QN)P8[=S"COHQ\X*[2AC
M)*]>+A2?G!17+Z7NA""M93.5B"6>T&*4TF5-8YK1[BNT>16"9N%^Z8"E'FQ9
M9ETJK#][QN$^A&!WD^ C%MA31V!#PN)KZ:C-MXZR&I+2*.!X*\IJ9,N^;KB2
MDC"Q?%7W,:LFXQ++KZ8V\(\&X:(F8[1.IJ"EJIKU VSK.+I.JF*<@N20K4@V
M>:JO>)V $0V%RFI3K;FJ(3W-N)HW4&8YR%^ ISJ*LLGA$N98,-K*6IMIZT32
M!X(IXZ:L!-"MF5#+'4:B0<.B5$%GBU2*=O5J%\C=^)S.V7]XOON#-I3.*79S
M- ?AQT$0'5^#RY?0DR4JNQ#SN<*8 3P9/]&#QM9N(Z.KDZBBC$DDP@"^4U4'
M.^/K)1T=F=>"B$X4BGUT=+HJWN].-?O;J89.SHNJUM*&>3;B'\8L8C)"<L[9
MLI[-TR1FF[-L%JZC1:?%V#N\L!'_A+#J() #>"<K$FU\F/@B#H\BE_99?(PT
M5=RBF2_@V!3-=!8-LZ(@AQEQ[?2#83%>VG>C5SG .:.0PRMY1AA.(P>[!OV%
MYC49^?"QS52V,ZYH/9^2[4:IT9NBA&-&#OYR#@IJ+B'55"K*QE&95I_P5[.B
MH@[@.@:&WQK#1LP&T3'[\*X^XM0/WXZT4<Z@R!<BWP!1KI05X=.8YJ (P9N(
M*7N8<<!BC/RI9=&$9.+7-OA=,5I@MU/<77TN)\6HJ6RW>^]JZCJJZ MC =D?
M$F^;E.(*OCN-)>AEC>^\XWO:K#^Q#@&\ZA!N!Y0:>3P^(LFJPA9Y&#/>O_O@
M8*+,SB6HI6=E3':^.NQE@N\"D58Y82 JG+DM@)TEV40G,5VYEY#.;SE*OO#Q
M(KUJY5Q=%-B66E$;&YN D$IIRQA5#Q=V8):&?0\#DG#5(WSOW2F_%,<NB7L[
MA]" /$!H'QY"^S) :)\:A'9["-IP-3]>K=#F=S%&M717#.]7B\:@?/(D6U:I
MB3E_P(;4 AD:PB:FN0#D4DXFV6M>YSTIC*SCL6T3+XX^Y<5-CIF)7T[.3SZ>
M'?=XRD>GXB&+X4[7K!E<-2L089/#M9<)P*3R9YJOW*ZML9.QP38"+<&*C;#"
M^###-*R;0S*)J=.W1\[$+%#J0UG4!2C"Z @-@8I^I,V3JP]'QC[1BR<%JTST
M3B6V>C[.-ART9A)''RY/CL^NSB[.;UO+6"" 19-AIGVQ #_9J[8RRS=QT@6<
M4O=&L$BOBQJQD+WR@-X.E:M)3AS&!3/F9(2DLI # +Z%J7Z5CQ=%FM=.^Q8W
M<3]*%I0VJ0R#->56#3PRYC0>K7VIVZOK?4<7"1\R5MC07;MIQ/%=9/2:\EK7
M_=KTJL)4:,EH5L:6JK*B5XW M5%4JSS,K,?3<-X7"?S[8C_:J32Q'S31V,2C
MB">!+#%%#'_N>8:D>VT-YYQXP06U(FLP+)/QDEU9D>&;! W9JB$47X>5"4=%
M0BJG:E@VL",&)+AGA%-FZ)RPI,-VM 'P%02*+RRK0:;4#(2D!)$@=4*P-RI"
M9):5F=)? JFMM>TO_3.L/@/-AY'UEH-KQP[RL+][\$H&@2>[0G>;DK).;Z,*
MG%'$$Z^^$K%UE+<:%0U($IC8P0W=TEW7 C2W(SUTH.#B,>6LFJD --%<U0;C
MC7HAEF1JRI$4W'J*"\%&Y["O(TZW^V\X.67<I'=E)$-0$.(,PA>HMPLE6>NT
M;NI>)U#'AK0[=HL/2$B@&P4_3.A:^Z]D(>'-XUF:)[&3&NYW$V/'281%F39P
M8A'@V:MR"(>/JEBK'1]Z#_]5*;M&QM%4*9T/^)^T-%ZG%X9+(E"J2QV$<Y69
MK(;S7 '0J:JF>&]EK(L1*AQ0G+CD% ,OBSEM"PSDQ>X/@^A-?SB>NOC8-BG6
MDYZPB\QX=0FH-60X328]S\H2$$NS0H6Y8#B^5U(&='52PX:">DMZ%>?:<R3+
M*3DM*-N$,BAV%<Q0@GUYD?,V>Z->D570B2]WG[_&)1E$%PR+OL<EY;ZC*X[#
M\9@Q,TH1W0\/OY*HX4J<3\2#>VU@><6(<J/P>'H4+2=<7"7&(%G0\ (:,T(Z
MR3L"D7#$, Q9+P>,IY-;G>%,<)2;4NG HS48NF_S_MN?31,=CD1$4\[_2G4;
MH/I@C]4<$93E\K5LMV]C4-B)<AMTL8G-IR&H! (WY@2FDB(MI4YIR#UV< %Z
MK><G[OBTU1TNLZ]RF8F%PK0M1F$CS&9(?(')A!-M=)U8!<$:>=E].M=$5%OJ
MXLCHYW;^3Y/4M4L:0(!3E'8TU**DAC,SI.O.\3/&*0RSI*^##C3^(JII4[%@
M;A0'+K3:8._-^_^=/VGQ Q]:?OBC1A#^M6AJ5(?N9QAF_BOV:ULKKX<O;>!]
M>R+[XRTRZZF089-EJFXA*,PR2N.P%Z^[NNKM_WR/KGJW=-N3?_SJGXV6PT=Q
M>2&%(ITK.2KT-<92 (6%:J^#^ 7QNX_X778&(+A(M65KQ&L,#<(%?T8TY9WO
M^B"Z073OISD3BKKI0%1+<]+R$&FQC@RBX;\BU$'Z@O3=2_I.[)6-EJ(6.[),
M,Z)_U9Z>,6_[?''$D+0ZCY-CRA!WQB:CW>F$2H/8!K']\OM>@Z4XZL'4"'.)
MK5/Y(9<M9NDD&)A!X+Y X,"D9%(-<E:B80.B$:[>(%+W$ZG3HLFYBBK)UN'7
M)11ID>[2AUS'RS$1RFAP=2UQ>=!V!A&>=L:<@M0&J;V7U%[DII\U96A:D$>3
MLR JB!FB,VQ4J!N W)$T,4DU?@<F7>!'*/3T.EJ@$"W?5K1<,#AI+A6FG-Z1
M['Q1UI,B2XLV$J@[K\H0^)/?8B>OPGGB.3)Q87;.R;;FL!>CF9I3J$;X)RIX
M3N/1&"7T/1F/K=(QD70"-DPII8=IZ0H<'*R$Z2R]-S7HF.^J$9E?U:V2%X0P
M]$_PM04W3%*DWI<N\H(6$6@#A4'3RAUXVE[@&H& =4$H!_M06QJ98+H.24.P
MHSP<])H**G0RPN$GP[H9-S<P5)Q6E2XA6!ID4@2O!1*B'X<@%G.DATL$79FT
MH*R!"U9[TXTW88*JBK+O)-J560$:G'Z=+!Y3%M!WZ#VT.%+$[3]?ZB-:Z'%,
MZ,I$"]96\R:K4ZPE<I9%O[3BU:!889O\+A2'/OGB4&;=B':.WNSO[@FJSTW$
M'5_\?O;VQ[U7H09T:Y?&):)7AFF.Z<ES!6H3>76.0'V/B@2!ZLPH7RLXU;AS
M@LWDC33P3-G06 I#Y?LN'2+^7&L#C\:2?F#8VZPTK$(U2#AZS&XC,H/HC<;O
MH@4BMO9<C6!9TXIJV#2KDSL,T&ZDFK4E8\9JK'1*QQ*9TM'E5<\HCHO??]S7
MIC_\SU@1QZ6O\>0,X/W@S+O@]#7["P2-=3/6_D*0+D:9+9HJNDXQW2QTGJ+"
M8>PU%](GM\*393B;[8.M9-.%GQMMBKY])@72]6&8IZR95FQ_=W^7%CUPTH>"
MF@<OJ'D5"FI"04TP&K[8:/!DP2]V92'0_$=C@W=7>5EDF0[L=RA_1,X;8J5V
MO08LPRP:$]6@O:+@-D6X<"D7F[VB),CF7U6FC(=A@V3+D+-HB:3[[JTQ['AI
M,F-82'.-?$ZY #+'U,%T-,/K?$PN+O%<(WLMK"52MU)ZV-;[@#.*%1PZQJ=+
M.0A',R,<-"S1)H,!%Q?+><@403.'6&?!='B;+*.7'FZGC=6)9@H^2P-][#9,
MZ@OA)NLHWIF#E=:4#.B#780)@6U,.5=A!X;E["-1*0AICH!PIU@)<8?D]V-[
M9,4XF70^3#*2073%P1TLG5/$L06,U_0RKULQKHU5+;^^D8!/[Q@S5;KU-_ N
M>Y9U@?:-(BBW,6%O2U:W:GJ\5'4E2&\^E98?3H.?J0K'_P'.H1A6".@=FR'1
M@A@D)BS=4-4W2N7&/L['YE#U#+.8_(A'30]33AP.@(-FQ;J6A/054[4DZI#
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M)A]KF*O&.W 3Z0GW4AA)=^=KC/-B^AFC28@E'-:(G&U*,JACB0@:X!9Q_O?
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M%C/'CB%4=)SF8,))QY =X_GY+42>D9GI/!ZUC=LAD8(^Q.X) W6>XO2#>$;
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M+6E+.$KP4F\4 VR:6:55;69+2E953597NL_O6&$#^4CS"\?XQU+Q>D0'KW[
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M+XI;1S>)Y'S\TU7#DJJ:8662 AC98)[,[DYKBI=%M/,I+VYRG C%"Y_!I=.
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M3)I,;DN\PEDB**H077TX@BNN5,I"4C5RA($K&/E%^Q!V(%,QR,!NWVQY!)V
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M)C-/^BQ?('#;, )I8=R>0I"K3@R+T%_ :T'%6>_@!]B>67174M2YB^Z8'([
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M<VZ<]--ZPD=![]&JK5P)IEV8[%1NR<C,:"CU5%I/]$MUU*@\&+U9Q1X$&T[
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MC&X<@WKN;:%4I7>6KCJ41>_ ^PJ]%I[ZL=O,<BV\1I1K3B8W1!OO%U,G]T6
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MRJS$/90S$,&O\JA7L:VN:][6#F.QJA^*GV06(]KGDY8)) %4E)+\R8+6 -S
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M3*OB!MP(TAYG=?1?WI^\>1G8C*US!BQVI6>E<%,<^K%WL2V[;!W(D&,[7(
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M"A;HX"1ZG*=EH01I2F('1XI7(:TNLH [FMZJWR^E_)J>R;:9:BS6-_IAI+B
MPCVM'1(I4>-284C*KA5L*/MLRV+2NM3-D(W%\FX4G]/:Y%XZ&("&X;#[",$4
M#A5>%B[#%89@[=_N1C*B9-M8+A$RB4UO,B)K+9?@)W9YH!+HC9;6I',94'3\
MLCB6\<JBYU?N&:%]<=0PG.D<(!T== C91,ZAI19<[9\'\F9X7U4!(X)?T'6S
MH4+.,(<V'^"_WP'^M^*8'&.P2KP0-YMB9>;:K#[36$JR<_3*)L\,.BCMC* X
M) I-9^P%[,IWBC5>%DXRR_JL H4B?'O/C8B?2OQ2FC[I^A@1"XK2RG<'KAA"
M1G?+.2(TDO3AIBCWR[YI97?PN1R/4Y=O%P3WB3IB'O%%M&6.;)1.VJMH<,1X
M,Y88H2K?9\*,6YQ8-M%NBR4%;=/NZ(TXKJV73;[N0LB!^F(TT:='G%@*1O;
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M!XCQ<TG[G%R7\VU32#5LUH[]]Y"GL^Z\M\[3F[$T]P=JK"@0;597XN%^EX%
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ME=H[J\(#.Q7DY_H#'ZIR"/%*"4;O,#"0ISW@^;CZ_8^KWZH=5@%.*7#&T3(
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M.+ED6QUZ.I2 ]LP=NQAG;]L%9$]9)_;QV2/)(-9]%VA*]4/Y* ^+?\O]&+O
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MJ?JUROHS"-=J6NN5?',B:K/*2MVD0=<O=8>'#1P[@PNSG0IA(%+1DX=/? %
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M_99+"R7D 'T)FN.H2+L'1C1\W?QMHYJL5SV>Q7I)W8;AZ%\VL$F*TL8ZN6V
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MT8M7;R)BQ=$$\@&E_?HVPX%6D(NA&YU(K@3Q64$K#PW;J5>W*=@-A.?MSM3
M.Y3%?Z-1ND24B<1UU3.9%2>",2#AK[+F%/FK<C#1=_ WT%FQ_J+\,:_(9ET5
MW>1?3V%4R_4-Q<,&N##;EZ^XZG55MP?@.M+.W_H&8[LJ#]HO#%T^61]X)?0#
M)F2GK2&!;2EJ/I;[/2-0X?+#"-#20R6"[-FS@G9"I3*#_T7KEV(GK6\SOO'K
M;'&!]'K=5&6^."?KOU_2]Y\A4_#XR9__$C>!^]A@#+3ZMH6JPI!O@5Q]X)=2
M3^)7"M?B+D./$9(($=^9- ?<<7_.EO,>+.??M;:%TW :NF) B&A?5=#3(4Z
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MR:"&>QCVBR-EM_?;+K,Z(2^ 38^$DP;=.1/A:\B@;QI51NOY$T3Q4*DAOPT
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MY9%J#[OE;HQTLN:E[!ZDQTUDKBF6],8-@,0O")LTC"H0,ZFH1OU.XPY[G$4
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M7@CGP&F.C_^RP)CK>1OXNARU#S6]7"] 8(S75L5AZ=&_57%8!MDQ 5I#J!:
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MW:UP_(P\^6UQ"I]5#[1['LL1\+78LX^[!_?D;BM:+^V)D3.-"%*0@J7Z,.(
MO"*Z,<,[*(52:52L/DZ7JC^YP!YL([VX%^!_;2>!-S.4]<N"LC)=/E[=,].
M>AX[U!'7X 28T:WW9DY?LR7=J?QSV,]'T[Q!4P"+#^Q&C9.6TA7"JMA"(FZ!
MZWCT[9'!LW25)'Q<6G!90YJ#R6 >OH*+S@T9D>IVE3<-M-#A\>'>*Y -\!'/
M[A.%&JY #5M)1FE?Y.9,#)\C/.;@KE.97+KVH%#H<'^L4\%)X _<QY!E'[A9
MT5TIBP%-=7E S( 2YG6^8V^^5G<&:72=BA#B.';?]9524]4##WM;UT[UWHK<
MP; ^+VC;-8&I[J=B1Z[9NU([?$YVX]Z.=+YX^SJ+67X&Q:7G7<)"][4ZK')/
ME+P2-WQ8\'S.< Y 2IX\>O3XJR>/OGIQD<5*YZE/)P%. #ZLN7T*Y3/PA]%3
M7.7]SCS.H D>%]K45 3E]K+R9!01Z3";N-_?Q/T6$@< /B/ZYM@D\Y2 6D.2
MFE'NPC2G:\C<@TF%J55F0BSO GD'>K',X;DN4,#*+ P;<158EDSJYHQ"%!OG
MF[A - VY5=I(>\&M"/EH,-*&>!!*B,Z)6@]N)S[9TAETV5"A.<WN+603@%.Q
MXWQ31Q5J +!12?\KWR!0[%VP)B',T;FUJ84-]\M%FCL 11TV!*;D!4Q;*P!8
M"N60[Z"/GT2Z)9+=@Z<S_L1H7J5_S[0>+40T>R7N*GTS<QF-=0$)6H9=#48F
M5^/>/33LU5@7X+(\E)4V5GG\^,2]AB_#R#S(J\X%YI6\7I>]&?)4A)&?+<ZK
MH]>0"GSP(20JQ>!T]:K>!9!2 OYG/HTN23J<IM1HPQJ)7P,!=3/1)ZH/AO>)
M"9YXU7%+6J>HY@O@9K0]MV PL;,0N8'('MNP;T._!1F(5=)A4%;7(#/:2@X;
M7B:?P?6*[N#HJ(>/:$\EG1NQ$\(&;VFLX3.XE3J].8]RZ]G"WX.%/Q>;T@/W
M4RA_R+HW'2FA]TW9(\F5T.CT?,'DMM"@'8AJRT)G^UIM=T72);T)"Y_!J6,+
M;TTB.1=MFUR874?>(ZBF&E!A^\+-Q=N7;R(D_M>J& $OD[9@^6XDGAHNR<!I
MK1M4GZ/J'LHCHXF<_\ @*\:2[LIU'MA*E"NWC,T!81JT/X<1R/+O&@ GW@AF
M4\3P*-92YF#0,O9RHYWIX;HEL%BF>U9V1FAE1/O:,Q8-D2.A/3G%[CZA([ML
MV][Z&&P9",H6:A73QCL73M*33Q/RO7GZL>2=X"9T+=.S6Y7-JM_#F*^85!R.
M-Y<A=$74AY/: ;W)MYBV#!_=_CF%<48:U"8>B3]OA/HN$&*PF1]T=,(YQ&$8
M-+9)1T/9PPM2^!U@LQL]"[C.@;-FQ*>3^-I.NB?AXTSP\X9^VZ.,P%M@R C5
M]ON]ED,F'E1Q><&D_\:9):CHQ2>#.6H+[EID=^_$K,/_L_34R%><:$;C?<99
M*YI8;.]%N4=<P*+8$:FD2JZ<?=S"6]J1IV%Z?%.!T=?98 [$HQR&ZNE!?EWF
M.@8WE_)"R$),W>9;B?_K:EL+LE;:'^W@[X<.]NFXC">B*DSC/45(&:310N&E
MKY?(5S!N-=R_)NT]WP_:>V;2HQDJ]=FA4H]GJ-0,E9H=^-\?*A4I^;?6!.2:
M=?BD[(J#936$!8GC:F0ZPI&AF=]P":TXM].TN1PN/B@5D67H@ESK7*;I[%CL
M:3%P8Y<>:K7&D?;KC"YF5Z-#_;!364 D:HHFZ6IBMO1UW3@G?:*=XP7%PN25
M_DB^[L'7YEVC4G*4KFL>E)VV:-K5GB7<D 871F>II*H.GVX*<LTX#J=C&^HH
MC,6R9%/;EYWAMG#FA_88-*M4]/&J0!V'&Q#1>@BY&G9$\.VY3GY_6<_0+9>D
M/D/>2T/AS#7.Y3=,(1W*)S%)YD3 ?KRXY%__^/-E@/6T*6V6$FD@&>.2+Q-9
MN(37@Y$O29'B @HEI2"N?LH;T"W_*^3;6<6#]\AK'RFPEDXBBBV_^XF+3+]!
M-CPT+"(Z^1&%D+#=+H>%D(DR#&]C\5.YP8 "\6T96)9.54[F=?_[K_OG<;4Y
M[G.)#T>E& T77IVG+;).-@(6-1:T(OH*"6#$LGVE-G!!T=RNWO9%:(B-F*-T
M*":<NCCOPNT989') 08IE+;GUI8U@D!KZH<*$#AT5E"'8(1DOKZF=6K&%T==
M>2U2DWP&A PVAO<J//NEE:'2+1'*9#^]N@QI^]J2U9**7H<UC=^^B2,YYY$L
M_DXA+F8?0E9'>D (U7.>I>(\KV::N:HQ>HR8MLNXC@K$52)U*U)J0FXGNFO:
M@(LE%DO'9S:8"#U]Q2#/[GC0CJ$ /5NRSA0]$0N0:K^A^1D9WRDHFAD#_H/5
M5;%'\_IQ0)MOV3!5#!-J_8<9]\>'<%REJOBC]LNVZ]>!_^8@=HL&N"UWXK:P
M3AGGO,KVW8F,!(V$MA+6E^4E3#XDS <?\)TP#4&$IQ0IET$;() ZHBT%V)Z6
M\,^3$OZYR]3%<GZL]0R(PD,6;$;G_%N@<TZ\]AF4<Y_41@'((<E!!2)8IG,7
M2*R<&0EB'H?$]8FP R2=V3M?LE%9!?6[0%;*]Y(B,%NIQ:MSS;:]K4V) +^4
MXY2K;)+\2WDE?9E"4IILW&+E@0O@5E^IZ(+GEL/7V S"!PA+VFQ006';[W\1
M3HW9N[H/,L3:R)_P)EI@QD-K4&9+(J*U<M/*1NX7R\;P!<QQZU^CK_Y8.0?G
M-NMB!,?,?>HL8A"2[#9"T"'H2)R<5P%<]MK1ESQX\Q+<B4^^>OS]X^\>GOG#
M32ZVS\GA*\ VV-25.A"^X!0OBR/ZIX2]7_;=Z[@;!GP*KWYZ'8_--R&3WRXN
MM63U-L+BM;#CYZE.L74ML]8U,L+\'7IF.%'PY+&2^ZSS(^AAWH=H"[%@X)".
M7&-'3_KB(0/8?<(HJ,9')QC/,>^_>]A_OY+WU6]I?VE])F$UPUMP:I8"0BK2
M8*3LG#ASU/]$(B"-NU];U\1EJ*:'IJ#7EPEVD\RW==B\OI05"@:^<=5*>S]\
M/TT;H70,VPR,.WI3)]#+-?=TO?.6@*YS-8 VN@CN07&V/<MT8RXNR$]>Y]GB
MS0UM-=F[&0C#,UB;)#'8/G3/A$:W=@K*Y]%:4UI=(N%>%)&I:=64+.XD<DZT
M^+> RV_RD_(B:&UY5ZS-K^>W;!K0\52NUE_1_$B&3\[H8)BQ;7]$_@Z= /CT
MO%7O Y1BSD[KO1TKT&+/6"4:*PP1;^B!XMV&+UDRC0]</71J_>2NI(/UN-H-
MN.NY,_$CM6K<;HNI.*[H%]990>=&I!C3#4Q&8U(G:8[JOJRH[L+Y66DD'VS[
M'-S=+Y_X5  3ZE.AN4Q IP)M$0S:JW,Y40)V*=2++@8D-CZ_QA4I#R+U7J1=
MP%V: 6!RWNXF>/,<.Z*>,2++[IQ&CQN*6,D7(9H\.0<E*U <>C)\6CRR<[,[
M'N12XU/85Q <Y)ZA5%9DH\>4%A# ]/62RQ*=;*(#;J$RDS5&4;#6IQH!^$ZR
MC<D8\O6U0IC(#<@/QREWP5RH\[<NR<H*P.//<F(N%\Y8B: 4\+L2HNX5C\G6
M"E!87=#QTP=<EVV1,VWF^<OG;S*<*2M TZJ"XO5U(>$"7YH^R=NXA59GOBRX
MD1%+_93.]W[?5T&4G4G?2M#4VQW)>?IANOF!M2LMOS#Y<,A2'@N'X(Z-.2_.
M#1_M>.OA53[Z1A%EM\Z+>&@VQFQJ>-98;<KQGDY.7BSG53*_P7"K4(DJR:F^
MUG.2_H!Q1.BZV]&OSI,P<GH[B&#+,A0!@I V6EV%)U!9!?,N,&(.<BTL#J>,
M?.7NZ/(N(T3KG08U>X_WVK0R^0XDX$.I9D&K(;>0+P\5I4PPM QJ9?T>-J52
M?HT,A.*+IN>#)'$4$HD;E$IL-KP:XBYL^8_U-D7P'"NYXNW.^U\5 #S#83JL
M?;T."@.\L:)K*F6+&$B&I.6=)A%)$"99#";# ,^:;)7\9#PF Z&%SH[H2%AM
M.$O3+2;0NBK*@TZOG*YT31UE  S/]&XS9O&S8Q:?S)C%&;,XG]#W(-3(X$.:
M*$V<J.K/:E>OWM&LUP?F1B\J'R;=- !H<%Z];@:Y]M"T&=$*@_X=Z3WD0YGQ
M\A'$D+?O7,LU'5/TJB375/.9'049(RA"*@;Y KT-UJ:9+?IJ)VK<Q;!!AYYS
M&WR!G+OPBQW""0Z4[.@^6YR[W[N3=8_WB,=3540_6FY]?;\J#J;8+-ZZS-[8
M:>?16*.@S)G ??)_,$V7=Y/-@<Z<\I-G"CO4I?@;G%^5P-5\?N?:GRU^.W"=
MD^?<>6/(V@E0)3@70N&,@3W^UGL&Y6;P.D/\W_90(D!XL?A'WSIEI0],=7#9
M&)$:ZCGCIM64B=J_6*X/T\A*R5JW(914^$N0QF;0*H:9#_IT%'4;^F-Y\50"
MRXV-HY*S,.B2<0'V.YHP3F"'YC8\,B\1\>P,D/7=G]U,2MW:.5GA=>@HYASE
MEYZC?)X4]><LY1\=?\:J-B=$-MS_Y5A+7!/>JCX$YK?I+(8"99$C;.@B6M3S
M[_BO$7G/O=-*D. R0/WML9Q:TZ.AS3AE^LF9FPQ_D"N6@Z+CW5,R3WT#P&T/
ME9^"M&@W>9+-L?(J1^#EGBQF7A7<&9^,TI@H.F0K@2(==* ^Q1.F/0!3 ^3*
MXJA[=8)SAU<)_S6$QZ$8Z\I+"JF>N(VDYM"]&_37&"0RF SU$N*'8H\MLU=*
M[X(2G?%'.=QVPH$"U0;[0Q@@'2L/]CWS4>IW31U1;OUP3GG=4V'DU$8X%,V^
M%'5J98UENF#H4K,TY$K>XHB%:LI;=-(8PEPRD#/'O&)#C>H>?KN)EZ0]TL,[
MP)U!$IL]$H #]I$,*W2?5PRT&=Q$L]OJ0R5ED?PZ+W>Y.=RG,'ZX+8RU(7O+
MZJ/-M1$\#:?GF%2B!@//%"?. B9D%+R]R%3>'*ZU=1<)?&&"3L K'L8$H#2.
MGQI9&6M,P8PDKRZS[A,U%4EY*C,&XA;>O$+-HUJB,;_0\M($88E#@V)TFL^R
M:$=DJAP(#MUR]JM#3"-K4+#^D4/QU)17HU5BDI*1NA3'1!,>D<=QJ#M130WD
M*<"/,]++'U.JXEBVAQYOA]_2B)0YMP\@X*QWO81P!5AGRG:O*=VCJ.!*Z\)2
M5T,S]/?!6!9H-.GY#8=^JMPX^^Y?NN_^&LOJ56A 6%SN\ADM?H] (Z94N!%(
M$6-OH];.U*L)1>C7K@:]+MI54RXM)<"6(O:4&#%%($HV3E=)- CW(./YV!18
M\RRNMB_RUG!\QD*"[!+%Y7MST7 W-IGU2NC00A^KGFMG"QIK:Q8.[-1L8Z0F
MI VMUMPZ 9/B+(P>$(8-0)4)L^93;DNT.17NJ 7/5K@P#6%,@N4"%YT:S0GA
M?F, \X2)S]03UZL@R<6RF38Q=V[XT7<$5@^=EVS!39@E3U9N(GC,UD.C&S^]
M$!JJSR+(13+JIKV61E1".&:F?4F#WI2GRH#\&!%KQGX;Y@7IQC@>^B9D(YJ.
M<V&C-BCZPFW3(>LI*322Q: 7@>#''BU?71GWW0234CDA&Q[4"!(-OE;(?22/
M:RLKE!V%KR4A;GX2@+HXXG@Q"[:%_:_=T0=#$5L*QS? >6,!,@LG,WL5] J,
M1X@.6Z5%FT_-+_W4)-OPWQ::7C)QT'QFWE]ZBXY*ZU Q& 3%/J'HOV%:V$#U
M2>> <32UQ?"/*GF7I%^81,Q'%.P.D\6-/5=1?('^DD(./F#ZS=BJF5OF;"#!
M%+<*=]&.@/,!G _:"&8LE-G457A>7"P4 G';@<7>^UH5UK4^@2X#.G:K]4#\
M=&C%LR"):J<\FS#8:%<6PP3?@7E+$<B#GAT\I_XE'-?<PV-1"/($:(/-Z6\5
M>0*J*$1+^JKU[)MW'(5.HS#(SMP6]^+Q)N*->%=7]6XM A A4*>Y LI2UL#(
M164 DK0SFF];JQZ(>#[<I.[4HRVWPRC#KA6*0&OE;O(;2)(4(SX+X3-=&K,?
M[2;1/F#V,QH 73"2KQ:['2.;.H;VMD9\J(#)S-*SZ <9D!ZV==^LN/<SZ4A'
MD7/U+M_R/\D3:G)(30C#'OE9XJL7()EKCK8] GWK5>QD*Q4-F4H^N.IK[T6O
M9\JU&;[TV>!+7\_PI1F^-)^AO\,96AV'A4UCD>$: C>3.-"1R+7A &5]+G%2
MN=V[#O0X4N: DC%#=J038:+"\) !3PGU@#6FZ(@D<^1YM:V6,>3@%\;^Y$%6
MTO,@2"!V?F>O[%[D($V>47RR6Y03E!(L]D7P0K*R&6N\R+J0VG#2O!IXNE%T
MSYFS/:"WN/D5JZZN0!-O3?*#"X1$S47\&-<J0D=F++S1\N=19B*.-=7/3/^+
M<-)P;./P[@1@(6R;P)HG@1K]X1?RSJZ 8GB): K$O.2_8FJ&DY&)/Y9SPU)9
M<^5KT",M82Y/&>!SB72ZS%-G(BR__8V?)%(VC.8>PYPWT_TT^L=R)MU[G87V
MA!>_9;9XV,HF^V>T=Y(=:=8[=(:K]751;U&M X&3;. 0Z3#^4K^(Y['U>T*U
MYY$16^HM ?&*6I3A0Y[Y_EE3O*>HYVVDU);,6"A3V-XWRD_L[A6#04#OGCDJ
M;?<<IZZ:Q:G34R^RXK B)D]^>D")PJ32%4S4F._*&JYSR\\C;/--7_%U@S';
M(4'!%BT,DQE($^:>#[W#4\\^YX>_]/SPN;63OM5VTC&#WYPPOG=*KM^FFD9]
MQ@<YIQ%\0GO5KN%9%'\2G,OIKCG9T#'+&13&EL=392LZH@/5JRIM1TI7](0B
MA<TC0T*W*4&!6E2%XB*/[DE:<0\X&S7ZL^#W.#U%1H9FJ& %M_CM2 .,R],O
M1DFMR)RJY"=5D0@9T8(K#_;  A=4_=]\C2)?*Z)QD.IF5B<N[3%NBQ<TZPIP
M;]^ZS+<5BQ(WH? <^J$Y1ZSMSP7X;@\YL[@:+0UY;7)Y&?;9XK)OVCZO GJ,
M4XN11TH[  +C)E@2T_V+MQ0H-L_?AA-MT*:)T*FN_M%7*K :")V!9I]N4.3W
MZL#_F#2Z@\S95..F0*RP6%,:W'BAE"$W0+)BAG[(;XJ48^W@2)QEY\/-H$I3
M0EF>%=4KS;CGTJYNQC.<XNWF735DTTPP7*NK'*2^!<N!Z6.>[VC[(('*(#[W
MN)BW_Y^]-VUN&\G2A3_?^16(&O<-.X)F:7/9KNI;$2I9[O)T>7DMUW3,IPX0
M2(IH@P ;BV3.KW_/EAL6BI)E6K+SQNT:62(3B<R3)\_RG.<,$&5.AHBV*=U>
MSK&&QU)>(VA,.'F<.+,&_LD.,#4F? 1;[82\P:Z4N)9A+8(6&/D>JZ1"+N%N
MY1*"=7I'K=-3ISSOQ.U>]>.)QL7 7XY%Z05#=6<Z[BR#I8G)#O+*!/7UXU#[
MF_# 0 _[Q-E%C F)OM!!+J?';Z=4TY4%9 #W!^J.,](@EQ0#8J7DBB:C52W$
MAC97O7!1(LI8  >DP 8*%'WPGP?5OU VZ%BW5%V#_:ZCHB7G'J.)FK$/]=>\
MS>=@UWC(/P<!]R,A)P62T67"1DB_E&*ZW4$R^DN>?51$+2H6E"WYT4$/NF%X
M@-)C[-2(S)$EFKB%/FVQ5 TO1,RMN&KS /-N.NIOZ&H$3,*-0R[ZK]U#E>LO
MF3YG&E3)34,&@__]W;&(_;)MZ%36%IZ:%2@EA>E[C5>5> O64"41(6^LR1S6
MY ')M)U &:83%XPR#7?17;^+7M >@VB^9G$ZQ=K[&CEEUN'BV5U"<>-]8IMX
M@@)C5]0A+W5R1:(2<#M_-'S#RNZH<_5P+R4JQ]2M6"1WP>4O=0-NKT:T8PYF
MS=:RU3QLPW.2AH!N6--C"A@I/H %HXOUK,J(\7J6@?KE"U;KJ(=,/RN:?K L
MBR+S<0ZKG:XMP!J]BT>ZYFF1S3)Q =B]M>I?&(3RM1.Z!WW%;HJ9K(;:"94=
M NT^9>:??L,)6M.,KSNTW0E\S8^U54Z@SRN$0%,22_#N/$&W9FOBT,4SVETG
M&=R+SU/W4SHX)]A% R=S*HW%G;;AI[7EQG/X=67;B8E@SLP =%[<S"+,M2<Q
M^.Z:D\E\RI;D.1\-7OA.D ?N!5V4Q4@8%.Q(LE0O#,U@65PCM3*VQV*%2;AM
M[K:GZDF.#/60X: 5& A# H=_W=_;8F;#\^&'/)KX!UO.54WGS8,WS D\H31'
M"W=7\UA*4@.&-<'35*FEL*-PKQJ_F$-K!FW.47V/!,\,KUJC YF;H'Z!J2Q
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M6\7A7W&*ME=1KXS+RJU&A+9,N-X)M/0.BC$NN)1[2 \9(*3(+]D8-MEWA1I
M941ET*1OI ]%5HCE,D'FXQEV)^*T0I.-!9K*JFI7SNT6F5HR)UGAE3L[QYH)
M*[75XV;5L.E' LO*G'T5J'-Z>07_1:6H&Z^97P@=DTZII[!9:^E<-V^1- ?3
M?#H/=\5F1)PEX:7"=;(,5\TBK>)+S9P$N@7LS=I^H%;9_V)J"-%@]8H3K!/G
M:S@RG5^7AXVN!2:VM/ P^WTGPD:C^>K-%YL^I]PDPJ0BQW:P!W25):)[,],X
MSYLN/DY?"A/$*FOFJ/X>!.VX&Y3\ +??"**$$MX=)=:_8QU&*--536LWM^,1
MD<R:5G^Z7R7B%S)J/=DYS)J"H&7.E-YSA=Y5N9%34F)E@9TDG"BC0'K"G?P5
MI:Y6H]89@G/1CJK)\];V,XFGT!DP7DX@7%K1(N)G1F!JW=]5($JB=:1!U3EX
MVOK"Q-9%+(<F!6&@S4/$,');8X;JG*DX8(;G)=VH1N@<TLK^^*[I(!!R;G[@
MB+KW4K:FMT>XA^I\'('NV<*&T98E7X]@N[[,6TKU>P@O/+XF=6!B\3S$1"ZQ
MI8JEM:+J8.=@$?#U1]OJ%K" #D95CV3T@("Z")2$$.UVZ5C5LL$,=Z&+>;G"
M' 59>+8-2U7"FDLV:NHZ8Z3-3'%.MW%D7S %JR_4$Y((<2TSSL5E3/A8"V9G
M0$5=+LINE]FY5'^PET6R@Q3#@M#XNUH[\EX;"\0-X3A.!EVTE-A!_5*V-3LT
ME-6($ZMW';0(%F%344*61&<L'W^N*&WTGD9V<K=G?[ZWW6 Z/,8C)?V\F2 >
M:UI\]@$UV)2C3W5$ X_UGW/@36YKS)$<["L#1Z5DES0M<YKA<D\X*60@"<F5
M3X2"WT.-2S!$J;1'R(J+>H55S:224=>!.?0'IFN/C$CD2F@!I3BFMM<*;:X9
MHJ1S521K>>!%5BL[ND65S43_23-=#:.]IB)X!R\I%6!'':U@U_"$03ZU39_)
MZW?7Q8*%X776ILN371$!KCJ^F/]2B%?@?G<=!=\1(IB3Y9K7SS0)?YP1I167
M#)-31CN#JY.E6;.V-G&XYW=PS[\NI?EXQ75S&P %)ORC)91DKJ^)7=' _<Y5
M;.BYC>OC.QR5YR$94O[N(47386DZ.L+G;"&E=0.-]ZD*(@ZE^UI?74&F=N2Q
M=(."Q&;F7KD=IG6WE@UNWP6\"Y6^D2\BL"$30^"P0;UHFRA%6F3_88)F(.M)
ME#/:*7FFP!Y)2Z%MLQZ2X_ 0VL492DP^XJH9#V.:_,^F#VD]*J45]O&X^V@%
M>)Y4C6T^6\/&Z012)"@U&?33V(*Q]NL+&)!!- =[>_L_/CO\\?1DXO_V\,?G
M1_3;?H5Q]/3@)RPP/K)<1)IAF. >;)S\S;:"Q^W]&X:$_55\)R%A8Z7\[;53
MZO]!$!U>62-;4 ,19_BJDXTC0'='U$;$BPQ#?NO.1^!;%=@TC/GQ;7\G7D@&
MR%7?QSW#2D4G8F\N9G)ZM"G&06C>VRL'-5@QTT-&DANHL*E(T D(#3"".T>,
MJ!12MTD)G[=..F, @[^5_.DX@;^*'<>)C$P*;ZXJ;G7KY028K=9]HTZ53;]%
MP14Y$F\?*WV+5(T^C81[COL.PH@GP,4::V-:$HWG+&Z2A0N%,S@NY]F#-2@@
MT1,=I<5JI-C2;\A0'%99+E5%5YVW-@X%:T4?;&OI?.R' ;N:S5&2G7362GL:
M64&."NW)QJ67^7E2 V^UJ>U=((P*V*J;8:N>!FS5G<96_0;Z*WF,>_+X914O
MU37VY(< :KG+H):S6"?F7YNDHS4:ZX!MV:F#Y: @-%Z>@1!X2GM!5K'_I"#2
MN>UUCENB<.*LV9&&BDC1DJUTJ%*" &LX];#&F,;.:O3X];RX-2[7O'3GW!;S
M./-L&X,>Z7+EDT=O$^]._NJ*_#MZBFB^KG4(8N/"C6;9L?: "#\(3H]MK9*R
MI4H.,JEI?MJ7H045HY=-1/.,&--FQ/0D"61W-E>':UV_T;$0S4XCF1M1JW:J
M[Z]"&+&53-_..(&3EDG+!KO,G^-WG=I\N^^N .D$'J<"=,J!+-,Q3GH"'>'0
M-4?MP68%BSL1:'^CSK$$'3/C3G3(Y8P>&?2=N[=#.5-Z.X?,W5]>O2!^MRG\
M5Y,U7 @\'XF6Y?%,F=H;L_W3Z#C/QR40&\_C6EFSVG4#=!, FDU-N]DODF8)
MT'!4AGXP6<VU)DI=OZMRD<TR*E[AD,%8>XWR,:=_E&%L<U^1G"+JML4HD9&2
MD")?]WLD:(UEY]+KI_K?6:G=4)$-SE'ZP)NK3KE#<:3[9U!(D9(7"$;RD"E.
M*LSB(\"IK#+P&_'8>*H M8?.WE&Q$Z-2&(IQM4X:4>:BSB1VR_7*B=%6M&J2
MHJ5GZB4J=(.O(9$C>6(D4()N(29?%(5YL!0L7.U?_FH' ;2!%1.?I& 7<J%D
M'#-''"/"'5E8VBI9"/6#/3D8?S!Q?8Y$4"%EY31N^?/O#ET:\Z%-O S>[^W2
M=B^ 01US+SK8VS]P&@F7U7E<F!C.958OZ.B56,>6._."<XZI'ZH%;9";X1QU
M6655&5;@ZV34P.0ZH4)9E#PV%]T2J=/*\](A;S3W_R@'&='FV*:Y-$6<.*$&
MF<A=]#$>*)<S$I:R6X0?\/EWW94Y+IKL\8D!+D9_6'LRN#%?@Y#+<REFJKDD
M?>6'L6U!-&D]:WI2,2O>=WSE\X4MMVLO5HW/2L&2PBH@E8]9156W9 .>GBJI
MOA;<CS<)N9_MQ]RKTWR'$+E8.?LGE\F*?2OY@5$GALUS,L(U'L2BH2K;>*CN
MV.344Q7I)ZG8R.,5="TRALB##U:DDL^"G\JJ)A4[,??+A)'4!"Q*.8[>>K>.
M9T_5FVRVF[V.-@;=;<9AC5NX :4L8&:]FQJY/9PR,":E?$0;<FP:6KBR2T<P
M8@<&/;*#=L;Q6H/)4]65F<*P\O8[K%#G7O&JV'[&5H!9G>38=6X:(3BB).O&
MT/+U A[2DHC8.&9*\_Q0>(6T0,9TPK;W]E!S)#.<,?,5>*+E&A^]R.H?T7-P
M/'=/M[B&UV2XK&@@3W:5MNFF9,4;P"B .<Y>'82C5TD'$ORPHP1]#3IQTXK;
M*$&-3>J4:33]V78/:J56;:-GB_"RB?:7D%XD@X.$'-<='\] 2K23QXG#<+:_
M(CU7QR2H%3:FY"1M4IX7S+"&%@0%,K&2(FDI41Y=M#DZ0]('7(I6;+P15KED
M;CTATL&HB9,FKY-R9<)7OTEES#&&WH3Q9V\:O6B5]LH'/V$.]SRN1NV..%DX
M;4H;K$M':#S>;I:R6!9#<Y,XH0J$V)IX%B6V$4&,-):.TT<]X1)\7WE#O'GI
M#0VR,&:X5:E1'F;,)OZHL*8ZL>U?_\X4SS0ERIR;%^V.PKU)G0 :XC7G<RPU
MP;Z025PAU)*0+UQ.K8$GDI%?4-LH4L\X2B'0<>,[XE2<(:FFFCM+6FZS1)A*
M!MRT<'Z_2*IB\#!P7)74J:*>!'.P3O7."7*+>_P]S*23G[T<ZDG7&Y"Z/^*#
MH>^>4P$9QKDR9G5EOFZR ^'K#[,;C2I4O6(0< "#>Z6BX<H=V)Q'W.@9]'V,
M-L"V%_J>@MFC@9 ++='#[$*&OFJT.9;J$.$-M>0US8ICKM%AXH0,0<N+.)]S
M>F,5$[J%7T2<#X.OY*"BR[4UO+^I6E'C#6%FP(U-E#U]8-B *N<449NO-"$5
MO81Y5D4,##0G[&;,/%%\&3.(RES&NBHJ_I0MVR7J3>( ZC1C%'>+5#VRI7*I
M=(C7W/5XC1MWM-<8[N9;BJIS0CJDH'>KURE\C','\PJ_;Y!HA<\O>L@$HWN:
MG)1\Z:*\9%YM+SD+0Y*Y3L@S/,!]@M,:OI^E+CKV754V98(D!3X/ZB Y*EH0
M2^8Q%.?K'_#&-6@/@JM<EM5'1-\2E!,+UDHPQD;27J!C3-66XD:Q%6DL6PW)
M[B"]8:=[ [QP+V[,53>VF0?*.'.X4J$7.":IKJB2FE[\O6&,U_#:#R?'&EZK
M2[4,GX.)NM1.<WM\5I[- QM:0.Q] <3>LX#8N].(O<"&=E=W_)IL:'62*>J(
M+&&1AQ:&CV2H;0TO)?71L!+S><W5%^AF(P0<C6)#XN_<$RXTS N_],LE6J*Q
MEUB,#J 3P-T%D_<HB!PP^EB%*4P:2S^H]TEJT$GBG,"%9P(4X%?HE+1TA48<
M?ZXH73X\03$E+5."#B]U2QP,R8<N0 DAA-V9FISU(4.'PD!"44^0 6-7$3I5
MZ*9?J OBH7+<TH/]Z"%^00REUZ]?&$N).0,X/D@/-$$L)_ ^UR9BS3&TJ*4R
M[+33=<[Y,GC!X))CU-KP\'I9,)R";1-7.R(W6I;_T<8')TASH[@QT0K$OJHY
M9J(G,L]4GM*!6Q"2PQB@DS[CS<!G+A1"%8DZ=^DML6;T3GF)G1YKN#4U-D73
MP;8"8_"B@N8MK81[K)SS/CRV]??"8=L%%Y<IGV5\*Z6,ND5MMM6=_1 FV&)$
M\A12)3B)_D#2H>AX"<N9$*G7<9W% QB>[2FRM )F>B(A@$/9.9<"T6PY:R5Q
M387N?.H<J*[\R/#B/.<H$(;SJ%,A/;_;NLC"+L<;"?WMY)WE"=N"]DI_5#4+
M*=&#,Y.M<AWYY,@]!>9*D(W,%'J]4"#[E4E._ZYR6(:/63@;N\A%"1:38JH]
MMCB_,PO%;D=VG[@9A#S%0O%!")<EZDDZ?9B6.=>9QRX[5^]<;*JE=Q'?DG9V
M3I(A,!/B,K?WPAAS6(<-K"K!WJ1JQ(% ZL'=E+]9F:>W$T9]_ORKQ%%_@Q<8
MBJ*.O>L/OYXRHD!N649VGL0K#+M&[U5=MA7<MB&"NC-M<LR$6;$.DE*,]&@B
M*F:!G!FJH*:Q8_%'6%33>$1O[E2^3]@6YL "3:6PWIDZ('A"(-:9:8+6GG,'
M%^RRJ)EAT-HE'HUI] ;+7GJ =&=(LNVD78O YH7QJRU$-^G69[HEGB8 P^PL
MK!#<PG29ZYBF?AU=@5%;JCII_\#*EZ9L)L*V.9+3AGMQ!Y+,6V00&+IQ8]-4
MG&2<1%AK<!'SSVRH-;+3H'T(H=20-4:@2 +Z79!>XFH;^%Y+]5&(4F@39!+1
M<I$5%W Q<7<D7P0$Q8Y$(B/GA^K]+76LY7_S4$M>9R9J2-(6&:."\$TT>X?0
MIQ*Y@LISXE>SW9ZDYPQFH&O!964-\]\M\>)F>VX5)Q_IO#Y$.#H"_&.A7S5=
MIHG-OGZ$",U:QTZR2I[&*-I"H+)V6%M3Q[A+,C6I9*3"5&[=/].=Y\&$RJ+E
MET [IED_HL...@,EQ@(PMDR7T$1IXX3@MT98B<O#73=E\E%^$<R*.VQ6O..>
ME1J \-*$\H(IL6,%;/N\L=F..X)PJ8NLHJ@G(T58H1@XE^%49 @J?:Q"8X&K
M&UEMC%WX]HF4-@7WIFQ4OM;*67,N,4#3RXUB3A0)</#LRRA4$F04NYX74R]E
M.1._IQ5U*&ZB@X/]Z 0A[/C%LV8ZB7YKLQRE9UC[1"*-!V!FG8$"4]'^WI-)
M] ]4VO%R8OGO7A71,6C(W$0,C45&J3'R_E'M(:L9OI1)OI(*?!M_C/Z&A9C1
M'^^8-9*6,()G(^MNR>VZ,BRI*O(R>A=7'R=@A.<9?+;(8E;0//),G6=<K_=?
M;2$\@/M/V$@4AU/W$\P-W.7P^?0)?Y1Z$P?->9<UYQ_J'+;N'5*C*5S_H#%W
M&.:D8#P2UR+P),.&>EKOK#4V%FS+,I=JR9SV:F7WRAB@4CEN-&%,&#R*-2(B
M[3(6ZK!B[7Z=3>2LT3JR9JPJAOTF#@@>=;D![L;GYQ7%^B>D$YE%P)#'2J-P
MJ>^=M34&CCB )!2)3EO[RNTV;Z D\%+OJ=8T%W;@LFUP)281WNA"YXR,CDR8
M59AG"[4O_%4K_B26TB#L'X]07++I5--P<T682XV6=IH1JZY491O"89P=QR.<
M7HV8+BP=8S"P2@6,RJUA5)X'C,I=PZCL$*0":CR%'7_^_-DSF";.P=I+UQG^
M7MI+GX$#WD:G;#28'A_G^4F\JJ\RG*Y:")I! _Y%C8#4G\&Y4!5F]C#,^OY$
M=ZD] S/_S?'?3E^?OOE@?O7BU=G)GV=GK]Z^B8[?O(#_'?_Q/V>OSJ*W+Z.7
MK]X<OSEY=?Q'=/+VS8M7'_1GWI^>_?G'!_K(VW>G[X_Q#V?!>-N9\78+@'+T
MLRQFP[:-EF9'<;Z67MN.^-2#MA2',P>,J:A>:":9"AFP,T)#Z(X[[,)YHV.,
M&Z_/6(H<Y%'8HLG)&H.UR6V0*X5^*$AZ3'% E=?JDEM0HKG(]=>?UO;K/V*B
M#C%8+=AY9U+LQC67EM-)(%.ZQA-&&5V;BD#/<\0P7^OA+FC,?;1PG3#R&U[-
M6QL.0W)@D%MWDGOM?<;:O ;M#)\! UP3>PR'!FY!FA[G9>F@<H8>=[.!W<UG
MCX%]$J=M25M(?3/S>!UCP$0*7]FF7FO+>>(O%Z+OXMS(+I?,"LF9]B[RM84M
MZ0^F1!PP8Q'ADM@\LVCZ;VG).Z=A"Y4A\QB(NQS>S8JB;R+N<JV=EN@+VH_8
MVB3<V[O+>(/ZP8!)2@B_A@F@J/R'HKM8HBC]0C0BD!$KR*\M]4%N-D[8)84Z
M4M/LXZ4&#U:"#:WBE:&HQK92Y45<4TDXGF ,M-;($MA[+O@IJC(<:]CNS+0G
MT_C$!I:FT9SF'>Z"9!%CT@WVNFZRA/E@8'H,_FF)YNU<%>4R2S9UW)"/F 1E
M!I)4?<2TN0F*>'R,1$;^"1RI%"O@UR5:)F7;X/ND67Q>E#B9"%?^W-"M3^E2
ML&$H&H1H]5&ODQY4*97+P[6<KX?V""-"JEA(NVM<<<)/:]YT12U7*2@N:Z#C
M2K5.!A-%C4,[1]&AD+K?T9$T%@$U:M' ,-C5E&Q1/+'@>L/&E/#)HV<'OT0/
M9RWL?%KF91XMUFE5)@L\'ZEZ9(K>[.G X"?AU,"FG559KGM," ;[^*7;KDJ?
M$K8&DT55%B!)(!H55S(C0DU_\_>7MHF$3!#GRMP/HBB$'M0.NR@UW3^>KF:]
M$H;6#%<+V?_1?DJK]ERT"':-*Y.,M)6P(^+>*30*%"9WXF0=;OL[?]N_5A42
M 1[K=%VX]7>7G/8RJ@;FAIIG$KW,JKJ)9'?.VMDD.E/H6SN_XC+O?@J6"S_\
M;26RLKJ-^5*FTE<?5@M794.<CM)A3]-@,V5QD]7S.-$IDLL8LQ/:2S8>?^WX
MO>(6]*?1?2].[RSQWSIY*Z]!;S:1]+'&NFG$$^7OL7P)$T&7J'.0<BR#V[Q:
M]Z(3&E->MV#87N#7=2K?,IGY$Y-Z:)=7N8XQ,'!!M*$11=3BQ#+.# \MJ^ -
M/?J^_?VEO_=_?7O+@)K=-I;SGB25*_S4K.8F/2E;IMP/A@,-<Y42RVY64&JP
MB3]9]!3-#GXS8L7-02BT"5<IEZW+H=!PRNU@FF=<*2<GYJ=G#V,A^Y!7>*5Q
M7N^1TZ-5T4G)Y1G[SY_]-'%*W(,-M0,%=^:K$<1B&'BM5AF:M;RG**1Y)%(:
M9;;]L7N4)I'9?NHT!'\?Y=!N&RI-= BDZH4DH+5N(7Y<0M>Y]:'TL7KD<U)T
MJ6,@')E$[*95#TY4"%R)\O(1*P NFT%N:SRS9:[@ !OE31OH4NC$4=$2X1MV
M2343ZL1(G7F!%Y9(>[B!DIRA]?:J_TX_@9N&_#+O\31:QH2'LUM;[A7YD7AE
M\8S[BW*3U0#]@"57/,G?T'V5AYS=<%G@G9.;OW.Y,NT -!/U@!#I5X?QVB6'
M"]D$<&[A./U76[/7$&]QS3(34GKSF5\2)JWQIK[Q)(SL7WS%2*,B_-EOC]X_
MD=;Q\Z?1G^9*83TTJGB8F5*$KZ-^O'O?C[&7<45L72DU!,!6C+0F2'V5$^B0
M!D!0MHR'=@1CA@D,D_87!/<L<G:'R.2(:@[_@$,A 4H5J4\8Z:DQ9\SV6X)2
MG7/_M;>M;0U1%FH=O5VQYL6%3;@5QS8Z12/KY&$$ETZ(?T[.]CDZMK3$L;#/
MQ(1>/)$E?(>?QQ0$SRLAXMR1<[AQBZ;1\19W SW$GL!;>%4"_]#;X9JC$:2E
M9.A-[9&@S<BE5>=6"JY T[PMB,<'UFG!5C 3^S ^?++%!&2^JOL>U&K;+$ZP
MA'9@"5GEX]^MI*;@2AKWE]J5\,1M%'9B00)3F6FGHEF,B4@4-Z+OMX-<SXS
M/NV)1*-GJF/M^!. ^WSD=J'/Z7M%WH\O$+>2P36Y!OXJC]YX!3$/Q=@TYNA2
MI)W[S=30&Z-DK,4S+[[^NK'TQ)K#5KL4D/^488(0;+GG3Z<_[?_%NLC+&67+
M.A"]P",5,'J?C]%[LA<P>G<-HQ=XI.[%CE^31\HM%+K>C4?>J7>EC5P<!]/#
MY_U[0QX\C9"%Q*U.U"ZMY@CQS8N)I0C>YKZGJ!OGG,T%:3.JM"NU:Z?*F \U
M,0,LQLV<BXFV8RE)V[@F<\-L^>*2;3""MG7I'WD>5<R%EDO,V?(&;'+_^H'<
M&6;>U=+82,[8FH]8[P#Z>QL-&&?YW2DZYI"8[+PK9HNNFHBP9_J&IXDZD&_-
M7W-V@%)_WGX5JB%?!+=$+TM6.T[1@R?3/2FQ@K$U_D<_APU1,4/%NV%&#:S\
MT*"K?*V%B^(@NI1Y^_ :Q7AU2SD/D#7H20;?9R>-"FR[4N]T\7$Z-7TP/U"Y
M$:E*=CVXBQD1^V#8C\2/H"3(GRV#?*X>9C^Z6TG4PUG"F'59<(@%^1,PZ<[<
M-J*\G522B#<(,'/,#I^CAS$"?C#202K>S<\-ZRTZ2MAR#3[=.VP"5W%*A9S*
MJZ+)L+"]T3"6D8/--XJ<;58C_N74>RH<-Q0=Y)2G?!*76NFT(5(FQKF_;89W
MM^ZZEYU''8!9O+ED5;]Y.,0[.<1#;26T^Z\!;$+FE')[0_51LWYQ3Q]#:> <
MOS%Z)Y/:(==_JW %?E*WS!F:K'=[/_0).CMYA.%Q;5;RZF3#(^?3W'85.;OC
M.HW_+8:!3J901I(61M-O"W*^H4P%@IBY1Y+BCLY.@IGL)F/BR>E#E#-7'_+T
MZU6>-9M7[F$VU]8#K!K<Z)@^ECR$11D\\IM#)!658U\_K*0K/#%$Q?V7_I<E
MAK;:F$W&<J58)3/OD07#B>5*DY:B@D,EJ3O8^)/V$EOTI_\N&XZ1EF!%QWEM
ML%)!C^R@BRM%Y>?=32+>4B9T1RN?"'EC(H<3TB3=HE",7DVJ@:1)A1O(ZP=0
MS3GW] QU&]'?9=8DOO,>[HO8,1C5PFC)--4V -YT9<7V23DCF@A#WE@CB<(F
MG0?'Z$ >,@YQQ5A4(LV)33X1DT8$<."F\0D_C:EL1)IA\$,9O,,9R:2)4D="
MM%)2%@)KF;:&&74%TEFFIM4D88M%]]2PX_IC@TFW 9?)I.J/9%:T\ULOKF'A
M8-]$J+?RS&31QM4,_,#Z5E)BK2BKK514)^!]Y77BF# 7 JTTDS3SV-:U%!7X
MQ%VQ.3-]V [LIR?FO8RY1A <VU<^EB;"@D8R]1M>>^$OL1RF,_!6Z5I70[]W
M)WRF)QQ4] Y5] EUK/<]&HL#<]+RNGVDEF2+ZAG3NM:ZTUK6[??HR9]G),HL
M!J]O1YMVFT=:=3R04M*^6BHY8J_[Y$CFV2@Y)P+!Q5!(_1/KR@HU6SMJF ^_
M1>%UGJ&9:K2Z<)K9R;F#)>?.4-L=/:-I265J95 (<P7^<OB03:S&866[RBQ"
MDJ*>EL?U$IQ?HKVGRP)#@!5'CABI1XM0SET;^'>$4IXE< 1&+KSW)8A+J:\Z
M[$/=5$@P_(I+)+CNS#"6EW,A_GG^U,/UP4O\Y+S$63LSS7Q=C=,#93$V/F-:
MR8AH'9G4C6UJ;O!)K'("XZ<PU<J/8<'/B,YP0F+[3Y],]O;V\'^NQR&:T :_
M8'6Y?!5E"2;6-MRN4;,[>G#2FR8K^U TNF:>ZO7R H!TUA84HJ#PBUSN7@3&
MCA?/R@L=NDE5GCE,ZS:D(F&1%&4/7U$;[+<1Q4'OH3&]IKG@'7&\Y[H#FHD)
MZJ?+^;J%AT\CLFJ)W<8<\W*6:V(8YFIDG:HZZI382!V=RFI2FDV@]V=,X4'M
MBM<X%F_IM<9VEG%B$+T=\]D-&SL=;_F9-/U)%_KMG'E=^HJ )=WG8>+VH23L
M0<'M+S'8;9AXQ.:LM5YV'JCM8[M<M:,T>OK7C2_,S$,YL.SF"5RK==0H#=;$
MCGI4]+91RH=K8T)P%)2/B^298*O4H+,XC?XD.(OSE;'KFB7).4U9E;1+%%YJ
M;-MQ0I'ABAXY4YZ@K>*^V,;>\^>*).W!T1&I^B!8N^AM[L3+X^C$CY*]4.BK
M&N'@V)SB77_/\H7[_@<VSHP](+H?U'LSZI^S&:JOAA-&]66H)[NH8U95X+]9
M;*_CQJD$*7^Y6H-,,3.1QKQ+SF1IKI\T_KYNT>!XR/8JFY8L.#H^$SUC3#[4
M>&EG=0>D&4<%B&:M*KE4NN!N?813F27;-I^_TH'P+("I;AU,M1_ 5 %,%2[L
M+P^FZMR3$[2LHHLX;U7T $[QWKY36]!+XFS,O=GJ]]\' DB;:X0T7H5*(W,V
M #7>23N^1#Y\K<HC#=9GI#;\_WKDLLOFCTV% *S58QQ;7WU>2)8@WA/=MYOB
MVEB@2F4OZ+6;J1I@S8J: W<G/ACPG2):2.*W9/5>8O6 L8G%C=MD<U78RWAR
MK47'T DQ$%QPA(_] -Q#Z5J(#8Y+*7HMUM?; "H^<[%9UJBAUHBZOH)\WOD\
M(^H0GHNQR)S((3H+_RHKIWBVZ=;JV.EMMPA.RIN2/-03A!%;PB:;\[)S.[N)
M6%G<U[(T\+QSC/5I%WBKI\ZZ3^6$].8==@KC^..^+&W,6<_6U.?:]E.#E<)'
MF]Z5%$" '0;-63"PL''6@+LSLPQ87[&S05N_O2Z20_N<HYPP]43R]?1J'!OM
MO%)JE\+?"J0$MDX%9_)SEB4[61)?8RYW996!07.77FM\(QY-HDSJ>001=TE\
M9<YZ=:1)(EYVPCPOPF9=P"J<LSQ)U\1R/A%69-OEBJ.ADN;"X:1#R+467GGX
M#AV>N^ZI819H@2*4"/F3GUU0ZFPM95<8G7[402PX$(0;'-FY/@0-;2H19U\N
M2)8:XJMOHL,]@^?ECG6DC269ML4;5FI)L1+Y!@%R74WFQ!951B_]\%C/*GH)
M/AQ*,?:,^># )J\G8[BR#W_3@^+)9">2VA9I;D;QM>F-S-G6.6:!,ILX]@ P
MSB_X<1"Y;'^PC'O0SY+OC#)/[6KW-7,BK;Q\7]1] &/8NN.3W)L-)E=#BEJ+
M=;>]@</.B'^5)^.TSTN#P-UBKTWW":'BL>>4:[AP\#R#:S@579J"5)1Y:Y@Y
MLF*\U</C=N4@"7 V(5"UD\:A;@?<JVM63:7\%O(R9'5XA=@9UP0[VHF*H_LD
M_T*W(,E0[T*]CD*4JN\>(,Q4J^YC@'0SKO.ZY>$ZB.Q<O'[_;7Q]YUVV6%?F
M:5UDLXPH9[E5*B^H9]IM,Q2NR%;PQ3DG,AV24E))]NJ2[K+\)HC].U>D9$VC
M-[1<<U1JB)02CEV\F05B@]4F2U2E="O&3F <6:'QD@#SX*$DI/,U03=@[9Y/
MGS__RR-CZ):H3*^'^!N^N@9T< ]'W%F!H+!V07W7]/%-/DC?9POQ_F390IJ!
M J9-= D=1#BEOFL^!MDGF]9?*I0\='USPE!<+N!PVA(8$V'6Y2,Z7=37O3T2
MI^YLS;"Y,YZ5\$6FYEA;CRU>+W13J(&L8N@L=&<Z"[TT6 C'& Z4=[O$ECFM
MT71*2LZ0@+ $/V*LZ#ZD5U_XF(I%'YJ,Y1X%W@CVQ_+)#7#BX1?78GP3'+D'
MB!@CL6(/W,[1Y;L9+R\<@-KY%N'M,QYL3>F#SCV:"0:_8[YF:$2Z)3M/>R6
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M.. P% >$XH!P8X4;Z\8WULL2.<,D0[,!OR[I#XMT)PZXVN3H$'/!:'!U(;E
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MW!_"_?<FW/]RH)E.N$6"+W87%_WN=8^\[I#]V1_<I%WK_=5Y=\TJ"%[AE\M
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M2(G671;G$8H-[A#\: )E#>QPSAF\BKS ,CJ/X5^PFW6&!F)%9CO<X6M.*U[
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M59=L!9=24<B6,^>\R6L36M4&(=D@6$R#';*4DVTAFT:2X@PX,E:E6FOK;\R
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M7AY5X)@P&KW61G$0+YB-V:4SL"R(JG:)6I6(*&W &?C:8%0-),Z!UPI?N@3
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M/@;SKD24AE:BIOJB@A+7H7N!P%_L%(5IB21@4A(&56Y(JU*>ZU/KFP/FH"F
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M[3;SIF/14RD>=2+*P3$VBW>Y8EN9*]:JZ."C>PL"@BTC+-#D@8Z.4!F'Y[6
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M2HI5G5JZ' *;V#-]:_3LUMJ\%)7JP@?FH;ZL3OL@<!Z+P!EUS,0:L<TJ>I7
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M0F^5&R07YBA-JQ5V$T8_#?5:H ^(6<<8RZ9,OQ]V=D>#T8@;>NW\:! -P2B
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M"$:-<_\,KA >O1-*FQ5*F&[-?:Y2*BON.!+O/EX\,8@Z?R$6S ,66@>4474
M)L.!:+WOWAT,*&OT+=:%8OH;"9F!]^YXT/@LQP_I;O_F!^D8>&B/0^.?"HT
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M:%@5W-SH\"@W3PFV.2AXM0HI*GQ.D?!2W-LH]O:2H'S2;7;+;N!1//L#@E4
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M<9)D8<W%T!_<RTU[@;8W.0HOLV( ]9D/DU7FJSR2SI;^LXAW4T<E;>X5IM]
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M#B,Q8.*O#4_=39Y(RYH']%WWF5Q^<LZ;1^?0-_2])'V_U/2M,L343Z43O[?
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M01@K<@AHAV<  >TV:2&@W<XU!REVN_?.:>/T" &-@ 9A"&C[$(: WO4,[$A
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M4([S45??Z@>]*/;3,!H^'XL;Q8-0ND."E35W4W9;@0J0'0?RFL%*J]-H=UM
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M.$SOO<-^<!/VPO2IMZ>R@OI,UV> M&46+B&M%2!#VK)[!$7:,GP&PA!AMLX
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M,\!N)BO*D-9*81 M+NH.CT[GN'%VPHF]M0M<@9@M$,,#(9L=G@%D,Z0%::T
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M&"9! F%#V/NK)@G:T)UUPQFU<6#JT;5Q1V<=(&6UZV(AQ%+PX)#0U?M.3F@
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M+_0'7CA4'TK#:-C\[1?Y>"\,O?WV2S_\I@TEMXX/'WZOBV/9<H61&2U/O)^
MKOBO^2&5Z)ZZH></OOOWR90J>*Z$M=857N'9Q96:ZCJEUU/TX)7'8_J3:ECT
M!POOX9D7\2:3DG^Q.*.>FE(QHVI"WW\4T_GL0_!E//#%=WO1(!(O<BV#"6&T
MG;/3S*HFJD7<\O/-8)S<UM*DS@J$TZENE3LWJ<[TS02[^-YM'-S\^^"G3U>7
MK5;[X(6J2?.B&^]2O)CX>O+;+[[&M_C/?_TF )[-AJYAN[K^.^BEJJKM2OBN
M..P'S]HK3$_YGR-3VE;P+JM<;(MS?1T-^COW+<L0R$)G\E*\P3Q7LNAE#U[\
M]>[BKU=O/[U^Y;W_<.6]N?KPYX5W>?7NU>MW'\7O+J_^?/GVG?CAXZ>+3Z__
M?/WNDW?UQKMZ__K#Q:>W5^\^_G8=__)"?,G[]/MK[]/_O/[C_[SV_KQZ]^GW
MC]YK<8U7WJO7EZ__?/GZ@]=M-[Q.J]-5W\A<3/'1+V_]>(ZU/?P2N3\\?#L4
MGB\:)_ZPGS2\X)]>("(S4\ V[!?+V>ZBL8# TRDWI\O;?EC9^=Z/_<+39?JW
M)9CQYYRI!>T-_%$B&#/[*?O3<T7ZBKV]GUJM5OZ5@G;S"DXB]5KF_R2&_K56
M!6IKZ29BE[\OD-1Z_.<L%)GG;C]";,^Y]H,:_&AU#=[YH08WU^Y,7[LUYTK9
M/HX(>AY?PFKF=%$(R8P\-".30&G!'(DI6G$5M8*X5,Z9P+UDEW\?G#!_CYB_
M3KMYLMVENF76V2XW'?V<;T6];&!-;2GM4ER:_CU,TBB65O3#U32HT'$J[#)_
MCYD_61VYT;P1 .8FP)BSM>?LJ'FVXIPQ/WN!*9Q654ZKN]ED1P#F)L"8L[7G
M[*39JEP(KG^^79O5Q4JF?1.KBZ"P-!V+TD3JP:A(EDKF[[QYO&)1'2N.+JTX
MGAQ>//74)N3%A\L+_=-U&(GG$*_7T/]^.^PU68_<5_[L[-N\5AWRG:]X4 H$
MZA:!OC0$>A6/O_KZQT^W@8!=,!;6E4"BD"@B]+$DNNIF#R3J$HE^BL4-_9[,
MMS9BM->3:6EB*,V_^W^/D_1.)VM"HGM%HOLUESO>T(,W7>+-=[+*!4+<,T)$
M5>YJ-Q9V=(D=W\>1QM(;5?&GA.2E*?:#-/>,-/=K+G>\PPY/NL23"U7D^FD0
MA4T#VOQ57",U P4.Q7QLF[^K41#[:K4I^&<D3P5(GM?^.),';[C4&2?;=^2N
MC_DJPWN\D2-D8 ^.U-VY<9\TCSCSU2:>F-+KG-0-K5B#!71*_?D'0H%0+#3N
M\V9W1>/>,YZ FVTV7[@9;JZM<9\V6S2@M(DGB"&A%5NQ@$ZQF7\V?NR(ZT.)
M^=ILOLAL_&%MC?NTV6G#S1;Q!#(;6K$5"^@4F_G'KH.2)AF"9 ,^8D+FL[ED
MG\^6=I58@M,[N^?T@Q<?@B3PX]ZMZI?0#[X%@V@D"U!KS^(0MC7#N\W \K.Z
MO_JHL\1A?YM$FOH6!<GCTP"QY>TUSFTW6NTN]NM&0 \$-@&!/0GDD8#6#"\2
MT&W.0 (^9-^K9UA.3P2VO5M_>-9I=W"(.$0<(J2!0]Q!6BL.T1[;QB&R2@((
M6"5!%)) [.908JD..$.\&^&+G?9=1;HPMLR6KMO\3+#B$ 0(5I" I&%S4&LI
MH"0UV^;4;&''0>P/5&:VW[\+AV&2RO-;OP70.#3NDE)$^B']+#)J,K+=,N"3
M1N>,\)WP?8\A (>C^]RC&(YEX%@&"XV; V^A85>&E_ ;Z58SHZ[B3%L,>)N[
MYR=GI]@OX??^0@ .1_>YENJ[@!]TW]1:$43E,??#O64/7IP<^D\A \C );V!
M@$! 6&34I%"[9<#GC?/S%O9+$+B_$(##T7VD4'.2-?N&4(?UPTOZ!ND;-37N
M*M)WX0G[HQAH!5I!DM1G>)$D<$=-C9N,4FC8E>%E,Y&%Z)H9-1FE;AGP:?L$
MZW4C" < ,#BJS_7A)9_4\GS2:_))(0.G] 8K<:S$66C<5>25PA/VQR70"K2"
M)*G+\-J:ZLAIL848DO1'Z,25X27"08K4U+A)?[2,)XAPH)4Z8 %)8CW5P!UP
MAX7&3?HC-.S*\.XH_5%PDM_[&J3/G*5FLFBLM^ZMY$%BR=5;\F'G"#-V(RP'
M"5MM.TQ>%-J0)$D+N6('29(]R  R<$J#L%['>IV%QDV2I&4\P18BM%('+"!)
M]C!)DH1(W"C48?GP$LT@.VIJW"1$6L831#/02AVP@"2QGFK@#KC#0N,F(1(:
M=F5X.0_2[9P9Z'<W>9 8<&4&W#D]PWK=",(!  R.ZG-]>$EUM#S5L4^J(V3@
ME-Y@)8Z5. N-FU1'RWB"S4%HI0Y80)+L8:HCYT$68DC2'Z$35X9W5>4RI5*^
M"V\8?9=^T6N/TH=$2Q(-POXRPF?52\X^?<<\_?)+M^-!T'96*+%J:SW.5L_$
M?"0HP!28JCFF;/1=U6TF@A[0@[!V>'CM(R=$ #16-YRMGD^,L 938 II@#2
MQJ"Q&N-L]5QWI &8*F&JW6@=MX"4U:Z+)3=+P8-#0E>3NF\K0>P@=?^&U'W(
M8(^5"@$!FJ9N.%N]BH @&TR!*==\%U$VZ'$%/0CK/2Q H=BD\F4/24"?.\YR
M=;<UVG7]X,&+3U'J#[QH%,1^*L;,"_X9!<,D2"!L"'M_U211&[JS;CBCQ =,
M/1)3IXW.^0F0LMIUL1!B*7AP2.CJ?2<G-  T5C><U:?"9]HJP-C.,';6:7<
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M?"/V1X$PYE[2\-X.>TV3@<_RWM:7]RY*6^9F2>@ZR-9?YJP"F76C'^Q$%"Q
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MD):Q;:&+G\,^(<(L8:-;@*DHH1<5&H(H[1<!$H)/4.P5"M'SF:/_]?B>#YU
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MI],7 [M.E(EN0<'#?8)_9!&][S.]'G_CO,DVPJI>5>]?JSL"5OTRZ'RY2<A
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MM7E:G'V*>ZZ8WU6%@"8;R&U6IF<Q*?MQ-.!L%RJTQ]*&(*J_07?OIE9KPV"
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MKT7T=M;:Z9*Z]M)<S3\H/7;JJ/(^9\G@D+/<1O]:%\+A[ZD6IFX.U6YREVM
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MW$&NC6M,?W:VIA.1GBUZ"PH,M-E"REIXS5V,60A,DHOR:#(4;]1'7"9%%.,
M4<;KR'.S"V$)RJ\9 2E$5XFK4&Q]L?5W:?_%UM]V'80-^HIQY:. :VDM_]&E
MZ/,EC2FAJ4/!8U>9&\XJH+7.E,,HK7;<40&APB/S:SUUE\>R&+&R-5$>B@YB
MJ<Q^1Q$)R9%R>#!Y-]J8K\_=3/ YFKQYL57A8&R0&%08;5LG4)WT&/,II!_B
M??FN' >YZ5XX;-2!U;U0\\OBD&1)V*?77(NNO@WB,B?-F1NYY%CSIB9!ADDQ
M=*X^JS-.&1B1%-&@)5@S#]:DEYAU+;V(RO XD,#Y4JQCX$6PG0+TS/F!O2B!
M>5N]9>ZB]_V9539W@5<-'YFRDJ6SIDRV%.R*VRZ?$Z9\AP7-;!\Y%8.8RMZ-
MCMS WZQ<C>(F%#>A\,5-N@D_L63;O,=O^2JO!ZM_B\=OYV\A=KN:5N+?@@;#
M)3)1-*VX.OU2? ^!C],$I##E^ Z",E<L_/&S.8D434SAZ%LQ[1#-\)T1RN21
MNDT[?DAN)_/3B<H&NM$,I9)4^,.H*%"S(-O:I;7[5&M2]&SQ/.V&M14:"25E
MPJV"3 >>JA-1!<*,X,.>[DODM@$2=XJX4W9I_\6=L@L,WNTK2FWK8L,%F\Z6
MN@3P;;&,Z0%(O-XW/+ZSQY]FJ*OQ33#OU*3@DI# %4O&]S'[UKD68U.<U=:P
MJJR:S0%L%R +#/?UVJJSQ3V^;F;(W<08[: 90TB'+9XQ\O##%8]MPSQX=E)F
MDY1[M<&?V-R-*WFLVPOS84C>+H$CM&PWF4_234:ZR=RIF\RQ=).1;C+23>;Q
M-EVXN]=!NLEL<Y<%Z29SO_=HUB3<D+DMW62DFXSPN:;QO@O=9$X?7?11@HW;
M90O/\X)M*+KXSV 0) /*9.#:R=E"A(T$&T\EV"C!QMV[A8N#C9R7Y@87T25[
M'=V@GS))BXC!)-#=R)D^-E@691.5Y>Q#;B_L\Q%R!#W?5?:<@Z/R3QSZ^\:Y
M&D5JZ+WYI@8E>8X_4*0T,V&]C[@XW)(#[S.Z6]T<O"JA:#CDD@>OG,#G\$H5
M30H;0^06WT[N7C.FF!]XN*DWEC$9&*]$W:)#%XX./>=V,:-HDN.(94P;2A%>
M7?A=JSAOR5[R+:C),"(W,>B#)A/+S<Q:J9"> 3)P*E4,@L"!$ V-]M/W%#JT
MX0RJO@&!]V>99N78UZ@I <VE93"&-:-TS6EU]C57M7?9%FJ($/\74]XHL<OB
M9DWP@-CCCV*%OVM)\:R6%E81YT;Q@)-VAX]4/<3X,*?>;9#; \3<O '5H89.
MLFA[TN?BO-$J;=1)-VW)%<6*GH #0"9E5.+3$I_>H?V7^/1#T E(-FIU@..;
MCE+ (H#X7)8FT8#;_XVC7(.GF8SF586PD<%1@7R4@JC$.V'$VC-8O)7")#6&
M%<X7V>M$FPBC8#)1B8F[5C]$J0:JP:5E]RARW+W(@?62Z((YJ^Q&QV67#GX/
M$$O+RFK<(0X)6WPIG1A5@_ S\5P'\SYPX\8S+2YMA-]D0V.XV%$9W.:<=WGA
M,AK#7K[O(W[<B& C9[6$ ^^?-?7H.U6C!<UX=-)!M>]SN@?-J#J=:UA2TZF/
MGJ?>  \D:2E$L<5^L!W?;/6KS<RH=(SEZ@'Y!:Q@3*WZFJ>@-V<PHWP2@SP+
M#[QWNG211DG2&M2HLPLJZ<P3,1M,.#GZ2("-XGMLGAW6_A1!419*2ESN@X>_
MFTWM7"XAQAL&45P54P!UET@#$;*$MLM%2,A :$AL]8M;4Z&G';4N#F/2-#:M
M#4/L-D^M@4-$S7>-V73A*M[$ZH.\N?2%E2QVL=KR-(NJ:?,X':D7D7H183(;
M;BMCE1GODH4-"(]_:>WDBK63C?ATS\2G*S[=G;^63UZ^3PVDLU;,BN"K2CK]
M;2;+ES.!M=K9TNA""]+9YW6.:H>#KH:)S;Z_U:;GU'3/LTW$#R9^L%W:?_&#
M;3L?13^8YE0:^X+<]!-L=5P4UN_$[$L[Q^:RSQI;JS$_4PAAN9EO/YID$8RF
M76W(/ZO?HNN&8F&!RQFU%PZ/K6"_29II7JQ7 _84O=8G-QKL2VLE1ZV:@H%P
M Q,%=#M&H[4?)=&X',^ \U+)PFU:(GXNNC7081%D4ZI8,#X;"L[!;'2_)>WL
M<+8"_\%V9$!]DMOK6+C]$JP>71D3=- EA6E)@&Z.-W 39P6)<3@&'" *-9H-
M>R1U:T/N:.5HI;>CE'[!=J8>RLJVKE<X_LF"]U\_GDU2Z@EA24U;IHQI3(@J
M[+QAFH!_GATRGPV#J;5O.5:4%[2&T+X]5#&\40]';E>_I5BDHH$.>[]&N6;Z
MYJP(4KKY&H$OEH*3'U!P<B(%)U)P(@4GCS<O6PI.[L2%MCX16PI.MJ2^00I.
MMNQ I.#D(?$Y*3C98H>?1"NWRQ;^ 04G_X>2?S82?SR7^*/$'W?OHLWX!SZ7
M9-YK!R;G@&'F9UX+(9J0H-MKS6;,43.V(#=#: ]O0'F?UA?/G9NK-%#V1_JF
M+""G8@ @#%-.0NEZ,)MO-NW/[29D$+Y!^5FFK]W<ED-S6M1-.P,"["BVR('*
M9AK:^H4:XO?08I]K\(5W.AFRSPNGV*A)5:R]"/]+?O69-$B] N,^;]\[JBYI
MK VA0JZ#+.0V>T/O=L0]E3ARP0E@+2NC',IHB&[S>E/PRH?O:Y1R+N1QWSOA
M:A[<5B0$S-_*$9<C4P7&&/22;#P%XRU!^$=:9HG[A>= SG/Z&"R/<B,EH"P!
MY5W:?PDH;[M@?*,3;5H[D>H K-N&E%L!:MGH+^Y_UVRJZG05K&03AW+;A%.-
M7<Z5 ?X"887?Z4YU^8'W+TXOK[K?TPLIV-AL1^^(=W^)!3965EH0G6K$UG5D
M2G_,^\YRK7M)[F:YD4_*<=(86:RJP"X:[ KZQS@HL(4L]>ZO23@;H<9 -W?Z
MLR\.K6Q"F06?P]\E1XVU F!%OTY^UG)M3$';%O@A_"#,@EMNPZT2*FEHQG1A
MS\N!<O=9;VU?Q>FM4[OQKM(L]*:9G'%<K:YVM81$06ZLZD4&4!?*AL[G$O5"
MRL5P?$UAZ"#9)10 DON<49' $QA*)Q4%%0-)_9;4;Q%EFTW]UBE3O_/-Y&(5
MATMMPNLB2=_B=-G]"UG=G;%S=V9J0W7.H4[8!M&X %W4[^JHX5>]-$P=I"/$
MR?U1ZX2,,AI_X-N2S>MK]!B@?*VG$PZC(<A^@QJP=WKXT_X2OI;:RXR[I-XK
MF911*D)4MDIQX&C(DD8N5O\.[K]8_0^!,_ML-H/=U,:TT+(99%&_8EPZ';S-
MQUGC[W4(NQ;X:,TJNQHGM?19:O92\IUJ<U,$;M!SM3W%=A3Y]JL"W2EWN2%3
MG<T\-"2C;V)GB9TES&.C=M9[RSW<8EMC=6W"RGHF5I9863M_'=V;@]+*E>BS
M=:LLT<C@8'-DUKE(,G&4EMF,)(<O_,I*R74XMU%3YG>:.?7V=<;3&9E:70<_
ME9LW&0AZM\QI88B .])T(:OIR6,\PVGR: +]+M":R01P%)O&]!H59_2)!D^B
M3PBVSJF)XJ-N>GE772$%:DR+(P+;I3/#O0T5=@WD?C_='9A@V Y%C8]W" I;
M5#^.4,$!1HZ)^H\$_\5K^XRTE--#O@>_*X"X43F<!!&,P4J=+1RKK50OS/G(
M*H7 !3+<VH#Z:F%KK""SW71YW9; =:;!E^J@BD;DWJBQ9@M-@TK;(ZQ9(OZ9
M&PKQP$?'1V:KD&[$%A=;?)?V7VSQ;9??WQF!KW/S=NNV13>8M?99& 2)1G(?
MH_!!'V:9 &4A/\PK10'[7Y HKZ=(89H2!C8;OMU0J;$M39\-?IN*:&NBUZ3Y
M=XFZ5AUAKB#ON77,=8E>*W'6XMQ49]]%K+MKW9A<%Y ]J7G^ 37/IU+S+#7/
M4O/\>$L#I>;Y3EQHZVL!I>9Y2TILI>9YRPY$:IX?$I^3FN<M]HA)^'B[;.$?
M4/-\&=Z0PUY'OSYQA096&[##WXTB?\S229H'\69@]R2.+''D';R7+7'D<<28
M-^2*9.<L7R8+L:&A]>9E;QF?[41?.K<J6+N L:P(K/^L\F^W902/@U#5&T!W
M52GO11H[9E)F>8GX"SK<:!I94C!/3[GRDEJ'\%YD!NA3!IAV&/.:=&'SPJQD
MQ+")W($PY.BZ@$U 'O..HQPCY_4OM=]7O]SX[>LHAS8N@*>BH[&U>+4>?*$/
M7/_.../W6NN3]F>"S]CJ%9X<I.,)=O:L.FI7\QNHL,0TZ%P5NLOK[#QU&3TY
MP!-+=O1J4S\NB"SW<.7?ZI!2<)-&'/]&FD[+?L'A('S#=8HG#_M?YLJY*3:(
M0HU>#;"C#B#I+@@.?>/%SYB0'2Y3G3>Q"Y4A,"0'5I:X];I 'D,S7-/HCI)A
M/2$"L>#;/Y6QXFGW3H*.3@K/3!>%/9TN4 $D9O#XOAX*E_OFVP!>>JV'O!P4
M^Y(5(%D!N[3_DA6P[:SYO0;BFXGX4U"Z^E0+5*S(1ORI0)M%6AYG3;/(Y<E&
M0\LEO5W2V^7F;32]_1*N8$B]$# ZB^0QQ*P:4KC>)8Z=LA$7Q86X*,1%L?-7
M\\G++\V4;8-OKQNQ%<9W$.!UJ]P+;2CSC C:VLN%EIJ;K#DZ2J[K'003O.0=
M73]\:Y[[WBB]53?<((?P>7E&8ZY-BV'J&CF=#0G=_T6QMX1*[DR#.BW"3?)7
MUTJ<2N<J8:VS68U>H.MHT4GSP03?/'_GR&R_)F#<S,'CT%/@QC)+S//LS#OZ
M^?BG]JFY/?4*O7N^W2,PT,)T4C1V*DK(L91CYDOEF>AH]6<H*%-QH+/VGE>.
M),[#L[H3GR*73C@)[!H)T #FI D8GD[S'*YX;%JQ,R@\+QRKNJB0@PON:F?[
M"JW@=V,7S.P&-MTP+UR/%3W+)>Z8PE_O=%.'R:F/I7<2![MQQE)Q5#EV&M.W
ML]:?:-\3[$D<!?THQL4/*?<RX<9Y83"&26$3/CA* [M<$.9PHJZ!D5![0=R"
MZRS-<^?#%_3IGID9,IEQPL)W[LQ\T]^/=U;WXF&?J%C[8NWOTOZ+M;\+BDW=
MRF\H,FYDHUZ>=%(K3WI1A0A09OFFP2N%$VY'#/*NNY1,+*P7ZS/8L,SI9\(N
MX"8L%\K>Q;+==JZ=54':.Z8TYN(;=:!(K[EK:T 1$_C(9)9Z5#D GW?X<V'"
M>".4[8Y;I/66+/T = 5O#^>$[/_H\ 4%D;'2S?N5ET*?]U[L^TU]Q"H*6C$A
ME6Z>%J<77S_CB%4T0J5G#2.$*><*U0@"9F,T-Z,OL&KDLTJ@@4MYWU#06?6F
M>:S&G<V]!PO"I!NZ0:\!J7+4]C;/2T6_KFNZ6CFDR<"*O2Q(ON;>'V6",("V
MI7+]M<U&A!&LIGTELPNIA=) K8,)YAQIL!!]H8L$UTG2>NW(D?#*!/%,+\89
MK1X^X%.ZWT6+#TY\<"(/[\\'QQ;0)KQM1X?B;1-OV\Y?PL6%J7"!_*9+H:FW
M6I5HJ=Y^[#MJ#A?$>3IGS)G\H3FNJUJM)ZL79V<="N219@Z.CZI==UWD%5RH
MRHH_0?P)N[3_XD_8=M9=^1.68LO+M.1KX;0_TMDP8ZMWA Q6L\SU;OU PUPP
MRJ5>_P?4ZY])O;[4ZTN]_N,M:Y5Z_3MQH:VO8Y5Z_?N]1U*OORL'(O7Z#XG/
M2;W^%GN;)!:W7;;P#ZC7_RT:P]><<Y=XK[5GB5PE!MCA-Y/[MY&H7$^B<A*5
MV[WK..O:Y<R381G'*B\\> H]I1-L$5H4]8ZQOH8UX?P5]2W*"W+E!NP/1H<C
MS=/Q#"/"J7'[5BWDJ=878V=]95-UXRDEZ\;*- 6@!"+,=VGVWI[)XL4/<4,&
M(WS%, K+043?EYCTG#M3./ N,7VGRIVO,L#':5A/XT62-F6^[_YO:[)WM9"F
M0Y<\L72\U+,^2PM=^D^[AN&[1ET^)<$OGE@S(8BRD09\#.DXRG5B^F!09I3C
MKZN?EQR=&O#KNGVX#M0IH+9_=YOU@=3>[\0]GG.)$PM/_\,NL9W"ZI?8^[_O
MWKU[U#>X.K_OO<$2T9:,@JW??\DH> #BBO+!7/4Q<X40!]@72R'^W09T26<^
MA!?OXBH@4^<2+UB$$3P$;8/_>*W@4TQ8P+9-.H,")8')1;=]II2I"1R6&8UF
MB^"X\@__Q;E@(]56\];,N3 E:)0=P5V4:C]>:K/[52T>9W[0+"I,GF4T$-S)
M/#6+GR/0&U5_]29"3BFF'EO/<Q:B:B4)W]@)L_P.P4^MNFI%!?4]370^3#7B
MDBJ %L[51*Q.,,FX9L"?([Z=G9-: *D%$,FST5J =_4ZX(UX'(_$XR@>QYV_
M@)P!P*!YIGJ>FUMJLQ4;0MX&.=</HC4+EOI4_ZL846UA8M&?N*FG_@T*1)23
MMKJ@KP8I;GV4W*3Q#0$.^IQ1:L?QX;6<@ ]/4A]*A;H*ZUTH7R.C'0R4XLS2
MVQ'GW0^B&P0I'&0D:.&O($18I;S(.+V4U((;4(6B:_Z VUWRPQ'RGD2+ZF_Z
M;^,TV0M,">E'^]ZJ=A1T'=0U'(TH&.B6$I4>B+N%JD9-9;5-"'Q/P4K3J5+5
MCGEPRES+A'/P]8[K,:POH?!,+PO4\8PS:-%;2"<VPP<)OP\I"8@'OPOQF.!"
MNQU6?3K5!%8SBB:^]P>H?(5W V.4&<RZR,J\J.9.K!S4(NPIJ9LMCO1.D/=*
M;^>ENT2SHP?>FV] !#D1"JI8K*O"4_SSB!*($ZT<DO(6>-7!5&HQ8E2:JA2+
M $YZOAD6*<#IJF;.#\D'MB\G7$RM@=(*/CIDEY>4K4=UQ\#] IX6%Z)RI0LL
M7K<[P5+11F<*?+5^KZE94V;9-2M*HZM5/3BU$LL;7;V  =L<;Y/ZBKLQTQ$C
MZWRM3B(W%2X'O'$C[9SD3B7PHDF9#4:H6^,2QK!N6GN4Y&7&NX@]4V %0YN,
M73$2YQ:8X[0T>PW#Y&P%5!H[]N;)B /HKYTKQ:=748A[VQ+/DMT@F 0#&(NN
MD.DPDI:%S=NF1VQZ/*+GEM3"%I^NV$N:T8DPMTS+.(2=N5'UK:D8J#M-/7.:
MC%V9N/#$A;=+^R\NO&W7XY9PX063"9A,Y(HC;QX[0E"MJ_HN((?GLI]9V3%$
M:=XMMXITG]QZ75V62.7(]1A6A)E.]%:&6:\4SSW7T^R>V#XJD-@0VBWS<=Q1
MH')<9TJW226%@?TT/!VKM.B)^%4G--=QA6H1R@XX/MA>V*BZ*\\HN02A#L*:
M(,I9P"P4_57YK7M8M3XPO9/3&DRU[DW=YJ?S&R&HY;UVE=ZQ%Y@&**LXZ>"K
M&:6S19^=Z[[K<*'-7=0+:BG2;VLHLL#W5YLF3_!NWL"6@9;W#\Y='!=-U^K7
M=!U<=2^LWN$OX_6U_F[VZ*\<>R9E%$O'4>4UJF^4#<HQEOL!Y?L,D-MJ0#8L
MQ"4-26/]V)OBF)#FA-9O(%9VWV0UNV]$@^4CU6KV<41BUI^_I(7'/^XR\9#0
MT!93RK7M'#N.0PEZ;U<VYY"]@2'"AA9.$13^V1M3&9I].--A5 A*L50]WG_5
MX[E4/4K5HU0]/M[B(*EZO!,7VOIJ(*EZW)(B.ZEZW+(#D:K'A\3G=JCJ\>CX
M\:9#;#+[X;&'*"0BM"7;+0&@+0L /7DYB8.D<F^BFY";GAOG=.6UI!A/'*MK
MFTO#CE/V&V*3,Q,E[W L.GY%G6#K1'#LLW#!0#ZTEJJUC821(.-AU2YL^+3*
M YEQ?%.K4!,$XLYMB5<]R5E,-BS/80KV)YM<$!-[T!&KO<J;&<#Q9HF:VD2
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M(/NJ"NL_?!]H3$+^G-4MX%I,A_\OS;[JY]Y\JV#"3<*F<CX;T_.3.$ ,9 ?
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MMH<1%"VW==J6="3UGF]^=4!@2<08!-BX2-9^^B^S"@!!BJ1Y P60:V)F3)$
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M&=]?O'I44$B8^&?E)N*0:1#^OU_._[P96<LYM_\AOEH#2R'2E"$>7=@)_8!
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M[\K[*=Z5]SU\6?#4XOFR&$N(:D%<*HQE_FD]B,KJ1&7,HQA.L/UA\&&D <A
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M3*A+ODG'=L65X7TG%.L( J)Z2Z00;!IN';9BW#JL'LYPY8].:M7QU,PRJW/
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M\O%E\=-,>UG,2[,+!7>:JIX33OI,\ZYEO+R;1G5\/=:,6*=>I17Q8-51M>U
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MI;'D[  .]Q4.ZUGP^UH#!!\$/P=C/6LWBR)9.@2W-AG<@JEZ/5.U?#+HC:I
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M.0U\FI]G%F=86K#T(AE?G!N-_;1R*M^;"!Y"C%]]\ZJU]JN-K.N5-J[=98Z
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M"8.FDIZG:YE]X8:!'QB.&D=8"+AU!3' @(L<5@/LJT2CL#EGZ(#2(H!)814
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M]\%13_D?PP[E0IF99K74;K6FE3HA'P/;#ML.?(1MS[J:>8,^\2&$'S[QZ^L
MZACV4!5@!\ =BP8QP Q@1HZ$&A6Z11'=N6&AH\)'A6J("H'=0MT7L%38#GLS
MVH::VWS7W%[(0-BN[X.MP</+;8WMA$U=]B2L-6]_V=-ZU-/5:W]#6]8*"UQY
MM.,H^P6(Y=I76!.$%G U-H=KP+'<^2-[JF?+5R(7ERLLG T^@CXB$0QVL<O#
M"W8!- .[R%S/EJ_7W@-Z<0R%!+T O=CEX06]B-$,VXB"9V2N<,O7CN>59BQ2
MEP2URD:M?K*[]LD:U4D7,CAW3'<@O[J^O]S&VLUZJ7U2/JFCJJ@XQG9S14G0
M=>S$#>]@QX8W?X %[V!7H W>P096!\ [@%HMYQVLLW1A'>>@ >>@:+86SD&^
M57U!YP ;A&.QPJXM5EAS4_U3PS8<4Y;%)VG*P9WT-!5MU,JB7JW7<;(,/.V\
MKX3 NN!"'N<QEYO7JVER7EV*FW?=P<!UU/$]:O6P?QD&?F X/,L)5:^F&+JO
MKAHGZ<U2N]8L-VO5<@TG^0 1"^4/8?>/'8/*GYY\M*>JL?Q*"'"%0BK $EQA
M.Z?\-5O,#\ +P O "P"+X 4Y4PWL.;\G&C"?&-1>@1@<EMKU>JM</:R!'8 =
M[!\[0'(3Y4&92_?RBP>6LN^0X=P9^OFE//5Z9I9^@8*>HU*[=MPH-ZMUF/SL
M;5)FI3E0_]>NS]E;O0 5SCWL(%!68/: 0-FL!!HVX=\+!9C/GE\A3'9<:C=K
MY<,CU-;L!&6&IN=%TW]JZE8N@C_$+OXHC"].8?RY[X=<VB[<>S)W7!)*PTG&
M2H1#^O@H_8!&4FL+77%-?WN6&<B>4"9-_$FF"R< P$E%W3L,]!+G8=4;JQ>N
M*^!AV)*]3Z%'<Z./M=)%[". 4I=UG@RO=R&#R_O/KG<OK2!4)>P+5K>?E-HG
MM7*U6L4:5(!=4;T:N"G(2>=(J)<O1M_@_K0G$'YL4OOZ.@"[";L)Z,@NO#?_
MDN@KI+MFZL_R=>&;L]'U*A0--CH'2@ ;#1L-Z("-SJ?^+%_:O4$378.>P42_
MO@Z@ZF/O5 $F!XQX9X<7C!CP!'C:7I'V!AEQ'7H&1OSZ.@!&O'>JD N3@QW#
M41B]:X71JI[PX,[P98\+HX?2\0VN_0/E@D>8VV+GGU-:V.97I:G[+M) C/SS
M?X &*H9S)-2O63%<;T#X$=AY?1V W83=!'3 ;F)[YYV4W?EK99MK;#S3Z?TG
M](,!=<&_=3LT/?Q\P[XRK-ZYTS6&%LVEBG2I0%<W%>>ZEG^'ED\H=R.]1\N4
M>I7MM33=!T<]Y7\,.Y0+;6/3JI;:A\<XR16V';8=^ C;7O#RWR:$'S[QZ^L
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M$R^2@5U\]3>WKR[%"9/9;^>"'2$W'#Z$/.-PY-8)#D<NK,L&A7W](X[W5B]
M9',/.\"17.((B.R&P\N0YQP1V76.0UF#R!Y62^V3\DG]$$061!8*NSR110$U
M<A/[DYOH]/X3^H':;) W(?0DV3#3(A%WHJ0%?\N?32Z8#GW9$S1W,ZJEP>;@
M%1;'AJ,@(-\% ?LJW*B(SAE0H- (N+(+N@!.DGNH 78 ._(HW"A^SAE0@)/L
M%*Z@^#FW <;B'FO3>'V=*+4_R:$G3<O@%!0L*MAXD8SL"FF[PH)%WK)U8.%;
M+W:&[&[N_+:L2IS3YK3C]#H#EV3J?]6?"YW6>%@KM6LMU(84SS6#HL+(@)@6
M?WA!3($9NR;4&1<O0W:W0TS7*5E>FYC6>1-V$%,04RAJYKD"%"@C?U"0_$':
MD/#QR5J.W/N#T)>"AEH&6E/^^]?C>JWV0?^1U">#I,&Q*Y*)ALW-I\W=5Z%&
MQJ$HLIM9QN$RMJ5?I>'+:V[R\OY/7W;8]J:M\]F/H71\N9BWURBU3[!$%=X>
MM!>6!VRUH! #S !FY$FHD88HBNQFEH;(AJTVB:TVP5;!5J&]6,> /,0^YB%N
M^H9'#S%X!Q33';#QP)H&^&R%,[2PG/FTG/LJU,@P%$5V,\LP*--ZRI:UFS*L
MBWEFK5+[\!B)!+AF4%(8&)#2@D(,, .8D2>A1B*A*+*;62)A'5)Z6&JW6B"E
M(*50TNSS!5C+@!Q"07((?)J'N/?<@>A9_M#U#9M7- P]7JX0/ O#Z0GY=V@-
M>3MVT#&X<$4RR+"P^;2P^RK4R^<5)H=_'8D^\*5Y8/TXZ%L]FKWW0O]+$FP&
M!ZW:!P&)7U_BC^NU.D0>CM5>*P%@'U2Q:! #S !FY$FH$>TOBNQF%NW_W; <
MCLY<.C>&+2_OKZ*8S)5-PW<6QV26/(GUJ-3&3IO@JM#=[), "/@CX)_#@'^7
M6GB0$R>F\DHT7P7[;<NXLVR<G@HGKGBV%R<*Y?M$H7T5;IR>FC.@R(BD U>
M*^ DNS.\X"3 CET5;IR>FC.@ "?9*5Q!%7&A@HJ-PNI)\_7UI-2^#/J2I#ST
M//HY"B?"VH*I%\D (Q67SU3<O@HU=B$IBNQFM@O)N6-ZO&?D)ZG_/7>4H>UJ
M.ZOVC_27+  Y+K5/&J@ *9XC!]6%V0%5+?[P@JH",W9-J%&M7!39S:Q:.0.J
M>E)J'U>/P57!5:&[J%9&8F%_$PM(*,!+*YYQA;7,I[7<5Z%&0J$HLKOMA,*%
MZYBK.VI'U5(;.TO"38/RPO" K!848H 9P(P\"?7R*86M[957QUYYV"LOKS@.
MJE@H)<#R 43Y$>7OF";):>#3_#RS.,,JP'DJDM&%%<VG%=U7H4:DORBRN\5(
M?VQDK[2-7>C8J*-:J5U'"18<-J@K3 WH:4$A9@7,(+4QS.\R. !X #QR%.1?
MBJ="B#<OQ&^VN()@#F-=H"JE7FH?'6.I:[&Y*U1XTRH\&9@MM=]B20&2#7N5
M;/!"26*8.D-;GW,Z&-KNLY3B3CKRWL*" _AYQ3+'L*\YL*_P\[:>CX 0;]O/
MVVQFXBPRO-?2-@+9^SHZ@F1)EZ]!+A\\/GA\4.85/+Z]U0LPV]S##G D!S@"
M9HL,Q@X(\38S&!MCMDUBMJTZJ"VH+;3Y59(96$V!!$?!$ASR!^<WI#[7U54;
M*:5.=P6+@PN85_,\88J?2-+=)Y9Y41L&\RRS[]I6;Q'KONPC7_:^'O5^<1X0
MVK(&"@"O-(_YEC758XO:!;W*AZ.\\<4IS%E2#G+'Z:F]J2[C4^I7=YY;I7:K
MCAVJBF.=-^=[ QN048([L6/#FS_ @CNQ*] &=V(322ZX$]"K5UXYE)T[<<A'
MZ#7A3A3&.L.=R#<V8$E2T3-V]<+J0B,/&;N/!%]./*JGKMU+AG/&.T?O=T>7
MTNT7,A"FX?=%Z,N>H%EU8R,GV#8]1OD^;J0-7@L_?7^9 /ST7>$,\-.1]H->
M%2OM1SRE2S3ERG,?K9[LG3[_27SEW$E<\DY"5I;TR(]*[5:Y6H-/7AQ+#)\\
MWSB %!]<!P 67(<=A#:X#DCQ0:^*E>++S'4X+K5KU?))#6OKBF.*X3OD&PBP
M*F_'<GR%U8S:#F3WV.Z)>YN>)NX]=R LYU'Z$\F]]\CNP47/.2]89U\7 -#J
M #3&%(835ASN\(8R:0"*3($B(P\ N )< 2?9G>$%)P%V[*IP;V*K.0 %. EP
M);,CUQ%ZW'CH42TOJ!56)^JOKQ.E]E7HF7W#E\*]%T./%P<$S_K$D[]#:SB@
M>V!GP='S:GIWM[2GL*B6MX0CW(5=7@PP*18K*MF!+\T#Z\=!W^J10+T7^E]2
M*C,X:#4^""CA^DIX7*_5H87YMG:;K9Z!#8,- Q4OZ/#F#YQ090\\VUV%0Y4]
M]"K/5?97QC-' _U;MV/^'5J>O(JBA5<V#6#'Z9W% <-TE?WLXOJ34AMU]<4Q
MOJBKS[?JHZY^%Y-;V#LK5WMG32NO1W4]7/.]9P?(DA6</L C1Y9LO2Q9$UDR
M9,GVP]HA2Y9;]8$- Q7?;W!"E@QXMKL*ARP9]"K/6;(9>U&=QX'#5?>B.JXB
M758D*XQT6;XQ ,?*%#@U5E@MR,$JR(UO.75O.89C6MAR"IYXH3@ MG<HWC+L
M?15N;#F5,Z#(B.T#5X KX"2[,[S@),".715N;#F5,Z  )]DI7$&E?E'"D:C4
M?_6@9%*I/XP2;^+N>6ID$H%). $YM^V[6R)46(C,6_82_@BJ]7^J9'.K]5NH
MUD>U_GY8.U3KYU9]8,- Q?<;G$#% 6,[IV>[4Z2_#2I^""H.*KX?U@Y4/+?J
M@Y-/BI1R*JSHYR INY%D4T^:U =?\JY0*O'$1Z:H#WQN"DTB;Y6(9!,\W)S;
M_'4JSOY2[:M+L4 -?F4>4SR+++*&$+_:2NO#-59:\SHT_M_9R-Y>2S_P+#.0
M/?ZAX_3&OTA=>453XO;.'6W$/T7&G/ZV0Y[GLQ\FC=.#O#8">79_+\VQ/8T7
M6*U=*[5;Y6JMB17;Q2MX!"*\_KKKO=4+T./<PPYP) <X GJ<S8H,"'&.Z/$Z
M&Q'EFA[72^U:M7P"?@Q^#$C ,1[(U.10,W*1J>G.2JV4Q9VDKC@TD'QR_;,T
M/%!!^)%Y-<\H),P=ON7-\L.CW>4U/8ON]@MUVI@ZS76MZZ_E6B]T..9QH]1N
MULO-9@L.<F$L,(H;<PH$L*MP#_8=G. > ,9V3L]V9YT1W(-\N0>U5ZM,6\P_
M:);:K4:YT3J!?U 8$PS_(*=(@,5/2*GM3TIM$\=_3,_(2?HVR<5AY1-\[CTW
M^*>V87X7]4J+GM=S0S(0,YX8__BB][55?.[B[D2:-VKPLACG-R!:?K)S6>H7
M-.M5W>]\>]^M4KMQ5&XV:O"^"V.,-^I] P@0UH:G4-3AS1\XP5,H.(S!4\AU
MH@Z>0F$UJ]AU?(>HXRN<,8:GD%,@P%E9R-W]_^R]:W/:2/8X_'KF4W0Q.[]*
MJC##Q08[R9\JXC@3[Y/8*=NS6_LJ):3&:",D1A?;[*=_SCG=NH' @,$6YFS5
M;##HTMWG?M_OV-UU-!X[<@2_&8X*P T<[U[8KI)Z(%?>L=K)AG1993>/MWT9
MQI$3Z^,ID<M.N T%MYA1;)51;$E+9[["?(5UDM=SO*R3,.]XK<B]B09OS"A8
M)V&^PNG^N^,R1.C]V%T_>NOE::+2/7?A<3(( 3ZVQ2*5U?&R2EG.M2D= RM;
M()!S;3;LN"QKKLV3AF^F]+9P^&:'AV_R\,W]$'R<UU):\F%'%VOE^\V<6"O?
M<3;&6OF&7??[K)4?LU;.6OE^"#[6RDM+/IQMSJ$C#AV=NZ8WDB(T'H0O!X"Q
M\(\I[3O)<22V6/=8<+/%NN,BGBU6CB-MS&(]88N5+=;]$'QLL9:6?#B.Q%KY
M?C,GULIWG(VQ5LYQI$UIY<"D62MGK7PO!!]KY:4EG\5QI%_I P:*\-L,-. -
M/P9.% Q_G$HLWW@M,,G%,([AI3%,FFO#Q*0#*@9*:_IUE>ZUE,(P36\T-MP)
M'*"X\$(XH] 3GVW7<$W;<.",C) Z[00:=!_^L.P[!:X$1E^OOKQ*J&R"3A;!
M)"84=#,BSX3_](<0V>K4"X7AW!N38(J[O2--0@]6RZP=/9?TG-SVB"^+_'E,
M7TG'HB[,[$/HC8@4*,F-68@* BE E #Z_1K >7 E;R/'@'M-S_%@(WW4G@ !
M/Q^T8ZPJH/=7B5*;(?29<&6"4LU9,O]@B*&/;1E_N[D\K=<;E2[%XW%&S2GV
MD"3:-M20&OS?+Q^ PF-PJ #^9?^_T@PII'\)6H-O6_)@E=%;^3_'.K /"\,F
MD3?->AM6B4M(L.!+20=[T?2?=6%/*0V+.,J=!T2\&9:2OO#)HXYZ5Z<]\?'\
M\ON7WM6W7E6<7YS6/O3]/[H7ES=GU^+F4GP^O^A=G)[WOHKKF][-V;>SBYOK
M_.@CW;ST(AH!',Q\[])VA?ZVW4A:O1!0[M*_-5S[?]3(#3"4>!O]T7.M[[X,
ML.\;_GDY2.14*J8^V8'I>$'D2[CZ&H[+'H".ZX8]$'01ON7V.SS/M&6 G.:C
MXYD_#\SV#US!#T Z&9C&&$XF]",YW2CUN=>5]E!M-NJ=DTJ6/DJJFFZ./DY.
MUB>0^>QQ"^3QIO%6Z;9$)S@2[#H:P5LFR& S@!8II$4,ZO6)Q.C;WH]/@*V^
M/58X]S$*;%<& 3U[LC1RXX/>+?.@'#8>-W/8V'IF;+1# +2Y']AX3GLMPLGL
M*>1Q,@-/Q,(8HAETBQLQ:V2+T4_CF)%TF'X"PC45QJR#J=V]U =;F],'FX?C
M<('E1ZP*X +OA=6#2'?-FGB#'JZFXF/TL?'^;548XI-TC'O#EX /_MCS"3>J
MP@[$4!K6WY'A8T\%2]BN^+<,PI'M!O!%%71+T/4-RZL)>AM<;P!,;1<]3CDD
M=SW:6Z4+!P\[U4B:+L^4$;FIA+94A3$>.V2O&F+L2],.$%E'T@*6ZDK\U?<,
M<XAV;#B4PI)WTO'&*(35P$9O!"B/PEF+<J206^E*>HDS$2&<E@QA1W"W;XR!
M36,W=6$:OF5[=T9@HBTC+#N01B #M3UR#G;>!\*!,X%5>59DAG"+:Z&*(''W
MH$;#(SRX\O"X^5Z\Z4<FNK\<SQ'#B>5[YA#."Q3KM_0V7'D(QQ+2NF&%1NBC
M/3ZP^[[M.&KA"<0^Q_!"*(SA1]0XQ+T=#H4Y]#TX<P26'XJ!83N@@B1W?DGN
MK"5<(<L#"OG">E3=9*K>,E6?NZ(W!NQ0ZDBSWFQ6"8\^>H"ZB$.?;""7T/,#
MT 30U68'0T!S0UR/)3E[3H$T[#!$MY +9PFX],V89)_FR]  (%OBJP$+ZD?^
MK;@9&@X P%67_9\Q&K^'Y]042P$2E'>&$R$)!"&P#GD+J.@1Q@3X M.)$-:
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M2,?S[BAZ&DID+[Y0+\+WIJ=TCV%4E?&?%#Y,A"E]W?+?"#/SWN0#SO<,=$V
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M1^/9X;,K*K>+SOB/T.+C+CKN_(,R &C4FL>KG?_]T [E 6C6)I"=Z]W[QK@
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M0Q_YRF\WEZ?U.C 32DE7PAR 2IJ\H50[^-\O'X#"$[O!"&SS &%R "QG)%>
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M$&](1?>B &@N>/NN2#&?2Q=/.]'N!VH>53R6)R&2I.4XJ'^_)^HHZ':.,0Y
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MB&'^E.'!SO*)71"%^XG-6[:\&'6W9H(M,=7^F9+P%QEE_TID,HX&7[(4J-/
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M8.J*)78=&EIWLB]:+DO\LG+(U:.D^W.,C+5EQ=IGTE-W5KZ7P/N=4S?&4ZK
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MG?<! -(+ $IBC':F, +A#<1TU!B_PP?#2U AMN&5J'=7!0@R<RCNO<BQQ-"
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MO6ESV\BV)?KYU*] L.IVV!&4B@!)4;)]&2'3\K5>NR2WI#K]WB<'!"1-5($
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MIB >QNU QNU5(*W66B]+3*ED\9I5V[0--J=UJC=@\6#QEE@\HV$T5Y@W@"/
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M6M=H-"X^_,Z_TCV-E^Z1N0Y[HJ>/!B:M4!2*U^H[+LEDMGJA6!";V6,K_F?
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M\(&/V)I75<^0 (,ZR9< V];O/2._M]X^U^'Y*F-5X?E*JMRPE:#\50<G4'[
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M">BT/$PO\K'SL6*$'D.DU,.8G2DN( F0)+&.@ D=>@? A  [51-ZC(M2#V/
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MV+@T.C+TQ]Y&P1!HVF%A<'O_"\6L\+]D6.MCJ/5!A6NA%:X@#2J1AC>TE]'
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M)2KSBZ_,%W6F)X]FR$@(_>&(>:')C0FH'OQ-:>OF9VT$S.XAS:XXJ,%X#\0
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MWL)!/D!$E9PA#/\X,JA\]>"CBJK&YGT0X I**L &7&%/A_QU.#\ +P O "\
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MG.1YK<EKIG'?[)K9,T\@2XQRX,\@("77_Y/4+6_\;&E-?7+O_+%FT]&BE<V
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ME+/B&HH&QNTU")E%63.+V:S5T.]'SV;  .KPJ9!41%(Q%_!LEY=4;%9RJBK
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MCTVY"Y?HV!X,&LJ"IOC!C4 /NAM/&O Q](%/_H5(N.B_^UV$!.[/@)83D>.
M499F;A!,)%CM*[#A!1G@T2]Q\:T&WE@@1 P&,F)=Y6)N.E=9G&3HL(3GSG[<
M#U\JDBKCI($"9!R+>S_*$ARGY%?EXU60NC_U<&7-H'SIP=0'&&\96X,A9SG
M_<29Y:;\N>_?G_RU0._7UW^\2D)?15:11P&P^9X'/#R&N67P3WU(,?VL]$(P
MEA[<25+* ON%<CM571YK['@>C9Y3F![EKSG%]2A?2<LB+[3FX:B)./FFF!OM
M'75H2V%':4.O;F [=Z_%71:X<*^'(;=?G![FLV*ZSF[G\"T+S\[JA*>AJ<ZT
MY/S-=88QZKF_W5Z>M5J@W*BPAXR!AJE,AW"EWPG^[R^_ 8<;WQ=H:&\7]V07
M5.!(++$G.V]V7]>F%!^1*\6<R*-5A ](FWRXN+SZX_3ZRVG#N?AZUORM%_]\
M\O7R]OS&N;UT/EU\/?UZ=G'ZV;FY/;T]_W+^]?:&KGCW+72SO@^VSOM9GDV$
M47]RL&@>1?PG PPPF#SBNE;C:Y=(X"5"2/:[SH9N? EX(P8LLMM9\*TF]\=Y
MAT9 LTP]I;1: NY/#XB>L(1:N82:)X] Z0S]1[!M[L*;@7*ES[T"ROH2HO>M
MWXQ'&2DV%OZH!W!7OH9 _3TZ!;.T0+=A1&NP<[(;#7;'$58F4T0(-R32.ZU]
MCPX6PAH[0^$&F+\4 J$5QR3=UV>7'ZYA.@]#@7:]@Q[) "P$'004L+@^*F5X
M<BP\@98#W:+@^\<L)DL9[B,?O33.BZX5;5XH&P >@Z3:AXF;1)EU^)!T]L"-
M7O(S7*+V8I9V9^>DO7\\-[4CJ=KIAB,W3/'I;B*\7?_'[M#O ^G]XLC_ E]Z
MZ6X;\W31#Z.WT+AC8C&BX(_T4+ =OUD[_J,V3;_ 7KA@>W\@N_ZA,94 V)B9
M9D-9^LZ(F$![HGHZR- W089%K'HS'#6,*JL>7P=[=X]^!'3EF5<T+(/?\K5U
M=;K:XSXCCM[7+'I_.0:10RKJ,SH_.45FDT+B,G1.LSN OLIG?4R,U))<7$@I
M=IV ?-,Y>$"U05'%'Z"E4A$\%H)Z0K3 %,:%.6/\R0W.DQ3>I8]D5NJ^Y+^#
MM*C\NCLG^XU.E>I+_INYL7 &0I"#/2)QYX Z\P,_]66$_]\B24>@OF Q&B:9
M66DV%%("HU.44 T""59XXO2RQ ]%DNCGY3+K$H28P1%MM=CO4 1V6K\6?J1?
MB"/HU_:O[R48D[N KD,[4[DRFQ%7W%IDU-V_]+.8$G/+*_P9ABN$X45Z\2V\
MY'* &!_7J[BD>SLG>YVRV[*0^-L30&HA\G75I"E:8KEL9;2D@NQ4A(0H[I'4
MS<=G=#G&;;^-SG^D\,SBC "\P/L$_4+Z[9&W32=]#X"RIW(]JX9QCJ <C"9Q
M.9@WHH.=$]KM\C++W4_\'\Z[>6-\YNY? P)\< ,D@N*P#G=.#LI#>E_8>IT/
ML-!^4?BH^.I$KH;HG_\8^_'D_P$01VOSBQRZ/9:CG9,;,4Z+<<^]\NC*?P/Q
M*:"B; /8>) K$^1VW/FQ*6Z*LM>I>$,#^!VLIR! LP?P+1 GS1V?)#\(D"P!
M_KGX$<8GAN4_R,U*;Z,/ H/*M$S!9,'H_-XQ)7U7A.<US$-Y0S/4@>:*]2!V
M_D<6"O-5NY*;,:GDN7KDJ6GRLY3(C1K2:5_F.[F!1+V?C!983,WL8X"ZVL(J
MJ1G7O*E:X\S3)5I9X!)7Z0>SP NIB':W_;B4H-4KB0B]:'-TQ'Y[YZ1S/%='
M(,ZW\O=@ZF4=V&T^7^J?)DDV(CF+4N0?6?].^J^"(/+(M74YD->%_:]12-/"
M/!*P9,.TD'R/O&)TL'&"8 )>X BB*<Q;$8G*;%$>BH;""K[,"-1 RM.OD%?+
M'XU?14DB>6F>"$-\ILFG09G+>(8:1B!S+$5(UCO8>3'F)R+1(?^"F097>6B4
M*<<*O"BCXU%DV6$V J90S'#.*"VD'3-ZW.G031<>^+1,9GR_?GR_U&&7*M[Y
M[ /W@V2:?''3+(;_4DAKZ1,O3WAT499T=DX^97"9<$!8^*-L5,C:[V?6V;0I
M&:)P="FF;P+Y,Q.$)%\DZJ1 XKPCVHZR!'@F>?_++(JN])L_;VU/?J-:%]5-
M! R[F *IK286R5:LXL'HW7$B?G'T)_W3+Q0)IY"V\S?06^86J^**8T7.4Z>E
M_H,Q1TQ-^,LZ6QO0\U]W:1RUT$?=9K?[W++F?U4[\A=N=+#*1@?2GAAK:L0"
M-&^ ,%^RP.3;7M[ZE<1:9]>R:HDE>Q5MK=RJ6PFM&;4F6:+5H^KDYKL",F?5
MOY[\7(-!57Q(KBFP#OMU.?CDHX\*7:4+50';QRI@QW-J4KYID5!#+;Q\84K6
MK1LN3UE6J%2G\GE6,EO$S[&(V1Q>N3DLZT')A"Z,[4H_K\[]8UC)AG)=5?1B
MRSM+:>+[Z=*M%1_;I#G?*E$O;XHN8O(Q[;XVN^\C1M@6L?+VV,I;LPI9FYG&
M7+MEMAI'-#=BO^%._[F]#HQ.':PX5#*_./YHG&':E;3A?$K42U+&8VS#;9,"
M?H)&!?9Q\:SA[M9*D6U2K6^5NM=LS#$1KYZ(W[V,6?<MQ#8$6.4+CSQX<.DI
MU?Q:S,;# O5LXFVUB<>\O/Z<E_<<HF,3[ZV9>&=XR ./;F&3N"AD>,:V75TU
M[^M-9&7MSN9F'<W-;4]C9;[:)@MXANVK$,IBIN[!SLG>$=NZ6Z-Q5YNTROR^
MO58R!T<W8CEO+6?4(KDU+T4F0Z*!5E(-)Y25.SRVI]F>9NTN'_D!R\L[G>8^
M/*\?84&8&4_4/TZ-OOT4>[JF9:Q?A?KG@Z$ULJA7QU]E"GDBO\VO_KMGBH4P
M0S[#KW74:7?8L55OS;=2NY;UV>82?*FQ$M52DD4A[4)-7(YL[>7(KJEEEZR1
M;Y7%LXO'W:E&8527KH_%OI(4C3)L!:QO5 7KL<ZH$(6"@K)<?V4M+W@>UA.D
MDHB/=<$[?GJIXJ*;$TOT+U2@?Q\;BG:JJT?BT!\9<?<)W4^?.^(C[,<XHQUC
M+)*Q+'D<3+C>_V;J_<]O]5GR:"S !L^HUSW#U[\871VCDW\&7?E4<-(- N.)
M4<4S;1&B.W\J>2'+<4;4#D3/7Q5:I4:;GB>;QJ+?I^<&5$ S&0J1-ITS-QG*
MLK=4I):2\I*I6I<CF&06RV*VL 7%E?;5^_'"R/B7/'SP@*H*4A?PJ.AY2IXI
MXK"]Z/S-79F\T$?2%MK;@Q9(N1DU<A>0<B\TZ#8(NNI!EP0=%>"5,D3T9]12
M=;'#RIVIIEH^24]5>_7FEZAB3J5*?WZ9W^I2X!,J%C-OG?ZMYG(J!WVM!VO*
MP[>+*]79.6DU]ZM+_N+;$KE$.MO5B;%D[JS9YG-:0#XM5CM[H5E^5*.[QAK1
MLL[V@K6T#[H[)X?3E;2Y"4GMFY!<N=B>T3G5%6*Y"<D&D0N5C@\FCY6.'\L]
MPB[Q=V&ID=D[%""J,KK91%T8/6^1_2T$01TGB'^^B#ZU\CZCMZ!<_4<$\PYA
M=W[/X$4]$=\5K@?)][^&\SL(/< *C&DW0AG?3$UGV2M9M20XS0LYZPYLV,@-
M$1\@LP1MQ8<H#F:I8'B?T;^*J&C&"3PHD!I(=6C.9"NW^.OIE=>1G:C&$34Z
MQ]X.\+C4=# XN_S7Q<<9+VP?J]<U+"@**^#+\O-)(R_2+EN\)P)U/%U,NA*(
M$'$D046DR>:,%UW%T4"]JIDWVOIW% QB=^1<9ZIQ]XWGXQP& !,^JL9:]*[3
M0/QP:<GO82A_9".4CJF#3Q5)@A>E=+_B&9SV[1#&U(L27Z+</\0([$<7_]2-
M"LYN_S",J/9O-ALJ+L-'8?="JE@-/.-B=[&FW.PA;$,VAJ50X#_?$& CD:11
M:->=3_16/O).6<P>]'Z W<JPQE&Q)05,H7NP]^M<0'+<+J1'[2_1SD//X9N<
M&#8[T9.YS.<"7U]'$S=()]:7!IL<6-!$9'$1F>SMG+2;!U/81%D6?A#@;*AS
MHWQ!80EU3?_HP4F .P)$<'<^PK?P3H!19CA$,2(R$G:BAEV;R'6\5QX=VM,1
MP$(/)@O23'68)-1;9F[5B\?L8!_!(EPDL"F,+*VN;@$VH":3] M= R):_RCU
M!7"79/6D:1JN3SG_*EJN?^:6Z]QR_6DMUX_>,D;@ENNO<U_7C?W4X-JE](1M
M[L(^OP7+O*XI-VGD?1_"T "XG/\W ^R"O4TK^FQ;78KV6YV.W6R;N[ZOT=6P
M9'_WP_<Z/CG=POUIGHN%WBM)Q_GD8W,HV/>9+5;9+;4"6CE:2"X]Q4EU*JVO
M+V[\7:1.>5?99;59EQ4VEJIV5)VY8]Q$-.<_"EBQ/AB/>T>=7YT;L-,2R\"Q
MO5:EWXJ^JW^ '9C<QBYNEG,1)JF?9JJ!X(ULDYTXGS^?R;Y6=_1H]5C[3OW,
MAC/.XB1S0S*:9!1>MNUVT6H:J'[?B0B"AO0YI$ "9(;1?U5W3_O10 U#-Q:F
M [AIZJTZU"6HR>"];HR9,=ECT:EVMV.;TA=?/RWEWC^CEY+VO'+CR_@&6_/U
M_X4OOA+Q#8YT5N0'?I<S*9K/^QC8 'PY';8:PVK1'6;):2GM>9L&C<R;F^--
M[416;=Y(<E(ON#(3ZN"LC.XZ[KWK!V1#F+@4<@0RGNPP)YMS1A3VR\@Y42#X
M6-RIC!7:?B \&1<.G4^PF%+_W\QPWW6U5_+=UTCY[KK=[HR+._M[^T?[ZH[W
M.IM&ND H-/VEV%V96D>>CF,_F.JX;+7@)/=@:85D2!V(D$+C))!P$<@ERS2]
MR3Z.LZ1E=ZZTE-VI_R?BJ-+ N$B23/0_9DCC(/[\J$\2$AT=]-.,]K<54O+@
MT8'NU6.@ASLG7Z.*<Z13?7N)$RB=8N3V[1Z3%3Q"@7B0&=2UEK%UW4.^7T1\
M!YO)(=^7D&<WP@!?8\ X@"7#1+*>@DP4_<J2A-JHA@YZ/Z3R:K><G@BBA]R9
M;^6;/,_IDKM7L*_U"%/(2)E?8VQ0]#$_,B&Y@WW7^SJ3J-H5TSU@5TP]73%'
MRA5#.[DKPZ_V;K,T6)\TL*AEE@-ER<[5-]Y0]+, ./9\- ZBB1#*+,X9U=Y<
MN_/[M?"BNQ!#D1)2$']7]6">[ZE=UP *XF2OM7/RZ1F)H7FZA'HC/4FVMT8!
M/+L#/.:KFAP&0E0S+B1.LEO%ZRGK;%P=3#:F$?D,5.X?!IN?TV5[$W0PMQ>W
M0Y\O[T4<^WVQF]>PTX>9:MR;NYV/]K'*#&=Y4+SJ$%3%:48U[O8S#J95/'ON
M>;6]Y<^K=18_KZ;VX>"P>;R_LM;=,P[[\7+7K.X ;@AP+$JY_[.SSYLS:W.Z
MK>;A9H]0+W+R\FS=*3W'&X'A:SANN4A&3[$-TO-@^&T.8KY($'..((8"ZD4@
M4\3CJZE.M,_Z[F7TW:.R]6VM]:P3_-ND!#MO;=.6V)R]9KO%2I"5X PEB";Z
M'/7&PI&%X[9MVA*;L]_L+KD[+!S?EG#LK@/[<V72]7FSN#+IRBN3_CZS*LZK
MKQ0V]X4UU?[;ON;KK,ZVHAZ.6RM/ZE8TC8N SJ7O3K-[O,8NCDS&*ZO]MTQ-
MMR5[5ZA L>A7QY'/96A[H1X6!T<[)^WVWIMJ8L$JO-8BCE7XELL^5N%SZ;O;
M/%A2?K *KZ,*+Q8Y?4$5?@PJ_*#[F KGWK+LAWIM?JCK0FDJ<2^":"P/3["Z
M8;1:3[3ZS'A1C1O+;JTLJQ_RX'ZRSW=\/9,KUL94CW>_H;)0:F/G-[DY8(Y\
MN4XX6)Z/&9/Q!>,+QA=;)\T87SS7*U=7?+%HOWIFITTY"@_JX2@\;.V<[$W7
MC%J]GY!SV-AW6'O?X2V656<-R$#^[0)Y[IB]Y<B#(^VU]AFND[^8LUX2T]<D
M]'_8?GO9>XQH:K.\C&A8[C*B>4M>2D8T6\M9CWDIZP)I.GC*]E%(([V4U"6-
MZM_-:*'&A3(W4 9\V:*8U41"-;4OQ[*S(+:P]M,)>9B?4?WRJ6\J4F1WYX1N
M<2*ZQTGSPL!/ZXPNZW87ZO139P9LY8Z-%^^%,P[@';+4MYNHFIC)4ZM/KF#!
MYY:9?)FRDJNJK_7&*YK,"ESL@Y8_>/XY!938O,+UL5AGEX4YY'V9M2][!\WV
MDD&\9^+N^?"8"\+4I2",TI_.998FJ1OB#ECU8;3X0["Z=/UCUE>;UU?S!.7;
M6N99KI0M469<XVSVOM2@ "0KLSHJ,S K>V"81@.J>*Q46X4Z8\'(@G%K]HL%
M(PO&YPK&?]-?JA+\*= 9C) ^G_\0L><G\H^KV/<$B\O7("[?UAXML1<UJ(_+
M(G*K1.2U&+E^B'X1_.L,[L207N8&]/>MB$?TX9T?2H:<"#=.WJ_(B;+,F837
MG5.P6J\^'T18W4$$[4*,<A>BY 0*#K9_E7]\%)Y ZZP02NS.@!G;3KUS7U@_
MQ+#MR[W6E&HN7E;';)^YC<\?R?:9T;TRCMWPCGIH?IA,=20^?7#COI)T5JQ$
M>IP6;91^N+=S<M ^:!RV#N?D![U5UEQ)W<P26I\#S^DG9NZ7/K__"FF>M?^K
M%C$L,VJ46/\*Q0>CV5='O,N@V<Y+85GM 5/.+QT:H*A )<+-$FSN7H5S]W=.
M]IJ'!V\%Y++"KZN 7-[=7R4@YQP3:'</"_R*Y0Y_Z6<Q>H$K>;7W.*_VEN95
MXZ.VW-/HF>[D;-G9;^\=@QQB8;]^87_8[.ZCJ"L?=UA-)("]_NSU?WFO_^\@
MM3!<]CHU.BOO&JPL6S?;HO 6KS6R:5\]B:GD(@1#Q8_ZO\=1DBSLK3\ *Z;3
M:+5:;\6.86<]<_=;<]:SIJ_#RK)?GL7#MA,QP]5MH=C%X>J*G?')4FAUA0[Y
MPYV3=O-@7E6:M\JUK-3K['LO+",G4+,K]36Z4K5@9V<J2^,:H=-5]GD[9&B[
M\39O=H>WMTKU[*9\2Z3/?@C6H;67)BP>6#R\72!XQ.3.0)"5XBM:V9JY^=BE
MQRZ]EW?I?8KB@0 !TG?<$ C0#3T1!.S@8SE<)UQ7\FML70-H8%+7^R[2W:V5
M5?6#C>_JF\JI9&H6B^0T[)__&/LQ/<'$RQ=.[ 0CI-UI'!UT.![^?!_',\7
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M>;!FV"[*>?#3H?/[Z>E5PW'1,)%@$.!'$#W0!<DPRH*^TQ/..([N_;[H._[
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MO\?; "V,HQRIX(\C.2*\%AXZ=N-4_Y*XB+K0.0LC3&,@$+D&C3D/51/_Y,>
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MKM.O,STB$M%KA78F$_=]E.[EPU]2P(+UG)^CRE$PF,ZQ2-716$*U9B"IF4N
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M&Z/M.3;<7ZK\R<QM2XRHJ*(K=?44+LWEBUMY"-H20$9C&)055745:SI7I4I
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M\TO>QJ'<YHIX.BN VBB _;6[]'QUU!,IZHPBEW<BG!<88AVP5AV@3BM;#HI
MW,EZ YBF0\?B9;&[&$M,*H$&Z^V'E&3QA)I L9 NM3#*#RX77E>5H_= 8I9.
M3,CB?'V_7W) W@OG>Q@]!*)_)[0SI3@-S L5F);JWF']$ RELSBJL3@Z6&_0
M&O72KLPL02H28<(URC<KB2YGU/]N+.B\-95)Z'J\TSF7R.LB1%,9?:%T ,;.
MS:7+\-L<W\DLJFFI@]+QCM)?)8B)QBJ1#% 0 %S*3U1NZ@<86]4/6>BG,K%+
MYX=A0*LZ@;.'M*CS-^43M5?6JF@<#0"VT:F:OEZ'!H4>L@#3A52:FZO 7K$"
M.F9!Q;A>W<-.X[C=613R3Z%5]!ZC_4!YF7FY=[.VCZ@!3+V3\\/"<%0)3UDC
M^;.P] 6+YQJ+Y\,UYQ15'UMDN;Q9A"@PV"I+>@0!EF)"^)[DFP,":J8,E];@
M4U(L32!Q5BR4 .&B*21[&Z:-!<O4/I,V5N54?H;0>-J19$9>+\[A%V7DM1SL
MDED>_U,9$021X'.GT3KL-KI'A[/PD<K@,">19/:&=18)&V-HI%-R+O%!C,V0
M!>6G+(G"J\FAW3@\.FX<'^X]AQPL8"MQK4&]3!\O8K!9^4O[3[76L ,":/'^
M2.2GYHSIH*JNQGA(MSK/9"I'J)#4,L\LD2<>E/&#+SJ2'YEX-DX\G4Y5'J&6
M'<K2-@=XS E&67S%O;N+L?R;< Z.CQH'!\=/BUVIP[(_L(QIX8ALIWEL'9%E
MZM@4=3QB*!QNJ< YR@4.8*2#+E(L$U6-B6IY.=1N=&5V\XHE4;=Y=#Q/$K%M
M6R_;]C1,_5[4GX 42CSL #>1$7@9US?'>-F;]5*XH_+XPE0-K<5V469GF$R0
ML*^2+NS<_]Q5AOGOJ(24F81&$?G5HB(N.M(#?,!8:3&1G9ZH91,)#"_($O]>
M4'6#H ^+()3,:E!N?MZ^0G6ZF!5ZF.SJ*W4 0MT@6])0ZHZJ2VWU6"7%2QL-
M%V :NJX[)7!V5$V"*D/1'/#K( #5G,F(+TBU-*\M=7G]S],9@P.C4 W*E%&1
M%:+I"(8^PPS*'KB2M')YTE:+AH;=CDTVZ;#JV%N=W*29*3NV4:4!$:B"%$!?
M(C7COO@\8]2=;FG0C4(]#5F1F'+[L7X(3F6A)3"J:':9HU[T( )=YT@=<*!R
MRGF]E44)'%^VT+"PDE@4SBI-@O5!S(5A%,ZX+!98P\0Z7YKOI!_ZJ5\N'W!4
M+-F(S-'/A)5EAM$O/#5#;5+T49P(5H)\%8G-'U/M762;#WA@K(\\ L'Z4=^1
M+&RQ;+>M698*M.!1R'P(R 16Z3S9WKB8A@>,E424684'B#2LW&_]7>^6/2[L
M%VB5R3:GA[BT-9^[6/VYBR,^=\'G+EY)8)W/7;"AL4I#HT -Q3V7C%T)$:S"
M"J4FC^KT9J+/AU*7<U6\!T_K&@3Z..1T7(7O=!Z.=;;8?W:Q(NST88XT6X-]
MT@A-YP]\*F$G/%/M>7&FTKI^VF\>%W$>S&<11%2Q_$7DI8MRS4%>BT'R.:,A
M\X0"5TAYU:C12IN77>2%70YS@;64ZX[W4,)KPE7K:N)7(&#/SH5Z.Q<Z6^A<
M:!^6!EV2;*XQ*O-J?+'P1SW*U]=$]5.WV2V*5JH*,"7-K$Z7"ZUD+OZL@U):
MRGT$S8'QE8(4[,K54G4,9:KLFL;1$^D#)IS^ [;*I+\H64RCF&;JY[L1D@H_
M A%7*7?.>6>:5;V?H<-,PWBJ_#1V)T25NIKA(RJ/%.STMJ_ 7?&(G\+: )IW
MY>K/F+!T]A1!0*F\RG(^'76,Y7G[, M+%,M?&E:;\E;I19OEXEJ:V%%?P,RZ
MJ@)SWYTD5GUWQ'QV#_!'T4UGR@>'&=FXP@^"&B'2#*Q,T.?S*\.6#<"6DD&
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M?OUX_O7F_*/SX?3SZ=>S<^?FC_/SVQN'?GWW[>OIMX\7M^<?W\N_*>0<90G
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M.>VV6[EWOOU\UCJ]N3F_O5D4>6P[=<]]84U!Q+:O^3++>]A>Q_*RV%FUV"G
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M!39-04N6R\C87FVXR.=<T_61Q)N*U)QKNEX8#);8VUV>[;9JMLS)IFM$ QS
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M/I^<79Y\=KZ<GAV='9\>?7,NKXZN3OXX.;NZI&=?_S@[^O'Y].KD\YMR9+B
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M>3M]>2SP7CVB])]B@N5O:1Q%(FP1;LM8XP2OQ\VRQ(67X]X3090&E!4"'6'
M$HX93P1N*!%AX*H5LV&0^"5A%<4$[ZV/V^C^F"CY J1Y#=?]7[TO."CL&G^A
MDKPD'B<!O!+NPQQFHBY7ONLVR(;.=0S&440WH6[0K$;7ID.G\-4"!R;X!L"C
MGR)#IXT89WJRH?I:JIA-Z3(2%ZC:02K%=R!G<L<H:?%O Y2HDG_A^YGNGY;N
MJ2' V_>I,X[1N$8_FH%D(OZ3!^B&,U2%XRP1MC_:EVTIX;[$L128GY/\VCGR
M1T"30.NNQ,9$LH:$3'C<.NS6@=T/XX2$"+PK0-D<TZK(7)"ZM'2@WQ/IVW-#
M%#DH*042M-,7P#U W*5Y0AB8#=V,%EG@7+=!&,+A/!'<P.'@9_R>.JQO3@NO
M.XT,TA*!/_S=P ('Z@T"D)!VTA>*E 2J';20I#"P13S1@G<E]%JY 7P:V'7E
M[?C1("?3PQQ3;56Q/,R@2&#A* <9C@_Z#GU/DS%""#,K")C$(&B; "#4#( ^
M4<C+B:3 W6$)H)]4:BRD7<%B:>X-*[<,[X=//3"!!GD(\D(>#(^.]Y#A[3/%
M/Q'%EYSL>>2"()8HAZ <W>%2=X;N#2*?B% T TE+9,4U$[\0*OA['BD)#M(^
M 'F>.M<B OZ.\*\B^H\(]R!9R65&*BP0_A&0/8A?HP47[.:?1T??C=Z.F#K.
M$QR4FVD>@K5'J9*Z1JAIC;U8YU* \BQ9$#Y[\@N0.KHF"AX%:8K,2[_\\N38
MO!'6=!/$0'-KQ5V!+HN8@2]L.T=T+_!@."'.,0'-F]0=J0%)MJ-V97V1-B/C
M'X8?@9I2/C\I-TI5$O7Q#V24('$+(-\!7+VK. (82017=X@V!A5*^.C*D4];
MK XP(@R P<AX3220TDGQ ,'N!DI#S$0M=RQV,H[3P!Q?,N,T#S."6X#_,>J!
MU 6IAB,$5)?VD'YZH,P\V91 2JM:>\QY#0<&/(05W^!6_W 3;RB?V.FJ1^@\
M #!])N LJ,@"6F8H-F!G^K68?N;A)>OW(ZN#TZ6H0$Y 3T8&B7<%^G4*4$7I
MIM%';G6:!;+[IV'NGW_&2 7',6K"[.=Y1L&UO)B*I:CID\>NJJNAW>N"+:26
M1NB"6C8,0)/Q,-X$7%9:CB[8O=?*(P*&6G2=MA2K@H/]U]76%^"!4$90"A^F
MJ&RI/UFYJ%K\*58+,C-)B:?TE<,8) AQOQK.U"IM?^CZSJO>V_9;^1#@48BO
M4X,16+=Z A2]1&'B&(E2A4^*&GB,\@'Y/]C+:!"@*B0U@( ,K10P .0,>0[\
M&U6<B.O8#@OU]#A.LD$,8%9F]W7BCD@+)Z< "6O$OLP=#/0JQ]H3J/'+ ;2F
M!K(M,LX)^Z5-+KV%<C0D?JQT-_K4M<R[&]3LQ[@7+?<0@PL[WCE6*=CXQ<(T
MH<UJ"TR:E[9_$9WIB/+T+?OL8@!O(?M)NY#N=A%96J#M'*);+FQ+1;Q:9U(O
MJMT=\( \DFK)M#,#WN?#=Y2UI-U"TI<\2%RXM9SLKK9S<@/L*1C4*D4U9R95
MI+"BX HRY%K&*0/L2D1D4,%WDS+ZJ8O&4U8O&C:1"ZDD:9>/LK)/2UM3GK9T
MII^-GE&H.>5RT[B(YX!KE]B4"?U^.HQ4H.CO -V\['$VR?V)"-VLY&4F/9RT
M5Z#N2#J\RT!%V%A^*(VPI?.VE%%*Q$!HAQ@>]'/""F:@C\] CU $2VVZ!GLC
M46:=-NFA\Y!X7 %;RUXHU7=C: 1P37)7E,!9C7_&1MQLF,3Y]="F2 23^%E/
M"9)KDLJ1*K)07H[YY&'\:^@4@?]Z<-Q9'.H';#:4;I8,\ B/9%\7.GSF9+Y=
M<.8;9[[=+_-MCS/?FI;Y5DI\PVP$;QMALOT%%"RQ!$RVZG*:.*'M@0EM:G=V
M!:7ED7B<)#565%:LJ%3+L:=(UFBSBVG6,W1T2_V5+@TQ6XG12@EF;8SZ\+1V
M+J"U0M%9622;*@.JGQ7-;M"IH"T4K3B-W EY.3&J=.,&(7$<Y4HW^G\I1@37
M*ZU-#M\\G89<L<C(^M.@DN99C59<HTNC=RJ5NJ\.P1>^!\08Q(>^%0PE8RMT
M)YBH (@L'?FI![B)2 =((#!_(R(:B$$C1;0H_!KD9!!V>%_[UO ]Y*ISX4=T
MA9->#Z0A+7#,0E%NNZJ!K#T8+<O_ASY!%:6U(@>5J(%E!ZIT*9DM5?+],38_
M<=H1^L>0 6E6ZI.]-)N'6FEI%MKB*N0Z0)RUF7'!1,,XU2T"(G$M'5A%($F^
MR<*8M.S4*R?>E5[GPGH9+8](]^IMNUMVQ?IYHMUPJPA,+>49EN']?)1+UXDO
MX%J"K':?C/E/P<<C&V[3,%-)*;[S:J?=F?+H7R>(9,9'8+)Q@A1#X#(-ZQ)N
M5Z3RJT?(U:A:%D7%.-&=--(L]GX6\6WZAG.$F<SJ@4M\H!1F?]7;N^>&W-(F
M,+;= M,X&^+?I"RXQ;06[=VC/#<G2P N,G*2.J]3(1RT2^3[N[TWC*M/X96[
M.#XJDCEE7G(+P&FRG77>L)TL@5_2B-,RX7RCZ:+E)%-.8N1-1]>)D-E>^.1W
MT!:(LXGD6I#_S+D0=JJC\]I*XE9/F24,NL)S1^,D"!5OU*S13A0AO"N']$ +
MP:QGN6<K$9;TG5(@+W%N7:#11*=O&.4#A(:@8 @@MXKO53?9<HXR0%C]^67>
MA[M)QG=>ZY<@23/K6\45DUHWPC^H!)Q(72]E9[?DAS)3&^.9092318&*S^TP
MQCA4?!LI!VO@!YB[@0DX"'L-O31/;L#^("6IV)HZ_4CNR8:,O=DR+JB,\5E;
MKMZ-A.#I:<OY]NVX=$<Z:=CDJ.I<=XNK(5RFKTR>*KX6!'5Z?_5R6Q44@X]2
M^\+A*U.K@]*LA7QQ7>A;EAFS,VZJM(RUP59EA_@5>Y<M9XH0B@H!D#$>!I\D
MNIKOZV].;YW@H?*?R#(P]0"1.R(3PRZI*%4K..=&OS(A1H"5?=>$2M57W+FP
M9#=Z'5IC -@:W^I;5OL/T!FOI!:LAQF2: NE]@5)2YF2H&B+9MDKF7-:^J-)
M6PQEZI4I(R'C V0#\%GB6)EP1RI7DD)L6% !>_3R5*8<6#$J+H98!WF'N3TJ
M9&V(1OP27FZSNVF&/EN^$4_UDF L4]N,K*/5=>PV -THI?J#*0%56IJ^3CB.
MRI608DJ$H0R:ZC6HG@>$WPU%H3%]F-Y8]#NVN<]W]=QW_9P1H>F0HEAQ?8A:
MU8!(+5*%O694+0RHUDF7+0#K!KU.>KK@M, /P-I?YEV4KPQ'#4925]1KP(FE
MLOEJKWW003-++JN3R$N[A6?>'M(S:C\4K:NHLK'*TOY%KP(I^:KWMJH!JUR$
M5*4#UJC(9CFCU[NS;+=ZY;G^2JKJM%*CD0]A3H3P)7/!SM>!'!%<H&[;N5P.
MN \%&J'K=)[N%/(9QJO.I\F(<JR01U AB4K:+]Y/HF'934]]B?Q&Z(6%Q4.J
M4YK*;);L0,DPTH$<E4DF_56X+0K*:K40;M_\8MDSTI,P;3--7P@BL,DM-8E!
M];FTXV LL&2YA1AV*\C5)_%:I>\40AWN8PQ;*[GB=/ZO=@I2T@5HM7F"Z!4G
M/ZT$(;K@.5E!.F&#A=83"*VO\6T14# B1J<,S;%B@#'F@/HC5/@UHR@L&6.Z
M879"4BYW2:UB#\OV*4I9AI@0[E/92O%D(8(*!QYBC "]J&SNFX5,/.*. (3.
M5ZK*9E0.\6%R3^LB7BUWO2#Q\E%*Y6NPFN((>>A7W=]C5RF!(%GU:GB# R&Y
M?J>]6R_\'"7VM#" #6L[;,9KI-7UH+>TL3!=*J"!24TW!IME 4XY1DWR>HPY
M>$)6;.62 VA+,%(JB*SG4TE]1?J;DFV3^3OM[MC>2G]6=< =>;Z4-V-'K/I"
MB9KI_$OT[2-[TQ@M2UU-/A&.C0),ZL>YS!ZR @7JPNHB!71A<21DAK]AX^H\
M4C3<V:AJSC&XAQ5G\CQ")L\^9_)P)L_S Y4S>3B3Y[E#T,N4%56K-]$C8U5$
M4O1*)2++HB /NRMH34)6)P L*2RMM3%\*/')*8"! U-<(/4P_6O]=^U:(M(V
M1F0BR^R'0AL!E<:+M4UJUPQDD^D:U?N55KEV814:"2-1SDJ6OM\YBA09[%,5
M5P\HKJ(KPT+>3%>WRLO PY*],UUNQ;W=7D1OM]ZC]G:[S$<C%2"[M'),CHJ:
M]^^@%GHT:X*[NJU%6>\/R0=.E$]Y)N!8!#^*"):"I!107M(/$%"T$QLHH* E
M3VVE6X+RLI2#=S'\]E.86 (ZO%!TC2WOUU^Y?RUTPP.4;3(M48HE+#5"R6T5
M!!:RJ2J+R"]0FD0IQ>$U>7EG?"\KW E6HL$\5X+IG3"].5-$9R6CR>>HD)+2
MTM)VB:N9JY$^WN)V,. :2J<T7K<4KG=[.K3JA'V_=&^%HO?7G,)/>[B/R1)"
MO FHHXT> B2G NE+N''#W* 5N?AG1*CZZ"[3 2IJ!Q:EJA7'K9OXY=<:UW8I
M&Q"7D#FUQ9UA?[ HOHTPPAOY]F0B66PX8S<8@T  %(V^U+=@!^)&->"C2!^A
M9) 5_3>D[PC626.9&EPT+2SY.MO..:I<L$.IA9'VUK*)0\C+JYZII<+JRB4L
M(R&2 ,N^5-RBHB&\L"3 GDZH;E)30IV@BV$'/\!T=9,!'$ZTYHJA$^LR$QO_
MN%E&XZ4JM<F(,IU+BWX/L!8 6R^"]">+V"<3L5^LYD18?VY),U/Z&E(!"A*<
M;;1)WW<%B)X$(O:&Q)#[2#;%@>> @\B&;=ARHL0;=9M177.0#H'AA#*,9-J/
MT;(EN8';#3*9>8&Q6"7)<.<M$HT([!;Q$/$+ ZG.0/BJQ11\E[J;D7 !=E<*
MD573S@L&)1//53!$A4]\09V)4G,V1MHG;TJJFVYF]^^0:>L7I@5HR^Z%9YI>
M>+H\IJ94&P,^$BL*[:1HOU'TI<!GLEO0,*F;G@S:^]:3YQ?_.IIQADZGJT]
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M+Q,HJ3XVA59."U2RJ"9-1-=P@[YJ!DG]+!?PP;!_X0D0\2R.$H'C<67*;=7
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M>.!)\]D_%2QN?Z(LDF/+!F7._RR<7[6&2VG(TL+. S6U\AJH7M4W:0<"]??
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MRL'J".T=])T+Y7>O9$3=>1"FIR>.;%-,D#"U0.**7T"5S:$SX$C[:,()98.
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M$B<JC?3/#BJQH$!.0VT+ _JP--X=KKTE50ZZX]\SGZ\;KKON,)WJ"SI3+[
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MNM3C<9SH8U<4%WFN5)U*8@^IW;=!*B312P0*!DX Z 78*/D +(P7P_&8)Q!
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MA<]$<@/R'!44U":IA$P;Y.,X4YJ!E?@]QUE>K96=E9[P2R1>(),(2AY!F?Y
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MF.EV=MH\%&O\@-F."PQGG*/2TI^8%AI "],#&/_^2$HF*Y2L4#93H:0(P.O
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M(P[LPQ-29E8)<+8_]*+B#_UN^T.!=V1!*)VO<C> .N^0["4[L,866YO4-?]
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M19[X,Y'*BB+*4I2E:&NEZ.,&^SWT]N61[GY+L-_Z9K*W3["_>;???_/F':O
M[1/AS.58B'1 B' B\]H+D=U7_==O=ON#O5M,J:NB8+D_\UKV9]Y]]/[,%U*W
M]#VGGM^?$U@UX9.JQ7V:GRU,%19?3..(XB_A[_R+\*3P9QYU<(^R\,8;RTA.
ME*]$"!_BZ\B;PWNQ@WWDO?X?C)+,&B)=?;%0F0B-M3F;)7$^G7DJ2ZNQS1@I
M"=N6;GL?JK&2%)'9&%V!;9^=R(JFYO*5WO*)].-I!-L:>#^]WA[H*X$<0A/C
M:1K7IWV@7G0V1Y)HT+2ZE\F5\H%H%DE\I3"$='SC-2Q9#FNMQW]&(_-&TT3*
M.2P@/==&>8*D3.0$+J;@3 P'Q<'KV%=Y)<-X@;?8(7D3*6VW:Q,CZDU4!/O\
MWR)"57@7]BGVM/PC4%>:^Q;GYO3BJ2.(UC?MXSXA1!2]^I6B7<T?&:*2V@L]
M$5Z+F[0&9GXFM&+486?L\*1M)T#63(]@C5==C_J5M"SZ0F<>GIF(5VY*<:.[
MHQYM*>PH;>CY)6SGUH6<YJ& >_TXC&$B8T1HF%VQ]6;0S(0G89[.7B1-/1$;
M+FAJ=YD'_R*\&?"%?_;^_OGL<##8Z0U)O\;S?0@30R[RRS^$%H<8A?L+G/!"
MDF/T_!;NR=:'1,SE _:DUX3+6FIJ>3Q<UL0I[@G+[A5M:$;GVJ\=%'9V\?N_
M1M[GWXXO1N?'OW\^.;SL>R>?#K<I0/#3V>?C2^_SF7=X]NGH^-/E\9'WX>33
MZ-/AR>C4N_P\^GS\\?C3YTL=7_C[I]'O1R>?CX\V&28].DRJ5T!=ADTA+ R(
M8(UH\,*4?.L :$F$P]&-%]B]ESP'*. QM221,[@0TWXPFV3;&U$&6 ."Z5<@
M#":# ';9KV(7@"LZ22WU@MPD^&A O0! C0E%,(!,J(BP0_P86(8N2Z2:C_,D
M-5_!! !B);FB?#.\ %8AR59DK>0+FZ]"X&9I!<<"%M:77CJ3,MOV3F!D0+$X
MC+XS,-CH>6JA9P/B,C.YAI7"W"?,^<E"'4$X!35#C_I:)/IOUZ\CG$PFDQPD
M_\H!R,)%.]N# 0%>-ZFI3.1KA,$.V.WC;(4WR1%'V\PB3'Z" 8OB"0'F19F_
MS5@W4BD]Y,YZ_]]NPKI47@> 42:^PC0_7$WCKP+@F15+D, L5**78"Z^8 IA
MM&*+2H1JMPHH3L(4(D#GXD;O.CS&D@[F,"[PBY] 1ZSA:[UEI%# *BT06@/Q
M"[M5<"-<1.F6_DP! K9GQ]>4"X,#\O4Q7\Z!Q\5P8(KVS8/'?G-"D"B+DYO*
M^V"CKB4L*6;9*4J^3.(;$8+^6BR-TL\%T+YB@;-X:ZX"N[@I4!$L]:HDKZG*
MK#H,^PA,B(ZS&?M$)6E&1(;[C^J6""5G=SY'WK%0B<X0_@"4E@(/C^ =1$2G
MIX?>!G* W<'!ZLOH@IV#S27U.GV(?MUW]/09,I$(C[I)-!2:Y!>+6$4F?KKI
M4>]CD03XGB-@$#Y0/))Y%-QC8(8#$)MVA-BR %-IFLM "P< <I39.(6C.#7,
MSHG,;#P'GCD!);.]!-J3J7[?R#LOXL:UQQYF6JQ\G]XVF:A0D7!$YH9/6+TU
M<$<&C+J0"8L$Q";>\M-@>^=UF0/:IP3/:4*)H4GL2QG0V'[:JS.C&@=_M=F\
M9.60"&C"8&'C]*:=V\$48DX;*-Q5QN5%@PJ(:1LU3U'U$;Q87RT0-2A*@(5)
M1;Y:P%]EIOM/NTL&DH:1/P2T#+9WOP^T"!^@A5X(B4&,Q>4KB-D5S<#2$K*<
MI"LF5P**5<M;[ @SU6=*F2_-70KI.,WG<-F-1IDEH=S8&@<IREU2EI'Z8]C+
MQ+)$#P[\&$X]4=4&2>4X3^&R=/,^6=+KE!7-2='?D!2]M[VWQTG1G!1=;!0<
M9$09_^SM=FW3'K YK[?W'K@[G"#=H03I*BPD2R7G.3]K(-JCB#6.)7_T6')K
M+K/F4T*>==LE645??#PYYS6W@%_<LKS/V0^4L[<>/SZ/*R;?2M][VV^>*-N*
MB?DI@DU?]=_M[W&^ L/$SL+$)@?[5K[H!EID8-B:Y65@N.ZRE-LZ,AI<;PK>
M?]78/9'-B(P/.X(/,;3Q#QV\Z)V-X3Z*,F6>SCBPK3CP.UV ]VB5PX4IUEZP
M,S3]?FCZN(GZ?*C6_E"]>2JPS,#X.X Q PG&:=W$:5S[9<U%"ON66PW9^'RM
M^?GJ#5_W]]_=4IZ/FXL^GG6MFH_B5&ZJ[\]]<U3@N-:S3V[ZM<P53D7I:F[$
MTQK;.16%4U'6?],>L#F<BL*I*)R*TD+UB'W([?8AC^I)]2:'^L4K\K>^L*5P
M8-W7G.,+NV.\8./@(QL'F9A_I"5N=^<5>T\9$G8!$F*)I\[ 0$9\K5G>]GFH
M.>AI[>4V1Q*VS2W-AVKM#]4NIF$_5>=T-IL^,D9F@,'XK9OXC2.@UES4L!&Q
MU5".S]>:GR^ <J_[.^]N,6URY\87U;EQ[]$[-U[FXU3^E6.8X_&5;D_%#1N?
ML4AZ66,_]20PT9S"2^55T:,G<YII>K&/,:D8KIJ6^V8[)][><,'IJ*@[.'X4
M-[??L;/G-@.@;C8B\P"W^;I90=GJ!UL91KIKB6V;A,U5$KCA2JB0PF%AE&-I
MVD=0SX1Z@T9\9"+Q FH;9+IEW/Z2>I\"=PV=%3++:6?^?_-H19>68NK[2U.'
M/])OF[.>%,QZZ4S]MO?,IPD;C2A_31CPTG%:YKZWL=83FFL3@W57H<I@S\07
M[]<DOI+>J12I9%[X;+SP+/)&BT2%6CCM[#;U(:FT4A%>**G-5[7-A[.#YT7O
MGMJV%@U[L.E+/)E@3QA21#V0F<0[ -I^E%%(G;&^]+U#F!-<&RFQ[2'3UF^F
M9DW JNCEQ"-42KS%S.&U8;CU?BW8\@S9V]Z[[=>FBPGLWBS5S\YB;+:KWV :
M4>%SL9&L;[JE $_Y:6?[5:W_[95I@&)?HQ^!+V/&TWK&,X)]QCY^1#"Z\Q'V
M)60&])P,Z$Y$]+:!*]W2? L;=B'7T5VR<(?G!J_A_;35U'P2OE"1G^CS"K\L
M]2W$9G9NK^T282 '*R!3V02I?#9UW]Y_N]M_M[.++]KM#][L]=^\>;?MZ1F;
M3H1-_)::%L+H31=">ADU]K8MEK!KM=O_:Z>_]^8U]OXRXRS:%V(7KJCH;>BT
MX=K;WG]7MN$J&%5#X^L+;GS-C:^_K?'U#C>^;EOCZVKG:^U2/!O_"7R3G(QG
M &82%<BMA[A]JQ^MJQ$&I@+8\9W! $:)0RBH  OT?M.;5BSUWK(E;[6\J4B:
M0^!^#2-Y;(JK80[0O[]ZHU48H[(Z#[$4.E/=I=$TKH\YZDT+I.]JQ1+]>G%,
MG;J]T:<C[_QT],D[^^!]/+[X]?B"OKHX/KOX=?3IY/^-/I^<?;K74CX$>M^'
MT&Y9R+LH;?>IE]%\U1L* "_3G]=M??:>;'WNTH%H_&3Z ]8\_SE? $;R 7(A
M35X<CKSW)V?GOXTN/H[ZWDGD;]N%;<%.'ZS;)C\;+_E\.KJTO./R]_?>X=G%
M.>_<BSN>&8S4^RB3*6@UE_G8.SGI8R/I-FTT.A9XLQ]AL\\N?O_7R/O\V_'%
MZ/SX]\\GAY=5?KPNB_M\M'=$]E5!-@TR^'K&RU1;,K8 L 7@D2P E1ARM@&T
MQ0;P?!: TNW1TBCRQW-[-'&0>WH][E74PV[V<BS#\D[?60S+H[\;=MK&M7!Q
MK)=1^,?NY\[VN[=<'.L'UEGZ446P>$.:-^3MZ^W=!X;=\^KS<7BQ&S+8WGW#
M=>!>;ATX<CGIXS&B,F[G\ [O4YQNMRL;L2C:N+?BL*YM-HK-3-S??O7 DW:?
MHW)V^)^6JECK4KWC.S,$+G5$M8E W/:.Y(3B 3%\!Z/)3_# +A*9B4Q=2>\\
MB:]4BK_>4DNQJ^E9G'#ZI,O[<%G/]8.>G@,M2_?OYDFCK=VGK=3:U?("CV-/
M:1+BK];V"+WZ\4>H-]S9WF%!RH+T>9;W46Q(#.4?GPLXV)NY 7,#AM4=Y@9-
ML)IP<9NL7B_KB#!(;CM(;B3_ETV4+!89)+>%"[1 +/:&9]E,)HZ96H1WV:F9
M93#+8"3=69;1C*0?N;W#VX?8EE^<L]AN??W9@]J3'MN?W G&<Y_%+7G1BN5F
MUO_#=^ QI$-]N3G@A0->NB7-'S?@91<#7E(_451W!K,1/I?5$SG"A14(5B"8
MY3Q)A,O.:PYQ8>M]AZSWNQSBPI*4K?>=EJ2Z@KDN=<+,@)D!P^H.,X,5=OG7
M'.+"(+F[()E#7%@N,DCNLESL#8\G$^EGJ>UHPWB9^0+CY<[SA6?&RXR-&1NW
M#!OOL0QD&<C8N,,RL#<\#.,4UNK ^Z"2-/,T5,:(;UR? ^]28L/%VM?,-IAM
M,'3N,-M@4S/#Z1:=B); Z<8,B)=-E"P7&4ZWA0NT0"[VAF?)5$3JO\)D4A[%
M?DZ-R0_<IJ0 J,^HZ7'"V93,,AA*=YEEL!7Z:<]#[3*X^U&0-#R'8?33P.A&
MTG_91+K,M&\AVT<6DT3)+",95K=71O:&AW$$>YN:G,+#>+X0T4W?V*R=5H\(
MK8W)VOGV^*]<93?X0YZH3$E&W8RZ&75WF:.L0-UOV(#-!NSN(N]&\G_91,ER
MD9%V6[A "^1B$0]B8Z4-U/[?O^_O[KP]2'4YCPG@ZO=Q_(5Q-/,+QM%=YA<K
M</1;MEXS9NX&9FXD]9=-E"P#&3.WA0NT0 ;VAI=YDDCX+7&,T]ZA6*A,A+ @
ML?^%F00S"0;*'682*X#R/AN<&3QW%SPWDO_+)DJ6BPR>V\(%6B 7>\-#$?IY
M*&R]Z$\R ^B<SBB4PV+I?XLPIRNVF6$PPV @W6&&L0)(OV.+,X/F;H#F1E)_
MV43),I!!<UNX0 MD8&_X(4^H;>/(-%9AAL ,@4%Q9QG"BN;F [8N,U#N+E#>
M::3_ETV5+!@9*;>%#;1 ,/:&V,<<?@J\S^*K]QF>E6$]#F8,S!@8,7>8,3PS
M8F9TS.BX;>B8VP>R$&1TW&4AV!O^H;+9+ YQO9@;,#=@2-QA;L!&9(;)+3H1
M;8')W$"0!2/#Y"X+1A"#BT4B5"I"[P*'P'4OF"4P5NXR2UB!E1M-:M^,E=\^
MQ'SLQR$<*=CTO1=R-NS6UY\]J#W).2S[^]NOOONP=(+QW&=Q2UZT8KF9]?_P
M'7@,Z5!?[A^GV[\X'E;7\Q^%03' ?WR _PO2G5W/]W$8%,NY8LYF?F.X% N
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M>[@&ELW[)+(\D1CR,9HF4B):9D;!C(+!<H<9Q3.#9;8O,X!> P#-Z9<L%QE
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M;M&): M2YAY]+!@9*7=9,/:&YXFZ$OX-%;PX$IGP+J6?)XH;6S-O8-#<:=[
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M-\;NOVRB9+G(&+HM7* %<K$W/%*I'\9IGDAF!LP,&"1WF!FL ,G<3YP!<4<
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MUIR+S3%;8+C<9;;PS'"9H3%#XY9!XSV6@2P#&1IW6 ;VAI]B75A.*&[IQ_R
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MNL'J!C,H[O&R#J>*K?KMMNKO<X\7EJ1LU>^T) 7!Y_MY(OP;W=YED<@4+M-
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MFGF'N+T3V.!,HFC]*).I3/J>BOPPQZ7T_.H%\ ,,+M:EM?"+;"8]_:C+3"Y
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MWCRCG5?.12$7-'9?Y D^+K/7:H,B7=0X3!(620Y#NW*& K+"?6AE9/9+9!K
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M[U>Y-ID?,#]8<WY0M"^_0+I?R0SH5-SM391_89JJD;U_Y;%NB!F/,2-.LP%
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M\V"J<XQ-BB*V,RSK3Y=>(?(;Z<X:U&L(?4C((C>L_]NV(D2W-;)4ZF%HK#*
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M7%LM"+TDUZZQ>GV,FD;G",P5$AH?SL+\!0KS]AT1<T+$%!C<E&JYS,FHM]&
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M?(A4WK0S=^2%Q!RHE+C19MMC)#.4F R40(E!B'[4F(-(UU&:X2/L]^S&4YA
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M"O[6)<U#E<._7ZUEJXIC-'0SEZ["]!3_V\/,QCL1Z#;'B?*">L3@0/HUHNT
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M>/W!Z\--<H,K9>#S+<Y"^JTE(Q9'E5M!7N1NHY@40GL*G<VA9TJ-]BOX0(7
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M &OUHC2W'5J.NYV)X9#K;<,:77<3(;$O4S9&[%@F3E>,PR<@]358\FH^@<F
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MN/R9%I=K<;FJM%&5EG[IH4]1.PP \5IX&L(-E;.Y0#I[+NR<#T8MD^KI_E0
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M<97GE.":BRIR/H_DF,GZ<#&2"OMTT>PGJO?#CCU7W-G\#/=E$?-<<6$K('Q
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M28KRSPZ4Q"(<O*JMU,%(T2:'A/ 88Y+#\^ _3XZ/P^/CXP[Y$5+\)X2'J2@
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MO,?A*85=G2%C[&P2IH-R/2)RI15W+:"XVMD#5-O@&4J.&_$5ZXGJ#\!(E\!
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M0%]>OW[=;WSJ8'YF9W_/[-Y-WMGOREPXNA@B4^A3C9E/9M6Z@GEJ<I#OX;J
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M-3,W1"#>6F\&+NF('@3(GQ0%YI<<$Z ^IE;B"[3G\KE@<(ABHX24NV,>P3L
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MTGHW4-0.ZB^@2;BA/TD>':R\,",3X_FS)6*/8;<Q14U^F!Q!CM= *DGN#9S
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M4S6K/_BQ@!NJ!^Y(73&PGP"_2^N85QSS:B(,X0Z!#&*6[<^L&3;%"N<&/-[
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MHZV9X*#DGG"(8K#]HWM,9]WA04QB3<J.OID&_V:V(&S*:V[4#=3R(X@QHUQ
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MG.XSIY>S.45S^M[8+?A7,@CWW]D]G.W'I.SJS\<'&6!>(VXX-%!)I/5)'?F
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MUITVZT:FW8.6?@_98*1,+^^3'*8(8@1,D6JPE3)-$ ;ZF+"",+0UTC$AH:1
MS$8L-5&YKY&R#:WD/&E.G#0CL^:/[N+'NG2K9)<!(Q @1(HT@VU1],A[^=!'
MR8(2\;B=Q)#A)-H$R0K:.X*)/$^ID^*%3].)%W"JZ"XM%G?P35NNIL,R]N(3
M]GLHV!$DJ%:7U9<8+8/).CP7#TWA>:Z=,M>&I]H7CD"Z,::=1TWN(M3!?LV
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M1-TJ E2L5B9GM,<M9 G !^+KQECDY&2GVM@D]0BQ%Y^%B=VKR&YGK7$))_>
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M T%^E=&1?LJ-R+F1MD#P-%1 .+3;>GE%^]RJS:6*HR)8'<?&4;>V^47BD-N
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M?*?V"JT2:^X-J/';W?"FKXJ?GL 1ZVECL=UFS-2 %"X.W8@G]P9ZNXL<9#N
M;"<:93_EY>M8D;[;S">#O-XR$IC&ZTLP+]E"J$UY@]\%6L/6N==N)R*Y85E=
M[!?=ATQ$";7ZMLJ7OO?V-3Q]?J#Z:T@A4 304P4 VR$%W&8E[BE=-%L3(\'
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MM^O2 2 -VB-SF"KFI\%9:;(&D[7=+>5FN!:Q6S=OV2Q"R4 H&;CGDH$?0LE
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MZ-LGYHR8)1DY0QQ?%[/(\^ &&94VSW900Q.J?;^Y./+@<63]N@>!!687[WV
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M2_5N?4=E0?5+LWW_2"HX%,V4B,6#G3^AZ/L9ZYJ?LPHTR&M#WHWOUC'I85K
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MA-5G07U=F+'1I%06"J^:EW6C0_(<G8PC!_ HY%*UT.C0CSA@G-4SV. 2-#T
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MUX:*YCU,MM0]: , +(RLFK?+ND'2H-HO"@]+>3>':)31-D.*8HEM\();1V$
M#C=3GKHBP^(27<$TN\I2U+!T-K&V/UDF%_!/[4E\']094UI5M#.6&(>C>K*R
MH$;8"1:5'*$C'U30G9T>*]1NKHP"=5>@[KI?ZJX?C@-U5Z#N>G#47<&(N!,C
M8K9&;FNTW>/AH"1EQQR2%%LT.QR"Z<80,6)29=1JHVR; 4= 3$R/CHHIIF**
MM=B*V^%>@.[S+\ ,Q0@HY@$'N/MC_3!-S6I: XY5"7%,QBGMD9PI3(@7VZ3;
M9I7.'!&;ZV(!\T3)(>-*81./)I=8#U48P2^QDAPSJ?2V?%?8%-DRCFRJ:565
M<Z4H5)9<P+5UXZX47% K]0GORDE9*4[&(N0*%O;/-KW0<ZT-<ZE@_@3";^B6
M!Q+IPG8*A:KB:*F6,_S_VJ9U,04+#VDP%57"V\[Q(YS'<JU43-FD+$4RVMA.
M!KS4A8R$7_6#4T)]97-X-(K#^]Q0L[7[OEMVSI=O'">C3"T S.[)Q'[<:0/!
M7&&8'[O:8TL9NV/$&Q]82=U#QMXNQ@AIGEQS9PP,C6:\B4P2/?Z.)OXH>FWD
MAQ.PFW\JRFLXBG@6F'3G,],UF!QI/5"<'Q3.%^<J*@PD4?+AHDIR$C!;5Q6D
M+@@#W(6X\^#2VEVGV%M9VP;38=T>0+$<_$NBQ@-YSQ"MN/-UEYZ6201><I*C
MN3&#I82WN.3RV3P#,90RD8NH*-1C;C93%HE.*Y)S4',"\+D9NFQW@"!V_+@B
M?.BP5-JTDBSY2T.Y%T?""R9D7##J2Y10^RT"IH6$%H669\NLL6#TNBND][6+
MQ,G)T<GQA*9[Q^3A\5TG#Q\_FWSNL+MN^[';?LWJN<KSI%!E6R.04JBC]F_/
M/4CV(A /@;V(-O)O9?'H(_&O<0^V#P.]?O\PO7ZGM+VCWXEZ;G-K8FW62@&(
M)-7P*N$-01]Y$P>8!IR :]UD"P(UL]=6-U5+%TC7T0[\>)#PUA9Z2>78SUD%
MON)KW<>0HL\Q#:\L\K7 OYC'3)PDCKEDE3#JN=1Y0S<3QW8_K:9)<4?VJ0J'
MYCL(W4U"-W"F\S8_ YF0HER8T 9'>>J)K&5"<(,$QPK"S>!1NQT[G8#9#*L[
M2.KJN&1?!+MR%X63%LE.#<R!IGG2=2Z54VB0I.6*XE+X8W\L0\'I;B][)WK*
MG>L[CQBIJ1GK-1HHRK]S3NC)4I3S=A4L[.66DR 9IL%3$&,N)=$2R4:ZJ7$(
M1VS@#MBP3I!'M4E%N0]E8E_W=#G1PMU^,2B"I,NW%D.*N1/QG0K7"L/H4I4U
MQ!F77: I1YVBX646!B&WFRC:487?28:WGSJ_*K-T#S5[((-E<?%'DDU+6@38
M^@;8^M<F?CW#?*YAGI8V3F)G7>/.,3R8^)?TPD8@0)DK< =UF8@OR\MK+>AB
M3^1B!DY@<C9+23\]BGXK;3Y/FIU+%LAR=&/7U,^JFF->D!+1H FKF /%,9+5
M766YNB#327*?3DF1D>'LS8*& 3<Y68\_#=.@_#1*L7_!\UB!E2M%!2A83\)S
M6QF=L_7.+_6@<3 Y?8$C1OIQ,R4R^MUNJ.N )'GL+ C2G8MN-+>6G"TEA-W%
MV_J8<-@W'/:O37OZ6^G!>&;8# %7"0\687KDQ%-T">$FFY/[L8Y$W?9<<)MQ
M(UV<\R!@E^TWAANJSQAPJT$:>2C;A*PO+)YV(V,M7 :[>MYJ^(6-E7G660<L
M8<Z5C-,R!<R4VT09!D83297E7/HEYJ$D(+F%7C:G05%+9).$S"CWB(WYBA"S
MV639/0F6'=/\%PWX/O9 O00_HD5\ VJ&^F7T^O,<UABSYJ#"7V/%;E46L/4(
M1;',ZEJP-#\G\SJ#\4^)+K'G>.F*8M8[]?Q2P5E&W)+Z?)G-,D1\. 'Q.G9.
M/;M2#H:G4@M52;U*/[R.5DJ3-:T@"!3/<N*-I&Y!F=<*]28I4:3)=1Z ETA9
M34+%K#">&8S<B"2*IU=)'B/J@"%_,]5<,YO)NIOS'B)#T16%RZ1!KUOTL\P2
M_CO$@4(<Z-O$@02VM<A0IX"%BDC";MY)5*<Y1^D-&BFA<I_#E*2D/^EP()B1
MTD]AUW_GNUY<DTE-'.UZ2H^^9F7$ML0KEX'#^^;,P%KEXT,T_>!B,,OPI=GK
M)C6E"MG\W#69_521]DC&L&KA)S4GEKU<Y>G3$ZU'7OUR_G8LF6*,8>R$AO(D
MR8D(1)L1L0E4"E2NXSI@G:$0%[":S?/NQ8Y"Q9)$K<GK9*D<+<W9<R4V"Y,/
MX?EW['4[^ /"(MM1>DAEXK7$!VO].4-Z&[%QJ)>KM84:UQ:"F[Y_]3-.*VA5
M^Z9UBT#V3'$:?9;)^/7=12%S]AM?#MXW=7O.;6K@%8K_0O'?71?_G83BOU#\
M%T(%&"IX&D(%#.^P(:JWR?7+Z+_:*JO3C,R%"9E2/2/%Z. ++%LKR"Z*M9)%
MRX$-EXX[P,4?>7)ML!X?&R&#?*7@XZ12,5A7%TF54@!2+J(?D"VW)!YTRQ_*
M3Y<HIA/N \>_F&>K7 E_6K& ;QBSCC<[BMZP/S]8M+?!X>^$72G<F2>42NX#
M^20(N[U>1O5KGG[$ON)15E7JJL176DOHPI@P1$<E>9M:0A^S);E;;/98\I<_
MG3U%5UZIHG6JLUI.L,#6@G6JUJ-+$V'MH+E[0]N 8L)TA[14M:5H[41!W"'P
M)OC8$E-999\_]DSZXA]%AO-&W]?1JPRV&-Q-?JRYS\S'WG["UKX4 I(]1)8O
MAK&ISD1';W1H>7!'F-U^J9"3EL/3C-!4#LU.OAYR@>%9;:T)46%1M>FY%_*I
M"[E_.B&A!$L[E[(PBO[7?-QHXU$]8PF'?8WKQQM>2FW'EUGWG*8-C75LZ6$T
M?&?<1\ZEME .3B0\C%P2V)7MDJIX2WLNO+.(PLOF->%YRM^I,#E7V9S. XT2
M)**EC36YT,WO9,N9#?@T6^!X\,8ZK3&T;?=R>_XPH>TY0LA]L-@NUV73F6(K
MDKK<TGJ-6VC7[.T#-2Z?!>.2C<L:\6U" 3&ADS%N36(,AZC/5F@GV,CSS##6
M:JICJI0O$)4BB!<Q3&:J4(L,];E?:3Q8M6^H0?G[%6KTAA+0-',A:/V]!ZTG
MFZHIA-JOHT *ZU-T<;JZ*A=QZ7EV(45.&)!F[TAC]&N->:T08@&^E@2U':/"
MA89Q"E6G1QV@6(?.)39P#+3XERM[B@R9"3]MF&'2OA>-8_AEQD?I#,1,R/#(
MC3Q!]"RG>Q=$JTCF4="KF_3J#T&O2B$D6L_3JG \X]PMCHMW-7,3F?XJ'6E@
MCH$#AO?4;0> 1BU7"*1E<5EX?:7FBJ!I]M;@X_*2EH5I ^+WR)""!&8YK<57
M I'WN?$ODT>!;"'BQE6ED' [CJZRA,@F5FU#Y@"1HS,%#98+8$B(K&9TSC)\
M6?:C*!3 (R(W2M_><% DC-4TG\^P 1\!0M#3]+C"[2S(CV'[S_U?@YM52TT%
MYLUSPF^:;-<!.5D6"^=GOS!BE56VW8>^Z:'M_/SLQ^/C:'6T/(H.<"_]?V7U
M*3HGJB_87X>Q$R23<=/\DL7#GJ$[U<0A1&$HF@2QI7!>J9("5CE;D5.;N)29
M,Y67US\&OH*Q4PD[P+;6+BNWB&2W63N]Q:Q14H;TR9Z2!9Y].#\#1Z"$T<(G
M<?2FF!_]O[/J;W\_.3[YX3@ZOVPKV*<?D@+^]P_<NA_;#$[DR?$Q7?6'JILE
M9J\1H'K^+GI^?'QZ$M%79WC22)I'YT?1?X'*K]0Z>J4^?0(3$"]XC>?TQ^@_
M_N,_PJ8>6QZ16_-R13[7@0LHP#"7 RI@?708]OKH9/Z1Y36(YX\P9UF11;^4
M95KA=/Y[LER]A.?4H %X[S]_?A*]V-[6^\OZ>C_;=>17B.B<)[ED: DM1CR?
M$[*)X [@731&/IRP?/@)*<>,;'A\?*I% TB%GTA2_PRC5DWC2H39@C_[/]?U
M174$5E78TF/3#@93F)PO/N_O"A7]FE2?P-9ZGR?_ C7X<:62*OJ="R]X2S]^
M+#KO(PSOYPHT8E;/2]C99]&+)R?'3YV=_9J(Y]^V3?T)[&!X4!W]GA3)I\3=
MY2JG[\TFCZ.JH8MNMNT?I%ID6\^I&0Y:;W2NWE7MIP11A56R4BTHDMJQ\D[!
M6CNO5#UG$@46X3^U64Y.R^EC:^_Q_OXCR6%OPU[]%5X)/)@6Y70='9\^>?JX
M:_6]3:X9M_G?.?B>FTV^   , ,"[!@">!@!@   &91E\R+N<S%^R68W9TE=M
M48@A>5ZUS1SCOV_?OC?FY.OE+*GF"4Q!&9V3D-.J]/39)CORY*2K1C^LX;I?
MVPIN\!-<#;LN^DE5B&0[OZPRL"RQ4Z4?4JF6</G_N:"AIC!0-B]G,_Q9[^-Y
MPS?H?!%R,QMR,\]#;H9R,^<ETSE,#3_[VO;=TQ"O$N2<YI[@@AI#G.;VJR#D
M0JF+;=S:>,Z&:DZ(M)RW0K'N%]QVZE^[];?HMB2?=/M3IEX2?OZDUFECP^S-
M/5#Q>*9#33UPH(A%0".;T+&+G&IC-[8!D%',DPK1IY+2I>0#0Z;<4JK-53M!
M)K@RX460"8(2Q/*Y"<*@D.0'8<2"V12RGSXZ@ML_(E[Y"BQB2DBVA0N(TC!0
ML)DX9R@?>'!3:U\E7*^+QXQN*"U%S!VY9Y A;5QJFD-326<&.W F-61[^YU+
M& ;CO?J3X+78L>_%75#L-^X+'D5OJ#:12AYM&YT%69H",J<N!"18O*F!C0..
MFT&([[@L&U:D SXS'8>%;@E'LTP^4?X;Q:Y&DR?.0E'>G5++&/,C-#-1\)NN
M*][P")F/$)O&X3*Y+HEC$RZ[K)*:FWW"997B;/7PG2*QSOM?Z&W(K\P=P>T>
M9(1=@M8[GI5YCB*[8=5%1#":*9,ENYE2-;ZM!][2D!0/H ='QE5'=1DMRQ2F
M!#O,O.%TN/11'2A@<,F59/(OD"5:>"D,90RGXC''C^IN<,4[<[W[B^I%&'ZE
MD:6A/AM@9V3P;MU*#5"@=68V)LC)HEQF<VSL(2@ "QIQU>T-AQWT\29]?'(\
MI)!/?KBU0MXG)?Q..H@M50H'Y"7F,UA(O5<5%7;#&9J4<G[-_% @/BR41B-M
M">Z4%=PJ2U?75_)N\J7#?X5P'B:V(>!18A",'M8*S/<VY\YJ?/H+:8UD*KD\
MBC<AVK+WQL=B%1YRUJQUSS!I&-:I&]%R5%EA9ZE?S6,*TSB<1HIC,;1TWF\'
MQL6L 0,*$&L?5B -4'YP\R!"?W$(: G/;!+P J2M4$QB&J%4R562Y:Q9;=.H
M&57=)"F\)#I1_&1]03F?MY66U2SMC787Q;/1C &YK_B=>8,.5C0*IMQH7#:1
M''H)Y$[4Y8'&RW+\*ZP<,FVZ81!9XT#IR$74S=$ZXSO$U:4QVNW)3=M(R9&B
MYL$B,:%XG:DU0O32#/8[I%JF/]MB;HTN_1<YKK -:$+E@4/3I]U65A=FAJB^
MQ:=E<%9!^#-DT;[[TD2:,H9!XM9*N02(%Z!SS.$S/B+PX9IVC5FO@0:!?+X'
MZDK=>K996:"0;"OE=!0$H0G'AG"$MN!VYN_1#D=HAP8+U[ IASOY&6YGI\HM
M:ZQX*5=H>=!/R.2B6MN%OQUC>]I65G78%Z 9(/%2J3Q3"XU_G"5UYACX[@M<
MXD'L"1)G8LVO<.%H#@;'H/NF%4Q>#0:B<[>%8-PYE#*T:L%ZVF@]#?;A>2#6
MTV\EUDQ5Z2/>L#]1E=,\2ZJI==KYK=.!SV$5%7N(MOQR!4<3'D8NM*",L2-N
M9:F)P*H1<PDK9%6%A^:@E*J8I!BJ[HI>4?[C'?AXJ5H6Y/!UZ8!$/;!@\LO!
MI.K$[<VS%YO#JX)]-JDBV$,6><P3:VKSC%8395(D#5;R78.4K4L,U@FC UNR
M(C!O&?R].P9C#^AP&W'IY'KO8MY!R^79?'C>/U#0+F7F7LRPVZ@+66"8]41\
M0O$IP%X"[.6>82^/ ^PEP%XF"WMY<F_*4&^P&C[)'\V35>UMLEF9IS"R-T7T
M1]90#/8/]G^WP_SO6W_+T.()61*>O4>._!QY=7K9 .XI;ZGD#8L4U>TMJ!%?
M,BLQR,:E=UTS@GU'>=G?RD=TCA[1N8CXI- GN)V=A=#NR#$(S7\S0APD8@[+
M#L)4_TM_]2/I Q+LT?\Z/CXV/Y$;.2*;]$<3'<O_X;E"!8U#K;:/\T-Y?5[F
M[;)X],P,]I+G]N14GU*Z66JD\T_F2D\9.6=;/D<1U?^4)&+_8SB,SH=RVK5P
M?>Q\1/+5_8!%K/L)'FS\NU.(PC?S;W3<OPQ^_5+F^<GSHQ]._PWU,0L?U(ST
MW\>HJ4%+]I?E+Y25N2C^]U_@/G]A<4HS^+<F?0B3Z=]H\_2>')T^O]GL7E]F
MC7H$)W(.IZ8HKZMDU9UQ[;Z/33><-3S1__LOCQ_RU#\%273\93O[_^'9]<PV
M$H_?I=5V%_[ N,UVLM$(^<'7H]L4,]7(;C<33K?==3<+Q2_&W?K8&[Y+1_]Z
M@A3^5?W]-KKNY,7#57;NST[N6_MMD\7?Y]1:^7N#R?XFNC#,OU6(1R]N./]!
M']ZG/NSYZ#]AT61?"80M'43*1.?_R>G1#T]NM@"=\.XUG(OR&D](=+)"@K="
M=4+ <N8E"+Q-)'U$QD?,IOS_51ODTMW(I;_5?QL@C+E+<S6$9H)Q^OW'91[N
M= ?3<UHB_B]__RU9JF!M!ADQG>F^A2T9A,3]"HE@] 6C;^(S&03Z9*<[&'U3
MD^>_8\%$L/J"D)C.= >K;W)2XOP2JX9^S@HD0DKRZ!UV&;YCVR_DIT-^>FK)
MC(#5FLY:!/#6Q-3"#0#E-\5R_?[V[&/TZ^L/O[S^$'W\QT_1^;L/[P,H*BB=
M?9O:_5$Z8?Y#D&)?]$P 1061LE_S'T!1#T$N!5!4R(_MP4R&T/=DISN8GM,2
M\0$4%63$U*8[I,<F)R2"T1>,OHG/9!#HDYWN8/1-39X'4%00$A.;[F#U34Y*
MO*]4C7V=FI"1#AGI?9G:_4D?!1A4@$'M@R+XBC"H-V_BZ.W;\P"$"FIGSZ9V
M?]1.F/\0F-@731. 4$&D[-?\!R#40Y!+ 0@5<F)[,),AW#W9Z0ZFY[1$? !"
M!1DQM>D.*;')"8E@] 6C;^(S&03Z9*<[&'U3D^<!"!6$Q,2F.UA]DY,2.P"A
MJ(\NS7'H2]SIXF@"T-%[;$K<E$[G1FSB_3Y/J-/SKZJZ4!5]]$&5U4529/^B
MQM>A77%H5WS/[8J?A';%H5UQ:%<<VA6'=L6A7?%W%P +[8JGYMX^).QW@'I/
MRA_8[.K>?V?A=U7[*8E^!SLB6:D6=D9-+88#^V4 ?>_;U :$YA[.?TC"3$OG
M!-!W$"E[/O\!]/T0Y!*"OM\FUY4JYBKZ[UQE10#_3#_V\=#%6- :$YGN8'=.
M2[X'Q'>0$5.;[H#]F9R0"!9?L/BF/)-!FD]VNH/%-S5A'N#>04A,;+J#R3<Y
M*<'-@%\3/BN[4MN; 0?P=P!_3W.C!_#W#N#OIP'\/37P]U=$?R=1EL**G^"8
M: AF%_SGZ317GX!4MUU[BC'HQ7_Q8F#UKTHXS%^F0YW+: B] 72TTT_P1C>D
M#L7#RU;E3QT5$=;O+M=/!.^=+^"[]V]^>_/NM^C=S]';?YR_>16=G[U_\_O9
MV^C7LP___?KWCZ.+>I,COY>+.J3M=US37=3]G:VA,V5/Z&Z#ZSA Z!OT[!WI
MV0&C_VQ593G+Q=,X.CT^#95M7V'2/YR?1;.LA(?"T#6<.4S[O4T[OF'GS[_\
M'2RX'XZC\\NVFE]&'Y("_O>/9!U'']NL45CV%);D:R_)'ZINEEE1P^/BZ/P=
MRZ7GQ\>G)V$MOO9:G&$E(494?H0)FJFJB5X?\8*  P:N?5B1K[TBYY=)5BTY
M_H7EGS^5297B'Z^R"CS=LJK#FMR[[OY5+>$PU.-K\./P(L"MPQ+LO@2GZ"*,
MK\(?B@NF9TH549)>95PVG331D&T51TGT2N7)=5*I: ZC+2N*%4<'__Z_GI^>
M'K_$']$_3UY&917)I^_A\J*1SP_C:%65J[*&M6C*B!RG*"O@G[ D&V/4![A/
M](/TA?:NLS7]*%F6Q06-/H[.&M@X^N<?VUET#F,>?POZ>71]6>;Y.BJO"YB*
MNIW569HEU1H'0G.BW]7>UHX![S!69[=U\NB'SNPYKWM>+L&/6^L''<&;T=>O
M%PLX+)@KP<T=NZ]ZG>4YEKLO\:,4_FPN:7@TU?A;N:<WK?Q[_WWPZUJMD@J+
MY-7G#(P*A.7(N>T^<:Z26AWAZYL'\.=P4K*B55AU3W=LJZOL"LZL-Q59X=[4
M'=E'<_VYO=[.Q_NVJMN$:_SQ5["IED:VF,T21^T*G@)CJ=OEDA_IO4<<J03,
MU_H2UXA"I/P*Y\D*DRT@+\KYI^B@A%_@^L#VI$OK\6LO54Y, PV<6GCG-8@N
M_#A;+A5LJT;!3@//$5>['%A1V(P9CX<7<P[6M<J1NP 6IE(-R$K^-U]!DT^G
M"I>)OE"?YWF+LA$$:UVC(0+__$B#/C1[!"8$$Z4JU0<QA4_GY1+7>PYO>:$H
M9@P2!_9PT:+@QC>V[\XG'*< 3I^\N?IG"[.@7TON _X!S#KO#UXC?!@\/\UP
M->K.ML)E6(*<BQ8MGLE:-3@(V,FR4<S*'NEI!P&>RIV) F+68E5'$Z5JD>&!
M1AJ-K)#Y(M&']UFJI(")@='4\RJ;X2U*V*(P]7RKWN.";KI_W?2[.^,D0-1R
ME<.9J5E#R:9;)FM875@&V":XF5;P=Q*E("S@(6!2\-)MWJMEV]0-_!@/QZ;C
M>&"/TT(D-(4($Y&(:=G.\-RMMSP/CF)+1VK5D5OG]BW3Z/<*)CR9T\$X!-$5
ML9($#=?"+_A\R<Y,+F"B+E!"PS56WY[\\+*.4/*4!3XNCB[*,HT6"2F#%>CA
MSYDO!N7>H$M9\LC@?X.#=Y[4ERPQ8!(4#.^O3^/CXV/\KR>IY2?O*^5%.8N2
M-L=?_O[H/"]KF$&)38)<XI6RPMQ?^"2ORX'5AT_F;86/RM>LW7 ,3.ZBE7FJ
M<E@ZUMT=13 '>9=DJ'&NP%<&<U._&I'#P 8"C8:R8$4WLZ-Q%TR$,XJ)]V#*
MHOBBFY!82? G)$=6&!A!P7R0%7KWP 3C*X&L:?7T:_WQ6]F@;#[(#ME+'- P
M[E;"]SS(],6KT5E?M'#H4CWI^E9_)!5LL@9,%)@+TGUS'.FNZLE==WW+G1?^
MYZR <P,?V)5_T\#1@,DW"@&>KN8J5?:$E#,0)HE1%K+;<!8<4P15((W452:T
M;6#/X^:EWZ)>R)%<B33Y7T]^>,J3"!(YQV>#9L2GP]O"F:G*I6<VW?PU@]+X
MB@X-S&\+>SAFT; NVXK,/CK[M!&$,\J3;B+]8 NJSRO8/7Q^9XH-X>M=;YW]
M7_:^Q3=J)<O[7['N[GQ*)"=# MP':$?*A3##+A=08!:M5JN1VZY.U\5M]_B1
MD/GKO_.JE^W. Q)P+C727-+==KE<=>H\?^><SFI6CLGB4?KWQ_L/0A*#JX5<
M$EJ6I,L^X@>F7OS+F^>-66JDN*] <4=(#KQ3(5G=>+N O( OY236BI2& ENT
M$"_)%/=/[;=O-LP2D5"'S)VI<:0IX-@# OWEI_T?_V2D)>G<6]Z@T"764#-O
M<+FVXVE-1NS*93+KW4#@+,'^KL\-[7L M<&"3#WJVF]ZN/]HEB\:"N)4N$*6
MY\B9?+WSLXG,K&049+-F*R+()J5, WHMR"9R9A"E(PMB39684$:'8(FO+4I4
MC9M/TJQO4?DD3Y;S5J'2A7P'#PL;Y*!K*_@ Q(B#X:&!Y2WAR2T*QG8_^8#*
M-FAG;0N47.@6*$&OR?1!1;,1.0;$ZA0VLE_(QTC7;4AGQK.$G\0_@ ^$3TLP
M>_!F>##1OQ6'N YO-KH2I9E5\'-E_!7L71-1:BH[<NE,FK(OP/$"N/@<_U/5
M[AUY)M;HAZL5*LBESA:ZU%AD,DV6?!:RTJFJN"UM7W;$'6IX.592TV31PRE"
M-1/>!W:"%]"Z$^%+W@.X*%=NTL*;X'QUWM/ 2NW($&EAO@5:GYDNR9*$M8U8
MW8C5O1.L[J][,6X\.ZCN-ZC3',7\EXKY@!;"V#030=\Z.87^B7J!:B1Y^2\2
MO'&CZ.Y$G65E;T2,^QOE"6JZF6ZSTKK368;A;YX4&XF@%)[8\*//)22X[)M*
MMRL30")?EQ&4,-.7&#0TXN_<F[;,3DGXJ"[/5)5?X).6F6YHOFHL DES8/=I
M1S(0+E?P%0B^,CM'3V:9L5$,5GE6?6SZ39=?H,KL/Z'50&V9T1W:J*U^!6WU
MC:>6%34L#Q(!+";JA[2A)5AB):I(*&>ZNH%=Z[)/1*W.MI$=XWUF==6WC++6
M>5W/1[J<B5D;^V:,*. [K$N/B!GU45"[R+TG<\1Y42C838RT5AP!ID#&&5KJ
MA<+@$!].M"TW#=IU^XF_%K($>-@JT)/)VH0#0.H@/3/SE+M-K>%@PXS/-!"7
M'-TP<H83&$7!Q$0."IU?;2O'<_%UK#BQDM#$H'UE*L8SP6'DC P"/ D:C"Z=
M3X2EZ9BX&^P^X]?HXCGECZ3^F2"NICAWI2A\Y (D/&!(I&#]P74P1UA\(-)%
MUAKC$HRJJE[KG,X#O-Q'U?G!6OR6YY3K)N_7&$.#<23&?^&%H?.,W.E.+( -
MVK<F.!=8:2^[I%W5?8DQ:)8(;8=1*[%L._CM=$7 #/7/'E^[4&>JK#?&*KH0
M:]$W%4DX%35Q)68;N)J!8=IO<!;(H<A A:4%.E@N=;,.;$YQ!&\Q?=$\AH71
M)&(O<%AX:%O'H_85/?^XQ^@I >6W$;UI4Q,$$]4(=:I;5"+.9(N-.+)6OPLJ
M+A3#4^Q0=$/./ZHJRX6.D8+_7FGXQ+[]=QU%*>7,XKO!ZR2G-6CD%0<?Y:>B
MAEWLX'2AGB.7>3-:U,6%O=9S2O@"4\%Q*.A9IZI"10FF!K^K#36X<!>"; (9
MLRE-]!2/"88GBGKCO<4[!6_/NB'2N14]*#9TVQ)8R<?D'#]S4"'\_H4594?N
MT>\PL ZBN&6);-_(J&E;WAPO6^ -\?!\A<,#BCR[&+--EB/K A:^O@JAZ2!Q
M'E&,+W,T H\P.ABP[A8I#Q]:"V_=P0\&#,??F7M%:OKZ4WJ5 D4Z7-CCA65,
M>@/=*BI5LR36H6HSE/6@,7P4,!MS(@+.H"+>LN:T- S3ZCBI47"0;B;\NZ36
MG*NR)**"YV&,N-$$AIQ0M@Q[ZSP0#T/U')/US':/?5>PO8QB-3A#A*:-X="_
MOOK'>M9458+VQS?N;>J6%O$)(JU G/J_=1<;]035J$O)\-'/SEWR]2AQ[PI2
M#")GB[XL53=(Y;3+B,5X@)G]^)3O"9M#'?ZT^?04UF!39A=/@)Q*,"OW%F5-
M3EA6*Z[_7YOU2?^<*.2&J XD10.K,3 M+(-[&@DL$MB7$1A%E[/R C&X)@"^
MZ<',RI&OV5"58Z[.@/3#E1CB)B^+T2]LH#(U 4C0WTMR_)EX.R@4J+; SRK#
M/$2">:\1M4XMVRC6;?1:!/11?@!9IC)/GD:C2K!1JVXX1P[GP7- C<@\KZ@-
MJ!**&%Y>3'&8^77>()ZY>.;NX,Q9*EYIQ+9B ;3+"1K!M&"=XF?VQ%^+PNG2
M2,*1A#^+A)_#RO9M:T)+AG8'5F=(<<1+R0ISA$U,G)TV'M3"PU],Z/*<*##"
M8E@N'8DZ$O4=\&7'=3VH$#-<L"E97V&6.[[2A+4:M:DI56O38."*OFXRTH'D
M4'!D=Z1_X56J\%0A<@2B7QSU_\(*C4C[D?;O@/8=%PYR,T>QR\%!P&LN-2'L
M:.9!+= QN^:-,(#Q%G ].UHBU4>J_Z94;["U&*?5%)1B^H;?ED ?F(6*!K 9
M(?+K2+EW3+E656CJA+PP'MER(M* 74>2BR1W!\Q2(WZE&O@JX)I6M;ZK#^DP
MQW2]1=^ O5@7JDPPN$X_5-C*\4)E#949^5WE-G3381:QK8JP454K[L#SE6(,
MB\THQC HU7! &"4:J 1':7NL1ZXY_I_3$UG7P">=-MFZ344[;],MGLV1GV73
M*%9U%A=B>>*=\7A]^^,UG#6U!OWCG#D"/XX)E *4[B=,PZD;(6?TGO2D6?M7
M>*DI<#P57<MG5LK-8'Z]R=A..88Z5&%L4MNF;[@R$*;0N)#N_B69+:]B9DO,
M;/F"S);#F-D2,ULB2N?V43HO,-W1X^<-)JXTPQS.:Q=5P*(S&W(/L3:&,,^%
MS1<%YF2*."U[JCJ%([ DTNT35TV%$&2:E,P:H;V#PC"<0$X%HS2:XZ[NQW/"
M3GAP,+'&!<_&,O:I5XI%G+48D:ZZS.%_SCDK7]RT%"4&%;#C@C"<ZS/"GF%2
M:]?T)CFW062=R<TU*;GT;/-P;UAZHXUJZ'WQ!GEGU& K*@] BH%Y5DO@/-V8
MVA?F5M912?+SN)RL$\SSJ52C.?.6(, _>65\+.ATL/9<CHSKL_%2((*KX1)+
M%L:^K;X;7@!ZI] $%O\AN"G\6)@8$OZ$M^,/+B#4C9*$L>Q0D%V":^=0O&$V
MBP^%9[*59<7$D#/,Q+K\U3%/&N\^1^RYW0"C%GW&&GIY8S)](:H<#D9+K)<O
MH?262DHDP5EU\Z]JI*VNT?)@,[1>XYEF("^OL20C\Y&@TRD@>TR<4?@XJ<9C
MD1>"A9#W"U])56JIARZ'J>SM+"COLXUZ,(18F?(_Y'S#HV<I"78(DRZH&!>F
MR;=^&3H/$'V4=TS4]9+_/?CEX4/29XFZ3,$.[PZ#+N7+I^Y_%-Y/!(,'E-,\
MW,1,$AQIYY09A__M.^6%A?I2/@E1TFO &ZW[\M0DXC6*#FT$J7X-D"K5$1KF
MKW0K^!*,1"IZVI+' _?>GG0A?MK(OK55 ":PUSOH,(%3XB.VD3OO)N8'25P(
M\HDNC\(0]-0)V@ ,38C7ZM0$X^4=Z!CQD2Z(RAAP_1MBL R9<SN$ "1^[ 9Z
M10,YC#AF)HALIP*.RR#W210*3L4 Z@:#%$].@;4MUQCCP4__[.O.I&N #!=1
MEK%4Z*A0JJ@-PAHX_X)31>0!1I#@:W,%M',XUK!;3BV1A7+[:G0:2:Y@CQ5S
M(=P03$%I5'=A:USHD@.\$\F.0R$,UQJ@!'&9XV=BSF-]MOK3A2L,(3>L,[H#
M/EP!6$_>>R1I4S?Q)3O=<2F\!FMK().RR5+;\P&,,PT7G&2?&N2Q2>X;E4'E
MJ?EYP-Y.<W40=MRMZG/\YZSFI& L#D)K(;J/K?IZ?3FY$_H3>7Z[X10X'37,
ME1LEMYJ2QU1JD8Y[>4$5_DSTL5 Y"14J!<C5YX;I>$8.<G[S&17M'4G $!_
M(J(DARG>TH:E0'!64F4^3$$TN18NGX)P!)1"U'"*$3Q5OD-Q;@K0-GP-I7,[
M&2?Z%&^6[Z1EGD RF8 'P^/GRFCZ-9#@.-8]*'I&)[JL4B]NE7L)F^'E!2S.
M:EQ.RL0SR@\LG^X\2% J,A6K-S'\OQTH*<F-=; P@9_2Z%V^2\=;P'60:_$3
M3]%7R*&$VE*_2"=,3%H\2E11P01MG9W*5KVLN8UFBVS2GE1@YC#_^D)YFTAJ
M_2#GVJ2?H9Y -7_) .!JEZDC6+EK. LT'S)=7"]WYO*45=(V)\Z\3:>6MZ )
M^O.(VLY7T'9>]3EL,Y:1,B55Z0ACD0:I/H5'?/ +?)4FBZ;^"$K**7"% 8:;
MZCJ0$()=1 =S9E1< WB"%<?L_78_.6J)?(W?>/P@>RVE!Z$]S7IR0[F<J(U8
ML]MFY>!HAHT[55LW/@.<H%FJN(['K5*G=:>)1Y!@0 T"X_M(*FAY8E5YT%QL
M%5BB88P[B-G65_+!/0^C6OH,+0!@/KD8['BMETI$Z $IDJX\P]0X8SQ3*A>5
M+1!B7O2-RQY<<3#)J:')$T&5%3 E3W&U<-P+L_"C6L=6 \6K1AHAELMO@10U
M,"^\">-J0=$OW4I1^5.\Z8K"[H-2):1N8 T'5Z6W47J]8--8<KLJ%\,HU!HF
M0BGK/C;#+Z9BTVKA9-,@EAB=UDPK3TM%W@6[7FYJZ)>2M9OVESF=?*% <(X6
M=6(=[7*)8G>3):-].J]9D\"P:BL5>8W$#M(JF0O@NG*B?4'*HQBC*[UQY@*5
M.T#27:(6G!E+UMQJ:W20GHPRBOQP@9:X' QP9_.U:L#D8Z\S[\M'V)=Y$*F%
M8R,]"5=:]B3J6Z4^BB:))?VF.%W=C(_PA3N&HAUZU?_@KS^SEJ,;+SUE^))<
M$Y?/"A,NOZ%57BV]$AFURO'G*(*_2E8L:7L-+!]*%N?H,S+,$+S'P81%N9U.
M_2Q7C[BP?#A).UM^1]C[@%I)KCCR(T@'C-&R89_E9-6F7)&U)@!%F90U4VV[
M L:6&/Q R^Y!,AX"]ZBI[.TKY#"Q0BTZHT/X^(LV+&K@SPU$;\\BU"_-CCI+
M66=!?1.OZC@8B4N:FEL=?'XZ-!H\4Y85:Z_N MR*!:NLRN$DZ14'\;)(>*SQ
M&"/A7Q()?Q@CX3$2'B7S[4OF9^B)Q[99XK7T(CM4<LX/VZ"J)KY?DBR^DFJJ
M]6R S>1&GI%+L>@;::?6=C"N;E=2L4M32)EDC"L>R;UJ4'C;=.D"88B=[;S&
M#IY*E6199Y*$E(;W<'1=:FZ10,<@.$GZC\JO5!S(RH$WN35"CT#P[<H-+U#*
MD=,G*/(GK>2*H,<'=00:A.]I:OC:M)S6UIU0G]V[1ZWUZS1YVF;;GF>M159X
MT71VN6:>YT_N1[K"&(VR^QRW\"MLX:^N7B##1TE"6?\L/.*T)E=?&'+!9:C[
MUBM>SPRMU+")PAL<14C?MFE\:I :8U&E*39BT6U08@HO3+=5A9HH"06W(YE=
M56LJ_:+J4%'#NL6^LO^-_;[ KBLO"$76IG'-[WS- Q3\KW $7F(GQGR A*<U
MH!Z->?"^"[@!!]'K4XQH_L</<%^3_\</78DL_!^M/MW_?7/Z0XB8/_CIE_W#
M!][_#C>?8&*?9,,.'CSXT],?_OP7"X4?T,#?'G[EO???^Y*]I[7XW)T_./2V
M_I=?)O8>>Q5^T>8?##?_;FB!=5[32?4W#LR"*OSJV6!#8T) =(/<LAOD4108
M<W.#?$4_2);H G;\X,$AS!*GX$3&X3QW?_XBP[N,IC":P(34F)(7VUY>SBX'
M_882(N[?;>Z?\-U;W\ 7;TY^2]Z\2)Z]^>WMT>O_2=X!7_BOO[UY]?SX)'GW
M][=OWYR\3X[^>G)\_-OQZ_?;=A@LKLSR@ILH>%N9X38K>(JE^0OP;)4U$USI
MMJDJY/_H3 %[]5V_0<>9CW4D=*I ;\WB;9WNX5>:+JUMH?*:$<I/&#NI*X7G
MV<S]RME^O<6UI:BUZ;V&,7&_Y0*[%8XVC2Z3AXQZ3LE5A:XK*NC+P<'W*]5D
M&]5W.@>E]F65[R/8Y;DJN7N=P>X,RZW?BYV3KI(SW#=!_2QT#:<;?KMJY>_3
MJK.O:9:+;CSUG D!,D05 ?C[WE'X.S?Y&2ZX<6S*.=PW1K3&I']&W%%:A?A3
M%WW';<8LNJ)02\H;:U>9:67/Z!Z+1I \2_3<YHU>,'R.G+(\_K:N1#O4,XE'
M)P?_[OZU)/FCVY#D6Q2CL6KS.1+^X5UOLVA))\?/7KX_>O4N*D!;3L&'OQV?
M'!^]2[U:+N6% ZRJ3RKO;9V+0I68O'AA_?_,15/__-"%1QV\E*'G=_T"?FPV
MVR4'B?OD'%@$/+L^I\/4+UI=:(1EN<C O>-\+W33=MXZS)#]I=,;]O(E^@Z#
M':,PDRHLAO="*JU=W+]]>4=H\GEO#$N24%VN_ QW>(&W94:(1 ]7?J+JYA3$
MS;]$*9,D1Z\'FNEDQ$FT!",$ ZBD'S%]D   \&(4H<-_IV'HG1\$O$^;/Q2S
M,]S[-%AS!I#NZ%UI&17R%(;'4PJ%@&4J(1>/*Z>.I1L^W?;-F3XSL>6U4%#+
M^6KVM\]ATUS20*9K'G?I+$?G4>8[^EY:C(5SQ#RVSB9O!?>DKN4[4^U$O-WK
M5W-UH\A[Q^KX#69(X]=39;]KG>P2U(5G4Z%[Q67"$]0"#V<3F ] SR=]J9*#
MA\7>0Z\2B45O'.7=KDU7K'HL*4\?)8]U:0^RB3%R!B)AW@OLP<D/N1=GXFB#
ML#[]*3F:T;F(Y^$ZYX&R);&&@=]A#F4+K(!):A4QA.#.BLI&5$&*KE_]1BY=
M97X1'X1&^><K& 4.F\M;CENV9<M>O_F0)N]QWUZ\.3E.I6R':40N*%[L&%KW
ME=2!03@M0G21RZ$+&!<9=YSSW;&;VS76^O%=>S[NSQ8<['_ELIGSYOG/)'_K
M.0I$5O?FQ/RW>1VWNQO%'SGP.DZX&O%";F\]Q0/W$RP[AV/XI>="/I<*+M46
MGJ#Y#9[L?I[P?%[O]/YXVYSR\</9'].=;'?RG#Z\E7,JRWZ?#!;,_>B:GNGG
M75:J&1U3L5V(K-MTE&A!9C4G3UY0-CZE9V(5AM&EI&:[:TG%X((/6.^DD;Q/
M*C678)+P&5<-P63T9JJ8STW&X\3H5HHXG6-1(CLN-F!G+V\X)-4_"09UV9HK
M59Q*&C5_X4W8RSEEQ6HE+@93WVZ9*,TW4:F5\H*37^PG+$O7:%(6R%(QYK]I
M0NM5OVN21K<?N4 "&D"4D&Y,&O,BU]/9ODM.M(B<*/02D^T[5_9##D&4P%>9
MZ,XO8-UVIGN]9^1L\3587QX^R:NY<:5?(!=K"@>XW@R*OC&'&]M$U]1Y"]2/
M'+^]*B(UTEE, 09F>N(#?%;6+7Y\#J\8&<%61I!'1A P@O<HQ)9S]**BT+N/
M*PF<88:+>2VUCE@D:2>^IH))>?JT8FL)-;Z459\EQB"H9&E#]2_)V9HFFQ)T
M)JK2L;K8H-*49UQG24K#G#:4CI<W2NH,-=1,!:M^4=FVI-2J2IUV9JJ&L)J6
M]^M%0^6?-=V*,1 WM%["R/0 _,I6Q2(#L>G;SEXYTL0]#0_8@%0=&6E80:5(
M60/NAXNYUE0)NA$MC[[!XKQ]GJNVI16 "XMZC2TP<E=:*"%.ZYZ/I5HZ_C(-
M:YW [;:5*54'R\YMD4J" \-VZ([?Q:Y:)\:T-W-[/2U2?<X5.JF>I@W)N?Q%
M$PTUP54*2954G5W*>](2#08$>47[P/*0RY+Z+[-KMV+HVR?5-HC 4B\TG!KG
MDE/(=T2(U]M1EOI4$#US+@ JPGYJ"TU*G=Z,O'KN-;'$(M=BE-IME.@IRKY7
M8M$FN0[%<"S3$O.3;C4_Z=G>0<Q/FEM^TC<HTQ+C!-/*SV&,$TQIJ"0#_[NF
MCM(G7E.'&:FM6(D\-*%=AQ(0NAX:)\!GWC"D]EU:P%_#*7]LVP8X[14T5RK(
M0@KA.RD?>P@&>?HUW"/'^)DU9_203.#/Q^ 3C@*ASN>=' ?&<E?:"D+L5B/5
MUO6IEC+F5,Z3@L6F(/9P5+R 1X@.G&_JR;V2? <$%UAI[L+:Z]R MELC_0TR
M8^-)I78J!O8[G(&V8$Y,1EWR5Z^]4'+4=ZO:6>D^F=HN55SRB*B)XAVN X]I
MW;.5<+GT&)EN8 Z99W$M,C+LC('H]8QB4DU6JIST>8:+TJ@S62G8)6Y,,+B>
MP+G27\KK0P0KG29B?E$HQ!7?M%BO +B2?)!N'03J-GSE%*S,)BL],*57BTB:
M=W#QVG%T6$2EM]]!6LU$MY/DQXD^)_="1QB^ZXQT HL>)[#N-<_F95S= S\A
ML9WQJV=>^RP"\YJ.%A(GU-W%I!OM&F*!/5.3([KF+3MP5&HN"(@DW]B/N\Z[
M@DP$#*>F4I?/19Y;*/)_T$]R:JD9EKPQN<8&977#I<E\5N=[2[8OD3U]-94%
M1GDO1_$&_(?BGL)^6/PK7_@'RI^_QQ^D/<\S;L\3Q>DWC8>\KCND$^-10WJ!
M0XKH]K)5!NSC$.M=DS438FZ=(?# ;QQC]2>A:8P:+@2.;YU_@6>VJ//>D/'B
MPGAI<QB80?T"-IBBT"-7VGI'5UYCQ3QK5;HEQ+_+;1C-L5PK@SW>=@XTJ+T%
M/B7A34]V:C@0>G0#==?P,QA2 AE:9(!Y>SZ,*4]@/+J;4#;&6%]+S.^FU.+1
MO&'(2@PO,%7A)V(+IL?9>$V,?W@TZ8E+;VF5KC?/.UK(D 'C5"2"T&6?$O<)
MCF1%?1H-I@TVX&S7]C3*6HFB!!KBJC8M'S)N$Y25MDT3N^<36*!LT(#$UDOU
MQT*X'99YI1=NW8*F7+0=7M&4/1SF5DW1NY_0!7,RYY->"LX-#)&OJ**DG8MA
M]\/1S?=O&[5G8N$ON$ C6X$HAQ:H%PZCY01$Y+9N9BSY=1 S<<  _X&Z;7M3
M\A*X%[:XE/@,RW2UA^7RX0ISPP?N^=I*?B*\*',(MG$[+HOKS :O0/"K[/SI
M_4A#D(X4<XJ$2NM@[Z#05L*D^I:%QQX<)""\3[LL!;R KCF[K#MRVY1>">";
M@-X35B%M[@6GBGF;* S%1*Z4@D<3K;@<E:U/YKQ)5H0*7Q/BO/MM;C'*@D2\
MGM/C,+NMRZA+&K OC?H*S*],1HD VSO#6/$+TR?64C8J*_!QIL<!H7.C\K55
M^2J^I?(U4+A$#TMQ*U>,A!Q2 M.@&.!C YYU]"9'\45&R,;Z,BR>TFKS J(:
M\-5)P-7U""B&/2Q=/8QAC\GZ44AW_XU.K-FA'Z\(=\08QPQC''\'B5E>.[8@
MANM:J<YUQ?)K'PWU2FR+=*[0R0%BN;0=P;M$4=0C*WZO>_8.LUNH[4!."YG[
M"%>8E-SA7,O2AYZ,Y;"1\;4F-NU16Y"7EP;!=M3.(63P/^RX0R\RV0I65J Y
M8>6"F<? JY62X_D*C_/.$=E!2V#:UNBB-ADVP]^\>-A+UW,6[OP:#C&\@P+^
MIM?K>Z_IE.CRS^ E3S-L)D7;?8123K!D;ZD[159&?>B;QG9>3GH)4'_MJ+(5
MB)!"D&\I[KKQH8Y Y4@TS)T1E488<ND_5BE$_*%.A02-YL5X;-NQ&S,]*AGI
M!D>('GBYOYE\O#D^D_"2$D>%E[T74MM$B!_&\_)-G;?225#"=^A9X@;9,#PV
MS^8/A49KORHDOF=]2*YE-%=BL,8WJ_=\\\"?LL">1UGK7"CTI+U^@QVFT;NB
MPAG L3+YI>+CR^OU0E?R 7[&3:+.L>8;704^08-=]HM"L".PU!]5:DNLF$ >
M'R^#K+;2#_N-F/:Q ECE2C#H0Q+<J@SOM56D-!?Z*5A)+N<2^N,,RP@Z#EO$
M+J>\R0>RN!H3K?4?+2A>?N."!;'W06ZGELC2OA0S<:F@GQ-W$=D:D:UWC&P]
MC,C6B&R-+IXMHO]1=/$$+A[6%745J.C/LDV68_SQ357.J0CUV-L#2GF8@3[T
MO-:E*FWW[RF5/S?OFFVIF!7@"TF5D&26ZXR82=2B9EC7$D9V<4U;7?BU>(Z#
M\AV$ W$@D*V/,X4WR3?<23TD^Z3&FT#XU.@<OAGQ/8Z<P^<<+QV^"CTTG^;-
M)Z2 %$[Y(\8L:]\/(9X&<B/P%<6NQ96AL4#QSZ$? XM6<* .]0F;M#=$E7G8
MY"0P"2G8& 2O)Q^SS'39NC1#!X>8<%+<"\*Q_HD9$8SQ,GO1YNL[G!FT[D 5
M@X%NU5'L3&6*:#N0XX4E0/+YLL\6FVNJ(@W'-L8P(G3 9.X1/:(P3]F4:Y0D
M3<)Y=5[>)T]R[=U87E#]O2'2F.&8['5GK"6P^3WL,IKL$)TN^[)T@$R*J.N.
M;/5=QA*Q^4^#5=F:<J.SG!&,;:>R(K4'8OAL[W!4UG4_[:ZW16^#G6BV1!PF
MK^8(PV5(TC4L 5Z)O^FEIA5.S?MYYQ>_R<,.UVD\SY]]GD>Y+2P2;"R0>3\Y
MK[W@.^71$/&:PR0:V5*\<0(=,PA)T&_X'E,E#0Z25%@;@0#VD\GD"('[T!/&
M"><X.%CUH,>BE@MT,I%L8VHC@L;');A%B'@ :'DIF$Y>]QM+L50W4[+=N='Y
MA60&5" 4=9/W:T0_Y/!B3C(*2";KV+<U^90 :,-E'IEI+8)ID>([Q%C(VM+"
MM)SF/UUZ;OQD?]/X/9AOHJF/")R<(#OHD$0GI]J2X105XQL>MA^C8NSSP]=U
M\JX&X2_MMV?$%<=J<<@'IZ'88<?QINY/5W[>G5B:;6H-31:BIXQ&Y1B?$\66
M/3D4*)[>E5YHUV@@^R@X7:M3&2'S>/_1MA@T,9OK7*=M/5D7SF#$*(4?D,U>
M+7D?W^JN3?3PM;NV[I&0V@3_A4V9%?HFLLJ;+=A/D57ZK/*YH-9=*XF7%68Q
MSI]QLF+!Z7,T<:.%<0;6OV *6S#%P,PHP[E=F4!E7J)*B>9 Z0'YV=C)5ZKH
M2QAMJ:W:1@K@\3-GR2'T 6N5EXJ2&+SJ/3ATWRB7OD/L5V96AVE@'#LF4[)0
MK"19<(4#9F@RH2IALW8^7K,9S_BY#/0#PVPF<M!'^JW+\"ELQE\1UO+TG")F
MM2E70UV6,,0YOVZIKTJ/?6IU=<;#I]LV6"YC]=C+R[![F=YHPT8I($0IQ1E9
MC4NQ>D$3UD#Q;$2NQ=P0FWW+-'5K]']6SE>Z*?88?VY=X%Z1@'O!3XST_VE.
MO"/*R)LMV,]11@[,B6/CGZ"^N)LFTVU6)B<X0OLT^9!A'LNLU,)M[G??78G\
MJ*]LGR4RS7>R7=Z@<WPG@89.^^GIBL(XT4V5!':FV]5*7<6^UH!2:?'X!R G
M\JLTK4@%<ZG%"VE8HZPQ7P^RVL!J LO'I)RQ)*'BA*[ _JY4*W19(R(H1_U$
MT/="+EU8IC/==#W/'X%%(T"O2T;W9P3*@\R3Q9>M%//CH9&#S__Z[!4C(7<6
MNW9AIZ(.MC3&HJ%"#U)61J$QR,Y:^'.=@?C(T)\),J_E)'.8\%E=]I@UC.F=
MF29P%/7QR/4&O2Z!:S9%4M5KH+>>@YV\Q[A7\CM<7F;G;)(FN-0=6:0,CI.*
MCPEC.NB[;<4_7,.T''4W59TJ#OB>@>E52'D+S,14ZF/+?6)^KR7*&Q2/M#+>
M9"N.:YJ8XLCJU%_?:Y?AF4!H(U<'_:%ENNTI2<RXX(9!*0QNF7Y^- <;+[#9
MDE[D0KYA#63*R3U4?"C/;R+'')'[BLXKP;BI>V@GY4=;U6%Y36XQAS"Y:VT^
MO#5Z&SJ+#!\E3N%T^,BU)M1_2<[L=& ^]8/EIEZIR:0.??]^8J*M@N+5Q; A
M>ULV1@@5.&LE51=&E5L4FCSY934>@F,]D2OI]L^F*;9AD\@)B@H5>617'',(
MDJDOU?9#Q] E4V=D)X$B?1Z(-2: K.1D33>4W.+#B4K5#47R+U&I\I6J$R7I
M ID#"$MVN7:)ZO/L47X)N$%>BM_G7++E8]F_^:?$H5HR 6W;AD<C_, 5S19B
M!\;;B23O&.P#*Y 32(R%+52&^74FNV%"Y"X9*&(;:MV+79EE>+^O2NKK:!45
M]8E\:B6JKMD4#,M+EX_GX0N6'@$ZU(0178VERAIC$I'-#$?CV'4: %/$*Q"(
M%WD_LO(N=HI>XZ$H!DK@U04%^=N7U1GHV[4SXV.234RRN=LDFX<QR28FV83*
M\4^WH1S/6Q=FE_/W4<]U)%2&+S\CH6P*O+(X/.&&,LODA6[:+CE1RQ[C!2B@
MG]5[U.'EN]C!DS<O3F:Y2:@)H:6XUV^\PF)#AQTWR>O.E1JE&J4CKR0;^!PP
M"30P$ A4D8^=AQXLW<N%1L]KO5[W%?I&-PUZN[$.;78.DMOV^AL:,T4MP+%A
M([]AIO40+!]"9Z_L&6@*:;>,G."RAE?>UBI2.L$&B-K^G0>OOTNWT#<KIV\0
MXR.$^00T'!U\+M>"3#1;(AJ.$[J=L#58&I:M!LLN:S R)34_/5?\N$XC\@:_
MP'V8A,$I$!3\"([D8*1SJ3S?<5V]UA3,=D6$;$$,"71(32;!WV?4%"#U\>/#
MLMJ#X.UTF'#WBXO@;[-1A]MBRZ@;CC]92'TGX);^DNV.*HA_26EU5?@CW4U)
M]4OF(&7657&]&Z9KL(]6<]"<;GMY^ENON.Y2];:_0VTB@Y@?%/GL-RW5\S[D
M1G@^%ZAV%;T 50@C ']OJ2 [U3H9>2,L7+\VM%3TRL)#;?V<242 #">,#*$3
MRJ2:[A)[9  &!K%I8JPJ:DFA&:KV_JPXUJSH0&\+JD_DE2)/)R& H7JRJ4V4
M]M@,R#GH++ PI,91JB^!/)A@E70VH=E,=4N1<G4N\CU$<[IT((MJ@0/8ES8Z
MS^ *@J[HNK1 #\*52 A\66(TGQ:#M&6S!X@C4,L,!Q,-N^(,(^,614]%DTE-
M]*6O@(]P))BV/UW5.Q!>20[J.5=E(E](4).)$!Y<]\RU(QT5=F>8)UZ&%9BM
M:/4FAY";H*7IH&C\58P:*%]U[2X^SE",>]S *4R($-Z#U.U ZI8=BQC((M.$
MTB %5:!!3 1 !5AB-Y7V/;S7%M>\H$ !3(8#-\![@3-Q'6<P(C0A0+*"2F65
M%S>HNR D>KTV.Y'5?\NJS@%72AU+0J;A<YIKL:BBYOK=&&UWK,759Q95-K6*
M;!I* %*B.(> M%>3K9PBW-^V<./VN;8.F\4 ;D.Z31VOJV:2RCQ2"\V2&8P>
MCKIOIDM!UPN#D [#B!U:,"+PZA-JM&!:/7M:QV<RGK^O=?[45SI_HRH:F6#8
MJ-8^NZ$(,D9)#5MS_29L2$2$ J&7EXDF=%'EJYH:54Q@:60^*(PGIV,5(AP'
M.XR P- M9CV2J0Q?T%G[9Z_(_Q8"V!P 9TMBS'A"KJ>V0$F!6:S1Y&E01@GH
ML>9:"78JIDJ1&!D4$V?EB,")(?AIG16D61D?X@ @ZB2];HQMAT@^SO <#G@&
M[SRT K_2PHS L#MF&;:\&5%(WYP!HP).]\S7HBS, U\#<8JH%"%'W=KF"%^P
MU)8IF> V^E\5 TY%Z0Q?W"9A?=9[DT<G_UC5YZ4J K"Q=>A[T"]YY+M^074J
MAX6SIE)E*R0S31*1VEEL.U2?)5(C*][*BI?3K/@.\)H?)@YK$&K([%G%V%!B
M2J13A@-7@+8Z ^*X4?1CY$R$,*DX39TK1=8+^;C)2A60..*OY:F6C">X-SX/
M%/E.86EX>_/(%KS2+I'HAD0]V$H9%MQ@!\UN$K0!W69#>/TY/=4%SD#&:H_3
M80QKF##++U%AG/'*6'W;3X8=3%YIV98!]X:),"@T J5O>/(.'DPCI1]\X<F[
M3^CH9W!"X(0Y1CVOY#)*; UXPT3S4K;)0M:V578;/W2+9;+I !O- 5. J :&
MR>]VQ>M-&9F13ZS.\[[A,A*FEX1BK_*9UY2OO+"MTYB1'=MK<-ELR:V=;/<F
MT+<11,-H5A@--ZE?3))>;ISS794*_=&>%Y'C3?CH):EZ!7 88NQ\*QB.?>?]
M+?%9\X5V^?SV.Q?.)6966H=\P0HL18RR4WE+X/0;@:#:I^#<-K14YJM%G34%
M+I<K0A)!@!$$>+<@P$<1!!A!@*$F]?,=:E+S5ISJ!=Q]IFRR=-UXC-YD__GB
M(&C 2)DN8QYN2V,,,K%1-$M,'H7U608_(E6@D+^D4.<6.-4P+RJEQJ;JDQ@%
MKKTM[8.Q98NZ7W1!AOE44BSE='MYJB8JCJ2_KKSF&I1AW2","DWH,U76&Q.Y
M1IV^OF!I[L)<84/QUK[<R TRS/JR?N%%"X+=%OGP7M]/=6G)0:*F>^*@2X@"
M@V.MS&A,5D\R66GD(O*RU>'A2P(J-@Q43,=*AH\"JY<F\7[:@R2(B:UVD;CQ
MQQVLG([&%N^TIB9U.E$74]+C<TI]BW;73>VN@VAWO9>C,K_B5Q/=3%T932I4
MQ?U]J9X1I\1)_'O9-W0@"29 S(RCJLZKI#)X?ZH3P,8.UTTR V/#>E.:?^2>
M]'K[$E[#SFF8260P;!U[KW! K";!4Q&W9B'Q]$%88<=8D@@*.V57L=QH<$9P
M7<$\N&.4ALE/DZB;I E.MH!?[$X9?V2GY?P3K<!@4KKUW]5Z9DV1X\LP(-NP
MPS?#=_]XJ^0W4?YP 9,%XAO49IW1L3!P[C]:7_&O5]CRGM2WEFZB<UJX&1T#
MUFT12'PO-M-D,Q\<SFD-0TW;B"M1!:9J) 99&9=>ZU6GP4B>.A/@&2' 1%I1
M&1IR_MGXI0&/F)B&Q;@L^]+BY4;/,FIR5(AO02$^C KQ;[K-55EFE:K[%KO,
M2$GX&9W=&,/^IH53[@49'UD#84Z$F[RNG>FR57!@N-LY1KP.W2Q!Q-#1WN5>
M!QFR#/5IQ6X7KXG, -4>#]$W33.[%X?HN.H05NO58WY6]QC:05)JGV+J 37C
M;9'4CDN@V*:N=,Y@JK5N6P&CO,AR<B;/R98<N5C\) _RD?#+.[O>]V2;LS3N
M?DCGK\<L)U6(T]5T5]%^1A166O5=R5R;U<#,X(!1A+5;.0<#=:PF%/&Z%MB,
MF<84^L]$R#G;23!$H[>68C VR09;(7)$GG"=9J_3Y/*23)1'H>$LB]HJB8G^
MQ5X"1UTIZSMN@1]2@=.F=SV#_";7&:53>GE GI^($D7<+(-"BKN4T(V)F+)(
M\'%I")&\8HY@.Y]@8="WSU\D'#5Q;]KV6+)22X%P3/T94X+Q>8G'FLOL3J1Q
M1N;[37//[@7S/7*90:^R\Z?)?_:-;@L=MC2?P8Y-NZKAP)Q2K@3I(3:&@\=<
M#?NP<1%4/#U8_\#Y3\4Y_%S!UUFC,$AUFC4%ER%;NAL8^,L5.&S.-C]]7(,!
MV'"5ZTW)<&B3[T0?<#!J&.GUS@FAE$8$>(A'<_Y-T0=T67,B6UB&.G0F3.AE
M3\BC<U6Y;G%O2ZN*?K'6G>4]%#UM46G\W:,53J945:]<S)%*."\3H!A8_^9B
MZY+[4%%IF"FI+3B"+4=!T8"!O/&G(*A1E(HH ^WSMSV3?OA[1=G)]'N;/-=2
MW9=O-M%A^W5 )UP+VBNU3?('ZQZW#*]F04E]$&UEY,%66S)>*0R1<RZEM.@H
MW%)SH^-AE!:>A565<4/O93.'@T/DP_/A,;2EL)@FDHW'CZB-<[/@Y%[@GC&5
M2X;I]JW5E4?%+8Y]MFUHF^/ UQ*&/ZLH_[."IY$V +38KREALG:G(3B!R(J<
M 0<// O)$U$<$EVG:0)_H_@2/9F-OBM?:L)TU#9L#_1W"M]4][Z!+1#F:DZ$
MN:U"QYD6P.=5_%S(#GF9+670D?<7U%4@HFNBR;]+5?%KY*[>B]-QU*+'9V8%
MTK9@&(!#F;()#.1Q4 9D7EZQ!*G'I2O,>PT[#7#]*\[@#90P-LK"I#G@F<A2
M38X>)]URQ35<MO:/%DW^FF+Y7JS<=:/)7W/A2.Y72DNMH>"@5"ZG2NI&#-M2
M4-+W5,*2Z4'2B@N8RCB4E/U=V,K <+ 8UD,N$D_)\$M"L;MJ2R-U5R;%:VZ.
M>O]ZXPZ6@5+*!+9V;I%7I7E,O]_V67H3\?+-IF9N60P&)MF9ANJ1J$M1RG[3
M#/5[P49>URC1&@)O 1ERUL^,F JU]EZ)@3-R.'"Q=LF/+#5V%M)MT"B\;IRG
M=HE)SQM)97_K2I31^4R=_$5!NU;%A8$>2@_(<^!N;8U,-[&)E O3[C*Z0V>9
ME'POSN [BDTP8&961^_(UJ!J+NU4QN4D\.!Q&;$:3XBO]1I#7W<]RTSY(G H
M.("15S#)-57SBHX%^<]P5C-=D4O2ABGL9*>J38J7[>J1Z^52LLS'BR O8))*
MS'MQ@1KWB_^"^\E+"OQ0/.GWOC@U\?+,])]#U^UZH\@E&2P-$$Y)Q?[8\7?I
MML1TQ9BN>+?IBH]CNF),5_SN>A8$21/;)!U[;MX:SPW>XDKI,)=?9Q_)M4W9
M*<K'W'I9*&2L4E5<# 10-TBZ8<3V*9*%QFBG$G0.82)@<@X+3EKQ9M5D+9<H
MH>1)4*URM64D29Z?^,&(=U<C-"C_2>ZI#+$FN.C4A+XEEZ^HYZ8<"JGESF)6
MV]6%B;><J-/EC-_I>6$GSV1=%[ DJJ 0*$7\SK8%_&R_7[?XIJ8QO(SN3.DY
M-L4I'X<:V4[L^&"MK_^B9A.F7VG+UE#)P"Q?(2A[&-G<U"W5G.)I@OY9U6N=
M8V(J[ O:3N0T8(>#UU'LAM..MLY66^<T>AK$RC'<Z:TKY34G:^?*N?ST17/Y
M\;I3.<.R4GE6BM9 L#L,RLUHK2YM)X!^6UUQ/KM!S9$_Q<!T,6'2=MECMTQC
MD@\SZPX-D'AYO^Y+*@KH2KPPRS;@$''5,"<3]XT;FU/(4_'82!MP[@$^#$H;
M4>/U?\>8C2EU+(^IE'F(K=<*;X1Y_BJ\=V)>C ;<C'4$#*O"U\1BBVP-"B5!
M0AAON(9G=IACS[\@>)%BWTM7M< O5KR@D'Y6P$LB%(6?;"Z@PD)&G)F&]V)8
M&OS.91;T.59LHW?FHSP)?I*8E55*V#KW2J1A]5>#),*BKQX,H*5"AXTR17 +
M;@CAQ02&%<S"E@:X:CA'1Y[2]QSU -)E>++P^%)J,15.3S-;XP7P.MV5K <0
M4.+WOLJ=O6\^M7X=-]MH?3J83GWA.9?9K!"%SD.XI;<+DG#\74"=:+T62KR^
MJ"(83,SHC/NUQ2],-4K>+-A-.>G(<>BP2Q&MB?P!#RFSJ+&V>-LWBIU#XN.1
MANX^,&\1$JC7-,3&=!R 63(4N+[%X.DFN=W'S^C.\1:L("N**:FDA,E;AK28
MNJ,6%,LT+T K0+R%\O>6)EU]D;7:<RSY+X U;,=<Q%M8>Q=N'*W!Y!RT*=#,
M5:-!@?9&,QF"XD>?V+6H76[5+E=1NS1Q+,2$S2MR=<2G5^?*-[.D0UH^"G-O
M37P:I"50,Q%7](CPF*"/[!SL)K\:J^XY5@Q&YY2PT58P?4D%:QA>9LKLILD2
M><\&=1!=8 .%C&H-;_I.?/@P7&4Z2A 0F9@@RA)-#)+P?@)4):W*5O 552//
M6"/R&Y2L. 5$L)!^"0WWBL;P)HO:OQ^TGU9*ZF,4H,2!7#K$CAC3)FH>ID>@
M=JA-#2EOT%V7??SCDP</DLW^>C_90=KXG[KYF#PC&0#TLIMZZH7,FU:7H#F,
M7_07&A;F:!=G+/+8JZ)DRTKS+\"U4#M._=G2V\D/X5OZ?;PLHO!@_Z=!62,O
M;.I5J>4'<ONB%I8 (0X$J^A$4_=J;N7U!F05=?+[,V[8K_[;A(5!1M^Y8OLW
M>K=VA<71%ZJLSR='X^EB<'8$1X]"8ZO0T#'\&E2I14: FZ>SV45@I1'20(>W
M2N<BZ+7SBO6FAL(WGM[NU5(3%S-\8&1#7>UM^@4,$!98I904X[>UU=RFN@1N
M::A@?T!8.FOXN2QS[A=Z0K6PT&=]>:H<%-R?BNC\'6%4I,U:#UM5;JL^1+8,
MOQ.*2=V20]H@*.$*$D?;ZM2/W<Q/+8--$\'<I<Y4'%;I,\^;?!',:CE:8C\4
M-(E2V^T._\PIY2^C%$JI9LL?G.)@FS+L6);OH/QOA86C!>25$<Y#V@X :*AI
M@\Y-?AQ@O;1+4K6N6^$[8'FZC#)#6!CL CV^MNB^\.4]>%_XFH/6@T%Q0'R(
M,?BG,JPF]PCD+E^KV[8G^R:GO!029+3O5J1S9RR4*F#R4$DQ:PT)U6=5!>N>
M>XT_!@FGUR#^+0=!+-RKR@A*=4.^FOZ\-F!QJF^OLJXY04U>PBM0SR3;.==-
MWJ\Q1]=$+&1=J-(^F8*\Y-2<Q]:PI[2,NIDHP;SE; Y"$]C.C*<3A?568?U[
M%-9A-W7,BVY4-\?JADHBKU+\3CI<2($W_UM=F2_Q='@_T*OZOTDH=YF4^B,6
M?<=.0DG?3K7ME3/:J*5JIG+XL74,\%P)V:+D%>%*7J@<(1^7H;SX!?-LX^Q6
M=,YA[PZR)V!*2VYIR#ED;*K1;/A#)=E"SLX]A=5SYIUDTGJ.57^K;:[_B1F1
MV(Y8/&Q@F];7BN7@)3^/G;)2@,29=.+)0I<QXN!R;@L.9%&(@];L BZA;;J-
M!7_)8V?'*=229*BQJ 91_K7*"+R6M?;*T<[R##"03IM$X==MV^_\!*AQ5"XD
ML2E[+K0@R';^S(-1S0(9GL79.FN!(F Z6![9:8[^@$NU1MR=D)/JT=O %X.1
M&%RP=0CWE*DQC"H9?#\8)1QA\,3]Y,-*5838[8:'4P88GD[YNC5? QT&O\ B
MV>,))#9]$E/V1D]LR )#.B68LTZ_"69E9#]!/EB'-X\[7RE2);B1GO-WP].7
MV!<T'!=5*PL#F6(BCE^99]>6\>@VC*[MFTL^L%MJN&BBG_A\"X&,$LKBTV+9
M4L0G1GSBW>(3?XSXQ(A/_.[PB5@#A)ASTEUL3.R K4_4,5K6QD#!*WJRZU@H
M>/%XWR.+!>MW2;E)4!^4IH7KH?9%]IUO\=HNU9GQR6;=MBM:KAJ'CA6#TJ-T
MG1ZL5+H<-4JL*,J%JVO^=QIH($+&5.6N1-T:ZXM>ZH^OB%R53LL*([P+WSLU
M*O;&I$;>WIO;[RK;G*+I2PD'.3\=M9-;]^6I<[V3(9!2#!3CQ10YF5HQK!^S
MIZHLMW=B^C"V9."R5'#!: V'LQ<I_N\BOTU3I\+8B/1K >I%UK2^\B-O)$VJ
M+ HA"/QS%$S<6RY)@_0F48@-UL?J^SAI@QSR[@S LJ-N[ M%_4?3*0+YZ]'1
MV[&"[T!(GJKOK0RM&_EEFKH_7=$F4V!*?"%PJ-)+S(;4E,,MO(!+,)SW0^KE
M=I<7O&C-U"85(++-'EC]$MTO60F4 <8!7C">%2:GYQD3-)QI&<P/3^V;4:?
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MM27HSLT@N#<1+F52.\UTU?+J,6_ .<)FP:)F990+WS8"^+KND B-:PAW"3@
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M!,K\<<V8PSL1KQS"*!M;"<]/L[R\*FWL*G4[7L(=X]%F]-:$:WUAV]DA!MI
MUR:@T$MV^MO6(/=B5V;INNVKDGI5N?(0GT@1!OV5DH>GW>VM]?C?BY6?Y7G
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MBCE2H3;STVUH,_-67L0B\9A^F9V'K5\&Y0BO4H#A;537[B(;-Y+8L?&!>X@
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MI8'(:Z8^&$0>^:Y?4#F287[T%'"Z0C+3)!%MC;2IM_\LD1I9\596O)QFQ7>
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M3A4J_X5&#(6[S"[@$MJNQ(N^X_B'':=02[)(C']J@)E:JXP@:UEKKQSM+,\
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M,)&W5I]RM>&7:56'TP8FR22;$L>L@;!IX1H-KW3>Z*Y3%;T"KI''FH83.==
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MMK9KT; 2X1:C>!HC#==EQ8L[#0<R:/W+T%>>XI0EE2(= H$*!*SXTL%W.0&
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MT!(-QG'"+#8#+KQ=]C@01$ =YH?3O/H2>!>PB<$\ GMS4G <8ICZ0BBB=WA
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M(!'!4IXRN2:Z9U,7+&I@)++<!9(;DU#,.5;IU:U5@!-B@B!GW"M0$>!\T5;
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M(YC"Z\)$[?IQ(2VM=_V=G9W5T)L;/0,#MWZ&MU7;2-_UMVH+CC*F##,.X%&
MC<XV 1#C]OVTNUV+F07A[^!E\ICTHMEJ[)3& J6Q[Y1&2VDLB;X.Z)R-T,A"
MNU9'N\&H0ROWTFJC$BE6YD'>MOJM?+=$/#%,4V^4TKWRJQ[@5HN8! /8 @WJ
MI474 J<&5U)3A_1^H1'+C<0X&\Z$X%=9P1R<G"I(-S$!,Z1">U_Q#ZP\DNHL
M7SH'+^-KI+QPC:JG"4KLY$./U>(AXQI(2Z.)+W4Z"4W^6;EEF98@W*6P+%4%
M?R,>A; ,26Q/ V:'C^&FP6O+3'E*(/W3)!(R% DMP\%\ 8M$;U+C-<ERT&K1
M([?I'/&&[^YOA=3AJC]XJ1B]AKVO?3=#NV[$?;EXW4%C0[5NACO5;9N@O)-*
MR5U%O$L<G:B,5>J<5P$ 806:5CV+*&.X5>N;]0>W 0>E+JU&?$[DH 'NQ+8^
MJ_53V)69=7VWKN_V8?MN]UW?K>N[K7N7^_?A70[;E^RH!8Z^3@0]9H6B%B[:
MM4VD.J1$K;S9"RXOL72_[(#S7<TTLTU%PK@L"Z]#V8F3PHH^:@"RW'$$V$KA
MJGI!T$IFLC5J4TTZ%C"20E(#LR $^F$9O!2Y?%WCM21GF$>-%T1 E_9+ZM)S
MWZM2TW.Q6AICV889T[YGV]C31-"8Z&N43V*&W&FOLDK5WV44BUFIY74:[\ J
M2N\HI=^JVX,W09Z#P"VV[^.-I#.&<&1,W M>DBT?/&I4J6Z@J[P&\^6&%@5\
M";."PEW6-1@H""B;)<$SSX#Y=6&PMGH/FGX. ;YMF L^K!K(IN])<M-489C!
MZQW=%PTO\Q[\2N.1F7PBCR,4UZ5KN<H;P@M:7^,CH;ZB0T&('P:LA6@Z$S@,
MD>G9X<>5BD&/33=0@_U4D6:78W8EV5IY3)VY'Y)L77K.'9%O.R*P94KCJ=I,
MH\ZZH1+J;64Z)HDU4SG"8TGZ9YW;D(PLU5$DYLJ*DM+HIBQ*#Y=A)+2^0CO[
MRCG0)@OC"2N)% N),78%ZZAU1>M360@:6!$)4(;/\&EP4\GJXTVK,3 NWB\#
MK<?07AU%$Z1U@#T16S'L?AXBAATV;R\EKQUWE,ZL%:H+:\UG>$!+Z=.412RU
M6)JUX"/O5Y764_ =V%%'Y093PP-;;.D(R B\ I78;/?$SOWEA24H@T"Q(@XL
MH<BA!<&)K5K LO987=K31 %<^5V/N9D1^<!?GY>MZA8^6&A== =^"1^.L.7[
M[(ULNMARLB-I:T(;MNVH7DL^1K58JBJXH##!.;K#6N2Y02QA+-+D<T3(=F@Q
MRO1ZWFQ3&\FK&V;*?W/274IW*Y\,V(G,!QS6LOMF].;-/_^LF&OI>;'W.- \
M::ES, R**F?!B S#F]?9.5MOC6?EH6NYQ Y UPO_'I>-Q$#,Q[33PS/=Z<C4
M2QWH9C*P$5NV8(Y$/.M^%,N'Z9%"/J%'V\@ K"K1;EJE9064&"J&X#+BC. 5
M;&V4VQ];M*]+1I]RA/"9.#FTU7_VY>QJ3-6;V#3NFI+5"O8F89B!^&MY^PS.
M)9S:K9?+TVR[.]_$V"]7Y6MJ2@(S7L)@104T 68OAC0K;YO&-5J0H0U&BK$?
MB6J?C<RK0S6C.Q[?*P<EB']L?VHVO8US2F)?JK-U2K#W%(BAP!G-U+ 8G"!M
M):P6U:IEHF$/*P3\12S>=9E]E6?-:"8)'0"%<"SXV$TUJ0#J^334NYK0B)Y5
M,T6=.C"_\U3NMUZC(:*WOM9AFLTHRE3KAU[L K]UN AB#L_>CW5T\66,U,N=
M/6>,XH#+=0L* 3[S<5J RJS0#%N^&(L>ID[[VU:R=;O=N*\4O'<&6Q98$;;;
M4&:7W$/#,";]M0<=UNDVX0"J)E'8+<&8 ,9[,]K9^1:[!A?"DQO0C!%TD*YE
M+=L(MG<"[DI"C<6F%\GOS",YQ4:21OYWX8W[:'>T.YB+,J^PE)]*)">J,R3&
M-A$4"!(%E,%B.-F0(=+XL%3H]R 7Q1BM1;6P;,NEBLQ$A57<JX?[F)JW2K*M
M$NU?-T_4B= "KSB.5BO"H8HR@7@R7N?2\IRS"H3A[LO@V>Y6L+VUVQD5=)6F
M"RI-G[M*TY; ^25"YHDGQ6 ;AU=C:<M5NB^>?OY\$WBZ&Z=E[UNY>I-X^+WE
M5=4FN^3>$787YQDPN'<LTU&&Q-KLY!W6<!H\3*7),!8)Z/*6U**ZQJ?L;I5^
M3X86QB)KJ"$2;.;XO)X7 W2;7]T6U.56[PSTERZ!6O3FG9%[!13=TW0XF%[#
M81:>4K.[[N<>:F-Q7SF_GK43".M(Z(-X<D)!"+:8=-!&5WHKE!S8+54=T\F>
M="?S:P.PO.ZJM$$$F'ON=4(+)Z+&\L*2@*,D&#EIM?Y\:KDM,G4@FW8BT#72
MHHN,29V9HI/2\3ZW H>@7GXQ&(*K074UJ ];@_K<U:"Z&M0G5X.Z L@,J@%&
MD4'07Z^I)_HR<23W%ZF_J:YK:.H&-"30LJPE2'C\;1A+$&>,R/)^:S5UK>77
M[#1UVX:F6OP4OVFTBHX7]==A]?1=T9G\I+5P%K28P GB!7<2=*5DI!VBY9("
MF:6'6ZEL7Q5D7;8[[9W!$@7CHC3OQW3F*:/Z]7TS!C"ZYI:XSNGP.1B]/.^N
MK/*T&46GV+ RS%>QMNUW6Y1H([/;?E+O<MH7WM9#>37ZV9,TA9^DRI?N9S>)
MMH."K05K$$4SF<<ZEW[;E%S/-:E2H !&%!GPG4*=N4SIM S,CK2?"W8L#'9T
M(HP\J6#'Z1C,!#XP!V,:)3(DM]#ASMY3QH6EJ"9EPWO33>I*RP7=*FZ#F]"'
M->^M%>;06Y&9\XBU533<&3=/5$Z/1=;1E[-BIJIKN@&7HW.=)UEE@4@&6@FU
ME*A9%6 ]Y-8P!%&;9O(NV -Z(IW.*Z-=E8+NDN)%G);B2W\)O:/,0NZ;S6O&
ML*M25%;<DTQ%;?%;OU?A)>.G7.) 9[:[I!=>DF:RM,[EJ'G*49E-J=BU0L\6
MN"8F=0Z_SWD&N]V>DGM6DY*^!_IG$QK<#)9+=(EF*W_2TS%C=^VK7IT:5W04
M(..7KN,L,1_(HZP/IUX2W*SP4 YU=NVK(,C%^:2:84Y^$HGE.",!8@PJ(@H_
MQUIZ1X-1PXSDS&PJIU8SI!U9[HY7.47A%,7WJ2C$@V;?K($TH[U3&UR&#[]J
MO%LISMP\E:KL#KZ'D75+L8R#@B</42$^2D//S(2IB90LI0%#V20.I(9< Y1(
MVX5]#38OC2-PG:/T,KB4HH^Z3"/QY5MSVS-3_L"""4L:47S)/!NJ<_P=U!5=
M3WCX 0KR'*1V9COIJDX1F+K,U7@A+C&+TM\S_J"!()30(##$BEZG";9>/B6[
M2 UB]/(%>H_<BI6-I3ZEG0@SJ2A[S^89YN$"G$T6E:!TLC34(1PN(RF;CU=@
ME3,5V-]]8>JRKH.DBHS(;EH<-": A;]&E3&MIJO20PJ>"UODT K-QJFJ:'HA
MF:1(G;A49\,M&Z8D6O!EU2[EX[AD^OR8@,52UT-6:0]Z>\J^X3[0#&M5[88*
M,_?LMJN,L XKA+2F#2RT'4+M*T1N@PW:>M6>?IQB,W4;>\-.P0UH2X:HX,C'
MZ?%I CR*<SRF(J]M&"X7W5H<W>J$0GQ2T:UWU>VS8\(-^!#$"6A&/*^X!. G
M20K8)3Y#0H*B9$Y3'TSA+7A"L H'9)9;74]K+,H>9+FIH6TG91KY@?Y4BA.#
M]S<!ADU8*M,*:)^16ZFRA6Q ')N1<QUPG$JM- =8%*0^_(B3>L0:5(BQ<&G=
M0NGH7);-MFVC)27+VQ(CF-H=5%T,4C,WBUKK#7HGG-C$5B=J)<8!HU4^N0JH
MIXB0%4'XHS^2?\&:?&O.I)V_V?;5FS2T>>/V)CZAGE+XO=W'YHS!0@IXZV*J
M'HUYS")(HE8LI<]8MGIR5;L2G+&N^<-==4-YE 2U]NHN0@]P@ @+WP$=LEJ1
M6=J3Z$0, YQRBZ&HH+AJ];3'!IQ#!225]XE-.YC'OH;3JWP$E9%M=:QMV[X7
MYHZ)1[!=JJN3I<RP-4H?CGF.)FD#G<=P^T2#&13;V@GL:XLW9TZ![A34321^
M4%A-R#?$#@%:\>HX5:W(0!_7\ZRZ.M<32@-:AK,J*6,04$Q!Q"/@<C1JSZ=C
MR-3 \;L:F+*(R$$/37=_'A?&:=.$M**3M#@92+(B:14DDZ6-:S[A:C '>FZP
M"030FX>JV-9FTJL@I.H!-?,J5M$4%*>Z'U3D+/J=A8Q6=NKYFXRQ#X3^$*"J
M]4GOJ4W6JJ1O@V%7B8VZSS!\^T^[C.!/<;QKJD\5N[6=_>B&(UZWLK0':*W[
M7*UV%-8Y98H4].X[].[,HZJ=^$ W(]F=D#V#P;L1#+2E(4/+[7/Y)Z(W=_8U
MJTK0:FK=M5[78_!1KO((5KO?0$@QM?399%(!U=6T;ME6C.F&9&^ITMKF&/!6
M4D1ME8H9"7\T^C,MVY_A.@2I@>*)]+V(ALA3#S2&2FDB>JMDN-8V?I+5T->9
M3IS>"7J#)^061$MU(]S#U0V[NN&'K1M^X>J&7=WPDZL;1G%-.I7F9&+>GV(%
MV) ?E[>F3=C7P!FFC@'!X\ ^0]V&^H;F;<83Q"6A^ *J#\F.J=3%-2H4,$6G
MG8,.NLI<IB8<)]:LLJ'[6W#Z.K2[,6G7,X@"*S9A![6:Y3 NY+PXY-S9$_VD
M0LYGP*_YM0ZF203H6 $,-SHT!^7C7#3,7O1&4L3[92<5_P_&7TG/CDN&I\KI
M=3ES^B6*YI:%AU)%JA! NUQE.:PHE!(R<7![CK0.661)I*$-\%:J#NCN.-2^
M-T7!1A&'.582S%E\(2T:@U,, B#>B"$FQ:%17Y]*R53A6>%;$X@LUEH8->MJ
MD!2&:EH8;&'AVH#K5 Z0AK3>*H,O/,D:/4CIXB.W0\\8H[MMQ.E2 8)7 SHX
MVWW=GE0DTHF\N (_+#^.</>%@3?%"45FF$$*"FC!= 9]:IK%3F=S1GTL_HA#
M3#70,84S0WT'\R#F\YO"JH'BP*MX4Z<3%^O$%T]>)W[(.76"O4'$L0,ZO1CB
M '6@%[@,/58TU[=HH#1K96,1$7RNR]E(]K?7U%P#'T5.4UCU27&XY$8C[P#^
MMOR=6<Q8V:V50HL4RC:IMA::*(?\]7JUBI,X-GZ\?&E:H+7ZT$)Z<3VL81$9
M\ZPBS*AJKDS]-,)O8"(A2\2%<-)ML71[^>2EVX6"4K@(O@Y,M%TTBN=;+:0+
MC,EOF?6B3AAA!*L( YC.N4"=IKHJ04FJ,)M4! "9WR+D_&Q.4E%-]4#"LC@2
M&%\5*J_'QE6O !6\M,!1[9?W386$1DKL'B+:D4N@#M[@ZPH+HF\J]HC3ZRRY
M-ECZ>F.L_A[=OM)J &YN!Z'BI0'V$=NN1Z ) 5(U+DKJ$V5:(TA.O15XY>A(
M1[UQ+X6:&] FOBK0IODTJG+7M.8HETH2$RI+HLE52F>253U-2J^CP*5>WLRS
M-F#CLEKI-3P#MBXNKDP_;[/>HWU?E=G&V^GB=5R&@\Q;H"XZ3>&'@\S;$)^V
M#,H*I\+P:;NBPSHH-4)!*VI9:T&"(?1S5[B5]V$=P"U[0 -!8)J_4.BB;T2)
MX'#S SN*P"160WGG*VW*LE"RG[V&/.253@A!FV2C=/T!/2(:+H4796G"^52K
MIIQMW[86KHODUON)RM19U,8\^#J8@0G =47^&_;R.&+P+$I/JZ!\U]24C,M-
M;IM=H@H.MP:4-_7>1T5\F4H.&>=V(+VXX,["2U#M'-@I83<MJ2VCR4/RS@:.
M9&$V075"K1)A64E2O[QO2?UJ;_""^M6H)DP=S&E39".W(\\>F!#JD 2V,T'Z
M.;L3W_2)LS-KFO<Q50>%+'CYL_-Y$@^+MSO:(OP:K-+-58QQ(51**V$@%':,
M_B=5_TNME SV(V2I:]E9\ 7+F;!ST$#?H]-C_5[87F&/>N?I-#SF+[C.XE"Y
MZF%6C4O?<K/4Q-8%N$02%^S0WYW._&H4VNY,ZI>-Z5P]2WI+];%%-68J%JM,
MHN)$%9@N^278",W$UULUG@WLD3&P;V$7*&(==< ^-"P87S:272R0D;?7>'PQ
M0PB%]O-KQ>.:GF=(9BON4:M9#G00TO232FUP!/N36=AC*Y4,;_&46U616>8T
MV.FV%<S1VU]_[_8L&;((I<,<&=U>)+!^1L;MVLOL>Z8@GED/7?^%.(1M,I@<
M::I7;FS:D(97@RIYUIL-YVSY)")$1,E#GD.G+/7ZR&;D$^/>=O<!\*1G2][6
MI&N0ANLMROR=UM7"(A2QI(;[L4!9 S?MB5I0G:!I3]R"ZAE@-*#SC(;3/1I*
M?M>P5SEQ!3T#=-NE 7/"&N)>%" R,"A,09&..@*29#)9BP>4\O.U+>:-JP*-
M@,(^O99%T%??F$=9?AFD\?_*)R"!@CFULJE/BCD</<)^(BV$@1T>BT+9VJMH
MQD($!Z)?4J/-]L+7<(7NKM#]80O=7[I"=U?H_N0*W>V^>2Z9K+6):VSCILJ)
M>68)N!G7W+G&>@HT7T6SH-$ZO>4F=]!G#2^;8:I%(7"UC4;BU?D*7IB9$NUS
MH0ZB1A&D27F[S6/,%RE15'B^ET0\\EIEDJD7$31<@;9M$H-0$9.64:G KD4U
M+;.$K;@ZUNR5B-WD(3I7HYT^H'U@=XM:SM$V-U^!]=-0]%3A#\/WS%I$-=(G
M6S=7W)76/2N]KAAI3*"",*C7W@NT(/J*M+T6.%5M/W SKJ*D,^ZADBNBA7$D
MX3=O&\_E>+]XX\"@P'/!*9&:V6-[R&S;X.M729$IC]<05).C!@]1D %35(E,
M>5<>D[_ H^'64HY';(1%/4RO>+O>+=N4"]KCI/;L.E_E3=9;RFB"@:&*04@&
M# _F8?BN3QWW0:J?F:[C HM,X(#=+39:J_6W2DJZTKX$Y9C$4:4+=)IYX19P
M"(>%FXEWAO_HQ0T@@Z32TY[MDJ%:,W6<:4R8>I\R7=8[D;<4B%SO"\&CX3^F
MP&81,P?<--)8\4(0E-77A2WY</>K %BE\S47O]3ZR(5K/V284\$.$C"5L7(!
M&:R )[,D'N#A90@&>Z*IEHR=Q]COCD$NCML'<V377$42*;S,O(G-]:9ZHH=L
M!AZU7GC6]W5]7.M5@VB<L2'0SDTL8>3^2CU^F>[WIUI"#0D0J6&[P/((7:,*
M\!B'Z-J"!J7"S1B-/J;]# ZN:B?"*WK>FW)X5Z9#JE[O J_-PYW)-+K*"-NE
MT)5YBT0,CX 3,2*#@Q<)LK1#?H_5X[6@:ZVA=SM+]>S"Z)@[*A8S)WW1AH^\
MBQKN:!KAE!"LH6V/2-9#V:UIUKXZ1'A9UH<19IPD<8N6L*%0<HKAQ0#6=%/'
MHIO"J=35084I*")B<U41LK%&F>=?N:RT-F^EH'O/->4X1HC11BQ\5>CQ?>].
M=Q5 #,7B<E\I+#(:6E45,:Q)XX%DWO6R^H5=*D6H\QK N&%*UIS3@+"%V0-M
M.T6];&V,4%U0I_+&O BNU%69-A&?:ON[]KJC\FO3IZ%C"F,X"HZY.P7",Q=2
M-?J*4F++[O/)HWD23)BU1$S>;G.7+G8!<BV]K=:Z[& [*!"D09)=9E7!,)/]
M,JA3X71.Y22Y%.CZ0TI(8&0"=J!$7+6<@+O)4A2U-9]'06Y,0CYRXRS[TI47
M]ILCN.3,]9T6K)",\-%[.[#>!'QH>%:(U1\U^YC2AUEJX_@M.G]?YWS^Z-T;
MF4KTRA.P8 A9!T^43I'#.AEJQ\PMA<T 4<Y%GBRJ/P>D:C]%E\'DMFY>XERT
M:$J8X9+I_(4S, =*X&Q;U20H)>%\$^AU[\ZZ+&A_%K037/>)9T$/@V12,5[_
ML&K&#D@>F<4)WM@&JJX!D;71YM5HH9S(B ;[L]T?=W=VEKZ!U4MYEU=XN>H;
MH$6',R8E$514X$3 :Y570Z(Q%ZJ@,TBXS+J A=O.VDZQ8^EOG\NUM+)-&E38
MMK&:L>V*MX -?G$FR8*HE<\5U4P9, ]1\->]*M?RT+?SKUW+PS)<HY# <@85
M'&3?XR[-6[IQ%<\R!KW>ZJXJW[O*;K!XV#>]P2: 8"YG%$R*](WC!'WEKDY1
M"]*\/G,V"A(=2)$WJ ^1L>#*,899EM+P->:H /PG"6[<B>[CC3?N1*^&6S"H
M\WR@>@/1P-$%#_6>AY42<S5H7#JD$XQCP9T8IY@Z#(NHQ*,-WU!.MBHDH&,I
M[:*JA%"\<AI,V3[J;QN0 MP>KIO_"QYNB)#=9MJF!=EK MMXK(N^J K<Y#++
M0FQYA.NW5-]KF'&DD#$:J4*A%G^A:6SF"RCD"#^*\&&JO!2\LT(2"$"BPM>M
MM0H6W08J,)<+6)H*,F!<O@:T@,,W\XIAQN@&@O1 ?^)@D*2VN7+B:BVX&623
M-I@QE;CD,O5B$N2(JR ;&%.9%B<N)[P?A80U-]J,?C.H8TQ1;^']2(?A[J*H
M,71IQG7A/BV936(?*M6L)"O!:*DVEZD&6J-"R#><.NW;T]V=D=.A':=O.1^?
M"1#+X YH6[L@:!8WXW-8?I['Z22>PTEC%<"S@.'P8=N=JJUC!< ?4TG;991.
M.HUA#NRCR%890 (;,),X[=Q>QW#J#6$)%LB[@ZI;XZ8'9D3=H;426EUO":U"
M;Z#.+X4#DO(P;\[DL E!\V_R+(TGR%^)3O, @Y#VO])C#FZN$.B50(TL3!'7
M.N%:)QZV=>*5:YUPK1-/KG5B13.\-95*NX5WE/??Z!>T;1<V**(9.Z_ L64W
M -[Z<Y(DXQ*,0;ZA YRAOZ$!Z)0:M1#*&Q5?ZIN!#..F7@PREY2SV6>)$9:Z
M_18\"9'<5AO@R2"RAUQ HALBK[(J9]@D\,#G8I2,;^_@8\,MP!W&V B5"%&]
M1G09)&8\ ]4%%LYYZG6>=IWSU+:4>;+VP"H%4NV/:%!+3+'J"+PT&774P/5#
MH$D43NI*LQJF\AUC(BA9,8H'0J3$86QP$!%]TE=>%'ZN?#(E@*G(JK@"(:9*
ME-EX[ZZDRG)9,+RQ)=))>LO<MZZ09A=Q(N_]SX>?_!J"@TJB4C35M"O@>TD[
M7L]#G93IE3)[3LITS #/LB_/CM(ROWT[W%G?%RNVG:AJ3C4@-*52R&<1OA[J
M^EDC"U&?52G1\<)K3F;52(KK2:/:0JRH/QD[L_9T1EH]Y@.B0!5T*Y0MNT*\
M@5%9'P+UK8MNELPSR/W:P6EL4^C=!,23H*8(C),)1B>\E#3_V.D1Z6[1R1TF
M#5VM)+EU;U!,3,C62&@!]G>BL4\T[CO1V!:-G\A(R+U?JC+FAN]56-\2HH.2
MH<?3]DC25=['%CT6@IN0Q/<2H)*/8BJ)&.(/1&B>W>*?ND.B'>E2SG6JMFZR
M@[!)'PNP\3I&P5=31="82A+=LA:8Q=AK]0785[64\F_MV_:OOWZW=J=.>W+X
M2B9JMB+QQC@?#$&2Z:VI<VI.B74]I59EY^ FC+LW+?4]*@VHU\27]Q6(';60
MZ@RAN.)6LEBCO&?<,-7832=->Z7I<R=-V]+TMP!/^J!$(GJS-[2L/C .RQ,-
M/(SV8D*/XUC:BUO%PS5E<=B+B5\(:,##F$MFX+SJ@ME +4F>(T!>^MG29)<9
M' OY8GUY$D=;9Y'TPH8>YBZ2<V0[7*&)=R0P;8KAJ OJ-!3OM<SC"?8P7;'A
MIT#;L>UNI;4Q* L\@1!/LLDD8 ^Z5J\XD>9"#,-J,J)$G.?QM8 "<..@:@VS
M7U"/59?&1ERJP"4N?QFNA:2WL>^\XONMPXLS;%0>4U<TMG-AW7)7MY2U]]3P
MM#0$8W=5^8T[X.<!-4^)O:XG21&IA&[66,=55.%E'J2J:I,[3F1:#-$AE);B
M^B"_E=K^5)NW6H_$F:U)A*H/KE&O9KU ?=PD&!G![UEN5;&N66_7P /V%Y;3
MKE?"$YAN0=D4*\#4VCAVZ/+(@!B)C[3DH=A/GLHQFV4AL!&N778JR\V0A["O
M(-#R3:WY0E)>YQM/$_O5,P0*D.-@H#Q\/!H87Z=F79]S+P0R3=?DN,Y +,L9
M_) +Q%/(4,?<9NA)5V=CR (%,Q<L>:O8=A9/K\7SPED\7:4NL!HI?A^4W?,;
M2"-<&X;!BWB,&&ID.AAY7YLA->:RT'R>1Z7"C1 ,#!;18[N%%P\?#4B5+D)+
M6"7!#?LU<=.$DN?%!5<8\SWASU?Q.):T CEPBVY,,K9A'5DO8#49I\EMLYG
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M>\]'2G:5=)QD 2?9,SI>S^BX_-!PZG9W0'#^60MRD(I),"] H*J?U)]^(IU
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MR;CP>$2%@:,I"$L$!989R;[2XGB$FD(--\O<.MCN6*H&5/*!H),&$ Y'"I<
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MK]MT40NXY!H\FU,7E;4OE+C]]>VR%KQE$I217<!75+-9S7S-@$CT[F!9SY-
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MA;,O+@ZT&",!D"KEE.XT#ZK0I_J$/)X%WC0 9\.+T%I*3<LY?$J9XT"#&\5
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M25!AZ77P#-4:T\0LD6HX1IDAD$-R(N-B40O=&KNWO1"Q@G96RB>83-:.QJJ
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M09?BO_GC$7E':UR\:&#QF/[-V=C!*T:6P,4N57=_"A>C8:1' %J:UGB?=71
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M#5LL,C2L*/I&I/OR'=K0GF/!6E%YU*U@U@T\200['_],=[GYEC*?4&BH/>\
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MA'T"(W.>J+D!V/I >VTRA<*B:0*'IXF.4*,$RG4^_Z1-SQGCVDM!7->Q>HL
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MV^20H:+J($,M*8"OA:&V-*T>9ZB-M9RXG,UDEXA$7Q.I%36&L08;0B(2V%W
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M1,A"CBD]/E&.V4:.*;O5(<=$U4&.65(,SY%CMA?BF+&#0:JV#,>\U@-+^>_
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M=WU(D" B!FQH>)>@?P@"N8, \C3D:<4;.<1HY&D(T2%$F[Z%1 U! (E:F5&
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M:%%1JCT_;%K ^_;'JW-.65!'ZMBF,FI0X3!(:L=A5!P:=(&6A^Y8NC<E_V_
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M!0YG.'!N72H!VV(2YR-Y:7ANCIB#G$V6633GT&!-D_I@XM";LUJJGE<*]_Y
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M2;>#*<TAS#57M(#+0;C;*_ZWS!#G3"W?<S3CWA\X)98^$*<#UT+1-7]4>5S
M6W%DZ682@[\YR9(1P67',7%#<YO-(=7M=#MQP<%36:4=>(J*$OU"Y@.8))0>
MR?E0NB'"%#WEZFEL\*-OM1?9OP+9=Q4$_:#,H[1 9_ZG "1)Y0CK;.Q0TA4/
M.;35.>WD9@M?XQ"W9Z*ZG7WW5=Z<PZO MT=GI\<?CRZ#L[?!>>^B=WA^]"[X
M<'[VZ_GA^\?238^K&?=W,>S62,GN/NQX]AYQ+O2S43L&DK;M=@R*#@>S&UQZ
M>#A0'*0!XQ2T.9D^*;<'0.K>>M0*81N(GQYG0^+[H+RE<XI(HG@+?X1'R4KA
MSVWDK^?GD9&F^4[KZ6?-0L 'DS(MJ)M![BI-X+3R$D8._SXF@T#S@84-!CCU
MI%"[5[NA*6")B@71\Z!0ZI,PJ)A^[[IU='!HBO[\UG.A-PXRA4SJ7X?-O1<M
M@@1[6-/L_OSQE][G23R(R^#PY^\_PNH=VOR]_CEV4X)YB48C>Y@U[@FG$6=:
MZ;5+/"%-5BP;\T!DD# 5)=R0L\#8$;+,,JD3HM5G6P^?&@V':E;R\441T2A(
M09+K*P<SB^E"I)Z@LS57)MF19BZVJ-N!]Y!DE@FA^I6]9+G@'\QC,P_&<,#B
M 5E_8U_0HR$V+(&#[(H# J'E0J ,J8>WP]I4QTQJJYJ*_,0935FL]Y.2V7(7
M'J=+[S$XC/-L2N?H3IGMX'\-S32<\MEX!_Z?H'.STKJ&947X#\Y;PMUAZJK9
M#MP)1FT&T^='X/2^Y3DB;V51!IVK+XK2<.90?G+5H8C@Y6H8S9 7VT-!.@:#
M%&VH40OD("J*;!@S[$]Q=LS6:##?-.\6'Q+P@(;_DU#H@VW_:$.(#?D H#J1
MR44<7!&.<2F)WEH7S"UJSN.KN73>%'#2)(ON$J+DT3,)'YW:3'KA7"/KI"&
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MWM]#E1%=/%;XD=?8TI7#J=-Z_&C<$]A6^T2@:^:UVZ&)I0VU9H:(<4XN$;A
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M/(ZI2%.6)[#-LNI!8UH*;&H[IZ\7=2KW L7(L[J<G_X3=E.7>GHP0U,THI*
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MI?33FN6$#%9&(SPI/1=AT1E1N(]8#T34Y+XT/D5PA1LZ)>*Z).#X^-C1T'^
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M!#'G?"]Y V0545K# D%MGDOO[$D\\X/6'B13P_Q;M;"TI-;$*ES/$E2I4_1
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M!N5>IW0B.H8//0N^68"6([4>3&',F1P,H"G3-,#!P^]A[/,2[]WOP>GWA_P
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MK&40X-?<,9.Q9]AK%P/+59!GMN=ZO^=&Y')3<,E-/^*8?./(*Q!L&D5T:2O
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M$3EXJU#JC/0I*\,#33GU38<B@E>H<;3 ?E >A,(Q&"11I>(.6']4EODX88B
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M<%*1_5;@,$JB!SEGK H%"RMQ_3!F*2P-"U3+:SP.T0N.+F!Y)>9F1LUA#K5
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M$XO$,+AR#B)5UU$&@C)!/Z5<-6W^[+X40_Z]4@O9]),:!\KD(@IS)=.HB+6
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M 91\3)C0W("(\-[G' /;U=J2<]2(AK<U]*8HY5:R5=_!D1\ZS."SI/ @85U
M^JT4J:<>X/15GK_7.2L\5V"=CVI0F5PGXYNN<S@QR)4W:""*1XS'-3F*!=_
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MZZ4SF306R23+(5T&G!:XQ]P"]S>G-D6.'&\MVP-NMCA;E4[?.+3:E#\P!8P
MPM"(EPTT.?%PL2 ZM"#<K*QL265S$C]*Q"CBOD;&3)-7?M45@A9\LIR!"K$+
M]^JC9"RX%Q%#</P=9.P5R]C0+Z[$@$'-JT=@7K0.O(:/E!14$[++KIT>.2JA
M^6FI$J^FR"5IEBH@PG'<&133U?G:;X#H%,!)Y10_R13U;1L5Y&C]Z?-1>KP+
MA[H"_D3)(B?OY#6QI!9]S0:6_E;I.@N]<X]@+9A,X&XI:'Y@?R='5MN5Q8U-
MSX+2TDX--H56RS[OM&Q.4:>M_]?.5Z^-7=Q?%OOY)V2QWQ[]_F9P=G6YU>GK
MYY2^MJD'O^<I(SY=%M]%M/3HJN^<JT:&2T5=X+&*O% 3\.'QJ,%VQ-D>4D<D
M%;/#3A2IGDMU#?OU5[@,X7VODTFU#*YF>5T2-!4C]$49[/SO%\^?A$^>/-EM
M[E0SCO:;F?V:K>K /+&=K42U>%"4MIW5N=,]:"&""HDKO,$0WC6]_D/L"_1[
MNA_MFCR!G+D32G4\WVW4(W?Z&@V$WXJG4S-<0N2ZRX?Q(7?]V  J,?V ^E-2
M",L&60W":'=\[*D.Q*-GW[J80A->^0GU(D;.! I]M%KV1&[E^V/H'/;[(76Y
M,_/:[]'$TD[?,FO(^.($PR22$*0M)7&5O>4*X&MDSFAHES?RHXNFP^Q4M!NN
M#LJ@S[#;<JO;]CHT'/U,5U31*/$Z_Q/6KJ;-1KL]&FX]9R?XO^:M7N45L@C4
M1&?@T(2;D2"W*\<7B4O<]#3M\'09Z5^Y-"8FI79BROJ((IZM2OOSD:INL.R_
M#2T''2,Z$>L$9M1TP;+,BY=[-)D0<%\9@S;4+@N/9T:ISG6MO$"7.PVM-8G3
MR@:>V-3OM66G;86PW]#OGAZ$P>&3PV<:1P&N6,TJC_EX3]28B23TA;PHKH!9
MK,2*00F#^,IUME))9UR3-<- CTW.-(K_J*7 P1L(+0O\/Q5#L.CAU>"LU5G%
MW1Z2;))&!J? 4P^*'B,#JF0/'Y7_2(-XG52#X:V2KO8V">P5H?(1[?4,8ZJ,
ML:$,8M@YO^QV*;>-4Z1/'U.DC13IT\<4Z8,5:QO!.,> 0?#O&G2=*D O>2E/
M"B5%8B$Z]G2W 8K:6/Q\@QHTJI7K<]P"*5(G4HN4+75DUF'<06*#<64:+\,O
MZZ+P>:N3C5G^W01IO0 %9X;0$1_CX(7OEDB76O=M@IU4-P]:%&H/G XF&,+S
MQ<<_X?0( 6"1)J:%&)5BZ'=QWAP\;>F14#K1^Z@HD"8MEUZHPB/AODK+:W--
M?#]W2$GPUK+KL;A-@ /J*7*=)TBR9<X0;=DU"O:,&4%W(#>L6>CNL43%AAS*
MS?0V6I?IQV_9V6,Y1SK"C$TB]@[&@,9R@@V#QHPD8#NZ*FFSH4UD@&'+:,PA
MQ3V]#YMMW+0/RIO4[<'2E0_@';1K\5YD?_B,!SN>^=BL&_6!\+:(%+:4PT[>
M$C\37NC8H3FSVS6GT>HL)R$3Y^-ZSE6RE@>]W^L8*-?Z>GF)QA0;>]()ZF)%
MD31")!4I9!\FRQ#-T4@LV7'GW)16&IU+(ZK2FPOU8:Q4S*'_CH%+D:\O1129
MT E_ B:*WC-UO&VON/-H<&A4/K?2!PW=[QE5Z0M90V7%"GTR?C^>8E;<N 4R
MV*6.SG2GTBR+-[]@STMJ17*#/,G8%W+]+(O":^C:.)EH=LL.1>L.N<JG#(ND
M_;9B[-A#W0[>P6)HT=(G3W[#Z^%B2Z5XU!LUA['<@71$PJ(1LM@U2\/I]T)S
MQ^!0F:)FY&#;S@!#3'3FUPACNSFFE:-J^&@WI/^"78>BP07RUIW#^M1BZ>=]
MR$UUZTP16JXM(A8__LM KYH&'SFH:T*G9O-V )\;WKQVW^_2&5&@UMIR7#?,
M=0%>,TKC C?&UMD+=45@U>N(VN^9PEJO/Q;8.4BL("TVT./7#KGFU;X-3OT1
M(+7]?L_%0'P<SLT/=&@#T=H0QE+$Q*7F^903WYFW)F$[:<%FHT.CT_0M;[J'
MK^U&"7-L93 :P:ZODPR4>8+'BW0F8KBKOV;46JZ['1'W#"*R"@Y N>V#"'8P
MF23$EH'1V @K3$Q[V\Z=!_(?+>GKS@"G+BW7@=W]X/*6UD7O%<R,$&7!;LW0
MW %!(: &C'ND4S/6A0A9234B7GXW5H>3VF3 &="RHI624*ZW)!;[%L,.K5*A
M6>#^/\Y=F$5"W\;Z?L;1R7&&$9#;U?'(Z35$C,-;*>F(D7Q#;@5/YANP<_*8
M5WQIBO*I$=8X*F?6.!6;QM@N+@4"&Z7O]B_WP:R73.B[RY/=-GNU82L7UF*Y
M?;_G-XT":Y649Y%GR3A JZ@,. O/+2F3^1S,:.XKZ328XNLPVS:*LO=Z=])>
MU'T&E,<";:WB4,8*YV![L-T_V4KY00J'J^B#4#=TL(ZW2+IAB8FO1*C(G8X4
M5?1!Q^!]E!WUT708?[C?J?982A/STA$C[G.-EQCCH+/[7KN9R9CZE%B]I=UZ
M)W%D1@3##?CY]#33>,WX7O .($%@*%("A"+1!O5H.$C12,>C.><[S_(TICNS
MZ=3U#37T+-"OP@:F>-+(!LQ<<#EH<VS!B#^HD/IF&^N,G^]_AQ!PZHTJZDS8
MPH8"/KRF@W,FE1^>AHMK2U,($\S,7+'V"#M/8.$#(Y5U0WQ>M6;V(K\!;D]G
M.%TLS0;&XZ+&U8)3&QOP^>PF. 9:[@6M;U;/><'AP(K(7!"@-?F E"R%9^V1
M_9U5SH_@< =9D":)&,T1GBS\R4_#GW_#D5R"F*@J^$=>%UF4$@1D!U5X&/R&
M7$5%%@RXR!K!#F&03((4J8 T5O)#,H<'(3-1JC-PYJ7PP5LH?ALGNYX])KL:
MR:YGC\FN!RW:S_=?P$0,_ET3NQP1-XAF'7P8DU?ADHQ)5,1:4@VHN36GI/[)
M=Z$U/R/% ]U@8ZDKZ31*H=_S\ Q-\,)S+Q%'M=P2AY.(/?/*TL%;%^,9EIY%
M#O3D<@9&;FFU[\'^DR=_TR-#BG ;3.(K(X-HBP7Z@?^F!PM&D7H2[\5)2H<+
M8Q9VHK*LY\:=,GAGBOPC7;_,"QU9]$F5<!?4;$_ZW\#,@VE,686RRL?OPX#^
M(RPX2&I7J#VTCY&#3K/IYA85@X'G@N+QY6ZH31X[%#A/QLXI1'4"48+4A\5[
M.$.P#MV\+9V4Z=*=%HW5;\X)SE>[B= HCPKR2.($S#GJQFS(.ADP(Q/J 618
M-IE3Q(TB^82*;"G289?H>]* I\@<CV86M4<(YO )GO?H<W!;F-!"4M@ =9G@
M-0N))=A\(>>]0&R42TTIU2L-=]>2'&N3H$ZK!)N;@W B9P#M$@%0J3526\JD
M2ZY$KMY B.T/*4# O_M:(HW!/Y'IX!Y$.BH=8UDB)>97.E OX[2,U0*DXN H
M6'4[!T]V@R5I(C\&TIH;\6]=J72B' 1W9?@=_B+%T(H+C#5:T#'PM2;L]TS>
MA8/3!7M<I!AY6]%HG*08DD@2KG9HJ2Y0E39@2Q+(B9KY.T+HNB^B<X#]GI\+
M,H^$_;97D+-MTH7MK!%]?,L$;80>5EELPM=_?0J^+U32\%VCI(%J%89G5X/3
MT\'QU;NCTV##*H>W%^=O!Q=7OP<7PU]^W?(RA^^HS.'\)@,-.$L6^]M:>?P*
M/)5I 8XU<KN]E9!C:3"W7JV5T_-3LJ0</,9_XFD,^@G/T(!;QHL'FM@V9FFJ
M(1CVJ<'P[;8E0@FQ)HDP3*!W,#_!O&S.0\2+UJ!H<\PC(3DJ7>)DMK=:)+DA
MU=QU+KY.ON3<R]"@JG52 R.*=Y&$-2\4!DEA@Y-<TIMAO"CGO:IS=#AJCC)3
MAT"ZN[!%\2>E!_5C\6OD(C88+4W#;<N%%VV^9"X2AT*L0F,^A*>G>!.T$.'W
MF)]9!A>27F5*Z7W-4<?S;HH:D52+TYA2:<-6+S*?-U>,^37:/V.\@^T/JI%!
M9>C:<"';B4L$7$@B"&W,@O[FR4#B?U-J;< 8DN6/RHZ(+6:"DH*%$RG^"R7!
MP=M$ZC.L#M$9.\QTN@&E;DN,S1/=[(/3OL"?:+U&O B._I,Q@=]F6[#>S/+0
MXUX)@ZG*%!EO-.443X^E$1:1JBL.OJ][%;CT+N2==C-IRC1'' C]%DO[@$ V
M/9^?6M_HFNXUSV")N<-JV#V\A9',[Z@\ZVU446X.IJD4"A5D3\5]D$4:137(
MB'J&0MQ_!P._G+ULSRO?J=Q:>X>:!S)RPVA!!R_2*N-N(D5,20P19XEF&M45
M-UM%/]X$(T*';S$$QPE+(!>R@/!/)#U$^XG:[RE>N^[M+&O6E6:G44A/X3;P
MQ-&OXYP;?PA2HD08JXM#9">21RNC1RV&<<&%*W3SAM I*W1AUP!UAC]X;;ST
M#2:]WT,(5[-D;>7$[#A:;I5"D6L;\8==/F5L;UE<)@N@8E#8)E+BV$JZ_8R3
M7Q7MZ+;I8.3''::;]:8SWR:NM')>C!?O\2^('=$A+<E\1&UBM%SH)!Q79C&%
M K>O)M(U)F98!VRUKT*_=H5'0D[K7Z"3\LOA%ZFP3K-C-0RB[HN)4+\GO6"J
M+CD*-A4CA,P9' 0ETIM[?+T:XM8W'Z6'W.ULEH4@Q*W)LJR\?B<(_ 3!6RG"
MX@R]W>HZ>#2TQ/ATW)+0)8CEP"D74?J:6 ,$=%X!%IIZ3Y="?(L7(/%JC*7Z
MJ6Y_SE';BK?/1(/Q6MP<ZR32+6^),9B+7$68Y1WI)GJC>5+JN"J;P#P HHUJ
MH:$,,E[Z>HOX'NYV1C9;<QW<?:IM]<N74%S-<Z*IMQRS_?,KKF"=WC)$^U]"
M<;6W_U8&0JATCQU:+ +/* U@&@=9R)'!U:,"0[?&J#!!]?#$'^?"4MII21'0
MV>L8L'39)L3G02KO>5+I8N6.^PPSZ9%4[K8HRUL\^%1=PHG9!2;8*ELH'[6%
M0'OF*)=$&.W I)H\2],$F5 >22PVQWL\?\1[-/ >SQ_Q'@]:M+\C2/R)FC"#
M'FB7XS1*X!1Y174F1!YH:^02)5CY(68/.58_4HA'!*5Z$Q7F^.)CD/1HCIHS
MP?@.WI@5;@,%[[=J0>?9;=5B"@>[=&5XFUG=:G\#GXCE"8_%S+OI^^;J<>\;
MBHR0K9ID$U3'JA0F8P)(U#1LJ4?C[[F08UVX5=['J3^4 *F3 6$0(+)33);L
MC#!252\%HAV-L8 A5"XN=A$XSGW(ON'"(NR='NRPI2?!4EU8A#_^Q\DQU40A
M<7==EO+[0DVC(C9MO$<$ &0,L#*6+5-I[ ?'&OIOXWOK(!5J]3&DWX_%1V?P
MP6PC<Y<)_ZA>SF;0VZ?>CM_0TG&OMO X^XZ* \[R?F\XAWF K2$3)IN["^EE
MS63=>3++A;<%=H+?TLDQF,+@GUE^L_=K?H.7K=D0IALDBW]BTTFY S?0GX%2
M2N:TA*0;3*T"US,X;3>=P3'/:-?=J.>(^[9./5J[T6.[7=<7L[0?!B[AWEL#
MOO@44L6+\ZO!,;8'#,Y?!\?G9Z^')X.SJ^'1:3 \>WU^\>8(O]MJ+,(+PB(<
MY]DDB?DH3JAHX-7/V/"!MKJO'1U\)S?H_8_&[/G]M[B2'/-&Z*'PQG7<JNXV
M@.@[\WG"\"I[*H7@'U=^]9T=LI-SI,**FIJ!$A&? 9_B<97F?!BUSE;_]Y@P
MTUZ\Z:!3:7IJ2E-W='V=Z$._V?UVZ4TOZ#DJN'>#<2<\-C-17*+2G#T\B\U;
MN+=$HLQ;[\G+*+V9.A;'!(6:G<MO9KE4.0>9<K%<B7WH2GAEEQ1("41\3=55
M'##R'RDC])98NH!+?:J.1;KI6I=%S;T?2$X)7E.=-2NX&H;&V-\$ ?<MSO8H
M?ZI+'S$H5)$5QZA(GE+$=T:$7NV4@-@!>S8+H_A%\;S2$1Z,N[86H2.*TRYJ
MZIYI;_QD*);@B 6$^!2,[1A//WB;A(2_E!JH"JTLC&06B:JB8BG 3;LFB2]V
MNKAK!W-2"3*G2:F-I6]PZB_QF;N<"7,6L>OE8ZZ7,K*/;:=UEK_.'#546^F^
M\Y;C#L3=,]@TM=N;B_#KL>$2%'.E/;A"OX5TM%\W5%N,WQSK-AY3F(KF PGW
MJYQ0'4MFJX"=W<VFI\9EXYEGM;WARO@832WYERXU-P9Q1Y5(=0^XPQ6?GZ@C
M*2"$26&J';NAUC?6 1.G.31N5X9TAF1<8H\:VBOR2:9!VI5I-=,<!VS$46&+
M*7S=Q"@/#$F_SW#KXJFG*VE?4ML=N)Z_$EQ^ZTQGAYV2$/" 0G\M_1I=%6$@
M[<U9A">-Z4EV#B9UD7%#;S$_FL]%H%7C$"^)+(E)]2?B?U ; HTG0=Q.D; 0
MR'[EK?B2F@S%- 84OH4B"4R79D^SKQ%S6,)6*31&Y?=?C)(XU-M>/ *OM_V=
M==0V[GN,0!T9+=KOG9A%8W^TP>BB4RA@7/B=8=F?"%YT6Z8K;2MW7>SJ7B<Y
M)Z70*NU2-2UKV+.A*:-FSX&D_''+LB\&#J.A=U27&F$)$1%H2T/."/1F753&
MD ^FN!4S(@P#)YVB<1-'M_X!+D49ZPU>4-6*<0 ,R@^>=.3XYQ&HWZ+&Q'2A
MIG4J6]3)S&"FI^ :]#2ZT206^E(L*['#TD^1WNF%!SB4YZ\H==>)8JXC3I (
M&8.=HF@<<5GD*1*(H&PC@SW7PZ@/8["O,!3N6N+!!H;XE'*MUBYCW(#/?DMF
M6N?Y9[G8Y.V<@3(G<F4BA(3&<3.BH2F/T@ A8^<V'Z2/]7[/Z>%#A&AEY8W
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M+]6D#B45XNM6]]+_"[L-B;!NX1&R<57Q#X]YT49>](?'O.B#%FVPCA!:>9K
M:6&A[*?Z;!78.A?58?F9"1'27Z\NJ)(."^.P)NUT$+S NC#\JA%J#*2T[AU\
M?&&N/GB"17/!V7DP^!=6K5W^BB5W6&1'Q7G]WJM!@-UAKTX')\'5>7 Q0 +1
M"ZE-@\O.KWZ%/[F2#_^^?#LX'AZ=4BD>-9;%?Q^?GUT._N>=M)D]Q[*YL^'5
M\%^#X.3HS=$O@TL< UQT)HUI?QM>_8J%<9?!T2\7 ZJG"_L]'&$P?!U<OL,W
M=I[[Z]$)O %6P$G57?#V_/)R*--T+K^01_VUH]UK-<@]QL //B$&_F9X>3PX
M/3TZ&YR_N]QJZMF# XI)#VUW/4I#$T=8CO$+::<U2Q9.^8KE'K @L"R6Z+*#
M5;<_9GM62K2E-IYQ>$YC/\-.EF-C8>8PYUXP[9;>Y0P97-"X0[NOTCG,,95#
M"Y>CH9?^ Y%N =IV-?<3%U*E8D_^H;S![MO.)4AV2?Q'CMO0R)'Z/*.F!6KA
M\2.&'O,:%OXE KW+=(%Y^^Y;:&:!/&+0[C7RAL(^C?Y0QCLW:T)V,2Z\ PUM
M9,DGVK9W ?AMJC-$3UJOL9.,9T?PO=P**'.9]]D87Q*^0F%'9H2OUFJW*Y+4
M'@P7LU N?1PA5=M(+7/-Z^;TXQ4?35=61H0B5J:])MT=TZ\1^!'@$&'F)(U&
M#)X%<1_ANV**90&.VCP9AS#D3/XU21":"C8]MG33?,4.1 0F;(J4&S#F:F:G
M^<B!\)Q&-]SD6% \>G2T1A128!:&C<K0Q-F4GM*ZW70D_8,]C[TYGP1,E]7E
M>"RB5ME+BK$P,[+NC*W.&"G"R1(V%5?B.J<^A\$\R< 8^@\[7HS;7OV6.#Q\
MH'21J+Q>>.:6A9KG.F=/KU0RBK<A%@XWE/"FS;FWF3L6BR(R0/K0LN;JZHY^
MSY7V;C! L+)C" @S.O3>@#'LR.\1WVG1^[U;5ETZ!9;U'.[BC'H_&#H<87J.
MS-ZF/H*-F(#SRB8*9*:DY$**><Y]K5TX>>B"C/T!8LAB90'%BLH@@KIY6W4[
ME3F&70=$$NB01K\,CK!R8563'0S%3Q4M >L<D*K!AUDRHFU=56"!"/]LE8=\
M_"=<X$!0&JS6#EF-J4J9[C-I75+7$_T4T\=;+W,3\T-0.@FR2_]BJ8Z@&%F-
M%#(JQFV!18L$@Q(<305610X6K,KKTN>D+B65(V,H0T/T0@J,8B_>(_>;#8@<
MV"->K>=EUP36^&#,IAC5FN<Q!91"KU0$AK[@H)8R?7FHIL%L5TNK'0@KY&CI
M=C#:3EGF5H?9WF\1EDDX!!!&,=D:!LK*E' "LX+@KCMM\V-]134#ZPQ7 EF5
MW#Z[H'YXU ! ?N9RL@NDD-F$*4:9")3/>9KP"!(NS^XAE )Z/;YOYT\H6GHS
MR[E=)UI5\,H20L6VZR@]D>3&)/3("E5_L1\<P6?RG$8UC80W:ZG0:HZ67XUZ
M,&J>I]!^&)4"3C3WZ/=DZQ(B _F8',Y0*71T'FAJ'@E*:=MO8<LBLQ$L%'<[
M]P&6*EXJ:GAI T3]WB5[9 AUUF>L:-BUF$9)36L["0F1;=> 1O/X)EEYA2:W
M?S_=#,AS#)'/;6(JST2F;E2A3.R\D],<;)THR6*]&3J@F"R(U-Z#N\K28<.%
M?NS!^B>,F(L,#A@A0:YC*U*Q%>]"#>5.,MU[NS$Q]C5T>VYZ<M<5_1XG1)"P
M.R>T9PFZ(2HPD<&(>&*",R8A^+)3HG5#$E^; MIJU8\U'D>F8% $_DP4;$,R
M-'-[9]+',4JEL80A7K80AFJY><<^<4^UB.V8M2Z=DV!-%FSWUHH&.R@<,0^W
M^<Z")_1@V-UO?6NG+SUT8PZ-L4<T'X7KJA*IL%!8?LFVLVK: F0:P^8:$"(%
M9GL3UF"NBBGFY+#5+/DFV"S-_LG%CE[A//M"W6_>LC([@PQ&F7@M5)A(6[S"
M1GTJ&Z<R-?Q4VXZ1UZAL[%Q'(7&W76NMP*$("@$?+!I0AUAB'&#,U@R#\-V?
M=]6DW#8F++=Q@B->!W"_JY&K?I)2%TJS[> 4[W+-ZRVMN>T,XSFSA3ILT_3E
MX9/']*6?OCQ\\IB^?-"B#<?S"Z8!78#I1.PG>5K;$LLK1_LB?<XTX\@>'FUX
M]HW@1 RP[HZP*S'?1ER),;8P >W")BB'@M#Y4H(%1"\!E3/^UV%_0^H.1 U:
M#E=SB*['A#@'I4?-TJ2#)9./*I6,R6=P4.M1E&XU@+QKZ=T>]*2B'A-2\G1;
M.1LB4)B!6%-:=-T6W%/;4[;1>WE7QU4X:-T>$N.36L-PIZ$<YPO"4$UP$>1-
M_;D)J:5OAG0#LV3!O,@WDB)J')7:%G$*I8:@9JB@ /L/O^4F \N *P*#'8?J
MPZ^9$*ET47I^S9@Q$-JD*/+;L.U#<+E8NW*,P8PE>]T8*E-SQKX5BH@P>"9%
MPGFV32QJ:WML76%:A>T@*N P[6PYM:*7@?M"EDZ06Z*]#N/TCKOT9P8MV2$$
MG:%P(PM^!D1^_@6ME@>Q0"-O@?0J:,N4.#4+2S9.H8#C6:(FP>"#)JDZGTQ@
M"4B7\E?GA-G$I3)?F52V<?O7W8K4QEO83J2_\-?"7#?+>6ASI= F%:[41I+!
MV:ULX294ZDW,*PMCU[<$AT96EVY>L-_#>&YTC89V8W]OJ;B8]EK#2<A$N#Y=
M$+5JW6R^0W<>#5DET1/)1$NW@TG8J.86@#_( '<]*,=%,O)I7P.T5U"XY=#S
M;D^XU$\?>^8=&:3B)39+.JVYERAE0OW6^>7@VB*OIS/CCD;%**D*D_0>,1U2
MAET5A GQ'T=O+CWX.?KNQ_E\42@8#F5>CNQ-P$BC?N0$&K''UHHVA?@N@P\+
M)&12WO44<4:2 [H;52'C>4V(>GP?G?[0O$/M.&2_YY'QTM*,=]FA=U_:0 ZX
MOD.B-9A*5Q)\P"G6OX!-N1_\MIJP2G=0<AF3G:=Y'!H"8Y;D(P97I76!T EB
MA-0\-K0Z["9WAP-.%WGMDJ,E$2%03$K./\%C:!@58;'M+[N%D>.7#H-4:!4@
M]G0@\WD\BQ(T0TT4&"<+W'=Z?F.Z@GE=5AQ-=8!(%AB><-]#DL4*&TK!U3RD
MI8H*3J6+4!?&_">T<D'TJ#HN-J>L,4<R"/&?2#$I7T9=.+C"-"^<:))S(P&*
MCY*\4FP>+[ :+!HK>.:8HJ;<S]+DKJ5F(4I24M5F+2F;Z2P=]XNH9O[$E+HG
MVFC)@1,]'>,HHV:YM+DI#FP%8Z1DM=UED)6TG+I[EE,WY W,)Q@BF+C*2<=F
MG)4FFA'1(W:<.^6NKI_4S]L/SG&^Y*=ZQ[BHE2;*'4Y-<,?4!\K(L#>&0*DZ
MTW5-AK+$W-3NF[S@7;M(([&@.[8OO/ZKO*QPB[V)X-7&LQH1_LR29VE9P"ZO
ME5"X>2B .;5H3Z5,L*4FD W#\MKI(CWO'9II9LYBNP,<9-,T*6>2(Y.@K^:$
M-<'YE-$/4BN41MFT1N=?[D/5IQ)XL[?D-I^I(&'&F"&/,D<]FL _I<4P<\*<
M-16?5/[KHFR:V@1N0$E%DV-TI(6N%%UF.OK,V>1S'_Z[Q@8HHHYU")98AL7X
MUFYWH][-75KC,*]6VMQ6!X5%7E2W[G%.)&HB%/S@MQ#B_ST@J<2*E7_O<WT+
MKBQHCZD%@-"NO4%6NP*55V$GU5-R%/%'TTW3+PE97EU46KWAJB@*?'J-YKTU
M($^$43^$-I  /-<KE=I]=*?":_PGIS0A#LB9=RV35N@7GK>.E^GKH (>A,5I
M^G:"$8:[6H,\F$]J76)??!:&A!;+L)%C<9F'=;/%($UTKR!?;I"LLE-FL%I,
MO==[C4AQEMUL-W97DG%2HGB($L72N)3:/.$P!=A2Z#@3S*4B$MD_ZDS(#JBV
M3[$1@$!;#L$P';:$O+I2(-LF.ZH5?? M]96!M."SQM% 9NX:2 ON,8ZFLS0>
M>P)GBS1^R].*.A%62;N48"*:G;8&.0BX<+_GQ?O0_(LSY=;"ELI_/C%+0V7E
M/F@+$T9P%GP/(OH+G9VDU$Z) JZ%UK.I-7W.<B8[=O 7*YPZ)BB>R!DSG^?9
M#36)P\]\^TQGC4TG%3J\G!;D$[[9 H1VG"S2K<0I;)SC.WC,\35R? >/.;X'
M+=J@C7X@]"4UF1;\S1$U[="(:U1 <$"L*..P\043K$<5%8-Q<TVVN 9+9N)&
MAZC%J(TY'Y42()/T(>)FT<PIZ:1)%-8KP?6(%TO)DQ^AQS\F)G9++6+ *"-.
M'E!L2JJKHSC&^^VH<E?>@\B -$4A&?1\B>L\8_ 0&TXG>5VFR#V.L(BH$E_G
MU@9 ^SI^:'2X6/UEC>'N1%& B(>C6<&%6+2TC@_W)2LKW1F,[0P*5TW %N:C
M7N*6IHV7G?G1LC69$G[X4 6O) 83G$32&<B_5-JW(I@-XQ:EOB^,Q[3+<I_F
M+I-Y 1HK _D%):3<."OS+.)OL&H'#YVDF// A=N6O@3?S(>M6_'4\"HG!M+5
M26$ECL5QT'X('5$2/DCLEA3Y_++R8/VRQJKYG-5E>ML^I3/ :#-N9(GUEI=O
MCXZ'9[_\]S=/OJ&_WQZ=G.B_[SR"FR2N9GCID[^9HP@YWZ)%"<I8_^L;TJ$_
M75WH!UQC<_AQE&JU XKZ&ZUGKT[T57)S44!:]UV=K+SR\/G?NKBI)A$H@.6/
MM[T+75N"7N%7_^;GX<3IF81RS*65/YI:57<H]_A<_<0K)-]?4$@3KAYFXWWW
MR? _%W>;U\XI[/[P_E[F\/ @. 9E@>9#<%G!45#]"=_B59VDY)L?/H6+P&%'
M M;G?\(7^0U->V0(?W,4/#E\]OSIG_ =CJH*!F+ROU_L#9P/[^LY]ZVL* _^
M8]"MH3A)?G^/?-1/#^8M_FKZZ<^OGHX'Y]UC_Y9,L9\_G\7WV6W)K\20\80H
M,L 77& _!P,M[?<&7#W)%(TZI(]^B[@IY#/^N^8V'AK-&?K,O$YY^Y221QJ$
MWW3*L!8PHZQ=6=I(&$/JQ7U%SQ.>(S<J+1Y 'D+14MBL5.W6<7\7Y;](:PRE
M[N MKM&90-(SI' '#\Z._@;;46K4F_Q<0&[@$_N?E[H='-[2^PJ&I+_K&-5(
MPQP=*,>LP%8)<A,='DP-A9$> CJ 9K#]'H[6_BA-6P_UR$1,?K/$@@?L7Z?C
M!E*'+REB]ZYT)_OT6)Y.X7PUH6R.$"P1*8 LHH8(1RY,U]3@&@+I.!_S)TT)
M\4K=&!HG,7].U*^XK6[!8NX+OVX#FTWML%<X[.&3#=)FQTW34MJ)2U\YRROH
M@TA7?Y?N/4ONT49WTLGR4E&_#)!H?F.4/FDQ9N=.)D.>*"@(RCU5B7&2FVNK
M)9V+ NDWMA&+^?&JNA:I9H'13':#UC;@ 1DA<#[-)QU;P*2PS2^(RP'OR(5,
MTL\OP>1;%:YX(9J/-O$GQA0POJ2H"+_BR#PFV/5T=97;\E#A[::[ ;?PT<JF
MW[.S;3H]P'29^OQ;!M?YFP[>6\YG.RJN5>:I%]!C!]"D #NSW=;.Y)"(GG_N
M1MD!X6WB$%Q &26:XEU;&&R'P7<J0UV_AKIW@3,:I5(4QI$A4\7G@4*$-( [
M$G6W*ME)=ET &R4)Y6P1;)]!U[BP%8$G,N,0\B';"@.9%U(.H9X7^5#>0G^:
MVZOII93S!65RDO=*SX@[J);Z,=6+A9D>*JZ66=800%/:[13FZ:ES[I:JBA'W
M/*@8B5NXTZ56;:2==OP:!;5'(3%^%!42@C24903FP105S!^[#=$C!A(]PA0+
MCXN:B]\Y^FAH_B/.S89.5T^C8A/96Y7>7+<<OXC1V^.2@,K1F 8R9'"GA'C2
MYX0MEUPQ3@*1\0"()_8];Q1,"NLESHO6L9AHXX>3>8QAU"G9DHACQY3 HZ+B
M,A\G4:69F5;>?I_9$V8J8F *(AE29IJQ)=EMYB_L!Z0,6H&L+6W9B'()J4)4
M:QJJ0\2X%GB,L])P>'#+4+#A,2B,+;-2IHT:VZ;JDBEFT\F>-_R6AAM 2L@-
M@8(HU6X^!S(IJ-V8,/FP=DX\XY(.(-&?NNAQ/DJF-3=])C1X)J5)]$EKDICJ
M(%N&?@6PNXPNG[SHC:1P$O48N^=PN 6F>,)*KT+,0&QB1C+$)5>KZ_$MF<,B
M*:L6EPEF+PCV#$."*;.RI0%K&M?FE*XVOY(7U#19[<FD<ILHYMY&82"S@;I:
MJ\]8HUD8,.?FDAPB:8'S&;[A,"!D9I%G2*65%U'J=/IHJ/>1JFY4 Y4-6S(J
M1(Q7,@MTO3'F&1BL*S6T%3?@Y2[VL"US(A[!KK?,-<=)<F\076V?.@16TV5Y
M#<5#_P[]WMI;$)P,4U28(=F^G#QZCP>4N10X\Q[O)@:\V +%M109J*LT(X1%
MPC2JP0V&R#2?6%6+#9M)FZ]L#.KV-&PYL_P91<6\*RA(1,W=4AN<!J-6=CR2
MTG\;Y+E@:SK5/JRFRECJ@B?_)ZU';*'<;(SE.'S$<C2P'(>/6(X'+=JH$I'C
M\SBOZ:"&'5X:,BT?M,$FAZ(B/+8.QLZ/I$Z&L.-HIS0-:BP]T9!V'>$PY[CY
M69-MCLN"VMQ2<E.LP+$QE)9)TQRRBP.A/.[)ZX Q&EC!I'L5V$]<[4MG/(6>
MFMQ"&*<QKV9_O(5Z$H6). :E@QR. _R*0;,),?*TZB8&TE^.Z6-+X0?DGZ/Y
M5!>%EK5V-XY,37,IW0K%;(T,LZAP#CJ8;X>5;4L7!TGS7B6"BQ^0]-(:K421
MWHD"IVWT.!X,%W(5?@NNT#&+V*MH<=1LZ4H])YULG4[92E?.-$OH 6R#++\!
M<VZJ+)\EQ7L8_^6 JW6C2=U@!+%JZD::D^O-) ZD=4JZ"C5]KX2=3W3ZL"VQ
M1$^PQ$#Q#U^:3F$< IEX_K2!E;,V-8#[R/6R"V4+8K5)2BHY+J))93O:>!ZV
M\(D[41+7%^UJ1J:[]=PV \V]0EU>;)!U$B7"Z"8\6<TUD[ O<>9.L' \X!Q$
M1QR 75-J<&<.5RG6@_M/80L6NEYX@<XFU:-K!\55BNU^R=NYM9 ^[KB>4PCN
MFBAJN$,U:\*S7%?GN*0&[<!7PJ$-S,5(D,(Z@W5&RX5<WLDXJ4RL6BXL\Y")
M6B+'3@+/W8S)U%Y+H,3O![[1\+R$4(3^/O$0<JSY,_>/;R:(;W&:GCXZ30VG
MZ>FCT[1N'W\M^,'&S4Z'6;_W6U(15/HW"? [#5(\8TE.!#I"C:/"FYDSO:0,
M+I1HD*.L2D9Y3'Q$8RSQX5/]?,%ULW;_9WP\XA2PH8=ZY23ZHE0DW>OUIX(@
M'Y_C*,_^^YM#,Z2VNKLOS)!\L$JL! _,@^L"W3F-@^X#TV17KN.F#VIFI&OO
M9O-R=_C89WW7M;/\>99N]2O<Y;J/F,<5-S2;]WYQ^Z^6W1!]<V#>8C%TZ3<9
MZ-/['>FWY;<\NG_N!X/K""'_^7Q1HMNW9ORZVN')QX_EH^3D<;GT<IU&-YR%
M_F>JDNP3E<QG5Z+?_,R6YEV5PKT]?B/I_M(J[Z\RN7\V6;S"'.17G*_C\_._
MEOQ]]0GM)FE\-+V^E-7<]>0'-N,?X?(8R_[7G$I;PN#T]/@OY.O\"5;M<9]\
MI3,23.+U^OSN-O'7<UL>!>4SVY[;:-<_+O]#,/TZ:[ ?5]X9XI_SZ/T\\V<J
M7_^$.:.UZ;ZN/.$W_[^]J^=I& :B?Z5BKTJ!=NC0 3$P@)" !2&&%J(N51L%
M.O#OJ4.BVL$?(1_GL_,6ED#][MX[8_M>W.7K4^D)RWM\^;6!+5H[;[[[-[9>
M[A55![=Q0];0U&3<1UT?]SV-R<UO&19WQ"Y&AS1-LO?59Z*7J5+JZV/J-]G^
ML/L0/;1]MA#&DZ_D3UWKE<@*<7Z[M@-PR](I!:@6#Y7AQ3IZ$;T'MXVG+GT1
ML-=@'9/D#),D-[.)OH8(A&P;N$[Y$DVU]AP0@;"6MI]$!.5E*7XK%;;"W68Q
MNDQ/'=+I[#127L";;/4]FI[.D2KS3O5QG[M+M0XL6UQM9/-H([LX[SPR=;G2
MZKQ#A4R111EZ[5PRI)>2EPXD$L,(_M+I6VQ#0!PSW8TF/0:X03KGY+%&'/HZ
M!2N4EHS\=X% ]!%>(Y;W <6AD'$C8'HN!M,\92C'7\ LL7)006A$CO-[;;H7
M)LL2K16,JV*[VS8Y4M]PSD#E=4NN[__X$ O$ K% +! +Q *Q1"*6H'?)Y'T%
M%GJI^08 ASV2ZPR/R5P2RZDH(W(C25YXB$'WH!"#[D$A!MV#0FRAV_C=<53.
M>YVMW>%ZGL/U+ 7,R/5,XG"NU@U+,S6=B3Q\WW!<CMI@H]&\!=MG9$'[;@+T
M!SOIY;U,].H5KEL:'.3/>HX)#S&H'[B'& ) [3>BGG*-([]\QX!5,[P6%\R2
MP3,O!+C9 /U^!+=LP+?,#2M3A81&<E^>9@@!WJ8PO$T0$H0$(4%($!*$!"%A
M<QE6\X&7SG3'6K#^X@ 39]>@'M2#>E ?+F)0#^I)J#?:AOOT7?JX<M_C;?_#
M'%KWY0"/AVTR+MW+)LNW<13)RGJF_+5<956#H\877B9%N*N+G[*[6@%9N-@G
MUP\W+Z)*)K?/]W?+'U!+ P04    "  0BM)83\>);R4#  #)"@  '0   &5A
M,#(P-3$R,C R97@R,RTQ7V%R8V%B:6\N:'1MS59M;],P$/Y>J?_A% D^]27M
M0$)K5JEO@T+9JC82XA-RDDMBY-C!<=C&K^><-%WW!@,&(A^2V#X_OKOGGDN\
M-_[[U;C=\MXL)G-Z@KT\?^FO%F.O7S]IM;];]J;G\X^P]3^N%B=.K*0YAH&;
M&_!YA@6<X05L5,9DIY[HP!8UCQW:2%O7S3Z#EZ;+!$_D,6B>I&8$&=,)IZ'K
MC+WI>'&9\H ;&![U!EY_2HZL;T$<V#^709&/?FBR7_0GT]4"9HO5:CV9SY=G
MKT\<UZG&V_5DUHQW ('2$>INJ(1@>8''T+R-X+&1C^""1R:UINXSFP;/WS3P
M7U$;'C+19,*H? 2'J1$8&Z>BQ//GS:X=WM#"[2)?OG\-V\WLQ,'+X5%W\,EU
M![W/>>+ 9.6?.#9Z?_X0S,MKF(>M7MZRHMOF3V*YY\3Q-6^/S^V>83*U+)^>
MG_F'*-T+M-5U#%+IC EG_&Y-J2+NO;XUW97%#3?^<I0#=W@$'YB0I8&MT8CF
M7YX^5:6@BN[ 3 FE6:3H[1Q>N4?N\&=N]"OE_+H(?Y/,FX&%* WJJC/,E"QH
M!"J&I8PP1[K1<(,)+\@&(UB7@> A3,)0E=)PF;1;IUQG][>1)W7OSW-PF\WF
MV"YQ71V]G]!U8;O[B4 9H[+*Z#%*^(#4S>I4&@4F12@+M%E5I0:-N=*FW8J8
MH82>8J!+IJ_J\ :=^CETAR\ZU-U,2N9%CN$>*.:2R9 S 84A@(S.*"SR9#.;
M0,!5GC+R@>@+>QW@,A1E1*>D1!ZGA# 9-4 :8YJ4(;9;-&,=BXE(*(ER71FD
MR"(B&)Y_*949+2YS4DA1#PBX,LFUJIPKB]X-T3]!$3QYT1-O=UOY\%8K_W^=
MO]-=GA#[;2EQ5W^O#@KP'Z3CKM!_Y>O_D'QOJ+7Y*E'QPQP%NV :0?",6_4)
MS@(NN+F"G&DC41<ISRN5,,@P"W"G"A*8K?<**Q$J(/DIG3#)OS'#E;3K_*!A
M'FPM@,4Q'6'%WFY5BJY0EC986>TFL%7MC_4QU_PK&<-")H(7*362+&?R:N]R
M< 4)-0Q&^['W]RCJVU_1^M_4_L)^!U!+ P04    "  0BM)8\,@#:O<!  #I
M!   '0   &5A,#(P-3$R,C R97@R,RTR7V%R8V%B:6\N:'1MK51+CZ) $+Z;
M^!\J'CPYHLX<-B-K(H@S;! ),-G,L<5".@O=;'<39_[]%+)FC?O()BL'FGI^
M7U5393^GFV#1[]G/WG)%)[2/G?IIX"ULJSO):OTPV\YV]0I)^AIXGP>Y%.81
MII/:0,HKU!#B$6)9,3'J%"-(4/%\0($4&IWC#+Z9.U;R@W@$Q0^%F4/%U(&3
M.!DL;&?AO15\QPW,[L<SVW*(2'25XL)_*':ZGO_J\J_L+L#)=3*'2WH9"H/J
M1,K=AHD7IK!=@Q^NO,BC%XFQ]^0GJ1=[*XA>G,!W8>FZVY<P]<.G?F_MQYO?
M5W!3>O_?@\NL)>;F"G:P^(I0H,+=.V12:,(%(\$4"(U&X((^N888#UP;Q0R7
M A+##%:M)PEKJ:I^+[E[ )G#,G:7L..R+IBJV A\D8U;O6P4**RE,K"GV#UL
MV#M,[T<PF\P>R%)28G$X ^=<,)%Q5H+^B93#5C7?&*1$EM78&)[I#F $QX)G
M!;"Z1J9TO_=WTF.@BEFIY76]"G/J@\BP530:&K%'=;(4R/8MOV&Y_][(N?=6
MHS)ZJ$Y2VR/=$/X?X&[VA]Q\(@8+2UL0*9[AD=BJ0M*5NU)2=1J"(+*=F( <
MJ8VD1!NF-<L*<C%& \U-9VZ'X$LC$*:?NNN\(3T".9=\,6E6NZJZW=6NN ]0
M2P,$%     @ $(K26 ?_@-!9U0  1^\   T   !T87)C85\P,#$N:G!G[+ME
M6)S!EB[:."%H<'>'$#RXTTAPAQ""NP;7X!;<(;@U[A \!)?@WDAP)[C3?9JY
M9\^=,V=F[_EQ?]YZ>.![JKY%K5JUY%VUZH,N0O\ L!5DY64!</!P<&QP;
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M,= 5CJJ/,B$V$IGU]VY]P1LHPK _[9S3<DO3<E\?\N\M6EPU:N37L7+GVZ\
M51*-2>/NN#2YJ*A6Q?^V8#VDPU:='%33I*BA-N#1/#M:X"G'>(8MH-ZR/^!.
MV>Y:<_'WQ"5"DPUG_?!F659YF[^"@,UG>+E=!:6>Q?LHP1&N\2B3\I*!K8\
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M0::J+H4FI,)VR1TH(P('Q-R8[1OQDURXS>9:<?G+[;*^L.[IHJM(&3$@"5\
MHL](S_F5S,N+)"<PJ!HU^,.^/2X0LSC;0.ZUNCPC .O=8EZ)-P-IS;8=T1W8
MQG45293UM=Q?G)4FO#7]S"6Q#RE$APIS/FR9P+]SE8E#[/N*\,Z,&9V0EGJ-
M48H9\=2;A#<88'J]"?C)P@6(BP)QUIT,'%?.ZM"$ &D<CT"B]D0(!GP<5;\U
MY*(18?8*W^]F<Z7!;\"'-V5,X:2R6;:KI.S-=JUN82HP"D_=CR4*'SAIL&)_
MO=(SIGX'7MV^E<Z$5,;^\4V1SZ/X"D")WY?_LVA_M+$DF1!0K(JU*SZQ-[V
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MOR6VRFU")[#F(L)F+HVUJI2PW7 <A9-$DD@[8X81!%\5QEU513V'A>^J2(D
M=:Z;O8F.RLX\YV)+.-E%'# M"H/D5N#K?W%>%..!>O==W]VR39RL4SF^JUHA
M4$.*M]%I8>"EVL8_BY#$6@1*:.YBW/S^IL+]IB34C"3BGEP\X=&;/I=)B !=
M:JM-R$IN]H>OC B]]I&GV?/(2%L,[^S[S$A"Y;P*FGE-?[I474@FZON VZ1;
M-/)RQ0#S>[4.5ENSF+]1W]MYZ:*0:7*DE1C/"93QJ$:ZUNWL72FS6CC+]>2Q
M@W_"+8^C[!3[ 40["4_:/V#%Q5TS0 $G5<]^OX0['=IT\IN.MJ^$[4?H RA+
M'W!_/@3$S1R<.N\\\MK39"/4[-*4YG<CA>O]6@TH[B;<W#L_M5GB"XU'PPPB
M;+'@5DZ9\[$"(I=$R[4@8MV!H("81SQ#.SCJ*K$T&6>CQ*LJ;SE5<YL;?QNR
MXK<E<N!! V7,E,H"=V1=DFW /$E"W($3EG"<,:OAKZT4#[.5*MLB$^D+5\96
M_W7._9^NMKP=/L7Y+4D3&V*_UH!/4,#;L(1Y<K_L,ON!N_GJ.,ZMX2*+ZA(2
MVENY)"_3TM)$>,3^IOHZX[*(6K)7&L^. K1>/X0NP7>_#A,#J^9%STA5M5@'
MFJAF-;][N1((]W3JR[))[7-JB6(;("?3+81CIGO(WA[E@*+T[90I"1E<:>&B
M?VFH2Z@3?06>?PQQYE:O@!<S2E1G-Z.-5QSSW1CZM-0W:3]?FS428.H04:5O
M.A"/.=4;6U+,5.3:X+#,/V[V^?;-C_"[;3;@HPRC6 K*1('\DF%5Q^UQ8F_2
MD @%I=J[/\Y5]'SOV7ND-//'6E_IR F66*(M,&&3^O3^=7H>VQUWY\!XVB7]
M,+U&H\WB9?O;3(R?#L&0VE:Y."8ZC:\S&;E%R>5^:);]LC0Q+OYI>+_=K&#G
MCG+A.>Z*\MAO:W>/T'K?V6'Q "XA.ISR*.X:T@$%M-R2.DPY[^^N5DRC4.4:
MQ%V'_UAPCT8I]'&?T.Y_Z@S+R5BE?7!/=80"O)12_I93KD(!<9;\8@^&'P.6
M,5?G!7P6H !6I>ZG"R 4H%.Z?^LS[I /^>]]9T@B$-U%D2T23XU6GJV>J\AY
M($IO.V$Q5%H&,5'IZXMS&0^^#WZ*&/8=OR];-HQLAEP*!8V>MCET'++9X[G,
M*>G5WZP<-3=[;S'CH$,!SNV6P!$>! .TL>2HHNB7"7PGP@T1I,X]MK 4KI1(
M9DBJ NO.DPUB2Q(D9[9;JC^,9J\+6(E;8X6SME^D- R\%M#=UIJU?XF#Q"]?
M\_G>!61-##:<+^RE?3&V*D-BF#_N"/%;:-#2WU^,'2RKKODM@^>-8WW@W'Z8
MQBF#:.NFRYPX>":RT%:Y#J-VV/JW&^9D/D:;F 8E7WAW2UV?OJPV?#XH2'7D
M5;Q>NTOL_F+WD$$\1?=**>/#O"A=>T09B%JU1Z$ YE!]_LOL_/_HV#'ZQ].^
M_5,AS&!7<O&[S_I' _[:M[W<,3+]]!\HRNL@L$UC/ULG$"5S?%#X6/G./=S=
MA.M98_X'Z!#1B^8Q*F32X7D.K4")AZ==S$Y'Z7TN,,;ES=0O/1+7?[N; H'A
MDL/Y@)3PBXU5(P$AESB!-F>O#SH#D,[1Z=D;[2/4J_A3_64-)%<1Z^:CU[+7
MQ)6SZ+E^/"3=H9/R.^[R%D7R,#BX7D@8/?#G//WX+458$F%$GZJZR;GN""IM
M<?Z@J?/5^;3JY-2,9!F&"#T]FR*9,P@M(@_.^#\>533>00&AM.Y]]['7^Q3)
MI:"R1XSP>8'8WII0LBJ\#/^!E12B]V^L0E(S6RB_'?6[62C*D%NC+B2*P[9D
M'@P+3]J,3R4/(YB+$.-N(O<3>[HYS^.WC[EUMHWB,Q(JD.AFB&7M>;T.*=%F
M819_\\%G!D7:CI'O#:&B1ZM^6/_YVM;_\#/<_ZL#Y/'$-+J]?IM4WU:Q&0;_
MHXNUFG-TV2\849U6\G'!36W6U-U=L PQ=+,:_"BHD)GOJCJY-QGD'[SJ4]@*
M4ZB-NS^K?N<5?KYAXZ9]Q)#[U7#BYG(Z7&+@1[>QIA]1>@5Z!1$:WZNO*T;O
M$<VGK:P.OM=1L<#@=.W+#:DFF Z$4CUY/'9PR/J6]*H>9N'HZ$UGG9:@69MG
MU"U1)ZR"X:O+=:N39]\?AQ"WN2=*6&11(QH'LE3!PGKIRRYT&]VI! SUS(NQ
M\?/+[-JFYCKX1BR_T3 I2/I=^$QS/2O /MQ2186A\B$E2[M0",$6U1)DXXI1
M(2G6=FM0]?A?J;%>A]6&XST4$,FX_CMLGE<$J'?B)$?.X1S='[<==[-BL)+2
MQ'3RU,:8?BZ"2M1'8'3T'+"810E#$*MEGO^+M;<.BJM=UD<G 3Z")P0([A(\
MN#,0@KN[!'=WFP0"!'<([A &=X<0W%T'=R>X#<-EOKK[UM[G[/,[I\[O_C,U
MM:K66J_TZGZZ^^E^>3Y-90*S/G)3)N463S)HT?Y,_3TA^G:("BVH46KFQ[G(
MO;_? !%7Z9P"17UDOLD66.O>$9#YO3Q?ZJL5_OLKVL"[2TXC[PL?TY>$\L59
MKOQV3#^:F[V=48LWO']LA"22PRIR2+<?XV/Y>F\4IXZ3J;UK6<(/SWB5H?=H
M*Z=IGW"Q7,CF2:0OUU"$B!32%QXN;#7DH8ZRT9U#DHSHMHG3=3)7(]3"]-B9
M*& DCE=724;*D5]L8.R!B^4:N\+Z34ZM&FC<'S])?'(TI;'\6,*=KI'_1@_!
M($_!<NG:[S?%98)7(.8QM?OX'#7JG?>5*H'0",OIBFZ\Z^C1N<4-IB;S8=LD
MP\%"40"N!G6N&&)86,>".L*>T'G]$R E*ZUIRF4G5*MA;EGQPXS.-R_\W-TO
MZA0BYP LENJ/$ ?]&NL&R-3+5Q-L.Q^_*.ZX7.RI0>)8CR\>$\F.OP.CG7=9
MI=ZWO3:@1XP*6:[CCWS7P( \#1)] KP6&FUM8X\$)HNT7'(*8?G8-[^_U LO
M_FON_@E0?\-_]*Y*XH70R]-U8VE2OU<$@I=<..&X"9:R+P'$(-5'T"HHI*K@
M^A@-$M2+?-_1-<'<ED>=&I(E$K4!CDS50-0RO+BJW+UX%.J"=CE'8/#CS7]2
M0Q)"2>/VZVR\3RH/M)\5$C8AB_W9,S5(J^-AB7A9-_F;(<,!!4=]BY$>T0KP
MYLAK,/[4Y[3>><%6%?]D+7%=HSR^2$5*4QG_*.Y+%,[+O%RA":92KT3S=GEE
M_A#*Q!'40$7!"O%#X(Q^D(QIG%U-')BZAF/<TSF:@L=X34E>E1'O"?#F9U;/
M[0WB:?OBQ4A],36D()EZ5HCC[46^[=;<4<7N^&S?CVOM]WCK[X()BQ5OLI%%
MHM9^F5<]^]_?-]@3".V)9S</]CGGHV=V0YGO^QY CM=W50X"CA9+S+1?L&ZV
M%!(>W-[OZ5KY6#F)(CZCHWUMQ5N4/9:!]TW 2:A/N <-CA'_:TB\S"69J=K+
MOL>&!X>*!Y!3_0F]0539J-4X*$:)*^N,^PGPPL<GDL>TS&JB%9DR0^?T_!YO
MOVT*)I23 KS?/\KRDWCX\@28ROCG,,#AJ2*T['E^%P-DCP99>3.G?/S?^?]+
M@P.N@3D!Z?IZ%;^1A"N'EG/Z7#1*WN//K]#31I5G%GDJ:3X!O%T^"/%RJ+2_
M-9W8,@O.W8N=XV)/0M\C6O8ITP7&@?H0SA%V-7X/FUGBU9B[RM-(NMAS" &3
MXO0*EXL+\N9=:35B*66ZVLYQU']^DS(+)./)DS(W=#MI6/V'WBQK@+Z?VQQ.
M*RKT#MG*)(S-[ ![<)EWKF!_I"*L#S%*M:I,0>TU/>?DE8>$REA^K*S9^9'H
M 'Z^L0C.AR['NB/SC3 (N9NJX9XUI*S5%>AP2O032GT[3%4@WY6<BIYLH/YJ
M98#&3^*\3]5XG0=)E9&YPH_N>? 7_[WB'^SXQ[]QR3OQ4Z$LGO.;VZZ@$+?C
MXAH<(@XZ6?W0<('P>!IQ5=J[96D2(?V7ZH1@K^6> /Z_Z+[ :346<-4J<3+:
M<W@<*"DLYN?0EE:]1Z\DJZK?PB/\UEYYJE>M,<X[O<>-F(U"G?;HEQ8\$U(,
M4P8)K 8)(80-*MLR;V/UE_<$_X7?5C632.931U@,#4=LRASCO+ C]+5OC([9
M-!V<I<M_;$_&@$=T!-J5?0M/QS(S((_0(SY&#[RMP>$?&(%S/A(A=)K!B_--
M16UX,PL"[G3]FM(TG[H%)_VOS-Q$61D%K-!.VF9J?3%A'Y<;((F>PKUWSNQ^
M'+.(DUO%]XLHE-'U-XF,U&YO5,T^4WKR0]XI$3.MNE>D$I*RUA:8RR0^2Y6#
M?_4!K&T_([S!>PI\'?S6^$B^^&,C%',1<ADN'9T;J"O+63$TK;'%"#;U.@ ?
MD.J FT-)K?+C-#V>K3"KT#]3-+! @GY3W)LPTV6(R#E3;0L/RHR SM=)\Q1?
MX%Z+E;U,XY'?!TX^OSZ5B/!?9M3WH? <G!1\Y:Y ZX+S^#5D0AS:*/3=(W7^
M0'=2;P+65P_2UCQ 0SL7)<3L%KP09T&-Z+F'UGLN^,?@T?%_;_I=$U;3(/9N
MY?TK)*$MAU/OZKAIY\8<,(;B8LI3B?$@/3/F['62NKVE1CEY[H#*)KR.OX%7
MO3O>\1$HC8R1(RW1*K6E"B9Q@XCS@_A3';8L!IZ8]PFJ+>DXA$V=B?E]S_$]
M0ZJ@+VMVM<I4,3D<[QA*DB8=M#5-+$O.M@G4FK =C]8L"+B8;63$8GLW?L!O
MMO79*A'\K"$7K.%I4%BH6!H_>.)E\BP?.3SPZD"TW8J^G^TJOI].A9.B4JQ=
M6J+-9DVOM2CEI3O<TROMV^+PI&1&<-QTXS$4%=EDDXI2Q1D.>IZ_]XHTE[S>
M8^*P_KWAJ*@"?1)I#0T-0 D]'ODYG,+_33CW:+EO\K%HSJ^AUMS2@U770:BI
MS?$ZT]HTL\9^V\K92DR=&KV:$#UL*M7[V[99@*8$DE8@/+RC6OJ X.#>IV^K
M,+:H3EEAZTXZ!DF;>Z%$H)W?;6\K3FO\138[IJ9 R+@T_$H22?X[/# B"_J/
MNU)FCD"O*IK722HLRQL/;7@3-N =LOG8/Z%N(( U<8]UN?5PU[N=L7-JRV\W
M^1=AG7]96>U.*^\83O"/6W^R)$7M59 #\>&*EI=[2Q'4+>1X<[PM<)4@51NQ
M2MD.V:$ ['UC--MW^02(XDJS]@0!#_R&'^B$3I5XXWBYSQ7/[ 14H^>OY8#)
MHFEEF9.?&,9X'UCL->]*\W+Z[#SL#WI*/V:AS+4'3:*ZG4SE7)%2Q\VGFPLR
M]K,02:$Z7-X(GH^U"8[52X0ZF-5%4F:TF.5K7UB+$HN\W15!'LI.? +0V\U1
M)Z?N L\O.!S7!!::R3X &3P*^)G4!7PLAY!.<\/"*2*=%<G4!A2140%X$428
M#B?.\[#S)0C^FV4M;79OB;ANT,%A='+7./<-I*UXP'+W!]D^>P/T'NMB3Z\+
MFEE4/-DDG\=)_-/*DGU V2<.!><*1VW1KJ?#=14J-"B@N<*PN!6TY%X??:\\
M3'9\;#D%$_3&U/?QH]9N:,(X-Z6Z"P:N[9DODJ34W_1\^@&U-K4J02).5%34
M1V0C0Y7&8<??#L@MI#.:HG^YEKBS1"3K6W:"V3GZEBMSA29**6BP/YN$/(B3
M812K6_#6%6?I&NVX '$JT70:22T^#@6?G(SE9PAAS28CN*K.9K,D&YP952@
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M5/ 37)SX.0 _^< T21,5^4IXD,RI>>DD#W*4,,1Y4DS(HIW1KZXD),VY+Q7
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M?ZIHSZ6)Z$T<]T#$:9X5OD%7Q^+[:?\?DR><YQSS=;2&_(F:2B^HHT*(W)\
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M49R-#_RL"]'A3P#"!HV=TE\;F#XVN\9Q8D*D\T-J98S2J$QU]("1\5VG*GP
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MF.SC#N1MBP%GDN>^<7%>;""SL$12IG'9YJ3?7//]ARM-2]O,@\/(Y,5'EY1
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M9#)-N]+9?=_+GXH?$U+#)_2*<$[E>%TQJ)9O_#FL)^44>[0S9DR L4\2+91
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MHK._N^%^JI)%K.X45!$39!=4%6/@=.YALE61*HC\Y;D5V8F>_VQJX/,%_GW
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M_7U]R_*7>W@[RC+3CE3@1?.B=D9&(TS(EV5)73NU;$0Z!O(8M%+K.J-U9"^
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M>7$E1S"31P"G7,<UC3J+K@VCL6:U (]QT3*TS&ABIHMD?99;JJ$I!:MM!DQ
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M:7Q%<#66%QY%6O9N]V]O=VD32QH9&;TOHL-'MD?<S:V5OR:\>W!A4?OM_ @
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M(NHR!UC$OZ:>-S45=2[?)%Q1W[9J6:&UG)QYHM"D$#CW&FJPB;VGOPI_"R+
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M+I6Y$=4U7DT[X< 1O8^W)JQ?^U9/Z^>9BAD8*M+""&)3?3LGPPTB"RH4GE#
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M?O>6#8"'\F%RT.(L#@O/2D&OD,9.GUEU5R ;SOSX]<A/!I&TV9)9(7B?LB+
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MCIUEP#N/3T\CN,_HG@1$#%!/ZPMW&\_H%#&T9WX%I1^AVV$MIR#J=GW#0N'
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M\+7.K;R3)R2'DP4\2KU7#6AVX85_BCBW=0BX+E2CKGH:D=7OG= ^IYV_.[&
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M9\LZG$7.TZ-S#Q3Y4Y@^Q"R]*&KG]<8G3QD)MV'*-S.9A]JJ+&')MW^4R-_
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M_SW_3\%W6"%L\BRC%?'RO'-&'#7I;7!=J%J<;V"!8-:<QC-XYV6'5_&>*5H
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MT1U^@ 7@V0^T(I=M+L'](S_LG&Y,W>-RJ,^E4ZQ-\0P)[6&#2$3#!>-A&C\
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M$0MIRMI]457+C0?SQ(X1_2"5:U9+G9H3XO9(KR2=@6I7A?_:J)'CT&S7(C7
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MC[#EAS(]@O<2[J._XP# -["N<5^Y!?5O1$$A'7A8RTYH<FU)G*E+4/;[&,5
MSB3-)W4 R7!DI 3[.4AV+CON P[ 70 S7[6*<]HO@\S^>\)467O^@?%[;\T1
M'" .--Q;[AJ)!8V7MJUR?-<D<M86EH=.U=%G_'7@/'R![4=NK!8#*;)"WXKY
MTLQ-( (IWQI='D_>K^U),,Z7$+LMCU)F!D(LV]8RCU_JZ.]9G<.9-)E:V,T>
M!-6#[I9:_LHY\=Y<>Q&4U%I\X1Z/'1_+LPXL_&(L;:-BHWW46HO8P7C"SA)@
M#(5TW"4P@M019A,=B;B'6,OF&:5;CL,%O0;"DKB8A%^&*N(.GNKQ_]SC%T)^
MJQ'**[AKT=@N(>WC!^U,@=..E_7F_+8%T7.GF45]AII^K[0V1!2?-.COF*UY
M8>I/@QW4C>@\K>317:TU-0,]G^KO\;\K7UF3!0GXCB>G\APQ&J;$<]G=Q28:
M-.SB^02#ZK$#JP]?DH/WPB5?K5;-N(PPEA49IR#FRJ5C)#-C2)YA7RA9"<^1
M[I?'*-WCN+EF9FZN'3J%PON[7I4_'"@[K6/\E<' ?0ILQU@UEXC\Y<RT,4I5
M>0QJ^,\11IPR=Z'O\VIYK%;V?NK$ V$J\A:P=DO-,NS&1KM\%_C[B+9)NARC
M4'L=C0,DHMPG@UI%D@I4MU2NV?1'=E&>U3PR"BGP_!?O,:&H\G3]FC#,PG\9
MUO*_*/7_$OR7%?P_I-1ZD(-B,WU-])JL:XW'4?6W0Q6BU_?C^PU.^+' Q\&C
MG@Y_-Y;LGRA+*WR<NZ!H?+2A&4>^&>3)&,Y/PQ=GD!.#DOY^5%-YJZ5'2&+O
MG?-%S$.KOD*:VI4"6-YI[4G^-@K+6DC:"1!^^/ %I;1.D"T8V1'8,W-#Y)$7
MKIZM,%Q LNU#%WO=U0"$!#R:Z:PE!68AP4H'Z0>M0?B*4.ZFJ'T)KRN8.F:J
MFU%!3*%&.1EZ?ZA69$7*&ZI<YH!.#>WI3M XGGOTN-Y[V9X[=@*)<,A3U3I?
MUQT<I5=OXJS:4E0IP0>59F[U90$AY3NK-!M*W,A8!-*;I>[H:8&"\\U.6=#&
MU%H&=%PTU&#NT E]I58!$R !A)?/C;#-WK)I!/NN/27TA<!#\W0#_4\3G7:F
M)D"R!09_>^!N@IHR]AIZHQ6C#[14G\;E)DEX:B\=>\BL.ZJ?X]^ <LMW]T;7
M71B_U-Z?B;W3"NER-M^IB<C'$XI\7K>;YJ&V,-J) UAN;IVJ+%72EF>-U[(:
MILB1C>=@Z5]COH$D0Y!?<XN>U,APK1@G5S55\OO B;7I<8# 6^T:PU\JR+Z-
M+U#^M\SX.B@2UK"B_O&*N3,1ZPV>DG>2B$S]8$AA4[@@EO4P0)W)B$7P<3L/
M_O5DJ KBI>0GX;3(B7JVBO@O#XWF+DEO_VZH"UO!PS9:>GHN;36\+H])I][=
M6TQ1R"=QRHC=.?<@;EOUP1<]'&;5YV9BZG\%AG\X+OY:$T;^)@'O*2WU#XY-
M[8*=B^O;PFZB+:L&+YC\[H$ZD2FEF#0 TXJ&679\&W+R[7W3IL!@T5^.W%S"
M> 9)?95UK!+GE_:[CW<E3<BG72FK6,YPJVEMO%APOR7>*O&99/@"'(D#Z$)1
M4SL;,=O24\A^V316P[R&RILPR_1Z7<=Q1>E9==ZW\O5V">? Q8,DH.PZ<^3#
MM_^91P4O'+O5Y;'IJ.7-@4/O$L4R"!V95&!J#*"&#@\5%&60^'$<VP%VZFW8
M009#S-LH&.SF&AZWKO^^#!4GJ#=B^VIY3[!$*./]D5X!U? BVS%*'_[G.OF$
M_,/"@_.ED4 P$!X(9WO2V40'SQ#-H!F96YB8G5?7JLY$8HD!;+"_FZ8=!.?7
MEUC;ZG^Y?:E+<R$&DE6_=WET?RGUQZ?R=WE*JRG0.U!/</M\JFMEOR.&?'%X
MM437+S!N]AO_(6A\B5?HOJ)8 VF'+AM*^P #W@&7=[<>E@('<(!'<P_:>K[A
MO4<%I1!]D']8LT 70+(MCHI42"7]XVQ#:DU,$!K:M'0QR+? &9LRM1^DTTW;
M+)9ARO9$W3I('\M?P^T[/RPJJ&D:P?AL[E5;\\CC%?25-7#I9MS3JQ[PGUY%
M[SU';A\1I5N*5$+9QF,MI0:>/7F9,_8=8OAYXOL](/OF$6CI!GR[".&<:;C9
M&@4TA1:5WYQC.H^(;V.YUJI5U;@RGQOG*2R*<S$_""[VU%I[A+@N"?9OR.F)
MXQV.M[H$G_M%-/OM?IQ(T""Z)NR?P^Q@;J]OOIV]I20[*.;I?&+/[GI".Z\E
M^Y$.> 0_IAXQTOID^;V"Z?.N,_K><^(E).IR<V(''PT\@,$0SQ:)  VCY:RB
MWTOE@.,U@J(:R5V*'XIU^[DQ^]@CCWTW4-14J6;3\FJI4T'!]C6:\PLMJ^U4
M9;62T4L^WKV>MW1GI7+<R#6O[VB4@>!>,KXB(L?7<C5SDYJ?\TEYT5&MMY,<
MJ^W(W%(YSP?"(F?'NI+HY,T!_Y2Q^IM:ZR[MG06?._I;O]6O7L"F_CW.HFZL
M:TQ_*;/^OJ&/Z;E.V 0<<N+T)OZQMNX[0]&W%Y7R\$;^#P*$0PC@,4HH;I*(
M5__J, 8'R*Y[]N?'HSVY,$M#F(K\%R>TZ2)3D..K*4^2[*\42E^(T[ =;//!
M0DGL42-A%OA_Q17/LP0^_DDE/H4%:Q,I&U+M%&7V?D]Y=%KDK,;O[0;@NU>T
M>8%]=.O\U  5]$1R/8)@!V/9>7DDYNBQW] P8)(],CO'5)H4]/91GDMYWOU-
M7=7='O5*&[\'$7#69;6!;ZS@U DUAEH7IU>7_RP7)4.\8)*C_IK+EY0J33>#
M=_GCXEIE<Y@2#E"/5FD1UX_W=E$Y_17TNF'Y^5]B%WK6-_CEQ(MYBJ&3;V5T
MO\#I[O?1*G6P:30VDK6)B0&MH"VN755DJ6%3<(K$@MW<;,U_!"8-/-YQ,,7"
M;<4I$*.0DZYJUSHU_0J8'(@#_&,MJT(>M>Q/E/CWM2FB_4,26;HY1Y MTTV$
M9364$$HKRUR,5:9T[L.*_-#,2"N"BZLIA<Y2>E[C8M.(<#KY0C38? %O]\@5
M!VBX*757XH>>7&-ZJ?+V=O%U[JL5,M[%J! 67!X+>$6JK_'>NTVY3@)N@S9"
M.QKN(SYL:R.Z5C8EL$_T=Q/D*QD((Z8.EAZ6[;IJ@+^+WUJ\EQ!:PN3GN>+[
M!R^TS.^WU'M21\Q'C/2>NE+#<8#/-VU"]H]54?Q8K2]G.TE#T=3F-*[5<NR0
MYW]<$9132T(#)"EOYIIXFU\:+, /8!7F.$!C^QVJ,]S $'P*/)"A3UR/F"%S
M(=U2LI3F7Z%%^ V7S/"G/!@;,?BM!K,%P2/N0=':;<^<C!CKI)%6[F)_)GA+
M\(^(@ /S0O\9_HUY=V"$.D9I;+]YI8XTN&9/>G [%4=+K5AR'X&@(I+PNMQ:
M%!:(TTQ1P&CV#V""_U,'Z'E$\@? Q@=JGJ-T?BE"OBWZP7AT.":]E#AK;S&@
MOFR6^#>CG7'DAFE6U@+"WG :@#2F46$]6BJ>H'&U%/UG))>P!R<!1D,A*DDO
MZ>/EY! ) -<K45AC59G)VXIH9G!1.!X.@(=]'*S]=#[!)4YE;_9S6["93J5T
ME7%*.+0=*$E#F2DYMK"L_GGV47Z@C:Y302"3DAGDIY5J)S9J-4R@"9P"S9,T
M*X)Z2K@(Y6Q_RDEBW$)W>8:^]1TSECG9,M*LA<K.":7%O+XJUTCSU@PJUE-)
M$_-CRPSIL_YP/$I#PZFZ:Z/9*=:/-MKX)"O'-E5.L3\O8$+(_]T@7.*/4<TE
MU$33+D-V4T?-0#)4D5+M\>_-54@E51GMN]Z7$(V@E?! 9DT>4GRN Y&"J\OC
MJHBWUJ6DM)&%=-A]$WNR>I]#DC@\'=H'5Z,'8#\_,D*0,W"7Y=F7R4Y[9?P%
M [N0<6K3W=TEXDN8^?*)IL.]HC1N^43U%=\$FY74KV]V7P/K?CQ2:.(5>YHX
M^>-FOH6,TIWW.Z;OD]^Q"4L5R0?%$.O0C!'9V*MZ^5([8>$L/#W^U4C9F $,
MN.71JU>BI81A%O=/ZM^G\D5.S#^6KZ_/RE*H^9?%N>V(7?XY[U8W]]8F4,NL
MRWV9(6P@F?$4WB*>((S_,PFO=3*V1?"!2ZT<F^?;VA^<JH1?T8FA7N#E[[YL
M=L+,+FQ2L]8;+I4Y)J;J/6NI2E5ZQJDI/Q/4T]ZC(">A"U^AW\&K6*BZ36/.
M^?U$$0"YL0A"[RO\/[7H]./2-5A3-_/[?WZKX"<#5U/_P:F-6_079'FFRFV"
MR*3Q$ OZ>D0[!Z6R8M93^[ T0XW.79G0[)WYS4W.?<+"U[PZRFU9"'M7?T=\
M%_2^HL+'UF\W]U/2QHQ4V@SZ U]@V)QE=IE/&"D2&UKN,YN#-__(9O#2'=O?
M=KP00ZS+Y<ILM='5E.#'MMG5__]WZ=W_=($$#F#ZS^G^58G5^G$!;O&#U]VU
MX@!VHQ=3. "5BB[H+Q!\FW!KM=*/=, !2(] L7^L&D!1A9NK+*__R^SA?PG^
M2PH6;-!=.$![) [ "T2K05[VWTY[4#J:!:#B W  D1T<H/KBVB( T\(&V\36
M DUS< #IA&@9[BMW1#W9'=*EP0=#M;??5ZVYP$QBHKIK^CW*L[XG\\9E5ZE9
M!S%N=;<0-/ W2$PM@.6PQ>&3<E3$%>TV[T!5=F5FJJ-C3.[W!(V/"^@"JW,)
MLQ?(V]OGC._3XL![\]JH-AS \^<(#F!/@ODFC^X:+/KV^^L(%X8JN@%;@/$\
M^\GPV%KGXL>4D>:25[L(5\-WIBRBSFL<@++<W)3$3K=\JEI7NAW]#KOL2K+'
M4H+=O+JN1.1?3L\:[W#DJRL1KY!B0]^G1A0W6A^2$+BP;^  )Q+_B$9LFY4S
M__?KJB5(+))+<:_D'--2CVQ<?%:2(?=TF1;#F!$NCC1>7;%MEP ^N@LR?KTQ
MO]A( Q((&UARI<WJ\&N?S@>Q;7D&TWMSWP-Z(I 6SA,W6:HN-;Q'A$"GX[8X
M,S8]C$0CY\;*+V4ZZ"E,?I^92^1)M94(%YOLZ^-'<074\':V=_C'IZ_;,X#;
M4/54Y-BNR["L"MN('_3M@%$I*7"AOQQ%Z?YY+9!R1=)WW;25T)CRNA8;UL51
MC'Z- [C\L=I,\&:[:US,O!QQ_!>951> LBS^HSS8T=ZZ%^^#,90HSS G\T"V
MO:7B-7>VB[@/0#H REFKJZ7_4SN\V>P80]GK' ;0+R>[F1<PUC_A9GNU%*?N
MYN87)J.(N04>!Y\G_CZ?6I&L7S)3;EV(Y(_F9K-F\;Z8D"=\MW,D"KX!6M7V
M#ZSW<,M"I)-RI#):?.T%CX":,(0.*+:N9038$@X9;IY"07OOWKXRQ/1^](C#
M_. "7KG!1VFTU+OR'[!ZPK'_(LRIM>WW^M/#OM!M*J>+,1F^D@_H8Q3(4X\S
MWO1*F+>W0V'S0MOU2:M0F&381MR+@,:'_G(,.@_U"@YB[R.#X&G?JTM:9AO:
M*TBBH_N7WH-N-M:1@J_G0=8X % -6$/QFZK@JM!V#[)5CI#<\@.L=;(MWDB#
MK&ZAZSSQ@XTHT()EYMV2N(M""4<KOBHWMV@MKWE0Q-6Q6)5]Q_G8DC1]KAK;
MSL]5",SS!@CQ(/ZB@H^MG_ U=0M@U%1DWY$#P!&5V%#[)!>JU,!*DWA^/E@6
M+-CX"B[^'\.\ECUI4KS+8CM"P ]:U[:?I,KK*0$NI9W/4_:LM)H&?W\HT29\
M [Z[Z"I'/4C^B .\/QU;05).E4P^NX87B^_)8[7*G_IO&*89DF<7:3+1:Y$@
M4TV5V2!P,;377P5CVA#.HMSXVEGELK+7!8571^PAPKD(_F]A"I]T?SS&\Y#H
MAV/S;YI^(J:8]&] D%)6"MC6>8&.<9NPG*:F6OT 8H<UU#'&[66\Q@])V=HP
M>9JQX<6FU D \54)ON=H;V]7[3W(I["IR_SL9(^<!U(-NE'*!:4?9YSCSD5P
M "+.<4.MW1:=K^Y38N@P 5K!_M]6R+13HZ1PVZ)G)@RIIIT[:583\.>YW+3/
M.&BX29"]NK6)DV<DC^B1FU%8V4V-BE^$DO!?RU[J,QTNWY^%Q\7E ]#55L_3
M-44U?1L[JT.?Q >R>V\I\@ SB79# _MGL1N&2S-TTL*;T+&^_CQ9B_=M-'FK
M9URC!E^W'7Q5!=K?PP1^8N/3D3XV2G^G^D5@E$-8?=@EXKII8WC[>A;/ZC;E
M&T3L:E;[3KH+HM)U_G79)C.-3EKP\<6XTXX :=) HMVEO&<%\ 3(8_5!F58'
M])0;'57*/]8>$ O/HR_JG<5+0*;-5TVB4PW'#9,&FKX\S?A>G:S>]NR&IX *
MKQ]OJ/=PPOB#2RCD)#\[*H/^M4A+990>",@A1Y0??CVN^YMY^!VAD+>N!,W7
M20%2BI2G9[3)ZF#=QVSE2RN\]IF*<KP((W0O^0G"XX>.L#HIG%!E-?(3]B/B
MX9S(3N !!QV\/F-D#F9U63DP(5([C\\]S=,.R*6$MLR8F8_FS.T-H%F8GF+'
MVU\J/)@.,9@OQAQ>L!;72*P70J;FU2@DX]3R&1*N1A:C[SUI*SI32 &5UFGO
M;.:Z9"JF*2(.P!HO7L_.KO.$)U,Z$;H \.>B7>4M\RDM]IP_Q_7U4X/3<^^.
MCG\&J?85Z8GC!:*3014WE6*/\+>Q%G2*9P9OC044]RHG7>7?ZJ,W6HX$4 YQ
MT<::D(+GA0RUTNYZ,N:YM&@<8$3\/YU(H7;4<?/8'S?7F5HA'9"M+S)ASR2V
MTK!3J_//"H;8Y=%J!X+^M@1D@,=4 @:7*HLX@")4]OB:I$?M?_]82CGYJ#TR
MKJ)CBAH]BC]5 W*6.Q>&:F=\C3_Z$*4>GRSP0[61\[(XGWAV'P=0KD<'HH($
M,%LB1'4V\Q0N.KM@?:NVU@)TUYZV4FW60&S%MP9[0__TH_[I\,) 8JS2W]'V
M"B I^@@H??WW;R=]:XJ2"AW^Q.RG"*OEV6PQBI-*B@;W4=J?^<[A@*;*!L)6
M*6;OUSOY0.+5_3$(B=6$;PRK@[+-TU3E84"0SL450SVR.F5^\&C]['I<YVN9
MD\E>?YQ!EEIY6ZU+UJS;FLLC8%)8'[T>Y9#V.,9J[UA[PM\T%I9YKW@'\.U"
M0M8R_8C,PK7KP%_5JTDXLF(EHQ O?\4@R^"1^&-S5C<W>=:5T%:8WD9_%HJ%
M8<4G.IW+&7QQ_Q9/A[BR+FQS]1":OAP<RR:0;+CC$&,W;T(W6P*FAEL-#_^0
MVSTGWH=&?C[5%G3&UL,IDLKW5TW2>6AM]^Y4II)"23"Q,ZG%#PWE.51,P0^Z
M(A^DN+*^&*Z3D YVO7W_.=$\:+YG\*WC3Q': B8?%"GKMX\A79.Z= 3R?1L%
M\VS\[!9DF;K7[F\>9&(S;PK,AHLC,+WLF-M 7M-6WD/@$RLK230ZEJ+,]LA+
MUBGK:9)#Z6.-I\)I[ UBLF7W/<**MG& ^3#_%0EGVO)Q]$!).Y%1\;&#M::K
M>>"\7@'^VW.4Q$Q=[46UR)5^S+GP0UJ:2!-#T"!;/1*-4CY]+,H]-8[E+S\M
MZ%K[K*1O*+)@9;X+T6Z/"8IF<:WH"M*':/9!MB6(_J#>OI ;8;@N5SZP=CSQ
M0<:*D@^&'&/?PIG/GKS8LS,1V,L=<2,%SN.!ZMMR]L7/RE>Q%.E*S6LK*=3O
MSZ=USND6#M2]X,>1B](^*H)2'\L2!U-:0NCXK^<\"V\RSD19IXF1_<\_T7>_
ME%/,E'V32EH:,JE6*B=1)C>ENQ&8'3]V_*3_R90TJ&<3 VYC<@#248Y<N[,N
MT_@/,KJFCKUT4<- ]H\$TE(0GT(#';EA&.!JL'T9/QJ876_*[-U8'AHR5L$F
M\&T)X;OZ5(,(H$G%ICOT+\*!SV^B][DGPGXELJ]24U"#5S[F>/W8F?>O5-CL
M%"L24(H FH$+_P2[C5?<LH+96\ZS&@'PRW\T D[CDF/CQI@#G7\03HFB=%/C
M0QA<WWV"L,OP4( @FI<&<ZFJ1(L=.KXHK;->GI@QY=>8<AFEU"J.1^K.3&Z$
M?T^;V6$NIW4^I@<50A."'_KGU[Q L--,EVOD[Z:<'.ROG+V*CL>4DSC ;Y1=
MSO4=N S&Q1V![;P98,KO+: H5#U()IQ"&ZT'G=--Z:IU]O?[A=4+5_9O2;%-
MC'<AJVM06=8G6@VUO]?;EU:%F]OL+17;+HQ']P;_KOF)&;%P7<^*I^8[%E='
MYXO!.6EJ1V1_9)G?VCKR_\0^*W%0+C(P5--_>UYQJ.T^)AZ@6U.]-;-@;)CH
M])WZ+BR4N)^K/[G_ZO5=YR)B8WVSEURM WGKO,/?; 9]O6CVE[)O;W!FYWN@
MR_&KEE9;@?D4I=U,DS^%^4P?BU--LY\D$+WX[5.WV2&1:%Y-<R]6K_ +(BX"
MD0*E@W7W&?0T6]@K D@EF4KP+D6X+XF+X.<J"!MT ]86 M/'9))WMOC@ (>>
M*##F#GO]UU0&\L_J54'#P)B/LB?@CDL0_HCK'-93W05CNX(Y_EI[0\XJ6S^_
M4*Z^M#5GN@NB@K$N-$WVN)S[WCC7%6O'M5P"?P8U&.$ GX9Q #$Z9?OCL++D
MJF:2N:Z&[XWXAZ*2M5/3%N'8DF .',!<IAO+C+WXYU%]/3'J/3A - [0RX8D
MKDI J)WO[&[^K$6H+?;S!$5YPUG/1G9R7\263HRK9!:/Z)7$<%<,[S7Z&?[^
MEJZK+J(ZWSI'LC&&- Y7DO(X]>PN#':DP"LL8(^Z(L-C$W LP-RLRJ[\<%0H
MB4N(I/PMSXFXYD<_Q9INO@)]E?7A3;R;7* +SL5OY[>&GIT-3=FQKW1[/A1]
MJVP7T\S_;OQQJR;#.Y2I\9'+3TE5ZXL&D'- TOO6W]\O-A*4#&D-1VKYM9]<
M<9$Q.9;?3&;N^ .+.HBB?\_(EWY$0)()=HU8C*?<<(#_U%CG.!JYK:QO)2Q;
MZ*_6)A7'=-4[P\7M0'03AS8AU82LIE'W6]/D"%?XG/=3M4L>" >%IIBAHMI_
M;:FE\-_E$4'NQE]AK3R5K[SM=]6-G8+"Z&SUL==50(C!P^P!![%]6_[V=@K^
MIQ%3?[P-?[OM4PHK/G_>%-?\B%]>7\U(4[)D'BYRQ0D5T./H\:A)*HQ@'1[9
MEF-490^7)RJ(2I9_+'_(=VC[U)A*OI"8@'HWJ-4S&C+*C?@4<K+<@LF=M]!/
M7,$8I@ATR$Z<3@[F/GB4?C'"$3#T9L9@S]MW)"2KJFQX5*WJ-<?#[*5!1:EV
M">-3RJV1H6]>QL-%_<Y<@###^HI#E,=>;N^H7\7]\JC7I6'?\8!YO+#I+Y?%
MV(>WZ/$P;C<!J)-'4LVJ16'#S9JAJ%FN^"QS:\!\!]+%-;.V8DA#$SPIPR#W
MZW(@,<-:SK+@9P_*UO,@L?^#%X-#0CXK1S0!TH >_XJSO/ZU^N6DWXPYA20I
M%V5#-/=E_1O;+;8?P&30!%MK._';$/>?IVO[B%69X,R3D]9G>VO7JWJ$@UO>
MQM\,+I\JZ5+W_&P6E2MZZ4?G^/XGFZ/4\!4%E"HGU%2#@$E)4]4!SJH>Q+<J
MUAG@3.;E7*&W/AP9'G$8&O2/G1&]0-3A %,]1U8W,E.Q.$#Q5,,F<ML=!SC?
MO(WXSYB@0(QZ[_]AXI!_)CZ&B$=W]=FB2<?>-_XCO))FHDN^S/EU?6 7CQ&A
MCYCEJ#%9V0F86M:@X9(.YL?GFGYWD1G#FC<BZ1?+X=3N9IBR:\JYOB* 0 F=
M??U(A)6"DE((DFM-+#ZQ!LQR/U*5C,1>!!'I;,G.Q!3H2XK^<'>U8L7?W5W?
M)^/;1I_[P3_ 8<^ED=F,SBPY_B%^GVQJ45^9VE$9!P][65%)98Z*K;WJ[ZOK
MFWJO?K!K='EF%TU&0>4H "0D:3,\>4OZC@%66:V>0W8/]%WRE94D*+-\;&IO
M)N.X1GMTO3QB=6KEZRDT==EPU=5WUF/,M+"EM#B>DSH_XW-<D'YRH:,RX#!?
MC&#SD]2+EV9_?TPP=9/,,^C<OLMWG+XN]EL^6!XC;;D]FBNM/I_MD8.SX('H
M^E[Y]T_D(W]#F+N +)_'_<&V.$ @#M!-R[@V+Q64J7T6P\R97WNY:$!-*_GJ
M=U>;A<KBED[0UV"SSK-7IR]%!UNGTVL)M7T(&:#9+-R-3:'#AC&2+BZS95&
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M8"(I#E'=)$[YWI<^0+A#;'AI7>]DHM?2U7WA-)NFCTG==#_Q28WJKB\M//W
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M?8P;]9OS_9 P8&FR<%@T<]SSJ0DXK;7'DNSR 8_S_W;:*:1M>%1/(@]CT73
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MI+GU2$D6/7;<?AGGA6R3>Z[]+S\NENH7R1IP=E6PP#[RE)8S2"%@Y>;AU"C
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M*Y.Y(DJG:'2'XM?$4QH\EWG%$-(%S1_V_WZT_L'"VL.3$)K/5U-5S! 9C#O
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MQ.S=QUE^%6.W*91UM4BN-7XX\L;&V2_S9QI^1)JVF(/A]KFE&OCO7K7T983
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MFNF,&#WC&&J ?T^D,G5!]Z#&LWDT(#NE$W*AO0VZS9CK?G 1AEQ/H@%_#="
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ML8^37*)3*?.Z@BS.$8&2/VQWEX+8&@56D%LLBNB#@)Z],\5?7$HMB&%?A-$
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M[,BL?T?ZLWQKWQ=D:-B_*8"<\7;5NW$F#.7H'(:+0WI>8H\=E(M-6"(W,]
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M..P3%4RTWEE<LRX@YB/_YOZ9\)P67MCDX"SE18)J^[E9Q#;<F@.,,7X+2F!
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M8:.6VIUCF<6L/),L"$AYC;DH5"*)20A+1LC6H?;&K>PE_P:T)O4GJ_T<%NR
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MN_LI&][Z8LT5M+.YSTKP5FRJGI8RK>3IA[LO$G >/?E87(30XT4"N,Z^ =V
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MA. 'WP@UZ^]OXE4O8-A"7B0WG>I-AJW3IP4#I0VN3Q"G?F%W,JW<#!81;B2
M _=>F5+9K[02]GH::IA3W2GEB;ZYPI<QN;BXL0C#TFMY]&4B5]:SRR=NO_'
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M.:T&ZOVF'687(LU[<D =I+F TV%-);NK,+32U6+W99CMR,LI?")[AH6)*MB
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M)4WQ//I9MU%_29N--??Z=TSJ)I]3T0L?.0;Z(D&7D(R2["2[D^TF$]G7G#V
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M<90#\ AWYG"HLFG?)\+F7E]M(J'S]^>B(2;N'ZE4Y$%36]N2)J(#4[).ZQ&
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M38B<[E,9???Z'0Y3\B:H1\N/=E"+#"M^R8P61#X%G%<  [ST.MF1*"K^Q>[
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M8O5;]5@34&@(1.@NO:G QYH9U4HU!*F'Y.,_'NL[2_35 *(*:FP 2;G1\2=
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M\;]R<;4^,US^Y1(LZ@(R,[,M*TL;Q%7$"U N]IQ,1' ?(A  3%>%VC)Y4EP
MVCB*S&#Q&R5KBR-8'\Q?&20N6FOV%^F4-TK?C11G[3?;OD5_C)QP7?=,)?/,
M7=]?2='27Y^O47O-(]?ZT@F^"6H<4\;?_VTR,PJ*W$ZQ3GY+6\,YO_">ARGZ
M?2 ,VT?\P,2A1.!'\JV[D^OH*R_7=*LD;2(4C)<C8>ZSK1M&%X1?WM_NG.W\
MG=T<<G:)SOG3(=KLN/ZC(QI#J;$C'"?IY,T;23FTU-+JWIEIA?)"T?!"$-_
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MF8D&?$;UXX&Z7S T4%U["RNXA_V[1A.:4QF"[:CR$S3Z"-,I-\95EU<&YY\
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M\>Y9*S)CGZ=F7P7O2$W"QBV\TI. ]:.<(8BI7I[;Q "A\JXL%6BC"R'+T$W
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M')134U.3H^K'D! GYI#'(^J+BH@HT)(& P 220*O@$G:;LKK&K(>FL\F'Q-
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M^:HT F+H28<VN$XC1*,%! F*X^<WK3N+-[<&_"/0 >CO%336:ZD^RQ(-JB>
M'?O51P$-H[CZH::ZD+[DI@-M0X\.;C$3 L7=-F PQJ'&C?GB^8A6(&KFW<D@
M(4^T<4YI2J<R&^#OF^+9;[:'9X\YJN7S>2[1CLDSC>WO<@5(72EQ4U]I7X.M
MNK+VN^-XH7;'/OZ,Z]XGW_?\:]H(^;&9=')>Q_6B3XU/Y2/?A;W-8$Q0*1@.
MV1C'1G:KQG\LU[*T9Z_94B]6%1OHB*N'9XX'4H-EUF:553"$IUR4,+A<!C>6
MZC%>Y"60EBJ%-AY),%?G2O0$UA"KN-+GJ059DO!C#^QD)4#7L>K7X*WT^X\Y
MN%5]05#=J*!-?*D,"27V2T9!PK+Z>^^HAVZ>1J Z64VJMWZE]87P=)V4,8%_
ML[GRY>5^XN1?[:^^^J&2JWF[PA+.;V#V(JDXY5L^MG$<$>0E%JGF5(T3%9BF
MULQ3^WB U]_I_*NB/_&Q:_)!TP@3;Y\ 95:93X"4M>7EMXP&@*9S!LQ\IGQ7
MYFUIIC8,(]8:,K#;K&[\<JIBXBA;;73+[$1UBA;TNZ84^57V,I;3>\*MR?Z%
MXN8816I40 &^CLG=SD/C)5S4H[2Z4(M#1O^-":.5]7@EQJ]TDQ#+"W0BGSM_
MB2QC,^,8>X:IL? ;4:P_;D?GM9YQHI^.!%U:,(LWQJY\/,;>O4L[?8=4( ":
MJEY*'7&]>MQ8; RBV"?];<^_<[8KT58U:E7D<,0(X# (F*VR]YXJOWBS;GF&
M6Z=%$UM2X$UK@LKK)F?873K1O>07(!;!_($Z/BU/OD6,=@/>^CV_3)R\DSTH
M*L"?Y^K:ZC@G^3D[EZLFS,,<1TDO*-_%SJ1Z0ZP,8>SH9=+F3,'2%E2S#-%^
M =MVRV#L7?@?NV18 R-0<]QV;%H7VC#YBM\\<633OOZ6JBD5\0WNFQD>&52'
M<#LDYK6.(1<R+WS$"*_?TZW#TC_</7?*J+2T>Z!),JH5)*5AEW88R*#Q=I_
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M5Z<#N67OV:]/@'[WXK/1[.^K@EJ5C.QT,+#2) >G$8G= M!J9ZQX6U%,%<S
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MX6>/9Z)%S=?&B;1WY/P=M/QOK MR-@?>4F]@6[ 7&SP,>, V/\U(X)Y9OO:
M0?(I&F1_)L'J=0^E?4A1%S=\F^(^)6&8O;NP^G19SUU$]=/!T=N7KMF1F"&,
M];/Y\.[-W@)"6WB^]IL"CV,6)U[GCCP7BY2R5Y14;*D_Q)/(R1MP=43;Y)=$
MN(YIAL[#6([1[VH7)P^4?FAR,#2D/'I(3R')P!6JSH<Q6%9W']*4B!V('N+\
M-JVH]B"X)8+P]!(@K8X),3%(AG$$^H-GQP4#O.%$ R)9<I!E]%::)4&LS6,Q
MYI#Z\1/,#!Y !0@E1(^&MY +O<(#*L4?S;:S0*[^W@71 46"56%W=;1Y8)N"
MI*!)[,9T7(V6*M?8!>P _:S)6H$01F: #%%Q0D)7[D-![-+^Z?Z^RW(^QHC1
MM7CP!"YS2)@K7/+J*,@!_"-"P;)Z[\C1NU,@3>:AZ(OD](-\>;!PDN%7%M/W
M#V@5\MM4]TCS3/S+G&]PX'X=SRL._FIV%\"QY3EKMIX#Q8K)+RI)>;ASV0P+
M7Z T']CB@>2QZG!W>)[S=;TI^WUJQ?$H<V3C8T]NX[10F,.;-B+NIB#KJ!:/
MT? 21^3J5I>R*C;KB&PT6GLZY1NM"Z/>DLB5CE50YB1KQ2^=/V^H>$DQNIO\
M&&1IMX#$'D/)[5@_C+S.973H,8II-$\WG(R!>GC* GJ(!Q(#ZD.SC/O[)_-S
M?9POA9Q^I:*+@%6<('K2@"M5O4N*."%\-\]KL.$TVJR5X,+_5KR0(TT)O(*-
M0?9)SS.!)Z7AH"2I:TMH$UA=>><"7:Z1KW5M&(VG)VPIMSJUTFF23,J&P#%>
MV,!]-1;)6TDU(S]T1V) ZF.8#,6T@FOW;)D^V+4J ]OJO02]%0_SQ0.A^39]
M8OQW8-=Y<X"[B&2DKPE=H"]5KI;W/FW+"D>/O )M\Y02ZF-)+]>L<9P+)6,%
MM,IJJ-$79YIV2F$I#_% '+7WNRU$0=D;[37_^ 'PC/EQ5TO]V&^"$UE?L9C4
MQ')P=>Y"M[37+[!(/7RL+Y8YP7P;4@LY7=1^VUBT]62,A&?W2OH3V4LW9C8Y
MA+9WOO_[7ZPJ'K\!#Z^3QV?%MTII*$\86].6K..E3F<IO)>M<M3.S[3@DIDY
MMVU4$#ZMS01<!"=RV(FH0BM^@ZD84!"J;;*\Y:KL?V KQK\S &9.N)5)S9FX
M/V^L@RJC<IZ%HMP#KRJ<6+W_-06P=A#*!Y40-70*69 _VRLI]=EGCID+E&N&
M!J':VU%QC427L\?8P*N2DX7PZ]XJ/PY[5>;$ZG&V5__?(B$6(?7_LV;]/^,9
MM?]3:?PG\+]+X'_P#J1Q$-G((S[,+.[MH ;]7[KOFY&9)A_-%XM/.<7F@@3]
MSA(RQ\@AWD%?N'P_,4$*4(S8OO21]VIZR\.BMYLB\N78.%IM(HZV<_5D0I(Y
MQGZ&\6LA=!"/E[[!3A?WK=8,PI<<%,!O-CF%-UYN+3<7\S]\YMA>^&7KE_1,
M?F0GNCI'=;$A^JWL$XXENA[.&(]=[_>>)*.;CAM'>(#Z7)K')1SY,(FOS9V_
M5@)."DT$B]TSCK!*R@IR7+=\%IPS67^^@#L3ZJL\OQ>8X33I[*M:-O"6WQEN
ML';A0+0^]G:L]^X(?3%)URRT8F/Z[8^'# ":O7;&AG3U1N/]#S@+:2>QR:0=
MQ_F$*B;T(G8?A9N=8?5,']>4^Q.7*ZKR7(]?IJ1C#)ZD9*%>/RM6!\LV9PXB
M*0^L_LT91'<E+78)-WG_$-U.OWTS.M]%A(YWC56=8!4+K5-U]^0;G?KD25$$
MXC2+;WCH3LW^[7!S%>K_4N4+-D,J)],6GJ<^(%[RB,Y3?^P2,H6#3)Y^+Z$;
MIS)(#U5H6RTZU%G+:(LG-ULC].&[K@B/A7;/=^UL@[4O6Q<26M!$*^YY]BE@
MAX2M;18C2\*P0I$>KH>K.*JA58QLNDK=W$>=3VASCX$ %\3;Y&[J?"\DG"/E
M]RH\C;US:VGK+G<'K/!J$-$SGQL7-=I)A!M2==U?R2#J+NW@SBD(22VZ=JPB
MIJA$N!,EY<QK,JJ4[<=WJQK0E9S8DMG/[#-UZ<.C"/"QMZ6CBW,C3ZR!/B>7
M_B1#T>K1T97T$(/2,SBXZ?3OTMPL='#7JZ=6=ZX7]2+Q"@)3>L(L5/NC!I5U
M>\W7GRG:C\BZKT5.S\Y3_($94]16'E)>1[,4/)6*!U[MK-S\+72@9G9! YG>
M9/7ICVFN$FU+(F&T<[]!(,XNEBGGS0'[D:_A)CCR,3=-24",K$!)2 OJ&JC&
M$DE^1X.9>FQG^HP[2KE"CK0_:QYQ7\%SP.:@GZ_D@:;!I=\'K$SS>6$ZT\#O
M=_G=XE!:*OL4&9B6!(W)MTP1+&2ACR>Q<(\=IL@/[I.6KHQ_2K0T<-A-^HN"
MKCNU*/>2PB@4/N*".=&<^$:4_+6BXYF2(,(Z6RX9&Y@FKMEV_\H7+1S]=U1"
MXJ<1%U"BF(-X _K+JEPVR[A-3_?:@Y%?Z:5ZBR%]0HQ7[P/%;Y"*7416REI)
M4,?( '-+EDZ(2<1,&P4V;S5"4W"T;8)C.RN0I@BTHWK:?^?30=N%?IE$;4T[
M-)*(3D^@8H<CM<=$2S.8_>.6K8?-6_ "'I!#G0R$'F_5UM0YC)8R%J4[L=HR
M;&?5Q&;=8?F6(+*;_?X%S'IZI//=Y29#< _%,&P#R<B?FQB2/?'WLJRWMF=L
M1N6KR2KT2E;73,.3O\;"8[5C0^L'N6:;@9 [^6C;(7H#YDIZ$?1+VG-E-Y]
M0:I;!_;W3H9Z'$_B20^=Y%WVZ\[E9E 08E\.F2,37IR'#<W!!@&$:@P:3,"'
M8PP"_*/<17#D9HV#,6@D"*%]UK.8KA+Y&I*\L_7A7>PT3UUKZ_</E]VU[^WM
M.0U/)'8ZK3$BMD--,=%KA\=;X.$OZ24'DP0>G7_SH%J%0H;=61(0<W<_#*05
M4:LA*<6XU6B8^_(&OY?%!,R!6NY[T;89C>Z &CQ[C/\&ACFHX@2;;JYU$,U$
MD4GL?6<^K<?3Y>V)G1Y_'M+_)2$UVX\'#Y2\4N*('AHG)'/\(LPBKA*4IR#]
M.??\C+L0.COR;F3@X6[BE^#B4.N/)=H9,I>A@IJ:?!^#D^R>U%#6 G/6X8H&
MURT6% 2SV\N\/>J+0;@I=K:&K1R:99LA[KH\TB)F\@NLW99ZV:>F1U%Y1P@/
M,("T79)18TG:Q".XKT4KWHE;1]N:0C86/!7=,\_3W_9 \RO0IZ\<( 71MV0.
MI(GVKNR>]=(6BKLHPQ[%^F$S6\A^OE[=KC9HV'9R*D[O2TGT_LTQ]ND=<8;
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MG5T+XJ<=Y1'\(9JRO-*<U;/,_LE7:AL25H>S]X@O/F>7/WQ(WI.XR50TT"Y
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M0(N6+T2D/JO:E1GZF'!479= -EI1K]6 L(;])>S >UI866RGM8XM@=AC^_)
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MM8N8C5FUM5$RWSXL0)SQX*WOY57 V6KBL[Q)I'>8'S>O<VZ7E?CP!I!9A72
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MR1%5H//V5I"U7":?/U4'Q^EE55.0X6JJYB,#)6N.*H%?7FEQ3?V*K?HJ,=E
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MCZCQ.)\L(O^X^X T"\B=> <(\1LQ/TLU$'^A-]E81IVB1JLL'3E%_1:..L-
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M(B)(2K*N.^6_ S2,SUJ?#+I98S*4[@#3>0/@U?2Y.\ FX\GM%@BS-(Z\ 2[
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M1\ZUP#JOH3L \1'6=(4>G/EX[4HK]DI0$R$ \8LAG1*_EG\?N'0[9<-S"O-
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M!-[G=-762![:QYU?!(_NISUC@W='ZK;H>YIGK)0VD*>LJ4LZ33HUK#<&%HN
M[)G%(<PD6B]D4T)W2 +0KZ_<L(C1H%\$0 0=5&@0>TY'T6PXC^N99[AF:==\
M/1USW_7!MP4CK )-RFOAW(!W^BPTNJJW.)(+.SSDF 24)9=]_C;\$W*C\.9X
MCS 0*10OX5.7,2=NREYM==M]13,U)KM%_(XL<Q10,U:UYN4W]A'!A(=H^T1B
M%[/!)"=DFV_?2\96LR\T(J#)%?UG&@R;>.J("';+V/Y13GX5?5W>:/ZZ%]9;
MC/[V$G/:5*73%B:?W[Q[KC\73F[SU$DS\P_@&)#(BSSC: YUE;![HB)([?SC
M(PE2&C"JF?G$H('EO_A)?O_RXEBMB #(*+7==\,OS<<V?)4>Y<"L%KVF%]53
MQ%C:"D_N;3V-Y''8LIF[T?ZVG*+4;+1'!END[;KJ4O'!)-,Q17S4A3]BI'[C
MA42@NM&G[!]8%!;F'47I;=<X4X\_7O%@9?0FP9L6'&=NP,.4[NA14LVUJ#'7
M^?":\KZ]^\R++-,P6UG=)"2RO"P!(=:V65B4\'!:C&I"(;RHY'E#LO*T?J(#
MA:MLC:>OM 5M%@)$?:E[:2@#_I2T+3=^P&ZDI>+9>WT7M0<Y!H3(0QU 0^U>
M07E7M;6@3 0*LG'OJ' -IO</E"@=^MMTMV;G=7-I_:*]1CNXT[&\EC;0FL$0
M'-^O<&%JP2C@,K7!6%J&UCF[]\3A7=&K$2K3/4IGL<^UK]EX8!33!("!R(/"
ME$CNB8R_XTMCHNW)"TI0YIC*T5(3&IPXL>-C!IJ?SKG2#H5*A^ N+^#+NF4B
M]PP3WO;]J"9?B-:OU9-4V&* 9/D>\BQJ/ZVDD@\E:ZZFZ.1H)ZZ2E\; ;J="
M&_=C?D%X]MY&3:2VV78A=7E8KC'Q+VS/S@OS$L.VE[%'D;:,Y7G;Q.@Q8G)X
M ]1]49H N(O!6X&8VE&KF[X7BCV[)FX5NP=)W:R>V2LNFL[67F*W(NL#_B#7
MJ'6^K3C&BJG>HMJIY0B6CA!JW1BZOFL)_S%UI$Q7)JL3?[*E8#]D:)"BQ+\U
M4?=4U-J$#/@L'HSE1S\UYAXX^/2X%+@O R]J_OGV\S;[19W_5 ),_Q2AP D"
MF(5 /&QD?L,G6T 3<"P%/B35:_O@8Q "RS]](V%D7&3X/<\UC]\,VSLZ'AL'
M=&>;^WY*JRZX]_,TNZ3;7BWYDT:3PVI96G)2L3Z[*8?K69R1V- #G=?KQ)/;
M-J+'2 K-65W-AM/@D9A[<X]4<>^LNKPY#,]_P9Z5K^)I-Q,K4]9@O5BSL,OK
M9RG+#.006?ILSESE3<::HFM>WLM;JR>!L7>#:X&E[K!BX"43%D?EM;W_$:9
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M5O@ @'>S-WK%N?YW>('%_\-%OL"J8.B+PM[2]Y>H.<GE; <8"HY>ODR0/"
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M[6Z\+D7ZON::1TF/4C[D\FCGY>(HI 3$00 0[23/,5;,>B]C(00 [;G0-DG
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M_KZS[1\YSY1C%5D!C*RHHGYE7YY7$A1G0X2K(M4GNYY%3<YA_(H^AI'*KOZ
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M."3@K;(E=^4)'E C<]ZLX/= 6IAK5*"WM?Z8'/2=4J-V_X=RS.#C^T.%DW?
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MQ18Z  ,:6X4:QC4G;G9F(LQMJ;_MG-AH&O4RK8?*8CJCFN\8B5!2RF?;]PB
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M\D72XIO_^>O%_QFH6<_FF.J%CB&E+RYS:EKJ,@3 U])XSBR4)9^S(R]^V-U
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MP('_2[1@V@K;1@ TAQ$ O""L"N)Y]\4O-TI[4U],K"\!(+I* %0<G9K[XAJ
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M"^(LY.=GT[WG\NX4?GIBPMMAPL=_)RD4MRHR)W7FOF4[RD(._P9_19.^@Y_
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M-9^'P\L(Z8[$6WK7C^T2JQ?'J<)BXV3LNDP1(E PY?LBPPVY;-RZ(N7FZ<(
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M_=DD$VV8\>+6:;D=)KHJ"DVO-/F9X^--+%DBP:F0*WH>4AJ<ES+N3U)MBRN
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M0D\_SS_]J?;,&E SZ.Y=5F9CG:=G*V3KH^#.KH9KK87Y_V'OK8/B^MINP4Z
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MA1AK@JWK/7$Y&DY*!WREV##3E/2:WW^9;)*9-,@XC-]5_?T*X.E%I'/J^"M
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M&(]3E&5F2J^\<<Z[_E<C._\_!_[[[*UI<8 5F7WXU> _1CL)4+H>9AS@<<+
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MX1.;>H;A (7]1<Y1-NF*\T1R1/36C[SC ^XBYMGN@QE;PZA<Z/H;FM_A "S
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MXG1?X=L,M:'3?EAR?TM4=AF+=7:O*J/@70KL \DW6=/L@^QS%UR2OW[?CPS
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MW,''2'B;>'U'0JHB_HVS_-3B1;B#77';OM-.^G6[ZLV"SS)9Z>S1RD(F"6<
MQ%_;TSWA\(%.S1#5HV$;IH^'<#:!.LJF['(BYN<^1C%)ZEQ.0N>1VU.;==>8
M"OW\E/F==+KNY'#2VV,[3CJ)^3^YO2DZ>MXB]+]][/%+_Y3 8E.71-$B /#
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M4L;, E>).S>X[%=\,E/0;ZFWOH7BX:)63<I/;]S& OY=VK=(\/&/U)%$L=F
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MPRHB+J+YZ\^9YQ91W;N8@&^_(:(U!7KQ\W<2U10/^HJ.5I08[,H@GXVI3H;
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ME"G=D^.[6']_Z-M)M0_GV]//Y3DVM:0P,>?)28@>6.M]A*X<B/=^ZNQH@8I
MU"-)S4O5XJ)OI#[[^R9!!.C?4O+.?5]KR)(</^$ HQEQ0.:YNUB%8IT+F04<
M@-L?[M>#Y&[X;+/>8'/WT\^Y'6I.K[[5!S*B!L]40#*R4;[?3)2(I4E9QYNK
M"'<2UM=5PO+SMY9EO^E$!S2Z=6N9]M<9[,:3Y!J\=X(21QN%LM2K  A[V=(
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M)2?<]F!RJ@O4U3E<$$K2IC8HU&1Y#3#=#Q+EC.+_\:S-@!Z25F%X!T\"_#B
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M/GRJ/K8=X+\^H0F=F9S'KLSC (-B^.R_"GQB@@,XW[GTQ@%*0).Q9@?Y2$S
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M:E9X=]9B^.HG5]6U;E0(A@"8&Y.3*,LR292S.F@0M@XZFRD<V *EI/QN\T>
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MM.;%HXIBGB.E[;+.6K7M-1 N#'=[\)1 Y -49,,6%X=5"R;.?U^!$L/KBZG
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M^MDS$"ANG7"]J-_*7G/'EO:DL=C:2]8MHVN(S</O$X3/V5!:^I7@:_Z9ON-
MZ4#/*1!CR*_M4QM7VS#H)S!V\YR,WY&\U^'!(:O5[FV6HZM28"">KI-J2HE@
M2_9^5E7<09EN@<97O)H0GKU"B)5D@LU*9;6><D48DX6@AB*C3BJ#92(>S>E>
MBN_*%:R4DOLOVZXJ=7><HQSVMD$.&:US[6' .# /NLEK^[?->BNA;W1]A33#
M"54_C5J;H4UO*?5X+J-K+OBX9TS#EF,C/R8_T"B 8ZND*,G2T"DOKI"#SF Z
M_<DUM6]'<QIS+B]U+FN$H5+,.(W]5)$>?ZSC9E+%>Y__'+8FWMT:Y$@@-2+;
M#ZC@R_O.56IYT5^M$8;7-3@Z>76$@Q]6GE8.Y13T4E3XYG(52LG>\X:-F^E4
MJOW#I\#.R #Q].+MBU0[&ZO#0@<N_X?\9?IS!:NVJQNKF?S$+>,4M);RQ"*.
M=A?[EL@88&9"'^%VF/99O>BJ,6M+L]WVD02.[GK;8G.YT"B.1Q'YM6@SUP+S
M(,WH^L\!/! 9)0W_>W;T7X6768.E6MP^NW0FD&_!1,]>?1XZF#70UXO15FH^
MR1$X6&[LDJV[R>%HG<O/?)CI.&,TDWX3I6/?X-S4)%_K^T>YJ4+8UG>P>K7%
MZ&BXW[4WEOM[%KFN*6E&1NDCD"X7F:$C.U51+AG9C\+41\'U<D6%#_<UTU@,
M?")QWV%%X*LMCE,!''_2!/C01,\4XG,K3#^;XI(-:DE*@4A)NM@B_X)S_HPA
MP'-@VD#GOR[ E_=VKUE[)*W?;2([,[WJ#=D;ZU)'3V-O^H1TYZ/*7\%Z0A^V
MD+5C8N1I2EX5=V*?2=)$N>#)BLS'$>P6#\/T-;7UF,3P_FHD0&K>P:\S9<]>
M&=TD?5"T/DF) >"*]E'-;4\0H(V@([%M:.K@GS I^!'=S''.XOYRH'W3L>,A
M;MRY<>=N=?<1AZBE?6[>J.W^*3PIOY(4I$')D=LNO<G_2N%:9 UA1CNZD!\N
M4I"<6_ (EX,P0Y?ED_YYB6P[\/6(M4A CKS2\T&#)L)<NR)G]<%.D]E5- @X
M).^ '$,LG.^6"YGWJR8LK1R?\KJ#^DSOUXC)AN-V5K#U^@ WR'YY0UC-*X4Z
MOK^:T**RSDC8Z7/Y 16K-5/RIY)M[C_*QD&L?'7RG/QDWF^C5#DHGR<+BIX+
M"/P1(^H>]F67F%.B-=W4?9#.'%D^'FG!^9Y.A@QF?KPM?[94+?4L^&[//)6V
M.6)U*;:FK1G%#O9_C?*.RQW:L4/?'7;V-;-+C4)8DWLT!C:KAZ8DNE2^&%D8
M&DHD<_1LCEHOV:QR%39]+K6?>-<3 4\RF U+>'2Q.0ZTZ5)MVF=-)*XHSW-0
MTTP?#NNYO6A%>](+BY4@/B*75\!,M];N5R\6YA=6XN;:[5+(%N8KW<BYZN%B
M#Y2USJ1CANQ*>W@9.FR=%V+.^J,2'%OU[=.M&T]8.(R-!362V1R12B5#4T4T
MW:U][2;^M9%8;XU> Z9)]M1K:G3=#Q4GR/_SD&K^-N&R#PJJ[2O#[U6@CQ6^
M^WDM3PIL1M)*4A1^A-.Z_VH ;O;!CI'RM'X80)L28;#LM3-:SW4,'<2" 22
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MJ0LP +%]X!X&X$F/)*%V1^:;H.>A>SQ%]#?TO!C -L<::D?]W(<? ZC'"<<
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M;O5KTE0V7(@RJ0](JC"-G2QI.K:B3+O_6LBE?:;Y]6)?@,.&0I&I0C><(9Q
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M&UV>)M/U5_UYDL'T4&0WWC!8R]\ZJ2"5<3ZY.(HVJ,+Y.O0_:AJH=P4'#RP
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MO.5?.RG<%^;?E6+1&G[#:E7-V>STN[A6P2N:YQ'-F/NB8UK2)A'LDD,B3R2
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MVN(].-G_.4TG:7OT)=W4QUYAJVV("-M+QTW"S)GDP\\1OJI2NY&..$&?PY!
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ME%=T:[KHB)Z(D*E@IQB1%;O%\G'W1[JC7>B)A9DE;B(J%I?FGOOJ>X#B0JS
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M &:4,24K.B">80"VMA-K"!4,X+JHZLKPJ!E9(PY$*6, 1^O"RIT-]WTB#,(
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M.0&F'P9WCKC+ #^K 1@ .P:@JZZA]VOH.OC<YW!,]G'=X,Q+$,E;P(::PR,
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MSWU0U[$]QWJM,S"1EE>5&67FJ.>Y^-716_:,H OBT"P619:8\'58DM+!]5
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MMT67O"T^O-Z #FJH8B?^V+ZGH09#I+V-2]^5!>H$$<L\]JS?SO/:"%'*F<R
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MJ[BPLT5VT7H#;%0[!&W$"AF:[N?TC"*"3F-KQ^]2!1@SCMD$OIU4UIAN7;1
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MS+8[*6P:RCE0*,I$;$9@<Z&1^>?=4GWQA7+/+AC$KC1!HK"4K[ .+['0T8*
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M=R>VN+?7D/ ^"5X-\!@;U"\ZHV#Z2_BNRLATJCCB(%$%N'-:1\[AW5R^4\V
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M36>%R.?^+LTQM$F==2C1M(27+V'D%FTMC]3*CI'"'2PGP^+([AX<P K:=]6
M V25/E\'@8[!&Z<@9)[7R?S_H?=L[1ZA._09!N17CW,_-P$9^"JR-G0'F:+*
MPBII"B[?<.W=?4=\U0W[)=Y,58&^&LBJV[/%/(:^.957/A2>!_5,',@)B:OK
M&^J2*BAIDJ^;>T)KFHG=KQS+I+=H'TV5)=XHC'JD0=W/&&^%T0XEQ@N293O&
MWY A;@LF$5Y?]B2#?+LOJWK2WD%_@E;PI4?'F+@L'?_=PAO."CU?M9F^$0'B
M?H8QU.-+](X3VNF3GHS,7 JPXTLS#K,PSF.E,'_\[*I%'>N//VD(W6))>?)I
MF)O_"<]EBA%AN_&*N_VTNS^T6?R?SLZPE',9%B]9W5&L!USAC<%"&Y#6GYF9
MD9O]D2C^CN#3L'-IA6Z\<=K&E%7TL!J[<.>4+^Z9.5P20,67)$>$3E9X.VVH
M6$* P+C>?-<I=\*KE;ZY!E\P['_L55;1P:KSPNU2^MRC<C@E0/I@P!_"U6C#
M'Y-&Z6Z9%I#P_,C'7QJ2J'ZY72?X89A67R&.5F3PIE:P2%^X.%/"6"B ,H6P
M]7G18.)@'Y++2,QW* K.%5#^!HBXH8>O"?<;=;5U#>C<7'^5&TL:YW*G78.R
M/Y+X:Q:Q0T,^S<#[890,?#?=[W"%"CL!;+X0/$YU^!N:.G(F%F(=HLNS4%IC
M^KD*WG4P1EA#E^O"7J[+^E1$E[77)5.$MPV--S)A&1@CGVM%!(5;(%]ODI7B
MW?Z@8.%BRD7"!NKXJNK9'M>TF-_0]AY7VM!OST&N"AY\\;NLGL);$M\OZ#M,
M V#BNR.=)!]:08\#!.)/-LOKL@M_WXQ'A\RCR;&;E-2<2 <C2L(Q8/%;=,H7
M_+QX*_> QW12LJCZYVD(VYJ_H'Y:'V@B-7LG5^2. H-V39EVC7N($,'\U'IZ
M7];5>2ON)UF1<Y2IS]M&# &."=O=?X=H6J24EF;FYI=\O;?V/]"'GSV77N^U
M&[]BI1Q)DEG4.?5#= %$P_A138,''7_T52BKI@BXF].GTX4!DY26@(2^,W-S
M2Y2F%6\I54Q7B6GQDL%]&)D)'T"8(! G 5T2,<2@H:"(H$)>R9#>0\*&\6\V
MZO?NIY>[C):,1BEK1L;1!#\EV/<@B-"][,=>O=PGZ[$NPR2#@@Z*OB<2[(F$
M\0Y06%AXVGIJZ^K6Z723"-"=K,Q-DN[Y>Y\2W))H%4RR/SFFHB%6XVF@]2Q%
M9%+PH6:*!X -[^?O/YX>O;>16N'HN/DL+"WL?#*P]0I?A"T[1,4F?HB;FC14
MV-)DB")YFZ0NT1'JZ4/H"UY>CC"34^$6VZ=E?YVOH0Y(=?_X8(X'[T]S$]X4
M$0HUIJ<,"C%Z_*%0)C6\T^S_&MIQEQV<P<2O[F0)3^%_GA!5X.A 2^VC3G"H
M!MS5+0 S)BZGFF A>UC=,N.^J"?1%8D#S!*PPUL0E2/KHT(K$JZ>R-OGL(/P
M + 0+ $8=)Q5Y)_X$:,<0Q*>3GS]^F785-!JU@J*<$K7BE\5>NEWE*6OW[[K
M,JMW@\1F]$97#.%T^:5EI3>;I@\-JY@;>N[VD0-3:"D)[&'O\5)NZ=N)F#>G
M1$MRA?[[U NNFK^.C;&/"A 9I_5757_P1$^]="GQ!F<$848^!@93]&+3TR=;
MOUEZ*/Z%:2ON_(*<T=0?!MKW/XIJZ:2(M!*GD/\B!,Z3V =Q7W\,3*0=O8^]
MUN'I*>WI;GE$P*=]5%1L#CKM)."CAD/'6IEZ FP=0=1*>/!'9F)B2821P921
M: +_E$)#DGP+:=A'P@3-UF-Y^_356'QY[SLD7.,E0UP+\R8L,UA6@P$5*:N3
M)G[T<S!7)T]Q/.IFN9/_%R(9$ NWI,+27(K0-VDT?0T+.("EV_6YOR:V"\^1
M#3CL)WDE5,C8I[3SQPE@2XA.4+0C.M>VON@8>?Q:?D;<K>O45OL@Q)LP^S^*
MI$J!B/NQ@?O,3W_$J QNC][X2W0]6MK/& T->W18PM=O9 @LPH/9;0C4U/]
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M*NJ++PX"='6'5!DZ=7Z LA$ @]+!,P0 U(O!E21]*BB1  A!J,HIC5.-7!$
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M55>:Y;=71H6W ^:6=#T!-TVN(49@7O_Z:23O&<.GQ80L4=>KT[UGVP\3S-_
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M[S8M5>/,< )8(+F%%:,I"#H]Q:)OG>/XW[BA>87=L6_JU_ )"$L"X"21POP
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ME7E$;K)SXMU!*/\'YRH%L3 'R'2O=. ?2;%KP'?5)'ZDV=XUG<:)%:[/VT>
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MC#?C13;>(*I ."("X+1QDP"HBUMAR;$A ()?+^[@((N7@BP;IF4&KSR+[A(
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MB%*0XE_FE:D#%=SHTEYM&!)MRRW0CZ'Z\'2SY;" Z0X8-);MLK12ZKB3OW'
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M0UUNVGO;IT?\5#FF_(Y(QH,^1&,6ESS0MU8QX#I01'F7L7*;\I#*A"+\H!D
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M>_4<<J$B=8^P'IVT:YJ[>:J/_7D/9[44Y4KS@^W%>AUD8US/B\W"%N]UZK&
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MW-BIU5SA&WRZ.@K:6I;RUVC@K^?_(K+]N[1O_2S3E+XX#K;.7R]TD$@Z-:E
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MOW*.L^V]/>2T_&V^V?NW4SM45DL''-@M+=/'R9)H_ 7#R,-8$J^M@QA/@97
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M/)T,6L[(Z5UJGMO-+R4Z4JMIN&23KK&*"3XB@ UI5]8 FA_.2@*7%_J,]VT
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MB9H='XXL_<KOUM5=.Q 9??3VJR1/W(B>SL2Q,6=VNYH*IUO11KP=6$Z)\X,
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M_/A<&*V[9T<P_VPEMZ/P>6H)_A02Y]&=P_EEY8.D0PA/IFN:R&W@?&%+D1W
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MYRWZ <;X2:M(_.G//X8L,3IGVA/3#F4>>\.O^H\5]>)W$LZ]+;UZ+UB'4!C
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MI"D;R/-H#)X?3Z6N.;66E25#N %WD).#4Z% [\B3/!5N?[TB.('0Y'9DY K
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MXPXAI/<[63)HXWZWKZ:HV,*]FQ?YA-<ZBH/0?ZF%4*H  X2V%_Y02W[0.@#
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MR(5%:G[1,O=+LLS?#P_V! -X79YK\9CI2B7VI=">&TO-N7C8'>WY/S9HI(O
MDN8$5E$=7:C;20G.]SV3.MWR\H)XV?2^.)1XLIVR$W*$WP,<L25#U_=\6ZZ.
MG(GQ<Y@.W Q:OPRRSS!/VQ'8LF5ZC?G#+/9P7_(=L0KKXK(&F)I/_^S?4J%C
M,?E.YKW7&#JQ'N,H8_W^R(>/*0W5.313?=5?X1^^H )6!@@T<CSC/W"=WG6^
MCN:"QH9A-P7?E7FX)EG^\!H5=T*"S*]B[#;)?@J\@'2)^?E SW:B'U;]^_ V
M&/M]@9WGQNYJ"5: JG[5N,#K=RP&:1;)2ES]Q5\?G91*U] 'VR^>*G(LR%BW
M]TJ74#/!;SI,:>YTH_^\(6Q(5W%/4$8)<R R'TOLC_7>,E6OS*66A2N.(!RW
M>_]<4.H(4T[Q\NQ[LI4DOU*9T-#.U8&F+\M&Y0 51][LHT[VY.%7*YG;8B"^
M409%D1]#/TQ-!EPH79N)"^4Y,^WPC#6%V":*\?L!684@J%8A)5)BV8C>E%Z&
M$417J%KW/<J+]5&I\.."1^41=+&214_ Y,F\D+E[ZE?,IT$&^@Z^#1?#R^G-
ML<O'#C BNTPH\?LU$>'H0*_P-E_CB!;* :4; &N"B:5U81.#^ZQVK6O#<>W(
MAXZ^&8=?:K!-+0)&5_M.=X+2D.E["ZKVCQ2&0KBM2^EQH28^UV,;YR+O;K99
MB;0:J&>YK8NUJ6$KCU4-H+K3Q@/\IN_!0$DG@O-I2^_$Q&)D"]-[\="K;,OT
MS;)?^^IKO[.I<HXTT>:"1J[LVFXZC=2M1<,RH3T/F064+Q1L2N6=<H\GI[1E
M1E<\#N3_C8[/->W#V&EN0:/CS%L#S(S4LLO_:;#1'PK:0[J2.5:FU3JGSG\K
MRZ:UZ]-E^E)KEUC"%EHO\<OP#L#Z$P_#GE.;*OS![5P!@>?L0&J=%FK>61EJ
M8F-?^U=725=)XLNG/%>)4AY8+<@XX@K"HIP(_.K_FLW%RGO^$MWQR\F)S$['
MSS;T6CSKJ6]K6WA==\(&Y=A=TA1DL)U/)'FD:T./L R%)DQG%9)25CZH$#O6
M@>L.1S.-(\<>,M^H];1G.=PZM-"F!?2E]4FW8X"T*QHHO28Y-P#0QI.28&]N
M:B(G<[/#[HG6KN%L38$(N5I6),PA*C$N$JVG),W+DVL(0R2)UC_XB'6LQ#NI
M#.V5N<  NE $3/#HMCXY&T]7LK$0*I.IET_H\Z/MP97(QN*C5[=[],[?%-B*
MXB7><A9Q&>R\(U(87(3R-*,[NF9N$VMJS\Q?@@XN.#]*5$(_$SS0,X10.>=H
M!;&TV<.S?,5E1C-*DA6<>-QMV H^Q#*O'W^CPK_%?8 >+%AFJZ2J'=MWW'SD
M,5%]HLV!SS%9],N,9L$H@K]SE_@33"(BY@/Q43W\6*_32<6A*:DA-Y(6>44U
M(:63 Y+0KU81%O+/(JAXFL'K+[5WVMOM7STW,8D[F^1:#[VH4H=4JU$)=)7<
M6,4.N_IK4I8PS>S#JF_!E\8OJCX0^YF NL</&]N[:TCN\A%9BIMJ;+#>'VUV
M<1< U<=I#?4,.K1OH55YJ.+0XRB/&61V31]1G=+@1@["T7@7#3*3''_<FKO;
M:B-26JG3] J0:E?)H.'.<973I(#BF1);..6@(L[0C'_CIQ)UW$F-&&-EAEU,
MX,0_%7$N*1(BD;85]O(&U#7!YXV--=L!:!SS@*- _#6L7>TCYYK<"> "GVEE
M=RN%,88I61Z2RQB/)7%'P ;[@7WH\R2@-Q]RFOWMZD6C&<*H24 !?XM;RG-_
M4ELD.)H;*A&RFBE5H[@^ 6  [^WE O]C7>%;KY=-[?'+U2\3J%F2M-%DFM)V
MXN]+\_K?$HZJCN<UY5A'0,9\25=\?7.2YY7Z/L5=AKMRU'QOZ/P7J&$<H.NL
MA+_Q>7-29U1@=X9:VSXH'W+K=%W=$"_(EZ*H*1+N_WL[&+9V$V)XX5?T],YL
MCNW"BN(939^AM*TQ +F.?;J$*IT\?Z0@!=_>#XB:-70DL!3F^@^!_C,"KTZ6
MLLR )10?2$UN3]-PV>G':,7G9/O.=%E,[N?6$:PC+-GEG+0!#ZF%7+,?EAKV
MD-&J*6YV[K)(%2C^_O7]5[_@?:RU),C*XXEXBH2%5E'(:>Y(Q0K-)HG^YR3G
M*N^KZP8S" \#X&NZ&E0BFR_!]#%NNRO0&3RB R4%#&#PP+=IK;A@(DJADX_9
MJZ]2>I,691KSG6P:Q;HYS0'7X';H ^#7Q6WZ-'O[6/BC)?' WSATYPUZ=W(P
ML4]C P4S\[TMNXCYWZ@V_'\IX/:1I!V1_']C<//ZK9<OJ,&\P:T3;^R>=IFJ
M.T_HW?ZB=SDE3TB7JI&&S2#D009:<L9<L@4#Q!.'HDZ[,0 ] ^@V1ISVO[S+
MP%0;"K('OOEG-0 ?F4@553BGG)IZK)QN79CWC0*L_O.T3JHI6>87[CB]7<2R
MYRU#?]2@,;2UU514U,LT@/+#&O;YV$S P)<5NU]*91?!Z)//Z6<B*[R5\S5&
M>_+,:V!(;S>"$-=,XB%>U'CYE<@%Z7]W2?C_16#*$M5V;S\#,0 7" 6&O^J\
M&G,DM35VOXUPQP!"ZQB@_.3<U/VN@6GW+[H29%2* =[8M2E#M@;.7'6MRKE_
MS*'#932)!@B?M^5;^&-]F-T3S] OP:/%8H1[:AY\]&K2XP"5P-:[*QANNP79
M+X5J\+LH+P;C=J?4=7PS<R,FA+P&63Q6@N\9@6EA0KJ]BF]TXS;%C'IQK,K#
M&;]$=L&E)?1KMMLO5M;#LSTVCQ\Z7_>]-@@UPRL(A]V<I?$T1Y"7XPN/,_7O
M=LZM%WOX\?7BE0;&\E&4NV7Y3.K5S,6>A=]$<\N>/6YE0I0-<<<@>6Z5;^VP
MI$%I:,.='L]PN=Y01O\'?JZY:%]WAMV8@P$>AX*0"=6W(6LSQ,C[W'?GVTG)
M\I+Z'F#.=BD7(E- 9/@QL;T^+6MPVVOQG3ZAG_#%5GSE[T)?DVX6_*7@ZS '
M4ZY8*P;.!;[5.K9V.N:X&/,:#-!S@6>P$3W$]BDBUL&!>>$N%/1/:G SK.4Q
M=%LN"*F=^S[DXJ'X="182%RAL JJ-7?G3\)@Q4;)_%O'7^WGUOH-_*KZ.N;+
MHP79X@T_'W$9%R]R<W(1X)BS!WS11^N#]FO_@FA$]+R/3_LY40FUQ%7/=2;^
M9:;8</CQ).JM_M#FS_.R>:3HT^/>0E;Q,F$7;$KF].D?TGW8T\PWLPG4D8'"
M!#J*Y^O!-[ ?,:Y1;BY,]4Q#DCPMK<F(V*0S6J,8<XD:EB1Z/(@Z(O8/[%-R
MNY5K1X02-)4,B8>"-5]:QPXHL_K-NSYUF*<!BVK,Z*>OLX[>KZ94]K.A;:ZO
ML1#4&RYB69Z/@@;S/@/ )YQ/"(73;J?1* 3%1>=WA@ZP'[??GP3?]PTX#>\1
ML**!59F?$_"]4P9A^N<.LKIZ[#0<X4^@W-8%><E*^<0C<_D._-6L^^^DLB>)
MBS6FY(N+,C' RVB6K2\OBG_'"HN%BGM@ !74^F01%G@K3A=Z\2,FUS)&'W%R
M?J]OAZ,-LG\Z0X572)%M_ XKP7K0ED 9ZU. UMUE1#IW='.BFG@&J5I?.4U(
M\"=YR@C-(J.U$FQ/_K$X(M O<.MG99 5E-@9!$>VL;5O&UCAVOUV09 DH"*P
M;DDW^PIYU0>I#7XCP\<L2"IQ)32_*M80EXW: ''V'C(W9TAV\[;?!G9DNYNH
M&R(,8$AK(_6D;(;89"*Q4)YT,&G4Q#:O=_HZ.3RO]K=RCCR#1 P=_],[HW6R
M .0DG<GRS&4N;Z*G:XCQKIV*7K&4@91']4W+^<HUMQV,IWZS]OQ,AJ+^)Z).
MO#(NO,+^V=>&JFE=+,IXQT>?<&D?8(GE[,(KH(O$1)]E^9&>=RU[%"NBQ*9L
MK> /IR\B\M+>A7,4LQ=IK<1:A"DD?DVB+0 XV<@V+"Q_6Q16<@4@LV,8WDFW
M<I5LI(\K5I.^%+M+V@U]89@9E6<1E, 47<1"JRP>::04SN,9B^B5?UOH4)H&
MOGD,3& Y_/X$AA--C@5$OQZ]!G6/U76M#?X/]MXK*JJFBQ9M).<@03((2 ;)
MX0.:'"7GK"3)"((2A"8H" @-C01!:'*3<U8$121+Z";GG!&0V/'PW:?[>,<Y
M=YSSCS/^USEJCU5K[UVKYEQ5JZIWSRNN_8RGT2PB<($E3DFOZ()>1M\"(>-N
MU'EV\<- .[4E.-!4IY?SI(- G_J26PO;XQ19QKB0"LE$*=H&]O#R7S C[AG:
M]CVUQM_@"!U81.QY/9:A&6'W([**+9;  >XU_JW5=#U[#<LT'>>UP2S,88'E
M>7[$A+JWI_O@0\-1!5N&Q#&R>  9(A"6G<VIJGCPAG$IJ\"VLEVX9B*!=F+K
M%#*IQV7)N^?]O.8MW8\^A]BM)93NC,# !FPP#JLV 5G,K1,Q:^)Z :)K8OL<
MK2;S=]W46"0X \KH51;B'A+2(<?4R6G/BA*'#&J'T]G[3RR+57R^HZ4JDT;=
M["3N? 7R"P-Z@=7[-VMTU"C.UZGC/__B'Q^^_(,#J)?E2 %>ECZ/OI2&&='G
MO6IJ<1(**S/D^L1 5MFP,SI#\.^NCC+9XB70-$I'TUKI+ZF=6?1LBO   ]PN
M')ZBU/7&,4>P$6X]8S$Y18#@*<XU7@V"Z4Z]!:@U8OA28GCQQEL%6T7"O,VO
M"A+!4BF][SY(N/9]%6"+!(VH307.Q4OP/(:'D)="82C+'L[#?XWEJEMDFD4"
M$>&.>.]F.VHM)K V#,X.X5&.@;JTK<R\7"^4A6L6T!A=)AP@X+CU?13/;:"R
M,&1_R=.T>F+=XOZ/%H;SVZC18)[CS_F\\5!J=@9IYY\%R90:CNGUJ)?TF89L
MAM(U3@*NT4'V4R7Y9E_?.L__6E5Z=6" GZXU6">< ;T*)PG(8UV2(.42(8+Q
MF*A2Y0H49SB/"M"?LPM%1&7X'QM.?YIG?2ZJTWGUFU,8$JL\&8\*=_MMK&[&
M5$M*J&5@[K*5R3;Y_5H49; C&^9?">NDN\J4WHQG']CM&]R\N@AHM&->/]UT
M8?>4T:5^6OGCC)CGRS' I9M@6I<@<,S6V)S"3','DDM;:D.DE7:/$D$[-!WD
M[V\XWF74 N@(@.  0CA Q05RC*$^D3VO^C%V2ONO+SO/<"LSGN[M3,OSMT)Q
MO$;#> !Y#ZN[::T('WS974)&I*;R67??:0KRU7U+HIF1GBHFFCA5T'D7CB%8
M3)():V2NVO-XE[E04-!F9SO()OP+O]K 3].67)?P=SYWC@"1I=.L_'DE$70;
MW7Q^D&WO6#.J.6E?J\8=>Z^K@_9<FFLBNF6(YS>A_TL9*=UI!?U]]P#-7^&)
M['6?7U8<K-TI"=J3^D@) I\ (WZ8Q]P52NAQ>W1N)04/!^@9+&VP AOL(R,C
M-NK^J13H:&=\@<8!G+U&?^^4SK*+Q:/V[QOE]#Y*HB4IQ(*V.,4Z'-\MII$0
M9&"1V,7!<6O(@8(G&RB#W2#!FJ+6W3XO4DRK PGZB3*G<4WOPSB+92P[UI#I
M-\5M5]PW4M@ ?D?LU*8/>AF56^)9:J<!V "DP#/@[,) E_STS^#D &=2JI@*
MA1,A"]'0-V"RL+.+>I.=M$&-IH-[*WD+JV?&5_@+MKRS2UI1S@?K4_'O<Y.J
MJ("4AJ&!E95<!<K/DHJ%,[UUQ]XKYC3B "Z^/[#SMGAHX/KA,V%57M\U:^TH
M]3CV5XV_W.3*7_IQ$Q4K*&'4L 57-(PWQH,6.$!"K4BY#&$.M>1R*9[="^#6
M_D(VJ2WDK%96K'6D4NAAK%WQ<%LG7@BG\>["8"W!9F<PV$QO0"NO[*R9;[/#
MZMD-PTL3O8I"P(>S\7N*=CW66^X#9#>5+A:A99EK7ID']-P-S]]9V\6C[XGI
MR&[.@T_>ZY[7#W<3E.WF#:9"QK;U8]2@YYNS5\')4!]#@F3/&>UIV$_+$A?1
MRZF%!Z!&_ 7B!?K/YD?C*'86/_0MM_2GW/A.@ 5G%LE^VQL"'_IC&64'22)Q
MHS/U1Q^*'<*3)5L3[JTU]! X+RBTI>?>4QF]" L8IY.*J;3UB>TS(H71)J$O
M[EPNY[/+?:0T')-T8*;+!GJ' ZR('C4_R8*-1DU.="FL+\V:"W%RGS:N":<)
M45/,CI>),NY+P#52H.Q)63(@'H0RBTAM/>J1&;E-(/;R:'@QB.!M"/-&./D?
M5K:T.%ZJC<\T= -7,RW[@6^7;,@$O%VJ^R<MXJT%W!KQK9'Y(F\Y]]0ZD(MS
MJ2LG<Z[T*!W3Z:OQ3@>6$I9&V(_I?BIC6*;>'?/26_[NG%S#N\[HS2SC:%&M
MVT:<_(]LH2IZ+@,3,-XT@LK,JJ:B/C/9O4I]F\>0,AU-&D5;0KS.2V;=\>*E
M:0%]&4@EIWAH=T):<OOP P&[?O.7RMF;B3$/MI?8]J86R4KNN?1#X[\7O%DS
MI *G594R]'PM21[Y'^_U*(&R5-1C%3\FZ?&657+[&RHK%*?1@5J4/#D/;Q!1
M[6BGYOEX!FG@<Z_QX;BR+TX'ION5LX,'*KRN^ R51;=8^)1*,SW#D+;K6&]@
M@-O+!9--=#<5*/P WY*8+#U]8#A?2KF$2ZRU8TL.__"8%:#X3W1+;&DEIWAS
MQ3%/O>!W-"T.</_D;7I?&<<#'N478=LOJVUW#T#U74RNA[/IP:YU41KN2G^?
M!5ROSBY_K]@_L/0R'L=HP*2'#-BHZ1__[+H1VWOT[/8BXV)W 5S!9:IS&\X#
M];#/ICH*3!.RB K>+_;:?AJR"*W--JR_Q '\CH7_X4AY]D[TYOE(XMV 2?DG
M9SX2[[NL8MK]D\96:LMN0V]/+[!35XWKZZG^,$8!W7]3!QP8[G&[!O;8KR\'
MRE]K'+#E11IVM_S*%_68$D98?T@N #VZBSLH[P)7&$]6MX[2G<C@_,-Q:52@
M<$A1I;^Z7PJ]E4?-&NK%*J;\63;_3UHE_)\%MJHK8U=FKXN%9[M&J2'N@2_(
M&@'@PS]/?*#ML!*9]*B5]O4%SK/-RVLL3^H7'&"9C_C;PXA6'$!8=A<'4,X
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M&OE@1WXY::*B/"+H^,@Y1T][Z<GQH<?BM&^J7KGG*.)0-U%R7D2$%$!7UNU
M;3FPN2"<3$V-3X]U9)G[B^](UJJGP'N&/AS8/813,A*6?>PW9//;%-WV3A)X
MUM HQTO\$$WME_QB#C92QL2:*:RN3?J7?M-9);MC28Q7Q, YI:0BM+XREUNT
M@\O1]HD?Z%3M^(GL/B/)YOF>..BK46?B;^+Z46K@53B-@"+JN?7?*PO3:!,@
ME)K&=(AQ6TT6.,]Y"$IH37X*AI1@A8L%%<J1^);I52I/33*>;*+1BL%#(06(
M@0EC%AT*E^("F)U)^P(I6<F^M18".H%-/E5=R^OD^^"M0@MMKIY_&;4V[N@K
M_Z89!:B?=S9*]CA86#3+*LK@Y+,SLC8H#2YR,8-:?9'D 'T'S7#TG?LU>O,*
ML'F='YC,W]9A=QZZI:=X#LCP)IF/;ZF,G_("OV1ZNTBG(?2V5/)T7ABCQDY4
M2I(CO H%3VD4I5BSDWJJ)+94Q\?A"8ZT:^\CL5W.\X_R/_@BQT_P7ED^_?H.
M.SX!,D 9\QAPWL?6ST_EA9I=3!*G;7C9Y89!H<CF&7VOARFV@E4"WL5^XB*@
MR*O13;!1O.?[MF+14E:(VM7>5RUZSI$J0Y?!Y;DB'AD<0$Z?S>/P^R:'5L7"
M7"/7TZ:FVA#S?<:U]C-\]D%AUQ+#XQO^Y8=?/K"8[_;-WEXL_UH5G23YR.%,
MRP%2BGJC&!PU/F#ZLUKM[:E%24FM)CF50BF;@/FZ]=V4H5\AR\L(!WE#PU*Y
M2ZF;\4MY,ME8]*<YPKQG4U_<S:,CY_OXZ<OTF7!1]U=R(TKO;. #Y@\%M5Z^
M<%S0\Q\%$H;>F^GL]$45=]Y"MP=V)V('L@OFR?E_"&?TIAMS47GJW"(]\UY:
MZS((,D+9[[VH-*"KIATX^!@GC &)Z5S@+U@M/?C >5/WH6CNN^L&7MRRQHZ/
MZ:[Y>?TN0C[H4AJN8VDL_-V:HEK14G,FTRTE3K@&:I-O+#2(3R42V2:>;"%W
MOHFM;RXQZ,[;CY6^5U1MER2>*< JLSDP&O((*BBJ;&<!GYDITZRK%1G=:O['
M;D<'NWKC#*V?POXA6&$F](%(H9N=E.^OJ$*(])I4;[0D'/(5C23U^HF,*_<"
MBX]2CE5DR=ZDVC7!F.0A60]\^.BJ#S@4S 3PG'DZIDC/&-EL^[NAY.M"'_%5
M2H/)\WQ(D!O2M_>"\.[(KO4BG.H?OQ,6J/(K"0XA(>]HB$APA;JNX90"^W2F
M$=@*\@L=]ZJGK:@IV#O7^GP?E3^J7<!<JR7D]?<VRE%XNZZ0?G(J -.7]&NS
MB$BQHT(B;5L8.LP\_4:HY5RF-_4Z6S^F^D#$)U!2(]%KU_CN,R7,EA\=GX@[
M-3#VDRH!")(0$^"FGH"10G/I/([PW2>&CEXP/VVA]B)I69&5=%YM_1CWC=U!
MX"PZ@KLC(@SLIP9C0]XB0WAL%OT9*W6*[%+A,!D",MJL[SP$Z &]E^U!9/@2
M[W_N5PGB'UH3IWLXZAM0Z53O'W78MJRXY+/8!+1=>66&@]6];JWB;D/R7X2Q
MJ+%K](MFIH$!MJ(O+WGOWP7@0955 QY2 NB\<?-X:?O7,<I)B;<; @:S8-H?
MT$QJCLR;[E_8SWZ&!)T>J6=P+4M'<\F?/-N)2?E%E(4.>6D  COL[]IM(ZK'
MCT'S,#7*7TOR(J6Y.V]IB <M<D_+0$"QMS4</O6GQSPGW?DM?W4;L[RE1RTF
ML^B6IS5^98H$$ST\('^A*N3?;Z[<GL.9HTQ;VWW2,^E1&UB:A'5>V]R></]2
MNFA;52DLR.GGMQ>B>^KZ(M@RD_!K:8.71Y9^(EO]UM>DJ%)NI8B'7?$/]8@R
M>4_KZ\<3-!P+]H\O$DV^ / JA=6],"SWG<_AA2LV7AOI:#K>0;W)A]XL"6B&
MFF&5'A/@BG+F5]V$=J#2+,89JB'L-U27^9X>WO^B,+!,KQY6> @QUQ%@62C$
MLL@'U^\B\T'.-^(HD#\K\+X,,%-17:[<:JI(>+LBS3OPITG8)K"Y" =X[DOA
MS_CN]:.U$E@6L]>;M FW92$S;L5WM@<FFB3\*1+S8.&*V&% 7L "'8'D8V(V
M*M 0XO7HYUOE$;%YCU__O)]+Y-4OT_]\3:=&D+OFMD469P*/V-E>8NX<I6TR
M_4YG#E<](Q!F>[.J2\9#D$H?E?[LYLKT%0Y@,Z#*D7"^MYN5)=J*OR1%IS20
MQ\9YF@%7/Z:85J89MG3UX1X(TXSRT" J;ZL5X"7K;SG7-2-N8_+W[!7]47*+
M_9U2MB/_WKV]*K= 26H[MH\SX/@@^.:K:7%L%8OODN]YZTIQ5TZ)@+I1^IJU
M/6<E=]8,0=Q3"YFL(E,L[=3++CWY*2_S6$*M4-H^@K@^CJB6TE<C:J:"<7*I
MOJW$[UQL'[E[[VT8O)\7-N/F(>E5M'(+5=U4QZ@S:VI.)$$E?;:OHE;;KRY<
M"?M_!O-5$*FO1?\T:W'57Q-\F&#TIL(IPR\$HRDNPW%=43P%H.^,K)=/2Z8N
M_6AN^6/525D=!W N2VRR_?FCVLZEXWS?[<VB/#>!*<0;[U&<R2U+&E B=W>D
M=-J0<?Y] W/20JE]M6Y' !T&:$)MPERS%,24ZG=S]3U51D&&LQGC?#!@ %OV
MW_DP\V 6T/RJC;J,^'CS*K5 8N(H4/_AJR$+Q-=<@S&ZO@>,6]$0B4Z>5.KF
M9,TV=[@Q4,KY'-U%XB_E='_#6TG^'0]#T6]H3MT;3+@]9:*:HR9'MI\'=U C
M@B]$1G.%'4!C? (?+'5:J.DEZNA 2O8O\'0.KW'0\].CHGXGNNZ@NF/?ZW%9
M$P@R#ZWA_3U7"IPBEFCKB5=6(B6?&7<<D^PW<7M:NF^V5UU&^D+U:RS2^!YV
MZ(_(#.*TSNOG!=^"0FKD<#W/GIG2Q\"*"X9*&&W?1 @_?I-4V"<UV,\Q&;29
MEH%13"\P.]NTJ:SSRV,F8$7$<L'JY:/R:.OU6S32.&+L=.X>D[G$)C>]](6=
MFW4*R/. SU^RA]C!:W2,P<XS35G0BV,A@2];W\'^K+]7L?[8&3[$N3LE\)KA
M"TNU?I0%IG5S )W_V)IE.+<25I-;'I;3(&DA\=Q?KQ.Y]/>B!\7IR9^X4CA[
MA0P/?KAX4M3NGCEOI)2PFTMK;,3)G63Y.\OP>[M+68TM?U%20Z+@1H5%@%#9
MQ7#+>;PH.Q;RX"+C!>6?XP[V0AY3X+,+V#BZVSFLN6U)1H^N'""B4[EN1DGZ
M]SL_P2WMC-YK*^T@2A<-DX,C?&EM21(<P-.>$ <@%^!$1$1<QYC_Z/SW"FVM
M+(=ZRGGZH/*W6RR!#$55MU"5L@%H72QTW.R6)5Q;17ZY4O,LGN<B>IM8N+]S
M\Q 4D-]O8?D1/ CJORCV-PV)I!U.4?527R+>LCZO]2HH:;/W16C62R&^#L,<
M2%/NK?<\],B,;OT6H\.+ [RK6*S]^N-#*XQJI9M:>/6'C!87_4UT$$D]A?DH
M&286ZDKI&Z%=+.WM%21A!/I=@]"W!/4J!7VAQ7Z5NS*5;\U9H[W"=YXO (O4
MR1DH,H6$,'._)U,=DN&FICC#?%5T/YWDA6Z968RQ"/\COLCNE+PZ5992H])S
MW'N5:"9_7KKY'@X]G2VB^0;Y0_<PVE,24]PJ4RN( OHI?J+Z8R?,*YVS10Z(
M&YW+^72D2G#05@LZMNZY037Y5](6 JA-I+ <E9'#9B?Z.N]_QNH2'A1&N<+_
MHD(O%E6""DKTK%D0>5G%-J#ZZ1)>Z)7<W:!<YEN:,4\%RIRCU/:U5X?A=@-K
M'16;BX)CD6H D.)EO_?\[U9W,X L&SY&'@?@C#*(W2F$7^V>'S0?E\^K,[@(
MI^(;*6N%AA0\%?JH_,%?#1 #.[Q!WLGEQ7]3U$<CFRDZQ!CG@"<+3B1J25(U
M%!.(V[-:1F@35"SCKXN3+4 U=8L10!XICN69?Y*EW0'3N?HZFK4,(7)>T(&E
MJ4#%/GD+_/0WO7&-$L=0W_V2?,G:U!KVY)>=JB-IVE1JL-VK$((?>%SD_QK[
M;CH)^?W-M3Y4STGD'L8*!YA=079TFA[.N"6YF47>1: \?.RY<D>5\9,A1?VH
M\46$%WU<T&SC%K4A#C" .;L:$0VO,-T2G)$),6/79>S^SFD /B->QC>9K5(,
MC4W .#>D-C32-2*<?I[2D$.O-E<ZSO8',_KH.<<KX P64X65CU;JJ#G_1.W=
ML"MP(;KEI K"%+5NKE41!Y,"] >".  UK"NXOD:*E1]YA'==EYO-&P7:.I B
ME\*[H%#% 9[]6995/%SM6OU/D8#_LT"]/ZA0Y2(TY !>,_Q#MNS>V@@]=/.B
M':UV;>9)/,I13XK1Y.B.M(J2N\@VWU51O*!R%6^XPFKP0_8YRFOJ:BO*Q'F;
MQJ('LE\K=GH G4/]OJ#"&D^LS98<;-5X(;I')T-6'KR(C,,9Z^,EU-?CJ[/O
ME$M#+ ^KA-H85'L?[#W' =RORWIV%X^AZ$W@Q>NF/Y=UVW^0<HN@WQ)3JY=#
MJZ!M6=!U$=:_&SORQP TWKX(O/T%VOL3A0/8G3CA "61[>A-]@A,T.O56T,H
M9@^45P]J0DVM_CV^&L<&0I'_K/;,?,GNV5OUPP'D!^X><,B_QIK?60WGW#E<
M/?IVYR@JLAD'^/P<FWK]_[(]VS/+'XD#?)S' 582;KNN4>+=HCB RJHO#K#+
M?&>V&X7QZ8S IERM_OT0\N>__?QO/_^_]K,L:OZP-J'9L6QA42/@:14;0_CH
M*Z$'_$_]I5N0;T;;^&.OF)2"(@N.T)5M0;>B[CX$(B_LY-,=P.J]WCQ;QIIY
M]5+^_ZR5;8].@?G"'A0"^>K2HH+WGQ^I37+^1X65_P+_F_<0I>, R@RNZ*5O
MWEZ$R<^[!-5C0+=EK.30Z_0_?,JY!$>7G'_@_YYG0ZY\P17@YRR?@ X.L7I<
M,ZE#7RRG_45O*R):PP8/V\-YIK(CS\N56MBYMY%0UL;T8L>S3+/L%0&[,6\@
M*>F4V(,L\Q#3P$LT]#FMT<@V&DGE9#OP,%_S^98P=AQ9/8%I_T<\N,9$=0IN
M3-8N86DR(%L>4$GHVL@$+-!IMA'_9*0(KK]]19X6:H'N&9M(UBJH'/]E^&HI
MMH-'&RRJ1%:%-UW1M?_L8(W<ACSBL;Z#VP6[ 4][K;5"N<KS.S69I6B=W]R:
M&VTI(Y(#&.)=V%$3*S1FI!T0^0 $2"8[IRC1!A"J#B![GFO^Z?Z=RIA32\I0
M)WP0Y92S3_I(QH=%M[(PO"HTY_V"O"W>!"F+/P/B_HTL&N5>,EV0NA ,\*[D
MI0NUZOQ;_\2'8X<VLOMQ:OQ[Z>2:QU2US!.]D'$%)N#!1Y"J,DQ [3!*6K<K
MNI+ %9#1-PIV@H0MO#0DB<_C,^6SEYB^FHKLX$^N)@H:&Y]-#44FQ^9:*K,?
M!R7JJM!PV.*/[!K%+80V3S-XJ1GC3TOI<]G DL=>RA,X:'FIN?B6T@1<M+<\
MCD]/P@$J@@4E[>TI_;3JO,!*+BTHT'-M'=%W3LV]3[U]H'XGAD.?!FHN6^AO
M<N,8V6':$IK3ZKIOIK\#?Q</B+S(@ UNH1PU[LBY5>"$\A^B_4#=4B&B0.>-
M,J'2.TZ+[[[\D1RKEMUK;M5G=%CF]MZBFIZI=4'51%#+B;V.5 [-;@'DO 0E
M%)$=2_XH['_A$W?3,ZAS [BX/8O,1D3D0L=U[#\O7/YAE4Z":.4E#&Y:O8.U
MTI\1*-&^[L2(1'Y<\C,9VC5>Q!J!L_/$K_0T/<F+-CP[!ID1)$#QJW ]L^ I
M,F3\/^6Q,'+M6"\?3\_=<P[GJ0D+7B=9+4LQO1=*Z?L(TB:&>?U6RT:L\V7X
M;,F7@I<6[PG!]@UU'\)NUS;!ZX"G5MU/EYJ.CAN:S/PPC;:?!D5+F#^C)<>,
MO6CH+B;QR.01I)?FHH@@T>/J(K:'2:0@GMM=K$!PCT=$\H&!5(WIV6GUF37@
M?BJ#J!DIF[(BV;QD&!,J3DLXR]G ?"+41!P!X%$M4D4&7ES966Y=7JYC_1,B
M(D<9+X?3'7FMVS[[9&38X0!I(>\"0Z::N6 "&ESNN>ZPQHQ,C&^/2<!)[#R8
MY5+O^OV,NKG>&%YAF1*8^B]GMI'TW.=@#[EACZ<Q;/DF)G;?[,G/(@U8[KN(
M5_;, +,A\SX95Z"J;IZ.57XXTD ?K;,QB -X>PT,WH*SC48@BQ_I#OHW/X9>
M[%4/$@W_%FGC,VE5?@C1^HYZY::4P$OM?:_4MIXJB2?U,$CQS="QS#CLOCI(
M$0?@1G1\(=G(59"X@2N[!5:1?>TWK:?T<\N.Y8,E%87(D9HU5P $NV).("==
MCQ7MJ86E/WU.8@O'?/;:B0)Y&#_YY(?Z^C*C5BLJZ)NF9I90J& 9EI7 2[;6
M@$&)VVO#S"99A">5,(%C@K73W7L6#=W% 8BUJQOG%Z(ME?_Q)JWXOG:?"-H?
M[:4QI5CL_4DA/?&YWY-S!1=#, (;<"Q=@P,D Q5O+]I\3M,%/C#@=80_W4C@
MN2I@?TU6 ZUXX=>/ \!V,>!N$2YDL.OSKL-[Q7&_.Z4O48KY'T:W7OP-$]C&
ML\%>*IV)/A$#+FR$> ZU3[8<<)JH[:ZL>[Q%A.]BG*$<2>TZJ<>JA:Y/6 KD
M_\KP@C1SPVD'BF"$<Q'A=IX\(WXBI+6&$B.2ZQM55C8EEH2J$+D/>936= XK
MNW-UO]#R]]2@V66*2>W',;GJ$T-" O1D[)EZE3**MEJA'I_V#+)!QU5/S+A_
M>94,<O\UW6C+).+@5]6;@I.\A<^_RVGITF.+55,98PF=#(T*W9.4]1E)113$
M=R!.C&^\#N2QJ[)5(O&L<MZ>X3!Q>S[U*O-R\0<??V:O'>AZ?2K'A[N?\W-%
MAUWEE\>KI1O/3^6T+2Y_*SH)F?@,IHG+,.*E/>_W^DG5Z"&;RG#^\0;)_NG#
MKR'^!3C"U%\$,CD=MN.CO+=_;H)0K1[K\>JI36RX&CU3[_4R=5(BUK9"=2]7
M0>#?TJ@WG^E3Y[&9C\#I_^[;)B[D4;.:)7[^[HNA;932,;2I&\- 2DZJ_2F_
MR\FV,[4.M,K.7 WCO1#>C<$ZMQ?68J\[';B183EX=J8YF$]F4N"1A 6>K<?V
M&L))":2MLDYDNEZEWK?G\FA+*8LG+NDJ*YE5O*Y"O]XM;P$#64;<M!X][O\3
MPD9'JRI/S8VMO_F6W*8\==CM[^;R)L:#)Y&HL/5EWWEY:'#ACSB]1%?;Z?F4
MO@XAH2HW2 ]W 26!9U41(XN0(O_7['.)CZ.K%4+:62*_&!=:)G)Q@+CB,82.
MHQ::8J;QZ6TX_;^7B5 U;0FAR%]L;O9IQ14NSB71@]9OCGO>ADTQ31GHGOW^
M[I!S>0#T+,SGNI.>A+474?S]^K,I4E/R<A'V]X3.G^@0I6T>,3SO/=_,A1?B
M )C[.T&9 G*,/H&6.IL>Y:5C2IDTE&)B='RY6;J;6^$F#EC18]@"/3*R6]0?
M9&&GP6;SS)' YV'+>LGMA8.<M?7.X6LK[0R?C?4A<PV3]YDV/ST%QV8D^L:%
M8\JVR ),-K"%1U^C^V<6+"M*;@,/[.?#FI:?6;M8)L6I^VC<6L_6/5@%+V<X
MFY0KL=L0G=12#%[35KYJUIYB:'*&%)+3&=9%MC(.3N46<#Y'*?NCEGP$+/"X
MZU[HUNG=BLDC+^J6,1)9"Z2&KX<T]$QUZ&>'C_<.2ZBL+Y(^D5$CHBJRV[D:
M.1!+?H\([_4$Z+XZ"6M?LMFKMIA@0?.#*\^)T7&%KA)QE>4569G<Q55?=%<#
M#2G2:6SR\ ]5?ZT>\X+JCVKF[O=2Y^MPO,O*.Y*8KM*@?ALKD<MY257^5);1
MFMN*KII3H%Q"@>J1KK]Z/"&^O.0+PQ]W5 <?ZO^]C5$)^-Q^N;/DB:4MJ:_U
M.Q^ST)@):.)")YHW75:.U=BL&NMOZ^UN2/%C7;M3'3]*MY$RBO(=!FHWKV2@
MEEJR6/"\O8.S9M<:.HAUT")F">9VE4T-SRKT3_G>XN.S?RY3JU!=-1B?JOJA
MX*VDZ8SYWOLTJS/'SLTTY:\S==T_;^]8U7BQ_<FSUGPEZ<RTV1$&C@0>1& ]
MC"K!]OFR+0N9-P75SU^N+7#Y\$^503)&5=;15KD)S/< [8V/];\N?*\/2:\,
M-#9VBAU7;E;P>,G]Z%-1_:*5JY$RUWYX?52"]]=4#R7!7/G=5-&68&_$-MG@
M_E6LY ,%8=X:M0[>P$B=EF:7;I'NW0AAF]E>#2,VJ]AO-A5_+Y4%JQ3E7LV8
M\MX85LIJ"'R\RN"QUS"$I"^:M7]BE!%Y(-B]E;ZT9)M2^P?NNZ/4B+7<YX,J
M%Z8),%3%_?H<F,IS>[M3X+X9$?+-#&+KNCP]<!^8'R=]LR!DBP<#,&2%?/Z'
M%;^O:Y\-*WJ4M#&FQH.&0LVR%D>#]/%2O$-C[.*2PCG%>2;$.QZS/B<F@2A=
M<JQEV87=N<UAYF'+RY&=:U/FIL;,7<.B_A/OJ5@DQ$DSVB4!K:R;1W"=(N#U
M\%G:FSV\7VIV )]4_)$$U8N-B+82-W6D6J0S?#]@L*>AIF(73%7Z,I(YK5:J
M(DZM%X'$Y </U8:A;2(C)S\V[.DP3#W&EZE3Z3,J&DP)TA!HZ.[;;^WL:3FB
MKC]2%B"GI"+].SSS+2I2-<AZAE<]P(,L[$[DM:/&VTAA4 .1?NU\7C*70O,*
MK)?KH]E&)%5DFT.]09+P&7L@*@NX6T)!/($Z2RM0.( L6IB2LGNDVH409*8]
M?MBK*XJ=BP6N1![;ZM2&BT-(;=9J!7>H;]0XU_;/&1,K2T.%I]W?^0OFVSB
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M8+L3X9Z6O?7GL-N>Z=V!,N5'VTND-+K"0MROUED4EDF8& %W<7+_<@NK_.>
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MLW-L)(?=2YGC!A;U_;_F:J;@_1? @XO]?ZRG@D/26SHBU^/J"/#I+24L7,H
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ME&+"TI(S.W  SOH;U%.5],G]MRN46@BR%R:&0O)K'(U$/DU=6D*M_8GM$SA
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M?W0WV]A*4GFQ+P=S B43YY_BW)6,0W"T6 SZFVW\&U-,-;38^BQXE+YT(3"
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MX1V9M0JHTT.[F$15\D=5N"+R2G>N[G\+(=;2YLB@[;KSNC&"):BYKG1Z.9?
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M#WF?*\C^7 [330\96.N20R4Z_,  3+G%K%+#0E!F:[LCRPKT/[BV^I)/SC"
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M.NK>^/)X[6V+/^UJ>:#;IJ_M#8'>TLIDLN('/KN9J[;' "H18;+B@LTM"NM
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M^H+E-3FWQL#%*:#+6W%T*3X=/3HZBSAS][MQL>S\?3.W[ 3OBX(U $L!(=&
MOC&DX'BF&/-H]SGR/;-$N[A(:)"OUSA[JYM@U&%TDT %.UFXHQ$!4\UU#/3G
M_3N!$'+L"]D;+C-K5@CKK_SF_PR@%V%&G+HC*9Y=%H(K"L8*LOBH"N2KHO67
M=/%O_8J!<U/Y"*^_C?Z%Y>DNY:R(!#G5#:CZX8Z_N?TZE1 B9LHE?E1Q 8.&
ML&D6+CJ\L@F] ?PIUYCTRL[4K_A@PQI*:] 2=0E8J%C!15"S8;X1AS2D_QP'
MI'8:97)#^,^/'QX>MHH#(Q4(A0M^^\=:YTGB_(SF(_N[DO!8YXEK]R_*]&Y.
M7<,-L[_N"/XC<Q'= LI!_W'"$%/2Y7]/KS.67=_#%12<@>JZ\50+SO!CY8!A
MX)AGR^/R7\?@P0O4Q>D[Z/.RJM?7V^G_39CZ_VO!G:^7Y?[":.^.W1L@L?M2
M53SCJ=,+U&S2#,JH>?2.A/F^!+T!HO;_T?U'!<D_4<80T-ADQQM@VG+[^K+S
M"3(,2W04/TZG^KOS+V0V_&:6_ZNJZCDZ_6D7OO6P:--=J^;M8 O,L%UIB/;-
M3:#G^\3*F8PFT<0^O)M:754O=EAKV77X<>3/CW7E*'=,S\Y\IAT<'1?NA_>2
M@%!CTQ7VCNS9B\L,3<']./DMY=(P61/@$VFH9%=\V_9*\,3J2MQVN##UR$!Y
M[?=27%%V9<JLTU+J=\UJ 11 0P)7^/K'V4N-HX!@U_6]WM:_EA1C*H9"R"38
MDVH%F248.$N(MW(<:F-M<P9JR9$ME9*TY-7Q@L"Q\HB2*%&.[N_"V/_?N%#^
M__>"17-8YQN@+?0-P"P.4RC@ZGV<<<:V^>SS'./S!N#=?P-47]\9^;PT4YUN
MO]:(&UZ\ ?A^-O^M.XJ\#4E45/]SF<G#*]*8<">U3&Y0VVK6WQWY$_Q CM<D
M#EMX W!^67C>1":#>:(\<Y^>]/2ZZ.RFC%C<.%MEQY.0E"Y@7,DH3WKTZX8L
ML"?<2WF,BGS>F-^=_Z$:5Q8531Y/\ 80!=DHZ*TG3=,U:FGSFA%I_K@&67J,
MHXC5.CF8;"K.W#D*A!$YD,)&"J= P,,'+W2C&B,$M@34ZT0E$1TT0<IR)%'V
MH."4EQQ00C?38GR:V,TW[<0/OPK._G- 4]43,VEPA#1?<4T%8=E.F46.G(N]
M] PQ2#U>?/G1Z^(4$W(0$'W"\!/[MBY/?/'A[F?YEI<5*48Z9213#:+Z61EV
M7!J&F;H@CB&_-_SQ0Y]U$YX;9*F#A35ANOBH+>3SIV2' ?'C.X)R?_S6K%6#
M2EM&VT=\%[IP(@I^3'L-&+UV@OC6 &'RP48]G7YRQ8F22^T!NF(^!2FDBV>#
MH)"7MQ;[^' QPC/K? ++.#X[T.Q'M@*]H2#WNO67G([J>?)/_"7Q!HS9)H8A
M^Y8JR-<Q":;OGI\C:K#_"N<\8.FWS/"%LA[IOW1+7Z@F_WULL_=AV+U06>Q@
M^9"R,/SPT; "R $2+ %R1)DJVL$^S!'G2V,X5)^*JI03,[[ IW]LV4L$E\).
MF!/6/$QH'N8)E+K<NU.]?!+1235;+ QS+='1L>BL4U%XX0[''5\J<TO[O'P,
M''MZ*M.+^9P&5].\*/+: YNK><>%9_D8UX=JHSN9]P?YOF(SI\';X:!=TDG6
M[>VYJ8JWO1CG(7 XUT#(!^S34 CH6DL4E]JI,N".OR1K! BT'0Q:L]@V+*X&
MEO^)79#*WA+:2!-3M#4LVBCCYT_/.S/[78HN\Y,@5'\J5:=,!R= SYDR#R;2
MNWJZ%%*LD8UGF/!)+3WPU:*X6J< 7/<CO1P\RGMSGD2/?6#M+>#MI-OU(;CZ
M!;"_^DVN[VQO1NE:3T0M2RP8=+:_Q%M9EJWT1"_';G7P%64.QO<KYH5]^.]S
MP&_.:U!..0<^D^#-_C!,_.PUB+U>ULZFO#0PCBG>P"*DBN7("H>U$6QM5K,H
M,TR#1GX-F=M!QRZ8+MQ<;%2T1Y9'F GL'7T6IK3WO_78*P;B911/-?Y"3(;$
MYJ9QI0&XNO 3#%?JX-A*O\K3_L.'^Z]%LW2G=/H,D9#]^!S@6DX8C?8PGU+*
ML-:P"I^1C+-U<E5^-BIS"(^V\CG)3^ZJ+FX=,RNZ5[B%##1LO*6'\<\Q64AH
M0L!X4?%%-?'5^9Z9O_NYVYD_O$_&5%0(T<N+=M9]1ZL*BQ.4&PD,SBD5]D+U
M\I1$Q%# -/!_6_#<<7]NAHW(P,%%D?LBJ);Y_F!H:2OEJT301<;\,%S9%5;A
M\ "=US+%]-[5 /_\Z&*M)\)]^C.!*-L-7G$7U>L:R,EPP>$8Y- I.P976+%^
M_N")ON&MU/(.2.B8BRE8^0R:G,-:@8E:L#O;N.]5I2@WS#.00:S9PN(_TZ.B
M]H'9=)>I3X$%UBKB<8JN;P!QZ8EDN3,LL6T3DZOXN%[UAZ.I/G.2!H*NSB[/
M7RY\8M[^3 ,KWZBLHUO4?J6<8@(3T7:,^U_&G03DPAUN;T^L&ES<5F7 26#L
MIHF$F\!>CMCXS2=F!MTVTN8DKT$^93X))8VT3--&5CI-YL0RZ60Z%7 0/I"M
MR#D:A(CGJ(+D&?8&()H9<#P6KRP>P8O[(.'[4O@&:,C_@5=9;?_,ZI3=R38U
M.[YH5HGDK=G91!5O'6;8[+]F8[NU]X]]"\9'D3W"T3O#ZT6<$5(C'"$+I[#M
MM79$R2-Z]8L.O(:>YH!\G-?6NKX,M#A4"5#ZEUS6WUI[7VK]P4T9('U7=E_5
M8( 3V) %9)OPVMYD;WVB$\ZE6IUCK5FU(*75'I3%?A8%'JZ0V3"V7G]>J_:)
M=0HVSW) 8G#WKG [\$Q7?]><^'&RG-=E%4Z!LDS Q7ZWPS<7^0V (B.@ZQH5
M>[P'7"Y&R%Q_'NORL'+X[&+E[KMF'9U?PUHD7[FJ/\V*1( ;!2LKT5VB$]"-
MB_U1H4XJ$[0K)^$Q_ 1J6/C@T<QW.)HL\>E +X+U=?0\_WSUHQ[IK%3'PT]/
M';Z[VKMCDH>_6?M)%G<RC/&V(I,'2!=[2JSP4_(=S62IX,4RO8N3H?V,'QQ$
M4F)I0#IN\,O7I_W;$U[55,<:&=_^2T="'E*%HM!\S-'/,!X($&FFA<<P4Q@J
M6TDG;?XIDN[*M6LCJJ3MB>K&$ZOCX8DN0R>W],DJ=2E7C 7$/:?FYH@.Z8XF
M\;O-1 17Y,YI0T8]WK_L9=%UZE3\F!\ESX .?V@,+O[Y>:V+XK0<C!A4T%0\
M.9SXV];PL*IO)G%<+1-R4P<IQ\8*9T\Q8-<EX@SI/[2KMF/X3?J@Z%C#+H^I
M?"D1)]+0D%ABOU-)+Y6@T-88-SC6TTI0HW"B4"]5OC[P!0F^0/Q>JX1Q7A"]
M]OIL<K+>SJ:D<L1TKDT@+NFLN#8=3U%QY(;)LLD!EWJV;MX9!6'%_<QG?44-
M-YN;I)S'GW*PC>'%V31U <PN>8-X=58EL'4Z/&,EH(.,5#86-&@5B-]QSXI=
M>&9 23S&C5A;INM$+\57*]=PP>9<C/$B??V+[7CN)X]X_VW=LWA3H<YW<&QQ
ML=9<71*Z1"!U.EMA4RC'Y!,LQ<,,Y"S_<$7-KGA5[B]@1]^>%J#\]:KP611+
M+(C]'&I1W_!1Y,]$_MRD66N<C#+^75;N'@..O?)6F2'QV4&H8^CIBXD3_B_N
M\30MD*UY=[R4C)A<24[7QVH9O) B%C@IQ:46Y&_I%8=J5YZUJZMQD<N\^ 8)
MY!\S?/5*6^"3\^R9U[Z3*&K]8JP,)3;+YX++*XRNT#>/H7TMG&%GAA \HRA=
M^&A__;L( &.XHR)GP7IM%#;2U0165D?=2<Y6]M@B1S78I>,PN(8&6Q15VQ*'
M%!CD.,;:/J_ 8Z1ORX/W9SQ\MYP%[# -B]MO;NL@;P!=80+OR&$,L8M8E83+
MGI)0"7.^%6CG1@.X(EX#_#%UD%0V0=[#\X=#VHSC8%"JT>713*(<A()LY>9F
MFS8CM2()74;M+V@Z.A J2/:N#"I5:<M"YN="GO]G9"FMS*FED75OR+*1[7*'
MI12!50<)T:P$'<.5M\ZGR9@_B@_4]<48'HP5V+=KTE;D%3':!HF!AI?NZRQ(
MNCPFBH\N&"TV"-]_ZL$NZPJS9^.S_B(JXZU:Z\;F[GN'5C)!>A0 C2N.2,PA
MY#[5\"+[TO:>:>'WC%_(JX0PVZ;W^<=Y*!>OUYV/^/61$!5'$EHS,X-5GC>1
MK?KL%(MY"ALO+6=46ZJ0C/QF"7GCMY?>$OT5@C_^"M5<*,7Z'>:TG@2Y22<*
M)+#.!]HP^^R#5V#R)GYS@XJ*AHY">X-"(MU0?Y)I>KI-^L=T:ST ;9(7_/"Z
MNS,!L7WVD_K=W9<?B>TSR=$[&>PJ8A;4-B_Y85B_3Z%Q\QVL'D9J':Z?XQP8
MI,.<M711W5GWX"?NYF1(*O6$6_R)5^RIPR!&\3<6O#>GHG_86>0QO!8'EL<C
M)<R=8 <\B^K.F&UII?E"E,+'^#U66O=(NU8\L@;R=$:98:>('A?'Y_MFOS7S
MD.A6G1TMA8'VN!Z2KX90Z!M Q&O@XVQ QE]ZU:-UC<'LW^KL'P_W%*,*JXH)
MG,<Z3\N3F2?T +A :R(BZ/,GSAG^-/$/,UE.Z[\P=A;,([_O_F/1V-.EJF15
M/L'V+;:ZR:1H&$Y A60PJJA :_CW@V19^*.Q7.S:E.'N:=_ZZ+"DN<G:F2\M
M9("PE'-EOW\H.>IDQNO/D%,O$.TV"UUE6_2C%O>0G ;G&FO#CC8]QIZ>MC.J
M_0G*LCITY0.H:S1/K,<(D__2.%YKJ#=S!V0CJV47:.2X]*D\@XIP:LV !5R2
M0.R*OP)3B-N3I5GHD:// "X2LQ-H&ZYL@NH:B;;*E NN/.F-]1:82E]57A7O
MC (>]X[VUO@:9JV;/FHV=F<M'')KDZ /9PQ7J^5[%\$K$%?C&BN07B!\Q %G
M&;H4F\G1ED0^^=/EI%5$2,C8Y5H ;\5W3DHL_85S" PI>USV>5/DR,;Y$*M#
M/9$?YNSM630_L?=S56V? 1XL?9A655!W%X>VKMY38-_>/_O[#,)L"C>X+:T&
MO74)P^U$7 =E\M>SOL36 (?(AEA</;/L"1#"M>AF"QFO."TQV^=99R\"B'-Q
M5<1LY-\ F.+]\PR,%<!UH3707D 3G(@G00A=&%([]SWNV'7G5V"$XLJ9D'O1
MDKQ&Q\Y[]C_#'MZQ"1FJGV_NU$<:"2OK2*/=GCQ;+\TR:@;VSS58F-RUY]F(
MQPRC0*'HT7H804@;,MSDB4"P%R*A<'#^W,K"8@_(1E' ]TSBRQ,4>J=UN#4_
M1C=X=,)-HCW7G$#AQ,<G?9VITERC%E<50I5$7I),^OC@?1+[L9.Z32$)#,?[
MY/G[R:B,-.,+EECZ)Z32K#/[!:J3$>O/;X!6EP<J]=0J:O#)*,'VWB=QX&MP
M4LMZ3T/B("*^FW0CT7=F6GR+Q6%A]'&HS 4]E;'+R*-N^Y"P@8-S;Q1.=H$)
MIUB*CM^7!UD<DJH"2)&,)*;@L^5+77E9%)B.DH_+6N PH9FG(>7[J\G1OPI^
M>Z+FY-ZPJS7^O:CP;J0LV/=9%$^2SAL.)R_K!X&H9<$)H%?@(;/,-WBZX'#V
MI]Z/3-:G;->;/0>U)LH\?T.#8FL#&E_CC=+Q/>!+F.'6&E=*MJ<=Y4[A3*O<
MFN1+:/>G=%JXA;->=26N-T!4;ZNQ,$;2L[]@VX92+JL%E X44;!SAO>K]%T[
M\'JZ%?W.B6)_/H3*]@P_B;K>FK_[M?4-X'^\3H^B:+8T3"&=5@1%FD-9F@#M
M@>I:#7.9YP854/!,1D")6-G'3(* ?]3SM6?%T=.*0&):Q3W'>#CEK@V6L*[L
M,/?U12+K!WMPT'Q-'67Q\Z/J_PYD^;\C.+DZ&QVN3 'US;\!: *:MW%@4- +
M/JC\'];]? G!_GL-?7X#X P;O0$ND\.VWP>MO0'2<CS> /FCO?N;7N?K"4_4
M*Z!I-O'K_G\O:+\MJONOZTH!"@_ZSH#MOWS_XGA@_AC.VY*Y8/';CUS;6I5#
MPJ2]5$&GEVWV5V' R'97'3]%EVN*?>)KWEQ&K!_:OF'!8WM_7:4,A<3K\\U(
M;[W*&#<T?8)@.BM"MN*X; 0X\X&RAG'+[C[JY7_Y=_@_@O^&0+^7HQ>RTSNF
M]@; M9G@?+DC"UM=VGS=VWP#3 J^ <Y@043_/-D)!>KSKTJJ+8K#_IZ,/JL=
M+T\'7CUGTI;_$2ON*_-BDS\VO*O3:8^?"J?<:U!I(21$D7^1!3WD!#I5.ZAC
MPKGKJY,^!MX^"__"_JG&),[C'+Y?Q%*HG6TA/RR-S7SUZ(ILQWPC?U=FS&)H
M6ZXI]T<>[S,J.K.7AKGQ0$R:%EB9'W;ZCG)'[?!U6K_% ^(UE@L:[ETYQ=:X
MC@3-C!"RB'0J'U$X9S[9?.ICLNID<H#7)P1*41'KFFBP]-:D3[AC7X@?G[X+
ML'/'1+\J]P+E5+2_BC\PJ,3QZI^UF??+6,EN@XMFWN.JU0JF]YV))>M=WSU:
M3#SL>$.AE"D%CBY6]NC8^77WH(97 OA CPU/]>]GJU7 Z"S$B:N@Y@A95@=9
M&QO4-\ G77X6I#YU9Y*<K")@\QN (Z.BY9%_OQT=>BY^1G6VN^#K+RO1J#UV
MSR/+D#8@(]MW'O?-MAIH1*(=(1YF8:HP#^GPN7-;^[T?CJ(L-^+^-R0:#%>E
M8/'%W[.WK'C](ZF]D$T_R,_>-#8,2U<[G[4X:B7:WH-MC^O@C)/.TOCQ];ON
MF=.O0BX=8MJ8[%<CM*6I95L)>'MG/HS?\"+M]]/ ;8J8I,+1_=8RYXV59^?0
M6'IM,CTT#)S^ /&T['0AF\IL4TF?O,/&',0Y+T+C6?.]ON7CX6K^/UZT.,2F
MA:2SLBA3)<7G'8\V,937AP(1P>@DX+,M@\+!%@_%A8ODDN;&A5G@<"T?R_2!
M[6<%^993!6R(DR;O$G*0[S]3A#ZG3 8RU4D=#\ VD814%IO=,@/+.2H<U#*F
MK)@.0C$G!-*L\%,GQ2M[1\)YWX%16$8_CAP&8;\@Q&',D2[8'(A/SGJ5AM)H
MI4LISG44O52($JW9HQ[4N!IJ457)FKX[O>>&?P,45,6\B(OO7XPZC< 75SR
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MT(Y 36WV_5BZ]S\<N*TLR!J1 DYU[S9C2 T&7-Q5F24ET_^A&\F\$1/I0E$
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M5,(6&-27F8.=L5LXS+L J';KZ>328^B(+]&9J]<A1:XWDPWB2/Y\7D_5^4A
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M<#6\V*2 XM8Y \RAQ^)K! :.SL)9'D+IX:8E9<65-3&L2?<+GQK'Y21%WG]
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MRG09K8IV==)]B/C9S9DL7H>'/MLW/T%FKD;= >9TDFIF.F&1T#D6XL.X$DT
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MBBS&2G<#.1;(>9&>P9RH9%*X L/71":[ 0"&E\;V^/(K_I\;E]HN+4XYV("
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M4NZ.A!C ?M#?P]0QS2&&+K\P,JUQ=* 1'.I*.I).T.,R5%6QPUO+GFWN\/J
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M&)+]<>HX>'Q5JJ/Y8;S#]QGP<2=@,[GV]X-AA;>%A)QD[L:(>=&Z#KZU4]'
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M9]8G31=S/\LY#Y\"V%.7GONJG@?+=_77.9@(V+05^-.92[0AJ:4M/X*2H3&
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M(+,?G]PZ&H$[PR<7CXI4'Y\![<JO@V3_."%U7::0@<S/@'B?I1I7X&ZXQ3-
M\I^T&L940^Y,1O[?CW3^?P5,_@QO(9(VW)X!D1,T#VN!1S1-6U<U+L^ ZPF:
MO^*];IZ0W8[ 9X#0VB-J0<SRGWS%_]W#3_\%_J<W>9D^UNK"D)80*0?KSTU$
M)CL+ E,"'TIYIV:#U4H,Z5%<9%^+Q_:4M0$3=^>:"Q!Y?__H'YQS&OX!88Y"
M=LKR1RVGYN>'E@,4RHJUWL3!L2B)V=QEDGJ35/# 'B<]=* [7L*_WP( 3RQK
MLV'<C1M""EG-S60_DRH>"TFK:J)MW-JHTY2]^2?H/(IS\)MJ("[D)/1@B!OX
MB<-I1/#0O>_,.-W4BH8G;U5#KT^[!H\S,.8M+_<<JZ3<E&H_LPO+'T9=AB.O
M,XY)R@6EFE5Q7N'@+O2U8=O;S=]%*3HN["8M?\X=@S(>H]<:$]N3%@L+XTI9
M,;[,WK'>9S!(C;5T&&V*$ZI&B7#E</]-?NP.UGT&6/GX8I_4MU;UF/WAE>=9
M[]/B*X/QC5ESZT68&T2C13KA>YQ^;''U'&*7POPK#D6$I]/GE#M]]?>WFLKW
MK*FI_7N7DEF2U"YR)0'B?U]ME&H;J_G]'N7&5"JG^I)A^\BL)?_;>HT;P:^F
MF_PC85_9FFH'!J'MN$R?2]'88N;3MY_&R;;/%>G'(-0+S+\J-C3B6PK_(FP=
MR(AQ==MZMQ\"Q"$DOKHG)9L:,RY?A_C% R(,&@@/3O)[IXF@(O5C[&7O,?AV
MP(Z#G\3GEXD2>+HW@N7>8-[WV&GVM#S@IJ$W:3O>ED+R=.N6\U[QYFU\B[M>
MYAWOKG?!U3' U5T;[Q^)I]5-4F8[/Q$I*'$BP-8!5N9:98JPK&6CQE=Y/8A3
M332]Z?^40T,L^87F&CD)W?R^YB"LR8YK^J+G;W$2(2X+*V.2,%[P"Y#59T)S
M4 =7;*_'Z?H8=Q$!A?:-<[-C9,7!=%U/>Y&+Q:]A&R]!&+.RH4T>G;P.@P?_
MVB?XC"-3D&$4EG,:KK9G! \%@;VXJQ&3<VXX?$S<)M2R7UU61:'$HJ10_HW3
M_& U='"Y@9C4;5ZZZ.CL OX,T UPH56>#]F,H.Y9[\@FQ>H'A8?)<LF8W[;(
M,[SC>&_,JT6'+EAW^Z9%DR;2TN V9#*6@1;ZBE*<-\>J^Z0P*$Z\V:RS#TRA
M&;R .R'*5^OC8Z"$MJFYJO^6H+SP7NDNS #[9,JZ&@\R.NL%;(9YK!!EA1E,
MD.@-)<T'WW-6<:E0\6'@&,CE G"M2'Z&J$:,:GRO>LN:XOWZL:!D/=#+[DS2
MM'=DUQ[>X)U+7%%<&49N'2"ZTEF4R,8.OTMC1<^597BC=%<]J9 ZU$T\O#+M
MY*LYHLM-7Y@W#@\[%5CW$>)Z.IV\$//D3L4//K<LM[E16$I<TKY$UT\>0V4_
M9D=1%40Y5ZI/V]!&M[B>>J!ZUU&Z$4S'E A+D%!$3"'$>?S%*XMUB(G(22,+
M2_-TQ.?G9C^CZA5 X? WDM;9Q#_C_.[8FK*X)!4U'J>GJ#12YL,P5^6!"TCJ
M+&KG]0KZ82JP>13K5S!2P_)SI8U< D8:Y95?&[O\$VR! !H&=%,JBCRDHM-'
MZCP#T 5F"HZE4\^E^_.3W05TSZBB9:-R6QZ6M(PT%%474'YH-]YX7VH/W0II
MJN F-= V\JWLHN@'OG*5Z.13(GH#5KRO%4]NLTNOL8G(6?AT54ZSQY#OA-GU
M$'J\6S:H[0J%9NJPI)-+6=F]JW0L5=>TR?M.9-]KJ&"-GCX/KJR7K\M$'>L-
ML'N*B[)X.DYNY%-0QOC;^"N<&GQ]^/.7K^W/];60^"=:J]]"*W@>@F3KD?QI
M)40OC-1G6? =;8Q2 7$&\F>G-!]#TD[?H^$C:QI@XE-I>9YQ+2@1"O*8"#65
M+!HHE8J6["LSGF8.M-2C?:@R[@(83Y3[0^UAF:XGWC0!;BA&:+& DYO#%R'P
M(=#AR/+!R^9XJRYD2C5=__7G'.)T*W!6GN?9:<1[/BYB%^J]LH@B>V)#UDY"
M2[BV(QB+O-2R,VV:<]AL<31E&N7QOC-W=85_+_N.!]$.MNU)MYU,9I+F(&W]
M6#%!1?Q.YG:8JK#FS.31@AE)A1;B.[OG(T"J"=0B;D\] .U08CXZ%1ITP1I2
M%E3TR O](8/>A*YJ>P_,&X.VUQXY-['1%6JM97G$[W#Q/G@SB*8!^6:S=GF.
MNR+F-WNYF@^.YI$T#1V%3GD.^2U3D%S[O-U#U(J_*XV'C(O9S?5Y8Y-)69W&
M.G4#5*CO#5 4J4&,6&$_PPJB4?/LWERG-%@?3?KE24.M=\FVD>RODYYR>-K7
M8'?5LQMD9W-:1J!NR[XIL"0911L-"E$J!@%\@1"DHO\,:&&".J1F[1Y?AKO9
M=,3=V1GR48=TT3@;YZ811A.TWJ(^?O:6N*/6"_8=DY4Q3';ZZ;!S<[9NJZ3[
MQ?_7967RCRT;P3&Y?/W&U,]Y2N8J@-NOHX0$ W8%KD\NPK_ET$4I96K2IXI-
MI__&KCP,=2@L#%K7S[;9<9 ;XKU1M<*S]7OT9"<,Y!@M5T0X!?*Z6L:AR(P_
MJ"':Z9IV84=R50^83^C39ZE(_9REG-2>:+@\Y\RQ<C2K)P*5).4EA>#\<AN=
M%Z5+/MHKDKXOPAT>7D5&YNA/98\;A@=KF)VCBXJOL!0? PMO5X&DY=W2UJSE
M?[KGMR3B!1B'X)D-8>D.YL<$WPJC"1?TC,QV.Y!9 6_YZ_SQB]^=R5V#>ER8
M4Z3]'P+>\=#V-4%3;"T2&FF:4Z1(8S<Z1:I-*8-?,1N;;O7U,2[X?5-8-/15
MMAP#V0M5C%3+]R52\J)$LQ?V(H?\UACCUZX/1=IC_E#CTA;&IRD^S)C&#.I*
M!V3]8]2>P )8<%9%,SEX-^(6]:.K*_ATH,/HZ+O1<BY'*I+N(>"K76U.1J2"
M(,OO)6 JY/N<=@8LG)X1S#B+K0;%WYM?DD>GX.]+C.%"[ ;ZE,5<MCX5%6N>
M>='U T^19L>/K;<_+/@]E:/Q<'\PNQ,:%5NGX"HDNBO-C)+\--Q98T:2_>4=
MGBHC3=\7TY\(JKO[)T?FRM9MIT<6%G 42\JOY,YG%7_1!0/EY3A5A+X;NPM>
MGS%<:!":J#RH*9!(-GE/"BG\C#^,3Y-L)Q4&FNCMP1F^[UC!?NBISI10X5%D
MK1B481Y"^[9DO[(4A]_6D3 2N$H<*[Q\(1KPGUF0Z";/;_G0BM^HVT17B%NK
M+K??*@W-CZ)4V\MO RB92?_&HONRAUY['YGIT*.J1TMPSG"];(P:0-U+]<;?
M1KLBZMKW317D^B>G5*9OZ<\D83=73HZ_:8-$1Q!YJI4,*)JM;K_\\9+GWW;@
MR2<40[/ILH0T;'8XL+1V'0O HDZ?.D'2Z?;SX53#M8WWYV E!'*S>,0<RE0"
MR3B*D=@B$O7S!&>=4MY:7]3TA0_[8HA^T54C) ?3/0.88H5$\229FH037N52
MWMO>($U$F :<>N/7I@FS$:C1Z\Q*<)$-Z<VUV\L)] _>R4U._/4-DCI";X9L
MRCLXCK$9'=68>=0Y3W4C4Z?*7L5P<_]*^)CX?6D\WXRC65IB7!'/5+<(+S&L
MBXDH5?M6R,^#@VM-,78W5"LML?+X2Y)"!> #R7:AH<=3%VGWA@LO=^RZJ/N#
ME/1FMCUOL.*'<1656CI8H5\U+/F48@*WOLU3<$Z0</2M25PJ?"Z??2M.2T6@
M)UVYBC.)<NF1BK,NN\QIYX-WF</9*H6R?7') (ZX[6059V<#(9-QO62:.?<[
M#J1\?.,J&<+;P_7P\VY(\.L' 3]K>MY]EC2#WZ.[8;@^J)4I,_<+"[.,.EBE
M\O9/,F^3;^ML+Z%%#$49]" X:%M-33I5(MQ/,S\UM?9*;K\(S*6CI:4-*%,>
MH6?RDS0F%K['_WN7DP\CKOF@\H92G#LPJQYOU(Q+P3-;+;F/2HJ+B;=B%F_!
M.RU.10G4QMD'Z0T,ML">U4(/NE></756^%M0/K O.:7V_M\/UIJ_=O-&^E-)
M)R<N;=JL24CQ\C/ 5*IQR99E5K)G3%SQ8TNF;F$7H.,94'8W-(]16,0'2BC+
M5;!JL5X5]!2$O9&4C -I6WTGS(=8!P=G# ;M;-\@;G*WW'0I3(L>GPAB'V8W
MU-IT[2_U)=/&1QS2E([=_<FHF9-.!VV&?R07>_"VUT5JLQ8[*#*L%+\MANT"
M%Q W9A_'U=5.#OIS]*IO3QX7I\;F=ZZT"2HY)*,53>GHV3\)\6><OGC"ND$6
M(%X,+]>XK9-HR"EJ(/>:1LWGY1G]*3R><M";!.L=F79LFO.QZK9? ]6.D ]'
M9TZL6O&2-[G"UE<,3]K/ !;P!\[^+1G(%HVS:)FB[E4F?T",NG?H\.TSX'55
M5[$/9E%K,7O(#/)5[8,YU-L)>U'1F/$>4O='87MVN("^\?$>NB0,G \.K@\0
M^!0:5]"15/P"\OUI9PUMJ4A_'H?">T&@ZQF 9KBE\J"\>],N.B\LQ8%\E>G8
M94RL"?F5.]L=(/19W6JIU$&1T9,K<"WO3_A9=4I<Y1_$/U\K2I,)&7=T?&11
M/O_&?'+\=?'=WU*ODD @C?3/M0L=MB@5,SFV8_MZLJ^?ZQ0T=HNJH6S557KH
M("@52M5UJLO'\R,4 T!^(N^F-T836G!AMTSH=(S#_LO8HB8LZVJ->GY'>WDL
MX+@0;6YE17?/M@Y$6D+%>K?93=_G&0#RQM-UHDD8WA797!RV^:@;\$V7)=9Z
M8"IE1%H\S%HW 6%&JL7>$[OM9X#M^9+'E8O61;-C5 [+F#W+GT([ZS'J\/PD
MEYO)4"$J%:.,$\(-T-I_;7AT:KISIMIX9OS:[_2?A6_WO7!SJ5KN.'B]G)+I
M8#-6:O1C@4!/18<O\;BD/'7W(128Z*@+(BBP!C'J4DW8$0\H8.KPI<YJYK0'
MHXMJC7V3;,>2]V$DP$Z-<O=QK *'^.R8B5]>G]B JYX!.&.(P>@5[>6JF1D@
M^9\>\YUR)P>^IVB3R,GM<) XNC*T4X?$5M14KI<\+:TT3DP&!X97+4,0Z.0\
MI9,FDTILR"9X7:0>HH.1)QT)FM+Z7*0041X(ET%8 7/E0TPT7H_TY  90O2"
MD@H0:IMKW5P7*Z)!B^MC+H_!\APSVWPI:YHP]D,/LG5G0OH9RZ)4;/O"5.O4
MW31_VX!,Z\Q($@FJ[@WGQ>DPXG ,T<75"&SF;_8>T->JX7J!G4L-T;NT]0G:
M=DH%58 :7#LAQ(W$,X ?N-]R18,HW+V/Y]AZ$"FYBU#\H.[V(61)-7>M;:([
MN?0^F9S)H(:\:K"50C>V3AM)^%*&2#!K(%TS^H[:*#R]*<I0X5)PR4 ++ X#
ML_<,. V7?0R^,CE1A+ZQ7P"C?!E47JS<^CX;LY]W'8K@NF[8T5,.,CB;B)_)
M_EC3SL#6Z+FFR+<DX02,^C$_6O^;V,@WU5.'7&HBO3"3L; R=>_-#FQ<E3BA
MV'Q@POFQPJU^\@^^8$2.<L*>\DR&,"O4+]XT9QT1Z;+(%"DO0Q2)_@Y5'0=1
M=WMSLC:'Z'U,VS(;;T%];/!<HREBNV=PL[PK98[QW6E>#*%:GSE]O#&"9I;4
MI'N!(^V2FIE RC^U!='@:$FSKV7'FN_^##T*YM+9.A*TLQ]K[\C[47[T.6J+
M=*B2S]2>?E$EXZ*MB34)][>CHIBL?09$,#X^':NV_9V9[P Z/7XL.'D&Q$H%
M-K;#8[#6.( Z3R>]IX_$U"^RTGTH<N8TT.:R LC8I7>HP+&I[$T98YKC7)P1
M+<;A=A\9ZQM4X+IVU26%#7S.>*CD)=BBB(.2YO5M+^?$(1(I5G@G125<\* C
M3C1T>"\N<>L'(>(9$-2+N)CG#PJ&KYFX37=QI8HN;K[5@SM<O:@1;6T+FIZQ
M]A1:2,:/ FGFRBJ"P0!_>FI_EK@9CFP61B/GJ[][67HTV.8O:GZ@&%^. LW1
M].#GG4O2>S2?B12^_,(!<5U5\UVAG@D*'K8&F2%=( S=S(_LB->_5:I]]4"V
M[3&[/?>&R*=SJ9,6@3:J81 RTS<7:&<#_*RK?O[!E?\UAL!;M,8>CR_P&>U9
MR6X_:&^IT1<NV3:307\&)6HN"KE4'&\Q#W7M7!9!!NH<TA6W9/VU4>=0G-$*
M#;HF/,<WLU\Q4;Y2WE[$/ ,F:G8_#FQ%F-$AL7TFQXXXES2"TO])#+.MKN$N
MW_V/#*U'P#GNN>'3T[+?T#&JT=@AV9]#5N9IZ>>\MX;L68KI4_CZI&O_SV<'
MC =E#6VJ6&/I@@VC\<J=U"-3S$5QS0^*OUSM(6V?KA_K1/Y8^/+(N7 7;JQT
MCZT227!(J*PM4TZ&I+$;XLQ7@]@(\?)ZP52R6;SDQ;G:,^YO1,K-@O<.Q4(U
M;.W4/R?FE_\"3):XJ38UNFF>#GZ5?96/LHB];4ID<WLX&L2.#,CC#B'R'1XQ
M[5\U^EC14CV'D%KMJ&E[D(")2',PO*+.<W<]SH+#H1L]DN0TOT2'NI1EQJ5T
M',$J:'P_ZL&4/E@F'9XNS2>42@8+A;%6BD2,A;.A$0#I(+;DH[BTL_49Z<TK
MX52;Q%4%8ZB QZRG8CK%SX"#(@N:1W;% ]_UK:2#]KDR:69GT_9XMT6+RRZ>
MU\;[UOW#.HFY<87.Z]=6+20T=%H9_R26O95;6UPB6TEBR$09T%U%:RV;/R4)
ME%FAN9T2\"O"B*9Q:3+C*/!Z<!)>J$ ZJF2%F.=_!B0_=ND=]/7L'UR]_6DW
MZGJ$(%R04*FL*.^6W1/(Y)X^.DWC[Z;J8+F4S#'5C>73Y K*#/KXVQ!Z7'Z8
M>27$J#5VN8!32B\OL2EFB/=K4Y0J@^P3UE\NF1=94( CD1XJ ]%/Y>9-BW27
M7%"J=C0V]S=T1Z6"42)8&24EX@W?1\SK>035*O '2S$D8X-&S9M[]:PG?L,M
M^W@BNJDD?[WM!Y<NC[O5'R&BK6'"AV%%+3TMU//'W?DKC:EX',,<%L/43YE:
MJYY!PHO\^HU)_$I]R[$XLNAJ;@XEWJQ""]^):E37KP4;-IA6"S'DV?./:</(
M[%IULZ*)RB@7<PC,$LQ^$.X"1VBRR6ORYJQ_FRA>O67+699("N>8$[Q]\/U"
M:K!$QJF[F9].\TJ-(;/B)=<K>E0=8GF?]SIX3'+BP8W= #>[NCX[>\YR4UJR
M-S>,D99#C2_WW670K*:D2-;/YXR-L]L_)\$=4P'$ZMW6"-QP=:^]N!I,)TA_
M?;>'I:^.,(>WM]I0\,6RZ#'%Z@>(I9Y%0ZOYK&JH9F$-L7QF'&E"+89-":PH
M3OT%_)U3@G?NZIK @DT"D[PN%"QY.$^3*ELV52#N-;_-.E/@2'V<(*T_=9!H
MEJY=L +\$;CWVO-Q^B0O)Z>A[=(D?#U':\7$;46"YF5N?BY7D\R&7EK)CU_N
MC<M9[.T@-G>YZM2@WUJ+[R0W0?L!>>V9QUC-2^EGE56FD[0Z5 8&<*$<<QAC
MXM 7LOR;0S&/SBD?]Q9N66L;&^-#"B5:S4YV@:P\T_IG -_K?;H-LQ_?VYM[
M O]T+QV?E74TY^E9!"13Q1U_X#9"C0URQ>3*_O%=\O>^E_]Q:;5CY:UE1Y7E
M>TLE'0L]/7^NNE,/9WPR"V[M-D_C,$>YFFV=8?NKX^SJ$^9+VC3U_(B7JUA$
M:'G\*^>'-HBRQY\A*D&G?Q=F\T@"O:QN;#=.SJ/&7"B;9W[X3*Y._1(0XG?N
M1-?=*#%.55#SLCDL!;%6,/F_%SWVG(NP9B/CXY?*2W6Y,]C\Q9S0 -.DA!D*
M8 SBJ^&?S'9-9=AN6.I;:Z,HF6OS"@%JLFG,5.-ZAB%_-:=^5)<>XW7,YHPO
M;.!?=3B?GH8 WS8+;/2UG& X6 Y\@:9Z"FDWR84SSZ>4T$+]^:+U=7SF=;25
MST_!D+/;JA^12B;;C//PF?2K*JQ;,89IE)F2/'%CF5 FG:1O9'<M!\KA1[U!
MQP',6S_L$&-!=4CKUIR.V@YAKMC%+K:&^DL[X255'UWZ(%V1\\.? 8:&G:E@
M&[")JT)A4BY(D_AJ$$2:F,6NM'Y\YU)[E=/<_R'*8)<^8C6#.D!FVTR:Y4 U
MYF.<59X?!1F:C%.)4UYCKN#CEW%4>,8=ZR'PO\DS_V= KVM^N:7_%F+Z:P],
M.',ZT9S*YF2H6QQ=0B-[DYA]S//D_V<N1+%>PG?""A6'W] HDF;V=[I>64[
M09Z82<S9ZI5&PI)6*G#FDNRU&:WXFRYH -[M_U]Z+/\%_M\".C%7)\C-EX_%
MSX!+YJ#^9\"6;*M4CLO6.=?6XUP\LF9XQF?K;AI2!KEO?"+<W#KZ\ RP?KQ
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M8U8Y,A"UX7QBTY6*8@=P'WA1,K2^ZDL'DQ'%F6U%+"%NS&SJAFU9V8..'<R
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M[4*8?:;1SUQ#>41__N'MP/SGTZFAR9B80!-^ZCH7&A?UO:FABN4NDW-O.R2
MV! )Z#1)IX^K*^*.\BNRRYTGJ_U$3*LP1S\@8W#R)S5^X=%5LXV?2KA#Q?D
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M,FG4H3JFR0\Q&@]7;DZR^[-&%EDLY3<XWRC8#'-+LE+F##2&.C.#F 1U=U>
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MT!8A-B?T".T^@:G7:C_OY4/'-<I;>,OL=?/9&,IK[FL5IGMRI"DS3?<>'M_
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MF6]E(S[Y]3)F 'I,]CRN)R">>2"P(:*N.;VYFL5T6Z-L>[YP-8S%Q@SE#=R
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M^*LMBV^86KH2?,Q@OD>)1V$"T"+E<<[]OM\I$B"^^ [1Z/^O!'XM_D0"NH]
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M^>%ZAB7A$&S(\#N'WW=<;'?U4F"6:'/1EP?ON();,.^,UNQ)%"OP \RA7#2
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M35D81$?G'-YODX;1@AOIY+&NR;W'T1W(>1X?7S[)%1OB)WW68#1X^CJ;-N!
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MX$!"\U\=%=8\=(]/=N#KK]^,<.G=_14*RWC#*X[M4C^O\[Z],"J6/LP@'<9
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M2= O[;O6B;S(L!E3UVP1\)TM7M(7*DBJ?QN/Q%4E;$.(G3CT,%N_(17D .S
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MA7PQ&>)K/L-8P^;[&R" ?Z"[X)+K(,6QA1(HHPC>2D(N ZC+%A9"]WQ_0W&
M2::"2LZ@CT&9D2$K->S#R*O'[AAPO-]>0E)"282F8BIH$/V:"BJE[%-JV*
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MMRB:D9C'/&3<SI<<GZP26!QL[/("SZFW0'-9NE"ITL__U51?6>?R<]#3$%,
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M;U6X2KA?_LJ?R-A0S^BD^K;-Y96#&]-#G;1)9E'.$IUSY_7)L7%G58J=9-3
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M=WQO&=2F?+<VG+XQ[+RJ+.1<9%KHC2.ZM3BG0+T8:56 ]@H)1TSX] !O'YW
M>4P)8;UQ$'W=_"VRIW3)_&<3<IW2O*WK_&EC% ,OHP\KG&'^S*UE76%4+B[
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M7K:\]F( OT:V&.\0CB5L7*^_EANVU=D"SM#K.X+758.W=?"*2$[+M7Q?*VC
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M:T<=&G1 8R*7YI.13V[8*])QO^%LB#ZCD%:7'R5E8NY@;LRSO!XC%)(HKFZ
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MTOX>YT/^,_#I2$.$TG6EEGX6(X4;Q:-/1X3A"1F0'_Q\KFR-< &R^J%[9D'
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MGR;V"MQMQ#4.P70$K-)% YA\;VT2-P0>,K57,NU )S1=7I/4?>1_[I+[6GV
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MBH*"19Z'&ODOXT\* .H1;!9P/M*J['FF9.0UWF=B@&[;.OD]SJ6[3L<P%-B
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M%VUJXY'M^M[MA"R6;:#//Q4J *BPN,8"P,(+_B$$_3AWO\]=MTT :*C:S1,
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MD SF<]ON>$C#[ZUC@!0D/J$F:'-N?Z0E(K-)-1SN.16Q[',_D,/1X*X>)V(
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M%PZ/+O+8'5%:")?0^G!_RL"R4,%'R>[S8*NJB<E]2V3-I\23&FZ72$FXT\>
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M*0R,!&E %<W< \QA#[RV1C);P9[2(5?1KM!6(RLU-:B93;K$3_&3++ORE\<
MY1=,%% &Q#9KYO5-027]RQ;/7"B;G:]YQ]6TYM$?FQPA*U.@5K)3#M%"5:\&
M0>@E_XX0$,V)+1=@=ZLO+"P0UT&)P(U8B_= ?!M.@LA@#NEO*+9+VCC59442
M2POSE6*. 07VF2O/U!P])]>B2H8JKY7V_B1WI:WDE4T%<-BL2:5TF(\8#[#_
M'A^Y]28I33(&3DGS21=GT(,T2A!Y;<$#TVANC(+;$U./#3X[QO[*5/M:)\+3
M_E2-P[?  J7]SLY9B?W]":(E;35%$M/I,[+KNZJHGIUC[F_#(LAP8"J*DVFQ
M$*+)T*27;(7#X4H+E/[((_BDM7 #!KO ])/_T.JEED>0"G-K +YZ3IUX$*WL
M;60V6[!FC,#KG]&5O_3^^RU;..4-^B/Z-!BASAA99CJA90\VVR<[_2 _TGNI
M=I[?5CJ5+[YU39JN%^I]UVZ_[N-[7FPYUS1WBE?@VL]E'N&1475]W;"G_D]S
M6'"+WPJ?X>Z5^T!,9O3]'I)/IPTU@D60HYN;2;8R&%R@?14VE6^<OY>T;?R
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M.YS[); M."^'WTP*]K$<1HD&HEX<V%J-F0TN+$Q:O_XW'*0O9,V5><91_E.
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MC_1IFFB?,S7UTI=]IV&5!R)#GOS/523=&IME2UPDC@'AHX#X3-;F,68Z0NZ
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MOZ"JB?34RU079'UFZN).-KCN.3XVW0LJV\[F.CVBXU6TI.6S;XUN=NV7[%P
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MX;7A/A%(V(MHT- @?_>E'I;JW!VLZ]*1!ZD4EQ!V 1C@1ZEI'"<,;ANFY5P
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M7-OO51U=@@\V5 /3X5_WUY=12*XU.D*/!_B3Y?#6DLV$6NL0!<S3[A_Z"Q-
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MCSMR#;E3C8S,3-99;^"O"D6]KY"E_A\6R8VX>>#-,QG*G?Z81;YK2F>,XQ<
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MZX\&K'U">-&$!9=\F:V*DT-$_PMI2[F[Q&Q0&UJ#&9!'Q N"I'PH[_$&MUN
ML(V3@#VR.:A("G>=]+2"7%S<)[EZU0LHZCMZ-/'.%6)JMX9PQ:!_[(H0;NK
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M)OLK(5'!==XCCJ<;]C"^<\"_V2[2:;\,H_NB67-/RH=D-E_\^IXEO[[WP-5
M4^[3US:G^MZ'X(#M5-25OZM@"GT@K3EO3=7@<"2P'DQL!ARS*!IU_/*PXCEF
M$/9FTHMX-4E1'.OQ3.(IBP9))\=!G^JS>&UY[3:ER,ZPH2R5]_#OED+&I$3Q
MO6-/-G\UIW/ :#COHG4TDRN!O,\61WKR@YO#U[KDQ9DNM6 ;62?8P4A+T(G
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M]F5M#5T1DS\_#BM,G+UBW@\5OLXUU-?X]T-2D>;Z'9%G(WT4"&=&I7'T5RV
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M"^/<);(VJC\< HG7J-^WOB!5D8-3JX>*&>M#PK:Z KHM?2M4R\E*J1L65DM
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MW^>SG%-^@C02JJ<AUBRT]C>QWG"T]]/I&_H+])K4FNO-]JN44%/Y\68;RN8
M\ALHY.H2?+7Z%"00!0P7: EIF1OO-W:1'$?YI%=4E:I:)I>79#Q-%E%\U.:/
M5[^'H*6X#)&K>Q4$NGB"=039YC<)UC46HHDQI^EP\0Q(,PWT5L0^%WN4^<MT
MM:#/09;-VS[?_Z63?;^3$$)@X^$ CZY "AK$_?)#+ 5[6.Q02:M[F^B7"Z.2
MH]FHZF.9JU#/BJTFH$K#Z7%UL-J;A;*@?:&$07O[SNW-E=6*63E/*Z80$^5*
M*Z_;3^%LIE+7#OWKJ+V<^>AWA+71; \4\N+R%4979N6]+=&.*:QY1U/3<;B
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ML]SPX..F^@M$]->4BK*<_(O"8'95G3DB7G K?EHZNYF:]&&'UHH[.??VZX_
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M)^I"[JZN2(LJV$.@-X<7 QX%F ^%>QRVW!;]"DY7]456<B&9JG3ZG%7+]P.
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M 'X+VG-BX40']BWZ..$>1Y6%BR3OX^E0X8JUVW=XE/!BA-"Z=LJK5MNVA(&
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MQB11+=VC:>9E*>^_Q?Y3D*=C>JWU$%4?RC'I=NP\E,+<@%8IIYV1^M-GF#5
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M4^Z\S QAV7-Z\%92>%2:U7^\= K%#>[#>.O?10*.XNEX#<><XMNHR4>+W1O
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M!3T9VIKETCW@^;X!%%!%,&8I]I^K7_0N?)8TX9EGU.+PEOC3152:D [J%N$
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M*P@MR:J9/:$Q^?5-S9WO.\,NDJ<$P15 ).1V5/)9$CP,&AVTL9VQ7%G'" [
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MN>?<Y_GOON<ZGX>$]:XYUQQKC#'''&_6S RCES$"'-!2TU0#6':PL$BP2
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M3D2^ZX6S8;XA!V='GV6HGWP"?W=OSER'A5>8BB7KMQ9XJ=/%&Z:>&TF=&ZC
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M59" 8(LJQ+FVEU,W46?1JW<D=S$9M4S76;M IFWB^ [#*(;:7*O)$&3<V_!
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MM_U36Q>[6)#[<\3G^)X+*@\-)"T='6Y8*7DDGCGVW*#6S:?BK"A!J&?38R?
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MQ-7.KK:?3A]X'3&'W%FL/,<>[WE=#%<LV";>/+KSP.,O8&PN6\=597POV-A
MYS-M(,E#5Q/71M".[KCO8#Q?4M 2&%U3]V3 ,RN+:!AAM4JQ\]N\E#O ;?S
MKDNH:?JQX>FT0VJ-.N%Y>3+52?SGTLXUT+=-. 2T5M9DL_8S@/>>;A;;*4Q[
M0Y -FA6ZNXR-!AO3)NI[;G!N9;=8$N^XQSR [T\6/EAI__7>8LB;2W,2,?L>
MCHK:1>Q>71;,;;QF>;A4CB,SPP>U14"4/,O.0 RO!8,(GCG0##S%I")/UVA3
MJ-N^>,A5:;G;R[&@LY*OHF30N8=LT </"12VFSC[K:Y\=?7N3%$UR!*".V.E
M-=7=5<7[N7[)))157Q_"]W4-I>MO8# /*I$_:IR=V3<8P 2,@G/%YI(%B$G_
M7-SK-_ ;^.\%I%&0_<P!-TP9+J,C:GH^P!9!DC/=>?@#HJ83Z_27!ID,P'9K
M4X>_\Q^K_T.-7T_*.['L-#0]D0&<V)@.ZJG"+M;^([09L(V'M!E *&WSWZ_P
M"_KC@;O )ZB' 3#GJ/KMRE'R4KK/8[P;[&]8.1-+HSG_+]7[][":$09@SP B
MP7',]O_D4G]@OY[[:ZR I0R@D;!*</+T\RE$[$7/$,CG&<!7OZ57/563?[L2
M^:^='?ET??L(E FCX*MTO3=O_U6Q0W^OV'\&!_@-_ ;^GP?F"+6@[]HLDQ6L
M;IXC61)&AAZ1:T^X+)Y+$G/KWL'7^)JW^H?-N+^RNKZ$KFI&LAJY21* ]1.J
MOAX(,>CLX;L=P^;O'R]'/>[E5Z,'VV;CHZ<Q@&E#4@,#N%:KR,S!0/<5:"CQ
M+1D]#3E5-#* ?7LAW=.:#LBFGI@W22Q5*H<Y&,"7LBDX,RQV(Y;'8#AFKE4Z
MBF_>P*VYO6\U=+=@+X//WW%WZM4<)]9$EUS\L5I7%Y-.._[L[4#ON/FU8@Q0
MWLEB"2[NV*?[&MB]!DOVM";--Y]^_=KW)37$9<9H Y?W[W\A=9;0CZGI""KE
M^]O1K]#K.KJH_D]CG-_ ;^ W\+\!S*32LRG1JTRRAC;I<FUHE*SZLD$PO5\N
MM,^EK&,@NM3UP-ZD#T9:QP1BHC*NL(Q'11M5<BJ?&O#I9C\X/:_EY3:U_TLT
MPK0!ABA190#/;S* <\@ < <&X7M[D %P(^ +2V$#9M/5'H>) ]2"K#?-DW9V
MJ[W;5>0S$6_O7S \<UYL(@:Z\+S+6'=''3'$X*GRE&_C.GFNRE23@Y0)C*.5
MNPH9@.#R1!:]H/8&*(X+VIX=PG'!IS$;Y7?)W=:"-?(QEJY+^QUUM#(CY5ZG
MA>5JS+Q__>G$6=UK(7IG*UE"R2YZMBJHJ<>1'4]$],2U]+]9\AWCFK*BK\&;
MJ?(>RPVH(/5Q :<?98-*;N_%WPY1:OL5$3C;NR+B/X9EAS_KL$H+W;R7+;KS
M;6,4QMBPD*-L;^<!,1%I-*4V9Z#Y;:E,).I'+7IDYA2%FP'L-6, 02S0747T
MF/--WXN#GF&I"WNJ#[IG>5HK<DHXNL8Y567FYN4,N'EF$L>>Y;\Z:IQR3/$*
MJ>YD9#740Q#-;F>'$>>AE)XPM)D\E\Y)$>08 XC5D(J'K>1)EL])A9O5C4M]
MQ@:;T:;4-OLN.=026Y>U*RO2L^H:HS\6MW>'\,,#CB1_FQ;-R2TXV96J=3:Y
M/RBR0Y2D*[8;_R,SR3/"YF8X*=,6PHNYYD#FZ)7LF@#2]"1G.^4IB7N<DTS)
M(9I')J?W)7(+Z%<(#O)$'VM:>:_\HJFM<[SHDN^1P1M-)5C^[.\)AZ_NN9C#
M$A:!1.*FNU[9Y;'6R2*M\?C)GV&0,ZYU*Y:*\GTUIQ-02"E^O?Q2$7VGS7FO
M$E%[H&30?1UK&!')/<X##GZ80SQ?(^KO<.)J0P\:[E2+PK/6)Q,DRV\5*&=J
MC*)1<7-#8)Q44S=%<:6G!C*Y7C2VD%TE_T#[P[UYNM.\7^)A[5FQU#0-3DV;
M1Z@K19=S)XW8]NO&QISU6;E5B(];(V_7V%L$=GPN);7NI=? ,Y-#F9[)8>F#
MIQK04R#KZZO&XN4Y& GG-SK-KS+87?4F[62DK>S=-Q27.4<="R8;&O>T'C)U
M.>?"_]I)A5WCD.'LYV1,Q7B7X7>[0Z4%CU'*Z%NNUU*8E_1>Y)MOK_#KZ4"S
M5-N#]%?9^8-RBEE991:;N4-'0_'^GWN(?/$M3OLQO?Y:L4VG(Y2U*I2/ \_G
M->Z<=4@-?XHK"8?P9.,"?^5FRP5@RW<6RG<MG'&FF A_=9S]F?2R6O'56YKP
M'=\G?6Y']W)6SFBGQ&+J',D(=Z.T9W<?']+5+T-X"Z%),_,"=W)1V&7KJ,_5
M(B&*@7[B 31/-T,)+MN&-=C[:,C\HB^:*:S#B$=LXW;BZO1DUF?'[55K6*]B
M*WM)4?6P:*U0?O9'T$]PY1Y:,:!QY#SYT,TB<+ PI.2IR;>H[^PUGG;:1_6G
M]9]V?Q(3RTSWBT<VX>9:S78R !GTU-U5&M5\_81'EE=(V"._3\F)#Q8D2_O:
M/L:'0"9<%;*RRA//;6?'=MGE97D-?#EF]$.#W?)&[M'@A!%O\F0G!]LN-ATP
M=JNH&_^8 7S^XO,H(OA5T1P#B';?SIP52XAPH945%[]/WG./-']!O2*]7SPP
M^BE]]S'UR29F_ FGG\'9,@ N&I_/3GU=?*\H#=DW;S<\V47_Y&U-C?%U_$B/
MF?7T8%-TFB#%<\0G]BE^3B#'.7XJ/1V623AF-&[@]N73&;@A9'S]]I'V:L]G
MK[+]<#B+3A7;LS X/0S9"7^/P\S[_;.L+?\-_ 9^ _\;@,TFDUDY,.F6/D6?
M ;S:4PMN)B<.-7Q$(CY@A.B$C]X?6BDH]NU*YQ$T=,9W&5JOQ&-(,!P%9>3\
M;#L-@L,[:-!AF:L7P.\!8X6\KYOYK<<W3IR@,8#4+EKSV>/#B\B;X$<:\0'N
M#@/8,Y=L_6O+"&!^1K';3[X#R;\AU$%,Y+9:: DM@6/M/I5N3"F?;[OWG!/&
MRT)JX/79%Q,^JYE447%OXI%I=I7&B((+/:\A#WZ!_VP$R@;?5U<@=M%CS0'[
MKM9^,^8C W@&,0"1PIC![3P$N^"S!6RDG(]W(MY,^&5:4X>ZI 4>=N7A^KJG
MYH5^V>VIFYU&^0_[D^YO1[\S][1B)Y'P6;&&4F^-=;?3L#&V^K\6+OH.M]/[
M0(KN]-?;N+5]*?/YUDTA>"]?DV;GR\[ZN]+K.MKNI[SUE=W]MC$S]>3=+,T%
M4F]!_)"VZ@?QVR[9#$ XR\S.VKA.!4);A 71)>[*@=++0;B.[=WCR"$/-Q,&
M\'*SC$1CIZ ,^<%9+(7=S _\_'3N[BNJG"_MW*F0<DU]M2*+'M[XV_=4H2]]
M0330[237)'2P(V 4W0K!O3O41SRV/[O0^\'5BXY2V[/P>:+U&)W0!.^E)"XB
M5X<*G:&#*5TT2^X5V ?%JZ\X0LWG>V%",IYORAQGKY7JC;LCN [R<5ZZ?^?J
MS4_GW!Y_,[B=4-ZSC?5XS;&3WK P6Z!^DSUH@0$8<^:H4&7([+>7<!3]5H_%
M[V%MGPWN>N=5(.R7MJ/+$X(%U+'X?NJMW,OW5T0ORW$EJ^E@L@EZWY5F7XA#
M9.P[V)K;XED#ZC@21\6JL-/%YP^&,AF^+"S *]A;3HN^K.:0NS]#HYQZI<YY
M(5%5. N;_UZJ^NE5Q">(NR=1#*-*^(AL[:['M3Z>(GP$@W#'MMYSQ2,/EQWY
MSM%1<R8[<V8I>M#G ?;4C]XY+?FF*3OQ1^>-+AZ!:>3'))Q:E@:$<S2OBTN&
MZ^K?\$ORBNXB:KXM])T#/]5A;S$ ^@A5D;Z*T ?%AH@M$Q@N^F,*BE[F4B-8
M<D*P;$ZHXTU>OP+5Y="='D=EPUMD@R@&4!G*4T=1.OXMW0:^CW6,*X,-:1W+
MC\]_OYJ3,^8[XR=-\R[%4M2B_%&3.<0BV (]96AY&VD$ \ QI>X;IVGJ%&\G
MZ2&"M=E3GQ[C?Q:>\QOX#?P&_G< (P)%GYW4036C?]\2'[>V\$41S53<EC!E
MBQ^&R ,5BPTU-AN*7U\UW4GV%Q70F@)2\DT/]R^[ ZRMU:(7 #9/.N&S=_'K
M/1*V=9TK^#CV/!7H)GA2466,G31$R5DM_N!"H:,=W% 6DT6*^!/EI+PJD=E<
MJ^\3]J</=G5P\[P7TTCXX*"6EU.TDT/)-GTUBSCG6SN4R[/+FNUM.&D$6)]'
M.U-N,@"2,_4G_0OD3'=? E_18)9.F.IY3"Y1$?W8>(F_J6'QTFA.^H#<)6/5
M5Z?/*!Y4%SN@^I4 #PU\Q=:$/3VCY.?=+RYC:YF0X$+UYBP_.DBS9B6482;[
MXV?45%AJW#?4G2<L]RO)GO!_K=_$ + I3!;T='IUZ9G!P7G(*3]?]^E)Y?GI
M\9^P1BR5F6^(#D=M-U018CRV#B[4%BQ\2R<R@.'0GQ5E_;J&=W-([XU&(Z6?
M#KC)EI;$O]$ON:&]4U^D2+HX+<FL\SVW%JP/LL@-MMG1TWR,=KEVN#B'+Y8>
MP "2SL%:F3V#B$W^U3FN&*5F^;ODZ4<>M>[::V&]E $UM(/5%_O251[JGNP'
MB2>4RV=SGHMFIF5EFKT8>QYQ5F_E7)[1GO$O+NLDR&3VO4C&(_:]-U=&)[CP
MQ*XR)@?#(B.,W9G,3FX66J?D17UN'4H2#FAR\%XB#"J&X6S:G4Y>="H0MX7!
MHG)LGO/;'WFMERE6F?8\9'7?UW0[!_E75Q56(' .,E?@85$;U?,T>/BMH4":
M2C;WXIK\M=90G-JWJN+E^Y@Z/IAH:>.69>S GIB[5<Y:M9&,=G$_/-VW'LA7
M'3IXB7XV6GK_R<?B2MHZ5TL'/EA>._4NZ?)]GK2#83M2,W%S:_/*<F4ITU_:
MQBK78-\P/P)AKY"-]M/3)N"IY63<#H^8ACY9W%G,%?>PP4%SM[*9:B1'9&I>
M6KW51H9!N\&DGG5J9GN%]R(\RTB(:;_6 -O]NQO%V-0+_+Q[U?PD.-ER1\9Y
MUN?Z"*.7"#MJ-4%)[+,3L6FU^HXUU27RV\Z>R^<8@'8H,3$9ZYDW+L^)/'8C
M=-.3:K7W<DFPP]'7 ^=K\*9GI?<>O-$S]1#A9W=^WX[,"@80/ ;/QT]&TQ,@
M+[H5Y)6TO996[B[4\IGN-4P+F$1<=W:ZC;(:79/;6'1([!IE  ,W'M4\R-'7
M*LO>%21QJ=U#H*,BQ("*A=.WJL1%VS.S^-6?*Z_/TB >)3H.>L0 SC. A&'N
MZJQQSJ:^Q+1[Y".W[[C_(!4.*(4JEZ0'%G+\-(T7/WF,6V>-Y>J,YI7/&^BN
MV1.K.Y_Q\*MT=&XG&:8]3+_48O9MBV6"2PT)\<C08ZJ-J2GD(]><F,[FY; 3
M>6J+]41EMEK'4+Q:@][TP[Z*<;LW;HB;$E&NEQPP:J]M7TY(5REZ'=LK@N :
M ]0/B*A;G+*3&]%69@"&.BY=#[I 21A%#_L#&1P-[H?0&UDZKL8-4.V\+T:<
M+ZANTGW*\I&S7=B'M[#!FO+H1L?@W.A;[/E!)Z,?&QM]XCY0RL7A\")M\-43
MV2* !2TVW@R;I'EG;81F[]"4'1G">#&3T+ZN=TS_M8/8Z7V0.8R_NC6E]HZ#
M>5))#FDP#;L05IS?3UP*\/.JMSQ>0M4UY;^8:G576XE7%*57AM<@<"P[%!P]
M_5P!S./SDHW(T-;Q4Y.>8S>[0LLR^J<)O[^!W\!OX+\.S"'_7%OB7/?7[5K_
M(\CG;TL^:/_9PU\[O/XA1?C?5H ,K&QM6ORY7 3S'QS]L6'P/X'J?@._@=_
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MB0>Z%.>-X56"@S(DT_'<MD=V6V ;6Y8RVJ'GVIQ&SYNI<@69*O.#-A<'SS,
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M18-0D;4J.MEN%[IA'/N02U)%#84LH:G7Q+CA2VKA!^5H7MOIT>2;W6!<AI_
M[NE?'KO8*O''J^OW]-PZM8<*[34D*P:[$UO$)\<Z+\NU56=DC655J^_=($8[
M +7,F5M,C&=S)2SA*UCV'N,N&95[N8"4D3P$$L<4]TR$EZE?%B%(#U7;!%*<
M/3_#!(M+5.3"ML\F61UEMGG84.QXSR='O/K1023YKRHJU77! ,=XKX&V4P_[
M*PJ0^-I?\8S4B)E@OI=;]:0476Z6P,4L!8*YZ(;9+WGPN_8I,"?F"'29\P;(
MB\+*B80U'D:E+THB84?MZ]5;?M\09LBS<W3[@)F0?+RP>0=7\7GJ8M:NA !K
MS*A3*](<:N$TJ*%H@?XSB>8'CKS7PDL3&D6V'QV9HM#3_F"!Y@CF KG3B3HY
M8F)"V#BPQ>(<YA)& !-"H_@OK]PDE6QI$#8H8U<;(>D;L\FIGC6HP61#E-;P
M3FO_+Y^T<8C=%3WG=\8%1#W 3+H,(NQ!<D%3$X]712-03H*#DC9[HG>!PW!0
MV9: 2:#/1AN;JD[FKD>4G7\,D^GA@<A G!:?E^R?BH"]#M64&__P,'YR>CGQ
M0!M)OB60E4N>IB5RI?1!=DYE(_!!36N"[#-Z/Q^8O%6@!V_?3$)YY:[?MVHB
M288>U=))UO>;LWL6J;K)M416(L3>G&=V'4#JRKV8G5W*GF;)M7DOB-[OFFN#
M[OVRDF_0F',RLZD13$Q]0)SQ>#J-@I'0V#&-2\QCWYB@R:[_''#JJ4FG=6"E
MX5RO?VH4HOJY#G4":&96"$?1:B3-5^D'JLKE.$&FQA9O$C/J*,-,N&G]V0!N
M0B_32V.9-4,@ N*K]!] %\+V2!)XM41+_JEKV (/Z+@.97V<7W,ZJVN>\EYJ
MO"&BV:)+]&9WMER!^=F )$$!XP;V+3_I#-R3MBBK:3 ++\?4E1" +G@G4I+9
M6Z33GYIM1?)4$?[F='D?6F2R6AB#S^-/547=7C 5C?D"#MS#P]SN<&WK16#
MT3F#;4;$##.F2.94W >?!&T^A1V),_9\@D0I A'1"D]+VT"DEQ,(L=G!XW-[
M0LFK].>TOI#?,Q5USYKYDKH '*B,LM"AYO^)K38OBPD;6XR1/E"[+M[8PPEA
M:!Q5ZLC4T3GEC<V*\2#U+)ODN40I5,^%,V^,\G]X8%]_$B0NHT6F&FJVPJ9_
MO0J,,/'<G))2)+G<:.YU'8U)0'IT#G\^V>F'X?U]0(=6O>9*]Q697,3,^%?&
M,;DX#59#+\:YV(%Z)]@1=L9X=$3_:VI/@'FB!7H)U(%P7ARSIA]LI^B7"V#5
M) \UL5II"*>#[!CE/; ]6LF02\IP\O4PFUOE"J<R:\CY7GC%+:5D@0[U7HZ;
M";Z/:!A=#!W6H4K_[1H^4TBS7,10T9BL(T]<80K9?4Q]^"+U0"^[_=V97@^3
M^S1@U-Y<NUX(3Z' 76"!XFC4]V Q!R ?/E:7UK=>=3S\^I,JQ9$C?74=;KX"
M"U YI=1OXN0@/-LNY2LF)8\!V:>>NAHY$C)D\)VAA;:;]EY=[(0Y$VGK)F=2
M;V^%>/&:W"KE LSX,IBNL+DRT>6U,59LA>DWV: @G_6F/K/U=FES.\^KZYP=
M002 !-CX*-9US?;!9]8&:K2"$[.K:V>"A<04'#99V-.5O'&GP?+8FS:_$25P
M(*(!=:AQBB\1XP!CO#2W=*AC-'%UUK\9K?PJC;7X;Q-U7%L!OV56<<6&DMZU
M^H]V]\Y%,%'8^Q]6D_SW5DM,AMX2-'6 P-;M,T9@$O+OK_C[D@=?/8PHB4LX
MHOZ%)\;BU'%GB/_PV]]73OY7OS4UPRTUT !9;IK3CY;/J?Z/?_?2_[N7%"RV
MI%W)A!PI5^PA>\H_.\"L^A]U0&*MV:?YQ[O^ MIM:I6;D715TB8SJZ^\QGVR
MO:A_?/4D\OCL_]'C21Q+-9*4@?^X*.!B_STL_]'B_X&%_^L3+/_91(J^B8/_
MV4#4_\\-1/H[I81?A$3,F;]O$O^^Z?4_:YSRG]Z/^6^]K_Q_/$#X+_>N3 74
M0KS>*F=J_S]N*?6W2OZ[CO^_ ^L#Q 8;=NA00Q0?':KJC;["<S,0\@(V,Z=M
M(=6"I0K1? CKOMXY7868B$73QXB,_C_I5)W2%]J/$T/,>KOJG;)4R/Z-9?%J
M@\7NO\*MR]FPM9@\WV1WH"PERW)HJ3UE;1"&G*F1\,4\XOL/QUY[91XZHD,M
M\7V/\!+G$J$/"FS^[F#-Y,9-URS6FFQSC('R8--;-+V1J'J3X/4M./?/10N(
M)2A]*46?-IW-@3\:(_W"$$].\%/2-/^W-4D.\\=]CJ"%X"2S.*QYKW->9G[-
M0+(6$."T_BQ\'A6QBJ!WG@#]#*B%#^/"U5W@L%E>BQK3!=+;NWQ.GK#_EGR=
MJ0;W@ - %]K_[*MY]ATS!;XE!+?_+?-C_\(%B^KT)&[9AOH_KME>^A*@K-\R
M(CT%52)"+/W][(/2VV6:O2&A*$#B-0#C:SAYP^.Y9>%F+(MW$:G7O/8DN>7N
MN,:[S-S341D3%>#))TWMK?)QWA /MMM";TMJ>L#2VP-KH0/@=YN3@7D[MA1B
M7AIH,S-7B?)J8V=9C]12TC-<4/2S'IJF(P+>0P IW91.N#FP'&$<K7G#V,)B
MOE%]=Q!WVK2)'< (INBM@5&-(J@_\[<!JHD1#K/WZ3CBZ<<&FG,BI\O?%\60
M%-88*M"O0P$.E+-CKTC#;;42DOH.C8N4I<ORYS"Y,3R!;(:HX/?'AM]D>& ?
MUK6%R8^"RM)I/4[R:Q6T.)@BG_/"IS<Y\@EL$&11[7QP^_A0' \Z#_169W@.
M[,*+25BK!U]>&4Q0G'R+U2K@QR@'D?*7S]S0?[8UP=FG!"LW??JIV/.,"O.-
M+(I 0ULC+JGQLQ$H]70L_'J5]9D+K\3(B;U/']R33((O!1BUKX"F$OU$N+DG
MGDJCQ#AJM' K U-N"?X%6DIE$B=V=<BQ_2ZCHGG^I[QH\,KK8"^!M3&JJ%P*
MT<8]+XD**8^T!; 7F4^M:<K!%%5L^H.[5WOL"?2S!'IE7_TI!,Z6Q?$Y5S&\
M]D]EF_9W%W8Q8(-UM'%<-,3[9>=6N!6'O*-M4Q^0J+$]D!AQ]KS'<=[8-@0,
M3C2M "0;:[36DXFP)920(_.=Q(KX@&=WLNEU\#E^V=1Y,L.'!M!/#XC'.E2>
M&4@=!%1@+2.^N!=3JU]$XAXD9!W[Z+;X-*XL>\/45S.Z<KZRR7([1*!1%<LJ
ME!@\)M4 /)*G6$^I(]&U/0XD4%)U/_*3O#1RJH$5N[0B\?<0N*!:+)Y=)2_S
M.NM^A; 1^N3O.^[)')H.TAFFSA;RTY>M$[W%4&*"2^#>DK@Q_;"/ASM@K@X1
M)4G"JVF3^6L5WIG/=S 7_?08:0>:2!/\K0M>FR6\<D*/SZEM)K_7H39P(W:#
M7ZT5N,& 6@W^MZ"20XT3N"Z WE9/#I=<NU=L[):__B>__3=_Y3$=*H*_!ZXQ
MO%K]LC8D9K?='/:4VZ8O+\]#Q\S2%H+D([U4ELJ(&I<7O_/TWA.>3W_X1$T'
MNZ86<T==Y@;,Q'B >3*%[;#_VKQ^",1)P[%EAU=9N02C3*MG>GV!5@M\<!H*
M;(_(< 6'8(UQ 9MTJ!%EI?=P1\&$,+$R(B@M1GE(_54)2O$P5C_;BJ_ET]'O
MVSN,P/:E@VIWQ=^C701\(+1W&<)"*Z06-H.X1ZGOJ!SFJE5U'PUC$,FJ:4_\
MX*%53[PEFJP06/=VIAM(HIYS4\L_Z%"AV_"(-L<69E$U1T!9-&R??NA<./<O
M)(FD<I/*K3[-WXV9*#24AX,$7(2JJYFEF,F'T>^+GTR"B4>BSSRS"OP]A:RM
M2"2_'W+G@%4:F]L31@U0R@N?]>V4?ZYK8LB83B5/NT2OUWL+^9?\L@0+,(7]
M^',@?48MA!]3>K"71)%:7X1/G%E2F*F2H=WD>S[_\!&*&QYV>S\.X4'?!NCJ
M=A#18131JI"OL&E _F[3!V]Z?[&7N[E-V&ZZ./;ZEMO,M!YC]/G(Z78/G0)G
M.(0\<\.T=TA#8(,N^ZAAZ"-IG'U%HO_T#@8G<VV][Q;YIL/DR= 5<$7;BN /
M TV$C-K1O"Q _?IM&7"O#292LQ2FK_';Q]5SS["OP1EH:?CYH&E+M];7MF09
M:+E-[WGFE7TZU'45^6$G_(SMGKA61%6*)=HTC)*BB&XY1>^/AP:AA (KG+<3
M?B'NVDE,^@_KA?>'B Z36DR@U6@_@,[Z^7F)J&$>1EW3FVJ4TUU.O/@E\L0E
M,V%%C-<3$Q@8":EIQ?J 5R%JNP[U RN5%6P4;RB[E"EST:'B\K.BCX1U'-_%
M=)7GKWH^A.C4A3$CV=R^]>LLQ"5#R2\;&C##"*\ZQQ4SH"DD.@K<2#XO/!Q@
M82NUK=F\"2/J*WCQ(-="Q%0G^N-A$HR;D+T85:*ODTMI([;;.O>V;'LSN^$\
M3SF=4G=Q(N<K6B$[W]LZ,U+H]=12LG9R#>;L-*WM_H2BM-:]M?+(F'!6WX?N
MCLAI4'0MTA QGAGX90!M#.$V4OJ"[#?T@YL9N;_U7\2,6@YNV5Q2XNLQ_[X:
MC-/B65O! !VJ2]1KK>W[>Y $'X:OURBFM=MP#CA[+9_L9RYHYW"80;,NZE!!
M#COTV5'_C R?[FR!09%,4(4DR?R5>$6F-O8-=>?I&[64F]1<F_RD3#B\S(EW
M:EW#I [UJ NLBC'C4&,""_&9VW6H84R_H%6LG+D[Q Q*WZ/_LN/)XN1]LPCE
MAQP*E!T;Q[^=_1$L/FPB=KNO\7,-WLWH,B;+:8L4^+!9'I^O^<>DZ%"JJSJ4
M=\8*_^=6G4D'UKG1XRB>3K'WSGJ8,SV;8_03^0]6NT*B&+-$_X)DS85R'>H5
M311>'H3P+/WG[GN16D&NN+3+.C=C@)I;^1S1_ DG=:@8.X;CAX 0T'<Z78P9
MX>^/>2#"=%6!2&JV>!Y,9_78'OINZ\1>> ::LX6+5=BU$V;4&:A_H5&S2_D5
MX#)O,4:4\'1>2N$[R-.BIOF3?KOT$:3SOQ?:<6^5[L** L$.C0V#$,@T3H?B
M*!LU7:=.=CBV[YAU=9+&'?6LC*]&O "6#K(:K^9WTPK8WCI4-M(*&H?J^X"G
M]:'1VX<DOY[7H>*]#+,^3(N_UU,;"DH?&R*)?@+"J\')NWWPH4[2AGL7AY.'
M<=*4# =V<ENN^YQ:_G?<-!AEX>P*W]X-8B^NIR]68KHX!X"1;AUJ^<\:XIE2
MKS4\*4Z:\(IO;>[=.<W*_)(\P@6%$(54-4P<@#O901HQ5V&MH$E)VL'L!FI@
M9]GF'P @=4V?PK'ML,>,NL@5XG2:]NT%OX)G.*'7("O9]!RG%+%:66N8#K4-
M/))]YI28!,5UF+.F Z^CF^#$+0NLXW9V5O(6##["V>^%1M( (?206C)7\T!&
M9K-TJ!PI?^TP.<N6NJ_F%5H%?FJGR[B%"&I,B0)[0%S?0K(0LI1PA6^+&==A
M'$_(;:_,7XBA0@EOZ#UX(-.@0'GRX#Q98[II5RH@G%5[KF%2(ZL91CC-J"U-
M!(A,2Z"32!2R"TF-3S1[35:'FA31? V:$P75MYQG_N(VBI58N4'G^S0;R.2H
MY2%JC$!U7/;.Z";@&,9W,E.UA#_)XBXX$0FO[=7$6ECS, 7;^^L(@."272-E
M9YQ AW*?$&!51:V/ \E';A4?E7JWVS_X/+SA/(LP7.5+2_,M7'B%A5-(CZ.5
ME/#BAV>0.,:'@B,EP%>O*M]+D\5^=OMH(_S/&],Y$7U+G3.%KXQVJ%]WE/M%
M63/55_!X_X36D#(=ZLT5@(J(]*CX\-\?=6F?HB?")=AQR2KL:2=R/F=)P)FR
MGA/%3XW-,%!WNH:<9G>Y9JBYGV8J>I70R<UG&D[P<Q)\;N[-6/B4:7!T0BKG
M6ZTVC'EC=BVPIH$SD56SKS"N8 W<R9,:83BMFN5) P-L^-A%\TY[V+OMRR*I
M=OJ"Z$MT-6WC!]<V>?'R9H_VRL+\-PE&?FT7:*I5= T^R$XX<[)/&,S^"M\<
MU&)X?)B\N2,$W<6_+S0%1GY-/:=#V6/\WNJ_1'T-!!0VW:65\&:M#D5G9(X3
MXG4H.]!:AWK'ZZFIJ(6/(FGPBN#Q&4GAIY1)YJE>JH\3[)L>-1VG[HDZ"'(1
MD:1#=9Y"6&JE2H<J: MFVD7%0C_E/[/7H'2H$ 0)J-/=H-SMBO6+Y3J41V_)
M:1WJFZ6;.O;/7N)GA,$,6V'.&8(H?D_6=2!)JW!^1H*S-O%Z&$%J,I*P(S*N
M2)8P "VVB&P8*A',<-M:&6+C+!##Y5UVY!.FAJ:ASW"B_=PG\+(8CQU)L[U&
M3W(O;&?(OOM1QDY77NLN0!ANVH;C[=T=I0MWD0JR(W[S#SN-&=VXGJ282_ZJ
M<+(0!&&ZDE_"7+GI<]N.+[BY#PS>*3$38&S66'CO^8+PX;61J[]EFL$N!=S>
MZ!2 3UT5#+ UE1-DR0[0/:OM_=4X_HX3)#JF,?Q]^D_/5P8JWW&.RGIUY21I
MK!6NK14[4,T"8C67AX3,91WA.Z8;,$BN/L*:K%HN7;$C.QGT#06-2A"$>O:8
M2)/0WMX8@MXQ-?X)3X@:3E 9>@AL;KL8%UP;UY,<9MR9/+BK^GPNY0PQQN_D
M!;"J...I#I62HV& _36_68#*+]3+55#W57C5P'<;>\+BCK>7]\4.[7FKV2V$
M<<Y/7R>6*?_R>#BX9:%'CK_([_!",VO]2/;XK*3*4T3YG@[%&? 6!:Z&[I37
MC$Z,X']1N$/D<<^5K%)9J\M"<FLR"JYE'%@>81*@C"VTWO&5"-S!'Z[R/-$P
M^=T" NR^!<(W)1KCK JK"G4E?C(>+=*?M+7/R+0E(0M_3^PI._O+.*EGP=4I
M<*_(48/W#18?TX\C.UA$:4_&:QM4ZI3JJZ<^ZU#\(P7KKB-A>*58AZJ>+YJP
MR!^$73DP8=7BGT!+'R;QV*#0 _SX0(?JGEY&U:B @4P65R#2H21*J'I[U#SM
M)F(M$_RIL%2-QE@B$6Y#\P-"G72HM6Z ] F4D"7G(<$,Q6HAG_C\\P4Z%-AP
M<0[^ASQ/A[I'BH&:$6ER%Z1#"2]VO45"_3A$%LF3O(IJ*?,E@0H[LN>XFWZJ
M^%5@Q^#NZC-!F5_=(!Y\FY]-K.XV@W_!.W7R4OPUIGD FT#()KQ#REOK\#]J
M7COUMS/$A<!YDE3VZ?1?@O=@GZ^/[U>$B)+<5( 0_**Q3#!""L^ X^&W,4VD
M3]JX/^]B#CV\&,@^O8MHUQ#J4TC#R6]!SSV/%+.)]YFS09ZYZC)CPKC3JG6N
M9I\.]3 E565C"3'L*PLS!F^0O@U55\YD RWKH.T6YM)9P";@*^.+?\=U+U*F
M,@@KQ"N'%^E0' 8^O-4'J9R9$,[7;?.?5RK0B,7KPM,R?ZQ:]Z)4Z1AD:+GJ
M]A;28EB:QF;=Z5?K4$IT(%(43"XI4C3T,9G2M%]T*$]A"YBL74P;M_BZWQ*O
MF-8M JK$8.&'3$V#*GKCTP/$M?X*M#1B.&OT:L *=LSBN0:\M64Y6T Y!5XK
M5AA7-R@Z_YZ(.7&R#C3&-((MMM9NXI2V9L;/KYE'JU >3D&<G&]D17UM]Y^O
M4LN"$-ZS6(<JQ"ML6FC%<<N!(2[/=KT-FR+8OAK8.?W A1/'?7*,_--G;)WT
ML5B[KM9IY<IY*BW86%]5TH2IV('%/0-_.#JP;_<//@QG-(U$+X#N5SAVXO\>
M<2ZM>7--A]*O&[0CG%-(L!%/_MX4 K41"S3*PS:/)#WF_%K]\>) B<F:O\<)
M_KY4\>X=]2AFSYX/T]0@-A"I(XE:Z,P4YWN*T;H@H\KR0I5M:UE4CS/CF]NR
M6PN);9R(N$FO_/U;6TD'4\N5,\+.%(D9</67+*1 8^T-?S^Y?\I"/^#^;,;(
M;K7+N9]*AXLVR>9%NVX5OBA\)XNY>9L4^FB2RMG#Q/3C?1<=Z_&R'W3G3O:8
M/V1[F%AO;E'?!Y.UU6O0%T:APEX3>?&>])5DR8Q61-.TOQN,W3#;Z10@,BC:
MSCNDN.'T8]:U<=@E^L_*PTXODB>L$(KC<TODE)-RK$S<0,TQ:%]_09]_-\#S
M$/6E. HKFFYCF7BIO+!I*K@Q<?/0Y1%,@1LI#)H&MGDU.W3+_]X!8LY@W+&-
ML/!9U2R\.4.-HC$@?(RZT19(=)JNBI@G7?*S;B2_/JL/K&-@M:ZP.7M^4(N*
MEUE7( .*WK<%!5;.A$0_=NZ$?QP$-(P8?^53T]<Q?"Y#%1&O:45@BH>GTJ3B
M(_I]'9+>8,15>#?U=A5<V_Y"6K;V3JG;,B(M<RL^<]+?5*EAH9V+ \]<Q70S
M_HIH?Y*>1>^==_Y0$5A]'0 8[ ^]'[?6JF2?#@BM*5 F(MC)_]B0Z(:QJQ;J
M4)=UJ*M*R3\NQ6#LDC)NQM^,F'<>B;Q'!()&>U8M>W^-KZVHF[VM]A$.;C@1
MI^9*XDIY\^^;/O63F5P86WI^&[EQI%.+42S2G\E (<$(IMV_&DY_^-T^877T
M]Q\]&>DZE*M7-AH0[:5I, $<?*0+J;-!*A!>:OZ(0=ZZO-#S4T$6;Y[#\X":
M@U#()$:YAB:_S>U7J36S<-+A$IK"Q-@C@&I1_U0E:[(^+[DV_*.KZWS2BSG^
MRB#[R;-PXE@P  R*,H)"JC@ 9XW-L<K##HGXQED(V\Y%EUCG!R0]Z*:M[WS1
M!=UFE'8BC3E%K\-K@@GM8B45X6,XZ(-:-E 5TC]?NM/6'&[(*/WKW;4W'U\]
M4&FTCWJL$ 3T("F?P AFI0RP\3!;3O,]W+F^_, ZP,(LT]U)E?(-3>V*F;_B
MA-/YAA6O=2ABM06M"ZP#NV)"&\*@?GB +??(V40>=27:FV=&=/?<*F^$E:/*
M.M<I]0:(\<N:/,:59$3;?E#4L)\%!=$X320Y\<=#>H@_^F/5M1_@9_^6&Z6E
MBFD!+1LM%QY2/%7.$GV[FC,@E*DA('-2\[NX\K@QJ, ,#;8&)#Y8D96)(<]Y
M6N]W!*S[U(@1[]$O'-V6IJ@%OKMI(?/?)P0NJQ7;U3%I6PE8YV#![I*9H($Z
M68=J1,"8\&+; AD2V</,OQ8(:178GP3A:0'-V18@:VQC1I^H,<3.:"6#A.7!
M=$]"FPZE7ZBA'X\@OO;G1RM[+-5D)7F227.E$"R]-'J?PU(=:JE2$"%)%W+#
M:0*P%QST@IRK9=4QHXD0 D%:?VX6LR:1\I\?)K=1MLFY/>8RNZ[.:.X_WG8&
M%H,430/R\Y*4ZC<1DDJ<$![7/UKL2[ED$CH!QFGH%?*@#]!_>HZK<Y:L^H*F
M!*9),..4 '];_!XA-Y+&A 9A*PF+[M5BTZ\\!*%I_K8Q_(9,I*&^2#- >_TM
M=0@?J<?=0DH%3@Y(@'$*GI'W+W8IMQ<[II])3\Z1,Y.2H:,ZU&-@T$M,(I^@
M-^6;^CF=K,2HH_3;:^.WWZ[V-V?DK][S;?=)X @FL\*8F]F ?48QK9C(RSMZ
MRNA.=2Z-*13O-Q"4I63O<9Z6[^5SRZD.(9A"+J24*X4QL<&7F2]#O K_GA!@
M][A1KNK_X%8H3PU<V%X$4@&)06_-&S 'MLS9=D7@2-8"O< @D:6F%4$XLM,E
MD_W2ZITU;\,F2Z"<K=&RAC823D[L+2-\1,1I/"P5 [<F]&"'" SGZK".0W":
M#E6ER;QGBSU,?*&E=:CDY+_+AK"CRN[?-A/ZV>#_V0:OOWU#BQ@MT!MWM!?]
M'<R9$/:B9/\Q_<S"(2YS4Y/<WPC,D[)#LN(0@7AL#R I4SR/^0ETD,;"!_+L
M0'KNL27\]M^%-/-;#IAQK)+B=[)_='.;'[:>W,>?_UIL$A=WU-[N=,Z6[=2N
M/K?)$I<^XKD/M$(C1E(@@J5Q&%_31):8>6SIHZ/2_C9[:(7DS/M-8L*=]N-_
M+0RXK468R9SJ9HGBY" 4]T$3]D!<;W'69$E#\1\CPR3-4:^"[9BB4+#ZM6@^
ME9_X9&^)HK&.I)A_4@J/B_*/<U8U-W^*%>FG45P6O;)@N#4_ .EMZ VO"</N
M,S@]3ZJW@GM)J?1.G^PK@/3<7Z:UB18^=4$2&L]28[+FZ4$# ?M *K01^&SC
M);_(YI1EB^K]UW0O.S"G\"^7ED ;3J+RU>N5X'-C]T&UOA]D;^+1HI<7LQH<
M=KVZU[?FZXR21FU.BV8D0X<Z#@Z1)IGEZS%V=Z430HP^A:!<N233E$R'4BK^
M(WH5D VS37[SM#WY(-)M/%)@]&L/G"^8Y>2]QUN.1!O$K&0DV?R8^GACH(S7
M,VN*UZLK#QR/?^4>K:68#Z]6:LD!/6<(RSRC.V?)+YN<8)<OPYV6*[;,^=#;
M;97656F]K*/=_^!G"O2%8<B]X>_.E1 '<Q((2>NO3Z^^EKU[O/7[;IK\:$'G
MF^-)<T-2=CL>H<M:7^W^U&$L5!/6)$.#>Q5?X,$?P, J '_88'VL#O7;#6T6
M[(6T/L.$J1=I(,*?R)"QF"2OJ]&A4GTG$<& %PS3M!EH'DPL2NGMW0W68[C[
MB;\VMF$F25%/.(;].M0&.H\!=C0ALF[^8H@'I92!Z0C_1)X7$XF4VOHG"#NS
M5@\&Z5"R  P]&PG(7-KPUMQ'BLSS9%5JN:*Z#)XXAE:6*$I-04X0,+ &>KTE
M<A="GG^C!49_@>+9#\YA&?66%*T19YL]7ZXF1</E>&M<5R"M7U#K^U=()7Q<
M2%+F5*_&%#&-3SXTCN^4Z-<\Y?ZJX,IK@\OA^BD:\$=T 2LW,7ZS9@%Y;$XY
M0=GH]W"ZFAD$':!,Y+[6URG6Z2!5'(0P0I'0??MXPVD]5+<?VDX)=3/TV15Y
M\XXAYZQ"+H8_XR*,B4I$K?LCIMKQQQ-M+<6PR1@K Y3O@&YAF3IY_2,=*I[I
MIS YM1B!^[GP8IC%@\W8KJ%_\6#S[Q!.^;E^\[)I"$L^C7NK>'S=?ZN'(+M>
MBS],GKQN*PJ5D]7;$$C(F>#75E9>LW'4N",<\/TQF?.7ZU=_1(4?DX+.TFQ
MA+836ILC OE-#T(R<0J;MM%CY,G[- D@DO6X%=U>N+O,2]0\D)F&^ #-\7C^
M9-41^B(SV JN[=X2&!;HJ+4/)4WPCR>"'O!0-U.T *!G><:P/#)RHL%0Z=6
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M;J^?8#E8:=,IL/8Z+*#OZU3<>0TVB>%I<5P<Z_8LT*+JC]N%TGMH;[Y)C?H
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MEF>8O\'G+JT1A)#_G"<>DB2@6AW(S61HG]<=S6FK2DV-+I=0P$8K96\#GNV
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M28TR(?SM#I^Z!<X [+&@T6CXLP#"S284$F?85J+_513>4?I39L/COO4I:N'
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M+;(IR4>T>F8K$Y=I4#,-#E9*?_2_*P(JR].@,2H0_96^HJM8-6J]7;"/HB<
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MS&T&JXU5C8YDF;CO88\\D'=0%^&]U%^1C]RZ#RM)<;YADL7;[83W/0>C?49
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M>_/H/$_Y> &^MJ8N*VXDW@A,$O>OUB*^,Y-?BTHQ##[Y\O /=U'H:86F$6E
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MPOATA37K:W*.WR2N.[HMRWA>0Z3(?5\S\&MM^N567-;?A_8.O05$84('Q<@
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M]A0'BNI9?^#)W;P?7D7#T_NKLY%L2_7K*M]D-QHFW9#Z\7MC;9+0(?/Z36"
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M!G'Z:UC32CO\YK*:P+VQWEI8X(R5X_](NLZX)M*O&Q>5593HWU54A*SKKM@
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M,R/'8600MQ,K<)*XK\U H3%#(PSE32"G[,>PXJO4^!I/)59>4TIGK2E<@QN
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M33S"^Z,DUH%?6!54B0[W PT@U VT+/RLFHZ*WVP0-4H?ON84O3<:_(@>V>;
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M^ DHK4!2[PS=&2=+0IY+\Q+]?L]5V=%TW"T5ID1'H4:Y1/^#%YJ0Y"?YEZ^
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M06GGH$<A^JQH.# V\,7*KA'):A?XY#M-DIA1<?(&*QPC_W/Y=6SGZ>H7 *+
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M69(^&([>ZBA[^VH0-D^Z+WC129T5;A5AZ?!O*:JW"Q)7\\62+-[3C15HUZ#
MQ:([;B5B8==V9I<E^_+N,C >2PAO'&IR8YZ\9B ^4#U*?4R%O?[];]7,V4M
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M(YC+>$39A1??9#G&!TQ!L= 5-8_;=;-:5MOC4%)4SS+2M$TF21G6OQR$<5V
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MACTCU'*YGTZ0Y8TG"=+X,LE52C_GLJP5[8UAKN/%3U@2NMAY!!/KC3:W>O8
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M<Y:_@[V4+(N"?NNU=S&W8QS)<EL^P&O\KZ@E<.;5V\G-WW)FG;P"]K6N55*
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ME9DJW()O<4#4P )HG/N/59F921=8ZX+60YT"WIG>!$Q8 G*%4+9]CTA)T':
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M *.KQM41\9\'S@)1%Z!1XO]]41G8ED]OP8NI%-=Q#C9$EOJL1:)2"_MO\T<
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MX_O'[Q]_;+8]S^?]>;\NG\_S>;_OL+O ]B\E:'$:SA 6Y-R3>'1?9I'">R!
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M:FYFH/G%KP"WK+J"8CUYY+\WIJF]%ZP_27$Y8QI5>3OD(!'6W)NON4G496J
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M CZFU-4/=0>^Y71>JV;F?%*16QCW8$NI18\*=^KHJ'8[Y,+^Y1'39K\OZ*+
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M#P#R8">,P!54#&4\&<4]&XO<1-#?._F+]!K;N;[>\[>#!7(YY!JYV=+H2[Q
MG#-C4U12Y@'IVYY<*>#)^L\ZAKI@%V/>6][TF1@(H.@ V&OULJKQ:=L<FU?_
MC4X9IE&#;I?+7&Z-6N9F[W<_Z:NX>&2YG!.IYD&'<9^7%,".]U3KE04PMMSX
MZ[</\@HH^Y?#MM-BM>O12S-LB2[E*.YGZ3\,AA*Q)BNWU8-3"+ ?YJB(LZ!J
MS!*I+#YO?P NW?+(@/X?&*O6')NPZDI3Z_=)*CL*\GB<P"Z+Q(8ID1.W8/:P
M[9K.MI A_R-"7&[]SJ,UO"0S_+&N!P@70CZ4+<<_C= .(G[*( .+!@8G[S[@
M3)CF<LE_,=:K9EP]0MH5';M!HO5\5T3Q@YI4UR[U-TK$</=Q &^%$>9L:8@2
M[-+H)7@QKWFBV#'O54_J3JCA?:/1O9$ZFD7SX!U^L?A*4W68W??O'F3+FYKT
MVLYZ!Z^R=X_N1E1E)W^<&% #>F6QM>2!(HM2J!LY^JGI9WCPH;X('[$NKN#K
M[L\Z:X[Y0)MDIKM,O.^%Y'YK&A%K30TMN1[8:Q'Y0\_?XUAJ'%+R]T;B$ 7V
MBP0O66-X>1\,TMN)D\N%KJ=>J39.!ATG7Z>KC(L8BLQT8X/;?ID_LOP:/P^>
ML&6?.N=>:23L*N<<SR)!P5IHNA2'\YMHL[P1F[S M7S+B?_<+B**]Y]=& 52
MI#%G*=_F]^88__MGQ<D^L]NI*]]^]>3=@ Y:VUFRPJ+.*4@2=<6KF5T+'_DV
M0F_:UXC(,;7GSBG8 Y].'W5-Q4>ORJSGN2D1ZLYGL;8RAF3:-#82GU03M-VV
M.UJ)N+]!ISSXW48PJQPF48A<.=!*;=+Z;O">]Y7D^)'9WM);'9@Z9WXH%8PN
MT# I.WC4PN2CR1?YX)6KO<=<7+#=MX-J26*M+WG[SRVZ@Y^"X%\1U2>3F;@H
MC(GS4-ZN\"L/I#DSM'OB)U_Z?.VTPILD:A8A'Z-.!;,\;WY1N1VZ1L,L@XX=
M'MH;FU^H8X =D@H4%K)DR6C;FP-2LWMGK'6A0C42KDT<NM+Q4\N)YP\E'HN3
M5#-2B6EUY%F3"4X3/S:U<).;U2EGU*MB^ZJ2<(]AC!2CF)(%14ZZZ+M! W\H
M$;.9:<SJM(P!5)ZZNJ23FA'YX+,H],L ,ZHBDD_I>/+-?^=U'6F_HML:DYOY
MF@W0=KQF3@.]3$5,A9GM/#TDIH5)_8*6C\Z!DP;G,KO?'_>\^&O#3L8'8YLQ
MTMG1NX(W\A@O?F'D<[ZJZBW-HF>P0OM*Z'USM3].09!.]NFQS/AEM.&VYAXB
MSSG;<;PMQ?YTNK-6)<I?-0I_EA8VB_9_,'B@8P"?5"5(2]PCS#XKW#^O_=#
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MVLJPG+2(ROXD [I,S9@!R1T'+QF#V^27.?J1,GW&0JB[W O2LX9$VV5(T/D
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MT? 433].7'[4MRD(OG(EHDV1F:;@^$(RS"04T)#F4+;V@!JC1&7NF,;]1.@
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M<,F![C6]O64#P :_ K,H1XAQ?S"GBW%$74!U154\B013P7 7A9%VWIT3^ZY
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M4_T5%M/E".WE/5IN",_($5Z*$B-W2)G>D[@EN<;KUN<<:=1:$CD&+)8-XRK
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M*D&&)EBF-L-0NRG:08YX)%#7DRHPRVQOR@*3_6%+C5F"?V?G^YD/&#8\UFB
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MM8_$?ZION78'I#^DH3BU7>*<$Z!;0,^%Z<&QB^1A47CPAQ!W_C-U]8;4BSO
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M-Y37_K<2I\^1X3['3#O,FCC=3=?)+O[]U^#OHW_NW$J;/A\#5C:7H_2YTZA
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M@?"M\;,9[S]'9OG^QFMJ6";>KU_AFR##>1*I-UK:"_E&86IW/">ZI\CH\Y+
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MGMP;L?,[?&4NUN,]&SE&/^]2!!)1R$5R+K=0WGY]NN5LMWG 9$]>R(_H<B9
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MD_W%,)5PA%_5RU2+C1>>/>/>E;/)=GBYO$(TWLI<,686 ,]P%U3QQ+6.BW!
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M'OFN/3G2"_118XG) !$2,A9]?,ZML04W_MHB4DZ;4%#9L;T_*4+9L_;YX19
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M"#G7>9\QNEFD4F=(N5>\Y^+!$WD[S]?]00F$EC6_SZ[&AEM*Y/W"35LUA,)
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M\$C&'NYTDJ[L:LAF,$(4F?G06V:I!/^3L+2+,N7TCI3U]H(M;Z Z^J&77RU
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M]""L6?(YW!;L8ZFUP+!_ZKY)/46F\^!;\3S>?[NVAP2,G/L>>?"5P)FV2)Y
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MX&/@%N()D58@2*'\H?]-%K]4,F&QF N[BD=3*.+6\2)X_X^G !<;(EAN%3-
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M(YT80[!&1U8D!/%5N<WY1>C;4F%&Q'3\8OD&CCZMK&SJ6C'>X'"9P-@@4A6
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M_]4XW-_PCU:>S#W?!L3QHXDW#/\<#!1AK@TZ7Y[>J>%]Y8\RS%L9F)BGBH9
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M22![8/1CHRH17N WUI\G\O %T/5RAE+.*@A.@4\ *(DBY@KI''4@[)<*HX%
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M@8E9XZ0<++62[\E%'^4U?.Y&R9X^CZA7B8S(P. H DQSC2BRC10J\B^-:9;
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MB_C ^EV) G3C[=\=U7'^*R%).S);)Z8DL(,EE2)%"U=?NR^K74QN]-J3+)\
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M]US:/: Z\RIJY<A_./Z.ON-IT*!^/V^;,7RETEEJS+8RKUCL-<(+/D4DB4N
M2Y]I/ VQ@XI*::^H$7%B0;DU:C[#=^'RY=[PX$+2K6/.7R/VKH/4^,*[IR\
MW2TB(ZYWFX-3-'ASE)Z FOZSH6W(Y3>\JT!?V3/1XEV>[,21KM^#SH[N/MK$
MUU_FE0_IR/J/><IIFQG X9.X@^*+C34"$$,\6'J@1_I-%$[[?O6F\I^G\2D(
M5.HY($H"TR6^0L=E%9":% %"8.WZ'2&%GPD'1H_,:BKT.>2_4229HH9C#C/?
M;.6OE9V?N>.Q8$!W^T<"VXVG.I'G2TWVUKF/DZZ*'G[K=:\;7\/1WQ/B5F.X
MX^Y%K<^*19@\*QM6MD:\$=34$Y6TMP!O+A:^TY@"N2?&^0K+K+1B7AQYATJO
MU?(N7N@$!+6D*F46?9][3TY_'[P6"ZUQOIK8MSK=@J ZTYTM_@\1DB?++Q8)
M'!2,%GSO"%.\T&:FL7QO:[C.DX75)CXY.B-%S_I.*3YP'5_T3*'-&4-9_=KV
MM_D*BZR8.T_0O@W (HT-QA;=X<EV-?K2(L_6&E#<W X-;>FRGYMMUZQ;>[QW
M.Q?W(TC%=KV[0*%@6AQ+,-7\<+#[D0066]@V+'\GU3.=-M-Y7O:J6@^XI<XN
M9\7B%"&TZ=["CLD@:MDGCZE\4T'AVFOG09Q0P:TCBWS%>WE45-ASIW$E;_K8
MV=%+ER6P&,XT/\2PMNE8B,;#.P'&\^P-43[/^K.=-J+^*CU#?T+T6J1M.W@%
M- V:3RM[EM/]9LVXC8+#(#]ZQ3/F2ZQH8.;'EQY6Y=N$,T8R<TZT/S*04&36
M[5Q$_$]#W(^TFS!9$^DX1K'GEM[8<6KZ3H?JF3='<H?3'AG,1\+6_TS0R6\1
M^[/;R ,OA_ZMV?N0V OYQ1NH!C4,$,NA<)7C(1Y?:/$J[IDQ@6Z<[_X!=Y8"
M7K:;-$X[U7:MO[A+U>1\-9ZS#\,EWMJ]]997SWB'-"BRO(@FYH(\O?:T6SHV
M%4YU!3S.M@6S4K[SUU> -2HQ5ND%5/MW+X\V+@[T4MGPH-/92L_JQ(BL[GOV
M+7O7<*+06WV$;*96)[M:;ZG0>ATF)>)VS+@$=OT/*U:H8V.>YE<%*;[YFHX:
MMWOU/$[MZB'B$DP/?7J,-LH2]!6=KQNK$C$XP=E!*LP^:$4">X&ZF>>)E%8/
M(/6&P#E;0,V^O\>E\-.^W\V87XZ@:JD/-(X-Q)ATIY5H7M-\+'071QD+(@//
MAZF)X:G)P,^N*$:3JQ\K/<H8"EXFF6-L1+;TJ$S:0"GE,RW$QJ.BQX$58KL@
M-ZWO:TBEZ X[#'W/KGHDPN I=/!VTIO?9][K;I;'&/[V:R161&L-Q4!;HFX+
M@O>%8MMT4IC*I^Q"U7MR?G:^<-A]]+NB^O%W_\#6?C5Y6Y=E,7$M"L!7G IS
M?_)@F\(\_L)\>%+0H'HI3N%L"W]1&N+3T!?(50)3BF $VOB]5*FH>; ^]$ %
M,V \U,^>9&=NBYG:QRH(H8IT(=4>2P?S@[/\+;(\V PE@*L6-"R!7>B&\S_8
M0J[/%I9G,C'+<)\K\[Y"BX2,K3'M/[$YT)H:LG</^MO[-]VZ.%%X52-_ W;>
M$2"(]&<,*_T5 WM&]'8I6Y"F.0\%U]G,:[[690-*2#???DVLC^_>J[&[]!W"
MR@K5+W6"^PQV DS7KH[;!]>I I/BF'P=KC'WXL,@:PD,H;)&W+Q8__%4Q^$'
MYQ>^3!54E'>-TY\Y^WE<C8](#S3R*EXZ(M5'J WKI?;\G\JK[R2PJW+@SRZH
MC42H1\ZT6&Y\CUFQ$S4>+ )2N=^/?Y:2\(#PY;/WMZ46O@RE4C-E//B".=K0
MFQ?\CX_%7 !+ E.U;]N.VN$5!I9;VO$=<6-<M8AMZ7LW.DZ8,KXW((+YP897
M@V6=*"RQPOGI@-Z,&/R]^_;7+(V"JHJ=K]S*,<S3<@7N7[+T]\3[F@;QB[\_
ML>G92^&+,[<,^!.J*=CK<O)'Z'9(2ZD;7)G1IA.?JL"[3^6@1RO^CLR_*VNC
M_+4UW#":7I<QOWR @M"O&1>%B8+F"P_:/G]MD;P>:+9^HL0\M6#Z!71-RPN:
M0@RRN&3X;A/'\92)8:66LD.DL^G#:=7?)\A PS0)3-*W['55VQ;MW)XK]O]"
MK+XZ>4//\GZ8N^A+L&W]BASSI-C4D#BC#'C\RGI_"CN._>_!G%Z52O+CQ JS
M0__D?AQ*NW)8ZZ\65)9_JE 4900G4]4A _V[.)["I="HFT-\4/R5](.275\6
MM4WD,CLWH815J7Z F/Y]*XEY;/RA?<]=NN>LA9J#YF-H^1]"=2)'SV\<]0;'
MWQ!A/%(['4'[>WR;;.H'\4<)+.D#J2XB]>X#Z/>'@4CRKMH\ZO?"BDV7'I7<
MD+,8<F?>OWW??*>&&,,34BAR]@B4U*9?-=GD*RRIMSEI;IE@^>>]XS*]I<AD
M+".?<UX#7ZUSHEJ%4&WU\(V=G\FHRQ4::%]UXT*#KE"!FX6L4AQ.V_U8:HV*
M12J&=4-2/*!@)T5$P.X/T(?:7D<KBMQE/$BUC@T]6_? TD/KA*>89<G3KBU"
M+.#^Z!&VB744V.6<:)2*YTR4:QIK1DK+Z1-#V8*+%S[:YYG+4GY!#TU.5MJO
MG!EQ&CJ'=D&*\!"ZW%L[+%@%D7D8?$4^ _S=@=ZO/&M$!;^+Z_4@A<L\V"*]
M#A<<[KMY.\I3 K-B_X5S,R)U4H,D,$<!YB*4(4;-JES.O=ON2GV5Y,\_;0*.
M97'<EB2P+L'2K287X\V'8-(DD7-6_/%#R8DVAYRF8FNEP'<>F_^TF<70,QH\
M? [Z'K.T>G(FG%,RG^(AEA69'5HBX:_DY&8;2F 'VS!+!U>G*^+$0R!--K\J
M(NO]$<]"3'?BHRB?"P!9A.Z9_Q;!_MO+^&X25J1 '<(#<6@S!C?8XCE=/R+I
MD)6I_9B7-(R)JQ=S?Y0R[2[^!=W[Z*YFAU /*);$B6MQ9!2DLT-$%2&P2ZHM
M%?Z&9H=W*D:PUZ]04_KT*[<3&>YKI08R\AP[",XC<B((Y/C'8F%R9[IF_8(*
M*@8:GY? %.=_+!QBT0^F_ T/<30CO^LD=UY!S/1L&MH*$82T\J=Y/9TZ$?L:
MGVTQ:6I*3H^(_S!K\@Z#$^_U45@<#;@O1L?7!"LFC0'2\/X[<Y6[D!AR B )
M%:(8PQ=<'+V=N%,0^R]/K,$PFP4_K%Z?:!MI,(I"=>2'9#V&A%NEMJUL]AUQ
MFL:$$>#8:A1.*.?Z1756#+ CIAT+I$!TQMI6NASA3CQ7XN_,[685*\YE=9%%
M@MQ;!FHG&PE7=<L,4I?270B'XS/@7K;W[A8E3G3Z%\#)2TS56G>:M]\5ZMCS
MTVMG]8Z>UD"<[FYX6/QGBDF]-#\H3DNW'__=L#Z@*YXJ@9VH.V78MV?A5\8A
MU.N/@R%I N6FC17*2FI6M@D&'S]>D\ NCWV2"6K[ QESU7V;^+[<4-#%Z*?4
M0Z[;XCECD6):_L=RFBJF^-?N5..(RH7R 7\\*H T#4>_89)5]8H0#/(I>ICL
M,>BV\NY97KN=F-2M>%7-N1N&'!_8I8N>F#/\5[3'E_48V@@YB.K,AM%%Q('L
MI9:U:"-[$)$9B9S&VLUI]R(Z6L<,$=+4^GIUKVFGG[KE-7KAK.R&K9,VWMIB
MI/0??MC*A'HK.B[LD_L6?4_+VO0AL2?"_1:GX_ZP;/P%)_[=2E'A64[42 HX
M-Q6,$4AEW1+U[3/@P06:P3JGMB7=,12J2H@BYT)^U/Y8<60U*E=0]R!@\6&A
M91]QDD7Z3P+K\6V9C<KHX!%[IU&ZO+($M/-*?7&]8F#WO'*6ECZE]]T:CI&7
MJ/X*NNH<<FQG\0OSG'5+]\T2YE!AI^3=L,T9(IL O4Y-,#E"G]9(( [^76KN
M11*>FIVT(R.FH%MH\Z=#R6$^B*%AYXQ-<OX#?7Y>YS]N@0%Z]QT*=YP5!T!M
M5"7FR)GV=A#W)*RCK74%5WK2?&64W#?22_,[%C;YB.^!&52P_-W,;R;7ZWK-
M-T ;(Q:^9$1UY;D.?QU3XIT[#>V$93!-/\2;K*">"J@#*5QF==?GK[>?I3I=
MZ%52UD9B^<_0:V;JW3F,D!'<_GHPJT1>M>D=GZV;&W6'S7W@D7JGYY87QX"I
M=SX_=FNJ_]C7?.R>GTXFO_])6X&0WG .1)L@1936+J-@R95.W45G-SY>/LY>
MN#VQ:<$15: RY#VYJHQF!R,5^8_9KC^&V*?<_<<(.N+=LRT6[W[XDBJ_7=D&
M_.9=-0\G4C&+B)_A&)H0G2)( %\I'/#2$A%[Z5W/?L[?X=#]- X>P:W5M*">
MA?"NJ;7@NV&MN-E!U\X]&X=>JWH1> A%SZ[Q,[=3#[V"UUO:"()MH_^!"!QU
M!,_W0!OWQ?8#L5_5'\E\Z5G<,_[U'?Z_-\L;& $@2R2+3X!N1%B'[/H=7S;7
M2;;Z_#GL?5]'^^V+T#\/E&P;S9#L1[U?ZYYT2GTV.K#LNO"+KW BJ:&'X+0D
M&YLB75)T!;$_)7LV^X=4,O>!8P*D'S"UIZ>_]-LQ([/Z6H+J@<1/75?]?,[:
M\@#*Q^N/]=W%D2!^#A<@['#V/1FV88VNR*!6G(7RM_;-HJ"D"RHH\/P:RY\
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MW.CV&L$=K\;BY)S&1SU?;H O)+"U:,8MKM KXYU/:,T_/7\+5(/=D$BLY0/
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M.@J+6N1>@DMW;L/@B\/:/[*OK2GU\C2W9-<S_0G>!K ',M^ZWZX4LD:[97W
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MF^VO4?VYIXJ=G'1E=31>\0$V3YB%CO$SX#?X_7[]E[A=[)?M[08N6TI@[.\
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M]6WBG>IY]-'H:;K@L<XPCBB2^Z$4'Z9*ANAJ>6?O\]FQ/#D%%G[UG>6XZ[!
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M&;G/W/3,+KRHU(X1:<6<AQV2?.GW^=[XIEU6C/3?<R_QQ_941+T$-F^E05]
M4N_"0!?[0P'A5W?V;59/XZ%ZY,?O9/.=N0V.AX7^95YM3\HFYH1@F0RE4SUH
M="OI%T[=WJG=#9?B:UJNN#B=<._  ]Q(-D1RQ"=9K+!Z)T?@ZK+>'8@E_)Z
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M50TWI0/D@$F5F3_O'C<3/>B+G=Q$91-ZH^R2$],G+W*^&7 -:+*HJ(JB:9B
MZ>(,ROV:2- L#671C1JQD2,66VX 4QG+IZ/PUMJ$4MJ) EO9P'WH.%:.,!@
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M1H#]YYO@PS-P G=\(5J\WB<>2)%]T/M!N[S& C_C-5;QP#-D]<$W<'(76'@
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M"/]G3V;XL(]SB0GJ06B1\_4<S4.?MRJL]Z@?NQEY?M6/L,C]U6&KZ/LW,VS
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M>.FVW"-+K^-GQ1 3PJW)-P?>+12=F0(=8M*0?C;4T!%6T6_*@[.K521,EY4
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ML)6VE>G,.,S8]*&:!'?8!A.M5L6A)J(:1B\X%.]ET/)WSQ'PH]!J4='L%X?
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M+"(_4!4JGGX<0@6ZH6=G63FJ8DB\,,PL'+DL2F#XZDS#VZ'"T:D XNG^M&W
M&:KBJ=68XBT-<TGZ0BMCN3U]V^RG*L!R[!S9J)]07$F'SO@[R4TA@S^U]?IU
M1FEN()-OAK$*.91H@"0XQY]47S,(1<CXGN?/ZHDAGSP6 3@3))-WC0#YHE@2
M4]X[R6]?[]DN<']M!!<^%TE0)?)C/]7[((B9]^FH<WMJUD?DK'7*V/29S);$
M:E(Z9G5'4O3?"G75I5>O'"(O32!Q@N$Y!L)OADJV0-+61;9=UZM'$V'O$LO
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MMBS_GGNP)WXI?<_D;Y.='WZZK?]-(XDAE $L<ML\K*=B\M,'FA\4+O-0NF<
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M"WIOBPZ<CONA0 *=0+\QL<Y^<[&H=KL$N>*_M#2\3;3IE<,LH:@O:Q-V25;
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MD&_P,?BB8?O#J4[8$LNX?N*YD"2$V\$+<R2*)9%"+\<#DYW"Z^RQJ11TAO_
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M5$M3URQ"X<<^VWG=)W_^ QP]2%O>)-#HT_@"&:/#HPU,^<0S7X[\\:G&KU[
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M?;++!*&4!.T13[KG?!S%H'C$O4\;D)]!@LNSH4,U"9#:BD9-S6OR;_IOA^8
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M-<P^<Q--F0I-JZ2]6R7GTZ4@0<0B24UHT5-&C]!69(NUB HS@,7SB4+#;DD
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M&7%#CZ:]&^-=PJ]@/U%&FO-ZNC_.)0=FXQGYET!%)[91O,VXK*2J CFR9$T
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M1& Y4\VU2O0+.VS2QF1);S'SR)3LJ3X]8GL)/LZ]1X'1& WQ#3O(*]J>=*P
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M3-W&,HDY[:%O&KY6Z+-[WX9E]-8UNE44$ <^$NZX4?Z9_\K9 J*0+(]K9]?
M1R02WN<Z1L^W3?A<3'FD&"- 3Y4G,%>T )9".4(GN1?]53BII<10_Z2W),!W
MUZ95&<-S^(7/LT.\U#Z:A?M(:X7;-M*5R14*X_"=SZ"Q_M,&DO,#P0PC%R?5
M)FN%JDF3>:GO[HF&->YM>T4.<Z>E!RRU%I/N6;S:CU*6+:?0I0W??_NA;WJA
M.3X9'EV*UEO;5>,*,^]S@W&;FRBU5M=PKY>6,W:9R+Y9 C0Y(INWI(=*(=.G
M<0W&=G9&_1L\@QO.JEFS3XX;=&47EQY&#S@0)7.PTM;QA%*\D"'F@V57':8A
MAW,105=-O=9HGKX>!-262H!R**&%, ]GH$8=]!@2HWK6@"&AHU)21QO:XIMP
M!]E%!C:!Y0EL[=9*&))N[1(GE$AQ<_;)=3=#*XR\Y @$9D8_!V@OUJ,6?OM1
M2J)L7NA-O<V/U_PM/$-JHAF33:D?=A5Z$'YLZ],J3I80X1,%&X895G0U\/ZD
MQ@U^1E<V->C >?-UFD*##)[=BX(4Q0_;_1S_<J!?/X6_YPVLN<PM5T:=5\4Q
MJTM2X[Z5Q\T]NK-ILQ/P=2@,,D@>9I6TS#WO=2^:S[QINKZE\)W;]/8SE"^/
M!+2&OLP<QZ#XQ>3M1\.(J#?+YB$[T"6>$T+ZX9<SF-8ES719R=;RSWJGH67Q
M;NM9U/!(XN)8;,;/,WKD9=5C/4UE(<U9^,F=A:\\\]?L:'X[O2OAG3C ^9F)
M!50[=5Y81\#?6%_^D9M"P ZPR<GHV&4]79]B&_P( ^857SR[5ILC5RQ%)#&,
M1/P^K=3;6^A1$8]QX/)ANV[S2])$G/3B9P^;58<T]7WO#+]ZZTZ<]1RO_&PX
M31O=8: *+.E/V#14.2='6(P;U@#[J<%]KVT\S##Y^_?S6M\_VAE5<ZV%)#+-
MD+X_:](LA'-#>./:OI!_21]&DI^#P;JV5S= [V[3J4E;4-,JUL+ILS@SR[]%
M8/'X92YIA)'G[\'L_@@^(:5U?0(C0HGX:U:UQ%,GCUQ=ZRA6VH$L5=%+@\'Q
M\@W/':.8DDW/ASS0?O]R/^ N%(#6BI%KT!7!G*8+E5-W>0T!!O4E/^N75Z-)
MEOIA8OR#7E)$[X&N3X+)*X43OVRX'V4^R$K7W-:N'<H]%A^*'[RA][9OE@0%
MO2MGJQ)Z\?L=_E&.WEF';4$EM].'%<(O4N4(_RGJUM_CRQ&MT^FPH(CY2G Z
MWL\F/=R4R;O&U)U"35<:AY4;<QD["<.'PV]2^>B.SFTM/(^F/N,A>P7DXH>$
MX/V*QC70C+_U^,7"R/*S/Y#]X]8\Y9'B E'RQRRB[3V&C8WSH4[9<0+*5N-=
M=>O/R#W.I*O@@ W_!&SLIH>=Z]$^:G1O-*_<]TK,!<V70[9(-.K)Y\PI!^'?
MTZUQI(-(;*=!B3W?IH+[J8V)\;]-)5S+S,VC/7OJD%_,V;\O\DCTX4_(F^3D
MUY%*%?HOA\;/2()4@@#1K>[B:ZHQ09(IS5\J-9*.E[MGT*/C\?&&;?31$]3&
M8R_J3#4UN>.EQ)%KEH:II&*WEON?KO_6IIK,(!6 DJ4FO?,%<Z VA!ID$T;^
M[)EZ*:C!";Q2S$)<?]%CKR%EZT26=O/H*[Z/@@\8-18PZ;7^=WC=VM_UI[RL
M!'U8'#>+T!U51X3V7'X;&LXVM--MSBZ6Q<-/.&2I?9?H E/T:!#L/72EE9-C
M6N=^U;T1'0N.EW>Y#RXVVOW*"ZDK#/S91J\-H@BKF;T^05.G[>C>I2V;9%N/
M>C:N=AO2>MSN^/BH?=O:I>0A-I_:+DL7F>8RLWD:Y22KI!W[]AB=FD,!']GF
MTJEGP@$OO&%)8T#K:_&]]^3YP%5>P%\:_4W+]C&/MCLGGAVO;6KJ7W9ZC^$I
M!%OZMLKXH:**'!$H7,>$1L^JAC;WI*53UMN 8^%G5\&6)9D>]G-S-=U@S;.^
M8<A1U25P;*C'P?N+ZN+[,ZW'!'8AX^B7SAGHYSDO_G856&Y 2)9ZF-';]<>0
MQ86LLJ4A>7A%:-.OIPF[$@ /-"I,ECMU?DIWOF_'#,IWTX"CVGXAL:(N+(SS
MIBI_KBOP'Z^_ETO,2.\]W'BML=7B\_VV*S\6MU\SS2WUYAMTCYY6[E5V_=[=
MW8<7'7=/M8_:;^9J.1JH4R(*A28F^@9,;C'43PYZ05_;K@''6<_R!*+9>O%
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M.K#H^6EO6Z]CC(9PJ5I0+GS<C:= UGM8U3HO__A>')>:D\D,V*YPY]ENP>^
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MUE=:#H/QUEX2$VD'<@9[[PF*(E7/: 'UD )"?9R;>J+2T:N1.F;T2DB3]<4
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MQOOSZENM>YX;7SJ4;WO;.;?X3G;::E4(S-B*$4_M\F6'/: /G8BWB&^(.4W
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M1R^.]7>I8KJVM3U/4H'&/ ]16D]J)WXO+-BGIOVJY0G[U-J2PO3!S*C(<^9
MW9A%F472]2U*J*"M"?SX6%J&E$5N)/+7O>I-GAX'%WL82!<Z<K.Z=>#!H%%*
MHWS"[.=K=@7T9]-I/7DG#?\I^:!Q,,I"F9QSYO'%NXH+>@_/R*5UW+]P4A:O
M]EGEJDW#_4O#TTM2%JA5,<E-R@^P$6>9HFR6R'\^=!N+WV:ISX&-^QES!R6P
MSNFY->*NDFCP_M/DR(?@ 0G,]?/C,0TI/3BC 4' ,,O>NG1/5DJ/=UZU:/VE
M"#=P3$4@CGCGZ'7JFZ#G?0SAR9\S3K2]-8=]_<1O9WZ,GK!9*\/KTFFQ6@2R
M)+"1B*SG 0(X.[2OJ'M^>4R\1$=CQJ&%=D<);"JB$"JY"9\QFLINPZE]D,#(
M'$4)K+BB@HVURI02R@#*$ZD:J@>&(LJ%XYCEHP&43)D18'A:??[E1"+S5"7X
MI!-[Z/@]"0P]>0:JG?0:&P J6&2/% !_8Y)[D9Y)X>]JO0;G.S2#BA0A)@S*
M^X$%>B 'MZ$$<9P>^'S7LZ?8M@-R&A"^SE00IO,<$PU?EL_!X(@KH4G<,EU*
MGW,!AS3/:%SF37KK2U."3"?:0< AFGU1/2#+VQSZ7>/0DU*[.^<0EKQ$9H+X
M&(90M=T3Q8<[XF46C%@0Y!AE;0%&-.)'5EONXQ!?WD^I3RH.;>7JWY7SZ2WX
MJNR+N^XE'Z0,JRP"QKX,H*<VDH3-/!6,!/:E'],>A5[1TRO9NFZ6.(:>]Z\7
MKS!.*Z2/"?JKTY-5[4WVFB8RXP4A$IB7]TP"CSW.$),I*WIV>RZVD(%.6Q&!
M"'A8'BCWBFM"Q$>0"--0$86LCESYXNT#3B@)D4CY%M<5GP3QM*@N>TJK_\K@
MIE928#27VOD\I["1::&5+(Z4Q7.'?O<MM0\<79V34L,R?M#W,CJ_4K8I#7D9
M.D;ONX?XS@V4\?EZ00)[ZLH[MH#FSO].!K^ *(\&=N4MT+E#QOT>9:OZJ*R
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MF(N?!'J%VC').E3^)0@]SGI+S[*TPA?11(,:S@-A#SS T_I):ZA=6A>?]HO
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MO:R:*RN[@NUL!-_XBH]X&N)GX$+0XY^8!P, 2:Q6YGCHR;4=_ 1<KU[$]X!
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M :U0!RN2!9V\)D<]=%M?;P!*#2F="*H_(A$.3]W\WOM#Q@']J-'"\&"\T+D
M1Q&Y,_%)]/,N]EE=75TL+W#_B<ACLQO($3@.V&7@..)5[TQI1DWVBK""?BZ&
MV)6)N"N&!>.X!?-#^]@J$ ?H(1\"-7YM7%H4<V)9X&<F-.SO5N)<#8[0(ITY
M)(;5N- 6XU01$[(*J\49Y/M'%]S2Z19Q;Q@UI7N;EEWR8FWVVE7$SG%::2-
MI.(*D#>W:?@E0*Y.1,.36X?*.G<J3?I!W^A.)PU1L=J(H]1ED#]<]W&I(QC-
MK+COJ\P#0K*VNY@6(]J [3E3H(_",EA'S?G[F/7)M9F5W3#FOG_.W<OK7)4-
MCJ/;'(OFF^GL&T3%YR<*!ZG6"%2&T'G@SR'Z11FOO5QK86-BUQCH..DO&OV&
M&*VN&9[4'W'UA3^;UF]2%/79L)QU58!^+2\2J*!3)(:5A0Q;"Y3$,&4F@6\!
M[NI2::4M698+_-+5)F47?4D""UX#I #=A#/Y68/4Z#2^Y#':%]O>OA7&>R]+
M69]3M1%>J1I-1Q<K1-.NOD:V=B.G^N)-C.TZU\-$W_"Q>CHP]4WA4ZU?ZL_<
M_\ZRJ/P%3T!M)R5F_*7%#>D(*_R+)J4L?:4;[+[3$\H_S[C2@_L^AC>?.BZ?
MHZ#<-?XT\_/7I_45^W]+U&H]A8>]<HJ!Q84_UPT9#]1V[-YU?2\LQ$ZAFVC$
M9C2!9P+F>9%+-F5G1#J0&&N<(NJ>]<;,#0@*3\Z[<! .3%=14+K Z?3M4+RL
MGH%DB[Q19L8)Q2[OCQ)\_V>2]V3"%\<HK[;GIQDXR02=[^7T3G5T]P.2U;O9
MP^._YG7+5[XM5CYR$V5$W6LIJ=8,,W5]+V\7GNVQR5C/1C_RU(T.>/*A.WT1
M<&N2TZ$N"6$9V^=,U!4SX FBJ7V=<+(BHN#B,L\NX"]]+F'@@BJ9:?:;H5@W
M2_Q6.JR9C<]UBMN]8%'5ML73Z-WNEK2);@@^@K@3YC6O$O?#G\WH_5+NE3R2
M(7F(Y:"[U]66_!,\$F#>9],K=_?UL(W"F(,1,X%2JI(B*$WZXY*7][;AL:.M
M_=9D-D+938__1HOP8;?[R&F,?G:^+5'C(/8;WLI=2*@^QXV1Y'T6P\[#8XBB
M+BK!4=&-P[5AD_3<ME)TMCYH<L&4)G\*W[B8YI2V./8X[D/HY9C(;86[8Y#^
M'W?*O;WPSVXWOFU<RNX][$^XX:8XF3C*Q*_4Q'C$O\N C#]M7 R[%F!$39#H
MKDPIX>YMYM':B;&59_R?.NWLVJ^3[DP[_.EQ3M:;E.#=CV4LUR1I%@Y_#"CQ
MACGHVKJV7VLHWK],YK_%WYY8PHXA+83E='GRROP0]0D7;NOSH:V1*9PX6D"/
M%3*(&I;KC!]&-W2=R$F-OK59<:[LR3%3R0<A0E)=]_5/^M)]0&TW'%!&8&FJ
M/DC]@*35,B4Z%00,6O7]S$D?< :%Q2G)+?)N/)V?29C+N_S5ZQGC7B%6[4WH
MLP%LVRYCD\S+5NO/2?NZ7MY^_N8D;@JT2[B[QV2KU_H?/U:;7T7QO"0";LW!
M)Y6$L3XN""G_IA'2'WP"7%8[Y/#'E)7Z)?]1U0&W^D9+9F[+RSSR/RW-P;0E
MZXYN>]6:\POD+7H*:(W3._T[L=N?F&S;C^>3:ORR?-[3M^R.LY1Q%[9-A+-.
M"0,8Z$1$LR<OTFM^69)G0I&='R'4X][:.#__A]$4/AN*_^7H&SK;@G[6_GA9
M4!$:;F0@K[&/^2US1DGXFFPBT86]93W'VG(MR7*;9"NIB$?)2R&:)&]I^?T!
M]GSIZ/,11)\<RO!O=69T%7C:EVMVLVO#C+]SNK_6@T?V5M79Q*;7.2F10$\W
M7/ (R9*GV)B.[$5%22[+6=0M1ADO'2$YH'1((?$?\$KMLA:/G]"/I\VVOG:A
M7><D]D!Z/")44:D@YVEJG!)=#-OZHO_C#H_<U" ];OSWR(KC_PA7FJ_]#,^'
M'7EMW_J5Q7L<4'LQH2S/4+)N5I@ST4DB"  = E>UEY[XGFHUE+?42\CY1[4U
M[)9]\/V-BT:_0IKGA61@:4O@NJ;&HU42'D9!<.])\%E8[(CV9<<[<IOO.?%*
M3TOE.PHK\MZ\'KS3ONUX(@JB%&MJSR3\KSW/;Q2(F?K]'F[U>*DXGESNFWXM
MI_BBH&#L<"O:9\[+WLXR.])RM_N7].0K9E\L70_];9K?JM72P7WYQ%?CPDGC
MHS'',R)-U5_5O+1/)E;9K;%\\%QR8H:#T\TC]ZN9><%\ ;/9;2 C@4U)2'Y/
MGN33BC5OC_3%5^ZYYW7,8!L]U6C3U5\]T4%-Y+7WMYUBNB!92P>DUZSVXY3/
M93PY].%0KU 4P-="WD6W3:0,=0-KJLT?*X?V9V3GY*\$+JD?I]F'#U&OIQ6W
MCSKE&-"S/%>\BLWK/)!S1]0EC,C*(N+4ZT$Q[/?WCH[+-\D[PW>E\L+@VN'/
MSRLD$9EO5?* TY>P KG-@EA/^PJNRP2AE1%S<B^%>N>E>OF-2/3N7R<]&+XH
M,L^0@Q@-;-HUF)WUM 86S0$RQWY<]#<W7>\LY)-P*S?$,',WMTK0IJ_U]]"*
MV@@/^&Q+'T0<62SC#TAOM7QA.A_U [O[?0PK1W]S\\:?F\^KN#]Z'O*=<)PT
MZ'94/^9[^1+3PPC^Y)(8AM -B^D9WOE*J+QO&3[KY0Q\,UR:&R9I<^=K7-E%
ME2INWB*M.D@+G$\4#.V^&++1MIP4<<MU0L*]K"LM[ECPG5_[F_/&#'OR\NY:
M!F\?WO9=J"BD3=)']!EX7/\TT,;SLL$ P$E\?,*0\+>V R\H0)VGTZ6SM5H;
M.\9V,#1 #N@\L>Z_USK]]_&3/,_=>XRO_IN>^>B1DW1_W='04P9*<9_KSX#P
MFX8X&^6"3\W*&[/(,A9_DQ;E5/D*8^1E\L 0J8<:0:KV#[":!:,;YJSS9H?"
M"L"SND--$S\7.HV>DL>6I"V<U"Z^M3K9D5VPS0J;04U/ZOJ)B!5MTL[>(J>L
MMS1&7NW[')(SS34C=#CQU+M?RC-6N$-RB'<M[<SO^&=>O4^];RL^[QZE*IF:
MW.H[K_P>1:NZ!3^2NCZYJV]7H\R=?IMG)5*3&WB6T%6RBZ8?> 9+MP83]]$F
M6A9MW(6R*^J+;:/Y]*&^0'9YA<4#<K&'?YVK^>U'9[H]-)[8>IAN/7;%4OV9
M=*KQ4:>>?0]9W8].>.'4D,6)I5T;[K_D"X/D)'4.+^SR<Y&>C%I6X+UV ^MK
MW6X8_C'[SOB0PA"],BS-+OA2=M"G]L,Z?&AZ5O8>)UU.==R!V!MGO@6\'\]<
MI]->'>QTS0!1"[I]-UO:;[V^VG)95(6QO0C1#BI(4,3[%'" 1MO%D1?#J$-W
MR[BAHXRJA&V,(1M,SO.;M?+-@^>_9^D;(S74+S_=';E?%%N=H+W^1^" NB4%
MN_1<[NS(OF[<F>Y0;TYW9O]%:3PG$(K,0.OBTN'N@:4G;[#".^ZA<K=)AW50
M,Z%3U$/FN%ADY?JC_$]^O9?%L&/X**(TD?1MO=H(N;&Z@(&()"'XO>XO*NQ?
MNLSFF[G&$KF?E9 ?VT:.)64!<D>_<IKT1KP_31I%?>D,WL$47=.YW+[FTDR=
M"#5!-HT\2U?*_.BD9'9)%U74\VV),5V]-L!H +<.5! &KN!*/2POQ&W[VG='
ME(=*Q,K*GQQ?WLG(_S.Q1:($=>R+@!'M<3!&SUFIQ+;RG(A$P-ILLFH4PV[N
MSKA:.1Z[U$&KY/+BA5K@8^(>ZD7G7"V4&108Y@$A _$XM%5WPD1Q(=,[Z0T]
MU?'(GQ^WK=;%9%O?-%#X)O>#0)22OKY=6A+,Y<EG-Z5]^VIY,-RA=W;$L[M/
M3T3B28&*5'=V=38)TGZSU4_$L'I'N*"(^TH>BD=*+7RY%3&6D?MZ0HT'.8G)
M13$,ZW7:?T\;PLC*L1<:*>0B=UZ2H3WDQ?K^Q_7^7G.:OZ&>X4W=DJY] CQ[
M%EEH0@QM%<,$VV+RQM3DOXW_&'IA#H1.//-=?W&&<X "<,;Z[_P<S 4R*!"4
M8)=FFHA)(1SUOCCA.D,P@ [0@ ).-NT;"_.^W3JO;5_7N P+G]:H=Q>6^ $/
MMT:Z8>I  S%LQRR_@2]+FO53*RO5'/2+1;=-]HQ1*?I\T=FM4K8 >G6IZ!TW
M"Q@D->79B&'.(#[69! N?'&1 O:<QXJ:T[A'F+2EJY5BF*FTZ+Z<E!IB/ <-
M?D+R2_TTJI?V91(R-9X/I\F#.)E%\*?\'^XCZ6DLVSJM-$/.8 $H@>0E:9'T
M)%"%L>^-X429%A^[DD'<7YV1@XO5@]]5L??0B23,9I=%<C__N86*YO3?0YR
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M&6R.";IM&<N"+[">N/_5G JQ^$\S$-:AV<26 <& 7ZZ;;G9A[!G3EJ?[-#Z
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M1#14*D)H^6S.;511@(FQ4;HD-2N&.:1N-71V(9T.#<<KE"D#Z=)RUM%0$+/
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M:38@0*VKC)D4!-(7'Y0AEMW,7L=@-TM>.8\[,].>L=YAW4?$^%VG3?EJKL>
MT<"2;?0M((HA2C@@^XBH_:M+*(9]&2-3HCYUS\T 6SZ^&#J2J._F-S&>\1JW
M-""!YI<#2 XX$'?'STS9[TG.\$6SX&&7DHT@Z2$X$5BD.28=:[FC8%J%.<OV
ML<FLO/J/DSB3"<5OBFV-RI)5W_R_XA3AYV%:"(L+]P]SUQCN=?\GXRN-^SH]
M]M#=&7 U5QE7B>[H7<E+1T025=ACN:45B8AN"OSEJ]G7I%M_!;XMR"4=_4MS
M)4.JJR1W&'1[/U4.).%6"S+_IRC4_VQ7\_]^01Z8!?Z@%N6IT7@O"\R5@**5
MMD5G"=-$GM00\0EE?W898V8Q>IZY:$!05H[=9I!*KK64OS[A<U-5HF1.@BCJ
M&3B0^O>JU,!E2#?DD,+D#4RA:-CKW-OF.\J]UBCDD1+FF\S:^[\1)SI0^_<6
MZ501, O3 ]&];-X-W76AFUW^+DL?.=@PGWCA[)[C1N_?'/N4F0*K&WPC6)IZ
M4&K$> 1H6UH'+;,1$P)MM;VC\P=-86,UBTL\(#@!O6Y!GW<SX QH^]%A"2Y7
MP7?TW^5CGBI;5^&OX*XKA@U_.[.=]:L_CK49:>#ZP,*B=NW.S2_EB$?7<+<R
M9GR0.QU5[L=H/$4X/C+ULSUXIE:$D_ZW'S71G6$.5"+&(=IXXN']4OL;T\&4
M_=]'R$S7*D!W96S9)&=I"+&$SM6<<G+1IG_R:G!8Q"+OFMK<4"T_:'7G"!Y^
M-U [6XEH?D)9SV:HR23+]4Y)<9#D1 @N*C/#[LQ5T_OM?&%%ARQ/M-K006J)
M,3V<PY-<Q!8*:(&L!D3Q-<IL/HE)A/XI)#]XBK<*++>63]G]:2PU;TV<=[;:
MMG?_]E8E250W-A.XM4R'3^9I9>KJ(Y/E)\U>] 8M9QA0!@PDU*_!SAT\K:-;
M"]J5<L![0,N^4:F6_-#I"DP5$Y-0RQGRO>?ZUM>!+#1#R[YJ?EC8]W=OF$IX
M"G5NY^WD9.\.L\\=19NN"<\6"C;-7;2DJT3+6F+?'PR71&D'*7&\*@9&-=]^
M4C[?JRAU)&,*Q=Z6+SM/)W4+U'JT/<*R$N=[_EN-QO^C:./_Y05&UL5+0.N+
M71#,/DDS5 #S=1<4A\Z)85_?B&&:4D+?+(CZT\6PCWVKI>AYB:$(KF&\J$,$
MT"#\*-"ZX?7]SUP+0>_F@]RFFZ):Q,*:UY#7X?M?UKKB]\*F-_]<?P#H@G*9
MM>V/0>AGR DU8\%"FFA^>'@2'!/5!2-Y9- MKFSP5$K33S@.^7.VFH$_."M4
M51$Z:VV=1W,4^TMB5=&^\-FQU,CFO<93J)_6PCTSV_3S_*OYCVPC+0V%E0U7
MQ#!VY< I,K6E!U@IZ*'$GR0O E4$7L5E"U=12Z\&^^ZI98(*76F)M(0+5E R
M:4/,8?%C?4Y;0[PGZ"0R G<]>8CI*W'UD!BF&GMG,$9123I>UH9KR1V#=.ZU
MV(8Q@3Q>I]Q.1QLCS1\#%0>^8A!L/Z^W@+, (F*NE!AV=@J21P-UTF)8^>=A
MLL!7^$D5[ ,8T]/!RZ(VR(,:*PK=*[3LEA"9I'0&'G*VP<!O_VUS*"K8MN"5
M30T25KQB2IM48!$<Q+C:"M:1S[T\UW-$MXMI!,WL5ZZ%9R^!IXQ4=4)\+%C4
M8C&,P6/9OZC(V\YW@K<F;-'0@+NIN5[%((9U(O>2&=JJ<H=]#1^XVJ9Z3<XH
MA$2 '//#;,B<+QN(=#[3/'=?5./\1?89\JZSJF77?_;!C0/]=+G7<WGO8G$U
M'A;MEB*-R6/)#7@!?"GK[6K:;(RJ;T%9_ AZ@,2"(W6[/4+>BL+ 5].HI,2X
MU+CPM>UZAW*HRYZ B08Q@CD@UR MO]V0BES:U6&SZ6%%TUR4*6O()=P^0]J'
M0?Q/9<7#S*4"UZ'R*#$LP8[;__(4;$DOYQ)@$@]I%<[FJ?- O3.'A2[FWC^+
M.VVX-.WZGSKT&O^I%V4@Y\L$(=C,F!E:O=*,5H30!C1:39NS^(%"K>XSY/7F
M7EMM>US H6P,X_R&%Y(F)',"$Y"<*<O_%?3QH@RZH1[*<HG*2=H<. <.!L#)
M78*-2_=1R9 ZU=#&+/0:\:27O)3]9;Q"_M-A7;\D5P(RO#;6I4\3]U_"+HEA
MB.O:F[60;JYR^#MGBDJ\[:YB,@MV6CS.@&.YWE>,(=SPEQKT+*4YKHR+"H">
MUB_W9O$O5+"M2< AOQN=W)[V1/2Z:_N\1DU;5BM*&4(W[/<'B@<U,>Q^'I%4
M&MDV!>>A,HY-D D'K9?P(LGVH4A\ZM\.48OR.Z49Z%:"WDOLXX/!=710E^RS
M9.#+7PC6A1S@89V])NA_(U%8.[F+ I+E_S'-IV6'EU>XA+NMZ]J&YVYXX\6P
M&P]0?>K?ZK4VFT7FRI024 \0!% E^39\98<8=LA$#-/'V9-82"C4C8!!@.W'
M1@Q@$N@D:@79S$DW86]DG2D8Z<GVZ)80]0V5G[$V.':>LE7>1 5\:1Q-WO?A
MD?0:V]M\Q3(?QK";_J#3AC.FX\K2RS! ]TW,OMI.W+L7O>\DPTR>V?>:.9"&
MGI_,XQ'XO5.@$G-Z*L('5[MX _40M?23/K8>IR_PTW<34BV*;5!R@O@(=T/.
MBU?7T+L? )7WE1S+A%_>$=.'M(Y5AW$?F_]D:=P#CBORO/+D9>WSOQZXA&CK
M"**>Q\[-2>X(?A4";$QNL']WTTB;^DDW=! +S<.'<W<+BD1#TAT 8J4Z98;0
M,R R1HS0]:4[D>PP(;+DYJ+<W:KJUE2!;S9;@C3B BQ<$\/\N=:C& JX+3X^
M"))..+U]%E&:M,$OKW=ZRHIA'M9B6)Y?Q]9J$D6(_.F@",E7,>R6@A ^RW*N
M%.J/?Q:1%FTW)]83]WG3(3TXBQ@-['232I,[IF6[I=\TK2SSV3?[.#QZO*!K
MZ[$_DBK72+:'L8('2#[X]\)'4Y;GRC4<H6U6BI+ANJ$GE=_+@2^S[FOJ& Z[
M'K1L'W)LV6S_-]ZN[\<ATKZ#-$BQXN<4J(C!\U)MHL34\17L?49U+B*-+*"1
MSA737:22(DKW;XW&P9?*KY4QU#AQ\2 %SHE"U[>QY.O\ORYV!1(W: Y>U3[=
MN'NAX]:[N_<\]2.WW.:,@&X2PF5R>?B6N[7MYKNRL .&ILN8Z/_4E_LM,/;N
M^"YW935;YDD6.4T.1M0 G7\"B\KS2/YN_VT>)$&8EK!73F[^N[5(C:=](*P+
MR-=);*EA12=QBY?W4/WQW%*;@^#!-ZI[RY]]]^1P2_Y X\T/-.SM1YRU:W+=
MJ@M<<DB[:/NSLNQ>W()PL5VG]/GG\UNV;EUW:/WZ$OONZ&;V2;5)W*)(]STF
M<?2:O1)#'UCT%)(4.B/:P XQ3!%H(!([@5VI\MR';_$#U%]8(4X]>,AR]YHL
MY/%8A=N/XF+($39\*I9,="7 39]?QF\"[?-,8)7!8<W/IVFD7E%8>?JVE-:*
MK2N7L/YQ\L3VS4M73OMQ5U[+Q[VWLT=;WP?15LZ8EQSXE M5#Z4MAH4DPX^/
MKGP(1\?6.2^+3LT>Q':)=$@6*9E"H!2R#8"OFEV42*TM&9T^62V&U4FRG+9\
MU"0(YMN*0%ND/+(M24NGUD;^M6BL_\*YYL>E/BWU[:9E!4U84.U+T_KH/48>
M#W"I1QPOD98Z%%;7FX8@VCYG.E)W4]=+##OF]X%#3+I_XF7+-=-U3HX<2JJL
MP8"5^?H<YCV&DF[B%MTUL;(F/.$VI #]@%(]O$@6.@N'-I"\^_#_R%E'2/\8
M-V2G"CDWU">UMF(0?JY_UXIA2NDA!Y^=+:  5]OS#F8LST1!UDL](@[MZGX!
MSQ3#3LBIJ]:Y^HK"''7+]PAS.C[439Y8+JLX6;*EZ-S=^P#M5I?1K6\;$ G;
MZ #[J^ S<WR1*439!6GMO:>8O,2B,Q^70;;8J002D-A29FLB[@G^CF@^A[75
M@33IR\:"!Z@D$9,8-0CQ; _M >2/KIT6PQIU9T!GZ066%FY94A0FZ. HA0@<
M2:IOD764]T RHA>QJ-ME.$6Q6(3,1"-EXF2-AR'DRY?4T#:F=A%NGNU/$F:G
MS\B^X<1(2MM^'MP<>3\\?@M&=Y,GRZ]<:>!'H#TV5^*E2+_/V7-*W5GKS79$
M N*/7\F';O;EO8>DJ18\=O#6CJ'#W6/9?5W.*QD9#5:/K2%RDTO;022-PY\H
M-1-ZX:O5%\_S?3#W2O:G8(9C/G(2QZA1%,OY %75^ZYZK$G.E3]1%,CN?2F;
M,GHP3IU!% T5Q>>[0)KK0%L_=H&25#^E2B5'.&&CGY*>J'3$!@/E:8*W.MIO
M1+<516[GN4=="0"J_4S]5NWHZ[2,F88<B ))1?92%-97&=;8O#MK,&%-PH]?
M-[ VH]4DS^I%%R,^4%9Q["M@T4@:Z].* QH"-JL1=-0&MGULF4;\0O(J9/Y!
MNI*U#-+Z\G>Q1'O9"@/5)5VV*.8ID$K55>OO_!!<W3K8O7+=!:.^.<V3BCVL
MBMAZTRP5:U#5608CCDE%GNB!V^K^.LB\1'U\4W\C2&4*_*Q+;39W&H^D\%@'
M.F9OW#B;]_2ZH$CCMB%M<EE_)3T^4#=U@R%K"CRW _O8A,2LV!433@TZY+<)
MP.6R*]6<QH\(G-YO/9PI;/Q /G["G36Z=TQ$J!##+$\YQ/[:L0XQ#P5%O)!X
MT^U,OB?R#VZ!Q>[]]KUZLT=+H8>&-^_>QDP RPROJ%8>R[#;NBL>1J:@C='L
M,D[E1P)ZJ)=D<!T*CE%P.$*KR<#K[ /YK69[V$)2M]G[K3J7O^^4D!*^O.0N
M0D[1YZS+C6,%]I!PNZF]%1H5S']LG-=VWZU>+']91;VK!J=\QL\W[Y']<&5+
M0M+X':V]6H6XS!'!MN4;8AA2:ML7YN:\6A:>2;XBKQV,VQ&97O];S<3D<M^_
ME:-E<"07]]1_+:HR>0'HGEFB1Z2?35A%D""O405D&I6^(KD,DONSWE.]]9]+
MQ^K%T&?ON=@TZ4>^F<#O*Z;L9U&>G[<]V0*PN]R9K[^\@ '=/-;1@?*GKK\M
M"U_QIIC,Z6UYC;<?ST2Z72N:F]D@,GWH[,E:+X9AG[G-M=='U<TR#(H&DJD&
M^[#&,L2FR(:VD9C"!-ZASV<D0-)9+!?_9&,YSNS#OU*\-!L(RRI[/ZERXG*:
MDZ-3;J#YUS^()?T"DD#:Q_8O"8ICA_0,PC+=5&_7N.)I\\+KF-"QFV/@YAS1
M3/^GB@OU@+:7K<;OV\.H0MR$0K*_*YN)$&YI_+,?9MF>I"#Z]P4I()<XNNK3
M$H/B<9K1$<\-FRG"URS%6KGUF@GTT6Y3;[ AB@W&*DP'9D4)=263'E-*IN2#
M16W:=?TBM-6&4;R@$0L1^3.0A%KD[)S<S0^<W.15VBK=X2?$SDY;<U3HTO]5
M+P321A4_P1 1@2C2@X@< J*9'G@[4,J=ST1 3Q$Q,^0[;^N?_U\+^0(,G,'S
MGOL9I)1%.KIT?K5H^-IE$&LC1TY2RR_X.><4E]_:C*MLG'#RN/G@<WQ@HOJ>
M.X$[X.G5NDE?X(QRSJX^31H^GAS/ S*]'/S [0NQ?S8)&^4#MWJ:Z_'6<PL4
MA($1F_NI+^$K;3S^E?TD4X]'SY>!FDB2H96]\Y9[8E@'>>#P$P=/,6P'!'R%
M3\2P)'ZY[\&#6 YMUGN3:W+A.*R-P)F=HL_\[@P!#Z[ES"P-Q0.NZPH$"O I
MN5MNCTM'[L"+5W/?$8-Y7^1^7T2[K)&&SRE_!ZI><WKGMN)%BU*"&NBJ%<_G
M>@W!HPBFW(5.UY;*&['D,?<7%+(0UF".S8.T+<+I</]LKV 'LA_4IR LN0>-
M$8XZB'.69(;:RL^/N!7<"M8YF?H (K>;](K$%,$@:IPQ]598,7'4MV OZ<B
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MEQ+>&*82:*.(_C4(!]Y&.BE5EW@U##/F% 3"0YNLY8$155U%/H ZB)T'B"5
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M=M!4[O+?[VJWIQDQ^B-.QQ&\XG<LT7ZJ^P_[V+%+"7H]'WO>Y*;K>!>YE=0
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MY,U6%NT667>:O[O+;IF,L74KG_4$7.\6'EB^I^WN-=16R18T64HZ>=R]Z45
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M!U%KJK^=2DZ-9WU2H!X4%G;2YRQ W"SUEIIZ(?.- +@F8&>RJ3[,*,X!(9^
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MZP)V 13&%XX9N).K].JJX9".XJ[[*IM+#V@*QY(C68U.HL4:I$.F/@^S.F=
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MGL]JDHG,Q,9I!J=8OVZYHA+G"\OZ$0?"!T6JE TTZ[&K3A:O@(G+\>-T0L<
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MYQ@"XMU'(3P^)Y[XWK[/S DJ">OG-Z&DC-3&#TM^>[CV\"\?/7L>G-Z\6:9
M?:U0H.)A,CFM6.^</R%UYA,9;R)[(3WUVHBX'-YZN48Z%VQ(NED\GL0QW2)@
MA,K!/N7]19Q2B6!J@PPGHRO/NI80I)E-7J76]13?+1M46LNT2Q%9;0[T4=YX
M< 78E][%NQ]F!AM+^#O/K#XW#7ZCP:;*$X^<7A]O^R%Y>1C 0WWMDX.XX%6M
M8=8I!_5O9OVJ7B@T>#"/*@X!152/H])+C(X!!6HS^2M"!U0_DX;Q#>8-7.#-
M1+/A\1D:=E;+9R20Z>Z[O&40>^GHGO>[SK><S5RQ^MG/JCPMO-4$7VHWYB*<
M9=[#];V.6/QVP9%4XE+.'Z/4@+0N'<:-+\S&#O-$G3?SSJ[@7 BNLWZ"^^P&
MQ8*C"!$(K)P@0\N3%2@.<(O%]7)1H'9GPKGT1+J@;Y0J/8P6%2JK? S C6ES
M"Q%.<,6W!'YR"&3D^B*H70](S( 2*#X3KKR/R*I3GK ( \UC^./?D1O0*XUL
MBO$C^*YVE[>YGW)=CY4\3]< ! CR$"##21J3>?R8FX"F/%O<[$ZOD#-]@>$(
M1+&2X)!9MKF1*[A_PX98B86O&W:XY%HCP@<^ UR>L=9N]X_G?^"1)KWG?PPJ
M:%2!KZ+ $IQ4)0?#8]^'D?9=%A+@L!8%2J"%O*E]7PDD9R$-C%>@[(-O*E!)
M"*<+Q$M54E>0ZJ?([5WVE->X$<>N2S3"\$&?7\:0Y-[2GZTNUTR[@H$.*<*$
MW]G/JG8BG_.Z$HSG"6Z(K&-0OW^7T83L$;@UY0Y>#WA_+X0P<J;KG!L30D8[
M&.2$=]$%6NX(O-&@4#ED"_F4I<$1RQ6H8ZWP RY)I@\T;(& MUHW,#.P_#P@
MIC&][EUF(N)SC9H0+&BG,JQC5-3CP#%]!:I)?5MFU:7[<#8]HM92GG-<+T??
M!C,@EAZJ2+F90I4P,1L89!'9T2WW3G']KTI"-J$;H+>$3$X=LMFWN'E.'"7/
M;",+W<'W?A"G +$%_S@()PFID(>>+C)H4TAW\ +>&%IZB"Q"''E<HQ2H4Z!&
M%QU>N9955_'%E?WYQ'8PZ.-T@ H\3W:JK\N]SR\3G@;HK5&R]L;Z&N=<F;?2
M+UZ5&#G<1^++<7R:+<^I\,BZN$9H-=%YT,X2/.FJ'6PJF\I("=MZU19T"Z3-
MI4D"=4"_@+AGFLZ8J3,(.GLG*%#.QI)0L.^S[+@"92P!I5%=)('I'00LL1-<
M%C>_@<5W^?>]@AW!".KO/\$ ZL "^;LR+1!'8(/B1:#D."LVRK?K4^V !?P>
M)&>".=&'2)(;:%$*TD!]LPE2-+EA^7)29B))<EGX^,:ZMUU;GN13'92'>1AC
M$R0,[YC0NN3>XBZW?<&(F2H5J/SV-;T>MY$QV7X/8)[R!TO8DBH7<#](F\WD
ML:"-:T#!5J'',4ND-2!&E"L,I$IY7@"T&1PZIVQF#<(:1]&(FV5-H"%T*A)7
M.!\X=8(ZU2H+9$AY<UAHLZFL&VPR1-S*V5KR".G[<00I3JU@0283=,X3)(YV
MAT'#(#D;S"$=4J":$T!*+K2@Q5IK;H/D)>.\^7&)L]!W/2:]E7P_SH3*N$V2
M,;XLAT^6#+G=/R$#N]0==+TE+^6V@-P%^!GW-VF$-G?\(4%;@=H7^?N7L7B=
MA',0Y)XPZF1*_E"[$X[$G_58^S#BV$Q,6=C(GVB)*.6>O UVQ)!'K)C&Y#11
M%TV!VABT"KPTH2(WPXO(4K5D%K>H$7&H6QCA!3)?Y2JN 7&<U1[ 6UUWTHSA
MJWU4D0J3U5YQ]K+M**"/.#7(<(JM++92H+X\11Q--1\)^90Y&2RP[:)*,8C-
MVN*[X QWZM0H1.7Q15+NG*[21$@,-QG^_4M>!U^SXJ][WP%;07&G7&]KI]N4
M!<VW?<"0$U-CY\$8;M YXJ_C-V8L?P E]4(^E%LNI]M-&('?J</X69\.K5&
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M\P=Z&'U]SSCWG6ZV_FA6K[C*Q4HJ/1.95<5:G/S:SX@T?SH 4>?9K026UN_
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MT@40FO%82,6#3+>A&@CVG6SADC?U1O#GW/EHM>Y10X?5;QUH9I')V6HW;"2
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MU]':=[T'A3B?DR>D5-E?//S&P46KD#LC\,:9M;"56V4"2#+-B'LK)/?4$%<
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M?YR]9UA37=0F'$3%CA54A*BHB(K8 &DY(@]BPZB * A109 :Z24D1T%%!8F
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M+D!1X9,[;WR+SK-ZO'.3^Q#H<$W/#;[M1?K"H\RCF:J-W"1I48@$R2H%-,N
ME3+0SNI,B4.=Q[/@[#J(*1NFDS^G[[?]RA"'CT]OIRW6LA1-<WEY_"T@M83
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M.\^$..6LZ2@=6O>^?6GGY+*OWDT\1SM/5VO/K6;UPFJ!:.S#HOXGE5-_SM=
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MB6&()\8CD:XL=@_O)LM-_^ 9;$A^'F'!NY]F'R=<>RE&-,Z'LY7:^MR>6JU
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M[7<-G^AYG.T<8.T\$I6A4Q#F@;29YE2)85,K%9S>L/?%T@RYJ+4ZVJ2XJ8/
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MFDL73C$WB&%5*\KR!:\(^\^YD(94A?L?HA#>T ,P[NO%6"?'S*-.^Z5#B?O
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M38$)7GE4:8T?A=SBF$A?I(D%T#]]_>YU[W#$"W.[WZN$O8PXT04VWC,N<#[
MX[3M35W\WV$A_0C[54M<?DF7\E.TR6!"<_OCH^0&S474GJM.(:N&7@> -+!6
M/[U;&^37\)?N>S,;?CCU;KO $Y8K/N6>N"2[M^/\7XTUA[5%9KO%L%O[02(Z
M74#)'Z,[RJI#8<#OE>X?UB?>'<C>P8X(CZA()V8N?2SZ+-2W]NF@>V4ZG:!O
M"D!G@)]R@L;GT%,0"1XI4V#2$'V@-&X96#DTOCQM >U.]E7_!(PL3R+BR)B9
M&K:@QH$Z^B"E%/IOE+UY/)3OVS\\I=+&M)!*3+LVM-@9DR1)3")"S">*$)-]
M'5>E4HHI"A$C8NP[8VE,$I-DWPW&O@^&6<QVS3.^W_MW/_?]/+\_[ON/^6>N
MU\QU7N=Y'._C_;Z.\SP.1"EI$(] K6UFD#H' @BV0[E ]2E=_+3[!W!W1\RC
MN/YK7QF/0]8Z\57RE/EW+[,:1E/J3;>5(YX %<-(YNHR H%S(^4_$4*^S5Z@
MV(7DK,+FY,[$^"UP;!</#R:& *\;VP'B #@$EE@/ K]>DT21LB#MPY,[I,/4
MZ7G9Q;PRF25D9:$.*&D:15U0^LXS$SA3?C3_0C45*"8U_I#@[?=I-1L0^&*%
MD&?:U5N0#/ X,(882^XP:K9UH@KRZH.\3*JLQ7\"<3SX%NUJ JO95,=\W%.V
MP+=[AW6AK5<>HF M$2AGV2K ]3W!L=J"=%:BMC+O_64^V8*V$H?QR+YJ8?+.
ML]OZK)G[@I-3%?/24\3X.\0',F^>]WC5MYXZ0Y;0LE!K\I'."VUYBUX9O,GF
M:\GKIGGM#&RTX/L/!Y%>]85FS>:Y!2>6&\:PKP0DI[%\WY;'CGCG-<*6XH00
MK&\YKCSH\_]BLW"&$.+"9=]R%HB!.Q'#6))/6IYIS97'E4'BG"3_J&ZE"]7:
M$_+=/_P]^JX84@Z%2WT&((1CBP-E 6(,(&]Q\Q0\;W1PZI727M<*^:H3N6&L
M7>/Y1<&[_QHFP:L)TO*ZO>>+\4V'18"D3.FHW/;J8"56A"%$=<2\+254 :O\
M$J;_U:P]E*-9=')!/HZ:Z/4BV_G8S];*\S\\1W-^V.0G4Q,),)H@A?3B1,R]
M\YD[58%T97T^UG"PI$*N9K44VR4A+JE5J-6_@Q/*OLUFURT^I;ED&UQSA!>K
M=6^95VXZE$')4+'>HL:-S<R0 ,F"\,JF3^IB%;0V;<\(=62C:QHK M::?RVX
M]0^BJ^;1X#F,AQLG!C7Y@26)Q1?!S,)M5H40.!SL-R6NK=)M)2P*[%;.$HK*
MJC,2HDJ_-3^=]SUPH_S.R&N;U(#]]_H"A) ?80=Y'P*SCI3 9J*W2=$%B(4?
M"%H\KBFWG_?!BYNTP@["@8=MVQS!X]=5 P5/0S'2$1KW4U.?1YS7N=5AUG'[
MDSJA;R_(!.7'MRD<18K"L/Y;GE+)[:OTR4M!O9R8SA?)MONG1"BM>N@IE >P
M='MMP5)2>N>N"2NLOLR*9=_[):5&3O!*>79L*C!>/1635@6ZCNDXA=W_E/,[
M0#)E0U:>E.%;FZD)VP_JY85O)(9J^6<T %G+&[#X.TBF?)';4M'?O9?]DNVE
MY.5(72T73QG.3*]>!!WE'B<N/IS'_:_[L>B!06&H>LE2Q%S-=48<;,&+2D<Y
M!Q\-R)@7G 6.W^]"+)EE](M@$!Y+908IY;I^1-.^?VQZ.5AJ_3=8@7^7?6M3
M%+2C6#816T_N7<:,;P;I@83JM4O,:&T/ZJ'WEV^\QUAA;^S7ML'!$&&!HSFL
M/#W(=OY34-$8S8U\WKQ@6+3*. M.,9I;:G,M+Z%*!,D?;<-*U%Y1WS;;5IXZ
MN]DA3,_@RA:;[$R!XL[SN]'L?$1!B7:^+V41<0VZ+.(ZG6K5)NTK_-G+"+1!
M3.E1*N:#GL5G@_P^V?V[,YZ*8))]&E3CMO\P$4+J!,!]=J+7\-0R4#33-7QR
M^,(@\'XN@]>#DRTOZNXJM0@_8/ F+=_L:B!B40.[O-X],*A<+?'$IZ-@;PK]
M6G10<AXTTR78SSYU_B _%+:CJAQTS&7)V[P&=H,'[A@;1]?KA0(R&ZD+\+K@
M=\&+)#JZ9QRI&^Y'T+[_;FTB;UO!U\."I.WBKGZ+$T1I]VOB_XRY]C"S]*,/
MG/M,X'LBYD7(P!.CQ6NB X:$$,+RZ%Q>%:TH1-61)Z[OUS80D/3A=5K=:&:S
MBM2WH,M;LG,!<F!X;Q0P#/\MZZQ<5T@C&4+U$JOKM/?IXM[SM/Q9_IWK1)9]
MF=VHS%.(FA%"?AE5"R'L?8A_8-Z(B3<50DBS2%=A?=!_J"NW2WG [Z# -1&;
M>C#9"5M[QT*"8S 'I*,0,FE)$4(Z"?P ADD+8N5.%4_K7R]_X?]S,^LIIAYE
M)S,:@)]QI#B2;1M:;A0[W]R];$Y45YJ<Y\I1;$V>Y^==7-JVK[Q@[_2]AU='
M1]]\_GY3+LV2-#*S]QMT!L?AY2#&..H<\V_LE0XJ,3P)#$:TK#YPKI;!>,C%
ME<2-E^UKZ==T[[:.K7/81Q(7TZ@?5_C2WI9XX5W$(_@IG\R.7K7W29*(;G(&
M68IG2/F17![$2LSYUR!=X/P94,3H+RBUUCIF!>$RJJ%CSK5@*2>M/>ETC79X
MD%.VG^0*36=D:+?Y=O<\+#D@^U2Y"M3HDI$E<_MGN;/[RG5M[G:]A] V05$7
MO<$"0IZ$Z="O?1GB*<>!+Z$H)>WK_+*UKZ6@H\^OI LD]K27;_EPXR3+?A3G
M[6/XJ-O7=$SZKOB>]Q<_!L7??CUN&="LN9*=#=E_2G+7UJ\@:@YNT15]65RJ
ME8**L_D(7%R:+"K64@_ENZW=7UZ:1*[N' +40^^A-8N"]WLL)<B6^(R6AS93
MQ.RGJ+81SU^=L:8<,+GY:8?)GM94/R.$S\=3PU(.&_=EB= ]/A1PMN]RW-D"
M@7A*'^"WQD%+F>7VAQYCGR*V\;570Q>;APIKSONHVGG,+\C7__T2:ZY@W+N?
M'5UR++KQYE_;(_<B\&SCS>[;O.I0Q,U;O=]OF.\^%P^Y$SX)IESJP9/^I$V$
M-TEB.>%T_8F"/\/=5-Y;/"E9_EC-2KS$IRIOU<J;EO7#=Y.:U?0=.D9GYD[$
MP-Z%] Q$/7- 'HC<]",T?H0]E7/>*1]H%?%/7E#Q^:L/[34$7P+XM0AW+8KM
MM.%O'?]?V->(8S4&=YX=95"-T<T"L5R8=S9)YG(C]FG#MN,6O7_C$,OH3/9E
M7PLNE(6HZ^Y:>R33U<;_T0C:N2)7@M.JPZ'T5G!O%ATHX<U/Z(K[\!,7^>6&
M$Z^FYL'I(>U@KP=GJQNB))IBL&N_NE\9WO3AH"7.79-3N2^W\?2'-T69*5F-
MB%8DAYMNT?9L.5\CT(H_=.\Q=?E+Z[O.^HO*?Y6GWC48<!$M[_ZF""'Y$D>Z
M$+ULCU9+$#4U6[-D  +3<W2U+9VI?=KJK@LA]N;*\?A^6[=M9<N?X>VQFD'<
MSE?DB#N/8_46*P^%IY>=ZDBM?QF^/7X[1,N"EAGM::\R@V)-F_P/DB'RP +P
M&T67I\04^-JI(ECTTT((W<I*" E"!'B21([]2X0#"<Y@>U"<.S!I@V)0)^$2
M&$U8PEO,'="5I^"%8U''T5[.A# F/AG-%J&(^-4O/[HZTM: IK:Q(E=2MDCW
M0]>H1;\.0:\RR?<81F [N+HX@.@&TSKLTV* 9;$9>+6477!NC3B8 PZ* !F>
M.3^D.G'I;HB4_.,,)ZRT.*.@,09@\7DGOP_?+V0((5;]'>GE2@%[61!$78>E
M4M=\I=.NI*52<'ZVX2JT@'=_(57)J[ 2;!"%<MP-TUX?TC-2' =I?#W[:V[&
M:INE8_9LA<,%*JJ []87U?$(/4I/69HA&.GKF[$8DQL0+C: O*NW&X#E43O[
MG\;"OB'F5F=3UUMCY72F]Q857,5<?*"+%SPB#6.+%9O>8O#I?B%:]0LQZ41U
M'ON&%IL8< G( <]F9+%\<3\1XZ+579<(;"!/"(D#EIFF17W)2HA?4>LM9+\?
MR-?P2<L70C(]/ #8?/ CDY$G\T/^0LCF3N:T@+ &_ KV!A\Q%XN"_;\)-/X/
MZ3.9/"^E.0 4-]UV=*77Q:;DF\>JPQ*? ,/(XD96I@>BN;MCN;X.FTG6*T.:
MC;@X*;A.KO).12/&ZCY*&+6J+0^SN4"-_.^"P-#=NH!^>@\OK+A-% @?M>KE
MA9H'FS]LD'FTM&\H<+NN6Z2'U@<7%S13"%%$C(/400!#'*1U8O91_,>!YIH7
M^Z8&]/*-[1"?"V[<+RNI-"Z?I&H.I&Z.W+<5\#M-&D,#3$&9MH<_C#((Z !%
MG>-70DZ)_V7#)F-X0;4*]_ZY =99=NQQ;YG,@='%!Y137XTS=(">^9\S6.1D
MA^T3YIVKGT0Q:<9;X8E%QQ9Q\9IB5/WI\/5%.3E=V@R*A/'J3 /%1RK]-$I5
M7*"?SRU19IG$]G=W^?;E1ITA+&5FGB4CW&(FH*Q#/,=_JNB&8>I<8I ?I^;;
MO-31SP@G0WW#(F<#^ /Z>E@E5\W+!1>(#(8L&*>611%[$+YT+?_+HOD>\Z6)
MB?CVF]Y2R>)_7Q\JBTJ8'_YWJH[F6.!S"+V;]9GV)J9;)-R]IV%V'N[\6R*+
M+USDR'0V;Z+.C7>\KO[T@T%>F+D:*1'9.MV78.W6B23G,]09Z\VJ:,[9OF2*
MKH+IC-Q_C*7:34ZU5TY"@!C&5.8R%RO_?5M*$-G^O]XV:; ?.JJQL^:VR&'=
M4ALWDYBPE2.T1$H)&FI*R730#9R3__OKBV5'7?L-\<%.,]=I[$IR()=G7&0M
MV*0@L)[OU/1366]MMWZZ$<;&.ATDF_ABAT),D]JT&O_]E5^/EEMF:/^LX3T<
M$\:2%W3'8,U.O-CM"^L9$5EFG\I<UZK<EF#^UJ\47V=PDSDZ*7ZK#N;,OWC4
M X)^74):>CEJ_(Y\-G4.Q)QB0Q_3M':^;Q@#>;Y.I\@9X2[CU\QIH3@C8&0_
M@0>CRT_NJ/$.<RX'=<.J0SM6#)+;&_ MI-9OYXAIN @_%ZTZWZVBO[;B?4B_
M+R)>:!;8A!K\K1!^WN=HN(/NS;/34<4.VLJNBS9"R&A1=^_8JLSAT4L!H^^R
M14BV?N)!]Z^:KENXG[3H+VBS-Q,=\0=WST%Y<F<>\EQJ*]3'<6PREZ>50)J!
MWX/9)\Q)757)W*? !?)H.V-+Q]N)E=U1B0^QS="U\X> [[S<(I^,2KS!]D?O
MANK[50,ESQ;%1Z89O((Q/=QBT%P,J#M2XQH8.2*ZU?8-_*IHOS?/;4_)/^BE
MJ2K@.:%IJ[7JZTV$\D:7]Z;=113.7;C<T7U^_!:)2>"- S[E2W#$)8P&3)?8
MMD-E?])\Q+L-;QO\)$/,<*TP+!OGI7RXQ9+:*G)7<3U[=S//)_OI&0#ZVJ[]
M'U>^>3*)@LCI*UH2K\,EG]:4H A# O*;RHW8H#:G B'$S0982V'M&\BK20Z.
M![HC1-B81AQT?=Y-2D-.(9K;Z+/QF+O6!0*H2*E%['2BIM[H,@^W"W0!NK"L
M.O LS>H%)@B=K^NK\W0KOY]8IDC4D"\8B:J*U3L,N9=T93 8.9H8^KU4+'\<
M+S[K$4ALY;M1JD;7P9HV[S3";+"X@\C!K9V6$4(B>7WZW2'W>\XJ<PO86(\U
M.-IZ[NIA*<3[N^NU^!T"LKH_Y82UF0P6;E],IS+,,*8'BZMQW#(;[P5"?"BT
ME3\$+W'@ SE-Z7X]>> )0CE+_VWW"+U_;RLWVUS$!EC5[K&%5H*[ZVTK",9&
ML^M[CH00YW0YPV[L>&<K#QT:>U R_F3EG.DE.53L)Y?369O=]28N<@UYOV%+
M]MU]U@'D<I+S]0)TP^!9=6A3OG3?VJD+FCNGD.IO4@?ZOL-#QQH7S[Q[.7.J
M:(TB&"0%AMXTI-<BD#-PG/6"VQ%R;-"14)?GU*;(S5#<9+LQA5A?$GIC8D4#
M>$L]4N58?,'V[NCH(*>F:#A^L?[/%4[TODU!6L<4EIE=E[60/6SNW@6)O\%J
MHX]#DP?W0*&'@W8]OM=(^# ^&.J0&D9+#Y(X7]V90;!G#L+=2G1='F,$@\$A
M4\>:?&O:%F_JFGM>HUCLM<][DZ%K(77D;M(I#RE<[>'H\8_JUQUDKMGL#*%S
MDM^QAOT&"I9TOYP2?-Q(:J61KSS4Y5/M?%EXWTE$C:Q*#R;2SZGJQ7CQW?8/
MB.GT$<&00N>R2$*\4HN<"@XF;70A]<^XZ9(W]^5NC)PUUT<R@WPTEEI^S'OD
M]3L7:7L7^R',?.<?T(-]EG1_#S$2E7>>+9XS.'<Z^G=\6]Y5U[^/=9^]&9$U
M393LH6"Q^(7UENRI$I3X^_V_]TQ,M%DM<'P.^=3,SSW2,O3T*S];414#[U0)
MA$\GY]+XNDL-3N5$Q8W=F5E9H-)QJ0PMMY,I\B(9C4R/J 0^'J?0?,PYSGE+
MAVAHOY\A/6&"NS-&<Z8-<Y(@><J;*$$9,AY<^R[A=TFFXN*0)ZF(UQ/]JD3)
M9^O<1(HS^IAZV\K!AH81WF[ULU6$0XZMJ165 ]ON;XHX>-!1@\/QB>_#'0E5
M8TL"\%(N>L+P.BM_E=(5N)W65*+56IBI7H^14U.['&-R0E$A^T+^K\'WRJ&&
M)]ZP#(O#K;CA2/=!BN1(R+Y-3UJS3N+0M!F?L+WFJ@BZ9M]M\QVW! )_'H"?
MN!=\MJAO6(?AJ<M#H['+OGN"#2_@OT "CJZG:H "VIX!AK-$O8$X;?Z@><O8
MO)=N+&+] HI<G4<,8$S$N(SVU@P!74 CE4[RFR,Z(_$\6"BNP/>SG:/8GYYI
M+HQ-7=*=*W29-TF6.[YJO?OH:T<QFA!R;!;DK=*NG@_R<7_H?#,YQF(J[?FY
M;40RWTU XI%+-H?WIEG_UM$R78RKCY!NZ+F]\QO34D5%+ :D]EO2?;?.6T*Z
M %UB>;F=Q[T._>3L_,;:F^ZLRT",)V/ZK2CH^V-4NW2WXG(\U)]W14-:<;AK
MT-TOR0XNOU14/DJ] %I(L@!^FGN/!Y6^>[+5;&AAE7#CX2^'BRIS;J=F7%V6
MA)#3:Q0 U;I/Q*!H]Z)EHR(ROA3PY(Y[)]GI6VUF">S\MJ1&5UC=NF7VX%DZ
MKX#C*,!D#/IQV-"%$.ZU&)>UD@ZL\V+E="*/4'GZFGJ HV9^2J<0LE'$9Y^5
M.J^"/,'SR)(G'2';JDQ\/AV,?8GD5$G?YRKW\JP(O:*K.(=3(1YO*>'6F,IN
M+IL40-)-7.;^1V#T[=%"_Q>RT/L=& ?I2P/_+3[[3MIR$ZGIL9_AP06R][ _
MUFLW];YE+#,7GPM>GIVXA FOV$ :7,Q(315"&O]9 \;@T8\K*BH263ZI#-@&
M&:XFG\R3V]8NHH_W >=HXZD@ES4F612>\U)\8\@@8DF>ENO3:_]OPD!R^V_D
MY;^,)^I?6SH&>X+8=J67GROMART3RM]&Y>=-!.WTOXH;W@E2!OQA;J*'<O(;
MGS6.%$(N00_Q3DT= 34W[0)UO[QE='\10M)A+HCI\;:D?^^@3ZKC'M)RS.>O
MWV,QX;\_\_^?/^0K<[$\J(>"/+'SFM4._2_D[O&+N$D+:<.WB;8"0BG;+QG!
MX7KN#S/KE:\<5,TL2U3PL<0T.*/[,R\>-%B)+W$S<2(Q8-Y,(HDBP3D;KUO"
M1PID4VJ6G!G4S#3QUPSXSL)GFYE]KKJ);ZE< ;S1')8)UJ66)!?R\**1=3(7
MB;0A,;P*SO[Y\,]A;>W-A+DB7G:VHK7K!NQCB1V 5%;6]@ N"L<Z' KT[%SU
M$T5F-V?/G;BXL YB]A_CC,WD)-<^6%,*)3_X2HCDEJBW(:,EB0#LNH0DPL_*
M8<GXSDW@+Z<1UK:^O9=T7_[&%'M@@;\C.=(?D[K9R_TUXLR$_#NU2V=?-G4>
M*/H4/UAVJCR=G)&,7$.!QP;#]\TZ5P!IC(-J[[X8Z%)94-->6!OP?3WOE$/_
M.HNT"TSD*O,_+3(Y.&8HY@07&[<6]'\,<'9I;[Z- OA!""'H+EV;][4OZ@>Z
M@>_!U/ .5(YNDA]MXLQ6TAR!.QB\JK./1/%U"V0ZYN_CP]@%OG02%:X]V6D7
MZBSW.F/UH=N%TF^X_*LH+'-I,7I52HU#G!-"KCV E_%)8US)L]4..Y.,4OKZ
M0EZQ?Y<]E3H\EG5:60B1RT'@>_B4/EV/@%?C@I]A#;,.M)>7CFV&N1OQL7:T
MO)?WO'*JU<L<'[(W-FS>++%;\5T]-(5W!<@D3(A&S,JY/_DY=SZP$K8?1$W,
M5A:\.'8U0!S[ ;[S%H &]=93, JS,O9?PC(:1*(+/#9<_Z5.H)_7DW0MEE#O
M?AE6T D:+H9YAGF E+S9 DGB- ]K!+85(MJ4UTNB+MP6 //Z'38NY-LA,!JP
M@N:C*?(*QCJF:;R@1R%8F_EARG+-<!D6=_MX>++X]'OHFOWX$/HP?63^1K?<
M)OAYRQAWI\+>32/J'F-D*E]71&%JN,';O3"A4<G10&*:B1"BM#_PI1"BS.%*
M$R.Y9V;K!D*)G0 A_>U<4*6<FM4_YRN?'/YC-E[\:X=-S;C@Y5-"<7M)'8H-
MRUG+34V[Q3O=86]://]9>6I 6Y_KB27T"EZS:ON^(NB'1%C*7 'V LJKOA-S
MBY51$S23#''F?B%D+4]0KAG4.LE#],]1OS\ C_%)S9V3DMT#I3^[[D82;QJ-
M.!:5ZL^#E:P:B6S9]5;7W3;+R2=)'E_!#9UJRW=>/2]]:OG>TPTP$V"R7PY3
M>?NU!IHUQ[N/L,F\N(6DZ?>QX[PR RQ%RD$(F7/1*0.6[.O*S3"^M0GHN&N=
M2?O^B%/:74#[\T!?SX5Q.M@4.B,BMTVNL+6"RK$^JT=(QG0NJE0(^30\#0;T
M@CI! _-]0%;!_[+&2:( /S_D5L^G!9&4GZ>NC:Z*NX[F>)%F]@99CE0KD?:3
M,'#='FK8#8MF_"V>ZX%?$4JA93>V<:&>Z(IJB\9#ZLNG-ZJV3R^?W1)5\RE+
MFGF_QU?0R!D8D.6!=L2*E,%CWR 0\:Y=FX$S8JR- 3XF#@M@=2ZE3S"N5^-7
M\D]V5N:\I.^\2^^'X(VA7W9@KA,*95'6MK9S1\IVNF2X]3B=K ]:C;^ZB9X!
MY5M==IKB''D^'!DW'_J"DOB6&$RX)!$Z6$L;"GN6_5MO0PZ*P(M(2#G7]<B@
M8M->YF&O].>!RF:*>6+GCS^8C+=Z:7 WX0FL-;WC,=!]@5G=75^6E+2)\24B
M8??DSV3G28YO,6Z%OC;Z<2V=;IL=9.6)1-I6/^G3:0 "MA\<?9]QKV4\F\?_
MJ()D/,K*]MF!31L4<?MWD9/$(C^W4T<UG/T<X)LOU+7=DM>4\T(,+SUQ8&LG
MJ$OT0!=0O#/;Q6QBL&>BKW/D<U']TV96-HM"B":8L7!#KI6.GQS^,\#!+)4'
MR?"H93SE#0274&YY'/3[X=?O2CUG%<C&F=]^/:V*&'Q:-WAG47)X@6ZW-<3@
MSL$W67>V<^/N:&SI,D"*]7@+6C5Y[@/U(B<9-E6,&G-8=G*\K',DAG5:6F53
MY]/C/E=8L& &R:G#K)NF2']>$('OE%,T0"\/O#<47+P#L:0NFPDA4E$T]>MU
M'WMVD^4N8Z=QR\Q$JWMQ57>5*E.Z2NOTN(6XYB!DR'/:H/-MIM]BJXEEFJK5
M"XVDK]>!IFG<Z?>W'HD":LV7O=Z@#(LV],N3TG@.-7!A=\S3C6(QJ,M:K-I2
MV<:RW5PU3@5#2I[DP@=;RK>!UG QY0;J*[L=O9JG]NZN=%/[EE@0T&9*^#)%
M*(D8^'I4_DZ6X+P-F+/! ]Y\*,O)CUBU655@M#-RTL1B.V(84G OB_=CM8"Y
MFDC8,3>R8=.FS@L&V.5DN+5_D?,M_/]R;[)9[VJ/$%)\>Q[@6^O&KE<2'/Y;
MKJ0.S-J"6D-7AT6\J%&M%PS*$_GJ MQZ K6\#R=X*)*YZ("L:J!2N>>F.Z)/
MCP7@\-ON[P$;(7INNSV 86*<0,FE/=YU.X>Q*U]!MJ<Z%NO=[N!)(WAU4^M6
MZ]9<A!!/_R+>@'+K*^J*LOL"#EFR"'R? LG?>D^.S2%V[LU\<*N#=*R#7"I1
MY/MET!LO"*]LZ*#.BH @84BP2>E(%D\K33FZBXHQJ'B$4 V8&T,@3'1[[ VN
M5^61K(+I+6]$)$$^Z&!L]L^J\"QN-QK<XWB?P 5C&" )A2^<JYL&\^44S8?K
MI@Q79YQ8.1E5V*6A4_\"A_^(>>@UN/J8CP0_6C0W_HLX_M5@DFC,CJP-;'WP
M#HT,/H*NL0U#<H20$V>1##*HW4FJ1_%.KF^!^N5>!K!E^Z>+2"LY(M8[F\B'
M[_7&\3\IU;2N,!YA_F*V!/W/4ZUY]B#2!KUF05X94I,O> H[+/$:+%[",H40
MW87O,@)ECFP&]N<X5Y]_NB.88RV$4(00 !?'I<H)(6P#X\7P$9C(/A5N. DA
M5_FDZ<5R,<X%NY6]XAV)\Y?HJ <+$DLK&\])GT#:TZ*:F^X\_BNI?[Q5M#:O
M>]NQU9&;3I0>3Y9VAEQZ;U*NNH%"%J N=-ZTNB,;SJTQY,OM0H4GO>%/J:/1
M[]1;$%$D:%5G*N71HG6V/\J(56,<O+@A-O P*'W(1UIJ2O/47<Q*;/')Y[WO
MN8;560Y/Q">%D'U![;?2OA=IB.9;"E'7?D\(>7E)".F',+"@BLR8%<B0KID;
M1'(=07L"#,HB3<H]OH\50IY: ,MZ(&-X%O0&[7,#F+G(E1<-L,^PO\Z<-!&?
M'&H^TN)8*"A1KD6_W=/]J\,P:L#N?.KC7Q]ONW@;R]\N#[IB=VX/ZGOA\2*W
M]UL*^A!HSE,!T<W,R9+?@NAO-@'^F5/@GU8HUU8(9BB3A9!)/+T5IA_'D>;_
MTD:)%[FHQ3=*5(JSM?-DUGI&;GX*+7,]=.?.E8ZTUH:$O3:&&[#$WEM28QCX
M6= \^7M3RJ<5LP@N!ZQ]KHNQ$E]571/P%WG.HUMZ:]&(5\#6H!+7D#W9?0)>
MM^UX>C#^1 7[VB RZN[H1:4]KS(^1&<ERB(/7I=!<KXZ[SLVW*BQ:0,2N5;2
M\^E1V:8DP]:7P+!A/SFM?X4]V2++2>7+@^88H]Z5CW&<%/Z[V8&H[I_C9Q$O
M+<QHJ,AWB=6EISZ7D>(=+MY-?]-!K;PYD&NHRS!0>;86"9TD\U7GOK$J$2\.
M6G G@"-(0B9N.74X]2<;]ALQ4=#YB1<3P%Q4".23!H-/YGCY>OCZO?*6-M$]
M!I/RO:L3)F.S_>EK$]U\^)&[NTSX6_+$>F'TKSW]$;GA'>$*W'-!FL':G.V,
MQ5_#%./0\1J19E YU^W1/*B1-ZW_?$B$VD>:VGHLQIQ[3GNIM+M'WKX5MUUA
MN]'MWD-8WRQY9U94V56=RYR193RE6U K(''$006*)S/T6[#W_Q3<K!2M!-\U
M ;HUP'G #@]I%T+.SOXKP:#=52VR\S-]0LA-1&,;M0-%7Q"9Y+*@50A9O,L^
MMN*\6PA1%5WQ%NF.+A\5(>2/U;^+9AK,Q&79=S+2,HL5?U+F?$4DF$X4#(>$
M)GYQ)>OAG)8"6<GR48?<#V<-VCXG9CX) "'2*'V0W&?[Q5^3XP>37>->Z*-M
MIF=IB"D<D-LL91=XQ0D\7:VZV%S/S9G/:<X*%$*BS@N0%?,>?0K?!6Y-$3Y'
M'1D_7U_H^,1J&(AC.5,"H.7BD1H=NC7-&47AX!&]SM19$;67O?.TH.^%!^:-
M+<J8A9OD2.!S^+'9'P';4'CXDM_\\%V!FR8/41[/&(QM\AX8GX#BKTDJ3E_6
M G-"1-RJ8O1(\RS7.Q,@Z 0GQ"6,"EK\$3I >$J,]>X $?O[ )< )Q:?)_U?
M,A&/5_$,]/H;NX62-/OOEW'7#T698$42VIXZ#PT.UPDR]#60DQ$T$;TYN34H
MEX4JZJ@8Q$0>[6N5]1M7Y09\,!N,[0:6Q?GB4^I4_WY\Y?)](<1J9<;P85DV
M93ZD]_DRO]5HJK_&,6AHM&9NSDC]M]SO"\"2 NY^/XN $\A/@UX^CS>)/<]<
MWXKUE],\WTMH:OR</YQHF4 E/[H(.92DJ,[W?W5++W%> /3Q0BE^N/L"=%=B
MAM*Y:(^VC;@S3PKZH-?47M7$%F_7FH$N6-YU?+:/&0J='JR*%EQ56P5@>K;/
M,G*F-!AC*N\-\LA,UNP+BL_T/<%_K_6\2)Q&SE!IX7PKD0&:,,N6'8JZ53^5
M.44G1(4OY>3,AW<*/.M)HC![G\FFM=P]=X0>;B)B;)PV\Y2#^ NXA;?;E<=D
MD0\QNKS9CW]<B"1$B6$KE[HD-JA(7-7I719(R;UGG"@MOFMBLB,H=#?8 B!*
MTE]I2V-_=0@A.U/2;&ZXV@HA[]O5F2PYBM]OO[60K=]1G,;VQ!NVU0=6C^%A
MA\3F]@K>L";.8Q V6?/)ST#=KK6Z;-_])T@71.%=?_AK.[JGS'B^8V\@;>G[
M\Y@G]TF-A'T;N[LN[]C^500N* &;.9(80! IM?!T2\+)*MO#XPOKI<RMGK::
M+QXRD;=YFQ"4:J@@>"GX;&./N0I7:9]56)B=U,4M8#(3PTV8K4-!_W=';?/N
M]V$/J'XJAXQ=W#\XRJ>NN:/XZ'Y#=1-;C9,B2\ C*?+<H*[0-JAQ4."FPL#P
M"9%X'FXYW=,"I72)2,@LXE\9_9,?%'_KV JFAYPKEK5JPGIE?SS6.RR$1+;R
M6LM'J\/RV$!VDC-+M#+_[F0RUV]>SFJ.9&\)/NA&(W.4+K&GA!!;W(.0GVXC
M^AVO7R604E362^=7[4'.(N9Q;)+#-E(9'VO$G:;5_-=2K>OYM_7C+ZW,F'5*
M])I53\9-@_:9&D!.;\JQ$BF/QZR._O/=EK'9^0>^CWZ%K41&B5@)4K?.-E5@
M,0PU3'PLA%S?,=XF<B7BEKU[7SW'RD:D27V42OE@>#60:3O/&)^E>5,""M><
M2+KQ$1,_0I01]D354U,IN,QUHH$10HX2F*SHL0'YR)0ORS.((5GDWLK#O'N1
M"D.[O0WN:61E5,"6][@!O^@TB09$D6@^5V<ZAH.<65P8X9L3(M#9;V=7_!#/
MPBLX9.#5VV#7HFEZ/%$(64T3 '36I4D/KV5LF'^W4OF/L2P>HAGT"-_5Q?P(
M/O+I_F%23]("QC!_8'?&P5*X-'04?J$9%AYM-,T-1HXR2'-N#<1]X,C @02=
M%O4B5JS&Y)GS'Q5?#JZY*MN9ZA]\+"XSE?U>$,C:-.V!<B/U/@5R!'=G;)MD
M2]7FW/$ZKGJU.\!Z[XZS$E4L< S?^_9/FZ1F6B=H;H+.BH5Y8HI=$.-R4)7D
MW4!A4,R6:[@3L:#$6RG-FX);._3T]=]S<1PB@Z>%X+B Y/Y%<KE<S[@)R4 [
M>4*M&I /D<RV]19"$$N3.^CJ)^)G_U+]T>#(<'Q(SPVYU2JN=]Z<NN6!E1?Q
M9X83E75*W>Q?S\S13,ULYW+U*G$<V_</*(HS'0>3(=L=5^<@4X!7HF>U4N'1
M9^\2<),16"VKG MKQOP?X#[@ K&@8I6ZI]I:O<;J86MDYK"MK)^#:?N@QHW'
M;TNOY-_4-30V>N=\T#(_%GZ\3\,V/TT[WSIV\(Z)9YW@SFRBI+_ZR:C3YK^>
M%+2^0B[,D$+"P0<X,7!/R"_L.-J?A77X)[BDXLF0L8#ZPQW,*1AB $N+'XKN
M/K]H,9+Z)N/J\3ATP03VD7N@4@GFONX]710AS9CJN2/[1XJGRLD:7_EP5>;,
M1$@:YT@':D?0I0#^6XYLU26>;7;Y/G-7=V)S-(5B=:PJIP?O_^#5T=="B"0Y
M>O1./+SI67V%0QJES1UF]T1_;X0H;#1WLVO<N%OOM&U/H)/CA9!MQS*$D#>H
M,Z 6?VQF-M0PQ'LX\%R!V<[%V=H>C\BE\HMR7J>F!_)C'B;X_I'VO-[6 DW\
M??VX6&N9.I]TK;; 2%'S=Y/TUM8_-<X+!S+G"GB&H-17?G)504C/XT?5B<6\
M:_=./.C[F[$Z+YF9U73?BOS--2TK-_KS12FV&E'EZI/')J]WF,?>"V1<TYQL
MC<;^Q4V)<[BZ5)AN:,@=3EEWH/WO-5LBV2N#^MO,T?_5S]^WC(HOR?JE%LZF
M'_B.\3Y7ZN.+]+5YJ[*]SGA6)WB'MQ]5MQV=?PEU[S9N8N;^'YU&20'BF5>(
MKHJJHAE9WI=S*_EYP4?27]@WW6WNS42BKK._Y>\YCGKIDP=^ZK=I=H0[)(+I
M;>P^4#UYI\^9!U*O'QSNUMA5696BYK;OL4Y9Q:*KTK;T *O6UM;?#.>_A_K+
M:)?V[[ID_B9?HXVOJBK_<8;(=Q8QXLU"R#GEC[:KF[LJ3">&DH#OZ@8V(ZQN
M?S<FOUI,VO;NPB:+M OGRN+G#ISYW'L]*5_S1)?W DI=T60[O6!UYC2ZI;U9
M20=L \[M!%L).0!-@MUKM[E8'>_NG[%&2;+KYL%D-OLQJ)0VI8-1[[J"S/:G
M:O=.' CG;\FXC8"U!1L2%M ^_3_$L=SOH-TAE/?-?6WM7AA=U*4)7>?LVR*Q
ML9P!F^ D#GL^_AP,E"_?G7N#>"6$A*[:77@?OF/_I4<KQA>_%F1\FVK0O_HG
M@+$B7C(YJ<)<?YD5)&[<JOSK=LWS-'Z2G2E:O;<R/[J9M:@=XDZC=O@23;Y7
M:X45E9LG44W,R[,>@:RT(P9RYZWR/IRZ%KO#(?+)=1W($%OQ0,LS'-/JZPF"
M1ML:7^+:69X&$),=)R)XTUG\=)$9HB4[4#'6"Y8]LWUJ3DU_VCWR"YK^N<AQ
MY7_:2U31]I>ZTCMIKYIQTBO7\L29A^<.;-,JG"@KBW@QW<EO(-'M]GK(CQGY
M=8MM$DE)Q"/P3D'3U[11Q.I'\![IKSK&I(L$X_DC7M$&OIM8&F[H&:HM^=8O
M'1AS_=[K9=6]77"E*^DWRF;KC9',K4CBT$I"PYEO(,:U-[DO>43W@2<,#5UA
MWD0LXW%3F$\SD4E/UY3I^&J>3$XP6*#DC3I.3[RTV:ILLV7+T-T,C0C$TM'B
ME\8E!WJB_EE\L/'6UA&]8AKN)DFG=[I.@$+@]$SO#[>P!KX76GCB#R;+.[_R
M7)&3QTVP^76A4'XF:-/)UTY?P/#]"63<Y!+I 0>^\?&A=\[23S/)W>W.<_1/
M3(,XA1CL6IBUR\1[];/U89O?$+#[*\&]J!*!86HXR?G=U=.Q-LXM8=B%69C(
MRW^+2/.?3B</Y0_1@&++'&<S!1ECGY%*\UML3A(,1+PY<W:.%)X .RG_\N&G
M0XC-?3&_=RH[T 1VSMBZWYQW0DA.N+':BTNV][:D,+YR#@8%6N4%(.+4GS!A
M>D+(SY>AMOX*@4N1E3U)9D5>*/5+MG7^'D8.^*L1Z6[CU_]Y:>2:797U;9L$
M7&/E9NNW/;H12G[8O')C)Y4UU] ;9SO]M+/OVJV-6)T,Z_GF6S0M8D4ZRI.J
M*P7>%HS0]J7(T=[JQ"!=??1"7MU@DKM983EH?N33YR-?L6O?8HPDX9-9OF<^
M/<V:-G]B-6@43#NNJQYUJ"NH4Z#/ >UN5B.J: >DGUW7.6TSXO3JHXZ&X^I,
M'Z#I05P+L^*7"B%5L+^(PFID;A5"=D!@L,_0A\'JE2U!*(VD67>\2LJ*W3[V
M\8YK9P7:: O9>#?:$412$EW,/?I:TY&23W68%095-YS?!08F;+=:T&22KZY*
M$T)/NV/7;I+^W$/\'&(2>0KC&!B9%"V$# Z-4WAH7EYB9F9N@7?,QO?UU\!3
MZ3V_(IPF!(9B?6\6KW]?[AW%XUIP4S,J>]1*MO8YN+U;[G+[87Z<ZR-2V:/[
MYH&W))6$W>;7QFO4-%9N1_]%4(LG5I#3 XT5N"8P=/8XK!]:5@*N=@HA*U?[
M$8V)!;KV(6G#N$V@?DC<0DU++0-]WXGG+3YHYZ:D(&-$H%=&:*[NN4S>87CL
M3KJ%J^..TX<V"#9XL$Y\4(F9" GO[W97LA]&[3FO>^3&7GN-%7G'Z>Y3_&^@
M'R^X!O&E5<__!>EP-5*33P@2KZRJ"W&72Z68'WN3GO;M9WO:I!>RS$?QFN&)
MD\:M&39?C^??R"Z\?=U+UF"9D0SI7)">8\N^($!1%W6^-VM\L:#SOU<-)(ID
M)@(]Z?@L+(LM;UY:C=V+Y8AA,4/=FC=:GK8<M)E3:VE^:7%1NGM76F/MZ:SC
MF]W5+;NN0)):SYYCNN)*8-,SWN6K.;\V&2+3O:?!WI[D^!D6RY(W)' IY^TM
M5I]:Z$_<FUV%<W[(D_%WSBHJTQ91IA>CCSJ^9H]+,/TMS7953(#NP).?!A4>
M_J0K1!Q:,KV?G533025_W.-V\Y9Y;V=J(UV<D\3WYS255NO[ACSZLZ0T6,M8
M8EO">;'9<[D-/Z+>+1:&F-W>F6BK8&,I=@J_0?7I#3N#1A:OO+EIUUK,>ST&
MHC75)"PT[#/ZZJY_<*]2IJ5']?@EW3'ND74OAP)N.HW]M(CX$GH#NW0J)]YF
MA-XLA'P]M+K8ULK<!<;!5A@83P_W-Q*L4,/,_H7,P[=J'Q))L$Y0!9[_ZHQ/
M]I\_E;-G-P5%%C!$T7R]OEJ_UBY3MTZG\:;:%T\#7$+G:O @I"T&Y X&,UGC
M/%*V]64/4)\/OTR)W^:4R\O._FH>EWW8RA([N_84BJ_HX(Z0<4P,\5QU];ZQ
MIP[Q,T'U8R/?\.?UW00&^0"LM\_>F"35F[)O6KV+49KV%(/ SR'HL"6 7N"J
M&#?+/9$<M#R[HG@^T7YZ7H# EVATI@9.SBXF6HUSZ>"JB$.F4AOPUZ=F3U2Q
MW+=,XE<QO<M_&Y3Y!/&DKV/9L7C!(A7IPMZ!A/'DXZVOUY_9]E7\):)[LDON
M:[7;W/Q<><_D-U"F*DM\Q$:DEC%NIT@0 2!/(W@ )MQ+OEEYSP[&'5O-"]K3
M,>D+K264O/ZV*G>1'R2*,*(9_0W0Y2F)X?:F<.\P!FQ-I*2"Y.=[<5BS.5>7
MV<.K2"O6Q_*)#P)@&%.B0D76%=S&OT1>%T(8+XMU0-B2))0KA-3_%7T4UTLB
M++T.Q< 9D4C$9&>>_.J ];9?%K9OQ6]?G@#V$#KYVZ8I[Q?/#WJ*(J=)?/\U
M/=@_<J=U(E+ZY,\!%-[%-S5I3=DS\,MYN 67[)S+4[%AQ^X28)?1Z^>U4)5-
MJ7N[[Z?7B_^5?$^T,E"Q5=ZK0N!]R6ITHJ%;3'.#,VK%.^NZE[[(\+2!?PHX
M07O&A9 H:M=Z@Q2KWCQU_#U!"5-,@*)CS N"J?;STC%<W'H9#U[.//PA>S'K
M/YMUFDV]US=U+B2&M_5YHUGRS)TDI(!@FVXD)VZ['3%6IIDT?;YR4)JFKP=P
M>AP#GGIR6 9%^DQY!+:SA-5N^+Z Y]B6N$#)"&*7K5<D1OY_7HG**A*-:3/I
M^8;V,^I#(@S<FD71[H"MH!8%H6JOODLB&B\ZUUJ#/ '=8PH88M]"BIM4]&ZX
MUJQW;&6T/1P1R.D%&X:G9[+:-&X3'U0^ S @00?J$[NX(S3_S*#6-@+"Z[%)
M@>97?)-<??SVU##Q,-BON= O0@B*36HMS%]M*;=%_;,TZYO<?((]_T%ORO0L
M1S*&\<&O9<U,U;(FC_))S^CK5]@O+W^WU2>(WS6O6&("]$,_;]3J$?I7 4QD
M^Z<=70CO0K_*5\"F9CT)7*H3+37FUMC!DF-6GN];'Y &\VZ1VC@U:;A9<%6D
MJ]TFFG9L& ]%K/G/ V'?9&P_=85'P;<@/LQZ*BKJ""%%9D%SMO10=V^!H<(L
M2%_08[Q'0F]N.:8#U>LQS"HW>'BCR_'4BFRHP[F+LH8G+SP7F=P<:[U&C&)P
MHZ4W@^$??:I1?,+0!#<HL825^<G*"+X[XEC2-W<3WRMX,SW+D.^(C/,24;M"
M'*QS=BDOLM4+6@IC:?TYMNAJ^D]N7Z";ER4SH DE(!!,IE;=09X0\@5CSK!]
MC5YF_G4*MMC15.(7>9U_4&ZL70AI^P40@U-D?ZQWUV::"Y(_SE.@_!N()<2"
M;X1=\X#X;-&%%%MZS2GB_/QZ^<C=B(5IO H-_[*7?Y_4W&ORA=:X);/<M/4;
M+,RZ0E4(:;\FA"!GEYI\*P:72V?+]QDWS(#Z^=M,!J6-<A;+3T(&6/<>6EZE
M"$0*3YH?W"^87Z-WNSDA"KN \PBT9''2L^J<'^ZU Y5TT\VD\)&BTD1S[->)
M#QPA!!J:&#LU")17<$#,2>Y'Y#/Q 5>@M2O!-*G/DNAQ@+#9C&NUN#/)R5CD
MM&1;*!OG=G\B\>QKP)8$>C#' P^/^/"?2L^^=)F>"ZI24756[#UV>*LJ6_4N
M9.*IGN@G$L6K9%[?\8R. Y6ZZ"TP]D&BQB_[T\?-9B=K2?TS/N_R/[#F$+!>
MT'#!XP0>;R2APXUZ?%U=89Z!6J.6)80F0&'?2$ASTV>*O*I57]GXQR9?[[#N
M%+4=_,OR!Y5P;D;1Q'>0@>Z8)WK[^+L%F(;!SAKD(:H!](HBWMWV)1VVLC+:
MH63WDC A6$AR\G_2A0+%K3RT6M<W>RQH2OX!VDFV7\5[ K=#F[*,BU?V_^-6
M[C310N._E(LWLWH 1#C,A?.'5@28C( ,$<]Y4M5=MX-$@QR;V'IL8>9!GVSA
M(JW$*#KV]>T'[M$I!:D0F]B"O<&V41KL4UX-LTQ6J/IE"D]_;^>?'$YO^N\D
MY&C8^CF92)YN\G8?JGPEIY.KSKLO6J_U<\=&Z;9Y99BM?(S,0&;X,ZB1DG>;
M6:%X'UJW_=<30WK5SN4B(20I:;UX(4%WO.5>V(Q':-AT05ISS_-^)5T#X#YL
M:N812W.F.K/!]^GFLM=B\Z"N0$5EWL"MS3:)UIS^)G\_JKK@S\3IS9%;Q&3Y
MIB*O@+7R@/OX:;EB*GC<GU'5Z^Z=I"+^-\&G4\:+EFV-I7\YN?"C'FT2JN\1
M4"N$;+SLM@-XQKJ5/*9_@(X7P*8[2VA(CU.E"K1C?+EM:X,-,$V)?>8'K*.:
MS+NC+S 9,K!Y0> (3W; X_S2KK4>*WEU@\>O+EV38HK#X7_/I45C].> 7G;!
MCH6Y(9')9B4/"^2);<'?-T2$S?MIO2; EK!5)MSWH2TQ#;H?F49R-0"UD=(A
MA)@LDP5$[6 )KRDE*/=[E>:0B!0^Y"'^:)T#F@;,1(H][_HW6:"86*4'FS<V
M6#\\#2_@QQP50A)P#.C=ZC(8Y] 0T+H'(%/R"C'A6E_^%_FH__Q"@J &W5%5
M:'U.'I VB*UWRNR(N?3J;_N7)%43N.>#W2;&1V0*QWI  NQI[%CM0SOHT &.
M%9:':$U/=)I6&])(WNCXY>!SB5.&K=,\:'_W!GXM>(_Z)R[=3]P1G=<=UF^G
M7;UJJ^W55.R0N<"/4MJ0E)N>J6+>?E^7W7UP0DK"K#W@RC,OL6!L(/Z? 9IB
M_I4749?Q/U%[<KO$D/=O]X_>Z)R,*C'O1WU7J+ M6Z0^1(.J+LS8YB>A3XUN
M-'+#R#RHI$*J-?\]:!OBMC9>I(W?0!44]&)0UM'#MN9/'O\9ZK>2AM\D!;Z)
MC:ZH/9-CY[#]Z7/W5H6WP3N#'2MJI60N#/K-^1R FO8"Y[?M/\P12RX6X_W
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MGU2DB>W6B$\FI@92=/3Y\7ETP*R_NUOU4L/%/^^_YUVSNI4=;M:0<J7W.GX
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M76I$\!1T)_Y5LDT(84O#G\+[A9!/P4]$L+)#")&7DULIX'^D 9W09?GDFC-
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MBT,O9$%Q\)*_<0WT%F[=GHG\(<(]^,BBG1UWB:S91Q,P[V=7B8P"MD-X^.C
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M5(K^*-%!69W[\1,-*&[(?.P=*U.3^F8?_7'V&3BIQ;P$6T5?/I2@G9Z317P
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MQ')JXUO31TV6:Q!@$0>Z1N(D_HU?C7W($6:&*"#;VL"16@%%BJ$0B%0O6*U
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M\4J20>_BM,_P#R@R(JX>*&^\"JB1IQ,'X:J;UT/Q&F\'0F-#_$V5B_3%GZ2
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MPDX-=\5-VKT?(B'.>G%XCA!Y@UA3-\IUH%^TD\%,7_L^]E1AZVH90X92&[D
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MM7+V*N#32"4#"%["C>IZ+>TK-U>$7BULRZ&=^^[RF9:?7UA+V+DS(FD(:/,
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MVLA4M3KI5M@>[Y?>B]H9M4]R@0*_$VV[8G+(>QT.W%?@P;5_=(RP_3ZT(3>
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ML_@SKW?<*P@)3OB=W'45[5R?[W7'E-2BH.HD)10''@:;%A1H1;.)LT.PK^G
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ML&QQZ?M\2&_N?W& _[5'920&=?(8/44Q#.EC#J?"%1OG.ID#GX>.K<D>;^#
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MOZPXYU8.ZU,D!,89/>EO:/;[?&*_Z1:'PN/M9[V=%B=5(RKD*;GD2V=(7M_
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MAKON:3?MU3:?M,I*>J!#V_>-#;HBC^Q#RJ<WU-@5I"WWG S+GPYFN1@C5+X
M^LV8)?D*$L*SGK$U1O-GIV]!FI'/8<<R*Z-N%R9]HY)X3\4Q)5.#<QB=:S3.
MCL/=SXP(6.4>\H&VPX[/EBB=O>)X\_H-;,B!+V^98W/S"Y-_&ATR?WS#0)-S
MS.9WDA\RX",: 9PC_64]\?B"#'XCW"=-*$GNBC!L2[CX.*,_GAQ\,W78RDWS
M=?>VUWO_E506A@2M>-Y1R7SLCM8:UB,^:Z]=?NRB\OK^9W#( CV:4EK-]/B+
M?0RJ1B[AH2*OO]1(/N;"W*1BM*3TF-K2<\^=&T]>PRO%??*P\;)_8F\7>''5
MY$OZ@95 IB/"B9NA(^4?-MDIFNNC!"O1KYNL*Q&E<#)A<+9Z=/[>U@G<_3[Z
MO$+!T(1915\LR=;O[Y$NS2&=?[C'YS:G_D[-VYCN96MWV(IZ_Y'7[@+%*J\(
M8XGEY-]_+)(*%=+U7^B^ :N;E<MDP.!I _RL:)7!Q#Q6:":A"_);K$?\!8>;
M;@^GU0:KJ&[0=FF,BDVO*T<IGKH_XES\#W3K()/^O!2S[RH(SCV@78N2'$F%
MC27_6,Q-MF#<($W"<QF@6'ET"+8/7C/PUZ^QO$^](#?"UK#C@WU?24Z[;1>;
MB6-J2X%#RC:%N4_\]Z:N2+'3"%;+F5Z^=/(D:94U2,[YJ.R<5*6@#_V6E.Y#
M[Y !"6\C'L\=^HHY)DD76,YY#+R$I[N\J74B6)*:E%$W?7!V4DUI1_N"&G'3
MI[L+KT^W%*:]/^YYF#65MN3XC4.N:' 8C',R2MV,&/(X$859!E<GDJ;[2QD7
M=PR/S'XLO6LVAE=Z%4A&IP_(@/+O?--WJ5A]&8!)I*?E_!"NDSS1:^4/?L:H
M9/[2E';3\\K.>J)=CQ7J0[]<9Z/<8ZDO;U&2*%S?L"GPN*GH/;=)4!"QX^@E
M+/F@]IB$W-,U+,6N3BHQD(\XMY\R&C_C;4SCA'\@<"E/S*";^HC.V'> 0H/>
MF$=53KG3*YA2-1G0+HXL^L@I.=MWI6=OQ)J?_=HZE,GJOW<1J04%5,QL[IB3
M 0W[)3-APU3U9W[:E/E.E,#8,42RZ:&QH#OW.9825C&P0@8X';2<5N(H1"_]
M/1\'ZR<$LPC&K?U+9,#*0L2QC%+N/MN+Z]Z=-1S!X2PV=^Z1 6L<W&=OL,>W
MO?P JYM:7)1TPSH/[6L2]O4>KA%5OL[5CS16:12:*M4HP&LI7"^_%&RY10AY
M?@F5"LZR7(M^_9]35TLJ,25F;7B_H*FLSD+H0[I<#O31OHXT0K7O""=I%%=>
MY*J(.+WVUYL];M'0S])8A?4-/-OCF,TYB7I-@^M7.K<=P>_<[EBCG'=$\\TA
M&*UVKW0N\[!=N>)!\>(K*14$26JTQ^J;WH G(W4&1>1 GWODJL9F>H5G8N^5
M>R,JCHI5UI]?YB6UM]0N/?^69G1B2="&\BS;J<"E'?R'2:]-/)'TMV)!&#2]
ML=C*+,B#G:'0.38WV2IED0(_Y^10!W.Y5_YY;.VN*:ASG/SS9V1)X'V%@=5+
MKNKNB%@^/?49K$[\*O^ML/2;#'B\VG+:I(]?!N^&CC1]E &:F.-!3\;^^C:,
MS85\#2Y?&440DT\ZY_MF>=7 ^TIV/00/E[JIB92Q)@>_W[U_)^D5\C1MJ/F)
M[[UR1Y>-?H!=JH5KO@;XR8 3N,?T[('']O,[TMB_#\#'F-H\ZY.$)H]<L\UV
M#RGH8^[#]':'C.ZH*>P0;I/:Y>BKC4;G=M<%K5I.ZI;(@"%12?,6>T+<!W&$
M)TR*LQTI@ ;/Q+NNZB_LE0&[X.627X+,V?!2_GF4%T(#_U3^[2EX%W\GDW]Y
MQDVUP1 ?_(M3>B_JL(9*4:;&MINM?U;P;\NKI<J-?8+N0T<R_@:D/=ASO!;Z
M"7T8;X&0W#?:\%JPB2X#MNEIN$L<V-/OI._F4L3B+2Z<1%*O[@NRW1S[\<N0
MM$?#20EJ^\1W&@T/U8#GM;&!%\J/ <MB"5Q_5MCWB\>3B6SFJ)Y:6:=P3)(T
MZ5OATF4P*WD7&1R$M?#]Q5"M/+4]ZM#]?BNWS+:O$'0$\WBBYT+A]SD1TT;]
MZXFFLCS/30>JQUXCOL&UO5WWH$U29M$DP-M[SL8.$ZPE)>/]^4+%UE//#+H[
M79+)8'D\=H^J.";GN\<S1\\O1VSL+!MSC*VWZEF9*N6M"UYXMA2SV()$U5SA
M2(U.'$'%8!O#)^A;Y@8AYPCI7VGD:1E0\G9B'UEP\ _*P\DF4@TQ:FHLK,<8
MFU3AIRBYD"4\!+7;QT5Y[/V8Z W/:YBW<DS-C),>2'T7F2ZEW.J3KN\T>K%0
MHZI]-Z;[M/EML+[U 8;"-GA7W3+M;(!XH1S/8Z.MATB3+$9[I3RLV'?S-_):
MZ]N/\&6 \ ^!SYBL>+8;N<-SQGC[Z6;&_%Y1K Q8RW>2 5/IA*XY,)H'17UA
M2I/%%H*PC>@)F$IOG9U(97:"OESS5WT)NBE=IZA54$EF\D8%O) ._:J(+FE:
M.*QWO.>^=_)<IO0A861"!GBWRH!_>NA^CQ(/!O,T_T5S[D'ED(7WR8C(EYW5
M$R=Z*?:!G6AP+G"KY(T,R N9(DC.AB-(YN_.V\1W@FTY5/@62C [WOF.,ISF
MP2/,J"1B#D+=NHNSZEQR$8Y7V6CP5 :\<T+<_5+8WC$-H9I+!&%DO#G\HTCQ
M?[V)A69[;P!(>4T5H_EX?H<,0/N4D)R65EA1YJ^LLYI"5.-LR1US)6\FQM.W
MB$0"1SU'<VKMJDTS$B-L=SVEZ+2S7>H;C-14,&O%AVS!88/3F 6J=9$SE/QM
MQ,HBY=PQE(!V8'ST[_WA0Z0%KI.40MYG0?R\X'O<UK*CY%3W*C[#0P9$S[^9
M))'09GG]M?F1Y98$&_2@7]+)V6*$O+:V03WZRCXNKR] ,5).L3Y=RA?U_]QB
M^7OH%FMG_Q"C=E:T![VQ]5[G_&7AB_AJ/6GZEB^E6CB_.XG/H*'747O#C)>A
M"Z^HP^1\S#7?H\9;YTXNY&P1NB>-[:I3'56N&R<\4[HA)SV(\$ #MPK7,U!\
MG!1A<6%\]#GJU\=()E<5BD)X8[;_O<9LAQH#E6U 7;V+67\^WS1ECK*3?BZ7
MV._(]:0NJ/[T@SKY!\01CN (O 'V[U"03H.]V;M8.P8BTB[CAY6RYEX9'F;^
M;GP-D\74W/9_I9ZBND,C6SI-CDA*SUX2E=(&+HCHGI+W%/A1$&-6I96=9S<$
MY<-Y@9@Q1%@$G=HB\I0!G&VE:Z\6A,1+&68042"V7$&UY*_YEB)<2^O0N2!Y
M\J?.7?<YY8_9Z&TD$>4LVYC;1N 6G$3RDC2ZF-I[SC3FE;&<A6"<A<%,?AD,
M/AF#8-?9X8A$+43'9HMXRUC[__N@M__V1?::NK[;/M.)7.Z<I72X$+N]5E%Q
M^ZPH+T2T>L;G+OPYO(IT6R<_;W[$> D >[<Q\GT9V/I [B?*]X5]J>+.</O6
M*3T]?8ZK]Q;L/31M6TP:K4EZ4TX4OMXLH RW\EN3&,>%XKXPY%O[-\A=7JH6
M82&Q/Z_@.5V.&;U_^:'_MBRGYT_D=C58+HKPN&!U'L+Z6^*EO\?W');?XZIV
M3U)Z1;P^,"I313IXK]22*:$0'"00$YZ=[E-EH0N5PTFA% 86?LVW6(7&<B/[
M/XL(7"@CZ-0?RB0X/.W32;J;X/%8!OP^M!R__@?%@I>-E<[RW'9(=RW.H[GX
MO'KRM!"*36/D1I]-T+Q!,8&JE*3CX;M[(_? 'Q;RFAZ(P88VBQL)VX.V_"TG
MV%+V5]-MWX>6;X7:S<MO'Z+)A_A?]F6?\\.=N,+[P#;U=$%;$_&"9EX'*T"<
MPIT&FURSO;U<"KY9"/2 0T=M71[8%(KC%8QCZ*D/C OE,>VV9R/DS?-9 3(
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M+IR *P02XRA-9-[Q]LGI>>X.;M?--+/VTL?5!DR'3W!J</7;[G"]3]Q=H L
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MZ=G^CL^5E9$Z!TQ59&POSUL,M-:@]NA6JX[;> SF<"6K/8?W7;BS?W=VV]V
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M#18*[\H,6\9\0YC*]/U/!P\*]S6K22=P'SN\N!IN+:[6W*?ANBS,M@VI]6)
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MF=<Z[77UCVO>;U3VW)\ZOJ^MN[_)Q9;1O0DKQ,+SC;3]J7I7'L=#+R:?6;Z
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MN)L8\=@,%8H)<@E"KU^>E&"]S%JZ9N'W_"^%A6;:%1U^_@*>XH2?[10#!6+
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M.<$1F80+$?4(]MSX,\0D*%\[$T,#/<7 #7[$D"// M'CW;63KJ)ZL>WV5]Y
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M=NTJ6&#\/)V(\IDQT-GZQ6UO.8S[GF=LX>F[E%Y1N]JZ;^70[&I!R;5+C\6
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MQ'<0)JW#K\! [4(8Y@^BOH$Q.5>+6C17SWU+PM3.+D%_JS+YCU?5_L\7COB
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MXV N'M4]>1*BBQ@BT.\VHY9*VB5:'SQN-DRKR#MW-OI,![M78XL(-3*]>K)
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M8\-$:9H2<;8RP4>)&(89!HQZLV(;G3ZKP+GC-O3 "TW[.A>F&U2:]''>Z4@
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MV-.7]N#1DH"V(>T]GK40B>0KD*X97SUM[;#<S?@%)V#Y*25BY]M\)<+?L2>
M9V^Q#:7J#^(TG%OVD)?)[<K)W1&<,I*1G]OUMDB*[&^',6>VO/ [Q/H,>)*N
MF/AS52PX%;OGK$2',?NN_6_'4 @[$7B5]D:P?&Q.)[O2-YEZO[,;,W" =,!5
MH7FY_\[\MDO^-K*EFC5*Q%Q=)0(E@KH!(9[FLG6^[)1CTGFDT#.O:NDUZZ(R
MH<EF8@\+.; ^_WLB7;&H_E*DU!V+CH7=U2,ZK798(0OJ+,R6G@HL^K=._=0.
MV<#_[E#NH^I0SET8"Z%F;!0X3@F00Y\(FD+E^1_.V87>"*E5CEF8#8;+HD6>
M"H"M^BS'1D9O"W4>))TLQ"?(>6@^A=""#Q7'X,T-:4J$EL513K?<S@_=HC[[
MD??9%Y@!*N4Y%*[4LKL<P.Y*X+4.Q0[M #Y!)Q^V'L$<EZ^P[U-,&ZCF9-+G
M9;P=+/ _M1CS(B)$@0K4_RF0D!KRT)XH.4:.D]GTC9O?8G!)7:AQ8 B&]M7B
M\1C:H) A@2.L4[]71NNC[X,HS*P/-R&*I" #3) 85HYIT_NY?:H6' KGTX1&
MV)+$'!XX;M6*=O"X\R/Q<RW5^P#N\M&L%)(&'?VTQ1Y$UU.7&_9:0Q_O(%F]
M%XE_5UKB0P<$/=?*T9^]Y39'E^M-X=%3P SZ5J:YS6!@U[,!P?0-7P:Z3=[U
M(S28K76T":CIJW1BE:"FQ2$Q>JS*TZ>:)3\U4+8>< @&L7MC<T>:W6;:!+-J
M,,D;0DE(N/IFK#U8P:J<*U?++_+<=4 G3XGHP5XZW=/1C)0L+<\N,"12AN8(
MP,=PV.#C=$!/]T<I2-M)+=\02*W!%-O!)+4]%EH0Z2%:N^]]X4N<EH7?4O23
M;='^O!R.9-73[(UN!%^H!C(=?I-D[O>K,SLM3=LF;55W3-SO83->YTJBK]'1
M+,B85^&LZ-V_@9SQ<+@K#!/RUZH@WW 3G[-KY=T&:_Y2(AH PN5SNWL]^@;"
M]KD&6$D=,G1E"\=?Y6_Z>.6@,[6S8*H>I*J.3:<@^1@//=F9)23/C'[!L2.7
M1($1M$4'PJ[PM))MG-9V?KIPXYG37'V[;>A3,H"!NW5S#?7(OD:6UY8W-U3G
M^_,JJ<&>>BF97(_2VJ>,KJ[/T4<B0:/.<3]T3X=CRG:^($D;,X\[D7)1S,Q4
M<^RAKC/S0[XK-YK';%1$,M.'FVFFUBVN:Q.]6YV63087%&]^W<=^\WZE_;.O
M0_MS<@X=J;T+!T45=,F\B2,7YKKL>C#888ZKRI,+&6UV=Y]NNG@')71.2^PC
MCQ(I890GH6(/$=.#BTRR4B+F3)HI$7BIF+).Z'MNS.Y(>4[VW37TX:@C>4FN
M"B 5/8$>O+C4O2<FJL#G;G\+$Q67D3] 4F#F<C!BNI>)."N@V3O-P\)<OGL\
M^7_2%;1@]>[7C.PI7=>8N7QYL#FY'7O$6> W1^T>HQ7:[CM1?+.8VH/D$GXD
ME\:^S7K#^I:LT<TKK*CD8J:[S7GMQ=@XZ]2AF5=%-BVHVLM;(UNYG^CE^J_-
M%H9AI+H"P\APVXF>4ZA.I+3R1IU?TLD <>'+$N-#FAMO"-I;^'X7%/+Y6Q4Z
M<K\83\HRL)J&R6OPY'^[\NV,9[9>WJY2J0[LOEW9W-O+4!2A5NBQ^M7D&3+%
MJL9O0TQ-00Y;?KV@,LZO.7&$ZCX'6B^0V=L#E G3K?T]<,SBCVYG9)X^NA.Q
M<]^0.H 6A:XH/!NZ;.N"728Q1)1M3"9U6K9A+J90*_.#B>IJNL%-8TN*+A,]
M$2C\\_&+-:9#8(@2$8[/'O\6&/2P!L3(.0J'7J$U5U')BH9RM(M#5LFH\ILJ
M!#E)S1,V0)ERRE@XG>3(9>&$WA"G5W$5#R3(M?PB"X1$OI@^/ZB@0AY&"=+V
M2CR22DVZ9H*.EE^?&UH6BTFP"F;JEYM:#O2FD/K;[O@>7($F]E/E-4+Z("BD
M/1#U"\6D_-89T79[Z!44CB8=GB 119:UM&U<5 GX[RELH1)1A>8 JG0=*V[O
MUEL.DN ?PZ^($K6[]=KHNKCN UT?EN+FY;KF^ZFQ(1<!AQ7XWE.DW?80L?S]
MJQ\XT%<%H/DIJ*Q(.'1M9?U51:(J>G>UCD&,;FEY(.G_2[;\=]3YTTZ/"YX"
MC5(Z&X]O_2B+/O HM+(LSB.B+RL!E >=K1%^'"ER1,E*,$6TA[AF&$(;,DVQ
M&MWHC\C#S&(H5CAU3?:_K7*<$RFK=@][5_8>+-@/46&]@Y&5C012)(8EJ3SL
MQWZSX5/MQ&TEX@)/?KMR>CW%27]F';(RERJ+_02E<R>L_9)IJUXSGS9C(+=3
M+4I$399G^A.^.Y\3&J!$+'SS1M4HZP.Q4Z.F6P?=HG6QM)31-IO_58FX3U>$
MY1>#U+;V_\[6P:C.(L,I8"Z7/AHL2@JWF;#8 ?M'?PV>UK6@Z=J+)W.^O_5W
M+:HZP> *&W:CIK:$U15@0>]KX=A/&V#0+>66N[4;;(5?-@5V]0T0X>G$B_:
M0_5+714EP$MU^&WQC-9NXKO=MLM.UTC0Q-2O\898$?*81\99M5D[B1'C[D+]
M"F0+A[S>4''<DN6S$-O')QBJ.A[0%H"=)^1A'_!1Z'$:W?4O48,1S;;SRB7Y
MQ6"3Z?F ;?_X+J 3H$R&TE$#,Q(CZ#N]9I8;YU:N5^'"@D[#KG$1%X.,N(@5
MG1,YOC58L21Y4(ZV)0Z4LA2$_6*BR3R!FJ*'^2LY>)8$TPHM-P>! ;P93!+2
M'VEO2F=@<(S,0+GP+TX7P) M&=-Y/!8]\.D/P 1XVD*<U7DK?_^.5GL? U-,
MWXDCWYX8B!]Y,SX2OR@1F'Z,1SKJ0PBEK-7AAY0!O@TJ_;#@@6><]R(6;(4]
M]4(T3D:WK#AVK95:2G/^OZA@(Z)%Z"%#"=&WGE69 8Q0E(A+KSM(DF(M?26B
MPIA0ZU8(YBH1WV$&&$,]1:U&S:BZ :5PT?)CD;EY;XF*%YF3BW3!479GL+U]
M6ZU? %9X.TB'A_XUHH #34T1=B"0\F64)CI#$D06EBH1'S%%/71/0.KV"^8*
M4K4>PTDOQ8N\@[@)H'/4M:%]FM.1+@I<$7QX953>_6@7QG/\G;0GF(.SWYL_
MVV3= 7*E0;;N<@$)6D::\J@[HP#:9\8VDA:/3U?J4$3GQ@M(W^P>K;EMWO>^
MZ_4?^I%\C#2H-4" 'IPX@GM_[M7U$/Z8)M:R+*WVF" +\+(66AHNM_5<N.$.
MWN^H/J0/B.E7GG77^$)W6Y?9WO2$* W9!'.,T%")<$""6CQF:B1HDR%C'O_.
M>@5-^LH^O/Z5%4OON4QL6@K0Y':5V)H2ZY-)):5\EQ2;U,^1%'_TA>/EVXN-
M!54BSA?]7(9B@6SVB*E$=2@-F8D6L6];SO0AM9$\^J?FFMZYW>N6;T3,HL<I
M5HR0J7NF1T6_^GH$V%ZPK=?V R+-_KK+LVO5[T&_$-34P5C&>U)%$D.@N>";
M'>,C*L7F:!)%=5SNZK;K**7QO!*1D 8,-#"A!ISMJ@M*Q#KFM<YN)6(FQAJV
MP@7S9&$O:?'3OA6>?H(6H*8)E_S@U@&Z\+;Z$U(%)I7X'W;ROYOM]B\%C@!A
MS,;!<@J",;%>B>!3?"5XTWXADIULUL:L4B(284:J\&834'82O*=HQ$[0S[/Q
M&"-U$_[M]/VTA3P#W!]FSZKT$I$RM?;_8TN#.*'.?VDTVN_U_/Y6\VMWYL]C
M-,5*52QBHOWC&-JIYHQPGO2A\Q<<H\X+ T<4P_TX,3TD-F1@L <W)D'-3CEL
ML%8B-J,3GD+86<'M\Z_^7D3=XJ&JNQ""S#[DW:;5*6EAE..5RZKF1RW_5"9&
M=J1T6=!CU8BM##GS/<K(ZJ='2.]&7[OL$V D6>_T!('N?S@%/;"?7FK?,,@8
MM)X=ZU(BJ&G2("(O0XDX#?0!HQP_!Q#&,?1)O-EOLFP_<]K*EIA7D+3*[KC5
MBWFGH#(EXK$HX<8'60A ;L\_F@Y1$C 6-ZTM3)J_6)DJLDXEW45A&<5]CL4@
MQZO97?X0][Y5H;43WD5W8$6H823$BXZ#+>J9K?]XG%$Z"'Y1P.#)(LI?6#)G
M C>%F8ZBF^PK@0$%FN>&[F.6W^K!B?<BI>0F^GD)AJUJH?Q]8EY3Y'\B[G8Z
M4AA>*?[;;&*;?L IIXLS+^A!=D(=V4K>VBEO^4>)A9GFNG>ABW9W]=#=G5MX
MR5UGVL/.O%L5T>OT :]2@7HQ.-BEE2R>O"? [PJ9WQZTL-J3]<M\RMC.OIB;
MP]T/<?V6.BL1*])0?)^<^@ !:B8R#*@>[ P+90.!=BV]:8K+Y%=UX1_1?'>S
MT\,WA3<6I^8RVJ?1PR,@NJ;+,>+E:-^%CN-[C8SH([G;X8#'VWHJT"*,V)"U
MM@?U15-RI075MRQV7FRML0%]56,(1)_2[BLKE45.7QC;V7(MTAZ&/25BU\M"
MVYC.LPJ/ML>Y ?*'[_YH<U2SL[,[:0MR@(RU(C3;X DJ'7K:=#&,^$?!#0L,
M0FVD9=;;QZW@1%E<P%1ECOFW'/1,S\*6=%@KY9.&[UY6Y.6A4A!J8Y*%5X?5
M#\DP+/JH3L54Q/DSK<SHVR0J>';T8\TBQ!_[97< ] "^(:>T?G1/&\5/^/^G
M#/F_L&]RJK8>.?SV]MUAX R)44)=)=%.=C]%58]U2GR>]ZQ\]A.X*4  5=>P
MPOJJ+3:R>=:1Q[.S9N><#[GP"89T^>;$S$8DR3W,,T>8 )LT"B?I#<O[/)#
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M$T2_9M0;PF8D%/K(!8+4%9G^\;)+#</QD?QQ<O)!"05L3U3F U$UC@8*@^%
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M6^9OSY$=%O#)Z0LMN/ #O[D:]]V\#M1=*;]5P4JS099E9*0@A0T2[BV_%*A
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M/,MTP$UU #8>$N"B(<$:N&B[00%L7D4 -/<EBYI@,\L&ZJ)/0;#I8T/5XP7
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M5J;D$W/+DZ%8^.IV)5!UX:*F&&('IW0-T!5)1%%L42<]L-\WA$,G9*[GIE.
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MD-G!Y\S,1(WE(9!NS-__?93G5:^8\9G9D^(CQY]S?=DPGQ09^V<HHZIM< ^
MZ/^<4VKWBO[X$6R4&<)&CPX,'MD??TUUE:T00% 50YRX^9\C<%VQ'@I/A:SW
M\._A>D"+.OX!N2F_IBR\50R)1L6V--PR=:7JBTIX/4Z7D4-@O/]U;#X6WC7C
MV)3\^\7 I<037\M7%V'$'-S"SD94Y8)<,F8P:'#P[VY?S6N>0#V"DA:57FO
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M%<X:9P'-C/S:-ISVO4TC(;\&&W[ Q_JPY .[P (0X&)O%UR/G#[U2!UW>:%
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M013(9G&, P&VPCZJL\?NV1A)^'-I<P;IB^&ACK/;E.LH BBA)CC-HQ>IS).
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M(W%YK@GTNG4]"K03RYE?O?@F/C$_AUY/$E0>%P.T!1[Z'XYER?%;S+@UM$/
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M^"VT]6H0(XR^)P4IN.VX/L!+1?$JD/:1P$Q?&8:'>:04#<X#T]0;+ZZ2VO*
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M2S/KHA;'C%>60;0L5KV2:9(EA!\=*KQN8]EK^$6T*1RPZ5@3<E@Z\_%Q1X]
MEYE_?J]),08?8NGWK^%USUSHG;DFKOL'73V])M#SN$961M%7?FZJNAIVVM"H
MT<K,#FYNC<DG]AZ30.+1[-W%NE*@E$ *F9TM'#X4=<O@DO.;42^3F4[7D3J@
M2L??7:/6WU\+?Z%\Y5/AYZ%:O;=;+2UN7EV>/*TN'IZ"S=!@4+K=@%];Y??5
MC NY2HMYNZY=$S_4=O-9GWXSVPB?U8Z'WL$L-(*<B.(D/U/8!+BV15$4.6!G
M-SOKLZ/)"2Q@?7M?X$PZ*G1F&81)S=U.C I:K!])Z77\<&;!8W>^T/Y:G^<0
M31X<X_@;3.:=AW8 /YQ XG#7X=!84L#.*M:.\1'$S*S''#H6VPA/&:XMBH])
M\/:T-+Y:=4^G6Z2O>A'6?-2 L$0!M4GD@4G+'7/GAW&-O9#S.[79&A@*&/K&
M]6#-%PGD]PAU5!:?8;C++D(:\._HW5@Z)=IBQL.D<N+2'5==.N-*\$;L_*8:
MH_(!J)-XKCDN*2T?5VIE9>4,"R;=A:^5AO(XX<I9M[1)$<8<+P\JV(71F49J
M._B+$HA+[MV4/YGA!_U#A>FJP?6S35^'RZH78B0012VC(BE4O,^$K3P@2WT=
M0"5<9H:^Y23R F*E\OC$^2@RA\_2P RHB\)C+CC"J$ E)SMSM]13A(;77?<[
M'E(7/SC)#*LUU._;*$_ZG-A]-U&1VS!"NZ$:_*TH+,A3H:7E-B,TDD)$/SR:
MOU[+)\C&!E"@?*9F:P<J\J_'T84[L(A&,*7_P8>OBBN^UZL7.CS4;[])"7*]
M@_OCZR)H&*\?&AC0LU@8L#W'<.Q,+[G@P328\.KO=)) =OUKN?9#8HK1N%07
MR\0Q[#?H@L"<JHG=C)X]"IUW#M?Z3@@7U(]$7^Y>TUQ=O9I@V# 2W>C58;")
MW0XG"J%(N9?#L#X8DLU,%\+_^YFB_Y\'M!',R;A4M5BWZXG*")$%8=*Q_03>
M,;&Z3/ZW;WD3<Z_;J.G'K<%JBM %-=*^X;\BO</!FD^SK=!?_6ZD&.;\[S+!
M_Z] :THN*=ZS^<Z]N-#[N3?LK9PILK5/CIC.Y;F:$D*5H2L]X=@<6*07<P]7
M[B,A"(AIZ(ASJ=\UT> ,/^VXV]"TP656]]"%@@;KCMZ+64-A7J ZQNMYC8#$
MJ#\W>Y..(QOJ7UMY:L0YZVU1" I&%LXD8EDRY%?/@X#\E5G8'S_0R%7JZDZE
M;(K/OH8(@0QX?37OT] ,H(,-_?XK"4YQ4/@!5FZ #IZ7$XJ89S6+9$H>R#;8
MEB^7B[R"_CH@.H#"^>0+UT:#6"X*; ^O6.%1\A$.4XS[?O;QT_.I)!&D20+9
MKB(-%B@VID;A3C5,92:;$&BGY01M3SY6K*PA__SSY%O<WT?55DF%^*%^\$0S
MON113%/E(GE.3Z-FZ'#<CATK,NJ9445F.A4$#0P70Y_O.G85Z*P5(._4'>3J
M3&;_^&DF$V9C^4GO2?$YZ*)F/G@7^%.']Y+*WA855>MNVXF&=:RX0LH7]'M>
M3-,0Q/KAF4]4IYK9)W?W>CAHW?CU_K5@\!4%.V?&VU8C@7P@Y#G3850JQ=?!
MO2::R K_="[N=S?F4LB9.<(D@,"1Q>^*"94'KE]0S+YR98@24VJ.DGUU-W$-
M#R2,HOO<4?BL[T[W6#NLYZ/J]P)&K7FRJB3ARW8J PY;?BV!J  CAF&Z"C>A
MLP[*=LP7]5HP+<.+PC;*U33-:(S]>@ED2N:0^0>.JI@:2._$]J2V 4@S6W5,
MX.3YC$'$$^-]9)?E '7Q*QW8@EJ?<:N5/5#2D"4O.(F=/-I=L:%A;5K<T6KO
M!L/83/7Y(_(EON5#Z! 8@Z#6SJEW$ ",;)I\TQ3BU<V@47*J%5.6#6.02E#O
MI' SBS=T*D4;(NAV*RRPDHM\*@6G*[@[BT!O2JQ=K?I9JRY&E-.]NH8:5$S:
MMZKB3,0*NY '391 X$A#_()Y?32L<J++!4L+GN'9O.,+G'-7V&\"G@#Q'M:I
MA5D=RNH59PXW,.U JR/3!W<;5PDB 01MWB> D<;HX'7X6HD??P@Q])D^)C1"
MFX*'ZN'S%GW\E9L74;RJ+C79:>E+G!!#B5*Y3K%C.;-UDDPB@/R9'MYLL-T)
M)[/*I[LW>6?&U\(^[+D$9,]W0G-A8_-=K7$XS[-=CX<?F%R+6X9*F2LV^ZM1
M6MA!(WHP\_B;.98[J J,W2UI*QR[N0JO+$'P'D9][X!B7Z(H>9MY??&O32'+
M\$M,O9>)2F;F9J97C[C.\L\+#NP.*D2:16(X!JOM#3\@3VR@"DYU84\WI+GX
M[,^E94N5:V,I#DP&.NK_*K]8+:QH3ORMEXWY ,QH$L@X*2$U&H+' *3\9O'S
MN2^G]JAC^)9#R\#HWH4@*Z)HWBW73$@RFM1R#+M"Y<1#ET9*9+%<:-9(P%;:
MPT(1532LC&3@KW3R$A?M2F>?9R2X>C(:.#J03<ZVM\Y<HLX?K?O29-'8/@I0
MGTL@9_-%R6NT..6#%UR<:B%K'B_=?/IMZ\?LR;W)&D(7Q5UC\R0IZQD,G4Z0
MZ]<$1@>N!>&X>01W#M_@9!9&C!,]@2ZSX'^/L;FUTKGKM)5 'CX$2'6*R=W#
M%+R_",9S)2O;Z2809P*ZNAX<<UMD4QOR_ADTXX5 ;_PC3 7K))#^8/5(E%U@
MT4-O+P1LG,@+>L^M1V%]IL3Q712QLOG.Y:U:9>"F4/0_P3@Y(PD$=*K2(K1:
M]ST<'4C>I=/FLU4"6;OVOIN1].V]-D,I*-!HL"R.AFR*>Q,?ONPA@82GH]O[
M40;=+"O@&U(@':_%3D,C!UG8'IVHNM3%F:EL8[@-)V[>HXM9L$\PDJU2<->1
MO&1A>1'H%WH+3%"!^*% /&H^FV]F&O+B02U1:T$?]O%0DCCJ&.@8J]S@?YTB
M12NXG,.G;I%=AO!>&!+-20D=L$[/K";H:$NE+<2PEG5%;LGQ^$?16^G8#HSH
MOIZ.,?57.5XD!U1&2T<_:\=7_9X7K!P"G+Q[*V<#.KE45_G]!6%!^(M_AT*!
MH:><=NJ36-()(,9$M/IK>DI ;>34E.#I*3MHJ[$A!&U!\7. +=5.*RPVW3ZD
M R^KM5,J/ZU='AGTWCW7Y4.>4Z@97_-(%2?[*:6ML<=#P?GM5LZVN])I^8;2
M]%D7@BE9(&-^,<4=XAKGMP#QHE!O1W!W'O$JH*56-EAQ607W@'-G>RG]2%X[
M;CDJ"N9[0$>@9JPN0J>787]_=S%PCC(3"7;[A)_0^MFRA7*DL8W4BRZX4@J<
M[1X!?S3TP4Z"1V9RR[_@N>;SXEI;(LRC/^/G=MXDNIF3UX)2&[G-^HP9K*D!
M/A\'?'P,7_\9%SZ%OO>+!$-GPZUNMD70W)([+P(M.M _U&5]X-\4G3Z"V-2Y
M+KEY\X.KMP--P&M2OI3SH$\.]\T=([BVG>^F+JJ[!P_Q-V(P)9 O"*4:DLN,
M-VMWC7Q%.=?_4<E.:H/1!.\]>/S?WUY-1@DK\QKKO_8W''GP9'=2B!#XV6>V
MHG2*]->@ =__ ];Q'GOF_+6CG)3(0C5*0ET =^4PJ?FVYM$XV?=N%@=8?12^
MY3D$W<L8]?A@(C0=40[^QO'UUIAY7I@6?LY8UG/F QZ]4K"\'B&R1GD )YAE
M5%=KFPWP;P'*FS1K3I,&.ZS1N;I2XV_>B* Y@81R[C&6,/_%2U-8LMZY,T5+
M?SCDF3<C/PG:>VC!PXG390$3H'P *_/&O2R<FO>D8N&5P_FJ4QHB<X*06&[G
M<44N\2UF;X?X6PPF$!/HT$5Y,D*4B>7H89>W]I[Q/1<!^RK;=KQX5Q@TC(^[
M=P$LB/4!8=\-)W0K#RH@8;0L6 NPXC>"J_^"&U[N %HKL.*[F'RC9L\DIO[8
MPG669\>!E-KJ@)B@:S_-P(GF;.+#^C8G6(^U]4NSU1:_(]8%1Q)2]('4#;B!
M>WXKH[JYA=7!GI1]$LB[+DV,L74/?'[6C>]</-:OCQG%P#LDD(]$_)9.-..)
M00(NU1. 6H$&0 G'IIR4JH&"KZSIY%952B#5S$#  SP\!G["F*,7WH4]"4G@
MAY<_*$ZCZLL]FSFN4(1@K$ 0(EE\%WQ;EP[P*T,"><Z2SN>P[CF$">2O 'C?
MW;L-.%Y'TFH!'Y13(@XO1B#Y SV]'J%8U$=2P[4&\>O^X,8%SW%!D?,7@XAB
M"21*&V@@/POE<6$U:.P4'[R#;3E'=_YK=I^9S%C!5'-5]LS-H;.[A(I^:.9>
MS &+\_:FT.>*2K#E!*X&#30(;LXM[/5PNC=^"_:>_EH(G&K]OJ(S"OJ?/H_+
ME:+0<S]'F<=MU?7;_14?MMK86FDI3?K#3ER!33FFU<3FFDNQ*Q9<FK^H4M",
M%'EAIF$#<WN?*?E-49(IH.7"9VD,,80U=Z;P@[^0G)]2Y4+=)C3I"J&)ROC%
M"P&'66/U_=;+LN/%XAY%,=(]^ AE#3XXT7A:!FMB#+J1<Q53%M3+T8E?,6/.
M'HIIS<;@3L1 5X/WP_M2Z/J[D,N-.3487E%YY73C:\+$9).%(J__/: V?%>;
M490>=FJU AJLM3M!%VO1WM>%93W9'>K]0Y&O.#_[UC_+&ZL7ZL>\H!E]<P@=
M_9HBL_":E'_!8 EX+;H=)B:4R-?AWB#C>F5%3R60Q!SW+P%>WTWK<T2Z]^"?
M<3%I6%*Z7/_M+RGSP]3-X+Z;9.LNANC&CX%JQE]66\:^/UTGG,OL!SN<HT<G
M,*<Y%Y%]@\KOPI?V8J1"RUED:%[[JFM!5P@[*?W 2U<T)K$S!T/;PY%3KU*'
M))"VLQLKG70PRF3UC0#MWU/:5#AGIV.W\9$PE*S@G@0RX2(2JS MT8 16@G[
M8E0Z]YI2(,E;RC/W I3K+_DEA3&/^.O^.9%I=]6(<"VJZ(P$PLBMBRCL.C]M
M.;FDRY?EZX7C+S ?#6H=O]A6/['3J,V#.C4[+K+[V\TFM1O(AUYTQ(;Z6F_P
MK'A+$%7-:L 6SE6$_N':(:"H#^=&NX'7] XN1;A:KD7'KD $! !$IVQ^T&6/
MF!9J;5R.42@WU-W[47;J\$?$<)2JJK4?G&*U.?G6D(F2,"<JY&,#N FYX.JD
M1![8W<S8(=0$VOHXH LA#C6M3WD/NUEV4F'3RQ3'A]L[@I-_3.KE%Q 2N+Z=
M85P6W^/%O5:$*.7X(BX<PS$:,;_EZKDOK@?;_VDV^KC+5*M\@A]^>5/V?&"/
M6C3)H]FF _8W !>\*;X4Q],([KKYX$Q/F#J*5XT9FYZ>$9'XZ^%L%0#^*-Y_
M&ETG/I )& ")N<<^ZQZ:<O2L>+\T)*,ISI&30%[6G?:]\Y"-:,4E/OOG;>9+
M=$5]P-9=(F=""Q&<6>W ( JSCJZ50*X1/O^1PJ6I<.?H(+YN9 TH3"(S=D@@
M&M9DS/,IO?2LHYI B\LP0OV,;2ALM.J:;2AAF3PPO_3F^O.0CZM%)C<;DGMU
M>@!J@KNH/"43..?Y>RBY@J*<YWM,W#NGUDP/K6RT%)_''&_*PT7*<*V7$&#2
M76'6[UC*8+'!0[-C(N)*MIG1#)-L3_I;8F<&5VAAMFL4NAD_@K5\ \T*?_Y/
M+IB7RG]RP5RF"%!V2(T/APQGKPHSR'"%5,T*2%(Q- ZO:5P$$5/TAK?"H'1"
M+&'Q[#&P:K5WBN]J[0':'T&-@M2?OVCW0GDQE0$@C29^F<$+GP(5, QP@Q#.
M"]HZ*I8%-P,CX74PM=R>$@ED#49 78(_HH,8OF\E-9Q!DR5#E^:APKN3 /?L
M@)(FX R; =4^447.#.@H#9@W[0K]OR2L)WP%6(:*S/#9$WS?=^?93?>"@MI=
MB!/N%L0NJ3> 1EUR-\J5IX-(.\YU0/'9DY$06!\G:W>(0KE%T!=&?<)_AF@<
MQH+RI',0I,84!9V<,\@6I5#?PT7PVCWP.]V=SX8G30:'$2=YGIJ*XMOXJNU)
ML"&>GMK\0#F*'<@Z@>'MP,[#1L3O&$"Q./DT^>2CX> B=7 -E$T&U05"&UF.
M!)+>>X#G Q:P=G&8CVNAE7?"M]J.MKF4PG[,?HS<BQ@W$4@@&*-?(6-5;<4#
M1!==D;ELMO_NW]%/;TCG]8R>+#T8D1\4IV'==PGS[/94\>T=._UZ@@&7'D]]
M%:RP/L_MCJZP%<,F2!65QC3=\6XBS>E%%FGLW*SQKD%AQ%R![4I2%_:QXLU)
M_E$R="6'@2ODT>TQXF".BQB(!*.YT'( FPFMHH*W/& S^^9.H/[$5!5D%321
M'^@'%:442" )-VU\F9=C "*#":- V75I!.[:/0<E$*\BPGP2@,U&<LQ/9.%Z
MI/#3CN+H'7,@#93;)6:>03\*^[T@J!ERN<^X-[2[L)]_"O;FYNV]J>"LX"4P
M@OZ91/W>6&>KO+L0Y:T0LG_6[-*);*0._M+,W''7C##S9W'9L-;TKQ+($8'
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MI,%H _0R@R<U!M VQ;I*)K8V(Q<4+IS=3Y)[H]=? !M_E\"@=@/.!K/&Q72
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MZS2-P(HS0<L_NS2X4G-N^J_ELO3AP\O_4BY+:M"'E^O_) ;=!'X%X0 'PS<
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MQW=KHW8E"WV7D?>6&R60/O]^/X,@K7/*L5+I)W_!$.AXNQ')VP(,&J9Z)^B
M2CT%1XQ535+>$+W#B!4W$6=71P=HCKY,WYXN=.L,NCL[4"YFH*I#9V\YP]_2
M/[QZ=L^--#][(\X-Z&4,<F@GWY[?'+4)?FO"H@<]ZK.-NS+:-]UTO$,8RK6[
MC:S-G$XM'8#-FO[5\R%LB"9\E[TBI_ S.R4X&<-;ZTYBGA78]Z$_OKW6Y*MR
MQ(PR#N+'V[E'%Y\OUGIRRGW6&GM<AMYRB:1181C5OEZB?%]>9>!?IRN+M[SK
M3:FER?$BV6N195!/Q3:E+.BX*9;)(U4C5?;:%3*32_.-U3)QZ)K?0@D$N?_X
MC?"J%@^RNDRDPF//V',.7[I/:PK>6!G=+^$UW$.(['.F-8]#9VD2"/S^55/5
MC_EP >:L![%C$IO+1T<TLR9]6 JBF<%?O8X'J:BJ3Q\KB]@V61]N/6T#MF>3
MK=?<P6\3K%VW!M8+7(<7$\N_J83<NC=2USDQ+GJNO]T/4Z$2>;R791\V]" F
MPNR[W:6%IL8O4B=&O#T9N\! [WC+>&>P75Q'MS<JCRN.+8C@843V8*6YKV+O
M!BD:8 (8GNF5QZ2J6L;J&6#T<5SMX<#IK=,L%Z5M&YAJ92LC1>\F%<G=MNT6
MYC=-XK<LNDQ/'CHP/2FU^6J9H"U)E^/.*7J1JWBV^F*UQG3,F0H%C%PS]+5J
M-.VC#SLI(DCY<NAAC%1D?M+\]@ N?/U#<>'$09&3G@TP#0CJ>UT3.;STI'OQ
MU MH"S?$>!=CEG#&:5&!7EX=Y?["<:-X@XP5> K>G 8?G0CFZ%Z:%7<G]^IF
MYP_8^QF8)F1*H]P7RD9^5O)IYF]-TX0- FJMNJ@#GR[%MVUP/U0/:T[;MLLO
MD/TS4;>DK^#SZVZ_B;.P[L7)=;>2VJW+3NTXJSE1YNAU!\._]"-\CHXVQ)OL
M9+L.PX8GE1-U$X%9.\Z@__9)Y-R1Z1F%\9: W\,SFTVC?XX(1B(@W?Z1,YJ^
M<K.N4 !@:F%$'OVJA+O/7-XT[,Q1O/9[Q>E)&\J !%+A=ZDD20)9DOGN]:+
MY)0>M%FD>L8?A^(@;+T4FOKL344XN9K $&&5_L]-;NSE38J*;/B\!!(+99'2
MN%Y"Y'.5+JV&6Y%*N/5+R!]ABT IS>'&68/]3X^G/OERP<;IR"WW7/?XV/QZ
MX%V[#7A0 AF1:J7<U,;3%FC]-3,Q :Y^)NVX6:<QAFI[#;NO59B5).6J)W'Q
MZR'7X*)SB4W:6\ND.$7!.D<;;'AM!EW["*)JKL+5<5J,'78SG$S#:,1X=!N'
MP>FGM4@+C,K)8YNN6Q7,U 4Y=33;V%[?:D.^YZ=7N5T6;#+:& [#U5P9VWN#
M7V[C1\LU%J6HU;X(%U9_(L\.EUC(*7D</_;]Y3;11-X)FLJBWS*'15/I=!\W
MHOH.'[H0H!8O.M</C&\3H#_5+IX##^Q]?L&E=Q>97\6O'"^X.W 8S[K_U'8X
M=[N_OJAI)H;6:\A,!4]X!AAU9Z9]&SGP X1>NW(HY\+51#"7-(J WTU>S5B;
MHY5T=46=]$YJF\"#^)D^=-U3Y\4PJP[[+]61J!ET3)_*9J3X-4WX*T*>.]:&
MX 'L%9SX9A :"&N20/*)1<2^QK:RX".YHY&"BH Y-SXAL/_(LU<N)]9<DE)V
MOWX6)2(9<Z+$R!;9VOPX_V3(%UE;X9?OW86D)\(H!2\/-<.1B;+77VJ^^BO
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M^0'%S1T:GVLW^YN:VEJ/!S8JD$['_;BJK#E3NUP PJX?7#BC;"[3*H'DOY!
M-BF6V26W<"_BGP1/_C+4\S?_:=3+"LM(UWJ>IA?\NTQH1F$9KB[#-A\:Z;8=
MSOXE=21=O*;I!IO[_9\I72X/] 0@'<]Q$40G T6<_-,)TZ<Z:?#+(Z3?DQG
M?1WS_'KN2SMJO1V6Y]:6-P!5T(=6'%,Q@&+[F#$%??Z9\B];6+VDZG=;NIC
MPM7M&SG?)K!L6#1=MH#I\V"VJ,GBSJ.<+#V^CZJ*7V2Y 4RO'BG+RJT@Z+\]
M*G_QLZ;FT= WW8AUH&' ?L:@BJNG9T"3U9R^8FF+[:P[8T[6PN*$U&3O5ZY#
ME%4(:-@?@@UB#C>@HNI$DZ.:I[O;5&<RM+P:JFWL(YN?FY;2]0RR$AT^&.$
M71CG#;\:0#3"(KVOI.S!SRGTMKBZY^5@H%TR%,&$F%0>RPU2<==W(]\\I;KE
MAO!TL3U\]/&N,V>@'/V-0M@(]5R0[32X^R,&:EYYP&UK7([.Q6L^RU"O<^<B
M[!1UMCS-AB+F*\KBOU;!O:LV/2*P;R^I,XBUM)!4A+*/^,/H-KS0T,-.5!&*
MORN='CK0-W2KMPU'K.Z6RXV!?<(S5+X?NE;;Q_G'_AYQ>QK:Z"EC\/2"X]3.
MUA-K@0?+PD,')! -QVQAYPWC:M3FX@L'FW3*<(HS5B()I#D_NMRT;C"J'U6>
M&&0:V^QZO]XNWT9U-=+0ZC4.E[/SY?FSX<L8T9>'IC4?XM&I#\[OSXI\K(=W
M.-<GSNGG,.?P*Y^^2E)X&C[)2^Y$\^W-*PC>.E78T_ +'(OW_7TKC*TX]8_N
MZY9&B!\+Q.$1_?86OT9^/+,TPK>33J& <K]';&]94V43![5/,]"7XAV%Y;7
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M%'%LU2;Q^:Y)K=6RL.X):GBW/\6)@_VL^K -1OY3BO[\9>4Z;.=<>U! ";E
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M0E0\HB!@05$$(G($12$B34"*@B(@1'H)R=:#@H(0!14%(2*]!J2$'A$A"&*
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MS"KCA1]GH/TK3LC]Z.TS'JMBBY9  ,.ACHGTR%E5OU0QE*@^]O;,@X ,\7<
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M1S$DY4\695O67MR2,9!Z?23@98'_><+7X"4B_.G,!&ED9"(>Q$UU7^?@&:=
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MW0!7*4U8N_ETTNW3U1]\7K(?3#N A[.BH@[ 5U.7\I!QF14BJ,+';8A$?Z7
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MTUX$UP40A>O+"*-2"6%BR*WUI/6,=)&>>]9W_":+F-"#CC8$;6-O,>1B%M2
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MC\+JBV/2'E@_[?E>I#)Q0?HX\>ST1^$52BTO:6:3O&/I0MN[$I\D#SS,^-T
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ME:GA;$)1F1AL\JP*4Q-R(LY[_EQL;WSZ.OMZ=FOHDUMNN7FM(Y2XL]7;HJU
M-JPYCP6;'"4J7XJ?[!O<.RMS^PSN.[Y&6C%V02HH>IQAMQFIC$ .&.O,,#<9
M4 U;.QO>_.QW)W4:>I[:<+.U:WFU>Z]-Y#*AZ\/4P]'<D\@X//^Y\:,L;'%V
MSPTYX!ML>@:T<=J$;,Y$#JJNN3AKTN^%\V$M.&Q<^&'^6&CK9W5JPI=*MV*R
MCN7BD;0?<PT[R2OS=N=N^!'+(GZJ87+-[!ZOK4(_NUHY[C+QC=G-2:U?SLR
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MA_/M7*_;[__M[B)&>_M TBS;*V#-VVTFSA%2)NM32'.&Z K8XXC>#4Z[F(2
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MZ)UOZRFRHC>_]?F>TMV;89WCE?M-M<QNL:GAXX_IORV],72V-F7"!9FSMA+
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M\Z4*)1V#8^00B,H'(Q+IF0.KKV5X':%TNU2(L:B.<7"*7[@SAJ4UN@&*57K
M]!0_^=LKYJ<,1-7@MQ\@IQ]<29D^]X4IF=+#9YO09/?F3XG!ZB2!)> T^-5
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M*6Y_?1Q4BEBMM2'#=$DK#Y4F W99%O8TA>VKZC@T0Y2BSW0=L6PO_"!+)KR
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M@@ZM/2\'@ODI#"U,BR:DI7-<(@K3D3T[\8Q"HFJQ4)(-&K(Z6"(2\\SY^)F
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M>X[\R"F7@(WFKNO#J%6V"M:8DZ6'3T6%/7*$;W^E8S(H\]6.!W5^2_-G[AN
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MV;)TKF)] DMD%CE</0AM'ZIS$:<AGMNS^6^.+I(T7),7K(3$C#Y!$V&QZDE
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M0]@R;&[AT%]W@,5DV).S)6=@VS)B^_02<VT6M/7?H\O'M6ENT<06V#!2B?E
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M8XN1^_?-#.>\)=Q@O4X-N:QU"--IPG?TPN:--0DL-?=R)5V$;#$G*?:3_];
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M_R'"\]X"UFJ$)J20YP!K;*ON\MUTU@5MS*\L8C<=OO<MCTNO%+<9]A%(9=X
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M8JP>2T59"]S@0EQ@(TF<7-K<CR.KB*6K>WC_.-R*7MQ3V3R7Z)^KNA[, P>
M+RI$4YXV']%=.,+J:G9'E=4OH3V5-;_>/TA+PG:[NM!6O[%9_CN5AGX5R/K/
M O^@$.-7J<A_+_4N0P_;#?W13\K?Z.=?LY<_]-#SM\?[7S3Q=S7_,1[E?@Q3
M;,8O;9D$_)!5_4=9IMB.WPSE#Q7__/Q6!^9GTPK^M9TJTC_&?;7?099=H[;&
M<.05M5T:H,]V\MFV3 Z6KT)I#Q%].29=UTOHEGOJ,;K1X97B;EW"@V.*8;FK
M$R7O)R+>"F9M,W1]H[S[/?]M_))8)T&UN%4)#>\P$4.MY4(^ G0BQ:KO0Z"5
M3<L*+M94^8>6W<4=@3]T6FP# \]"I^'@+M2\0;X/)(F_N PQ<H(O)+LTN+]!
MQZ(B]9O.L#30WV.HC_O<,X:^$PJ;A3 ]C4^O4]&(RV(Y ,W=3>CYM%L&3+F
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M9U:Y>FJ-+5P?.[6\7V P.=FOXTZQUM5[1J?67FQ_W.M004_JLE/\0#4L!"-
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MVIM!.7H8W ,# YJ*QMXK&FL ^W32P8R8455HS"F6,8%!F/NBJ&A<'O7S'N6
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MI0[(20?I&HE0JG1ZIQ-"OZ-&UC++0+F-O.='2FR 02W!M>#YJ&O:40Q+HLU
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MSO"M[/%OFM A,/:U+&(^7X3,NQNZJ&A7U$&!,@4&EC]%#^.PI]T#Y&7WY5O
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M2 L&.E8AL6-](_'II5 ![VL223[5&1$M+ELZ7Z89)1W<5OOHMS5M:A0?(PN
M@;D\9B%$=:37JRC+#&.K$ ]F6$/U9AHC_NS*K_XY5H&%G$P-.BL3/2)D+% L
MW>-_ZS'*B]MR"?G3,O$G6IXRU1L)5@V'BPT)U'.8]F$[E".W"24B" )8>8(
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MEY9R:PT)S %5@.@N%N;F46KY8=-<$XRNNXME8)'4S*6[+F_FE6$\7\_:<H-
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MXGMR^+C\_:*-7:!(F:+UZ#!/TQCQHEM\A-#'HD\PQBS-LQI%,%?.&VZ1!V>
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MKD&D#- H'@6/82D^OX)OC!L.Z,&OF'WR1[Y#F%?2\G.7$G8-^L^.Y",9M9B
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M3@/$'E2G(G?K*E&E&*7XXM8!+QR;]#6D^(?NH7Q2TN3P<[,XK421[KFA8AJ
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ME/B0WZ@*C4P@UZT'E0J_WY[UOUN_F!$ ON:ZNZ1[?F%%60+/P,/K.GP$TYM
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MJ6%CT*95E07$LVR2=?'!WR;.[4*H9Q9@H^!C+FQ5/6AX;\/$$K:.7U4#(TG
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M-&3M1GVFP0D#0DJ/J(JD/Y=/(.S=09 -8(AEE@:P$H<>-#3PH*+E'.>74Z^
MOP*[V.<1K3=,'HU-%6I;U#MXMI+D77YN71R[30-L%;SZVH] LEULG8P@7=TD
MYP0TT@#5&XA'^K"$2UF63H<&]HO9HP&>9<C"5'[B+CG,,'D2W>M1A1)[5NA
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M8.NZVTL#)W7+EP6 C2%!2W<Z*G_PFJ5<,,E\8X34$RODP@YNS+V&PH+%N/'
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MNDI&GB>/0^&$:(QBTRN+<&;=3OATVT!"#^<9%7%6YE^\VGMV@%TXNC0/B4?
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M"L,;W("8C8&.@B-K9[#\+T@/7RVPT1G]$0J0.;]3G!=S7<@2QI-/D1, "@*
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MR;*Z)J4-ZUZ2QS%077PTS:M^M)%$?+"$YTL6ST#.8$NS_,?4Y@#KY>J8J/3
M[LU/J$%MG]^<J7T:!O\\WW-=S#UUH*LWQF3H^:KJ)_%^6B]^E/"-4I[=3WFB
MVB#[^A8R/A:Y7I/%&BK-K>YC[K'Y*E+W.JKWQ?!QRY$#8><GN\MO;8]@^P@
MI0M.2!"@N3/J3,U]Y:D]L]2D*X]*)*I<D"_-6UX']GAXWA  +_2NNWU]YLZM
M-%+=^_C2GEBS9<_ZB2 43C88ZN%:OR;8-7NFS"FG&BG&Z)O97N[ :5[N",7+
MV-(*4&9H8XC_1SZ4_[T-OT:*7=ZXS)R )IA0YPLX&*^+L,OVG5%9ENSG/-%T
M-NQ!$TO>_-(#6HN]B@5Z]=FT08TF28EC"W=>C'R_(#[Y^>2/A]KXREMB!P7
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M=1)KFO$QH).KT.*ER6PU+J^3YF@5,#K.08%'A$IQ:*$>HB/3$$LW'! </$D
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M$HU>\<C@4G_?&CVX^^<8%^.KM7 O@[WT_!X$UEHQ/&9&%W5\G.O_%5<!+Q<
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MH"#$CN4(=HX@;!$542$J"BA"5"STB%0)R58141"B(J(B1*6$'I 2!$)$!%1
M>@TD2(<0:GK9^3?GW/N5>\[7;OT?GP=A9L^>V3-KUGK?*6O]<I_R#CQUY324
MBF_Q(J\9]N/UO*MXML<H,/AP'B,I61CF5^/SG<>B4_.=+5*&1P0W$X9(O(GZ
MW X%0-.276UYOJ'8FW-YC=8R)?&BJ'Q"=':FW@FMYI*>H[*>":^JPXC(/!>T
MGM1/=NB'2NLS5S@H@#WFQRV,R!16OK^7$&V?573CZ^><'&^0?W@,._RC60$T
M5<3?M[[B&M [8R?SN/+I4I+]EI=@-X'^!J7+)WY_N8" O&@M.2'3P#_GFGZ+
M!\XBN6/=JRV=T?G#&;IP;0%V DYEW[MS,U>YU[^-9!,'F+XP1-GJ]?E^*XY?
M]K5XQR_@$X.-Y%=506L,7&X>0'4=(^<C0&PQ>\20_1D,S8>,7MEY!!@&BXG?
M-6W4#LO>#E&?[%BOH7%CGEW-T0LMWLUCX-68>/3Q=W><V64R1+F?$@E]YVJ7
M5M1.<,YC)Q9 BW_ %4=,VMW_T^K5AEQMZ7S\Y:!Y9,';GTIS\/IWU3^!?5B/
MN@?&"B#Y"\246L]KWDY B4SMK>/>2ZBBN0H M)HK*RJ<N7!LO"8N=>V+FKWL
M3WT"54<%<#XL^YQ@8D*^^RC(1'1S_IAG8.DSXO?[>W<.+IQZBWXQR)%N&H+^
MEPDA(COC:O)'Y#$3=L&-&VC<X<(BO=E$QE9:093;69U=&XIXU@,N@XN>F#\H
M"]45S<!-2*1:D^7M49MT--3]9-%).++>0RM<9];U\@I9^P\XQ<O>H*&7?$2F
M1FGS.R'X-/(HN3-G9:DY-C-O@SM"]D@!=W8V^;5Y[1%OH74%R@T?IET^Y_AD
M7S(Z/!;KI/F3;VHJZ'XFSOC _O3(%^,9,^]B4)CL=PH -?5"%*1ULCLY+^JK
M NAFF3SY1:4^TLQ2()"#[DUY^YF2#KQ!1%3&&='[GZB)"4:,^D'0:;2_;)<C
M3<]O>75:3T/S8E#GOB%95JF_SL_;U$,0OR*\J\S-_G[\FV_N'A_\OZ>Z8<ZT
M66UY%[3^R?.DCH[[^V^[\00A;EG]D<K>ZJ]MPSPXM:^8'?/G_ISAOC64<)YT
M]].K,SO>;#V]^6/2I;Z(4W6Q@^X2#CHBQIJ&IZ6Y<)P%+._W2[XUW79(<4K9
MT;72:4LR=,+[U,PYZ\9O:=6.;C]^D6'Q6:(N7M)71];!^>QG7M1S<3A[<:7%
MS3D]K]3%BP\;5ZCS8D9JGFE>:I*7U,DU"N(Z%A8;3&G'5KBVQ'_:%C##A[N(
M)BV(<,#X;O&C%R>RN-==-GQV6Y.N=*!BA@6Y0QQ>WBY@?7NSG_]F3W*B^68Q
M;['L*7S)3F4"_SZI@):YPXX<U;DO+$,O<H^R_8A^^C>E^6<=ZQQ?7T IY9^>
M =];PJW<EFC>7G6L(.7PD:P^[&E3RB%978W/_K=@X W'70^6OQ#<L3QDQ4?C
MH@ZX*(!]4"C/J_A**V/+@B@:J'4S"40_9D\8M>AN>])+GGH"#>H\6"=T+B/)
MS-%\G7P%D&YX7K6JHU'*='>3UX1)OYT@XA8>?AF_/&<=^O1FE^3]"H ^!VT_
M0V(KP7)&GG,J'LU$DG36):NVP3F1X'#-,9RC;(4A&&5!9+?KEVZ19RJ C?2/
M$HC*+44'-7U&8RK>!&;[%RXO\AC817.TGE&<=?O*]@_MBX\Z1^!)@^8U/$':
M%^'FQ$MIM[RTV&+_^2\"7%2Z+DC\O7*'N-Q3#!\[G:YO*J:Q\2OU%W!(R2EE
MV\HJ^ J (!(HL??VYE:.5_L_O@6^O-;IRJN>>&4Y-8CIG^722D*L*DK *GU,
M'>3MW2M&3*Q84C(:L^>_#>7]DSCP#&Z*)#;6.QQ@G]&JX9[I@$?WHEFN!7,'
MU<S-M>;H26-3\^5'S#!W/R^VLLKLZ2!QOY?QK>]:BZQR]\C6D<0,HZS*L<VC
M2WHS;".&[NBI 5N45NXT4GVQYTU-HOXV\!O8/:)I5K_+5VLH3FK8UTEVL+5(
M [N,.N+J/<YT$!:>FQE/<%>J4.Z(_,X,_W#"BAT\2ZXKU38T897>-'##'Z47
M5D5Y/35YM./48>ER1U2-=<8VA/AYAD/4S-T0I;'NAE&:0YHNHBLN0JP*&EK&
MZ!W\9 %&V= _U-O_+^^,'D(S?[VH29 F]G+.*8!^DQ8FHQNLU,D3VS;Z7Z2P
M;0.E4X<<F5CFJ&&!)-4IZ.&:[#,'P"$]5=7N\D/M%//)[\>=PG9?/3J) RN#
MR2\Y*H:-$H:SL-)0 ;B<9)\Y6'4OX,"B]I,MI\Z'U,KF&9DZ9T2-R*F==.N6
M&,;[X05,AP W?;>&AZ:K0\YMW3QOA3'ZU"SLA$B"KW"3E @*:0L_#O3K#U9L
M&MONJ1E6).A=\GG)XV\W462T;M1!W_<6),F_;43^ <:<ON4^;,KP^D_ZY)#H
M64W*)$TM\+(%RI+3HGKRG6;F,RBO"I19LB[@E\B#6F0-N/'8-V0O1D<E)$X!
M/])=2[+B)I!)9.O);RN\H0 PZ9J@#%-TL7_'\5!J)G3;6\=M8R93G@ZKU(>V
MG;G@OWW8-$_R]VZE_M65738'+F4S:OW/#DCU$S #E0K@"B87FKB<IP=S;A(G
M4:UH\68%D(.8YU/H L;H? 50O4L!:-F'H2;)"'RZ.;W@4>KIK0#&3%X*Y@@]
MX>,T: C\YJ\B]54 ZRNA]Z"H:[BD8A@<QXJH^4U0D]1_16D%%4_]5[W4I3V!
M/D;^YM"&:TY%M=6[% ?5.! ?_#$->()(G6@IV'</XEEG]O?(&2,*0/G(<P@E
MH6-.(/#]W/\OB\F_2VA&SX2L%( [V!T[EL8?S<93?ONJ4N5!<-P!YADF<3H/
M0%0IRI%,LN?H%OP'2?QP.E/ZVA=]&F1#1=*)6/H>2KIC00W,XK:21<^E<7!N
MS>BQ=B-4E0((?'.M;P+%2X4M,L:8_^:ZX0_[,C3X"T( -$Q[?.H3OE_?[-"A
M00-75'@/V#L$I>[T=KA;C1,IA\=)S+?S=]T 2_BG5B3WB$PE105>LQ<:EU9-
MQXQ(>956ALOHZ;R>2S2^:NLY^G1.NW1W]*4;S[Y^B4^(7[5V_O@;&X@Z&G;:
MVPA#>3S\(*7TV,5;Y%V"V'LU;KQ_T&_*MHPT'YC[/%H7/I='N[K2M 3W>J7T
MYV?J4-+]#O84GBWQY)8_TTLR*B:<NMSP:(FL8*?=FBF,+Q^V7-($;4UIIZK8
MIH2Z^/9ICUJ>':8SBBA/!W5AHJ31=M@PO^FGS;)HF?STG4(2>H\"T*-892^+
MM=E?BRJDI'8'BOS@X@;^,)3$KV074/_%\9Z)75LP+J"9"&(KEI6_B]N7Z[+3
MSUR;\[1LB2T)/7(R$\V1GIS]S,GPB!%K'67FX!-,#7A]5MT>^%@G>=4SS<KZ
M6\Y45B*U7&#Q/<$=<*5(0RMMPX_OJE4 F5J?#)H2C*'OY,JWB[YW+8=RT./A
M5&RK=5SQ/[C7^]]N&);7[);!"Q4 <WJKP"?@(&3T<A5D%&KARNR=9$\TYX\)
M0S*A;L.OA:M8LSM0LETRNG' EZU5;/X"J*16EGJR])-+1M']GSS@J0J>8,1;
MDS]H?L-4L&SZ;%=Q**(+JI[O<B'=;[W:(SM47.:J $;?0-5.8 ^G45F3(2/%
M*X"$L]2I<Y)=Y"J)"69\:V_?T0%NWB4%$)&0 $YH??MPU>4&@PM]TE^%_]B^
M=WXY+\12NIA_EJ&^LPW5QV80][D'=)H[BIRF(JZ.S"NB7[7S<':+*^ZAW,N)
MF#\L]9]<,:[4F)OAY&?(.-)O\RWCRH/-8/T*]'4N7^R]9/),EO2L-$]9W55O
M[U5CK%"K-\SXL/E1?_49Y[=/-@42IGR>FH$O]293K=7"[3I;]=/ GD2C3PI@
MQ#1OW\W^37G,,0WI^5=(OX4'L;K:]PSHN>H4*8=AJY; F(':ZY.AN1(.!8JF
M58Q^XE9/!'+<0D-%M!=QZ9TK_8,_EQPW.DA=O>8!H'OSLT<)3#YHPG2+,\O;
M>5CK;1)D" T,9K\2XNTHK]/=]>8GT-*?Q>4'+6]Q=[)Z\T5Y^??7LTSJ^,B
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M.T\P"LZX\WF/\>S8+5L/JT=/'M_)EB# $)__<GGNW.U@7"DECW>_7G<.LW'
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M8R[<@J$?''1>@?D_Z^4+6VVK9X@^Z TO_6QYM7 76AN^<1ICJ0 .2\_4U>_
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M&616%ISBS=5NA(P*I.Q(SQM@\9&*P1T\>-1IH.5N0X.8S^X,0(38ND@!]!9
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M(4<K#0<>D.ZLQAM*/DTK3FC>&Z(VB$F%;@X?,Y-A\.;8,,3GS>V-KIE2FE7
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M1J_RY7<#2G>$=XTC:9NJ72F;MVJX3U,^7Y'!]J(91'?V'NYT8XQW*;(*S5S
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M3HXY/B=%._VQ=5G6E-'IRC\)"4*/_R8W=]W_6I130X0+_R9ZMA2;K26#U6!
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M51D<[W >E5$M!!HHC3^'N$43"KME@<DK0N"^^0B9QX\744:<U,KA!BF0$*L
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M^JI28#DR3?HQ\/UT/V9^AYSX_F\G\E-J%S@0IAO5FJ'^_VN&]_\[D"L*T.'
M<;%V(5"ZP(>F1L+>%Q305+I%__\D[1,"!U=:Z:;S*?Z3 ?8TI:*9)1=S'FT>
M/@-K,T-QKD"MC(-(J%N8'TDO'YPZB)V$$[@0K]>(KCR55-KF6M6S"TVZ+ZW0
M:TX4K.C=<+]'@2[(B;8W\PCO[Y$%E>>6!X1 %U7 ;NKJE<.HL*!'U82 /CE+
MGOT'*B36>XX%7_N8P5N[.DD>T;;,1=][.D#CF:TY0;N^S87J=@[V>%'.!W^-
M$3E4OEEJ_ON'U_N9[3&_-EL;J!K)UNJJ<F2Q-4)@*WUKTT '(TA0MHZ^OBR)
MCR0F39M.."7HXLA$U#?WM4%"H(.U:"FZE7DN;;.A90))Z?5@<1U6QDSQ >NG
M8:H2-'3_J$64)U^W0"P60]5R66DSW$:NVAA_X15LL,:=8-PYP0[K=W7AK9N]
M#<M^A0XBP6VPZ]3VMMA-4H^ZPQT,],^U[UH67[]&H*2P(""OU!!"_.U01+V<
MBN7]\7:\&92?89+E>\% \1P8 [Z6*FWZA>V8QET1N5L*&)VQ9M60S4<NVW)*
ME^25]/?WZO_!5_Z8%?]1A)D6 B-R9D$)T585#BX1W/Q<"MQOQ,%W2U=_05B?
M(7*K\;(#'E^S539'<16U#47H2MB@MJ^_B$-WW70D%0@+*CH^H-:-^K55/WC4
M&\\*W-T#UBF,4\/LK(HTD2?W9.ZRZ-U7J';/^-47I9H&1C^R.<85@-EX@*[]
MTF^=@V1C"5FR.4) <FG#B&%A'LF9*%_M:=^N')/MU3JUH_/(?N-+I_1:$1_3
M58'CBIT-<6(!+H8_>@J@M*_S9]XQ"(54BF)8?>L6QZ/SLJ=>NCA!EK#NC(Z0
MB[U6CYIN&N4.E!><'RD7$ SECJ.R[ 3$I4AI@2[CX($*+#Z.9SDR/R5&+/),
M:\;DKHBNS-B)C/&*(9G6B*<$*@0QRYAXY[*>@5UA/'F?".?DO81],06"QP_]
MA !JD?7IIR^E1YRS:%[DDL\=E3YQZWK8;^=K;E_: $=Q CIU7&_[^EZ=<2U?
M:NQA$'R8N5HNM_IO$^=*]I&Z38V%@!5&XDGY^D&DQVOSK=.;=M0 !^KA8_/:
MNA9RQ73S(!R4$4&1VB$A^V+=34G@@4?->;/O61*GFU-VZ'EN6)[S!-FX1B'0
MR<9 #RVC,H>Z,+U4P3\H\6#HBB9[I5G\9G5#N!^+Q?H>Y#"E+\'O:7@>EY%D
MW'S'C2 $5G^]8>GL?QW5M'IB"DK/=?EU;?@S!TPG.:RH6='5%!.\WGU1DM%]
MH-SG]7%D/"5S-DOW799FCTFR9MP#+Y0I<]#<N<@GB:*ELV4I=5."8SB(RWB[
MP(W!(=*6 R-\G?++8NK=($.J33?[ZXNMR\AV+BXNWXW,1X'$880X!H/>@&GV
MLO_]&-!T7F0A7IV:@R%=DKXTZZV#"7 5'R%0F?71.1^6$F8SV!_5]2L MRU)
MW[];,&V6RH?5/5Z^#M;H/D3'S[/:#BU^3ZNX4T*=0M3X!RU'\ALFZ@VO]@ZP
M;C60IC4.OQ^<3240WLWOA&[%CO;,%L-+B#?,?T:.[;Q9"X9/T(H"9#.F</M>
MI^7>4]<.23AP4.>:L^ORY8Q@:/$TX<S!M,5\?R#^[MS]A;,BIGR:L[B'FQF(
M]"^]XE_LK_K>>WW?EJT_+IFO ;+Q:>* PJ'+C<8VAN>)P/; /@BKBXU])?8>
M(?-E-GA HDX\:'GD#GO_IT%<9BG#BDQKOB:=Q:?\<X/H/VN@&3(P""FR'XUL
M^-0CU_/UUX#6:9G7'_O]>%Z%EB47(Y 7=QVZ,5F^QUI_BRZ$,>W]=88=5"0$
MC!R+7H^_&VDQ&R)6%0H!QP=^=U<?Y2RF3KFFT*9?TC+3.M!61%)QW';'ZZ.W
M?[@4GE*]*1VY.0\Y(&4'9=A:I"I5+6GCG =0VU%=^Z>-+NT"T'E4UWZBSAV+
MI/T%6<"N'?CE-&KSTP.S@I43"&^H+6WCD!2:2A'SSV[>U$-X&R T%6[WOQ5N
M=\G".Q8F[5AJDR&_GW'3[$/.>8J ,VY&GZY2 &9P%KWS9_FE"M#8Q>+_5>>Z
M_\$ XL]>3Y4K4X,UTON)R@V#%$_)4I^LF_4=0T2)C35M292I+V_NH9A8'H)H
M[/[@2(#ME5[/&V>@UY'UD#%"D::98\+"4OSK_IAN:";^+#+/81YP16<_D EK
MD#/^K6?/E0CL([!NV\CU99PM@^AQRE=_;*%F$NY+W!@H%:-!B.(&R,%V\D8_
MS22]H,G_S/A8Y;O&^/6/^WTO?.">N!\U+MR;=HL6)/C50/D-$7#SDT,E6 #L
MF8Q$SH%MR- &?T+/_%3U=MX@+U0$'F80%9E5 IMB5I?9_U@B87NCQ#H),]T#
M-RZ%_3_$O7=<$]^Z+CZ*@I5\58K2HJ*B(F*A24E$1$1%1*H445"0&I#>,B@J
M"D(05)06I7=$2NA!BJ"4@'0"1'H)+4 2TB8WNL_9YW?.^>Y]]][WW-_]BV%]
M)C-K9I[UOL_SKO6^J\%F1MO%R\M59]U%4>ZD_,R1>";6<93C'O/H:Y5JJ?Z.
MN.55Q;EGD&'@TV'\Z4IYA\"',ZI7YD<Z8I5.KRNG6L'*'YYT85_/E=K_I0/:
MH&1<K5G2%NUZEG-P)W++*G7V?E[9^RL:LM,K4MAI3J*U3",RPL)P#'?#ECF]
M.>=8?*Y9D07=.SA/RD+ZU<XTD]:F^9F0H"I^=CSE85 PJH!_S#/R2:];_(,6
M*0F IQ#O468(&U"4<OQGLG['[%V"%:OOGUE ^)N49$*<'^C4 /K_#/75]/96
M=K?W)WUR$S<O6J"?_-G_GGVD/Q>289^HN7I8]V9WL)X;DN .(?6SRM0F7[P=
M7 N/5-@?B(G5)G;?)&Q[YVNT9SI8V[\G/Y[AQ054ZG7/ETB^J-QJRW*"VN[5
ML=$"E.T6&#\Y^W;+2B?1.?."A?U@SZ#7#BGKX44,ZRUR>B]R=4D[?*+/G N<
M(CQ7R<M*7!*<G'\I)[*"/8 AVKK2W^H@KO6OB_@7'$C/"4 3850NT!\@L;(X
MVI+P4X%HOMM6]?:;<^,=IN_DE&];;FKS3+4-VT!.@I]\!N'7C=E] 6?O.R_6
M#21^K#ZN]'7ERUUEQ+9*V15$X#W272O]R33.VT0KNRZ;#4!_N*#V-YRKVZ2:
M;NJ+O&W/:Y'IH>,'4SA[,)<"4">6?*)\"ZTBC-ML)52DMG<VKH/+L8SW7K'?
M\I-)09V5RCOU3>Z<?2_&F=0V'%E=S-RLX,M\WKMV[*Q8HC$0K#" @5\/:JHB
MM4L4>.!D!U**WV=N,%M>D^_(>%L>X!=F8O&X1$7HIH;Z6F2I:G4HEISS:VK\
M*T09\5._G8[DF_6GEZKB_]1#].P#S^B'<0%55E&5$GIQO:B\2,45_X&<>X34
M;'"W,CFCX-@S [NL-]VV[,(BJT<'OZ.<8D /7$G@Z.>%M]';)RCG)>L-#,QC
MNHT)\<)3"_NC]USJOGS8R0#S:@X_!EGBVW>E1<0$+=JL8#XPKGSE @LYBV!_
MP"MG/_+K2<0?Q9PG7"#Z^J/EE9I5)VP./ %<D[](')\Z.RWZ+:EN6/)6MQ5Q
MX%;>:,DIX0%VGN#5JC.^>]%$R9O%%YL,$7HB5XTJ*""%:=U/"HR-+;?KR<_/
MNQXKK,B?E%3-3_.5+UC<L<M*;D-&'4R,7:.3\H8+[!QFC^(#H#/7)S+<K_#Q
MK21@:'"*&SM@(Q>X76Y2(_H#/,MC??Y"H''Y8^RB&1=(L%Z3M]C$WD\>&9K#
MA%<[]'%85J;O%@(E$8LN/QSI,O3%/)GFZ<-O94WX[TPO""U+]'/\E.B8H?&@
M^Q76TL2X#_G).P,)V)MT^07ZJTO7$DY?NUG,UR(5)(Z_$QGY+T>;_H9>^ =4
MQ^]%Q%@,)YLTKS$DTVV?T2"3;+%J.J;4PGC_HURPLM4HX>1*W<4!J&)>4M.N
M<?+0_L]2@G%7BN:R,B0.243U_M3_'OB3Y44*'C!\HY6 I=K3J,(!L<V](^,N
MC7HFQOL23QE%;O(S\K,)?92IH#H3>(JA7P,!M';[,?SW+4[>I:V0TOI0H[#Y
M VCN7G:NJ=QUO2<L\ 3 W[<C];K*BO5^934#O'D)-7@_WU#YX6^K0BN*HQ#!
M[-BW(:+[/#0*/[FZ(VSPT8/4NB;GX, =9GD.5V1OB+&-!,15.LO>)D6:.;89
M:QAO;38P[0ARQ(?M1O:/D/I6%U6<3+F <GNUG9#IGHUHTH#^0*^A5 &A+RIH
M_KOM3!48X;7]-W'M 'NNOYEA(;%6YF-U;,MH7R9K*&-.U6ETO <=2%]_&L40
M+2HD=N7=2ZWSX0*WVJSBR0FYCLBAIT<YOF(E;&U33M*6_;,X95I (4^K71Y3
MVFN)><>SV<H&&>42$1R'8EG705>5''"[VZJ P($:ZU.J&2>K2%G5QQP+>]8G
MORQ=VVSV92DQ/@I9GTWQLJ-Q"M8G]'CRE(*8.%]($ W?2_@5]I>\VZ+I(3=0
MY.AH[G1#QT5;!W9014J@Y2/\';[]$42"%!<PL#SR]@8O<6(B*DNJ:^V_H&%!
MYR__M'U!&$*&$)Q2L$XJAN290E;',][/R(W$]QT.;;$I%6EN['%=) [/%%<J
MWQE#T?=P@=TEV=EKX4W7=/=OH-+&4RY]F<C3_<"7ZEWI]97LZ9S[G=QU([4+
MWC#TH&0UH]DT)WM=<;D7,Z[4W^(Z3+FE7:'65VC9AUKX\83OFHJ,<(3$W%>>
MPGHP4A\L_X6VA:3L(-E6L8RDO)I!MI![[P>X-_<.%;B,M\6'7%BZ(NJ,:1;<
M)OMH2D\7^70OV@A&IM)$GB%21<NR9G'$Q/^>%/:[X7?)[7YL\&PS<S-"RV>J
M=GVTI[R]8_X:)G3G!?3WMQ'!>R;.G-N5_?;Q>\RLSR9++I W3W8DFC-OBN#W
MJ\3,(.TU1^Z1\DHEJX:MSB1G;BI4 $ROHW\\$'A?^XUL#8^T.C:$; N=E )+
M6*[^N:8W1].3@^BOD@UI:V7$V=3^?AD7Z<6Y."[@<]:CL5G5?$R.[!'R=J'M
MM09FUR(B9+UJ]=H&6APU,C#D&Q%3S?JQY',Q:-\5O7U9;4?O_$Q_5)EJ!R3U
MUP)B+I1'7^XJU<@+ERI5'T'NPM$:CYSER=).\1]=7>.7EYOV6$?W2L134,MT
M3*QXN-[)]!;\AAD!*S&B\T=4Y[.L'3(RW4F)06_7[OZV_;]BP/_,DHW?@>-?
M!_]">N%?0ZE])O!Q:(CETQ#/H?04!W*!+WWYR$R>0%_ \[M6LY#V+,G[%"Z
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M6D>2B[_J'@S&ZA<E+YICW"WDN\6P8ED8^?W'XNR2C,<GY/8P M@%(]@C3%;
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M);-<H<=Y6=INE #/+%-%IJWC#X1QJE1#R@DCXE>O#,[G4#'LX]TXJ8\)&S=
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M*L^(O7HYPP([VO,(:^Y9]* L9!9U)#2RB@ND)YMV+;"9Y[A RU5&,/OF($G
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M(-?0,)<OXVA[R=A=#YLSVQMM&)+&,Q7=H$,[_MT'XRR+%EEY_(_CJ&/?1C@
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MFHAE'PI*INN-89.@X#62_DI'$"*^F#M0HNI)[)F@3P]SER('.H# @N^)T7\
M@JN?3';UZ,$\MS>4NI\7YCX*0*& E$=',).CHXVZP[WS4X^X(+S=ME%W&;*W
M5%5 [>L:52]55>CO*&!%:YIRQ\Y*6<70\W4D\D;7[.CU1'AU"!"GS'92C1!J
MC9(X=*WDBX= HK$TC*1$%9P_ZF=;56%T1O]*X(-&_K.%,NXQ^%3+<5_E<(S$
M0\W7JM!48_9=NDU[[O;.PIA9.DX5.J58WSE5B4'@"1\9,2I5/H+/?2J4PUP"
MJ=PS[ZN#<ETZW.Z-JOM<EO"Z_& LO?]&@HFS_/M:?+EDC[MWD';<[_N/"J2G
MHHQ#R!1F;36_JV\X G:X!/"CTD+\'<#@,K@>40]\O,D<JTXOJ$;2;?J]M2Q7
ML:6E/O<'2/S)3=,5%1<^YCA.O7^8;4T0C]XJ/0V:.S1>!9I9NSJKT:L-^S0X
MR\6.>'U@;@S+=Q/G^GZPL>%00@0'<)Y=I/_)]Q<TS.H0 PCK#0JA._>/PRH%
MK2EB0.&$2>*\3C5BZJN3ZNUK;O=.:,WU/SD\8S@]^E%0ADC[U#)!FB&V7_K:
M7^H/'$;$Z_H*:U3,MQVM&3ZPZG0P]R7TN/$<.STRM^@WNB$RCGYUB^<DV0JX
M2>3:9$S'U8]I0YK7,/@7R3'2M4Y4BN'&N@CYP9J^^@/@Z+VBS*]^!I\+FWR[
M1,;=BX?9*Y4U)SO9'Z3O0-)>0AQV<X7G)DPJQK,$WXX\/([L?@[H/7,\S.AK
M =@$[,4].>TJ!]E80W1L5<@XG7^4:)RMIW?W#9[HUP!*-'\-W&$<]7RQ"[9Z
MW<F*^YK'4%4>KG4N&+REX<[<C9_H[^E'J.'>Q/ &'##"G57S7LIEYP;=R6UB
MNP%HI(2+(M4<@!;S?I*Q[R8'X(^W,F:?6JRAQ+<D9]&/,R?@@1!W4F[P$B:
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M;B=, )F&1H4FW[)%K^8AL])SDV_QT)NQI#^Q^2'Q6-R/N25]\J&Z*_>O=>,
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M(BNTAO'Z_4+L.4>>'.8RA#!P\_ZT7]7;^3VR.O:(.?!F:<]@BT HBGU<M(I
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MA)'D2"H+U5 5!U.63.]#S@W)\=SUY1,DVZ\J1IO4J$*W0?$[.6]7F#ZLH%@
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M+3,DDMF-E,;:#PW?!.XA]E%C*]=PY5/AQ++ T/<@N(DQ/2\D_?P$8:O([K,
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M-3S.'.&MKZ<?_.79,F_;4T?%ZO_]:LL]S5>R9K[7H/Y6A15,4^N1"^UL$0O
M;42 =L\MZH1X1<G$X1&-^V+-8MUU_5T>@:O%N=_B&FOE:K3<9@M*N1HDCE_0
M--*16^6]*ONL;,/R/)$YY]'-/3D6T^FJ %3&[;40#%^;GQ83W;!5J*WEG][]
M_9>;'G^X/M!.S_<E*"E2,T MX"4]GK9&2)<4J:P67$CHB8VOE0L,SKA65;Y>
M?$<_3D\B&$&."K[[-2XEL>=$1M>-0%05^.6=A)X31,5ED<$K"D=_FSRGQ]Z]
MN(Q/"O*T^N@IG2]\:QOQ,^\(=7HHR)C*&5::1#M-SU2WH;_I@58M-39A\P]2
M<J^H=Y:.DX=:DS\9).O'R3U9R\DIY:(D"3V/*$DSO6;]@>CG]>Q:5-N$P=>+
M&YY?A"Z<P+T]H1YXI__$(6_G&#\]9?"]X3D29[M:=E(TZ7;17#L_-A=!SU8'
M!?#N:]/DMV$HQ3J=9YZ_:#W/A<>:O$0B2WYB1$1]1.7OJ";YDBU=+4U/ZW*+
ML6&R^T!:70\GSSK4U40(EO> N4UF0G^26("H98VN@^<X8W"#P=[>TF]N(RH)
M,6:G[.O& J0SE9$*]*:F7N"[3K-YMT7#VENC=&FY4G'SBQX_'J[Z?5@Y9?!Z
M>$>5H^B:.%&?Y'&0@ &UFP1!'PB]RZ \#3!H6BG#G)O;E@@V9@'$QR_5@6@!
M])<=\R2%T9A8Q=-^"J;'W7A-HU,NT]QA$@FGS^]#WG:R %;A;@=%(\0P%8V(
M<HVB;34W?$A(]$.OO^;VS&I8 +U<NMJ3SQ]8@'ML](LA45<:SSGE+->*">I1
MEQ[\7[2$TUNJJK'R.98UT< ]'(-_DI&UU.M"'R2N:BC#J-?PA,9L;CJ)ABOY
MS;2%]N-F([>5VW>UP7.O_/O.^;X0O1!&#9%\\9C(IZ4>:%XK9\0?/ &;3&)>
MTM#]JU+*[6Q8NK7'+/;/)0\.DXAES-U0$O,;!]P:E0K;#MA+I?^2S^Q MMS2
MF'PR$:DS.)T>K#N>KISN;J/$;F/ 7Z!"W+XC91BM)=@V5@:YP;X2AHPVLDLU
MZ'@U2"H$2I#R0]%PLR_.T%(6H(4%L%_/;5]N^Z'VX$\X(R"](/B^)V.LEJJ.
MG\!C I:\FZP<W>EGW;R]!#L:14*Y1:2DS]>:XH9,,\'9G*U_S8]:$G2NU.W'
MU<X-OLTP5&V\S +T-M'R0FV93A=MIR=0O)CG)K.-Q@%SBE/D+O_CZ#P\T<JH
M,08[-]\9EN_AV.@2JQ(^KXP"_S[OEXH/&(RBES*_[?0I.=K>FM56UUQ4O@H7
M1<T\1/7ZS)I#_'<[-W YM#.3L5@!LD=\R]F^5;T;*5?U)BZ+:L**X=YY)';W
M#EW-ES=. L:L!53BB]G9:)6# 2W.))@$:9N;S+4".@3&6T4R"[%D^49E5,[^
MF@#9&XGTIO)@UYK3E-C L]>O'[<+>'[A[9NUI7!U;*!YM^#/7*$3B[BSF6D+
M$)ZRX-$6[5X R.L3T\;=>^[ @3J?OMT*)):M)S@[AA]XQK!SG*TZ^-.<XY]E
M*SQ[>UX*C(][$AT6MGJ]=+C%J:1^;XF.A]R@Y]!@4RS T>">R#J7ILTYAB']
M*\%/)=%I8':+=VTBW.'5L_ K/ ^&$/%O) 8EPE\=PPQ-$,?M.=8.E+4H]X_R
MB,=QET,EA-0L>O]4@19?L3.$_ ]QK1?#,F#-FKC&TG=,#RCG//-9++V<ER'=
M389J:NJF"@C!#VJSGX*^9\QW.@]9/UI[O'3A+K-N7M  >90=*B,=']W)AV8W
MP7",#6>&B*XX&0K].VA7SO^GD\&A:6GQ@RH>F@)0+[:V4:40HO%[5\2,1&-3
M'6KVG?2J+E92NW"+KZO"BZYG07ZR^Q449"KP+FZS=;9SZM?ZNE:[1;D\$[CM
MF[RA'\1U.2V(E+W#ABN"*D/38>V$A:6)YM,#=E>Q=89TVI&'[/ZM+(!.DVBB
M[R/)AYFW[\K)FYC-%>1_,NNQ2>'V4.2M6,*;X<T_G-SYTPBI%Z$^/;!58"!/
M"X4AS/)OW). (_>E>)4JZ0?BMU<"4O$C7I#_T^W?_T\&WLR 5G7H*:#9EMWI
M-B9BKQSQC2)AH\ [QT#NA0S5_::@BM0"[^=^LOJ3T(['>J\F=RC/B._@TR>@
MD11JGSP4U4@8PP&IAW[]VI\R_K@?T05^P%0+-2#1;E-H<Z<.OGI(7++WA>K1
M_*.CM9O,@U6UU:4?:R.3?EWT46 A_Y]:XILOI^19@&Q?FL5&*(GF]Z/7VFI+
MZ\.\#Q,IM)%0F\-LFUOY^#T$PO:MY3CRMP^#RXJQ-GZ]T&L7K6?A) 2=7LO9
MC\0S[F"9HX3QU B.'6?E(>YR#NN6)(+Q?DLN/#CMHB=(IW5%X4%_<,<,T.U/
M'U-/* ':@FP*9 &6U50,&P++#? K;NE6C-V##36BC'IXH31/87E^!/70HEAY
M,U%L4V6B^]"=L^GV=NI5%J A:'?9(<G=-3C*( TBCG-0S,M/"\I-D M)#H>G
M_31LX,(#%N"W,EA5<5?]<'E3#DP0,;+V4?9J_QU!GQUH+?1[B!-:/5-LWXL"
M+:*D3^W_8]/B>DT6X"]GZ,BA&!^8NK4S4/,K:IC#PS'ZC5L/^U?]-N0G[4C^
MB<QA(@MP_^#DYB5E%;QJHP-59W#JOUH*W/_>2@SU'S4X<8U>?PJ(1OZKN04>
M;2P CQJ:!8B(6&8!)O@Q;E04L1&L=)Z*V L>@#'/TT2S)IA.K4?7X(Y'O ZL
M/(\>"M>Z08/4(P9\09 3W_+%G*%$XWB V=-)?$^+I_=]9 &RQ%P(ASYX_5"\
MQZ5FW+B@SBP 8,43+_HE$L\":/BAN(SX2KQVSK0SH$5 $O@Y#SU8J8$%D*$I
M#PE40;/LMC^-,:)'0S0/Y5B$B&VLH^*G#M+=IJN73K9<X:Z?D#9T=>5?P%[\
M7CL $V:7."EQK&'P*H/@[)#/D]6P#%N=IX!JH?W#]5 YT&+OB%VOPYQT&Y']
M %DX 1=NRG69X\QKN3%K6ZZ?"0ENB?N[-/IR$82:[C4C*3C]Y8O9U^(WN>]*
MSYT7?)]1[7@H2Z6,N,R@&DZ]WT*W,?GJ$$CX1_)J.2C)CIQ!,\:#;KP"_7*B
M59HZ2K3H;2"M43H[BII<_:8U@WIV-9TO7B7%0J>QL]?OO[0GV=XZL ';6/]\
M]AK13'H&^XGD(Z\4^2)"WQG3PN!+<VA<:?V&S"<[=N9C3Z$5IL7GS:3;[J#N
ML[_7B+L52%YK/Z*'SF[3,5WVHZ(OE@N]!2\%\>N'Z'7U7I:^H#T<IC-F$YM3
M)^0[8^E;Y=+W3O:2?'L0;9]&*9IJQ1^JYE869LEE$,0;+.\[>X#)A3BA1VHF
M/[(]]_AN" Z>NQX"%):6<S[K'Z>4=K)8(M=R/H[_S3%G$^ZHZ72A!E*.*%@/
M7OUUU:B5-J?NP+"%KE-0\[_W7$OMA^[F*K(QH%2AGYQM.XQ+D@Z"H73(2XJ.
M\:X771+FX!<9\OC9=K-'^J\= P/(V 2Y0Y#'$G&^NGB5-+K:]8+1D%N*,(GY
M>2KUC,G-OP\NW:<\ A<AR,OJ!B"16P=:P8*HF:=JXL-J?A7,<[M(._=^1$53
MFN?X5#H_7*'V)A?>LK&4LU9\96W9/MG[^['V^0WQ]-CK/5<53_VE<KI!NN.)
M,5?KT<A>FB]C L+^"GQF*.MREAA9C1.T1$.2X<*HSR"R/7XRF=M V[P)<B7T
M463E;%==0T'Q%#ZK:.GRIU$;>L*0)F;@S?'%)7P=G&W^T/F]@KJV]5IP[<R,
M]-K]VBRO$_N)F"=MFWE%JH%&)D^;PL>;0ZH#XMP*ZPI4G@_7\2/OG#WK5QYJ
M>9_BOD>SS,R'Z$PT7$N9+C_94A"L)S\/\BH<&\3!?L9PB?71OY?JP>#D93$6
MX-TX77LOWX+^=3_16W,D##QZA_!IV.8]"#(? ,%U;JRLK58V%*"ES^:L[KA\
MS>[,<7CPC<]F (9+#I _]OF4><&T<?;O^#=+:!@0(^@V1O^VZ[BVUTL&,KE$
M!N$7?>XL-YHC6B3H#1-X'IA HL+0D!_#R33^ZSB-0SOIH'ZYI,2%YZGT6YU'
M=Q6I]F(O;_5K,,+SPG>ZAMO/'X!3]YN5:S;W'D2B0; #^#0JD#KEY4!IV2:J
MS4SQE5=,C1D0ZJX'O*M\ZAV8X?!X.C_JVXJ>Q$)1@MEK@6'Y"%XLU%F)[P72
MLOU8X$N@%[QXQ:#YQ14-X8\_+N,B4POO5]-N^B&L?9%T"9U%#E-?BK3\^>&#
M4["%"$Y'>]D$'4$AQ4B^U$[GSDX=V;:XY+SP![4]1[WR&3(?ISMU.AZ!XM<\
M[G6V.-RB7(/"<S1IVOIL= EY6A(\VQD"AE9@/^52RV:&A>!W"0MJLF<:?59Y
MZ9)8KVWI4C8F=\/6T6Z/\V;T6Y;IT=OLCD_*T'3NR#KS QE*:&-0''@4NK21
M. E%R@*O0V=L,\MJF8\\+MD2?_IU0%@ 0\08?D[PVA[5MG0\7K?6=3#*0+;W
MTLF+B%.!"28W?J0_VBW.V\KY!BF 8PIVG-63 "1*/O1G\)AP4\MQJ+@>"Y!I
MHT(V;XBTH,#Z>EP%$9]7,ZQM&L"#R7<^UF4&WIX8"I1PJ7STHNJ5V5%]">%$
MM%'>P&LN5ZHE,I4S;1IZ9?"C\%W9R7;S0YP028\L.;YN)\,X'E8UW)"XYV17
MC&(*7VS^\H/QX4!'7Z:#.8QJ#3[&-/0EV.RBZ)($%PK*U2/&<6O4C]+L4R])
MS9KNK+L7U^A1B$,+WZOUS=[_&E>5)F[Q0/7*WT_@[N/6T2%&5Z;E1_)$_='\
M4%5*.I/[R$@ZL SZA4!N)UB==B).IC;L?ET?"SCNYCHK7M>-2'_AM7J"A#4Y
M!<+K3NO.-W'DENU=?DU)ZEP\9[=GX$*+*Y/[/*^@L+&MT,%%HN\_80'D)LOJ
MF/K0GX<BNL/;Q0_=!.O;5V8JQ>*M@#Z-.M&?+SGJJ-; />DFOQ>0%VP+1*I-
MUCZQ*]?7IIO=!!<Q/J\TF&7F[EE1E^AM5%\D"_#^@Z_8/8^S47OO)T+ #NZQ
MQ>.;^/3T4D,OUZ=%_L.&QAZS-QWKC8?2-.9,LC/%+;^4^>D.&[FO^>)-VY%_
ME<$6!J,_#$K$9 GYS5F;+*EY$+:Z^%KXZ/ILRRC^8$%W$-IC#D&C7IJ0?:G^
M8Z 6036@9M7R_?E73S6,$0O CA\:WGY1%/S0S\OFH#X@+*CDUHXIWPW]SQ)7
MKCS5/71M'>;FE2XGZN B>W]GK:,X%@9/DXQI+$ XXSZE@K>7L#!,_]8D,(M^
M3''JWFA<V:C<F\,FNBMG-4SL#.\(RO(H.HL;" IR[+X]?\RBX!>WN.D1Z>'Y
MD\EOP!X__.[\5<.TFUDIYE'33E;/O7T@I_ZK]D^NRHT!C^;J[RQ DET'#";Y
M;AW\,1WZO QLM!ZHHF<P5H?DMA8(YWP;P1_;0[F18-QM<!G=_,SLC<&QAQ6R
M[Y'5DN*A1J7DPYU!?PQJLUT/7#U0?:_, _VRV09>;-N.S%,N+ YP(F?LZ9 X
MA$<.T.PZ0YFIE4RPNT&LS=]<-;4W\&[\M6/?PA0,I/1*P05*+MPK9]Y\M'AX
M@W2WX$]N"0:-T(:!CCL>N X=7*]?265R#7_8"&N@5Z$2%Z=H@MJR80MOBTM;
MJ>]O?%EU)W<D_R2ZVR@8A<9*JIJ6Y3^3>G1Q-*)!JBB)1\3B%TR3>=XP(W'G
M,SP-/N^&D]DSQMHIT.,[6(#%3")P-RJV C2KUO2,\BXTE<X(]OJ(6LR%)I;1
M)5#3QBQ .6K3:90'K X[1*KB:XB0U7]3H#Q$QZ@__;4ZB@SRV M3]CRQE@H(
M0^Z]@9(.0>Y^",0%Y61R<>UX(C./!>C6G%252=7?"S/8W<A88WO_8!I.56<H
MK5$J7'!7O/8N/-A/9( (',$?]@3=X;9-2QLU) 8$M8DB0*!"DX>P"<NT110R
MCA8M"IB<BBY#E.P>8N[-W_T[C$=IE(PW[*M'6 "AH'T"4Y)8#(;AWJS%Y1_
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M3ROE&V@=4LA8&HMM6:BW:/O" B2#MU=4J8J[JJ 7#P0-9(,*Y8<NN%(XMEB
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M[O.&HL=AM^,/=.X3[:]=YK$>_'Z$_D-L>Y7  B2CR:_W2/2*1I4*Y4WNY*X
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M7-(;W9EJO4BKUY:=/QAU>P)A.H/P0^L(LDP9J7;!\./8ND+1A?=]F%SR0RQ
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MQPB$_,!A.9^J+60]#R X%Y_[@!>\?"L9F%!_+QE=H=* ;^!N?LK+U!IH;J$
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M.P=#3-@&^(:<L#RFGF"46)307MKT=U"/9L!V-??-<PK I;OH73+TF_RM$0I
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M=(OS']172G[[^?8_NCOET^A5B6B[\4E%8*0HPS]_7N,+R!C*IP,-SO?L::4
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M#SS1W0/VT3W8>USE*\'D\,>C2I-3+M9=(#O;TZ0*L$MOY[6;>=():L]O]9"
M,^S)N)>)T:8]!\C%W(FQ[ Z4.R_**_EC\!;3$IR=S+_[")I8^7J(X.=7O ,)
MA@Y6>7&;3ZCHJJBA2%WA/0X"+KSQO]=N&9$:^+X'UOS362LSDW1]>?4[=^M^
ME<F1WOG54.+C/F.?=,6@'%(S^5:0DTBXYN<SFLR32Z/?#RH=[4W69IH@F12
MA$QE@16!M367 @@WFXQGC?U1EKVCWF2L-#/ZKF_V=H^P''_ :FO2U.ZNA>7X
MGFU58RVX&=<7;1;^3O@;[=8QHV@EL@"G]K-0L]$DNW!95 KL ':JG*$V@*8
MS7?3Z*TI /[,J&2!*0G.<1;ZU8I7W$T2Y*O0D ]+A4A$6-K;>AVOB3/K4A4
M.LC1:;<#94<;XN#%HK+%V"DE'R5VT]R],,WI<4/&[UW]KJ?)*P<UX< ZNIB.
MWZFKITJ.L!!&?X4:7RIK'!L.[1]4 ^<$L50>W6MIXJE*$O@V*;+F>DME*_N'
M8AS5H[R9.?0K"]""0Z*>?H'^!]67.5^F 5.%P;H;ZGUR?<,]#%&2Y@_7,]J$
MR9^]N0B"Q)0G,=<?7 10V^-\E;(K]=>"'4L9H%D?A*'X:;B4<8C *76D;77E
MH] MYBVN_3/LG(YS)9Z# @!K=Z3M!C9/+PLN'?X#<CD)J3FTFW3[&"!F1%9?
MF=5H>!%BNO_ZI(<"^+:1"_(N+P[J OZ\*$/!1P,,F5]94D^ACK&M/B%^$L3V
ME:A4PPTB>,;7:XY@D>GIH[!,?^N(_,<'FN:P92U[DU46_/R//\%W/CVH'61V
M7-E-1 SL=G3OA51L&C-]F-R/J(XM1#U0'XE..;SI(>Z8O2)YDN>R\@Z["7G@
M(&!_/<BI_L?@U*GK041/,LW*5671+(A0$"IM_&T#KO19J'3:PT?T#>T7<IT'
MJ7N(W:\@LQUO>/CIH>34L6JU(.533HW^C(XAIS+<#L9;YD7PG5##[T^T5)7[
M0 D^)4&7[)2/>![-X:CD0E>\UEED)C^R-B-ND\0_C?$4KX3>'"?S9Z%%Y,T:
M( Y5 EVVRB\O/8R,^>P?OST08.85V;4)W'AP^*KV7+%L65P!C(@XJG=K:IRH
M>Y^X\$!ZSKITAVE'XTU\+#]!B8,V+$,NT-O*.M%[[1P>=LGQO359NGH%=W8,
M;7%\]WX?MR]N4,X,4Z6_'GW!&XHR1YR:SFH[&C34_,!;K$OU,D9-Y[7M/BO.
M[SZ)LP4D>BC(!W=/CVB##!MRHJYOY6#?JKS[Q7?-D6E;O]](;+$??A?]J[IT
M.TO;$&"K4CA+9H-YYWJ&>5BSAV9=6N?Y#&-/TU[[Y>%'^_FC*$=*S^OR"#+[
M"7"/?8L4D D[.+WM^/6.VRAYK@!-S'32DLOZ3R92_D]#<&?F9 <*AB^$MYI-
M[4PYV9]41*."7#]Z1E*+-,$5G1X$H5!6K*G(/<&>N&+1"5'1]]+RG/[>'DV6
MH4^S%5-C7M:32P4I /T2#2-;P"V-1 7?)>$!XXWA]A]=?C_*=IK.ABQP=*N+
M8B1N^>0A^832$7L!=7L7S @JWGHF7&5^9> ]SS\V,3!,Q/!'%4\C@V!UI6?:
M?8TK$..5X(0 $Q9[4WW:^&PQR;1()O97;F3(C\%W:_9*^)=.)Q0 O8UZMIS,
M"5CX '80F2[86?"UTU6= D"@-'M.@-OG/G4S%W[-C@.02X_,N8UQ,PU (1>I
M".]!43)KU'W@G )\>JOK[+#'Z--,9.D* 1IUG#<%1BQ(=QBS/;>;QT(7@SNN
MG$6F/=,NP1 TT.!ALW*)M,_H<,AU3Z8!MF*9MT%R<;LF2]@PEG&/XG@;G2FS
M5)KG%<QCTEN-$^KUIJM?.!H.F#\_OBQY4=G9<TJ_?Z[I"PZF8\M0@E6^UE\"
M'[T@FT'$<7!#3PK A (06&S+VO0GS.BVB#QI>P$1WE(WN<HU_WODV[PW=6\#
M[[:=HMPXYP<+%TVW#\VJYY[O'T.$4NFP=.N2C!2 +O70=.Z? XD-<9GUA,%]
M]=/$N?>+!;G;D*3T\4,W()V5%]<;B]5MV\V_QJ$4P&T?"*O>:^6?UCTV9JZ7
M4WT5O&QR"4!41CJ\2<B:SX6,2%3BKI=1*C\3,=N+'-Y37ZMO+OSH0&/@FAH;
ML%^V_6'3FO=3<RY2AI^*_?U[OKL!@L=L@^2HH9TM#7A^-Y3V2SG44KH"O+9&
M'!5//&+/)42G;PE5_Q[%.$6<GW@"#:8=RRI/?5K\06X.(_&1'4^N'+>K-RE%
ME2KX&#7**SU)2W!WQUFY60NZ70A6IC%)H3??J-:M[=9Z@C&;I7XA9"OH".UR
ML/)^!G$?N08;2[U;UDP!T*K%S7MS$WK#A@=$]"[=D]R^Z2_./0*)*>-?R<U]
M/X=5+LT3KH\R[.+Y2W_6OA@S(-)Q#03=QD.7S^"P4/_L6=+"(;JXQ:ZQ.;(T
M^YR[&I=_?V^!)":^(A-ITOC"]?KAH8YN?,1?VU"6*>GJQK6WL1Y73D.8$7A9
M_+&%C>C@+SK@[W8SW$H^[+.5KYNMQUOL/"O+Y&?R7\PCT/U'"=W;\U/[<EXJ
M\44Q53?NR^Y'OGIY 'L'&V5V\67Q+6^ G?BW24G%I=R5W]"H15*7*"R 1_@)
M:;OH&)+FX2L)8IE/37"K3*KEWF+OSOPCX(LB(% W>.?7K00;5_Y(ZZ?.):(L
M(L[VUY]ND!_)\DCS'"ZFU)M-X_Q*-R8[_5QV,Z-86DIK6#K6N=5WH2&H0Z\?
M2@]"Y]Q-IB-W2U2;5:+$V%ZN)3^?4WAU.2?J^;3=]\LX[N8&<# ),GS</&91
MSM%?F&^3&;5IL!LY,F,B7U-+2IP[1]E[!!OO#CYP-4KTV3>>O,9-_TKESC@+
MS5F\A]8J"X_6-#B&OF:U8>O-N&WG=DM'(O61[([PND$:05][HH5?,' ;!F/-
MG):AML.]78=BVQ8T6@YCW[B5?B\JL'GN7HPCJS*9Y6^B#3@GSE^TU=[OKLD\
M@982%]B57HS23$LN=:=)FHDBV>0NR4T?31,*CL7[,4+S: I@2"E/_/2MAP/=
M!M+*EQY\U,(:DAMVH\[@CUT2E):!?\).3WET)_JGSB>5*T-.RD)77U[+W#[9
M$IBFOU&0>W$'.FE9-*#]C6?FL'#H @0K47_&T++RUJHN=V"CRL0!TI2[(&8'
MCWG-W)I6I7Y+-NYP/=<ZSU#QHU#BI4F3+SB59J/\UHL:%GJR.3:EDB=Z)<VR
M%9JH5,)#QI7):SIEG85=PJ^@Z(&J5HV]/KF89"*ZAB68X$E<(FPP_=/U(W-I
MW_U4XIW621D+MCA[GKW$M=&'UP[U!/?KG9CS,&#N+YOB._GU01_V>,OKU[&R
M]+/$9H&$%%%SHD&OBRGS7YO)CI, <N5N>^G.PKD)C'S9EZJR0?A3@Z0^!7#W
MG*JYB&,@'O#%';%ZOV/"*':W>6L][;B$Q>)*X*KRTA8%P#CI0^PBF]<!664*
M*]J?N%._PDD,:Z2PAC5L2T3*9/N<BL!FXXS<G)3[1.=3IUWU[\!0,S53UW.5
MXP.-K/G4<.)0A,:)?_P%UF:J<#87E7$%3</H3_S;@[)R/U  (GM_+V#X<7/8
MBO#1';Q%"MZM&:1DY>H+7=EWP&2,Y>PYA#5*7/YAB8KW#M6XJK>(O'KG,=?]
M!"M7]CO?)R"-J%9H,,D8/(E@%6'L'XB:H -_(&4.6TT7D9*)(P$J5C(M'3Y!
M?Z%8T@)8\ #,Z,;(8K1*;6XE V$=FXAQE+19+RF;;>%+:?Y& 7B+Z%R>FU#D
M-7/G,0A4BL:+YP0(C/^\<'O8C^13!Q_D>3?6"A[H:]>II)/U,>DB(I^A=@B?
M-:'/'7]LM6%F4D5HGZ[+M!2X>F<'+QKI,U:[%@15S7_'*FDW>GXXGPMZ.5#0
MSO!P^TX49\9@(7C[:.NUA/3;#+9/<62_  ]D_*7MWYX!QW-RP74XA)E]:X.,
M"^86"8[KP\VRA(:"Q3C?,OF,MOE?>YU=F_7Y3J"V68  /=N0I4KYV?O:Z:%I
M@GLK#AWN,VTL!CO$(2*FFS<P% #SR5X;)N._?(_@_XC!.9A\990"*+\(3US)
M=,@Y=&#,-S.89)J;73ESGG6AVO[_.K3L?S&4U)+=TNF;R0H7RF<_J4VNZJGM
M BEVVZW%4YU+*$FGS41#:TK+4:+O9>GV><B'G!C)EU=B!*3.RE%IU,5(+")3
MQ2KLN!.X783 2PL GS<SD5EK"69^BAAAF,JT;X\_)K0#!A1JAG[$[?8(UGF)
MJUV"B39%A#2QB4<)BIF)JST2B[]A6B 3=NW:/R[VQTYKY$I\>^J=G8CB'7(_
M5SQ6"O3^>+/A>*,O<FNW_0Q/=H;T'RUM=+:E5\%_L\MA^9M]]3)M3Z^Z1SD@
M#(P>3,V0VFYJIWU7<(4'"^L%80QT[M[1&O[HXBSJ7(A!8O[-4_<?_ XO,C"Z
M?Y_QGH.=$F=\:IU2?'TZUI!*?B3\]P443>X*%#'X.U$4I;0>;.YYGR'68;44
MS@E.1<K*Y]H+&%G6&NJGH*X"OMSY>AERXP V8[>Q8QIG/&;X3$PT&^"M#=[.
MVC&M7)?' @FYF:O(#A#($]TS$C3M*U'9[%6"*_0@#G03OW3OD;*;Q -00Q]M
MGC4)M?>.$5SK'YA,\_3NZ,?EJ7Y/BM<?M8[ZT_Z>2 $@">;$YK<5HK85*I)'
MU,AUV<U;U*BI/ZGLU3)JME8!?!Z6(BM]V 4Y_^8S)CO]?3*Y8*&.V<^R=Q 3
MSJ%.Q\[Y->95?&79P/<P+82G$T]S?=IEWU_E_)MR/D;W<K7%H'?-'B!1Y$O3
MPA%H7CZR/,YK:+%PWE^LR2<5?&C6X&SB 5)RWC,.V#7I46I^+IC0N\'#]'#-
M!D0!W#^ S]4GQT_WYX7YVKX^\ <AW[*/KZU%ID40/]RR,R2VT5<BD7*W*8 -
MA;&.I[ZOF YDJL@2[GIJ[:=,O<AUJND+1/>R@F",)^_3%112U3I+-7[MT8ZR
M*& 8D@VDN:5' 6BI,#V;6XS/UR@<G@!BW?LV;E-ST,!D?2B S*S2580#!2 !
M3$M7:0]X<4*-Q<Z#;WS<OVD1T+F;&6MRBJ6ZE9PWUV+FU1TGE>PB^>BZSV[[
MQ\.MQ^&(ITD#$SV:>OH98[1./:\@(D?GU!MC5M&+P>] 7RZMX>X2G%EY M0H
M +ZVHQH?J[]T&+()(:(^D*! K'I^G&2:U.OIE^OTR6MQ?GX&OP4WG?VM?CO$
M9;(E77\O_+NN-I+O&LWNTL^]3BB6B)\FP62/5ZNN?=O^:W>$+8PB!]1MP> M
MOH1!O^[MM,H^TV;\9?1E+XB5V=L_>\"X]&0L+6W;H9$P4XQ"_M#D;@IKQSTI
MORE#BYMU#-__*=.<O-I3/GQ;V!_L1(^%?CM12%'AO5]"^,(+6=4@2(.QIT)J
MRUZ.?JQX.=VJ<QGX@4EOE1?8H L+\=PW]O?7D8H,1XVDEDAM&P:RJ7''#)L5
MI33J7/\#B+[BH^QDC3[QT;U^1Y?L!Q:&],/@V7;K>T,+"\4'R+5@0WO9>T:Q
M_I[TB/;UF181![.-PW:(8'+7I/9H#TOYL;3T<[CT3R+08JJI,6A7CGDAY?6-
MSLKT9R*3TL1BO '6J1H<O?'+*4P&7')DL$C>,40'C>]'UN4,CG(J,)V]0)KQ
MN^7/3(1J$_F27[J^Y !E.^?Y@@\U)K<>'SS-\*Y\/?CEB6VH&>C].-GL3P_Y
M@@T 9<*: RR@W(O(;4RB08LG4U\%:8]U;8&E ,;_#]#ISYY#-NLU\!/CV/HT
MP4\MUYCT^.YW5CUIL2OQ;Z0 KH-7MPMH;"M XXB;S\]]\GY7X%DN%,:AW,DT
MJI0 .DX<H@"22(DH_[;&ZH[AH!:9($<G=7@B L?H^,\;Q>6A\?412R.@=F!6
MB2Z9Y29?655IT*,O7SMZ>WDT4.22 *NCK13^VUU%<CR75F#2Q**K<O3_G.I
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M]$]C<-46U_UD^Z/0'IQ,'RU1V0P:VCB2&,';R,9JUL=1X^DP(BO.5;5%P"M
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M@BZ_FI%0,-B"-+_/5&N^_V-4W\:6NGI[A \O\KM,7/C^,6_$"JC;/_)KS"'
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MD@$>#0QUB_*Z=T6YH_X-YY=F&T'7\;.[1=LM&M?,N4XL1]U]6W+A[=XEQ))
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MQU:7.1PGSY)?CL:?WK;D@;S%<PORYN+.R;ZM4]"9!85R9N B<Z-L?7WD&QK
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M&N+7Z2B__UCU!2^E7_'R3\W\J_>=UM/_-[7[)%!8I0%*(,W89;C])MUTWC3
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M/(O3D:#QB^K+:>DC@JOBBYR$E2X7&D 03F>LH]9487).^EQ'?Z*W3LE&GG%
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M\/#<])"Y*;GE>J;I2K"NP+Z,L^CRMQ'719FZN=AZ--;O,5XO./%DJ&0SX$3
MXU1X*@_UM<DE+EWVE0+3**P )!&.PH92]%:T2OPEW5'ND'-W/8@XIK"RP2!.
M@QW[CN9,7! HNZNY1W<4GG4QAW5T0&IMS3([;W2V>_E1_-9=ZO**P%B6**4(
MDZ8F:[=[.2RVJCG =\G+QGRU\O/&R^206GVRX,)P!$%HA;M0AI.<@3MSJ-'T
M&9*+5.S5LUZB3PZD 2X[)Y0[]O4JY$2>L Q-<N?@.5/'SB$1J-,E%,41H2VZ
MD_<^?F;F>E&$T&&.E\;*LHU)!A>Y:KR<X)?;WE)-*<X5R)%KICP2Z]7EM:H=
MYF4P%%<)87_HX,6V^9R&.YE-4^5'2Z$/FRQ4N*423(Y4/#UXHN,GQMZ[K;A&
MLUMWPS\PVPJ@WG<%0LXE*'L8O76.L'"^$;WU"3] 2D5XW*832KA''NI//H:,
M/W3'%XC#)O8GWP?MEKF G^P>] N*_& TR5(]:)R(*#<+?'E[_\7;$3#VI_5R
MNKKZ==$&ULVE<8:2FS8.)1H#M2_TB=XTP(-H3E'1]R[/BA13,8_LY+G2HO ,
M?9=&):Z2W0FP+L@NR//8^K# 33\RJOQ0FV,@1*B<;T9ZI#/Q*4;(H]:QH/R.
M>=K"?"_K^;5@#2[>D^%)IW4C&XZ(3MA<=SR:-'#N\-)"/F",$+*%Q&A45J'/
ME*.8_[@;)<6_G?5H=U<%-/;9M.><=% _MFUJ$M:VI\_&-P+'%;>ILC1685O%
M "-:C2$M5'KA%<48GXTY<57(R;04A*S@GL+&]F)8@A*;#G[ZG5OHU?OJ $8H
M>AQ<8R@(>W:LX)[R/I8+\MM/J[$<ZVII6@/Z<FUN8$ <D!&%?FK6_/#X_#DB
MBMZRGTO$\*JMPZQ%O$-;Q?HOD1G:QUQ[E@O90Y)8BA=M&MQ",S-?:$7K]\2(
M^(]>?G=:,5-6RNM)P#I7Q,)R4_GJF:A- +^ V@5FFQM3\YE^JE/#+57[W6&"
M9'Z]L6N89G=(HV X%"%I(OVZHM: [#6MZ!'*:-96;9C,F6S?8G@AZL.UL+G*
MG]Y67? W]JVVJ60<:#&X0NS3?.)\ -T"O6K4@^PY[@ 0$+W&;'W>VD9-L!B6
M/&5<5"WP4>\-]L&0SK)D-:E(NI=.;>MG=S#Z>Y3?Z5T_I9E^$F%W0;.S?4I@
M1T!$O4)$@D;*BE/([#N#9MM@=GUZPW6[4A0^L;XVO/K3]1./ )F1]Y]D::IQ
M)#%D )O:<NF]A_(2=ASZCI*XTC=^Z!WR6>(&-40"8JWE&S*TXG"44]#,PU]5
M"8*3YSIA>F$O>Q8X<END:'J:K?>>6#Y<XU7;]0A5?M_@U55RK1^_LJ)]CVG#
M@F'$EK;H!D8 Z(Q3RO1EM7$(=O^:G <>N"I$F#FT>E3R1*Q'V$ALN2VH&B6S
M-F=TD'G]I5OJCMZ5_4JW5VUVBGHA)P!V^@7)T>[:SF.JP%@5_\5(M="\V1X5
MSFY8?^XJGD# ZW"6DYME3,E#FUWD:,E#>9X4*Q7?U"%3<7%LPR(*;3XSX<ML
M.8]A8 YA]PT\ZI72K/D\9R3O@.8U]1Z"6^8]P$#::TWF798[7@A<!LN#5X=.
M5HQ>">1XQ!*9Y7TP-=/E^E&!FVOTUN)"<BCD!"C*1&T4UP)\C)2HU?2 >'O
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M3FZS['B&8T0W(V\7Q?+0Z@<QG?*GK_/+>RVS94BMAJM?0[Y 'JU6(XAYP-]
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M411ACQ/U#F24ADV+50S*<[([ZR+V2W=-%E?WG'[O#.,4K3OW]R?G$")5YTY
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M $ L;81"ODHTQA;2*4&(4$;D"?RR(#EZ)71KI#K^^)303!*@_LD7L5Q\[+<
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M[/:8_;O<7#)FI*-8KG,\F*9-XQ\?K;R ,@9(.%X#8AEV4_!D#?6I*J-6%WQ
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MKUA]MGWY_?"5B+.89MAML/5%U10HV81C82X"?PE]H;;U^Y3,UOH"AA #HM6
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M2+_ 0OG;SSY7>C%ZG%6%_^)":S.S3/6C67K"U"7TL\B2 $;E0V\%K[\,?<C
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MF[_SA,<?GOD;5/Z*_H(" AJXJ:HKC_MR_B]8^(M5_@(6<+[YV5AW'1OO?]R
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M&!H"VU+-9XD,CLN8L SVK%V+M@Z_86#J5M[+I3" /OD0! (0"('['P+M)$"
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M=\2WW_D[FD4M^L7,EZXVWLME'GVDRT^INU3C3?$N?[;;<A0$7E5NVMY;<IE
MKAI)?)(;?[1TO-%PDGBZ_.J#T1_-DWE6S)0PM&6H^K6--8TQ'@.#:DZA_2$
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MIC;,88^.]D[0DWCQI8U+M".8!#G=J_/5/]/:(%+K@*+1+@T?,H8(7240UT!
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MQ=BKN5?S_U?-WG3BV&E$L@M9@*:4"'$X%1# V*(4 KQ"=6(67%;",\Q4M_E
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M$CTN4=N==2)72E3!-6I5LMS<<:751.O11:U'2XEEM4C84JV?><?TE/D:OIW
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MWG\O$8#VD;3CM<1V(K*-L8AZ*T7-31Q4GP!I=*2N9#2Y:^_<S5T,BZEX=O5
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M_/^;8?<_5_/[[SI=R&>?[*)Y%;2G!4*[973B&J_C8/DW@;(CN D[?PG"P@D
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MT;7QSG7@J59S,.XK+-5M4%'TF=-JP&G\$$=\SX\,]."B%LH,R9[(5;P_4FC
MO:/$ALA9&X=8&/K7"QW?@R=]S[1TOX55%]TEF@+K+)\!ZXBPAS>WC#VM%^V#
M)1N0Y00\/0,/D%9E_MM/KXC:B5\P-(W/+5.RJ=*>;:/^C3IJ?UW\>[EGS=Z&
M,H9N.V(F_$FQU%?>$NB*9<C7IRBUUYS=U$O<QE6%!4,PI%IU&!Y*G;GQK5;4
M"H<-/1Q?/9$:3%YPV2]MG#.,:CJLUJ_''S!K1PUL2(]HKQ]I^L\=T\H*O[?;
MD55Z8.+7<W\64652_F']]L@WZ&'>/5^#_M!,->+4V/NN<6!,9-9-./QZ?BPQ
MZ#28<"RQ(?J.,6&.SL<_?:K1MT+$X_4-$N%D;TDK"(1XQ\8))%KTO.O5-"LP
MI4T(X0CCB0EN1I3<KFGB^RBLI%-V&P#ZYM?4,%KP&V ^,C6\)_4)B[DCB*G#
M9L)X03^E?A\*UG!?NM:>1Q[.-$Y5O/:UKGL]KWDH5W>8%D?:\(J=^YM>X8XI
M?/XUQ!8>RQ)IF1^9FUWM'&6:YO3(_H][O:')[9QJ^HDG-MU4P.6=/-<.,I#Q
MX>,?H9C+"R;<2H/U^J;&F6Y?5 )=>Z4XG0,! (.U^O)S8XH\SCY0M7:)=-D%
M/U]K6QN>GKQNL2IB$,>"!JK?N5WWQ*%*VIVK,IXI9H]UQ8L_T?SYL$=XV:A:
MBTP 1P ,CC[":\>QJ\"DH^(,O5L,/Z?,3Z5@=2L.7UE,C-88?I@-X>U4-'UN
M"?(-Z^R'D)5]B'FBD5QY7[\AH':>@N_M(1K,Q0G!'9V=>E"QX&'5P?@[X_S'
MNYT0S_-CZXN9T63BAE](2QC430%B]6KZ,C\&42EQ[NWX<.%5S$/4P_4NRZ-8
M02_W+8$*>3F513,8O"KQP^U'T>#T)Q#L:2X-U7(WIA3V;_S\^-_41.80<,78
MS;'&+Z#S@VZWU,;,3D&JN'9HJ6>ZO26D)[5?F/Y))T\67XW2JKBB):]JW.FG
M_ B7^0MZW^A;5XI27M9@.-FF,>;4!'8(ET*'PB\@8W3O2"94DN876<[P:UE9
M^27&F &C*=15JOB?ZJ(%.R\[3'W<YQ)JS[ PTNRM/X;VG[M^/<&_K[R1%$@;
M&_ :#(EUM\SL)0!*=WP:L;:X]ZC3^!HA=^%T:[ZKV(SRUAC86+XN<P-E]%%'
M'XWKK02W&:UO)$M$9LV3QK0;\O@8ZA.C45RH@;.LS!;(X1XL4]N4 " .)0 J
M#2]6"8 PS T8>,\E51GIXN=;-U((@"A^(^##*X4+,EU>7'7KWL+-T03 D;[/
M#9N[:1GUU@'/7QIC"VZ:5I%@!5^4=,UD*N@0\=49!7S"RK$B.BU5'L:D25GM
M32]@0C:20)(;U=F)SYGN3A!3P8_C W8VEX&V!   ;7J0 1*,6W)JLUN,IIPU
M8MC\P^%\16>[6U)G(!0_D4#C,!33J88<ZWB/D%-]J@7FD->-?L^D(!\M'E)[
M!2Y-,"OAAF:^O05:0_^S4_4BR9P%8TXU0 QGX&-GO(44>3B69B9S 'CK2"&[
MD?:'8&R[@V/\M%:YY<OVI9W" G2A 9,<'S_3C]?"##(1F:[:@[3ZZWK)U/YI
M<\WY<QO"WWOZ MC-E:\#U;^<$5^G[. DJW[>,@*]5B63T\4_'28 !"'K!WAF
M?"$!,!]IC-JW7WY^!<.>%Y)]O<[!$16##C,&RR++\!8@H7-_>7C/7G/8=/VG
M3Y]BFNP:X7[FN1FF")(P<3YA9GE=X]E$2Y-_WU(765Y.WL4P@:_Z;MU8&[>U
M'!Y8'GC6^-C-O749?/$+J=L1^;5?4U,;'-R!^QK),_A!H*J;Y ]O<S)44.!^
M#[!3O7"@=L)MYUZ@&Z[T[\=7I[+@3)>3Z0LP"M2/#R@F +"&9W5Z5K#$I,[T
M^="Y*Y\HNUV^8)2OJY_%1J^LTGU^IBFW1[*9^!?[?=41I ZL6I4T;I?4R@\C
MD,E%KA&)&V]E$![,NVPY9\%3X;$*Z6_ANVB#X36G!H])+-X%QN59.Q##-G/5
M;HU+G9?0M/EM9^GGN+0H)M[P3&]&.T<G+_4E90&7V MR)S/5(Q*/5T4FP=0@
MFXA0(T?V:R-_@.^L.>[K$ R4L83R-YR?)HNZODK=WQ\/*-^]'@VDH576$^6;
M*TFB>6=K][M/CF5&JD2G6EVP35/?ZF=;=%-T5Y0"BVTMPH(OGC9)&P2D_8DS
M-/H2"5ZFO^=UZY@ T!:7S)3 W\9-+LY:EXGHWO3=1N^1 5U-89U4@&<IXLJ:
M*@K]@*77;#L E0^UVRJ_B.WBLCMD44 <H>2L#)6+\\[H?JI7V/M:\2HS\ V&
M1W$!!:8*<IV%NI>!H&UW;BQZE[Y.EP#@;EV?G]+WGP_;51YJZ=]E2-!H/=M3
ML1"8@>WCNQ"YP4P*FE."$)UV-=80>;,QIBG$'W-'HV@53^9;RD6T/MH3XQBT
MZM^C%;&C8[0I>#V/ ' \O[@Y;7C_N/%5=O:93#T!\.=&;0PJW(Q/QC0IA@.;
MRRFH!<X8=;'7?3- C?=0NY%PA]_3BTQU\M*DY+UT$Z6HTN[N]<<1'2K1WNH(
M'?V<L&!]Q9>]:P)[-D0K0J"#3XO'!^#R$G!VV04E+*DD%I1"-+!V07>DXH,+
MS$<='DCURL;]W9-*J$5;Q:;&YO#^V1" U+A5D'-I0-XG4/21)ZR1/] 8S7W\
M^[IE')VG5Z0\"1\!@+'BML^:;H;C(2RIT/KBH!*6%G7,M/53MV=H &]R018N
M134]H?\KD<[>+;\M+YCS&9!(6UO!4'.&F-/9FT0_IF"'Y--5:JG-V#!7Q]_V
MW87U/9%-@6)Y><B1!*WN[NVO9.6ZN\-JGS%#K^YYX7J%I*B,+U1 N$%P4NM%
MU&41 >#Q!F;_I^RK\1X!L+E0($UQ%G7(&)-^AT20 &C+$$1(:@S\6("QLFDE
MW V4 ADZ(IA-'C!K*A;V!13^)3>[=5Y+ ,2"UT [6VB7(UP27ER\''2A1<7"
M?T2693^KFY&V]HV7Q<-)+7R^HIYA'\2N+>EQXT#0>V3<-[U#>F-VAG'>XB7.
MV"C,B2(L-9%=6!L7#4J(A,;&%OHQLE.,'5G9F49DB%GV?J+MS!%\\ND+3INX
MN-]!02U+CTB_^M7S8S((JS2L0+PN!M?Z%S8\V=[:=U#3T"Z(JV[AV=^5WIR=
M\-4U=6,<GTU;91=1IE44\'[<F 6EOX%B(@_M7!M[6ZZ\Z'[X2)OZ!\?B?WM#
M(@8IM^[G34>5IT:AR*!<2HSNMS.K2IQ ,2W;LP:;V%X<8F'V]?LTZP/23(R]
MVYY2]C=$PE%CL-_2SI:^N:5.!#31YKMF5L%2H%QSF&B'P'1;21")R76V"(-W
M?>:I]\FM X<H#,4;'-XWV/;4T]-$&G2^;]_8J'K97G4N#["PY329:W2I_6CY
M,*\PE),RSN*L!CKZ=OBADF6J(/$[C"RM%'U,/BHOND'=SE +YV<G>.3N<_\-
MZ.MGJB6BX6NM+8S?P<6C8P.80T;3C#&( $AC[_SD.%DX=XI=:(#O_=(!%;^(
M8_V1=V678EN4W;ZB0HTH^AO#".^VI4IQYZI,FG84>-=9LI=<P^'6*,(E6>#7
M;90=TS$._'IC(?,FAV$49VS@(OPKG _Z4]=1^QFCK,E)M\&G[;J%A2+A$YIO
MLU[ARHJ56I :E ^TY[>2673B:V8BGHX=IOZPNY6"MY0KA$X0;)E)JJT4W<>K
MHU_.AK7_?U"L;S('=%@ VVC$_24 $M=!W7[L[>(XG6Z4_Y^:*ZJKY[7VXH6D
M5QJA/:9H 74SD]S2/EF#+]W#^J2JSGH[%<=*G#^KQ3]\^L^4ZC*%3O_F<>/!
M2CM;4(HGCA/BN8+Y@S/BBG/%6?>1$ "J9CI^C7? "G))"YM.[O.RN87;DE[7
M-5I0!Y(A\JQ8)_?]NGL7[/^I&8H'+U(<I]LO2(DB(9Z9%I^@S<WU9\^]SI)L
M)LY^QJR+(+5%WH5*R,I%I?ZPD4V E^;""X)*D^[1QV-XMU-9K4CWFY&X_V;*
M/OL6;KIU;])XH(H H+RSH8"_*NF^:2Y$W?1L(6PV2IH=MCR(N8G1 #7T?UY3
M1\9_CX\(6QP_FL7# SKB$,N+5SYJ[>%*3/[E-0J#Z^$@P;\LXTMV\9&[(V$?
ML@?=[ND!S'S#*GH;TJ.-#=*6-4X67AQQ/=>'?IYX7E_B?@OR@?&K:I]$JG[
MD<C8M<#P#WCMU^VRTM15;<[C+=TSP2V)_XJ$&P,Y(!%P>K_]WVY3J_D!0VM%
MH:T=FNKUC#'/J;;6Z2U*\Z/D'3UXKQ4Z-SW''9X#CQ\O64<('?:QBH6>9YZQ
MG2_VULZWVGS3V5C0]4W#RBCR%N="*7GS*Q6'J,98V=5B+03"J))SO#8>21M&
M=37&F!,1DZI(>',5W$O&Q5-@X._.4+.S*JN@;H?KN03J7[7L$H$[Z</3OHEP
M#XAFOG(J;_//3/:SU_]4-'15/HP^T%("4WW<L:*%>E?G/.2?;FT<&MQ-^!/4
M5?<\;EOEQS;E0]8AJOM^'%]ZWBJ)\0V]94+O=>BCE#Q?<#"'K9M,%'[3[*IF
MT8((L4O[VPM6^(87O3DJ6\49,APKK.UOX2T:-\M?9!O5=WMT;0^9,F:TBAK%
M0#96AN[4C7'YO7=[W4>;AUQOC:5!X*KXM%4 2K]Z*<WFR'Z\"_[[F?M7YNGC
MBJ!V#_N(VM%/=8_^B'I;=)BM>#._Z)F.L2PVX7%C:U+$O8,7S>X!8QGL:P.,
M/4CEW7T3RWQQ0A?.S8TP/]DZB:<?1#I+@EG!2CK3EW-/!:C^S*QFL.?$VDB:
MZK-XY:7&1BP]EK4[(!Z78XU_47!0UH,E^T@ )"'J7!;W2NK>N%_+-]+1\+&,
M,CU;AX:JO) :4]>VJ\YW>3?"F8]WJ6^ 9D27SF>2-VXZ?FJ-KK=**Q25DKS
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M6OD9IVU;+WME;GA;9W\*29ZJ-N ?')%'5F)W7XR10?>1;/NF.LQ2+ "V>X)
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MM-Q?:DMHB?'1!BG"7RDR5LX6Y\?5:N)-'XR!^W*)KX,RJ\H 8E]P_X#EQ 1
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MH7Z?TP[><+[66K7L,7B>%MGXVMTF'QS/K5_(=@!Y.GA/F>/VV\4G)^TGT*#
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M.#.YHJQJ]C,_HZW.HZ3$5MF72?F2CQ/+;!H%T5839A 0BW\#$O8CR5G=[8)
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MJV!:1KFIPNS(6&"=G&!6C[4C9QGP=<Z.$,@^(25MF.:]VVT3R$JA#KUB)6N
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M@1C05:L?QZV,*C0PF2?'_$XMW/N/:Q*D0ODEI66C<CL+?5/1H::F,M+@&<6
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MON\$#E<?5_"WF6Z8&#6^\H KQ72.=VKPD24_Y[$>TV!O)7+1&TL^S[:&/A(
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M:ZF>2$\TW12=Q_&:8.4U%S9*RMKH NH170G7%@HZ7-JRD=R;XLF:03.N" *
MX3/U$>?%)/+[(N\D%)K0>LA&&?TC&(Z3 UM! /!!.G$M^&L[,=FE&-"\J?\L
MB+5-:U?U@9CC1&>=:-%2YPY;MVV.DU)\=[F[ROO>.LK=JL0Q^'+9<EB$/7,B
MJW#;^0'79W]SV><O?FC'?S'%<-#V9/]JY7O08#G%23]'I9U @R+B3 Q[5:M8
MDL_U7R)M2E^3,S0N=@H=)4%B+^W_?7X7MAQTMG2S-?=H]P;H?-_X*?&GXY")
M%C[\*5YA=^XA<IK";*_^=!?+!/-MA_ZV^6WSV^:O8S->,#]TBQ0D,8_1,"4
M@'Q-L6=+=7ZH2?,T<Q,B4BYO/EMV?Y9Z)D0,'X]:<[[LRE7\%<#P?W[$50DL
MDPGEB=G%%3;%VNV:S7W;"?JQ%30S8%W7K>+IVN[H]<-5HEQBE/Y]EW&"55['
M4MMQ*'=9RZ.F?CTU,MW1?J'B\YIWS9F<H1MK@YC^K(EW!,#[7JL#P_*FY]I"
M=(E+=P[GQY(5KQLNX_DHS#45Q*GZR1SG'9___'*8'$U$V)J<E51B3"V.C/F)
MI:MLNT*$:;Y& B#%_+6WGC[PULBDZBP5A@^65M'7?WSOT[,:&K[6V@-Q95RK
M-:7F$L64[HB^7D>-BA:U;MQ7/'+6)?S_Q-UZ_Z45[V[^_-B;VIVS$<UT5*=A
MZ9)X*DH J.%EX8$#FZJ]^$1\D#2)N0N>:1>&.)589R?.N#H"@ (]OTVD/,2Y
MN UK/T.?@H+.)^FIVQZ1UN#GYYN(T[<-@0/.@^J)6/S;Y+?);Y-_E(GQ1Y#T
M/1QHL!E/.0B$]IL5_!D\9K<WKW7D6!  ''*#&E1*H%$!#(7)R"GSNLU?A<'_
M3X+A(R(@T6#>H)C<O<._SJ]:[26"*X$L_H^P;]P89AO1=[N5MQOYD9!!*X_J
M1:>\B@XKAY[RWC&KY<[!:!5Y.M8R/[^6UR+/N12(Z J[BN,Q7XV9\8L21>.?
M2V^0+.?OLYN*;TM/U&8\2&!S7\X#;YSTCIKE;M*^]!3ZF#,>.-%$YCVXC[<!
M[GW>S0'V(ZLD*;$!UD&D.%,,\PS"?)G?K=[_AO,J3Q6-[//$#MOE=@L4(N16
MG74_O\OQ++6$MN7^$#FE:CIOYF"EUK,YY*P;Y#<D_L44P3<[8LW4W\^-Y]:/
M$  [W<?,4WB2/T'Q)T]Z$HW.&0=60Q8=<@;%JQ$ T:=BZR*Y7KM73\UQF00
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M7WGF6DY*](4&Y^=*8L6W@JHPH<$;NZM6N!H"()5_:=>U=$!O6[H5T5 1BJR
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M.0T+RH/=O':"79NFF7YHX"DK<4.@5*B&]_Q ZP**=;$8=7/N\.QY0]WQ GA
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M+@]<E,-4_R71QH'[7E?M]*9#)!%'FC5^%^?_5OR74HRTXZF4" "W!J(_62,
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MYOF!G%X1"J\3W.P_O2IKM+9--*AX"O'T%.7NC/5?;HFTMNA.8(F3)=?;!
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MLNU=>Y8%RZ#<5=5*#8[5B\_S821%3/\L5_)%^M3_(\&K?PK^MU7K'F8F('"
MRV SA@K^D\4DDM5^6R%1$J!.9B69"?:E['K4RO&WXPRDW.;$&[^F^^)$4!S
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M3+FW%>>JPFFED_CM651&8&#("% NIBB,#\]?4_ZM>4_>.3)LJ");S^D>54B
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M"&[$[[#>]LDFQH\ZM.*>-7'GQZQ,W^=*[QZ0RK\077,C98P"[_QG5ZFF['$
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M;FAT$_A$(\#]B(W!N23]C.(,+2 ^;GOF Y]10U@9"A"U2S*# N +N4%%GF3
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MY/W&'[H[\3\9/8ZRLAB-Z$5*4J^2@A)VDP 0R%M),$B-I;>1L!CR7@:M@1
M2+3_ZVI-K9EYS1X].5$!K12U?DTEH#+;)'7"1'ZB/%Q!1TX#JY817Q+]+\4P
M_G!UI>;D4PXBK=EQ$C$!40U5=771(,;WX:0>'B8DZEJ$"B\ 7']ED>TP!X&?
MV5B71!9D%K!LEY8%2;()*SYA*"QG&QJ11"-\)O07"74LFS3>I1^:!&;T:TJ&
M);+4SVB9?0YA_>04':4Q]NO=1+VLUEL-:58Z]8?;EAK]6P^J3U>G*F;LK)>7
M>H]8E6^7%RFD%,>PC04Q>_;,1K!&JGT-)"_4OU'N7&A/^/=@/6($!TC '%>\
MI"LRIYOY2J+7RA(L7U)VRX0G%/3*^/0Z/M2/S:T<HOM7KRUQY(C@Q%6.6O 2
MZU9^$L[4'PM58M*AP1'%__Y<M$&9G<-9-A+3P@(+@Q'Z8(SR6\[U1J>YQTG<
M[<TK;.4%L:"284M6*S-6SO-6!7-MEGE!P;J[OTQP9Q8+GNSGN.:88!9X:+Y%
M%E%"&'WXALWT^/-6[3KTOA78@^/L+OS''!/(=-:  %W5C'*GK3[ID@?%C8T?
MGT!-[A0..MNZ1.1*W/MI3;RY!O-_./CB>G\0!Y[<)N')T8B>>V:.4,VMN_"$
M[Q>_(LQ<2X/[@&T0?"@ 9CL"L1+ */[NRF(<Z6%X-7LKW0J!-$%4;2X<Z' Z
MF8J@NBL]DSJ;9>[W[!J7H*?LFI_+;=:*PGLEE0GDM0;16*T6X#YY<L@OEDA3
M%."J.S<A%[&^FGO?_%>FK=.#R!3WX[N;]F?TS4,:=Q-T.3I.W!UUQ]U[Z#2<
MY=+X#+8RP+P^RGHK1N=\BBV 6&UZ8*P*:VZ<U$[-FM6I6Y1&T6@E=-ARPSOM
M==JO#+3_"MGDM >1"J;:',28<XF'9HBFD*0T82H1VSH)B":2O"=[\?$O3P#[
M(VV,1H,[48#T-(.C\8IY.A&(=)$@Z?H^M@4L=WV%""?&+ZP#S&);4<]7?32R
MMD#55=1W9*,?R6'H^P8^HZ3"\F*V<4:T(>+!LPJKSQ!*P0CENY N2G?TWSO*
M^2=0NI_=8V%KCN_=KQ0N.E  U^;F93<,L]X6=M8_9U[A'[4:K=\/X9C]H+"A
MS#VVZ3"I=@0=-;<C"M/[[8_#C#A<$; 84CJ,X.NIE:7H"2,FC62W\\;T\:J4
MS(*2 FNL(C5)+!%(PU.@1E^@V$,G*@3$C[_2CD((HP#<+*ZTCI" 6!&5:CHQ
M>;!C4TUJB3?5:X]'X@.*?I@^ \W1X!0VL87V%KP';[':O9N^+4224-Z;W@T(
M5ANLR0VV=J?=VDFD^00P+RFT"=]M+90:T+5:ETP\(VK(XKE3LZL"2@E\IYR4
M*#(=0P$V_IH%F@/^-^HG,1B>I0[/>#!AGU]<\!/9'P3T1[L3_(X?&,"=._I(
M@[L>R_MV2ETNM+]7XB+V/;51HM(6O0-_7B#>Y146%8(%HT@(6UK+R]/8+^8%
M!N+1E!ZTLWR9XH!&EJ#E\F(5#V/(/NP$!2!0"EI1K:^GJ$IHL6[!U2%J9Q@=
MUI1<JUZ=F9*3%M?/R:<L9H&SV( @,+!(N1DEJ,$?_)YE64DV?U' AH^)1=>Y
M!$]!0\Y9,6F%"/UKWJRT#AW98SE*XXLT"\>NH4'W(SZ<]GT/<2J3!;/V0?-+
M';.IXS(A97]VFJ"#G,,!N_N:Q#$9T:;Z.1V+WSV_7)9($KW(^@7$9%1A9K3M
MB3\GZ4>>I&(ILK<:][_+_$6?NJZQK![KB:^L+&.:D*I(:+U, <;!B& !5MGJ
M3RE,EA+*9^EEPPTJJDZ]_*JZ??@HNKRW'7P+#L7[8)XYPY/K.]9U69H\72<0
M.7QG'NUHBNKA3>N",AW^I\A>#"#U6)48N^!H1UUB]>_X#T?2M0!V17R-=AOY
M&EPL/SD5D0;6%TU:\GVSTX&MZHK317>MK @W+G>58S@%<F[9@#2MMD6;[WEJ
MT;4U^GKA,K2D%%--TT?+_5N&5;\R\<^Y*86,TGZ3>:_\5-;E-R\]B^3DX4"X
MXB1;GCO@7LRM#J-U_&/0L^H$(U'<[(11A8*2Y+@OI41,GMX_W<@DDV$BEC2-
M&@V-D&UFVIO<SDM9?6I_9#6,0O'ZDL[U(":CZ<2S(7GTY]3G>I!G),)IVJ*@
MLJ#BP:MSN>.K<II?:D5(-WZV.<W^Q);YEG&W-5+@B28 $T,E3W+81&'R@SDK
M##'_)E&924:-S<G*;:_L[:RRZ^QX4DS%*@KPDEU0\ J>G5;+ Z$C.HVB"NZK
M\=QP>0NS%TV/BT.XXFCO%P^+RX+9*&%'4DWE1:-:O41*V(2BR;-U?2U?L*\H
M:;*E(@)I7W*@9VF/AI;GFUAKB+;B-I&?O/K9'_A8$4=.K0\C7*#'-#(A5R5F
ML*^C2]H5="XR(Z361)5;)SCXX9+T@IZXA$&@39!VD:0_/T;CC3ZP)$@J,C*O
M\T?4K<"R[C!M\_4WV4-D>E\*"H"A5#GLANU9JRUAK?XI1J=!)>7BGXGM_ OX
M[P[\GV9D_03"LA;>UE[*N+LZ_MX<7K!5-&I_QA0:8HGF!]OU4PFW \R4ZAF:
M<>.8DX@!8X3!T;&R$$Y#G:3AN4G#^.H<Q<SV]@SL&H81A[$Q_R(4H,,/@W9E
M-Z?@\=_('YKS^<,MYF+N; \,YSK^@%JK>J7U#'!7Y8V+X(D$);:+6'I+X=8V
MA5)4^J'M!J/%(XU5;TI5\FMD7?\M57!..D"HNK=_T_MJ_?B'W,2O/\!5"9]M
MQ_.CBR$'LB\L.^V3)@,>.M8+P,S(2$_MS K;=2KTXL5"X#;+VN?;O#C04:!J
M8  3B_\;7TND"1TY3X8]9%$/!=C42SR$':MK3.EHRL2-7LCN_C"[0@&TY-#.
ML?=F=<>,X(=Z%B'D<H+H9O-G19%=^W#VYL$S/$1A]"(*\*1+]8I.^OS3PG7O
MF6.M/S_(U,X>TM;"Z6%R<).;6B$M5W^6H6=CQ?!]$@U1F2J,G<.HV2_(R38G
M^S!/>Y&J/ICD&'F?O3H['? C\(I[2-1([[)D< ^Y?#A;LUCO4-6;6?KM,"=E
MR8O\LHIPX_-SN89]'HU9S$1!!8UZ<'%!($,&'=RG(OQZ9D5,TN!D=%W9+".V
M;L]:R.C=><[:#]!'GQ^17YS.(84.ZS96SEJO@9,TFM,:TOQNY_V%LR<%.0I_
MN4BMQ)@$<@B*)'E@;5%X)Z,H@-^Q\E\+NLM-9J:WL-<^.W-H:F(JA8T-&&RN
MRQ#[AKAAF*$.*_R!$#,"'OV-$$O2NOK-7+X:/J#F'CR:WP/'SHLPNW -CLT!
M>Q9;Q[0MJA.M:A'4$\QD24455?V:9IG9>];KU<6)!4R>IF4AL+].H-#(/6W9
MK[J?"QAW14P<'$T<XUR<4OEJ7FR?#HT=X8ZONIVW1C#GNO[V,6 \]^P0>UPB
M\N3+(&6A:MS@##K^S$"5NIBA70HPA78?CA8PSHQP"."V[^T0CELOU;CCNCY6
M.J-#1%YQ'0[J7%&"Q$5<M@2K%_HYLL*:?*2TRE]QK^GN8844#\YI]3,)'U%/
ML)9$^D1:/S"^1<NB=L<:?U$0GOZYD::Q"53,=A;*]ZBV606=F?>^6<1^IEA
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M_3Q<Z=CSBVH2WC;]57Y8$$=4OV,\:+K; [#AT9CI*ZYR?U'WMS.=GHG_YZK
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M'!LZ_E>OS'^K ST.EQ@Y6S/Z+I%@-):$^'(E- QK^>B+CVB:SH*8WN5=7W6
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M0$GUYGUF)L\L&IJ%HC%H?L$:S4+&7Y\_[5E*<D+<^3M3)M66F[E7&J9$#HB
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MEC7#'CV 5#"(*U)'A;]&R3Y*=15CD]6IX1"LABJ?)?&I$[91IMC$0REL#!'
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MY<^XE.I[((;(UKVVBU*-_H"6H]I\]UIO_O8@E[-(U865\EDQ!&+U]H',;R+
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M<XJ_2@'#'.TN7!J<2_5;Q5<^D+MJ7#&\4B U= '<4/KEQ:/K"#FK]/7R^RU
M>4SS_7EUT>:&+;Y3-?\%9\V$N^8WN'E*LK-!%JN6K.N["=D5E;N9%IGN/5J\
M%!2,R@QK4M9;40]Y[LES8*D#?P;,!Z]CO0_BQ-@C@[T<6W"&JF^MUBWZ25SD
MLEXF%<I"+*Q9-\U#\RM;[\LI< (3 ^X8F"6G/Q:@M7847%PG#%W9<A:8Z*CY
M:TSIZ/)G^7KT-R1LW:NSJ3+]/:=_5C6_W><=TO2.G:W"0XTK2$2;,.&D7\*N
MG<W"/N%MM>F:R][)CEFTC\_PF+?+8<ON./*EBQ%9(F1Y"2U-!!@\NOC+)_HG
MB.VIGE)W81=M(1&0T8+O*E=R^![6B<]'[WZ?QW)>D+T47TK?01M]CM@F57FY
MF5TTZ#CK<]LYM>MLJT_MT8'>Y=^SPY.^F=[.\VOXJS3U%U,:UT36YX0X:QW>
MPH)"D_9]$XT3:(?->'R5;\@%<+5TZ ,,EHML3)+W7>:BLB^E6A7N>Q*FN?3>
MQIOIX(W)@ZS(R<PS7ZO"\O]NKO@G\(\'J%"<:;)<-"\3'F80 1&@"2( =W+^
MYR8:4 'N'ZB9_X] Z3V8XR#!D0C8S]3X202(>DYIXD?G,JX$D.&9L7<;FX4=
MPLF"ZS$50XF#'O-O_>S'AF*0'DC?YS_+2X)B,5 M<TR/4A1N]G6 (/!146$,
MRK> +@R&2(W! + S^X&FIS']NWV'>[]A@^38V06:JI&]R#4]+G#8T-[6UFL/
MSO$?%SV)?2O.P/$(;3)W,NF4PLRRT#OGMM,F/T?[Y[=13@;_RJ_-^/*MYLX]
MGBC_A3$CI=DJ=R\SS^\@QZ@0:(-/QAU<J$.#Y&:^CTCOV$B7GC035*="A4,Z
MN^JQDKMB%=L[_TN.E:Y%8#8)H,";@4D=@;)>&II'#AI=COD;R3'=9!<(3_GG
M+X>4@CJNI:-$;;%LHWF'!M2Y*=FWS1*M@KR"J"F>1*<+7EH.3/=U%LSJ28)G
M9LGQ-*9P]J3O6UA@$1>QQ:MME$[ 8^W<ZN;A>X2>PC:'30^M'I677SU5H$*D
MWVQ,U(0$M&XM[8M="H>/&1)$0,)"VWG&JAIR@4[L>_8YK,R5[LHP;JJ"(.0D
M@?BLEIR !&T75QS71SY>CY#X$N*F@Z6.G'CUG44WKD_"5@=XT3N.75&2F(*+
M$@&]R!7N3:P1'A[P%!^ZX!%K[K5N[>>W7;*&[VF[JUVJZYH4PEHM9"H"*$"9
M%]GFC7+G&,4FVW>A?'-V+XT+^46PNZB<B OD+%_3AN7L-"/BI5A:>'Z<F;?D
M8[J$S'1%P.A7-Y[E4TJ::5E>5#Z.\KF@]G#YHT2$_@X'#_YS0(?<[/>"DU/L
M#(B#IJ&2S@+:Y>+WHU?/"N*2;, A$OJPV36UN(+OB)(G;$[_W+"1G,73J7N$
M.CL\@RLJXW:<JO^;"+Y3Q4#<R*/BJBVQ%X"KK*&\L5/UZLI=*70L[U@6"^01
MAIFA+PJ4 5?.E&\HKZHK%TS;<K2FW19$W/:U#!.OSV[S?*+UVU/!;FG_\*3C
MAGSKD">Y[UG^=,9'X/"XF1?]RAR6^KPVR;\E3 A(V9%+0F? 3"H([E!U9QM<
MI-($NO:JQQ<!K=U)(9F$QXM;'$82_1=:][^UAX_579$IZ.;IWC^F3XYJ)I#L
ME>+J<:#J;1R)W8BG)V'VF$;AWO36:Z@D=3Q#HTM#ZMTZ&_8--;M27]* WWEQ
MH45+#_,L)0P"9M-KR]*:'J]4LF=JYU*G4S)1O@C]T=U]))E)W_C],\#P S56
M[_K]5<P0$D-'[N9G/I>0^KWH-/^:^^ZL6L\XEKRCQS1:@4S"@EFV*<(@-5H;
M^$A;>XC37;^I[9M[E.T+_DF%>S:,(2M.-B'3.6PWHW)IUVLS5C6Q[D/1MYY%
M"Q(N^Y]U\VXMX?$:KS]5V%8RS'*^<&#IW*[AO,)1MJVWN+SVX.F.JWHXJ+]"
M^J4DV\L8HY6[3V]NW'(I;U,T#DT9*0(O_DGT6YP*:88$, OB;DN0I((7];K3
M2F>A1E#@/%*E0D '1 3PU#L_'6SM1$=>/,\JR=DY?VJ3&UKL,JEMJIB_,#T=
MQ4T?%T8;NZ3/S.8S]3%!J:Z#*8 ^J"GS09Z\W7V,-'AGJ%T)O1P)GW*ILAZ5
M9]/,M:H>D0MXV!Z?_FK#_TQOU& ^?I8N1Z[N"3.E_/:N,I5+Y6I607Z*JM,[
M^]+4B>G&F- 4@]%;;M,7G]6^APJGK453GXT&TO8>R*>Z-#R18U,?9Z3$N[[.
MM>JGNG-N1M\DY"T5K1=F.T:)5QVEEPS9Q+J[7GQWC_E'\?C_!/YQ@/_3%41A
M/+;UE.6P8:L)-7+T)U?1,@QTFC_5O]NT*>(QOG=68>\"/0+JW U1UOZ.PAFK
M +5[OO'?FLQ3^,IMRG3[DK\F086>5G@.[:P 3;]/6.UQ\ WXGCF:)R'QE>J>
MKX>CE$0%Y$3=3>I3@:V^R)LVX(F:G"Z/L\I=$92.695[[&0]OVZ;)DOQI<%D
MO P]PO!L82M.AY)G=!BG]8)6_[ ZL8Q,7+S%L/;N>5-'=9%P66O;WL]![HB/
M3OWJ#V]/9_C'H:9W&Z%Q(SHKY.9:?;2NHV:SV=1.#)?VW_[7UR3'N4'/B8!L
M'T2%>"H4QG5S<-NX;)9J][C92U[M2U 856U1+J2XT#DKK5>.QD96UYM&^45U
M!<DE#]K"URT]&0[1<SC&E<#^]]E'3IA<)$W2=S^\XYFX47INIV5#D"J=8@9)
M,T[7_(<2_52ZN)HT['X*>\QLD;<J0 V,;AHI( )"2):V^19ZSP-FM]X_0-,J
MM$M]8W@LJ3 $$Z;DHM.2^[0QL!"1^J(F86-3A4Z2A7KO73<@FMK'D[OXCBC8
M QU-<7@7&S5RX8TOEE3#5V<NX!A=CP.6SW*F#<J*YP21M7&<CNNE.T8->FI0
ME[JY2(?7 GT9/;K#8]*+!C]K8(IS17_2(:L2-.C$X?"[V/=^][;\#[^6(W%#
M]GYVVS:GN@N]52DII*&K.>^A1F1O9*5IQ]VF7O/0?8WZUCFXDX=$^18S_VV7
M<<: ..'! AYQ("& [R0"?E"*..'; U8[/6+Z%GX,.R3CKED(3XNGQU#6>4&&
MFQX<8U;5KZ_JR)I09>F=I'\V?'GQM[5T ZG_-S<9_J/L#?B/ >7>9:VJJKF(
MHKK?TQ=26:?H&K*/'@L(C^9_E"_[G\#_,E!3<?GQ/@A$HJ46+V7Z&;0)3 0@
MG,HN@Q$/>."_5R NM<_??KZAM7EI 91QNV;_*[]VX(/!%<:NSM%>JKBG_9&D
MU6+%B5'71.^TLP&0MGD5 B/&>TTS._=2(V9R@GC?3'% N'-^76W72?E FOZY
M_,2IF9\(&-J<)@*P&*?ST]VA*Q<4.QO,!#@>1@0HT("QO6*G.)$%JL#UHYU
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MKWL!K\?PFF<7XV>HU(.MGTY/APPL!;#1W3DIDK_2LW,$;@#E-[K7BK?9JAX
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MY^^H9X)NI-_M,G/UT+?=ZJ?TT>NB5*.#MN_\-;UI82&5-Y(DRQE98M^K]Z4
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MEQ,!"[ IR4NO@9+Z]Y[7T<9/$ %K#L<( N-W(@"59E5-0T^"N90"^C*G^41
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M>"MQ+*;PO0]E8_]@9=-?(4$I_(JQ'X_@X0"KF/&1CMR?:Z0RD"FB3]2]F:Y
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M%QX)UOS8&4_HC/Y8]1'+QL:O7Q\IY:'\#)*;'NB!#J98DZX_Y3FGVFZ.FC:
M^S%\P%=AGXPRT.U#%01>4A<Y>S?V&\RW%W8UO:Z8@/I3Z/\6R9,3#7TS,D#K
M"EV6UT8W#<<<HIUBC\"W [14]C%)53DK.Q)TTW='G$V3ODQ$M;I@2J\-OU3
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M&!]5$DX/K>=ULBD<PE#8\N11RKX93O[VLK)+_3Y2!=,\_KYK)*.?BIK8<-&
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ML^F11D]9)UHXWK3:"7,UI<JO5^H5U]+G]Q;&[$)\NJ_6;USHZUO[$-*]MG,
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MW,Z7!V-C8^JL1HN?;VJCT4D\T 1V0.!4='9!YL\[S7TEKD7V7N30S 0[Z^<
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M7J7PDV!"_X^"8'L**V1:QV>2P@$AN^CBW8^:(+U;#9 !/R4<IWL^%0!46K9
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M*+=$XI.PERD93DYK:R^.6\4,)R5$= 6[>#_JZ^77ON(Y36L!N59%7N^)O.<
MW7"KOK+@1::)Q\I" F?$:GBOJGSX>;+N7,9+4<_I \(>!(AH#A]!;WR1-K)
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M$]Q#.<"N;F#'%<HI.I5*F]E<AZ?+;U&,J(#;1]YN@<@-^DSHJO>R%-AV22S
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MCX8(EE-^018TD\[$_YNUYF?(GXB+XQ 11:6#H:XX7'OC_/K<\G2S0CK<\_?
M07V!88O%I5Z9+TCTDF=#XNCX\$!NC*2.\CT]/11M>FCW0.[F0,V+QZ=$(B!W
ME: .-N!;7UWY5)48/FT$JCU9E"74$<)'T0V> ]'31Z@O;P8GC":'+SV?S^^9
MU+=V*MO9?OJ2PJ-[6QN(;[PX@[;QV,RJATG9CWS7P1V7?WG[*K:V\>VC;A4%
MR2M*I[0Y^)@XY&T^_"PJBGJTJ'MH^)@<0+!8(_P_UI,9S^T3S;,PD'Y4/B5
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M)_O'H-^Q&-#A$(7\V*]. G?)EXKN6=PUUQ@@EM\?DY?D^^.;Z).,=)G#1-X
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M[?F">MYLA">Y0#1&(JOR<R:0O!<QB^0MP4),# M$Y65"T^A;HH%[B-9IS+4
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M3&Z=VZM^I*'^"W=]F,Y^IJJ2[W9@7<T9F96[(Q4#O=9E]SMAQ,,>WIYES1K
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M<"2I.O-P*S,.OY4!64AE##-OL4 J["$LD 8F::D-+8JRUY+U'6LO*A%4J@N
MVJ\SW#;OQ:_W+C46D)///)K]R><L:W5'L/A;ISKT3=B#/)<GA5:Q)MSU>T:$
MJ6'P5C%XT7/4!COGW-&<3XO<PF:K2\O1!(9F^'R>_UJ5\'Y@,/%W:08+%+2[
MM_ZP*'Z#$X,WX5(Z6:C+V0^=C?4$T/,A^V,6Z.J]#[T 4#S'QR.Z9[AJ+UVO
M?8A:^[*G@X+T2AT$1W?Q?U6>+<URRK>+[%Q(STWWOYLC?ROLP^"04;D.9S:
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MQ'8[S_[DW[<4/"'O514NGMA&DFBT$':/EU8;;M:N+!LY;J@:XU*X\FWUE1/
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MR2G* 037" BX";@! (< N#7L7#U=/>Q<WSX0Y'T*/'^IJ$J( /Z66W\U  *
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M&[TWW.!^SLX859;=HEX;#Q^'<"4'.U90D4&.+&AZ05>9X<:W-;'&AL[<I/=
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MWH)D8\*7.D%/@E4"LK,)$2UQ_T_."L6A6#X:LT,?\.ZKOZ=7M/^0%_B*WW%
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MN)/QO56J@1#E<]8RB5"/H3X@=\YO@C0Q!81^LW%N/9#TF==]?G]C]3-704@
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M3'J]'5;74??%Z+@J-;6E>1L:=,<?-HU2&68X W1KD[^2T8\=)_R&5'8]["R
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M)9Q2W/_$ATE&^#<)7*1*O*_O]=?[(SKC>%Y &_<4+LLB%XX@=WB3R5]4*/Q
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M?_I&Q;P\E^9:B^RQ&F%MY[YM];A1G5)&N2[P6) OQL&Z5VFO+T_UC=&LP^)
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MTBB5 *&VTZGF_H[J\&8X2DK8\3H;8>(QJ-MW)M_Z[)[V68VJLZO)69BI$\/
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M:542=%-Q8++'UOPAHV,?E#@+[4:1;X:ET1 W;'?^/ZZUHI1:0GM]$=54P%:
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MON.#5*^1N86A]*=!QQ+_.(#HG-#=$"F@ 9R,:$!9YD- X;_:R[#__P2\86C
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M3!FEQ"]['#"%&WP/"F[S&!)*\_O,=L4Y:NNE>LH&+/A>#G!A8&!P[XZNK]B
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M5J]?2F]7/X".K@AT6E2J:U*#</"S'M"8F)E>?RA<KV^W/X[(B4G$WYP9369
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MT2PN;MM/H2-,8$,YL &>LNI[LS<]]\+P0* &J(T( 1JG>1;-L8Q8'4$#J-"
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M1<3W,MZ-S:<\I^\S4*6<7+;F%6CRUM\HZ9Y46 ]FEBAE30AG&,XWT]*QXR<
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MZ245*R<VM8V=T<Z\&S-K4W60Q+O#66];]6BTQ7Q>A\D9W[@G>^/YF[*1FY\
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M^@1=\=]W6WD[LT!C;4F?XJ947SH8&%I[;C.5YGVAO=.KM\=HK8TZ9J'$K?!
M4X#=:@1 F//:]-(M.MD X-.X+#%4=UQD]1'F0/O=_K$9[,I7JEG.O:EPBG]4
MB/]DU*1,\ZS%Y4[@'%YV'TA3*&X670F>#UD]C?4#8I@R.3'0;C=?XT5R<7^#
M'=15DBO[_S,'W/]U*1@: #FC]#@6(0"Z7.87+R=Q<A@W%_QR#SX-'[1% 2,
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MW66Z5Z%JDLWD21\I/N9^#TS*=.=8B5.,[++FFE9\OQP=]=Y3(ICC\_-[F?D
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M1;%Z\D(ZBKRJU0P%7.&649(O,ZUK4+%:YE%)1A.=1*!RN-]V>D[7J,?S6\8
ME+=G[62$,S$_/Z-,=Q_WQ]?['7*5!_==1M@]C8+G$78Q9#7">'MG9>JFCAP[
M2KS2J9'BX-K9Z(W6:-4EEN]*6=WF[!\*"GB7E$0&F/<S^YHFIV>$X']$9#*+
MAD!"#M\:T)&JM3)"@89^NGY*FA'3,B\8J6N:MR*P]\*"B$!P  G63WL'L0]P
M,#C&,Y(6^Y@0 _,O488M2,.Z#_\@^L'!C6U3(!Y)<3RWHUK1P36NBD<2\*/$
M&2:^;;%&\.OC54_FMWL[#=M4.4H"A8?56IA5/Z6(>*7OF9D%A(V/ I6? OW5
M/"XFP34\PR54S*MGT--*(]H4E/X%$XP:A-L7OTF;1N O#N#@L-T;1. $[)U.
M!- 3VY6GQ226(0)W30]=> CYZ/G=LO,"03SY.'(6M7]M"?D[XDQC]P"["0I-
M]2*$GN^RJ8PDSU4ZPKS$^P\.'4+[=]"O]52X<$8_Q,6V2DTY9"Y$@2^,%O,M
MCI87"<<]IFULRZI,2AKYQ( ^RI-%H#)0XLD>?XQYM37I+:(X0%^CER5KX6?:
M"'P]5H (?%O*1Z[[M*&O_//Q2L^IG8E E#?<#M;1H;NR-T&@W26D^7+BG':0
M9TZ@:"8:/)\+PIC$8CMZ*,@I636LT<B4*8% %D@$8%:"&%'!V3,S?#Z>6YIM
M RW?OK#0V;/0;M.J$YIR9%QS,#]JU$H$-)WJLQ2&R^3I-6PN/Z%Y&#I'2[B%
MVM\5KM_#^C?)&'LG[\RX,7J*A5 8ZR/VWH];%&Q:%A4UCZU5.#LRUA;P)A1V
M<QL&ZVISA>O$#K]",36DWZ>_W?0&5CD<MSQI_<8Z[B//+V'_B,=[XT']7T!P
M(^:C/&57QPZ3LFD6X6&LU)T?]1/F2[  =&KY5]IJ47HI-0%=U9$Q/35M:7GY
M%R-=TFJZ+RIZ1"I$HJ2$:;=+9CKMVK,Q1WR!= B-KQ?RZ0"GBQF064_WPD\$
M6S"XB1YW.[D 0?[Q:(<)V22_7.$R%?YYJUB]:]HKOF*=K_RN+,N5W=8=XY:P
MDFC'YBO/'>E9H#QV!;P& <RT3S\DC!NBI/N>)Y&U1C^3F?N&\!FG*N;Y?MM-
MY(7&W2Z,/IH(B'FROT*NRN..&K;HY;7WB0#FQ1O/7($6$47:6AD%-RJHP&T0
M\Z%&U11S.[F+E>3%>YL_E/C:NRA% F(S_#XPR?-&VT-!;3PB![I+)\SAP>U;
M=3/Y>R47]&)LV>DN9 6?B-,,+'NX/"?Y%4_<9],S#?>>I8-,M:^DP&RY3G4,
MM@ZOH)<SETW*[\)YI45%./ALLN<R<&?G!/1L<;Z<V?IN,*6[ \]6HQ\IHL^!
MW<F3-P*%81=A(,5O"^XVI? C7JVZ!<A 1LC_4NA&N9%LC(D(Y!*!=$_-VD_N
M/9Y$H GYBU,:.OOWZ#3#%-AO[WSS=M@CT)I^V.=LC\=XK)K<M5[=')L"J:+E
MT)M5Q=\8^%^\*:?,) 5_Z52'Q&#0$7+9Y!.N**1G%U-$!, ](UPXKB':#T3@
M<=D:"Q)QD81:<_8H73J*E.*;2I$B4LD-V#*VM,^</ 462=#JB+?A0@4$",/(
MNIK,3'M"QL4S6&>C5VQX0\_P>^]GO!XCK[-P_B6Y7O%VT%G,*$M!A;BO9+1@
MM7C$:T>?LKIRW;UF3;FH7V]/QB%W$C**_0HE+#QR\@HC62SUM!C\KBY-2=[*
MOKFL**>D::E53';IAFSGO> ;GN,=A%ND%[24.KA&"F (45(;!!4T)N_"ILO.
M30_2/J<$$!;!N'''LV4?J.!V<@;R?V99O>2[)!--"&J6:>3)=18J,<%K_IOA
M#2V+CV.<O]H^GOQI/=@R9+%N:VYR^XGY9S9YD+R&= R8]B0M,/)3(7 $^K-E
M0!.K(S(*WRN ^T7_2N+H.KJN.Q;VWKOZ\;9@S*LQ+U_P6] M%#YOJA6T0_N/
MGN0]HFPBN9<5)&X8O#]5'X\C]0)Z$=Q%ZN?;[+#=_;.Q7=3;$^V_T,3FNF-+
M!#[PPU;+2+7N&!EC.=:=Q[-A%,@=;M J.1'X:NH!&T>&F?3O@&=$_H%XLBY7
M2(%NN8[DP42"SN[_[V9&N[0_1"!191I\%HY $ X-P)9=K3Y9&2U[8+,M0\$S
MI>K+[+!K,O++PY<,SY$QNE7THFSZ47:J[MK')?)T5'TE3"N\=]^1_<P]76S'
MSI^$_)UE3M>_#ZLED8EH!,Y9DA32 VR&1\!M@B'5 Y?4#" 'M (JEY7DA5O4
M#,:Q@7:U;%$3%&P:S_NS_,RU?/WG3B!H)KP@1M%P;?[T-O@?$#/^RU12"KDX
MWP$+PTY4$=XLB97^V2B^3S*SZ>0\6[/3Q5VJMN^&P>]8QW]!KZ^(ZDJ[*?RH
M*F]A*GR@N!)G^R OW%:C\.JT'F4*Y#EJ*Z%XT9;SWKTE3=/N-,MS5P6\/6X9
MED #@TZ3GU'@4A"N[HJ+^PDS@H8.Z.,&MDFL$,)A*2NS;=$,-<I3<Z)PA5?Y
M52;6,JMU3>A&,[.==_[7SNN&[=SE[.GB"4":O]/NJ;Z%;G4R77N<^ZM-[B<7
M>"#*MR0+B$#JU.ZJ?#T12(@X2)F9[[6W<H$8.J20B#;+%6%R%/OZ>*NF_/%I
MGDYJ'^M.B13BQ[VH7.5OMB_ ]BF="I<@YNE^6R4OGO.\D/\Z;&>8V.*T@#N_
M-VNXO[,=]N>;4JQ+L6>AU%)I81S]PJ_(CB+(?S2E;RL&01O];5@%'):PR(4;
M-SU;3GWW>7#2VV1N?2[QUYMUVW*/UR =USG0S="L4#FE\+8EL4!6$C"KW-HK
M;Z&C8.0^Y_V\G7$&KSH2";VL09[^][C0#EQ!1G T@5YTS]!C6L$;+BMG_.1]
MCM:K$_)N9IM7SS._-SWUO,50/OIJKA5PIOE'<C=D=^.%,N1R'2G:BD3@W!S"
MD8>^!-W4V0-4I:3<JF++P[&,S;($,*OS$0-5@V9*M^Z??:EH^T5W:E-7LP<9
M UH6'RY$-?E5.EN67+;B']4=M.3(+>)A.,ZM^/F*3.E*M@/;(!$HPJ7>W46Q
MQV_'W^Z_94.XY7'3</ [#27\ =7+!T&%2_D$Z'S_X9\JK9;#4XQO"ZK1-3 S
MQAHK;/VG2.Q(13YLB2>^_R1(#V']KC/RCUZB>3)]V.A%T=]\7[3X2W; %5%!
M0XT0LB18?&;NO+M );ZG9C1KO^,U66O4M?"[]",$>P+!"-;+MA1T2+7!._?[
M#!/2N9TW9>#AUD[83"$(T@?-2,.2TA(+'X<(R%!Z%O*&^GC3H<7$FJ*>1V5K
M*3Z0U;XL_Y1C0J_,;MITX%XX>8;82(/<3_E%.0VR8=T 2GAW5J \!;[Z0DOC
MO]V@_G\J)5?F^%"+L1J'R.^->W\B1L,E]$WWR?]^X*N@R*(9EM(B.:O6JPUX
M?^ ZSP%/I"F.PFID2#=^_F\R\?-?7Y L&Y'?V?]#NX00J'15YDGTP<[\KMPF
MC)7T$YU9N^P5T?WR6P7LMUH/)NW?)@E%\( FX'EG9'^GX>)((/19!';P&W(^
M]??:_?_Y:,P1$9!A:9@&,\$2!KI*(L:<UMZ2.KVW(:M>E^_'*)4 BXR<N-(4
MZA9CB@.GC8Z VFN,;[3-6L"RPHT=VT@B8&UE<"G9UL!<:Q3/:8&Y <' XC7=
M12B@#Y?#!4R7G-N?#-I1W_Z$#WG.=];GK([(.&L>KD6&@Y@]^=+W=JPS-G;R
M)GW<^%@R/U;H>NE#+<HE^-M4OVL/LZD9:*L)Z/1'OBAA[]6]<2,=S)_&=UO&
M$C[M&045:,M6NC7^M3#SITTZ37R>CA%)&BI/&D KAV#T!.=WO?)7%+UQG!AP
MN7B2F@&'KF3NV PF5%K6SV"#X7&X6E=E3:LJ5:+>6YM9PZW[@:/3J5E/65[B
M-@AV1TRKZ[@G%O4 [:5\3/.(!C<5S>T1K*0!2</:GV=)(YJN.("_)R]FEG%-
M@AXVH"J\8%+)G5J*2M]),CQ18?+H@PZ[TZ^[=D)&,.'HL#'ZJUTFHA3F]O6U
M0AO,-RZ#2*)90/)#C)E5U;Y)3JY[9"%/E.WZ(UO3 88MLW_D]LF"GVGFX>OE
MEO4)S*EW2#*THPR?@#9%E6$=SS;61?N(P $DG@ E F.MZSX$9=#)YGR Z=DW
MDNCU[.M!A\RCX?C'1(!&Y01T2DF#R8;O#XUE8U6&$'\W'9-HH%.8,/<1MT8:
MT"(.,,)5F;43]SHB8$'S-T^GY\7W"&PBR;.+PM8PGJ=]<&PP.<87MGAGB@@<
MERV7(4E-7.M(2"9\WD(%X>))8FB5U/>79J%U)+X<,,R$W0-C/2(.2<]K^P;&
MXGR5L9(S1* BB!0:[J2#^6!U\?.'^@18?$DI/NKHR99>Q)F>./[[;L<\SG!&
MD'#..G7RH0)F-[\!ZY:\]&$7^Q5^: !;BG+)6(]8&ZKPY3P.)%_J.!3;[-_?
MV(TV%J]P0GDVB(9.:NQ <^83MNFY6\T0<RW=%G;[&ICW,4>/1W6DY"%A0IU]
M$/WLJALB6.>4S2^!6AYZ ;X*R,T.Y8Q5G1^:]'L>RQID4/;L*IRRSL<_*92T
MZI\@P2BN)F0JS:'$%G)5=II%I<X3MD#>5MT"V6\@0_)PI?>Y77%T&!!;G:I[
M_4X^VZ]).Z54K3FN>] ^XYN-3;G&@#Z[T*B7I[71U5!E._3^S5_4=$2 0V8:
MXQ+5QK'*U/8SDE+V!O[&8D#")U=MT7Z[QP$7LEF+[V".8(+4XYC88;SV#)*1
MK3!Y>;=U=B)R#G61/JS0D']\$_7Q[6_]G>LR,_EQ'@\(PHK&5?L&JI"$5(6H
MS#0^%1V$&L)8H($>%A! T[.&&U#P[JGJJFV/DOUF!K4]_/.RGT_C:EE"+B]$
M_C0;N:"*9"AG>5]+DY3J.)MZ\\#>PF+#V3AB(B;5ZGM95K^#G9V-S&J9?;.1
M:5AA.W[06<L9,UF^FMRU:+!Y4^^M\TDB1;&+U=.K;-GCN*5WM^/O+W[7UA(2
MM7_F+/MK@CYCO<R%M0-#C]M%)KJKXXZV2]-F9]GV5!9[L5Y2PPPE6$5M>=/)
MXP;[APT3]BI?R[,C.,2T'XU^?#KK<V?6(BNKHR645J?S:?A1:(.WPCU9MY9_
M:D&: ?#;E^C,^$1!MGH72S]&AI9@X1J&FW(MGTN4DP ^;3F2U5-F;):VS".O
MUL=[O.O+2YB9I"[8?7(J:*ZW4,!1)@5YMR(FMOZ[N4YH3[OHIPN%OB;5TV-Y
M;V?I%R;/,\K0C4GR2B\Y8^E PIK#X1Z(CVBR9^K?+HH^C5>AQ"?2'RVUY(3+
M87X<(0]E"?KSO3M9Q6[JA"U\UPB85MQOMY?UW/]2N9KVI+3%9(2<?@W?#X/B
MWZ-#V5C))I8/P;:?7DV_U.Y$Y%?82V2-R>G1Y75&5$[DJ6.I3ZW>FU^G?''N
M#\BPV]U\+O_(>RN<69(T[!?$P">;#[.(0&O(+ R[7VFRT0!S\&TFD(W@X$2
M_8PP04*1L*'_D,<<M^'3")+8"0^I.\6W_O.>N:D!:R+0D5$-VT,UDX1B1?R4
MQ-+@I-.&TJZQ8XD\.,X=WYJ#(_'-/JV[(X&P&\;:7PJ;>4($1F"#/F1N Q@!
MTE#N$SP?&9_1_9_*Y=7ER>)ZJ$?P /7,DP3JPYW3&0\9!(%/:6]KN68K'>V+
M;--LD40W(AMKH \WTUE\HF$SD'K4]Y.'K\P,$H0M/MQF7 Y/SZ^$UM]1F=W/
MS[&/HA+&!<"F-EE72W)J$BDB;G0W?[I(N<F@31!I\W@3J3Z'./Y_36==(X '
M<(TJMO@$(J ,;AZ[1?+EZC"2Y).%+8ZO(D\'C\4KC7>Q?_/2$+0'I;XC9Q1)
MBH_D:IDC2G+PT2[B6Q":53XBX"P,>[B+$ZIG(P)>!/0)J:$6D.>.Y^3IG"ND
M(=X#P^01 :-Z&>1>GB/6]83D+6D[-&&#V)!I:![6^02TQQJ*Z2 H'?B0H!W$
M8B!X4$D$$%!ODM)KTUJ?QY_6"MJ6@:MA1WT$UC WTU-J&DP6".?DXN.3NS[P
MKZ%ZY! SN3TW=9:%&Y%Y0.+<XGB-56SEDJ+1'S>9BQ^;/V?%"S[L[-XNGCN!
M<]W6D@PVV' N'FUH?]HT6U(8Q?CQO4A%^\&S]0J)67_^O2IZLF_Y91=;<//[
M/F02@1+\@AG(01,18\$\#MO2;%S^&'F / 6#-*@W",>]M*"W][OMZUG+#QEY
M7.KNZQ5^I4I/+HO_P=Y[AT79)6GCCXIB @R 2&H5D"R2,RT@("(@.8/D#)($
M2:T@07*.0I-SSKE5DB3).4=)36B@H>FF^]>\NSO??+^=O3;,.SOO?CM<E_\4
M<IX3JNZZJTZ=<XX>+W?NB.3H9Y"9YO2NL3!;+^1DYT9^5Q\=Z(RSZ"Q@,M?W
MRA;6_1P_E#D2B54(C4\J-F^C7(70/[?:O_09 %BC%(3RH*N6&H@;!7BE%Z<I
M$K,W<O""(&ZLY+ZTGQUX-]&MK&;\X,<[4>*O.]3$/=-:E+*,N?D"G@KC^:T4
MBTEOHPP+'MY5V(MW&7>G';FZ*5%]+3?;"34&@XJ?Q7<$N$;,*NEK!E]X_?;E
MK;0@U3QEDE-EI\Y,R0-S[-)'K 'TQ \).;-&L<(;(<=$O^FZ*-L,^)\#B)/'
M6[;])BG$[J-W41=PP'0;)*4?RR:+ ^:7$1J38[_.8L ;D!_-%U Z9[WX(#T)
M=H!I)H0]?"HZB@F#)(:_Q2 FO:2:/'P7-'IJNU<]8#1E&_J%#\>288YKL.;W
MIT&3+)OF_E$9\8(,=HK7>)V6]X>5S:PX91E$(ND+UR==KWYZ_F%C+_IK&&CM
M2 #M/MKKZ#BZ$O\R9$]>Y8&XNO2RB@'+R%B:Z^V@ZPD*&*P[E>2:JYX=*-B@
MAZ2X$5HC)N-J]^,G'+;K;VY>\F-2[UJMDUM7'K\T9DZP*=34B?ZD0"AQ+3=.
M@#Y3*Y)J)RM"2OYUM^W:I1(K%M_OU>P(4E&VY,2[#BI$@9;T;Z2+&919L(_9
M1"JDB5[D)FP$_*4,2V,S#K""X7VWN]P/@QVZ/UW*/H3M:J Z*I3!L%)A?[@N
M[V+9[?#PYD5B@Q:<!%?;'\)6:2X*_AE,R>%M:$WYR!5+5QR- YK&N"<E]\&6
MZU9?"">$QAA7X\_:&??P#9!-0HXC4 ;;2R3'U\X7+M:=8/[\!8MYK"5H3W[@
M?(]/^J0/0>AFV/+ \\?)<277;'3BR<>)Q*:.]<D$VV:=!E;+<M1,O\&.5V/3
MYM,$]P;WTR^VQ'*EF5D]4M)1/\I6E-.34J^[?XY+5OW1L.ST;#G4<@OKG;JV
MQ9QU:^9K]M2]D@A6[=@' Y01US\\ZR-Z>V'3>P0/QL\P&O->+A\"C#Q=4>PP
M,84=(0K."4@86M)RF=N<LT4_<G;?+70UJ-LD)[\CT=">1DV,UGV9[,NRY&:H
MU?3S0$=5COV[85^"O\!SQ=--+$FNQEXS@K"I](=:KNHZ2^* Z)VYW>)F#)ZM
M:X"[,'8<E^>%.Y?#=N!AG=,45@D%^VAA]EE>" W:/=BX5>E2'Q4?<;#'T!+#
M?H_09Z8$MF&F.PV%0SFC/&^)GGE9YFD<9+LS3WS*=$WH"^"T,@R;U;][.>_;
MT%5MU% S!4DR^)B4!('_5!L''J>V#+H,;*?_A?]MZ"_^$^!E0;[QZ\@=$V*Z
M]0?Q_].E&7:<U(5^K$ 'IR&:_X@FT1[["U#K]2>H9?USJ,TZQK""L5UTRR L
MFZD]%BTZONO!B P]KQ4LQM/!(.B!*J03E"EUSO-/H+/S3-Y$<"ML^'2BWE',
M^MQT.IQ]NFSOZ=@*/[FU.<297V&\R[1FC=B?,I&++*&+>U!5E,=R!2U=&,75
M!PJ3YDL<N^91KO02LRFD]Y/*L]$O[3:1%+6@4MN'(B+"Q#[+#6VS#WZP^Y!%
M?/=ZE@GW#PIKH,:&'AJ%'N8FVZ'-90=>S#6GA:S06W9ZV8$9T[]NE&\]_7Z=
M/"<_-;@]U+]\?ZCC>J<2*8.=[9-1=EE2UC;>9Z3+NJF%EGUC(4&E^?0GK]RI
M(UI)*34$%[^>?G 8Y81PM6!0<C,07G \#CBX@"(;\*A=)FP7<76WT:L?%-:H
M7'G)OAH^E6(X*0PJXP]X@U1GL#2*OZM41]?-<QC1>Z5 ERZ08&^XV%9[B^?%
M<A2#$%3V<6SN12912ZR^;^/,P8R>CMY+?Z;G>:2"%P(<R\U _FEO&2D5282M
M\$K[1IY(\1LDG(P4T2XJ@@-8WJJ(BW"QE?7=; 9/DY"6O_2+C8W]J$[@0]19
MU7A>O1F# SXYV_=#_\\6;?<L& =PQ1?"]FELH&=KY:G=H,]H14G5!;%O8^5@
M-M@.,_@#[*2D!V_1 =TXP/P6I$X1FXPI''B, [!R<?@AO\ !/G9XI[VV-0'I
ME5R<[R$)@_ WL)36"D<OAG5G^T3#O 6W/?UERYP%6=SUQC_\-#\6(R$BV.4#
M/_2?M12]K*<GJD<+9O?W+TF389QZ:M1GE$C)E^:T5XX)%=,5. 5-&39WN9KR
M:-RVBB+##M$O?_,O,@GB)P;RP)R=;R'?4R'Q-K-63CK<=JYCI]M-[02J"0IA
M=C4!H#KK8V)%>1KR2^Q0FY\RU\MYA@L4V8G,Y _O+OADR#^MP0'.KX@M (Q:
M.R&T%+%1^?.=U 7E[8Z8D(=CLNU@?Y@AF.7H!O9NY5YEPRF=A6<:2FI.% *6
M,\6^L;>MK:O1>-D7ZGD3S6]DV^M_VC^@H0;?&+J_OS_2/^$X;.QP]/H;#T_,
M-;H'9"R%\.Y%DV'*I$^DHYMOP5UC*!V[J DY!Y9UR_G7^$"J2.HMDT>8*/,'
M*Z%)CDD#B98_JP."_.W+@,X%9:I#PV//#?,_,X3"*EK7(:.L-VY!VFZ=/XH0
M4CQ%?$/TLD3L::#5$PJ(3_<'7^P])>QY5Q(8OJXNT?.2%F,Y26- ^[1\]MY;
MLT98$KR.Q5XO/8V9WU<\/_)Z(J:"566!;:I VD7/C\$NH!11K_&4(5\>!Y">
MGZ>%^:Z"5R4*L=G\&)7S,[;_:.$?+?Q5+0QX3:5\+'<7-OSE(5?/[S^]N5,[
MA7=F> 3SV/):L^#K&,''452]RS4[="<E3ARB["(@)X/X[$S?KD=;21D"8]N;
M1)$W_8.NB?DRYN2DL(\TA9#)D!L!9#Q+WN:Y\@'U?,<6V_#Z"2^'Y';[E,]-
MG*J3?86-R&H7/GN['39>H_BL;L.*PSN*1%(B:?J"1N_4J7UDFKEB>03H C<'
M?U3DF3[P8;G*2P!ZZJZ. PB[(=U^&F<O[4]RFUV\FS$@9CR*DQD<,<.6SJO,
MCO<\<S%Y:I"1''Q0=&ZR\]\04$0ZW@DK)V.9S^T8\F<MG-OV[]]"#SDA!W/%
MX,NF,U/F6Z!E=$@+7NB=,77G#FU+NIIW#B5$!;IGJ?<,M'T)<IY=SHYE9Q E
ME:"TB&/JY#,H!.7D&CLJGD3C?Y-_GO9];D\AGV<%+-Q/-\8R2J;AF9$.?I5?
MV/_.=RH,DUM;PU.ZD+ Y]D:?_K.0[QG!)V-TH!BTT,?#U/C=_%_[=3A -0Z\
MO/MFN/@6"6WJX!V\^Y4*$QA5NDW*\HCI>EY0&@"0 ^<5)O'X:8E^[Y5<Q7_9
M]+$DN/K=G-/#9ZH#XZ9[;KVQIK<UM$B'5,>&>O<G(S4M#'\0;HINWQ$:! XS
MU:Y?S+M><+$@#V"Z^!40^W#>5F_Z1_4+>)^L#O@3:/J0C(#P?19/:U_F5&H2
M:'*YPG<?U$.O2AISZ-#U.")5YJ7;\N6B--W@"8\CZ_%\A=S?X?6YDCOMU(-=
M-P>S!GK#\0PAF-ZQ\U&,VXH, 5<9_2UQ@O/^/#7D\Q^>YE!Z/#V%=K7O4I<M
M\'Q\C^JS>]3+<EXB<7D%_=4+0J6'M$A940M 2.G_?W/+?^ #7 O(ELGI:RKD
M4]-U[,TT-M\S*D1HZ4"?7]:/D&EM*OND?GFQ<.>2:#_8P.-QL\5U9_2NGOU?
M'-D&6+*JIH2#6>-+AVT*+*S/Y :OMU$ 46A6MWH\?7WA#Y5A&;9/\REVX\<-
MX\6OB6-HC\9._^+,1$N:V>PGV?[@2YVB^@S5,?>_0<[]ZIBHN,(G_J?\"!4*
M3'NL,E85%M/REQJ0&[+QBA6/LSDB[I\:>=\)B)E%VR]9(GX"(< DA>4=XS;F
M(\AV^+KHKI*H]0L:%M&MXJ,_5]6A<&L)DQZ9!Z<JK3Q9..!;]%?",]-S'$O^
M ^Q=_%$$6: 3I5]G]>%KBEB=?AQPV4 :_70*5FN G-\?'K!/AJVD<&#P44YA
M_F $5AZ&W +A \F3XC,/'- P# _NAQN<<4,",HFBSUI]L98RY]<I:+E6S5+^
M5V&&=XT)$FC\*U<)G7;M#0Z(*Y_)J\?CR9-:''"NX 2?R!@T;XD_\&$3I[XE
M?OZ'^G^@N?R?([B-K+Z0D^F>3SZD3L9$,O(L?L &,GI'\73LW&S^XAU+_TL%
M+\![F?UH)U O%%,+Q5YO"44:_JET>9X?TB7T3Y7+*ID/,<D0^!CX$@[8USD]
MQ@$NN=/WH%.P4S,<0")-Q8@.(,0,A6.%A"IV+1MX_IIUC!0.OHC@7F&*J.2=
MRKE,FP-6X;%&,:*?.:% 4'SO'WK]@6;O?X1@*/ZR3U2+5'Z^<LP+\95;5B_
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M6:Q.P0&S>AHPE\S68C?8(BL4N5EDCV5C=( ,-.I,QL'/ZM&$)X3B80KG%UA
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M]Q)TU6XR*TJ&M"V5#PR+RRO>="B0NLF9\2A/#;AQ'F#,_]ZVK0C["47%[^*
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MO"N!VI"D%#*EV%?V^[J'MT0EADO,,B^HT;+T;OJDG]DJEY^6R TS W>>(65
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M!%G\F)Y&?O  P&I#1Z-9D#^#59"JS&E1)GX1J6IES#?E8-D?FLX_/W/)66@
M*>E3,K8Q[&F3CLYM)/KQD<[QTW-(T<#/?E'X"?OBO7&ZQ=)FQ_Y;'^Z1J$V$
MP\.?,P)&^(J^ASIE\8:U5&W)(2XD:AK2-B(=?X=HM2:H6>#($4G*[F2VE>,3
MQ,+(3E*+?7T^[>W'AJ=;57EX\(OBVO(GQZC*);71V;&SOTWK2N">4.LFARL%
MJ+V\"ZL6G=?3<V@N][1X0:_5<?331ESF-7ZQBM/"P*W.6Y1I[!>WY^;--X7D
M&@!/>HP2;(T+Z6,F3O?QI$^IC\LE@?G>0*L_:*FWX7OLF9WV5PTV/EP3FY;;
ML&9R-QVM];S"K( PWLAB27R]+P6/N(EL!W[B/)&B=Q&!,LC0ZD8$?)S;UI$T
M(".ZI9)E*M[-2ZJZJT\ATSS;7R<\^=)9:UD8[VGFA\$5V0=W.3D;,V0I5[9Q
M*2,(-3J/6?S._81 ^T6#O17\G_M,*@444C5YV6?:Z%7"._-?OE\S*?@:?L)0
M%&T3)TWU_MTM,ZY@EG*FP_D4O;GJVFFRT;4Z8^IP003U.S7XZ;L_AI;$M*"7
M+C0NHKUU(C6_.IWN!6DS*)G'BFNRE03. 5_(J^354Y8$+TF ;O\=Q$8-.9-Q
M_DD  T#)Z1E@ +I\D&;)32!";QSM70+>-RC)GP%N?'1 K&(1K.3ZT[/FQMVG
M7K(.I1>57NT6]OKM>Q&+M;5/?\W6>RVV-;FG'P^NU6Y.SVNQNBJ(^!D(I?5/
MJ*BJC+\/U9')CR:5FD#.%9J(Q4XE!X1^)ZB60]L#CXK8)EM.M<O#,OJ*6$N4
M32O9JBJ7&;LHRZ!N!PN18HGDE QKK>.6\G^69.!W21#P;<HB=]C1E8!40*U)
MF%V3HFM&%>J:>.& KLGDNA6<^#[QY.(R\:38"^65#^?8//RVJ >+W?/KG6NJ
M>C0-HW%G5_V!9''8PSNN*WZCIKO&D5)6WCNJWO)>05L!4M CHHZO^HU.1QL_
MKL)XNF'^UXP+J'A_;U2V^*Z+H%OP,>WK[\["?'A.&6DL4[)(NVI>#(!E0<KO
MJ59ROH<R,M12=GH=%/#!"3%>.M@HE^UEL^;PR= K./.JW^SLF;9=?"'Z0:7;
MTWN!]K\MMTK3X)6\@S)B)/K6186Y5G#X%I>B<-F8 DW3T[<O#TQY350G;O\M
M@W6D_*!%]Z]I(2U7,U$WC_DP2<AKJNV>ML3KW<7XT,=23]*+X"\?^W0*OK""
MRJ9X6!/_42"2QEVW47+-.'Y6<<X2T1'ZW#/T#TDTOJT:@@R4L7@%_:<09C6L
M,.'1+&9PG\-.5H;'?.X7'\P91 LMUS7VEQ\5'Z]1U+,@]:OL#@JKU%*S$^WE
M:ACA)VH2X]WKL33O)\95[J-VE!\H4F/G^;$\% ,XBBG?=#\E=N=P]+G<7S#H
MMA:9%'[[:#9Z3V%:]^3A^M":EV"XO>#W=:?ZA3-]/FX^P02Q1QJJH!8%_M!T
M)LZ]O [1W46[MJ-@-#$OJM#O:?>W(<6QTA/WJHI2135OJO7=5>1SR>C\,ML(
M$?UG9;'/PN8F/CS@P;/2).15H94I*])\1(.=F@D&,,"Q"OF$*KED.@&N1?Z&
M?S?' +(66NAF!)8:9V>:^<9>V$H9C>WM_=RU+?_4NOG9*:EYD4!SGZY]>L P
M* 4D%3WVY&^)8(S@7UK 1,V!Y8W9XYSUKA%$[.2DGDB]$']C[=+A#%(4Z@LZ
MN+ Z$MC_*A;28T_O5[_DW9<0*1O2-]8BHCJNA@%$%7H,^-%@1:$TS_>_S;%_
MB3F6/34E+J9 )[_9$_CUZ<0!6-X*W(L!1"#MM268M1!@T>^A--PXE+YWXVMB
M-2=Z587T%F;5#.0M@=A/)@RE.('$5V!*#J,";HRD/_^"1P+N/".>UQ/ZSVQ#
M\IXQ7">H@2]CFAZB:PX@'N ^\$D#!C!AMG7)L,O2D(%6!UY]P<X:7^03M/GG
M+HG7WP(&R@N!>Y4Y&$!'_(S!6;FK=SM:%0.('T;G< #;@-IZ QC "=:VF: K
MOS2";XALXFKE3#)=;)JS-9T4.QX\6(G)QG]Z,O<BN7"%N7+X*3=%7;%I$+TS
MP/PQJ8I'P];2"Y=]^'[S-%O[;0G-IV./!:)"'CYFV;2:^G2BD 7;*,A4N17S
M8.WN$<Z2>N%U"QD&<.GX"&LV"5/N8@!# U+7?A?,X/*-8%3.)[\9#&";/0=X
M%H5%H+@D\)(!:I%=<'GSP\1>VK[_[//KK'JGR>2KT"3JTM*BKA:>>RE!12TI
M:@$:+J!<9E;17#^1=.?EYJ<^_=ZDX4KR$4R&+T*MR)0S>&B/]$,N, !K^P:_
M(;E>AI"$-P_4"54UU#LE@<^DGBTT3:B/"MSD=G+) E'"1T!D6,+%8^3-X7GB
M& #O*@:0T1CO^QUKH'2C9F)13./07QF(J$LPTN! \7J&RMHW&?L7OL&IBL-5
MO9?BP18J 6L9ICB!N[WHKK%2:]86A5WXNED,X*S)#1G4X(+6=,< TG</D5IP
MG67PQD<#Q&H5UF2D>*&8D7'*YN:.IN+$BG@@[X'TQ2Y:QA$\K((!3!9Z0:YC
ML/U\P0!.A\#P/=]7C$A<9."1G%VH]L#;B#EWC;&.. MMU<O\/XMV\04?(@=:
M!1FM>7J=\C]\M']'JX%J0P9&&S%;T:*%GXS5E"02PP56)/#%3G@0KBY\W<C#
M[QL3S%&7W#"HZ>.=%VN:+,J;+&.X:YJ==C7S32ROFMWSY5R-?R?R\O'?>KI<
MTC&&5Z3SW(1TLH:JPQ'A_'.8*>A-J]!SRM\!T%G<6O24KHM9F+Y^\S;^U]=/
M>&P*U0!:NY&*G>HO18GA@D(7=Q92(S6;=>4DOO:$\P2IN^5P\MR1#[F45*2D
MV1HY3;Q\,F5"'"L@T@_[8&FR2T"]7NGM[ ,^YE1DF/']\\;.B]_2I]$G-%:B
MT_Y.X3I!64O0O###D7GC,4]=<.D*4UGPQTQJ%4DKI?L\IR^]<.:0T_67A6N2
M=BMP/2\5I3EF7BMZ<\!8=<'K5JE,H=]H9,%<6D3ZKGR_""UY_H,($3IESAKV
MG?E?YEX.Y.5Y&U#2^Z@ G?M3'7,_RTWKNN;J'KCU%F4;RA9V):^42HK(PLL'
MWVV;'!(,-,5_\?ZBUT7$W,X;I*-T_;EZ?+WCSR/;B-VDW<BK!=W=9\'%0\K[
MI6U-11=L.&36L<@JS?C"3E.XG)6@L-2KE]\V^RA4M1\4SXB;+>5O+**]MW.L
M-%[8DX'T1>](*T/Z90S%5I28WY6_;UFS#/.;?5T5(QF1%XH3DAH<_E@0DN8:
M)45&+#^>A5R']%.DSE* ^#IG_KR%VK4I1V2\U4W.AF;)D@F;@?@TR!AI(O-+
M>H74E#M+X[ZHO[\C6H;KMX8L-AO0=:JHT'X0EQ6=J_29E,(48#H9QECZ!L?9
M9H0A2J2J:8:C<W_M@S#U*N\'5NTT62)'QML5T&0&?ZBX>[==+$P0NM;EPALZ
M?S3ML(>:]&ZGJN7J55:DK8X>5U8U.08]N!6I+%S]1T417Z)P6BFZ-K"H'>S
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M89B9;[)7=J#L&U8;Z27A*CE#+)R_+S,11(!D?=(S;^(>2MQ1S(W@<T4_(PR
M,6/S<Z7E:N=!:_[^PN;0GD_^,C1 9+?I/*%W08BJPFUH*J2(:26_.,_'SNV\
MNY\49$J-_S-"/2?!/6S1NW1A,CZ.*ZKO)U=EE'I<6,#]J\";7(%K;!]ER]<X
MFB@(\)#5G1\=&]Q+A9[\6VFKOZ.UH'RK!6O-WD*KP[!O6CQ_'R0<2(Y^O^4^
M[.KF<$6(WK2S'HH[6,Q1B$-O^D#@!&T+^@KM35A^^" 2>F3LE@9ZAPPM: YZ
M0N*5Y_H!*[Y;8C>"7-U]PM([N@&+/3PY*,J*S@O@"!?Q#7>S7.)B>1,7:U3)
MN1.M%A5/0I3ID(,SD1OP-S=TX/^+;FCXO8^MPJ"7\1S&[>-$5!>FI;X/+M&)
MP-^$M>STCU^9('R&%75_61CFG"(( ICR8SQ-4S0X:,N&]L"L75MH'I$@BK 8
M1>*1+!)J@".%R85^Z01#[YJQ6Z3\5WQG&E)7K_HGH\$XVCKOQ*A&D)9#H9;:
M4IN"KN_VF$EA1KO!Q[::J#VLF8:85\  #$1VX31H.@S BVIK%ZS(<%2'[,4
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MRA:"-'G<6CMDMGX&A8++3&+<'XYYJK4?I045YT5GQZO'5<KF%@,D]R1O4+P
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M8YRD]]BU,<C3?Z#F:(6E>P1ZHTV)(_GGNR:B_1U9^2'0KY\$:F6VP><A$KZ
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MH04/[*3MN<X<5$-^@8]'T">]1)VHT4+_91O4F';H%;9V]5*1)13S@0@>L)=
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M/8H:3_C[_F[GZ*R$A_$L/.R7AP>BMK!U5&@WZ%R>FQQNY4_O'.?^Q;+R?]V
M$@1TO'=DA;NK.X-%(GV.],1%1T)QMVH)^\@G@/NY'QY4V&M5#8F.,Q-II=
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M?AY5'!Z8-#Y$X90_EI3./)7\%^KE.7\BYFT 0[!,*Z8M ]BXZ]Q"A?T_Z_#
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MGB9-E,Z7>]K6MMF@?-Y4W&IK5WQ'I&AC.K'G&5$XWB"PRXP[Y>T_J 9KJ?#
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M@;#W4RO6S<.TNTHT*4LJQ)BH7RI\2>NJG[<:]HW2KU4(C#6LAS<O(^<(I="
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M\XPE@2Y(GLP>\"#6]=[<W^Z#PGR5  P->(%C!SYVB;MZY-6$!M#-H@%C$FB
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M21K.+8Q_!%D\^VD(KOKI\0++XEJ75%6)Y5/R'$?.ALVDS@>]Y\'E6$(RP]B
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M;EF>^%.8J\)MXJA,:'_1_\H(Q.G)NG'L>."AT\XF]%C;WS1FNO/!8A35ZQ5
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M5,.N!80(Y)YEZAP[60@:_;X\%]W:-TK*"GN4'4RR'DQB)),51JNU%L8X0>L
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ML+%V/OU!9*C5Z[_TKN,?*2KWKR(M_R.$6$S(O_UE8_WZ<S5^#\Z63)OK.S2
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MT?PMI_+F;SF5]K_55$!_-UI@X(0A%F)E-. )T<%G12G> &\5Y W*RIZ=TU+
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M&9'OE_FR70+/^CI=1;\B[1$NE8[):<-+P%?P+3!XD^]FD^6=FI?=%Q57J9Y
MEE<$CV,S!KOT+Y\-2M++\<4"&V^9/7?HWE9$/*"7>]@J3;C3>B/]^M$90=).
M'1K 6G8MMZ G-GT-C 7R[U8(^Y\]A)#IP>I0[)WT7/8NW1W?<US$G][&YL9"
M4QV.!+YDW,4+C:^N.=!*7*<F,7_EK5A\\]+_]<%JP0E.3\PN&D \JGXT_<XO
M:1A,23/@$7:#!G2Y>,H^5*4>E\8=AWTJ>O@AYGLLYO='4T2AXD&XQ#)*6"5V
M1J<3OIZ;_X"%GCNBI&EBQ50Q,R>7<G/3JX&K(R!C7%!8D(P&*-AWOJBZ#[$
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M[]/KZW;?1F@J_ZMB!@]4HL7&?1"%/VZ=,>4[7:OCHC;U"+Q'T5"I?]D64J>
M&%SEN].!B$RNX:X2G>KF[%[ELU_,RZ<=&^WX^*M:E5FHYQYI9G)"L"1"W(H>
M5U#E;7;8)R^KE'"-3SIF/EUOPCQ8[)%A9)R@3<C[Z:A>>6-<Y7QW&V/R/8ZN
M:[4WV#QV@XF $\KE52_\(ANL'$\MQ4Z:8".2DMX=7$N= O:/+K%9^,?NI)=,
M-RM^FP9RB(.57CHU1R?UK[F*UJ?534@#H7<&=$ V4!][CM2J@O?+ID]5;+N/
M'I&^;VM'^C_[?O_T?;\S05Q3,1N&SL'@]KRAU';%:M%L)%@6'V]-!)PKGG9>
MO50S)E%^+"D,M]Y?4/Z]L+CQ&"TW_*>#-N0&MWTXNX;P !"QBEXCZ("OH/7,
MCFJLK('69F^-H.7[#;T$]%[X+FQ&(G+PIG@1WQODC^-?_*Y6*[ ^4+A":8JO
M9/'XJ#Q=3+P?G\[HTF-RQ&^>[6%IQ.C6_D3.SI*]Y$N2ZZ,^5M$0))>A7M$[
M4#<,6&Z"\ J=)KG@0)TV1ISO.O6PT$_2FO[..'7+3RD0.Q7&"HG>9&ZJ4,.9
M'Q_<>E1OEGG=1L-.P?T3B-J]3BX2L04:M8Z,C&II:P\/C[8J*RI?U/G^Y4NE
M(IFH@ A-R0OMT=8;V=GW,G7D2>SH_'ROK_@V\*\VT1)M64HU)\KG0II7(YYH
M*\1U+9\(2YB!IZ+]KNFQL]@6.C(?AG=[A!I;,<XW62#L\F+B#LIHV<CDXLU4
MQ[1;:>-A%^MJ*G>]:/R%@=.%L;A!I16XT^IQCF:=4CF*Y3ZOY-5"^^=!Z@G/
ML^6*6N:ACY1DQYC0_0]4;@0M;]3>7-Y$J.Q-.A#"P \+<.RY_96&XK=@*_K@
M=U$5<LCU@COFF]5WS75*\W_M2B94WIGE5# 'D4<7,I!<=,#4 =DB$4#"29\S
MB8#S1Z#54U$B0 Y?LHX3&!UG4_,PILJ@ZH3O%6QBOF1T"&Y/;IUBBJ# "9SK
MX3*<^H<QD-$4)4($D$GZB/GI+-X(-(<NEJLZ.L__?!WT68::.ORR2&'7,G?A
ML[*TFUJJ%W5O>R\C8=_?OE(6[_JU8,>%X\JK;&4&GH?@WU'ONR,1Z6G_$$_Y
M[\:*!B3F]92R%7Q8@K*YFQZQ @!^,T46LK#21V3T3\B?>5)3?.WVC_MH/ZV'
MN<44]N5@Z3,1, 1#@=OF.W0]@V9U<(K1?:M#GJB=V=O4']Y@<2=@=%VN\;]P
MI\BP!=S6U&A4[>>%E;.JEG:]Z5L;G=/R[,C%'6W-YC)BQ;?6>Y3XR,63M>V7
M:GQ.9^7]8 ;C*?U9A.,HC)\.:9Z2_S2(3<1D>TZ.(+?0FX'5W,M8!2/9Z]>/
MBY 9*^FXG=WOF7/-Q5/X]HG3"TUN-C5;,]FA%>A/\;[F&.9;QV\>\]I_?J+?
MZUW4 ;1DU1$5X"_?;1[O!K=K$ %\@J<3&3^I\>S@*"B^C,2DW&U.M)<G9?T=
M9AHH(Y"C.2?@3$\-HS<@YU_Y YL:WZ<#]&K>&D&:6,+;)YU?A<Q/U;^BYYB^
M4O101Z1JHN>JVOYP*^UC)0L0QF3#['^<%E/@@[X-TZ_@@0SL$?B12=(F]9K
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M*$#%]D9KA:=HL5M;6PNDJADQV^3'=$G%4XD'M4_Y4I$4>Q/!;4&!6DYE'43
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M25IU<_7IJ:6'IUOEOM^%BA-5'B,#=4HR_JK=@+[PHJ@6^POJLK$E7:,VW,+
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M[V<>TZ!@<%'6O1A"/F>@DL):2^E[J0FSEJ2.<YD_E3/SY'5>&W2QI_"/NH[
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MJK/R5>DD,Y=\7(BU2.!(7P>O>:HW!(X>G8$;W:_O:3LYP:?=:VPV\K]65U
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M TM2PDJMD\SUEZ-BKV.&[IIDOMH$CH"Q\G2OW^F2R>",ZI6])%6YB8RWLJU
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MZ5!3[BO@+P":1--+'_(Y]C0C%P]XT OMQ>I@P<[G%9<IT]!_\?MR]##F7'@
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MO4<W.JX#-H61M!3Y(AP5/O6:_]M,[7]$4*TQ#GXE""%*6@M;T(4V!X"8L3=
ME[=XWQS__E'G2V%Y&&=&2H95 HL?C[" 4.3 <6WYLPMZHY5+=YA!*"/7^/RU
M@JWOPA9B;25Y$=ZW>KJ)H@?/8<UEOAK%[%QD#" H:P6IGWG6JW?5%+D/[@NI
MG[^@^Z+_99*'9_L%T65+7L+/W\+/M4$7D>MR>$#NJU@\8/^21P\KS4$'>7!4
M6<,/2MT]6M %ZR!E$R2*N-WLO53]8371Y'EIOK:R76/W8=)NQ.&6@[#0N+#P
MO=YO[;MKS-$?1L,NSWV>0W]YGQD?L2_";]:O+^-LXJ4"#1?U@-%-V07E[Z2^
M?IU):HZ 9&U?).;9UP4KD&#;L[*R"CO!227S=S6T]!;E!2]F!1A;IAI;_MUK
M0/Y*@281@0Q$X 'U5+[K>$"?%1[PN^T<?3DP4?R7B^PX'M!]AEL@PS3"#S4;
M<_  U]N$)69[W.\_JV44RO'=1;=%B17G'=2 MK-78C8]CRZG!K4+D& NMVJC
MO,@/8HMXXVP9B>5_4U^U"P!U*M$HX@%1FG>PA,)=HS/RLXOZ:X4&U![BYD<E
MPYVWBGKP ,?+^-E_'K40IKXWILA6D*++!E1Z&)WC@J.+"B3\+R]?R%?[A[9D
MG%G5XRO)5SO4<RZB>".=MRQ!$Y>^D&4%&?=,L;E&(S?30-\_V8SCD!5L)IU&
MKXN[W-4>_\=K6?]3K=ZO2#+F%0_\C>@LGT49()[Q9@@5-[YW'K46XTU2)NZU
MMM_HLQ8P,'#<PU!(ZZ=PKE?T6KX??SK+FN#)(C31M9;P]$2<4-*1.JH$LPA/
M@6 X-1H12XA?BQ6(.6"6F(CFL7#+M4F147#T@H3]OA:H%<B.5GWJHEEI_J*=
M+2/4:_/)>$?[8Y[B^^+)4E.-<^]1-PAF)XI )A7V8X+V6@DZ5(;Q-]&4L^\,
M_!!-G5!WH]'9NS5H[KSO<#H^<SBE/C)I9<_-X]Y!N6!==4?=2%PK-"8TV2A;
MN<)MO\[J;QGWHZ@*B&D%,6KR,-.,(I18.) 1SX '%7M%IGI!#W0P4A)4 S>+
M4Z"!N=*R=A,RQ<KWT87?I=FKQCEQ@9M ;%#DN0\'S-&BU\+;"P^H'FFGCVD%
MDDSU82-BRB/I!15+(_+[(_+T(,>6)C=.]67>,(5]O,4M- 7TWOD+P\$R%58G
MC[OW^@TI.+Q7"DH#:?7M#X]&M2$R>DH2[29)"FI$5]7EF,6?6+)ISJD775FT
M6#-X[/#%M.7%=GB9HI6VQ@L*S;#;[YZ^E7R^*=,W/^#5BZRI<Z)JW#+II=75
MSB'I9R*)!#[R)L8#9C@V8:A))W[LC1W0)L)DZ"1Y&HI0AP[:@H:&F[ >'A4K
M7W$N_(:1G["W;X!^G=VLO&#L,C#'7?\!],<#]-)#L"<<F/58#-;GGY^5CZ3\
MW&4B\+2?B2E!G$&;*2"6-B+GJUI$2F@P<7[^QU?5 J/1']U9846L1_O@FMJ(
M3M8 -M+HXFS.W\69 !"S>,3C\MR6^/7XKQ*5'N;MU72Q:(BJT;AKU[]5VBGS
MG-D(4X4HJ-L\$[?&_ET8Q8FSEO*9"9'[N[J]Y&\ND%BV2Z%<OOWF?/NPME!A
MI8=1N*H3L7.A3/"51@17=/_2?_5DS#>]MQMY_.K]QI]49X:3FXKQJ-TR"J8O
MVWE*K*')=E7WQCHM+(-F7HMTOWC^[=*E*> !^1'I> "L<A)VP;CGC&N\]+0Y
MT'1@'VAM"8B<1"562:!;Q77>OG;:C]U=B*\392>K%#]ZZR[M7,\^FURWL^OT
M<\XQID?9XQJ356A&>8Q\OF5>3-R06OZ#/)8%GV(D'O#)'1.YQ[2#TY,8*FNB
M%]!H< '121Q)3+08QW5K3FI;%'H?\5>?)F"S9[6HM6(U:0)I#+_;YW055Y52
MQ<HHT;%J'@826.*,T=]PT?\;?[_#NG=#X/Q3BV9]TM<N,'6&!RY$KC,:-]Y^
MR4RNH1QG8GKL(D2%-?-7VHB^18_CV&&C!ICGHZ!_8'S&?YUMZ&T5%W.N*X?J
M9=R,6K (F\8#/K-LRM0SSP.'"*T+<H0W/>RARBT_')NBYW6B2+*+'";^?OP=
M#]#PAVSA @G+$NP_4E3YW3ZJ.TK"HPJWGG0B^WC+*SNHU(J\6&,4F+D+B6,4
M 9>=LMW#+(.6=-+O'3[*<??U/[]#,87B00I1:QG4U_/;3$!$/)Z[B:H_L%#.
MR^XVS_U\P% FG,=B]\9217?:6!?VD'4<.5S?>*8&79(\@?5WH:(Q_BA+-0S"
M)?5KJS\E)G+&Y]'C].P#PX+JNM%3!A1O_FKI DH5WNZH(CW1TU$?=GNYN$CP
M.K>=7&%$1 X1IV?QZF4:F.DY],^K9?X?3LU%VXC/AM35C1#K51X\(-0J^T=:
MI[6+TYO/Q@Q:<TV^^[OY2X-K:U] =B0]J\7]:KAYN7MCET==[/^G$&>A2-(L
M]TFMYLV'M0FO;.,5T"I?S7&_3D_[Z[;$VGF.CK8V"SS][T'^N$:5S0JQ%V0F
M*3='WSI5 DWJ 4BATT&G.J*3\J^G5CWQ@))35UN*30H&C?6G_H,QM<)NFH[9
M^3=-[:-$BD@G\8#7F$#<#YAEU<L1TX^,M K<??',)_1S?G])YOQ?( CEDV,Q
M/L[);)DI#3_-:-E3^/?8Q/^+!$.JBM%E>  #MP*:",().O GR.@N42@8/F2/
M\O* '$F=DZ>=5P[[P$I.(TU6T9"R^G;:",2 4__U 175P;)NS=6M]6Z'@7CX
M3M#+K]K9Q&_>L]QVZTZ[1W!H,8CC:Y C,,'WHOX0 +$\K+L"MW;I?KCJ/#"/
MH*@('2<',+^);\HYN$[4=:QQX_V<Q/NSNHOYZ6U3B)"<*(?M^@5/^9:]A6"I
MS<A 2N85VC0)ZCMP NA?Q0-X*=<ZQJ"]8\ONX^??QR;BF\)MW]6BQZHD[O'+
M*H4/NGM86Q<>QAF$>%ELVBRZ%LB'D"O(RBBL%PJ/:VH>K]NFB,83NOIMZ.\1
M]+\,NI84I$5<?1< ((M1NN1)7NF+]K3>*L]T7-QB&CYTY[Z5$XR2A?X< @XS
M7:+^0%NV&%LFO5POR_=%J]%?FRHQU0*LE[X\Y+]I(C_FHG\R!("8"'*JNOQU
M$7V!9-J;15CA6LJ30H!Q!\^]BXX65EQ%UHD_ <@F_C]?W_SFVX!*/BSX70^Q
MEAA;X[#?:RW9P?"* )VEC3('TA=H%4ULE^8,6!S4ONP<T2KM$@L+WP8_;*V[
M25==T7BFC]@'P7P4<%3H/Y0;.FV(#\]41\Z_+S2IIY;:<P-;Z5+M'7$_=G87
M_Q27)3I9>E"J[?.A^*0H[%)MM)>/A)W)U9F+0T4CZA+T>GTJ7%-PKXW_Q"X&
MG4-CYOR.CKI8JG'JOB&_++BJ4PW*#S5GZ. 1"^91^>'DC)H- S]EPV&>%EFQ
M;WHTDK+R,H/ZK7CMAR",]CX5;@VWU.2(U=INN;3=$LA5D[O+ZR)'97?WZ4HX
M@+080/@C(HSAF[]EF/8_%I"$LZG'/%(,;V,I= /ME%R5VBQT8#CYUO%.8(S<
M:*93<R%'(>\]ZF,+#1[P /:Z_OPQS"9O;B7V0\$,SBFAHT$)>,^X'H-EWW:/
M=_40'FU3AP=Q_.3"I3VSQ -B0VKN.D; ;Y*@@"?^?OR1KO+G'X']KC_5(LMS
MX?/JD+N1)34.YGB Z:.  NS'TZ#?GJUL+,BN5S&NB4LF4,D3RCE#B;^ZCV:I
MSKM36,[+TRGVL#UZK  >0&ETB@>H_%V!U;^Y((5R$H'L)'@%E[5+*.:'!X@?
MK/.WPN/K?V+J>_>;=UH*9ND#:686_"KAC3Y##Y,ZE@JR%MV><>NG(%I^-JK&
M/K>]$Z47]S7@&3'!3@NLL=</D4VX/Y$K4[B0].A_V'D9=@;RP ]NX*2@FUXS
MEW/Z[-\\5%8#C=HX N\"U[<.*2M;%4\AV@Z+.8,.L!AZ>"Z7Z&)7W_K1TY1Y
MU;D=)A@BRIJ;NQK17'L7/*/QX[ BDTW8PCOYLB_N3']72/;;N*;LJUOQU'=S
MG[0W9BB(:@$AIZNI@&<<'PEU97Y]N_\%63H^WK%U^#LZ_\*RJ'ZD@!D'VPR,
MW'E/F/*N,7_+49ZMYKFNKA47K*TNRT/T5@;X0HI :H3WPG[WJVTFAR#4@Y0_
M_A LNJ\<=!51/&DB_<G_RJ4J-?Y)'\5XP 89YJ=8)'(59[Q0B=PH$N\-;*HW
M&NW9 ]<&M0\9:,^!B+2:/*A%%V*]G/73:!*R*I/J"R<D;TN2"P_=(I<2[#[J
M(C1E:&R%!/D;YP3[D\=T%+C&T4O1,3_W*M. S4#1YZS:A=H3&QDT%_G&NFP&
M=/\B)FZ9N;OK7F90;I:PYTD,R;-;:?'=YJF$8<H&(A=QVL:WX?$P]0FWD(Z]
M2!$FX_=MGV)KFNS=QF52]J3G^DQ,RR)IHQ=]@KGU.=NI!N)*[!B,I#-" Z(F
M!H<U6&.'6%MW%G2[_G?A4.&]Y<,),2&UL29@R><)!CR@XI&M\QG,H:7YG8L:
M6MSK,>-3 6R+,+A6X-V;KC,J/&!8X7$M<)==CQ(]5%-1USG/+=V&\SXN$N.B
M":><!0VHIK+-%.Q<>XL'7$L@@_9L/<0#LOP*'$M&X#9X@'4>6>-%Q2YHUQ7!
M/M:3=RS%"Q]3*<_% [[%B  /I*<=JV1^A1SA 4^W3N97).U _*?>P6@/01@R
M6!>JF7(=8[S)!D=WU:7\TL* OD4>'6\CVA%?3P-Q3CFB0$ZX/FE.!U9 B-#$
MC_ Y'X=91=!-;/K3QRN@S_Z+E0SN,E"M:W:(+6^]#CQ@KJ#Q 8.+-C:DY,OP
M'TML3CG(U! /X-:"H@;$L+0'1F1XP$UL2-EY#T;V-*+EE!J!S-/! ]+&H",9
MV-_P/[!I[[,P6#O(9H>Y8[7G6]?D$=;6F@C[76;_UZSLN<$I4[&3.? +U&9'
MT 0Y9/]ZD!\Z>1]4<((41#=4Q^'N39"ORAY2Y+'/](,FTUGP@, A2O2H!/JM
M(Q+&[6^>/[AR^X@#*06.M-&I1_6&*G:A7[UBH:Q8:0_$;LSUU7Y??HXMR#=P
ME?EQ#TVB>L=A,P2UO46/>71Y#L?+(Q:[0WB&4A04A0=\W4I8@,3@QO  ZE'Q
MUG0N>[NB'%YUV@SAQS+OBAW(J$GY<=^8!EADZ(*87J13=Z_+\_H.>'_9QVK\
MLY7D@384,,-H%I2IVYF"LW3CCE3TC)M427.]T72OFK,^YE3ZEL6#6^QB/& M
MF<>D^=>MW4M<W:*>?"/6[]PIY>U8H6:/HUXREO[\+-!;@O45\_.+5/#-O"=@
M3Z#JYW2Q(W6<]TG<\8DKO&>/([\X@#O%*UKL4"DS0R2!ZS4!F%\(?F/!0IW]
M^.#H,YR@MQP:\0X/B -=%+>PUG,<85$SA^8"=8(P:7A\Z_%V>?&\ETA7W>GL
M1%/!'1$A0<4!R)=$]Q7!IW:8@,],<IV0I XE5O\RFQR-IZD.[\<5F#F&0Z'5
MF$:(F-#\WJK(1,DC)MYR.EAOFI^N;^-,?3:ZK=1?R8WIU\'CU/GCIK8R"0XB
M2$-=G7?"LZ(!.=8A-BDPHQNULIP(GR6;G.1X_/C[[%<0->*HWI)'3ZZIRYN9
ME0604[[8\?G4*!<CI&5R0SH3VT+&M#7VKUVBCO& \SJL&QJXP#&U$'D(7YE'
ML-2[;^^)@V-39JG.^0YAB>3U'+,&!1*/5]&.(1 -S=!X764[#=:2Y9;7Q"'<
MI$T2;@UFM#7+M<(G3+FN:LW[=_<J28+9XQ)(M>Q?<X)]9+TU0F#:,E5'U.@0
M:T=)G'H\YSNO@>J ?@N;G @;\YR*GN4M>WLN\^"LQ9>ZJ\E1O&&Z5ZQ8$;/J
MG-ZBUW/R^%O<6O]M2MW.-SP@J0NR:PQK(0!ZVS\^): %OXGZ,VUDM^76EFG6
MS!R1K>-B$P)]$5#"$54:;5E1VH,'Y%R$*GLK<\X\I+ J3";M(M[6GD@13:23
M(5JW>XX'\,N]=QJ1=6/,?]5-9F+Z_-8[?V\PEW&ZP$0 &CQ2\&_Y1NTLHO^H
MROL,]<O5&3F;O>,8&;6#FYD>1S?"*^U*WH\<,+P<=2COFQ^24Y"E-IY1;#4,
M83!=?/)"4XRXD,U;+^1C?@61LL8Z:&CD%KHG&"?!!P@!Z^]$APCG@;)V-B9&
MT3+_^/WRB=MX@,#!1O($'D#>Q U;H9$]"5Y"62,W'K*Q,:1;5K&5^-X?[+6X
M)GG\0&K(.*#+NHHZ.3DS;5PVH'UX7.6.P@)8WN)KM[E]?6K09#OW!0SY]@AU
M3+> BI'ZWGXG!RR N;FVD7+57N7#%>&5YS*;,; 4Z)^"T@2ILT5^E*OK-8JI
M#..6[#D];CK=,RJJZ^Q%P:%-#MJ8PDXG(HYPX3YO;@]!1N[H:E[3YP'])MT3
M&#Q@D^FKP=O%0;F:YUY79811.,)8 =#BHL"K<)AH.^KF LFR3E]YZKSQK59M
MAGYZ9^J:^K3O#TXS-N>U- _'A_=J"^>3FJ_+DB66Z"T+/]B-EXR>^)*M;]>3
MG\)I*#4X;V9\YX;;"9,AK6-:=V),JE=4VY/.X&Z0:>: 4!OS<DY9@%2B*]N.
MVF ASAO6?[9:8>EA]>.\%M/:6-\XI.A47'I_&T;9+-0PF^9V:P;;%30W@;IQ
MY%-R-Z4$U"2B<I^(/?8>D6G^!GF]'%V)9(H;:<0LBA)2G_GF38^;!V_E3P?@
M+[-2W^>M#E?VB2)B=T8"G=<?8G!:>I'(3S.YG+RNIZ02NF3IW"W!2J!A *0.
MEX# HO$ 6BEN[-9W/*#W <&#]XP5M#EO8*-V*>,>P((1$M*/G2B#L4/?D=-E
M937O]!PRK-'PF$4O/=;LSCULQX>%.>@5@U"5/$V7MD\5H05\$"TVY9<6X:X0
ML8(YUX(O]^R97)=!R1A,E]:W]4@Z:'[CYQ\;9(7C D54O15T[M&OYWE^U35A
M^EOU]Z$!>,"-INHUZ8'9),:#[^+U6'J"2<VB4PH>*@02IH=?D[.IVX0U0M,L
M-S3+]XG3EMVCPV_-T<S.2M*C^C(G@L1E/&^P'V!(U_?-3B1V=5Z_ML<*ZFK*
M\[569'>FX G.?89#1SE+-$J8@D4##:(J,0Y;:&[DLH&QP_@JSQ//H7V(X\%B
M8PZ:+JPT9EPLA3R'^F6KO&B,#MD6$:+\]X4MJ79-OO\P)<K[=*B!<7*&@Z=
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MU0].;Q;18Q5O?3X,G+;'--YZ?/+=*"AA=MS3FKDI7*7V)[5%GD)/L PU Z0
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M(1P_!NCDK53O.'K$FGUZK"Z #9-^J?,%!163M(DC<4GSEPZ\)R,;VO%Z9$7
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M@7.3^?DK+<4,9<W>-6GA+[5S)'W&I\)U5BD-'#4UQB;&AI1TB$4T:U_W033
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MM<I/&:N'6C)65LS7 &]B(,.7*>=$J;"W=?J98QK/'IPS;%Y=V;=@H)V'0DX
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M(VO!O445+GPB!.-W0;G)L3X.]Z;8GPE7^!G=&-RT*2\<-4$N?0K2'[$F:C,
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MRL;[+*V<&2+1C_1U5XY8V#3#1"9'59.J^JCS/G?1:C(/&F,!/BSJ[-01W%B
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MZ2)6>\29]_46! +Y@ .+]\F\MC&U?[V;?K1+G[C^[*&BC/21*O&A)NT@\>A
M(5N$\7?!VMH:XH('<G];\8R:3+:1C+7=_M*/Q$1L9Y5LOR)U8VV.^DU>ZG_@
MX-W+(I!JZE"2RI/8N[<G2TL;$4\B_>[KNG+0W;(R%7S$HF$JK^JU*G!Y.S+
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M!_#;E80] 58E**H'*9_]52'Y\J\VL?\7!N1(;3#\R5C &:7 #?'?DA3XOY_
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M%#_(W1?\]';C1Y]4.EP2J4(-;Q#",=(6_K<&&ZSF.K!&A*BKV%(WJ 5I:0F
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MW]. GZ.9S^:(WHB/:.]7D7E!W3Q[O7_ W\C:@UK%@?Y6@*P(CUYRILJEE#I
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M+5XKERWN0TJI^2/GKX>\/%"^P"BF6$K/.F!U7Z]7]?%@A]L78G5:B*K7:$Q
M794K[R&5D^&0SJZ *E>? (*Q8FV'@<LOKT'5]$W *^94REFHPK4&FOMN'\\'
MLPHG] <*/;6W%L.<6^_,'4&T&[MK;3F6(S?DIJ7&-9SX@GF"Y7EQF.NK'2GC
MSF439HCOLW<.=U_'/E=5?YRN]?Y-<&_NH0V4E))00"83"\0P-GVY(4#4<[J6
M)RRYO_DX@:DB<&B"QAT4'D0H&*3ZH*=30\U-UV?V"S<3I"IGMOPKA]^*66AA
M<VJA?&  ^X^@R%.+FF)-A.=4G0&QE"T[9&! 9KQ6W5X[C.*AQ>PL@EO_C0M)
ME\(.J8S:Q1W)G= T*<X6\DE*;O3:4*-J"FH03H.10CT&6T*=R8^0?74V?=N;
M7]+I[^ZMJV"V%#9-FV;\F.+<C=9K KZV*C;^V).:+51($M]MI2DSL4IVI3$9
M^L3H];P+0KY+2(YNP] 4MG0N##LEV@^9N2 U Y$'&9REH(_C]JJ-A_3\"E<X
MRZQM(MA8]_NEEN+A!'<^"Z,"&.)->+I%,T8RW2R6B$;Z9$BLI*1V-CU38B8O
M\ AN!(R$Y[/2N:?[VW"*2V+:BT[N;&;^1)^,'-7(XXR.1VGGP>WG]$ZJ>B6A
MYYBG&U$TDU(GY!R@-9"KU^Q:=V,&9!&WZ'1%*Q#;1VNPLU[]LQ.07R'XAA^?
M2J6NL^RQV>!9YM[EGZC/<)I#(89K]\8LR(<4#RXM9AEF+U<D\!<J]O4VR,GQ
ML%&:-%RW9!,R"KWB_P1ZG&>X-KZP,.1EU"T^?-P 'Z65P (^2GI88//&'.JU
MZ^,*-'_16/Y,10T6R%-ULJ!H8KA@LA&0*!73I<_R)5^(B(#J\17ZX,^J=A_>
MA8@]J&U9+V[.6\_1.%\'\X(:#,:)6L,YS*=3CXG&G]:L@YL"RSI4E/;A*@ND
M0U3?VGNZ?V9-:?C&)_LP9G JN?-/]J;YR^<*/AF,]9+:;B($"6<)E/;68K1^
MLG^?.H4"Y\HM/P*L 'FNQ4> :@7T@W]\>UGQ*)%&:L=DSD1\A2;08_5R.^VE
M<[-K9PB2+.FPMA)2K2-J]Q94YJQK_Q#RAK=%@WJ-\70<N$/:42HUZ[,%6HXC
ME"M;<%\CT:5W4 *^&MI? ]I1VMQU9AE4]5F+VO7/_.2(FA=3;'HPT+E[YWU_
M^]/G]*%731D>2-O';UAE#5I%$"[KFKA $#(+AS;SJS)]?:WHGRDQ*TD.6D?S
MQLD1,P%IGEG]K2^-M:W2\CS)$BC?N2?[PJ1HIQ"$2YA7E4O'-HW'E2?\6W,_
M5I830"$:.DV<)WJ^1X)[B11N30X!D(M621C"NJ8?9_%&1]9/T:W'5\KY@ZQM
M+O5_W\^X5^<J:D'1V#Z@X40KXJU6,?F2](E2/))JMF5NC3Y96/NB>,Q*Z[;T
M+N2BY3U4FOHP-Y6+60#_Q5-QR*)&S4EAZ1JJ3J+Y5>PH=YW=U[5*@L=40LCJ
M2LL&I8VO$?JO//E]5_,;_.]P7Z,C5EKTN(F992H2/N0>[LY_T)]R.@P^7#!;
MP +R&D@L '^$TMG! KG]^:Z@ \<#$\3-Y1UE,"GF68.GI*)'C5(^<Y"'PL6(
MP5.).YH1"<J!:M\[Z:$O^UXEC_5Q79MP,CI*K,PMO.'=+?4)@AX75NG?:+;\
M%)=Q>*"RXG/1)( \>N[$;-;1-MU!M#LG(PT1U_Q=BKFICCJ*_"?(XO@DZZBF
MDMCTP/6?%GP+'OO0A(?<%@-#;:YGGKW_A@^9(D^_:/$]/1%(7('<!&VXX4DV
M:-I[6(#_!'(2 CHCQS."7V[" EWU89@TG#V)XPL/T]\YX'N%:5@@^Q86Z/VU
MX;#M#T.OK8!77\+W?^V*_\GE3R[_K;BL:UM^=./8MP,-)7!AMI7Q;0G&XB%9
MDKVT"OO*\CG@H:N$.-[5?UAY_/_]^F?0QLIG[CTL<#<3,I+UCGE0XI8RU<6,
M:1'&>2R0@R/CTP.1__E3M#@-88'HJ";00O>@XF%AZV9K\MCV$%*5JGW$/OFN
M3LDI"XLT#;'W2!P_66I6KIZQ=V1&B2@!)77$VX*,RR,<.#:JH(4S+'"5Z7@'
MW02.#=*T7E)"P\?N([S)H\!AZ9-.PF%&!GSZ1VM=^:F-*E*,AH?$)KWSV4R/
M<FES,WP\5IBRKD$E_ .9<RH]<RQL-@NO)8-GP+A$>6ZKS65G=X]@2"#,U18G
M[#.7X\HGFH55*WR9FC;"\UVZ,+;0%IOZ?F=*@K33&-W86.>%5U;&XA\.0[^=
M]\#I;4WH/YZ!/=6QC'!0C\A("U(B)Z/8H>"8N$"7W_D1"YB[?KR#FYCD5"+/
M]$9%;ZT'BTX\8J( E<&%LX!P6!\B:(<N;+.N'_FW9C2NE,1JGH-,_;(Z3VPM
MN:;$'6DU;35CHW1/WN"4ZJO7_(+3QK?Q6R\0#*'SARDL<,^1K08)7^ MT!$<
M'WYOSJ%:NE9R?%UB9"&[^$E_$XHLCVHZKBWCTT'A^ K@Q[$X'%+^X !*LOS#
M%@M S80WULPF!\?' HP/#[=^= =D:U%P*L^M%I3.?7@ZQR^9#153(($J]]VT
M;KV=((:L<4\;S@]YZQ/4# H T3BZSTV;H.W772:'!4HO!'_;NBXAOU1,5C?,
M9DM%-.C3)B],;MFC>QA!TR^?+B:M(G$8-BPHIR#X3M*-YO'Z_0%7%^7S!/Q*
MUO<:5^-SM^MAOO&=FN[M%=I!3CI[,91A&IJJHA"JN8D8UDU:6J^\KAD.3I?!
M.\HB_&19^ZS;@70BJ_U"ZJGYGWRMKZ[?2,3H45XHIUY]58I3"+D3J+!B']18
M(;ZX;JRY(U);-/*D@XFC3T'[Q7.WZ-M%3:PQ8I+[-*WI+Z6TH:4)9><H;\ ?
MN%)!#UP):SC/&KZ&E0@8S.L.;HV-1Y%"'G.14@G71#')H0G-13DE,AYA@0#H
MT\0-(Q%B"I/S$A=UIN(/WO]\:E-4MEQ_P(XL3$20[CQ[F[U<U[^#A!\\ZIXO
M&9>@'9>WB*5L_YC1\4HO.R,K;<S-EX=&IIO9AZ6GMA29],S#MJ,P#-:>#T@H
M/JJ_AEH'/>(W6&!8V)C,'"7O)HYJ[1X;J/[<MB'[F.L"S\4J0=YKV=LCG8B$
MK\K6#NK?VX.STW:[?!XR]\NN;6A_5BHTZG1\<A_B?[I%OM=NCTY)9"M+?&=.
ME9T^4O;:/G>/Z"M->^.E(9]5YN*M3X$^1H7ND5TQA'!%UVE&.1O;_J6AE=C]
MN3WD7 +J6*S79$C@ E/Y^^.%J5JX96S=C&84<E88>4<NTC.%O>K[3]3%*16>
ME637:2E@TNO>OEG:<.&30KEI7E>N+40HF)*#4JRX9%R&M/H1'U5O>Z=FS=H>
MR5/>C&\Z5MPV/J2O0!?BLSBYH-G>#_0N7L@.'P&)C\DY[EW=9T1['BU5UK^T
M9E#-K'R:ZD<]8LQDVV7?O >WK<QX\+')JUN1]W-8<PE7HWP.:5I&@F'5D,N*
MADBA!DW='?.V(Z_=J$H,B5EB8.V6W<%CT5);VYWQ/1U4G'G AJIGUWI=K6AP
M)I+7MB:U<"Z/3#*RSD@NVT J-%X_U)*KYK3J?;Y"8TX$G77A\>B.S#Q[JV;F
MH!-QGEU7X[?USM*+Y1I8P&P3/;72.(=2,?<5%-2P51PW,%K,R,K,N*D"HBCI
M)W (%5.B245FC;!357Q+B-UVL4/W50R1WZNLP.P?J7HT:#UBLK3W?\5W9X0D
M_/Z$S74FB)28A-R-!JCDG.3WG"S@W-8D KPP7+J[_%WK!%XK8#(WK'\ :I=#
M#L<0M2/H.K66N5Q$Y2(PMWS&>9Y^H7V7,Y\Y8?^%J_Y%&),<5%FU64?W9D'M
MZK4<#QY0=WY?JA#IC9)E^*+:P+@H99^ 4D4]N%+SW4PB4:73-?: B5&AG<J*
M=?\MV>AUY:J(3",CE1?A90>P]R&C.GO1@U='2K[T',A?7E8_TMENMT6KKV..
M)M0TIP.FR&$E.J-88'(B[9@UWQ954/"#HO/M7(?%(^.B<))>.375Z%!K=>.:
MJ?N>3GX5\0>?A@:-^AI_(IM=4#MAAH>1%USU*B+52YT.*PQ<M-/&>(Y]3XR=
MQ27(?%/<$JF/O]PX%YK&<RU2LD\9\).4^]9?43@Z'*Z4-[U>89%XZ(0%1I,P
M+&58H J\['?JCJ;=*@5-$\_=0TQ@ 6(,P2',##.,%H6AQU$;FF7'P_G]/&O$
M77"<.<Q/]:Y.7&IL-V.5TV_9,.4]:6NMS=TC(1F\[V_+Q2(F)"RT/4)Q*B1E
M/,\<2B?YG"^8_,*\&;@T'[>D0>S"S(?W3+82LK8*_*;LY=(GZWBX6S]G3O9T
M/^Z;>&V4&9ECJO]"G9_Y.!F^Z^M=0&,=R9\I;BBIIFJXGR5(_%:OP/&E^:N0
MX]Y=L)F>X]K\/6WK3&6; I7X[+U]ERO^D^7C"/M^[S3K'ZH+E>F:UMS*$,[O
MQD1/;6-(9^S1IC9.B@5B<.&Z%_8'%W2=N3<%[^UBIA+O?% K*#<["(_BN3'9
MI</EE))JQ'-)U78.I5ZO79*KKZ BRHR8?*GRX$%$D??JP1.Y*(+<H;+9>(::
MI21$="+R%>+;@8&\+43$(C[S[B7W)H71$(M['0>;/_.24J*L9FW3S2X)7U[=
MN3E/E?-&:5A)>O9>/SVKBC)JMJTYH\[^/#]7XJUZIM:=*2^GS?RUVOGUA(V-
MO-X)H3A$NJ>THV.;1T)!1M0MC_0PJ<!(,I;%D#2F.]*[L)>6$A>?#(ZKCN#\
M)5-O"^I5_N]00_V3\&\0GH.WL[9.+26Z+- 5%ICKX" \\#T^C\>T&Q!T$'RC
M!]&>BP5(97+ *!%B''3)Y[2GR?:4=NC5]=0UG!<_X2PJ!NV\$$[ O7;1[NY=
MV>N;?7RG0696HJH/K_H]<-L,JRY2>4[46D0-._FT63<HOPY:8D=7U2HM[,,)
M^>?F;0D=41MBYJI$(J*53YSBF(IV3^,(?7*[] X+[I09%1-_S"_,3$^*B6<R
M60QJO].7EZ]*_JU^;=*870X+7.G&F( Z&)<2C0[!>PP;EWDEWBJ8(U /)\O&
M4\TMUA-U3*.Y#C[,\=HAZ[R")JHCQT?F4R(A96_0RD_FY!2K4UN5KT;#)IWR
M)S /T ^.&K;)L[-.+&91JEJ.*%.FS)P)LM>])J@$=&?#J[+.:K[#C6Q1M? "
M/0V6+LQ3^:/L.4_2UU&33JEF?T?CB=CG<9N8J-NO^WLOE0[R8W*I% EX!^#(
M93 #&M_: $/J&'%8K\E)W'Q)49N@&[.A0U>H904?)TX"+'$LLC&_1__,GX3?
M@K":#H_VVJO&O 6W$S_S'<$"#+46=&?%7[ZU5A>[\ T)P!Z.4/J.4*^1/I;A
MD7@Q$+W.;>/_0Z?+CM[_M)@B7VY!4M\0QY$0@[^MQP<<"=Z[MRZ'Z*<4&W5J
M+Q"HM>D='-QP3=N*C^6].S\1)D\CH^HU/NY^)VHRSAS!4%P=*:A)9>M8G1JH
M1NWY>B8F%2?/[C_&X^0MO5]Z9-M\X5DUIZ>6__B(<\('&J-D8]]/HCXI"?5Y
M#:\2LD'(5V/R5LW?7/ )\1YP?(;>QP(QA'M=&\@C!?37D\)21RR0SE<NVC-;
MXY4?K[>9,/!=<8 .ZH#9GCZJ67Z$RQZ8:1S1SCP#T;&O)S)D'FI2Q4C4H%3G
MT#'P&<[7D(6-&EOV=HO(N(2@TGJHV7XB4W%%?5.K[NQJ5U"+_GLUBKLBS":#
M6;H3HR$RT5D>.3E:?I2O^D#E;BF&R87X3MN^O^?$1K_B +2M2+&1;K>REU81
M>?;!(@D4:DJXA-/J"W%R7>3=6/]:UNX&]:>M.P]/,/MN8T&GDD7_DMW#<G*8
M4YA3'EW-26+.^?0N)^7;N2,\?>$W6[Q_$OY3">X)L^N=B+Y)B3$79"USUK)M
MH9)-%VJ]LUTC.-^=7$2B\I!AM'7S2R?45CP[DME>)Z-)<K?[X57?:QQ%^([#
M_C#,[<J="K^%0]%%T%[(L4E%EH# ?*(3VG>*7.#=)MO,B^H)X8[O\MI%3F&.
M>HY#[N]E8B(]KS!7Z@KH4,GN\EP2,,O@#TC)-!JRL-GTWT(S#_]45=NR<-/P
M._YH4] AP+6 ^$$T-U@[=VU"2"?@*55[FZDQIJ71[$L%^%E5Q0(KSY[23^9*
M7_,:YL,8O:;V@(0,LI^^ZMWL.!.N1)>X0ODZNS^"[P@K#D*U5_<FJ_L%8&QU
MT]>@!/J\-]H:FGC[-JY>=6 :)"5Z/#M^+&U$3<W-?N?%G#H?3C%!D+]6U[][
MV6TF1@)QN Q;&,0"ONF#H-,D+YR1JB2UW2=]1_::5._=Y7=BWM1G(O@=;YOE
M;F_876&.^<IZG;E*9&#<"D6E[@*,!\&I"1N.T]$;VOSJUW9PR;3S%2'YRSWJ
M4/&0AXS-!>MMGV)\<-#@1PV==V]+SO(JM'> D[^H6$7EXDTX_@J'97#'NO<\
MNX*WGD_G2&\;\@=DX(B>CP5S=1@T2XBW_!LY6:M9>D\&&]@$4T\YF1YXG:19
MI!+O7,3O%(C_WP-'ADC?@@H(*;U@^6U7%3JV-+BJUC?0K"3NWWU+9,7Z5B4+
M!K?8"3>RHP4ST731;KF8$D\L@&]_7WZ1@NS52=GN54*>M\Q]7EL-$J4+L-7!
ML.(UG?$;V,*?A-^/4,"^=/4@!'_$=5%R@"'IE2NQ<Z($=T-'H@'C*_.CW8=?
MWR6293J\1 0\*&S"]P"IP;;#KCH^A8<62DC)$7 K00\S6YC]/P=+W)91>EV7
M7\6DZ-@<(.) (,1]R].I,I!;8P5Z 8?E5]#[6C^ZT8E8(#I4/X"SM[ )TQ1[
M1_5IIM]1N=!UF_LW0\EHOF;4,&M=M..?9_[(8<8XZ902@,M$WCJ[PVEA7GZO
MZ4EZ%UVE&!A;/MV<ZVY[O! J>H% 4PH%4;*E.REG.RK"C4<+W[_L# */IAQS
M80$'TBG$"1_.D6 !7;QYHDZY80SP+9K:82P@OH@GK_]J:,("^G[SW6?SJC@D
MLSPQC07.@O$9A)\5:MAA2Y;>?&Q*J'N<O-1<MW[\*'!ZHL[O*U>5-!8HS75_
M*(6JRLO0SKGBK-37).@J.2X;DIL?(T*U-GD1GT#<*P)1UZX9SRSS'@YO;DZ-
MVU]79D@D<_]FJ[+7.+,SL"@1WB#BC]3/GO'@D>S,X%:P91AFQ GT"B=8KW,,
M%OCJNP4[(X_#2UI"C/<29['L86!4B.8:%DC] ,<"AR*_-EQ*Q78-,+LL=?!]
M<PLL@&GY59,_-*R7Q0)38G:%F(!./(M1_)9*%;AU*[2$B-/9<XOI+JKOK!P1
M#3L9+<4#GM>(T:AC2IS:SDTB3G@J<7J _7)/AWH8"?C4<SL+3( 9"@L,__)7
M9S'PD&E4,.4X3A(-%RQP</HOFH3-VYW-$]KB-#DT#3]SQ?NTWX"O/BP<1!]L
M! D^6_05]JTK1X03'UYXC]>IU=^>_;7I?]H4U&$Z[[4FGK84'&"!WFH$%CBE
M_LMH_@&+]M\2FVNQ7L1N:"$]T,O2SLY\:3DE2[HJ:T\S[.MN63%4@J(H7=;Z
M8#2[5U<YON<I\'&=71N_11*-!:1<@K" $.80"_3D"F"!0?RJ?BNVZS2?QH&\
M#GY8VW9?ZZ7OHY2-^#,*2XD'GR7G7G9_S$D"<']X!73_UU36?]$Y_O]?;.O6
MN*VIPXF>1DBU0&Y%)2[$9!C;<[D$?;4JZN]H4TCW9$9WOD@EY65-(L<7<=*F
M3V36X<=;J$J,A]HT!I\M]N&$^?]=2W^*_3N('3;:M;^YT3707>T45,YWK3<O
M5W*TZ_MDM7ZZ6AM99$SN[@'!A>CP(@V8)*('CS82XLH%A -3KM:\0DZ'EUN7
MBBG)0.5J4==)209O\K=?WY:[*Z9&22;*PG3QYF6^7ZG ?UO5_BGV'[J0U>JW
M-N,[!7DT@BIK1=\K]S?]S,SJW#H;CDBX?*TLX;Y^8?NKMMCHB@CJ-V'X[[T-
M?L4"-(&'6]>7]HPQ, $PST1\;O08E/*TK#ALPSE3:W/=<S*.4D8D^/2-<Y7T
MUQ\#G1==+^[\T&:NN?OM-7XHZ[#_O*PHJ?3K2>&5J3KZ"4W:ZE0WL^H)%[41
M(=4JFAQ/_EBC]_$>926G$BR48H+%;26T(E'!_)Q%[R2IW?%=XL8RN&3EX=;G
M%<S78S-TUND2CT0I1LE9[YAQ)"Z3=/"X*GN'S'?23T.THJ)Y7RZ//@W9'N%%
M6G789&.FW%'25G:\*G7N5,5;;+.NMQ(+>*@Y-X].,J%+^;J;UAE6TZ+F)3J^
M;#:MW:A:<^9^;\#7;&"HL'566%5[ATVN(L6WPE)"Z ;U3P^(VV(FQW7E=69I
M3J="&[/I-J_93=49^.[,D<U.JJ5V\8C<S% \8X42?+98@55963.B5CW7Y?"-
MI)C00UP*&&3N[R<G(![ [;%@F8V_DRJ/%G\P0!#><Q-.AMCB=\*M13'/;UA@
MK1*O+RSP7 2MCUMT*[A%=Y?\ A8H^*7+LW.$.W&8O4S<ZGIM2HRIQ1?0J[!
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M J&(JOG;QMHT X2.*1.$38@T@RV,[&"8H)>0"A6 I0;]IRQBRH/!_1C?!<F
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M QH/UDN*=%?'YS*R/G@;L2?%*$8_O1><U2=:U@2^WL<B'<;6\DS0V72&KHK
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M&*+D\X:=ZR.<$&+WS,,G'815]-1-3!Z.*3>,ZPLF/2*83]>QMK9-^5@+\=*
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MRD6^1"8YEA55%52\%A5Q7W=YFVFC<%D] "KXTX/3&" L#(__/83#/X;_MF&
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MO1R4?LQ\<\_\9HEM;7EUEH*3S+ ^0,TBHH$).$]],*(BD4$5WH90WRZAL,C
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M97]M,"&%SRR!<($0*3Y_E+\Y9Q;D=4UO*2-VV*BD0IC_AH<[3Z]04<Z;DB.
MJ57O,7@4F*  %!/4/\,$K6FR\KT/W+/$F//ZUUW%03>8H%8L N#I%O< 9RA
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M!)5<?$W@Z,"'='S_SC[S[A/L],;\R/S,F;:6X^24,AH<+E!JV_1UMS+I81)
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MP=4TAZ!$]2R@>N--4YE+).@7IHS!?((_*;LWC+3T6J;]7I_=8".$TAFG/=?
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M<K27T9*_G[']7%+HHN_P;PI&KR=>&4DV%_X7F&:@9_^"[2Y!E]@9@ ^2^0Q
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M+=T?- "E)!K+!YD?\Z&%KL9T3:B/P%H9 "XLEJ]*6?PYR'88_G/W.^=VS79
M^C')](=OW8/G[U<\=_]5.:;ZNV-$@<G69]"])RF_H-*&BXO#:A%%&O>6=W5]
MG!!C=H[EG S V7T\=PV"[A&Z=F/Y37%6ROD&4#3*L[%P-!U]VEKZ0C<LR%WZ
M$V=ER1W%S()8)%F[B'YQA-;39,$ R/_1L-R=]J"!?M)>[F54C67M0EL,8%6@
MY,<1#I<EA;8'HHBL_-SV%G/EB2$)U@B/<K70Y)J*X<3;D_JG5G)RWVHI,1%9
MJ_>/;DL3!.WZ1?ID/^TG>O.$*0.P;E;+3#6 GA I^AW<=P8@O.\D P T;6*&
MA,G?0#G]GV,HE5V2IPUK7&< I R^C:*6%T&ZH?-*9 _O1Z-#&"#?16>#AN7@
MOC/<AE]*(D3T#6UT%3EO:#VYK"*]VI/+QV>'@Y08H=/ZM]XQ .__0)4>)PJ$
MX%0,/UN#JT$AUVSSOZM-,R.DC&^YV)_"*I%][DZ+BN&UI7%+R1;.^D<G3+/C
M*[[%F-X<:3GQR!:/<V^EY:)2*,]H+REQ&?W06WWQDT(2JAR74]-DRG&WUVS,
MO+$MR[[ 5)Y;?*B0  WCTC#EW4E<7>"YCR$ASZ:;)>]X;@/?5]UEHFXX@F+/
M "@9OM?LF>?&C&N&Q39D-=->YN#O@%9;B+8([[K66=^#Z$M[[YR>$+X&F1KH
M*?(_V6G3%KQNK)!G^N&(RR4F&P__F^@>$*7;0U7VYRG>-"V"T)>0DEJP\_9$
MHYU)A6N14G(;CS]*?B2=6@Y"V,Z[;0JUDVY_O*V@F/[-0Y)MY#PF/LTX;6&
M#U(&?*0 V\AM[+33-[#1HB5I?A7PXO*ZHQ@ 3(3Q>*Q*N*^XBU@6KKK!A0M>
MY>=GBK/%Y!9)'+_ P>S(LHMS8]W2+AVP2*SU8O+>:NG WO>W/;,H#E_O3"1%
M]JTM<NUQQ8^=/B*.ZB'Q98U?.[A(<+IMS+XV>FEE*:E92;#T="?K(0B^=S
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MTJ=07UW(CZQ?ZNM&30MDH%!GQ)(Z'7YE/1G2UF)+W*[1-V-E J):Z.^QP2#
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MBA;,S Y/,64 ;A7']GM'4#+&;<";/BX[&BM[\R3=.N1%SYW1L:DO$ZYJ_@'
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M-Z/S01QN\&S)UW!X]H^SA[,HH_50;E7Y9>]NNB7Z.#1-Z,4\R*43NCB_H;5
MA"J'[VF:A17U#8X F_019"19M\-K,3*WM'V.!(&=&:<\_&@K\RC*XMJUM,M!
MJQ]2N+@"S)BA%7(W5(.,,*=EK,B44DX.0F+8L2,"C94;Z<OVRUGY:9'P#4OX
M_<Q34A4U>ES.(K*?4FQN -E6!+39'>5^2HK&5<8RB9"9O;S/80!ZPNA.T+T1
MH<\P:ML.E!E?*4P> R^A0X)1Z]-[CDR"C$8Z_2(3]]MTQ7NAB3SFI3"?8+4_
MJW_^P'SMW>6^K)H/C*-:3L1S9JL^['+?U[+@$I4;,A\)Z3V))%M8;AC.<NA
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M'I'[6PQF-_,78[V)@IL]VXB>'D-GA]6@]%#OAV6H3BC0/:CJO-SBBI5JCI:
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M=C58HA+XWDW@(#4WK>4]9C>W.3<'C9[,W^3S>R<0]2TW]WND0\SM;+/[3[(
MAR<%D/]_O.H_\ AH7D,,Q^DOZ0)&R2USI(19O$C'G'C'_(J4<^O"54G[LG8]
M$[8R+4O>)^9/H^JN/*7N!.VHLD/\&X*V<O[L[NI6R"E^*08M]D"/?RO):QMQ
M?/ZV0'LYWFJ]6D\L_WO4&=1-<R63YX:":W#K""O1L^K!KZ@Y8&?JQ06++L$V
MG*7$EC4JA):^WMA>7SEB8F!D9)%0M';0$Y7W,/):AD2A:W;4]:O2YCSGC3RS
M./S[KVAS!M?SM:EE3")*M+BX:*]7A9=Y'4,( _WN\!-4UK=NE(3!D^-C60CK
MH]!F:\2EE1_0VZJ>,IBT^G((=<["SX%Z[2UK9TX[_[6)R?23*C55EFRO$DU,
M1YX085QB=WK"GR;7:INS$MF4B8XW2PZJ\0<Y.2Q4KO $!N"R9E6A<IQH4HEX
M9-.)E[H87?#>23M]0U^85M/?90WK/Y<A-Y,ZG<Z,)>^EM<==4WP.9;LLW2T6
MWC>F&Q%Y8-Y:I<RQ'P["[A]C/%YZLXV879+BB/[VYDRW^OV*7U$R#YC!\-MA
MQ.XZ78T,UOE)<H%38U^L<\2.*&#;D#(SW_J&C#V%9G'0.G^4]:M%L4D5+2UM
MP\@?RZ"1 'FSCN['YE^[8@:X0&3;U>_^L(T\Z$(*@GK)N[J84A(&[QQ:<MN0
M]_84,B-[S^._V1C;W\\4;/FQTZ;K.OHB)]G)4NZFF5[L!W?05YT8/#-M&0'"
M7(!C_FOJ91AU_2:E,L>=MMU?0RZ@F+T)E1[0 H8:?=[\=#CJ8FJKJ>GOT7L/
M)#'/$N,L>5B,3R+)^F7,>)4GLK<B=IG2L%[9',Q>"R(*IA;)40Y^)F2WO/ -
M^&!F6R22V-%OH*7UZ.,/[F3M)P\.MR69(B:G-W+*%NH'ZEUO0E*6-6V)M*^D
MAUD!?=@U6]*O5GY H LL8$>F[[^P]]Y136_MNFC6LF!#EE*E105$NE*E+T5
M0 2DA")%JI006H+2LFR@E(0.@H#TWCL($9'>I!-"B/2: *&$0$AN\HV[[SGC
MW'WOV6?O[]Z]]ACGWW? S)SS-^?S/F^=LSQ:M_>5BD3*B;J6.\6BS<)-)*.
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M$&W='-[G4F27]_)6KY/(49+O?LB%]*HZ9]9'\28F\7TW7_/J\/VD4\/=KS3
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MYSI,S;J,I+6-'E]B^Z:RY\ZCEW=OM-_J0='4!6X0KU)%J<S(UK^6Y?@/K ;
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M>R@!/R@JAVTZ/]']N1R^RJ,"F4??/<N'G'<:6>8;9B;\[<? '^LFW*40/31
MO/'8N+&>"BM@M?=/ 6Q@IE7%T<6L0%A^N;NR0VY 4O7Z$=)G@91A,@X#/O/
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M 21QH&,SH5X$<E$+S*:[+&$FG&E45GU)N.4^;6\U@ETINNC=E-#6N2")+U2
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M&7V:]7FZT7ES=1JD7.@5KH1 1F3Z1"G51^6FOV)9]3B\6ULW'%3I8]<B1 6
M(,73UCWG^<E309&O%A^\II1N0GZ!9S"<C)8Z8=]P#/@I4OY4P"FBML2;5?YC
M6K )Q+V$K/]K?:-$L&3]DLL=FW']SCON-&TPZ70/GQ\H)<4$!T]#Y4_Z2/7!
MB<3(V5,,HA3EOXCH0L<V]@)1>QAX(!50Y2ENAYR\@E'PUG^P3Q >^>F07QJ
MQRM87O">=BDLD3AK]:M@W7-M=;Y[*.&A3B*:(=2_JR&'M$UN <F%%Y]42M=_
MD6JTFIYNZC4G;%:L?HG(I/^K51C3^-/KFF[CVLN(9S8%%2[FY^*C$I1H4X.9
MN%HM4'RM)=#IG09!Y$%2]%[0%T4&\AOL_.70A[ZP[Q4+ SXLEOQ.OOU>/X[\
M@X^D0\>[[:RK:]V13B\3W=J?]VE>DG-4@W^8>7JF!'L4E7DID.,2+5;&S7>0
ML^8-+5:;*"S!\)VXR-/BV>2'LZ%C>5M+ZV8>Z5HZSG9.+TM<Z"R6_ I7X5%(
MU5V7XIQL1VN3>)H5<:08G0S5*'H2"'V<*Z\;$>B7E5W@DZ92BA3YVD:Z;.Q&
M_J: W.7"VOJ',?-X#FUDM!Q&DOLKJKUF38@GMV]L$2.D')DG]4.[;ERTDH9-
MUO[[QOG_*N&'Q;0E_[AEJQJ0T];UH^C*;D6&R_IB1K2D:D;X[;7:J9ZB6D-/
MT'WA>.VBH\/SN-;T (ZZQ_*!?XB;EK S<+/]U:[?I?ZQW=9IS[2$-\& 181!
M+D5.XXZ><*'S1X_1MN+BZ/IW T/(0W1M+C"*M!.!"6I V)/#-DZQ(V;/-EVX
MOG0;B5BMM([IJ0AQ&?7IZ;SOM+.'>]O'YD:E-&2\W)R(@FS/7\TM>C4NO?*7
M0=[DF]G;X/&(+C<11'+.X O\V*9)3.^BH&UI3CG<II<77O0A':A<;$ ROL#V
MAUI#]]T?AZ&/@/)!D__'7=W_!N&-:";)8 ^UQ&<="IE+V&&HW<(.C:-J/5S=
M>F>"=/P6)"Q0+]RV2U.*6QUW07TN(AHX$81U;.^(^A66I!^ER<B;^E=H6+2"
M[$PQ4F)LX2+GD:3QB!P_!V5[W'Q* )TJ9_T1LW3 1G:I^0S[D;NG ^+2V,R^
M32C!;=+=-=:UP2I>R.Y[KW.N2Z"&O_,,S3X5)093 6U2Z-18'.G:I^WGUNZ$
MSKX-X9;=.-])<@!FH,[VF[Y>7SPK>W8?!C7W7'TV0 1F*FW0?CO6Y5C.1(!>
MUSYF%!M4GGS"UA3*!17#?9RA M:5JY'A"U2 \F'*Q#=7RS@5I"P#F_WV5]&9
MF48D^Z7I:8PLDY$>T I<'5"B$6BN%7+!B(7WNA'W&=:\H_3W]WT%7D2X<V;<
M+MC32.Q8CN'9 P,/P!Q5/AJI,B]MQ,Y*6EZC/U,!^]I]OC$TFRT"?3M%.ADE
MI0<7MMDA=YQ<8SX8Q74CNK*:4=6,X.3M[,%R*+)S6X.L.EN1@+X%_K27KU?4
M8^R4\SZD"TDP\B1/*E[2IP*$T42-09T%!<5ER'B33,/1NC#!"9?QJE6Y"<46
M$OP6@QH*@#)^N%?@B#$-'C#7M?G>L^)"YRLY4!+B1K//LVJY:^N>6.[1M.,[
M <[WG0(K*YW6U@6&;<(R4C*=;>[!X6'2YVPC;NL*%OV\?]:JVKR=_/O LH?2
M;BEZ]<GDU'-?%:O>V?E;2*:0U?W=<DU=6_]8QLI0'E'^:P:\7'0:$TM==H[9
MTFE1N>*C3LTE9V\WQS2L$X'DOE#VX I2Y)Q2[ZA7\*/99H/]=I LY,A$.[@Z
MM:;!SE($[[PG$--SA/O6=R@S-<L?]!-U_IZ10=+LP_ZHX3&P:?S[0MG7(;1
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M6LDV.)](!8Q,N5II K\>36JXE37+F\HSD.8S)S(2+QSZ'/SQ0]>6]Y&@QM7
M/9X!7/,(8E6I8W#F[&+,771J9>_\1VO%%C>_25.".XW!Q$F\4J&BJ?\U@A5V
MCLC0%B;7W_FS,"J.J4[\A[U@ VZTI[9'5*:B!B8@(JT"! M[9)@I3")1L!7W
MO4U22G 'Z=H>>A':E3V-A3&'_K9<A:H%[3,NQ8&/+HUA..]Y-5THJ BIG CQ
M9S$MPV:&QA:Z^@I#$G/>J^XDI9?4/WF:=$A;N 'GOCO%/(!Q.69/!TJ>(-J2
MAUN<?= ]'-'P&5!*JA/!L=^\?+OA9"(7//2FW4Z\J;RX::U#^^?<(5$^ZVGC
M\?6+QOS<>G?T^_Z,UQIMIPE-/!7P $<:(N=3 7_U',%[@),Q>>VX[$.*=8CE
M#";S5JP-<0/8T>*!.>^Q>K<KD9U'ET^_Q?IJ\D6;D;\]'_441:+Y"+[!'A*<
MC H5(,@.Z&1!I8XZ5[#0FX%*]'M=990'_MG6!4CX(EH-8M7<_O*87^##3",9
MK,*PLZW06K6VE_[UR(27N;K/VGAL+8[]^B!E$\O;(N;'N4^WM4_NIP)^*;*M
MKKBM6:? [N03=Y+7XC[7F<F7R_I-DI_-9V6.F,5.]#F4&C?[L_B19IK9IJ0\
M1NVH@ \RX!+"E;>;R>L_RZ"^N 9[$FSOVB^UWH'(Z")2^WB(_;2"YYC8Y[DD
M:6REM8R8RY:MHMQ#24QLY5TO8G"H(G.G_L64W$+P]:?PY(MGIR>6P1X4$Z7=
M+*54%*>WGW6GSD?K&T&UE7Y^^WV'N*6YS*MY'LM'$Y(!/ZL:@5TI;3(O'!=S
MBU.B+R+%#\'"8KR/(HI9[61E:/%P_HGU5]J:6+- ,ZR4XMD0S>'7Y,&)O@I&
M#S=1U'H%8<ORG=HG]9MR2U_F@OY,%(F8'9MJFT<KWMO\)5P6_S5!Z"Y-11UV
MEG_M)9+<?;J>+Z."2*ZT"$D#,EA%HG]27V,6<CA,4AN M'S/G\+C D/J7+RL
M._!5]:J3)5A6ISN,,]DIN;D!A2KQ&C1T;<SZ_UU=?=F7S$6TQAOXVA(FN]'O
M8;=!)T$V?J>BHQT[')MKHL7;X/&8F;I'[!4VD1!; L/QS.O99H[YO+[55R6Y
MN;'VA;&%-:^-S@]PR]+ /,W\2NV<O:[1[$RFQ:LCLL1-*F#FK-N0*KI(3KF@
M1=%U*G#SRW%XZ;%R93%>FA0@PZ_K2@^?0,G0->B-:&7K ZMKQ1\^YWE-@SGE
M\IN !)LO*+:SG,4M10S%'-HWVG+"D-<05/N+LR-V8JMDD<G>OX&R-HC$LD7*
M_9C]\R3Z7@KF4!_WB,N@P!R%^_TQ,_#NV=?L6PZ2;']UZ;[<I9D;5>Y;:CIQ
MG39[24D'M[=\+_*H7^2EOT@O[&F@-SS2>B??4[7D_1L X.R6K>H1PFB+87<S
M9'-,H;1A'1%GX2<ZUPU1V*LK+?%B3ML>:/#:N^/:<%F 3[0FHN:YL7E\QM6B
M"Z5 ,.BK_J48K 4V" Z.K)9Q-]F*@4TT^S=X8,1>^%*F6EV;$^MDMND>]E^:
MG FR9=5\ASF!7HN%&X9%WHKLT%/1N?#LMWR]-XK9M"GP0>]1 <D(_ [)?CHI
MJP</^D6+V_T(3OKZMI[;S?Y^P_#B@:6U!ULQT3FSD@;JFAQK>5^>7E>YJ2Z8
M]TSL#PXN71JP>5TUY:J*_;[X@ W*$M/ZHBJ).:U,YA:]LN;'[POB 43N@B^=
MB^)U>D_4GCQ1T;S112?.I<;NPO(8<,:Z1_]#6/X9>Y/^@PD>IGEJ"4]C;JIK
MI%OJ&2W=S_FC^]MOR[JF5D=G+RZO-06_GT;?E15AF.WQ8;1;/#)V/*<0HJUS
M.2TW)Y4%F6*4S^S99V;PKE_^QG"9=U'44ZE1UJ2FCU\\?005Q<?-6RPO83FQ
M,.Y2Q#*_,:%+=>E!<H+NY!B__7::H,/,A1^/\6T2^@;L+2P6W/FJO.%W"QQ]
M#+2COG<U&!86**6:7VQ\L+9UXEYZ^*\NQ;P$VD:SY2LA4$5.LDN<!W3'?OHL
MR60(;6M&;P^R(:B F[=RT817&;0O1ZPI+% JP$W>FJR)OD,%T/PL;0@MZ&"*
MEN-WZU4%<CHT'>'4H'E]K])I: ;-"@JO=A&48 &!2O"H'=>=,L6.?ER41D9)
M&0<VMZ\28B\([U%6HQM2?YN*<_F](->T>1*)9%RQW2]=W/D>]P:XAV<+\N/H
MJ?QF?QP4;'.<'9'H\;*F^NB(.(NQ$(J>!NDXE$O;5;OI9?>/?:]5U[*/RGX/
MUA,PM?'CV,0:<>(%J8!&*R0MS&;9)+V%[IR0=&AF+N\R#>-X/-59,MCU368Q
M-R9)X"6*+JEQ/@!1'N >7YQ2NU,^)&?(^.5,T<N"LQG%R0O0;+4AQG<PL19#
M@JQ^L!?1X,U,XUPZT7<46)NP_AZ%"U>([H0&$5J.*2SZ3<T$Y<>D.^:]Q?>&
M]< ZZ5^BLLT#O77KK3:QQI%D ::?!#R$8J9$+U/YA&RX/I#UEA2-":FNEU2/
M+]X2F9_.*JT/;'=9W&<!57HX;/HW;,V.6X#<5_'7GL1&Q":P!YM=64DP5&,>
MC:<Y)S@5T)85V.5,B!4B<?@,$C5FLF)F.1_)C9;Y!P>43'0M"<K 7ACX_C_L
MO7=4TUO7[YN];1L5V2J(@A 5 >G2!82("$@3*:$7Z8(4::&3K6Q!D5X%!)1.
M:-(A@41 "!WI)81(;R% @!0(R0G/&&?<<\8X=]SWO><]Y]SG/N^_"P:LWUIS
MS?GYKC+GRO@L2VR/1HTLAWM3:$O[C3')V.X7K">73K.HJF.?<!2]H;USF\!<
MX$VY5UNYR];$+M9WNYB550-W;'-2_^*AO*]'OQ^%T+(URW--Q94HPJ*B&]V]
M.SY@9#$-OV-3I1"_R_Q3+U'S%E2:P 9=VUQLN*&F[@:VN5D)L3@(_>US)UC=
M\F/_O#2'@FZ<B$ALQ9N<\_"+L:Q/?-6$KR1IS+^Y=:+_NA@ >;:57PS N6!$
M ?T>S3Z"=1K8#UV.Q$UGZ2PR );ZR@\_#3;]("1?F@TG;MTH+"W*PQQILAKH
MFT@6-;R\55:6GY-G1 /Q)*4!_0GO&(!EL9VLQ7CBK_7064PQ$K[:A'P1,*&M
MTD[U)AJ]AIR]((1 Z%2_6H)U#WR(D$T;,%[F=-CBZB]\\F#J@B;YBI:L^W!T
M="G@).4T<Y3K>'E6::D!A*4966/++*^%H]$\XL%T"X>'@!''6=F ;)M)MR%D
M?J:;JYU>1TIQOGU,I]O=\^ZJ3"UC&I1./=[E]J*9QJ^8>+4>CL1_==QTLQGZ
M&"1 Z!@;,;%[=;_O4P':?D'[77F/)U<[[M59E0=Z[N-_/[I#/%1F+M,J"1K?
MII^3/*H#EVTYJA"1Y>[<&+#'M14[G([Q__V+?F--!KUJG5:I=NY^V=NT<KT/
M967!$&+GS?28#;#\J9/C"1H_D.XHL2?" '25T/YF>FCYLI/-^6T&(,"?N>[Y
M&0!JR<EV1SZ=PYL!D.*DND$7C<.5&8!M[IF31<"*^C1X@ =]A@Y!2T I.+?0
MRBW]#[ELNT!N(:5NC[D4O((B-#2T  _K\0&?LS?>=H*4]B\6_# $EYMU+R1>
MR65)2+M'W^DTT".T#C^E!X+ZY*FW& #AH>5Y7'-%U@CE'#4$.]7OC%Z;&6
M,-SDVB,;C\ET[/7>_CGR]_G&AMT!!](Q[R1FP-K<-KVH:[3EAZ;N7H;;[7/,
MM<P 8&,JF.OY; ?'B^]08?I?EJ6GW?1R)S;ZO*DFIR]33EC51(V6$.[H!^P>
M6M;?80#\W.-ZIPZN^D5US>6OAV^B-2W?83PFPCZ,*GO40VSVNSRM %&L>K5,
M1>D;HWUXF;2_?\6^S-6Y2$Q/]-G<)M8@O0.59BV)8  ^#^V]IOM1!\@:N;\'
M^[K37.FV"+Z6&)E/]+H>%X1T#?V^O_,"-L'S\&&8K,JO&26=H%_0./"RFV/)
MVW1/@K!BVF>#\YKQV)"2W)T:^L&6EF+?K^(V\8;2DJ]=M+JM6$S.W NGL^(1
M/F#_-)WR'1[O.JDEONAR]J.^VDB3_-X>#F6;.]'/:Z3F)/P)<.KX[NHIYC@P
ME]'?1'(Z>C!G6V^W)<1W>=7#8R#>&BE]WVCA2WP= EK5T#!'6%=LCW"SWZ5Z
M9-6MKL<E]S&CM()5JK\>AW&)38-YSG4@-B0OEA8/FI=!75+Q9"JPS]#N[52S
MRM$"0E7B".GAL5;SSE&Q0AUTF'?XNXNO):<S(49E6".*!5$\Z/1->L5$=T#6
M@\=3)=CN][L>*R<)$W]C /[HWN+].5,+E8R/P."4+WFY^W':XZTQ]:5K,"*X
MZ;, H7\9 :P*T:&<GN8O#"31?\$V:<K@A_9)B2VE#T<$DR 7"*T3>\C_X+/;
M?]7]S__;!E5]WP,-4#.)5\W!T?<HRIW?&LP1)O?*PU3VVN.D6J!$&ML=7(>U
M.G]OW^D(G=]O:#\MV73R$&A]&1WM][P!:DJ;6X\=;MP-Y.W#M&(F)%*_%O48
M;4=GE-0V]=_+ ;5^-E[*;)1XLOO\=ER&*U'A>G["6U?MBM@^C?:"YP?:#^;'
M(Y9\'M#469V-Q*PU8[H<UI?+JKJ7W+[D??U:\.9B\K@)>*S%>']LIZLP&YMJ
M?"'9R\-O53?$* 2//8BGB]203>:P@5AUKD8OIS6I_=TF9Z.;-<^'[D<^[U8U
MJ?U=)8>D>C/XYZV==8-MZ_^KSJ)P+A?]2J@=)2)G.W9H%U..&E[Q79IT<U:J
M16RBD&$1""@2FYU;T;,DA<G::AS$SXZ%>!$VI3DD2&;OUR1WJ:()PK!W3.0U
M[=N.!'$A@_:QMF@FFQ][T5.#XQ"O?S5:FXS0*5[8V.6AK5*77!9;6D@%^=G0
M; _)<$QA5^QEI,[,DQ=GF.3SD=@Q+]@%_*S,0^\+Z!5GZB6M8W&IHU?*Q_UT
M*NE2+P/@@U#K.<;"Z+O^*_@9RZIC=)#E,'E.H>H(1F=^R'6EJ*+@_"5.*\^X
M+P1ZRXQUZ03WR#MO3+&#5XS8M5^8#)C92C3L-].XJFBSEGW_UYH/KXIGE*[&
MWHU-'#<+J?(WQ%YENI Q^C/<S<8!J/U!;@=>FP!K135!.OF=]_#T9;R;!^HC
M5D9Z8>^J1TPX#2_6H?YFEC6V)%"HEGTM(YK=66;\>6WW29F1#_NF'<!86ZYP
M"8?PZWZYELRN(V7MY<@O/'0#+*&A\H3%H]!SKJMDDU5<"A#'BH'[8@YM%YL'
M-I-S>ZDFF>D$/Z,6 _05329Q?EQ8[1S\0+$>5N)>U.R*C:7'!NM40%MPLQ6I
MQRMS2FB*!!D=2.!AHAZ31=$H\J4-;#-P0:G1WW2<.0N30_-[E+SA\YI<(55^
MS\-?0P6&EMMHG8V>;-^09C2/=J_!SN\.ZSMCV1%_8956*QH+(><3C(_3+KSV
MO-0TB[! ^"YX;YMLZ5Q3AR%_)MV2+'MP4FP<871R85D(F[Y;!J7I,/GRDIPR
MIRZD[LBDN%9H<?8XD<W!J[1!@_ Q; NT?0XRZJ4=OIJ3_AO\SM[(J&9.=-+U
M[/6TVSI\[<QPPJ6R0K>UO4Q_;!!J]X7PK*P<=Y\F.X< 58<_Z$O 5T[G54XI
M3=H575$NRRWOF2=/*/&CW+S[&E_V%2VE2[!:/K'XRN^2@(*3U32[)>);%8C%
M160R>CN!FY-[6ADT3='$8'#.R\+$J2DIRD0.5U.LBNUO"3\\+PIH1S=D"D=;
M;)R'6\PHOD\RXX][8L*$9@Z/91I,Y0\(L$/O*PU)'M)=:73Y$19A^[[;G5XV
M2 Z +KE].T&.F\BYO )\=-QH^*2[.*ZT5X?GK(KNYD\#@_?KM]\)O8B\SC3'
M2^$OH'=QR[%[F-K[UAU$]"+HT 3O43])N531[BFQ/T"\8'^<]F.&>G'%],Q;
M^N4);$7M-S#(P;99Q/&HM-2Q/'V@2,O:\#Z2V2O]PS-H*CMT[B(#@.^G=3 ]
M\MN3,^V" \$VT =KX*Y4_*]&&[^BV8@%IVL7@K=2UO6P";.MV0T;.\H?X.1K
ME+D'+:T!+B[RD8N#(ROR)IM59?4>'JK%KF\?V<?=.[D-_!ZHQ\0\)@XEYSX)
MX)5O#3Z:+YKBWCN5S9WEH8D@X]P@UP8Q"FL^"<XOI3[IO4$V=LU/IXR;A;Z3
M4F8)OG'F4N(O%CNF992;+DIT0&.9!E&JY!.Q&&_% .3#GI$(RM.XXS).,BK<
M<WM;WV/[4_4.(7NZ*HP0.R3 1BD(+#DWY:#'*\4&Q(]VF5<16L?8HD$L*O=I
MM[Z3;*8HK1.V:^ASLSRE32&UU2^A3(_4"FJQSH:75 ?22"M'.1W8K)K:J^3]
M0 O'(^$;0MZ[@54W_^A?9CJ4 7J/2Q>4Q(S@TTS:TT#MI:+6TH_/0@OUM]-.
M+@YDF-.,*)-DRZ/XXPT&0!.XZWN,0]+9:)I'(._\469T+ >)()FND8IZLZE7
M38PJ1XU V(J/C+P"7*R?,P"A1^><F! 9HN0V["1)X1D@*P<AY+*=+?'W]L!"
M)/ (V&&9./>4)_4\DS9OA"[3S6S/@C[1.=WM5>S]>'%;%ME)!\#9K?%KMK[X
M5G*#T*:;T(;/@_YGU*GFUD;XG;:EY4*-$G2K<8IATR5[HG 3D\5/K<4OJ=%*
M5.0/5CW]BTUHH.F4!S8'4UGH<B4UI:8 >3LOWL[!@Q5ZI^H[; CHZ@QW?H!3
MR 6'7\04]FH;T;,ZG(LE']R>5SS?.]'ET] :MMU'-#FOY2,),Q-PJ*;2'_Y1
MA_<J\.'C5:ER7*:5VJR-G'8F7A^.M(45M5,,3E6ZZ^F?%Y6$M\,BF(!T!H/;
M^0Q=FL:.6UZJ#0Z5[S R/L#9XG.JVL?PA$&"QT?3Y.DPW_J=$ FG82_AX^*I
MP,^1E $[2"6V((\NFY96*P]F?S0VH4NR8UIRI-J.VGRK?.<,ZAT[ \"M&,<6
MS;%_(;YR+1 2IRB.K#">-<:T27$$%JB[?3[T.G_/9U& */?$*4]["#0+ZU6>
MA$]NTCD\:/6(S96 KIQH*G#7R,,S;'6. ;@0$+<]6U$'$=-0E:?;ELNW7L)6
MS4Y7MJ(7P#73Q^1JLKZMG<A:24GT9,_3\2JM9=A3UQ5F8#212&8 [H(^@VA"
MP!JD+$VWDE(-KBX-EGC89-.9^PK/0ZV'\.+PLP,";,!6)2]X;=8*S,(Z]7AF
M^B#1V/"%[D+#^>"9=\46/66N"[;^A(8\N@^JW[>: 9@'02_0_Z0]I[P9IK0>
M@9&'\?Y^$F:DP?4A9]C7C99&30_/"DQ@:"&DHP #WO7"8EHU**'OV'U7UI()
MN[6;166Q&4;8D"(VBM80<6([-PIT\VAUB=Q[4V!S^KAM3_\U7G1.Q-'++1JU
M'2Y8+B<FL-'W0M[DH&M)**]O0;[*WI,7W3,^;F3:IVQE+#.F+SPZI@/F9/)>
MP\A_YO[XW]"0P%,UP\U=$-Q1K91<6SN&L*P,+G,DA'?@+.,:S8O:ML2RWY4/
MK1)]"MSV]$B!O2Q6&M$C3[\+__[C%'-D^Q:I;Z'*N=D,0+]ED&>&7)4[!-0)
MC)8]2-T/\Q_.!L%%Y%0(LTIW-%Z^K&G%H4@#5D'8X<^S?B_TP-%%9;H\4D]O
M/RT4WNL3) [=+MR"$;@14F7+?$:/C7=$7[K:W+HX^H&X=@:Y%V(Q.!'B%BD4
M">FN^F1 _*6U1]Q;>^.7VV^;F7N-["]AY\?9,SB7U[\8XZ,R@K,D^WLIQV='
M"G&Y>A_XF>M6]RYPM<;FE/&8:AF+RG2GH6IC)S$(SG<%,];Y"1=%LI^.$;M+
M!"<*0N&B&.K(%C]+$PQ^-<V@$#UT76;_"T@%68#K#5AU'J;;H\[ +9?"L3F!
M9.5G/!"@MT?OQJ<-(D8"#E$7XY7^!IDSS'O@BER.#4';:CVW*W:;=?*7U8H$
MRL?:]3@$%KXLX#+7.AW\YTO-Y;$L[O+$\O?^(@#5@W.W]D6':6MKDJWD:VW8
M&\H=D]161'8%9D^G];[43X=7(I+$5N4GB:8.Q;WH^**])S,V389G+8%;OVW/
M71W)5PXQJU"4G7I(O^"[L.X;XB4=/7O=;8EHL/RM^;QND5R%A/W8P9BTOIY4
M1-M(%QKC5\1FNH[YWZ]EM&S[N:GS3$*+CS@I7HA3;JU&^"+D3M>//^#-V;@H
M?J[Y".KIPM\UNJ3'K:7W !-FF=X[RB^>_+G?[F+?77U(C!O39454+:73=N[0
M?1"K*^\QV:R"6O[%73W!EWC>"7@%5&[@E 8OS2B/266(X5@O2?/\A1D9CJLJ
MDMDW-C3] [GR_,!H^CH3J:$V_[IZ596M^]+V%(XK&-1 ?PSQ:WZJN%FHN >!
MA%-S6>+<D?:LI37?ZH-H^*E^B[Y32Z_LNWYV#[=75O !\I-.;G:V[7HMI5N$
M?J<<CZ,$%"%62\=VLTH> <Y]N3[VS]@45&YLEGGOZB7^D%4W^JDG6B?>+N?3
M]D=K['?F@.&$5)B3Q<3$>&PAT:&I<%!U@D>Y 0/QTB+-W5V53K!+@G\$BD[A
M'X\9MH8.ZUC%.)A>?,YM-07T)^320>3P+JK8\+$6\6JY4Z_^I/7D9)9^+4F&
MVN)K+WUU2V_S7<'0KZ*>A1ES'(^EN!Q<+ND:Y.54ZL,(YNQ\/?ENL^6T>W>2
M@I;BKMO%+F>Z6O^CW %1ZV[<X[LO_TK2 OSFR_S-+[9Y*II^T!YL59,\^A'$
M9&HK-KF!W+6P^3ER=SH5U4FJUR#,V#IFQ0/?#7TOYFP2J@9S]%T8_]EGH#%:
MEJ?=R<74#JPY__71J: [ W ?&!\FM@=<A+99;X-;[FSGIIJQ8IL.D])O--C>
MKA>11/!Q-M5R1U$(BQ93HRS*LF>G2OU,/[04Y)7ROV>2/P^*.6U7GDW37X!X
M#RU70%T,P%O$7%F@.@XD_(T;X7W +R[MCE1S,W& :$AX.\NS[6*[ZJN+K@2[
ML58;KE5=#=)2-]3YDTDB2N'_]N= $BFY=^&CS)6*)HQ0)6<-5V]M7LK!>"#D
M"XZ\KOAF=-_OL5:/3W.'W'83LD&^+*S4D"R+O,=:Z7Z28W N8>LXB\A6"(]
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M]6*KO&%G[H9;Z#5,FU&%B:F(<6T/JZB4/H>,;;T>^X&TCJSN^DWOKOB[20_
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M6C-N7QTIX>E\2.:8/B=M?II=2O>[YD6Q/\\XK;[IGUN:KA-<V_K<L[;\.'Y
MY^K1N1E%EL[NR3L&!](E^FMO+4E_ HZ+*T:A\R#4'TAQ!D BKG2VJ7Y;K!63
M*TE_/#E/5!Y%./Y8)J4IWL7\=.1V/0"![<ER2MR6!K606)7'148&,.W^KL=!
M,"<S!PLWX0=EWBTMLYYSA_L; 0HJCX( #_^ZSO/4Q*1A0J[/U4TF+R:8UJ/B
M>% #JN,1^7=25P40.N\%)>D"SZ)VE2'Z]*.9DW?U%M"]L_27MKWD:E"J_L"E
M_!E;1220@-ULII\)( Q-*X<T'N$JI)2BY)'%:\K#JK5R77.8J>/V@_'FP]B1
MN@0#@PYN'7[3.)G'/TXJ_\*NTJ^ :6TJ'#1;NB6V;1(HJ&*S?TYCVP*5&98,
MEUOI(USZ-8T @N1Z>O;3T6Y<#U?X6)KWC#FB/"<]=9\9RF3>HUTQ437\34KT
MY*K9K-?B4'_\!YP8JI4!P%>%)JR#$J!K# #E''GQF VB,8:7(,23JR@XLLM1
MY_%4SQ+J;RB0OK6D,CJ43U#I]>#<;66"MM2__7[8?]<099Z(7J3C*._".-BP
M8_QB$G-@53VRK*$M6D]_Q6_/6,M+6VR*?E)8J.A$_' [>J];?6JHRK?Z7+=2
M^= 7_$BDH/#BFIMA0E-)\.O=;Q.<>F,?=TXX5OJ?\J+)/V'#-^-1(Q-5,3&G
MAQQ^M5_C@MT^Y>>PY(.,TVZ \Q/9]F^=*+#3IQ8;-33ADEF#N3"(^J65#E-T
M*MI)LDGXH4-;\KL?WQQY<WE3QOQEO^GF/5U*D_=+.6=X\Q1A9B:ERF)$Q.9O
MUM4/@RZ0G(4.CVRTW/"L@JBZOP"GK]'PR!)_NV/1FXDD%+Z,+^G\I_G,F=&1
M3HFOP_OP-2ZNSP>+B<,N:ZV)Q$6G[1MKB(!:DJF#_[=.XT+^)WY[Z@B^'NG'
M+PLT]1H_^G[I6K S,C5&RG.Q0(<ADHDS]X)++EX*EI_#;!S_V_P[F(,V"TK>
MUF, Y+<B1H^#9K'%T]G6[]<'<$V-.7>JRNUFAI+Z'!O/7DL_QR^GK3<>.3!2
MR"HKIG3?+,^<2^-TTWDUIC91S]T_7=RF?]0'3<L]$"E&'=F<;!OB_@>-&^N@
M%$ZB]EKNTBJ]7_Z0?6MP9@M$LF< AN7)Z<=" H.VOVS7/AX+0,_2SQR/8J:8
M6O4J Z!U /4G\]I2V*[%JK3:;&*M_Y\+[@C;RB*=_8J_>\5AAI8FH6!"H.*1
M\]B+:@_5&E*73@!AH+,YP,8^V7-+N:+Q=>#2[Z'(A2''6X5O-IP*\S\LL3[<
MU;@0[T^HZ\]=ANY=I7K0J Q \J1G:,TZMG/7<E'>?OO9SBR0E2Y%B!X]2^WR
M$ 4:$ZP@ ?4A4;\/&YD:D<2I'V4U["R:OEB%*Y^1%3V/#.Z/@I,M(5!I7.:#
M[>6M'>FEJCXXW"I<1V0,<:9@BF)54AD*@=8&0&PYJX/1+ GQ-U@U5'<S6(^:
MO=?-[,&[!E3'H#NQO,;,(8RD"S( MT4%!X$QQ]Y[G-1$6B(U (D,#GTS70S?
M"<NH#VGT.3BBZ?.@_BH<>-%@J^V.U[/V',,X>+YX]7*QJC@ITT)(,+8TO^AM
MCFS\2=:;?"IKZ!>J *)L99783/TZ[8_%$(%4#Y+-] PBI(5X7]<G#+7+ $ =
M7KD=]BDT$<'3H0VOQ%HD4Z9\91T/\./V$2+QD6Z9&R7"&[E,&HC?C5A@>\0
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M4G):5C<1+FR'3'V4+2^WX5S$"-CRD)U1! -XI%PGJ4TW:VRK(>Q]0;W 2#J
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MG.Q.CAN'UY8WB%%J;T45GQBT7S#T']R33HSA<PXP/]G[\BS]AA:C$O0%-]-
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MSX$N/J?DJ&01*^%_]/W1=;NYS W*W/7X_-<2Q*M$&/!*;4&GY1C%:^8XR)O
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MOH75&:OZ7C?^ 4TK($U0;E$; Q%-=9L9?,6A3XDQR]5!^D5KO)4Q&P>+A_=
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M0,B3;W?@APP[C7 M300]J&F1#0Z;/?83, Z?Y?+*50 KAO7I/!\RMJZ2BXE
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MJ* 75(+V[-!]]T;^QL?5U\3F\2D3GH2T=<OQS1ATF$*"]U843R-:)J/B?G7
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M2[,Z1@V^9G/HF31/-IZ&SHN$G(JE&%*1RAFK'7TY_1=E PPT)RX;CMXX8ZG
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MT.C?@K\%?PO^UQ/0I_\W4$L#!!0    ( !"*TEC14^578N4# "O0!  .
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M99/ _8%G@.^U9JT3"BP__M?)%H;>JA)COF_J9A LSB*]FM< ^\S'?I\C?M9
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M>V6LIN,^PWZQ7@%I _JE:9A#-+X  8?T2;FT-HG],@R7$0B2E<RF.G&]Z["
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M3A))'\H]'=T/](0HFD1TZK&2!M)84P5P];9\5T>CW8X+B,<Y4U_66ENYLU_
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M":UJ]BL1E<C9!N+4HE#:4":3D:?38]DTVV.?I@LHTVV5# \?=!,1L<6S[O'
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M[=CCU",Z.PPA3?AU7X0U=9%NS11T.V23:Y9,%K'Q6;.]*OZCX)N+R-IP:\D
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MDO90TXFGBL+R;F/J$2<0$OK&F UEVLDO#$/0=FN7A5O/,X:AH,2'E%&J3D0
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M\D@R*4-L\^MIK/!PGK!WN]9#GBRY+<-6NYH@FE.?C%#_G+G,LBR?$N&%1]^
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MK-,:5N\9O#G62;6CAZSD>[1>:Z! V^TJI/7>\&WA)6TT[IF;F#."?UEPD>Z
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MR%%)*>HD%R?5PPMSMDO2-"P*D]2-Z*)ZY.?B=8'Y44=%3&'#PX1*&$QT?DR
MONS]E..\7S4T\"20(>'K/H;\GYF,T9K,[0)76%2VQD(BRE>VBBJNL]JQ'/?Z
M)X6' JQD[87H>]F]I41DB>9!IN8:%&"P+-ZA;)AYGA\.(32O]\8T1-38D02$
M=V -F$X++..-<W//K&7+^R<[>F;_9$?\N_%DN]B-$\7):< J%L\+P%QL.7US
M ]97MHRH-.9H<C[*&)@F(1\U*?DR3!E5+?L0]A%(7UI@$M'%WR*')SW(=S<E
M-V&3_*774,98#82*4JE-R8N6>GD0;8193F<^7IF#"9'#L!MAB4HL.3?;Q#]1
M&%B1.Q_*F7.]_8H8.5I96[:<YO<R;M"G<I2,-:[226JY<UTVLV]"SXT$6I28
M9+Z;(3*1P@#8'NYBA&_(2(_FDRZ&_)F%LP3H3BM=V^:')%F_TR TRH<$,HM%
MA!D&%R,\-\WZ]/)FFMJC%KW?3K88%?  MU7MKYY7#H:)/U@:?^ CLI2P62W,
M#B=08R'"5:#/MV52HIOY<:KHS5W]+DV*$P-W>[Z1-I D;7.(]]#2FI0QJ"@'
M2T0IFPV'7"7U<M]B3L]BCD*XQN[)>;H%Q?C:U<!Z=8-J^2ET3D<]P'B]R#=\
M1E%/X\:MU9BPEKO#60>BJOPY"O5"D;6Z;2LVI4&P.UG!.#%U?K*TNX84 R-.
M9HWYQMDM1YJ0A@E"_MH/4%SQ*BKSEGT1D3YE8X.5T>KR3.!B3;'P:_"X;*JN
M@1V(><+#&#GZEY[-1?B3&(2\MBX!E% ]A'D&)NCA5ICH+XT0R7?@EO\H@XE.
M'2"*WD\=]<:=LG2/#E7S-3JU/Q"=ESI@7%#J7'7CA+^8<_E5]-WRN),@7F:_
M5-*H4P&5HO6!7IX.! L"<E";.:[M8R<MS&$I*CIX$Z?,%;H6I.052PN,;USZ
MZ.7(FDF]SE _RZ$85K=FT1?$9[2WCG>G32!U9J$G8-F9L)G5 &.%]8Y%-8T6
M]ETQV&8_:'!,N"7FRAO(;?/5H,8L.@U%_IY1Q?!N J&LKQ->BX^0R'+DJACK
M" L=-$S197+V;XBI&&/_/;#S+-&]WRT!U=ID?I1@_IE=Q"+215@HT*RO?/W<
MU7>D35F1O< O&5S&X6D8;+S)=Q)M/3'UO?BL<= XM[!;)$1:@PJ;/3.*=RTL
MD;D;K[,$OQ=/-$A;PX5=,XFNRE#&L'LZSFVVJ4*!%1I&"/AG)#$ :,R*"N%S
MFEX8=U*3Z:-951[!&SQ]V#6K"9*.42MD5(4NSXO]D]XSW?YAY7'^S$4!Q4!Q
M'!*6_2<!3RW'EF5]]E#3Q+FHI-@4GTY%F1S$6KVU<A]I%D3B[<W/B9H;@\E1
M?X7;O<RB>Z[I%D3N8Y?9I.UHZ9&\L6;D<ITE"_S<4A5+X&Q&5 7NGYO4G.0&
M+%Y+8\XN#M/,C]2CT$0YEBA82N)DG:!@+X3;F?OR!=R0.XUTOW,*^H8*"42_
M]]&3.U1(.13*.L#*&5]VK%M#""I7?944+K]IGX95E)00SD>8,.6%9< /S-+:
M<U4!0K*A\/SB)-$I.:[!X5V-#Y^=:>4^E=00&_U49X"A4,7TZ001_7QCS@1_
M_7,/D+TY(3/P F#!^=D4'8:06K>1RSYW[J#DN^5)67KRK3UTM5FKZ/]>G;KX
M<)2A($?0Q#@XU,14HM] K[TB/H2#2"SNYUZM.1JZ?5J=!JV&>*D#N #97P 8
M1"@RA"AOW#6BI7NG;#[AFI,2QN46PF48LF>SIW_/MJ'=96W5(.OWZEV>%U+'
MHLTJUXY&6J(6^6L<;Y)-3D9[EA@_!%<$,,N(1"QIZ6XKF+V20Q--R[1+:1ZD
MOI L^QRS<N*K92O&4IKF]+4 O2BTR!\(46.FPP>*]/(Z*R[-]FAI@:"D,J9F
M4/5:S.X8(,M_DHY])=P(3]\/M3<G;RU_T!0%O*^O;&SK" DJ;_;*+Y8+\N>#
M.B?]FR$<2J>9]]_D"-?0IY;^HZTJ.E-V&2'3CH:\+TS,XW@7GALXO16I"%2^
MH:U=I6,;Q"+AC,,6A]/"=&98#84JMRDCO,?$G#%_< .>2:-<D%<6)*DHQZ$O
M6%*Y9(:@ZFYPD;PF1]\4Q4:_QY62.3G:: ?C%_VXO!  XN#Z& GB4F8^BP@/
M9N4W['RNNNGHQ<!\WO@+Z3(("*CF&5T_^FW->G42)_6EV]3!V6TPE=9)74Q5
M3BA@<'X^(+S=;LE6J?>2@C$J49S.K@ B ANLW:M?3;8ZUN23!/*JU:A>&$KX
M>.L$[2ZF&WA:MXZ.K.@XHK9\C=KL55MW19M;2DGA<CLXX)OF&)'3D% EK[TF
MO,@!G@^0T6*CT\[;4^1]2H@1*:(>]Q=X^&:"R20A\I=2[> WYPO@+//S-EG:
MRN1IZ#-K&?G,1]K$(@1)U,P*B1>MO.XW2,_4KI%_9KKF"\!OW*W8_WG^E]3>
M#:.^T]($MUMO0H%LCNUM;EW%:-W]E?12G>%(:3>+]CCQ^\=7L&U9)U,^Q7M#
MI--=S\4[_JE-"HWO3MCOV<(J<HZ$HRF<6TRS#S,&U*\XQI6V#UVZ.Z$> O5\
M3'G&24&RYCMVQD5A6OHRY,VG7IG/GP@?C*EO^CNKBXKIH!LBC 'JF6H4; T(
MFEJ'<\BKNU@P[F^,_35T6"++KGZI$#SIWP8M#&I.RZP.J\Z$:@_R%:GG,AL6
MJ<1)T=E@"-C\*F%Y38*/3OW(B)9!XJPZ;=!_>&^R>0MR<4C>'!&U1B9MZ,WI
M3)O5N7I:?6.9-#\@UOJJ>+YZLC1]*&!^*,7P;2\A$%*('@+W69KP^J.NL,8=
MRLT8KGA?##,8;"Z94%I@DUKKL<Q3=7-^ <B4*%YL9D:.:2/)[G*F-<O_)Q<T
M2L'70BISK[PE=^^YE1:,LH-;[.71V1-2L_Q^KF-D(EB?,BBS.5-2-@P*!'IH
M2=1U.I6%[RRSLV-:G71WYQC98.: )26P<5Z#I9)E-ZO#J-?55$3EHCZ%$O+R
M]F\>3O CLOIK[K];IT5V6@A]&XOM-CLCN[2>LA;\N_C8)QS<->6B)W"56HB8
M'VR]JFT$#J9YI,;Q#7*'E<<K0[^MV6K4,.Z4W#/)IZ)B9\<&&2:P% 6B^F5W
MX6-QXD@G&]8I_2>/VYGVNPA'>Q^UJ*YXT$\J67+3P0OOKJ*E^7'SK?H)=I7'
M4_C9G/.US\W=9B 9PFXRHRU^'ZZ6ATAD4\56YVMM[)N2##$:&-,BDJA3RQ^6
M82)P;8R2,5$_R= SX=-H,@;]D%52>U#)5-M7M3YKE@RTQY,445U44O:Z5,RP
MW)W<W%+LB0J]-_AU.-*TFOZI898,WF)FX1K5G:<WDKSX C!I_LH-&C>\D)07
M]!'2S@$32U;Y++K3%\0/N']W"(&4L'5:MS8%UB9+1E9B*1<KQUAH8T8@'QQV
M)OG;A*C+@[&;:"+J<OY2MF+SW0Z<AE,07#(6.V1\O. WYOGA[&+)\FMDRV72
MQJI]@A-B/3!;&*6L$U#1NT70Q1DT62="M7?0%>U3N<2PN$WPWZ*N&LI_;F'D
M7VA_7AW.N<2N2AHF0,! H-3K?])_3B%5<I<^#EJE<11F@=?3RJWJ!!1 A02V
M;_MN89S^UCD0_52>[A? >UV_KE[M.GS%9EG44N)QX&O\]J?'SA]OIZ!/P@0]
M4R+G^U/:DZT")8K)^@_22 /*C =N==AZ.5RE=G-7]NK\O&735MY+:G^D>%R8
MRL732JAP ?_D7?WHK'=7PK)D:H.D;,5G7;"+:<.GV/2QF')X\BUTB:$-;S]2
M^8/&[<6)0^UE/0RJ-HXQCDJB]!8@T+Q<4.JB'))+""E#E=F0^4:7R9B=9_4"
M^'P:RB]<*B3KM+)\ .N[[AL:F9LG0VPQK/"?.D!^WRC64A,N#":69'VF=V%2
M%WT=<C[#'2MV_9-6X-']UC.4+DS=9X^(F+; 4YT+0EB A5-FN3LEUR :2H-Z
MG%##6WS"SK3B5C&8Q1[_U(:L?2:X;9!PINIC']LGMUD_> [X<US6,#G.L#>R
M4<-OFFP^J:HTSO#94<4X9TFYUFG:J839*^]I(I2T9'00IP5QZJI>([!WY?[^
MXY<" V6Z&6F@V]D_RU+:8DS075D]HRHM'Z,!!N2A*'=%^JSD(?6?M5X F#Y4
MM@)]IDX5JG**BZE'1NN<>L4=#>6N=0T?Y@>R24FMZK<&3(#FS!\-0_6!ZC]-
MT'.5;BB?O-MT3X"TB8^OBB0@XA7E"1COQO!99H_K]ZQ)FC_;$[(.CTY?E>!;
M1!'!-#D-AMZO/:MN^]VW?)91G4 F.0UCC+P @E?2@]]2J*4'X&CXE1;!NY6W
M<SJG(6H;+%"+K=3S'2E,.E-.>#\K#Z*N_JO/IS,P/[KJWX#OL4K_I-+BT:-X
M<8TK/(.J2!B7SIVH'RT8+9$6F8'S J 4XG!R[=&/0W20/WPVZJEYL(06[D2_
MJSYT=&?;)K=H=2!*E8^3@_PN'="8D8+HQ)2X:!WD0[0$I(GIU=Y]KMA>*N :
M7LPH5L\V^/7_@,)G=I*?J5LYC.E_@4) 1D!17#+\GL*7M=5GIWQ4!>E>!.Z(
M6Y)K/O2(N"D_M0ZF]P!3B XQ##SS/R'2,LPB*<RW^@3Q8^"U?_&(Y!%IGU,P
M!I;08AE^G5N\ $#<A_<:$ _)KW+*=QS:>],K%+Z3T"EDXVY>QI0PMA#(R]/F
M1"'CH%5HH!<9OKQ <8UX= BG-= +&33A^B+(9B*NZ3'8'&'*SM=/9YR&@2$+
M=4>M$__'IS:N[RJXW4IUNI1"P$!"TI]*0 M=]=I]*^)8!'0\V](:O*?I]PXV
MF@J30+%^ =!5;*?7>NRV-D?;(!WB/\RNTCKHX# C="23ZQMJN:\OG*,D86S^
MVF9ZO4 .>Z/#$J >;6X:JHDOYL_U]R3</M"...EM"^A9$%Z5.)VE4IG^TC0V
MFX&^(+5>T 3>)MZ$,5 7#4K!D'=N^.M>]<;)]%G="_,N_=+(VCJCYD(15IG^
MY"(HM6RE-T LVF%I=F:CGRGU3-#(0:3V+8UDUT-;/9/I4!R$1A)QWF\D6O#H
M<VQ?%_?=H3F0Y'L)!MY2*48F0R)).9^&ZP^LL]<0+/F F$$[.PGT-5[RJ]]W
M)<C&9PJO+Z,G&=OC;5+89%4\C4[+;7DMMPI&-:Z"3BIN=:KMGO9S6Q=?5+[Y
MXU^=*1+B\['&24YB^9SZMBZ=R!9SS6BL_P,XN2\&*M$8J4:9]O'X OY$A:.7
MO(RI\'%*O+Q=&1])\^K&J>0UH\-M1S]EQP+XYW%'/!$9:4GSK?)2DU71<(>.
M\IA(T \1'0/ER#[O C;Y/0DL^B_)ZL6_HHC\W2NV&\-X*>"QT+,>P%3I3#4J
M6/J2(5/O&U&^7?]%49X,3*MX-%;$WYQ)D"_Z>3!+S+>&_WE4ZO9CQT+D"T!"
M>$_NB?H%X'Y)_'ST='M.M;[:*1SBB]*QXO&\>6>[[&LTDC=UNMI*_^!;,/.@
MC01S4U%F@,I8N@9K[YU/\Z-[S_=7\R2@/J0'!2P*0DX5DE2+0@G7_Y][!Z4=
M%P0EY?,=[+X967U\#RA1 15"EI#3"(S:'.1T^BE7&].FDP&><_31EY14M3:Y
M).W UTP+=!9O!9;\=2S?!X)F;'"1$3\LD?-1E+I@C_<7CX29)_C,,N'1*7&U
MS[(X5$+UYC=H>\K_]UA]2.8QNC;K\1< 6KL$&^&UJI/K&&7M*'>"VJ' /GKW
M3@U[518]?T627LMK/^"Z9'SOQYE6FX!,\>@#TT8_7,RD:J8*C+B\W<,]^W&#
MM/PSVB"5=^\$K"QZ_3A> (P5E/7&89H[4=]R8AF"C&4,DQCQ65C]#P8[UQ-_
MOL&UDJKD$8UJ>OS?SO0%']N10.;X?/7E%LA2WO9\]+R-&B_:3\/:CU[<GT(D
MO_*3F?*6B8@KG8N875C"8I&<A_N^"\S&( 4;RA6+$'<-3UW<5&'TKC"D'6):
MP"#,!<EWD6Y7BBU6L;:D7BJ;DG +:B^U,FC9_HS]OVUZ)_,"N)CO,F7B=*?L
MO__9PE2TPZEFO?QWH44E+:I8MOINUTN]I]>8Z-6G"E0G-CM!;9O\"P/[TRV5
MUYVPNT32O*?]>9]Q#V!T/!NNOWR$X'LVG,?!XJ?@DM8!+[*[MIB[\)@[]@R=
MT%XOXXH%U2.1.;?FM##GH"1H=+MVBB6I%@N:"FM&R635CD=TN[+*Z.123-A)
M?-F?EEDOI<6ZWVDO /],M75YNSU)JUQS+RS:+A:8]!_80^O=M5J+V3-!Z#E&
M,/SVK<SI"R#&]^NC;\E.[XRR<V__:L8A9HIWHJK:)-6FCN5;J:""/Q*_15C@
M8Y P..Q5YK1?"_ZG^ P;;4@J;4/DWQ).*<GXK6'-*LIL/ -]"H*^(:524P9W
M/>ELS.MWETH P(,:J<]*L-#"LZ0!+K]KOA#OM:2!LVOA6V^DXB)O1OC$/PA\
M3;KHM?;I[C.LO]:9V2R"5KLA*1@8ZK,H1W+3[M22,IR'%%DAJHK*0'X;:%-]
MFM9_$:7#VM):<N(]C6M5PF/'17VR#/,YF=P1R6A?B.A4WOCAI!"N1U&-P5X
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MPY<T7/E(X7Z:/_H4P_-CL*GX4#D47LN#N:V#%1754@',NYTQ5I5-:&WAS-\
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MP(?^G&ZT*)&#O9Z\M2XD(/'Z5\7.*:/CUD! WXE2\<V5BDICV4Y6Q2=7]<5
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M\R@0?"T!$; '.K$UNKXTNH@#C<UVK0V!4KCN=ZY_0NY9*R*0@-D3__MN/R2
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MC&KV%%[BU=2"6M54358E])GIHW3B/]\O[Y>EDICQ:6N'0!G^23>D?>EUJ)@
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M1[,,P(-'L5O>)##;X6,F;_MB(P*9!6)A )RNL-62 M6@GLM'Y6P'\" XHJZ
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M'?"8:JL\+%!)AZ97"4[X)>"-RK_^O-^8$3TF7TW( 0I)&:4YW$F:BX#Z$:.
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M>0FCPONSJ=<5/IK>S$[17THQ$[2D<$ZU 5LR0!P6QQF"MN2>AZD$V>Y&Q[7
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MD6C &[JOSA)61\$)Q4R5L%I!H[';_DY-8G-R0OP97.(?KQVH&4V6QQ<P8$S
M2B7Z(VJ>93%M9VSU968RXS6_RJ2GZLH\S P:*TPT*19J^=_&0OV:M<W.S%+9
M,,Y^<T)S[XN$'V*6S9+SPO*TM9BJ&NUBY6^&55?>_W#OWUH2Q/AS%Y]UEMKT
M=DRU>50VG]"UV6L\%67HH5"J_ 0P\UNE,>2+6J:CE?>YJ5J<"YU2BE*W3+]2
M^(3XOU;?^O_G#V#K0YWU:.00?#8^D':?<4G4-P@JO_]X<&.3P+RH_"D:PU6
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MNY\MW_RKST7+6TE85P49G<T>NAP]4M\5L%T.2@2JF? ,%$[/_RW6'C4X?5S
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MWH;-/;1*$GU*PW^KL_];_"D#1<"19 !!@]BV^]Q7^RAID+/"<H9 C& IR_N
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M^+>%D$@,J0@]^YQT.*"_+OS;H\Y<0.JC1C@]S<2$1&%95C#MZ"T)0.\-+H
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MYQ1E?@(7!@ZP5BJ3W46Z,AX"M<?NU).AC(0?!)H[Q>17B+]T$.@-5ATYS)&
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M4=/K/:>J[+R>T:[]8+,\+&:^\2RQ\, T-2B?2-"K5M759<XI[;,YH)7\4Z+
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M:\BZ,E8-PKA& J!$0V/A7-)IZ$(T7>6@QE7K#^9+3^ZQKCU6K;ZC8/0ERK]
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M9.THK=3?V:.3,F"SV#JS*^@^R:HGY6=;$1>M>3! ?T/A=GWD*(4;&!MC>O6
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M;!OZP*FCIZ<$IT5J:P[$J4B P,<BZDFJ!*\YE7S^+,V.Q%4+,F5A_$ "2)(
MJ\O[#97N2XC*U5*M;?66JEH(S!(KDFT0GRR2G-/M\M24TDWHS>137WDSTQ'&
MP&XK)\=U5=[<G.P"?X?55ZM*9.Y]SZ]\URP1&Y[[QQNI>QS0,8^6J"L#)T?3
M3,TXN0^OO*\87%;+*,B:*$K[)S/3GL\X@BL]]T.6BO]3UVL-)R_M& F;H%A;
MLZ\>M@)$3R_YAS><K&9$3.HEY,)-FT(*LT.$U+_&Y=Z(+LW)06$%/SE7VX@(
MXRP+G.ZF&5G1)K12[%XTW,;OHG?W(]8UVAO4UYMXBD[;#_0\D/?<$=Y"U.(Y
M$SM-M2KF]=+99K(9@O1%CNHG_EFSCZ<G'<7O*M#[2=PZ?/]B[",5F1AA.L__
MOW$@]Q^O']=L#J-URHK 4UJX9V2J2<'ZSNJ%TJ(U[\UPC+!YWU/)Q4!?Y(\O
M?UE9Q\CW^:%$O&]\)0/_P_,*/GQ#Z/D0:$F+YI1L+H4>X*//'9K*(1W+^S\1
M7;=D Z+\!7AJ<HQ?C4N)O*/,H*-]=_7\3^]T$#"G2>6=IDX.>JJZ3&[9$6L:
MV^ ^N'K<L3>#3RVNVY=ZL#^FZ7K=04!(8(4"$SW2]T#F5.S$WL;)V^CV4$R
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M)2O2\L3R@H(217]%-GCRBZ*QV);Z<]W8%,SP<?D2%_:&"C(?DVP"(_2'/F&
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M/<0:1^\BO*K0=39%P']M:^MYB ]>P]D9Q&X/:O+<P\DY0E#+>8^:299(0\U
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MT;UZX_7NA;X.;U/!8N(X>&%.7I]<- K/8H\DS&YCFVBIH%LO.;<@22#5^DU
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M"SUIP\\"U;\*KBCOTC!XN)XVS(.27I1YGS8@;<#V.AQ>?Z-I%:#MB;KL9=
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MM-?'BD^X<E;.&UQ/!)J,4ZZ .;4!^Y/*,N]B!:2"&'IFI(Z'&4IF2FYA,M!
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ME9HKFJZEVS:.PPM@E],+)0U>G960#'47W]X>%.#EDLZ.YS95Q\9NMKGFQ(#
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M;KR[Q2+1_,NE$TC9\;%7Q%FB@!9M)!=U*IO',\PRPS=O'!_VB79J*+LN6?M
M=+IP=P>RJ$48SQ09'W%:295.&A7'D5F.EJ( ?#B_J-Y&ZQ,A99SQV4QHNM1.
M5&>EEA<4>G._%<FNZ$W:2?<+F%PUJ6V=-N1]D%C,XVUX BI944K1"?%H=K&<
M6>T5TC;'>] )4TIO4]LS/U%X=FN1%]$LR><M!N+[_>D[O$';8R+GZ:0^G9#
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MR::S.$B%IDJ %AP<B?:>PN<EU'7 OEZ[2T!:= A+[O5DCQ(CJ1\-5LRO--W
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M1,F0HT]G(?($CX@8HZ5X-XD!^7RL.!'9R.VH4?C!,&W4\8KA6V60SX:- _O
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M$ Z+A$06ME\:_F^"/>_GV4JK0$5#KZ7/%=;AHL@K"_M!I<XED58ORV+W7O9
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MF^LIH@7Q2ACJI&?'X+>-6:HON5Y.<TO!B\7S/JD9@6*@PQY-/2I:4B9KFJ=
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M=MGKBL:91]U]DD6QC7-VE]=A9G+[JDS$XZYV:M'% >Y_3,H_]?#K,'(VQ/7
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MRG/]L01 (*P[">N0L*FQ9YC7:LZX2JU4P0^$7XER#H@;*X1G@5,R"'9V9!
M#X\M*7JD+2TE9=4UD4+S4>(-^@H\>2::I0O>+])=T XIC;(P:A4)PU'%P9B!
M]^=4.RN*#AK-T_BZ"X:_:=<97;)BMSM IVPD4\_TBX=-_0.C%T7]:@J?HO5F
M8<<68M.H;*E])/]F@/'/=WRTE+:\ZWR&8+\1 '[#[Q"8]=6P3V>%Z4BNJ)PB
M]7)R"=/O%\9Y#D/L\^\OZ^2[#TGDYI<&>,Y3; UU%K(%,6];_'R( NZAL]'K
M, R0?@ONAD]GO%E%Z/>+7X3^<]_@'2L-$=<OW*C_?@RD^Q7,VQ%ZR+&5="YB
MA0 (&(4M^NV[H^R.]H7 =&:3M[QUA>B6)KZ3O_7^CE'3';F<36/-3$RO*PI7
MOQS92JQ@G''>3/^)Y;R8F72\ ,G5R L)949'$I55'_/JU9%B%(X42ATTU&\S
M6)FV*6S80DWF+89I!A8.?*(ESFA0N9D^$RGQUW%MZ#^&)"]Q'I%%=7!%:,G_
M*-%0GI;\7=:SF:7I(@?M^TG.'!I!PKTG[3E/EGV_:IUIVN2CE\#\VPH42_Z.
M@E-:XISLO3O!J</'LI.&/"=E<!=V-BJR%WF(HWD[Z[^"^_KW 8"XHF_N[^C@
M>XG4XU&HSVU<F?!G^^V&8-2/Q[[!-%2IA3F9?EM6)\G=:J^YH0TEPEXU&A>Q
M,L#%9.OIX4ML?%%GV4>MI<PQ8+1U=Z($FX/'+H(YO&E@S5?!+*X'Z2$RTWJF
MCG!^V*M&VFB,H+RR?FZUKFDO.TTE3N@DG_,311NJ@CSN=UVT?YS0\!L=>'CG
MO ",:Z:3%K@V"$SV (-S,X^3X":*YT>.QQ;30V"?JP<MI(<MK@>\N^BJ!Z;K
MNI7LG(J,#*4#O4>YT5K]ATO]#PM0K/@0 '3J'M%53G[?J3!DY?4'3O<"S7+P
MR)*F^<<3'L:GP\<JFF6S]4<C/B>6_J;/">AU $PZ-&M[ONX,YWP,.U,:-;CP
M 5>9<AH'\4]=J =D?B3WW\EDV__29$X:NJ"'+,WI]RXN"0Z2KB!]-#DCE-\F
M89!/J)MV];+*P$C5#35[ ?VN@@R!TCPMBU0/Q&[-K9/_>XZ<N&DY=P@RZ>=
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M[MY\>']P%HQ"&91,@^P%B5V=ZVGN&I//CNU!0P">D'\A_;SI/9V[9CE /O4
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MK\=/=]I?U*QA2D>9%)E/-7]633R[CRE#E<#<X-;_/876%[-_]U,8_"+ACE<
MYHUU;G3WF6$A\_1R[T38P#EBLEVQ^=M^JF'=7$22SKN (.6>B?MO'P2.@G'W
M.SH-$  M@2O<U-2%K\S6=]XO&9Y<87WIM+]T^/L?TO:?V4< ;C3&#\3[2O?(
M3Q]T<TO3O(]V;[L)FD^%*#98&E<ZLJNJ-G7<P0L( *Z^4X%N8#T]D-./&[^6
MPNWHR^BFT3D/+ H>>,2QS71Z#$LY$D\):7V@/H9 YSV/ZO8-6E%P6RE>GV2-
M;I:XU*N-]=XL0;"=QK^2K)M#6F2#[KR_:\F!*BB +==ZK_\A6NM?(0!![N#A
M3S<X"$!$P*/*7"%Q]B&Y<T0 Z(:48$6KE_:WS\\+X= CX 3VS>VE768_P\,R
MRRD0 6!I?("W;QT:M72>&;8@ &D45]'8,C#4!QE.\,CJ;3N#%LZ1V.\/_PN-
MY1P7[Z5FQ2YG?(8*[QQM31L+#1P/V*117>V'4ZL@G@Q4"=#W\_2%Q84)-*GH
MZW\2<C=2"61PM%FJ.Y+L4Q@"PM]'$FD[(8-#MK'0OO?)ZR^"O$BDF(.ED;DS
MD,GK6>;TNEN!:R*=K'E[&:.E2^V9\#I_R:.2U/NTMA^OMDKX-R,/"O(D,$+7
ME@B+R/&')KZCZ8^\<)H=EV8VN1-DL"VU=70O\_5\VM?\YM/[Y*?&XI8GU3?H
M-X2_3?."]U@#O=H[6D[R2^<&^R0WD\-&Q,=O0M;)AF*&9E9%@)[V#M\7TES\
M[/R^ARW["'BL<:7%V1[98=J8%97^YN',NZAWK?VA*V2<00"25C-!NWXRBK30
M*D6=X$JGH_UR\$^MPE-LU3K5LCTR-'-CC"H^9!QE"5*)7=!AQ==_3GG5Z(V"
MB*11U,,'HELD? L:CC,!C+GA:2I\O.GWL=L%*!CQ;6I%X05$*"'&K]4=\\+E
M!XY.N.H#^239LDJ^OOS(C8V%!V^)]GKR)? P\0M)(>6CWOT%.]VW GY<527X
M]U=IY,)'.Q-W'M')E1%6,M]L=>ICV]Q@QS?OD' H5,S!SD/%_/3F=M<T:H_^
MF[FL=$(,HSUKM<:/*#'>-Y%"/%\9MIYG,VOD>*/G5)#Y@6+,X0R'J,B0SVT#
M0]4N>.0D:S,%0J+3G8.%I]CBHF^H&SKC"\]9#^QSYS00@"%L6-  ^P",9RHA
M_HZ@M+'AL)^G8S<P@$TNM*(ROHXOQ53FZLSD[*ES<XM >$^IAEDE@<LL0S>O
MI/>"SZ%%:7\XZN]J(4JLY[K!NNZDOK3*(0G-P>\W12S6%D5=U4V4]HH(!]:M
M4Q^H,B@O:S*;0HJ1_E6<L!**!Y-D[!ME?M"FP!("P,9V>'+^Y+3S+J)!51;K
M-D^GUF@%'UIYD_MC?)U%Z>3JR]A-_4AI/WW-EW&PVU$H:H]2,L6H3Q$X3>N'
M4M#J\+4/7+'GDJ"_/'I%9-)QUBUX/JCW(*G<_:>L:> WLV*KB8HXH8@AA>#*
MDO"6Q/ ,?5>74.;"]/7"/RTP&N__\PU^RXD1@#4JISHCYO/!F>8;BN;-UP+K
M]JNS$.#<?$CS<7I\(>/A-P2 K/F^X3SS[!+WK-5FFV0"&/SACC[4[8+\^JD;
MV_\B4U/O.S=YT$KC@45<XHLV69\N C<+=96U1B?NH_145$ *)=D37E5>N?+0
M_IO476K56C;1VHT=H(MB1;F:DJK0IH-K7+P#LX2/%]JK7@!M@$JQK>*:(?Z3
M8.S8)Q"KK;IM0BL1"]GDC#R5*BMK?6*,7[$_? >,SL /5GY!3=<5()@3_#1"
MH%[<\%),P6%\023:\V%:<?>SS61M!Y"&YY/E$MX49W@HB]M@<PO-=:#65R*;
M'_KW TX2A"O\+6)?IRR>=^'V)A<^8\#K#3ZD-,WQ5]_62OFY[*?1#"EY#LX)
M0@ RBS-WL=9V9OK\UQ5#_FE1FG^E@3&.,Y$*IM:0+)'"DM)6%K>+:5232__K
M^?K[VFJ7H?IS$8?,CQLE3)8CZV>*&HPLU=7OS[N5^^39 Z77E!ZQ4F>YZQC1
M.9BACVU[X!_Y:!!I$ #N^\XI! "'TP"LT'FV*-+*X\-B?/C5X6Z)\+[XL[R#
MIBC=Z\5,$G9')BGY&E/Z5,@S%Y;^&)K^COUE1[6Q15RL\M\KR?O,#EW+9(T*
MLP9*LWJXF?6-'1\=?&=V%')#<OL*UH;-XA/ZS7GD%%F82R2HO;:ARG[^C^#%
M_TNHV"( \$U@*L,WS*13QYV^;H7)L^CRDTQ&6W&AJQ##B8L>NX2!)-^9^X5*
M<0KR$L:%S-&8")JWI_X/4/JWVOKS_M,/6Y(( )\I A -@3YZ@Q\8X)/@F]W?
M" "8A4'K!N?TH+B),/W@"P(0Z9/)GP>NHKQC5R1CCUL7TR9H=?OOZ:U4F@F+
M][7:4SSX779TLTHHG.(1K;EN43Z_&(>O/[>73,"@(9N 5S/'J\%;<[(B1&./
MQ?=.N7:O% -2$:F^D3UI N>Z6:T2UB4/Z'6K8&"9?0XM&IT:=^">#Q\X2[ )
MAP57.M<KFVN8A$II*-%R3[(ZL7$%F41I>8.PZO3C#*$R03#\TQZBJQX+QRT*
M^8GW/>[^[@T96#^^C?=FA9YZA8=1YJS$G^C4?8="DYBU9".C?%--Q==F3OY6
MM^0&<KVL=/NUQY/NUEQ<2T.BZK08@J[R(OEK WF-"(R11S U+X0JO"(RD)@X
MU7,IH%B2ZF]U2X'">/?'Y?]4"+RSA'U" (8+=ROAAHY;YPA 9ZFI#^Y9Y5TL
M!_QT%0%8P+O'/5Z=*X1?+( 7U,7('3]40/Y[+,^,(\Q#1=6= <Z(#>N]QNVM
MQR<AL7 34)#2'Z OFM&U[Y04?9+9^[0NC5@D^A72NAII*DHQ*LE0<H,M(3RE
MP%G\PPAP8^?J@G!167S#]<'X718\/!P!Z ,=_)MK4W5'P%U9694K" "!.)4K
M.P^-#J3X" 'XVF[:4'#'U"9M!0X\PL A#9_H1AX'Z27F)(-X/.'CDE1F7,%(
M&6^=')U$-Y'6%M^O=[S#!R8^(3QCR.KDHTIES"E^LB/%>T'5.229R2D\[Y^1
M0:Q-F5\01EE8$"SL[4EM@!&&$22E+(A1 D Z$0MHP7-+^Y_:1ZFU=2/?&P&H
M:A!0.^Z8W3],F#?(A(QN":^:.8S,2S4ZZ]RXETZ H((V-LW9<?07F ;2EI"O
M,K1RW")9DJ5_EG3JGG1V]ZAXR!S\>P_L=@S PN*E<WYN31X-QX,'"K$<?;ZO
M5>W87[$9J/!SX$V?V;\N*DXBDZ3%V\[.YWX_#GN>*/"GRA/[.P+ Y+BC=6*1
MU-ZZ[KB3>QJ12W,X,LIAX1MX]'-JSQ=W)+&\]SMUMUK:TEWM,S5EQFI7__=%
MQ<3MC-47LX'A&)[2T8\BY6 PXQ5]C*UW>>7K@,$VQY-&8V.!LM<;C <#KJOC
MG8-??N)5Y@RN-4KA>&$I%Y%#\?[:<-?Q+\5"I?-&"\^6X:TOAA8!TE;O>HR+
M@\F<2'K2@Z+*@<<A]/_A[KW#FN[6M-$H"(H@HJ)T4$!Z[S4@TGL)58A([]([
M45! >J_2>^^]! 2D2Y<.TB'T4 ,A.7'/[#DSUYEWOOWNF=GSS?EWY;KR6^59
MSW/?ZVF!RW:W4 S :B9"A/"]DR[BN7(F)"/0-EBXR6$].32S"\,S5(-.D^9,
M<PM2WQW8YD8_-\?)$6IR=JUSNOHBD%*<;47(?R<8<!_0VUC-V[(X:Z*Y.@$'
M@;#@@ =Q\#";I[/V3]0\WJ+LM!E.Z-++1&8XLJC_1IM"" >O.6@@ZW;"MT9O
MIAMH%[R?>:D%,Q/C=>I)@91<QS:XXNDIQDT+7T[0/?I,\U!#.N99C #WG(#G
MN<BGYGH[[N>%XJ\]_44[26ASO?^IC=]@$8E:Y!'1MNQ#GTC]%J3[H<H-2HJ:
M@8L:'Z5W@%>&!ARQU-?H,:-B#_1B=)1;XUVQ!L&J9(BEA'0FV'/2!>F!"46.
M8P4<TP3UJ.0+N_KIQ?O\"[9/Z$\E/(X(3]_X@7AQI1QY1V>SB-H^[R$CW]>[
MVQ7_?.5#JGI%W7>%O_Z>^F&/K(&72;4@LET\B.U+><[ .WB<RRR%O2+E[^XC
M3\X*J[M$'[\>IA@=)F?)R2$V>QX7)7F!S1U']U 2YQ/%0UF-)+X^F$7S6?M_
M0DW ^.Q,2:Z$FZ_RF12E%,7,%#^SOW;I,^R[O1Y5['%[Z_C0FH^,4+Q667CJ
M O6H14J=NH<Z1NBE!!,SZM7X:,=5YTLEO_GN?D:6LUO:Q>2/6.WM3L4W*WQT
M_8X_0 8K@?5ZP.%)J_WW&$Z=B++)N&J@-I"^_BP<*_SOSJFH!-&(!C"+Y2 [
MA*_8.W8/:V:IV9N['IG"?G0$0E84$X+(::=ZZT^<\U+W3=-RO?!:OCC6.9%&
MMR_I-UI$>1*FFV[(*VG\5)17I@_>4I:^7RCNTO7@0:,0GH1L2I.>P&5W=-HS
MHI!>FAZKJ%(9*R/<D*^1G(K3\$"4C<%(0X.R0T=&ZN501 >B8"J'OL%QJB4E
MS'ASL6J?40]6!%L1UA ;D99]/,(11N*D%3QUNKG+^++UNF]L_SA\PO:%(I/E
M8GX[D8GDR:C*':>RF=D\-7@!K]A:ZOV5;)APV%HW'HOZ1G$RS=N(C1ZKRNG&
M@JRM_^DG;'*W7L<SV=>V.RV/FUN>F9^I=.8-V>T1V%_L$70JUW'Q3GE7-^/;
M\Y.5AMM&C6O<;+XJ3DGG3S&52="=T,X'8/Y1!2B*8D4#!)>CQ9:E9\&#TXA,
MU\COU!%3BY!Z1D8O%+3HJ"W;&EY;#6ISLV;-TUX>B+UCJZGQ/;I7=^PC3AV>
MJ?%O3I0[@@;0+6_-1QT.-\&7W2%"?K$#%Y W>U^7!F8-(UN$GU$GA-JM.F^D
M,G-ZP/9;V EO\2OPK)679?=.3$UU%-T!O:Z4B:YHOC!X"&%9*+#_Z:-?\.UB
M>2B] K&\0,Y0?4UK?C@2Y2N)PY](H*GWI8(;GS&44%8Z/*3%H5.4E\\*WU8C
MFT%^1JNT+WUW43?Q#UTVNW T -7/L?$,Q5+A!CGDB_W]=I9 ?13%C,<DXE[C
MY*31@2 #!L\K^"?49>/HKO1MOH_1>AUIIT@QHJCT(W,V3$YUY^E7H9N^C>$\
M:TL-;MGH%X!;R&*K\_2<!VH2[KX]A<QT;PF3<+3I_%R(KW$-]JX#KF+_Q"-P
ML0;*@7J@/&@3-?[] BRG>M.-R)N8C..[,6FK:@J:)T@.<M B@_FPV=E*ZZ>4
MIV?V\[]LE2<?FZHDY-;LVZ<([7MSM%#SO*&1BO[KU*/O$G;"@3$=5'PD9K\&
M-]2$<4_ +.67_KHJH<';)E%DCZ74<L..!]*9G40[[Z(!<>XGS@/N*/V<%?=A
M/#VOP<UE?46#NMZ+E$]V.:T1,]H*F9/C=\<CW<;I5,XFY4HH]5FFU6B"M335
M*[9^2!D6R6S49SP=T.=D=O40;KSM$<> UTMSWFZIQ\!\8@"NJFZCHISTH GQ
MJ#VATB^*P;E[\$:+O5-\M3WH/RY'];]PX/4@(N24'X60/1+!\.]>]M*^-4?#
M\$4HY;5!&;^AMGF[$NBQJ;L]57%,2GI]/GWTSO8N792DJ+_0;6G:&MD7_N$8
MB8P2LM]$/(]?NDD;NP2OLRWKBJW-00?F2Z )+ZD+K;W\\8Q*\_?LH0LMO4PO
M=U&GP=M'FON76</J4^,@=GUA:$L.$U)&C&@]$G.?)I'/=PP7CZ$K#3VJD2W7
MCNS[RY0,QVL%S17N!W);"?G"0PG='6HF+.:!\NGR1ECJRC3!+0E<G]O: Q:]
M<Z3_T-X4 %-'Y%R>9 R.(#Z<?_^UDUY<L4R"!H2(K37"O&^7E#OR)?>D8M6S
MX/-9Q5GS1%T76V:&2=$4/I(ANLV]8\ ^_U+1.RDW]I>>B7G!42#V$>)!S++,
MA.0+ANZ^%;_Q7,*MT1YD:0?U;3^Q#P#J;P)9E4\W&OAM8U'=UQPJE&R_N1/A
M?Q=W"KX8_C$V[W&0OR=>]$;5S-S]^^:<%I_N&[^)G;+E-BMSO5U-A:_EU+B&
M7T+4SR>>ABBL1P,T^K"^&\B6,%8@=;>'7!ML]PYFL_I-W9P.B?.[IWJD=04B
M]>V-:A/[N3V?=>%L=*]:%$6J_I0SB>$33WB[X+VL_R+MGOC-SV9 B^I:?L]>
M:YWX678&S\^;II "3CO4ZFYQ7H>%50?>T_1R58JXIE:KNUG;W%I3+A$YP?'?
MFO\I$)PSLM5;),M_S4_SUXY3*O=3CQT_A;/TI]E*+WH>A2JV'#%/@:XU-&S)
MBIE8JN@6-XJR#&3$]%V;L;K.71P<]=X8N9-+)WTSK4*$R2BD, ^YZ1#K4;U*
MR2;]/*[+\#F=R<1QH+I*0PAWZ:I PD]Q(ZCG*[\,E# )P3)*4EK/7%]"'M>S
MWA)K/SJIJ:76-Z:JJH[=1)] NA*O1TDI17N[]!:V]Y2L]K@OH90*+M!_4=#6
M?&V>M%1E;7ZVF=DG@5SL8U]78G9)0;':F);&E&9KE);DBRCUL5E=<G_9MC.C
MM/__\#A5U..MD"!W=S3@)!E!53/X1L1ARWQ]_A04: DSOO8M2EQLRGVR%]R!
M$^GZC5Q:*[K6"O!:XF,>I7-8WO,J_P_8=3*(J6\!X(M(%;YMCL&JGXI%UO)6
MLQ ZNLA+-*"BP(#?^_8IXS]]2A$Q+QF[!]U41(9Z\5"JB7]SB)U=FEJ8.59A
M)M/WC?TZ,V5#/_XLG8-*.$#XPQ?LUP-&KA-XS1%->@E+O>^3PBY92/A65G'!
M-1&QNV&.VQSM@2FP<1I+41GGDZ/3ADMF(##1@/_ZKU_[O=(OF#T>^4C]")A$
MK<^AY5._HUPR[_TNPFJ7_\9>_F6/.><4W[TLV)'G "E3]4Q*D!IV8$HY7[*$
M?,+KTVN,0@FKICY*,>RMA\$LA1\CAB%\Y?$SK"Q6QRT/0M>)_8S20V)*L?7)
M/"U9.!6L7GRZZ]^OM#?&S!JQ_M3!]2"("O/Q3]/(%W/D$P[GD8,1WQ$,R $1
M:NMAD'H],\K^O$S'ZBW7L%%P_.T,VTH%O!EK!19%'!!<C8=5=14N1?X;=]P;
M4U=?L]SAFH$I6./[WN%]HL7+JT;/RMFEX"^8%<CX+==1)J2XN)A8"P# P@B5
MQA_GO8JA 7@8L4HF..)  YY..T,.H8M4O>TSD'ZWZ1O>C#-S%?\W9QBT5(3J
M1@-*BJ;&(2^)35$ZT <!)4QB5F\Z.">Z-JM+"S(ZL8EN)*&U?K_(#G4@)[IH
MP >7AGC@>JH=&L ;BZ34.ZQT?_7@3V11%/L,7#J,0X6N@.]=P.Z_YEKN11O'
MS8LD4F;CER\-:?2PNGB6BBGF!+,P?:IF86&14L<:5-:DJ#V1)Z=RNN!\ Q\>
M6-2O(S&.0W(_SP,%)?%>2V9A/R243FT?P[FXY>\($L+VD5M2*NB+G)&6Q'XD
M_!,-6.48++]!*2Q>1Z+ X*%GS_4:VUD.F/N7US+ZNOT]M[GB'O]X)/0N>JB:
M?5F//MQ)<#,:QDG\@"YL.#*%R2S1_<9_>L%&L\6.5GD #6CBGYD<5D!HE%HJ
M5#Z)\A*D+;RP6BQ8W_F^V)CR#5*9<?3Y5-0RNY9FDP?VB:C^7( ^8FAMVVDF
MY(JUG(5!7A4<WK]FG5->4.A?AAVMC#W&(\O*G<-"6T)L1N/_5S9&0O,K8++P
MKK'ZY/*_EX7^-Y87^M';ET]=(;!II+MD>>S-XV)J&LA-G&9I:1%7'-O!^O0;
M:JG!T(GQS(RZ-J+H>78L'/AKUY#C4E$9.QI)>H!,=N$"(2L7G]PC:<^<V<^H
MH7OG49] +(<KT"B - )?M$$7<VE1AFJHV7PT0$!]I*X+^4H*#> @0 .T5W?-
M"=]/:ZC^\1Q?HP$_"!$:&W[@\;?B*DBS0<5*<2N7-GI*O_&!=]SWZU.=)_:;
M_. A_DIAYJ2,/#.(C[8JD@5:VD KC7XL*4UI>B="40Z.A)HV\*,?MG*YUD>#
M>$^Q^#3$^59E9*3O\J0@WAZLV+-%A"95AW$5)X^K5AQEL./B$E / !&M/?!D
M:W$69&6(> 6BZF<U:+^UG,-QC"!?P-GN)^^9QL284J5OQ%:.QXQIU3M>UH$S
M%_5@\=64CS^\USD6M-JKQ-GB:LW,A%O9] #1^EE(#@2_I7YKV3"XS<;.150D
MZ6C L3R)CA ,0GX7!$,:>[,J_@?AX#ANK5=)F7?+6_N(X@."H-IK@;*&<G8?
M]KV9Z^4[JDU<R7C6D5/$RO1:3E(TV#@R$\4"(!=F6*G8=/,TV!L-^&9ZI6F_
MQ5)-C8OR0 ,X'380==5\9;%^^=NJ47KF<W%U/$H6"3Z^%%/OS:S2]4BJ'ID7
M2+_-IP^7B<4@1\HF-.!> JQMWV -T8/LAB83CBA'347IZ+A2.R.CAD;WP\+B
M8GIY"6/]R09*6P^QHX-D"X;&A1MU\/%^/U+9TH_=$(PODWE-.YP>]AZ4S]R(
M3,WK,>/<?W=VL)@_+[A-52^3D@^YPTV34%[NYFG-3,<A]GIH?(0NAH<+HV+T
M_Y"F&OJ!T8!9>F0V&M#C>C!RLUG]^U5^@@/U"#>BZ'=3B);HD*>\3Z#$S=]C
M\G/4JH?C^]2&'^E?149;%=^MI+&DB7;T[%I0>-E9RU'*E7$M$ $=.B.!FQFX
M+D0B^8)N0+'(10?? T*8RI]UYKU&8?3I@ [IB3MAV*']EWZIG]0\PN7I(5!3
M!U'7-ZF^SL?[.\H@*I[GADK'PU+1N86U24/9L6RLF5+/C[CEE6GAU&(-K%7U
M351LN76/9#",Z_-]1D&:,.ZOG(C3!YOE(,/CUZ,9#U9%>VD*RP@DZ"PBI!PU
MNX9<'D&8T(#-G8S]FS'0D?.6\GU7BV&5^I)4\_%I>\MG#N7'&0Z13RI5'UL%
M)KIF%\3HO@,ZQ+RR+KSM/[G=DNY)P+].GO[3QX#)NT6E E?GA&G]WD#Z]/ ]
M^8&%R>D(6X>@(%=JJW)1!<](-JU^+'R11&(L8P='':D?_].QJ_^E0+W@1+SO
M0H8!X>HS/^#CAKJ(..Q%FAP(_ZBQ;R](J1!M4O"A-WAUJ5L4#\L=R'PP&:H2
MKF%!%.)JA7R+D= B62?D'DK..PCU>-?_\O,T-6L#:F?OYN-X4:L75CF,IZ71
M[9V[&?FZ4Y)\-0Z9OB>OU$SRO6)3=<8>*1EM)7<$G=93S%P<5?V)#1<-CA)7
MZ<']ZM'4SYG]>$_#%F><F9ZX#C>;SGNL??4Z*T #&-X$K(NO%'^2>,V,[T^O
M-9Z#(5>&?[A" XQH7,]!AJL?5"+J*MW W1FAJ:&_XE55[/=D5)MK;J8T)5MQ
MI@?L"M& UN1;]1^M/5D*7R8RQDUN3:A%?=,E9,):M'6$C:(!\=^AYZ]08C;2
M4LC'[C,,X\M+2C]B42UL&+CTR'=*T-5*G';LYL*^Z!^D*)^"7$U==60URL/X
M;O\N2_U0%K/J$'[--2.#<GA=R^!J^U8VK+7.#"0C*S395&C>=X9RLBZ *\%7
MW[ZP:P)S3:' P5P$MJ;%V>4K8K"XE:DZG<AKL5O$8A6!2Q#Z=BY;OS[8K+!W
MO6-+:-WFC[W]GCOL1@%T\=X*M7E^2R-2^"X&(1_SW^;%/R_U!TL;4HI4VTQY
M+:5@[4PE2N'S'LO>$57OQ):KZL%G?"$-^L5<_.$)80?68G.!WA_&5_YM ]+4
M+>UD>P]0/]  TF6QT.73N"I[PR^M5?,ZEA?B8!OCPNI%&QVIJ&_KEE6UU6QB
M?(9/5<GE]<NS-\M$>R=5:]*@/HFV3[Z\*])Y-?RHACA:C^21[.U2V1DO*=>&
M7L_CQ/S<MUB5MZ(#F#)I/ZKY+06I5.V&J)3/Q]@UBRW.I/X4<G+5DQTZ=[LH
M6YYE \D_\2,N*W=/$-;]2<^$9Q6NE]8Q35O%T=PDH%Q8S,[T6BWT&C=C)$]=
M=@5/*^.T.Q9Y1226O_-?JC=VA%H%\,EEK>S3IK5NY<V3.PLT6DL9?1=EXZWC
M\':VXZ)VDYZ4../=?3TA9M.&L69V<Y[X%O!?BVV?4TJ+^C=;"C88[-P(_%2J
M8N3->&L%*<@37-TLV'2"2^(2M9S@T-S\0.,*8!_!Y1>)VXPY$KCY8)1?P<:H
M35S4#4.PLE*,2(RO30'*M\+@A3>VR\M_)DL;-ALB4J@GP\CF^B?JFEK[Z5&7
M95!O5;;26#IBO2OQ[D_MB<G9QA=/6FQ?)FF V ^&MJ,M*>U6[,[)$_FF6/M)
M3O>XH)?W(>S^%V;YBV^5- 331BK<<M& %VB >+W=^9U_U;[M\7("-1!%YD."
M^H4&U#C"'QN[R%ZIHT[1@!PTX+!-6HFZ!]($[(*$^E;,3VB!]R"A:SXIM?,'
MM'6(!@R9O4!17R/X($N=5\\P_TW*@6KXO<?+1VC <G\)ZIQP%(HXZH><M6#D
M3GLK:-"DYC+,R)U(HR[IZT_A(+:P4MVEYVSB,O0II+?["F%4 MHUC,;>#PFI
M,+O@^(>"7"2 9-%!F>IT+"/U%]?0@/9=U^NHMF(T(.:L HFA.K6>S;@G%\@8
M"S0@%7SF)5[!@5""S->AGF(HP)W9C+.BMMB37F0"!W K6_7R>'LB ;*>]IO%
MT*(!$0]*169T<OZL@+%0<[:3GUK\$$\9/,WPL<M)Z@ -)2NW97QO5C<[$E(P
M,PM@"2RS7.>MBV9IYF0\FGP%UYSL87TD3TYI2]'I.JAS>W.JMK(3EQGF44+(
M";'DI?&_M=W@-O=V*8OS#7N>$)52J2"QN"SR1>8DALC$KF4,4$<M]P6T_KH$
MG[@V/#-!TB\B%%+2@PY]Q+E]PCRLK><B0<H49NO1EB^X84-ONZM!)OEL>A'Z
MA1:JJX]Q]JOGO--LW2EKE-P+@=_9^K'TL) ,1^U8[ZTY>2-M!9@0+XPMO!3G
MN6Y(BPRQ1I%!2:N"(14$3?4_-N=;)NQ_7;B-_7CGSO]S828%_V!Q09?YLCH.
M-*DGEV!M7:R?I+>:GNZ11DE)4<*$_8BP\:5N"@[CKQ*FYW'^=VE^Q[J)]FK$
M"$;A:-Q]D1GF3YBT<S+O:_!W7-S,:0RPW%1U@Z)H#3'DM;FYPMH6#:B/O!%&
M WJ#E(>/!&8@G3^AT*,$-.#:'0UPP!S]JALNZMC0]T#_ HI2&(.,T$'.O/QR
MH#9HP'H& _(4>&,06A8KUI4F3_D?ZU'IC.$*A.1;/U,3X.SGRVTKX8;-"G#=
MTY7YEH9[H)N?Y,7*]2]B0B+I#55&VU[:1TUT(3G8UO68%FG]LU7KB13EZ9T8
M@$!V@?%%;0,AY@IR B,2Z\E"/FRR-/G.SSZ7_HB2N&DO,!7A1)/"$\?YP@J
MW+"TB$%(1J)D+[P<Y8#PFUCD./+>BL=/DSY1K; )["WH/^@SF8]V8!YR\4^S
MROM0JC9ZT(#SXFUPBFT>:I>ZH(])W4($CC=#LW!>LZ8GQW<^%4:#!G"G@X3
MG^',FG H7]U\*OGQRB*#51D@(3U=O[6/Q'BAL6/&9D%S].1_"%IE>D/%)5RF
M>W[D+:;MP^]75E+J3(J07SZ[:/$[\*0+"0RX'H[-Z1KUG"/9B/+]J?I<6B4A
M#+7>1_"Y[\((U@!<00.@L3HW>]19D).5&#1@U_WW_Z(!A#?(%.CAVYO[:$ &
M?B(:8/#[0-^!*?T4750'C2IZ+G1Z'PS.WS1,Z;5&F#P.7B8'_YCDXR/W<\LK
MBWA6&(CKK*P1^3@J1:J$K5_S]TO/'U82^8-H-S'H"G5Q?\)AMZNIRR5B5&&@
M2_Z.:2GV0T]L:F>')IKR_IH -(!Q!T.?:6#<ZSF&@TZT-T@(;&_1@>'@$4SY
M[W'%)@%3J>&QLU"Q^CJ@I:NO"K!4_*WK!AW(%S+[I/3]\68@76GMC,^-,K=O
MGVXZUSGQ;K&/2R[Q(\W:J.3[T9X'*MK.^!V#5B]_.S_?Z]WJL3IFZ@JC&/T0
MR0LO=NBC"[MTOY>T3E+&31P\S-)QK!F]>4\'I0<97O,8/>P7!Z !/(STF.4D
M>)-S*5;S_[A<\L?GX]^,G_3->Z!?+/2 GW5#H19H8H"];/(U0M]9:1_$:EZ[
M^[4)C^?9H6'<Y<^(^]5Y\B%?Y7!;Y(8ER6*"M.](.K [&^Q>$?1YZ#"_\I^\
MK7#4MS_I4VBY'#11%GW3[2OW?[B]_VL&7/10YLCH7A^QRPPX[0:[CJWVH0)5
M (SM>([;CL+7Z=U&?_UX5D(Q,W%Q-)T"J"C^D4!2S_,OI+E$"EHR2[N+ULDU
M JHG88O>)PX^S;/41XF'&[.*<][EJ:3MY].NZR+/BOB7SNZG8HP\?7DJO6%C
MU75$*./EU4?\"F[-GW='_$TEVNDQXN30'O7C/&)GQSYS87&EZGC19%$DM.0<
MQ[WA:IXHM6"A-M7;Q>R8-YX\ %<10T9+\OHT5YW&0>.]F@1OQE2B6:L&7W#^
M+EJ5]8?BV0I):9_N,(<F7@Q2]L1]U_RYV8P&9'H[>.SM?<JK&S4]3A+^[E].
M0\(B3PKX !N ,/MNAYR9\8K)HXP,Z:<,P&O@WO;^#MM2%0X?"R]O.]6$!:UA
MSA3WX0EI/@/A9"7]@L3)=1GV:6#LH8+P?$KL^=G;]OVI?S]2X+]MH$P&DB0[
M\F!R*8/!W:BKWRXME>&-"[69@W)1_;DVQ!X/VAY+2+L*XW:-_R97K3:I54NH
M+LM'8$@1%S*JB'73_2HKQ;Q"(2=,H[W-"*IM#X[VA4RE6<W.^P4Y^P3OM.U/
MM\CZJ$ZGQM(_/C>?#G)>LX(#;:03BJV]Q/:)J=.R.=?I<@<6"/BF1BS;%EPZ
M 6M!E\*"8GH+:<X+,]:ETT8'@MQKQ#I( <<5:ZO\+K/*LP^/)DF_*IN^-W7D
MZS?QL"[*=L*IP_^LNT=VIL$TFG;H:_-_ ]W^-P-T&4,5WB#7:?@IHJVUZDQ1
M*K[+!W3H_+G,- ),X.LWUS<^JIAMN1'R*CZVXY6H;81,X%.&V?S^NXVM'TFT
M>,?\Q20=C:C9HPZ<2.SR7#N)FG!'/_.NC2FA)'PA H80)L)@P;EJ_09'N\7K
M&>('QI;L:1];>)JL15B<S7JG--A+9D]W#5@ ^$W?UF#N3#.>G*H7G[6 PUZR
M@Y673]4)05.H<T5(8DG$.>GV[E^FK&<?5%:Q#[[4>C94VC(F\LM/!,D\9_ T
M@)&R-J2L2[62Y9,T[[>!PY?N@L4D2I\T:S\&-OH_<""RJ[][QSNOT:*@_W4P
M9*UDIS>SK87TPDJ9BX(Y'E&E0[TBWBH\6_#7.@=_42KZRP*0^-Y>2$;;V5%O
M2[ND1D^K8P8!#V5_7)?+3]@<B1BB5N"=NS(57D1]HLMJC0OQV%2G%/)VC)>T
M\BUFH)/DRT]8&/%U;)>&<*JNATZ+G<T9$AXG(F[M =/X#)\W%_-SV+@]ZX5N
MG$PWV4$CAM;RTM,;*.\H>6O7YQ?K*X1X9G.+L8F)CE $IECE@)]?&&U/NG!\
MCUSW1-ZT$UY$#%_.8HA"L?BS<QQ:MWV[H'D^$8Y5"T,7-,#V[*>.[9;E"5>/
M*ECR<TD@GEV7:F!)-D^GUJH7D],3T#U5$"6(5WQWT8ZGUNU41-':+KQ(59W>
ME-S$P=CME-B9)GQ#B8U7:Y"V^ J4]@Y?XM?CWV$A>81_>$,5@2OZG(H"4DCB
M&-[)."C3A<])FH25S.[BV$/1*-7RUT^?B2YOWWO$44=4<_AS_;TZ%_#Y+SGH
MBO$H3\;"RRE.<7,:<8L>*13 JXUP0U%*/1)E ,4K@D715?MX[0YLX&'PB .#
M3!UG:FAH+7<6+>Q>U3JUJ<]!9T/H &1 *>=<B)(</IJ_^)N%O/@+"R&<,?C3
M+.0OR>\7_8=A8@)P-"#_0E7F(N%G@/->V0A.KNN$JF%8>8'VDV1;93T=+]:T
MQTV6>6J2=U;CZ?WUWCDK9W@TSM@_W9P-$:;NB^0SWL1 \Z<K#5W-KT95LN(#
M90N&O(C6O:8:RD0B-R!(AJ[FJK3[<)[K_F7P8&25\^$S?3<W%FK:^H54%M[X
MQ_T2=Y,T3-^%:2E'SX^HKQ;C(2BT0C8+M8;=O5TCF\^_PT:4R,-L]-XQ//H
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MT*938D4[<1X1KO/W]\;^KQJ 8>S*RBMR> $&BS&.),1K/9*FDG5>N^HU'D=
M%65;W2.6<RH,[KUSZGUZ-N<"J]EA#R=QW%/OC[H?_@/@<7L8D<U#N(G[VJ>?
M*W! 0[0#W)_$A)+-*4(V\U/JZ/I@7>I45C\YUC!S&^DI#\G\H?DM"^1$4%]5
MO0ZHEBU!ULO?2&,)P+RK&&953@2;6M*E?XWW=>VQRZ$,2>S&2-A6I7I,)/Q&
M,ZDB+*J7$OXI"9 %F<:26 =-Y3CY<="=5_A$4'QW5HSG2_^(2A'%FO6&N_G+
M3,V!DA=R'_GK\'/97E5&6+LGL/3Y<XUP]Y[.NRT32RLYR4F(8FT;@R^RQ4>M
M1L%F$"HX7(* +_NVKQIWQA%A7T2]];_TL_W]25#%"0O*@OIH(6/; /5^=Z-@
M$'C:BXJ&[B4*'U[?(+%N,%;X%AH0>G@@>Y[1 XF 1/OZ0"UT3H^O?U=" &^T
M(#?=$SN42^#W\XK0@-C>$ZJ%-,46<:GS!I\S]I.N4TI['A=0A9-.NW;%L];M
M]$]J8D:/S!68E=+8-7*G1J65JL<TQ,1R,4?U [HB+K++ @>NCYR8(#)F@<3M
MKY :!Q71BVG': !/RLQ-U31Q"ZV]5/TYB@$8-%^;ZDP;]:3..U8PB!@,;H3-
M$TI2@(28!3-#7K.Q8!97J_,?BHKF\J4V]4WLQ;=EI)[=-!K0JN*^D+&/BTQ8
M0P-2G-" 7D()L"-D/0D-V,&,1+IZ9_Q_FGZQ_-NF7S0;4 3#/&3X+G0M=&SS
MG.R?2?^?E]IMEH/R&%A&M*%5LS"DN5Z&L+)YUT/=-\'=SJ((.=80%A28?>]A
M[FE\;76QHC((NVI2<ZB(E9LNI/3I_GS8M=*@H^T^1;!U:?XG3^I:(O\'=SN?
M[/ M?M4YKM5D=+$E-E;S00,L5PD?.@E/3E<*1V[B(AE:FN"&TZ/*S>*2:  [
MY4ER#AH@1WZ?)]9JO5-<0>Z7=/_=-:[5ZJJ^04H<)SQP?2D5,VO,/7ULSQ\_
M41B+Y6CGGKWL*'GE=$N2[8XCC&OATY0?W?>L2;!8WC+-D'G#%%\LU65_44A!
MY& $R=N(Z6'RLHQV6I^.;6BJH=BG [^@Q=KY@#M@BB?S0;?46=]O')'2DO6+
M4PN]BI$[!9U>!6'7:G[7R$[1*\H-L0@46 S<360GF]O!J^P#?OY9BU\PK QD
MQ_E$-!E==U#I0'2O;(8[7;S82I\3_J(5R!41CEMM'^;U)QP0CS? -S$7_=1(
MB;0NC%B<R\X&3ORKW-K8133 %",4Y$C<8@RK^30)F:_#L/SNB[F,LY+'!Z\N
M@E"*JA@ZGXVY-MO4^\O(&(SXJ#(@?<XJJ1L;LGK_1AOF@ &<T(WX431@R*3T
MY7P++"+5PFUS.3/-JZ65BR2W9,#8G-54W[JP.VZ+(R#]%6;[>6'U[@DI"OIE
MQ'CL&P^<FC?N(>54"F=0I71C%! Q5M$D_/<T99*$SH3LDD-JETYNC:@?$B)1
M: !ST8G^UL"GVTQ8:\ 3&@08F=^B<_\H$5'VKJ8EM6 =#7B^DQ$[,U6\^#WC
MV:N=VP-U*(ZFA6NG)'D50S*BM*Z28(N"PB\[5DRYX6NQ>YZPQ0:V3Y_CS&TT
MI0^$.LJ((JPR")#!-).4#2?$TRQ*K W6M1;7+!\UU;AB+X/P4/0GA33A%6X1
MAW,M:(#-+X'Z[PM)8BLU#=K,H4+U#2IS U*IO=-CIFKR=T"4AB+]=UX_IL61
ME36C.?+MG.@X+Q_K*XW(+6&Y75K**8D1@4U"#9=_J:A!X_] $OMMP'CHO.$_
ML/^GBW:[%?(K1D26UX!F/ICME4JK6U[>WKI.10-(8G/X#R]J7,V@;=<!Q!_1
M $>/&_D+:F.DYJ&UKY0TO=CKC)F&WQGK*YDHI]02$PAO^/S)H0F$(7(3V,@_
M[8ETGJ,D7/"PVS@^KR%M/.(Y2[-3-F+@J&4NVH;SGL4U63*_R!M8*[;F&O32
MM^Z#Y9GR;BUZYU"/+O,[0X>I$=O(!_LJWU&&R_SB''NJ86U6<%7"<>_EJBOK
MAL=WW-;WV"KT0(9Z4![-/ (J0ERI+]W:8RO;.ZD,]-HFM.2*;*).W-2N!PV\
M_^%6_ &3X_[-Y+)"@ F.,?<BR\6YLFAO,NVS#IPOK%SLKM5./P?M12P7ULQ/
M%!\@K_J@QXCF1? "Z63!?^90'D>F+&.C1'W.8?U7@^W\7UU/U+JB8]^=XSQ_
MD;- ;E[SH@JWM$NGU8FDM>R.4&%^-%UN"9%,':<";:1$0*)GRF'\UN.Y-D$;
M*4V*#SKXS"S=H[]")A]Z,2WQ&_C":8F_34<DD+B(%_M$PD7OTE+:Z$TM/T=9
M06C$)WI<G@W:NJTBL)#0"S?[ O(IL9*&GTIA,[IC:6LH/&N+,4FUVL[<\GF0
M<_$B50F1EHG\>EGB(7]XRZ(<V:'#Q)TK]B)CZSNQDRGXZZN2YW+,DD0;[2N>
M?4YE;8MFM29R&\2LZ0%P"C6$V8.[(N]."]S/9/O:Z^;%H..I6W=F?%U;"E&'
M]YLXB<4M^Z7RK;V"D^A.72>KK2.R$SQR"@OB]9ERY)\4!KA3-OOFFS<TR42\
MYC4S?B5&.$04)7.WCQ>F5ML:@N)B9:4D#V J!.Y%8#OBXF;IS+''G?U?XAW[
M>ZZD-!J0/$DYK(EL:;>5//YE+W,P*\[C?ONLV':EA'T6^*O._$G/A_OUDM/Z
M$\&]<0-JTM=YOT.M<LLOE\%'27N1<*VB[V=&B[ PAV'KC#!%Q9^U3\AE>9XY
M2R[$)?5! LE:R^AY3/7IEOQQTB6-9D+"WB<SI2C(W/6=;EZ*_?69PUW=A_[R
MBSQ<:UVU3\$A7(R6T U_L(?>Z2#I?$G0XE$;!CWTS],D$S;JYQ!QD7U\_B69
MMPH# J;_T%31@(<-WDO6H@$)B2-L4Z#73EKS-JON7O9X8>\=20LC"1I*8$8/
MATI+-G0'%HIN7]!$B&UOE86Y;"$K&VS)T0"$JP_MLDLE2&/" 1PFQM=BM5/R
M59[7\4")DO*=+ ^3F96Z^:V^=_=O2](N!PJ?D*6<>K7]%Y<T^!MBU2(;@'N9
M[?08^-Z_ +SNF[X>VS7)$?JK#^I3=&[AL<(7.B=:63HG1E<SQW>E!)W8Y _]
MVC';PY ,"9L]J!\P<Z_H'IZ7GM(+R[.=M;U0.R"3Y[[Q3DW/3$A>)KZG4%8'
M%GFH;$]E^:1R"B2M>X]J5^$][*JD]R8]0<P!KDC0Z"Y*J3>G>Z]9M964WMJO
M95'(TGKGA$FI>;UT3BBJ4N/ FEBQYO)=2/57K(LXK6[GYK/L=M^W,. U(T="
MQJ63RP4*SDN%%![;_N']ISO9_I</U%6A 9_E#U@7((/39<U==AIU?LXM[?IG
M0/#$:$C5*_J':P)/M>FYY?I5=_O6CL?F]-1QH$S&:]"J7IH7H9OQP]AJ_<]Y
M*XZ*5M+Q5<281DU2]<(+PZ658E[@3P@9(R<)1\K"SG\\2+6U&X;6%_;Q>GO?
M"^D<)Y8B.5Y]&Y$NPL(33V9"\>P=D-6OO1/?]9&OU^-;*NDWNV5G/8NTLC&R
MNFOA>HN+_I_QV.49/@"N,GXS(1XTX%Y\WX2;K*K/%8((BW=YIV"KU\Q4N]K4
M-4%WK6?5.3I9M/QD^0:Y]S-V\C[?;%)=D.@9:7W"W-/5A"I_\;?5&9>'DG[:
M42JQ?8)\W9^HH_%D+[W^WVK@?U$,()2>S])E\A'86'86S":R6^$E8OU3.MF'
M:(DTU-29L.&7?LB [8.G\<P\0E<S+SP&-4T*F2U:HQG#:H/)%[W+5-JM(=]:
MJHE<IXT/T("-@J/4>I'4LO,[#A?N'LB.0X+XY,X]? (_;04\6W L99!LNKJA
M9K2_8,Z@Q1$?E4Y>N!7#==X]#-;;A3"F9Z)L#%1"VZX+$ 7(Z!G?IA;O]3,_
MU<(KAY(=VMQ.UR4!^_KUHK*<_.LW]MQ?M@9D4[M[:)E!DR3'4;Y+*LV*PMX5
MKDZHOZ9 "8PL1[9MP2,S?VT?A!\4"3^[/IQ=-%%<N-YZ;!#=9;ZQ6RQ:RG,H
MRC_?OSK+PJ6W]Y.9/]>_R#2,U6F8-(60)@7H>E DLLG1$QE!/9BX?@$?CD18
MG"W< $]PV\7?N9YW+*<Y_"0O;JYFNYCDI/=5-=^\9G@,COFZ537OYJ^N2>55
M9-JGMFZMOEK\4D\+L\V"%EXGI1A617CBBN@Y;MAXL.@W>CF%;&R67?5;Z#BE
M<A"*#K4QNR@8Q/=3]9PZ"$.1W=LIK'&=&1)G>28;2<RD3O#L8/A!R)?<L8.V
MT1QD]06.0XX?AJ)Q+V_4238)L&]N9X3S02B\6]9 +_<7^$32:VQ^^2FML.S"
MK]G)%L+BA9B_BI.+A*?[6*0W0QKR2WF#7X2DTSNX'I2];-E([ DSLS,7H(>#
MUU! VLCBPJR*S/(#PR9YWL<:0A&ZYB%*,:T:W;"![0%2W8<2M+_K>31!OF5>
M5^1Y&V2W/S?Q&FST:JGB3G*(2LUAB_YNJWSS98GXX43[Z)#FE_P@:CUU.D[$
M2VDX]^?)5TM[8@-&(R_+=@AS-3+6<1%>MZXC)N?)M^A,$+$HE7IAE,'DO0B4
M$1J :S4N$VUZ&7\,:ZT!W!4R+ HI-EL["N=2OY%XMC4C]95<>]\;#1#3P3I7
M6,NB9@^Q.U\^&2&\,3"*R*C<DA7[3RCA"6WW.Y\626SS%Q8:?<Q_S2,&\$JU
M;7!3,D.9Y'64WP0*%<&L"G0"/>C#DPTI\:IC[M(NKD5GOQV0H_&_RTL3R2D+
MPN"2%YF_ CHBZ@P0.L@RE!*$G7UBR&<-I:[G<WC$[,3M6W"L*"T#"_'Q%>&=
MXKU$.B:.-!Z9/G-8^2X5GV7AZ0AB7>+-2W53<:W9O-2QW02P?&-I_FQF\K%P
M/ 22=Y1"8/*%*W]K4$>TC19LAWW5[Z"LT &YVRF>Y?=<,_/(J(P<80L10 6@
MWM92+R0;BXG!=; DQNW;XQ:)!\N+"K5N%HWF2Z*-A:P%]2B&[X4(PR0(%R17
M[ZG3L'P5PCF,&PF&:"]&FFYSI=_Z[A(CZ*BYKB+Q"'[!-W_X*[/4F?'P2V,D
MK0K9!V#2R>V<$N=S['_UD/)_"NJQVMIQ*^B*3/#.KR>%,=8O?_>[')F:&/_,
MW:KK6Q9?&$W[H"]01J[/4.E.7Q-6AODU-@X,-4>?R>&(Y^\!RE7/F!^G''>T
ML^,-UWC$1/+Q>\BGM7-7$.0HM531!)I@-%O*\T7&NTG$AK4J^-3C$Y_6I/"]
MIDGY; [O!Q1LC4T4WJU7#4VXN8Z$EQW C6V.?=B$=>3F./7E/"'<U3=][4'@
MGQ"2,4^$Y+%)KM\[UZ>_=E2N9FL-&BRV:#TM8?B.7='=.KD.E.+@^V_&^E^*
ML,C102CZ<KEYNK@555E'^VQJ''1$[GQ;F&N2!<]T?=&FLK:*@G2I1!V(N(B4
MRI!.<F<8T5P%K,M&4UKWR,<AIC V8''/PU&OL ;*#$PP.EPDLRPIZHSP;9_M
M'^Q[/CDN77?Q8I"VSRH-#?"W^&(>H6"]8^[C,M=?[]WP-&_"IHG9E#K0D/:\
M>=01-<[5S5TX18K3=H[8MA'[8DO=\S3G^E;1RI'0B;:)<IX?.[)FFR-9S$1Z
M'DS5@D7<7E\[GO=4/_VV)5PP9(ULX'+AA[ !R*0D1U;[>."#W&?SSWD?QV4^
M791%["9N\E\X)BV8Z@2P68%H\;FZ?;]ZQ?(OCA/,<;&U!!F1K!*2$753' EM
M]WHS[4#^,?A)[D?7GGT[3"RV282ESOW[V*Y1R^S,+ ]YC>_A<*]L[?O+ ;ED
M4+$-''0B*2M_UUUZFG6@.5G[@@;#\.K*$+]31Q,NX^LOQ)WSH8E0I8O($T[$
M+2G)N*+\SM,'?0/\LT&7!A/2]-(RAEQG33Z?R12U0IBY#+S:8V3(E$V-Y PQ
MAN@!,!;2!][21$Y<!V2A 4F]+N<C$J<%\*7<BD,YQPP2KY288OQR6'%FWH*W
MN+]H5E%>15D"/KMC3%-!R4*T-.ODPW[5+V#N?N6#MI^SZ?]LV6+F-RE7-*O=
M/P.-IE8*!4ZO#=Y+5>TVD/5=;CL_&E=J[+?I5E=FRHZH[9CX%"C+A3,>9EN
M,=3V(KV(-SYO+ZN0K=? =31@>.ED7REQ^$?%SO[U'/DAPM]$! WPFCC0I[R)
M#4QO%SI7XDC(SLK^/IC6NU+$Y>V&S\H+XI)6E:8GKQU_=F&T VT2Z=U@\#W-
M@)->TBZ1U_BX4CM"N/?,[-<0D?$S"++R]H4S;YTUL)%DFT#Y(_PR_&/E!NN+
MU_&"C=S*RNH$3M)\(#&&X&0B#$-XUH);6*\#+T&] P[.05<WI82F(91^[FY
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M^%G*0A_Q0C"!R,KP;2Y[="XN26S0Q\--08(OT8X&\Q'BUHG^8F'<!,!H0"Y
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MRA6QQ=$56#7B'\CP9V*PA][FK?_%@@AY(FX>*\9V5SN=_?^@ 3YDR_T>X'H
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M4_TFV=4NY_GE"DR 5^>,RZ_4%I:"4Z^I7R;X**:J#(=ZI"2O3VVD?"F6+X*
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M/:VQW]T[Y>>CMJQA/]-1/6;$-=K/*4LTG(/21SKJ,^EJEX+)OL\%0U[>4%R
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MXIYSR+OI-Q_BT3 L.\ %Q8HS*>8\.(+DS8P06.5F*4*J;<(Z4<U=G??DA2$
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M6<+$U652?#!W%'9HK*/"P8^F:YN16O"<\$S^W8\W@<G]TS2VK_\T5/"]@8#
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M2>-QAJC-&P/V"RI/6C0=7+H2(L4I;3D#,;Z:Z2^6!O@I\G_H'M/%)(YS#V#
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MQT?+11*'!A65Y6JX8%.BBB]>_G3Q,.GJ'H1]B@G+>0<,_ D)1@B!K_;T@Y&
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M1GO,>$]Z7BR!.5VUO6$_S271S0^2=K:J'D@7F*\PL1S5&Y"5/RR_-=8>=S7
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M4W)'3F6IW%>[=8V)B*)+]AQ(.!QU:R+R,/ GM++L-7?04J*UW/KB+3_)#*I
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M,]1;7N<+!PD7-GM/NM7Y/&>(O^8>;0D&<;HH*Z?3I/C+B=RU[)\? E88<"*
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MX6YNE)_O2S-6$%6@HOKD<U$& /QDCCA37/./07S"%)/;M<'QWGV;030DHV1
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MD@6 Q-XJJ;4(.O2F3D(46_:]KXU85X.'79X @=!X?0X4$OIC;CHJS_&DWK>
M,ZG&?-"6N:@VO'/D*O,$^2I_(>$ /*RL^UA)UBCI9Q^I]_UN[_&Z1]Y_A .T
MIJ'<LR.H/8-V5'7+?UR#[G?!AO!(N-C^N@:=SQ.-Q!.M0]"$)H&H9M'<^"JF
MM[DH#-ZW5S:YK=@]M:&BM'9 S(/BK-1XF\,"_6J?2L$&8]M5-7!9%K7>$J[,
MI&JK! 0=V9@4 A;<[+?L6J]R,I+^\?;/_[L' F$],.1^70\&0)RQQ(Y&)9?M
M212P SLQ@/?'ED)_4\KJWSZ@U>T5D-WMDH-B.EI S_MET4^G IO(]JA^= _>
M 0=#M#\FE6Y,Z3&+K:C030K50V)52#7"PF2C7AC H]BJFP54ZK0_A\+H]V>@
M'V!V/=\:.RUJS#\[4+ >GY<9@Q:!%>MC?3Y_ZM.13WM^Z'++VPZ5U62RIL'9
M\W5BVJAD,SV8EK/&Q%;V.?8V<,1\L5.&%FI.\U)!0\]06*F&5R :3S!5[_('
M.P8@?"S7^_@.:Y;16B)TKE/O\/@:;<<4]Z;J0]GV?,D-BT,S*/44#HPR#VM9
MO4TXE?JP===^#)DPIZ4\H0V5S E,+P='/,%B\<-WQ&6L.;\U/GX/7R11^F&X
M>(6T5YU*U=/0,2*:3V]C<&Y1TF9L;N=DW/\'M[+('0-8?/V#,N2 -1Q7=V;^
MLQ1)&7H;?C?L]-:ENBU4VNX\&X0XUE'$ "R %T88@-I\P1<DA$SB +@TU?Z%
M+#5TEN6IJF*&:KT=6>\8,-90"A0I)9AJWG$_V>?9CA I!O WEZ;X#XBJZ"/C
M18*</RQ.U*P7,&J3JT=/6N36TYK7V6P?W^1F(;5L"Y0L2 _@=%LLSLG_@$M/
MJ[8^%SA>4!"S"%<!HV31QGI8RADO#V2J]1HO@AZK<$,OF+J5JFPDWU<(M/+L
MO(ML'[]7-X\?Y5>>UFP@[SNR&\W2DL/-<M!\LN&Z6;(N,/K$.O6,9:6I>0Y(
MY3J+E45LZ-%@HKO8)J'X[28SC;3YD=MX>'EIH*QQ%UG42E[IZ#3!UECPLQXA
M+0S@W6F'ILLIOBN[NMUL%FS?Y).CL4NV2RI7Q"N2 _FG$2DI!N>A8 E@#-6>
MUO$0X8;(V6X5_(&SS]>](]@Y9W@$^F3_2H<WT,,1K]4!F1P77(&\ E6&#E87
M0] E>G4$03E)"T"[\XM&#."O78',--.'C+7MZ!1$3E*&5>YKCUBL#JG!L+\[
M;(9_Z-9[&UB,&VC^I<$Q39/6BH._%&?^UY6+EGSC'> J26W=LJO,-.CF90%H
M1+N=N"#&Q18JI!9MRA3(.SFTNCELV9;)3TKV+D3(RXF3,3:=2]<B_2N_L\P[
M'@\IF]0U[<.2)1?#J!(TU)EAJ5,1;[5]R.5TJ'UDF:K(2#N!YL&GZ82N)ZJ=
M/L/5GY>UOSQ]?H=L5(*J9M$?J; *SW(.ZP==6Z"GIID=D#A[F_RK#G6R!FT0
M_Z&-8*V1MU*;2&1HK&5-:(=2]F-J8ALQ38V9%T)<G>IAXAUS%R7_,_P PE<Z
MO';FC]89%GQEG=WZDNM=M@]D6Z5-T0)5AO<_B*@0'41%ROC=B!JVG3+G.SXR
MP%%O_/,.@W_I!*)?HU0V[*(FN'Z>/=-;JJ$X#I>Y3^ZD@F@S?3FG3'H5*O\U
M2U52!YQ([)H3G7LD2A/D.42$Z&YS@RA,LJ]>'D4M^JFPU#7AN8:8GD[LT:ZP
M\*="1D>4X7T9(B9>WI:4]5%?T_DLX_OY*^0R/MPEO\R.Y'/>"R@YN/_)MA3M
M<"R@S@T>!W'SZ[D>NQH8$J?PHV()L#3!XMLM<%:DQS#'Z$.AJC>&4321::-T
M6%(V_B=;XLRK3O *"*^/,\S38%Q@5"BNTG4'.WQ4PK<[,T9U=91/NAM7$#*J
MO$F-1# M>SKES'XHD2-BZ4AS_?.+I&_U )J<T-[U\\^V9,YPA>">/;D:UBH
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MYZWR=U!$;K<HJ>)LC"'C1N-I]O0<'_/W.>;"YXAFY5TR*64E4TVF_*5$$C7
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M[_@F _%20M8T?<O+NG:2R2YPW(;'L@3!T=,%.3R[BZ'@3$@L?0SSP0AK$&%
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MTXJD[*V^,,BIXY=%3&^>@Y?F'EZQB4GP2%^_[V3O12]UUB@]83?"IYB$Z+X
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MQB-YDK&U]-0(AX"/1:-WP"N=EJOX3B*F'1:HE&UXU_  VS!5@'N\.MI>)'U
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MY@#%-9P#TPYPEFZWAXAM/$(TRD ,J0!!V!%)&\\:Q!VUCHPVH0+F&>R'K*B
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M?2.E[A"L,1A_,7IC56 5EV*D-UAX@5_WE%/^&=R<J2/S\+LC[R'V.PT.6U3
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M(P# O?!?:U1 61_M%UCO-:^8I='VK62%,K3:^&W=++_#XG:S_G[U_D3M<4]
M3$(,D/$^FZG5P^''#[A/F9^^.@OPW!LWP?ED40%/R/;$W1T?N[XRQ0>N"#U7
MK=["$GBV.W85^B%L7"^>2<=L7TK;PBX_(>>+OTJ"*>Q&)^LS@$^IJ_2_*TOP
M#Q_("(TFGMJ&B.)4Y@,-9L;:'B;Z5:L)3Z5B3 :PL%SGQL> &P_CDFS:DCO$
M;=]I.]S2U<LK\'\>4D"#M<8>B2V0$$[^ FF<30<D#,+AIP1>7WX3AU4N_%9O
M CWH_I2W"SVCCPF'4V1N#PL8#E>VN;W_$M=\-4HL7(1V?AYCD*X4DL_^^7WL
M<>PP^JS?K7T/\PVY.J&#:LI::1@KM^5B66P78]3#<7*)!)VFJ8K$(^&RQ$!7
M\XAEK83;-(5]\[]=S\"'Y!$_M0-0,WIACE SO_4< : "5'W%1B6<1-)0N8P3
MWUS N@;:3S/*H_ERO7YZ+D8;Z7MB4PKS 2</ 4+$J0!9X,P?[/S;H#QTLK)W
M"LF+G$X<22+NC*(%Y%TRI!N'<3BQAITCT->OAMUD=!,AGH4^YY;QYWM ;N&J
M"G146V71\#CY'>(:32:?)/PB8COR)?F/%>!G!<QTBGJV-S.Z6KESNL'KT[I:
M3GI)$>5HUD#LO""262W>Z^)ZJY1HXJ: [<HJ3WAZ7!3XTDE82ZB""OC,3^C'
MX]EEZ+I$L@F[Q>)X3G>_GUA6 Q]WY@"1/VKI(_;^&$_6_!&>W];\Z7M7E'!9
M,UF)78/#Y> GB0IPHNV*,J:< G+E!,$VH\=-(R>.7*!.HC'R:::I R8P?22W
M01V!<6"H1_)!;=Y,GCA&\YSIPXK>2;N?'UJ&U*)-,?6'3Q)B2=,(P5M40+0V
M7#>3]&/(C1VO:,U>!7H7 4]JZ8C/:[\G('9ULV\&CV,1WXAR>_N\Q'6$=CM=
M5\Y&NFT6J]-D,/:%_T'J(1\KPO>6NLPHQ+$)1!?ZZGOB$*&T7E'!O+ZKKC[(
MS7Q-0GO_W#UF4=XG2=^TS#,2Z K:K&>"3V5],,MA9N#ET;F003NF&40"PZ[>
M)%X<G7"^G?(*R7.]E")E(6"^?I%CIGW!0V:[N#0<6>(BY9E4+EE'7]BV\WQ>
MYZ)79J"150S+HCU3<L&S42,:]+D/N48%)'L0#DA#]1)'K+-!G=,EFY=WJS-[
MAA>D%05+2IT6P^]-%1@+=H?S\4NHAK=;BHGIJ?[&<E'-+B_5RO_9*H? C ?-
ME0ME43R0G8'H>3T(XS+EM2M.Q:,O*0BJ^],"R><L;F4O?BE$XXE/!='C4%D#
M9<G^DE$H5<J;"L#)/:+9M"^W@DA8UVR/W?@.*D#(Z(T/'9-_TUZVVV-W!64/
M+H.XSH,>L]FF_D$WG/1]BXS<C.3(,_?,&^V,<]+MF<Q=8Y*XG$^*%FL]#G9Z
MW,:>>$!>;M3D1#H[FF6M^\Z]C2G_#&ZJ0EE<-C%1L_H8Q1,&.FL5%9T/$SUY
M$55 1[)$R!3'8]%=*C.BG5M(''HH50++*51A2JHI>Q/B57WO?&-%OD?U6O/'
M?,5%[W';<])TE]05U(?G;\@7[:X]H<^G_?);N";% G^>XKI0,THW:]!A5KM%
MOV1<C_!]C=(JS[E5_\ J=26SR-A^U5ZUH*R\CY7'K7)%BN=]2?"XG#UM[RX0
M/7;M/Y$?;T3&(,4H>G"M/JA6U6;O]"2I9&E5.$+7?IVLQ6EO.9?>9OY&=_.%
M]8W"HYYG' _$K[9J\NA8\MS7_M;XGL:0;T*".;M%9T"]9-A*)UR9Q#G&/IW"
MH68U;8@KC4J.Y U5(PG>R4E#7X_V#Q505S7@Y7V6FQ<3_C)O1S90]?1)W\LO
M-I8(6<X%KPG@'0MB=IF?XU[$XI9]4=4]?!N4#?;&/:NT8[1/0=+PL]F,-QCK
M]0(U/-3Q^Y?,KCZC>;'<(+W^(-IBRI]3 ?*PN!+*FSK@@L,]T,O9KX9F<25Y
M6IB\WGE!0I+91.&4H?$M+51.&[VKWIZN]D^K;H,>(;UAD<=%6C&Z//<$:4::
MJ1% GNV"H</P=X]V%T6[1#^8#-FZ.G6DC8_O'FP]LJJ0-W#82*VH%$.Y>S_D
MV\G'U4ZQ-C?8%HA+73:K[&_@+C:EURM7E7CH0#/86SNBI%R$J%.J?":PK/$N
MO'AU\R=>WOXA3DO78K9@]8!B.[C1F9U1U#YH[B+Y:2I0Z3K3DZAW45DYR<&C
MACP1Z;-IS BWS5C? 3(>G1"$"9G^WNJATJV5/<[26[S^FW>%+_1;E:DKR5AX
MKRP+PR'F.JP[;S]YDR?":"$G)_FB9RIOFN&?71<&YE=[A]<BMM8:D%A?I0;W
M)0NW-"J@26=3(:GA($'K89L\]U,C!-O>R-5K)37T10\LW6QQX)$XFI-M_'O8
MJW'WPFW,02E9$ )3%>>U K4AWU;T/;-TBQH<MDEH%+>XS'US(E^&G-%9 )5@
MOV'MSB8DR=;XQ_>8S:#%TV<H-ZF Q$?^&:93!B$FP_#@-\#O.,>>?TE4K$91
M 3-/48.Y-HB[R-B!_I$&)O>MXA5<XMD!?]50T8;[UT9;?[$_'K;(+[P#?:J<
M"!7F?':G4?6C9EW33;W3&Z0B1Y5U287?=Q\&"K$\^\&E,M_[A=(/TN?:5B_-
M7D6\1__NW9M=->8(#$MEKGKSYH,827 ;9<-R[D4]?84M83BK](O::G)E(=.9
M"8XUYWT/736Q$J.;#']T@[K&,M5O^B7?G)O+9G)8>WIF::#H("#;]+]*".'_
M#/R?@;]W (3H.Z),C9!_4 $[I^>!AU81M/\9_1:%D$-\-%TC1\H=DBS@VKF;
MB%B(O$PI86X%'Q0\X&LU8%)2KB;2;%*V[2,DJVL07]"F8X[^\',UN\!+<*8H
MF6XG75GL&<])V"J=9/#M$$U +8/FN7><JMW'VOR^Q=JM3Q:_PW)V&]1[7W&*
M?I 6V^L(S?\0Z.V;+?19SS"L9*U]N.,I**:@U%] 8%EC]SF(7N*XM/[PJ0')
M"^XR@>BF6V F"S#/*1/7<?@I3Z<X4_4=9=/<J=3"(4_*YPX;P9?-FP)?358#
M[%7\FYX_"FN#\;3ISQ1RM=S.SPH)N,V?[(U$)>)\LG,)3W''&'(7Q=X-"(4G
MK!V/J"%B2IMDB!XQ+;#D!]:%[1[6A.(N: \F*;.CV>  #,9/'7\36 WH8HO;
MKW@D)L@A6$<C,<6B>PNAQ*"1F+TMPA%))7%SHZ+,[YGVQD8Z^1T5D 3ZO@X[
M7K_EVR>]QR)5T H>')KGXW2Z_"*)[*=V:]PXC6%W!-@:I]M*.Y%!;MB(96$U
MY2)*+.2F<(,U*PLXODEX3>?NJOUME;2X9]5&YQYF9PZ?2]'$G+05,F:C KBI
M@ 6N$2J@FR&?XN$N8P\O)JV,IIBPD+L5M=W\$'-4  8=C2F@03/GY_VS!]GP
M>)\ NANW2@IJ^%](B*J#M3FT&$3811AO,3[NX:\_U/<E[RB>,I>3(.F135:
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M?^<L5L[WYI9WP3=?C3B)^B%C+E-NH>=M:[2),#:*3^'V%%M(KQ#IZ8$3(2=
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M!B:ZT>J*]V/'^")D0["_8"?3T$J@ :.KY.C_NEO;J94=3-IOS&EX!7H2MD/
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M/NM\2[_=YV#F,'\!CU04E!4 6-A86-Q8W   Y@C K6'KXN'B;NORZ;D [VN
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M=+HEE@R^\H;"*Y&#R*J8RD0NJE*O("I<G%]1>)5DY.J RX*XG1WXTQU%RYD
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MWKOUO/5=T5<\R^HGS[7);6W5'N1)!:74G.P 4?/^ DCPV)]LZK.Z:N%8%%(
M;O&*AV&TXM O']AT>I&@-VZ^D5@BO2Z:(.2ETMYB5F('UY[2+N" .C#[_)%[
MP<;E=N@_]HVG*SF,JGSO.O;9!LEGRJ00=0!UJ<"J=_AB@.B:QH2*+:S]<;Q
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MI8 W^\1>;PO)DDL>Z6@-3FV^2M@;KAT ,MVK ZTS.X95A^6>%JE/[!JR!M@
MP4+2D=>,\=??=12L=8LD(6=';NE+0QOL)LI,(4TOZC]=4F6PQHJV[Z@)1D_0
M./'=5GO6,OZ_X!^__X<'@ET2C9VRCTUCEY&3MZ:NVDXD(PO+/ N!3DW>5LSW
MR?!;]:JHV*$QJ\(;,ZO4-^Q0SL(,@V=BR7A*'\D:A-V_V14F?/X86Z&]^5H7
M/WS33CVC.6*$]CF+*A>[6;?V8\US^@ T.,7T7+@*K=AZTBXE@FJY]F]E&CVF
MWU U;A68\S.4N"=00V&AMKT2BHFG?W:NCF3"CTM-Z'HDA5M8H)#,*IIZVVUG
M\ZVSD0/ZD:)]&>/GY!XTT^51*8Y_0AK6#$&EB];+&$!Y\=_FR&#6!LKI38Y,
M[.;2YY,3#?O;PBNT2#KPF[%,8QLXZ&- Z+%4 M*_B6V.^KL-2 ,,V!L<Z4P]
M6%B(WL(+E&=U=]@I;>)UHX3PZ=R7R[$QMOGQWU8Q.KJ^V+&+35R&DC\3F-[>
M=+KK$='A"K)O* GUYG=OC!5>T@;=?DIBCF8Q9F8OV.=4)>;/?@<2 Y(-%31@
M $3]2Z;<K-5[RY6Y<T;J:6NA#/X$Z0?H_I#:R#H=H_U"ZHPXKJ@<W!%ED_I'
MYK]58J\?F/.3/ZF5N_TXMFA[!#VD_NGWFB-;BDKCR^D$K.8LR"3PQ8Y>9@1,
M,51#+N@5>5RL!$<.8ZZ>%:JN71$U>O J9#EX67KXI*J10,G35-&3H7<Y4#[S
MX"8Z*,@QIVMAT?2XJ'\&M.[-NY7S_GN\K (3Q&<7DFJ :Z=:69%/<MP[8U3_
MS=DKOG_!R(2#29)=Z*7%3L+YKF+C\@=F$I9UJ"T5C?L<)<U:K@1X9-KHTO1<
M">VW.FQWJP>[IQ&0WI7$A0Z:*]*#ZM]'*KS=AC31C28?U)Z5.K[+X&YW#LEB
M2TEAA:2":XL+BHM]R_8R*Q:4K1\MNZ'':W;#K@S>5V"!23.U(#&"B01'S$1[
M5#@%MB*!71[3/!6N$9TO/&=!&I^N/U<?XH2J$>[/=23-GMMG(2,=5R;FEGMF
MQSW9!E=C4UPM6M/,S$JYM,*@(IDE\9NN@IZO=!**?1Q*]^T<^"9&-"6YUY^S
MIJL'RRT-#76TT#,(SQ(7:KM$3>*')<.91'']+'%BTGSNMBNJ8);1$_+P*GE%
MQM>NW0&G:I]445W@7,61V)WC]XR='1&M1AM-ZIY5;\7HI%0W5P:R;)R)H+[[
M.U$A!17'T*@'F_U6=GLEF2HJ$LP_+!(,,^T'K!]-:=.AM^>OFA.J=NPLS;1^
M\-=6\7/"PDBY2BFZ>;C&/RUYT^X]DR7O_?;9FIAP5/3/IG5RWIKAA1B8G6SG
M(3QW<W:(8>^:[+P:<I7S"XDW[=.VEQ$N4G,VL<84&_@EH:!OZU.&(5/\X(0:
M?X-+3AR3O,&5I^#XC:[:IZG1/@&WD?95)_JM[Z'K;@2NN AL65S.&XT03K)M
MG"Q6A-#FF)-;L*4,T$DF[[G&5*YA",F#N^(T) 0#$*M.D 3";VW O+E;?=-&
M#@UHX"8_;5"XGQ7"6G"G[&_U,B5'4L&O=3L%16JE!HT-J[ ZEOBJ<DH/P<-Q
M&)>BIJ10BW]*'JS!X6#'=HUJ$H+[9X_YJI'K,Z!,>LRH_8Z;HK(22I!\-OU+
M6_>[GN  \Q^R)LHZ%+Q=#@,00+:S7IKVNFP;_)'T;CS/(+U;O.N9;D-,9NAS
M?LI0"4QI1+ ^Y?H\J#6I.]N%;\_AS<*BK4Y",Z#.3*CZ/'KD4&>@T8M1^WRN
M?_-!E(1;<,43CX^_/V.W%3&^MML7>[YM]*T#RQPF3]!-7$WO0<.%7=)"(,10
MT)ZM?](?MTU]KH=T G. MUXM== *(]2/I6I63.EAU=7BW%=>HX/'RJ7NKQI<
MY^D(2]+HTWN8/>:)Q#XL##+?1[#M3QL$K3)5V(!#A[-W_))@U&\#:D$J0# 3
M?E6QXZ96CL[NS(E[\T*%4]'7%R :+GMB6Q5LCK=\7PQ1L(Z@"^3Y#]@!TN'X
M9)NJ@?,'DN>>+=/9BG^KXG 7LH[*;.)JYYO" ):_RX-$PVR+*D8W^2[(^_+M
MGRC:?C4WV[@BK5M@;FXW8L45^;;6@%^01\/71P, %A/0># U+VG16KBQZRDT
ME)5 HX)SM60N=V%@9M,,1FZT?X#6*"H5J1Q^P-,!;!%G>],H%ONE4KC-:S$,
M\KA.2^Q#F$KA26V+7OI(IOW^NTE.7$%^8](?*L<."T=7#M60)EX/:!JO[(LL
M04H=E*!TKK+7P[TF=@F[D*B:AT6/!*.MB[8;]C?;POS$#T!$U=L]J#_MX( N
M)/79&/+#876L.&T56DS7\M17#;'2H Q*'Q@*'P1&.48K7=:]Y:@5HO3D408"
M@TMO_3SX]6:8IRE/B\+O3!:O_)5LEFBL?<.*]<MDB,+R2]<Y.>WY;;$ .2'2
M;<>(AY$OZ_5_]X39<6G),IWFBM%\_*N=H"$F@@$,+>ZXG.L.H3I73$G!Z7I=
M?H..UC2Y+UBEMT14/4?=TJPGM+MD2=^&T1QVT2R1RC&F0[Q4_*+LFSG+H/TE
MY847TY*$UN?U1WN.3;J@F2(<XNAV-G+"O'Q*"#:[@MPG/.=%L,]Y_5,^K9""
M=R2%0U3V,PUP(3B$7.B>=H32'5=G-G0,2Q>QWSZM;-1E,G=2FQ0$$_+/W=P0
MVHL(,4^WNODUC7(;W)1Q+/#\>@$QA95T)Q%R4TV<!U<S]5ASLW(>E26A/FJ,
MXS'C &U.IS9TP3:R.;:)._OK1X;X#(1]OH>L;:L]LM?@H9D^_Z:=N'/NZQI4
M4ZWQ'CQIS?_$):O%9*+_4#)[PICZ2^GJ,S%#HFM4\UUG,]N"@=.ZG:MV_<5E
M]6MJI2TH5+#^1>D(<.DW?IQM34?'J=/.I#,E7ZH6Y5]+P+I8HAK^:TYW]5"R
M9F-#0Y_:'JC]9)>,TKJMO^H?#;TX.O,V'6F[ -3]\[)[V/1Q@K/NTB; =#6!
M]$\HG([?;X^FV6K.Z*V?^>=4L10,;'VZ:(UWYK1EH9A@WFTXDJ2CXF(QEA20
M _&\#INUF7/AE4I\8\VKC 7%KL/Z19Y<3:,-4.H4HF)O7FHRL@W*W_BF-*#Q
MK#9."^?T,E^0X+G&Q/06\AR>M(V NX%35XE@(/MI5/ *)75E0\L-Q-?:CKEG
M?/+H9[8)H_>4ULRFVZT7QUH<-9Z\TQ/HFE".:#1H.(:"P,BF::%)NOAG?$3R
MK.$7D,Y4,Q':$N?+3J9-8>A224?MV5'\4[.OYAQA$_-0)+:"XOS63&ON:8;3
M'NKW:_]SZ4:TJ">;R0EC)&T<S \9I.^%OS%@P>%V_8 \I-+,\;V0?RZ5$9\?
MB(FQZ;>E6M^X6G)L8&?8P"^[[.YUZ0D9TE2:G[</+E%R>4UL QYM-07IJKF/
M(VF")[>6I$P4RPV0)*B-=N^ [\C.#C0)F)VAX&!Y#31)^),O&[*472B/H-QN
MLM/NBQG0&1=R"A)Y&MUM#H^>^C2D2>_18IB8J-5=OQ#T5\1F2#CUB8-O2VMU
M9%$?G:7]\ZBHOU,)N3Q,D65Y8LTKQ[S'A@L]E+NEWGY_'ME%/?ZU,0KYG%=&
MB28 B^2FSH&SQE"-TIGA&H<K-2='(XRYI?X457;HU:?I=F4V%460"OU::C'"
MOT.3D]J91#=OUF0U<KOV=]?+9S2E3H:\>B</KA V$>;RX$@2F0L3*D#T38AL
MUV+0^>OF&]5NG?BI?)4]L]R,"V8ZOT=D]*EWP3<4EUJKH[G;&( K^%5UJ%#'
M"S\!QAJX_WY6?2/IB(K)[]_3-F>]2>Z!?TMY@(JF,;G#[;A_?I=BC4Q7'\H-
MWFK[3Z]W<GPLUI]6(JC7&V8\]=!L-VU?=)Q4P/JH[8VMH,3PSN_F4DT<A/R.
M 4C%99C2-^X,Q(5VD-^DT4ZUREF;6RP;?1/'(U7E:$<\6=+$/\VU_WB P 7U
M?>G=LBO?V]LKA$\/)]1V&8!,3,*2U80[ZYU 6?XMFS/Z?]B[;=TR1[_H/@]1
MHB2(P&%.Y)EU[8A0<R&WRZLJ3',F*;*G!'SIGHJE[M/U1B5U9!U)G\L=T)]$
M')) 0N<8F<1LKBFN2"D<,H-#ARR:&+/9Z])]]K=*RXH42HM+0Z"Q*M"PDGBY
MYZ4>9>^BXS*1EO"+\J+4R(.\3'M<K;R)#"KJ/(*KV.@KDD.7QYDQO,E3>'8Y
MN $QI*)QVY[F:(W5ET'ZER)#)[F!>J?>!:^S%^%ZK74&%HW[WKW6W+RS"W.!
M7V ")&E+!@B_!4*;,&JWZP4_6W+H"Y9WNP_%'^Q!%7\.6.#U9!<U:5%&"6+5
M1[6FO2NH>L!(6"8A]M!Q5JO+TYV.B$;13:'PG4;5-$\F^D5PW]9T6X #V@T\
M#"[  #+8#,"O,(!M\/2=?'16,^+)PH(/S]@/6P5^:%1U'5L.2:6IG$YL=?\Z
M_#HZ5K/LK)*V$^\=;H;U=S4U"8%P%U^3WN/.$R]$_+4G=[5<:+Y9IZV,6'F\
M3V#8U>+]?1865CA)/"8&-'OKU]7LY27B=&E1"QA NO?HJYB[\,E<6BD<E.I2
MV]"B<0NI<&-3(T*A<VC+R^OY-IPGML_L;[5B[QKC*QU!D+*>D)=73AJUNEV.
M[;:0WQ[A&V_K^U8[Y\J5ANTO<3N3>=%D2RE?IWK%1/+ND,^2LY.!>6-$J[#G
M(P_>3US!H!QNCC@3J$T;. M\#D/KW25,^0*W:2?:2-IA1O7NU 6,U78<'S/U
M77F B.LE:PN*9)^:><< @<DI4(DJ/;].#W-$[:!%I@H?2QR/TX<NVF_4+ :/
MB)55 B)IW,BP93O71;&!WFVKA\=A>TRV<YM]IG.$$HHTCQ-^G;T\[,C:.0>%
M(]T"E.?;)F<7!1CG I.66S+IZR;3*R>WB[M!;5["[RM: I8$SR=F@?+R*C4X
MRGCO!( 2XPHVP1*)>7JI;\"(RX'0+)4\[LV =]AX!(^U@!2?!7)P$0'+'1Z=
MZUAEZ7L:/MHA]D%OOQ,P/%OG[/-#5=QG?9Z+5?6_4CHV8N'KU>Z>,X8DH=^K
M]HZ+%QHD(W,@!<M [-+8;\Z;S%7E>/MFL5 5XA(ED/UM**,#);SL@C:HRYNC
MR8!-X1A;F8A3&V?[EY]YOD,7;FS45NNRTP9Y[=NN^F29K=V@WX'N*I.QBGJ:
MS?>>Q, (D4Y%F4I+ 3VJK3U8+:AK=KD0P+ZVK5!HM[.HB+!ZC:NV4="#<CL.
MR.,M-S<9.RBD\%N7W&MH95AV?EG4\VY_)F/30*K6HA3S)S+^1%&)2T  ITQU
M7A6GUVUZ4\--1DI2/?E7;VQ;CJUMN\R O4P-ZRZT9>YIP3UOYFH.^G3!U@N.
MT\ZEJ:ESONMJ$&9Q)G& ^T:SSD,MR_R4N$2H&+R%^<8GM7LO*4."RS>C((=V
MQJA'S]L#XRQ^I!NJ"?:^QW=5(^KV'2?AVELN*8!$[HJ3[L",NYU?QO)0<Y;
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M(T E)]TQYYY-_G')DEYZ>@M"2X@!.HZGI%'UN6BCME(,(#L<70 >F@3#^S&
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M]NP:Y+#-4&%W-I#EV3..#MLU!Q+N'7*AZN4:3"#M8%R(%'#'XI(&N)USBT5
ME59,F*[1)1#'-??C!5*X6;@U6IRD"PAMG<S3+$Z,EAC[O*CBLN/]-"1CT(1A
MF)A+\",^[9&:]6L72E>-AHR?]G8Y5%)Q\_G,(#Z+->N'6Q,-A^0]GZY48BS#
M10TZQ8I+B$)#='?0XE<;Z+--H]]I9>T2D)<:8SUN'7.F9X':'D*Q\W!HJF"W
M=*CS0BCF?1(]?\1VSW2;H'TVN-F8(=Y*V3C7F#XG0;4QHZJ"O^I>4\VI<9)J
MW/!>N38%@6H/#\8HYUC(9'EYB9!\]..#.]F4#0FZ'V 4+A9C^>JXG']"&ZS*
MP1D8^%E*R0T@;45ZIQ?;_;<JT$$::X4ZAM:W2>H8&R2/3AZ!<*NG#,/7H5*Y
MO.@FWJ3"0!"5FBXOV=\DXL30-0\Q=RJD::<31VZC]L!:K5I5'6=<!^ E&9^>
M#NBQ>?*AA%>76.-]3TYVB1]/P%[.<^MLW\1ZR)W)I11P%*A;^K3#G=<P8Q9H
M.H99()^NR><R2C\Y03.N]AIX\I>%)X\8G*/J^#+.-KS%A"ND>ACL[ >FZY7>
M&%B32HE%]*#V)[L295Y^Z9@&#55U)T&C/H$_6VZRK#Y54O=96?#R'399'OG3
M2Y'U.*PRL:K[_<L8Z*L<9AK(9EB#7\0@'F+!UN#>A<H:65DR<G*UB,,Z/%F6
M'GKA3P'V8J+0(U'722CK=U2J#-C/R]!4<(;:/F#756?DAUJ-O!=K9:?8K4[^
ML*1 SIM3_EE;?XJ(P2?62BG6)\D@[9<R0^I,)-G'Z7$C<69^/[_C)0C##6#-
ML/4&\ I-'*C9&KV:L>2_X2?W=^519V1!04*C'Z]\P[YE:>ESL:@2K::W.U&O
M-9(>$B81?YA!/'<Y,I6G\+&;<59[P$9YCR7IH>(FW]Y4Y/,E#PU;ZEGNSW_T
M\S[*R]7QQ8J"S:%/<'PNC8'=...KC4FO(R8:#]=-_.L)OQ#..RD\S)J^$BM+
M6 ?/C=+2[:*8VBYU8[/TWGL%":J)W>L"5NS<GY9,_25UAQ0+WNBGV^CX/ VI
MTYNL]$M2:N%0SG_J'##.=P>2NGN^(<>A<N:!I^J<[&!U<GJ&0&(__>D '6E5
M!ZC%*N_--S'YV0#:E=38HZ2&OS#I)]0HCUS,4)48SA3 VK>PQ8&PX EWVQD-
M6,QA1=^FIEP(?47*,7GU\S-'*DU/\;M$GIBPV<SZ5>#E#<#KO[NYL<#!:.<I
M=Z8JM]CD!0T%J^1G^$V)-HUQ([=W[#.^>.[<[+*@(][N"+JMV_@0_1"0#7)D
MA[XJO+M .?4^Q=OMN1")00A+HO6=V;9H73#E%5'X:YI&R:8::(_+^H<6Q^#9
M>FUUSZ.G!)M/V,E\_Y):1&04EP.3Q1TZ5[]C6U*L+SA)UD>-BOX=5-N-&**(
MBI;/KYPLW7KD5,C5!14B3#(WS^9&=-24IPI@/^/?F \=T3'"QD(%=\Q ]I12
M'\F-#$ ?>S_K :@NSCD8V6@0C=_&OPWR&2:ZB1'G>%4ZDRS,_I0EQ"7> +(=
MS/P[0'X/[2#"6:VM@3O6?JNFQP(W@/JG&-]EQC#T!\WJM+S*P8W)\%9G1:5W
M,W4OP/>*2]*>IG9 C=XNI%((-1<[9-^GE-:M[-___N>U6+4N04E@%-.TK0]M
M_7PC=Z%RP'YNXH]3.W%M^>=?')UE8E]76=X ^.!AP&&7;2Y_/Q)T$=[Z_7EC
M?Z9@D.126]@LO5M"<W6=OK'F@A'7RAQ*\_>II4B=?KP=BU\Y%,;T6T?-C$EX
M0(6T4]7\4^JQA*GJQK+ FWB1S]\C39+,"9*A%#Q%N<YW@[Z#]5/L&I<KS0YW
M>)YR9 (TZ3L^SZB.N"A,5PAWE70\"K6!B MM]>#& QDQGKC:8V%TK9.?^<$!
M,@G^NZ=Y']N03Z^R)"Y$3NS VH2NJV/,^[;&H%165EPE0/3RV];S>&T]=9I+
MV5JW53^,!\KFA)[W/9%5%(%. >V[3TI3"B9),H$5W\^/9OR9"[L^Y.[]KGQM
M[:U+T$DC7O'DJX(*CE?RF7PDYCNN&MULLJAA+TJOTRQ"SP15*.3^4QP>ZX.*
MY,P.*+"#<EM_-\Y:""\-'WY-A-7LYS6?/->G! $  ^P%3<S $5?*]>F$UTPP
M+0!!_OX2)+OO3.L0N'5\6FRYTR[14UN+S%K&'O-5O\#N<(^[IY.W4A"RTBHW
M5#C2+)(N%\3/Z%2(^3XI5HHO3N=)9!?Y^DK1,C:DR3;UQQM-6S+:?H!1?R!^
M+/7EML#"10EA+X&]V]-L0J+9[&#@$'H_"YCJT565,&TQ]- ON!4SA5L*TFM$
MMT9720AN'.!C#KK -0TL-L(+(M:;^=WU<E*J>XWO5'GMTJ6^G8A92WW(SA&0
M%='XHU;CGHQJXFA+RG04CQOC,-=&Z+ZEE8W(-GC5HR7%A>3G,)5(W]Z:__*[
MD.:^,^">SC+?CGSLL^SR)0S@!K $=8*@]VX EU8I%TJCJVA#"*;^!L"D]?V5
M!5[M=EP2N(&:8+H!?(YRSZJ.W3M.O6*X[@O+&P4O(E5D7CK_;),5-RTR8H05
M%?H6!]#:@]*_%48]IYQ4C8GTTR48:XYOG%:8%COIKQ#6G@'6Y'4X[C;"F#Y0
MDD9=)15Z*^3!&[Y>^.JO#M3FX+4=\)ZXIJN%FHY43H<_\/YAC>9EO_U,7QH2
MQ]ECYY%/V97%PY/LKUS;&3MU8DOBR\1ZT2,RND.<84P4?^1'GC24.7A(+WTX
M?22&SW\:JXL@K&.8)G7X(L4]CZHD'S[EQU-]0LZ7V^:+:])%>57*!M9J[/Q"
MA34#TV\ ?8$0&&2,-[I5SMN'Y=_N<C)A>0WP$<>OS=(]"7>G2S])UQL 7??1
M@J=/O8&"\QX[U$+63(Q&75Q35$^&=%.]3<S4-6_E5Y\'=]R3TVANZ]P'.K F
ML6* :HXX2;YBPWT/[2$_%L?!1^UTNOJ4BT$F:315E 0(ZF+3@J#H?TSGE2DX
M7E$\TBGI!M"-G68]#A"RT7I] X#!( 4)>*E \C,';/@-P!G2]U69#<.#R]T5
M&, 5M<NZ.\OU+=*Y2O:ME'RUOGS7G#DBR.16#NVB% BR)X)QYT7EL3*[4H+T
MP9HZU+]@FT0R4U9BTC&E@R[L7Q*(]HW$J<__8N59S'CG*_.31T7*N;_1=.3I
M USV#BZT,>?R%B=I\V5!0$SN+594Q3'>FRY6FW,U[XU\'F_7@[\!>%XP$[LX
MIW$K7.DJ=?^I_4AL>6*6'T,30!J#V7U@UC)YGV2?7"XB_&5=4]7B4!<Q_-FX
M2Y):4UM3VD.KF7V^BG.>XOF'3%'7;?=63U)!S@Z8-MPX'T,V<5EX[1/-NWIO
MBMY J_S=E9/%@ISUDW(_MWRR%\Y]FF3*L5.+Y[+!Q]VNV/,],!^D61*RUX<+
MU8J'CW+AUT%XX]4K;QS1#6"U,>&B*@FR^<7_XAUDYLL>Y\WM/N<PA6!J;P!&
MIODSN"E(FN3P8,>VYF3'8./:JITK)$8\*Z*5E'P-3>5GM7O)X:)_0?1^ED-"
MCO=?8(N):D[N%YLP2@)CB_AT*<?]DOPZJ,H0EKEJ7*T)R0=Z%%?-PTO.S:N:
MN[YJ"4B7I/C>&#(**8..$K\=^JCQ61_*!=@(A]?%\;X\5X&?Y,1&,M:NMTMN
M_#A^N/T8V2&*E[^04/Q@5VOJ4N.B!:3ZW/UGK\2*GDD0"5K.?$O'Y^+P(@?;
M;0*G[N7>='1FOOLSMJGR#_I;15X$.X!8WH@C\JDH4P.!C#"4CIFDN6AX\3D]
M)TR-[L3Y;@XU.S>U.=O8'#1PP073; 5)OF62)Z<'%<#4%!]WELA>NQ.LBO_?
M['\+K1["S6<O'"22*:#IY3J3UB<+)65.FWE#WYSW2A&SDE%64FI$TZ<&>A^;
MS=5W!1<.M56G+?>G2?73-Y--;._<8WLYXJB4@389<J?=BQ*0U^4S>ZU'3=S$
MF?>5'EV2*SB$-X0,>V.L@T/Z<=U7ZK@18>G:#</!A>/%=K.RGV<AIF!8KT,R
M5V%9X:+HM#LS/(O^WGY^_+.2?E&9;2$R;W!NHAV)\+PWT:JFOU.1BF527C5Q
MW5 88P6/1H!ATZZDX)!_G=*&Z;(!C3$BB;K0L]Y7?(S!86=R:MMB" B[ 0PW
MXJF*OQYG#_: B<_W6-.E;=S\.3>[W'J7IJ7S21JJQ?6IF^>=+ 4TGKT*60J/
MJ%Y312B#PLNZR.Z544K6HQJPQ-@_N:4_V7L?Z/>.I+/0Y]63,//_!!MUM&7X
M+_XTI.9[.B?_>I^<]^5Z@?X_Q&X_1 @8"Q0*(L&XGW_MIVC%!QFS1-RBX ^I
M1K9KU#S).GYY>9KQ#G-4P@V YO?F>]^,&FB LOAS/\HQM0?Z"J?#\8G)(CW8
M&52!Y*0BY^JZZJ35SP""N.I. ,]5V:^0+/XEMTK;>C7*,Q 1W4G<9U*1^_QR
M#%ZRS, KK93NL>]PEHNY@9#S4X^=;.!V42^*%%K<XTY7C7R8O'L#.,*KV/5E
ME133B"UDCH)J0*6+[Z:<(Q%.V1R19-F:CFP".R&309>1@@+#9.E732'R43&/
M2KE)TQ^IBO>!,.:_I=_X15GQMF>3&JD!,+2OGL8JS@YE_VHC;9DYV$2),7+A
M:7QQS9+MNZK/?E^RHK>.*-(/!F>C^[76#A97>I?3Z)!(0RG?E\&)/(SE,6@U
MR8]Y&.J.EDM%E;.N*QU<?[NM'^OO 3SS9+#;JAG?Z1ED4[JC+E!R\V)_!(6J
M:&D,G<_^WF#;7&K6>-$<,RMYU_6[RGQFCP#UU !=>7@#7W?V 5(;B./V\+X!
MR,G T6MCVK>12ZL!;Y)AL9'RSWR_H7( 9UJQFN!>.*0D"SXI6=?LRNZW">V$
M]_,*:=@^*.X=&NOP/6K@/AZMQ]M9<  3N,ZH]V\ <%G(:01\BV5WW_V\>-\L
MXY0XI,L@;,#:4]J(-7%I0L-?0K>E$3M@U(QX/[[@#$OIY@:Z"J?^-R\XFO*(
M/ %I,8#](PBQL=M#3V< -U8&]ZZ[X_EZ.#@]BBP9'8149'1+U9CB9S?8?3CN
M#!'VZ-S_P!FE<FF^WP),_NEC\?R6.-YTC*9L;2^7ER*S?*>0'N-PL@;:J[P2
M6"M%DL\5LE7NI-/FX+F5O)Z.?+/$NUJ#WCQCA'FNN(R:+M'* 9(;N'8+A7#6
MZ[_ IAO WTB)L1N Q7\E&KM)'.IJH?H6Y1O!$$&M\05L)3!YZ>M&N6SQ7 BJ
MU2\"V6LIR2PAR+"H 14ER,P0P4:$=#[-'Y[6E*=E>E,W8="J3T,+\3V*LL#Q
M#'G_;2#$".$:^OP%E$7-4?D'J(Z9MX/-B[PM;>L9L31FG^G6J*LUSB;JF<Z]
MOUAWV("-=M1X<-7 6RNQ\&U33.'U+0;*-B3]@]'+S<E(,\53E8W1 63J6^>.
MGXRQ[SWT%^?W52^V9:9E/&"CAH:=(IHZ8GEBJJ4UXC/W-<F50-@JG]>ASW /
M,+*X.6G_BEL(MCB+6E*KDSISF2XZOMU<-<7*Y9UNI%)_50J6LS[=-1 72_L^
M8%)&KJ S.QEI8\&ZV@-J^#UQ:Y6ZJ-+2+]HT^G<-="P!_P! P']]BU\>R94O
MAFQ-A^1/MJ+#R8KZ42L_5T(<6D_K7T1]V^GU*/?5$FGA5'AM^7=&]\$[2*5<
M^W]/=>:O[7CNR"G[>J#A>.6,QA"#;6S".OQ,_YB\&9U/$%M@7(A?@PC^.TP^
MZNF!0=^<::-P64J^+'S,_-5]6_ '_*0H<;;\VYDA,/4K"S> K;;YCI.<U:W3
MN0F;/RNKPXJ^/D)N./[Y1/H];G3:<,<8:>Q1L7VF3X)&Q79Q<FD5"K'!S;.8
M"O@='_8)&51&<P/X<A<'JKRZ%73WFY;@C"WM<-&,)3BM8RB7&VK"B+9E,"K&
MO:\LKWMNJTR)GX<JLF;FA:%^8P0WF[U3>&]U::SO$=0"#.$?W43A2PY"I_?A
M.\VX 4DN$S^6OB7&/JN=%QDIEH:3^NO^=YG$Q404^4TU)^*F^L,[H3#2C$<J
M_QW A6]YG_:M][*Y0UZ1=?P>RX _DW/W%W+;E'RBCXM!9C77[BS]'?=3[NXY
MYN4-\ P8-*L.ZW%PX2L>UIKQ?5N:?K7"T3?]1#\[:>?6/9HA:S*L)-)<FQWH
MD8.8QK<W (F'F:R,:&30O-G #VG%C12MK88D"CZ''1Y_.=UF)TT*(_<Y.\=]
MD=3293^0'2(S0<=(XF/)':&62\,'TQ9D^!?G'F<55VOJBQTCP&V'0?@V\\3U
MLP[)]H%]]^E%L8Q\1I:^U::LGF^57V6SEY8DX(^_%>M8&!C?%0]U3_9H26!E
M]VHUG!10:;G4UYN #W3)XF;P2C> WV%EN1BJ>:1_XAYP6QY=RW,Z5MXP:_9C
M_@F*IS%BJ[SG*.M7SX+=HW%=B>=/H.R(_*_/C/7 .HR$3.T'2+=X'*PCC=AF
M)Z5WN;?O6.--2-!9PKIAT#5Q\*]]J8NHJ/98Z89%9UZW7W6\U:E>V._<#G$?
M-L1.YA0M5(AJ5302_NOV:3Y^RXA"7R##1@URBL$'>*V.8?#F6&?E8<F1QLKH
M\<R>5/#*Z)(O<U@-+_Q97(;W^86U;'Z386!I3&91:7;@_*FOW4ZR%&U 6789
M,BAW#N.&:\/;9@GAQEL?8!0A+]H7]F.39]["8\!HEU(YK4/R:HJ^40AYM+#Z
M]VCF%F$?_>G$^_Q[>B\FG=KWB</OL]2RT02./&FYU .NF00$AP#1OJL92E5Z
M+=+ CE!95[GVSBG>:4,[4:%,>KN<OBG"G;+R!.;(_OX?4WWLP_'21..50T=M
ML_U!YA'%] U^1Q+51+X?<+3/(TK%O9X:\_!L?/]EQ_Z"K#C.%?)?'X^0_V6%
MX?_W .5Q-OQN2P+FVU]FE3ZM_66S[_47FEK'2T$3Z"RSE%XKD;PR%PQ^15C.
M]'%& =8?^Q4M-)\B82:8N3SE@"Q8<'CR^"X_ ;4GZ)(T@ 8X5B#]/=Q=A\Z6
MG^#IC",%>7#G#8!$[>&5N^"M:([ W'X6\>=^5?_(;P JD-TQ[!S.^_'U(?;A
M.K ;MQJ">W@%1%[W%1N="+'&QM)66;3B,2D'<BV1ZQ^R.;A]G+'BAG#XSFR'
M/]=4B("I\G>:DAF0WF02KN41GCR8?W_U(RN+Q$XO-&/L^'JH6J+=PV>G1 29
MEMAG__Y8XJ@BN;W0'DX3U:53IR96_OS!ZYA'@&&4GX#[4D'&,,J+6WNDX%'.
M%Q1!\!"KD'E%XWS1TJ,O]WGK<YVI8. XEO8L6G@D?/#)AD,7)%7VX,RBW+_C
MPTZ0WB8SB</&939AJ/L[8K#'9+&K>XP[JC_33!#HNHY^4?>*R4S&IS>X0A5D
M'\]!!3*T?;$<D!XR.BNM1OLBWG%2_X5-+BDIK-OS50[]'D?V ,WWKN5G[R>=
M2]B=&%*%"ZE9V.A?[K+CK2SZ/=:,SB@.58ZRMK'8$NF\]@16Q68L(4)$3(Q+
MEI8%CBH9]6:&Y53EE946%;^U-FF"95?D1-!Q9K^U^L(&L=O&CGR7X1[\&?",
MB9(Z04_A'MMA!:]:H6:@@_?6DMM$?1/O5=DS0+J-.!%K0](OFN+7@A9XJL>X
MQO=(MII_]J1'%TL&00X^<\?,G4NF-KZHW4OSC;*J_*A(RV$CVXL&0YB, ;57
M[:3V^/A$)UG-B.A]^W1C9FMOU#^MJ2QR@\G'GQSE3?[P"8;:PI1EOJJM)@DP
M/'LTS;T8?4>\NE $E.GP$6!49HQ).>';F!L]CE79@(2NB6!D"Q4Y1=GJ+N5(
MGK'PR88-6CD5YA<.6[N89P=^*,LOSOZP8)^?GNRX!7NU5_"]#DN!,OVY)+/^
M@9PQC(1W\+T\BR5^HON14N"KCJ7UY3QA$*],;#K\^<-;-6*Y40K=/;Y2/T;_
MW7\9Q'S)N7;4_F?(H[)C-<0_?,@C<Y8<V/KX>-C.G?/=+"4LA9#FP1&(U'D;
M%E7U#&P*5C=B$M>>8)] W#$=A;2W\L@SW/5]3RT9H$M'7$95E/_TL4YX($?#
M%I^IYRHCK6Z]-6]N&%$4-\T8Y4/##-Q/8,I7T U @")I^9IJ0AI>YV\_@<S*
M3T>50U4::M]F'JF)&"]K43T4>Z3Y];>ED^$7)T\QUV_3'MQ)V_9I\?%L3U<E
M!_PQ;Z:(R!X]O7>/^F[&J:A#$^:O2SW*"R6<NL$O;XWLIM(%H FG\AZ??<53
MU9ZH;/>Y. 0-%E75MG#57H:XV9N&V$H%\407]NRX'/Q.>Q_ I&ST)#Y")@;&
M!7,J*<K'IK&G.]=EYUF(9+@QH0+JE)^943Z]>O,1EC].8R>&89@:S'JZ'&"_
MY 5Y7,_&PG&/H7U<?FP!G!4H;#'4B!'#2>)-%IB.3O;*[4]7F:N;3A,L:YB;
ME^@#-2ZLR7S?1/*G+MOZ4-,-NXO G-AB!JUR:41WE;+S]-\H*;6=R<Y>*Z5^
M_#C]G%3 "90.4\.J%3F!_A:[S*,NTE,[^3V-OYMD.GT$L%J.\IGXO,,'0'X'
MM#,%HX]Q8P/,8VW8! 3VP8>N;[$_K Y<LYDV:M"6>\]RPYLFMX1ICM7BG4&!
M'[9@/#B1;S.+\.%)]>?(C"SWB[?!1(];PD$'Y 8(!*&Z(*]+-NSH7:U'\\!Z
MM:]-GQI]D:BV]T0DYA,N2TX\>/$*>YJQ\=7=CZM?QF_TJN)CMQOJ:U-#!+JS
M)WM Y>MO;4O=?,^Y;8E9>X9_S0BODR&Q'Y.Z:;PL:O<F.VDH9H9K450#7I2]
M)B;[=[7B#6<6:9+3UM![9O@AV@U*1399RL2GWY4_::D35XWM3/0=0[YVL.(U
M<:% ^J!5FZD+24,R02HJL$H*(M!DWZEA2VIJ?'/W8!>_&,A4(5)96%(LC![]
MHB$BHV'DT*1I]2*;EO?/;/[.EJ));/Q>2$^!OU=J 4%BU"/(S*<S9NUL-CRE
M/Z[]= F=XF5TT3%PB!\JZB?%2!VSM?I=BQG<JQ&]3L2 9)O5XZB50,HK3R+*
M7DLY)RM3Y'->LEPGJ+[]I)O^NSYTD9;/8A N^$E](#GLG.H9327L-]Q.X1-X
MM$.NX=X2*UV@117^U=BI4;G?=R%CG\Z#ML[9M]=MM7<F!U1BEZ=]J7V]NV1U
M#>HP/*';3INEI3248[HCLFK9*N]_(3S8LSU8%(R'G#E^]HM?PX6TF.]O-*IJ
M*W\"A;TFB=N]90G!V*W""> 06Z7D\5L?B4-4Q=+'0TT4+6[$X.+(_V%V>50-
M VGP!VBRA@0) :G>!Z=\ZQJ]_G]#K)PP:CJ/C,,E7#1_)W7I+@,A 2CA*JTV
M.]XM2#](@>[6A]Q4=(AF/P80[(W[0O':'8S"\&$H>#N:^/+XR3'&!9U&O$CE
M_H[0%140DB+1'4<6B$H:<7KW9DPD]OANCR4EI57;*^V =&\K;*M&*.NI3OT-
MP&G=:T8+.+%V-J89NAF]CZ^IJIK,!W?F1Z2?8$[WIZ^_!KX\ %==&37B^F,C
MX%?)6,D;@,\TRV:5ZPU@.:UC^S9UQD+#@H_Q&WTW ''@SNQNMT/'VHL;P-!4
MF[.$D(>-]_7:E#ZVULFU'']PD%VYG/K!\_WT['B7K&WJ%7I>IM"<[Y@C+AG*
M6U04_7=*[U>#=C@%I*-6[_$$QWV"96%/N?'?=9CP$+6]=[A"I_>_M38K>$M>
MZV%HQ*KZP_9FCL^+NXZ^[4&BT<$*^P(E@0=%%I9'H1W4C'Z^XBO,&^HZFK#^
M 5,C9CV#;=[%TMN%1*C%)#0@:.*(+AXW+W/\S%P&+6;^L 8/?<PI!!0"F$@H
M/K\P47&CBQ(N?)U#>/TNU"%R]R'>C'5(/0^2K/+.8^7'KMO"DFDCP7S&H@ F
MO0RU?,0J:TQC*T9]=<K,G^I*<8>ZZ&1*N<>V./X\64Z3G=NTW:/6 \U?2Z1;
MEN-(=I<7O&X_&JA6C])!W;.)J;Y;S_R&RH1@DZ18?E8:HX!S[86(O *F\S.N
M_K3HV*H:M&5TU&SV)*^MW[IXMT3Y6OB@P4B\T(M*9A#X\PG-1U6UB+];\MM.
M(U^/4,)7D![EN>OBR#Z#E[?RY>N8K#@6)E3V;["] _0=2 QE<.G:Z<L1VN%"
M/[@*._-N[UA(*U^1'1EO&XK#TV%KW_MD_^FS9AN:MC:D>S:@WQG7,]<F9R[U
M4I= 3UV&(#Q_C'J2QUZO[BQD=.I^XP.F> Q_Z5N!]Z_SR:C2&7"([+2.K5VA
M+2J#"=RB"(&<<<DK)EX>/$7XX26.,P@3M.4EJXYC],.ESK>%S33C+D[[_>4F
M#M^Q+Y7YVM<FO5SL'CQRQJW,C>B-Z'PO[;O/#8N AM\S+ZI8X2E(;=)AE36O
M^D;WIO^/4,1@Y^/7;*"[OCE/QV>+"5_NI6RYV(_+^]IRU(<7+D02EQN;%.7E
M?QSH,Y0\Z\(X!1OB;<R"PN9O .P7#:8<J0M#<2%?%X/ '+2+2#JUFO%R<5T=
MPPJQNO==NKH\G/FE?=,VF^G<=LZ*["]J*%VQJ-&^9T%^A4X(U=(7Q'5LN)QP
M K%7LO1'TOK2>7=3#9,FN\@*HBQO ''3#*0QOGJ,1GC*N1-8BJ>;5.7X,209
M.5,CH?CAX@;P]EBPI]>F6EWC5)$I44!0E%PMOK @KHO>KL_09G.*B6^S+C27
M"AOFKWR2'RX17)O'_&:V_LCZ_L#Z0ZH)*712,]^Z3&79Q_+K'-W$7T0!GFP?
M]_]*@]=)>E>VKM9T3KE"SP5G^H.#0LHB%N97&OMT,FE81*+=V-6B\8^FW8CF
M6V*,PVD+TM-5M[[$T7A4_#;$QES47H.D[XO3SIG P RS]17>)G-CN40-7N G
MX8.DVH+9 (+?B6M@7D_T_F>>CC7N54(KI+:AOK_#X.)*:_$RH2>T"AZ NMHS
M&_[8)CK;UTA9HC>D%3\E$_^YXJ2*)EQ3A+OOVDO(!_?H8*JX>WRQ?34JTQOD
M5)4B/[;O6Q_*X[,_DZ\]=0-@KB(SK"^&F]+_[5 _A_1!*Q;,!*88I:E^! Y5
M>4Y8-F3/_.X=(A>[-\8.'6.3F:$1%QW@/Z>A4F,_%Z=4DT&K\4,/[S4WP]#*
MR8;\P\YJZ^!_'0X*'ZQ,?>]]O'OG(P7 ASO(IC@P![PS,HG=N5LKQPL1U4I<
M] WJ:((DK09N8/MD&SS?^@QL>6?9-.-7F1=>!CX]%RO;TI#Q,D(BZ^35##9(
MT?^]IL#P!@!?NDUV;CCW!/*FZE:5GZ$2.-@!F1UD2<M(*'*9T2-41]%4R8"H
M^H445W%Z=EYZ'CWM6]O'8*+X(0:I6XQ1<KD!W(^^:H3E]IV'7F&J<".M;.L4
MC (JIE^O@#_;369F?"MD:9_G'WDUO>G5VW J8^M>MP-!:D]FNTR?A-.*5_'6
M5=QR74\KT-$MM&,QR,':-9-"U,45E1'6C0HI:_A15Z:H(@_]U<DLP,S,SWVG
MYZZXC$YOU-WPDO\P3^=_SDH]6QV*Q03X-*)_7TU!KZK'@^!UDOX6-I+)AZN/
M[*4AXI%CVYKFIS >WOS &$$JC_'T#XL<I]Q])-I:S:SALG,M_I@Q7+N<"$28
MHK;;MZH?A4@J3W X8G#;FI5-J#ZK.:Q UHDF2KRPEQ@-3&7(]'75BJ_6K9G2
MF.B[?*3!]OKV I70K!O 9PPN<!'9-1<RA';92AF#;S])V"O?EO;]NS*$:47+
ME37ZK2P/6R^]HW=^][H@'Q35SZ[O" LP3Z2YNU=H67[+_1:Q__.ZO\JKQS@X
MGA<BZ/X7XX4FR15!5B6LL K[.[NWG7X]Y,<S"D3^XMT6;:Z-7DR\&B9F*8VF
MG3&>4V0.<0=YD#-31G85H/6#JGPY@(FLW;9XARK<(I'TY75:PP*)(QGKJ8P4
M2EAW7NBH>5F1Y86-\/6:=.#5F;9W[\-&+ES*@ /+ 9+N.(/U;JC0#>#%"JSR
MZAK=5[[;RE>Y,V)SJ<Q!K%SFL5E-'ZPPQ"QH09Z4DY[=RFA!9D#S*"7*,F%*
M4Y9#PWM2'TR4?8#4%W^"XQS;P&^7_'([AD%D@>G@86CTDC$I6;+TAM$ .*4^
MH]9NC)/6<2O'Y/!6;D7#5/=H7] X%14T;SKIY-]N4*.EE'V*\K%S.<4\;[.0
M.I$0X>1Y7V8SV/[^,+G,/$_#EL']7K7/P4[@^I>S?0G@/Z=7././ O]9\/X-
M(,>Y7<Y-:="U,AQSBIL.%0YV'S8<T]$[E2R4LYE;NV"GQAB3I8%(0;RX4(6?
MDW9F.[#\8[X#AX#B=$5A0]6-2_/],8F'Z,&KE&D@82L?QL=G=&305ZBO<F[?
M?&Y?%BDX-B2@O)8NN--EL";:W#NTE3,8,KN>G%Z](I4^Z)QJ\^%/C![#6YNB
M6W.2=5"%<OO"N\:B0\"G5%4N_G)'^RLY"R15)P9F&3JQ8YL'U6@U'?;HY$ F
M/U%F??3U\+=U&5OA&F,-B&[(7 OO*GE'XM=>UL\9)%L/U7Q7/.JD"3=4!BN6
M?OH;[EXU+]>W>GQP-6MEM12PD[-Y4.\UG>% 'U_P:VZCU#(W.?I9TL"SHOPB
M26QR:0GBTGPW;/P&\-NEQ=1JRM;/J,]B6QJW),?WESPD%%09N^'Q)G@(L=2J
M2$\;:)3!IAZ37]YMI/%C5HU_4G6FUD@#/<2>H"Y1P88,*H-?!9PL;73\&HU<
M8F4*?>%*:MZVCZK2L8!%L]37VAWPU="_KS!-'+3ES0:51X#*"ZS5"N/B(JF%
MO_V)XIZZ72 ?_+L@'3DWB#@X&SB27B3EC,^9?UD"20'^'I[6GWG1E]QYSOQ^
MYOAZ0NL,=#(S,>OQV%0-6A;^<N(/3;7C;(V:9,NE*>W_DJ.0_S\'HO- L4S?
M:E2>UZ@QEOC:>5G?DWFD0L3Z7UO<,K0_GHH5UXI7\#CLLT$QM,]=;24OT] 8
M8$*JIQ:"-8*\]DM'BTH^/4SJMJ60.WYOF5=65/A$ZNGMUUT:O5$7*^&B>=K<
M!''"EG(S=EQG5?(9*_IU/T-"^L',1 #PO'SQEM87R&?(23;D(_Q^*]_]Y?D6
M\[YCEHG% *G@V8%EV9F,OBTG3]\Z6S&:^64M/OJH7/%I-#>,(:II?ZLXD;]N
MA*RDDNH(MQ?4FAL9E?=8^6TG0_ND.D-PF>*V5)#[5IE9<WV)O=6O9F*X)>#A
M:!+F;W!'*@D:N^NQ#9PX]?$((9^"]JPWBE.<+TJWVM@ZG;Z*D3-BO:O).SVI
M;J1FIL:NIV<PK2A#-:G&5-WV2TV7QX9KX3*MX=5/1R<3FF=?#!+'Q\<_;5+<
MV^WS6LI#LIT45O!I*]^3RX]]#4%/X'61K+CJBY3W;H)UAX(S*! %NG2Q]EA*
M<*ZB9VXCWZR86"M=K&^#6[C.4\'%:G T:81/:X:'AM\!])J0;[49ZFYI&V!
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M1$^""'!VV4=3CHG-B'N/<>B?4\J^2:"'=EAB&NF/N/ZE^(GLDU?6/852%_*
M+,D(PJ"?=8Q[R,Q)2^YK2GV(8A&O8L#,Q<+UN5IO &L\%G=J,_*%+.I:$[:
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M6QL9/L;<.PAV&^CA_+X4*2N0#CR24<A\U#12*YSO[HM>6:\=V^>/+JYXRY-
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M_V&?- 6!*4'4SFT0^&1#%#B[#@(3UWS"[V%FRDG.J@@"W]%G7]F_:<'OMH&
M#+:,K CRT.E/$I5CX&\-E&L389"]W>19&M*B;TLR:\S[P:19-340B/*= 0$1
MR H3^E1U-*&]! 3B43MX8T?#=<E%B[]:4_^"_5NCE^4_JQ]_('XF;R"./0(!
M*@M)3Y0JO"]BDS(MKSVE].ZN.PA$L,:I@H O:@,U:X+>K#>^>5A,1.X7UN%6
MB$=$^8U)NG:DCP$(Z./U38Y(D: /"+#A-B[,#=?GP_.(O$@?4D)<#P*1,-R;
M[16,'F00!&B&ZPEP#+RU[NC[ 70CCW49!()7,/_X#80I[QK<8 06W@3=0)GB
M,-L"OJ3OA"VW'**F:W 8Y-'& 1W*T_1V'=:"8+IE#-L8)N#P(9BO G$F_W/'
MU1,Q3'/2:^(#ZVCF.Y(4P[%!)3Y3(@A"-IZ9_-439UHE"&G*=OF/J'9%C_7V
M&#C6VS\3<%-WC=$JM+]SXI>5$/ "<@6U#_NP9GZ6 ])KNDF9ROS= GN%E&8H
MD"27)9ZX[KQ"W(1,)V$V%13Q%L/U__S_[\+C#$L=SA5NBO,' >I_*$Z2<I#:
MA-]53:K][-\53,\6I,\$9ICP"]XD_;O*V2P-6Y\GHC9.$;E_5T(G!5<P'N*_
MTW;6+?7?Q<BM").C:A3RZ!M)\?ZA8!GJA4-WDO)X,KSV[[+FU_^& TB%Y62]
M>GG/KWDOS2\B&^\& B=6(1V7%^5 X#&\H6<\*ODIR2 S33=WI6#D6+9_Q_31
MX)P]H5S-ZWF3B>C)VB,G;) .=/W&#JP%MAY?JJ @KU987%C L]TIM:/$I/&
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M6@3$QG$T:''/"!\PY!2,@L"+TQPW$_)H>S34C?CN+]WXO&8:Z1D6%[I6O9G
MP!_'+\-2Z%-_1FZP.>[&C%S>YT):D5S;RW$MO"+*2X5L-&UH,LIR[994WN+Z
M^_UK236CXWF.TVK:TB.1VA>107D#NBPZ85G"[WY*U9/%WMU-U5IOM[[077<F
M=\4J1^+^ DP=)?%^\QYQX,<:TU!W^Y#L@RA&2XF!7J4[-N<,/H9V7&;V*RN6
MB4K2,6><7&0,>I)K(JVVRH*=:!^[,)R@?J_$W40B[K)L=!QT(Y6G0>] PM/.
M//QL4;BH8)>?_<G5*.,&C;!?54@3_GBWVU!:>)GK96NSU<?6$U'Q42FW3[D[
M.GRDT:D^-YAHR<:1I'3IPHU'@BVY2A3![1YY)^8&/R;+1-=QCAG%%7FH.SXK
M[9WNB[9<)W]L?6UFR22QPW5@CLU96*2$S%'$Q<#OZ_),I/-E9>@O>Y,/!K?W
M)D>9(*U>R^^*S'T+<\+YR]A3(G4#=6;3(&X4"S_=M.0/E5WS#D.<U2G+\R*>
MUFR42R9 +8K1T4GI8_M.B!8+85'8V^=IMG8+QG7J&G8\W.FW#?64JT*?UQ36
M7&P<VR@!6IZ<_K+[*6,]:6\"9B,Z]HG']VO+:H<.MEQC[6F87+2E=<:/2!Q%
M?HULC&ZT-OT-<\U0E\L9XF7^X74Y7W8=:S:\--U9VK\Y,YR+3V+J9%3B9X=\
M:)06_BIZ:;ED^;(Z4S"CX@!@!L@LRDM4B2ZRK7=-H!GU7=8HJU?&*!R=]B:I
MF(H[8\XJVJ;$ZKT5OT5_V])SGG,D1BZL*Y;#MJ3@I5>>Z!V)V^@PB(W R]V;
MPJ4IXUJSMRIC*;VM[>V^8AQU:9ST60O%PMW"^KQL0@;<>$IJ#%X8YG/+JB'L
M-4V"U'ZLH3>T1XNQ7'I9HQD=&AHWU5^L,P_S%HBP*<9:O=%]</W<G%\ICW+'
M]NES_LQA#Z>S\V@[R;0.^VM*M:W%Y]O6SFV6'<4AMW0EW^8)5&;8<O,L<FMR
MQEI2.##<S?(/XC$V'61RB(#3[#![BD<ND;U=!8%(XX@W7<X$_W>C98S:S-J&
M+%S.EFE)*/8G55.Y0P+7>$6:#Q6' >M=N0L7%=Q.,=ME+.0RSXW>6Z;,'!F/
MA@PG.$FMJTOO?98NK]^\['0N-R,\*>.S6;""!$72'<WW0^PO0T^@ZDXD5:A)
MK,R:XKN2PT!@WU,#OCY.L]'^#3L_+>'6X8ZSVG!J0C/RYF:,>CJXM]K:"AV@
M9T3B[7C,/WS?^G&9^2-?F]!U@T]WPC)LJ84$4!HGM(<12BE+1D/,&.-J]PBS
M@?50.4$G8GX$%V&V^=G$5ZAIHWD.U,O^,V";D9$3H>AQXN,="6.=YTBCBSWB
M%;"\FLHN'N/&"G$ZS7JY64/;FKXL5X6HY[&:##FBPO=9-6Z4D_N1;S.;[C65
M^0]"K_:BOPU:V;^HJLE?%WPQ^GDQ=_:G>11"8C#@97H[@RJCD*+_1J;_G..+
MB]]2EV>RG;U6?/[3=X-5A5%;L X0&!N^ 0)&R1.1MH0H>(;I)F5*70NA-8YH
M!\%[[@ZN*2C^.\Y!^VO&-/79T;SB(==*SM?14[A872GQR2@),CR#9M!5XZ J
M"T]2><6YKQLQD@$"?FYMFO7NCH)6<:Z_L ++!MN":@IBY>G6XF3+,NGC%WW(
MMZ"$%! (S+0M,U;ZS@T18<=?=VN!.*R>N\#=G1^:OML0@?C$BOULQ@T"7+!G
ME?90/+Q(D/2WRM58I"F!,MG^.@A<T,]!+;G:JX( [;)C0YSS=XL7?<KJAV,=
M%BO/L(='V1O/([XSH_IR08!?PO6P] 5J[%H_0<H/'E ')48MQ,5+!Z)L]*98
M'G.]@<(?-J#O_\.KJ8IP&Y-RF\':Q*'DN15,U4F\OECC:E0V_A02[HW[L2?B
M8V6BNQ^VXEJD><EH*9>%U[^U;L17O@FY@3&4]+Z3W.E'&J0)8= ZF9D4WY6'
M)1P$#J-"W>O4+ZWB*867!2([R1N(J ,IO_$=8A%I3C!?[;.F&)!C@R! 9G)H
M7"$CW H"2^S](,#"#%-PT?'-K;@I#5<2Y+0L(#B=.D\- FJ*OYOE>DZZ4.'2
MB;YUQ@52A8QKF]^(.BL8-+$G?M(8!"(R\329XR]4L8<[;($N^X<P7#]:_/ 6
MJ_DI(DL=MM9KL\(:!%1YJ3:A&!SOJS80. F3O$5JMNW )^+-BER*J08!UI8Z
M G5+:.?!+582$74%=%-EZEV/G#?#:T#@D3,D[T9]Y: V4<HP52V--* ;X?=O
M W7O#DUWFE'N=ON9'T&@(OM  K>QF7RFKNK((I=0SGR>V:6GEM=%WS*U0]_I
MYX_LS&!%_XF7WQ]5EEYHOO1!X=?1S4E'VD&=7 LM!1=DW,,D_0F,RRN:06J>
MP)$:SV09:7JT_X 15;Y5FWKIEO;,?+N"^D6'Z-EE>RP_M[G?^3FH$9WX]9.>
MU;]@E-$F;U-.]'S>,';^MQ/UA.V14#4XO?&;KAG!T7P9M?@G4K%<_/(LC^+3
MZ)N2N']]-N$V=VGD3=6ZR_Z[A,:;!8^+^(8*3YC8,WWH?6>_MM\X:&]01V/#
MMV2QH+RDI*CA:4-60#R*-2P@*_;\.V.71C;V,_=_/KS%LH)FD!XO$XL%@7'#
MNKCZO7KT9*WDRQ[5X F8NOL4=^5-X1LJ6OR<HHYG++6U!K5;(3HO?[1B/OB0
M?)ALEZP1_AY._=;-VWJ_O]?G]-&79@].!0VL$QUR'GEIL2<F>N;64E9NN%"P
M+H>[_+-<'4$.4C/+?RD(3U @\-T"/D\RC3O=>).+:!"HNG/$Y(IJL0<!J4@0
M>%-#L3U\(>)@*9KHL_*<RLSW]5^=7?Y)@-N;R?*+9)OM5T0)<R PRTI'RG97
M^QT?CN5N@X" '.-L/4M$$O( E\&U14;,)J#P]J/)O\\QR['J^$ &CR1P_PQC
MOK(34R1P@ZSJ6-^N.OP#$"")D_,_U/K/@4 .91U6H9]@6HJ$7X(OP\=!H+GN
MZ/>9=J2/YBX(Z*^N8'ZP'B:3XO??M?R(0[\5S''_?\O^E^4Y8>6Z0E$.@Y<B
M]E8AC6@3]@Q"4"O4LU#IV5[$)B'Q8GVC,>6_8RW]+P&XT/WXNOISWA&31>X*
M<+SH?B-:VO\,C9B(LTG/(KJR;CM"58&]_:+(X"@35%Y>7D1+A9=#JW4K-TKE
MUK8,$KH>YG25[/7X76_KR7%/;Q/,MV?/<[>JO%FNLE+>#(]*BGPHKZZJ>E*!
MXM(//QXV-H3?/]ZW@ES_;W??"F)JY*"K8UFF8>UQ)I?R1@%:I<:#YE56?#+=
MA^9F]LS"_$C.</EFW?PVH2[RR&=FY_BH*"^=HU\J4N1BIN</1!NMN#LI>XO]
M6ER;*2E^J:4_T%TEI&*JR60=?#-2NWG?RVR#6R,XS5C^'7F^0U:F[<)@H'Y[
M&J[6"U<FB1.NJ^RT%I N-1O345$8&J'H$G(05=764EH@7/5$<\3?F?UY=Z>-
M^MG/AT-5-[Q2S]2\6I.>JL9Y--N]%\\:ZUXKZ _N<NQP?R(U3YM.R1-_[VQP
MJ]36(V8;S5<T\,[6:P8W0BL_:F#G19G%K,47+-;7/X_7Z2H,&I5XS\.='"6N
MB3/I-&<SBY[D%!G OM?(F]%/NC:S_9Z9]DJ788,QNPXP5.>4$:R=B;1QR]K(
M6)%)=<P]_:I@<,"7)[?X8P5;*B),!,L/<%)D\2!T>+Y*O3/(&;:2N:CEM?7D
M1!^LR(/.PCNHQ4P"1S-8FV#S0YCZGG3WEXF/45K]_3XE4I:/^EH 2UF^@HQ(
MD7@:+<G8RC=TW4B&RCCUNO*W 2$N,W?&AS-Y<)6F%IO4!E]8-D=V8VCH<^I_
MWAVZN^#)]>;AC_9;6TI98D.%82^VDD_MK/SPKIG;"K%RXF/9GCPXY+NY/&9L
M&YE&/<)W=N,KS<L!>FXT#X6\WO2UJ%3OV&)#W5.MFI]>=7IMD[LU%=M75JKL
M!3EHZF)C-]$NSE\66W_9NZ]=4#T=P!"\E,*OT?Y+,2.\$F?0YDE^J?45>TL5
MY5=)I25(<86"F9;#QL>/U9VI5=RN1F]N08+Z;]Y$0 L3>5YVBF_B!$WJ[_1Q
M4]$6_6S%*-"-LJ47 ,^]!'ULBU=>LC()'E%QR^M7;M\SSJW:$NZWS,E(C4UR
M*!M\8QE+IA.I^$KO(7G -Q"077^]D.<?'GS[JEU3:9%H@H(KWF5"LK*8VQ[!
MUFP]G8U$M.@J2%6&*W%F1I*%B]P^$?[K#<.D,%*U[0![7\;80,# S,AQU8%2
MS+@V? P*<>:TLL8TZ:H8G>$K[Q-!,K0+MZXV:@RO6%'E</.:&]W,S@92%D]L
M=")KMY@CA@F]Y6($ZV75/+5/7R<9&9"B"@'T=AR4D<W(&PKAA9F&@]<>/:33
M>GU4\D4;4=3I1559X&SF'F'K%KX6F"\>>\%NJM*:6>MI^$U#FP=GE=_:U=3\
M"!8[XM$(@# J/ZP*-Z0I"\PV]X.F:WEUCB<ZC% N%*P^7C">@PF;K7M=TZME
M#@BW"P[FJ4IY>]&1B:_0:?.L5D=Q)._ME)^I7[.97[WUTL$^:LQ$*XT(-?5O
M8DW(Q"M*8?IG8@J]%DM<99-#O\\KVWV.E[YP;:CK\J.T$,:[E)-X=9-3&7J-
MDSZY?>.R@D-7H3++'4ZD%#C/,72>+< AYH*8\APGWP>)3FI7DP>I=6:+D>9F
M+9AW%Y.^GG_JMH1AA%=X.#]V$*P2PUH[>]4O>(>;TI7?B=9G,+#,0AC$&BS5
M3W<$][YG.)0+2[EJIO[1SVOGI()*TL$X+$1PW.=4U \S8</'[HQ031UKWJV1
MZI64C# ASU&*&*$F1H63YV;<^5;3E8OK_'&9=Z4=WRK<GX<7+$GLE(G7J\"@
M8K#2"M\59%[[6L=;=$!:02YG09+RVP#Y-_TJ)WC97S%=8=>__ZTB02^=#-$7
MQ)Z*R1#;LV$N%W_K&YB[:>P1WR[W[-LS>YZ\P"%.!N7-T-=0+<G^9I/[?F\>
MR50*ONGU*D;J::H%[RV.>X:NDZ+=R/T-E%BWG53Y"\WZEB:=0II$=*C01UN;
M=X]RS8C7/G.42K3Z^<62+0PJ'KCY>L$N5.]M/'%D$MO*B<IVZ9G)>!RH D%+
MG+>)5;S^ZK9LN:APX^4;[VH8A2E5'.R\7.3)'NK70>O_TQ>[FY)O%:<[YDWT
M%7NL7M*]NG9]W@:?)-VZE_4A$^X/_R81*-!@_YZ4T?G^SG##$.@$D[?32)=G
MUY\1@MH:\XA*PSD$A9G)R?5;^S41>XU(A8H)E<VF&T>7<XF4T:5[A=^RS)%5
MS]P7\$TTJHHS!,1=0_BD3[;C$!I^#>\/^<5\6^UI730;^T$)U6;1$HK OS:*
MFAX-FQA%8KGHW]@^. 2!O.<@D(J'.>/*;*8H,4LZ(!";*$UXD@@I\TP' ?7K
MK+_("DEKW-%;%Z_;%>@KE(I':W<G(4P2HF&DU*L_&79XP/A:X* 'NC%1Q-4"
M)44G*OH@<((9BH>5V=_+'-G/-T_N.WBZK L"IHCOO:@9@B(.F5/C>YD'!+)>
MP!N&ZR.<0J:K/$! B=YT'ZM@3$"]T,&T?1B]]FL8,MNCJR-!Y+>]3,K23 =>
M%1V:8LHFQ:]>.CK%NHE=@SWUIIVJ[_.#LU&9$%?=516R\HIG_!GF8D,<M2?@
M >4S]D;;ZD>G-C J+R>LLT<"2;%6D?K;@>3=/M2^D 3N\&YA;O5/][/87-3R
M$ZEW+9P;\%Y;'5<B"^&H.F$Z5G:/ 9Z,]"7($;O&3A _B[*.:P[#%R/L.T&
MCJ&@(<[B,('S<Y06?+B'';]#1*%\%]_AY<?7+(C*T(T5T>\@8,VNOAOI3V3
M2B0@]FAN&3/ZTAO [;(0:5DXVEFI?-0&+>JZZ7A(N5'V+];/7'BN+,MYR=&[
M/Q5&J.%^E$E+>WH]F95!#F8?D4L>38W"E/R'B?3UR3-K<R5O[K*!P-?P*)DU
M*!>])0C S"!FTC(/(E(RR<O*1-P:^%,>//[@_\Q))*<2H'+.M_L*L)HM,79L
M>S]6'U," 2HM B;KWX[]%LV7,/O5UO#ELU2'HZOW.N GX5F07XNNI)1_K)T8
M __NQ5KWNB;R/QQ 'C^4_A\  M;;OCS TY*FA,@. C?W(:1UV=0F0<ANF#A,
M]%V\T>GJ:4+7;8H_Z#'^Q^>M5G>^'[A=^I_[:-B?.JX!!,.<W9@HL5QGAE ;
ML8E3,E^[NPWYM;1BGV*I2> $@7,';M;2 36Q$G^2>?W#V9"_YA: 'L<Q I3,
MUI$\+%TS)HZ*1AYZT5ZO49GWFD_("OGE),%E2.)3N+J[=C:B:+ /:6_6[^ 8
M5EV1GF/7NK='=CDPO&#F4EG>^^SP+XH:M.1/%7+\FH?+N^N8L,7AR74K!7_!
M)O6_7JQIBYX8=R9G+I4,//_>H.'VJ%09]0E';'6L7'G=>LR*;O:#6*-9!95G
MG_ORX%,+EF(5-R5"?W'A&8+I>T  B<#,;'BI/QF04$F./F(H8EWO0J^J3J^Y
MG!NO?60X&"$V;_/:3U'J#5=@ ]LD(;W GME=TKYR.X6Y<FL',AW]:0'-F!3M
M6,0ZN+009G#5HN'CY9:A&4R.M-=>FG?-ZJR,UIQGUCA!I=S".;=]-J^DKP"5
MKE46>;4!!*#).8<&R;XMW4@;)'/(-A=OLWK-IN>Y<6QCQ9ZHM,>1+8^W4$3*
MX=W#A E ^C"]'ZEQB)WI>=41A_>NFQLWY(0LW/AA'>W\ [/R(U?"EVZ+X&CN
M<Z3?"EV#"/<ZM;G-_PSDCPPN9*HPZQ\>^EYJY2K<L<H>^9'V^1AO,?"4Z+AJ
M[UC>R,9[AR.&C,^[I34\K7;2HN:MON*H#MFSUZ8WV47)<G?KX"4Y:U/CU]Y6
M]@ST\3MC\9VS1-1&P9K=VB;7:=,.?;SH(D)U>=U$"#7;!)\I6Y(]*T#_N(:[
M>(!Z4>;]&287JKV?*;X^N08QGH#,-XF'N"M*L=806](2G4O<Z)?^ \_<_]O
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M2E+Y.9'Z[8 )30HJZK<$V$2RS2LI/[=OA*DG**.R+4X2A(FQ:I0_JH7IG#E
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M:LARGRXU=EI@7:^*4I4J_<)3:2*I]#J02%B16B:%PEJ(&%&S ;DQ7155:\4
MVFF75\]-4LB-UR#+&, Z!N!O.\ ,H4T_*@Y81-_9FUY/OH V% [1[Q@[ <N?
MSCR%J/U&X;4S1C_J.@&J,S$9/^'% *P4QAMG4G((3D-%,0 MUB,'$<*G,+KQ
MBN[QM4NY1%#(#:2VC+F5:>=KJ)];_:.VRWN6_4/3]8SY6I/FQP9!S%R&#/B&
M;#]33;BE&.1?>IO&B3/;RO);.)<7(B_Z8S[-K,SP\ <7B:A_Q3.-]>+$+I/
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MZS89RO@(RC" >R]7)4QZFZ&B3G+4N)KG4^>Q#*(,(B25,@ YFW5=M;?K'9H
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M$$_ [-P$U ]PY$\,.)Z*VMN7-^$-M'M\A/6YV=:G2&$ &Q2@YJ1795^Q<MP
MV<R!  #@7B#6L2BLQ'WU'_**%93D\"8RO6-'$:[ WOFP-P#_X%RKH/RL5!CM
M?/3)7RH<4L(=K, H<2,$%UK\X%;B %3IQ1\W;RG>BX(@G5;K,MO.4;[[O5<8
M0,.?X,5ES5_@0@H&0/NGGB(D8,8'/GEQ5$.[@5Y%"QPMC/X%/Y@A_U(E$870
M@ZVJS+8/ :,1P*M5B)WH'SSQKX\^L*KP_\_S:- 'S;M,#"^1N='P+)M#BFRW
MZA%1[/.+@U>*_U*8!RR*MJ2]V]*[F=6O''5][UAV)XEXS6DD,Q7JL%>9R3HS
MU7GIP+\&0__JZ]2CYYO#"],2TNC,Z()&%5<ENHU H69ZV6'2<",HSNDY6A?(
MV1RZ)?/[>AC9T^X&&>:(8YHD=XHV-%.I%]J@G6ZQLS_X@;:,%X[U\?/@3J:4
MY5=NKX]Z?%K(F)'T9#U.X:N<GQALV<C\6$(+>VJ:LUM-28TD1E-C]%DB-<,]
M0^IGI.86](\EL"EI;^T%%_O1@D-S5+?A:,.B+SN1X<"BQ">2@_AGNXPA&;"%
M0'FXHDS-E 1Y2O?&[$O&LO<XMZM-,/HGA8M!)<[[ R=]L3PO079.U"VSRRZ5
MSF_P1UOAY?L#TB&]9M9<UN:9X/)"2]V-2!*@0<WC,/)4S5M#I45M@[R&),&M
MG)0+%TB6OR\:W ]NKTF@M,MO86EJYW="I\^W%+8(D&<]5?F^[!OO9%99?NV%
M$_=E6 =WRC:*5\S&-/)6A$J5__,:T[X7SG,>=V!K2E^Z?@T&9?_<L#U-C!E_
M*<\C*_-U3J9:Q/K#YY\V),9060C>Q494^ =:SIO+0BX^_K%]Z+>4F.J.AET+
MC?RY^61&61RD_ZH$-*U74ES?(^EI;1&W'A[[*Y=UNNX9:5D1X;@@YH?4!4HF
M>;I@9BR&QB:343)X;K//G(/APP#8]/^.P<&S:S%VW$"(XT^=J5FFNUAQ56\Q
ML9B"/A<E"7XL^?&=GH]%T)_$-9 L]>O F:G"84J%?KG-6,9?EV/&\P39'2R'
M-UTJ3PZ.6X*YA<\8R#@(^84R'V9'R8.9]CX7V]B:Q!+WJW])B)+,YZK[B?-1
MIXQ8N<UP >%).W_E"$H+YUT,?Q.9S"1O0"J"+U75>>_#IOR+8KW.W;P$0.T0
MNTXZD<Y4M\_%)^4O1W^'TNI_LX$[J$$,@',5+2-^-3N7EX0!C(LO $>799$7
MZ,\8@  01OL66"6KA@'\?]]7UZ@PDY^)0>I)8]WTEI8(!O!9 )[[T_OBXY=C
MG$OWNQ\."1Z1UP@62=!CL<L\NZ:-^N!K/Q(<SG% +5;_21S[TR4+[:G[?8>U
MVM^0]$\'Y\Q\)&_"_+4Q@'NGMN(';>,5+XW8LXXDD2BA%L/!XS!)]#AD>.K5
M/G[\LWL-8E1!#KLE>L 5LIU%*^?  #Y4FT@+VR(P1WP['QA:Y.KAT?F]MGXS
MC_'GBN!VPB<T$R4A/,M=^ ?62?0.VC'#R+C5Z9P1V4>[)BH37^]SPS^Q^/5A
MW:T%I]9[O8/4_G%KB-V$ZQJ1P/[H*QQE#C:CAING!^:T:XXY#2[[PC&IS,7Z
MEUK13]4\Q ,;(OR!3QN: ZX:T'3H4^#P9'!BA=\88=TL[6@Y!C"Q,F?W@$D
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MIL<MX2W'*0.1/6:!W*MT!*=S+:=ZU%ITJ+/F$BO77CTR^EMWE'7+#=D@5UK
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ML_&[\P<O__G4U4&/@)Y97A9-?$%XM(7WI_/G=0D,<B=2)T9V6/<H6<((BXP
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M<&=GN7X=V2R&49?_/$=.KU.1$]3X65#Q3_/TJBGD1_>5";"',&:Y'T6F_.U
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M+RRV-9,7$K?&JD 2[(51HS%AW8UKCJ+JM(#%BH:V%B>G==*MP5MYT=OY-#1
MXPY,WKLBOLCU68D5UC%KD!GL6KR2&5NX:@<677G<CP^993Q9_^PP*'3C>NL/
M:W?,8/O^^'XQX.ZC P!BK+2L&M[\O[<!7%\\?*'? =Q%5Z';J\;8?\C%OI6#
M\%^TE4:7,9N3!*[ AVC SDJP<?5?DLTE=&X$C+0I!ZT\VE_]JQ363??^?W__
M'WV'@8B(2MD>&DEK/G"]I03'M"C<%AT ?^W-T='-WKY$ _!E..9$2H3^87,>
MQBQ))Q&673&P95=\\K7-@DI9DBF^3[. 2$Q,C( _045T@A=*R"-3-G+P R1A
M27O_#\K.Q^_#O[J;YQX>W%;'MV'(LLZ4D%.$4$T+&D#W0MAQ;9E4;+0-ZXTL
MW]OZDT/#G+>VSEZ06L(8:2Y+;UM;>C?O$M8M[:(_&)0J^BY2:H&% JIXG8!Q
MG0.X)=>U3\V*E]SGCEH/CE)>3D(]4M-%,O*7=& :&P]"DP.3[!6Q:%3<CQH0
M*#V:(<]<8)I*SQ#V %Y(C$A(SW#&@+T_HJK1I)#,H;[I JDYJ6W*$<4X.3DD
MOE(37I'LM7D_-QR29AG]R$C!JWVVI8KF;S9<QM6.58)H'J%4'$4M?R,H3E@V
M8GP<AP2 \QM"0'NWD=75YH?99^"$\*$D3"5)C1CR@$DY,V(,E;N>C%PA>1*R
MZ!5IN;K8],T2&^-S3D'/6M57O8?5;FZ)4ZP,(9EI:0^B26E#!$!RXT3/WH
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M;!;-?*S+TRHO5;MAN[LYKHV17^BUP4/B<C&,X]?NWZR 5[5/R"C/KGK!QL@
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MD2BB$^C6M!Q:Y!+[.+ABVU^J%L.2-=O9REGK3];HY#28%0063_F^(BCA<>#
M)@CBT5VS/_XC3OXEEO5K"%^"?Y6734[OJ[L <Y4\"=MH_,YP@)\*9.X@.*@(
MDYG/>=:AA&[=6QAJO)"VD_8^%;ZI2.H[-)(@I].P*!\93DH8D,%]:\X*+8AD
M-2C)-_4Z+$M%.0<XH*+0BT&R=VZFFG\ VA0]B2N4$$7KH@HZV*XPSTKVHV/$
MK;P]@FQ\K'DHC/3WHY,YB!_9+9_/OQ-CX(L J:(^P(B%E'/[#MM'^S!6,_@Q
M_F%W_X/U7<9),AVNW9HX2_*W<;'PHT8%W0+8E1DW<GP<PX])YGV6X*W4SN:-
M"P**M;2UZE.1T>T2O QJDR')<Q#F,4ZOPR@@<@;CF,/4(01FJ-IZ@O#/J15-
M;6E\]&/X**JL@^L0'^)Y]'61Q/-0K %H[W3I(T:JT'&V="^];UQ7VV)WSX8O
MI03^O=,%EZ]KP1^:E?F'>F-S'J-H>(VJ_7T+$ #F\* []L&AXCE(H/>R>U:O
M#[[I4&/K SS#Y,J?X^^+0Y!I@VA#/P>UC>T++/R(07I^3RU7#I&WXM,M9H-@
M_J-DZA>=*TQ+>*)+]N<-MX#Y)1:,XOF1VRD'?J!+UH!FI\]#UB>B+^O9[&NV
M&#(@+<7%':D/&C1?O47V'LDR?M;#N?EJ?_<I5M0M #+9.3#<N@KO VZ<G12@
MVM%+A[ W/;.7+NFF5!+J9W+6EN?>ZW/-8H$J.AL571J'QID1!?")[H1B17L:
M 5.&^$][^:6A93+BFBIWR644&5J#&T-$]2ZI55-78WQ*L[;'W#R9F?*)SKVD
M9#/7MW3;OG<>^;>*[']HEIOPZ^]7#F30#@S4YL?#QN,[2ZZO3ZS@X^I2+EI/
MT:> R5'8E@\._M"6I/\HOG^_)YC^#Z5MAN595>+=7S.2:OJFE>F;@"ZRY#*B
MH;6LL@7!\F9^."#I\&:(<6+NC/0>16R9S#LVKD20JC;=AU&>*D-Z31GV"4\W
M,7<%EEN NJ/W8XO4@!9;RWA[0UM-HSG6AR!737CD.-9]^=?W@!6ZAFU55)/W
M^\,],R.HE0VV50%Y9EV?*F7>8A&(HDDP=N(1"]3TC="?P'1JRHW+1F2CXPJU
ME]--JT+3*W=SW@G"NAU-S7-^FJ+H$2)1?F45D+&QBK9R8HMJG/)V]]>!/G6G
M!KMFIXO[NY.94@*0./*)WUS"([@AK\<)7Y^V6F[:<3I3]1^^=!&I_-827 8M
M,8L.B*#P4'O[.,@=S /Z:DB'"ML'?NS$%BE8N[!R7NB>($1<"&O.:_F6#O&#
MHP032R,-YITW?HQ:V.9W691DX2D[(R<FY<B:>'Z66PR(%308'1 XMQ;6]I0)
MAN:_)*'WQGTDQVX/#V$FS*$;HSQ)<UF9UW3Y%LMH'?7+@MG]$?Q7&0<VH>54
MT4?XVR,K,-\M8#/DCZ[[61 8%1.@<KD5O6TRL$02$[OPZ7=K0P-.M-$DK9T#
MF2VLD7'3/GTY+U*Q:<5>46]3GB&&M>W+9:J!N\[ T!/:_0M!*C'UNFRBGRQ3
MV( \K6C<##?&0O,LAJ9-IQ$S6X1'*#Z.G-8QC379D])>:W-7MG7F9PZCO9B[
M4C<(:NY@1(=?,AT/Y'GGZ#O'3"(;:VX!+:T-9=6N**/C'HLR#T/_IS("$IE$
MZ5W4XM+-1L%UB4/TMBR X_C]7LF^>:A+QYRI\7Q;9$.UP]L07<WMA!(E-HMO
M./<TR\)/!#=5WV?:-=<U?E*/^96A]\VB2(IVF<7H(E'#EJ5K%'@R@JITSJX\
M-*[_T[4,,GS?H8:>FB>U79DG-VD1@=VTUNV8R61H9F='MI+"ZGIVQV30.AED
MC[U INI//]CM4FS$RL>>+S1RC$DY61?4AX@I9(8\?SX#IV2$XN"[&;A\_7T^
MSI'\^<FA(8.*IW1=A=%GH)4LCSPLM#X[W7D;[F5]OVJ]P0'&VJK/?6+ITZZK
M_M[='^2D7ON !EIHM&G!:\RGI;Y 7Y8!HQ'69"XNUEQ3DUTY/>(-I.VEK7BN
MV(^D3F<.Y^WY:!$"H@HA_FP5'2CY[A80WE->BGIH+73&)&8KY%4)UP-+J,X<
M4F_R3E/2U%YME=E)$'@W!CB_B=Y;1 PN>YC"3[Q$[2.SLW:/4=(C;P@C!X>E
M7K!S4Y"+J$V/=;$8A/&4U_H?))$'C3!,0.1=S$,8(41L^?P)WTB5_6!$!NU+
M!#DT:5?3V8QM\V-8TL0U\L?TA0)0VVD&^4 ^=ITL*);OG[F7\]P3J:,.*"]D
M3CF&) "\M$33:N[7>=C1FQL^;G:<0=;*D= G%$P9D:M/^@*V!\MZH<0EGVB$
MK.E^^4UPID&_.7175,F5O]=.\P\L.H6O$M!W@B3=[O2:7YT]6-QT"<&V%4K\
M?L^4QU6DH$WN)!(U-*D/BJ6</.%<63+TO/AY"T@6[7I0+R"QB;CNSZ_R<MJ^
MD%91EX(,%VG[RZBKB+^XWHA>/AXC$V+R+^]A-I%+C/<>V&AJ1%2N9QQ.DBX8
M<-$FT=S[K$;P6+Q^XGLU83?H;?<F8D_GLP/",G)Q99(PK#PAI13[1VX>:=$]
M-3P/R=$_J!MTKX\I7'5Z%Q@!?.4'"5L'#F8?12#]'=ZO>\B]B/QIGCCBV.!G
MN\B"I8&C"-?KV$SC$!<[X]62CB(8)MV(U5"9>^)RQ"!P'K]2^+0T:TCTN>_7
MZ,UDDE.Q)>%/#2B+NH:XGJ94UHPZ6 E:.2 4'R$UCH]$8<P7X(O@UZW3*YR#
M)L6SQOS(M;QO>H$K27"O'O. RD>\8?WPF.3=$IWB,CH&WA_$-GA<4DFE)Y)Z
ML2VXO*SM0T9%#V?M'FZ8T0W8B?*4)KSKC2T*(4MZV$+^&K<4I5T1EF;5T932
M<T L&OZN%HN^H R;WV!=4^U'U8ML<<#28";J(B#@,B%JGM+C>)JM#O,.'0^%
M&+F/JFDI9,Z)^N5GN!#> A9Q4R1@F4?VN2P\%%[8/O/L,(U*OS?\9$B7^NFO
M/P?X?]MRQ'J]*-:_1T1&].E'2<&W<>48(Y$WF\X!#;/:!1_+:__@\(3;R_D^
MZ@^%/8,M[U3XM5-UEB_H4X;5N)/OXAJ_N:B<$W6N_3"VPF*=EQ_'IBWW=)VN
M(#3?KW2E2+$A31JB-40K2V2B3_**._F[3,(7K_'2NJDO.Z5%MH *H>7 K&?Y
M[%KVQ3"<\1"['%X,5?+B[.[-?[?F:66A9X$)/CTYFW>Y2L34R^?(WB?'6,<S
MZ(&OTTT]:(*4_:$$:TECO0RVBN8TF.S[IOYZ3/7O\#:5Y_=R]-RUJNZ^L)-P
M"_AB"F:/EB4N<+?J, SXWGTPIT@#@8U8^C2:CJK+J&IQ92N6>BM^C]]YO<>#
M7?WP_"]P&?'G"$-0A?[FM]1^I;E^"WB'[D<]130OQ5).3[;#0PI[O$U-CMC%
MFIVKAM1MCD^%=;J<M-/M[&'<O8GT7J[*OU./>V-L[J!@P^5_.R?ID=J.(+3>
M+C"5$ON/J:^WM'I #HHI=/XZKOQJY&5DZ9 6^-E<4O)DS?1&,31FN4M#NRNJ
M/Y*%=3U<1T%&FU*B,>3['2:71*D@!]8N?@[G#OE ^TQZNL^JC%9@)=4.">5%
MI0/:T^ON12E1+\.[?TMI0@8VRK+TWQ<6%F7X\M5B_8X=N,.45I>=Z)D.TH#:
M@]FK1U47<I;[L0>8?85VK@7#I2RZ5K\'W&F_Q@GJB2Y%G&;#N\$DH?%1PRPF
M"K3OZ"U??%Y;\"]C^&>DZR^IZ"<QMX!T'W07\/B#H ]FN6O?;?@60%F%1LIA
MB+=Y!XS> +>*0:B+BESQ3U<O_XW AT80;NT8U%3XN>J#S8X;T%.^H&B4P4IZ
M+JA8Y .!0CKA#._V[\(8Y3?B^SAG^6]W:LTOJ(W.Q:5/#97<)8T3H#'%J:2:
M*@("!>\R20E8PU?MU)WY^?P^S]M7TRV%TU4]?)1'ZQ?.8@;)AWVP*UTU=A\1
MB\)AQI0/OBNY!1A=3QON39P1GKD6R;#_F?CQ>I+B%%G>^QVCG91,=V/QEZ:<
M9L#%\/A<_9;3^[RR)?]=?15^QC$$C@,]0=S^Q'#D\7@(9J:VMR"1\A/M#X=)
M)<U\^%+3&]1\%EB[U:=MIOP-/KEQW->S\_EI/;-()WG[O5VB+"O((]M/]Q7H
M[F6\I1V3;(E_)E+P8&MZ!(HA!*%;KR]\?4+I-IG4' ,'9J_)>;\U'([L.YH,
M=PTU\0B)')32_QZ?&I!19H"EOC*4XQ=)+_B4DFUKQ8]-H)>VT^TWQR]2,'+'
M<-"506:W .[AG3EC]=\+"NW4+E:"]"19%_/I3A7Z*O7>17C\RJ[K2.'HN@@\
MDD3*EZV16*7\DQK,T.*0C?</ H6GYWQ*KJ VGE!CQ\7:F9D6(^<'5@>!K?6V
M&61Z.QLE44ZC73*X9RID51EYJY^46HT2@P*OZO<FH.] _R [L?_[#00OSG<Y
M'\ G*;,:&QZJ?\L\$I]N'<>K\5"(3R28\ TH%BC&=5*#?>&KZ\FN7HE7C#01
M%YD@?O"W<-LMH$OZCO4W=1Y9"^/?<-SLW *F./^*5 P9$X:H^Q;@S]T+WG$Y
M F&J__I%V[CUS.,15"3:XK*B\_S5"?^1<,=;GQ[3=>+=A6LE7]!<NL0"'T*V
MT]E)D177YIB]GH%2^C[%,! (1+#+\EW',9N/"]UES<J7__38%0N=CF(;6\)O
MX:P.DD.'+%X>MN^^J?CQ]7!_OAG;MY=@@)*?@9)!3!):T6?I8 TMRB\,H;*'
ME>9_IK=)^*OE(^=*L,7[46]EZN[A+6!W/ME$M[PU[OU![.!,>D"*@"/])$G@
MBAQ1(+;T1#(;I0S;@!*?\VA_%+W/V&[Y8ZJ]!>WS?4Q0SH"HK7/@9#CLP+EO
M>+\]JAT\>GA^E)5ZO!7H8M+0;463P>J79G^QR7E/N^$7'^]@A*8Z94#2,7DB
MBS;['2-M8G\(?M3R[8/32(/[Y<*/1D'B-\&"GX97]BQZQW34-VCU=V"E]K0V
MD7Z^*YX?UF59=W\DQ0?>3?W@/_YT6][YYSY'ZU2K=V!7D\W[O(XEREAH[82.
MEI"$B-^'(V]OH.:5NO/@NSC_^^VV&9X$7D<FAQQ+3;D'BPN?9#W?M"?6F!R!
M@J'NI)2C(9FONY0(!DK)!K_+OW@]R_=]-U>7J8#EL-WT?\"!*]]\EOXP\TU7
M1Y;YX*5^2$RZO!7P]^?'5\'@.[OMSO[4HKAN 4+@NX2F@'18&>GI3#3%.08_
MQBB=JYXNI.=  L/J?$Q0AVW\SXY_2H;X19LP?C47*$?$LBK:>SYL:8%]L@]H
M)OE):O#Q;BD<<GHU4?X!D1B]'.SURS*DDN!8:XZ7V754T)%3:U,+T-O&1T<"
M2M2V"E<N,_! .#A.C*V_KHRLQW73''GZ]G6\,KT='<CKL,QF+0?-]-+'$W[2
ML9 #=/>_KF25('*J'#HP31"_-SI3L9#5:U-]?=%8[?E\>@#R4^=@_?OO-68D
M9!UFMYDWKZ']K?O@-%E970E+8F^!M.KK+: _;%.5"14Q]M?.RH8F(NO%MR#0
M864-= =SLVN:*,1ZU9[7YN9Y.B%TY3=5]7-,R\J.S6[[6 ](;[=B9_A*MD\?
M!R?#8,3K,)83.72)0 ^UC+A=V'C< GB.4EM!S3[33I;F@:G'1P7;N^_W*L+D
M$]/I2?RB*T7">+4UQ=3'I$MI+W?4;1[:[\"H_FJ.E@Q#.F,,C/?0;1?@DY?S
ME..M(JD>H^@FE'_+]77%ZB[ZT(*?@YA<6#LIF\QQ=>.;D'1Q'TQ7FDI$M_SC
M\RM[$H#A@G_^JSIPTBW@Q/82A(8'N:#3,";&\#]AP/&E0?)JENM'-1Y +C?1
M 0_GK"Q&$'_&X-3X\O&U&W-IC4)$CK@)=Y]ZAI[]LB*KP7:>O4L[V.LP$?BJ
M,\ED#6.Z].06D&72A;%>.)HVW%I-[6^I.$8(=\;?:/"BVG?D(KAMGBEY'N+!
MO#_DP;>VQXQTK%F-5&3=":L,,KP4PVE"=N^B%!KAM[3QC!K%%@"9JP..4*^.
M.-P"V&(;=IPP[4\C]X:B!8!6+OIN,[#J\%WT@<1A]QK/-2^Y9BM]#TU/A8D-
MIR&(SH+ CU5A+1+H=5CAL#R-3/L%YLZY5*KJ H>U5Z=GEOL4:;^Y03T8;T5Q
M.V1BGJ3,(ZX#;;RG5.V%Q3BTI2 (P_1E6*1P?D*I0^&?P<H7-W<IP%JD;&4+
MS;SU[>(6 (^)0R9NQ74'?;W<^YVNK+_8BEA]P\9_@]F'47;4340I904+?BS^
MKMZA$9MMD^%GNT-;F)U7%$>MMO<<>A=?-OC_*=OP^K> 8=$/+I0QZ!H),QMO
M#@YC$[^@;V&.JDF\&;YTW4=?&P2?9)4^RXVO2Q,+E?6IKTSXUK*X;'%PTZ9K
M.)2O^-:44$!&TA)[ MQ@]11U2K&Y4]B(>$/&I?3!\OWOCQ,Z_)A(R%*J.C!1
M=FCO)AE=V\&@<3;]9\<-A:DK7C1,::1^G06=)Z_,]QN\F!\HG=VU<X=HC7%9
MM[&H)NT2"$'XEYH$>>:/!*WM)Q1[Z[OI5">@ _*/M@S6,\XJ09^%! ;<J!\0
M5)\<!MUQCIB7YZ[++)-&4U;'IARW@!4%PZ=N9S)RQ^*E?S)S>:X-ZWUTJ%[R
MTZUOEPIJ\]6!O5/#AX@U_<=^RY,LQ. 9R3_^TD16XA25F"W<37:^S*>HZJE#
M!_MJ)W_GJH[0D=RN>RTGK&VR^5/W:Y[C\5,_MZO"P52A+>/HWH$F]7*^=KX!
M?L4_>8FB_O,JR+-A8*%=ILE>)(HF^RC/,#X_$T^!&4&H$!D9AYTER6$[RZ-"
MFB+$]W:=F!T)H.]PJC7?..@8\5+(LJ82(KZ2>@@L72@=__@57RPN?ALRO==H
MO(G<<K%-@LN#XF 9<C;.\?/*]*CW5XECXZNI>F@(QG&)6U#B.\;2E($Q;PB-
MLS]GM&FXLOFJRJZAGE'S4D9:JRHQM#C"MM3>K7;Z>\*(+CO_F2RD@B#6WMXH
M6I7 I;$A(*:Q,%.\70=#D']<.#5@ $D:(GGPG8@L5(J'*ME)8%ILW&^@646V
M-HFZ6&NL,%)]+[+T]7%IW@^<!49PNK/@>N<@<"NOT<]EE=%VY1JX=J'N>%.F
MU+8+2X&$V7<EYY<,;OK0]?=QAAH%&/8D$_M]L"PCLE.A%.)_\>Z%'%-]RH_^
M([>FRI)#1NO'$BR>\; T)"/QC]<:'<TV:2%3!YWT BI%*^'WX2M1:@P981&%
M9=]UZJCT*&X!2>("4BC7NP09!P$/[*UK^8.!,X&S"K&+-R D5=FK\V:.\?.$
MD00#FXK2E.+JG=HZB/8D"56#)"@%/J59.P'B2E 21J5FGOL[+8YHP)]P*SGC
M:5!\? P L'PRP"EC!%!R;!")-3>--!K%CW PQ)HSCQW3$R@P-K_6&@U>GR[P
MN@7@D*,P2Z1!?-W'C56\M(G-0:H6/!\"ODYH<^"I4EO1V <,.?TF@&PN7K8$
MRGA)HYY8F#$PG\L<"+(&H=NOFD/,&FAJN)#'VM>/?GWX T ;D_F'# );. (>
MC^R.:!/2$\4="XB-_!1RHW?=,SU*R.'!W%MIZ409[X]$',SR&X8M5[FM"?;L
MC!Q6I'A']%4:M&)GS.NK'>MH/V%S%VXC$NL-39\CZ8UETGH'4105?.-",-3<
M%_3\Z38ED?;D]@]C.M-X;7>A3WO(^X>9BS,),PQYYD[6LO0%'#JP83B 8##W
M3Q74T 3,%;<)G#?%\_$Q= I*O^1$@+E+&WO&>YW;AE?WC&(MJ*7"Y7=#Q(E$
M1Z)F$3"<B#)M5H;JC(>Q?+)/:?M)WV,T-MB<S16H-L_9Q'%A^6^_M$LR?BH.
MC[28CDL626J.2F.:3<<BKC':PU50T5+42!ZG^&H?*.2E8CH$:FTEW^QYB>+U
MTG4^C?58VZ=FEU#0M?:Y!2@[.]ZHVM=2L A*X-N8K965Y)!^2M.:6&DDEH7)
MKW=W,?!,T=-$$/#*&\4U= \,M8&<A')VG.K@/"5JOWJ0U0#>9;ZW]TF"%4^?
M;9;M"%HAS+(YG^Z^>2#FJ,#Z(!]@7PJI(9 $Q%*24&\=X+T*.)]&+F-,#$4B
M<=JV['VL&(_G21PE]4Q??B[D.MBU3X%^*9"2.>=OC76R5[>((F<Q'=]A/J^/
M'7^XTBJ<&SF?#^$:$_Q ="*2C"VNYVDU$BE(ZMCPA]7JJRC 3G["CFDZF/L6
M8.^7B6XTISQ!']T",N*"G$.J2OM/0Y07GM;NN.]2[^_L\!PTALC0IE/_K%*H
MV3@F!(AIU_)BV^E1>H"ORS;:*R?YQIQTG^D.[CR[=T;7DX<JH3)V205-'_E<
MX,&J[4*D?#GD^:B^=*LC^4_$WV$,U!O[EK;TT4-!EN^98*5[3JEA<6N8!\+8
M= QO9&N>N.HIVF<H?L<($X@Y_\HPQHGM$9G3+^0V)C8\"<9L;;0W.OM]B%7Y
M0=1?>DQQ7\(Z2 (FZZ'HOAKT9_&H2J>%\/&]8M+0$#X@Y].P@@?16D\Q%IT$
M$F*.+AEW *EJV:<G&S8K^H"\333<1]!%G$]CXT3?R!O(%A/AX$'Z-3K9U[&V
M.^K7X6:T]K3*>E)-\'-V?3#S4:J@J/-.BTD?75+P]Z@^PB9'U@HBV>*XE?O!
M X5MW0U2>(=+%H[AGXIY%38'Z<;L!^WUDO%3Z!.WIA:"EBN+5/]E# N*N]1(
MV46)(Z,V;) [&-4<:M'/)O%S2_S0)?W#O?D_VI-C14%,A$N.=;[TN26?H73A
M^3WJAV3IW.S'XQOV'<.DFS'F2+G#]DF_6X#83>FL<&P_1H7Z3V8EY&!A-F/V
ME/Q!KL"TF[.(H\V?=)[3IJLT[^S% :M2G8J\E!PG,V^,OR"CZ"$]5(ZOUF^S
MN,BV?;I%T?O5=_W.%4'JH6D4R":(Z>+(\9Q3#;US\' [=F8F,$%;4DG<Z/E6
M0\/B8.!Z6J0!;F @F60G]^1,;U%W^837Q+.>2JV2.I.]A4!\\7]2[F5$-Y<&
M#ELO^8]'_-'!^XH44VM&U#-.-R'3HJJIERG^'YPKQIGFG!8*&DM2D#J;M;.O
M(K.SF4?3[B.36<C_N@2J*2S!YCTM?PL0S5DW70*R7A X'V4"N7TX1YSG4 RF
M,IS7T8B?P94[9G,W'HWY"E:AXNW3E[!2YM<)"GYSC96]BOMGWG=<L:)V$S-*
M>8U& 9,ZU9PO8<@%B]_&+Y$#&]<'PGMTF:\,FYE#.1V7:TAQ/?=62TJ^:X]@
MR^#V4_GY%GF\BF0JY?&O\F+#$))^+IDU!OWQWR3NBS72=0U0QI@#7WD@;+PM
MI G/Y![-"0?7"U+=+\Z7]E4E%W^F 1%I4J-FB7V]:XY\<-@^]1WS7]T@W-3L
M%L 'VMB:0"QYG%59H;]O'R1V>NN8E-UK.<]>6>2VV+-ELXTI*BX-Z2G9D'((
MQF"Y!F;\J%XTRH4(,5@)XY;\>H%\[1EJ/#SWD!G94R[T>?<Q.F(W';C"*:P<
MY%&*";2N)G*UY-8'9XA&L417%8/I/<;7N>N077Q.-X4I@CJ:*"Q_@I,QDO4&
M'4+:*2[)U<?L^-)ME2MCW@]SY^4EJ=Z'[-G> MZ;A%#^VT"=U@G2@2:IZC!K
M-5WN#K<_RPBFC@U5FA/1*\V'O [^ _$E,SVV(^V (@:ZB@WC))<,==>/LX)K
MRES'AIXIBH]^B4W.9=(DRPA?M=T':O3']@Z<6IE#/P?NG^7%?AE)N(G*6@Q,
M;';CUTYF^327#D,_9'O&2$OH*!8#XI>,IN3@0Q;&E,=(XA2=EE"=Y@=75)?N
MO)J</8 _7.O>1UOOC!S,O[D<6A' ^%]2*DD?$"L6,^N/OG50A$WA%J@;0ED'
MH385SRJVS,\ZAO>BW_<X*8L1TB3A#'[Y"-+5Z-H](\(5@Q#X/G6-\J=E7D/0
M3T,_0I44ED.+24MA9I'YV?DLK[.?K!$4%.:6T97=+R\O_/SX=;#%D;%+KA#:
M=H<W!?/&6X8SLV_SFCNAW$#%IQWS6^L#WRU@J)U*%&RQ4$]55N@II#D^/B:)
MQT'_?%QC7(:"\'3BF)V[)P$ "X^\#_O[;697\>DRK\Q_D-Z9_U\'E'](6M-H
M2UI;"P#P2YG^_-7*&W&$%O+YCG\];!J6<Z4IRG8+J KZ!9RD1&#4*F\!^QDN
M5P_R7?:HEFX!+#IW'#&;\^II@69C(^/"PHP?1U<][XSQR,<^V;&UVDQ_EH?V
ML7G:D2F?BS,4S)*EV.YK]S;1[8K']Y&_4VQBE7LNB14D5^#U?C7W,_Y]'A&_
M"]6*ORVDJJE)I%;0-C755I&2E%(1MW)RLMQ3P>4:9_%E2)%C38"3L?'R<FFK
M*;S&]P=4Y_:)/3)@3!>G$1EH],MI.5_/["IN!5:)NMAV)\)^#K3X#?BM^1P*
M.S!#6!@+[?>U58QY)KHH_M3^LIHJHR56(U70]C>3F,-0_G*7/GVD'-X[(89'
M\D!J;YQXVLVDLLF8WF!<@\NJ!%5*EX<_IYKT?R^?BBF<J[.GLQ7<?0R]PZ)X
M 2-_:(Q?E%_S)9OQRV;JIFE&9+WL*Y"M(;Y86Z@3R-+BJV!3UAUK=U"K$+L<
M'\X2N:[ZOV14+>81F4[[[:U?%Z[AKLOGV>,((=C^X?H">28'Z!/<8MO-K6Z2
M/WFR7D-&14%!!4=T@+VFT"T_Q1OGR?D^5_M N5L9+S<.++>6]^5; !%]XL>'
M("V(=HA2,P[LB34]X.^A1^D[.56M=)77#O86C5O:+@NILZW47&>CYH(YILX9
ME%L1,$=+I,9$A8 <N;@*Q0%($_=W/X$U=W\<N?[D1_?#88<GN)H%/:O)"D0)
M(6]I\S[2YG[F[A+76-P4K2.0[M]UD)7%+0X-_4* ]QB*&!N?<\[^S]DYW>8Y
MK/S==1JF<C[M>4AFD+'_2.TL!7V NX%'.LXWX?^ 2#>E-)*NZ( ]?DRD*J]=
MVC7H+['",4,4.[H)8R-^E(G*0U]TV/N<)M\"GH@TYDNH+'M?P)M]-KRI<>M;
M><0D-A4#"VI7H*F/).5BXEX^8[=B2K+>V]4W3T#RB"M7W%5_(%KF\@%Z\HYS
M2I+@IU /9G68K9\[G\W<Q#2YMELTN.O?=,N (/-ZT8[DP==5]3%X[EUU7$V1
M1K%D*;'RJR5/Z?<JGG;S'=S5IL6</ZFFFWCSG4!@*H.72Z_39/K^L^7+LWG1
ML")>RIBF74,:R#Q)R7%:^>(KNJ0R%VT351*><345WMT,K_S(XGP%>Z84V;LU
MLN3\)]$]E7V7Z$ <*1B'&SQT=ZL#9=) %[H%F"H'KTKT--8FXK.&A#5>C]LX
M!<"TG7L=Z.(%I*S.C&+MW#K$M281T9.JPVO$U54M%[)1O+.( FCG"I._#]BQ
M+47N:8O;4K]4!=>,XR(U R-53:CQ1LWQ!TUC!5W\(\U)]6+)XE#Y67J%%XH*
MY!_W[M:I,8#B,F\R"X1NDA *4(;-?O##M!9=MG]KH+I"D"H'TO_9V)AO#?KJ
M+%RC/EXU-S%AS08K*X9Y85NFV+C*O[Z#(=M1MX"?;LCK_AR4W:J?OY^U^_5G
M<)0I+48%;8)(-[I1]O*J"-G%6X@OZM:<$&.M7J)6XM&0+=$G>$PKWQNCKKO@
M7[;\UX$AT5(GDP0P0!]!$K.#9&L4 *DZB6'\Q*M"Y\GWWJ09&'R-KCLC<I C
MK.2KE]+4F.A]M:LA")R5F#30&PKJ?BWK?;_P-?O;$B)XBIRRD1'<GE^Q_V.&
M=OC]-KN<V@K5.PS?.# 2#;[+F!GX2#[8Y<+"C?\"(8)Z8ZH?NC#N2+'O6P^7
M6-Z7J+=G@+%@G& ZL25P\ 0M>.=0;J.B9<T%<8%/)1BG]4BUGLU CM_.5#'V
M4^;"NJZ/=]#+LC%U8W8\UN.QNFN1^:UYX]][_^\Q4NA\LZ3WK 6AW9KCIL6G
MY9DK U)Y/LVOC Q>+?X$K&<O) \D>OMF0UT_]'N5 6/6 W&W;SX/ST8T?5XY
MC2</U:0+2/2E*T!_:O*:")L(4L%0 -U69DL!F_MJ$: :NT^3;RM!LA8+?IW_
M<7U4["F"E.EPW56>4T)](U6=R#+RI.[U4HV6[.+L9C*6Y>PGVOD9I/G6<G(:
ME85E]Y]0W<T=^@2\(M;9Y^T,CZI;0H$]M^=_PV#FJ[V') (K.)N253:,3M[1
M8>JO4WY ='H5WA+>X4JWF383WD?1<#/7IEU<"7)\286H7ZMNG@EK.Z5VU<?E
M:IJ:D@2%:I)8\A$4MI'AD41O 7]MT*G^I]7H,5/__2SHK*BHY]DY^KN%CT[_
MX@QNP]2"OPOGH_FQ:8N3>'%^8_8=5V4/*;K2:BR374E 6,4AU9A,"B/K]H_D
M3WDZFFIR@U29&41-4N0?^[^7L1!AO7B'WQM;(DB$#O7AU%=J]M;M.=I40D[G
M=H@<L:<HT33Y*3GI]FEHZ?96K< W66I)>K>3<KE&Z,R9LFL "=H#/&6^]"CQ
M8<,#GD6G\\3YU_>LK8IL670-*.4&?0!0UD?Q9!*R O6Q<\A-9CV(N<Y*1@Q'
MMQS9<@KA!"@K!\UV^>BWZ;VK3H[I!>R(\BC!YD6QV//]@RW:0_9#?SH5\D(B
M?8/PJ02J[/3"^"XYU;K345\&VU&K;+O"AQZO^(P]I%<=\IF;Y'_;Q?*?JF<$
M%A>N%O[V9)AM$!)@;A.ZUU<F2JEZL LGNN9Z%$_Y #Q CG+!WYBM:X62IAQ&
M^._Y78 MNF;("\!:9Y=[S9D'=M%N8P/*O+[C:JN5!70:UM<E/^PAGXG&C =]
M1S+#!!2>TDO<EWH>04?P(1@K8_J=)B%AW@J\T*A^ )XZ)F,7H)LB12<1\[ 0
M5U/3=^+X9&7<VQ]ERP<>1#B#N0]K#TM:%BN=$D&U_C[0U3V:S"@?_&I8#TA3
MPLGC%&B.''V#FW\+>%3*HAD=F9=M2A/#^4I(U\HIVS8 -'%,D]0'>O3Z-V.P
MT1Y:ZIE;+ S=K#+DP[P^>A5$D;!=%?%+JR$/U'4)^LXK-=$9N33@;!I["Q"4
M, B87Z <Q;<_PD_4L++E%J(^M11P<(J6E>-X)NFFD( 13W8L=-.T^%-7#*HI
M0 9&*O?Y_$Y>1'5>5"(<&N O(CAJX+^F5SLR[(M#QE/<L0TR2DV-#P):3U\U
MOAIY[9W]$1]?(4;RTJ&T[&/NLE:%W?8 &@Y.'@9N.1]OOUF>69B-OYQ<6J*Z
M>-QWH#K7Y<BW=*(D!U)+QU$49D9P?ZEKFF_CGM10ME^@14Y)GR(CL]Q$^RFV
M?<V%#S:^&$FZ9IC08DBJ<*:ECC4D ?==[?G.5"TVJI9B<$?[S3*()R!8T[%\
MQ44G@,@)-\(154HZ=(-[J]16F#68ZQGZ2)$*<V \4$\W:ZS_.7\W=2_ N@]^
MV4T?$:W0*+#F%Y%#4:%*3^TRI"-KK>LWONKBMKF1XQ!E7__E!UDS1(?G,D;T
M&&M,:/L><@2;.NR-/O(X$J/RTQ>KLI^ Z^7;"+'O1WZ)>W'=>V]9P3PNG].6
M-FF.B\O6%GS>,^EJXQW7"TZ1!T@,DO\9U3HH4"</@5,44[1JC4YI_RC7S9-D
M$7#S9&X&IF<F5>G\80J_WT(X7:!FME=T^1S_01<4E6A!T64_U5VGG1R\,_VN
MN(V?\X4Z?*0@>=K?@:%6Y!9@OH^>\A*4M;!W/*AMJ$&D<UL\;B;[2D1(6#L=
M22,N7T#D_@L9CJV<SQ'$3;<S(=7(\Z301KV0E_NIP0X6!-N6394HMPHJITX3
M\RY1 X UEOS:K?C#J0HP[17R:B\G9P%<TX#96"2OA;52EUZ\7PH4G<]\ A'K
M6>RWB].*AXS*GXXK@.38$[JU53@S4C)L8;00PO>T&\[VF<E%/C$:\AM2%-]Z
M62$T2*!8QOOE>$FLV(B+@U".*WXY:UE9?(IPV^VN07#9[\CG^&^WNJ@W3#]>
M(N:;P4E92TOMR2?X&\ZZ+B-U=OZ)=>9"O=5"_5]>B$N\?#XYJY,'40Q4XXN!
MI!5R\FGM87D1L?%@S+9T%PZZ8^I>S!F$3B_#(4.[A^]2;H+[ZW/S50I24EW2
M%D!L\T9$HZL=]ZOR2^B9;Z"Q[O;$Z R,JA=E&9+N6Y LVA45M4#]3!#H9W$\
MXQ)_J5I?$%!$O%54%/,Z:P<M',#75!ZB];@%1EI&%^O!(.VY1W^"(MZ?1[,[
M$0PCQ\CKOM0:IG.9FSMD3TW4HX4J[_'=C_!YHRFHB^_AY,;1JDAD_22!]I.R
M5@R'\D,BZ'-6%4?R%6A74,HEQ^B,1/@V6L7JS5)N>>FP,V571HI(6Z4_=T(L
M\^X)J7UX?JAP&5/L8UJU>#@AEQ2>&'>A.NW'3JX3O!%>H_K)<>U8(EFBYSJ1
MN8EO60,5Z"$*]*?^M?M_'-6>^KO)D-)O9,416T0F@K[AW+%53^.+5\@-Z,)?
M%PJLP-SMHPC3;N H5$=EFOQ!<>@O"'8>I( Z.3<@.GTMV[/T%A!U:*X-Q3P@
M*QN.ID?^9/#0\VU"[%?5T7L>,QY;INJ)?&3VW!F-[FF>W%!4.S7EY'S2R#>?
MOK?2O5+H]^%E6:M.^<J,)BC+07TR_?J1)_V_<NN\$A/0.>"SV=C[;/C2#OT#
MG+((<IX(Z+H4;.(]$ZILFT?Y*5,8QN%E0,@Z&PMR&!@DWAB$0T-A*?F1-2VQ
M./M!LA4R1AY2N)K759Z*P"139 K&XB83/2((/HG&N%Q6E-5<@XFB!E>O?*#<
MOE?LZZ?-(O.@"^N<UTE-[)6:3\,0,RJM#%[BV!3I."VPC/[$A"R:DD^L9>+3
M+=('G,&=0X:HNV0L9%*",D/W-:@BMCE#E@:VVAL?2JUY8[L]^1:ZFVGOW"DQ
MFT@46C9HY5$EL-Z[TC!DHM%(HY%4S_=-4B'FTY>KOUZ!_^>/T@C= K@Y-Z:1
MB1N-?7&1U+0MKS8.N[>[+W-DVD[(I2I%E=:.C]"XB%H?SKGB(PS9=>8]^>8V
M55YC 8E\6WN&/)X1#KKQMA/2.RMS;P'9QJ_0HZY+PX(H]H.@;M3%J/]TFZ#I
MM0AXF[K^SRT -W_N0WL!FLUF=" ;P];0@RPS'D*;?"E\;DHG=^Y<[++8\>G.
MHFPPMW%7VJ4"NO<6D#1R@G44"%=>P [?JUR[5$*.M+U\I1OVRVD^QWEMV[ZA
M8ZW_AP+%:9/C,U/OL3K-$5VU.D^<7JL$3[G7%R8[J:C>BT[=@-F%G'O@E*/N
MP^Y9\25$UN2)8'[K2-WV5:NG7,?[N4#]W_I///S#/+?8N&),%:(B=E?A/][5
M5Y%-*6WH/5 @2+@C*@/9_]5'RH)K[XR20R(.@WXLW)3- 0FNMGS/J6Z&=9Q5
MEEIJ)GW!S965O92:6BJK?7+/?016Z+3O?P=@MW\U/,$^@#U>RY#1)L0A^_@L
M:F.N FI^1,!+15]"?Z9^QZZ,9 5=SIA& IZ1041P95]N>B__,B\Q9^_#$Q D
M!>&^8#$?U!%*T#*.^+:>N"\WXFP%F4V;R-3KDRA,8<H/TI4D4X4Q8__ZB/_V
M?FP#Y!QK6_W?J$;PX/P(?I.%T)!,K,HN>]!4^OK:<]A"0Y!'NJW<2UUHG$?.
MHS!,SA!AD@-J9=.$U4SGY]5[F\S/(@;-_>Q96OUKF,G>(J#T$7*-?R341C/"
MCE\IP@IQIX"NO14NS^V2X(?KT[$BN80K$YCOEQ$SI,08Y-J%JJ"W<W1=LC#>
M.+:EU&.JRM(Y.7M!P*_1+$G/7IIU>V*\M;@?<!-F/S7/G.ZVGM%Y+<.C&@=N
M3]>#1@Q;7)?&)$X92/YID8K1\F.+V*1/M%]\)G:?\L!F3X>,GC64*6=_<\'/
M0(Y;PU@$5*=RJWZ.39 4]&_N,L;LIO!:T+O*K?%MWP)FIH;G'/4)(5'+V>T?
M.J&R2D7^C4_F]6"S=B4Y>-F_2&1-G[*OEK!.F,+%"'9 [&^TPYC+H_F^5<OZ
MU>SL]L^UD =.E_V]EMJ-@T=;2N@[ITB%.ZZU"&Y<](%.9>;TG1+#]XV"IF\!
M4IFW + OU^QNRQ69XD@[@ER7/Q;$H?.F64Q%A\F4&!JAOF9SYZE1J]"3WQ@M
M(/^U'.58)X6$^?["QEQZPPNGA>1F;]7#79'!\F+AHFM'X,6 B]-ES=EG5M^O
MXZ-]8KM1)3WW- *G6WA;RU"? F1F@;PMXRA_YR $AA1Y"V@24 &;GTVK@UT;
M^5V.*01XPEPMH>48("@DU5'#-G\.-2NFK5]B W3*,^?D%_FKI;/O7\7\FD'H
M6T#(?3#38NU1,T;@B#.SW25Z'X:[H3,S-"D9,K+1,"7((,.7-*YN>1%#Q1A8
M*LG^LHM5==R:@-5'HYY ^M>#N_C^I:$]-CTVKJLV,3XUJC/>I2NGK\ ST<VN
MS4HE;)[PE#ZA-YI47P'W\>N_FI>\Z/[1MB3_VX%19=0&(M%3[N=14F"CC#KE
M&U/+4Q<+2^_]L89D4ONOCJ=-'T&GCE]/HUQ*V\.89I<X9O#&71L:Q>@S^%U.
MBT*K-DRB!,MJS>SXNB*E]R5^%^>,5.C> I)]%&\!C(R73R/W\;^V%JPN^+@Y
MXW7-I@]UA2Q1SA+S^JBM5D^.K=HRKR(N]S<DW)\P!%/9EQ:$45\05"A.=)5:
MR?&"Q9=.J(^LXYP,\W#"DW'=N"/22LR];%G=)^@S<-3^[+)OD!NG7OC5[S0<
MZS6;T4>MWBLI(>0H>7\?0.5%X9>%KNU0=#;]0CVPA2I$-^Y^U9K,P@L]BFF,
MN?Q4*\J:2F,HP^"MR\;XNEU-L5^DI;<'R%T?XA-:P_)4315W5>W*<(LCRS?5
M!^'(Q-=D"X13\>3^?E.K_!S?(KF$-KJIB/6(XU#.$N%2N8KY8>U2I(LK:RB_
M*OEZ5^T#66AIA9T3\!4PG7IP>'-/M0,E-W<+H!;I*I8@<EK,'/)F"O1I6*TL
MS^VS8CU?I(55-NVKE,S"OGXE2>[_F:15NTY5/EVTRZ(?#"<%''TM,FL884AZ
MV<<_FR:'Q7I/&_MG511C_--D?IJW8ZX3_+F=]IM/R[8U=O4@S%@&&\D16/'U
M(@2%7QX!JGM[L=3BH\QO 3PCFXW(N,I&8+]I1,Z3%IZXU9[YL@7^3!_R^>L!
M)L;319+V//H!;0$L"Z30OI>X'F']BYIV2JW[)1D&=GL9CWQQG5%2%C.;Q((7
MB>20Y[Q29)?/6^^%33SEZA4:L[O#O\\1'L0[+? SG931Q_?,\W7-V&%M.#L'
M&G9;ZB98T0FM7K< _H,8Q"V@#]$LX>64E1Z>V__[P!&JY^Q<O%A?[]O"+*BS
M7 X_0'%-OES9XQ8F:_/2/6Y13-O\7!Q:ML^DL'1 K_LBM:NW9N8$RU"S^763
M&ZNZ0O@#QKQR+MS[\9*X_/<?5O''#;G-[Q\UY7]\]R(/]EW!^)XJY EV^/ S
MR)/Q=6JOK:'8&HQ13K_<6MP'T*@HW8,9((TML^ CO0"O;1A[SU.BE'GC$L9^
MM2*A@>E#Y0I*6K-NPN3:=F-UWP-*=K]=NV4<9U]G9\>E2@[I88V'9AS=76P\
M,D\>*XS184WC $A6;9_LI/DT-8/M/B__RBO2YN["2=:!J!D!GKAC\Z@&O84\
M4LPNPUC<H1\_Z 9<,L 98[Y$*>)1QI7S9GF02?KH3>I\?;IF=+]:6N3!00^;
MNR_SGCNW@G9<44E&O.:[VJFQ/AREET/+UA=)#8B##O^%8M]"@9  S_3[NSH]
M=6/8A+_C*S1E^%^/51K<5>F*=9W6+^JY31-F']+BBSSRSMSHB,S>*A!2V%:C
M'J$'.B2=<U+]H<M0Y/YV5L+\S<"4O[O1D8=WG)M-&9<AKX.B!10BPE*0"TFI
MHF/-@'VP/)[^M0H#-4:R!!!IC$/GFB6FGF(O"-HMDE@&<G7CE*EP87V6+6<F
M%'Z]K#4&(T5@S+.5&KXA5O499";I(=QZ^?3W<W]K1U0!Y)!.M'(]IBFW (E6
M33-T\=[PWF6(Y!B8Y4K4:?-EA6"#=3"_W 3Y"!L'AY;>+@QW4BM?G]L3Q6R6
MT4)F-*F<_UG2/HTU13J&ZJ3ZP)L H>+B:5V?]2GAE=SDST^A158DDX6C"FI/
M'WRN8U!%M)@NP,4TW])FTTA;E.ULF$,5=-:*"YKNRV-9U]]/Z4PX\@I(G2??
MV[P%G# <X<+U.'N&3C(6SL"T@N=;O9ON^F@&%QT+^T89*FI;31 D0T2\6>7A
M+C1<<^1BC)UP0DO+X26+3\+-,,*QHJ!F]D '5")C>D_KM0)6.2T'#<Z3^#0'
M-4("!?[E>T9A_EZN%X;)74R?-]K>=0_01),"%"%8[Q5=%8H U+SV2T,%*(AW
MCNP1*,N4$D-\NGPI-9TLVLFBBV_ODC&QI/]?N'OKJ#:C;F\PA;:T%&EQA^).
M\1:G%'<)+L4AN 4G+2W0!@@0'(J[%W<I[N[N[A1)">&C[UIWUG=G[KWKG;7N
MW'EG_MWKR<G)SG[._FTYOXU\VI6R.F#EDF9JHAK:TQ7&=QE<S$\D03<Q*:T$
MFD<;EKS[,,_N&&_7U!A_8#'Z"/KF(TS^"=! ;7*^D%DFE2;)F_P>H'_]HA&\
MR%&2]<=B6@[^GC$*_TF\,M ]TL[HP^A$?Y[G)L:%_[Y*Q@WN!(2OIGM@V"EL
MI7??D(HN1\A1*(O0PW&M/[N]DE0/J/Q$#<;.H<QA".3I0D^TA+W]J,GPP;C#
M0.?UHB-Y=J-=0WHMNU4"DHTL:O$1FQ'P,;H261) 538YA+_#TI1RO^A= C.4
M^XRW+E]362L'V^LTO8"&[ O*&B)R#TB$&/K1K?@[7*ANX*I[Q!(/.-3B3!P8
M(2;(*PJ;:VX5#:"E_4?^2^&EO98>EJ":^:T-0JWJ\C:KWSV/ ]_-O[X',+BV
M#$'J>SB7W-C3%.8WY2.YOF>_T:-CQ;#QIRQFDXIN<W^Y'7[K6O'3O2F8[\\G
M=3(FCK7]#.;5,P>RVYCQK"#>Z8ZT ?,\U?=^SV^2IRHW:#HLW_@S5;HN1).B
ML3ZK%)[&W:C_.0_0CMDZ!Y;01<R\MJ:/J_^.:'2Y.ZI?,D33Y1O)3A4BV%.=
M+01025'*431;WC9T/Y,#%,OGXY#U%@5,T\^,1,AZSGIFI?[/-+L'&M_M0W%N
M=DOW=P]S_!**K=T\N,PO9619L&AS]M(/E42M:$%!X=_TR$@.2-OAZ*_,+_]"
M@T'M1@>(Z$AH&M9M*.+QNMCCJX"-A;NB94*/JJ61GSZUSHZZYV^5NAS%:BJ^
M8#38F"F7<<X-3*^_+DICTE&#JZLK1V7U)EEBQ8@=+)F,V#N-Q*2=_L#=[#C=
M68_O085E'(LG4#-4^&?57@=O+22RP_:2'9R&;I7<>*?6?WJ%&6DZ%OX09?C@
MU4\;^]L9P>T^I4SIIS'PZMIXOT=\C5M\H*RN-3[B?"^_PR]XX=* MQ[U'CSM
MUE1+;+)91AFPV#V]?D9BSTG-\A(,H\C([>PS47]95;7=;+,/!+%8?'C0S8,K
M_+>NC;1M'44P5^]*J.C1Z)+RHIYXQ-V7!7_/'[.^OO7.=0C7V&3_6CRH3]*^
MKNT!]Y2X,_-RYMMELC^VF9YX'2(:M'4/J^F/))H\:DU<Z3S9PCWW+6 13^#J
M-HSO0L%O@ N-X,H\ <^VMP*$VK(.#DN5QG;EDW-5*[$EDE'][UFQ$I]FIJHV
M).YGRUM831TWCX:?F:R+#SA%W@-.D[%.9)RHUN?NN@Q6J ?*2LG7 _H61(V;
M;046<[+G8NJQJ*;[-^EZ+>D7/:8(JV[^>/8FL'B<2[/[?/^+Y,9OW)";8GAJ
M]P V5!7BU9+HW4R*6_T?NLRKXQ$$^91PD1LCN=?'VA&M=5L7@U [^1H>59S-
M-%Y.QR0Y&QH^;%&OU"2Y#YD>YL?-X]$H_*,)T:))R(!4R47S4@U;C;@-\MMA
MZCY"N4% 14,HG]6%;?D6UL@=GET K6$&K>6_#>D9HG=CBA.,A4L5_YV(5=KZ
M5]4SFVF=K3#(&P$8OJE?W'Y*\T*CN,/QVUHP+GH]0Q&4S"^&KYI/7CO-5E-I
M&YA37! &<FVP<.0R(])SQ'<8-,:P,&-62,)CQ1:/W!/M*O8T5RHL?I2/Q<K6
MWCI2HOQP=-P#VIV@*]B0)(QSD:R;CO%;@SS;1HRMY>Z"9;6C1#M+TN<",Z8>
M#:-5*]Y +<E<_?V?#7SW@!\..NOCXIR.\>1Q*W5>YWQ)'X4\R,;+A_3]JRC1
M!8N8[8\/D?1:Q9D-$H19/2K43@8%OJ%"E/\UC]B$BN<[Z,);/YCO.P,<<4)H
M+KRTIA0\7OC]ACH.;$:H993X#?@X4O0VPGAMS&8V@2(-[-@0L+)"@#=^B%2J
MX-)VP%PE(?EU#PBM-C3.MF5XK2^F6B#YN(M"E:$O/4\+75M5IG9)Z/^Y<M#_
M;P4?LK8]+XAN=) MX!3.(X3'.:Z9!YKE&4($-CT_)S3'<QOZCHJF.Y:Z[6I;
M3*AX&6@:YT4'5_ A#B:*$Q>)8@/]K?3FM[X67].]NSZG?MW2<(T00CX[;%DO
MF$LH3M5Q]PQQL!\,WLGIW#AK=>%+] ;7S*6L=V]DIZ>7IJ96<M?;2DSXA/FO
MQ3V]-MXE16E0/WNPVOB+S.45(D@R[E#$-D-\OWN9NM^/!<KJ&?]'L/2BXKRR
MLIN=QAD:6_'&&.Q/<[=F9&&EW!\)?ZIOVEED36Q69DN*SC2LK/R??^S3QN1<
M'XC/":KIR']KBM*NT5<QO[5)?#>KHE:@JVNG\M;\=DFE*M'I^,JJ,,X01GR3
MP\K.#['6Q%WL?.QF)_&W.266O-;&@>,>4%/IR^5_Y-_8# 9OI2<3UEVE'K5K
M.BI9O8_+UE< S6/VYN84YD4&Y&]]CVK]1P$9=Q<W^!Z AV+!VKT9.LO+_//\
M^EW8L0(L8W^1RV3(^/58!AM3M_J$LB:%)4&AW"&T0R/?3/[A<WW_+H,)N0=\
M[;X'##:B3--NFL@;[P'.IE=O=R"P&90WW3W@A3OI5BDQ]<4$$_)V>I2J[>[Y
M/^$.04,[W.1.Q#I)(Q:VW+J%)&'5P"GX-W7 'U=O*_./A8^LZ)_\VUMIF,S0
M@I*55Y>NS2F93>%DU8^K=)9_H6G)6][E$2<D;?<M?^FS1G?[#)XWB;Q2_$W
M<D'<K1!/LJ:-PU!4<&Z;@Q]0@(E4Z2WT2:/<)F!\B,Y8/M<.6^50]Y3K(Z"
M?[]-,X>IV:,%?KN"JU,'-CYI,U^B*QMV\$-1064=,"LM"AB#>0Q.T1L64:*'
MYB54^?TM@;7$!D!8[_BDVLSHI**BGBSP5:!<]J=8=_>/I'JZ+R6I5O9@L)EV
MH\IXX6@/IZ?!7C]=/AHX]@@7Z&X7%!7DYK]^OC;_;&^XR$0UULG!<&Q$1Z78
M:<%(^!\6DUYVD76B"J,F:UU37WG:V+@UF)#?(FRO^LV+-;4_6K"\4)@Q1BHA
MM+:\BLJ>@0-'(;,)0E2<7I%#D"M0U<G:;>0_T\">-DB\*=XVLEV)?/C7XL2&
M4$JM5)O]URUM)WXX5T?#YP<!<6G9K[^@U_#>^F3"[%-(NS<8B[+:,!6*OR;J
MW[PFF6W2JCIAF^[#>D ,5.+;T2F(5[4/[]D] .U<'/_*Q.CD)!*.9.U;:YAQ
MNEK>*)U/MF3U9,1H+)_R5MIRY(EX'46RB"-06,O$QS<9+JHQEJ2;))B@D'JP
MI!O?2;WM@.QK"$%TKMX#8EHO!%5#;Z^YET5%ZVZ=,FXU-P30!3]]UL&0KZOD
MUISNB6%>QORA,CLBRZZI01\SI159J*U-CY)]L$\OQ/?YE9$R#V3NT5+RF1WZ
M:<2:20>L>($/WSX";O)&D-VW(0MBL9D)]S:.HR!T-+AMA;WC(B3_%=FA,3D^
M1C_WFM_R0[G9VL-*Z7YO[@%!3ZZW[U# !Q/WW-KQOI0%@IV\[@%<#F=Z,V<C
M9^,^R-3AY8CDPMR>-3>M(4)ME8PW6E,>')J19;D%(.N.]CGFIF=&Y@^+T=[4
M(P<@*1%]R_5[JI'4) $?[@',]X!DWSP_[<M@SUI(_-6O$9R\Y04IW,8LG[!8
M#LL :S=I8&BON:G\6GY< :C3XTWCQIX;VPM-H&^9AYGX4 BBPB]J%S=J!?<>
M$"_^*SQT8BI-2,QX+=YW)!J!FQA_6U!><_FNE$LGUMY(25E/9.67X,L9K(IB
M%_,M+]LBQM0DXFOC/;K3+$2ZW\0!9-M2%IDGGC@DVTUY,K=4,%&=,G$6O2G8
MU<=#4FR\EME)T1I-F-QMD3I9#TI2KJUCE0MD)DH%">9]* K.3,I^V%'Y]&K[
MN*,2CI/CS( !-H[O*WC[]%!X<32E6I3E:R]Z&U9:-G9\5CD%N3!2LL'LEW][
M<K-.+L9NIL[P$5;W  [E#F0SZ@V$ZVXA<G;IX.%LC6@0LW7D^)QR2%D^=5%S
MT8.?M.R[@0OK=73OG1B;D)>'YLT(-^,T@/-Z)3=[=!YV4'UR/C5+KE/8&K_3
MP5DY>]=:VWAM<T@=WBQ;)7#M>D26UM!YS&K4&IR=$\H0ZL2WQ3W^[4@97V$$
MBS5*-(4$U^,8MO,O=/OU/Q240,37Y.]JG_Y"&<8:/+$ EYZ(;1R$PUBR:*BK
MY\='&G92CJ7785F/I$FK1^ V=T(>//TMP[/DS5N6YX$L].)'(4&JM9=L5^BC
MZ(M%Y4XU?-9A%3)?SL48(!L$MW*[/C=GR+C6^*NQ/5A\^B$DU-^EZ5888]H7
M+Q[BZ-]!Z&&W61DSVV#9/ZVE*6H]SYU?>ALR:ON[I&VBI\)A9E%T>GM=&[JM
M%9[M^JU$(E\W%BVQ+7UWO">ZYM;+7">0T5(::_!3W,=TO "+G<P'((A)TFU:
MP]3!%=J*(\3F>*32FGGL!">7LG'P_USMPG=K3L)]ZQKWLX2=+\:%_HTFIR?+
ME[CWD=1&"8&#C@Q7J5)B6VYU2[SU@?/R>K-Q#A\^R=-OQN!V_I8]QO0"OYF3
M(!2QW?BN!2@DT/H$6$6W716JY-I^<B;N?L5TWG)T\AU"E=^RXFSVQ\3" :=F
M83;HRZOKF#M58$AQR'.5,GJMR7M 5_Z;$0GH.+WB#N8@T<ZL8*QG9\6R:6LC
MOPEIJ@RH&BOILYL"7*NFC,=V-!DR/W_@$#>^@M&.":TB'%-@+@%@$:M& A >
M2D;$R&7PCCJ$RR'^M*<L0,SS2'9D*60B\G? BPQ5U:T/H?'Z4K 0UREZ>4K5
MTROOC>(D7 (/N!;WEP\V]P P/>5$9-(]P"/:.<GKR=?HQ*15I9A1W7K)Z!65
ML4[OG1!)[-9DHO%?[!O!3D5RVMS/OQ_D SY'X/1O;E)S?M\9$ _S3SG]@N#Q
ML[AQ2N[J4%QIY0DP,;_%^ GV\^B@^7W)_W9V-;N#CKZ,>%FCFG$HN""# TVK
MY#U3O/YPNVBH_Y=$;]B.Z^,$]B-2<Y!&81Y'&QFEQDL<&VE;!7?9AB.\0U]Z
M 3XJCJ%VK\#J+ &)7[19"BRT61C3S;HF%Z,W3BW$I:WQ<7]FWZI,#?VV[O@Q
M+6QQ5<J6P2_5X.SK8UY-$^KL\&NCD&]JDB#9QR:]D$^3@5!J;(CGYD/VX^:*
M;9*L.!1+V'N[*@Y\0XC%^2.6T<M<DCX-5GZ 1!_EL_H#*[A%%?SU:]A26Z34
M768&,W\.6^SS,#+MID</9ZWOA DIRLFO?[?D9'HI"CDOIN=QTFTXS%8/WNE5
MC6U>D(J<TU7^]:EW7*>4"A[!54TWH"VO8_2M$YI0/O7[7.64.25@/&$2G<IT
MR:G>R2F)-'/^B+[^*7'@-"V3S9S<I()"_Q/*?%TRK0FF;%^!!=MFHRX^5Y-%
M>GHY^ C3'@;V:;A-L;(6?AX)88\\*@U!&H%2;A5O3?1PZE_./!;MP^U?[J>,
M.#OPMU?.K"_T[ZS6&QI+"L57U=$4Y>,P@*,NQF3%OEO<^A229B4ZFG(>KU6G
M.5^5U.D.8";+#7H^I]OC_A3%6,'L*_M5=?!-7@IY93-%2IUQ<G9D:#S>^]ZD
M+_!Q@<]IWPYR1+6F$TIJ+W5Z3U*:-Y"5 1K7,]Y^GNT>J@Z;?T*:7%,>3=Y*
M82?Y#7E@D4->,^(5T7TO+<SOA<X7QD/?%F2=3FJS/\UD]7IB*<+\J&7N:JC5
MN[:JIHZGG>&S=2+T\>.&D/$VV_$G*EEJ;.]5X'(-,RXMC0M6=4FO*%HH2@@D
MN,W0X$DAE+)H7YC"G[A#(VZ>5[?.%:/>KS &D/A!0KTDSQ6M9.LJ4L*#"A;<
M'.H*W;PYUG12TA?<]5@[E&4-]!(7DAU3@PM$5L>2>C>*SK*Z=?V'W,(CDARN
MV4J>+@U:"4R217T#8B5I%Z,UQAEZV@K9I0:*-+]:$GANGS[)*$GCDEWF'97
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M)H.5#V**X T5K" (%=6[_3WM%-!CM[M!YGJ[*.+$C<8X\O#G#LK8]*8?8G%
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M8D)17L.U%E-]@"%$/&)S[JRR/( /68$RN1-=3GLY4W"]8VCN6[21V]-]J!3
MF>R\;I47P2&F4U8>&MR]X:*%K4F>ZV1J#BK$>M44FZ4HKWG</-9]#_A:\I?O
MZ7,C^9JJ]#V R[C]A,+)")GK.'+(ZE!;(5A*U(HAG5IPQ+% ]_'L1FECHH:L
MDLV$4QOVS(:L1J@OUTJ7)E8]P;?,HY'ZGT^'F=P#UKA;+SCO 0G6**ZGQ_>
M11)_V+N5C>I[0*K</:!]Z:FW75 /\G??/4#LL@KCI_A[Q_^8MPM/GD*]J:)!
MEL!F7)X^[!50S; 2_R, ;3,M[^&)T*?F6R=JZZ[G9NO1+E9FP5;!AMW4Q 15
MGS+&NXQ!"8RQCYX.46 5OWO?%NB4?JELGB'%L+CD$3X;.EM29[M?LW@-#58
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MBY .ZU*-:BWJ@*I)L^*QR1YV8Y/*3RVA5=S\8U+"V]-@@[Z2%Z#3;(LI9:'
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MQ$Z>:O:H:9WS/C)D.J,X^6AA6_X62MW<>PA2\F=:VF3=6[\  CM4B9K=%"E
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MDRLSG>-#,7:V_<SI-.25,3T#E1:TXH7X"_W'E".%IWR$QAGZKHIM,+M(QC.
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MF6EA&5;V9.\20?<M[ V:#>*VM)%6Q6$YA&7E'S)S^^ =$Y&GA0C&!\4GDV<
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M=HEX.IF;)8WR4,79[9G4JN-[.G4$/M.1(ZW$XG*TVHDL^>"*O&Q'X."H6IO
M,UU>(:K26YS5-ZM6N/'*>"A8%6Y27D_M<$I9&!4IS8:H X:O4U+.ZZ^.9N,
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M=W5-+,QM'/*[$A_W;K5DF Z_SK]6.#=1#)GD*JNM-E^PN!/'JOJ<S\UW*4Y
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MHC>&W3<1<@G*L1\6@%BE>B1W&/-RKR1/5#3H /7E@(4!)>?GF*DOV>93JI5
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M_/K*]^>D*Z2O-*8H"X2J4$!EQI9A 7&G0FEY->]74$_&OQW.1]A?]5#L?W0
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MAN-Q+>SDK <;NL(S8D(DJ4)(H4W&;G0+HSC>UI=0J,HY*QP2/)@PR\-18'S
M0?G;_N:0(-:L_3!3$DFF^Q2=GCU3\>+(DSI,G2,]"%6\2-4^,SPBX&%!WUMW
M=+9\_'.C]U>6<7J7R4>=0E;*-[D=%6&EF5)Y&;E1%_:ENK4WT ^KA?@9Q;[+
ME[86-GJBL:^_H.BR=/SF8)C&'3[MW+%ED_>S4<3AX4Q&:L^W>H9?/T#X:KN<
M"\S:7U]%<$JR7BP&(](_:N\KQQJB03G=$JGZK(V*,-X>TS>8F'4B79*F<<:K
MXF)+O&C=SBKGV.MQC$I3&0+)4R,1RO.K,PGUF2CLSN0(K:O!%> RHTU%RN8,
M!0X0(J8_AB"0F'\^%3>_\X-]3T=DD<#*$[_#9:<#!PB><M8^[4TN.\XB6=<6
MO;O2TJJJ"@'Y%O499LHRTLG0LXC3>*^\2C#.E -#D5'ZW=4+^K(X@%!*&WIH
M?Q/M QWM1POARW3/[IPTHT2*ZPB!7Y S$[KF S$EAF:(C[\VXE4-]VO@3:)H
M8"ECBKD!>5K.6> #?2@RQ&7O*Y8#1;5:O4^%57L:4J3*@>K.X#EGWS.=7^$3
M2H%/0W7T+5RR;N$ #!.=8DJ1FBAJW58ZV*V/&RRNZTN?X]Z>&ES,P#OP'S4#
M2C9S6+#8E50D:2SLL422.C@+J[^C-[(=,CTC]GF[6?5Z_Z9-V=><+.R5BI*3
M@D/;W2\0*'.K#BO46M1LQ-K"'\8_8LU6>RRY@V%KMU>32^V1*')_"44RM&&U
MSY7W?F98P;CUOO<M<^Q';W]*B4S77:P6K/2R9N&('*_3><J>9Q=C-P*1 8K)
M!2[="<P^UEN[@]5%D)W*H.N/A'ZFINKWW"JJ"NC\!A37.X:U,0;.>(TKJZTZ
M([LV%4,*_>BD,-P$:C^2&)-[U6^N=D(^8?;E;R<32TR#""\\A2$BA@"E_PDA
MAHA'[*6U&#LDZ(?ITH2O@Z,D2'D2Z@_5%^&39ZH-C_1/CGZ"-CY$MG_Z@7PT
M=?*&6YFY'<SRH8Y@B*KV6(?P3Q!4_&=K[$M@NL5!2-* .8"WOF?\! [0W':T
M/OMA2VRB)(G[!1HH-7VGOQ/L8U'KVE5_D!^7\JF;H8*4VMB<6477:ZPVMSB8
ML4-GWM;1\^JFU4[GSSJ_,JRY9\"&6/F,6,T^&U=*8?<1_D44O36M^]A\GUJW
MQ]B_*E*L(2*%HKWY=E!JJSQCY-T]4/Z,1T8>)JA1V;F]JV^Y=80N#N%@GKIC
MDSFCFX1"5+N\@G)K\Z+#@GI'?K5IY;BF\PT;V>\J@54?/6?)<\N\(N Z-..1
M[_-'F?S^=S,S21_7]>*W9Y>FH16:,PW##>\0=4)B$9T_*RJ&#W1(*35BX(GI
MZ@\,?1^QLYA3?Z:49//YK>Q4Q!YF3?_DM;KIPDY;0=R^U!8V94Y"POO%+R$-
M1Q?!I2Z75;-MU_6-,T8AK:3V01MV9Y/%C(DZG0<*'[H6#".!8^V]HH&B*TS=
M@N%09'7-B?V%81=J*0YK\!K4)W7^R6WNZ=RLNES-K6M0XK'*,<$/)GBKH69J
MP6'.Y_8EVZ*Q,>F!QN>4[&=TK/SNK%>OEGQ01C8,I/Q1:AJ]\-.]7(A$1K-C
MQKU<M,"^[5DR*BI'2&/?Z,1P;(9CE[RX^M'<X;?<LF?L#OLV8:W3![.<SJI0
M@C9"=PMAZMD@_T0W"C,XN>CLYHP5*P;M_?J8L75GN7SR(M0)F_(GSIC3K:YW
MCUN,4[.9]$]DG'=C0$WS4\M]^<#WXY;RJ(K!P\Y.D)IK-ES3]!:'=$GGQ5!%
MT%(8?V\J)\1WFZ9I&$WM1EQ!HZ6GW09QWXS8RWW&.XD%[;:3C=\W.8T5G47;
M7!QH6. =K=\<G/9E/H>E/7RO.B)7^CV-&7*LMS$'BZ/J_)+3D^ISD=9Z@Y&$
MP#?.JTCO\/$ZA*NR4CZKJ%N-.5DJ/WO,B)9YF#IA\PVA"JGKV><R%^LZ_[]Z
MYY)ZV#HAST-'Q)(:W,^*\^LLO;>P#;-).490=3X!A6J@BZ"^[:*%!:K..Y59
MDYCU&CIQ_%U&6+;=.Y]LLNXU]=\S]46GW0H'X+EP7JFF>VK;Q2ODXR)XC#5G
MQ7:>$QW0L=;'"06Y/=:*)3^VPA!Y8;&!Y7S1(E%.2T/<GHU2;V_S5Z"RR,^+
MPQ[]KN)5C>YQ"<8X8B$P,0^3)#&2L>X%;X&CQV.3Z/7L,#R%I*T-?63CS31>
M_Y 104.^%Q5K:F@VLR'YNZ47HU%'!,T1(N:99:PQL).YV:FY-*&Y'NB&7E;K
M\=U%VZCSRLJ2&MWMR/:A09-1SEDAET$K6KG)$ PT&",8]3!4 <ZRRU2O?:&1
MF9UL]^ B=X(\][%,83_;T+P1+_DRP3$]Z.C$FP9G3Z5WSC$L:IH;DKI1\,*.
MD2!W30.P@(+14*>UBAQ2GA&*_/"'I2U*0MU$6S-:.  A 58]J5D\4MF:Y/0D
M;9]QT?O6,RZB</GS7TU5W*XRDER044*+H$GW1Z/)6@DK=@-,9)-Q%V&[_FXZ
MYZ*Q.)\G:.W>;7=L,YH/T^%-<UC5/G40S165EVO%L*S;KJO&'+;7+",)#B!5
M5;H3R^H$XB^8#*@]UCC_P[W(:#N6/ ('@,;C &UCGKTXP!+;Q24?]9=5DY-,
M<0#>\-5*U)D#2_S,"'@/D>,M^\X,OF:4(5 'JS^"L*A!#QPZGA?D!.X&$Q72
MFOF;$/[LO7^QVS:IK$SIRB3F9>?(G!7'22\"9>,<M*WG^ZV4WMRL-/-W;=PN
M2#DBAH>Q\$(!%FB,=6B8V?I2_P^\%05Y;H;-&?T_S%_F>: O]C^OXO"$5W,
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M1:/B?7$ 5E+^5;D6S3*6F!T(GV:@N88C/(U^&%),#Z.3*L0]8.M9I43PQO!
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MZ\GO*K" OHW<VEC&[0RR[#%@=+IK2T@H([2R 8MK@!)4+T1R4X]\#(SU\KE
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MG4LZ*_4B,4?O/,R3W#CXF.6"[J$]1BOX+!.9J?O:[W]V5"'8H/:R!H;^2)
M;A]9B2@F"5'"0D+:)W@R\J7T;Z9G7PCU;A/]E</O>NK(B,&U-\*_'Z*OXVP?
MQ94V1IUB!:"YFS+W9E=)*S.S_$I[7T+=:/SCMQB>14_^&(*1.BIW9K]<T]7*
M[=!6&N[+\Y;(K\A7"4R?M$[7?;,Z>#4)<'Y!+-TD9>?ZIN$R<@CZ>U *3EV6
MUM]!>:F*1E*L!4,)ZEJ/GPJ ;S;5(M;;'#=<BEOF"SQ]R5.>OX2^.'O< ",K
M<ND>*G>01][(6A8@V#C*($>W$-V,JS6D0&%7,<.0X<.4) G%ITVLB>RGIO@A
M41M_Y>>4FN2)HQ2J,UP( C?2W7^W1=V<WL?YWP.G<AVT"S,_@K<?[:4<N),/
M.4^)#6IYU41B@]!;&#33$'J1#:+](!VJQ-OHEGPP:8$-^@K0(J\\$$2-*Z:'
M>U'"T2WO52N]4>X %9QB@Z1FW^([^#-Z29?^6L.%!4\T/)GRN"7:"5D(+,;O
M'U&UU8O5+5QSMZOYD/S"\CNW6>O9I$0=*7?DI0VBU<K!\59F?1/E/,N3#5I5
M+D?OWSY<7OP*/%@.J31)!-H40YJYH:DDD[#((_0EL!$3W=U[D4=W*A3E=3 E
M*)_K8KE8%"D0521W5=?LMT4XPFPW" =W%^J2+-AIY&%^5#\&MUO_4L,!A\5&
MVJKO%W-<X12Y9 I^C>U<='>6O%;@BBTMS101OZ)QM296ZRT0U\4\_VYR[!_#
M_]=@A&->KV4X^_@LPYF$"CPW-CX?3_BI'&A,PQJ2 C;<R[>])7I$P5>BO\(Z
MG8O%C_HZ;:==2- BW3DI]_N05&6>JF$Q4)7^25\"$&=T"L-%4(%Q18-[Q.::
MNI@6/>27XP%VU?UW[[YL_5ZHS&/0E1<KJ)/4^XZEQY74#%F<S[>2O( Y\?9E
MGU-ZJH*)E/$A7("WLF"#S&F"G@\T$:.L'NQS:72#$F/;74<3-&PWC#@(C<%F
MQ[RJ57H\-N)4/C)Q6E-]OIU$:HS-SVNSWX4TG]%Q+2M-3G;Y'=)-;OPV=.D_
M<4IN#6.*2B8F?%(JD>_05UJ>G KU:3.5_M$^D:Y3F#39'),H]ZO7B8\__T._
MWF6#?AM@25:HGT7UTP\^W8Q]OAF"8:P1P$TVB'RW_*P7Q6)5B)@_K-T_R>GP
MNTGNU6A)/^B)&B2$/Y%1&VO( R^),(<:< QK]$V?E2OCF"L-L[7R&*%]U<69
M^4E5;/5/O*<F?GYR@JFULQE(K-=)RPLLTC')\-5@>E]XYN#.[U&8HQVE*=S+
MU4#3PC#XD7L+#$/ Q4A&/U72#VY 7I.(F:/7CMLL_/(MX^>K\OH&SJ:4LO7V
MR1UG]_&/87CQFG8)@I-V0-+Z@S"=JP,D<N.0V#SR*[F9#7HYB);'+'./@25#
MI)@O2)>>,RHG\&CI0;64@7UUSE[C=QD\F41^S@R]L%AQ=0Z>Q)*R#N_-:!G=
MB--%D$&GPJ,W3"$MW8>[]-()\C0+-"KF</Z6:4-!QZF)-Q!N.ZGJX?:%_. 6
M#RA[N;9MS\=G5\70)J3LNNR\&*7L/N>UM;QN<Z,1A:1;:\63+W2D'Q8 1; =
M&T3]_7=4+".:N=F4.CVR*ZU'!"OR+4!M+/A#UI-M*[?#0C<+-JZOGPQ+72SP
M/6^>H:=PLUI.\Y0@U^$!O;, *7]@@VH; 0!^WK3MJ*S-8I+;@3 ?]J$"0KNN
M%OQ.F779CLH&S6Q@@P]/OV]SL1:468^;Z&5^: K_R.&>F5QH)*:7.Z\I$<@(
M* //C*; (B?50JN0.%_F_MH=A$"A6[DBXWJ%32Q^FS'N@7W8;L&E>ST^!?9-
M:\G#&BH5]^I-'!X0U#8/F7< ESQF7F3D49%Y!$GXX?ZGI"E/%#)F+WM\RD>M
M\6/0O10>/>-'\5]%R^)#D1;?I"3*%9EFOM6;"N/Q0/1(8+;R;'-,J5R,?'1+
M"$&)%/%;94963I/RS/KT^=Q"D^W'?E.X$J>RTBPU8[FAH05$F6_VA//85=.>
M\FBW(P!LUZ_\&ZFW_VZ&@MNG792E07E="ZN^_BV:B::+XL(EL2:_'G%[:P4'
MZ4>7R0 A!K^:E9X5\YN[^^6PY/0LQ8B3@0')OPT:64I<_:OH?3 (Q'6(,:^8
M8RQ[YL>)QN<[&\%, T8L-4$NY"S<H+NW=PA\@2"WVR[_&$YVP'A_\WX8==#6
MA)<A>)12F"[)MUQND7+?.MTT\S49CH)H.D6;FI(;![:IW(QW2+[/K+55V;=-
M(LI,*Y]735+@Y+Z-V53;++S!!;<GMBM#-MZ<%!FP8#P64A"1@H:E21:NN7F*
M)MD(WX_443!YL&T&5+O6!&4:<N<V13:EZ0PX92R(.3+;=&G_N,]2!GA'G%*Z
M7]ZP8V_FNH/'5M0.S6_;^E8Q,IL26XUAO0GAQ1$GDN/3K1MHV67Q'\K3AO(Q
M@!0P9FG/7@M:61+ZTC<XVW1UWY63&+0/0W4R]$<3@]@@&*Q+L#"BJ'6W;QX5
M(O[TG *GPE.'Y$Q%DV>2GA*G3V<%3M;+J@)IR\<&*4"71HFVI3OR#"1:SB>,
MKI:=P)#<VJ^VGSS(JZD]8QWK5K.Q7CHGZ&\U[7];9P@L"A4PA*:&\A_3]%)X
M[U*\[#KRXG"N\>C^!L,<E;O91#?F:#-<?E6+*?U 'QX6U#G>0?PQH4945%KR
MZ"<O_VSGS6D3.5HU_&>U3<JE4TI:2D.5'S6R[P"0Y16JJ:$9G1\1*:BM=U?[
M3!.G"(^*R9<L+9E)QS\+&M)2,\[H7*,>!L*?3;T^<[$[0;-"EW^F++E2RQBY
M@3^Q'G.(LAD2^$UC,Z'"7Y7CCI*Y2:V8?F)>A\@EO8L2%8/?WH4X" L>K39[
M,JP 7[MVY?!)-E,9#"LV2!6ZG$;-F>=S1"OICVV#\]554/<V32<2!1VWBV43
M2TK[Q]JL7I?9BUP;7A:_9-T_]\3D0M>[%C5.\6)K%6,1IW@P@%&1'5'MK;;&
MB>%"&KRZ90H1Q<*"U]SO%)\W*K[6?#^FZ"SHV.M?- FA@%HP_9]*A_NSO:T,
M!,UB1Y'Q"Y,0Z"G_:O(F\]B:]\)7YEN&14+/RAQ+++,+IB(1(5U9O1T0IHNI
MSRT)PTKK)\8'.L62Y (+UWDMKT48PLDX\^L?7ES__N+67-CYH>OV;XYZ1)[_
M!6(&XC$#@7[]_$0->%G"OXE6^L?POS H?GN\57^R*' S3(C/UD8GA^0I>7/;
MK)LONAH7HZWE/\3*=I!Z=O%P.?#3C'G"L;#N92K7';/S*.<0\QI=#T3Q6_N.
M+SL/!K]$4"1?:DE$1%F.@_[CNJ\J)_KNK-5Z4X)05^@B[AZRJ?/3K"VJGU':
M6!.RNLD5SP;U../1*,2E(S)37\P7*HD"->5/=I._?IXK*KBY-:2NDI]<>7'(
MV#'ORU!?WP  )/:J"=4$,R_#M\0=YIN/P?VS^A-@*?4 . <2A:#<HO4&>@OB
MMO$UR;6!>X+J?+[-BSTF,AU%XU,)1^XY)SG%W,F3OL/C?M3>_7#50JUC9GA9
M'<P&J1-(%' F&W0E1(6Y3N^EVC2%J*(@:\'U5$^U;Z5O-F#%$6UBT*&YAG7=
M96S7W4^%X.B4?J#0+\ %?$]1O1O_ON!5A08QJ'1<7<JIXC8F"GJQ@A'X<[K,
M1G+@0".^RUD.8FAK;&IL6UL^U&]L?*=DJ%=AJ%(57^[J8/7FVN&U.&:U'>"E
M,2*:$_V.#>K")&:*/)]41/_&0L/M!/QH89=BI36?=\'*1B<5D^#B;[%MQ_)Y
MQJ,^%W2/&MYQ^5!(?3:9DB0<=D2*L$'\I:E3CV' 3*9?H?8SL#39KU]5BD7&
MV"!YO.=90F"Q4+6R0D9-GMNJL@&C]UROB9ECH7UN@75P6XQ$>;<1 9+(<5#M
M"HRR,_B0Y;*GA7YG@^:TP;P$*$T;QN1D.(]BI$/D$&&>S\B"20-LD&+0$?G,
M!#? =\G\[D_]W_:->(LC?J07WOQCF.S_YF;T7H61>/0)FMV:)Q,'3N+J1XGM
M7"0++4\P!_=E"ZAH8>456UFK79JQO[D67CST\P#$R&&;;%M\V=+M0\[[CO2
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MRV$5!%V*+670!L>3VI]>G5S+V;@'/P/SW",81%B*^TXAA5_&)W_41"!T\LR
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M92U8']YJ,K8B;W42DEVVGZ[[T&M48=;G5D&$_.GG0%>>OV4YHG_;S@17[L]
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M/*:47MA-#7.65>#EZ77XF:TU*Q/2;L@K:O3?\\GOAD94[/CVF@ZDN1+CP=>
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M!30NI5M<:M/@\Z',5I>F]RW>\7^]"WKL<P<:$^,8M_A><O-+06'BME2DG:Y
M,:9__N2W1ACG9?Y 1A%(@QN,>7L;QSS_D:XLS^P!H^DB"]V,X;VIQY0<Y%I%
MWT #IK&Z@MP [_CL?I!Q=5"4UU;'M+[SRC4M-ZF<JCLJI6C&8]LA'./LMWDB
M!XKP:P ILB-9/'AEC>; 0/_AW0V[P@I*F%B@$.<#;'ZL;!J#>6U\\Q5,S9Q8
M26A^QSL$ H@KJ$CPFHF:6:KYW.<FC#J.(;%2.X%YEEVK]<PV8Z9Q-5"*OOJ3
MTU-*2@V]W%#I.CI&&;Q"+$@1^33GCK?7R:T(>Z=B_/S)MY *UTVI=_?\=P2X
MW7O.<84K'I8N*>IXM67TY,53+JY2AJ>W+NB]6% !\!4%0N .ZFH*QIK.?=NY
M8V]FFLQ:VZ(43^OQ-X- .3J2SW!/K,! 565#L[-HAID$]],A/NQKVT $+:42
MY OS[L\MY9*O$,<_L-8EK(F)Q7#N47'K<T0AW#YUK?ISS\1VF.Y<EX&E423!
M+&CN"O\5VJM?S^,"_E R'M-JXHJ[6$3-O"9?+GP058!['D R8\QW_.3[@!?$
M:7L^+:%O<^*(8#%W/Q'"RJ2#H\#7Q3N8'OZHH143;WNDE^.,U6XA1UQ@SU]U
M/$W0N-F"P$74%*8T,=2B\("PMMY[M!=#L@1]8:FPUS#1I\:.>8A#Y>K+ O70
MW/9F+3_1K*!T\R= ?!8IU%O"EK%)/M>3%%/Q:#G=,IJ;'^)*=THV*<M$R(#X
MJJ+9EB@&AS(GSS,C4!T.=[ N'RJ&77(A(5Y],J7=)D8F$^/-!J*W_,;//@G^
M0Y;_*;E0_61/6KH9?$49TB^[ G_!L/@V7[:5N_ZK<47P6<>&."*7KVYC)[<Q
M\^OZS^7D:*_ H=._PP6&G7W3E/LN L+'=9L%6V4"OPR;!Y<45)1S15A]J_:M
M]?J*E%X8JST[?.([_._]D1TSEC0]<A'B3^6MM7Y3_HUZS\J>Y$D-N60B>*\5
M6)YKB.U>2?]G-^NI@4'X#>4S-\*GT!*DJS@U-F&>=)XF?HNAUTWI:0+9AOEP
M8& I?*:D]5+)2]!TBK\#H\3#SX%A?LK#<<<CH;A*[:H7(:.,8*DIF2B>4E;X
MQ>1YTYYST,FN^S&/&N@A%;P62.N L\\R!V@9JQS"/.36S8X "]]]O5YX'*!V
M>7*&+%^?7E,:/I;1[\3P.B,3#<PN[FRWO*(B^B9?9B)MU*0^Z7;S>"A7HRRN
M&/K"Y?AR('*'4D&[Z^&PTDY#Q'=_R6.>V:-$&J.8P==KDS=  MYOVD"J>YS&
MW+%^%BO54M"Q_KK%  ^)[=..RD[7:J[]4I&G*5D8QP5H7C:)&YX*\$PP_8#S
MJLE4_-JA7Q7Z5)##P=E7[*>SE@E50Q2[M3F*'N;.GLA D"FE-+OV9F3':7?O
MA=0T!"SC=M+W24>R@\"827<>F?CG_\,9!?A;.*V#TYYML>Z/8LD_X!*HJ2>P
MTOZ\+98V;0H?<8\=012_6>91QGF\6C+' A:U^B!D1;.'*<0!5.->L,P+QZK.
MKL3>[VK7?YD=]<RU"W$%&8_&"88A6*O?\X<]\,N;!CVCA,-U2 ^UYJ=BC"T_
M03+?DVJIOMT=$X9[$"F-+K]2&*2^[Q"ZWF@I4/RYO-S29]SGA_J_]U7'>KB-
MZ<,SCWEN:P3NJ#!9C1P!?U+',0\B]!0FU (3<7L= (O886);0V(]]KH5BP]%
MW+:KQSX-;5\G L4F!ZJO YQ#M&Z_#H[[TOIX[7W9%7>8^SNN$''SH+I7).Z0
M._)B7Z:M96';(=75[ FNV05QYL8)VE!SJ*72M'S6]#1ZKML=>[L@JXQV-_ON
M?$A_WP.3T6_5<O1_?C^YMZ@9'D$FNOVH SR(#@K3Y,#PI[4.EU"AWHJ?('+X
M3+T=G\V\AF%/W+LAJ&A!JQ^PL4T%$Q'K!^4]2N@V:$:.AZH5%UFMS0F'R)2Y
MTOSI1L4/O9^>''JXERN1/P<9<$!&!'N"D_!BN*?L_P;"\N9RP3.Y]V>.Q&DC
M?NPWW?NG04(5ZA%?*V8L;?+FNAW+D=W6PKD$3</9.=]EI>Y(:4$;M=I+E7]Q
MI0B"XPD(?,T=Q:.I,9'&-8UG#)2]/:.'WL4LH WGUQV<*@E4['^,?+;)/,R9
MGWF*:Q]8WM?5 .?VC#I*:T"O?K?H20P#ZN@J%PK++ 1MO.-Z$DT*/B9?P@W-
MM_"U8C.BD\R.=CSF 7JG@!5\1.%'LQ4U-9M'D71^K\ C&"'\AV&<X&M*4T]?
M2_V9>KL72X6UO5TZLM76/[T#J#$6/?A88J,^C;"X_=5N9 2N$7?,X[T+@;)A
M7=[@.*98[#308US$/2*:R)QK(4WG_<S_(B)LV>!:W%T"_3"Z+VJ^VJ_S=_>S
M:"F@J0<5.Y'MS3N4P72:!0]5NN[CN[V3L*PDUA1>@C*2T(R5IY%\ ],U@I<;
M<DV:D<J>GI/>IV.J.[VTJA1<SGYZ'[5<W;V\W#U1'#+1)/_<@1LH@_Z*UON2
M4JP_]KR-5M6O[';_'^;>^ZOIK7L79;\6;,AV2Y62K4AOTH50-B(@7:1WE=YK
M0@F0O74+2N\(D:!T0J^!Q 05(72DEQ BO84 H81 @!/>L[]CO-\SSB_WGG/'
MN'] /EEKKCF?^3QKS377 8:5DH7/@]B-*[-4.>BVO!AL'TU=R&>6XGC"*<C_
M(@BPV)E8_N9)V4DZ(/W\I?F"33J&H?P WS\G?_-_%3Z8&N5/X63D*ND$*&>H
M^XL]]VAZRJ;#UZ; XP;.I@!04XBR>O6@7^QT(_3+KN?OL:RF2,MT'OFK-\P#
M<CV&-4#D5Z?YIXZ ^Z>@]EW<XHI[Y'L:\_8Q@^,_B#IIBZ@0W6DN71AT<!-S
M63N%OT+7-!MQ>*GW3M(V!V,CEX4D!@*&GID[__YF=]A<VU!<,!=;>MX8T-$?
MD#99\X;(=PJD[QUR?J!E[C0LE*R2\V/.F)0\J:PXHZ\SP'%LP\+>Y'IT,5D2
MAJS7<2<"Y0)\5[5UK.Z^_=3G\K-[M$.!SZQ;-^W\+,3AU";/%=E,[<?TH]4O
M[ITQ]3HE 7K33))H?1J>^\G=:A68HP8O%XA4A5I<.=XBRJX>_:L0]$K+Y]_(
M7+N@AT<JO"Q_E'\LB1&+0[E[.8'(2284AXT3VCCT2A&>+[D^--2);$FSV"T,
MD)J=/?9K\+*ZPS(V UL0C*]FR]P>&;VCFJ6"R$5D^0.2"G(]2M_ 16\EHZAF
M9TSO;WXA0MJ7A"D)@YN2F>A0X^O5IX'^:B.3W%6MS1MR(>\E7$U,#HQ55)/<
M2G*Y7W0^U4NI+"JQC<N.$RJ#<VGE"&HS_#7^LDF#DC2%0I.A]^"#0@#=L[,
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M-IEOBX[P]%394)I$0VLT<FN,P0,']H[C902V27V6Q F^&@6.G[U<S^$28 U
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MO49JTNI&_YA%@Y("QVHR=XNBMMF/Y5H;YD]P4$'?2W'G-'ASW,M,^88*;=7
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MC%I_*Y!XV\ N@8@??.X[VS(;-#3.M4H9!<HVUZ.O*H!$G]5;S0.$L^)R/]D
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MXK\0" )%H!Y2A9%[0"+KFZ1]Y7W@O!JCB$1 EM3<0@;UA4_2 (ZARWHSN@Z
M8**]U*#TPF.:&-#[4;-1G*GO2@\^"?9:CW!4)BRSVIR>>IQ7UN&R>J5[N3'8
MO>[ /CWN=$RI-A2:D$B)</8J+OXO6,7BWKW+_]SV\9(Y^FO_/.0_+A8>2MF]
M2QX_%-)TJ^B%*A B45,7I=?X+GF_Y,XU ;J\O\.$UXO/1Z!4WI5]FC3*H&])
MW^\P@-GYH]A&QXVN <(=>NRGIJ8$^_[/3RR21V63=Y0Y>-[P^O![U[ F'7$!
M[Z_$\0:X9@%P1-5ZA<6"U><U'4=/1R+=687<HEPAKIR N@[\F7HIR/O]PZJ0
M/:B&X^>QHPY"HR.<^EWLYZ#(1HJ+3PWPZ8H>7G82J^!#5RU>8\0<"IW051NN
MVJGM"[S8"#6;MY_(U=1,G)G8:^8H.7S\]I!Z<W+P7?29QA4G9<]/Q8*0N<F&
MSAR,,S&<<J2:6CJVJ&YM'\LB,J\20O.7-LU/]'W,>9VLZ\#<@ W2?NK]3 @3
MJ:N=$ZOW7"Q+GFU(N]NDK/7^GZ/IT9=IR'3D@&P84L[<>%>4HT]J%Y_A@#FI
M"U4N+DN-<,].N\" LT >(S*[N>=%89&<?N0#?_444OIB<V%9B;.YMW5!KLRE
M2UI'/1U(R@+!X8S=/_D$IM:5A,(-ZZX,^839[+/97=M)BS%!W_6(RL27=_ZL
M*>D?"85C0P-5$?DYCTN4XDYK7\);NUA>*I+]M6JR4O'U7P(-K">6U[6;NBCS
M#*G&P_12DG-EEZ._<5K)CT )^IEU-]OEXC:F]V&;%*S:<_J JHOG\O/)U&6E
M?9J<&[$*/SGFO4*P'SQKKIWLV'G-PDI7@* RR_6S,GI :[CY^J%0-DX]8LF=
M/LD1F;1SB0H,@;B&= OW]- 63M@T*%WN'(KMBZ^QNI+[K<M"/U K&6]L8:V>
MF'#A5O-1BNQOOA\. #2"VW%TF4'PL&\AGR5W:_G'D6J#2W6ZJC\W9TUG"0W(
M*PC;"6B'HT3FL*&5JA=:@"K!8I<#=D8G!X%_7[Q6?E1S5Q31#"!1,WM >7:X
MRWRCT)*3U)/.^SY?W78XCN_Z//1<I":<(IMSV7MYLUES-3(2TM(5%3<RY@?&
MP,ERU^Q[2A5,]'7>:6B_4RLE1U2,T-L7=N.6D[XRJ,6[+DT==Z&32!?X!PZ5
M5PV(>LY[VA6R=T$^RO<)5@$-BW;T&Z'EC4L]&E[6O(4N_W8O"Z4T&;*W1*<6
M?>I>2Q#PC7$N#,[EB+[E/T(-NE M5(,#C$D&HAUWD>ITW'K;.KI=\^&X!T*#
M :<?\S-TN1\H!7]GF%#BG)G</-$[]*W<ZS2]?0QUC(0"='C!B ,\-3PD65)T
MR6V._;REC56R+RVB/GYQ?E"2$N'UDP6&?"XQ#K?W7$DL%6_B<2NE$EZGGFBR
MGU?RRSD46O0J24P1@=(KZU;YIGL&<.37V(BE>A;1">S6M4FAFNP4-6.,'4:V
MS&'\Z?%5T2INJ6;"5[QM&G[$ 7RV$KWY3$/KN;:W1HXY'=CHX)!][>'1/%\.
M46J=B:'J!@?*Q!Y(SDFZ+"+&U@W^Q9T#_@WS>4++_] )F4.'!L%38S1/2)Y\
MT[4BRZ=_UT$+9_HN7ZOXTZ.DK"R\15'Q6@_>U#.7'%%(( I\M\)J;6_-*MMD
MQ]%WW]AZ3YI/SBOES0!O\]"T 1\'U8WH2CD>5O?$R-<1>EY"%,'!;GS$COYK
MGRG% ^1J:WQ_DME_I3<^Y'QS_B;9Z5"(N<!P8VV5 SU_8'KS5C%<*R0/P/'-
M91\8SEV4RCWI9M)VLSG"\!GDLJ6Q\INBC,=08;]\%/227J/1XJ>\]3?;X^/O
MSAR=5<^H2*0Z,H6BC<S&64%E^H!M[)T)E$@H")_7.#)Z;_11?E^?U^Y!Z@3)
M/]SK.B9M)ON"_*RU9^,?#?$!:4YA;RWNFZ06)J8<$P20_<).1"O?'*F.6E$?
M!UUM<VQ"KWX+BR!R1.#N6^#I@8=0LEJ@=QD3JM\^,V(42](BO;E\^=%47WQ:
MXR1QQ'[(U[TX.E\L/-MO78#N4L]1 ZG+ECMLS$YX:0/_X1X&/_2%K)^Y"RK&
M5H;]R,1_6.T%3Y(G#X7.LTJ,W3T:R!8360>X=L6BXEZ[L>[4.;&9,PB;F!.>
MQ46FBH6]IV(-H/3\GS*<U[P]&B1*YHXFV0<=BH?S7K.K!<+Y[&B$Y(M5X,W)
M'VA>W]:=06#GL)>N7*CU2NZO8XQ(;#/&TCO\\9,D&6$_9Z7;5S[&V\4Z"2S+
MV1>X05QSN/\2BD!>;^:;6,.+*1<OX[H#HR8.(N<I?X0:WPT]@9^3N:H;%S 7
M;0B'UB@<^[=L7O+%VXWRRJ#W-)Z^OK=-16+E:9:MA>WQQVX"@0F*DM$ FM&1
MF1<14>1L4#I23@^ A%XX%*+8DUD42G]<&%RJ;$:RT<>S3#H7W.YFYAL8V9I+
MXB:)I59>[.V^DQW^>_V9]$F.08?34P$%1'"Z<S+K$<$"[3O\3D+^+!$[CF 1
M^Q/QW^P]/E87#]1V709>*O)[NJII6HSHCV2<K4<EW3^7##SUO\[C'XZ:%'+F
M<=/D=%ZFP8?2WJ$OI%NFB;Q*1M+**Q)HW;GT3S'@<@\]*4X2_V));[Y2)B/V
MUHN7;>UY)HWH;AW%@GSYPO-EH].?WPJV\[,?9$5T#*L6_ -BNO_6(+2;[%K:
M%/ZB\L$4&SOCPH(8O:?=\I4M=3Y8^'?6Z6Q1W/VJ#P?CDRN^2P5QK$V+.](X
M 7<[PC27@,J?#% ^>$1WS19]CL;O9T#>@O0:N>.A^R4[\&]V:1?/KDZN_H+>
MGQ=.T;MS8I9$"L]4L#VN#S20.#-ISG3P4E+>I&:4"Q;T/_5;D%3R[FX<9\Q[
M_V0/+C;R.^D88@]Y=SB+X]'V8AMHYK40CH6L^(;W^XXOUF6+8M;]-&Z3\9G5
M?7:9KYT':+H<*=!KDZ.19W7ZC60LZOFAT+6SC4P13HA[<(3R"_<.D2<1@"75
M;UL_"0#GMLP#J>\%M46SMYT'R)Z[*\4Y9P):O*OR<?VJ]3;I?Q(*C02;53+(
M6]-0AT\6SH/FP:V9' ^+[5VYM$"JZ!<-"Y*6OJ\%\]=O+VK^EA/=._XW>UU;
ME/7W@^3[.>("2K70'^1U(9X$6"3PT#_%ZX,/XL;)N\SA)5UW7CI'9?;@[(ZX
M"G,3MK5'&J%-1?D%!L:@@P"94E)>.E8O;48G5E^TA/.\KMTJ3!F;G*1>.4H.
M1@5V\\C\QP%#G[Y .Q9F\L;?45RXJZ[B/< ZC@L6ESGL29O;#ZY9F9[$\C'A
MBS_US.6 BT.0&X]?#D3/9>3'2;=XN(BS7JTO]>#E;PI$A L0S!M@Y"UMBZY:
M/6*IB!,2*1O"'^8.A?J5T7IXJA44?H%,$0D5#MODW]U2"AQNTG"!R#7O]Z@!
M4-_,XHMJ/U5\^;Y^I:*X3T[2^E2.3DZ1P))KX.'+G%8*3J3#FO>936E^T1R!
M \-^2"G4\25'H9X2"5PB>S#F\[.;7(I^6]",KWHSA]^7%-".")9$+U:5X".Q
M#VWQ/#?GMSE64'H,B(IB5@;Q7L]'KM9A%/JF$?<78353FP,KND]"03V/D[YU
MK,PV2ZPWGL^NB%QOJJB+"!5]3TI/L;6ND;UR+_J_WV5K2LIRZMC%TIMD18$\
MABV6XZ&@/E""M*TU!B@,W^"([+A42^L]*G<OF<FB?.>.>RWX9ESP.D]R](<\
MMCSQ5T@#/NZAM:.%X$"Y'@KI,%+TB3L*WQW]0S%X)]@;UWZ,+JO'M;+A4 @W
MH?:^"[!/] NH+G"Y\.!6BE-*?@ XO$'SAO6=N@NBWY*N^0GHOC!4V(J3AVRD
MMB#.V,.ITR*-&(5O-]3Z+P)6XA;I_\N$/=&8R"UI?$8,O''BE-,&;"+7KR'L
MNH:B4^;MQU6_GYG>N18-[3WJ:OG[MMHJ<@BY$OR^!ZI*HB?D[2!51LB_Z>KV
M2I-GR+=C*=GZU,\; ,/&\*EW02\#"=HP20CME8R]9P,T;J&R*O_Q!ZV0W:6,
MM'X!0_PM/<OW0"D#0.4=6B$/3JM/<46HF0$"1Y"4BNJO;>+RXYZ:Y)%:&/N6
M'O,S4H/M.O/35349(HL1F7\V?G_LK8>3M38Q='J?3M7>MOZM5! R'_?_G]X+
M?(QEK!@3(H=W*CFQ(=);?;Q*CN(HB<NQ/A2ZF;#G2HD\X+5@,CMG$Y*Q.K"!
M/GT=<OCGC+%9;K NAB6MK."@GAP;IO%#]*F$<B43"6_HIK=/]C\QR#+ (Y.X
MADL4$T@;@EF^98XR_O'V@;9.:(]P+Z7E?Z$/I&.5Q"KG'UE4OI]A-VO\PM)P
M]%%<+(CG;.;GGR8<I;)A:P8"\VO8N%^+ETECOT18[%<;1T+H!:@PGOSLH5 ?
MH^%9^*'0L3JLBTY3NC;)I0W9NH,4&Z:97[!)573\4#T'E0S6:IG->LX>>#%E
MJ"=P+EY ,'R!\VI4 %H=]YY@,H/!D#=YKHW"8ZA%*T^(5?1>WNXH:>SM_KX&
M5LUEUC7F=4&?-QJ>#%8,OLAY8GK0OG\^Y,=>C_-DKJW@8;^"$T9G#WR8$/[Y
M5*9P5-,^TF-T*XD:N;/;<A.@J3DUK4]$:Q1:MM$'5J8^5FE\<]1\_57EK,7M
M<P]$=8V=*=_^C)43G/J'M-ITRD P6F=X5[(WA(7XP3(*0%(Y.XV+1.\?_ E\
MR 6%Y^B% 89(DJ1C8X-+Z)W)4TU9KODO4NTZ)9^N"QM=Z3U?DA%[PT[=48 W
MON$15,B@2NT\I6_W]GP>@9A[*%2+S*8X[2>"#,8!_A6^.I;*-<$NH"IOFKDU
M*??]Q""J;^GJ1SQQL7)Y0-\\7:-)^\?VTD3[#0'Q_#E;NU+,! 6"D^+S<F,Y
M7M9,*:XA->EN2&;0GK$9[T^R/4A*$78H])+Q#XS4T<LY]G[V8KE&=H"]CH^T
M[ZXHN&( YEWSOLLJJC \(UJ@0W* =^&I#,AK&?U#H3RKWK.E'9EUH2JP*;[U
M@7W=/MBJ#!5L8SL%3Y^3Y ;2*BH^@&<36#H+KJ\L!)%^&:S[P/!%[\[(Y^2)
M.T>CW?[^?"@T&$P]V7/&L==U_ ,>7L))FG 17< AX=&?:"+),OVE$3Q1@$<D
MU,QF8E$G#_R@\5E@E;"C+SWG<5JYR5)QIF;\Q>P$+YCYU(UZP68JP1Q!O.%9
MG)Y!"G")(\D,]631*?,&?P$VU5&=3_5LI2:K_R5#<3( ):^H +LE?Z^,VF<Y
MQH2>J_TJ, NYQ P'0EO?=JW ((QS/H:6]DGG%[+5&A$*X [L#("US!KN:&#/
M8$.-O0-/SO_0 C@&;W5TSDGTM3G_MEHBB)WGM"REZ^>'+]M,=$MI&Q9K[=X\
M(L9]Y  H WG.%YGC^#=D?JZ+1?'D/>$_XL9QHN$!##CQT:*.ZXMW]>UO$R21
M,/>ZYV.TK?BLZL$&V<KB_)S8&/KS/92_K=6UID&GHRXJQE6 &,X'>D<_.V(G
M*A)>M_E!X1GO"WL<V^$/B_$.5$N\]:QPLTH!-+HU%V@,VKJ!>%#3D*IO#6K5
MK;Y1G3/WYV2_A;'A3>??G1L,&@2K^R101) L_8)9 VG@U66L>)4FZ'J')%(?
M%=\.BN)()6\6Q7SSUL%#X:%;%C1#5&^@WJEQ<VSI:?1NJYZOHN_FE9ZIY;7U
M8D4C,UNM/P2:RSO"A2I#2$J*).SF+M9"64@;ECRR""A&,\B-O,(TQC[7,I )
M:GITL&3;?E-S(>+OTH"'_>\^]K@'D^Y,H9VC1'ZE=%9\$C'4-I(H*Q,L+QN.
M$&#N7S&#5E%2/@:$FE&.%=% )=3@Z1X%C(3C,L'+[/JZH)G(>J* Y8U3-BRX
MZ:2+%X:?+O?2^HJ=+_'0RV75'RO\IC74#?_O<J0XA$H38(XN7Q(I/TP=W974
MG\=*AH;4R!<MJ3F"D][=JBDNB$UQC9IW?94P??%#ABXT]6 =P'^E*ZRF8EMA
M$L3,JJBO6[)[R3RJMI- H7</.EOX"EZZPB(>3TIG9+;+D>GM)@E)3P/:SJ9+
M61I4HFL1[FO^#;[WSAO*?:@L*4G89&I?VJCT4;DQ9"(D.*^_!;:3Y\B[O%[^
M<?HMS/[PYF78T-&_3$.5)4'8T-J?CN#%JRG2:;.1[ZQ4?62U@O"JCH!6&$UA
M>R[=RS$E-'W(Q%/,].AV/F 5F8T*@BH\9 0\&/@22"O 16 Y9-X*.S21$FFT
M$R5+FF2?K1Z_G4=,KIG;AJX0/J+4<)A!-]D %8"5E@9':8.BGJ8Y]K#?[*CV
M4J5^=YR3H/L(WC;=?H\HHX!XZ*V'\H,'SY.5F6:8CE_ :G&D1KD$"B ]*"\[
MCK\$OJS:0^*2P@(^B&D_0(I>N!0G8Y'FW*L^9JUO)'NP*HBG8(XGKVZ.O-<!
MP'GZ=#RJ[=4[BT*'KSYWW]<-AC\CP(WI><7V.2AUBZR8L$#3>'ER-Y&V4>[[
M+%I&]E[,FQOUCK9V%@[W;9*@]&34-2QN97^![^,2MR1B&EI"6$,EY-WCX=JZ
M5HR]?;S6PX6GYC@W!I'N#/CEW-#+,WI]SI?NN(6>1"^+:;:9V)K)W7@0U[.G
M:2JPHHZZ]P1J!94CA6I&W.*5=G4Q(<U^@$TD] QW>$&'R'>,3#4DLJ7>SLXT
M?RJOF26/'PS'L6N0?D\:TK)-/U/!2V6D[.*>B:ZD'H^,!HEQ<L1'-<Y_>^!#
M(:L,U&!F&!TX&Q,R$C@XR/M7(^2E'KWZR]BPM!J2%T<HD3UKEA&KMGC>FK9<
MG.Q<J/CKC'W:J0/$]2;!7H8C#)$:!LF 6FK2@-NGC:%!QM!_)(&KA4UO2K?W
MA"0Q1RD@O6>Z0ZN]6P/@E9JRK;.=F'TT.//XO[&504N^?WU=8-[ZL!Z;S+2A
M9IQ:4[0E1Q2@/O%=>?.<0Z$9KF3I?HG+%1Y64U+M.P:/2\5=J8^(*RYG#3$M
M&$Q1E3;U$.Z#7+'V)[&Y(I@ZF;F!M#V-B:>>!.*IC6=_[E1;,H^R4TY,!7_X
M5X'BY]]M=MV=B_3 8&'"LYST?^>W?X!'DY[3<JJBAS<2O^24ZB>FZEM=,(T-
M)#9_?)V($Y>UZWQ;659V7JPYP4PLT+B-Y1#*ZP7^3:<DDN\1.>U%Y .K$5&(
MV\HL5N8YI/I0J%'3M;5%4L3:,*W7\[K>N/L3]1FE@]UI^W=)]S_V9%VZZ(O@
M*MS0?OWOPTD!^-00@WGC],2=-9'\0Z%+7+7Z"!^L#N@!C,5TV1HJHU'>(\_Y
M\R\R*F;=ECGBS<\:0ISRJAW_G4UK55(*)]?(?^RWIL5[:M[8';_HY1=\G>6V
MP42</10B=1WUJ^7?&/XFPS]I67?4\ MPXB?_Z:&07(??H9 F(G_#("T2NK-4
M#I2FXY( /@6%487U^NEI_:M<A7+TU(\^:XABH\8-BZ9"@O<5KXLSUQMV3^7\
MEZI@)'7MQ-'8..RAD+;T$$=J$O<'5D22Z0!Z]\-U9WNW%D!4GJ"<!RK39?+(
M@T#:G)/SANFX=?/'&0!6 AW>:O!Z<MS:<V.GUBF[+*,D/[]17%5?OE( FAVA
M:KTR*3)ZAT(9%&8C?7!]QH28ERV^F\%>&G>9Q<B,U=.\^Z@_B3B?F:RSD[9H
M388V;*KOX>5K8:>J+H\1+E;F%\:6WW]>>)3_P"3SO<BCX^TJV)L D!AFG^'!
M,MYMX."V9U$->JF+DTA_SYLD_^(7I J<+/;*9E["/1W;2$@.SX'X1U/#O>OA
M??C^Y8$?:>?&!NGMX[KNAT):(OGZ1CM%*RY;GVCY8_TA)-X% AS"<6>ROO=L
ML8-:9X?XM#Q,G2YBD/SR1LD4Z595 D(CH]W_:M^3FW;UL7<:U*8CY[7Z!50X
MF;P%[N(43:+TZPW. "*6A^;HY':FS$(H-+3GVY:SY;NNO1K;I^".PF&:"L[Z
M C VNJ(B1AN],?[2T-',+)6;LQ%6QK.7N-1;HA=);"O&O3F8W-5=0C+WV;$W
M<QGM:QT:$,L=OI=VW@Q39@GU[0.(H#]<SW1QQ&*,+AR[2#(]@WA1#J.OU082
MTWJ]<-A6Q\)DWYWZR _RBBAR1'4&,A,'6P7>Y;G-ZD>U1O27 8U]+)>W5# N
MI$B5YH:(8Y+)20&KRNO7;170NT*>L/FU3WACXQ,0R>OVI81BJ^A;'Y\M))$C
M2FOS]?NQ>B*+F&<P1/=6?MS&67*,:W'<5YAQ[VQ\$LM15'YCR..YC;V5X7^Q
MC_-#E9KV4L\ +WWHDO>Y\:P>%6RNE'#_*$>SH[MKS=&=RBU:N3 QZ[HZ1[FB
MDS_'MZ/H\ /V9)["R]B_9+ AR5\AD(31AU9)G[YVILQB55/# SBIM\V6WVZ/
M38Y>>G:N5MEA,K"2'%$4]I9CNUN[M$_CNQP4,,4_PT2@4,I0>_WG=8#M)UB2
MV>A6KXZWH\@$-JKI^1Y V<!*?=#KXQO:^@[4-RO6 T0UG7WTW(>7<'1_TY7X
M&?@<GLQVY34)%$QFKW!;[28D%74'EUX:!#:(?P3.+_PV$GA#W'-_:*2/YBS5
MV.91*<&+]KDP>>L_35&J<TW^Y\BYII"L]C\+! &[>RB4+4- ]+ Q.Q52I/$F
MEZ<(\A9]B[VW@ZUZ@5V2L<WL7-@UD,7DB_N,^^R>3TNU&78Q?/VXJ;DDW6^=
M3_]'MECSJ[R&P$S9=\>0*%=_RG+P4+#+LAIBA)=%>BE"-=XU# V@];3;QVZ0
MN\]G(;K6?W[@ZW6@CE]UK[Q.ZDZ\U2J+MYUX4'U'^\64GLI15]GW!9RBW7YO
M^%7V)&\FXB16CV4PJ4_"=JB!$5_8KC$;9Z#"FK_7\1_3>2=FOMG0:"M*)U8K
MY@'>N3#WC8U-Y?S',%-GOQ;9;H^41\LQ1W_N\D:!]^"I:QLBK[FVB_25:0 @
M@E?(X4Y2Q%G E:W(3]RIZ"@P(R]W6@*>$'*+75J<4G0E"06QMA_[JE0^5?'H
M^.5)K1&[?NNCV:9J@-WAY>&O80:Y)T89[:MO.!"%3N2[/*O=8Z6A:=@+424-
MV?]$N&7"O\)*EJ+^E_3NY74-KIY.G*Q)XFMK0[O^.Z)6)X^JJ](!N*:.2+@C
M^5#H) C;81<PM/:%1Z/]AE!A7-8Y]C$H]P\HG;65\*X5\X \EROM%]X6&U]#
M^;8,&[10<0 $F:7F5"A^+Q/;3@L/:R>VO3P4>K/W/31:G..]Y:3K=I 9CD]F
M,'*M8DHCFXTPF=(M=-J6J=ZRH<EFN<3E#V+9__/VOGFIR.S/;4.9HQ*6+N@1
MI6>YT U2\AACS;BK&QKM"O-2>U.1HMNX:ER&@D?H$)[2,O]Z;IRV&A4,XTL^
M(^9$CF.].JG'M1](!HTL[D\TC]A2GS6,/9P ".A8X(VR4;NJG&.\]LT._5"+
M$Q.DW-TRH >M*O0>M-04TC8 <?9!AX8P3 U39B7.K%BB31T"WSF*D,? WMGF
M[-OK3W)$E:8./@,WR6K/ 4NK*%]X%NAURZ%0NHM_)<NGYU HQE5F7N8:\#ZM
MYK\O]("2G?D#5@[YUD]S-\J7E?LM*KC&[5':Y3>)%G+>IM5*Y;X)7C<FQAWL
M!4LS90T_A]>LB;P'#0#:L3ZRXYKPEC4KMB5?N0'U''I'K+6ZP*E%#UD'?+!\
M\_:SYYR7'\M?^1,E$RIZGRZG%"HIE2O5CQ =;3NE//F;9($H0^9(58ZG@_IJ
MT"DX&?L8CFX;YK'4SOV6WY0V&F[1JL<D\752ZD^N:VFKY7X9_</=TL/[W^O"
MOPGBKB*B]B5\D2.[C>7XPJ=H:N^EH* IB@(P#*EL^7T.>;&.K&_T[N/L(U4"
M+:\@?;8)X!."=]#DG!E2J7C^A[="7[.K_DMNZ[-U]7!90WH[\2R1-XMPA[3P
M34-QIE.\N+*^'ZB7H42G'U9?^6C^HSR!\I1!+(6?#K;"Y)\=)+$#B]Q\69:T
MS)-IYR<O!G89QI%LB/>LT@O[30P?,NCM4UTRUSH>!2+C*:>Q'BL.!YW>ZA>%
MJ]8"AH.7==S<Y+J79PN31%D3$>'_5+CEN?<[.+8#]3V2EYKM*N()!.E-LM\>
MKRYBMQ1QC=?-]HG]6$FS8N!V93?:U^L0\!46OL=M?*WJ/NHJT^DQ\=F3W2 O
M[FG?0+BWMWGS@^\4[E.9AO*JFIQ3 :?8YV*S^@5A9\Q:61V2R9*289HM7S@=
M%JJSPC:9)-VD*?*O[3_XP88X4?2EVJ^#(![*#7OMQ=,OE2Z7^/L0+BQFJB=E
M_%I+HK@;6UD]]JIV:CZ2ZG?P@Y8]),E^SA#8HJ@#(0,]'OK/OLB7:LS4 7F&
M?:*(M"*]N2D5E5K1Y_-"$I'$/A1R]UR([':Z0,1KO5,UA2R\_$>A,/KC@$ -
MG_\=EY-$Z&@BR]Q$EXPQ@"N<WYOV5YDE',RN3QE7E&K\Y0RF"YXH&@$'Q[Z&
M1\I?.),Q.1.2.^XSD-T'NJ86G5'SW_C=]#!G=&6@VR99BM_$.;T[7@6 <%S
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M+*TX/VFOM3L^,3KYT-%F4$4N4LI>*TE4H!5._  QU[[L84(#&2F1,TS;9=3
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MRYXCLVHC,6,>=2ITV"U4-WSQ!>@T4)4(U^H9L7>@P?.D?V[V$6[N*;^=K[-
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M 6'NP= 1<T.W](3C3;KU0Q_N^30W&)LI-T]/2>3IIET^HW/7Y"IK2*CG+&8
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M^P/#;H'_:H<;VQU-$CD%7C-G,<20[Z,(SKN,6CK<2/4':KW/FV.[09[;_TC
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MZF%JY:,Y.#\^;OAW!K$>[JU'MB,V+A;$6Q=%"-1_3+R\G#3_M-I<L;I)ZBT
MS8W.T/\L@F+B*C$C/3Y/"@>_X-7]4$'/?[G+ORHOT?_<;;[U1%.Y=5:-/1Q\
MF@.\(K>K5/'.(?EIO.K9Z_HH +.)8?\=>,MUM19T"3NYCSG_F6Y9Z] *QT7P
MIM-R&JO(,HQ--H>8P86V.S\5S,LTQ./C []^Z84_A JJF3M63\BUW(W4SZTL
MBQZH^V0,)+(*TJ-.X]Z?HC[?@NQ#PRP-T<6,*Z2M[^5S1[B@K=*!3)=]FO=T
MW<RZ/#K#A41?M;&N:9)&6V=192AXXYOQ=95*IZ]4Q@>7?H8T'T LGLGP<37L
M3&>B4>3$N\\NG.'7?O?=H3J@ZL>2W-V/=E+F=^=<U"(S18KR<[[D_7LC_*;%
MHZ6_2T%_\*//Z-RTBQA'\,%@<+=MCJ:I8WCU'6N.P194Q5;_R'/8Y SNL%B@
MZ'KRP I%05M/1]> [>+0UNG-T[T@(++47094>*?2CM1(%43E:"65JWESI#W:
MCNBC-^/OQFE2YD:+YL'+MD4P98^X7\J%[-E<A8.K-XI[S4O\>3G./5U+P"-*
MU1DVV;WJM+=(=?MO _!D)&PKM';<>N#8;%]EH(()*L6K4Z^CJ4&'$&$[UJ$G
MJS9"(WCU(B&-4P&!4O+FNXJ&PI&%;?Q<#H!<M+UE @T":$$CNV^;YK<H9YL@
M-'YH1"+-"GQU+]XF),AYDZA-XM1 W@GSH,HMG_,BL07$^>;$2=>POKCJR[,A
MF8]314K*OJ9=- 8*1I8)RH!32P\+Z'F_LW(.WOFH5[7IN+R4OY!Y.%(O'Q"
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MI-]_K<@I'0:/.'T+-D4I_Z5+C"GN,75I\X1GL4B>,5M@_\O)[3?*6RAH+B4
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MXMBU<Q3<\ZWMV"J?BH:91*&)-QJ.5K&_[/-+NF"LEMF!D^S.]GRNJY[^&9@
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M!=3D-Q,D6[FR1\;2/$)\9PF"FLK>T 5;)&^1= LJV=K= T[PW&Y.MPD.F7*
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MX?"DG44R5O^?@NW\[XEOO,; WO7BQY.'7;7K[HZ%.?F0>?S5&S;Z[EF%A1B
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M6:H]RDK$U1U5ZF^[YWBUN8JD19TSO"8)28LOY-8&6DB;6*1L[ >"!&;A;^3
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M#W2*J' FZ!T/78UA==BR]HRTF2R['-%?=]'$-$"S:WA$XPQD610K'7K+N.7
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MXJ]BU"7.1<]Q;:N)S( )+4^[V*(M_E_]%_KGS<^F2Y"YC& 3ZKU2W!46]_N
MIT @5'D&3(L5,,(7)HIF,K!RG [PS6FO$"%GLFP1GY UIH;+O/^2[ FZ3W*T
MD>!7Y0](*G@Y!&P.;I=8<I<LC/T6.M5<'ALEW,\$K<*I$?-HO=4U:DU^V33
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M%0+I2\ED>#.=Z1G8FX<8^%+$KC"C9(:8-0N1 AE!?1B.;7%=P_NPL1GZK^@
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M6R\EO/J<=#.VP\(*<<G"NKQ.4;P"B-HL\O:UUK;(WF>^:3^U,/SJ<64=;DH
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MKAWQU#2(/7G1;%2O,O73_Z/OT:9ON_Y#F73Q#&@^;D3'* KWVY*]X4NK*5&
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MQ43 !(WXY>@G]O5*\:Y#JL?"(86O+R5DNRX(!T[K\4L9)H[;-8[>E-01_%2
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MUK.KIFMEX_":8B[/5OU9I$Z+,)1-5%3X[13WF1Z#E((""PE=R_Z1_DTQ%:!
M(.$7R@_XO3QCAR>R\FK4L,Y^RP?MX]3C^6KU A[!)O_RY;;)PK@:OJ]M+];6
MMYLT!#X>F_<)RO\+-F-CIY+X0G B>"=[5:$WJ0%=,5>H^PQ^@4X$+>!6E-.>
M%NP6XNU0AO;NAO;'R7^1KH?TU!^(?^DQC!>8+UJ])'-A\(J)6/?L!M'>'87Z
M:,9G>=;*[!?4^V<<0O_=TIK_AP;7(Z06>%Z+U'O$^-O;L7VFM6'4+AM#<QPW
ML1"9HPY^(O),"M:H)V3_.A?_9F6;)WYPG[9"O/)=XA96^N^RHLQ'=C.6I]C4
MR*;+FVY$VO&ECR=TK) 6RXV6KBYWF#\P$($N#6Z64;G\@JM*?PF.<RC_EH_/
MTDTL*TV\Z+V$[[JB\/WVHMXH6WZ"SI88I<HI:'I1GUX5]*02M)6'%^X((J[K
MAG]?6/N]1D)!DS_N0T9X>/KUR-^NN']+P@'3R-;^?_'ZGW'X"8=*_++2"++W
MA&,A_("A1+!Z;6,U+$N=+=E(\_G=G,8]3>6*%7Z*]W9]EMQ1(^Z388/JL2I]
M4J[);ZIM5/+K=X &0[2\R5 F-M00\3T!$W* &/#./$*J.VQO>FX&G9_=)M K
M%JX):(]#= T,'.M"[^RM104^'L/38QODA:PJSAI9/]]Z@E-,WKE;9<5^F#DQ
MLZ:^P<E+OJ[R0.TT7YT:;*#-^6!P'']/XU'1';HP]N_<".'(#I?;WZRB,@!"
MG"46>\56AJW )OU_PV2C,.C%"()M:?B%U\Y5301)^T1WKG)!%1VCI$[757<S
MG+GN9]Q$I[:$E_AV8H70I^Y_ISZPBV'4^N#7=868&2S!*7$=T[A&3& ZR&:S
M5OS<<'CAD#I$'-3=!.:M<CP[8]NB)T:O=ZZ*J;,2$;W[L- R9F (\/_?B/^/
M7@[U?SJPZ\T* /.",VQVC5F!(8[;IZN#2"KC64J.%FGX$PZ^@']LO]93UV+K
MMEE1,D\W/0)2]'WFL01K'?B2\W=]$)1?6T^M7J.C?9[P4#RWN CH*HC-3\@K
M&B[S/#A8);WSAZ8STF._T)I*?TWOMKX'CH+Z^*A800]#E\O";S]V\*/U]X_:
M++D3SF44^-^0.6L%$.2>_[V7 OUGX#\#_QGXS\#_8@![,OU?4$L#!!0    (
M !"*TEAUZYAB[FL! *]] 0 /    =&]R=6MA7VQO9V\N:G!GO'IE4%Q=L^[@
M$@C!78)[< NNP=TMN$-P]^ PN(?!W9U! @2W$-PAP. .89!!;MZOZGRW3M7]
M<>N<>^Y3NVI7=:^J_:Q>O;I[]=JORZ^_ >\49.5E 7#P<'"L<*P P.L9@%7-
MUL7#Q=W6Y0L5-SL'0$!27AGA#/ /WOTS @ '@/N/]^LY %?"TL7<"F#YCQX.
M"0 O+_VZ!OCZ=\C_->#_-Q#^C?^D__L@_&?U?P+B_PFO?0!L5+AL.&,$.&P
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MQ-RGPU,)ODQ40\!'#WAC9-5,J":PO_L(,_$*W- <=*J#R#W),I2?S:G$Z.:
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M(YPU>%34TF-+\(:WE_'Z?+MG$D&>Y"B2RZY.Y\>'%:-\&<0'3S7*B[/3LQT
M;&J@BU]%8?R-?491D6&NO9=>I:WMT=RU!HF]S\,<B6LRY7FO^5HPQL< M >X
M%YS)8"[5;)'/WK#N _;/"-]/_'MR*4H3UR*DU:^UU"'%A?[M04+G%'5]V]XX
MVAB;? I">MYL,D)V1NQN-E3#<6:T63%Q-:XJ?;C,2=N\PR4B$^N[-M^-UU>:
M?#21Z0'!)%@/3ZXT<Q&V?A3N6RVP<OJSW*#CU$#EP@2=J[1@*TY1J9CH>21G
MWEV%T-F3'6\G[<_>>,:N695V'*2Q=F*AV5EV@P?9!A*(2H&*BCES!>546H?,
MR& TYH,74^#Q5'NU9>DZE4_+D^MEY4,YR2L TZ'/@Q8J!J)?\];:8_MA[C51
M%)2K^TBV[I$HDQDA!DQ#T,2U$MUV;CJI.G]P6O/TS+8^?B+7E(H;KN55.<Q
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MOAD?>:2U5;V'Q?X.,\PN:H]XHW2*K>6;8HMR=D+GPGX&A2GFGH E#09(%6E
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MME&JZ#1DW9 7#5=>+*/Y"L!0C=K7UY:KEP7FE(&:0"2=0M',E?;F\D?'=J5
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M5B663W*B20"Q#X+^X"=;GN-\*V.G;4OY*O,7X)5-1QV>OP97/MJ;'IJO$2[
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M;G_NOE6;\7#SUDO$Q$BAD!*V"MR1.B3,7]$Q:.>G=&9<2#!U5S\>GXP3Y^P
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MJFW&3=KT<4Z6(L;&S,[S%\)SJ#OP^6$.TX?7"/SO P3A+Z=(!_-]YY(KGW*
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MZUJS<!-.?<]@#8D4G2H.F$\!"1V;C=>@O^E):FVJ>9=._U/ZBBZ\(H'V]%]
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M/9:>H)T3- <SB59B5L;+*@7GIH_L /@Y-94PA')5OB^3^U.C>J#UAG.0I&:
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MQK274C41<]\D:^_"CBL:0@+MA9[=JDA-%33,^M/\3LW*T@K84E954K,5D$J
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MTU3DHO34BVUU.,&J3,2VO,$C1Z7?8%JS&==P94>!!]W7Z36R)8\M2DY<XZ>
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M 7 ?#U^O6%)DXB:$U3)V9P:#(E=JG[_DF-ETLL$%1$\.;\'$"3A#YI$M,=\
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M$YHJ4TBKZ(AM!PCFT)V^"?4%?L"W]PN7',^R(J7@FMF0O4KI.-Y5R/:<7ZK
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M0$'X,&G,>VPS"E0&@=/32VJI-*(()^O;F.DM3]Y?C5 J_3*=8IT_U\AI(-_
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MPH!/69KBJ*/]&1=8F^?FC%!)W^O I PN+5AV"Z;Z,#V_[KG^.#E%7Q]8T?P
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MOE3-<H7%7,]+-3_^H7D6->OI(D$C01+>^EF!T-PAVR7S/M0W,B+LBIN&0M+
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M?1T1 0QP)11RL1]/U5,=_R^.#HX*P.9,75Q53$-=>.94/3B>%##_URDDWI.
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MF*_>[2Z>8HVZ1S0NE1=>8J!3P@FEH5;D#CK-(X:]EQ;SS!W#N8XUFVAX4:K
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M-!5OIW%QJ!58(C\KQT?* 7^++K[-<XM$-O@*\(X+G'8>)N&4XRG#IU$?Z0\
M:&8.N,F+?FN[,(AKOQ1.S%.AWF%.)0'CI8+R^D"47_"BPGA8T/M5\CC$X7'<
MO!7]:XIVRW;";/,0LWB$=S7\I4[N]"=/0<'#%5XNEAP&EQZ<ZZ<78736/-WD
M[ZJ#9;<0!5\E%.+3W%^;BQ).-+$U_%+=<<'E:2:]UD9RP[LG^KI5],$RVO;#
MBH#C@=)-R1)M.M#9 \/MS57.SY7)40_]V9$J_:'!>L8<BKX6?_KK2APLP/W,
MC]:;]671QG@^N,_RD6M2BIGJU$@7?XBRKT"I@9"MC'$B[U@JP.0IN"7AWWLD
M\N\#<H8OEDF1'93G9^6_FO=8<KC-C R[RUF4"#1.V/,D!E/]?A(GZUM;'SF_
M)&$H;)!-)SY&U+[3=,.&[UCC]5.LCARB=SMA%*G$L&^D>KL/>#-FXI1D9#8F
MXCI^,VC@=JUA-,$H@DGJX6!*JKU3*]7/P+_9W/QXB\7QV*;SO6S_U\XY^[UW
M</N7E)R]<H0BFIH$[)%7,)6E^L>6NG5'%=W<?S&R1O] !-,GJ*O# L/57=[@
ME%9' I/8$7UXOYEM!?9-QTV)0N9@\VV,;SI+G//<U(6O.-K>I$$"=(O"+=#P
M:/D7Y)2 &X3,0Q@KJ;(9R[#Z MBR\\:X3(.Q-LE0.B?0>?[1D<?LC/CZBCJO
M=ROA$8>"-IR5I9+ZG9<'7TU UNG<T-KX(0:J)$LYSY?9M/"G .SA^2S_G=;U
MTY_=#A8SB0V#MJ_N69R^(US2Q*H47^"^FO'GO=Z1Z3KR!FXZBHIYN"B[W O0
M:LD54V<P;/9-R)9;R#'NFVJ[47 I,1<_^ 3>3WLJ+7O'==DL=8G@4@=FTZ9=
MFL)4$8YX_7)W=+V,XB&]V]+\S T/Q?'G!A_?3#S@?40E4]1Q^[8];Z1Y-M90
M$D> 4#1Z8A/3Q$ 9J:"BK8#QKC<A.P2]5J1.G5 -%S]6YRT*Z^E*7&O!;+L,
MO;?>6 =Z7-<[<2V@J>DVJBC_&0JSTLA*KF M3&O+X@4 ?A?%4O(F!B6%%I4"
M(Q%,YJ>MK>+NYJ%YQ@3IQ>#2VK*AM'/W((HJFFUJWHX"<20]U9?EI=(FOH.X
M&R"%NM]RNN#WX_]EN?8T#MWN^?>9/W_-/] 0D2_W8%5+1GL-;<5ZW'EH?A^T
M.-KX]!,3O4^6+J&OGH+K*;X(Z<H9OK?MCY5I,;7ACB4CDJCMO>%[L5V\KO('
M@]6YCJOLR.2/)5.TW)N0A,3$D9/\-N]<?\WMX<*5O.;5;$8'".LK_@?J"FE1
MU<_SP9_1=E,03RU;]>V$D82A+ ;A#HW$?C)F/'\H?8GNPY/!$AMQ+%:N,_FN
M!$8J"P:PT-S8E(*?QI9?A)O,S)\"Q<6Y%/!(\H+*G!.,*29$+?C<2:C?4KA8
MG*:)C;I0>!O(8ZC"1!499%\ \DRV/^O(_,0[YB_J?DR/MOIBOH6T+(:.3GM9
M2;R1W'F 21<2X5,'4FVT;U7J'LS*^L8=':;#%G5MFHH7.?1K<G(=C?? 8N2\
MGX(^M;\!9M/D# SUR  5WTEYOOY%T<SLH31MWAB9T:CU6Y+B,NLG_X*FTS5*
M&=&M3T+^SIA#>Y/LUV6'E(HL!U9%6R;?B &YPMB:*\S=6S(C)[8/YH>1NEV_
M]V].!1< YYO5%[,*TLK'0*/EB )IH $":'-;SM;<P?(:J)PJ59/R ZH4@/3L
M>@A<:?0Y68!L/D LYA99J<1,>%C45"K2I;"C275O>X:8] S3>E54B/(66<:\
M:YKGEO*+H]K/]\^,_11 DN\N[]1.L?;N#97-TDEFU05F_265*_]4'W&)PAK#
MR!V.S<,!L=:[L1(B"[*J[Y\G<?T-"(T^5^2O_3.;:KW)9NU+22M6CJ O%V9F
M1CCM##CAT&EZFBT,"2\ZI2S/^<,W'\&=A9[6F[%0&[$"+M!"U_.(Z_N]P:7U
MV.8233\V%GJ$)M4ZNR:QYO[QDHK]$3-!_]4%7#!.Q%>9WP7EGLE%6L\$),V\
M;.13^S"9#\4=6:RF/CX9@@7NC3LG2U(V_$%:G0=?C2ZN0_V7%OO]QGTK'5B\
MXPY#0J&[R5S8 [CE(G=N+F+GK14!_U](BO\Y, %9(58V.)M+^P69EC$O+^]I
MN]M/7"H8W*+]QA@5*/=$E],03DW_P'GC-MQXU."@[W;T=PG5QG.JF/HOM.BS
MDD2/82.?<CLA;]E*PRE8WST,$KZ3 ?)_!(J5J)3SQZ_Z=33L'DLERIX+ FP/
MMJH2<PDU2.*]Y%VQP")3JN,42I]0>>*N;J.%UY9:.V:]&F,18H11?W_P8(3S
M(A@EZ? ./G;3,UVR37<@FT0K/!2UZ?$ATZA]TLPETAY+-R CYOR^\J$%8XVH
MAB2,G5Z)U #37-@FPI.60(L (69FU> #"@A9YS42AFUS0\:4%Z3"E%&(4TNC
MY^USY7A%\(+1DKV[UG)HZ,]A2RY4ZAA//!'@(@K%[[U"=CO7RKRUTU5/@YC&
M&I\TH&9=TXJ!L!)ER[T-K5BJ-Y.F28?-T.#7*)Y.EI6%3Z&M?J%C>U[(D3DV
MJ9+B^R@I8@$8&1$>HV<..ZLEEYXKNZB6:#9B95 TADL+ <21C&(-=WNF]N7F
MVN74)NOBL1U;9V?IHI;I<LTS&LVBGE<F^2%EUEU71;>Q<+\?/GZ1^=^-D-1*
M$(_$XV[B,IIW.DZGSUK']MI6(I1<A$>THZ)[HK,>&++(*2?+[_*G78E+*G*K
M/'B99DT<W8X4 OM'&@LK1J;+P.^UP3(_I]6WI&+NIN-C+82:OI<"FF^3=ZHB
M^;[13XL4EVB3@#$_JNWK\XI)GAS:WRA$0QI3\G?+-S'=M2[VZ\,["!*L>A>\
MRMQP2="U.C$Q8WS"A(8-_YF^-'6O-LWC(TSY^FF9YV<:<F:%MV^?$.W3=T-G
M)U9Y3?62<\S7:FKC4=V4*6\T"J2D4INQ4VA63" %U]<&4JFY+KW1JJH/-5LB
MLG!4@2]G1HTW<+P1W_$ZZ5S[EOC\'GE.DE$MC(YP6BP!9@SC &3NM]_*Q\R=
MFNSLZ'(I$ROR^E6[Q&IFY\;BKPY\B%\GBKO<D<"CV>@CYE K+&PDB0A,]__1
MWXLMZPB=.'WL8=R^%@9>N2CCK"P51$,Y$?U4"78+PRZYZ15#QR-2,A+ZI98Q
M'#^MEC3(XFUH09,8$?MJI.Y/< $-,,G2HA\3[MNR7IEQ^#L&IR@"2&.DDB)F
M.?)8]!KJ;$0/:4NJ[6U8*+(-0ZBP+'2MT:!Y8/A=V@TJIHEA7Z27>(XFC9O7
M(1M;QM-W$2:+G2_J,\N1YO7\'D'-@E?7VY%EPTQC%IK(I;GT.QB2Y-FZ<);;
M7N\0E_W[:+?P\<O 7E8_WT7!XIBP"%QY^X=/=CS6?AXB5N=OZD \E!+KE30H
M=;W+O5]STE?IV)_;3$[7-BW?(;0BH4@3M4PIC(<XJ-2VF$Y5P$PO2G,/S*?\
M]I/F,JXLM\=^Q$L2[/$*Z"D<O#;88G1"<%!PNJ85WO5;/H,Z%!PF?HE$%E7X
M:VPT)_>9<D[7)C1([W#01=A"]U-H1O[!IF(B+>I57I@0N"C4$\NW<VF*B.>6
MP"Q6!<6G4;ZD*,I1)%0YZ=D5F*2+?4POH/^3K5GL0;5&CK*IEL6?ZN,Y%5G8
MMW)0ID<Z\V>Q3>6:X'\634WS;3X^Q%">$W6)*I%S20L_H!_I12_EXT95XG&+
MR1?7*"'ZGJ[)&:)2^K$&O\ILEAKN4SWL!(7OFE'-$7T=?%26YCS$?6^4+HI)
MP>XGV+?TRTRDV)8#,G1<JHR[*Z 9=GIE_0& DGI8\:8(\9S 6M,"+F#/37H.
M%R;6UN8I0_B^S353+U#FQ_L5V#0QKL:5V1_T M#WP8>'-M%6]%_I=>KM_ Q\
MPJ5,?IY V9LQ.E;N9=L:0_%@?&8V1A=T8'\'MIKT7Z5=?JK4@IVB'W'_1ZZ3
M_P> "O;8=(28GATN@]!:*]KR;C/SQ$['S?U-:QN.^JGFV$IJ3)'/;<FIQ1\&
MZ:+]%X??(6DQ<EUH\_T2P3F&QW?;1R.%R?!@Y2+(/7-V0?%%[C8=6M?F5Q<-
M5R^UV9?JTEQ'S%J".+7"!TME2[A,3>-4 F8RU@#8GSSX'@\/2-W7Y&A[1^D3
M"Q$3HN17>*;2A0KTG%BXU54H5(ED:<)7 !^BD4-;QUE/] ^#?5#?!THGB@B0
M)60C^7X%LN4\J]^BI#1SIKBG5<TINHF6_6Z3>@@M8NH?*5;W/1*?#(O;'=OE
M,:=<N*,9L-XL4<R0T!/5$DE%CB <6C^_!1[[!<\O,[._*V^1-W[&*<&&S\H^
M&\B7WX:O1G;$[Y0ZN:E\']IA?HZ3!9YW?-/^?%-P>_RP4.*A#"ZA*'2WP9 F
M@5I_S;)$ELO/D3&YY."[&)H:TY[Z%  @.B'&6JSN&31&)HFZ_S"[?.*@$IUU
M[X9SJ2+L0B[XB:9U]K0H>H[9LR\Y^H=[5KG*57*MEU;RP?NX7K.J>@AL>&+6
MU#:62/Y+7GGHP>$[HD-9VV(:3S.T??J\(CG\WZ0LHBG=3L@C)OI>X,UB WD;
MIKSB@2N*J."D!OXTM^[ZS@9/>XG2Y&UD'1350UE!/"V4R\,E?^Y^!7(YNSA9
M L48B[ST@%I1M15=8_5/"_AF"?*OH#596(!;V..QF<AX\]T/\8]BXYB,CRUC
M*E9:R#=G22)HULR,ID_L9 9@.);8>))D9U6ENO8_61_EPIU)T%O!,_4GP:]'
M+#VM*K;Z8,?-V+<?JG?%*66>OXYX/@1:4M=]&X%;P<9U'&I_V3R/ 1W4DMKD
M[)]7+Q&:>*9_UY"+^HL86]_,?=E6 =^?-PCI^C2:L.IHX)0.RZ9V9+IAK0V/
M2H!09IA-H]:W')SWA+@K6>P+@-_DL0<& CL3O'O'K6+I;PD20[JLYAGQGBF1
M\J%;']T<GL_7R_[\6VZRP\XG32</Y0V>/$*+_M^T PS/O<:_U&60.Y&+<D-A
MU[/0\69X=*K,3JDXQ0DVA4JM[@L@LW0.QV<A\> 4?_<SL&BB:PH&^A,/[7^5
M.9Y%]LG>B% I?$1!3E]:+EZWY$\S-4G5+^T;O%JU<59,]44]>:%#"YDI-VJ&
M]@I4O+*;R_;>FH%R&E==#:1(^3<8HFB9XW^U#_MQ=M4*&2IUT&>SAM20UQ,[
MJ#+7('5,+NR=R<3%3#9A<LB4-&Q,/&I-<R)4Y]#9PD9Q(-(.R=FL6"ZJ< KX
M:4*.4:2V<7J!V?D&;M$>DU_OT>#2JQX*7%/!KL(1,U!X[#RKY#WAH*W8P] /
M4?A(9I-7=\7%1DQFE]\V*"IHGYD,?P&P*]#2K?88-Q0E\*3N<.TZ.QG8*?'4
M6V,BF:5=S(R!\"F^);+X-2U!MG79V6@R,K^\*3QY5?X"(")E7FM_WO79-\0L
M=&BLF6'<M-!%>5#O5O6W\F9+QFQO$^9W>0ICP@C;7!&T7LJI*<G1I7<J_Y))
M&3^@R<V"NZ]2H:N#'IUS_)&:N76TU:SZW-(L;(Q36A4 Q]-T E+.J-6?Z+\
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MN2MFWQIEL.>8N&MS$,'!4*+,$).%AKH1J!$1-SE]MWR^UHEJ %K0OPF9,J,
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M@$\1$<#,Y#V$7^%]<[>)]*'KF##WYH 4)*FU((2S>OB\P#$85^PUB)NT"T
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MI>_SLEZUM%EQ0/)3#YG$F-_<.+$NAI37M\!75?\RR64<GXC^E7O#U-H^HU
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MJ/W82D_/0FLMOR _<9R:6DGB'@FZ1ODS*^L!WS1CO@&6%+:-[[^^DGT*!0%
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MKJVU5/18\0Y!?[[@S_7E3M#5&&6+TW>-R7AQUR4L6@=R,C5+ $X:-ZA7Z@A
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MKK05LJ$IL6Q@GP#PN];URZ<UBQYUZ^F%&ML^_N0N?2MC=\[S#W;W&?)BI8@
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M3FD;I/Z](PC^;3I1?_<X$0 _*N0!FP0+7M^E'.\*F=B2_&GA!]Y:\V#!R1&
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MKR5WA)G_!5!+ 0(4 Q0    ( !"*TE@3A1M7^!$  (:Y   1
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M7V%R8V%B:6\N:'1M4$L! A0#%     @ $(K26$_'B6\E P  R0H  !T
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M86=E7S P,2YJ<&=02P$"% ,4    "  0BM)8!#2_/ETL# "?"PX #@
M        @ &EKQ< =&EM86=E7S P,BYJ<&=02P$"% ,4    "  0BM)8&M7S
MO%]  @#_H , #@              @ $NW", =&EM86=E7S P,RYJ<&=02P$"
M% ,4    "  0BM)8N0X@D^&E P!;X00 #@              @ &Y'"8 =&EM
M86=E7S P-"YJ<&=02P$"% ,4    "  0BM)8ZK8S+S]* 0"5V0$ #@
M        @ '&PBD =&EM86=E7S P-2YJ<&=02P$"% ,4    "  0BM)8T5/E
M5V+E P KT 0 #@              @ $Q#2L =&EM86=E7S P-BYJ<&=02P$"
M% ,4    "  0BM)8:L5\&@:# P"/Z00 #@              @ &_\BX =&EM
M86=E7S P-RYJ<&=02P$"% ,4    "  0BM)8TD>?/B)I  !'<P  #@
M        @ 'Q=3( =&QU8VED7W-I9RYJ<&=02P$"% ,4    "  0BM)8=>N8
M8NYK 0"O?0$ #P              @ $_WS( =&]R=6MA7VQO9V\N:G!G4$L%
3!@     4 !0 #P4  %I+-     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>ea0205122-02_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abio="http://www.arcabiopharma.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2020-08-29</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-29</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-32">ARCA BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-43">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-169">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-181">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-195">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0" id="ixv-466">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-36462" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-36463" unitRef="usd">42445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-36464" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-36465" unitRef="usd">254000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-36466" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-36467" unitRef="usd">42699000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-36468" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-36469" unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-36470" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-36471" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-36472" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-36473" unitRef="usd">18000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-36474" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-36475" unitRef="usd">43085000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-36476" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-36477" unitRef="usd">334000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36478" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-36479" unitRef="usd">173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-36480" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-36481" unitRef="usd">216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36482" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-36483" unitRef="usd">625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36484" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-36485" unitRef="usd">1132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-36486" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-36487" unitRef="usd">280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-36488" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-36489" unitRef="usd">1412000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-36490"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-36491"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-36492"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-36493"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-36494"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-36495"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-36496"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-36497"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-36498"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-36499"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-36500"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-36501"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-36502"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-36503"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-36504"
      unitRef="shares">14410143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-36505"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-36506" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-36507" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-36508" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" id="ixv-36509" unitRef="usd">225061000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-36510" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-36511" unitRef="usd">-183402000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-36512" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-36513" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-36514" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-36515" unitRef="usd">43085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-36516" unitRef="usd">6283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-36517" unitRef="usd">5847000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c8" decimals="-3" id="ixv-36518" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c9" decimals="-3" id="ixv-36519" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-36520" unitRef="usd">1013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-36521" unitRef="usd">4749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" id="ixv-36522" unitRef="usd">7296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-36523" unitRef="usd">10596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-36524" unitRef="usd">-7296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-36525" unitRef="usd">-10596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c6" decimals="-3" id="ixv-36526" unitRef="usd">1957000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c7" decimals="-3" id="ixv-36527" unitRef="usd">675000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="-3" id="ixv-36528" unitRef="usd">5000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-36529" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-36530" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-36531"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-36532"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-36533"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-36534"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-36535"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-36536" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-36537" unitRef="usd">224505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-36538" unitRef="usd">-173476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-36539" unitRef="usd">51043000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c18" decimals="-3" id="ixv-36540" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c7" decimals="-3" id="ixv-36541" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-36542" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-36543" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-36544"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-36545" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-36546" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-36547" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-36548" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c23"
      decimals="0"
      id="ixv-36549"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c24" decimals="-3" id="ixv-36550" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c6" decimals="-3" id="ixv-36551" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="-3" id="ixv-36552" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-36553" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-36554"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-36555" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-36556" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-36557" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-36558" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-36559" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-36560" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-36561" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-36562" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c6" decimals="-3" id="ixv-36563" unitRef="usd">96000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="-3" id="ixv-36564" unitRef="usd">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-36565" unitRef="usd">686000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-36566" unitRef="usd">556000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="-3" id="ixv-36567" unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-36568" unitRef="usd">-93000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-36569" unitRef="usd">-808000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-36570" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="-3" id="ixv-36571" unitRef="usd">28000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" id="ixv-36572" unitRef="usd">-783000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c6" decimals="-3" id="ixv-36573" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c7" decimals="-3" id="ixv-36574" unitRef="usd">-752000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="-3" id="ixv-36575" unitRef="usd">-526000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="-3" id="ixv-36576" unitRef="usd">-934000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-36577" unitRef="usd">-5014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-36578" unitRef="usd">-10912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-36579" unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-36580" unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-36581" unitRef="usd">-5014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-36582" unitRef="usd">-10914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-36583" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-36584" unitRef="usd">53359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-36585" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-36586" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c6" id="ixv-21079">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c6" id="ixv-21082">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c6" id="ixv-21090">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c6" decimals="INF" id="ixv-36587" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c6" id="ixv-21140">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c6" id="ixv-21146">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c6" id="ixv-21151">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c6" id="ixv-21156">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c6" id="ixv-21161">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c1" decimals="INF" id="ixv-36588" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c6" id="ixv-21167">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c6" id="ixv-21186">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c6" id="ixv-21192">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c6" id="ixv-21201">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c6" id="ixv-21206">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c6" decimals="0" id="ixv-36589" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c6" id="ixv-21211">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c6" id="ixv-21234">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c6" id="ixv-21242">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c6" id="ixv-21247">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c6" id="ixv-36590">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c62"
      decimals="0"
      id="ixv-36591"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c63"
      decimals="0"
      id="ixv-36592"
      unitRef="shares">704960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c65"
      decimals="0"
      id="ixv-36593"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="0"
      id="ixv-36594"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="0"
      id="ixv-36595"
      unitRef="shares">795960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c6" id="ixv-21313">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#x2019;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-73"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;no&lt;/span&gt;&lt;/span&gt; transfers between any fair value hierarchy levels in 2023 or 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did &lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;not&lt;/span&gt;&lt;/span&gt; have any debt outstanding.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-36596" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c67" decimals="-5" id="ixv-36597" unitRef="usd">42400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c6" id="ixv-21334">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c6" id="ixv-36598">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69" id="ixv-36599">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-36600" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-36601" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71" id="ixv-36602">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-36603" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-36604" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73" id="ixv-36605">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-36606" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c74" decimals="-3" id="ixv-36607" unitRef="usd">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c75" id="ixv-36608">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-36609" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="-3" id="ixv-36610" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-36611" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-36612" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-36613" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-36614" unitRef="usd">204000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-36615" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-36616" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-36617" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-36618" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c6" id="ixv-21494">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c77" decimals="0" id="ixv-36619" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c78" decimals="0" id="ixv-36620" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c79" decimals="0" id="ixv-36621" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c6" id="ixv-21507">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies:&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-75"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#x2019;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one&lt;span class="nobreak"&gt;-time&lt;/span&gt; termination benefits, none of which remains unpaid.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#x2019;s primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36&lt;span class="nobreak"&gt; &lt;/span&gt;month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#x2019;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non&lt;span class="nobreak"&gt;-current&lt;/span&gt; portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Gencaro License&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-36622" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-36623" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-36624" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c1" decimals="0" id="ixv-36625" unitRef="usd">311000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-36626" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c7" decimals="2" id="ixv-36627" unitRef="pure">0.67</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="c7" decimals="0" id="ixv-36628" unitRef="pure">12</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c82" decimals="0" id="ixv-36629" unitRef="usd">755000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c83" decimals="0" id="ixv-36630" unitRef="usd">470000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c84" decimals="0" id="ixv-36631" unitRef="usd">285000</us-gaap:RestructuringCharges>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-36632" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-36633">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c86" id="ixv-21524">option to renew for an additional 36 month term at the then prevailing rental rate.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c85" id="ixv-36634">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-36635" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c88" id="ixv-36636">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c6" id="ixv-21526">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c6" id="ixv-36637">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="-3" id="ixv-36638" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="-3" id="ixv-36639" unitRef="usd">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="-3" id="ixv-36640" unitRef="usd">100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c1" decimals="-3" id="ixv-36641" unitRef="usd">25000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="-3" id="ixv-36642" unitRef="usd">314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="-3" id="ixv-36643" unitRef="usd">34000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-36644" unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-36645" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c89" decimals="0" id="ixv-36646" unitRef="usd">119000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c90" decimals="0" id="ixv-36647" unitRef="usd">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-36648" unitRef="usd">280000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="0" id="ixv-36649" unitRef="usd">127000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="0" id="ixv-36650" unitRef="usd">131000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-36651">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="2" id="ixv-36652" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-36653" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c6" id="ixv-21637">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;22, 2020, ARCA entered into a Capital on Demand&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;TM&lt;/span&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA&#160;common stock&#x201d;), having an aggregate offering price of up to $54.0&#160;million (the &#x201c;Shares&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made in 2023 or 2022.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one&lt;span class="nobreak"&gt;-third&lt;/span&gt; of ARCA&#x2019;s public float in any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c92"
      decimals="INF"
      id="ixv-36654"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell contextRef="c92" decimals="-5" id="ixv-36655" unitRef="usd">54000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
    <abio:SellingCommissionPerAdditionalSharesSoldPercentage contextRef="c93" decimals="3" id="ixv-36656" unitRef="pure">0.03</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="0"
      id="ixv-36657"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c95"
      decimals="0"
      id="ixv-36658"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c6" id="ixv-21664">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s equity incentive plan, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;the 2020 Equity Incentive Plan &lt;/span&gt;(the &#x201c;Equity Plan&#x201d;),&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; &lt;/span&gt;was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425&lt;span class="nobreak"&gt; &lt;/span&gt;shares.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718&lt;span class="nobreak"&gt; &lt;/span&gt;shares were reserved for future awards.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of &lt;span style="-sec-ix-hidden: hidden-fact-97"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;four&lt;/span&gt;&#160;years from the date of grant and have a maximum term of &lt;span style="-sec-ix-hidden: hidden-fact-99"&gt;ten&lt;/span&gt;&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#x2019;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in&lt;span class="nobreak"&gt;-the-money&lt;/span&gt; options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA granted restricted stock units (&#x201c;RSUs&#x201d;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the respective vesting period. The stock awards granted had a requisite service period of &lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;one&lt;/span&gt; year.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Non-cash Stock-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not recognize any tax benefit related to employee stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost as a result of the full valuation allowance on its net deferred tax assets.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c96"
      decimals="INF"
      id="ixv-36659"
      unitRef="shares">1167425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-36660"
      unitRef="shares">601900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-36661"
      unitRef="usdPershares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c97"
      decimals="INF"
      id="ixv-36662"
      unitRef="shares">459718</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c100"
      decimals="INF"
      id="ixv-36663"
      unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <abio:PercentageHoldingForStockOptionsExercisePrice
      contextRef="c98"
      decimals="INF"
      id="ixv-36664"
      unitRef="pure">0.10</abio:PercentageHoldingForStockOptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c101"
      decimals="INF"
      id="ixv-36665"
      unitRef="pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-36666"
      unitRef="shares">14807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-36667"
      unitRef="usdPershares">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c103"
      decimals="INF"
      id="ixv-36668"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <abio:PurchaseAggregateShares
      contextRef="c104"
      decimals="0"
      id="ixv-36669"
      unitRef="shares">60000</abio:PurchaseAggregateShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c6" id="ixv-21695">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ixv-36670">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="2" id="ixv-36671" unitRef="pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-36672" unitRef="pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ixv-36673" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-36674"
      unitRef="usdPershares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c6" id="ixv-36675">A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c16"
      decimals="INF"
      id="ixv-36676"
      unitRef="shares">904123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c16"
      decimals="2"
      id="ixv-36677"
      unitRef="usdPershares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c7"
      decimals="INF"
      id="ixv-36678"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-36679"
      unitRef="usdPershares">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-36680"
      unitRef="shares">259163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-36681"
      unitRef="usdPershares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-36682"
      unitRef="shares">704960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-36683"
      unitRef="usdPershares">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c7" id="ixv-21887">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="-3" id="ixv-36684" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-36685"
      unitRef="shares">88253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      decimals="2"
      id="ixv-36686"
      unitRef="usdPershares">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-36687"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-36688"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c6" id="ixv-21970">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-36689"
      unitRef="shares">463068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-36690"
      unitRef="usdPershares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-21993">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-36691"
      unitRef="shares">616661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-36692"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-22016">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c105" decimals="0" id="ixv-36693" unitRef="usd">367000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c108" id="ixv-36694">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c6" id="ixv-36695">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-36696"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      decimals="2"
      id="ixv-36697"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-36698"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c2"
      decimals="2"
      id="ixv-36699"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-36700"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-36701"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c107"
      decimals="INF"
      id="ixv-36702"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c6" id="ixv-22201">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c89" decimals="-3" id="ixv-36703" unitRef="usd">526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-36704" unitRef="usd">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c109"
      decimals="-3"
      id="ixv-36705"
      unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c110"
      decimals="-3"
      id="ixv-36706"
      unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-36707" unitRef="usd">686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-36708" unitRef="usd">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c6" id="ixv-22264">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="c6" id="ixv-36709">matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c111"
      decimals="INF"
      id="ixv-36710"
      unitRef="pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c111"
      decimals="2"
      id="ixv-36711"
      unitRef="pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c112"
      decimals="2"
      id="ixv-36712"
      unitRef="pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c112"
      decimals="2"
      id="ixv-36713"
      unitRef="pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c6" decimals="0" id="ixv-36714" unitRef="usd">56000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c7" decimals="0" id="ixv-36715" unitRef="usd">96000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c6" id="ixv-22268">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;(&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;10)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective June&#160;1, 2005, ARCA changed from an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt; to a C&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;. As an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;, the net operating loss carryforwards were distributed to ARCA&#x2019;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#x2019;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning &lt;span style="-sec-ix-hidden: hidden-fact-107"&gt;2025&lt;/span&gt; through &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;2037&lt;/span&gt;. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#x2019;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#x2019;s open tax&#160;years extend back to &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;2009&lt;/span&gt;. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#x2019;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="-5" id="ixv-36716" unitRef="usd">208100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c113"
      decimals="-5"
      id="ixv-36717"
      unitRef="usd">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c6" id="ixv-36718">The net operating loss carryforwards beginning in 2018, have no expiration.</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="c116" id="ixv-36719">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance contextRef="c1" decimals="-5" id="ixv-36720" unitRef="usd">55500000</abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance>
    <abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount contextRef="c6" decimals="-5" id="ixv-36721" unitRef="usd">1200000</abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c6" id="ixv-36722">Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-36723" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-36724" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-36725" unitRef="usd">-1121000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-36726" unitRef="usd">-2085000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c6" decimals="-3" id="ixv-36727" unitRef="usd">-192000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="-3" id="ixv-36728" unitRef="usd">-357000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c6" decimals="-3" id="ixv-36729" unitRef="usd">47000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c7" decimals="-3" id="ixv-36730" unitRef="usd">2000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c6" decimals="-3" id="ixv-36731" unitRef="usd">107000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c7" decimals="-3" id="ixv-36732" unitRef="usd">186000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="-3" id="ixv-36733" unitRef="usd">1159000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" id="ixv-36734" unitRef="usd">2254000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c6" id="ixv-36735">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c1" decimals="-3" id="ixv-36736" unitRef="usd">51190000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c2" decimals="-3" id="ixv-36737" unitRef="usd">50008000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c1" decimals="-3" id="ixv-36738" unitRef="usd">371000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c2" decimals="-3" id="ixv-36739" unitRef="usd">393000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="-3" id="ixv-36740" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c2" decimals="-3" id="ixv-36741" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-36742" unitRef="usd">951000</abio:DeferredTaxAssetResearchAndDevelopment>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-36743" unitRef="usd">979000</abio:DeferredTaxAssetResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="-3" id="ixv-36744" unitRef="usd">354000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c2" decimals="-3" id="ixv-36745" unitRef="usd">356000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="-3" id="ixv-36746" unitRef="usd">232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="-3" id="ixv-36747" unitRef="usd">205000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="-3" id="ixv-36748" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="-3" id="ixv-36749" unitRef="usd">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c1" decimals="-3" id="ixv-36750" unitRef="usd">69000</abio:DeferredTaxAssetsLeaseLiabilities>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-36751" unitRef="usd">94000</abio:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="-3" id="ixv-36752" unitRef="usd">55594000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-36753" unitRef="usd">54461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-36754" unitRef="usd">55531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-36755" unitRef="usd">54372000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c1" decimals="-3" id="ixv-36756" unitRef="usd">63000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-36757" unitRef="usd">89000</us-gaap:DeferredTaxAssetsNet>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-36758" unitRef="usd">61000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-36759" unitRef="usd">84000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-36760" unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-36761" unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c1" decimals="INF" id="ixv-36762" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c2" decimals="0" id="ixv-36763" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c6" decimals="0" id="ixv-36764" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c7" decimals="0" id="ixv-36765" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-36766" unitRef="usd">35903000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-36767" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-36768" unitRef="usd">767000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-36769" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-36770" unitRef="usd">36670000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-36771" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-36772" unitRef="usd">17000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-36773" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-36774" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-36775" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-36776" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-36777" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-36778" unitRef="usd">36706000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-36779" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c5" decimals="-3" id="ixv-36780" unitRef="usd">529000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-36781" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-36782" unitRef="usd">84000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36783" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-36784" unitRef="usd">968000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36785" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-36786" unitRef="usd">1581000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-36787" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-36788" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-36789" unitRef="usd">1581000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-36790" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-36791"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-36792"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-36793"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-36794"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-36795"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-36796"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-36797"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-36798"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c5" decimals="-3" id="ixv-36799" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-36800" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-36801" unitRef="usd">225861000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-36802" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-36803" unitRef="usd">-190750000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-36804" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-36805" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-36806" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-36807" unitRef="usd">36706000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-36808" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-36809" unitRef="usd">2317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c10" decimals="-3" id="ixv-36810" unitRef="usd">1406000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c11" decimals="-3" id="ixv-36811" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c12" decimals="-3" id="ixv-36812" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-36813" unitRef="usd">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="-3" id="ixv-36814" unitRef="usd">390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-36815" unitRef="usd">2482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c10" decimals="-3" id="ixv-36816" unitRef="usd">1796000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-36817" unitRef="usd">-2482000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c10" decimals="-3" id="ixv-36818" unitRef="usd">-1796000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c0" decimals="-3" id="ixv-36819" unitRef="usd">473000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c10" decimals="-3" id="ixv-36820" unitRef="usd">450000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-36821" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-36822" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-36823"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ixv-36824"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-36825"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ixv-36826"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-36827"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-36828" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-36829" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-36830" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-36831" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c30" decimals="-3" id="ixv-36832" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c10" decimals="-3" id="ixv-36833" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" id="ixv-36834" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-36835" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-36836"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-36837" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-36838" unitRef="usd">225265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-36839" unitRef="usd">-184748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-36840" unitRef="usd">40531000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" id="ixv-36841" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c39" decimals="-3" id="ixv-36842" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-36843" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c39" decimals="-3" id="ixv-36844" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-36845"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-36846" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-36847" unitRef="usd">225452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-36848" unitRef="usd">-186228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-36849" unitRef="usd">39238000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-36850" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="-3" id="ixv-36851" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-36852" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-36853" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-36854"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-36855" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-36856" unitRef="usd">225606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-36857" unitRef="usd">-187652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-36858" unitRef="usd">37968000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c52"
      decimals="0"
      id="ixv-36859"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c53" decimals="-3" id="ixv-36860" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c55" decimals="-3" id="ixv-36861" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c54" decimals="-3" id="ixv-36862" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" id="ixv-36863" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-36864"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-36865" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-36866" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-36867" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-36868" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c57" decimals="-3" id="ixv-36869" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-36870" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-36871" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-36872" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="0"
      id="ixv-36873"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="-3" id="ixv-36874" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-36875" unitRef="usd">225861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-36876" unitRef="usd">-190750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-36877" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-36878" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-36879" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-36880" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-36881" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-36882" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c10" decimals="-3" id="ixv-36883" unitRef="usd">25000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-36884" unitRef="usd">114000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="-3" id="ixv-36885" unitRef="usd">204000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-36886" unitRef="usd">606000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c10" decimals="-3" id="ixv-36887" unitRef="usd">598000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-36888" unitRef="usd">167000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c10" decimals="-3" id="ixv-36889" unitRef="usd">32000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="-3" id="ixv-36890" unitRef="usd">-16000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c10" decimals="-3" id="ixv-36891" unitRef="usd">62000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-36892" unitRef="usd">803000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c10" decimals="-3" id="ixv-36893" unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-36894" unitRef="usd">-1528000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="-3" id="ixv-36895" unitRef="usd">-1595000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-36896" unitRef="usd">-1528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c10" decimals="-3" id="ixv-36897" unitRef="usd">-1595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-36898" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-36899" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-36900" unitRef="usd">35903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="-3" id="ixv-36901" unitRef="usd">40850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-36902" unitRef="usd">214000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-24530">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c0" id="ixv-24533">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-24548">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c0" decimals="INF" id="ixv-36903" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-24610">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-24630">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c5" decimals="INF" id="ixv-36904" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-24636">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-24642">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c0" id="ixv-24651">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-24656">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-24669">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-36905">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c117"
      decimals="0"
      id="ixv-36906"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c118"
      decimals="0"
      id="ixv-36907"
      unitRef="shares">664857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c120"
      decimals="0"
      id="ixv-36908"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-36909"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c10"
      decimals="0"
      id="ixv-36910"
      unitRef="shares">755857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-24726">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There were &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;no&lt;/span&gt; transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c121"
      decimals="-5"
      id="ixv-36911"
      unitRef="usd">35900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-36912" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-24755">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-36913">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-36914">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c122"
      decimals="-3"
      id="ixv-36915"
      unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-36916" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c123" id="ixv-36917">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c123"
      decimals="-3"
      id="ixv-36918"
      unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-36919" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-36920">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c124"
      decimals="-3"
      id="ixv-36921"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-36922" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-36923">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c125"
      decimals="-3"
      id="ixv-36924"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-36925" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-36926" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-36927" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-36928" unitRef="usd">215000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-36929" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-36930" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-36931" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-36932" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-36933" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-24915">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s Former President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c127" decimals="0" id="ixv-36934" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c126" decimals="0" id="ixv-36935" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c77" decimals="0" id="ixv-36936" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-24921">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-115"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-36937" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-36938" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-36939" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c5" decimals="0" id="ixv-36940" unitRef="usd">311000</abio:RetentionBonuses>
    <abio:RetentionBonuses contextRef="c128" decimals="0" id="ixv-36941" unitRef="usd">444000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-36942" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-36943" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-36944">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-36945">to extend the lease term six (6)&#160;months through September&#160;2024</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="c0" id="ixv-36946">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c5" id="ixv-36947">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:OperatingLeasesExtendedExpiryYearsAndMonth contextRef="c0" id="ixv-36948">September&#160;2024</abio:OperatingLeasesExtendedExpiryYearsAndMonth>
    <abio:PercentageOfBaseRentToBePaidMonthly contextRef="c0" decimals="2" id="ixv-36949" unitRef="pure">1.25</abio:PercentageOfBaseRentToBePaidMonthly>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-36950" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c131" id="ixv-36951">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c0" id="ixv-24949">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-36952">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c5" decimals="-3" id="ixv-36953" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c5" decimals="-3" id="ixv-36954" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c5" decimals="-3" id="ixv-36955" unitRef="usd">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-36956" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseCost contextRef="c129" decimals="0" id="ixv-36957" unitRef="usd">22000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c130" decimals="0" id="ixv-36958" unitRef="usd">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-36959" unitRef="usd">48000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-36960" unitRef="usd">23000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c10" decimals="0" id="ixv-36961" unitRef="usd">33000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-36962">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="2" id="ixv-36963" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-36964" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-25022">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;&lt;/span&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;"&gt;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2020, ARCA entered into a Capital on Demand&#x2122; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA common stock&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made under the Sales Agreement in 2024 or 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;See &#x201c;Financing Transaction&#x201d; discussion in Note&#160;10 below.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c132"
      decimals="INF"
      id="ixv-36965"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c133"
      decimals="INF"
      id="ixv-36966"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c134"
      decimals="INF"
      id="ixv-36967"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-25036">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-25040">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/div&gt;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c129"
      decimals="-3"
      id="ixv-36968"
      unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c130"
      decimals="-3"
      id="ixv-36969"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c136"
      decimals="-3"
      id="ixv-36970"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-36971" unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c10" decimals="-3" id="ixv-36972" unitRef="usd">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-36973">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/div&gt;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-36974"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-36975"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c137" id="ixv-25149">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-36976"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-36977"
      unitRef="usdPershares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-36978"
      unitRef="shares">12862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-36979"
      unitRef="usdPershares">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-36980"
      unitRef="shares">645845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-36981"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-25213">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-36982"
      unitRef="shares">502517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-36983"
      unitRef="usdPershares">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-25230">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-36984"
      unitRef="shares">645816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-36985"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-25247">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-25257">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#x2019;s deferred tax assets will not be realized. ARCA&#x2019;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has &lt;span style="-sec-ix-hidden: hidden-fact-119"&gt;no&lt;/span&gt; reserve for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-25262">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(10)&#160;Subsequent Events&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;), (b)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#x201c;Out of the Money Options&#x201d;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#x201c;Parent Closing Price&#x201d;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;adjusted to the extent that ARCA&#x2019;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders equal in the aggregate to ARCA&#x2019;s reasonable, good faith approximation of the amount by which ARCA&#x2019;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#x201c;ARCA Voting Proposals&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non&lt;span class="nobreak"&gt;-solicitation&lt;/span&gt; of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#x201c;Registration Statement&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#x2019;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott&lt;span class="nobreak"&gt;-Rodino&lt;/span&gt; Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders to ARCA&#x2019;s transfer agent for further distribution to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders. Each party&#x2019;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;B Preferred Stock&#x201d;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as&lt;span class="nobreak"&gt;-if-converted-to-ARCA&lt;/span&gt; common stock &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At the effective time of the First Merger (the &#x201c;First Effective Time&#x201d;), the combined company&#x2019;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#x2019;s chief executive officer.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Financing Transaction&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock (together, the &#x201c;PIPE Securities&#x201d;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with Dr.&#160;Bristow&#x2019;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#x201c;Separation Agreement&#x201d;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#x2019;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non&lt;span class="nobreak"&gt;-revocation&lt;/span&gt; by Dr.&#160;Bristow of a legal release of claims.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#x201c;Consulting Agreement&#x201d;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#x2019;s 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Appointment of Thomas Keuer as President&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#x2019;s Chief Operating Officer, to serve as ARCA&#x2019;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#x2019;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8&lt;span class="nobreak"&gt;-K&lt;/span&gt; filed with the SEC on April&#160;3, 2024.&lt;/p&gt;
		&lt;p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#x201c;Payment Event Date&#x201d; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abio:NumberOfConsecutiveTradingDays contextRef="c138" id="ixv-36986">P5D</abio:NumberOfConsecutiveTradingDays>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c139"
      decimals="4"
      id="ixv-36987"
      unitRef="pure">0.9762</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c140"
      decimals="4"
      id="ixv-36988"
      unitRef="pure">0.0238</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <abio:ThresholdAmountOfAdjustedExchangeRatio
      contextRef="c138"
      decimals="-5"
      id="ixv-36989"
      unitRef="usd">5000000</abio:ThresholdAmountOfAdjustedExchangeRatio>
    <abio:ThresholdAmountOfDeclaredCashDividend contextRef="c141" decimals="0" id="ixv-36990" unitRef="usd">5000000</abio:ThresholdAmountOfDeclaredCashDividend>
    <abio:SubscriptionAgreementReceiptAmount
      contextRef="c142"
      decimals="INF"
      id="ixv-36991"
      unitRef="usd">175000000</abio:SubscriptionAgreementReceiptAmount>
    <abio:PaymentOfOtherPartyTerminationFee contextRef="c143" decimals="0" id="ixv-36992" unitRef="usd">440000</abio:PaymentOfOtherPartyTerminationFee>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c144"
      decimals="INF"
      id="ixv-36993"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <abio:MinimumPercentageOfOriginallyIssuedShares
      contextRef="c145"
      decimals="2"
      id="ixv-36994"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedShares>
    <abio:MinimumPercentageOfOriginallyIssuedOutstanding
      contextRef="c145"
      decimals="2"
      id="ixv-36995"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c146"
      decimals="0"
      id="ixv-36996"
      unitRef="shares">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares
      contextRef="c147"
      decimals="4"
      id="ixv-36997"
      unitRef="pure">0.0999</abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares>
    <abio:ExceptedNumberOfBoardMembers
      contextRef="c148"
      decimals="0"
      id="ixv-36998"
      unitRef="pure">5</abio:ExceptedNumberOfBoardMembers>
    <abio:AggregatePurchasePrice
      contextRef="c149"
      decimals="-5"
      id="ixv-36999"
      unitRef="usd">275000000</abio:AggregatePurchasePrice>
    <abio:NumberOfMonthsBaseSalary contextRef="c150" id="ixv-37000">P12M</abio:NumberOfMonthsBaseSalary>
    <abio:CashPayment contextRef="c150" decimals="0" id="ixv-37001" unitRef="usd">25000</abio:CashPayment>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c151" decimals="0" id="ixv-37002" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c152" decimals="0" id="ixv-37003" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:RetentionBonuses contextRef="c153" decimals="0" id="ixv-37004" unitRef="usd">165000</abio:RetentionBonuses>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-4/A</dei:DocumentType>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-7"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-8"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="hidden-fact-9"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-10"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="hidden-fact-13"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-14"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c17"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c6"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c31"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c38"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c46"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c52"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c53"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c54"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c55"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c52"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c54"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c56"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c58"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c7"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c6"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c7"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c7"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c10"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c10"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c10"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c10"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c10"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c64"
      id="hidden-fact-70"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c1"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c2"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c6"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c68"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c6"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-79"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c1"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c1"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c16"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c16"
      id="hidden-fact-86"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c1"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      id="hidden-fact-96"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c98" id="hidden-fact-97">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c99" id="hidden-fact-98">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c6" id="hidden-fact-99">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c106" id="hidden-fact-100">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c6"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c7"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c114" id="hidden-fact-107">2025</abio:OperatingLossCarryforwardsExpirationYear>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c115" id="hidden-fact-108">2037</abio:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OpenTaxYear contextRef="c6" id="hidden-fact-109">2009</us-gaap:OpenTaxYear>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c1"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c135"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-37127">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-37128">0000907654</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822598368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822619712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,903<span></span>
</td>
<td class="nump">$ 37,431<span></span>
</td>
<td class="nump">$ 42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,670<span></span>
</td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">42,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset &#8211; operating</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">37,861<span></span>
</td>
<td class="nump">43,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">225,861<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,750)<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,125<span></span>
</td>
<td class="nump">37,020<span></span>
</td>
<td class="nump">41,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 36,706<span></span>
</td>
<td class="nump">$ 37,861<span></span>
</td>
<td class="nump">$ 43,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822403344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821909424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,317<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
<td class="nump">$ 5,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">2,482<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(7,296)<span></span>
</td>
<td class="num">(10,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WeightedAverageSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WeightedAverageSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_WeightedAverageSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822498864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657820504592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 224,505<span></span>
</td>
<td class="num">$ (173,476)<span></span>
</td>
<td class="nump">$ 51,043<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">$ 40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,452<span></span>
</td>
<td class="num">(186,228)<span></span>
</td>
<td class="nump">39,238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,606<span></span>
</td>
<td class="num">(187,652)<span></span>
</td>
<td class="nump">37,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 225,861<span></span>
</td>
<td class="num">$ (190,750)<span></span>
</td>
<td class="nump">$ 35,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821482880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset &#8211; operating</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">53,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">35,903<span></span>
</td>
<td class="nump">40,850<span></span>
</td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets and operating lease liabilities &#8211; amended lease term</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823326848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ARCA and Summary of Significant Accounting Policies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823356144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-70">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823442464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823274288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823397552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823459360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36<span class="nobreak"> </span>month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823506576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity Financings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Financings</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $54.0&#160;million (the &#8220;Shares&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823416992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-116">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-117">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-118">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425<span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900<span class="nobreak"> </span>shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718<span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807<span class="nobreak"> </span>shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000<span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-76">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-77">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-78">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-79">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-80">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-81">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-82">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-83">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-84">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-85">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-86">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-87">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-88">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-89">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-90">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-91">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-92">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-93">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-94">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-95">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-96">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823563776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823289216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-101">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-102">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-103">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-104">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823300400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822493200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DescriptionOfBusinessPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates in the Preparation of Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedOutsourcingExpensesPolicyTextBlock', window );">Accrued Outsourcing Expenses</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedOutsourcingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourcing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AccruedOutsourcingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823397552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares of Common Stock</a></td>
<td class="text">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-70">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823447696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823478080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Due</a></td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657824445296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-117">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-118">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-76">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-77">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-78">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-79">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-80">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-81">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-82">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-83">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-84">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</div></td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-85">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-86">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-87">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-88">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-89">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-90">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-91">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-92">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-93">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-94">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-95">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-96">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash, Share-based Compensation Expense</a></td>
<td class="text">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-116">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657824506688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</a></td>
<td class="text">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-101">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-102">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-103">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-104">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-redline:true;margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net deferred tax assets and liabilities</a></td>
<td class="text">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657823313872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Off-balance-sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821917296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821436640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Fair value hierarchy</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets between hierarchy levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueDisclosuresDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822505392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822418656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657915628864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements (Details) - Chief Executive Officer [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="num">$ (91,000)<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfUnrestrictedResearchGrants', window );">Payment of unrestricted research grants</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfUnrestrictedResearchGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of unrestricted research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfUnrestrictedResearchGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657819943152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th">
<div>Aug. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfRetentionBonuses', window );">Percentage of retention bonuses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonusPaid', window );">Retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Remains unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease renewal option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew for an additional 36 month term at the then prevailing rental rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to extend the lease term six (6)&#160;months through September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities', window );">Square feet office facilities (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LesseeOperatingSubleaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent', window );">Lessee operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Indicates (true false) whether lessee has option to extend operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfBaseRentToBePaidMonthly', window );">Percentage Of Base Rent To Be Paid Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember', window );">Clinical development decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Patent Assignment Agreement | University Medical Center Of Johannes Gutenberg University Mainz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations', window );">Royalty obligations (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense | One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of real estate property sublease additional office facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LesseeOperatingSubleaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LesseeOperatingSubleaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLeasesExtendedExpiryYearsAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfBaseRentToBePaidMonthly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of base rent to be paid monthly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfBaseRentToBePaidMonthly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfRetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential upfront and milestone obligations and royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonusPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonus paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonusPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822503696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657820876272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of commission rate equal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember', window );">Sales Agreement | Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, authorized offering amount under agreement to sell.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling commission per additional shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SellingCommissionPerAdditionalSharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657824407904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">904,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options award, expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">601,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares</a></td>
<td class="nump">459,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageHoldingForStockOptionsExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember', window );">Incentive Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember', window );">Incentive Stock Option | Stockholders | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock awards granted service period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageHoldingForStockOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum ownership percentage for 110% fair market value on the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageHoldingForStockOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SharebasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SharebasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657961959872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract', window );"><strong>Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share (in Dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657819501552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822577280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of RSU Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfRsuActivityAbstract', window );"><strong>Schedule of RSU Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, beginning of period</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, RSUs outstanding, Vested and released</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfRsuActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfRsuActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822372400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657824108512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Matching contribution</a></td>
<td class="text">matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution (in Dollars)</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember', window );">First 3% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember', window );">Next 2% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EmployeeBenefitPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EmployeeBenefitPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657820098416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 208,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">The net operating loss carryforwards beginning in 2018, have no expiration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount', window );">Increase in net deferred tax assets and liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and experimentation credits</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax assets and liabilities change in amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822366816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract', window );"><strong>Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax benefit at statutory rates</a></td>
<td class="num">$ (1,121)<span></span>
</td>
<td class="num">$ (2,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset', window );">Deferred tax asset adjustment</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of the carrying value of deferred tax assets during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822022992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 51,190<span></span>
</td>
<td class="nump">$ 50,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and experimentation credits</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized intangibles</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,594<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(55,531)<span></span>
</td>
<td class="num">(54,372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821425600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657820495104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657824499696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657821425760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657822154592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139657820404432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Apr. 03, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfDeclaredCashDividend', window );">Declared cash dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfAdjustedExchangeRatio', window );">Adjusted exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of noncontrolling ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares', window );">Initially specified percentage for beneficial number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Oruka Therapeutics Inc | Common Stock and Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedShares', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Thomas A. Keuer and C. Jeffrey Dekker [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfOtherPartyTerminationFee', window );">Payment of other party termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubscriptionAgreementReceiptAmount', window );">Subscription agreement receipt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember', window );">Merger Agreement | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember', window );">First Merger | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExceptedNumberOfBoardMembers', window );">Excepted number of board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember', window );">First Merger | Series B Preferred Stock | ARCA | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock convertible shares issuable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember', window );">Seperation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfMonthsBaseSalary', window );">Number of months base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember', window );">Second Amendment of Certain Retention Bonus Letters | Thomas A. Keuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember', window );">Second Amendment of Certain Retention Bonus Letters | C. Jeffrey Dekker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExceptedNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excepted Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ExceptedNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncreaseOfRetentionBonusToEachExecutive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase of retention bonus to each executive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncreaseOfRetentionBonusToEachExecutive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initially specified percentage for beneficial number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfMonthsBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfMonthsBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfOtherPartyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of other party termination fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfOtherPartyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubscriptionAgreementReceiptAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement receipt amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubscriptionAgreementReceiptAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfAdjustedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of adjusted exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfAdjustedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfDeclaredCashDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of declared cash dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfDeclaredCashDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
